FN Clarivate Analytics Web of Science VR 1.0 PT J AU Visby, L Kehlet, H Secher, EL Moller-Sorensen, H Hansen, HJ Petersen, RH AF Visby, Lasse Kehlet, Henrik Secher, Erik Lilja Moller-Sorensen, Hasse Hansen, Henrik Jessen Petersen, Rene Horsleben TI Outcomes of Video-Assisted Thoracoscopic Lobectomy in Octogenarians Following Enhanced Recovery After Surgery Protocols SO LUNG CANCER LA English DT Article DE Octogenarian; Enhanced recovery; VATS; Fast-track; Readmissions; Complications ID STEREOTACTIC BODY RADIOTHERAPY; CELL LUNG-CANCER AB Objectives: The improvements from minimally invasive surgery and Enhanced Recovery After Surgery (ERAS) protocols have enabled more octogenarians to be considered for curative treatment of early-stage lung cancer. However, evidence on short-term outcomes after ERAS-guided Video-Assisted Thoracoscopic Surgery (VATS) lobectomy in this age group remains limited. The aim was to evaluate perioperative outcomes and assess specific challenges in octogenarians undergoing VATS lobectomy following a well-established ERAS-protocol. Methods: We conducted a retrospective observational study of consecutive adults undergoing VATS lobectomy within an ERAS program from 2009 to 2024. All patients followed standardized care and followed an ERAS protocol. Patients aged >= 80 years underwent an additional preoperative risk assessment. Results: Among 4,602 patients, 335 (7.3%) were octogenarians (median age 82 years, IQR 81-83). Median length of stay was one day longer among octogenarians (4 (IQR: 2-7) vs 3 days (IQR: 2-6), p = 0.004). Overall complication rates were comparable between octogenarians and younger patients, except for postoperative atrial fibrillation (octogenarians 12% vs 7.6%, p = 0.012). Within 30 days, 40 octogenarians (11.9%) were readmitted, most commonly for pneumonia (30%), pneumothorax (25%), and pleural effusion (20%). 30-day mortality was not statistically different between octogenarians and younger patients (octogenarians 1.8% vs 1.2%, p = 0.29). The number of octogenarians undergoing VATS lobectomy has increased from 2.5% of all patients in 2009 to 11.7% in 2024. Conclusion: VATS lobectomy within an ERAS framework appears safe and feasible in carefully selected octogenarians, yielding acceptable short-term outcomes. Chronological age alone should not preclude surgical treatment. C1 [Visby, Lasse; Hansen, Henrik Jessen; Petersen, Rene Horsleben] Rigshosp, Copenhagen Univ Hosp, Dept Cardiothorac Surg, Copenhagen, Denmark. [Secher, Erik Lilja; Moller-Sorensen, Hasse] Rigshosp, Heart Ctr, Dept Cardiothorac Anesthesiol, Copenhagen, Denmark. [Kehlet, Henrik] Rigshosp, Copenhagen Univ Hosp, Sect Surg Pathophysiol, Copenhagen, Denmark. [Visby, Lasse; Kehlet, Henrik; Secher, Erik Lilja; Moller-Sorensen, Hasse; Hansen, Henrik Jessen; Petersen, Rene Horsleben] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark. C3 Rigshospitalet; University of Copenhagen; Copenhagen University Hospital; University of Copenhagen; Copenhagen University Hospital; Rigshospitalet; Rigshospitalet; University of Copenhagen; Copenhagen University Hospital; University of Copenhagen RP Visby, L (corresponding author), Rigshosp, Dept Cardiothorac Surg, Inge Lehmans Vej 7, DK-2100 Copenhagen, Denmark. EM lasse.visby@regionh.dk FU Novo Nordisk Foundation, Denmark [NNF22OC0079013] FX This work was supported by a grant from Novo Nordisk Foundation, Denmark (Reference Number: NNF22OC0079013) . CR Amar D, 2002, ANESTHESIOLOGY, V96, P352, DOI 10.1097/00000542-200202000-00021 Batchelor TJP, 2019, EUR J CARDIO-THORAC, V55, P91, DOI 10.1093/ejcts/ezy301 Bin Sumaida A., 2025, CUREUS J MED SCIENCE Bongiolatti S, 2021, SURG ONCOL, V37, DOI 10.1016/j.suronc.2021.101530 Bray F, 2024, CA-CANCER J CLIN, V74, P229, DOI 10.3322/caac.21834 Cao C, 2019, J THORAC CARDIOV SUR, V157, P362, DOI 10.1016/j.jtcvs.2018.08.075 Christensen K, 2009, LANCET, V374, P1196, DOI 10.1016/S0140-6736(09)61460-4 Grossi W, 2020, CURR CHALL THORACIC, V2, P16, DOI 10.21037/ccts.2019.12.07 Hansen HJ, 2012, ANN CARDIOTHORAC SUR, V1, P70, DOI 10.3978/j.issn.2225-319X.2012.04.15 Haro GJ, 2021, ANN SURG, V274, pE1008, DOI 10.1097/SLA.0000000000003719 Howington J, 2025, CHEST, V168, P810, DOI 10.1016/j.chest.2025.06.023 Huang L, 2022, EUR J CARDIO-THORAC, V62, DOI 10.1093/ejcts/ezac385 Khoury AL, 2021, JTCVS OPEN, V7, P370, DOI 10.1016/j.xjon.2021.07.007 Li H, 2019, J SURG RES, V243, P346, DOI 10.1016/j.jss.2019.04.083 Lim E, 2022, NEJM EVID, V1, DOI [10.1056/evidoa2100016, 10.1056/EVIDoa2100016] Port JL, 2011, ANN THORAC SURG, V92, P1951, DOI 10.1016/j.athoracsur.2011.06.082 Razi SS, 2021, ANN THORAC SURG, V111, P1659, DOI 10.1016/j.athoracsur.2020.06.097 Rogers LJ, 2018, J THORAC CARDIOV SUR, V155, P1843, DOI 10.1016/j.jtcvs.2017.10.151 Sarkaria IS, 2019, J THORAC DIS, V11, P2420, DOI 10.21037/jtd.2019.05.52 Sui XZ, 2015, ANN THORAC CARDIOVAS, V21, P529, DOI 10.5761/atcs.oa.15-00126 Zer A., 2025, ANN ONCOL Zhang BL, 2014, RADIOTHER ONCOL, V112, P250, DOI 10.1016/j.radonc.2014.08.031 NR 22 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0169-5002 EI 1872-8332 J9 LUNG CANCER JI Lung Cancer PD MAY PY 2026 VL 215 AR 109384 DI 10.1016/j.lungcan.2026.109384 PG 7 WC Oncology; Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Respiratory System GA GB2FY UT WOS:001732252400001 PM 41904848 OA hybrid DA 2026-04-17 ER PT J AU Liu, ZL Zhao, ZZ Xiao, YQ Zhang, Y Ge, LL Luo, J Zhou, Y Bao, R Deng, XM Wang, JF AF Liu, Zhi-li Zhao, Zhen-Zhen Xiao, Ya-Qin Zhang, Ying Ge, Ling-Ling Luo, Jie Zhou, Yan Bao, Rui Deng, Xiao-ming Wang, Jia-Feng TI The Effects of Nonintubated Anesthesia on Neutrophil-to-Lymphocyte Ratio and Tumor Markers Among Patients Undergoing Thoracoscopic Lung Resection: A Randomized Controlled Trial SO JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA LA English DT Article DE nonintubated anesthesia; neutrophil-to-lymphocyte ratio; tumor markers; video-assisted thoracoscopic surgery ID THORACIC-SURGERY; IMMUNE-RESPONSE; CANCER; MATRIX-METALLOPROTEINASE-9; LOBECTOMY; MMP-9; DEXMEDETOMIDINE; SAFETY; CELLS AB Objectives: To assess the influence of nonintubated anesthesia on the neutrophil-to-lymphocyte ratio (NLR) and tumor marker level in patients undergoing thoracoscopic resection of lung cancer. Design: A prospective, randomized, controlled trial. Setting: A tertiary medical institution. Participants: Fifty-eight patients underwent video-assisted thoracoscopic lung surgery. Intervention: Patients were randomly divided into the nonintubated video-assisted thoracic surgery group (NIVATS group, n = 29) and the traditional video-assisted thoracic surgery group (VATS group, n = 29) in a 1:1 allocation ratio. Measurements and Main Results: The primary outcome was the NLR in peripheral blood, measured 24 hours postoperatively. Secondary outcomes included a range of peripheral blood tumor markers (derived neutrophil to lymphocyte ratio/lactate dehydrogenase (dNLR/LDH), citrullinated histone H3, matrix metalloproteinase 9, programmed death ligand 1, systemic inflammatory immune index, vascular endothelial growth factor) at the same time point, as well as intraoperative minimum blood oxygen saturation, thoracotomy conversion rate, blood loss, recovery metrics (chest tube duration, discharge time), and postoperative complications (chest air leaks, pneumonia, acute respiratory distress syndrome incidence, new-onset atrial fibrillation, hoarseness, sore throat, dysphonia). Notably, 24 hours after surgery, the NLR and neutrophil percentage were significantly lower in the NIVATS group compared to the VATS group (p = 0.031, p = 0.006), accompanied by a higher lymphocyte percentage (p = 0.013). However, enzyme-linked immunosorbent assay results for peripheral blood tumor markers showed no significant differences between the 2 groups, both before and 24 hours after surgery. Conclusions: Compared to the VATS group, the use of nonintubated anesthesia resulted in less postoperative NLR elevation but had no significant impact on the levels of tumor biomarkers. (c) 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies. C1 [Liu, Zhi-li] Xuzhou Med Univ, Jiangsu Prov Key Lab Anesthesiol, Xuzhou, Jiangsu, Peoples R China. [Liu, Zhi-li; Zhao, Zhen-Zhen; Xiao, Ya-Qin; Zhang, Ying; Ge, Ling-Ling; Luo, Jie; Zhou, Yan; Bao, Rui; Deng, Xiao-ming; Wang, Jia-Feng] Naval Med Univ, Changhai Hosp, Fac Anesthesiol, Shanghai 200433, Peoples R China. C3 Xuzhou Medical University; Naval Medical University RP Wang, JF (corresponding author), Naval Med Univ, Changhai Hosp, Fac Anesthesiol, Shanghai 200433, Peoples R China. EM jfwang@smmu.edu.cn FU National Natural Science Foundation of China [82472186, 82272214]; New Technology Incubation Project of Naval Medical University [ZXJS2024C08] FX The authors declare that they have no financial conflicts of interest to disclose. This work was supported by the National Natural Science Foundation of China (grant numbers 82472186 and 82272214) and New Technology Incubation Project of Naval Medical University (ZXJS2024C08) . CR Aguilar-Cazares D, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01399 Bray F, 2024, CA-CANCER J CLIN, V74, P229, DOI 10.3322/caac.21834 Chang CH, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.759497 Chen JS, 2011, ANN SURG, V254, P1038, DOI 10.1097/SLA.0b013e31822ed19b Chen L, 2023, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1034916 Cupp MA, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01817-1 Desmond F, 2015, ANTICANCER RES, V35, P1311 Diem S, 2017, LUNG CANCER, V111, P176, DOI 10.1016/j.lungcan.2017.07.024 Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730 Elena G, 2003, LAB ANIM-UK, V37, P193, DOI 10.1258/002367703766453038 Gong L, 2016, ONCOTARGET, V7, P18458, DOI 10.18632/oncotarget.7607 Gothard J, 2006, CURR OPIN ANESTHESIO, V19, P5, DOI 10.1097/01.aco.0000192783.40021.c1 Gu XB, 2015, SCI REP-UK, V5, DOI 10.1038/srep12493 Huang LL, 2021, ONCOL LETT, V21, DOI 10.3892/ol.2020.12367 Inada T, 2004, ANAESTHESIA, V59, P954, DOI 10.1111/j.1365-2044.2004.03837.x Kim EY, 2020, WORLD J SURG ONCOL, V18, DOI 10.1186/s12957-020-02059-4 Kim R, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1389-7 Lacin S, 2020, TECHNOL CANCER RES T, V19, DOI 10.1177/1533033820971677 Li LN, 2013, ASIAN PAC J CANCER P, V14, P4107, DOI 10.7314/APJCP.2013.14.7.4107 Li Y, 2012, MED ONCOL, V29, P3394, DOI 10.1007/s12032-012-0283-z Lian PL, 2016, WORLD J GASTROENTERO, V22, P3852, DOI 10.3748/wjg.v22.i14.3852 Lin NP, 2022, INT J SURG, V107, DOI 10.1016/j.ijsu.2022.106959 Liu WL, 2023, INT J SURG, V109, P3519, DOI 10.1097/JS9.0000000000000650 Ma YF, 2015, BIOMARK MED, V9, P845, DOI 10.2217/bmm.15.60 Mineo TC, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071466 Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444 Nie M, 2019, CLIN CANCER RES, V25, P1867, DOI 10.1158/1078-0432.CCR-18-1226 Ohashi K, 2024, SCI REP-UK, V14, DOI 10.1038/s41598-023-50378-9 Schilling T, 2005, ANESTH ANALG, V101, P957, DOI 10.1213/01.ane.0000172112.02902.77 Siegel RL, 2024, CA-CANCER J CLIN, V74, P12, DOI 10.3322/caac.21820 Sunaga H, 2017, CURR OPIN ANESTHESIO, V30, P1, DOI 10.1097/ACO.0000000000000413 Teijeira A, 2020, IMMUNITY, V52, P856, DOI 10.1016/j.immuni.2020.03.001 Templeton AJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju124 Tsudaka S, 2021, ANN SURG ONCOL, V28, P4880, DOI 10.1245/s10434-021-09690-9 Wang J, 2014, CLIN CHIM ACTA, V433, P225, DOI 10.1016/j.cca.2014.03.023 Wang K, 2018, ONCOL LETT, V15, P7153, DOI 10.3892/ol.2018.8205 Wang YL, 2015, J SURG RES, V194, P147, DOI 10.1016/j.jss.2014.10.008 Wang YX, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1276107 Wu CY, 2013, ANN THORAC SURG, V95, P405, DOI 10.1016/j.athoracsur.2012.10.082 Yan TD, 2009, J CLIN ONCOL, V27, P2553, DOI 10.1200/JCO.2008.18.2733 Yang XH, 2017, EUR REV MED PHARMACO, V21, P1112 Yousef EM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-609 Zhu M, 2016, BRIT J ANAESTH, V116, P870, DOI 10.1093/bja/aew124 NR 43 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1053-0770 EI 1532-8422 J9 J CARDIOTHOR VASC AN JI J. Cardiothorac. Vasc. Anesth. PD APR PY 2026 VL 40 IS 4 BP 1205 EP 1213 DI 10.1053/j.jvca.2025.10.046 PG 9 WC Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease WE Science Citation Index Expanded (SCI-EXPANDED) SC Anesthesiology; Cardiovascular System & Cardiology; Respiratory System GA FJ9DD UT WOS:001720512400001 PM 41320620 DA 2026-04-17 ER PT J AU Woolard, A Davenport, D Saha, S AF Woolard, Amie Davenport, Daniel Saha, Sibu TI Incidence and Impact of Atrial Fibrillation after Open Thoracotomy and VATS Pulmonary Lobectomy: A Single-Center Experience SO SOUTHERN MEDICAL JOURNAL LA English DT Article DE atrial fibrillation; lobectomy; minimally invasive surgery; video-assisted thoracoscopic surgery ID CELL LUNG-CANCER; ASSISTED THORACOSCOPIC SURGERY; THORACIC-SURGERY; RISK-FACTORS; METAANALYSIS; PROPHYLAXIS AB Objective: The purpose of this study was to measure the incidence and impact of atrial fibrillation (AF) after open thoracotomy versus video-assisted thoracoscopic surgery (VATS) lobectomy at an academic medical center. Methods: With institutional review board approval, 899 patients who underwent a pulmonary lobectomy from January 2005 to December 2021 were included in this study. Postoperative AF (POAF) was defined by electrocardiography. Patients with a preoperative diagnosis of AF were excluded. Univariate analyses were conducted to identify risk factors and outcomes of POAF. Multivariate analyses were conducted to identify independent predictors and associated complications of POAF. Results: The overall incidence of AF was 9.2%. This incidence after open thoracotomy (13.0%) and VATS procedures (6.5%) was significantly different (P=0.001). An independent risk factor for POAF was age (odds ratio [OR] 1.05, P<0.001). POAF significantly increased the average number of other complications (P<0.001). Multivariate analysis revealed that postoperative acute respiratory distress syndrome (OR 3.94, P <= 0.001) and atelectasis (OR 3.89, P=0.004) were independently associated with POAF. POAF did not affect in-hospital mortality (P=0.341). Patients with POAF had a significantly longer average hospital length of stay compared with those without (8.80 vs 5.84, P<0.001). The same is true for the first (3.52 vs 2.54, P=0.014) and the total length of stay in the intensive care unit (4.68 vs 3.10, P=0.009). POAF significantly increased the rate of postoperative mechanical ventilation (P=0.004), reintubation (P<0.001), and return to the operating room (P=0.003). Conclusions: The incidence of POAF in patients who underwent an open lobectomy was significantly higher than those who underwent a VATS lobectomy. An independent risk factor for developing POAF was age. In the end, POAF greatly increased a patient's rate of postoperative complications, length of hospital and intensive care unit stay, and postoperative procedures. C1 [Woolard, Amie] Univ Kentucky, Coll Med, Lexington, KY 40536 USA. [Saha, Sibu] Univ Kentucky, Div Healthcare Outcomes & Optimal Patient Serv, Lexington, KY 40536 USA. [Saha, Sibu] Univ Kentucky, Div Cardiothorac Surg, Lexington, KY 40536 USA. C3 University of Kentucky; University of Kentucky; University of Kentucky RP Woolard, A (corresponding author), Univ Kentucky, 740 S Limestone,Suite A 301, Lexington, KY 40536 USA. EM awoolard@uky.edu; daniel.davenport@uky.edu; ssaha2@email.uky.edu FU National Center for Advancing Translational Sciences [UL1TR001998] FX The authors would like to thank Lance Butler, BA, for assistance with data analysis. CR Cao C, 2013, INTERACT CARDIOV TH, V16, P244, DOI 10.1093/icvts/ivs472 Crispi V, 2022, POSTGRAD MED J, V98, P177, DOI 10.1136/postgradmedj-2020-138904 Falcoz PE, 2016, EUR J CARDIO-THORAC, V49, P602, DOI 10.1093/ejcts/ezv154 Garner M, 2017, INTERACT CARDIOV TH, V24, P260, DOI 10.1093/icvts/ivw348 He GX, 2020, J CARDIOTHORAC SURG, V15, DOI 10.1186/s13019-020-01260-6 Hollings DD, 2010, AM J SURG, V199, P558, DOI 10.1016/j.amjsurg.2009.11.006 Imperatori A, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-4 Iwata T, 2016, SURG TODAY, V46, P877, DOI 10.1007/s00595-015-1258-4 Jahangir A, 2007, CIRCULATION, V115, P3050, DOI 10.1161/CIRCULATIONAHA.106.644484 Lederer MR, 2021, INNOVATIONS, V16, P249, DOI 10.1177/1556984521994206 Lee SH, 2016, ANAESTHESIA, V71, P1424, DOI 10.1111/anae.13644 Neustein SM, 1998, J CARDIOTHOR VASC AN, V12, P659, DOI 10.1016/S1053-0770(98)90238-5 Oesterte A, 2018, AM J MED, V131, P795, DOI 10.1016/j.amjmed.2018.01.032 Park BJ, 2007, J THORAC CARDIOV SUR, V133, P775, DOI 10.1016/j.jtcvs.2006.09.022 Riber LP, 2014, ANN THORAC SURG, V98, P1989, DOI 10.1016/j.athoracsur.2014.06.069 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Scheggi V, 2023, CARDIOTHORAC SURG, V31, DOI 10.1186/s43057-023-00109-7 Tong CY, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-20-5035 Tsao, 2023, CIRCULATION, V147, pE622, DOI 10.1161/CIR.0000000000001137 Veiga Oliveira Paulo, 2021, Port J Card Thorac Vasc Surg, V28, P33, DOI 10.48729/pjctvs.192 Whitson BA, 2008, ANN THORAC SURG, V86, P2008, DOI 10.1016/j.athoracsur.2008.07.009 Zhang LZ, 2016, J CARDIOVASC PHARM, V67, P351, DOI 10.1097/FJC.0000000000000351 NR 22 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0038-4348 EI 1541-8243 J9 SOUTH MED J JI South.Med.J. PD APR PY 2026 VL 119 IS 4 BP 173 EP 178 DI 10.14423/SMJ.0000000000001957 PG 6 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA FY8ZH UT WOS:001730675900006 DA 2026-04-17 ER PT J AU Shen, GH Wang, RY Xu, JY Chen, JW Chen, RY Wang, YR Zhang, XQ Wang, KY Dai, YP Li, JF AF Shen, Guohang Wang, Ruoyan Xu, Jingyi Chen, Jingwen Chen, Ruoyu Wang, Yiru Zhang, Xianquan Wang, Kaiyong Dai, Yupei Li, Junfeng TI Comparative effectiveness of robotic and video assisted thoracic surgery for lung cancer across key outcomes SO ISCIENCE LA English DT Article ID LOBECTOMY; RESECTION; SEGMENTECTOMY AB Robotic-assisted thoracic surgery (RATS) and video-assisted thoracoscopic surgery (VATS) are widely used for minimally invasive resection of pulmonary tumors, but they differ in technical capabilities and resource demands. We conducted a PRISMA-based systematic review and meta-analysis of randomized and cohort studies identified by searching PubMed, Embase, Web of Science, Scopus, and the Cochrane Library through June 2025. Across 25 studies including 41,417 patients, RATS was associated with lower conversion to thoracotomy rates and less blood loss, more extensive lymphadenectomy, higher R0 resection rates, and shorter chest tube duration, ICU stay, and hospital stay. Pneumonia and atrial fibrillation were less frequent, whereas overall complications, pneumothorax, and 30-and 90-day mortality were similar. Hospitalization costs were higher, and pooled survival data suggested a possible long-term advantage. These findings clarify platform tradeoffs and motivate large randomized trials and cost-effectiveness analyses. C1 [Shen, Guohang; Wang, Ruoyan; Zhang, Xianquan; Wang, Kaiyong; Dai, Yupei; Li, Junfeng] Capital Med Univ, Beijing Anzhen Nanchong Hosp, Dept Thorac Surg, Nanchong 637000, Sichuan, Peoples R China. Nanchong Cent Hosp, Nanchong 637000, Sichuan, Peoples R China. [Shen, Guohang; Wang, Ruoyan; Xu, Jingyi; Chen, Jingwen; Chen, Ruoyu; Wang, Yiru; Zhang, Xianquan; Wang, Kaiyong; Dai, Yupei; Li, Junfeng] North Sichuan Med Coll, 234 Fujiang Rd, Nanchong 637000, Sichuan, Peoples R China. [Wang, Ruoyan] North Sichuan Med Coll, Sch Basic Med & Forens Med, 234 Fujiang Rd, Nanchong 637000, Sichuan, Peoples R China. [Wang, Kaiyong; Dai, Yupei] Ningxia Med Univ, Dept Clin Med, Yinchuan 750004, Ningxia Hui Aut, Peoples R China. C3 Capital Medical University; North Sichuan Medical University; North Sichuan Medical University; North Sichuan Medical University; Ningxia Medical University RP Li, JF (corresponding author), Capital Med Univ, Beijing Anzhen Nanchong Hosp, Dept Thorac Surg, Nanchong 637000, Sichuan, Peoples R China.; Li, JF (corresponding author), North Sichuan Med Coll, 234 Fujiang Rd, Nanchong 637000, Sichuan, Peoples R China. EM liwlny@163.com RI Shen, Guohang/OLQ-2473-2025 OI Shen, Guohang/0009-0005-8551-2885 CR Amir-Behghadami M, 2020, EMERG MED J, V37, P387, DOI 10.1136/emermed-2020-209567 Barmanwalla Amira, 2025, Cureus, V17, pe86432, DOI 10.7759/cureus.86432 Bottet B, 2025, J ROBOT SURG, V19, DOI 10.1007/s11701-024-02174-4 Bray F, 2024, CA-CANCER J CLIN, V74, P229, DOI 10.3322/caac.21834 Cui Y, 2020, JNCI CANCER SPECT, V4, DOI 10.1093/jncics/pkaa028 Dai Feng, 2018, Zhongguo Fei Ai Za Zhi, V21, P206, DOI 10.3779/j.issn.1009-3419.2018.03.18 Duclos G, 2018, J THORAC DIS, V10, P3558, DOI 10.21037/jtd.2018.05.179 Fabbri G, 2023, J CLIN MED, V12, DOI 10.3390/jcm12206609 Ioannidis JPA, 2019, JAMA-J AM MED ASSOC, V321, P2067, DOI 10.1001/jama.2019.4582 Jin RS, 2022, ANN SURG, V275, P295, DOI 10.1097/SLA.0000000000004922 Kneuertz PJ, 2019, J THORAC CARDIOV SUR, V157, P2018, DOI 10.1016/j.jtcvs.2018.12.101 Li CW, 2019, TRANSL LUNG CANCER R, V8, P820, DOI 10.21037/tlcr.2019.10.15 [刘星池 Liu Xingchi], 2018, [中国肺癌杂志, Chinese Journal of Lung Cancer], V21, P849 Luo DH, 2018, STAT METHODS MED RES, V27, P1785, DOI 10.1177/0962280216669183 Ma JL, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08241-5 Mcgrath S, 2024, RES SYNTH METHODS, V15, P332, DOI 10.1002/jrsm.1686 Nelson DB, 2019, ANN THORAC SURG, V108, P370, DOI 10.1016/j.athoracsur.2019.03.051 Novellis P, 2018, J THORAC DIS, V10, P790, DOI 10.21037/jtd.2018.01.123 Page MJ, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n160 Park BJ, 2012, J THORAC CARDIOV SUR, V143, P383, DOI 10.1016/j.jtcvs.2011.10.055 Qiu T, 2020, J THORAC CARDIOV SUR, V160, P838, DOI 10.1016/j.jtcvs.2019.10.158 Ricciardi R, 2025, ANN SURG, V281, P748, DOI 10.1097/SLA.0000000000006572 Sarkaria IS, 2016, J THORAC CARDIOV SUR, V152, P998, DOI 10.1016/j.jtcvs.2016.07.020 Seder CW, 2022, ANN THORAC SURG, V114, P1879, DOI 10.1016/j.athoracsur.2021.09.061 Sezen CB, 2023, J LAPAROENDOSC ADV S, V33, P626, DOI 10.1089/lap.2022.0554 Shahoud J, 2024, J THORAC DIS, V16, P7539, DOI 10.21037/jtd-24-919 Shi JD, 2023, STAT METHODS MED RES, V32, P1338, DOI 10.1177/09622802231172043 Stefani A, 2012, MINERVA CHIR, V67, P489 Veluswamy RR, 2020, CHEST, V157, P1313, DOI 10.1016/j.chest.2019.09.017 Veronesi G, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.726408 Veroniki AA, 2016, RES SYNTH METHODS, V7, P55, DOI 10.1002/jrsm.1164 Wang LL, 2023, J CANCER RES CLIN, V149, P10235, DOI 10.1007/s00432-023-04920-x Wang YS, 2024, J THORAC DIS, V16, P7257, DOI 10.21037/jtd-24-1020 Worrell SG, 2019, J ROBOT SURG, V13, P239, DOI 10.1007/s11701-018-0844-z Wu H, 2021, EUR J CARDIO-THORAC, V59, P732, DOI 10.1093/ejcts/ezaa426 Xu H, 2024, J LAPAROENDOSC ADV S, V34, P67, DOI 10.1089/lap.2023.0171 Yang HX, 2017, ANN SURG, V265, P431, DOI 10.1097/SLA.0000000000001708 Yu K, 2025, INT J SURG, V111, P2227, DOI 10.1097/JS9.0000000000002205 Zhang JF, 2025, JTCVS OPEN, V24, P383, DOI [10.1016/j.xjon.2025.01.007, 10.1016/j.xjon.2025.01.007] Zhang KX, 2024, EJSO-EUR J SURG ONC, V50, DOI 10.1016/j.ejso.2024.108481 Zhang YJ, 2020, J THORAC CARDIOV SUR, V160, P1363, DOI 10.1016/j.jtcvs.2019.12.112 Zhou QJ, 2020, TRANSL LUNG CANCER R, V9, P306, DOI 10.21037/tlcr-20-533 Zhou Z Q, 2024, Zhonghua Yi Xue Za Zhi, V104, P3221, DOI 10.3760/cma.j.cn112137-20240226-00410 NR 43 TC 0 Z9 0 U1 1 U2 1 PU CELL PRESS PI CAMBRIDGE PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA EI 2589-0042 J9 ISCIENCE JI iScience PD MAR 20 PY 2026 VL 29 IS 3 AR 114898 DI 10.1016/j.isci.2026.114898 EA MAR 2026 PG 22 WC Multidisciplinary Sciences WE Science Citation Index Expanded (SCI-EXPANDED) SC Science & Technology - Other Topics GA EV3DO UT WOS:001710594700001 PM 41809046 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Chen, JD Wang, H Shang, CH Fan, ZX Sheng, ZY Chu, TQ Zhang, M Zhao, L AF Chen, Jindong Wang, Hao Shang, Conghui Fan, Zixu Sheng, Ziyi Chu, Tianqing Zhang, Min Zhao, Liang TI The impact of SGLT2i on the outcome of advanced lung cancer in patients with diabetes SO FRONTIERS IN ONCOLOGY LA English DT Article DE advanced lung cancer; cardiotoxicity; diabetes; outcome; SGLT2i ID GLUCOSE; MECHANISMS; LEVEL; RISK AB Objective Sodium-glucose cotransporter-2 inhibitors (SGLT2i), a novel pharmacological agent for diabetes and heart failure, may influence oncologic outcomes. Their role in advanced lung cancer patients with diabetes is unclear. Our study aims to evaluate SGLT2i's effects in this population.Methods We performed a retrospective analysis of advanced lung cancer patients diagnosed with diabetes at our center between July 2020 and July 2024. The case cohort include patients who received SGLT2i, while the control cohort did not. The primary endpoint was overall mortality, and the secondary endpoint was a composite of cardiac events.Results The cohort included 188 patients, with 94 cases and 94 controls. Over a median follow-up of 16 months, the use of SGLT2i was significantly associated with improved survival for advanced lung cancer with diabetes. (hazard ratio, (HR) 0.56; 95% CI 0.35-0.87, P = 0.009). The survival rate was lower in major adverse cardiovascular events (MACE) group than non-MACE group, however the differences were not statistically significant (HR 1.69; 95% CI 0.96- 2.97, P = 0.067). During follow-up, the incidence of MACE (24 cases in total, with new-onset atrial fibrillation/flutter being the most common) did not differ significantly between SGLT2i and control groups (11.7% vs. 13.8%; P = 0.662).Conclusions In advanced lung cancer patients with diabetes, SGLT2i was associated with a lower all-cause mortality rate. Yet SGLT2i had insignificant impact on the incidence of MACE and the post-MACE survival. C1 [Chen, Jindong; Wang, Hao; Shang, Conghui; Fan, Zixu; Zhang, Min; Zhao, Liang] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Sch Med, Dept Cardiol, Shanghai, Peoples R China. [Sheng, Ziyi; Chu, Tianqing] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Sch Med, Dept Clin Res Unit, Shanghai, Peoples R China. C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University RP Zhang, M; Zhao, L (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Sch Med, Dept Cardiol, Shanghai, Peoples R China.; Chu, TQ (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Sch Med, Dept Clin Res Unit, Shanghai, Peoples R China. EM ctqxkyy@163.com; zhangminxk@126.com; zhaoliang80112@126.com CR Bray F, 2024, CA-CANCER J CLIN, V74, P229, DOI 10.3322/caac.21834 Cowie MR, 2020, NAT REV CARDIOL, V17, P761, DOI 10.1038/s41569-020-0406-8 Dabour MS, 2024, JACC-CARDIOONCOL, V6, P159, DOI 10.1016/j.jaccao.2024.01.007 Flausino LE, 2025, BMC CANCER, V25, DOI 10.1186/s12885-025-13966-8 Gallagher EJ, 2015, PHYSIOL REV, V95, P727, DOI 10.1152/physrev.00030.2014 Ganti AKP, 2021, J NATL COMPR CANC NE, V19, P1441, DOI 10.6004/jnccn.2021.0058 Halimi S, 2014, DIABETES METAB, V40, pS28, DOI 10.1016/S1262-3636(14)72693-X Han XQ, 2020, METABOLISM, V105, DOI 10.1016/j.metabol.2020.154169 Icard P, 2018, DRUG RESIST UPDATE, V38, P1, DOI 10.1016/j.drup.2018.03.001 Koepsell H, 2017, PHARMACOL THERAPEUT, V170, P148, DOI 10.1016/j.pharmthera.2016.10.017 Li WC, 2024, FRONT PHARMACOL, V15, DOI 10.3389/fphar.2024.1416403 Liang J, 2024, CURR PHARM DESIGN, V30, P1541, DOI 10.2174/0113816128302667240422110226 Luo JH, 2012, LUNG CANCER, V76, P242, DOI 10.1016/j.lungcan.2011.10.019 Maurea N, 2020, ANN ONCOL, V31, pS1106, DOI 10.1016/j.annonc.2020.08.1361 O'Hara DV, 2024, NAT REV NEPHROL, V20, P513, DOI 10.1038/s41581-024-00836-y Okada J, 2020, MOLECULES, V25, DOI 10.3390/molecules25030495 Okada J, 2018, CLIN COLORECTAL CANC, V17, pE45, DOI 10.1016/j.clcc.2017.09.005 Padda IS., 2025, SODIUM GLUCOSE TRANS Paul S, 2022, SEMIN CANCER BIOL, V86, P1216, DOI 10.1016/j.semcancer.2022.09.007 Perelman MG, 2024, CARDIO-ONCOLOGY, V10, DOI 10.1186/s40959-023-00199-6 Perry RJ, 2020, J BIOL CHEM, V295, P14379, DOI 10.1074/jbc.REV120.008387 Pollack R, 2023, DIABETES CARE, V46, P156, DOI 10.2337/dc22-1318 Quagliariello V, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207802 Ren Y., 2019, BIORXIV, P622126, DOI [10.1101/622126, DOI 10.1101/622126] Riely GJ, 2024, J NATL COMPR CANC NE, V22, P249, DOI 10.6004/jnccn.2204.0023 Scafoglio CR, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat5933 Schwartz L, 2017, SEMIN CANCER BIOL, V43, P134, DOI 10.1016/j.semcancer.2017.01.005 Seshasai SRK, 2011, NEW ENGL J MED, V364, P829, DOI 10.1056/NEJMoa1008862 Zhao LJ, 2026, SIGNAL TRANSDUCT TAR, V11, DOI 10.1038/s41392-025-02401-w Zhou J, 2020, BIOMED PHARMACOTHER, V132, DOI 10.1016/j.biopha.2020.110821 NR 30 TC 0 Z9 0 U1 1 U2 1 PU FRONTIERS MEDIA SA PI LAUSANNE PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND SN 2234-943X J9 FRONT ONCOL JI Front. Oncol. PD FEB 20 PY 2026 VL 16 AR 1759702 DI 10.3389/fonc.2026.1759702 PG 8 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA EQ1BH UT WOS:001707049100001 PM 41800058 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Wang, JS Wang, X Li, YX Huang, CX Xu, XP Zhang, M AF Wang, Jiesong Wang, Xue Li, Yaxin Huang, Chunxia Xu, Xiaopeng Zhang, Mei TI Safety evaluation of tarlatamab: A pharmacovigilance study based on the FAERS database SO LUNG CANCER LA English DT Article DE Tarlatamab; FAERS; Imdelltra; Small cell lung cancer; Pharmacovigilance study; AMG757 AB Objectives: Tarlatamab (Imdelltra, AMG757) has been approved for extensive-stage small cell lung cancer (ESSCLC) treatment, yet post-marketing data remain limited. Existing studies lack conclusive evidence on its realworld safety profile. Materials and methods: Leveraging the FDA Adverse Event Reporting System (FAERS), this study evaluated adverse events (AEs) attributed to Tarlatamab between Q2 2024 and Q1 2025. Disproportionality analysis using reporting odds ratio (ROR) and Bayesian confidence propagation neural network (BCPNN) quantified associations between Tarlatamab and AEs. Results: Among 448 analyzed AE reports, the median time to AE onset was 5.0 days. Tarlatamab-associated AEs reports showed elevated hospitalization (21.7 %) and fatality rates (16.7 %). Significant signals emerged across 5 System Organ Classes (SOCs) and 31 Preferred Terms (PTs), including unlabeled events: atrial fibrillation (IC025: 0.77), ageusia (IC025: 3.79), mental status changes (IC025: 2.45), and unresponsiveness to stimuli (IC025: 2.22). Notable discrepancies with labeled information included dual hypertension (IC025: 0.18) and hypotension (IC025: 1.61) signals, suggesting complex blood pressure effects, and a higher mortality risk in male patients. Mild AEs correlated with reduced severe outcome risks. Conclusion: These findings offer critical insights for clinicians to identify and manage Tarlatamab-related AEs, highlighting underestimated risks and informing tailored practice. C1 [Wang, Jiesong; Wang, Xue; Li, Yaxin; Huang, Chunxia; Zhang, Mei] Shihezi Univ, Sch Med, Dept Prevent Med, Shihezi, Xinjiang, Peoples R China. [Xu, Xiaopeng] Shihezi Univ, Sch Econ & Management, Dept Accounting, Shihezi, Xinjiang, Peoples R China. C3 Shihezi University; Shihezi University RP Zhang, M (corresponding author), Shihezi Univ, 59 North 2nd Rd, Shihezi 832003, Xinjiang, Peoples R China. EM 13986520203@163.com; wx15536365713@163.com; 15514056505@163.com; huangchunxiaszh@aliyun.com; xxp_jm@shzu.edu.cn; 13150400463@163.com CR Addeo A, 2023, TRANSL LUNG CANCER R, V12, P1628, DOI 10.21037/tlcr-23-215 Ahn MJ, 2023, NEW ENGL J MED, V389, P2063, DOI 10.1056/NEJMoa2307980 [Anonymous], 2023, CANCER DISCOV, V13, P2494, DOI 10.1158/2159-8290.CD-NB2023-0081 Bate A, 2007, DRUG SAFETY, V30, P623, DOI 10.2165/00002018-200730070-00011 Bolte FJ, 2025, CLIN LUNG CANCER, V26, DOI 10.1016/j.clc.2025.03.006 Capellà D, 2002, DRUG SAFETY, V25, P7, DOI 10.2165/00002018-200225010-00002 Chavant F, 2011, BRIT J CLIN PHARMACO, V72, P898, DOI 10.1111/j.1365-2125.2011.04009.x Chiang AC, 2025, ESMO OPEN, V10, DOI [10.1016/j.esmoop.2025.104538, 10.1016/j.esmoop.2025.104538] Cortinovis DL, 2022, FRONT MED-LAUSANNE, V9, DOI 10.3389/fmed.2022.989405 Crescioli S, 2025, MABS-AUSTIN, V17, DOI 10.1080/19420862.2024.2443538 Dhillon S, 2024, DRUGS, V84, P995, DOI 10.1007/s40265-024-02070-z Kim SY, 2025, JAMA-J AM MED ASSOC, V333, P1906, DOI 10.1001/jama.2025.0560 Kong S, 2025, CLIN PHARMACOKINET, V64, P729, DOI 10.1007/s40262-025-01499-z Paz-Ares L, 2023, J CLIN ONCOL, V41, P2893, DOI 10.1200/JCO.22.02823 Sandberg L, 2020, DRUG SAFETY, V43, P999, DOI 10.1007/s40264-020-00957-w Sands JM, 2025, CANCER-AM CANCER SOC, V131, DOI 10.1002/cncr.35738 Shields MD, 2025, CANCER-AM CANCER SOC, V131, DOI 10.1002/cncr.35770 Shrestha P, 2025, MOL ONCOL, V19, P1998, DOI 10.1002/1878-0261.13696 Shu YM, 2022, CLIN EPIDEMIOL, V14, P789, DOI 10.2147/CLEP.S365513 Tang DL, 2023, TRANSL LUNG CANCER R, V12, P1355, DOI 10.21037/tlcr-23-115 Tregunno PM, 2014, DRUG SAFETY, V37, P249, DOI 10.1007/s40264-014-0146-y U.S. Food and Drug Administration, 2024, LABEL IMDELLTRA Zhou S, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1044744 Zhou Y, 2022, DRUG SAFETY, V45, P951, DOI 10.1007/s40264-022-01210-2 NR 24 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0169-5002 EI 1872-8332 J9 LUNG CANCER JI Lung Cancer PD APR PY 2026 VL 214 AR 108801 DI 10.1016/j.lungcan.2025.108801 EA FEB 2026 PG 6 WC Oncology; Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Respiratory System GA DR7VF UT WOS:001690522900001 PM 41679015 DA 2026-04-17 ER PT J AU Zhang, JY Liu, SY Li, JY Wang, YQ Ni, M Jiang, C Huang, SQ Guo, ZF AF Zhang, Jingyu Liu, Siyu Li, Jiayao Wang, Yuqian Ni, Ming Jiang, Cheng Huang, Songqun Guo, Zhifu TI Risk factors for atrial fibrillation after lung cancer surgery: a meta-analysis SO FRONTIERS IN CARDIOVASCULAR MEDICINE LA English DT Review DE atrial fibrillation; lung cancer; meta-analysis; risk factors; surgery ID NATRIURETIC PEPTIDE; PULMONARY RESECTION; THORACIC-SURGERY; QUALITY AB Background: This study aims to explore potential risk factors for atrial fibrillation (AF) following lung cancer surgery through a meta-analysis. Methods: PubMed, Embase, and the Cochrane Library databases were searched to identify all relevant studies on postoperative AF following lung cancer surgery. Inclusion criteria specified adult patients with lung cancer surgery who had clearly reported risk factors for AF. The search was conducted up to October 20, 2025. The quality of included studies was assessed using the standardized NOS scoring tool, and statistical analysis was performed using Stata 15. Data from all included studies were analyzed using a random-effects model. Results: A total of 13 articles involving 20,701 lung cancer patients were included. The meta-analysis results suggest that age >65[OR = 1.68, 95% CI (1.30, 2.16)], Postoperative high BNP [OR = 3.82, 95% CI (1.43, 10.25)], male [OR = 1.82, 95% CI (1.35, 2.45)], smoking [OR = 1.72, 95% CI (1.35, 2.21)], hypertension [OR = 1.63, 95% CI (1.08, 2.48)], patients with TNM stage II lung cancer [OR = 2.21, 95% CI (1.22, 4.01)], transfusion [OR = 3.74, 95% CI (2.28, 6.12)] were associated with an increased risk of postoperative AF after lung cancer surgery. Conclusions: This study suggesting that factors such as age >65 years, male gender, smoking, hypertension, elevated postoperative BNP levels, TNM stage II, and perioperative blood transfusion may be associated with an increased risk of postoperative AF in lung cancer patients. C1 [Zhang, Jingyu; Liu, Siyu; Wang, Yuqian; Ni, Ming; Jiang, Cheng; Huang, Songqun; Guo, Zhifu] Naval Med Univ, Changhai Hosp, Dept Cardiol, Shanghai, Peoples R China. [Li, Jiayao] Air Force Med Univ, Dept Nursing, Xian, Shaanxi, Peoples R China. C3 Naval Medical University; Air Force Medical University RP Huang, SQ; Guo, ZF (corresponding author), Naval Med Univ, Changhai Hosp, Dept Cardiol, Shanghai, Peoples R China. EM guozhifu@126.com; hsq8593@163.com CR Ahn HM, 2025, DRUG RESIST UPDATE, V79, DOI 10.1016/j.drup.2024.101198 Ajabnoor AM, 2024, CANCER-AM CANCER SOC, V130, P1316, DOI 10.1002/cncr.35152 Brecher O, 2017, ANESTH ANALG, V124, P1099, DOI 10.1213/ANE.0000000000001471 Cao CH, 2025, TRENDS PHARMACOL SCI, V46, P1041, DOI 10.1016/j.tips.2025.10.007 Cardinale D, 2007, CIRCULATION, V115, P1339, DOI 10.1161/CIRCULATIONAHA.106.647008 Cassivi SD, 2008, ANN THORAC SURG, V86, P927, DOI 10.1016/j.athoracsur.2008.04.021 Chen XY, 2025, PERIOPER MED-LONDON, V14, DOI 10.1186/s13741-025-00538-4 Ciszewski P, 2013, INTERACT CARDIOV TH, V17, P680, DOI 10.1093/icvts/ivt238 Figas-Powajbo Elzbieta, 2007, Pol Arch Med Wewn, V117, P290 Georghiou GP, 2025, MEDICINA-LITHUANIA, V61, DOI 10.3390/medicina61101815 Gong JL, 2021, J THORAC DIS, V13, DOI 10.21037/jtd-20-2740 Gong ZW, 2025, FRONT CARDIOVASC MED, V12, DOI 10.3389/fcvm.2025.1679973 Gridelli C, 2001, LUNG CANCER-J IASLC, V31, P277, DOI 10.1016/S0169-5002(00)00194-X Han Y, 2024, VASC HEALTH RISK MAN, V20, DOI 10.2147/VHRM.S463648 Hardavella G, 2024, EUR RESPIR REV, V33, DOI 10.1183/16000617.0232-2023 Imperatori A, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-4 Ishibashi H, 2020, WORLD J SURG, V44, P3952, DOI 10.1007/s00268-020-05694-w Ivanovic J, 2014, INTERACT CARDIOV TH, V18, P340, DOI 10.1093/icvts/ivt520 Iwata T, 2016, SURG TODAY, V46, P877, DOI 10.1007/s00595-015-1258-4 Joglar JA, 2024, CIRCULATION, V149, pe1, DOI 10.1161/CIR.0000000000001193 Khodjaev Md Soidjon, 2014, J Atr Fibrillation, V7, P1106, DOI 10.4022/jafib.1106 Liang LC, 2024, ANN THORAC SURG, V118, P287, DOI 10.1016/j.athoracsur.2023.12.004 Ngufor C, 2025, JACC-CLIN ELECTROPHY, V11, P977, DOI [10.1016/j.jacep.2024.12.013, 10.1016/j.jacep.2024.12.013] Nojiri T, 2015, CHEST, V148, P1285, DOI 10.1378/chest.15-0852 Nojiri T, 2010, EUR J CARDIO-THORAC, V37, P787, DOI 10.1016/j.ejcts.2009.09.043 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Page MJ, 2021, BMJ-BRIT MED J, V372, DOI [10.1016/j.rec.2021.07.010, 10.1136/bmj.n71] Peng M, 2024, MOL CANCER, V23, DOI 10.1186/s12943-024-02167-9 Schäfer M, 2025, ECHOCARDIOGR-J CARD, V42, DOI 10.1111/echo.70105 Scheggi V, 2025, INTERN EMERG MED, V20, P1097, DOI 10.1007/s11739-025-03930-6 Shaaban A, 2024, J MOL CELL CARDIOL, V194, P118, DOI 10.1016/j.yjmcc.2024.06.005 Siontis KC, 2024, LANCET NEUROL, V23, P335, DOI 10.1016/S1474-4422(24)00051-6 Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z Tohidinezhad F, 2024, RADIOTHER ONCOL, V201, DOI 10.1016/j.radonc.2024.110544 Tong CY, 2024, INT J SURG, V110, P1645, DOI 10.1097/JS9.0000000000001006 Tsaban G, 2024, EUR HEART J, V45, P379, DOI 10.1093/eurheartj/ehad726 Vedovati MC, 2018, INT J CARDIOL, V269, P152, DOI 10.1016/j.ijcard.2018.07.138 Vincenti A, 2019, J CARDIOVASC MED, V20, P745, DOI 10.2459/JCM.0000000000000864 Walls GM, 2024, RADIOTHER ONCOL, V192, DOI 10.1016/j.radonc.2024.110085 Wang SL, 2024, NICOTINE TOB RES, V26, P678, DOI 10.1093/ntr/ntad193 Wu DD, 2025, J THORAC DIS, V17, P6711, DOI [10.21037/jtd-22-1664, 10.21037/jtd-2025-533] Xiao X, 2025, CANCER LETT, V621, DOI 10.1016/j.canlet.2025.217701 Yoo SK, 2024, RADIOTHER ONCOL, V201, DOI 10.1016/j.radonc.2024.110566 Zhang LF, 2024, ASIAN J SURG, V47, P176, DOI 10.1016/j.asjsur.2023.06.108 Zhang RF, 2025, JAMA CARDIOL, V10, P1240, DOI 10.1001/jamacardio.2025.3664 NR 45 TC 0 Z9 0 U1 1 U2 1 PU FRONTIERS MEDIA SA PI LAUSANNE PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND SN 2297-055X J9 FRONT CARDIOVASC MED JI Front. Cardiovasc. Med. PD FEB 11 PY 2026 VL 13 AR 1768794 DI 10.3389/fcvm.2026.1768794 PG 13 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA EE5YU UT WOS:001699234500001 PM 41756510 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Graven-Nielsen, CS Jakobsen, A Brondum, R Milo, ML Nielsen, MS Ettrup-Christensen, A Laursen, KL Szejniuk, WM AF Graven-Nielsen, Christoffer Sander Jakobsen, Anna Brondum, Rasmus Milo, Marie Louise Nielsen, Martin Skovmos Ettrup-Christensen, Asbjorn Laursen, Kasper Lind Szejniuk, Weronika Maria TI Association of right atrium and sinoatrial node irradiation with atrial fibrillation and radiation-induced heart disease in non-small cell lung cancer SO ACTA ONCOLOGICA LA English DT Article DE Non-small-cell lung; radiotherapy; cardiac toxicity; atrial fibrillation; sinoatrial node; organs at risk; thoracic radiation; right atrium; radiation-induced heart disease ID CONTOURING ATLAS; SUBSTRUCTURES; METHODOLOGY; RISK AB Background and purpose: Radiotherapy (RT) is a key treatment for locally advanced non-small cell lung cancer (NSCLC). Tumours near the heart may result in unintended cardiac radiation exposure, increasing the risk of cardiotoxicity, such as de novo atrial fibrillation (DNAF) and de novo heart diseases (DNHD) as ischemic heart disease, heart failure, arterial hypertension or sudden cardiac death.This study investigated associations between radiation dose to cardiac substructures and risk of DNAF and DNHD. Patient/material and methods: This retrospective cohort study included patients treated between January 1, 2010, and December 31, 2020 for NSCLC with definitive RT. The heart, right atrium (RA) and sinoatrial node (SAN) were delineated. Associations between dose-volume parameters and cardiac outcomes were analysed using multivariable models adjusted for relevant confounders. Kaplan-Meier curves estimated survival; p-values < 0.05 were significant. Results: Among 273 included patients, 9.5% had AF pre-RT and 12.8% developed DNAF. DNAF was significantly associated with SAN D-max (hazard ratio [HR] = 1.01), RA D-max(HR = 1.02), RA D-mean (HR = 1.03), mean heart dose (MHD) (HR = 1.04) and heart V40Gy (HR = 1.03). One-year probabilities of DNAF and DNHD were 9.3% and 11%, increasing to 12.2% and 13.2% at 2 years. DNHD was significantly associated with SAN D-max (HR = 1.02), RA D-max (HR = 1.02), RA D-mean (HR = 1.04), MHD (HR = 1.06), heart V25Gy (HR = 1.03) and V40Gy (HR = 1.03). Interpretation: The RA and SAN may be considered organs at risk in future RT planning. Minimising cardiac radiation is important to reduce DNAF and DNHD risk. Validation in an independent cohort is warranted. C1 [Graven-Nielsen, Christoffer Sander; Jakobsen, Anna; Milo, Marie Louise; Nielsen, Martin Skovmos; Szejniuk, Weronika Maria] Aalborg Univ, Dept Clin Med, Hobrovej 18-22, DK-9000 Aalborg, Denmark. [Graven-Nielsen, Christoffer Sander; Jakobsen, Anna; Milo, Marie Louise; Nielsen, Martin Skovmos; Szejniuk, Weronika Maria] Aalborg Univ Hosp, Dept Oncol, Aalborg, Denmark. [Graven-Nielsen, Christoffer Sander; Jakobsen, Anna; Milo, Marie Louise; Nielsen, Martin Skovmos; Szejniuk, Weronika Maria] Aalborg Univ Hosp, Clin Canc Res Ctr, Aalborg, Denmark. [Brondum, Rasmus] Aalborg Univ, Ctr Clin Data Sci, Aalborg, Denmark. [Brondum, Rasmus] Aalborg Univ Hosp, Aalborg, Denmark. [Nielsen, Martin Skovmos; Laursen, Kasper Lind] Aalborg Univ Hosp, Dept Med Phys, Aalborg, Denmark. [Ettrup-Christensen, Asbjorn] Aalborg Univ Hosp, Dept Cardiol, Aalborg, Denmark. C3 Aalborg University; Aalborg University; Aalborg University Hospital; Aalborg University; Aalborg University Hospital; Aalborg University; Aalborg University; Aalborg University Hospital; Aalborg University; Aalborg University Hospital; Aalborg University; Aalborg University Hospital RP Szejniuk, WM (corresponding author), Aalborg Univ, Dept Clin Med, Hobrovej 18-22, DK-9000 Aalborg, Denmark.; Szejniuk, WM (corresponding author), Aalborg Univ Hosp, Dept Oncol, Aalborg, Denmark.; Szejniuk, WM (corresponding author), Aalborg Univ Hosp, Clin Canc Res Ctr, Aalborg, Denmark. EM wms@rn.dk RI Szejniuk, Weronika/AAF-8665-2021 OI Jakobsen Kragh, Anna/0009-0009-1812-7257; Laursen, Kasper Lind/0009-0007-6424-4687 CR Atkins KM, 2021, JAMA ONCOL, V7, P206, DOI 10.1001/jamaoncol.2020.6332 Bedi R, 2023, ARRHYTH ELECTROPHYSI, V12, DOI 10.15420/aer.2022.44 Benjamin EJ, 1998, CIRCULATION, V98, P946, DOI 10.1161/01.CIR.98.10.946 Brundel BJJM, 2022, NAT REV DIS PRIMERS, V8, DOI 10.1038/s41572-022-00347-9 CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8 Christiansen CB, 2016, EUROPACE, V18, P1689, DOI 10.1093/europace/euv401 Goldstraw P, 2007, J THORAC ONCOL, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a Goldstraw P, 2016, J THORAC ONCOL, V11, P39, DOI 10.1016/j.jtho.2015.09.009 Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208 Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010 Kashou AH, 2024, PHYSL SINOATRIAL NOD Kim KH, 2022, JAMA ONCOL, V8, P1624, DOI 10.1001/jamaoncol.2022.4202 Loap P, 2021, PRACT RADIAT ONCOL, V11, pE434, DOI 10.1016/j.prro.2021.02.002 Loap P, 2021, ACTA ONCOL, V60, P1038, DOI 10.1080/0284186X.2021.1907860 Matarese A, 2019, INT J CARDIOL, V276, P149, DOI 10.1016/j.ijcard.2018.10.075 McWilliam A, 2020, INT J RADIAT ONCOL, V108, P1073, DOI 10.1016/j.ijrobp.2020.06.031 Medicinradet, 2019, MEDICINRADETS ANBEFA MIDDLEKAUFF HR, 1991, CIRCULATION, V84, P40, DOI 10.1161/01.CIR.84.1.40 Milo MLH, 2020, RADIOTHER ONCOL, V150, P121, DOI 10.1016/j.radonc.2020.06.015 Ming X, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005051 Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710 Perman M, 2024, ACTA ONCOL, V63, P240, DOI 10.2340/1651-226X.2024.19677 Shantsila E, 2024, LANCET REG HEALTH-EU, V37, DOI 10.1016/j.lanepe.2023.100784 Staerk L, 2017, CIRC RES, V120, P1501, DOI 10.1161/CIRCRESAHA.117.309732 Tohidinezhad F, 2024, RADIOTHER ONCOL, V201, DOI 10.1016/j.radonc.2024.110544 Varian Medical Systems, ARIA Walls GM, 2024, RADIOTHER ONCOL, V192, DOI 10.1016/j.radonc.2024.110085 NR 27 TC 0 Z9 0 U1 0 U2 0 PU Medical Journal Sweden AB PI Uppsala PA Kungsngsvgen 27St, Uppsala, SWEDEN SN 0284-186X EI 1651-226X J9 ACTA ONCOL JI Acta Oncol. PD FEB 6 PY 2026 VL 65 BP 66 EP 74 DI 10.2340/1651-226X.2026.43885 PG 9 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA EX1IY UT WOS:001711832300001 PM 41645869 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Nakamura, D Hara, D Mishima, S Terada, Y Kumeda, H Miura, K Eguchi, T Hamanaka, K Shimizu, K AF Nakamura, Daisuke Hara, Daisuke Mishima, Shuji Terada, Yukihiro Kumeda, Hirotaka Miura, Kentaro Eguchi, Takashi Hamanaka, Kazutoshi Shimizu, Kimihiro TI Complex lung segmentectomy: comparative perioperative outcomes of robotic and video-assisted approaches SO GENERAL THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article; Early Access DE Robotic-assisted thoracic surgery; Video-assisted thoracoscopic surgery; Lung segmentectomy; Complex segmentectomy; Perioperative outcomes ID ATRIAL-FIBRILLATION; CANCER AB Objective Segmentectomy is the standard treatment for small peripheral non-small cell lung cancer. While video-assisted thoracoscopic surgery (VATS) and robot-assisted thoracic surgery (RATS) are widely used, evidence focusing on complex segmentectomy (CS) is limited. Therefore, we aimed to compare the perioperative outcomes of VATS and RATS for segmentectomy, focusing on CS. Methods We retrospectively reviewed 497 segmentectomies performed at Shinshu University Hospital (January 2020 and February 2025). After excluding cases of thoracotomy, benign tumors, and prior lung resection, 391 patients (268 CS) were included. Propensity score matching (PSM) generated 159 VATS-RATS pairs for all segmentectomies and 99 pairs for CS. The perioperative outcomes and complications were compared. Results For all segmentectomies, the operative time was longer with RATS (median, 219 vs. 192 min; p < 0.001), whereas blood loss, drainage duration, length of stay, reoperation, and readmission were comparable. Although not significantly different, arrhythmia incidence was less frequent in the RATS group after PSM (1.9% vs. 5.7%; p = 0.077). In CS, RATS had longer operative time (220 vs. 189 min; p < 0.001) but fewer Clavien-Dindo grade >= 2 complications (10.1% vs. 20.2%; p = 0.047) and arrhythmia incidences (1.0% vs. 7.1%; p = 0.030). No 90-day mortalities were observed. Conclusions Despite longer operative times, RATS achieved perioperative outcomes comparable to VATS and was associated with a lower incidence of postoperative arrhythmia, particularly in CS, potentially related to a reduced extent of lung resection. C1 [Nakamura, Daisuke; Hara, Daisuke; Mishima, Shuji; Terada, Yukihiro; Kumeda, Hirotaka; Miura, Kentaro; Hamanaka, Kazutoshi; Shimizu, Kimihiro] Shinshu Univ, Sch Med, Dept Surg, Div Gen Thorac Surg, 3-1-1 Asahi, Matsumoto 3908621, Japan. [Eguchi, Takashi] Univ Texas Southwestern Med Ctr, Dept Cardiovasc & Thorac Surg, Dallas, TX USA. C3 Shinshu University; University of Texas System; University of Texas Southwestern Medical Center RP Shimizu, K (corresponding author), Shinshu Univ, Sch Med, Dept Surg, Div Gen Thorac Surg, 3-1-1 Asahi, Matsumoto 3908621, Japan. EM kmshimizu@gmail.com RI Eguchi, Takashi/AAS-9215-2021 FU Shinshu University FX Open Access funding provided by Shinshu University CR Altorki N, 2023, NEW ENGL J MED, V388, P489, DOI 10.1056/NEJMoa2212083 Catelli C, 2023, EJSO-EUR J SURG ONC, V49, DOI 10.1016/j.ejso.2023.107256 Cerfolio RJ, 2011, J THORAC CARDIOV SUR, V142, P740, DOI 10.1016/j.jtcvs.2011.07.022 Eguchi T., 2023, Interact CardioVasc Thorac Surg, V37 Francis J, 2024, J CARDIOTHORAC SURG, V19, DOI 10.1186/s13019-024-03015-z Hamanaka K, 2023, CANCERS, V15, DOI 10.3390/cancers15225400 Handa Y, 2019, ANN THORAC SURG, V107, P1032, DOI 10.1016/j.athoracsur.2018.11.018 Haruki T, 2024, GEN THORAC CARDIOVAS, V72, P338, DOI 10.1007/s11748-023-01983-y Miura K, 2024, EUR J CARDIO-THORAC, V65, DOI 10.1093/ejcts/ezae061 Motono N, 2021, BMC SURG, V21, DOI 10.1186/s12893-021-01305-0 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Saji H, 2022, LANCET, V399, P1607, DOI 10.1016/S0140-6736(21)02333-3 Sakakura N, 2023, J PERS MED, V13, DOI 10.3390/jpm13020230 Zhang JY, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.853530 Zhang YJ, 2020, J THORAC CARDIOV SUR, V160, P1363, DOI 10.1016/j.jtcvs.2019.12.112 Zhou QJ, 2020, TRANSL LUNG CANCER R, V9, P306, DOI 10.21037/tlcr-20-533 NR 17 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER JAPAN KK PI TOKYO PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005, JAPAN SN 1863-6705 EI 1863-6713 J9 GEN THORAC CARDIOVAS JI Gen. Thorac. Cardiovasc. Surg. PD 2026 JAN 31 PY 2026 DI 10.1007/s11748-026-02258-y EA JAN 2026 PG 9 WC Cardiac & Cardiovascular Systems; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Surgery GA CX4YQ UT WOS:001676759300001 PM 41619147 OA hybrid DA 2026-04-17 ER PT J AU Song, YW Wang, YY Dilixiati, N Wang, DM Wang, YR Ye, Q AF Song, Yawen Wang, Yuanying Dilixiati, Nafeisa Wang, Dongmei Wang, Yiran Ye, Qiao TI Distinct comorbidity profiles and outcomes in asbestosis versus idiopathic pulmonary fibrosis: a 6-year prospective cohort study SO BMC PULMONARY MEDICINE LA English DT Article DE Asbestosis; Idiopathic pulmonary fibrosis; Comorbidity; Progressive pulmonary fibrosis; Mortality ID MALIGNANT MESOTHELIOMA; LUNG-FUNCTION; EMPHYSEMA; DIAGNOSIS; DISEASE; ASSOCIATION; EXPOSURE; UPDATE; HYPERTENSION; PREVALENCE AB Background Asbestosis and idiopathic pulmonary fibrosis (IPF) share overlapping clinical and pathological features; however, differences in comorbidities and prognostic patterns between the two diseases remain poorly defined. This study aimed to compare comorbidities and prognostic factors associated with pulmonary fibrosis progression and mortality in asbestosis and IPF. Methods This prospective cohort study included 254 patients with asbestosis and 548 patients with IPF enrolled between 2016 and 2020, with follow-up through 2022. Outcomes included progressive pulmonary fibrosis (PPF) and all-cause mortality. Multivariable Cox models were applied to identify independent risk factors associated with these outcomes. Results Patients with asbestosis exhibited a higher comorbidity burden. Specifically, they more frequently had asthma, lung cancer, pleural disease, cardiovascular/cerebrovascular disease, and connective tissue disease, whereas emphysema was more common in IPF (all P < 0.05). Over a median follow-up of 44 months (IQR 24-61), IPF patients had a higher cumulative incidence of endpoint events than those with asbestosis. In asbestosis, a usual interstitial pneumonia (UIP) pattern on HRCT predicted disease progression. In IPF, risk factors for progression included hypoxemia, forced vital capacity (FVC) < 80%, and UIP compared with probable UIP. Interestingly, combined emphysema was protective against IPF progression. Mortality in asbestosis was associated with lung cancer, pulmonary hypertension (PH), and atrial fibrillation, whereas in IPF, it was linked to FVC < 80% and PH. Conclusions Asbestosis and IPF show distinct comorbidity patterns and prognostic drivers. IPF prognosis is mainly determined by fibrosis severity, while asbestosis mortality is driven largely by asbestos-related complications. C1 [Song, Yawen; Wang, Yuanying; Dilixiati, Nafeisa; Wang, Dongmei; Wang, Yiran; Ye, Qiao] Capital Med Univ, Beijing Chao Yang Hosp, Beijing Inst Resp Med, Clin Ctr Interstitial Lung Dis, Beijing, Peoples R China. [Song, Yawen; Wang, Yiran; Ye, Qiao] Capital Med Univ, Beijing Chao Yang Hosp, Dept Occupat Med & Toxicol, Beijing, Peoples R China. C3 Capital Medical University; Capital Medical University RP Ye, Q (corresponding author), Capital Med Univ, Beijing Chao Yang Hosp, Beijing Inst Resp Med, Clin Ctr Interstitial Lung Dis, Beijing, Peoples R China.; Ye, Q (corresponding author), Capital Med Univ, Beijing Chao Yang Hosp, Dept Occupat Med & Toxicol, Beijing, Peoples R China. EM yeqiao_chaoyang@sina.com FU the Beijing High-level Public Health Talent Construction Project [DL-02-21 to QY] FX This work was supported by the Beijing High-level Public Health Talent Construction Project (DL-02-21 to QY). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. CR Allwood BW, 2021, RESPIRATION, V100, P751, DOI 10.1159/000512531 [Anonymous], 2023, EUR HEART J, V44, P1312, DOI [10.1093/eurheartj/ehad005, 10.1183/13993003.00879-2022] Berry TA, 2022, INT J ENV RES PUB HE, V19, DOI 10.3390/ijerph19074031 Bestall JC, 1999, THORAX, V54, P581, DOI 10.1136/thx.54.7.581 Bianchi C, 2007, IND HEALTH, V45, P379, DOI 10.2486/indhealth.45.379 Brims FJH, 2020, AM J RESP CRIT CARE, V201, P57, DOI 10.1164/rccm.201901-0096OC Caminati A, 2019, EUR RESPIR REV, V28, DOI 10.1183/16000617.0044-2019 Castria D, 2012, INT J IMMUNOPATH PH, V25, P681, DOI 10.1177/039463201202500314 Cen ZK, 2024, ANN MED, V56, DOI 10.1080/07853890.2024.2406439 Chang AY, 2019, LANCET PUBLIC HEALTH, V4, pE159, DOI 10.1016/S2468-2667(19)30019-2 Chen T, 2024, J CLIN MED, V13, DOI 10.3390/jcm13237170 Chen TH, 2019, JAMA ONCOL, V5, P779, DOI 10.1001/jamaoncol.2019.0446 Chen ZF, 2025, SCI REP-UK, V15, DOI 10.1038/s41598-025-91702-9 Chuang CS, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002944 Çiftci F, 2019, ADV MED SCI-POLAND, V64, P285, DOI 10.1016/j.advms.2019.03.005 Cottin V, 2022, AM J RESP CRIT CARE, V206, pE7, DOI 10.1164/rccm.202206-1041ST Desai Rupak, 2024, J Med Life, V17, P35, DOI [10.25122/jml-2023-0324, 10.25122/jml-2023-0324] Dong Z, 2022, INFECT DIS POVERTY, V11, DOI 10.1186/s40249-022-01009-4 Duckworth A, 2021, LANCET RESP MED, V9, P285, DOI 10.1016/S2213-2600(20)30364-7 Ek S, 2022, AGING CLIN EXP RES, V34, P129, DOI 10.1007/s40520-021-01896-x Fan YL, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-038874 Fisher JH, 2019, BMC PULM MED, V19, DOI 10.1186/s12890-019-0986-4 Glaspole I, 2021, RESP RES, V22, DOI 10.1186/s12931-021-01695-y Grant-Orser A, 2023, AM J RESP CRIT CARE, V208, P695, DOI 10.1164/rccm.202302-0271OC Guidotti TL, 2004, AM J RESP CRIT CARE, V170, P691, DOI 10.1164/rccm.200310-1436ST Hambly N, 2022, EUR RESPIR J, V60, DOI 10.1183/13993003.02571-2021 Hammar SP, 2015, AM J IND MED, V58, P1034, DOI 10.1002/ajim.22512 Hu XT, 2020, LAB INVEST, V100, P801, DOI 10.1038/s41374-020-0404-9 International Labour Office, 2011, INT CLASSIFICATION R, V22 Jang JH, 2024, MEDICINE, V103, DOI 10.1097/MD.0000000000038226 Kadariya Y, 2022, CARCINOGENESIS, V43, P1137, DOI 10.1093/carcin/bgac089 Kang QU, 2024, BMC PULM MED, V24, DOI 10.1186/s12890-024-02961-7 Kataoka K, 2023, SCI REP-UK, V13, DOI 10.1038/s41598-023-40508-8 Keskitalo E, 2023, J OCCUP ENVIRON MED, V65, P349, DOI 10.1097/JOM.0000000000002777 Khor YH, 2023, CHEST, V163, P345, DOI 10.1016/j.chest.2022.08.2233 Kitaguchi Y, 2014, INT J CHRONIC OBSTR, V9, P805, DOI 10.2147/COPD.S65621 KREMER R, 1972, ANN NY ACAD SCI, V200, P413, DOI 10.1111/j.1749-6632.1972.tb40206.x Kurashima K, 2010, RESPIROLOGY, V15, P843, DOI 10.1111/j.1440-1843.2010.01778.x Kwon BS, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01562-2 Lasseniusa MI, 2020, EUR CLIN RESPIR J, V7, DOI 10.1080/20018525.2019.1702618 Lettieri CJ, 2006, CHEST, V129, P746, DOI 10.1378/chest.129.3.746 Li CY, 2021, J CLIN ENDOCR METAB, V106, P3367, DOI 10.1210/clinem/dgab553 Li XH, 2021, INT IMMUNOPHARMACOL, V101, DOI 10.1016/j.intimp.2021.108327 Maher TM, 2021, RESP RES, V22, DOI 10.1186/s12931-021-01791-z Mao WM, 2017, JAMA ONCOL, V3, P562, DOI 10.1001/jamaoncol.2016.5487 Maremanda KP, 2020, FRONT PHARMACOL, V11, DOI [10.3389/fphar.2020.584637, 10.21203/rs.3.rs-35347/v1] Melo-Narváez MC, 2024, CELLS-BASEL, V13, DOI 10.3390/cells13131129 Millaire É, 2023, ANN AM THORAC SOC, V20, P328, DOI 10.1513/AnnalsATS.202206-474RL Myall KJ, 2023, CHEST, V164, P1232, DOI 10.1016/j.chest.2023.05.013 O'Hara A, 2024, CLIN APPL THROMB-HEM, V30, DOI 10.1177/10760296241253844 Pfau JC, 2024, AUTOIMMUN REV, V23, DOI 10.1016/j.autrev.2024.103603 Raghu G, 2022, AM J RESP CRIT CARE, V205, pE18, DOI 10.1164/rccm.202202-0399ST Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL Rajala Kaisa, 2017, ERJ Open Res, V3, DOI [10.1183/23120541.00084-2017, 10.1183/23120541.00084-2017] Rong Yi, 2015, Prev Med Rep, V2, P920, DOI [10.1016/j.pmedr.2015.10.005, 10.1016/j.pmedr.2015.10.005] Salisbury ML, 2017, RESP MED, V131, P229, DOI 10.1016/j.rmed.2017.08.025 Shannahan JH, 2012, TOXICOL APPL PHARM, V260, P105, DOI 10.1016/j.taap.2012.02.006 Shannahan JH, 2012, ENVIRON HEALTH PERSP, V120, P85, DOI 10.1289/ehp.1103990 Shen CH, 2015, THROMB HAEMOSTASIS, V113, P952, DOI 10.1160/TH14-10-0858 SISON RF, 1989, CHEST, V95, P831, DOI 10.1378/chest.95.4.831 Tomasini M, 1981, Am J Ind Med, V2, P167, DOI 10.1002/ajim.4700020211 Travis WD, 2013, AM J RESP CRIT CARE, V188, P733, DOI 10.1164/rccm.201308-1483ST Tsushima Y, 2024, HISTOPATHOLOGY, V85, P104, DOI 10.1111/his.15179 Wang JW, 2023, FRONT ONCOL, V13, DOI 10.3389/fonc.2023.1172496 Wang T, 2024, EUR RESPIR J, V63, DOI 10.1183/13993003.01720-2023 Wolff H, 2015, SCAND J WORK ENV HEA, V41, P5, DOI 10.5271/sjweh.3462 Xu WJ, 2023, BMJ OPEN, V13, DOI 10.1136/bmjopen-2022-068628 Yang XL, 2018, CLIN RESPIR J, V12, P1676, DOI 10.1111/crj.12728 Yen CM, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003972 Yin XQ, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aax4067 Yoon HY, 2019, RESPIROLOGY, V24, P55, DOI 10.1111/resp.13387 Yu SW, 2022, OCCUP ENVIRON MED, V79, P723, DOI 10.1136/oemed-2021-108095 NR 72 TC 0 Z9 0 U1 0 U2 0 PU BMC PI LONDON PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1471-2466 J9 BMC PULM MED JI BMC Pulm. Med. PD JAN 29 PY 2026 VL 26 IS 1 AR 94 DI 10.1186/s12890-025-04070-5 PG 10 WC Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System GA EB1RF UT WOS:001696902900005 PM 41612278 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Xu, H Zheng, YH Li, TY Mei, Y Yang, MY Chen, CS Hua, ZD Zhao, HJ AF Xu, Hao Zheng, Yanhong Li, Tianye Mei, Yao Yang, Mengya Chen, Chengshui Hua, Zhidan Zhao, Hongjun TI Association of the advanced lung cancer inflammation index and controlling nutritional status score with atrial fibrillation in COPD patients: a multicenter cross-sectional study SO FRONTIERS IN NUTRITION LA English DT Article DE advanced lung cancer inflammation index; atrial fibrillation; chronic obstructive pulmonary disease; controlling nutritional status; cross-sectional study ID RISK-FACTORS; HYPERTENSION; PREVALENCE; GUIDELINES; SERUM AB Background: The coexistence of chronic obstructive pulmonary disease (COPD) and atrial fibrillation (AF) is common and portends a poorer prognosis. This study evaluated whether the Advanced Lung Cancer Inflammation Index (ALI) and Controlling Nutritional Status (CONUT) score-composite biomarkers of inflammation and malnutrition-are associated with AF prevalence in COPD patients. Methods: This multicenter, cross-sectional study included 1,510 hospitalized patients with COPD. AF was diagnosed according to the European Society of Cardiology (ESC) guidelines, encompassing both a documented clinical history and electrocardiographic evidence. The ALI and CONUT scores were calculated from baseline data. Their independent and combined associations with AF were assessed using multivariate logistic regression, restricted cubic splines (RCS), and analyses of joint groups based on optimal cut-off values. Model performance and improvement were evaluated using the area under the receiver operating characteristic curve (AUC), net reclassification improvement (NRI), integrated discrimination improvement (IDI), and decision curve analysis (DCA). The robustness of the findings was further tested through extensive subgroup and sensitivity analyses. Results: Among 1,510 patients with COPD, 425 (28.15%) had AF. After comprehensive adjustment for confounders, both a lower ALI and a higher CONUT score were independently associated with increased odds of AF. A nonlinear, L-shaped relationship was identified for ALI (inflection point: 16.09), while CONUT exhibited a linear, positive association. Patients in the combined "low ALI and high CONUT" group had the highest odds of AF (OR = 2.420, 95% CI: 1.721-3.403). The integration of both indices into the baseline model yielded a statistically significant improvement in discriminative power (AUC: 0.842 vs. 0.835, p = 0.031), accompanied by substantial reclassification improvement (NRI = 0.273, p < 0.001). The findings remained consistent across extensive sensitivity analyses and most clinical subgroups, with a notable interaction observed specifically in patients with pulmonary hypertension. Conclusion: Lower ALI and higher CONUT scores were significantly associated with a higher prevalence of AF in COPD patients. These readily available composite indices, particularly when used in combination, may aid in identifying patients at increased odds of AF, who could be prioritized for further evaluation. C1 [Xu, Hao; Zheng, Yanhong; Yang, Mengya; Chen, Chengshui; Hua, Zhidan; Zhao, Hongjun] Wenzhou Med Univ, Zhejiang Prov Engn Res Ctr Endoscope Instruments &, Quzhou Peoples Hosp,Clin Res Ctr, Dept Pulm & Crit Care Med,Quzhou Affiliated Hosp, Quzhou, Peoples R China. [Li, Tianye; Mei, Yao; Chen, Chengshui] Wenzhou Med Univ, Affiliated Hosp 1, Dept Pulm & Crit Care Med, Key Lab Intervent Pulmonol Zhejiang Prov, Wenzhou, Peoples R China. C3 Wenzhou Medical University; Wenzhou Medical University RP Hua, ZD; Zhao, HJ (corresponding author), Wenzhou Med Univ, Zhejiang Prov Engn Res Ctr Endoscope Instruments &, Quzhou Peoples Hosp,Clin Res Ctr, Dept Pulm & Crit Care Med,Quzhou Affiliated Hosp, Quzhou, Peoples R China. EM huazhidan@wmu.edu.cn; zhaohongjun@wmu.edu.cn FU Quzhou High-level Medical and Health Talents Program [KYQD2022-26]; Quzhou science and technology plan projects [2023 K106, 2024 K081] FX The author(s) declared that financial support was received for this work and/or its publication. This study was supported by the Quzhou High-level Medical and Health Talents Program KYQD2022-26(HZhao); Quzhou science and technology plan projects 2023 K106, 2024 K081 (H Zhao). CR Adeloye D, 2022, LANCET RESP MED, V10, P447, DOI 10.1016/S2213-2600(21)00511-7 Aggarwal K, 2024, CURR CARDIOL REP, V26, P885, DOI 10.1007/s11886-024-02089-4 Agustí A, 2023, EUR RESPIR J, V61, DOI 10.1183/13993003.00239-2023 Amer Diabet Assoc Professional Pra, 2022, DIABETES CARE, V45, pS17, DOI 10.2337/dc22-S002 Amin AM, 2025, CARDIO-ONCOLOGY, V11, DOI 10.1186/s40959-024-00295-1 [Anonymous], 2023, EUR HEART J, V44, P1312, DOI [10.1093/eurheartj/ehad005, 10.1183/13993003.00879-2022] Bañuls C, 2019, NUTR J, V18, DOI 10.1186/s12937-019-0514-7 Barnes PJ, 2009, EUR RESPIR J, V33, P1165, DOI 10.1183/09031936.00128008 Bode D, 2024, NAT REV CARDIOL, V21, P682, DOI 10.1038/s41569-024-01038-6 Bosy-Westphal A, 2021, OBES REV, V22, DOI 10.1111/obr.13190 Bucci T, 2024, J AM HEART ASSOC, V13, DOI 10.1161/JAHA.123.032785 Byrne RA, 2023, EUR HEART J, V44, P3720, DOI 10.1093/eurheartj/ehad191 Carná Z, 2021, PHYSIOL RES, V70, pS511, DOI [10.33549//physiolres.934744, 10.33549/physiolres.934744] Carnagarin R, 2019, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.01058 Chien SC, 2017, BIOMARK RES, V5, DOI 10.1186/s40364-017-0111-x Di Vincenzo F, 2024, INTERN EMERG MED, V19, P275, DOI 10.1007/s11739-023-03374-w Durheim MT, 2018, HEART, V104, P1850, DOI 10.1136/heartjnl-2017-312735 Fabbri LM, 2023, LANCET RESP MED, V11, P1020, DOI 10.1016/S2213-2600(23)00261-8 Goette A, 2017, HEART RHYTHM, V14, pE3, DOI 10.1016/j.hrthm.2016.05.028 Grymonprez M, 2019, INT J CARDIOL, V276, P118, DOI 10.1016/j.ijcard.2018.09.056 Harada M, 2015, CIRC J, V79, P495, DOI 10.1253/circj.CJ-15-0138 Hawkins NM, 2024, HEART, V110, P702, DOI 10.1136/heartjnl-2023-323487 Hegazi R, 2025, REV ENDOCR METAB DIS, V26, P719, DOI 10.1007/s11154-025-09986-1 Huo QY, 2023, FRONT PHYSIOL, V14, DOI 10.3389/fphys.2023.1231448 Ignacio de Ulíbarri J., 2005, Nutr. Hosp., V20, P38 Jafri SH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-158 Jeejeebhoy KN, 2001, CLIN NUTR, V20, P181, DOI 10.1054/clnu.2001.0413 Kleindorfer DO, 2021, STROKE, V52, pE364, DOI 10.1161/STR.0000000000000375 Knuuti J, 2020, EUR HEART J, V41, P407, DOI 10.1093/eurheartj/ehz425 Koliaki C, 2019, CURR OBES REP, V8, P458, DOI 10.1007/s13679-019-00359-9 Kornej J, 2020, CIRC RES, V127, P4, DOI 10.1161/CIRCRESAHA.120.316340 Krijthe BP, 2013, INT J CARDIOL, V168, P5411, DOI 10.1016/j.ijcard.2013.08.048 Lee Y, 2018, EUR HEART J, V39, DOI [10.1093/eurheartj/ehy566.5047, 10.1093/eurheartj/ehy566.5047, DOI 10.1093/EURHEARTJ/EHY566.5047] Li T, 2024, BMC CARDIOVASC DISOR, V24, DOI 10.1186/s12872-024-04193-3 Li XT, 2023, HEART RHYTHM, V20, P1759, DOI 10.1016/j.hrthm.2023.08.026 Liao KM, 2017, INT J CHRONIC OBSTR, V12, P2523, DOI 10.2147/COPD.S143691 Liao LZ, 2020, EUR J EPIDEMIOL, V35, P113, DOI 10.1007/s10654-019-00583-6 Linz D, 2019, INT J CARDIOL, V287, P181, DOI 10.1016/j.ijcard.2018.11.091 Liu RQ, 2025, FRONT NUTR, V12, DOI 10.3389/fnut.2025.1598463 Liu T, 2007, J AM COLL CARDIOL, V49, P1642, DOI 10.1016/j.jacc.2006.12.042 Lu GM, 2024, FRONT NUTR, V11, DOI 10.3389/fnut.2024.1402328 Ma SX, 2024, WORLD J SURG ONCOL, V22, DOI 10.1186/s12957-024-03432-3 McDonagh TA, 2021, EUR HEART J, V42, P3599, DOI 10.1093/eurheartj/ehab368 Misialek JR, 2013, CIRC J, V77, P323, DOI 10.1253/circj.CJ-12-0886 Oca MMD, 2025, LANCET RESP MED, V13, DOI 10.1016/S2213-2600(24)00339-4 Pfenniger A, 2024, J MOL CELL CARDIOL, V196, P141, DOI 10.1016/j.yjmcc.2024.09.011 Rajvanshi N, 2024, INDIAN PEDIATR, V61, P781, DOI 10.1007/s13312-024-3260-7 Roubín SR, 2020, J AM COLL CARDIOL, V76, P828, DOI 10.1016/j.jacc.2020.06.058 Reilly SN, 2011, CIRCULATION, V124, P1107, DOI 10.1161/CIRCULATIONAHA.111.029223 Romiti GF, 2023, EUROPACE, V26, DOI 10.1093/europace/euae021 Rytter MJH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105017 Schols AM, 2014, EUR RESPIR J, V44, P1504, DOI 10.1183/09031936.00070914 Shu HY, 2023, CARDIOVASC DIABETOL, V22, DOI 10.1186/s12933-023-01913-5 Simati S, 2023, CURR OBES REP, V12, P75, DOI 10.1007/s13679-023-00497-1 Song MM, 2022, J CACHEXIA SARCOPENI, V13, P2504, DOI 10.1002/jcsm.13032 Sultan D, 2025, CELLS-BASEL, V14, DOI 10.3390/cells14110839 Van Gelder IC, 2024, EUR HEART J, V45, P3314, DOI 10.1093/eurheartj/ehae176 Vandenberk B, 2024, FRONT CARDIOVASC MED, V10, DOI 10.3389/fcvm.2023.1327387 von Elm E, 2007, BMJ-BRIT MED J, V335, P806 Wagner PD, 2008, EUR RESPIR J, V31, P492, DOI 10.1183/09031936.00074807 Wanamaker B, 2018, ARRHYTH ELECTROPHYSI, V7, P43, DOI 10.15420/aer.2018.3.2 Wang YL, 2021, FRONT NUTR, V8, DOI 10.3389/fnut.2021.728353 Wei SB, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1185221 Williams B, 2018, EUR HEART J, V39, P3021, DOI [10.1093/eurheartj/ehy339, 10.1016/j.im.2025.104135] Xiao XC, 2019, CHEST, V155, P918, DOI 10.1016/j.chest.2018.12.021 Yao J, 2025, FRONT NUTR, V12, DOI 10.3389/fnut.2025.1550490 Ye JL, 2022, HEART LUNG, V51, DOI 10.1016/j.hrtlng.2021.09.001 Youn JY, 2013, J MOL CELL CARDIOL, V62, P72, DOI 10.1016/j.yjmcc.2013.04.019 Zhang Y, 2023, BMC CANCER, V23, DOI 10.1186/s12885-023-10682-z NR 69 TC 0 Z9 0 U1 0 U2 0 PU FRONTIERS MEDIA SA PI LAUSANNE PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND SN 2296-861X J9 FRONT NUTR JI Front. Nutr. PD JAN 27 PY 2026 VL 13 AR 1722288 DI 10.3389/fnut.2026.1722288 PG 16 WC Nutrition & Dietetics WE Science Citation Index Expanded (SCI-EXPANDED) SC Nutrition & Dietetics GA DK6VL UT WOS:001685703800001 PM 41675387 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Li, Y Lu, XL Qin, Z Yu, JB AF Li, Ying Lu, Xuelin Qin, Zuoan Yu, Jiangbiao TI Association between advanced lung cancer inflammation index levels and ischemic stroke in patients with atrial fibrillation: a propensity score-matching analysis SO FRONTIERS IN NEUROLOGY LA English DT Article DE ALI; atrial fibrillation; ischemic stroke; inflammation; propensity score matching ID PREVENTION; GUIDELINES; RESECTION; DISEASE; BURDEN AB Introduction Inflammation is closely associated with atrial fibrillation (AF) complicated by stroke. The Advanced Lung Cancer Index (ALI) is a comprehensive indicator of inflammation; however, its relationship with AF-related stroke is unclear. Therefore, this retrospective study was conducted to explore the correlation between ALI and ischemic stroke in patients with AF.Methods Patients were divided into two groups according to the optimal cutoff value of ALI: low ALI and high ALI groups. The primary outcome was ischemic stroke in patients with AF. To ensure robustness of the findings, propensity score matching, multivariate logistic regression, inverse probability weighting models, and doubly robust analysis were performed.Results Of 2,630 eligible patients (screened: 1,879), 15.6% had a past medical history of ischemic stroke. Restricted cubic splines showed a linear dose-response relationship between baseline ALI and stroke risk (p for non-linearity = 0.46). A propensity-adjusted doubly robust analysis of 874 matched patients revealed a graded protective effect with increasing ALI quintiles: compared with the Q1 group, the Q4 and Q5 groups had odds ratios of 0.38 (95% CI 0.25-0.58) and 0.54 (0.35-0.82), respectively. Consistency across subgroups and sensitivity analysis confirmed the robustness of the results.Conclusion ALI showed a significant protective association with ischemic stroke in participants with AF, as increased ALI level was associated with lower prevalence of ischemic stroke. C1 [Li, Ying] Cent South Univ, Changde Hosp, Peoples Hosp Changde City 1, Xiangya Sch Med,Dept Sci & Educ, Changde, Peoples R China. [Lu, Xuelin] Cent South Univ, Changde Hosp, Peoples Hosp Changde City 1, Xiangya Sch Med,Dept Pathol, Changde, Peoples R China. [Qin, Zuoan; Yu, Jiangbiao] Cent South Univ, Changde Hosp, Peoples Hosp Changde City 1, Xiangya Sch Med,Dept Cardiol, Changde, Peoples R China. C3 Central South University; Central South University; Central South University RP Yu, JB (corresponding author), Cent South Univ, Changde Hosp, Peoples Hosp Changde City 1, Xiangya Sch Med,Dept Cardiol, Changde, Peoples R China. EM biaobiaoyu@hotmail.com FU Regional Joint Fund Project of the Hunan Provincial Natural Science Foundation [2025JJ70665] FX The author(s) declared that financial support was received for this work and/or its publication. The Regional Joint Fund Project of the Hunan Provincial Natural Science Foundation (2025JJ70665). CR Aarnink E, 2023, J CLIN MED, V12, DOI 10.3390/jcm12206491 AHO K, 1980, B WORLD HEALTH ORGAN, V58, P113 Austin PC, 2015, STAT MED, V34, P3661, DOI 10.1002/sim.6607 Austin PC, 2011, MULTIVAR BEHAV RES, V46, P399, DOI 10.1080/00273171.2011.568786 Azur MJ, 2011, INT J METH PSYCH RES, V20, P40, DOI 10.1002/mpr.329 Bilimoria MM, 2001, ARCH SURG-CHICAGO, V136, P528, DOI 10.1001/archsurg.136.5.528 Bitterman DS, 2019, AM J CLIN ONCOL-CANC, V42, P564, DOI 10.1097/COC.0000000000000560 Boursier-Bossy V, 2020, J Med Vasc, V45, P72, DOI [10.1016/j.jdmv.2020.01.153, 10.1016/j.jdmv.2020.01.153] Brachmann J, 2021, JACC-CLIN ELECTROPHY, V7, P594, DOI 10.1016/j.jacep.2020.11.021 Braun R, 1978, Z Arztl Fortbild (Jena), V72, P990 Cheng J, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.1047326 Cianfrocca C, 2010, INT J CARDIOL, V142, P22, DOI 10.1016/j.ijcard.2008.12.052 Cole SR, 2008, AM J EPIDEMIOL, V168, P656, DOI 10.1093/aje/kwn164 Ding MZ, 2018, CURR EPIDEMIOL REP, V5, P252, DOI 10.1007/s40471-018-0159-7 Ding WY, 2021, CARDIOVASC RES, V117, P1046, DOI 10.1093/cvr/cvaa258 Escudero-Martinez I, 2023, TRENDS CARDIOVAS MED, V33, P23, DOI 10.1016/j.tcm.2021.12.001 Fan WJ, 2021, CLIN APPL THROMB-HEM, V27, DOI 10.1177/10760296211060455 Imazio M, 2012, G ITAL CARDIOL, V13, P665, DOI 10.1714/1145.12619 Jafri SH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-158 Kotalczyk A, 2021, ARRHYTH ELECTROPHYSI, V10, P65, DOI 10.15420/aer.2021.07 Kusunoki K, 2021, COLORECTAL DIS, V23, P84, DOI 10.1111/codi.15248 Li L, 2013, INT J BIOSTAT, V9, P215, DOI 10.1515/ijb-2012-0030 Li QX, 2022, FRONT CARDIOVASC MED, V9, DOI 10.3389/fcvm.2022.811790 Li YY, 2020, J INT MED RES, V48, DOI 10.1177/0300060520921671 Lin KB, 2022, EUR J MED RES, V27, DOI 10.1186/s40001-022-00733-9 Lippi G, 2021, INT J STROKE, V16, P217, DOI 10.1177/1747493019897870 Lu M, 2022, FRONT NEUROL, V13, DOI 10.3389/fneur.2022.1029010 Martins GL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093226 Migdady I, 2021, SEMIN NEUROL, V41, P348, DOI 10.1055/s-0041-1726332 Niskala A, 2024, BRIT J PHARMACOL, V181, P4939, DOI 10.1111/bph.16470 Ruopp MD, 2008, BIOMETRICAL J, V50, P419, DOI 10.1002/bimj.200710415 Sato T, 2003, EPIDEMIOLOGY, V14, P680, DOI 10.1097/01.EDE.0000081989.82616.7d Seiffge DJ, 2024, LANCET NEUROL, V23, P404, DOI 10.1016/S1474-4422(24)00037-1 Shang LX, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.682538 Van Gelder IC, 2024, EUR HEART J, V45, P3314, DOI 10.1093/eurheartj/ehae176 Vitolo M, 2021, CARDIOVASC RES, V117, P1420, DOI 10.1093/cvr/cvaa330 von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013 Wang Q, 2013, BRIT J CANCER, V109, P573, DOI 10.1038/bjc.2013.352 Wen BJ, 2022, SCI ADV, V8, DOI 10.1126/sciadv.abj6779 Wong CX, 2024, NAT REV CARDIOL, V21, P841, DOI 10.1038/s41569-024-01091-1 Wu S, 2021, ANGIOLOGY, V72, P819, DOI 10.1177/00033197211000495 Zhou XX, 2020, FRONT CARDIOVASC MED, V7, DOI 10.3389/fcvm.2020.00062 Zou RJ, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1790-x NR 43 TC 0 Z9 0 U1 0 U2 0 PU FRONTIERS MEDIA SA PI LAUSANNE PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND SN 1664-2295 J9 FRONT NEUROL JI Front. Neurol. PD JAN 7 PY 2026 VL 16 AR 1652042 DI 10.3389/fneur.2025.1652042 PG 11 WC Clinical Neurology; Neurosciences WE Science Citation Index Expanded (SCI-EXPANDED) SC Neurosciences & Neurology GA CH0YG UT WOS:001665626200001 PM 41573398 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Yip, R Jirapatnakul, A Avila, R Gutierrez, JG Naghavi, M Yankelevitz, DF Henschke, CI AF Yip, Rowena Jirapatnakul, Artit Avila, Ricardo Gutierrez, Jessica Gonzalez Naghavi, Morteza Yankelevitz, David F. Henschke, Claudia I. TI Artificial Intelligence in Low-Dose Computed Tomography Screening of the Chest SO JOURNAL OF THORACIC IMAGING LA English DT Article DE artificial intelligence; low-dose computed tomography; comprehensive health check; screening ID CORONARY-ARTERY CALCIFICATION; OBSTRUCTIVE PULMONARY-DISEASE; OUTPERFORMS NT-PROBNP; ATRIAL-FIBRILLATION; HEPATIC STEATOSIS; CT SCANS; LUNG; EMPHYSEMA; PROGRESSION; SMOKERS AB The integration of artificial intelligence (AI) with low-dose computed tomography (LDCT) has the potential to transform lung cancer screening into a comprehensive approach to early detection of multiple diseases. Building on over 3 decades of research and global implementation by the International Early Lung Cancer Action Program (I-ELCAP), this paper reviews the development and clinical integration of AI for interpreting LDCT scans. We describe the historical milestones in AI-assisted lung nodule detection, emphysema quantification, and cardiovascular risk assessment using visual and quantitative imaging features. We also discuss challenges related to image acquisition variability, ground truth curation, and clinical integration, with a particular focus on the design and implementation of the open-source IELCAP-AIRS system and the ScreeningPLUS infrastructure, which enable AI training, validation, and deployment in real-world screening environments. AI algorithms for rule-out decisions, nodule tracking, and disease quantification have the potential to reduce radiologist workload and advance precision screening. With the ability to evaluate multiple diseases from a single LDCT scan, AI-enabled screening offers a powerful, scalable tool for improving population health. Ongoing collaboration, standardized protocols, and large annotated datasets are critical to advancing the future of integrated, AI-driven preventive care. C1 [Yip, Rowena; Jirapatnakul, Artit; Yankelevitz, David F.; Henschke, Claudia I.] Icahn Sch Med Mt Sinai, Dept Diagnost Mol & Intervent Radiol, New York, NY USA. [Avila, Ricardo] Paraxial Technol, Clifton Pk, NY USA. [Gutierrez, Jessica Gonzalez] Arnau Vilanova & Santa Maria Univ Hosp, IRBLleida, Translat Res Resp Med, Lleida, Spain. [Gutierrez, Jessica Gonzalez] Carlos III Hlth Inst, CIBER Resp Dis CIBERES, Madrid, Spain. [Naghavi, Morteza] HeartLung AI, Houston, TX USA. C3 Icahn School of Medicine at Mount Sinai; CIBER - Centro de Investigacion Biomedica en Red; CIBERES RP Henschke, CI (corresponding author), Icahn Sch Med Mt Sinai, One Gustave L Levy Pl, Box 1234, New York, NY 10029 USA. EM rowena.yip@mountsinai.org; artit.jirapatnakul@mountsinai.org; rick.avila@paraxialtech.com; jgonzalezgutierrez88@gmail.com; morteza.naghavi@americanhearttechnologies.com; david.yankelevitz@mountsinai.org; claudia.henschke@mountsinai.org RI Yip, Rowena/KIC-7581-2024; Jirapatnakul, Artit/J-4044-2014 CR Air Force Research Laboratory, About the Information Directorate (RI) American College of Radiology, Lung CT Screening Reporting & Data System (Lung-RADS) v2022 [Anonymous], 1994, Bus Week Ash SY, 2021, RADIOLOGY, V299, P222, DOI 10.1148/radiol.2021203531 Ashizawa K, 2025, JPN J RADIOL, V43, P333, DOI 10.1007/s11604-024-01695-0 Avila RS, 2023, QUANT IMAG MED SURG, V13, P6193, DOI 10.21037/qims-22-320 Baraghoshi D, 2023, RADIOLOGY, V307, DOI 10.1148/radiol.222786 Beyer F, 2007, EUR RADIOL, V17, P2941, DOI 10.1007/s00330-007-0667-1 Bild DE, 2002, AM J EPIDEMIOL, V156, P871, DOI 10.1093/aje/kwf113 Bristol Myers Squibb Foundation & Veterans Affairs, 2017, VA Partnership to Increase Access to Lung Screening (VA-PALS) Bureau of Alcohol Tobacco Firearms and Explosives, 2025, National Integrated Ballistic Information Network (NIBIN) Callister M E J, 2015, Thorax, V70 Suppl 2, pii1, DOI 10.1136/thoraxjnl-2015-207168 Cao K, 2023, NAT MED, DOI 10.1038/s41591-023-02640-w Chen PT, 2023, RADIOLOGY, V306, P172, DOI 10.1148/radiol.220152 Chen XM, 2020, CLIN IMAG, V60, P237, DOI 10.1016/j.clinimag.2019.12.009 Chen XM, 2017, EUR J RADIOL, V94, P174, DOI 10.1016/j.ejrad.2017.06.024 Coxson HO, 2013, LANCET RESP MED, V1, P129, DOI 10.1016/S2213-2600(13)70006-7 Cueff C, 2011, HEART, V97, P721, DOI 10.1136/hrt.2010.198853 DAWBER TR, 1958, NUTR REV, V16, P1, DOI 10.1111/j.1753-4887.1958.tb00605.x El Kaddouri B, 2021, RADIOLOGY, V298, P441, DOI 10.1148/radiol.2020200563 Estépar RSJ, 2025, AM J RESP CRIT CARE, V211, P709, DOI 10.1164/rccm.202410-2012SO Ettinger DS, 2022, J NATL COMPR CANC NE, V20, P497, DOI 10.6004/jnccn.2022.0025 Fuhrman JD, 2019, MED PHYS, V46, pE122 Fuhrman JD., 2020, SPIE, V11314, p113140A Fuhrman JD., 2019, SPIE, V10950, P1095039 Gould MK, 2013, CHEST, V143, pE93, DOI 10.1378/chest.12-2351 Guo Z, 2020, RADIOLOGY, V294, P89, DOI 10.1148/radiol.2019190467 Gutierrez J., 2025, Emphysema on baseline low-dose CT lung cancer screening predicts death from chronic obstructive pulmonary disease and cardiovascular disease up to 25 years later Gutierrez JG, 2025, RADIOLOGY, V316, DOI 10.1148/radiol.250949 Han MLK, 2013, LANCET RESP MED, V1, P43, DOI 10.1016/S2213-2600(12)70044-9 Hecht HS, 2014, EUR HEART J, V35, P2792, DOI 10.1093/eurheartj/ehu296 Henschke C., 1995, Neural networks for the analysis of small pulmonary nodules Society of Thoracic Radiology Henschke C., 1996, Neural networks for the analysis of small pulmonary nodules American Roentgen Ray Society Scientific Session Henschke CI, 1996, RADIOL CLIN N AM, V34, P21 Henschke CI, 1997, CLIN IMAG, V21, P390, DOI 10.1016/S0899-7071(97)81731-7 HENSCHKE CI, 1994, CLIN IMAG, V18, P16, DOI 10.1016/0899-7071(94)90140-6 Henschke CI, 1999, LANCET, V354, P99, DOI 10.1016/S0140-6736(99)06093-6 Henschke CI, 2006, NEW ENGL J MED, V355, P1763, DOI 10.1056/NEJMoa060476 Henschke CI, 2023, RADIOLOGY, V309, DOI 10.1148/radiol.231988 Henschke CI, 2021, TRANSL LUNG CANCER R, V10, P1064, DOI 10.21037/tlcr-20-761 Henschke CI, 2021, J THORAC IMAG, V36, P6, DOI 10.1097/RTI.0000000000000538 Henschke CI, 2016, J MED IMAGING, V3, DOI 10.1117/1.JMI.3.3.035505 Hoesein FAAM, 2011, THORAX, V66, P782, DOI 10.1136/thx.2010.145995 Hsu HH, 2021, CLIN RADIOL, V76, DOI 10.1016/j.crad.2021.04.006 Htwe Y, 2015, CLIN IMAG, V39, P799, DOI 10.1016/j.clinimag.2015.04.006 International Early Lung and Cardiac Action Program, About us International Early Lung and Cardiac Action Program Automated Image Reading System (I-ELCAP AIRS), Automated Image Reading System (I-ELCAP AIRS) International Early Lung Cancer Action Program, INT C SCREEN LUNG CA International Early Lung Cancer Action Program Investigators, INT C SCREENING LUNG International Early Lung Cancer Action Program Investigators, 2023, International Early Lung Cancer Action Program (IELCAP): Screening Protocol Jirapatnakul A, 2020, EUR J RADIOL, V122, DOI 10.1016/j.ejrad.2019.108723 Kaucic RA, 2003, INT CONGR SER, V1256, P990, DOI 10.1016/S0531-5131(03)00446-1 Kenner B, 2021, PANCREAS, V50, P251, DOI 10.1097/MPA.0000000000001762 Kim DW, 2021, EUR RADIOL, V31, P7047, DOI 10.1007/s00330-021-07803-2 Koos R, 2006, RADIOLOGY, V241, P76, DOI 10.1148/radiol.2411051163 Korfiatis P, 2023, GASTROENTEROLOGY, V165, P1533, DOI 10.1053/j.gastro.2023.08.034 Kronmal RA, 2007, CIRCULATION, V115, P2722, DOI 10.1161/CIRCULATIONAHA.106.674143 Lancaster HL, 2025, EUR J CANCER, V220, DOI 10.1016/j.ejca.2025.115323 Lee CI, 2010, RADIOLOGY, V257, P313, DOI 10.1148/radiol.10101437 Liu S., 2015, SPIE, V9414, P941403 Liu S, 2017, J MED IMAGING, V4, DOI 10.1117/1.JMI.4.4.041308 Liu S, 2015, PROC SPIE, V9414, DOI 10.1117/12.2082410 Lloyd-Jones DM, 2004, CIRCULATION, V110, P1042, DOI 10.1161/01.CIR.0000140263.20897.42 Lung Cancer Policy Network, Interactive map of lung cancer screening Lynch DA, 2015, RADIOLOGY, V277, P192, DOI 10.1148/radiol.2015141579 Magudia K, 2021, RADIOLOGY, V298, P319, DOI 10.1148/radiol.2020201640 Marr B., 2024, Forbes McCulloch C., RADIOLOGICAL SOC N A McCulloch Warren S., 1943, BULL MATH BIOPHYS, V5, P115, DOI 10.1007/BF02478259 Mulshine JL, 2025, EUR J CANCER, V220, DOI [10.1016/j.ejca.2025.115345, 10.1016/j.ejca.2025.115345] Mulshine JL, 2025, EUR J CANCER, V218, DOI 10.1016/j.ejca.2025.115264 Mulshine JL, 2020, JCO CLIN CANCER INFO, V4, P89, DOI 10.1200/CCI.19.00099 Mulshine JL, 2015, J AM COLL RADIOL, V12, P390, DOI 10.1016/j.jacr.2014.12.003 Naghavi M, 2024, JACC-ADV, V3, DOI 10.1016/j.jacadv.2024.101300 Naghavi M, 2024, NPJ DIGIT MED, V7, DOI 10.1038/s41746-024-01308-0 Naghavi M, 2024, J CARDIOVASC COMPUT, V18, P383, DOI 10.1016/j.jcct.2024.04.005 Naghavi M, 2024, J CARDIOVASC COMPUT, V18, P392, DOI 10.1016/j.jcct.2024.04.006 Naghavi Morteza, 2024, Res Sq, DOI 10.21203/rs.3.rs-4433105/v1 Naghavi M, 2023, EUR J RADIOL OPEN, V10, DOI 10.1016/j.ejro.2023.100492 Naghavi MRAAK., 2025, AI-powered coronary artery calcium scans (AI-CAC) cardiac volumetry predicts heart failure comparably to cardiac MRI New York Early Cancer Action Inv, 2007, RADIOLOGY, V243, P239, DOI 10.1148/radiol.2431060467 Oelsner EC, 2014, ANN INTERN MED, V161, P863, DOI 10.7326/M13-2570 Oudkerk M, 2017, LANCET ONCOL, V18, pE754, DOI [10.1016/s1470-2045(17)30861-6, 10.1016/S1470-2045(17)30861-6] Pickhardt PJ, 2021, KOREAN J RADIOL, V22, P1934, DOI 10.3348/kjr.2021.0775 Pompe E, 2020, RADIOLOGY, V295, P218, DOI 10.1148/radiol.2020191429 Rainey T., 1994, Analysis of pulmonary nodules Rainey T., 1994, Analysis of pulmonary nodules Rasmussen Robert, 2022, Am Soc Clin Oncol Educ Book, V42, P1, DOI [10.1200/edbk_350862, 10.1200/EDBK_350862] Regan EA, 2015, JAMA INTERN MED, V175, P1539, DOI 10.1001/jamainternmed.2015.2735 Rosenblatt F., 1962, PRINCIPLES NEURODYNA, DOI DOI 10.1001/ARCHPSYC.1962.01720030064010 Rosenhek R, 2000, NEW ENGL J MED, V343, P611, DOI 10.1056/NEJM200008313430903 ScreeningPLUS, About us Shaker SB, 2004, ACTA RADIOL, V45, P417, DOI 10.1080/02841850410005525 Shemesh J, 2006, CLIN IMAG, V30, P181, DOI 10.1016/j.clinimag.2005.11.002 Shemesh J, 2010, RADIOLOGY, V257, P541, DOI 10.1148/radiol.10100383 Shemesh JYR., IN PRESS Starekova J, 2021, RADIOLOGY, V301, P250, DOI 10.1148/radiol.2021204288 Steiger D, 2020, CLIN IMAG, V63, P16, DOI 10.1016/j.clinimag.2019.11.011 Suzuki K, 2005, ACAD RADIOL, V12, P191, DOI 10.1016/j.acra.2004.11.017 Tanabe N, 2011, AM J RESP CRIT CARE, V183, P1653, DOI 10.1164/rccm.201009-1535OC Weston AD, 2019, RADIOLOGY, V290, P669, DOI 10.1148/radiol.2018181432 Willmann JK, 2002, RADIOLOGY, V225, P120, DOI 10.1148/radiol.2251011703 Wisnivesky J., 2009, Radiological Society of North America Scientific Session World Health Organization, 2024, World health statistics 2024: monitoring health for the SDGs, sustainable development goals Xie YT, 2014, PROC SPIE, V9035, DOI 10.1117/12.2043840 Xiong Y, 2025, NAT COMMUN, V16, DOI 10.1038/s41467-025-56784-z Yankelevitz D., 1998, Radiology, V209, P17 Yankelevitz DF, 1999, RADIOLOGY, V212, P561, DOI 10.1148/radiology.212.2.r99au33561 Yip R., 2025, Enabling global, comprehensive, and scalable LDCT screening: the ELCAP Management System for Preventive Medicine Yip R, 2025, EUR J CANCER, V225, DOI 10.1016/j.ejca.2025.115570 Yip R, 2021, TRANSL LUNG CANCER R, V10, P1141, DOI 10.21037/tlcr-20-746 Zhang P, 2024, HEPATOL INT, V18, P422, DOI 10.1007/s12072-023-10630-w Zhou Qinghua, 2018, Zhongguo Fei Ai Za Zhi, V21, P67, DOI 10.3779/j.issn.1009-3419.2018.02.01 Zhu YQ, 2024, CLIN IMAG, V109, DOI 10.1016/j.clinimag.2024.110115 Zhu YQ, 2020, EUR RADIOL, V30, P2658, DOI 10.1007/s00330-019-06614-w Zhu YQ, 2020, EUR RADIOL, V30, P6847, DOI 10.1007/s00330-020-07049-4 Zulueta JJ, 2012, CHEST, V141, P1216, DOI 10.1378/chest.11-0101 NR 117 TC 1 Z9 1 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0883-5993 EI 1536-0237 J9 J THORAC IMAG JI J. Thorac. Imaging PD JAN PY 2026 VL 41 IS 1 AR e0854 DI 10.1097/RTI.0000000000000854 PG 10 WC Radiology, Nuclear Medicine & Medical Imaging WE Science Citation Index Expanded (SCI-EXPANDED) SC Radiology, Nuclear Medicine & Medical Imaging GA AB0EA UT WOS:001643861700003 DA 2026-04-17 ER PT J AU Wang, YX Xie, SY Liu, JY Wang, H Yu, JG Li, WY Guan, AK Xu, S Cui, Y Tan, WF AF Wang, Yaxuan Xie, Shiyang Liu, Jiayun Wang, He Yu, Jiangang Li, Wenya Guan, Aika Xu, Shun Cui, Yong Tan, Wenfei TI Predicting postoperative complications after pneumonectomy using machine learning: a 10-year study SO ANNALS OF MEDICINE LA English DT Article DE Lung cancer, nomogram; machne learning; postoperative cardiovascular and neurological complications; thoracic surgery; video-assisted thoracoscopic surgery ID PATIENT-CONTROLLED-ANALGESIA; ATRIAL-FIBRILLATION; RISK-FACTORS; THORACIC-SURGERY; MANAGEMENT; MORTALITY; OUTCOMES; STROKE AB BackgroundReducing postoperative cardiovascular and neurological complications (PCNC) during thoracic surgery is the key to improving postoperative survival.ObjectiveWe aimed to investigate independent predictors of PCNC, develop machine learning models, and construct a predictive nomogram for PCNC in patients undergoing thoracic surgery for lung cancer.MethodsThis study used data from a previous retrospective study of 16,368 patients with lung cancer (training set: 11,458; validation set: 4,910) with American Standards Association physical statuses I-IV who underwent surgery. Postoperative information was collected from electronic medical records to help build models based on cause-and-effect and statistical data, potentially revealing hidden dependencies between factors and diseases in a big data environment. The optimal model was analyzed and filtered using multiple machine-learning models (Logistic regression, eXtreme Gradient Boosting, Random forest, Light Gradient Boosting Machine and Na & iuml;ve Bayes). A predictive nomogram was built and receiver operating characteristics were used to assess the validity of the model. The discriminative power and clinical validity were assessed using calibration and decision-making curve analyses.ResultsMultivariate logistic regression analysis revealed that age, surgery duration, intraoperative intercostal nerve block, postoperative patient-controlled analgesia, bronchial blocker use and sufentanil use were independent predictors of PCNC. Random forest was identified as the optimal model with an area under the curve of 0.898 in the training set and 0.752 in the validation set, confirming the excellent prediction accuracy of the nomogram. All the net benefits of the five machine-learning models in the training and validation sets demonstrated excellent clinical applicability, and the calibration curves showed good agreement between the predicted and observed risks.ConclusionThe combination of machine-learning models and nomograms may contribute to the early prediction and reduction in the incidence of PCNC. C1 [Wang, Yaxuan; Liu, Jiayun; Wang, He; Yu, Jiangang; Cui, Yong; Tan, Wenfei] China Med Univ, Hosp 1, Dept Anesthesiol, Nanjingbei St 155, Shenyang 110001, Peoples R China. [Xie, Shiyang] China Med Univ, Hosp 1, Dept Radiat Oncol, Shenyang, Peoples R China. [Li, Wenya; Xu, Shun] China Med Univ, Hosp 1, Dept Thorac Surg, Shenyang, Peoples R China. [Guan, Aika] Queen University, Kingston, ON, Canada. C3 China Medical University; China Medical University; China Medical University RP Tan, WF (corresponding author), China Med Univ, Hosp 1, Dept Anesthesiol, Nanjingbei St 155, Shenyang 110001, Peoples R China. EM winfieldtan@hotmail.com RI tan, wen-fei/F-9114-2010 FU National Natural Science Foundation of China [82171187]; Wu Jieping Foundation [320.6750.2024-05-14]; Natural Science Foundation of Liaoning Province of China [2022-MS-191, 2022-MS-222] FX This work was supported by a grant from the National Natural Science Foundation of China (No. 82171187 to T.W.), the Wu Jieping Foundation (No.320.6750.2024-05-14 to T.W.), the Natural Science Foundation of Liaoning Province of China (No. 2022-MS-191 to S.X.) and the Natural Science Foundation of Liaoning Province of China (No. 2022-MS-222 to Y.W.). CR Alban J, 2022, SEMIN ONCOL, V49, P261, DOI 10.1053/j.seminoncol.2022.06.012 Bateman BT, 2009, ANESTHESIOLOGY, V110, P231, DOI 10.1097/ALN.0b013e318194b5ff Bessissow A, 2015, J THROMB HAEMOST, V13, pS304, DOI 10.1111/jth.12974 Bhave PD, 2012, AM HEART J, V164, P918, DOI 10.1016/j.ahj.2012.09.004 Bijlsma S, 2006, ANAL CHEM, V78, P567, DOI 10.1021/ac051495j Bugada D, 2021, MINERVA ANESTESIOL, V87, P230, DOI 10.23736/S0375-9393.20.14515-2 Clayton-Smith A, 2015, J CARDIOTHOR VASC AN, V29, P955, DOI 10.1053/j.jvca.2014.11.017 Cozowicz C, 2017, PAIN, V158, P2422, DOI 10.1097/j.pain.0000000000001047 D'Amico F, 2022, J CLIN MED, V11, DOI 10.3390/jcm11236955 Danelich IM, 2014, J AM COLL SURGEONS, V219, P831, DOI 10.1016/j.jamcollsurg.2014.02.038 Frauenknecht J, 2019, ANAESTHESIA, V74, P651, DOI 10.1111/anae.14582 Frendl G, 2014, J THORAC CARDIOV SUR, V148, pE153, DOI 10.1016/j.jtcvs.2014.06.036 Giambrone GP, 2016, J THORAC CARDIOV SUR, V151, P982, DOI 10.1016/j.jtcvs.2015.11.057 Grass JA, 2005, ANESTH ANALG, V101, pS44, DOI 10.1213/01.ANE.0000177102.11682.20 Heise D, 2021, SURG INNOV, V28, P714, DOI 10.1177/1553350621991223 Hernesniemi JA, 2019, ANN MED, V51, P156, DOI 10.1080/07853890.2019.1596302 Hu XY, 2022, CNS NEUROSCI THER, V28, P608, DOI 10.1111/cns.13758 Kadomatsu Y, 2024, SURG TODAY, V54, P1482, DOI 10.1007/s00595-024-02878-y Kissin I, 2009, ANESTH ANALG, V108, P1945, DOI 10.1213/ane.0b013e3181a1a481 Knoll H, 2006, ANESTHESIOLOGY, V105, P471, DOI 10.1097/00000542-200609000-00009 Li WL, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.797103 Li WL, 2021, BMC MUSCULOSKEL DIS, V22, DOI 10.1186/s12891-021-04414-2 Lim E, 2022, HEALTH TECHNOL ASSES, V26, DOI 10.3310/THBQ1793 Lin MH, 2019, STROKE, V50, P1364, DOI 10.1161/STROKEAHA.118.023921 Mashour GA, 2011, ANESTHESIOLOGY, V114, P1289, DOI 10.1097/ALN.0b013e318216e7f4 Massoth C, 2021, J CLIN ANESTH, V75, DOI 10.1016/j.jclinane.2021.110437 Mathis MR, 2018, ANESTHESIOLOGY, V129, P619, DOI 10.1097/ALN.0000000000002384 Momeni M, 2006, DRUGS, V66, P2321, DOI 10.2165/00003495-200666180-00005 Ramamoorthy V, 2023, SCI REP-UK, V13, DOI 10.1038/s41598-023-29632-7 Ren YF, 2022, JAMA NETW OPEN, V5, DOI 10.1001/jamanetworkopen.2022.11973 Riddersholm S, 2019, STROKE, V50, P1052, DOI 10.1161/STROKEAHA.118.024496 Salati M, 2021, WORLD J SURG, V45, P1585, DOI 10.1007/s00268-020-05948-7 Salicath JH, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010434.pub2 Shanthanna H, 2021, ANESTHESIOLOGY, V134, P645, DOI 10.1097/ALN.0000000000003572 Smilowitz NR, 2020, JAMA-J AM MED ASSOC, V324, P279, DOI 10.1001/jama.2020.7840 Smilowitz NR, 2017, EUR HEART J, V38, P2409, DOI 10.1093/eurheartj/ehx313 Smilowitz NR, 2017, JAMA CARDIOL, V2, P181, DOI 10.1001/jamacardio.2016.4792 Surace P, 2019, J ARTHROPLASTY, V34, P426, DOI 10.1016/j.arth.2018.11.015 Szczepaniak A, 2022, EUR J PHARMACOL, V933, DOI 10.1016/j.ejphar.2022.175214 Gómez-Hernández MT, 2022, EUR J CARDIO-THORAC, V62, DOI 10.1093/ejcts/ezac503 van Boekel RLM, 2019, ANN SURG, V269, P856, DOI 10.1097/SLA.0000000000002583 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Vlisides P, 2016, CAN J ANESTH, V63, P193, DOI 10.1007/s12630-015-0494-9 Wang QC, 2022, BMC PHARMACOL TOXICO, V23, DOI 10.1186/s40360-022-00632-z Wilcox T, 2021, CAN J CARDIOL, V37, P224, DOI 10.1016/j.cjca.2020.04.034 Ziemann-Gimmel P, 2014, BRIT J ANAESTH, V112, P906, DOI 10.1093/bja/aet551 NR 46 TC 2 Z9 2 U1 2 U2 11 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 0785-3890 EI 1365-2060 J9 ANN MED JI Ann. Med. PD DEC 31 PY 2025 VL 57 IS 1 AR 2487636 DI 10.1080/07853890.2025.2487636 PG 10 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA 1AZ1X UT WOS:001460721800001 PM 40193241 OA Green Submitted, Green Accepted, gold DA 2026-04-17 ER PT J AU Lin, CY Su, PL Kuo, CW Tsai, IL Liu, TH Yang, J Lin, CC Lin, SH AF Lin, Chien-Yu Su, Po-Lan Kuo, Chin-Wei Tsai, I-Lin Liu, Ting-Hui Yang, Jen Lin, Chien-Chung Lin, Sheng-Hsiang TI Increased Cardiovascular Risk With Lorlatinib in Patients With ALK-Mutated Lung Cancer: A Real-World Comparative Study SO JOURNAL OF THE AMERICAN HEART ASSOCIATION LA English DT Article DE ALK rearrangement; cancer therapy-related cardiovascular diseases; cardio-oncology; lorlatinib; non-small cell lung cancer ID CLINICAL-PRACTICE; SINGLE-ARM; OPEN-LABEL; CRIZOTINIB; ROS1; MULTICENTER; INHIBITION; MORTALITY AB Background The discovery of driver mutations has transformed advanced non-small cell lung cancer treatment, with ALK (anaplastic lymphoma kinase)-rearranged patients achieving longest overall survival. However, the risk of cancer therapy-related cardiovascular diseases (CTRCVDs) is underrecognized, particularly comparing second-generation ALK-tyrosine kinase inhibitors alectinib and brigatinib to the third-generation tyrosine kinase inhibitor lorlatinib, which offers the longest progression-free survival. We aimed to compare CTRCVDs risks among patients with lung cancer receiving ALK-tyrosine kinase inhibitor, assess incidence trends, and identify clinical risk factors associated with ALK-tyrosine kinase inhibitor-related CTRCVDs. Methods This retrospective cohort study of 946 848 adults with lung cancer (2010-2024) using TriNetX compared CTRCVDs risk in ALK-mutated patients treated with lorlatinib versus brigatinib/alectinib. After excluding ROS1-mutated cases and 1:1 propensity score matching, 744 patients per group were analyzed. CTRCVDs, defined as myocardial infarction, stroke, arterial embolism, or heart failure, were evaluated with Kaplan-Meier analysis and Cox proportional hazards models over 2 years. Results Lorlatinib treatment was associated with a significantly increased risk of CTRCVDs (hazard ratio [HR], 3.00 [95% CI, 1.65-5.45]; P<0.001). Incidence rose from 2.2% at 6 months to 6.6% at 3 years, versus 1.7% and 2.2% in the brigatinib/alectinib cohort. Multivariable analysis identified advanced age (HR, 1.02 [95% CI, 1.00-1.04]; P=0.04), atrial fibrillation/flutter history (HR, 2.39 [95% CI, 1.13-5.07]; P=0.002), and lorlatinib use (HR, 2.42 [95% CI, 1.57-3.72]; P<0.001) as independent predictors. Conclusion These findings underscore the importance of routine cardiovascular monitoring, particularly in older patients and those with atrial arrhythmias. C1 [Lin, Chien-Yu; Kuo, Chin-Wei; Lin, Chien-Chung; Lin, Sheng-Hsiang] Natl Cheng Kung Univ, Inst Clin Med, Coll Med, 138 Sheng Li Rd, Tainan, Taiwan. [Lin, Chien-Yu; Su, Po-Lan; Kuo, Chin-Wei; Tsai, I-Lin; Lin, Chien-Chung] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med, Tainan, Taiwan. [Su, Po-Lan] Ohio State Univ, Comprehens Canc Ctr, Dept Internal Med, Div Med Oncol, Columbus, OH USA. [Liu, Ting-Hui] Chi Mei Med Ctr, Dept Psychiat, Tainan, Taiwan. [Yang, Jen] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Med Imaging, Tainan, Taiwan. [Lin, Chien-Chung] Natl Cheng Kung Univ, Inst Mol Med, Coll Med, Tainan 701, Taiwan. [Lin, Chien-Chung] Tainan Hosp, Minist Hlth & Welf, Tainan 701, Taiwan. [Lin, Sheng-Hsiang] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Biostat Consulting Ctr, Tainan, Taiwan. [Lin, Sheng-Hsiang] Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, Tainan, Taiwan. C3 National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Chi Mei Hospital; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University RP Lin, CC; Lin, SH (corresponding author), Natl Cheng Kung Univ, Inst Clin Med, Coll Med, 138 Sheng Li Rd, Tainan, Taiwan.; Lin, CC (corresponding author), Natl Cheng Kung Univ, Inst Mol Med, Coll Med, Tainan 701, Taiwan.; Lin, CC (corresponding author), Tainan Hosp, Minist Hlth & Welf, Tainan 701, Taiwan.; Lin, SH (corresponding author), Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Biostat Consulting Ctr, Tainan, Taiwan. EM joshcclin@gmail.com; shlin922@mail.ncku.edu.tw RI Kuo, Chin-Wei/AHB-2353-2022; Yang, Jen/GXV-3679-2022; Lin, Chien-Chung/T-1496-2019 OI Kuo, Chin-Wei/0000-0001-8663-7288; Lin, Chien-Yu/0009-0003-1740-1994; Yang, Jen/0000-0002-7165-2140; Su, Po-Lan/0000-0002-8470-6590 FU National Science and Technology Council of Taiwan [110-2314-B- 006-098-MY3, 113- 2314- B- 006- 107- MY3] FX National Science and Technology Council of Taiwan 110-2314-B- 006-098-MY3, 113- 2314- B- 006- 107- MY3. CR Alloubani A, 2021, CURR CARDIOL REV, V17, DOI 10.2174/1573403X16999201210200342 Arenare L, 2024, ESMO OPEN, V9, DOI 10.1016/j.esmoop.2024.102941 Bak M, 2025, J THORAC ONCOL, V20, P167, DOI 10.1016/j.jtho.2024.10.003 Bauer TM, 2019, ONCOLOGIST, V24, P1103, DOI 10.1634/theoncologist.2018-0380 Blais N, 2021, CURR ONCOL, V28, P265, DOI 10.3390/curroncol28010029 Camidge DR, 2021, J THORAC ONCOL, V16, P2091, DOI 10.1016/j.jtho.2021.07.035 Camidge DR, 2021, J THORAC ONCOL, V16, P528, DOI 10.1016/j.jtho.2020.12.022 Chung WT, 2023, J CLIN EPIDEMIOL, V163, P92, DOI 10.1016/j.jclinepi.2023.09.014 Cleary Y, 2018, CLIN PHARMACOL THER, V104, P505, DOI 10.1002/cpt.956 Cognigni V, 2022, CANCERS, V14, DOI 10.3390/cancers14194765 Davare MA, 2015, P NATL ACAD SCI USA, V112, pE5381, DOI 10.1073/pnas.1515281112 Di Lodovico E, 2022, CIRC-HEART FAIL, V15, DOI 10.1161/CIRCHEARTFAILURE.121.008755 Doherty KR, 2013, TOXICOL APPL PHARM, V272, P245, DOI 10.1016/j.taap.2013.04.027 Ewer MS, 2021, J CLIN ONCOL, V39, P328, DOI 10.1200/JCO.20.01171 Franquiz MJ, 2023, JACC-CARDIOONCOL, V5, P839, DOI 10.1016/j.jaccao.2023.07.006 Gaggini M, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24010075 Girard N, 2022, ESMO OPEN, V7, DOI 10.1016/j.esmoop.2022.100418 Howlader N, 2020, NEW ENGL J MED, V383, P640, DOI 10.1056/NEJMoa1916623 Igawa YS, 2024, LUNG CANCER, V196, DOI 10.1016/j.lungcan.2024.107954 Kim MK, 2017, EUR HEART J, V38, P3560, DOI 10.1093/eurheartj/ehx585 Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448 Li HQ, 2024, FRONT PHARMACOL, V15, DOI 10.3389/fphar.2024.1385036 Lin CY, 2024, JAMA NETW OPEN, V7, DOI 10.1001/jamanetworkopen.2024.48364 Lin JJ, 2017, J THORAC ONCOL, V12, P1611, DOI 10.1016/j.jtho.2017.08.002 Liu YH, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.858279 Lu Shun, 2024, Clin Lung Cancer, V25, pe295, DOI 10.1016/j.cllc.2024.04.017 Lyon AR, 2022, EUR HEART J, V43, P4229, DOI 10.1093/eurheartj/ehac244 McEvoy JW, 2025, EUR HEART J, V46, P1300, DOI [10.1093/eurheartj/ehae178, 10.1093/eurheartj/ehaf031] Mok T, 2020, ANN ONCOL, V31, P1056, DOI 10.1016/j.annonc.2020.04.478 Pourmir I, 2024, ANN ONCOL, V35, P569, DOI 10.1016/j.annonc.2024.03.006 Reed M, 2020, ADV THER, V37, P3019, DOI 10.1007/s12325-020-01365-3 Riely GJ, 2024, J NATL COMPR CANC NE, V22, P249, DOI 10.6004/jnccn.2204.0023 Schneider JL, 2023, NAT CANCER, V4, P330, DOI 10.1038/s43018-023-00515-0 Shaw AT, 2019, LANCET ONCOL, V20, P1691, DOI 10.1016/S1470-2045(19)30655-2 Shaw AT, 2017, LANCET ONCOL, V18, P1590, DOI 10.1016/S1470-2045(17)30680-0 Shih JY, 2024, J FORMOS MED ASSOC, V123, P875, DOI 10.1016/j.jfma.2023.12.019 Siegel RL, 2024, CA-CANCER J CLIN, V74, P12, DOI 10.3322/caac.21820 Solomon BJ, 2024, J CLIN ONCOL, V42, DOI 10.1200/JCO.24.00581 Solomon BJ, 2018, LANCET ONCOL, V19, P1654, DOI 10.1016/S1470-2045(18)30649-1 Stoltzfus KC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15639-5 Sun JY, 2021, INT J CARDIOL, V330, P186, DOI 10.1016/j.ijcard.2021.02.025 Torresan S, 2025, INT J MOL SCI, V26, DOI 10.3390/ijms26020554 Visseren FLJ, 2022, EUR J PREV CARDIOL, V29, P5, DOI 10.1093/eurjpc/zwab154 Wang MN, 2021, NAT MED, V27, P1345, DOI 10.1038/s41591-021-01450-2 Weickhardt AJ, 2013, CANCER-AM CANCER SOC, V119, P2383, DOI 10.1002/cncr.28089 Wharton S, 2020, CAN MED ASSOC J, V192, pE875, DOI 10.1503/cmaj.191707 Wilcox NS, 2024, NAT REV CARDIOL, V21, P617, DOI 10.1038/s41569-024-01017-x Xu ZF, 2024, AUTOPHAGY, V20, P416, DOI 10.1080/15548627.2023.2259216 Zhang Zhushan, 2017, Cardiooncology, V3, DOI [10.1186/s40959-017-0020-z, 10.1007/s12559-017-9484-2, 10.1186/s40959-017-0020-z] Zia V, 2023, TRANSL LUNG CANCER R, V12, P1563, DOI 10.21037/tlcr-22-619 NR 50 TC 2 Z9 2 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA EI 2047-9980 J9 J AM HEART ASSOC JI J. Am. Heart Assoc. PD DEC 16 PY 2025 VL 14 IS 24 AR e043620 DI 10.1161/JAHA.125.043620 PG 12 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA AA3HS UT WOS:001643396800001 PM 41378495 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Boutellier, S Zehnder, A Gelpke, H Najafi, A Buehler, PK Scherr, BF AF Boutellier, Susanne Zehnder, Adrian Gelpke, Hans Najafi, Arash Buehler, Philipp Karl Scherr, Benedikt Florian TI Chylous pericardial tamponade following postoperative chylothorax after right upper lobectomy: a case report of a rare entity SO BMC PULMONARY MEDICINE LA English DT Article DE Chylopericardium; Pericardial tamponade; Chylothorax; Lobectomy; Thoracic duct ligation AB Background Postoperative chylothorax is a known but uncommon complication of lung cancer surgery. Progression to chylous pericardial effusion and tamponade is exceedingly rare but can be rapidly fatal if not recognized and treated promptly. Case presentation A 72-year-old man underwent right upper lobectomy with bronchus-sleeve resection and systematic mediastinal lymphadenectomy for squamous cell carcinoma. In the early postoperative course, a high-output chylothorax was diagnosed. On postoperative day (POD) 4, he developed paroxysmal atrial fibrillation with hemodynamic instability, requiring brief ICU admission for cardioversion. On POD 6, he suddenly deteriorated with obstructive shock with hypotension, tachycardia, pronounced mottled skin extending to the abdomen, and decreased level of consciousness. Bedside transthoracic echocardiography revealed a large pericardial effusion with tamponade physiology. Emergency pericardiocentesis drained 800 mL of milky fluid with high triglycerides, consistent with chylopericardium, and resulted in immediate hemodynamic stabilization. Interventional radiology attempted bilateral intranodal lymphangiography and thoracic duct embolization via lymphatic, venous and percutaneous routes; despite partial opacification of lymphatic channels, catheterization and embolization was unsuccessful. On POD 7, surgical re-thoracotomy with thoracic duct ligation above the diaphragm and lymphatic fistula closure was performed. The pericardial drain was removed on POD 8, echocardiography confirmed no recurrence, and the patient recovered uneventfully. Discussion Chylous pericardial tamponade is extremely rare but life-threatening. Previous reports describe a spectrum from successful conservative therapy to surgical interventions, with at least one fatal outcome despite drainage (Fukumoto et al. Surg Case Rep. 11:87; 2025). Our case highlights three points: (1) transthoracic echocardiography is indispensable for rapid diagnosis of tamponade in unstable postoperative patients; (2) interventional radiology, although attempted, was unsuccessful and should not delay definitive treatment; (3) surgical thoracic duct ligation and pericardial drainage remain the most reliable interventions. Conclusion Chylous pericardial tamponade should be considered in patients with postoperative chylothorax who deteriorate hemodynamically. Rapid echocardiography, emergency pericardial drainage, and timely surgical management are key to survival. C1 [Boutellier, Susanne; Buehler, Philipp Karl; Scherr, Benedikt Florian] Cantonal Hosp Winterthur, Dept Intens Care Med, Winterthur, Switzerland. [Zehnder, Adrian; Gelpke, Hans] Cantonal Hosp Winterthur, Dept Thorac & Visceral Surg, Winterthur, Switzerland. [Najafi, Arash] Cantonal Hosp Winterthur, Dept Radiol & Nucl Med, Winterthur, Switzerland. [Buehler, Philipp Karl; Scherr, Benedikt Florian] Univ Zurich, Zurich, Switzerland. C3 University of Zurich RP Scherr, BF (corresponding author), Cantonal Hosp Winterthur, Dept Intens Care Med, Winterthur, Switzerland.; Scherr, BF (corresponding author), Univ Zurich, Zurich, Switzerland. EM benedikt.scherr@ksw.ch RI Zehnder, Adrian/IYJ-0851-2023 CR Fukumoto K, 2025, SURG CASE REP, V11, DOI 10.70352/scrj.cr.25-0275 Jeon H., 2020, Curr Chall Thorac Surg, V2, DOI [10.21037/ccts.2020.03.03, DOI 10.21037/CCTS.2020.03.03] Mizushima Y, 1996, TUMORI, V82, P264 Verma B, 2023, HEART, V109, P1281, DOI 10.1136/heartjnl-2022-321798 Wait Michael A, 2013, Proc (Bayl Univ Med Cent), V26, P280 Yang WX, 2017, INTERACT CARDIOV TH, V25, P145, DOI 10.1093/icvts/ivx018 Zhang GF, 2023, J CARDIOTHORAC SURG, V18, DOI 10.1186/s13019-023-02126-3 NR 7 TC 0 Z9 0 U1 0 U2 0 PU BMC PI LONDON PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1471-2466 J9 BMC PULM MED JI BMC Pulm. Med. PD DEC 10 PY 2025 VL 26 IS 1 AR 36 DI 10.1186/s12890-025-04054-5 PG 5 WC Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System GA DA6GK UT WOS:001678883500001 PM 41372861 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Sun, J Sheng, Y Yang, TL AF Sun, Jun Sheng, Yu Yang, Tianlong TI The impact of VATS anatomic segmentectomy on postoperative stress response and respiratory function in early-stage NSCLC patients SO MEDICINE LA English DT Article DE anatomic segmentectomy; non-small cell lung cancer; respiratory function; stress response; video-assisted thoracoscopic surgery ID CELL LUNG-CANCER; OPEN SURGERY; EPIDEMIOLOGY; DIAGNOSIS; LOBECTOMY AB Non-small cell lung cancer (NSCLC) is associated with high malignancy, mortality, and recurrence. While early symptoms are subtle, timely surgery significantly improves outcomes. Video-assisted thoracoscopic surgery (VATS) anatomic segmentectomy is an increasingly important technique in early-stage NSCLC management. This study evaluates its effects on postoperative pain, stress response, respiratory function, and quality of life (QOL). This study aims to investigate the impact of VATS anatomic segmentectomy on stress response and pulmonary function in early-stage NSCLC patients. From December 2021 to December 2023, 98 early-stage NSCLC patients were allocated by surgical method: 45 underwent VATS pulmonary lobectomy (control group) and 53 underwent VATS anatomic segmentectomy (observation group). Perioperative outcomes, stress markers (cortisol, growth hormone, adrenocorticotrophic hormone, prostaglandin E2), complications, pain (visual analog scale scores), pulmonary function (forced vital capacity, forced expiratory volume in 1 second, peak expiratory flow, maximal voluntary ventilation, transfer factor for carbon monoxide of the lung), and QOL were compared. Surgical duration and lymph node retrieval did not differ significantly (P > .05). However, the observation group showed less intraoperative bleeding, lower postoperative drainage, shorter extubation time, and reduced hospital stay (P < .05). Preoperative stress markers were similar between groups. Postoperatively, cortisol and prostaglandin E2 were significantly lower in the observation group, while growth hormone and adrenocorticotrophic hormone levels showed no group difference (P < .05). Rates of complications (pneumonia, atelectasis, atrial fibrillation, prolonged air leak, empyema, hoarseness, arrhythmia) were comparable (P > .05). Pain scores at 24, 48, 72 hours, and day 5 were lower in the observation group (P < .05). Preoperative lung function was similar, but at 1 month, the observation group demonstrated higher forced vital capacity, forced expiratory volume in 1 second, peak expiratory flow, maximal voluntary ventilation, and transfer factor for carbon monoxide of the lung (P < .05). QOL was initially comparable, but at 1 and 3 months, the observation group reported significantly better QOL (P < .05). VATS anatomic segmentectomy provides favorable clinical outcomes for early-stage NSCLC. It reduces postoperative stress and pain, enhances lung function recovery, and improves QOL, supporting its value as a surgical option. C1 [Sun, Jun; Sheng, Yu; Yang, Tianlong] Zhejiang Jinhua Guangfu Tumor Hosp, Thorac Tumor Surg Dept, Jinhua 321000, Zhejiang, Peoples R China. RP Sheng, Y (corresponding author), Zhejiang Jinhua Guangfu Tumor Hosp, Thorac Tumor Surg Dept, Jinhua 321000, Zhejiang, Peoples R China. EM a13586990736@163.com CR Balata H, 2019, J THORAC ONCOL, V14, P1513, DOI 10.1016/j.jtho.2019.06.011 Bendixen M, 2016, LANCET ONCOL, V17, P836, DOI 10.1016/S1470-2045(16)00173-X Bertolaccini L, 2022, CANCERS, V14, DOI 10.3390/cancers14246157 Billiet C, 2020, REV MAL RESPIR, V37, P735, DOI 10.1016/j.rmr.2020.06.018 Cheng AM, 2015, J NATL COMPR CANC NE, V13, P166, DOI 10.6004/jnccn.2015.0024 De La Torre M, 2016, MINERVA CHIR, V71, P46 Deng C, 2022, CLIN BREAST CANCER, V22, P115, DOI 10.1016/j.clbc.2021.05.006 Deshpand R, 2022, INDIAN J CANCER, V59, pS90, DOI 10.4103/ijc.IJC_52_21 Duma N, 2019, MAYO CLIN PROC, V94, P1623, DOI 10.1016/j.mayocp.2019.01.013 Esakov Yu S, 2018, Khirurgiia (Mosk), P5, DOI [10.17116/hirurgia20181115, 10.17116/hirurgia20181115] Ettinger DS, 2017, J NATL COMPR CANC NE, V15, P504, DOI 10.6004/jnccn.2017.0050 Hvas AM, 2019, SCAND J CLIN LAB INV, V79, P513, DOI 10.1080/00365513.2019.1663555 Imyanitov EN, 2021, CRIT REV ONCOL HEMAT, V157, DOI 10.1016/j.critrevonc.2020.103194 Ismail Nur A, 2015, Surg Technol Int, V26, P206 Jonna S, 2019, DISCOV MED, V27, P167 Kaasa S, 1995, EUR J CANCER, V31A, P2260, DOI 10.1016/0959-8049(95)00296-0 Klapper J, 2015, J NATL COMPR CANC NE, V13, P162, DOI 10.6004/jnccn.2015.0023 Leshnower BG, 2010, ANN THORAC SURG, V89, P1571, DOI 10.1016/j.athoracsur.2010.01.061 Mao YS, 2016, SURG ONCOL CLIN N AM, V25, P439, DOI 10.1016/j.soc.2016.02.001 Merritt RE, 2023, THORAC SURG CLIN, V33, P43, DOI 10.1016/j.thorsurg.2022.09.002 Okazaki M, 2023, EUR J CARDIO-THORAC, V63, DOI 10.1093/ejcts/ezad048 Pagès PB, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-012963 Postmus PE, 2017, ANN ONCOL, V28, P1, DOI 10.1093/annonc/mdx222 Saji H, 2022, LANCET, V399, P1607, DOI 10.1016/S0140-6736(21)02333-3 Socinski MA, 2016, J THORAC ONCOL, V11, P1411, DOI 10.1016/j.jtho.2016.05.024 Takamori S, 2022, INTERACT CARDIOV TH, V34, P1038, DOI 10.1093/icvts/ivab323 Tosi D, 2021, INTERACT CARDIOV TH, V32, P546, DOI 10.1093/icvts/ivaa298 NR 27 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7974 EI 1536-5964 J9 MEDICINE JI Medicine (Baltimore) PD DEC 5 PY 2025 VL 104 IS 49 AR e46356 DI 10.1097/MD.0000000000046356 PG 6 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA N8525 UT WOS:001631988100050 PM 41366977 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Yoshimura, H Zakkak, N Lyratzopoulos, G Lip, GYH Schmidt, F Providencia, R AF Yoshimura, Hiroyuki Zakkak, Nadine Lyratzopoulos, Georgios Lip, Gregory Y. H. Schmidt, Floriaan Providencia, Rui TI Risk of cancer following presentation with new-onset atrial fibrillation using data from UK national databases SO EUROPACE LA English DT Article DE Arrhythmia; Neoplasia; Prediction; Prognosis; Comorbidity AB Aims Atrial fibrillation (AF) and cancer are both highly prevalent conditions and are known to be associated. Our aim was to identify predictors and develop models for all cancer types, in men and women, and for the four most common cancer types in the AF population using linked primary and secondary care data from the UK.Methods and results We included 163 549 patients diagnosed with AF between January 1998 and May 2016, and no previous history of cancer. Following TRIPOD methodology, we developed a ridge-penalized multivariable logistic regression model to predict 1-year cancer incidence after AF diagnosis, using 70% of the data for derivation and 30% for validation. Age was associated with an increased risk across all cancer types. Socioeconomic deprivation, smoking, excessive alcohol intake, family history of cancer, chronic kidney disease, anaemia, and several cancer-related symptoms and clinical signs (e.g. rectal bleeding, loss of appetite) were associated with an increased risk in one or more cancer types. The prediction models showed moderate-to-good discrimination in the validation set, with c-statistic of 0.69 (0.68-0.70) for all cancer in men, 0.63 (0.62-0.65) for all cancer in women, 0.70 (0.68-0.73) for lung cancer, 0.70 (0.66-0.73) for colorectal cancer, 0.59 (0.53-0.65) for breast cancer, and 0.78 (0.72-0.84) for prostate cancer.Conclusion Most of the identified potential risk factors for cancer in the AF population are also associated with cardiovascular disease. The 1-year cancer prediction models showed moderate to good predictive performance and may help improve the management of patients with AF. C1 [Yoshimura, Hiroyuki; Providencia, Rui] UCL, Inst Hlth Informat Res, 222 Euston Rd, London NW1 2DA, England. [Zakkak, Nadine; Lyratzopoulos, Georgios] UCL, Inst Epidemiol & Hlth Care, Dept Behav Sci & Hlth, Epidemiol Canc Healthcare & Outcomes Grp ECHO, London, England. [Zakkak, Nadine] Canc Res UK, Canc Intelligence, London, England. [Lip, Gregory Y. H.] Liverpool John Moores Univ, Univ Liverpool, Liverpool Ctr Cardiovasc Sci, Liverpool, England. [Lip, Gregory Y. H.] Liverpool Heart & Chest Hosp, Liverpool, England. [Lip, Gregory Y. H.] Aalborg Univ, Danish Ctr Hlth Serv Res, Dept Clin Med, Aalborg, Denmark. [Lip, Gregory Y. H.] Med Univ Bialystok, Dept Cardiol, Lipidol & Internal Med Intens Coronary Care Unit, Bialystok, Poland. [Schmidt, Floriaan] UCL, Inst Cardiovasc Sci, London, England. [Schmidt, Floriaan] Univ Med Ctr Utrecht, Dept Cardiol, Div Heart & Lungs, Utrecht, Netherlands. [Providencia, Rui] Barts Hlth NHS Trust, Barts Heart Ctr, London, England. C3 University of London; University College London; University of London; University College London; Cancer Research UK; University of Liverpool; Liverpool John Moores University; Liverpool Heart & Chest Hospital; Aalborg University; Medical University of Bialystok; University of London; University College London; Utrecht University; Utrecht University Medical Center; Barts Health NHS Trust RP Yoshimura, H (corresponding author), UCL, Inst Hlth Informat Res, 222 Euston Rd, London NW1 2DA, England. EM hiroyuki.yoshimura.21@ucl.ac.uk RI ; Lyratzopoulos, Georgios/AGJ-0902-2022; Providência, Rui/HTN-7692-2023; Schmidt, Amand Floriaan/G-6602-2017; Yoshimura, Hiroyuki/PBV-1129-2025 OI Zakkak, Nadine/0000-0003-4155-7756; Lyratzopoulos, Georgios/0000-0002-2873-7421; Providência, Rui/0000-0001-9141-9883; Schmidt, Amand Floriaan/0000-0003-1327-0424; Yoshimura, Hiroyuki/0009-0009-1991-5001 FU University College London British Heart Foundation Research Accelerator [AA/18/6/34223]; UK Research and Innovation European Research Council [10103153 ARISTOTELES]; National Institute of Health Research [NIHR129463]; National Institutes of Health Research (NIHR) [NIHR129463] Funding Source: National Institutes of Health Research (NIHR) FX R.P.: Supported by the British Heart Foundation (grant AA/18/6/34223), the National Institute for Health and Care Research (grant NIHR129463), and United Kingdom Research and Innovation (grant 10103153 ARISTOTELES). CR [Anonymous], 2025, CPRD GOLD June 2024 Dataset Barca L, 2025, HEART RHYTHM, V22, P3323, DOI [10.1016/j.hrthm.2025.01.029, 10.1016/j.hrthm.2025.01.029] Bhaskaran K, 2014, LANCET, V384, P755, DOI 10.1016/S0140-6736(14)60892-8 Boriani G, 2024, EUR HEART J, V46, P775, DOI 10.1093/eurheartj/ehae792 Bray F, 2024, CA-CANCER J CLIN, V74, P229, DOI 10.3322/caac.21834 Buckley BJR, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.121.021970 Cancer Research UK, 2025, Cancer incidence for common cancers Chen QG, 2024, EUR HEART J, V45, P2201, DOI 10.1093/eurheartj/ehae222 Cheng SY, 2024, EUROPACE, V26, DOI 10.1093/europace/euae195 Chung SC, 2023, FRONT CARDIOVASC MED, V10, DOI 10.3389/fcvm.2023.1204892 Conen D, 2016, JAMA CARDIOL, V1, P389, DOI 10.1001/jamacardio.2016.0280 Francis J, 2008, J AM COLL CARDIOL, V51, P1149, DOI 10.1016/j.jacc.2007.10.062 Goette A, 2024, EUROPACE, V26, DOI 10.1093/europace/euae204 Grewal K, 2025, CIRCULATION, V151, P773, DOI 10.1161/CIRCULATIONAHA.124.070865 Harding JL, 2016, J HYPERTENS, V34, P149, DOI 10.1097/HJH.0000000000000770 Hart PC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.595835 Health Data Research UK (HDR UK), 2025, Phenotype Library Hippisley-Cox J, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007825 Hippisley-Cox J, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2573 Jackson SS, 2022, CANCER-AM CANCER SOC, V128, P3531, DOI 10.1002/cncr.34390 Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43 Tran KB, 2022, LANCET, V400, P563, DOI 10.1016/S0140-6736(22)01438-6 Kyrgiou M, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j477 Linz D, 2024, LANCET REG HEALTH-EU, V37, DOI 10.1016/j.lanepe.2023.100786 Lip GYH, 2023, EUROPACE, V25, DOI 10.1093/europace/euad226 Maron BJ, 2022, J AM COLL CARDIOL, V79, P372, DOI 10.1016/j.jacc.2021.12.002 Mei DA, 2024, EUR J INTERN MED, V128, P63, DOI 10.1016/j.ejim.2024.06.022 Mont L, 2009, EUROPACE, V11, P11, DOI 10.1093/europace/eun289 Moons KGM, 2015, ANN INTERN MED, V162, pW1, DOI 10.7326/M14-0698 National Institute for Health and Care Excellence (NICE), 2025, Overview | Suspected Cancer: Recognition and Referral | Guidance | NICE National Institute for Health and Care Excellence (NICE), 2025, Overview | Atrial Fibrillation: Diagnosis and Management | Guidance | NICE Ostenfeld EB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102861 Park Y, 2018, CANCER RES, V78, P1898, DOI 10.1158/0008-5472.CAN-17-3043 Petrova D, 2022, PLOS MED, V19, DOI 10.1371/journal.pmed.1004110 Providencia R, 2024, EUR HEART J OPEN, V4, DOI [10.1093/ehjopen/oeae058, 10.1093/ehjopen/oeae058] QCancer, 2025, QCancer Rasmussen PV, 2022, EUR HEART J, V43, pE38, DOI 10.1093/eurheartj/ehz964 Remme CA, 2023, EUROPACE, V25, DOI 10.1093/europace/euad210 Rienstra M, 2024, EUROPACE, V26, DOI 10.1093/europace/euae298 Romiti GF, 2022, THROMB HAEMOSTASIS, V122, P406, DOI 10.1055/a-1515-9630 Schmidt AF, 2025, COMMUN MED-LONDON, V5, DOI 10.1038/s43856-025-00855-1 Seretis A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45014-4 White B, 2022, CANCER EPIDEMIOL, V76, DOI 10.1016/j.canep.2021.102072 Wilcox NS, 2024, NAT REV CARDIOL, V21, P617, DOI 10.1038/s41569-024-01017-x Zakkak N, 2025, NEOPLASIA, V59, DOI 10.1016/j.neo.2024.101080 NR 45 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1099-5129 EI 1532-2092 J9 EUROPACE JI Europace PD DEC PY 2025 VL 27 IS 12 AR euaf319 DI 10.1093/europace/euaf319 PG 9 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA AB7ZL UT WOS:001644391700001 PM 41379769 OA Green Submitted, hybrid DA 2026-04-17 ER PT J AU Tian, Y Zanfrini, E Abdelnour-Berchtold, E Zellweger, M Perentes, JY Krueger, T Gonzalez, M AF Tian, Ye Zanfrini, Edoardo Abdelnour-Berchtold, Etienne Zellweger, Matthieu Perentes, Jean Yannis Krueger, Thorsten Gonzalez, Michel TI Outcomes After VATS Single Versus Multiple Segmentectomy for cT1N0 Non-Small-Cell Lung Cancer SO CANCERS LA English DT Article DE segmentectomy; sublobar resection; video-assisted thoracoscopic surgery (VATS); non-small cell lung cancer; minimal invasive surgery ID LOBECTOMY; MULTICENTER AB Objective: The optimal extent of segmentectomy for clinical T1N0 non-small cell lung cancer (NSCLC) remains unclear. This study compared perioperative and oncological outcomes of video-assisted thoracoscopic surgery (VATS) single segmentectomy (SS) versus multiple segmentectomy (MS) for tumors <= 3 cm. Methods: This single center study retrospectively analyzed all consecutive patients who underwent VATS anatomic segmentectomy for cT1N0 NSCLC between 2017 and 2022. Patient demographics, perioperative outcomes, and survival were compared between SS and MS groups. Results: In total, 334 patients underwent pulmonary segmentectomy: single in 211 (63%) and multiple in 123 patients (37%). In the SS group, 83 (39%) were simple and 128 (61%) complex segmentectomies; while in the MS group, 67 (54%) were simple and 56 (46%) were complex. Baseline characteristics were similar between groups. SS was associated with shorter operative time (117 vs. 132 min; p = 0.007), reduced length of drainage (1 vs. 3 days; p < 0.001), reduced hospital stay (5 vs. 6 days; p < 0.001), and lower atrial fibrillation (1.4% vs. 5.7%; p = 0.042). Total mean tumor size was 14.3 mm, with no statistical difference between groups (14.3 vs. 15.5 mm; p = 0.115). Surgical margins were larger in SS (median 13 vs. 11 mm; p = 0.038), while the number of lymph nodes dissected was similar. After a median follow-up of 30 months, no significant differences were observed in overall survival (OS) (94.5% vs. 90.7%) and disease-free survival (DFS) (83.2% vs. 79.1%). Conclusions: SS and MS provide equivalent short-term oncological outcomes in cT1N0 NSCLC <= 3 cm. SS may be preferred when adequate margins are achievable, offering equivalent oncologic outcomes with better perioperative recovery. C1 [Tian, Ye; Perentes, Jean Yannis; Krueger, Thorsten; Gonzalez, Michel] Univ Lausanne UNIL, Fac Biol & Med, CH-1011 Lausanne, Switzerland. [Zanfrini, Edoardo; Abdelnour-Berchtold, Etienne; Zellweger, Matthieu; Perentes, Jean Yannis; Krueger, Thorsten; Gonzalez, Michel] Lausanne Univ Hosp CHUV, Dept Thorac Surg, CH-1011 Lausanne, Switzerland. C3 University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV) RP Gonzalez, M (corresponding author), Univ Lausanne UNIL, Fac Biol & Med, CH-1011 Lausanne, Switzerland.; Gonzalez, M (corresponding author), Lausanne Univ Hosp CHUV, Dept Thorac Surg, CH-1011 Lausanne, Switzerland. EM ye.tian@unil.ch; edoardo.zanfrini@chuv.ch; etienne.abdelnour@chuv.ch; matthieu.zellweger@chuv.ch; jean.perentes@chuv.ch; thorsten.krueger@chuv.ch; michel.gonzalez@chuv.ch RI Krueger, Thorsten/AAK-1780-2021 OI Abdelnour-Berchtold, Etienne/0000-0003-4002-9046 CR Al-Thani S, 2025, EUR J CARDIO-THORAC, V67, DOI 10.1093/ejcts/ezaf082 Altorki N, 2023, NEW ENGL J MED, V388, P489, DOI 10.1056/NEJMoa2212083 Aokage K, 2023, LANCET RESP MED, V11, P540, DOI 10.1016/S2213-2600(23)00041-3 Bédat B, 2019, J THORAC DIS, V11, P4109, DOI 10.21037/jtd.2019.10.07 Bédat B, 2019, J CARDIOTHORAC SURG, V14, DOI 10.1186/s13019-019-1021-9 Bertolaccini L, 2023, EJSO-EUR J SURG ONC, V49, DOI 10.1016/j.ejso.2023.107101 Bottet B, 2024, CANCERS, V16, DOI 10.3390/cancers16233981 Brünelli A, 2023, EUR J CARDIO-THORAC, V63, DOI 10.1093/ejcts/ezad224 Cardillo G, 2023, EUR J CARDIO-THORAC, V64, DOI 10.1093/ejcts/ezad222 Chan EG, 2021, J THORAC CARDIOV SUR, V161, P1639, DOI 10.1016/j.jtcvs.2020.03.041 Darras M, 2021, THORAC CANCER, V12, P453, DOI 10.1111/1759-7714.13766 Forster C, 2023, INTERDISC CARDIOV TH, V36, DOI 10.1093/icvts/ivad037 Ginsberg Robert J., 1995, Annals of Thoracic Surgery, V60, P615, DOI 10.1016/0003-4975(95)00537-U Handa Y, 2019, ANN THORAC SURG, V107, P1032, DOI 10.1016/j.athoracsur.2018.11.018 Hattori A, 2024, LANCET RESP MED, V12, P105, DOI 10.1016/S2213-2600(23)00382-X Hattori A, 2022, INTERACT CARDIOV TH, V35, DOI 10.1093/icvts/ivac246 Huang L, 2025, INTERDISC CARDIOV TH, V40, DOI 10.1093/icvts/ivaf064 Kamigaichi A, 2020, CLIN LUNG CANCER, V21, pE528, DOI 10.1016/j.cllc.2020.04.015 Kim IH, 2025, EUR J CARDIO-THORAC, V67, DOI 10.1093/ejcts/ezaf281 Mathey-Andrews CA, 2025, CHEST, V168, P1506, DOI 10.1016/j.chest.2025.05.047 Merritt RE, 2025, SEMIN THORAC CARDIOV, V37, P99, DOI [10.1053/j.semtcvs.2024.11.002, 10.1053/j.semtcvs.2024.11.002] Nakagawa K, 2025, J THORAC ONCOL, V20, P157, DOI 10.1016/j.jtho.2024.10.002 Petersen RH, 2022, EUR J CARDIO-THORAC, V61, P108, DOI 10.1093/ejcts/ezab457 Saji H, 2022, LANCET, V399, P1607, DOI 10.1016/S0140-6736(21)02333-3 Seitlinger J, 2023, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.1078606 Siegel RL, 2025, CA-CANCER J CLIN, V75, P10, DOI 10.3322/caac.21871 Stamatis G, 2022, LUNG CANCER, V172, P108, DOI 10.1016/j.lungcan.2022.08.013 Wang LL, 2022, J CARDIOTHORAC SURG, V17, DOI 10.1186/s13019-022-01867-x Wang SL, 2023, MEDICINE, V102, DOI 10.1097/MD.0000000000033648 Winckelmans T, 2020, EUR J CARDIO-THORAC, V57, P1051, DOI 10.1093/ejcts/ezz339 Zhang WF, 2023, FRONT ONCOL, V13, DOI 10.3389/fonc.2023.1270030 Zhang Y, 2025, J CLIN ONCOL, V43, DOI 10.1200/JCO-25-00610 NR 32 TC 0 Z9 0 U1 0 U2 0 PU MDPI PI BASEL PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND EI 2072-6694 J9 CANCERS JI Cancers PD NOV 28 PY 2025 VL 17 IS 23 AR 3814 DI 10.3390/cancers17233814 PG 15 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA R1831 UT WOS:001635335700001 PM 41375015 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Liu, J Ding, LF Ma, WH Wang, JY Song, XL Cao, Y Wu, CE AF Liu, Jie Ding, Longfei Ma, Wuhua Wang, Jiyong Song, Xiuling Cao, Ying Wu, Caineng TI Effects of electroacupuncture on the incidence of postoperative supraventricular arrhythmia and sleep quality in patients undergoing thoracoscopic surgery: a randomized controlled trial SO FRONTIERS IN NEUROLOGY LA English DT Article DE electroacupuncture; thoracoscopic surgery; supraventricular tachycardia; sleep disturbance; lung cancer ID ATRIAL-FIBRILLATION; ACUPUNCTURE; STIMULATION; ACUPOINT; INFLAMMATION; MODULATION; PREVENTION; MANAGEMENT AB Background Supraventricular arrhythmia and sleep disturbance frequently occur after thoracoscopic surgery for lung cancer. The present study is designed to evaluate the hypothesis that electroacupuncture is an effective treatment of supraventricular arrhythmia and sleep disorders following thoracoscopic lung cancer surgery. Methods Adult patients scheduled for single-port thoracoscopic lung cancer surgery were randomly assigned to the Electroacupuncture (EA) and control groups. The primary outcome of this trial was the incidence of new-onset supraventricular tachycardia (SVT) including atrial flutter, atrial fibrillation, atrial tachycardia and atrioventricular junctional tachycardia during the first 24 h after surgery. Results The authors analyzed 77 patients (EA, 38; control, 39). The incidence of new-onset SVT was significantly lower in the EA group compared with the control group during the first 24 postoperative hours; 4 (10.5%) vs. 13 (33.3%), respectively, p = 0.02. Patients in the EA group had longer total sleep time (119.0 vs. 209.5, p = 0.02), longer duration of nonrapid eye movement sleep on the first postoperative night (p < 0.05). The awake time was significantly shorter compared with the control group (134.5.0 vs. 225.0, p = 0.01). Dosage of remifentanil and incidence of intraoperative hypotension were significantly reduced in the EA group (911.1 vs. 1095.9, p = 0.01). However, VAS scores after surgery did not differ between groups. In all the patients recruited, adverse effects such as redness, swelling and inflammatory reactions were not observed at the acupuncture site. Conclusion The results of this study suggest that perioperative electroacupuncture treatment could be a promising strategy to reduce the incidence of new-onset SVT and improve sleep disturbance in patients undergoing thoracoscopic surgery for lung cancer. This potential impact on future treatments should inspire hope and optimism in the medical community.Clinical trial registration https://www.chictr.org.cn/indexEN.html, identifier ChiCTR2300077984. C1 [Liu, Jie; Ding, Longfei] Guangzhou Univ Chinese Med, Clin Med Coll 1, Guangzhou, Peoples R China. [Liu, Jie; Ding, Longfei; Ma, Wuhua; Song, Xiuling; Wu, Caineng] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Anesthesiol, Guangzhou, Peoples R China. [Liu, Jie; Ma, Wuhua; Wang, Jiyong; Song, Xiuling; Wu, Caineng] Guangdong Clin Res Acad Chinese Med, Guangzhou, Peoples R China. [Wang, Jiyong] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Thorac Surg, Guangzhou, Peoples R China. [Cao, Ying] Southern Med Univ, Sch Pharmaceut Sci, NMPA Key Lab Res & Evaluat Drug Metab, Guangdong Prov Key Lab New Drug Screening, Guangzhou, Peoples R China. C3 Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Southern Medical University - China RP Wu, CE (corresponding author), Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Anesthesiol, Guangzhou, Peoples R China.; Wu, CE (corresponding author), Guangdong Clin Res Acad Chinese Med, Guangzhou, Peoples R China.; Cao, Y (corresponding author), Southern Med Univ, Sch Pharmaceut Sci, NMPA Key Lab Res & Evaluat Drug Metab, Guangdong Prov Key Lab New Drug Screening, Guangzhou, Peoples R China. EM yingcao@163.com; wucaineng861010@163.com FU National Natural Science Foundation of China [82374451] FX The author(s) declare that financial support was received for the research and/or publication of this article. This work was funded by National Natural Science Foundation of China (82374451). CR Akita T, 2022, J INTEGR COMPLEMENT, V28, P791, DOI 10.1089/jicm.2022.0526 Bayliff CD, 1999, ANN THORAC SURG, V67, P182, DOI 10.1016/S0003-4975(98)01226-0 Chen KB, 2019, INT J SURG, V70, P93, DOI 10.1016/j.ijsu.2019.08.034 de Oliveira RM, 2012, REV BRAS ANESTESIOL, V62, P10, DOI 10.1016/S0034-7094(12)70098-3 Diallo EH, 2023, ANAESTHESIA, V78, P491, DOI 10.1111/anae.15957 Feingold KL, 2023, JTCVS OPEN, V16, P321, DOI 10.1016/j.xjon.2023.05.010 Feng XZ, 2016, INT J SURG, V30, P104, DOI 10.1016/j.ijsu.2016.04.042 Feng XX, 2023, TECHNOL HEALTH CARE, V31, pS533, DOI 10.3233/THC-236047 Frendl G, 2014, J THORAC CARDIOV SUR, V148, P772, DOI 10.1016/j.jtcvs.2014.06.037 Huang S, 2017, J ANESTH, V31, P58, DOI 10.1007/s00540-015-2057-1 Lai Z, 1991, J Tradit Chin Med, V11, P128 Lapar DJ, 2014, ANN THORAC SURG, V98, P527, DOI 10.1016/j.athoracsur.2014.03.039 Li J, 2012, ACUPUNCT MED, V30, P47, DOI 10.1136/acupmed-2011-010060 Li YJ, 2023, ANAESTH CRIT CARE PA, V42, DOI 10.1016/j.accpm.2023.101273 Li YB, 2022, EUR J MED RES, V27, DOI 10.1186/s40001-022-00738-4 Lin Y, 2021, TRIALS, V22, DOI 10.1186/s13063-020-04967-y Liu HZ, 2024, INT IMMUNOPHARMACOL, V140, DOI 10.1016/j.intimp.2024.112702 Liu J, 2022, MINERVA ANESTESIOL, V88, P490, DOI 10.23736/S0375-9393.21.16034-1 Lombardi F, 2012, WORLD J CARDIOL, V4, P60, DOI 10.4330/wjc.v4.i3.60 Lomuscio A, 2011, J CARDIOVASC ELECTR, V22, P241, DOI 10.1111/j.1540-8167.2010.01878.x Lu Z, 2015, BRIT J ANAESTH, V115, P183, DOI 10.1093/bja/aev227 Ou-yang CL, 2024, EUR J ANAESTH, V41, P226, DOI 10.1097/EJA.0000000000001952 Park BJ, 2007, J THORAC CARDIOV SUR, V133, P775, DOI 10.1016/j.jtcvs.2006.09.022 Saran T, 2011, BRIT J ANAESTH, V106, P785, DOI 10.1093/bja/aer096 Segar MW, 2023, TEX HEART I J, V50, DOI 10.14503/THIJ-23-8221 Shen JL, 2024, BRAIN RES, V1826, DOI 10.1016/j.brainres.2023.148715 Song BJ, 2021, SLEEP BREATH, V25, P571, DOI 10.1007/s11325-020-02187-x Takemura N, 2024, JAMA ONCOL, V10, P176, DOI 10.1001/jamaoncol.2023.5248 Tan AY, 2008, CIRCULATION, V118, P916, DOI 10.1161/CIRCULATIONAHA.108.776203 Tsai WC, 2023, JACC-BASIC TRANSL SC, V8, P1398, DOI 10.1016/j.jacbts.2023.03.019 Wang D, 2022, PAIN RES MANAG, V2022, DOI 10.1155/2022/7570533 Wang Z, 2024, PRION, V18, P1, DOI 10.1080/19336896.2023.2298520 Wang ZG, 2017, INFLAMMATION, V40, P1351, DOI 10.1007/s10753-017-0578-5 Wiles MD, 2017, ANAESTHESIA, V72, P335, DOI 10.1111/anae.13785 Witt CM, 2017, EUROPACE, V19, P1075, DOI 10.1093/europace/eux011 Wu CN, 2020, EUR J ANAESTH, V37, P323, DOI 10.1097/EJA.0000000000001137 Wu CN, 2018, EUR J ANAESTH, V35, P792, DOI 10.1097/EJA.0000000000000837 Yan ST, 2023, J CLIN SLEEP MED, V19, P1633, DOI 10.5664/jcsm.10632 Yang MX, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0351-6 Yin JK, 2019, J CARDIOVASC ELECTR, V30, P910, DOI 10.1111/jce.13924 Yuan W, 2019, CHINESE MED J-PEKING, V132, P707, DOI 10.1097/CM9.0000000000000123 Zhai S, 2023, J SLEEP RES, V32, DOI 10.1111/jsr.13906 Zhang JL, 2023, BREAST CANCER RES, V25, DOI 10.1186/s13058-023-01645-0 Zhang LX, 2020, PSYCHOL HEALTH MED, V25, P1201, DOI 10.1080/13548506.2020.1738015 Zhao QY, 2018, EUROPACE, V20, P712, DOI 10.1093/europace/eux003 Zhou KH, 2011, J ALTERN COMPLEM MED, V17, P1007, DOI 10.1089/acm.2010.0652 Zhu YX, 2022, CARDIOVASC DIAGN THE, V12, P114, DOI 10.21037/cdt-21-400 NR 47 TC 0 Z9 0 U1 0 U2 0 PU FRONTIERS MEDIA SA PI LAUSANNE PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND SN 1664-2295 J9 FRONT NEUROL JI Front. Neurol. PD NOV 20 PY 2025 VL 16 AR 1580759 DI 10.3389/fneur.2025.1580759 PG 10 WC Clinical Neurology; Neurosciences WE Science Citation Index Expanded (SCI-EXPANDED) SC Neurosciences & Neurology GA M8933 UT WOS:001631028400001 PM 41356247 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Kim, Y Yang, G Oh, J Gwak, SY Kim, KH Lee, J Kim, JS Lee, CG Cho, J Ky, B Yoon, HI Grassberger, C AF Kim, Yejin Yang, Gowoon Oh, Jaewon Gwak, Seo-Yeon Kim, Kyung Hwan Lee, Joongyo Kim, Jin Sung Lee, Chang Geol Cho, Jaeho Ky, Bonnie Yoon, Hong In Grassberger, Clemens TI Consolidation ICIs Alter cardiac subregion radiosensitivity in NSCLC patients treated with Chemo-Radiotherapy SO CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY LA English DT Article DE Cardiac toxicity; Chemoradiotherapy; Immunotherapy; Non-small cell lung cancer ID IMMUNE CHECKPOINT-INHIBITORS; LUNG-CANCER; RADIATION-THERAPY; CORONARY-ARTERY; EVENTS; RISK; RADIOTHERAPY; TOXICITY; ATLAS; CARDIOTOXICITY AB Purpose: he addition of immune checkpoint inhibitor (ICI) as consolidation therapy after chemoradiation (CRT) has improved survival rates in non-small cell lung cancer (NSCLC) patients. However, the cardiotoxicity of CRT combined with ICI remains underexplored. This study assesses if ICI exposure alters the critical cardiac subregion linked to radiation-induced heart disease (RIHD) following CRT. Methods: We conducted a retrospective analysis of 321 locally advanced NSCLC patients treated with definitive CRT from August 2008 to December 2019, including 67 who received consolidation ICI. Cardiac contours include the entire heart, chambers, major coronary arteries, and conduction nodes. The primary endpoint was RIHD, defined as a major adverse cardiac event and atrial fibrillation. We used Fine-Gray analysis to investigate associations between RIHD and mean doses to cardiac subregions. Results: In total, 53 patients (18.4 %) developed RIHD, with no significant difference between CRT and CRT + ICI groups. Doses to cardiac subregions were similar between the groups. In the CRT group, multivariable analysis shows that dose to the base of the heart, especially the sinoatrial node (SAN), correlated with increased RIHD risk (HR = 1.02 per 1 Gy, 95 %CI [1.01-1.03], p < 0.001). In the CRT + IO group, the left ventricle (LV) dose was a significant predictor (1.06 [1.06-1.1], p = 0.006). Conclusions: Doses to the SAN and the base of the heart correlate with RIHD in CRT patients, while doses to LV in CRT + ICI patients. While the 2-6 % increased risk per Gy seems modest, it is clinically significant as the subregions, being small structures, can potentially be completely spared with a carefully optimized plan. C1 [Kim, Yejin; Yang, Gowoon; Kim, Jin Sung; Lee, Chang Geol; Cho, Jaeho; Yoon, Hong In] Yonsei Univ, Hlth Syst, Yonsei Canc Ctr, Dept Radiat Oncol,Coll Med, Seoul, South Korea. [Kim, Yejin; Grassberger, Clemens] Univ Washington, Fred Hutch Canc Ctr, Dept Radiat Oncol, Seattle, WA USA. [Yang, Gowoon] Cha Univ, Ilsan Cha Hosp, Dept Radiat Oncol, Sch Med, Ilsan, South Korea. [Oh, Jaewon; Gwak, Seo-Yeon] Yonsei Univ, Severance Cardiovasc Hosp, Cardiol Div, Coll Med, Seoul, South Korea. [Oh, Jaewon; Gwak, Seo-Yeon] Yonsei Univ, Cardiovasc Res Inst, Coll Med, Cardiol Div, Seoul, South Korea. [Kim, Kyung Hwan] Yonsei Univ, Heavy Ion Therapy Res Inst, Yonsei Canc Ctr, Dept Radiat Oncol,Coll Med, Seoul, South Korea. [Lee, Joongyo] Gachon Univ, Gil Med Ctr, Dept Radiat Oncol, Coll Med, Incheon, South Korea. [Ky, Bonnie] Univ Penn, Perelman Sch Med, Dept Med, Div Cardiol, Philadelphia, PA 19104 USA. C3 Yonsei University; Yonsei University Health System; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Pochon Cha University; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Gachon University; University of Pennsylvania RP Yoon, HI (corresponding author), Yonsei Univ, Heavy Ion Therapy Ctr, Yonsei Canc Ctr, Dept Radiat Oncol,Coll Med, 50-1 Yonsei Ro, Seoul 03722, South Korea.; Yoon, HI (corresponding author), Yonsei Univ, Res Inst, Yonsei Canc Ctr, Coll Med, 50-1 Yonsei Ro, Seoul 03722, South Korea.; Grassberger, C (corresponding author), Fred Hutch Canc Ctr, Dept Radiat Oncol, UW Med, 1959 NE Pacific St,Box 356043, Seattle, WA 98195 USA. EM yhi0225@yuhs.ac; clemensg@uw.edu RI ; Lee, Chang Geol/HME-1129-2023 OI Oh, Jaewon/0000-0002-4585-1488; Cho, Jaeho/0000-0001-9966-5157; Kim, Jin Sung/0000-0003-1415-6471; Kim, Yejin/0000-0002-3416-1502; Lee, Chang Geol/0000-0002-8702-881X; Yoon, Hong In/0000-0002-2106-6856; Ky, Bonnie/0000-0002-6628-9981; Grassberger, Clemens/0000-0002-4425-4489 FU National Research Foundation of Korea (NRF) grants - the Korean government (MSIT) [RS-2023-00279682]; Yonsei University College of Medicine [6-2022-0174] FX This work was supported by the National Research Foundation of Korea (NRF) grants funded by the Korean government (MSIT) (RS-2023-00279682) and a faculty research grant from the Yonsei University College of Medicine for (6-2022-0174). CR Antonia SJ, 2017, NEW ENGL J MED, V377, P1919, DOI 10.1056/NEJMoa1709937 Atkins KM, 2024, JACC-CARDIOONCOL, V6, P544, DOI 10.1016/j.jaccao.2024.07.005 Atkins KM, 2021, INT J RADIAT ONCOL, V110, P1473, DOI 10.1016/j.ijrobp.2021.03.005 Atkins KM, 2021, JAMA ONCOL, V7, P206, DOI 10.1001/jamaoncol.2020.6332 Awadalla M, 2020, J AM COLL CARDIOL, V75, P467, DOI 10.1016/j.jacc.2019.11.049 Banfill K, 2021, J THORAC ONCOL, V16, P216, DOI 10.1016/j.jtho.2020.11.002 Belzile-Dugas E, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.121.021686 Ben Zadok OI, 2023, JACC-CARDIOONCOL, V5, P732, DOI 10.1016/j.jaccao.2023.09.004 Bradley JD, 2020, J CLIN ONCOL, V38, P706, DOI 10.1200/JCO.19.01162 Brock G, R code for calculating the competing risks estimates Choi MS, 2020, RADIOTHER ONCOL, V153, P139, DOI 10.1016/j.radonc.2020.09.045 Craddock M, 2023, J THORAC ONCOL, V18, P57, DOI 10.1016/j.jtho.2022.09.004 Darby SC, 2013, NEW ENGL J MED, V368, P987, DOI 10.1056/NEJMoa1209825 Dess RT, 2017, J CLIN ONCOL, V35, P1395, DOI 10.1200/JCO.2016.71.6142 Feng M, 2011, INT J RADIAT ONCOL, V79, P10, DOI 10.1016/j.ijrobp.2009.10.058 Filippi AR, 2024, ESMO OPEN, V9, DOI 10.1016/j.esmoop.2024.103464 Gaasch A, 2020, RADIAT ONCOL, V15, DOI 10.1186/s13014-020-01520-8 Gergely TG, 2024, NAT REV CARDIOL, V21, P430, DOI 10.1038/s41569-023-00986-9 Hahn E, 2017, INT J RADIAT ONCOL, V98, P1116, DOI 10.1016/j.ijrobp.2017.03.026 Huang HT, 2024, RADIOTHER ONCOL, V200, DOI 10.1016/j.radonc.2024.110477 Jang BS, 2020, RADIOTHER ONCOL, V152, P126, DOI 10.1016/j.radonc.2020.09.050 Jimenez RB, 2022, INT J RADIAT ONCOL, V114, P140, DOI 10.1016/j.ijrobp.2022.05.011 Kakiuchi Y, 2024, CLIN LUNG CANCER, V25, P661, DOI [10.1016/j.clc.2024.07.001, 10.1016/j.cllc.2024.07.001] Kim KH, 2022, JAMA ONCOL, V8, P1624, DOI 10.1001/jamaoncol.2022.4202 Laenens D, 2022, J CLIN ONCOL, V40, P3430, DOI 10.1200/JCO.21.01808 Lee JG, 2021, KOREAN J RADIOL, V22, P1764 Liu GH, 2024, HELIYON, V10, DOI 10.1016/j.heliyon.2024.e25747 Loap P, 2021, PRACT RADIAT ONCOL, V11, pE434, DOI 10.1016/j.prro.2021.02.002 Loap P, 2020, INT J RADIAT ONCOL, V107, P386, DOI 10.1016/j.ijrobp.2020.02.017 Lyon AR, 2018, LANCET ONCOL, V19, pE447, DOI 10.1016/S1470-2045(18)30457-1 McKenzie E, 2023, INT J RADIAT ONCOL, V115, P1138, DOI 10.1016/j.ijrobp.2022.11.033 McWilliam A, 2023, J THORAC ONCOL, V18, P599, DOI 10.1016/j.jtho.2023.01.085 McWilliam A, 2017, EUR J CANCER, V85, P106, DOI 10.1016/j.ejca.2017.07.053 Meattini I, 2021, JAMA ONCOL, V7, P924, DOI 10.1001/jamaoncol.2020.7468 Melosky B, 2019, LUNG CANCER, V134, P259, DOI 10.1016/j.lungcan.2019.05.027 Moey MYY, 2020, JACC-CARDIOONCOL, V2, P491, DOI 10.1016/j.jaccao.2020.07.005 Naidoo J, 2017, J CLIN ONCOL, V35, P709, DOI 10.1200/JCO.2016.68.2005 Rengan R, 2011, CLIN CANCER RES, V17, P4192, DOI 10.1158/1078-0432.CCR-10-2760 Thuny F, 2022, JACC-CARDIOONCOL, V4, P624, DOI 10.1016/j.jaccao.2022.06.008 Walls GM, 2024, JACC-CARDIOONCOL, V6, P529, DOI 10.1016/j.jaccao.2024.05.009 Wang K, 2017, J CLIN ONCOL, V35, P1387, DOI 10.1200/JCO.2016.70.0229 Yegya-Raman N, 2024, RADIOTHER ONCOL, V190, DOI 10.1016/j.radonc.2023.110005 Yegya-Raman N, 2018, J THORAC ONCOL, V13, P1508, DOI 10.1016/j.jtho.2018.05.028 Zhang T, 2020, THORAC CANCER, V11, P2916, DOI 10.1111/1759-7714.13631 NR 44 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND EI 2405-6308 J9 CLIN TRANSL RAD ONCO JI Clin. Transl. Radiat. Oncol. PD JAN PY 2026 VL 56 AR 101069 DI 10.1016/j.ctro.2025.101069 EA NOV 2025 PG 7 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA I8015 UT WOS:001626911000002 PM 41334110 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Otsuka, S Shiiya, H Takagi, R Okada, K Sasaki, A Ohtaka, K Fujiwara-Kuroda, A Ujiie, H Aragaki, M Kato, T AF Otsuka, Shinya Shiiya, Haruhiko Takagi, Ryo Okada, Kazufumi Sasaki, Akihiro Ohtaka, Kazuto Fujiwara-Kuroda, Aki Ujiie, Hideki Aragaki, Masato Kato, Tatsuya TI Preoperative brain natriuretic peptide levels are associated with postoperative all-cause mortality in patients with lung cancer SO SURGERY TODAY LA English DT Article; Early Access DE Lung cancer; Radical resection; Brain natriuretic peptides; Overall survival ID ATRIAL-FIBRILLATION; THORACIC-SURGERY; RISK; MULTICENTER; PREDICTION; BIOMARKERS AB Purpose Serum levels of cardiovascular markers, including brain natriuretic peptide (BNP), are associated with the prognosis of cancer patients. This study examined the relationship between the preoperative blood BNP level and the long-term prognosis after curative lung cancer resection. Methods Patients who underwent radical resection for lung cancer at our institution between January 2012 and June 2019 were divided into the high- (>= 18.5 pg/ml) and low- (< 18.5 pg/ml) BNP groups. Kaplan-Meier curves were used to analyze the postoperative overall survival (OS) and relapse-free survival (RFS). The cumulative incidence function (CIF) was analyzed using the Gray's test. Univariate and multivariate Cox proportional hazards models were used to identify independent predictors of the OS. Results The postoperative OS was significantly worse in the high-BNP group than in the low-BNP group (p = 0.03), but there was no statistically significant difference in the RFS (p = 0.09). A CIF analysis indicated that non-cancer-related deaths had a greater impact on the RFS than cancer recurrence. Blood BNP levels possibly affected the OS independently (hazard ratio, 1.50). Conclusions Preoperative BNP levels in patients with lung cancer may indicate a potentially compromised condition and can be associated with the postoperative OS. However, the link between the BNP level and lung cancer severity remains unclear. C1 [Otsuka, Shinya; Shiiya, Haruhiko; Sasaki, Akihiro; Ohtaka, Kazuto; Fujiwara-Kuroda, Aki; Ujiie, Hideki; Aragaki, Masato; Kato, Tatsuya] Hokkaido Univ Hosp, Grad Sch Med, Dept Thorac Surg, Kita 14,Nishi 5,Kita Ku, Sapporo, Hokkaido 0608648, Japan. [Takagi, Ryo; Okada, Kazufumi] Hokkaido Univ Hosp, Inst Hlth Sci Innovat Med Care, Data Sci Ctr, Promot Unit, Sapporo, Hokkaido, Japan. C3 Hokkaido University; Hokkaido University RP Kato, T (corresponding author), Hokkaido Univ Hosp, Grad Sch Med, Dept Thorac Surg, Kita 14,Nishi 5,Kita Ku, Sapporo, Hokkaido 0608648, Japan. EM katotatu7@msn.com RI ; Fujiwara-Kuroda, Aki/ABW-2873-2022; Aragaki, Masato/AAW-7688-2020; Kato, Tatsuya/G-1648-2012; Ujiie, Hideki/I-1939-2019 OI Otsuka, Shinya/0000-0002-2489-9992; Fujiwara-Kuroda, Aki/0000-0002-6231-4844; Takagi, Ryo/0000-0002-5930-0329; Ujiie, Hideki/0000-0001-6119-8776 CR Altorki N, 2023, NEW ENGL J MED, V388, P489, DOI 10.1056/NEJMoa2212083 Aujollet N, 2010, CLIN LUNG CANCER, V11, P341, DOI 10.3816/CLC.2010.n.043 Azam F, 2019, CASE REP ONCOL, V12, P728, DOI 10.1159/000503095 Biccard BM, 2014, ANAESTHESIA, V69, P484, DOI 10.1111/anae.12635 Bonow Robert O, 2008, Circulation, V118, pe523, DOI 10.1161/CIRCULATIONAHA.108.190748 Burjonroppa SC, 2007, AM J CLIN ONCOL-CANC, V30, P287, DOI 10.1097/01.coc.0000256101.04404.b0 Cagini L, 2014, EUR J CARDIO-THORAC, V46, pE74, DOI 10.1093/ejcts/ezu348 Cardinale D, 2007, CIRCULATION, V115, P1339, DOI 10.1161/CIRCULATIONAHA.106.647008 De Vito P, 2014, PEPTIDES, V58, P108, DOI 10.1016/j.peptides.2014.06.011 Dickie L, 2021, Lung solid tumor rules Forde PM, 2022, NEW ENGL J MED, V386, P1973, DOI 10.1056/NEJMoa2202170 Fu HF, 2022, CANCERS, V14, DOI 10.3390/cancers14163981 Goldstraw P, 2016, J THORAC ONCOL, V11, P39, DOI 10.1016/j.jtho.2015.09.009 Haruki T, 2025, SURG TODAY, V55, P1124, DOI 10.1007/s00595-025-02992-5 Hasin T, 2017, AM J MED, V130, P780, DOI 10.1016/j.amjmed.2017.02.024 Hou JL, 2008, WORLD J GASTROENTERO, V14, P2582, DOI 10.3748/wjg.14.2582 Hua GR, 2023, CLIN OTOLARYNGOL, V48, P200, DOI 10.1111/coa.14009 Kashiwagi M, 2023, SURG TODAY, V53, P1139, DOI 10.1007/s00595-023-02670-4 Kent MS, 2016, ANN THORAC SURG, V102, P239, DOI 10.1016/j.athoracsur.2016.01.063 Komarnicki P, 2023, ENDOCR CONNECT, V12, DOI 10.1530/EC-23-0249 Lee TH, 1999, CIRCULATION, V100, P1043, DOI 10.1161/01.CIR.100.10.1043 Lenneman CG, 2016, CIRC RES, V118, P1008, DOI 10.1161/CIRCRESAHA.115.303633 Levy S, 2022, CANCERS, V14, DOI 10.3390/cancers14102361 Lyon AR, 2022, EUR HEART J, V43, P4229, DOI 10.1093/eurheartj/ehac244 Maisel AS, 2002, NEW ENGL J MED, V347, P161, DOI 10.1056/NEJMoa020233 Manimala NJ, 2013, EUR J CLIN INVEST, V43, P1156, DOI 10.1111/eci.12153 Nguyen JP, 2012, EUR J CLIN INVEST, V42, P1061, DOI 10.1111/j.1365-2362.2012.02695.x Ohsaki Y, 1999, ONCOLOGY-BASEL, V56, P155, DOI 10.1159/000011957 Pavo N, 2015, HEART, V101, P1874, DOI 10.1136/heartjnl-2015-307848 Romann SW, 2024, ESC HEART FAIL, V11, P366, DOI 10.1002/ehf2.14587 Saji H, 2022, LANCET, V399, P1607, DOI 10.1016/S0140-6736(21)02333-3 Samuel NA, 2024, CARDIO-ONCOLOGY, V10, DOI 10.1186/s40959-024-00238-w Shi C, 2020, J INTERN MED, V288, P207, DOI 10.1111/joim.13053 Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660 The Japanese Circulation Society The Japanese Heart Failure Society, 2017, Guidelines for Diagnosis and Treatment of Acute and Chronic Heart Failure (JCS 2017/JHFS 2017) Toufektzian L, 2015, INTERACT CARDIOV TH, V20, P654, DOI 10.1093/icvts/ivu454 Tsuboi M, 2023, NEW ENGL J MED, V389, P137, DOI 10.1056/NEJMoa2304594 Tuñón J, 2021, J CLIN MED, V10, DOI 10.3390/jcm10184042 Vesely BA, 2005, EUR J CLIN INVEST, V35, P388, DOI 10.1111/j.1365-2362.2005.01501.x Zhang YT, 2023, CARDIO-ONCOLOGY, V9, DOI 10.1186/s40959-023-00162-5 Zhang YT, 2021, ECLINICALMEDICINE, V40, DOI 10.1016/j.eclinm.2021.101128 NR 41 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES SN 0941-1291 EI 1436-2813 J9 SURG TODAY JI Surg. Today PD 2025 NOV 17 PY 2025 DI 10.1007/s00595-025-03108-9 EA NOV 2025 PG 14 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA 9XD1Q UT WOS:001617126100001 PM 41247465 DA 2026-04-17 ER PT J AU Tarantini, L Gallucci, G Inno, A Camerini, A Canale, ML Larocca, M Zanelli, F Pagano, M Alberti, G Ciammella, P Maurea, N Gori, S Navazio, A Pinto, C AF Tarantini, Luigi Gallucci, Giuseppina Inno, Alessandro Camerini, Andrea Canale, Maria Laura Larocca, Mario Zanelli, Francesca Pagano, Maria Alberti, Giulia Ciammella, Patrizia Maurea, Nicola Gori, Stefania Navazio, Alessandro Pinto, Carmine TI A New Era, New Risks: The Cardio-Oncology Perspective on Immunotherapy in Non-Small Cell Lung Cancer SO CANCERS LA English DT Review DE non-small cell lung cancer; cardiovascular diseas; immunotherapy; cardio-oncology; cardio-immuno-metabolic risk; cardiovascular toxicity ID IMMUNE CHECKPOINT INHIBITORS; POSTOPERATIVE ATRIAL-FIBRILLATION; LYMPHOCYTE RATIO NLR; GROWTH-FACTOR-I; COMPUTED-TOMOGRAPHY; NONCARDIAC SURGERY; OPEN-LABEL; CARDIOVASCULAR COMORBIDITIES; CORONARY ATHEROSCLEROSIS; PROGNOSTIC-SIGNIFICANCE AB Lung cancer (LC) remains the leading cause of cancer-related mortality worldwide. In recent years, mortality rates have declined due to antismoking policies, earlier detection, and the advent of targeted therapies and immunotherapy, particularly for non-small cell lung cancer (NSCLC), which accounts for 85% of all cases. With improved survival, however, LC patients are increasingly exposed to competing causes of mortality, among which cardiovascular disease (CVD) is highly prevalent, affecting 30-50% of patients and contributing to nearly 30% of deaths. This burden reflects both shared risk factors and the cardiotoxic potential of radiotherapy, chemotherapy, and immunotherapy. Beyond acute adverse cardiovascular events during treatment, real-world data indicate that immune checkpoint inhibitors (ICIs) may also exert chronic cardiovascular effects, significantly accelerating the atherosclerotic process in multimorbid patients. These findings underscore the importance of accurate baseline assessment and aggressive management of cardiovascular risk factors in LC patients-particularly in the adjuvant and neoadjuvant settings, where longer survival is anticipated. Moreover, long-term monitoring should be implemented through a tailored, multiparametric strategy that integrates novel biomarkers and advanced artificial intelligence-assisted imaging techniques. Achieving this ambitious goal requires the close collaboration of a multidisciplinary team, with cardiologists playing a pivotal role. This review will address the complexity of LC patients, focusing on the interplay of cardio-immuno-metabolic factors, summarizing the cardiovascular impact of immunotherapy across metastatic, locally advanced, and perioperative settings, and outlining practical strategies for the management of these vulnerable patients. C1 [Tarantini, Luigi; Navazio, Alessandro] AUSL IRCCS Tecnol Avanzate & Modelli Assistenziali, Cardioncol Clin Cardiol Osped, Dipartimento Sci Sociali Cognit & Quantitat, I-42100 Reggio Emilia, Italy. [Inno, Alessandro; Gori, Stefania] IRCCS Osped Sacro Cuore Don Calabria, Med Oncol, I-37024 Negrar Di Valpolicella, Italy. [Camerini, Andrea] Azienda USL Toscana Nord Ovest, Versilia Hosp, Med Oncol, Lido Di Camaiore, Italy. [Canale, Maria Laura] Azienda USL Toscana Nord Ovest, Versilia Hosp, Cardiol, I-55041 Lido Di Camaiore, Italy. [Larocca, Mario; Zanelli, Francesca; Pagano, Maria; Alberti, Giulia; Pinto, Carmine] AUSL IRCCS Tecnol Avanzate & Modelli Assistenziali, Dept Oncol & Adv Technol, Prov Med Oncol, I-42100 Reggio Emilia, Italy. [Ciammella, Patrizia] Azienda USL IRCCS Reggio Emilia, Radiat Oncol Unit, I-42100 Reggio Emilia, Italy. [Maurea, Nicola] Ist Nazl Tumori IRCCS Fdn G Pascale, Cardiol Div, I-80131 Naples, Italy. C3 Ospedale Versilia; Ospedale Versilia; IRCCS Fondazione Pascale RP Tarantini, L (corresponding author), AUSL IRCCS Tecnol Avanzate & Modelli Assistenziali, Cardioncol Clin Cardiol Osped, Dipartimento Sci Sociali Cognit & Quantitat, I-42100 Reggio Emilia, Italy. EM luigi.tarantini@ausl.re.it; pina.gallucci@tiscali.it; alessandro.inno@sacrocuore.it; andrea.camerini@uslnordovest.toscana.it; marialaura.canale@uslnordovest.toscana.it; mario.larocca@ausl.re.it; francesca.zanelli@ausl.re.it; maria.pagano@ausl.re.it; giulia.alberti@ausl.re.it; patrizia.ciammella@ausl.re.it; n.maurea@istitutopascale.na.it; stefania.gori@sacrocuore.it; alessandro.navazio@ausl.re.it; carmine.pinto@ausl.re.it RI Ciammella, Patrizia/AAB-4222-2021; Maurea, Nicola/AAC-2341-2022; ZANELLI, FRANCESCA/AAL-5507-2020; GORI, Stefania/N-8827-2016; Pinto, Carmine/AAC-2184-2020; Inno, Alessano/AAA-8268-2022; Alberti, Giulia/ABC-3936-2021 OI Pinto, Carmine/0000-0002-3159-5268; Canale, Maria Laura/0000-0003-0990-6397; Navazio, Alessandro/0000-0001-8417-7783; Inno, Alessano/0000-0001-6331-6908; Camerini, Andrea/0000-0002-1436-8397; tarantini, luigi/0000-0003-2580-0963; Alberti, Giulia/0000-0003-2616-7477 FU Italian Ministry of Health-Ricerca Corrente Annual Program 2025 FX This study was partially funded by the Italian Ministry of Health-Ricerca Corrente Annual Program 2025. CR Aberle DR, 2011, NEW ENGL J MED, V365, P395, DOI 10.1056/NEJMoa1102873 Aburaki R, 2024, CANCER TREAT REV, V131, DOI 10.1016/j.ctrv.2024.102833 Addison D, 2023, CIRCULATION, V148, P297, DOI 10.1161/CIR.0000000000001158 Afari ME, 2016, EXPERT REV CARDIOVAS, V14, P573, DOI 10.1586/14779072.2016.1154788 Afzali AM, 2018, AUTOIMMUN REV, V17, P518, DOI 10.1016/j.autrev.2017.12.005 Aggarwal C, 2023, JCO PRECIS ONCOL, V7, DOI 10.1200/PO.23.00191 Agostinetto E, 2021, EUR J CANCER, V148, P76, DOI 10.1016/j.ejca.2021.01.043 Al-Nusair J, 2025, J CLIN ONCOL, V43, pe20613, DOI 10.1200/JCO.2025.43.16_suppl.e20613 Albini A, 2021, EUR J INTERN MED, V85, P27, DOI 10.1016/j.ejim.2020.12.018 Alexandre J, 2018, PHARMACOL THERAPEUT, V189, P89, DOI 10.1016/j.pharmthera.2018.04.009 Almatrafi A, 2023, J MED SCREEN, V30, P3, DOI 10.1177/09691413221117685 Altan M, 2019, J THORAC ONCOL, V14, P1102, DOI 10.1016/j.jtho.2019.02.026 Amar D, 2019, J THORAC CARDIOV SUR, V157, P2493, DOI 10.1016/j.jtcvs.2019.01.075 Antonia SJ, 2017, NEW ENGL J MED, V377, P1919, DOI 10.1056/NEJMoa1709937 Atkins KM, 2021, PRACT RADIAT ONCOL, V11, pE459, DOI 10.1016/j.prro.2020.12.006 Atterman A, 2020, EUROPACE, V22, P58, DOI 10.1093/europace/euz306 Bacmeister L, 2025, CIRC-CARDIOVASC IMAG, V18, DOI 10.1161/CIRCIMAGING.124.016851 Baek J, 2020, CLIN LUNG CANCER, V21, pE265, DOI 10.1016/j.cllc.2020.02.016 Baskaran G, 2024, J CLIN ANESTH, V97, DOI 10.1016/j.jclinane.2024.111540 Batra A, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07487-9 Battisti NML, 2022, JACC-CARDIOONCOL, V4, P238, DOI 10.1016/j.jaccao.2022.03.004 Beattie WS, 2021, BRIT J ANAESTH, V126, P56, DOI 10.1016/j.bja.2020.09.023 Bei YP, 2021, AGING CLIN EXP RES, V33, P147, DOI 10.1007/s40520-020-01517-z Bell CF, 2023, JACC-CARDIOONCOL, V5, P431, DOI 10.1016/j.jaccao.2023.01.010 Benker M, 2022, GEN THORAC CARDIOVAS, V70, P248, DOI 10.1007/s11748-021-01710-5 Bergerot C, 2024, ECLINICALMEDICINE, V78, DOI 10.1016/j.eclinm.2024.102942 Bergqvist D, 2007, EUR J VASC ENDOVASC, V34, P253, DOI 10.1016/j.ejvs.2007.06.014 Bhalraam U, 2026, EUR J PREV CARDIOL, V33, P214, DOI 10.1093/eurjpc/zwaf026 Bianchini E, 2025, JACC-CARDIOVASC IMAG, V18, P1220, DOI 10.1016/j.jcmg.2025.05.017 Bishnoi R, 2020, LUNG CANCER, V150, P172, DOI 10.1016/j.lungcan.2020.10.017 Blank CU, 2018, NAT MED, V24, P1655, DOI 10.1038/s41591-018-0198-0 Boen HM, 2024, JACC-CARDIOONCOL, V6, P183, DOI 10.1016/j.jaccao.2023.12.009 Bonney A, 2022, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD013829.pub2, 10.1002/14651858.CD013829] Bonsu J, 2019, CIRCULATION, V139, P2594, DOI 10.1161/CIRCULATIONAHA.118.039180 Borg M, 2022, ACTA ONCOL, V61, P1256, DOI 10.1080/0284186X.2022.2135134 Borghaei H, 2021, J CLIN ONCOL, V39, P723, DOI 10.1200/JCO.20.01605 Bott MJ, 2019, J THORAC CARDIOV SUR, V158, P269, DOI 10.1016/j.jtcvs.2018.11.124 Boulet J, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.117.005996 Bray F, 2024, CA-CANCER J CLIN, V74, P229, DOI 10.3322/caac.21834 Brunelli A, 2020, EUR J CARDIO-THORAC, V57, P740, DOI 10.1093/ejcts/ezz287 Bu DX, 2011, ARTERIOSCL THROM VAS, V31, P1100, DOI 10.1161/ATVBAHA.111.224709 Burdett S, 2014, LANCET, V383, P1561, DOI 10.1016/S0140-6736(13)62159-5 Caan BJ, 2018, CANCER RES, V78, P1906, DOI 10.1158/0008-5472.CAN-17-3287 Calabretta R, 2024, LIFE-BASEL, V14, DOI 10.3390/life14010146 Cantini L, 2021, EUR J CANCER, V144, P41, DOI 10.1016/j.ejca.2020.10.031 Cao WL, 2025, BMC CANCER, V25, DOI [10.1186/s12885-025-13997-1, 10.1186/s12885-025-13997-1] Caro-Codón J, 2022, EUR J PREV CARDIOL, V29, P859, DOI 10.1093/eurjpc/zwaa034 Carreras-Torres R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177875 Carroll R, 2022, BMC CANCER, V22, DOI 10.1186/s12885-022-09342-5 Cascone T, 2024, NEW ENGL J MED, V390, P1756, DOI 10.1056/NEJMoa2311926 Cavalheri V, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009955.pub3 Chan SHY, 2025, CANCERS, V17, DOI 10.3390/cancers17020311 Chang SH, 2017, JAMA-J AM MED ASSOC, V318, P1250, DOI 10.1001/jama.2017.13883 Chen SJ, 2024, CLIN TRANSL ONCOL, V26, P3202, DOI 10.1007/s12094-024-03543-z Chen X, 2022, BMC PUBLIC HEALTH, V22, DOI 10.1186/s12889-022-13281-y Cheng XT, 2024, SCI REP-UK, V14, DOI 10.1038/s41598-024-72864-4 Cho AR, 2025, J THORAC CARDIOV SUR, V169, DOI [10.1016/j.jtcvs.2025.02.013, 10.1016/j.jtcvs.2025.02.013] Cho IY, 2021, CURR PROB CANCER, V45, DOI 10.1016/j.currproblcancer.2020.100615 Cortes-Ibáñez FO, 2024, SCI REP-UK, V14, DOI 10.1038/s41598-024-57889-z Cui ZW, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1259908 D'Souza M, 2021, EUR HEART J, V42, P1621, DOI 10.1093/eurheartj/ehaa884 Damluji AA, 2023, CIRCULATION, V147, P1534, DOI 10.1161/CIRCULATIONAHA.123.064071 de Jesus M, 2024, FRONT ONCOL, V14, DOI 10.3389/fonc.2024.1258991 de Koning HJ, 2020, NEW ENGL J MED, V382, P503, DOI 10.1056/NEJMoa1911793 Delombaerde D, 2025, ESMO REAL WORLD DATA, V7, DOI 10.1016/j.esmorw.2024.100111 Demkow U, 2013, RESP PHYSIOL NEUROBI, V187, P64, DOI 10.1016/j.resp.2013.03.013 Dess RT, 2017, J CLIN ONCOL, V35, P1395, DOI 10.1200/JCO.2016.71.6142 Devereaux PJ, 2008, LANCET, V371, P1839, DOI 10.1016/S0140-6736(08)60601-7 Ding D, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001917 Dolladille C, 2021, EUR HEART J, V42, P4964, DOI 10.1093/eurheartj/ehab618 Dong ZK, 2024, PHARMACOL THERAPEUT, V264, DOI 10.1016/j.pharmthera.2024.108750 Drobni ZD, 2020, CIRCULATION, V142, P2299, DOI 10.1161/CIRCULATIONAHA.120.049981 Drobni ZD, 2023, J IMMUNOTHER CANCER, V11, DOI 10.1136/jitc-2023-007307 Dzaye O, 2022, EUR HEART J-CARD IMG, V23, P708, DOI 10.1093/ehjci/jeab099 Dziadziuszko R, 2008, J THORAC ONCOL, V3, P815, DOI 10.1097/JTO.0b013e31818180f5 Fa'ak F, 2023, J IMMUNOTHER CANCER, V11, DOI 10.1136/jitc-2023-006814 Farvid MS, 2021, EUR J EPIDEMIOL, V36, P937, DOI 10.1007/s10654-021-00741-9 Faubry C, 2022, FRONT CARDIOVASC MED, V9, DOI 10.3389/fcvm.2022.878211 FAVONI RE, 1994, INT J CANCER, V56, P858, DOI 10.1002/ijc.2910560618 Felip E, 2025, J CLIN ONCOL, V43, DOI 10.1200/JCO-24-01681 Felip E, 2021, LANCET, V398, P1344, DOI 10.1016/S0140-6736(21)02098-5 Fernandez DM, 2019, NAT MED, V25, P1576, DOI 10.1038/s41591-019-0590-4 Flores R, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.37508 Florido R, 2022, J AM COLL CARDIOL, V80, P22, DOI 10.1016/j.jacc.2022.04.042 Florido R, 2019, AM J EPIDEMIOL, V188, P2188, DOI 10.1093/aje/kwz088 Forde PM, 2025, NEW ENGL J MED, V393, P741, DOI [10.1056/nejmoa2502931, 10.1056/NEJMoa2502931] Forde PM, 2022, NEW ENGL J MED, V386, P1973, DOI 10.1056/NEJMoa2202170 Frendl G, 2014, J THORAC CARDIOV SUR, V148, pE153, DOI 10.1016/j.jtcvs.2014.06.036 Fujiwara Y, 2024, LANCET ONCOL, V25, P62, DOI 10.1016/S1470-2045(23)00524-7 Gallucci G, 2025, INT J MOL SCI, V26, DOI 10.3390/ijms26010334 Ganti AK, 2021, JAMA ONCOL, V7, P1824, DOI 10.1001/jamaoncol.2021.4932 Garassino MC, 2023, J CLIN ONCOL, V41, P1992, DOI 10.1200/JCO.22.01989 García-Pardo M, 2023, J THORAC ONCOL, V18, P313, DOI 10.1016/j.jtho.2022.10.020 Gaudino M, 2023, EUR HEART J, V44, P1020, DOI 10.1093/eurheartj/ehad019 Gendarme S, 2024, JNCI CANCER SPECT, V8, DOI 10.1093/jncics/pkae082 Ghosh Arjun K, 2018, Curr Treat Options Cardiovasc Med, V20, P60, DOI [10.1007/s11936-018-0654-7, 10.1007/s11936-018-0654-7] Gietema JA, 2000, LANCET, V355, P1075, DOI 10.1016/S0140-6736(00)02044-4 Gilchrist SC, 2019, CIRCULATION, V139, pE997, DOI 10.1161/CIR.0000000000000679 Götze H, 2018, J CANCER SURVIV, V12, P712, DOI 10.1007/s11764-018-0708-6 Gogishvili M, 2022, NAT MED, V28, P2374, DOI 10.1038/s41591-022-01977-y Goldstraw P, 2016, J THORAC ONCOL, V11, P39, DOI 10.1016/j.jtho.2015.09.009 Gong BX, 2024, BMC MED, V22, DOI 10.1186/s12916-024-03261-x Goss G, 2024, ANN ONCOL, V35, P1238, DOI 10.1016/j.annonc.2024.08.2289 Gotsman I, 2007, J CLIN INVEST, V117, P2974, DOI 10.1172/JCI31344 Gougis P, 2024, ECLINICALMEDICINE, V70, DOI 10.1016/j.eclinm.2024.102536 Gould MK, 2017, ANN AM THORAC SOC, V14, P1571, DOI 10.1513/AnnalsATS.201701-030OC Guha A, 2025, CURR CARDIOL REP, V27, DOI 10.1007/s11886-025-02215-w Ha DM, 2025, SEMIN RESP CRIT CARE, V46, P436, DOI 10.1055/a-2649-9311 Halvorsen S, 2022, EUR HEART J, V43, P3826, DOI [10.1714/3956.39326, 10.1093/eurheartj/ehac270] Hansen RN, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-06734-3 Hecht HS, 2017, J THORAC IMAG, V32, pW54, DOI 10.1097/RTI.0000000000000287 Hektoen HH, 2025, BRIT J CANCER, V132, P93, DOI 10.1038/s41416-024-02895-1 Herbst RS, 2020, NEW ENGL J MED, V383, P1328, DOI 10.1056/NEJMoa1917346 Hernandez D, 2022, ONCOL RES, V30, P173, DOI 10.32604/or.2022.027262 Heymach JV, 2023, NEW ENGL J MED, V389, P1672, DOI 10.1056/NEJMoa2304875 Hidayat K, 2016, NUTRIENTS, V8, DOI 10.3390/nu8120810 Higgins KA, 2022, J CLIN ONCOL, V40, P576, DOI 10.1200/JCO.21.01707 Higuchi S, 2019, CAN J CARDIOL, V35, P1449, DOI 10.1016/j.cjca.2019.07.008 Howlader N, 2020, NEW ENGL J MED, V383, P640, DOI 10.1056/NEJMoa1916623 Hu H, 2025, INT J CANCER, V156, P608, DOI 10.1002/ijc.35195 Hu X, 2024, CANCER TREAT RES COM, V40, DOI 10.1016/j.ctarc.2024.100833 Huang JJ, 2022, CHEST, V161, P1101, DOI 10.1016/j.chest.2021.12.655 Hussaini S, 2021, CANCER TREAT REV, V92, DOI 10.1016/j.ctrv.2020.102134 Iachina M, 2015, LUNG, V193, P291, DOI 10.1007/s00408-014-9675-5 Ichinose J, 2022, EUR J CARDIO-THORAC, V63, DOI 10.1093/ejcts/ezac529 Jain P, 2021, ESMO OPEN, V6, DOI 10.1016/j.esmoop.2021.100252 Jiang L, 2025, CLIN LUNG CANCER, V26, pE91, DOI 10.1016/j.cllc.2024.10.012 Jin J, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-035031 Joglar JA, 2024, CIRCULATION, V149, pe1, DOI 10.1161/CIR.0000000000001193 Johns AC, 2023, CANCER IMMUNOL IMMUN, V72, P2005, DOI 10.1007/s00262-023-03371-0 Johnson DB, 2016, NEW ENGL J MED, V375, P1749, DOI 10.1056/NEJMoa1609214 Jonas DE, 2021, JAMA-J AM MED ASSOC, V325, P971, DOI 10.1001/jama.2021.0377 Kaneko H, 2022, EUR J PREV CARDIOL, V29, P2324, DOI 10.1093/eurjpc/zwac195 Kanji S, 2022, DRUGS, V82, P793, DOI 10.1007/s40265-022-01707-1 Katagiri H, 2007, CIRC RES, V101, P27, DOI 10.1161/CIRCRESAHA.107.151621 Kaufmann KB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199807 Khan HM, 2023, J CLIN ONCOL, V41, P3051, DOI 10.1200/JCO.22.01799 Kimura D, 2023, SURG TODAY, V53, P1388, DOI 10.1007/s00595-023-02691-z Kobo O, 2022, EUR HEART J-QUAL CAR, V8, P787, DOI 10.1093/ehjqcco/qcac045 Kocher F, 2015, CLIN LUNG CANCER, V16, P305, DOI 10.1016/j.cllc.2014.12.007 Koutroumpakis E, 2022, FRONT CARDIOVASC MED, V9, DOI 10.3389/fcvm.2022.1071701 Kratzer TB, 2024, CANCER-AM CANCER SOC, V130, P1330, DOI 10.1002/cncr.35128 Kravchenko J, 2015, LUNG CANCER, V88, P85, DOI 10.1016/j.lungcan.2015.01.006 La J, 2020, JCO CLIN CANCER INFO, V4, P918, DOI 10.1200/CCI.20.00084 Lamperti M, 2025, EUR J ANAESTH, V42, P1, DOI 10.1097/EJA.0000000000002069 Larabee CM, 2020, NAT REV ENDOCRINOL, V16, P30, DOI 10.1038/s41574-019-0283-6 Largeau B, 2021, BRIT J CLIN PHARMACO, V87, P3043, DOI 10.1111/bcp.14752 Lee A, 2022, CANCER TREAT RES COM, V33, DOI 10.1016/j.ctarc.2022.100648 Lee CRT, 2022, JACC-CARDIOONCOL, V4, P660, DOI 10.1016/j.jaccao.2022.11.008 Lei Z, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245773 Leigh NB, 2019, LANCET RESP MED, V7, P347, DOI 10.1016/S2213-2600(18)30500-9 Leiter A, 2023, NAT REV CLIN ONCOL, V20, P624, DOI 10.1038/s41571-023-00798-3 Leshem Y, 2024, INT J CARDIOL, V397, DOI 10.1016/j.ijcard.2023.131642 Li FY, 2024, BMC PULM MED, V24, DOI 10.1186/s12890-024-03180-w Li HX, 2025, J INTERN MED, V297, P36, DOI 10.1111/joim.20028 Li M, 2025, EUR J CLIN INVEST, V55, DOI 10.1111/eci.14347 Li MM, 2024, CHEST, V165, P213, DOI 10.1016/j.chest.2023.08.003 Li Y, 2023, JAMA NETW OPEN, V6, DOI 10.1001/jamanetworkopen.2023.23584 Liao YH, 2025, JCO ONCOL PRACT, V21, DOI [10.1200/op-24-00583, 10.1200/OP-24-00583] Libby P, 2013, IMMUNITY, V38, P1092, DOI 10.1016/j.immuni.2013.06.009 Ligibel JA, 2022, J CLIN ONCOL, V40, P2491, DOI 10.1200/JCO.22.00687 Lim SM, 2023, NAT COMMUN, V14, DOI 10.1038/s41467-023-42900-4 Lin E, 2000, SURGERY, V127, P117, DOI 10.1067/msy.2000.101584 Liu J, 2016, CANCER DISCOV, V6, P1382, DOI 10.1158/2159-8290.CD-16-0577 Liu JX, 2024, DIABETOL METAB SYNDR, V16, DOI 10.1186/s13098-024-01308-w Liu KT, 2025, J INFLAMM RES, V18, P195, DOI 10.2147/JIR.S500474 Liu SR, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.908173 Liu XY, 2023, SUPPORT CARE CANCER, V31, DOI 10.1007/s00520-023-07997-9 Lococo F, 2023, BMC CANCER, V23, DOI 10.1186/s12885-023-10997-x López-Jiménez T, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0264634 Lorenzo-Esteller L, 2024, CANCERS, V16, DOI 10.3390/cancers16203466 Lu S, 2024, JAMA-J AM MED ASSOC, V331, P201, DOI 10.1001/jama.2023.24735 Lu T, 2019, CANCER MANAG RES, V11, P943, DOI 10.2147/CMAR.S187317 Luo JH, 2023, BRIT J CANCER, V128, P1541, DOI 10.1038/s41416-023-02177-2 Lyon AR, 2022, EUR HEART J, V43, P4229, DOI 10.1093/eurheartj/ehac244 Maccio U, 2025, MODERN PATHOL, V38, DOI 10.1016/j.modpat.2024.100683 Malaty MM, 2022, EUR J CLIN INVEST, V52, DOI 10.1111/eci.13831 Marrone MT, 2025, CLIN LUNG CANCER, V26, P201, DOI [10.1016/j.cllc.2024.12.008, 10.1016/j.clc.2024.12.008, 10.1016/j.cllc.2024.12.008] Mascalchi M, 2021, EUR J RADIOL, V145, DOI 10.1016/j.ejrad.2021.110040 Mateos JJ, 2025, J CARDIOTHOR VASC AN, V39, P1763, DOI [10.1053/j.jvca.2025.03.023, 10.1053/j.jvca.2025.03.023] McEwen BS, 1998, ANN NY ACAD SCI, V840, P33, DOI 10.1111/j.1749-6632.1998.tb09546.x MCEWEN BS, 1993, ARCH INTERN MED, V153, P2093, DOI 10.1001/archinte.153.18.2093 Meyer HJ, 2025, ACAD RADIOL, V32, P1306, DOI 10.1016/j.acra.2024.10.046 Mitchell JD, 2023, ESMO OPEN, V8, DOI 10.1016/j.esmoop.2023.101830 Montano M, 2023, J GERONTOL A-BIOL, V78, pS19, DOI 10.1093/gerona/glad036 Moore SC, 2016, JAMA INTERN MED, V176, P816, DOI 10.1001/jamainternmed.2016.1548 Moslehi JJ, 2018, LANCET, V391, P933, DOI 10.1016/S0140-6736(18)30533-6 Mountzios G, 2023, NAT REV CLIN ONCOL, V20, P664, DOI 10.1038/s41571-023-00794-7 Naqash AR, 2022, J CLIN ONCOL, V40, P3439, DOI 10.1200/JCO.22.00369 Neff TA, 2022, ANESTH ANALG, V134, P123, DOI 10.1213/ANE.0000000000005639 Nguyen NN, 2024, DIABETES RES CLIN PR, V218, DOI 10.1016/j.diabres.2024.111930 Nishizawa N, 2022, BMJ OPEN RESPIR RES, V9, DOI 10.1136/bmjresp-2022-001327 Novello S, 2023, J CLIN ONCOL, V41, P1999, DOI 10.1200/JCO.22.01990 O'Brien M, 2022, LANCET ONCOL, V23, P1274, DOI 10.1016/S1470-2045(22)00518-6 O'Sullivan DE, 2024, CURR ONCOL, V31, P447, DOI 10.3390/curroncol31010030 Obeng-Gyasi S, 2022, JAMA NETW OPEN, V5, DOI 10.1001/jamanetworkopen.2022.21626 Ogedegbe OJ, 2025, J AM COLL CARDIOL, V85, P2874 Oh MS, 2021, CLIN LUNG CANCER, V22, pE57, DOI 10.1016/j.cllc.2020.07.016 Oh S, 2023, EUR J PREV CARDIOL, V30, P670, DOI 10.1093/eurjpc/zwad046 Ortiz C, 2022, PREV MED, V155, DOI 10.1016/j.ypmed.2021.106911 Osawa K, 2020, HEART VESSELS, V35, P1483, DOI 10.1007/s00380-020-01624-x Owen DH, 2025, J CLIN ONCOL, V43, pe45, DOI 10.1200/JCO-25-01062 Parashar Y, 2025, CLIN CHEM, V71, P664, DOI 10.1093/clinchem/hvaf023 Park MJ, 2023, METABOLISM, V144, DOI 10.1016/j.metabol.2023.155577 Pasello G, 2020, CANCER TREAT REV, V87, DOI 10.1016/j.ctrv.2020.102031 Passiglia F, 2021, J CLIN ONCOL, V39, P2574, DOI 10.1200/JCO.20.02574 Paz-Ares L, 2021, LANCET ONCOL, V22, P198, DOI 10.1016/S1470-2045(20)30641-0 Peng B, 2015, INT J CLIN EXP MED, V8, P3098 Peng Y, 2025, J AM HEART ASSOC, V14, DOI 10.1161/JAHA.124.038180 Perelman MG, 2024, CARDIO-ONCOLOGY, V10, DOI 10.1186/s40959-023-00199-6 Pillon NJ, 2013, AM J PHYSIOL-ENDOC M, V304, pE453, DOI 10.1152/ajpendo.00553.2012 Piras L, 2024, INT J MOL SCI, V25, DOI 10.3390/ijms25052502 Poels K, 2020, JACC-CARDIOONCOL, V2, P599, DOI 10.1016/j.jaccao.2020.08.007 Poels K, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9091987 Potter AL, 2022, BMJ-BRIT MED J, V376, DOI 10.1136/bmj-2021-069008 Power JR, 2026, EUR HEART J, V47, P1050, DOI 10.1093/eurheartj/ehaf315 Proietti M, 2022, AGEING RES REV, V79, DOI 10.1016/j.arr.2022.101652 Qureshi A., 2024, Int. J. Multidiscip. Res, V6, P1 Rahal Z, 2025, NAT REV CLIN ONCOL, V22, P463, DOI 10.1038/s41571-025-01021-1 Rahouma M, 2019, IMMUNOTHERAPY-UK, V11, P725, DOI 10.2217/imt-2018-0118 Ravera F, 2025, EUR J CLIN INVEST, V55, DOI 10.1111/eci.14370 Reck M, 2021, J CLIN ONCOL, V39, P2339, DOI 10.1200/JCO.21.00174 Reck M, 2019, J CLIN ONCOL, V37, P537, DOI 10.1200/JCO.18.00149 Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774 Ren BX, 2023, NUTR CANCER, V75, P685, DOI 10.1080/01635581.2022.2153879 Riba MB, 2023, J NATL COMPR CANC NE, V21, P450, DOI 10.6004/jnccn.2023.0026 Ridker PM, 2025, JACC-CARDIOVASC INTE, V18, P1229, DOI [10.1016/j.jcin.2025.03.030, 10.1016/j.jcin.2025.03.030] Riely GJ, 2024, J NATL COMPR CANC NE, V22, P249, DOI 10.6004/jnccn.2204.0023 Rogers JR, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.4732 Roy P, 2022, NAT REV IMMUNOL, V22, P251, DOI 10.1038/s41577-021-00584-1 Ruetzler K, 2021, CIRCULATION, V144, pE287, DOI 10.1161/CIR.0000000000001024 Sabaté-Ortega J, 2025, FRONT ONCOL, V15, DOI 10.3389/fonc.2025.1528950 Salem JE, 2018, LANCET ONCOL, V19, P1579, DOI 10.1016/S1470-2045(18)30608-9 Sanaiha Y, 2019, J SURG RES, V235, P202, DOI 10.1016/j.jss.2018.09.062 Sazgary L, 2021, EUR HEART J-ACUTE CA, V10, P550, DOI 10.1093/ehjacc/zuaa008 Schneider BJ, 2021, J CLIN ONCOL, V39, P4073, DOI 10.1200/JCO.21.01440 Schneider L, 2014, ANN THORAC SURG, V98, P1976, DOI 10.1016/j.athoracsur.2014.06.068 Sepesi Boris, 2022, J Thorac Cardiovasc Surg, V164, P1327, DOI [10.1016/j.jtcvs.2022.01.019, 10.1016/j.jtcvs.2022.01.019] Sezer A, 2021, LANCET, V397, P592, DOI 10.1016/S0140-6736(21)00228-2 Shah AN, 2023, CANCER TREAT RES COM, V36, DOI 10.1016/j.ctarc.2023.100742 Shah S, 2024, BIOMEDICINES, V12, DOI 10.3390/biomedicines12091968 Shahraki N, 2024, BMC CARDIOVASC DISOR, V24, DOI 10.1186/s12872-024-03761-x Shelley B, 2023, BRIT J ANAESTH, V130, pE66, DOI 10.1016/j.bja.2022.06.035 Shemesh J, 2006, CLIN IMAG, V30, P181, DOI 10.1016/j.clinimag.2005.11.002 Shen EJ, 2023, J DIABETES INVEST, V14, P1209, DOI 10.1111/jdi.14057 Shin YE, 2023, CLIN DRUG INVEST, V43, P289, DOI 10.1007/s40261-023-01254-x Siegel RL, 2025, CA-CANCER J CLIN, V75, P10, DOI 10.3322/caac.21871 Sin S, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgaa596 Singareddy A, 2022, CLIN LUNG CANCER, V24, P114, DOI 10.1016/j.cllc.2022.11.005 Smilowitz NR, 2018, HEART, V104, P1180, DOI 10.1136/heartjnl-2017-312391 Smilowitz NR, 2017, EUR HEART J, V38, P2409, DOI 10.1093/eurheartj/ehx313 Smilowitz NR, 2017, JAMA CARDIOL, V2, P181, DOI 10.1001/jamacardio.2016.4792 Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948 Soh CH, 2025, AM HEART J, V288, P159, DOI 10.1016/j.ahj.2025.04.026 Song JM, 2024, J GEN INTERN MED, DOI 10.1007/s11606-024-09076-z Spence J, 2019, CAN MED ASSOC J, V191, pE830, DOI 10.1503/cmaj.190221 Spigel DR, 2022, J CLIN ONCOL, V40, P1301, DOI 10.1200/JCO.21.01308 Spigel DR, 2019, J THORAC ONCOL, V14, P1628, DOI 10.1016/j.jtho.2019.05.010 Stabellini N, 2024, J AM HEART ASSOC, V13, DOI 10.1161/JAHA.123.033295 Strauss L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aay1863 Strickland SS, 2023, BJS OPEN, V7, DOI 10.1093/bjsopen/zrad021 Strongman H, 2019, LANCET, V394, P1041, DOI 10.1016/S0140-6736(19)31674-5 Suero-Abreu GA, 2022, JACC-CARDIOONCOL, V4, P598, DOI 10.1016/j.jaccao.2022.11.011 Sun JY, 2021, INT J CARDIOL, V330, P186, DOI 10.1016/j.ijcard.2021.02.025 Sun YM, 2024, INT J SURG, V110, P4688, DOI 10.1097/JS9.0000000000001514 Szilveszter B, 2025, JACC-CARDIOVASC IMAG, V18, DOI 10.1016/j.jcmg.2025.05.018 Takada K, 2023, CLIN LUNG CANCER, V24, P581, DOI 10.1016/j.cllc.2023.08.017 Tamargo J, 2024, PHARMACOL RES, V200, DOI 10.1016/j.phrs.2024.107077 Tan S, 2023, CANCER EPIDEMIOL, V83, DOI 10.1016/j.canep.2023.102334 Tang M, 2022, LUNG CANCER, V166, P40, DOI 10.1016/j.lungcan.2022.01.024 Tenuta M, 2021, CANCERS, V13, DOI 10.3390/cancers13246355 Teske AJ, 2023, CIRC-CARDIOVASC QUAL, V16, DOI 10.1161/CIRCOUTCOMES.123.009905 Thompson A, 2024, CIRCULATION, V150, pE351, DOI 10.1161/CIR.0000000000001285 Thygesen K, 2018, EUR HEART J, V39, P3757, DOI 10.1093/eurheartj/ehy655 Tohidinezhad F, 2022, CLIN TRANSL RAD ONCO, V33, P134, DOI 10.1016/j.ctro.2022.02.007 Tong BC, 2022, J THORAC CARDIOV SUR, V163, P427, DOI 10.1016/j.jtcvs.2021.02.099 Topalian SL, 2020, SCIENCE, V367, P525, DOI 10.1126/science.aax0182 Toufektzian L, 2015, INTERACT CARDIOV TH, V20, P654, DOI 10.1093/icvts/ivu454 Uchoa RB, 2020, BMC ANESTHESIOL, V20, DOI 10.1186/s12871-020-01037-3 Udumyan R, 2020, CANCER EPIDEM BIOMAR, V29, P119, DOI 10.1158/1055-9965.EPI-19-0710 Van Gelder IC, 2024, EUR HEART J, V45, P3314, DOI 10.1093/eurheartj/ehae176 Vancoppenolle J, 2025, ESMO OPEN, V10, DOI 10.1016/j.esmoop.2025.105293 VANMIEGHEM W, 1994, CHEST, V105, P1642, DOI 10.1378/chest.105.6.1642 Vernooij LM, 2021, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013139.pub2 Vieira AR, 2016, ANN ONCOL, V27, P81, DOI 10.1093/annonc/mdv381 Voorn MJJ, 2023, EJSO-EUR J SURG ONC, V49, P879, DOI 10.1016/j.ejso.2023.01.024 Voruganti T, 2023, JAMA ONCOL, V9, P334, DOI 10.1001/jamaoncol.2022.6901 Vuong JT, 2022, J AM COLL CARDIOL, V79, P577, DOI 10.1016/j.jacc.2021.11.048 Wagle NS, 2025, CA-CANCER J CLIN, V75, P308, DOI 10.3322/caac.70011 Wakelee H, 2023, NEW ENGL J MED, V389, P491, DOI 10.1056/NEJMoa2302983 Walls GM, 2025, BRIT J CANCER, V132, P311, DOI 10.1038/s41416-024-02888-0 Wang C, 2019, NUTRIENTS, V11, DOI 10.3390/nu11081791 Wang JJ, 2020, INT IMMUNOPHARMACOL, V88, DOI 10.1016/j.intimp.2020.106907 Wang JS, 2022, ENDOCR RES, V47, P18, DOI 10.1080/07435800.2021.1955255 Wang K, 2017, J CLIN ONCOL, V35, P1387, DOI 10.1200/JCO.2016.70.0229 Watson H, 2025, IMMUNOTHERAPY-UK, V17, P491, DOI 10.1080/1750743X.2025.2504868 Wei XX, 2021, AM J CLIN NUTR, V114, P2043, DOI 10.1093/ajcn/nqab298 Wei ZC, 2024, SCI REP-UK, V14, DOI 10.1038/s41598-024-79260-y Wislez M, 2022, J IMMUNOTHER CANCER, V10, DOI 10.1136/jitc-2022-005636 Wong CK, 2025, J AM HEART ASSOC, V14, DOI 10.1161/JAHA.124.038668 Wood AM, 2021, CANCER EPIDEM BIOMAR, V30, P1489, DOI 10.1158/1055-9965.EPI-21-0058 Wu LL, 2023, CELL COMMUN SIGNAL, V21, DOI 10.1186/s12964-023-01139-8 Wykrzykowska J, 2009, J NUCL MED, V50, P563, DOI 10.2967/jnumed.108.055616 Xin YZ, 2014, EUR J CARDIO-THORAC, V45, P247, DOI 10.1093/ejcts/ezt383 Xue XJ, 2014, INT J CLIN EXP MED, V7, P1542 Yan JT, 2023, ONCOL THER, V11, P343, DOI 10.1007/s40487-023-00234-7 Yan XB, 2022, INT IMMUNOPHARMACOL, V113, DOI 10.1016/j.intimp.2022.109383 Yang M, 2019, CHEST, V156, P101, DOI 10.1016/j.chest.2019.04.115 Yazawa T, 2016, AM J TRANSL RES, V8, P5059 Yegya-Raman N, 2023, CURR ONCOL REP, V25, P433, DOI 10.1007/s11912-023-01387-4 Yoon DW, 2019, LUNG CANCER, V136, P115, DOI 10.1016/j.lungcan.2019.08.025 Yu DX, 2018, JNCI-J NATL CANCER I, V110, P831, DOI 10.1093/jnci/djx286 Yu H, 1999, JNCI-J NATL CANCER I, V91, P151, DOI 10.1093/jnci/91.2.151 Yu XY, 2025, ECLINICALMEDICINE, V79, DOI 10.1016/j.eclinm.2024.102997 Zahergivar A, 2024, BMC MED IMAGING, V24, DOI 10.1186/s12880-024-01544-6 Zhang L, 2022, INT J CLIN PRACT, V2022, DOI 10.1155/2022/3429462 Zhang N, 2023, EUR J PREV CARDIOL, V30, pE78, DOI 10.1093/eurjpc/zwad256 Zhang TT, 2023, BMC CANCER, V23, DOI 10.1186/s12885-023-11512-y Zhang YY, 2024, CRIT REV ONCOL HEMAT, V204, DOI 10.1016/j.critrevonc.2024.104525 Zheng YY, 2025, CARDIOVASC TOXICOL, V25, P805, DOI 10.1007/s12012-025-09979-1 Zhou W, 2021, INT J CANCER, V148, P1077, DOI 10.1002/ijc.33292 Zhou YX, 2024, JAMA NETW OPEN, V7, DOI 10.1001/jamanetworkopen.2024.1285 Zhu D, 2024, BMC CANCER, V24, DOI 10.1186/s12885-024-13261-y Zullig LL, 2023, J CANCER SURVIV, V17, P595, DOI 10.1007/s11764-022-01212-0 NR 324 TC 3 Z9 3 U1 4 U2 4 PU MDPI PI BASEL PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND EI 2072-6694 J9 CANCERS JI Cancers PD OCT 27 PY 2025 VL 17 IS 21 AR 3443 DI 10.3390/cancers17213443 PG 32 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA 9QG5O UT WOS:001612453500001 PM 41228236 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Gong, ZW Hella, S Shi, J Liu, XY AF Gong, Ziwei Hella, Slamuguli Shi, Jing Liu, Xinya TI Construction of a risk prediction model for postoperative atrial fibrillation in lung cancer patients based on multi-dimensional feature fusion and ensemble learning SO FRONTIERS IN CARDIOVASCULAR MEDICINE LA English DT Article DE lung cancer; machine learning; postoperative atrial fibrillation; risk factors; prediction model AB Introduction Surgery remains a cornerstone in lung cancer treatment, yet a subset of patients face high risks of recurrence or mortality postoperatively. Poor prognosis significantly shortens survival time, underscoring an urgent clinical need to accurately identify high-risk individuals. To address this, numerous studies have focused on constructing risk prediction models that integrate multi-dimensional data (clinical, pathological, and emerging biomarkers) to quantify postoperative adverse event probabilities, guiding personalized adjuvant therapy and enhancing follow-up management. To investigate risk factors for postoperative atrial fibrillation (POAF) in lung cancer patients and develop/validate a predictive model based on multi-dimensional feature fusion and ensemble learning.Methods This retrospective cohort study analyzed 369 lung cancer patients undergoing surgical resection at Xinjiang Medical University Affiliated Tumor Hospital (2019-2024). Univariate analysis screened potential risk factors, followed by multivariable logistic regression to confirm independent predictors. Nine machine learning algorithms were employed to build predictive models, among which the top three performers were selected for ensemble modeling via weighted averaging, resulting in the final risk prediction model.Results Multivariate analysis revealed three independent predictors of POAF: cardiac insufficiency (OR = 64.55, 95% CI: 2.41-1727.70), ventricular rate (OR = 1.17, 95% CI: 1.1-1.25), and elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP, OR = 1.005, 95% CI: 1-1.009). The Support Vector Machine (SVM), Random Forest (RF), and Gradient Boosting Machine (GBM) demonstrated the highest accuracy (ACC = 0.9041, 0.9178, and 0.9178, respectively). The ensemble model srg-LCPOAF further improved ACC to 0.9452, significantly outperforming individual algorithms.Discussion This study is the first to integrate cardiopulmonary function, biomarkers, and surgical parameters into an ensemble model (srg-LCPOAF), providing evidence-based support for early intervention in high-risk POAF patients. C1 [Gong, Ziwei] Xinjiang Med Univ, Coll Publ Hlth, Urumqi, Peoples R China. [Hella, Slamuguli; Shi, Jing] Xinjiang Med Univ, Dept Oncol & Cardiol, Affiliated Canc Hosp, Urumqi, Peoples R China. [Liu, Xinya] Xinjiang Med Univ, Dept Cardiol, Affiliated Hosp 5, Urumqi, Peoples R China. C3 Xinjiang Medical University; Xinjiang Medical University; Xinjiang Medical University RP Liu, XY (corresponding author), Xinjiang Med Univ, Dept Cardiol, Affiliated Hosp 5, Urumqi, Peoples R China. EM 13899935339@163.com FU Open project of Xinjiang Key Laboratory of Oncology: Construction and Application Research of a Risk Early Warning Model for Atrial Fibrillation After Lung Cancer Surgery Based on the Combination of Characteristic Metabolites and Clinical Factors through M [XJKLO-2023Y008] FX The author(s) declare that financial support was received for the research and/or publication of this article. The research funds for this study are supported by the Open project of Xinjiang Key Laboratory of Oncology: Construction and Application Research of a Risk Early Warning Model for Atrial Fibrillation After Lung Cancer Surgery Based on the Combination of Characteristic Metabolites and Clinical Factors through Machine Learning XJKLO-2023Y008. CR Allan KS, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017577 Amar D, 2016, J CARDIOTHOR VASC AN, V30, pS19, DOI [10.1053/j.jvca.2016.03.060, 10.1053/j.jvca.2016.03.060, DOI 10.1053/J.JVCA.2016.03.060] Bandyopadhyay D, 2019, IJC HEART VASC, V22, P216, DOI 10.1016/j.ijcha.2019.02.012 Blázquez-García A, 2022, ACM COMPUT SURV, V54, DOI 10.1145/3444690 Bonaca MP, 2019, CIRCULATION, V140, P80, DOI 10.1161/CIRCULATIONAHA.118.034497 Cao MM, 2019, THORAC CANCER, V10, P3, DOI 10.1111/1759-7714.12916 Chamberlain AM, 2011, HEART RHYTHM, V8, P1160, DOI 10.1016/j.hrthm.2011.03.038 Chen WQ, 2018, CHINESE J CANCER RES, V30, P1, DOI 10.21147/j.issn.1000-9604.2018.01.01 Chinese Thoracic Society Chinese Medical Association, 2024, Zhonghua Jie He He Hu Xi Za Zhi, V47, P716, DOI 10.3760/cma.j.cn112147-20231109-00300 Choi You-Jung, 2025, J Cardiovasc Imaging, V33, P12, DOI 10.1186/s44348-025-00057-2 Frost L, 2004, ARCH INTERN MED, V164, P1675, DOI 10.1001/archinte.164.15.1675 Gaudino M, 2023, EUR HEART J, V44, P1020, DOI 10.1093/eurheartj/ehad019 Hashimoto H, 2019, CANCERS, V11, DOI 10.3390/cancers11040488 Heymans MW, 2022, J CLIN EPIDEMIOL, V151, P185, DOI 10.1016/j.jclinepi.2022.08.016 Jiang JD, 2021, J CARDIOTHOR VASC AN, V35, P1424, DOI 10.1053/j.jvca.2020.09.107 Kumar V, 2025, SLAS TECHNOL, V33, DOI 10.1016/j.slast.2025.100314 Lausser L, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-25942-4 Liu Yuhua, 2024, NPJ Cardiovasc Health, V1, DOI [10.1038/s44325-024-00003-z, 10.1038/s44325-024-00003-z] Mascia G, 2025, J CARDIOVASC MED, V26, P454, DOI 10.2459/JCM.0000000000001758 Maturi B, 2025, J CLIN MED, V14, DOI 10.3390/jcm14020625 Middeldorp ME, 2022, J HYPERTENS, V40, P2337, DOI 10.1097/HJH.0000000000003278 Mont L, 2009, EUROPACE, V11, P11, DOI 10.1093/europace/eun289 Muranishi Y, 2017, SURG TODAY, V47, P252, DOI 10.1007/s00595-016-1380-y Ortiz BL, 2024, JMIR MHEALTH UHEALTH, V12, DOI 10.2196/59587 Pezel T, 2025, RADIOLOGY, V314, DOI 10.1148/radiol.233030 Qian LQ, 2022, TRANSL LUNG CANCER R, V11, P1132, DOI 10.21037/tlcr-22-395 Rainio O, 2024, SCI REP-UK, V14, DOI 10.1038/s41598-024-56706-x San TMM, 2024, CARDIOVASC REVASCULA, V66, P27, DOI 10.1016/j.carrev.2024.03.023 Semeraro GC, 2021, CANCERS, V13, DOI 10.3390/cancers13164012 Staartjes VE., 2022, Foundations of Feature Selection in Clinical Prediction Modeling, P51 Sundaram DM, 2023, CUREUS J MED SCIENCE, V15, DOI 10.7759/cureus.42880 Teh R, 2023, BMC GERIATR, V23, DOI 10.1186/s12877-023-03902-5 Tohidinezhad F, 2024, RADIOTHER ONCOL, V201, DOI 10.1016/j.radonc.2024.110544 Tong CY, 2024, INT J SURG, V110, P1645, DOI 10.1097/JS9.0000000000001006 Van Gelder IC, 2024, EUR HEART J, V45, P3314, DOI 10.1093/eurheartj/ehae176 Wu FY, 2021, CURR OPIN ONCOL, V33, P40, DOI 10.1097/CCO.0000000000000703 Yang Z, 2024, AM J CARDIOL, V221, P120, DOI 10.1016/j.amjcard.2024.04.018 Zhang LF, 2024, ASIAN J SURG, V47, P176, DOI 10.1016/j.asjsur.2023.06.108 Zhao D, 2024, CURR PROB CANCER, V48, DOI 10.1016/j.currproblcancer.2023.101036 Zhou Yan, 2024, Clin Epidemiol, V16, P45, DOI [10.2147/clep.s442152, 10.2147/CLEP.S442152] Zuo K, 2019, GIGASCIENCE, V8, DOI 10.1093/gigascience/giz058 NR 41 TC 2 Z9 2 U1 1 U2 1 PU FRONTIERS MEDIA SA PI LAUSANNE PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND SN 2297-055X J9 FRONT CARDIOVASC MED JI Front. Cardiovasc. Med. PD OCT 24 PY 2025 VL 12 AR 1679973 DI 10.3389/fcvm.2025.1679973 PG 16 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA 9LG5C UT WOS:001609042400001 PM 41210335 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Liu, Z Zheng, C Jia, ZX Zhao, CW Liu, XY Shao, WP Chen, F Zhu, H Guo, HB AF Liu, Zhan Zheng, Chong Jia, Zongxiao Zhao, Chengwei Liu, Xiangyu Shao, Weipeng Chen, Feng Zhu, Hui Guo, Hongbo TI Deep learning radiomics model of epicardial adipose tissue for predicting postoperative atrial fibrillation after lung lobectomy in lung cancer patients SO FRONTIERS IN ONCOLOGY LA English DT Article DE postoperative atrial fibrillation; deep learning radiomics; epicardial adipose tissue; lung lobectomy; lung cancer ID RESECTION AB Objective To develop and validate a deep learning (DL) radiomics model based on epicardial adipose tissue (EAT) for identifying high-risk lung cancer patients with postoperative atrial fibrillation after lung lobectomy.Methods A total of 1,008 patients from two centers were included. Handcrafted and DL radiomics features were extracted from the preoperative contrast-enhanced chest CT images of EAT. Clinical features and handcrafted and DL radiomics signatures were integrated to construct predictive models using the logistic regression algorithm as the baseline model. Twenty DL radiomics models were constructed through various combinations of machine learning algorithms and resampling techniques. The post hoc Nemenyi test was employed to compare the predictive performance in terms of the area under the receiver operating characteristic curve (AUC), G-mean, and F-measure.Results Advanced age and male sex were identified as independent risk factors for POAF. The DL radiomics model, integrating clinical features, handcrafted radiomics signature, and DL radiomics signature, outperformed the clinical model, achieving AUC values of 0.890 (95% CI: 0.816-0.963), 0.876 (95% CI: 0.755-0.997), and 0.803 (95% CI: 0.651-0.955) in the training, testing, and validation cohorts, respectively. The results of the post hoc Nemenyi tests indicated that neither machine learning algorithms nor resampling techniques significantly improved model performance, as measured by the AUC, G-mean, or F-measure.Conclusion The DL radiomics model based on preoperative EAT images effectively identifies high-risk lung cancer patients with POAF following lung lobectomy and offers a novel tool for risk stratification. C1 [Liu, Zhan; Zhao, Chengwei; Shao, Weipeng; Chen, Feng; Guo, Hongbo] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Lung Surg Ward 2, Jinan, Shandong, Peoples R China. [Zheng, Chong; Liu, Xiangyu] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiol, Jinan, Shandong, Peoples R China. [Jia, Zongxiao] Shandong First Med Univ, Dept Thorac Surg, Feicheng Hosp, Tai An, Shandong, Peoples R China. [Zhu, Hui] Shandong First Med Univ & Shandong Acad Med Sci, Dept Radiat Oncol, Shandong Canc Hosp & Inst, Jinan, Shandong, Peoples R China. C3 Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences RP Guo, HB (corresponding author), Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Lung Surg Ward 2, Jinan, Shandong, Peoples R China.; Zhu, H (corresponding author), Shandong First Med Univ & Shandong Acad Med Sci, Dept Radiat Oncol, Shandong Canc Hosp & Inst, Jinan, Shandong, Peoples R China. EM drzhuh@126.com; guomutong@126.com RI Zhao, Chengwei/W-2059-2019 FU Qingmiao Foundation of Shandong Cancer Hospital [2024-qm04]; Natural Science Foundation of Shandong Province, China [ZR2024QH419] FX The author(s) declare financial support was received for the research and/or publication of this article. This study was supported by the Qingmiao Foundation of Shandong Cancer Hospital and Institute (Grant Nos. 2024-qm04) and Natural Science Foundation of Shandong Province, China (Grant Nos. ZR2024QH419). CR Amar D, 2019, J THORAC CARDIOV SUR, V157, P2493, DOI 10.1016/j.jtcvs.2019.01.075 Batchelor TJP, 2019, EUR J CARDIO-THORAC, V55, P91, DOI 10.1093/ejcts/ezy301 Bera K, 2022, NAT REV CLIN ONCOL, V19, P132, DOI 10.1038/s41571-021-00560-7 Chen M, 2023, SEMIN CANCER BIOL, V93, P97, DOI 10.1016/j.semcancer.2023.05.004 Conen D, 2020, EUR HEART J, V41, P645, DOI 10.1093/eurheartj/ehz431 Crispi V, 2022, POSTGRAD MED J, V98, P177, DOI 10.1136/postgradmedj-2020-138904 Cui YF, 2022, ECLINICALMEDICINE, V46, DOI 10.1016/j.eclinm.2022.101348 Dablain D, 2023, IEEE T NEUR NET LEAR, V34, P6390, DOI 10.1109/TNNLS.2021.3136503 Deng YS, 2023, REV CARDIOVASC MED, V24, DOI 10.31083/j.rcm2411327 Diallo EH, 2023, ANAESTHESIA, V78, P491, DOI 10.1111/anae.15957 Gabrys HS, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00035 Gaur L, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.822666 Ghezel-Ahmadi V, 2023, J THORAC DIS, V15, P4648, DOI 10.21037/jtd-23-506 Guiot J, 2022, MED RES REV, V42, P426, DOI 10.1002/med.21846 Guo YS, 2025, INT J SURG, V111, P6592, DOI 10.1097/JS9.0000000000002839 Hayashi T, 2024, CURR PROB SURG, V61, DOI 10.1016/j.cpsurg.2024.101502 Iacobellis G, 2022, NAT REV CARDIOL, V19, P593, DOI 10.1038/s41569-022-00679-9 Ishibashi H, 2020, WORLD J SURG, V44, P3952, DOI 10.1007/s00268-020-05694-w Kotova S, 2017, ANN THORAC SURG, V103, P1566, DOI 10.1016/j.athoracsur.2016.11.007 Lambin P, 2017, NAT REV CLIN ONCOL, V14, P749, DOI 10.1038/nrclinonc.2017.141 Lambin P, 2012, EUR J CANCER, V48, P441, DOI 10.1016/j.ejca.2011.11.036 Lee CT, 2019, THORAC CARDIOV SURG, V67, P125, DOI 10.1055/s-0038-1675638 Lee SH, 2016, ANAESTHESIA, V71, P1424, DOI 10.1111/anae.13644 Li W, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1180908 Li XG, 2021, MED PHYS, V48, P4279, DOI 10.1002/mp.15012 Lin H, 2025, J IMMUNOTHER CANCER, V13, DOI [10.1136/jitc-2024-010723, 10.1136/jitc-2024-010723] Lin MH, 2019, STROKE, V50, P1364, DOI 10.1161/STROKEAHA.118.023921 Liu Z, 2023, FRONT CARDIOVASC MED, V9, DOI 10.3389/fcvm.2022.1046931 Malhotra R, 2023, PHYS MEDICA, V110, DOI 10.1016/j.ejmp.2023.102591 Mancio J, 2022, EUR HEART J-CARD IMG, V23, P1248, DOI 10.1093/ehjci/jeac092 Martell MB, 2024, NPJ PRECIS ONCOL, V8, DOI 10.1038/s41698-024-00502-3 Oh AR, 2023, FRONT MED-LAUSANNE, V9, DOI 10.3389/fmed.2022.983330 Oka Hiroki, 2024, Comput Biol Med, V180, P108879, DOI [10.1016/j.compbiomed.2024.108879, 10.1016/j.compbiomed.2024.108879] Passman RS, 2005, ANN THORAC SURG, V79, P1698, DOI 10.1016/j.athoracsur.2004.10.058 Riley RD, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m441 Smith H, 2020, EUR J CARDIO-THORAC, V57, P874, DOI 10.1093/ejcts/ezz341 Surov A, 2024, RESP RES, V25, DOI 10.1186/s12931-024-02977-x Wang WL, 2024, ECLINICALMEDICINE, V67, DOI 10.1016/j.eclinm.2023.102385 West HW, 2023, JACC-CARDIOVASC IMAG, V16, P800, DOI 10.1016/j.jcmg.2022.11.018 Xie CY, 2020, EUR J NUCL MED MOL I, V47, P2826, DOI 10.1007/s00259-020-04756-4 Yu LH, 2025, RADIOL MED, V130, P1602, DOI 10.1007/s11547-025-02063-2 Yuan XY, 2025, NPJ PRECIS ONCOL, V9, DOI 10.1038/s41698-025-01095-1 Zhang L, 2022, BRIT J RADIOL, V95, DOI 10.1259/bjr.20211274 Zheng YL, 2022, EUR RADIOL, V32, P6953, DOI 10.1007/s00330-022-08830-3 NR 44 TC 0 Z9 0 U1 3 U2 3 PU FRONTIERS MEDIA SA PI LAUSANNE PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND SN 2234-943X J9 FRONT ONCOL JI Front. Oncol. PD OCT 13 PY 2025 VL 15 AR 1623248 DI 10.3389/fonc.2025.1623248 PG 11 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA 8XT1Y UT WOS:001599849300001 PM 41158854 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Muñoz-Carrillo, FJ Reyes, RM Pesántez, D Carrera, G Cascos, E Castro, P Fernández-Méndez, S Font, C González-Aguado, L Grafiá, I Llavata, L Monge-Escartín, I Padrosa, J Reguart, N Téllez, A Tuca, A Viladot, M Zamora-Martínez, C Amorós-Reboredo, P Marco-Hernández, J AF Munoz-Carrillo, Francisco Javier Reyes, Roxana Maribel Pesantez, David Carrera, Gemma Cascos, Enric Castro, Pedro Fernandez-Mendez, Sara Font, Carme Gonzalez-Aguado, Laura Grafia, Ignacio Llavata, Lucia Monge-Escartin, Ines Padrosa, Joan Reguart, Noemi Tellez, Adrian Tuca, Albert Viladot, Margarita Zamora-Martinez, Carles Amoros-Reboredo, Patricia Marco-Hernandez, Javier TI Retrospective Cohort Study of Intrapericardial Cisplatin for Risk Reduction of Malignant Pericardial Effusion Recurrence SO CURRENT ONCOLOGY LA English DT Article DE malignant pericardial effusion; cisplatin; intrapericardial infusion; multidisciplinary approach ID ESC GUIDELINES; LUNG-CANCER; MITOMYCIN-C; MANAGEMENT; INSTILLATION; BLEOMYCIN; PERICARDIOCENTESIS; CHEMOTHERAPY; MITOXANTRONE; DIAGNOSIS AB Simple Summary Malignant pericardial effusion is a life-threatening complication in patients with cancer and frequently recurs after standard drainage procedures. Our study evaluated the use of intrapericardial cisplatin, a chemotherapy drug administered directly into the pericardial space, as an approach to prevent recurrences. We analyzed data from 41 patients with solid neoplasms (mainly lung cancer), treated with a standardized, multidisciplinary protocol at a tertiary hospital over a 13 year period. Patients with hematological malignancies were excluded. Our goal was to assess the safety, feasibility, and effectiveness of this technique. The treatment was generally well tolerated, with a very low rate of fluid recurrence and manageable side effects. These findings support the integration of intrapericardial cisplatin into multidisciplinary care pathways, making it a safe and effective procedure to consider for managing malignant pericardial effusion in patients with solid tumours.Abstract Malignant pericardial effusion (MPE) is a life-threatening condition in patients with cancer, with common recurrences after simple pericardiocentesis. Consequently, the intrapericardial instillation of sclerosing or cytotoxic agents has been explored, with limited evidence from small studies with different methodologies. We undertook an observational, retrospective, single-centre study, including all patients diagnosed with a solid neoplasm and clinically significant and/or recurrent, cytology-confirmed MPE, treated with Intrapericardial Instillation of Cisplatin (IPIC), between 2009 and 2022. Patients with hematological malignancies were excluded. The procedure followed a multidisciplinary approach and a standardized protocol. Variables collected included baseline patient characteristics, neoplasm details, MPE impact, adverse events (AEs) from procedures (pericardiocentesis and IPIC) and outcomes (time to MPE recurrence and survival). This study adhered to the STROBE guidelines. A total of 41 patients were included, 51% female, with a median age of 61 (51-69) years. Non-small cell lung cancer (NSCLC) was the predominant primary tumour (78%) and in 44% of the cohort, MPE was identified at cancer diagnosis. Most patients (90.2%) presented symptoms related to MPE at diagnosis, and 88% had cardiac tamponade on echocardiography. IPIC was administered a median of four times. IPIC-related AEs occurred in 10 patients (24.4%), with transient atrial fibrillation (AF) being the most frequent one. Two patients (4.9%) experienced MPE recurrence within 30 days after IPIC. The median survival time from MPE diagnosis was 161 days (5.4 months; IQR 73-455 days). IPIC appears to be a feasible, effective and safe option for reducing the risk of MPE recurrence, mainly in NSCLC. C1 [Munoz-Carrillo, Francisco Javier; Reyes, Roxana Maribel; Pesantez, David; Carrera, Gemma; Font, Carme; Gonzalez-Aguado, Laura; Grafia, Ignacio; Llavata, Lucia; Padrosa, Joan; Reguart, Noemi; Tuca, Albert; Viladot, Margarita; Zamora-Martinez, Carles; Marco-Hernandez, Javier] Hosp Clin Barcelona, Med Oncol Dept, Barcelona 08036, Spain. [Munoz-Carrillo, Francisco Javier; Reyes, Roxana Maribel; Pesantez, David; Carrera, Gemma; Font, Carme; Gonzalez-Aguado, Laura; Grafia, Ignacio; Llavata, Lucia; Padrosa, Joan; Reguart, Noemi; Tuca, Albert; Viladot, Margarita; Zamora-Martinez, Carles; Marco-Hernandez, Javier] IDIBAPS, Translat Genom & Targeted Therapies Solid Tumors, Barcelona 08036, Spain. [Cascos, Enric] Hosp Clin Barcelona, Cardiol Dept, Barcelona 08036, Spain. [Castro, Pedro; Fernandez-Mendez, Sara; Grafia, Ignacio; Padrosa, Joan; Tellez, Adrian; Zamora-Martinez, Carles; Marco-Hernandez, Javier] Hosp Clin Barcelona, Internal Med Dept, Med Intens Care Unit, Barcelona 08036, Spain. [Monge-Escartin, Ines] Hosp Clin Barcelona, Hosp Pharm Dept, Barcelona 08036, Spain. [Tuca, Albert] Barcelona Univ, Chair Palliat Care, Barcelona 08036, Spain. [Tuca, Albert] EAPS Fundacio La Caixa, Barcelona 08019, Spain. [Amoros-Reboredo, Patricia] Hosp Santa Creu & Sant Pau, Inst Recerca St Pau IR St PAU, Pharm Dept, Barcelona 08041, Spain. [Amoros-Reboredo, Patricia] Hosp Santa Creu & Sant Pau, Inst Recerca St Pau IR St PAU, Digital Impulse Strategy & Transformat Area, Barcelona 08041, Spain. C3 University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital of Santa Creu i Sant Pau; Hospital of Santa Creu i Sant Pau RP Marco-Hernández, J (corresponding author), Hosp Clin Barcelona, Med Oncol Dept, Barcelona 08036, Spain.; Marco-Hernández, J (corresponding author), IDIBAPS, Translat Genom & Targeted Therapies Solid Tumors, Barcelona 08036, Spain.; Marco-Hernández, J (corresponding author), Hosp Clin Barcelona, Internal Med Dept, Med Intens Care Unit, Barcelona 08036, Spain. EM frmunoz@clinic.cat; pcastro@clinic.cat; jmarco@clinic.cat RI ; TUCA, ALBERT/ABI-7280-2020; Amorós-Reboredo, Patrícia/HRC-5052-2023; Paosa Pulido, Joan/AFU-2201-2022; de Castro, Pedro/AAM-2517-2020 OI Téllez, Aián/0000-0003-3502-5999; Zamora-Martinez, Carles/0000-0002-3838-0809; Cascos Garcia, Enric/0000-0002-9093-3642; TUCA, ALBERT/0000-0002-4633-5856; Muñoz i Carrillo, Javier/0000-0002-0162-7767; Amorós-Reboredo, Patrícia/0000-0001-9258-2623; Paosa Pulido, Joan/0000-0002-3354-5811; Marco-Hernández, Javier/0000-0001-8486-5404 FU Generalitat de Catalunya; CERCA Programme FX This research was funded by CERCA Programme/Generalitat de Catalunya. CR Adler Y, 2015, REV ESP CARDIOL, V68, P1126, DOI 10.1016/j.rec.2015.10.008 Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS), 2022, Cisplatino: Ficha Tecnica Bischiniotis Theodoros S, 2005, Hellenic J Cardiol, V46, P324 Bishiniotis TS, 2000, AM J CARDIOL, V86, P362, DOI 10.1016/S0002-9149(00)00937-1 Burazor I, 2013, CARDIOLOGY, V124, P224, DOI 10.1159/000348559 Colleoni M, 1998, J CLIN ONCOL, V16, P2371, DOI 10.1200/JCO.1998.16.7.2371 DAVIS S, 1984, J CLIN ONCOL, V2, P631, DOI 10.1200/JCO.1984.2.6.631 de Castro G Jr, 2023, JTO CLIN RES REP, V4, DOI 10.1016/j.jtocrr.2023.100580 Defruyt L, 2022, ACTA CLIN BELG, V77, P51, DOI 10.1080/17843286.2020.1790180 Doebele RC, 2012, CANCER-AM CANCER SOC, V118, P4502, DOI 10.1002/cncr.27409 Dybowska M, 2022, DIAGNOSTICS, V12, DOI 10.3390/diagnostics12061453 European Society of Medical Oncology (ESMO), 2016, ESMO Handbook of Oncological Emergencies, V2nd ed. Fallet V, 2021, TRANSL LUNG CANCER R, V10, P3457, DOI 10.21037/tlcr-20-1152 FIGOLI F, 1987, CANCER CHEMOTH PHARM, V20, P239, DOI 10.1007/BF00570493 Fontanals S, 2023, CANCER MED-US, V12, P17112, DOI 10.1002/cam4.6360 Gevaert SA, 2021, EUR HEART J-ACUTE CA, V10, P947, DOI 10.1093/ehjacc/zuab056 Gornik HL, 2005, J CLIN ONCOL, V23, P5211, DOI 10.1200/JCO.2005.00.745 Guglin M, 2009, EUROPACE, V11, P1579, DOI 10.1093/europace/eup300 Ilerhunmwuwa N, 2022, CUREUS J MED SCIENCE, V14, DOI 10.7759/cureus.33123 Imazio M, 2020, HEART, V106, P569, DOI 10.1136/heartjnl-2019-315852 Imazio M, 2013, EUR HEART J, V34, P1186, DOI 10.1093/eurheartj/ehs372 Jama GM, 2014, INTERACT CARDIOV TH, V19, P1019, DOI 10.1093/icvts/ivu267 Kaira K, 2005, JPN J CLIN ONCOL, V35, P57, DOI 10.1093/jjco/hyi019 Kotake M, 2019, CANCER CHEMOTH PHARM, V84, P655, DOI 10.1007/s00280-019-03897-0 Kunitoh H, 2009, BRIT J CANCER, V100, P464, DOI 10.1038/sj.bjc.6604866 Lafaras C, 2009, INTENS CARE MED, V35, P279 Lambert A, 2020, B CANCER, V107, P756, DOI 10.1016/j.bulcan.2020.04.010 LEE LN, 1994, THORAX, V49, P594, DOI 10.1136/thx.49.6.594 LENTZSCH S, 1994, ONKOLOGIE, V17, P504 Lestuzzi C, 2015, EXPERT REV CARDIOVAS, V13, P377, DOI 10.1586/14779072.2015.1025754 Lestuzzi C, 2011, LUNG CANCER, V72, P340, DOI 10.1016/j.lungcan.2010.10.013 Maisch B, 2002, EUR HEART J, V23, P1625, DOI 10.1053/euhj.2002.3328 Maisch B, 2010, PROG CARDIOVASC DIS, V53, P157, DOI 10.1016/j.pcad.2010.06.003 Martinoni A, 2004, CHEST, V126, P1412, DOI 10.1378/chest.126.5.1412 Maruyama R, 2007, J THORAC ONCOL, V2, P65, DOI 10.1097/JTO.0b013e31802c8260 Moya I, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.e19687 Musch E, 2003, ONKOLOGIE, V26, P135, DOI 10.1159/000069833 Oida T, 2010, WORLD J GASTROENTERO, V16, P740, DOI 10.3748/wjg.v16.i6.740 Sánchez-Enrique C, 2016, AM J CARDIOL, V117, P664, DOI 10.1016/j.amjcard.2015.11.023 Seferovic PM, 2013, HEART FAIL REV, V18, P255, DOI 10.1007/s10741-012-9335-x SHEPHERD FA, 1987, AM J CARDIOL, V60, P1161, DOI 10.1016/0002-9149(87)90411-5 Tomkowski WZ, 2004, SUPPORT CARE CANCER, V12, P53, DOI 10.1007/s00520-003-0533-x Tsang TSM, 2000, MAYO CLIN PROC, V75, P248 Vakamudi S, 2017, PROG CARDIOVASC DIS, V59, P380, DOI 10.1016/j.pcad.2016.12.009 Virk SA, 2015, HEART, V101, P1619, DOI 10.1136/heartjnl-2015-307907 Wei JW, 2023, CANCER MED-US, V12, P18211, DOI 10.1002/cam4.6404 Zaij S, 2023, BMC HEALTH SERV RES, V23, DOI 10.1186/s12913-023-09512-6 NR 47 TC 1 Z9 1 U1 1 U2 1 PU MDPI PI BASEL PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND SN 1198-0052 EI 1718-7729 J9 CURR ONCOL JI Curr. Oncol. PD OCT 11 PY 2025 VL 32 IS 10 AR 568 DI 10.3390/curroncol32100568 PG 14 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA 9BL1E UT WOS:001602351700001 PM 41149488 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Kallieri, M Hillas, G Bartziokas, K Loukides, S Toumpanakis, D AF Kallieri, Maria Hillas, Georgios Bartziokas, Konstantinos Loukides, Stelios Toumpanakis, Dimitrios TI COPD and the burden of multimorbidity: navigating the complexity SO EXPERT REVIEW OF RESPIRATORY MEDICINE LA English DT Review DE Cardiovascular disease; chronic obstructive pulmonary disease; comorbidities; depression; lung cancer; metabolic syndrome; multimorbidity; obstructive sleep apnea ID OBSTRUCTIVE PULMONARY-DISEASE; CELL LUNG-CANCER; SYSTEMIC INFLAMMATION; EXERCISE INTOLERANCE; AIRWAY INFLAMMATION; ATRIAL-FIBRILLATION; ACUTE EXACERBATION; PHYSICAL-ACTIVITY; OXIDATIVE STRESS; ADIPOSE-TISSUE AB IntroductionChronic obstructive pulmonary disease (COPD) is a chronic condition that affects millions of people worldwide. The majority of patients with COPD have multiple coexisting chronic diseases, such as cardiovascular diseases, osteoporosis, lung cancer, and metabolic syndrome, a phenomenon that is known as multimorbidity. The coexistence of these diseases with COPD complicates diagnosis, treatment, and prognosis.Areas coveredThis review explores the underlining mechanisms that connect COPD and multimorbidity, such as shared risk factors and pathophysiological pathways. It also highlights the challenges in managing multimorbid patients and emphasizes the fact that the complexity of comorbidities may require a multidisciplinary approach in COPD management.Expert opinionManaging COPD in the context of multimorbidity requires a multidisciplinary approach. This approach should combine pharmacological and non-pharmacological treatments for COPD, adhere to evidence-based guidelines for managing comorbidities, and target modifiable shared risk factors to improve overall patient outcomes. C1 [Kallieri, Maria; Hillas, Georgios; Bartziokas, Konstantinos; Loukides, Stelios] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Resp Med Dept 2, Athens, Greece. [Toumpanakis, Dimitrios] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Dept Crit Care Med 2, Rimini 1, Athens 12462, Greece. C3 University Hospital Attikon; National & Kapodistrian University of Athens; National & Kapodistrian University of Athens; University Hospital Attikon RP Toumpanakis, D (corresponding author), Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Dept Crit Care Med 2, Rimini 1, Athens 12462, Greece. EM dtoumpanakis@med.uoa.gr RI Kallieri, Maria/KFR-5911-2024 CR Adamson PD, 2018, J AM COLL CARDIOL, V72, P1126, DOI 10.1016/j.jacc.2018.06.051 Adcock IM, 2011, RESPIRATION, V81, P265, DOI 10.1159/000324601 Agusti A, 2011, EUR RESPIR REV, V20, P183, DOI 10.1183/09059180.00004311 Agustí A, 2017, LANCET RESP MED, V5, P935, DOI 10.1016/S2213-2600(17)30434-4 Ahmad A, 2013, AM J RESP CELL MOL, V49, P78, DOI 10.1165/rcmb.2012-0107OC Ahmed Ishfaq, 2024, Cureus, V16, pe69858, DOI [10.7759/cureus.69858, 10.7759/cureus.69858] Aldaham S, 2015, INT J INFLAMM, V2015, DOI 10.1155/2015/439396 Amer Diabet Assoc, 2021, DIABETES CARE, V44, pS111, DOI 10.2337/dc21-S009 Armstrong M, 2023, ERJ OPEN RES, V9, DOI 10.1183/23120541.00074-2023 Austin V, 2016, CLIN SCI, V130, P1039, DOI 10.1042/CS20160043 Badr C, 2002, AUST J PHYSIOTHER, V48, P95, DOI 10.1016/S0004-9514(14)60203-8 Bai P, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-157 Baird C, 2017, RESP MED, V129, P130, DOI 10.1016/j.rmed.2017.06.006 Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407 Benjafield AV, 2019, LANCET RESP MED, V7, P687, DOI 10.1016/S2213-2600(19)30198-5 Bianco A, 2013, NUTRIENTS, V5, P4115, DOI 10.3390/nu5104115 Birbrair A, 2013, STEM CELLS DEV, V22, P2298, DOI 10.1089/scd.2012.0647 Birim Ö, 2006, EJSO-EUR J SURG ONC, V32, P12, DOI 10.1016/j.ejso.2005.10.001 Biselli P, 2015, J APPL PHYSIOL, V119, P266, DOI 10.1152/japplphysiol.00455.2014 Biton J, 2018, AM J RESP CRIT CARE, V198, P928, DOI 10.1164/rccm.201706-1110OC Bouloukaki I, 2022, BREATHE, V18, DOI 10.1183/20734735.0073-2022 Bray F, 2024, CA-CANCER J CLIN, V74, P229, DOI 10.3322/caac.21834 Brighton LJ, 2024, ERJ OPEN RES, V10, DOI 10.1183/23120541.00774-2023 Briot K, 2017, OSTEOPOROSIS INT, V28, P3301, DOI 10.1007/s00198-017-4189-7 Buch P, 2003, EUR RESPIR J, V21, P1012, DOI 10.1183/09031936.03.00051502 BUTLER J, 1988, AM REV RESPIR DIS, V138, P350, DOI 10.1164/ajrccm/138.2.350 Calverley P, 2003, LANCET, V361, P449, DOI 10.1016/S0140-6736(03)12459-2 Campo G, 2015, COPD, V12, P560, DOI 10.3109/15412555.2014.995293 cancer, US Cao LM, 2020, ENVIRON HEALTH-GLOB, V19, DOI 10.1186/s12940-020-00621-x Cavaillés A, 2013, EUR RESPIR REV, V22, P454, DOI 10.1183/09059180.00008612 Chahal H, 2015, AM J CARDIOL, V115, P1700, DOI 10.1016/j.amjcard.2015.03.018 Chalmers JD, 2023, LANCET RESP MED, V11, P637, DOI 10.1016/S2213-2600(23)00093-0 Chen WJ, 2015, LANCET RESP MED, V3, P631, DOI 10.1016/S2213-2600(15)00241-6 Cho MH, 2022, LANCET RESP MED, V10, P485, DOI 10.1016/S2213-2600(21)00510-5 CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003 Clini E, 2013, INTERN EMERG MED, V8, P283, DOI 10.1007/s11739-011-0700-x Cooper CB, 2006, AM J MED, V119, pS21, DOI 10.1016/j.amjmed.2006.08.004 Corlateanu A, 2018, COPD, V15, P405, DOI 10.1080/15412555.2018.1464551 Cosgun A, 2020, ANN NONINVAS ELECTRO, V25, P157, DOI 10.1111/anec.12691 Cranston JM, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001744.pub2 Criner GJ, 2022, COPD-J COPD FDN, V9, DOI 10.15326/jcopdf.2022.0296 Cruz-Jentoft AJ, 2010, AGE AGEING, V39, P412, DOI 10.1093/ageing/afq034 Curtis HJ, 2018, DIABETES OBES METAB, V20, P2159, DOI 10.1111/dom.13346 Cyphert TJ, 2015, AM J PHYSIOL-REG I, V309, pR1144, DOI 10.1152/ajpregu.00442.2014 De Rosa A, 2013, EUR J ENDOCRINOL, V169, P37, DOI 10.1530/EJE-12-1039 de Torres JP, 2007, CHEST, V132, P1932, DOI 10.1378/chest.07-1490 deOca MM, 1996, AM J RESP CRIT CARE, V154, P1284 Divo M, 2012, AM J RESP CRIT CARE, V186, P155, DOI 10.1164/rccm.201201-0034OC Dogan ADA, 2022, INT J CHRONIC OBSTR, V17, P405, DOI 10.2147/COPD.S350133 Dong WG, 2020, CLIN RESPIR J, V14, P345, DOI 10.1111/crj.13139 Dou S, 2018, INT J CHRONIC OBSTR, V13, P2041, DOI 10.2147/COPD.S163243 Douillet D, 2023, DIAGNOSTICS, V13, DOI 10.3390/diagnostics13010141 Dransfield MT, 2019, NEW ENGL J MED, V381, P2304, DOI 10.1056/NEJMoa1908142 Dransfield MT, 2022, J AM HEART ASSOC, V11, DOI 10.1161/JAHA.121.024350 Du QX, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150532 Durham AL, 2015, LUNG CANCER, V90, P121, DOI 10.1016/j.lungcan.2015.08.017 Fabbri LM, 2023, LANCET RESP MED, V11, P1020, DOI 10.1016/S2213-2600(23)00261-8 Fadel PJ, 2017, HYPERTENSION, V69, P778, DOI 10.1161/HYPERTENSIONAHA.117.08999 FEINSTEIN AR, 1970, J CHRON DIS, V23, P455, DOI 10.1016/0021-9681(70)90054-8 FLENLEY DC, 1985, CLIN CHEST MED, V6, P651 Franssen FME, 2008, THORAX, V63, P1110, DOI 10.1136/thx.2007.086827 Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146 Fu XF, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0256480 Galvano A, 2021, ESMO OPEN, V6, DOI 10.1016/j.esmoop.2021.100124 Gao GY, 2021, TRANSL LUNG CANCER R, V10, P2573, DOI 10.21037/tlcr-21-371 goldcopd, GLOBAL STRATEGY PREV Goldstein MF, 1999, CHEST, V116, P1733, DOI 10.1378/chest.116.6.1733 Gulsvik AK, 2012, J EPIDEMIOL COMMUN H, V66, P1030, DOI 10.1136/jech-2011-200312 Guo YB, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004225 Hanania NA, 2011, AM J RESP CRIT CARE, V183, P604, DOI 10.1164/rccm.201003-0472OC Harrison RA, 2007, J BONE MINER RES, V22, P447, DOI 10.1359/jbmr.061202 Hellmann MD, 2017, LANCET ONCOL, V18, P31, DOI [10.1016/S1470-2045(16)30624-6, 10.1016/s1470-2045(16)30624-6] Hermann EA, 2024, EUR RESPIR J, V64, DOI [10.1183/13993003.01922-2024, 10.1183/13993003.00820-2024] Heslop-Marshall K, 2018, ERJ OPEN RES, V4, DOI 10.1183/23120541.00094-2018 Hill K, 2008, EUR RESPIR J, V31, P667, DOI 10.1183/09031936.00125707 Hohlfeld JM, 2018, LANCET RESP MED, V6, P368, DOI 10.1016/S2213-2600(18)30054-7 Hoiseth AD, 2011, THORAX, V66, P775, DOI 10.1136/thx.2010.153122 Huang JTJ, 2022, AM J RESP CRIT CARE, V206, P417, DOI 10.1164/rccm.202108-1943OC Iyer AS, 2018, ANN AM THORAC SOC, V15, P158, DOI 10.1513/AnnalsATS.201711-901ED Jolliffe DA, 2019, THORAX, V74, P337, DOI 10.1136/thoraxjnl-2018-212092 Jorgensen NR, 2008, CURR OPIN PULM MED, V14, P122, DOI 10.1097/MCP.0b013e3282f4efb6 Karuga FF, 2023, J CLIN MED, V12, DOI 10.3390/jcm12185907 Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395 Kim ES, 2016, INT J CHRONIC OBSTR, V11, P1317, DOI 10.2147/COPD.S105206 Kirdar S, 2009, SCAND J CLIN LAB INV, V69, P219, DOI 10.1080/00365510802474400 Kostikas K, 2023, AM J RESP CRIT CARE, V208, P502, DOI 10.1164/rccm.202304-0691LE Kovacs G, 2022, CHEST, V162, P202, DOI 10.1016/j.chest.2022.01.031 Kovacs G, 2018, AM J RESP CRIT CARE, V198, P1000, DOI 10.1164/rccm.201801-0095PP Krommidas G, 2010, RESP MED, V104, P40, DOI 10.1016/j.rmed.2009.08.012 Kryston TB, 2011, MUTAT RES-FUND MOL M, V711, P193, DOI 10.1016/j.mrfmmm.2010.12.016 Kunik ME, 2008, PSYCHOL MED, V38, P385, DOI 10.1017/S0033291707001687 Kwok WC, 2025, CLIN RESPIR J, V19, DOI 10.1111/crj.70086 Kyriakopoulos C, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11081447 Laurin C, 2009, PSYCHOSOM MED, V71, P667, DOI 10.1097/PSY.0b013e3181a82849 Li J, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-140 Liao D, 1999, CHEST, V116, P150, DOI 10.1378/chest.116.1.150 Lin M, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1038715 Lipovec NC, 2016, COPD, V13, P399, DOI 10.3109/15412555.2016.1140732 Liu JM, 2021, SCI TOTAL ENVIRON, V780, DOI 10.1016/j.scitotenv.2021.146660 Liu X, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.732349 Loganadane G, 2016, CANCER TREAT REV, V50, P240, DOI 10.1016/j.ctrv.2016.10.002 López-Cano C, 2022, DIABETES, V71, P315, DOI 10.2337/db21-0688 Lunn S, 2017, CHRON RESP DIS, V14, P45, DOI 10.1177/1479972316688914 Maclagan Laura C, 2023, Eur Respir J, V62, DOI 10.1183/13993003.02364-2022 MacNee W, 2001, EUR J PHARMACOL, V429, P195, DOI 10.1016/S0014-2999(01)01320-6 Maddocks M, 2016, THORAX, V71, P988, DOI 10.1136/thoraxjnl-2016-208460 MAHLER DA, 1984, AM REV RESPIR DIS, V130, P722 Majumdar SR, 2010, RESP MED, V104, P260, DOI 10.1016/j.rmed.2009.09.013 Malhotra A, 2021, SLEEP, V44, DOI 10.1093/sleep/zsab030 Marengoni A, 2018, CHEST, V154, P21, DOI 10.1016/j.chest.2018.02.014 Marin JM, 2010, AM J RESP CRIT CARE, V182, P325, DOI 10.1164/rccm.200912-1869OC Matamis D, 2014, J CRIT CARE, V29, DOI 10.1016/j.jcrc.2013.11.011 Mathur S, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00104 Maurer J, 2008, CHEST, V134, p43S, DOI 10.1378/chest.08-0342 McShane PJ, 2024, AM J RESP CRIT CARE, V210, P128, DOI 10.1164/rccm.202402-0466RL Mitchell GF, 2010, CIRCULATION, V121, P505, DOI 10.1161/CIRCULATIONAHA.109.886655 Mittal N, 2016, J PRIM CARE COMMUNIT, V7, P10, DOI 10.1177/2150131915603202 Mkorombindo T, 2020, CLIN CHEST MED, V41, P475, DOI 10.1016/j.ccm.2020.05.006 Mo JH, 2020, WORLD J SURG ONCOL, V18, DOI 10.1186/s12957-020-1792-4 Monteiro F, 2012, LUNG, V190, P403, DOI 10.1007/s00408-012-9381-0 Ng TP, 2007, ARCH INTERN MED, V167, P60, DOI 10.1001/archinte.167.1.60 Ni YM, 2015, INT J CHRONIC OBSTR, V10, DOI 10.2147/COPD.S83910 Nicholson K, 2019, HEALTH PSYCHOL, V38, P783, DOI 10.1037/hea0000739 Nuti R, 2009, OSTEOPOROSIS INT, V20, P989, DOI 10.1007/s00198-008-0770-4 O'Donnell DE, 2001, AM J RESP CRIT CARE, V164, P770, DOI 10.1164/ajrccm.164.5.2012122 O'Donnell DE, 2017, ANN AM THORAC SOC, V14, pS30, DOI 10.1513/AnnalsATS.201610-834FR O'Donnell RA, 2004, THORAX, V59, P1032, DOI 10.1136/thx.2004.028043 Oda R, 2019, SURG TODAY, V49, P369, DOI 10.1007/s00595-018-1746-4 Omote N, 2017, INT J CHRONIC OBSTR, V12, P3541, DOI 10.2147/COPD.S149456 OSWALDMAMMOSSER M, 1991, RESPIRATION, V58, P304 Pajvani UB, 2003, J BIOL CHEM, V278, P9073, DOI 10.1074/jbc.M207198200 Park SK, 2013, HEART LUNG, V42, P163, DOI 10.1016/j.hrtlng.2012.07.004 Patel ARC, 2011, EXPERT REV RESP MED, V5, P647, DOI [10.1586/ers.11.62, 10.1586/ERS.11.62] Paz-Díaz H, 2007, AM J PHYS MED REHAB, V86, P30, DOI 10.1097/PHM.0b013e31802b8eca Polverino E, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.00328-2018 Polverino E, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00629-2017 Polverino F, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-26650-9 Pradhan R, 2022, BMJ-BRIT MED J, V379, DOI 10.1136/bmj-2022-071380 Putman-Casdorph H, 2009, HEART LUNG, V38, P34, DOI 10.1016/j.hrtlng.2008.02.005 Rafiq R, 2022, AM J CLIN NUTR, V116, P491, DOI 10.1093/ajcn/nqac083 Ragnoli B, 2025, THER ADV CHRONIC DIS, V16, DOI 10.1177/20406223251314286 Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X Roberts MH, 2022, INT J CHRONIC OBSTR, V17, P701, DOI 10.2147/COPD.S348714 Rogliani P, 2016, AM J RESP CELL MOL, V55, P804, DOI 10.1165/rcmb.2015-0311OC Rothnie KJ, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007824 Rusinowicz T, 2017, ADV EXP MED BIOL, V1022, P53, DOI 10.1007/5584_2017_41 Saito H, 2017, THORAC CANCER, V8, P451, DOI 10.1111/1759-7714.12466 Sakornsakolpat P, 2019, NAT GENET, V51, P494, DOI 10.1038/s41588-018-0342-2 Salpeter SR, 2004, CHEST, V125, P2309, DOI 10.1378/chest.125.6.2309 Santos G, 2024, SOC PSYCH PSYCH EPID, V59, P2093, DOI 10.1007/s00127-024-02645-x Sayers I, 2024, NAT REV GENET, V25, P534, DOI 10.1038/s41576-024-00695-0 Schetter AJ, 2010, CARCINOGENESIS, V31, P37, DOI 10.1093/carcin/bgp272 Schroeder EB, 2005, ATHEROSCLEROSIS, V180, P367, DOI 10.1016/j.atherosclerosis.2004.12.012 Sekine Y, 2002, LUNG CANCER-J IASLC, V37, P95, DOI 10.1016/S0169-5002(02)00014-4 Senoner T, 2019, NUTRIENTS, V11, DOI 10.3390/nu11092090 Sepúlveda-Loyola W, 2020, J CACHEXIA SARCOPENI, V11, P1164, DOI 10.1002/jcsm.12600 Sever ZK, 2020, CLIN RESPIR J, V14, P1032, DOI 10.1111/crj.13238 Shen TC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128461 Shi Xian-Rong, 2024, World J Clin Cases, V12, P4057, DOI [10.12998/wjcc.v12.i20.4057, 10.12998/wjcc.v12.i20.4057] Shrine N, 2023, NAT GENET, V55, P410, DOI 10.1038/s41588-023-01314-0 Sin DD, 2003, AM J MED, V114, P10, DOI 10.1016/S0002-9343(02)01297-4 Söderholm M, 2012, STROKE, V43, P2598, DOI 10.1161/STROKEAHA.112.658427 Spyratos D, 2017, LUNG CANCER-TARGETS, V8, P101, DOI 10.2147/LCTT.S117178 Stading R, 2021, SEMIN CANCER BIOL, V76, P3, DOI 10.1016/j.semcancer.2021.07.001 Su VYF, 2017, CHRON RESP DIS, V14, P151, DOI 10.1177/1479972316680846 Szucs B, 2018, J THORAC DIS, V10, P6482, DOI 10.21037/jtd.2018.10.104 Taki Y, 2013, NEURORADIOLOGY, V55, P689, DOI 10.1007/s00234-013-1157-6 Tomoda K, 2007, CHEST, V132, P135, DOI 10.1378/chest.07-0227 Touyz RM, 2005, ANTIOXID REDOX SIGN, V7, P1302, DOI 10.1089/ars.2005.7.1302 Traversi L, 2021, ERJ OPEN RES, V7, DOI 10.1183/23120541.00399-2021 Truelsen T, 2001, INT J EPIDEMIOL, V30, P145, DOI 10.1093/ije/30.1.145 Tsai HL, 2025, LIFE-BASEL, V15, DOI 10.3390/life15020154 Turcani P, 2015, BIOMED PAP, V159, P422, DOI 10.5507/bp.2014.002 Umer Farooq Mian Muhammad, 2025, Cureus, V17, pe83054, DOI 10.7759/cureus.83054 VANBALKOM RHH, 1994, NETH J MED, V45, P114 Vanfleteren LEGW, 2013, AM J RESP CRIT CARE, V187, P728, DOI 10.1164/rccm.201209-1665OC Viby NE, 2013, ENDOCRINOLOGY, V154, P4503, DOI 10.1210/en.2013-1666 Vizza CD, 1998, CHEST, V113, P576, DOI 10.1378/chest.113.3.576 Wade R Chad, 2025, Eur Respir J, V65, DOI [10.1183/13993003.00171-2024, 10.1183/13993003.00171-2024] WANNAMETHEE SG, 1995, STROKE, V26, P2004, DOI 10.1161/01.STR.26.11.2004 Watanabe Y, 2017, J AM GERIATR SOC, V65, P66, DOI 10.1111/jgs.14355 Watz H, 2014, EUR RESPIR J, V44, P1521, DOI 10.1183/09031936.00046814 White LH, 2013, J PHYSIOL-LONDON, V591, P1179, DOI 10.1113/jphysiol.2012.245159 who.int, US Xu JT, 2025, CELLS-BASEL, V14, DOI 10.3390/cells14030221 Xu J, 2019, GENES IMMUN, V20, P273, DOI 10.1038/s41435-018-0033-0 Xu J, 2023, J AM MED DIR ASSOC, V24, DOI 10.1016/j.jamda.2023.03.032 Young RP, 2010, EUR RESPIR J, V36, P1375, DOI 10.1183/09031936.00033310 Young RP, 2011, APPL CLIN GENET, V4, P1, DOI 10.2147/TACG.S15758 YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704 Zhang KN, 2022, TRANSL LUNG CANCER R, V11, P2306, DOI 10.21037/tlcr-22-667 Zhang PF, 2013, COPD, V10, P650, DOI 10.3109/15412555.2013.813928 Zhao LY, 2022, WORLD J CLIN CASES, V10, P3449, DOI 10.12998/wjcc.v10.i11.3449 Zhou JB, 2021, TRANSL LUNG CANCER R, V10, P2148, DOI 10.21037/tlcr-21-214 Zhu Min, 2011, Front Med, V5, P53, DOI 10.1007/s11684-011-0121-2 Zhu T, 2015, INT J MOL SCI, V16, P20195, DOI 10.3390/ijms160920195 Ziólkowska-Suchanek I, 2015, SCI REP-UK, V5, DOI 10.1038/srep13502 NR 198 TC 2 Z9 3 U1 8 U2 9 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1747-6348 EI 1747-6356 J9 EXPERT REV RESP MED JI Expert Rev. Respir. Med. PD MAR 4 PY 2026 VL 20 IS 3 BP 251 EP 266 DI 10.1080/17476348.2025.2569126 EA OCT 2025 PG 16 WC Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System GA EM8CB UT WOS:001588445600001 PM 41054835 DA 2026-04-17 ER PT J AU Wang, TY Miao, XE Wang, Y Chandran, SC Xia, YL AF Wang, Tongyu Miao, Xinge Wang, Yin Chandran, Sadees Clarance Xia, Yunlong TI Exploration of plasma genetic markers mediating lung cancer-induced cardiovascular disorders based on genome wide association studies SO MAMMALIAN GENOME LA English DT Article DE Lung cancer; Cardiovascular diseases; Mendelian randomization; Genetic loci; Mediating markers AB Lung cancer is strongly associated with increased cardiovascular disease (CVD) risk, yet the molecular mechanisms remain poorly understood. Batched two-sample Mendelian randomization (MR) analysis was performed to investigate cancer types and CVDs with significant associations. Local genetic correlation analyses were performed to identify meaningful genetic regions. Genomic Structural Equation Modeling (gSEM) was applied to identify latent factors shared between selected cancer types and CVDs. A transcriptome-wide association study (TWAS) was performed to identify relevant genetic markers. A two-stage MR analysis was performed to investigate potential mediators. Colocalization analysis was performed to assess the sensitivity of the results. Seventeen cancer types were positively associated with CVD risk, with lung cancer exhibiting the strongest link. Using LAVA and rho-HESS, we identified local genetic correlations between lung cancer and specific CVDs, including coronary artery disease (CAD), heart failure (HF), abdominal aortic aneurysm (AAA), and atrial fibrillation (AF). Weighted median MR analysis identified a negative effect for IREB2 (OR = 0.9; 95% CI 0.84-0.95; P < 0.05), and positive effects for both KRTCAP2 (OR = 1.1; 95% CI 1.02-1.21; P < 0.05) and MTX1P1 (OR = 1.1; 95% CI 1.02-1.21; P < 0.05), on lung cancer-induced AAA. ZBTB7B exhibited a positive mediating effect in the association between lung cancer and HF risk (OR = 1.04; 95% CI 1.01-1.07; P < 0.05). This study highlights IREB2, KRTCAP2, MTX1P1, and ZBTB7B as potential therapeutic targets for cancer-related CVD risk, emphasizing the importance of considering genetic factors in understanding and managing cardiovascular complications associated with lung cancer. [GRAPHICS] C1 [Wang, Tongyu; Chandran, Sadees Clarance; Xia, Yunlong] Dalian Med Univ, Dept Cardiol, Affiliated Hosp 1, Dalian, Liaoning, Peoples R China. [Miao, Xinge] Dalian Med Univ, Dept Canc Med, Affiliated Hosp 1, Dalian, Liaoning, Peoples R China. [Wang, Yin] Univ Hong Kong, Sch Biol Sci, Pokfulam Rd, Hong Kong, Peoples R China. C3 Dalian Medical University; Dalian Medical University; University of Hong Kong RP Xia, YL (corresponding author), Dalian Med Univ, Dept Cardiol, Affiliated Hosp 1, Dalian, Liaoning, Peoples R China. EM dlmu_xiayunlong@163.com RI ; Reuter, Karsten/D-9442-2011 OI Wang, Yin/0000-0002-9101-4146; FU Liao Ning Revitalization Talent program FX Thanks for all authors for contributing to this work. CR Al-Kindi SG, 2016, MAYO CLIN PROC, V91, P81, DOI 10.1016/j.mayocp.2015.09.009 Ben SQ, 2023, CELL COMMUN SIGNAL, V21, DOI 10.1186/s12964-023-01110-7 Bossé Y, 2020, INT J CANCER, V146, P1862, DOI 10.1002/ijc.32771 Corna G, 2006, J MOL MED, V84, P551, DOI 10.1007/s00109-006-0068-y Dasgupta S, 2025, OMICS, V29, P8, DOI 10.1089/omi.2024.0179 Dasgupta S, 2024, OMICS, V28, P585, DOI 10.1089/omi.2024.0175 de Jesus M, 2024, FRONT ONCOL, V14, DOI 10.3389/fonc.2024.1258991 Deng C, 2025, NPJ PRECIS ONCOL, V9, DOI 10.1038/s41698-025-00895-9 Gao HW, 2024, FRONT ONCOL, V14, DOI 10.3389/fonc.2024.1453090 Ghazal R, 2025, CIRC RES, V136, P773, DOI 10.1161/CIRCRESAHA.124.325402 Gusev A, 2016, NAT GENET, V48, P245, DOI 10.1038/ng.3506 Gwon HR, 2025, PLOS ONE, V20, DOI 10.1371/journal.pone.0315898 He HP, 2025, ISCIENCE, V28, DOI 10.1016/j.isci.2025.111880 Hong RA, 2010, CLIN CARDIOL, V33, P733, DOI 10.1002/clc.20823 Huang L, 2024, GENE, V931, DOI 10.1016/j.gene.2024.148877 Kannan K, 2015, CANCERS, V7, P2083, DOI 10.3390/cancers7040878 Kara JPS., 2013, AM J CLIN ONCOL-CANC, V37, P364 Karlstaedt A, 2022, NAT REV CARDIOL, V19, P414, DOI 10.1038/s41569-022-00698-6 Kravchenko J, 2015, LUNG CANCER, V88, P85, DOI 10.1016/j.lungcan.2015.01.006 Larsson SC, 2023, EUR HEART J, V44, P4913, DOI 10.1093/eurheartj/ehad736 Li YY, 2025, THERANOSTICS, V15, P6737, DOI 10.7150/thno.110162 Michel L, 2020, HERZ, V45, P619, DOI 10.1007/s00059-020-04951-x Nava RS., 2023, CUREUS J MED SCIENCE, V15, pe47818 Ng HS, 2024, CANCER MED-US, V13, DOI 10.1002/cam4.70057 Nolde M, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.918404 Pedersen Shona, 2021, Metabol Open, V12, P100127, DOI [10.1016/j.metop.2021.100127, 10.1016/j.metop.2021.100127] Raisi-Estabragh Z, 2023, HEART, V109, P1819, DOI 10.1136/heartjnl-2022-321324 Sun PP, 2023, COLLOID SURFACE B, V222, DOI 10.1016/j.colsurfb.2023.113124 Vosa U, 2021, NAT GENET, V53, P1300, DOI 10.1038/s41588-021-00913-z Wallace C, 2021, PLOS GENET, V17, DOI 10.1371/journal.pgen.1009440 Wang JC, 2023, J CARDIOL, V82, P274, DOI 10.1016/j.jjcc.2023.04.022 Wang JC, 2023, BMC CARDIOVASC DISOR, V23, DOI 10.1186/s12872-022-03012-x Wang ZY, 2024, DRUG DES DEV THER, V18, P1415, DOI 10.2147/DDDT.S448140 Wen SD, 2022, BMC CANCER, V22, DOI 10.1186/s12885-022-09296-8 Werme J, 2022, NAT GENET, V54, P274, DOI 10.1038/s41588-022-01017-y Xia HB, 2023, CELL DEATH DIFFER, V30, P1293, DOI 10.1038/s41418-023-01138-9 Yang YB, 2024, ARTHRITIS RES THER, V26, DOI 10.1186/s13075-024-03348-z Yujun Z., 2024, INT J CARDIOL HEART, V54 Zhang SS, 2024, J THORAC ONCOL, V19, P80, DOI 10.1016/j.jtho.2023.09.004 Zhao XY, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay6191 NR 40 TC 0 Z9 0 U1 4 U2 4 PU SPRINGER PI NEW YORK PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES SN 0938-8990 EI 1432-1777 J9 MAMM GENOME JI Mamm. Genome PD DEC PY 2025 VL 36 IS 4 BP 1237 EP 1247 DI 10.1007/s00335-025-10158-4 EA SEP 2025 PG 11 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity WE Science Citation Index Expanded (SCI-EXPANDED) SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity GA 9FT7F UT WOS:001575982400001 PM 40973822 DA 2026-04-17 ER PT J AU Zhang, JQ Liu, M Li, ZJ AF Zhang, Jiqing Liu, Mu Li, Zhongjun TI tRNA-derived small RNAs: emerging regulators of ferroptosis in human diseases SO HUMAN CELL LA English DT Review DE Ferroptosis; Regulator; Human disease; tRF; tiRNA ID CELL-DEATH; GASTRIC-CANCER; METABOLISM; ANGIOGENIN; PEROXIDATION; PATHOGENESIS; PERSPECTIVE; PROGRESSION; MECHANISMS; DEPRESSION AB tRNA-derived small RNAs (tsRNAs) are functional non-coding RNAs that play crucial roles in transcriptional, translational, and epigenetic regulation. Ferroptosis is an iron-dependent form of programmed cell death driven by lipid peroxidation, and its core mechanisms involve dysregulated iron homeostasis, redox imbalance, and lipid peroxidation. Emerging evidence indicates that tsRNAs serve as pivotal regulators of ferroptosis by targeting key components of the ferroptosis pathway. This regulatory interplay critically influences the activation or suppression of ferroptosis in various human diseases, including non-alcoholic steatohepatitis, perioperative neurocognitive disorders, acute kidney injury, non-small cell lung cancer, gastric cancer, diabetic kidney disease, atrial fibrillation, acute pancreatitis, depression, and acute lung injury, thereby affecting disease pathogenesis, progression, and therapeutic responses. This review summarizes the mechanisms underlying the interplay between tsRNAs and ferroptosis in human diseases and highlights the potential of tsRNAs as novel regulators of ferroptosis, providing insights into disease mechanisms. C1 [Zhang, Jiqing; Li, Zhongjun] Guangdong Med Univ, Sch Clin Med 1, Zhanjiang 524023, Guangdong, Peoples R China. [Zhang, Jiqing; Liu, Mu; Li, Zhongjun] Dongguan Peoples Hosp, Dept Obstet, Dongguan 523000, Guangdong, Peoples R China. C3 Guangdong Medical University RP Li, ZJ (corresponding author), Guangdong Med Univ, Sch Clin Med 1, Zhanjiang 524023, Guangdong, Peoples R China.; Li, ZJ (corresponding author), Dongguan Peoples Hosp, Dept Obstet, Dongguan 523000, Guangdong, Peoples R China. EM 1165124230@qq.com CR Alicic RZ, 2017, CLIN J AM SOC NEPHRO, V12, P2032, DOI 10.2215/CJN.11491116 An XN, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39349-1 Bai YJ, 2020, ACCOUNTS CHEM RES, V53, P1034, DOI 10.1021/acs.accounts.9b00600 Bai YS, 2019, BIOCHEM BIOPH RES CO, V508, P997, DOI 10.1016/j.bbrc.2018.12.039 Bogdan AR, 2016, TRENDS BIOCHEM SCI, V41, P274, DOI 10.1016/j.tibs.2015.11.012 BOREK E, 1977, CANCER RES, V37, P3362 Calle P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082806 Chen BY, 2024, J DENT RES, V103, P712, DOI 10.1177/00220345241242389 Chen K, 2021, J INFLAMM RES, V14, P7079, DOI 10.2147/JIR.S347955 Chen X, 2021, AUTOPHAGY, V17, P2054, DOI 10.1080/15548627.2020.1810918 Chen X, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.590226 Chu XH, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.954431 Correa P, 2013, GASTROENTEROL CLIN N, V42, P211, DOI 10.1016/j.gtc.2013.01.002 Dixon SJ, 2014, ELIFE, V3, DOI 10.7554/eLife.02523 Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042 Doll S, 2019, NATURE, V575, P693, DOI 10.1038/s41586-019-1707-0 Duma N, 2019, MAYO CLIN PROC, V94, P1623, DOI 10.1016/j.mayocp.2019.01.013 El-Sehrawy AAMA, 2025, FUNCT INTEGR GENOMIC, V25, DOI 10.1007/s10142-025-01579-0 Evans DR, 2004, J BIOL CHEM, V279, P33035, DOI 10.1074/jbc.R400007200 Evered L, 2018, BRIT J ANAESTH, V121, P1005, DOI 10.1016/j.bja.2017.11.087 Evered LA, 2018, ANESTH ANALG, V127, P496, DOI 10.1213/ANE.0000000000003514 Fan XR, 2023, WORLD J GASTROENTERO, V29, P4642, DOI 10.3748/wjg.v29.i30.4642 Gao MH, 2016, CELL RES, V26, P1021, DOI 10.1038/cr.2016.95 Gao Y, 2025, J MED GENET, V62, P152, DOI 10.1136/jmg-2024-110437 Gebetsberger J, 2012, ARCHAEA, V2012, DOI 10.1155/2012/260909 Goodarzi H, 2015, CELL, V161, P790, DOI 10.1016/j.cell.2015.02.053 Gu XL, 2025, CARCINOGENESIS, V46, DOI 10.1093/carcin/bgaf026 Hamilton JP, 2015, BIOL PSYCHIAT, V78, P224, DOI 10.1016/j.biopsych.2015.02.020 Hansen M, 2004, PROTEIN SCI, V13, P1031, DOI 10.1110/ps.03533004 Hassannia B, 2019, CANCER CELL, V35, P830, DOI 10.1016/j.ccell.2019.04.002 Herbst RS, 2018, NATURE, V553, P446, DOI 10.1038/nature25183 Hu YF, 2024, J OBSTET GYNAECOL RE, V50, P1317, DOI 10.1111/jog.16008 Huang JZ, 2024, J MOL HISTOL, V55, P1147, DOI 10.1007/s10735-024-10256-8 Huang T, 2024, J CANCER, V15, P2613, DOI 10.7150/jca.93531 Huang XT, 2019, INT J MOL MED, V44, P2213, DOI 10.3892/ijmm.2019.4387 Huang ZK, 2025, EMERG MICROBES INFEC, V14, DOI 10.1080/22221751.2025.2459132 Humphreys BD, 2018, ANNU REV PHYSIOL, V80, P309, DOI 10.1146/annurev-physiol-022516-034227 Ingold I, 2018, CELL, V172, P409, DOI 10.1016/j.cell.2017.11.048 Ivanov P, 2011, MOL CELL, V43, P613, DOI 10.1016/j.molcel.2011.06.022 Ji XM, 2018, ONCOGENE, V37, P5007, DOI 10.1038/s41388-018-0307-z Jiang L, 2021, BLOOD, V138, P689, DOI 10.1182/blood.2020008986 Jiang S, 2023, CELL COMMUN SIGNAL, V21, DOI 10.1186/s12964-023-01323-w Jiao D, 2025, MEDICINE, V104, DOI 10.1097/MD.0000000000041218 Jin EJ, 2024, FRONT ENDOCRINOL, V15, DOI 10.3389/fendo.2024.1447148 Jin T, 2024, STEM CELL RES THER, V15, DOI 10.1186/s13287-024-04066-8 Ju MJ, 2018, CELL CYCLE, V17, P2001, DOI 10.1080/15384101.2018.1509635 Kagan VE, 2017, NAT CHEM BIOL, V13, P81, DOI [10.1038/NCHEMBIO.2238, 10.1038/nchembio.2238] Kim HK, 2020, MOL THER, V28, P2340, DOI 10.1016/j.ymthe.2020.09.013 Kim HK, 2019, CELL REP, V29, P3816, DOI 10.1016/j.celrep.2019.11.062 Kim HK, 2017, NATURE, V552, P57, DOI 10.1038/nature25005 Kraft VAN, 2020, ACS CENTRAL SCI, V6, P41, DOI 10.1021/acscentsci.9b01063 Krishna S, 2019, EMBO REP, V20, DOI 10.15252/embr.201947789 Kumar P, 2014, BMC BIOL, V12, DOI 10.1186/s12915-014-0078-0 Leopold KT, 2023, THORAC SURG CLIN, V33, P343, DOI 10.1016/j.thorsurg.2023.04.003 Lewington AJP, 2013, KIDNEY INT, V84, P457, DOI 10.1038/ki.2013.153 Li CL, 2021, BMC GASTROENTEROL, V21, DOI 10.1186/s12876-021-01906-2 Li D, 2024, BBA-MOL BASIS DIS, V1870, DOI 10.1016/j.bbadis.2024.167277 Li DS, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00216-5 Li EZ, 2023, BRAIN RES BULL, V204, DOI 10.1016/j.brainresbull.2023.110773 Li N, 2022, PHARMACOL RES, V175, DOI 10.1016/j.phrs.2021.106033 Li SP, 2012, J CELL PHYSIOL, V227, P2822, DOI 10.1002/jcp.23051 Liang DG, 2022, MOL CELL, V82, P2215, DOI 10.1016/j.molcel.2022.03.022 Lin Z, 2025, CLIN EXP MED, V25, DOI 10.1007/s10238-025-01766-0 Liu DS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14844 Liu MR, 2025, GENES DIS, V12, DOI 10.1016/j.gendis.2024.101326 Liu SB, 2018, MED SCI MONITOR, V24, P7646, DOI 10.12659/MSM.908422 Mahanna-Gabrielli E, 2019, BRIT J ANAESTH, V123, P464, DOI 10.1016/j.bja.2019.07.004 Mathew BA, 2023, MOL NEUROBIOL, V60, P655, DOI 10.1007/s12035-022-03078-w Mayerle J, 2019, GASTROENTEROLOGY, V156, P1951, DOI 10.1053/j.gastro.2018.11.081 Mohan S, 2024, HELIYON, V10, DOI 10.1016/j.heliyon.2024.e24786 Mun SH, 2024, MOL CELLS, V47, DOI 10.1016/j.mocell.2024.100008 Ocansey DKW, 2023, INT J MOL MED, V51, DOI 10.3892/ijmm.2023.5256 Osmani L, 2018, SEMIN CANCER BIOL, V52, P103, DOI 10.1016/j.semcancer.2017.11.019 Peng HY, 2012, CELL RES, V22, P1609, DOI 10.1038/cr.2012.141 Pope LE, 2023, TRENDS CELL BIOL, V33, P1077, DOI 10.1016/j.tcb.2023.05.003 Pu FF, 2022, GENES DIS, V9, P347, DOI 10.1016/j.gendis.2020.11.019 Qi J, 2020, AM J PATHOL, V190, P68, DOI 10.1016/j.ajpath.2019.09.011 Qiao YY, 2024, ACTA PHARMACOL SIN, V45, P1032, DOI 10.1038/s41401-024-01228-5 Qin MZ, 2015, INT J CLIN EXP PATHO, V8, P12943 Qiu WS, 2020, FRONT NEUROENDOCRIN, V59, DOI 10.1016/j.yfrne.2020.100854 Razi S, 2025, CELL SIGNAL, V125, DOI 10.1016/j.cellsig.2024.111503 Rochette L, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24010449 Roemhild K, 2021, TRENDS PHARMACOL SCI, V42, P640, DOI 10.1016/j.tips.2021.05.001 Rogers PA, 2018, CURR PROB CARDIOLOGY, V43, P240, DOI [10.1016/j.cpcardiol.2017.06.001, 10.1016/j.cpcardiol.2018.04.001] Ruggero K, 2014, J VIROL, V88, P3612, DOI 10.1128/JVI.02823-13 Saeed BI, 2025, N-S ARCH PHARMACOL, V398, P12927, DOI [10.1007/s00210-025-04115-w, 10.1007/s00210-025-04115-w] Schuster S, 2018, NAT REV GASTRO HEPAT, V15, P349, DOI 10.1038/s41575-018-0009-6 Shen L, 2013, LANCET ONCOL, V14, pE535, DOI 10.1016/S1470-2045(13)70436-4 Shu SQ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8030207 SPEER J, 1979, CANCER-AM CANCER SOC, V44, P2120, DOI 10.1002/1097-0142(197912)44:6<2120::AID-CNCR2820440623>3.0.CO;2-6 Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021 Sun XR, 2025, BMC PREGNANCY CHILDB, V25, DOI 10.1186/s12884-025-07672-3 Sun YT, 2020, BIOMED PHARMACOTHER, V127, DOI 10.1016/j.biopha.2020.110108 Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660 Tang DL, 2021, CELL RES, V31, P107, DOI 10.1038/s41422-020-00441-1 Tang MZ, 2018, J CELL PHYSIOL, V233, P9179, DOI 10.1002/jcp.26954 Thomas HY, 2022, J BIOL ENG, V16, DOI 10.1186/s13036-022-00299-4 Thurlow JS, 2021, AM J NEPHROL, V52, P98, DOI 10.1159/000514550 Tonneijck L, 2017, J AM SOC NEPHROL, V28, P1023, DOI 10.1681/ASN.2016060666 Trivedi MH, 2006, AM J PSYCHIAT, V163, P28, DOI 10.1176/appi.ajp.163.1.28 Vilagut G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155431 Wang K, 2024, PHARMACOL RES, V206, DOI 10.1016/j.phrs.2024.107279 Wang LJ, 2024, FRONT CELL NEUROSCI, V18, DOI 10.3389/fncel.2024.1359453 Wang S, 2024, CANCER CELL INT, V24, DOI 10.1186/s12935-024-03391-5 Wang S, 2024, NPJ PRECIS ONCOL, V8, DOI 10.1038/s41698-024-00538-5 Wang WX, 2022, INT IMMUNOPHARMACOL, V107, DOI 10.1016/j.intimp.2022.108690 Wang YX, 2025, FRONT BIOSCI-LANDMRK, V30, DOI 10.31083/FBL26345 Xie LZ, 2024, EXP CELL RES, V435, DOI 10.1016/j.yexcr.2024.113923 Xu XY, 2025, CANCER SCI, V116, P1255, DOI [10.1111/cas.70003, 10.1111/cas.70003] Yamasaki S, 2009, J CELL BIOL, V185, P35, DOI 10.1083/jcb.200811106 Yan B, 2021, MOL CELL, V81, P355, DOI 10.1016/j.molcel.2020.11.024 Yang J, 2024, MOL CELLS, V47, DOI 10.1016/j.mocell.2024.100160 Yang JCZ, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040872 Yang J, 2024, FRONT PHARMACOL, V15, DOI 10.3389/fphar.2024.1283465 Yang WS, 2016, P NATL ACAD SCI USA, V113, pE4966, DOI 10.1073/pnas.1603244113 Yang YX, 2024, J ETHNOPHARMACOL, V334, DOI 10.1016/j.jep.2024.118557 Younossi Z, 2018, NAT REV GASTRO HEPAT, V15, P11, DOI 10.1038/nrgastro.2017.109 Yu T, 2021, BIOL REPROD, V105, P603, DOI 10.1093/biolre/ioab086 Zhang JQ, 2025, CLIN CHIM ACTA, V576, DOI 10.1016/j.cca.2025.120405 Zhang L, 2023, CELL DEATH DIS, V14, DOI 10.1038/s41419-023-06250-9 Zhang YW, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26909-1 Zhang YP, 2024, FRONT CELL DEV BIOL, V12, DOI 10.3389/fcell.2024.1344060 Zhang Y, 2024, J ZHEJIANG UNIV-SC B, V25, P438, DOI 10.1631/jzus.B2300215 Zhao YQ, 2024, BBA-MOL BASIS DIS, V1870, DOI 10.1016/j.bbadis.2024.167354 Zhao YL, 2025, FRONT PHARMACOL, V16, DOI 10.3389/fphar.2025.1516601 Zhou CL, 2025, 3 BIOTECH, V15, DOI 10.1007/s13205-024-04176-3 Zhou JH, 2017, J GEN VIROL, V98, P1600, DOI 10.1099/jgv.0.000852 Zhou W, 2025, BMC BIOL, V23, DOI 10.1186/s12915-025-02268-x Zhou ZX, 2023, CELLS-BASEL, V12, DOI 10.3390/cells12020311 Zhu JM, 2025, INT J NANOMED, V20, P1637, DOI 10.2147/IJN.S496644 Zhu JJ, 2025, CLIN EPIGENETICS, V17, DOI 10.1186/s13148-025-01813-3 Zhu LW, 2019, CANCER LETT, V452, P31, DOI 10.1016/j.canlet.2019.03.012 Zou YL, 2020, NAT CHEM BIOL, V16, P302, DOI 10.1038/s41589-020-0472-6 NR 133 TC 1 Z9 1 U1 3 U2 4 PU SPRINGER JAPAN KK PI TOKYO PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005, JAPAN SN 0914-7470 EI 1749-0774 J9 HUM CELL JI Hum. Cell PD SEP 17 PY 2025 VL 38 IS 6 AR 162 DI 10.1007/s13577-025-01293-w PG 13 WC Cell Biology WE Science Citation Index Expanded (SCI-EXPANDED) SC Cell Biology GA 7KN0Y UT WOS:001573193100002 PM 40960548 DA 2026-04-17 ER PT J AU Wu, DD Ye, H Dong, MY Wu, XH Dai, JJ Le, HB Yan, BE AF Wu, Dongdong Ye, Hong Dong, Meiyuan Wu, Xiaohua Dai, Jianjuan Le, Hanbo Yan, Boer TI Development and internal validation of a nomogram to predict postoperative atrial fibrillation in elderly patients with lung cancer SO JOURNAL OF THORACIC DISEASE LA English DT Article DE Advanced age; postoperative atrial fibrillation (POAF); lung cancer; nomogram; prediction model ID SURGERY; OUTCOMES; RISK AB Background: The elderly are at high risk of developing postoperative atrial fibrillation (POAF) after lung resection, which is more likely to trigger serious complications such as heart failure, myocardial infarction, pulmonary embolism, and ischemic stroke, seriously affecting the recovery and prognosis of patients. This study aimed to develop and validate a nomogram for predicting POAF in elderly lung cancer patients. Methods: We retrospectively analyzed the medical records of 960 elderly patients undergoing thoracoscopic lung cancer surgery at Zhoushan Hospital from January 2022 to December 2023. Patients were divided into the POAF group and the non-POAF group. The least absolute shrinkage and selection operator (LASSO) identified univariate and multivariate logistic regression predictors. A nomogram was constructed using the selected variables, with internal validation performed via 500 bootstrap repetitions. Model accuracy was evaluated using calibration curves and the Hosmer-Lemeshow goodness-of-fit test (HL test), while predictive performance was assessed using the area under the receiver operating characteristic curve (AUC), and decision curve analysis (DCA) was conducted to assess predictive performance. Results: POAF incidence was 8.65% in the observation period. The nomogram included age [odds ratio (OR) 1.086; 95% confidence intervals (CI): 1.041-1.132], respiratory illness (OR 2.545, 95% CI: 1.234-5.247), non-hypertensive cardiovascular diseases (OR 2.212, 95% CI: 1.300-3.764), pulmonary lobectomy (OR 1.776, 95% CI: 1.047-3.013), anti-infection treatment (OR 1.657, 95% CI: 0.963-2.850), lymph node dissection (OR 2.181, 95% CI: 1.241-3.833) and drainage duration (OR 1.083, 95% CI: 1.010-1.161). The AUC value of the predictive model and the internal validation was 0.782 (0.734-0.830) and 0.782 (0.734-0.835), respectively. The calibration curves and result of the HL test (P=0.50) showed satisfactory consistency, and DCA demonstrated good clinical utility. Conclusions: This nomogram exhibits good predictive performance and applicability, assisting clinicians in POAF prevention and management for elderly lung cancer patients. C1 [Wu, Dongdong; Ye, Hong; Wu, Xiaohua] Zhoushan Hosp, Dept Geriatr & Integrated Chinese & Western Med, Zhoushan, Peoples R China. [Dong, Meiyuan; Yan, Boer] Zhoushan Hosp, Dept Nursing, 739 Dingshen Rd, Zhoushan 316000, Peoples R China. [Le, Hanbo] Zhoushan Hosp, Dept Cardiothorac Surg, Zhoushan, Peoples R China. RP Yan, BE (corresponding author), Zhoushan Hosp, Dept Nursing, 739 Dingshen Rd, Zhoushan 316000, Peoples R China. EM zsyhb@163.com RI Brizard, christian/JRW-3140-2023; Dong, Meiyuan/ADB-7555-2022; Buratto, Edward/AAW-9469-2020 OI Wu, Damien M/0000-0002-7463-0684; Wu, Dongdong/0000-0002-1828-6786; FU Medical Science and Technology Project of Zhejiang Provincial Health Commission [2023KY1299] FX Funding: This work was supported by the Medical Science and Technology Project of Zhejiang Provincial Health Commission (grant No. 2023KY1299) . CR Aguilar Martin, 2021, Card Electrophysiol Clin, V13, P123, DOI [10.1016/j.ccep.2020.11.010, 10.1016/j.ccep.2020.11.010] Alexander M, 2020, LUNG, V198, P897, DOI 10.1007/s00408-020-00407-5 Ali H, 2023, INDIAN J GASTROENTER, V42, P780, DOI 10.1007/s12664-023-01426-9 Apaydin Z, 2023, BRAZ J CARDIOV SURG, V38, DOI 10.21470/1678-9741-2023-0017 Bae SJ, 2022, WORLD J CLIN CASES, V10, P3379, DOI 10.12998/wjcc.v10.i11.3379 Chen LT, 2020, CANCER CONTROL, V27, DOI 10.1177/1073274820974013 Cruz NI, 2022, P R HEALTH SCI J, V41, P243 Dhole S, 2023, CUREUS J MED SCIENCE, V15, DOI 10.7759/cureus.47858 Díez-Villanueva P, 2019, J GERIATR CARDIOL, V16, P49, DOI 10.11909/j.issn.1671-5411.2019.01.005 Fabiani I, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010037 Gaudino M, 2023, EUR HEART J, V44, P1020, DOI 10.1093/eurheartj/ehad019 Gaudino M, 2022, J AM COLL CARDIOL, V79, P2529, DOI 10.1016/j.jacc.2022.04.029 Ge PB, 2022, FRONT CARDIOVASC MED, V9, DOI 10.3389/fcvm.2022.1032116 Goulden CJ, 2022, PERFUSION-UK, V37, P675, DOI 10.1177/02676591211019319 Han Y, 2024, VASC HEALTH RISK MAN, V20, DOI 10.2147/VHRM.S463648 Hao JQ, 2022, ANN THORAC CARDIOVAS, V28, P18, DOI 10.5761/atcs.ra.21-00126 Huang QB, 2023, J THORAC DIS, V15, P3908, DOI 10.21037/jtd-23-923 Jagadish PS, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.07.10 Jiang SJ, 2023, FRONT CARDIOVASC MED, V10, DOI 10.3389/fcvm.2023.1273547 Kashiwagi M, 2022, J GASTROINTEST SURG, V26, P2451, DOI 10.1007/s11605-022-05493-9 Kotecha D, 2020, EUR HEART J, V41, P652, DOI 10.1093/eurheartj/ehz412 Liang XY, 2025, SCI REP-UK, V15, DOI 10.1038/s41598-025-90052-w Malektojari A, 2025, CJC OPEN, V7, P35, DOI 10.1016/j.cjco.2024.10.008 Migdady I, 2021, SEMIN NEUROL, V41, P348, DOI 10.1055/s-0041-1726332 Ng EP, 2016, J THORAC DIS, V8, P2079, DOI 10.21037/jtd.2016.07.68 Nomani H, 2021, J CARDIOVASC DEV DIS, V8, DOI 10.3390/jcdd8030024 Patzer RE, 2021, JAMA SURG, V156, P675, DOI 10.1001/jamasurg.2021.0537 Quan I, 2024, J CLIN MED, V13, DOI 10.3390/jcm13164948 Rathnayake A, 2024, J CARDIOTHORAC SURG, V19, DOI 10.1186/s13019-024-02569-2 Ripoll JG, 2025, J CARDIOTHOR VASC AN, V39, P818, DOI 10.1053/j.jvca.2024.11.020 Saljic A, 2023, N-S ARCH PHARMACOL, DOI 10.1007/s00210-023-02402-y Segar MW, 2023, TEX HEART I J, V50, DOI 10.14503/THIJ-23-8221 Semeraro GC, 2021, CANCERS, V13, DOI 10.3390/cancers13164012 Senbu MF, 2025, J CARDIOTHORAC SURG, V20, DOI 10.1186/s13019-024-03268-8 Shao LL, 2023, J TISSUE VIABILITY, V32, P85, DOI 10.1016/j.jtv.2023.01.002 Shi SB, 2022, LANCET REG HEALTH-W, V23, DOI 10.1016/j.lanwpc.2022.100439 Son YJ, 2024, BMC CARDIOVASC DISOR, V24, DOI 10.1186/s12872-024-04247-6 Tong CY, 2024, INT J SURG, V110, P1645, DOI 10.1097/JS9.0000000000001006 Tong CY, 2022, J CLIN ANESTH, V79, DOI 10.1016/j.jclinane.2022.110770 van Boven WJ, 2021, LANCET, V398, P2052, DOI 10.1016/S0140-6736(21)02435-1 Van Calster B, 2018, EUR UROL, V74, P796, DOI 10.1016/j.eururo.2018.08.038 van de Kar MRD, 2024, EUR HEART J, V45, P2620, DOI 10.1093/eurheartj/ehae267 van der Heijden CAJ, 2022, IJC HEART VASC, V39, DOI 10.1016/j.ijcha.2022.100976 Van Gelder IC, 2024, EUR HEART J, V45, P3314, DOI 10.1093/eurheartj/ehae176 Wong CX, 2024, NAT REV CARDIOL, V21, P841, DOI 10.1038/s41569-024-01091-1 Xie JYY, 2021, EUROPACE, V23, P159, DOI 10.1093/europace/euaa303 Zhang LF, 2024, ASIAN J SURG, V47, P176, DOI 10.1016/j.asjsur.2023.06.108 NR 47 TC 4 Z9 4 U1 2 U2 7 PU AME PUBLISHING COMPANY PI SHATIN PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA SN 2072-1439 EI 2077-6624 J9 J THORAC DIS JI J. Thorac. Dis. PD SEP 30 PY 2025 VL 17 IS 9 BP 6711 EP 6723 DI 10.21037/jtd-2025-533 EA SEP 2025 PG 13 WC Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System GA 9IJ0C UT WOS:001576860600001 PM 36910070 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Demmy, T Abdelhady, S Tomaszewski, G Petroziello, M Hasan, O Hennon, M Dexter, E Vadehra, D Gupta, A Grand'Maison, A Dy, G Yendamuri, S AF Demmy, Todd Abdelhady, Samah Tomaszewski, Garin Petroziello, Michael Hasan, Omar Hennon, Mark Dexter, Elisabeth Vadehra, Deepak Gupta, Ajay Grand'Maison, Anne Dy, Grace Yendamuri, Sai TI Pulmonary Suffusion Refinements for Primary and Secondary Malignancies: Preliminary Analyses of Phase I Safety and Drug Delivery Data SO CANCERS LA English DT Article DE pulmonary suffusion; metastasectomy; DNA-damaging agents; colorectal cancer; soft tissue sarcoma ID ISOLATED LUNG PERFUSION; REGIONAL CHEMOTHERAPY; METASTASES; DOCETAXEL; GEMCITABINE; CISPLATIN; INFUSION; SARCOMAS; CANCER AB Objectives: We sought to document interim methodologic improvements and preliminary results for pulmonary suffusion. Methods: A Phase I/II trial of thoracoscopic lung suffusion for resectable sarcoma and colorectal carcinoma metastases followed a pilot study on oligometastatic lung malignancy at a comprehensive cancer center. Primary-specific chemotherapy doses (cisplatin, oxaliplatin, doxorubicin, or gemcitabine) suffused unilaterally for 30 min were escalated to amplify regional deliveries three-fold. Drug delivery was measured with tissue, blood samples, and 99Tc; pulmonary function tests and clinical adverse events (AEs) assessed safety and tolerance. Results: From 2008-2025, 31 ECOG 0-2 patients (10 male) aged 33-75 years had unilateral lung suffusion (16 right, 14 left, 1 aborted, and 8 sides selected randomly). Vascular occlusion intolerance was immediate or delayed (25 min) in two cases. Two catheter-positioning grade 3 AEs occurred: hypotension with troponin leak (1) and atrial fibrillation (1). Patients averaged 1.3 +/- 1.2 metastasectomies (17 sub-lobar, 8 lobar resections, and 2 intentional open cytoreductive metastasectomies). Hospitalizations were brief (1-4 days) except for 6-7 day stays in the only two open cases and one doxorubicin (grade 4 hypoxic respiratory failure) case. Ninety-day survival was 100%, and the Phase I delivery goal of 12.75 mg/m2 65 (15% systemic) was achieved for oxaliplatin. Lung function was preserved according to 99Tc differentials within 6.1 +/- 7.1% of the predicted reductions at 30 days. Sampling delays, tracer discordances, and atypical pharmacokinetics reduced tissue drug detections. Recent pulmonary artery snaring cases (two) demonstrated in-flow control more stable than that of balloon occlusions. Conclusions: Suffusion for metastatic malignancies appears safe and warrants further investigation. C1 [Demmy, Todd; Hennon, Mark; Dexter, Elisabeth; Yendamuri, Sai] Roswell Pk Comprehens Canc Ctr, Dept Thorac Surg, Elm & Carlton Strs, Buffalo, NY 14263 USA. [Abdelhady, Samah; Gupta, Ajay] Roswell Pk Comprehens Canc Ctr, Dept Pediat Hematol & Oncol, Elm & Carlton Strs, Buffalo, NY 14263 USA. [Tomaszewski, Garin; Petroziello, Michael; Hasan, Omar] Roswell Pk Comprehens Canc Ctr, Dept Radiol, Elm & Carlton Strs, Buffalo, NY 14263 USA. [Vadehra, Deepak; Dy, Grace] Roswell Pk Comprehens Canc Ctr, Dept Med Oncol, Elm & Carlton Strs, Buffalo, NY 14263 USA. [Grand'Maison, Anne] Erie Cty Med Ctr & Labs, Ctr Canc & Oncol Care, Buffalo, NY 14215 USA. C3 Roswell Park Comprehensive Cancer Center; Roswell Park Comprehensive Cancer Center; Roswell Park Comprehensive Cancer Center; Roswell Park Comprehensive Cancer Center RP Demmy, T (corresponding author), Roswell Pk Comprehens Canc Ctr, Dept Thorac Surg, Elm & Carlton Strs, Buffalo, NY 14263 USA. EM todd.demmy@roswellpark.org; samah.abdelhady@roswellpark.org; garin.tomaszewski@roswellpark.org; michael.petroziello@roswellpark.org; omar.hasan@roswellpark.org; mark.hennon@roswellpark.org; elisabeth.dexter@roswellpark.org; deepak.vadehra@roswellpark.org; ajay.gupta@roswellpark.org; agrandmais@ecmc.edu; grace.dy@roswellpark.org; sai.yendamuri@roswellpark.org RI Gupta, Ajay/AAW-6583-2020 OI Gupta, Ajay/0000-0001-6074-9847; Demmy, Todd/0000-0002-4800-2297 FU Roswell Park Comprehensive Cancer Center; Roswell Park Comprehensive Cancer Center including editorial assistance through National Cancer Institute [P30CA016056]; NCI FX This research was funded by Roswell Park Comprehensive Cancer Center including editorial assistance through National Cancer Institute grant no. NCI P30CA016056. CR Bell MD, 2022, ARCH PATHOL LAB MED, V146, P1486, DOI 10.5858/arpa.2021-0287-OA Cypel M, 2016, THORAC SURG CLIN, V26, P139, DOI 10.1016/j.thorsurg.2015.12.002 Demmy TL, 2002, J BIOMED SCI, V9, P334, DOI 10.1007/BF02256589 Demmy TL, 2016, THORAC SURG CLIN, V26, P109, DOI 10.1016/j.thorsurg.2015.09.013 Demmy TL, 2009, ANN THORAC SURG, V88, P385, DOI 10.1016/j.athoracsur.2009.04.101 Detweiler D.K., 1979, Best Taylor's Physiologic Basis of Medical Practice Ducoulombier A, 2016, CRIT REV ONCOL HEMAT, V98, P73, DOI 10.1016/j.critrevonc.2015.10.020 Forster C, 2021, J CARDIOTHORAC SURG, V16, DOI 10.1186/s13019-021-01740-3 Furrer K, 2025, JHLT Open, V9, P100253, DOI 10.1016/j.jhlto.2025.100253 Grootenboers MJJH, 2006, PERFUSION-UK, V21, P267, DOI 10.1177/0267659106073984 Hendriks Jeroen M H, 2006, Thorac Surg Clin, V16, P185, DOI 10.1016/j.thorsurg.2005.11.003 Hohenforst-Schmidt W, 2013, DRUG DES DEV THER, V7, P571, DOI 10.2147/DDDT.S46393 Jiang RW, 2026, ADV SCI, V13, DOI 10.1002/advs.202500396 Johnson MJ, 2016, EUR RESPIR J, V47, P1861, DOI 10.1183/13993003.02089-2015 Kanzaki R, 2024, INTERDISC CARDIOV TH, V38, DOI 10.1093/icvts/ivae028 KARAKOUSIS CP, 1981, J SURG ONCOL, V18, P249, DOI 10.1002/jso.2930180305 Kessel KA, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-6635-8 Mallick R, 2011, INNOVATIONS, V6, P1, DOI 10.1097/IMI.0b013e31820b1e63 Nakanishi M, 2008, LUNG CANCER, V61, P227, DOI 10.1016/j.lungcan.2007.12.017 Nakanishi M, 2012, LUNG CANCER, V77, P353, DOI 10.1016/j.lungcan.2012.04.006 National Comprehensive Cancer Network, 2025, Colon Cancer Nitsche LJ, 2025, JTCVS OPEN, V24, P484, DOI [10.1016/j.xjon.2024.12.012, 10.1016/j.xjon.2024.12.012] Ramadan K., 2025, P 105 ANN M SEATTL W Sastry P, 2014, INTERACT CARDIOV TH, V18, P495, DOI 10.1093/icvts/ivt526 Seddon B, 2017, LANCET ONCOL, V18, P1397, DOI 10.1016/S1470-2045(17)30622-8 SMYTH NP, 1960, J THORAC CARDIOV SUR, V40, P653, DOI 10.1016/S0022-5223(19)32588-7 Sparks Preston J, 2014, World J Oncol, V5, P1, DOI 10.14740/wjon788w Stella GM, 2019, CANCERS, V11, DOI 10.3390/cancers11071010 Subramanian J, 2025, J AEROSOL MED PULM D, V38, P90, DOI 10.1089/jamp.2025.19211.js Thandra KC, 2021, WSPOLCZESNA ONKOL, V25, P45, DOI 10.5114/wo.2021.103829 Treasure T, 2022, J CARDIOTHORAC SURG, V17, DOI 10.1186/s13019-022-01757-2 Vogl TJ, 2013, SEMIN INTERVENT RAD, V30, P176, DOI 10.1055/s-0033-1342959 Ward A, 2016, THORAC SURG CLIN, V26, P55, DOI 10.1016/j.thorsurg.2015.09.008 Xiao GX, 2025, MOL CANCER, V24, DOI [10.1186/s12943-025-02318-6, 10.1186/s12943-025-02318-6] Yang Jessie, 2013, Hosp Pharm, V48, P550, DOI 10.1310/hpj4807-550 Younes RN, 2009, CLINICS, V64, P535, DOI 10.1590/S1807-59322009000600008 Yue XZ, 2025, EUR RADIOL, V35, P6302, DOI 10.1007/s00330-025-11419-1 Zhan YX, 2024, FRONT IMMUNOL, V15, DOI 10.3389/fimmu.2024.1446511 Zhang FX, 2025, FRONT ONCOL, V15, DOI [10.3389/fonc.2025.1551644, 10.3389/fonc.2025.1551644] Zhou W, 2024, J PHARM ANAL, V14, DOI 10.1016/j.jpha.2023.12.008 NR 40 TC 0 Z9 0 U1 1 U2 1 PU MDPI PI BASEL PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND EI 2072-6694 J9 CANCERS JI Cancers PD SEP 2 PY 2025 VL 17 IS 17 AR 2880 DI 10.3390/cancers17172880 PG 19 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA 7FG6A UT WOS:001569633400001 PM 40940977 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Ajabnoor, AM Baamer, RM AF Ajabnoor, Alyaa M. Baamer, Reham M. TI Predictive Performance of HAS-BLED Score in Patients with Atrial Fibrillation and Cancer: A Meta-Analysis SO CARDIOLOGY LA English DT Article; Early Access DE Atrial fibrillation; Cancer; Stroke; Bleeding and HAS-BLED ID BLEEDING RISK SCORES; APPLICABILITY; SCHEMES; PROBAST; BIAS; TOOL AB Introduction: Patients with atrial fibrillation (AF) and history of cancer face unique bleeding risks, complicating the applicability of standard bleeding risk scores like HAS-BLED. This meta-analysis aimed to evaluate the performance of HAS-BLED in predicting bleeding events in this high-risk population. Methods: The MEDLINE, PubMed, and EMBASE databases were searched from 1st of January 2010 to 30th of November 2024 for relevant studies using keywords, such as "AF" "cancer" "bleeding," and "HAS-BLED." Data on C-statistics were extracted to assess the predictive performance of HAS-BLED score. Results: Our analysis included seven retrospective cohort studies, recruiting a total of 436,102 patients. The quality of the included studies was deemed acceptable for analysis. The reported C-statistics for HAS-BLED score varied widely across studies, ranging from 0.45 to 0.77. Subgroup analyses demonstrated moderate discrimination in patients with breast cancer (0.56-0.80), prostate cancer (0.58-0.72), and lung cancer (0.59-0.80), while poorer performance was observed in hematological malignancies (0.45-0.70) and in anticoagulated patients (pooled C-statistic = 0.55; 95% confidence interval: 0.54-0.56). Significant heterogeneity was observed in the overall analysis and most subgroups (I2 > 90%), except for the anticoagulated subgroup. A sensitivity analysis excluding the largest study reduced heterogeneity and improved funnel plot symmetry, indicating that study size contributed to variability in HAS-BLED performance. Conclusion: The HAS-BLED score has shown variable predictive abilities in AF patients with cancer ranging from poor to good, with notable heterogeneity across studies secondary to various contributing factors. This emphasizes the need for individualized risk assessment tailored to the unique characteristics of cancer patients to effectively guide clinical decision-making. C1 [Ajabnoor, Alyaa M.; Baamer, Reham M.] King Abdulaziz Univ, Fac Pharm, Dept Pharm Practice, Jeddah, Saudi Arabia. [Ajabnoor, Alyaa M.] Univ Manchester, Fac Biol Med & Hlth, Sch Hlth Sci, Div Pharm & Optometry, Manchester, England. [Baamer, Reham M.] Univ Nottingham, Sch Pharm, Div Pharm Practice & Policy, Nottingham, England. C3 King Abdulaziz University; University of Manchester; University of Nottingham RP Ajabnoor, AM (corresponding author), King Abdulaziz Univ, Fac Pharm, Dept Pharm Practice, Jeddah, Saudi Arabia.; Ajabnoor, AM (corresponding author), Univ Manchester, Fac Biol Med & Hlth, Sch Hlth Sci, Div Pharm & Optometry, Manchester, England. EM ammajabnour@kau.edu.sa RI Ajabnoor, Alyaa/LDG-3802-2024; Baamer, Reham/OOL-5748-2025 OI Ajabnoor, Alyaa/0000-0001-5154-6183; CR Ajabnoor AM, 2024, EUR HEART J OPEN, V4, DOI [10.1093/ehjopen/oeae053, 10.1093/ehjopen/oeae053] Brown JD, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.007901 Chang GD, 2020, J THROMB HAEMOST, V18, P791, DOI 10.1111/jth.14692 Chen CY, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-97 Farmakis D, 2022, ONCOL LETT, V23, DOI 10.3892/ol.2022.13244 Friberg L, 2012, EUR HEART J, V33, P1500, DOI 10.1093/eurheartj/ehr488 Gage BF, 2006, AM HEART J, V151, P713, DOI 10.1016/j.ahj.2005.04.017 Gao XX, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.757087 Hajjar LA, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.590768 Higgins JPT, 2009, J R STAT SOC A STAT, V172, P137, DOI 10.1111/j.1467-985X.2008.00552.x Hindricks Gerhard, 2021, Eur Heart J, V42, P373, DOI 10.1093/eurheartj/ehaa612 Key NS, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.01461 Leiva O, 2024, J THROMB THROMBOLYS, V57, P186, DOI 10.1007/s11239-023-02900-z Leiva O, 2023, J CARDIOL, V81, P260, DOI 10.1016/j.jjcc.2022.10.007 Mehran R, 2011, CIRCULATION, V123, P2736, DOI 10.1161/CIRCULATIONAHA.110.009449 Moons KGM, 2019, ANN INTERN MED, V170, pW1, DOI 10.7326/M18-1377 Ouzzani M, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0384-4 Parikh NS, 2016, J STROKE CEREBROVASC, V25, P543, DOI 10.1016/j.jstrokecerebrovasdis.2015.11.005 Pastori D, 2021, EUR HEART J, V42, P438 Pastori D, 2022, J AM HEART ASSOC, V11, DOI 10.1161/JAHA.121.026388 Pisters R, 2010, CHEST, V138, P1093, DOI 10.1378/chest.10-0134 Proietti M, 2018, J INTERN MED, V283, P282, DOI 10.1111/joim.12702 Proietti M, 2022, EUR HEART J-QUAL CAR, V8, P778, DOI 10.1093/ehjqcco/qcab069 Raposeiras-Roubin S., 2022, SSRN J Raposeiras-Roubin S, 2022, AM J CARDIOL, V180, P44, DOI 10.1016/j.amjcard.2022.06.044 Schulman S, 2005, J THROMB HAEMOST, V3, P692, DOI 10.1111/j.1538-7836.2005.01204.x Senoo K, 2016, INT J CARDIOL, V221, P379, DOI 10.1016/j.ijcard.2016.07.100 Trinks-Roerdink EM, 2023, OPEN HEART, V10, DOI 10.1136/openhrt-2023-002273 Truong B, 2024, CARDIOVASC TOXICOL, V24, P365, DOI 10.1007/s12012-024-09843-8 Tufano A, 2024, Thrombosis Update, V15, P100169, DOI [10.1016/j.tru.2024.100169, 10.1016/j.tru.2024.100169, DOI 10.1016/J.TRU.2024.100169] Ursua A., 2012, P IEEE, V100, DOI [DOI 10.1186/s13643-021-01626-4, 10.1109/JPROC.2011.2156750] Van Gelder IC, 2024, EUR HEART J, V45, P3314, DOI 10.1093/eurheartj/ehae176 Wolff RF, 2019, ANN INTERN MED, V170, P51, DOI 10.7326/M18-1376 Zhu WG, 2015, CLIN CARDIOL, V38, P555, DOI 10.1002/clc.22435 NR 34 TC 0 Z9 0 U1 4 U2 5 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0008-6312 EI 1421-9751 J9 CARDIOLOGY JI Cardiology PD 2025 AUG 29 PY 2025 DI 10.1159/000548224 EA AUG 2025 PG 13 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA 8EI8S UT WOS:001586654100001 PM 40880284 OA Green Submitted, hybrid DA 2026-04-17 ER PT J AU Heil, KM Rivinius, R Helmschrott, M Rahm, AK Ehlermann, P Frey, N Darche, FF AF Heil, Karsten M. Rivinius, Rasmus Helmschrott, Matthias Rahm, Ann-Kathrin Ehlermann, Philipp Frey, Norbert Darche, Fabrice F. TI Pre-Transplant Heavy Smoking Is Associated with Reduced Survival After Heart Transplantation Due to Infection and Malignancy SO JOURNAL OF CLINICAL MEDICINE LA English DT Article DE heart transplantation; pulmonary infection; mortality; lung cancer; pack-year; smoking ID LUNG TRANSPLANTATION; INTERNATIONAL SOCIETY; CARDIOVASCULAR-DISEASE; ATRIAL-FIBRILLATION; LISTING CRITERIA; RISK; GUIDELINES; COPD; CARE AB Background: Tobacco smoking is a known risk factor for adverse cardiovascular events. Many patients after heart transplantation (HTX) have a history of smoking, but the prognostic role of pre-transplant smoking remains uncertain. We thus investigated the effects of pre-transplant heavy smoking (>= 20 pack-years) on outcomes after HTX. Methods: This observational retrospective single-centre study included 639 patients receiving HTX at Heidelberg Heart Center between 1989 and 2019. Patients were stratified by intensity of pre-transplant smoking (<20 pack-years or >= 20 pack-years). Analysis covered donor and recipient demographics, post-transplant medications, mortality including causes of death after HTX, and early post-transplant atrial fibrillation (AF) after HTX. Results: A total of 219 of the 639 HTX recipients (34.3%) had a pre-transplant history of heavy smoking (>= 20 pack-years). These patients showed an increased 5-year post-transplant mortality (44.3% versus 28.6%, p < 0.001) and had a higher percentage of death due to infection/sepsis (21.5% versus 12.1%, p = 0.002) as well as due to malignancy (5.5% versus 1.7%, p = 0.007). Multivariate analysis demonstrated pre-transplant heavy smoking (>= 20 pack-years) as an independent risk factor for five-year mortality after HTX (HR: 2.173, 95% CI: 1.601-2.950, p < 0.001). Analysis of secondary outcomes also showed a significantly higher rate of 30-day post-transplant AF (17.8% versus 11.7%, p = 0.032) in patients with a pre-transplant history of heavy smoking (>= 20 pack-years). Conclusions: Pre-transplant heavy smoking is associated with early post-transplant AF, lung cancer, infection, and reduced survival after HTX. C1 [Heil, Karsten M.; Rivinius, Rasmus; Helmschrott, Matthias; Rahm, Ann-Kathrin; Ehlermann, Philipp; Frey, Norbert; Darche, Fabrice F.] Heidelberg Univ Hosp, Dept Cardiol Angiol & Pneumol, D-69120 Heidelberg, Germany. C3 Ruprecht Karls University Heidelberg RP Rivinius, R (corresponding author), Heidelberg Univ Hosp, Dept Cardiol Angiol & Pneumol, D-69120 Heidelberg, Germany. EM rasmus.rivinius@med.uni-heidelberg.de RI Rivinius, Rasmus/S-6820-2019; Darche, Fabrice/AAE-8467-2021; Rahm, Ann-Kathrin/AAC-7262-2021 OI Rivinius, Rasmus/0000-0003-1146-6319; Darche, Fabrice Fernand/0000-0003-4896-9219 FU Fondation Coeur-Daniel Wagner, Fondation de Luxembourg; Fondation Coeur-; Fondation de Luxembourg; Deutsche Forschungsgemeinschaft; Heidelberg University FX This work was supported by the Fondation Coeur-Daniel Wagner, Fondation de Luxembourg (F.F.D. and R.R.). For the publication fee we acknowledge financial support by Deutsche Forschungsgemeinschaft within the funding program 'Open Access Publikationskosten' as well as by Heidelberg University. CR Ambrose JA, 2004, J AM COLL CARDIOL, V43, P1731, DOI 10.1016/j.jacc.2003.12.047 Annabi Christopher, 2025, Cardiol Rev, DOI [10.1097/crd.0000000000000941, 10.1097/CRD.0000000000000941] Burns DM, 2003, PROG CARDIOVASC DIS, V46, P11, DOI 10.1016/S0033-0620(03)00079-3 Chamberlain AM, 2011, HEART RHYTHM, V8, P1160, DOI 10.1016/j.hrthm.2011.03.038 Chemmalakuzhy J, 2001, J HEART LUNG TRANSPL, V20, P1075, DOI 10.1016/S1053-2498(01)00299-6 Corbett C, 2012, TRANSPLANTATION, V94, P979, DOI 10.1097/TP.0b013e318263ad5b Crespo-Leiro MG, 2008, AM J TRANSPLANT, V8, P1031, DOI 10.1111/j.1600-6143.2008.02196.x Darche FF, 2021, ESC HEART FAIL, V8, P4265, DOI 10.1002/ehf2.13552 Dellgren G, 2017, INT J CARDIOL, V231, P188, DOI 10.1016/j.ijcard.2016.12.186 Duncan MS, 2022, JAMA CARDIOL, V7, P195, DOI 10.1001/jamacardio.2021.4990 Duncan MS, 2019, JAMA-J AM MED ASSOC, V322, P642, DOI 10.1001/jama.2019.10298 Gali K, 2016, PROG TRANSPLANT, V26, P117, DOI 10.1177/1526924816640687 Heil KM, 2021, LIFE-BASEL, V11, DOI 10.3390/life11121344 Hwang J, 2024, TOB INDUC DIS, V22, DOI 10.18332/tid/189952 Khan NA, 2020, TOB CONTROL, V29, pS102, DOI 10.1136/tobaccocontrol-2019-054958 Khanna AK, 2009, CIRCULATION, V120, P1814, DOI 10.1161/CIRCULATIONAHA.108.840223 Krist AH, 2021, JAMA-J AM MED ASSOC, V325, P962, DOI 10.1001/jama.2021.1117 Mehra MR, 2006, J HEART LUNG TRANSPL, V25, P1024, DOI 10.1016/j.healun.2006.06.008 Mehra MR, 2016, J HEART LUNG TRANSPL, V35, P1, DOI 10.1016/j.healun.2015.10.023 Messner B, 2014, ARTERIOSCL THROM VAS, V34, P509, DOI 10.1161/ATVBAHA.113.300156 Ohar JA, 2010, CHEST, V137, P1345, DOI 10.1378/chest.09-2681 Ohiomoba RO, 2020, IJC HEART VASC, V30, DOI 10.1016/j.ijcha.2020.100599 Peled Y, 2024, J HEART LUNG TRANSPL, V43, DOI 10.1016/j.healun.2024.05.010 Rivinius R, 2022, FRONT CARDIOVASC MED, V9, DOI 10.3389/fcvm.2022.890359 Rivinius R, 2018, CLIN EPIDEMIOL, V10, P1359, DOI 10.2147/CLEP.S171929 Sánchez-Lázaro IJ, 2007, TRANSPL P, V39, P2377, DOI 10.1016/j.transproceed.2007.06.067 Sözen F, 2018, EXP CLIN TRANSPLANT, V16, P162, DOI 10.6002/ect.TOND-TDTD2017.P46 Stenman C, 2024, TRANSPL INT, V37, DOI 10.3389/ti.2024.12109 Stilley C.S., 2002, J. Heart Lung Transplant, V21, P81, DOI [10.1016/S1053-2498(01)00508-3, DOI 10.1016/S1053-2498(01)00508-3] Taghavi S, 2013, J HEART LUNG TRANSPL, V32, P1005, DOI 10.1016/j.healun.2013.05.018 NR 30 TC 1 Z9 1 U1 1 U2 2 PU MDPI PI BASEL PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND EI 2077-0383 J9 J CLIN MED JI J. Clin. Med. PD AUG 26 PY 2025 VL 14 IS 17 AR 6024 DI 10.3390/jcm14176024 PG 15 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA 7HV8Q UT WOS:001571386400001 PM 40943784 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Kim, TJ Lee, JS Oh, MS Park, S Yu, KY- Lee, BY- Yoon, B Ko, S- AF Kim, Tae Jung Lee, Ji Sung Oh, Mi Sun Park, Soo-Hyun Yu, Kyung-Ho Lee, Byung-Chul Yoon, Byung-Woo Ko, Sang-Bae TI Long-Term Outcomes and Predictors in Cancer-Related Stroke Using the Linked Data Set SO JOURNAL OF THE AMERICAN HEART ASSOCIATION LA English DT Article DE cancer; ischemic stroke; long-term outcomes ID DIRECT ORAL ANTICOAGULANTS; ACUTE ISCHEMIC-STROKE; ATRIAL-FIBRILLATION; EVENTS; RISK; MORTALITY; SUBTYPE; POOR AB Background Data on long-term prognostic factors in patients with cancer-related stroke are limited. The purpose of this study was to evaluate long-term outcomes and investigate prognostic factors of cancer-related stroke using a linked data set.Methods Between January 2008 and December 2014, patients with cancer-related stroke (n=690) were included in a linked data set comprising the Health Insurance Review and Assessment Service claims database and the Clinical Research Center for Stroke registry data. Outcomes were long-term mortality, major bleeding including intracerebral hemorrhage and gastrointestinal bleeding, and recurrent ischemic stroke after ischemic stroke. Clinical factors related to outcomes after ischemic stroke, including vascular risk factors, acute stroke management, and types of cancer, were evaluated.Results Of the 690 patients with cancer-related stroke (mean age, 68.5 years and 61.7% male) during a median 1.7 year period, 401 (58.1%) patients died during follow-up duration. Multivariate Cox regression analysis revealed that old age (hazard ratio [HR], 1.30 per 10 years [95% CI, 1.17-1.45]), stroke severity (HR, 1.05 [95% CI, 1.03-1.06]), anticoagulation at discharge (HR, 1.67 [95% CI, 1.02-2.74]), and types of cancer, such as pancreatic (HR, 3.73 [95% CI, 2.70-5.16]), hepatobiliary (HR, 2.31 [95% CI, 1.78-3.00]), and lung cancers (HR, 1.73 [95% CI, 1.33-2.25]), were significantly associated with long-term mortality. Major bleeding occurred in 42 patients (6.1%), and recurrent ischemic stroke was observed in 89 patients (12.9%) during the follow-up period.Conclusion Long-term outcomes of cancer-related stroke are poor. Treatment at discharge and cancer type are crucial factors associated with long-term mortality. C1 [Kim, Tae Jung; Ko, Sang-Bae] Seoul Natl Univ, Coll Med, Dept Neurol, Seoul, South Korea. [Kim, Tae Jung; Ko, Sang-Bae] Seoul Natl Univ Hosp, Dept Crit Care Med, Seoul, South Korea. [Lee, Ji Sung] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Clin Epidemiol & Biostat, Seoul, South Korea. [Oh, Mi Sun; Yu, Kyung-Ho; Lee, Byung-Chul] Hallym Univ, Sacred Heart Hosp, Dept Neurol, Anyang, South Korea. [Park, Soo-Hyun] Soonchunhyang Univ, Seoul Hosp, Dept Neurol, Seoul, South Korea. [Yoon, Byung-Woo] Uijeongbu Eulji Med Ctr, Dept Neurol, Uijongbu, South Korea. C3 Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital; University of Ulsan; Asan Medical Center; Hallym University; Soonchunhyang University RP Kim, TJ (corresponding author), Seoul Natl Univ, Dept Crit Care Med, Dept Neurol, Coll Med,Seoul Natl Univ Hosp, 101 Daehak Ro, Seoul 03080, South Korea.; Ko, S- (corresponding author), Seoul Natl Univ Hosp, Dept Neurol & Crit Care Med, 101 Daehak Ro, Seoul 03080, South Korea. EM ttae35@gmail.com; sangbai1378@gmail.com OI Yu, kyung-ho/0000-0002-8997-5626; Lee, Byung-Chul/0000-0002-3885-981X; Ko, Sang-Bae/0000-0002-9429-9597 FU Ministry of Science and ICT [RS- 2023-00208062] FX This work was funded by the Ministry of Science and ICT (RS- 2023-00208062). The funding organizations had no role in the study or the preparation of this report CR ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35 Allaire M, 2024, HEPATOLOGY, V79, P213, DOI 10.1097/HEP.0000000000000291 Angelini DE, 2019, AM J HEMATOL, V94, P780, DOI 10.1002/ajh.25494 Bang OY, 2020, J STROKE, V22, P1, DOI 10.5853/jos.2019.02278 Cestari DM, 2004, NEUROLOGY, V62, P2025, DOI 10.1212/01.WNL.0000129912.56486.2B Chen YJ, 2022, BRAIN BEHAV, V12, DOI 10.1002/brb3.2738 Cho SW, 2023, ENDOCRINOL METAB, V38, P10, DOI 10.3803/EnM.2023.102 Choi BK, 2023, BMC NEUROL, V23, DOI 10.1186/s12883-023-03208-4 Choi DW, 2023, CANCER MED-US, V12, P14707, DOI 10.1002/cam4.6093 Chu CN, 2011, BRIT J CANCER, V105, P1419, DOI 10.1038/bjc.2011.361 Cutting S, 2017, J STROKE CEREBROVASC, V26, P809, DOI 10.1016/j.jstrokecerebrovasdis.2016.10.021 De Bruin ML, 2009, JNCI-J NATL CANCER I, V101, P928, DOI 10.1093/jnci/djp147 Gon Y, 2023, J AM HEART ASSOC, V12, DOI 10.1161/JAHA.123.029618 Heo JH, 2024, J STROKE, V26, P164, DOI 10.5853/jos.2023.03279 Hsu JY, 2019, TZU CHI MED J, V31, P144, DOI 10.4103/tcmj.tcmj_55_19 Jang HS, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00052 Kim TJ, 2025, INT J STROKE, V20, P75, DOI 10.1177/17474930241278808 Kim TJ, 2023, J KOREAN MED SCI, V38, DOI 10.3346/jkms.2023.38.e294 Kim TJ, 2023, INT J STROKE, V18, P812, DOI 10.1177/17474930231158211 Kim TJ, 2018, J KOREAN MED SCI, V33, DOI 10.3346/jkms.2018.33.e343 Kim YD, 2015, INT J STROKE, V10, P541, DOI 10.1111/ijs.12013 Kneihsl M, 2016, J NEUROL, V263, P150, DOI 10.1007/s00415-015-7954-6 Kolmos M, 2021, J STROKE CEREBROVASC, V30, DOI 10.1016/j.jstrokecerebrovasdis.2021.105935 Kwon JY, 2023, CANCERS, V15, DOI 10.3390/cancers15194895 Lee JH, 2024, ACUTE CRIT CARE, V39, P554, DOI 10.4266/acc.2024.00808 Lee Kang-Po, 2023, eNeurologicalSci, V32, P100474, DOI [10.1016/j.ensci.2023.100474, 10.1016/j.ensci.2023.100474] Lee SR, 2020, STROKE, V51, P416, DOI 10.1161/STROKEAHA.119.028030 Lee SR, 2019, J AM COLL CARDIOL, V73, P3295, DOI 10.1016/j.jacc.2019.04.052 Lee SR, 2019, J AM COLL CARDIOL, V73, P919, DOI 10.1016/j.jacc.2018.11.051 Lu QH, 2016, MED SCI MONITOR, V22, P1716, DOI 10.12659/MSM.898642 Milionis H, 2020, INT J STROKE, V15, P377, DOI 10.1177/1747493019873594 Misra UK, 2009, NEUROLOGY, V73, P160, DOI 10.1212/WNL.0b013e3181ab9b46 Mosarla RC, 2019, J AM COLL CARDIOL, V73, P1336, DOI 10.1016/j.jacc.2019.01.017 Nam KW, 2017, EUR J NEUROL, V24, P205, DOI 10.1111/ene.13184 Navi BB, 2021, STROKE, V52, P1121, DOI 10.1161/STROKEAHA.120.032002 Navi BB, 2018, ANN NEUROL, V83, P873, DOI 10.1002/ana.25227 Navi BB, 2015, ANN NEUROL, V77, P291, DOI 10.1002/ana.24325 Navi BB, 2014, NEUROLOGY, V83, P26, DOI 10.1212/WNL.0000000000000539 Navi BB, 2011, STROKE, V42, P3392, DOI 10.1161/STROKEAHA.111.620336 Nezu T, 2022, J NEUROL SCI, V436, DOI 10.1016/j.jns.2022.120246 Nielsen SF, 2012, NEW ENGL J MED, V367, P1792, DOI 10.1056/NEJMoa1201735 Nilsson G, 2005, EUR J CANCER, V41, P423, DOI 10.1016/j.ejca.2004.11.013 Pana TA, 2021, CANCERS, V13, DOI 10.3390/cancers13092193 Park EH, 2024, CANCER RES TREAT, V56, P357 Peduzzi P, 1995, J CLIN EPIDEMIOL, V48, P1503, DOI 10.1016/0895-4356(95)00048-8 Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3 Riaz IB, 2023, JAMA NETW OPEN, V6, DOI 10.1001/jamanetworkopen.2023.25283 Rogers LR, 2010, SEMIN NEUROL, V30, P311, DOI 10.1055/s-0030-1255224 Sener U, 2022, MAYO CLIN PROC, V97, P2139, DOI 10.1016/j.mayocp.2022.09.003 Sun MY, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24097981 van der Sluijs AV, 2021, NEPHROL DIAL TRANSPL, V36, P170, DOI 10.1093/ndt/gfaa216 Veerbeek JM, 2011, STROKE, V42, P1482, DOI 10.1161/STROKEAHA.110.604090 Won YW, 2021, CANCER RES TREAT, V53, P908, DOI 10.4143/crt.2021.325 Yaghi S, 2015, STROKE, V46, P3322, DOI 10.1161/STROKEAHA.115.011164 Yoo J, 2021, STROKE, V52, P2026, DOI 10.1161/STROKEAHA.120.032380 Yoo J, 2019, STROKE, V50, P507, DOI 10.1161/STROKEAHA.118.023044 Yoon SY, 2024, J CLIN NEUROL, V20, P551, DOI 10.3988/jcn.2024.0221 Zaorsky NG, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13120-6 Zhang YY, 2007, CEREBROVASC DIS, V23, P181, DOI 10.1159/000097639 Zhou Q, 2023, FRONT ONCOL, V13, DOI 10.3389/fonc.2023.1234713 NR 60 TC 1 Z9 1 U1 1 U2 2 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA EI 2047-9980 J9 J AM HEART ASSOC JI J. Am. Heart Assoc. PD AUG 19 PY 2025 VL 14 IS 16 AR e040883 DI 10.1161/JAHA.124.040883 PG 8 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA 6IV3F UT WOS:001554389000001 PM 40767297 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Rini, BI Best, AF Bowman, MD Mishkin, GE Denicoff, AM Rubinstein, LV Harris, L Geiger, AM Mark, NM Pergam, SA Warner, JL Khorana, AA Gnjatic, S Yen, TWF Liles, DK Bestvina, CM Shah, NJ Norrell, JT Hershman, DL Holter-Chakrabarty, JL Poklepovic, AS Chanock, SJ Sankaran, H Korde, LA AF Rini, Brian I. Best, Ana F. Bowman, Mel D. Mishkin, Grace E. Denicoff, Andrea M. Rubinstein, Larry V. Harris, Lyndsay Geiger, Ann M. Mark, Nicholas M. Pergam, Steven A. Warner, Jeremy L. Khorana, Alok A. Gnjatic, Sacha Yen, Tina W. F. Liles, Darla K. Bestvina, Christine M. Shah, Neil J. Norrell, Jacqueline T. Hershman, Dawn L. Holter-Chakrabarty, Jennifer L. Poklepovic, Andrew S. Chanock, Stephen J. Sankaran, Hari Korde, Larissa A. TI Risk Factors for COVID-19-Related Hospitalization and Death in Patients With Cancer: The National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS) SO JAMA ONCOLOGY LA English DT Article ID SEVERITY AB Importance Retrospective case series have identified having cancer and receiving treatment for cancer as risk factors for inferior COVID-19 outcomes. Objective To determine risk factors for hospitalization and death in patients with cancer with COVID-19 infection. Design, Setting, and Participants The National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS) is a prospective longitudinal natural history cohort study examining the impact of COVID-19 on patients with cancer. Adults were eligible within 14 days of an initial positive SARS-CoV-2 test result if they were receiving active treatment for cancer or had prior stem cell/bone marrow transplant or CAR T-cell treatment. The statistical analysis took place between September 2024 and April 2025. Main Outcomes and Measures The primary objective of the study was to determine patient factors, therapy types, and cancer types associated with COVID-19 severity, defined as hospitalization for or death from COVID-19 within 30 and 90 days after the first positive SARS-CoV-2 test result. Multivariable regressions were performed for COVID-19-specific hospitalization and mortality (proportional hazard and cause-specific hazard models). Results Of 1572 eligible adult patients (median [range] age, 60 [18-93] years; 840 female [53.4%]), 1066 (67.8%) had a solid tumor, with 683 (64.0%) having metastatic disease; breast (252 [23.6%]) and lung cancer (148 [13.9%]) were most common. At enrollment, 1013 patients (64.4%) were unvaccinated for SARS-CoV-2. COVID-19-related mortality at 90 days was 3.0% and did not increase at subsequent time points. The cumulative incidence of COVID-19-specific death in the first 90 days was highest in patients with lymphoma, intermediate in patients with acute leukemia and lung cancer, and lowest in patients with other solid tumors and other hematologic cancers. In multivariable analysis, receipt of chemotherapy (hazard ratio [HR], 1.97; 95% CI, 1.52-2.54) and baseline history of stroke, atrial fibrillation, or pulmonary embolism (HR, 1.78; 95% CI, 1.33-2.38) were associated with a higher risk of hospitalization. Vaccination prior to SARS-CoV-2 infection was associated with a lower risk of hospitalization (HR, 0.52; 95% CI, 0.38-0.70). Over 2 years of follow-up, there were 1739 cancer treatment disruptions, of which 881 (50.7%) were attributed to COVID-19, with most disruptions occurring within the first 30 days. Conclusions and Relevance The results of this prospective cohort study showed that COVID-19 had a significant impact on patients with cancer, including hospitalization, treatment disruptions, and death. C1 [Rini, Brian I.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Best, Ana F.; Rubinstein, Larry V.; Sankaran, Hari] NCI, Biometr Res Program, Div Canc Treatment & Diag, Bethesda, MD USA. [Bowman, Mel D.] Emmes Co LLC, Rockville, MD USA. [Mishkin, Grace E.; Denicoff, Andrea M.; Harris, Lyndsay; Korde, Larissa A.] NCI, Div Canc Treatment & Diag, Bethesda, MD USA. [Geiger, Ann M.] NCI, Ctr Strateg Sci Initiat, Rockville, MD USA. [Mark, Nicholas M.] Swedish Med Ctr, Seattle, WA USA. [Pergam, Steven A.] Fred Hutchinson Canc Ctr, Seattle, WA USA. [Warner, Jeremy L.] Brown Univ, Warren Alpert Med Sch, Providence, RI USA. [Warner, Jeremy L.] Brown Univ, Sch Publ Hlth, Dept Biostat, Providence, RI USA. [Khorana, Alok A.] Cleveland Clin, Cleveland, OH USA. [Gnjatic, Sacha] Icahn Sch Med Mt Sinai, New York, NY USA. [Yen, Tina W. F.] Med Coll Wisconsin, Milwaukee, WI USA. [Liles, Darla K.] East Carolina Univ, Brody Sch Med, Greenville, NC USA. [Bestvina, Christine M.] Univ Chicago, Dept Med, Hematol Oncol, Chicago, IL USA. [Shah, Neil J.] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol, New York, NY USA. [Norrell, Jacqueline T.] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA. [Hershman, Dawn L.] Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY USA. [Holter-Chakrabarty, Jennifer L.] Univ Oklahoma, Coll Med, Oklahoma City, OK USA. [Poklepovic, Andrew S.] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA. [Chanock, Stephen J.] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA. C3 Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); NIH Division of Cancer Treatment & Diagnosis; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); NIH Division of Cancer Treatment & Diagnosis; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Swedish Health Services; Fred Hutchinson Cancer Center; Brown University; Brown University; Cleveland Clinic Foundation; Icahn School of Medicine at Mount Sinai; Medical College of Wisconsin; University of North Carolina; East Carolina University; University of Chicago; Memorial Sloan Kettering Cancer Center; Rutgers University System; Rutgers University New Brunswick; Rutgers University Biomedical & Health Sciences; Rutgers Cancer Institute of New Jersey; Columbia University; University of Oklahoma System; University of Oklahoma Health Sciences Center; Virginia Commonwealth University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics RP Korde, LA (corresponding author), Canc Therapy Evaluat Program, Breast Canc & Melanoma Therapeut, 9609 Med Ctr Dr,5W344, Rockville, MD 20850 USA. EM larissa.korde@nih.gov RI Geiger, Ann/LKK-3696-2024; Hershman, Dawn/AAG-2114-2020; Gnjatic, Sacha/MIU-0767-2025; Khorana, Alok/JAO-0943-2023; Rini, Brian/MGV-8275-2025; Chanock, Stephen/AGL-9345-2022; Sankaran, Hari/IWM-2799-2023; Pergam, Steven/C-2286-2008 OI Gnjatic, Sacha/0000-0001-5643-9520; FU Coronavirus Aid, Relief, and Economic Security (CARES) Act; National Cancer Institute National Clinical Trials Network; Experimental Therapeutics Clinical Trials Network; Community Oncology Research Program FX This study was funded in part by the Coronavirus Aid, Relief, and Economic Security (CARES) Act, and also by the National Cancer Institute National Clinical Trials Network, Experimental Therapeutics Clinical Trials Network, and Community Oncology Research Program grants via the U10 funding mechanism. CR [Anonymous], 2021, Coronavirus (COVID-19) [Anonymous], Policy for coronavirus disease-2019 tests during the public health emergency Aydillo T, 2020, NEW ENGL J MED, V383, P2586, DOI 10.1056/NEJMc2031670 Barclay NL, 2024, CLIN EPIDEMIOL, V16, P417, DOI 10.2147/CLEP.S463160 Best AF, 2023, JNCI-J NATL CANCER I, V115, P597, DOI 10.1093/jnci/djad015 Geskus RB, 2011, BIOMETRICS, V67, P39, DOI 10.1111/j.1541-0420.2010.01420.x Grivas P, 2021, ANN ONCOL, V32, P787, DOI 10.1016/j.annonc.2021.02.024 HURVICH CM, 1989, BIOMETRIKA, V76, P297, DOI 10.1093/biomet/76.2.297 Khoury E, 2022, JAMA NETW OPEN, V5, DOI 10.1001/jamanetworkopen.2022.10880 Lim YJ, 2024, BRIT J HAEMATOL, V205, P440, DOI 10.1111/bjh.19562 Muñoz-Gómez MJ, 2024, J INFECT PUBLIC HEAL, V17, DOI 10.1016/j.jiph.2024.102473 Ozonoff A, 2022, EBIOMEDICINE, V83, DOI 10.1016/j.ebiom.2022.104208 Várnai C, 2022, JAMA NETW OPEN, V5, DOI 10.1001/jamanetworkopen.2022.0130 Whisenant JG, 2022, J THORAC ONCOL, V17, P661, DOI 10.1016/j.jtho.2021.12.015 Zhang JJ, 2023, CLIN REV ALLERG IMMU, V64, P90, DOI 10.1007/s12016-022-08921-5 NR 15 TC 3 Z9 4 U1 2 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2374-2437 EI 2374-2445 J9 JAMA ONCOL JI JAMA Oncol. PD SEP PY 2025 VL 11 IS 9 BP 990 EP 998 DI 10.1001/jamaoncol.2025.2010 EA JUL 2025 PG 9 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA 7OG4U UT WOS:001531735200001 PM 40674082 OA Green Submitted, hybrid DA 2026-04-17 ER PT J AU Alrumaihi, F Rahmani, AH Prabhu, SV Kumar, V Anwar, S AF Alrumaihi, Faris Rahmani, Arshad Husain Prabhu, Sitrarasu Vijaya Kumar, Vikalp Anwar, Shehwaz TI The Role of Plant-Derived Natural Products as a Regulator of the Tyrosine Kinase Pathway in the Management of Lung Cancer SO CURRENT ISSUES IN MOLECULAR BIOLOGY LA English DT Review DE natural product; lung cancer; pathogenesis; tyrosine kinase; tyrosine kinase inhibitors; tyrosine-kinase-inhibitor-acquired resistance ID GROWTH-FACTOR-RECEPTOR; GREEN TEA POLYPHENOL; CELL-CYCLE ARREST; REVERSES CISPLATIN RESISTANCE; HUMAN PROSTATE-CANCER; BETULINIC ACID; CUCURBITACIN-B; CLINICAL CHARACTERISTICS; IN-VITRO; HEPATOCELLULAR-CARCINOMA AB One of the most common malignant tumors worldwide is lung cancer, and it is associated with the highest death rate among all cancers. Traditional treatment options for lung cancer include radiation, chemotherapy, targeted therapy, and surgical resection. However, the survival rate is low, and the outlook is still dreadfully dire. The pursuit of a paradigm change in treatment approaches is, therefore, imperative. Tyrosine kinases (TKs), a subclass of protein kinases, regulate vital cellular function by phosphorylating tyrosine residues in proteins. Mutations, overexpression, and autocrine paracrine stimulation can transform TKs into oncogenic drivers, causing cancer pathogenesis. Tyrosine kinase inhibitors (TKIs) have emerged as an attractive targeted therapy option, especially for non-small cell lung cancer (NSCLC). However, resistance to TKIs, and adverse cardiovascular effects such as heart failure, atrial fibrillation, hypertension, and sudden death, are among the most common adverse effects of TKIs. There is increasing interest in plant-derived natural products in the hunt for powerful chemosensitizer and pathway modulators for enhancing TKI activity and/or overcoming resistance mechanisms. This highlights the mechanism of TKs' activation in cancer, the role of TKIs in NSCLC mechanisms, and the challenges posed by TKI-acquired resistance. Additionally, we explored various plant-derived natural products' bioactive compounds with the chemosensitizer and pathway-modulating potential with TKs' inhibitory and anticancer effects. Our review suggests that a combination of natural products with TKIs may provide a novel and promising strategy for overcoming resistance in lung cancer. In future, further preclinical and clinical studies are advised. C1 [Alrumaihi, Faris; Rahmani, Arshad Husain] Qassim Univ, Coll Appl Med Sci, Dept Med Labs, Buraydah 51452, Saudi Arabia. [Prabhu, Sitrarasu Vijaya] Natl Coll Autonomous, Dept Biotechnol Microbiol & Bioinformat, Tiruchirappalli 620001, India. [Kumar, Vikalp; Anwar, Shehwaz] Mohan Coll Nursing & Paramed Sci, Dept Med Lab Technol, Bareilly 243302, India. C3 Qassim University RP Anwar, S (corresponding author), Mohan Coll Nursing & Paramed Sci, Dept Med Lab Technol, Bareilly 243302, India. EM f_alrumaihi@qu.edu.sa; shehwazanvar25@mipharmacy.org.in RI SITRARASU, VIJAYAPRABHU/LCD-5496-2024; Anwar, Shehwaz/AAW-9387-2021; HUSAIN RAHMANI, ARSHAD/KBA-6736-2024 OI Anwar, Shehwaz/0000-0003-3448-9353; HUSAIN RAHMANI, ARSHAD/0000-0002-1329-1391; Alrumaihi, Faris/0000-0002-0850-5500; , Vikalp Kumar/0009-0009-3566-621X FU Deanship of Graduate Studies and Scientific Research at Qassim University [QU-APC-2025] FX The researchers would like to thank the Deanship of Graduate Studies and Scientific Research at Qassim University for financial support (QU-APC-2025). CR Abd El-Hafeez A, 2018, CYTOTECHNOLOGY, V70, P913, DOI 10.1007/s10616-017-0124-1 Abou-Khalil R, 2009, J PHOTOCH PHOTOBIO B, V95, P189, DOI 10.1016/j.jphotobiol.2009.03.005 Ahmadu AA, 2021, MOLECULES, V26, DOI 10.3390/molecules26154599 Al-Yozbaki M, 2021, CURR MED CHEM, V28, P7988, DOI 10.2174/0929867328666210322103906 Alakurtti S, 2006, EUR J PHARM SCI, V29, P1, DOI 10.1016/j.ejps.2006.04.006 Alghasham AA, 2013, INT J HEALTH SCI-IJH, V7, P77, DOI 10.12816/0006025 Alix-Panabières C, 2021, CANCER DISCOV, V11, P858, DOI 10.1158/2159-8290.CD-20-1311 Almatroodi SA, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24119719 Almatroodi SA, 2021, MOLECULES, V26, DOI 10.3390/molecules26051315 Almatroodi SA, 2020, GENE REP, V21, DOI 10.1016/j.genrep.2020.100966 Almatroodi SA, 2020, MOLECULES, V25, DOI 10.3390/molecules25143146 Alrumaihi F, 2024, Uro, V4, P60, DOI [10.3390/uro4020006, 10.3390/uro4020006, DOI 10.3390/URO4020006] Alsahli MA, 2021, MEDIAT INFLAMM, V2021, DOI 10.1155/2021/6661937 Ansó E, 2010, BIOCHEM PHARMACOL, V79, P1600, DOI 10.1016/j.bcp.2010.02.004 Anto RJ, 2002, CARCINOGENESIS, V23, P143, DOI 10.1093/carcin/23.1.143 Anwar S., 2023, IJCRT, V11, pf249 Anwar S., 2017, J. Protein Proteom, V8, P1 Anwar Shehwaz, 2024, Saudi Journal of Biological Sciences, V31, P104003, DOI [10.1016/j.sjbs.2024.104003, 10.1016/j.sjbs.2024.104003] Anwar S, 2020, ANTI-CANCER AGENT ME, V20, P2025, DOI 10.2174/1871520620666200705220307 Anwar S, 2020, PROCESSES, V8, DOI 10.3390/pr8040468 Auwal A, 2025, ANTI-CANCER AGENT ME, V25, P1103, DOI 10.2174/0118715206359811241227032311 Baby B, 2018, NAT PROD RES, V32, P2928, DOI 10.1080/14786419.2017.1385015 Basha S.H., 2014, Eur. J. Biotechnol. Biosci, V2, P30 Baur F, 2020, CANCERS, V12, DOI 10.3390/cancers12010028 Bernard P., 2000, International Journal of Cosmetic Science, V22, P219, DOI 10.1046/j.1467-2494.2000.00019.x Bethune Gillian, 2010, J Thorac Dis, V2, P48 Biersack B., 2024, Receptors, V3, P58, DOI DOI 10.3390/RECEPTORS3010005 Birnboim-Perach R, 2024, INT J BIOL SCI, V20, P3911, DOI 10.7150/ijbs.93697 Bota M, 2024, PHARMACEUTICALS-BASE, V17, DOI 10.3390/ph17050598 Cai YL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0669-8 Calil NO, 2012, LETT DRUG DES DISCOV, V9, P8 Canli Ö, 2017, CANCER CELL, V32, P869, DOI 10.1016/j.ccell.2017.11.004 Carneiro BA, 2020, NAT REV CLIN ONCOL, V17, P395, DOI 10.1038/s41571-020-0341-y Castaneda AM, 2022, HELIYON, V8, DOI 10.1016/j.heliyon.2022.e09519 Cathcart MC, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2740-0 Cetinkaya M, 2023, VACCINES-BASEL, V11, DOI 10.3390/vaccines11030554 Chang HB, 2015, INT J NANOMED, V10, P5059, DOI 10.2147/IJN.S87225 Chang JH, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0869-1 Chanvorachote P, 2009, CANCER INVEST, V27, P624, DOI 10.1080/07357900802653472 Chaturvedi S, 2020, NEUROTOXICOLOGY, V79, P1, DOI 10.1016/j.neuro.2020.03.002 Chen BH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-62136-2 Chen JC, 2005, NAT PROD REP, V22, P386, DOI 10.1039/b418841c Chen P, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1234-8 Chen YC, 2013, AM J CHINESE MED, V41, P1439, DOI 10.1142/S0192415X13500961 Chen Z, 2022, PHARMACOL RES, V175, DOI 10.1016/j.phrs.2021.105998 Chen ZS, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00260 Cheng ZN, 2024, ONCOL REP, V51, DOI 10.3892/or.2023.8675 Chian S, 2019, ANTI-CANCER DRUG, V30, P838, DOI 10.1097/CAD.0000000000000781 Christopoulos P, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08460-w Cicenas J, 2018, CANCERS, V10, DOI 10.3390/cancers10030063 Cichewicz RH, 2004, MED RES REV, V24, P90, DOI 10.1002/med.10053 Clark S.B., 2025, StatPearls [Internet] Clericuzio M, 2004, J NAT PROD, V67, P1823, DOI 10.1021/np049883o Clericuzio M, 2006, J NAT PROD, V69, P1796, DOI 10.1021/np060213n /clinicaltrials, The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial-Stage III (POISE) /clinicaltrials, Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers clinicaltrials, An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH (ASCENT) Codex Y., Advancements in Targeted Kinase Inhibitors: Revolutionizing Personalized Medicine in Oncology Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385 Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341 Corvaja C, 2024, CANCER TREAT REV, V130, DOI 10.1016/j.ctrv.2024.102824 Cui JJ, 2014, ACS MED CHEM LETT, V5, P272, DOI 10.1021/ml500091p Dai PC, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317697555 Dai YM, 2019, EXP THER MED, V17, P953, DOI 10.3892/etm.2018.7001 Dankner M, 2018, ONCOGENE, V37, P3183, DOI 10.1038/s41388-018-0171-x Davidson MR, 2013, J THORAC DIS, V5, pS463, DOI 10.3978/j.issn.2072-1439.2013.08.43 de Visser KE, 2023, CANCER CELL, V41, P374, DOI 10.1016/j.ccell.2023.02.016 Denk D, 2022, TRENDS CANCER, V8, P901, DOI 10.1016/j.trecan.2022.07.002 Dorai T, 2000, MOL UROL, V4, P1 Du ZF, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0782-4 Ekonomopoulou MT, 2011, INT J GYNECOL CANCER, V21, P435, DOI 10.1097/IGC.0b013e31820d3e42 Elumalai P, 2022, NUTR CANCER, V74, P1894, DOI 10.1080/01635581.2021.1957487 Eno MS, 2022, J MED CHEM, DOI 10.1021/acs.jmedchem.2c00704 Farabegoli F, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20170168 Feng Y, 2013, FOOD CHEM, V136, P73, DOI 10.1016/j.foodchem.2012.07.088 Ferry DR, 1996, CLIN CANCER RES, V2, P659 Fischer B, 2007, CANCER TREAT REV, V33, P391, DOI 10.1016/j.ctrv.2007.01.006 Forder A, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24032859 Foucquier J, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.149 Fu K, 2022, J HEMATOL ONCOL, V15, DOI 10.1186/s13045-022-01391-4 Fukuda S, 2024, BIOMEDICINES, V12, DOI 10.3390/biomedicines12071412 Gahtori R, 2023, FUTUR J PHARM SCI, V9, DOI 10.1186/s43094-023-00465-5 Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198 Gómez-López S, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02470-x Gowda R, 2017, ONCOTARGET, V8, P28260, DOI 10.18632/oncotarget.16002 Guo BY, 2015, CANCER CHEMOTH PHARM, V75, P353, DOI 10.1007/s00280-014-2651-1 Hajiaghaalipour F, 2015, FOOD CHEM, V169, P401, DOI 10.1016/j.foodchem.2014.07.005 Han SY, 2012, LUNG CANCER, V75, P30, DOI 10.1016/j.lungcan.2011.06.001 Han Y, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.802168 Held MA, 2013, CANCER DISCOV, V3, P52, DOI 10.1158/2159-8290.CD-12-0408 Helms Steve, 2004, Altern Med Rev, V9, P259 Hilal T, 2017, THER ADV MED ONCOL, V9, P189, DOI 10.1177/1758834016678149 HOLLEY RW, 1975, NATURE, V258, P487, DOI 10.1038/258487a0 Holthoff JH, 2010, BIOCHEM PHARMACOL, V80, P1260, DOI 10.1016/j.bcp.2010.06.027 Hong RL, 1999, CLIN CANCER RES, V5, P1884 Hong SH, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00062 Hong Z, 2014, BRIT J PHARMACOL, V171, P2842, DOI 10.1111/bph.12610 Hou DX, 2010, ANTIOXID REDOX SIGN, V13, P691, DOI 10.1089/ars.2009.2816 Hu WJ, 2018, BIOMED PHARMACOTHER, V102, P681, DOI 10.1016/j.biopha.2018.03.111 Huang GD, 2023, AM J CANCER RES, V13, P4145 Huang LH, 2015, ACTA PHARM SIN B, V5, P390, DOI 10.1016/j.apsb.2015.07.001 Huang RX, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00648-7 Huang ST, 2017, SCI REP-UK, V7, DOI 10.1038/srep40382 Huang SJ, 2020, J CANCER, V11, P2123, DOI 10.7150/jca.34981 Huang TH, 2019, J ETHNOPHARMACOL, V243, DOI 10.1016/j.jep.2019.112075 Huang YT, 1999, BRIT J PHARMACOL, V128, P999, DOI 10.1038/sj.bjp.0702879 HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897 HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0 Hwang YP, 2011, MOL NUTR FOOD RES, V55, P594, DOI 10.1002/mnfr.201000292 Ibodeng Gogo-Ogute, 2023, Ann Transl Med, V11, P261, DOI [10.21037/atm-22-4479, 10.21037/atm-22-4479] Jäger S, 2007, PLANTA MED, V73, P157, DOI 10.1055/s-2007-967106 Jäger S, 2009, MOLECULES, V14, P2016, DOI 10.3390/molecules14062016 Jänne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817 Jan R, 2019, ADV PHARM BULL, V9, P205, DOI 10.15171/apb.2019.024 Jelic D, 2016, J CHEM-NY, V2016, DOI 10.1155/2016/2510621 Jeong H, 2017, PHARMACOGN MAG, V13, P595, DOI 10.4103/pm.pm_535_16 Jiang K, 2017, INT IMMUNOPHARMACOL, V42, P195, DOI 10.1016/j.intimp.2016.10.001 Jiang ZS, 2017, BIOMED PHARMACOTHER, V96, P378, DOI 10.1016/j.biopha.2017.09.129 Jiao LJ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00732 Jiao QL, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0801-5 Jin H, 2015, ONCOL REP, V34, P2782, DOI 10.3892/or.2015.4258 Jin L, 2021, BMB REP, V54, P563, DOI 10.5483/BMBRep.2021.54.11.101 Jing SY, 2020, CHIN J NAT MEDICINES, V18, P483, DOI 10.1016/S1875-5364(20)30058-3 Jung YY, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23179848 Bhanumathy KK, 2021, CANCERS, V13, DOI 10.3390/cancers13020184 Kausar H, 2013, CANCER LETT, V332, P35, DOI 10.1016/j.canlet.2013.01.008 Khaddour K, 2021, CANCERS, V13, DOI 10.3390/cancers13133164 Kim JK, 2018, EXCLI J, V17, P856, DOI 10.17179/excli2018-1538 Kim JH, 2006, CARCINOGENESIS, V27, P475, DOI 10.1093/carcin/bgi272 Kim KC, 2015, INT J ONCOL, V47, P2296, DOI 10.3892/ijo.2015.3216 Kim KC, 2014, INT J MOL MED, V34, P592, DOI 10.3892/ijmm.2014.1804 Kim SP, 2011, FOOD FUNCT, V2, P348, DOI 10.1039/c1fo10030k Kim YM, 2002, J BIOL CHEM, V277, P16340, DOI 10.1074/jbc.M200678200 Klaeger S, 2017, SCIENCE, V358, DOI 10.1126/science.aan4368 Ko JL, 2018, ENVIRON TOXICOL, V33, P1153, DOI 10.1002/tox.22621 Kobayashi K, 2013, TARGET ONCOL, V8, P27, DOI 10.1007/s11523-013-0258-9 Kuo LK, 2024, ANTICANCER RES, V44, P4915, DOI 10.21873/anticanres.17317 Labrecque L, 2005, CARCINOGENESIS, V26, P821, DOI 10.1093/carcin/bgi024 Lahiri A, 2023, MOL CANCER, V22, DOI 10.1186/s12943-023-01740-y Laszczyk M, 2006, PLANTA MED, V72, P1389, DOI 10.1055/s-2006-951723 Laudadio E, 2024, ACS CHEM BIOL, V19, P839, DOI 10.1021/acschembio.4c00028 Lee JY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023756 Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011 Leung HWC, 2007, FOOD CHEM TOXICOL, V45, P403, DOI 10.1016/j.fct.2006.08.021 Li L, 2022, DRUG DEVELOP RES, V83, P461, DOI 10.1002/ddr.21878 Li LM, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0388-x Li SQ, 2013, ONCOL RES, V21, P137, DOI 10.3727/096504013X13832473330032 Li WH, 2019, INT J CLIN EXP PATHO, V12, P957 Li Y, 2016, NUTRIENTS, V8, DOI 10.3390/nu8030167 Li YY, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-33 Liang XY, 2021, DIABET METAB SYND OB, V14, P1871, DOI 10.2147/DMSO.S304817 Liang Y, 2021, AM J CHINESE MED, V49, P753, DOI 10.1142/S0192415X2150035X Lin CK, 2015, BRIT J PHARMACOL, V172, P4481, DOI 10.1111/bph.13233 Lin HY, 2017, RSC ADV, V7, P48404, DOI 10.1039/c7ra09825a Lingaraju MC, 2015, CYTOKINE, V71, P101, DOI 10.1016/j.cyto.2014.09.004 Litvak AM, 2014, J THORAC ONCOL, V9, P1669, DOI 10.1097/JTO.0000000000000344 Liu PF, 2019, MOLECULES, V24, DOI 10.3390/molecules24030647 Liu TH, 2019, BIOMED PHARMACOTHER, V120, DOI 10.1016/j.biopha.2019.109483 Liu T, 2016, ONCOTARGET, V7, P40800, DOI 10.18632/oncotarget.8315 Liu XY, 2012, MOL CANCER THER, V11, P1421, DOI 10.1158/1535-7163.MCT-12-0026 López-Lázaro M, 2009, MINI-REV MED CHEM, V9, P31, DOI 10.2174/138955709787001712 Lou W, 2017, BIOL PHARM BULL, V40, P1306, DOI 10.1248/bpb.b17-00271 Lu YM, 2014, IN VITRO CELL DEV-AN, V50, P840, DOI 10.1007/s11626-014-9779-5 Ma J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05228-y Madsen KM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014763 Maher HM, 2017, J PHARMACEUT BIOMED, V137, P258, DOI 10.1016/j.jpba.2017.01.039 Manash K., 2004, INT J MEDICAL SCI, V1, P101, DOI DOI 10.7150/IJMS.1.101 Martellucci S, 2020, CANCERS, V12, DOI 10.3390/cancers12061448 McKay DL, 2006, PHYTOTHER RES, V20, P519, DOI 10.1002/ptr.1900 Mendes Jessica Bitencourt Emilio, 2012, ScientificWorldJournal, V2012, P542937, DOI 10.1100/2012/542937 Milligan SA, 2009, CLIN CANCER RES, V15, P4885, DOI 10.1158/1078-0432.CCR-09-0109 Min KJ, 2014, INTEGR MED RES, V3, P16, DOI 10.1016/j.imr.2013.12.001 Min L, 2022, AM J TRANSL RES, V14, P1551 Minnelli C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111833 Mirzaei S, 2021, PHARMACOL RES, V171, DOI 10.1016/j.phrs.2021.105759 Mokhtari RB, 2017, ONCOTARGET, V8, P38022, DOI 10.18632/oncotarget.16723 Espíndola KMM, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00541 Morgillo F, 2016, ESMO OPEN, V1, DOI 10.1136/esmoopen-2016-000060 Najmi A, 2022, MOLECULES, V27, DOI 10.3390/molecules27020349 Navarro-Núñez L, 2009, BRIT J PHARMACOL, V158, P1548, DOI 10.1111/j.1476-5381.2009.00440.x Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757 Ning XH, 2020, J BIOCHEM MOL TOXIC, V34, DOI 10.1002/jbt.22491 Notas G, 2006, BBA-GEN SUBJECTS, V1760, P1657, DOI 10.1016/j.bbagen.2006.09.010 Olsson M, 2011, CELL DEATH DIFFER, V18, P1441, DOI 10.1038/cdd.2011.30 Ortiz MA, 2021, CELL COMMUN SIGNAL, V19, DOI 10.1186/s12964-021-00750-x Osada M, 2004, FEBS LETT, V575, P59, DOI 10.1016/j.febslet.2004.08.036 Özçelik B, 2011, PHARM BIOL, V49, P396, DOI 10.3109/13880209.2010.519390 Paik PK, 2011, J CLIN ONCOL, V29, P2046, DOI 10.1200/JCO.2010.33.1280 Pal D, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14122624 Paller CJ, 2016, CLIN ADV HEMATOL ONC, V14, P447 Pan J, 2022, TISSUE CELL, V75, DOI 10.1016/j.tice.2022.101740 Pan J, 2017, CANCER PREV RES, V10, P133, DOI [10.1158/1940-6207.CAPR-16-0129, 10.1158/1940-6207.capr-16-0129] Pápay ZE, 2017, J AEROSOL MED PULM D, V30, P274, DOI 10.1089/jamp.2016.1316 Park HJ, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22105181 Park W, 2024, INT J MOL SCI, V25, DOI 10.3390/ijms25020807 Patel N, 2025, J MOL STRUCT, V1322, DOI 10.1016/j.molstruc.2024.140392 Paunovic D, 2023, CHIN MED-UK, V18, DOI 10.1186/s13020-023-00869-8 Pawson T, 2001, TRENDS CELL BIOL, V11, P504, DOI 10.1016/S0962-8924(01)02154-7 Peng MH, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.908031 Petty WJ, 2023, JAMA ONCOL, V9, P419, DOI 10.1001/jamaoncol.2022.5631 Pinmai K, 2008, WORLD J GASTROENTERO, V14, P1491, DOI 10.3748/wjg.14.1491 Popat S, 2023, TARGET ONCOL, V18, P9, DOI 10.1007/s11523-022-00941-7 Pophali PA, 2016, CANCER J, V22, P40, DOI 10.1097/PPO.0000000000000165 Porro C, 2015, CURR PHARM DESIGN, V21, P5277, DOI 10.2174/1381612821666150928155612 Poudel G, 2022, CANCERS, V14, DOI 10.3390/cancers14143300 Pratheeshkumar P, 2014, TOXICOL APPL PHARM, V281, P230, DOI 10.1016/j.taap.2014.10.008 Preljevic K, 2024, FITOTERAPIA, V174, DOI 10.1016/j.fitote.2024.105871 Rahmani AH, 2015, BIOMED RES INT-UK, V2015, DOI 10.1155/2015/925640 Rahmani AH, 2023, MOLECULES, V28, DOI 10.3390/molecules28135152 Rahmani AH, 2022, MOLECULES, V27, DOI 10.3390/molecules27249009 Rahmani AH, 2022, MOLECULES, V27, DOI 10.3390/molecules27186051 Ranaware AM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082362 Raufi AG, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24044238 Ressmann AK, 2017, GREEN CHEM, V19, P1014, DOI [10.1039/C6GC02641A, 10.1039/c6gc02641a] Rudin CM, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-020-00235-0 Sabarwal A, 2022, FASEB J, V36, DOI 10.1096/fj.202200669RR Sabbula B.R., 2025, StatPearls [Internet] Sablina AA, 2007, CELL, V129, P969, DOI 10.1016/j.cell.2007.03.047 Sadava D, 2007, BIOCHEM BIOPH RES CO, V360, P233, DOI 10.1016/j.bbrc.2007.06.030 Sakurai MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100124 Saleem M, 2005, CANCER RES, V65, P11203, DOI 10.1158/0008-5472.CAN-05-1965 Salehi B, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6030091 Saneja A, 2018, ANN NY ACAD SCI, V1421, P5, DOI 10.1111/nyas.13570 Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/S0092-8674(00)00114-8 Sengupta P, 2024, Exploration of Neuroscience, V3, P1, DOI [10.37349/en.2024.00033, DOI 10.37349/EN.2024.00033, 10.37349/en.2024.00033] Sharma A, 2022, MOL DIVERS, V26, P3337, DOI 10.1007/s11030-022-10396-7 Shi S, 2022, INT J BIOL MACROMOL, V223, P1145, DOI 10.1016/j.ijbiomac.2022.11.123 Shi Y, 2014, J THORAC ONCOL, V9, P154, DOI 10.1097/JTO.0000000000000033 Shimizu M, 2011, MOL NUTR FOOD RES, V55, P832, DOI 10.1002/mnfr.201000622 Shin SH, 2023, INT WOUND J, V20, P2414, DOI 10.1111/iwj.14075 Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590 Silva MGV, 2008, MOLECULES, V13, P2482, DOI 10.3390/molecules13102482 Springob K, 2009, PLANT-DERIVED NATURAL PRODUCTS: SYNTHESIS, FUNCTION, AND APPLICATION, P3, DOI 10.1007/978-0-387-85498-4_1 Su CW, 2024, AM J CHINESE MED, V52, P565, DOI 10.1142/S0192415X24500241 Su CX, 2024, TRANSL CANCER RES, V13, P3929, DOI 10.21037/tcr-24-406 Dev SS, 2023, J FUNCT FOODS, V110, P105845, DOI [10.1016/j.jff.2023.105845, 10.1016/j.jff.2023.105845, DOI 10.1016/J.JFF.2023.105845] Suganuma M, 2006, INT J CANCER, V119, P33, DOI 10.1002/ijc.21809 Suh YA, 2015, INT J ONCOL, V46, P1405, DOI 10.3892/ijo.2014.2808 Sun CY, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.684243 Sun LK, 2019, INT J ONCOL, V54, P98, DOI 10.3892/ijo.2018.4604 Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660 Sweeney PL, 2023, CANCER DRUG RESIST, V6, P858, DOI [10.20517/cdr.2023.89, 10.20517/cdr.2023.89] Tabasum S, 2019, CHEM-BIOL INTERACT, V303, P14, DOI 10.1016/j.cbi.2019.02.020 Tai QD, 2020, TRANSL CANCER RES, V9, P1455, DOI 10.21037/tcr.2020.01.40 Tan KT, 2019, APPL BIOCHEM BIOTECH, V187, P1328, DOI 10.1007/s12010-018-2869-1 Tan QQ, 2020, ENVIRON TOXICOL, V35, P643, DOI 10.1002/tox.22899 Tang SM, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109604 Tang Y, 2013, ANAL CHIM ACTA, V767, P148, DOI 10.1016/j.aca.2013.01.001 Tay KC, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00820 Thimmappa R, 2014, ANNU REV PLANT BIOL, V65, P225, DOI 10.1146/annurev-arplant-050312-120229 Thoennissen NH, 2010, ONCOGENE, V29, P285, DOI 10.1038/onc.2009.335 Tian Y, 2020, CHEM-BIOL INTERACT, V316, DOI 10.1016/j.cbi.2019.108936 Tomuleasa C, 2024, SIGNAL TRANSDUCT TAR, V9, DOI 10.1038/s41392-024-01899-w Tsai YJ, 2016, INT J NANOMED, V11, P1907, DOI 10.2147/IJN.S103759 Twum Y, 2023, BIOFACTORS, V49, P1143, DOI 10.1002/biof.1983 Varjas T, 2009, PHYTOTHER RES, V23, P1399, DOI 10.1002/ptr.2786 Wakimoto N, 2008, CANCER SCI, V99, P1793, DOI 10.1111/j.1349-7006.2008.00899.x Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(00)00088-5 Wang FP, 2018, ONCOL LETT, V15, P109, DOI 10.3892/ol.2017.7293 Wang J, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0981-0 Wang K, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02880-5 Wang LJ, 2020, ONCOL LETT, V20, P1239, DOI 10.3892/ol.2020.11679 Wang QN, 2021, LIFE SCI, V275, DOI 10.1016/j.lfs.2021.119414 Wang XS, 2023, JNCI-J NATL CANCER I, V115, P742, DOI 10.1093/jnci/djac015 Wang XF, 2022, MOLECULES, V27, DOI 10.3390/molecules27196441 Wang YC, 2013, FOOD CHEM TOXICOL, V53, P376, DOI 10.1016/j.fct.2012.12.018 Wang YW, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00728 Wei L, 2014, CANCER GENE THER, V21, P194, DOI 10.1038/cgt.2014.18 Wiart C, 2013, CANCER LETT, V328, P188, DOI 10.1016/j.canlet.2012.01.033 Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738 Wu JP, 2023, MOLECULES, V28, DOI 10.3390/molecules28031022 Wu SG, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0777-1 Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449 Xia L, 2025, EUR J MED CHEM REP, V13, DOI 10.1016/j.ejmcr.2025.100251 Xiao K, 2013, J PHARMACOL SCI, V123, P102, DOI 10.1254/jphs.13085FP Xie CQ, 2020, THORAC CANCER, V11, P2101, DOI 10.1111/1759-7714.13487 Xie SM, 2021, BIOMED PHARMACOTHER, V138, DOI 10.1016/j.biopha.2021.111450 Xie YL, 2016, EXP THER MED, V12, P2709, DOI 10.3892/etm.2016.3670 Xing LN, 2021, LIFE SCI, V269, DOI 10.1016/j.lfs.2021.119068 Xu F, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0878-0 Xu J, 2019, BIOMED PHARMACOTHER, V115, DOI 10.1016/j.biopha.2019.108860 Xu LY, 2024, FRONT PHARMACOL, V15, DOI 10.3389/fphar.2024.1446414 Xu T, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/7826753 Yamauchi Y, 2014, PHYTOTHER RES, V28, P728, DOI 10.1002/ptr.5056 Yan NN, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.863043 Yang CS, 2009, NAT REV CANCER, V9, P429, DOI 10.1038/nrc2641 Yang JCH, 2017, J CLIN ONCOL, V35, P1288, DOI 10.1200/JCO.2016.70.3223 Yang Q, 2018, TOXICOL APPL PHARM, V356, P1, DOI 10.1016/j.taap.2018.07.031 Yang Y, 2013, J MED CHEM, V56, P9725, DOI 10.1021/jm4014168 Yang Z, 2018, INT J BIOL SCI, V14, P204, DOI 10.7150/ijbs.22955 Yao Z, 2017, NATURE, V548, P234, DOI 10.1038/nature23291 Yao Z, 2015, CANCER CELL, V28, P370, DOI 10.1016/j.ccell.2015.08.001 Ye MX, 2012, PHYTOMEDICINE, V19, P779, DOI 10.1016/j.phymed.2012.03.005 Ye Q, 2017, CELL PHYSIOL BIOCHEM, V43, P1617, DOI 10.1159/000482025 Yin B, 2019, EUR J MED CHEM, V182, DOI 10.1016/j.ejmech.2019.111664 Younus H, 2016, INT J HEALTH SCI-IJH, V10, P261 Yu XY, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01566-2 Yu Y, 2012, FREE RADICAL RES, V46, P1393, DOI 10.3109/10715762.2012.720017 Zappa C, 2016, TRANSL LUNG CANCER R, V5, P288, DOI 10.21037/tlcr.2016.06.07 Zeng Y, 2019, CURR MED CHEM, V26, P1849, DOI 10.2174/0929867324666170523123655 Zhang F, 2019, CLIN RESPIR J, V13, P23, DOI 10.1111/crj.12976 Zhang JJ, 2012, INT J PHARMACEUT, V436, P311, DOI 10.1016/j.ijpharm.2012.07.002 Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559 Zhang J, 2020, CYTOM PART A, V97, P70, DOI 10.1002/cyto.a.23869 Zhang N, 2023, MEDCOMM, V4, DOI 10.1002/mco2.446 Zhang W, 2018, PHYTOMEDICINE, V48, P51, DOI 10.1016/j.phymed.2018.04.058 Zhang X, 2016, MOL MED REP, V14, P4489, DOI 10.3892/mmr.2016.5792 Zhang X, 2008, INT J CANCER, V123, P1005, DOI 10.1002/ijc.23585 Zheng MM, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/8174345 Zheng RZ, 2017, CURR CANCER DRUG TAR, V17, P376, DOI 10.2174/1568009616666161213141608 Zheng YF, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8781690 Zheng YF, 2019, J CELL PHYSIOL, V234, P4277, DOI 10.1002/jcp.27196 Zhong L, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00572-w Zhong W., 2017, A Global Scientific Vision-Prevention, Diagnosis, and Treatment of Lung Cancer Zhou CC, 2012, TRANSL LUNG CANCER R, V1, P72, DOI 10.3978/j.issn.2218-6751.2011.12.04 Zhou CH, 2023, EUR J MED RES, V28, DOI 10.1186/s40001-023-01271-8 Zhou Q, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0316-8 Zhou RX, 2023, EUR J PHARMACOL, V938, DOI 10.1016/j.ejphar.2022.175449 Zhou Z, 2021, CANCER BIOL MED, V18, P490, DOI 10.20892/j.issn.2095-3941.2020.0120 Zhu X, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01044 Zhu YZ, 2022, BBA-MOL BASIS DIS, V1868, DOI 10.1016/j.bbadis.2022.166557 Zhu YS, 2015, SCI REP-UK, V5, DOI 10.1038/srep17730 Zhu ZY, 2016, FOOD FUNCT, V7, P1992, DOI 10.1039/c5fo01464f NR 323 TC 7 Z9 8 U1 4 U2 5 PU MDPI PI BASEL PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND SN 1467-3037 EI 1467-3045 J9 CURR ISSUES MOL BIOL JI Curr. Issues Mol. Biol. PD JUN 30 PY 2025 VL 47 IS 7 AR 498 DI 10.3390/cimb47070498 PG 53 WC Biochemistry & Molecular Biology WE Science Citation Index Expanded (SCI-EXPANDED) SC Biochemistry & Molecular Biology GA 5SO7U UT WOS:001543332400001 PM 40728967 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Gawli, CS Patil, BR Nagpure, NR Patil, CR Kumar, A Patel, HM AF Gawli, Chandrakant S. Patil, Bhatu R. Nagpure, Narendra R. Patil, Chandrgaouda R. Kumar, Anoop Patel, Harun M. TI Prevalence of osimertinib-induced cardiotoxicity in non-small cell lung cancer patients: a systematic review and meta-analysis SO LUNG CANCER LA English DT Article DE Osimertinib; Cardiotoxicity; EGFR; NSCLC; QT prolongation; Meta-analysis; Tyrosine kinase inhibitor ID T790M MUTATION; OPEN-LABEL; MULTICENTER; METASTASES; SAFETY AB Objective: Osimertinib, a third-generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI), is the standard of care for patients with EGFR-mutated Non-Small Cell Lung Cancer (NSCLC). While clinically effective, concerns have emerged regarding its potential cardiotoxicity. This study aims to systematically evaluate the prevalence and types of cardiotoxicity associated with Osimertinib. Methods: A systematic review and meta-analysis were performed in accordance with PRISMA guidelines. Literature searches of PubMed and ClinicalTrials.gov were conducted for studies published between October 2014 and October 2024. Data from 68 studies encompassing 14,050 patients were analyzed using the metafor package in R Studio (version 4.4.1). A generalized linear mixed model with logit transformation was used to estimate pooled prevalence. Heterogeneity was assessed via I2 statistics, and publication bias was evaluated using Egger's and Begg's tests. Results: The overall pooled prevalence of Osimertinib-induced cardiotoxicity was 4.00 % (95 % CI: 2.9-5.48; I2 = 76.9 %). QT prolongation was the most commonly reported event (6.03 %), followed by atrial fibrillation (1.50 %) and cardiac failure (1.21 %). Subgroup analysis showed higher prevalence in randomized controlled trials (4.98 %) versus observational studies (0.78 %), and in combination therapies (4.89 %) versus monotherapy (3.64 %). Regional variation was noted, with the highest prevalence in North America (5.56 %). Egger's test indicated significant publication bias (p < 0.0001) for several cardiotoxic outcomes. Conclusion: Osimertinib is associated with a modest but clinically significant risk of cardiotoxicity, particularly QT prolongation. These findings support the need for routine cardiac monitoring in high-risk patients and emphasize the importance of standardized cardiotoxicity reporting in future trials to enhance the safety profile of Osimertinib in NSCLC treatment. C1 [Gawli, Chandrakant S.; Patil, Bhatu R.; Nagpure, Narendra R.; Patil, Chandrgaouda R.; Patel, Harun M.] RC Patel Inst Pharmaceut Educ & Res, Dhule 425405, Maharashtra, India. [Kumar, Anoop] Delhi Pharmaceut Sci & Res Univ DPSRU, New Delhi 110017, India. C3 Delhi Pharmaceutical Sciences & Research University (DPSRU) RP Patel, HM (corresponding author), RC Patel Inst Pharmaceut Educ & Res, Dhule 425405, Maharashtra, India.; Kumar, A (corresponding author), Delhi Pharmaceut Sci & Res Univ DPSRU, New Delhi 110017, India. EM abitmesra@gmail.com; hpatel_38@yahoo.com RI ; Patel, Harun/L-7942-2019 OI Nagpure, Narena/0009-0003-8399-7618; Gawli, Chanakant/0000-0002-6917-4610; FU Indian Council of Medical Research (ICMR) [IIRPIG-2023-0000318] FX Authors would like to thank Indian Council of Medical Research (ICMR) for funding the Investigator Initiated Research Projects-Inter-mediate Extramural Grants (Grant No. IIRPIG-2023-0000318) ." CR Ahmad I, 2024, DRUG DEVELOP RES, V86, DOI 10.1002/ddr.70036 Ahmad I, 2024, J BIOCHEM MOL TOXIC, V39, DOI 10.1002/jbt.70077 Ahmad I, 2022, J BIOMOL STRUCT DYN, V40, P3046, DOI 10.1080/07391102.2020.1844801 Akamatsu H, 2018, CANCER SCI, V109, P1930, DOI 10.1111/cas.13623 Anand K, 2019, JACC-CARDIOONCOL, V1, P172, DOI 10.1016/j.jaccao.2019.10.006 Ang YLE, 2023, CANCERS, V15, DOI 10.3390/cancers15204999 [Anonymous], 2015, Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific (AURA17) Bar J, 2023, J THORAC ONCOL, V18, P169, DOI 10.1016/j.jtho.2022.10.004 Bennouna J., Phase II study evaluating Bhatt VR, 2017, J GLOB ONCOL, V3, P208, DOI 10.1200/JGO.2016.003392 Blakely CM, 2024, J CLIN ONCOL, V42, DOI 10.1200/JCO.24.00071 Cao YB, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221575 Cho BC, 2022, FUTURE ONCOL, V18, P639, DOI 10.2217/fon-2021-0923 Cuppens K, 2021, DRUGS-REAL WOR OUTC, V8, P141, DOI 10.1007/s40801-021-00243-w Eide IJZ, 2020, LUNG CANCER, V143, P27, DOI 10.1016/j.lungcan.2020.03.009 Feng R, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0382-1 Gawli CS, 2025, BIOORGAN MED CHEM, V123, DOI 10.1016/j.bmc.2025.118146 Goss G, 2016, LANCET ONCOL, V17, P1643, DOI 10.1016/S1470-2045(16)30508-3 Grande E, 2019, J PHARMACOL EXP THER, V369, P291, DOI 10.1124/jpet.118.255919 Harvey RD, 2018, BRIT J CLIN PHARMACO, V84, P2877, DOI 10.1111/bcp.13753 Herbst RS, 2023, J CLIN ONCOL, V41, P1830, DOI 10.1200/JCO.22.02186 Hsieh PC, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.869390 Huang L, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017705 Ito K, 2018, J THORAC DIS, V10, pS3071, DOI 10.21037/jtd.2018.07.52 Janzic U, 2022, CURR ONCOL, V29, P5833, DOI 10.3390/curroncol29080460 Jebbink M, 2023, JTO CLIN RES REP, V4, DOI 10.1016/j.jtocrr.2023.100481 Kim C, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.728155 Kim C, 2021, CANCERS, V13, DOI 10.3390/cancers13133342 Kim DW, 2023, J THORAC ONCOL, V18, P650, DOI 10.1016/j.jtho.2022.12.021 Kiura K, 2018, CANCER SCI, V109, P1177, DOI 10.1111/cas.13511 Le XN, 2025, J CLIN ONCOL, V43, DOI 10.1200/JCO.24.00533 Lee J.B., 2025, J. Thorac. Oncol., DOI [10.1016/j., DOI 10.1016/J] Lin LF, 2020, EPIDEMIOLOGY, V31, P713, DOI 10.1097/EDE.0000000000001232 Lin LF, 2018, BIOMETRICS, V74, P785, DOI 10.1111/biom.12817 Liu K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057043 Lu S, 2024, ANN ONCOL, V35, P1116, DOI 10.1016/j.annonc.2024.08.2243 Majem M, 2021, EUR J CANCER, V159, P174, DOI 10.1016/j.ejca.2021.09.039 Malik PS, 2022, INDIAN J CANCER, V59, pS1, DOI 10.4103/ijc.ijc_1374_21 Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097 Nair AS, 2024, INDIAN J ANAESTH, V68, P922, DOI 10.4103/ija.ija_623_24 Nie KK, 2018, LUNG CANCER, V121, P5, DOI 10.1016/j.lungcan.2018.04.012 Ohe Y, 2020, JPN J CLIN ONCOL, V50, P909, DOI 10.1093/jjco/hyaa067 Park S, 2020, ANN ONCOL, V31, P1397, DOI 10.1016/j.annonc.2020.06.017 Park S, 2024, J CLIN ONCOL, V42, DOI 10.1200/JCO.24.00708 Pasello G, 2024, ONCOLOGIST, V29, P596, DOI 10.1093/oncolo/oyae043 Patil BR, 2025, EUR J MED CHEM, V283, DOI 10.1016/j.ejmech.2024.117140 Peled N, 2022, NEURO-ONCOL ADV, V4, DOI 10.1093/noajnl/vdab188 Planchard D, 2023, NEW ENGL J MED, V389, P1935, DOI 10.1056/NEJMoa2306434 Planchard D, 2016, CANCER CHEMOTH PHARM, V77, P767, DOI 10.1007/s00280-016-2992-z Poels KE, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23912-4 Provencio M, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-07922-5 Schwarzer G., 2015, Meta-Analysis with R, DOI [DOI 10.1007/978-3-319-21416-0, 10.1007/ 978-3-319-21416-0] Sequist LV, 2020, LANCET ONCOL, V21, P373, DOI 10.1016/S1470-2045(19)30785-5 Shirani M, 2023, BMC INFECT DIS, V23, DOI 10.1186/s12879-023-08504-5 Sooy RA, 2022, ANN ONCOL, V33, P181, DOI 10.1016/j.annonc.2021.11.010 Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137 Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919 Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262 van Veelen A, 2022, LUNG CANCER, V171, P97, DOI 10.1016/j.lungcan.2022.07.012 Vishwanathan K, 2020, PHARMACOL RES PERSPE, V8, DOI 10.1002/prp2.613 Vishwanathan K, 2020, CTS-CLIN TRANSL SCI, V13, P41, DOI 10.1111/cts.12688 Vishwanathan K, 2019, CLIN PHARM DRUG DEV, V8, P198, DOI 10.1002/cpdd.467 Vishwanathan K, 2018, BRIT J CLIN PHARMACO, V84, P1156, DOI 10.1111/bcp.13534 Vishwanathan K, 2018, J CLIN PHARMACOL, V58, P474, DOI 10.1002/jcph.1035 World Health Organization, 2025, US Wu YL, 2024, LANCET ONCOL, V25, P989, DOI 10.1016/S1470-2045(24)00270-5 Xing LG, 2020, CLIN CANCER RES, V26, P6168, DOI 10.1158/1078-0432.CCR-20-2081 Yamamoto N, 2020, ADV THER, V37, P759, DOI 10.1007/s12325-019-01187-y Yang JCH, 2020, J CLIN ONCOL, V38, P538, DOI 10.1200/JCO.19.00457 Yang JCH, 2023, INVEST NEW DRUG, V41, P306, DOI 10.1007/s10637-023-01341-y Yu HA, 2021, CLIN CANCER RES, V27, P992, DOI 10.1158/1078-0432.CCR-20-1690 Yu HA, 2020, JAMA ONCOL, V6, P1048, DOI 10.1001/jamaoncol.2020.1260 Zhang L, 2023, THORAC CANCER, V14, P1355, DOI 10.1111/1759-7714.14880 Zhao HY, 2018, J CLIN PHARMACOL, V58, P504, DOI 10.1002/jcph.1042 Zhao S, 2023, NAT COMMUN, V14, DOI 10.1038/s41467-023-39139-4 Zhao Y, 2019, BMJ-BRIT MED J, V367, DOI 10.1136/bmj.l5460 Zhou Q, 2023, J CANCER RES CLIN, V149, P10771, DOI 10.1007/s00432-023-04923-8 Zhou Y., ECLINICALMEDICINE NR 78 TC 3 Z9 4 U1 1 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0169-5002 EI 1872-8332 J9 LUNG CANCER JI Lung Cancer PD JUL PY 2025 VL 205 AR 108629 DI 10.1016/j.lungcan.2025.108629 EA JUN 2025 PG 14 WC Oncology; Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Respiratory System GA 4LL9E UT WOS:001520841300001 PM 40555063 DA 2026-04-17 ER PT J AU Lang, T Meng, LB AF Lang, Tong Meng, Lingbing TI CYBB identified as a key immune hub gene linking lung cancer and atrial fibrillation SO JOURNAL OF CARDIOTHORACIC SURGERY LA English DT Article DE Lung cancer; Atrial fibrillation; CYBB; Prognosis AB BackgroundThe proportion of patients with lung cancer complicated by atrial fibrillation (AF) is increasing. Identifying shared molecular targets between these two conditions may provide important prognostic insights for patients with comorbidities.MethodsThe GSE8569 and GSE41177 datasets were downloaded from the Gene Expression Omnibus (GEO) database. Differential expression analysis was performed using the limma package in R. Weighted gene co-expression network analysis (WGCNA) was conducted to identify significant gene modules. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, along with gene set enrichment analysis (GSEA), were used to explore biological functions. Clinical survival data for lung cancer were obtained from The Cancer Genome Atlas (TCGA), and receiver operating characteristic (ROC) analysis was conducted using the R package ROC (version 1.17.0.1).ResultsA total of 598 differentially expressed genes (DEGs) were identified. These DEGs were primarily enriched in cell proliferation, inflammatory responses, non-small cell lung cancer, the p53 signaling pathway, and the cell cycle. Three core genes (CYBB, ITGB2, FCER1G) were identified. Notably, CYBB was downregulated in lung cancer compared to normal tissue. Patients in the low-risk group had significantly better survival outcomes. Heatmap visualization showed that expression of CYBB decreased with increasing risk scores, suggesting a protective role.ConclusionCYBB expression may influence lung cancer prognosis and contribute to the pathogenesis of AF. Further research is needed to clarify CYBB's role in patients with both conditions. C1 [Lang, Tong] Weifang Second Peoples Hosp, Dept Resp & Crit Care Med, 7 Yuanxiao St, Weifang 261041, Shandong, Peoples R China. [Meng, Lingbing] Chinese Acad Med Sci & Peking Union Med Coll, Fuwai Hosp, Natl Clin Res Ctr Cardiovasc Dis, Natl Ctr Cardiovasc Dis,Cardiometab Med Ctr, A 167 Beilishi Rd, Beijing 100037, Peoples R China. [Meng, Lingbing] Chinese Acad Med Sci & Peking Union Med Coll, Natl Ctr Cardiovasc Dis, Dept Cardiol, Natl Clin Res Ctr Cardiovasc Dis,Fuwai Hosp, A 167 Beilishi Rd, Beijing 100037, Peoples R China. [Meng, Lingbing] State Key Lab Cardiovasc Dis, A 167 Beilishi Rd, Beijing 100037, Peoples R China. [Meng, Lingbing] Weifang Second Peoples Hosp, Translat Med Ctr, 7 Yuanxiao St, Weifang 261041, Shandong Provin, Peoples R China. C3 Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Peking Union Medical College RP Meng, LB (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Fuwai Hosp, Natl Clin Res Ctr Cardiovasc Dis, Natl Ctr Cardiovasc Dis,Cardiometab Med Ctr, A 167 Beilishi Rd, Beijing 100037, Peoples R China.; Meng, LB (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Natl Ctr Cardiovasc Dis, Dept Cardiol, Natl Clin Res Ctr Cardiovasc Dis,Fuwai Hosp, A 167 Beilishi Rd, Beijing 100037, Peoples R China.; Meng, LB (corresponding author), State Key Lab Cardiovasc Dis, A 167 Beilishi Rd, Beijing 100037, Peoples R China.; Meng, LB (corresponding author), Weifang Second Peoples Hosp, Translat Med Ctr, 7 Yuanxiao St, Weifang 261041, Shandong Provin, Peoples R China. EM 314597690@qq.com CR Alonso A, 2021, TRENDS CARDIOVAS MED, V31, P469, DOI 10.1016/j.tcm.2020.10.010 Becher N, 2024, EUR HEART J, V45, P2824, DOI 10.1093/eurheartj/ehae373 Berry IM, 2020, J INFECT DIS, V221, pS292, DOI 10.1093/infdis/jiz286 Bhavya K, 2022, LIFE SCI, V294, DOI 10.1016/j.lfs.2022.120334 Chen C, 2024, NUTR DIABETES, V14, DOI 10.1038/s41387-024-00323-0 De Heredia APLF, 2024, CURR PROB CARDIOLOGY, V49, DOI 10.1016/j.cpcardiol.2023.102239 Ding R, 2025, CLIN EXP RHEUMATOL, V43, P282, DOI [10.55563/clinexprheumatol/fok820, 10.55563/clinexprheumatol/fok820] Fan JJ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2317-3 Gluschko A, 2022, AUTOPHAGY, V18, P1090, DOI 10.1080/15548627.2021.1969765 Hsu CL, 2021, LIVER CANCER, V10, P346, DOI 10.1159/000515305 Jiang P, 2022, NAT REV CANCER, V22, P625, DOI 10.1038/s41568-022-00502-0 Krishnan A, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10092501 Kuntic M, 2020, EUR HEART J, V41, P2472, DOI 10.1093/eurheartj/ehz772 Leiter A, 2023, NAT REV CLIN ONCOL, V20, P624, DOI 10.1038/s41571-023-00798-3 Lemaigre C, 2022, J CLIN IMMUNOL, V42, P60, DOI 10.1007/s10875-021-01140-1 Liao CH, 2023, J ANTIMICROB CHEMOTH, V78, P1891, DOI 10.1093/jac/dkad179 Long WX, 2021, MED ONCOL, V38, DOI 10.1007/s12032-021-01529-3 Menezes AD Jr, 2024, INT J MOL SCI, V25, DOI 10.3390/ijms25010535 Noreng S, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-33711-0 Prieto LI, 2023, CANCER CELL, V41, P1261, DOI 10.1016/j.ccell.2023.05.006 Rather MA, 2023, INT J BIOL MACROMOL, V233, DOI 10.1016/j.ijbiomac.2023.123549 Rosas D, 2021, CANCERS, V13, DOI 10.3390/cancers13205038 Saadane A, 2021, AM J PATHOL, V191, P1805, DOI 10.1016/j.ajpath.2021.06.006 Shen MJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1161-8 Singer ED., 2023, Hemoptysis Cancer Patients Cancers (Basel), V15, P4765, DOI [10.3390/cancers15194765, DOI 10.3390/CANCERS15194765] Stanger L, 2023, PHARMACOL THERAPEUT, V246, DOI 10.1016/j.pharmthera.2023.108420 Stephens EKH, 2023, TRANSL LUNG CANCER R, V12, P2129, DOI 10.21037/tlcr-23-291 Stewart AN, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02161-8 Teixidor-Vila E, 2024, LUNG CANCER, V197, DOI 10.1016/j.lungcan.2024.107995 van der Weyden L, 2020, G3-GENES GENOM GENET, V10, P1869, DOI 10.1534/g3.120.401128 Vyas V, 2020, EUROPACE, V22, P1609, DOI 10.1093/europace/euaa214 Wang Y, 2024, HELIYON, V10, DOI 10.1016/j.heliyon.2024.e29549 Xie ZH, 2023, BIOLOGY-BASEL, V12, DOI 10.3390/biology12010121 Yu HH, 2021, CLIN REV ALLERG IMMU, V61, P101, DOI 10.1007/s12016-020-08800-x NR 34 TC 0 Z9 0 U1 3 U2 4 PU BMC PI LONDON PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND EI 1749-8090 J9 J CARDIOTHORAC SURG JI J. Cardiothorac. Surg. PD JUN 18 PY 2025 VL 20 IS 1 AR 262 DI 10.1186/s13019-025-03510-x PG 16 WC Cardiac & Cardiovascular Systems; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Surgery GA 3XW9K UT WOS:001511623400004 PM 40533809 OA Green Submitted, gold DA 2026-04-17 ER PT J AU El-Rayes, M Agmon, IN Yu, C Osataphan, N Yu, HA Hope, A Sacher, A Yu, AF Abdel-Qadir, H Thavendiranathan, P AF El-Rayes, Malak Agmon, Inbar Nardi Yu, Christopher Osataphan, Nichanan Yu, Helena A. Hope, Andrew Sacher, Adrian Yu, Anthony F. Abdel-Qadir, Husam Thavendiranathan, Paaladinesh TI Lung Cancer and Cardiovascular Disease Common Pathophysiology and Treatment-Emergent Toxicity SO JACC: CARDIOONCOLOGY LA English DT Review DE cardio-oncology; cardiovascular disease; chemotherapy; lung cancer; radiation therapy; targeted therapy ID ADVERSE CARDIAC EVENTS; ATRIAL-FIBRILLATION; ADULT CANCERS; RISK; RADIATION; SURVIVORS; OUTCOMES; CARDIOTOXICITY; RADIOTHERAPY; CHEMOTHERAPY AB Among patients with cancer, those with lung cancer have the highest prevalence of pre-existing cardiovascular disease (CVD) and the highest risk of cardiovascular events postdiagnosis. This is driven by shared risk factors, particularly smoking and socioeconomic factors, and common biology. Furthermore, multimodality therapies for lung cancer, including surgery, radiation, chemotherapy, immunotherapy, and targeted therapy, are associated with CVD. Improvements in prevention, screening, and therapy for lung cancer have led to improved cancer survival, increasing the relevance of CVD for overall survival and quality of life. This review provides an overview of lung cancer and its treatment and discusses drivers of CVD, risk assessment, surveillance, prevention, and treatment strategies. (JACC CardioOncol. 2025;7:325-344) (c) 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). C1 [El-Rayes, Malak] Hop Cite Sante, Ctr Integre Sante & Serv Sociaux Laval, Div Cardiol, Dept Med, Laval, PQ, Canada. [El-Rayes, Malak] Univ Montreal, Dept Med, Montreal, PQ, Canada. [Agmon, Inbar Nardi; Yu, Christopher; Osataphan, Nichanan; Abdel-Qadir, Husam; Thavendiranathan, Paaladinesh] Univ Toronto, Univ Hlth Network, Ted Rogers Program Cardiotox Prevent, Dept Med,Div Cardiol,Peter Munk Cardiac Ctr, Toronto, ON, Canada. [Osataphan, Nichanan] Chiang Mai Univ, Fac Med, Dept Internal Med, Div Cardiol, Chiang Mai, Thailand. [Yu, Helena A.; Yu, Anthony F.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA. [Yu, Helena A.; Yu, Anthony F.] Weill Cornell Med Coll, Dept Med, New York, NY USA. [Hope, Andrew] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada. [Hope, Andrew] Univ Hlth Network, Princess Margaret Canc Ctr, Radiat Med Program, Toronto, ON, Canada. [Sacher, Adrian] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Dept Med,Div Med Oncol, Toronto, ON, Canada. [Abdel-Qadir, Husam] Womens Coll Hosp WCH, Toronto, ON, Canada. [El-Rayes, Malak] Hop Cite Sante, Ctr Integre Sante & Serv Sociaux Laval, Div Cardiol, 1755 Blvd Rene Laennec, Laval, PQ H7M 3L9, Canada. C3 Centre Integre de Sante et de Services Sociaux de Laval; Universite de Montreal; Universite de Montreal; University of Toronto; Peter Munk Cardiac Centre; University Health Network Toronto; Chiang Mai University; Memorial Sloan Kettering Cancer Center; Cornell University; Weill Cornell Medicine; University of Toronto; University of Toronto; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Health Network Toronto; Princess Margaret Cancer Centre; Universite de Montreal; Centre Integre de Sante et de Services Sociaux de Laval RP Thavendiranathan, P (corresponding author), Toronto Gen Hosp, Peter Munk Cardiac Ctr, Ted Rogers Program Cardiotox Prevent, Div Cardiol, 4N-490,200 Elizabeth St, Toronto, ON M5G 2C4, Canada.; El-Rayes, M (corresponding author), Hop Cite Sante, Ctr Integre Sante & Serv Sociaux Laval, Div Cardiol, 1755 Blvd Rene Laennec, Laval, PQ H7M 3L9, Canada. EM malak.el-rayes.med@ssss.gouv.qc.ca; dinesh.thavendiranathan@uhn.ca RI Sacher, Aian/I-8080-2016 OI Sacher, Aian/0000-0001-7865-2701 FU Tier II Canada Research Chair in Cardio-Oncology [950-2326 46]; Canadian Cancer Society/Canadian Institutes of Health Research's W. David Harg raft Grant; Canadian Institutes of Health [187923] FX Dr Thavendiranathan is supported by a Tier II Canada Research Chair in Cardio-Oncology (#950-2326 46) and the Canadian Cancer Society/Canadian Institutes of Health Research's W. David Harg raft Grant. Yu is supported by funding from the Canadian Institutes of Health Research funding (#187923). Dr Abdel-Qadir has received consultinghonoraria from Amgen. The authors have reported that they have norelationships relevant to the contents of this paper to disclose. CR Abdel-Rahman O, 2016, CRIT REV ONCOL HEMAT, V102, P89, DOI 10.1016/j.critrevonc.2016.04.003 Aikawa T, 2023, J AM HEART ASSOC, V12, DOI 10.1161/JAHA.123.030072 Ajufo E, 2021, JAMA CARDIOL, V6, P179, DOI 10.1001/jamacardio.2020.4939 Alexandre J, 2021, EUR HEART J-CARD PHA, V7, P312, DOI 10.1093/ehjcvp/pvaa037 Altorki N, 2023, NEW ENGL J MED, V388, P489, DOI 10.1056/NEJMoa2212083 American Cancer Society, Key Statistics for Lung Cancer 2024 American Cancer Society, 2024, Lung Cancer survival rates Anand K, 2019, JACC-CARDIOONCOL, V1, P172, DOI 10.1016/j.jaccao.2019.10.006 Armenian SH, 2017, J CLIN ONCOL, V35, P893, DOI 10.1200/JCO.2016.70.5400 Asnani Aarti, 2017, Cardiooncology, V3, P2, DOI [10.1186/s40959-017-0021-y, 10.1186/s40959-017-0021-y] Atkins KM, 2022, JCO CLIN CANCER INFO, V6, DOI 10.1200/CCI.21.00095 Atkins KM, 2021, INT J RADIAT ONCOL, V110, P1473, DOI 10.1016/j.ijrobp.2021.03.005 Atkins KM, 2021, JAMA ONCOL, V7, P206, DOI 10.1001/jamaoncol.2020.6332 Atkins KM, 2019, J AM COLL CARDIOL, V73, P2976, DOI 10.1016/j.jacc.2019.03.500 Balanescu DV, 2020, INT J CARDIOL, V313, P1, DOI [10.36106/ijar/7206503, 10.1016/j.ijcard.2020.04.050] Bastos DA, 2010, J THORAC ONCOL, V5, P752, DOI 10.1097/JTO.0b013e3181d6b9e8 Batra A, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07487-9 Belani N, 2023, JACC-CARDIOONCOL, V5, P542, DOI 10.1016/j.jaccao.2023.04.005 Belzile-Dugas E, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.121.021686 Ben Zadok OI, 2023, JACC-CARDIOONCOL, V5, P732, DOI 10.1016/j.jaccao.2023.09.004 Brenner DR, 2022, CAN MED ASSOC J, V194, pE601, DOI 10.1503/cmaj.212097 Caini S, 2022, J THORAC ONCOL, V17, P623, DOI 10.1016/j.jtho.2021.12.005 Camidge DR, 2018, NEW ENGL J MED, V379, P2027, DOI 10.1056/NEJMoa1810171 Cascone T, 2024, NEW ENGL J MED, V390, P1756, DOI 10.1056/NEJMoa2311926 Chang LK, 2022, ESMO OPEN, V7, DOI 10.1016/j.esmoop.2021.100354 Chen WH, 2024, J INT MED RES, V52, DOI 10.1177/03000605241238077 Cheng Y, 2024, NEW ENGL J MED, V391, P1313, DOI 10.1056/NEJMoa2404873 Chevallier M, 2021, WORLD J CLIN ONCOL, V12, P217, DOI 10.5306/wjco.v12.i4.217 Chiles C, 2015, RADIOLOGY, V276, P82, DOI 10.1148/radiol.15142062 Cho BC, 2024, NEW ENGL J MED, V391, P1486, DOI 10.1056/NEJMoa2403614 Cirne F, 2021, LUNG CANCER, V161, P9, DOI 10.1016/j.lungcan.2021.08.014 Curigliano G, 2020, ANN ONCOL, V31, P171, DOI 10.1016/j.annonc.2019.10.023 Daly ME, 2024, J CLIN ONCOL, V42, DOI 10.1200/JCO-24-01324 De Heredia APLF, 2024, CURR PROB CARDIOLOGY, V49, DOI 10.1016/j.cpcardiol.2023.102239 de Koning HJ, 2020, NEW ENGL J MED, V382, P503, DOI 10.1056/NEJMoa1911793 Dess RT, 2017, J CLIN ONCOL, V35, P1395, DOI 10.1200/JCO.2016.71.6142 Dolladille C, 2021, EUR HEART J, V42, P4964, DOI 10.1093/eurheartj/ehab618 Drilon A, 2020, LANCET ONCOL, V21, P261, DOI 10.1016/S1470-2045(19)30690-4 Drobni ZD, 2020, CIRCULATION, V142, P2299, DOI 10.1161/CIRCULATIONAHA.120.049981 Drobni ZD, 2023, J IMMUNOTHER CANCER, V11, DOI 10.1136/jitc-2023-007307 Ebner PJ, 2020, ANN THORAC SURG, V109, P225, DOI 10.1016/j.athoracsur.2019.07.017 El-Rayes M, 2025, JACC-CARDIOONCOL, V7, P157, DOI 10.1016/j.jaccao.2024.10.014 Ewer MS, 2021, J CLIN ONCOL, V39, P328, DOI 10.1200/JCO.20.01171 Finke D, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.729713 Futamura K, 2023, INT CANCER CONF J, V12, P299, DOI 10.1007/s13691-023-00620-y Ganti AK, 2021, JAMA ONCOL, V7, P1824, DOI 10.1001/jamaoncol.2021.4932 Garassino MC, 2023, J CLIN ONCOL, V41, P1992, DOI 10.1200/JCO.22.01989 Gevaert SA, 2021, EUR HEART J-ACUTE CA, V10, P947, DOI 10.1093/ehjacc/zuab056 Glen C, 2023, JACC-CARDIOONCOL, V5, P628, DOI 10.1016/j.jaccao.2023.04.004 Groth SS, 2015, THORAC SURG CLIN, V25, P335, DOI 10.1016/j.thorsurg.2015.04.006 Guddati AK, 2016, J CANCER RES CLIN, V142, P471, DOI 10.1007/s00432-015-2056-5 Guha A, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.014248 Ha D, 2016, J THORAC ONCOL, V11, P1397, DOI 10.1016/j.jtho.2016.04.021 Hajizadeh M, 2020, PUBLIC HEALTH, V185, P189, DOI 10.1016/j.puhe.2020.04.023 Halvorsen S, 2022, EUR HEART J, V43, P3826, DOI [10.1714/3956.39326, 10.1093/eurheartj/ehac270] Haugnes HS, 2010, J CLIN ONCOL, V28, P4649, DOI 10.1200/JCO.2010.29.9362 Hecht HS, 2017, J CARDIOVASC COMPUT, V11, P74, DOI 10.1016/j.jcct.2016.11.003 Heiden BT, 2023, ANN SURG, V277, pe933, DOI 10.1097/SLA.0000000000005312 Herr DJ, 2022, PRACT RADIAT ONCOL, V12, pE376, DOI 10.1016/j.prro.2022.01.002 Heymach JV, 2023, NEW ENGL J MED, V389, P1672, DOI 10.1056/NEJMoa2304875 Howlader N, 2020, NEW ENGL J MED, V383, P640, DOI 10.1056/NEJMoa1916623 Inno A, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.652186 Ju CS, 2024, ESC HEART FAIL, V11, P3911, DOI 10.1002/ehf2.14981 Kearney M, 2022, RADIOTHER ONCOL, V172, P118, DOI 10.1016/j.radonc.2022.05.007 Keating GM, 2014, DRUGS, V74, P1891, DOI 10.1007/s40265-014-0302-9 Khosla AA, 2023, PHARMACEUTICALS-BASE, V16, DOI 10.3390/ph16101461 Khurshid H, Systemic therapy for small-cell lung cancer: ASCO-Ontario Kondapalli L, 2023, JACC-CARDIOONCOL, V5, P114, DOI 10.1016/j.jaccao.2022.12.002 Kravchenko J, 2015, LUNG CANCER, V88, P85, DOI 10.1016/j.lungcan.2015.01.006 Kunadian V, 2024, NEW ENGL J MED, V391, P1673, DOI 10.1056/NEJMoa2407791 Kunimasa K, 2020, JACC-CARDIOONCOL, V2, P1, DOI 10.1016/j.jaccao.2020.02.003 Largeau B, 2021, BRIT J CLIN PHARMACO, V87, P3043, DOI 10.1111/bcp.14752 Leiter A, 2023, NAT REV CLIN ONCOL, V20, P624, DOI 10.1038/s41571-023-00798-3 Leong DP, 2024, JACC-CARDIOONCOL, V6, DOI 10.1016/j.jaccao.2024.06.005 Leong DP, 2023, JACC-CARDIOONCOL, V5, P415, DOI 10.1016/j.jaccao.2023.05.008 Li HX, 2025, J INTERN MED, V297, P36, DOI 10.1111/joim.20028 Li SH, 2006, CLIN NEUROL NEUROSUR, V108, P150, DOI 10.1016/j.clineuro.2005.03.008 Locquet M, 2024, BMC CANCER, V24, DOI 10.1186/s12885-024-13281-8 Lopez-Mattei J, 2023, J CARDIOVASC COMPUT, V17, P66, DOI 10.1016/j.jcct.2022.09.002 LoPiccolo J, 2024, NAT REV CLIN ONCOL, V21, P121, DOI 10.1038/s41571-023-00844-0 Lyon AR, 2022, EUR HEART J, V43, P4229, DOI 10.1093/eurheartj/ehac244 Mahmood SS, 2018, J AM COLL CARDIOL, V71, P1755, DOI 10.1016/j.jacc.2018.02.037 Marenzi G, 2025, ESC HEART FAIL, V12, P554, DOI 10.1002/ehf2.14907 Mincu RI, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.8890 Mitchell JD, 2023, ESMO OPEN, V8, DOI 10.1016/j.esmoop.2023.101830 Mitchell JD, 2021, JACC-CARDIOONCOL, V3, P360, DOI 10.1016/j.jaccao.2021.06.003 Mok T, 2020, ANN ONCOL, V31, P1056, DOI 10.1016/j.annonc.2020.04.478 Moore RA, 2011, J CLIN ONCOL, V29, P3466, DOI 10.1200/JCO.2011.35.5669 Nagano T, 2019, CURR CANCER DRUG TAR, V19, P595, DOI 10.2174/1568009619666181210114559 National Comprehensive Cancer Network, 2025, Small Cell Lung Cancer National Comprehensive Cancer Network, 2025, Non-small cell lung cancer (Version 3.2025) Nerlekar N, 2025, JAMA-J AM MED ASSOC, V333, P1403, DOI 10.1001/jama.2025.0584 Nicholson AG, 2022, J THORAC ONCOL, V17, P362, DOI 10.1016/j.jtho.2021.11.003 Nicholson AG, 2016, J THORAC ONCOL, V11, P300, DOI 10.1016/j.jtho.2015.10.008 Nielsen DL, 2024, JAMA ONCOL, V10, P1390, DOI 10.1001/jamaoncol.2024.3065 No HJ, 2023, JACC-CARDIOONCOL, V5, P775, DOI 10.1016/j.jaccao.2023.08.007 Osman M, 2022, CARDIOVASC REVASCULA, V35, P121, DOI 10.1016/j.carrev.2021.04.015 Owen DH, 2024, J CLIN ONCOL, V42, pe44, DOI 10.1200/JCO.24.00762 Palassin P, 2022, CANCER IMMUNOL IMMUN, V71, P3093, DOI 10.1007/s00262-022-03208-2 Paterson DI, 2022, JACC-CARDIOONCOL, V4, P85, DOI 10.1016/j.jaccao.2022.01.100 Phillips JD, 2020, J THORAC DIS, V12, P3110, DOI 10.21037/jtd-20-180 Pruis MA, 2023, JACC-CARDIOONCOL, V5, P102, DOI 10.1016/j.jaccao.2022.09.006 Raisi-Estabragh Z, 2024, JACC-CARDIOONCOL, V6, P631, DOI 10.1016/j.jaccao.2024.07.017 Ramalingam SS, 2020, NEW ENGL J MED, V382, P41, DOI 10.1056/NEJMoa1913662 Rao VJU, 2021, J AM COLL CARDIOL, V77, P2693, DOI 10.1016/j.jacc.2021.04.009 Reckling S, 2024, The ASCO post Rosenzweig KE, 2000, INT J RADIAT ONCOL, V48, P81, DOI 10.1016/S0360-3016(00)00583-6 Roviello G, 2021, INVEST NEW DRUG, V39, P879, DOI 10.1007/s10637-021-01068-8 ROWINSKY EK, 1991, J CLIN ONCOL, V9, P1704, DOI 10.1200/JCO.1991.9.9.1704 Salem JE, 2018, LANCET ONCOL, V19, P1579, DOI 10.1016/S1470-2045(18)30608-9 Schultz WM, 2018, CIRCULATION, V137, P2166, DOI 10.1161/CIRCULATIONAHA.117.029652 Semeraro GC, 2021, CANCERS, V13, DOI 10.3390/cancers13164012 Shabtaie SA, 2023, JACC-CARDIOONCOL, V5, P203, DOI 10.1016/j.jaccao.2022.10.016 Shaw AT, 2020, NEW ENGL J MED, V383, P2018, DOI 10.1056/NEJMoa2027187 Singh N, 2023, J CLIN ONCOL, V41, pE42, DOI 10.1200/JCO.23.00281 Slotman BJ, 2015, LANCET, V385, P36, DOI 10.1016/S0140-6736(14)61085-0 Smilowitz NR, 2017, JAMA CARDIOL, V2, P181, DOI 10.1001/jamacardio.2016.4792 Speirs CK, 2017, J THORAC ONCOL, V12, P293, DOI 10.1016/j.jtho.2016.09.134 Strongman H, 2019, LANCET, V394, P1041, DOI 10.1016/S0140-6736(19)31674-5 Sun R, 2024, SCI REP-UK, V14, DOI 10.1038/s41598-024-55829-5 Takahashi T, 2017, LANCET ONCOL, V18, P663, DOI 10.1016/S1470-2045(17)30230-9 Tao YX, 2022, INVEST NEW DRUG, V40, P831, DOI 10.1007/s10637-022-01242-6 Thai AA, 2021, LANCET, V398, P535, DOI 10.1016/S0140-6736(21)00312-3 Tjong MC, 2022, RADIOTHER ONCOL, V169, P105, DOI 10.1016/j.radonc.2022.02.010 van Rijswijk JW, 2020, CARDIOVASC PATHOL, V45, DOI 10.1016/j.carpath.2019.107176 Venkatesulu BP, 2018, JACC-BASIC TRANSL SC, V3, P563, DOI 10.1016/j.jacbts.2018.01.014 Waliany S, 2021, J THORAC ONCOL, V16, P2029, DOI 10.1016/j.jtho.2021.07.030 Waliany S, 2021, JACC-CARDIOONCOL, V3, P137, DOI 10.1016/j.jaccao.2021.01.004 Walls GM, 2024, JACC-CARDIOONCOL, V6, P529, DOI 10.1016/j.jaccao.2024.05.009 Wang B, 2020, J CELL MOL MED, V24, P7717, DOI 10.1111/jcmm.15479 Wang C, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.950971 Wang H, 2021, J THORAC DIS, V13, DOI 10.21037/jtd-20-1717 Wang XN, 2023, JAMA NETW OPEN, V6, DOI 10.1001/jamanetworkopen.2023.11966 Wilcox NS, 2024, NAT REV CARDIOL, V21, P617, DOI 10.1038/s41569-024-01017-x Wu YL, 2024, NEW ENGL J MED, V390, P1265, DOI 10.1056/NEJMoa2310532 Wu YL, 2020, NEW ENGL J MED, V383, P1711, DOI 10.1056/NEJMoa2027071 Yang Q, 2020, ARQ BRAS CARDIOL, V114, P1004, DOI 10.36660/abc.20190201 Yun JP, 2021, JACC-CARDIOONCOL, V3, P221, DOI 10.1016/j.jaccao.2021.03.006 Zhang SC, 2024, J MED IMAG RADIAT ON, V68, P950, DOI 10.1111/1754-9485.13716 Zhang SS, 2024, J THORAC ONCOL, V19, P80, DOI 10.1016/j.jtho.2023.09.004 NR 140 TC 6 Z9 6 U1 1 U2 1 PU ELSEVIER PI AMSTERDAM PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS SN 2666-0873 J9 JACC-CARDIOONCOL JI JACC-Cardiooncol. PD JUN PY 2025 VL 7 IS 4 BP 325 EP 344 DI 10.1016/j.jaccao.2025.05.003 EA JUN 2025 PG 20 WC Oncology; Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Cardiovascular System & Cardiology GA 4BW4O UT WOS:001514324400001 PM 40537184 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Mulder, FI Horváth-Puhó, E van Es, N Pedersen, L Büller, HR Cronin-Fenton, D Christiansen, CF Botker, HE Bhaskaran, K Sorensen, HT AF Mulder, Frits I. Horvath-Puho, Erzsebet van Es, Nick Pedersen, Lars Buller, Harry R. Cronin-Fenton, Deirdre Christiansen, Christian F. Botker, Hans Erik Bhaskaran, Krishnan Sorensen, Henrik T. TI Risk of Cardiovascular Disease in Cancer Survivors after Systemic Treatment A Population-Based Cohort Study SO JACC: CARDIOONCOLOGY LA English DT Article DE acute coronary syndrome; arrhythmia; cancer survivorship; cancer; cohort study; epidemiology; kidney failure; myocardial infarction; neoplasm; stroke; venous thromboembolism ID AMERICAN SOCIETY; ADULT CANCERS; DANISH AB BACKGROUND Patients face an increased risk of cardiovascular disease shortly after a cancer diagnosis, but evidence on long-term risk among cancer survivors remains limited. OBJECTIVES In this study the authors sought to estimate the risk of cardiovascular disease in cancer survivors previously treated with systemic cancer therapy. METHODS Using Danish population-based registries, we identified individuals who had received systemic cancer treatment and were free of both cancer and treatment 3 years after diagnosis (index date). For each cancer survivor, 5 cancer-free individuals from the general population were randomly selected, matched by birth year, sex, and calendar year. Participants were followed from the index date for up to 5 years. HRs were estimated using Cox regression, adjusted for potential confounders. RESULTS Compared with 457,035 matched individuals, the 91,407 cancer survivors had an increased risk of heart failure or cardiomyopathy (HR: 1.08; 95% CI: 1.02-1.15), venous thromboembolism (HR: 1.50; 95% CI: 1.41-1.61), pericarditis, endocarditis, or myocarditis (HR: 1.30; 95% CI: 1.11-1.52), and kidney failure (HR: 1.17; 95% CI: 1.10-1.25), but not of ischemic heart disease, stroke, or atrial fibrillation. Estimates varied substantially by cancer type and treatment agent. For example, venous thromboembolism risk was consistently increased across nearly all cancer types, whereas hypertension risk was elevated for none. Ischemic heart disease risk was increased only among lung cancer survivors. Stroke was associated with platinum compounds but not with other systemic treatments. CONCLUSIONS Several cardiovascular disease risks were elevated among cancer survivors, with substantial variation by cancer type and treatment. (JACC CardioOncol. 2025;7:360-378) (c) 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). C1 [Mulder, Frits I.; van Es, Nick; Buller, Harry R.] Univ Amsterdam, Dept Vasc Med, Amsterdam Cardiovasc Sci, Amsterdam UMC, Meibergdreef 9, NL-105 AZ Amsterdam, Netherlands. [Mulder, Frits I.] Tergooi Hosp, Dept Internal Med, Hilversum, Netherlands. [Mulder, Frits I.; Horvath-Puho, Erzsebet; Pedersen, Lars; Cronin-Fenton, Deirdre; Christiansen, Christian F.; Sorensen, Henrik T.] Aarhus Univ Hosp, Dept Clin Epidemiol, Aarhus, Denmark. [Horvath-Puho, Erzsebet; Pedersen, Lars; Cronin-Fenton, Deirdre; Christiansen, Christian F.; Sorensen, Henrik T.] Aarhus Univ, Dept Clin Med, Aarhus, Denmark. [Botker, Hans Erik] Aarhus Univ Hosp, Dept Cardiol, Aarhus, Denmark. [Bhaskaran, Krishnan] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London, England. C3 University of Amsterdam; Aarhus University; Aarhus University; Aarhus University; University of London; London School of Hygiene & Tropical Medicine RP Mulder, FI (corresponding author), Univ Amsterdam, Dept Vasc Med, Amsterdam Cardiovasc Sci, Amsterdam UMC, Meibergdreef 9, NL-105 AZ Amsterdam, Netherlands. EM f.i.mulder@amsterdamumc.nl RI Christiansen, Christian/B-5870-2014; Bøtker, Hans Erik/AFB-5630-2022; Bhaskaran, Krishnan/HSF-7747-2023; Pedersen, Lars/AAX-4382-2021; Toft Sørensen, Henrik/Z-6181-2019 OI Christiansen, Christian/0000-0002-0727-953X; Bøtker, Hans Erik/0000-0001-6358-8962; Bhaskaran, Krishnan/0000-0001-5364-8757; Toft Sørensen, Henrik/0000-0003-4299-7040; Horváth-Puhó, Erzsébet/0000-0002-3594-2212 FU Cardiovascular Sciences MD/Postdoc grant; Welcome Senior Research Fellowship [220283/Z/20/Z] FX This study was supported by a research grant from the Karen Elise Jensen Foundation. Dr van Es is supported by an Amsterdam Cardiovascular Sciences MD/Postdoc grant. Dr Bhaskaran is supported by a Welcome Senior Research Fellowship (220283/Z/20/Z) . The Department of Clinical Epidemiology at Aarhus University receives funding for other studies from companies in the form of research grants to (and administered by) Aarhus University. None of these studies has any relation to the present study. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.r Cardiovascular Sciences MD/Postdoc grant. Dr Bhaskaran is supported by a Welcome Senior Research Fellowship (220283/Z/20/Z) . The Department of Clinical Epidemiology at Aarhus University receives funding for other studies from companies in the form of research grants to (and administered by) Aarhus University. None of these studies has any relation to the present study. The authors have reported that they have no relationships relevant to the contents of this paper to disclose. CR Akinyemiju TF, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1282-2 [Anonymous], 2021, Guidelines for ATC classification and DDD assignment 2022 Armenian SH, 2017, J CLIN ONCOL, V35, P893, DOI 10.1200/JCO.2016.70.5400 Ayanian JZ, 2006, J CLIN ONCOL, V24, P5149, DOI 10.1200/JCO.2006.06.7207 Bell CF, 2023, JACC-CARDIOONCOL, V5, P431, DOI 10.1016/j.jaccao.2023.01.010 Curigliano G, 2012, ANN ONCOL, V23, P155, DOI 10.1093/annonc/mds293 Denlinger C, 2021, Cardiovascular Toxicity in Cancer Survivors: Current Guidelines and Future Directions Gjerstorff ML, 2011, SCAND J PUBLIC HEALT, V39, P42, DOI 10.1177/1403494810393562 Heide-Jorgensen U, 2018, CLIN EPIDEMIOL, V10, P1325, DOI 10.2147/CLEP.S164456 Kjaer TK, 2019, JAMA ONCOL, V5, P537, DOI 10.1001/jamaoncol.2018.7192 Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565 Mohammed T, 2021, CARDIO-ONCOLOGY, V7, DOI 10.1186/s40959-021-00101-2 Mulder FI, 2021, BLOOD, V137, P1959, DOI 10.1182/blood.2020007338 Mulder FI, 2021, JACC-CARDIOONCOL, V3, P205, DOI 10.1016/j.jaccao.2021.02.007 Plana JC, 2014, J AM SOC ECHOCARDIOG, V27, P911, DOI [10.1016/j.echo.2014.07.012, 10.1093/ehjci/jeu192] Pottegård A, 2017, INT J EPIDEMIOL, V46, P798, DOI 10.1093/ije/dyw213 Schmidt M, 2019, CLIN EPIDEMIOL, V11, P563, DOI 10.2147/CLEP.S179083 Schmidt M, 2015, CLIN EPIDEMIOL, V7, P449, DOI 10.2147/CLEP.S91125 Schmidt M, 2014, EUR J EPIDEMIOL, V29, P541, DOI 10.1007/s10654-014-9930-3 Shapiro CL, 2018, NEW ENGL J MED, V379, P2438, DOI 10.1056/NEJMra1712502 Shelburne N, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju232 Strongman H, 2019, LANCET, V394, P1041, DOI 10.1016/S0140-6736(19)31674-5 Sundboll J, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012832 Totzeck M, 2019, INT J CARDIOL, V280, P163, DOI 10.1016/j.ijcard.2019.01.038 Wilcox NS, 2024, NAT REV CARDIOL, V21, P617, DOI 10.1038/s41569-024-01017-x Zamorano J, 2016, EUR HEART J-CARD IMG, V17, P9, DOI 10.1093/ehjci/jev282 NR 26 TC 9 Z9 9 U1 0 U2 0 PU ELSEVIER PI AMSTERDAM PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS SN 2666-0873 J9 JACC-CARDIOONCOL JI JACC-Cardiooncol. PD JUN PY 2025 VL 7 IS 4 BP 360 EP 378 DI 10.1016/j.jaccao.2025.03.008 EA JUN 2025 PG 19 WC Oncology; Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Cardiovascular System & Cardiology GA 4BW4O UT WOS:001514324400004 PM 40537185 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Forster, C Chriqui, LE Abdelnour-Berchtold, E Zellweger, M Perentes, JY Krueger, T Gonzalez, M AF Forster, Celine Chriqui, Louis-Emmanuel Abdelnour-Berchtold, Etienne Zellweger, Matthieu Perentes, Jean Yannis Krueger, Thorsten Gonzalez, Michel TI Repeated Anatomical Pulmonary Resection for Second Primary Nonsmall-Cell Lung Cancer: Safety and Short-Term Outcomes SO THORACIC CANCER LA English DT Article DE lobectomy; nonsmall-cell lung cancer; segmentectomy; VATS ID ASSISTED THORACOSCOPIC SURGERY; LOBECTOMY AB Background: Repeated anatomical pulmonary resections in second primary nonsmall-cell lung cancer (NSCLC) pose significant challenges due to prior surgery. This study evaluates the feasibility and short-term outcomes of repeated anatomical pulmonary resections for second primary NSCLC. Method: We retrospectively reviewed all consecutive cases of repeated anatomical pulmonary resections for second primary NSCLC performed in our institution from January 2014 to December 2023. Results: A total of 55 patients (median age 68 years; interquartile range [IQR]: 61.5-72) underwent repeated anatomical pulmonary resections for second primary NSCLC. Adenocarcinoma predominated in both primary (78.2%) and secondary (76.4%) cases. Video-assisted thoracoscopy (VATS) approach was used in 94.5% and 96.4% for first and repeated resection, respectively (p = 0.647). The extent of pulmonary resection differed between first and repeated resection, with a predominance of lobectomy during first resection (56.4%) and segmentectomy during repeated resection (85.5%, p < 0.001). We did not observe any significant difference in postoperative overall morbidity after first and repeated resection (23.6% vs. 40%, p = 0.065). However, there was an increased incidence of atrial fibrillation (16.4% vs. 0%) and prolonged air leak (> 5 days) after repeated resection (25.5% vs. 5.5%, p = 0.008). The median length of hospital stay was similar after first and repeated resection (5 vs. 5 days, p = 0.089). The three-year overall survival (OS) was 73% after first resection and 87% after repeated resection. Overall disease recurrence rate was not statistically different between first and repeated resection (1.8% vs. 3.6%, p = 0.558). Conclusion: Our series demonstrated that second primary NSCLC can be safely managed by VATS segmentectomy, yielding favorable short-term survival and low recurrence rates. C1 [Forster, Celine] Ctr Hosp Valais Romand CHVR, Dept Thorac Surg, Sion, Switzerland. [Chriqui, Louis-Emmanuel; Abdelnour-Berchtold, Etienne; Zellweger, Matthieu; Perentes, Jean Yannis; Krueger, Thorsten; Gonzalez, Michel] Lausanne Univ Hosp CHUV, Dept Thorac Surg, Lausanne, Switzerland. [Perentes, Jean Yannis; Krueger, Thorsten; Gonzalez, Michel] Univ Lausanne UNIL, Fac Biol & Med, Lausanne, Switzerland. C3 University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne RP Forster, C (corresponding author), Ctr Hosp Valais Romand CHVR, Dept Thorac Surg, Sion, Switzerland. EM celine.forster@hopitalvs.ch RI ; Krueger, Thorsten/AAK-1780-2021 OI Forster, Céline/0009-0006-4902-913X; CR Abid W, 2021, EUR J CARDIO-THORAC, V59, P1287, DOI 10.1093/ejcts/ezaa438 Altorki N, 2023, NEW ENGL J MED, V388, P489, DOI 10.1056/NEJMoa2212083 Batchelor TJP, 2019, EUR J CARDIO-THORAC, V55, P91, DOI 10.1093/ejcts/ezy301 Chen L, 2023, THORAC CANCER, V14, P298, DOI 10.1111/1759-7714.14755 Falcoz PE, 2016, EUR J CARDIO-THORAC, V49, P602, DOI 10.1093/ejcts/ezv154 Fink-Neuboeck N, 2020, CLIN LUNG CANCER, V21, P333, DOI 10.1016/j.cllc.2020.02.011 Forster C, 2020, J CARDIOTHOR VASC AN, V34, P1858, DOI 10.1053/j.jvca.2020.01.038 Hamaji M, 2013, J THORAC CARDIOV SUR, V145, P683, DOI 10.1016/j.jtcvs.2012.12.051 Hattori A, 2021, J THORAC CARDIOV SUR, V162, P1389, DOI 10.1016/j.jtcvs.2020.06.124 Jensen SO, 2024, J THORAC ONCOL, V19, P1415, DOI 10.1016/j.jtho.2024.07.014 Kozower BD, 2013, CHEST, V143, pE369, DOI 10.1378/chest.12-2362 Lim E, 2022, HEALTH TECHNOL ASSES, V26, DOI 10.3310/THBQ1793 MARTINI N, 1975, J THORAC CARDIOV SUR, V70, P606 Muranishi Y, 2018, INTERACT CARDIOV TH, V26, P631, DOI 10.1093/icvts/ivx389 Okazaki M, 2023, EUR J CARDIO-THORAC, V63, DOI 10.1093/ejcts/ezad048 Saji H, 2022, LANCET, V399, P1607, DOI 10.1016/S0140-6736(21)02333-3 Sato S, 2021, INTERACT CARDIOV TH, V32, P896, DOI 10.1093/icvts/ivab025 Sato S, 2020, SURG TODAY, V50, P1452, DOI 10.1007/s00595-020-02038-y Soro-García J, 2023, ARCH BRONCONEUMOL, V59, P743, DOI 10.1016/j.arbres.2023.07.027 Stinchcombe TE, 2024, J CLIN ONCOL, V42, DOI 10.1200/JCO.23.01306 Thakur MK, 2018, J THORAC ONCOL, V13, P46, DOI 10.1016/j.jtho.2017.09.1964 Zhao J, 2023, BMC SURG, V23, DOI 10.1186/s12893-023-02003-9 Zhou JL, 2024, CANCER EPIDEMIOL, V93, DOI 10.1016/j.canep.2024.102693 NR 23 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1759-7706 EI 1759-7714 J9 THORAC CANCER JI Thorac. Cancer PD JUN PY 2025 VL 16 IS 12 AR e70116 DI 10.1111/1759-7714.70116 PG 8 WC Oncology; Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Respiratory System GA 4II6H UT WOS:001518713500010 PM 40563142 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Howard, JM Saha, SP AF Howard, Jordan M. Saha, Sibu P. TI Surgical Management of Primary Pulmonary Carcinoid Tumors SO SOUTHERN MEDICAL JOURNAL LA English DT Article DE postoperative complications; pulmonary carcinoid tumor; survival rate; thoracic surgery ID SUBLOBAR; LUNG AB Objective: Primary pulmonary carcinoid tumors constitute 1% to 2% of primary lung neoplasms, with limited surgical outcome data due to the rarity of these neoplasms. The aim of our study was to review the complications and long-term outcomes following surgery for primary pulmonary carcinoid neoplasms. Methods: With institutional review board approval, the charts of patients with lung neoplasms from 2000-2022 were reviewed. In total, 605 total charts were reviewed, with 535 excluded for not having a primary pulmonary carcinoid tumor or not receiving surgical treatment. Typical, atypical, and cumulative survival rates were calculated along with complications. Results: Major presenting symptoms included 31% (n = 22) persistent cough, 30% (n = 21) dyspnea, 9% (n = 6) hemoptysis, and 7% (n = 5) constitutional symptoms (fever, weight loss, and/or night sweats). Fifty-one percent (n = 36) were found incidentally, and 14% (n = 10) had unknown presentation. There were complications in 26 patients (41%). Minor complications included chest wall pain (n = 6), chest tube air leak (n = 4), dyspnea (n = 3), atelectasis (n = 2), ileus (n = 2), postpneumonectomy syndrome (n = 1), and chronic cough (n = 1). Serious complications included atrial fibrillation (n = 2), respiratory failure (n = 1), hemothorax (n = 1), hypovolemic shock (n = 1), and intraoperative tension pneumothorax (n = 1). No patients died during surgery or secondary to any complications of surgery. Outcomes: The cumulative 2-year survival rate was 98.5%, and the cumulative 5-year survival rate was 96.3%. There were seven total deaths during the study period, but the cause of death was not reported. Conclusions: This study confirms that resection of primary pulmonary carcinoid tumors is relatively low risk, with excellent long-term survival rates. C1 [Howard, Jordan M.] Univ Kentucky, Coll Med, Lexington, KY USA. [Saha, Sibu P.] Univ Kentucky, Div Cardiothorac Surg, Lexington, KY USA. C3 University of Kentucky; University of Kentucky RP Howard, JM (corresponding author), 1120 W Michigan St Gatch Hall Suite 630, Indianapolis, IN 46202 USA. EM reprintsolutions@wolterskluwer.com; ssaha2@email.uky.edu FU National Center for Advancing Translational Sciences, National Institutes of Health [UL1TR001998] FX Association's 70th annual meeting, Orlando, Florida, November 2-5, 2023. J.M.H. discloses the following: The authors used the Center for Clinical and Translation Sciences (CCTS) at our institution to obtain a list of patients to use in our study. The CCTS receives funding through the National Center for Advancing Translational Sciences, National Institutes of Health grant no. UL1TR001998 and requested that we list the grant in our paper. The authors did not receive any monies/funding from the grant. S.P.S. did not report any financial relationships or conflicts of interest. CR Baudin E, 2021, ANN ONCOL, V32, P439, DOI 10.1016/j.annonc.2021.01.003 Bernard A, 2023, BMJ OPEN, V13, DOI 10.1136/bmjopen-2023-075463 Dogru MV, 2021, ACTA CHIR BELG, V121, P301, DOI 10.1080/00015458.2020.1753147 Fox M, 2013, AM J SURG, V205, P200, DOI 10.1016/j.amjsurg.2012.05.008 Goldstraw P, 2016, J THORAC ONCOL, V11, P39, DOI 10.1016/j.jtho.2015.09.009 Herde RF, 2018, AM J CLIN ONCOL-CANC, V41, P24, DOI 10.1097/COC.0000000000000221 Kasprzyk M, 2017, KARDIOCHIR TORAKOCHI, V14, P225, DOI 10.5114/kitp.2017.72225 Kneuertz PJ, 2018, ANN THORAC SURG, V106, P981, DOI 10.1016/j.athoracsur.2018.05.044 Modlin IM, 2003, CANCER-AM CANCER SOC, V97, P934, DOI 10.1002/cncr.11105 Randhawa S, 2021, THORAC SURG CLIN, V31, P469, DOI 10.1016/j.thorsurg.2021.05.005 Reuling EMBP, 2019, LUNG CANCER, V134, P85, DOI 10.1016/j.lungcan.2019.04.016 Saha SP., 1996, Contemp Surg, V49, P23 Strosberg J, 2017, NEW ENGL J MED, V376, P125, DOI 10.1056/NEJMoa1607427 Thakur S, 2021, ASIAN CARD THORAC AN, V29, P532, DOI 10.1177/02184923211010090 Yoon JY, 2019, J THORAC ONCOL, V14, P184, DOI 10.1016/j.jtho.2018.10.166 NR 15 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0038-4348 EI 1541-8243 J9 SOUTH MED J JI South.Med.J. PD JUN PY 2025 VL 118 IS 6 BP 307 EP 312 DI 10.14423/SMJ.0000000000001840 PG 6 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA 2VD7G UT WOS:001492065000009 PM 40456541 DA 2026-04-17 ER PT J AU Zhou, ZQ Chen, YJ Xu, H AF Zhou, Zheng-qing Chen, Yi-jing Xu, Hua TI Does perioperative electroacupuncture reduce the incidence of atrial fibrillation after lung cancer surgery? A randomized, controlled, assessor-blinded clinical trial SO FRONTIERS IN MEDICINE LA English DT Article DE postoperative atrial fibrillation; clinical trial; Visual Analog Scale; NT-proBNP; interleukin-6 ID RISK-FACTORS AB Background Atrial fibrillation (AF) is a common complication of lung cancer surgery, with high incidence during the perioperative period. Electroacupuncture is considered a potential complementary therapy for the management of AF. We aimed to evaluate the preventive effects of perioperative electroacupuncture on new-onset AF in patients undergoing lung cancer surgery.Methods This was a single-center, randomized, controlled, assessor-blinded clinical trial. We randomly divided 90 patients with cancer who underwent lung surgery into an electroacupuncture group (EA) and a sham electroacupuncture group (SA). Four acupuncture points on the surgical side were selected for the intervention. The EA group was needled with an EA instrument using sparse and dense waves alternating at 2/100 Hz. Electroacupuncture treatments were administered thrice. The incidence of newly developed AF within 72 h after surgery was used as the main indicator, and the Visual Analog Scale, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and blood levels of Interleukin-6 (IL-6) were used as secondary outcomes.Results The EA group showed a 14.6% absolute risk reduction in POAF incidence compared to the SA group (P = 0.013). NT-proBNP level (MD: +32.57 pg/mL, 95% CI: 5.8-59.3, P = 0.018) and interleukin-6 level (MD: +9.29 pg/mL, 95% CI: 1.45-17.1, P = 0.021) increased significantly in the SA group compared to the EA group at 72h. No significant differences were observed in VAS scores (12 h: MD -0.27, 95% CI: -0.8 to 0.2, P = 0.572; 72h: MD -0.50, 95% CI: -0.4 to 0.3, P = 0.238).Conclusion This study confirmed that electroacupuncture reduced the incidence of new-onset AF in the perioperative period, providing a possible complementary therapy for the prevention of arrhythmia after lung cancer surgery.Clinical trial registration https://www.chictr.org.cn/showproj.html?proj=127920, identifier ChiCTR2100047499. C1 [Zhou, Zheng-qing; Chen, Yi-jing; Xu, Hua] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western M, Dept Anesthesia, Shanghai, Peoples R China. C3 Shanghai University of Traditional Chinese Medicine RP Chen, YJ; Xu, H (corresponding author), Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western M, Dept Anesthesia, Shanghai, Peoples R China. EM ChenYijing2020@126.com; huaxhappy@yeah.net FU Clinical Research Project of Health Industry by Shanghai Health Commission [202040310] FX The author(s) declare that financial support was received for the research and/or publication of this article. This research was funded by Clinical Research Project of Health Industry was established by Shanghai Health Commission (No. 202040310). CR Alam N, 2007, ANN THORAC SURG, V84, P1085, DOI 10.1016/j.athoracsur.2007.05.053 Crispi V, 2022, POSTGRAD MED J, V98, P177, DOI 10.1136/postgradmedj-2020-138904 Fan Wen-Chao, 2012, Zhongguo Zhen Jiu, V32, P715 Feingold KL, 2023, JTCVS OPEN, V16, P321, DOI 10.1016/j.xjon.2023.05.010 Furak J, 2022, FRONT SURG, V9, DOI 10.3389/fsurg.2022.883322 Gaudino M, 2023, EUR HEART J, V44, P1020, DOI 10.1093/eurheartj/ehad019 Hindricks Gerhard, 2021, Eur Heart J, V42, P373, DOI 10.1093/eurheartj/ehaa612 Jia XY, 2021, ANATOL J CARDIOL, V25, P872, DOI 10.5152/AnatolJCardiol.2021.69299 Lapar DJ, 2014, ANN THORAC SURG, V98, P527, DOI 10.1016/j.athoracsur.2014.03.039 Lee JM, 2022, MEDICINA-LITHUANIA, V58, DOI 10.3390/medicina58010041 Li JL, 2021, CARDIOVASC DIAGN THE, V11, P1067, DOI 10.21037/cdt-21-201 Li YB, 2022, EUR J MED RES, V27, DOI 10.1186/s40001-022-00738-4 Liu YQ, 2024, MEDICINE, V103, DOI 10.1097/MD.0000000000040474 Lombardi F, 2012, WORLD J CARDIOL, V4, P60, DOI 10.4330/wjc.v4.i3.60 Luo X, 2025, BMC ANESTHESIOL, V25, DOI 10.1186/s12871-025-03043-9 Montagne F, 2021, CANCERS, V13, DOI 10.3390/cancers13153711 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Su Y, 2022, NEUROMODULATION, V27, P1196, DOI 10.1016/j.neurom.2022.11.005 Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660 van Boven WJ, 2021, LANCET, V398, P2052, DOI 10.1016/S0140-6736(21)02435-1 Van Gelder IC, 2024, EUR HEART J, V45, P3314, DOI 10.1093/eurheartj/ehae176 Wang WY, 2025, HEART, V111, P109, DOI 10.1136/heartjnl-2024-324685 Wang XM, 2022, EUR J CLIN PHARMACOL, V78, P1777, DOI 10.1007/s00228-022-03383-2 NR 23 TC 2 Z9 2 U1 2 U2 2 PU FRONTIERS MEDIA SA PI LAUSANNE PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND EI 2296-858X J9 FRONT MED-LAUSANNE JI Front. Med. PD MAY 12 PY 2025 VL 12 AR 1565359 DI 10.3389/fmed.2025.1565359 PG 8 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA 2YJ7T UT WOS:001494265000001 PM 40421295 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Chen, XY Wu, Y Zheng, XF AF Chen, Xiaoyu Wu, Yan Zheng, Xiaofang TI Postoperative arrhythmias in geriatric lung cancer patients undergoing thoracoscopic surgery: an exploration of prevalence and influencing factors SO PERIOPERATIVE MEDICINE LA English DT Article DE Arrhythmias; Geriatric; Lung cancer; Surgery; Treatment; Care ID ATRIAL-FIBRILLATION; CARDIAC-SURGERY; PREDICTION AB Background Arrhythmias are a frequent complication in the postoperative period following surgical procedures. This study aims to investigate the incidence and contributing factors of arrhythmias in elderly patients with lung cancer who have undergone thoracoscopic surgery, thereby providing scientific evidence to support clinical treatment and nursing care. Methods This retrospective cohort study included elderly patients diagnosed with lung cancer who underwent treatment at our hospital between June 1, 2022, and October 31, 2024. Patients were categorized into two groups based on the development of postoperative arrhythmias following thoracoscopic surgery: the arrhythmia group and the non-arrhythmia group. A comparative analysis of the clinical data was conducted between these two groups. Results A total of 208 patients were enrolled, with an incidence of postoperative arrhythmias of 19.71% (41/208). Logistic regression analysis identified age >= 70 years (OR = 2.586, 95% CI: 1.805-3.221), hypertension (OR = 2.761, 95% CI: 2.103-3.588), history of smoking (OR = 2.070, 95% CI: 1.741-2.446), TNM stage II (OR = 3.181, 95% CI: 2.842-3.690), postoperative pulmonary infection (OR = 2.122, 95% CI: 1.836-2.690), and postoperative constipation (OR = 2.495, 95% CI: 1.988-3.072) as independent risk factors for postoperative arrhythmias (all p < 0.05). Conclusion The incidence of postoperative arrhythmias in elderly patients with lung cancer following thoracoscopic surgery is relatively high. Targeted interventions addressing the identified risk factors are essential to mitigate the risk of postoperative arrhythmias. C1 [Chen, Xiaoyu; Wu, Yan; Zheng, Xiaofang] Fujian Med Univ, Affiliated Hosp 1, Nursing Dept, Fuzhou, Fujian, Peoples R China. C3 Fujian Medical University RP Wu, Y (corresponding author), Fujian Med Univ, Affiliated Hosp 1, Nursing Dept, Fuzhou, Fujian, Peoples R China. EM mvh7k9@sina.com RI Zheng, Xiaofang/ABB-4402-2021 CR Benker M, 2022, GEN THORAC CARDIOVAS, V70, P248, DOI 10.1007/s11748-021-01710-5 Chandy M, 2024, CARDIOVASC TOXICOL, V24, P435, DOI 10.1007/s12012-024-09850-9 Chen YY, 2024, LANCET PUBLIC HEALTH, V9, pe1005, DOI 10.1016/S2468-2667(24)00043-4 Cho JH, 2024, JAMA NETW OPEN, V7, DOI 10.1001/jamanetworkopen.2024.42639 El-Sherbini AH, 2023, AM J CARDIOL, V209, P66, DOI 10.1016/j.amjcard.2023.09.079 Elsebaie Abdelrahman, 2024, Port J Card Thorac Vasc Surg, V31, P41, DOI 10.48729/pjctvs.403 Florez N, 2024, CLIN LUNG CANCER, V25, P1, DOI 10.1016/j.cllc.2023.10.007 Fukui K, 2019, SURG CASE REP, V5, DOI 10.1186/s40792-019-0686-6 Gaalema DE, 2024, PREV MED, V188, DOI 10.1016/j.ypmed.2024.108013 Ganea G, 2023, LIFE-BASEL, V13, DOI 10.3390/life13122278 Gong D., 2022, J Cardiopulm Vasc Dis, V41, P903 Ishida M, 2024, J ATHEROSCLER THROMB, V31, P189, DOI 10.5551/jat.RV22015 Iwata T, 2016, SURG TODAY, V46, P877, DOI 10.1007/s00595-015-1258-4 Jiang SJ, 2023, FRONT CARDIOVASC MED, V10, DOI 10.3389/fcvm.2023.1273547 [蒋怡佳 Jiang Yijia], 2023, [中华胸心血管外科杂志, Chinese Journal of Thoracic and Cardiovascular Surgery], V39, P352 Kashiwagi M, 2023, SURG TODAY, V53, P1139, DOI 10.1007/s00595-023-02670-4 King J, 2023, J GERIATR ONCOL, V14, DOI 10.1016/j.jgo.2023.101635 Kratzer TB, 2024, CANCER-AM CANCER SOC, V130, P1330, DOI 10.1002/cncr.35128 Li DJ, 2024, INT J SURG, V110, P1620, DOI 10.1097/JS9.0000000000000996 Liang G., 2022, Adv Cardiovasc Med, V43, P870 Liu H., 2024, China Pharmaceutical Herald, V21, P128 Lu G., 2014, China J Gerontol, V11, P3 Luo YH, 2021, J THORAC ONCOL, V16, P519, DOI 10.1016/j.jtho.2020.10.155 Mao B., 2023, J Zhengzhou Univ, V58, P200 Mattioni G, 2023, J ROBOT SURG, V17, P797, DOI 10.1007/s11701-022-01512-8 O'Brien B, 2024, JAMA-J AM MED ASSOC, V332, P979, DOI 10.1001/jama.2024.17888 Semeraro GC, 2021, CANCERS, V13, DOI 10.3390/cancers13164012 Shen Y., 2021, China J Clin, V49, P1210 Shi JK, 2024, J AM HEART ASSOC, V13, DOI 10.1161/JAHA.124.036202 Suero OR, 2024, J THORAC DIS, V16, P1503, DOI 10.21037/jtd-23-1626 Tohidinezhad F, 2022, CLIN TRANSL RAD ONCO, V33, P134, DOI 10.1016/j.ctro.2022.02.007 Tong CY, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-20-5035 [王前伟 Wang Qianwei], 2023, [中华胸心血管外科杂志, Chinese Journal of Thoracic and Cardiovascular Surgery], V39, P101 Wang Z., 2013, Chinese J Exp Surg, V30, P3 Wilcox NS, 2024, NAT REV CARDIOL, V21, P617, DOI 10.1038/s41569-024-01017-x Wu FY, 2021, CURR OPIN ONCOL, V33, P40, DOI 10.1097/CCO.0000000000000703 Xiao Y., 2019, Mod Oncol Med, V27, P2864 Xue J., 2022, Pract J Cardiovas Pul Vasc Dis, V30, P6 Yim J, 2024, JACC-CLIN ELECTROPHY, V10, P1720, DOI 10.1016/j.jacep.2024.06.009 Zhang J., 2022, J Cap Med Univ, V43, P564 Zhao J., 2019, Chinese J Thorac Cardiovasc Surg, V35, P3 Zhou RX, 2024, J THORAC ONCOL, V19, P883, DOI 10.1016/j.jtho.2024.01.014 NR 42 TC 1 Z9 1 U1 2 U2 2 PU BMC PI LONDON PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND EI 2047-0525 J9 PERIOPER MED-LONDON JI Perioperative Med PD MAY 9 PY 2025 VL 14 IS 1 AR 55 DI 10.1186/s13741-025-00538-4 PG 8 WC Anesthesiology; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Anesthesiology; Surgery GA 2MA2W UT WOS:001485852900001 PM 40346666 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Zhu, SL Fu, K Li, SJ Yang, C Pan, C Wang, XP Wang, F Yu, XY To, KKW Fu, LW AF Zhu, Shuangli Fu, Kai Li, Sijia Yang, Chuan Pan, Can Wang, Xueping Wang, Fang Yu, Xiyong To, Kenneth Kin Wah Fu, Liwu TI Cardiotoxicity of small-molecule kinase inhibitors in cancer therapy SO EXPERIMENTAL HEMATOLOGY & ONCOLOGY LA English DT Review DE Cancer; Small-molecule kinase inhibitors; Cardiotoxicity ID CHRONIC LYMPHOCYTIC-LEUKEMIA; CELL LUNG-CANCER; GASTROINTESTINAL STROMAL TUMORS; CONGESTIVE-HEART-FAILURE; PHASE-III TRIAL; ATRIAL-FIBRILLATION; IMATINIB MESYLATE; DOUBLE-BLIND; VENTRICULAR-ARRHYTHMIAS; CARDIAC DYSFUNCTION AB Cancer is one of the leading causes of death worldwide. Recent advances in precision oncology have enabled many specific cancer patient populations to respond well and achieve longer survival with small-molecule kinase inhibitors, which have become a new therapeutic strategy for tumors. Since 2001, the Food and Drug Administration has approved 108 and 63 new anticancer drugs for treating solid tumors and hematological malignancies, respectively, 89 of which belong to the large group of small-molecule kinase inhibitors (SMKIs). Compared to conventional chemotherapeutic agents such as cyclophosphamide, doxorubicin, and 5-FU, SMKIs offer better efficacy with fewer toxic side effects. Nevertheless, with the development of more novel SMKIs and their wider clinical application to a larger population of cancer patients, variable degrees of cardiotoxic adverse events have emerged for some SMKIs during cancer therapy. This review comprehensively summarizes the most updated progress in the cardiotoxicity of SMKIs in cancer therapy and discusses the new findings and mechanisms, which will provide emerging strategies for the prevention of cardiotoxicity caused by small molecule targeted drugs and the design of the next generation of low cardiotoxicity targeted drugs. C1 [Zhu, Shuangli; Fu, Kai; Li, Sijia; Yang, Chuan; Pan, Can; Wang, Xueping; Wang, Fang; Fu, Liwu] Sun Yat Sen Univ, Guangdong Prov Clin Res Ctr Canc, Canc Ctr, State Key Lab Oncol South China,Collaborat Innovat, Guangzhou 510060, Guangdong, Peoples R China. [Yu, Xiyong] Guangzhou Med Univ, Key Lab Mol Target & Clin Pharmacol, Guangzhou 511436, Peoples R China. [Yu, Xiyong] Guangzhou Med Univ, Sch Pharmaceut Sci, State Key Lab Resp Dis, Guangzhou 511436, Peoples R China. [Yu, Xiyong] Guangzhou Med Univ, Affiliated Hosp 5, Guangzhou 511436, Peoples R China. [To, Kenneth Kin Wah] Chinese Univ Hong Kong, Sch Pharm, Hong Kong 999077, Peoples R China. C3 Sun Yat Sen University; State Key Lab Oncology South China; Guangzhou Medical University; State Key Laboratory of Respiratory Disease; Guangzhou Medical University; Guangzhou Medical University; Chinese University of Hong Kong RP Fu, LW (corresponding author), Sun Yat Sen Univ, Guangdong Prov Clin Res Ctr Canc, Canc Ctr, State Key Lab Oncol South China,Collaborat Innovat, Guangzhou 510060, Guangdong, Peoples R China. EM zhusl@sysucc.org.cn; fukai@sysucc.org.cn; lisj0414@163.com; yangchuan@sysucc.org.cn; pancan@sysu.org.cn; Wangxuepz@sysucc.org.cn; wangf@sysucc.org.cn; yuxycn@aliyun.com; kennethto@cuhk.edu.hk; fulw@mail.sysu.edu.cn RI To, Kenneth/M-4500-2013 FU National Natural Science Foundation of China [82073882, U21A20421]; Key Project of Science Technology Program of Guangzhou [2023B03J0029] FX This work was supported by Grants from the National Natural Science Foundation of China (No.82073882, U21A20421) and the Key Project of Science Technology Program of Guangzhou (No.2023B03J0029). CR Abdel-Qadir H, 2021, J CLIN ONCOL, V39, P3453, DOI 10.1200/JCO.21.00693 Alanazi WA, 2022, SAUDI PHARM J, V30, P1159, DOI 10.1016/j.jsps.2022.06.020 AlAsmari AF, 2020, SAUDI PHARM J, V28, P509, DOI 10.1016/j.jsps.2020.03.002 Alhoshani A, 2020, CHEM RES TOXICOL, V33, P1719, DOI 10.1021/acs.chemrestox.0c00005 Anand K, 2019, JACC-CARDIOONCOL, V1, P172, DOI 10.1016/j.jaccao.2019.10.006 [Anonymous], 2022, National Comprehensive Cancer, N Version 1 Atallah E, 2007, BLOOD, V110, P1233, DOI 10.1182/blood-2007-01-070144 Awan FT, 2022, BLOOD ADV, V6, P5516, DOI 10.1182/bloodadvances.2022007938 Awan FT, 2019, BLOOD ADV, V3, P1553, DOI 10.1182/bloodadvances.2018030007 Ayala-Aguilera CC, 2022, J MED CHEM, V65, P1047, DOI 10.1021/acs.jmedchem.1c00963 Bedard PL, 2020, LANCET, V395, P1078, DOI 10.1016/S0140-6736(20)30164-1 Bello CL, 2009, CLIN CANCER RES, V15, P7045, DOI 10.1158/1078-0432.CCR-09-1521 Beltran B, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-11 Bhat SA, 2022, BLOOD, V140, P2142, DOI 10.1182/blood.2022016953 Bray F, 2021, CANCER-AM CANCER SOC, V127, P3029, DOI 10.1002/cncr.33587 Brigatinib MA., 2017, Drugs, V77, P1131, DOI [10.1007/s40265-017-0776-3, DOI 10.1007/S40265-017-0776-3] Brown JR, 2022, HAEMATOLOGICA, V107, P1335, DOI 10.3324/haematol.2021.278901 Brown JR, 2020, BLOOD, V136, DOI 10.1182/blood-2020-134797 Brown JR, 2017, HAEMATOLOGICA, V102, P1796, DOI 10.3324/haematol.2017.171041 Brown TM, 2024, CIRCULATION, V150, pe328, DOI 10.1161/CIR.0000000000001289 Buck B, 2023, JAMA ONCOL, V9, P552, DOI 10.1001/jamaoncol.2022.6869 Burger JA, 2020, LEUKEMIA, V34, P787, DOI 10.1038/s41375-019-0602-x Burstein HJ, 2010, J CLIN ONCOL, V28, P1301, DOI 10.1200/JCO.2009.25.8707 Byrd JC, 2021, J CLIN ONCOL, V39, P3441, DOI 10.1200/JCO.21.01210 Byrd JC, 2020, CLIN CANCER RES, V26, P3918, DOI 10.1158/1078-0432.CCR-19-2856 Chatsiproios D, 2010, BREAST CARE, V5, P16, DOI 10.1159/000285776 Chen ST, 2022, J HEMATOL ONCOL, V15, DOI 10.1186/s13045-022-01302-7 Choi HD, 2017, BREAST CANCER RES TR, V166, P927, DOI 10.1007/s10549-017-4460-9 Choueiri TK, 2010, J CLIN ONCOL, V28, P2280, DOI 10.1200/JCO.2009.27.2757 Chu TF, 2007, LANCET, V370, P2011, DOI 10.1016/S0140-6736(07)61865-0 Commander H, 2011, DRUGS, V71, P1355, DOI 10.2165/11595310-000000000-00000 Cortes JE, 2018, BLOOD, V132, P393, DOI 10.1182/blood-2016-09-739086 Dahlén T, 2022, AM J HEMATOL, V97, P421, DOI 10.1002/ajh.26463 Danilov AV, 2021, BRIT J HAEMATOL, V193, P15, DOI 10.1111/bjh.17184 Dasari A, 2023, LANCET, V402, P41, DOI 10.1016/S0140-6736(23)00772-9 de Claro RA, 2015, CLIN CANCER RES, V21, P3586, DOI 10.1158/1078-0432.CCR-14-2225 Deeks ED, 2021, DRUGS, V81, P1775, DOI 10.1007/s40265-021-01588-w Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097 Demetri GD, 2013, LANCET, V381, P295, DOI 10.1016/S0140-6736(12)61857-1 Dent Susan F, 2020, Am Soc Clin Oncol Educ Book, V40, P1, DOI [10.1200/edbk_286019, 10.1200/EDBK_286019] Desai A, 2023, CANCER-AM CANCER SOC, V129, P1634, DOI 10.1002/cncr.34743 Dickerson T, 2019, BLOOD, V134, P1919, DOI 10.1182/blood.2019000840 Dimopoulos MA, 2023, J CLIN ONCOL, V41, P5099, DOI 10.1200/JCO.22.02830 Distler JHW, 2007, ANN RHEUM DIS, V66, P836, DOI 10.1136/ard.2006.067710 Doherty KR, 2013, TOXICOL APPL PHARM, V272, P245, DOI 10.1016/j.taap.2013.04.027 Du BB, 2020, JACC-CARDIOONCOL, V2, P614, DOI 10.1016/j.jaccao.2020.08.012 Ekram J, 2024, CANCER CONTROL, V31, DOI 10.1177/10732748241285755 Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655 Ettrich Thomas J, 2018, Recent Results Cancer Res, V211, P45, DOI 10.1007/978-3-319-91442-8_3 Fernández A, 2007, J CLIN INVEST, V117, P4044, DOI 10.1172/JCI32373 Ferreri AJM, 2012, CRIT REV ONCOL HEMAT, V83, P293, DOI 10.1016/j.critrevonc.2012.02.005 Fruquintinib SM., 2018, Drugs, V78, P1757, DOI [10.1007/s40265-018-0998-z, DOI 10.1007/S40265-018-0998-Z] Furman RR, 2021, LEUKEMIA, V35, P3201, DOI 10.1038/s41375-021-01252-y Gilchrist SC, 2019, CIRCULATION, V139, pE997, DOI 10.1161/CIR.0000000000000679 Goodman VL, 2007, CLIN CANCER RES, V13, P1367, DOI 10.1158/1078-0432.CCR-06-2328 Gridelli C, 2007, ONCOLOGIST, V12, P191, DOI 10.1634/theoncologist.12-2-191 Guardiola S, 2019, TRENDS PHARMACOL SCI, V40, P941, DOI 10.1016/j.tips.2019.10.004 Guha A, 2018, J AM COLL CARDIOL, V72, P697, DOI 10.1016/j.jacc.2018.06.002 Guignabert C, 2016, J CLIN INVEST, V126, P3207, DOI 10.1172/JCI86249 Hallberg B, 2016, ANN ONCOL, V27, P4, DOI 10.1093/annonc/mdw301 Han BH, 2018, JAMA ONCOL, V4, P1569, DOI 10.1001/jamaoncol.2018.3039 Hillmen P, 2023, J CLIN ONCOL, V41, P1035, DOI 10.1200/JCO.22.00510 Hnatiuk AP, 2022, CANCER RES, V82, P2777, DOI [10.1158/0008-5472.CAN-21-365, 10.1158/0008-5472.CAN-21-3652] Ho T., 2017, Cardiooncology, V3, P1 Horn L, 2021, JAMA ONCOL, V7, P1617, DOI 10.1001/jamaoncol.2021.3523 Hsieh PCH, 2006, CIRCULATION, V114, P637, DOI 10.1161/CIRCULATIONAHA.106.639831 Hsu WT, 2018, THERANOSTICS, V8, P3176, DOI 10.7150/thno.23207 Huang J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61571-5 Jain D, 2017, CURR CARDIOL REP, V19, DOI 10.1007/s11886-017-0846-x Jiang H, 2022, BIOMED PHARMACOTHER, V153, DOI 10.1016/j.biopha.2022.113280 Jiang L, 2019, HEART RHYTHM, V16, P1374, DOI 10.1016/j.hrthm.2019.04.008 Jiang Q, 2022, J HEMATOL ONCOL, V15, DOI 10.1186/s13045-022-01334-z Jiang XJ, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01709-5 Jimenez-Fonseca P, 2022, CANCER MED-US, V11, P17, DOI 10.1002/cam4.5127 Jonas DE, 2018, JAMA-J AM MED ASSOC, V320, P485, DOI 10.1001/jama.2018.4190 Kaira K, 2020, J THORAC ONCOL, V15, pE54, DOI 10.1016/j.jtho.2019.11.029 Kamba T, 2007, BRIT J CANCER, V96, P1788, DOI 10.1038/sj.bjc.6603813 Kappers MHW, 2012, HYPERTENSION, V59, P151, DOI 10.1161/HYPERTENSIONAHA.111.182220 Kappers MHW, 2010, HYPERTENSION, V56, P675, DOI 10.1161/HYPERTENSIONAHA.109.149690 Kerkelä R, 2006, NAT MED, V12, P908, DOI 10.1038/nm1446 Khakoo AY, 2008, CANCER-AM CANCER SOC, V112, P2500, DOI 10.1002/cncr.23460 Khountham S, 2021, LEUKEMIA LYMPHOMA, V62, P716, DOI 10.1080/10428194.2020.1838508 Kim DW, 2017, J CLIN ONCOL, V35, P2490, DOI 10.1200/JCO.2016.71.5904 Kim MS, 2020, CANCER-AM CANCER SOC, V126, P4270, DOI 10.1002/cncr.33058 Kim SY, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00384 Koehler VF, 2021, THYROID, V31, P1531, DOI 10.1089/thy.2021.0091 Korashy HM, 2016, TOXICOL LETT, V252, P50, DOI 10.1016/j.toxlet.2016.04.011 Kudinov A, 2020, JACC-CARDIOONCOL, V2, P630, DOI 10.1016/j.jaccao.2020.10.001 Kühn B, 2013, NEW ENGL J MED, V368, P875, DOI 10.1056/NEJMc1215887 KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009 Lampson BL, 2017, BLOOD, V129, P2581, DOI 10.1182/blood-2016-10-742437 Lee DH, 2022, HEART, V108, P445, DOI 10.1136/heartjnl-2021-319110 León-Mateos L, 2015, REDOX BIOL, V6, P421, DOI 10.1016/j.redox.2015.09.007 Leong DP, 2016, BLOOD, V128, P138, DOI 10.1182/blood-2016-05-712828 Li DJ, 2024, CHEM-BIOL INTERACT, V388, DOI 10.1016/j.cbi.2023.110829 Li J, 2016, J CLIN ONCOL, V34, P1448, DOI 10.1200/JCO.2015.63.5995 Li J, 2015, LANCET ONCOL, V16, P619, DOI 10.1016/S1470-2045(15)70156-7 Li PW, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1177003 Li PS, 2024, CANCER INNOV, V4, DOI 10.1002/cai2.151 Li X, 2024, FRONT PHARMACOL, V15, DOI 10.3389/fphar.2024.1404692 Li YL, 2024, INT J BIOL SCI, V20, P2622, DOI 10.7150/ijbs.86479 Li YL, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.904314 Lindauer Markus, 2018, Recent Results Cancer Res, V212, P29, DOI 10.1007/978-3-319-91439-8_2 Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857 Lu S, 2022, J THORAC ONCOL, V17, P411, DOI 10.1016/j.jtho.2021.10.024 Lynch DR, 2011, J THROMB THROMBOLYS, V32, P120, DOI 10.1007/s11239-010-0539-4 Lyon Alexander R, 2022, Eur Heart J Cardiovasc Imaging, V23, pe333, DOI [10.1093/eurheartj/ehac244, 10.1093/ehjci/jeac106] Maharsy W, 2014, EUR J HEART FAIL, V16, P367, DOI 10.1002/ejhf.58 Maione P, 2015, THER ADV MED ONCOL, V7, P263, DOI 10.1177/1758834015595048 Markham A, 2018, DRUGS, V78, P139, DOI 10.1007/s40265-017-0852-8 Marslin G, 2015, INT J NANOMED, V10, P3163, DOI 10.2147/IJN.S75962 McMullen JR, 2014, BLOOD, V124, P3829, DOI 10.1182/blood-2014-10-604272 Meyer T, 2009, J THROMB HAEMOST, V7, P171, DOI 10.1111/j.1538-7836.2008.03212.x Mohamad HE, 2024, INT IMMUNOPHARMACOL, V132, DOI 10.1016/j.intimp.2024.111963 Mok TS, 2017, NEW ENGL J MED, V376, P629, DOI 10.1056/NEJMoa1612674 Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525 Morissette MP, 2019, CAN J PHYSIOL PHARM, V97, P786, DOI 10.1139/cjpp-2018-0737 Moslehi J, 2010, CIRCULATION, V122, P1004, DOI 10.1161/CIRCULATIONAHA.109.922427 Mossé YP, 2017, J CLIN ONCOL, V35, P3215, DOI 10.1200/JCO.2017.73.4830 Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044 Motzer RJ, 2013, LANCET ONCOL, V14, P552, DOI 10.1016/S1470-2045(13)70093-7 Muslin AJ, 2005, TRENDS CARDIOVAS MED, V15, P225, DOI 10.1016/j.tcm.2005.06.008 Nagasaka M, 2021, J THORAC ONCOL, V16, P740, DOI 10.1016/j.jtho.2020.11.028 Niimura T, 2023, DRUG SAFETY, V46, P545, DOI 10.1007/s40264-023-01300-9 Nuvola G, 2019, J THORAC ONCOL, V14, pE145, DOI 10.1016/j.jtho.2019.02.027 Omori S, 2018, J THORAC ONCOL, V13, pE207, DOI 10.1016/j.jtho.2018.05.020 Ou SHI, 2013, CANCER-AM CANCER SOC, V119, P1969, DOI 10.1002/cncr.28040 Ou SHI, 2011, J THORAC ONCOL, V6, P2135, DOI 10.1097/JTO.0b013e3182307e06 Pan YL, 2024, FRONT PHARMACOL, V15, DOI 10.3389/fphar.2024.1513913 Pandrala M, 2022, J MED CHEM, DOI 10.1021/acs.jmedchem.1c01853 Park YH, 2006, CANCER LETT, V243, P16, DOI 10.1016/j.canlet.2005.11.014 Pretorius L, 2009, AM J PATHOL, V175, P998, DOI 10.2353/ajpath.2009.090126 Pruis MA, 2023, JACC-CARDIOONCOL, V5, P102, DOI 10.1016/j.jaccao.2022.09.006 Qi SY, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23136934 Qi WX, 2013, BRIT J CLIN PHARMACO, V75, P919, DOI 10.1111/j.1365-2125.2012.04417.x Quintas-Cardama A, 2009, BLOOD, V113, P1619, DOI 10.1182/blood-2008-03-144790 Ratain MJ, 2021, JAMA ONCOL, V7, P177, DOI 10.1001/jamaoncol.2020.5742 Remon J, 2021, CANCER TREAT REV, V95, DOI 10.1016/j.ctrv.2021.102178 Roskoski R Jr, 2024, PHARMACOL RES, V200, DOI 10.1016/j.phrs.2024.107059 Salem JE, 2019, J AM COLL CARDIOL, V74, P1667, DOI 10.1016/j.jacc.2019.07.056 Sarszegi Z, 2012, MOL CELL BIOCHEM, V365, P129, DOI 10.1007/s11010-012-1252-8 Saura C, 2020, J CLIN ONCOL, V38, P3138, DOI 10.1200/JCO.20.00147 Savage DG, 2002, NEW ENGL J MED, V346, P683, DOI 10.1056/NEJMra013339 Schöffski P, 2018, LANCET RESP MED, V6, P431, DOI 10.1016/S2213-2600(18)30116-4 Schwartz RG, 2013, J NUCL CARDIOL, V20, P443, DOI 10.1007/s12350-013-9707-1 Seymour JF., 2023, Blood, DOI [10.1182/blood.2022018818, DOI 10.1182/BLOOD.2022018818] Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480 Shah RR, 2015, DRUG SAFETY, V38, P693, DOI 10.1007/s40264-015-0300-1 Shaw AT, 2016, LANCET ONCOL, V17, P234, DOI 10.1016/S1470-2045(15)00488-X Shaw AT, 2014, NEW ENGL J MED, V370, P1189, DOI 10.1056/NEJMoa1311107 Shaw AT, 2011, LANCET ONCOL, V12, P1004, DOI 10.1016/S1470-2045(11)70232-7 Shi YK, 2022, LANCET RESP MED, V10, P1019, DOI 10.1016/S2213-2600(22)00168-0 Singh AP, 2019, CARDIOVASC RES, V115, P966, DOI 10.1093/cvr/cvz006 Smith CEP, 2021, AM FAM PHYSICIAN, V103, P155 Solomon BJ, 2022, J CLIN ONCOL, V40, P3593, DOI 10.1200/JCO.21.02278 Solomon BJ, 2018, LANCET ONCOL, V19, P1654, DOI 10.1016/S1470-2045(18)30649-1 Sourdon J, 2021, THERANOSTICS, V11, P3830, DOI 10.7150/thno.49837 Sourdon J, 2017, THERANOSTICS, V7, P2757, DOI 10.7150/thno.19551 Steinberg SF, 2004, BIOCHEM J, V384, P449, DOI 10.1042/BJ20040704 Suh E, 2020, LANCET ONCOL, V21, P421, DOI 10.1016/S1470-2045(19)30800-9 Sun L, 2022, BIOENGINEERED, V13, P48, DOI 10.1080/21655979.2021.2004980 Sun WP, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002554 Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660 Syed YY, 2020, DRUGS, V80, P91, DOI 10.1007/s40265-019-01252-4 Tam CS, 2022, BLOOD ADV, V6, P1296, DOI 10.1182/bloodadvances.2021005621 Telli ML, 2008, ANN ONCOL, V19, P1613, DOI 10.1093/annonc/mdn168 Tousif S, 2023, CIRC RES, V132, P267, DOI 10.1161/CIRCRESAHA.122.321504 Trent JC, 2010, CANCER-AM CANCER SOC, V116, P184, DOI 10.1002/cncr.24683 Truell JS, 2005, ARCH PATHOL LAB MED, V129, P1044 Tzogani K, 2015, ONCOLOGIST, V20, P196, DOI 10.1634/theoncologist.2014-0177 U.S. Food and Drug Administration, 2018, Lorbrena (lorlatinib) tablets Ulhoi MP, 2021, CASE REP ONCOL, V14, P1323, DOI 10.1159/000518081 Update on imbruvica (ibrutinib) U.S, 2023, Accelerated approvals for mantle cell lymphoma and marginal zone lymphoma indications. News release Valade E, 2019, CANCER CHEMOTH PHARM, V84, P621, DOI 10.1007/s00280-019-03896-1 van der Veldt AAM, 2008, BRIT J CANCER, V99, P259, DOI 10.1038/sj.bjc.6604456 Van Horn L, 2016, CIRCULATION, V134, pE505, DOI 10.1161/CIR.0000000000000462 Voigtlaender Minna, 2018, Recent Results Cancer Res, V211, P19, DOI 10.1007/978-3-319-91442-8_2 Waliany S, 2021, J THORAC ONCOL, V16, P2029, DOI 10.1016/j.jtho.2021.07.030 Wang WJ, 2022, FRONT CARDIOVASC MED, V9, DOI 10.3389/fcvm.2022.873829 Wilhelm SM, 2011, INT J CANCER, V129, P245, DOI 10.1002/ijc.25864 Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443 Wirth LJ, 2018, CANCER-AM CANCER SOC, V124, P2365, DOI 10.1002/cncr.31344 Won E, 2019, CLIN CANCER RES, V25, P3811, DOI 10.1158/1078-0432.CCR-18-3789 Xia CF, 2022, CHINESE MED J-PEKING, V135, P584, DOI 10.1097/CM9.0000000000002108 Xiao L, 2020, CIRCULATION, V142, P2443, DOI 10.1161/CIRCULATIONAHA.120.049210 Xu JM, 2020, LANCET ONCOL, V21, P1489, DOI 10.1016/S1470-2045(20)30493-9 Xu ZF, 2024, AUTOPHAGY, V20, P416, DOI 10.1080/15548627.2023.2259216 Xu ZF, 2022, AUTOPHAGY, V18, P1152, DOI 10.1080/15548627.2021.1965712 Yamaguchi K, 2005, PATHOPHYSIOL HAEMO T, V34, P48, DOI 10.1159/000088548 Yamaguchi O, 2004, J CLIN INVEST, V114, P937, DOI 10.1172/JCI200420317 Yang Y, 2019, PHARM BIOL, V57, P625, DOI 10.1080/13880209.2019.1657905 Yang Y, 2016, CHEM-BIOL INTERACT, V257, P125, DOI 10.1016/j.cbi.2016.08.006 Yu B, 2022, JACC-CARDIOONCOL, V4, P371, DOI 10.1016/j.jaccao.2022.06.004 Yu Ruiqi, 2024, Biomed Pharmacother, V180, P117503, DOI [10.1016/j.biopha.2024.117503, 10.1016/j.biopha.2024.117503] Zaborowska-Szmit M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051268 Zain R, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.694853 Zang JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030353 Zhang QQ, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.833929 Zhang YY, 2022, FRONT CARDIOVASC MED, V9, DOI 10.3389/fcvm.2022.934214 Zhang Zhushan, 2017, Cardiooncology, V3, DOI [10.1186/s40959-017-0020-z, 10.1007/s12559-017-9484-2, 10.1186/s40959-017-0020-z] Zhao YN, 2024, J AM HEART ASSOC, V13, DOI 10.1161/JAHA.123.032357 Zhong L, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00572-w Zhu VW, 2021, J THORAC ONCOL, V16, P1778, DOI 10.1016/j.jtho.2021.07.005 NR 203 TC 5 Z9 5 U1 1 U2 6 PU BMC PI LONDON PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND EI 2162-3619 J9 EXP HEMATOL ONCOL JI Exp. Hematol. Oncol. PD MAY 9 PY 2025 VL 14 IS 1 AR 68 DI 10.1186/s40164-025-00660-5 PG 27 WC Oncology; Hematology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Hematology GA 2LI9L UT WOS:001485398300001 PM 40346640 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Liu, B Zhou, J He, W Xie, B Zhang, R Cheng, XC Zhang, YM Xu, L Guo, SL AF Liu, Bin Zhou, Jia He, Wei Xie, Bo Zhang, Rui Cheng, Xiaocheng Zhang, Yueming Xu, Li Guo, Shuliang TI Safety of bronchial artery infusion immunotherapy: from comparative analysis in beagle canines to clinical validation SO DISCOVER ONCOLOGY LA English DT Article DE Bronchial artery infusion; Immune checkpoint inhibitors; Non-small cell lung cancer; Safety ID IN-VIVO; CELL; CHEMOTHERAPY; PEMBROLIZUMAB; INHIBITORS; NIVOLUMAB AB Background Despite advancements in systemic chemotherapy and immune checkpoint inhibitors (ICIs), advanced non-small cell lung cancer (NSCLC) continues to exhibit poor prognosis, underscoring an urgent need for safer and more effective therapeutic strategies. This study investigates the safety profile and biological effects of bronchial arterial infusion (BAI)-administered anti-PD-1 monoclonal antibody (aPD-1 mAb) using a preclinical beagle model and a clinical cohort of advanced NSCLC patients. Methods In preclinical evaluations, male beagles (n = 3/group) were randomized to receive 5 mg/kg aPD-1 mAb via BAI or intravenous routes (Venous group). Safety assessments included longitudinal imaging, biochemical analyses, and histopathological evaluation. Clinically, patients with advanced NSCLC meeting stringent inclusion criteria underwent BAI immunotherapy, with systematic monitoring of adverse events (AEs). Results Both administration routes demonstrated comparable safety in canines, with no evidence of immune-related pneumonitis or structural lung alterations on CT or histology. Transient AEs (e.g., hematoma, lameness) resolved spontaneously. Pharmacokinetic analysis revealed similar systemic drug concentrations and tissue distribution between BAI and Venous groups (all p > 0.05). Biochemical profiling identified isolated mild LDH elevation in one BAI-treated canine. Notably, the BAI group exhibited significantly enhanced systemic IL-2 levels (80.15 +/- 5.24 pg/mL vs. 66.47 +/- 5.24 pg/mL in Venous groups, p = 0.001) at day 28, paralleled by elevated pulmonary IL-2 expression (626.90 +/- 18.49 vs. 559.18 +/- 45.61 pg/mg, p = 0.03). In the clinical cohort (n = 17; 94.1% male, mean age 61.6 +/- 7.1 years), BAI immunotherapy was well-tolerated with mild AEs including nausea (n = 1), dyspnea (n = 1), atrial fibrillation (n = 1), and puncture-site hematoma (n = 1). No severe immune-related toxicities (e.g., pneumonitis) emerged during follow-up. Conclusion Our study suggest the preliminary safety and feasibility of delivering aPD-1 mAb via BAI in both canine models and NSCLC patients. C1 [Liu, Bin; Zhou, Jia; He, Wei; Zhang, Rui; Cheng, Xiaocheng; Zhang, Yueming; Xu, Li; Guo, Shuliang] Chongqing Med Univ, Dept Pulm & Crit Care Med, Affiliated Hosp 1, Youyi Rd 1, Chongqing 400016, Peoples R China. [Liu, Bin] Cent South Univ, Zhuzhou Cent Hosp, Xiangya Sch Med, Dept Pulm & Crit Care Med,Zhuzhou Hosp, 116 Changjiang South Rd, Zhuzhou 412007, Hunan, Peoples R China. [Xie, Bo] Cent South Univ, Zhuzhou Cent Hosp, Xiangya Sch Med, Dept Med Adm,Zhuzhou Hosp, Zhuzhou 412007, Hunan, Peoples R China. C3 Chongqing Medical University; Central South University; Central South University RP Guo, SL (corresponding author), Chongqing Med Univ, Dept Pulm & Crit Care Med, Affiliated Hosp 1, Youyi Rd 1, Chongqing 400016, Peoples R China. EM guosl999@sina.com CR Alharbi AF, 2019, CANCER CHEMOTH PHARM, V83, P387, DOI 10.1007/s00280-018-3757-7 Bell R, 2018, EUR CELLS MATER, V36, P44, DOI 10.22203/eCM.v036a04 Blum SM, 2023, IMMUNOL REV, V318, P167, DOI 10.1111/imr.13262 Bray F, 2021, CANCER-AM CANCER SOC, V127, P3029, DOI 10.1002/cncr.33587 Carbone DP, 2017, NEW ENGL J MED, V376, P2415, DOI 10.1056/NEJMoa1613493 Cortiula F, 2022, ANN ONCOL, V33, P893, DOI 10.1016/j.annonc.2022.06.013 Das S, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0805-8 Day CP, 2015, CELL, V163, P39, DOI 10.1016/j.cell.2015.08.068 De Velasco G, 2017, CANCER IMMUNOL RES, V5, P312, DOI 10.1158/2326-6066.CIR-16-0237 Francis DM, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay3575 Garassino MC, 2023, J CLIN ONCOL, V41, P1992, DOI 10.1200/JCO.22.01989 He GH, 2023, EUR J RADIOL, V161, DOI 10.1016/j.ejrad.2023.110747 Herbst RS, 2020, NEW ENGL J MED, V383, P1328, DOI 10.1056/NEJMoa1917346 Herbst RS, 2018, NATURE, V553, P446, DOI 10.1038/nature25183 Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7 Keam S, 2024, FRONT IMMUNOL, V15, DOI 10.3389/fimmu.2024.1447021 Khunger M, 2017, CHEST, V152, P271, DOI 10.1016/j.chest.2017.04.177 Kim JM, 2016, ANN ONCOL, V27, P1492, DOI 10.1093/annonc/mdw217 Kitano M, 2024, ASIA-PAC J CLIN ONCO, V20, P463, DOI 10.1111/ajco.14059 Liu XF, 2021, EUR REV MED PHARMACO, V25, P2554, DOI 10.26355/eurrev_202103_25419 Luo YY, 2023, LUNG CANCER, V184, DOI 10.1016/j.lungcan.2023.107319 Maddaus MA, 1999, CHEST, V115, P1230, DOI 10.1378/chest.115.5.1230 Marabelle A, 2017, ANN ONCOL, V28, P33, DOI 10.1093/annonc/mdx683 Miller M, 2021, BMJ-BRIT MED J, V375, DOI 10.1136/bmj.n2363 Mok TSK, 2019, LANCET, V393, P1819, DOI 10.1016/S0140-6736(18)32409-7 Nooreldeen R, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168661 Novello S, 2023, J CLIN ONCOL, V41, P1999, DOI 10.1200/JCO.22.01990 Pasqualotto E, 2023, CANCERS, V15, DOI 10.3390/cancers15215143 Reck M, 2019, J CLIN ONCOL, V37, P537, DOI 10.1200/JCO.18.00149 Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774 Sakuma K, 2022, ANTICANCER RES, V42, P4293, DOI 10.21873/anticanres.15929 Shen L, 2022, J CLIN ONCOL, V40, P3065, DOI 10.1200/JCO.21.01926 SHIMIZU E, 1991, EUR J CANCER, V27, P1046, DOI 10.1016/0277-5379(91)90278-L Wang JYJ, 2019, YALE J BIOL MED, V92, P771 Weber JS, 2017, J CLIN ONCOL, V35, P785, DOI 10.1200/JCO.2015.66.1389 Xu S, 2023, QUANT IMAG MED SURG, DOI 10.21037/qims-23-287 Yang XJ, 2022, J IMMUNOL RES, V2022, DOI 10.1155/2022/4518898 Yi M, 2022, MOL CANCER, V21, DOI 10.1186/s12943-021-01489-2 Zhang L, 2022, LUNG CANCER, V171, P56, DOI 10.1016/j.lungcan.2022.07.013 Zhu J, 2017, THER ADV RESPIR DIS, V11, P301, DOI 10.1177/1753465817717169 NR 40 TC 1 Z9 1 U1 0 U2 2 PU SPRINGER PI NEW YORK PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES EI 2730-6011 J9 DISCOV ONCOL JI Discov. Oncol. PD APR 26 PY 2025 VL 16 IS 1 AR 621 DI 10.1007/s12672-025-02398-2 PG 16 WC Oncology; Endocrinology & Metabolism WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Endocrinology & Metabolism GA 1YW0N UT WOS:001476909100004 PM 40285957 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Shu, C Han, HQ Li, H Wei, LR Wu, H Li, CT Xie, X Zhang, B Li, ZX Chen, X Zhao, JC Zhou, YH He, YZ Xu, C AF Shu, Chi Han, Huiqiao Li, Hong Wei, Linru Wu, Hong Li, Changtao Xie, Xuan Zhang, Bin Li, Zhexuan Chen, Xin Zhao, Jichun Zhou, Yanhong He, Yazhou Xu, Chuan TI Cancer risk subsequent to cardiovascular disease: a prospective population-based study and meta-analysis SO BMC MEDICINE LA English DT Article DE Cardiovascular disease; Cancer; Population-based cohort; Meta-analysis ID HEART-FAILURE; VENOUS THROMBOEMBOLISM; MYOCARDIAL-INFARCTION; COLORECTAL-CANCER; ATRIAL-FIBRILLATION; GENERAL-POPULATION; INCIDENT CANCER; ISCHEMIC-STROKE; LUNG-CANCER; FOLLOW-UP AB BackgroundPrevious preclinical studies have revealed the biological links between cardiovascular diseases (CVD) and cancer. However, population-based evidence remained inconclusive. MethodsWe assessed cancer incidence among individuals with and without CVD condition in a prospective cohort from the UK Biobank (UKB). Multivariable Cox regression and competing risk models were fitted to estimate hazard ratios (HR). A systematic literature search was conducted in Medline, Embase and Cochrane Library databases to identify published population-based cohort studies (last updated on 1 October 2023) investigating the associations between CVD status and subsequent cancer risk. Random-effects meta-analysis was employed to pool relative effect estimates reported by eligible cohorts. Subgroup and sensitivity analyses were conducted to evaluate the associations across various CVD and cancer subtypes. ResultsFor the cohort study in the UKB, after a median follow-up of 11.58 years, a total of 18,471 and 66,891 cancer cases occurred among 94,845 CVD patients and 368,695 non-CVD individuals (Incidence rate: 25.62 vs. 15.41 per 1000 person-years). Individuals with prior CVD exhibited higher overall cancer risk (HR 1.14, 95% CI 1.12-1.17, p < 0.001), and we observed consistently higher cancer risk after adjusting for competing risk from non-cancer deaths. The effect size of CVD on cancer risk was greater among younger individuals (< 65 years) than those >= 65 years (p for interaction < 0.001). The meta-analysis included 47 population-based cohort studies where a total of 1.49 million cancer cases were documented among over 45 million participants (9.49 million CVD patients). A 13% higher risk of overall cancer was observed among individuals with prior CVD (pooled RR 1.13, 95% CI 1.11-1.15, p < 0.001). The associations remained significant between various CVD subtypes and cancer risk at multiple sites. ConclusionsOur study identified a significantly higher cancer risk among individuals with CVD conditions compared with the non-CVD population, underpinning the need for continued cancer surveillance among CVD patients and further exploration of the possible etiological relation between CVD and cancer. C1 [Shu, Chi; Zhao, Jichun] Sichuan Univ, West China Hosp, Dept Gen Surg, Div Vasc Surg, Chengdu, Peoples R China. [Shu, Chi; Wu, Hong; He, Yazhou; Xu, Chuan] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sichuan Acad Med Sci, Dept Oncol, Chengdu, Peoples R China. [Shu, Chi; Wu, Hong; He, Yazhou; Xu, Chuan] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Canc Inst, Sichuan Acad Med Sci, Chengdu, Peoples R China. [Shu, Chi; Li, Zhexuan; He, Yazhou; Xu, Chuan] Yu Yue Pathol Sci Res Ctr, Chongqing, Peoples R China. [Shu, Chi; Li, Zhexuan; He, Yazhou; Xu, Chuan] Jinfeng Lab, Chongqing, Peoples R China. [Han, Huiqiao; Zhang, Bin] Chinese Acad Med Sci & Peking Union Med Coll, Natl Ctr Cardiovasc Dis, Fuwai Hosp, Dept Cardiol, Beijing, Peoples R China. [Li, Hong; Wei, Linru; Li, Changtao; Xie, Xuan; Chen, Xin; He, Yazhou] Sichuan Univ, Dept Oncol, Chengdu, Peoples R China. [Li, Hong; Wei, Linru; Li, Changtao; Xie, Xuan; Chen, Xin; He, Yazhou] Sichuan Univ, West China Sch Publ Hlth, Dept Epidemiol & Med Stat, Chengdu, Peoples R China. [Li, Hong; Wei, Linru; Li, Changtao; Xie, Xuan; Chen, Xin; He, Yazhou] Sichuan Univ, West China Hosp 4, Chengdu, Peoples R China. [Zhou, Yanhong] Sichuan Univ, West China Hosp, Dept Lab Med, Chengdu, Peoples R China. [He, Yazhou] Univ Edinburgh, Usher Inst, Edinburgh, Scotland. C3 Sichuan University; University of Electronic Science & Technology of China; Sichuan Provincial People's Hospital; University of Electronic Science & Technology of China; Sichuan Provincial People's Hospital; Jinfeng Laboratory; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Fu Wai Hospital - CAMS; Sichuan University; Sichuan University; Sichuan University; Sichuan University; University of Edinburgh RP He, YZ; Xu, C (corresponding author), Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sichuan Acad Med Sci, Dept Oncol, Chengdu, Peoples R China.; He, YZ; Xu, C (corresponding author), Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Canc Inst, Sichuan Acad Med Sci, Chengdu, Peoples R China.; He, YZ; Xu, C (corresponding author), Yu Yue Pathol Sci Res Ctr, Chongqing, Peoples R China.; He, YZ; Xu, C (corresponding author), Jinfeng Lab, Chongqing, Peoples R China.; He, YZ (corresponding author), Sichuan Univ, Dept Oncol, Chengdu, Peoples R China.; He, YZ (corresponding author), Sichuan Univ, West China Sch Publ Hlth, Dept Epidemiol & Med Stat, Chengdu, Peoples R China.; He, YZ (corresponding author), Sichuan Univ, West China Hosp 4, Chengdu, Peoples R China.; He, YZ (corresponding author), Univ Edinburgh, Usher Inst, Edinburgh, Scotland. EM yazhou.he@ed.ac.uk; xuchuan100@uestc.edu.cn RI zhao, jichun/KRQ-8828-2024 OI Li, Hong/0009-0002-5327-1106 FU National High Level Hospital Clinical Research Funding FX The authors would like to thank the participants of the UK Biobank study. CR Aboumsallem JP, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.013754 Austin PC, 2017, STAT MED, V36, P4391, DOI 10.1002/sim.7501 Banke A, 2016, EUR J HEART FAIL, V18, P260, DOI 10.1002/ejhf.472 BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446 Bell CF, 2023, JACC-CARDIOONCOL, V5, P431, DOI 10.1016/j.jaccao.2023.01.010 Bertero E, 2022, JACC-CARDIOONCOL, V4, P98, DOI 10.1016/j.jaccao.2021.11.007 Bosetti C, 2020, ANN ONCOL, V31, P558, DOI 10.1016/j.annonc.2020.02.012 Bray F, 2024, CA-CANCER J CLIN, V74, P229, DOI 10.3322/caac.21834 Burn J, 2020, LANCET, V395, P1855, DOI 10.1016/S0140-6736(20)30366-4 Campi R, 2023, NAT REV UROL, V20, P669, DOI 10.1038/s41585-023-00781-8 Chen CW, 2017, ONCOTARGET, V8, P108989, DOI 10.18632/oncotarget.22480 Cheung YB, 2003, J CLIN EPIDEMIOL, V56, P38, DOI 10.1016/S0895-4356(02)00536-X Christensen DH, 2018, CLIN EPIDEMIOL, V10, P907, DOI 10.2147/CLEP.S158869 Conen D, 2016, JAMA CARDIOL, V1, P389, DOI 10.1001/jamacardio.2016.0280 Copland E, 2021, LANCET ONCOL, V22, P558, DOI 10.1016/S1470-2045(21)00033-4 Crowder SL, 2024, ANN BEHAV MED, V58, P156, DOI 10.1093/abm/kaad068 De León LE, 2020, J THORAC CARDIOV SUR, V160, P1064, DOI 10.1016/j.jtcvs.2019.12.115 de Wit S, 2024, CARDIOVASC RES, V120, P612, DOI 10.1093/cvr/cvae038 DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2 Dreyer L, 1998, EPIDEMIOLOGY, V9, P178, DOI 10.1097/00001648-199803000-00013 Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629 Einstein AJ, 2007, JAMA-J AM MED ASSOC, V298, P317, DOI 10.1001/jama.298.3.317 Erichsen R, 2013, CANCER EPIDEM BIOMAR, V22, P1994, DOI 10.1158/1055-9965.EPI-13-0444 Fontvieille E, 2023, BMC MED, V21, DOI 10.1186/s12916-023-03114-z Freisling H, 2020, BMC MED, V18, DOI 10.1186/s12916-019-1474-7 Friedman DJ, 2018, JAMA-J AM MED ASSOC, V319, P365, DOI 10.1001/jama.2017.20125 Frisch M, 2000, JNCI-J NATL CANCER I, V92, P1500, DOI 10.1093/jnci/92.18.1500 GREENLAND S, 1987, EPIDEMIOL REV, V9, P1 Hasin T, 2016, J AM COLL CARDIOL, V68, P265, DOI 10.1016/j.jacc.2016.04.053 Hasin T, 2013, J AM COLL CARDIOL, V62, P881, DOI 10.1016/j.jacc.2013.04.088 Hatlen P, 2014, J THORAC ONCOL, V9, P940, DOI 10.1097/JTO.0000000000000180 He YZ, 2018, ANN INTERN MED, V169, P543, DOI 10.7326/M18-0808 Higgins JPT, 2003, BMJ-BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557 Hu WS, 2018, INT J CARDIOL, V270, P319, DOI 10.1016/j.ijcard.2018.06.053 Hung YP, 2019, INT J CARDIOL, V296, P81, DOI 10.1016/j.ijcard.2019.08.021 Huynh J, 2019, NAT REV CANCER, V19, P82, DOI 10.1038/s41568-018-0090-8 Infantino V, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115703 Jacob L, 2019, J CANCER RES CLIN, V145, P1013, DOI 10.1007/s00432-019-02855-w Kaneta K, 2023, FRONT CARDIOVASC MED, V10, DOI 10.3389/fcvm.2023.1236144 Kang J, 2021, J THORAC ONCOL, V16, P76, DOI 10.1016/j.jtho.2020.08.021 Karazisi C, 2022, LANCET REG HEALTH-EU, V18, DOI 10.1016/j.lanepe.2022.100407 Keating ST, 2023, CARDIOVASC RES, V119, P357, DOI 10.1093/cvr/cvac058 Kim DS, 2021, DIABETES METAB J, V45, P799, DOI 10.4093/dmj.2021.0077 Koene RJ, 2016, CIRCULATION, V133, P1104, DOI 10.1161/CIRCULATIONAHA.115.020406 Kwak S, 2021, J CARDIOL, V77, P231, DOI 10.1016/j.jjcc.2020.07.026 Kwak S, 2020, INT J CARDIOL, V313, P25, DOI 10.1016/j.ijcard.2020.04.085 Lai SW, 2013, KUWAIT MED J, V45, P31 Lambe M, 2005, CARDIOVASC INTER RAD, V28, P36, DOI 10.1007/s00270-004-0059-8 Lanfranca MP, 2020, GASTROENTEROLOGY, V158, P1417, DOI 10.1053/j.gastro.2019.12.010 Lau B, 2009, AM J EPIDEMIOL, V170, P244, DOI 10.1093/aje/kwp107 Lau ES, 2021, JACC-CARDIOONCOL, V3, P48, DOI 10.1016/j.jaccao.2020.12.003 Leader A, 2022, J THROMB HAEMOST, V20, P635, DOI 10.1111/jth.15600 Leedy DJ, 2021, EUR J HEART FAIL, V23, P1712, DOI 10.1002/ejhf.2207 Leening MJG, 2023, EUR J EPIDEMIOL, V38, P853, DOI 10.1007/s10654-023-00984-8 Lincaru C, 2015, Journal of Social and Economic Statistics, V4, P1 LUNN M, 1995, BIOMETRICS, V51, P524, DOI 10.2307/2532940 Malmborg M, 2018, BMC CARDIOVASC DISOR, V18, DOI 10.1186/s12872-018-0932-z Mandalenakis Z, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.6762 Mensah GA, 2019, J AM COLL CARDIOL, V74, P2529, DOI 10.1016/j.jacc.2019.10.009 Montomoli J, 2015, BMJ OPEN GASTROENTER, V2, DOI 10.1136/bmjgast-2015-000043 Morita Kojiro, 2021, Ann Clin Epidemiol, V3, P97, DOI [10.37737/ace.3.4_97, 10.37737/ace.3.4_97] Morita K, 2018, J AM GERIATR SOC, V66, P728, DOI 10.1111/jgs.15295 Munch TN, 2015, NEURO-ONCOLOGY, V17, P718, DOI 10.1093/neuonc/nou312 Murchison JT, 2004, BRIT J CANCER, V91, P92, DOI 10.1038/sj.bjc.6601964 Nardi-Agmon I, 2023, AM J CARDIOL, V202, P50, DOI 10.1016/j.amjcard.2023.06.021 Ostenfeld EB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102861 Pedersen SB, 2015, EUROPACE, V17, P902, DOI 10.1093/europace/euv076 Pehrsson SK, 2005, J INTERN MED, V258, P124, DOI 10.1111/j.1365-2796.2005.01518.x Picano E, 2024, EUR HEART J-CARD IMG, V25, P1620, DOI 10.1093/ehjci/jeae257 Prandoni P, 2010, J THROMB HAEMOST, V8, P1126, DOI 10.1111/j.1538-7836.2010.03797.x Qureshi AI, 2015, CEREBROVASC DIS, V39, P262, DOI 10.1159/000375154 Rask-Andersen M, 2023, CANCER CELL, V41, P1186, DOI 10.1016/j.ccell.2023.05.010 Reicher-Reiss H, 2001, AM J CARDIOL, V87, P459, DOI 10.1016/S0002-9149(00)01405-3 Ren QW, 2021, EUR HEART J, V42, P3049, DOI 10.1093/eurheartj/ehab325 Rinde LB, 2017, EUR J EPIDEMIOL, V32, P193, DOI 10.1007/s10654-017-0231-5 Rioux B, 2022, CAN J NEUROL SCI, V49, P225, DOI 10.1017/cjn.2021.55 Roderburg C, 2021, ESC HEART FAIL, V8, P3628, DOI 10.1002/ehf2.13421 Schmidt SAJ, 2015, THROMB RES, V135, P96, DOI 10.1016/j.thromres.2014.11.002 Schwartz B, 2020, INT J CARDIOL, V316, P209, DOI 10.1016/j.ijcard.2020.05.035 Sealy-Jefferson S, 2018, WOMEN HEALTH ISS, V28, P29, DOI 10.1016/j.whi.2017.10.012 Selvaraj S, 2018, J AM COLL CARDIOL, V71, P1501, DOI 10.1016/j.jacc.2018.01.069 Silveira EA, 2021, OBES REV, V22, DOI 10.1111/obr.13088 Skowronki K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103243 Sorensen HT, 2022, CLIN EPIDEMIOL, V14, P173, DOI 10.2147/CLEP.S345054 Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z Sun LM, 2016, J THROMB HAEMOST, V14, P495, DOI 10.1111/jth.13251 Totolici S, 2024, INT J MOL SCI, V25, DOI 10.3390/ijms25063442 TOWNSEND P, 1987, J SOC POLICY, V16, P125, DOI 10.1017/S0047279400020341 Uruski P, 2024, BIOMOLECULES, V14, DOI 10.3390/biom14111374 Vinter N, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.009543 von Elm E, 2007, PLOS MED, V4, P1623, DOI [10.1371/journal.pmed.0040296, 10.1016/S0140-6736(07)61602-X, 10.1371/journal.pmed.0040297] Von Itter R, 2024, JACC-CARDIOONCOL, V6, P67, DOI 10.1016/j.jaccao.2023.12.004 Vyas MV, 2021, ANN EPIDEMIOL, V62, P69, DOI 10.1016/j.annepidem.2021.06.006 Wang C, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.950971 Wassertheil-Smoller S, 2017, AM J EPIDEMIOL, V185, P372, DOI 10.1093/aje/kww185 Watanabe Y, 2005, J EPIDEMIOL, V15, pS168, DOI 10.2188/jea.15.S168 Wilbers J, 2020, EUR J NEUROL, V27, P85, DOI 10.1111/ene.14037 Wilcox NS, 2024, NAT REV CARDIOL, V21, P617, DOI 10.1038/s41569-024-01017-x Wilcox NS, 2022, CIRC RES, V130, P632, DOI 10.1161/CIRCRESAHA.121.319901 Yamauchi Y, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00509 Zhang SS, 2024, J THORAC ONCOL, V19, P80, DOI 10.1016/j.jtho.2023.09.004 NR 101 TC 11 Z9 11 U1 5 U2 8 PU BMC PI LONDON PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1741-7015 J9 BMC MED JI BMC Med. PD MAR 31 PY 2025 VL 23 IS 1 AR 192 DI 10.1186/s12916-025-04013-1 PG 12 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA 0VB5S UT WOS:001456711300004 PM 40165228 OA Green Submitted, Green Published, gold DA 2026-04-17 ER PT J AU Ari, M Ari, E AF Ari, Maside Ari, Emrah TI Efficacy of Age-Adjusted Dyspnea, Eosinopenia, Consolidation, Acidemia and Atrial Fibrillation Score in Predicting Long-Term Survival in COPD-Related Persistent Hypercapnic Respiratory Failure SO LIFE-BASEL LA English DT Article DE A-DECAF; DECAF; HRF; survival ID DECAF SCORE; ACUTE EXACERBATIONS; HOSPITAL MORTALITY AB Background and Objectives: Hypercapnic respiratory failure (HRF) is a critical clinical condition commonly encountered in acute exacerbations of chronic obstructive pulmonary disease (COPD), leading to high morbidity and mortality rates. The existing scoring systems have primarily been developed for short-term mortality prediction, and their impact on long-term survival has not been sufficiently investigated. This study aims to identify the prognostic factors affecting long-term survival in patients with persistent HRF due to COPD and to evaluate the effectiveness of the Age-Adjusted DECAF (A-DECAF) score, which was created by incorporating the age variable into the existing DECAF score, in predicting long-term survival. Materials and Methods: This retrospective study included patients admitted to an intensive care unit from an emergency department with HRF between April 2022 and November 2023. The demographic data, comorbidities, the laboratory results, and the treatment protocols were recorded. The A-DECAF scores were calculated and analyzed using Kaplan-Meier and ROC analyses. Survival assessment was conducted with Kaplan-Meier analysis, while univariate and multivariate Cox regression analyses were performed to identify the prognostic factors. Results: Among 357 patients, 24.4% died within one year after discharge. The deceased patients were significantly older (p < 0.001) and had higher APACHE-II, DECAF, and A-DECAF scores (p < 0.001 for all). ROC analysis showed that the A-DECAF score had the highest sensitivity (93.1%) and accuracy (AUC = 0.813) for survival prediction. Kaplan-Meier analysis indicated lower survival rates with increasing A-DECAF scores. Cox regression identified the A-DECAF score as the strongest independent predictor (p < 0.001), while lung cancer (p = 0.044) and invasive mechanical ventilation (p = 0.039) also negatively impacted survival. Conclusions: The A-DECAF score is an effective tool for predicting long-term survival in patients with COPD and persistent HRF, particularly aiding clinical decisions regarding elderly populations. Further research is needed to validate its use in diverse patient groups. C1 [Ari, Maside] Ankara Ataturk Sanat Training & Res Hosp, Dept Pulmonol, TR-06290 Ankara, Turkiye. [Ari, Emrah] Mamak Publ Hosp, Dept Emergency Med, TR-06270 Ankara, Turkiye. RP Ari, M (corresponding author), Ankara Ataturk Sanat Training & Res Hosp, Dept Pulmonol, TR-06290 Ankara, Turkiye. EM masidetuten@icloud.com; dremrahari25@gmail.com RI arı, Emrah/KLY-9201-2024; Arı, Maşide/KLD-3383-2024 OI Arı, Maşide/0000-0002-5078-3176 CR Adler D, 2017, AM J RESP CRIT CARE, V196, P200, DOI 10.1164/rccm.201608-1666OC Almarshoodi K, 2024, HOSP PHARM, V59, P234, DOI 10.1177/00185787231209218 [Anonymous], 2019, WORLD POPULATION PRO, DOI DOI 10.18356/13BF5476-EN Ari M, 2025, DIAGNOSTICS, V15, DOI 10.3390/diagnostics15010014 Barisich PS, 2024, REV ASSOC MED BRAS, V70, DOI 10.1590/1806-9282.20240463 Chung E, 2023, BMC GERIATR, V23, DOI 10.1186/s12877-023-04526-5 Chung YW, 2024, BMJ OPEN RESPIR RES, V11, DOI 10.1136/bmjresp-2023-002266 Echevarria C, 2016, THORAX, V71, P133, DOI 10.1136/thoraxjnl-2015-207775 Flaatten H, 2021, CHEST, V160, P1587, DOI 10.1016/j.chest.2021.06.012 Guillon A, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03100-4 Hong Y, 2022, TUBERC RESPIR DIS, V85, P195, DOI 10.4046/trd.2021.0106 Hu X, 2024, INT J TUBERC LUNG D, V28, P564, DOI 10.5588/ijtld.24.0252 Jiang JC, 2023, ARTIF INTELL MED, V138, DOI 10.1016/j.artmed.2022.102437 MacIntyre NR, 2023, RESP CARE, V68, P973, DOI 10.4187/respcare.10560 Rousseau AF, 2021, CRIT CARE, V25, DOI 10.1186/s13054-021-03535-3 Shen MH, 2021, EUR REV MED PHARMACO, V25, P4037, DOI 10.26355/eurrev_202106_26045 Simpson A, 2021, J INTENSIVE CARE SOC, V22, P143, DOI 10.1177/1751143720914229 Sjoding MW, 2016, CRIT CARE MED, V44, P1353, DOI 10.1097/CCM.0000000000001664 Vykopal Martin, 2023, Cas Lek Cesk, V162, P13 NR 19 TC 3 Z9 3 U1 0 U2 1 PU MDPI PI BASEL PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND EI 2075-1729 J9 LIFE-BASEL JI Life-Basel PD MAR 24 PY 2025 VL 15 IS 4 AR 533 DI 10.3390/life15040533 PG 12 WC Biology; Microbiology WE Science Citation Index Expanded (SCI-EXPANDED) SC Life Sciences & Biomedicine - Other Topics; Microbiology GA 1YK3S UT WOS:001476605000001 PM 40283088 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Liu, GX Diao, F Lu, G Zheng, Q Fu, B Jiao, HC Wang, KZ Liu, DH AF Liu, Guo-Xuan Diao, Fan Lu, Guang Zheng, Qiang Fu, Bin Jiao, Hua-Chen Wang, Ke-Zhou Liu, Dong-Hai TI Alectinib causes sinus bradycardia by suppressing L-type calcium current in sinus node SO EUROPEAN JOURNAL OF PHARMACOLOGY LA English DT Article DE Alectinib; Cacna1d; Cardio-oncology; Sinus bradycardia; L -type calcium current ID CELL LUNG-CANCER; ATRIAL-FIBRILLATION; FUNNY CURRENT; CHANNELS; DYSFUNCTION; EXPRESSION; CH5424802 AB Alectinib is the first-line therapy for anaplastic lymphoma kinase rearranged non-small cell lung cancer globally. Sinus bradycardia, as the major adverse cardiac events of alectinib, still widely impact patient's quality of life. However, its underlying mechanism remains elusive. The aim of this study was to reveal the pathogenesis of the alectinib induced sinus bradycardia (AISB) in a rat model, including the electrophysiology alterations and the molecular mechanism. SD rats were administered alectinib (10 mg/kg/day) by gavage for 7-10 days to mimic the clinical AISB. 3-days alectinib treatment did not change heart rate and sinus node recovery time (SNRT) as assessed through in vivo electrophysiology study. Also, alectinib didn't influence automaticity in isolated heart or single sinus node cardiomyocytes, indicating alectinib cannot decrease sinus node function rapidly. The decreased heart rate and prolonged SNRT was found after 7-days alectinib treatment. The inducibility of atrial fibrillation was not affected under the same condition. The RNA-seq assay revealed the transcriptomic alterations in sinus node of alectinib treated rats, and the dysregulation of genes in cardiac function were observed. The decreased expression of L-type calcium channel Cacna1d was confirmed among the channel candidates identified from RNA-seq assay. Subsequently, the patch-clamp test revealed the reduction in the corresponding L-type calcium current density in 7-days alectinib treated rats. These findings revealed that the AISB was caused by the reduction in Cacna1d expression which resulted in the electro-dysfunction mediated by the suppressed ICaL. C1 [Liu, Guo-Xuan; Diao, Fan; Zheng, Qiang; Fu, Bin; Wang, Ke-Zhou; Liu, Dong-Hai] Shandong First Med Univ & Shandong Acad Med Sci, Sch Lab Anim, Jinan, Peoples R China. [Liu, Guo-Xuan; Diao, Fan; Zheng, Qiang; Fu, Bin; Wang, Ke-Zhou; Liu, Dong-Hai] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Lab Anim Ctr, Jinan, Peoples R China. [Lu, Guang] Shengli Oilfield Cent Hosp, Dept Hematol, Dongying, Peoples R China. [Jiao, Hua-Chen] Shandong Univ Tradit Chinese Med, Dept Cardiol, Affiliated Hosp, Jinan, Peoples R China. C3 Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University of Traditional Chinese Medicine RP Liu, DH (corresponding author), Shandong First Med Univ & Shandong Acad Med Sci, 6699 Qingdao Rd, Jinan 250000, Shandong, Peoples R China. EM liudonghai@sdfmu.edu.cn OI Liu, Donghai/0009-0006-3270-7651 FU Natural Science Foundation of Shandong Province, China [2022HWYQ-080, ZR2022QC163] FX This work was supported by the Natural Science Foundation of Shandong Province, China (Grant No: 2022HWYQ-080 and ZR2022QC163) . CR Baig SM, 2011, NAT NEUROSCI, V14, P77, DOI 10.1038/nn.2694 Camidge DR, 2019, J THORAC ONCOL, V14, P1233, DOI 10.1016/j.jtho.2019.03.007 Chia PL, 2014, CLIN EPIDEMIOL, V6, P423, DOI 10.2147/CLEP.S69718 Díaz-Serrano A, 2018, DRUGS, V78, P893, DOI 10.1007/s40265-018-0916-4 DiFrancesco D, 2010, CIRC RES, V106, P434, DOI 10.1161/CIRCRESAHA.109.208041 Hennis K, 2024, CIRC RES, V134, P1348, DOI 10.1161/CIRCRESAHA.123.323250 Hiram R, 2019, J AM COLL CARDIOL, V74, P1332, DOI 10.1016/j.jacc.2019.06.066 Iwasaki YK, 2014, J AM COLL CARDIOL, V64, P2013, DOI 10.1016/j.jacc.2014.05.077 Jin Y, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00891 Kapoor N, 2013, NAT BIOTECHNOL, V31, P54, DOI 10.1038/nbt.2465 Liu DH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22737-5 Liu YH, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.858279 Mangoni ME, 2006, CIRC RES, V98, P1422, DOI 10.1161/01.RES.0000225862.14314.49 Mangoni ME, 2003, P NATL ACAD SCI USA, V100, P5543, DOI 10.1073/pnas.0935295100 Morcos PN, 2017, CANCER CHEMOTH PHARM, V79, P559, DOI 10.1007/s00280-017-3253-5 Muto T, 2007, AM J PHYSIOL-HEART C, V293, pH2710, DOI 10.1152/ajpheart.01399.2006 Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI [10.4103/0976-0105.177703, 10.4103/0976-0105.177703] Paik J, 2018, DRUGS, V78, P1247, DOI 10.1007/s40265-018-0952-0 Pikor LA, 2013, LUNG CANCER, V82, P179, DOI 10.1016/j.lungcan.2013.07.025 Pineda-Gayoso R, 2020, CURR TREAT OPTION ON, V21, DOI 10.1007/s11864-020-00764-6 Platzer J, 2000, CELL, V102, P89, DOI 10.1016/S0092-8674(00)00013-1 Pruis M.A., 2022, JACC. CardioOncol Sakamoto H, 2011, CANCER CELL, V19, P679, DOI 10.1016/j.ccr.2011.04.004 Salem JE, 2019, J AM COLL CARDIOL, V74, P1667, DOI 10.1016/j.jacc.2019.07.056 Seto T, 2013, LANCET ONCOL, V14, P590, DOI 10.1016/S1470-2045(13)70142-6 Shah RR, 2013, DRUG SAFETY, V36, P295, DOI 10.1007/s40264-013-0047-5 Sunder SS, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392-023-01469-6 Toyoda F, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08191-8 van der Maarel LE, 2023, DIS MODEL MECH, V16, DOI 10.1242/dmm.050101 Xiao L, 2020, CIRCULATION, V142, P2443, DOI 10.1161/CIRCULATIONAHA.120.049210 Yeh YH, 2009, CIRCULATION, V119, P1576, DOI 10.1161/CIRCULATIONAHA.108.789677 Yuan DQ, 2023, THORAC CANCER, V14, P479, DOI 10.1111/1759-7714.14769 Zang JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030353 Zhang Z, 2005, CIRCULATION, V112, P1936, DOI 10.1161/CIRCULATIONAHA.105.540070 Zhang Zhushan, 2017, Cardiooncology, V3, DOI [10.1186/s40959-017-0020-z, 10.1007/s12559-017-9484-2, 10.1186/s40959-017-0020-z] NR 35 TC 1 Z9 1 U1 3 U2 8 PU ELSEVIER PI AMSTERDAM PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS SN 0014-2999 EI 1879-0712 J9 EUR J PHARMACOL JI Eur. J. Pharmacol. PD JUL 5 PY 2025 VL 998 AR 177527 DI 10.1016/j.ejphar.2025.177527 EA MAR 2025 PG 10 WC Pharmacology & Pharmacy WE Science Citation Index Expanded (SCI-EXPANDED) SC Pharmacology & Pharmacy GA 0UB0Y UT WOS:001456020500001 PM 40118326 DA 2026-04-17 ER PT J AU Brascia, D Mangiameli, G Giudici, VM Cecconi, ER Luppichini, M Marulli, G AF Brascia, Debora Mangiameli, Giuseppe Giudici, Veronica Maria Re Cecconi, Emanuela Luppichini, Matilde Marulli, Giuseppe TI Does the surgical approach affect the incidence of postoperative atrial fibrillation after thoracic surgery? A systematic review and meta-analysis SO UPDATES IN SURGERY LA English DT Article DE Open thoracotomy; Postoperative atrial fibrillation; Surgical approach; VATS ID RISK-FACTORS; LUNG-CANCER; LOBECTOMY; PREVENTION; MECHANISMS; SOCIETY; ONSET; AGE AB Postoperative atrial fibrillation (PAF) is a common complication after lung resection, since surgical stress may act as a trigger. The VATS approach reduces surgical stress and alleviates inflammation and oxidative stress commonly associated with open lung surgery. However, only a few studies have investigated the possible impact of the surgical approach on the incidence of PAF. A literature review was performed through PubMed, EMBASE, and Google Scholar in March 2024, to identify any study published since 2000 evaluating the role of the VATS vs the open approach to perform lung resections as a risk factor for postoperative atrial fibrillation. Pooled odds ratio (OR) estimates with 95% confidence intervals (CIs) were calculated. Twenty-one studies, including 59,101 patients, met the criteria for inclusion. Both propensity-matched and non-matched data showed that VATS was associated with a significant reduction in PAF compared to open thoracotomy (OT) (OR 0.73; 95% CI 0.58-0.91; I2 = 10.1%, p = 0.349). A meta-regression was conducted to explore contributing factors, showing the geographic regions in which the studies were conducted may be a significant source of heterogeneity. Subgroup analyses revealed less heterogeneity in studies conducted in Europe and on those focused solely on lobectomy. Postoperative atrial fibrillation risk following VATS is significantly lower than OT. Further prospective randomized controlled trials with large sample sizes are needed to confirm these findings. C1 [Brascia, Debora; Mangiameli, Giuseppe; Marulli, Giuseppe] Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini 4 Pieve Emanuele, I-20072 Milan, Italy. [Brascia, Debora; Mangiameli, Giuseppe; Giudici, Veronica Maria; Re Cecconi, Emanuela; Luppichini, Matilde; Marulli, Giuseppe] IRCCS Humanitas Res Hosp, Div Thorac Surg, Via Manzoni 56, I-20089 Milan, Italy. C3 Humanitas University RP Marulli, G (corresponding author), Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini 4 Pieve Emanuele, I-20072 Milan, Italy.; Marulli, G (corresponding author), IRCCS Humanitas Res Hosp, Div Thorac Surg, Via Manzoni 56, I-20089 Milan, Italy. EM giuseppe.marulli@hunimed.eu RI MARULLI, GIUSEPPE/LOS-8884-2024; Mangiameli, Giuseppe/AAX-1916-2020; Brascia, Debora/HKN-8837-2023 OI MARULLI, GIUSEPPE/0000-0001-6570-615X; Mangiameli, Giuseppe/0000-0002-8394-2719; Brascia, Debora/0000-0003-0860-1647 CR Allessie MA, 2001, CIRCULATION, V103, P769 Amar D, 2003, J AM COLL CARDIOL, V42, P1262, DOI 10.1016/S0735-1097(03)00955-0 Amar D, 2002, ANESTHESIOLOGY, V96, P352, DOI 10.1097/00000542-200202000-00021 Amar D, 2006, ANN THORAC SURG, V82, P1057, DOI 10.1016/j.athoracsur.2006.03.103 Amar D, 2019, J THORAC CARDIOV SUR, V157, P2493, DOI 10.1016/j.jtcvs.2019.01.075 Berry MF, 2014, ANN THORAC SURG, V98, P1199, DOI 10.1016/j.athoracsur.2014.05.038 Bland JM, 2000, BRIT MED J, V320, P1468, DOI 10.1136/bmj.320.7247.1468 Crispi V, 2022, POSTGRAD MED J, V98, P177, DOI 10.1136/postgradmedj-2020-138904 Demmy TL, 1999, ANN THORAC SURG, V68, P194, DOI 10.1016/S0003-4975(99)00467-1 Dyszkiewicz W, 1998, EUR J CARDIO-THORAC, V13, P625, DOI 10.1016/S1010-7940(98)00084-0 Echahidi N, 2008, J AM COLL CARDIOL, V51, P793, DOI 10.1016/j.jacc.2007.10.043 EGGER M, 1997, BMJ-BRIT MED J, V315, DOI DOI 10.1136/BMJ.315.7109.629 Falcoz PE, 2016, EUR J CARDIO-THORAC, V49, P602, DOI 10.1093/ejcts/ezv154 Fong LS, 2020, ANZ J SURG, V90, P752, DOI 10.1111/ans.15788 Garner M, 2017, INTERACT CARDIOV TH, V24, P260, DOI 10.1093/icvts/ivw348 Gómez-Caro A, 2006, ARCH BRONCONEUMOL, V42, P9, DOI 10.1016/S1579-2129(06)60107-9 Halloran SJ, 2024, J SURG RES, V295, P350, DOI 10.1016/j.jss.2023.11.031 Harbord RM, 2006, STAT MED, V25, P3443, DOI 10.1002/sim.2380 He GX, 2020, J CARDIOTHORAC SURG, V15, DOI 10.1186/s13019-020-01260-6 Hollings DD, 2010, AM J SURG, V199, P558, DOI 10.1016/j.amjsurg.2009.11.006 Ishibashi H, 2020, WORLD J SURG, V44, P3952, DOI 10.1007/s00268-020-05694-w Ivanovic J, 2014, INTERACT CARDIOV TH, V18, P340, DOI 10.1093/icvts/ivt520 Kotova S, 2017, ANN THORAC SURG, V103, P1566, DOI 10.1016/j.athoracsur.2016.11.007 Lee SH, 2016, ANAESTHESIA, V71, P1424, DOI 10.1111/anae.13644 Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135 Muranishi Y, 2017, SURG TODAY, V47, P252, DOI 10.1007/s00595-016-1380-y Nojiri T, 2015, WORLD J SURG, V39, P1092, DOI 10.1007/s00268-015-2943-6 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Park BJ, 2007, J THORAC CARDIOV SUR, V133, P775, DOI 10.1016/j.jtcvs.2006.09.022 Richardson WS., 1995, ACP J CLUB, V123, pA12, DOI [DOI 10.7326/ACPJC-1995-123-3-A12, 10.7326/ACPJC-1995-123-3-A12] Scheggi V, 2023, CARDIOTHORAC SURG, V31, DOI 10.1186/s43057-023-00109-7 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Veiga Oliveira Paulo, 2021, Port J Card Thorac Vasc Surg, V28, P33, DOI 10.48729/pjctvs.192 Villamizar NR, 2009, J THORAC CARDIOV SUR, V138, P419, DOI 10.1016/j.jtcvs.2009.04.026 Wang H, 2021, J THORAC DIS, V13, DOI 10.21037/jtd-20-1717 Wells G, NEWCASTLE OTTAWA SCA Xin YZ, 2014, EUR J CARDIO-THORAC, V45, P247, DOI 10.1093/ejcts/ezt383 Zhang CK, 2024, BMC SURG, V24, DOI 10.1186/s12893-024-02331-4 NR 38 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER-VERLAG ITALIA SRL PI MILAN PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY SN 2038-131X EI 2038-3312 J9 UPDATES SURG JI Updates Surg. PD SEP PY 2025 VL 77 IS 5 BP 1279 EP 1288 DI 10.1007/s13304-025-02164-7 EA MAR 2025 PG 10 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA 7EI3D UT WOS:001443850900001 PM 40082340 DA 2026-04-17 ER PT J AU El-Rayes, M Adam, M Fang, LM Wang, XS Leong, I Austin, PC Ha, ACT Fradley, MG Boyle, TA Amir, E Thavendiranathan, P Abdel-Qadir, H AF El-Rayes, Malak Adam, Mohamed Fang, Liming Wang, Xuesong Leong, Irene Austin, Peter C. Ha, Andrew C. T. Fradley, Michael G. Boyle, Thomas A. Amir, Eitan Thavendiranathan, Paaladinesh Abdel-Qadir, Husam TI The Association of Malignancy With Stroke and Bleeding in Atrial Fibrillation A Population-Based Cohort Study SO JACC: CARDIOONCOLOGY LA English DT Article DE anticoagulation; arrhythmia; ATRIA; atrial fibrillation; bleeding; cancer; cerebrovascular disease; CHA2DS2-VASc score; epidemiology; stroke; thrombosis ID ARTERIAL THROMBOEMBOLISM; TERM OUTCOMES; RISK-FACTOR; CANCER; SCORE; VALIDATION; HEMORRHAGE; ACCURACY AB BACKGROUND It is undetermined if malignancy independently increases stroke risk in atrial fibrillation (AF). OBJECTIVES This study sought to determine the association of malignancy with stroke and bleeding in AF. METHODS Population-based cohort study using administrative datasets of people aged >= 66 years with newly diagnosed AF. People diagnosed with malignancy within 5 years before AF diagnosis were matched to cancer-free control subjects on age, sex, AF diagnosis details, CHA2DS2-VASc score, and ATRIA bleeding score. Outcomes included hospitalizations for stroke and hospitalization/emergency visits for bleeding. Cause-specific regression was used to determine the HR for malignancy after adjusting for time-varying anticoagulation status. Analyses were repeated for specific subgroups of cancer patients (with matched control subjects). RESULTS Among 199,710 AF patients, 24,991 (12.5%) people had prior malignancy. Malignancy was associated with more inpatient diagnoses of AF (vs outpatient) and less anticoagulation. We matched 43,802 people with AF (21,901 with malignancy, mean age 78.1 years; 59.5% male). After adjusting for anticoagulation status, malignancy had a similar hazard of stroke (HR: 1.01; 95% CI: 0.88-1.15) but higher hazard of bleeding (HR: 1.45; 95% CI: 1.37-1.53) compared with cancer-free control subjects in the matched sample. Analyses of cancer subgroups with comparison to matched control subjects mostly showed consistent results, except for: 1) increased hazard of stroke in lung cancer; and 2) lack of increased bleeding hazard in breast cancer and lymphoma. CONCLUSIONS People with AF and malignancy generally had similar hazards of stroke but higher hazards of bleeding compared with cancer-free control subjects, suggesting that malignancy should not lower the threshold for anticoagulation in AF. (J ACC CardioOncol. 2025;7:157-167) (c) 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). C1 [El-Rayes, Malak; Ha, Andrew C. T.; Thavendiranathan, Paaladinesh; Abdel-Qadir, Husam] Univ Hlth Network, Dept Med, Div Cardiol, Toronto, ON, Canada. [El-Rayes, Malak] Hop Cite la Sante, Ctr Integre Sante & Serv Sociaux Laval, Dept Med, Div Cardiol, Laval, PQ, Canada. [El-Rayes, Malak] Univ Montreal, Dept Med, Montreal, PQ, Canada. [El-Rayes, Malak; Thavendiranathan, Paaladinesh; Abdel-Qadir, Husam] Ted Rogers Program Cardiotox Prevent, Toronto, ON, Canada. [Adam, Mohamed; Abdel-Qadir, Husam] Womens Coll Hosp, Room 6452, 76 Grenville St, Toronto, ON M5S1B2, Canada. [Adam, Mohamed] Univ Toronto, Temerty Fac Med, Toronto, ON, Canada. [Fang, Liming; Wang, Xuesong; Leong, Irene; Austin, Peter C.; Abdel-Qadir, Husam] ICES, Toronto, ON, Canada. [Austin, Peter C.; Abdel-Qadir, Husam] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada. [Fradley, Michael G.; Boyle, Thomas A.] Univ Penn, Perelman Sch Med, Philadelphia, PA USA. [Amir, Eitan] Univ Hlth Network, Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada. C3 University of Toronto; University Health Network Toronto; Centre Integre de Sante et de Services Sociaux de Laval; Universite de Montreal; University of Toronto; Womens College Hospital; University of Toronto; University of Toronto; University of Toronto; University of Pennsylvania; University of Toronto; University Health Network Toronto; Princess Margaret Cancer Centre RP Abdel-Qadir, H (corresponding author), Womens Coll Hosp, Room 6452, 76 Grenville St, Toronto, ON M5S1B2, Canada. EM h.abdel.qadir@utoronto.ca RI Amir, Eitan/L-6052-2019; Boyle, Thomas/AAW-6319-2021 FU Canadian Cardiovascular Society Atrial Fibrillation Research Award; Ted Rogers Program in Cardiotoxicity Prevention; Heart & Stroke/Richard Lewar Centre of Excellence in Cardiovascular Research; Heart and Stroke Foundation of Canada; Tier II Canada Research Chair; Canadian Cancer Society/Canadian Institutes of Health Research's W. David Hargraft Grant [706710]; ICES - Ontario Ministry of Health; Ministry of Long-Term Care; Medtronic; AstraZeneca FX This study was funded by the Canadian Cardiovascular Society Atrial Fibrillation Research Award and the Ted Rogers Program in Cardiotoxicity Prevention. Dr Adam was funded by the Heart & Stroke/Richard Lewar Centre of Excellence in Cardiovascular Research. Dr Abdel-Qadir was supported by a National New Investigator Award from the Heart and Stroke Foundation of Canada. Dr Thavendiranathan was supported by a Tier II Canada Research Chair and the Canadian Cancer Society/Canadian Institutes of Health Research's W. David Hargraft Grant (no. 706710) . This study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and the Ministry of Long-Term Care. This study also received funding from the sources described previously. The analyses, conclusions, opinions and statements expressed herein are solely those of the authors and do not reflect those of the funding or data sources; no endorsement is intended or should be inferred. Dr Abdel-Qadir has received consulting and speaker honoraria from Amgen, AstraZeneca, and Jazz Pharmaceuticals. Dr Amir has received honoraria from Seagen, Gilead, Pfizer, and Novartis; and served as a consultant or advisor for AstraZeneca and Novartis. Dr Ha has received speaker honoraria from Bayer, BMS/Pfizer Alliance, and Servier. Dr Thavendiranathan has received consulting and speaker honoraria from G E, Amgen, Boehringer Ingelheim, and AstraZeneca. Dr Fradley has received research grants from Medtronic and AstraZeneca; and consulting fees from AstraZeneca, AbbVie, Janssen, Johnson and Johnson, Pfizer, and Zoll. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. CR Abdel-Qadir H, 2022, CIRCULATION, V146, P159, DOI 10.1161/CIRCULATIONAHA.122.058949 Abdel-Qadir H, 2021, J CLIN ONCOL, V39, P3453, DOI 10.1200/JCO.21.00693 Abdel-Qadir H, 2021, JAMA CARDIOL, V6, P918, DOI 10.1001/jamacardio.2021.1232 Abdel-Qadir H, 2018, CIRC-CARDIOVASC QUAL, V11, DOI 10.1161/CIRCOUTCOMES.118.004580 [Anonymous], 2004, Personal Health Information Protection Act Ardeshirrouhanifard S, 2022, PHARMACOTHERAPY, V42, P375, DOI 10.1002/phar.2679 Arnason T, 2006, THROMB RES, V118, P253, DOI 10.1016/j.thromres.2005.06.015 Aspberg S, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2019.104560 Austin PC, 2024, JAMA-J AM MED ASSOC, V331, P2125, DOI 10.1001/jama.2024.4970 Austin PC, 2020, STAT MED, V39, P103, DOI 10.1002/sim.8399 Austin PC, 2016, CIRCULATION, V133, P601, DOI 10.1161/CIRCULATIONAHA.115.017719 Austin PC, 2009, COMMUN STAT-SIMUL C, V38, P1228, DOI 10.1080/03610910902859574 Buhari H, 2024, EUR HEART J, V45, P104, DOI 10.1093/eurheartj/ehad508 Bungo B, 2022, IJC HEART VASC, V41, DOI 10.1016/j.ijcha.2022.101072 D'Souza M, 2018, EUR J PREV CARDIOL, V25, P651, DOI 10.1177/2047487318759858 Fang MC, 2011, J AM COLL CARDIOL, V58, P395, DOI 10.1016/j.jacc.2011.03.031 Farmakis D, 2014, J AM COLL CARDIOL, V63, P945, DOI 10.1016/j.jacc.2013.11.026 Gage BF, 2006, AM HEART J, V151, P713, DOI 10.1016/j.ahj.2005.04.017 Gervaso L, 2021, JACC-CARDIOONCOL, V3, P173, DOI 10.1016/j.jaccao.2021.03.001 Hall R, 2016, CAN J NEUROL SCI, V43, P765, DOI 10.1017/cjn.2016.278 Hindricks Gerhard, 2021, Eur Heart J, V42, P373, DOI 10.1093/eurheartj/ehaa612 Isogai T, 2021, AM J CARDIOL, V141, P154, DOI 10.1016/j.amjcard.2020.12.003 Jakobsen CB, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6314-9 Joglar JA, 2024, J AM COLL CARDIOL, V83, P109, DOI [10.1016/j.jacc.2023.08.017, 10.1161/CIR.0000000000001193] Kattelus H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205454 Leader A, 2023, JACC-CARDIOONCOL, V5, DOI 10.1016/j.jaccao.2022.08.014 Leiva O, 2021, JACC-CARDIOONCOL, V3, P619, DOI 10.1016/j.jaccao.2021.08.011 Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006 Lip GYH, 2011, J AM COLL CARDIOL, V57, P173, DOI 10.1016/j.jacc.2010.09.024 Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584 Lubitz SA, 2015, CIRCULATION, V131, P1648, DOI 10.1161/CIRCULATIONAHA.114.014058 Lyon Alexander R, 2022, Eur Heart J Cardiovasc Imaging, V23, pe333, DOI [10.1093/eurheartj/ehac244, 10.1093/ehjci/jeac106] Malavasi VL, 2022, EUR J CLIN INVEST, V52, DOI 10.1111/eci.13773 Matetic A, 2023, EUR HEART J-QUAL CAR, V9, P749, DOI 10.1093/ehjqcco/qcac090 Mcintyre WF, 2023, ANN INTERN MED, V176, P1299, DOI 10.7326/M23-1411 Nakajima E, 2023, CJC OPEN, V5, P597, DOI 10.1016/j.cjco.2023.05.007 Navi BB, 2017, J AM COLL CARDIOL, V70, P927, DOI 10.1016/j.jacc.2017.06.047 Nielsen PB, 2018, CIRCULATION, V137, P832, DOI 10.1161/CIRCULATIONAHA.117.029081 Pastori D, 2022, INTERN EMERG MED, DOI 10.1007/s11739-022-03156-w Pastori D, 2021, CANCER-AM CANCER SOC, V127, P2122, DOI 10.1002/cncr.33470 ROBLES SC, 1988, J CLIN EPIDEMIOL, V41, P495, DOI 10.1016/0895-4356(88)90052-2 Roubín SR, 2022, AM J CARDIOL, V167, P139, DOI 10.1016/j.amjcard.2021.11.053 Schull M J, 2020, Int J Popul Data Sci, V4, P1135, DOI [10.23889/ijpds.v4i2.1135, 10.23889/ijpds.v4i2.1135] Shabtaie SA, 2023, JACC-CARDIOONCOL, V5, P203, DOI 10.1016/j.jaccao.2022.10.016 Siegel RL, 2023, CA-CANCER J CLIN, V73, P17, DOI 10.3322/caac.21763 Sorigue M, 2019, J ONCOL PRACT, V15, P641, DOI 10.1200/JOP.18.00592 Thomas LE, 2021, JAMA CARDIOL, V6, P871, DOI 10.1001/jamacardio.2021.1239 Tsao CW, 2023, CIRCULATION, V147, pE93, DOI 10.1161/CIR.0000000000001123 Tu JV, 2015, CIRC-CARDIOVASC QUAL, V8, P204, DOI 10.1161/CIRCOUTCOMES.114.001416 Tu K, 2016, CAN J CARDIOL, V32, P1561, DOI 10.1016/j.cjca.2016.06.006 NR 50 TC 3 Z9 3 U1 0 U2 1 PU ELSEVIER PI AMSTERDAM PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS SN 2666-0873 J9 JACC-CARDIOONCOL JI JACC-Cardiooncol. PD FEB PY 2025 VL 7 IS 2 BP 157 EP 167 DI 10.1016/j.jaccao.2024.10.014 EA FEB 2025 PG 11 WC Oncology; Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Cardiovascular System & Cardiology GA Y1Z0K UT WOS:001430180400001 PM 39967202 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Liang, XY Li, PW Qin, YW Yu, JM Mo, Y Chen, DW AF Liang, Xinyi Li, Pengwei Qin, Yiwei Yu, Jinming Mo, You Chen, Dawei TI Excessive lymph node dissection increases postoperative cardiovascular disease risk in non-small cell lung cancer patients SO SCIENTIFIC REPORTS LA English DT Article DE Lymph node dissection; Surgical treatment; Non-small cell lung cancer; Radiotherapy; Cardiovascular death ID ATRIAL-FIBRILLATION; RANDOMIZED-TRIAL; RADIOTHERAPY; RESECTION; SURVIVAL; IMPACT; COUNT AB Heart disease is the second leading cause of death in lung cancer (LC) patients, with postoperative cardiovascular disease (CVD) commonly linked to lymph node dissection (LND). This study aimed to clarify the optimal number of lymph nodes (LNs) to be dissected by investigating the impact of LND on CVD related death in patients with surgically resected non-small cell lung cancer (NSCLC). We analyzed data from the Surveillance, Epidemiology, and End Results (SEER) database for a total of 154,566 patients with stage IA-IIIA NSCLC that underwent curative surgery from 2000 to 2020, and further validated using clinical data from a single-center cohort. For patients with negative lymph nodes, the optimal LND threshold was 3 without RT (SHR = 0.909, 95% CI: 0.841-0.982, p = 0.016) and 11 with RT (SHR = 0.877, 95% CI: 0.757-1.015, p = 0.079). For positive lymph nodes (PLNs), 0.53 was the structural breakpoint for the PLNs ratio (p < 0.001). Data from a single-center cohort of 200 patients showed that with LND between 10 and 12, cardiovascular events significantly increased (OR = 18.870, p = 0.044). Excessive dissection of immune-functioning LNs may contribute to the occurrence of death from heart disease and amplify the effects of RT on cardiovascular mortality. C1 [Liang, Xinyi] Shandong Second Med Univ, Sch Clin Med, Weifang 261000, Shandong, Peoples R China. [Liang, Xinyi; Li, Pengwei; Qin, Yiwei; Yu, Jinming; Chen, Dawei] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Shandong Prov Key Lab Precis Oncol, 440 Jiyan Rd, Jinan 250000, Shandong, Peoples R China. [Mo, You] Shantou Univ, Med Coll, Dept Cardiovasc Med, Affiliated Hosp 1, Shantou 515000, Guangdong, Peoples R China. [Qin, Yiwei] Shandong Univ, Cheeloo Coll Med, Dept Radiat Oncol, Jinan 250012, Shandong, Peoples R China. C3 Shandong Second Medical University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shantou University; Shandong University RP Chen, DW (corresponding author), Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Shandong Prov Key Lab Precis Oncol, 440 Jiyan Rd, Jinan 250000, Shandong, Peoples R China.; Mo, Y (corresponding author), Shantou Univ, Med Coll, Dept Cardiovasc Med, Affiliated Hosp 1, Shantou 515000, Guangdong, Peoples R China. EM moyou.moyou@163.com; dave0505@yeah.net RI Liang, xinyi/MSW-6318-2025; Li, Pengwei/GPK-6660-2022; mo, you/GZB-1291-2022 FU National Natural Science Foundation of China [82172676, 82373217]; Natural Science Foundation of Shandong [ZR2024JQ032]; Shandong Natural Science Foundation Major Basic Research Project [ZR2023ZD26]; State Key Program of National Natural Science of China [82030082] FX This work was funded by the National Natural Science Foundation of China (82172676, 82373217), the Natural Science Foundation of Shandong (ZR2024JQ032), Shandong Natural Science Foundation Major Basic Research Project (ZR2023ZD26), Project supported by the State Key Program of National Natural Science of China (82030082). CR Ahn HJ, 2005, EUR J CARDIO-THORAC, V28, P19, DOI 10.1016/j.ejcts.2005.01.017 Asamura H, 2023, J THORAC ONCOL, V18, P564, DOI 10.1016/j.jtho.2023.01.088 Aspelund A, 2016, CIRC RES, V118, P515, DOI 10.1161/CIRCRESAHA.115.306544 Boos CJ, 2006, EUR HEART J, V27, P136, DOI 10.1093/eurheartj/ehi645 Burdett S, 2013, LUNG CANCER, V80, P350, DOI 10.1016/j.lungcan.2013.02.005 Cardinale D, 2016, ANN SURG, V264, P244, DOI 10.1097/SLA.0000000000001626 Chelazzi C, 2011, ISRN Cardiol, V2011, P203179, DOI 10.5402/2011/203179 Chiappetta M, 2019, EUR J CARDIO-THORAC, V55, P405, DOI 10.1093/ejcts/ezy311 Corso CD, 2015, J THORAC ONCOL, V10, P148, DOI 10.1097/JTO.0000000000000406 Darling GE, 2011, J THORAC CARDIOV SUR, V141, P662, DOI 10.1016/j.jtcvs.2010.11.008 Deng HS, 2024, INT J SURG, V110, P238, DOI 10.1097/JS9.0000000000000774 Felip E, 2023, ANN ONCOL, V34, P907, DOI 10.1016/j.annonc.2023.07.001 Forde PM, 2022, NEW ENGL J MED, V386, P1973, DOI 10.1056/NEJMoa2202170 Hanahan D, 2022, CANCER DISCOV, V12, P31, DOI 10.1158/2159-8290.CD-21-1059 He M, 2023, J IMMUNOTHER CANCER, V11, DOI 10.1136/jitc-2022-005539 Jin Y, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.012219 Lamm G, 2006, J CARDIOTHOR VASC AN, V20, P51, DOI 10.1053/j.jvca.2005.03.026 Lardinois D, 2005, ANN THORAC SURG, V80, P268, DOI 10.1016/j.athoracsur.2005.02.005 Le Pechoux C, 2022, LANCET ONCOL, V23, P104, DOI 10.1016/S1470-2045(21)00606-9 Liang WH, 2017, J CLIN ONCOL, V35, P1162, DOI 10.1200/JCO.2016.67.5140 Liu XL, 2020, NATURE, V588, P705, DOI 10.1038/s41586-020-2998-x Nakagawa K, 2021, EUR J CARDIO-THORAC, V59, P109, DOI 10.1093/ejcts/ezaa267 Natl Hlth Comm People's Republic, 2019, CHINESE J CANCER RES, V31, P1, DOI 10.21147/j.issn.1000-9604.2019.01.01 Oka T, 2001, ANESTH ANALG, V93, P253, DOI 10.1097/00000539-200108000-00003 Raisi-Estabragh Z, 2023, HEART, V109, P1007, DOI 10.1136/heartjnl-2022-321888 Rami-Porta R, 2024, J THORAC ONCOL, V19, P1007, DOI 10.1016/j.jtho.2024.02.011 Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914 Riely GJ, 2024, J NATL COMPR CANC NE, V22, P249, DOI 10.6004/jnccn.2204.0023 Song Guoyuan, 2024, Cardiol Rev, DOI [10.1097/crd.0000000000000743, 10.1097/CRD.0000000000000743] Vieira JM, 2018, J CLIN INVEST, V128, P3402, DOI 10.1172/JCI97192 Wu YL, 2002, LUNG CANCER-J IASLC, V36, P1, DOI 10.1016/S0169-5002(01)00445-7 Zhang Y, 2023, J THORAC ONCOL, V18, P931, DOI 10.1016/j.jtho.2023.02.010 Zhou J, 2020, JPN J CLIN ONCOL, V50, P44, DOI 10.1093/jjco/hyz120 Zhu ZH, 2021, TRANSL LUNG CANCER R, V10, P815, DOI 10.21037/tlcr-20-1024 NR 34 TC 3 Z9 3 U1 3 U2 6 PU NATURE PORTFOLIO PI BERLIN PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD FEB 17 PY 2025 VL 15 IS 1 AR 5698 DI 10.1038/s41598-025-90052-w PG 11 WC Multidisciplinary Sciences WE Science Citation Index Expanded (SCI-EXPANDED) SC Science & Technology - Other Topics GA X3L3V UT WOS:001424402700031 PM 39962283 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Bak, M Park, H Lee, SH Lee, N Ahn, MJ Ahn, JS Jung, HA Park, S Cho, J Kim, J Park, SJ Chang, SA Lee, SC Park, SW Kim, EK AF Bak, Minjung Park, Hyukjin Lee, Se-Hoon Lee, Nuri Ahn, Myung-Ju Ahn, Jin Seok Jung, Hyun Ae Park, Sehhoon Cho, Jinhyun Kim, Jihoon Park, Sung-Ji Chang, Sung-A Lee, Sang-Chol Park, Seung Woo Kim, Eun Kyoung TI The Risk and Reversibility of Osimertinib-Related Cardiotoxicity in a Real-World Population SO JOURNAL OF THORACIC ONCOLOGY LA English DT Article DE Osimertinib; Cardiotoxicity; EGFR-mutated NSCLC; Global longitudinal strain ID BREAST-CANCER; TRASTUZUMAB; ASSOCIATION; THERAPY; SOCIETY AB Introduction: Although osimertinib, a third-generation EGFR tyrosine kinase inhibitor, as the first-line therapy for metastatic NSCLC was found to have substantial survival benefits, concerns have arisen regarding its potential cardiotoxicity, particularly in real-world clinical settings. We aimed to investigate the incidence, risk factors, and reversibility of osimertinib-related cardiotoxicity. Methods: We analyzed 1126 patients with NSCLC treated with osimertinib from May 2016 to April 2023 in two cancer centers. Osimertinib-related cardiotoxicity was defined as a composite of osimertinib-related cardiac dysfunction (ORCD), newly developed arrhythmia, and cardiac death. Total follow-up duration was 20.6 (10.8- 35.2) months. Results: The osimertinib was administered for a median of 12.4 months. The incidence of osimertinib-related cardiotoxicity was 4.7%. Advanced age (adjusted hazard ratio with 95% confidence interval: 1.07 [1.04-1.09], p < 0.001), a history of heart failure (3.35 [1.67-9.64], p = 0.025), atrial fibrillation (3.42 [1.27-9.22], p = 0.015), and baseline low left ventricle strain (0.87 [0.79-0.96], p = 0.005) were independently associated with development of cardiotoxicity. The recovery rate of ORCD was 82.4%, which did not differ between patients who discontinued medication and those who did not. Conclusions: In real-world practice, the incidence of osimertinib-related cardiotoxicity was 4.7%, including 3.4% for ORCD requiring cardiologic intervention, which is higher than previously reported. Given the long-term medication of osimertinib and increased mortality associated with cardiotoxicity, vigilant monitoring is crucial, especially in patients with advanced age, history of heart failure, atrial fibrillation, or decreased baseline left ventricular strain. (c) 2024 Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer. C1 [Bak, Minjung; Kim, Jihoon; Park, Sung-Ji; Chang, Sung-A; Lee, Sang-Chol; Park, Seung Woo; Kim, Eun Kyoung] Sungkyunkwan Univ, Heart Vasc Stroke Inst, Dept Internal Med, Div Cardiol,Samsung Med Ctr,Sch Med, 81 Irwon Ro, Seoul 06351, South Korea. [Park, Hyukjin; Lee, Nuri] Chonnam Natl Univ, Hwasun Hosp, Dept Cardiol, Hwasun, South Korea. [Lee, Se-Hoon; Ahn, Myung-Ju; Ahn, Jin Seok; Jung, Hyun Ae; Park, Sehhoon] Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol & Oncol,Sch Med, Seoul, South Korea. [Cho, Jinhyun] Inha Univ Hosp, Dept Med, Div Hematol & Oncol, Inchon, South Korea. C3 Sungkyunkwan University (SKKU); Samsung Medical Center; Chonnam National University; Sungkyunkwan University (SKKU); Samsung Medical Center; Inha University; Inha University Hospital RP Kim, EK (corresponding author), Sungkyunkwan Univ, Heart Vasc Stroke Inst, Dept Internal Med, Div Cardiol,Samsung Med Ctr,Sch Med, 81 Irwon Ro, Seoul 06351, South Korea. EM ekbobi.kim@samsung.com CR Anand K, 2019, JACC-CARDIOONCOL, V1, P172, DOI 10.1016/j.jaccao.2019.10.006 Bonifazi M, 2013, ONCOLOGIST, V18, P795, DOI 10.1634/theoncologist.2013-0065 Bouwer NI, 2021, BREAST CANCER RES TR, V186, P851, DOI 10.1007/s10549-020-06039-w Cochet A, 2011, BREAST CANCER RES TR, V130, P845, DOI 10.1007/s10549-011-1714-9 Erickson AW, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.1617 Ewer MS, 2021, J CLIN ONCOL, V39, P328, DOI 10.1200/JCO.20.01171 Heidenreich PA, 2022, J AM COLL CARDIOL, V79, P1757, DOI 10.1016/j.jacc.2021.12.011 Kobo O, 2022, EUR HEART J-QUAL CAR, V8, P787, DOI 10.1093/ehjqcco/qcac045 Koulaouzidis G, 2021, CURR PROB CANCER, V45, DOI 10.1016/j.currproblcancer.2021.100723 Kunimasa K, 2020, JACC-CARDIOONCOL, V2, P1, DOI 10.1016/j.jaccao.2020.02.003 Lang RM, 2015, EUR HEART J-CARD IMG, V16, P233, DOI 10.1093/ehjci/jev014 Lemmens K, 2007, CIRCULATION, V116, P954, DOI 10.1161/CIRCULATIONAHA.107.690487 Lyon AR, 2022, EUR HEART J-CARD IMG, V23, pE333, DOI 10.1093/ehjci/jeac106 Melosky B, 2022, MOL DIAGN THER, V26, P7, DOI 10.1007/s40291-021-00563-1 Mok TS, 2017, NEW ENGL J MED, V376, P629, DOI 10.1056/NEJMoa1612674 Perik PJ, 2007, EXPERT REV ANTICANC, V7, P1763, DOI 10.1586/14737140.7.12.1763 Ramalingam SS, 2020, NEW ENGL J MED, V382, P41, DOI 10.1056/NEJMoa1913662 Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137 Sundararajan V, 2004, J CLIN EPIDEMIOL, V57, P1288, DOI 10.1016/j.jclinepi.2004.03.012 Suter TM, 2007, J CLIN ONCOL, V25, P3859, DOI 10.1200/JCO.2006.09.1611 Tan-Chiu E, 2005, J CLIN ONCOL, V23, P7811, DOI 10.1200/JCO.2005.02.4091 NR 21 TC 18 Z9 19 U1 5 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD FEB PY 2025 VL 20 IS 2 BP 167 EP 176 DI 10.1016/j.jtho.2024.10.003 EA FEB 2025 PG 10 WC Oncology; Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Respiratory System GA X2V7V UT WOS:001423996600001 PM 39395664 DA 2026-04-17 ER PT J AU Furuya, N Tsubata, Y Hotta, T Yokoyama, T Yamasaki, M Ishikawa, N Fujitaka, K Kubota, T Kobayashi, K Isobe, T AF Furuya, Naoki Tsubata, Yukari Hotta, Takamasa Yokoyama, Toshihide Yamasaki, Masahiro Ishikawa, Nobuhisa Fujitaka, Kazunori Kubota, Tetsuya Kobayashi, Kunihiko Isobe, Takeshi TI Arterial Thromboembolism in Patients With Advanced Lung Cancer: Secondary Analyses of the Rising-VTE/NEJ037 Study SO CANCER MEDICINE LA English DT Article DE arterial thromboembolism; cancer-associated thromboembolism; direct oral anticoagulants; lung cancer; prospective cohort study ID VENOUS THROMBOEMBOLISM; THROMBOSIS; MUTATIONS; STROKE; NSCLC; DEATH; RISK AB BackgroundCancer-associated thromboembolism has been thoroughly investigated in previous studies, and direct oral anticoagulants (DOACs) were established for the treatment and prevention of venous thromboembolism (VTE). However, the risks of cancer-associated arterial thromboembolism (ATE) and the efficacy of DOACs remain unclear.ObjectivesTo evaluate the risk factors and the clinical activity of edoxaban (EDO) for the prevention of ATE in patients with advanced lung cancer.MethodsFrom the prospective Rising-VTE/NEJ037 study which investigated VTE in newly diagnosed advanced lung cancer, we investigated the incidence rate and the risk factors of ATE as secondary endpoints.ResultsA total of 1008 patients were screened for VTE at study baseline and were followed up for 2 years. Excluding patients with a contraindication to DOACs, those with VTE were treated with EDO. ATE events were identified in 41 patients (4.1%). The most common location for ATE was cerebral infarction (N = 31, 75.6%), followed by myocardial infarction (N = 4, 9.8%). Multivariate analysis determined the incidence of VTE, D-dimer, a comorbidity of atrial fibrillation, and four other factors as independent risk factors of ATE. For VTE (+) patients, the incidence rate of ATE was 15.9% for the EDO administration (+) patients, compared with 11.1% for the EDO administration (-) patients (p = 0.626).ConclusionsThe incidence rate of ATE was 4.1% over 2-year follow-up in advanced lung cancer patients. VTE was further identified as an independent risk factor for ATE, while intervention with DOACs was seen as less effective for the prevention of ATE in advanced lung cancer patients with VTE.Trial RegistrationThis trial was registered in the Japan Registry of Clinical Trials (jRCTs061180025) C1 [Furuya, Naoki] St Marianna Univ, Sch Med, Dept Internal Med, Div Resp Med, Kawasaki, Japan. [Tsubata, Yukari; Hotta, Takamasa; Isobe, Takeshi] Shimane Univ, Fac Med, Dept Internal Med, Div Med Oncol & Resp Med, Izumo, Japan. [Yokoyama, Toshihide] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Japan. [Yamasaki, Masahiro] Hiroshima Red Cross Hosp, Dept Resp Dis, Hiroshima, Japan. [Yamasaki, Masahiro] Atom Bomb Survivors Hosp, Hiroshima, Japan. [Ishikawa, Nobuhisa] Hiroshima Prefectural Hosp, Dept Resp Med, Hiroshima, Japan. [Fujitaka, Kazunori] Hiroshima Univ Hosp, Dept Resp Med, Hiroshima, Japan. [Kubota, Tetsuya] Kochi Univ Hosp, Dept Resp Med & Allergol, Kochi, Japan. [Kobayashi, Kunihiko] Saitama Med Univ, Int Med Ctr, Dept Resp Med, Saitama, Japan. C3 St Marianna University; Shimane University; Kurashiki Central Hospital; Hiroshima University; Kochi University; Saitama Medical University RP Tsubata, Y (corresponding author), Shimane Univ, Fac Med, Dept Internal Med, Div Med Oncol & Resp Med, Izumo, Japan. EM ytsubata@med.shimane-u.ac.jp RI Furuya, Naoki/AAP-6618-2020 OI Furuya, Naoki/0000-0001-7162-5946 FU Daiichi Sankyo Company [Rising-VTE/NEJ037] FX We thank all patients, their families, coordinators, and investigators involved in Rising-VTE/NEJ037 study. We also thank Dr. Hiroyuki Kuroda and Dr. Megumi Nakamura for the Image As-assessment Committee, Dr. Takashi Yoshioka and Dr. Teruhisa Azuma for the Safety Monitoring Committee, Ms. Rie Nagira and Ms. Saori Houda (Research assistant of Rising-VTE/NEJ037) for study management, Ms. Reiko Nagata (Clinical research coordinator, St. Marianna University School of Medicine) for clinical data collection, and Mr. Jason Tonge for the reviewing the language of this article. CR Agnelli G, 2020, NEW ENGL J MED, V382, P1599, DOI 10.1056/NEJMoa1915103 Awano N, 2022, JTO CLIN RES REP, V3, DOI 10.1016/j.jtocrr.2022.100392 Blom JW, 2005, JAMA-J AM MED ASSOC, V293, P715, DOI 10.1001/jama.293.6.715 ClinicalTrials.gov, 2024, About us Corrales-Rodriguez L, 2014, THROMB RES, V133, P48, DOI 10.1016/j.thromres.2013.10.042 Falanga A, 2012, HAMOSTASEOLOGIE, V32, P115, DOI 10.5482/ha-1170 Fernandes CJ Jr, 2019, EUR RESPIR REV, V28, DOI 10.1183/16000617.0119-2018 Gervaso L, 2021, JACC-CARDIOONCOL, V3, P173, DOI 10.1016/j.jaccao.2021.03.001 Gomez-Rosas P, 2023, CANCERS, V15, DOI 10.3390/cancers15184588 Khorana AA, 2007, J THROMB HAEMOST, V5, P632, DOI 10.1111/j.1538-7836.2007.02374.x Lin MZ, 2022, LUNG CANCER, V172, P29, DOI 10.1016/j.lungcan.2022.06.011 Liu YH, 2023, J CANCER, V14, P3561, DOI 10.7150/jca.89231 Mulder FI, 2021, JACC-CARDIOONCOL, V3, P205, DOI 10.1016/j.jaccao.2021.02.007 Navi BB, 2021, STROKE, V52, P1121, DOI 10.1161/STROKEAHA.120.032002 Ohashi Y, 2022, THROMB RES, V213, P203, DOI 10.1016/j.thromres.2021.09.012 Ohashi Y, 2020, JPN J CLIN ONCOL, V50, P1246, DOI 10.1093/jjco/hyaa112 Ou WF, 2023, CANCER MANAG RES, V15, P1251, DOI 10.2147/CMAR.S430868 Pernod G, 2024, ARCH CARDIOVASC DIS, V117, P101, DOI 10.1016/j.acvd.2023.11.007 Poénou G, 2022, CANCERS, V14, DOI 10.3390/cancers14081937 Qdaisat A, 2022, CANCERS, V14, DOI 10.3390/cancers14184510 Raskob GE, 2018, NEW ENGL J MED, V378, P615, DOI 10.1056/NEJMoa1711948 Sener U, 2022, MAYO CLIN PROC, V97, P2139, DOI 10.1016/j.mayocp.2022.09.003 Sonbol YT, 2023, J STROKE CEREBROVASC, V32, DOI 10.1016/j.jstrokecerebrovasdis.2023.107154 Tsubata Y, 2023, INT J CLIN ONCOL, V28, P69, DOI 10.1007/s10147-022-02257-y Tsubata Y, 2022, THER ADV MED ONCOL, V14, DOI 10.1177/17588359221110171 Tsubata Y, 2022, J HEMATOL ONCOL, V15, DOI 10.1186/s13045-022-01259-7 Wang HY, 2022, ESMO OPEN, V7, DOI 10.1016/j.esmoop.2022.100742 Wang H, 2019, J CANCER RES THER, V15, P344, DOI 10.4103/jcrt.JCRT_121_18 Xu Y, 2023, JACC-CARDIOONCOL, V5, P520, DOI 10.1016/j.jaccao.2023.04.003 Young AM, 2018, J CLIN ONCOL, V36, P2017, DOI 10.1200/JCO.2018.78.8034 NR 30 TC 1 Z9 1 U1 0 U2 1 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2045-7634 J9 CANCER MED-US JI Cancer Med. PD JAN 9 PY 2025 VL 14 IS 1 AR e70568 DI 10.1002/cam4.70568 PG 9 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA R5X6P UT WOS:001392179200001 PM 39783855 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Chan, SHY Fitzpatrick, RW Layton, D Webley, S Salek, S AF Chan, Stefanie Ho Yi Fitzpatrick, Raymond W. Layton, Deborah Webley, Sherael Salek, Sam TI Cancer Therapy-Induced Cardiotoxicity: Results of the Analysis of the UK DEFINE Database SO CANCERS LA English DT Article DE non-small cell lung cancer; non-small cell lung cancer treatments; cardiotoxicity; cardiovascular adverse events; pharmacoepidemiology ID PHASE-II; IRINOTECAN; DIAGNOSIS; ONCOLOGY; DISEASE; DRUG AB Background: The accelerated development of novel cancer therapies necessitates a thorough understanding of the associated cardiotoxicity profiles, due to their significant implications for the long-term health and quality of life of cancer survivors. Objectives: The aim of this study was to determine the association between cardiotoxicity and non-small cell lung cancer (NSCLC) treatments using a hospital medicines usage database in England. Methods: An observational study based on a retrospective design using real-world data from the UK DEFINE database was performed. Monthly secondary data of 40 shortlisted drugs from April 2017 to July 2022 were extracted. Results: The cardiology drug that was associated with most oncology drugs was apixaban. Atezolizumab, bevacizumab, nintedanib, osimertinib, paclitaxel, pembrolizumab, gemcitabine and vincristine were all mostly associated with apixaban, which indicated association with atrial fibrillation. Afatinib, erlotinib and methotrexate were mostly associated with atenolol, hence suggesting the association with ischaemia or hypertension. Docetaxel and epirubicin were associated with verapamil, which indicated association with arrhythmia or hypertension. Conclusions: From the correlation and regression analyses, it can be concluded that hypertension was the most associated cardiovascular disease with the 20 shortlisted oncology drugs. The findings of this study have provided a better understanding of the association between each NSCLC-Cardio drug pair. C1 [Chan, Stefanie Ho Yi; Layton, Deborah; Webley, Sherael; Salek, Sam] Univ Hertfordshire, Sch Life & Med Sci, Hatfield AL10 9AB, England. [Chan, Stefanie Ho Yi] UCL Sch Pharm, Dept Pharmaceut, London WC1N 1AX, England. [Fitzpatrick, Raymond W.] Keele Univ, Ctr Med Optimisat, Sch Allied Hlth Profess & Pharm, Newcastle ST5 5BG, England. [Layton, Deborah] PEPI Consultancy Ltd, Southampton SO53 1GR, England. C3 University of Hertfordshire; University of London; University College London; Keele University RP Chan, SHY; Salek, S (corresponding author), Univ Hertfordshire, Sch Life & Med Sci, Hatfield AL10 9AB, England.; Chan, SHY (corresponding author), UCL Sch Pharm, Dept Pharmaceut, London WC1N 1AX, England. EM ho.chan.16@ucl.ac.uk; r.fitzpatrick@keele.ac.uk; drdeborahlayton@outlook.com; m.s.salek@herts.ac.uk RI Chan, Stefanie Ho Yi/HTQ-7273-2023 OI Chan, Stefanie Ho Yi/0000-0002-1912-3081; Layton, Deborah/0009-0008-2080-044X; Salek, Sam &/0000-0002-4612-5699; Ray, Fitzpatrick/0000-0003-3193-6920 FU Jenny Greenhorn Memorial Research Scholarship FX This research was part of a programme funded by the Jenny Greenhorn Memorial Research Scholarship. CR [Anonymous], 2013, SIGN Antithrombotics: Indications and Management. A National Clinical Guideline [Anonymous], 2019, Global oncology trends 2018 [Anonymous], NHS England Digital Cancer Registrations Statistics, England 2021-First Release, Counts Only Armando RG, 2020, INT J ONCOL, V56, P651, DOI 10.3892/ijo.2020.4966 BMA, 2022, COVID-19: Impact of the pandemic on healthcare delivery Burns L, 2022, CLIN THER, V44, P420, DOI 10.1016/j.clinthera.2022.01.012 Chan SHY, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1137983 Chen YJ, 2017, THORAC CANCER, V8, P170, DOI 10.1111/1759-7714.12420 Cheng H, 2010, PROG CARDIOVASC DIS, V53, P114, DOI 10.1016/j.pcad.2010.06.006 Coleman N, 2023, NPJ PRECIS ONCOL, V7, DOI 10.1038/s41698-022-00338-9 Dagenais S, 2022, CLIN PHARMACOL THER, V111, P77, DOI 10.1002/cpt.2480 Economopoulou P, 2015, CANCER MANAG RES, V7, P133, DOI 10.2147/CMAR.S77400 Falcone R, 2022, CANCERS, V14, DOI 10.3390/cancers14040889 Ferlay J., 2018, Global Cancer Observatory: Cancer Today Force T, 2007, NAT REV CANCER, V7, P332, DOI 10.1038/nrc2106 Fu CM, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.752468 Fujita K, 2015, WORLD J GASTROENTERO, V21, P12234, DOI 10.3748/wjg.v21.i43.12234 Gollerkeri A, 2001, INT J CANCER, V93, P139, DOI 10.1002/ijc.1295 Gong L, 2012, PHARMACOGENET GENOM, V22, P310, DOI 10.1097/FPC.0b013e32834f94cb Guo YQ, 2012, CANCER TREAT REV, V38, P904, DOI 10.1016/j.ctrv.2012.04.007 Gutierrez C, 2016, AM FAM PHYSICIAN, V94, P442 Keeling D, 2011, BRIT J HAEMATOL, V154, P311, DOI 10.1111/j.1365-2141.2011.08753.x Khozin S, 2017, CLIN CANCER RES, V23, P2131, DOI 10.1158/1078-0432.CCR-16-1773 Kurzrock R, 2020, NAT REV CLIN ONCOL, V17, P140, DOI 10.1038/s41571-019-0313-2 Liang ZH, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms231810617 Liu B, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-016-0378-2 Menna P, 2017, CHEMOTHERAPY, V62, P159, DOI 10.1159/000455823 Moslehi JJ, 2016, NEW ENGL J MED, V375, P1457, DOI 10.1056/NEJMra1100265 Mudd TW, 2021, AM J CANCER RES, V11, P1132 Nogami N, 2012, ACTA ONCOL, V51, P768, DOI 10.3109/0284186X.2011.648342 Prystowsky EN, 2015, JAMA-J AM MED ASSOC, V314, P278, DOI 10.1001/jama.2015.7505 Rehman B., 2020, StatPearls Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948 Socinski Mark A, 2002, Clin Lung Cancer, V4 Suppl 1, pS15, DOI 10.3816/CLC.2002.s.017 Steffel J, 2018, EUR HEART J, V39, P1330, DOI 10.1093/eurheartj/ehy136 Takiguchi Y, 2007, LUNG CANCER, V58, P253, DOI 10.1016/j.lungcan.2007.06.004 TAN C, 1967, CANCER-AM CANCER SOC, V20, P333, DOI 10.1002/1097-0142(1967)20:3<333::AID-CNCR2820200302>3.0.CO;2-K Tromp J, 2017, CLIN PHARMACOL THER, V101, P481, DOI 10.1002/cpt.614 Xu F, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4715-9 Zhao XC, 2022, CTS-CLIN TRANSL SCI, V15, P2293, DOI 10.1111/cts.13379 NR 40 TC 2 Z9 2 U1 1 U2 2 PU MDPI PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND EI 2072-6694 J9 CANCERS JI Cancers PD JAN PY 2025 VL 17 IS 2 AR 311 DI 10.3390/cancers17020311 PG 17 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA T2Y1A UT WOS:001403716300001 PM 39858093 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Butler, S No, H Guo, F Merchant, G Park, NJ Jackson, S Clark, DE Vitzthum, L Chin, A Horst, K Hoppe, RT Loo, BW Diehn, M Binkley, MS AF Butler, Santino No, Hyunsoo Guo, Felicia Merchant, Gibran Park, Natalie J. Jackson, Scott Clark, Daniel Eugene Vitzthum, Lucas Chin, Alex Horst, Kathleen Hoppe, Richard T. Loo, Billy W. Diehn, Maximilian Binkley, Michael Sargent TI Predictors of Atrial Fibrillation After Thoracic Radiotherapy SO JACC: CARDIOONCOLOGY LA English DT Article DE breast cancer; esophageal cancer; Hodgkin lymphoma; left coronary arteries; myocardial sleeves; non-small cell lung cancer; pulmonary veins; radiation toxicity ID LUNG-CANCER; CARDIAC TOXICITY; RADIATION-THERAPY; CONTOURING ATLAS; RISK; CARDIOTOXICITY; ASSOCIATION; MORTALITY; ISCHEMIA; EVENTS AB BACKGROUND Atrial fibrillation (AF) has been associated with thoracic radiotherapy, but the specific risk with irradiating different cardiac substructures remains unknown. OBJECTIVES This study sought to examine the relationship between irradiation of cardiac substructures and the risk of clinically significant (grade >= 3) AF. METHODS We analyzed data from patients who underwent definitive radiotherapy for localized cancers (non-small cell lung, breast, Hodgkin lymphoma, or esophageal) at our institution between 2004 and 2022. The 2-Gy fraction equivalent dose was calculated for cardiac substructures, including the pulmonary veins (PVs), left atrium, sinoatrial node, and left coronary arteries (the left main, left anterior descending, and left circumflex arteries). Competing risk models (subdistribution HRs [sHRs]) for AF incidence were adjusted for the Mayo AF risk score (MAFRS). RESULTS Among 539 patients, the median follow-up was 58.8 months. The 5-year cumulative incidence of AF was 11.1% for non-small cell lung cancer, 8.3% for esophageal cancer, 1.3% for breast cancer, and 0.8% for Hodgkin lymphoma. Increased AF risk was associated with a higher PV maximum dose (d(max)) (sHR: 1.22; P < 0.001), larger left atrial volume (sHR: 1.01; P = 0.002), greater smoking history in pack-years (sHR: 1.01; P = 0.010), and higher MAFRS (sHR: 1.16; P < 0.001). PV d(max) remained a significant predictor of AF across different MAFRS subgroups (P-interaction = 0.11), and a PV d(max) >39.7 Gy was linked to a higher AF risk, even when stratified by MAFRS. CONCLUSIONS PV d(max) is a significant predictor of grade >= 3 AF regardless of underlying risk factors. These findings highlight the importance of cardiac substructures in radiation toxicity and suggest that various PV dose metrics should be further validated in clinical settings. (c) 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). C1 [Butler, Santino; No, Hyunsoo; Guo, Felicia; Merchant, Gibran; Park, Natalie J.; Jackson, Scott; Vitzthum, Lucas; Chin, Alex; Horst, Kathleen; Hoppe, Richard T.; Loo, Billy W.; Diehn, Maximilian; Binkley, Michael Sargent] Stanford Univ, Sch Med, Dept Radiat Oncol, Palo Alto, CA USA. [Clark, Daniel Eugene] Stanford Univ, Dept Cardiol, Sch Med, Palo Alto, CA USA. C3 Stanford University; Stanford University RP Binkley, MS (corresponding author), Stanford Univ, Dept Radiat Oncol, 875 Blake Wilbur Dr, Stanford, CA 94305 USA. EM msb996@stanford.edu RI No, Hyunsoo/GLQ-9048-2022; Clark, Daniel/AGD-8509-2022 OI Hoppe, Richard/0000-0003-0125-0194; Binkley, Michael/0000-0002-2640-5255; Clark, Daniel/0000-0002-8054-0642; Jackson, Scott/0000-0002-0062-3131; Guo, Felicia/0000-0001-7122-4827 FU RSNA; ACRO FX Dr No has received materials/services from Limbus AI and Co reline Soft; has received payment/honoraria from AAMD; and has received grants from RSNA and ACRO. Dr Loo is a lecturer for Mevion; is a consultant for Beigene; holds equity in TibaRay; and is an advisor for NCCN. All other authors have reported that they have no relation-ships relevant to the contents of this paper to disclose. CR [Anonymous], Dietary supplements for exercise and athletic performance Arnold SV, 2023, J AM COLL CARDIOL, V82, P833, DOI 10.1016/j.jacc.2023.04.003 Atkins KM, 2024, JACC-CARDIOONCOL, V6, P544, DOI 10.1016/j.jaccao.2024.07.005 Atkins KM, 2019, J AM COLL CARDIOL, V73, P2976, DOI 10.1016/j.jacc.2019.03.500 Banfill K, 2021, J THORAC ONCOL, V16, P216, DOI 10.1016/j.jtho.2020.11.002 Bergom C, 2021, JACC-CARDIOONCOL, V3, P343, DOI 10.1016/j.jaccao.2021.06.007 Bratt A, 2019, RADIOL-CARDIOTHORAC, V1, DOI 10.1148/ryct.2019190057 Brunner KJ, 2014, MAYO CLIN PROC, V89, P1498, DOI 10.1016/j.mayocp.2014.08.016 Cai GX, 2023, INT J RADIAT ONCOL, V115, P366, DOI 10.1016/j.ijrobp.2022.08.013 Chiles C, 2015, RADIOLOGY, V276, P82, DOI 10.1148/radiol.15142062 Duane F, 2017, RADIOTHER ONCOL, V122, P416, DOI 10.1016/j.radonc.2017.01.008 Ellis CR, 2018, JACC-CLIN ELECTROPHY, V4, P412, DOI 10.1016/j.jacep.2017.11.011 Galbraith S, 2010, J NEUROSCI, V30, P10601, DOI 10.1523/JNEUROSCI.0362-10.2010 Haïssaguerre M, 2000, J CARDIOVASC ELECTR, V11, P2, DOI 10.1111/j.1540-8167.2000.tb00727.x Haïssaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003 Hassani C, 2017, RADIOGRAPHICS, V37, P1928, DOI 10.1148/rg.2017170050 Kim KH, 2022, JAMA ONCOL, V8, P1624, DOI 10.1001/jamaoncol.2022.4202 Kravchenko J, 2015, LUNG CANCER, V88, P85, DOI 10.1016/j.lungcan.2015.01.006 Larsson SC, 2014, J AM COLL CARDIOL, V64, P282, DOI 10.1016/j.jacc.2014.03.048 Lau Dennis H, 2019, Card Electrophysiol Clin, V11, P563, DOI [10.1016/j.ccep.2019.08.007, 10.1016/j.ccep.2019.08.007] Lau DH, 2017, HEART LUNG CIRC, V26, P887, DOI 10.1016/j.hlc.2017.05.119 Loap P, 2021, PRACT RADIAT ONCOL, V11, pE434, DOI 10.1016/j.prro.2021.02.002 Miller ED, 2024, INT J RADIAT ONCOL, V118, P124, DOI 10.1016/j.ijrobp.2023.08.011 Nabialek-Trojanowska I, 2020, CARDIOL J, V27, P836, DOI 10.5603/CJ.a2018.0120 No HJ, 2023, JACC-CARDIOONCOL, V5, P775, DOI 10.1016/j.jaccao.2023.08.007 O'Sullivan B, 2003, SEMIN RADIAT ONCOL, V13, P274, DOI 10.1016/S1053-4296(03)00037-7 Osranek M, 2006, J AM COLL CARDIOL, V48, P779, DOI 10.1016/j.jacc.2006.03.054 Pu CY, 2022, JTO CLIN RES REP, V3, DOI 10.1016/j.jtocrr.2022.100377 Qian YS, 2017, PRACT RADIAT ONCOL, V7, pE525, DOI 10.1016/j.prro.2017.04.005 Rodríguez B, 2004, AM J PHYSIOL-HEART C, V286, pH2078, DOI 10.1152/ajpheart.01175.2003 Tice BM, 2007, EUROPACE, V9, P46, DOI 10.1093/europace/eum204 Vrinzen CEJ, 2023, CANCER RES, V83, P1147, DOI 10.1158/0008-5472.CAN-22-1336 Walls GM, 2024, JACC-CARDIOONCOL, V6, P529, DOI 10.1016/j.jaccao.2024.05.009 Walls GM, 2024, RADIOTHER ONCOL, V192, DOI 10.1016/j.radonc.2024.110085 Walls GM, 2023, RADIOTHER ONCOL, V184, DOI 10.1016/j.radonc.2023.109680 Walls GM, 2023, JAMA ONCOL, V9, P573, DOI 10.1001/jamaoncol.2022.7875 Wang K, 2017, J CLIN ONCOL, V35, P1387, DOI 10.1200/JCO.2016.70.0229 Wang X, 2020, J THORAC ONCOL, V15, P1682, DOI 10.1016/j.jtho.2020.06.014 Yegya-Raman N, 2023, JAMA ONCOL, V9, P572, DOI 10.1001/jamaoncol.2022.7872 Yegya-Raman N, 2018, J THORAC ONCOL, V13, P1508, DOI 10.1016/j.jtho.2018.05.028 Yun JP, 2021, JACC-CARDIOONCOL, V3, P221, DOI 10.1016/j.jaccao.2021.03.006 Zyzanski SJ, 2004, ANN FAM MED, V2, P199, DOI 10.1370/afm.197 NR 42 TC 9 Z9 9 U1 0 U2 1 PU ELSEVIER PI AMSTERDAM PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS SN 2666-0873 J9 JACC-CARDIOONCOL JI JACC-Cardiooncol. PD DEC PY 2024 VL 6 IS 6 BP 935 EP 945 DI 10.1016/j.jaccao.2024.08.007 EA DEC 2024 PG 11 WC Oncology; Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Cardiovascular System & Cardiology GA R6I4E UT WOS:001392459400001 PM 39801654 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Bayraktar, N AF Bayraktar, Necmi TI A rare complication of transurethral resection: Transient blindness SO ULUSAL TRAVMA VE ACIL CERRAHI DERGISI-TURKISH JOURNAL OF TRAUMA & EMERGENCY SURGERY LA English DT Article DE Glycine intoxication; transient blindness; transurethral resection; TUR syndrome. ID 1.5-PERCENT GLYCINE; FLUID ABSORPTION; PROSTATE AB Transient blindness is an extremely rare complication of transurethral resection (TUR) syndrome, which is a well-known complication recognized by urologists and anesthesiologists. TUR syndrome arises from the intravascular absorption of hypotonic fluids during the procedure. In this case report, an 80-year-old male patient experienced transient blindness after undergoing transurethral resection of the prostate. The patient's medical history included hypertension, lung cancer in remission, and paroxysmal atrial fibrillation. The surgery was performed under spinal anesthesia. During the procedure, the patient was found to be blind. The patient's postoperative blood samples revealed elevated plasma glycine levels, which is a known risk factor for TUR syndrome. The patient's visual impairment began to improve without further intervention. This case report highlights the importance of considering the patient's medical history and the potential risks associated with TUR syndrome. C1 [Bayraktar, Necmi] Burhan Nalbantoglu State Hosp, Dept Urol, Nicosia, Cyprus. RP Bayraktar, N (corresponding author), Burhan Nalbantoglu State Hosp, Dept Urol, Nicosia, Cyprus. EM nbayraktar@ciu.edu.tr RI bayraktar, necmi/HNP-9166-2023 CR Collins JW, 2005, BJU INT, V96, P368, DOI 10.1111/j.1464-410X.2005.05633.x Ezri T, 2006, J CLIN ANESTH, V18, P245, DOI 10.1016/j.jclinane.2005.12.008 Hahn RG, 2006, BRIT J ANAESTH, V96, P8, DOI 10.1093/bja/aei279 Kil HK, 2020, J INT MED RES, V48, DOI 10.1177/0300060520922422 Koyuncu H, 2012, Turk Urol Sem, V3, P10 Olsson J, 1999, BRIT J ANAESTH, V82, P250, DOI 10.1093/bja/82.2.250 Tauzin-Fin P, 2002, THERAPIE, V57, P48 Tuzcu K, 2014, Cumhuriyet Med J, V36, P274 WANG JML, 1989, ANESTHESIOLOGY, V70, P36, DOI 10.1097/00000542-198901000-00009 Zhang YX, 2020, TRANSL ANDROL UROL, V9, P1192, DOI 10.21037/tau-19-780 NR 10 TC 0 Z9 0 U1 0 U2 0 PU TURKISH ASSOC TRAUMA EMERGENCY SURGERY PI ISTANBUL PA KOPRULU MEHMET PASA SOC, DENIZ ABDAL MAH, DADASOGLU AP, 25-1 SEHREMINI, ISTANBUL, 00000, Turkiye SN 1306-696X EI 1307-7945 J9 ULUS TRAVMA ACIL CER JI Ulus. Travma Acil Cerrahi Derg. PD DEC PY 2024 VL 30 IS 12 BP 921 EP 924 DI 10.14744/tjtes.2024.33979 PG 4 WC Emergency Medicine WE Science Citation Index Expanded (SCI-EXPANDED) SC Emergency Medicine GA O9P9N UT WOS:001374370300012 PM 39668538 OA Green Submitted, hybrid DA 2026-04-17 ER PT J AU Chuang, CY Wang, BW Yu, YJ Fang, WJ Lin, CM Shyu, KG Chua, SK AF Chuang, Cheng-Yen Wang, Bao-Wei Yu, Ying-Ju Fang, Wei-Jen Lin, Chiu-Mei Shyu, Kou-Gi Chua, Su-Kiat TI Exosomal MALAT1 from Rapid Electrical Stimulation-Treated Atrial Fibroblasts Enhances Sox-6 Expression by Downregulating miR-499a-5p SO CELLS LA English DT Article DE microRNA-499a-5p; MALAT1; sox-6; rapid electrical stimulation; apoptosis ID LONG NONCODING RNA; FIBRILLATION; DISEASE AB Background: Atrial fibrillation (AF) is a common cardiac arrhythmia associated with significant morbidity and mortality. Rapid electrical stimulation (RES) of atrial fibroblasts plays a crucial role in AF pathogenesis, but the underlying molecular mechanisms remain unclear. This study investigates the regulatory axis involving MALAT1, miR-499a-5p, and SOX6 in human cardiac fibroblasts from adult atria (HCF-aa) under RES conditions. Methods: HCF-aa were subjected to RES at 0.5 V/cm and 10 Hz. The expression levels of metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), miR-499a-5p, and SRY-Box Transcription Factor 6 (SOX6) were measured using qPCR and Western blot analyses. Luciferase reporter assays were performed to confirm target relationships. The effects of MALAT1 siRNA, miR-499a-5p mimics/inhibitors, and SOX6 overexpression on gene expression and apoptosis were assessed. Results: RES increased exosomal MALAT1 expression, peaking at 2 h. MiR-499a-5p levels initially increased, then decreased at 2 h, coinciding with peak MALAT1 expression. SOX6 mRNA and protein levels increased, peaking at 4 and 6 h, respectively. Luciferase assays confirmed MALAT1 and SOX6 as miR-499a-5p targets. MALAT1 knockdown increased miR-499a-5p levels and reduced SOX6 expression. MiR-499a-5p overexpression decreased SOX6 levels and inhibited RES-induced apoptosis. Conclusion: In HCF-aa under RES, increased exosomal MALAT1 expression counteracts miR-499-5p's suppression of SOX6, suggesting that MALAT1-containing exsosomes derived from HCF-aa may offer a novel cell-free therapeutic approach for AF. C1 [Chuang, Cheng-Yen; Wang, Bao-Wei; Yu, Ying-Ju; Fang, Wei-Jen; Lin, Chiu-Mei; Shyu, Kou-Gi; Chua, Su-Kiat] Shin Kong Wu Ho Su Mem Hosp, Dept Internal Med, Div Cardiol, Taipei 11101, Taiwan. [Lin, Chiu-Mei] Shin Kong Wu Ho Su Mem Hosp, Dept Emergency Med, Taipei 11101, Taiwan. [Chua, Su-Kiat] Fu Jen Catholic Univ, Coll Med, Sch Med, New Taipei 24205, Taiwan. C3 Shin Kong Wu Ho Su Memorial Hospital; Shin Kong Wu Ho Su Memorial Hospital; Fu Jen Catholic University RP Chua, SK (corresponding author), Shin Kong Wu Ho Su Mem Hosp, Dept Internal Med, Div Cardiol, Taipei 11101, Taiwan.; Chua, SK (corresponding author), Fu Jen Catholic Univ, Coll Med, Sch Med, New Taipei 24205, Taiwan. EM m014190@ms.skh.org.tw; baowei@ms22.hinet.net; kinki1983yu@gmail.com; wjfang0719@gmail.com; mei882153@gmail.com; shyukg@ms12.hinet.net; benchua1131@hotmail.com OI Chua, Su-Kiat/0000-0003-1893-6360 FU Shin Kong Wu Ho Su Memorial Hospital FX This research was funded by Shin Kong Wu Ho Su Memorial Hospital. CR Chugh SS, 2014, CIRCULATION, V129, P837, DOI 10.1161/CIRCULATIONAHA.113.005119 Cohen-Barak O, 2003, NUCLEIC ACIDS RES, V31, P5941, DOI 10.1093/nar/gkg807 Han XY, 2023, OPEN MED-WARSAW, V18, DOI 10.1515/med-2023-0654 Hindricks Gerhard, 2021, Eur Heart J, V42, P373, DOI 10.1093/eurheartj/ehaa612 Huang SQ, 2019, J CELL PHYSIOL, V234, P2997, DOI 10.1002/jcp.27117 Michalik KM, 2014, CIRC RES, V114, P1389, DOI 10.1161/CIRCRESAHA.114.303265 Nappi F, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms241814277 Nattel Stanley, 2017, JACC Clin Electrophysiol, V3, P425, DOI [10.1016/j.jacep.2017.03.002, 10.1016/j.jacep.2017.03.002] Riancho J, 2018, NEW ENGL J MED, V379, P2180, DOI 10.1056/NEJMc1813170 Sarkar A, 2013, CELL STEM CELL, V12, P15, DOI 10.1016/j.stem.2012.12.007 Shyu KG, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031095 Shyu KG, 2019, INT J CARDIOL, V274, P271, DOI 10.1016/j.ijcard.2018.09.118 Sluijter JPG, 2010, ARTERIOSCL THROM VAS, V30, P859, DOI 10.1161/ATVBAHA.109.197434 Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986 Tsai CT, 2008, J HYPERTENS, V26, P570, DOI 10.1097/HJH.0b013e3282f34a4a Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002 van Rooij E, 2007, SCIENCE, V316, P575, DOI 10.1126/science.1139089 Viereck J, 2017, CIRC RES, V120, P381, DOI 10.1161/CIRCRESAHA.116.308434 Yuan Y, 2024, J TRANSL INTERN MED, V12, P106, DOI 10.2478/jtim-2023-0129 Zhang JH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09831-5 Zhou QF, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.758653 NR 21 TC 2 Z9 2 U1 1 U2 1 PU MDPI PI BASEL PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND EI 2073-4409 J9 CELLS-BASEL JI Cells PD DEC PY 2024 VL 13 IS 23 AR 1942 DI 10.3390/cells13231942 PG 13 WC Cell Biology WE Science Citation Index Expanded (SCI-EXPANDED) SC Cell Biology GA P2F3B UT WOS:001376129200001 PM 39682691 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Braghieri, L Gharaibeh, A Nkashama, L Abushouk, A Abushawer, O Mehdizadeh-Shrifi, A Honnekeri, B Calabrese, C Menon, V Funchain, P Collier, P Sadler, D Moudgil, R AF Braghieri, Lorenzo Gharaibeh, Ahmad Nkashama, Lubika Abushouk, Abdelrahman Abushawer, Osama Mehdizadeh-Shrifi, Amir Honnekeri, Bianca Calabrese, Cassandra Menon, Venu Funchain, Pauline Collier, Patrick Sadler, Diego Moudgil, Rohit TI Long-term cardiovascular outcomes of immune checkpoint inhibitor-related myocarditis: A large single-centre analysis SO ESC HEART FAILURE LA English DT Article DE Immune-checkpoint inhibitor; Cardio-oncology; ICI-related myocarditis ID ADVERSE EVENTS; DEFINITION; STATEMENT; HEART AB Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI-related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI-related adverse events. Additionally, whether incident irM portends worse long-term CV outcomes remains unclear. We aimed to determine the incidence of long-term CV comorbidities and CV mortality among irM patients. Patients and methods The ICI-related adverse event (irAE) registry was queried to identify irM patients by using Bonaca criteria. Random controls were selected after excluding patients with other concomitant irAEs. Patients' demographics, comorbidities and myocarditis presenting features were gathered. Outcomes included 2-year freedom from CV comorbidities (composite of atrial fibrillation, stroke, myocardial infarction and heart failure) and freedom from CV death. IrM was treated as a time-varying covariate. Results Seventy-six patients developed irM at a median of 167 days (mean age 69, 63.2% male, 47% lung cancer). Majority of patients had new wall motion abnormalities or EKG changes on presentation. Mean LVEF was 43%, median peak TnT was 0.81, and median NTproBNP was 2057 at irM onset. Two-year freedom from CV comorbidities (67% vs 86.8%, P < 0.001) and death (93.4% vs 99.3%, P = 0.003) was lower among irM patients. Incident irM was an independent predictor of CV death (HR 8.28, P = 0.048), but not CV comorbidities (HR 2.21, P = 0.080). Conclusions This is the largest case-control study on irM highlighting worse long-term CV outcomes. Future studies are needed to establish appropriate therapeutic strategies and efficient screening strategies for irM survivors. C1 [Braghieri, Lorenzo; Gharaibeh, Ahmad; Abushawer, Osama; Honnekeri, Bianca] Cleveland Clin Fdn, Dept Internal Med, Cleveland, OH USA. [Nkashama, Lubika] WashU Barnes Jewish Hosp, Dept Internal Med, St Louis, MO USA. [Abushouk, Abdelrahman] Yale Univ, Dept Internal Med, New Haven, CT USA. [Mehdizadeh-Shrifi, Amir] Cincinnati Childrens Hosp, Dept Cardiothorac Surg, Cincinnati, OH USA. [Calabrese, Cassandra] Cleveland Clin Fdn, Dept Rheumatol & Immunol Dis, Cleveland, OH USA. [Menon, Venu; Moudgil, Rohit] Cleveland Clin Fdn, Heart Vasc & Thorac Inst, Dept Cardiovasc Med, 9500 Euclid Ave, Cleveland, OH 44195 USA. [Funchain, Pauline] Cleveland Clin, Taussig Canc Ctr, Dept Hematol & Oncol, Cleveland, OH USA. [Collier, Patrick] Cleveland Clin Fdn, Heart Vasc & Thorac Inst, Dept Cardiovasc Med, Div Cardiac Imaging, Cleveland, OH USA. [Sadler, Diego] Cleveland Clin Fdn, Heart Vasc & Thorac Inst, Dept Cardiovasc Med, Div Cardiac Imaging, Weston, FL USA. C3 Cleveland Clinic Foundation; Yale University; Cincinnati Children's Hospital Medical Center; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation RP Moudgil, R (corresponding author), Cleveland Clin Fdn, Heart Vasc & Thorac Inst, Dept Cardiovasc Med, 9500 Euclid Ave, Cleveland, OH 44195 USA. EM moudgir@ccf.org RI ; Funchain, Pauline/AAN-6658-2021; Mehdizadeh-Shrifi, Amir/PLS-0553-2026; Abu-Shawer, Osama/HTT-4856-2023 OI Mehdizadeh-Shrifi, Amir/0000-0001-9980-0160; Funchain, Pauline/0000-0002-7568-8626; CR [Anonymous], 2018, NAT REV DRUG DISCOV, V17, P854, DOI 10.1038/nrd.2018.210 [Anonymous], 2019, ANN RHEUM DIS Ball S, 2019, J AM COLL CARDIOL, V74, P1714, DOI 10.1016/j.jacc.2019.07.079 Bhat T, 2013, EXPERT REV CARDIOVAS, V11, P55, DOI [10.1586/erc.12.159, 10.1586/ERC.12.159] Bonaca MP, 2019, CIRCULATION, V140, P80, DOI 10.1161/CIRCULATIONAHA.118.034497 Bozkurt B, 2021, J CARD FAIL, V27, P387, DOI 10.1016/j.cardfail.2021.01.022 Calkins H, 2007, HEART RHYTHM, V4, P816, DOI 10.1016/j.hrthm.2007.04.005 Carai P, 2022, CARDIOVASC RES, V118, P3331, DOI 10.1093/cvr/cvac052 Diehl A, 2017, ONCOTARGET, V8, P114268, DOI 10.18632/oncotarget.23217 Dolladille C, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000261 Drobni ZD, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.018306 Ferreira VM, 2018, J AM COLL CARDIOL, V72, P3158, DOI 10.1016/j.jacc.2018.09.072 Gentzler R, 2016, IMMUNOTHERAPY-UK, V8, P583, DOI 10.2217/imt-2015-0029 Guasti L, 2011, THROMB HAEMOSTASIS, V106, P591, DOI 10.1160/TH11-02-0096 Hicks KA, 2018, J AM COLL CARDIOL, V71, P1021, DOI 10.1016/j.jacc.2017.12.048 Hoos A, 2016, NAT REV DRUG DISCOV, V15, P235, DOI 10.1038/nrd.2015.35 Isawa T, 2022, ONCOLOGIST, V27, pE410, DOI 10.1093/oncolo/oyac056 Liang L, 2023, ESC HEART FAIL, V10, P1907, DOI 10.1002/ehf2.14340 Mahmood S, 2018, J AM COLL CARDIOL, V71, P699, DOI [10.1016/S0735-1097(18)31240-3, 10.1016/j.jacc.2018.02.037] Moslehi JJ, 2018, LANCET, V391, P933, DOI 10.1016/S0140-6736(18)30533-6 Naqash AR, 2022, J CLIN ONCOL, V40, P3439, DOI 10.1200/JCO.22.00369 Nso N, 2020, WORLD J CARDIOL, V12, P584, DOI 10.4330/wjc.v12.i11.584 Palaskas N, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.013757 Palaskas NL, 2021, EUR J HEART FAIL, V23, P1725, DOI 10.1002/ejhf.2265 Pavana A, 2019, ONCOLOGIST, V24, P1128, DOI 10.1634/theoncologist.2018-0563 Postow MA, 2018, NEW ENGL J MED, V378, P158, DOI [10.1056/NEJMra1703481, 10.1056/NEJMc1801663] Postow MA, 2015, J CLIN ONCOL, V33, P1974, DOI 10.1200/JCO.2014.59.4358 Rubio-Infante N, 2021, EUR J HEART FAIL, V23, P1739, DOI 10.1002/ejhf.2289 Sacco RL, 2013, STROKE, V44, P2064, DOI 10.1161/STR.0b013e318296aeca Salem JE, 2018, LANCET ONCOL, V19, P1579, DOI 10.1016/S1470-2045(18)30608-9 Shao J, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20192347 Snapinn SM, 2005, AM STAT, V59, P301, DOI 10.1198/000313005X70371 Tang J, 2018, NAT REV DRUG DISCOV, V17, P783, DOI 10.1038/nrd.2018.167 Tschöpe C, 2021, NAT REV CARDIOL, V18, P169, DOI 10.1038/s41569-020-00435-x Vinco G, 2018, EUR HEART J, V39, P160 Wang D, 2023, BIOLOGY-BASEL, V12, DOI 10.3390/biology12030472 Zamami Y, 2019, JAMA ONCOL, V5, P1635, DOI 10.1001/jamaoncol.2019.3113 Zhang LL, 2020, CIRCULATION, V141, P2031, DOI 10.1161/CIRCULATIONAHA.119.044703 NR 38 TC 6 Z9 6 U1 0 U2 2 PU WILEY PERIODICALS, INC PI SAN FRANCISCO PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA SN 2055-5822 J9 ESC HEART FAIL JI ESC Heart Fail. PD APR PY 2025 VL 12 IS 2 BP 1237 EP 1245 DI 10.1002/ehf2.15131 EA OCT 2024 PG 9 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA 0FW2I UT WOS:001358275900001 PM 39482568 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Mensah, SA Ahmad, S Alruwaili, W Raval, R Gonuguntla, K Patel, B AF Mensah, Samuel Akaakole Ahmad, Syed Alruwaili, Waleed Raval, Rutu Gonuguntla, Karthik Patel, Brijesh TI Cardiovascular events in eGFR-mutation non-small-cell lung cancer patients on osimertinib SO EUROPEAN JOURNAL OF HOSPITAL PHARMACY LA English DT Article DE Atrial Fibrillation; CHEMOTHERAPY; Heart Failure; Hypertension; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS ID INHIBITORS AB Objectives There have been cases of cardiotoxicity induced by osimertinib in patients with non-small-cell lung cancer (NSCLC). However, limited data exist for a comprehensive cardiotoxicity profile analysis for osimertinib use in NSCLC patients. The aim of this study was to report the entire profile of cardiotoxicities after the initiation of osimertinib in consecutive patients with epidermal growth factor receptor (EGFR) mutation at a single health system.Methods The data were retrospectively collected from electronic medical records for all patients who were started on osimertinib for NSCLC at West Virginia University Health System. Prevalence of heart failure (HF), atrial fibrillation, and prolonged QT before and after starting osimertinib were calculated.Results This study had 116 participants and the median age was 72 years. The frequency of each new cardiotoxicity was between 6% and 9%, and the overall percentage of patients who had developed any of the four cardiotoxicities while on osimertinib was 19.9%. The median time of follow-up was 477 days and the median time on osimertinib for all patients was 390 days. The strongest risk factor in predicting a new onset cardiac event was hypertension with a hazard ratio (HR) of 6.35 (confidence interval (CI) 1.48 to 27.23, p=0.013) and HR 5.36 (CI 1.23 to 23.39, p=0.025) in univariate and multivariate analysis respectively.Conclusion Osimertinib appears to be associated with an increase in cardiac abnormalities. Given the association between this medication exposure and the observed cardiac toxicities, use of osimertinib may entail closer cardiac monitoring of electrocardiogram (ECG) and echocardiogram abnormalities. C1 [Mensah, Samuel Akaakole; Ahmad, Syed; Alruwaili, Waleed] West Virginia Univ, Dept Med, Morgantown, WV 26506 USA. [Raval, Rutu; Gonuguntla, Karthik; Patel, Brijesh] West Virginia Univ, Heart & Vasc Inst, Morgantown, WV USA. C3 West Virginia University; West Virginia University RP Mensah, SA (corresponding author), West Virginia Univ, Dept Med, Morgantown, WV 26506 USA. EM sakaakole@gmail.com; syed.ahmad@hsc.wvu.edu; waleed.alruwaili@hsc.wvu.edu; rutu99raval@gmail.com; karthik.gonuguntla@hsc.wvu.edu; brijesh.patel@wvumedicine.org RI ; Alruwaili, Waleed/LRS-8630-2024 OI Mensah, Samuel/0000-0002-0691-6410; CR Anand K, 2019, JACC-CARDIOONCOL, V1, P172, DOI 10.1016/j.jaccao.2019.10.006 Bozkurt B, 2023, J CARD FAIL, V29, P1412, DOI 10.1016/j.cardfail.2023.07.006 Byun JY, 2024, EXPERT OPIN DRUG SAF, V23, P1007, DOI 10.1080/14740338.2023.2294924 Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337 Eaton H, 2023, CARDIO-ONCOLOGY, V9, DOI 10.1186/s40959-023-00172-3 Franquiz MJ, 2023, JACC-CARDIOONCOL, V5, P839, DOI 10.1016/j.jaccao.2023.07.006 Hartmann JT, 2009, CURR DRUG METAB, V10, P470, DOI 10.2174/138920009788897975 Kunimasa K, 2021, LUNG CANCER, V153, P186, DOI 10.1016/j.lungcan.2020.10.021 Li PW, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1177003 Mok Tony S, 2017, N Engl J Med, V376, P629, DOI 10.1056/NEJMoa1612674 Noubiap JJ, 2024, J AM COLL CARDIOL, V84, P1501, DOI 10.1016/j.jacc.2024.07.014 Patel Shruti R, 2020, JACC Case Rep, V2, P641, DOI [10.1016/j.jaccas.2019.12.038, 10.1016/j.jaccas.2019.12.038] Ruiz-Briones P, 2023, J ONCOL PHARM PRACT, V29, P1015, DOI 10.1177/10781552221143787 Saito Z, 2023, CASE REP ONCOL, V16, P1100, DOI 10.1159/000533826 Sayegh N, 2023, CURR CARDIOL REP, V25, P269, DOI 10.1007/s11886-023-01845-2 Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137 NR 16 TC 0 Z9 0 U1 1 U2 4 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2047-9956 EI 2047-9964 J9 EUR J HOSP PHARM JI Eur. J. Hosp. Pharm. PD JAN PY 2026 VL 33 IS 1 BP 2 EP 6 DI 10.1136/ejhpharm-2024-004319 EA OCT 2024 PG 5 WC Pharmacology & Pharmacy WE Science Citation Index Expanded (SCI-EXPANDED) SC Pharmacology & Pharmacy GA AS2GH UT WOS:001358986200001 PM 39461730 DA 2026-04-17 ER PT J AU Yoo, SK Kim, KH Noh, JM Oh, J Yang, G Kim, J Kim, N Kim, H Yoon, HI AF Yoo, Sang Kyun Kim, Kyung Hwan Noh, Jae Myoung Oh, Jaewon Yang, Gowoon Kim, Jihun Kim, Nalee Kim, Hojin Yoon, Hong In TI Development of learning-based predictive models for radiation-induced atrial fibrillation in non-small cell lung cancer patients by integrating patient-specific clinical, dosimetry, and diagnostic information SO RADIOTHERAPY AND ONCOLOGY LA English DT Article DE Atrial fibrillation; Radiotherapy; Non-small cell lung cancer; Predictive Models; Machine learning; Deep learning ID CARDIAC TOXICITY; RADIOTHERAPY; DISEASE; EVENTS; RISK AB Background and purpose: Radiotherapy (RT) in non-small cell lung cancer (NSCLC) can induce cardiac adverse events, including atrial fibrillation (AF), despite advanced RT. This study integrates patient-specific information to develop learning-based models to predict the incidence of AF following NSCLC chemoradiotherapy (CRT) and evaluates these models using institutional and external datasets. Materials and methods: Institutional and external patient cohorts consisted of 321 and 187 NSCLC datasets who received definitive CRT, including 17 and 6 AF incidences, respectively. The network input had 159 features with clinical, dosimetry, and diagnostic. The class imbalance was mitigated by synthetic minority oversampling technique. To handle various types of input features, machine learning-based model adopted an intervention technique that chose one feature with the largest weight at each dosimetry sub-group in feature selection process, while deep learning-based model employed a hybrid architecture assigning different types of networks to corresponding input paths. Performance was assessed by area under the curve (AUC). The key features were investigated for the machine and deep learning-based models. Results: The hybrid deep learning model outperformed the machine learning-based algorithm in internal validation (AUC: 0.817 vs. 0.801) and produced more consistent performance in external validation (AUC: 0.806 vs. 0.776). Importantly, maximum dose to heart and sinoatrial node (SAN) were found to be the key features for both learning-based models in external and internal validations. Conclusions: The learning-based predictive models showed consistent prediction performance across internal and external cohorts, identifying maximum heart and SAN dose as key features for the incidence of AF. C1 [Yoo, Sang Kyun; Kim, Kyung Hwan; Yang, Gowoon; Kim, Hojin; Yoon, Hong In] Yonsei Univ, Coll Med, Heavy Ion Therapy Res Inst, Dept Radiat Oncol,Yonsei Canc Ctr, 50-1 Yonsei Ro, Seoul, South Korea. [Yoo, Sang Kyun] Yonsei Univ, Coll Med, Med Phys & Biomed Engn Lab MPBEL, Seoul, South Korea. [Noh, Jae Myoung; Kim, Nalee] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Radiat Oncol, Seoul, South Korea. [Oh, Jaewon] Yonsei Univ, Severance Cardiovasc Hosp, Dept Internal Med, Div Cardiol,Cardiovasc Res Inst,Coll Med, Seoul, South Korea. [Yang, Gowoon] Cha Univ, Ilsan Cha Hosp, Dept Radiat Oncol, Sch Med, Gyeonggi Do, South Korea. [Kim, Jihun] Yonsei Univ, Coll Med, Gangnam Severance Hosp, Dept Radiat Oncol, Seoul, South Korea. C3 Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Sungkyunkwan University (SKKU); Samsung Medical Center; Yonsei University; Yonsei University Health System; Pochon Cha University; Yonsei University; Yonsei University Health System RP Kim, H; Yoon, HI (corresponding author), Yonsei Univ, Coll Med, Heavy Ion Therapy Res Inst, Dept Radiat Oncol,Yonsei Canc Ctr, 50-1 Yonsei Ro, Seoul, South Korea. EM hjhenrykim@yuhs.ac; yhi0225@yuhs.ac RI ; Kim, Nalee/KGK-4760-2024; Kim, Hojin/AAS-2315-2021 OI Oh, Jaewon/0000-0002-4585-1488; Kim, Hojin/0000-0002-4652-8682; Yoon, Hong In/0000-0002-2106-6856 FU National Research Foundation of Korea (NRF) - Korean government (MSIT) [RS-2023-00279682, NRF-2021R1A2C2005824]; Yonsei University College of Medicine [6-2022-0174] FX This work was supported by the National Research Foundation of Korea (NRF) grants funded by the Korean government (MSIT) (RS-2023-00279682 and NRF-2021R1A2C2005824) and a faculty research grant from the Yonsei University College of Medicine for (6-2022-0174) . CR Atkins KM, 2021, INT J RADIAT ONCOL, V110, P1473, DOI 10.1016/j.ijrobp.2021.03.005 Atkins KM, 2021, JAMA ONCOL, V7, P206, DOI 10.1001/jamaoncol.2020.6332 Atkins KM, 2019, J AM COLL CARDIOL, V73, P2976, DOI 10.1016/j.jacc.2019.03.500 Banfill K, 2021, J THORAC ONCOL, V16, P216, DOI 10.1016/j.jtho.2020.11.002 Bogart JA, 2021, Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC) Chawla NV, 2002, J ARTIF INTELL RES, V16, P321, DOI 10.1613/jair.953 Choi BS, 2023, MED PHYS, V50, P6409, DOI 10.1002/mp.16398 Chung SY, 2021, INT J RADIAT ONCOL, V110, P473, DOI 10.1016/j.ijrobp.2020.12.053 Dosovitskiy A, 2021, Arxiv, DOI arXiv:2010.11929 Faivre-Finn C, 2017, LANCET ONCOL, V18, P1116, DOI 10.1016/S1470-2045(17)30318-2 Graves A, 2012, STUD COMPUT INTELL, V385, P1, DOI [10.1162/neco.1997.9.8.1735, 10.1162/neco.1997.9.1.1, 10.1007/978-3-642-24797-2] Guo CA, 2017, PR MACH LEARN RES, V70 Hansen CR, 2020, RADIOTHER ONCOL, V147, P15, DOI 10.1016/j.radonc.2020.03.013 Janiesch C, 2021, ELECTRON MARK, V31, P685, DOI 10.1007/s12525-021-00475-2 Jolliffe IT, 2016, PHILOS T R SOC A, V374, DOI 10.1098/rsta.2015.0202 Kim E, 2022, NUCL ENG TECHNOL, V54, P1439, DOI 10.1016/j.net.2021.10.020 Kim KH, 2022, JAMA ONCOL, V8, P1624, DOI 10.1001/jamaoncol.2022.4202 Kingsbury D, 2015, P1, DOI [DOI 10.1145/1830483.1830503, DOI 10.1021/bk-2015-1214.ch001] Ko EC, 2018, CLIN CANCER RES, V24, P5792, DOI 10.1158/1078-0432.CCR-17-3620 Kokhlikyan N, 2020, Arxiv, DOI [arXiv:2009.07896, 10.48550/arXiv.2009.07896] Kravchenko J, 2015, LUNG CANCER, V88, P85, DOI 10.1016/j.lungcan.2015.01.006 Lecun Y, 1998, P IEEE, V86, P2278, DOI 10.1109/5.726791 LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539 Medsker L.R., 2001, Design and Applications, V5, P2 Paszke A, 2019, ADV NEUR IN, V32 Pedregosa F, 2011, J MACH LEARN RES, V12, P2825, DOI 10.1145/2786984.2786995 Puttanawarut C, 2021, RADIAT ONCOL, V16, DOI 10.1186/s13014-021-01950-y Ramchoun H, 2016, INT J INTERACT MULTI, V4, P26, DOI 10.9781/ijimai.2016.415 Russakovsky O, 2015, INT J COMPUT VISION, V115, P211, DOI 10.1007/s11263-015-0816-y Spigel DR, 2022, J CLIN ONCOL, V40, P1301, DOI 10.1200/JCO.21.01308 Sundararajan M, 2017, PR MACH LEARN RES, V70 Tibshirani R, 1996, J ROY STAT SOC B, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x van Nimwegen FA, 2016, J CLIN ONCOL, V34, P235, DOI 10.1200/JCO.2015.63.4444 van Nimwegen FA, 2015, JAMA INTERN MED, V175, P1007, DOI 10.1001/jamainternmed.2015.1180 Wang K, 2017, J CLIN ONCOL, V35, P1387, DOI 10.1200/JCO.2016.70.0229 Wang X, 2020, J THORAC ONCOL, V15, P1682, DOI 10.1016/j.jtho.2020.06.014 Yegya-Raman N, 2018, J THORAC ONCOL, V13, P1508, DOI 10.1016/j.jtho.2018.05.028 Yu H, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.768811 Zhou Y, 2022, MACH LEARN, V111, P345, DOI 10.1007/s10994-021-06056-w Zhu C, 2020, PHYS MED BIOL, V65, DOI 10.1088/1361-6560/ab63b6 NR 40 TC 5 Z9 5 U1 0 U2 10 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-8140 EI 1879-0887 J9 RADIOTHER ONCOL JI Radiother. Oncol. PD DEC PY 2024 VL 201 AR 110566 DI 10.1016/j.radonc.2024.110566 EA OCT 2024 PG 8 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA J3L9U UT WOS:001336123800001 PM 39362606 DA 2026-04-17 ER PT J AU Mangiameli, G Bottoni, E Tagliabue, A Giudici, VM Crepaldi, A Testori, A Voulaz, E Cariboni, U Cecconi, ER Luppichini, M Alloisio, M Brascia, D Morenghi, E Marulli, G AF Mangiameli, Giuseppe Bottoni, Edoardo Tagliabue, Alberto Giudici, Veronica Maria Crepaldi, Alessandro Testori, Alberto Voulaz, Emanuele Cariboni, Umberto Cecconi, Emanuela Re Luppichini, Matilde Alloisio, Marco Brascia, Debora Morenghi, Emanuela Marulli, Giuseppe TI Early Hospital Discharge on Day Two Post-Robotic Lobectomy with Telehealth Home Monitoring SO JOURNAL OF CLINICAL MEDICINE LA English DT Article DE enhanced recovery after surgery; telemedicine; telehealth home monitoring; thoracic surgery; robotic surgery; lung cancer; NSCLC ID SURGERY; PROGRAM; FEASIBILITY; RECOVERY; OUTCOMES; CANCER AB Background: Despite the implementation of enhanced recovery programs, the reported average postoperative length of stay after robotic lobectomy remains as 4 days. In this prospective study, we present the outcomes of early discharge (on day 2) with telehealth home monitoring device after robotic lobectomy for lung cancer in selected patients. Methods: All patients with a caregiver were discharged on postoperative day 2 (POD 2) with a telemonitoring device provided they met the specific discharge criteria. Inclusion criteria: <75 years old, stage I-II NSCLC, with caregiver, ECOG 0-2, scheduled for lobectomy, logistic proximity to hospital (<60 km); intra-postoperative exclusion criteria: conversion to open surgery, early complications needing hospital monitoring or redo-operation, difficult pain management, <92 HbO2% saturation on room air or need for O2 supplementation, altered vital or laboratory parameters. Teleconsultations were scheduled as follows: the first one in afternoon of POD2, two on POD3, then once a day until chest tube removal. After discharge, patients recorded their vital signs at least four times a day using the device, which allowed two surgeons to monitor them via a mobile application. In the event of sudden changes in vital signs or the occurrence of adverse events, patients had access to a direct phone line and a dedicated re-hospitalization pathway. The primary outcome was safety, assessed by the occurrence of post-discharge complications or readmissions, as well as feasibility. Secondary outcomes: comparison of safety profile with a matched control group in which the standard of care and the evaluation of resource optimization were maintained and economic evaluation. Results: Between July 2022 and February 2024, 48 patients were enrolled in the present study. Six patients (12.5%) dropped out due to unsatisfied discharge criteria on POD2. Exclusion causes were: significant air leaks (n:2) requiring monitoring and the use of suction device, uncontrolled pain (n:2), atrial fibrillation, and occurrence of cerebral ischemia (n:1 each). The adherence rate to vital signs monitoring by patients was 100%. A mean number of four measurements per day was performed by each patient. During telehealth home monitoring, a total of 71/2163 (1.4%) vital sign measurements violated the established acceptable threshold in 22 (52%) patients. All critical violations were managed at home. During the surveillance period (defined as the time from POD 2 to the day of chest tube removal), a persistent air leak was recorded in one patient requiring readmission to the hospital (on POD 13) and re-intervention with placement of a second thoracic drainage due to unsatisfactory lung expansion. No other postoperative complication occurred nor was there any readmission needed. Compared to the control group, the discharge gain was 2.5 days, with an economic benefit of 528 /day (55.440 on the total enrolled population). Conclusions: Our results confirm that the adoption of telehealth home monitoring is feasible and allows a safe discharge on postoperative day two after robotic surgery for stage I-II NSCLC in selected patients. A potential economic benefit (141 days of hospitalizations avoided) for the healthcare system could result from the adoption of this protocol. C1 [Mangiameli, Giuseppe; Bottoni, Edoardo; Tagliabue, Alberto; Giudici, Veronica Maria; Crepaldi, Alessandro; Testori, Alberto; Voulaz, Emanuele; Cariboni, Umberto; Cecconi, Emanuela Re; Luppichini, Matilde; Alloisio, Marco; Brascia, Debora; Marulli, Giuseppe] IRCCS Humanitas Res Hosp, Div Thorac Surg, Via Manzoni 56, I-20089 Milan, Italy. [Mangiameli, Giuseppe; Tagliabue, Alberto; Giudici, Veronica Maria; Voulaz, Emanuele; Cecconi, Emanuela Re; Luppichini, Matilde; Brascia, Debora; Morenghi, Emanuela; Marulli, Giuseppe] Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini 4, I-20090 Milan, Italy. [Morenghi, Emanuela] IRCCS Humanitas Res Hosp, Biostat Unit, Via Manzoni 56, I-20089 Milan, Italy. C3 Humanitas University RP Mangiameli, G (corresponding author), IRCCS Humanitas Res Hosp, Div Thorac Surg, Via Manzoni 56, I-20089 Milan, Italy.; Mangiameli, G (corresponding author), Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini 4, I-20090 Milan, Italy. EM giuseppe.mangiameli@hunimed.eu RI voulaz, emanuele/K-9667-2016; Edoardo, Bottoni/GZG-3495-2022; Brascia, Debora/HKN-8837-2023; Morenghi, Emanuela/AIB-8563-2022; MARULLI, GIUSEPPE/LOS-8884-2024; Mangiameli, Giuseppe/AAX-1916-2020; alloisio, marco/GYV-1110-2022; Testori, Alberto/ABR-7789-2022; crepaldi, alessandro/LXA-2414-2024; Cariboni, Umberto/KQU-5570-2024 OI voulaz, emanuele/0000-0002-9091-6797; Edoardo, Bottoni/0000-0002-7585-5754; Brascia, Debora/0000-0003-0860-1647; Morenghi, Emanuela/0000-0002-0254-3143; MARULLI, GIUSEPPE/0000-0001-6570-615X; Mangiameli, Giuseppe/0000-0002-8394-2719; FU Finanziamento 5 x 1000 Ministero della Salute FX This work was supported by a specific grant from "Finanziamento 5 x 1000 Ministero della Salute", the grant was obtained in IRCCS Humanitas Research Hospital. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. CR Almizani MS, 2024, TELEMED E-HEALTH, V30, P858, DOI 10.1089/tmj.2023.0289 Amato Simona, 2020, Ig Sanita Pubbl, V76, P288 Batchelor TJP, 2019, EUR J CARDIO-THORAC, V55, P91, DOI 10.1093/ejcts/ezy301 Bottoni E, 2023, CANCERS, V15, DOI 10.3390/cancers15041146 Bouwsma EVA, 2014, J OCCUP REHABIL, V24, P425, DOI 10.1007/s10926-013-9475-4 Bouwsma EVA, 2018, BMJ OPEN, V8, DOI [10.1136/bmjopen-2017-017781, 10.1136/bmjopen-2017-017782] Cecconi ER, 2024, FRONT ONCOL, V13, DOI 10.3389/fonc.2023.1268362 Cuschieri S, 2019, SAUDI J ANAESTH, V13, P31, DOI 10.4103/sja.SJA_543_18 Dorrell RD, 2017, SURG ENDOSC, V31, P5457, DOI 10.1007/s00464-017-5625-7 Dorsey ER, 2020, LANCET, V395, P859, DOI [10.1016/s0140-6736(20)30424-4, 10.1016/S0140-6736(20)30424-4] Downing M, 2023, JTCVS OPEN, V16, P500, DOI [10.1016/j.xjon.2023.09.016, 10.1016/j.xjon.2023.09.016] Faiz O, 2018, Digital Medicine, V4, P133, DOI [10.4103/digm.digm_26_18, DOI 10.4103/DIGM.DIGM2618] Falcoz PE, 2016, EUR J CARDIO-THORAC, V49, P602, DOI 10.1093/ejcts/ezv154 Graetz I, 2018, GYNECOL ONCOL, V150, P311, DOI 10.1016/j.ygyno.2018.06.007 Grygorian A, 2024, JAMA NETW OPEN, V7, DOI 10.1001/jamanetworkopen.2024.8555 Gunter RL, 2018, J AM COLL SURGEONS, V226, P277, DOI 10.1016/j.jamcollsurg.2017.12.013 Haveman ME, 2024, J TELEMED TELECARE, V30, P215, DOI 10.1177/1357633X211047710 Huang L, 2022, BJS OPEN, V6, DOI 10.1093/bjsopen/zrac050 Jin RS, 2022, ANN SURG, V275, P295, DOI 10.1097/SLA.0000000000004922 Mangiameli G, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.858242 Noordegraaf AV, 2014, BJOG-INT J OBSTET GY, V121, P1127, DOI 10.1111/1471-0528.12661 Parker RS, 2022, INT J CANCER, V151, P1913, DOI 10.1002/ijc.34202 Patel YS, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0261767 Paul JE, 2019, PILOT FEASIBILITY ST, V5, DOI 10.1186/s40814-019-0415-8 Pezzuto A, 2022, J INT MED RES, V50, DOI 10.1177/03000605221094531 Pickens R, 2019, AM SURGEON, V85, P909 Scarci Marco, 2022, Semin Thorac Cardiovasc Surg, V34, P726, DOI [10.1053/j.semtcvs.2021.03.038, 10.1053/j.semtcvs.2021.03.038] Sun V, 2017, JAMA SURG, V152, P852, DOI 10.1001/jamasurg.2017.1519 Tartaglia Edoardo, 2022, Smart Health (Amst), V26, P100324, DOI [10.1016/j.smhl.2022.100324, 10.1016/j.smhl.2022.100324] van der Meij E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158612 Veronesi G, 2010, J THORAC CARDIOV SUR, V140, P19, DOI 10.1016/j.jtcvs.2009.10.025 Yang HX, 2016, CHIN J CANCER, V35, DOI 10.1186/s40880-016-0117-z NR 32 TC 3 Z9 3 U1 0 U2 1 PU MDPI PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND EI 2077-0383 J9 J CLIN MED JI J. Clin. Med. PD OCT PY 2024 VL 13 IS 20 AR 6268 DI 10.3390/jcm13206268 PG 13 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA K3C6F UT WOS:001342693300001 PM 39458218 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Salem, PP Chami, P Daou, R Hajj, J Lin, HB Chhabra, AM Simone , CB II Lee, NY Hajj, C AF Salem, Peter P. Chami, Perla Daou, Remy Hajj, Joseph Lin, Haibo Chhabra, Arpit M. Simone II, Charles B. Lee, Nancy Y. Hajj, Carla TI Proton Radiation Therapy: A Systematic Review of Treatment-Related Side Effects and Toxicities SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES LA English DT Review DE proton radiation therapy; neurotoxicity; pulmonary toxicity; cardiac toxicity; gastrointestinal toxicity; hematological toxicity; urological toxicity; osteological toxicity; oral toxicity; endocrine toxicity ID CELL LUNG-CANCER; QUALITY-OF-LIFE; BEAM THERAPY; PHOTON RADIATION; CONCURRENT CHEMOTHERAPY; DOSE-ESCALATION; RISK-FACTORS; STAGE-II; CLINICAL-FEATURES; MOYAMOYA SYNDROME AB Cancer is the second leading cause of death worldwide. Around half of all cancer patients undergo some type of radiation therapy throughout the course of their treatment. Photon radiation remains (RT) the most widely utilized modality of radiotherapy despite recent advancements in proton radiation therapy (PBT). PBT makes use of the particle's biological property known as the Bragg peak to better spare healthy tissue from radiation damage, with data to support that this treatment modality is less toxic than photon RT. Hence, proton radiation dosimetry looks better compared to photon dosimetry; however, due to proton-specific uncertainties, unexpected acute, subacute, and long-term toxicities can be encountered. Reported neurotoxicity resulting from proton radiation treatments include radiation necrosis, moyamoya syndrome, neurosensory toxicities, brain edema, neuromuscular toxicities, and neurocognitive toxicities. Pulmonary toxicities include pneumonitis and fibrosis, pleural effusions, and bronchial toxicities. Pericarditis, pericardial effusions, and atrial fibrillations are among the cardiac toxicities related to proton therapy. Gastrointestinal and hematological toxicities are also found in the literature. Genitourinary toxicities include urinary and reproductive-related toxicities. Osteological, oral, endocrine, and skin toxicities have also been reported. The side effects will be comparable to the ones following photon RT, nonetheless at an expected lower incidence. The toxicities collected mainly from case reports and clinical trials are described based on the organs affected and functions altered. C1 [Salem, Peter P.; Chami, Perla] Amer Univ Beirut, Fac Med, Beirut 1107, Lebanon. [Daou, Remy] Hotel Dieu France Hosp, Family Med Dept, Beirut 1660, Lebanon. [Hajj, Joseph] Univ Balamand, Fac Med, Beirut 1100, Lebanon. [Lin, Haibo; Chhabra, Arpit M.; Simone II, Charles B.; Lee, Nancy Y.; Hajj, Carla] New York Proton Ctr, New York, NY 10035 USA. [Simone II, Charles B.; Lee, Nancy Y.; Hajj, Carla] Mem Sloan Kettering Canc Ctr, New York, NY 10027 USA. C3 American University of Beirut; University Balamand; Memorial Sloan Kettering Cancer Center RP Hajj, C (corresponding author), New York Proton Ctr, New York, NY 10035 USA.; Hajj, C (corresponding author), Mem Sloan Kettering Canc Ctr, New York, NY 10027 USA. EM pps05@mail.aub.edu; pnc00@mail.aub.edu; remy.daou@dbayehmedical.com; joseph.hajj@std.balamand.edu.lb; hlin@nyproton.com; achhabra@nyproton.com; simonec1@mskcc.org; leen2@mskcc.org; hajjc@mskcc.org OI Hajj, Carla/0000-0001-8774-1845; Chami, Perla/0009-0001-0409-0088; Simone, Charles/0000-0002-0867-3694 FU NCI NIH HHS [P30 CA008748] Funding Source: Medline CR Abramowicz AE., 2022, Bronchopleural Fistula. StatPearls Abugroun Ashraf, 2017, World J Oncol, V8, P171, DOI [10.14740/wjon1063w, 10.14740/wjon1063w] Aldrich KD, 2021, J NEURO-ONCOL, V155, P93, DOI 10.1007/s11060-021-03847-y Alterio D, 2017, STRAHLENTHER ONKOL, V193, P971, DOI 10.1007/s00066-017-1206-x Antunes C, 2023, StatPearls Arroyo-Hernández M, 2021, BMC PULM MED, V21, DOI 10.1186/s12890-020-01376-4 Ashizawa Tetsuo, 2016, Continuum (Minneap Minn), V22, P1208, DOI [10.1212/con.0000000000000362, 10.1212/CON.0000000000000362] Ataullah A. H. M., 2023, Gait Disturbances Bagley AF, 2020, RADIOTHER ONCOL, V142, P133, DOI 10.1016/j.radonc.2019.07.012 Barcellini A, 2021, TUMORI J, V107, pNP67, DOI 10.1177/03008916211007930 Barney CL, 2014, NEURO-ONCOLOGY, V16, P303, DOI 10.1093/neuonc/not155 Bavle A, 2021, NEURO-ONCOL PRACT, V8, P31, DOI 10.1093/nop/npaa061 Bielamowicz K, 2018, PEDIATR HEMAT ONCOL, V35, P257, DOI 10.1080/08880018.2018.1471111 Bishop AJ, 2014, INT J RADIAT ONCOL, V90, P354, DOI 10.1016/j.ijrobp.2014.05.051 Bower AS, 2022, NEUROLOGY, V98, P767, DOI 10.1212/WNL.0000000000200347 Bradley DJ, 2007, CLIN PHARMACOL THER, V81, P284, DOI 10.1038/sj.clpt.6100062 Brandsma D, 2008, LANCET ONCOL, V9, P453, DOI 10.1016/S1470-2045(08)70125-6 Brodin NP, 2021, RADIAT ONCOL, V16, DOI 10.1186/s13014-021-01745-1 Bronk JK, 2022, ADV RADIAT ONCOL, V7, DOI 10.1016/j.adro.2022.101044 Brown PD, 2021, NEURO-ONCOLOGY, V23, P1337, DOI 10.1093/neuonc/noab040 Bryant C, 2016, INT J RADIAT ONCOL, V95, P422, DOI 10.1016/j.ijrobp.2016.02.038 Buckley LF, 2018, EUR HEART J-CARD PHA, V4, P46, DOI 10.1093/ehjcvp/pvx018 Bush DA, 2023, CANCER-AM CANCER SOC, V129, P3554, DOI 10.1002/cncr.34965 Bush DA, 2013, INT J RADIAT ONCOL, V86, P964, DOI 10.1016/j.ijrobp.2013.05.002 Cao JZ, 2021, RADIOTHER ONCOL, V160, P32, DOI 10.1016/j.radonc.2021.03.036 Chang JY, 2017, JAMA ONCOL, V3, DOI [10.21767/2471-9668.100029, 10.1001/jamaoncol.2017.2032] Chang JY, 2017, RADIOTHER ONCOL, V122, P274, DOI 10.1016/j.radonc.2016.10.022 Cheng JY, 2020, RADIAT ONCOL, V15, DOI 10.1186/s13014-020-01605-4 Chhabra AM, 2023, RADIOTHER ONCOL, V183, DOI 10.1016/j.radonc.2023.109551 Chi A, 2017, RADIOTHER ONCOL, V123, P346, DOI 10.1016/j.radonc.2017.05.007 Chiang JS, 2021, INT J PART THER, V8, P82, DOI 10.14338/IJPT-20-00087.1 Chilukuri S, 2022, INT J PART THER, V9, P42, DOI 10.14338/IJPT-21-00042.1 Cho YC, 2014, CARDIOVASC INTER RAD, V37, P750, DOI 10.1007/s00270-013-0735-7 Chuong M, 2020, ACTA ONCOL, V59, P196, DOI 10.1080/0284186X.2019.1698764 Cohen LE, 2005, ENDOCRIN METAB CLIN, V34, P769, DOI 10.1016/j.ecl.2005.04.008 Colaco RJ, 2015, INT J RADIAT ONCOL, V91, P172, DOI 10.1016/j.ijrobp.2014.08.353 Cordova-Madera SN, 2021, EUR HEART J, V42, P24 Curigliano G, 2016, CA-CANCER J CLIN, V66, P310, DOI 10.3322/caac.21341 De Leo AN, 2021, RADIOTHER ONCOL, V158, P125, DOI 10.1016/j.radonc.2021.02.012 DeCesaris CM, 2020, J THORAC ONCOL, V15, P1054, DOI 10.1016/j.jtho.2020.01.024 Delaney G, 2005, CANCER-AM CANCER SOC, V104, P1129, DOI 10.1002/cncr.21324 Desai SS, 2006, INT J RADIAT ONCOL, V65, P1222, DOI 10.1016/j.ijrobp.2006.01.038 Eaton BR, 2016, NEURO-ONCOLOGY, V18, P881, DOI 10.1093/neuonc/nov302 Elkatatny A, 2023, NEUROSURG REV, V46, DOI 10.1007/s10143-023-02055-8 Fangusaro JR, 2009, CANCER TREAT RES, V150, P155, DOI 10.1007/b109924_11 Fernandes A, 2016, INT J RADIAT ONCOL, V95, P483, DOI 10.1016/j.ijrobp.2015.12.005 Foster-Thomas E, 2023, INT J PART THER, V9, P50, DOI 10.14338/IJPT-22-00011.1 Foti PV, 2022, CANCERS, V14, DOI 10.3390/cancers14010215 Foti PV, 2021, INSIGHTS IMAGING, V12, DOI 10.1186/s13244-021-01000-x Frankart AJ, 2021, J THROMB THROMBOLYS, V51, P877, DOI 10.1007/s11239-020-02303-4 Fuji H, 2011, SKULL BASE-INTERD AP, V21, P201, DOI 10.1055/s-0031-1275636 Gaito S, 2023, CLIN ONCOL-UK, V35, P283, DOI 10.1016/j.clon.2023.01.024 Galle JO, 2015, INT J PART THER, V2, P11, DOI [10.14338/theijpt-14-00029.1, 10.14338/THEIJPT-14-00029.1, DOI 10.14338/THEIJPT-14-00029.1] Gentile MS, 2018, INT J RADIAT ONCOL, V100, P719, DOI 10.1016/j.ijrobp.2017.11.026 Giuranno L, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00877 Gjyshi O, 2021, J THORAC ONCOL, V16, P269, DOI 10.1016/j.jtho.2020.10.013 Global Cancer Observatory (GCO), International Agency for Research on Cancer Estimated Number of New Cases in 2020, World, Both Sexes, All Ages (excl. NMSC) Gomez DR, 2013, INT J RADIAT ONCOL, V86, P665, DOI 10.1016/j.ijrobp.2013.03.035 Gordon K, 2021, RADIAT ONCOL, V16, DOI 10.1186/s13014-021-01961-9 Gordon K, 2021, CASE REP ONCOL, V14, P78, DOI 10.1159/000513030 Greenfield Brad J, 2016, Clin Transl Radiat Oncol, V1, P9, DOI [10.1016/j.ctro.2016.08.002, 10.1016/j.ctro.2016.08.002] Gunther JR, 2017, PRACT RADIAT ONCOL, V7, pE401, DOI 10.1016/j.prro.2017.05.002 Harada H, 2016, CANCER SCI, V107, P1018, DOI 10.1111/cas.12955 Harjani RR, 2016, REP PRACT ONCOL RADI, V21, P560, DOI 10.1016/j.rpor.2016.08.003 Hashimoto T, 2006, INT J RADIAT ONCOL, V65, P196, DOI 10.1016/j.ijrobp.2005.11.043 Herrmann J, 2020, NAT REV CARDIOL, V17, P474, DOI 10.1038/s41569-020-0348-1 Holtzman AL, 2022, ACTA ONCOL, V61, P1026, DOI 10.1080/0284186X.2022.2101900 Hong TS, 2014, INT J RADIAT ONCOL, V89, P830, DOI 10.1016/j.ijrobp.2014.03.034 Hopcraft MS, 2010, AUST DENT J, V55, P238, DOI 10.1111/j.1834-7819.2010.01229.x Hoppe BS, 2022, INT J RADIAT ONCOL, V113, P732, DOI 10.1016/j.ijrobp.2022.03.005 Hoppe BS, 2020, INT J RADIAT ONCOL, V107, P455, DOI 10.1016/j.ijrobp.2020.03.015 Hoppe BS, 2012, CANCER-AM CANCER SOC, V118, P4619, DOI 10.1002/cncr.27398 Hopper A, 2023, J NEURO-ONCOL, V161, P277, DOI 10.1007/s11060-022-04175-5 Hu ZX, 2022, TRANSL CANCER RES, V11, P3400, DOI 10.21037/tcr-22-256 Indelicato DJ, 2021, INT J RADIAT ONCOL, V109, P1406, DOI 10.1016/j.ijrobp.2020.11.051 Indelicato DJ, 2018, ACTA ONCOL, V57, P644, DOI 10.1080/0284186X.2017.1413248 Indelicato DJ, 2014, ACTA ONCOL, V53, P1298, DOI 10.3109/0284186X.2014.957414 Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467 Jairam V, 2021, ADV RADIAT ONCOL, V7, DOI 10.1016/j.adro.2022.100949 Janopaul-Naylor J, 2021, PEDIATR BLOOD CANCER, V68, DOI 10.1002/pbc.29241 Jeter MD, 2018, INT J RADIAT ONCOL, V100, P730, DOI 10.1016/j.ijrobp.2017.10.042 Jimenez RB, 2019, J CLIN ONCOL, V37, P2778, DOI 10.1200/JCO.18.02366 Kahalley LS, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.01706 Kaiser A, 2019, JOVE-J VIS EXP, DOI 10.3791/58372 Kalapurakal JA, 2006, INT J RADIAT ONCOL, V65, P800, DOI 10.1016/j.ijrobp.2006.01.006 Kammerer E, 2018, CANCER TREAT REV, V63, P19, DOI 10.1016/j.ctrv.2017.11.006 Kawashima M, 2005, J CLIN ONCOL, V23, P1839, DOI 10.1200/JCO.2005.00.620 Khan M, 2018, AM J NEURORADIOL, V39, P1576, DOI 10.3174/ajnr.A5671 Koetsier KS, 2021, OTOL NEUROTOL, V42, P1560, DOI 10.1097/MAO.0000000000003313 Kushida C.A., 2013, Encyclopedia of sleep, VFirst, DOI [DOI 10.1016/B978-0-12-378610-4.00148-0, 10.1016/B978-0-12-378610-4.00148-0] Ladra MM, 2014, J CLIN ONCOL, V32, P3762, DOI 10.1200/JCO.2014.56.1548 Landier W, 2016, CANCER-AM CANCER SOC, V122, P1647, DOI 10.1002/cncr.29779 Laughlin BS, 2023, INT J PART THER, V10, P43, DOI 10.14338/IJPT-23-00001.1 Leinonen V, 2018, HAND CLINIC, V145, P25, DOI 10.1016/B978-0-12-802395-2.00004-3 Leopold D, 2002, CHEM SENSES, V27, P611, DOI 10.1093/chemse/27.7.611 Li Yun Rose, 2016, Int J Part Ther, V3, P320, DOI [10.14338/ijpt-16-00013.1, 10.14338/IJPT-16-00013.1] Liao ZX, 2018, J CLIN ONCOL, V36, P1813, DOI 10.1200/JCO.2017.74.0720 Lin SH, 2020, J CLIN ONCOL, V38, P1569, DOI 10.1200/JCO.19.02503 Lin YL, 2019, WORLD J CLIN ONCOL, V10, P256, DOI 10.5306/wjco.v10.i7.256 Lindberg K, 2021, J RADIOL PROT, V41, pS355, DOI 10.1088/1361-6498/ac28ef LITTLEY MD, 1989, Q J MED, V70, P145 Liu Hui, 2011, Chin J Cancer, V30, P315 Liu KX, 2021, INT J RADIAT ONCOL, V109, P726, DOI 10.1016/j.ijrobp.2020.09.049 Lu FG, 2004, INT J RADIAT BIOL, V80, P39, DOI 10.1080/09553000310001642876 Makishima H, 2017, MOL CLIN ONCOL, V7, P547, DOI 10.3892/mco.2017.1372 Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1 McCusker MG, 2019, J THORAC ONCOL, V14, pE185, DOI 10.1016/j.jtho.2019.05.013 McGovern SL, 2014, INT J RADIAT ONCOL, V90, P1143, DOI 10.1016/j.ijrobp.2014.08.354 Meixner E, 2023, RADIAT ONCOL, V18, DOI 10.1186/s13014-023-02198-4 Merchant TE, 2023, LANCET ONCOL, V24, P523, DOI 10.1016/S1470-2045(23)00146-8 Merchant TE, 2010, INT J RADIAT ONCOL, V76, P496, DOI 10.1016/j.ijrobp.2009.01.079 Miyatake SI, 2015, NEUROL MED-CHIR, V55, P50, DOI 10.2176/nmc.ra.2014-0188 Mohan R, 2017, INT J RADIAT ONCOL, V99, P304, DOI 10.1016/j.ijrobp.2017.05.005 Mohan R, 2017, ADV DRUG DELIVER REV, V109, P26, DOI 10.1016/j.addr.2016.11.006 Monje M, 2008, DEV DISABIL RES REV, V14, P238, DOI 10.1002/ddrr.26 Murphy ES, 2015, J NEURO-ONCOL, V122, P421, DOI 10.1007/s11060-015-1732-2 Nagano T, 2012, JPN J CLIN ONCOL, V42, P965, DOI 10.1093/jjco/hys115 Nakagawa Norihiko, 2022, Am J Ophthalmol Case Rep, V28, P101715, DOI [10.1016/j.ajoc.2022.101715, 10.1016/j.ajoc.2022.101715] Nakajima K, 2024, RADIOTHER ONCOL, V196, DOI 10.1016/j.radonc.2024.110276 Nakajima K, 2018, RADIAT ONCOL, V13, DOI 10.1186/s13014-018-1144-5 Ning MS, 2017, INT J RADIAT ONCOL, V99, P70, DOI 10.1016/j.ijrobp.2017.05.022 Oshiro Y, 2014, J RADIAT RES, V55, P959, DOI 10.1093/jrr/rru034 Paganetti H, 2013, SEMIN RADIAT ONCOL, V23, P77, DOI 10.1016/j.semradonc.2012.11.002 Paulino AC, 2018, RADIOTHER ONCOL, V128, P128, DOI 10.1016/j.radonc.2018.01.002 Paulino AC, 2010, SEMIN RADIAT ONCOL, V20, P12, DOI 10.1016/j.semradonc.2009.08.003 Pennington L, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006937.pub3 ptcog, Patients Treated with Protons and C-Ions Worldwide 2007-2012 Pugh Thomas J, 2016, Int J Part Ther, V3, P27, DOI [10.14338/ijpt-16-00006.1, 10.14338/IJPT-16-00006.1] Quintero-Martinez JA, 2022, J CLIN MED, V11, DOI 10.3390/jcm11010146 Nguyen QN, 2015, RADIOTHER ONCOL, V115, P367, DOI 10.1016/j.radonc.2015.05.014 Raggio BS, 2018, CURR OPIN OTOLARYNGO, V26, P254, DOI 10.1097/MOO.0000000000000459 Raghavan KC, 2020, J ADOLESC YOUNG ADUL, V9, P299, DOI 10.1089/jayao.2019.0103 Read R., 2002, Duanes Foundation of Clinical Ophthalmology Reynolds MR, 2016, PEDIATR NEUROSURG, V51, P297, DOI 10.1159/000446075 Riechardt AI, 2017, GRAEF ARCH CLIN EXP, V255, P2263, DOI 10.1007/s00417-017-3737-3 Rosenzweig SJ, 2022, ADV RADIAT ONCOL, V7, DOI 10.1016/j.adro.2021.100881 Routman DM, 2019, ADV RADIAT ONCOL, V4, P63, DOI 10.1016/j.adro.2018.09.004 Ruben JD, 2006, INT J RADIAT ONCOL, V65, P499, DOI 10.1016/j.ijrobp.2005.12.002 Rutenberg MS, 2023, INT J PART THER, V9, P18, DOI 10.14338/IJPT-22-00021.1 Saeed AM, 2020, ADV RADIAT ONCOL, V5, P978, DOI 10.1016/j.adro.2020.03.022 Saguil A, 2014, AM FAM PHYSICIAN, V90, P99 Sanford NN, 2017, INT J RADIAT ONCOL, V99, P787, DOI 10.1016/j.ijrobp.2017.07.008 Sawada T, 2021, CLIN TRANSL RAD ONCO, V27, P32, DOI 10.1016/j.ctro.2020.12.004 Scala M, 2019, WORLD NEUROSURG, V123, P306, DOI 10.1016/j.wneu.2018.12.048 Seibel I, 2016, GRAEF ARCH CLIN EXP, V254, P1787, DOI 10.1007/s00417-016-3429-4 Seibel I, 2016, GRAEF ARCH CLIN EXP, V254, P1625, DOI 10.1007/s00417-016-3356-4 Sherman JC, 2016, J NEURO-ONCOL, V126, P157, DOI 10.1007/s11060-015-1952-5 Shih HA, 2015, CANCER-AM CANCER SOC, V121, P1712, DOI 10.1002/cncr.29237 Simone CB II, 2017, SEMIN RADIAT ONCOL, V27, P370, DOI 10.1016/j.semradonc.2017.04.009 Singh A, 2023, JAMA OTOLARYNGOL, V149, P151, DOI 10.1001/jamaoto.2022.4165 Siva S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109560 Smart D, 2017, SEMIN RADIAT ONCOL, V27, P332, DOI 10.1016/j.semradonc.2017.04.006 Stewart W D, 1889, Ind Med Gaz, V24, P356 Sumiya T, 2020, CANCERS, V12, DOI 10.3390/cancers12071840 SUZUKI J, 1969, ARCH NEUROL-CHICAGO, V20, P288, DOI 10.1001/archneur.1969.00480090076012 Takada A, 2016, CANCER MED-US, V5, P506, DOI 10.1002/cam4.607 Takaoka T, 2023, JPN J CLIN ONCOL, V53, P419, DOI 10.1093/jjco/hyad005 Tseng YD, 2021, INT J RADIAT ONCOL, V109, P220, DOI 10.1016/j.ijrobp.2020.08.055 Uemura S, 2022, CANCER MED-US, V11, P1502, DOI 10.1002/cam4.4553 Uezono H, 2020, INT J RADIAT ONCOL, V107, P974, DOI 10.1016/j.ijrobp.2020.04.043 Ungaro R, 2017, LANCET, V389, P1756, DOI 10.1016/S0140-6736(16)32126-2 Upadhyay R, 2022, NEURO-ONCOLOGY, V24, P1571, DOI 10.1093/neuonc/noac044 Vakamudi S, 2017, PROG CARDIOVASC DIS, V59, P380, DOI 10.1016/j.pcad.2016.12.009 VALK PE, 1991, AM J NEURORADIOL, V12, P45 Vennarini S, 2022, CANCERS, V14, DOI 10.3390/cancers14071653 Verma V, 2017, CANCERS, V9, DOI 10.3390/cancers9090120 Vogel J, 2019, ACTA ONCOL, V58, P1752, DOI 10.1080/0284186X.2019.1659996 Wang HR, 2019, INT J BIOL SCI, V15, P2128, DOI 10.7150/ijbs.35460 Weinberg BA, 2024, INT J RADIAT ONCOL, V118, P362, DOI 10.1016/j.ijrobp.2023.09.015 WOJNO KJ, 1994, ACTA CYTOL, V38, P1 World Cancer Research Fund, International Worldwide Cancer Data Xia CC, 2020, FUTURE MED CHEM, V12, P2161, DOI 10.4155/fmc-2019-0162 Yang TJ, 2021, NEURO-ONCOLOGY, V23, P134, DOI 10.1093/neuonc/noaa152 Yang XJ, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/4793517 Yegya-Raman N, 2024, INT J RADIAT ONCOL, V119, P56, DOI 10.1016/j.ijrobp.2023.08.047 Yu JB, 2024, J CLIN ONCOL, V42, DOI 10.1200/JCO.23.01604 ZEHETMAYER M, 1993, OPHTHALMOLOGICA, V206, P18, DOI 10.1159/000310356 Zeng QS, 2007, J NEURO-ONCOL, V84, P63, DOI 10.1007/s11060-007-9341-3 Zhang WC, 2017, RADIOTHER ONCOL, V123, P401, DOI 10.1016/j.radonc.2017.05.006 Zhao J, 2017, ONCOTARGET, V8, P97623, DOI 10.18632/oncotarget.18824 Zwagerman NT, 2014, PEDIATR BLOOD CANCER, V61, P1490, DOI 10.1002/pbc.24961 NR 181 TC 19 Z9 21 U1 4 U2 19 PU MDPI PI BASEL PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND SN 1661-6596 EI 1422-0067 J9 INT J MOL SCI JI Int. J. Mol. Sci. PD OCT PY 2024 VL 25 IS 20 AR 10969 DI 10.3390/ijms252010969 PG 43 WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary WE Science Citation Index Expanded (SCI-EXPANDED) SC Biochemistry & Molecular Biology; Chemistry GA K1Q6A UT WOS:001341699600001 PM 39456752 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Shingu, Y Yokota, I Kato, T Hida, Y Kaga, K Gao, JW Wakasa, S AF Shingu, Yasushige Yokota, Isao Kato, Tatsuya Hida, Yasuhiro Kaga, Kichizo Gao, Jingwen Wakasa, Satoru TI L-Carnitine: A New Therapeutic Option for the Prevention of Atrial Fibrillation in Non-Cardiac Surgery-A Single-Group Interventional Pilot Study SO JOURNAL OF CLINICAL MEDICINE LA English DT Article DE lung cancer; postoperative atrial fibrillation; L-carnitine; fatty acid-binding protein 4 ID RISK AB Background: L-carnitine is essential in lipid metabolism and reportedly has preventive effects for arrhythmia. Our objective was to examine the incidence of postoperative atrial fibrillation (POAF) and changes in serum biomarker levels following perioperative L-carnitine administration in patients with lung cancer. Methods: Thirteen patients undergoing a lobectomy with preoperative serum brain natriuretic peptide levels >24 pg/mL were perioperatively administered L-carnitine for 5 days (3 g/3x). Accurate 95% confidence intervals (CI) for POAF incidence were calculated. Serum biomarkers for POAF in lung cancer and target proteins for L-carnitine were evaluated by using open-source data from proteomic analysis. Results: The incidence of POAF was 38.5% (95% CI 13.9%-68.4%). Fatty acid-binding protein 4 (FABP4) was selected as a candidate biomarker from 1472, 63, and 26 proteins related to lung cancer, L-carnitine, and AF, respectively. A positive correlation was observed between the predicted POAF incidence rate and preoperative FABP4 levels (Pearson's r = 0.5183). The mean change in serum FABP4 after L-carnitine administration for 5 days was -2.9 ng/mL (95% CI -4.9 to -0.89 ng/mL). Conclusions: The incidence of POAF after a lobectomy was 38.5% after the perioperative administration of L-carnitine for patients at a high risk of POAF. The serum FABP4 level demonstrates potential as a candidate biomarker for POAF prediction. C1 [Shingu, Yasushige; Gao, Jingwen; Wakasa, Satoru] Hokkaido Univ, Fac Med, Dept Cardiovasc Surg, Sapporo 0608638, Japan. [Shingu, Yasushige; Gao, Jingwen; Wakasa, Satoru] Hokkaido Univ, Grad Sch Med, Sapporo 0608638, Japan. [Yokota, Isao] Hokkaido Univ, Grad Sch Med, Dept Biostat, Sapporo 0608638, Japan. [Kato, Tatsuya] Hokkaido Univ Hosp, Dept Thorac Surg, Sapporo 0608648, Japan. [Hida, Yasuhiro] Fujita Hlth Univ, Dept Adv Robot & Endoscop Surg, Toyoake 4701192, Japan. [Kaga, Kichizo] Tonan Hosp, Dept Thorac Surg, Sapporo, Japan. C3 Hokkaido University; Hokkaido University; Hokkaido University; Hokkaido University; Fujita Health University RP Shingu, Y (corresponding author), Hokkaido Univ, Fac Med, Dept Cardiovasc Surg, Sapporo 0608638, Japan.; Shingu, Y (corresponding author), Hokkaido Univ, Grad Sch Med, Sapporo 0608638, Japan. EM shingu@huhp.hokudai.ac.jp RI Kaga, Kichizo/A-7759-2012; Yokota, Isao/AAB-2910-2021; Hida, Yasuhiro/A-7761-2012; Wakasa, Satoru/E-1936-2012; Kato, Tatsuya/G-1648-2012; Shingu, Yasushige/E-1939-2012 OI Shingu, Yasushige/0000-0001-8471-5166; GAO, JINGWEN/0009-0004-8663-9418 FU The 1st JATS award FX This research was conducted with the 1st JATS award for transitional clinical research in 2018 given to Y.S. CR Amar D, 2019, J THORAC CARDIOV SUR, V157, P2493, DOI 10.1016/j.jtcvs.2019.01.075 Brierley J.D., 2016, International Union Against Cancer (UICC): TNM Classification of Malignant Tumors, V8th Dastan F, 2018, SEMIN THORAC CARDIOV, V30, P7, DOI 10.1053/j.semtcvs.2017.08.006 DiNicolantonio JJ, 2013, MAYO CLIN PROC, V88, P544, DOI 10.1016/j.mayocp.2013.02.007 Guaita-Esteruelas S, 2018, MOL CELL ENDOCRINOL, V462, P107, DOI 10.1016/j.mce.2017.02.002 Horikoshi Y, 2017, J CLIN ANESTH, V38, P111, DOI 10.1016/j.jclinane.2017.01.036 Hu AQ, 2023, ANAL CHEM, V95, P862, DOI 10.1021/acs.analchem.2c03299 Jiang F, 2015, ONCOL RES TREAT, V38, P511, DOI 10.1159/000439550 Kavurmaci O, 2018, HEART LUNG CIRC, V27, P835, DOI 10.1016/j.hlc.2017.06.729 Kim MS, 2023, EUR J CARDIO-THORAC, V63, DOI 10.1093/ejcts/ezad152 Li PT, 2021, NUTR METAB, V18, DOI 10.1186/s12986-021-00592-x Lind L, 2017, HEART, V103, P379, DOI 10.1136/heartjnl-2016-309764 Muthuramalingam P, 2023, EUR J PHARMACOL, V940, DOI 10.1016/j.ejphar.2022.175479 Lopez-Canoa JN, 2019, INT J CARDIOL, V292, P131, DOI 10.1016/j.ijcard.2019.04.031 Nojiri T, 2010, J THORAC CARDIOV SUR, V140, P764, DOI 10.1016/j.jtcvs.2009.11.073 Nojiri T, 2010, EUR J CARDIO-THORAC, V37, P787, DOI 10.1016/j.ejcts.2009.09.043 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Shingu Y, 2021, GEN THORAC CARDIOVAS, V69, P1460, DOI 10.1007/s11748-021-01616-2 Tisdale JE, 2010, J THORAC CARDIOV SUR, V140, P45, DOI 10.1016/j.jtcvs.2010.01.026 Wineinger NE, 2019, HEART RHYTHM, V16, P26, DOI 10.1016/j.hrthm.2018.08.012 Xin YZ, 2014, EUR J CARDIO-THORAC, V45, P247, DOI 10.1093/ejcts/ezt383 Yang Jing, 2022, Comput Math Methods Med, V2022, P3764914, DOI [10.1155/2022/3764914, 10.1155/2022/3764914] NR 22 TC 0 Z9 0 U1 0 U2 1 PU MDPI PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND EI 2077-0383 J9 J CLIN MED JI J. Clin. Med. PD OCT PY 2024 VL 13 IS 20 AR 6228 DI 10.3390/jcm13206228 PG 8 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA K2Z0E UT WOS:001342598000001 PM 39458176 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Tohidinezhad, F Nurnberg, L Vaassen, F Bekke, RMAT Aerts, HJWL El Hendriks, L Dekker, A De Ruysscher, D Traverso, A AF Tohidinezhad, Fariba Nurnberg, Leonard Vaassen, Femke Bekke, Rachel M. A. ter Aerts, Hugo J. W. L. El Hendriks, Lizza Dekker, Andre De Ruysscher, Dirk Traverso, Alberto TI Prediction of new-onset atrial fibrillation in patients with non-small cell lung cancer treated with curative-intent conventional radiotherapy SO RADIOTHERAPY AND ONCOLOGY LA English DT Article DE Lung cancer; Radiotherapy; Atrial fibrillation; Prediction model; Machine learning ID CHRONIC KIDNEY-DISEASE; ATHEROSCLEROSIS RISK; RADIATION-THERAPY; SURVIVAL; ALCOHOL AB Background: Atrial fibrillation (AF) is an important side effect of thoracic Radiotherapy (RT), which may impair quality of life and survival. This study aimed to develop a prediction model for new-onset AF in patients with Non-Small Cell Lung Cancer (NSCLC) receiving RT alone or as a part of their multi-modal treatment. Patients and Methods: Patients with stage I-IV NSCLC treated with curative-intent conventional photon RT were included. The baseline electrocardiogram (ECG) was compared with follow-up ECGs to identify the occurrence of new-onset AF. A wide range of potential clinical predictors and dose-volume measures on the whole heart and six automatically contoured cardiac substructures, including chambers and conduction nodes, were considered for statistical modeling. Internal validation with optimism-correction was performed. A nomogram was made. Results: 374 patients (mean age 69 +/- 10 years, 57 % male) were included. At baseline, 9.1 % of patients had AF, and 42 (11.2 %) patients developed new-onset AF. The following parameters were predictive: older age (OR=1.04, 95 % CI: 1.013-1.068), being overweight or obese (OR=1.791, 95 % CI: 1.139-2.816), alcohol use (OR=4.052, 95 % CI: 2.445-6.715), history of cardiac procedures (OR=2.329, 95 % CI: 1.287-4.215), tumor located in the upper lobe (OR=2.571, 95 % CI: 1.518-4.355), higher forced expiratory volume in 1 s (OR=0.989, 95 % CI: 0.979-0.999), higher creatinine (OR=1.008, 95 % CI: 1.002-1.014), concurrent chemotherapy (OR=3.266, 95 % CI: 1.757 to 6.07) and left atrium D-max (OR=1.022, 95 % CI: 1.012-1.032). The model showed good discrimination (area under the curve = 0.80, 95 % CI: 0.76-0.84), calibration and positive net benefits. Conclusion: This prediction model employs readily available predictors to identify patients at high risk of newonset AF who could potentially benefit from active screening and timely management of post-RT AF. C1 [Tohidinezhad, Fariba; Nurnberg, Leonard; Vaassen, Femke; Dekker, Andre; De Ruysscher, Dirk; Traverso, Alberto] Maastricht Univ, Med Ctr, Sch Oncol & Reprod GROW, Dept Radiat Oncol,Maastro Clin, Dr Tanslaan 12, NL-6229ET Maastricht, Netherlands. [Nurnberg, Leonard; Bekke, Rachel M. A. ter; Aerts, Hugo J. W. L.] Harvard Med Sch, Artificial Intelligence Med AIM Program, Mass Gen Brigham, Boston, MA USA. [Bekke, Rachel M. A. ter; Aerts, Hugo J. W. L.] Maastricht Univ, Med Ctr, Dept Radiol & Nucl Med, Maastricht, Netherlands. Maastricht Univ, Med Ctr, Cardiovasc Res Inst Maastricht, Dept Cardiol, Maastricht, Netherlands. [Bekke, Rachel M. A. ter] Harvard Med Sch, Dana Farber Canc Inst, Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA USA. [Aerts, Hugo J. W. L.] Harvard Med Sch, Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiol, Boston, MA USA. [El Hendriks, Lizza] Maastricht Univ, Sch Oncol & Reprod GROW, Dept Pulm Dis, Med Ctr, Maastricht, Netherlands. [Traverso, Alberto] Libera Univ Vita Salute San Raffaele, Sch Med, Milan, Italy. C3 Maastricht University; Harvard University; Harvard Medical School; Mass General Brigham; Maastricht University; Maastricht University; Harvard University; Harvard University Medical Affiliates; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University Medical Affiliates; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Maastricht University RP Traverso, A (corresponding author), Maastricht Univ, Med Ctr, Sch Oncol & Reprod GROW, Dept Radiat Oncol,Maastro Clin, Dr Tanslaan 12, NL-6229ET Maastricht, Netherlands. EM traverso.alberto@hsr.it RI ; Traverso, Alberto/LSL-1408-2024; Hendriks, Lizza/IAM-9992-2023; Aerts, Hugo/ABF-2821-2020 OI Tohidinezhad, Fariba/0000-0001-8880-3593; ter Bekke, Rachel/0000-0003-4278-0132; Traverso, Alberto/0000-0001-6183-4429; Dekker, Andre/0000-0002-0422-7996; FU Netherlands Organization for Health Research and Development (ZonMw) [60-64400-98-105] FX The study was funded by The Netherlands Organization for Health Research and Development (ZonMw): 60-64400-98-105. CR Abed HS, 2013, JAMA-J AM MED ASSOC, V310, P2050, DOI 10.1001/jama.2013.280521 Alexandre J, 2018, PHARMACOL THERAPEUT, V189, P89, DOI 10.1016/j.pharmthera.2018.04.009 Alonso A, 2011, CIRCULATION, V123, P2946, DOI 10.1161/CIRCULATIONAHA.111.020982 Amin H, 2023, StatPearls Chawla NV, 2002, J ARTIF INTELL RES, V16, P321, DOI 10.1613/jair.953 Craddock M, 2023, J THORAC ONCOL, V18, P57, DOI 10.1016/j.jtho.2022.09.004 De Ruysscher D, 2019, RADIOTHER ONCOL, V135, P141, DOI 10.1016/j.radonc.2019.03.009 De Ruysscher D, 2017, RADIOTHER ONCOL, V124, P1, DOI 10.1016/j.radonc.2017.06.003 Delaney GP, 2015, CLIN ONCOL-UK, V27, P70, DOI 10.1016/j.clon.2014.10.005 Essa H, 2022, J CARDIOVASC PHARM, V80, P531, DOI 10.1097/FJC.0000000000001216 Finnegan RN, 2023, PHYS ENG SCI MED, V46, P377, DOI 10.1007/s13246-023-01231-w Gallagher C, 2017, INT J CARDIOL, V246, P46, DOI 10.1016/j.ijcard.2017.05.133 Gasalberti DP, 2024, StatPearls Goldstraw P, 2007, J THORAC ONCOL, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a Hattu D, 2022, RADIOTHER ONCOL, V175, P152, DOI 10.1016/j.radonc.2022.08.030 Hawryszko M, 2023, CANCERS, V15, DOI 10.3390/cancers15245723 Hindricks G, 2021, EUR HEART J, V42, P373, DOI 10.1093/eurheartj/ehaa612 Hu YF, 2013, INT J CARDIOL, V165, P355, DOI 10.1016/j.ijcard.2012.08.036 Johnson LSB, 2014, EUROPACE, V16, P182, DOI 10.1093/europace/eut255 Kim KH, 2022, JAMA ONCOL, V8, P1624, DOI 10.1001/jamaoncol.2022.4202 Ladbury C, 2023, CANCERS, V15, DOI 10.3390/cancers15112916 Lee SN, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-07534-4 Li JJ, 2014, CIRCULATION, V129, P971, DOI 10.1161/CIRCULATIONAHA.113.004050 Lip GYH, 2017, NAT REV CARDIOL, V14, P627, DOI 10.1038/nrcardio.2017.153 Loap P, 2021, PRACT RADIAT ONCOL, V11, pE434, DOI 10.1016/j.prro.2021.02.002 López-Fernández T, 2019, REV ESP CARDIOL, V72, P749, DOI 10.1016/j.rec.2019.03.019 Lu YK, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.845037 Lyon AR, 2022, EUR HEART J, V43, P4229, DOI 10.1093/eurheartj/ehac244 Ma M, 2022, NUTRIENTS, V14, DOI 10.3390/nu14091878 Maisel WH, 2001, ANN INTERN MED, V135, P1061, DOI 10.7326/0003-4819-135-12-200112180-00010 McWilliam A, 2017, EUR J CANCER, V85, P106, DOI 10.1016/j.ejca.2017.07.053 Menezes AR, 2015, PROG CARDIOVASC DIS, V58, P117, DOI 10.1016/j.pcad.2015.07.001 Rangaswami J, 2019, CIRCULATION, V139, pE840, DOI 10.1161/CIR.0000000000000664 Roelofs E, 2012, J THORAC ONCOL, V7, P165, DOI 10.1097/JTO.0b013e31823529fc Simons SO, 2021, EUR HEART J, V42, DOI 10.1093/eurheartj/ehaa822 Tan ZF, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.688625 van Baardwijk A, 2010, J CLIN ONCOL, V28, P1380, DOI 10.1200/JCO.2009.24.7221 van der Burgh AC, 2022, J AM HEART ASSOC, V11, DOI 10.1161/JAHA.122.025303 Velagapudi P, 2011, SOUTH MED J, V104, P667, DOI 10.1097/SMJ.0b013e3182299e6c Vinod SK, 2020, RESPIROLOGY, V25, P61, DOI 10.1111/resp.13870 Vivekanandan S, 2017, INT J RADIAT ONCOL, V99, P51, DOI 10.1016/j.ijrobp.2017.04.026 Voskoboinik A, 2020, NEW ENGL J MED, V382, P20, DOI 10.1056/NEJMoa1817591 Walls GM, 2024, JACC-CARDIOONCOL, V6, P529, DOI 10.1016/j.jaccao.2024.05.009 Walls GM, 2024, RADIOTHER ONCOL, V192, DOI 10.1016/j.radonc.2024.110085 Watanabe H, 2009, AM HEART J, V158, P629, DOI 10.1016/j.ahj.2009.06.031 Wu FH, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11101791 Xu DZ, 2015, AM J CARDIOL, V115, P328, DOI 10.1016/j.amjcard.2014.10.041 NR 47 TC 7 Z9 7 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-8140 EI 1879-0887 J9 RADIOTHER ONCOL JI Radiother. Oncol. PD DEC PY 2024 VL 201 AR 110544 DI 10.1016/j.radonc.2024.110544 EA SEP 2024 PG 7 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA I1X1Y UT WOS:001328247100001 PM 39341504 OA Green Published, hybrid DA 2026-04-17 ER PT J AU Gronich, N Saliba, W Schwartz, JB AF Gronich, Naomi Saliba, Walid Schwartz, Janice B. TI Prevalence and proportion by age and sex of chronic health conditions in a large healthcare system SO PLOS ONE LA English DT Article ID TRIALS AB Background Disease prevalence and distribution by patient characteristics data are needed to guide "representative" patient enrollment in clinical trials and assess relevance of results to patient populations. Our objective was to describe disease prevalence, and age/sex distribution of patients with common chronic conditions from a large population sample.Methods A cross-sectional study of all members of Clalit Health Services, alive on January 1, 2020. Included were 26 chronic diseases, and 21 types of malignancies regarded as active by being diagnosed between January 1, 2018- to January 1, 2020, or by prescription of oncologic treatment medications January 1, 2018 and January 1, 2020.Results Data from 4,627,183 individuals, 2,274,349 males and 2,352,834 females from newborn to 110 years. Obesity (19%), hypertension (13%), diabetes mellitus (9%), esophagitis-gastritis (5.5%), thyroid disease (5.3%), asthma (5.1%), ischemic heart disease (4.5%), depression (4.5%), osteoporosis (3.8%), and atopic dermatitis (3.6%) were the ten most prevalent conditions. Proportions of age groups varied between conditions (67% of hypertensives were >= 65 years old, 24% >= 80 years; 73% with ischemic heart disease were >= 65 years, 29% >= 80 years; 59% of diabetics were >= 65 years, 17% >= 80 years; 42% of atrial fibrillation patients were >= 80 years; 40% of heart failure patients were >= 80 years). Proportions of males and females for most conditions paralleled prevalence except proportions of women increased after age 80 for cardiovascular diseases, and for diabetes after age 75. The five most frequent active cancers were breast, prostate, colon/rectal, lymphoma and melanoma. The prevalence of cancers increased with age beginning in the middle-aged groups and peaking at very old ages. Women had lower prevalence of lung cancers and accounted for lower percentages of patients with lung cancers (45 vs 55%) but similar percentages for women and men were seen in the patients with colon and rectal cancer (50.4 vs. 49.6% in women) and lymphoma (50.7 vs. 49.3% in women).Conclusions Prevalence of medical conditions and distributions differ by age and sex. This information serves as an example and resource for data needed to describe a "representative" clinical population. C1 [Gronich, Naomi; Saliba, Walid] Clalit Hlth Serv, Lady Davis Carmel Med Ctr, Dept Community Med & Epidemiol, Haifa, Israel. [Gronich, Naomi; Saliba, Walid] Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel. [Saliba, Walid] Lady Davis Carmel Med Ctr, Translat Epidemiol Unit & Res Author, Haifa, Israel. [Schwartz, Janice B.] Univ Calif San Francisco, Dept Med, Div Geriatr & Clin Pharmacol, San Francisco, CA USA. C3 Clalit Health Services; Carmel Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Clalit Health Services; Carmel Medical Center; University of California System; University of California San Francisco RP Gronich, N (corresponding author), Clalit Hlth Serv, Lady Davis Carmel Med Ctr, Dept Community Med & Epidemiol, Haifa, Israel.; Gronich, N (corresponding author), Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel. EM gronichn@clalit.org.il CR AdministrationonAging, 2021, 2020 Profile of Older Americans [Anonymous], 2021, NEW ENGL J MED, V385, P1429, DOI 10.1056/NEJMe2114651 [Anonymous], 2021, Health Promot Chronic Dis Prev Can, V41, P30, DOI [10.24095/hpcdp.41.1.04, 10.24095/hpcdp.41.1.04] [Anonymous], Cause of death, by non-communicable diseases (% of total)-Uganda | Data [Anonymous], 2014, Global status report on noncommunicable diseases 2014 [Anonymous], Cancer rates by Human Development Index -World Cancer Research Fund International [Anonymous], 2022, Improving representation in clinical trials and research: building research equity for women and underrepresented groups [Anonymous], Human Development Index | Human Development Reports Atella V, 2019, AGING CELL, V18, DOI 10.1111/acel.12861 Bennett JE, 2018, LANCET, V392, P1072, DOI 10.1016/S0140-6736(18)31992-5 Blauvelt A, 2023, J EUR ACAD DERMATOL, V37, P137, DOI 10.1111/jdv.18571 Bureau USC, The graying of America: more older adults than kids by 2035 2018 Cerreta F, 2015, J NUTR HEALTH AGING, V19, P232, DOI 10.1007/s12603-014-0494-4 Cerreta F, 2012, NEW ENGL J MED, V367, P1972, DOI 10.1056/NEJMp1209034 Congress, C US, P26172023 Conrad N, 2024, BMJ-BRIT MED J, V385, DOI 10.1136/bmj-2023-078523 Emadi M, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-11793-7 FDA, 1989, Guidelines for the Study of Drugs Likely to be Used in the Elderly FEINBERG WM, 1995, ARCH INTERN MED, V155, P469, DOI 10.1001/archinte.155.5.469 Fidler MM, 2016, INT J CANCER, V139, P2436, DOI 10.1002/ijc.30382 Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI [10.1001/jamaoncol.2016.5688, 10.1001/jamaoncol.2018.2706] Flores LE, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.37640 Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039 Guttman-Yassky E, 2023, J ALLERGY CLIN IMMUN, V151, P172, DOI 10.1016/j.jaci.2022.09.023 Helfand BKI, 2020, JAMA INTERN MED, V180, P1546, DOI 10.1001/jamainternmed.2020.5084 IOM, 1990, Report of a workshop: Drug development for the geriatric population Javier-DesLoges J, 2022, CANCER-AM CANCER SOC, V128, P770, DOI 10.1002/cncr.33991 Kang S, 2021, NUTRIENTS, V13, DOI 10.3390/nu13103595 Kuri L, 2023, CLIN TRIALS, V20, P585, DOI 10.1177/17407745231180506 Lau SWJ, 2022, JAMA NETW OPEN, V5, DOI 10.1001/jamanetworkopen.2022.36149 Liu Q, 2022, CLIN PHARMACOL THER, V112, P210, DOI 10.1002/cpt.2452 Lockett J, 2019, J AM GERIATR SOC, V67, P218, DOI 10.1111/jgs.15786 Lukewich Julia, 2020, CMAJ Open, V8, pE895, DOI [10.9778/cmajo.20190233, 10.9778/cmajo.20190233] National Academies of Sciences E and Medicine, 2021, DRUG RES DEV AD OLD NIH, NIH INCL LIF 2 WORKS Papi A, 2022, NEW ENGL J MED, V386, P2071, DOI 10.1056/NEJMoa2203163 Reges O, 2020, CLIN EPIDEMIOL, V12, P477, DOI 10.2147/CLEP.S230677 Rennert G, 2001, ISR MED ASSOC J, V3, P404 Saliba W, 2020, J THROMB HAEMOST, V18, P916, DOI 10.1111/jth.14754 Saliba W, 2019, DIABETES CARE, V42, P682, DOI 10.2337/dc18-2472 Scott PE, 2018, J AM COLL CARDIOL, V71, P1960, DOI 10.1016/j.jacc.2018.02.070 Sedrak MS, 2022, JAMA NETW OPEN, V5, DOI 10.1001/jamanetworkopen.2022.35714 Silverberg JI, 2023, NEW ENGL J MED, V388, P1080, DOI 10.1056/NEJMoa2206714 Singh H, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.10009 Steinberg JR, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.13749 Varma T, 2023, BMJ MED, V2, DOI 10.1136/bmjmed-2022-000395 Vos T, 2020, LANCET, V396, P1204, DOI 10.1016/S0140-6736(20)30925-9 Xi JY, 2022, J GLOB HEALTH, V12, DOI 10.7189/jogh.12.04093 NR 48 TC 5 Z9 7 U1 3 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 26 PY 2024 VL 19 IS 9 AR e0308031 DI 10.1371/journal.pone.0308031 PG 13 WC Multidisciplinary Sciences WE Science Citation Index Expanded (SCI-EXPANDED) SC Science & Technology - Other Topics GA H0Y1U UT WOS:001320777500055 PM 39325771 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Wu, Y Yin, TC Jian, GL Wan, T Zhou, BH AF Wu, Yue Yin, TianChen Jian, Guilin Wan, Tao Zhou, BenHong TI Cost-effectiveness analysis of direct oral anticoagulants versus low-molecular-weight heparin and no thromboprophylaxis in primary prevention of cancer-associated venous thromboembolism in China SO FRONTIERS IN PHARMACOLOGY LA English DT Article DE primary thromboprophylaxis; direct oral anticoagulants; cost-effectiveness; cancer-associated venous thromboembolism; low-molecular-weight heparin ID CELL LUNG-CANCER; PHASE-III TRIAL; ATRIAL-FIBRILLATION; AMBULATORY PATIENTS; HIGH-RISK; RIVAROXABAN; THERAPY; DALTEPARIN; SURVIVAL; ENOXAPARIN AB Background and objective Cancer-associated venous thromboembolism (CAVTE) is a preventable, life-threatening complication with a considerable morbidity and mortality. Primary venous thromboembolism (VTE) prophylaxis is currently recommended; however, the health and economic benefits have not been evaluated and compared in China. This study aimed to assess and compare the cost-effectiveness of anticoagulants in primary CAVTE prevention among cancer patients in China.Methods A Markov model with a 5-year horizon was established to evaluate the costs and effectiveness of direct oral anticoagulants (DOACs) compared to low-molecular-weight heparins (LMWHs) and no prevention in primary prophylaxis of CAVTE in China. Key clinical outcomes were obtained from the available clinical trials, comparing DOACs (rivaroxaban and apixaban) with LMWHs or with no thromboprophylaxis. Utility and the cost inputs were all obtained from the published literature or local data with public sources. The total costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) were estimated as the main endpoints of the modal for each strategy. The assessment of uncertainty was performed involving deterministic sensitivity analysis and probabilistic sensitivity analysis (PSA). Impact of time horizon, generic drug price, and individual DOACs were assessed in scenario and subgroup analyses.Results Primary prophylaxis using DOACs were projected to yield 1.866 QALYs at a cost of $3,287.893, resulting in the ICERs of $12,895.851 (DOACs vs. no-thromboprophylaxis) and $43,613.184/QALYs (LMWHs vs. DOACs). Sensitivity analysis revealed that ICER was sensitive to the VTE and bleeding risk, drug cost of anticoagulants, self-payment ratio, and overall death rate of cancer. Probabilistic sensitivity analysis showed that DOACs and LMWHs had a 48% and 45% probability of being cost-effective at a 5-year time horizon, respectively. When the time horizon extended to 10 years, DOACs achieved a cost-effective probability of 43%. Among individual DOACs, apixaban was found to be the preferred strategy in VTE prevention due to its incremental health gain with an acceptable cost increase.Conclusion Primary thromboprophylaxis with DOACs was cost-effective in cancer patients at a willing-to-pay (WTP) threshold of $37,125.24/QALY in China. Cancer death rate, risk of VTE and major bleeding, and the drug cost assumed greater relevance and importance in the decision-making process for primary thromboprophylaxis in cancer. C1 [Wu, Yue; Yin, TianChen; Jian, Guilin; Wan, Tao; Zhou, BenHong] Wuhan Univ, Renmin Hosp, Dept Pharm, Wuhan, Peoples R China. [Wu, Yue; Yin, TianChen; Jian, Guilin; Wan, Tao; Zhou, BenHong] Wuhan Univ, Sch Pharmaceut Sci, Wuhan, Peoples R China. [Wan, Tao] Changzhou Jintan Dist Hosp Tradit Chinese Med, Dept Pharm, Changzhou, Peoples R China. C3 Wuhan University; Wuhan University RP Wu, Y; Zhou, BH (corresponding author), Wuhan Univ, Renmin Hosp, Dept Pharm, Wuhan, Peoples R China.; Wu, Y; Zhou, BH (corresponding author), Wuhan Univ, Sch Pharmaceut Sci, Wuhan, Peoples R China. EM maymoon@whu.edu.cn; benhongzh@whu.edu.cn FU Scientific Research Project of Hubei Health Commission [WJ2023F026]; Pharmaceutical Research Capacity Building Project of Bethune Charitable Foundation [Z04JKM2021005] FX The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The work was supported by the Scientific Research Project of Hubei Health Commission (Grant No. WJ2023F026) and the Pharmaceutical Research Capacity Building Project of Bethune Charitable Foundation (Grant No. Z04JKM2021005). CR Agnelli G, 2019, NEW ENGL J MED, V380, P781, DOI 10.1056/NEJMe1816060 Agnelli G, 2009, LANCET ONCOL, V10, P943, DOI 10.1016/S1470-2045(09)70232-3 Akin Muharrem, 2015, Cardiovascular & Hematological Disorders - Drug Targets, V15, P92, DOI [10.2174/1871529x1502151209110620, 10.2174/1871529X1502151209110620] Altinbas M, 2004, J THROMB HAEMOST, V2, P1266, DOI 10.1111/j.1538-7836.2004.00871.x [Anonymous], 2013, Blood, DOI DOI 10.1182/BLOOD.V122.21.580.580 Attard LM, 2022, VASC HEALTH RISK MAN, V18, P793, DOI 10.2147/VHRM.S271411 Ay C, 2017, THROMB HAEMOSTASIS, V117, P219, DOI 10.1160/TH16-08-0615 Baloch MF, 2023, CUREUS J MED SCIENCE, V15, DOI 10.7759/cureus.43447 Büller HR, 2012, NEW ENGL J MED, V366, P1287, DOI 10.1056/NEJMoa1113572 Carrier M, 2019, NEW ENGL J MED, V380, P711, DOI 10.1056/NEJMoa1814468 de Jong LA, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-039057 Di Nisio M, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008500.pub4 Du JY, 2020, CLIN DRUG INVEST, V40, P653, DOI 10.1007/s40261-020-00926-2 [陈兴宝 CHEN Xingbao], 2011, [中国药房, China Pharmacy], V22, P2787 Ek L, 2018, ANN ONCOL, V29, P398, DOI 10.1093/annonc/mdx716 Farge D, 2022, LANCET ONCOL, V23, pE334, DOI 10.1016/S1470-2045(22)00160-7 Fox KAA, 2011, EUR HEART J, V32, P2387, DOI 10.1093/eurheartj/ehr342 Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656 Girardi L, 2023, ARTERIOSCL THROM VAS, V43, P824, DOI 10.1161/ATVBAHA.123.318779 Haas SK, 2012, CLIN APPL THROMB-HEM, V18, P159, DOI 10.1177/1076029611433769 Heisen M, 2017, J MED ECON, V20, P813, DOI 10.1080/13696998.2017.1331912 Kakkar AK, 2004, J CLIN ONCOL, V22, P1944, DOI 10.1200/JCO.2004.10.002 Khorana AA, 2019, NEW ENGL J MED, V380, P720, DOI 10.1056/NEJMoa1814630 Khorana AA, 2017, THROMB RES, V151, P89, DOI 10.1016/j.thromres.2017.01.009 Kim K, 2018, KOREAN CIRC J, V48, P406 Kimpton M, 2019, BLOOD, V134, DOI 10.1182/blood-2019-127286 Klerk CPW, 2005, J CLIN ONCOL, V23, P2130, DOI 10.1200/JCO.2005.03.134 Lanitis T, 2016, CLIN THER, V38, P478, DOI 10.1016/j.clinthera.2016.01.020 Lecumberri R, 2013, THROMB RES, V132, P666, DOI 10.1016/j.thromres.2013.09.026 Levine MN, 2012, J THROMB HAEMOST, V10, P807, DOI 10.1111/j.1538-7836.2012.04693.x Li A, 2020, CANCER-AM CANCER SOC, V126, P1736, DOI 10.1002/cncr.32724 Macbeth F, 2016, J CLIN ONCOL, V34, P488, DOI 10.1200/JCO.2015.64.0268 Martinez C, 2018, PULM CIRC, V8, DOI 10.1177/2045894018791358 Meyer G, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.01220-2018 Mulder FI, 2021, BLOOD, V137, P1959, DOI 10.1182/blood.2020007338 Nakano Y, 2024, CIRC J, V88, DOI 10.1253/circj.CJ-20-1247 Nielsen PB, 2015, CIRCULATION, V132, P517, DOI 10.1161/CIRCULATIONAHA.115.015735 Ning HY, 2023, MED CLIN-BARCELONA, V160, P245, DOI 10.1016/j.medcli.2022.06.022 Ogino Y, 2021, J CLIN MED, V10, DOI 10.3390/jcm10204648 Ottosen TP, 2016, STROKE, V47, P1837, DOI 10.1161/STROKEAHA.116.012945 Pelzer U, 2015, J CLIN ONCOL, V33, P2028, DOI 10.1200/JCO.2014.55.1481 Perry JR, 2010, J THROMB HAEMOST, V8, P1959, DOI 10.1111/j.1538-7836.2010.03973.x Rutjes A. W., 2020, COCHRANE DATABASE SY, V12, pCd008500, DOI 10.1002/14651858.CD008500.pub4 Schulman S, 2006, J THROMB HAEMOST, V4, P734, DOI 10.1111/j.1538-7836.2006.01795.x Shin YE, 2022, CLIN DRUG INVEST, V42, P1075, DOI 10.1007/s40261-022-01217-8 Sideras K, 2006, MAYO CLIN PROC, V81, P758, DOI 10.4065/81.6.758 Streiff MB, 2018, J NATL COMPR CANC NE, V16, P1289, DOI 10.6004/jnccn.2018.0084 Timp JF, 2013, BLOOD, V122, P1712, DOI 10.1182/blood-2013-04-460121 Tsoukalas N, 2022, SUPPORT CARE CANCER, V30, P8559, DOI 10.1007/s00520-022-07235-8 van Doormaal FF, 2011, J CLIN ONCOL, V29, P2071, DOI 10.1200/JCO.2010.31.9293 [王慧敏 Wang Huimin], 2005, [肿瘤, Tumor], V25, P250 Wumaier K, 2021, THROMB J, V19, DOI 10.1186/s12959-021-00319-1 Yang L, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-038433 Zeng HM, 2024, J NATL CANCER CTR, V4, P203, DOI 10.1016/j.jncc.2024.06.005 Zhang YM, 2013, J CLIN PULM MED, V18, P2082, DOI DOI 10.3969/J.ISSN.1009-6663.2013.11.067 Zhu M., 2014, Mod. J. Integr. Traditional Chin. West. Med, V23, P378 Zwicker JI, 2013, BRIT J HAEMATOL, V160, P530, DOI 10.1111/bjh.12163 NR 57 TC 3 Z9 3 U1 1 U2 4 PU FRONTIERS MEDIA SA PI LAUSANNE PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND EI 1663-9812 J9 FRONT PHARMACOL JI Front. Pharmacol. PD SEP 23 PY 2024 VL 15 AR 1373333 DI 10.3389/fphar.2024.1373333 PG 14 WC Pharmacology & Pharmacy WE Science Citation Index Expanded (SCI-EXPANDED) SC Pharmacology & Pharmacy GA H9R0S UT WOS:001326720600001 PM 39376608 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Atkins, KM Zhang, SC Kehayias, C Guthier, C He, JH Gasho, JO Bakhtiar, M Silos, KD Kozono, DE Zei, PC Nohria, A Nikolova, AP Mak, RH AF Atkins, Katelyn M. Zhang, Samuel C. Kehayias, Christopher Guthier, Christian He, John Gasho, Jordan O. Bakhtiar, Mina Silos, Katrina D. Kozono, David E. Zei, Paul C. Nohria, Anju Nikolova, Andriana P. Mak, Raymond H. TI Cardiac Substructure Radiation Dose and Associations With Tachyarrhythmia and Bradyarrhythmia After Lung Cancer Radiotherapy SO JACC: CARDIOONCOLOGY LA English DT Article DE atrial fibrillation; arrhythmia; bradyarrhythmia; cardiac toxicity; lung cancer; radiotherapy ID ATRIAL-FIBRILLATION; DISEASE; MANAGEMENT; MORTALITY; TOXICITY; SURVIVAL; EVENTS; TRIALS AB BACKGROUND Arrhythmias are common following radiotherapy for non-small cell lung cancer. OBJECTIVES The aim of this study was to analyze the association of distinct arrhythmia classes with cardiac substructure radiotherapy dose. METHODS A retrospective analysis was conducted of 748 patients with locally advanced non-small cell lung cancer treated with radiotherapy. Cardiac substructure dose parameters were calculated. Receiver-operating characteristic curve analyses for predictors of Common Terminology Criteria for Adverse Events grade >= 3 atrial fibrillation (AF), atrial flutter, non-AF and non-atrial flutter supraventricular tachyarrhythmia (SVT), bradyarrhythmia, and ventricular tachyarrhythmia (VT) or asystole were calculated. Fine-Gray regression models were performed (with noncardiac death as a competing risk). RESULTS Of 748 patients, 128 (17.1%) experienced at least 1 grade >= 3 arrhythmia, with a median time to first arrhythmia of 2.0 years (Q1-Q3: 0.9-4.2 years). The 2-year cumulative incidences of each arrhythmia group were 8.0% for AF, 2.7% for atrial flutter, 1.8% for other SVT, 1.4% for bradyarrhythmia, and 1.1% for VT or asystole. Adjusting for baseline cardiovascular risk, pulmonary vein (PV) volume receiving 5 Gy was associated with AF (subdistribution HR [sHR]: 1.04/mL; 95% CI: 1.01-1.08; P = 0.016), left circumflex coronary artery volume receiving 35 Gy with atrial flutter (sHR: 1.10/mL; 95% CI: 1.01-1.19; P = 0.028), PV volume receiving 55 Gy with SVT (sHR: 1.03 per 1%; 95% CI: 1.02-1.05; P < 0.001), right coronary artery volume receiving 25 Gy with bradyarrhythmia (sHR: 1.14/mL; 95% CI: 1.001.30; P = 0.042), and left main coronary artery volume receiving 5 Gy with VT or asystole (sHR: 2.45/mL; 95% CI: 1.214.97; P = 0.013). CONCLUSIONS This study revealed pathophysiologically distinct arrhythmia classes associated with radiotherapy dose to discrete cardiac substructures, including PV dose with AF and SVT, left circumflex coronary artery dose with atrial flutter, right coronary artery dose with bradyarrhythmia, and left main coronary artery dose with VT or asystole, guiding potential risk mitigation approaches. (JACC CardioOncol 2024;6:544-556) (c) 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). C1 [Atkins, Katelyn M.; Zhang, Samuel C.; Gasho, Jordan O.; Silos, Katrina D.] Cedars Sinai Med Ctr, Dept Radiat Oncol, Los Angeles, CA USA. [Atkins, Katelyn M.] Cedars Sinai Med Ctr, Dept Cardiol, Los Angeles, CA USA. [Kehayias, Christopher; Guthier, Christian; He, John; Bakhtiar, Mina; Kozono, David E.; Mak, Raymond H.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA USA. [Zei, Paul C.; Nohria, Anju] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Cardiovasc Med, Boston, MA USA. [Mak, Raymond H.] Dana Farber Canc Inst, Dept Radiat Oncol, 450 Brookline Ave, Boston, MA 02115 USA. C3 Cedars Sinai Medical Center; Cedars Sinai Medical Center; Harvard University; Harvard University Medical Affiliates; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard University Medical Affiliates; Dana-Farber Cancer Institute; Brigham & Women's Hospital; Harvard University; Harvard University Medical Affiliates; Dana-Farber Cancer Institute RP Mak, RH (corresponding author), Dana Farber Canc Inst, Dept Radiat Oncol, 450 Brookline Ave, Boston, MA 02115 USA.; Mak, RH (corresponding author), Brigham & Womens Hosp, 450 Brookline Ave, Boston, MA 02115 USA. EM rmak@partners.org RI Zei, Paul/KVY-4296-2024; Nohria, Anju/AAD-4925-2022; Zhang, Shuo/LCE-1656-2024; Kozono, David/AED-0045-2022 OI He, John/0009-0002-9787-0426; Kozono, David/0000-0002-8916-396X FX FUNDING SUPPORT AND AUTHOR DISCLOSURES Dr Atkins has received honoraria from OncLive. Dr Mak is a consultant for AstraZeneca, ViewRay, Novartis, Sio Capital Management, and Varian Medical Systems; is an advisory board member for ViewRay and AstraZeneca; and has received grant funding from AstraZeneca and ViewRay. Dr Nohria has received research support from Bristol Myers Squibb; and has received consulting fees from Altathera Pharmaceuticals, AstraZeneca, Bantam Pharmaceuticals, Regeneron Pharmaceuticals, and Takeda Oncology. All other authors have re-ported that they have no relationships relevant to the contents of this paper to disclose. CR Al-Kindi SG, 2016, MAYO CLIN PROC, V91, P81, DOI 10.1016/j.mayocp.2015.09.009 [Anonymous], DRINK LEV DEF Arnett DK, 2019, CIRCULATION, V140, pE563, DOI 10.1161/CIR.0000000000000677 Atkins KM, 2021, PRACT RADIAT ONCOL, V11, pE459, DOI 10.1016/j.prro.2020.12.006 Atkins KM, 2021, JAMA ONCOL, V7, P206, DOI 10.1001/jamaoncol.2020.6332 Atkins KM, 2019, J AM COLL CARDIOL, V74, P1739, DOI 10.1016/j.jacc.2019.07.051 Atkins KM, 2019, J AM COLL CARDIOL, V73, P2976, DOI 10.1016/j.jacc.2019.03.500 Cai GX, 2023, INT J RADIAT ONCOL, V115, P366, DOI 10.1016/j.ijrobp.2022.08.013 Curigliano G, 2020, ANN ONCOL, V31, P171, DOI 10.1016/j.annonc.2019.10.023 Dess RT, 2017, J CLIN ONCOL, V35, P1395, DOI 10.1200/JCO.2016.71.6142 Gray H., 2015, Grays Anatomy: With Original Illustrations by Henry Carter Gray JE, 2020, J THORAC ONCOL, V15, P288, DOI 10.1016/j.jtho.2019.10.002 Haïssaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003 Isensee F, 2021, NAT METHODS, V18, P203, DOI 10.1038/s41592-020-01008-z Kim KH, 2022, JAMA ONCOL, V8, P1624, DOI 10.1001/jamaoncol.2022.4202 Lin WS, 2003, CIRCULATION, V107, P3176, DOI 10.1161/01.CIR.0000074206.52056.2D Liu XH, 2012, STAT MED, V31, P2676, DOI 10.1002/sim.4509 Loap P, 2021, PRACT RADIAT ONCOL, V11, pE434, DOI 10.1016/j.prro.2021.02.002 Lyon Alexander R, 2022, Eur Heart J Cardiovasc Imaging, V23, pe333, DOI [10.1093/eurheartj/ehac244, 10.1093/ehjci/jeac106] McKenzie E, 2023, INT J RADIAT ONCOL, V115, P1138, DOI 10.1016/j.ijrobp.2022.11.033 McWilliam A, 2023, J THORAC ONCOL, V18, P599, DOI 10.1016/j.jtho.2023.01.085 McWilliam A, 2017, EUR J CANCER, V85, P106, DOI 10.1016/j.ejca.2017.07.053 Miller ED, 2024, INT J RADIAT ONCOL, V118, P124, DOI 10.1016/j.ijrobp.2023.08.011 Mitchell JD, 2021, JACC-CARDIOONCOL, V3, P360, DOI 10.1016/j.jaccao.2021.06.003 No HJ, 2023, JACC-CARDIOONCOL, V5, P775, DOI 10.1016/j.jaccao.2023.08.007 Schottstaedt AM, 2023, PHYS IMAG RADIAT ONC, V28, DOI 10.1016/j.phro.2023.100504 Song WH, 2023, CURR PROB CARDIOLOGY, V48, DOI 10.1016/j.cpcardiol.2022.101478 Spigel DR, 2022, J CLIN ONCOL, V40, P1301, DOI 10.1200/JCO.21.01308 Stam B, 2017, RADIOTHER ONCOL, V123, P370, DOI 10.1016/j.radonc.2017.04.017 Tjong MC, 2023, CLIN TRANSL RAD ONCO, V42, DOI 10.1016/j.ctro.2023.100660 Tjong MC, 2022, RADIOTHER ONCOL, V169, P105, DOI 10.1016/j.radonc.2022.02.010 Walls GM, 2024, CLIN ONCOL-UK, V36, P119, DOI 10.1016/j.clon.2023.11.029 Walls GM, 2024, RADIOTHER ONCOL, V192, DOI 10.1016/j.radonc.2024.110085 Walls GM, 2023, RADIOTHER ONCOL, V184, DOI 10.1016/j.radonc.2023.109680 Wang K, 2017, J CLIN ONCOL, V35, P1387, DOI 10.1200/JCO.2016.70.0229 Wang X, 2022, CANCERS, V14, DOI 10.3390/cancers14051304 Wasserthal J, 2023, RADIOL-ARTIF INTELL, V5, DOI 10.1148/ryai.230024 Yegya-Raman N, 2018, J THORAC ONCOL, V13, P1508, DOI 10.1016/j.jtho.2018.05.028 Zhang DM, 2021, CLIN ONCOL-UK, V33, P723, DOI 10.1016/j.clon.2021.09.001 Zhang DM, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25730-0 NR 40 TC 23 Z9 24 U1 1 U2 3 PU ELSEVIER PI AMSTERDAM PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS SN 2666-0873 J9 JACC-CARDIOONCOL JI JACC-Cardiooncol. PD AUG PY 2024 VL 6 IS 4 BP 544 EP 556 DI 10.1016/j.jaccao.2024.07.005 EA AUG 2024 PG 13 WC Oncology; Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Cardiovascular System & Cardiology GA E1H6B UT WOS:001300589700001 PM 39239344 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Jiang, LY Zhang, XF Ding, SA Tang, M Ding, FB Mei, J Liu, H AF Jiang, Lianyong Zhang, Xuefeng Ding, Shi-ao Tang, Ming Ding, Fangbao Mei, Ju Liu, Hao TI Simultaneous thoracoscopic surgery in patients with atrial fibrillation and early-stage lung cancer SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Article DE Atrial fibrillation; Lung cancer; Surgical ablation; Thoracoscopic; Simultaneous surgery ID ABLATION; LOBECTOMY; OUTCOMES AB Objectives: Atrial fibrillation (AF) and early-stage lung cancer can both be treated under thoracoscopy. This study aims to evaluate the feasibility and safety of simultaneous thoracoscopic surgery for atrial fibrillation and earlystage lung cancer.
Methods: This was a single-center, retrospective study of 865 patients with paroxysmal or non-paroxysmal AF who underwent surgical ablation between October 2014 and December 2021. Patients were divided into two groups according to whether they have undergone simultaneous thoracoscopic early-stage lung cancer surgery and resulting in 24 pairs of patients.
Results: In total, 48 patients (24 matched pairs) were analyzed. The age was 63.71 f 8.43 years. Procedure time and postoperative mechanical ventilation time were significantly lower in the group AF than group AFLC (Atrial fibrillation and lung cancer) (140.38 f 27.53 vs. 230.79 f 59.06 min, P<0.001; 5 vs 6.5 h, P = 0.002). There was no significant difference between the groups in terms of operative bleeding volume (90.00 f 29.78 vs 85.83 f 53.56 ml, P = 0.741), total postoperative drainage volume (1020.83 f 516.5 vs 1406.25 f 840.33 ml, P = 0.067), ICU (intensive care unit) length of stay (LOS) (43.5 vs 44 h, P = 0.33), hospitalization LOS (9.29 f 1.92 vs 8.58 f 1.98 days, P = 0.214) and incidence of freedom from AF or complications.
Conclusions: Simultaneous thoracoscopic surgical AF ablation and early-stage lung cancer is safe and feasible. It can be used as an alternative method for coexisting atrial fibrillation and lung cancer with acceptable operative risks. C1 [Jiang, Lianyong; Ding, Shi-ao; Tang, Ming; Ding, Fangbao; Mei, Ju; Liu, Hao] Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Cardiothorac Surg Dept, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China. [Zhang, Xuefeng] Naval Med Univ, Affiliated Hosp 1, Dept Radiol, Shanghai 200433, Peoples R China. C3 Shanghai Jiao Tong University; Naval Medical University RP Liu, H (corresponding author), Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Cardiothorac Surg Dept, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China. EM liuhao@xinhuamed.com.cn RI Liu, Hao/D-9086-2019 FU National Natural Science Foundation of China [82170315] FX This work was supported by National Natural Science Foundation of China (grant numbers: 82170315) . CR Abdellateeft A, 2020, THORAC CANCER, V11, P1414, DOI 10.1111/1759-7714.13392 Ad N, 2021, EUR J CARDIO-THORAC, V60, P1351, DOI 10.1093/ejcts/ezab291 Cao JL, 2018, ANN THORAC SURG, V105, P1483, DOI 10.1016/j.athoracsur.2018.01.032 Castellá M, 2010, J THORAC CARDIOV SUR, V140, P633, DOI 10.1016/j.jtcvs.2009.11.009 Edgerton JR, 2009, ANN THORAC SURG, V88, P1655, DOI 10.1016/j.athoracsur.2009.05.046 Fukushima S, 2022, J CARDIOL, V79, P219, DOI 10.1016/j.jjcc.2021.09.015 Guha A, 2019, EUR HEART J, V40, P3007, DOI 10.1093/eurheartj/ehz649 Jame S, 2020, HEART, V106, P10, DOI 10.1136/heartjnl-2019-314898 January CT, 2019, CIRCULATION, V140, pE125, DOI [10.1161/CIR.0000000000000665, 10.1016/j.jacc.2019.01.011] Jiang ZL, 2015, HEART VESSELS, V30, P675, DOI 10.1007/s00380-014-0594-4 Kanzaki R, 2017, SURG TODAY, V47, P795, DOI 10.1007/s00595-016-1436-z Kirchhof P, 2020, NEW ENGL J MED, V383, P1305, DOI 10.1056/NEJMoa2019422 Lee PC, 2013, ANN THORAC SURG, V96, P951, DOI 10.1016/j.athoracsur.2013.04.104 Lu RX, 2018, INTERACT CARDIOV TH, V26, P402, DOI 10.1093/icvts/ivx346 Marrouche NF, 2018, NEW ENGL J MED, V378, P417, DOI 10.1056/NEJMoa1707855 Mei J, 2014, J THORAC CARDIOV SUR, V147, P242, DOI 10.1016/j.jtcvs.2012.10.005 Papiashvilli M, 2012, INNOVATIONS, V7, P15, DOI 10.1097/IMI.0b013e3182566221 Patterson E, 2005, HEART RHYTHM, V2, P624, DOI 10.1016/j.hrthm.2005.02.012 Pompili C, 2021, LUNG CANCER, V162, P71, DOI 10.1016/j.lungcan.2021.10.004 Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660 Suzuki K, 2022, J THORAC CARDIOV SUR, V163, P289, DOI 10.1016/j.jtcvs.2020.09.146 Thomas PA, 2021, LUNG CANCER, V152, P86, DOI 10.1016/j.lungcan.2020.12.009 Wang ML, 2021, J FORMOS MED ASSOC, V120, P1949, DOI 10.1016/j.jfma.2021.04.018 Whitson BA, 2008, ANN THORAC SURG, V86, P2008, DOI 10.1016/j.athoracsur.2008.07.009 Winckelmans T, 2020, EUR J CARDIO-THORAC, V57, P1051, DOI 10.1093/ejcts/ezz339 Yang XY, 2018, J THORAC DIS, V10, P2186, DOI 10.21037/jtd.2018.03.74 Zhang Y, 2020, ANN THORAC SURG, V110, P1796, DOI 10.1016/j.athoracsur.2020.04.094 Zotov A, 2020, BRAZ J CARDIOV SURG, V35, P841, DOI [10.21470/1678-9741-2019-01430, 10.21470/1678-9741-2019-0143] Khan MZ, 2021, J ARRYTHM, V37, P1205, DOI 10.1002/joa3.12589 NR 29 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 EI 1874-1754 J9 INT J CARDIOL JI Int. J. Cardiol. PD NOV 1 PY 2024 VL 414 AR 132422 DI 10.1016/j.ijcard.2024.132422 EA AUG 2024 PG 6 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA D4W1C UT WOS:001296192500001 PM 39098610 DA 2026-04-17 ER PT J AU Lim, JU Kang, HS Moon, MH Yeo, CD Sa, YJ Kim, TJ Cho, DG Kim, KS AF Lim, Jeong Uk Kang, Hye Seon Moon, Mi Hyoung Yeo, Chang Dong Sa, Young Jo Kim, Tae-Jung Cho, Deog Gon Kim, Kyung Soo TI PD-L1 expression from surgically resected lung tumors predictive of early progression in patients previously treated with targeted therapy for initially unresectable non-small cell lung cancer SO TRANSLATIONAL LUNG CANCER RESEARCH LA English DT Article DE Salvage surgery; adenocarcinoma; resection; epidermal growth factor receptor (EGFR); targeted therapy ID AIR SPACES; EGFR; CLASSIFICATION; OSIMERTINIB; MUTATION; SPREAD AB Background: Recent evidences showed that resection of lung tumor post-targeted therapy has shown progression-free survival (PFS) benefits in initially unresectable patients. The aim of this study is to evaluate pathologic findings of resected lung tumor samples in patients who have undergone prior epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) treatment, and also to assess the prognostic factors related to outcomes after resection. Methods: The deidentified data of non-small cell lung cancer (NSCLC) patients admitted to seven university hospitals affiliated with the Catholic University of Korea were obtained from the Clinical Data Warehouse (CDW) database. Among screened patients, 40 individuals who had previously undergone targeted therapies and later received surgical resection of a primary lung tumor were evaluated for the study. Results: All 40 patients were diagnosed with adenocarcinoma. Of these, 36 with EGFR mutations received prior EGFR TKI treatment. Only one postoperative complication, atrial fibrillation, was observed. At the time of resection, 19 patients showed primary lung tumor size regressing or unchanged, while 21 patients showed primary lung tumor regrowth or new lesions being developed before the resection. The group with no programmed death-ligand 1 (PD-L1) expression from resected samples showed significantly better post- resection PFS when compared to the other group (P=0.01). In the Model II multivariate analysis for post- resection PFS, PD-L1 detection from the resected sample was significantly associated with PFS [P=0.03; hazard ratio (HR) =5.465; 95% confidence interval (CI): 1.200-24.885]. Furthermore, an increase in PD-L1 expression compared to the baseline value was associated with an increasing lung tumor burden at the time of resection (P=0.03). Conclusions: Resected specimen following targeted therapy can provide valuable clinical information that can be used to predict the prognosis of patients with initially unresectable NSCLC. C1 [Lim, Jeong Uk] Catholic Univ Korea, Yeouido St Marys Hosp, Dept Internal Med, Div Pulm & Crit Care Med,Coll Med, Seoul, South Korea. [Kang, Hye Seon] Catholic Univ Korea, Bucheon St Marys Hosp, Coll Med, Dept Internal Med,Div Pulm Allergy & Crit Care Med, Bucheon Si, South Korea. [Moon, Mi Hyoung; Kim, Kyung Soo] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Thorac & Cardiovasc Surg, 222 Banpo Daero, Seoul 06591, South Korea. [Yeo, Chang Dong] Catholic Univ Korea, Eunpyeong St Marys Hosp, Coll Med, Div Pulm Crit Care & Sleep Med,Dept Internal Med, Seoul, South Korea. [Sa, Young Jo] Catholic Univ Korea, Yeouido St Marys Hosp, Coll Med, Dept Thorac Surg, Seoul, South Korea. [Kim, Tae-Jung] Catholic Univ Korea, Dept Hosp Pathol, Yeouido St Marys Hosp, Coll Med, Seoul, South Korea. [Cho, Deog Gon] Catholic Univ Korea, St Vincents Hosp, Coll Med, Dept Thorac & Cardiovasc Surg, Suwon, South Korea. C3 Catholic University of Korea; Catholic University of Korea; Seoul St. Mary's Hospital; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea RP Kim, KS (corresponding author), Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Thorac & Cardiovasc Surg, 222 Banpo Daero, Seoul 06591, South Korea. EM cskks@catholic.ac.kr RI Lim, Jeong Uk/AAI-7281-2020; Kang, Heeseog/LJL-5469-2024 OI Lim, Jeong Uk/0000-0001-8364-2380; FX The present study was previously presented in the poster session of ESMO 2023. Funding: None. CR Bencze E, 2022, PATHOL ONCOL RES, V28, DOI 10.3389/pore.2022.1610607 Choudhury NJ, 2023, J THORAC ONCOL, V18, P463, DOI 10.1016/j.jtho.2022.11.022 Goldstraw P, 2016, J THORAC ONCOL, V11, P39, DOI 10.1016/j.jtho.2015.09.009 Kadota K, 2015, J THORAC ONCOL, V10, P806, DOI 10.1097/JTO.0000000000000486 Li K, 2021, THORAC CANCER, V12, P2161, DOI 10.1111/1759-7714.14044 Li WH, 2018, CANCER LETT, V423, P9, DOI 10.1016/j.canlet.2018.03.005 Lindeman NI, 2013, J MOL DIAGN, V15, P415, DOI 10.1016/j.jmoldx.2013.03.001 Liu J, 2021, LUNG CANCER, V155, P28, DOI 10.1016/j.lungcan.2021.03.004 Lu SH, 2017, J THORAC ONCOL, V12, P223, DOI 10.1016/j.jtho.2016.09.129 Masuda T, 2023, SCI REP-UK, V13, DOI 10.1038/s41598-023-45337-3 Ofiara LM, 2012, CURR ONCOL, V19, pS16, DOI 10.3747/co.19.1062 Ohtaki Y, 2021, LUNG CANCER, V153, P108, DOI 10.1016/j.lungcan.2020.12.037 Park S, 2023, TRANSL LUNG CANCER R, V12, P1912, DOI 10.21037/tlcr-23-160 Peng SL, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1073-4 Peng ZY, 2021, WORLD J SURG ONCOL, V19, DOI 10.1186/s12957-021-02254-x Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003 Suzuki S, 2023, WORLD J SURG ONCOL, V21, DOI 10.1186/s12957-023-03177-5 Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630 Vaclova T, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22057-8 Watanabe M, 2015, CLIN CANCER RES, V21, P3552, DOI 10.1158/1078-0432.CCR-14-2151 NR 20 TC 3 Z9 3 U1 2 U2 4 PU AME PUBLISHING COMPANY PI SHATIN PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA SN 2218-6751 EI 2226-4477 J9 TRANSL LUNG CANCER R JI Transl. Lung Cancer Res. PD JUL 30 PY 2024 VL 13 IS 7 DI 10.21037/tlcr-24-215 PG 20 WC Oncology; Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Respiratory System GA E7L1M UT WOS:001304774000002 PM 39118882 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Kaprin, A Pikin, O Ryabov, A Aleksandrov, O Larionov, D Garifullin, A AF Kaprin, Andrey Pikin, Oleg Ryabov, Andrey Aleksandrov, Oleg Larionov, Denis Garifullin, Airat TI Surgical intervention for lung cancer in patients aged 75 and above: potential associations with increased mortality rates-a single-center observational study SO JOURNAL OF CARDIOTHORACIC SURGERY LA English DT Article DE Pulmonary surgical procedure; Elderly; Complications; Perioperative period ID ATRIAL-FIBRILLATION; RISK-FACTORS; LOBECTOMY; RESECTION; SURGERY; OCTOGENARIANS; CLASSIFICATION; MORBIDITY; SURVIVAL AB BackgroundLung cancer, which is diagnosed two to three times more frequently in patients over the age of 70, is a leading cause of cancer-specific mortality. Given the elevated risk of morbidity and mortality, surgical intervention may not always be the most appropriate primary treatment option. This study aims to evaluate specific risk factors associated with postoperative morbidity and mortality in elderly patients and to optimize patient selection therefore improving surgical outcomes.Patients and methodsThe study encompassed a cohort of 73 patients aged 75 and above who underwent surgical treatment for non-small cell lung cancer (NSCLC) at the Department of Thoracic Surgery of the P. Hertsen Moscow Oncological Research Institute between 2015 and 2021. All patients underwent preoperative evaluation, including PET/CT staging and functional assessment, carried out by a multidisciplinary team comprising thoracic surgeons, anesthesiologists, and other medical specialists.ResultsThe investigation revealed a postoperative mortality rate of 5.5% and a postoperative morbidity incidence of 16.4%, with occurrences of atrial fibrillation in 41.6%, persistent air leak in 33.3%, and pneumonia in 25% of complicated cases. At the one-year follow-up, 88% of patients remained free from relapse, whereas at three years, this rate stood at 66%. During the follow-up period, 16 patients (22%) passed away, with a median survival duration of 44 months. Survival rates at one year, three years, and five years were 71%, 66%, and 35%, respectively. Multivariate analysis disclosed several significant factors predicting a complex postoperative period, including stage IIIb (p = 0.023), pN1 (p = 0.049), pN2 (p = 0.030), and central location (p = 0.007). Additionally, overall survival was primarily influenced by a Charlson comorbidity index of 6 (p = 0.044), stage Ia2 (p = 0.033), and the necessity for thoracotomy (p = 0.045).ConclusionEach case of lung cancer in patients aged 75 and older necessitates an individualized approach. Given the higher mortality rate relative to younger patients, comprehensive risk assessment and preoperative management of underlying comorbidities are imperative, with the involvement of anesthesiologists, intensive care physicians, cardiologists, and other relevant specialists as needed. C1 [Kaprin, Andrey] Minist Healthcare Russian Federat FSBI NMRRC, Fed State Budget Inst, Natl Med Res Radiol Ctr, Moscow, Russia. [Kaprin, Andrey] Peoples Friendship Univ Russia, Moscow, Russia. [Pikin, Oleg; Ryabov, Andrey; Aleksandrov, Oleg; Larionov, Denis; Garifullin, Airat] P Hertsen Moscow Oncol Res Inst, 3,2 Botkinskiy Proezd, Moscow 125284, Russia. [Aleksandrov, Oleg] Natl Med Res Ctr Phthisiopulmonol, Moscow, Russia. C3 Peoples Friendship University of Russia RP Aleksandrov, O (corresponding author), P Hertsen Moscow Oncol Res Inst, 3,2 Botkinskiy Proezd, Moscow 125284, Russia.; Aleksandrov, O (corresponding author), Natl Med Res Ctr Phthisiopulmonol, Moscow, Russia. EM alexandrov.oleg.al@gmail.com RI Kaprin, Andrey/K-1445-2014 CR Altorki N, 2023, NEW ENGL J MED, V388, P489, DOI 10.1056/NEJMoa2212083 Bagheri R, 2019, KARDIOCHIR TORAKOCHI, V16, P53, DOI 10.5114/kitp.2019.86355 Balduyck B, 2009, EUR J CARDIO-THORAC, V35, P1070, DOI 10.1016/j.ejcts.2009.01.050 Berry MF, 2009, ANN THORAC SURG, V88, P1093, DOI 10.1016/j.athoracsur.2009.06.012 Cao C, 2014, ANN CARDIOTHORAC SUR, V3, P134, DOI 10.3978/j.issn.2225-319X.2014.03.08 CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8 Clavien PA, 2009, ANN SURG, V250, P187, DOI 10.1097/SLA.0b013e3181b13ca2 Damhuis RAM, 1996, EUR RESPIR J, V9, P7, DOI 10.1183/09031936.96.09010007 Dyussenbayev A, 2017, Advances in Social Sciences Research Journal, V4, DOI [10.14738/assrj.46.2924, 10.14738/assrj.46.2924, DOI 10.14738/ASSRJ.46.2924] Dziedzic R, 2018, EUR J CARDIO-THORAC, V54, P547, DOI 10.1093/ejcts/ezy101 Ettinger David S, 2023, J Natl Compr Canc Netw, V21, P340, DOI 10.6004/jnccn.2023.0020 GINSBERG RJ, 1983, J THORAC CARDIOV SUR, V86, P654 Hassanzadeh DM, 2014, J Cardiothorac Med, V2, P167, DOI [10.22038/JCTM.2014.2613, DOI 10.22038/JCTM.2014.2613] He W., 2016, An aging world: 2015, DOI DOI 10.13140/RG.2.1.1088.9362 HOLMES CE, 1995, ANN THORAC SURG, V60, P615, DOI 10.1016/0003-4975(95)00537-u Hope WW, 2007, AM SURGEON, V73, P22 Husain ZA, 2015, CLIN LUNG CANCER, V16, pE183, DOI 10.1016/j.cllc.2015.04.007 Hutchins LF, 1999, NEW ENGL J MED, V341, P2061, DOI 10.1056/NEJM199912303412706 KnottCraig CJ, 1997, ANN THORAC SURG, V63, P1405, DOI 10.1016/S0003-4975(97)00252-X Lim Tae Yoon, 2019, Korean J Thorac Cardiovasc Surg, V52, P195, DOI [10.5090/kjtcs.2019.52.4.195, 10.5090/kjtcs.2019.52.4.195] Lim W, 2018, QUANT IMAG MED SURG, V8, P709, DOI 10.21037/qims.2018.08.02 Mun M, 2008, ANN THORAC SURG, V85, P406, DOI 10.1016/j.athoracsur.2007.10.057 Myrdal G, 2001, EUR J CARDIO-THORAC, V20, P694, DOI 10.1016/S1010-7940(01)00875-2 NAUNHEIM KS, 1994, EUR J CARDIO-THORAC, V8, P453, DOI 10.1016/1010-7940(94)90013-2 Nomori H, 2001, SURG TODAY, V31, P395, DOI 10.1007/s005950170128 Okada A, 2012, GEN THORAC CARDIOVAS, V60, P97, DOI 10.1007/s11748-011-0880-3 Okami J, 2009, J THORAC ONCOL, V4, P1247, DOI 10.1097/JTO.0b013e3181ae285d Park HW, 2012, CURR OPIN CARDIOL, V27, P24, DOI 10.1097/HCO.0b013e32834dc4e8 Passman RS, 2005, ANN THORAC SURG, V79, P1698, DOI 10.1016/j.athoracsur.2004.10.058 Port JL, 2011, ANN THORAC SURG, V92, P1951, DOI 10.1016/j.athoracsur.2011.06.082 Roviaro G, 2004, CHEST, V126, P725, DOI 10.1378/chest.126.3.725 Salati M, 2016, CURR SURG REP, V4, DOI 10.1007/s40137-016-0158-x Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387 Singh N, 2016, CLIN LUNG CANCER, V17, P205, DOI 10.1016/j.cllc.2015.10.002 Takayuki N, 2018, BIOMED RES INT-UK, V2018, DOI 10.1155/2018/8202971 Thomas ET, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-028150 Zhao L, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-017-0452-0 NR 37 TC 7 Z9 7 U1 0 U2 0 PU BMC PI LONDON PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND EI 1749-8090 J9 J CARDIOTHORAC SURG JI J. Cardiothorac. Surg. PD JUL 29 PY 2024 VL 19 IS 1 AR 471 DI 10.1186/s13019-024-02922-5 PG 12 WC Cardiac & Cardiovascular Systems; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Surgery GA ZV6V9 UT WOS:001278110700001 PM 39069611 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Ruan, YD Han, JW Yang, AM Ding, QG Zhang, T AF Ruan, Yingding Han, Jianwei Yang, Aiming Ding, Qingguo Zhang, Ting TI Impact of preoperative inflammatory indices and postoperative pneumonia on postoperative atrial fibrillation in patients with non-small cell lung cancer: a retrospective study SO BMC PULMONARY MEDICINE LA English DT Article DE Non-small cell lung cancer; Pulmonary surgery; Postoperative atrial fibrillation; Preoperative inflammatory indices; Postoperative pneumonia ID C-REACTIVE PROTEIN; RISK-FACTORS; THORACIC-SURGERY; PREDICTOR AB Background This study aimed to evaluate the impact of preoperative inflammatory indices and postoperative pneumonia (POP) on postoperative atrial fibrillation (POAF) in non-small cell lung cancer (NSCLC) patients. Methods All consecutive patients who underwent pulmonary resection at our hospital (January 2016-October 2019) were enrolled. Preoperative inflammatory indices, demographic data, surgical details, and postoperative conditions were analyzed. Univariate and multivariate analyses of risk factors associated with POAF were also conducted. Results Among the 382 patients included in the study, 32 (8.38%) developed POAF. Compared to non-POAF patients, POAF patients had greater incidence of POP (P = 0.09). Approximately 31 patients (96.9%) developed atrial fibrillation within three days after surgery. The POAF group had a significantly greater mean age (68.94 years) than did the non-POAF group (63 years) (P = 0.002). Additionally, compared to non-POAF patients, POAF patients exhibited an increased number of resected mediastinal lymph nodes (P < 0.001) and mediastinal lymph node stations (P < 0.001).The POAF group also had a greater intraoperative blood volume (P = 0.006), longer surgical duration (P = 0.022), and greater drainage volume (P = 0.003). IA/B stage (P < 0.001) and IIIA/B stage(P < 0.001), and lobectomy resection (P = 0.008) and wedge resection (P = 0.023) were also associated with POAF. Compared to those in the non-POAF group, the POAF group had longer postoperative hospital stays (10.54 days vs. 9 days; P = 0.001) and longer drainage times (7 days vs. 5 days; P = 0.004). Multivariate analysis revealed age, POP, and stage IIIA/B as independent influencing factors of POAF in NSCLC patients. Conclusion Preoperative inflammatory indices were not significantly associated with POAF, but age, POP, and stage IIIA/B were identified as independent influencing factors. Advanced-stage NSCLC patients may have a greater susceptibility to POAF than early-stage patients, although further validation is needed. Additionally, POAF was linked to a longer postoperative hospital stay. C1 [Ruan, Yingding; Han, Jianwei; Yang, Aiming; Ding, Qingguo; Zhang, Ting] First Peoples Hosp Jiande, Dept Thorac Surg, Jiande, Peoples R China. [Zhang, Ting] Zhejiang Univ, Affiliated Hosp 2, Radiotherapy Dept, Sch Med, 88 Jiefang Rd, Hangzhou 310009, Peoples R China. C3 Zhejiang University RP Zhang, T (corresponding author), First Peoples Hosp Jiande, Dept Thorac Surg, Jiande, Peoples R China.; Zhang, T (corresponding author), Zhejiang Univ, Affiliated Hosp 2, Radiotherapy Dept, Sch Med, 88 Jiefang Rd, Hangzhou 310009, Peoples R China. EM zezht@zju.edu.cn RI Han, Jianwei/G-8716-2011 FU Jiande Municipal Science and Technology Bureau FX No Statement Available CR Al Sawalhi S, 2021, GEN THORAC CARDIOVAS, V69, P487, DOI 10.1007/s11748-020-01491-3 Alonso-Coello P, 2017, ANESTH ANALG, V125, P162, DOI 10.1213/ANE.0000000000002111 Amar D, 2002, ANESTHESIOLOGY, V96, P352, DOI 10.1097/00000542-200202000-00021 Boons J, 2021, J CARDIOTHOR VASC AN, V35, P3394, DOI 10.1053/j.jvca.2020.11.030 Bruins P, 1997, CIRCULATION, V96, P3542 Ciriaco P, 2000, EUR J CARDIO-THORAC, V18, P12, DOI 10.1016/S1010-7940(00)00428-0 Crispi V, 2022, POSTGRAD MED J, V98, P177, DOI 10.1136/postgradmedj-2020-138904 del Campo A, 2017, J CARDIOL, V70, P578, DOI 10.1016/j.jjcc.2017.03.011 Dobrev D, 2019, NAT REV CARDIOL, V16, P417, DOI 10.1038/s41569-019-0166-5 Gabryel P, 2024, CANCERS, V16, DOI 10.3390/cancers16020346 Gaudino M, 2003, CIRCULATION, V108, P195, DOI 10.1161/01.cir.0000087441.48566.0d Georges O, 2024, INTERDISC CARDIOV TH, V38, DOI 10.1093/icvts/ivad212 Goldstraw P., IN PRESS Hak L, 2009, J INTERF CYTOK RES, V29, P327, DOI 10.1089/jir.2008.0082.2906 Ishibashi H, 2020, WORLD J SURG, V44, P3952, DOI 10.1007/s00268-020-05694-w Ivanovic J, 2014, INTERACT CARDIOV TH, V18, P340, DOI 10.1093/icvts/ivt520 Jiang R, 2023, THORAC CANCER, V14, P30, DOI 10.1111/1759-7714.14691 Jin F, 2023, FRONT ONCOL, V13, DOI 10.3389/fonc.2023.1114302 Kashiwagi M, 2023, SURG TODAY, V53, P1139, DOI 10.1007/s00595-023-02670-4 Motono N, 2022, BMC SURG, V22, DOI 10.1186/s12893-022-01628-6 Muranishi Y, 2017, SURG TODAY, V47, P252, DOI 10.1007/s00595-016-1380-y Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Rimner A, 2023, J THORAC ONCOL, V18, P1386, DOI 10.1016/j.jtho.2023.07.008 Song YP, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.777564 Tane S, 2019, ANN THORAC SURG, V108, P1543, DOI 10.1016/j.athoracsur.2019.05.052 Targonski R, 2008, KARDIOL POL, V66, P729 Ueda T, 2018, GEN THORAC CARDIOVAS, V66, P95, DOI 10.1007/s11748-017-0858-x Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Zhang LF, 2024, ASIAN J SURG, V47, P176, DOI 10.1016/j.asjsur.2023.06.108 NR 29 TC 4 Z9 4 U1 1 U2 4 PU BMC PI LONDON PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1471-2466 J9 BMC PULM MED JI BMC Pulm. Med. PD JUL 23 PY 2024 VL 24 IS 1 AR 355 DI 10.1186/s12890-024-03174-8 PG 12 WC Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System GA ZK9N7 UT WOS:001275312000001 PM 39044167 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Kong, XL Yue-Zhang Yu-Jia Ni, BX Wang, M Jin, XY Xu, H Xu, SD AF Kong, Xiang-Long Yue-Zhang, Yue- Yu-Jia, Yu- Ni, Bo-Xiong Wang, Mingyu- Jin, Xiang-Yuan Xu, Hai Xu, Shi-Dong TI Safety of one 8.5-Fr pigtail catheter for postoperative continuous open gravity drainage after uniportal video-assisted thoracoscopic surgery pneumonectomy SO JOURNAL OF CARDIOTHORACIC SURGERY LA English DT Article DE Chest tube; Uniportal video-assisted thoracoscopic surgery; Pneumonectomy; Postoperative drainage ID CHEST TUBE DRAINAGE; PULMONARY-FUNCTION; OUTCOMES AB ObjectivesUniportal video-assisted thoracoscopic surgery pneumonectomy (U-VATS-P) is feasible and safe from a perioperative standpoint. How to choose the proper chest tube and drainage method is important in enhanced recovery after surgery (ERAS) protocols. In this study, we aimed to assess the safety of one 8.5-Fr (1Fr = 0.333 mm) pigtail catheter for postoperative continuous open gravity drainage after U-VATS-P.MethodsWe retrospectively reviewed a single surgeon's experience with U-VATS-P for lung cancer from May 2016 to September 2022. Patients were managed with one 8.5-Fr pigtail catheter for postoperative continuous open gravity drainage after U-VATS-P. The clinical characteristics and perioperative outcomes of the patients were retrospectively analyzed.ResultsIn total, 77 patients had one 8.5-Fr pigtail catheter placed for postoperative continuous open gravity drainage after U-VATS-P for lung cancer. The mean age was 60.9\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\pm$$\end{document}7.39 (40-76) years; The mean FEV1 was 2.1\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\pm$$\end{document}0.6 (l/s), and the mean FEV1% was 71.2\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\pm$$\end{document}22.7. The median operative time was 191.38\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\pm$$\end{document}59.32 min; the mean operative hemorrhage was 109.46\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\pm$$\end{document}96.56 ml; the mean duration of postoperative chest tube drainage was 6.80\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\pm$$\end{document}2.33 days; the mean drainage volumes in the first three days after operation were 186.31\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\pm$$\end{document}50.97, 321.97\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\pm$$\end{document}52.03, and 216.44\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\pm$$\end{document}35. 67 ml, respectively; and the mean postoperative hospital stay was 7.90\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\pm$$\end{document}2.58 days. No patient experienced complications resulting from chest tube malfunction. Ten patients experienced minor complications. One patient with nonlife-threatening empyema and bronchopleural fistula required short rehospitalization for anti-inflammatory therapy and reintubation. Three patients with chylothorax were treated with intravenous nutrition. Four patients had atrial fibrillation that was controlled by antiarrhythmic therapy. Two patients had more thoracic hemorrhagic exudation after the operation, which was found in time and was cured effectively, so they were discharged from the hospital uneventfully after early hemostatic therapy and nutritional support.ConclusionsAll patients in this study received early postoperative rehabilitation, and the rate of relevant complications was low. We therefore recommend a single 8.5-Fr pigtail catheter for postoperative continuous open gravity drainage as an effective, safe and reliable drainage method for the management of U-VATS-P. C1 [Kong, Xiang-Long; Yu-Jia, Yu-; Ni, Bo-Xiong; Wang, Mingyu-; Jin, Xiang-Yuan; Xu, Hai; Xu, Shi-Dong] Harbin Med Univ, Dept Thorac Surg, Canc Hosp, 150 Hapin Rd, Harbin 150081, Peoples R China. [Yue-Zhang, Yue-] Harbin Med Univ, Affiliated Hosp 2, Dept Area B, ICU, Harbin, Peoples R China. C3 Harbin Medical University; Harbin Medical University RP Xu, SD (corresponding author), Harbin Med Univ, Dept Thorac Surg, Canc Hosp, 150 Hapin Rd, Harbin 150081, Peoples R China. EM xusd163@163.com RI Kong, Quentin/JTU-5704-2023 FU Clinical Application Study of Single hole Thoracoscope [Z2017ZWS02] FX This work was funded by the Clinical Application Study of Single hole Thoracoscope (Z2017ZWS02) CR Bao FC, 2020, EUR J CARDIO-THORAC, V58, P613, DOI 10.1093/ejcts/ezaa097 Chen Lei, 2021, Zhongguo Fei Ai Za Zhi, V24, P577, DOI 10.3779/j.issn.1009-3419.2021.101.23 Cui ZH, 2019, THORAC CANCER, V10, P1993, DOI 10.1111/1759-7714.13183 Gao SG, 2017, J THORAC DIS, V9, P3255, DOI 10.21037/jtd.2017.08.165 Guo X K, 2020, Zhonghua Wai Ke Za Zhi, V58, P131, DOI 10.3760/cma.j.issn.0529-5815.2020.02.011 Hennon MW, 2019, J THORAC ONCOL, V14, P107, DOI 10.1016/j.jtho.2018.09.024 Higuchi M, 2018, FUKUSHIMA J MED SCI, V64, P30, DOI 10.5387/fms.2017-10 Li PF, 2019, J THORAC DIS, V11, pS1947, DOI 10.21037/jtd.2019.08.26 Li SB, 2017, EUR J CARDIO-THORAC, V51, P689, DOI 10.1093/ejcts/ezw364 Liu YQ, 2016, J THORAC DIS, V8, P3537, DOI 10.21037/jtd.2016.12.24 Lo EYW, 2020, HEART LUNG CIRC, V29, P1887, DOI 10.1016/j.hlc.2020.03.006 Morcos K, 2014, INTERACT CARDIOV TH, V18, P671, DOI 10.1093/icvts/ivt563 Okur E, 2009, EUR J CARDIO-THORAC, V35, P32, DOI 10.1016/j.ejcts.2008.09.009 Petrella F, 2016, EXPERT REV RESP MED, V10, P919, DOI 10.1080/17476348.2016.1188694 Refai M, 2012, EUR J CARDIO-THORAC, V41, P820, DOI 10.1093/ejcts/ezr126 Song YB, 2021, J CARDIOTHORAC SURG, V16, DOI 10.1186/s13019-021-01479-x Wu CJ, 2022, ADV THER, V39, P3668, DOI 10.1007/s12325-022-02182-6 Yan S, 2017, J THORAC DIS, V9, P5061, DOI 10.21037/jtd.2017.11.08 Yang JT, 2021, J CARDIOTHORAC SURG, V16, DOI 10.1186/s13019-021-01657-x Yu Wenfeng, 2020, Zhongguo Fei Ai Za Zhi, V23, P509, DOI 10.3779/j.issn.1009-3419.2020.104.06 Zhang JT, 2020, ANN THORAC SURG, V109, P1040, DOI 10.1016/j.athoracsur.2019.11.029 NR 21 TC 2 Z9 3 U1 1 U2 2 PU BMC PI LONDON PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND EI 1749-8090 J9 J CARDIOTHORAC SURG JI J. Cardiothorac. Surg. PD JUL 18 PY 2024 VL 19 IS 1 AR 457 DI 10.1186/s13019-024-02894-6 PG 8 WC Cardiac & Cardiovascular Systems; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Surgery GA YX2B9 UT WOS:001271708300003 PM 39026246 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Stabellini, N Cullen, J Bittencourt, MS Moore, JX Sutton, A Nain, P Hamerschlak, N Weintraub, NL Dent, S Tsai, MH Banerjee, A Ghosh, AK Sadler, D Coughlin, SS Barac, A Shanahan, J Montero, AJ Guha, A AF Stabellini, Nickolas Cullen, Jennifer Bittencourt, Marcio S. Moore, Justin X. Sutton, Arnethea Nain, Priyanshu Hamerschlak, Nelson Weintraub, Neal L. Dent, Susan Tsai, Meng-Han Banerjee, Amitava Ghosh, Arjun K. Sadler, Diego Coughlin, Steven S. Barac, Ana Shanahan, John Montero, Alberto J. Guha, Avirup TI Allostatic Load/Chronic Stress and Cardiovascular Outcomes in Patients Diagnosed With Breast, Lung, or Colorectal Cancer SO JOURNAL OF THE AMERICAN HEART ASSOCIATION LA English DT Article DE allostatic load; breast cancer; cardiovascular disease; colorectal cancer; lung cancer; stress ID SOCIAL DETERMINANTS; DISEASE; HEALTH; INFLAMMATION; SURVIVORS; RISK AB Background Cardiovascular disease and cancer share a common risk factor: chronic stress/allostatic load (AL). A 1-point increase in AL is linked to up to a 30% higher risk of major cardiac events (MACE) in patients with prostate cancer. However, AL's role in MACE in breast cancer, lung cancer, or colorectal cancer remains unknown.Methods and Results Patients >= 18 years of age diagnosed with the mentioned 3 cancers of interest (2010-2019) and followed up at a large, hybrid academic-community practice were included in this retrospective cohort study. AL was modeled as an ordinal measure (0-11). Adjusted Fine-Gray competing risks regressions estimated the impact of AL precancer diagnosis on 2-year MACE (a composite of heart failure, ischemic stroke, acute coronary syndrome, and atrial fibrillation). The effect of AL changes over time on MACE was calculated via piecewise Cox regression (before, and 2 months, 6 months, and 1 year after cancer diagnosis). Among 16 467 patients, 50.5% had breast cancer, 27.9% had lung cancer, and 21.4% had colorectal cancer. A 1-point elevation in AL before breast cancer diagnosis corresponded to a 10% heightened associated risk of MACE (adjusted hazard ratio, 1.10 [95% CI, 1.06-1.13]). Similar findings were noted in lung cancer (adjusted hazard ratio, 1.16 [95% CI, 1.12-1.20]) and colorectal cancer (adjusted hazard ratio, 1.13 [95% CI, 1.08-1.19]). When considering AL as a time-varying exposure, the peak associated MACE risk occurred with a 1-point AL rise between 6 and 12 months post- breast cancer, lung cancer, and colorectal cancer diagnosis.Conclusions AL warrants investigation as a potential marker in these patients to identify those at elevated cardiovascular risk and intervene accordingly. C1 [Cullen, Jennifer] Houston Methodist Neal Canc Ctr, Canc Control & Populat Sci, Houston, TX USA. [Stabellini, Nickolas; Cullen, Jennifer] Case Western Reserve Univ, Sch Med, Cleveland, OH USA. [Stabellini, Nickolas; Montero, Alberto J.] Univ Hosp Seidman Canc Ctr, Dept Hematol Oncol, Cleveland, OH USA. [Stabellini, Nickolas] Hosp Israelita Albert Einstein, Fac Israelita Ciencias Saude Albert Einstein, Sao Paulo, SP, Brazil. [Stabellini, Nickolas; Nain, Priyanshu; Weintraub, Neal L.; Coughlin, Steven S.; Guha, Avirup] Augusta Univ, Med Coll Georgia, Dept Med, Augusta, GA USA. [Cullen, Jennifer] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH USA. [Bittencourt, Marcio S.] Univ Pittsburgh, Dept Med, Div Cardiol, Pittsburgh, PA USA. [Moore, Justin X.] Univ Kentucky, Ctr Hlth Equ Transformat, Markey Canc Ctr, Dept Behav Sci,Coll Med, Lexington, KY USA. [Sutton, Arnethea] Virginia Commonwealth Univ, Coll Humanities & Sci, Dept Kinesiol & Hlth Sci, Richmond, VA USA. [Hamerschlak, Nelson] Hosp Israelita Albert Einstein, Oncohematol Dept, Sao Paulo, SP, Brazil. [Weintraub, Neal L.] Augusta Univ, Med Coll Georgia, Vasc Biol Ctr, Augusta, GA USA. [Dent, Susan] Duke Univ, Duke Canc Inst, Dept Med, Durham, NC USA. [Tsai, Meng-Han] Augusta Univ, Dept Med, Med Coll Georgia, Canc Prevent & Populat Hlth Program, Augusta, GA USA. [Tsai, Meng-Han] Augusta Univ, Georgia Prevent Inst, Augusta, GA USA. [Banerjee, Amitava] UCL, Inst Hlth Informat, London, England. [Ghosh, Arjun K.] Univ Coll London Hosp, Hatter Cardiovasc Inst, Cardiooncol Serv, London, England. [Sadler, Diego] Cleveland Clin Florida, Dept Cardiovasc Med, Weston, FL USA. [Barac, Ana] Inova Heart & Vasc Inst, Inova Schar Canc Inst, Cardiooncol Program, Fairfax, VA USA. [Shanahan, John] Univ Hosp, Canc Informat, Seidman Canc Ctr, Cleveland, OH USA. [Guha, Avirup] Augusta Univ, Med Coll Georgia, Dept Med, Cardiooncol Program,Cardiol Div, Augusta, GA USA. C3 Houston Methodist; University System of Ohio; Case Western Reserve University; Hospital Israelita Albert Einstein; University System of Georgia; Augusta University; University System of Ohio; Case Western Reserve University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Kentucky; Virginia Commonwealth University; Hospital Israelita Albert Einstein; University System of Georgia; Augusta University; Duke University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University of London; University College London; University of London; University College London; University College London Hospitals NHS Foundation Trust; Cleveland Clinic Foundation; Inova Fairfax Hospital; University Hospitals of Cleveland; University System of Georgia; Augusta University RP Stabellini, N (corresponding author), Univ Hosp Seidman Canc Ctr, Breen Pavil,11100 Euclid Ave, Cleveland, OH 44106 USA. EM nickolas.stabellini@uhhospitals.org RI Stabellini, Nickolas/C-9753-2018; Sommer Bittencourt, Marcio/C-1444-2011; Ghosh, Arjun/ABC-9543-2020; Dent, Susan/JXX-5355-2024; Guha, Avirup/I-2611-2019; Hamerschlak, Nelson/M-8060-2015; Sutton, Arnethea/MGT-3896-2025; Banerjee, Amitava/D-4381-2014; Montero, Alberto/AAF-9565-2021; Barac, Ana/JXL-7983-2024 OI Stabellini, Nickolas/0000-0002-3135-7980; Tsai, Meng-Han/0000-0001-6511-156X; Sommer Bittencourt, Marcio/0000-0002-3711-1754; Moore, Justin Xavier/0000-0002-5496-752X; Ghosh, Arjun/0000-0003-4992-2412; Coughlin, Steven Scott/0000-0003-1704-0466; Dent, Susan/0000-0002-9183-9340; Guha, Avirup/0000-0003-0253-1174; Hamerschlak, Nelson/0000-0002-5140-5310; Sutton, Arnethea/0000-0002-4398-0278; FU American Heart Association-Strategically Focused Research Network Grant in Disparities in Cardio-Oncology [847740, 863620]; Department of Defense Prostate Cancer Research Program's Physician Research Award [HT94252310158] FX AG is supported by American Heart Association-Strategically Focused Research Network Grant in Disparities in Cardio-Oncology (#847740, #863620) and Department of Defense Prostate Cancer Research Program's Physician Research Award (#HT94252310158). CR An JL, 2021, ONCOIMMUNOLOGY, V10, DOI 10.1080/2162402X.2021.2004659 [Anonymous], Posit. Posit [Anonymous], Multiple Cause of Death Data on CDC WONDER Antoni MH, 2023, ANNU REV PSYCHOL, V74, P423, DOI 10.1146/annurev-psych-030122-124119 Antoni MH, 2019, CANCER-AM CANCER SOC, V125, P1417, DOI 10.1002/cncr.31943 Baraghoshi D, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.7_suppl.113 Barre PV, 2018, INDIAN J PSYCHOL MED, V40, P232, DOI 10.4103/IJPSYM.IJPSYM_512_17 Black PH, 2002, J PSYCHOSOM RES, V52, P1, DOI 10.1016/S0022-3999(01)00302-6 Bray F, 2021, CANCER-AM CANCER SOC, V127, P3029, DOI 10.1002/cncr.33587 Dai SR, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01492 de Jesus M, 2024, FRONT ONCOL, V14, DOI 10.3389/fonc.2024.1258991 Duong MT, 2017, J RACIAL ETHN HEALTH, V4, P455, DOI 10.1007/s40615-016-0246-8 EMERSE, 2022, Electronic medical record search engine Freijeiro-González L, 2022, INT STAT REV, V90, P118, DOI 10.1111/insr.12469 Gillespie SL, 2019, PSYCHONEUROENDOCRINO, V109, DOI 10.1016/j.psyneuen.2019.06.020 Greten FR, 2019, IMMUNITY, V51, P27, DOI 10.1016/j.immuni.2019.06.025 Guidi J, 2020, PSYCHOTHER PSYCHOSOM, V90, P11, DOI 10.1159/000510696 Hanauer DA, 2020, JCO CLIN CANCER INFO, V4, P454, DOI 10.1200/CCI.19.00134 Hsu HY, 2022, INT J COLORECTAL DIS, V37, P887, DOI 10.1007/s00384-022-04129-3 Jafri SH, 2019, CLIN MED INSIGHTS-ON, V13, DOI 10.1177/1179554919835798 Juster RP, 2010, NEUROSCI BIOBEHAV R, V35, P2, DOI 10.1016/j.neubiorev.2009.10.002 Koene RJ, 2016, CIRCULATION, V133, P1104, DOI 10.1161/CIRCULATIONAHA.115.020406 Mehta LS, 2018, CIRCULATION, V137, pE30, DOI 10.1161/CIR.0000000000000556 Patnaik JL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2901 Peters A, 2017, PROG NEUROBIOL, V156, P164, DOI 10.1016/j.pneurobio.2017.05.004 Powell-Wiley TM, 2022, CIRC RES, V130, P782, DOI 10.1161/CIRCRESAHA.121.319811 Rodriquez EJ, 2019, J URBAN HEALTH, V96, P3, DOI 10.1007/s11524-019-00345-5 Siegel RL, 2024, CA-CANCER J CLIN, V74, P12, DOI 10.3322/caac.21820 Song H, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l1255 Stabellini N., 2024, J Clin Oncol, V42, P263, DOI [10.1200/JCO.2024.42.4suppl.263, DOI 10.1200/JCO.2024.42.4SUPPL.263] Stabellini N, 2023, CANCERS, V15, DOI 10.3390/cancers15184630 Stabellini N, 2023, JCO CLIN CANCER INFO, V7, DOI 10.1200/CCI.22.00143 Stabellini N, 2023, J NATL COMPR CANC NE, V21, P705, DOI 10.6004/jnccn.2023.7023 Stabellini N, 2022, JACC-CARDIOONCOL, V4, P555, DOI 10.1016/j.jaccao.2022.10.004 Stabellini N, 2023, JNCI CANCER SPECT, V7, DOI 10.1093/jncics/pkad005 Stabellini N, 2023, SCI REP-UK, V13, DOI 10.1038/s41598-023-27578-4 Stabellini N, 2023, CANCER MED-US, V12, P6711, DOI 10.1002/cam4.5461 Stabellini N, 2022, JTO CLIN RES REP, V3, DOI 10.1016/j.jtocrr.2022.100307 Stabellini N, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-09193-x Strongman H, 2019, LANCET, V394, P1041, DOI 10.1016/S0140-6736(19)31674-5 Tibshirani R, 1996, J ROY STAT SOC B, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x Zhang LY, 2020, AM J CANCER RES, V10, P1294 NR 42 TC 21 Z9 22 U1 0 U2 3 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA EI 2047-9980 J9 J AM HEART ASSOC JI J. Am. Heart Assoc. PD JUL 16 PY 2024 VL 13 IS 14 AR e033295 DI 10.1161/JAHA.123.033295 PG 10 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA ZA0S0 UT WOS:001272458600038 PM 38979791 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Catelli, C D'Alessandro, M Mathieu, F Addamo, E Franchi, F Paladini, P Luzzi, L AF Catelli, Chiara D'Alessandro, Miriana Mathieu, Federico Addamo, Emanuele Franchi, Federico Paladini, Piero Luzzi, Luca TI Clinical and biological effects of different energetic surgical devices currently used for mini-invasive anatomical lung resections for the treatment of NSCLC: a prospective interventional study SO SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES LA English DT Article DE VATS; Lobectomy; Energy devices; NSCLC; Inflammatory response; Surgical device innovation ID ASSISTED THORACOSCOPIC LOBECTOMY; ATRIAL-FIBRILLATION; PULMONARY LOBECTOMY; ULTRASONIC ENERGY; CONTROLLED-TRIAL; VESSELS; CELLS AB BackgroundThis study aims to compare three commonly used energy devices for dissection during Video-Assisted Thoracoscopic Surgery (VATS) lobectomy: monopolar hook, advanced bipolar, and ultrasonic device, in terms of duration of the surgical procedure and clinical intra- and post-operative outcomes. Materials and methodsIn this prospective single-center study, 75 patients undergoing VATS lobectomy for non-small cell lung cancer between January 2022 and May 2023 were enrolled and divided into 3 groups based on the device used during the surgical procedure (Group 1: Ultrasonic Device, Group 2: Advanced Bipolar, Group 3: Monopolar Hook). The duration of the surgical procedure, daily pleural fluid production, post-operative pain, length of hospital stay, and occurrence of post-operative complications were compared for each group. In a subgroup of 20 patients (10 from Group 1 and 10 from Group 3), concentrations of inflammatory cytokines in pleural fluid at 3 h and 48 h post-surgery were analyzed. ResultsPleural fluid production on the first and second post-operative days was significantly lower in patients treated with the Ultrasonic device compared to the other two groups (p < 0.001). The duration of the surgical procedure was significantly shorter when using the Ultrasonic device (p < 0.001). There were no significant differences in length of hospital stay (p = 0.975), pain on the first and second post-operative days (p = 0.147 and p = 0.755, respectively), and blood hemoglobin levels on the first post-operative day (p = 0.709) and at discharge (p = 0.795). No differences were observed in terms of post-operative complications, although the incidence of post-operative cardiac arrhythmias was borderline significant (p = 0.096), with no cases of arrhythmias recorded in Group 1. IL-10 levels in pleural fluid of patients in Group 3 peaked at 3 h post-surgery, with a significant reduction at 48 h (p = 0.459). DiscussionThe use of the ultrasonic device during VATS lobectomy may reduce pleural fluid production and shorten the duration of the surgical procedure compared to using a monopolar hook or advanced bipolar device. The choice of energy device may influence the local inflammatory response, although further studies are needed to confirm these results. C1 [Catelli, Chiara; Luzzi, Luca] Univ Siena, Lung Transplant Unit, Azienda Ospedaliero Univ Senese, Siena, Italy. [D'Alessandro, Miriana] Univ Siena, Dept Med & Surg Sci & Neurosci, Resp Dis & Lung Transplant Unit, I-53100 Siena, Italy. [Mathieu, Federico; Addamo, Emanuele; Paladini, Piero] Univ Hosp Siena, Thorac Surg Unit, Siena, Italy. [Franchi, Federico] Univ Hosp Siena, Dept Med Surg & Neurosci, Anesthesiol & Intens Care, Siena, Italy. C3 University of Siena; University of Siena; University of Siena; University Hospital of Siena; University of Siena; University Hospital of Siena RP Catelli, C (corresponding author), Univ Siena, Lung Transplant Unit, Azienda Ospedaliero Univ Senese, Siena, Italy. EM chiara.catelli1992@gmail.com RI MATHIEU, Florence/MTD-2230-2025; Luzzi, Luca/AIB-7155-2022; d'Alessandro, Miriana/AAA-8803-2020; Catelli, Chiara/KIB-2487-2024; Paladini, Piero/AAA-5004-2020 OI Luzzi, Luca/0000-0002-8379-4306; d'Alessandro, Miriana/0000-0002-2368-5722; Catelli, Chiara/0009-0006-2473-8511; Addamo, Emanuele/0009-0001-6127-9610; CR ANTONY VB, 1993, J IMMUNOL, V151, P7216 Campisi A, 2023, GEN THORAC CARDIOVAS, V71, P715, DOI 10.1007/s11748-023-01942-7 Catelli C, 2023, EJSO-EUR J SURG ONC, V49, DOI 10.1016/j.ejso.2023.107256 Goudie E, 2020, INTERACT CARDIOV TH, V31, P847, DOI 10.1093/icvts/ivaa192 Goudie E, 2018, ANN THORAC SURG, V105, P214, DOI 10.1016/j.athoracsur.2017.08.013 Goudie E, 2016, ANN THORAC SURG, V102, P1088, DOI 10.1016/j.athoracsur.2016.04.050 Goudie E, 2016, THORAC SURG CLIN, V26, P229, DOI 10.1016/j.thorsurg.2015.12.010 Hansen HJ, 2012, ANN CARDIOTHORAC SUR, V1, P70, DOI 10.3978/j.issn.2225-319X.2012.04.15 Jung M, 2004, EUR J IMMUNOL, V34, P481, DOI 10.1002/eji.200324323 Liu SL, 2023, FRONT MED-LAUSANNE, V10, DOI 10.3389/fmed.2023.1152421 Martucci N, 2015, EUR J CARDIO-THORAC, V47, pE13, DOI 10.1093/ejcts/ezu391 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Sabat R, 2010, CYTOKINE GROWTH F R, V21, P331, DOI 10.1016/j.cytogfr.2010.09.002 Schuchert MJ, 2010, J THORAC CARDIOV SUR, V140, P1168, DOI 10.1016/j.jtcvs.2010.06.064 Sugi K, 2000, Jpn J Thorac Cardiovasc Surg, V48, P161 Sutton PA, 2010, BRIT J SURG, V97, P428, DOI 10.1002/bjs.6901 Toishi M, 2014, INTERACT CARDIOV TH, V19, P448, DOI 10.1093/icvts/ivu176 White A, 2016, ANN THORAC SURG, V101, P1334, DOI 10.1016/j.athoracsur.2015.10.070 Yoshida K, 2014, ANN THORAC CARDIOVAS, V20, P353, DOI 10.5761/atcs.oa.13-00014 NR 19 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES SN 0930-2794 EI 1432-2218 J9 SURG ENDOSC JI Surg. Endosc. PD AUG PY 2024 VL 38 IS 8 BP 4753 EP 4761 DI 10.1007/s00464-024-11014-3 EA JUL 2024 PG 9 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA A2L8N UT WOS:001265975900003 PM 38987484 DA 2026-04-17 ER PT J AU Sun, LL Lu, YT Zhang, YF Jin, C Yuan, ZW Xu, RH AF Sun, Lili Lu, Yutong Zhang, Yanfang Jin, Chan Yuan, Zhenwei Xu, Renhua TI Risk factors for enhanced recovery after surgery failure in patients undergoing lung cancer resection with concomitant cardiovascular disease: A single-center retrospective study SO ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING LA English DT Article DE Lung cancer; Cardiovascular; Enhanced recovery after surgery; Risk factors; Retrospective study ID POSTOPERATIVE ATRIAL-FIBRILLATION; AMERICAN-COLLEGE; PULMONARY LOBECTOMY; EUROPEAN-SOCIETY; PLEURAL EFFUSION; ESC GUIDELINES; TASK-FORCE; MANAGEMENT; VENTILATION; STATISTICS AB Objective: Enhanced recovery after surgery (ERAS) has been widely used in patients with lung cancer, and its effectiveness has been confirmed; however, some lung cancers with poor clinical outcomes lead to ERAS failure after radical resection. This study aimed to analyze risk factors associated with ERAS failure after radical resection in patients with lung cancer and concomitant cardiovascular disease. Methods: In total, 198 patients who underwent ERAS following radical lung cancer surgery for concomitant cardiovascular disease between January 2022 and September 2023 were enrolled in this retrospective study. The patients were categorized into two groups based on the definition of ERAS failure: ERAS success group (n = 152) and ERAS failure group (n = 46). Univariate and multivariate analyses were performed to investigate the risk factors of ERAS failure. Results: Univariate analysis showed that gender, tumor location, operation time, estimated blood loss (EBL), suction drainage, and total cholesterol were associated with ERAS failure. Multivariate analysis showed that operation time (odds ratio [OR] = 1.015; P = 0.011) and suction drainage (OR = 3.343; P = 0.008) were independent risk factors for ERAS failure. Conclusions: Operation time and suction drainage were independent risk factors for ERAS failure after radical resection of combined cardiovascular lung cancer. Therefore, improving surgical efficiency and postoperative chest drain management are important for successful ERAS. C1 [Sun, Lili; Lu, Yutong; Zhang, Yanfang; Jin, Chan; Xu, Renhua] Binzhou Med Univ, Sch Nursing, Sch Gerontol, Yantai, Peoples R China. [Yuan, Zhenwei] Binzhou Med Univ, Lib, Yantai, Peoples R China. C3 Binzhou Medical University; Binzhou Medical University RP Xu, RH (corresponding author), Binzhou Med Univ, Sch Nursing, Sch Gerontol, Yantai, Peoples R China.; Yuan, ZW (corresponding author), Binzhou Med Univ, Lib, Yantai, Peoples R China. EM yuanzhenwei@bzmc.edu.cn; renhua_xu@bzmc.edu.cn RI ; lu, tong/HFZ-8889-2022 OI Xu, Renhua/0000-0002-3588-1018; Sun, Lili/0000-0003-3887-3889 FU Projects of Shandong Provincial Social Science Planning and Management Office [21CGLJ01]; Shandong Province Natural Science Foundation [ZR2016CL08] FX This study was supported by the Projects of Shandong Provincial Social Science Planning and Management Office (Grant No. 21CGLJ01) , Shandong Province Natural Science Foundation (Grant No. ZR2016CL08) . The funders had no role in considering the study design or in the collection, analysis, interpretation of data, writing of the report, or decision to submit the article for publication. CR Aggarwal BB, 2009, CLIN CANCER RES, V15, P425, DOI 10.1158/1078-0432.CCR-08-0149 Agusti AGN, 1997, AM J RESP CRIT CARE, V156, P1205, DOI 10.1164/ajrccm.156.4.9612113 Aiolfi A, 2021, SURGERY, V169, P436, DOI 10.1016/j.surg.2020.09.010 [Anonymous], 2015, J NUCL CARDIOL, V22, P1041, DOI [10.1007/s12350-015-0209-1, 10.1016/j.jacc.2014.12.018] [Anonymous], 2023, Licence: CC BY-NC-SA 3.0 IGO [Anonymous], 2021, Guideline for the pharmacological treatment of hypertension in adults. Web Annex A. Summary of evidence Batra A, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07487-9 Beattie WS, 2001, ANESTH ANALG, V93, P853, DOI 10.1097/00000539-200110000-00010 Bhave PD, 2012, AM HEART J, V164, P918, DOI 10.1016/j.ahj.2012.09.004 Bjerrum E, 2020, EUR J ANAESTH, V37, P671, DOI 10.1097/EJA.0000000000001265 Bray F, 2024, CA-CANCER J CLIN, V74, P229, DOI 10.3322/caac.21834 Calkins H, 2019, EUR HEART J, V40, P3812, DOI 10.1093/eurheartj/ehz837 Cerfolio RJ, 2005, CHEST, V128, P816, DOI 10.1378/chest.128.2.816 Cerfolio RJ, 2018, ANN THORAC SURG, V105, P991, DOI 10.1016/j.athoracsur.2018.01.003 Cerfolio RJ, 2016, ANN THORAC SURG, V101, P1110, DOI 10.1016/j.athoracsur.2015.09.004 Chen JS, 2020, LANGENBECK ARCH SURG, V405, P1025, DOI 10.1007/s00423-020-01975-z Deng HY, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.00649-2019 Dexter E, 2022, ANN THORAC SURG, V114, P941, DOI 10.1016/j.athoracsur.2022.01.040 Dindo D, 2004, ANN SURG, V240, P205, DOI [10.17116/hirurgia2018090162, 10.1097/01.sla.0000133083.54934.ae] Durmaz E, 2020, ANN NONINVAS ELECTRO, V25, DOI 10.1111/anec.12718 Fawcett WJ, 2021, BRIT J ANAESTH, V126, P751, DOI 10.1016/j.bja.2020.12.027 Fleisher LA, 2014, CIRCULATION, V130, pE278, DOI 10.1161/CIR.0000000000000106 Flint AC, 2019, NEW ENGL J MED, V381, P243, DOI 10.1056/NEJMoa1803180 Garcia YA, 2020, CHEST, V157, P205, DOI 10.1016/j.chest.2019.07.019 Glikson M, 2022, EUROPACE, V24, P71, DOI 10.1093/europace/euab232 Gocyk W, 2016, ANN THORAC SURG, V102, P1119, DOI 10.1016/j.athoracsur.2016.04.066 Gould MK, 2017, ANN AM THORAC SOC, V14, P1571, DOI 10.1513/AnnalsATS.201701-030OC Greenberg CC, 2016, JAMA SURG, V151, P282, DOI 10.1001/jamasurg.2015.4442 Healy Kirsten O, 2010, Congest Heart Fail, V16, P45, DOI 10.1111/j.1751-7133.2009.00130.x Hoefsmit PC, 2021, CLIN MED INSIGHTS-ON, V15, DOI 10.1177/1179554920987105 Jensen K, 2015, INTERACT CARDIOV TH, V21, P420, DOI 10.1093/icvts/ivv183 Joglar JA, 2024, CIRCULATION, V149, pe1, DOI 10.1161/CIR.0000000000001193 KAPLAN LM, 1995, AM J RESP CRIT CARE, V151, P904 Karp R B, 1970, Ann Thorac Surg, V10, P370 Kaufmann KB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199807 Kehlet H, 1997, BRIT J ANAESTH, V78, P606, DOI 10.1093/bja/78.5.606 Kehlet H, 2017, ANESTH ANALG, V125, P2154, DOI 10.1213/ANE.0000000000002231 Keramati AR, 2014, NEW ENGL J MED, V370, P1909, DOI 10.1056/NEJMoa1301824 Lang P, 2016, EUR J CARDIO-THORAC, V49, P611, DOI 10.1093/ejcts/ezv133 Lohser J, 2015, ANESTH ANALG, V121, P302, DOI 10.1213/ANE.0000000000000808 Marcus GM, 2020, CIRCULATION, V141, P1404, DOI 10.1161/CIRCULATIONAHA.119.042434 Mashour GA, 2011, ANESTHESIOLOGY, V114, P1289, DOI 10.1097/ALN.0b013e318216e7f4 McFalls EO, 2004, NEW ENGL J MED, V351, P2795, DOI 10.1056/NEJMoa041905 Medrek S, 2022, FRONT CARDIOVASC MED, V9, DOI 10.3389/fcvm.2022.984951 Misthos P, 2005, EUR J CARDIO-THORAC, V27, P379, DOI 10.1016/j.ejcts.2004.12.023 Miyazaki T, 2019, INTERACT CARDIOV TH, V28, P728, DOI 10.1093/icvts/ivy319 Morris PB, 2015, J AM COLL CARDIOL, V66, P1378, DOI 10.1016/j.jacc.2015.07.037 Passman RS, 2005, ANN THORAC SURG, V79, P1698, DOI 10.1016/j.athoracsur.2004.10.058 Rana MN, 2022, CURR DIABETES REP, V22, P27, DOI 10.1007/s11892-021-01446-9 Razazi Keyvan, 2014, Ann Am Thorac Soc, V11, P1018, DOI 10.1513/AnnalsATS.201404-152OC Reilly DF, 1999, ARCH INTERN MED, V159, P2185, DOI 10.1001/archinte.159.18.2185 Siegel RL, 2024, CA-CANCER J CLIN, V74, P12, DOI 10.3322/caac.21820 Skaarup SH, 2020, J BRONCHOL INTERN PU, V27, P172, DOI 10.1097/LBR.0000000000000627 Sturgeon KM, 2019, EUR HEART J, V40, P3889, DOI 10.1093/eurheartj/ehz766 Takenaka K, 2006, J CRIT CARE, V21, P48, DOI 10.1016/j.jcrc.2005.07.001 Takenaka T, 2013, INTERACT CARDIOV TH, V16, P270, DOI 10.1093/icvts/ivs489 Timmis A, 2022, EUR HEART J-QUAL CAR, V8, P377, DOI 10.1093/ehjqcco/qcac014 Tong CY, 2023, CANCERS, V15, DOI 10.3390/cancers15020371 Tsubochi H, 2018, GEN THORAC CARDIOVAS, V66, P71, DOI 10.1007/s11748-017-0864-z Ujiie H, 2019, EXPERT REV RESP MED, V13, P571, DOI 10.1080/17476348.2019.1610399 Umbrello M, 2017, CRIT CARE RESUSC, V19, P64 van den Heuvel M, 2020, SPAN J PSYCHOL, V23, DOI 10.1017/SJP.2020.55 Wang C, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.950971 Wang Z, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-018-0625-5 Wilcox NS, 2024, NAT REV CARDIOL, V21, P617, DOI 10.1038/s41569-024-01017-x Wu Y, 2022, J NURS MANAGE, V30, P827, DOI 10.1111/jonm.13541 Wu YZ, 2014, CANCER LETT, V345, P164, DOI 10.1016/j.canlet.2013.08.014 Youn JC, 2020, INT J CARDIOL, V317, P167, DOI 10.1016/j.ijcard.2020.04.080 Zhou J, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.751396 Zhou J, 2019, INTERACT CARDIOV TH, V28, P29, DOI 10.1093/icvts/ivy216 NR 70 TC 1 Z9 1 U1 1 U2 22 PU ELSEVIER SCIENCE INC PI NEW YORK PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA SN 2347-5625 EI 2349-6673 J9 ASIA-PAC J ONCOL NUR JI Asia-Pac. J. Oncol. Nurs. PD AUG PY 2024 VL 11 IS 8 AR 100532 DI 10.1016/j.apjon.2024.100532 EA JUL 2024 PG 9 WC Nursing WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI) SC Nursing GA YI1E6 UT WOS:001267760800001 PM 39092140 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Guo, L Ou, SL Zhang, SY Li, D Ma, XC AF Guo, Lin Ou, Songlei Zhang, Shaoyan Li, Dong Ma, Xuchen TI Neoadjuvant therapy bridging percutaneous coronary intervention (PCI) and video-assisted thoracoscopic (VATS) lobectomy: a retrospective study SO TRANSLATIONAL CANCER RESEARCH LA English DT Article DE Coronary artery disease (CAD); non-small cell lung cancer (NSCLC); percutaneous coronary intervention (PCI); neoadjuvant therapy; video-assisted thoracoscopic lobectomy ID CELL LUNG-CANCER; RISK-FACTORS; SINGLE-ARM; CHEMOTHERAPY; GEFITINIB; RESECTION; SURVIVAL; DISEASE AB Background: Currently, there is no unified standard for the treatment of coronary artery disease (CAD) in non-small cell lung cancer (NSCLC), and the treatments have their own advantages and disadvantages. Thus, this study aimed to analyze the safety and feasibility of neoadjuvant therapy during the dual antiplatelet therapy (DAPT) period before surgery in patients with NSCLC coexisting with CAD after percutaneous coronary intervention (PCI) treatment. Methods: We retrospectively included 13 patients with T2aN0M0 (stage IB) NSCLC who also had concomitant CAD. After PCI treatment, neoadjuvant targeted or immunotherapy was administered based on the type of lung cancer, and the effects on treatment and impact on surgery were observed. Results: The objective response rate (ORR) after neoadjuvant treatment in 13 patients was 53.8% [95% confidence interval (CI): 25.1-80.8%], and the disease control rate (DCR) reached 100%. Ten patients (76.9%) experienced adverse events (AEs) <= grade 2. All patients underwent standard VATS lobectomy with lymph node dissection. One case (7.7%) required conversion to open thoracotomy, and all cases achieved R0 resection. The median operative time was 150 [interquartile range (IQR) 125-250] minutes, median intraoperative blood loss was 180 (IQR 150-235) mL, median postoperative drainage tube placement time was 4 (IQR 3-5) days, median total drainage volume was 1,310 (IQR 780-1,705) mL, and the median postoperative hospitalization was 7 (IQR 7-8) days. One patient (7.7%) experienced rapid atrial fibrillation. No deaths occurred. Postoperative pathological evaluation in three cases achieved major pathological response (MPR) (23.1%, 95% CI: 5-53.8%), with two cases achieving pathological complete response (pCR) (15.4%, 95% CI: 1.9-45.4%). Conclusions: The study presents initial evidence suggesting for the safety and feasibility of performing PCI treatment followed by neoadjuvant therapy during the DAPT period for patients with T2aN0M0 (IB) stage NSCLC coexisting with CAD. This approach presents a potential treatment option to control the disease while eliminating concerns about tumor progression and metastasis. C1 [Guo, Lin; Ou, Songlei; Zhang, Shaoyan; Li, Dong; Ma, Xuchen] Capital Med Univ, Beijing Anzhen Hosp, Beijing Inst Heart Lung & Blood Vessel Dis, Dept Thorac Surg, 2 Anzhen Rd, Beijing 100029, Peoples R China. C3 Capital Medical University RP Ma, XC (corresponding author), Capital Med Univ, Beijing Anzhen Hosp, Beijing Inst Heart Lung & Blood Vessel Dis, Dept Thorac Surg, 2 Anzhen Rd, Beijing 100029, Peoples R China. EM maxunchenanzhen@126.com RI Guo, Lin/LBG-8567-2024 OI Guo, Lin/0009-0003-5009-202X FU STI2023-Major Projects of China [2021ZD0200603] FX Funding: This study was supported by the STI2023-Major Projects of China (grant No. 2021ZD0200603) . CR [Anonymous], 2023, BIOMED ENVIRON SCI, V36, P669, DOI 10.3967/bes2023.106 Bablekos GD, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.06.02 Basaraba JE, 2017, J CARDIOL, V69, P353, DOI 10.1016/j.jjcc.2016.07.021 Bhatt DL, 2021, JACC-CARDIOVASC INTE, V14, P1667, DOI 10.1016/j.jcin.2021.06.024 Bott MJ, 2019, J THORAC CARDIOV SUR, V158, P269, DOI 10.1016/j.jtcvs.2018.11.124 Bundhun PK, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007410 Chaft JE, 2022, J CLIN ONCOL, V40, P546, DOI 10.1200/JCO.21.01589 Forde PM, 2022, NEW ENGL J MED, V386, P1973, DOI 10.1056/NEJMoa2202170 Hattori A, 2016, ANN THORAC SURG, V102, P407, DOI 10.1016/j.athoracsur.2016.02.074 Hong Y, 2023, HEART SURG FORUM, V26, pE656, DOI 10.59958/hsf.5877 Jelic MD, 2021, J CANCER RES THER, V17, P22, DOI 10.4103/jcrt.JCRT_862_16 Koene RJ, 2016, CIRCULATION, V133, P1104, DOI 10.1161/CIRCULATIONAHA.115.020406 Lara-Guerra H, 2012, LUNG CANCER, V76, P235, DOI 10.1016/j.lungcan.2011.10.020 Lara-Guerra H, 2009, J CLIN ONCOL, V27, P6229, DOI 10.1200/JCO.2009.22.3370 Lawton JS, 2022, CIRCULATION, V145, pE18, DOI 10.1161/CIR.0000000000001038 Lengel HB, 2023, J THORAC CARDIOV SUR, V165, P1682, DOI 10.1016/j.jtcvs.2022.10.056 Li Molly S C, 2023, Ann Transl Med, V11, P358, DOI [10.21037/atm-22-4444, 10.21037/atm-22-4444] Lv C, 2023, LUNG CANCER, V178, P151, DOI 10.1016/j.lungcan.2023.02.011 Lv C, 2020, J THORAC DIS, V12, P5324, DOI 10.21037/jtd-20-1265 Madhavan MV, 2020, J AM COLL CARDIOL, V75, P590, DOI 10.1016/j.jacc.2019.11.058 Provencio M, 2022, J CLIN ONCOL, V40, P2924, DOI 10.1200/JCO.21.02660 Provencio M, 2020, LANCET ONCOL, V21, P1413, DOI 10.1016/S1470-2045(20)30453-8 Remon J, 2023, ANN ONCOL, V34, P468, DOI 10.1016/j.annonc.2023.02.012 Rosner S, 2023, CLIN CANCER RES, V29, P705, DOI 10.1158/1078-0432.CCR-22-2994 Smilowitz NR, 2017, JAMA CARDIOL, V2, P181, DOI 10.1001/jamacardio.2016.4792 Sun L, 2023, JAMA ONCOL, V9, P1075, DOI 10.1001/jamaoncol.2023.1891 Sun X, 2021, THORAC CANCER, V12, P1358, DOI 10.1111/1759-7714.13908 Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660 Suzuki K, 2022, J THORAC CARDIOV SUR, V163, P289, DOI 10.1016/j.jtcvs.2020.09.146 Travis WD, 2020, J THORAC ONCOL, V15, P709, DOI 10.1016/j.jtho.2020.01.005 Tricard J, 2021, EUR J CARDIO-THORAC, V59, P610, DOI 10.1093/ejcts/ezaa360 Tsutani Y, 2019, ANN THORAC SURG, V108, P1484, DOI 10.1016/j.athoracsur.2019.05.080 Wilcox T, 2021, CAN J CARDIOL, V37, P224, DOI 10.1016/j.cjca.2020.04.034 William WN, 2013, J THORAC ONCOL, V8, P222, DOI 10.1097/JTO.0b013e3182774108 Xia CF, 2022, CHINESE MED J-PEKING, V135, P584, DOI 10.1097/CM9.0000000000002108 Yang CFJ, 2018, ANN THORAC SURG, V105, P924, DOI 10.1016/j.athoracsur.2017.09.030 Yeginsu A, 2018, BRAZ J CARDIOVA SURG, V33, P483 Yin JC, 2019, J SURG ONCOL, V120, P1486, DOI 10.1002/jso.25724 Zhang Y, 2021, J THORAC CARDIOV SUR, V161, P434, DOI 10.1016/j.jtcvs.2020.02.131 Zhong WZ, 2021, J CLIN ONCOL, V39, P713, DOI 10.1200/JCO.20.01820 Zhong WZ, 2019, J CLIN ONCOL, V37, P2235, DOI 10.1200/JCO.19.00075 NR 41 TC 0 Z9 0 U1 0 U2 4 PU AME PUBLISHING COMPANY PI SHATIN PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA SN 2218-676X EI 2219-6803 J9 TRANSL CANCER RES JI Transl. Cancer Res. PD JUN 30 PY 2024 VL 13 IS 6 BP 2662 EP 2673 DI 10.21037/tcr-24-132 PG 12 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA D0R9P UT WOS:001293355600007 PM 38988932 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Batchelor, TJP AF Batchelor, Timothy J. P. TI Postoperative care after thoracic surgery in the times of ERAS SO BEST PRACTICE & RESEARCH-CLINICAL ANAESTHESIOLOGY LA English DT Article DE Enhanced recovery after surgery; Chest tube management; Opioid-sparing analgesia; Early mobilization ID CHEST TUBE REMOVAL; ASSISTED THORACOSCOPIC SURGERY; LUNG-CANCER PATIENTS; ENHANCED RECOVERY; ATRIAL-FIBRILLATION; PULMONARY RESECTION; OPIOID USE; IMPACT; GUIDELINES; MANAGEMENT AB This review documents the importance of postoperative interventions that accelerate the functional recovery of the thoracic surgical patient. Enhanced recovery after surgery (ERAS) pathways aim to mitigate the harmful surgical stress response. Improvements to the entire patient pathway, by removing unnecessary care elements while introducing evidence-based interventions, have synergistic effects. At the same time, some key care elements appear to be more important than others, including early removal of chest tubes, early mobilization, and the limited use of opioids. These care elements are all intertwined. The goals of early mobilization and opioid-sparing analgesia are more readily achieved once a chest tube has been removed. A focus on achieving these goals earlier, including on the day of surgery, may benefit a patient's recovery further. The result is superior patient outcomes including a quicker restoration of normal function, fewer complications, reduced opioid requirements, reduced costs, and a shorter length of stay. C1 [Batchelor, Timothy J. P.] St Bartholomews Hosp, Barts Thorax Ctr, Dept Thorac Surg, London EC1A7BE, England. RP Batchelor, TJP (corresponding author), St Bartholomews Hosp, Barts Thorax Ctr, Dept Thorac Surg, London EC1A7BE, England. EM tim.batchelor@nhs.net OI Batchelor, Timothy/0000-0003-4103-6061 CR Alex J, 2003, ANN THORAC SURG, V76, P1046, DOI 10.1016/S0003-4975(03)00884-1 Andalib A, 2013, J THORAC ONCOL, V8, P554, DOI 10.1097/JTO.0b013e3182862e7e Batchelor TJP, 2024, CURR OPIN ANESTHESIO, V37, P69, DOI 10.1097/ACO.0000000000001333 Batchelor TJP, 2021, J THORAC CARDIOV SUR, V161, P1703, DOI 10.1016/j.jtcvs.2020.01.020 Batchelor TJP, 2019, EUR J CARDIO-THORAC, V55, P91, DOI 10.1093/ejcts/ezy301 Bendixen M, 2016, LANCET ONCOL, V17, P836, DOI 10.1016/S1470-2045(16)00173-X Berna P, 2021, ANAESTH CRIT CARE PA, V40, DOI 10.1016/j.accpm.2020.100791 Bjerregaard LS, 2014, EUR J CARDIO-THORAC, V45, P241, DOI 10.1093/ejcts/ezt376 Blessberger H, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013438 Brown LM, 2021, ANN SURG, V274, pE70, DOI 10.1097/SLA.0000000000003561 Castelino T, 2016, SURGERY, V159, P991, DOI 10.1016/j.surg.2015.11.029 Cerfolio RJ, 2008, J THORAC CARDIOV SUR, V135, P269, DOI 10.1016/j.jtcvs.2007.08.066 Coughlin SM, 2012, CAN J SURG, V55, P264, DOI 10.1503/cjs.001411 Deng B, 2010, EUR J CARDIO-THORAC, V38, P210, DOI 10.1016/j.ejcts.2010.01.050 Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109 Falcoz PE, 2016, EUR J CARDIO-THORAC, V49, P602, DOI 10.1093/ejcts/ezv154 Forster C, 2021, TRANSL LUNG CANCER R, V10, P93, DOI 10.21037/tlcr-20-891 Forster C, 2020, J CARDIOTHOR VASC AN, V34, P1858, DOI 10.1053/j.jvca.2020.01.038 Frendl G, 2014, J THORAC CARDIOV SUR, V148, pE153, DOI 10.1016/j.jtcvs.2014.06.036 Gao SG, 2017, J THORAC DIS, V9, P3255, DOI 10.21037/jtd.2017.08.165 Giambrone GP, 2016, J THORAC CARDIOV SUR, V151, P982, DOI 10.1016/j.jtcvs.2015.11.057 Gillis C, 2015, ANESTHESIOLOGY, V123, P1455, DOI 10.1097/ALN.0000000000000795 Gómez-Caro A, 2006, EUR J CARDIO-THORAC, V29, P562, DOI 10.1016/j.ejcts.2006.01.019 Grigor EJM, 2017, ANN THORAC SURG, V104, P382, DOI 10.1016/j.athoracsur.2017.05.025 Gross DJ, 2023, JTCVS OPEN, V15, P508, DOI 10.1016/j.xjon.2023.06.017 Haro GJ, 2021, ANN SURG, V274, pE1008, DOI 10.1097/SLA.0000000000003719 Holbek BL, 2019, EUR J CARDIO-THORAC, V55, P673, DOI 10.1093/ejcts/ezy361 Hoogeboom TJ, 2014, CURR OPIN ANESTHESIO, V27, P161, DOI 10.1097/ACO.0000000000000062 Huang L, 2021, PERIOPER MED-LONDON, V10, DOI 10.1186/s13741-021-00199-z Huang L, 2021, J THORAC DIS, V13, P1130, DOI 10.21037/jtd-20-3130 Kehlet H, 2011, LANGENBECK ARCH SURG, V396, P585, DOI 10.1007/s00423-011-0790-y Khandhar SJ, 2018, EUR J CARDIO-THORAC, V53, P1192, DOI 10.1093/ejcts/ezy061 Khoury AL, 2021, JTCVS OPEN, V7, P370, DOI 10.1016/j.xjon.2021.07.007 Kotova S, 2017, ANN THORAC SURG, V103, P1566, DOI 10.1016/j.athoracsur.2016.11.007 Lee L, 2014, SURGERY, V155, P211, DOI 10.1016/j.surg.2013.10.002 Lim E, 2022, NEJM EVID, V1, DOI [10.1056/evidoa2100016, 10.1056/EVIDoa2100016] Ljungqvist O, 2017, JAMA SURG, V152, P292, DOI 10.1001/jamasurg.2016.4952 Mainini C, 2016, SAGE OPEN MED, V4, DOI 10.1177/2050312116673855 Martin LW, 2018, ANN THORAC SURG, V105, P1597, DOI 10.1016/j.athoracsur.2018.01.080 Miserocchi G, ESTS Textbook of thoracic surgery Nelson JA, 2022, J CARDIOTHOR VASC AN, V36, P2177, DOI 10.1053/j.jvca.2021.05.011 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Pastene B, 2022, BJS OPEN, V6, DOI 10.1093/bjsopen/zrac063 Petersen RH, 2021, EUR J CARDIO-THORAC, V59, P291, DOI 10.1093/ejcts/ezaa435 Pfeuty K, 2020, INTERACT CARDIOV TH, V31, P657, DOI 10.1093/icvts/ivaa170 Piccioni F, 2020, PERIOPER MED-LONDON, V9, DOI 10.1186/s13741-020-00168-y Piccioni F, 2020, PERIOPER MED-LONDON, V9, DOI 10.1186/s13741-020-00159-z Puri V, 2015, J THORAC CARDIOV SUR, V150, P1496, DOI 10.1016/j.jtcvs.2015.08.067 Qiu T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068087 Rahman NM, 2015, JAMA-J AM MED ASSOC, V314, P2641, DOI 10.1001/jama.2015.16840 Rahman NM, 2010, CHEST, V137, P536, DOI 10.1378/chest.09-1044 Razi SS, 2021, J THORAC CARDIOV SUR, V161, P1689, DOI 10.1016/j.jtcvs.2019.12.137 Refai M, 2012, EUR J CARDIO-THORAC, V41, P820, DOI 10.1093/ejcts/ezr126 Rogers LJ, 2018, J THORAC CARDIOV SUR, V155, P1843, DOI 10.1016/j.jtcvs.2017.10.151 Smart NJ, 2012, COLORECTAL DIS, V14, pE727, DOI 10.1111/j.1463-1318.2012.03096.x Strobel RJ, 2023, ANN THORAC SURG, V115, P241, DOI 10.1016/j.athoracsur.2022.05.060 Turner KM, 2023, ANN THORAC SURG, V115, P249, DOI 10.1016/j.athoracsur.2022.05.059 Van Haren RM, 2018, ANN THORAC SURG, V106, P272, DOI 10.1016/j.athoracsur.2018.01.088 Varela G, 2009, EUR J CARDIO-THORAC, V35, P28, DOI 10.1016/j.ejcts.2008.09.005 Weimann A, 2021, CLIN NUTR, V40, P4745, DOI 10.1016/j.clnu.2021.03.031 Wildgaard K, 2009, EUR J CARDIO-THORAC, V36, P170, DOI 10.1016/j.ejcts.2009.02.005 Yang R, 2022, J THORAC DIS, DOI 10.21037/jtd-22-707 You JZ, 2020, WORLD J SURG ONCOL, V18, DOI 10.1186/s12957-020-01945-1 Zhou J, 2018, EUR J CARDIO-THORAC, V54, P635, DOI 10.1093/ejcts/ezy141 NR 64 TC 2 Z9 2 U1 1 U2 4 PU ELSEVIER PI AMSTERDAM PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS SN 1521-6896 EI 1878-1608 J9 BEST PRAC RES-CL ANA JI Best Pract. Res.-Clin. Anaesth. PD MAR PY 2024 VL 38 IS 1 BP 81 EP 89 DI 10.1016/j.bpa.2024.04.004 EA JUN 2024 PG 9 WC Anesthesiology WE Science Citation Index Expanded (SCI-EXPANDED) SC Anesthesiology GA UX8W3 UT WOS:001251465000001 DA 2026-04-17 ER PT J AU Dai, MY Chen, Y Qin, J AF Dai, Meiyan Chen, Yue Qin, Jin TI Atrioventricular re-entrant tachycardia and atrioventricular node re-entrant tachycardia in a patient with cancer under chemotherapy: a case report and literature review SO FRONTIERS IN CARDIOVASCULAR MEDICINE LA English DT Article DE chemotherapy; arrhythmia; cancer; ion channel; case report ID SENSITIVE POTASSIUM CHANNELS; LACTATE; MECHANISM; CARDIOTOXICITY; CARDIOMYOPATHY; CARDIOMYOCYTES; IDENTIFICATION; INVASION; PATHWAYS; THERAPY AB Cardio-oncology is a new field of interest in cardiology focusing on the detection and treatment of cardiovascular diseases, such as arrhythmias, myocarditis, and heart failure, as side-effects of chemotherapy and radiotherapy. The association between chemotherapeutic agents and arrhythmias has previously been established. Atrial tachyarrhythmias, particularly atrial fibrillation, are most common, but ventricular arrhythmias, including those related to treatment-induced QT prolongation, and bradyarrhythmias can also occur. However, the association between chemotherapeutic agents and atrioventricular re-entrant tachycardia (AVRT)/atrioventricular node re-entrant tachycardia (AVNRT) remains poorly understood. Here, we report a patient with new-onset AVRT/AVNRT and lung cancer who underwent chemotherapy. We considered that chemotherapy or cancer itself may have been a trigger for the initiation of paroxysmal AVRT/AVNRT, and that radiofrequency catheter ablation was effective in treating this type of tachycardia. Here, possible mechanisms and potential genes (mostly ion channels) involved in AVRT/AVNRT are summarized and the mechanisms underlying the possible regulatory patterns of cancer cells and chemotherapy on ion channels are reviewed. Finally, we considered that ion channel abnormalities may link cancer or chemotherapy to the onset of AVRT/AVNRT. The aim of the present study was to highlight the association between chemotherapeutic agents and AVRT/AVNRT and to provide new insights for future research. Understanding the intermediate mechanisms between chemotherapeutic agents and AVRT/AVNRT may be beneficial in preventing chemotherapy-evoked AVRT/AVNRT (and/or other arrhythmias) in future. C1 [Dai, Meiyan; Qin, Jin] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Internal Med, Div Cardiol,Tongji Med Coll, Wuhan, Peoples R China. [Chen, Yue] Huazhong Univ Sci & Technol, Tongji Hosp, Dept & Inst Infect Dis, Tongji Med Coll, Wuhan, Peoples R China. C3 Huazhong University of Science & Technology; Huazhong University of Science & Technology RP Qin, J (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Dept Internal Med, Div Cardiol,Tongji Med Coll, Wuhan, Peoples R China. EM Qinjin_lch@163.com FU National Natural Science Foundation of China FX We thank our colleague Huaping Li for stimulating discussions. We would like to thank Editage (www.editage.com) for English language editing. CR AKHTAR M, 1993, CIRCULATION, V88, P282, DOI 10.1161/01.CIR.88.1.282 Alberti P, 2020, NEUROPHARMACOLOGY, V164, DOI 10.1016/j.neuropharm.2019.107905 Andreasen L, 2018, EUR J HUM GENET, V26, P660, DOI 10.1038/s41431-017-0092-0 Bastos DB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202515 Blackwell DJ, 2022, CIRC RES, V130, P1926, DOI 10.1161/CIRCRESAHA.122.320258 Bloom MW, 2016, CIRC-HEART FAIL, V9, DOI 10.1161/CIRCHEARTFAILURE.115.002661 Brembilla-Perrot B, 2001, INT J CARDIOL, V78, P293, DOI 10.1016/S0167-5273(01)00392-8 Buchanan PJ, 2016, EUR BIOPHYS J BIOPHY, V45, P621, DOI 10.1007/s00249-016-1144-z Buza V, 2017, CIRC-ARRHYTHMIA ELEC, V10, DOI 10.1161/CIRCEP.117.005443 Capatina AL, 2022, REV PHYSIOL BIOCH P, V183, P1, DOI 10.1007/112_2020_46 Ceyhan GO, 2009, GASTROENTEROLOGY, V136, P177, DOI 10.1053/j.gastro.2008.09.029 Chang KT, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23042279 Cheung SM, 2020, BRIT J CANCER, V123, P261, DOI 10.1038/s41416-020-0886-7 Coban-Akdemir ZH, 2020, AM J MED GENET A, V182, P1387, DOI 10.1002/ajmg.a.61571 D'Este D, 2001, EUROPACE, V3, P216, DOI 10.1053/eupc.2001.0175 Deneke T, 2009, Herzschrittmacherther Elektrophysiol, V20, P33, DOI 10.1007/s00399-009-0036-7 Duan Jialin, 2018, Oncotarget, V9, P25738, DOI [10.18632/oncotarget.25008, 10.18632/oncotarget.25008] Ergir E, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-22225-w Fahdi IE, 2004, AM J CARDIOL, V93, P1052, DOI 10.1016/j.amjcard.2003.12.061 Fan JJ, 2022, REV PHYSIOL BIOCH P, V183, P103, DOI 10.1007/112_2020_48 Fitzsimmons PJ, 2001, AM HEART J, V142, P530, DOI 10.1067/mhj.2001.117779 Fox DJ, 2008, MAYO CLIN PROC, V83, P1400, DOI 10.1016/S0025-6196(11)60791-X Fraser SP, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0105 Gan L, 2020, CIRCULATION, V141, P968, DOI 10.1161/CIRCULATIONAHA.119.042640 Gollob MH, 2001, CIRCULATION, V104, P3030, DOI 10.1161/hc5001.102111 Gollob MH, 2001, NEW ENGL J MED, V344, P1823, DOI 10.1056/NEJM200106143442403 Grabon W, 2016, CELL BIOCHEM FUNCT, V34, P483, DOI 10.1002/cbf.3211 HAN J, 1993, PFLUG ARCH EUR J PHY, V425, P546 Hayes JJ, 2004, PACE, V27, P73, DOI 10.1111/j.1540-8159.2004.00388.x Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809 Herrmann J, 2020, NAT REV CARDIOL, V17, P474, DOI 10.1038/s41569-020-0348-1 Hu SB, 2018, CANCER MANAG RES, V10, P4603, DOI 10.2147/CMAR.S172948 Huang JC, 2022, FRONT CARDIOVASC MED, V9, DOI 10.3389/fcvm.2022.910826 Huang MH, 2015, CELL PHYSIOL BIOCHEM, V37, P1390, DOI 10.1159/000430404 Huizar JF, 2019, J AM COLL CARDIOL, V73, P2328, DOI 10.1016/j.jacc.2019.02.045 Hurwitz SN, 2016, ONCOTARGET, V7, P86999, DOI 10.18632/oncotarget.13569 JAZAYERI MR, 1985, TEX HEART I J, V12, P249 Jiang L, 2019, HEART RHYTHM, V16, P1374, DOI 10.1016/j.hrthm.2019.04.008 Kalra H, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001450 Kang S, 2017, MOL CANCER THER, V16, P217, DOI 10.1158/1535-7163.MCT-16-0169-T Karakikes I, 2015, CIRC RES, V117, P80, DOI 10.1161/CIRCRESAHA.117.305365 Kerslake R, 2023, J CLIN MED, V12, DOI 10.3390/jcm12010217 KEUNG EC, 1991, J CLIN INVEST, V88, P1772, DOI 10.1172/JCI115497 Khozin S, 2015, CLIN CANCER RES, V21, P2436, DOI 10.1158/1078-0432.CCR-14-3157 Kilickap S, 2007, SOUTH MED J, V100, P262, DOI 10.1097/01.smj.0000257382.89910.fe Lastraioli E, 2015, BRIT J CANCER, V112, P1076, DOI 10.1038/bjc.2015.28 Lee C, 2021, HEART RHYTHM, V18, P1223, DOI 10.1016/j.hrthm.2021.02.017 Lee EL, 2008, AM J PHYSIOL-CELL PH, V294, pC1398, DOI 10.1152/ajpcell.00428.2007 Lehky RJ, 2004, MUSCLE NERVE, V29, P387, DOI 10.1002/mus.10559 Li J, 2023, MEDICINE, V102, DOI 10.1097/MD.0000000000034799 Luo R, 2020, CLIN TRANSL MED, V10, P238, DOI 10.1002/ctm2.25 Manolis AA, 2021, TRENDS CARDIOVAS MED, V31, P290, DOI 10.1016/j.tcm.2020.04.011 Markowitz SM, 2018, J INTERV CARD ELECTR, V52, P271, DOI 10.1007/s10840-018-0392-5 Marzlin KM, 2017, AACN ADV CRIT CARE, V28, P223, DOI 10.4037/aacnacc2017151 Marzlin KM, 2017, AACN ADV CRIT CARE, V28, P84, DOI 10.4037/aacnacc2017887 Maurea N, 2016, J CARDIOVASC MED, V17, pS19, DOI 10.2459/JCM.0000000000000377 Mehedineanu AM., 2021, Int J Mol Sci, V22, DOI [10.1007/s11481-019-09891-w, DOI 10.1007/S11481-019-09891-W] Nilsson MB, 2020, J NEUROIMMUNE PHARM, V15, P27, DOI 10.1007/s11481-019-09891-w Nishimura H, 2001, SCIENCE, V291, P319, DOI 10.1126/science.291.5502.319 O'Donnell M, 2009, ANNU REV NEUROSCI, V32, P383, DOI 10.1146/annurev.neuro.051508.135614 Olsen EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200/JCO.2006.10.2434 Palm D, 2007, PROG EXP TUMOR RES, V39, P91, DOI 10.1159/000100049 Perez IE, 2019, CLIN MED INSIGHTS-CA, V13, DOI 10.1177/1179546819866445 Porter MJ, 2004, HEART RHYTHM, V1, P393, DOI 10.1016/j.hrthm.2004.05.007 Quan XH, 2022, HELIYON, V8, DOI 10.1016/j.heliyon.2022.e11006 Rapetti-Mauss R, 2017, P NATL ACAD SCI USA, V114, P4159, DOI 10.1073/pnas.1702913114 Rizzuto R, 2012, NAT REV MOL CELL BIO, V13, P566, DOI 10.1038/nrm3412 Romisher A, 2015, BLOOD, V126 ROWINSKY EK, 1991, J CLIN ONCOL, V9, P1704, DOI 10.1200/JCO.1991.9.9.1704 Salat K, 2020, PHARMACOL REP, V72, P508, DOI 10.1007/s43440-020-00106-1 Servage KA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64718-6 Siegel R.L., CA-CANCER J CLIN, V2020, P7, DOI [10.3322/caac.21590, DOI 10.3322/CAAC.21590] Silversides CK, 2006, AM J CARDIOL, V97, P1206, DOI 10.1016/j.amjcard.2005.11.041 Song YJ, 2017, JCPSP-J COLL PHYSICI, V27, P657, DOI 2730 Sorrentino MF, 2012, CARDIOL J, V19, P453, DOI 10.5603/CJ.2012.0084 STEINBERG JS, 1987, CANCER-AM CANCER SOC, V60, P1213, DOI 10.1002/1097-0142(19870915)60:6<1213::AID-CNCR2820600609>3.0.CO;2-V Stewart TA, 2015, BBA-BIOMEMBRANES, V1848, P2502, DOI 10.1016/j.bbamem.2014.08.016 Sugumar H, 2017, HEART LUNG CIRC, V26, P524, DOI 10.1016/j.hlc.2016.07.014 Suh EH, 2021, CANCER METAB, V9, DOI 10.1186/s40170-021-00267-4 TANAKA H, 1994, CARDIOVASC RES, V28, P1507, DOI 10.1093/cvr/28.10.1507 Tosatto A, 2016, EMBO MOL MED, V8, P569, DOI 10.15252/emmm.201606255 Totzeck M, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.006278 Urrego D, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0094 Wang CY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125766 Yang XY, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01058 Zhang K, 2010, J MOL CELL CARDIOL, V49, P829, DOI 10.1016/j.yjmcc.2010.08.018 Zhang YQ, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.150735 Zhao H, 2022, CIRC RES, V130, P1490, DOI 10.1161/CIRCRESAHA.121.320458 Zhong RJ, 2022, FRONT CARDIOVASC MED, V9, DOI 10.3389/fcvm.2022.839104 NR 89 TC 1 Z9 2 U1 2 U2 12 PU FRONTIERS MEDIA SA PI LAUSANNE PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND SN 2297-055X J9 FRONT CARDIOVASC MED JI Front. Cardiovasc. Med. PD JUN 7 PY 2024 VL 11 AR 1367893 DI 10.3389/fcvm.2024.1367893 PG 10 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA UV5W7 UT WOS:001250860400001 PM 38911514 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Xu, HF Zhou, J Ye, F Gao, YZ AF Xu, Haifeng Zhou, Jie Ye, Fei Gao, Yongzhuang TI Serum lipopolysaccharide associated with new-onset atrial fibrillation in patients with non-small-cell lung cancer a retrospective observational study SO FRONTIERS IN SURGERY LA English DT Article DE lipopolysaccharide; atrial fibrillation; non-small-cell lung cancer; surgery; new-onset AF ID RISK-FACTOR; INFLAMMATION; SURGERY AB Lipopolysaccharide (LPS) is related to atrial fibrillation (AF). But so far, the relationship between LPS and new-onset AF (NOAF) in patients with lung cancer is unrevealed. This study was to investigate the association between LPS and NOAF in patients after lung cancer surgery. This was a single-center retrospective clinical observational study. Patients diagnosed with non-small-cell lung cancer (NSCLC) were enrolled. All patients receiving lung cancer surgery and at least 24 h electrocardiogram (ECG) examination was recorded during the hospitalization. The incidence of NOAF in this study was 34/406 (8.4%). The univariate analysis showed that NOAF was associated with age, intraoperative blood transfusion (IBT), chronic obstructive pulmonary disorder (COPD), and LPS. After adjusting risk factors, it was found that age, IBT and LPS (OR, 1.031; 95% CI: 1.001-1.042; P = 0.002) were still risk factors for NOAF. The area under curve (AUC) value was 0.709 for the LPS. When the LPS was added to the conventional model, the Net reclassification index (NRI) and integrated discrimination index (IDI) were improved significantly. Elevated LPS is associated with an increased risk of NOAF in patients after lung cancer surgery. LPS contributed to the discrimination of the NOAF risk model and improved it markedly. C1 [Xu, Haifeng; Zhou, Jie; Ye, Fei; Gao, Yongzhuang] Xuzhou Med Univ, Peoples Hosp Sihong Cty 1, Dept Thorac Surg, Affiliated Hosp,Sihong Branch, Suqian, Jiangsu, Peoples R China. C3 Xuzhou Medical University RP Zhou, J (corresponding author), Xuzhou Med Univ, Peoples Hosp Sihong Cty 1, Dept Thorac Surg, Affiliated Hosp,Sihong Branch, Suqian, Jiangsu, Peoples R China. EM jiezhoudoctor@163.com FU Suqian guiding science and technology plan project FX No Statement Available CR Amar D, 2002, ANESTHESIOLOGY, V96, P352, DOI 10.1097/00000542-200202000-00021 Amar D, 1996, CHEST, V110, P437, DOI 10.1378/chest.110.2.437 Amar D, 2016, J THORAC CARDIOV SUR, V151, P913, DOI 10.1016/j.jtcvs.2015.09.041 Berry MF, 2014, ANN THORAC SURG, V98, P1199, DOI 10.1016/j.athoracsur.2014.05.038 Ciszewski P, 2013, INTERACT CARDIOV TH, V17, P680, DOI 10.1093/icvts/ivt238 Crusz SM, 2015, NAT REV CLIN ONCOL, V12, P584, DOI 10.1038/nrclinonc.2015.105 Diakos CI, 2014, LANCET ONCOL, V15, pE493, DOI 10.1016/S1470-2045(14)70263-3 Ettinger DS, 2017, J NATL COMPR CANC NE, V15, P504, DOI 10.6004/jnccn.2017.0050 Ferro D, 2020, NUTRIENTS, V12, DOI 10.3390/nu12092762 Gawalko M, 2022, CARDIOVASC RES, V118, P2415, DOI 10.1093/cvr/cvab292 Ghosh S, 2015, J GERONTOL A-BIOL, V70, P232, DOI 10.1093/gerona/glu067 Grunkemeier GL, 2015, ANN THORAC SURG, V99, P388, DOI 10.1016/j.athoracsur.2014.10.084 Habibzadeh F, 2024, J KOREAN MED SCI, V39, DOI 10.3346/jkms.2024.39.e35 Huo JY, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.712338 Imperatori A, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-4 Lasek-Bal A, 2015, INT J CARDIOL, V195, P210, DOI 10.1016/j.ijcard.2015.05.117 Liu HT, 2021, SCI PROGRESS-UK, V104, DOI 10.1177/00368504211050275 McCauley MD, 2020, CIRC-ARRHYTHMIA ELEC, V13, DOI 10.1161/CIRCEP.120.008296 Menichelli D, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.779503 O'Neal WT, 2018, J AM COLL CARDIOL, V72, P1913, DOI 10.1016/j.jacc.2018.07.077 Olesen OJ, 2020, EUROPACE, V22, P1182, DOI 10.1093/europace/euaa088 Pastori D, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.005784 Pudil R, 2023, COR VASA, V65, P350, DOI 10.33678/cor.2023.032 Rohrmann S, 2018, EUR HEART J-ACUTE CA, V7, P639, DOI 10.1177/2048872617729636 Rozencwajg S, 2017, ANAESTH CRIT CARE PA, V36, P185, DOI 10.1016/j.accpm.2016.04.005 Seo EJ, 2021, BMC CARDIOVASC DISOR, V21, DOI 10.1186/s12872-021-02224-x Shen XY, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.668532 Shi HY, 2016, ANIM NUTR, V2, P99, DOI 10.1016/j.aninu.2016.03.005 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Wang H, 2021, J THORAC DIS, V13, DOI 10.21037/jtd-20-1717 Wang M, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/2405972 Wang ZN, 2018, PROTEIN CELL, V9, P416, DOI 10.1007/s13238-018-0549-0 Weymann A, 2018, KARDIOL POL, V76, P440, DOI 10.5603/KP.a2017.0242 Yao CX, 2018, CIRCULATION, V138, P2227, DOI 10.1161/CIRCULATIONAHA.118.035202 Zhang Y, 2022, CARDIOVASC RES, V118, P785, DOI 10.1093/cvr/cvab114 Zoni-Berisso M, 2014, CLIN EPIDEMIOL, V6, P213, DOI 10.2147/CLEP.S47385 NR 36 TC 3 Z9 3 U1 0 U2 1 PU FRONTIERS MEDIA SA PI LAUSANNE PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND SN 2296-875X J9 FRONT SURG JI Front. Surg. PD MAY 9 PY 2024 VL 11 AR 1404450 DI 10.3389/fsurg.2024.1404450 PG 6 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA RR1A9 UT WOS:001229285500001 PM 38783859 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Peng, Y Liu, FB Wang, P Wang, XX Si, CY Gong, JX Zhou, HJ Zhang, M Song, FF AF Peng, Yu Liu, Fubin Wang, Peng Wang, Xixuan Si, Changyu Gong, Jianxiao Zhou, Huijun Zhang, Ming Song, Fangfang TI Association between walking pace and risks of major chronic diseases in individuals with hypertension based on a prospective study in UK Biobank: Involvement of inflammation SO PREVENTIVE MEDICINE LA English DT Article DE Walking pace; Chronic diseases; Low-grade inflammation; UK biobank ID CARDIOVASCULAR-DISEASE; PHYSICAL-ACTIVITY; CANCER; EPIDEMIOLOGY; STRENGTH; MARKERS; MEN AB Objective: Walking pace is associated with risks of major chronic diseases including cancer, cardiovascular disease (CVD) and diabetes mellitus type 2 (T2DM) in the general population. However, whether increasing walking pace could reduce risks of major chronic diseases in individuals with hypertension remains to be explored, and the underlying mechanism potentially mediated by low-grade inflammation is also unclear. Methods: A total of 160,470 participants with hypertension were included based on the UK Biobank. The relationships of the walking pace and low-grade inflammation with risks of major chronic diseases in individuals with hypertension were assessed by the Cox proportional hazards model. Mediation analyses were performed to investigate the contribution of low-grade inflammation to the association between walking pace and risks of major chronic diseases. Results: Individuals with hypertension at the brisk walking pace had decreased risks of overall cancer and sitespecific cancers (liver, lung, and endometrial cancers), all CVD events (angina, atrial fibrillation, heart failure, myocardial infarction, peripheral vascular disease and stroke), and T2DM (hazard ratios: 0.42-0.91). Increasing low-grade inflammation was associated with higher risks of aforementioned diseases except liver cancer and atrial fibrillation. Furthermore, low-grade inflammation partially mediated associations of the walking pace with risks of lung cancer, T2DM, and all CVD events (except atrial fibrillation), with mediation proportion of 2.0%- 9.8%. Conclusions: Brisk walking pace was linked to reduced risks of major chronic diseases in individuals with hypertension, partially mediated by low-grade inflammation. Improving walking pace may be beneficial for health in individuals with hypertension. C1 [Peng, Yu; Liu, Fubin; Wang, Peng; Wang, Xixuan; Si, Changyu; Gong, Jianxiao; Zhou, Huijun; Song, Fangfang] Tianjin Med Univ, Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Minist Educ,Dept Epidemiol & Biostat,Key Lab Mol C, Tianjin 300060, Peoples R China. [Zhang, Ming] Shenzhen Prevent & Treatment Ctr Occupat Dis, Comprehens Management Dept Occupat Hlth, Shenzhen 518020, Peoples R China. C3 Tianjin Medical University RP Song, FF (corresponding author), Tianjin Med Univ, Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Minist Educ,Dept Epidemiol & Biostat,Key Lab Mol C, Tianjin 300060, Peoples R China.; Zhang, M (corresponding author), Shenzhen Prevent & Treatment Ctr Occupat Dis, Comprehens Management Dept Occupat Hlth, Shenzhen 518020, Peoples R China. EM mingle1981@163.com; songfangfang@tmu.edu.cn RI zhang, ming/LTF-3574-2024; Song, Fangfang/CAF-0119-2022 OI zhang, ming/0000-0002-2169-0755; FU National Key Research and Devel-opment Program of China [2021YFC2500400, 2021YFC2500401]; Tianjin Key Medical Discipline (Specialty) Construction Project [TJYXZDXK-009A]; Guangdong Basic and Applied Basic Research Foundation [2022A1515010436] FX This work was supported by the National Key Research and Devel-opment Program of China (2021YFC2500400 and 2021YFC2500401) , funded by Tianjin Key Medical Discipline (Specialty) Construction Project (TJYXZDXK-009A) and Guangdong Basic and Applied Basic Research Foundation (2022A1515010436) . CR Barbé-Tuana F, 2020, SEMIN IMMUNOPATHOL, V42, P545, DOI 10.1007/s00281-020-00806-z Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2 Beaudart C, 2019, CALCIFIED TISSUE INT, V105, P1, DOI 10.1007/s00223-019-00545-w Bonaccio M, 2016, HAEMATOLOGICA, V101, P1434, DOI 10.3324/haematol.2016.144055 Boone-Heinonen J, 2009, OBES REV, V10, P204, DOI 10.1111/j.1467-789X.2008.00533.x Boonpor J, 2023, DIABETES OBES METAB, V25, P1900, DOI 10.1111/dom.15053 Boonpor J, 2022, MAYO CLIN PROC, V97, P1631, DOI 10.1016/j.mayocp.2022.02.028 Boonpor J, 2022, SCAND J MED SCI SPOR, V32, P1356, DOI 10.1111/sms.14197 Caspersen CJ, 2008, MED SCI SPORT EXER, V40, pS519, DOI 10.1249/MSS.0b013e31817c6737 Celis-Morales CA, 2019, MED SCI SPORT EXER, V51, P472, DOI 10.1249/MSS.0000000000001795 Cesari M, 2004, J GERONTOL A-BIOL, V59, P242 Cruz BD, 2022, JAMA INTERN MED, V182, P1139, DOI 10.1001/jamainternmed.2022.4000 Cruz BD, 2022, J AM HEART ASSOC, V11, DOI 10.1161/JAHA.121.023290 Du MM, 2014, INT J CANCER, V134, P2707, DOI 10.1002/ijc.28599 Dupont J, 2021, J CACHEXIA SARCOPENI, V12, P1818, DOI 10.1002/jcsm.12785 Furman D, 2019, NAT MED, V25, P1822, DOI 10.1038/s41591-019-0675-0 Guo JH, 2021, EXP GERONTOL, V152, DOI 10.1016/j.exger.2021.111439 Hamer M, 2008, SCAND J MED SCI SPOR, V18, P736, DOI 10.1111/j.1600-0838.2007.00747.x Imran TF, 2019, ATHEROSCLEROSIS, V289, P51, DOI 10.1016/j.atherosclerosis.2019.08.001 Pedersen BK, 2006, ESSAYS BIOCHEM, V42, P105, DOI 10.1042/bse0420105 Peng Y, 2023, METABOLISM, V144, DOI 10.1016/j.metabol.2023.155586 Petrie JR, 2018, CAN J CARDIOL, V34, P575, DOI 10.1016/j.cjca.2017.12.005 Quan MH, 2020, J SPORT HEALTH SCI, V9, P521, DOI 10.1016/j.jshs.2019.09.005 Renner SW, 2022, AGING CLIN EXP RES, V34, P367, DOI 10.1007/s40520-021-01923-x Richman EL, 2011, CANCER RES, V71, P3889, DOI 10.1158/0008-5472.CAN-10-3932 Sionakidis A, 2021, CLIN SCI, V135, P1609, DOI 10.1042/CS20200307 Stamatakis E, 2018, BRIT J SPORT MED, V52, P761, DOI 10.1136/bjsports-2017-098677 Timmins IR, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-01357-7 Ukawa S, 2014, CANCER CAUSE CONTROL, V25, P787, DOI 10.1007/s10552-014-0380-8 Unger T, 2020, HYPERTENSION, V75, P1334, DOI 10.1161/HYPERTENSIONAHA.120.15026 Veronese N, 2018, J AM MED DIR ASSOC, V19, P981, DOI 10.1016/j.jamda.2018.06.007 Wang MY, 2022, EUR J PREV CARDIOL, V29, P2101, DOI 10.1093/eurjpc/zwac135 Welsh CE, 2020, MAYO CLIN PROC, V95, P879, DOI 10.1016/j.mayocp.2019.12.032 Willén C, 2004, ARCH PHYS MED REHAB, V85, P1923, DOI 10.1016/j.apmr.2003.11.040 Williams PT, 2014, MED SCI SPORT EXER, V46, P312, DOI 10.1249/MSS.0b013e3182a4e89c NR 35 TC 2 Z9 2 U1 1 U2 11 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD JUL PY 2024 VL 184 AR 107986 DI 10.1016/j.ypmed.2024.107986 EA MAY 2024 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC Public, Environmental & Occupational Health; General & Internal Medicine GA TC5V4 UT WOS:001239082300001 PM 38714275 DA 2026-04-17 ER PT J AU Baik, SH Baye, F Mcdonald, CJ AF Baik, Seo H. Baye, Fitsum Mcdonald, Clement J. TI Use of menopausal hormone therapy beyond age 65 years and its effects on women's health outcomes by types, routes, and doses SO MENOPAUSE-THE JOURNAL OF THE MENOPAUSE SOCIETY LA English DT Article DE Cancers; Cardiovascular conditions; Dementia; Menopausal hormone therapy; Survival ID ESTROGEN REPLACEMENT THERAPY; MULTIPLE PROPENSITY SCORE; BILATERAL OOPHORECTOMY; POSTMENOPAUSAL WOMEN; OVARIAN CONSERVATION; COLORECTAL-CANCER; PLUS PROGESTIN; LUNG-CANCER; RISK; HYSTERECTOMY AB Among senior Medicare women, the implications of menopausal hormone therapy use beyond age 65 years vary by types, routes, and strengths. Risk reductions appear to be greater with low rather than medium or high doses, vaginal or transdermal rather than oral preparations, and with estradiol rather than conjugated estrogen. ObjectivesThe study aims to assess the use of menopausal hormone therapy beyond age 65 years and its health implications by types of estrogen/progestogen, routes of administration, and dose strengths.MethodsUsing prescription drug and encounter records of 10 million senior Medicare women from 2007-2020 and Cox regression analyses adjusted for time-varying characteristics of the women, we examined the effects of different preparations of menopausal hormone therapy on all-cause mortality, five cancers, six cardiovascular diseases, and dementia.ResultsCompared with never use or discontinuation of menopausal hormone therapy after age 65 years, the use of estrogen monotherapy beyond age 65 years was associated with significant risk reductions in mortality (19% or adjusted hazards ratio, 0.81; 95% CI, 0.79-0.82), breast cancer (16%), lung cancer (13%), colorectal cancer (12%), congestive heart failure (CHF) (5%), venous thromboembolism (3%), atrial fibrillation (4%), acute myocardial infarction (11%), and dementia (2%). For the use of estrogen and progestogen combo-therapy, both E+ progestin and E+ progesterone were associated with increased risk of breast cancer by 10%-19%, but such risk can be mitigated using low dose of transdermal or vaginal E+ progestin. Moreover, E+ progestin exhibited significant risk reductions in endometrial cancer (45% or adjusted hazards ratio, 0.55; 95% CI, 0.50-0.60), ovarian cancer (21%), ischemic heart disease (5%), CHF (5%), and venous thromboembolism (5%), whereas E+ progesterone exhibited risk reduction only in CHF (4%).ConclusionsAmong senior Medicare women, the implications of menopausal hormone therapy use beyond age 65 years vary by types, routes, and strengths. In general, risk reductions appear to be greater with low rather than medium or high doses, vaginal or transdermal rather than oral preparations, and with E2 rather than conjugated estrogen. C1 [Baik, Seo H.; Baye, Fitsum; Mcdonald, Clement J.] US Natl Inst Hlth, Lister Hill Natl Ctr Biomed Commun, Natl Lib Med, Room 10SN1010,8600 Rockville Pike Bldg 38A, Bethesda, MD 20894 USA. C3 National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM) RP Baik, SH (corresponding author), US Natl Inst Hlth, Lister Hill Natl Ctr Biomed Commun, Natl Lib Med, Room 10SN1010,8600 Rockville Pike Bldg 38A, Bethesda, MD 20894 USA. EM baiksh@nih.gov; fitsum.baye@nih.gov; clemmcdonald@mail.nih.gov FU Intramural Research Program of the National Library of Medicine, National Institutes of Health FX This research was supported by the Intramural Research Program of the National Library of Medicine, National Institutes of Health. CR Adams H, 2016, CHILD NERV SYST, V32, P493, DOI 10.1007/s00381-015-3006-x Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701 Avis NE, 2015, JAMA INTERN MED, V175, P531, DOI 10.1001/jamainternmed.2014.8063 Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2 Brown S, 2012, CLIMACTERIC, V15, P275, DOI 10.3109/13697137.2012.660048 Faubion SS, 2022, MENOPAUSE, V29, P767, DOI 10.1097/GME.0000000000002028 Gartoulla P, 2015, MENOPAUSE, V22, P694, DOI 10.1097/GME.0000000000000383 Henderson KD, 2010, AM J EPIDEMIOL, V171, P415, DOI 10.1093/aje/kwp434 Hodis HN, 2012, CLIMACTERIC, V15, P217, DOI 10.3109/13697137.2012.656401 Husain H, 2018, J PHYS CONF SER, V979, DOI 10.1088/1742-6596/979/1/012087 Koch T, 2022, INT J CANCER, V150, P38, DOI 10.1002/ijc.33776 Langer RD, 2017, CLIMACTERIC, V20, P91, DOI 10.1080/13697137.2017.1280251 Luyer MDP, 2001, J CLIN ENDOCR METAB, V86, P3629, DOI 10.1210/jc.86.8.3629 Manson JE, 2017, JAMA-J AM MED ASSOC, V318, P927, DOI 10.1001/jama.2017.11217 Manson JE, 2013, JAMA-J AM MED ASSOC, V310, P1353, DOI 10.1001/jama.2013.278040 Mohammed K, 2015, J CLIN ENDOCR METAB, V100, P4012, DOI 10.1210/jc.2015-2237 National Library of Medicine, DailyMed Newcomb PA, 2007, CANCER RES, V67, P7534, DOI 10.1158/0008-5472.CAN-06-4275 Parker WH, 2014, MENOPAUSE, V21, P192, DOI 10.1097/GME.0b013e31829be0a0 Parker WH, 2010, J MINIM INVAS GYN, V17, P161, DOI 10.1016/j.jmig.2009.12.016 Pesatori AC, 2013, BRIT J CANCER, V109, P1954, DOI 10.1038/bjc.2013.506 Putter H, 2007, STAT MED, V26, P2389, DOI 10.1002/sim.2712 Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321 Samson LW, 2017, MED CARE, V55, pE158, DOI 10.1097/MLR.0000000000000606 Schwartz AG, 2007, J CLIN ONCOL, V25, P5785, DOI 10.1200/JCO.2007.13.3975 Shintani AK, 2009, CRIT CARE MED, V37, P2939, DOI 10.1097/CCM.0b013e3181b7fbbb Shreibati JB, 2018, AM HEART J, V198, P108, DOI 10.1016/j.ahj.2017.12.016 Speth RC, 2018, AM J PHYSIOL-HEART C, V315, pH1765, DOI 10.1152/ajpheart.00041.2018 Spreeuwenberg MD, 2010, MED CARE, V48, P166, DOI 10.1097/MLR.0b013e3181c1328f Stute P, 2020, CLIMACTERIC, V23, P447, DOI 10.1080/13697137.2020.1767568 Symer MM, 2018, CLIN COLORECTAL CANC, V17, pE281, DOI 10.1016/j.clcc.2018.01.003 The Centers for Medicare & Medicaid Services, 2013, CMS Announces New Data Sharing Tool | CMS The Chronic Condition Warehouse, Chronic Conditions Data Warehouse: CCW Chronic Condition Algorithms Vehkavaara S, 2001, THROMB HAEMOSTASIS, V85, P619, DOI 10.1055/s-0037-1615643 Willems SJW, 2018, STAT METHODS MED RES, V27, P323, DOI 10.1177/0962280216628900 Wyss R, 2020, EPIDEMIOLOGY, V31, P82, DOI 10.1097/EDE.0000000000001107 NR 36 TC 32 Z9 39 U1 3 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1072-3714 EI 1530-0374 J9 MENOPAUSE JI Menopause-J. Menopause Soc.. PD MAY PY 2024 VL 31 IS 5 BP 363 EP 371 DI 10.1097/GME.0000000000002335 PG 9 WC Obstetrics & Gynecology WE Science Citation Index Expanded (SCI-EXPANDED) SC Obstetrics & Gynecology GA OP9L4 UT WOS:001208595900005 PM 38595196 OA Green Submitted, hybrid DA 2026-04-17 ER PT J AU Liao, KM Yu, CH Wu, YC Wang, JJ Liang, FW Ho, CH AF Liao, Kuang-Ming Yu, Chia-Hung Wu, Yu-Cih Wang, Jhi-Joung Liang, Fu-Wen Ho, Chung-Han TI Risk of Atrial Fibrillation in Patients with Different Cancer Types in Taiwan SO LIFE-BASEL LA English DT Article DE atrial fibrillation; cancer; competing risk; incidence rate; Taiwan Cancer Registry ID BREAST-CANCER; SMOKING; MORTALITY; THERAPY AB Atrial fibrillation (AF) commonly occurs in approximately 2% of cancer patients, and the incidence of AF among cancer patients is greater than in the general population. This observational study presented the incidence risk of AF among cancer patients, including specific cancer types, using a population database. The Taiwan Cancer Registry was used to identify cancer patients between 2008 and 2017. The diagnosis of AF was based on the International Classification of Diseases codes (ICD-9-CM: 427.31 or ICD-10-CM: I48.0, I48.1, I48.2, and I48.91) in Taiwan national health insurance research datasets. The incidence of developing AF in the cancer population was calculated as the number of new-onset AF cases per person-year of follow-up during the study period. The overall incidence of AF among cancer patients was 50.99 per 100,000 person-years. Patients aged older than 65 years and males had higher AF incidence rates. Lung cancer males and esophageal cancer females showed the highest AF incidence risk (185.02 and 150.30 per 100,000 person-years, respectively). Our findings identified esophageal, lung, and gallbladder cancers as the top three cancers associated with a higher incidence of AF. Careful monitoring and management of patients with these cancers are crucial for early detection and intervention of AF. C1 [Liao, Kuang-Ming] Chi Mei Med Ctr, Dept Internal Med, Tainan, Taiwan. [Liao, Kuang-Ming] Min Hwei Jr Coll Hlth Care Management, Dept Nursing, Tainan, Taiwan. [Yu, Chia-Hung; Wang, Jhi-Joung] Chi Mei Med Ctr, Dept Anesthesiol, Tainan, Liouying, Taiwan. [Yu, Chia-Hung] Southern Taiwan Univ Sci & Technol, Dept Comp Sci & Informat Engn, Tainan, Taiwan. [Wu, Yu-Cih; Wang, Jhi-Joung; Ho, Chung-Han] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan. [Liang, Fu-Wen] Kaohsiung Med Univ, Coll Hlth Sci, Dept Publ Hlth, Kaohsiung 807378, Taiwan. [Liang, Fu-Wen] Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung 807377, Taiwan. [Liang, Fu-Wen] Kaohsiung Med Univ, Ctr Big Data Res, Kaohsiung 807378, Taiwan. [Ho, Chung-Han] Southern Taiwan Univ Sci & Technol, Dept Informat Management, Tainan 710301, Taiwan. [Ho, Chung-Han] Taipei Med Univ, Taipei Municipal Wanfang Hosp, Canc Ctr, Taipei 116079, Taiwan. C3 Chi Mei Hospital; Chi Mei Hospital; Southern Taiwan University of Science & Technology; Chi Mei Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University RP Ho, CH (corresponding author), Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan.; Liang, FW (corresponding author), Kaohsiung Med Univ, Coll Hlth Sci, Dept Publ Hlth, Kaohsiung 807378, Taiwan.; Liang, FW (corresponding author), Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung 807377, Taiwan.; Liang, FW (corresponding author), Kaohsiung Med Univ, Ctr Big Data Res, Kaohsiung 807378, Taiwan.; Ho, CH (corresponding author), Southern Taiwan Univ Sci & Technol, Dept Informat Management, Tainan 710301, Taiwan.; Ho, CH (corresponding author), Taipei Med Univ, Taipei Municipal Wanfang Hosp, Canc Ctr, Taipei 116079, Taiwan. EM abc8870@yahoo.com.tw; dkntstar@hotmail.com; cih830927@gmail.com; 400002@mail.chimei.org.tw; fwliang@kmu.edu.tw; ho.c.hank@gmail.com RI Liao, Kuang Ming/AAF-4994-2020; Liang, Fu-Wen/ODJ-5894-2025; Yu, Chia-Hung/IXN-3202-2023 OI Liao, Kuang Ming/0000-0003-4364-8248; Yu, Chia-Hung/0000-0002-7711-5178; Ho, Chung-Han/0000-0001-5925-8477; Jhi-Joung, Wang/0000-0002-3688-6945 FU Chi Mei Medical Center [ICHSM 2023]; Kyoto, Japan FX The abstract for this paper was presented at a 2023 6th International Conference on Healthcare Service Management (ICHSM 2023), Kyoto, Japan. We are also grateful to the Health Data Science Center, National Cheng Kung University Hospital, for providing administrative and technical support. CR Aliot E, 2014, EUROPACE, V16, P787, DOI 10.1093/europace/eut369 Ay C, 2023, RES PRACT THROMB HAE, V7, DOI 10.1016/j.rpth.2022.100026 Carlisle MA, 2019, JACC-HEART FAIL, V7, P447, DOI 10.1016/j.jchf.2019.03.005 Chang CH, 2014, ATHEROSCLEROSIS, V232, P224, DOI 10.1016/j.atherosclerosis.2013.11.036 Chang YT, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168776 Chao TF, 2014, CAN J CARDIOL, V30, P1190, DOI 10.1016/j.cjca.2014.05.009 Chen QG, 2024, EUR HEART J, V45, P2201, DOI 10.1093/eurheartj/ehae222 Chiang CJ, 2019, J FORMOS MED ASSOC, V118, P856, DOI 10.1016/j.jfma.2019.01.012 Chiang CJ, 2015, JPN J CLIN ONCOL, V45, P291, DOI 10.1093/jjco/hyu211 Chu G, 2019, BLOOD REV, V35, P59, DOI 10.1016/j.blre.2019.03.005 Conen D, 2016, JAMA CARDIOL, V1, P389, DOI 10.1001/jamacardio.2016.0280 D'Souza M, 2019, HEART RHYTHM, V16, P343, DOI 10.1016/j.hrthm.2018.10.017 Erichsen R, 2012, INTERN EMERG MED, V7, P431, DOI 10.1007/s11739-011-0701-9 Farmakis D, 2014, J AM COLL CARDIOL, V63, P945, DOI 10.1016/j.jacc.2013.11.026 Giannopoulos G, 2022, DIAGNOSTICS, V12, DOI 10.3390/diagnostics12020479 Guha A, 2022, EUR HEART J, V43, P300, DOI 10.1093/eurheartj/ehab745 Guzzetti S, 2008, INTERN EMERG MED, V3, P227, DOI 10.1007/s11739-008-0124-4 Hajjar LA, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.590768 Hindricks Gerhard, 2021, Eur Heart J, V42, P373, DOI 10.1093/eurheartj/ehaa612 Hsieh CY, 2019, CLIN EPIDEMIOL, V11, P349, DOI 10.2147/CLEP.S196293 Hu YF, 2015, NAT REV CARDIOL, V12, P230, DOI 10.1038/nrcardio.2015.2 Huang JJ, 2021, CANCERS, V13, DOI 10.3390/cancers13010141 Jakobsen CB, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6314-9 Jeong SM, 2021, EUR HEART J, V42, P4141, DOI 10.1093/eurheartj/ehab578 Lee CH, 2005, INT J CANCER, V113, P475, DOI 10.1002/ijc.20619 Li YM, 2022, JACC-CARDIOONCOL, V4, P287, DOI 10.1016/j.jaccao.2022.08.002 Lin LJ, 2008, CLIN THER, V30, P1726, DOI 10.1016/j.clinthera.2008.09.010 Lippi G, 2021, INT J STROKE, V16, P217, DOI 10.1177/1747493019897870 López-Fernández T, 2019, REV ESP CARDIOL, V72, P749, DOI 10.1016/j.rec.2019.03.019 Menichelli D, 2021, PROG CARDIOVASC DIS, V66, P28, DOI 10.1016/j.pcad.2021.04.004 O'Neal WT, 2015, AM J CARDIOL, V115, P1090, DOI 10.1016/j.amjcard.2015.01.540 Ording AG, 2017, CANCER MED-US, V6, P1165, DOI 10.1002/cam4.1054 Ostenfeld EB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102861 Prabhu A, 2014, AM J GASTROENTEROL, V109, P821, DOI 10.1038/ajg.2014.71 Thrall G, 2006, AM J MED, V119, DOI 10.1016/jamjmed.2005.10.057 Tsai MC, 2022, CANCERS, V14, DOI 10.3390/cancers14235844 Tsai YW, 2008, J WOMENS HEALTH, V17, P971, DOI 10.1089/jwh.2007.0621 Vedovati MC, 2018, INT J CARDIOL, V269, P152, DOI 10.1016/j.ijcard.2018.07.138 Wang LJ, 2022, NUTRIENTS, V14, DOI 10.3390/nu14142957 Yuan M, 2019, CARDIOL RES PRACT, V2019, DOI 10.1155/2019/8985273 Yun JP, 2021, JACC-CARDIOONCOL, V3, P221, DOI 10.1016/j.jaccao.2021.03.006 Khan MZ, 2021, J ARRYTHM, V37, P1205, DOI 10.1002/joa3.12589 NR 42 TC 6 Z9 6 U1 0 U2 6 PU MDPI PI BASEL PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND EI 2075-1729 J9 LIFE-BASEL JI Life-Basel PD MAY PY 2024 VL 14 IS 5 AR 621 DI 10.3390/life14050621 PG 13 WC Biology; Microbiology WE Science Citation Index Expanded (SCI-EXPANDED) SC Life Sciences & Biomedicine - Other Topics; Microbiology GA SB8R6 UT WOS:001232095800001 PM 38792641 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Findik, G Çetin, M Nomenoglu, H Türk, I Acemoglu, S Solak, N Can, MA AF Findik, Gokturk Cetin, Mehmet Nomenoglu, Hakan Turk, Ilteris Acemoglu, Serdar Solak, Necati Can, Mehmet Ali TI A new technique for closure of pericardial defects: pericardial rug weave SO BMC SURGERY LA English DT Article DE Complication; Herniation; Intrapericardial; Pericardial mesh; Pneumonectomy ID CARDIAC HERNIATION; PNEUMONECTOMY AB Background Pericardial defect that occurs after intrapericardial pneumonectomy can cause many fatal complications, and closing the defect with mesh is a widely used surgical method to prevent these complications.Methods Data of patients who underwent intrapericardial pneumonectomy and pericardial resection in our clinic between October 2010 and June 2022 were retrospectively reviewed. Patients were divided into two groups, those who had prolene mesh used to close the pericardial defect and those who underwent the "Rug Weave" technique we proposed as an alternative, and the results were compared.Results The study included 23 patients, one of whom was female. All patients underwent surgery due to malignancy. The vast majority of the patients had a diagnosis of squamous cell lung carcinoma (86.9%). Atrium was added to three patients and rib resection was added to one patient during intrapericardial pneumonectomy and pericardial resection. There was no significant difference between the two groups in terms of average age, gender, and length of hospital stay. There was no significant difference between the two groups in terms of complications, including atrial fibrillation, which is commonly seen in these patients (p = 0.795). The Rug Weave group had an average defect width of 23.96 cm2 and was found to be advantageous in terms of overall survival compared to the mesh group (p = 0.017).Conclusions The "Rug Weave" technique we proposed for closing pericardial defects after pneumonectomy can be used as a cheaper method safely and effectively that reduces complications as much as the traditional method of using mesh. C1 [Findik, Gokturk; Nomenoglu, Hakan; Turk, Ilteris; Acemoglu, Serdar] Ataturk Sanatoryum Training & Res Hosp, Dept Thorac Surg, Ankara, Turkiye. [Cetin, Mehmet] Omer Halisdemir Univ Training & Res Hosp, Dept Thorac Surg, Nigde, Turkiye. [Solak, Necati] Sincan State Hosp, Dept Thorac Surg, Ankara, Turkiye. [Can, Mehmet Ali] Ataturk Sanatoryum Training & Res Hosp, Dept Radiol, Ankara, Turkiye. C3 Nigde Omer Halisdemir University; Dr. Nafiz Korez Sincan State Hospital RP Çetin, M (corresponding author), Omer Halisdemir Univ Training & Res Hosp, Dept Thorac Surg, Nigde, Turkiye. RI findik, gokturk/R-6908-2016; NOMENOĞLU, HAKAN/AAG-9855-2021; Türk, İlteriş/KIB-4780-2024; ÇETİN, MEHMET/KHZ-0260-2024 OI findik, gokturk/0000-0002-8861-7608; NOMENOĞLU, HAKAN/0000-0003-4169-4638; Türk, İlteriş/0000-0001-6385-4722; ÇETİN, MEHMET/0000-0001-5471-2239; acemoğlu, serdar/0000-0001-9915-9158; Solak, Necati/0000-0003-1046-5410 CR Alimi Faouzi, 2016, Asian Cardiovasc Thorac Ann, V24, P590, DOI [10.1177/0218492315589199, 10.1177/0218492315589199] BETTMAN RB, 1948, ANN SURG, V128, P1012, DOI 10.1097/00000658-194811000-00021 Chambers N, 2005, ANAESTH INTENS CARE, V33, P403, DOI 10.1177/0310057X0503300319 Fukui M, 2019, GEN THORAC CARDIOVAS, V67, P644, DOI 10.1007/s11748-018-1008-9 Gadhinglajkar S, 2010, ANN CARD ANAESTH, V13, P249, DOI 10.4103/0971-9784.69045 He GX, 2021, J CARDIOTHORAC SURG, V16, DOI 10.1186/s13019-021-01439-5 Kawamukai K, 2011, INTERACT CARDIOV TH, V12, P73, DOI 10.1510/icvts.2010.245282 Kobayashi K, 2022, J CARDIAC SURG, V37, P2429, DOI 10.1111/jocs.16585 Lan YP, 2020, THORAC CANCER, V11, P797, DOI 10.1111/1759-7714.13355 Mehanna MJ, 2007, J THORAC IMAG, V22, P280, DOI 10.1097/RTI.0b013e31803bb451 Nishizawa N, 2020, J SURG CASE REP, DOI 10.1093/jscr/rjaa011 Veronesi G, 2001, EUR J CARDIO-THORAC, V19, P89, DOI 10.1016/S1010-7940(00)00612-6 Zhao YJ, 2017, J CARDIOTHOR VASC AN, V31, P270, DOI 10.1053/j.jvca.2016.04.008 NR 13 TC 1 Z9 1 U1 1 U2 3 PU BMC PI LONDON PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND EI 1471-2482 J9 BMC SURG JI BMC Surg. PD APR 13 PY 2024 VL 24 IS 1 AR 106 DI 10.1186/s12893-024-02368-5 PG 6 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA NO8X1 UT WOS:001201495300005 PM 38614997 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Zhang, GD Liang, TY Li, YL Liang, KC Gong, ZX Guo, W Zhang, ZN Ju, RH AF Zhang, Guodong Liang, Tingyu Li, Yanlin Liang, Kaichao Gong, Zhaoxuan Guo, Wei Zhang, Zhuoning Ju, Ronghui TI Segmentation of the left atrium and proximal pulmonary veins based on dimensional decomposition attention SO INTERNATIONAL JOURNAL OF IMAGING SYSTEMS AND TECHNOLOGY LA English DT Article DE attention mechanism; dimensional decomposition; left atrium and proximal pulmonary vein segmentation; medical imaging ID CONVOLUTIONAL NEURAL-NETWORK; FUSION; NET AB Pulmonary vein anatomical structure typing plays a crucial role in the preoperative assessment and postoperative evaluation of lung tumor resection, atrial fibrillation radio frequency ablation, and other medical procedures. The accuracy of such typing relies heavily on the segmentation results of the left atrium and proximal pulmonary veins. However, due to the similarities in intensity between the left atrium, proximal pulmonary veins, and adjacent tissues in CT images, segmentation errors often occur, leading to subsequent inaccuracies in pulmonary vein classification. To address this issue, we propose an attention module called Dimensional Decomposition Attention (DDA), which combines Dimensional Decomposition Spatial Attention (DDSA) and Dimensional Decomposition Channel Attention (DDCA). DDA effectively leverages the spatial and channel information of 3D images to enhance the segmentation accuracy of the left atrium and proximal pulmonary veins. In DDSA, the input features are decomposed into three one-dimensional directional features (height, width, and depth) and fused to generate weights that emphasize spatial shape features and focus on the region of interest. On the other hand, DDCA encodes the input features into dimensional channel features, fuses them with one-dimensional directional features, and utilizes position encoding to reinforce the channel features and prioritize channels with relevant information. The performance of DDA was evaluated using a two-stage experimental approach on datasets provided by The People's Hospital of Liaoning Province and the MM-WHS CT dataset, yielding average Dice values of 93.93% and 90.80%, respectively, demonstrating the effectiveness of DDA. C1 [Zhang, Guodong; Liang, Tingyu; Li, Yanlin; Liang, Kaichao; Gong, Zhaoxuan; Guo, Wei] Shenyang Aerosp Univ, Coll Comp Sci, Shenyang, Peoples R China. [Zhang, Zhuoning] Luyuan Hydropower Co Maintenance Co, Dandong, Peoples R China. [Ju, Ronghui] Peoples Hosp Liaoning Prov, Dept Radiol, Shenyang 110016, Peoples R China. C3 Shenyang Aerospace University RP Ju, RH (corresponding author), Peoples Hosp Liaoning Prov, Dept Radiol, Shenyang 110016, Peoples R China. EM sau_rjh@163.com OI Zhang, Guodong/0000-0002-1023-6805; Ju, Ronghui/0009-0008-2284-6812; , Guodong Zhang/0009-0006-2570-484X; guo, wei/0009-0003-9993-454X; Gong, Zhaoxuan/0009-0005-1092-3241; , Zhaoxuan Gong/0009-0007-2441-2746; Guo, Wei/0009-0007-3822-3399; Liang, Tingyu/0009-0004-6079-6968 FU National Natural Science Foundation of China; Project of Liaoning Province Education Department [LJKMZ20220523]; Aeronautical Science Foundation of China [2019ZE054009]; [61971118]; [61373088]; [61402298] FX This work was supported in part by National Natural Science Foundation of China (No. 61971118, No. 61373088, No. 61402298), Project of Liaoning Province Education Department (No. LJKMZ20220523) and Aeronautical Science Foundation of China (2019ZE054009). CR Caizi Li, 2019, Statistical Atlases and Computational Models of the Heart. Atrial Segmentation and LV Quantification Challenges. 9th International Workshop, STACOM 2018. Held in Conjunction with MICCAI 2018. Revised Selected Papers: Lecture Notes in Computer Science (LNCS 11395), P255, DOI 10.1007/978-3-030-12029-0_28 Cao Y, 2019, IEEE ICC Cardoso M J., 2022, arXiv, DOI DOI 10.48550/ARXIV.2211.02701 Cheng Bian, 2019, Statistical Atlases and Computational Models of the Heart. Atrial Segmentation and LV Quantification Challenges. 9th International Workshop, STACOM 2018. Held in Conjunction with MICCAI 2018. Revised Selected Papers: Lecture Notes in Computer Science (LNCS 11395), P237, DOI 10.1007/978-3-030-12029-0_26 Fu J, 2019, PROC CVPR IEEE, P3141, DOI 10.1109/CVPR.2019.00326 Ghosh S, 2020, I S BIOMED IMAGING, P1756, DOI [10.1109/ISBI45749.2020.9098646, 10.1109/isbi45749.2020.9098646] Gu R, 2021, IEEE T MED IMAGING, V40, P699, DOI 10.1109/TMI.2020.3035253 He Z., 2001, J Pract Radiol, V24, P896 Hou QB, 2021, PROC CVPR IEEE, P13708, DOI 10.1109/CVPR46437.2021.01350 Hu J., 2018, P 2018 IEEECVF C COM, P7132, DOI [10.1109/CVPR.2018.00745, DOI 10.1109/CVPR.2018.00745] Huang G, 2017, PROC CVPR IEEE, P2261, DOI 10.1109/CVPR.2017.243 International Agency for Research on Cancer, 2020, Latest Global Cancer Data: Cancer Burden Rises to 19.3 Million New Cases and 10.0 Million Cancer Deaths in 2020 Kausar A, 2023, MULTIMEDIA SYST, V29, P1739, DOI [10.1080/14328917.2021.1934281, 10.1007/s00530-021-00776-8, 10.1080/14328917.2021.1934281] Khened M Kollerathu VA Krishnamurthi G, Med Image Ana, V51, P21 Li Feiyan, 2023, Left Atrial and Scar Quantification and Segmentation: First Challenge, LAScarQS 2022, Held in Conjunction with MICCAI 2022, Proceedings. Lecture Notes in Computer Science (13586), P124, DOI 10.1007/978-3-031-31778-1_12 Litjens G, 2017, MED IMAGE ANAL, V42, P60, DOI 10.1016/j.media.2017.07.005 Liu XL, 2022, APPL SCI-BASEL, V12, DOI 10.3390/app12083764 Liu YC, 2021, Arxiv, DOI [arXiv:2111.12419, 10.48550/arXiv.2111.12419, DOI 10.48550/ARXIV.2111.12419] Liu Yichao., 2021, arXiv, DOI DOI 10.48550/ARXIV.2112.05561 Long J, 2015, PROC CVPR IEEE, P3431, DOI 10.1109/CVPR.2015.7298965 Lourenco Ana, 2021, Statistical Atlases and Computational Models of the Heart. M&Ms and EMIDEC Challenges 11th International Workshop (STACOM 2020). Held in Conjunction with MICCAI 2020. Revised Selected Papers. Lecture Notes in Computer Science (LNCS 12592), P137, DOI 10.1007/978-3-030-68107-4_14 Luo GN, 2018, IEEE T BIO-MED ENG, V65, P1924, DOI 10.1109/TBME.2017.2762762 Luo XZ, 2023, IEEE T PATTERN ANAL, V45, P9206, DOI 10.1109/TPAMI.2022.3225418 Masci J, 2011, LECT NOTES COMPUT SC, V6791, P52, DOI 10.1007/978-3-642-21735-7_7 Mortazi A, 2018, LECT NOTES COMPUT SC, V10663, P199, DOI 10.1007/978-3-319-75541-0_21 Of Radiologists C. A, 2020, Zhonghua Xin Xue Guan Bing Za Zhi, V48, P906 Payer C Stern D Bischof H Urschler M, Multi-label Whole Heart Segmentation Using CNNs and Anatomical Label Configurations, DOI [10.1007/978-3-319-75541-0_20, DOI 10.1007/978-3-319-75541-0_20] Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28 Savioli N., 2018, 2018 INT WORKSH STAT Techasith T, 2011, JACC-CARDIOVASC IMAG, V4, P905, DOI 10.1016/j.jcmg.2011.04.017 TSOTSOS JK, 1990, BEHAV BRAIN SCI, V13, P423, DOI 10.1017/S0140525X00079577 Tsotsos JK., 2021, A Computational Perspective on Visual Attention Vaswani A, 2017, ADV NEUR IN, V30, DOI 10.1007/s11356-023-31437-0 Vesal Sulaiman, 2019, Statistical Atlases and Computational Models of the Heart. Atrial Segmentation and LV Quantification Challenges. 9th International Workshop, STACOM 2018. Held in Conjunction with MICCAI 2018. Revised Selected Papers: Lecture Notes in Computer Science (LNCS 11395), P319, DOI 10.1007/978-3-030-12029-0_35 Wang F, 2017, PROC CVPR IEEE, P6450, DOI 10.1109/CVPR.2017.683 Wang S, 2023, BIOMED SIGNAL PROCES, V85, DOI 10.1016/j.bspc.2023.104946 Wang SH, 2018, J REAL-TIME IMAGE PR, V15, P631, DOI 10.1007/s11554-017-0717-0 Wang XL, 2018, PROC CVPR IEEE, P7794, DOI 10.1109/CVPR.2018.00813 Woo SH, 2018, LECT NOTES COMPUT SC, V11211, P3, DOI 10.1007/978-3-030-01234-2_1 Xiong ZH, 2019, IEEE T MED IMAGING, V38, P515, DOI 10.1109/TMI.2018.2866845 Yang G, 2020, FUTURE GENER COMP SY, V107, P215, DOI 10.1016/j.future.2020.02.005 Yushkevich PA, 2006, NEUROIMAGE, V31, P1116, DOI 10.1016/j.neuroimage.2006.01.015 Zhang YD, 2020, INFORM FUSION, V64, P149, DOI 10.1016/j.inffus.2020.07.006 Zhang YD, 2018, J COMPUT SCI-NETH, V27, P57, DOI 10.1016/j.jocs.2018.05.005 Zhuang XH, 2019, IEEE T PATTERN ANAL, V41, P2933, DOI 10.1109/TPAMI.2018.2869576 Zhuang XH, 2016, MED IMAGE ANAL, V31, P77, DOI 10.1016/j.media.2016.02.006 NR 46 TC 1 Z9 1 U1 1 U2 10 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0899-9457 EI 1098-1098 J9 INT J IMAG SYST TECH JI Int. J. Imaging Syst. Technol. PD APR 2 PY 2024 VL 34 IS 3 AR e23075 DI 10.1002/ima.23075 PG 16 WC Engineering, Electrical & Electronic; Optics; Imaging Science & Photographic Technology WE Science Citation Index Expanded (SCI-EXPANDED) SC Engineering; Optics; Imaging Science & Photographic Technology GA MQ6S6 UT WOS:001195139200001 OA Bronze DA 2026-04-17 ER PT J AU Kwon, J Kim, BH AF Kwon, Jeanny Kim, Byoung Hyuck TI Risk of clinically significant cardiovascular disease associated with postoperative radiotherapy in non-small cell lung cancer patients receiving surgical resection followed by adjuvant chemotherapy: A Korean nationwide cohort study SO RADIOTHERAPY AND ONCOLOGY LA English DT Article DE Cardiovascular disease; Postoperative radiotherapy; Non -small cell lung cancer ID IMPACT AB Background: There are no large-scale datasets that analyze the relationship between postoperative radiotherapy (PORT) and various cardiovascular diseases (CVDs) in patients with locally advanced non-small cell lung cancer (NSCLC). Therefore, we aimed to investigate the incidences of CVDs with PORT using a national populationbased database. Methods: Patients diagnosed with NSCLC who underwent curative surgery followed by adjuvant chemotherapy were included from 2007 to 2017. Patients with a prior diagnosis of heart failure (HF), atrial fibrillation (AFib), or heart surgery were excluded. A total of 11,141 patients were included in the final analysis. PORT was used in 1334 patients. Most patients received lobectomy with mediastinal lymph node dissection. Results: Major adverse cardiac events mostly occurred within 3-4 years from the diagnosis. After the median follow-up duration of 70.6 months, HF was the most diagnosed disease (5.3 %), followed by AFib (4.5 %), stroke (4.1 %), and pulmonary embolism (3.5 %). All the incidences of clinically significant CVDs did not differ by PORT. This result remained unchanged after the propensity score matching comparison. Age >= 65, underlying hypertension, and history of ischemic heart disease were the most related factors to the occurrence of HF and AFib. No significant difference in CVD-free survivals according to PORT status was observed. When stratified by proposed scoring, there were no subgroups showed increased incidence by PORT. Conclusions: These results suggest that PORT had no significant impact on various CVD occurrences in NSCLC patients without underlying heart disease. C1 [Kwon, Jeanny] Chungnam Natl Univ, Dept Radiat Oncol, Sch Med, Munhwa Ro 282, Daejeon 35015, South Korea. [Kim, Byoung Hyuck] Seoul Natl Univ, SMG SNU Boramae Med Ctr, Dept Radiat Oncol, Coll Med, 20,Boramae Ro 5-gil, Seoul 07061, South Korea. C3 Chungnam National University; Seoul National University (SNU); Seoul National University Hospital RP Kim, BH (corresponding author), Seoul Natl Univ, SMG SNU Boramae Med Ctr, Dept Radiat Oncol, Coll Med, 20,Boramae Ro 5-gil, Seoul 07061, South Korea. EM karlly71@snu.ac.kr RI KIM, BYOUNG HYUCK/IRZ-5874-2023 FU Chungnam National University Hospital [2022-CF-031] FX This research was supported by Chungnam National University Hospital (#2022-CF-031) to Jeanny Kwon. CR Bogart JA, 2005, CLIN CANCER RES, V11, p5004S, DOI 10.1158/1078-0432.CCR-05-9010 Bosco E, 2021, BMC MED RES METHODOL, V21, DOI 10.1186/s12874-021-01440-5 Choi EK, 2020, KOREAN CIRC J, V50, P754 Corso CD, 2015, J THORAC ONCOL, V10, P148, DOI 10.1097/JTO.0000000000000406 Hui ZG, 2021, JAMA ONCOL, V7, P1178, DOI 10.1001/jamaoncol.2021.1910 Jeong H, 2023, RHEUMATOL INT, V43, P265, DOI 10.1007/s00296-022-05222-0 Kepka L, 2011, RADIOTHER ONCOL, V98, P238, DOI 10.1016/j.radonc.2010.09.020 Kim BH, 2023, RADIAT ONCOL J, V41, P144, DOI 10.3857/roj.2023.00430 Kim HC, 2021, GLOB HLTH MED-JPN, V3, P134, DOI 10.35772/ghm.2021.01008 Kim JA, 2017, J KOREAN MED SCI, V32, P718, DOI 10.3346/jkms.2017.32.5.718 Kim KH, 2022, JAMA ONCOL, V8, P1624, DOI 10.1001/jamaoncol.2022.4202 Kim S, 2020, KOREAN J FAM MED, V41, P146, DOI 10.4082/kjfm.20.0062 Le Pechoux C, 2022, LANCET ONCOL, V23, P104, DOI 10.1016/S1470-2045(21)00606-9 Lee SH, 2023, INT J RADIAT ONCOL, V117, P1270, DOI 10.1016/j.ijrobp.2023.06.009 Lee YG, 2014, THROMB HAEMOSTASIS, V111, P1112, DOI 10.1160/TH13-11-0956 Ma ZL, 2023, ADV RADIAT ONCOL, V8, DOI 10.1016/j.adro.2023.101213 Park CS, 2018, INT J EPIDEMIOL, V47, P289, DOI 10.1093/ije/dyx175 Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83 Tian CM, 2023, ONCOL LETT, V25, DOI 10.3892/ol.2023.13791 Walls GM, 2024, CLIN ONCOL-UK, V36, P119, DOI 10.1016/j.clon.2023.11.029 Wang L, 2023, THER ADV CHRONIC DIS, V14, DOI 10.1177/20406223231195622 Wang X, 2021, RADIAT ONCOL, V16, DOI 10.1186/s13014-021-01912-4 Yang PS, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84256-z NR 23 TC 3 Z9 3 U1 2 U2 7 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-8140 EI 1879-0887 J9 RADIOTHER ONCOL JI Radiother. Oncol. PD JUN PY 2024 VL 195 AR 110241 DI 10.1016/j.radonc.2024.110241 EA MAR 2024 PG 8 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA QY0Z8 UT WOS:001224324400001 PM 38522599 DA 2026-04-17 ER PT J AU Cheong, MA Leader, A AF Cheong, May Anne Leader, Avi TI Cancer and arterial thrombosis: therapeutic options SO RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS LA English DT Article DE acute coronary syndrome; atrial fibrillation; neoplasms; stroke; thromboembolism; thrombosis ID ACUTE MYOCARDIAL-INFARCTION; ACUTE ISCHEMIC-STROKE; RISK-FACTORS; MYELOPROLIFERATIVE NEOPLASMS; ATRIAL-FIBRILLATION; EMBOLIC STROKE; TISSUE FACTOR; THROMBOEMBOLISM; EVENTS; DISEASE AB A State of the Art lecture titled "Cancer and Arterial Thrombosis: Therapeutic Options " was presented at the International Society on Thrombosis and Haemostasis Congress in 2023. This State of the Art review delves into the complex relationship between cancer and arterial thromboembolism (ATE), encompassing acute coronary syndrome, ischemic strokes, and peripheral arterial disease. The burden of cancer-associated ATE is not well de fined, but studies indicate elevated risks, particularly in the 6 months after a cancer diagnosis. Incidence varies among cancer subtypes, with lung cancer displaying the highest rates. Additionally, the pathophysiology of cancer-associated ATE involves a multifaceted interplay of cancerinduced hypercoagulopathy, cancer therapy -related thrombosis, and personal risk factor contributors. ATEs are clinically heterogeneous and in the context of cancer have particular mechanistic differences compared with ATE patients without cancer. This requires modi fica- tions in approach and tailored management considerations. Speci fic etiologies contributing to ATE, such as coronary vasospasm and non -bacterial-thrombotic endocarditis, need to be considered. The diagnosis of cancer alone usually does not contraindicate patients to standard guideline-based therapies for the management of ATE, although nuances in treatment may need to be considered in light of the underlying cancer. Atrial fibrillation in cancer patients further complicates the thrombotic landscape. Cancer patients with atrial fibrillation are at a higher risk of ATE, necessitating careful consideration of anticoagulation therapy as clinical bene fits and bleeding risks need to be weighed. ATE may also be a presenting sign of underlying malignancy, which requires increased awareness and focused clinical evaluation for cancer in selected cases. Finally, we summarize relevant new data on this topic presented during the 2023 International Society on Thrombosis and Haemostasis Congress. C1 [Cheong, May Anne] Singapore Gen Hosp, Dept Haematol, Singapore, Singapore. [Leader, Avi] Mem Sloan Kettering Canc Ctr, Dept Med, Hematol Serv, New York, NY 10065 USA. C3 Singapore General Hospital; Memorial Sloan Kettering Cancer Center RP Leader, A (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Hematol Serv, New York, NY 10065 USA. EM leadera@mskcc.org RI ; Leader, Avi/AEQ-0513-2022 OI Cheong, May Anne/0000-0002-1333-6596; FU NCI NIH HHS [P30 CA008748] Funding Source: Medline CR Abbott JD, 2007, AM J CARDIOL, V100, P190, DOI 10.1016/j.amjcard.2007.02.083 Aboyans V, 2018, EUR HEART J, V39, P763, DOI 10.1093/eurheartj/ehx095 Aggarwal Saurabh, 2013, Ther Adv Cardiovasc Dis, V7, P87, DOI 10.1177/1753944712474332 Al-Samkari H, 2020, J THORAC ONCOL, V15, P1497, DOI 10.1016/j.jtho.2020.04.033 Alexandre J, 2023, JACC-CARDIOONCOL, V5, P216, DOI 10.1016/j.jaccao.2022.11.019 Alexandre J, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.018403 Balanescu DV, 2020, INT J CARDIOL, V313, P1, DOI [10.36106/ijar/7206503, 10.1016/j.ijcard.2020.04.050] Bannow BTS, 2018, J THROMB HAEMOST, V16, P1246, DOI 10.1111/jth.14015 Barbui T, 2013, BLOOD, V122, P2176, DOI 10.1182/blood-2013-03-460154 Batra A, 2021, OPEN HEART, V8, DOI 10.1136/openhrt-2021-001849 Ben Zadok OI, 2022, THROMB RES, V213, pS127, DOI 10.1016/j.thromres.2021.11.024 Bianco M, 2020, INT J CARDIOL, V301, P200, DOI 10.1016/j.ijcard.2019.11.132 Brenner B, 2018, AM J MED, V131, P1095, DOI 10.1016/j.amjmed.2018.04.037 Buijs JT, 2020, THROMB RES, V191, pS43, DOI 10.1016/S0049-3848(20)30396-0 Bungo B, 2022, IJC HEART VASC, V41, DOI 10.1016/j.ijcha.2022.101072 Cappellari M, 2013, J NEUROL SCI, V325, P100, DOI 10.1016/j.jns.2012.12.008 Casini A, 2013, J THROMB HAEMOST, V11, P1215, DOI 10.1111/jth.12265 Casini A, 2021, BLOOD, V138, P2021, DOI 10.1182/blood.2020010116 Cedervall J, 2023, Res Pract Thromb Haemost, V7 Cestari DM, 2004, NEUROLOGY, V62, P2025, DOI 10.1212/01.WNL.0000129912.56486.2B Chen PC, 2011, STROKE, V42, P3034, DOI 10.1161/STROKEAHA.111.615534 Chen Q, 2023, Res Pract Thromb Haemost, P7 Costamagna G, 2023, NEUROLOGY, V100, pE2477, DOI 10.1212/WNL.0000000000207341 ctep.cancer, 2009, Common terminology criteria for adverse events (CTCAE) Diener HC, 2019, NEW ENGL J MED, V380, P1906, DOI 10.1056/NEJMoa1813959 Falanga A, 2022, HEMASPHERE, V6, DOI 10.1097/HS9.0000000000000750 Falanga A, 2015, SEMIN THROMB HEMOST, V41, P756, DOI 10.1055/s-0035-1564040 Feldman S, 2023, JACC-CARDIOONCOL, V5, P246, DOI 10.1016/j.jaccao.2023.01.009 Ganatra S, 2017, JACC-CARDIOVASC INTE, V10, P2334, DOI 10.1016/j.jcin.2017.06.068 Grilz E, 2019, J THROMB HAEMOST, V17, P1335, DOI 10.1111/jth.14484 Grilz E, 2018, HAEMATOLOGICA, V103, P1549, DOI 10.3324/haematol.2018.192419 Gross CM, 2008, J AM COLL CARDIOL, V51, P1232, DOI 10.1016/j.jacc.2007.11.061 Grover SP, 2021, ARTERIOSCL THROM VAS, V41, P1291, DOI 10.1161/ATVBAHA.120.314378 Grover SP, 2018, ARTERIOSCL THROM VAS, V38, P709, DOI 10.1161/ATVBAHA.117.309846 Habib G, 2015, EUR HEART J, V36, P3075, DOI [10.5603/KP.2015.0227, 10.1093/eurheartj/ehv319] Harloff A, 2018, NEW ENGL J MED, V379, P986, DOI 10.1056/NEJMc1809065 Hart RG, 2014, LANCET NEUROL, V13, P429, DOI 10.1016/S1474-4422(13)70310-7 Haugnes HS, 2010, J CLIN ONCOL, V28, P4649, DOI 10.1200/JCO.2010.29.9362 Howard DPJ, 2015, CIRCULATION, V132, P1805, DOI 10.1161/CIRCULATIONAHA.115.016424 Iliescu CA, 2016, CATHETER CARDIO INTE, V87, pE202, DOI 10.1002/ccd.26379 Jung S, 2018, INTERV NEURORADIOL, V24, DOI 10.1177/1591019918776207 Kahn SR, 2023, RES PRACT THROMB HAE, V7, DOI 10.1016/j.rpth.2023.100193 Khorana AA, 2006, J CLIN ONCOL, V24, P484, DOI 10.1200/JCO.2005.03.8877 Khorana AA, 2003, J THROMB HAEMOST, V1, P2463, DOI 10.1111/j.1538-7836.2003.00501.x Khorana AA, 2008, BLOOD, V111, P4902, DOI 10.1182/blood-2007-10-116327 Kleindorfer DO, 2021, STROKE, V52, pE364, DOI 10.1161/STR.0000000000000375 Lanza GA, 2011, CIRCULATION, V124, P1774, DOI 10.1161/CIRCULATIONAHA.111.037283 Laridan E, 2019, SEMIN THROMB HEMOST, V45, P86, DOI 10.1055/s-0038-1677040 Larsen T, 2023, Res Pract Thromb Haemost, V7 Larsen TL, 2023, THROMB RES, V228, P128, DOI 10.1016/j.thromres.2023.05.017 Latifi Y, 2019, BLOOD, V133, P1597, DOI 10.1182/blood-2018-10-881557 Leader A, 2023, JACC-CARDIOONCOL, V5, DOI 10.1016/j.jaccao.2022.08.014 Leader A, 2022, J THROMB HAEMOST, V20, P635, DOI 10.1111/jth.15600 Leiva O, 2021, JACC-CARDIOONCOL, V3, P619, DOI 10.1016/j.jaccao.2021.08.011 Lipton JH, 2016, LANCET ONCOL, V17, P612, DOI 10.1016/S1470-2045(16)00080-2 Lyon AR, 2022, EUR HEART J, V43, P4229, DOI 10.1093/eurheartj/ehac244 Malmborg M, 2018, BMC CARDIOVASC DISOR, V18, DOI 10.1186/s12872-018-0932-z Martinez-Majander N, 2020, EUR J NEUROL, V27, P841, DOI 10.1111/ene.14172 Massberg S, 2010, NAT MED, V16, P887, DOI 10.1038/nm.2184 Merkulova A, 2019, BLOOD ADV, V3, P2312, DOI 10.1182/bloodadvances.2019000034 Moschonas IC, 2019, ATHEROSCLEROSIS, V288, P9, DOI 10.1016/j.atherosclerosis.2019.06.919 Mulder FI, 2021, JACC-CARDIOONCOL, V3, P205, DOI 10.1016/j.jaccao.2021.02.007 Murphy ES, 2015, J NEURO-ONCOL, V122, P421, DOI 10.1007/s11060-015-1732-2 Navi BB, 2021, ANN NEUROL, V90, P159, DOI 10.1002/ana.26129 Navi BB, 2021, STROKE, V52, P1121, DOI 10.1161/STROKEAHA.120.032002 Navi BB, 2019, BLOOD, V133, P781, DOI 10.1182/blood-2018-06-860874 Navi BB, 2017, J AM COLL CARDIOL, V70, P927, DOI 10.1016/j.jacc.2017.06.047 Navi BB, 2014, NEUROLOGY, V83, P26, DOI 10.1212/WNL.0000000000000539 Nikolovski S, 2023, Res Pract Thromb Haemost, V7 Nopp S, 2023, Res Pract Thromb Haemost, P7 Noumegni SR, 2022, THROMB RES, V214, P93, DOI 10.1016/j.thromres.2022.04.016 Ntaios G, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.012858 Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191 Polk A, 2014, BMC PHARMACOL TOXICO, V15, DOI 10.1186/2050-6511-15-47 Potts JE, 2019, EUR HEART J, V40, P1790, DOI 10.1093/eurheartj/ehy769 Quartermaine C, 2023, JACC-CARDIOONCOL, V5, P570, DOI 10.1016/j.jaccao.2023.09.002 Rak J, 2006, SEMIN THROMB HEMOST, V32, P54, DOI 10.1055/s-2006-933341 Raposeiras-Roubin S, 2022, AM J CARDIOL, V180, P44, DOI 10.1016/j.amjcard.2022.06.044 Reeves DJ, 2022, CURR OPIN CARDIOL, V37, P372, DOI 10.1097/HCO.0000000000000969 Sanossian N, 2013, J STROKE CEREBROVASC, V22, P1146, DOI 10.1016/j.jstrokecerebrovasdis.2012.11.016 Seok JM, 2010, ANN NEUROL, V68, P213, DOI 10.1002/ana.22050 Setiawan B., 2023, Res Pract Thromb Haemost., V7 Siegal DM, 2020, BLOOD ADV, V4, P6259, DOI 10.1182/bloodadvances.2020003269 Sobolewski P, 2015, INT J CLIN PRACT, V69, P666, DOI 10.1111/ijcp.12586 Sundboll J, 2018, CIRCULATION, V138, P669, DOI 10.1161/CIRCULATIONAHA.117.032617 Tawil N, 2023, Res Pract Thromb Haemost, V7 Texakalidis P, 2020, HEAD NECK-J SCI SPEC, V42, P1077, DOI 10.1002/hed.26102 Thålin C, 2016, THROMB RES, V139, P56, DOI 10.1016/j.thromres.2016.01.009 Ueki Y, 2019, JACC-CARDIOONCOL, V1, P145, DOI 10.1016/j.jaccao.2019.11.001 Valent P, 2015, BLOOD, V125, P901, DOI 10.1182/blood-2014-09-594432 Velders MA, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.014383 Verhoeven JI, 2023, JAMA NETW OPEN, V6, DOI 10.1001/jamanetworkopen.2023.5002 Verschoof MA, 2022, NEUROLOGY, V98, pE993, DOI 10.1212/WNL.0000000000013316 Wang JS, 2021, MAYO CLIN PROC, V96, P592, DOI 10.1016/j.mayocp.2020.05.045 Xu Y, 2023, JACC-CARDIOONCOL, V5, P520, DOI 10.1016/j.jaccao.2023.04.003 Yhim H, 2023, Res Pract Thromb Haemost, V7 Yoo J, 2023, STROKE, V54, P2981, DOI 10.1161/STROKEAHA.123.044910 Yusuf SW, 2012, CLIN CARDIOL, V35, P443, DOI 10.1002/clc.22007 Zaleska M, 2018, FUTURE ONCOL, V14, P1497, DOI 10.2217/fon-2017-0543 Zamorano JL, 2016, EUR HEART J, V37, P2768, DOI [10.1093/eurheartj/ehw211, 10.1002/ejhf.654] Zhao Q, 2021, LANCET PLANET HEALTH, V5, pE415, DOI 10.1016/S2542-5196(21)00081-4 Zhu J, 2023, CANCER MED-US, V12, P18531, DOI 10.1002/cam4.6455 Zmaili MA, 2021, AM J MED, V134, P361, DOI 10.1016/j.amjmed.2020.06.047 Zöller B, 2012, EUR J CANCER, V48, P1875, DOI 10.1016/j.ejca.2012.01.005 Zöller B, 2012, EUR J CANCER, V48, P121, DOI 10.1016/j.ejca.2011.09.015 Zwicker JI, 2009, CLIN CANCER RES, V15, P6830, DOI 10.1158/1078-0432.CCR-09-0371 NR 106 TC 3 Z9 4 U1 0 U2 1 PU ELSEVIER PI AMSTERDAM PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS EI 2475-0379 J9 RES PRACT THROMB HAE JI Res. Pract. Thromb. Haemost. PD MAR PY 2024 VL 8 IS 3 AR e102393 DI 10.1016/j.rpth.2024.102393 EA MAR 2024 PG 12 WC Hematology; Peripheral Vascular Disease WE Science Citation Index Expanded (SCI-EXPANDED) SC Hematology; Cardiovascular System & Cardiology GA RY2K7 UT WOS:001231151300001 PM 38660456 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Truong, B Hornsby, L Fox, B Chou, CH Zheng, JY Qian, JJ AF Truong, Bang Hornsby, Lori Fox, Brent Chou, Chiahung Zheng, Jingyi Qian, Jingjing TI Benefit and risk of oral anticoagulant initiation strategies in patients with atrial fibrillation and cancer: a target trial emulation using the SEER-Medicare database SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS LA English DT Article DE AFib; Cancer; Oral anticoagulants; Stroke; Bleeding ID UNITED-STATES; STROKE RISK; THROMBOEMBOLISM; MANAGEMENT; WARFARIN; EPIDEMIOLOGY; DIAGNOSIS AB Oral anticoagulants (OACs) are recommended for patients with atrial fibrillation (AFib) having CHA2DS2-VASc score >= 2. However, the benefits of OAC initiation in patients with AFib and cancer at different levels of CHA2DS2-VASc is unknown. We included patients with new AFib diagnosis and a record of cancer (breast, prostate, or lung) from the 2012-2019 Surveillance, Epidemiology, and End Results (SEER)-Medicare database (n = 39,915). Risks of stroke and bleeding were compared between 5 treatment strategies: (1) initiated OAC when CHA2DS2-VASc >= 1 (n = 6008), (2) CHA2DS2-VASc >= 2 (n = 8694), (3) CHA2DS2-VASc >= 4 (n = 20,286), (4) CHA2DS2-VASc >= 6 (n = 30,944), and (5) never initiated OAC (reference group, n = 33,907). Confounders were adjusted using inverse probability weighting through cloning-censoring-weighting approach. Weighted pooled logistic regressions were used to estimate treatment effect [hazard ratios (HRs) and 95% confidence interval (95% CIs)]. We found that only patients who initiated OACs at CHA2DS2-VASc >= 6 had lower risk of stroke compared without OAC initiation (HR 0.64, 95% CI 0.54-0.75). All 4 active treatment strategies had reduced risk of bleeding compared to non-initiators, with OAC initiation at CHA2DS2-VASc >= 6 being the most beneficial strategy (HR = 0.49, 95% CI 0.44-0.55). In patients with lung cancer or regional/metastatic cancer, OAC initiation at any CHA2DS2-VASc level increased risk of stroke and did not reduce risk of bleeding (except for Regimen 4). In conclusion, among cancer patients with new AFib diagnosis, OAC initiation at higher risk of stroke (CHA2DS2-VASc score >= 6) is more beneficial in preventing ischemic stroke and bleeding. Patients with advanced cancer or low life-expectancy may initiate OACs when CHA2DS2-VASc score >= 6. C1 [Truong, Bang; Fox, Brent; Chou, Chiahung; Qian, Jingjing] Auburn Univ, Harrison Coll Pharm, Dept Hlth Outcomes Res & Policy, 4306d Walker Bldg, Auburn, AL 36849 USA. [Hornsby, Lori] Auburn Univ, Harrison Coll Pharm, Dept Pharm Practice, Auburn, AL USA. [Zheng, Jingyi] Auburn Univ, Coll Sci & Math, Dept Math & Stat, Auburn, AL USA. C3 Auburn University System; Auburn University; Auburn University System; Auburn University; Auburn University System; Auburn University RP Qian, JJ (corresponding author), Auburn Univ, Harrison Coll Pharm, Dept Hlth Outcomes Res & Policy, 4306d Walker Bldg, Auburn, AL 36849 USA. EM bct0022@auburn.edu; hornslb@auburn.edu; foxbren@auburn.edu; czc0109@auburn.edu; jzz0121@auburn.edu; jzq0004@auburn.edu RI Truong, Bang/JFB-1699-2023; zheng, jing/MEP-7995-2025 OI Truong, Bang/0000-0002-8654-5444; Qian, Jingjing/0000-0003-4624-9963; FU National Cancer Institute; Centers for Medicare & Medicaid Services, Information Management Services (IMS), Inc.; California Department of Public Health [103885]; Centers for Disease Control and Prevention's (CDC) National Program of Cancer Registries [1NU58DP007156]; National Cancer Institute's Surveillance, Epidemiology and End Results Program [HHSN261201800032I, HHSN261201800015I, HHSN261201800009I] FX This study used the linked the SEER-Medicare database. The interpretation and reporting of these data are the sole responsibility of the authors. The authors acknowledge the efforts of the National Cancer Institute; the Centers for Medicare & Medicaid Services, Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database. The collection of cancer incidence data used in this study was supported by the California Department of Public Health pursuant to California Health and Safety Code Sect. 103885; Centers for Disease Control and Prevention's (CDC) National Program of Cancer Registries, under cooperative agreement 1NU58DP007156; the National Cancer Institute's Surveillance, Epidemiology and End Results Program under contract HHSN261201800032I awarded to the University of California, San Francisco, contract HHSN261201800015I awarded to the University of Southern California, and contract HHSN261201800009I awarded to the Public Health Institute. The ideas and opinions expressed herein are those of the author(s) and do not necessarily reflect the opinions of the State of California, Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors. CR Adelborg K, 2019, J THROMB HAEMOST, V17, P1305, DOI 10.1111/jth.14475 [Anonymous], 2019, About multiple cause of death, 1999-2019 [Anonymous], 2013, Epidemiol Method, V2, P1, DOI [DOI 10.1515/EM-2012-0006, 10.1515/em-2012-0006] Ardeshirrouhanifard S, 2022, PHARMACOTHERAPY, V42, P375, DOI 10.1002/phar.2679 Atterman A, 2020, EUROPACE, V22, P58, DOI 10.1093/europace/euz306 Austin PC, 2015, STAT MED, V34, P3661, DOI 10.1002/sim.6607 Benjamin, 2020, CIRCULATION, V141, pE33, DOI 10.1161/CIR.0000000000000746 Boriani G, 2021, EUR J PREV CARDIOL, V28, P611, DOI 10.1093/eurjpc/zwaa054 Bungo B, 2022, IJC HEART VASC, V41, DOI 10.1016/j.ijcha.2022.101072 Cain LE, 2016, INT J EPIDEMIOL, V45, P2038, DOI 10.1093/ije/dyv295 Cain LE, 2010, INT J BIOSTAT, V6, DOI 10.2202/1557-4679.1212 Cereda A, 2023, CANCERS, V15, DOI 10.3390/cancers15092574 Chesnaye NC, 2022, CLIN KIDNEY J, V15, P14, DOI 10.1093/ckj/sfab158 Cho K, 2021, J INFECT DIS, V224, P967, DOI 10.1093/infdis/jiab330 Chung MNK, 2020, CIRCULATION, V141, pE750, DOI 10.1161/CIR.0000000000000748 Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561 Cunningham A, 2011, PHARMACOEPIDEM DR S, V20, P560, DOI 10.1002/pds.2109 D'Souza M, 2018, EUR J PREV CARDIOL, V25, P651, DOI 10.1177/2047487318759858 Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765 Deitelzweig S, 2021, JACC-CARDIOONCOL, V3, P411, DOI 10.1016/j.jaccao.2021.06.004 Del Prete C, 2018, CL LYMPH MYELOM LEUK, V18, P74, DOI 10.1016/j.clml.2017.09.008 Doll KM, 2018, JAMA SURG, V153, P588, DOI 10.1001/jamasurg.2018.0501 Duchesneau ED, 2022, CANCER EPIDEM BIOMAR, V31, P2079, DOI 10.1158/1055-9965.EPI-22-0495 Fanola CL, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.008987 Fradley MG, 2020, JACC-CARDIOONCOL, V2, P747, DOI 10.1016/j.jaccao.2020.09.008 Garg RK, 2011, PHARMACOEPIDEM DR S, V20, P313, DOI 10.1002/pds.2041 Gupta S, 2021, JAMA INTERN MED, V181, P41, DOI 10.1001/jamainternmed.2020.6252 Hernán MA, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.k182 Hernán MA, 2016, J CLIN EPIDEMIOL, V79, P70, DOI 10.1016/j.jclinepi.2016.04.014 Hernán MA, 2016, AM J EPIDEMIOL, V183, P758, DOI 10.1093/aje/kwv254 Iyengar V, 2022, BLOOD, V140, DOI 10.1182/blood-2022-156895 January CT, 2019, CIRCULATION, V140, pE125, DOI [10.1161/CIR.0000000000000665, 10.1016/j.jacc.2019.01.011] Jensen PN, 2012, PHARMACOEPIDEM DR S, V21, P141, DOI 10.1002/pds.2317 Joglar JA, 2024, J AM COLL CARDIOL, V83, P109, DOI [10.1016/j.jacc.2023.08.017, 10.1161/CIR.0000000000001193] Labrecque JA, 2017, EUR J EPIDEMIOL, V32, P473, DOI 10.1007/s10654-017-0293-4 Leader A, 2023, JACC-CARDIOONCOL, V5, DOI 10.1016/j.jaccao.2022.08.014 Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584 Liu Yang, 2015, Int J Stat Med Res, V4, P287, DOI 10.6000/1929-6029.2015.04.03.7 López-Fernández T, 2023, JACC-CARDIOONCOL, V5, DOI 10.1016/j.jaccao.2023.01.007 Lyon Alexander R, 2022, Eur Heart J Cardiovasc Imaging, V23, pe333, DOI [10.1093/eurheartj/ehac244, 10.1093/ehjci/jeac106] Malavasi VL, 2019, EUR J INTERN MED, V59, P27, DOI 10.1016/j.ejim.2018.10.012 Matetic A, 2023, EUR HEART J-QUAL CAR, V9, P749, DOI 10.1093/ehjqcco/qcac090 Mehta HB, 2022, CIRC-CARDIOVASC QUAL, V15, DOI 10.1161/CIRCOUTCOMES.122.008951 Melloni C, 2017, EUR HEART J, V3, P192, DOI 10.1093/ehjqcco/qcx004 National Cancer Institute, 2021, OVERVIEW SURVEILLANC National Cancer Institute. Division of Cancer Control and Population Sciences, 2023, MEASURES ARE LTD NOT National Cancer Institute. Division of Cancer Control and Population Sciences (DCCPS), 2023, NCI COMORBIDITY INDE Navi BB, 2017, J AM COLL CARDIOL, V70, P927, DOI 10.1016/j.jacc.2017.06.047 O'Neal WT, 2018, J AM COLL CARDIOL, V72, P1913, DOI 10.1016/j.jacc.2018.07.077 Park J, 2019, HEART RHYTHM, V16, P197, DOI 10.1016/j.hrthm.2018.08.023 Pastori D, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.012596 Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638 Patel NJ, 2014, CIRCULATION, V129, P2371, DOI 10.1161/CIRCULATIONAHA.114.008201 Pereira J, 2004, ONCOLOGIST, V9, P561, DOI 10.1634/theoncologist.9-5-561 Prandoni P, 2002, BLOOD, V100, P3484, DOI 10.1182/blood-2002-01-0108 Raposeiras-Roubin S, 2022, AM J CARDIOL, V180, P44, DOI 10.1016/j.amjcard.2022.06.044 Seelig J, 2019, VASC HEALTH RISK MAN, V15, P399, DOI 10.2147/VHRM.S187656 Shah S, 2018, BLOOD ADV, V2, P200, DOI 10.1182/bloodadvances.2017010694 Sorigue M, 2019, J ONCOL PRACT, V15, P641, DOI 10.1200/JOP.18.00592 The Surveillance E, 2023, OBS RES EC TOOLB Thigpen JL, 2015, CIRC-CARDIOVASC QUAL, V8, P8, DOI 10.1161/CIRCOUTCOMES.113.000371 Timp JF, 2013, BLOOD, V122, P1712, DOI 10.1182/blood-2013-04-460121 Warren Joan L, 2002, Med Care, V40, pIV Yeh YH, 2022, AM J MED, V135, pE248, DOI 10.1016/j.amjmed.2022.03.011 Yoshida K, 2015, NAT REV RHEUMATOL, V11, P437, DOI 10.1038/nrrheum.2015.30 NR 65 TC 2 Z9 2 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0929-5305 EI 1573-742X J9 J THROMB THROMBOLYS JI J. Thromb. Thrombolysis PD APR PY 2024 VL 57 IS 4 BP 638 EP 649 DI 10.1007/s11239-024-02958-3 EA MAR 2024 PG 12 WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular Disease WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Hematology GA OC6Z3 UT WOS:001186605700001 PM 38504063 OA Green Submitted, hybrid DA 2026-04-17 ER PT J AU Tong, CY Niu, ZY Zhu, HW Li, TT Xu, YY Yan, Y Miao, Q Jin, RS Zheng, JJ Li, HC Wu, JX AF Tong, Chaoyang Niu, Zhenyi Zhu, Hongwei Li, Tingting Xu, Yuanyuan Yan, Yan Miao, Qing Jin, Runsen Zheng, Jijian Li, Hecheng Wu, Jingxiang TI Development and external validation of a novel model for predicting new clinically important atrial fibrillation after thoracoscopic anatomical lung cancer surgery: a multicenter retrospective cohort study SO INTERNATIONAL JOURNAL OF SURGERY LA English DT Article DE lung cancer; nomogram; postoperative atrial fibrillation; thoracoscopic surgery ID THORACIC-SURGERY; RISK-FACTORS; OPEN LOBECTOMY; PREVENTION; MANAGEMENT; AMIODARONE; SOCIETY; REDUCE AB Background:New clinically important postoperative atrial fibrillation (POAF) is the most common arrhythmia after thoracoscopic anatomical lung cancer surgery and is associated with increased morbidity and mortality. The full spectrum of predictors remains unclear, and effective assessment tools are lacking. This study aimed to develop and externally validate a novel model for predicting new clinically important POAF.Methods:This retrospective study included 14 074 consecutive patients who received thoracoscopic anatomical lung cancer surgery from January 2016 to December 2018 in Shanghai Chest Hospital. Based on the split date of 1 January 2018, we selected 8717 participants for the training cohort and 5357 participants for the testing cohort. For external validation, we pooled 2941 consecutive patients who received this surgical treatment from July 2016 to July 2021 in Shanghai Ruijin Hospital. Independent predictors were used to develop a model and internally validated using a bootstrap-resampling approach. The area under the receiver operating characteristic curves (AUROCs) and Brier score were performed to assess the model discrimination and calibration. The decision curve analysis (DCA) was used to evaluate clinical validity and net benefit. New clinically important POAF was defined as a new-onset of POAF that causes symptoms or requires treatment.Results:Multivariate analysis suggested that age, hypertension, preoperative treatment, clinical tumor stage, intraoperative arrhythmia and transfusion, and operative time were independent predictors of new clinically important POAF. These seven candidate predictors were used to develop a nomogram, which showed a concordance statistic (C-statistic) value of 0.740 and good calibration (Brier score; 0.025). Internal validation revealed similarly good discrimination (C-statistic, 0.736; 95% CI: 0.705-0.768) and calibration. The decision curve analysis showed positive net benefits with the threshold risk range of 0-100%. C-statistic value and Brier score were 0.717 and 0.028 in the testing cohort, and 0.768 and 0.012 in the external validation cohort, respectively.Conclusions:This study identified seven predictors of new clinically important POAF, among which preoperative treatment, intraoperative arrhythmia, and operative time were rarely reported. The established and externally validated model has good performance and clinical usefulness, which may promote the application of prevention and treatment in high-risk patients, and reduce the development and related adverse outcomes of this event. C1 [Tong, Chaoyang; Zhu, Hongwei; Li, Tingting; Miao, Qing; Wu, Jingxiang] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Sch Med, Dept Anesthesiol, Shanghai, Peoples R China. [Tong, Chaoyang; Zheng, Jijian] Shanghai Jiao Tong Univ, Shanghai Childrens Med Ctr, Sch Med, Dept Anesthesiol, Shanghai, Peoples R China. [Niu, Zhenyi; Yan, Yan; Jin, Runsen; Li, Hecheng] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Thorac Surg, Shanghai, Peoples R China. [Xu, Yuanyuan] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Sch Med, Dept Thorac Surg, Shanghai, Peoples R China. [Wu, Jingxiang] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Sch Med, Dept Anesthesiol, 241 Huaihai Rd West, Shanghai 200030, Peoples R China. [Jin, Runsen; Li, Hecheng] Shanghai Jiao Tong Univ, Affiliated Ruijin Hosp, Med Sch, Dept Thorac Surg, 197 Ruijin Er Rd, Shanghai 200025, Peoples R China. [Zheng, Jijian] Shanghai Jiao Tong Univ, Shanghai Childrens Med Ctr, Sch Med, Dept Anesthesiol, 1678 Dong Fang Rd, Shanghai 200127, Peoples R China. [Zheng, Jijian] Shanghai Jiao Tong Univ, Natl Childrens Med Ctr, 1678 Dong Fang Rd, Shanghai 200127, Peoples R China. C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University RP Wu, JX (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Sch Med, Dept Anesthesiol, 241 Huaihai Rd West, Shanghai 200030, Peoples R China.; Jin, RS; Li, HC (corresponding author), Shanghai Jiao Tong Univ, Affiliated Ruijin Hosp, Med Sch, Dept Thorac Surg, 197 Ruijin Er Rd, Shanghai 200025, Peoples R China.; Zheng, JJ (corresponding author), Shanghai Jiao Tong Univ, Shanghai Childrens Med Ctr, Sch Med, Dept Anesthesiol, 1678 Dong Fang Rd, Shanghai 200127, Peoples R China.; Zheng, JJ (corresponding author), Shanghai Jiao Tong Univ, Natl Childrens Med Ctr, 1678 Dong Fang Rd, Shanghai 200127, Peoples R China. EM 2415007153@qq.com; zhenyiniu@qq.com; zhuhongwei06@163.com; Ittdottie@126.com; xyyvincent@foxmail.com; yanyan990220@126.com; miaoqmz@163.com; nkvincent@163.com; zhengjijian626@sina.com; lihecheng2000@hotmail.com; wjx1132xk@163.com RI zhu, hongwei/LSK-9010-2024; miao, qing/LWH-6832-2024; Li, Tingting/GPK-7292-2022; Wu, Jingxiang/GON-5965-2022 FU National Natural Science Foundation of China [82071233]; Shanghai Shen Kang Hospital Development Center Project [SHDC2020CR4063] FX This work was supported by National Natural Science Foundation of China (82071233) and Shanghai Shen Kang Hospital Development Center Project (SHDC2020CR4063). CR Ai D, 2015, J CARDIOTHOR VASC AN, V29, P396, DOI 10.1053/j.jvca.2014.05.013 Alonso-Coello P, 2017, ANESTH ANALG, V125, P162, DOI 10.1213/ANE.0000000000002111 Amar D, 2002, ANESTHESIOLOGY, V97, P1618, DOI 10.1097/00000542-200212000-00039 Amar David, 2022, Anesthesiology, V136, P916, DOI 10.1097/ALN.0000000000004201 Amar D, 2019, J THORAC CARDIOV SUR, V157, P2493, DOI 10.1016/j.jtcvs.2019.01.075 Bhave PD, 2012, AM HEART J, V164, P918, DOI 10.1016/j.ahj.2012.09.004 Billmeier SE, 2011, PRINCIPLES AND PRACTICE OF GERIATRIC SURGERY, SECOND EDITION, P605, DOI 10.1007/978-1-4419-6999-6_48 Brecher O, 2017, ANESTH ANALG, V124, P1099, DOI 10.1213/ANE.0000000000001471 de Angelis P, 2023, ANN SURG, V278, pE1259, DOI 10.1097/SLA.0000000000005696 Dobrev D, 2019, NAT REV CARDIOL, V16, P417, DOI 10.1038/s41569-019-0166-5 Falcoz PE, 2016, EUR J CARDIO-THORAC, V49, P602, DOI 10.1093/ejcts/ezv154 Frendl G, 2014, J THORAC CARDIOV SUR, V148, P772, DOI 10.1016/j.jtcvs.2014.06.037 Gialdini G, 2014, JAMA-J AM MED ASSOC, V312, P616, DOI 10.1001/jama.2014.9143 Haïssaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003 Haverkamp W, 2016, CURR OPIN ANESTHESIO, V29, P26, DOI 10.1097/ACO.0000000000000285 Iwata T, 2016, SURG TODAY, V46, P877, DOI 10.1007/s00595-015-1258-4 Lanters EAH, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.007879 Li Y, 2015, THORAC CANCER, V6, P704, DOI 10.1111/1759-7714.12241 Mathew G, 2021, INT J SURG, V96, DOI 10.1016/j.ijsu.2021.106165 Nojiri T, 2010, J THORAC CARDIOV SUR, V140, P764, DOI 10.1016/j.jtcvs.2009.11.073 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Park BJ, 2007, J THORAC CARDIOV SUR, V133, P775, DOI 10.1016/j.jtcvs.2006.09.022 Sihoe ADL, 2020, RESPIROLOGY, V25, P49, DOI 10.1111/resp.13920 Smith H, 2020, EUR J CARDIO-THORAC, V57, P874, DOI 10.1093/ejcts/ezz341 Tisdale JE, 2009, ANN THORAC SURG, V88, P886, DOI 10.1016/j.athoracsur.2009.04.074 Tong CY, 2023, CANCERS, V15, DOI 10.3390/cancers15020371 Tong CY, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-20-5035 Tong CY, 2020, ANN THORAC SURG, V109, P1522, DOI 10.1016/j.athoracsur.2019.12.009 Van Calster B, 2018, EUR UROL, V74, P796, DOI 10.1016/j.eururo.2018.08.038 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Xu J., 2021, Clin Lung Cancer, VS1525-7304, P00158 Yang CFJ, 2021, ANN SURG, V273, P595, DOI 10.1097/SLA.0000000000003231 NR 32 TC 10 Z9 10 U1 1 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1743-9191 EI 1743-9159 J9 INT J SURG JI Int. J. Surg. PD MAR PY 2024 VL 110 IS 3 BP 1645 EP 1652 DI 10.1097/JS9.0000000000001006 PG 8 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA LE3M5 UT WOS:001185065100086 PM 38181118 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Borgers, JSW van Schijndel, AW van Thienen, JV Klobuch, S Seijkens, TTP Tobin, RP van Heerebeek, L Driessen-Waaijer, A Rohaan, MW Haanen, JBAG AF Borgers, J. S. W. van Schijndel, A. W. van Thienen, J. V. Klobuch, S. Seijkens, T. T. P. Tobin, R. P. van Heerebeek, L. Driessen-Waaijer, A. Rohaan, M. W. Haanen, J. B. A. G. TI Clinical presentation of cardiac symptoms following treatment with tumorinfiltrating lymphocytes: diagnostic challenges and lessons learned SO ESMO OPEN LA English DT Article DE cardiotoxicity; tumor-infiltrating lymphocytes; interleukin-2; melanoma; non-small-cell lung cancer; guidelines ID TUMOR-INFILTRATING LYMPHOCYTES; CHEMOTHERAPY DOSE ADJUSTMENT; STEM-CELL TRANSPLANTATION; METASTATIC MELANOMA; OBESE-PATIENTS; T-CELLS; RECOMBINANT INTERLEUKIN-2; CARDIOVASCULAR TOXICITY; MARROW-TRANSPLANTATION; THERAPY AB Background: Treatment with tumor-infiltrating lymphocytes (TILs) is rapidly evolving for patients with solid tumors. Following metastasectomy, TILs (autologous, intratumoral CD4+ and CD8+ T cells with the potential to recognize tumor-associated antigens) are isolated and non-specifically expanded ex vivo in the presence of interleukin-2 (IL-2). Subsequently, the TILs are adoptively transferred to the patients after a preconditioning non-myeloablative, lymphodepleting chemotherapy regimen, followed by administration of high-dose (HD) IL-2. Here, we provide an overview of known cardiac risks associated with TIL treatment and report on seven patients presenting with cardiac symptoms, all with different clinical course and diagnostic findings during treatment with lymphodepleting chemotherapy, TIL, and HD IL-2, and propose a set of clinical recommendations for diagnosis and management of these symptoms. Patients and methods: This single-center, retrospective study included selected patients who experienced TIL treatment-related cardiac symptoms at the Netherlands Cancer Institute. In addition, 12 patients were included who received TIL in the clinical trial setting without experiencing cardiac symptoms, from whom complete cardiac biomarker follow-up during treatment was available [creatine kinase (CK), CK-myocardial band, troponin T and Nterminal pro-B-type natriuretic peptide]. Results: Within our TIL patient population, seven illustrative cases were chosen from the patients who developed symptoms suspected of severe cardiotoxicity: myocarditis, myocardial infarction, peri-myocarditis, atrial fibrillation, acute dyspnea, and two cases of heart failure. An overview of their clinical course, diagnostics carried out, and management of the symptoms is provided. Conclusions: In the absence of evidence-based guidelines for the treatment of TIL therapy-associated cardiotoxicity, we provided an overview of literature, case descriptions, and recommendations for diagnosis and management to help physicians in daily practice, as the number of patients qualifying for TIL treatment is rapidly increasing. C1 [Borgers, J. S. W.; Klobuch, S.; Seijkens, T. T. P.; Rohaan, M. W.; Haanen, J. B. A. G.] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands. [van Thienen, J. V.] Netherlands Canc Inst, Dept Intens Care, Amsterdam, Netherlands. [van Schijndel, A. W.] Netherlands Canc Inst, Dept Cardiol, Amsterdam, Netherlands. [van Schijndel, A. W.; Seijkens, T. T. P.] Univ Amsterdam, Dept Med Biochem, Med Ctr, Amsterdam, Netherlands. [Tobin, R. P.] Univ Colorado Anschutz Med Campus, Dept Surg, Div Surg Oncol, Aurora, CO USA. [van Heerebeek, L.] Onze Lieve Vrouw Hosp, Dept Cardiol, Amsterdam, Netherlands. [Driessen-Waaijer, A.] Dept Radiol, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands. [Rohaan, M. W.] Netherlands Canc Inst, Dept Radiotherapy, Amsterdam, Netherlands. [Haanen, J. B. A. G.] Leiden Univ, Med Ctr, Dept Med Oncol, Leiden, Netherlands. [Haanen, J. B. A. G.] CHU Vaudois, Melanoma Clin, Lausanne, Switzerland. [Haanen, J. B. A. G.] Netherlands Canc Inst, Dept Med Oncol, Plesmanlaan 121, NL-1066CX Amsterdam, Netherlands. C3 Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; University of Amsterdam; University of Colorado System; University of Colorado Anschutz; Onze Lieve Vrouwe Gasthuis Hospital; Netherlands Cancer Institute; Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Netherlands Cancer Institute RP Haanen, JBAG (corresponding author), Netherlands Canc Inst, Dept Med Oncol, Plesmanlaan 121, NL-1066CX Amsterdam, Netherlands. EM j.haanen@nki.nl RI Haanen, John/AAD-8534-2022; Rohaan, Maartje/AAP-8186-2020; Borgers, Jessica/AAQ-6462-2021 OI Borgers, Jessica/0000-0002-6478-7821; van Schijndel, Anne/0000-0001-5774-675X; Tobin, Richard/0000-0003-3890-4534 CR Ali A, 2019, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01866 Alvi RM, 2019, J AM COLL CARDIOL, V74, P3099, DOI 10.1016/j.jacc.2019.10.038 Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105 Baik AH, 2021, CIRC RES, V128, P1780, DOI 10.1161/CIRCRESAHA.120.315894 Besser MJ, 2013, CLIN CANCER RES, V19, P4792, DOI 10.1158/1078-0432.CCR-13-0380 Boyman O, 2006, SCIENCE, V311, P1924, DOI 10.1126/science.1122927 Boyman O, 2012, NAT REV IMMUNOL, V12, P180, DOI 10.1038/nri3156 BRAVERMAN AC, 1991, J CLIN ONCOL, V9, P1215, DOI 10.1200/JCO.1991.9.7.1215 Brudno JN, 2016, BLOOD, V127, P3321, DOI 10.1182/blood-2016-04-703751 Bubalo J, 2014, BIOL BLOOD MARROW TR, V20, P600, DOI 10.1016/j.bbmt.2014.01.019 Creelan BC, 2021, NAT MED, V27, P1410, DOI 10.1038/s41591-021-01462-y Dafni U, 2019, ANN ONCOL, V30, P1902, DOI 10.1093/annonc/mdz398 Dhesi S, 2013, J INVEST MED HIGH IM, V1, DOI 10.1177/2324709613480346 Dudley ME, 2005, J CLIN ONCOL, V23, P2346, DOI 10.1200/JCO.2005.00.240 Fajgenbaum DC, 2020, NEW ENGL J MED, V383, P2255, DOI 10.1056/NEJMra2026131 Fradley MG, 2021, J IMMUNOTHER, V44, P86, DOI 10.1097/CJI.0000000000000341 Furlanetto J, 2016, ANN ONCOL, V27, P2053, DOI 10.1093/annonc/mdw315 Ganatra S, 2022, JACC-CARDIOONCOL, V4, P616, DOI 10.1016/j.jaccao.2022.07.014 Ganatra S, 2020, CIRCULATION, V142, P1687, DOI 10.1161/CIRCULATIONAHA.120.048100 Ganatra S, 2019, J AM COLL CARDIOL, V74, P3153, DOI 10.1016/j.jacc.2019.10.049 GOTTDIENER JS, 1981, ARCH INTERN MED, V141, P758, DOI 10.1001/archinte.141.6.758 Gutheil J., 2001, FDAITCS, V3rd, P208 Khammari A, 2020, CANCER IMMUNOL IMMUN, V69, P1663, DOI 10.1007/s00262-020-02572-1 Klapper JA, 2008, CANCER-AM CANCER SOC, V113, P293, DOI 10.1002/cncr.23552 Lee DW, 2019, BIOL BLOOD MARROW TR, V25, P625, DOI 10.1016/j.bbmt.2018.12.758 Linette GP, 2013, BLOOD, V122, P863, DOI 10.1182/blood-2013-03-490565 Mank A, 2003, ACTA HAEMATOL-BASEL, V109, P163, DOI 10.1159/000070964 Marabondo S, 2017, EXPERT OPIN DRUG SAF, V16, P1347, DOI 10.1080/14740338.2017.1382472 García AM, 2021, REV ESP CARDIOL, V74, P438, DOI 10.1016/j.recesp.2020.11.014 Martino R, 2001, BRIT J HAEMATOL, V115, P653, DOI 10.1046/j.1365-2141.2001.03153.x Morandi P, 2001, BONE MARROW TRANSPL, V28, P277, DOI 10.1038/sj.bmt.1703132 Muranski P, 2006, NAT CLIN PRACT ONCOL, V3, P668, DOI 10.1038/ncponc0666 Newbery Gisella, 2019, J Cardiol Cases, V20, P88, DOI [10.1016/j.jccase.2019.05.001, 10.1016/j.jccase.2019.05.001] Pathan N, 2004, LANCET, V363, P203, DOI 10.1016/S0140-6736(03)15326-3 /proleukin, Proleuking prescribing information Pudil R, 2023, COR VASA, V65, P350, DOI 10.33678/cor.2023.032 Ritchie DS, 2001, BONE MARROW TRANSPL, V28, P101, DOI 10.1038/sj.bmt.1703098 Rohaan MW, 2022, NEW ENGL J MED, V387, P2113, DOI 10.1056/NEJMoa2210233 ROSENBERG SA, 1994, J NATL CANCER I, V86, P1159, DOI 10.1093/jnci/86.15.1159 ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527 Saberian C, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002449 Shanholtz C, 2001, CRIT CARE CLIN, V17, P483, DOI 10.1016/S0749-0704(05)70196-2 Shem-Tov N, 2015, ONCOLOGIST, V20, P50, DOI 10.1634/theoncologist.2014-0187 SPRIANO M, 1994, HAEMATOLOGICA, V79, P218 van Besien K, 2003, BONE MARROW TRANSPL, V32, P471, DOI 10.1038/sj.bmt.1704166 van den Berg JH, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000848 NR 46 TC 7 Z9 11 U1 1 U2 2 PU ELSEVIER PI AMSTERDAM PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS EI 2059-7029 J9 ESMO OPEN JI ESMO Open PY 2024 VL 9 IS 2 AR 102383 DI 10.1016/j.esmoop.2024.102383 EA FEB 2024 PG 12 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA LO3F5 UT WOS:001187697400001 PM 38364453 OA Green Submitted, Green Accepted, gold DA 2026-04-17 ER PT J AU Walls, GM McCann, C O'Connor, J O'Sullivan, A Johnston, DI McAleese, J McGarry, CK Cole, AJ Jain, S Butterworth, KT Hanna, GG AF Walls, Gerard M. McCann, Conor O'Connor, John O'Sullivan, Anna Johnston, David I. McAleese, Jonathan McGarry, Conor K. Cole, Aidan J. Jain, Suneil Butterworth, Karl T. Hanna, Gerard G. TI Pulmonary vein dose and risk of atrial fibrillation in patients with non-small cell lung cancer following definitive radiotherapy: An NI-HEART analysis SO RADIOTHERAPY AND ONCOLOGY LA English DT Article ID RADIATION-THERAPY; CARDIAC TOXICITY; DISEASE; SUBSTRUCTURES AB Background and purpose: Symptomatic arrhythmia is common following radiotherapy for non -small cell lung cancer (NSCLC), frequently resulting in morbidity and hospitalization. Modern treatment planning technology theoretically allows sparing of cardiac substructures. Atrial fibrillation (AF) comprises the majority of postradiotherapy arrhythmias, but efforts to prevent this cardiotoxicity have been limited as the causative cardiac substructure is not known. In this study we investigated if incidental radiation dose to the pulmonary veins (PVs) is associated with AF. Material and methods: A single -centre study of patients completing contemporary (chemo)radiation for NSCLC, with modern planning techniques. Oncology, cardiology and death records were examined, and AF events were verified by a cardiologist. Cardiac substructures were contoured on planning scans for retrospective dose analysis. Results: In 420 eligible patients with NSCLC treated with intensity-modulated (70%) or 3D-conformal (30%) radiotherapy with a median OS of 21.8 months (IQR 10.8-35.1), there were 26 cases of new AF (6%). All cases were grade 3 except two cases of grade 4. Dose metrics for both the left (V55) and right (V10) PVs were associated with the incidence of new AF. Metrics remained statistically significant after accounting for the competing risk of death and cardiovascular covariables for both the left (HR 1.02, 95%CI 1.00-1.03, p = 0.005) and right (HR 1.01 (95%CI 1.00-1.02, p = 0.033) PVs. Conclusion: Radiation dose to the PVs during treatment of NSCLC was associated with the onset of AF. Actively sparing the PVs during treatment planning could reduce the incidence of AF during follow-up, and screening for AF may be warranted for select cases. C1 [Walls, Gerard M.; McAleese, Jonathan; McGarry, Conor K.; Cole, Aidan J.; Jain, Suneil; Hanna, Gerard G.] Belfast Hlth & Social Care Trust, Canc Ctr Belfast City Hosp, Lisburn Rd, Belfast, North Ireland. [Walls, Gerard M.; Johnston, David I.; McGarry, Conor K.; Jain, Suneil; Butterworth, Karl T.; Hanna, Gerard G.] Queens Univ Belfast, Patrick G Johnston Ctr Canc Res, Jubilee Rd,Lisburn Rd, Belfast BT9 7AB, North Ireland. [McCann, Conor] Belfast City Hosp, Dept Cardiol, Belfast Hlth & Social Care Trust, Lisburn Rd, Belfast, North Ireland. [O'Connor, John] Univ Ulster, Sch Engn, York St, Belfast, North Ireland. [O'Sullivan, Anna] Univ Coll Dublin, Sch Med, Dublin, Ireland. C3 Queens University Belfast; Belfast City Hospital; Ulster University; University College Dublin RP Walls, GM (corresponding author), Queens Univ Belfast, Patrick G Johnston Ctr Canc Res, Jubilee Rd,Lisburn Rd, Belfast BT9 7AB, North Ireland. EM g.walls@qub.ac.uk RI McCann, Conor/ODJ-4170-2025; O'Connor, John/OOK-7991-2025; Walls, Gerard/I-5652-2019; Hanna, Gerard/AAC-6466-2020; Butterworth, Karl/I-7476-2019 OI Walls, Gerard/0000-0003-0845-9732; Hanna, Gerard/0000-0003-1003-5138; Butterworth, Karl/0000-0001-7170-6789 FU Irish Clinical Academic Training Programme Fellowship; Wellcome Trust; Health Research Board [203930/B/16/Z]; Health Service Executive National Doctors Training and Planning; Health and Social Care, Research and Development Division, Northern Ireland; Cancer Research UK Post-doctoral Fellowship [RCCPOB-Nov22/100010] FX This data collection for this work was funded by an Irish Clinical Academic Training Programme Fellowship (GW) , which is supported by the Wellcome Trust and the Health Research Board (Grant Number 203930/B/16/Z) , the Health Service Executive National Doctors Training and Planning and the Health and Social Care, Research and Development Division, Northern Ireland. The lead author conducted this analysis during a Cancer Research UK Post-doctoral Fellowship (RCCPOB-Nov22/100010) . CR Andrade JG, 2023, NEW ENGL J MED, V388, P105, DOI 10.1056/NEJMoa2212540 [Anonymous], 2023, R Foundation for Statistical Computing Bavrina AP, 2015, B EXP BIOL MED+, V159, P103, DOI 10.1007/s10517-015-2901-1 Brundel BJJM, 2022, NAT REV DIS PRIMERS, V8, DOI 10.1038/s41572-022-00347-9 Bucknell NW, 2022, J THORAC ONCOL, V17, P961, DOI 10.1016/j.jtho.2022.05.003 Cai GX, 2023, INT J RADIAT ONCOL, V115, P366, DOI 10.1016/j.ijrobp.2022.08.013 Cha MJ, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.120.019072 Chen L, 2019, ULTRASOUND MED BIOL, V45, P98, DOI 10.1016/j.ultrasmedbio.2018.09.012 Dalloz F, 1999, FREE RADICAL BIO MED, V26, P785, DOI 10.1016/S0891-5849(98)00259-7 Darby SC, 2013, NEW ENGL J MED, V368, P987, DOI 10.1056/NEJMoa1209825 Ellsworth S.G., 2023, Int J Radiat Oncol Biol Phys Ferris MJ, 2018, INT J RADIAT ONCOL, V102, P383, DOI 10.1016/j.ijrobp.2018.05.066 Hui RN, 2019, LANCET ONCOL, V20, P1670, DOI 10.1016/S1470-2045(19)30519-4 Khan R, 2004, CARDIOVASC RES, V64, P387, DOI 10.1016/j.cardiores.2004.07.025 Kim KH, 2022, JAMA ONCOL, V8, P1624, DOI 10.1001/jamaoncol.2022.4202 Koop Y, 2022, EUR J CARDIOVASC NUR, V21, P235, DOI 10.1093/eurjcn/zvab057 LAUK S, 1985, INT J RADIAT ONCOL, V11, P801, DOI 10.1016/0360-3016(85)90314-1 Loap P, 2021, PRACT RADIAT ONCOL, V11, pE434, DOI 10.1016/j.prro.2021.02.002 Lubberts S, 2023, J CLIN ONCOL, V41, P3512, DOI 10.1200/JCO.22.01016 McKenzie E, 2023, INT J RADIAT ONCOL, V115, P1138, DOI 10.1016/j.ijrobp.2022.11.033 McWilliam A, 2020, INT J RADIAT ONCOL, V108, P1073, DOI 10.1016/j.ijrobp.2020.06.031 Meyre P, 2019, CAN J CARDIOL, V35, P1332, DOI 10.1016/j.cjca.2019.05.024 Oral H, 2002, CIRCULATION, V105, P1077, DOI 10.1161/hc0902.104712 Rozen G, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.009024 Sohns C, 2023, NEW ENGL J MED, V389, P1380, DOI 10.1056/NEJMoa2306037 Spigel DR, 2022, J CLIN ONCOL, V40, P1301, DOI 10.1200/JCO.21.01308 Tjong MC, 2022, RADIOTHER ONCOL, V169, P105, DOI 10.1016/j.radonc.2022.02.010 Vivekanandan S, 2017, INT J RADIAT ONCOL, V99, P51, DOI 10.1016/j.ijrobp.2017.04.026 von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI 10.2471/BLT.07.045120 Walls GM, 2023, RADIOTHER ONCOL, V186, DOI 10.1016/j.radonc.2023.109762 Walls GM, 2022, PHYS IMAG RADIAT ONC, V23, P118, DOI 10.1016/j.phro.2022.07.003 Walls GM, 2022, RADIOTHER ONCOL, V173, P19, DOI 10.1016/j.radonc.2022.04.030 Wang K, 2017, RADIOTHER ONCOL, V125, P293, DOI 10.1016/j.radonc.2017.10.001 Zhang DM, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25730-0 NR 37 TC 31 Z9 32 U1 1 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-8140 EI 1879-0887 J9 RADIOTHER ONCOL JI Radiother. Oncol. PD MAR PY 2024 VL 192 AR 110085 DI 10.1016/j.radonc.2024.110085 EA FEB 2024 PG 8 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA KR0N3 UT WOS:001181577200001 PM 38184145 OA Green Submitted, Green Published, hybrid DA 2026-04-17 ER PT J AU Chen, BS Xu, AY He, YJ Zhang, YM Cheng, DY Fang, YY Ruan, JL Dai, M Wang, Y Zhang, J AF Chen, Bangsheng Xu, Anyi He, Yujing Zhang, Yueming Cheng, Dongying Fang, Yingying Ruan, Jiale Dai, Min Wang, Yu Zhang, Jie TI The cardiac-related adverse events of PD-1/PD-L1 immunotherapy in advanced or metastatic lung cancer: a RCT-based meta-analysis SO SUPPORTIVE CARE IN CANCER LA English DT Review DE PD-1/PD-L1; Immunotherapy; Cardiotoxicity; Safety; Pericardial effusion; Meta-analysis ID 1ST-LINE TREATMENT; DOUBLE-BLIND; NONSQUAMOUS NSCLC; PHASE-3; PLATINUM; ATEZOLIZUMAB; CARBOPLATIN; COMBINATION; PACLITAXEL AB Background This study aims to investigate the effect of PD-1/PD-L1 immunotherapy on cardiac-related adverse events in patients with advanced or metastatic lung cancer. Methods We conducted a detailed search in PubMed, Web of Science, Cochran, and Embase for articles on the application of immunotherapy for lung cancer and report cardiac-related adverse events with respect to myocardial ischemia, pericardial effusion, myocarditis, and electrophysiology. The dichotomous variables were assessed by relative risk (RR) and 95% confidence intervals (CI). Results A total of 7132 subjects were included in 12 phase III randomized controlled trials (RCTs). The results showed that under the fixed effects model, the probability of cardiac-related adverse events in pericardial effusion was higher in the experimental group than in the control group (RR 2.30, 95% CI 1.01-5.21, P = 0.05). Under the random effects model, there was no statistical difference between the two groups (RR 2.03, 95% CI 0.81-5.12, P = 0.13). No statistical difference is observed between the experimental group and the control group (under the fixed effects model and the random effects model) for other cardiac-related adverse events, including myocarditis, acute coronary syndrome, myocardial infarction, acute myocardial infarction, myocardial ischemia, unstable angina, ventricular tachycardia, supraventricular tachycardia, tachycardia, bradycardia, atrial flutter, atrial fibrillation, cardiac failure, cardiac arrest, cardiopulmonary failure, acute heart failure, cardiac arrest (all P > 0.05). Conclusions PD-1/PD-L1 immunotherapy in advanced or metastatic lung cancer is generally safe for cardiac-related adverse events. C1 [Chen, Bangsheng] Ningbo Yinzhou 2 Hosp, Emergency Med Ctr, Ningbo, Zhejiang, Peoples R China. [Xu, Anyi; Fang, Yingying; Ruan, Jiale; Wang, Yu] Zhejiang Chinese Med Univ, Clin Med Coll 1, Hangzhou, Zhejiang, Peoples R China. [He, Yujing; Dai, Min] Zhejiang Chinese Med Univ, Clin Med Coll 2, Hangzhou, Zhejiang, Peoples R China. [Zhang, Yueming] Hosp Zhejiang Peoples Armed Police, Intens Care Unit, Hangzhou, Zhejiang, Peoples R China. [Cheng, Dongying] Ningbo Yinzhou 3 Hosp, Community Dept, Ningbo, Zhejiang, Peoples R China. [Zhang, Jie] Zhuji Peoples Hosp, Emergency Dept, 9 Jianmin Rd,Taozhu St, Shaoxing 311899, Zhejiang, Peoples R China. C3 Zhejiang Chinese Medical University; Zhejiang Chinese Medical University RP Zhang, J (corresponding author), Zhuji Peoples Hosp, Emergency Dept, 9 Jianmin Rd,Taozhu St, Shaoxing 311899, Zhejiang, Peoples R China. EM cbs113@126.com; 1371256123@qq.com; 1371152411@qq.com; zymjz2020@sina.com; 843909602@qq.com; fangyingying@zcmu.edu.cn; 1557169101@qq.com; 17386320608@163.com; 1007244783@qq.com; immunolung28@163.com RI He, Yujing/HJY-9184-2023 FU Ningbo Natural Science Foundation FX No Statement Available CR Antonia SJ, 2017, NEW ENGL J MED, V377, P1919, DOI 10.1056/NEJMoa1709937 Baik AH, 2021, CIRC RES, V128, P1780, DOI 10.1161/CIRCRESAHA.120.315894 Cham J, 2021, J MED CASE REP, V15, DOI 10.1186/s13256-021-02858-7 Gan L, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.962596 Garassino MC, 2020, LANCET ONCOL, V21, P387, DOI [10.1016/51470-2045(19)30301-0, 10.1016/S1470-2045(19)30801-0] Heinzerling L, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0152-y Johnson DB, 2016, NEW ENGL J MED, V375, P1749, DOI 10.1056/NEJMoa1609214 Jotte R, 2020, J THORAC ONCOL, V15, P1351, DOI 10.1016/j.jtho.2020.03.028 Katsume Y, 2018, INTERNAL MED, V57, P3157, DOI 10.2169/internalmedicine.0255-17 Läubli H, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0057-1 Lahiri A, 2023, MOL CANCER, V22, DOI 10.1186/s12943-023-01740-y Mahmood SS, 2018, J AM COLL CARDIOL, V71, P1755, DOI 10.1016/j.jacc.2018.02.037 Nishimura T, 2023, INTERNAL MED, V62, P1319, DOI 10.2169/internalmedicine.0505-22 Nishio M, 2021, J THORAC ONCOL, V16, P653, DOI 10.1016/j.jtho.2020.11.025 Owonikoko TK, 2021, J CLIN ONCOL, V39, P1349, DOI 10.1200/JCO.20.02212 Paz-Ares L, 2019, LANCET, V394, P1929, DOI 10.1016/S0140-6736(19)32222-6 Rudin CM, 2020, J CLIN ONCOL, V38, P2369, DOI 10.1200/JCO.20.00793 Slawinski G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197195 Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948 Sugawara S, 2021, ANN ONCOL, V32, P1137, DOI 10.1016/j.annonc.2021.06.004 Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660 Thai AA, 2021, LANCET, V398, P535, DOI 10.1016/S0140-6736(21)00312-3 West H, 2019, LANCET ONCOL, V20, P924, DOI 10.1016/S1470-2045(19)30167-6 Wu T, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1243980 Yang YP, 2020, J THORAC ONCOL, V15, P1636, DOI 10.1016/j.jtho.2020.07.014 Yun S, 2015, CASE REP ONCOL MED, V2015, DOI 10.1155/2015/794842 Zhou CC, 2021, J THORAC ONCOL, V16, P1501, DOI 10.1016/j.jtho.2021.04.011 Zhou YW, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01350 NR 28 TC 2 Z9 2 U1 0 U2 4 PU SPRINGER PI NEW YORK PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES SN 0941-4355 EI 1433-7339 J9 SUPPORT CARE CANCER JI Support. Care Cancer PD FEB PY 2024 VL 32 IS 2 AR 140 DI 10.1007/s00520-024-08344-2 PG 10 WC Oncology; Health Care Sciences & Services; Rehabilitation WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Health Care Sciences & Services; Rehabilitation GA GQ5A8 UT WOS:001154136700001 PM 38294563 DA 2026-04-17 ER PT J AU Tamargo, J Villacastín, J Caballero, R Delpón, E AF Tamargo, Juan Villacastin, Julian Caballero, Ricardo Delpon, Eva TI Drug-induced atrial fibrillation. A narrative review of a forgotten adverse effect SO PHARMACOLOGICAL RESEARCH LA English DT Review DE Atrial fibrillation; Drug -induced atrial fibrillation; Anticancer drugs; Treatment ID STEM-CELL TRANSPLANTATION; DOBUTAMINE STRESS ECHOCARDIOGRAPHY; CARDIAC AUTONOMIC DYSFUNCTION; OBSTRUCTIVE PULMONARY-DISEASE; HIGH-DOSE CHEMOTHERAPY; LONG-TERM; RISK-FACTORS; MOLECULAR-MECHANISMS; BREAST-CANCER; LUNG-CANCER AB Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with an increased morbidity and mortality. There is clinical evidence that an increasing number of cardiovascular and non -cardiovascular drugs, mainly anticancer drugs, can induce AF either in patients with or without pre-existing cardiac disorders, but drug -induced AF (DIAF) has not received the attention that it might deserve. In many cases DIAF is asymptomatic and paroxysmal and patients recover sinus rhythm spontaneously, but sometimes, DIAF persists, and it is necessary to perform a cardioversion. Furthermore, DIAF is not mentioned in clinical guidelines on the treatment of AF. The risk of DIAF increases in elderly and in patients treated with polypharmacy and with risk factors and comorbidities that commonly coexist with AF. This is the case of cancer patients. Under these circumstances ascribing causality of DIAF to a given drug often represents a clinical challenge. We review the incidence, the pathophysiological mechanisms, risk factors, clinical relevance, and treatment of DIAF. Because of the limited information presently available, further research is needed to obtain a deeper insight into DIAF. Meanwhile, it is important that clinicians are aware of the problem that DIAF represents, recognize which drugs may cause DIAF, and consider the possibility that a drug may be responsible for a new -onset AF episode. C1 [Tamargo, Juan; Caballero, Ricardo; Delpon, Eva] Univ Complutense Madrid, Sch Med, Dept Pharmacol & Toxicol, Inst Invest Sanitaria Gregorio Maranon,CIBERCV, Madrid 28040, Spain. [Villacastin, Julian] Univ Complutense Madrid, Hosp Clin San Carlos, CardioRed1, CIBERCV, Madrid 28040, Spain. C3 CIBER - Centro de Investigacion Biomedica en Red; CIBERCV; Complutense University of Madrid; Hospital Clinico San Carlos; Complutense University of Madrid; CIBER - Centro de Investigacion Biomedica en Red; CIBERCV RP Caballero, R (corresponding author), Univ Complutense Madrid, Sch Med, Dept Pharmacol & Toxicol, Inst Invest Sanitaria Gregorio Maranon,CIBERCV, Madrid 28040, Spain. EM rcaballero@med.ucm.es RI Tamargo, Juan/J-7772-2016; Delpon, Eva/K-8631-2014 FU Ministerio de Ciencia e Innovacion [S2022/BMD-7229]; Comunidad de Madrid [CIBERCV: CB16/11/00303]; Instituto de Salud Carlos III [CB16/11/00458]; [PID2020-118694RB-I00] FX This work was supported by Grants from the Ministerio de Ciencia e Innovacion (PID2020-118694RB-I00) , Comunidad de Madrid (S2022/BMD-7229) and Instituto de Salud Carlos III (CIBERCV: CB16/11/00303; CB16/11/00458) . CR Abdel-Qadir H, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.11838 Abrahamsen B, 2009, J INTERN MED, V265, P581, DOI 10.1111/j.1365-2796.2008.02065.x Agarwal S, 2023, EUROPACE, V25, DOI 10.1093/europace/euad263 Ahmad J, 2022, FRONT CARDIOVASC MED, V9, DOI 10.3389/fcvm.2022.739044 Akçakoyun M, 2014, BIOMED RES INT-UK, V2014, DOI 10.1155/2014/451520 Al-Hasani R, 2011, ANESTHESIOLOGY, V115, P1363, DOI 10.1097/ALN.0b013e318238bba6 Alexandre J, 2023, JACC-CARDIOONCOL, V5, P216, DOI 10.1016/j.jaccao.2022.11.019 Alexandre J, 2021, EUR HEART J-CARD PHA, V7, P312, DOI 10.1093/ehjcvp/pvaa037 Alexandre J, 2018, PHARMACOL THERAPEUT, V189, P89, DOI 10.1016/j.pharmthera.2018.04.009 Aliot E, 2011, EUROPACE, V13, P161, DOI 10.1093/europace/euq382 Alvi RM, 2019, J AM COLL CARDIOL, V74, P3099, DOI 10.1016/j.jacc.2019.10.038 Amioka M, 2016, AM J CARDIOL, V118, P1386, DOI 10.1016/j.amjcard.2016.07.049 Ando M, 2000, BONE MARROW TRANSPL, V25, P185, DOI 10.1038/sj.bmt.1702106 [Anonymous], Common Terminology Criteria for Adverse Events (CTCAE) Arai M, 2000, CIRC RES, V86, P8, DOI 10.1161/01.RES.86.1.8 Arbuck S G, 1993, J Natl Cancer Inst Monogr, P117 Archibald WJ, 2021, ANN HEMATOL, V100, P143, DOI 10.1007/s00277-020-04094-3 Argalious M, 2005, CRIT CARE MED, V33, P1327, DOI 10.1097/01.CCM.0000166876.41694.CA Arun M, 2017, BONE MARROW TRANSPL, V52, P1349, DOI 10.1038/bmt.2017.148 Awan GM, 2000, AM J MED SCI, V320, P69, DOI 10.1097/00000441-200007000-00011 Bäck M, 2012, EUR HEART J, V33, P1928, DOI 10.1093/eurheartj/ehr421 Baggish AL, 2017, CIRCULATION, V135, P1991, DOI 10.1161/CIRCULATIONAHA.116.026945 Baik AH, 2021, CIRC RES, V128, P1780, DOI 10.1161/CIRCRESAHA.120.315894 Baptiste F, 2019, OPEN HEART, V6, DOI 10.1136/openhrt-2019-001049 Basaria S, 2010, NEW ENGL J MED, V363, P109, DOI 10.1056/NEJMoa1000485 Bassand JP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191592 Beavers CJ, 2022, CIRCULATION, V145, pe811, DOI 10.1161/CIR.0000000000001056 BELHASSEN B, 1981, BRIT HEART J, V46, P679 Bénardeau A, 2001, CARDIOVASC RES, V50, P85, DOI 10.1016/S0008-6363(01)00201-2 Berger D, 2019, MATURITAS, V125, P5, DOI 10.1016/j.maturitas.2019.03.015 Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a Bettoni M, 2002, CIRCULATION, V105, P2753, DOI 10.1161/01.CIR.0000018443.44005.D8 Bhatt DL, 2019, NEW ENGL J MED, V380, P11, DOI 10.1056/NEJMoa1812792 Bielecka-Dabrowa A, 2009, THYROID RES, V2, DOI 10.1186/1756-6614-2-4 Bischiniotis Theodoros S, 2005, Hellenic J Cardiol, V46, P324 Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312 Boriani G, 2018, HEMATOL ONCOL, V36, P624, DOI 10.1002/hon.2503 Bouvy ML, 2000, ARCH INTERN MED, V160, P2477, DOI 10.1001/archinte.160.16.2477 BRISTOW MR, 1980, J CARDIOVASC PHARM, V2, P487, DOI 10.1097/00005344-198009000-00002 Brown JR, 2017, HAEMATOLOGICA, V102, P1796, DOI 10.3324/haematol.2017.171041 Brugada J, 2020, EUR HEART J, V41, P655, DOI 10.1093/eurheartj/ehz467 Brundel BJJM, 2022, NAT REV DIS PRIMERS, V8, DOI 10.1038/s41572-022-00347-9 BUFF DD, 1991, J CLIN PSYCHIAT, V52, P174 Byrd JC, 2021, J CLIN ONCOL, V39, P3441, DOI 10.1200/JCO.21.01210 Byrd JC, 2015, BLOOD, V125, P2497, DOI 10.1182/blood-2014-10-606038 Caballero R, 2010, J AM COLL CARDIOL, V55, P2346, DOI 10.1016/j.jacc.2010.02.028 Caldeira D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211228 Camaiti A, 2001, Eur J Emerg Med, V8, P99 Carasso S, 2006, INT J CARDIOL, V111, P53, DOI 10.1016/j.ijcard.2005.07.001 Carson MP, 2002, OBSTET GYNECOL, V100, P1096, DOI 10.1016/S0029-7844(02)02106-3 Ceyhan C, 2004, J CLIN PHARM THER, V29, P267, DOI 10.1111/j.1365-2710.2004.00556.x Chang PC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123868 CHAZAN R, 1995, INT J CLIN PHARM TH, V33, P170 Chen DY, 2022, JACC-CARDIOONCOL, V4, P223, DOI 10.1016/j.jaccao.2022.05.002 Chen PS, 2006, HEART RHYTHM, V3, P1373, DOI 10.1016/j.hrthm.2006.08.010 Chen PS, 2014, CIRC RES, V114, P1500, DOI 10.1161/CIRCRESAHA.114.303772 Chen YC, 2002, J AM COLL CARDIOL, V39, P366, DOI 10.1016/S0735-1097(01)01731-4 Cheung JW, 2012, CIRC-ARRHYTHMIA ELEC, V5, P659, DOI 10.1161/CIRCEP.112.971945 Chiang CE, 2002, CARDIOVASC RES, V55, P290, DOI 10.1016/S0008-6363(02)00438-8 Chou RH, 2017, INT J CARDIOL, V227, P134, DOI 10.1016/j.ijcard.2016.11.185 Christiansen CF, 2009, ARCH INTERN MED, V169, P1677, DOI 10.1001/archinternmed.2009.297 Chugh SS, 2014, CIRCULATION, V129, P837, DOI 10.1161/CIRCULATIONAHA.113.005119 Chung MK, 2001, CIRCULATION, V104, P2886, DOI 10.1161/hc4901.101760 Conen D, 2007, BMJ-BRIT MED J, V335, P432, DOI 10.1136/bmj.39269.672188.AE Corradi D, 2014, CARDIOVASC PATHOL, V23, P71, DOI 10.1016/j.carpath.2013.12.001 Cuffe MS, 2002, JAMA-J AM MED ASSOC, V287, P1541, DOI 10.1001/jama.287.12.1541 Cull G, 2022, BRIT J HAEMATOL, V196, P1209, DOI 10.1111/bjh.17994 Cummings SR, 2007, NEW ENGL J MED, V356, P1895, DOI 10.1056/NEJMc076132 De Caterina R, 2010, ARCH INTERN MED, V170, P1450, DOI 10.1001/archinternmed.2010.305 Deng YQ, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.012540 Diederichsen A, 2022, CIRC-CARDIOVASC IMAG, V15, DOI 10.1161/CIRCIMAGING.121.013165 Din MAU, 2022, CL LYMPH MYELOM LEUK, V22, P98, DOI 10.1016/j.clml.2021.08.006 DINDOGRU A, 1978, MED PEDIATR ONCOL, V5, P65, DOI 10.1002/mpo.2950050110 DOIUCHI J, 1985, CLIN CARDIOL, V8, P176, DOI 10.1002/clc.4960080311 Dong XJ, 2023, EUROPACE, V25, P793, DOI 10.1093/europace/euac237 Duncan DJ, 2010, CELL CALCIUM, V47, P378, DOI 10.1016/j.ceca.2010.02.002 Dutcher JP, 1997, CANCER J SCI AM, V3, P157 Ehrlich JR, 2003, J PHYSIOL-LONDON, V551, P801, DOI 10.1113/jphysiol.2003.046417 Elhendy A, 2000, CHEST, V117, P649, DOI 10.1378/chest.117.3.649 EMARA MK, 1986, POSTGRAD MED J, V62, P1125, DOI 10.1136/pgmj.62.734.1125 Erichsen R, 2012, INTERN EMERG MED, V7, P431, DOI 10.1007/s11739-011-0701-9 Ershad A., 2023, Medicina Clnica Prctica, V6 Escudier M, 2017, CIRCULATION, V136, P2085, DOI 10.1161/CIRCULATIONAHA.117.030571 ESKILSSON J, 1988, RADIOTHER ONCOL, V13, P41, DOI 10.1016/0167-8140(88)90296-4 Falk R.H., 1992, Atrial Fibrillation: Mechanisms and Management, P283 FALK RH, 1988, NEW ENGL J MED, V318, P640 Farmakis D, 2014, J AM COLL CARDIOL, V63, P945, DOI 10.1016/j.jacc.2013.11.026 Feliz V, 2011, CLIN CARDIOL, V34, P356, DOI 10.1002/clc.20904 Feneck RO, 2001, J CARDIOTHOR VASC AN, V15, P306, DOI 10.1053/jcan.2001.23274 FITTON A, 1990, DRUGS, V39, P308, DOI 10.2165/00003495-199039020-00009 Fleming GA, 2008, CIRCULATION, V118, P1619, DOI 10.1161/CIRCULATIONAHA.108.790162 Font J, 2023, ARCH CARDIOVASC DIS, V116, P219, DOI 10.1016/j.acvd.2023.02.005 Fradley MG, 2021, CIRCULATION, V144, pE41, DOI 10.1161/CIR.0000000000000986 Fradley MG, 2019, AM J CARDIOL, V124, P539, DOI 10.1016/j.amjcard.2019.05.029 FREDERIKSEN MC, 1983, AM J OBSTET GYNECOL, V145, P108, DOI 10.1016/0002-9378(83)90350-2 Friberg L, 2010, EUR HEART J, V31, P967, DOI 10.1093/eurheartj/ehn599 Frustaci A, 1997, CIRCULATION, V96, P1180, DOI 10.1161/01.CIR.96.4.1180 Fuggle NR, 2020, DRUGS, V80, P1537, DOI 10.1007/s40265-020-01364-2 FUJIMOTO S, 1990, AM J NEPHROL, V10, P231, DOI 10.1159/000168087 Ganatra S, 2022, JACC-CARDIOONCOL, V4, P616, DOI 10.1016/j.jaccao.2022.07.014 Ganatra S, 2018, JACC-CLIN ELECTROPHY, V4, P1491, DOI 10.1016/j.jacep.2018.06.004 Gen W, 2001, BASIC RES CARDIOL, V96, P623, DOI 10.1007/s003950170014 Gencer B, 2021, CIRCULATION, V144, P1981, DOI 10.1161/CIRCULATIONAHA.121.055654 Georgiopoulos G, 2023, JACC-CARDIOONCOL, V5, P1, DOI 10.1016/j.jaccao.2022.12.005 Ghia P, 2020, J CLIN ONCOL, V38, P2849, DOI 10.1200/JCO.19.03355 Gibson PH, 2010, AM J CARDIOL, V105, P186, DOI 10.1016/j.amjcard.2009.09.007 Glatter KA, 1999, CIRCULATION, V99, P1034, DOI 10.1161/01.CIR.99.8.1034 Goette A, 2016, EUROPACE, V18, P1455, DOI 10.1093/europace/euw161 Goldman A, 2021, J AM COLL CARDIOL, V78, P1800, DOI 10.1016/j.jacc.2021.08.044 Gong IY, 2021, AM HEART J, V232, P47, DOI 10.1016/j.ahj.2020.09.016 Gorenek B, 2017, EUROPACE, V19, P190, DOI 10.1093/europace/euw242 GOTTDIENER JS, 1981, ARCH INTERN MED, V141, P758, DOI 10.1001/archinte.141.6.758 Gottlieb LA, 2023, HEART RHYTHM, V20, P291, DOI 10.1016/j.hrthm.2022.10.009 Greten FR, 2019, IMMUNITY, V51, P27, DOI 10.1016/j.immuni.2019.06.025 Gridelli C, 2001, LUNG CANCER-J IASLC, V31, P277, DOI 10.1016/S0169-5002(00)00194-X Guha A, 2022, EUR HEART J, V43, P300, DOI 10.1093/eurheartj/ehab745 Guieu R, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051366 Guo DL, 2011, J CARDIOVASC PHARM, V57, P79, DOI 10.1097/FJC.0b013e3181ffe8b3 Guzzetti S, 2002, CIRCULATION, V106, pE40, DOI 10.1161/01.CIR.0000028399.42411.13 Hahn VS, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000665 Hanrahan JP, 2008, MEDICINE, V87, P319, DOI 10.1097/MD.0b013e31818fcc02 Hasegawa K, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.120.017267 Havrilla PL, 2009, ANN PHARMACOTHER, V43, P532, DOI 10.1345/aph.1L544 Hayashi K, 1999, JPN HEART J, V40, P827, DOI 10.1536/jhj.40.827 Heijman J, 2014, CIRC RES, V114, P1483, DOI 10.1161/CIRCRESAHA.114.302226 HENDERSON A, 1992, ANAESTH INTENS CARE, V20, P56, DOI 10.1177/0310057X9202000111 HENG MK, 1975, AM HEART J, V90, P487, DOI 10.1016/0002-8703(75)90431-7 Herrmann J, 2020, NAT REV CARDIOL, V17, P474, DOI 10.1038/s41569-020-0348-1 Hewitt RE, 2005, CLIN EXP IMMUNOL, V139, P101, DOI 10.1111/j.1365-2249.2005.02665.x Heywood EG, 2019, J SURG RES, V238, P23, DOI 10.1016/j.jss.2019.01.017 Hindricks G, 2021, EUR HEART J, V42, P373, DOI 10.1093/eurheartj/ehaa612 Howard PA, 2010, AM J CARDIOVASC DRUG, V10, P359, DOI 10.2165/11584720-000000000-00000 Hu P, 2022, FRONT CARDIOVASC MED, V9, DOI 10.3389/fcvm.2022.952430 Hu YF, 2015, NAT REV CARDIOL, V12, P230, DOI 10.1038/nrcardio.2015.2 Huang WF, 2010, MENOPAUSE, V17, P57, DOI 10.1097/gme.0b013e3181b34749 Huerta C, 2005, EPIDEMIOLOGY, V16, P360, DOI 10.1097/01.ede.0000158743.90664.a7 Huh JH, 2023, KOREAN J INTERN MED, V38, P282, DOI 10.3904/kjim.2022.266 Illiano A, 2000, ANTICANCER RES, V20, P3999 Imperatori A, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-4 Isogai T, 2021, AM J CARDIOL, V141, P154, DOI 10.1016/j.amjcard.2020.12.003 ISOMOTO S, 1994, JPN CIRC J, V58, P1 Jain N, 2019, NEW ENGL J MED, V380, P2095, DOI 10.1056/NEJMoa1900574 Jain P, 2021, ESMO OPEN, V6, DOI 10.1016/j.esmoop.2021.100252 Jara M, 2007, DRUG SAFETY, V30, P1151, DOI 10.2165/00002018-200730120-00007 JEREMIC B, 1990, J CHEMOTHERAPY, V2, P264, DOI 10.1080/1120009X.1990.11739029 Jiang L, 2019, HEART RHYTHM, V16, P1374, DOI 10.1016/j.hrthm.2019.04.008 Johnson DB, 2016, NEW ENGL J MED, V375, P1749, DOI 10.1056/NEJMoa1609214 Kaakeh Y, 2012, DRUGS, V72, P1617, DOI 10.2165/11633140-000000000-00000 Kamineni P, 2003, J NATL MED ASSOC, V95, P977 Kanei Y, 2008, INT J CARDIOL, V129, pE15, DOI 10.1016/j.ijcard.2007.05.090 Kasinath NS, 2003, CAN J ANAESTH, V50, P229, DOI 10.1007/BF03017789 Kattelus H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205454 Kawabata M, 2008, EUROPACE, V10, P282, DOI 10.1093/europace/eun012 Kemeny-Suss N, 2009, VASC PHARMACOL, V51, P350, DOI 10.1016/j.vph.2009.09.002 KEUNG EC, 1991, J CLIN INVEST, V87, P2108, DOI 10.1172/JCI115241 KIAT H, 1995, J AM COLL CARDIOL, V26, P1159, DOI 10.1016/0735-1097(95)00298-7 Kilickap S, 2007, SOUTH MED J, V100, P262, DOI 10.1097/01.smj.0000257382.89910.fe Kirchhof P, 2020, NEW ENGL J MED, V383, P1305, DOI 10.1056/NEJMoa2019422 Klein I, 2007, CIRCULATION, V116, P1725, DOI 10.1161/CIRCULATIONAHA.106.678326 Klimovic S, 2022, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.789730 Knecht S, 2008, EUR HEART J, V29, P2125, DOI 10.1093/eurheartj/ehn341 Koene RJ, 2016, CIRCULATION, V133, P1104, DOI 10.1161/CIRCULATIONAHA.115.020406 Kurt IH, 2008, CLIN DRUG INVEST, V28, P527, DOI 10.2165/00044011-200828080-00008 Lainscak M, 2008, INT J CARDIOL, V128, P311, DOI 10.1016/j.ijcard.2007.12.078 Lashgari S, 2003, OBSTET GYNECOL, V101, P814, DOI 10.1016/S0029-7844(03)00058-9 Lau Dennis H, 2007, Int J Cardiol, V117, pe86, DOI 10.1016/j.ijcard.2006.11.199 Lee CWS, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003102 LEE RE, 1989, J CLIN ONCOL, V7, P7, DOI 10.1200/JCO.1989.7.1.7 Lefebvre B, 2020, JACC-CARDIOONCOL, V2, P193, DOI 10.1016/j.jaccao.2020.04.012 Lendeckel U, 2005, PACE, V28, pS275, DOI 10.1111/j.1540-8159.2005.00073.x Li YD, 2015, MED SCI MONITOR, V21, P1414, DOI [10.12659/msm.894320, 10.12659/MSM.894320] Lincoff AM, 2023, NEW ENGL J MED, V389, P107, DOI 10.1056/NEJMoa2215025 Liu G, 2014, AM J CARDIOL, V114, P1523, DOI 10.1016/j.amjcard.2014.08.015 Liu M, 2010, CIRC RES, V107, P967, DOI 10.1161/CIRCRESAHA.110.220673 Liu R, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01984-1 Liu T, 2010, INT J CARDIOL, V145, P365, DOI 10.1016/j.ijcard.2010.02.039 Liu YW, 2023, CANCER MED-US, V12, P6637, DOI 10.1002/cam4.5438 Lombardi D, 2004, TUMORI, V90, P285, DOI 10.1177/030089160409000304 Lombardi M, 2021, EUR HEART J-CARD PHA, V7, pE69, DOI 10.1093/ehjcvp/pvab008 López-Fernández T, 2019, REV ESP CARDIOL, V72, P749, DOI 10.1016/j.rec.2019.03.019 Low RA, 1998, J CLIN PSYCHOPHARM, V18, P170, DOI 10.1097/00004714-199804000-00010 Lu YM, 2016, INT J CARDIOL, V223, P182, DOI 10.1016/j.ijcard.2016.08.100 Lyon AR, 2022, EUR HEART J, V43, P4229, DOI 10.1093/eurheartj/ehac244 Macri V, 2014, HEART RHYTHM, V11, P1055, DOI 10.1016/j.hrthm.2014.03.002 Madnick DL, 2022, CURR CARDIOL REP, V24, P1517, DOI 10.1007/s11886-022-01769-3 Magnani JW, 2014, CIRC-ARRHYTHMIA ELEC, V7, P307, DOI 10.1161/CIRCEP.113.001322 Mahmood SS, 2018, J AM COLL CARDIOL, V71, P1755, DOI 10.1016/j.jacc.2018.02.037 Maior AS, 2013, SCAND J MED SCI SPOR, V23, P548, DOI 10.1111/j.1600-0838.2011.01436.x MAISTER AH, 1983, CAN ANAESTH SOC J, V30, P419, DOI 10.1007/BF03007867 MARGOLIN KA, 1989, J CLIN ONCOL, V7, P486, DOI 10.1200/JCO.1989.7.4.486 Mariani MV, 2021, J THROMB THROMBOLYS, V51, P419, DOI 10.1007/s11239-020-02304-3 Martin RIR, 2014, HEART, V100, P1506, DOI 10.1136/heartjnl-2014-305482 Martinello R, 2019, BREAST J, V25, P444, DOI 10.1111/tbj.13240 MASONI A, 1979, J ELECTROCARDIOL, V12, P361, DOI 10.1016/S0022-0736(79)80004-7 Master SR, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.2568 Mazur Matylda, 2017, JACC Clin Electrophysiol, V3, P139, DOI [10.1016/j.jacep.2016.08.009, 10.1016/j.jacep.2016.08.009] McMullen JR, 2014, BLOOD, V124, P3829, DOI 10.1182/blood-2014-10-604272 Mebazaa A, 2007, JAMA-J AM MED ASSOC, V297, P1883, DOI 10.1001/jama.297.17.1883 MERTES H, 1993, CIRCULATION, V88, P15, DOI 10.1161/01.CIR.88.1.15 Mileshkin LR, 2005, LEUKEMIA LYMPHOMA, V46, P1575, DOI 10.1080/10428190500235884 Montaigne D, 2013, J AM COLL CARDIOL, V62, P1466, DOI 10.1016/j.jacc.2013.03.061 Moreau P, 1999, BONE MARROW TRANSPL, V23, P1003, DOI 10.1038/sj.bmt.1701763 Morelli MB, 2022, FRONT CARDIOVASC MED, V9, DOI 10.3389/fcvm.2022.847012 Mosarla RC, 2019, J AM COLL CARDIOL, V73, P1336, DOI 10.1016/j.jacc.2019.01.017 Mulligan T, 2006, INT J CLIN PRACT, V60, P762, DOI 10.1111/j.1742-1241.2006.00992.x MURDOCK CJ, 1990, AM J CARDIOL, V66, P755, DOI 10.1016/0002-9149(90)91144-U Murphy E, 2016, CIRC RES, V118, P1960, DOI 10.1161/RES.0000000000000104 Murtaza M, 2022, FRONT CARDIOVASC MED, V9, DOI 10.3389/fcvm.2022.867002 Mustroph J, 2017, PHARMACOL THERAPEUT, V176, P22, DOI 10.1016/j.pharmthera.2016.10.006 Nabar A, 2001, HEART, V85, P424, DOI 10.1136/heart.85.4.424 Nattel S, 2020, CIRC RES, V127, P51, DOI 10.1161/CIRCRESAHA.120.316363 Nattel S, 2016, NAT REV CARDIOL, V13, P575, DOI 10.1038/nrcardio.2016.118 Nattel S, 2013, CAN J CARDIOL, V29, P1147, DOI 10.1016/j.cjca.2013.07.797 Nicholls SJ, 2020, JAMA-J AM MED ASSOC, V324, P2268, DOI 10.1001/jama.2020.22258 O'Brien S, 2018, CL LYMPH MYELOM LEUK, V18, P648, DOI 10.1016/j.clml.2018.06.016 O'Neal WT, 2017, ENDOCRINE, V58, P91, DOI 10.1007/s12020-017-1385-3 O'Neal WT, 2015, AM J CARDIOL, V115, P1090, DOI 10.1016/j.amjcard.2015.01.540 Odutayo A, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i4482 Olivieri A, 1998, BONE MARROW TRANSPL, V21, P1049, DOI 10.1038/sj.bmt.1701217 Olshansky B, 2023, J AM HEART ASSOC, V12, DOI 10.1161/JAHA.121.026756 Papp Z, 2020, J CARDIOVASC PHARM, V76, P4, DOI 10.1097/FJC.0000000000000859 PATEL AK, 1981, CHEST, V80, P661, DOI 10.1378/chest.80.6.661 Pazianas M, 2010, J BONE MINER RES, V25, P2, DOI 10.1359/jbmr.091201 Pereira-Junior PP, 2006, EUR J APPL PHYSIOL, V96, P487, DOI 10.1007/s00421-005-0111-7 Petrini I, 2012, CANCER CHEMOTH PHARM, V69, P773, DOI 10.1007/s00280-011-1753-2 Phillips BG, 1997, PHARMACOTHERAPY, V17, P1238 POLDERMANS D, 1994, AM J CARDIOL, V73, P456, DOI 10.1016/0002-9149(94)90675-0 Polk A, 2014, BMC PHARMACOL TOXICO, V15, DOI 10.1186/2050-6511-15-47 POUKKULA A, 1989, J INTERN MED, V226, P229, DOI 10.1111/j.1365-2796.1989.tb01385.x Qureshi WT, 2015, JAMA INTERN MED, V175, P1058, DOI 10.1001/jamainternmed.2015.1045 Rahman F, 2016, JAMA CARDIOL, V1, P384, DOI 10.1001/jamacardio.2016.0582 Rajkumar SV, 2008, J CLIN ONCOL, V26, P2171, DOI 10.1200/JCO.2007.14.1853 Ramalho NJD, 2022, PFLUG ARCH EUR J PHY, V474, P303, DOI 10.1007/s00424-021-02646-8 Ramanna H, 2001, J AM COLL CARDIOL, V37, P1403, DOI 10.1016/S0735-1097(01)01132-9 Razvi S, 2019, THYROID, V29, P174, DOI 10.1089/thy.2018.0251 Reddy V, 2017, INDIAN HEART J, V69, P545, DOI 10.1016/j.ihj.2017.07.004 Reithmann C, 2000, EUR HEART J, V21, P565, DOI 10.1053/euhj.1999.1865 Richards WG, 2006, J CLIN ONCOL, V24, P1561, DOI 10.1200/JCO.2005.04.6813 Rochette L, 2015, TRENDS PHARMACOL SCI, V36, P326, DOI 10.1016/j.tips.2015.03.005 RODRIGUEZ S, 1980, BRIT J PHARMACOL, V70, P15, DOI 10.1111/j.1476-5381.1980.tb10899.x Rosenberg MA, 2018, CLIN CARDIOL, V41, P830, DOI 10.1002/clc.22965 Ruhela M, 2018, International Journal of Basic & Clinical Pharmacology, V7, P813, DOI 10.18203/2319-2003.ijbcp20181192 Sag CM, 2011, J MOL CELL CARDIOL, V51, P749, DOI 10.1016/j.yjmcc.2011.07.016 Saif MW, 2009, EXPERT OPIN DRUG SAF, V8, P191, DOI [10.1517/14740330902733961, 10.1517/14740330902733961 ] Salaria V, 2005, CLIN CARDIOL, V28, P131, DOI 10.1002/clc.4960280306 Salem JE, 2020, J AM COLL CARDIOL, V75, P2521, DOI 10.1016/j.jacc.2020.02.070 Salem JE, 2019, J AM COLL CARDIOL, V74, P1667, DOI 10.1016/j.jacc.2019.07.056 Salem JE, 2018, LANCET ONCOL, V19, P1579, DOI 10.1016/S1470-2045(18)30608-9 Salpeter SR, 2004, CHEST, V125, P2309, DOI 10.1378/chest.125.6.2309 Sampson KJ, 2008, J PHYSIOL-LONDON, V586, P627, DOI 10.1113/jphysiol.2007.141333 Samuel M, 2021, CIRCULATION, V144, P1991, DOI 10.1161/CIRCULATIONAHA.121.057464 Sasaki N, 2001, AM J PHYSIOL-HEART C, V280, pH1882, DOI 10.1152/ajpheart.2001.280.4.H1882 Schäcke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163-7258(02)00297-8 Schmidt M, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3450 Schneider RA, 2008, AM J HEALTH-SYST PH, V65, P2122, DOI 10.2146/ajhp070615 Schreiber DH, 2006, J EMERG MED, V31, P61, DOI 10.1016/j.jemermed.2005.08.011 Secknus MA, 1997, J AM COLL CARDIOL, V29, P1234, DOI 10.1016/S0735-1097(97)00039-9 SESSLER CN, 1990, CHEST, V98, P672, DOI 10.1378/chest.98.3.672 Shaibani A, 2009, J PAIN, V10, P818, DOI 10.1016/j.jpain.2009.01.322 Shanafelt TD, 2017, LEUKEMIA LYMPHOMA, V58, P1630, DOI 10.1080/10428194.2016.1257795 Sharma R, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.004880 Sheldon SH, 2011, J AM SOC ECHOCARDIOG, V24, P86, DOI 10.1016/j.echo.2010.10.008 SHENASA M, 1988, AM J CARDIOL, V62, P403, DOI 10.1016/0002-9149(88)90967-8 Shrestha B, 2020, CIRCULATION, V142, DOI 10.1161/circ.142.suppl_3.16180 Sirohi B, 2000, BONE MARROW TRANSPL, V25, P533, DOI 10.1038/sj.bmt.1702188 Staerk L, 2017, CIRC RES, V120, P1501, DOI 10.1161/CIRCRESAHA.117.309732 Stein-Merlob AF, 2021, CURR CARDIOL REP, V23, DOI 10.1007/s11886-021-01440-3 Sticherling C, 2000, CIRCULATION, V102, P2503, DOI 10.1161/01.CIR.102.20.2503 Strickberger SA, 1997, ANN INTERN MED, V127, P417, DOI 10.7326/0003-4819-127-6-199709150-00001 Sueda S, 2001, AM J CARDIOL, V88, P570, DOI 10.1016/S0002-9149(01)01744-1 Suenari K, 2012, J CARDIOVASC ELECTR, V23, P200, DOI 10.1111/j.1540-8167.2011.02173.x Suetomi T, 2018, CIRCULATION, V138, P2530, DOI 10.1161/CIRCULATIONAHA.118.034621 Sullivan ML, 1999, J EMERG MED, V17, P851, DOI 10.1016/S0736-4679(99)00095-5 Svennberg E, 2022, EUROPACE, DOI 10.1093/europace/euac038 Swanson DR, 2006, MED HYPOTHESES, V66, P1085, DOI 10.1016/j.mehy.2006.01.006 Tahhan AS, 2017, HEART RHYTHM, V14, P1849, DOI 10.1016/j.hrthm.2017.07.028 Tai CT, 1999, J CARDIOVASC ELECTR, V10, P1180, DOI 10.1111/j.1540-8167.1999.tb00293.x Tam CS, 2020, BLOOD, V136, P2038, DOI 10.1182/blood.2020006844 Tamargo J., 2020, Antiarrhythmic Drugs, P265, DOI 10.1007/978-3-030-34893-9_6 Tamargo J., 2017, Cardiac Electrophysiology: From Cell to Bedside, P513 Tamargo J., 2020, Antiarrhythmic Drugs, P107 Tamargo J, 2015, DRUG SAFETY, V38, P129, DOI 10.1007/s40264-014-0258-4 Tamargo J, 2012, EXPERT OPIN DRUG SAF, V11, P615, DOI 10.1517/14740338.2012.698609 Tan AY, 2008, AM J PHYSIOL-HEART C, V295, pH691, DOI 10.1152/ajpheart.01321.2007 Tebbenjohanns J, 1997, J Interv Card Electrophysiol, V1, P33, DOI 10.1023/A:1009758501195 Tfelt-Hansen P, 2013, EXPERT OPIN DRUG MET, V9, P91, DOI 10.1517/17425255.2013.744394 Thompson PA, 2016, BRIT J HAEMATOL, V175, P462, DOI 10.1111/bjh.14324 Thotamgari SR, 2023, POSTGRAD MED, V135, P562, DOI 10.1080/00325481.2023.2218188 Tilleman TR, 2009, J THORAC CARDIOV SUR, V138, P405, DOI 10.1016/j.jtcvs.2009.02.046 Tisdale JE, 2020, CIRCULATION, V142, pE214, DOI 10.1161/CIR.0000000000000905 Tomkowski WZ, 2004, SUPPORT CARE CANCER, V12, P53, DOI 10.1007/s00520-003-0533-x Totzeck M, 2022, EUR HEART J, V43, P1928, DOI 10.1093/eurheartj/ehac106 Trohman RG, 2019, TRENDS CARDIOVAS MED, V29, P285, DOI 10.1016/j.tcm.2018.09.005 Tsao CW, 2022, CIRCULATION, V145, pE153, DOI 10.1161/CIR.0000000000001052 Tscheschner H, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215992 TYRAS DH, 1979, J THORAC CARDIOV SUR, V77, P310 van der Hooft CS, 2006, ARCH INTERN MED, V166, P1016, DOI 10.1001/archinte.166.9.1016 van der Hooft CS, 2004, J AM COLL CARDIOL, V44, P2117, DOI 10.1016/j.jacc.2004.08.053 Varga ZV, 2015, AM J PHYSIOL-HEART C, V309, pH1453, DOI 10.1152/ajpheart.00554.2015 VARRIALE P, 1993, PACE, V16, P1953, DOI 10.1111/j.1540-8159.1993.tb00987.x Veloso HH, 2005, EMERG MED J, V22, P823, DOI 10.1136/emj.2004.015982 Vinogradova TM, 2006, CIRC RES, V98, P505, DOI 10.1161/01.RES.0000204575.94040.d1 Voigt N, 2014, CIRCULATION, V129, P145, DOI 10.1161/CIRCULATIONAHA.113.006641 Wamique S, 2008, CURR PROB CARDIOLOGY, V33, P163, DOI 10.1016/j.cpcardiol.2008.01.002 Weiss JN, 2017, CIRC-ARRHYTHMIA ELEC, V10, DOI 10.1161/CIRCEP.116.004667 WHITE WB, 1985, ARCH GEN PSYCHIAT, V42, P424 Wiczer TE, 2017, BLOOD ADV, V1, P1739, DOI 10.1182/bloodadvances.2017009720 Wymer JP, 2009, CLIN J PAIN, V25, P376, DOI 10.1097/AJP.0b013e318196d2b6 Yang XY, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01058 Yao CX, 2018, CIRCULATION, V138, P2227, DOI 10.1161/CIRCULATIONAHA.118.035202 Yaylaci S, 2011, CLIN TOXICOL, V49, P440, DOI 10.3109/15563650.2011.588605 Ye JZ, 2021, JACC-CARDIOONCOL, V3, P88, DOI 10.1016/j.jaccao.2021.01.009 Yoshida H, 2012, J MOL CELL CARDIOL, V52, P410, DOI 10.1016/j.yjmcc.2011.08.013 Yuan M, 2018, CARDIOVASC THER, V36, DOI 10.1111/1755-5922.12475 Yun JP, 2021, JACC-CARDIOONCOL, V3, P221, DOI 10.1016/j.jaccao.2021.03.006 Zamorano JL, 2016, EUR HEART J, V37, P2768, DOI [10.1093/eurheartj/ehw211, 10.1002/ejhf.654] Zellos L, 2009, J THORAC CARDIOV SUR, V137, P453, DOI 10.1016/j.jtcvs.2008.07.055 Zhang K, 2010, J MOL CELL CARDIOL, V49, P829, DOI 10.1016/j.yjmcc.2010.08.018 Zhang MX, 2020, CARDIOL RES PRACT, V2020, DOI 10.1155/2020/2372067 Zhang S, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2408-9 Zhou KS, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01174-3 Zimmermann M, 2001, J CARDIOVASC ELECTR, V12, P285, DOI 10.1046/j.1540-8167.2001.00285.x NR 322 TC 12 Z9 15 U1 0 U2 13 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1043-6618 EI 1096-1186 J9 PHARMACOL RES JI Pharmacol. Res. PD FEB PY 2024 VL 200 AR 107077 DI 10.1016/j.phrs.2024.107077 EA JAN 2024 PG 23 WC Pharmacology & Pharmacy WE Science Citation Index Expanded (SCI-EXPANDED) SC Pharmacology & Pharmacy GA JP9T7 UT WOS:001174494100001 PM 38244650 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Pernod, G Cohen, A Mismetti, P Sanchez, O Mahé, I AF Pernod, Gilles Cohen, Ariel Mismetti, Patrick Sanchez, Olivier Mahe, Isabelle CA INNOVTE CAT Working Grp TI Cancer-related arterial thromboembolic events SO ARCHIVES OF CARDIOVASCULAR DISEASES LA English DT Review DE Cancer; Thromboembolism; Acute coronary syndrome; Stroke; Atrial fibrillation; Peripheral artery disease ID IMMUNE CHECKPOINT INHIBITORS; ACUTE ISCHEMIC-STROKE; ACUTE LIMB ISCHEMIA; ATRIAL-FIBRILLATION; RISK-FACTORS; VENOUS THROMBOEMBOLISM; BREAST-CANCER; THROMBOSIS; METAANALYSIS; OUTCOMES AB Cancer is associated with a hypercoagulable state and is a well-known independent risk factor for venous thromboembolism, whereas the association between cancer and arterial thromboembolism is less well established. Arterial thromboembolism, primarily defined as myocardial infarction or stroke is significantly more frequent in patients with cancer, independently of vascular risk factors and associated with a three-fold increase in the risk of mortality. Patients with brain cancer, lung cancer, colorectal cancer and pancreatic cancer have the highest relative risk of developing arterial thromboembolism. Antithrombotic treatments should be used with caution due to the increased risk of haemorrhage, as specified in current practice guidelines.(c) 2023 Elsevier Masson SAS. All rights reserved. C1 [Pernod, Gilles] Univ Grenoble Alpes, Serv Med Vasc, Grenoble, France. [Cohen, Ariel] Sorbonne Univ, Hop St Antoine, Hop Tenon, AP HP, Paris, France. [Cohen, Ariel] Sorbonne Univ, Inst Hosp Univ, Inst Cardiometab & Nutr ICAN, Unite INSERM,UMRS 1166,Unite Rech Malad Cardiovasc, F-75013 Paris, France. [Mismetti, Patrick] Hop Nord St Etienne, Serv Medecine Vasc & Therapeut, Serv Med Vasc & Therapeut, St Etienne, France. [Sanchez, Olivier] Hop Europeen Georges Pompidou, AP HP, APHP, Paris, France. [Sanchez, Olivier; Mahe, Isabelle] Univ Paris Cite, Inserm, Innovat Therapeut Hemostase, UMR S1140, Paris, France. [Mahe, Isabelle] Hop Louis Mourier, Serv medecine interne, Serv Med Interne, Colombes, France. [Pernod, Gilles; Mismetti, Patrick; Sanchez, Olivier; Mahe, Isabelle] F CRIN INNOVTE Network, St Etienne, France. [Pernod, Gilles] Medecine Vasc, Med Vasc, F-38043 Grenoble 9, France. C3 Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Assistance Publique Hopitaux Paris (APHP); Sorbonne Universite; Hopital Universitaire Tenon - APHP; Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Sorbonne Universite; CHU de St Etienne; Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Hotel-Dieu - APHP; Hopital Universitaire Europeen Georges-Pompidou - APHP; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Louis-Mourier - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm) RP Pernod, G (corresponding author), Medecine Vasc, Med Vasc, F-38043 Grenoble 9, France. EM GPernod@chu-grenoble.fr OI Mismetti, Patrick/0000-0003-1511-0555; Mahé, Isabelle/0000-0003-1760-7880 FU Leo Pharma; BMS-Pfizer; Roche; Ligue contre le Cancer 92; Sanofi FX This project received funding in the form of unrestricted grants from Leo Pharma, BMS-Pfizer, Roche, Ligue contre le Cancer 92 and Sanofi. CR Aboyans V, 2018, EUR HEART J, V39, P763, DOI 10.1093/eurheartj/ehx095 Alexandre J, 2023, JACC-CARDIOONCOL, V5, P216, DOI 10.1016/j.jaccao.2022.11.019 Alexandre J, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.018403 Alexandre J, 2021, EUR HEART J-CARD PHA, V7, P312, DOI 10.1093/ehjcvp/pvaa037 Aloizou AM, 2022, J CLIN MED, V11, DOI 10.3390/jcm11164696 Arnold D, 2017, ANN ONCOL, V28, P2932, DOI 10.1093/annonc/mdx514 Bharadwaj A, 2020, EUR HEART J, V41, P2183, DOI 10.1093/eurheartj/ehz851 Brenner B, 2018, AM J MED, V131, P1095, DOI 10.1016/j.amjmed.2018.04.037 Chen PC, 2011, STROKE, V42, P3034, DOI 10.1161/STROKEAHA.111.615534 Choueiri TK, 2010, J CLIN ONCOL, V28, P2280, DOI 10.1200/JCO.2009.27.2757 Delluc A, 2019, J THROMB HAEMOST, V17, P1247, DOI 10.1111/jth.14478 Deng YQ, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.012540 Dittrich TD, 2023, EUR STROKE J, V8, P549, DOI 10.1177/23969873231151488 Dolladille C, 2021, EUR HEART J, V42, P4964, DOI 10.1093/eurheartj/ehab618 Drobni ZD, 2020, CIRCULATION, V142, P2299, DOI 10.1161/CIRCULATIONAHA.120.049981 Duarte CW, 2017, JCO CLIN CANCER INFO, V1, DOI 10.1200/CCI.16.00071 Ederhy S, 2019, ARCH CARDIOVASC DIS, V112, P657, DOI 10.1016/j.acvd.2019.06.012 El Sakka K, 2005, BRIT J SURG, V92, P1498, DOI 10.1002/bjs.5125 Farge D, 2022, LANCET ONCOL, V23, pE334, DOI 10.1016/S1470-2045(22)00160-7 Fitzpatrick T, 2017, THROMB RES, V155, P101, DOI 10.1016/j.thromres.2017.05.006 Font J, 2023, ARCH CARDIOVASC DIS, V116, P219, DOI 10.1016/j.acvd.2023.02.005 Frere C, 2021, THROMB RES, V208, P214, DOI 10.1016/j.thromres.2021.02.028 Garibaldi S, 2022, J CLIN MED, V11, DOI 10.3390/jcm11154452 Gevaert SA, 2021, EUR HEART J-ACUTE CA, V10, P947, DOI 10.1093/ehjacc/zuab056 Govsyeyev N, 2021, J VASC SURG, V74, P1033, DOI 10.1016/j.jvs.2021.03.058 Greco A, 2023, J AM COLL CARDIOL, V82, P1538, DOI 10.1016/j.jacc.2023.07.025 Grilz E, 2021, EUR HEART J, V42, P2299, DOI 10.1093/eurheartj/ehab171 Grilz E, 2017, WIEN KLIN WOCHENSCHR, V129, pS126 Grilz E, 2018, HAEMATOLOGICA, V103, P1549, DOI 10.3324/haematol.2018.192419 Guha A, 2022, EUR HEART J, V43, P300, DOI 10.1093/eurheartj/ehab745 Ha J, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.013215 Haguet H, 2020, Cancers (Basel), P12 Haguet H, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01007 Hang XF, 2011, EUR J CLIN PHARMACOL, V67, P613, DOI 10.1007/s00228-010-0988-x Hindricks Gerhard, 2021, Eur Heart J, V42, P373, DOI 10.1093/eurheartj/ehaa612 Huang S, 2020, AM J TRANSL RES, V12, P4795 Ibeh C, 2021, CURR CARDIOL REP, V23, DOI 10.1007/s11886-021-01604-1 Iliescu CA, 2016, CATHETER CARDIO INTE, V87, pE202, DOI 10.1002/ccd.26379 Javid M, 2008, EUR J VASC ENDOVASC, V35, P84, DOI 10.1016/j.ejvs.2007.08.014 Kim JM, 2013, J NEURO-ONCOL, V111, P295, DOI 10.1007/s11060-012-1011-4 Kleindorfer DO, 2021, STROKE, V52, pE364, DOI 10.1161/STR.0000000000000375 Kuan AS, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-53 Kuan AS, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001336 Lapébie FX, 2021, EUR J VASC ENDOVASC, V62, P439, DOI 10.1016/j.ejvs.2021.05.028 Leader A, 2023, JACC-CARDIOONCOL, V5, DOI 10.1016/j.jaccao.2022.08.014 Lee MJ, 2017, J STROKE, V19, P77, DOI 10.5853/jos.2016.00570 Lipton JH, 2016, LANCET ONCOL, V17, P612, DOI 10.1016/S1470-2045(16)00080-2 Lun RD, 2022, FRONT NEUROL, V13, DOI 10.3389/fneur.2022.966190 Lyon AR, 2022, EUR HEART J, V43, P4229, DOI 10.1093/eurheartj/ehac244 Mahé I, 2023, RESPIR MED RES-FRANC, V84, DOI 10.1016/j.resmer.2023.101056 Mariani MV, 2021, J THROMB THROMBOLYS, V51, P419, DOI 10.1007/s11239-020-02304-3 Martinez-Majander N, 2020, EUR J NEUROL, V27, P841, DOI 10.1111/ene.14172 Mery B, 2022, AM J CLIN ONCOL-CANC, V45, P155, DOI 10.1097/COC.0000000000000904 Mery B, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-06838-w Milazzo V, 2020, J CLIN MED, V9, DOI 10.3390/jcm9113642 Moik F, 2022, THROMB RES, V213, pS58, DOI 10.1016/j.thromres.2022.01.004 Morris-Stiff G, 2010, INT J SURG, V8, P233, DOI 10.1016/j.ijsu.2010.01.007 Mulder FI, 2021, JACC-CARDIOONCOL, V3, P205, DOI 10.1016/j.jaccao.2021.02.007 Navi BB, 2019, RES PRACT THROMB HAE, V3, P639, DOI 10.1002/rth2.12223 Navi BB, 2018, NEUROLOGY, V90, pE2025, DOI 10.1212/WNL.0000000000005636 Navi BB, 2018, JAMA NEUROL, V75, P379, DOI 10.1001/jamaneurol.2017.4211 Navi BB, 2017, J AM COLL CARDIOL, V70, P927, DOI 10.1016/j.jacc.2017.06.047 Navi BB, 2015, ANN NEUROL, V77, P291, DOI 10.1002/ana.24325 Navi BB, 2014, NEUROLOGY, V83, P26, DOI 10.1212/WNL.0000000000000539 Nicolajsen CW, 2015, J VASC SURG, V62, P1598, DOI 10.1016/j.jvs.2015.06.223 Pastori D, 2022, INTERN EMERG MED, DOI 10.1007/s11739-022-03156-w Petrelli F, 2012, ANN ONCOL, V23, P1672, DOI 10.1093/annonc/mdr592 Pothineni NV, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.11.29 Powers WJ, 2019, STROKE, V50, pE344, DOI 10.1161/STR.0000000000000211 Pushparaji B, 2023, CURR TREAT OPT CARD, V25, P143, DOI 10.1007/s11936-023-00982-9 Qi WX, 2014, CRIT REV ONCOL HEMAT, V92, P71, DOI 10.1016/j.critrevonc.2014.04.004 Roule V, 2020, BMC CARDIOVASC DISOR, V20, DOI 10.1186/s12872-020-01352-0 Salem JE, 2019, J AM COLL CARDIOL, V74, P1667, DOI 10.1016/j.jacc.2019.07.056 SAPHNER T, 1991, J CLIN ONCOL, V9, P286, DOI 10.1200/JCO.1991.9.2.286 Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086 Solinas C, 2020, THROMB RES, V196, P444, DOI 10.1016/j.thromres.2020.09.038 Sonbol YT, 2023, J STROKE CEREBROVASC, V32, DOI 10.1016/j.jstrokecerebrovasdis.2023.107154 Sun MY, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24097981 Totzeck M, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.006278 Tsang JS, 2011, ANN VASC SURG, V25, P954, DOI 10.1016/j.avsg.2011.06.002 Waldman AD, 2020, NAT REV IMMUNOL, V20, P651, DOI 10.1038/s41577-020-0306-5 Wang TF, 2023, CURR ONCOL, V30, P3032, DOI 10.3390/curroncol30030230 Yun JP, 2021, JACC-CARDIOONCOL, V3, P221, DOI 10.1016/j.jaccao.2021.03.006 Yusuf SW, 2012, CLIN CARDIOL, V35, P443, DOI 10.1002/clc.22007 Zöller B, 2012, EUR J CANCER, V48, P1875, DOI 10.1016/j.ejca.2012.01.005 Zöller B, 2012, EUR J CANCER, V48, P121, DOI 10.1016/j.ejca.2011.09.015 NR 86 TC 14 Z9 16 U1 3 U2 3 PU ELSEVIER MASSON, CORP OFF PI PARIS PA 65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE SN 1875-2136 EI 1875-2128 J9 ARCH CARDIOVASC DIS JI Arch. Cardiovasc. Dis. PD JAN PY 2024 VL 117 IS 1 BP 101 EP 113 DI 10.1016/j.acvd.2023.11.007 EA JAN 2024 PG 13 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA FI0H9 UT WOS:001145010900001 PM 38057257 DA 2026-04-17 ER PT J AU Li, Y Sandeep, B Xiao, ZW AF Li, Yang Sandeep, Bhushan Xiao, Zongwei TI An overview regarding the article 'clinical outcomes and mortality in patients with atrial fibrillation and recently diagnosed lung cancer in oncology outpatient settings' SO CURRENT PROBLEMS IN CARDIOLOGY LA English DT Review DE Atrial fibrillation; Lung cancer; Cardiovascular events; Clinical outcomes AB Cancer-related inflammation, anti-cancer treatment and other cancer-related comorbidities are proposed to affect atrial remodeling, increasing the susceptibility of lung cancer patients for developing atrial fibrillation. Moreover, cancer is assumed to modify the risk of thromboembolisms and bleeding. An association between AF and malignancy has been reported but incompletely defined. The earliest publications of cancer predisposing to AF came in the 1940s-50s with reports of neoplastic cardiac infiltration or mechanical pressure on the heart, and with oncologic thoracic surgery. Subsequently, multiple studies have reported an increased risk of AF after cancer therapy with surgery (particularly thoracic) and chemotherapy. However, the prevalence of AF appears to be higher in patients with cancer at the time of diagnosis even before undergoing therapy. The emerging field of cardio-oncology has revealed that these seemingly disparate disease processes are intertwined, owing to the cardiovascular sequelae of anticancer therapies, shared risk factors that predispose individuals to both cardiovascular disease and cancer, as well the possible potentiation of cancer growth by cardiac dysfunction. Although direct oral anticoagulants (DOAC) seem to represent a safe and effective option, compared to Vitamin K antagonists (VKA), in this population, this statement is based mainly on observational studies and sub analyses of pivotal trials of the DOAC. C1 [Li, Yang; Sandeep, Bhushan; Xiao, Zongwei] Chengdu Second Peoples Hosp, Dept Cardiothorac Surg, Chengdu 610017, Sichuan, Peoples R China. RP Sandeep, B (corresponding author), Chengdu Second Peoples Hosp, Dept Cardiothorac Surg, Chengdu 610017, Sichuan, Peoples R China. EM dr.sandeep07@outlook.com RI Bhushan, Sandeep/AAK-1339-2021 OI Bhushan, Sandeep/0000-0002-7505-3831 CR Chen JD, 2023, FRONT ONCOL, V13, DOI 10.3389/fonc.2023.1125592 López-Bueno R, 2024, CURR PROB CARDIOLOGY, V49, DOI 10.1016/j.cpcardiol.2023.102176 Petermann-Rocha F, 2023, CURR PROB CARDIOLOGY, V48, DOI 10.1016/j.cpcardiol.2023.101934 Semeraro GC, 2021, CANCERS, V13, DOI 10.3390/cancers13164012 Wamique S, 2008, CURR PROB CARDIOLOGY, V33, P163, DOI 10.1016/j.cpcardiol.2008.01.002 NR 5 TC 1 Z9 1 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0146-2806 EI 1535-6280 J9 CURR PROB CARDIOLOGY JI Curr. Probl. Cardiol. PD MAR PY 2024 VL 49 IS 3 AR 102414 DI 10.1016/j.cpcardiol.2024.102414 EA JAN 2024 PG 3 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA JS1Z9 UT WOS:001175075600001 PM 38246319 DA 2026-04-17 ER PT J AU Bradfield, JP Kember, RL Ulrich, A Balkiyarova, Z Alyass, A Aris, IM Bell, JA Broadaway, KA Chen, ZH Chai, JF Davies, NM Fernandez-Orth, D Bustamante, M Fore, R Ganguli, A Heiskala, A Hottenga, JJ Iñiguez, C Kobes, S Leinonen, J Lowry, E Lyytikainen, LP Mahajan, A Pitkänen, N Schnurr, TM Have, CT Strachan, DP Thiering, E Vogelezang, S Wade, KH Wang, CA Wong, A Holm, LA Chesi, A Choong, C Cruz, M Elliott, P Franks, S Frithioff-Bojsoe, C Gauderman, WJ Glessner, JT Gilsanz, V Griesman, K Hanson, RL Kaakinen, M Kalkwarf, H Kelly, A Kindler, J Kähönen, M Lanca, C Lappe, J Lee, NR McCormack, S Mentch, FD Mitchell, JA Mononen, N Niinikoski, H Oken, E Pahkala, K Sim, X Teo, YY Baier, LJ van Beijsterveldt, T Adair, LS Boomsma, D de Geus, E Guxens, M Eriksson, JG Felix, JF Gilliland, FD Biobank, PM Hansen, T Hardy, R Hivert, MF Holm, JC Jaddoe, VWV Järvelin, MR Lehtimäki, T Mackey, DA Meyre, D Mohlke, KL Mykkänen, J Oberfield, S Pennell, CE Perry, JRB Raitakari, O Rivadeneira, F Saw, SM Sebert, S Shepherd, JA Standl, M Sorensen, TIA Timpson, NJ Torrent, M Willemsen, G Hypponen, E Power, C McCarthy, M Freathy, RM Widén, E Hakonarson, H Prokopenko, I Voight, BF Zemel, BS Grant, SFA Cousminer, DL AF Bradfield, Jonathan P. Kember, Rachel L. Ulrich, Anna Balkiyarova, Zhanna Alyass, Akram Aris, Izzuddin M. Bell, Joshua A. Broadaway, K. Alaine Chen, Zhanghua Chai, Jin-Fang Davies, Neil M. Fernandez-Orth, Dietmar Bustamante, Mariona Fore, Ruby Ganguli, Amitavo Heiskala, Anni Hottenga, Jouke-Jan Iniguez, Carmen Kobes, Sayuko Leinonen, Jaakko Lowry, Estelle Lyytikainen, Leo-Pekka Mahajan, Anubha Pitkanen, Niina Schnurr, Theresia M. Have, Christian Theil Strachan, David P. Thiering, Elisabeth Vogelezang, Suzanne Wade, Kaitlin H. Wang, Carol A. Wong, Andrew Holm, Louise Aas Chesi, Alessandra Choong, Catherine Cruz, Miguel Elliott, Paul Franks, Steve Frithioff-Bojsoe, Christine Gauderman, W. James Glessner, Joseph T. Gilsanz, Vicente Griesman, Kendra Hanson, Robert L. Kaakinen, Marika Kalkwarf, Heidi Kelly, Andrea Kindler, Joseph Kahonen, Mika Lanca, Carla Lappe, Joan Lee, Nanette R. McCormack, Shana Mentch, Frank D. Mitchell, Jonathan A. Mononen, Nina Niinikoski, Harri Oken, Emily Pahkala, Katja Sim, Xueling Teo, Yik-Ying Baier, Leslie J. van Beijsterveldt, Toos Adair, Linda S. Boomsma, Dorret, I de Geus, Eco Guxens, Monica Eriksson, Johan G. Felix, Janine F. Gilliland, Frank D. Biobank, Penn Medicine Hansen, Torben Hardy, Rebecca Hivert, Marie-France Holm, Jens-Christian Jaddoe, Vincent W. V. Jarvelin, Marjo-Riitta Lehtimaki, Terho Mackey, David A. Meyre, David Mohlke, Karen L. Mykkanen, Juha Oberfield, Sharon Pennell, Craig E. Perry, John R. B. Raitakari, Olli Rivadeneira, Fernando Saw, Seang-Mei Sebert, Sylvain Shepherd, John A. Standl, Marie Sorensen, Thorkild I. A. Timpson, Nicholas J. Torrent, Maties Willemsen, Gonneke Hypponen, Elina Power, Chris McCarthy, Mark, I Freathy, Rachel M. Widen, Elisabeth Hakonarson, Hakon Prokopenko, Inga Voight, Benjamin F. Zemel, Babette S. Grant, Struan F. A. Cousminer, Diana L. CA Early Growth Genetics Consortium TI Trans-ancestral genome-wide association study of longitudinal pubertal height growth and shared heritability with adult health outcomes SO GENOME BIOLOGY LA English DT Article ID CHILDHOOD GROWTH; AGE; BIRTH; SITAR; TEMPO; ADOLESCENCE; REGRESSION; MUTATIONS; VARIANTS; SPECTRUM AB BackgroundPubertal growth patterns correlate with future health outcomes. However, the genetic mechanisms mediating growth trajectories remain largely unknown. Here, we modeled longitudinal height growth with Super-Imposition by Translation And Rotation (SITAR) growth curve analysis on56,000 trans-ancestry samples with repeated height measurements from age 5 years to adulthood. We performed genetic analysis on six phenotypes representing the magnitude, timing, and intensity of the pubertal growth spurt. To investigate the lifelong impact of genetic variants associated with pubertal growth trajectories, we performed genetic correlation analyses and phenome-wide association studies in the Penn Medicine BioBank and the UK Biobank.ResultsLarge-scale growth modeling enables an unprecedented view of adolescent growth across contemporary and 20th-century pediatric cohorts. We identify 26 genome-wide significant loci and leverage trans-ancestry data to perform fine-mapping. Our data reveals genetic relationships between pediatric height growth and health across the life course, with different growth trajectories correlated with different outcomes. For instance, a faster tempo of pubertal growth correlates with higher bone mineral density, HOMA-IR, fasting insulin, type 2 diabetes, and lung cancer, whereas being taller at early puberty, taller across puberty, and having quicker pubertal growth were associated with higher risk for atrial fibrillation.ConclusionWe report novel genetic associations with the tempo of pubertal growth and find that genetic determinants of growth are correlated with reproductive, glycemic, respiratory, and cardiac traits in adulthood. These results aid in identifying specific growth trajectories impacting lifelong health and show that there may not be a single "optimal" pubertal growth pattern. C1 [Bradfield, Jonathan P.; Glessner, Joseph T.; Mentch, Frank D.; Hakonarson, Hakon; Grant, Struan F. A.] Childrens Hosp Philadelphia, Ctr Appl Genom, Philadelphia, PA 19104 USA. [Bradfield, Jonathan P.; Ganguli, Amitavo; Grant, Struan F. A.; Cousminer, Diana L.] Childrens Hosp Philadelphia, Ctr Spatial & Funct Genom, Philadelphia, PA 19104 USA. [Kember, Rachel L.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Ulrich, Anna; Balkiyarova, Zhanna; Kaakinen, Marika; Prokopenko, Inga] Univ Surrey, Dept Clin & Expt Med, Guildford, Surrey, England. [Ulrich, Anna; Balkiyarova, Zhanna] Imperial Coll London, Dept Metab Digest & Reprod, London, England. [Balkiyarova, Zhanna; Prokopenko, Inga] Univ Surrey, People Ctr Artificial Intelligence Inst, Guildford, Surrey, England. [Alyass, Akram; Meyre, David] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada. [Aris, Izzuddin M.; Fore, Ruby; Oken, Emily; Hivert, Marie-France] Harvard Med Sch, Dept Populat Med, Div Chron Dis Res Lifecourse, Boston, MA 02215 USA. [Aris, Izzuddin M.; Fore, Ruby; Oken, Emily; Hivert, Marie-France] Harvard Pilgrim Hlth Care Inst, Boston, MA 02215 USA. [Bell, Joshua A.; Davies, Neil M.; Wade, Kaitlin H.; Timpson, Nicholas J.] Univ Bristol, MRC Integrat Epidemiol Unit, Bristol, Avon, England. [Broadaway, K. Alaine; Mohlke, Karen L.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA. [Chen, Zhanghua; Gauderman, W. James; Gilliland, Frank D.] Univ Southern Calif, Dept Populat & Publ Hlth Sci, Los Angeles, CA 90032 USA. [Chai, Jin-Fang; Sim, Xueling; Teo, Yik-Ying; Saw, Seang-Mei] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore. [Chai, Jin-Fang; Sim, Xueling; Teo, Yik-Ying; Saw, Seang-Mei] Natl Univ Hlth Syst, Singapore, Singapore. [Davies, Neil M.; Wade, Kaitlin H.] Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol, Avon, England. [Davies, Neil M.] Norwegian Univ Sci & Technol, KG Jebsen Ctr Genet Epidemiol, Dept Publ Hlth & Nursing, NTNU, Trondheim, Norway. [Fernandez-Orth, Dietmar; Bustamante, Mariona; Guxens, Monica] ISGlobal, Barcelona, Spain. [Heiskala, Anni; Lowry, Estelle; Jarvelin, Marjo-Riitta; Sebert, Sylvain] Univ Oulu, Ctr Life Course Hlth Res, Oulu, Finland. [Hottenga, Jouke-Jan; van Beijsterveldt, Toos; Boomsma, Dorret, I; de Geus, Eco; Willemsen, Gonneke] Vrije Univ Amsterdam, Dept Biol Psychol, Amsterdam, Netherlands. [Iniguez, Carmen] Univ Valencia, Dept Stat & Computat Res, Valencia, Spain. [Iniguez, Carmen; Guxens, Monica; Torrent, Maties] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain. [Iniguez, Carmen] Univ Jaume 1, Univ Valencia, Epidemiol & Environm Hlth Joint Res Unit, FISABIO, Valencia, Spain. [Kobes, Sayuko; Hanson, Robert L.; Baier, Leslie J.] NIDDK, Phoenix Epidemiol & Clin Res Ctr, NIH, Bethesda, MD 20892 USA. [Leinonen, Jaakko; Widen, Elisabeth] Univ Helsinki, Inst Mol Med Finland, Helsinki, Finland. [Lyytikainen, Leo-Pekka; Kahonen, Mika] Tampere Univ, Fac Med & Hlth Technol, Finnish Cardiovasc Res Ctr Tampere, Dept Clin Physiol, Tampere 33014, Finland. [Lyytikainen, Leo-Pekka; Kahonen, Mika] Tampere Univ Hosp, Dept Clin Physiol, Tampere 33521, Finland. [Mahajan, Anubha; McCarthy, Mark, I] Univ Oxford, Wellcome Ctr Human Genet, Oxford OX3 7BN, England. [Pitkanen, Niina; Pahkala, Katja; Mykkanen, Juha; Raitakari, Olli] Univ Turku, Res Ctr Appl & Prevent Cardiovasc Med, Turku, Finland. [Pitkanen, Niina; Pahkala, Katja; Mykkanen, Juha; Raitakari, Olli] Univ Turku, Ctr Populat Hlth Res, Turku, Finland. [Pitkanen, Niina; Pahkala, Katja; Mykkanen, Juha; Raitakari, Olli] Turku Univ Hosp, Turku, Finland. [Schnurr, Theresia M.; Have, Christian Theil; Holm, Louise Aas; Frithioff-Bojsoe, Christine; Hansen, Torben; Holm, Jens-Christian; Sorensen, Thorkild I. A.] Univ Copenhagen, Novo Nordisk Fdn Ctr Basic Metab Res, Fac Hlth & Med Sci, Copenhagen, Denmark. [Strachan, David P.] St Georges Univ London, Populat Hlth Res Inst, Cranmer Terrace, London SW17 0RE, England. [Thiering, Elisabeth; Standl, Marie] Helmholtz Zentrum Munchen, Inst Epidemiol, German Res Ctr Environm Hlth, Neuherberg, Germany. [Thiering, Elisabeth] Univ Munich, Dr von Hauner Childrens Hosp, Div Metab & Nutr Med, Med Ctr, Munich, Germany. [Vogelezang, Suzanne; Felix, Janine F.; Jaddoe, Vincent W. V.] Univ Med Ctr Rotterdam, Erasmus MC, Generat Study Grp R, Rotterdam, Netherlands. [Vogelezang, Suzanne; Rivadeneira, Fernando] Univ Med Ctr Rotterdam, Dept Epidemiol, Erasmus MC, Rotterdam, Netherlands. [Vogelezang, Suzanne; Felix, Janine F.; Jaddoe, Vincent W. V.] Univ Med Ctr Rotterdam, Dept Pediat, Erasmus MC, Rotterdam, Netherlands. [Wang, Carol A.; Pennell, Craig E.] Univ Newcastle, Fac Med & Hlth, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia. [Wang, Carol A.; Pennell, Craig E.] Hunter Med Res Inst, Newcastle, NSW 2305, Australia. [Wong, Andrew] UCL, MRC Unit Lifelong Hlth & Ageing, London, England. [Holm, Louise Aas; Frithioff-Bojsoe, Christine; Holm, Jens-Christian] Copenhagen Univ Hosp Holbaek, Dept Pediat, Childrens Obes Clin, Holbaek, Denmark. [Chesi, Alessandra] Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Choong, Catherine] Univ Western Australia, Fac Hlth & Med Sci, Perth, WA, Australia. [Cruz, Miguel] Inst Mexicano Seguro Social, Ctr Med Nacl Siglo 21, Hosp Especialidades, Unidad Invest Med Bioquim, Mexico City, DF, Mexico. [Elliott, Paul] Imperial Coll London, Fac Med, MRC Ctr Environm & Hlth, Sch Publ Hlth, St Marys Campus,Norfolk Pl, London, England. [Franks, Steve; Kaakinen, Marika] Imperial Coll London, Inst Reprod & Dev Biol, London, England. [Gilsanz, Vicente] Childrens Hosp Los Angeles, Ctr Endocrinol Diabet & Metab, Los Angeles, CA 90027 USA. [Griesman, Kendra] Haverford Coll, Haverford, PA 19041 USA. [Kalkwarf, Heidi] Univ Cincinnati, Cincinnati Childrens Hosp, Dept Pediat, Cincinnati, OH USA. [Kelly, Andrea; McCormack, Shana; Mitchell, Jonathan A.; Hakonarson, Hakon; Zemel, Babette S.; Grant, Struan F. A.] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. [Kelly, Andrea; McCormack, Shana; Grant, Struan F. A.] Childrens Hosp Philadelphia, Div Endocrinol & Diabet, Philadelphia, PA 19104 USA. [Kindler, Joseph] Univ Georgia, Coll Family & Consumer Sci, Athens, GA 30602 USA. [Lanca, Carla] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore. [Lappe, Joan] Creighton Univ, Dept Med & Coll Nursing, Sch Med, Omaha, NE USA. [Lee, Nanette R.] Univ San Carlos, USC Off Populat Studies Fdn Inc, Cebu, Philippines. [Mitchell, Jonathan A.; Zemel, Babette S.] Childrens Hosp Philadelphia, Div Gastroenterol Hepatol & Nutr, Philadelphia, PA 19104 USA. [Mononen, Nina; Lehtimaki, Terho] Tampere Univ, Fac Med & Hlth Technol, Finnish Cardiovasc Res Ctr Tampere, Dept Clin Chem, Tampere 33014, Finland. [Mononen, Nina; Lehtimaki, Terho] Fimlab Labs, Dept Clin Chem, Tampere 33520, Finland. [Niinikoski, Harri] Turku Univ Hosp, Dept Pediat & Adolescent Med, Turku, Finland. [Niinikoski, Harri] Univ Turku, Turku, Finland. [Niinikoski, Harri] Univ Turku, Dept Physiol, Turku, Finland. [Oken, Emily] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Pahkala, Katja] Univ Turku, Paavo Nurmi Ctr, Unit Hlth & Phys Act, Turku, Finland. [Adair, Linda S.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Nutr, Chapel Hill, NC USA. [Boomsma, Dorret, I] Amsterdam Reprod & Dev AR&D Res Inst, Amsterdam, Netherlands. [Guxens, Monica] Univ Pompeu Fabra UPF, Barcelona, Spain. [Eriksson, Johan G.] Univ Helsinki, Inst Clin Med, Dept Gen Practice & Primary Hlth Care, Helsinki, Finland. [Eriksson, Johan G.] Folkhalsan Res Ctr, Helsinki, Finland. [Eriksson, Johan G.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Obstet & Gynecol, Singapore, Singapore. [Hardy, Rebecca] UCL Inst Educ, Cohort & Longitudinal Studies Enhancement Resourc, London, England. [Holm, Jens-Christian] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark. [Jarvelin, Marjo-Riitta; Sebert, Sylvain] Imperial Coll London, MRC PHE Ctr Environm & Hlth, Sch Publ Hlth, Dept Epidemiol & Biostat, London W2 1PG, England. [Jarvelin, Marjo-Riitta] Oulu Univ Hosp, Unit Primary Hlth Care, OYS, Kajaanintie 50, Oulu 90220, Finland. [Mackey, David A.] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Ctr Eye Res Australia, Lions Eye Inst, Perth, WA, Australia. [Meyre, David] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada. [Meyre, David] Univ Lorraine, Inserm UMR S1256 Nutr Genet Environm Risk Exposur, Nancy, Meurthe Moselle, France. [Meyre, David] Univ Hosp Ctr Nancy, Dept Biochem Mol Biol Nutr, Nancy, Meurthe Moselle, France. [Oberfield, Sharon] Columbia Univ, Div Pediat Endocrinol, Med Ctr, New York, NY USA. [Pennell, Craig E.] John Hunter Hosp, Dept Matern & Gynaecol, Newcastle, NSW 2305, Australia. [Perry, John R. B.] Univ Cambridge, Sch Clin Med, Wellcome MRC Inst Metab Sci, Metab Res Lab, Cambridge, England. [Perry, John R. B.] Univ Cambridge, Sch Clin Med, Wellcome MRC Inst Metab Sci, MRC Epidemiol Unit, Cambridge, England. [Raitakari, Olli] Turku Univ Hosp, Dept Clin Physiol & Nucl Med, Turku, Finland. [Rivadeneira, Fernando] Univ Med Ctr Rotterdam, Dept Internal Med, Erasmus MC, Rotterdam, Netherlands. [Shepherd, John A.] Univ Hawaii, Dept Epidemiol & Populat Sci, Canc Ctr, Honolulu, HI USA. [Sorensen, Thorkild I. A.] Univ Copenhagen, Fac Hlth & Med Sci, Dept Publ Hlth, Copenhagen, Denmark. [Torrent, Maties] Fundacio Inst Invest Sanitaria Illes Balears IdIS, Palma De Mallorca, Spain. [Hypponen, Elina; Power, Chris] UCL Great Ormond St Inst Child Hlth, London, England. [Hypponen, Elina] Univ South Australia, Australian Ctr Precis Hlth, Unit Clin & Hlth Sci, Adelaide, SA, Australia. [Hypponen, Elina] South Australian Hlth & Med Res Inst, Adelaide, SA, Australia. [Freathy, Rachel M.] Univ Exeter, Fac Hlth & Life Sci, Dept Clin & Biomed Sci, Exeter EX2 5DW, Devon, England. [Prokopenko, Inga] Univ Lille, Inst Pasteur Lille, CNRS, UMR 8199 EGID, F-59000 Lille, France. [Voight, Benjamin F.; Grant, Struan F. A.; Cousminer, Diana L.] Univ Penn, Dept Genet, Philadelphia, PA 19104 USA. [Voight, Benjamin F.] Univ Penn, Perelman Sch Med, Dept Syst Pharmacol & Translat Therapeut, Philadelphia, PA 19104 USA. [Voight, Benjamin F.] Univ Penn, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA. [Grant, Struan F. A.; Cousminer, Diana L.] Childrens Hosp Philadelphia, Div Human Genet, Philadelphia, PA 19104 USA. [Cousminer, Diana L.] GlaxoSmithKline, 1250 S Collegeville Rd, Collegeville, PA 19426 USA. [McCarthy, Mark, I] Genentech Inc, 1 Dna Way, San Francisco, CA 94080 USA. C3 University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Surrey; Imperial College London; University of Surrey; McMaster University; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; University of Bristol; University of North Carolina; University of North Carolina Chapel Hill; University of Southern California; National University of Singapore; National University of Singapore; University of Bristol; Norwegian University of Science & Technology (NTNU); ISGlobal; University of Oulu; Vrije Universiteit Amsterdam; University of Valencia; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; University of Valencia; Universitat Jaume I; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Helsinki; Tampere University; Tampere University; Tampere University Hospital; University of Oxford; Wellcome Centre for Human Genetics; University of Turku; University of Turku; University of Turku; University of Copenhagen; Novo Nordisk Foundation; City St Georges, University of London; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; University of Newcastle; Hunter Medical Research Institute; University of Newcastle; University of London; University College London; University of Copenhagen; Copenhagen University Hospital; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Western Australia; Instituto Mexicano del Seguro Social; Imperial College London; Imperial College London; Children's Hospital Los Angeles; Haverford College; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University System of Georgia; University of Georgia; Singapore National Eye Center; National University of Singapore; Creighton University; University of San Carlos; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Tampere University; University of Turku; University of Turku; University of Turku; Harvard University; Harvard T.H. Chan School of Public Health; University of Turku; University of North Carolina; University of North Carolina Chapel Hill; Pompeu Fabra University; University of Helsinki; Folkhalsan Research Center; National University of Singapore; University of London; University College London; UCL Institute of Education; University of Copenhagen; Imperial College London; University of Oulu; Centre for Eye Research Australia; Lions Eye Institute; University of Western Australia; McMaster University; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine; CHU de Nancy; Columbia University; John Hunter Hospital; University of Cambridge; University of Cambridge; University of Turku; Erasmus University Rotterdam; Erasmus MC; Cancer Research Center of Hawaii; University of Hawaii System; University of Copenhagen; Institut Investigacio Sanitaria Illes Balears (IdISBa); University of London; University College London; Adelaide University; University of South Australia; South Australian Health & Medical Research Institute (SAHMRI); University of Exeter; Pasteur Network; Universite de Lille; Institut Pasteur Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; GlaxoSmithKline; Glaxosmithkline USA; Roche Holding; Genentech; Roche Holding USA RP Grant, SFA (corresponding author), Childrens Hosp Philadelphia, Ctr Appl Genom, Philadelphia, PA 19104 USA.; Grant, SFA; Cousminer, DL (corresponding author), Childrens Hosp Philadelphia, Ctr Spatial & Funct Genom, Philadelphia, PA 19104 USA.; Grant, SFA (corresponding author), Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA.; Grant, SFA (corresponding author), Childrens Hosp Philadelphia, Div Endocrinol & Diabet, Philadelphia, PA 19104 USA.; Grant, SFA; Cousminer, DL (corresponding author), Univ Penn, Dept Genet, Philadelphia, PA 19104 USA.; Grant, SFA; Cousminer, DL (corresponding author), Childrens Hosp Philadelphia, Div Human Genet, Philadelphia, PA 19104 USA.; Cousminer, DL (corresponding author), GlaxoSmithKline, 1250 S Collegeville Rd, Collegeville, PA 19426 USA. EM grants@email.chop.edu; dianal.cousminer@gsk.com RI ; Iñiguez, Carmen/AAA-5866-2019; Grant, Struan/AFM-3357-2022; de Geus, Eco/M-9318-2015; Rivadeneira, Fernando/O-5385-2015; Holm, Jens-Christian/T-4594-2017; Aris, Izzuddin/C-1855-2017; Guxens, Monica/T-2285-2018; Schaan, Beatriz/I-7518-2017; Mitchell, Jonathan/A-8723-2011; Voight, Benjamin/F-1775-2011; Schnurr, Theresia/AAY-9287-2020; Pennell, Craig/ABD-6902-2020; Lehtimäki, Terho/AAD-1094-2022; Pahkala, Katja/GPX-7471-2022; Raitakari, Olli/AAQ-7389-2021; Thiering, Elisabeth/B-3342-2013; Hansen, Torben/J-8065-2012; Chesi, Alessandra/AAT-8248-2020; Perry, John/HCH-1858-2022; Balkhiyarova, Zhanna/AAS-9975-2020; Bustamante, Mariona/ABB-9142-2021; Widén, Elisabeth/HMD-1188-2023; Lança, Carla/AAY-8275-2020; Freathy, Rachel/ACG-5527-2022; Zemel, Babette/JDV-5959-2023; Hardy, Rebecca/AFR-1989-2022; McCarthy, Mark/M-3763-2015; Mackey AO, David/H-5340-2014; Holm, Louise Aas/LRT-4095-2024; Cruz Lopez, Miguel/O-5493-2018; Fernandez Orth, Dietmar/M-3738-2014; Meyre, David/D-7315-2011; Hypponen, Elina/B-2596-2014; Hakonarson, Hakon/ABZ-4865-2022; Hivert, Marie-France/GWN-0455-2022; Heiskala, Anni/MXJ-9138-2025; Timpson, Nicholas/O-7548-2015; Davies, Neil/AGL-5017-2022; Lyytikäinen, Leo-Pekka/C-8544-2016; Prokopenko, Inga/AAU-9895-2020; Standl, Marie/AFO-7435-2022; Mykkänen, Juha/Q-1663-2015; Zhang, Jihui/U-7562-2017; Wong, Andrew/M-8899-2016 OI Wade, Kaitlin/0000-0003-3362-6280; Grant, Struan/0000-0003-2025-5302; de Geus, Eco/0000-0001-6022-2666; Rivadeneira, Fernando/0000-0001-9435-9441; Aris, Izzuddin/0000-0002-9239-7476; Mitchell, Jonathan/0000-0003-3765-2419; Voight, Benjamin/0000-0002-6205-9994; Baier, Leslie/0000-0002-8773-9670; , Carmen/0000-0003-3471-4928; Lehtimäki, Terho/0000-0002-2555-4427; Thiering, Elisabeth/0000-0002-5429-9584; Hansen, Torben/0000-0001-8748-3831; Leinonen, Jaakko/0000-0001-7530-6918; Kaakinen, Marika/0000-0002-9228-0462; Adair, Linda/0000-0002-3670-8073; Bustamante, Mariona/0000-0003-0127-2860; Widen, Elisabeth/0000-0001-7108-2806; van Beijsterveldt, Toos/0000-0002-6617-4201; Lança, Carla/0000-0001-9918-787X; Freathy, Rachel/0000-0003-4152-2238; Mackey AO, David/0000-0001-7914-4709; Holm, Louise Aas/0000-0002-5439-5429; Kähönen, Mika/0000-0002-4510-7341; Cruz Lopez, Miguel/0000-0001-9985-6172; Fernandez Orth, Dietmar/0000-0002-1237-3192; Oken, Emily/0000-0003-2513-3339; Hypponen, Elina/0000-0003-3670-9399; Willeen, Gonneke/0000-0003-3755-0236; Hakonarson, Hakon/0000-0003-2814-7461; Strachan, David/0000-0001-9500-6373; Heiskala, Anni/0009-0009-2342-2488; Timpson, Nicholas/0000-0002-7141-9189; Davies, Neil/0000-0002-2460-0508; Hottenga, Jouke- Jan/0000-0002-5668-2368; Prokopenko, Inga/0000-0003-1624-7457; Fore, Ruby/0009-0009-0396-1484; FU Daniel B. Burke Endowed Chair for Diabetes Research; National Institutes of Health [T32HL129982]; Wellcome Trust [212259/Z/18/Z]; Academy of Finland [322112]; Medical Research Council [MC_UU_12015/2, MC_UU_00006/2]; Wellcome Senior Research Fellowship [WT220390]; MRC (UK) Programme grant [G0802782]; Diabetes UK [20/0006307]; European Union [H2020-SC1-2019-874739]; Agence Nationale de la Recherche [ANR-18-IBHU-0001]; European Union through the "Fonds europeen de developpement regional" (FEDER); "Conseil Regional des Hauts-de-France" (Hauts-de-France Regional Council); "Metropole Europeenne de Lille" (MEL, European Metropolis of Lille); [R01 HD056465]; MRC [MC_UU_12015/2, MC_UU_00006/2] Funding Source: UKRI; Wellcome Trust [212259/Z/18/Z] Funding Source: Wellcome Trust; Agence Nationale de la Recherche (ANR) [ANR-18-IBHU-0001] Funding Source: Agence Nationale de la Recherche (ANR); Medical Research Council [MC_UU_12019/2, G0802782, MC_UU_12015/2, G9815508, MC_PC_15018] Funding Source: researchfish; NNF Center for Basic Metabolic Research [Hansen Group] Funding Source: researchfish; Wellcome Trust [217065/Z/19/Z] Funding Source: researchfish FX Cohort funding can be found in the Supplementary Data. S.F.A.G. is funded by R01 HD056465 and the Daniel B. Burke Endowed Chair for Diabetes Research. K.A.B is funded by the National Institutes of Health (T32HL129982). M.McC is a Wellcome Trust Investigator (funding through 212259/Z/18/Z). K.P. is funded by an Academy of Finland research fellowship (no. 322112). J.P. is supported by the Medical Research Council (Unit programs: MC_UU_12015/2, MC_UU_00006/2). R.M.F. is supported by a Wellcome Senior Research Fellowship (WT220390). S.F. is supported by an MRC (UK) Programme grant (G0802782). I.P. and Z.B. are funded by the Diabetes UK (BDA number: 20/0006307), the European Union's Horizon 2020 research and innovation programme (LONGITOOLS, H2020-SC1-2019-874739). I.P. is supported by Agence Nationale de la Recherche (PreciDIAB, ANR-18-IBHU-0001), by the European Union through the "Fonds europeen de developpement regional" (FEDER), by the "Conseil Regional des Hauts-de-France" (Hauts-de-France Regional Council) and by the "Metropole Europeenne de Lille" (MEL, European Metropolis of Lille). CR Abbassi V, 1998, PEDIATRICS, V102, P507 Aksglaede L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008450 Andersen K, 2018, J INTERN MED, V283, P346, DOI 10.1111/joim.12717 Antonisamy B, 2017, J PEDIATR-US, V180, P53, DOI 10.1016/j.jpeds.2016.09.059 Aris IM, 2022, HUM REPROD, V37, P54, DOI 10.1093/humrep/deab235 Berge T, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-021704 Bjerregaard LG, 2017, PAEDIATR PERINAT EP, V31, P284, DOI 10.1111/ppe.12366 Bulik-Sullivan BK, 2015, NAT GENET, V47, P291, DOI 10.1038/ng.3211 Bycroft C, 2018, NATURE, V562, P203, DOI 10.1038/s41586-018-0579-z Cao ZQ, 2018, COMPUT METH PROG BIO, V163, P79, DOI 10.1016/j.cmpb.2018.05.030 Choi SW, 2019, GIGASCIENCE, V8, DOI 10.1093/gigascience/giz082 Cole TJ, 2016, INT J EPIDEMIOL, V45, P1125, DOI 10.1093/ije/dyw134 Cole TJ, 2010, INT J EPIDEMIOL, V39, P1558, DOI 10.1093/ije/dyq115 Cole TJ, 2018, ANN HUM BIOL, V45, P314, DOI 10.1080/03014460.2018.1453948 Cousminer DL, 2013, HUM MOL GENET, V22, P2735, DOI 10.1093/hmg/ddt104 Crump C, 2018, AM J EPIDEMIOL, V187, P417, DOI 10.1093/aje/kwx255 Day FR, 2017, NAT GENET, V49, P834, DOI 10.1038/ng.3841 Díaz-Gonzalez F, 2022, J MED GENET, V59, P28, DOI 10.1136/jmedgenet-2020-107177 Eriksson JG, 2002, DIABETOLOGIA, V45, P342, DOI 10.1007/s00125-001-0757-6 FISCHBEIN S, 1987, ACTA GENET MED GEMEL, V36, P171, DOI 10.1017/S0001566000004402 Frysz Monika, 2018, Wellcome Open Res, V3, P90, DOI 10.12688/wellcomeopenres.14708.1 German A, 2015, PEDIATR RES, V78, P445, DOI 10.1038/pr.2015.129 Jelenkovic A, 2018, EARLY HUM DEV, V120, P53, DOI 10.1016/j.earlhumdev.2018.04.004 Jelenkovic A, 2016, SCI REP-UK, V6, DOI 10.1038/srep28496 Kamat MA, 2019, BIOINFORMATICS, V35, P4851, DOI 10.1093/bioinformatics/btz469 Kania K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-57011-8 Kember RL, 2021, BIOL PSYCHIAT, V89, P236, DOI 10.1016/j.biopsych.2020.06.026 Kember RL, 2020, CIRC-GENOM PRECIS ME, V13, P114, DOI 10.1161/CIRCGEN.119.002553 Lai FY, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1175-7 Leinonen JT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048785 Llop-Viñolas D, 2004, ACTA PAEDIATR, V93, P874, DOI 10.1111/j.1651-2227.2004.tb02683.x Lope V, 2016, CANCER EPIDEMIOL, V40, P22, DOI 10.1016/j.canep.2015.11.004 Mägi R, 2017, HUM MOL GENET, V26, P3639, DOI 10.1093/hmg/ddx280 Marceau K, 2011, DEV PSYCHOL, V47, P1389, DOI 10.1037/a0023838 Marott JL, 2018, EUR HEART J, V39, P4012, DOI 10.1093/eurheartj/ehy367 McCarthy S, 2016, NAT GENET, V48, P1279, DOI 10.1038/ng.3643 Mikkola TM, 2017, OSTEOPOROSIS INT, V28, P2717, DOI 10.1007/s00198-017-4048-6 Nelson CP, 2015, NEW ENGL J MED, V372, P1608, DOI 10.1056/NEJMoa1404881 Ohlsson C, 2020, DIABETOLOGIA, V63, P1141, DOI 10.1007/s00125-020-05121-8 Ohlsson C, 2019, JAMA PEDIATR, V173, P860, DOI 10.1001/jamapediatrics.2019.2315 Okasha M, 2002, BEST PRACT RES CL EN, V16, P225, DOI 10.1053/beem.2002.0204 Pagnamenta AT, 2021, J MED GENET, DOI 10.1136/jmedgenet-2021-108027 Palmert MR, 2001, J CLIN ENDOCR METAB, V86, P2364, DOI 10.1210/jc.86.6.2364 Pantsiotou S, 2008, ACTA PAEDIATR, V97, P217, DOI 10.1111/j.1651-2227.2007.00598.x PHILLIPS K, 1990, ACTA GENET MED GEMEL, V39, P143, DOI 10.1017/S0001566000005389 Regalado ES, 2011, CIRC RES, V109, P680, DOI 10.1161/CIRCRESAHA.111.248161 Rhodes M, 2009, PEDIATR BLOOD CANCER, V53, P635, DOI 10.1002/pbc.22137 Silventoinen K, 2008, AM J HUM BIOL, V20, P292, DOI 10.1002/ajhb.20717 Silventoinen K, 2022, INT J OBESITY, V46, P1901, DOI 10.1038/s41366-022-01202-3 Simpkin AJ, 2017, ANN HUM BIOL, V44, P715, DOI 10.1080/03014460.2017.1391877 Staley JR, 2016, BIOINFORMATICS, V32, P3207, DOI 10.1093/bioinformatics/btw373 Suresh S, 2015, CHEST, V147, P1118, DOI 10.1378/chest.14-0698 van de Laar IMBH, 2012, J MED GENET, V49, P47, DOI 10.1136/jmedgenet-2011-100382 Wang X, 2006, AM J MED GENET A, V140A, P1846, DOI 10.1002/ajmg.a.31372 Watanabe K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01261-5 Widén E, 2010, AM J HUM GENET, V86, P773, DOI 10.1016/j.ajhg.2010.03.010 Winkler TW, 2014, NAT PROTOC, V9, P1192, DOI 10.1038/nprot.2014.071 Yang W, 2008, J HUM GENET, V53, P368, DOI 10.1007/s10038-008-0253-7 Zhang WW, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/968135 NR 59 TC 11 Z9 11 U1 1 U2 9 PU BMC PI LONDON PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1474-760X J9 GENOME BIOL JI Genome Biol. PD JAN 16 PY 2024 VL 25 IS 1 AR 22 DI 10.1186/s13059-023-03136-z PG 19 WC Biotechnology & Applied Microbiology; Genetics & Heredity WE Science Citation Index Expanded (SCI-EXPANDED) SC Biotechnology & Applied Microbiology; Genetics & Heredity GA LC2E3 UT WOS:001184506500001 PM 38229171 OA Green Submitted, Green Published, gold DA 2026-04-17 ER PT J AU Leshem, Y Etan, T Dolev, Y Nikolaevski-Berlin, A Miodovnik, M Shamai, S Merimsky, O Wolf, I Havakuk, O Tzuberi, M Topilsky, Y Banai, S Rozenbaum, Z Laufer-Perl, M AF Leshem, Yasmin Etan, Tal Dolev, Yardenna Nikolaevski-Berlin, Alla Miodovnik, Mor Shamai, Sivan Merimsky, Ofer Wolf, Ido Havakuk, Ofer Tzuberi, Maor Topilsky, Yan Banai, Shmuel Rozenbaum, Zach Laufer-Perl, Michal TI The prognostic value of beta-1 blockers in patients with non-small-cell lung carcinoma treated with pembrolizumab SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Article DE Immunotherapy; Beta 1-selective; Beta-blockers; Lung cancer; NSCLC ID CANCER-PATIENTS; TUMOR-GROWTH; EPIDEMIOLOGY; CHEMOTHERAPY; SUPPRESSES; DIAGNOSIS; SURVIVAL; OUTCOMES; IMPACT; RISK AB Background: Immune checkpoint inhibitors (ICIs) such as pembrolizumab have revolutionized the treatment of metastatic non-small cell lung cancer (mNSCLC). Beta-adrenergic activation contributes to cancer initiation and progression. While non-selective beta-blocker were found to improve the efficacy of ICIs therapy, the role of beta-1 (beta(1))-selective -blocker (beta B-1) in lung cancer patients is unknown. Objective: To evaluate the effect of beta B-1 on overall survival (OS) and progression-free survival (PFS) in patients diagnosed with mNSCLC and treated with pembrolizumab. Methods: We performed a retrospective analysis of patients diagnosed with mNSCLC and treated with first-line pembrolizumab at our center. Results: Of 200 eligible patients, 53 (27%) were pretreated with beta B-1. Patients in the beta B-1 cohort were older (73 +/- 8 vs. 67 +/- 10 years, p < 0.001) with a higher prevalence of cardiac risk factors and cardiovascular (CV) diseases including ischemic heart disease (32% vs. 16%, p = 0.010), heart failure (9% vs. 3%, p = 0.043) and atrial fibrillation (23% vs. 3%, p < 0.001). Compared to the non-beta B-1 group, patient pretreated with beta B-1 had a significant shorter median OS (12 vs. 24 months, p = 0.004) and PFS (6 vs. 8 months, p < 0.001). In a multivariate analysis, including all CV risk factors and diseases, the use of baseline beta B-1 was a strong and independent predictor for accelerated disease progression (HR 1.92, 95%CI 1.32-2.79, p < 0.001) and shorter OS (HR 1.8, 95%, CI 1.18-2.75, p = 0.007). Conclusions: The use of baseline beta B-1 showed a strong and independent association for shorter OS and PFS in patients diagnosed with mNSCLC and treated with pembrolizumab. C1 [Leshem, Yasmin; Etan, Tal; Dolev, Yardenna; Nikolaevski-Berlin, Alla; Miodovnik, Mor; Shamai, Sivan; Merimsky, Ofer; Wolf, Ido] Tel Aviv Sourasky Med Ctr, Div Oncol, Tel Aviv, Israel. [Havakuk, Ofer; Topilsky, Yan; Banai, Shmuel; Rozenbaum, Zach; Laufer-Perl, Michal] Tel Aviv Sourasky Med Ctr, Div Cardiol, 6 Weizmann St, Tel Aviv, Israel. [Wolf, Ido; Havakuk, Ofer; Tzuberi, Maor; Topilsky, Yan; Banai, Shmuel; Rozenbaum, Zach; Laufer-Perl, Michal] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel. [Rozenbaum, Zach] Tulane Univ, New Orleans, LA USA. [Leshem, Yasmin] Weizmann Inst Sci, Dept Immunol, Rehovot, Israel. C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tulane University; Weizmann Institute of Science RP Laufer-Perl, M (corresponding author), Tel Aviv Sourasky Med Ctr, Div Cardiol, 6 Weizmann St, Tel Aviv, Israel. EM michallp@tlvmc.gov.il RI ; Topilsky, Yan/AFK-7827-2022; Rozenbaum, Zach/AAN-3130-2020; laufer perl, michal/HNJ-5064-2023 OI Wolf, Ido/0000-0001-9319-7612; Topilsky, Yan/0000-0002-2269-802X; CR Ackland GL, 2010, CRIT CARE MED, V38, P388, DOI 10.1097/CCM.0b013e3181c03dfa Barron TI, 2011, J CLIN ONCOL, V29, P2635, DOI 10.1200/JCO.2010.33.5422 Berry JD, 2012, NEW ENGL J MED, V366, P321, DOI 10.1056/NEJMoa1012848 Bodor JN, 2018, J ONCOL PRACT, V14, P529, DOI 10.1200/JOP.18.00250 Bucsek MJ, 2017, CANCER RES, V77, P5639, DOI 10.1158/0008-5472.CAN-17-0546 Cohen JB, 2019, JACC-CARDIOONCOL, V1, P238, DOI 10.1016/j.jaccao.2019.11.009 Cole SW, 2012, CLIN CANCER RES, V18, P1201, DOI 10.1158/1078-0432.CCR-11-0641 Cortellini A, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001361 Duma N, 2019, MAYO CLIN PROC, V94, P1623, DOI 10.1016/j.mayocp.2019.01.013 Gadgeel S, 2020, J CLIN ONCOL, V38, P1505, DOI 10.1200/JCO.19.03136 Gorre F, 2010, ACTA CARDIOL, V65, P565, DOI 10.1080/AC.65.5.2056244 Guo YP, 2011, CELL PHYSIOL BIOCHEM, V28, P315, DOI 10.1159/000331747 Howlader N, 2020, NEW ENGL J MED, V383, P640, DOI 10.1056/NEJMoa1916623 Jensen AWP, 2021, CANCERS, V13, DOI 10.3390/cancers13030394 Kennedy OJ, 2022, EUR J CANCER, V165, P97, DOI 10.1016/j.ejca.2022.01.017 Kennedy OJ, 2022, J IMMUNOTHER, V45, P303, DOI 10.1097/CJI.0000000000000433 Kokolus KM, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1405205 Kokolus KM, 2013, P NATL ACAD SCI USA, V110, P20176, DOI 10.1073/pnas.1304291110 Leshem Y, 2023, CANCER-AM CANCER SOC, V129, P2789, DOI 10.1002/cncr.34918 Li W, 2022, J MOL MED, V100, P1299, DOI 10.1007/s00109-022-02238-8 Oh MS, 2021, CLIN LUNG CANCER, V22, pE57, DOI 10.1016/j.cllc.2020.07.016 Oren O, 2020, AM J CARDIOL, V125, P1920, DOI 10.1016/j.amjcard.2020.02.016 Paz-Ares L, 2021, LANCET ONCOL, V22, P198, DOI 10.1016/S1470-2045(20)30641-0 Pedersen L, 2016, CELL METAB, V23, P554, DOI 10.1016/j.cmet.2016.01.011 Peters S, 2019, ANN ONCOL, V30, P884, DOI 10.1093/annonc/mdz109 Poirier L, 2014, CAN J CARDIOL, V30, pS9, DOI 10.1016/j.cjca.2013.12.001 Qiao GX, 2019, CANCER IMMUNOL IMMUN, V68, P11, DOI 10.1007/s00262-018-2243-8 Quagliariello V, 2021, EUR REV MED PHARMACO, V25, P6797, DOI 10.26355/eurrev_202111_27124 Quagliariello V, 2022, FRONT CARDIOVASC MED, V9, DOI 10.3389/fcvm.2022.930797 Reck M, 2022, J CLIN ONCOL, V40, P586, DOI 10.1200/JCO.21.01497 Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774 Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914 Thiele M, 2015, LIVER INT, V35, P2009, DOI 10.1111/liv.12782 Watkins JL, 2015, CANCER-AM CANCER SOC, V121, P3444, DOI 10.1002/cncr.29392 Woodall MJ, 2020, CANCERS, V12, DOI 10.3390/cancers12051230 NR 35 TC 7 Z9 7 U1 1 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 EI 1874-1754 J9 INT J CARDIOL JI Int. J. Cardiol. PD FEB 15 PY 2024 VL 397 AR 131642 DI 10.1016/j.ijcard.2023.131642 EA JAN 2024 PG 6 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA HC5S6 UT WOS:001157310700001 PM 38065325 DA 2026-04-17 ER PT J AU Walls, GM O'Connor, J Harbinson, M Duane, F Mccann, C Mckavanagh, P Johnston, DI Giacometti, V Mcaleese, J Hounsell, AR Cole, AJ Butterworth, KT Mcgarry, CK Hanna, GG Jain, S AF Walls, G. M. O'Connor, J. Harbinson, M. Duane, F. Mccann, C. Mckavanagh, P. Johnston, D. I. Giacometti, V. Mcaleese, J. Hounsell, A. R. Cole, A. J. Butterworth, K. T. Mcgarry, C. K. Hanna, G. G. Jain, S. TI The Association of Incidental Radiation Dose to the Heart Base with Overall Survival and Cardiac Events after Curative-intent Radiotherapy for Non-small Cell Lung Cancer: Results from the NI-HEART Study SO CLINICAL ONCOLOGY LA English DT Article DE Autosegmentation; cardiovascular disease; heart base; intensity-modulated radiotherapy; lung cancer; radiation cardiotoxicity ID FRACTIONATION; OUTCOMES; THERAPY; TRIALS AB Aims: Cardiac disease is a dose -limiting toxicity in non -small cell lung cancer radiotherapy. The dose to the heart base has been associated with poor survival in multiple institutional and clinical trial datasets using unsupervised, voxel-based analysis. Validation has not been undertaken in a cohort with individual patient delineations of the cardiac base or for the endpoint of cardiac events. The purpose of this study was to assess the association of heart base radiation dose with overall survival and the risk of cardiac events with individual heart base contours. Materials and methods: Patients treated between 2015 and 2020 were reviewed for baseline patient, tumour and cardiac details and both cancer and cardiac outcomes as part of the NI -HEART study. Three cardiologists verified cardiac events including atrial fibrillation, heart failure and acute coronary syndrome. Cardiac substructure delineations were completed using a validated deep learning -based autosegmentation tool and a composite cardiac base structure was generated. Cox and Fine -Gray regressions were undertaken for the risk of death and cardiac events. Results: Of 478 eligible patients, most received 55 Gy/20 fractions (96%) without chemotherapy (58%), planned with intensity -modulated radiotherapy (71%). Pre-existing cardiovascular morbidity was common (78% two or more risk factors, 46% one or more established disease). The median follow-up was 21.1 months. Dichotomised at the median, a higher heart base Dmax was associated with poorer survival on Kaplan -Meier analysis (20.2 months versus 28.3 months; hazard ratio 1.40, 95% confidence interval 1.14-1.75, P = 0.0017) and statistical significance was retained in multivariate analyses. Furthermore, heart base Dmax was associated with pooled cardiac events in a multivariate analysis (hazard ratio 1.75, 95% confidence interval 1.03-2.97, P = 0.04). Conclusions: Heart base Dmax was associated with the rate of death and cardiac events after adjusting for patient, tumour and cardiovascular factors in the NIHEART study. This validates the findings from previous unsupervised analytical approaches. The heart base could be considered as a potential sub -organ at risk towards reducing radiation cardiotoxicity. (c) 2023 Published by Elsevier Ltd on behalf of The Royal College of Radiologists. C1 [Walls, G. M.; Johnston, D. I.; Mcaleese, J.; Hounsell, A. R.; Cole, A. J.; Mcgarry, C. K.; Hanna, G. G.; Jain, S.] Belfast Hlth & Social Care Trust, Canc Ctr Belfast City Hosp, Belfast, North Ireland. [Walls, G. M.; O'Connor, J.; Giacometti, V.; Hounsell, A. R.; Cole, A. J.; Butterworth, K. T.; Mcgarry, C. K.; Hanna, G. G.; Jain, S.] Queens Univ Belfast, Patrick G Johnston Ctr Canc Res, Belfast, North Ireland. [Harbinson, M.; Mccann, C.; Mcgarry, C. K.] Belfast Hlth & Social Care Trust, Dept Cardiol, Belfast, North Ireland. [Harbinson, M.] Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, Belfast, North Ireland. [Duane, F.] St Lukes Hosp, St Lukes Radiat Oncol Network, Dublin, Ireland. [Duane, F.] St James Hosp, Trinity St Jamess Canc Inst, Dublin, Ireland. [Mckavanagh, P.] Ulster Hosp, South Eastern Hlth & Social Care Trust, Dept Cardiol, Dundonald, North Ireland. [Walls, G. M.] Queens Univ Belfast, Patrick G Johnston Ctr Canc Res, Jubilee Rd, Belfast, North Ireland. C3 Queens University Belfast; Queens University Belfast; Trinity College Dublin; Trinity College Dublin; Queens University Belfast RP Walls, GM (corresponding author), Queens Univ Belfast, Patrick G Johnston Ctr Canc Res, Jubilee Rd, Belfast, North Ireland. EM g.walls@qub.ac.uk RI Hanna, Gerard/ABA-5427-2020; O'Connor, John/OOK-7991-2025; Walls, Gerard/I-5652-2019; Butterworth, Karl/I-7476-2019; McCann, Conor/ODJ-4170-2025 OI Hanna, Gerard/0000-0003-1003-5138; Walls, Gerard/0000-0003-0845-9732; Butterworth, Karl/0000-0001-7170-6789; Duane, Frances/0000-0001-7838-5957 FU Irish Clinical Academic Training Programme Fellowship - Wellcome Trust; Health Research Board [203930/B/16/Z]; Health and Social Care, Research and Development Division, Northern Ireland FX This work was funded by an Irish Clinical Academic Training Programme Fellowship (G.M. Walls) , which is supported by the Wellcome Trust and the Health Research Board (grant number 203930/B/16/Z) , the Health Service Executive National Doctors Training and Planning and the Health and Social Care, Research and Development Division, Northern Ireland. CR [Anonymous], 2010, COMMON TERMINOLOGY C [Anonymous], 2023, R Foundation for Statistical Computing Atkins KM, 2021, JAMA ONCOL, V7, P206, DOI 10.1001/jamaoncol.2020.6332 Banfill K, 2021, RADIOTHER ONCOL, V161, pS497 Banfill K, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.1007577 Brada M, 2022, J THORAC ONCOL, V17, P532, DOI 10.1016/j.jtho.2022.01.006 Bradley JD, 2020, J CLIN ONCOL, V38, P706, DOI 10.1200/JCO.19.01162 Bradley JD, 2015, LANCET ONCOL, V16, P187, DOI 10.1016/S1470-2045(14)71207-0 Brink C, 2022, RADIOTHER ONCOL, V172, P126, DOI 10.1016/j.radonc.2022.05.002 Craddock M, 2023, J THORAC ONCOL, V18, P57, DOI 10.1016/j.jtho.2022.09.004 Deasy JO, 2003, MED PHYS, V30, P979, DOI 10.1118/1.1568978 Dess RT, 2017, J CLIN ONCOL, V35, P1395, DOI 10.1200/JCO.2016.71.6142 Duane F, 2017, RADIOTHER ONCOL, V122, P416, DOI 10.1016/j.radonc.2017.01.008 Ferris MJ, 2019, PRACT RADIAT ONCOL, V9, pE473, DOI 10.1016/j.prro.2019.04.013 Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170 GILLETTE EL, 1985, INT J RADIAT ONCOL, V11, P2091, DOI 10.1016/0360-3016(85)90089-6 Hall MD, 2021, INT J RADIAT ONCOL, V111, pE173, DOI 10.1016/j.ijrobp.2021.07.659 Haq R, 2020, PHYS IMAG RADIAT ONC, V14, P61, DOI 10.1016/j.phro.2020.05.009 Johnson-Hart C, 2020, RADIOTHER ONCOL, V152, P177, DOI 10.1016/j.radonc.2020.04.008 Johnson-Hart CN, 2018, INT J RADIAT ONCOL, V102, P434, DOI 10.1016/j.ijrobp.2018.05.052 Kim KH, 2022, JAMA ONCOL, V8, P1624, DOI 10.1001/jamaoncol.2022.4202 Levis M, 2018, RADIOTHER ONCOL, V127, P481, DOI 10.1016/j.radonc.2018.04.014 Liu Xiaonan, 2020, IISE Trans Healthc Syst Eng, V10, P243, DOI [10.1080/24725579.2020.1795012, 10.1080/24725579.2020.1795012] Loap P, 2021, PRACT RADIAT ONCOL, V11, pE434, DOI 10.1016/j.prro.2021.02.002 McWilliam A, 2023, J THORAC ONCOL, V18, P599, DOI 10.1016/j.jtho.2023.01.085 McWilliam A, 2020, PHYS IMAG RADIAT ONC, V15, P46, DOI 10.1016/j.phro.2020.07.002 McWilliam A, 2020, INT J RADIAT ONCOL, V108, P1073, DOI 10.1016/j.ijrobp.2020.06.031 McWilliam A, 2017, EUR J CANCER, V85, P106, DOI 10.1016/j.ejca.2017.07.053 Osorio EMV, 2020, INT J RADIAT ONCOL, V108, P1082, DOI 10.1016/j.ijrobp.2020.06.068 Price G, 2022, CLIN ONCOL-UK, V34, P407, DOI 10.1016/j.clon.2021.12.017 SCHULTZHECTOR S, 1992, RADIOTHER ONCOL, V23, P33, DOI 10.1016/0167-8140(92)90303-C Shameer K, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.672916 Steenbakkers RJHM, 2022, INT J RADIAT ONCOL, V112, P306, DOI 10.1016/j.ijrobp.2021.09.023 Turtle L, 2021, RADIAT ONCOL, V16, DOI 10.1186/s13014-021-01824-3 von Elm E, 2007, ANN INTERN MED, V147, P573, DOI 10.7326/0003-4819-147-8-200710160-00010 Walls GM, 2022, PHYS IMAG RADIAT ONC, V23, P118, DOI 10.1016/j.phro.2022.07.003 Wang K, 2017, J CLIN ONCOL, V35, P1387, DOI 10.1200/JCO.2016.70.0229 Yegya-Raman N, 2018, J THORAC ONCOL, V13, P1508, DOI 10.1016/j.jtho.2018.05.028 Zhang TW, 2019, INT J RADIAT ONCOL, V104, P582, DOI 10.1016/j.ijrobp.2018.12.044 NR 39 TC 24 Z9 26 U1 0 U2 5 PU ELSEVIER SCIENCE LONDON PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0936-6555 EI 1433-2981 J9 CLIN ONCOL-UK JI Clin. Oncol. PD FEB PY 2024 VL 36 IS 2 BP 119 EP 127 DI 10.1016/j.clon.2023.11.029 EA JAN 2024 PG 9 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA GU5X5 UT WOS:001155210200001 PM 38042669 OA Green Submitted, Green Accepted, hybrid DA 2026-04-17 ER PT J AU Jiang, H Wu, GW Lu, B Li, XB AF Jiang, Hao Wu, Guanwen Lu, Biao Li, Xiaobing TI The Relationship between the Duration of Surgery for Thoracoscopic Lobectomy and Postoperative Complications in Patients with Stage I Non-small Cell Lung Cancer SO ANNALI ITALIANI DI CHIRURGIA LA English DT Article DE lung cancer; thoracoscopic complications; duration of surgery ID OPERATIVE DURATION; ENHANCED RECOVERY; IMPACT; VENTILATION; OUTCOMES; TIME AB Objective: To investigate the relationship between the duration of surgery for thoracoscopic lobectomy and postoperative complications in patients with stage I non-small cell lung cancer (NSCLC). Methods: The clinical data of patients who underwent thoracoscopic lobectomy in the Department of Cardiothoracic Surgery, Shaoxing Central Hospital from September 2018 to September 2023 were retrospectively analyzed. Results: A total of 263 patients with thoracoscopic lobectomy were enrolled in this study. The duration of surgery was longer for patients with postoperative hospital stay >7 days, atrial fibrillation, postoperative pulmonary air leakage (>5 days), pleural effusion, or pneumonia compared to patients without corresponding complications, and the differences were statistically significant. Further regression analysis showed that prolonged duration of surgery was a risk factor for pneumonia, pleural effusion, atrial fibrillation, and postoperative hospital stay >7 days, and the predictive value of prolonged duration of surgery for the above complications was moderate. The results of chi-square tests showed that pneumonia, atelectasis, urinary tract infection, liver dysfunction, postoperative pulmonary air leakage (>5 days), pleural effusion, and atrial fibrillation were associated with postoperative hospital stay >7 days. Conclusion: Prolonged duration of surgery is a risk factor for complications such as pneumonia, pleural effusion, atrial fibrillation, and postoperative hospital stay >7 days. C1 [Jiang, Hao; Wu, Guanwen; Lu, Biao; Li, Xiaobing] Shaoxing Cent Hosp, Dept Vasc Surg, Shaoxing 312030, Zhejiang, Peoples R China. [Jiang, Hao; Wu, Guanwen; Lu, Biao; Li, Xiaobing] Shaoxing Univ, Dept Cardiothorac Surg, Cent Hosp, Shaoxing 312020, Zhejiang, Peoples R China. C3 Shaoxing University RP Li, XB (corresponding author), Shaoxing Cent Hosp, Dept Vasc Surg, Shaoxing 312030, Zhejiang, Peoples R China.; Li, XB (corresponding author), Shaoxing Univ, Dept Cardiothorac Surg, Cent Hosp, Shaoxing 312020, Zhejiang, Peoples R China. EM sxszxyylxb@163.com RI Lu, Biao/F-7366-2010 CR Bernatz JT, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.7.FOCUS1534 Daley BJ, 2015, J AM COLL SURGEONS, V220, P550, DOI 10.1016/j.jamcollsurg.2014.12.040 Dexter E, 2022, ANN THORAC SURG, V114, P941, DOI 10.1016/j.athoracsur.2022.01.040 Elrakhawy HM, 2018, HEART SURG FORUM, V21, pE9, DOI 10.1532/hsf.1864 Ettinger DS, 2021, J NATL COMPR CANC NE, V19, P254, DOI 10.6004/jnccn.2021.0013 Faraj KS, 2021, CAN J UROL, V28, P10603 Feng Y, 2016, MED SCI MONITOR, V22 Guidolin K, 2022, SURG ENDOSC, V36, P5076, DOI 10.1007/s00464-021-08871-7 Hardy KL, 2014, AESTHET SURG J, V34, P614, DOI 10.1177/1090820X14528503 Hou LD, 2017, Medical Journal of the Chinese People's Armed Police Force, V28, P1005 Jones D, 2017, J GASTROINTEST SURG, V21, P1865, DOI 10.1007/s11605-017-3573-0 Lai GZ, 2020, TUMORI J, V106, P47, DOI 10.1177/0300891619900805 Leeds IL, 2017, DIS COLON RECTUM, V60, P1092, DOI 10.1097/DCR.0000000000000879 Leonardi B, 2023, THORAC CANCER, V14, P281, DOI 10.1111/1759-7714.14747 [李华伟 Li Huawei], 2019, [中国胸心血管外科临床杂志, Chinese Journal of Clinical Thoracic and Cardiovascular Surgery], V26, P425 Liu CS, 2023, Shanghai Medical and Pharmaceutical Journal, V44, P14 Liu XL, 2022, Chinese Journal of Health Care and Medicine, V24, P408 Lohser J, 2015, ANESTH ANALG, V121, P302, DOI 10.1213/ANE.0000000000000808 Lugg ST, 2016, THORAX, V71, P171, DOI 10.1136/thoraxjnl-2015-207697 Maaliki N, 2021, Journal of Cardiology Cases, V25, P42 Oncology Society of Chinese Medical Association, 2023, Zhonghua Zhong Liu Za Zhi, V45, P539, DOI 10.3760/cma.j.cn112152-20230510-00200 Polites SF, 2017, J PEDIATR SURG, V52, P1239, DOI 10.1016/j.jpedsurg.2016.11.043 Qin C, 2015, INT J SURG, V20, P107, DOI 10.1016/j.ijsu.2015.05.051 Reames BN, 2015, SURG OBES RELAT DIS, V11, P207, DOI 10.1016/j.soard.2014.03.018 Tsumura Hideyo, 2021, AANA J, V89, P227 Tsutani Y, 2021, J THORAC CARDIOV SUR, V162, P1244, DOI 10.1016/j.jtcvs.2020.10.024 [王晨 Wang Chen], 2022, [中华麻醉学杂志, Chinese Journal of Anesthesiology], V42, P1187 Wang HD, 2022, Shandong Medical Journal, V62, P10 Zhong PG, 2022, Chinese Journal of Gerontology, V42, P2924 NR 29 TC 1 Z9 1 U1 1 U2 4 PU EDIZIONI LUIGI POZZI PI ROME PA VIA PANAMA 68, 00198 ROME, ITALY SN 0003-469X EI 2239-253X J9 ANN ITAL CHIR JI Ann. Ital. Chir. PD JAN-FEB PY 2024 VL 95 IS 1 BP 64 EP 69 PG 6 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA LE4X5 UT WOS:001185102200012 PM 38469614 DA 2026-04-17 ER PT J AU Zhang, LF Li, X Wu, HF Luo, J AF Zhang, Lifu Li, Xinv Wu, Haifeng Luo, Jie TI Risk factors associated with atrial fibrillation following lung cancer surgery: A multi-center case-control study SO ASIAN JOURNAL OF SURGERY LA English DT Article DE BNP; Case -control study; Postoperative atrial fibrillation ID ASSISTED THORACIC-SURGERY; BRAIN NATRIURETIC PEPTIDE; BLOOD-CELL COUNT; NONCARDIAC SURGERY; SEX-DIFFERENCES; HEART-FAILURE; ARRHYTHMIAS; PREDICTOR; LOBECTOMY; RESECTION AB Background: Postoperative atrial fibrillation (POAF) is a common complication after major thoracic operations. The objective of this case-control study was to identify the risk factors for POAF following lung cancer surgery Methods: In total, 216 patients with lung cancer who were selected from three different hospitals were followed up between May 2020 and May 2022. They were divided into two groups: case group, patients with POAF and control group, patients without POAF (case-control). Risk factors associated with POAF were investigated using univariate and multivariate logistic regression analyses. Results: Risk factors that were significantly associated with POAF were preoperative brain-type natriuretic peptide (BNP) levels [odds ratio (OR): 4.46; 95% confidence interval (CI): 1.52-13.06; P = 0.0064], sex (OR: 0.07; 95%CI: 0.02-0.28; P = 0.0001), preoperative white blood cell (WBC) count (OR: 3.00; 95% CI: 1.89-4.77; P < 0.0001), lymph node dissection (OR: 11.49; 95%CI: 2.81-47.01; P = 0.0007), and cardiovascular disease (OR: 4.93; 95%CI: 1.14-21.31; P = 0.0326). Conclusion: In summary, data from the three hospitals suggested that preoperative BNP levels, sex, preoperative WBC count, lymph node dissection, and hypertension/coronary heart disease/myocardial infarction were associated with a significantly high risk of POAF following lung cancer surgery. (c) 2023 Asian Surgical Association and Taiwan Robotic Surgery Association. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/). C1 [Zhang, Lifu] Nanchang Med Coll, Jiangxi Canc Hosp, Affiliated Hosp 2, Jiangxi Clin Res Ctr Canc, ECG Room, Nanchang 330029, Peoples R China. [Li, Xinv] Xinyu Peoples Hosp, Dept Nephrol, Xinyu 338000, Jiangxi, Peoples R China. [Wu, Haifeng] Nanchang Med Coll, Jiangxi Prov Peoples Hosp, Dept Resp Med, Affiliated Hosp 1, Nanchang 330006, Peoples R China. [Luo, Jie] Nanjing Univ, Jinling Hosp, Dept Hlth Care, Med Sch, Nanjing 210002, Peoples R China. [Wu, Haifeng] Jiangxi Prov Peoples Hosp, Dept Resp Med, 152 Aiguo Rd, Nanchang 330029, Peoples R China. [Luo, Jie] Nanjing Univ, Jinling Hosp, Dept Hlth Care, Med Sch, 305 East Zhongshan Rd, Nanjing 210002, Peoples R China. C3 Nanchang Medical College; Nanchang Medical College; Nanjing University; Nanjing University RP Wu, HF (corresponding author), Jiangxi Prov Peoples Hosp, Dept Resp Med, 152 Aiguo Rd, Nanchang 330029, Peoples R China.; Luo, J (corresponding author), Nanjing Univ, Jinling Hosp, Dept Hlth Care, Med Sch, 305 East Zhongshan Rd, Nanjing 210002, Peoples R China. EM wuhaifeng1688@qq.com; 371358894@qq.com FU Science and Technology Plan Project of Jiangxi Provincial Health Commission [202211025] FX Declaration of competing interest The authors declare no competing interests. Acknowledgements This study was supported by the Science and Technology Plan Project of Jiangxi Provincial Health Commission (No. 202211025) . References CR AMAR D, 1995, CHEST, V108, P349, DOI 10.1378/chest.108.2.349 Amar D, 2002, ANESTHESIOLOGY, V96, P352, DOI 10.1097/00000542-200202000-00021 Amar D, 2012, J THORAC CARDIOV SUR, V144, P1249, DOI 10.1016/j.jtcvs.2012.06.051 Angele MK, 2000, SHOCK, V14, P81, DOI 10.1097/00024382-200014020-00001 ASAMURA H, 1993, J THORAC CARDIOV SUR, V106, P1104, DOI 10.1016/S0022-5223(19)33985-6 Ata Y, 2009, HEART SURG FORUM, V12, pE211, DOI 10.1532/HSF98.20091014 Bozkurt B, 2021, EUR J HEART FAIL, V23, P352, DOI 10.1002/ejhf.2115 Cardinale D, 2007, CIRCULATION, V115, P1339, DOI 10.1161/CIRCULATIONAHA.106.647008 Daniels LB, 2007, J AM COLL CARDIOL, V50, P2357, DOI 10.1016/j.jacc.2007.09.021 Dyszkiewicz W, 1998, EUR J CARDIO-THORAC, V13, P625, DOI 10.1016/S1010-7940(98)00084-0 ELLENBOGEN KA, 1991, J AM COLL CARDIOL, V18, P891, DOI 10.1016/0735-1097(91)90743-S Fontes ML, 2009, J CARDIOTHOR VASC AN, V23, P484, DOI 10.1053/j.jvca.2009.01.030 Gharagozloo F, 2003, ANN THORAC SURG, V76, P1009, DOI 10.1016/S0003-4975(03)00267-4 Gungor H, 2017, MED PRIN PRACT, V26, P164, DOI 10.1159/000453614 Harpole DH, 1996, ANN THORAC SURG, V61, P977, DOI 10.1016/0003-4975(95)01174-9 Jacob KA, 2017, INT J CARDIOL, V228, P971, DOI 10.1016/j.ijcard.2016.11.038 Jaklitsch MT, 1996, CHEST, V110, P751, DOI 10.1378/chest.110.3.751 Karthikeyan G, 2009, J AM COLL CARDIOL, V54, P1599, DOI 10.1016/j.jacc.2009.06.028 Kimmerly DS, 2007, AM J PHYSIOL-REG I, V292, pR715, DOI 10.1152/ajpregu.00366.2006 Kondo H, 2016, HEART RHYTHM, V13, P241, DOI 10.1016/j.hrthm.2015.07.001 Lainscak M, 2009, HERZ, V34, P589, DOI 10.1007/s00059-009-3316-4 Lamm G, 2006, J CARDIOTHOR VASC AN, V20, P51, DOI 10.1053/j.jvca.2005.03.026 McKenna RJ, 2006, ANN THORAC SURG, V81, P421, DOI 10.1016/j.athoracsur.2005.07.078 Muranishi Y, 2017, SURG TODAY, V47, P252, DOI 10.1007/s00595-016-1380-y Nojiri T, 2015, WORLD J SURG, V39, P1092, DOI 10.1007/s00268-015-2943-6 Nojiri T, 2010, EUR J CARDIO-THORAC, V37, P787, DOI 10.1016/j.ejcts.2009.09.043 Nugent AC, 2011, INT J PSYCHOPHYSIOL, V80, P182, DOI 10.1016/j.ijpsycho.2011.03.001 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Otto CM, 2021, CIRCULATION, V143, pe72, DOI [10.1161/CIR.0000000000000923, 10.1016/j.jacc.2020.11.035, 10.1161/CIR.0000000000000932, 10.1016/j.jacc.2020.11.018] Passman RS, 2005, ANN THORAC SURG, V79, P1698, DOI 10.1016/j.athoracsur.2004.10.058 Podrid PJ, 1999, J AM COLL CARDIOL, V34, P340 Polanczyk CA, 1998, ANN INTERN MED, V129, P279, DOI 10.7326/0003-4819-129-4-199808150-00003 Pu ZY, 2019, THORAC CARDIOV SURG, V67, P120, DOI 10.1055/s-0037-1609037 Rena O, 2001, EUR J CARDIO-THORAC, V20, P688, DOI 10.1016/S1010-7940(01)00890-9 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Semeraro GC, 2021, CANCERS, V13, DOI 10.3390/cancers13164012 Sun RR, 2015, CELL BIOCHEM BIOPHYS, V72, P857, DOI 10.1007/s12013-015-0551-6 Szczeklik W, 2020, CAN MED ASSOC J, V192, pE1715, DOI 10.1503/cmaj.200840 Tada H, 2001, AM J CARDIOL, V88, P436, DOI 10.1016/S0002-9149(01)01698-8 Tan AY, 2007, HEART RHYTHM, V4, pS57, DOI 10.1016/j.hrthm.2006.12.011 Targonski R, 2008, KARDIOL POL, V66, P729 VanMieghem W, 1996, ANN THORAC SURG, V61, P1083, DOI 10.1016/0003-4975(96)00073-2 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 VONKNORRING J, 1992, ANN THORAC SURG, V53, P642, DOI 10.1016/0003-4975(92)90325-X Wang H, 2021, J THORAC DIS, V13, DOI 10.21037/jtd-20-1717 Wickramasinghe SR, 2013, CIRCULATION, V128, P1566, DOI 10.1161/CIRCULATIONAHA.113.001596 NR 46 TC 8 Z9 8 U1 0 U2 5 PU ELSEVIER SINGAPORE PTE LTD PI SINGAPORE PA 3 KILLINEY ROAD 08-01, WINSLAND HOUSE 1, SINGAPORE, 239519, SINGAPORE SN 1015-9584 EI 0219-3108 J9 ASIAN J SURG JI Asian J. Surg. PD JAN PY 2024 VL 47 IS 1 BP 176 EP 183 DI 10.1016/j.asjsur.2023.06.108 EA DEC 2023 PG 8 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA GQ8P4 UT WOS:001154230000001 PM 37419802 OA gold DA 2026-04-17 ER PT J AU Eguchi, T Ide, S Matsuoka, S Iijima, Y Mishima, S Hara, D Kumeda, H Miura, K Hamanaka, K Shimizu, K AF Eguchi, Takashi Ide, Shogo Matsuoka, Shunichiro Iijima, Yasuhiro Mishima, Shuji Hara, Daisuke Kumeda, Hirotaka Miura, Kentaro Hamanaka, Kazutoshi Shimizu, Kimihiro TI Predicting 1-year non-cancer-related adverse events after lung resection SO INTERDISCIPLINARY CARDIOVASCULAR AND THORACIC SURGERY LA English DT Article; Proceedings Paper CT 60th Annual Meeting of the Japan-Society-of-Clinical-Oncology CY OCT 20-22, 2022 CL Kobe, JAPAN SP Japan Soc Clin Oncol DE Anatomical lung resection; Atrial fibrillation; Nomogram; Non-cancer-related outcome; Resected volume; Segmentectomy ID SEGMENTECTOMY AB OBJECTIVES: Assessing the risk for non-cancer-related outcomes following lung cancer surgery is crucial for high-risk patients. This study examined non-cancer-related adverse events within 1 year after lung resection, emphasizing the role of resected lung volume and post-operative atrial fibrillation (POAF). METHODS: We conducted a retrospective analysis of 460 patients who underwent anatomical lung resection for malignant lung tumours. We assessed perioperative factors, such as the number of resected subsegments and POAF, as potential predictors of 1-year non-cancer-related adverse events. Additionally, we validated a previously published nomogram for predicting POAF. RESULTS: One-year non-cancer-related adverse events occurred in 20% of patients. Multivariable analysis identified higher age, lower percentage-predicted forced expiratory volume in 1 second, greater number of resected subsegments and POAF as independent predictors of these adverse events. The incidence of POAF was 8.5%, with higher age, history of atrial fibrillation, and open thoracotomy as independent predictors. A temporal link between POAF and other severe postoperative complications was observed, as 71% of POAF cases preceded other complications. The nomogram's predicted risk for POAF was associated well with the actual incidence. CONCLUSIONS: Resected lung volume and POAF are statistically significant factors associated with non-cancer-related outcomes after lung resection. Minimizing resected lung volume when oncologically and technically feasible, along with identifying patients at risk for POAF, may contribute to improved postoperative outcomes. Our results have implications for risk stratification and preoperative decision-making in lung cancer surgery. C1 [Eguchi, Takashi; Ide, Shogo; Matsuoka, Shunichiro; Iijima, Yasuhiro; Mishima, Shuji; Hara, Daisuke; Kumeda, Hirotaka; Miura, Kentaro; Hamanaka, Kazutoshi; Shimizu, Kimihiro] Shinshu Univ, Dept Surg, Div Gen Thorac Surg, Sch Med, Matsumoto, Japan. [Eguchi, Takashi] Shinshu Univ, Shinshu Univ Hosp, Sch Med, Div Gen Thorac Surg,Dept Surg, 3-1-1 Asahi, Matsumoto 3908621, Japan. C3 Shinshu University; Shinshu University RP Eguchi, T (corresponding author), Shinshu Univ, Shinshu Univ Hosp, Sch Med, Div Gen Thorac Surg,Dept Surg, 3-1-1 Asahi, Matsumoto 3908621, Japan. EM eguchi_t@shinshu-u.ac.jp RI ; Eguchi, Takashi/AAS-9215-2021 OI HAMANAKA, KAZUTOSHI/0000-0002-4640-5690; Eguchi, Takashi/0000-0001-9460-0696 FU Japan Medical Education Foundation (JMEF) [J2203] FX This study was partially funded by the Research Grant for Medical Education (No. J2203) from the Japan Medical Education Foundation (JMEF). CR Altorki N, 2023, NEW ENGL J MED, V388, P489, DOI 10.1056/NEJMoa2212083 Altorki NK, 2018, LANCET RESP MED, V6, P915, DOI 10.1016/S2213-2600(18)30411-9 Amar D, 2019, J THORAC CARDIOV SUR, V157, P2493, DOI 10.1016/j.jtcvs.2019.01.075 Deslauriers J, 2006, ANN THORAC SURG, V81, P1019 Eguchi T, 2017, J CLIN ONCOL, V35, P281, DOI 10.1200/JCO.2016.69.0834 Hristov B, 2019, ANN SURG, V270, P1161, DOI 10.1097/SLA.0000000000002772 Hyun J, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.120.018548 Kuroda H, 2021, THORAC CANCER, V12, P1033, DOI 10.1111/1759-7714.13841 Nomori H, 2021, ANN THORAC SURG, V112, P1127, DOI 10.1016/j.athoracsur.2020.09.036 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Saji H, 2022, LANCET, V399, P1607, DOI 10.1016/S0140-6736(21)02333-3 NR 11 TC 1 Z9 1 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND EI 2753-670X J9 INTERDISC CARDIOV TH JI Interdiscip. Cardiovasc. Thorac. Surg. PD DEC 5 PY 2023 VL 37 IS 6 AR ivad199 DI 10.1093/icvts/ivad199 EA DEC 2023 PG 9 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA DA0H2 UT WOS:001129190500001 PM 38085252 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Wang, SL Yang, PW Liu, H Wang, ZW Hu, PY Ye, P Xia, JH Chen, S AF Wang, Shilin Yang, Peiwen Liu, Hao Wang, Zhiwen Hu, Poyi Ye, Ping Xia, Jiahong Chen, Shu TI Assessing Causality Between Second-Hand Smoking and Potentially Associated Diseases in Multiple Systems: A Two-Sample Mendelian Randomization Study SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID PASSIVE SMOKING; TOBACCO-SMOKE; HEART-DISEASE; ATRIAL-FIBRILLATION; EXPOSURE; RISK; INSTRUMENTS; INFERENCE; COTININE; BURDEN AB Introduction The global disease burden may be exacerbated by exposure to passive smoking (SHS), with the workplace being a primary location for such exposure. Numerous epidemiological studies have identified SHS as a risk factor for diseases affecting various systems, including cardiovascular, respiratory, immune, endocrine, and nervous systems. The conventional observational study has certain methodological constraints that can be circumvented through a Mendelian randomization (MR) study. Our MR study intends to investigate the causal link between workplace exposure to SHS and the potential associated diseases.Aim and Methods Summary statistics data involving European participants were sourced from three databases: the UK Biobank, the FinnGen study, and the European Bioinformatics Institute. Genetic variants linked with exposure to SHS in the workplace were identified as instrumental variables. The MR was carried out using inverse variance weighted (IVW), MR-Egger, and weighted median methods. Sensitivity tests were also undertaken within the MR to evaluate the validity of the causality.Results According to the IVW model, genetically determined atrial fibrillation (AF) and stroke (p = 6.64E-04 and 5.68E-07, odds ratio = 2.030 and 2.494, 95% confidence interval = 1.350 to 3.051 and 1.743 to 3.569) were robustly associated with exposure to SHS in the workplace. Suggestive associations were found between workplace SHS and myocardial infarction (MI), asthma, and depression.Conclusions The MR study demonstrates that exposure to SHS in the workplace is a significant risk factor for AF and stroke in European individuals. Whether workplace exposure to SHS influences other diseases and the causality between them requires further exploration.Implications This study explored the causality between exposure to SHS in the workplace and potential associated diseases in multiple systems, including MI, AF, stroke, lung cancer, asthma, allergic disease, type 2 diabetes, and depression, using an MR study. The MR study can circumvent the methodological constraints of observational studies and establish a causal relationship. The two-sample MR analysis provides evidence supporting the causal association of frequent workplace SHS with AF and stroke. Individuals exposed to SHS in the workplace may also have a heightened risk of MI, asthma, and depression. However, whether SHS affects other diseases and the causality between them requires further investigation. To our knowledge, this is the first two-sample MR study to determine the causal relationship between SHS and potential diseases. Exposure to SHS in the workplace is a prevalent issue and may contribute to a global disease burden. The reduction of exposure following the introduction of smoke-free laws has led to a decrease in the admission rate for cardiac events and an improvement in health indicators. It is crucial to further advance smoke-free policies and their implementation. C1 [Wang, Shilin; Yang, Peiwen; Liu, Hao; Wang, Zhiwen; Hu, Poyi; Xia, Jiahong; Chen, Shu] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Cardiovasc Surg, Wuhan, Peoples R China. [Ye, Ping] Huazhong Univ Sci & Technol, Cent Hosp Wuhan, Tongji Med Coll, Dept Cardiol, Wuhan, Peoples R China. C3 Huazhong University of Science & Technology; Huazhong University of Science & Technology RP Chen, S (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Cardiovasc Surg, Wuhan, Peoples R China. EM shu_chen@hust.edu.cn RI ; Chen, Shu/HLP-9210-2023 OI Wang, Shilin/0000-0002-8738-403X; CR Alves RF, 2022, PULMONOLOGY, V28, P193, DOI 10.1016/j.pulmoe.2020.03.004 Babb S, 2018, NICOTINE TOB RES, V20, P1327, DOI 10.1093/ntr/ntx202 Bowden J, 2015, INT J EPIDEMIOL, V44, P512, DOI 10.1093/ije/dyv080 Burgess S, 2017, EPIDEMIOLOGY, V28, P30, DOI 10.1097/EDE.0000000000000559 Burgess S, 2016, GENET EPIDEMIOL, V40, P597, DOI 10.1002/gepi.21998 Callinan JE, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005992.pub2 Caramaschi D, 2018, TRANSL PSYCHIAT, V8, DOI 10.1038/s41398-018-0313-5 Chen CY, 2008, AM J PHYSIOL-HEART C, V295, pH632, DOI 10.1152/ajpheart.91535.2007 Chen D, 2022, OSTEOARTHR CARTILAGE, V30, P551, DOI 10.1016/j.joca.2021.12.001 Davey Smith G, 2014, HUM MOL GENET, V23, pR89, DOI 10.1093/hmg/ddu328 Elsworth B.L., 2020, BIORXIV, DOI [DOI 10.1101/2020.08.10.244293, 10.244293] Gan Q, 2007, TOB CONTROL, V16, P417, DOI 10.1136/tc.2007.021477 GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V273, P1047, DOI 10.1001/jama.273.13.1047 Groh CA, 2019, J AM COLL CARDIOL, V74, P1658, DOI 10.1016/j.jacc.2019.07.060 He Y, 2008, CIRCULATION, V118, P1535, DOI 10.1161/CIRCULATIONAHA.108.784801 Hedman L, 2011, THORAX, V66, P20, DOI 10.1136/thx.2010.143800 Hemani G, 2018, ELIFE, V7, DOI 10.7554/eLife.34408 Hong MJ, 2018, MUCOSAL IMMUNOL, V11, P894, DOI 10.1038/mi.2017.93 Kearley J, 2015, IMMUNITY, V42, P566, DOI 10.1016/j.immuni.2015.02.011 Larsson SC, 2022, EBIOMEDICINE, V82, DOI 10.1016/j.ebiom.2022.104154 Lawal AO, 2018, INFLAMMATION, V41, P356, DOI 10.1007/s10753-017-0682-6 Lawlor DA, 2008, STAT MED, V27, P1133, DOI 10.1002/sim.3034 Li A, 2022, FRONT PUBLIC HEALTH, V10, DOI 10.3389/fpubh.2022.852572 Lin GM, 2022, PROG CARDIOVASC DIS, V74, P38, DOI 10.1016/j.pcad.2022.10.006 López MJ, 2007, TOB CONTROL, V16, P373, DOI 10.1136/tc.2006.019679 Minelli C, 2021, INT J EPIDEMIOL, V50, P1651, DOI 10.1093/ije/dyab084 Naha N, 2018, HUM EXP TOXICOL, V37, P540, DOI 10.1177/0960327117698543 Ni YM, 2020, ENVIRON RES, V181, DOI 10.1016/j.envres.2019.108910 Nitturi V, 2021, NICOTINE TOB RES, V23, P310, DOI 10.1093/ntr/ntaa163 Öberg M, 2011, LANCET, V377, P139, DOI 10.1016/S0140-6736(10)61388-8 Qiu CL, 2022, FRONT PUBLIC HEALTH, V10, DOI 10.3389/fpubh.2022.921089 Saulyte J, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001611 Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070 Strzelak A, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15051033 Su CP, 2019, MMWR-MORBID MORTAL W, V68, P604, DOI 10.15585/mmwr.mm6827a2 Sudlow C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001779 Swerdlow DI, 2016, INT J EPIDEMIOL, V45, P1600, DOI 10.1093/ije/dyw088 Taha F, 2014, J AFFECT DISORDERS, V168, P367, DOI 10.1016/j.jad.2014.07.014 Taylor AE, 2014, ADDICTION, V109, P1013, DOI 10.1111/add.12514 Teo KK, 2006, LANCET, V368, P647, DOI 10.1016/S0140-6736(06)69249-0 Thacher JD, 2016, ALLERGY, V71, P239, DOI 10.1111/all.12792 Titus AR, 2021, NICOTINE TOB RES, V23, P1527, DOI 10.1093/ntr/ntab038 Tong X, 2020, MOL METAB, V37, DOI 10.1016/j.molmet.2020.100975 Verbanck M, 2018, NAT GENET, V50, P693, DOI 10.1038/s41588-018-0099-7 Whincup PH, 2004, BRIT MED J, V329, P200, DOI 10.1136/bmj.38146.427188.55 Ye XH, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16071249 Ye XH, 2015, PSYCHIAT RES, V229, P533, DOI 10.1016/j.psychres.2015.06.008 Zhai CX, 2023, SCI TOTAL ENVIRON, V862, DOI 10.1016/j.scitotenv.2022.160677 NR 48 TC 11 Z9 11 U1 1 U2 15 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 EI 1469-994X J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD MAY 22 PY 2024 VL 26 IS 6 BP 678 EP 684 DI 10.1093/ntr/ntad193 EA DEC 2023 PG 7 WC Substance Abuse; Public, Environmental & Occupational Health WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI) SC Substance Abuse; Public, Environmental & Occupational Health GA RN5L7 UT WOS:001129565400001 PM 37788476 OA Green Submitted, hybrid DA 2026-04-17 ER PT J AU Jiang, LY Hu, FQ Xiao, X Zhang, XF Rui, B AF Jiang Lianyong Hu Fengqing Xiao Xie Zhang Xuefeng Rui Bi TI Single-Stage Surgical Procedure for Patients with Primary Esophageal and Lung Cancers SO THORACIC AND CARDIOVASCULAR SURGEON LA English DT Article DE esophageal surgery; lung cancer treatment (surgery medical); outcomes (includes mortality morbidity); surgery; complications ID PULMONARY COMPLICATIONS; SUBLOBAR RESECTION; LOBECTOMY; CARCINOMA AB Background: The aim of this study was to evaluate the safety and feasibility of simultaneous surgery for patients with primary esophageal and lung cancers.Methods: Patients with primary esophageal and lung cancers who underwent simultaneous surgical procedures between January 2016 and January 2022 were retrospectively analyzed. The data of patients who underwent esophagectomy and lobectomy (group EL) were compared with those of patients who underwent esophagectomy and sublobar resection (group ES).Results: A total of 21 patients were included with an average age of 64.62 +/- 5.24 years. Group EL contained 8 patients and group ES contained 13 patients. All procedures were completed uneventfully with a mean operative time of 251.19 +/- 66.93 minutes. Pulmonary complications occurred in six (28.57%) patients. Other complications included anastomotic leakage in 1 patient, pleural effusion requiring drainage in 8 patients, atrial fibrillation in 2 patients, and incision infection in 1 patient. All patients were followed up for 30.23 +/- 21.82 months. During the follow-up period, nine patients had a recurrence of cancer and died of tumor progression, and one patient died of a tracheothoracogastric fistula. Complications and mortality in group EL did not increase when compared to those in group ES.Conclusion: It is safe and feasible to perform a single-stage surgical procedure for patients with primary esophageal and lung cancers. Simultaneous esophagectomy and lobectomy did not increase postoperative complications or mortality compared with esophagectomy and sublobar resection. C1 [Jiang Lianyong; Hu Fengqing; Xiao Xie; Rui Bi] Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Dept Cardiothorac Surg, Shanghai, Peoples R China. [Zhang Xuefeng] Naval Med Univ, Affiliated Hosp 1, Dept Radiol, Shanghai, Peoples R China. C3 Shanghai Jiao Tong University; Naval Medical University RP Rui, B (corresponding author), Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Dept Cardiothorac Surg, Shanghai, Peoples R China.; Zhang, XF (corresponding author), Naval Med Univ, Affiliated Hosp 1, Dept Radiol, Shanghai, Peoples R China. EM zhangxf0622@126.com; birui@xinhuamed.com.cn CR Altorki NK, 2014, J THORAC CARDIOV SUR, V147, P754, DOI 10.1016/j.jtcvs.2013.09.065 Avendano CE, 2002, ANN THORAC SURG, V73, P922, DOI 10.1016/S0003-4975(01)03584-6 Brunelli A, 2007, CHEST, V131, P141, DOI 10.1378/chest.06-1345 Cao JL, 2018, ANN THORAC SURG, V105, P1483, DOI 10.1016/j.athoracsur.2018.01.032 Cukic Vesna, 2014, Med Arch, V68, P231, DOI 10.5455/medarh.2014.68.231-235 Fabiani I, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010037 Fang WT, 2003, ANN THORAC SURG, V76, P903, DOI 10.1016/S0003-4975(03)00549-6 FEKETE F, 1994, ANN THORAC SURG, V58, P837, DOI 10.1016/0003-4975(94)90763-3 Ferguson MK, 2011, ANN THORAC SURG, V91, P1494, DOI 10.1016/j.athoracsur.2010.12.036 Fiorelli A, 2016, SURG TODAY, V46, P1370, DOI 10.1007/s00595-016-1314-8 Fukuda H, 1990, Nihon Kyobu Geka Gakkai Zasshi, V38, P1053 Ishii H, 2008, GEN THORAC CARDIOVAS, V56, P126, DOI 10.1007/s11748-007-0200-0 Kim SJ, 2015, ANN THORAC SURG, V99, P210, DOI 10.1016/j.athoracsur.2014.07.066 Li Fang, 2011, Zhonghua Yi Xue Za Zhi, V91, P1064 Matsubara T, 1997, J AM COLL SURGEONS, V185, P520, DOI 10.1016/S1072-7515(97)00102-6 Ohi M, 2019, SURG TODAY, V49, P176, DOI 10.1007/s00595-018-1721-0 Paul DJ, 2011, ANZ J SURG, V81, P700, DOI 10.1111/j.1445-2197.2010.05598.x Raymond DP, 2016, ANN THORAC SURG, V102, P207, DOI 10.1016/j.athoracsur.2016.04.055 Saji H, 2022, LANCET, V399, P1607, DOI 10.1016/S0140-6736(21)02333-3 Semeraro GC, 2021, CANCERS, V13, DOI 10.3390/cancers13164012 Singhal S, 2017, J LAPAROENDOSC ADV S, V27, P288, DOI 10.1089/lap.2016.0443 Strand TE, 2006, THORAX, V61, P710, DOI 10.1136/thx.2005.056481 Tajima Tetsuya, 2017, Kyobu Geka, V70, P822 van Workum F, 2017, ANN THORAC SURG, V103, P267, DOI 10.1016/j.athoracsur.2016.07.010 Wang XX, 2012, CHINESE MED J-PEKING, V125, P193, DOI 10.3760/cma.j.issn.0366-6999.2012.02.006 Yoshida N, 2014, SURG TODAY, V44, P526, DOI 10.1007/s00595-013-0577-6 Zhou C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132889 Zingg U, 2011, ANN SURG ONCOL, V18, P1460, DOI 10.1245/s10434-010-1474-5 NR 28 TC 2 Z9 2 U1 0 U2 3 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0171-6425 EI 1439-1902 J9 THORAC CARDIOV SURG JI Thorac. Cardiovasc. Surg. PD AUG PY 2024 VL 72 IS 05 BP 387 EP 393 DI 10.1055/a-2205-2479 EA DEC 2023 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA A2B1R UT WOS:001128741300001 PM 37935427 OA Bronze DA 2026-04-17 ER PT J AU Ajabnoor, AM Parisi, R Zghebi, SS Ashcroft, DM Faivre-Finn, C Morris, C Mamas, MA Kontopantelis, E AF Ajabnoor, Alyaa M. Parisi, Rosa Zghebi, Salwa S. Ashcroft, Darren M. Faivre-Finn, Corinne Morris, Charlotte Mamas, Mamas A. Kontopantelis, Evangelos TI Oral anticoagulant prescribing among patients with cancer and atrial fibrillation in England, 2009-2019 SO CANCER LA English DT Article DE anticoagulation; atrial fibrillation; cancer; oral anticoagulant; prescribing ID RISK; THROMBOEMBOLISM; STROKE; MANAGEMENT AB BackgroundAnticoagulation of patients with atrial fibrillation (AF) and cancer is challenging because of their high risk for stroke and bleeding. Little is known of the variations of oral anticoagulant (OAC) prescribing in patients with AF with and without cancer.MethodsPatients with first-time AF during 2009-2019 from the Clinical Practice Research Datalink were included. Cancer diagnosis was defined as a history of breast, prostate, colorectal, lung, or hematological cancer. Competing-risk analysis was used to assess the risk of OAC prescribing in patients with AF and cancer adjusted for clinical and sociodemographic factors.ResultsOf 177,065 patients with AF, 11.7% had cancer. Compared to patients without cancer, patients with cancer were less likely to receive OAC: prostate cancer (subhazard ratio [SHR], 0.95; 95% CI, 0.91-0.99), breast cancer (SHR, 0.93; 95% CI, 0.89-0.98), colorectal cancer (SHR, 0.93; 95% CI, 0.88-0.99), hematological cancer (SHR, 0.70; 95% CI, 0.65-0.75), and lung cancer (SHR, 0.44; 95% CI, 0.38-0.50). The cumulative incidence function (CIF) of OAC prescribing was lowest for patients with lung cancer and hematological cancer compared with patients without cancer. The difference between the CIF of OAC prescribing in patients with and without cancer becomes narrower in the most deprived areas. Elderly patients (aged >= 85 years) overall had the lowest CIF of OAC prescribing regardless of cancer status.ConclusionsIn patients with AF, underprescribing of OAC is independently associated with certain cancer types. Patients with hematological and lung cancer are the least likely to receive anticoagulation therapy compared with patients without cancer. Underprescribing of OAC in cancer is linked to old age. Further studies of patients with AF and cancer are warranted to assess the net clinical benefit of anticoagulation in certain cancer types. There is an independent association between cancer and underprescribing of oral anticoagulants (OACs) in patients with atrial fibrillation, which may be driven by the risk of bleeding in certain types of cancer. Underprescribing of OACs was more common in patients with a history of lung cancer and hematological malignancies. Overall, underprescribing of OACs seems to be more common in elderly patients aged >= 85 years. C1 [Ajabnoor, Alyaa M.] King Abdulaziz Univ, Fac Pharm, Dept Pharm Practice, POB 80324, Jeddah 21589, Saudi Arabia. [Ajabnoor, Alyaa M.; Parisi, Rosa; Kontopantelis, Evangelos] Univ Manchester, Fac Biol Med & Hlth, Div Informat Imaging & Data Sci, Sch Hlth Sci,Manchester Acad Hlth Sci Ctr, Manchester, England. [Zghebi, Salwa S.; Morris, Charlotte] Univ Manchester, Manchester Acad Hlth Sci Ctr, Div Populat Hlth Hlth Serv Res & Primary Care, Sch Hlth Sci,Fac Biol Med & Hlth, Manchester, England. [Ashcroft, Darren M.] Univ Manchester, Ctr Pharmacoepidemiol & Drug Safety, Div Pharm & Optometry, Sch Hlth Sci,Fac Biol Med & Hlth, Manchester, England. [Ashcroft, Darren M.] Univ Manchester, Natl Inst Hlth & Care Res NIHR, Greater Manchester Patient Safety Translat Res Ctr, Manchester, England. [Faivre-Finn, Corinne] Christie Natl Hlth Serv Fdn Trust, Manchester, England. [Faivre-Finn, Corinne] Univ Manchester, Manchester, England. [Mamas, Mamas A.] Keele Univ, Inst Primary Care & Hlth Sci, Ctr Prognosis Res, Keele Cardiovasc Res Grp, Keele, England. C3 King Abdulaziz University; University of Manchester; University of Manchester; University of Manchester; University of Manchester; Christie NHS Foundation Trust; University of Manchester; Keele University RP Ajabnoor, AM (corresponding author), King Abdulaziz Univ, Fac Pharm, Dept Pharm Practice, POB 80324, Jeddah 21589, Saudi Arabia. EM ammajabnour@kau.edu.sa RI Ashcroft, Darren/G-3244-2015; Faivre-Finn, Corinne/JXN-7003-2024; Kontopantelis, Evangelos/H-2966-2019; Ajabnoor, Alyaa/LDG-3802-2024; Mamas, Mamas/A-2549-2019 OI Ashcroft, Darren/0000-0002-2958-915X; Faivre-Finn, Corinne/0000-0001-5617-9781; Kontopantelis, Evangelos/0000-0001-6450-5815; Ajabnoor, Alyaa/0000-0001-5154-6183; Morris, Charlotte/0000-0002-9047-0481; Zghebi, Salwa S/0000-0002-7978-1094 FU National Health Service (NHS); Ministry of Education of Saudi Arabia as part of a PhD scholarship at The University of Manchester - National Institute of Health and Care Research Greater Manchester Patient Safety Translational Research Centre [PSTRC-2016-003]; National Institute for Health and Care Research (NIHR) School for Primary Care Research/Welcome Trust PhD Programme for Primary Care Clinicians FX This study was conducted with Clinical Practice Research Datalink (CPRD) data obtained under license from the UK Medicines and Healthcare Products Regulatory Agency. The data were provided by patients and collected by the National Health Service (NHS) as part of their care and support. The Office for National Statistics (ONS) is the provider of the ONS data contained within the CPRD data. Hospital Episode Data and ONS data, (c) 2021, are reused with the permission of NHS Digital, all rights reserved. We are grateful to the contributing patients and practices in the CPRD who have allowed their data to be used for research purposes. Alyaa M. Ajabnoor's research was supported by the Ministry of Education of Saudi Arabia as part of a PhD scholarship at The University of Manchester. Darren M. Ashcroft is funded by the National Institute of Health and Care Research Greater Manchester Patient Safety Translational Research Centre (PSTRC-2016-003). Charlotte Morris is funded by the National Institute for Health and Care Research (NIHR) School for Primary Care Research/Welcome Trust PhD Programme for Primary Care Clinicians. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. CR Ajabnoor AM, 2023, J AM HEART ASSOC, V12, DOI 10.1161/JAHA.123.029423 Ajabnoor AM, 2022, PLOS MED, V19, DOI 10.1371/journal.pmed.1004003 Ardeshirrouhanifard S, 2022, PHARMACOTHERAPY, V42, P375, DOI 10.1002/phar.2679 Boriani G, 2021, EUR J PREV CARDIOL, V28, P611, DOI 10.1093/eurjpc/zwaa054 CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8 Conen D, 2016, JAMA CARDIOL, V1, P389, DOI 10.1001/jamacardio.2016.0280 Davis MK, 2021, JACC-CARDIOONCOL, V3, P425, DOI 10.1016/j.jaccao.2021.07.003 Delluc A, 2019, J THROMB HAEMOST, V17, P1247, DOI 10.1111/jth.14478 Fradley MG, 2020, JACC-CARDIOONCOL, V2, P747, DOI 10.1016/j.jaccao.2020.09.008 Gevaert SA, 2022, EUR HEART J-ACUTE CA, V11, P865, DOI 10.1093/ehjacc/zuac107 Green D, 2007, SEMIN THROMB HEMOST, V33, P427, DOI 10.1055/s-2007-976178 Guzzetti S, 2008, INTERN EMERG MED, V3, P227, DOI 10.1007/s11739-008-0124-4 Herrett E, 2015, INT J EPIDEMIOL, V44, P827, DOI 10.1093/ije/dyv098 Hindricks G, 2021, EUR HEART J, V42, P373, DOI 10.1093/eurheartj/ehaa612 Howlett J, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-06930-1 Hu YF, 2013, INT J CARDIOL, V165, P355, DOI 10.1016/j.ijcard.2012.08.036 Kim K, 2018, KOREAN CIRC J, V48, P406 Kirchhof P, 2016, EUR HEART J, V37, P2893, DOI 10.1093/eurheartj/ehw210 Kobo O, 2022, INT J CARDIOL, V363, P210, DOI 10.1016/j.ijcard.2022.06.053 Kontopantelis Evangelos, 2017, BMC Res Notes, V10, P41, DOI [10.1186/s13104-016-2365-z, 10.1186/s13104-016-2365-z] Lee YJ, 2016, INT J CARDIOL, V203, P372, DOI 10.1016/j.ijcard.2015.10.166 Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584 Masnoon N, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0621-2 Mery B, 2017, INT J CARDIOL, V240, P196, DOI 10.1016/j.ijcard.2017.03.132 Mitchell A, 2021, BMC MED, V19, DOI 10.1186/s12916-021-02067-5 Navi BB, 2017, J AM COLL CARDIOL, V70, P927, DOI 10.1016/j.jacc.2017.06.047 NHS Digital Cancer Registration Statistics, 2019, CANC STAT ENGLAND O'Neal WT, 2015, AM J CARDIOL, V115, P1090, DOI 10.1016/j.amjcard.2015.01.540 Pisters R, 2010, CHEST, V138, P1093, DOI 10.1378/chest.10-0134 Shah SJ, 2019, CIRC-CARDIOVASC QUAL, V12, DOI 10.1161/CIRCOUTCOMES.119.006212 Shah S, 2018, BLOOD ADV, V2, P200, DOI 10.1182/bloodadvances.2017010694 Sorigue M, 2019, J ONCOL PRACT, V15, P641, DOI 10.1200/JOP.18.00592 Wolf A, 2019, INT J EPIDEMIOL, V48, P1740, DOI 10.1093/ije/dyz034 Wu JH, 2020, EUROPACE, V22, P1311, DOI 10.1093/europace/euaa126 Zamorano J, 2016, EUR HEART J-CARD IMG, V17, P9, DOI 10.1093/ehjci/jev282 NR 35 TC 2 Z9 2 U1 0 U2 4 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD APR 15 PY 2024 VL 130 IS 8 BP 1316 EP 1329 DI 10.1002/cncr.35152 EA DEC 2023 PG 14 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA LM3C5 UT WOS:001127348800001 PM 38115738 OA hybrid DA 2026-04-17 ER PT J AU De Heredia, APLF Ortiz, MR Cabeza, AIP Expósito, AD Valenzuela, MIF Bailén, MC Cubiles, IAD Vega, AM Aguilar, MZ Muñoz, MC Manrique, TG Llergo, JT Granados, ALO Fernández, JJS Cadenas, JC Rubio, DM AF De Heredia, Alberto Piserra Lopez-Fernandez Ortiz, Martin Ruiz Cabeza, Alejandro I. Perez Exposito, Arancha Diaz Valenzuela, Maria I. Fernandez Bailen, Magdalena Carrillo Cubiles, Inara Alarcon De La Lastra Moreno Vega, Alberto Aguilar, Manuel Zalabardo Munoz, Marinela Chaparro Manrique, Teresa Garcia Llergo, Javier Torres Granados, Ana Laura Ortega Fernandez, Jose J. Sanchez Cadenas, Julio Calvete Rubio, Dolores Mesa CA Working Grp Atrial Fibrillation Andalusian Soc Cardiology TI Clinical outcomes and mortality in patients with atrial fibrillation and recently diagnosed lung cancer in oncology outpatient settings SO CURRENT PROBLEMS IN CARDIOLOGY LA English DT Review DE Lung cancer; Atrial fibrillation; Cardiovascular events; Major bleeding; Mortality ID RISK; ANTICOAGULATION; THROMBOEMBOLISM; INSIGHTS; STROKE; SCORE; CARE AB Introduction: Our aim was to investigate the prevalence of atrial fibrillation (AF) and recently diagnosed lung cancer in the outpatient oncology clinic and to describe the clinical profile, management and outcomes of this population.Methods: Among 6984 patients visited at the outpatient oncology clinics attending lung cancer patients in five university hospitals from 2017 to 2019, all consecutive subjects with recently diagnosed (<1 year) disease and AF were retrospectively selected and events in follow up were registered.Results: A total of 269 patients (3.9 % of all attended, 71 +/- 8 years, 91 % male) were included. Charlson, CHA2DS2-VASc and HAS-BLED indexes were 6.7 +/- 2.9, 2.9 +/- 1.5 y 2.5 +/- 1.2, respectively. Tumour stage was I, II, III and IV in 11 %, 11 %, 33 % and 45 % of them, respectively. Anticoagulants were prescribed to 226 patients (84 %): direct anticoagulants (n = 99;44 %), low molecular weight heparins (n = 69;30 %) and vitamin K antagonists (n = 58;26 %). After 46 months of maximum follow-up, 186 patients died (69 %). Cumulative incidences of events at 3 years were 3.3 +/- 1.3 % for stroke/systemic embolism (n = 7); 8.9 +/- 2.2 % for thrombotic events (n = 18); 9.9 +/- 2.6 % for major bleeding (n = 16), and 15.9 +/- 3,0 % for cardiovascular events (n = 33). In patients with early stages of cancer (I-II), 2-year mortality was significantly higher in those with cardiovascular events or major bleeding (85 % vs 25 %, p = 0.01).Conclusion: Nearly 4 % or all outpatients in the oncology clinic attending lung cancer present recently diagnosed disease and AF. Major bleeding and cardiovascular event rates are high in this population, with an impact on mortality in early stages of cancer. C1 [De Heredia, Alberto Piserra Lopez-Fernandez; Ortiz, Martin Ruiz; Rubio, Dolores Mesa] Reina Sofia Univ Hosp, Dept Cardiol, Ave Menendez Pidal S-N, Cordoba 14004, Spain. [Ortiz, Martin Ruiz; Rubio, Dolores Mesa] IMIBIC, Maimonides Inst Biomed Res Cordoba, Cordoba, Spain. [Cabeza, Alejandro I. Perez] CIBERCV Virgen Victoria Univ Hosp, Cardiol Dept, Malaga, Spain. [Exposito, Arancha Diaz] Virgen Victoria Univ Hosp, Dept Cardiol, Malaga, Spain. [Valenzuela, Maria I. Fernandez; Munoz, Marinela Chaparro] Virgen Macarena Univ Hosp, Dept Cardiol, Seville, Spain. [Bailen, Magdalena Carrillo; Llergo, Javier Torres; Fernandez, Jose J. Sanchez] Jaen Univ Hosp, Dept Cardiol, Jaen, Spain. [Cubiles, Inara Alarcon De La Lastra; Fernandez, Jose J. Sanchez] Puerta del Mar Univ Hosp, Dept Cardiol, Cadiz, Spain. [Moreno Vega, Alberto] Reina Sofia Univ Hosp, Dept Med Oncol, Cordoba, Spain. [Aguilar, Manuel Zalabardo] Virgen Victoria Univ Hosp, Dept Med Oncol, Malaga, Spain. [Manrique, Teresa Garcia] Virgen Macarena Hosp Univ, Dept Med Oncol, Seville, Spain. [Granados, Ana Laura Ortega] Jaen Univ Hosp, Dept Med Oncol, Jaen, Spain. [Cadenas, Julio Calvete] Puerta del Mar Univ Hosp, Dept Med Oncol, Cadiz, Spain. C3 Hospital Universitario Virgen Macarena; Universidad de Cadiz; Hospital Universitario Puerta del Mar; Hospital Universitario Reina Sofia - Cordoba; Universidad de Cadiz; Hospital Universitario Puerta del Mar RP Ortiz, MR (corresponding author), Reina Sofia Univ Hosp, Dept Cardiol, Ave Menendez Pidal S-N, Cordoba 14004, Spain. EM maruor@gmail.com RI ; Ruiz Ortiz, Martín/ADB-0537-2022; AGUILAR-DIOSDADO, MANUEL/A-2549-2009 OI Ortega Granados, Ana Laura/0000-0002-5727-3371; Moreno-Vega, Alberto Luis/0000-0002-4063-7773; López Suárez, Ana/0000-0002-8181-5046; Ruiz Ortiz, Martín/0000-0002-1479-7044; FU Andalusian Society of Cardiology; Daiichi Sankyo FX This work has received financial support by the Andalusian Society of Cardiology and Daiichi Sankyo. The sponsor had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. CR Alduais Y, 2023, MEDICINE, V102, DOI 10.1097/MD.0000000000032899 Atar D, 2020, EUROPACE, V22, P195, DOI 10.1093/europace/euz292 Bandyopadhyay D, 2019, IJC HEART VASC, V22, P216, DOI 10.1016/j.ijcha.2019.02.012 Barbarawi M, 2022, CURR PROB CARDIOLOGY, V47, DOI 10.1016/j.cpcardiol.2022.101346 Boriani G, 2021, EUR J PREV CARDIOL, V28, P611, DOI 10.1093/eurjpc/zwaa054 CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8 Chen ST, 2019, EUR HEART J-QUAL CAR, V5, P145, DOI 10.1093/ehjqcco/qcy040 D'Souza M, 2018, EUR J PREV CARDIOL, V25, P651, DOI 10.1177/2047487318759858 Deng YQ, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.012540 Fanola CL, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.008987 Fradley MG, 2020, JACC-CARDIOONCOL, V2, P747, DOI 10.1016/j.jaccao.2020.09.008 Hindricks Gerhard, 2021, Eur Heart J, V42, P373, DOI 10.1093/eurheartj/ehaa612 Hu YF, 2013, INT J CARDIOL, V165, P355, DOI 10.1016/j.ijcard.2012.08.036 Jakobsen CB, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6314-9 Kravchenko J, 2015, LUNG CANCER, V88, P85, DOI 10.1016/j.lungcan.2015.01.006 Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584 López-Fernández T, 2019, REV ESP CARDIOL, V72, P749, DOI 10.1016/j.rec.2019.03.019 Malavasi VL, 2019, EUR J INTERN MED, V59, P27, DOI 10.1016/j.ejim.2018.10.012 McDonagh TA, 2021, EUR HEART J, V42, P3599, DOI 10.1093/eurheartj/ehab368 Melloni C, 2017, AM J MED, V130, P1440, DOI 10.1016/j.amjmed.2017.06.026 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Ording AG, 2017, CANCER MED-US, V6, P1165, DOI 10.1002/cam4.1054 Sanz AP, 2019, BREAST, V46, P163, DOI 10.1016/j.breast.2019.05.017 Pastori D, 2021, CANCER-AM CANCER SOC, V127, P2122, DOI 10.1002/cncr.33470 Pisters R, 2010, CHEST, V138, P1093, DOI 10.1378/chest.10-0134 Pudil R, 2023, COR VASA, V65, P350, DOI 10.33678/cor.2023.032 Roubín SR, 2022, AM J CARDIOL, V167, P139, DOI 10.1016/j.amjcard.2021.11.053 Schulman S, 2005, J THROMB HAEMOST, V3, P692, DOI 10.1111/j.1538-7836.2005.01204.x Turakhia MP, 2013, AM HEART J, V165, P93, DOI 10.1016/j.ahj.2012.10.010 Vitolo M, 2022, EUR J INTERN MED, V105, P54, DOI 10.1016/j.ejim.2022.08.004 Yun JP, 2021, JACC-CARDIOONCOL, V3, P221, DOI 10.1016/j.jaccao.2021.03.006 NR 31 TC 5 Z9 5 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0146-2806 EI 1535-6280 J9 CURR PROB CARDIOLOGY JI Curr. Probl. Cardiol. PD FEB PY 2024 VL 49 IS 2 AR 102239 DI 10.1016/j.cpcardiol.2023.102239 EA DEC 2023 PG 12 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA FM1R9 UT WOS:001146128700001 PM 38056515 DA 2026-04-17 ER PT J AU Tran, TN Lee, S Kim, HJ Lee, Y Tu, TM Choi, JH Song, JW Cho, H AF Tran, Thi-Ngoc Lee, Sanghee Kim, Hak Jin Lee, Youngjoo Tu, Thao Minh Choi, Jin-Ho Song, Jae Won Cho, Hyunsoon TI Treatment-related cardiovascular events in patients with non-small cell lung cancer: Evidence from real-world data with a competing risks approach SO CANCER LA English DT Article DE cardio-oncology; cardiovascular event; non-small cell lung cancer; real-world evidence; surgery; systemic therapy ID ATRIAL-FIBRILLATION; CARDIO-ONCOLOGY; THERAPIES; TOXICITY; SURGERY AB BackgroundUnderstanding cancer treatment-related cardiovascular (CV) events is important for cancer care; however, comprehensive evaluation of CV events in patients with lung cancer is limited. This study aimed to assess the cumulative incidence and associated risks of various CV event types in patients with non-small cell lung cancer (NSCLC).MethodsA total of 7868 individuals aged 40 years and older, recently diagnosed with NSCLC (2007-2018), were assessed with data obtained from the National Cancer Center, Korea. This study included nine types of CV events. A 2-year cumulative incidence function (CIF) of CV events was estimated, with death as a competing event. The associated risks were assessed by subdistribution hazard ratio (sHR) in the Fine-Gray competing risks model.ResultsCV events were observed in 7.8% of patients with NSCLC, with the most frequently observed types being atrial fibrillation and flutter (AF) (2.7%), venous thromboembolic disease (2.0%), and cerebrovascular disease (CeVD) (1.5%). Overall, all CV events were highest in the group treated with systemic therapy (CIF, 10.6%; 95% confidence interval [CI], 9.5%-11.8%), followed by those treated with surgery (CIF, 10.0%; 95% CI, 8.6%-11.6%); the incidence of AF (CIF, 5.7%; 95% CI, 4.6%-7.0%) was highest in patients treated with surgery. Individuals treated with systemic therapy were found to exhibit a higher CeVD risk than those treated with surgery (sHR, 4.12; 95% CI, 1.66-10.23). Among the patients who underwent surgery, those with lobectomy and pneumonectomy had a higher AF risk (vs. wedge resection/segmentectomy; sHR, 7.79; 95% CI, 1.87-32.42; sHR, 8.10; 95% CI, 1.60-40.89).ConclusionsThese findings revealed treatment-related CV event risks in patients with NSCLC, which suggests that the risk of AF in surgery and CeVD in systemic therapy should be paid more attention to achieve a better prognosis and improve cancer survivorship outcomes.Plain Language SummaryAtrial fibrillation and flutter (AF) is the most common cardiovascular event, particularly at a high risk in patients with non-small cell lung cancer (NSCLC) undergoing surgery.Patients receiving surgery with poor performance status, diagnosed with regional stage, and undergoing lobectomy or pneumonectomy are at a high risk of AF.Systemic/radiotherapy is associated with cerebrovascular and ischemic heart disease in patients with NSCLC. This study revealed that cardiovascular events occurred in approximately 8% of patients with non-small cell lung cancer during 2-year treatment periods, with atrial fibrillation and flutter, venous thromboembolic disease, and cerebrovascular disease being the most common types. The findings further emphasize the importance of monitoring atrial fibrillation in patients receiving surgery and cerebrovascular disease in those treated with systemic therapy to enhance cancer care and survivorship outcomes. C1 [Tran, Thi-Ngoc; Lee, Sanghee; Tu, Thao Minh] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Dept Canc Control & Populat Hlth, Goyang, South Korea. [Kim, Hak Jin] Natl Canc Ctr, Dept Internal Med, Div Cardiol, Goyang, South Korea. [Kim, Hak Jin] Gumdan Top Gen Hosp, Dept Cardiol, Incheon, South Korea. [Lee, Youngjoo] Natl Canc Ctr, Dept Internal Med, Div Hematol & Oncol, Goyang, South Korea. [Choi, Jin-Ho; Song, Jae Won] Natl Canc Ctr, Res Inst & Hosp, Dept Thorac Surg, Goyang 10408, South Korea. [Cho, Hyunsoon] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Dept Canc AI & Digital Hlth, 323 Ilsan Ro, Goyang 10408, South Korea. [Cho, Hyunsoon] Natl Canc Ctr, Res Inst, Div Canc Data Sci, Integrated Biostat Branch, Goyang, South Korea. C3 National Cancer Center - Korea (NCC); National Cancer Center - Korea (NCC); National Cancer Center - Korea (NCC); National Cancer Center - Korea (NCC); National Cancer Center - Korea (NCC); National Cancer Center - Korea (NCC) RP Cho, H (corresponding author), Natl Canc Ctr, Grad Sch Canc Sci & Policy, Dept Canc AI & Digital Hlth, 323 Ilsan Ro, Goyang 10408, South Korea. EM hscho@ncc.re.kr RI ; Song, Jaewon/HMV-0601-2023 OI Lee, youngjoo/0000-0003-0180-189X; Cho, Hyunsoon/0000-0002-3261-3114; Tran, Thi Ngoc/0000-0002-0597-1522 FU National Cancer Center of Korea [NCC-2110450-2, NCC-2210880-2, NCC-2310450-1]; Korean National Cancer Center FX This work was supported by the Korean National Cancer Center (Grants NCC-2110450-2, NCC-2210880-2, and NCC-2310450-1). The funding source played no role in the design of the study, data curation, or analysis and interpretation of the data. CR Albini A, 2010, JNCI-J NATL CANCER I, V102, P14, DOI 10.1093/jnci/djp440 Alexandre J, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.018403 [Anonymous], 2002, SAS 94 HELP DOCUMENT [Anonymous], META DATA INTRO [Anonymous], 2024, R: A language and environment for statistical computing Baik AH, 2021, CIRC RES, V128, P1780, DOI 10.1161/CIRCRESAHA.120.315894 Bishnoi R, 2020, LUNG CANCER, V150, P172, DOI 10.1016/j.lungcan.2020.10.017 Borkenhagen JF, 2019, CLIN LUNG CANCER, V20, P435, DOI 10.1016/j.cllc.2019.05.014 Cardinale D, 2007, CIRCULATION, V115, P1339, DOI 10.1161/CIRCULATIONAHA.106.647008 Cardinale D, 2016, ANN SURG, V264, P244, DOI 10.1097/SLA.0000000000001626 Cha HS, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16132290 Doroshow DB, 2018, JAMA ONCOL, V4, P569, DOI 10.1001/jamaoncol.2017.5190 Dubois RW, 2015, J COMP EFFECT RES, V4, P199, DOI 10.2217/cer.15.17 Farmakis D, 2014, J AM COLL CARDIOL, V63, P945, DOI 10.1016/j.jacc.2013.11.026 Guha A, 2019, TRENDS CARDIOVAS MED, V29, P29, DOI 10.1016/j.tcm.2018.06.001 Herbach E, 2022, J AM HEART ASSOC, V11, DOI 10.1161/JAHA.122.027288 Herrmann J, 2020, NAT REV CARDIOL, V17, P503, DOI 10.1038/s41569-020-0347-2 Hirsch FR, 2017, LANCET, V389, P299, DOI 10.1016/S0140-6736(16)30958-8 Hirsch FR, 2016, LANCET, V388, P1012, DOI 10.1016/S0140-6736(16)31473-8 Ishibashi H, 2020, WORLD J SURG, V44, P3952, DOI 10.1007/s00268-020-05694-w Kadowaki H, 2020, CIRC J, V84, P1446, DOI 10.1253/circj.CJ-20-0467 Kawaguchi Y, 2018, GEN THORAC CARDIOVAS, V66, P537, DOI 10.1007/s11748-018-0960-8 Khorana AA, 2009, J CLIN ONCOL, V27, P4839, DOI 10.1200/JCO.2009.22.3271 Khozin S, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx187 Lasiter L, 2022, CLIN PHARMACOL THER, V111, P444, DOI 10.1002/cpt.2443 Le Pechoux C, 2022, LANCET ONCOL, V23, P104, DOI 10.1016/S1470-2045(21)00606-9 Lewis JH, 2003, J CLIN ONCOL, V21, P1383, DOI 10.1200/JCO.2003.08.010 Lyon AR, 2018, LANCET ONCOL, V19, pE447, DOI 10.1016/S1470-2045(18)30457-1 Mandawat A, 2017, HEART FAIL CLIN, V13, P403, DOI 10.1016/j.hfc.2016.12.010 Moore RA, 2011, J CLIN ONCOL, V29, P3466, DOI 10.1200/JCO.2011.35.5669 Moslehi JJ, 2016, NEW ENGL J MED, V375, P1457, DOI 10.1056/NEJMra1100265 Navi BB, 2017, J AM COLL CARDIOL, V70, P927, DOI 10.1016/j.jacc.2017.06.047 Nonaka M, 2021, BIOCHEM PHARMACOL, V190, DOI 10.1016/j.bcp.2021.114599 OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014 Pérez-Callejo D, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-1012-4 Phillips CM, 2020, CANCER-AM CANCER SOC, V126, P1717, DOI 10.1002/cncr.32697 Putter H, 2007, STAT MED, V26, P2389, DOI 10.1002/sim.2712 Sase K, 2021, CURR TREAT OPTION ON, V22, DOI 10.1007/s11864-021-00869-6 Schoormans D, 2018, CANCER MED-US, V7, P4952, DOI 10.1002/cam4.1754 Strongman H, 2019, LANCET, V394, P1041, DOI 10.1016/S0140-6736(19)31674-5 Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660 Tan C., 2018, CARDIOVASCULAR TOXIC Ueda T, 2018, GEN THORAC CARDIOVAS, V66, P95, DOI 10.1007/s11748-017-0858-x Waliany S, 2021, J THORAC ONCOL, V16, P2029, DOI 10.1016/j.jtho.2021.07.030 Wang H, 2021, J THORAC DIS, V13, DOI 10.21037/jtd-20-1717 Wei KK, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/5357917 Wolbers M, 2014, EUR HEART J, V35, P2936, DOI 10.1093/eurheartj/ehu131 Yegya-Raman N, 2023, CURR ONCOL REP, V25, P433, DOI 10.1007/s11912-023-01387-4 Zaborowska-Szmit M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051268 Zamorano J, 2016, EUR HEART J-CARD IMG, V17, P9, DOI 10.1093/ehjci/jev282 NR 50 TC 3 Z9 3 U1 1 U2 6 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD APR 15 PY 2024 VL 130 IS 8 BP 1303 EP 1315 DI 10.1002/cncr.35143 EA DEC 2023 PG 13 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA LM3C5 UT WOS:001125517600001 PM 38103206 OA Bronze DA 2026-04-17 ER PT J AU Hawryszko, M Slawinski, G Tomasik, B Lewicka, E AF Hawryszko, Maja Slawinski, Grzegorz Tomasik, Bartlomiej Lewicka, Ewa TI Cardiac Arrhythmias in Patients Treated for Lung Cancer: A Review SO CANCERS LA English DT Review DE lung cancer; cardio-oncology; cardiac arrhythmias; radiation therapy; stereotactic arrhythmia radioablation ID ATRIAL-FIBRILLATION; ELECTROCARDIOGRAM ABNORMALITIES; RADIATION-THERAPY; THORACIC-SURGERY; RISK; AMIODARONE; BLOCK; PREVENTION; MANAGEMENT; RESECTION AB Simple Summary Anticancer treatment can lead to cardiotoxicity, including arrhythmias, which are the least understood complication. Atrial fibrillation is common in this patient population, and cancer patients may be at increased risk for thromboembolic events. Ventricular arrhythmias are less common than supraventricular arrhythmias. Diagnostic methods are the same as in patients without cancer, i.e. ECG, Holter monitoring, electrophysiological study and echocardiography. Amiodarone is recommended for supraventricular and ventricular arrhythmias. There are also possible invasive treatments for arrhythmias - transcatheter ablation and stereotactic radioablation of arrhythmias - but these are used much less frequently than drug treatment. There is limited data on atrioventricular conduction abnormalities in lung cancer, probably related to immune checkpoint inhibitor-induced myocarditis. Cancer and heart disease are leading causes of death, underscoring the importance of developing cardio-oncology and training specialists to treat cardiovascular complications in cancer patients.Abstract Cardio-oncology currently faces one of the greatest challenges in the field of health care. The main goal of this discipline is to ensure that patients treated for cancer do not suffer or die from cardiovascular disease. The number of studies on the mechanisms of heart injury during cancer treatment is constantly increasing. However, there is insufficient data on heart rhythm disorders that may result from this treatment. This issue seems to be particularly important in patients with lung cancer, in whom anticancer therapy, especially radiotherapy, may contribute to the onset of cardiac arrhythmias. The observed relationship between cardiac dosimetry and radiotherapy-induced cardiotoxicity in lung cancer treatment may explain the increased mortality from cardiovascular causes in patients after chest irradiation. Further research is essential to elucidate the role of cardiac arrhythmias in this context. Conversely, recent reports have highlighted the application of stereotactic arrhythmia radioablation (STAR) in the treatment of ventricular tachycardia. This review of available studies on the epidemiology, pathogenesis, diagnosis, and treatment of arrhythmias in patients treated for lung cancer aims to draw attention to the need for regular cardiological monitoring in this group of patients. Improving cardiac care for patients with lung cancer has the potential to enhance their overall therapeutic outcomes. C1 [Hawryszko, Maja; Slawinski, Grzegorz; Lewicka, Ewa] Med Univ Gdansk, Fac Med, Dept Cardiol & Heart Electrotherapy, Smoluchowskiego 17 St, PL-80214 Gdansk, Poland. [Tomasik, Bartlomiej] Med Univ Gdansk, Fac Med, Dept Oncol & Radiotherapy, Smoluchowskiego 17 St, PL-80214 Gdansk, Poland. C3 Fahrenheit Universities; Medical University Gdansk; Fahrenheit Universities; Medical University Gdansk RP Slawinski, G (corresponding author), Med Univ Gdansk, Fac Med, Dept Cardiol & Heart Electrotherapy, Smoluchowskiego 17 St, PL-80214 Gdansk, Poland. EM maja.klimkiewicz@gmail.com; gslawinski@gumed.edu.pl; bartlomiej.tomasik@gumed.edu.pl; elew@gumed.edu.pl RI Tomasik, Bartlomiej/HHM-2882-2022; Lewicka, Ewa/K-3474-2018 OI Tomasik, Bartlomiej/0000-0001-5648-345X; Sławiński, Grzegorz/0000-0002-1974-6393; Hawryszko, Maja/0000-0001-6929-5896; Lewicka, Ewa/0000-0002-0162-2659 CR Amar David, 2022, Anesthesiology, V136, P916, DOI 10.1097/ALN.0000000000004201 Asnani Aarti, 2017, Cardiooncology, V3, P2, DOI [10.1186/s40959-017-0021-y, 10.1186/s40959-017-0021-y] Atkins KM, 2022, INT J RADIAT ONCOL, V114, pS58 Ball S, 2019, J AM COLL CARDIOL, V74, P1714, DOI 10.1016/j.jacc.2019.07.079 Banfill K, 2021, J THORAC ONCOL, V16, P216, DOI 10.1016/j.jtho.2020.11.002 Bedi R, 2023, ARRHYTH ELECTROPHYSI, V12, DOI 10.15420/aer.2022.44 Behling J, 2017, MELANOMA RES, V27, P155, DOI 10.1097/CMR.0000000000000314 Bergom C, 2021, JACC-CARDIOONCOL, V3, P343, DOI 10.1016/j.jaccao.2021.06.007 Borkenhagen JF, 2019, CLIN LUNG CANCER, V20, P435, DOI 10.1016/j.cllc.2019.05.014 Bukamur HS, 2019, CUREUS J MED SCIENCE, V11, DOI 10.7759/cureus.4869 Buza V, 2017, CIRC-ARRHYTHMIA ELEC, V10, DOI 10.1161/CIRCEP.117.005443 Cacioppo F, 2022, JAMA NETW OPEN, V5, DOI 10.1001/jamanetworkopen.2022.37234 Cardinale D, 2016, ANN SURG, V264, P244, DOI 10.1097/SLA.0000000000001626 Chang WT, 2023, FRONT ONCOL, V13, DOI 10.3389/fonc.2023.1172036 Chen VW, 2014, CANCER-AM CANCER SOC, V120, P3781, DOI 10.1002/cncr.29045 Cheng CW, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007649 Christensen AM, 2019, EUROPACE, V21, P465, DOI 10.1093/europace/euy268 Chun SG, 2017, J CLIN ONCOL, V35, P56, DOI 10.1200/JCO.2016.69.1378 Cuculich PS, 2017, NEW ENGL J MED, V377, P2325, DOI 10.1056/NEJMoa1613773 Elbey Mehmet Ali, 2021, J Atr Fibrillation, V13, P20200446, DOI [10.4022/jafib.20200446, 10.4022/jafib.20200446] Enevoldsen C, 2020, Open Journal of Thoracic Surgery, V10, P6, DOI [10.4236/ojts.2020.101002, 10.4236/ojts.2020.101002, DOI 10.4236/OJTS.2020.101002] Enriquez Andres, 2017, JACC Clin Electrophysiol, V3, P50, DOI [10.1016/j.jacep.2016.03.001, 10.1016/j.jacep.2016.03.001] Farmakis D, 2014, J AM COLL CARDIOL, V63, P945, DOI 10.1016/j.jacc.2013.11.026 Fendler W, 2022, POL ARCH INTERN MED, V132, DOI 10.20452/pamw.16190 Font J, 2023, ARCH CARDIOVASC DIS, V116, P219, DOI 10.1016/j.acvd.2023.02.005 Fradley MG, 2021, CIRCULATION, V144, pE41, DOI 10.1161/CIR.0000000000000986 Ganatra S, 2023, CARDIO-ONCOLOGY, V9, DOI 10.1186/s40959-023-00171-4 Ghezel-Ahmadi V, 2023, J THORAC DIS, V15, P4648, DOI 10.21037/jtd-23-506 Gianni C, 2020, HEART RHYTHM, V17, P1241, DOI 10.1016/j.hrthm.2020.02.036 Giustozzi M, 2021, J INTERV CARD ELECTR, V60, P419, DOI 10.1007/s10840-020-00745-7 Gomez DR, 2014, J THORAC ONCOL, V9, P1554, DOI 10.1097/JTO.0000000000000306 Grehn M, 2023, EUROPACE, V25, P1284, DOI 10.1093/europace/euac238 Guo GG, 2023, J GERIATR CARDIOL, V20, P242, DOI 10.26599/1671-5411.2023.03.009 Han XQ, 2017, NPJ PRECIS ONCOL, V1, DOI 10.1038/s41698-017-0034-x Haq S, 2019, CUREUS J MED SCIENCE, V11, DOI 10.7759/cureus.6090 Hardardóttir H, 2022, LAEKNABLADID, V108, P17, DOI 10.17992/lbl.2022.01.671 He Y., 2021, J. Cardiol. Cardiovasc. Sci, V5, P7 Heinzerling L, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0152-y Hindricks G, 2021, EUR HEART J, V42, P546, DOI 10.1093/eurheartj/ehaa945 Hotca A, 2019, CLIN TRANSL RAD ONCO, V19, P96, DOI 10.1016/j.ctro.2019.09.003 Hu CH, 2022, OPEN MED-WARSAW, V17, P2109, DOI 10.1515/med-2022-0611 Huang Y, 2022, EUR REV MED PHARMACO, V26, P6, DOI 10.26355/eurrev_202201_27741 Huang Y Jessica, 2016, Adv Radiat Oncol, V1, P106, DOI [10.1016/j.adro.2016.04.002, 10.1016/j.adro.2016.04.002] Ilangovan B, 2022, IHJ Cardiovascular Case Reports (CVCR), V6, P16, DOI [10.1016/j.ihjccr.2021.12.010, 10.1016/j.ihjccr.2021.12.010, DOI 10.1016/J.IHJCCR.2021.12.010] Imperatori A, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-4 Kaira K, 2020, J THORAC ONCOL, V15, pE54, DOI 10.1016/j.jtho.2019.11.029 Kasprzyk M, 2015, KARDIOCHIR TORAKOCHI, V12, P18, DOI 10.5114/kitp.2015.50563 Khozin S, 2015, CLIN CANCER RES, V21, P2436, DOI 10.1158/1078-0432.CCR-14-3157 Kilickap S, 2007, SOUTH MED J, V100, P262, DOI 10.1097/01.smj.0000257382.89910.fe Kim KH, 2022, JAMA ONCOL, V8, P1624, DOI 10.1001/jamaoncol.2022.4202 Kohno H, 2005, ANN THORAC SURG, V79, P117, DOI 10.1016/j.athoracsur.2004.06.062 Krug D, 2023, STRAHLENTHER ONKOL, V199, P621, DOI 10.1007/s00066-023-02091-9 Kumar M, 2022, J GERIATR CARDIOL, V19, P1, DOI 10.11909/j.issn.1671-5411.2022.01.001 Kumar S, 2023, AM J CARDIOL, V202, P176, DOI 10.1016/j.amjcard.2023.06.068 Lee C, 2021, HEART RHYTHM, V18, P1223, DOI 10.1016/j.hrthm.2021.02.017 Lee JW, 2019, J MED CASE REP, V13, DOI 10.1186/s13256-019-2111-y Liu SYM, 2023, J HEMATOL ONCOL, V16, DOI 10.1186/s13045-023-01436-2 Ma J, 2021, J CELL MOL MED, V25, P2764, DOI 10.1111/jcmm.16350 Madnick DL, 2022, CURR CARDIOL REP, V24, P1517, DOI 10.1007/s11886-022-01769-3 Mery B, 2017, INT J CARDIOL, V240, P196, DOI 10.1016/j.ijcard.2017.03.132 Miszczyk M, 2023, RADIOTHER ONCOL, V188, DOI 10.1016/j.radonc.2023.109857 Mo Y, 2023, CANCER MED-US, V12, P1025, DOI 10.1002/cam4.4948 Mocini D., 2005, Case Rep. Ital. Heart J, V6, P931 Morcos PN, 2017, CANCER CHEMOTH PHARM, V79, P559, DOI 10.1007/s00280-017-3253-5 Niska JR, 2018, EXPERT REV CARDIOVAS, V16, P931, DOI 10.1080/14779072.2018.1538785 No H.J., 2023, JACC CardioOncol, DOI [10.1016/j.jaccao.2023.08.007, DOI 10.1016/J.DIAMOND] Ou SHI, 2016, CANCER MED-US, V5, P617, DOI 10.1002/cam4.622 Pallangyo P, 2022, J MED CASE REP, V16, DOI 10.1186/s13256-021-03244-z Pay L, 2023, ANATOL J CARDIOL, V27, P126, DOI 10.14744/AnatolJCardiol.2023.2799 Phillips JD, 2020, J THORAC DIS, V12, P3110, DOI 10.21037/jtd-20-180 Porta-Sánchez A, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.007724 Pruis MA, 2023, JACC-CARDIOONCOL, V5, P102, DOI 10.1016/j.jaccao.2022.09.006 Pudil R, 2023, COR VASA, V65, P350, DOI 10.33678/cor.2023.032 Rhea I, 2019, CARDIOL CLIN, V37, P459, DOI 10.1016/j.ccl.2019.07.011 Riber LP, 2012, ANN THORAC SURG, V94, P339, DOI 10.1016/j.athoracsur.2011.12.096 Robinson CG, 2019, CIRCULATION, V139, P313, DOI 10.1161/CIRCULATIONAHA.118.038261 Rozencwajg S, 2017, ANAESTH CRIT CARE PA, V36, P185, DOI 10.1016/j.accpm.2016.04.005 Rudin CM, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-020-00235-0 Shabtaie SA, 2023, JACC-CARDIOONCOL, V5, P203, DOI 10.1016/j.jaccao.2022.10.016 Shangguan WF, 2022, J CLIN MED, V11, DOI 10.3390/jcm11123549 Siedow M, 2021, CLIN TRANSL RAD ONCO, V31, P71, DOI 10.1016/j.ctro.2021.02.005 Siegel RL, 2023, CA-CANCER J CLIN, V73, P17, DOI 10.3322/caac.21763 Slawinski G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197195 Stefanidis K, 2022, AM J ROENTGENOL, V218, P52, DOI 10.2214/AJR.21.26408 Tamura Mio, 2012, J Cardiol Cases, V5, pe118, DOI 10.1016/j.jccase.2011.12.005 Thandra KC, 2021, WSPOLCZESNA ONKOL, V25, P45, DOI 10.5114/wo.2021.103829 van der Ree MH, 2023, EUROPACE, V25, P1015, DOI 10.1093/europace/euad020 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Vasic N, 2011, RESP MED, V105, pS78, DOI 10.1016/S0954-6111(11)70016-6 Viani GA, 2023, CLIN ONCOL-UK, V35, P611, DOI 10.1016/j.clon.2023.04.004 Vinod SK, 2020, RESPIROLOGY, V25, P61, DOI 10.1111/resp.13870 Vivekanandan S, 2017, INT J RADIAT ONCOL, V99, P51, DOI 10.1016/j.ijrobp.2017.04.026 Walls GM, 2023, RADIOTHER ONCOL, V184, DOI 10.1016/j.radonc.2023.109680 Wang FF, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.986357 Wang K, 2017, RADIOTHER ONCOL, V125, P293, DOI 10.1016/j.radonc.2017.10.001 Wang SY, 2023, HEART RHYTHM, V20, P1327, DOI 10.1016/j.hrthm.2023.04.052 Wang XM, 2022, EUR J CLIN PHARMACOL, V78, P1777, DOI 10.1007/s00228-022-03383-2 Zadok OIB, 2023, AM J CARDIOL, V191, P32, DOI 10.1016/j.amjcard.2022.12.013 Zhang DM, 2021, CLIN ONCOL-UK, V33, P723, DOI 10.1016/j.clon.2021.09.001 Zhang DM, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25730-0 Zhang TW, 2019, INT J RADIAT ONCOL, V104, P582, DOI 10.1016/j.ijrobp.2018.12.044 NR 101 TC 7 Z9 7 U1 2 U2 16 PU MDPI PI BASEL PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND EI 2072-6694 J9 CANCERS JI Cancers PD DEC PY 2023 VL 15 IS 24 AR 5723 DI 10.3390/cancers15245723 PG 17 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA DH4T5 UT WOS:001131132100001 PM 38136269 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Çakar, A Kamaci, I Orhan, EK Durmus, H Parman, Y AF Cakar, Arman Kamaci, Ibrahim Orhan, Elif Kocasoy Durmus, Hacer Parman, Yesim TI Pembrolizumab-induced peripheral nervous system damage: A combination of myositis/ myasthenia overlap syndrome and motor axonal polyneuropathy SO IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE LA English DT Article DE myocar; -ditis; intravenous immunoglobulin ID TRANSIENT ISCHEMIC ATTACK; NEUROGENIC STUNNED MYOCARDIUM; ATRIAL-FIBRILLATION; STROKE; RISK; DIAGNOSIS AB Introduction - Immune-checkpoint inhibi-tors (ICI) are effective drugs in cancer treat- ment that block immune checkpoints and stimulate an attack on cancer cells. However, various side effects were reported with ICIs. Peripheral nervous system (PNS) side effects are three times more frequent than those the central nervous system. Case report - A 63-year-old male patient was admitted to our department with a 10-day history of dyspnea, diplopia, and generalized weakness. He had a diagnosis of non-small cell lung cancer, which was treated with pembrolizumab. His neuro- logical symptoms appeared one week after the second course of pembrolizumab, and gradually worsened. His neurological exam- ination showed nasal speech, bilateral ptosis, tongue and neck flexor weakness, prominent asymmetrical upper limb weakness, and lower limb weakness. Deep tendon reflex- es and sensory examination were normal. He had an elevated creatine kinase level (4430 U/L). Needle electromyography (EMG) showed a myopathic pattern, and single EMG demonstrated an increased jitter in right frontal muscle. Pembrolizumab treat- ment was discontinued, and intravenous methylprednisolone followed by intravenous immunoglobulin (IVIg) were initiated. His symptoms gradually improved. However, weakness began to worsen after a month, and repeated nerve conduction studies showed a predominantly motor axonal polyneuropathy. Thereafter, the patient was treated with IVIg infusions (0.4 g/every two weeks) to maintain his motor function. Conclusion - Our case showed that ICIs could simultaneously or sequentially cause damage in multiple domains of the PNS. Early recognition of these adverse events is essential since the outcome is favorable with rapid cessation of the causative ICI and administration of immune-modulator treatment. C1 [Cakar, Arman; Durmus, Hacer; Parman, Yesim] Istanbul Univ, Istanbul Fac Med, Neurol Dept, Neuromuscular Unit, Istanbul, Turkiye. [Kamaci, Ibrahim; Orhan, Elif Kocasoy] Istanbul Univ, Istanbul Fac Med, Neurol Dept, Istanbul, Turkiye. [Cakar, Arman] Millet Caddesi,Istanbul Tip Yerleskesi,Norol Binas, TR-34093 Istanbul, Turkiye. C3 Istanbul University; Istanbul University RP Çakar, A (corresponding author), Millet Caddesi,Istanbul Tip Yerleskesi,Norol Binas, TR-34093 Istanbul, Turkiye. EM arman.cakar@istanbul.edu.tr RI Durmus, Hacer/AAU-2723-2020; Parman, Yesim/AAU-5771-2020; Orhan, Elif/AAD-4657-2020; Cakar, Arman/AAE-5475-2020 OI Cakar, Arman/0000-0002-8129-4172 CR ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35 Bhatla A, 2021, NEUROLOGY, V96, pE1655, DOI 10.1212/WNL.0000000000011633 Biso Sylvia, 2017, Cardiovasc Psychiatry Neurol, V2017, P5842182, DOI [10.1155/2017/5842182, 10.1155/2017/5842182] Cerasuolo JO, 2017, CURR OPIN NEUROL, V30, P28, DOI 10.1097/WCO.0000000000000410 Colivicchi F, 2005, STROKE, V36, P1710, DOI 10.1161/01.STR.0000173400.19346.bd Fridman S, 2022, CEREBROVASC DIS, V51, P152, DOI 10.1159/000520101 Toledo MEG, 2013, J STROKE CEREBROVASC, V22, pE486, DOI 10.1016/j.jstrokecerebrovasdis.2013.05.015 Hsieh CY, 2018, INT J CARDIOL, V261, P68, DOI 10.1016/j.ijcard.2017.11.047 Ileri C, 2022, IDEGGYOGY SZEMLE, V75, P15, DOI 10.18071/isz.75.0015 Lang RM, 2015, J AM SOC ECHOCARDIOG, V28, P1, DOI 10.1016/j.echo.2014.10.003 Li SY, 2019, CHINESE MED J-PEKING, V132, P2053, DOI 10.1097/CM9.0000000000000390 Meyer S, 2004, NEUROREPORT, V15, P357, DOI 10.1097/00001756-200402090-00029 Mierzewska-Schmidt M, 2015, ANAESTH INTENSIVE TH, V47, P175, DOI 10.5603/AIT.2015.0017 Paquet M, 2018, J STROKE CEREBROVASC, V27, P606, DOI 10.1016/j.jstrokecerebrovasdis.2017.09.038 Patel PJ, 2016, HEART RHYTHM, V13, P527, DOI 10.1016/j.hrthm.2015.11.008 Sposato LA, 2022, STROKE, V53, pE94, DOI 10.1161/STROKEAHA.121.034777 Sposato LA, 2018, NEUROLOGY, V90, pE924, DOI 10.1212/WNL.0000000000005126 Sposato LA, 2015, INT J STROKE, V10, P801, DOI 10.1111/ijs.12555 Sposato LA, 2015, LANCET NEUROL, V14, P377, DOI 10.1016/S1474-4422(15)70027-X Sposato LA, 2014, NEUROLOGY, V82, P1180, DOI 10.1212/WNL.0000000000000265 Sposato LA, 2012, J STROKE CEREBROVASC, V21, P210, DOI 10.1016/j.jstrokecerebrovasdis.2010.06.010 Sun YY, 2022, J STROKE CEREBROVASC, V31, DOI 10.1016/j.jstrokecerebrovasdis.2022.106445 Wang YC, 2019, CARDIOLOGY, V144, P112, DOI 10.1159/000502971 Yang XM, 2019, STROKE, V50, P1124, DOI 10.1161/STROKEAHA.118.024176 ZAMRINI EY, 1990, NEUROLOGY, V40, P1408, DOI 10.1212/WNL.40.9.1408 NR 25 TC 1 Z9 3 U1 0 U2 2 PU LITERATURA MEDICA PI BUDAPEST PA MARGIT KRT 31-33, BUDAPEST, 1024, HUNGARY SN 0019-1442 EI 2498-6208 J9 IDEGGYOGY SZEMLE JI Ideggyogy. Szle. PD NOV 30 PY 2023 VL 76 IS 11-12 DI 10.18071/isz.76.0422 PG 71 WC Clinical Neurology; Neurosciences WE Science Citation Index Expanded (SCI-EXPANDED) SC Neurosciences & Neurology GA DG0Y8 UT WOS:001130770300005 PM 38051685 DA 2026-04-17 ER PT J AU Jin, SQ An, L Chen, LS Liu, HQ Chen, HF Lv, X AF Jin, Shuqing An, Long Chen, Linsong Liu, Huqing Chen, Hongfei Lv, Xin TI Prevention of new-onset atrial fibrillation in elderly patients undergoing anatomic pulmonary resection by infusion of magnesium sulfate: protocol for a randomized controlled trial SO FRONTIERS IN CARDIOVASCULAR MEDICINE LA English DT Article DE atrial fibrillation; anatomic pulmonary resection; older patients; magnesium sulfate; randomized controlled trial ID NONCARDIAC THORACIC-SURGERY; LUNG-CANCER; RISK-FACTORS; PROPHYLACTIC DIGITALIZATION; CARDIAC-FUNCTION; AMIODARONE; ARRHYTHMIAS; DILTIAZEM AB Atrial fibrillation (AF) is the most commonly sustained arrhythmia after pulmonary resection, which has been shown to predict higher hospital morbidity and mortality. The lack of strong evidence-based medical evidence makes doctors have very few options for medications to prevent new-onset AF following thoracic surgery. Magnesium can prevent perioperative AF in patients undergoing cardiac surgery. However, this has not yet been fully studied in patients undergoing non-cardiac thoracic surgery, which is the aim of this study. This is a single-center, prospective, double-blind, randomized controlled trial. In total, 838 eligible patients were randomly assigned to one of two study groups, namely, the control group or the magnesium group. The patients in the magnesium group preoperatively received 80 mg magnesium sulfate/kg ideal weight in 100 ml normal saline 30 min. The control group received the same volumes of normal saline simultaneously. The primary outcome is the incidence of new-onset AF intra-operative and on the first, second, and third postoperative days. The secondary outcomes are bradycardia, hypertension, hypotension, and flushing. The occurrence of stroke or any other type of arrhythmia is also recorded. Postoperative respiratory suppression and gastrointestinal discomfort, intensive care unit stays and total duration of hospital stays, in-hospital mortality, and 3-month all-cause mortality are also recorded as important outcomes. This study aims to prospectively evaluate the prophylactic effects of magnesium sulfate against AF compared with a placebo control group during and following anatomic pulmonary resection. The results may provide reliable evidence for the prophylactic value of magnesium against AF in patients with lung cancer. The trial was approved by the Clinical Research Ethics Committee of Shanghai Pulmonary Hospital and has been registered at Chinese Clinical Trial Registry: www.chictr.org.cn, identifier: ChiCTR2300068046. C1 [Jin, Shuqing; An, Long; Chen, Linsong; Liu, Huqing; Lv, Xin] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Anesthesiol, Shanghai, Peoples R China. [An, Long] Kashgar Reg Second Peoples Hosp, Dept Anesthesiol, Kashgar, Xinjiang, Peoples R China. [Chen, Hongfei] Shanghai Jiao Tong Univ, Sch Med, Tongren Hosp, Dept Anesthesiol, Shanghai, Peoples R China. C3 Tongji University; Shanghai Jiao Tong University RP Lv, X (corresponding author), Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Anesthesiol, Shanghai, Peoples R China.; Chen, HF (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Tongren Hosp, Dept Anesthesiol, Shanghai, Peoples R China. EM xinlvg@126.com; chf1772132@163.com RI chen, linsong/IWM-4109-2023; Lv, Xin/L-2274-2019 OI Lv, Xin/0000-0002-3352-7162 FU National Natural Science Foundation of China FX No Statement Available CR Amar D, 1997, ANN THORAC SURG, V63, P1374 Amar D, 2000, J THORAC CARDIOV SUR, V120, P790, DOI 10.1067/mtc.2000.109538 Amar D, 2002, ANESTHESIOLOGY, V96, P352, DOI 10.1097/00000542-200202000-00021 Arsenault KA, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003611.pub3 Bhave PD, 2012, AM HEART J, V164, P918, DOI 10.1016/j.ahj.2012.09.004 BORGEAT A, 1991, ANN THORAC SURG, V51, P964, DOI 10.1016/0003-4975(91)91016-O Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583 De Decker K, 2003, ANN THORAC SURG, V75, P1340, DOI 10.1016/S0003-4975(02)04824-5 Diallo EH, 2023, ANAESTHESIA, V78, P491, DOI 10.1111/anae.15957 DICARLO LA, 1986, J AM COLL CARDIOL, V7, P1356, DOI 10.1016/S0735-1097(86)80157-7 Fabiani I, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010037 Fairley JL, 2017, J CRIT CARE, V42, P69, DOI 10.1016/j.jcrc.2017.05.038 Frendl G, 2014, J THORAC CARDIOV SUR, V148, pE153, DOI 10.1016/j.jtcvs.2014.06.036 Haverkamp W, 2016, CURR OPIN ANESTHESIO, V29, P26, DOI 10.1097/ACO.0000000000000285 Imperatori A, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-4 Ivanovic J, 2014, INTERACT CARDIOV TH, V18, P340, DOI 10.1093/icvts/ivt520 Jakobsen CJ, 1997, J CARDIOTHOR VASC AN, V11, P746, DOI 10.1016/S1053-0770(97)90169-5 KAISER A, 1994, HELV CHIR ACTA, V60, P913 Khalil MA, 2013, J ANESTH, V27, P56, DOI 10.1007/s00540-012-1478-3 Liu J, 2022, MINERVA ANESTESIOL, V88, P490, DOI 10.23736/S0375-9393.21.16034-1 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Riber LP, 2012, ANN THORAC SURG, V94, P339, DOI 10.1016/j.athoracsur.2011.12.096 Riber LP, 2014, ANN THORAC SURG, V98, P1989, DOI 10.1016/j.athoracsur.2014.06.069 RITCHIE AJ, 1993, ANN THORAC SURG, V55, P86, DOI 10.1016/0003-4975(93)90478-Z Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Tangvoraphonkchai K, 2018, ADV CHRONIC KIDNEY D, V25, P251, DOI 10.1053/j.ackd.2018.02.010 Terzi A, 1996, THORAC CARDIOV SURG, V44, P300, DOI 10.1055/s-2007-1012041 Tiryakioglu O, 2009, J CARDIOTHORAC SURG, V4, DOI 10.1186/1749-8090-4-8 Ueda T, 2018, GEN THORAC CARDIOVAS, V66, P95, DOI 10.1007/s11748-017-0858-x VANMIEGHEM W, 1994, CHEST, V105, P1642, DOI 10.1378/chest.105.6.1642 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 VIGORITO C, 1991, AM J CARDIOL, V67, P1435, DOI 10.1016/0002-9149(91)90478-4 WHITE RE, 1989, BIOCHEM PHARMACOL, V38, P859, DOI 10.1016/0006-2952(89)90272-4 NR 34 TC 1 Z9 1 U1 0 U2 2 PU FRONTIERS MEDIA SA PI LAUSANNE PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND SN 2297-055X J9 FRONT CARDIOVASC MED JI Front. Cardiovasc. Med. PD NOV 17 PY 2023 VL 10 AR 1171713 DI 10.3389/fcvm.2023.1171713 PG 6 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA Z9RB8 UT WOS:001115368600001 PM 38045914 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Liu, Q Cai, WX Wang, XY Hu, HB Sun, XC Pan, XL Wang, AL AF Liu, Qiong Cai, Weixun Wang, Xianyun Hu, Haibin Sun, Xianchao Pan, Xianli Wang, Ailan TI Recent death early warning value of ECG changes in patients with NSCLC SO MEDICINE LA English DT Article DE chemotherapy; electrocardiogram; non-small cell lung cancer; radiotherapy; recent early warning value ID CELL LUNG-CANCER; CARDIOVASCULAR TOXICITY; OPEN-LABEL; CARDIAC-DISEASE; BREAST-CANCER; RADIOTHERAPY; DIAGNOSIS; PREVENTION; MANAGEMENT; EFFICACY AB We aimed to explore the predictive value of abnormal electrocardiogram (ECG) changes in non-small-cell lung carcinoma non-small cell lung cancer (NSCLC) patients for near-term mortality. Seventy-eight NSCLC patients hospitalized in Chaohu Hospital Affiliated to Anhui Medical University from October 2017 to August 2021 were selected as the observation group. Baseline medical history and type of ECG abnormalities were the same. Seventy-eight patients were included in the control group. To compare the difference in mortality within 3 months between the observation group and the control group after the occurrence of the same type of electrocardiogram abnormalities, and to explore the value of electrocardiogram abnormalities in the early warning of NSCLC patients recent death. When the average ventricular rate of patients in the observation group was >= 100 beats/minute, ST-segment depression >= 0.05 mm, QRS voltage decrease >= 0.5 mm, new atrial fibrillation and other electrocardiogram changes, all patients died within 3 months. The control group with the same abnormal ECG had no death within 3 months (P < .05). In the resting 12-lead synchronous ECG in NSCLC patients, when the average ventricular rate v100 beats/minute, QRS wave voltage significantly decreased >= 0.5 mm, ST segment depression >= 0.05 mm, new atrial fibrillation appeared, it suggested that the patients' cardiac function decreased and the potential for near-term adverse outcomes is high. C1 [Liu, Qiong] Anhui Med Univ, Chaohu Hosp, Dept ECG Room, Hefei, Anhui, Peoples R China. [Cai, Weixun] Zhejiang Prov Peoples Hosp, Dept ECG Funct, Hangzhou, Zhejiang, Peoples R China. [Wang, Xianyun] Anhui Med Univ, Affiliated Hosp 1, Dept ECG Heart Funct, Hefei, Anhui, Peoples R China. [Hu, Haibin] Liangzhou Hosp, Dept Cardiol, Wuwei, Gansu, Peoples R China. [Sun, Xianchao] Jiaxing City First Hosp, Dept ECG, Jiaxing, Zhejiang, Peoples R China. [Pan, Xianli] Anhui Med Univ, Chaohu Hosp, Dept Gen Practice, Hefei, Anhui, Peoples R China. [Wang, Ailan] Anhui Med Univ, Chaohu Hosp, Dept ECG Room, Hefei, Anhui, Peoples R China. [Cai, Weixun] Zhejiang Prov Peoples Hosp, 158 Shangtang Rd, Hangzhou, Zhejiang, Peoples R China. C3 Anhui Medical University; Hangzhou Medical College; Zhejiang Provincial People's Hospital; Anhui Medical University; Anhui Medical University; Anhui Medical University; Hangzhou Medical College; Zhejiang Provincial People's Hospital RP Cai, WX (corresponding author), Zhejiang Prov Peoples Hosp, 158 Shangtang Rd, Hangzhou, Zhejiang, Peoples R China. EM 13905650210@163.com; weixuncai2008@163.com; 13505658695@163.com; 15009350309@163.com; hysxc771201@163.com; panxianli8368@outlook.com; 13505658695@163.com RI pan, xianli/GPW-8843-2022 CR Abdel-Qadir H, 2017, CANCER TREAT REV, V53, P120, DOI 10.1016/j.ctrv.2016.12.002 Anderson C, 2022, GYNECOL ONCOL, V167, P51, DOI 10.1016/j.ygyno.2022.08.014 Branda SR, 2022, METABOLISM, V134, DOI 10.1016/j.metabol.2022.155250 Calle MCA, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4935-z Cardinale D, 2010, J AM COLL CARDIOL, V55, P213, DOI 10.1016/j.jacc.2009.03.095 Chang HM, 2017, J AM COLL CARDIOL, V70, P2552, DOI [10.1016/j.jacc.2017.09.1095, 10.1016/j.jacc.2017.09.1096] Desai MY, 2019, J AM COLL CARDIOL, V74, P905, DOI 10.1016/j.jacc.2019.07.006 Desai MY, 2018, JACC-CARDIOVASC IMAG, V11, P1132, DOI 10.1016/j.jcmg.2018.04.028 Earl HM, 2019, LANCET, V393, P2599, DOI 10.1016/S0140-6736(19)30650-6 Ettinger DS, 2019, J NATL COMPR CANC NE, V17, P1464, DOI 10.6004/jnccn.2019.0059 Fan CJ, 2021, J THORAC ONCOL, V16, P1359, DOI 10.1016/j.jtho.2021.04.018 Felip E, 2021, LANCET, V398, P1344, DOI 10.1016/S0140-6736(21)02098-5 Ferlay J., 2018, Global Cancer Observatory: Cancer Today Fradley MG, 2021, CIRCULATION, V144, pE41, DOI 10.1161/CIR.0000000000000986 Gu LP, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.938269 Herbst RS, 2020, NEW ENGL J MED, V383, P1328, DOI 10.1056/NEJMoa1917346 Hosny A, 2022, LANCET DIGIT HEALTH, V4, pE657, DOI 10.1016/S2589-7500(22)00129-7 Hu WB, 2022, COMPUT MATH METHOD M, V2022, DOI 10.1155/2022/7963146 Livi L, 2021, JAMA ONCOL, V7, P1544, DOI 10.1001/jamaoncol.2021.3395 Mahmood SS, 2018, EUR J HEART FAIL, V20, P1454, DOI 10.1002/ejhf.1215 Miller KD, 2020, CA-CANCER J CLIN, V70, P443, DOI 10.3322/caac.21637 Muhandiramge J, 2022, CURR ONCOL REP, V24, P1579, DOI 10.1007/s11912-022-01309-w Murakami Y, 2022, PHYS MEDICA, V95, P126, DOI 10.1016/j.ejmp.2022.02.003 Paz-Ares L, 2021, LANCET ONCOL, V22, P198, DOI 10.1016/S1470-2045(20)30641-0 Plana JC, 2018, JACC-CARDIOVASC IMAG, V11, P1173, DOI 10.1016/j.jcmg.2018.06.003 Sezer A, 2021, LANCET, V397, P592, DOI 10.1016/S0140-6736(21)00228-2 Shi YK, 2021, LANCET RESP MED, V9, P829, DOI 10.1016/S2213-2600(20)30455-0 Shirasawa M, 2018, CANCER MANAG RES, V10, P6039, DOI 10.2147/CMAR.S181789 Soumarová R, 2020, REP PRACT ONCOL RADI, V25, P182, DOI 10.1016/j.rpor.2019.12.008 Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660 Swain SM, 2003, CANCER, V97, P2869, DOI 10.1002/cncr.11407 Wang K, 2017, J CLIN ONCOL, V35, P1387, DOI 10.1200/JCO.2016.70.0229 Wang MN, 2021, NAT MED, V27, P1345, DOI 10.1038/s41591-021-01450-2 Wu LF, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.906815 Yao YF, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.958505 Yoldas T, 2019, CARDIOL YOUNG, V29, P904, DOI 10.1017/S1047951119001094 Zamorano JL, 2016, EUR HEART J, V37, P2768, DOI [10.1093/eurheartj/ehw211, 10.1002/ejhf.654] NR 37 TC 1 Z9 1 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7974 EI 1536-5964 J9 MEDICINE JI Medicine (Baltimore) PD NOV 17 PY 2023 VL 102 IS 46 AR e35698 DI 10.1097/MD.0000000000035698 PG 5 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA Y6TU8 UT WOS:001106572600044 PM 37986366 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Tsaban, G Ostrovsky, D Alnsasra, H Burrack, N Gordon, M Babayev, AS Omari, Y Kezerle, L Shamia, D Bereza, S Konstantino, Y Haim, M AF Tsaban, Gal Ostrovsky, Daniel Alnsasra, Hilmi Burrack, Nitzan Gordon, Michal Babayev, Amit Shira Omari, Yara Kezerle, Louise Shamia, David Bereza, Sergey Konstantino, Yuval Haim, Moti TI Amiodarone and pulmonary toxicity in atrial fibrillation: a nationwide Israeli study SO EUROPEAN HEART JOURNAL LA English DT Article DE Amiodarone; Interstitial lung disease; Primary lung cancer; All-cause mortality; Atrial fibrillation ID RHYTHM CONTROL; RISK; THERAPIES; DEATH AB Background and Aims Amiodarone-related interstitial lung disease (ILD) is the most severe adverse effect of amiodarone treatment. Most data on amiodarone-related ILD are derived from periods when amiodarone was given at higher doses than currently used.Methods A nationwide population-based study was conducted among patients with incident atrial fibrillation (AF) between 1 December 1999 and 31 December 31 2021. Amiodarone-exposed patients were matched 1:1 with controls unexposed to amiodarone based on age, sex, ethnicity, and AF diagnosis duration. The final patient cohort included only matched pairs where amiodarone therapy was consistent throughout follow-up. Directed acyclic graphs and inverse probability treatment weighting (IPTW) modelling were used. Patients with either prior ILD or primary lung cancer (PLC) were excluded. The primary outcome was the incidence of any ILD. Secondary endpoints were death and PLC.Results The final cohort included 6039 amiodarone-exposed patients who were matched with unexposed controls. The median age was 73.3 years, and 51.6% were women. After a mean follow-up of 4.2 years, ILD occurred in 242 (2.0%) patients. After IPTW, amiodarone exposure was not significantly associated with ILD [hazard ratio (HR): 1.45, 95% confidence interval (CI): 0.97, 2.44, P = 0.09]. There was a trivial higher relative risk of ILD among amiodarone-exposed patients between Years 2 and 8 of follow-up [maximal risk ratio (RR): 1.019]. Primary lung cancer occurred in 97 (0.8%) patients. After IPTW, amiodarone was not associated with PLC (HR: 1.18, 95% CI: 0.76, 2.08, P = 0.53). All-cause death occurred in 2185 (18.1%) patients. After IPTW, amiodarone was associated with reduced mortality risk (HR: 0.65, 95% CI: 0.60, 0.72, P < 0.001). The results were consistent across a variety of sensitivity analyses.Conclusion In a contemporary AF population, low-dose amiodarone was associated with a trend towards increased risk of ILD (15%-45%) but a clinically negligible change in absolute risk (maximum of 1.8%), no increased risk of PLC, and a lower risk of all-cause mortality. C1 [Tsaban, Gal; Alnsasra, Hilmi; Kezerle, Louise; Shamia, David; Bereza, Sergey; Konstantino, Yuval; Haim, Moti] Soroka Univ, Med Ctr, Cardiol Dept, POB 151,101 Rager Blvd, IL-84101 Beer Sheva, Israel. [Tsaban, Gal; Ostrovsky, Daniel; Alnsasra, Hilmi; Burrack, Nitzan; Omari, Yara; Kezerle, Louise; Shamia, David; Bereza, Sergey; Konstantino, Yuval; Haim, Moti] Ben Gurion Univ Negev, Fac Hlth Sci, POB 653, IL-84105 Beer Sheva, Israel. [Ostrovsky, Daniel; Burrack, Nitzan; Gordon, Michal; Babayev, Amit Shira] Soroka Univ, Med Ctr, Clin Res Ctr, Beer Sheva, Israel. C3 Ben-Gurion University of the Negev; Soroka Medical Center; Ben-Gurion University of the Negev; Ben-Gurion University of the Negev; Soroka Medical Center RP Tsaban, G (corresponding author), Soroka Univ, Med Ctr, Cardiol Dept, POB 151,101 Rager Blvd, IL-84101 Beer Sheva, Israel.; Tsaban, G (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, POB 653, IL-84105 Beer Sheva, Israel. EM tsabang@post.bgu.ac.il RI Haim, Mordechai/K-7381-2014; konstantino, yuval/KFS-1144-2024; Ostrovsky, Daniel/HGU-4083-2022 OI Haim, Mordechai/0000-0001-6673-0506; konstantino, yuval/0000-0002-3655-5329; Burrack, Nitzan/0000-0001-6926-8505; Ostrovsky, Daniel/0000-0002-2587-5263 CR [Anonymous], 1993, Am J Cardiol, V72, P280 DUSMAN RE, 1990, CIRCULATION, V82, P51, DOI 10.1161/01.CIR.82.1.51 Filc D, 2014, INT J EQUITY HEALTH, V13, DOI 10.1186/s12939-014-0115-1 Goldschlager N, 2007, HEART RHYTHM, V4, P1250, DOI 10.1016/j.hrthm.2007.07.020 Goodman DC, 2017, ISR J HEALTH POLICY, V6, DOI 10.1186/s13584-017-0135-6 Greene HL, 2003, J AM COLL CARDIOL, V42, P20, DOI 10.1016/S0735-1097(03)00559-X Hernán MA, 2022, JAMA-J AM MED ASSOC, V328, P2446, DOI 10.1001/jama.2022.21383 Hindricks G, 2021, EUR HEART J, V42, P373, DOI 10.1093/eurheartj/ehaa612 Jackevicius CA, 2011, AM J CARDIOL, V108, P705, DOI 10.1016/j.amjcard.2011.04.024 Kirchhof P, 2020, NEW ENGL J MED, V383, P1305, DOI 10.1056/NEJMoa2019422 Kolonics-Farkas AM, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.729203 Kwok WC, 2022, BMC PULM MED, V22, DOI 10.1186/s12890-022-01926-y Lumer GB, 2002, EUR HEART J, V23, P1050, DOI 10.1053/euhj.2001.2986 MARTIN WJ, 1988, CHEST, V93, P1067, DOI 10.1378/chest.93.5.1067 Piccini JP, 2009, EUR HEART J, V30, P1245, DOI 10.1093/eurheartj/ehp100 Rasmussen PV, 2020, HEART RHYTHM, V17, P560, DOI 10.1016/j.hrthm.2019.11.025 Reges O, 2020, CLIN EPIDEMIOL, V12, P477, DOI 10.2147/CLEP.S230677 Ruzieh M, 2019, AM J CARDIOL, V124, P1889, DOI 10.1016/j.amjcard.2019.09.008 Saksena S, 2011, J AM COLL CARDIOL, V58, P1975, DOI 10.1016/j.jacc.2011.07.036 Sauleda Jaume, 2018, Med Sci (Basel), V6, DOI [10.3390/medsci6040110, 10.3390/medsci6040110] Schwaiblmair M, 2010, CLIN RES CARDIOL, V99, P693, DOI 10.1007/s00392-010-0181-3 Siemers LA, 2021, CJC OPEN, V3, P109, DOI 10.1016/j.cjco.2020.09.013 Sim I, 1997, CIRCULATION, V96, P2823, DOI 10.1161/01.CIR.96.9.2823 Singh BN, 2005, NEW ENGL J MED, V352, P1861, DOI 10.1056/NEJMoa041705 Singh SN, 1997, J AM COLL CARDIOL, V30, P514, DOI 10.1016/S0735-1097(97)00157-5 Steinberg E, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75142-1 Su VYF, 2013, CANCER-AM CANCER SOC, V119, P1699, DOI 10.1002/cncr.27881 Ullal AJ, 2015, AM HEART J, V170, P1033, DOI 10.1016/j.ahj.2015.07.023 Van Gelder IC, 2002, NEW ENGL J MED, V347, P1834, DOI 10.1056/NEJMoa021375 Vassallo P, 2007, JAMA-J AM MED ASSOC, V298, P1312, DOI 10.1001/jama.298.11.1312 Vorperian VR, 1997, J AM COLL CARDIOL, V30, P791, DOI 10.1016/S0735-1097(97)00220-9 Wyse DG, 2002, NEW ENGL J MED, V347, P1825, DOI 10.1056/nejmoa021328 Yamada Y, 2007, CIRC J, V71, P1610, DOI 10.1253/circj.71.1610 Zimetbaum P, 2007, NEW ENGL J MED, V356, P935, DOI 10.1056/NEJMct065916 NR 34 TC 19 Z9 20 U1 0 U2 22 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD FEB 1 PY 2024 VL 45 IS 5 SI SI BP 379 EP 388 DI 10.1093/eurheartj/ehad726 EA NOV 2023 PG 10 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA HC9R4 UT WOS:001101486800001 PM 37939798 OA Bronze DA 2026-04-17 ER PT J AU Catelli, C Corzani, R Zanfrini, E Franchi, F Ghisalberti, M Ligabue, T Meniconi, F Monaci, N Galgano, A Mathieu, F Addamo, E Sarnicola, N Fabiano, A Paladini, P Luzzi, L AF Catelli, C. Corzani, R. Zanfrini, E. Franchi, F. Ghisalberti, M. Ligabue, T. Meniconi, F. Monaci, N. Galgano, A. Mathieu, F. Addamo, E. Sarnicola, N. Fabiano, A. Paladini, P. Luzzi, L. TI RoboticAssisted (RATS) versus Video-Assisted (VATS) lobectomy: A monocentric prospective randomized trial SO EJSO LA English DT Article DE Lung cancer; RATS; VATS; Lobectomy; Mini -invasive surgery ID LUNG-CANCER; THORACOSCOPIC SURGERY; THORACIC-SURGERY; STAGE-I; OUTCOMES; EXPERIENCE; RESECTION AB Introduction: The study aim is to compare Video-Assisted (VATS) and Robotic-Assisted (RATS) lobectomy in the effort to identify advantages and limits of robotic procedures considering the high costs and specific surgeon training. Materials and methods: This is a monocentric prospective randomized trial in which patients suitable for miniinvasive lobectomy were randomized 1:2 in two groups: Group A, RATS (25 patients), and Group B, VATS (50 patients). The two groups were compared in terms of perioperative and postoperative results with a mean follow up of 37.9 (+/- 10.9) months. Results: We observed a significant reduction of pleural effusion on day 1 (140 ml vs 214, p = 0.003) and day 2 (186 vs 321, p = 0.001) for group A. The Visual Analogue Scale (VAS) showed significantly lower pain in the 1st p.o. day in group A (0,92 vs 1,17, p = 0,005). Surgery time in Group B was significantly lower (160 min vs 180, p = 0.036), but had a higher onset of atrial fibrillation and other cardiac arrhythmias (0/25 vs 9/50, p = 0.038). The OS and DFS were similar between the two groups (95.5 % vs 93.1 %, and 95.5 % vs 89.7 %, respectively). Furthermore, no statistical difference in the evaluation of quality of life during follow-up was found. Conclusions: The RATS approach, although burdened by higher surgical costs, constitutes a valid alternative to VATS; as it determines a lower inflammatory insult, with a consequent reduction in pleural effusion, less postoperative pain and cardiological comorbidities for the patient, it can potentially determine the shortening in hospitalization. In addition, RATS allows accurate lymph node dissection, which permit to reach results that are not inferior to VATS in terms of long-term outcomes. C1 [Catelli, C.] Univ Padua, Padua Univ Hosp, Dept Cardiothorac Surg & Vasc Sci, Div Thorac Surg, Via Giustiniani 1, Padua, PD, Italy. [Corzani, R.; Zanfrini, E.; Ghisalberti, M.; Ligabue, T.; Meniconi, F.; Monaci, N.; Galgano, A.; Mathieu, F.; Addamo, E.; Sarnicola, N.; Fabiano, A.; Paladini, P.; Luzzi, L.] Univ Hosp Siena, Thorac Surg Unit, Siena, Italy. [Franchi, F.] Univ Hosp Siena, Dept Med Surg & Neurosci, Anesthesiol & Intens Care, Siena, Italy. [Catelli, C.] Via Borgo Giannotti 309, I-55100 Lucca, Italy. C3 University of Padua; Azienda Ospedaliera - Universita di Padova; University of Siena; University Hospital of Siena; University of Siena; University Hospital of Siena RP Catelli, C (corresponding author), Via Borgo Giannotti 309, I-55100 Lucca, Italy. EM chiara.catelli1992@gmail.com RI Paladini, Paolo/AAH-9545-2019; Catelli, Chiara/KIB-2487-2024; Luzzi, Luca/AIB-7155-2022; Ghisalberti, Marco/AAL-6715-2020 OI Galgano, Angela/0000-0002-9090-4139; Addamo, Emanuele/0009-0001-6127-9610; Catelli, Chiara/0009-0006-2473-8511; Luzzi, Luca/0000-0002-8379-4306; Franchi, Federico/0000-0002-4448-1892; Mathieu, Federico/0000-0001-5429-5869; Ghisalberti, Marco/0000-0001-9424-7511 CR Adams RD, 2014, ANN THORAC SURG, V97, P1893, DOI 10.1016/j.athoracsur.2014.02.043 Aiolfi A, 2021, SURGERY, V169, P436, DOI 10.1016/j.surg.2020.09.010 Andersson Saana E-M, 2021, Cancer Treat Res Commun, V27, P100362, DOI [10.1016/j.ctarc.2021.100362, 10.1016/j.ctarc.2021.100362] Augustin F, 2013, LANGENBECK ARCH SURG, V398, P895, DOI 10.1007/s00423-013-1090-5 Bendixen M, 2016, LANCET ONCOL, V17, P836, DOI 10.1016/S1470-2045(16)00173-X Freystaetter K, 2021, FRONT SURG, V8, DOI 10.3389/fsurg.2021.597410 Gallina FT, 2021, FRONT SURG, V8, DOI 10.3389/fsurg.2021.666158 Gomez-Hernandez MT, 2021, Cir Esp (Engl Ed) Haruki T, 2020, GEN THORAC CARDIOVAS, V68, P984, DOI 10.1007/s11748-020-01312-7 Hoy H, 2019, CRIT CARE NURS CLIN, V31, P303, DOI 10.1016/j.cnc.2019.05.002 Hu JJ, 2020, INT J MED ROBOT COMP, V16, DOI 10.1002/rcs.2123 Kent M, 2014, ANN THORAC SURG, V97, P236, DOI 10.1016/j.athoracsur.2013.07.117 Li JT, 2019, J THORAC DIS, V11, P882, DOI 10.21037/jtd.2019.01.78 Liang HR, 2018, ANN SURG, V268, P254, DOI 10.1097/SLA.0000000000002346 Louie BE, 2016, ANN THORAC SURG, V102, P917, DOI 10.1016/j.athoracsur.2016.03.032 Louie BE, 2012, ANN THORAC SURG, V93, P1598, DOI 10.1016/j.athoracsur.2012.01.067 Ma JL, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08241-5 Mahieu J, 2016, THORAC CARDIOV SURG, V64, P354, DOI 10.1055/s-0035-1548733 Mao JJ, 2021, TRANSL CANCER RES, V10, P3883, DOI 10.21037/tcr-21-646 Merritt RE, 2019, INNOVATIONS, V14, P263, DOI 10.1177/1556984519845672 Montagne F, 2022, CANCERS, V14, DOI 10.3390/cancers14112611 Mungo B, 2016, J LAPAROENDOSC ADV S, V26, P243, DOI 10.1089/lap.2016.0049 Oh DS, 2017, ANN THORAC SURG, V104, P1733, DOI 10.1016/j.athoracsur.2017.06.020 Paul S, 2013, EUR J CARDIO-THORAC, V43, P813, DOI 10.1093/ejcts/ezs428 Qsous G, 2022, CUREUS J MED SCIENCE, V14, DOI 10.7759/cureus.31688 Rajaram R, 2017, ANN THORAC SURG, V103, P1092, DOI 10.1016/j.athoracsur.2016.09.108 Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654 Singer E, 2019, ANN CARDIOTHORAC SUR, V8, P194, DOI 10.21037/acs.2018.05.18 Testori A, 2022, J CLIN MED, V11, DOI 10.3390/jcm11041108 van der Ploeg APT, 2020, J ROBOT SURG, V14, P131, DOI 10.1007/s11701-019-00953-y Veronesi G, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.726408 Wu H, 2021, EUR J CARDIO-THORAC, V59, P732, DOI 10.1093/ejcts/ezaa426 Yang S, 2018, EUR J CARDIO-THORAC, V53, P348, DOI 10.1093/ejcts/ezx310 Zhang JY, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.853530 Zheng L, 2022, J THORAC DIS, V14, P689, DOI 10.21037/jtd-22-238 NR 35 TC 35 Z9 37 U1 1 U2 2 PU ELSEVIER SCI LTD PI London PA 125 London Wall, London, ENGLAND SN 0748-7983 EI 1532-2157 J9 EJSO-EUR J SURG ONC JI EJSO PD DEC PY 2023 VL 49 IS 12 AR 107256 DI 10.1016/j.ejso.2023.107256 EA NOV 2023 PG 5 WC Oncology; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Surgery GA Z0PR4 UT WOS:001109193900001 PM 37925829 OA Green Submitted, Bronze DA 2026-04-17 ER PT J AU Aboukheir, AA Villanueva, EQ III Garrett, JR Moodie, CC Tew, JR Toloza, EM Fontaine, JP Baldonado, JJAR AF Aboukheir, Aihab Aboukheir Villanueva III, Emilio Q. Garrett, Joseph R. Moodie, Carla C. Tew, Jenna R. Toloza, Eric M. Fontaine, Jacques P. Baldonado, Jobelle J. A. R. TI Association between the Preoperative Standard Uptake Value (SUV) and Survival Outcomes after Robotic-Assisted Segmentectomy for Resectable Non-Small Cell Lung Cancer (NSCLC) SO CANCERS LA English DT Article DE non-small cell lung cancer (NSCLC); segmentectomy; standard update value (SUV); lobectomy; overall survival (OS); recurrence-free survival (RFS) ID POSITRON-EMISSION-TOMOGRAPHY; SUBLOBAR RESECTION; PROGNOSTIC VALUE; LOBECTOMY; MULTICENTER AB Background: Lung-sparing procedures, specifically segmentectomies and wedge resections, have increased over the years to treat early-stage non-small cell lung cancer (NSCLC). We investigate here the perioperative and long-term outcomes of patients who underwent robotic-assisted segmentectomy (RAS) at an NCI-designated cancer center and aim to show associations between the preoperative standard update value (SUV) to tumor stage, recurrence patterns, and overall survival. Methods: A retrospective analysis was performed on 166 consecutive patients who underwent RAS at a single institution from 2010 to 2021. Of this number, 121 robotic-assisted segmentectomies were performed for primary NSCLC, and a total of 101 patients were evaluated with a PET-CT scan. The SUV from the primary tumor was determined from the PET-CT. The clinical, surgical, and pathologic profiles and perioperative outcomes were summarized via descriptive statistics. Numerical variables were described as the median and interquartile range because all numerical variables were not normally distributed as assessed by the Shapiro-Wilk test of normality. Categorical variables were described as the count and proportion. Chi-square or Fisher's exact test was used for association. The main outcomes were overall survival (OS) and recurrence-free survival (RFS). Kaplan-Meier (KM) curves were constructed to visualize the OS and RFS, which were also stratified according to tumor histology, the pathologic stage, and standard uptake value. A log-rank test for the equality of survival curves was performed to determine significant differences between groups. Results: The most common postoperative complications were atrial fibrillation (8.8%, 9/102), persistent air leak (7.84%, 8/102), and pneumonia (4.9%, 5/102). The median operative duration was 168.5 min (IQR 59), while the median estimated blood loss was 50 mL (IQR 125). The conversion rate to thoracotomy in this cohort was 3.9% (4/102). Intraoperative complications occurred in 2.9% (3/102). The median hospital length of stay was 3 days (IQR 3). The median chest tube duration was 3 days (IQR 2), but 4.9% (5/102) of patients were sent home with a chest tube. The recurrence for this cohort was 28.4% (29/102). The time to recurrence was 353 days (IQR 504), while the time to mortality was 505 days (IQR 761). The NSCLC patients were divided into the following two groups: low SUV (<5, n = 55) and high SUV (>= 5, n = 47). Statistically significant associations were noted between SUV and the tumor histology (p = 0.019), tumor grade (p = 0.002), lymph-vascular invasion (p = 0.029), viscera-pleural invasion (p = 0.008), recurrence (p < 0.001) and the site of recurrence (p = 0.047). KM survival analysis showed significant differences in the curves for OS (log-rank p-value 0.0204) and RFS (log-rank p-value 0.0034) between the SUV groups. Conclusion: Robotic-assisted segmentectomy for NSCLC has reasonable perioperative and oncologic outcomes. Furthermore, we demonstrate here the prognostic implication of preoperative SUV to pathologic outcomes, recurrence-free survival, and overall survival. C1 [Aboukheir, Aihab Aboukheir] Ponce Hlth Sci Univ, St Luke Episcopal Med Ctr, Dept Gen Surg, Gen Surg Residency, Ponce, PR 00716 USA. [Aboukheir, Aihab Aboukheir; Garrett, Joseph R.; Moodie, Carla C.; Tew, Jenna R.; Toloza, Eric M.; Fontaine, Jacques P.; Baldonado, Jobelle J. A. R.] H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Med Oncol, Tampa, FL 33612 USA. [Villanueva III, Emilio Q.] Univ Philippines, Dept Pathol, Coll Med, Manila City 1000, Philippines. [Villanueva III, Emilio Q.] Expanded Hosp Res Off, UP Philippine Gen Hosp, Manila City 1000, Philippines. C3 Ponce Health Sciences University; H Lee Moffitt Cancer Center & Research Institute RP Baldonado, JJAR (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Med Oncol, Tampa, FL 33612 USA. EM aihab.aboukheiraboukheir@moffitt.org; eqvillanueva@up.edu.ph; joe.garrett@moffitt.org; carla.moodie@moffitt.org; jenna.tew@moffitt.org; eric.toloza@moffitt.org; jacques.fontaine@moffitt.org; jobelle.baldonado@moffitt.org RI ; Villanueva III, Emilio/GXW-3042-2022 OI Baldonado, Jobelle/0000-0002-3120-4319; Villanueva III, Emilio/0000-0001-8543-9239; Aboukheir, Aihab/0000-0001-5491-1035 CR Altorki NK, 2018, LANCET RESP MED, V6, P915, DOI 10.1016/S2213-2600(18)30411-9 Berghmans T, 2008, J THORAC ONCOL, V3, P6, DOI 10.1097/JTO.0b013e31815e6d6b Blumenthaler AN, 2022, ANN THORAC SURG, V113, P1835, DOI 10.1016/j.athoracsur.2021.06.017 Brunelli A, 2009, BREATHE, V6, P141, DOI 10.1183/18106838.0602.141 Charloux A, 2017, EUR RESPIR REV, V26, DOI 10.1183/16000617.0079-2017 Chevrollier GS, 2019, INNOVATIONS, V14, P218, DOI 10.1177/1556984519836821 Cistaro A, 2013, RADIOL ONCOL, V47, P219, DOI 10.2478/raon-2013-0023 Nguyen D, 2019, EUR J CARDIO-THORAC, V55, P427, DOI 10.1093/ejcts/ezy332 Eguchi T, 2022, J PERS MED, V12, DOI 10.3390/jpm12091417 Eguchi T, 2021, CANCERS, V13, DOI 10.3390/cancers13133137 El-Sherif A, 2006, ANN THORAC SURG, V82, P408, DOI 10.1016/j.athoracsur.2006.02.029 Helminen O, 2021, EUR J CARDIO-THORAC, V60, P1286, DOI 10.1093/ejcts/ezab330 Herrera LJ, 2021, INNOVATIONS, V16, P441, DOI 10.1177/15569845211030917 Hino H, 2021, GEN THORAC CARDIOVAS, V69, P1196, DOI 10.1007/s11748-021-01606-4 Kagimoto A, 2020, JPN J CLIN ONCOL, V50, P440, DOI 10.1093/jjco/hyz199 Kamigaichi A, 2021, CLIN LUNG CANCER, V22, P120, DOI 10.1016/j.cllc.2020.12.010 Kandemir O, 2024, CURR RADIOPHARM, V17, P111, DOI 10.2174/1874471016666230829100703 Li CQ, 2019, ANN THORAC SURG, V107, P1480, DOI 10.1016/j.athoracsur.2018.11.059 Ma JL, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08241-5 Mantziari S, 2020, BMC MED IMAGING, V20, DOI 10.1186/s12880-019-0401-x Motono N, 2022, THORAC CANCER, V13, P2985, DOI 10.1111/1759-7714.14647 Nakamura K, 2010, JPN J CLIN ONCOL, V40, P271, DOI 10.1093/jjco/hyp156 Ohtsuka Takashi, 2015, Asian Cardiovasc Thorac Ann, V23, P828, DOI [10.1177/0218492315589476, 10.1177/0218492315589476] Paesmans M, 2010, J THORAC ONCOL, V5, P612, DOI 10.1097/JTO.0b013e3181d0a4f5 Perroni G, 2020, J THORAC DIS, V12, P3404, DOI 10.21037/jtd.2020.02.53 Roy PM, 2018, J ANAESTH CLIN PHARM, V34, P296, DOI 10.4103/joacp.JOACP_89_17 Saji H, 2022, LANCET, V399, P1607, DOI 10.1016/S0140-6736(21)02333-3 Shiono S, 2011, J THORAC ONCOL, V6, P43, DOI 10.1097/JTO.0b013e3181f9abca Stiles BM, 2013, ANN THORAC SURG, V95, P397, DOI 10.1016/j.athoracsur.2012.07.038 Sun GH, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2842604 Suzuki K, 2019, J THORAC CARDIOV SUR, V158, P895, DOI 10.1016/j.jtcvs.2019.03.090 Terra Ricardo Mingarini, 2019, Rev Col Bras Cir, V46, pe20192210, DOI 10.1590/0100-6991e-20192210 Toker A, 2016, SURG ENDOSC, V30, P676, DOI 10.1007/s00464-015-4259-x Wang CG, 2021, FRONT SURG, V8, DOI 10.3389/fsurg.2021.637441 Winton T, 2005, NEW ENGL J MED, V352, P2589, DOI 10.1056/NEJMoa043623 Zhang ZR, 2019, J THORAC DIS, V11, P1838, DOI 10.21037/jtd.2019.05.20 NR 36 TC 0 Z9 0 U1 0 U2 1 PU MDPI PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND EI 2072-6694 J9 CANCERS JI Cancers PD NOV PY 2023 VL 15 IS 22 AR 5379 DI 10.3390/cancers15225379 PG 12 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA CD5K8 UT WOS:001123323300001 PM 38001639 OA Green Submitted, gold DA 2026-04-17 ER PT J AU King, J Taylor, M Booton, R Crosbie, P Shah, D Evison, M Ng, C Rammohan, K Shah, RJ Shackcloth, M Grant, SW Sinnott, N AF King, Jenny Taylor, Marcus Booton, Richard Crosbie, Phil Shah, Dinakshi Evison, Matthew Ng, Cassandra Rammohan, Kandadai Shah, Rajesh Shackcloth, Michael Grant, Stuart W. Sinnott, Nicola TI Safety of curative-intent lung cancer surgery in older patients (octogenarians): A contemporary multicentre cohort study SO JOURNAL OF GERIATRIC ONCOLOGY LA English DT Article DE Lung cancer; Surgery; Outcomes; Octogenarians ID THORACIC-SURGERY; HIGH-RISK; RESECTION; IMPACT; COMORBIDITY; MORTALITY; PROJECT; PROGRAM; PATHWAY AB Introduction: Despite octogenarians representing an ever-increasing proportion of patients with lung cancer, there is a paucity of evidence describing outcomes after lung resection for these patients. We aimed to evaluate short and mid-term outcomes for octogenarians after lung resection.Materials and Methods: A total of 5,470 consecutive patients undergoing lung resection for primary lung cancer from 2012-2019 in two UK centres were included. Primary outcomes were perioperative, 90-day, and one-year mortality in the octogenarian vs. non-octogenarian cohort. Appropriate statistical tests were used to compare outcomes between octogenarian and non-octogenarian patients. Secondary outcomes were post-operative complications and to validate the performance of the Thoracoscore model in the octogenarian cohort.Results: Overall, 9.4% (n=513) of patients were aged >= 80. The rates of 90-day mortality, one-year mortality, and post-operative atrial fibrillation were significantly higher for octogenarians. The one-year mortality rate for octogenarians fell significantly over time (2012-2015: 16.5% vs 2016-2019: 10.2%, p=0.034). Subgroup analysis (2016-2019 only) demonstrated no significant difference in peri-operative, 90-day, or one-year mortality between octogenarian and non-octogenarian patients. Validation of the Thoracoscore model demonstrated modest discrimination and acceptable calibration. Discussion: Mortality for octogenarians fell significantly over time in this study. Indeed, when confined to the most recent time period, comparable rates of both 90-day and one-year mortality for octogenarian and nonoctogenarian patients were seen. Whilst preventative strategies to reduce the incidence of post-operative atrial fibrillation in octogenarians should be considered, these findings demonstrate that following appropriate patient selection, octogenarians can safely undergo lung resection for lung cancer. C1 [King, Jenny; Taylor, Marcus; Booton, Richard; Crosbie, Phil; Shah, Dinakshi; Evison, Matthew; Ng, Cassandra; Rammohan, Kandadai; Shah, Rajesh; Sinnott, Nicola] Manchester Univ Hosp NHS Fdn Trust, Wythenshawe Hosp, Manchester, England. [King, Jenny; Booton, Richard; Crosbie, Phil; Ng, Cassandra] Univ Manchester, Div Infect Immun & Resp Med, Manchester, England. [Shackcloth, Michael] Liverpool Heart & Chest Hosp, Dept Cardiothorac Surg, Liverpool, England. [Grant, Stuart W.] Univ Manchester, Div Cardiovasc Sci, ERC, Manchester, England. [King, Jenny] Univ Hosp South Manchester NHS Fdn Trust, North West Lung Ctr, Southmoor Rd, Manchester M23 9LT, England. C3 Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of Manchester; Liverpool Heart & Chest Hospital; University of Manchester; Wythenshawe Hospital NHS Foundation Trust RP King, J (corresponding author), Univ Hosp South Manchester NHS Fdn Trust, North West Lung Ctr, Southmoor Rd, Manchester M23 9LT, England. EM jenny.king@manchester.ac.uk RI Crosbie, Phil/G-4504-2011; Shackcloth, Michael/AAK-1070-2021; Booton, Richard/NIS-5833-2025 OI Crosbie, Phil/0000-0001-8941-4813; Evison, Matthew/0000-0003-4066-5253; Shackcloth, Michael/0000-0002-6494-9907; Taylor, Marcus/0000-0001-5379-7090; Grant, Stuart/0000-0003-3468-591X; King, Jenny/0000-0002-0834-4911; CR Alberts WM, 2003, CHEST, V123, p1S, DOI 10.1378/chest.123.1_suppl.1S Audisio RA, 2005, ONCOLOGIST, V10, P262, DOI 10.1634/theoncologist.10-4-262 Baitar A, 2013, J GERIATR ONCOL, V4, P32, DOI 10.1016/j.jgo.2012.08.001 Battafarano RJ, 2002, J THORAC CARDIOV SUR, V123, P280, DOI 10.1067/mtc.2002.119338 Birim Ö, 2005, EUR J CARDIO-THORAC, V28, P759, DOI 10.1016/j.ejcts.2005.06.046 Damhuis RAM, 1996, EUR RESPIR J, V9, P7, DOI 10.1183/09031936.96.09010007 Evison M, 2020, CLIN MED, V20, P401, DOI 10.7861/clinmed.2019-0218 Evison M, 2020, CLIN MED, V20, P196, DOI 10.7861/clinmed.2019-0336 Falcoz PE, 2007, J THORAC CARDIOV SUR, V133, P325, DOI 10.1016/j.jtcvs.2006.09.020 Fay KA, 2020, ANN THORAC SURG, V109, pE137, DOI 10.1016/j.athoracsur.2019.08.075 Fitzmaurice C, 2015, JAMA ONCOL, V1, P505, DOI 10.1001/jamaoncol.2015.0735 Fountain SW, 2001, THORAX, V56, P89 Gonzalez-Rivas D, 2016, ANN CARDIOTHORAC SUR, V5, P75, DOI 10.21037/acs.2016.03.04 Laohathai S, 2019, J GERIATR ONCOL, V10, P436, DOI 10.1016/j.jgo.2018.08.011 Maconachie R, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.l1049 Moore JA, 2017, ANAESTHESIA, V72, P317, DOI 10.1111/anae.13763 NICE, 2019, Excellence NIfHaC Nwaejike N, 2016, INTERACT CARDIOV TH, V22, P397, DOI 10.1093/icvts/ivv389 Physicians RCo, 2020, Partnership HQI Rami-Porta R, 2014, J THORAC ONCOL, V9, P1618, DOI 10.1097/JTO.0000000000000334 Soubeyran P, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.9001 Sourdet S, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-06878-2 Statistics OfN, 2018, Home People, Population and Community Births, Deaths and Marriages Ageing Living longer Living Longer: How Our Population is Changing and Why it Matters Taylor M, 2021, EUR J CARDIO-THORAC, V59, P1030, DOI 10.1093/ejcts/ezaa422 Tomaszek SC, 2011, EUR J CARDIO-THORAC, V40, P1151, DOI 10.1016/j.ejcts.2011.02.042 Torring ML, 2013, EUR J CANCER, V49, P2187, DOI 10.1016/j.ejca.2013.01.025 Tremblay D, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001483 Tsai CH, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-034351 Tutic-Horn M, 2017, J THORAC DIS, V9, P296, DOI 10.21037/jtd.2017.02.22 UK CR, 2021, Lung Cancer Mortality Statistics Vazirani J, 2018, ANZ J SURG, V88, P1322, DOI 10.1111/ans.14861 Ziabari Y, 2017, BJA EDUC, V17, P255, DOI 10.1093/bjaed/mkx003 NR 32 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER PI AMSTERDAM PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS SN 1879-4068 EI 1879-4076 J9 J GERIATR ONCOL JI J. Geriatr. Oncol. PD NOV PY 2023 VL 14 IS 8 AR 101635 DI 10.1016/j.jgo.2023.101635 EA OCT 2023 PG 7 WC Oncology; Geriatrics & Gerontology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Geriatrics & Gerontology GA W3XO5 UT WOS:001090992400001 PM 37812970 OA Green Submitted, hybrid DA 2026-04-17 ER PT J AU Ajabnoor, AM Parisi, R Zghebi, SS Ashcroft, DM Faivre-Finn, C Morris, C Mamas, MA Kontopantelis, E AF Ajabnoor, Alyaa M. Parisi, Rosa Zghebi, Salwa S. Ashcroft, Darren M. Faivre-Finn, Corinne Morris, Charlotte Mamas, Mamas A. Kontopantelis, Evangelos TI Common Cancer Types and Risk of Stroke and Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Population-Based Study in England SO JOURNAL OF THE AMERICAN HEART ASSOCIATION LA English DT Article DE atrial fibrillation; bleeding; cancer; oral anticoagulant; stroke ID MANAGEMENT; THERAPY; COMPLICATIONS; INSIGHTS; HISTORY AB BackgroundThe association between cancer and stroke or bleeding outcomes in atrial fibrillation is unclear. We sought to examine how certain types of cancer influence the balance between stroke and bleeding risk in patients with nonvalvular atrial fibrillation (NVAF).Methods and ResultsWe estimated stroke and bleeding risk among adult patients with NVAF and certain types of cancer (breast, prostate, colorectal, lung, and hematological cancer) from 2009 to 2019 based on data from the UK Clinical Practice Research Datalink GOLD and Aurum databases. The control group included patients with NVAF only. Of 177 065 patients with NVAF, 11379 (6.4%) had cancer (1691 breast, 3955 prostate, 1666 colorectal, 2491 hematological, and 1576 lung). Compared with patients without cancer, stroke risk was higher in patients with breast cancer (adjusted hazard ratio [aHR], 1.20 [95% CI, 1.07-1.35) and with prostate cancer (aHR, 1.11 [95% CI, 1.01-1.12) if diagnosed within 6 months before NVAF. The risk of bleeding was increased in subjects with hematological cancer (aHR, 1.55 [95% CI, 1.40-1.71]), lung cancer (aHR, 1.49 [95% CI, 1.25, 1.77]), prostate cancer (aHR, 1.38 [95% CI, 1.28-1.49]), and colorectal cancer (aHR, 1.36 [95% CI, 1.21-1.53]), but not for subjects with breast cancer. The more recent the cancer diagnosis before NVAF diagnosis (within 6 months), the higher the risk of bleeding.ConclusionsBreast and prostate cancer are associated with increased stroke risk, whereas in some cancer types, the risk of bleeding seemed to exceed stroke risk. In these patients, prescribing of oral anticoagulant should be carefully evaluated to balance bleeding and stroke risk. C1 [Ajabnoor, Alyaa M.] King Abdulaziz Univ, Fac Pharm, Dept Pharm Practice, Jeddah, Saudi Arabia. [Ajabnoor, Alyaa M.; Parisi, Rosa; Kontopantelis, Evangelos] Manchester Acad Hlth Sci Ctr MAHSC, Fac Biol Med & Hlth, Sch Hlth Sci, Div Informat Imaging & Data Sci, Manchester, England. [Zghebi, Salwa S.; Morris, Charlotte] Manchester Acad Hlth Sci Ctr MAHSC, Fac Biol Med & Hlth, Sch Hlth Sci, Div Populat Hlth Hlth Serv Res & Primary Care, Manchester, England. [Ashcroft, Darren M.] Fac Biol Med & Hlth, Ctr Pharmacoepidemiol & Drug Safety, Sch Hlth Sci, Div Pharm & Optometry, Manchester, England. [Ashcroft, Darren M.] Univ Manchester, Natl Inst Hlth & Care Res NIHR, Greater Manchester Patient Safety Res Collaborat P, Manchester, England. [Faivre-Finn, Corinne] Christie NHS Fdn Trust, Manchester, England. [Faivre-Finn, Corinne] Univ Manchester, Manchester, England. [Mamas, Mamas A.] Keele Univ, Inst Primary Care & Hlth Sci, Ctr Prognosis Res, Keele Cardiovasc Res Grp, Keele, England. [Ajabnoor, Alyaa M.] King Abdulaziz Univ, Sch Pharm, Dept Pharm Practice, POB 80324, Jeddah 21589, Saudi Arabia. C3 King Abdulaziz University; University of Manchester; Christie NHS Foundation Trust; University of Manchester; Keele University; King Abdulaziz University RP Ajabnoor, AM (corresponding author), King Abdulaziz Univ, Sch Pharm, Dept Pharm Practice, POB 80324, Jeddah 21589, Saudi Arabia. EM ammajabnour@kau.edu.sa RI ; Mamas, Mamas/A-2549-2019; Ashcroft, Darren/G-3244-2015; Faivre-Finn, Corinne/JXN-7003-2024; Kontopantelis, Evangelos/H-2966-2019; Ajabnoor, Alyaa/LDG-3802-2024 OI Morris, Charlotte/0000-0002-9047-0481; Mamas, Mamas/0000-0001-9241-8890; Ashcroft, Darren/0000-0002-2958-915X; Zghebi, Salwa S/0000-0002-7978-1094; Faivre-Finn, Corinne/0000-0001-5617-9781; Parisi, Rosa/0000-0002-0968-9153; Kontopantelis, Evangelos/0000-0001-6450-5815; Ajabnoor, Alyaa/0000-0001-5154-6183 FU This study was conducted using CPRD data obtained under license from the UK Medicines and Healthcare products Regulatory Agency. The data are provided by patients and collected by the National Health Service as part of their care and support. The ONS is th FX This study was conducted using CPRD data obtained under license from the UK Medicines and Healthcare products Regulatory Agency. The data are provided by patients and collected by the National Health Service as part of their care and support. The ONS is the provider of the ONS data contained within the CPRD data. Hospital Episode Data and the ONS data, (c) 2021, are reused with the permission of National Health Service Digital. All rights reserved. We are grateful to the contributing patients and practices in the CPRD who have allowed their data to be used for research purposes. CR Ajabnoor AM, 2022, PLOS MED, V19, DOI 10.1371/journal.pmed.1004003 [Anonymous], 2022, Atrial Fibrillation: Diagnosis and Management [Anonymous], 2019, English indices of deprivation 2019 Aspberg S, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2019.104560 Baker C., 2019, Cancer statistics for England CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8 Chen ST, 2019, EUR HEART J-QUAL CAR, V5, P145, DOI 10.1093/ehjqcco/qcy040 Cheng WL, 2016, INT J CARDIOL, V219, P186, DOI 10.1016/j.ijcard.2016.06.009 Chu G, 2021, EUR HEART J, V42, P2870 Fanola CL, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.008987 Farmakis D, 2014, J AM COLL CARDIOL, V63, P945, DOI 10.1016/j.jacc.2013.11.026 Field TS, 2019, THROMB HAEMOSTASIS, V119, P981, DOI 10.1055/s-0039-1683429 Gershman E, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.04.91 Grazioli S, 2018, THROMB RES, V165, P33, DOI 10.1016/j.thromres.2018.03.011 Green D, 2007, SEMIN THROMB HEMOST, V33, P427, DOI 10.1055/s-2007-976178 Hajjar LA, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.590768 Herrett E, 2015, INT J EPIDEMIOL, V44, P827, DOI 10.1093/ije/dyv098 Hu YF, 2013, INT J CARDIOL, V165, P355, DOI 10.1016/j.ijcard.2012.08.036 Jang HS, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00052 Kirchhof P, 2007, EUR HEART J, V28, P2803, DOI 10.1093/eurheartj/ehm358 Kirchhof P, 2016, EUR HEART J, V37, P2893, DOI 10.1093/eurheartj/ehw210 Kobo O, 2022, INT J CARDIOL, V363, P210, DOI 10.1016/j.ijcard.2022.06.053 Kontopantelis Evangelos, 2017, BMC Res Notes, V10, P41, DOI [10.1186/s13104-016-2365-z, 10.1186/s13104-016-2365-z] Lacoin L, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015363 Masnoon N, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0621-2 Melloni C, 2017, AM J MED, V130, P1440, DOI 10.1016/j.amjmed.2017.06.026 Melloni C, 2017, EUR HEART J, V3, P192, DOI 10.1093/ehjqcco/qcx004 Mery B, 2017, INT J CARDIOL, V240, P196, DOI 10.1016/j.ijcard.2017.03.132 Navi BB, 2018, ANN NEUROL, V83, P873, DOI 10.1002/ana.25227 Navi BB, 2017, J AM COLL CARDIOL, V70, P927, DOI 10.1016/j.jacc.2017.06.047 Navi BB, 2015, ANN NEUROL, V77, P291, DOI 10.1002/ana.24325 Ording AG, 2017, CANCER MED-US, V6, P1165, DOI 10.1002/cam4.1054 Parisi R, 2015, J INVEST DERMATOL, V135, P2189, DOI 10.1038/jid.2015.87 Pisters R, 2010, CHEST, V138, P1093, DOI 10.1378/chest.10-0134 Sanossian N, 2013, J STROKE CEREBROVASC, V22, P1146, DOI 10.1016/j.jstrokecerebrovasdis.2012.11.016 Schulman S, 2005, J THROMB HAEMOST, V3, P692, DOI 10.1111/j.1538-7836.2005.01204.x Siddiqi TJ, 2022, EUR J PREV CARDIOL, V29, P625, DOI 10.1093/eurjpc/zwab018 Springate DA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099825 Wolf A, 2019, INT J EPIDEMIOL, V48, P1740, DOI 10.1093/ije/dyz034 Wu JH, 2022, LANCET REG HEALTH-EU, V17, DOI 10.1016/j.lanepe.2022.100386 Yano YX, 2008, PHARMACOEPIDEM DR S, V17, P869, DOI 10.1002/pds.1599 Yun JP, 2021, JACC-CARDIOONCOL, V3, P221, DOI 10.1016/j.jaccao.2021.03.006 Zakeri R, 2021, BMC MED, V19, DOI 10.1186/s12916-021-02048-8 NR 43 TC 21 Z9 22 U1 0 U2 3 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA EI 2047-9980 J9 J AM HEART ASSOC JI J. Am. Heart Assoc. PD OCT 3 PY 2023 VL 12 IS 19 AR e029423 DI 10.1161/JAHA.123.029423 PG 13 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA U1ZP6 UT WOS:001082860300034 PM 37750567 OA Green Submitted, Green Published, gold DA 2026-04-17 ER PT J AU Baldonado, JJAR Naffouje, SA Parvathaneni, S Roy, E Toloza, EM Fontaine, JP AF Baldonado, Jobelle J. A. R. Naffouje, Samer A. Parvathaneni, Sirish Roy, Esha Toloza, Eric M. Fontaine, Jacques P. TI Outcomes of robotic lobectomy for non-small cell lung cancer in a National Cancer Institute-Comprehensive Cancer Center vs. National Cancer Database SO JOURNAL OF THORACIC DISEASE LA English DT Article DE Lung cancer; perioperative outcomes; robotic surgery; pulmonary lobectomy; survival ID THORACOTOMY; RESECTION AB Background: Our study aims to compare outcomes of robotic lobectomy (RL) for non-small cell lung cancer (NSCLC) at a National Cancer Institute-designated Comprehensive Cancer Center (NCI-CCC) to those of open lobectomy (OL), video-assisted thoracoscopic lobectomy (VL), or RL as reported in the National Cancer Database (NCDB).Methods: The first 1021 patients with NSCLC who underwent RL between 2010 and 2020 were matched with peers from the NCDB who had OL, VL, or RL. Matching was performed based on a propensity score calculated by logistic regression using multiple variables. Surgical outcomes included numbers of examined lymph nodes, performance of mediastinal lymphadenectomy, length of stay (LOS), and 30-day mortality. Kaplan-Meier curves and overall survival (OS) were analyzed using log-rank tests.Results: Most common postoperative complications were persistent air leak, atrial fibrillation, and pneumonia. Median LOS was 4 days, and the 30-day mortality rate was 1% (n=10/1,021). Compared to NCDB patients who underwent OL, NCI-CCC patients had a higher mean number of retrieved lymph nodes (P=0.001), higher rate of mediastinal lymphadenectomy (P<0.001), and shorter median LOS (4 vs. 6 days; P<0.001). There was no difference in 30-day mortality (P=0.176). Kaplan-Meier analyses showed no differences in median OS (log-rank P=0.953) or 5-year OS (P=0.774). Compared to NCDB VL, NCI-CCC patients had a higher nodal yield (P<0.001), higher rates of mediastinal lymphadenectomy (P<0.001), and lower conversion rates (4.1% vs. 13.8%, P<0.001). There were no differences in 30-day mortality (P=0.379) or in median LOS (P=0.351). Kaplan-Meier analyses showed no differences in median OS (P=0.720) or 5-year OS (P=0.735). NCI-CCC patients were also matched with NCDB RL patients and had a higher nodal yield (P<0.001), higher rates of mediastinal lymphadenectomy (P<0.001), and lower conversion rates (4.1% vs. 9.5%; P <0.001). There were no differences in 30-day mortality (P=0.899) or in median LOS (P=0.252). Kaplan-Meier analyses showed no differences in median OS (P=0.484) or 5-year OS (P=0.524).Conclusions: RL for NSCLC performed in an NCI-CCC appears to have improved perioperative outcomes with comparable long-term OS compared to national benchmarks in OL and VL. C1 [Baldonado, Jobelle J. A. R.; Toloza, Eric M.; Fontaine, Jacques P.] H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, 12902 USF Magnolia Dr, Tampa, FL 33612 USA. [Baldonado, Jobelle J. A. R.; Naffouje, Samer A.; Fontaine, Jacques P.] H Lee Moffitt Canc Ctr & Res Inst, Dept Gastrointestinal Oncol, Tampa, FL 33612 USA. [Baldonado, Jobelle J. A. R.; Toloza, Eric M.; Fontaine, Jacques P.] Univ South Florida Hlth, Morsani Coll Med, Dept Surg, Tampa, FL 33620 USA. [Baldonado, Jobelle J. A. R.; Toloza, Eric M.; Fontaine, Jacques P.] Univ South Florida Hlth, Morsani Coll Med, Dept Oncol Sci, Tampa, FL 33620 USA. [Parvathaneni, Sirish] Presbyterian Healthcare Serv, Albuquerque, NM USA. [Roy, Esha] Santa Barbara Cottage Hosp, Dept Surg, Santa Barbara, CA USA. C3 State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Santa Barbara Cottage Hospital RP Baldonado, JJAR (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, 12902 USF Magnolia Dr, Tampa, FL 33612 USA.; Baldonado, JJAR (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Gastrointestinal Oncol, Tampa, FL 33612 USA.; Baldonado, JJAR (corresponding author), Univ South Florida Hlth, Morsani Coll Med, Dept Surg, Tampa, FL 33620 USA.; Baldonado, JJAR (corresponding author), Univ South Florida Hlth, Morsani Coll Med, Dept Oncol Sci, Tampa, FL 33620 USA. EM Jobelle.baldonado@moffitt.org FU Moffitt Cancer Center's Office of Scientific Publishing by Daley Drucker and Gerard Hebert FX Editorial assistance was provided by the Moffitt Cancer Center's Office of Scientific Publishing by Daley Drucker and Gerard Hebert; no compensation was given beyond their regular salaries. Funding: None. CR Boffa DJ, 2012, ANN THORAC SURG, V94, P347, DOI 10.1016/j.athoracsur.2012.04.059 Bott MJ, 2015, ANN THORAC SURG, V100, P2048, DOI 10.1016/j.athoracsur.2015.05.100 Cerfolio RJ, 2018, J THORAC CARDIOV SUR, V155, P778, DOI 10.1016/j.jtcvs.2017.09.016 Cerfolio RJ, 2011, J THORAC CARDIOV SUR, V142, P740, DOI 10.1016/j.jtcvs.2011.07.022 Feczko AF, 2019, ANN THORAC SURG, V108, P1013, DOI 10.1016/j.athoracsur.2019.04.046 Haruki T, 2021, INTERACT CARDIOV TH, V33, P409, DOI 10.1093/icvts/ivab112 Hendriksen BS, 2019, INNOVATIONS, V14, P342, DOI 10.1177/1556984519849037 Kneuertz PJ, 2020, CLIN LUNG CANCER, P2 Krist AH, 2021, JAMA-J AM MED ASSOC, V325, P962, DOI 10.1001/jama.2021.1117 Lim E, 2022, NEJM EVID, V1, DOI [10.1056/evidoa2100016, 10.1056/EVIDoa2100016] Medbery RL, 2016, J THORAC ONCOL, V11, P222, DOI 10.1016/j.jtho.2015.10.007 Merritt RE, 2019, J CARDIOTHORAC SURG, V14, DOI 10.1186/s13019-019-0937-4 Park BJ, 2012, J THORAC CARDIOV SUR, V143, P383, DOI 10.1016/j.jtcvs.2011.10.055 Park JS, 2011, WORLD J SURG, V35, P590, DOI 10.1007/s00268-010-0913-6 Rajaram R, 2017, ANN THORAC SURG, V103, P1092, DOI 10.1016/j.athoracsur.2016.09.108 Roberts AW., 2018, Am Community Surv Reports Samson P, 2013, J THORAC CARDIOV SUR, V145, P1512, DOI 10.1016/j.jtcvs.2012.05.028 Servais EL, 2022, ANN THORAC SURG, V114, P409, DOI 10.1016/j.athoracsur.2021.10.067 Shindo Y, 2023, SURG TODAY, V53, P428, DOI 10.1007/s00595-022-02578-5 Takase Y, 2022, J THORAC DIS, DOI 10.21037/jtd-22-553 Yang HX, 2017, ANN SURG, V265, P431, DOI 10.1097/SLA.0000000000001708 Zirafa C, 2019, SURG ENDOSC, V33, P153, DOI 10.1007/s00464-018-6288-8 NR 22 TC 3 Z9 3 U1 0 U2 2 PU AME PUBLISHING COMPANY PI SHATIN PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA SN 2072-1439 EI 2077-6624 J9 J THORAC DIS JI J. Thorac. Dis. PD OCT PY 2023 VL 15 IS 10 BP 5349 EP + DI 10.21037/jtd-22-1340 EA SEP 2023 PG 17 WC Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System GA CN2O0 UT WOS:001081115700001 PM 37969299 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Fu, Y Gao, JM Zhang, ZY Zhang, N Yu, J Chen, C Wen, ZM AF Fu, Yu Gao, Jiameng Zhang, Zhiyuan Zhang, Nan Yu, Jing Chen, Chang Wen, Zongmei TI Effects of preoperative mildly elevated pulmonary artery systolic pressure on the incidence of perioperative adverse events undergoing thoracoscopic lobectomy: an observational cohort study protocol SO BMJ OPEN LA English DT Article DE echocardiography; thoracic surgery; adult thoracic medicine; adult anaesthesia ID CELL LUNG-CANCER; INTRAOPERATIVE HYPOTENSION; MYOCARDIAL INJURY; MANAGEMENT; HYPERTENSION; DEFINITIONS; ASSOCIATION; GUIDELINES; SURGERY; CARE AB IntroductionEchocardiography provides a non-invasive estimation of pulmonary artery systolic pressure (PASP) and is the first diagnostic test for pulmonary hypertension. Recent studies have demonstrated that PASP of more than 30 mm Hg related to increased mortality and morbidity. However, perioperative risks and management for patients with mildly elevated PASP are not well established. This study aims to explore the association between mildly elevated PASP and perioperative adverse outcomes.Methods and analysisThis will be a retrospective cohort study conducted at Shanghai Pulmonary Hospital in Shanghai, China. Eligible patients are adults (>= 18 years) who performed preoperative echocardiography and followed thoracoscopic lobectomy. Our primary objective is to determine the effect of preoperative mildly elevated PASP on the incidence of hypotension during surgery. Whether mildly elevated PASP is related to other perioperative adverse events (including hypoxaemia, myocardial injury, new-onset atrial fibrillation, postoperative pulmonary complications, 30-day readmission and 30-day mortality) will be also analysed. An estimated 2300 patients will be included.Ethics and disseminationThe study has been approved by the institutional review board of Shanghai Pulmonary Hospital (approval No: 2022LY1143). The research findings intend to be published in peer-reviewed scientific publications.Trial registration numberChinese Clinical Trial Registry (ChiCTR2200066679). C1 [Fu, Yu; Gao, Jiameng; Zhang, Zhiyuan; Zhang, Nan; Yu, Jing; Wen, Zongmei] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Anesthesiol, Shanghai, Peoples R China. [Chen, Chang] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Thorac Surg, Shanghai, Peoples R China. C3 Tongji University; Tongji University RP Wen, ZM (corresponding author), Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Anesthesiol, Shanghai, Peoples R China. EM wzm1103@126.com RI ; Wen, Zongmei/LBH-7022-2024 OI Zhang, Zhiyuan/0000-0001-7362-3362; Fu, Yu/0000-0003-0881-7165 FU National Natural Science Foundation of China [82170107]; Shanghai Municipal Health Commission [202140406]; Excellent Subject Leader Program of Shanghai Municipal Health Commission [2022XD007]; Foundation of the Science and Technology Commission of Shanghai Municipality [19ZR1443000, 23ZR1453300] FX Funding was received from the following: National Natural Science Foundation of China (82170107), Shanghai Municipal Health Commission (202140406), Excellent Subject Leader Program of Shanghai Municipal Health Commission (2022XD007), and Foundation of the Science and Technology Commission of Shanghai Municipality (19ZR1443000, 23ZR1453300) CR Abbott TEF, 2018, ANESTH ANALG, V126, P1936, DOI 10.1213/ANE.0000000000002560 Bédat B, 2019, J CARDIOTHORAC SURG, V14, DOI 10.1186/s13019-019-1021-9 Bijker JB, 2007, ANESTHESIOLOGY, V107, P213, DOI 10.1097/01.anes.0000270724.40897.8e Brunelli A, 2008, EUR J CARDIO-THORAC, V33, P77, DOI 10.1016/j.ejcts.2007.09.028 D'Andrea A, 2013, INT J CARDIOL, V164, P48, DOI 10.1016/j.ijcard.2011.06.058 Deljou A, 2020, J CARDIOTHOR VASC AN, V34, P1506, DOI 10.1053/j.jvca.2019.10.059 Dell'Amore A, 2022, EUR J CARDIO-THORAC, V61, P533, DOI 10.1093/ejcts/ezab430 Devereaux PJ, 2017, JAMA-J AM MED ASSOC, V317, P1642, DOI 10.1001/jama.2017.4360 Elrakhawy HM, 2018, HEART SURG FORUM, V21, pE9, DOI 10.1532/hsf.1864 Ettinger DS, 2022, J NATL COMPR CANC NE, V20, P497, DOI 10.6004/jnccn.2022.0025 Ferrara F, 2016, INT J CARDIOL, V223, P736, DOI 10.1016/j.ijcard.2016.08.275 Frendl G, 2014, J THORAC CARDIOV SUR, V148, pE153, DOI 10.1016/j.jtcvs.2014.06.036 Galiè N, 2016, EUR HEART J, V37, P67, DOI 10.1093/eurheartj/ehv317 Galiè N, 2015, EUR RESPIR J, V46, P903, DOI 10.1183/13993003.01032-2015 Gregory A, 2021, ANESTH ANALG, V132, P1654, DOI 10.1213/ANE.0000000000005250 Howington JA, 2013, CHEST, V143, pE278, DOI 10.1378/chest.12-2359 Jammer I, 2015, EUR J ANAESTH, V32, P88, DOI 10.1097/EJA.0000000000000118 Jankowich M, 2021, LANCET RESP MED, V9, P1185, DOI 10.1016/S2213-2600(21)00072-2 Johnston BW, 2022, BRIT J ANAESTH, V128, P759, DOI 10.1016/j.bja.2021.11.016 Kehl KL, 2022, JAMA ONCOL, V8, P717, DOI 10.1001/jamaoncol.2022.0039 Kolte D, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.009729 McCall PJ, 2015, ANAESTHESIA, V70, P1382, DOI 10.1111/anae.13267 McCall PJ, 2019, J THORAC CARDIOV SUR, V158, P556, DOI 10.1016/j.jtcvs.2019.01.067 Minai OA, 2013, CHEST, V144, P329, DOI 10.1378/chest.12-1752 Pilkington SA, 2015, ANAESTHESIA, V70, P56, DOI 10.1111/anae.12831 Postmus PE, 2017, ANN ONCOL, V28, P1, DOI 10.1093/annonc/mdx222 Price LC, 2021, BRIT J ANAESTH, V126, P774, DOI 10.1016/j.bja.2021.01.005 Salmasi V, 2017, ANESTHESIOLOGY, V126, P47, DOI 10.1097/ALN.0000000000001432 Sessler DI, 2019, BRIT J ANAESTH, V122, P563, DOI 10.1016/j.bja.2019.01.013 Shelley B, 2023, BRIT J ANAESTH, V130, pE66, DOI 10.1016/j.bja.2022.06.035 Smilowitz NR, 2019, AM J CARDIOL, V123, P1532, DOI 10.1016/j.amjcard.2019.02.006 Soria R, 2016, J APPL PHYSIOL, V121, P1151, DOI 10.1152/japplphysiol.00394.2016 Stapelfeldt WH, 2021, J CLIN ANESTH, V75, DOI 10.1016/j.jclinane.2021.110516 Stapelfeldt WH, 2017, ANESTH ANALG, V124, P1135, DOI 10.1213/ANE.0000000000001797 Strange G, 2019, J AM COLL CARDIOL, V73, P2660, DOI 10.1016/j.jacc.2019.03.482 Strange G, 2012, HEART, V98, P1805, DOI 10.1136/heartjnl-2012-301992 Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660 Tsujimoto Y, 2022, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012809.pub2 Zheng RS, 2022, J NATL CANCER CTR, V2, P1, DOI 10.1016/j.jncc.2022.02.002 NR 39 TC 2 Z9 2 U1 0 U2 3 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-6055 J9 BMJ OPEN JI BMJ Open PD SEP PY 2023 VL 13 IS 9 AR e072084 DI 10.1136/bmjopen-2023-072084 PG 5 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA T4BO7 UT WOS:001077459700004 PM 37748854 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Cheng, C Wang, SW Dong, JJ Zhang, SL Yu, DL Wang, ZB AF Cheng, Can Wang, Shuwei Dong, Jianjun Zhang, Shengli Yu, Dongliang Wang, Zuobin TI Effects of targeted lung cancer drugs on cardiomyocytes studied by atomic force microscopy SO ANALYTICAL METHODS LA English DT Article ID EGFR-MUTATED NSCLC; CARDIAC TOXICITY; CULTURE AB The epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) has become one of the important targeted drugs for the treatment of non-small cell lung cancer (NSCLC). But the cardiac adverse events (AEs) related to the EGFR-TKI treatment occur frequently. And the cases of TKI-associated cardiac AEs remain poorly understood. In order to study the effects of EGFR-TKIs on cardiomyocytes, atomic force microscopy (AFM) was used to measure and analyze the physical properties of cardiomyocytes under the actions of three drugs (gefitinib, afatinib and osimertinib) with different concentrations. By comparing the height, adhesion, Young's modulus, the amplitude and the time of the contraction and relaxation process, it was found that the changes of the mechanical properties of cells were well correlated with the symptoms of AEs, such as cardiomyocyte hypertrophy, QT prolongation, atrial fibrillation, ejection fraction reductions, and cardiac failure. In addition, osimertinib has the most obvious effect on cardiomyocytes at a low concentration, and gefitinib has the greatest effect with the increase of concentration, while afatinib has the least effect on cardiomyocytes. This provides a new method for screening drugs and exploring the principle of action in the process of cancer treatment at the cellular level. C1 [Cheng, Can; Dong, Jianjun; Zhang, Shengli; Yu, Dongliang; Wang, Zuobin] Changchun Univ Sci & Technol, Int Res Ctr Nano Handling & Mfg China, Changchun 130022, Peoples R China. [Cheng, Can; Dong, Jianjun; Zhang, Shengli; Yu, Dongliang; Wang, Zuobin] Changchun Univ Sci & Technol, Ctr Opto Bionano Measurement & Mfg, Zhongshan Inst, Zhongshan 528437, Peoples R China. [Cheng, Can; Dong, Jianjun; Zhang, Shengli; Wang, Zuobin] Changchun Univ Sci & Technol, Minist Educ, Key Lab Cross Scale Micro & Nano Mfg, Changchun 130022, Peoples R China. [Wang, Zuobin] Univ Bedfordshire, JR3CN, Luton LU1 3JU, Beds, England. [Wang, Zuobin] Univ Bedfordshire, IRAC, Luton LU1 3JU, Beds, England. [Wang, Shuwei] Jilin Med Univ, Affiliated Hosp, Jilin, Jilin, Peoples R China. C3 Changchun University of Science & Technology; Changchun University of Science & Technology; Changchun University of Science & Technology; University of Bedfordshire; University of Bedfordshire; Jilin Medical University RP Wang, ZB (corresponding author), Changchun Univ Sci & Technol, Int Res Ctr Nano Handling & Mfg China, Changchun 130022, Peoples R China.; Wang, ZB (corresponding author), Changchun Univ Sci & Technol, Ctr Opto Bionano Measurement & Mfg, Zhongshan Inst, Zhongshan 528437, Peoples R China.; Wang, ZB (corresponding author), Changchun Univ Sci & Technol, Minist Educ, Key Lab Cross Scale Micro & Nano Mfg, Changchun 130022, Peoples R China.; Wang, ZB (corresponding author), Univ Bedfordshire, JR3CN, Luton LU1 3JU, Beds, England.; Wang, ZB (corresponding author), Univ Bedfordshire, IRAC, Luton LU1 3JU, Beds, England. EM wangz@cust.edu.cn RI Wang, Ying/KMY-1020-2024 FU National Natural Science Foundation Program of China [62175020]; Jilin Provincial Science and Technology Program [20220201098GX, 20210101038JC, 20190702002GH]; Zhongshan Science and Technology Program [2022B2008]; EU Horizon Europe Program (ENSIGN) [101086226]; "111" Project of China [D17017] FX This work was supported by the National Natural Science Foundation Program of China (No. 62175020), Jilin Provincial Science and Technology Program (No. 20220201098GX, 20210101038JC and 20190702002GH), Zhongshan Science and Technology Program (No. 2022B2008), EU Horizon Europe Program (ENSIGN No. 101086226), and "111" Project of China (No. D17017). The authors thank the Laboratory Animal Center of Jilin University for its help in animal experiments. CR Alhoshani A, 2020, CHEM RES TOXICOL, V33, P1719, DOI 10.1021/acs.chemrestox.0c00005 Altschuler SJ, 2010, CELL, V141, P559, DOI 10.1016/j.cell.2010.04.033 Anand K, 2019, JACC-CARDIOONCOL, V1, P172, DOI 10.1016/j.jaccao.2019.10.006 Bardaro F, 2022, J ONCOL PHARM PRACT, V28, P989, DOI 10.1177/10781552211073823 Benech JC, 2014, AM J PHYSIOL-CELL PH, V307, pC910, DOI 10.1152/ajpcell.00192.2013 BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930 Cai BZ, 2014, J MOL CELL CARDIOL, V74, P297, DOI 10.1016/j.yjmcc.2014.06.006 Chhikara B.S., 2023, Chemical Biology Letters, V2023, P451 Costa KD, 2003, TISSUE ENG, V9, P567, DOI 10.1089/107632703768247278 Demircan D. C., 2020, CURR PROB CANCER, V44 DERJAGUIN BV, 1975, J COLLOID INTERF SCI, V53, P314, DOI 10.1016/0021-9797(75)90018-1 Ehler Elisabeth, 2013, J Vis Exp, DOI 10.3791/50154 Evans-Anderson HJ, 2008, CIRC RES, V102, P686, DOI 10.1161/CIRCRESAHA.107.163428 Ewer Michael S, 2015, Cardiooncology, V1, P3, DOI [10.1186/s40959-015-0006-7, 10.1186/s40959-015-0006-7] Ferlay J, 2021, INT J CANCER, V149, P778, DOI 10.1002/ijc.33588 Gong ZY, 2021, INT J ROBOT RES, V40, P449, DOI 10.1177/0278364920917203 Guo YJ, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.610923 Hannula PM, 2017, ELECTROCHIM ACTA, V232, P495, DOI 10.1016/j.electacta.2017.03.006 Heidemann SR, 1999, J CELL BIOL, V145, P109, DOI 10.1083/jcb.145.1.109 Hertz HJ., 1882, ANGEW MATH, V92, P156, DOI [10.1515/crll.1882.92.156, DOI 10.1515/CRLL.1882.92.156] Ikebe S, 2021, INT CANCER CONF J, V10, P68, DOI 10.1007/s13691-020-00450-2 Korashy HM, 2016, TOXICOL LETT, V252, P50, DOI 10.1016/j.toxlet.2016.04.011 Kunimasa K, 2020, JACC-CARDIOONCOL, V2, P1, DOI 10.1016/j.jaccao.2020.02.003 Li A, 2020, J CANCER RES CLIN, V146, P1737, DOI 10.1007/s00432-020-03228-4 Lin YX, 2014, AM J CANCER RES, V4, P411 Liu JW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037559 Lynch DR, 2011, J THROMB THROMBOLYS, V32, P120, DOI 10.1007/s11239-010-0539-4 Melosky B, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00244 Miller BS, 2020, NATURE, V587, P588, DOI 10.1038/s41586-020-2917-1 Negro A, 2004, RECENT PROG HORM RES, V59, P1, DOI 10.1210/rp.59.1.1 Niederer SA, 2019, J MOL CELL CARDIOL, V127, P11, DOI 10.1016/j.yjmcc.2018.11.015 Nuvola G, 2019, J THORAC ONCOL, V14, pE145, DOI 10.1016/j.jtho.2019.02.027 Pena B, 2022, LANGMUIR, DOI 10.1021/acs.langmuir.2c02623 Perez EA, 2008, CLIN BREAST CANCER, V8, pS114, DOI 10.3816/CBC.2008.s.007 Piper-Vallillo A. J., 2020, CARDIO-ONCOLOGY, V2, P119 Pribyl J, 2019, METHODS MOL BIOL, V1886, P343, DOI 10.1007/978-1-4939-8894-5_20 Rebuzzi SE, 2020, CRIT REV ONCOL HEMAT, V146, DOI 10.1016/j.critrevonc.2019.102820 Sanchez-Soria P, 2010, SEMIN CELL DEV BIOL, V21, P929, DOI 10.1016/j.semcdb.2010.09.011 Sneddon I.N., 1965, International Journal of Engineering Science, V3, P47, DOI [10.1016/00207225(65)90019-4, DOI 10.1016/00207225(65)90019-4, DOI 10.1016/0020-7225(65)90019-4] Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137 Sreejit P, 2008, IN VITRO CELL DEV-AN, V44, P45, DOI 10.1007/s11626-007-9079-4 Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660 Takeuchi K., 2012, J CANC THER, V3, P424, DOI DOI 10.4236/JCT.2012.324055 Thein K. Z., 2018, ANN ONCOL, V29 Touhami A, 2003, LANGMUIR, V19, P4539, DOI 10.1021/la034136x Xin Z., 2016, BIOCHIM BIOPHYS ACTA, V1863, P486 Xu JW, 2017, SENSOR ACTUAT B-CHEM, V244, P38, DOI 10.1016/j.snb.2016.12.088 NR 47 TC 7 Z9 8 U1 0 U2 19 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1759-9660 EI 1759-9679 J9 ANAL METHODS-UK JI Anal. Methods PD AUG 24 PY 2023 VL 15 IS 33 BP 4077 EP 4084 DI 10.1039/d3ay00784g EA AUG 2023 PG 8 WC Chemistry, Analytical; Food Science & Technology; Spectroscopy WE Science Citation Index Expanded (SCI-EXPANDED) SC Chemistry; Food Science & Technology; Spectroscopy GA X8J5F UT WOS:001045798900001 PM 37565311 DA 2026-04-17 ER PT J AU Khambaty, M Devalapalli, AP Silbert, RE Kashiwagi, DT Regan, DW Sundsted, KK Mauck, KF AF Khambaty, Maleka Devalapalli, Aditya P. Silbert, Richard E. Kashiwagi, Deanne T. Regan, Dennis W. Sundsted, Karna K. Mauck, Karen F. TI Practice Changing Updates in Perioperative Medicine Literature 2022. A Systematic Review SO AMERICAN JOURNAL OF MEDICINE LA English DT Review DE Perioperative analgesia; Perioperative atrial fibrillation; Perioperative pulmonary complications; Peri-operative stroke; Perioperative thromboembolism; Timing of elective surgery after COVID-19 infection ID POSTOPERATIVE PULMONARY COMPLICATIONS; ATRIAL-FIBRILLATION; INHALED TIOTROPIUM; CANCER PATIENTS; LUNG-CANCER; MANAGEMENT; MORTALITY; SURGERY; MULTICENTER; PREVENTION AB Perioperative medicine is a rapidly growing multidisciplinary field with significant advances published each year. In this review, we highlight important perioperative publications in 2022. A multi-database literature search from January to December of 2022 was undertaken. Original research articles, systematic reviews, meta-analyses, and guidelines were included. Abstracts, case reports, letters, protocols, pediatric and obstetric articles, and cardiac surgery literature were excluded. Two authors reviewed each reference using the Distiller SR systematic review software (Evidence Partners Inc., Ottawa, Ont, Canada). A modified Delphi technique was used to identify 8 practice-changing articles. We identified another 10 articles for tabular summaries. We highlight why these articles have the potential to change clinical perioperative practice and areas where more information is needed. (C) 2023 Elsevier Inc. All rights reserved. C1 [Khambaty, Maleka; Devalapalli, Aditya P.; Kashiwagi, Deanne T.; Regan, Dennis W.; Sundsted, Karna K.] Mayo Clin, Div Hosp Internal Med, Dept Med, Rochester, MN USA. [Silbert, Richard E.; Mauck, Karen F.] Mayo Clin, Dept Med, Div Gen Internal Med, Rochester, MN USA. [Silbert, Richard E.; Mauck, Karen F.] Mayo Clin, Coll Med, Rochester, MN USA. [Kashiwagi, Deanne T.] Mayo Clin, Dept Internal Med, Sheikh Shakhbout Med City Partnership, Abu Dhabi, U Arab Emirates. [Khambaty, Maleka] Mayo Clin, Div Hosp Internal Med, Dept Med, 200 1st St SW, Rochester, MN 55905 USA. C3 Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic RP Khambaty, M (corresponding author), Mayo Clin, Div Hosp Internal Med, Dept Med, Rochester, MN USA.; Khambaty, M (corresponding author), Mayo Clin, Div Hosp Internal Med, Dept Med, 200 1st St SW, Rochester, MN 55905 USA. EM Khambaty.maleka@mayo.edu RI Mauck, Karen/A-6998-2009 FU Divisions of General Internal Medicine and Hospital Internal Medicine, Mayo Clinic, Rochester, Minnesota FX Funds for Distiller SR systematic review software (Evidence Partners Inc., Ottawa, Ont, Canada) were provided through internal funding from the Divisions of General Internal Medicine and Hospital Internal Medicine, Mayo Clinic, Rochester, Minnesota. CR Abrard S, 2023, BRIT J ANAESTH, V130, pE160, DOI 10.1016/j.bja.2021.11.033 American Society of Anesthesiologists; Anesthesia Patient Safety Foundation, 2021, ASA SPEC PUBL [Anonymous], 2022, J BONE JOINT SURG AM, V104, P180, DOI 10.2106/JBJS.21.01529 Badiola I, 2022, REGION ANESTH PAIN M, V47, P437, DOI 10.1136/rapm-2021-103109 Bartels K, 2022, BMC ANESTHESIOL, V22, DOI 10.1186/s12871-022-01679-5 Benesch C, 2021, CIRCULATION, V143, pE923, DOI 10.1161/CIR.0000000000000968 Beverly Anair, 2017, Anesthesiol Clin, V35, pe115, DOI [10.1016/j.anclin.2017.01.018, 10.1016/j.anclin.2017.01.018] Boyer N, 2022, CLIN J AM SOC NEPHRO, V17, P1535, DOI 10.2215/CJN.16541221 Bykov K, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.31647 Chen J, 2022, CLIN REHABIL, V36, P1229, DOI 10.1177/02692155221097762 Douketis JD, 2022, CHEST, V162, pE207, DOI 10.1016/j.chest.2022.07.025 Douketis JD, 2022, CHEST, V162, P1127, DOI 10.1016/j.chest.2022.08.004 El-Boghdadly K, 2022, ANAESTHESIA, V77, P580, DOI 10.1111/anae.15699 Fabritius ML, 2016, ACTA ANAESTH SCAND, V60, P1188, DOI 10.1111/aas.12766 Fernandez-Bustamante A, 2017, JAMA SURG, V152, P157, DOI 10.1001/jamasurg.2016.4065 Fielding-Singh V, 2022, JAMA-J AM MED ASSOC, V328, P1837, DOI 10.1001/jama.2022.19626 Flemons K, 2022, PERIOPER MED-LONDON, V11, DOI 10.1186/s13741-021-00236-x Fushida S, 2015, INT J CHRONIC OBSTR, V10, P2177, DOI 10.2147/COPD.S89098 Geerds MAJ, 2022, INJURY, V53, P2818, DOI 10.1016/j.injury.2022.06.017 Gilbert-Kawai N, 2022, BJA EDUC, V22, P111, DOI 10.1016/j.bjae.2021.11.006 Glance LG, 2022, JAMA SURG, V157, DOI 10.1001/jamasurg.2022.2236 Goodman SM, 2022, ARTHRITIS RHEUMATOL, V74, P1464, DOI 10.1002/art.42140 Guay J, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010108.pub2 Jorgensen ME, 2014, JAMA-J AM MED ASSOC, V312, P269, DOI 10.1001/jama.2014.8165 Kobayashi S, 2009, RESPIROLOGY, V14, P675, DOI 10.1111/j.1440-1843.2009.01543.x Kougias P, 2022, ANN SURG, V276, P554, DOI 10.1097/SLA.0000000000005552 Lee BH, 2022, ANESTH ANALG, DOI [10.1213/ANE.0000000000006070, DOI 10.1213/ANE.0000000000006070] Lockstone J, 2022, CRIT CARE MED, V50, P1522, DOI 10.1097/CCM.0000000000005628 Oprea AD, 2022, MAYO CLIN PROC, V97, P375, DOI 10.1016/j.mayocp.2021.11.010 Oprea AD, 2022, MAYO CLIN PROC, V97, P397, DOI 10.1016/j.mayocp.2021.11.011 Park CM, 2022, JAMA INTERN MED, V182, P1117, DOI 10.1001/jamainternmed.2022.3680 Pöpping DM, 2008, ARCH SURG-CHICAGO, V143, P990, DOI 10.1001/archsurg.143.10.990 Prasada S, 2022, J AM COLL CARDIOL, V79, P2471, DOI 10.1016/j.jacc.2022.04.021 Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493 Rosén J, 2022, HEALTH SCI REP-US, V5, DOI 10.1002/hsr2.616 Russell LA, 2022, MAYO CLIN PROC, V97, P1551, DOI 10.1016/j.mayocp.2022.05.002 Sahai SK, 2022, MAYO CLIN PROC, V97, P1734, DOI 10.1016/j.mayocp.2022.03.039 Sidhu VS, 2022, JAMA-J AM MED ASSOC, V328, P719, DOI 10.1001/jama.2022.13416 Stronati G, 2022, AM J CARDIOL, V170, P56, DOI 10.1016/j.amjcard.2022.01.020 Ueda K, 2010, THORAC CARDIOV SURG, V58, P38, DOI 10.1055/s-0029-1186269 Verret M, 2020, ANESTHESIOLOGY, V133, P265, DOI 10.1097/ALN.0000000000003428 Yan T, 2022, ANESTHESIOLOGY, V136, P551, DOI 10.1097/ALN.0000000000004159 Zhou R, 2022, CAN RESPIR J, V2022, DOI 10.1155/2022/4415313 NR 43 TC 1 Z9 1 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA SN 0002-9343 EI 1555-7162 J9 AM J MED JI Am. J. Med. PD AUG PY 2023 VL 136 IS 8 BP 753 EP + DI 10.1016/j.amjmed.2023.04.021 EA JUL 2023 PG 11 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA P4YU3 UT WOS:001050743100001 PM 37148994 DA 2026-04-17 ER PT J AU Fang, SF Wang, T Weng, L Han, XM Zheng, RS Zhang, HY AF Fang, Sufang Wang, Ting Weng, Ling Han, Ximei Zheng, Rongshan Zhang, Hongying TI Lung cancer-derived exosomal miR-132-3p contributed to interstitial lung disease development SO WORLD JOURNAL OF SURGICAL ONCOLOGY LA English DT Article DE Interstitial lung diseases; miR-132-3p; Exosome; NHLF; SPRY1 ID ATRIAL-FIBRILLATION; LIVER FIBROSIS; TARGETS AB Purpose Interstitial lung diseases (ILDs) have high morbidity and mortality and poor prognosis. The significance of microRNAs (miRNAs) was highlighted in ILDs development. Currently, we attempted to confirm the functions of lung cancer-derived exosomal miR-132-3p and reveal the underlying mechanism. Method Characteristics of exosomes were verified by transmission electron microscope (TEM), nanoparticle tracking analysis, and Western blot assay. Exosome uptake for the normal human lung fibroblasts (NHLF) was assessed using a PKH67 staining assay. MTT and colony formation assays were applied to examine the proliferation abilities of NHLF. The interaction between miR-132-3p and sprouty1 (SPRY1) was confirmed by a luciferase reporter assay. Results Lung cancer-derived exosomes promoted normal human lung fibroblast activation. Exosome inhibitor GW4869 reversed the effects of Exo on NHLF. Subsequently, miR-132-3p in lung cancer-derived exosomes activated the normal human lung fibroblast and promoted interstitial lung disease development ex vivo. Next, SPRY1 was verified to be the binding protein of miR-132-3p, and sh-SPRY1 abrogated the effects of the miR-132-3p inhibitor on NHLF. Conclusion Exosomal miR-132-3p from A549 cells accelerated the development of interstitial lung disease through binding to SPRY1, which might serve as an important target for ILDs. C1 [Fang, Sufang; Wang, Ting; Weng, Ling; Han, Ximei; Zheng, Rongshan; Zhang, Hongying] Teaching Hosp Fujian Med Univ, Fuzhou Pulm Hosp Fujian Prov, Resp Dept, Fuzhou 350008, Peoples R China. RP Zhang, HY (corresponding author), Teaching Hosp Fujian Med Univ, Fuzhou Pulm Hosp Fujian Prov, Resp Dept, Fuzhou 350008, Peoples R China. EM doctor6507@163.com RI Wang, Ting/D-2900-2014 CR Bijkerk R, 2016, KIDNEY INT, V89, P1268, DOI 10.1016/j.kint.2016.01.029 Cai Y, 2018, BBA-MOL CELL RES, V1865, P297, DOI 10.1016/j.bbamcr.2017.10.011 Ding JQ, 2019, EUR J PHARMACOL, V859, DOI 10.1016/j.ejphar.2019.172549 Dinh PUC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14344-7 Eskildsen TV, 2015, J RENIN-ANGIO-ALDO S, V16, P1288, DOI 10.1177/1470320314539367 Farahzadi R, 2023, TRANSPL IMMUNOL, V77, DOI 10.1016/j.trim.2023.101797 Fathi E, 2022, IRAN J BASIC MED SCI, V25, P1222, DOI 10.22038/IJBMS.2022.66737.14633 Gao M, 2021, CLIN SCI, V135, P347, DOI 10.1042/CS20200573 Guiot J, 2020, THORAX, V75, P870, DOI 10.1136/thoraxjnl-2019-214077 Ibrahim A, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11010087 Ji XM, 2015, SCI REP-UK, V5, DOI 10.1038/srep14131 Jiang Z, 2017, SCAND J RHEUMATOL, V46, P122, DOI 10.3109/03009742.2016.1167950 Jin XC, 2017, CLIN CANCER RES, V23, P5311, DOI 10.1158/1078-0432.CCR-17-0577 Ko WC, 2011, CIRC J, V75, P1592, DOI 10.1253/circj.CJ-10-0892 Lacedonia D, 2021, BMC PULM MED, V21, DOI 10.1186/s12890-021-01550-2 Li YQ, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075-020-02411-9 Montesi SB, 2020, AM J RESP CRIT CARE, V202, P500, DOI 10.1164/rccm.202002-0360UP Ning ZW, 2017, ANTIOXID REDOX SIGN, V27, P1, DOI 10.1089/ars.2016.6669 Ortiz-Quintero B, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061556 Pellegrini KL, 2016, TOXICOL APPL PHARM, V312, P42, DOI 10.1016/j.taap.2015.12.002 Qiao G, 2018, PATHOL RES PRACT, V214, P308, DOI 10.1016/j.prp.2017.04.021 Qiao G, 2017, MOL MED REP, V16, P4143, DOI 10.3892/mmr.2017.7045 Ren JL, 2021, INT IMMUNOPHARMACOL, V91, DOI 10.1016/j.intimp.2020.107288 Shetty SK, 2017, AM J PATHOL, V187, P1016, DOI 10.1016/j.ajpath.2016.12.020 Shi ST, 2020, AM J PHYSIOL-CELL PH, V319, pC895, DOI 10.1152/ajpcell.00479.2019 Song YJ, 2019, J CELL BIOCHEM, V120, P9147, DOI 10.1002/jcb.28190 Sugiyama Y, 2020, MOD RHEUMATOL, V30, P878, DOI 10.1080/14397595.2019.1661584 Sun XY, 2021, KOREAN J INTERN MED, V36, pS160, DOI 10.3904/kjim.2019.098 Thum T, 2008, NATURE, V456, P980, DOI 10.1038/nature07511 Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043 Wang G, 2020, BIOSCIENCE REP, V40, P1 Wong AW, 2020, RESP RES, V21, DOI 10.1186/s12931-020-1296-3 Yao WX, 2018, TOXICOL SCI, V166, P465, DOI 10.1093/toxsci/kfy221 Zhang SG, 2020, J CELL MOL MED, V24, P1658, DOI 10.1111/jcmm.14858 NR 34 TC 5 Z9 7 U1 0 U2 7 PU BMC PI LONDON PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND EI 1477-7819 J9 WORLD J SURG ONCOL JI World J. Surg. Oncol. PD JUL 15 PY 2023 VL 21 IS 1 AR 205 DI 10.1186/s12957-023-03095-6 PG 11 WC Oncology; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Surgery GA L8SM9 UT WOS:001025908200001 PM 37454094 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Chen, JD Cao, SH Jin, Y Rong, WW Wang, H Xi, SQ Gan, T He, B Zhong, H Zhao, L AF Chen, Jindong Cao, Shuhui Jin, Yu Rong, Wenwen Wang, Hao Xi, Siqi Gan, Tian He, Ben Zhong, Hua Zhao, Liang TI Construction and validation of a nomogram of risk factors for new-onset atrial fibrillation in advanced lung cancer patients after non-surgical therapy SO FRONTIERS IN ONCOLOGY LA English DT Article DE risk factor; new-onset atrial fibrillation; advanced lung cancer; pericardial effusion; centric pulmonary carcinoma ID ORAL ANTICOAGULANTS; THROMBOEMBOLISM; INSIGHTS; OUTCOMES; BLOOD AB ObjectiveRisk factors of new-onset atrial fibrillation (NOAF) in advanced lung cancer patients are not well defined. We aim to construct and validate a nomogram model between NOAF and advanced lung cancer. MethodsWe retrospectively enrolled 19484 patients with Stage III-IV lung cancer undergoing first-line antitumor therapy in Shanghai Chest Hospital between January 2016 and December 2020 (15837 in training set, and 3647 in testing set). Patients with pre-existing AF, valvular heart disease, cardiomyopathy were excluded. Logistic regression analysis and propensity score matching (PSM) were performed to identify predictors of NOAF, and nomogram model was constructed and validated. ResultsA total of 1089 patients were included in this study (807 in the training set, and 282 in the testing set). Multivariate logistic regression analysis showed that age, c-reactive protein, centric pulmonary carcinoma, and pericardial effusion were independent risk factors, the last two of which were important independent risk factors as confirmed by PSM analysis. Nomogram included independent risk factors of age, c-reactive protein, centric pulmonary carcinoma, and pericardial effusion. The AUC was 0.716 (95% CI 0.661-0.770) and further evaluation of this model showed that the C-index was 0.716, while the bias-corrected C-index after internal validation was 0.748 in the training set. The calibration curves presented good concordance between the predicted and actual outcomes. ConclusionCentric pulmonary carcinoma and pericardial effusion were important independent risk factors for NOAF besides common ones in advanced lung cancer patients. Furthermore, the new nomogram model contributed to the prediction of NOAF. C1 [Chen, Jindong; Wang, Hao; Xi, Siqi; Gan, Tian; He, Ben; Zhao, Liang] Shanghai Jiao Tong Univ, Sch Med, Shanghai Chest Hosp, Dept Cardiol, Shanghai, Peoples R China. [Cao, Shuhui; Zhong, Hua] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Sch Med, Dept Pulm, Shanghai, Peoples R China. [Jin, Yu] Naval Med Univ, Affiliated Hosp 2, Dept Resp Med, Shanghai, Peoples R China. [Rong, Wenwen] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Stat Ctr, Sch Med, Shanghai, Peoples R China. C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Naval Medical University; Shanghai Jiao Tong University RP He, B; Zhao, L (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Chest Hosp, Dept Cardiol, Shanghai, Peoples R China.; Zhong, H (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Sch Med, Dept Pulm, Shanghai, Peoples R China. EM heben241@126.com; eddiedong8@hotmail.com; zhaoliang80112@126.com FU Yang Fan plan of Shanghai Science and Technology Commission Research Project [22YF1442700]; National Natural Science Foundation of China [81970276]; Translational Medicine Interdisciplinary Research Foundation of Shanghai Jiao Tong University [ZH2018QNB31] FX Funding This research was funded by a grant from Yang Fan plan of Shanghai Science and Technology Commission Research Project (No.22YF1442700); National Natural Science Foundation of China (No. 81970276); Translational Medicine Interdisciplinary Research Foundation of Shanghai Jiao Tong University (ZH2018QNB31). CR Andrade J, 2014, CIRC RES, V114, P1453, DOI 10.1161/CIRCRESAHA.114.303211 Asnani Aarti, 2017, Cardiooncology, V3, P2, DOI [10.1186/s40959-017-0021-y, 10.1186/s40959-017-0021-y] Bandyopadhyay D, 2019, IJC HEART VASC, V22, P216, DOI 10.1016/j.ijcha.2019.02.012 Barbarawi M, 2022, CURR PROB CARDIOLOGY, V47, DOI 10.1016/j.cpcardiol.2022.101346 BENJAMIN EJ, 1994, JAMA-J AM MED ASSOC, V271, P840, DOI 10.1001/jama.271.11.840 Boyle EM, 2015, INNOVATIONS, V10, P296, DOI 10.1097/IMI.0000000000000200 Chu G, 2019, BLOOD REV, V35, P59, DOI 10.1016/j.blre.2019.03.005 Conen D, 2016, JAMA CARDIOL, V1, P389, DOI 10.1001/jamacardio.2016.0280 Deitelzweig S, 2021, JACC-CARDIOONCOL, V3, P411, DOI 10.1016/j.jaccao.2021.06.004 El Haddad D, 2015, J AM COLL CARDIOL, V66, P1119, DOI 10.1016/j.jacc.2015.06.1332 Farmakis D, 2014, J AM COLL CARDIOL, V63, P945, DOI 10.1016/j.jacc.2013.11.026 Fradley MG, 2021, CIRCULATION, V144, pE41, DOI 10.1161/CIR.0000000000000986 Frost L, 2001, ARCH INTERN MED, V161, P272, DOI 10.1001/archinte.161.2.272 Gaudino M, 2022, J AM COLL CARDIOL, V79, P2529, DOI 10.1016/j.jacc.2022.04.029 Gaudino M, 2021, LANCET, V398, P2075, DOI 10.1016/S0140-6736(21)02490-9 Guha A, 2019, EUR HEART J, V40, P3007, DOI 10.1093/eurheartj/ehz649 Hindricks Gerhard, 2021, Eur Heart J, V42, P373, DOI 10.1093/eurheartj/ehaa612 Imazio M, 2020, HEART, V106, P569, DOI 10.1136/heartjnl-2019-315852 Kim SR, 2020, J AM COLL CARDIOL, V76, P1551, DOI 10.1016/j.jacc.2020.08.003 Krijthe BP, 2013, INT J CARDIOL, V168, P1453, DOI 10.1016/j.ijcard.2012.12.057 O'Neal WT, 2015, AM J CARDIOL, V115, P1090, DOI 10.1016/j.amjcard.2015.01.540 Peña JM, 2012, EUR HEART J, V33, P531, DOI 10.1093/eurheartj/ehr460 Prandoni P, 2002, BLOOD, V100, P3484, DOI 10.1182/blood-2002-01-0108 Semeraro GC, 2021, CANCERS, V13, DOI 10.3390/cancers13164012 Short NJ, 2014, ONCOLOGIST, V19, P82, DOI 10.1634/theoncologist.2013-0239 Siegel RL., 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442 St-Onge S, 2018, ANN THORAC SURG, V105, P321, DOI 10.1016/j.athoracsur.2017.07.045 Temel JS, 2022, J CLIN ONCOL, V40, P626, DOI 10.1200/JCO.21.01710 Wu BC, 2022, CANCERS, V14, DOI 10.3390/cancers14030552 Zhang MX, 2020, CARDIOL RES PRACT, V2020, DOI 10.1155/2020/2372067 NR 30 TC 2 Z9 3 U1 0 U2 2 PU FRONTIERS MEDIA SA PI LAUSANNE PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND SN 2234-943X J9 FRONT ONCOL JI Front. Oncol. PD JUL 13 PY 2023 VL 13 AR 1125592 DI 10.3389/fonc.2023.1125592 PG 10 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA N0QL4 UT WOS:001034163900001 PM 37519821 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Sunder, SS Sharma, UC Pokharel, S AF Sunder, Sunitha Shyam Sharma, Umesh C. Pokharel, Saraswati TI Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management SO SIGNAL TRANSDUCTION AND TARGETED THERAPY LA English DT Review ID CHRONIC MYELOID-LEUKEMIA; ENDOTHELIAL GROWTH-FACTOR; RENAL-CELL CARCINOMA; SUNITINIB-INDUCED CARDIOTOXICITY; PULMONARY ARTERIAL-HYPERTENSION; GASTROINTESTINAL STROMAL TUMORS; CARDIOVASCULAR TOXICITY; BREAST-CANCER; CHRONIC-PHASE; PRACTICAL MANAGEMENT AB Since their invention in the early 2000s, tyrosine kinase inhibitors (TKIs) have gained prominence as the most effective pathway-directed anti-cancer agents. TKIs have shown significant utility in the treatment of multiple hematological malignancies and solid tumors, including chronic myelogenous leukemia, non-small cell lung cancers, gastrointestinal stromal tumors, and HER2-positive breast cancers. Given their widespread applications, an increasing frequency of TKI-induced adverse effects has been reported. Although TKIs are known to affect multiple organs in the body including the lungs, liver, gastrointestinal tract, kidneys, thyroid, blood, and skin, cardiac involvement accounts for some of the most serious complications. The most frequently reported cardiovascular side effects range from hypertension, atrial fibrillation, reduced cardiac function, and heart failure to sudden death. The potential mechanisms of these side effects are unclear, leading to critical knowledge gaps in the development of effective therapy and treatment guidelines. There are limited data to infer the best clinical approaches for the early detection and therapeutic modulation of TKI-induced side effects, and universal consensus regarding various management guidelines is yet to be reached. In this state-of-the-art review, we examine multiple pre-clinical and clinical studies and curate evidence on the pathophysiology, mechanisms, and clinical management of these adverse reactions. We expect that this review will provide researchers and allied healthcare providers with the most up-to-date information on the pathophysiology, natural history, risk stratification, and management of emerging TKI-induced side effects in cancer patients. C1 [Sunder, Sunitha Shyam; Pokharel, Saraswati] Roswell Pk Comprehens Canc Ctr, Dept Pathol & Lab Med, Cardiooncol Res Grp, Buffalo, NY 14203 USA. [Sharma, Umesh C.] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Div Cardiovasc Med, Buffalo, NY USA. C3 Roswell Park Comprehensive Cancer Center; State University of New York (SUNY) System; University at Buffalo, SUNY RP Pokharel, S (corresponding author), Roswell Pk Comprehens Canc Ctr, Dept Pathol & Lab Med, Cardiooncol Res Grp, Buffalo, NY 14203 USA. EM saraswati.pokharel@roswellpark.org OI Shyam Sunder, Sunitha/0000-0002-8167-0369 FU NIH/NHLBI [R01HL152090]; National Heart Lung and Blood Institute [R01HL152090, R01HL150266] Funding Source: NIH RePORTER FX AcknowledgementsS.P. received support from NIH/NHLBI (grant no. R01HL150266). U.C.S. received support from NIH/NHLBI (grant no. R01HL152090). All figures were created from BioRender.com with permission for publication. CR Abdel-Qadir H, 2017, CANCER TREAT REV, V53, P120, DOI 10.1016/j.ctrv.2016.12.002 Abruzzese E, 2014, MEDITERR J HEMATOL I, V6, DOI 10.4084/MJHID.2014.028 Agarwal M, 2018, CURR ONCOL REP, V20, DOI 10.1007/s11912-018-0708-8 Aghel N, 2017, VASC HEALTH RISK MAN, V13, P293, DOI 10.2147/VHRM.S108874 Alexandre J, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.018403 Alivon M, 2015, J HYPERTENS, V33, P1310, DOI 10.1097/HJH.0000000000000550 Ameri P, 2018, EUR J HEART FAIL, V20, P879, DOI 10.1002/ejhf.1165 Anand K, 2019, JACC-CARDIOONCOL, V1, P172, DOI 10.1016/j.jaccao.2019.10.006 Ancker OV, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030625 Aprile L, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.1482.1482 Aslan G, 2020, ANATOL J CARDIOL, V24, P397, DOI 10.14744/AnatolJCardiol.2020.44388 Ayirookuzhi SJ, 2005, ARCH DERMATOL, V141, P368, DOI 10.1001/archderm.141.3.368 Ballardini P, 2009, CLIN DRUG INVEST, V29, P487, DOI 10.2165/00044011-200929070-00007 Bargiel W, 2021, MEDICINA-LITHUANIA, V57, DOI 10.3390/medicina57070701 Barresi V, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23168875 Bercusson A, 2018, BLOOD, V132, P1985, DOI 10.1182/blood-2017-12-823393 Bergeron A, 2007, AM J RESP CRIT CARE, V176, P814, DOI 10.1164/rccm.200705-715CR Berman E, 2006, NEW ENGL J MED, V354, P2006, DOI 10.1056/NEJMoa051140 Bernardeschi P, 2019, EUR J HAEMATOL, V103, P442, DOI 10.1111/ejh.13290 Bi J, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11020166 Bikiewicz A, 2021, ESC HEART FAIL, V8, P2397, DOI 10.1002/ehf2.13365 Billemont B, 2008, BRIT J CANCER, V99, P1380, DOI 10.1038/sj.bjc.6604709 Bojan A, 2021, DIS MARKERS, V2021, DOI 10.1155/2021/6616265 Borge M, 2015, HAEMATOLOGICA, V100, pE140, DOI 10.3324/haematol.2014.119669 Bouitbir J, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01106 Bozkurt B, 2021, CIRC-CARDIOVASC QUAL, V14, DOI 10.1161/HCQ.0000000000000102 BRISTOW MR, 1978, ANN INTERN MED, V88, P168, DOI 10.7326/0003-4819-88-2-168 Broekman F, 2011, WORLD J CLIN ONCOL, V2, P80, DOI 10.5306/wjco.v2.i2.80 Brown JR, 2019, BRIT J HAEMATOL, V184, P558, DOI 10.1111/bjh.15690 Brown JR, 2018, BLOOD, V131, P379, DOI [10.1182/blood-2017-08-764712, 10.1182/blood-2018-02-832071] Brümmendorf TH, 2015, BRIT J HAEMATOL, V168, P69, DOI 10.1111/bjh.13108 Buza V, 2017, CIRC-ARRHYTHMIA ELEC, V10, DOI 10.1161/CIRCEP.117.005443 Byrd JC, 2020, BLOOD, V135, P1204, DOI 10.1182/blood.2018884940 Cabanillas ME, 2011, J THROID RES, V2011, DOI 10.4061/2011/985780 Caldemeyer L, 2016, CURR HEMATOL MALIG R, V11, P71, DOI 10.1007/s11899-016-0309-2 Cameron D, 2017, LANCET, V389, P1195, DOI 10.1016/S0140-6736(16)32616-2 Caocci G, 2019, INT J CARDIOL, V288, P124, DOI 10.1016/j.ijcard.2019.04.051 Celutkiene J, 2020, EUR J HEART FAIL, V22, P1504, DOI 10.1002/ejhf.1957 Chae YK, 2017, ONCOTARGET, V8, P16052, DOI 10.18632/oncotarget.14109 Chai KL, 2017, LEUKEMIA LYMPHOMA, V58, P2811, DOI 10.1080/10428194.2017.1315115 Chandrasekhar S, 2019, CURR TREAT OPTION ON, V20, DOI 10.1007/s11864-019-0657-y Chang HM, 2017, J AM COLL CARDIOL, V70, P2552, DOI [10.1016/j.jacc.2017.09.1095, 10.1016/j.jacc.2017.09.1096] Chang HM, 2017, J AM COLL CARDIOL, V70, P2536, DOI 10.1016/j.jacc.2017.09.1096 Chau V, 2020, CANCER MANAG RES, V12, P7321, DOI 10.2147/CMAR.S216605 Chen P, 2017, ONCOTARGETS THER, V10, P5391, DOI 10.2147/OTT.S147438 Chen Z, 2016, MOL CLIN ONCOL, V4, P675, DOI 10.3892/mco.2016.800 Choe CH, 2014, AM J OPHTHALMOL, V158, P831, DOI 10.1016/j.ajo.2014.07.003 Choi HD, 2017, BREAST CANCER RES TR, V166, P927, DOI 10.1007/s10549-017-4460-9 Chu TF, 2007, LANCET, V370, P2011, DOI 10.1016/S0140-6736(07)61865-0 Chung R, 2020, J CLIN MED, V9, DOI 10.3390/jcm9103346 Claiborne RT, 2022, OPTOMETRY VISION SCI, V99, P88, DOI 10.1097/OPX.0000000000001833 Cortes JE, 2018, BLOOD, V132, P393, DOI 10.1182/blood-2016-09-739086 Cortes JE, 2016, J CLIN ONCOL, V34, P2333, DOI 10.1200/JCO.2015.64.8899 Curigliano G, 2020, ANN ONCOL, V31, P171, DOI 10.1016/j.annonc.2019.10.023 Curigliano G, 2010, PROG CARDIOVASC DIS, V53, P94, DOI 10.1016/j.pcad.2010.05.006 Dahlén T, 2016, ANN INTERN MED, V165, P161, DOI 10.7326/M15-2306 de Groot JWB, 2005, CLIN PHARMACOL THER, V78, P433, DOI 10.1016/j.clpt.2005.06.010 de la Torre BG, 2022, MOLECULES, V27, DOI 10.3390/molecules27031075 De Leo A, 2021, CANCERS, V13, DOI 10.3390/cancers13235961 de Souza TF, 2019, MAGN RESON IMAGING C, V27, P533, DOI 10.1016/j.mric.2019.04.001 Deininger MWN, 2003, J CLIN ONCOL, V21, P1637, DOI 10.1200/JCO.2003.11.143 Deng SS, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.756672 Díaz-Serrano A, 2018, DRUGS, V78, P893, DOI 10.1007/s40265-018-0916-4 Dib EG, 2005, LEUKEMIA RES, V29, P233, DOI 10.1016/j.leukres.2004.05.015 Dickerson T, 2019, BLOOD, V134, P1919, DOI 10.1182/blood.2019000840 Dimopoulos M, 2020, BLOOD ADV, V4, P6009, DOI 10.1182/bloodadvances.2020003010 Dobbin SJH, 2021, CLIN SCI, V135, P71, DOI 10.1042/CS20200305 Dobie G, 2019, BLOOD ADV, V3, P4298, DOI 10.1182/bloodadvances.2019000640 Dou XL, 2019, ONCOLOGIST, V24, pE1141, DOI 10.1634/theoncologist.2019-0109 Du W, 2015, ONCOGENE, V34, P3215, DOI 10.1038/onc.2014.291 Du XLL, 2011, MED ONCOL, V28, pS80, DOI 10.1007/s12032-010-9717-7 Dubovsky JA, 2013, BLOOD, V122, P2539, DOI 10.1182/blood-2013-06-507947 Emir H, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.257.257 Eschenhagen T, 2018, JACC-BASIC TRANSL SC, V3, P277, DOI 10.1016/j.jacbts.2018.01.011 Ewer MS, 2014, EUR J CANCER, V50, P2162, DOI 10.1016/j.ejca.2014.05.013 Ewer MS, 2005, J CLIN ONCOL, V23, P2900, DOI 10.1200/JCO.2005.05.827 Ewer SM, 2008, DRUG SAFETY, V31, P459, DOI 10.2165/00002018-200831060-00002 Fachi MM, 2019, BRIT J CLIN PHARMACO, V85, P2280, DOI 10.1111/bcp.13933 Faruque LI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101145 Flaig T, 2009, INVEST NEW DRUG, V27, P83, DOI 10.1007/s10637-008-9146-z Force T, 2007, NAT REV CANCER, V7, P332, DOI 10.1038/nrc2106 Fox LC, 2017, BLOOD ADV, V1, P802, DOI 10.1182/bloodadvances.2016003889 Fradley Michael G, 2015, Card Electrophysiol Clin, V7, P341, DOI [10.1016/j.ccep.2015.03.013, 10.1016/j.ccep.2015.03.013] Francis JH, 2017, OPHTHALMOLOGY, V124, P1788, DOI 10.1016/j.ophtha.2017.05.038 Fujioka I, 2018, ANN HEMATOL, V97, P2081, DOI 10.1007/s00277-018-3412-8 Galanis A, 2015, HAEMATOLOGICA, V100, pE77, DOI 10.3324/haematol.2014.117028 Galderisi M, 2017, EUR HEART J-CARD IMG, V18, P1301, DOI 10.1093/ehjci/jex244 Galinsky I, 2009, CLIN J ONCOL NURS, V13, P329, DOI 10.1188/09.CJON.329-335 Ghatalia P, 2015, BRIT J CANCER, V112, P296, DOI 10.1038/bjc.2014.564 Ghia P, 2020, J CLIN ONCOL, V38, P2849, DOI 10.1200/JCO.19.03355 Giles FJ, 2013, LEUKEMIA, V27, P1310, DOI 10.1038/leu.2013.69 Giudice V, 2020, LIFE-BASEL, V10, DOI 10.3390/life10120344 Goldblatt M, 2009, AM J MED SCI, V338, P414, DOI 10.1097/MAJ.0b013e3181ae9227 Goldman A, 2021, TARGET ONCOL, V16, P471, DOI 10.1007/s11523-021-00817-2 Gomez JA, 2022, AM HEART J PLUS, V17, DOI 10.1016/j.ahjo.2022.100144 Gover-Proaktor A, 2015, BLOOD, V126, DOI 10.1182/blood.V126.23.2798.2798 Gozgit JM, 2012, MOL CANCER THER, V11, P690, DOI 10.1158/1535-7163.MCT-11-0450 Granatowicz A, 2015, KOREAN J FAM MED, V36, P197, DOI 10.4082/kjfm.2015.36.5.197 Gratacap MP, 2009, BLOOD, V114, P1884, DOI 10.1182/blood-2009-02-205328 Grossman M., 2021, PROTEIN KINASE INHIB Guan JY, 2021, ONCOL LETT, V21, DOI 10.3892/ol.2020.12361 Hadzijusufovic E, 2017, LEUKEMIA, V31, P2388, DOI 10.1038/leu.2017.245 Hägerkvist R, 2007, FASEB J, V21, P618, DOI 10.1096/fj.06-6910com Haguet H, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01007 Hakkola J, 2020, ARCH TOXICOL, V94, P3671, DOI 10.1007/s00204-020-02936-7 Hall PS, 2013, JACC-HEART FAIL, V1, P72, DOI 10.1016/j.jchf.2012.09.001 Hamberg Paul, 2006, J Clin Oncol, V24, pe30, DOI 10.1200/JCO.2006.06.5318 Hantschel O, 2015, ACS CHEM BIOL, V10, P234, DOI 10.1021/cb500886n Hartmann JT, 2009, CURR DRUG METAB, V10, P470, DOI 10.2174/138920009788897975 Hashiguchi MH, 2022, JTO CLIN RES REP, V3, DOI 10.1016/j.jtocrr.2021.100271 Heidary N, 2008, J AM ACAD DERMATOL, V58, P545, DOI 10.1016/j.jaad.2008.01.001 Heinzerling L, 2019, ESMO OPEN, V4, DOI 10.1136/esmoopen-2019-000491 Henkes Martin, 2008, Ther Clin Risk Manag, V4, P163 Henri Christine, 2016, Biomark Cancer, V8, P39, DOI [10.4137/bic.s31798, 10.4137/BIC.S31798] Herrmann J, 2016, CIRCULATION, V133, P1272, DOI 10.1161/CIRCULATIONAHA.115.018347 Herrmann J, 2014, MAYO CLIN PROC, V89, P1287, DOI 10.1016/j.mayocp.2014.05.013 Hirsh V, 2011, CURR ONCOL, V18, P126 Hochhaus A, 2016, LEUKEMIA, V30, P1044, DOI 10.1038/leu.2016.5 Hsiao LT, 2002, BRIT J HAEMATOL, V117, P620, DOI 10.1046/j.1365-2141.2002.03499.x Hur H, 2008, WORLD J GASTROENTERO, V14, P6096, DOI 10.3748/wjg.14.6096 Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691 Iberri DJ, 2018, BRIT J HAEMATOL, V180, P164, DOI 10.1111/bjh.14302 Ibrahim NE, 2018, CIRC RES, V123, P614, DOI 10.1161/CIRCRESAHA.118.312706 Jabbour E, 2011, LEUKEMIA, V25, P201, DOI 10.1038/leu.2010.215 Jacobsen AV, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419-022-04740-w Jhaveri KD, 2015, JAMA ONCOL, V1, P1133, DOI 10.1001/jamaoncol.2015.1713 Jin Y, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00891 Jones JA, 2017, BRIT J HAEMATOL, V178, P286, DOI 10.1111/bjh.14660 Kalash R.S., 2016, Theranostics. Biomater. Nanoarchitectonics, P197, DOI DOI 10.1016/B978-0-323-37127-8.00012-1 Kamba T, 2007, BRIT J CANCER, V96, P1788, DOI 10.1038/sj.bjc.6603813 Kandula P, 2011, KIDNEY INT, V80, P1271, DOI 10.1038/ki.2011.288 Kanemura H, 2021, THORAC CANCER, V12, P549, DOI 10.1111/1759-7714.13790 Kappers MHW, 2010, HYPERTENSION, V56, P675, DOI 10.1161/HYPERTENSIONAHA.109.149690 Kearon C, 2016, CHEST, V149, P315, DOI 10.1016/j.chest.2015.11.026 Keisner SV, 2011, DRUGS, V71, P443, DOI 10.2165/11588960-000000000-00000 Keller-von Amsberg G, 2013, BIOL-TARGETS THER, V7, P115, DOI 10.2147/BTT.S30182 Kerkela R, 2009, CTS-CLIN TRANSL SCI, V2, P15, DOI 10.1111/j.1752-8062.2008.00090.x Khan TH, 2008, CURR CARDIOL REV, V4, P101, DOI 10.2174/157340308784245810 Lacouture ME, 2021, ONCOLOGIST, V26, pE316, DOI 10.1002/onco.13552 Lamore SD, 2020, CHEM RES TOXICOL, V33, P125, DOI 10.1021/acs.chemrestox.9b00387 Lampson BL, 2017, BLOOD, V129, P2581, DOI 10.1182/blood-2016-10-742437 Launay-Vacher V, 2014, CANCER-AM CANCER SOC, V120, P2158, DOI 10.1002/cncr.28709 Le XN, 2022, CLIN CANCER RES, V28, P1117, DOI 10.1158/1078-0432.CCR-21-2733 Lee H, 2021, INT J HEMATOL, V113, P632, DOI 10.1007/s12185-021-03126-6 Li LL, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392-022-01018-7 Li MC, 2020, BBA-MOL CELL RES, V1867, DOI 10.1016/j.bbamcr.2019.06.007 Li XQ, 2021, WORLD J PSYCHIATR, V11, P736, DOI 10.5498/wjp.v11.i10.736 Li YL, 2021, ONCOL LETT, V21, DOI 10.3892/ol.2020.12355 Lipsky A, 2020, HEMATOL-AM SOC HEMAT, P336, DOI 10.1182/hematology.2020000118 Liu C., 2022, J CANCER RES CLIN Liu Duanrui, 2018, Oncotarget, V9, P8120, DOI [10.18632/oncotarget.23429, 10.18632/oncotarget.23429] Lodish MB, 2010, ENDOCR-RELAT CANCER, V17, pR233, DOI 10.1677/ERC-10-0082 Lu JF, 2006, CLIN PHARMACOL THER, V80, P136, DOI 10.1016/j.clpt.2006.04.007 Lyon AR, 2020, EUR J HEART FAIL, V22, P1945, DOI 10.1002/ejhf.1920 Lyon AR, 2018, LANCET ONCOL, V19, pE447, DOI 10.1016/S1470-2045(18)30457-1 Ma WJ, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00434 Markman Timothy M, 2018, F1000Res, V7, P113, DOI [10.12688/f1000research.12598.1, 10.12688/f1000research.12598.1] Maroun J A, 2007, Curr Oncol, V14, P13, DOI 10.3747/co.2007.96 Mato AR, 2018, HAEMATOLOGICA, V103, P874, DOI 10.3324/haematol.2017.182907 Mazharian A, 2011, BLOOD, V117, P5198, DOI 10.1182/blood-2010-12-326850 McMullen CJ, 2021, FRONT CARDIOVASC MED, V7, DOI 10.3389/fcvm.2020.630480 Mehta LS, 2018, CIRCULATION, V137, pE30, DOI 10.1161/CIR.0000000000000556 Mendel DB, 2003, CLIN CANCER RES, V9, P327 Mercurio V, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9070641 Michel L, 2018, J THORAC DIS, V10, pS4282, DOI 10.21037/jtd.2018.08.15 Miljkovic F, 2018, ACS OMEGA, V3, P17295, DOI 10.1021/acsomega.8b02998 Mishra Ajay Kumar, 2020, Acta Biomed, V91, P142, DOI 10.23750/abm.v91i1.8914 Mishra PK, 2019, AM J PHYSIOL-HEART C, V317, pH891, DOI 10.1152/ajpheart.00259.2019 Montani D, 2012, CIRCULATION, V125, P2128, DOI 10.1161/CIRCULATIONAHA.111.079921 Moslehi JJ, 2016, NEW ENGL J MED, V375, P1457, DOI 10.1056/NEJMra1100265 Moslehi JJ, 2015, J CLIN ONCOL, V33, P4210, DOI 10.1200/JCO.2015.62.4718 Mouhayar E, 2011, TEX HEART I J, V38, P263 Mulder TA, 2021, HEMASPHERE, V5, DOI 10.1097/HS9.0000000000000564 Muraru D, 2016, EUR HEART J-CARD IMG, V17, P1279, DOI 10.1093/ehjci/jev309 Nair P, 2019, STEM CELL TRANSL MED, V8, P758, DOI 10.1002/sctm.18-0279 Nelson RP, 2006, ANN ALLERG ASTHMA IM, V97, P216, DOI 10.1016/S1081-1206(10)60016-6 Nishihara S, 2022, GENES-BASEL, V13, DOI 10.3390/genes13122183 O'Brien S, 2018, CL LYMPH MYELOM LEUK, V18, P648, DOI 10.1016/j.clml.2018.06.016 O'Sullivan S, 2009, J CLIN ENDOCR METAB, V94, P1131, DOI 10.1210/jc.2008-2324 Ohmori T, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020792 Oikonomou EK, 2019, JAMA CARDIOL, V4, P1007, DOI 10.1001/jamacardio.2019.2952 Omar NE, 2021, ESMO OPEN, V6, DOI 10.1016/j.esmoop.2021.100315 Ostojic A, 2012, THER CLIN RISK MANAG, V8, P95, DOI 10.2147/TCRM.S23277 Pardanani A, 2015, JAMA ONCOL, V1, P643, DOI 10.1001/jamaoncol.2015.1590 Pasquale R, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.1012268 Pasvolsky Oren, 2015, Cardiooncology, V1, P5, DOI [10.1186/s40959-015-0008-5, 10.1186/s40959-015-0008-5] Pavo N, 2015, HEART, V101, P1874, DOI 10.1136/heartjnl-2015-307848 Perez IE, 2019, CLIN MED INSIGHTS-CA, V13, DOI 10.1177/1179546819866445 Petrelli F, 2012, LUNG CANCER, V78, P8, DOI 10.1016/j.lungcan.2012.06.009 Pezzilli R, 2010, J PANCREAS, V11, P291 PIERCE GF, 1989, J CELL BIOL, V109, P429, DOI 10.1083/jcb.109.1.429 Pilot PR, 2006, LEUKEMIA, V20, P148, DOI 10.1038/sj.leu.2404025 Pinilla-Ibarz J., 2013, BLOOD, V122, P4007, DOI DOI 10.1182/BLOOD.V122.21.4007.4007 Pinkhas Daniel, 2017, Cardiooncology, V3, DOI [10.1186/s40959-017-0024-8, 10.1186/s40959-017-0024-8] Plana JC, 2014, J AM SOC ECHOCARDIOG, V27, P911, DOI [10.1016/j.echo.2014.07.012, 10.1093/ehjci/jeu192] Pleyer C, 2019, BLOOD, V134, DOI 10.1182/blood-2019-121675 Pluzanski A, 2016, ONCOL CLIN PRACT, V12, P113, DOI 10.5603/OCP.2016.0004 Pophali PA, 2016, CANCER J, V22, P40, DOI 10.1097/PPO.0000000000000165 Porta-Sánchez A, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.007724 Pretel-Irazabal M, 2014, ACTAS DERMO-SIFILOGR, V105, P655, DOI 10.1016/j.ad.2013.01.009 Qian J, 2020, CANCER MANAG RES, V12, P3293, DOI 10.2147/CMAR.S237968 Quintás-Cardama A, 2009, CANCER-AM CANCER SOC, V115, P3935, DOI 10.1002/cncr.24432 Quintás-Cardama A, 2009, BLOOD, V114, P261, DOI 10.1182/blood-2008-09-180604 Ramaekers Ryan, 2013, N Engl J Med, V369, P1968, DOI 10.1056/NEJMc1311795 Rambhatla A, 2021, J ASSIST REPROD GEN, V38, P1897, DOI 10.1007/s10815-021-02181-6 Ramspek CL, 2021, CLIN KIDNEY J, V14, P49, DOI 10.1093/ckj/sfaa188 Rao VJU, 2021, J AM COLL CARDIOL, V77, P2693, DOI 10.1016/j.jacc.2021.04.009 Rea D, 2015, LEUKEMIA, V29, P1206, DOI 10.1038/leu.2014.342 Rea D, 2015, ANN HEMATOL, V94, pS149, DOI 10.1007/s00277-015-2318-y Rimassa L, 2019, CANCER TREAT REV, V77, P20, DOI 10.1016/j.ctrv.2019.05.004 Rini BI, 2019, NEW ENGL J MED, V380, P1116, DOI 10.1056/NEJMoa1816714 Robinson AA, 2007, LANCET ONCOL, V8, P738, DOI 10.1016/S1470-2045(07)70242-5 Rock EP, 2007, ONCOLOGIST, V12, P107, DOI 10.1634/theoncologist.12-1-107 Rogers S, 2010, OPHTHALMOLOGY, V117, P313, DOI [10.1016/j.ophtha.2009.07.017, 10.1016/j.ophtha.2010.01.060] Rousselot P, 2021, BRIT J HAEMATOL, V194, P393, DOI 10.1111/bjh.17654 Russo E, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22126538 Ryan CE, 2020, BLOOD ADV, V4, P1458, DOI 10.1182/bloodadvances.2020001678 Saglio G, 2010, NEW ENGL J MED, V362, P2251, DOI 10.1056/NEJMoa0912614 Salem JE, 2019, J AM COLL CARDIOL, V74, P1667, DOI 10.1016/j.jacc.2019.07.056 Sampat KR, 2013, ONCOLOGIST, V18, P430, DOI 10.1634/theoncologist.2012-0388 Sasaki K, 2016, CL LYMPH MYELOM LEUK, V16, P152, DOI 10.1016/j.clml.2015.12.003 Satoh T., 2013, THER RES, V34, P1221 Schneider C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23630-w Secombe KR, 2020, INTEGR CANCER THER, V19, DOI 10.1177/1534735420928493 Sennino B, 2012, NAT REV CANCER, V12, P699, DOI 10.1038/nrc3366 Sestier M, 2021, CURR ONCOL REP, V23, DOI 10.1007/s11912-021-01102-1 Shah DR, 2013, DRUG SAFETY, V36, P413, DOI 10.1007/s40264-013-0050-x Shah NP, 2015, AM J HEMATOL, V90, P1060, DOI 10.1002/ajh.24174 Shah RR, 2013, DRUG SAFETY, V36, P491, DOI 10.1007/s40264-013-0048-4 Sharman JP, 2020, LANCET, V395, P1278, DOI 10.1016/S0140-6736(20)30262-2 Shatzel JJ, 2017, J THROMB HAEMOST, V15, P835, DOI 10.1111/jth.13651 Shim JV, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00651 Sibaud V, 2020, AM J CLIN DERMATOL, V21, P799, DOI 10.1007/s40257-020-00535-x Sierra JR, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-75 Sillaber C, 2009, EUR J CLIN INVEST, V39, P1098, DOI 10.1111/j.1365-2362.2009.02206.x Singh AP, 2019, CARDIOVASC RES, V115, P966, DOI 10.1093/cvr/cvz006 Slamon D, 2011, NEW ENGL J MED, V365, P1273, DOI 10.1056/NEJMoa0910383 Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101 Som A, 2019, WORLD J CLIN CASES, V7, P405, DOI 10.12998/wjcc.v7.i4.405 Steegmann JL, 2016, LEUKEMIA, V30, P1648, DOI 10.1038/leu.2016.104 Stephens DM, 2019, BLOOD, V133, P1298, DOI 10.1182/blood-2018-11-846808 Stone JR, 2021, JCO ONCOL PRACT, V17, P228, DOI 10.1200/OP.20.00924 Stuhlmiller TJ, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.006635 Suh CH, 2018, LUNG CANCER, V123, P60, DOI 10.1016/j.lungcan.2018.06.032 Suh KJ, 2017, INT J HEMATOL, V106, P229, DOI 10.1007/s12185-017-2225-1 Tam CS, 2021, EXPERT REV CLIN PHAR, V14, P1329, DOI 10.1080/17512433.2021.1978288 Tam CSL, 2020, J CLIN ONCOL, V38 Tao G, 2021, TOXICOL RES-UK, V10, P476, DOI 10.1093/toxres/tfab026 Taylor MH, 2020, J CLIN ONCOL, V38, P1154, DOI 10.1200/JCO.19.01598 Terada T, 2015, PHARMACOL THERAPEUT, V152, P125, DOI 10.1016/j.pharmthera.2015.05.009 Teuma C, 2017, CANCER CHEMOTH PHARM, V79, P1043, DOI 10.1007/s00280-017-3300-2 Thijs AMJ, 2015, J HYPERTENS, V33, P2075, DOI 10.1097/HJH.0000000000000662 Thomas A, 2016, LANCET ONCOL, V17, pE254, DOI 10.1016/S1470-2045(16)30030-4 Thomas SA, 2017, US PHARM, V42, pHS24 Tillman BF, 2018, EUR J HAEMATOL, V100, P325, DOI 10.1111/ejh.13020 Togasaki-Yoshimoto E, 2014, LEUKEMIA LYMPHOMA, V55, P453, DOI 10.3109/10428194.2013.806805 Tolcher AW, 2011, CANCER CHEMOTH PHARM, V67, P751, DOI 10.1007/s00280-010-1372-3 Tomaszewska B, 2021, Oncoreview, V11, P12, DOI [10.24292/01.or.122030321, 10.24292/01.OR.122030321] Torino F, 2009, NAT REV CLIN ONCOL, V6, P219, DOI 10.1038/nrclinonc.2009.4 Touyz RM, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0056-z Touyz RM, 2017, HYPERTENSION, V70, P220, DOI 10.1161/HYPERTENSIONAHA.117.08856 Truitt R, 2018, JACC-BASIC TRANSL SC, V3, P265, DOI 10.1016/j.jacbts.2017.12.007 Tseng LW, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms231911809 Turner J. R., 2017, CARDIOVASCULAR SAFET, P201 Ueda T, 2006, J SURG RES, V134, P223, DOI 10.1016/j.jss.2005.12.032 Vaitiekus D., 2017, J MED SCI MED SCI, V1, P1 van de Bovenkamp AA, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.121.021165 Van Glabbeke M, 2006, EUR J CANCER, V42, P2277, DOI 10.1016/j.ejca.2006.03.029 Vandyke K, 2010, J BONE MINER RES, V25, P1759, DOI 10.1002/jbmr.85 Varricchi G, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00167 Verma D, 2011, BLOOD, V118, P4353, DOI 10.1182/blood-2011-06-362889 Volkova M, 2011, CURR CARDIOL REV, V7, P214, DOI 10.2174/157340311799960645 Walraven M, 2011, ANGIOGENESIS, V14, P135, DOI 10.1007/s10456-010-9197-6 Wanchoo R, 2016, CLIN KIDNEY J, V9, P245, DOI 10.1093/ckj/sfv149 Wang H, 2019, CELL SYST, V8, P412, DOI 10.1016/j.cels.2019.03.009 Wang L, 2021, ONCOL REP, V45, P13, DOI 10.3892/or.2020.7851 Wang XM, 2016, XENOBIOTICA, V46, P651, DOI 10.3109/00498254.2015.1109160 Wang Z, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.20165 Wilkes GM, 2018, ASIA-PAC J ONCOL NUR, V5, P137, DOI 10.4103/apjon.apjon_79_17 Winnik S, 2013, INT J CARDIOL, V168, P2453, DOI 10.1016/j.ijcard.2013.03.010 Wu FL, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00641-0 Xiang QF, 2015, LIVER INT, V35, P1010, DOI 10.1111/liv.12524 Xie Yu, 2015, Curr Treat Options Cardiovasc Med, V17, P60, DOI [10.1007/s11936-015-0421-y, 10.1007/s11936-015-0421-y] Xu CF, 2010, BRIT J CANCER, V102, P1371, DOI 10.1038/sj.bjc.6605653 Xu XH, 2011, J CARDIOTHORAC SURG, V6, DOI 10.1186/1749-8090-6-54 Yaghoubi S, 2020, J CELL PHYSIOL, V235, P31, DOI 10.1002/jcp.28967 Yamamoto N, 2011, MOL PHARMACOL, V80, P466, DOI 10.1124/mol.110.070862 Yang JCH, 2013, EXPERT REV ANTICANC, V13, P729, DOI [10.1586/era.13.31, 10.1586/ERA.13.31] Ye L, 2010, ENDOCR REV, V31, P578, DOI 10.1210/er.2009-0031 Yim E, 2018, KOREAN J INTERN MED, V33, P446 Zamorano JL, 2016, EUR HEART J, V37, P2768, DOI [10.1093/eurheartj/ehw211, 10.1002/ejhf.654] Zentilin L, 2010, FASEB J, V24, P1467, DOI 10.1096/fj.09-143180 Zhang YY, 2020, THROMB RES, V192, P141, DOI 10.1016/j.thromres.2020.05.012 Zheng PP, 2018, MED RES REV, V38, P325, DOI 10.1002/med.21463 Zhong L, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00572-w Zhu J, 2021, J GERIATR CARDIOL, V18, P307, DOI 10.11909/j.issn.1671-5411.2021.04.009 Zogg H, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23052736 Zuo RC, 2015, JAMA DERMATOL, V151, P170, DOI 10.1001/jamadermatol.2014.2734 NR 298 TC 363 Z9 407 U1 11 U2 49 PU SPRINGERNATURE PI LONDON PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND SN 2095-9907 EI 2059-3635 J9 SIGNAL TRANSDUCT TAR JI Signal Transduct. Target. Ther. PD JUL 7 PY 2023 VL 8 IS 1 AR 262 DI 10.1038/s41392-023-01469-6 PG 27 WC Biochemistry & Molecular Biology; Cell Biology WE Science Citation Index Expanded (SCI-EXPANDED) SC Biochemistry & Molecular Biology; Cell Biology GA L7KY8 UT WOS:001025024100002 PM 37414756 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Chan, SHY Khatib, Y Webley, S Layton, D Salek, S AF Chan, Stefanie Ho Yi Khatib, Yasmin Webley, Sherael Layton, Deborah Salek, Sam TI Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review SO FRONTIERS IN PHARMACOLOGY LA English DT Review DE anticancer drugs; cancer treatments; cardiotoxicity; cardiovascular events; non-small cell lung cancer (NSCLC) ID RANDOMIZED PHASE-II; HIGH-DOSE EPIRUBICIN; PACLITAXEL PLUS CARBOPLATIN; DOUBLE-BLIND; 1ST-LINE THERAPY; OPEN-LABEL; GEMCITABINE-CISPLATIN; WEEKLY DOXORUBICIN; TRIAL; CHEMOTHERAPY AB Introduction: In the last few decades, there has been a rapid development in cancer therapies and improved detection strategies, hence the death rates caused by cancer have decreased. However, it has been reported that cardiovascular disease has become the second leading cause of long-term morbidity and fatality among cancer survivors. Cardiotoxicity from anticancer drugs affects the heart's function and structure and can occur during any stage of the cancer treatments, which leads to the development of cardiovascular disease.Objectives: To investigate the association between anticancer drugs for non-small cell lung cancer (NSCLC) and cardiotoxicity as to whether: different classes of anticancer drugs demonstrate different cardiotoxicity potentials; different dosages of the same drug in initial treatment affect the degree of cardiotoxicity; and accumulated dosage and/or duration of treatments affect the degree of cardiotoxicity.Methods: This systematic review included studies involving patients over 18 years old with NSCLC and excluded studies in which patients' treatments involve radiotherapy only. Electronic databases and registers including Cochrane Library, National Cancer Institute (NCI) Database, PubMed, Scopus, Web of Science, ClinicalTrials.gov and the European Union Clinical Trials Register were systematically searched from the earliest available date up until November 2020. A full version protocol of this systematic review (CRD42020191760) had been published on PROSPERO.Results: A total of 1785 records were identified using specific search terms through the databases and registers; 74 eligible studies were included for data extraction. Based on data extracted from the included studies, anticancer drugs for NSCLC that are associated with cardiovascular events include bevacizumab, carboplatin, cisplatin, crizotinib, docetaxel, erlotinib, gemcitabine and paclitaxel. Hypertension was the most reported cardiotoxicity as 30 studies documented this cardiovascular adverse event. Other reported treatment-related cardiotoxicities include arrhythmias, atrial fibrillation, bradycardia, cardiac arrest, cardiac failure, coronary artery disease, heart failure, ischemia, left ventricular dysfunction, myocardial infarction, palpitations, and tachycardia.Conclusion: The findings of this systematic review have provided a better understanding of the possible association between cardiotoxicities and anticancer drugs for NSCLC. Whilst variation is observed across different drug classes, the lack of information available on cardiac monitoring can result in underestimation of this association. C1 [Chan, Stefanie Ho Yi; Khatib, Yasmin; Webley, Sherael; Salek, Sam] Univ Hertfordshire, Sch Life & Med Sci, Hatfield, England. [Layton, Deborah] IQVIA UK, London, England. [Layton, Deborah] PEPI Consultancy Ltd, Southampton, England. [Layton, Deborah] Univ Keele, Keele, England. C3 University of Hertfordshire; Keele University RP Chan, SHY; Salek, S (corresponding author), Univ Hertfordshire, Sch Life & Med Sci, Hatfield, England. EM h.chan7@herts.ac.uk; m.s.salek@herts.ac.uk RI ; Chan, Stefanie Ho Yi/HTQ-7273-2023 OI Layton, Deborah/0009-0008-2080-044X; Chan, Stefanie Ho Yi/0000-0002-1912-3081 FU Jenny Greenhorn Research Scholarship FX This study is part of a programme funded by the Jenny Greenhorn Research Scholarship. CR Akamatsu H, 2018, CANCER SCI, V109, P1930, DOI 10.1111/cas.13623 Ameri P, 2021, BRIT J CLIN PHARMACO, V87, P3690, DOI 10.1111/bcp.14793 [Anonymous], 2021, Global trends 2040: A more contested world AstraZeneca, 2021, PAT REC 2 LIN TREATM DB, 2018, Journal of Biodiversity & Endangered Species, V09, DOI [10.4172/2329-9517.1000345, 10.4172/2329-9517.1000345, DOI 10.4172/2329-9517.1000345] Baggstrom MQ, 2017, J THORAC ONCOL, V12, P843, DOI 10.1016/j.jtho.2017.01.022 Barlesi F, 2018, LANCET ONCOL, V19, P1468, DOI 10.1016/S1470-2045(18)30673-9 Berghmans T, 2013, ANTICANCER RES, V33, P5477 Bi N, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.18070 Blumenschein GR, 2010, CLIN CANCER RES, V16, P279, DOI 10.1158/1078-0432.CCR-09-1675 Bodai Balazs I, 2015, Perm J, V19, P48, DOI [10.7812/tpp/14-241, 10.7812/TPP/14-241] Boehringer Ingelheim, 2018, LUX LUNG 6 RAND OP L Boehringer Ingelheim, 2020, LUX LUNG 7 RAND OP L Boehringer Ingelheim, 2018, RAND OP LAB PHAS 3 S Bonomi P, 2000, J CLIN ONCOL, V18, P623, DOI 10.1200/JCO.2000.18.3.623 Boutsikou E, 2013, ONCOTARGETS THER, V6, P125, DOI 10.2147/OTT.S42245 Butts CA, 2007, J CLIN ONCOL, V25, P5777, DOI 10.1200/JCO.2007.13.0856 Camidge DR, 2018, NEW ENGL J MED, V379, P2027, DOI 10.1056/NEJMoa1810171 Cappuzzo F, 2006, LUNG CANCER-J IASLC, V52, P319, DOI 10.1016/j.lungcan.2006.03.004 Carrasco R, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/8863789 Chan S. H. Y., 2020, IDENTIFICATION CARDI CHANG AY, 1993, J NATL CANCER I, V85, P388, DOI 10.1093/jnci/85.5.388 Choy H, 2013, J THORAC ONCOL, V8, P1308, DOI 10.1097/JTO.0b013e3182a02546 Chung R, 2020, J CLIN MED, V9, DOI 10.3390/jcm9103346 Cortot AB, 2020, EUR J CANCER, V131, P27, DOI 10.1016/j.ejca.2020.02.022 Csapo Melinda, 2014, Clujul Med, V87, P135, DOI 10.15386/cjmed-339 Curigliano G, 2016, CA-CANCER J CLIN, V66, P310, DOI 10.3322/caac.21341 Currow D, 2017, ANN ONCOL, V28, P1949, DOI 10.1093/annonc/mdx192 DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235 Dobbin SJH, 2021, CLIN SCI, V135, P71, DOI 10.1042/CS20200305 Douillard JY, 2004, LUNG CANCER, V46, P361, DOI 10.1016/j.lungcan.2004.05.009 Eli Lilly and Company, 2021, RAND MULT OP LAB PHA Eli Lilly and Company, 2019, RAND PHAS 2 TRIAL PE Eli Lilly and Company, 2015, RAND MULT PHAS 3 STU Eli Lilly and Company, 2019, RAND MULT OP LAB PHA Eli Lilly and Company, 2022, RAND MULT OP LAB PHA EU Clinical Trials Register, 2011, EUDRACT NUMB 2011 00 Ewer MS, 2015, NAT REV CARDIOL, V12, P547, DOI 10.1038/nrcardio.2015.65 FELD R, 1992, J CLIN ONCOL, V10, P297, DOI 10.1200/JCO.1992.10.2.297 Ferlay J, 2010, BREAST CANCER EPIDEMIOLOGY, P1, DOI 10.1007/978-1-4419-0685-4_1 Fukuda M, 2019, LUNG CANCER, V132, P1, DOI 10.1016/j.lungcan.2019.01.008 Gatzemeier U, 2004, ANN ONCOL, V15, P19, DOI 10.1093/annonc/mdh031 GlaxoSmithKline, 2019, MULT NONR OP LAB PHA GlaxoSmithKline, 2014, PHAS 2 OP LAB MULT R Gollerkeri A, 2001, INT J CANCER, V93, P139, DOI 10.1002/ijc.1295 Gridelli C, 2001, LUNG CANCER-J IASLC, V31, P277, DOI 10.1016/S0169-5002(00)00194-X Groen HJM, 2011, J CLIN ONCOL, V29, P4320, DOI 10.1200/JCO.2011.35.5214 Hahn VS, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000665 Heigener DF, 2013, LUNG CANCER, V80, P319, DOI 10.1016/j.lungcan.2013.02.007 Herbst RS, 2011, LANCET, V377, P1846, DOI 10.1016/S0140-6736(11)60545-X Hida T, 2017, LANCET, V390, P29, DOI 10.1016/S0140-6736(17)30565-2 Higgins J.P. T., 2011, Cochrane Handb Syst Rev Interv, DOI [10.1002/9781119536604, DOI 10.1002/9781119536604] Howlader N, 2010, J NATL CANCER I, V102, P1584, DOI 10.1093/jnci/djq366 Huang MJ, 2020, INVEST NEW DRUG, V38, P478, DOI 10.1007/s10637-019-00811-6 Jänne PA, 2014, J THORAC ONCOL, V9, P126, DOI 10.1097/JTO.0000000000000037 Jemal A, 2005, JAMA-J AM MED ASSOC, V294, P1255, DOI 10.1001/jama.294.10.1255 Jemal A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009584 Johnson BE, 2013, J CLIN ONCOL, V31, P3926, DOI 10.1200/JCO.2012.47.3983 Johnson DH, 2004, J CLIN ONCOL, V22, P2184, DOI 10.1200/JCO.2004.11.022 Kato T, 2018, DRUG SAFETY, V41, P229, DOI 10.1007/s40264-017-0596-0 Kerkelä R, 2006, NAT MED, V12, P908, DOI 10.1038/nm1446 Koch A, 2011, EUR J CANCER, V47, P1546, DOI 10.1016/j.ejca.2011.03.035 Kosmidis PA, 2008, ANN ONCOL, V19, P115, DOI 10.1093/annonc/mdm430 Kotsakis A, 2015, LUNG CANCER, V88, P57, DOI 10.1016/j.lungcan.2015.01.012 Kubota K, 2017, J CLIN ONCOL, V35, P3662, DOI [10.1200/jco.2017.72.7297, 10.1200/JCO.2017.72.7297] Langer CJ, 2017, CLIN LUNG CANCER, V18, P489, DOI 10.1016/j.cllc.2017.04.003 Lara PN, 2016, J THORAC ONCOL, V11, P420, DOI 10.1016/j.jtho.2015.11.003 León-Mateos L, 2015, REDOX BIOL, V6, P421, DOI 10.1016/j.redox.2015.09.007 Li J, 2013, J CLIN ONCOL, V31, P3219, DOI 10.1200/JCO.2013.48.8585 Martoni A, 1999, Ann Oncol, V10 Suppl 5, pS19 MARTONI A, 1991, EUR J CANCER, V27, P1231, DOI 10.1016/0277-5379(91)90087-T Maurea N, 2016, J CARDIOVASC MED, V17, pS19, DOI 10.2459/JCM.0000000000000377 McGowan JV, 2017, CARDIOVASC DRUG THER, V31, P63, DOI 10.1007/s10557-016-6711-0 Mellor HR, 2011, TOXICOL SCI, V120, P14, DOI 10.1093/toxsci/kfq378 Miller RP, 2010, TOXINS, V2, P2490, DOI 10.3390/toxins2112490 Mizugaki H, 2015, CANCER CHEMOTH PHARM, V76, P1063, DOI 10.1007/s00280-015-2876-7 Moslehi JJ, 2016, NEW ENGL J MED, V375, P1457, DOI 10.1056/NEJMra1100265 Movsas B, 2005, J CLIN ONCOL, V23, P2145, DOI 10.1200/JCO.2005.07.167 Mudd TW, 2021, AM J CANCER RES, V11, P1132 National Cancer Institute (NCI), 2019, PHAS 2 RAND STUD OSI Novello S, 2014, ANN ONCOL, V25, P2156, DOI 10.1093/annonc/mdu384 Novello S, 2014, J THORAC ONCOL, V9, P1154, DOI 10.1097/JTO.0000000000000227 Oun R, 2017, EUR J PHARMACOL, V811, P125, DOI 10.1016/j.ejphar.2017.05.063 Page Matthew J, 2021, J Clin Epidemiol, V134, P103, DOI [10.1136/bmj.n160, 10.1016/j.jclinepi.2021.02.003] Park CK, 2017, CLIN LUNG CANCER, V18, pE289, DOI 10.1016/j.cllc.2017.01.002 Passardi A, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-65 Paz-Ares L, 2015, J THORAC ONCOL, V10, P1745, DOI 10.1097/JTO.0000000000000693 Perez EA, 2004, J CLIN ONCOL, V22, P322, DOI 10.1200/JCO.2004.01.120 Reck M, 2015, LUNG CANCER, V90, P267, DOI 10.1016/j.lungcan.2015.08.003 Reinmuth N, 2019, BIODRUGS, V33, P555, DOI 10.1007/s40259-019-00363-4 Saito K, 2003, ANN NUCL MED, V17, P481, DOI 10.1007/BF03006439 Santoni M, 2017, CANCER TREAT REV, V59, P123, DOI 10.1016/j.ctrv.2017.07.006 Sebastian M, 2019, CANCER IMMUNOL IMMUN, V68, P799, DOI 10.1007/s00262-019-02315-x Sequist LV, 2013, J CLIN ONCOL, V31, P3327, DOI 10.1200/JCO.2012.44.2806 Seto T, 2014, LANCET ONCOL, V15, P1236, DOI 10.1016/S1470-2045(14)70381-X Shah C, 2018, LEUKEMIA LYMPHOMA, V59, P2557, DOI 10.1080/10428194.2018.1437269 Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886 SMIT EF, 1992, BRIT J CANCER, V65, P405, DOI 10.1038/bjc.1992.82 Smith LA, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-337 Solomon BJ, 2014, NEW ENGL J MED, V371, P2167, DOI [10.1056/NEJMoa1408440, 10.1056/NEJMx150034] Srinivasa GT, 2020, CLIN CANCER INVESTIG, V9, P27, DOI 10.4103/ccij.ccij_94_19 Stathopoulos GP, 2004, ANN ONCOL, V15, P1048, DOI 10.1093/annonc/mdh260 Swain SM, 2003, CANCER, V97, P2869, DOI 10.1002/cncr.11407 TAN C, 1967, CANCER-AM CANCER SOC, V20, P333, DOI 10.1002/1097-0142(1967)20:3<333::AID-CNCR2820200302>3.0.CO;2-K Tocchetti CG, 2019, ANTIOXID REDOX SIGN, V30, P2110, DOI 10.1089/ars.2016.6930 UMSAWASDI T, 1989, CANCER-AM CANCER SOC, V64, P1995, DOI 10.1002/1097-0142(19891115)64:10<1995::AID-CNCR2820641004>3.0.CO;2-L VALDIVIESO M, 1984, J CLIN ONCOL, V2, P207, DOI 10.1200/JCO.1984.2.3.207 Wachters F, 2003, Proc Am Soc Clin Oncol, V659 Wachters FM, 2004, ANTICANCER RES, V24, P2079 Wang XJ, 2018, J BUON, V23, P92 WEISS AJ, 1976, CANCER TREAT REP, V60, P813 WEISS AJ, 1977, CANCER-AM CANCER SOC, V40, P2046, DOI 10.1002/1097-0142(197711)40:5<2046::AID-CNCR2820400508>3.0.CO;2-5 WHOCC, 2022, WHOCC ATC DDD IND William WN, 2007, J THORAC ONCOL, V2, P745, DOI 10.1097/JTO.0b013e31811f4719 WILS J, 1990, EUR J CANCER, V26, P1140, DOI 10.1016/0277-5379(90)90271-T World Health Organization, 2020, GLOB HLTH EST Wu SH, 2008, LANCET ONCOL, V9, P117, DOI 10.1016/S1470-2045(08)70003-2 Wu YL, 2020, LANCET RESP MED, V8, P1132, DOI 10.1016/S2213-2600(20)30154-5 Wu YL, 2018, CLIN LUNG CANCER, V19, pE465, DOI 10.1016/j.cllc.2018.03.009 Yoshioka H, 2017, ANN ONCOL, V28, P285, DOI 10.1093/annonc/mdw621 Zaborowska-Szmit M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051268 Zatloukal P, 2004, LUNG CANCER-J IASLC, V46, P87, DOI 10.1016/j.lungcan.2004.03.004 Zhang S, 2012, NAT MED, V18, P1639, DOI 10.1038/nm.2919 Zhang XN, 2019, LIFE SCI, V232, DOI 10.1016/j.lfs.2019.06.001 Zinner RG, 2015, J THORAC ONCOL, V10, P134, DOI 10.1097/JTO.0000000000000366 NR 125 TC 10 Z9 10 U1 3 U2 10 PU FRONTIERS MEDIA SA PI LAUSANNE PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND EI 1663-9812 J9 FRONT PHARMACOL JI Front. Pharmacol. PD JUN 13 PY 2023 VL 14 AR 1137983 DI 10.3389/fphar.2023.1137983 PG 37 WC Pharmacology & Pharmacy WE Science Citation Index Expanded (SCI-EXPANDED) SC Pharmacology & Pharmacy GA M9HM3 UT WOS:001033250400001 PM 37383708 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Leiva, O Alam, U Bohart, I Yang, EH AF Leiva, Orly Alam, Usman Bohart, Isaac Yang, Eric H. TI Interventional Cardio-Oncology: Unique Challenges and Considerations in a High-Risk Population SO CURRENT TREATMENT OPTIONS IN ONCOLOGY LA English DT Review DE Cardio-oncology; Percutaneous coronary intervention; Transcatheter valve replacement; Atrial fibrillation; Left atrial appendage occlusion; Atrial fibrillation ablation ID PERCUTANEOUS CORONARY INTERVENTION; SUBMASSIVE PULMONARY-EMBOLISM; ACUTE MYOCARDIAL-INFARCTION; ATRIAL APPENDAGE OCCLUSION; AORTIC-VALVE-REPLACEMENT; LUNG-CANCER; MULTICENTER TRIAL; RANDOMIZED-TRIAL; TERM OUTCOMES; SINGLE-ARM AB Opinion StatementPatients with cancer are at risk of developing cardiovascular disease (CVD) including atherosclerotic heart disease (AHD), valvular heart disease (VHD), and atrial fibrillation (AF). Advances in percutaneous catheter-based treatments, including percutaneous coronary intervention (PCI) for AHD, percutaneous valve replacement or repair for VHD, and ablation and left atrial appendage occlusion devices (LAAODs) for AF, have provided patients with CVD significant benefit in the recent decades. However, trials and registries investigating outcomes of these procedures often exclude patients with cancer. As a result, patients with cancer are less likely to undergo these therapies despite their benefits. Despite the inclusion of cancer patients in randomized clinical trial data, studies suggest that cancer patients derive similar benefits of percutaneous therapies for CVD compared with patients without cancer. Therefore, percutaneous interventions for CVD should not be withheld in patients with cancer, as they may still benefit from these procedures. C1 [Leiva, Orly] New York Univ, Dept Med, Div Cardiol, Grossman Sch Med, New York, NY USA. [Alam, Usman; Bohart, Isaac] New York Univ, Dept Med, Grossman Sch Med, New York, NY USA. [Yang, Eric H.] Univ Calif Los Angeles, Dept Med, UCLA Cardiooncol Program, Div Cardiol, 100 Med Pl, Suite 630, Los Angeles, CA 90095 USA. C3 New York University; New York University; University of California System; University of California Los Angeles RP Yang, EH (corresponding author), Univ Calif Los Angeles, Dept Med, UCLA Cardiooncol Program, Div Cardiol, 100 Med Pl, Suite 630, Los Angeles, CA 90095 USA. EM EHYANG@mednet.ucla.edu RI Alam, Uazman/I-9173-2019; Leiva, Orly/HNR-5290-2023; Yang, Eric/I-2670-2019 OI Alam, Uazman/0000-0002-3190-1122; Yang, Eric/0000-0003-4889-7454 CR Alexandre J, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.018403 Alkhouli M., 2022, LEFT ATRIAL APPENDAG, V1, P1 Alshak MN, 2019, CUREUS J MED SCIENCE, V11, DOI 10.7759/cureus.6072 Andrade JG, 2021, NEW ENGL J MED, V384, P305, DOI 10.1056/NEJMoa2029980 [Anonymous], 2021, Circulation, V143, pe229, DOI 10.1161/CIR.0000000000000955 Arangalage D, 2017, ANN INTERN MED, V167, P683, DOI 10.7326/L17-0396 Avgerinos ED, 2021, JACC-CARDIOVASC INTE, V14, P1364, DOI 10.1016/j.jcin.2021.04.049 Berkovitch A, 2018, J INVASIVE CARDIOL, V30, P105 Bernhardt AM, 2023, J CARD FAIL Bharadwaj A, 2020, EUR HEART J, V41, P2183, DOI 10.1093/eurheartj/ehz851 Bungo B, 2022, IJC HEART VASC, V41, DOI 10.1016/j.ijcha.2022.101072 Callese TE, 2021, ANN VASC SURG, V77, P243, DOI 10.1016/j.avsg.2021.05.057 Chauhan S, 2022, MED KAUNAS, V58 Cho Sungbin, 2019, Korean J Thorac Cardiovasc Surg, V52, P25, DOI [10.5090/kjtcs.2019.52.1.25, 10.5090/kjtcs.2019.52.1.25] Collado FMS, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.121.022274 Cosyns B, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.766996 Curigliano G, 2016, CA-CANCER J CLIN, V66, P310, DOI 10.3322/caac.21341 Dagenais GR, 2020, LANCET, V395, P785, DOI 10.1016/S0140-6736(19)32007-0 Darby SC, 2013, NEW ENGL J MED, V368, P987, DOI 10.1056/NEJMoa1209825 De Bruyne B, 2012, NEW ENGL J MED, V367, P991, DOI 10.1056/NEJMoa1205361 Dolladille C, 2021, EUR HEART J, V42, P4964, DOI 10.1093/eurheartj/ehab618 Donnellan E, 2018, JACC-CARDIOVASC IMAG, V11, P1072, DOI 10.1016/j.jcmg.2018.04.019 Drobni ZD, 2020, CIRCULATION, V142, P2299, DOI 10.1161/CIRCULATIONAHA.120.049981 Eitel C, 2021, J CLIN MED, V10, DOI 10.3390/jcm10163669 Fernández-Cruz A, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007913 Frigeri M, 2018, CAN J CARDIOL, V34, DOI 10.1016/j.cjca.2017.09.025 Ganatra S, 2023, CARDIO-ONCOLOGY, V9, DOI 10.1186/s40959-023-00171-4 Garibaldi S, 2022, J CLIN MED, V11, DOI 10.3390/jcm11154452 Giustozzi M, 2021, J INTERV CARD ELECTR, V60, P419, DOI 10.1007/s10840-020-00745-7 Guha A, 2022, EUR HEART J, V43, P300, DOI 10.1093/eurheartj/ehab745 Guha A, 2020, AM J CARDIOL, V125, P1355, DOI 10.1016/j.amjcard.2020.01.047 Gujral DM, 2016, HEART, V102, P269, DOI 10.1136/heartjnl-2015-308765 Haq IU, 2022, J INTERV CARD ELECTR, V65, P751, DOI 10.1007/s10840-022-01341-7 Hobohm L, 2019, JACC-CARDIOVASC INTE, V12, P1044, DOI 10.1016/j.jcin.2019.04.002 Howlader N, 2020, NEW ENGL J MED, V383, P640, DOI 10.1056/NEJMoa1916623 Iannaccone M, 2018, EUR HEART J-ACUTE CA, V7, P631, DOI 10.1177/2048872617706501 Isogai T, 2021, AM J CARDIOL, V141, P154, DOI 10.1016/j.amjcard.2020.12.003 Ito D, 2012, HEART VESSELS, V27, P634, DOI 10.1007/s00380-011-0222-5 Jakobsen CB, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6314-9 January CT, 2019, CIRCULATION, V140, pE125, DOI [10.1161/CIR.0000000000000665, 10.1016/j.jacc.2019.01.011] Katapadi A, 2021, J INTERV CARDIOL, V2021, DOI 10.1155/2021/9923440 Key NS, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.01461 Khan S, 2023, IJC HEART VASC, V44, DOI 10.1016/j.ijcha.2022.101165 Kirchhof P, 2020, NEW ENGL J MED, V383, P1305, DOI 10.1056/NEJMoa2019422 Kochanek M, 2022, INTENS CARE MED, V48, P332, DOI 10.1007/s00134-022-06635-y Konstantinides SV, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.01647-2019 Kosaraju N, 2022, CLIN CARDIOL, V45, P977, DOI 10.1002/clc.23927 Landes U, 2019, JACC-CARDIOVASC INTE, V12, P78, DOI 10.1016/j.jcin.2018.10.026 Lebehn M, 2020, EUR HEART J-CASE REP, V4, DOI 10.1093/ehjcr/ytaa432 Leiva O, 2023, COMPREHENSIVE REV PA Leiva O, 2020, J MED VASC, V45, p6S8 Leiva O, 2021, JACC-CARDIOONCOL, V3, P619, DOI 10.1016/j.jaccao.2021.08.011 Leon MB, 2016, NEW ENGL J MED, V374, P1609, DOI 10.1056/NEJMoa1514616 Levine GN, 2016, J AM COLL CARDIOL, V68, P1082, DOI [10.1016/j.jacc.2016.07.715, 10.1016/j.jacc.2016.03.513] Lipshultz SE, 2013, CIRCULATION, V128, P1927, DOI 10.1161/CIR.0b013e3182a88099 Mack MJ, 2019, NEW ENGL J MED, V380, P1695, DOI 10.1056/NEJMoa1814052 Mahmood S, 2018, J AM COLL CARDIOL, V71, P699, DOI [10.1016/S0735-1097(18)31240-3, 10.1016/j.jacc.2018.02.037] Marmagkiolis K, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.641268 McCarthy CP, 2017, EUR HEART J, V38, P3488, DOI 10.1093/eurheartj/ehx531 Memon S, 2022, CATHETER CARDIO INTE, V100, P667, DOI 10.1002/ccd.30319 Mhanna M, 2022, CURR PROB CARDIOLOGY, V47, DOI 10.1016/j.cpcardiol.2022.101353 Minamino-Muta E, 2018, EUR HEART J-QUAL CAR, V4, P180, DOI 10.1093/ehjqcco/qcy010 Mohamed MO, 2021, EUR HEART J-ACUTE CA Mohanty BD, 2022, CATHETER CARDIO INTE, V99, P1877, DOI 10.1002/ccd.30154 Monlezun DJ, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.620857 Mosarla RC, 2019, J AM COLL CARDIOL, V73, P1336, DOI 10.1016/j.jacc.2019.01.017 Moslehi JJ, 2018, LANCET, V391, P933, DOI 10.1016/S0140-6736(18)30533-6 Murphy AC, 2021, CATHETER CARDIO INTE, V97, P157, DOI 10.1002/ccd.28969 Navi BB, 2017, J AM COLL CARDIOL, V70, P927, DOI 10.1016/j.jacc.2017.06.047 Nidorf SM, 2020, NEW ENGL J MED, V383, P1838, DOI 10.1056/NEJMoa2021372 Osmancik P, 2022, J AM COLL CARDIOL, V79, P1, DOI 10.1016/j.jacc.2021.10.023 Otto CM, 2021, CIRCULATION, V143, pe72, DOI [10.1161/CIR.0000000000000923, 10.1016/j.jacc.2020.11.035, 10.1161/CIR.0000000000000932, 10.1016/j.jacc.2020.11.018] Park C, 2021, ARTIF ORGANS, V45, pE236, DOI 10.1111/aor.13922 Patel Nikhil, 2018, J Innov Card Rhythm Manag, V9, P3291, DOI [10.19102/icrm.2018.090803, 10.19102/icrm.2018.090803] Piazza G, 2015, JACC-CARDIOVASC INTE, V8, P1382, DOI 10.1016/j.jcin.2015.04.020 Popma JJ, 2019, NEW ENGL J MED, V380, P1706, DOI 10.1056/NEJMoa1816885 Postow MA, 2018, NEW ENGL J MED, V378, P158, DOI [10.1056/NEJMra1703481, 10.1056/NEJMc1801663] Potts JE, 2019, EUR HEART J, V40, P1790, DOI 10.1093/eurheartj/ehy769 Räber L, 2018, EUR HEART J, V39, P3281, DOI [10.1093/eurheartj/ehy285, 10.4244/EIJY18M06_01] Ramasamy A, 2020, EUR HEART J, V41, P3201, DOI 10.1093/eurheartj/ehaa004 Ranpura V, 2010, ACTA ONCOL, V49, P287, DOI 10.3109/02841860903524396 Reddy PKV, 2021, EUR HEART J-CASE REP, V5, DOI 10.1093/ehjcr/ytab122 Rhea IB, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0797-z Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914 Sara JD, 2018, THER ADV MED ONCOL, V10, DOI 10.1177/1758835918780140 Shabtaie SA, 2023, JACC-CARDIOONCOL, V5, P203, DOI 10.1016/j.jaccao.2022.10.016 Shabtaie SA, 2021, CIRCULATION, V144 Shalaby K, 2022, BMC PULM MED, V22, DOI 10.1186/s12890-021-01808-9 Sim JJL, 2022, ANN HEMATOL, V101, P1395, DOI 10.1007/s00277-022-04855-2 Singal PK, 1998, NEW ENGL J MED, V339, P900, DOI 10.1056/NEJM199809243391307 Singh Vinit, 2022, Eur J Case Rep Intern Med, V9, P003149, DOI [10.12890/2022_003149, 10.12890/2022_003149] Sista AK, 2021, JACC-CARDIOVASC INTE, V14, P319, DOI 10.1016/j.jcin.2020.09.053 Stein-Merlob AF, 2021, ESC HEART FAIL, V8, P4301, DOI 10.1002/ehf2.13545 Stevens SM, 2021, CHEST, V160, pE545, DOI 10.1016/j.chest.2021.07.055 Stevens SM, 2021, CHEST, V160, P2247, DOI 10.1016/j.chest.2021.07.056 Stone GW, 2018, NEW ENGL J MED, V379, P2307, DOI 10.1056/NEJMoa1806640 Suero-Abreu GA, 2022, JACC-CARDIOONCOL, V4, P598, DOI 10.1016/j.jaccao.2022.11.011 Takeuchi T, 2021, INT HEART J, V62, P238, DOI 10.1536/ihj.20-452 Tapson VF, 2018, JACC-CARDIOVASC INTE, V11, P1401, DOI 10.1016/j.jcin.2018.04.008 Tardif JC, 2019, NEW ENGL J MED, V381, P2497, DOI 10.1056/NEJMoa1912388 Thompson JA, 2022, J NATL COMPR CANC NE, V20, P387, DOI 10.6004/jnccn.2022.0020 Timp JF, 2013, BLOOD, V122, P1712, DOI 10.1182/blood-2013-04-460121 Tu T, 2019, JACC-CARDIOVASC INTE, V12, P859, DOI 10.1016/j.jcin.2018.12.022 Valgimigli M, 2021, NEW ENGL J MED, V385, P1643, DOI 10.1056/NEJMoa2108749 Wang K, 2017, J CLIN ONCOL, V35, P1387, DOI 10.1200/JCO.2016.70.0229 Watanabe Y, 2016, AM J CARDIOL, V118, P572, DOI 10.1016/j.amjcard.2016.05.052 Wazni OM, 2021, NEW ENGL J MED, V384, P316, DOI 10.1056/NEJMoa2029554 Writing Committee Members, 2022, J Cardiovasc Comput Tomogr, V16, P54, DOI 10.1016/j.jcct.2021.11.009 Zammit SC, 2014, QJM-INT J MED, V107, P355, DOI 10.1093/qjmed/hct261 Zhang YQ, 2022, CIRCULATION, V146 NR 110 TC 3 Z9 3 U1 0 U2 3 PU SPRINGER PI NEW YORK PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES SN 1527-2729 EI 1534-6277 J9 CURR TREAT OPTION ON JI Curr. Treat. Options Oncol. PD AUG PY 2023 VL 24 IS 8 BP 1071 EP 1087 DI 10.1007/s11864-023-01110-2 EA JUN 2023 PG 17 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA M1EB8 UT WOS:001003968300002 PM 37296366 OA Green Submitted, hybrid DA 2026-04-17 ER PT J AU Walls, GM McCann, C Ball, P Atkins, KM Mak, RH Bedair, A O'Hare, J McAleese, J Harrison, C Tumelty, KA Crockett, C Black, SL Nelson, C O'Connor, J Hounsell, AR McGarry, CK Butterworth, K Cole, AJ Jain, S Hanna, GG AF Walls, Gerard M. McCann, Conor Ball, Peter Atkins, Katelyn M. Mak, Raymond H. Bedair, Ahmed O'Hare, Jolyne McAleese, Jonathan Harrison, Claire Tumelty, Karen A. Crockett, Cathryn Black, Sarah-Louise Nelson, Catherine O'Connor, John Hounsell, Alan R. McGarry, Conor K. Butterworth, Karl Cole, Aidan J. Jain, Suneil Hanna, Gerard G. TI A pulmonary vein atlas for radiotherapy planning SO RADIOTHERAPY AND ONCOLOGY LA English DT Article DE Radiation cardiotoxicity; Pulmonary veins; Lung cancer; Cardio-oncology; Atrial fibrillation; Oesophageal cancer ID THORACIC RADIATION-THERAPY; ATRIAL-FIBRILLATION; CONTOURING ATLAS; ELECTROCARDIOGRAM ABNORMALITIES; VOLUME DELINEATION; HEART; SEGMENTATION; MORPHOLOGY; IMPACT AB Background and Purpose: Cardiac arrhythmia is a recognised potential complication of thoracic radiother-apy, but the responsible cardiac substructures for arrhythmogenesis have not been identified. Arrhythmogenic tissue is commonly located in the pulmonary veins (PVs) of cardiology patients with arrhythmia, however these structures are not currently considered organs-at-risk during radiotherapy planning. A standardised approach to their delineation was developed and evaluated. Materials and Methods: The gross and radiological anatomy relevant to atrial fibrillation was derived from cardiology and radiology literature by a multidisciplinary team. A region of interest and contouring instructions for radiotherapy computed tomography scans were iteratively developed and subsequently evaluated. Radiation oncologists (n = 5) and radiation technologists (n = 2) contoured the PVs on the four-dimensional planning datasets of five patients with locally advanced lung cancer treated with 1.8- 2.75 Gy fractions. Contours were compared to reference contours agreed by the researchers using geo-metric and dosimetric parameters. Results: The mean dose to the PVs was 35% prescription dose. Geometric and dosimetric similarity of the observer contours with reference contours was fair, with an overall mean Dice of 0.80 +/- 0.02. The right superior PV (mean DSC 0.83 +/- 0.02) had better overlap than the left (mean DSC 0.80 +/- 0.03), but the infe-rior PVs were equivalent (mean DSC of 0.78). The mean difference in mean dose was 0.79 Gy +/- 0.71 (1. 46% +/- 1.25). Conclusion: A PV atlas with multidisciplinary approval led to reproducible delineation for radiotherapy planning, supporting the utility of the atlas in future clinical radiotherapy cardiotoxicity research encom-passing arrhythmia endpoints. (c) 2023 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 184 (2023) 1-9 This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). C1 [Walls, Gerard M.; O'Hare, Jolyne; McAleese, Jonathan; Harrison, Claire; Tumelty, Karen A.; Crockett, Cathryn; Black, Sarah-Louise; Nelson, Catherine; Hounsell, Alan R.; McGarry, Conor K.; Cole, Aidan J.; Jain, Suneil; Hanna, Gerard G.] Belfast Hlth & Social Care Trust, Belfast City Hosp, Canc Ctr, Lisburn Rd, Belfast, North Ireland. [Walls, Gerard M.; O'Connor, John; Hounsell, Alan R.; McGarry, Conor K.; Butterworth, Karl; Cole, Aidan J.; Jain, Suneil; Hanna, Gerard G.] Queens Univ Belfast, Patrick G Johnston Ctr Canc Res, Lisburn Rd, Belfast BT9 7AB, North Ireland. [McCann, Conor] Belfast Hlth & Social Care Trust, Belfast City Hosp, Dept Cardiol, Lisburn Rd, Belfast, North Ireland. [Ball, Peter] Belfast Hlth & Social Care Trust, Royal Victoria Hosp, Dept Radiol, 274 Grosvenor Rd, Belfast, North Ireland. [Atkins, Katelyn M.] Cedars Sinai Med Ctr, Dept Radiat Oncol, Los Angeles, CA USA. [Mak, Raymond H.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA USA. [Mak, Raymond H.] Brigham & Womens Hosp, Boston, MA USA. [Bedair, Ahmed] ltnagelvin Hosp, North West Canc Ctr, Glenshane Rd, Derry, North Ireland. C3 Belfast City Hospital; Queens University Belfast; Belfast City Hospital; Cedars Sinai Medical Center; Harvard University; Harvard University Medical Affiliates; Dana-Farber Cancer Institute; Harvard University; Harvard University Medical Affiliates; Brigham & Women's Hospital RP Walls, GM (corresponding author), Queens Univ Belfast, Patrick G Johnston Ctr Canc Res, Lisburn Rd, Belfast BT9 7AB, North Ireland. EM g.walls@qub.ac.uk RI O'Connor, John/OOK-7991-2025; McCann, Conor/ODJ-4170-2025; Butterworth, Karl/I-7476-2019; Hanna, Gerard/ABA-5427-2020; Walls, Gerard/I-5652-2019 OI Butterworth, Karl/0000-0001-7170-6789; Hanna, Gerard/0000-0003-1003-5138; Walls, Gerard/0000-0003-0845-9732 FU Wellcome Trust; Health Research Board [203930/B/16/Z]; Health Service Executive National Doctors Training and Planning; Health and Social Care, Research and Development Division, Northern Ireland FX This work was performed within the Irish Clinical Academic Training (ICAT) Programme, supported by the Wellcome Trust and the Health Research Board (Grant Number 203930/B/16/Z) , the Health Service Executive National Doctors Training and Planning and the Health and Social Care, Research and Development Division, Northern Ireland. None of the the funders had any role in the conduct of the research. CR Apte N, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.610915 Atkins K, 2022, INT J RADIAT ONCOL, V358, P202 Bandyopadhyay D, 2019, IJC HEART VASC, V22, P216, DOI 10.1016/j.ijcha.2019.02.012 Bode F, 2015, EUROPACE, V17, P1868, DOI 10.1093/europace/euu406 Bucknell NW, 2022, J THORAC ONCOL Cai GX, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00153 Chang JH, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-91660-y Chard M, 2009, PHARMACOL THERAPEUT, V124, P207, DOI 10.1016/j.pharmthera.2009.07.002 Di Monaco A, 2022, FRONT CARDIOVASC MED, P9 Duane F, 2017, RADIOTHER ONCOL, V122, P416, DOI 10.1016/j.radonc.2017.01.008 Duffton Aileen, 2021, Tech Innov Patient Support Radiat Oncol, V17, P102, DOI [10.1016/j.tipsro.2021.02.003, 10.1016/j.tipsro.2021.02.003] Ellis CR, 2018, JACC-CLIN ELECTROPHY, V4, P412, DOI 10.1016/j.jacep.2017.11.011 Feng M, 2011, INT J RADIAT ONCOL, V79, P10, DOI 10.1016/j.ijrobp.2009.10.058 Fradley MG, 2020, CIRCULATION, pE41 Gomez DR, 2014, J THORAC ONCOL, V9, P1554, DOI 10.1097/JTO.0000000000000306 Hanna GG, 2010, CLIN ONCOL-UK, V22, P515, DOI 10.1016/j.clon.2010.05.006 Haq R, 2020, PHYS IMAG RADIAT ONC, V14, P61, DOI 10.1016/j.phro.2020.05.009 Hotca A, 2019, CLIN TRANSL RAD ONCO, V19, P96, DOI 10.1016/j.ctro.2019.09.003 Khan R, 2004, CARDIOVASC RES, V64, P387, DOI 10.1016/j.cardiores.2004.07.025 Kim KH, 2022, JAMA ONCOL, V8, P1624, DOI 10.1001/jamaoncol.2022.4202 Kistler PM, 2006, J AM COLL CARDIOL, V48, P1010, DOI 10.1016/j.jacc.2006.03.058 Konski A, 2012, RADIOTHER ONCOL, V104, P72, DOI 10.1016/j.radonc.2012.04.016 Loap P, 2021, PRACT RADIAT ONCOL, V11, pE434, DOI 10.1016/j.prro.2021.02.002 Milo MLH, 2020, RADIOTHER ONCOL, V150, P121, DOI 10.1016/j.radonc.2020.06.015 Ogino I, 2016, STRAHLENTHER ONKOL, V192, P359, DOI 10.1007/s00066-016-0956-1 Pinter C, 2012, MED PHYS, V39, P6332, DOI 10.1118/1.4754659 Qian PC, 2020, J ARRYTHM, V36, P67, DOI 10.1002/joa3.12283 Ren XY, 2021, J APPL CLIN MED PHYS, V22, P79, DOI 10.1002/acm2.13239 Schwartzman D, 2003, J AM COLL CARDIOL, V41, P1349, DOI 10.1016/S0735-1097(03)00124-4 Sherer MV, 2021, RADIOTHER ONCOL, V160, P185, DOI 10.1016/j.radonc.2021.05.003 Socha J, 2021, RADIOTHER ONCOL, V161, pS975 Vinod SK, 2016, RADIOTHER ONCOL, V121, P169, DOI 10.1016/j.radonc.2016.09.009 Vivekanandan S, 2017, INT J RADIAT ONCOL, V99, P51, DOI 10.1016/j.ijrobp.2017.04.026 Walls GM, 2022, PHYS IMAGING RAD ONC Walls GM, 2022, IN PRESS Yun JP, 2021, JACC-CARDIOONCOL, V3, P221, DOI 10.1016/j.jaccao.2021.03.006 Zei PC, 2018, HEART RHYTHM, V15, P1420, DOI 10.1016/j.hrthm.2018.04.015 NR 37 TC 13 Z9 15 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-8140 EI 1879-0887 J9 RADIOTHER ONCOL JI Radiother. Oncol. PD JUL PY 2023 VL 184 AR 109680 DI 10.1016/j.radonc.2023.109680 EA MAY 2023 PG 9 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA I4WE6 UT WOS:001002793200001 PM 37105303 OA Green Submitted, Green Published, hybrid DA 2026-04-17 ER PT J AU Kimura, D Yamamoto, H Endo, S Fukuchi, E Miyata, H Fukuda, I Ogino, H Sawa, Y Chida, M Minakawa, M AF Kimura, Daisuke Yamamoto, Hiroyuki Endo, Shunsuke Fukuchi, Eriko Miyata, Hiroaki Fukuda, Ikuo Ogino, Hitoshi Sawa, Yoshiki Chida, Masayuki Minakawa, Masahito TI Postoperative cerebral infarction and arrhythmia after pulmonary lobectomy in Japan: a retrospective analysis of 77,060 cases in a national clinical database SO SURGERY TODAY LA English DT Article DE Lung cancer; Left upper lobectomy; Left lower lobectomy; Postoperative cerebral infarction; Postoperative new-onset arrhythmia ID ATRIAL-FIBRILLATION; LUNG-CANCER; VEIN STUMP; RISK-FACTOR; THROMBOSIS; THROMBOGENESIS; FLUTTER; STROKE AB PurposeTo investigate the incidence of postoperative cerebral infarction after curative lobectomy, its association with the type of lobectomy, and how postoperative new-onset arrhythmia contributes to postoperative cerebral infarction.MethodsThe subjects of this analysis were 77,060 patients who underwent curative lobectomy for lung cancer between 2016 and 2018 according to the National Clinical Database. Incidences of postoperative cerebral infarction and postoperative new-onset arrhythmia were analyzed. Moreover, mediation analysis was performed to evaluate the causal pathway between postoperative new-onset arrhythmia and postoperative cerebral infarction.ResultsPostoperative cerebral infarction occurred in 110 (0.7%) patients after left upper lobectomy and in 85 (0.7%) patients after left lower lobectomy. Left upper lobectomy and left lower lobectomy were associated with a higher likelihood of postoperative cerebral infarction than right lower lobectomy. Left upper lobectomy was the strongest independent predictor of postoperative new-onset arrhythmia. However, in the mediation analysis, the odds ratio for cerebral infarction did not change after the addition of the factor of postoperative new-onset arrhythmia.ConclusionCerebral infarction occurred significantly more often not only after left upper lobectomy, but also after left lower lobectomy. Postoperative new-onset arrhythmia was less likely to be related to cerebral infarction after left upper lobectomy. C1 [Kimura, Daisuke; Endo, Shunsuke; Fukuda, Ikuo; Ogino, Hitoshi; Sawa, Yoshiki; Chida, Masayuki; Minakawa, Masahito] Japanese Assoc Thorac Surg, Tokyo, Japan. [Kimura, Daisuke; Minakawa, Masahito] Hirosaki Univ, Grad Sch Med, Dept Thorac & Cardiovasc Surg, 5 Zaifu cho, Hirosaki, Aomori 0368562, Japan. [Yamamoto, Hiroyuki; Fukuchi, Eriko; Miyata, Hiroaki] Univ Tokyo, Grad Sch Med, Dept Healthcare Qual Assessment, Tokyo, Japan. [Endo, Shunsuke] Jichi Med Univ, Dept Thorac Surg, Saitama Med Ctr, Saitama, Japan. [Fukuda, Ikuo] Suita Tokushukai Hosp, Cardiovasc Ctr, Osaka, Japan. [Ogino, Hitoshi] Tokyo Med Univ Hosp, Dept Cardiovasc Surg, Tokyo, Japan. [Sawa, Yoshiki] Osaka Police Hosp, Osaka, Japan. [Chida, Masayuki] Dokkyo Med Univ, Dept Gen Thorac Surg, Mibu, Tochigi, Japan. C3 Hirosaki University; University of Tokyo; Jichi Medical University; Tokyo Medical University; Osaka Police Hospital; Dokkyo Medical University RP Kimura, D (corresponding author), Japanese Assoc Thorac Surg, Tokyo, Japan.; Kimura, D (corresponding author), Hirosaki Univ, Grad Sch Med, Dept Thorac & Cardiovasc Surg, 5 Zaifu cho, Hirosaki, Aomori 0368562, Japan. EM d-suke@hirosaki-u.ac.jp RI Daisuke, Kimura/GXF-5114-2022 OI Daisuke, Kimura/0000-0002-5484-8686; Yamamoto, Hiroyuki/0000-0003-3337-7595 CR Blackshear JL, 1996, ANN THORAC SURG, V61, P755, DOI 10.1016/0003-4975(95)00887-X Detterbeck FC, 2017, CHEST, V151, P193, DOI 10.1016/j.chest.2016.10.010 Frendl G, 2014, J THORAC CARDIOV SUR, V148, pE153, DOI 10.1016/j.jtcvs.2014.06.036 Fukuda Y, 2018, INTERNAL MED, V57, P633, DOI 10.2169/internalmedicine.9243-17 Hashimoto H, 2019, CANCERS, V11, DOI 10.3390/cancers11040488 Hattori A, 2022, EUR J CARDIO-THORAC, V61, P92, DOI 10.1093/ejcts/ezab370 Hattori A, 2019, GEN THORAC CARDIOVAS, V67, P247, DOI 10.1007/s11748-018-1017-8 Ishibashi H, 2020, WORLD J SURG, V44, P3952, DOI 10.1007/s00268-020-05694-w Kimura D, 2019, GEN THORAC CARDIOVAS, V67, P306, DOI 10.1007/s11748-018-1024-9 Libby P, 2001, CIRCULATION, V103, P1718, DOI 10.1161/01.CIR.103.13.1718 Lin MH, 2019, STROKE, V50, P1364, DOI 10.1161/STROKEAHA.118.023921 Matsumoto K, 2020, SURG TODAY, V50, P1383, DOI 10.1007/s00595-020-02032-4 Mazzucco S, 2020, JAMA NEUROL, V77, P1279, DOI 10.1001/jamaneurol.2020.1948 Minegishi K, 2020, J THORAC DIS, V12, P4099, DOI 10.21037/jtd-20-1170 Miyata H, 2014, SURG TODAY, V44, P1991, DOI 10.1007/s00595-013-0802-3 Mizukami Y, 2020, J THORAC DIS, V12, P2210, DOI 10.21037/jtd.2020.04.02 Morinaga Y, 2019, WORLD NEUROSURG, V129, P28, DOI 10.1016/j.wneu.2019.05.203 Nagaoka E, 2008, J THORAC CARDIOV SUR, V135, P709, DOI 10.1016/j.jtcvs.2007.11.035 Nakano T, 2012, J CLIN PHARM THER, V37, P431, DOI 10.1111/j.1365-2710.2011.01315.x Nakanoz T, 2019, GEN THORAC CARDIOVAS, V67, P450, DOI 10.1007/s11748-018-1032-9 Ohtaka K, 2014, J CARDIOTHORAC SURG, V9, DOI 10.1186/s13019-014-0159-8 Ohtaka K, 2014, J CARDIOTHORAC SURG, V9, DOI 10.1186/1749-8090-9-5 Ohtaka K, 2013, ANN THORAC SURG, V95, P1924, DOI 10.1016/j.athoracsur.2013.03.005 Ohtaka K, 2012, J THORAC CARDIOV SUR, V143, pE3, DOI 10.1016/j.jtcvs.2011.09.025 Otsuka T, 2018, J PSYCHOSOM RES, V111, P36, DOI 10.1016/j.jpsychores.2018.05.004 Oyama R, 2021, GEN THORAC CARDIOVAS, V69, P1506, DOI 10.1007/s11748-021-01691-5 Rena O, 2001, EUR J CARDIO-THORAC, V20, P688, DOI 10.1016/S1010-7940(01)00890-9 Semeraro GC, 2021, CANCERS, V13, DOI 10.3390/cancers13164012 Song CY, 2020, GEN THORAC CARDIOVAS, V68, P1047, DOI 10.1007/s11748-019-01200-9 Ueno H, 2022, J STROKE CEREBROVASC, V31, DOI 10.1016/j.jstrokecerebrovasdis.2022.106593 Umehara T, 2020, J THORAC DIS, V12, P5542, DOI 10.21037/jtd-20-1606 Usui G, 2019, INTERNAL MED, V58, P1349, DOI 10.2169/internalmedicine.1962-18 Wankhede D, 2021, LUNG, V199, P535, DOI 10.1007/s00408-021-00480-4 Watson T, 2009, LANCET, V373, P155, DOI 10.1016/S0140-6736(09)60040-4 Xin YZ, 2014, EUR J CARDIO-THORAC, V45, P247, DOI 10.1093/ejcts/ezt383 Yamamoto T, 2016, SURG TODAY, V46, P780, DOI 10.1007/s00595-015-1233-0 NR 36 TC 7 Z9 7 U1 0 U2 6 PU SPRINGER PI NEW YORK PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES SN 0941-1291 EI 1436-2813 J9 SURG TODAY JI Surg. Today PD DEC PY 2023 VL 53 IS 12 BP 1388 EP 1395 DI 10.1007/s00595-023-02691-z EA MAY 2023 PG 8 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA Y5ZY8 UT WOS:000982732100001 PM 37147511 DA 2026-04-17 ER PT J AU Tajima, K Yamakawa, K Kuwabara, Y Miyazaki, C Sunaga, H Uezono, S AF Tajima, Karin Yamakawa, Kentaro Kuwabara, Yuki Miyazaki, Chika Sunaga, Hiroshi Uezono, Shoichi TI Propofol anesthesia decreases the incidence of new-onset postoperative atrial fibrillation compared to desflurane in patients undergoing video-assisted thoracoscopic surgery: A retrospective single-center study SO PLOS ONE LA English DT Article ID NONCARDIAC THORACIC-SURGERY; LEFT UPPER LOBECTOMY; LUNG-CANCER SURGERY; RISK-FACTORS; PREOPERATIVE ELECTROCARDIOGRAM; POTASSIUM CURRENTS; MANAGEMENT; SEVOFLURANE; REPOLARIZATION; COMPLICATIONS AB BackgroundPostoperative atrial fibrillation (POAF) increases postoperative morbidity, mortality, and length of hospital stay. Propofol is reported to modulate atrial electrophysiology and the cardiac autonomic nervous system. Therefore, we retrospectively examined whether propofol suppresses POAF in patients undergoing video-assisted thoracoscopic surgery (VATS) compared to desflurane. MethodsWe retrospectively recruited adult patients who underwent VATS during the period from January 2011 to May 2018 in an academic university hospital. Between continuous propofol and desflurane administration during anesthetic maintenance, we investigated the incidence of new-onset POAF (within 48 hours after surgery) before and after propensity score matching. ResultsOf the 482 patients, 344 received propofol, and 138 received desflurane during anesthetic maintenance. The incidence of POAF in the propofol group was less than that in the desflurane group (4 [1.2%] vs. 8 patients [5.8%], odds ratio [OR]; 0.161, 95% confidence interval (CI), 0.040-0.653, p = 0.011) in the present study population. After adjustment for propensity score matching (n = 254, n = 127 each group), the incidence of POAF was still less in propofol group than desflurane group (1 [0.8%] vs. 8 patients [6.3%], OR; 0.068, 95% CI: 0.007-0.626, p = 0.018). ConclusionsThese retrospective data suggest propofol anesthesia significantly inhibits POAF compared to desflurane anesthesia in patients undergoing VATS. Further prospective studies are needed to elucidate the mechanism of propofol on the inhibition of POAF. C1 [Tajima, Karin; Yamakawa, Kentaro; Kuwabara, Yuki; Miyazaki, Chika; Sunaga, Hiroshi; Uezono, Shoichi] Jikei Univ, Sch Med, Dept Anesthesiol, Tokyo, Japan. C3 Jikei University RP Yamakawa, K (corresponding author), Jikei Univ, Sch Med, Dept Anesthesiol, Tokyo, Japan. EM KYamakawa@jikei.ac.jp RI KUWABARA, YUKI/IWE-2041-2023; Yamakawa, Kentaro/MXX-0399-2025 OI KUWABARA, YUKI/0000-0001-9214-6979; Yamakawa, Kentaro/0000-0003-4918-099X CR Aizawa Yoshifusa, 2017, J Atr Fibrillation, V10, P1724, DOI [10.4022/jafib.1724, 10.4022/jafib.1724] Aldhoon B, 2010, PHYSIOL RES, V59, P1, DOI 10.33549/physiolres.931651 Alonso-Coello P, 2017, ANESTH ANALG, V125, P162, DOI 10.1213/ANE.0000000000002111 Amar D, 2003, J AM COLL CARDIOL, V42, P1262, DOI 10.1016/S0735-1097(03)00955-0 Amar D, 2007, CURR OPIN ANESTHESIO, V20, P43, DOI 10.1097/ACO.0b013e32801158bb Andrade JG, 2018, CAN J CARDIOL, V34, P429, DOI 10.1016/j.cjca.2017.11.022 Beck-Schimmer B, 2016, ANESTHESIOLOGY, V125, P313, DOI 10.1097/ALN.0000000000001164 Bhave PD, 2012, AM HEART J, V164, P918, DOI 10.1016/j.ahj.2012.09.004 Bosch NA, 2018, CHEST, V154, P1424, DOI 10.1016/j.chest.2018.03.040 Cervigón R, 2013, PACE, V36, P1176, DOI 10.1111/pace.12137 Chebbout R, 2018, ANAESTHESIA, V73, P490, DOI 10.1111/anae.14118 Chen PS, 2007, HEART RHYTHM, V4, pS61, DOI 10.1016/j.hrthm.2006.12.006 Chiamvimonvat N, 2017, J PHYSIOL-LONDON, V595, P2229, DOI 10.1113/JP272883 Courtemanche M, 1999, CARDIOVASC RES, V42, P477, DOI 10.1016/S0008-6363(99)00034-6 De Decker K, 2003, ANN THORAC SURG, V75, P1340, DOI 10.1016/S0003-4975(02)04824-5 De Hert SG, 2004, ANESTHESIOLOGY, V101, P299, DOI 10.1097/00000542-200408000-00009 Dindo D, 2004, ANN SURG, V240, P205, DOI [10.17116/hirurgia2018090162, 10.1097/01.sla.0000133083.54934.ae] EBERT TJ, 1993, ANESTHESIOLOGY, V79, P444, DOI 10.1097/00000542-199309000-00006 Eger EI II, 2004, AM J HEALTH-SYST PH, V61, pS3, DOI 10.1093/ajhp/61.suppl_4.S3 Fernando HC, 2011, ANN THORAC SURG, V92, P1144, DOI 10.1016/j.athoracsur.2011.06.104 Frendl G, 2014, J THORAC CARDIOV SUR, V148, pE153, DOI 10.1016/j.jtcvs.2014.06.036 Garner M, 2017, INTERACT CARDIOV TH, V24, P260, DOI 10.1093/icvts/ivw348 Gong JL, 2021, J THORAC DIS, V13, DOI 10.21037/jtd-20-2740 Gu JW, 2017, J CARDIOTHOR VASC AN, V31, P69, DOI 10.1053/j.jvca.2016.05.036 Guizy M, 2008, J MOL CELL CARDIOL, V44, P323, DOI 10.1016/j.yjmcc.2007.11.004 Gunes H, 2018, MEDICINA-LITHUANIA, V54, DOI 10.3390/medicina54040058 HAZEN MS, 1991, AM HEART J, V122, P823, DOI 10.1016/0002-8703(91)90531-L He GX, 2020, J CARDIOTHORAC SURG, V15, DOI 10.1186/s13019-020-01260-6 Ivanovic J, 2014, INTERACT CARDIOV TH, V18, P340, DOI 10.1093/icvts/ivt520 Jakobsen CJ, 2007, J CARDIOTHOR VASC AN, V21, P664, DOI 10.1053/j.jvca.2007.03.002 Jakobsen CJ, 1997, J CARDIOTHOR VASC AN, V11, P746, DOI 10.1016/S1053-0770(97)90169-5 Jiang JD, 2021, J CARDIOTHOR VASC AN, V35, P1424, DOI 10.1053/j.jvca.2020.09.107 Kanaya N, 2003, ANESTHESIOLOGY, V98, P34, DOI 10.1097/00000542-200301000-00009 Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244 Kawanishi R, 2022, BMC ANESTHESIOL, V22, DOI 10.1186/s12871-022-01669-7 Lancaster TS, 2016, ANN THORAC SURG, V102, P1181, DOI 10.1016/j.athoracsur.2016.06.066 Li F, 2015, BMC ANESTHESIOL, V15, DOI 10.1186/s12871-015-0107-8 Li GR, 1996, CIRC RES, V78, P689, DOI 10.1161/01.RES.78.4.689 Li GR, 2008, CIRCULATION, V117, P2449, DOI 10.1161/CIRCULATIONAHA.108.769554 Liu Q, 2011, ACTA PHARMACOL SIN, V32, P817, DOI 10.1038/aps.2011.42 Materazzo C, 2007, EUR J CARDIO-THORAC, V31, P812, DOI 10.1016/j.ejcts.2007.02.007 McKenna RJ, 2006, ANN THORAC SURG, V81, P421, DOI 10.1016/j.athoracsur.2005.07.078 Min JJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152060 Muranishi Y, 2017, SURG TODAY, V47, P252, DOI 10.1007/s00595-016-1380-y Muzi M, 1996, ANESTHESIOLOGY, V85, P737, DOI 10.1097/00000542-199610000-00008 Nattel S, 2002, DRUGS, V62, P2377, DOI 10.2165/00003495-200262160-00005 Odening KE, 2019, EUROPACE, V21, P366, DOI 10.1093/europace/euy215 Ohtaka K, 2013, ANN THORAC SURG, V95, P1924, DOI 10.1016/j.athoracsur.2013.03.005 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Owczuk R, 2008, CLIN EXP PHARMACOL P, V35, P1071, DOI 10.1111/j.1440-1681.2008.04963.x Riber LP, 2014, ANN THORAC SURG, V98, P1989, DOI 10.1016/j.athoracsur.2014.06.069 Riddersholm S, 2019, STROKE, V50, P1052, DOI 10.1161/STROKEAHA.118.024496 Seguin P, 2004, CRIT CARE MED, V32, P722, DOI 10.1097/01.CCM.0000114579.56430.E0 Senoner T, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/8782387 Shaver CM, 2015, CRIT CARE MED, V43, P2104, DOI 10.1097/CCM.0000000000001166 SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Weibel S, 2021, ANAESTHESIA, V76, P962, DOI 10.1111/anae.15295 Wu DH, 2012, ANN THORAC SURG, V94, P193, DOI 10.1016/j.athoracsur.2012.03.057 Wu MH, 1997, BRIT J PHARMACOL, V121, P617, DOI 10.1038/sj.bjp.0701155 Xin YZ, 2014, EUR J CARDIO-THORAC, V45, P247, DOI 10.1093/ejcts/ezt383 Yamamoto T, 2016, SURG TODAY, V46, P780, DOI 10.1007/s00595-015-1233-0 Yang J, 2014, INT J MED SCI, V11, P863, DOI 10.7150/ijms.8912 Yang L, 2015, ANESTHESIOLOGY, V122, P571, DOI 10.1097/ALN.0000000000000495 Yoshizawa T, 2014, INT HEART J, V55, P422, DOI 10.1536/ihj.14-052 Zafeiropoulos S, 2022, J AM COLL CARDIOL, V79, P682, DOI 10.1016/j.jacc.2021.12.010 NR 66 TC 2 Z9 3 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 2 PY 2023 VL 18 IS 5 AR e0285120 DI 10.1371/journal.pone.0285120 PG 15 WC Multidisciplinary Sciences WE Science Citation Index Expanded (SCI-EXPANDED) SC Science & Technology - Other Topics GA F8OM4 UT WOS:000984886700026 PM 37130135 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Chang, WT Lin, HW Chang, TC Lin, SH Li, YH AF Chang, Wei-Ting Lin, Hui-Wen Chang, Ting-Chia Lin, Sheng-Hsiang Li, Yi-Heng TI The association between tyrosine kinase inhibitors and fatal arrhythmia in patients with non-small cell lung cancer in Taiwan SO FRONTIERS IN ONCOLOGY LA English DT Article DE NSCLC; tyrosine kinase inhibitors; platinum analogues; death; arrhythmia ID CARDIOTOXICITY; SURVIVAL; THERAPY; TRANSACTIVATION; CHEMOTHERAPY; MECHANISMS; TOXICITY AB ObjectiveAs a standard therapy, tyrosine kinase inhibitors (TKIs) improved survival in patients with non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) mutation. However, treatment-related cardiotoxicity, particularly arrhythmia, cannot be ignored. With the prevalence of EGFR mutations in Asian populations, the risk of arrhythmia among patients with NSCLC remains unclear. MethodsUsing data from the Taiwanese National Health Insurance Research Database and National Cancer Registry, we identified patients with NSCLC from 2001 to 2014. Using Cox proportional hazards models, we analyzed outcomes of death and arrhythmia, including ventricular arrhythmia (VA), sudden cardiac death (SCD), and atrial fibrillation (AF). The follow-up duration was three years. ResultsIn total, 3876 patients with NSCLC treated with TKIs were matched to 3876 patients treated with platinum analogues. After adjusting for age, sex, comorbidities, and anticancer and cardiovascular therapies, patients receiving TKIs had a significantly lower risk of death (adjusted HR: 0.767; CI: 0.729-0.807, p < 0.001) than those receiving platinum analogues. Given that approximately 80% of the studied population reached the endpoint of mortality, we also adjusted for mortality as a competing risk. Notably, we observed significantly increased risks of both VA (adjusted sHR: 2.328; CI: 1.592-3.404, p < 0.001) and SCD (adjusted sHR: 1.316; CI: 1.041-1.663, p = 0.022) among TKI users compared with platinum analogue users. Conversely, the risk of AF was similar between the two groups. In the subgroup analysis, the increasing risk of VA/SCD persisted regardless of sex and most cardiovascular comorbidities. ConclusionsCollectively, we highlighted a higher risk of VA/SCD in TKI users than in patients receiving platinum analogues. Further research is needed to validate these findings. C1 [Chang, Wei-Ting; Lin, Sheng-Hsiang] Natl Cheng Kung Univ, Inst Clin Med, Coll Med, Tainan, Taiwan. [Chang, Wei-Ting] Chi Mei Med Ctr, Dept Internal Med, Div Cardiol, Tainan, Taiwan. [Chang, Wei-Ting] Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan. [Lin, Hui-Wen; Li, Yi-Heng] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med, Tainan, Taiwan. [Lin, Hui-Wen; Lin, Sheng-Hsiang] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Biostat Consulting Ctr, Tainan, Taiwan. [Chang, Ting-Chia] Chi Mei Med Ctr, Dept Internal Med, Div Pulmonol, Tainan, Taiwan. [Lin, Sheng-Hsiang] Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, Tainan, Taiwan. C3 National Cheng Kung University; Chi Mei Hospital; Southern Taiwan University of Science & Technology; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital; Chi Mei Hospital; National Cheng Kung University RP Lin, SH (corresponding author), Natl Cheng Kung Univ, Inst Clin Med, Coll Med, Tainan, Taiwan.; Li, YH (corresponding author), Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med, Tainan, Taiwan.; Lin, SH (corresponding author), Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Biostat Consulting Ctr, Tainan, Taiwan.; Lin, SH (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, Tainan, Taiwan. EM shlin922@mail.ncku.edu.tw; heng@mail.ncku.edu.tw RI Chang, Wei-Ting/PHO-3872-2026 OI Chang, Wei-Ting/0000-0001-9525-2144 CR Alanazi A, 2021, LUNG CANCER MANAG, V10, DOI 10.2217/lmt-2020-0011 Albini A, 2010, JNCI-J NATL CANCER I, V102, P14, DOI 10.1093/jnci/djp440 Anand K, 2019, JACC-CARDIOONCOL, V1, P172, DOI 10.1016/j.jaccao.2019.10.006 Austin PC, 2011, MULTIVAR BEHAV RES, V46, P399, DOI 10.1080/00273171.2011.568786 Avan A, 2015, ONCOLOGIST, V20, P411, DOI 10.1634/theoncologist.2014-0044 Batson S, 2017, ONCOTARGETS THER, V10, P2473, DOI 10.2147/OTT.S134382 Belzile-Dugas E, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.121.021686 Bonura F, 2012, CARDIOVASC TOXICOL, V12, P93, DOI 10.1007/s12012-011-9141-z Burdett S, 2008, J CLIN ONCOL, V26, P4617, DOI 10.1200/JCO.2008.17.7162 Chang HM, 2017, J AM COLL CARDIOL, V70, P2552, DOI [10.1016/j.jacc.2017.09.1095, 10.1016/j.jacc.2017.09.1096] Chang WT, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051672 Chen MH, 2008, CIRCULATION, V118, P84, DOI 10.1161/CIRCULATIONAHA.108.776831 Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087 Cheng MF, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.758010 Di Lisi D, 2017, INT J CARDIOL, V227, P11, DOI 10.1016/j.ijcard.2016.11.174 Du ZF, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0782-4 Ewer MS, 2021, J CLIN ONCOL, V39, P328, DOI 10.1200/JCO.20.01171 Ferroni P, 2011, REJUV RES, V14, P293, DOI 10.1089/rej.2010.1141 Grisanti LA, 2014, J MOL CELL CARDIOL, V72, P39, DOI 10.1016/j.yjmcc.2014.02.009 Heuckmann JM, 2012, J CLIN ONCOL, V30, P3417, DOI 10.1200/JCO.2012.43.1825 Huang K, 2021, PHARMACOEPIDEM DR S, V30, P97, DOI 10.1002/pds.5168 Jie Ling-Jun, 2021, Eur J Pharmacol, V910, P174441, DOI [10.1016/j.ejphar.2021.174441, 10.1016/j.ejphar.2021.174441] Khouri MG, 2015, FUTUR CARDIOL, V11, P471, DOI [10.2217/fca.15.16, 10.2217/FCA.15.16] Kornej J, 2020, CIRC RES, V127, P4, DOI 10.1161/CIRCRESAHA.120.316340 LASSEN U, 1995, J CLIN ONCOL, V13, P1215, DOI 10.1200/JCO.1995.13.5.1215 Lin JJ, 2016, J THORAC ONCOL, V11, P556, DOI 10.1016/j.jtho.2015.12.103 Missan S, 2006, J PHYSIOL-LONDON, V573, P469, DOI 10.1113/jphysiol.2005.104422 Noma T, 2007, J CLIN INVEST, V117, P2445, DOI 10.1172/JCI31901 Novo G, 2020, ONCOLOGY-BASEL, V98, P445, DOI 10.1159/000505486 Oronsky B, 2017, CANCER CHEMOTH PHARM, V80, P895, DOI 10.1007/s00280-017-3392-8 Orphanos GS, 2009, ACTA ONCOL, V48, P964, DOI 10.1080/02841860903229124 Shi Y, 2014, J THORAC ONCOL, V9, P154, DOI 10.1097/JTO.0000000000000033 Tamargo J, 2012, EXPERT OPIN DRUG SAF, V11, P615, DOI 10.1517/14740338.2012.698609 Waliany S, 2021, J THORAC ONCOL, V16, P2029, DOI 10.1016/j.jtho.2021.07.030 Zellos L, 2009, J THORAC CARDIOV SUR, V137, P453, DOI 10.1016/j.jtcvs.2008.07.055 NR 35 TC 5 Z9 5 U1 1 U2 2 PU FRONTIERS MEDIA SA PI LAUSANNE PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND SN 2234-943X J9 FRONT ONCOL JI Front. Oncol. PD APR 17 PY 2023 VL 13 AR 1172036 DI 10.3389/fonc.2023.1172036 PG 8 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA E6AA6 UT WOS:000976336600001 PM 37139162 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Raisi-Estabragh, Z Cooper, J McCracken, C Crosbie, EJ Walter, FM Manisty, CH Robson, J Mamas, MA Harvey, NC Neubauer, S Petersen, SE AF Raisi-Estabragh, Zahra Cooper, Jackie McCracken, Celeste Crosbie, Emma J. Walter, Fiona M. Manisty, Charlotte H. Robson, John Mamas, Mamas A. Harvey, Nicholas C. Neubauer, Stefan Petersen, Steffen E. TI Incident cardiovascular events and imaging phenotypes in UK Biobank participants with past cancer SO HEART LA English DT Article DE epidemiology; magnetic resonance imaging ID RISK-FACTORS; DISEASE; CARDIOTOXICITY; PREVALENCE AB ObjectivesTo evaluate incident cardiovascular outcomes and imaging phenotypes in UK Biobank participants with previous cancer. MethodsCancer and cardiovascular disease (CVD) diagnoses were ascertained using health record linkage. Participants with cancer history (breast, lung, prostate, colorectal, uterus, haematological) were propensity matched on vascular risk factors to non-cancer controls. Competing risk regression was used to calculate subdistribution HRs (SHRs) for associations of cancer history with incident CVD (ischaemic heart disease (IHD), non-ischaemic cardiomyopathy (NICM), heart failure (HF), atrial fibrillation/flutter, stroke, pericarditis, venous thromboembolism (VTE)) and mortality outcomes (any CVD, IHD, HF/NICM, stroke, hypertensive disease) over 11.8 +/- 1.7 years of prospective follow-up. Linear regression was used to assess associations of cancer history with left ventricular (LV) and left atrial metrics. ResultsWe studied 18 714 participants (67% women, age: 62 (IQR: 57-66) years, 97% white ethnicities) with cancer history, including 1354 individuals with cardiovascular magnetic resonance. Participants with cancer had high burden of vascular risk factors and prevalent CVDs. Haematological cancer was associated with increased risk of all incident CVDs considered (SHRs: 1.92-3.56), larger chamber volumes, lower ejection fractions, and poorer LV strain. Breast cancer was associated with increased risk of selected CVDs (NICM, HF, pericarditis and VTE; SHRs: 1.34-2.03), HF/NICM death, hypertensive disease death, lower LV ejection fraction, and lower LV global function index. Lung cancer was associated with increased risk of pericarditis, HF, and CVD death. Prostate cancer was linked to increased VTE risk. ConclusionsCancer history is linked to increased risk of incident CVDs and adverse cardiac remodelling independent of shared vascular risk factors. C1 [Raisi-Estabragh, Zahra; Cooper, Jackie; Petersen, Steffen E.] Queen Mary Univ London, William Harvey Res Inst, NIHR Barts Biomed Res Ctr, London, England. [Raisi-Estabragh, Zahra; Manisty, Charlotte H.; Petersen, Steffen E.] Barts Hlth NHS Trust, St Bartholomews Hosp, Barts Heart Ctr, London, England. [McCracken, Celeste; Neubauer, Stefan] Univ Oxford, Oxford Univ Hosp NHS Fdn Trust, NIHR Oxford Biomed Res Ctr, Div Cardiovasc Med,Radcliffe Dept Med, Oxford, England. [Crosbie, Emma J.] Univ Manchester, Fac Biol Med & Hlth, Div Canc Sci, Manchester, England. [Crosbie, Emma J.] Manchester Univ NHS Fdn Trust, St Marys Hosp, Manchester Acad Hlth Sci Ctr, Dept Obstet & Gynaecol, Manchester, England. [Walter, Fiona M.; Robson, John] Queen Mary Univ London, Wolfson Inst Populat Hlth, London, England. [Walter, Fiona M.] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England. [Manisty, Charlotte H.] UCL, Inst Cardiovasc Sci, London, England. [Mamas, Mamas A.] Univ Manchester, Inst Populat Hlth, Manchester, England. [Mamas, Mamas A.] Keele Univ, Keele Cardiovasc Res Grp, Keele, England. [Harvey, Nicholas C.] Univ Southampton, MRC Lifecourse Epidemiol Ctr, Southampton, England. [Harvey, Nicholas C.] Univ Southampton, NIHR Southampton Biomed Res Ctr, Southampton, England. [Harvey, Nicholas C.] Univ Hosp Southampton NHS Fdn Trust, Southampton, England. [Petersen, Steffen E.] Hlth Data Res UK, London, England. [Petersen, Steffen E.] Alan Turing Inst, London, England. [Raisi-Estabragh, Zahra] Queen Mary Univ London, William Harvey Res Inst, London E1 4NS, England. C3 University of London; Queen Mary University London; University of London; Queen Mary University London; Barts Health NHS Trust; University of Oxford; Oxford University Hospitals NHS Foundation Trust; University of Manchester; University of Manchester; Manchester University NHS Foundation Trust; University of London; Queen Mary University London; University of Cambridge; University of London; University College London; University of Manchester; Keele University; University of Southampton; University of Southampton; University of Southampton; University Hospital Southampton NHS Foundation Trust; Alan Turing Institute; University of London; Queen Mary University London RP Raisi-Estabragh, Z (corresponding author), Barts Hlth NHS Trust, St Bartholomews Hosp, Barts Heart Ctr, London, England.; Raisi-Estabragh, Z (corresponding author), Queen Mary Univ London, William Harvey Res Inst, London E1 4NS, England. EM zahraraisi@doctors.org.uk RI ; Walter, Fiona/GYR-1347-2022; Petersen, Steffen/A-8389-2011; Sahm, Felix/GQY-8202-2022; Neubauer, Stefan/B-8448-2011; Harvey, Nicholas/JWO-4341-2024; Manisty, Charlotte/AAN-3723-2021; Mamas, Mamas/A-2549-2019 OI Davidson, Emma/0000-0003-0284-8630; Petersen, Steffen/0000-0003-4622-5160; Harvey, Nicholas/0000-0002-8194-2512; Manisty, Charlotte/0000-0003-0245-7090; Mamas, Mamas/0000-0001-9241-8890; Raisi-Estabragh, Zahra/0000-0002-7757-5465 FU British Heart Foundation Clinical Research Training Fellowship [FS/17/81/33318]; NIHR Advanced Fellowship [NIHR300650]; NIHR Manchester Biomedical Research Centre [IS-BRC- 1215-20007]; Cancer Research UK [CC8640/A23385]; Oxford NIHR Biomedical Research Centre; Oxford British Heart Foundation Centre of Research Excellence; 'SmartHeart' EPSRC programme [EP/P001009/1]; European Union [825903]; British Heart Foundation; MRC [MC_PC_21003, MC_PC_21001]; NIHR Southampton Biomedical Research Centre; NIHR Biomedical Research Centres at University College London Hospitals; Barts Health NHS Trusts; London Medical Imaging and Artificial Intelligence Centre for Value Based Healthcare (AI4VBH); Data to Early Diagnosis and Precision Medicine strand of the government's Industrial Strategy Challenge Fund; Medical Research Council [MR/L016311/1]; EPSRC [EP/P001009/1] Funding Source: UKRI; MRC [MR/L016311/1, MC_PC_21000, MC_PC_21001, MC_UU_12011/2, MC_PC_21022, MC_PC_21003] Funding Source: UKRI; British Heart Foundation [PG/14/89/31194] Funding Source: researchfish; Cancer Research UK [23385] Funding Source: researchfish; Engineering and Physical Sciences Research Council [EP/P001009/1] Funding Source: researchfish; Medical Research Council [MC_U147585819, MC_UP_A620_1015, U1475000001, G0400491, MC_U147585824, G0601019, MC_UU_12011/2, MC_UU_12011/1, U1475000002, MC_UP_A620_1014, MC_U147585827, MR/L016311/1] Funding Source: researchfish; National Institute for Health Research [10/33/04, NF-SI-0513-10085, NF-SI-0508-10082] Funding Source: researchfish FX ZR-E recognizes the National Institute for Health Research (NIHR) Integrated Academic Training programme which supports her Academic Clinical Lectureship post and was also supported by British Heart Foundation Clinical Research Training Fellowship No. FS/17/81/33318. EJC is supported by an NIHR Advanced Fellowship (NIHR300650) and the NIHR Manchester Biomedical Research Centre (IS-BRC- 1215-20007). FMW is co-Director of the CanTest Collaborative, which is funded by Cancer Research UK (CC8640/A23385). SN and CM were supported by the Oxford NIHR Biomedical Research Centre and SN by Oxford NIHR Biomedical Research Centre and the Oxford British Heart Foundation Centre of Research Excellence. SEP acknowledges support from the 'SmartHeart' EPSRC programme grant (www. nihr.ac.uk; EP/P001009/1) and the European Union's Horizon 2020 research and innovation programme under grant agreement No 825903 (euCanSHare project). SEP and SN acknowledge the British Heart Foundation for funding the manual analysis to create a cardiovascular magnetic resonance imaging reference standard for the UK Biobank imaging-resource in 5000 CMR scans (www.bhf.org.uk; PG/14/89/31194). NCH acknowledges support from MRC (MC_PC_21003; MC_PC_21001) and NIHR Southampton Biomedical Research Centre. CHM is supported directly and indirectly from the NIHR Biomedical Research Centres at University College London Hospitals and Barts Health NHS Trusts. Barts Charity (G-002346) contributed to fees required to access UK Biobank data [access application #2964]. This article is supported by the London Medical Imaging and Artificial Intelligence Centre for Value Based Healthcare (AI4VBH), which is funded from the Data to Early Diagnosis and Precision Medicine strand of the government's Industrial Strategy Challenge Fund, managed and delivered by Innovate UK on behalf of UK Research and Innovation (UKRI). Views expressed are those of the authors and not necessarily those of the AI4VBH Consortium members, the NHS, Innovate UK, or UKRI. This project was enabled through access to the MRC eMedLab Medical Bioinformatics infrastructure, supported by the Medical Research Council (www.mrc.ac.uk; MR/L016311/1). The funders did not have any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. CR Alam N, 2020, LANCET, V395, P1903, DOI 10.1016/S0140-6736(20)30222-1 [Anonymous], 2007, UK Biobank: Protocol for A LargeScale Prospective Epidemiological Resource, V06, P1 [Anonymous], Cancer registration statistics Austin PC, 2011, PHARM STAT, V10, P150, DOI 10.1002/pst.433 Bai WJ, 2018, J CARDIOVASC MAGN R, V20, DOI 10.1186/s12968-018-0471-x Belzile-Dugas E, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.121.021686 Cohen AT, 2017, THROMB HAEMOSTASIS, V117, P57, DOI 10.1160/TH15-08-0686 Crosbie EJ, 2022, LANCET, V399, P1412, DOI 10.1016/S0140-6736(22)00323-3 Duléry R, 2021, JACC-CARDIOONCOL, V3, P250, DOI 10.1016/j.jaccao.2021.02.011 Ferlay J, 2018, EUR J CANCER, V103, P356, DOI 10.1016/j.ejca.2018.07.005 Force T, 2007, NAT REV CANCER, V7, P332, DOI 10.1038/nrc2106 Hann E, 2021, MED IMAGE ANAL, V71, DOI 10.1016/j.media.2021.102029 Kitson SJ, 2018, GYNECOL ONCOL, V148, P154, DOI 10.1016/j.ygyno.2017.11.019 Koene RJ, 2016, CIRCULATION, V133, P1104, DOI 10.1161/CIRCULATIONAHA.115.020406 Liu D, 2019, AGING-US, V11, P7948, DOI 10.18632/aging.102301 Lyon Alexander R, 2022, Eur Heart J Cardiovasc Imaging, V23, pe333, DOI [10.1093/eurheartj/ehac244, 10.1093/ehjci/jeac106] Petersen SE, 2016, J CARDIOVASC MAGN R, V18, DOI 10.1186/s12968-016-0227-4 Raisi-Estabragh Z, 2023, EUR HEART J-QUAL CAR, V9, P54, DOI 10.1093/ehjqcco/qcac016 Ratosa I, 2019, REP PRACT ONCOL RADI, V24, P629, DOI 10.1016/j.rpor.2019.09.002 Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101 StataCorp L., 2015, STATACORP STATA STAT Strongman H, 2019, LANCET, V394, P1041, DOI 10.1016/S0140-6736(19)31674-5 Sturgeon KM, 2019, EUR HEART J, V40, P3889, DOI 10.1093/eurheartj/ehz766 Timmis A, 2022, EUR HEART J, V43, P716, DOI 10.1093/eurheartj/ehab892 Nguyen TL, 2017, BMC MED RES METHODOL, V17, DOI 10.1186/s12874-017-0338-0 van Nimwegen FA, 2015, JAMA INTERN MED, V175, P1007, DOI 10.1001/jamainternmed.2015.1180 Volkova M, 2011, CURR CARDIOL REV, V7, P214, DOI 10.2174/157340311799960645 Zhang XC, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247919 NR 28 TC 28 Z9 31 U1 1 U2 7 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1355-6037 EI 1468-201X J9 HEART JI Heart PD JUL PY 2023 VL 109 IS 13 BP 1007 EP 1015 DI 10.1136/heartjnl-2022-321888 EA MAR 2023 PG 9 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA L3II1 UT WOS:000981498700001 PM 37072241 OA Green Submitted, Green Published, hybrid DA 2026-04-17 ER PT J AU Kobat, H Davidson, M Elkonaissi, I Foreman, E Nabhani-Gebara, S AF Kobat, Hasan Davidson, Michael Elkonaissi, Islam Foreman, Emma Nabhani-Gebara, Shereen TI Multiple cardiotoxicities during osimertinib therapy SO JOURNAL OF ONCOLOGY PHARMACY PRACTICE LA English DT Article DE Lung cancer; anti-cancer treatment; drug safety; cardiotoxicity; case report ID PHASE-III; CHEMOTHERAPY; GEMCITABINE; CRIZOTINIB AB Introduction The tyrosine-kinase inhibitor osimertinib is an oral anti-cancer agent that is used for the treatment of patients with metastatic non-small cell lung cancer harbouring sensitising EGFR mutations. Patients receiving osimertinib are at higher risk of developing cardiac toxicity, and here we present the case of a 72-year-old male who developed multiple cardiotoxicities during therapy (i.e. QTc prolongation, atrial fibrillation, heart failure). Case Report A 72-year-old white British, ex-smoker male patient was admitted to our cancer centre with adenocarcinoma of the lung. Afatinib, gefitinib, osimertinib, and carboplatin plus pemetrexed chemotherapy were the treatments he received. At the 15th month of osimertinib therapy, the patient developed QTc prolongation. Two weeks after the first incidence of QTc prolongation, electrocardiography showed rate-controlled atrial fibrillation. In addition to his atrial fibrillation, echocardiography revealed severely impaired left ventricular systolic function (left ventricular ejection fraction: 30%). Management and Outcomes Baseline to osimertinib, an electrocardiography investigation was carried out as per the protocol. Baseline drug history was reviewed and rosuvastatin was discontinued before initiating osimertinib as both drugs contribute to QTc prolongation. Dabigatran, bisoprolol, and digoxin were started for the treatment of atrial fibrillation. Ramipril and spironolactone were prescribed for the treatment of heart failure but osimertinib continued uneventfully. The patient died of non-small cell lung cancer. Discussion Recommendations for practical and clinically relevant baseline and on-treatment assessments are considered which may reduce the risk of cardiac toxicity during osimertinib therapy. These include baseline cardiac risk stratification, consideration of concomitant medications that may result in additive cardiac risk, and use of electrocardiography and echocardiography surveillance. C1 [Kobat, Hasan; Nabhani-Gebara, Shereen] Kingston Univ London, Sch Life Sci Pharm & Chem, Dept Pharm, Kingston Upon Thames, England. [Davidson, Michael] Royal Marsden NHS Fdn Trust, Lung Unit, London, England. [Elkonaissi, Islam] Sheikh Shakhbout Med City, Abu Dhabi, U Arab Emirates. [Foreman, Emma] Royal Marsden NHS Fdn Trust, Pharm Dept, London, England. [Kobat, Hasan] Kingston Univ London, Sch Life Sci Pharm & Chem, Dept Pharm, Penrhyn Rd, Kingston Upon Thames KT1 2EE, England. C3 Kingston University; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; Kingston University RP Kobat, H (corresponding author), Kingston Univ London, Sch Life Sci Pharm & Chem, Dept Pharm, Penrhyn Rd, Kingston Upon Thames KT1 2EE, England. EM k1411572@kingston.ac.uk RI Kobat, Hasan/CAE-8692-2022; Nabhani-Gebara, Shereen/M-7050-2017 OI Kobat, Hasan/0000-0003-1194-6427; Foreman, Emma/0000-0002-4348-9040; Nabhani-Gebara, Shereen/0000-0002-5784-4779 CR Anand K, 2019, JACC-CARDIOONCOL, V1, P172, DOI 10.1016/j.jaccao.2019.10.006 [Anonymous], 2015, NEW ENGL J MED, V373, P1582, DOI 10.1056/NEJMx150036 AstraZeneca Pharmaceuticals LP, 2015, TAGRISSOTM OS TABL O Bagnes C, 2010, CURR DRUG SAF, V5, P93, DOI 10.2174/157488610789869111 Cardinale D, 2018, J THORAC DIS, V10, pS4306, DOI 10.21037/jtd.2018.10.06 Fallah-Rad N, 2011, J AM COLL CARDIOL, V57, P2263, DOI 10.1016/j.jacc.2010.11.063 Heinzerling L, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0152-y Ikebe S, 2021, INT CANCER CONF J, V10, P68, DOI 10.1007/s13691-020-00450-2 Ito Shunsuke, 2020, Gan To Kagaku Ryoho, V47, P609 Jin Y, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00891 Kunimasa K, 2021, LUNG CANCER, V153, P186, DOI 10.1016/j.lungcan.2020.10.021 Moey MYY, 2020, JACC-CARDIOONCOL, V2, P491, DOI 10.1016/j.jaccao.2020.07.005 Mok Tony S, 2017, N Engl J Med, V376, P629, DOI 10.1056/NEJMoa1612674 NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154 Plante I, 2012, J PHARM SCI-US, V101, P868, DOI 10.1002/jps.22809 Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774 Scagliotti GV, 2008, J CLIN ONCOL, V26, P3543, DOI 10.1200/JCO.2007.15.0375 Shinomiya S, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000022301 Sollena Pietro, 2019, Drugs Context, V8, P212613, DOI [10.7573/dic.212613, 10.7573/dic.212613] Solomon BJ, 2014, NEW ENGL J MED, V371, P2167, DOI [10.1056/NEJMoa1408440, 10.1056/NEJMx150034] Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137 Soria JC, 2017, LANCET, V389, P917, DOI 10.1016/S0140-6736(17)30123-X Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660 Syrigos KN, 2010, ANN ONCOL, V21, P556, DOI 10.1093/annonc/mdp392 Tsai MF, 2014, WORLD J CLIN ONCOL, V5, P865, DOI 10.5306/wjco.v5.i5.865 Watanabe H, 2017, INTERNAL MED, V56, P2195, DOI 10.2169/internalmedicine.8344-16 NR 26 TC 1 Z9 2 U1 0 U2 5 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1078-1552 EI 1477-092X J9 J ONCOL PHARM PRACT JI J. Oncol. Pharm. Pract. PD FEB PY 2026 VL 32 IS 2 BP 392 EP 398 DI 10.1177/10781552231164301 EA MAR 2023 PG 7 WC Oncology; Pharmacology & Pharmacy WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Pharmacology & Pharmacy GA FM9LZ UT WOS:000954139300001 PM 36942434 OA Green Submitted, hybrid DA 2026-04-17 ER PT J AU Kashiwagi, M Hirai, Y Kuroi, A Ohashi, T Yata, Y Fusamoto, A Iguchi, H Higashimoto, N Tanimoto, T Tanaka, A Nishimura, Y AF Kashiwagi, Manabu Hirai, Yoshimitsu Kuroi, Akio Ohashi, Takuya Yata, Yumi Fusamoto, Aya Iguchi, Hideto Higashimoto, Natsuki Tanimoto, Takashi Tanaka, Atsushi Nishimura, Yoshiharu TI Relationship between postoperative atrial fibrillation and its recurrence after lung resection SO SURGERY TODAY LA English DT Article DE Lung cancer; Atrial fibrillation; Postoperative ID SUPRAVENTRICULAR ARRHYTHMIA; NATRIURETIC-PEPTIDE; PULMONARY RESECTION; NONCARDIAC SURGERY; CANCER; RISK; DYSRHYTHMIAS; STROKE AB PurposeAtrial fibrillation (AF) frequently occurs after pulmonary resection and is commonly referred to as postoperative atrial fibrillation (POAF). This study explored whether or not POAF is related to the recurrence of AF in the chronic phase.MethodsA total of 1311 consecutive patients without a history of AF who underwent lung resection based on a diagnosis of lung tumor were retrospectively analyzed.ResultsPOAF occurred in 46 patients (3.5%), and a logistic regression analysis revealed that the age (p < 0.05), history of hyperthyroidism (p < 0.05), and major lung resection (p < 0.05) were independent predictors of POAF. AF events in the chronic phase were observed in 15 (32.6%) and 45 (3.6%) patients with and without POAF, respectively. A Cox regression analysis revealed that POAF was the only independent predictor of AF development in the chronic phase (p < 0.01). The Kaplan-Meier curve and log-rank test revealed that the cumulative incidence of AF in the chronic phase was significantly higher in patients with POAF than in those without POAF (p < 0.01).ConclusionPOAF was an independent predictor for AF in the chronic phase after lung resection. Further investigations including cases of catheter ablation and optimal medical therapy for patients with POAF after lung resection are needed. C1 [Kashiwagi, Manabu; Kuroi, Akio; Higashimoto, Natsuki; Tanimoto, Takashi; Tanaka, Atsushi] Wakayama Med Univ, Dept Cardiovasc Med, 811-1 Kimiidera, Wakayama, Wakayama 6418509, Japan. [Hirai, Yoshimitsu; Ohashi, Takuya; Yata, Yumi; Fusamoto, Aya; Iguchi, Hideto; Nishimura, Yoshiharu] Wakayama Med Univ, Dept Thorac & Cardiovasc Surg, Wakayama, Japan. C3 Wakayama Medical University; Wakayama Medical University RP Kashiwagi, M (corresponding author), Wakayama Med Univ, Dept Cardiovasc Med, 811-1 Kimiidera, Wakayama, Wakayama 6418509, Japan. EM mkashi@wakayama-med.ac.jp FU JSPS KAKENHI [18K15858, 20K08406]; Grants-in-Aid for Scientific Research [20K08406] Funding Source: KAKEN FX AcknowledgementsThis work was supported in part by JSPS KAKENHI Grant Numbers 18K15858 and 20K08406. CR AMAR D, 1995, CHEST, V108, P349, DOI 10.1378/chest.108.2.349 Amar D, 1996, CHEST, V110, P437, DOI 10.1378/chest.110.2.437 Brathwaite D, 1998, CHEST, V114, P462, DOI 10.1378/chest.114.2.462 Butt JH, 2018, J AM COLL CARDIOL, V72, P2027, DOI 10.1016/j.jacc.2018.07.088 Cardinale D, 2007, CIRCULATION, V115, P1339, DOI 10.1161/CIRCULATIONAHA.106.647008 Ciriaco P, 2000, EUR J CARDIO-THORAC, V18, P12, DOI 10.1016/S1010-7940(00)00428-0 Curtis JJ, 1998, ANN THORAC SURG, V66, P1766, DOI 10.1016/S0003-4975(98)00942-4 Diab M, 2020, CIRC-ARRHYTHMIA ELEC, V13, DOI 10.1161/CIRCEP.119.008301 Dyszkiewicz W, 1998, EUR J CARDIO-THORAC, V13, P625, DOI 10.1016/S1010-7940(98)00084-0 Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864 Hamatani Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep31042 Higuchi S, 2019, CAN J CARDIOL, V35, P1449, DOI 10.1016/j.cjca.2019.07.008 Imperatori Andrea, 2012, J Cardiothorac Surg, V7, P4, DOI 10.1186/1749-8090-7-4 Ishibashi H, 2020, WORLD J SURG, V44, P3952, DOI 10.1007/s00268-020-05694-w Iwata T, 2016, SURG TODAY, V46, P877, DOI 10.1007/s00595-015-1258-4 Kanmanthareddy A, 2015, J CARDIOVASC ELECTR, V26, P385, DOI 10.1111/jce.12619 Kanzaki R, 2017, SURG TODAY, V47, P795, DOI 10.1007/s00595-016-1436-z Maesen B, 2012, EUROPACE, V14, P159, DOI 10.1093/europace/eur208 McIntyre WF, 2021, CAN J CARDIOL, V37, P803, DOI 10.1016/j.cjca.2020.11.012 Natale A, 2021, CIRC-ARRHYTHMIA ELEC, V14, DOI 10.1161/CIRCEP.120.008867 Nojiri T, 2012, J THORAC CARDIOV SUR, V143, P488, DOI 10.1016/j.jtcvs.2011.09.003 Pisters R, 2010, CHEST, V138, P1093, DOI 10.1378/chest.10-0134 Polanczyk CA, 1998, ANN INTERN MED, V129, P279, DOI 10.7326/0003-4819-129-4-199808150-00003 Raman T, 2012, J THORAC CARDIOV SUR, V143, P482, DOI 10.1016/j.jtcvs.2011.08.025 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Sekine Y, 2001, CHEST, V120, P1783, DOI 10.1378/chest.120.6.1783 NR 26 TC 6 Z9 6 U1 0 U2 3 PU SPRINGER PI NEW YORK PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES SN 0941-1291 EI 1436-2813 J9 SURG TODAY JI Surg. Today PD OCT PY 2023 VL 53 IS 10 BP 1139 EP 1148 DI 10.1007/s00595-023-02670-4 EA MAR 2023 PG 10 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA S1VV3 UT WOS:000949615600001 PM 36894737 DA 2026-04-17 ER PT J AU Yegya-Raman, N Berlin, E Feigenberg, SJ Ky, B Sun, LV AF Yegya-Raman, Nikhil Berlin, Eva Feigenberg, Steven J. Ky, Bonnie Sun, Lova TI Cardiovascular Toxicity and Risk Mitigation with Lung Cancer Treatment SO CURRENT ONCOLOGY REPORTS LA English DT Review DE Cardiotoxicity; Cardio-oncology; Lung cancer; MACE; Radiation therapy; Immunotherapy ID DOSE-ESCALATION TRIALS; ATRIAL-FIBRILLATION; INDUCED CARDIOTOXICITY; CARDIAC TOXICITY; RADIATION-THERAPY; THROMBOEMBOLIC EVENTS; HEART SUBSTRUCTURES; RADIOTHERAPY; MANAGEMENT; DISEASE AB Purpose of ReviewPatients with lung cancer often have concomitant cardiovascular comorbidities and receive potentially cardiotoxic therapies. As oncologic outcomes improve, the relative impact of cardiovascular disease on lung cancer survivors is expected to increase. This review summarizes cardiovascular toxicities observed after treatment for lung cancer, as well as recommended risk mitigation strategies.Recent FindingsA variety of cardiovascular events may be observed after surgery, radiation therapy (RT), and systemic therapy. The risk of cardiovascular events after radiation therapy (RT) is higher than previously appreciated (23-32%), and RT dose to the heart is a modifiable risk factor. Targeted agents and immune checkpoint inhibitors have been associated with cardiovascular toxicities distinct from those of cytotoxic agents; these are rare but can be severe and require prompt intervention.Optimization of cardiovascular risk factors is important at all phases of cancer therapy and survivorship. Recommended practices for baseline risk assessment, preventive measures, and appropriate monitoring are discussed herein. C1 [Yegya-Raman, Nikhil; Berlin, Eva; Feigenberg, Steven J.] Univ Penn, Perelman Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA. [Ky, Bonnie] Univ Penn, Perelman Sch Med, Dept Med, Div Cardiol, Philadelphia, PA 19104 USA. [Sun, Lova] Univ Penn, Perelman Sch Med, Dept Med, Div Hematol Oncol, 3400 Civ Ctr Blvd,West Pavil,2nd Floor, Philadelphia, PA 19104 USA. C3 University of Pennsylvania; University of Pennsylvania; University of Pennsylvania RP Sun, LV (corresponding author), Univ Penn, Perelman Sch Med, Dept Med, Div Hematol Oncol, 3400 Civ Ctr Blvd,West Pavil,2nd Floor, Philadelphia, PA 19104 USA. EM Lova.Sun@pennmedicine.upenn.edu RI ; feigenberg, steven/X-9309-2018 OI Ky, Bonnie/0000-0002-6628-9981; FU NIH; American Heart Association; Pfizer; Roche; American College of Cardiology; National Cancer Institute [R01CA157823] Funding Source: NIH RePORTER FX Dr. Ky has received grants from NIH, and the American Heart Association, and other funding from Pfizer, Roche, and American College of Cardiology. Other authors have nothing to disclose. CR Alexandre J, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.018403 AlTurki A, 2020, CIRC-ARRHYTHMIA ELEC, V13, DOI 10.1161/CIRCEP.119.007437 Anand K, 2019, JACC-CARDIOONCOL, V1, P172, DOI 10.1016/j.jaccao.2019.10.006 [Anonymous], 2022, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), B-cell Lymphomas, Version 5 Antonia SJ, 2018, NEW ENGL J MED, V379, P2342, DOI 10.1056/NEJMoa1809697 Arbuck S G, 1993, J Natl Cancer Inst Monogr, P117 Armenian SH, 2017, J CLIN ONCOL, V35, P893, DOI 10.1200/JCO.2016.70.5400 Atkins KM, 2022, JCO CLIN CANCER INFO, V6, DOI 10.1200/CCI.21.00095 Atkins KM, 2021, INT J RADIAT ONCOL, V110, P1473, DOI 10.1016/j.ijrobp.2021.03.005 Atkins KM, 2021, JAMA ONCOL, V7, P206, DOI 10.1001/jamaoncol.2020.6332 Atkins KM, 2019, J AM COLL CARDIOL, V73, P2976, DOI 10.1016/j.jacc.2019.03.500 Aupérin A, 2010, J CLIN ONCOL, V28, P2181, DOI 10.1200/JCO.2009.26.2543 Banfill K, 2021, J THORAC ONCOL, V16, P216, DOI 10.1016/j.jtho.2020.11.002 Bergom C, 2021, JACC-CARDIOONCOL, V3, P343, DOI 10.1016/j.jaccao.2021.06.007 Bradley JD, 2020, J CLIN ONCOL, V38, P706, DOI 10.1200/JCO.19.01162 Bradley JD, 2019, J CLIN ONCOL, V37 Bradley JD, 2015, LANCET ONCOL, V16, P187, DOI 10.1016/S1470-2045(14)71207-0 Cardinale D, 2016, ANN SURG, V264, P244, DOI 10.1097/SLA.0000000000001626 Choueiri TK, 2011, J CLIN ONCOL, V29, P632, DOI 10.1200/JCO.2010.31.9129 Chun SG, 2017, J CLIN ONCOL, V35, P56, DOI 10.1200/JCO.2016.69.1378 Curigliano G, 2020, ANN ONCOL, V31, P171, DOI 10.1016/j.annonc.2019.10.023 D'Souza M, 2021, EUR HEART J, V42, P1621, DOI 10.1093/eurheartj/ehaa884 Dahlberg SE, 2010, J CLIN ONCOL, V28, P949, DOI 10.1200/JCO.2009.25.4482 Darby SC, 2013, NEW ENGL J MED, V368, P987, DOI 10.1056/NEJMoa1209825 Dess RT, 2017, J CLIN ONCOL, V35, P1395, DOI 10.1200/JCO.2016.71.6142 Devereaux PJ, 2017, JAMA-J AM MED ASSOC, V317, P1642, DOI 10.1001/jama.2017.4360 Drobni ZD, 2020, CIRCULATION, V142, P2299, DOI 10.1161/CIRCULATIONAHA.120.049981 Du SS, 2018, J THORAC ONCOL, V13, P510, DOI 10.1016/j.jtho.2017.12.002 Escudier M, 2017, CIRCULATION, V136, P2085, DOI 10.1161/CIRCULATIONAHA.117.030571 Ewer MS, 2021, J CLIN ONCOL, V39, P328, DOI 10.1200/JCO.20.01171 Fabiani I, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010037 Felip E, 2021, LANCET, V398, P1344, DOI 10.1016/S0140-6736(21)02098-5 Ferguson MK, 2014, ANN THORAC SURG, V97, P1135, DOI 10.1016/j.athoracsur.2013.12.032 Fleisher LA, 2014, J AM COLL CARDIOL, V64, P2373, DOI [10.1016/j.jacc.2014.07.945, 10.1016/j.jacc.2014.07.944] Forde PM, 2022, NEW ENGL J MED, V386, P1973, DOI 10.1056/NEJMoa2202170 Gettinger SN, 2016, LANCET ONCOL, V17, P1683, DOI 10.1016/S1470-2045(16)30392-8 Gong JY, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002771 Imperatori Andrea, 2012, J Cardiothorac Surg, V7, P4, DOI 10.1186/1749-8090-7-4 Islam KMM, 2015, CANCER EPIDEM BIOMAR, V24, P1079, DOI 10.1158/1055-9965.EPI-15-0036 Johnson-Hart CN, 2018, INT J RADIAT ONCOL, V102, P434, DOI 10.1016/j.ijrobp.2018.05.052 Karamichalis John M, 2006, Thorac Surg Clin, V16, P253, DOI 10.1016/j.thorsurg.2006.05.009 Kim KH, 2022, JAMA ONCOL, V8, P1624, DOI 10.1001/jamaoncol.2022.4202 Kocher F, 2015, CLIN LUNG CANCER, V16, P305, DOI 10.1016/j.cllc.2014.12.007 Laenens D, 2022, J CLIN ONCOL, V40, P3430, DOI 10.1200/JCO.21.01808 Leiva O, 2021, JACC-CARDIOONCOL, V3, P619, DOI 10.1016/j.jaccao.2021.08.011 Liu D, 2018, J THORAC DIS, V10, P5545, DOI 10.21037/jtd.2018.08.91 Lyon AR, 2020, EUR J HEART FAIL, V22, P1945, DOI 10.1002/ejhf.1920 Mahmood S, 2018, J AM COLL CARDIOL, V71, P699, DOI [10.1016/S0735-1097(18)31240-3, 10.1016/j.jacc.2018.02.037] García AM, 2021, REV ESP CARDIOL, V74, P438, DOI 10.1016/j.recesp.2020.11.014 McWilliam A, 2020, INT J RADIAT ONCOL, V108, P1073, DOI 10.1016/j.ijrobp.2020.06.031 McWilliam A, 2017, EUR J CANCER, V85, P106, DOI 10.1016/j.ejca.2017.07.053 Moore RA, 2011, J CLIN ONCOL, V29, P3466, DOI 10.1200/JCO.2011.35.5669 Morcos PN, 2017, CANCER CHEMOTH PHARM, V79, P559, DOI 10.1007/s00280-017-3253-5 Omland T, 2022, JACC-CARDIOONCOL, V4, P19, DOI 10.1016/j.jaccao.2022.01.101 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Pande A, 2007, ANTICANCER RES, V27, P3465 Paterson DI, 2022, JACC-CARDIOONCOL, V4, P85, DOI 10.1016/j.jaccao.2022.01.100 Pekmezi DW, 2011, ACTA ONCOL, V50, P167, DOI 10.3109/0284186X.2010.529822 Rao VJU, 2021, J AM COLL CARDIOL, V77, P2693, DOI 10.1016/j.jacc.2021.04.009 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Rubio-Infante N, 2021, EUR J HEART FAIL, V23, P1739, DOI 10.1002/ejhf.2289 Salem JE, 2018, LANCET ONCOL, V19, P1579, DOI 10.1016/S1470-2045(18)30608-9 Sandler AB, 2000, J CLIN ONCOL, V18, P122, DOI 10.1200/JCO.2000.18.1.122 Sandler AB, 2004, CLIN CANCER RES, V10, p4258S, DOI 10.1158/1078-0432.CCR-040023 Sazgary L, 2021, EUR HEART J-ACUTE CA, V10, P550, DOI 10.1093/ehjacc/zuaa008 Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086 Schonewolf CA, 2021, SEMIN RADIAT ONCOL, V31, P112, DOI 10.1016/j.semradonc.2020.11.005 Sellers D, 2018, ANAESTHESIA, V73, P34, DOI 10.1111/anae.14138 Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI 10.3322/caac.21708 Smilowitz NR, 2017, JAMA CARDIOL, V2, P181, DOI 10.1001/jamacardio.2016.4792 Stam B, 2017, RADIOTHER ONCOL, V123, P370, DOI 10.1016/j.radonc.2017.04.017 Stoltzfus KC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15639-5 Strongman H, 2022, JACC-CARDIOONCOL, V4, P113, DOI 10.1016/j.jaccao.2022.01.102 Tammemagi CM, 2003, INT J CANCER, V103, P792, DOI 10.1002/ijc.10882 Tartarone A, 2015, FUTURE ONCOL, V11, P2043, DOI 10.2217/fon.15.47 Thor M, 2020, CLIN CANCER RES, V26, P4643, DOI 10.1158/1078-0432.CCR-19-2627 Thuny F, 2022, EUR HEART J, V43, P4458, DOI 10.1093/eurheartj/ehac456 Thuny F, 2021, JACC-CARDIOONCOL, V3, P157, DOI 10.1016/j.jaccao.2020.12.001 van Nimwegen FA, 2016, J CLIN ONCOL, V34, P235, DOI 10.1200/JCO.2015.63.4444 Waliany S, 2021, JACC-CARDIOONCOL, V3, P137, DOI 10.1016/j.jaccao.2021.01.004 Wang K, 2022, INT J RADIAT ONCOL, V112, P188, DOI 10.1016/j.ijrobp.2021.08.017 Wang K, 2017, RADIOTHER ONCOL, V125, P293, DOI 10.1016/j.radonc.2017.10.001 Wang K, 2017, J CLIN ONCOL, V35, P1387, DOI 10.1200/JCO.2016.70.0229 World Cancer Research Fund, ABOUT US World Health Organization Fact Sheets, US Wu YL, 2020, NEW ENGL J MED, V383, P1711, DOI 10.1056/NEJMoa2027071 Xin YZ, 2014, EUR J CARDIO-THORAC, V45, P247, DOI 10.1093/ejcts/ezt383 Xu T, 2021, INT J RADIAT ONCOL, V111, P907, DOI 10.1016/j.ijrobp.2021.07.035 Yegya-Raman N, 2021, J THORAC ONCOL, V16, pS901 Yegya-Raman N, 2018, J THORAC DIS, V10, pS2474, DOI 10.21037/jtd.2018.07.29 Yegya-Raman N, 2018, J THORAC ONCOL, V13, P1508, DOI 10.1016/j.jtho.2018.05.028 Yegya-Raman N, 2018, INT J RADIAT ONCOL, V101, P1104, DOI 10.1016/j.ijrobp.2018.03.025 Yun JP, 2021, JACC-CARDIOONCOL, V3, P221, DOI 10.1016/j.jaccao.2021.03.006 Zaborowska-Szmit M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051268 Zhang LL, 2021, JACC-CARDIOONCOL, V3, P35, DOI 10.1016/j.jaccao.2020.11.012 Zhu RF, 2019, THORAC CANCER, V10, P8, DOI 10.1111/1759-7714.12910 NR 96 TC 15 Z9 18 U1 0 U2 6 PU SPRINGER PI NEW YORK PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES SN 1523-3790 EI 1534-6269 J9 CURR ONCOL REP JI Curr. Oncol. Rep. PD MAY PY 2023 VL 25 IS 5 BP 433 EP 444 DI 10.1007/s11912-023-01387-4 EA FEB 2023 PG 12 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA D4LV8 UT WOS:000936270900002 PM 36811807 DA 2026-04-17 ER PT J AU Sayegh, N Yirerong, J Agarwal, N Addison, D Fradley, M Cortes, J Weintraub, NL Sayed, N Raval, G Guha, A AF Sayegh, Nicolas Yirerong, Juliet Agarwal, Neeraj Addison, Daniel Fradley, Michael Cortes, Jorge Weintraub, Neal L. Sayed, Nazish Raval, Girindra Guha, Avirup TI Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors SO CURRENT CARDIOLOGY REPORTS LA English DT Review DE Tyrosine kinase inhibitor; Cardiovascular toxicity; Vascular endothelial growth factor; BCR-ABL; Bruton tyrosine kinase ID CELL LUNG-CANCER; CHRONIC LYMPHOCYTIC-LEUKEMIA; PREVIOUSLY TREATED PATIENTS; CONGESTIVE-HEART-FAILURE; ATRIAL-FIBRILLATION; ADVERSE EVENTS; TREATMENT-NAIVE; RISK-FACTORS; FOLLOW-UP; IN-VITRO AB Purpose of Review To provide a detailed overview of cardiovascular adverse events associated with the use of tyrosine kinase inhibitors across different tumor types. Recent Findings Despite an undeniable survival advantage of tyrosine kinase inhibitors (TKIs) in patients with hematologic or solid malignancies, the accompanying off-target cardiovascular adverse events can be life-threatening. In patients with B cell malignancies, the use of Bruton tyrosine kinase inhibitors has been associated with atrial and ventricular arrhythmias, as well as hypertension. Cardiovascular toxic profiles are heterogeneous among the several approved breakpoint cluster region (BCR)-ABL TKIS. Notably, imatinib might be cardioprotective. Vascular endothelial growth factor TKIs, constituting the central axis in the treatment of several solid tumors, including renal cell carcinoma and hepatocellular carcinoma, have strongly been associated with hypertension and arterial ischemic events. Epidermal growth factor TKIs as therapy for advanced non-small cell lung cancer (NSCLC) have been reported to be infrequently associated with heart failure and QT prolongation. Summary While tyrosine kinase inhibitors have been demonstrated to increase overall survival across different types of cancers, special consideration should be given to cardiovascular toxicities. High-risk patients can be identified by undergoing a comprehensive workup at baseline. C1 [Sayegh, Nicolas; Agarwal, Neeraj] Univ Utah, Huntsman Canc Inst, Dept Internal Med, Div Oncol, Salt Lake City, UT USA. [Yirerong, Juliet] Yale Bridgeport Hosp, Dept Internal Med, Div Cardiol, Bridgeport, CT USA. [Addison, Daniel; Guha, Avirup] Ohio State Univ, Cardiooncol Program, Div Cardiol, Med Ctr, Columbus, OH 43210 USA. [Fradley, Michael] Univ Penn, Dept Med, Div Cardiol, Philadelphia, PA USA. [Cortes, Jorge; Raval, Girindra] Augusta Univ, Dept Med, Div Hematol & Oncol, Med Coll Georgia, Augusta, GA USA. [Cortes, Jorge; Raval, Girindra; Guha, Avirup] Augusta Univ, Med Coll Georgia, Georgia Canc Ctr, Cardiooncol Program, 1410 Laney Walker Blvd,CN 5313, Augusta, GA 30912 USA. [Weintraub, Neal L.; Guha, Avirup] Augusta Univ, Med Coll Georgia, Dept Med, Div Cardiol, Augusta, GA 30912 USA. [Weintraub, Neal L.] Augusta Univ, Med Coll Georgia, Vasc Biol Ctr, Augusta, GA USA. [Sayed, Nazish] Stanford Univ, Cardiovasc Res Inst, Dept Vasc Surg, Palo Alto, CA USA. C3 Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Yale University; Yale New Haven Hospital; University System of Ohio; Ohio State University; University of Pennsylvania; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; Stanford University RP Guha, A (corresponding author), Ohio State Univ, Cardiooncol Program, Div Cardiol, Med Ctr, Columbus, OH 43210 USA.; Guha, A (corresponding author), Augusta Univ, Med Coll Georgia, Georgia Canc Ctr, Cardiooncol Program, 1410 Laney Walker Blvd,CN 5313, Augusta, GA 30912 USA.; Guha, A (corresponding author), Augusta Univ, Med Coll Georgia, Dept Med, Div Cardiol, Augusta, GA 30912 USA. EM aguha@augusta.edu RI SAYEGH, NICOLAS/AAV-4500-2021; Guha, Avirup/I-2611-2019; Cortes, Jorge/ABA-0627-2022 OI Guha, Avirup/0000-0003-0253-1174; Cortes, Jorge/0000-0002-8636-1071 FU NHLBI NIH HHS [L30 HL149063, K23 HL155890, R01 HL161002] Funding Source: Medline; National Heart Lung and Blood Institute [K23HL155890, R01HL161002] Funding Source: NIH RePORTER CR Abbas HA, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.668162 Abdel-Qadir H, 2021, J CLIN ONCOL, V39, P3453, DOI 10.1200/JCO.21.00693 Alexandre J, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.018403 Alhawiti N, 2016, THROMB RES, V145, P54, DOI 10.1016/j.thromres.2016.07.019 Anand K, 2019, JACC-CARDIOONCOL, V1, P172, DOI 10.1016/j.jaccao.2019.10.006 [Anonymous], 2019, TAGRISSO TABLETS 40 Baptiste F, 2019, OPEN HEART, V6, DOI 10.1136/openhrt-2019-001049 Baumgart B, 2017, CANCER CHEMOTH PHARM, V79, P711, DOI 10.1007/s00280-017-3264-2 Briasoulis A, 2022, J CARDIOVASC DEV DIS, V9, DOI 10.3390/jcdd9030066 Brown JR, 2018, LEUKEMIA, V32, P83, DOI 10.1038/leu.2017.175 Brown JR, 2017, HAEMATOLOGICA, V102, P1796, DOI 10.3324/haematol.2017.171041 Burger JA, 2015, NEW ENGL J MED, V373, P2425, DOI 10.1056/NEJMoa1509388 Burger JA, 2020, LEUKEMIA, V34, P787, DOI 10.1038/s41375-019-0602-x Byrd JC, 2021, J CLIN ONCOL, V39, P3441, DOI 10.1200/JCO.21.01210 Byrd JC, 2015, BLOOD, V125, P2497, DOI 10.1182/blood-2014-10-606038 Chen ST, 2022, J HEMATOL ONCOL, V15, DOI 10.1186/s13045-022-01302-7 Chintalgattu V, 2009, HEMATOL ONCOL CLIN N, V23, P97, DOI 10.1016/j.hoc.2008.11.004 Chitturi KR, 2022, CURR ONCOL REP, V24, P475, DOI 10.1007/s11912-022-01215-1 Choueiri TK, 2010, J CLIN ONCOL, V28, P2280, DOI 10.1200/JCO.2009.27.2757 Cicènas S, 2016, LUNG CANCER, V102, P30, DOI 10.1016/j.lungcan.2016.10.007 Cortes JE, 2013, NEW ENGL J MED, V369, P1783, DOI 10.1056/NEJMoa1306494 Cortes J, 2021, BLOOD, V138, P2042, DOI 10.1182/blood.2021012082 Cortes JE, 2018, BLOOD, V132, P393, DOI 10.1182/blood-2016-09-739086 Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337 D'Souza M, 2018, EUR J PREV CARDIOL, V25, P651, DOI 10.1177/2047487318759858 Dickerson T, 2019, BLOOD, V134, P1919, DOI 10.1182/blood.2019000840 Dobbin SJH, 2021, CLIN SCI, V135, P71, DOI 10.1042/CS20200305 Du ZF, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0782-4 Ewer Michael S, 2015, Cardiooncology, V1, P3, DOI [10.1186/s40959-015-0006-7, 10.1186/s40959-015-0006-7] Fradley MG, 2019, AM J CARDIOL, V124, P539, DOI 10.1016/j.amjcard.2019.05.029 Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038 Giles FJ, 2013, LEUKEMIA, V27, P1310, DOI 10.1038/leu.2013.69 González-Pacheco FR, 2006, AM J PHYSIOL-HEART C, V291, pH1395, DOI 10.1152/ajpheart.01277.2005 Gronich N, 2017, BRIT J CANCER, V116, P1366, DOI 10.1038/bjc.2017.88 Guha A, 2022, JACC-CARDIOONCOL, V4, P235, DOI 10.1016/j.jaccao.2022.05.007 Guha A, 2018, J AM COLL CARDIOL, V72, P697, DOI 10.1016/j.jacc.2018.06.002 Guignabert C, 2016, J CLIN INVEST, V126, P3207, DOI 10.1172/JCI86249 Gustafson D, 2020, CURR HEMATOL MALIG R, V15, P20, DOI 10.1007/s11899-020-00560-x Hamnvik OPR, 2015, CANCER-AM CANCER SOC, V121, P311, DOI 10.1002/cncr.28972 Herbst RS, 2011, LANCET, V377, P1846, DOI 10.1016/S0140-6736(11)60545-X Jiang L, 2019, HEART RHYTHM, V16, P1374, DOI 10.1016/j.hrthm.2019.04.008 Kantarjian HM, 2021, LEUKEMIA, V35, P440, DOI 10.1038/s41375-020-01111-2 Korashy HM, 2016, TOXICOL LETT, V252, P50, DOI 10.1016/j.toxlet.2016.04.011 Kota V, 2021, LEUKEMIA RES, V111, DOI 10.1016/j.leukres.2021.106690 Kunimasa K, 2021, LUNG CANCER, V153, P186, DOI 10.1016/j.lungcan.2020.10.021 Kunimasa K, 2020, JACC-CARDIOONCOL, V2, P1, DOI 10.1016/j.jaccao.2020.02.003 Kus T, 2015, ONCOTARGETS THER, V8, P1341, DOI 10.2147/OTT.S84480 Lipsky A, 2020, HEMATOL-AM SOC HEMAT, P336, DOI 10.1182/hematology.2020000118 Liu B, 2016, ONCOTARGET, V7, P67661, DOI 10.18632/oncotarget.11813 Lynch DR, 2011, J THROMB THROMBOLYS, V32, P120, DOI 10.1007/s11239-010-0539-4 Lyon AR, 2020, EUR J HEART FAIL, V22, P1945, DOI 10.1002/ejhf.1920 Mato AR, 2018, CANCER BIOL THER, V19, P1, DOI 10.1080/15384047.2017.1394554 McMullen JR, 2014, BLOOD, V124, P3829, DOI 10.1182/blood-2014-10-604272 Metibemu DS, 2019, EGYPTIAN J MED HUMAN, V20, DOI 10.1186/s43042-019-0035-0 Miklos D, 2017, BLOOD, V130, P2243, DOI 10.1182/blood-2017-07-793786 Mok Tony S, 2017, N Engl J Med, V376, P629, DOI 10.1056/NEJMoa1612674 Montani D, 2012, CIRCULATION, V125, P2128, DOI 10.1161/CIRCULATIONAHA.111.079921 Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525 National Comprehensive Cancer Network, 2022, CHRON MYEL LEUK VERS Nuvola G, 2019, J THORAC ONCOL, V14, pE145, DOI 10.1016/j.jtho.2019.02.027 O'Brien S, 2018, CL LYMPH MYELOM LEUK, V18, P648, DOI 10.1016/j.clml.2018.06.016 O'Brien S, 2016, LANCET ONCOL, V17, P1409, DOI 10.1016/S1470-2045(16)30212-1 Omori S, 2018, J THORAC ONCOL, V13, pE207, DOI 10.1016/j.jtho.2018.05.020 Orphanos GS, 2009, ACTA ONCOL, V48, P964, DOI 10.1080/02841860903229124 Pineda-Gayoso R, 2020, CURR TREAT OPTION ON, V21, DOI 10.1007/s11864-020-00764-6 Pinquié F, 2016, ONCOLOGY-BASEL, V90, P176, DOI 10.1159/000444186 Qi WX, 2014, BRIT J CLIN PHARMACO, V78, P748, DOI 10.1111/bcp.12387 Qi WX, 2013, CANCER CHEMOTH PHARM, V71, P431, DOI 10.1007/s00280-012-2025-5 Réa D, 2021, BLOOD, V138, P2031, DOI 10.1182/blood.2020009984 Reda G, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0626-0 Rini BI, 2011, LANCET, V378, P1931, DOI 10.1016/S0140-6736(11)61613-9 Sadiq S, 2019, LEUKEMIA, V33, P1810, DOI 10.1038/s41375-018-0337-0 SAGIE A, 1992, AM J CARDIOL, V70, P797, DOI 10.1016/0002-9149(92)90562-D Salem JE, 2019, J AM COLL CARDIOL, V74, P1667, DOI 10.1016/j.jacc.2019.07.056 Scemblix United States Prescribing Information, 2021, DOCS LAB 2021 Shah AM, 2015, EUR HEART J, V36, P623, DOI 10.1093/eurheartj/ehu035 Shah NP, 2008, J CLIN ONCOL, V26, P3204, DOI 10.1200/JCO.2007.14.9260 Shah RR, 2013, DRUG SAFETY, V36, P295, DOI 10.1007/s40264-013-0047-5 Sharman JP, 2020, LANCET, V395, P1278, DOI 10.1016/S0140-6736(20)30262-2 Sonpavde G, 2013, CRIT REV ONCOL HEMAT, V87, P80, DOI 10.1016/j.critrevonc.2012.12.006 Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137 Tang ZW, 2022, ANTI-CANCER DRUG, V33, pE840, DOI 10.1097/CAD.0000000000001244 Thein KZ, 2018, ANN ONCOL, V29, P500 Thomas A, 2012, HEMATOL ONCOL CLIN N, V26, P589, DOI 10.1016/j.hoc.2012.02.001 Totzeck M, 2018, EUR J PREV CARDIOL, V25, P482, DOI 10.1177/2047487318755193 Tran H, 2004, JAMA-J AM MED ASSOC, V292, P1867, DOI 10.1001/jama.292.15.1867 Trent JC, 2010, CANCER-AM CANCER SOC, V116, P184, DOI 10.1002/cncr.24683 Treon SP, 2015, NEW ENGL J MED, V372, P1430, DOI 10.1056/NEJMoa1501548 Truell JS, 2005, ARCH PATHOL LAB MED, V129, P1044 Walker AJ, 2013, EUR J CANCER, V49, P1404, DOI 10.1016/j.ejca.2012.10.021 Wang ML, 2015, BLOOD, V126, P739, DOI 10.1182/blood-2015-03-635326 Wang ML, 2013, NEW ENGL J MED, V369, P507, DOI 10.1056/NEJMoa1306220 Weatherald J, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00217-2017 Wiczer TE, 2017, BLOOD ADV, V1, P1739, DOI 10.1182/bloodadvances.2017009720 Xiao L, 2020, CIRCULATION, V142, P2443, DOI 10.1161/CIRCULATIONAHA.120.049210 Yamaguchi K, 2005, PATHOPHYSIOL HAEMO T, V34, P48, DOI 10.1159/000088548 Zaborowska-Szmit M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051268 Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6 Zang JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030353 Zhu XL, 2009, ACTA ONCOL, V48, P9, DOI 10.1080/02841860802314720 NR 100 TC 37 Z9 39 U1 0 U2 6 PU SPRINGER PI NEW YORK PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES SN 1523-3782 EI 1534-3170 J9 CURR CARDIOL REP JI Curr. Cardiol. Rep. PD APR PY 2023 VL 25 IS 4 BP 269 EP 280 AR s11886-023-01845-2 DI 10.1007/s11886-023-01845-2 EA FEB 2023 PG 12 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA AF1U7 UT WOS:000938871100002 PM 36795308 OA Green Submitted DA 2026-04-17 ER PT J AU Gabryel, P Kasprzyk, M Roszak, M Campisi, A Smolinski, S Zielinski, P Piwkowski, C AF Gabryel, Piotr Kasprzyk, Mariusz Roszak, Magdalena Campisi, Alessio Smolinski, Szymon Zielinski, Pawel Piwkowski, Cezary TI Comparison of the LigaSure™ bipolar vessel sealer to monopolar electrocoagulation for thoracoscopic lobectomy and lymphadenectomy: a prospective randomized controlled trial SO SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES LA English DT Article DE High-energy device; LigaSure; Lymphadenectomy; Lobectomy; Vessel sealer; Bipolar ID LYMPH-NODE DISSECTION; LUNG-CANCER; ATRIAL-FIBRILLATION; EUROPEAN-SOCIETY; HARMONIC SCALPEL; CLASSIFICATION; DIATHERMY; OUTCOMES; SURGERY; SYSTEM AB Background High-energy devices allow better vessel sealing compared with monopolar electrocautery and could improve the outcomes of surgical operations. The objective of the study was to compare tissue dissection by the LigaSure (TM) device with that by monopolar electrocoagulation for thoracoscopic lobectomy and lymphadenectomy.Methods This pragmatic, parallel group, prospective randomized controlled trial was funded by the Medtronic External Research Program (ISR-2016-10,756) and registered at (NCT03125798). The study included patients aged 18 years or older, who had undergone thoracoscopic lobectomy with lymphadenectomy at the Department of Thoracic Surgery of Poznan University of Medical Sciences between May 3, 2018, and November 4, 2021. Using simple randomization, the patients were assigned to undergo tissue dissection with either the LigaSure device (study group) or monopolar electrocautery (control group). Participants and care givers, except operating surgeons, were blinded to group assignment. The primary outcome was postoperative chest drainage volume. Secondary outcomes were change of the esophageal temperature during subcarinal lymphadenectomy and C-reactive protein level 72 h after surgery.Results Study outcomes were analyzed in 107 patients in each group. We found no differences between the study and control groups in terms of chest drainage volume (550 vs. 600 mL, respectively; p = 0.315), changes in esophageal temperature (- 0.1 ?? vs. - 0.1 ??, respectively; p = 0.784), and C-reactive protein levels (72.8 vs. 70.8 mg/L, respectively; p = 0.503). The mean numbers of lymph nodes removed were 12.9 (SD: 3.1; 95% CI, 12.4 to 13.5) in the study group and 11.6 (SD: 3.2; 95% CI, 11.0 to 12.2) in the control group (p < 0.001).Conclusions The use of the LigaSure device did not allow to decrease the chest drainage volume, local thermal spread, and systemic inflammatory response. The number of lymph nodes removed was higher in patients operated with the LigaSure device, which indicated better quality of lymphadenectomy. C1 [Gabryel, Piotr; Kasprzyk, Mariusz; Smolinski, Szymon; Zielinski, Pawel; Piwkowski, Cezary] Poznan Univ Med Sci, Dept Thorac Surg, Szamarzewskiego 62 St, PL-60569 Poznan, Poland. [Roszak, Magdalena] Poznan Univ Med Sci, Dept Comp Sci & Stat, Poznan, Poland. [Campisi, Alessio] Univ & Hosp Trust Osped Borgo Trento, Dept Thorac Surg, Verona, Italy. C3 Poznan University of Medical Sciences; Poznan University of Medical Sciences RP Gabryel, P (corresponding author), Poznan Univ Med Sci, Dept Thorac Surg, Szamarzewskiego 62 St, PL-60569 Poznan, Poland. EM piotrgabryel@gmail.com RI Campisi, Alessio/HDN-7577-2022; Zielinski, Pawel/LMO-2804-2024; Gabryel, Piotr/F-8517-2014 OI Zielinski, Pawel/0000-0002-8552-2566; Gabryel, Piotr/0000-0001-6402-8430 FU Medtronic External Research Program [ISR-2016-10756] FX This work was supported by the Medtronic External Research Program, Grant No. ISR-2016-10756. CR Bertolaccini L, 2014, EUR J CARDIO-THORAC, V45, P693, DOI 10.1093/ejcts/ezt445 BOLLEN ECM, 1993, ANN THORAC SURG, V55, P961, DOI 10.1016/0003-4975(93)90126-3 Craig SR, 2001, EUR J CARDIO-THORAC, V20, P455, DOI 10.1016/S1010-7940(01)00841-7 Ding Z, 2005, J Obstet Gynaecol, V25, P49, DOI 10.1080/01443610400024609 Doddoli C, 2005, EUR J CARDIO-THORAC, V27, P680, DOI 10.1016/j.ejcts.2004.12.035 Druzijanic N, 2012, CAN J SURG, V55, P317, DOI 10.1503/cjs.000711 Dziedzic R, 2018, EUR J CARDIO-THORAC, V54, P547, DOI 10.1093/ejcts/ezy101 Falcoz PE, 2016, EUR J CARDIO-THORAC, V49, P602, DOI 10.1093/ejcts/ezv154 Fernandez FG, 2015, ANN THORAC SURG, V99, P368, DOI 10.1016/j.athoracsur.2014.05.104 Goldstraw P, 2016, J THORAC ONCOL, V11, P39, DOI 10.1016/j.jtho.2015.09.009 Homma T, 2022, AME SURG J, V2, DOI 10.21037/asj-21-85 Homma T, 2022, GEN THORAC CARDIOVAS, V70, P207, DOI 10.1007/s11748-022-01775-w Kennedy JS, 1998, SURG ENDOSC-ULTRAS, V12, P876, DOI 10.1007/s004649900733 Kim S, 2018, SURG ENDOSC, V32, P2550, DOI 10.1007/s00464-018-6140-1 Leonardo C, 2005, J ENDOUROL, V19, P976, DOI 10.1089/end.2005.19.976 Lijkendijk M, 2018, ANN THORAC SURG, V105, P393, DOI 10.1016/j.athoracsur.2017.08.048 Litta P, 2015, MOL MED REP, V12, P2985, DOI 10.3892/mmr.2015.3677 Martucci N, 2015, EUR J CARDIO-THORAC, V47, pE13, DOI 10.1093/ejcts/ezu391 Miyajima M, 2021, J THORAC DIS, V13, P3458, DOI 10.21037/jtd-21-169 Oyama S, 2021, SURG ENDOSC, V35, P1453, DOI 10.1007/s00464-020-08043-z Paul S, 2013, EUR J CARDIO-THORAC, V43, P813, DOI 10.1093/ejcts/ezs428 Rami-Porta R, 2016, Staging Manual in Thoracic Oncology Rami-Porta R, 2021, CANCERS, V13, DOI 10.3390/cancers13112583 SETHI GK, 1978, ANN THORAC SURG, V25, P74, DOI 10.1016/S0003-4975(10)63492-3 Singh SM, 2008, CIRC-ARRHYTHMIA ELEC, V1, P162, DOI [10.1161/CIRCEP.107.789552, 10.1161/CIRCEP.108.789552] Sutton PA, 2010, BRIT J SURG, V97, P428, DOI 10.1002/bjs.6901 TALEB N., 2007, The American Statistician, V61, P198, DOI DOI 10.1198/000313007X219996 Tang MB, 2020, WORLD J SURG ONCOL, V18, DOI 10.1186/s12957-020-01941-5 Toishi M, 2014, INTERACT CARDIOV TH, V19, P448, DOI 10.1093/icvts/ivu176 Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630 Zhao WG, 2019, J THORAC DIS, V11, P505, DOI 10.21037/jtd.2019.01.39 NR 31 TC 6 Z9 7 U1 0 U2 1 PU SPRINGER PI NEW YORK PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES SN 0930-2794 EI 1432-2218 J9 SURG ENDOSC JI Surg. Endosc. PD JUN PY 2023 VL 37 IS 6 BP 4449 EP 4457 DI 10.1007/s00464-023-09892-0 EA FEB 2023 PG 9 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA I1JG5 UT WOS:000933683200003 PM 36792782 OA Green Submitted, hybrid DA 2026-04-17 ER PT J AU Wei, MY Wang, P Zhu, XF Morishima, M Liu, YG Zheng, MQ Liu, G Osanai, H Yoshimura, K Kume, S Kurokawa, T Ono, K AF Wei, Mengyan Wang, Pu Zhu, Xiufang Morishima, Masaki Liu, Yangong Zheng, Mingqi Liu, Gang Osanai, Hiroki Yoshimura, Kenshi Kume, Shinichiro Kurokawa, Tatsuki Ono, Katsushige TI Electrophysiological evaluation of an anticancer drug gemcitabine on cardiotoxicity revealing down-regulation and modification of the activation gating properties in the human rapid delayed rectifier potassium channel SO PLOS ONE LA English DT Article ID CELL LUNG-CANCER; LONG-QT SYNDROME; ATRIAL-FIBRILLATION; N-GLYCOSYLATION; PHASE-II; PLUS PLACEBO; MULTICENTER; COMBINATION; VANDETANIB; INHIBITION AB Gemcitabine is an antineoplastic drug commonly used in the treatment of several types of cancers including pancreatic cancer and non-small cell lung cancer. Although gemcitabine-induced cardiotoxicity is widely recognized, the exact mechanism of cardiac dysfunction causing arrhythmias remains unclear. The objective of this study was to electrophysiologically evaluate the proarrhythmic cardiotoxicity of gemcitabine focusing on the human rapid delayed rectifier potassium channel, hERG channel. In heterologous hERG expressing HEK293 cells (hERG-HEK cells), hERG channel current (I-hERG) was reduced by gemcitabine when applied for 24 h but not immediately after the application. Gemcitabine modified the activation gating properties of the hERG channel toward the hyperpolarization direction, while inactivation, deactivation or reactivation gating properties were unaffected by gemcitabine. When gemcitabine was applied to hERG-HEK cells in combined with tunicamycin, an inhibitor of N-acetylglucosamine phosphotransferase, gemcitabine was unable to reduce I-hERG or shift the activation properties toward the hyperpolarization direction. While a mannosidase I inhibitor kifunensine alone reduced I-hERG and the reduction was even larger in combined with gemcitabine, kifunensine was without effect on I-hERG when hERG-HEK cells were pretreated with gemcitabine for 24 h. In addition, gemcitabine down-regulated fluorescence intensity for hERG potassium channel protein in rat neonatal cardiomyocyte, although hERG mRNA was unchanged. Our results suggest the possible mechanism of arrhythmias caused by gemcitabine revealing a down-regulation of I-hERG through the post-translational glycosylation disruption possibly at the early phase of hERG channel glycosylation in the endoplasmic reticulum that alters the electrical excitability of cells. C1 [Wei, Mengyan; Wang, Pu; Zhu, Xiufang; Liu, Yangong; Zheng, Mingqi; Liu, Gang] Hebei Med Univ, Dept Cardiol, Hosp 1, Shijiazhuang, Hebei, Peoples R China. [Wei, Mengyan; Wang, Pu; Zhu, Xiufang; Liu, Yangong; Osanai, Hiroki; Yoshimura, Kenshi; Kume, Shinichiro; Kurokawa, Tatsuki; Ono, Katsushige] Oita Univ, Dept Pathophysiol, Sch Med, Oita, Japan. [Morishima, Masaki] Kindai Univ, Fac Agr, Dept Food Sci & Nutr, Nara, Japan. C3 Hebei Medical University; Oita University; Kindai University (Kinki University) RP Ono, K (corresponding author), Oita Univ, Dept Pathophysiol, Sch Med, Oita, Japan. EM ono@oita-u.ac.jp CR [Anonymous], VAND GEMC PLAC PLUS Bukachi F, 2005, Eur J Echocardiogr, V6, P107, DOI 10.1016/j.euje.2004.07.009 Buza V, 2017, CIRC-ARRHYTHMIA ELEC, V10, DOI 10.1161/CIRCEP.117.005443 Chen R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08436-6 ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438 Gintant GA, 1996, CIRC RES, V78, P26, DOI 10.1161/01.RES.78.1.26 Gong QM, 2002, AM J PHYSIOL-HEART C, V283, pH77, DOI 10.1152/ajpheart.00008.2002 Gridelli C, 2001, LUNG CANCER-J IASLC, V31, P277, DOI 10.1016/S0169-5002(00)00194-X Gridelli C, 2014, J THORAC ONCOL, V9, P733, DOI 10.1097/JTO.0000000000000120 Hilmi M, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13100325 Hirashita Y, 2021, LAB INVEST, V101, P1036, DOI 10.1038/s41374-021-00590-w Jeevaratnam K, 2018, J CARDIOVASC PHARM T, V23, P119, DOI 10.1177/1074248417729880 Johnson JN, 2008, HEART RHYTHM, V5, P704, DOI 10.1016/j.hrthm.2008.02.007 Kindler HL, 2011, LANCET ONCOL, V12, P256, DOI 10.1016/S1470-2045(11)70004-3 Kirchhof P, 2003, J CARDIOVASC ELECTR, V14, P1027, DOI 10.1046/j.1540-8167.2003.03165.x Klein A L, 1991, J Am Soc Echocardiogr, V4, P379 Lamothe SM, 2018, FASEB J, V32, P1933, DOI 10.1096/fj.201700832R Li DS, 2001, CIRC RES, V88, P1168, DOI 10.1161/hh1101.091266 Ling YH, 2009, CANCER CHEMOTH PHARM, V64, P539, DOI 10.1007/s00280-008-0902-8 Liu SG, 1996, BIOPHYS J, V70, P2704, DOI 10.1016/S0006-3495(96)79840-5 Ma FF, 2016, HEART VESSELS, V31, P1176, DOI 10.1007/s00380-015-0762-1 Macharoen K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186896 Mandyam MC, 2013, HEART RHYTHM, V10, P1562, DOI 10.1016/j.hrthm.2013.07.023 Masuda K, 2018, J PHYSIOL SCI, V68, P759, DOI 10.1007/s12576-017-0590-4 Miyahara K, 2015, PANCREAS, V44, P551, DOI [10.1097/mpa.0000000000000321, 10.1097/MPA.0000000000000321] Morishima M, 2016, CIRC J, V80, P1346, DOI 10.1253/circj.CJ-15-1276 NISHIMURA RA, 1990, CIRCULATION, V81, P1488, DOI 10.1161/01.CIR.81.5.1488 Petrecca K, 1999, J PHYSIOL-LONDON, V515, P41, DOI 10.1111/j.1469-7793.1999.041ad.x Platonov PG, 2019, CIRC-ARRHYTHMIA ELEC, V12, DOI 10.1161/CIRCEP.119.007213 PLUNKETT W, 1995, SEMIN ONCOL, V22, P3 Rademaker-Lakhai JM, 2007, CLIN CANCER RES, V13, P4474, DOI 10.1158/1078-0432.CCR-06-2912 Sandler A, 1999, Oncologist, V4, P241 Santini D, 2000, ANN ONCOL, V11, P479, DOI 10.1023/A:1008380208045 Santoro A, 2015, ANN ONCOL, V26, P542, DOI 10.1093/annonc/mdu576 SHIBASAKI T, 1987, J PHYSIOL-LONDON, V387, P227, DOI 10.1113/jphysiol.1987.sp016571 Skrenkova K, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00188 Vandenberg JI, 2012, PHYSIOL REV, V92, P1393, DOI 10.1152/physrev.00036.2011 Veerman G, 1996, CANCER CHEMOTH PHARM, V38, P335, DOI 10.1007/s002800050492 Wang Y, 2020, CIRC J, V84, P1931, DOI 10.1253/circj.CJ-20-0288 Witchel HJ, 2000, CLIN EXP PHARMACOL P, V27, P753, DOI 10.1046/j.1440-1681.2000.03337.x Zellerhoff S, 2009, J CARDIOVASC ELECTR, V20, P401, DOI 10.1111/j.1540-8167.2008.01339.x NR 41 TC 2 Z9 3 U1 1 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 2 PY 2023 VL 18 IS 2 AR e0280656 DI 10.1371/journal.pone.0280656 PG 22 WC Multidisciplinary Sciences WE Science Citation Index Expanded (SCI-EXPANDED) SC Science & Technology - Other Topics GA E1AV6 UT WOS:000972956700001 PM 36730356 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Han, Y Yu, QD Ma, QL Zhang, J Shi, YH Zhang, ZR Qiang, GL Xiao, F Liang, CY AF Han, Yu Yu, Qiduo Ma, Qianli Zhang, Jin Shi, Yuhui Zhang, Zhenrong Qiang, Guangliang Xiao, Fei Liang, Chaoyang TI Assessment of preoperative anxiety and depression in patients with pulmonary ground-glass opacities: Risk factors and postoperative outcomes SO FRONTIERS IN SURGERY LA English DT Article DE ground-glass opacity; anxiety; depression; morbidity; quality of life; tumor ID QUALITY-OF-LIFE; LUNG-CANCER; PAIN AB ObjectiveA large number of patients with pulmonary ground-glass opacities (GGOs) have anxiety and depression. However, the contributing factors and effects of anxiety and depression on postoperative outcomes are still unclear. MethodsClinical data for patients undergoing surgical resection for pulmonary GGOs were collected. We prospectively evaluated levels and risk factors for anxiety and depression in patients with GGOs before surgery. The relationship between psychological disorders and postoperative morbidity was evaluated. Quality of life (QoL) was also assessed. ResultsA total of 133 patients were enrolled. Prevalence rates of preoperative anxiety and depression were 26.3% (n = 35) and 18% (n = 24), respectively. Multivariate analysis revealed depression [odds ratio(OR) = 16.27, p < 0.001] and multiple GGOs (OR = 3.146, p = 0.033) to be risk factors for preoperative anxiety. Anxiety (OR = 52.166, p < 0.001), age > 60 (OR = 3.601, p = 0.036), and unemployment (OR = 8.248, p = 0.006) were identified as risk factors for preoperative depression. Preoperative anxiety and depression were associated with lower QoL and higher postoperative pain scores. Our results also revealed that the incidence of postoperative atrial fibrillation was higher in patients with than in those without anxiety. ConclusionsIn patients with pulmonary GGOs, comprehensive psychological assessment and appropriate management are required before surgery to improve QoL and reduce postoperative morbidity. C1 [Han, Yu; Yu, Qiduo; Ma, Qianli; Zhang, Jin; Shi, Yuhui; Zhang, Zhenrong; Qiang, Guangliang; Xiao, Fei; Liang, Chaoyang] China Japan Friendship Hosp, Dept Gen Thorac Surg, Beijing, Peoples R China. [Han, Yu; Yu, Qiduo; Ma, Qianli; Zhang, Jin; Shi, Yuhui; Zhang, Zhenrong; Qiang, Guangliang; Xiao, Fei; Liang, Chaoyang] Natl Ctr Resp Med, Dept Thorac Surg, Beijing, Peoples R China. C3 China-Japan Friendship Hospital RP Xiao, F; Liang, CY (corresponding author), China Japan Friendship Hosp, Dept Gen Thorac Surg, Beijing, Peoples R China.; Xiao, F; Liang, CY (corresponding author), Natl Ctr Resp Med, Dept Thorac Surg, Beijing, Peoples R China. EM shawbjmu@163.com; chaoyangliang@hotmail.com RI Qiang, Guangliang/KGL-7581-2024; Yu, Qiduo/ITT-2640-2023 FU National High Level Hospital Clinical Research Funding [2022-NHLHCRF-YS-04]; Elite Medical Professionals Project of China-Japan Friendship Hospital [ZRJY2021-QM23, ZRJY2021-GG07] FX This study was supported by the National High Level Hospital Clinical Research Funding (2022-NHLHCRF-YS-04), the Elite Medical Professionals Project of China-Japan Friendship Hospital (NO.ZRJY2021-QM23) and the Elite Medical Professionals Project of China-Japan Friendship Hospital (NO.ZRJY2021-GG07). CR Annunziata MA, 2020, SUPPORT CARE CANCER, V28, P3921, DOI 10.1007/s00520-019-05244-8 Aokage K, 2018, J THORAC ONCOL, V13, P533, DOI 10.1016/j.jtho.2017.11.129 Arrieta O, 2013, ANN SURG ONCOL, V20, P1941, DOI 10.1245/s10434-012-2793-5 Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3 Chabowski M, 2018, J THORAC DIS, V10, P2303, DOI 10.21037/jtd.2018.03.108 De Cosmo G, 2008, CLIN J PAIN, V24, P399, DOI 10.1097/AJP.0b013e3181671a08 Fayers PM, 2001, EUR J CANCER, V37, P1331, DOI 10.1016/S0959-8049(01)00127-7 Feng TT, 2020, INT J CARDIOL, V306, P95, DOI 10.1016/j.ijcard.2019.11.107 Hernández-Palazón J, 2018, J CARDIOTHOR VASC AN, V32, P236, DOI 10.1053/j.jvca.2017.04.044 Humphrey LL, 2013, ANN INTERN MED, V159, P411, DOI 10.7326/0003-4819-159-6-201309170-00690 Johnson CGB, 2014, J PSYCHOSOC ONCOL, V32, P59, DOI 10.1080/07347332.2013.855963 Jung JY, 2018, PSYCHO-ONCOLOGY, V27, P465, DOI 10.1002/pon.4513 Kummer S, 2020, THORAX, V75, P1065, DOI 10.1136/thoraxjnl-2020-215054 Lee Y, 2019, CANCER MANAG RES, V11, P7587, DOI 10.2147/CMAR.S188926 Li LH, 2020, THORAC CANCER, V11, P1433, DOI 10.1111/1759-7714.13406 Machingura A, 2022, EUR J CANCER, V170, P1, DOI 10.1016/j.ejca.2022.03.039 Paredes AZ, 2020, ANN SURG, V272, P419, DOI 10.1097/SLA.0000000000004118 Park S, 2016, EUR J CARDIO-THORAC, V49, pE16, DOI 10.1093/ejcts/ezv336 Polanski J, 2018, ADV EXP MED BIOL, V1023, P29, DOI 10.1007/5584_2017_50 Rutkowski J, 2017, REP PRACT ONCOL RADI, V22, P217, DOI 10.1016/j.rpor.2017.01.002 Signorelli MS, 2020, FUTURE ONCOL, V16, P41, DOI 10.2217/fon-2018-0835 Slatore CG, 2015, ANN AM THORAC SOC, V12, P184, DOI 10.1513/AnnalsATS.201406-283OC Su CH, 2024, CANCER NURS, V47, P56, DOI 10.1097/NCC.0000000000001150 Walker J, 2020, J PSYCHOSOM RES, V138, DOI 10.1016/j.jpsychores.2020.110218 Wang XQ, 2022, SUPPORT CARE CANCER, V30, P5539, DOI 10.1007/s00520-022-06961-3 Yan XR, 2019, CANCER MANAG RES, V11, P4347, DOI 10.2147/CMAR.S202119 Zhang Y, 2020, ANN THORAC SURG, V110, P1796, DOI 10.1016/j.athoracsur.2020.04.094 Zhang Y, 2020, J THORAC CARDIOV SUR, V160, P824, DOI [10.1016/j.jtcvs.219.10.145, 10.1016/j.jtcvs.2019.10.145] NR 28 TC 7 Z9 8 U1 1 U2 3 PU FRONTIERS MEDIA SA PI LAUSANNE PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND SN 2296-875X J9 FRONT SURG JI Front. Surg. PD JAN 30 PY 2023 VL 10 AR 1102352 DI 10.3389/fsurg.2023.1102352 PG 8 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA 8Y3PD UT WOS:000932611100001 PM 36793311 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Leiva, O Bohart, I Ahuja, T Park, D AF Leiva, Orly Bohart, Isaac Ahuja, Tania Park, David TI Off-Target Effects of Cancer Therapy on Development of Therapy-Induced Arrhythmia: A Review SO CARDIOLOGY LA English DT Review ID CELL LUNG-CANCER; ATRIAL-FIBRILLATION; RISK-FACTORS; SRC KINASE; INDUCED CARDIOTOXICITY; CLINICAL-FEATURES; BREAST-CANCER; PHASE-II; IBRUTINIB; EPIDEMIOLOGY AB Background: Advances in cancer therapeutics have improved overall survival and prognosis in this patient population, however this has come at the expense of cardiotoxicity including arrhythmia. Summary: Cancer and its therapies are associated with cardiotoxicity via several mechanisms including inflammation, cardiomyopathy, and off-target effects. Among cancer therapies, anthracyclines and tyrosine kinase inhibitors (TKIs) are particularly known for their pro-arrhythmia effects. In addition to cardiomyopathy, anthracyclines may be pro-arrhythmogenic via reactive oxygen species (ROS) generation and altered calcium handling. TKIs may mediate their cardiotoxicity via inhibition of off-target tyrosine kinases. Ibrutinib-mediated inhibition of CSK may be responsible for the increased prevalence of atrial fibrillation (AF). Further investigation is warranted to further elucidate the mechanisms behind arrhythmias in cancer therapies. Key Messages: Arrhythmias are a common cardiotoxicity of cancer therapies. Cancer therapies may induce arrhythmias via off-target effects. Understanding the mechanisms underlying arrhythmogenesis associated with cancer therapies may help design cancer therapies that can avoid these toxicities. C1 [Leiva, Orly; Bohart, Isaac; Ahuja, Tania; Park, David] NYU, Grossman Sch Med, Dept Med, Div Cardiol, New York, NY USA. [Leiva, Orly] NYU, Grossman Sch Med, Dept Med, Div Cardiol, 435 E 30th St, New York, NY 10016 USA. C3 New York University; New York University RP Leiva, O (corresponding author), NYU, Grossman Sch Med, Dept Med, Div Cardiol, 435 E 30th St, New York, NY 10016 USA. EM Orly.Leiva@nyulangone.org RI Leiva, Orly/HNR-5290-2023; Ahuja, Tania/KMY-3918-2024 OI Park, David/0000-0001-5858-5353; CR Adabag AS, 2010, NAT REV CARDIOL, V7, P216, DOI 10.1038/nrcardio.2010.3 Advani RH, 2013, J CLIN ONCOL, V31, P88, DOI 10.1200/JCO.2012.42.7906 Ahn IE, 2021, J CLIN ONCOL, V39, P576, DOI 10.1200/JCO.20.00979 Al-Samkari H, 2020, J THORAC ONCOL, V15, P1497, DOI 10.1016/j.jtho.2020.04.033 Albrecht A, 2021, CANCERS, V13, DOI 10.3390/cancers13102303 Altomare C, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.658790 Anker MS, 2021, EUR J HEART FAIL, V23, P145, DOI 10.1002/ejhf.2059 BENJAMIN EJ, 1994, JAMA-J AM MED ASSOC, V271, P840, DOI 10.1001/jama.271.11.840 Bogle BM, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002398 Briukhovetska D, 2021, NAT REV CANCER, V21, P481, DOI 10.1038/s41568-021-00363-z Brown JR, 2017, HAEMATOLOGICA, V102, P1796, DOI 10.3324/haematol.2017.171041 Bugger H, 2011, CANCER CHEMOTH PHARM, V67, P1381, DOI 10.1007/s00280-010-1441-7 Buza V, 2017, CIRC-ARRHYTHMIA ELEC, V10, DOI 10.1161/CIRCEP.117.005443 Caldeira D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211228 Camidge DR, 2018, NEW ENGL J MED, V379, P2027, DOI 10.1056/NEJMoa1810171 Cappetta D, 2017, BRIT J PHARMACOL, V174, P3696, DOI 10.1111/bph.13791 Cirne F, 2021, LUNG CANCER, V161, P9, DOI 10.1016/j.lungcan.2021.08.014 Conen D, 2010, EUR HEART J, V31, P1730, DOI 10.1093/eurheartj/ehq146 Coumbe BGT, 2018, CURR CARDIOL REP, V20, DOI 10.1007/s11886-018-1010-y Dagenais GR, 2020, LANCET, V395, P785, DOI 10.1016/S0140-6736(19)32007-0 DINDOGRU A, 1978, MED PEDIATR ONCOL, V5, P65, DOI 10.1002/mpo.2950050110 Ell P, 2021, CURR TREAT OPTION ON, V22, DOI 10.1007/s11864-021-00868-7 Enriquez Andres, 2017, JACC Clin Electrophysiol, V3, P50, DOI [10.1016/j.jacep.2016.03.001, 10.1016/j.jacep.2016.03.001] Erichsen R, 2012, INTERN EMERG MED, V7, P431, DOI 10.1007/s11739-011-0701-9 Escudier M, 2017, CIRCULATION, V136, P2085, DOI 10.1161/CIRCULATIONAHA.117.030571 Farmakis D, 2021, EUR J HEART FAIL, V23, P154, DOI 10.1002/ejhf.2079 Farolfi A, 2013, HEART, V99, P634, DOI 10.1136/heartjnl-2012-303151 Feliz V, 2011, CLIN CARDIOL, V34, P356, DOI 10.1002/clc.20904 Fradley MG, 2021, CIRCULATION, V144, pE41, DOI 10.1161/CIR.0000000000000986 Franco Therese H, 2008, Ther Clin Risk Manag, V4, P1367 Ganatra S, 2018, JACC-CLIN ELECTROPHY, V4, P1491, DOI 10.1016/j.jacep.2018.06.004 Ghiaseddin A, 2018, ONCOLOGIST, V23, P157, DOI 10.1634/theoncologist.2017-0501 Gillis AM, 2017, CIRCULATION, V135, P593, DOI 10.1161/CIRCULATIONAHA.116.025312 GOTTDIENER JS, 1981, ARCH INTERN MED, V141, P758, DOI 10.1001/archinte.141.6.758 Gottschlich A, 2021, CANCERS, V13, DOI 10.3390/cancers13030477 Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025 Groarke JD, 2015, CIRCULATION, V131, P1946, DOI 10.1161/CIRCULATIONAHA.115.016704 Guha A, 2022, EUR HEART J, V43, P300, DOI 10.1093/eurheartj/ehab745 Gustine JN, 2016, AM J HEMATOL, V91, pE312, DOI 10.1002/ajh.24366 Herrmann J, 2020, NAT REV CARDIOL, V17, P474, DOI 10.1038/s41569-020-0348-1 Herrmann J, 2016, CURR ONCOL REP, V18, DOI 10.1007/s11912-016-0514-0 Hilmi M, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13100325 Horacek J. M., 2009, Experimental Oncology, V31, P115 Huang LL, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00977-0 Ikeda S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46367-6 Jakobsen CB, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6314-9 Kass DA, 2004, CIRC RES, V94, P1533, DOI 10.1161/01.RES.0000129254.25507.d6 Khan MA, 2012, J PAK MED ASSOC, V62, P430 Kilickap S, 2007, SOUTH MED J, V100, P262, DOI 10.1097/01.smj.0000257382.89910.fe Kim GY, 2019, J ONCOL PHARM PRACT, V25, P229, DOI 10.1177/1078155217729564 Kloth JSL, 2015, BRIT J CANCER, V112, P1011, DOI 10.1038/bjc.2015.82 Kohlhaas M, 2010, CIRCULATION, V121, P1606, DOI 10.1161/CIRCULATIONAHA.109.914911 Kong LH, 2022, J CELL MOL MED, V26, P5303, DOI 10.1111/jcmm.17560 Leiva O, 2021, JACC-CARDIOONCOL, V3, P619, DOI 10.1016/j.jaccao.2021.08.011 Leong DP, 2016, BLOOD, V128, P138, DOI 10.1182/blood-2016-05-712828 Lloyd-Jones DM, 2004, CIRCULATION, V110, P1042, DOI 10.1161/01.CIR.0000140263.20897.42 Lyon A., 2022, Eur Heart J, P1 Lyon AR, 2018, LANCET ONCOL, V19, pE447, DOI 10.1016/S1470-2045(18)30457-1 Markman TM, 2016, ONCOLOGY-BASEL, V91, P61, DOI 10.1159/000446374 Mauro AG, 2023, TRANSL RES, V252, P9, DOI 10.1016/j.trsl.2022.08.004 Mazur Matylda, 2017, JACC Clin Electrophysiol, V3, P139, DOI [10.1016/j.jacep.2016.08.009, 10.1016/j.jacep.2016.08.009] McMullen JR, 2007, P NATL ACAD SCI USA, V104, P612, DOI 10.1073/pnas.0606663104 McMullen JR, 2014, BLOOD, V124, P3829, DOI 10.1182/blood-2014-10-604272 Melendez J, 2004, J BIOL CHEM, V279, P53516, DOI 10.1074/jbc.M408475200 Mestroni L, 2014, J AM COLL CARDIOL, V63, P935, DOI 10.1016/j.jacc.2013.10.082 Nowsheen S, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.008637 Nozaki N, 2004, CIRCULATION, V110, P2869, DOI 10.1161/01.CIR.0000146889.46519.27 Okada M, 2012, INT J BIOL SCI, V8, P1385, DOI 10.7150/ijbs.5141 Olivieri A, 1998, BONE MARROW TRANSPL, V21, P1049, DOI 10.1038/sj.bmt.1701217 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Ou SHI, 2016, CANCER MED-US, V5, P617, DOI 10.1002/cam4.622 Ou SHI, 2013, CANCER-AM CANCER SOC, V119, P1969, DOI 10.1002/cncr.28040 Ou SHI, 2011, J THORAC ONCOL, V6, P2135, DOI 10.1097/JTO.0b013e3182307e06 Peres E, 2010, BONE MARROW TRANSPL, V45, P149, DOI 10.1038/bmt.2009.97 Peters S, 2017, NEW ENGL J MED, V377, P829, DOI 10.1056/NEJMoa1704795 Peto J, 2001, NATURE, V411, P390, DOI 10.1038/35077256 Pretorius L, 2009, AM J PATHOL, V175, P998, DOI 10.2353/ajpath.2009.090126 Riad A, 2008, EUR J HEART FAIL, V10, P233, DOI 10.1016/j.ejheart.2008.01.004 Richards WG, 2006, J CLIN ONCOL, V24, P1561, DOI 10.1200/JCO.2005.04.6813 Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401 Robinson DR, 2000, ONCOGENE, V19, P5548, DOI 10.1038/sj.onc.1203957 Rutledge CA, 2014, J AM COLL CARDIOL, V63, P928, DOI 10.1016/j.jacc.2013.10.081 Ryder KM, 1999, AM J CARDIOL, V84, p131R Salem JE, 2019, J AM COLL CARDIOL, V74, P1667, DOI 10.1016/j.jacc.2019.07.056 Sara JD, 2018, THER ADV MED ONCOL, V10, DOI 10.1177/1758835918780140 Schnabel RB, 2015, LANCET, V386, P154, DOI 10.1016/S0140-6736(14)61774-8 Schnabel RB, 2009, AM J CARDIOL, V104, P92, DOI 10.1016/j.amjcard.2009.02.053 Shaw AT, 2009, J CLIN ONCOL, V27, P4247, DOI 10.1200/JCO.2009.22.6993 Shi WM, 1999, CIRC RES, V85, pE1 Siu CW, 2005, PACE, V28, pS120, DOI 10.1111/j.1540-8159.2005.00024.x Solomon BJ, 2014, NEW ENGL J MED, V371, P2167, DOI [10.1056/NEJMoa1408440, 10.1056/NEJMx150034] Sovari AA, 2011, J AM COLL CARDIOL, V58, P2332, DOI 10.1016/j.jacc.2011.07.048 STEINBERG JS, 1987, CANCER-AM CANCER SOC, V60, P1213, DOI 10.1002/1097-0142(19870915)60:6<1213::AID-CNCR2820600609>3.0.CO;2-V Tapio S, 2016, J RADIAT RES, V57, P439, DOI 10.1093/jrr/rrw064 Thomas RM, 2004, IMMUNITY, V20, P181, DOI 10.1016/S1074-7613(04)00023-8 Thompson PA, 2016, BRIT J HAEMATOL, V175, P462, DOI 10.1111/bjh.14324 Topkara VK, 2011, J MOL CELL CARDIOL, V51, P594, DOI 10.1016/j.yjmcc.2010.11.003 Touyz RM, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0056-z Wagner S, 2006, J CLIN INVEST, V116, P3127, DOI 10.1172/JCI26620 Waliany S, 2021, J THORAC ONCOL, V16, P2029, DOI 10.1016/j.jtho.2021.07.030 Wang ML, 2013, NEW ENGL J MED, V369, P507, DOI 10.1056/NEJMoa1306220 Waxman AJ, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2017.4519 Woyach JA, 2018, NEW ENGL J MED, V379, P2517, DOI 10.1056/NEJMoa1812836 Xiao L, 2020, CIRCULATION, V142, P2443, DOI 10.1161/CIRCULATIONAHA.120.049210 Yao CX, 2018, CIRCULATION, V138, P2227, DOI 10.1161/CIRCULATIONAHA.118.035202 Yun JP, 2021, JACC-CARDIOONCOL, V3, P221, DOI 10.1016/j.jaccao.2021.03.006 Yusuf SW, 2017, FRONT CARDIOVASC MED, V4, DOI 10.3389/fcvm.2017.00066 Zhang S, 2012, NAT MED, V18, P1639, DOI 10.1038/nm.2919 Zhang Zhushan, 2017, Cardiooncology, V3, DOI [10.1186/s40959-017-0020-z, 10.1007/s12559-017-9484-2, 10.1186/s40959-017-0020-z] NR 109 TC 9 Z9 9 U1 3 U2 10 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0008-6312 EI 1421-9751 J9 CARDIOLOGY JI Cardiology PD AUG PY 2023 VL 148 IS 4 BP 324 EP 334 DI 10.1159/000529260 EA JAN 2023 PG 11 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA JE2D5 UT WOS:000955100700001 PM 36702116 OA Green Submitted, hybrid DA 2026-04-17 ER PT J AU Diallo, EH Brouillard, P Raymond, JM Liberman, M Duceppe, E Potter, BJ AF Diallo, E. -H Brouillard, P. Raymond, J. -M Liberman, M. Duceppe, E. Potter, B. J. TI Predictors and impact of postoperative atrial fibrillation following thoracic surgery: a state-of-the-art review SO ANAESTHESIA LA English DT Review DE atrial fibrillation; health economics; healthcare costs; length of stay; thoracic surgery ID CARDIAC-SURGERY; RHYTHM-CONTROL; RISK-FACTORS; LUNG-CANCER; PREVENTION; AGE; FIBROSIS; PATHOPHYSIOLOGY; METAANALYSIS; MECHANISMS AB This review of 19 studies (39,783 patients) of atrial fibrillation after thoracic surgery addresses the pathophysiology, incidence, and consequences of atrial fibrillation in this population, as well as its prevention and management. Interestingly, atrial fibrillation was most often identified in patients not previously known to have the disease. Rhythm control with amiodarone was the most commonly used treatment and nearly all patients were discharged in sinus rhythm. Major predictors were age; male sex; history of atrial fibrillation; congestive heart failure; left atrial enlargement; elevated brain natriuretic peptide level; and the invasiveness of procedures. Overall, patients with atrial fibrillation stayed 3 days longer in hospital. We also discuss the importance of standardising research on this subject and provide recommendations that might mitigate the impact postoperative atrial fibrillation on hospital resources. C1 [Diallo, E. -H; Brouillard, P.] Univ Montreal, Dept Med, Montreal, PQ, Canada. [Raymond, J. -M; Potter, B. J.] Montreal Univ Hosp Ctr, Div Cardiol, Montreal, PQ, Canada. [Duceppe, E.] Montreal Univ Hosp Ctr, Dept Med, Div Internal Med, Montreal, PQ, Canada. [Liberman, M.] Montreal Univ Hosp Ctr, Dept Surg, Div Thorac Surg, Montreal, PQ, Canada. C3 Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal RP Potter, BJ (corresponding author), Montreal Univ Hosp Ctr, Div Cardiol, Montreal, PQ, Canada. EM brian.potter@umontreal.ca RI ; Duceppe, Emmanuelle/AAW-9843-2020; Potter, Brian/A-5083-2015 OI Diallo, El Hadji/0009-0004-7050-368X; Brouillard, Philippe/0000-0002-3501-7414; CR Abdelmoneim SS, 2021, JACC-CLIN ELECTROPHY, V7, P1134, DOI 10.1016/j.jacep.2021.02.005 Akoum N, 2018, EUROPACE, V20, P1086, DOI 10.1093/europace/eux260 Albini A, 2021, EUR J INTERN MED, V85, P27, DOI 10.1016/j.ejim.2020.12.018 AlTurki A, 2020, CIRC-ARRHYTHMIA ELEC, V13, DOI 10.1161/CIRCEP.119.007437 Amar D, 2019, J THORAC CARDIOV SUR, V157, P2493, DOI 10.1016/j.jtcvs.2019.01.075 Andrade JG, 2020, CAN J CARDIOL, V36, P1847, DOI 10.1016/j.cjca.2020.09.001 Antzelevitch Charles, 2011, Card Electrophysiol Clin, V3, P23, DOI 10.1016/j.ccep.2010.10.012 Bessissow A, 2015, J THROMB HAEMOST, V13, pS304, DOI 10.1111/jth.12974 Burgess DC, 2006, EUR HEART J, V27, P2846, DOI 10.1093/eurheartj/ehl272 Campbell NG, 2022, J CARDIOTHOR VASC AN, V36, P739, DOI 10.1053/j.jvca.2021.10.009 Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Cardinale D, 2016, ANN SURG, V264, P244, DOI 10.1097/SLA.0000000000001626 Carlsson J, 2003, J AM COLL CARDIOL, V41, P1690, DOI 10.1016/S0735-1097(03)00332-2 Cerfolio RJ., 2001, J THORAC CARDIOV SUR, V122, P318 Cheniti G, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01458 Chin JH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154931 Dobrev D, 2019, NAT REV CARDIOL, V16, P417, DOI 10.1038/s41569-019-0166-5 Forster C, 2021, INTERACT CARDIOV TH, V33, P892, DOI 10.1093/icvts/ivab187 Frendl G, 2014, J THORAC CARDIOV SUR, V148, pE153, DOI 10.1016/j.jtcvs.2014.06.036 Garcia Santiago, 2011, J Atr Fibrillation, V4, P363, DOI 10.4022/jafib.363 GOLDMAN L, 1978, CHEST, V73, P450, DOI 10.1378/chest.73.4.450 Gramley F, 2009, AGE, V31, P27, DOI 10.1007/s11357-008-9077-9 Haïssaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003 Hamaguchi S, 2016, BIOL PHARM BULL, V39, P1216, DOI 10.1248/bpb.b15-01013 Henri C, 2012, CIRC-ARRHYTHMIA ELEC, V5, P61, DOI 10.1161/CIRCEP.111.964569 Hindricks G, 2021, EUR HEART J, V42, P373, DOI 10.1093/eurheartj/ehaa612 Hyun J, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.120.018548 Ikeda T, 1996, CIRCULATION, V94, P1962, DOI 10.1161/01.CIR.94.8.1962 Imperatori Andrea, 2012, J Cardiothorac Surg, V7, P4, DOI 10.1186/1749-8090-7-4 Irshad K, 2002, CAN J SURG, V45, P264 Ivanovic J, 2014, INTERACT CARDIOV TH, V18, P340, DOI 10.1093/icvts/ivt520 Iwasaki YK, 2011, CIRCULATION, V124, P2264, DOI 10.1161/CIRCULATIONAHA.111.019893 Jalife J, 2015, TRENDS CARDIOVAS MED, V25, P475, DOI 10.1016/j.tcm.2014.12.015 January CT, 2014, CIRCULATION, V130, pE199, DOI 10.1161/CIR.0000000000000041 Kavurmaci O, 2018, HEART LUNG CIRC, V27, P835, DOI 10.1016/j.hlc.2017.06.729 Kim D, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n991 Kim MH, 2011, CIRC-CARDIOVASC QUAL, V4, P313, DOI 10.1161/CIRCOUTCOMES.110.958165 Kirchhof P, 2020, NEW ENGL J MED, V383, P1305, DOI 10.1056/NEJMoa2019422 Kornej J, 2020, CIRC RES, V127, P4, DOI 10.1161/CIRCRESAHA.120.316340 Lee SH, 2016, ANAESTHESIA, V71, P1424, DOI 10.1111/anae.13644 Lee SH, 2014, AM HEART J, V167, P593, DOI 10.1016/j.ahj.2013.12.010 Lennerz C, 2017, INT J CARDIOL, V249, P127, DOI 10.1016/j.ijcard.2017.08.039 Lowres N, 2018, INTERACT CARDIOV TH, V26, P504, DOI 10.1093/icvts/ivx348 Mathew JP, 2004, JAMA-J AM MED ASSOC, V291, P1720, DOI 10.1001/jama.291.14.1720 Melillo E, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55090511 Nair SG, 2010, ANN CARD ANAESTH, V13, P196, DOI 10.4103/0971-9784.69047 Nattel S, 2016, CARDIOVASC RES, V110, P295, DOI 10.1093/cvr/cvw092 Nielsen TD, 2004, CHEST, V126, P496, DOI 10.1378/chest.126.2.496 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Opolski G, 2004, CHEST, V126, P476, DOI 10.1378/chest.126.2.476 Osmancik P, 2022, J AM COLL CARDIOL, V79, P1, DOI 10.1016/j.jacc.2021.10.023 Papanastasiou CA, 2021, J GEN INTERN MED, V36, P3122, DOI 10.1007/s11606-021-06954-8 Passman RS, 2005, ANN THORAC SURG, V79, P1698, DOI 10.1016/j.athoracsur.2004.10.058 Patel DC, 2022, ANN THORAC SURG, V113, P1634, DOI 10.1016/j.athoracsur.2021.05.053 Patti G, 2015, EUROPACE, V17, P855, DOI 10.1093/europace/euv001 Phan K, 2015, EUR J CARDIO-THORAC, V48, P817, DOI 10.1093/ejcts/ezu551 Potaris Konstantinos, 2014, Asian Cardiovasc Thorac Ann, V22, P1072, DOI 10.1177/0218492314527992 Rao VP, 2012, EUR J CARDIO-THORAC, V42, P438, DOI 10.1093/ejcts/ezs085 Ray IB, 2018, TEX HEART I J, V45, P168, DOI 10.14503/THIJ-18-6686 Reddy VY, 2017, J AM COLL CARDIOL, V70, P2964, DOI 10.1016/j.jacc.2017.10.021 Reiffel James A, 2014, Am J Med, V127, pe15, DOI 10.1016/j.amjmed.2013.06.002 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Simmers D, 2015, J CARDIOTHOR VASC AN, V29, P389, DOI 10.1053/j.jvca.2014.05.015 Towe CW, 2018, J THORAC DIS, V10, P5870, DOI 10.21037/jtd.2018.09.99 Turagam MK, 2015, EXPERT REV CLIN PHAR, V8, P233, DOI 10.1586/17512433.2015.1018182 Van Gelder IC, 2002, NEW ENGL J MED, V347, P1834, DOI 10.1056/NEJMoa021375 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Veenhuyzen GD, 2004, CAN MED ASSOC J, V171, P755, DOI 10.1503/cmaj.1031364 Violi Francesco, 2014, J Atr Fibrillation, V7, P1112, DOI 10.4022/jafib.1112 Voigt N, 2014, CIRCULATION, V129, P145, DOI 10.1161/CIRCULATIONAHA.113.006641 Wakili R, 2011, J CLIN INVEST, V121, P2955, DOI 10.1172/JCI46315 Waks JW, 2014, ARRHYTH ELECTROPHYSI, V3, P90, DOI 10.15420/aer.2014.3.2.90 Wang H, 2021, J THORAC DIS, V13, DOI 10.21037/jtd-20-1717 Wu DH, 2012, ANN THORAC SURG, V94, P193, DOI 10.1016/j.athoracsur.2012.03.057 Wyse DG, 2002, NEW ENGL J MED, V347, P1825, DOI 10.1056/nejmoa021328 Yao, 2019, CIRCULATION, V139, pE889, DOI 10.1161/CIR.0000000000000694 Zhu J, 2012, INTERN MED J, V42, P1078, DOI 10.1111/j.1445-5994.2012.02844.x NR 77 TC 13 Z9 14 U1 0 U2 15 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0003-2409 EI 1365-2044 J9 ANAESTHESIA JI Anaesthesia PD APR PY 2023 VL 78 IS 4 BP 491 EP 500 DI 10.1111/anae.15957 EA JAN 2023 PG 10 WC Anesthesiology WE Science Citation Index Expanded (SCI-EXPANDED) SC Anesthesiology GA Q5SX8 UT WOS:000910099300001 PM 36632006 OA Bronze DA 2026-04-17 ER PT J AU Chen, M Li, C Zhang, JW Cui, X Tian, WQ Liao, P Wang, QS Sun, J Luo, L Wu, H Li, YG AF Chen, Mu Li, Cheng Zhang, Jiwei Cui, Xin Tian, Wenqi Liao, Peng Wang, Qunshan Sun, Jian Luo, Li Wu, Hong Li, Yi-Gang TI Cancer and Atrial Fibrillation Comorbidities Among 25 Million Citizens in Shanghai, China: Medical Insurance Database Study SO JMIR PUBLIC HEALTH AND SURVEILLANCE LA English DT Article DE cardiovascular; malignancy; arrhythmia; cardio-oncology; prevalence; epidemiology; atrial fibrillation ID BREAST-CANCER; RISK; SEX; STATISTICS AB Background: With population aging, the prevalence of both cancer and atrial fibrillation (AF) have increased. However, there is scarce epidemiological data concerning the comorbid state of cancer and AF in low-and middle-income countries, including China. Objective: We aimed to evaluate the site-, sex-, and age-specific profiles of cancer and AF comorbidities in Chinese populations.Methods: Data from the Shanghai Municipal Health Commission database between 2015 and 2020 were screened, covering all medical records of Shanghai residents with medical insurance. Site-specific cancer profiles were evaluated for the population with AF relative to the age-and sex-adjusted population of residents without AF. The sex distribution and peak age of cancer diagnosis were also assessed.Results: A total of 25,964,447 adult patients were screened. Among them, 22,185 patients presented cancers comorbid with AF (median 77, IQR 67-82 years of age; men: n=13,631, 61.44%), while 839,864 presented cancers without AF (median 67, IQR 57-72 years of age; men: n=419,020, 49.89%), thus yielding a higher cancer prevalence among residents with AF (8.27%) than among those without AF (6.05%; P<.001). In the population with AF, the most prevalent cancer type was lung cancer, followed by colorectal, male genital organ, stomach, breast, liver, bladder, thyroid, leukemia, and esophageal cancers. AF was associated with an average of nearly 1.4-fold (prevalence ratio [PR] 1.37, 95% CI 1.35-1.38) increased prevalence of cancer after adjusting for age and sex. For site-specific analyses, an increased prevalence of cancer in the population with AF was observed in 20 of 21 cancer sites. This increased prevalence was most prominent for nonsolid tumors, including multiple myeloma (PR 2.56, 95% CI 2.28-2.87), leukemia (PR 1.73, 95% CI 1.57-1.90), and non-Hodgkin lymphoma (PR 1.59, 95% CI 1.43-1.77); intrathoracic malignancies, including mediastinum (PR 2.34, 95% CI 1.89-2.90), lung (PR 1.64, 95% CI 1.59-1.69), and esophageal cancers (PR 1.41, 95% CI 1.28-1.56); bone and soft tissue neoplasms (PR 1.56, 95% CI 1.37-1.77); and kidney cancer (PR 1.53, 95% CI 1.36-1.72). Cancer prevalence in the population with AF relative to that in the population without AF was higher in men than in women in 14 of 18 cancer sites, and female predominance was only observed for thyroid cancer. The peak age of index cancer diagnosis was lower in the population with AF (age group: 70-74 years) than in that without AF (age group: 75-79 years), especially for specific cancer types, including thyroid, central nervous system, mediastinum, esophageal, bladder, and biliary cancers.Conclusions: Patients with AF are associated with increased prevalence, heightened male predominance, and younger peak age of cancer. Further studies are needed to determine whether early screening of specific cancers is cost-effective and beneficial for patients with AF. C1 [Chen, Mu; Li, Cheng; Wang, Qunshan; Sun, Jian; Li, Yi-Gang] Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Dept Cardiol, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China. [Zhang, Jiwei] Shanghai Univ Tradit Chinese Med, Inst Chinese Mat Med, Shanghai Key Lab Cpd Chinese Med, Key Lab Standardizat Chinese Med,Minist Educ, Shanghai, Peoples R China. [Cui, Xin; Tian, Wenqi] Shanghai Hlth Stat Ctr, Shanghai, Peoples R China. [Liao, Peng; Luo, Li] Fudan Univ, Sch Publ Hlth, Shanghai, Peoples R China. [Wu, Hong] Shanghai Municipal Hlth Commiss, Shanghai, Peoples R China. C3 Shanghai Jiao Tong University; Shanghai University of Traditional Chinese Medicine; Fudan University RP Li, YG (corresponding author), Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Dept Cardiol, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China. EM liyigang@xinhuamed.com.cn RI ; Chen, Mu/HTN-8636-2023 OI Wang, Qunshan/0000-0002-6643-400X; Chen, Mu/0000-0002-7291-0041 FU Shanghai Hospital Development Center [SHDC2020CR2026B]; Clinical Research Plan of Shanghai Municipal Health Commission [20224Y0078]; National Natural Science Foundation of China [81900288, 82130009, 82070515]; Shanghai Municipal Science and Technology Commission [19YF1431900] FX Acknowledgments This work was supported by the Shanghai Hospital Development Center (grant SHDC2020CR2026B) , the Clinical Research Plan of Shanghai Municipal Health Commission (grant 20224Y0078) , the National Natural Science Foundation of China (grants 81900288, 82130009, and 82070515) , and the Shanghai Municipal Science and Technology Commission (grant 19YF1431900) . CR [Anonymous], 2020, Shanghai Statistical Yearbook Bassand JP, 2016, EUR HEART J, V37, P2882, DOI 10.1093/eurheartj/ehw233 Brachmann J, 2016, CIRC-ARRHYTHMIA ELEC, V9, DOI 10.1161/CIRCEP.115.003333 Brand NR, 2019, ONCOLOGIST, V24, pE1371, DOI 10.1634/theoncologist.2019-0057 Cao W, 2021, CHINESE MED J-PEKING, V134, P783, DOI 10.1097/CM9.0000000000001474 Chen M, 2022, LANCET REG HEALTH-W, V23, DOI 10.1016/j.lanwpc.2022.100470 Chu G, 2019, BLOOD REV, V35, P59, DOI 10.1016/j.blre.2019.03.005 Conen D, 2016, JAMA CARDIOL, V1, P389, DOI 10.1001/jamacardio.2016.0280 Dein E, 2017, J IMMUNOTHER, V40, P312, DOI 10.1097/CJI.0000000000000174 Edgren G, 2012, EUR J EPIDEMIOL, V27, P187, DOI 10.1007/s10654-011-9647-5 Guha A, 2022, EUR HEART J, V43, P300, DOI 10.1093/eurheartj/ehab745 Herrmann J, 2020, NAT REV CARDIOL, V17, P474, DOI 10.1038/s41569-020-0348-1 Hu YF, 2019, AM J CARDIOL, V123, P782, DOI 10.1016/j.amjcard.2018.11.046 Hu YF, 2013, INT J CARDIOL, V165, P355, DOI 10.1016/j.ijcard.2012.08.036 Hussain M, 2020, OPEN HEART, V7, DOI 10.1136/openhrt-2020-001412 Jakobsen CB, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6314-9 Khan AA, 2020, CLIN RES CARDIOL, V109, P409, DOI 10.1007/s00392-019-01545-4 Kwon S, 2022, J MED INTERNET RES, V24, DOI 10.2196/37970 Marijon E, 2013, CIRCULATION, V128, P2192, DOI 10.1161/CIRCULATIONAHA.112.000491 Nazarian S, 2021, J MED INTERNET RES, V23, DOI 10.2196/28974 O'Neal WT, 2015, AM J CARDIOL, V115, P1090, DOI 10.1016/j.amjcard.2015.01.540 Pastori D, 2021, CANCER-AM CANCER SOC, V127, P2122, DOI 10.1002/cncr.33470 Rahman F, 2014, NAT REV CARDIOL, V11, P639, DOI 10.1038/nrcardio.2014.118 Risom T, 2022, CELL, V185, P299, DOI 10.1016/j.cell.2021.12.023 Sankaranarayanan R, 2014, ANN GLOB HEALTH, V80, P412, DOI 10.1016/j.aogh.2014.09.014 Schliemann D, 2022, J MED INTERNET RES, V24, DOI 10.2196/36316 Shah SC, 2019, J GLOB ONCOL, V5, DOI 10.1200/JGO.18.00200 Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332 Smith RA, 2019, CA-CANCER J CLIN, V69, P184, DOI 10.3322/caac.21557 Volgman AS, 2019, J AM COLL CARDIOL, V74, P2812, DOI 10.1016/j.jacc.2019.09.045 Wei WQ, 2020, LANCET ONCOL, V21, pE342, DOI 10.1016/S1470-2045(20)30073-5 Wilcox NS, 2022, CIRC RES, V130, P632, DOI 10.1161/CIRCRESAHA.121.319901 Yun JP, 2021, JACC-CARDIOONCOL, V3, P221, DOI 10.1016/j.jaccao.2021.03.006 NR 33 TC 7 Z9 7 U1 0 U2 6 PU JMIR PUBLICATIONS, INC PI TORONTO PA 130 QUEENS QUAY East, Unit 1100, TORONTO, ON M5A 0P6, CANADA SN 2369-2960 J9 JMIR PUBLIC HLTH SUR JI JMIR Public Health Surveill. PY 2023 VL 9 AR e40149 DI 10.2196/40149 PG 12 WC Public, Environmental & Occupational Health WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI) SC Public, Environmental & Occupational Health GA Y7ZS7 UT WOS:001107411000001 PM 37847541 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Tong, CY Shen, YF Zhu, HW Zheng, JJ Xu, YY Wu, JX AF Tong, Chaoyang Shen, Yaofeng Zhu, Hongwei Zheng, Jijian Xu, Yuanyuan Wu, Jingxiang TI Continuous Relationship of Operative Duration with Risk of Adverse Perioperative Outcomes and Early Discharge Undergoing Thoracoscopic Lung Cancer Surgery SO CANCERS LA English DT Article DE thoracoscopic surgery; operative duration; lung cancer; outcomes ID PROLONGED AIR LEAK; COMPLICATIONS; EXTUBATION; THORACOTOMY; ANESTHESIA; TIME AB Simple Summary Operative duration is considered an important predictor of poor prognosis in several surgical specialties; however, for patients receiving thoracoscopic lung cancer surgery, whether this association remains, and what the trigger point of operative duration contributing to a dramatic increase in adverse perioperative outcomes (APOs) and a significant decrease in early discharge is, is unknown. This retrospective cohort study included 12,392 patients who underwent this surgical treatment and explored the continuous relationship of operative duration with risk of the six most common APOs and early discharge using restricted cubic spline (RCS). The results showed that the risk of APOs exponentially increases as the operative duration exceeds 90 min, accompanied by a significant decrease in the likelihood of early discharge, indicating that shortening the operative duration to less than 90 min may be an important adjustable factor to greatly reduce APOs and accelerate early discharge. Background: For thoracoscopic lung cancer surgery, the continuous relationship and the trigger point of operative duration with a risk of adverse perioperative outcomes (APOs) and early discharge remain unknown. Methods: This study enrolled 12,392 patients who underwent this surgical treatment. Five groups were stratified by operative duration: <60 min, 60-120 min, 120-180 min, 180-240 min, and >= 240 min. APOs included intraoperative hypoxemia, delayed extubation, postoperative pulmonary complications (PPCs), prolonged air leakage (PAL), postoperative atrial fibrillation (POAF), and transfusion. A restricted cubic spline (RCS) plot was used to characterize the continuous relationship of operative duration with the risk of APOs and early discharge. Results: The risks of the aforementioned APOs increased with each additional hour after the first hour. A J-shaped association with APOs was observed, with a higher risk in those with prolonged operative duration compared with those with shorter values. However, the probability of early discharge decreased from 0.465 to 0.350, 0.217, and 0.227 for each additional hour of operative duration compared with counterparts (<60 min), showing an inverse J-shaped association. The 90 min procedure appears to be a tipping point for a sharp increase in APOs and a significant reduction in early discharge. Conclusions: Our findings have important and meaningful implications for risk predictions and clinical interventions, and early rehabilitation, for APOs. C1 [Tong, Chaoyang; Shen, Yaofeng; Zhu, Hongwei; Wu, Jingxiang] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Anesthesiol, Shanghai 200052, Peoples R China. [Tong, Chaoyang; Zheng, Jijian] Shanghai Jiao Tong Univ, Shanghai Childrens Med Ctr, Sch Med, Dept Anesthesiol, Shanghai 200127, Peoples R China. [Xu, Yuanyuan] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Lung Canc Ctr, Shanghai 200030, Peoples R China. C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University RP Wu, JX (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Anesthesiol, Shanghai 200052, Peoples R China.; Zheng, JJ (corresponding author), Shanghai Jiao Tong Univ, Shanghai Childrens Med Ctr, Sch Med, Dept Anesthesiol, Shanghai 200127, Peoples R China. EM zhengjijian626@sina.com; wjx1132@163.com RI Wu, Jing-xiang/GON-5965-2022; zhu, hongwei/LSK-9010-2024 OI Wu, Jing-xiang/0000-0002-2858-9668; FU National Natural Science Foundation of China [82071233]; Shanghai Shen Kang Hospital Development Center Project [SHDC2020CR4063] FX This work was supported by the National Natural Science Foundation of China (82071233) and the Shanghai Shen Kang Hospital Development Center Project (SHDC2020CR4063). CR Albi-Feldzer A, 2021, ANESTHESIOLOGY, V135, P1091, DOI 10.1097/ALN.0000000000003989 Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E Bernatz JT, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.7.FOCUS1534 Bickler PE, 2017, ANESTH ANALG, V124, P146, DOI 10.1213/ANE.0000000000001421 Campos JH, 2020, J CARDIOTHOR VASC AN, V34, P423, DOI 10.1053/j.jvca.2019.08.017 Cheng H, 2018, J SURG RES, V229, P134, DOI 10.1016/j.jss.2018.03.022 Chudgar NP, 2021, ANN THORAC SURG, V111, P1643, DOI 10.1016/j.athoracsur.2020.08.021 Cywinski JB, 2009, J CARDIOTHOR VASC AN, V23, P766, DOI 10.1053/j.jvca.2009.03.022 Daley BJ, 2015, J AM COLL SURGEONS, V220, P550, DOI 10.1016/j.jamcollsurg.2014.12.040 Dawson NV, 2012, MED DECIS MAKING, V32, P225, DOI 10.1177/0272989X12437605 Dexter E, 2022, ANN THORAC SURG, V114, P941, DOI 10.1016/j.athoracsur.2022.01.040 Falcoz PE, 2016, EUR J CARDIO-THORAC, V49, P602, DOI 10.1093/ejcts/ezv154 Forster C, 2021, INTERACT CARDIOV TH, V33, P892, DOI 10.1093/icvts/ivab187 Frendl G, 2014, J THORAC CARDIOV SUR, V148, P772, DOI 10.1016/j.jtcvs.2014.06.037 Gal J, 2022, J CLIN ANESTH, V77, DOI 10.1016/j.jclinane.2021.110636 Gauthier J, 2020, BONE MARROW TRANSPL, V55, P675, DOI 10.1038/s41409-019-0679-x Jakuscheit A, 2017, EUR J ANAESTH, V34, P297, DOI 10.1097/EJA.0000000000000597 Jammer I, 2015, EUR J ANAESTH, V32, P88, DOI 10.1097/EJA.0000000000000118 Jin RS, 2021, TRANSL LUNG CANCER R, V10, P3616, DOI 10.21037/tlcr-21-186 Kaufmann KB, 2019, ACTA ANAESTH SCAND, V63, P1009, DOI 10.1111/aas.13388 Kwon ST, 2017, J THORAC CARDIOV SUR, V154, P652, DOI 10.1016/j.jtcvs.2017.02.008 Lohser J, 2015, ANESTH ANALG, V121, P302, DOI 10.1213/ANE.0000000000000808 Mazo V, 2014, ANESTHESIOLOGY, V121, P219, DOI 10.1097/ALN.0000000000000334 Petersen RH, 2012, ANN CARDIOTHORAC SUR, V1, P47, DOI 10.3978/j.issn.2225-319X.2012.04.05 Reames BN, 2015, SURG OBES RELAT DIS, V11, P207, DOI 10.1016/j.soard.2014.03.018 Routh JC, 2008, BJU INT, V102, P301, DOI 10.1111/j.1464-410X.2008.07663.x Sihoe ADL, 2020, RESPIROLOGY, V25, P49, DOI 10.1111/resp.13920 Skloot GS, 2017, CLIN GERIATR MED, V33, P447, DOI 10.1016/j.cger.2017.06.001 Tane S, 2021, EUR J CARDIO-THORAC, V60, P607, DOI 10.1093/ejcts/ezab237 Tong CY, 2022, J CLIN ANESTH, V79, DOI 10.1016/j.jclinane.2022.110770 Tong CY, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-20-5035 Tong CY, 2020, ANN THORAC SURG, V109, P1522, DOI 10.1016/j.athoracsur.2019.12.009 Tran J, 2022, J CLIN ANESTH, V78, DOI 10.1016/j.jclinane.2022.110682 Valentini LG, 2008, NEUROSURGERY, V62, P88, DOI 10.1227/01.NEU.0000311065.95496.C5 Valsangkar N, 2018, SURGERY, V164, P866, DOI 10.1016/j.surg.2018.06.020 Vannucci A, 2021, EUR J ANAESTH, V38, P494, DOI 10.1097/EJA.0000000000001316 Varela G, 2005, EUR J CARDIO-THORAC, V27, P329, DOI 10.1016/j.ejcts.2004.11.005 Varghese J, 2016, ANN THORAC SURG, V102, P1588, DOI 10.1016/j.athoracsur.2016.04.030 Xu JM, 2022, CLIN LUNG CANCER, V23, P170, DOI 10.1016/j.cllc.2021.06.007 Yang CFJ, 2021, ANN SURG, V273, P595, DOI 10.1097/SLA.0000000000003231 Zhang W, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.38 Zhao KJ, 2017, J THORAC DIS, V9, P1219, DOI 10.21037/jtd.2017.04.31 NR 42 TC 10 Z9 12 U1 0 U2 8 PU MDPI PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND EI 2072-6694 J9 CANCERS JI Cancers PD JAN PY 2023 VL 15 IS 2 AR 371 DI 10.3390/cancers15020371 PG 14 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA 7Y7MY UT WOS:000915059700001 PM 36672321 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Valenzuela-Rodriguez, G Diaz-Arocutipa, C Collins, JA Lopez-Fernandez, T Gomez, HL Hernandez, AV AF Valenzuela-Rodriguez, German Diaz-Arocutipa, Carlos Collins, Jaime A. Lopez-Fernandez, Teresa Gomez, Henry L. Hernandez, Adrian V. TI Severe cardiac events induced by combination immunotherapy in patients with cancer: a meta-analysis SO ARCHIVES OF MEDICAL SCIENCE LA English DT Review DE cancer; adverse effects; meta-analysis; immunotherapy; cardiac ID IMMUNE CHECKPOINT INHIBITORS; IPILIMUMAB; NIVOLUMAB AB Introduction: The use of combined immunotherapy could increase non-se-vere and severe cardiac events in patients with cancer. To examine the occurrence of severe cardiac adverse events of combined immunotherapy compared to single immunotherapy, we analysed 4 electronic databases from inception to August 2021.Material and methods: We selected randomized controlled trials (RCTs) comparing combined versus single immunotherapy, for the treatment of melanoma, oesophagogastric cancer, renal cell carcinoma, and non-small cell lung cancer. Pre-defined combined immunotherapy included monoclonal antibodies against programmed cell death 1 (PD-1 inhibitors) plus against cytotoxic T lymphocyte antigen 4 (CTLA-4 inhibitors) or against programmed cell death ligand 1 (PD-L1 inhibitors) plus CTLA-4 inhibitors. The pooled risk ratios (RR) with their 95% confidence intervals (CI) were estimated using a random-effects model.Results: Four RCTs involving 1581 patients were included, with a follow-up time between 18 and 39 months. The use of combined immunotherapy in comparison with single immunotherapy was not associated with an in-creased risk of severe cardiac adverse events: acute coronary syndromes (RR = 1.76, 95% CI: 0.29-10.83, very low certainty of evidence (CoE)), myo-cardial infarction (RR = 3.93, 95% CI: 0.44-35.39, very low CoE), heart fail-ure (RR = 2.99, 95% CI: 0.61-14.79, very low CoE), and atrial fibrillation (RR = 2.26, 95% CI: 0.62-8.16, very low CoE).Conclusions: Our meta-analysis shows that the risk of severe cardiac ad-verse events with combined immunotherapy seems similar to single immu-notherapy, but the evidence is very uncertain. Therefore, more RCTs with longer follow-ups and adequately powered to assess cardiac adverse events are needed to confirm these findings. C1 [Valenzuela-Rodriguez, German] Clin Delgado, Serv Med Interna & Cardiol, Lima, Peru. [Valenzuela-Rodriguez, German; Diaz-Arocutipa, Carlos; Collins, Jaime A.; Hernandez, Adrian V.] Univ San Ignacio de Loyola, Unidad Revis Sistemat & Metaanal URSIGET, Vicerrectorado Invest, Lima, Peru. [Collins, Jaime A.] Hosp Nacl Guillermo Almenara Irigoyen EsSalud, Serv Med Interna, Lima, Peru. [Lopez-Fernandez, Teresa] Hosp Univ La Paz, Unidad Cardiooncol, Madrid, Spain. [Lopez-Fernandez, Teresa] Hosp Univ Quiron Pozuelo, Serv Cardiol, Madrid, Spain. [Gomez, Henry L.] Clin Delgado, Serv Oncol Clin, Lima, Peru. [Gomez, Henry L.] ONCOSALUD, Lima, Peru. [Hernandez, Adrian V.] Univ Connecticut, Sch Pharm, Hlth Outcomes Policy & Evidence Synth HOPES Grp, Storrs, CT USA. [Valenzuela-Rodriguez, German] Univ San Ignacio de Loyola USIL, Unidad Revis Sistemat & Metaanal URSIGET, Vicerrectorado Invest, Av La Fontana 550, Lima 15024, Peru. C3 Universidad San Ignacio de Loyola; Seguro Social de Salud del Peru; Hospital Universitario La Paz; University of Connecticut; Universidad San Ignacio de Loyola RP Valenzuela-Rodriguez, G (corresponding author), Univ San Ignacio de Loyola USIL, Unidad Revis Sistemat & Metaanal URSIGET, Vicerrectorado Invest, Av La Fontana 550, Lima 15024, Peru. EM gvalenzuela@usil.edu.pe RI Valenzuela, German/IZE-6324-2023; Gomez, Henry/AGN-8948-2022; Lopez-Fernandez, Teresa/AAK-8968-2020; Diaz-Arocutipa, Carlos/AAX-6200-2021; Collins, Jaime/LZF-2845-2025 OI Gomez, Henry/0000-0003-2660-1843; Diaz-Arocutipa, Carlos/0000-0002-5101-2832; CR Agostinetto E, 2021, EUR J CANCER, V148, P76, DOI 10.1016/j.ejca.2021.01.043 Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015 Feng R, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0382-1 Ferris RL, 2020, ANN ONCOL, V31, P942, DOI 10.1016/j.annonc.2020.04.001 Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1016/j.bandl.2008.10.005 Jagielska B, 2020, IUBMB LIFE, V72, P1160, DOI 10.1002/iub.2299 Khunger M, 2017, CHEST, V152, P271, DOI 10.1016/j.chest.2017.04.177 Lal JC, 2021, CARDIO-ONCOLOGY, V7, DOI 10.1186/s40959-021-00106-x Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI 10.1056/NEJMoa1504030 Li HL, 2022, IMMUNOTHERAPY-UK, V14, P577, DOI 10.2217/imt-2021-0223 Mahmood SS, 2018, J AM COLL CARDIOL, V71, P1755, DOI 10.1016/j.jacc.2018.02.037 Nso N, 2020, WORLD J CARDIOL, V12, P584, DOI 10.4330/wjc.v12.i11.584 Page MJ, 2021, BMJ-BRIT MED J, V372, DOI [10.1016/j.rec.2021.07.010, 10.1136/bmj.n71] Page MJ, 2022, COCHRANE HDB SYSTEMA Postow MA, 2015, NEW ENGL J MED, V372, P2006, DOI 10.1056/NEJMoa1414428 Rizvi NA, 2020, JAMA ONCOL, V6, P661, DOI 10.1001/jamaoncol.2020.0237 Sweeting MJ, 2004, STAT MED, V23, P1351, DOI 10.1002/sim.1761 Veroniki AA, 2016, RES SYNTH METHODS, V7, P55, DOI 10.1002/jrsm.1164 Wang DY, 2018, JAMA ONCOL, V4, P1721, DOI 10.1001/jamaoncol.2018.3923 Zarifa A, 2021, KOREAN CIRC J, V51, P579 Zhou YW, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01350 Zhuo ML, 2020, ASIA-PAC J CLIN ONCO, V16, pE154, DOI 10.1111/ajco.13365 NR 22 TC 1 Z9 2 U1 0 U2 2 PU TERMEDIA PUBLISHING HOUSE LTD PI POZNAN PA KLEEBERGA 2, POZNAN, 61-615, POLAND SN 1734-1922 EI 1896-9151 J9 ARCH MED SCI JI Arch. Med. Sci. PY 2023 VL 19 IS 6 BP 1662 EP 1670 DI 10.5114/aoms/168124 PG 9 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA Z0AG5 UT WOS:001108790700031 PM 38058705 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Yan, T Zhu, M Weng, F Zhu, SJ Wang, CS Guo, CF AF Yan, Tao Zhu, Miao Weng, Fan Zhu, Shijie Wang, Chunsheng Guo, Changfa TI Comprehensive analysis of roles of atrial-fibrillation-related genes in lung adenocarcinoma using bioinformatic methods SO MEDICAL ONCOLOGY LA English DT Article DE Atrial fibrillation; Lung cancer; Prognosis; Immune infiltration; Non-coding RNA ID MICRORNA BINDING-SITES; WEB SERVER; DNA METHYLATION; CANCER; EXPRESSION; PROLIFERATION; INTEGRATION; PREDICTION; SOCIETY; CERNA AB Atrial fibrillation (AF) is the most common tachyarrhythmia in the world. Lung cancer is the leading cause of cancer deaths in 93 countries. Previous studies demonstrated that the prevalence of AF was higher in patients with lung cancer. However, research on the associations between AF and lung cancer is still rare. In the present study, we first identified AF-related genes using weighted gene correlation network analysis. We then analyzed the expression profiles, prognosis, immune infiltration, and methylation characteristics of these genes in LUAD patients using bioinformatics analysis. We found several AF-related genes, including CBX3, BUB1, DSC2, P4HA1, and CYP4Z1, which differently expressed between tumor and normal tissues. Survival analysis demonstrated that CYP4Z1 was positively correlated with overall survival in LUAD patients, while CBX3, BUB1, DSC2, and P4HA1 were negatively correlated. Moreover, we found that the methylation level of DSC2 in normal lung tissues was significantly higher than that in tumor tissues, and six methylation sites in the DNA sequences of DSC2 were identified negatively correlated with its expression levels. Immune infiltration analysis suggested that levels of immune cell infiltration were related to gene expression levels in varying degrees. We identified AF-related genes and found these genes were correlated with prognosis, immune infiltration, and methylation levels in lung cancer patients. We also constructed a risk signature based on these genes in LUAD patients. We hoped that the current study could provide a novel insight into roles of AF-related genes in lung cancer patients. C1 [Yan, Tao; Zhu, Miao; Weng, Fan; Zhu, Shijie; Wang, Chunsheng; Guo, Changfa] Fudan Univ, Zhongshan Hosp, Dept Cardiovasc Surg, 180 Fenglin Rd, Shanghai 200032, Peoples R China. C3 Fudan University RP Wang, CS; Guo, CF (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Cardiovasc Surg, 180 Fenglin Rd, Shanghai 200032, Peoples R China. EM wangchunsheng@fudan.edu.cn; guo.changfa@outlook.com RI ; zhu, shijie/LFS-9954-2024; Wang, Chun-Sheng/AAQ-4374-2020 OI Yan, Tao/0000-0002-2464-2361; Guo, Changfa/0000-0001-7787-5532; FU General Program of the National Natural Science Foundation of China [81770408] FX This work was supported by the General Program of the National Natural Science Foundation of China (No. 81770408). CR Alam H, 2018, CANCER RES, V78, P3834, DOI 10.1158/0008-5472.CAN-17-3571 Andrade J, 2014, CIRC RES, V114, P1453, DOI 10.1161/CIRCRESAHA.114.303211 Andriani F, 2012, J THORAC ONCOL, V7, P631, DOI 10.1097/JTO.0b013e318244aed0 Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609] Camm AJ, 2010, EUROPACE, V12, P1360, DOI [10.1093/eurheartj/ehq278, 10.1093/europace/euq350] Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002 Chen K, 2006, NAT GENET, V38, P1452, DOI 10.1038/ng1910 Chen W, 2021, CANCER RES, V81, P3509, DOI 10.1158/0008-5472.CAN-19-3806 Chen Y, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00252-1 Conway K, 2015, CANCER EPIDEM BIOMAR, V24, P921, DOI 10.1158/1055-9965.EPI-14-1228 Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088 Gordon DJ, 2012, NAT REV GENET, V13, P189, DOI 10.1038/nrg3123 Hindricks G, 2021, EUR HEART J, V42, P546, DOI 10.1093/eurheartj/ehaa945 Hu ZY, 2019, TRANSL LUNG CANCER R, V8, P1091, DOI 10.21037/tlcr.2019.10.17 Imperatori A, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-4 January CT, 2019, CIRCULATION, V140, pE125, DOI [10.1161/CIR.0000000000000665, 10.1016/j.jacc.2019.01.011] Johnson AM, 2021, J THORAC ONCOL, V31, P490 Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135 Koch A, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1847-z Kocher F, 2021, LUNG CANCER, V159, P84, DOI 10.1016/j.lungcan.2021.06.020 Leek JT, 2010, NAT REV GENET, V11, P733, DOI 10.1038/nrg2825 Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035 Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248 Li TW, 2017, CANCER RES, V77, pE108, DOI 10.1158/0008-5472.CAN-17-0307 Li WH, 2021, MOL THER-NUCL ACIDS, V24, P528, DOI 10.1016/j.omtn.2020.12.023 Lin HX, 2020, DIS MARKERS, V2020, DOI 10.1155/2020/2412741 Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031 Modhukur V, 2018, EPIGENOMICS-UK, V10, P277, DOI 10.2217/epi-2017-0118 Morishima M, 2016, CIRC J, V80, P1346, DOI 10.1253/circj.CJ-15-1276 Ning Y, 2021, J CANCER, V12, P6685, DOI 10.7150/jca.63147 Nyati S, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005379 O'Neal WT, 2015, AM J CARDIOL, V115, P1090, DOI 10.1016/j.amjcard.2015.01.540 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Paraskevopoulou MD, 2013, NUCLEIC ACIDS RES, V41, pW169, DOI 10.1093/nar/gkt393 Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007 Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014 Sami E, 2022, CANCER GENE THER, V29, P304, DOI 10.1038/s41417-021-00311-x Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247 Uhlen M, 2015, SCIENCE, V347, DOI [10.1126/science.347.6227.1274-c, 10.1126/science.1260419] Vejnar CE, 2012, NUCLEIC ACIDS RES, V40, P11673, DOI 10.1093/nar/gks901 Wang K, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.737152 Wang SS, 2019, CELL MOL IMMUNOL, V16, P6, DOI 10.1038/s41423-018-0027-x Warde-Farley D, 2010, NUCLEIC ACIDS RES, V38, pW214, DOI [10.1093/nar/gkq537, 10.1002/adma.202504015] Xiong YC, 2017, NUCLEIC ACIDS RES, V45, pD888, DOI 10.1093/nar/gkw1123 Xu F, 2021, MOL THER NUCL ACIDS, V24, P780, DOI 10.1016/j.omtn.2021.04.003 Yang X, 2017, CURR PHARM DESIGN, V23, P2060, DOI 10.2174/1381612823666170207150156 Zhang B, 2005, STAT APPL GENET MOL, V4, DOI 10.2202/1544-6115.1128 Zhang C, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.771062 Zhao Q, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.754580 Zhou HT, 2020, BIOMED RES INT-UK, V2020, DOI 10.1155/2020/8024138 Zhu LH, 2021, J CANCER, V12, P3291, DOI 10.7150/jca.56218 NR 52 TC 2 Z9 2 U1 0 U2 5 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1357-0560 EI 1559-131X J9 MED ONCOL JI Med. Oncol. PD DEC 21 PY 2022 VL 40 IS 1 AR 55 DI 10.1007/s12032-022-01912-8 PG 13 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA 7F7CW UT WOS:000902001900001 PM 36542177 DA 2026-04-17 ER PT J AU Ruiz-Briones, P Escudero-Vilaplana, V Collado-Borrell, R Vicente-Valor, J Alvarez, R Villanueva-Bueno, C Narrillos-Moraza, A Herranz, A Sanjurjo, M AF Ruiz-Briones, Paula Escudero-Vilaplana, Vicente Collado-Borrell, Roberto Vicente-Valor, Juan Alvarez, Rosa Villanueva-Bueno, Cristina Narrillos-Moraza, Alvaro Herranz, Ana Sanjurjo, Maria TI Possible heart failure caused by osimertinib in a lung cancer patient SO JOURNAL OF ONCOLOGY PHARMACY PRACTICE LA English DT Article DE Osimertinib; cardiotoxicity; LVEF decrease; heart failure ID CARDIOVASCULAR TOXICITY AB Introduction Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) indicated for the treatment of epidermal growth factor receptor mutated non-small cell lung cancer (NSCLC). It has demonstrated better results concerning effectiveness than other TKIs for the same indication. However, despite a good safety profile, it could produce some cardiotoxicity that does not occur with other drugs of the same group. Case report We report the evolution and management of a female patient diagnosed with NSCLC who developed a grade 3 cardiotoxicity due to treatment with osimertinib. This patient suffered from a left bundle branch block, dyslipidemia, and hypertension as cardiovascular risk factors. After a long period of treatment with osimertinib, she developed a severe heart failure (HF) with an important decrease in left ventricular ejection fraction (LVEF), which triggered an admission to the oncology unit for eight days. Management and outcomes Treatment with osimertinib was first suspended and then resumed after stabilization of the HF. She also developed atrial fibrillation during admission and has required narrow cardiac monitoring and management since the debut of the HF. After evaluating the benefit-risk balance, osimertinib was reintroduced and the patient continues in treatment at the moment, although the baseline LVEF is not recovered. Discussion There is scarce evidence in the literature concerning HF and important LVEF decrease due to osimertinib. However, its severity and repercussion for the patient justify the thorough screening of cardiovascular risk factors before starting the therapy. C1 [Ruiz-Briones, Paula; Escudero-Vilaplana, Vicente; Collado-Borrell, Roberto; Vicente-Valor, Juan; Villanueva-Bueno, Cristina; Narrillos-Moraza, Alvaro; Herranz, Ana; Sanjurjo, Maria] Hosp Gen Univ Gregorio Maranon, Pharm Dept, Madrid, Spain. [Alvarez, Rosa] Hosp Gen Univ Gregorio Maranon, Oncol Dept, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain. [Escudero-Vilaplana, Vicente] Hosp Gen Univ Gregorio Maranon, Pharm Dept, Doctor Esquerdo 46, Madrid 28007, Spain. C3 General University Gregorio Maranon Hospital; General University Gregorio Maranon Hospital; General University Gregorio Maranon Hospital RP Escudero-Vilaplana, V (corresponding author), Hosp Gen Univ Gregorio Maranon, Pharm Dept, Doctor Esquerdo 46, Madrid 28007, Spain. EM vicente.escudero@salud.madrid.org RI ; ALONSO, ANA/E-9456-2018; Escudero-Vilaplana, Vicente/R-6683-2018; ALVAREZ, ROSA/MZR-5280-2025 OI VICENTE VALOR, JUAN/0000-0001-9319-5107; Escudero-Vilaplana, Vicente/0000-0003-4417-8321; Ruiz Briones, Paula/0000-0003-4285-148X; ALVAREZ, ROSA/0000-0003-0935-8298 CR Andalusian society of intensive medicine and coronary units (SAMIUC), CARDIOVASCULAR CALCU [Anonymous], Common Terminology Criteria for Adverse Events (CTCAE) Bardaro F, 2022, J ONCOL PHARM PRACT, V28, P989, DOI 10.1177/10781552211073823 Curigliano G, 2020, ANN ONCOL, V31, P171, DOI 10.1016/j.annonc.2019.10.023 Ettinger DS, 2021, J NATL COMPR CANC NE, V19, P254, DOI 10.6004/jnccn.2021.0013 European Medicines Agency, European Public Assessment Report (EPAR)-Abrysvo Ewer MS, 2021, J CLIN ONCOL, V39, P328, DOI 10.1200/JCO.20.01171 Goss G, 2016, LANCET ONCOL, V17, P1643, DOI 10.1016/S1470-2045(16)30508-3 Jänne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817 Kunimasa K, 2021, J CLIN ONCOL, V39, P2050, DOI 10.1200/JCO.21.00266 Kunimasa K, 2020, JACC-CARDIOONCOL, V2, P1, DOI 10.1016/j.jaccao.2020.02.003 García AM, 2021, REV ESP CARDIOL, V74, P438, DOI 10.1016/j.recesp.2020.11.014 Mok TS, 2017, NEW ENGL J MED, V376, P629, DOI 10.1056/NEJMoa1612674 NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154 Piper-Vallillo AJ, 2020, JACC-CARDIOONCOL, V2, P119, DOI 10.1016/j.jaccao.2020.01.003 Planchard D, 2018, ANN ONCOL, V29, P192, DOI 10.1093/annonc/mdy275 Rao VJU, 2021, J AM COLL CARDIOL, V77, P2693, DOI 10.1016/j.jacc.2021.04.009 Sequist LV, 2013, J CLIN ONCOL, V31, P3327, DOI 10.1200/JCO.2012.44.2806 Shinomiya S, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000022301 Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137 Zaborowska-Szmit M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051268 Zamorano JL, 2016, EUR HEART J, V37, P2768, DOI [10.1093/eurheartj/ehw211, 10.1002/ejhf.654] NR 22 TC 4 Z9 6 U1 1 U2 7 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1078-1552 EI 1477-092X J9 J ONCOL PHARM PRACT JI J. Oncol. Pharm. Pract. PD JUN PY 2023 VL 29 IS 4 BP 1015 EP 1020 DI 10.1177/10781552221143787 EA DEC 2022 PG 6 WC Oncology; Pharmacology & Pharmacy WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Pharmacology & Pharmacy GA J8MS8 UT WOS:000895494400001 PM 36480925 DA 2026-04-17 ER PT J AU Yang, XX Jiang, YF Xie, MS Wang, XL Fang, WT Luo, QQ Zhou, QJ Yao, F Yu, H Shen, L He, B Shen, LH AF Yang, Xiaoxiao Jiang, Yifeng Xie, Mengshi Wang, Xiaolei Fang, Wentao Luo, Qingquan Zhou, Qianjun Yao, Feng Yu, Hong Shen, Lan He, Ben Shen, Linghong TI Nongated Computed Tomography Predicts Perioperative Cardiovascular Risk in Lung Cancer Surgery SO ANNALS OF THORACIC SURGERY LA English DT Article; Proceedings Paper CT European-Society-of-Cardiology (ESC) Congress CY AUG 29-SEP 01, 2020 CL ELECTR NETWORK SP European Soc Cardiol ID CORONARY-ARTERY CALCIUM; ATRIAL-FIBRILLATION; EVENTS; SCORE; MORTALITY; SOCIETY; COMPLICATIONS; ASSOCIATION; ANGIOGRAPHY; GUIDELINES AB BACKGROUND The coronary artery calcification score (CACS), a strong predictor of cardiovascular events and mor-tality, can be assessed by nongated chest computed tomography (CT). The study aimed to determine whether CACS based on nongated CT is predictive of perioperative cardiovascular events during intermediate-risk lung cancer surgery. METHODS In this retrospective, single-center study, we used nongated CT images to evaluate CACS in 4491 patients with lung cancer who underwent intermediate-risk surgeries. Perioperative cardiovascular events were defined as in -hospital cardiac death, nonfatal myocardial infarction, heart failure, atrial and ventricular arrhythmia with hemody-namic compromise, and complete heart block. Risk factors of perioperative cardiovascular events were identified by multivariate logistic regression analysis. RESULTS In total, 110 inpatients (2.5%) experienced perioperative cardiac events. Coronary calcification was observed on nongated CT in 1070 (23.8%) patients. CACS was significantly associated with the incidence of cardiovascular events and longer hospital stays. According to receiver operating characteristic curve analysis, the CACS cutoff value was set to 1. In the multivariate analysis, CACS double dagger 1 (odds ratio, 1.75; 95% CI, 1.14-2.68; P = .011) or the number of calcified vessels (odds ratio, 1.23; 95% CI, 1.01-1.50; P = .043), age, forced expiratory volume in 1 second/predicted, operation time, and thoracotomy were predictive of cardiovascular complications. CONCLUSIONS CACS is an independent predictor of severe perioperative cardiovascular risk in patients undergoing intermediate-risk lung cancer surgery. CACS may represent a valuable tool for preoperative risk assessment of these patients. (Ann Thorac Surg 2022;114:2050-8)(c) 2022 The Authors. Published by Elsevier Inc. on behalf of The Society of Thoracic Surgeons.This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). C1 [Yang, Xiaoxiao; Xie, Mengshi; Wang, Xiaolei; Shen, Lan; He, Ben; Shen, Linghong] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Cardiol, 241 W Huaihai Rd, Shanghai 200030, Peoples R China. [Jiang, Yifeng; Yu, Hong] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Radiol, Shanghai, Peoples R China. [Fang, Wentao; Yao, Feng] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Thorac Surg, Shanghai, Peoples R China. [Luo, Qingquan; Zhou, Qianjun] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China. [Shen, Lan] Shanghai Jiao Tong Univ, Clin Res Ctr, Shanghai, Peoples R China. C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University RP Shen, LH (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Cardiol, 241 W Huaihai Rd, Shanghai 200030, Peoples R China. EM rjshenlinghong@126.com RI Luo, Qingquan/KFR-8000-2024; jiang, yifeng/HSI-1947-2023; yu, hb/HDO-5531-2022 FU National Natural Science Foundation of China [91539106, 81830010, 81900308]; Emerging and Advanced Technology Programs of Hospital Development Center of Shanghai [SHDC12018129, 16CR1012A]; Shanghai Science and Technology Committee [18411950400, 19JC1415702]; Clinical research grant of Shanghai Jiaotong University, School of Medicine [dly201512]; Shanghai Chest Hospital Project of Collaborative Innovation [YJXT20190103] FX This work was supported by the National Natural Science Foundation of China, Grant/Award Numbers: 91539106, 81830010, 81900308; Emerging and Advanced Technology Programs of Hospital Development Center of Shanghai, Grant/Award Number: SHDC12018129, 16CR1012A; Shanghai Science and Technology Committee, Grant/Award Number: 18411950400, 19JC1415702; Clinical research grant of Shanghai Jiaotong University, School of Medicine, Grant Number: dly201512; Shanghai Chest Hospital Project of Collaborative Innovation ,Grant Number: YJXT20190103. CR AGATSTON AS, 1990, J AM COLL CARDIOL, V15, P827, DOI 10.1016/0735-1097(90)90282-T Ahn JH, 2013, J AM COLL CARDIOL, V61, P661, DOI 10.1016/j.jacc.2012.09.060 Allison MA, 2006, CIRCULATION, V113, P861, DOI 10.1161/CIRCULATIONAHA.105.552844 Bensenor IM, 2016, AM HEART J, V174, P51, DOI 10.1016/j.ahj.2015.12.018 Brunelli A, 2013, CHEST, V143, pE166, DOI 10.1378/chest.12-2395 Budoff MJ, 2011, J CARDIOVASC COMPUT, V5, P113, DOI 10.1016/j.jcct.2010.11.002 Detrano R, 2008, NEW ENGL J MED, V358, P1336, DOI 10.1056/NEJMoa072100 Erbel R, 2013, ATHEROSCLEROSIS, V229, P531, DOI 10.1016/j.atherosclerosis.2013.04.015 Ferguson MK, 2014, ANN THORAC SURG, V97, P1135, DOI 10.1016/j.athoracsur.2013.12.032 Fernandez FG, 2016, ANN THORAC SURG, V102, P370, DOI 10.1016/j.athoracsur.2016.02.098 Fleisher LA, 2014, J AM COLL CARDIOL, V64, pE77, DOI 10.1016/j.jacc.2014.07.944 Hecht HS, 2017, J CARDIOVASC COMPUT, V11, P74, DOI 10.1016/j.jcct.2016.11.003 Jacobs PC, 2012, AM J ROENTGENOL, V198, P505, DOI 10.2214/AJR.10.5577 Kong YG, 2015, BRIT J ANAESTH, V114, P437, DOI 10.1093/bja/aeu384 Kristensen SD, 2014, EUR HEART J, V35, P2383, DOI [10.1093/eurheartj/ehu282, 10.5603/KP.2014.0193] Lapar DJ, 2014, ANN THORAC SURG, V98, P527, DOI 10.1016/j.athoracsur.2014.03.039 Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805 O'Neal WT, 2014, AM J CARDIOL, V114, P1707, DOI 10.1016/j.amjcard.2014.09.005 Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205 Pletcher MJ, 2004, ARCH INTERN MED, V164, P1285, DOI 10.1001/archinte.164.12.1285 Polonsky TS, 2010, JAMA-J AM MED ASSOC, V303, P1610, DOI 10.1001/jama.2010.461 Raggi P, 2000, CIRCULATION, V101, P850, DOI 10.1161/01.CIR.101.8.850 Rudd KE, 2020, LANCET, V395, P200, DOI 10.1016/S0140-6736(19)32989-7 Shalaeva EV, 2016, INT J CARDIOL, V221, P806, DOI 10.1016/j.ijcard.2016.06.165 Sheth T, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1907 Takx RAP, 2015, EUR RADIOL, V25, P65, DOI 10.1007/s00330-014-3384-6 Takx RAP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091239 Thomas DC, 2017, ANN THORAC SURG, V104, P389, DOI 10.1016/j.athoracsur.2017.02.006 Thygesen K, 2019, EUR HEART J, V40, P237, DOI 10.1093/eurheartj/ehy462 NR 29 TC 8 Z9 8 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD DEC PY 2022 VL 114 IS 6 BP 2050 EP 2057 DI 10.1016/j.athoracsur.2022.04.023 EA NOV 2022 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 7D9CK UT WOS:000900779900013 PM 35490773 OA hybrid DA 2026-04-17 ER PT J AU Wang, JH Chen, ZR Yang, HK Li, H Chen, RD Yu, JS AF Wang, Junhong Chen, Zirong Yang, Hongkuan Li, Hua Chen, Rudong Yu, Jiasheng TI Relationship between the Hemoglobin-to-Red Cell Distribution Width Ratio and All-Cause Mortality in Septic Patients with Atrial Fibrillation: Based on Propensity Score Matching Method SO JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE LA English DT Article DE atrial fibrillation; sepsis; hemoglobin-to-red blood cell distribution width ratio; all-cause mortality; MIMIC-IV database ID C-REACTIVE PROTEIN; LUNG-CANCER; CARDIOVASCULAR EVENTS; ANEMIA; SEPSIS; OUTCOMES; RISK; TRANSFUSION; SURVIVORS AB (1) Objective: To reveal the correlation between the hemoglobin-to-red cell distribution width ratio (HRR) and all-cause mortality (ACM) among the septic patients with atrial fibrillation. (2) Methods: Specific clinical information was collected from the Medical Information Mart for Intensive IV (MIMIC-IV) database. The optimal cut-off value of HRR was calculated through ROC curve analysis conducted by using the maximum Youden index for the prediction of survival status. In addition, univariable and multivariable Cox regressive analyses were carried out to assess the prognostic significance of HRR and the Kaplan-Meier (K-M) analysis was conducted to draw the survival curves. Then, the 1:1 propensity score matching (PSM) method was adopted to improve the reliability of research result while balancing the unintended influence of underlying confounders. (3) Results: There were 9228 patients participating in this retrospective cohort study. The optimal cut-off value of the HRR was determined as 5.877 for in-hospital mortality. The PSM was performed to identify 2931 pairs of score-matched patients, with balanced differences exhibited by nearly all variables. According to the K-M analysis, those patients with a lower HRR than 5.877 showed a significantly higher level of in-hospital mortality, 28-day mortality, and 90-day mortality, compared to the patients with HRR >= 5.877 (p < 0.001). After the adjustment of possible confounders, those patients whose HRR was below 5.877 had a significantly higher level of in-hospital mortality than the patients with HRR >= 5.877, as revealed by the multivariable Cox regression analysis (HR = 1.142, 95%CI: 1.210-1.648, p < 0.001). Similarly, the ACM remained substantially higher in those patients with a lower HRR than in the patients with higher HRR after PSM. (4) Conclusion: A lower HRR (<5.877) was evidently associated with an increased risk of ACM, which made it applicable as a prognostic predictor of clinical outcomes for those septic patients with atrial fibrillation. C1 [Wang, Junhong; Chen, Zirong; Yang, Hongkuan; Li, Hua; Chen, Rudong; Yu, Jiasheng] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Neurosurg, Wuhan 430074, Peoples R China. C3 Huazhong University of Science & Technology RP Chen, RD; Yu, JS (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Neurosurg, Wuhan 430074, Peoples R China. EM rudongchen@tjh.tjmu.edu.cn; yujiasheng2000@tjh.tjmu.edu.cn RI Li, Hua/G-9884-2012; Wang, Junhong/HKE-0286-2023 OI Wang, Junhong/0000-0002-3931-7529 CR Acosta JN, 2021, CRIT CARE MED, V49, P828, DOI 10.1097/CCM.0000000000004891 Altman AD, 2013, INT J GYNECOL CANCER, V23, P1569, DOI 10.1097/IGC.0b013e3182a57ff6 Annane D, 2008, AM J RESP CRIT CARE, V178, P20, DOI 10.1164/rccm.200701-031OC Arbel Y, 2014, THROMB HAEMOSTASIS, V111, P300, DOI 10.1160/TH13-07-0567 Austin PC, 2015, STAT MED, V34, P3661, DOI 10.1002/sim.6607 Austin PC, 2011, MULTIVAR BEHAV RES, V46, P399, DOI 10.1080/00273171.2011.568786 Bashar SK, 2020, IEEE J BIOMED HEALTH, V24, P3124, DOI 10.1109/JBHI.2020.2995139 Bozkaya Y, 2019, INT J CLIN ONCOL, V24, P798, DOI 10.1007/s10147-019-01417-x Chen JL, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237947 Cheng C, 2022, AM J EPIDEMIOL, V191, P1140, DOI 10.1093/aje/kwac043 Förhécz Z, 2009, AM HEART J, V158, P659, DOI 10.1016/j.ahj.2009.07.024 Fyles AW, 2000, RADIOTHER ONCOL, V57, P13, DOI 10.1016/S0167-8140(00)00245-0 Gauthier I, 2007, LUNG CANCER, V55, P357, DOI 10.1016/j.lungcan.2006.10.021 Holgersson G, 2012, MED ONCOL, V29, P3176, DOI 10.1007/s12032-012-0247-3 Johnson Alistair, 2023, PN Kuipers S, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0688-5 Li L, 2013, INT J BIOSTAT, V9, P215, DOI 10.1515/ijb-2012-0030 Moreno-Torres V, 2022, J CRIT CARE, V71, DOI 10.1016/j.jcrc.2022.154069 Ou SM, 2016, AM J RESP CRIT CARE, V194, P209, DOI 10.1164/rccm.201510-2023OC Pascual-Figal DA, 2009, EUR J HEART FAIL, V11, P840, DOI 10.1093/eurjhf/hfp109 Petrella F, 2021, CANCERS, V13, DOI 10.3390/cancers13040710 Qu JL, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.728800 Rahamim E, 2022, J CLIN MED, V11, DOI 10.3390/jcm11030886 Ray-Coquard I, 2012, ADV THER, V29, P124, DOI 10.1007/s12325-011-0093-2 Ridker PM, 2001, NEW ENGL J MED, V344, P1959, DOI 10.1056/NEJM200106283442601 Sadaka Farid, 2013, J Intensive Care Med, V28, P307, DOI 10.1177/0885066612452838 Sesso HD, 2003, JAMA-J AM MED ASSOC, V290, P2945, DOI 10.1001/jama.290.22.2945 Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287 Skrivankova VW, 2021, JAMA-J AM MED ASSOC, V326, P1614, DOI 10.1001/jama.2021.18236 Su YC, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9060672 Tonelli M, 2008, CIRCULATION, V117, P163, DOI 10.1161/CIRCULATIONAHA.107.727545 Topaz G, 2017, J CRIT CARE, V41, P166, DOI 10.1016/j.jcrc.2017.05.014 Vannella L, 2013, ALIMENT PHARM THER, V37, P375, DOI 10.1111/apt.12177 Walkey AJ, 2013, AM HEART J, V165, P949, DOI 10.1016/j.ahj.2013.03.020 Walkey AJ, 2011, JAMA-J AM MED ASSOC, V306, P2248, DOI 10.1001/jama.2011.1615 Wang AY, 2018, AM J EMERG MED, V36, P949, DOI 10.1016/j.ajem.2017.10.056 Wang L, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2019.12.142 Wu FF, 2020, THORAC CANCER, V11, P888, DOI 10.1111/1759-7714.13330 Xiu WJ, 2022, FRONT CARDIOVASC MED, V9, DOI 10.3389/fcvm.2022.726025 Xu WS, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000612 Yende S, 2014, AM J RESP CRIT CARE, V189, P1065, DOI 10.1164/rccm.201307-1321OC Yilmaz A, 2020, IRISH J MED SCI, V189, P91, DOI 10.1007/s11845-019-02153-x Yilmaz H, 2021, FUTURE ONCOL, V17, P3853, DOI 10.2217/fon-2021-0040 Zhai Z, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/8729869 Zhao WC, 2022, ANN TRANSL MED, V10, DOI 10.21037/atm-21-6348 Zheng YY, 2019, THROMB HAEMOSTASIS, V119, P1021, DOI 10.1055/s-0039-1681103 NR 46 TC 37 Z9 39 U1 0 U2 9 PU MDPI PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND EI 2308-3425 J9 J CARDIOVASC DEV DIS JI J. Cardiovasc. Dev. Dis. PD NOV PY 2022 VL 9 IS 11 AR 400 DI 10.3390/jcdd9110400 PG 16 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA 6V6XX UT WOS:000895189100001 PM 36421935 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Inoue, K Tajiri, K Xu, DZ Murakoshi, N Ieda, M AF Inoue, Keiko Tajiri, Kazuko Xu, DongZhu Murakoshi, Nobuyuki Ieda, Masaki TI Risk Factors and In-Hospital Outcomes of Perioperative Atrial Fibrillation for Patients with Cancer: A Meta-Analysis SO ANNALS OF SURGICAL ONCOLOGY LA English DT Article ID LUNG-CANCER; THORACIC-SURGERY; ESOPHAGEAL; PROPHYLAXIS; AMIODARONE; PREVENTION; MORBIDITY; TRIAL; AGE; ARRHYTHMIAS AB Background Perioperative atrial fibrillation is a common postoperative complication. Adverse consequences associated with POAF include hemodynamic instability, increased risk of stroke, extended hospital stays, and increased mortality. Methods To determine the risk factors for POAF and to investigate the outcomes of POAF for patients with cancer, a systematic search of the PubMed and Cochrane Library databases was conducted from inception of the study to 1 September 2021. The inclusion criteria specified studies reporting the prevalence of POAF among patients with cancer. The study excluded articles not written in English, review articles, case reports, letters, commentaries, systematic reviews, meta-analyses, and conference abstracts. Results The search identified 49 studies with 201,081 patients, and the pooled prevalence of POAF was 13.5% (95% confidence interval [CI], 11.6-15.7%). Meta-analyses showed that the incidence of POAF among patients with cancer was associated with age (mean difference [MD], 4.31; 95%CI, 3.16-5.47), male sex (odds ratio [OR], 1.39; 95% CI, 1.19-1.62), chronic obstructive pulmonary disease (OR, 2.47; 95% CI, 1.71-3.56), hypertension (OR, 1.47; 95% CI, 1.23-1.75), intraoperative blood transfusion (OR, 4.58; 95% CI, 2.31-9.10), and open surgery (OR, 1.51; 95% CI, 1.26-1.81). Patients with POAF had significantly higher in-hospital mortality (OR, 4.25; 95% CI, 2.79-6.45), longer hospital stays (MD, 3.07; 95% CI, 1.63-4.51), and higher incidences of pneumonia (OR, 3.32; 95% CI, 2.85-3.86), stroke (OR, 6.57; 95% CI, 1.56-26.00), and myocardial infarction (OR, 3.00; 95% CI, 1.45-6.20) than those without POAF. Conclusions For patients with cancer, POAF is associated with an increased burden of comorbidities and worse outcomes. C1 [Inoue, Keiko; Tajiri, Kazuko; Xu, DongZhu; Murakoshi, Nobuyuki; Ieda, Masaki] Univ Tsukuba, Fac Med, Dept Cardiol, Tsukuba, Ibaraki, Japan. [Tajiri, Kazuko] Natl Canc Ctr Hosp East, Dept Cardiol, Kashiwa, Chiba, Japan. C3 University of Tsukuba; National Cancer Center - Japan RP Tajiri, K (corresponding author), Univ Tsukuba, Fac Med, Dept Cardiol, Tsukuba, Ibaraki, Japan.; Tajiri, K (corresponding author), Natl Canc Ctr Hosp East, Dept Cardiol, Kashiwa, Chiba, Japan. EM ktajiri@east.ncc.go.jp RI Ieda, Masaki/HSH-1849-2023; Tajiri, Kazuko/HSI-1931-2023 OI Ieda, Masaki/0000-0003-4724-3299; Tajiri, Kazuko/0000-0002-9759-1008 FU Japanese Society for the Promotion of Science KAKENHI [JP20K08396]; Grants-in-Aid for Scientific Research [20K08396] Funding Source: KAKEN FX This work was supported by grants from the Japanese Society for the Promotion of Science KAKENHI (Grant no. JP20K08396) to Kazuko Tajiri. We thank Editage (www.editage.jp) for English language editing. CR Al Sawalhi S, 2021, GEN THORAC CARDIOVAS, V69, P487, DOI 10.1007/s11748-020-01491-3 Amar D, 2000, J THORAC CARDIOV SUR, V120, P790, DOI 10.1067/mtc.2000.109538 Amar D, 2002, ANESTHESIOLOGY, V96, P352, DOI 10.1097/00000542-200202000-00021 Aoki Y, 2020, JA CLIN REP, V6, DOI 10.1186/s40981-020-00338-3 Bhave PD, 2012, AM HEART J, V164, P918, DOI 10.1016/j.ahj.2012.09.004 Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Chen LT, 2020, WORLD J SURG ONCOL, V18, DOI 10.1186/s12957-020-02011-6 Chin JH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154931 Chu G, 2019, BLOOD REV, V35, P59, DOI 10.1016/j.blre.2019.03.005 Ciszewski P, 2013, INTERACT CARDIOV TH, V17, P680, DOI 10.1093/icvts/ivt238 Devereaux PJ, 2008, LANCET, V371, P1839, DOI 10.1016/S0140-6736(08)60601-7 Dyszkiewicz W, 1998, EUR J CARDIO-THORAC, V13, P625, DOI 10.1016/S1010-7940(98)00084-0 Fong LS, 2020, ANZ J SURG, V90, P752, DOI 10.1111/ans.15788 Garner M, 2017, INTERACT CARDIOV TH, V24, P260, DOI 10.1093/icvts/ivw348 Gialdini G, 2014, JAMA-J AM MED ASSOC, V312, P616, DOI 10.1001/jama.2014.9143 Glover JR, 2016, J THORAC DIS, V8, P3614, DOI 10.21037/jtd.2016.12.11 Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370 Gómez-Caro A, 2006, ARCH BRONCONEUMOL, V42, P9, DOI 10.1016/S1579-2129(06)60107-9 Hahm TS, 2007, YONSEI MED J, V48, P474, DOI 10.3349/ymj.2007.48.3.474 He GX, 2020, J CARDIOTHORAC SURG, V15, DOI 10.1186/s13019-020-01260-6 Herrmann J, 2020, NAT REV CARDIOL, V17, P474, DOI 10.1038/s41569-020-0348-1 Higuchi S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216239 Hindricks G, 2021, EUR HEART J, V42, P507, DOI 10.1093/eurheartj/ehaa798 Hollings DD, 2010, AM J SURG, V199, P558, DOI 10.1016/j.amjsurg.2009.11.006 Horikoshi Y, 2017, J CLIN ANESTH, V38, P111, DOI 10.1016/j.jclinane.2017.01.036 Imperatori Andrea, 2012, J Cardiothorac Surg, V7, P4, DOI 10.1186/1749-8090-7-4 Ishibashi H, 2020, WORLD J SURG, V44, P3952, DOI 10.1007/s00268-020-05694-w January CT, 2014, CIRCULATION, V130, pE199, DOI 10.1161/CIR.0000000000000041 Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244 Kavurmaci O, 2018, HEART LUNG CIRC, V27, P835, DOI 10.1016/j.hlc.2017.06.729 Leiva O, 2021, JACC-CARDIOONCOL, V3, P619, DOI 10.1016/j.jaccao.2021.08.011 Lubitz SA, 2015, CIRCULATION, V131, P1648, DOI 10.1161/CIRCULATIONAHA.114.014058 Ma JY, 2006, WORLD J GASTROENTERO, V12, P449, DOI 10.3748/wjg.v12.i3.449 Mansour Z, 2009, ANN THORAC SURG, V88, P1737, DOI 10.1016/j.athoracsur.2009.07.016 Mc Cormack O, 2014, ANN SURG, V260, P772, DOI 10.1097/SLA.0000000000000960 Mita N, 2017, J CARDIOTHOR VASC AN, V31, P464, DOI 10.1053/j.jvca.2016.09.003 Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535 Munger TM, 2014, J BIOMED RES, V28, P1, DOI 10.7555/JBR.28.20130191 Muranishi Y, 2017, SURG TODAY, V47, P252, DOI 10.1007/s00595-016-1380-y Murthy SC, 2003, J THORAC CARDIOV SUR, V126, P1162, DOI 10.1016/S0022-5223(03)00974-7 Nagatsuka Y, 2021, ESOPHAGUS-TOKYO, V18, P496, DOI 10.1007/s10388-020-00804-y Nassoiy SP, 2016, AM J SURG, V211, P559, DOI 10.1016/j.amjsurg.2015.10.024 Ng EP, 2016, J THORAC DIS, V8, P2079, DOI 10.21037/jtd.2016.07.68 Ojima T, 2017, BRIT J SURG, V104, P1003, DOI 10.1002/bjs.10548 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Park BJ, 2007, J THORAC CARDIOV SUR, V133, P775, DOI 10.1016/j.jtcvs.2006.09.022 Passman RS, 2005, ANN THORAC SURG, V79, P1698, DOI 10.1016/j.athoracsur.2004.10.058 Rao VP, 2012, EUR J CARDIO-THORAC, V42, P438, DOI 10.1093/ejcts/ezs085 Riber LP, 2012, ANN THORAC SURG, V94, P339, DOI 10.1016/j.athoracsur.2011.12.096 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Seesing MFJ, 2018, DIS ESOPHAGUS, V31, DOI 10.1093/dote/doy028 Sekine Y, 2001, CHEST, V120, P1783, DOI 10.1378/chest.120.6.1783 Siu CW, 2005, PACE, V28, pS120, DOI 10.1111/j.1540-8159.2005.00024.x Smith HA, 2021, TRIALS, V22, DOI 10.1186/s13063-021-05318-1 Sohn Gwan Hyeop, 2009, Korean Circ J, V39, P100, DOI 10.4070/kcj.2009.39.3.100 Song EY, 2020, J GASTROINTEST ONCOL, V11, P68, DOI 10.21037/jgo.2019.12.05 Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z Stawicki SPA, 2011, GEN THORAC CARDIOVAS, V59, P399, DOI 10.1007/s11748-010-0713-9 Tang J, 2019, J CARDIOTHORAC SURG, V14, DOI 10.1186/s13019-019-0885-z Tisdale JE, 2009, ANN THORAC SURG, V88, P886, DOI 10.1016/j.athoracsur.2009.04.074 VANMIEGHEM W, 1994, CHEST, V105, P1642, DOI 10.1378/chest.105.6.1642 Villamizar NR, 2009, J THORAC CARDIOV SUR, V138, P419, DOI 10.1016/j.jtcvs.2009.04.026 Wang M, 2021, WORLD J UROL, V39, P1509, DOI 10.1007/s00345-020-03337-2 Wells CI, 2018, ANZ J SURG, V88, pE268, DOI 10.1111/ans.14054 Xie, 2018, MEDICINE, V97 Yoshida T, 2017, ESOPHAGUS-TOKYO, V14, P97, DOI 10.1007/s10388-016-0553-5 Yuan M, 2019, CARDIOL RES PRACT, V2019, DOI 10.1155/2019/8985273 Zhang LZ, 2016, J CARDIOVASC PHARM, V67, P351, DOI 10.1097/FJC.0000000000000351 Zhao BC, 2017, CHEST, V151, P149, DOI 10.1016/j.chest.2016.08.1476 NR 69 TC 7 Z9 8 U1 0 U2 18 PU SPRINGER PI NEW YORK PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES SN 1068-9265 EI 1534-4681 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2023 VL 30 IS 2 BP 711 EP 721 DI 10.1245/s10434-022-12690-y EA OCT 2022 PG 11 WC Oncology; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Surgery GA I9OX6 UT WOS:000871175800002 PM 36273057 DA 2026-04-17 ER PT J AU Lau, SWJ Huang, Y Hsieh, J Wang, SG Liu, Q Slattum, PW Schwartz, JB Huang, SM Temple, R AF Lau, S. W. Johnny Huang, Yue Hsieh, Julie Wang, Shenggang Liu, Qi Slattum, Patricia W. Schwartz, Janice B. Huang, Shiew-Mei Temple, Robert TI Participation of Older Adults in Clinical Trials for New Drug Applications and Biologics License Applications From 2010 Through 2019 SO JAMA NETWORK OPEN LA English DT Article ID MOLECULAR ENTITY DRUGS; WOMEN; FDA AB IMPORTANCE Older age may be accompanied by changes in the pharmacokinetics or pharmacodynamics or both of medications that can result in altered safety and efficacy profiles. OBJECTIVE To assess representation of older adults in clinical trials of new drug applications (NDAs) and biologics license applications (BLAs). DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study analyzed US Food and Drug Administration (FDA) data for NDAs and BLAs approved from 2010 through 2019. Age distribution of clinical trial participants was compared with age distribution of the US population with the disease or disorder (prevalent population). Data were from adults enrolled in registration trials for depression, heart failure, insomnia, non-small cell lung cancer (NSCLC), nonvalvular atrial fibrillation (NVAF) stroke prevention, osteoporosis, and type 2 diabetes or adults sampled from US prevalent population in community-dwelling health data. Data were analyzed from November 2020 to February 2021. EXPOSURES Trial enrollment. MAIN OUTCOMES AND MEASURES Representativeness of trial populations was assessed by the participation to prevalence ratio (PPR) defined as the percentage of patients by age group among clinical trial participants to the percentage of patients by age group among US prevalent population. RESULTS Data from 166 clinical trials (229 558 participants) for 44 NDAs and BLAs were analyzed. The most consistent finding was the limited enrollment of the oldest age groups, namely those 75 years and above for type 2 diabetes and NSCLC, and 80 years and above for NVAF stroke prevention, insomnia, heart failure, and osteoporosis. Adults aged 60 to 74 years were enrolled in equal or greater proportion than the US prevalent population. CONCLUSIONS AND RELEVANCE In this cross-sectional study, underrepresentation of the oldest adults existed during evaluation of new drugs and biologics, yet the older adults may represent significant proportions of the treatment population. Closing the representation gap between clinical trial enrollment and potential treatment populations is essential for safe and effective use of new drugs and biologics. C1 [Lau, S. W. Johnny; Huang, Yue; Hsieh, Julie; Wang, Shenggang; Liu, Qi; Schwartz, Janice B.; Huang, Shiew-Mei] US FDA, Off Clin Pharmacol, Off Translat Sci, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA. [Wang, Shenggang] DataRev USA LLC, Rockville, MD USA. [Slattum, Patricia W.] Virginia Commonwealth Univ, Dept Pharmacotherapy & Outcomes Sci, Richmond, VA USA. [Slattum, Patricia W.] Virginia Commonwealth Univ, Virginia Ctr Aging, Richmond, VA USA. [Schwartz, Janice B.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Schwartz, Janice B.] Univ Calif San Francisco, Dept Bioengn, San Francisco, CA 94143 USA. [Schwartz, Janice B.] Univ Calif San Francisco, Dept Therapeut Sci, San Francisco, CA 94143 USA. [Temple, Robert] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA. C3 US Food & Drug Administration (FDA); Virginia Commonwealth University; Virginia Commonwealth University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Food & Drug Administration (FDA) RP Lau, SWJ (corresponding author), US FDA, 10903 New Hampshire Ave,Bldg 51,Rm 3148, Silver Spring, MD 20993 USA. EM sze.lau@fda.hhs.gov RI wang, shenggang/PBV-0991-2025 CR American Journal of Managed Care, 2019, AJMC PERSPECTIVES BL [Anonymous], [No title captured] [Anonymous], 2025, Off. of Pers. Mgmt. v. Am. Fed'n of Gov't Emps. [Anonymous], 2020, Solriamfetol Drug Summary pdr.net Benjamin EJ, 2019, CIRCULATION, V139, pE56, DOI [10.1161/CIR.0000000000000659, 10.1161/CIR.0000000000000746] Brody Debra J, 2020, NCHS Data Brief, P1 Budnitz DS, 2021, JAMA-J AM MED ASSOC, V326, P1299, DOI 10.1001/jama.2021.13844 Casagrande S, 2018, DIABETES, V67, DOI 10.2337/db18-1478-P Chen A, 2018, J WOMENS HEALTH, V27, P418, DOI 10.1089/jwh.2016.6272 Dall TM, 2013, HEALTH AFFAIR, V32, P2013, DOI 10.1377/hlthaff.2013.0714 Dubrall D, 2020, BMC PHARMACOL TOXICO, V21, DOI 10.1186/s40360-020-0392-9 Eshera N, 2015, AM J THER, V22, P435, DOI 10.1097/MJT.0000000000000177 European Medicines Agency, 1994, ICH E7 GUID IND STUD Javier-DesLoges J, 2022, CANCER-AM CANCER SOC, V128, P770, DOI 10.1002/cncr.33991 Kantor ED, 2015, JAMA-J AM MED ASSOC, V314, P1818, DOI 10.1001/jama.2015.13766 Khezrian M, 2020, THER ADV DRUG SAF, V11, DOI 10.1177/2042098620933741 Liu Q, 2022, CLIN PHARMACOL THER, V112, P210, DOI 10.1002/cpt.2452 Lockett J, 2019, J AM GERIATR SOC, V67, P218, DOI 10.1111/jgs.15786 Martin, 2019, PRESCRIPTION DRUG US, V334 Mather M., 2015, POPUL BULL, V70 Mentzer G, 2019, HEART FAIL CLIN, V15, P19, DOI 10.1016/j.hfc.2018.08.003 Naccarelli GV, 2009, AM J CARDIOL, V104, P1534, DOI 10.1016/j.amjcard.2009.07.022 National Cancer Institute Surveillance Epidemiology and End Results Program, SEER EXPL DAT Pang HH, 2016, J CLIN ONCOL, V34, P3992, DOI 10.1200/JCO.2016.67.7088 Poon R, 2013, J WOMENS HEALTH, V22, P604, DOI 10.1089/jwh.2012.3753 Santo L., National Ambulatory Medical Care Survey: 2018 National Summary Tables [Internet]. [cited 2023 Feb 2];Available from Scott PE, 2018, J AM COLL CARDIOL, V71, P1960, DOI 10.1016/j.jacc.2018.02.070 Steinberg JR, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.13749 Steinman MA, 2012, J AM GERIATR SOC, V60, P1872, DOI 10.1111/j.1532-5415.2012.04158.x U.S. Food and Drug Administration, FDA's Drugs@FDA database U.S. Food & Drug Administration, Drug Trials Snapshots | FDA United States Census Bureau, GRAYING AM MOR OLD A US Food and Drug Administration, 2020, GUID DOC INCL OLD AD US Food and Drug Administration, 2012, ICH GUID GUID DOC E7 US Food and Drug Administration, ESK SUMM REV US Food and Drug Administration, CAN LAB US Food and Drug Administration, 2019, LEMB LAB US Food and Drug Administration, 2020, GUID DOC ENH DIV CLI US Food and Drug Administration, 2020, GUID DOC GER INF HUM van Marum RJ, 2020, BRIT J CLIN PHARMACO, V86, P2014, DOI 10.1111/bcp.14539 Villarroel M.A., 2020, NCHS Data Brief, V379 Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269 NR 42 TC 71 Z9 77 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2574-3805 J9 JAMA NETW OPEN JI JAMA Netw. Open PD OCT 14 PY 2022 VL 5 IS 10 AR e2236149 DI 10.1001/jamanetworkopen.2022.36149 PG 10 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA 5H7QQ UT WOS:000867869800005 PM 36239939 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Xu, GW Wang, GX Mei, XY Wu, MS Li, T Xie, MR AF Xu, Guangwen Wang, Gaoxiang Mei, Xinyu Wu, Mingsheng Li, Tian Xie, Mingran TI Sequential pulmonary resections by uniportal video-assisted thoracic surgery for bilateral multiple pulmonary nodules SO FRONTIERS IN ONCOLOGY LA English DT Article DE bilateral; uniportal; multiple primary lung cancers; multiple pulmonary nodules; sequential ID CELL LUNG-CANCER; SUBSOLID NODULES; SIZE AB ObjectiveThe aim of this study was to evaluate the effect of sequential pulmonary resections by uniportal video-assisted thoracoscopic surgery (VATS) for bilateral multiple pulmonary nodules (BMPNs). MethodsA single-center, prospective, nonrandomized study was performed on patients who underwent one-stage or two-stage operations by uniportal VATS. The clinical, pathological and perioperative data were summarized and analyzed from January 2021 to December 2021. ResultsA total of 80 patients were included during the study period. Sequential pulmonary resection by uniportal VATS was underwent in 40 patients. There were no perioperative deaths and serious complications, 2 patients had postoperative pneumonia, 3 patients had transient atrial fibrillation, 1 patient had persistent severe air leakage, 1 patient occurred hemoptysis. The one-stage group had less operative time, surgical blood loss, pleural drainage, chest tube duration and postoperative admission duration(P<0.05). The results of pathological examination of pulmonary nodules revealed adenocarcinoma in situ (n=12), minimally invasive adenocarcinoma (n=24), invasive adenocarcinoma (n=42), squamous carcinoma (n=1),and benign nodules (n=10). The pathological diagnosis included multiple primary lung cancers (30/40, 75%), single primary lung cancer (6/40, 15%). The most advanced pathologic stage of the primary lung cancer was classified as IA (n=19), IB (n=5), II (n=3), and IIIA (n=2). ConclusionFor patients with excellent pulmonary function, sequential pulmonary resection by uniportal VATS is a safe and feasible for BMPNs. Strict control of surgical indications, reasonable preoperative planning, accurate intraoperative operation, and standardized perioperative management can effectively reduce complications and maximize benefits for suitable patients. C1 [Xu, Guangwen; Wang, Gaoxiang; Mei, Xinyu; Wu, Mingsheng; Li, Tian; Xie, Mingran] Univ Sci & Technol China USTC, Univ Sci & Technol China, Dept Thorac Surg, Div Life Sci & Med,Affiliated Hosp 1, Hefei, Peoples R China. C3 Chinese Academy of Sciences; University of Science & Technology of China, CAS RP Li, T; Xie, MR (corresponding author), Univ Sci & Technol China USTC, Univ Sci & Technol China, Dept Thorac Surg, Div Life Sci & Med,Affiliated Hosp 1, Hefei, Peoples R China. EM ahslyyxwklt@163.com; xmr1981@ustc.edu.cn FU National Natural Science Foundation of China; Key research and development projects in Anhui Province [81973643, 202004j07020017] FX This work was supported by the grants from the National Natural Science Foundation of China and Key research and development projects in Anhui Province (NO.81973643 and 202004j07020017). CR Hernandez-Arenas LA, 2018, J THORAC DIS, V10, pS1205, DOI 10.21037/jtd.2018.02.47 Bai CX, 2016, CHEST, V150, P877, DOI 10.1016/j.chest.2016.02.650 Beyreuther H, 1924, VIRCHOWS ARCH A, V250, P230, DOI 10.1007/BF01891568 Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609] Chen KN, 2020, GEN THORAC CARDIOVAS, V68, P697, DOI 10.1007/s11748-019-01267-4 Deng JJ, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.06.61 Desseroit MC, 2016, EUR J NUCL MED MOL I, V43, P1477, DOI 10.1007/s00259-016-3325-5 Ettinger DS, 2019, J NATL COMPR CANC NE, V17, P1464, DOI 10.6004/jnccn.2019.0059 Gonzalez D, 2011, INTERACT CARDIOV TH, V12, P514, DOI 10.1510/icvts.2010.256222 Gould MK, 2013, CHEST, V143, pE93, DOI 10.1378/chest.12-2351 Ji CY, 2017, J THORAC DIS, V9, P3711, DOI 10.21037/jtd.2017.09.39 Li JG, 2019, THORAC CANCER, V10, P1334, DOI 10.1111/1759-7714.13040 Lin BY, 2021, TRANSL LUNG CANCER R, V10, P2487, DOI 10.21037/tlcr-21-132 MacMahon H, 2017, RADIOLOGY, V284, P228, DOI 10.1148/radiol.2017161659 MARTINI N, 1975, J THORAC CARDIOV SUR, V70, P606 Migliore M., 2000, Thoracic surgery and interdisciplinary symposium on the threshold of the third millennium, P29 Migliore M, 2020, EUR J CARDIO-THORAC, V57, P612, DOI 10.1093/ejcts/ezz221 Nakada T, 2021, J THORAC DIS, V13, P3171, DOI 10.21037/jtd-20-3380 Qu RR, 2020, J CARDIOTHORAC SURG, V15, DOI 10.1186/s13019-020-01107-0 Rocco G, 2004, ANN THORAC SURG, V77, P726, DOI 10.1016/S0003-4975(03)01219-0 Romaszko AM, 2018, ADV CLIN EXP MED, V27, P717, DOI 10.17219/acem/68631 Schreuder A, 2021, CANCERS, V13, DOI 10.3390/cancers13112812 Smith RA, 2019, CA-CANCER J CLIN, V69, P184, DOI 10.3322/caac.21557 STRONG MS, 1984, J OTOLARYNGOL, V13, P1 Travis WD, 2016, J THORAC ONCOL, V11, P1204, DOI 10.1016/j.jtho.2016.03.025 Xu GW, 2020, THORAC CANCER, V11, P612, DOI 10.1111/1759-7714.13305 Xu GQ, 2019, J THORAC DIS, V11, P535, DOI 10.21037/jtd.2019.01.10 Yao F, 2016, J THORAC DIS, V8, P469, DOI 10.21037/jtd.2016.02.66 Zhang Y, 2020, ANN THORAC SURG, V110, P1796, DOI 10.1016/j.athoracsur.2020.04.094 Zhang YX, 2018, J THORAC DIS, V10, P6452, DOI 10.21037/jtd.2018.11.10 NR 30 TC 7 Z9 10 U1 1 U2 3 PU FRONTIERS MEDIA SA PI LAUSANNE PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND SN 2234-943X J9 FRONT ONCOL JI Front. Oncol. PD OCT 3 PY 2022 VL 12 AR 961812 DI 10.3389/fonc.2022.961812 PG 8 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA 5N5JP UT WOS:000871826000001 PM 36263215 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Sánchez, AC Molina, GMM Fernández, SF García, AM Ramos, AC Hernández, EM Trancho, FH Mata, NM AF Sanchez, Alberto Cabanero Molina, Gemma Maria Munoz Fernandez, Sara Fra Garcia, Alfonso Muriel Ramos, Angel Cilleruelo Hernandez, Estor Martinez Trancho, Florentino Hernando Mata, Nicolas Moreno CA Ge-Vats TI Impact of neoadjuvant therapy on postoperative complications in non-small-cell lung cancer patients subjected to anatomic lung resection SO EJSO LA English DT Article ID THORACOSCOPIC LOBECTOMY; CHEMOTHERAPY; MORTALITY AB Objective: To study the impact of neoadjuvant therapies on postoperative complications and mortality among non-small-cell lung cancer (NSCLC) patients subjected to anatomic lung resection and included in the Spanish cohort of the video-assisted thoracic surgery (GE-VATS) multicenter database. Methods: The study included a total of 3085 patients from 33 centers between December 2016 and March 2018. We performed a comparative analysis of the complications and mortality in patients who received neoadjuvant therapies (n = 263) versus those who did not (n = 2822). A propensity scorematched analysis was used to adjust for potential confounders. Association between exposure in two groups and outcomes were estimated by logistic regression weighted by inverse of probability of receiving the treatment that actually received. Results: In the unadjusted analysis, the chemotherapy (CT) and chemoradiotherapy (CRT) group presented a higher frequency of ICU readmissions, reinterventions, empyema, cardiovascular complications, a greater frequency of atrial fibrillation, and an increased need for blood product transfusions. In the adjusted group, CT and CRT patients had a higher rate of cardiovascular complications (CT p = 0.002; OR 2.29; 95% CI 1.34e3.94 and CRT p = 0.001; OR 2.90; 95% CI 1.52-5-52), arrhythmias (CT p = 0.013; OR 2.23; 95% CI 1.18e4.20 and CRT p = 0.046; OR 2.22; 95% CI 1.01e4.90) and transfussions (CT p = 0.042; OR 2.95; 95% CI 1.04e8.35 and CRT p < 0.001; OR 7.74; 95% CI 3.01-19-92). Conclusions: Based on our series, neoadjuvant CT and CRT were associated with a higher rate of cardiovascular complications, arrhythmias and transfussions in patients with NSCLC subjected to anatomic lung resection. (c) 2022 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved. C1 [Sanchez, Alberto Cabanero; Molina, Gemma Maria Munoz; Fernandez, Sara Fra; Mata, Nicolas Moreno] Hosp Univ Ram Cajal, Serv Cirugia Toracica, Madrid, Spain. [Garcia, Alfonso Muriel] Univ Alcala, Hosp Univ Ramon & Cajal, Unidad Bioestadist Clin, IRYCIS,CIBERESP, Alcala De Henares, Spain. [Ramos, Angel Cilleruelo] Univ Valladolid, Hosp Clin, Serv Cirugia Toracica, Valladolid, Spain. [Hernandez, Estor Martinez] Hosp Univ Ribera, Serv Cirugia Toracica, Alzira, Spain. [Trancho, Florentino Hernando] Hosp Univ Clin San Carlos, Serv Cirugia Toracica, Madrid, Spain. C3 Hospital Universitario Ramon y Cajal; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Universidad de Alcala; Universidad de Valladolid RP Sánchez, AC (corresponding author), Hosp Univ Ram Cajal, Serv Cirugia Toracica, Madrid, Spain. EM alberto.cabanero@salud.madrid.org RI Cabañero Sánchez, Alberto/G-8857-2017; Hernando-Trancho //, Florentino/K-5982-2015; Fra Fernández, Sara/AAK-3428-2021; Cilleruelo Ramos, Ángel/LBH-2306-2024 OI Cabañero Sánchez, Alberto/0000-0002-9617-9935; Moreno Mata, Nicolas/0000-0002-1230-068X; Martínez-Hernández, Néstor J/0000-0002-5529-9615; Hernando-Trancho //, Florentino/0000-0002-2296-0593; Fra Fernández, Sara/0000-0001-7723-0347; Cilleruelo Ramos, Ángel/0000-0002-1872-0714; RECUERO-DÍAZ, JOSE LUIS/0000-0002-0731-6222 FU Spanish Society of Thoracic Surgery FX All costs related to the start-up and maintenance of the GE-VATS database were covered by Ethicon, Johnson & Johnson. The authors had freedom of investigation and full control of the design of the study, methods used, outcome parameters and results, data analysis, and production of the written report. The GE-VATS was awarded a grant from the Spanish Society of Thoracic Surgery as the best national research project of 2015. CR Bott MJ, 2019, J THORAC CARDIOV SUR, V158, P269, DOI 10.1016/j.jtcvs.2018.11.124 Brunelli A, 2020, EUR J CARDIO-THORAC, V57, P740, DOI 10.1093/ejcts/ezz287 Burdett S, 2014, LANCET, V383, P1561, DOI 10.1016/S0140-6736(13)62159-5 Embun R, 2020, ARCH BRONCONEUMOL Evans NR, 2010, J THORAC CARDIOV SUR, V139, P991, DOI 10.1016/j.jtcvs.2009.11.070 Franco F, 2019, J THORAC DIS, V11, P4092, DOI 10.21037/jtd.2019.09.68 Kamel MK, 2017, J LAPAROENDOSC ADV S, V27, P495, DOI 10.1089/lap.2016.0540 Kim AW, 2012, J THORAC CARDIOV SUR, V143, P55, DOI 10.1016/j.jtcvs.2011.09.002 Krantz SB, 2018, ANN THORAC SURG, V105, P1008, DOI 10.1016/j.athoracsur.2017.10.056 McMillan RR, 2014, ANN THORAC SURG, V98, P1769, DOI 10.1016/j.athoracsur.2014.06.024 NCCN Clinical Practice Guidelines in Oncology, 2020, NONSM CELL LUNG CANC Petersen RP, 2007, ANN THORAC SURG, V83, P1245, DOI 10.1016/j.athoracsur.2006.12.029 RUSCH VW, 1993, ANN THORAC SURG, V55, P820, DOI 10.1016/0003-4975(93)90097-2 Uprety D, 2020, J THORAC ONCOL, P30425 Xiong LW, 2019, ONCOLOGIST, V24, P157, DOI 10.1634/theoncologist.2018-0120 Yamamoto Y, 2017, J CARDIOTHORAC SURG, V12, DOI 10.1186/s13019-017-0668-3 Yang CFJ, 2020, ANN THORAC SURG, V109, P1503, DOI 10.1016/j.athoracsur.2019.09.065 Yang CFJ, 2016, EUR J CARDIO-THORAC, V49, P1615, DOI 10.1093/ejcts/ezv428 Yendamuri S, 2018, EUR J CARDIO-THORAC, V53, P656, DOI 10.1093/ejcts/ezx406 Zhang ZY, 2019, J THORAC DIS, V11, pE88, DOI 10.21037/jtd.2019.05.49 Zhao W, 2020, ANN THORAC SURG Zhong WZ, 2019, J CLIN ONCOL, V37, P2235, DOI 10.1200/JCO.19.00075 Zhong WZ, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0151-3 NR 23 TC 7 Z9 7 U1 0 U2 3 PU ELSEVIER SCI LTD PI London PA 125 London Wall, London, ENGLAND SN 0748-7983 EI 1532-2157 J9 EJSO-EUR J SURG ONC JI EJSO PD SEP PY 2022 VL 48 IS 9 BP 1947 EP 1953 DI 10.1016/j.ejso.2022.03.008 EA SEP 2022 PG 7 WC Oncology; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Surgery GA 6F2MX UT WOS:000883902900010 PM 35379545 DA 2026-04-17 ER PT J AU Medrek, S Szmit, S AF Medrek, Sabina Szmit, Sebastian TI Are cardiovascular comorbidities always associated with a worse prognosis in patients with lung cancer? SO FRONTIERS IN CARDIOVASCULAR MEDICINE LA English DT Review DE lung cancer; cardio-oncology; survival; prognosis; heart failure; thromboembolism ID ACUTE MYOCARDIAL-INFARCTION; LONG-TERM SURVIVORS; PULMONARY-EMBOLISM; ATRIAL-FIBRILLATION; HEART-RATE; VENOUS THROMBOEMBOLISM; CO-MORBIDITY; CLINICAL CHARACTERISTICS; EXPERT CONSENSUS; GLOBAL BURDEN AB Many factors contribute to mortality in lung cancer, including the presence of concomitant cardiovascular disease. In the treatment of early stage of lung cancer, the presence of comorbidities and occurence of cardiotoxicity may be prognostic. The effect of cardiotoxicity of radiotherapy and chemoradiotherapy on overall survival has been documented. Acute arterial and venous thromboembolic events seem to correlate with the degree of the histological malignancy, its clinical advancement, and even with optimal cardiac treatment, they may influence the survival time. In the case of high-grade and advanced lung cancer stage especially in an unresectable stadium, the prognosis depends primarily on the factors related to the histopathological and molecular diagnosis. Electrocardiographic and echocardiographic abnormalities may be prognostic factors, as they seem to correlate with the patient's performance status as well as tumor localization and size. C1 [Medrek, Sabina] Subcarpathian Oncol Ctr, Dept Cardiol, Brzozow, Poland. [Szmit, Sebastian] European Hlth Ctr, Ctr Postgrad Med Educ, Dept Pulm Circulat Thromboembol Dis & Cardiol, Otwock, Poland. RP Medrek, S (corresponding author), Subcarpathian Oncol Ctr, Dept Cardiol, Brzozow, Poland. EM sabp@wp.pl RI Szmit, Sebastian/N-2487-2017 OI Szmit, Sebastian/0000-0002-3075-1943 CR Ahlbrecht J, 2012, J CLIN ONCOL, V30, P3870, DOI 10.1200/JCO.2011.40.1810 Al-Kindi SG, 2016, MAYO CLIN PROC, V91, P81, DOI 10.1016/j.mayocp.2015.09.009 Alberg AJ, 2003, CHEST, V123, p21S, DOI 10.1378/chest.123.1_suppl.21S Albrecht A, 2021, CANCERS, V13, DOI 10.3390/cancers13102303 Ambrogi V, 2003, EUR J CARDIO-THORAC, V23, P811, DOI 10.1016/S1010-7940(03)00093-9 Anker MS, 2021, EUR J HEART FAIL, V23, P145, DOI 10.1002/ejhf.2059 Anker MS, 2018, EUR J HEART FAIL, V20, P1382, DOI 10.1002/ejhf.1252 Anker MS, 2016, EUR J HEART FAIL, V18, P1524, DOI 10.1002/ejhf.670 Arcadi T, 2014, WORLD J RADIOL, V6, P381, DOI 10.4329/wjr.v6.i6.381 Banasiak W, 2018, POL ARCH INTERN MED, V128, P244, DOI 10.20452/pamw.4254 Bandyopadhyay D, 2019, IJC HEART VASC, V22, P216, DOI 10.1016/j.ijcha.2019.02.012 Barros GP, 2012, INT J GEOPHYS, V2012, DOI [10.1155/2012/459497, 10.5402/2012/137289] Barsoum MK, 2010, THROMB RES, V126, P373, DOI 10.1016/j.thromres.2010.08.010 Batra A, 2021, OPEN HEART, V8, DOI 10.1136/openhrt-2021-001849 Batra A, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07487-9 Beaney T, 2020, HYPERTENSION, V76, P333, DOI 10.1161/HYPERTENSIONAHA.120.14874 Benjamin EJ, 2019, CIRCULATION, V139, pE56, DOI [10.1161/CIR.0000000000000659, 10.1161/CIR.0000000000000746] Berkovitch A, 2018, J INVASIVE CARDIOL, V30, P105 Bharadwaj A, 2020, EUR HEART J, V41, P2183, DOI 10.1093/eurheartj/ehz851 Bui AL, 2011, NAT REV CARDIOL, V8, P30, DOI 10.1038/nrcardio.2010.165 Canonico ME, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12020259 Chan J, 2012, HEART LUNG CIRC, V21, P255, DOI 10.1016/j.hlc.2012.02.004 CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8 Chen HY, 2013, AM J EPIDEMIOL, V177, pS37, DOI 10.2147/CLEP.S49485 Chen PS, 2014, CIRC RES, V114, P1500, DOI 10.1161/CIRCRESAHA.114.303772 Chu G, 2019, BLOOD REV, V35, P59, DOI 10.1016/j.blre.2019.03.005 Chuang YM, 2009, ONCOLOGY-BASEL, V77, P100, DOI 10.1159/000229503 Coebergh JWW, 1999, J CLIN EPIDEMIOL, V52, P1131, DOI 10.1016/S0895-4356(99)00098-0 Colinet B, 2005, BRIT J CANCER, V93, P1098, DOI 10.1038/sj.bjc.6602836 Conen D, 2016, JAMA CARDIOL, V1, P389, DOI 10.1001/jamacardio.2016.0280 Cosyns B, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.766996 Cui YQ, 2021, CLIN RESPIR J, V15, P65, DOI 10.1111/crj.13270 Dentali F, 2010, THROMB RES, V125, P518, DOI 10.1016/j.thromres.2010.03.016 Dominguez-Ventura A, 2006, ANN THORAC SURG, V82, P1175, DOI 10.1016/j.athoracsur.2006.04.052 Farmakis D, 2021, EUR J HEART FAIL, V23, P154, DOI 10.1002/ejhf.2079 Farmakis D, 2014, J AM COLL CARDIOL, V63, P945, DOI 10.1016/j.jacc.2013.11.026 Florido R, 2022, J AM COLL CARDIOL, V80, P22, DOI 10.1016/j.jacc.2022.04.042 Giustozzi M, 2021, J THROMB HAEMOST, V19, P2751, DOI 10.1111/jth.15461 Giustozzi M, 2020, THROMB HAEMOSTASIS, V120, P847, DOI 10.1055/s-0040-1709527 GLANZMANN C, 1994, RADIOTHER ONCOL, V30, P43, DOI 10.1016/0167-8140(94)90008-6 Grilz E, 2018, HAEMATOLOGICA, V103, P1549, DOI 10.3324/haematol.2018.192419 Grossman A, 2015, EUR J PHARMACOL, V763, P15, DOI 10.1016/j.ejphar.2015.06.027 Grymonprez M, 2019, INT J CARDIOL, V276, P118, DOI 10.1016/j.ijcard.2018.09.056 Guha A, 2019, EUR HEART J, V40, P1487, DOI 10.1093/eurheartj/ehz267 Habib G, 2010, EUR J ECHOCARDIOGR, V11, P202, DOI 10.1093/ejechocard/jeq004 Heit JA, 2016, J THROMB THROMBOLYS, V41, P3, DOI 10.1007/s11239-015-1311-6 Hemu M, 2021, J THORAC DIS, V13, P4845, DOI 10.21037/jtd-21-779 Hering D, 2003, AM J CARDIOL, V92, P226, DOI 10.1016/S0002-9149(03)00546-0 Rivera DH, 2019, CLIN TRANSL ONCOL, V21, P1220, DOI 10.1007/s12094-019-02047-5 Herrmann J, 2020, NAT REV CARDIOL, V17, P503, DOI 10.1038/s41569-020-0347-2 Hull MC, 2003, JAMA-J AM MED ASSOC, V290, P2831, DOI 10.1001/jama.290.21.2831 Iachina M, 2015, LUNG, V193, P291, DOI 10.1007/s00408-014-9675-5 Imperatori A, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-4 Islam KMM, 2015, CANCER EPIDEM BIOMAR, V24, P1079, DOI 10.1158/1055-9965.EPI-15-0036 Iung B, 2019, CIRCULATION, V140, P1156, DOI 10.1161/CIRCULATIONAHA.119.041080 Jain P, 2021, ESMO OPEN, V6, DOI 10.1016/j.esmoop.2021.100252 Jakobsen CB, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6314-9 Janssen-Heijnen MLG, 1998, LUNG CANCER, V21, P105, DOI 10.1016/S0169-5002(98)00039-7 Kamp DW, 2011, ONCOLOGY-NY, V25, P400 Kattelus H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205454 Keller K, 2020, EUR HEART J, V41, P522, DOI 10.1093/eurheartj/ehz236 Kendal WS, 2008, CANCER, V112, P1354, DOI 10.1002/cncr.23315 Kim K, 2019, CIRC J, V83, P452, DOI 10.1253/circj.CJ-18-0609 Knuuti J, 2020, EUR HEART J, V41, P407, DOI 10.1093/eurheartj/ehz425 Kocher F, 2015, CLIN LUNG CANCER, V16, P305, DOI 10.1016/j.cllc.2014.12.007 Kravchenko J, 2015, LUNG CANCER, V88, P85, DOI 10.1016/j.lungcan.2015.01.006 Landes U, 2019, JACC-CARDIOVASC INTE, V12, P78, DOI 10.1016/j.jcin.2018.10.026 Landes U, 2017, CORONARY ARTERY DIS, V28, P5, DOI 10.1097/MCA.0000000000000429 Lange SA, 2021, CANCERS, V13, DOI 10.3390/cancers13246203 Leedy DJ, 2021, EUR J HEART FAIL, V23, P1712, DOI 10.1002/ejhf.2207 Li YP, 2018, J CANCER, V9, P3046, DOI 10.7150/jca.26008 Licker M, 1999, EUR J CARDIO-THORAC, V15, P314, DOI 10.1016/S1010-7940(99)00006-8 Liu JJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58345-4 Lonn EM, 2014, CLIN RES CARDIOL, V103, P149, DOI 10.1007/s00392-013-0644-4 Ma L, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006638 Malanca M, 2010, J AM SOC ECHOCARDIOG, V23, DOI 10.1016/j.echo.2009.08.006 Malgor RD, 2012, ANN THORAC SURG, V94, P311, DOI 10.1016/j.athoracsur.2012.03.025 Mangner N, 2018, J INTERV CARDIOL, V31, P188, DOI 10.1111/joic.12458 Matetic A, 2021, INT J CARDIOL, V341, P76, DOI 10.1016/j.ijcard.2021.07.054 Medrek S, 2022, CANCERS, V14, DOI 10.3390/cancers14082010 Meinardi MT, 2000, J CLIN ONCOL, V18, P1725, DOI 10.1200/JCO.2000.18.8.1725 Mendoza DP, 2020, J THORAC IMAG, V35, P129, DOI 10.1097/RTI.0000000000000458 Ming S, 2021, HEART SURG FORUM, V24, pE628, DOI 10.1532/hsf.3937 Mishra PK, 2009, EUR J CARDIO-THORAC, V35, P439, DOI 10.1016/j.ejcts.2008.10.029 Mitchell JD, 2021, JACC-CARDIOONCOL, V3, P360, DOI 10.1016/j.jaccao.2021.06.003 Mulder FI, 2021, BLOOD, V137, P1959, DOI 10.1182/blood.2020007338 Navi BB, 2017, J AM COLL CARDIOL, V70, P927, DOI 10.1016/j.jacc.2017.06.047 Nichols L, 2012, ARCH PATHOL LAB MED, V136, P1552, DOI 10.5858/arpa.2011-0521-OA Niksic M, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08801-9 Ostenfeld EB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102861 Ou SHI, 2013, CANCER-AM CANCER SOC, V119, P1969, DOI 10.1002/cncr.28040 Ou SHI, 2011, J THORAC ONCOL, V6, P2135, DOI 10.1097/JTO.0b013e3182307e06 Piccirillo JF, 2004, JAMA-J AM MED ASSOC, V291, P2441, DOI 10.1001/jama.291.20.2441 Plana JC, 2014, EUR HEART J-CARD IMG, V15, P1063, DOI 10.1093/ehjci/jeu192 Ponikowski P, 2014, ESC HEART FAIL, V1, P4, DOI 10.1002/ehf2.12005 Potts JE, 2019, EUR HEART J, V40, P1790, DOI 10.1093/eurheartj/ehy769 Rachow T, 2021, J CANCER RES CLIN, V147, P195, DOI 10.1007/s00432-020-03445-x Ram P, 2019, HEART FAIL REV, V24, P989, DOI 10.1007/s10741-019-09808-y Raskob GE, 2014, ARTERIOSCL THROM VAS, V34, P2363, DOI [10.1161/ATVBAHA.114.304488, 10.1016/j.thromres.2014.08.014] Rohrmann S, 2018, EUR HEART J-ACUTE CA, V7, P639, DOI 10.1177/2048872617729636 Roth GA, 2020, J AM COLL CARDIOL, V76, P2982, DOI 10.1016/j.jacc.2020.11.010 Sagstuen H, 2005, J CLIN ONCOL, V23, P4980, DOI 10.1200/JCO.2005.06.882 Saliba W, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190324 San Román JA, 2007, AM J MED, V120, DOI 10.1016/j.amjmed.2006.05.071 Shields Margot, 2011, NCHS Data Brief, P1 Shinagare AB, 2012, LUNG CANCER, V78, P161, DOI 10.1016/j.lungcan.2012.08.007 Shinagare AB, 2011, CANCER-AM CANCER SOC, V117, P3860, DOI 10.1002/cncr.25941 Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654 Singh N, 2016, CLIN LUNG CANCER, V17, P205, DOI 10.1016/j.cllc.2015.10.002 Sogaard Mette, 2013, Clin Epidemiol, V5, P3, DOI 10.2147/CLEP.S47150 Soultati A, 2012, CANCER TREAT REV, V38, P473, DOI 10.1016/j.ctrv.2011.09.002 Steingart RM, 2013, SEMIN ONCOL, V40, P690, DOI 10.1053/j.seminoncol.2013.09.010 Sun JM, 2010, LUNG CANCER, V69, P330, DOI 10.1016/j.lungcan.2009.11.015 Sun MZ, 2022, ARQ BRAS CARDIOL, V118, P478, DOI 10.36660/abc.20200478 Takenaka T, 2013, INTERACT CARDIOV TH, V16, P270, DOI 10.1093/icvts/ivs489 Tammemagi CM, 2003, INT J CANCER, V103, P792, DOI 10.1002/ijc.10882 Vahanian A, 2021, EUR HEART J, V42, P3736, DOI [10.1093/eurheartj/ehab395, DOI 10.1093/EURHEARTJ/EHAB395] van Herk-Sukel MPP, 2013, LUNG, V191, P501, DOI 10.1007/s00408-013-9485-1 Wanamaker B, 2018, ARRHYTH ELECTROPHYSI, V7, P43, DOI 10.15420/aer.2018.3.2 Watanabe Y, 2016, AM J CARDIOL, V118, P572, DOI 10.1016/j.amjcard.2016.05.052 Wendelboe AM, 2016, CIRC RES, V118, P1340, DOI 10.1161/CIRCRESAHA.115.306841 Yan LZ, 2018, J ONCOL PHARM PRACT, V24, P209, DOI 10.1177/1078155217690921 Yang XY, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01058 Yun JP, 2021, JACC-CARDIOONCOL, V3, P221, DOI 10.1016/j.jaccao.2021.03.006 Zaborowska-Szmit M, 2021, CANCERS, V13, DOI 10.3390/cancers13184534 Zaborowska-Szmit M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051268 Zaborowska-Szmit M, 2016, PHARMACOL REP, V68, P1140, DOI 10.1016/j.pharep.2016.07.003 Zamorano JL, 2016, EUR HEART J, V37, P2768, DOI [10.1093/eurheartj/ehw211, 10.1002/ejhf.654] Zaorsky NG, 2017, ANN ONCOL, V28, P400, DOI 10.1093/annonc/mdw604 NR 129 TC 10 Z9 11 U1 0 U2 5 PU FRONTIERS MEDIA SA PI LAUSANNE PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND SN 2297-055X J9 FRONT CARDIOVASC MED JI Front. Cardiovasc. Med. PD SEP 23 PY 2022 VL 9 AR 984951 DI 10.3389/fcvm.2022.984951 PG 10 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA 5Q4LY UT WOS:000873806500001 PM 36211566 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Kim, KH Oh, J Yang, G Lee, J Kim, J Gwak, SY Cho, I Lee, SH Byun, HK Choi, HK Kim, J Chang, JS Kang, SM Yoon, HI AF Kim, Kyung Hwan Oh, Jaewon Yang, Gowoon Lee, Joongyo Kim, Jihun Gwak, Seo-Yeon Cho, Iksung Lee, Seung Hyun Byun, Hwa Kyung Choi, Hyo-Kyoung Kim, Jinsung Chang, Jee Suk Kang, Seok-Min Yoon, Hong In TI Association of Sinoatrial Node Radiation Dose With Atrial Fibrillation and Mortality in Patients With Lung Cancer SO JAMA ONCOLOGY LA English DT Article ID CARDIAC EVENTS; HEART-DISEASE; SINUS-NODE; RISK; RADIOTHERAPY; SURVIVAL; ATLAS; CHEMORADIOTHERAPY; PATHOPHYSIOLOGY; TOXICITY AB IMPORTANCE Atrial fibrillation (AF) can develop following thoracic irradiation. However, the critical cardiac substructure responsible for AF has not been properly studied. OBJECTIVE To describe the incidence of AF in patients with lung cancer and determine predictive cardiac dosimetric parameters. DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort studywas performed at a single referral center and included 239 patients diagnosed with limited-stage small cell lung cancer (SCLC) and 321 patients diagnosed with locally advanced non-small cell lung cancer (NSCLC) between August 2008 and December 2019 who were treated with definitive chemoradiotherapy. EXPOSURES Radiation dose exposure to cardiac substructures, including the chambers, coronary arteries, and cardiac conduction nodes, were calculated for each patient. MAIN OUTCOMES AND MEASURES Main outcomeswere AF and overall survival. RESULTS Of the 239 and 321 patients with SCLC and NSCLC, the median (IQR) age was 68 (60-73) years and 67 (61-75) years, and 207 (86.6%) and 261 (81.3%) were men, respectively. At a median (IQR) follow-up time of 32.7 (22.1-56.6) months, 9 and 17 patients experienced new-onset AF in the SCLC and NSCLC cohorts, respectively. The maximum dose delivered to the sinoatrial node (SAN D-max) exhibited the highest predictive value for prediction of AF. A higher SAN Dmax significantly predicted an increased risk of AF in patients with SCLC (adjusted hazard ratio [aHR], 14.91; 95% CI, 4.00-55.56; P <.001) and NSCLC (aHR, 15.67; 95% CI, 2.08-118.20; P =.008). However, SAN Dmax was not associated with non-AF cardiac events. Increased SAN Dmax was significantly associated with poor overall survival in patients with SCLC (aHR, 2.68; 95% CI, 1.53-4.71; P <.001) and NSCLC (aHR, 1.97; 95% CI, 1.45-2.68; P <.001). CONCLUSIONS AND RELEVANCE In this cohort study, results suggest that incidental irradiation of the SAN during chemoradiotherapymay be associated with the development of AF and increased mortality. This supports the need to minimize radiation dose exposure to the SAN during radiotherapy planning and to consider close follow-up for the early detection of AF in patients receiving thoracic irradiation. C1 [Kim, Kyung Hwan; Yang, Gowoon; Lee, Joongyo; Kim, Jihun; Byun, Hwa Kyung; Kim, Jinsung; Chang, Jee Suk; Yoon, Hong In] Yonsei Univ, Yonsei Canc Ctr, Heavy Ion Therapy Res Inst, Dept Radiat Oncol,Coll Med, Seoul, South Korea. [Oh, Jaewon; Gwak, Seo-Yeon; Cho, Iksung; Kang, Seok-Min] Yonsei Univ, Severance Cardiovasc Hosp, Cardiovasc Res Inst, Dept Internal Med,Coll Med, Seoul, South Korea. [Lee, Seung Hyun] Yonsei Univ, Dept Biochem & Mol Biol, Coll Med, Seoul, South Korea. [Choi, Hyo-Kyoung] Korea Food Res Inst, Res Grp Healthcare, Wanju Gun, Jeollabuk Do, South Korea. C3 Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Korea Food Research Institute (KFRI) RP Kang, SM (corresponding author), Yonsei Univ, Div Cardiol, Dept Internal Med, Coll Med, 50 1 Yonsei Ro, Seoul 03722, South Korea.; Yoon, HI (corresponding author), Yonsei Univ, Dept Radiat Oncol, Coll Med, 50 1 Yonsei Ro, Seoul 03722, South Korea. EM smkang@yuhs.ac; YHI0225@yuhs.ac RI ; Chang, Jee Suk/ABU-3301-2022; Kim, Jihun/AAS-7978-2021; Kim, Jin Sung/AAS-7978-2021; Lee, Seung-Hyun/HKV-3475-2023 OI Yoon, Hong In/0000-0002-2106-6856; Gwak, Seo-Yeon/0000-0002-5550-4156; Byun, Hwa Kyung/0000-0002-8964-6275; Chang, Jee Suk/0000-0001-7685-3382; Kim, Jihun/0000-0003-4856-6305; Cho, Iksung/0000-0001-5927-5410; Kim, Jin Sung/0000-0003-1415-6471; Kim, Jin Sung/0000-0003-1415-6471; Kang, Seok-Min/0000-0001-9856-9227; Oh, Jaewon/0000-0002-4585-1488 FU Severance Hospital Research fund for Clinical excellence (SHRC) [C-2020-0040]; National Research Foundation of Korea (NRF) [NRF-2021R1I1A1A01060135, NRF-2019R1C1C1009359]; Korea Food Research Institute - Ministry of Science, ICT & Future Planning [E0210400-01] FX This work was supported by the Severance Hospital Research fund for Clinical excellence (SHRC) (grant number C-2020-0040) to Dr Yoon); National Research Foundation of Korea (NRF) (grant numbers NRF-2021R1I1A1A01060135 [to Dr Oh] and NRF-2019R1C1C1009359 [to Dr Chang]); and Korea Food Research Institute funded by the Ministry of Science, ICT & Future Planning (grant number E0210400-01 [to Dr Choi]). CR Abravan A, 2020, J THORAC ONCOL, V15, P1624, DOI 10.1016/j.jtho.2020.06.008 Atkins KM, 2021, INT J RADIAT ONCOL, V110, P1473, DOI 10.1016/j.ijrobp.2021.03.005 Atkins KM, 2021, JAMA ONCOL, V7, P206, DOI 10.1001/jamaoncol.2020.6332 Atkins KM, 2019, J AM COLL CARDIOL, V73, P2976, DOI 10.1016/j.jacc.2019.03.500 Banfill K, 2021, J THORAC ONCOL, V16, P216, DOI 10.1016/j.jtho.2020.11.002 Bergom C, 2021, JACC-CARDIOONCOL, V3, P343, DOI 10.1016/j.jaccao.2021.06.007 Bogart JA, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.8505 Bradley JD, 2020, J CLIN ONCOL, V38, P706, DOI 10.1200/JCO.19.01162 Choi MS, 2020, RADIOTHER ONCOL, V153, P139, DOI 10.1016/j.radonc.2020.09.045 Chung SY, 2021, INT J RADIAT ONCOL, V110, P473, DOI 10.1016/j.ijrobp.2020.12.053 Darby SC, 2013, NEW ENGL J MED, V368, P987, DOI 10.1056/NEJMoa1209825 Faivre-Finn C, 2017, LANCET ONCOL, V18, P1116, DOI 10.1016/S1470-2045(17)30318-2 Feng M, 2011, INT J RADIAT ONCOL, V79, P10, DOI 10.1016/j.ijrobp.2009.10.058 Gal R, 2021, JAMA ONCOL, V7, P1024, DOI 10.1001/jamaoncol.2021.1144 Goldberger JJ, 2015, CIRCULATION, V132, P278, DOI 10.1161/CIRCULATIONAHA.115.016795 Guha A, 2022, EUR HEART J, V43, P300, DOI 10.1093/eurheartj/ehab745 Heagerty PJ, 2005, BIOMETRICS, V61, P92, DOI 10.1111/j.0006-341X.2005.030814.x Hicks KA, 2018, J AM COLL CARDIOL, V71, P1021, DOI 10.1016/j.jacc.2017.12.048 Holm H, 2011, NAT GENET, V43, P316, DOI 10.1038/ng.781 Iwasaki YK, 2011, CIRCULATION, V124, P2264, DOI 10.1161/CIRCULATIONAHA.111.019893 Jang BS, 2020, RADIOTHER ONCOL, V152, P126, DOI 10.1016/j.radonc.2020.09.050 John RM, 2016, CIRCULATION, V133, P1892, DOI 10.1161/CIRCULATIONAHA.116.018011 Kravchenko J, 2015, LUNG CANCER, V88, P85, DOI 10.1016/j.lungcan.2015.01.006 Lamas GA, 2002, NEW ENGL J MED, V346, P1854, DOI 10.1056/NEJMoa013040 Lee JG, 2021, KOREAN J RADIOL, V22, P1764 Loap P, 2021, PRACT RADIAT ONCOL, V11, pE434, DOI 10.1016/j.prro.2021.02.002 McWilliam A, 2020, INT J RADIAT ONCOL, V108, P1073, DOI 10.1016/j.ijrobp.2020.06.031 McWilliam A, 2017, EUR J CANCER, V85, P106, DOI 10.1016/j.ejca.2017.07.053 Nielsen JC, 2011, EUR HEART J, V32, P686, DOI 10.1093/eurheartj/ehr022 O'Neal WT, 2014, AM J CARDIOL, V114, P1707, DOI 10.1016/j.amjcard.2014.09.005 Oh J, 2021, STEM CELL RES, V56, DOI 10.1016/j.scr.2021.102508 Perez MV, 2019, NEW ENGL J MED, V381, P1909, DOI 10.1056/NEJMoa1901183 Raafs AG, 2022, JACC-CARDIOVASC IMAG, V15, P1015, DOI 10.1016/j.jcmg.2022.01.016 Speirs CK, 2017, J THORAC ONCOL, V12, P293, DOI 10.1016/j.jtho.2016.09.134 Spigel DR, 2022, J CLIN ONCOL, V40, P1301, DOI 10.1200/JCO.21.01308 Staerk L, 2017, CIRC RES, V120, P1501, DOI 10.1161/CIRCRESAHA.117.309732 Taunk NK, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00039 Thor M, 2020, CLIN CANCER RES, V26, P4643, DOI 10.1158/1078-0432.CCR-19-2627 Thorolfsdottir RB, 2021, EUR HEART J, V42, P1959, DOI 10.1093/eurheartj/ehaa1108 Thorolfsdottir RB, 2017, J AM COLL CARDIOL, V70, P2157, DOI 10.1016/j.jacc.2017.09.005 Tisdale JE, 2020, CIRCULATION, V142, pE214, DOI 10.1161/CIR.0000000000000905 van Nimwegen FA, 2016, J CLIN ONCOL, V34, P235, DOI 10.1200/JCO.2015.63.4444 van Nimwegen FA, 2015, JAMA INTERN MED, V175, P1007, DOI 10.1001/jamainternmed.2015.1180 Vinter N, 2018, EUR HEART J-CARD IMG, V19, P926, DOI 10.1093/ehjci/jex201 Vonder M, 2022, JACC-CARDIOVASC IMAG, V15, P366, DOI 10.1016/j.jcmg.2021.07.012 Wang K, 2017, J CLIN ONCOL, V35, P1387, DOI 10.1200/JCO.2016.70.0229 Wang X, 2020, J THORAC ONCOL, V15, P1682, DOI 10.1016/j.jtho.2020.06.014 Yang XY, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01058 Yegya-Raman N, 2018, J THORAC ONCOL, V13, P1508, DOI 10.1016/j.jtho.2018.05.028 NR 49 TC 70 Z9 71 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2374-2437 EI 2374-2445 J9 JAMA ONCOL JI JAMA Oncol. PD NOV PY 2022 VL 8 IS 11 BP 1624 EP 1634 DI 10.1001/jamaoncol.2022.4202 EA SEP 2022 PG 11 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA 6L3CT UT WOS:000857177000008 PM 36136325 OA Green Submitted DA 2026-04-17 ER PT J AU Wang, XM Zhang, DM Ren, YX Han, JJ Li, GL Guo, XY AF Wang, Xiaomei Zhang, Demei Ren, Yanxia Han, Jingjing Li, Guangling Guo, Xueya TI Pharmacological interventions for preventing atrial fibrillation after lung surgery: systematic review and meta-analysis SO EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY LA English DT Review DE Postoperative atrial fibrillation; Lung surgery; Prophylaxis; Pharmacological interventions; Meta-analysis ID NONCARDIAC THORACIC-SURGERY; DOUBLE-BLIND; PROPHYLACTIC DIGITALIZATION; PULMONARY RESECTION; CARDIAC-SURGERY; RISK-FACTORS; AMIODARONE; DILTIAZEM; DYSRHYTHMIAS; CANCER AB Background Postoperative atrial fibrillation/flutter (POAF) is one of the most common cardiac complications after lung surgery. We aimed to assess the safety and efficacy of pharmacological interventions for new-onset POAF prophylaxis in patients with lung cancer after lung surgery. Methods PubMed, Embase, Web of Science, Scopus, and the Cochrane Library were searched to identify randomized controlled trials comparing the effects of pharmacological interventions to prevent POAF following lung surgery. Results A total number of 19 studies with 2,922 participants were included. Pharmacological interventions significantly reduced the incidence of POAF (odds ratio [OR] 0.36, 95% confidence interval [95% CI] 0.26-0.52) while did not increase the incidence of severe pulmonary complications (OR 1.17, 95% CI 0.57-2.41) after lung surgery compared with placebo/usual care. Among different trials, beta-blockers appeared to be the most effective with an OR of 0.13 (95% CI, 0.07-0.27) and a number needed-to-treat (NNT) of 3.63 and was considered safe with no serious adverse events recorded. The risk of POAF decreased from 25.6 to 11.4% (P < 0.001) overall and from 34.2 to 6.7% (P < 0.001) with beta-blockers as monotherapy. Pharmacological interventions did not reduce the 30-day mortality (OR 0.89, 95% CI 0.43-1.84, I-2 = 0%), but showed a trend toward reducing major cardiovascular complications including myocardial ischemia/infarction, cardiac arrest, heart failure, and stroke (OR 0.41, 95% CI 0.13-1.29, I-2 = 0%). Conclusion Current clinical evidence supports the effectiveness of pharmacological intervention with beta-blockers, amiodarone, magnesium sulfate, or calcium-channel blockers to reduce the incidence of POAF after lung surgery in patients with lung cancer. In the absence of contraindications, prophylaxis with beta-blockers seems to be the most effective of the treatments studied. C1 [Wang, Xiaomei; Zhang, Demei; Han, Jingjing; Li, Guangling; Guo, Xueya] Lanzhou Univ, Lanzhou Univ Second Hosp, Dept Cardiol, Lanzhou, Peoples R China. [Ren, Yanxia] Lanzhou Univ, First Hosp Lanzhou Univ, Dept Cardiol, Lanzhou, Peoples R China. C3 Lanzhou University; Lanzhou University RP Guo, XY (corresponding author), Lanzhou Univ, Lanzhou Univ Second Hosp, Dept Cardiol, Lanzhou, Peoples R China. EM wangxiaomei241@163.com; guoxueya2006@126.com CR Amar D, 1997, ANN THORAC SURG, V63, P1374 AMAR D, 1995, CHEST, V108, P349, DOI 10.1378/chest.108.2.349 Amar D, 2000, J THORAC CARDIOV SUR, V120, P790, DOI 10.1067/mtc.2000.109538 Amar D, 2003, J AM COLL CARDIOL, V42, P1262, DOI 10.1016/S0735-1097(03)00955-0 Amar D, 2015, J THORAC CARDIOV SUR, V149, P1532, DOI 10.1016/j.jtcvs.2014.12.016 Arsenault Kyle A, 2013, Cochrane Database Syst Rev, pCD003611, DOI 10.1002/14651858.CD003611.pub3 Bayliff CD, 1999, ANN THORAC SURG, V67, P182, DOI 10.1016/S0003-4975(98)01226-0 Bessissow A, 2018, EUR J CARDIO-THORAC, V53, P945, DOI 10.1093/ejcts/ezx422 Cardinale D, 2016, ANN SURG, V264, P244, DOI 10.1097/SLA.0000000000001626 CHAFFMAN M, 1985, DRUGS, V29, P387, DOI 10.2165/00003495-198529050-00001 Ciszewski P, 2013, THORAC CARDIOV SURG, V61, P365, DOI 10.1055/s-0032-1311537 Curtis JJ, 1998, ANN THORAC SURG, V66, P1766, DOI 10.1016/S0003-4975(98)00942-4 Dobrev D, 2019, NAT REV CARDIOL, V16, P417, DOI 10.1038/s41569-019-0166-5 ENGLAND MR, 1992, JAMA-J AM MED ASSOC, V268, P2395, DOI 10.1001/jama.268.17.2395 Gialdini G, 2014, JAMA-J AM MED ASSOC, V312, P616, DOI 10.1001/jama.2014.9143 Hogue CW Jr, 2000, ANN THORAC SURG, V69, P300, DOI 10.1016/S0003-4975(99)01267-9 Jakobsen CJ, 1997, J CARDIOTHOR VASC AN, V11, P746, DOI 10.1016/S1053-0770(97)90169-5 KAISER A, 1994, HELV CHIR ACTA, V60, P913 Khalil MA, 2013, J ANESTH, V27, P56, DOI 10.1007/s00540-012-1478-3 LINDGREN L, 1991, BRIT J ANAESTH, V66, P205, DOI 10.1093/bja/66.2.205 Maisel WH, 2003, J AM COLL CARDIOL, V42, P1269, DOI 10.1016/S0735-1097(03)00959-8 Nct, 2008, AM PROPH ATR FIBR PA Nojiri T, 2015, CHEST, V148, P1285, DOI 10.1378/chest.15-0852 Nojiri T, 2012, J THORAC CARDIOV SUR, V143, P488, DOI 10.1016/j.jtcvs.2011.09.003 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Passman RS, 2005, ANN THORAC SURG, V79, P1698, DOI 10.1016/j.athoracsur.2004.10.058 Riber LP, 2012, ANN THORAC SURG, V94, P339, DOI 10.1016/j.athoracsur.2011.12.096 Riber LP, 2014, ANN THORAC SURG, V98, P1989, DOI 10.1016/j.athoracsur.2014.06.069 RITCHIE AJ, 1992, THORAX, V47, P41, DOI 10.1136/thx.47.1.41 Shin DG, 2006, CIRC J, V70, P94, DOI 10.1253/circj.70.94 Tamura T, 2017, J CLIN ANESTH, V42, P1, DOI 10.1016/j.jclinane.2017.07.009 Terzi A, 1996, THORAC CARDIOV SURG, V44, P300, DOI 10.1055/s-2007-1012041 Tisdale JE, 2009, ANN THORAC SURG, V88, P886, DOI 10.1016/j.athoracsur.2009.04.074 Toraman F, 2001, ANN THORAC SURG, V72, P1256, DOI 10.1016/S0003-4975(01)02898-3 Triggle DJ, 2007, BIOCHEM PHARMACOL, V74, P1, DOI 10.1016/j.bcp.2007.01.016 VanMieghem W, 1996, ANN THORAC SURG, V61, P1083, DOI 10.1016/0003-4975(96)00073-2 VANMIEGHEM W, 1994, CHEST, V105, P1642, DOI 10.1378/chest.105.6.1642 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Yagi K, 2016, Open Journal of Anesthesiology, V06, P119, DOI 10.4236/ojanes.2016.68020 Zhang LZ, 2016, J CARDIOVASC PHARM, V67, P351, DOI 10.1097/FJC.0000000000000351 Zhao BC, 2017, CHEST, V151, P149, DOI 10.1016/j.chest.2016.08.1476 Zhen-Han L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10600-x Zimetbaum P, 2007, NEW ENGL J MED, V356, P935, DOI 10.1056/NEJMct065916 NR 43 TC 5 Z9 6 U1 0 U2 10 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0031-6970 EI 1432-1041 J9 EUR J CLIN PHARMACOL JI Eur. J. Clin. Pharmacol. PD NOV PY 2022 VL 78 IS 11 BP 1777 EP 1790 DI 10.1007/s00228-022-03383-2 EA SEP 2022 PG 14 WC Pharmacology & Pharmacy WE Science Citation Index Expanded (SCI-EXPANDED) SC Pharmacology & Pharmacy GA 5D6MT UT WOS:000856612300001 PM 36136141 DA 2026-04-17 ER PT J AU Dexter, E Attwood, K Demmy, T Yendamuri, S AF Dexter, Elisabeth Attwood, Kristopher Demmy, Todd Yendamuri, Sai TI Does Operative Duration of Lobectomy for Early Lung Cancer Increase Perioperative Morbidity? SO ANNALS OF THORACIC SURGERY LA English DT Article ID INTENSIVE-CARE-UNIT; RISK-FACTORS; POSTOPERATIVE COMPLICATIONS; THORACOSCOPIC LOBECTOMY; PULMONARY COMPLICATIONS; HOSPITAL VOLUME; STAGE-I; READMISSION; OUTCOMES; SURGERY AB BACKGROUND Longer bariatric, colorectal, plastic, spine, and urologic operations increase complications and lengths of stay. We aimed to determine whether this is a risk factor for lung lobectomy morbidity.METHODS The Society of Thoracic Surgeons General Thoracic Surgery Database was queried for early-stage non -small cell lung cancer lobectomy with surgical duration treated as a continuous variable. Univariate and multivariate analyses compared patient and clinical characteristics with perioperative outcomes and procedure durations. Robotic cases were combined with thoracoscopic cases for duration analyses into a minimally invasive group. All analyses were conducted in SAS v9.4 (SAS Institute, Cary, NC) at a significance level of .05.RESULTS In 17,852 patients mean duration of thoracotomy, thoracoscopy, and robotic lobectomies were 178 +/- 84,185 +/- 73, and 214 +/- 82 minutes, respectively (P < .001). The most common complications were prolonged air leak (12.3%), atrial fibrillation (12%), pneumonia (4.4%), and atelectasis requiring bronchoscopy (4.1%). Procedure duration was associated with increased odds of intraoperative packed red blood cell transfusion (P < .001) and length of stay > 5 days (P < .001) for both thoracotomy and minimally invasive lobectomy. Increased odds of pneumonia (P < .001), atelectasis (P < .001), and unexpected intensive care unit admission (P = .006) for thoracotomy lobectomy were associated with longer procedure duration. Increased lobectomy duration was not associated with readmission (P = .549) or 30-day mortality (P = .208).CONCLUSIONS Longer early-stage lung cancer lobectomy durations are associated with postoperative morbidity and increased length of stay. Although the effects of protracted operation times on long-term survival are unknown, short-term mortality differences were not detected. Measures that decrease operative durations without sacrificing safety and oncologic outcome should be undertaken by surgeons and hospital systems.(Ann Thorac Surg 2022;114:941-8)(c) 2022 by The Society of Thoracic Surgeons C1 [Dexter, Elisabeth; Attwood, Kristopher; Demmy, Todd; Yendamuri, Sai] Roswell Pk Comprehens Canc Ctr, Dept Thorac Surg, Buffalo, NY USA. SUNY Univ Buffalo, Dept Surg, Buffalo, NY USA. Roswell Pk Comprehens Canc Ctr, Dept Biostat & Bioinformat, Buffalo, NY USA. SUNY Univ Buffalo, Dept Biostat, Buffalo, NY USA. [Dexter, Elisabeth] Roswell Pk Comprehens Canc Ctr, Dept Thorac Surg, Elm & Carlton St, Buffalo, NY 14263 USA. C3 Roswell Park Comprehensive Cancer Center; State University of New York (SUNY) System; University at Buffalo, SUNY; Roswell Park Comprehensive Cancer Center; State University of New York (SUNY) System; University at Buffalo, SUNY; Roswell Park Comprehensive Cancer Center RP Dexter, E (corresponding author), Roswell Pk Comprehens Canc Ctr, Dept Thorac Surg, Elm & Carlton St, Buffalo, NY 14263 USA. EM elisabeth.dexter@roswellpark.org OI Dexter, Elisabeth/0000-0002-7554-9060 FU Roswell Park Comprehensive Cancer Center, Buffalo, NY; National Cancer Institute [P30CA016056]; National Cancer Institute [P30CA016056] Funding Source: NIH RePORTER FX Data for this research were provided by The Society of Thoracic Surgeons National Database Participant User File Research Program. Data analysis was performed at the investigators institution. This work was supported by the Roswell Park Comprehensive Cancer Center, Buffalo, NY, and National Cancer Institute grant P30CA016056. CR Ballantyne JC, 1998, ANESTH ANALG, V86, P598, DOI 10.1097/00000539-199803000-00032 Bernatz JT, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.7.FOCUS1534 Brunelli A, 2017, ANN THORAC SURG, V104, P1020, DOI 10.1016/j.athoracsur.2017.02.083 Chen FF, 2013, EJSO-EUR J SURG ONC, V39, P957, DOI 10.1016/j.ejso.2013.06.016 Choe EK, 2019, J CLIN MED, V8, DOI 10.3390/jcm8050667 Daley BJ, 2015, J AM COLL SURGEONS, V220, P550, DOI 10.1016/j.jamcollsurg.2014.12.040 Dexter E, 2017, J AM COLL SURGEONS, V225, pE9, DOI 10.1016/j.jamcollsurg.2017.07.545 Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4 Ettinger DS, 2019, J NATL COMPR CANC NE, V17, P1464, DOI 10.6004/jnccn.2019.0059 Hardy KL, 2014, AESTHET SURG J, V34, P614, DOI 10.1177/1090820X14528503 Howington JA, 2013, CHEST, V143, pE278, DOI 10.1378/chest.12-2359 Jung JJ, 2017, THORAC CANCER, V8, P33, DOI 10.1111/1759-7714.12406 Kim BD, 2014, SPINE, V39, P510, DOI 10.1097/BRS.0000000000000163 Licker M, 2001, EUR J ANAESTH, V18, P540, DOI 10.1046/j.1365-2346.2001.00890.x Lohser J, 2015, ANESTH ANALG, V121, P302, DOI 10.1213/ANE.0000000000000808 McAlister FA, 2005, AM J RESP CRIT CARE, V171, P514, DOI 10.1164/rccm.200408-1069OC Nagano A, 2021, J NUTR HEALTH AGING, V25, P507, DOI 10.1007/s12603-021-1587-5 Owen RM, 2013, SURG ENDOSC, V27, P3555, DOI 10.1007/s00464-013-2949-9 Park HS, 2012, ANN THORAC SURG, V93, P372, DOI 10.1016/j.athoracsur.2011.06.054 Pei GT, 2014, J THORAC DIS, V6, P1230, DOI 10.3978/j.issn.2072-1439.2014.07.23 Polites SF, 2017, J PEDIATR SURG, V52, P1239, DOI 10.1016/j.jpedsurg.2016.11.043 Qin C, 2015, INT J SURG, V20, P107, DOI 10.1016/j.ijsu.2015.05.051 Reames BN, 2015, SURG OBES RELAT DIS, V11, P207, DOI 10.1016/j.soard.2014.03.018 Richardson J, 1999, J CARDIOVASC SURG, V40, P445 Routh JC, 2008, BJU INT, V102, P301, DOI 10.1111/j.1464-410X.2008.07663.x Skloot GS, 2017, CLIN GERIATR MED, V33, P447, DOI 10.1016/j.cger.2017.06.001 Song SW, 2007, ANN THORAC SURG, V84, P1838, DOI 10.1016/j.athoracsur.2007.06.074 Tchouta LN, 2017, CHEST, V151, P329, DOI 10.1016/j.chest.2016.09.008 Valentini LG, 2008, NEUROSURGERY, V62, P88, DOI 10.1227/01.NEU.0000311065.95496.C5 NR 29 TC 22 Z9 23 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD SEP PY 2022 VL 114 IS 3 BP 941 EP 947 DI 10.1016/j.athoracsur.2022.01.040 EA AUG 2022 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 5A9PS UT WOS:000863211600025 PM 35183506 OA Green Submitted DA 2026-04-17 ER PT J AU Zheng, S Shi, QL Ma, QY Fu, Q Qiao, K AF Zheng, Shuo Shi, Qinlang Ma, Qinya Fu, Qiang Qiao, Kun TI The short-term outcomes for the early removal of pigtail catheter drainage within 24 hours of uniportal video-assisted anatomic surgery in patients with lung cancer SO TRANSLATIONAL CANCER RESEARCH LA English DT Article DE Lung cancer; surgery; enhanced recovery after surgery (ERAS); drainage ID CHEST TUBE REMOVAL; RESECTION; IMPACT AB Background: Early removal of the chest tube has advantages of reducing postoperative pain and speed recovery. This study aimed to confirm its safety and feasibility of early removal of a pigtail catheter used as a chest drain in patients undergoing anatomical surgery. Methods: This retrospective cohort study included 126 patients who removed pigtail catheter <= 24 h after surgery, and 56 patients >24 h who underwent uniportal video-assisted thoracic surgery (u-VATS) between January 2020 and April 2022. All patients had stage I lung cancer and underwent anatomical surgery (lobectomy or segmentectomy). The clinical characteristics, perioperative data, and postoperative complications of both groups were analyzed and compared. Results: The >24 h group had more patients with a higher body mass index (BMI) (P<0.001), a lower forced expiratory volume in the first second (FEV1) (P<0.001), Chronic obstructive pulmonary disease (COPD) (P<0.001), and current smokers (P=0.006) than the <= 24 h group. There were no significant differences in terms of age, sex, type of resection, operation time, and bleeding loss between the two groups (P>0.05). The pain of patients in the <= 24 h group was significantly less than that in the >24 h group only on the third postoperative day (P=0.035). There were no significant differences in the postoperative visual analogue scale (VAS) at postoperative day 0, day 1, day 7, and 1 month between the two groups (P>0.05). With the exception of a higher occurrence of subcutaneous emphysema in the >24 h group (71.7% vs. 100%, P=0.001), there were no statistically significant differences in the postoperative complications (e.g., pneumonia, atrial fibrillation, atelectasis, pleural effusion, and wound infection) between the 2 groups (P>0.05). During the 30-day follow-up period, none of the patients required tube reinsertion for pneumothorax. A total of 8 patients in the <= 24 h group and 4 in the >24 h group required tube reinsertion (6.7% vs. 7.1%, P>0.99) due to pleural effusion. Conclusions: In stage I lung cancer patients who underwent u-VATS anatomic surgery, the pigtail catheter used as a thoracic drainage tube removed with 24 h after was safe and feasible. C1 [Zheng, Shuo; Shi, Qinlang; Ma, Qinya; Fu, Qiang; Qiao, Kun] Southern Univ Sci & Technol, Affiliated Hosp 2, Shenzhen, Peoples R China. [Zheng, Shuo; Shi, Qinlang; Ma, Qinya; Fu, Qiang; Qiao, Kun] Third Peoples Hosp Shenzhen, Dept Thorac Surg, Shenzhen, Peoples R China. C3 Southern University of Science & Technology; The Third People's Hospital of Shenzhen RP Qiao, K (corresponding author), Third Peoples Hosp Shenzhen, Dept Thorac Surg, 29 Bulan Rd, Shenzhen 51800, Peoples R China. EM szqiaokun@163.com RI 乔, 坤/HPD-3540-2023 FU Third People's Hospital of Shenzhen [2022-077-02] FX This work was supported by the clinical research project of The Third People's Hospital of Shenzhen (No. 2022-077-02). CR Batchelor TJP, 2019, EUR J CARDIO-THORAC, V55, P91, DOI 10.1093/ejcts/ezy301 Bediwy AS, 2012, International Scholarly Research Notices, V2012, DOI [10.5402/2012/143295, DOI 10.5402/2012/143295] Carmichael JC, 2017, DIS COLON RECTUM, V60, P761, DOI 10.1097/DCR.0000000000000883 De Waele M, 2017, J THORAC DIS, V9, P1598, DOI 10.21037/jtd.2017.05.78 Detterbeck FC, 2017, CHEST, V151, P193, DOI 10.1016/j.chest.2016.10.010 Dhanasopon AP, 2017, SURG CLIN N AM, V97, P751, DOI 10.1016/j.suc.2017.03.006 Ettinger DS, 2022, J NATL COMPR CANC NE, V20, P497, DOI 10.6004/jnccn.2022.0025 Gammie J S, 1999, JSLS, V3, P57 Hu YN, 2014, J THORAC CARDIOV SUR, V148, P2261, DOI 10.1016/j.jtcvs.2014.04.026 Molins Laureano, 2008, Thorac Surg Clin, V18, P321, DOI 10.1016/j.thorsurg.2008.04.003 Park BJ, 2016, J CARDIOTHORAC SURG, V11, DOI 10.1186/s13019-016-0563-3 Pfeuty K, 2020, INTERACT CARDIOV TH, V31, P657, DOI 10.1093/icvts/ivaa170 Prisciandaro E, 2020, INTERACT CARDIOV TH, V31, P499, DOI 10.1093/icvts/ivaa141 Refai M, 2012, EUR J CARDIO-THORAC, V41, P820, DOI 10.1093/ejcts/ezr126 Remon J, 2021, ANN ONCOL, V32, P1637, DOI 10.1016/j.annonc.2021.08.1994 Sun Xicai, 2015, Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V50, P890 Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660 Wang WD, 2020, FRONT SURG, V7, DOI 10.3389/fsurg.2020.584578 NR 18 TC 1 Z9 1 U1 0 U2 2 PU AME PUBLISHING COMPANY PI SHATIN PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA SN 2218-676X EI 2219-6803 J9 TRANSL CANCER RES JI Transl. Cancer Res. PD SEP PY 2022 VL 11 IS 9 BP 3260 EP 3266 DI 10.21037/tcr-22-1910 EA AUG 2022 PG 7 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA U2WC1 UT WOS:000852208700001 PM 36237245 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Silk, AW Saraiya, B Groisberg, R Chan, N Spencer, K Girda, E Shih, W Palmeri, M Saunders, T Berman, RM Coric, V Chen, SZ Zloza, A Vieth, J Mehnert, JM Malhotra, J AF Silk, Ann W. Saraiya, Biren Groisberg, Roman Chan, Nancy Spencer, Kristen Girda, Eugenia Shih, Weichung Palmeri, Marisa Saunders, Tracie Berman, Robert M. Coric, Vlad Chen, Suzie Zloza, Andrew Vieth, Joshua Mehnert, Janice M. Malhotra, Jyoti TI A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors SO EUROPEAN JOURNAL OF MEDICAL RESEARCH LA English DT Article DE Glutamate; Prodrug; Immunotherapy resistance ID PHARMACOLOGICAL BLOCKADE; GLIOMA-CELLS; RILUZOLE; EXPRESSION; CANCER; TRIAL AB Background Glutamate signaling activates MAPK and PI3K/AKT pathways in tumor cells. Treatment with riluzole, a glutamate release inhibitor, has been previously shown to be safe in melanoma patients and produced biologic effects, but did not lead to radiographic responses, possibly due to poor pharmacokinetic properties. Therefore, we conducted a phase Ib trial to determine the safety and tolerability of the combination of the riluzole prodrug troriluzole (BHV-4157, trigriluzole) and the PD-1 antibody nivolumab in patients with advanced solid tumors. Methods Patients with advanced or refractory solid tumors and measurable disease per RECIST 1.1 were treated with increasing doses of troriluzole using a semi-Bayesian modified toxicity probability interval dose escalation procedure. Troriluzole monotherapy was orally self-administered for a 14-day lead-in period followed by continuation of troriluzole in combination with nivolumab 240 mg IV every 2 weeks. Endpoints included safety, pharmacokinetics (PK) and efficacy. Results We enrolled 14 patients with advanced solid tumors (melanoma = 3, NSCLC = 3, renal cell carcinoma = 2, bladder/urothelial = 2, ovarian cancer = 1, adenoid cystic carcinoma = 1, pleural mesothelial = 1, head and neck cancer = 1). Eleven patients had cancer progression on prior therapy with PD-1 or PD-L1 agent. Patients received troriluzole total daily doses from 140 to 560 mg (divided). The most common treatment-related adverse events (TRAE) occurring in >= 5 patients (> 35%) were transaminitis and increased lipase. DLT (dose-limiting toxicity) occurred in 3 patients: (1) grade 3 anorexia, (2) grade 3 fatigue and, (3) grade 3 atrial fibrillation. Six patients were treated at the MTD (maximum tolerated dose). No subjects discontinued treatment due to AEs. One response occurred (7%), which was a partial response in a subject who had PD-1 refractory disease. The 6-month PFS rate was 21%. PK data showed that the prodrug troriluzole was efficiently cleaved into riluzole by 2-h post-dosing in all dose cohorts tested. Conclusion The combination of troriluzole and nivolumab was safe and well-tolerated. The MTD of troriluzole was determined to be 420 mg total daily dose. The observed antitumor activity, primarily disease stabilization, is of interest in patients with PD-1 resistant tumors. Trial Registration ClinicalTrials.gov Identifier NCT03229278. C1 [Silk, Ann W.] Dana Farber Canc Inst, 450 Brookline Ave,Room LW503, Boston, MA 02115 USA. [Silk, Ann W.] Harvard Med Sch, 450 Brookline Ave,Room LW503, Boston, MA 02115 USA. [Silk, Ann W.; Saraiya, Biren; Groisberg, Roman; Chan, Nancy; Spencer, Kristen; Girda, Eugenia; Shih, Weichung; Palmeri, Marisa; Saunders, Tracie; Chen, Suzie; Zloza, Andrew; Vieth, Joshua; Mehnert, Janice M.; Malhotra, Jyoti] Rutgers Canc Inst New Jersey, New Brunswick, NJ 08901 USA. [Silk, Ann W.; Saraiya, Biren; Groisberg, Roman; Chan, Nancy; Spencer, Kristen; Girda, Eugenia; Shih, Weichung; Palmeri, Marisa; Saunders, Tracie; Chen, Suzie; Zloza, Andrew; Vieth, Joshua; Mehnert, Janice M.; Malhotra, Jyoti] Univ Med & Dent New Jersey, New Brunswick, NJ 08901 USA. [Chan, Nancy; Mehnert, Janice M.] Laura & Isaac Perlmutter Canc Ctr, New York, NY USA. [Chan, Nancy; Mehnert, Janice M.] NYU, Grossman Sch Med, New York, NY USA. [Shih, Weichung] Rutgers State Univ, Sch Publ Hlth, New Brunswick, NJ USA. [Shih, Weichung] Chi Sq Consulting LLC, Piscataway, NJ USA. [Berman, Robert M.; Coric, Vlad] Biohaven Pharmaceut, New Haven, CT USA. [Chen, Suzie] Rutgers State Univ, Sch Pharm, Piscataway, NJ USA. [Zloza, Andrew] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Zloza, Andrew] Rush Med Coll, Dept Internal Med, Chicago, IL 60612 USA. [Vieth, Joshua] JDRF Int, New York, NY USA. C3 Harvard University; Harvard University Medical Affiliates; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Rutgers University System; Rutgers University New Brunswick; Rutgers University Biomedical & Health Sciences; Rutgers Cancer Institute of New Jersey; Rutgers University System; Rutgers University New Brunswick; Rutgers University Biomedical & Health Sciences; New York University; Rutgers University System; Rutgers University New Brunswick; Rutgers University System; Rutgers University New Brunswick; Rush University; Rush University RP Silk, AW (corresponding author), Dana Farber Canc Inst, 450 Brookline Ave,Room LW503, Boston, MA 02115 USA.; Silk, AW (corresponding author), Harvard Med Sch, 450 Brookline Ave,Room LW503, Boston, MA 02115 USA.; Silk, AW (corresponding author), Rutgers Canc Inst New Jersey, New Brunswick, NJ 08901 USA.; Silk, AW (corresponding author), Univ Med & Dent New Jersey, New Brunswick, NJ 08901 USA. EM ann_silk@dfci.harvard.edu RI Vieth, Joshua/J-9349-2016; Groisberg, Roman/X-2743-2019 OI Vieth, Joshua/0000-0001-8756-2759; Malhotra, Jyoti/0000-0001-8586-0234; FU NCI-CCSG [P30CA072770-5920]; Biohaven Pharmaceuticals FX Biohaven Pharmaceuticals funded the clinical trial. Services in support of the research project were generated by the Rutgers Cancer Institute of New Jersey Immune Monitoring Shared Resource, supported, in part, with funding from the NCI-CCSG P30CA072770-5920. CR [Anonymous], 2016, RILUTEK Arcella A, 2005, NEURO-ONCOLOGY, V7, P236, DOI 10.1215/S1152851704000961 Aronica E, 2003, EUR J NEUROSCI, V17, P2106, DOI 10.1046/j.1460-9568.2003.02657.x BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901 Brocke Katja S, 2010, Cancer Biol Ther, V9, P455, DOI 10.4161/cbt.9.6.10898 Chang HJ, 2005, CLIN CANCER RES, V11, P3288, DOI 10.1158/1078-0432.CCR-04-1912 D'Onofrio M, 2003, J NEUROCHEM, V84, P1288, DOI 10.1046/j.1471-4159.2003.01633.x Fabbi M, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/3958069 Gao L, 2016, ONCOTARGET, V7, P87037, DOI 10.18632/oncotarget.13523 Hamid O, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-204 Haratani K, 2017, ANN ONCOL, V28, P1532, DOI 10.1093/annonc/mdx183 Ji YA, 2010, CLIN TRIALS, V7, P653, DOI 10.1177/1740774510382799 Medikonda R, 2022, J NEUROSURG, V136, P379, DOI 10.3171/2021.1.JNS202482 Mehnert JM, 2018, PIGM CELL MELANOMA R, V31, P534, DOI 10.1111/pcmr.12694 Mirlekar B, 2021, CANCERS, V13, DOI 10.3390/cancers13020167 Namkoong J, 2007, CANCER RES, V67, P2298, DOI 10.1158/0008-5472.CAN-06-3665 Pollock PM, 2003, NAT GENET, V34, P108, DOI 10.1038/ng1148 Silk AWSB., 2020, CLIN IMMUNO ONCOL S, DOI [10.1200/JCO.2020.38.5_suppl.79, DOI 10.1200/JCO.2020.38.5_SUPPL.79] Speyer CL, 2012, BREAST CANCER RES TR, V132, P565, DOI 10.1007/s10549-011-1624-x Stepulak A, 2009, HISTOCHEM CELL BIOL, V132, P435, DOI 10.1007/s00418-009-0613-1 Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954 Yin MZ, 2016, J CLIN INVEST, V126, P4157, DOI 10.1172/JCI87252 Yip D, 2009, CLIN CANCER RES, V15, P3896, DOI 10.1158/1078-0432.CCR-08-3303 Zona C, 1998, NEUROSCIENCE, V85, P931, DOI 10.1016/S0306-4522(97)00604-0 NR 24 TC 15 Z9 18 U1 0 U2 5 PU BMC PI LONDON PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0949-2321 EI 2047-783X J9 EUR J MED RES JI Eur. J. Med. Res. PD JUL 2 PY 2022 VL 27 IS 1 AR 107 DI 10.1186/s40001-022-00732-w PG 7 WC Medicine, Research & Experimental WE Science Citation Index Expanded (SCI-EXPANDED) SC Research & Experimental Medicine GA 2Q2EA UT WOS:000820239700003 PM 35780243 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Nishizawa, N Okawara, M Mori, M Fujino, Y Matsuda, S Fushimi, K Tanaka, F AF Nishizawa, Natsumasa Okawara, Makoto Mori, Masataka Fujino, Yoshihisa Matsuda, Shinya Fushimi, Kiyohide Tanaka, Fumihiro TI Postoperative cerebral infarction risk is related to lobectomy site in lung cancer: a retrospective cohort study of nationwide data in Japan SO BMJ OPEN RESPIRATORY RESEARCH LA English DT Article DE thoracic surgery; clinical epidemiology; lung cancer ID PULMONARY VEIN STUMP; ATRIAL-FIBRILLATION; PREDICTING STROKE; THROMBOSIS; REGISTRY; SCHEMES; THERAPY; IMPACT AB Objectives To determine the incidence of cerebral infarction after lobectomy at different sites using inpatient data from a diagnosis procedure combination database. Design Retrospective cohort study. Setting Data were retrieved from the Japanese diagnosis procedure combination inpatient database for patients who underwent lobectomies for lung cancer between April 2018 and March 2020. Participants The analysis included 37 352 patients from 556 institutions who underwent lobectomies for lung cancer. Main outcomes and measures The occurrence of cerebral infarction after lobectomy during hospitalisation was estimated using multilevel logistic regression models adjusted for sex, age, body mass index, smoking history, activity of daily living, surgical approach (thoracotomy or video-assisted), clinical cancer stage, comorbidities and hospital-level factors to describe the association between cerebral infarction and different lobectomy sites. Results Overall cerebral infarction after lobectomy occurred in 99 patients (0.27%): 29 with left upper lobectomy (0.39%), 19 with left lower lobectomy (0.34%), 32 with right upper lobectomy (0.24%), 6 with right middle lobectomy (0.21%) and 13 with right lower lobectomy (0.16%). The multilevel multivariate logistic regression analysis revealed high ORs for the left upper lobectomy and left lower lobectomy groups. In both univariate and multivariate analyses, left upper lobectomy had the highest OR for the occurrence of cerebral infarction compared with lobectomies at other sites. Conclusions and relevance Left upper lobectomy had the highest OR for the occurrence of cerebral infarction after lung cancer lobectomy during hospitalisation. There is an urgent need to investigate the specific mechanisms underlying postoperative cerebral infarction after left upper lobectomy and to establish preventive measures such as altering surgical methods, using radiological examinations for early detection and better use of anticoagulants. C1 [Nishizawa, Natsumasa; Mori, Masataka; Tanaka, Fumihiro] Univ Occupat & Environm Hlth Japan, Dept Surg 2, Kitakyushu, Fukuoka, Japan. [Okawara, Makoto; Fujino, Yoshihisa] Univ Occupat & Environm Hlth Japan, Inst Ind Ecol Sci, Dept Environm Epidemiol, Kitakyushu, Fukuoka, Japan. [Matsuda, Shinya] Univ Occupat & Environm Hlth Japan, Dept Publ Hlth, Kitakyushu, Fukuoka, Japan. [Fushimi, Kiyohide] Tokyo Med & Dent Univ, Dept Hlth Policy & Informat, Grad Sch Med & Dent Sci, Bunkyo Ku, Tokyo, Japan. C3 University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan; Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU) RP Nishizawa, N (corresponding author), Univ Occupat & Environm Hlth Japan, Dept Surg 2, Kitakyushu, Fukuoka, Japan. EM nmasamed@med.uoeh-u.ac.jp RI Okawara, Makoto/ACJ-5728-2022 OI Okawara, Makoto/0000-0002-2777-743X; Nishizawa, Natsumasa/0000-0002-0749-8871 FU Ministry of Health, Labour, and Welfare, Japan [20AA2005] FX This study was funded by the Ministry of Health, Labour, and Welfare, Japan (grant number: 20AA2005). CR [Anonymous], 2016, GUID MAN OB DIS Asai K, 2014, GEN THORAC CARDIOVAS, V62, P244, DOI 10.1007/s11748-013-0229-1 Association EHR, 2010, EUR HEART J, V31, P2369, DOI [10.1093/eurheartj/ehq278, DOI 10.1093/EURHEARTJ/EHQ278] Chan Kwan-Leung, 1998, Annals of Internal Medicine, V128, P639 DAGOSTINO RB, 1994, STROKE, V25, P40, DOI 10.1161/01.STR.25.1.40 Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864 Grisold W, 2009, ACTA NEUROL SCAND, V119, P1, DOI 10.1111/j.1600-0404.2008.01059.x Hattori A, 2019, GEN THORAC CARDIOVAS, V67, P247, DOI 10.1007/s11748-018-1017-8 Ichimura H, 2014, ANN THORAC CARDIOVAS, V20, P613, DOI 10.5761/atcs.cr.13-00079 Kodani E, 2018, EUR HEART J-QUAL CAR, V4, P59, DOI 10.1093/ehjqcco/qcx032 Koga T, 2016, The Journal of the Japanese Association for Chest Surgery, V30, P621, DOI [10.2995/jacsurg.30.621, 10.2995/jacsurg.30.621, DOI 10.2995/JACSURG.30.621] KOUDSTAAL PJ, 1993, LANCET, V342, P1255 LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449 Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584 Manabe S, 2014, CASE REP NEPHROL DIA, V4, P103, DOI 10.1159/000363224 Matsumoto K, 2020, SURG TODAY, V50, P1383, DOI 10.1007/s00595-020-02032-4 Matsumoto K, 2018, SURG TODAY, V48, P571, DOI 10.1007/s00595-017-1620-9 National Cancer Center Japan, CANC INF JAP Nojiri T, 2015, SURG TODAY, V45, P740, DOI 10.1007/s00595-014-1032-z Nozawa T, 2006, INT J CARDIOL, V109, P59, DOI 10.1016/j.ijcard.2005.05.049 Ohtaka K, 2014, J CARDIOTHORAC SURG, V9, DOI 10.1186/s13019-014-0159-8 Ohtaka K, 2013, ANN THORAC SURG, V95, P1924, DOI 10.1016/j.athoracsur.2013.03.005 Ohtaka K, 2012, J THORAC CARDIOV SUR, V143, pE3, DOI 10.1016/j.jtcvs.2011.09.025 Pearce LA, 2000, AM J MED, V109, P45, DOI 10.1016/S0002-9343(00)00440-X Rami-Porta R, 2015, J THORAC ONCOL, V10, P990, DOI 10.1097/JTO.0000000000000559 Shimizu H, 2020, GEN THORAC CARDIOVAS, V68, P414, DOI 10.1007/s11748-020-01298-2 Suzuki S, 2015, CIRC J, V79, P432, DOI 10.1253/circj.CJ-14-1131 The Ministry of Health Labour and Welfare Japan, VAR INF MED FEE The Ministry of Health Labour and Welfare Japan, SURV IMP ASS DPC INT Tomita F, 2000, JPN CIRC J, V64, P653, DOI 10.1253/jcj.64.653 Trousseau A, 1865, CLIN MED HOTEL DIEU, V3, P654 Tsai YH, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00786 Xin YZ, 2014, EUR J CARDIO-THORAC, V45, P247, DOI 10.1093/ejcts/ezt383 Yamamoto T, 2016, SURG TODAY, V46, P780, DOI 10.1007/s00595-015-1233-0 Yasunaga H, 2010, AM J TROP MED HYG, V83, P104, DOI 10.4269/ajtmh.2010.09-0780 Zorowitz R D, 1999, J Stroke Cerebrovasc Dis, V8, P192, DOI 10.1016/S1052-3057(99)80026-3 NR 36 TC 4 Z9 5 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND EI 2052-4439 J9 BMJ OPEN RESPIR RES JI BMJ Open Respir. Res. PD JUL PY 2022 VL 9 IS 1 AR e001327 DI 10.1136/bmjresp-2022-001327 PG 7 WC Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System GA 3E5TS UT WOS:000830046500001 PM 35868837 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Ren, MD Ma, YY Wei, M Ning, YY Liu, H Shi, X Yao, Y Guo, FW AF Ren, Mengdi Ma, Yuyan Wei, Meng Ning, Yuye Liu, Hui Shi, Xue Yao, Yu Guo, Fengwei TI Atrial Cardiomyopathy Predicts Worse Outcome in Patients With Lung Cancer SO FRONTIERS IN CARDIOVASCULAR MEDICINE LA English DT Article DE lung cancer; atrial cardiomyopathy; atrial fibrillation; oncocardiology; ischemic stroke ID CRYPTOGENIC STROKE; CARDIOVASCULAR-DISEASE; MAGNETIC-RESONANCE; FIBRILLATION; RISK; CARDIOPATHY; SURVIVORS AB BackgroundReports of the clinical outcomes associated with the co-occurrence of atrial cardiomyopathy (ACM) and lung cancer (LC) are limited. ObjectivesThis study aims to investigate the influence of ACM on the prognosis of LC patients and related clinical determinants. MethodsNewly diagnosed LC patients from January 1st, 2015, to December 31st, 2020, were retrospectively enrolled at the First Affiliated Hospital of Xi'an Jiaotong University. The demographics and overall survival (OS) of the patients with or without ACM were compared. The survival rate was analyzed using the Kaplan-Meier method and multivariate Cox regression analysis. Binary logistic regression analysis was used to determine the risk factors for ACM. ResultsA total of 306 patients (65.04 +/- 10.30 years of age, 72.88% male) were analyzed. The prevalence of ACM in the non-small cell lung cancer (241, 78.76%) and small cell lung cancer (65, 21.24%) population was not statistically different. Overall, 53 (17.32%) LC patients had coexisting ACM. ACM patients were older (69 vs. 64, p = 0.0013) and had higher D-dimer levels (1.0 vs. 0.6, p = 0.001), lower serum calcium levels (2.23 vs. 2.31, p = 0.001), lower left ventricular ejection fraction (LVEF) values (67% vs. 69%, p = 0.036) and had more frequent coronary comorbidity disease (16.98% vs. 8.82%, p = 0.031). The median OS for patients with or without ACM was 15 months and 25 months, respectively (p = 0.018). Coexisting ACM compared to non-ACM was associated with worse OS in patients with LC (HR = 1.543, 95% CI: 1.042-2.283, p = 0.030). ConclusionCoexisting ACM is associated with undesirable survival outcomes in patients with LC. These findings could help us to better understand the cardiac burden in these patients and provide additional risk stratification for them. C1 [Ren, Mengdi; Ma, Yuyan; Yao, Yu] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Oncol, Xian, Peoples R China. [Wei, Meng] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Neurol, Xian, Peoples R China. [Ning, Yuye] Shaanxi Prov Peoples Hosp, Dept Neurol 2, Xian, Peoples R China. [Liu, Hui; Shi, Xue] Xi An Jiao Tong Univ, Affiliated Hosp 1, Biobank, Xian, Peoples R China. [Guo, Fengwei] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Cardiovasc Surg, Xian, Peoples R China. C3 Xi'an Jiaotong University; Xi'an Jiaotong University; Xi'an Medical University; Xi'an Jiaotong University; Xi'an Jiaotong University RP Yao, Y (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Oncol, Xian, Peoples R China.; Guo, FW (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Cardiovasc Surg, Xian, Peoples R China. EM 13572101611@163.com; guofengwei@xjtu.edu.cn RI Ma, Yuyan/LKM-3343-2024; Yao, Yufei/KIA-0679-2024 CR Akoum N, 2013, J CARDIOVASC ELECTR, V24, P1104, DOI 10.1111/jce.12199 Alvarez-Cardona JA, 2020, J AM COLL CARDIOL, V76, P2267, DOI 10.1016/j.jacc.2020.08.079 Armenian SH, 2016, J CLIN ONCOL, V34, P1122, DOI 10.1200/JCO.2015.64.0409 Brambatti M, 2014, CIRCULATION, V129, P2094, DOI 10.1161/CIRCULATIONAHA.113.007825 Cao X, 2022, J SURG RES, V269, P249, DOI 10.1016/j.jss.2021.08.028 Chu G, 2019, BLOOD REV, V35, P59, DOI 10.1016/j.blre.2019.03.005 D'Souza M, 2019, HEART RHYTHM, V16, P343, DOI 10.1016/j.hrthm.2018.10.017 Dong M, 2011, INT J CARDIOL, V151, P394, DOI 10.1016/j.ijcard.2011.07.003 Duarte CW, 2017, JCO CLIN CANCER INFO, V1, DOI 10.1200/CCI.16.00071 Esposito K, 2012, DIABETES CARE, V35, P2402, DOI 10.2337/dc12-0336 Goette A, 2016, EUROPACE, V18, P1455, DOI 10.1093/europace/euw161 Goldberger JJ, 2015, CIRCULATION, V132, P278, DOI 10.1161/CIRCULATIONAHA.115.016795 Gretarsdottir S, 2008, ANN NEUROL, V64, P402, DOI 10.1002/ana.21480 Guichard JB, 2017, J AM COLL CARDIOL, V70, P756, DOI 10.1016/j.jacc.2017.06.033 Hammwöhner M, 2019, INT J CARDIOL, V287, P174, DOI 10.1016/j.ijcard.2018.11.121 Healey JS, 2019, JAMA NEUROL, V76, P764, DOI 10.1001/jamaneurol.2019.0617 Hoit BD, 2014, J AM COLL CARDIOL, V63, P493, DOI 10.1016/j.jacc.2013.10.055 Hu YF, 2015, NAT REV CARDIOL, V12, P230, DOI 10.1038/nrcardio.2015.2 Jakobsen CB, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6314-9 Jalini S, 2019, NEUROLOGY, V92, pE288, DOI 10.1212/WNL.0000000000006748 Kamel H, 2019, INT J STROKE, V14, P207, DOI 10.1177/1747493018799981 Kamel H, 2016, STROKE, V47, P895, DOI 10.1161/STROKEAHA.115.012004 Kurotobi T, 2011, EUROPACE, V13, P803, DOI 10.1093/europace/eur039 Leifer D, 2019, NEUROLOGY, V92, P155, DOI 10.1212/WNL.0000000000006749 Leiva O, 2021, JACC-CARDIOONCOL, V3, P619, DOI 10.1016/j.jaccao.2021.08.011 Lyon AR, 2020, EUR J HEART FAIL, V22, P1945, DOI 10.1002/ejhf.1920 Mac Grory B, 2019, CURR TREAT OPT CARD, V21, DOI 10.1007/s11936-019-0786-4 Mao YS, 2016, SURG ONCOL CLIN N AM, V25, P439, DOI 10.1016/j.soc.2016.02.001 Meijers WC, 2018, CIRCULATION, V138, P678, DOI 10.1161/CIRCULATIONAHA.117.030816 Mulder FI, 2021, JACC-CARDIOONCOL, V3, P205, DOI 10.1016/j.jaccao.2021.02.007 Narayan V, 2020, J AM COLL CARDIOL, V75, P2726, DOI 10.1016/j.jacc.2020.03.067 Navi BB, 2018, ANN NEUROL, V83, P873, DOI 10.1002/ana.25227 Navi BB, 2017, J AM COLL CARDIOL, V70, P927, DOI 10.1016/j.jacc.2017.06.047 Ntaios G, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.012858 Oakes RS, 2009, CIRCULATION, V119, P1758, DOI 10.1161/CIRCULATIONAHA.108.811877 Patel SR, 2021, J CLIN MED, V10, DOI 10.3390/jcm10153313 Patnaik JL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2901 Pavo N, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12905 Ren MD, 2021, CARDIOL RES PRACT, V2021, DOI 10.1155/2021/6685953 Salazar-Camelo RA, 2021, CRIT REV ONCOL HEMAT, V157, DOI 10.1016/j.critrevonc.2020.103181 Stoltzfus KC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15639-5 Sturgeon KM, 2019, EUR HEART J, V40, P3889, DOI 10.1093/eurheartj/ehz766 Sundboll J, 2018, CIRCULATION, V138, P669, DOI 10.1161/CIRCULATIONAHA.117.032617 Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660 Tuñón J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126741 Win TT, 2015, HEART RHYTHM, V12, P155, DOI 10.1016/j.hrthm.2014.09.044 Yaghi S, 2017, EXPERT REV CARDIOVAS, V15, P591, DOI 10.1080/14779072.2017.1355238 Yaghi S, 2016, J STROKE CEREBROVASC, V25, P110, DOI 10.1016/j.jstrokecerebrovasdis.2015.09.001 Zhai RH, 2014, CHEST, V145, P346, DOI 10.1378/chest.13-1176 Zhang FF, 2021, NEUROLOGY, V96, pE513, DOI 10.1212/WNL.0000000000011264 Zhao HK, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00658-5 Zhou MG, 2019, LANCET, V394, P1145, DOI 10.1016/S0140-6736(19)30427-1 NR 52 TC 3 Z9 3 U1 2 U2 8 PU FRONTIERS MEDIA SA PI LAUSANNE PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND SN 2297-055X J9 FRONT CARDIOVASC MED JI Front. Cardiovasc. Med. PD JUL 1 PY 2022 VL 9 AR 932044 DI 10.3389/fcvm.2022.932044 PG 9 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA 3B1VQ UT WOS:000827736200001 PM 35845051 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Huang, L Kehlet, H Petersen, RH AF Huang, Lin Kehlet, Henrik Petersen, Rene Horsleben TI Reasons for staying in hospital after video-assisted thoracoscopic surgery lobectomy SO BJS OPEN LA English DT Article ID PROLONGED AIR LEAK; CELL LUNG-CANCER; ENHANCED RECOVERY; VATS LOBECTOMY; EUROPEAN-SOCIETY; IMPACT; RESECTION; OUTCOMES; PATHWAY; SCORE AB Background Despite implementation of enhanced recovery after surgery (ERAS) in lung surgery, potential barriers for improvements should be identified. The aim of this single-centre, prospective ERAS cohort study was to explore reasons for delayed patient discharge after video-assisted thoracoscopic surgery (VATS) lobectomy with a median length of hospital stay (LOS) of 2 days. Methods Consecutive patients referred for VATS lobectomy were consulted twice daily by an investigator for the primary reasons for continued hospitalization. The secondary outcomes were risk factors for delayed recovery using univariate and multivariate regression analyses. Results A total of 147 patients were included (69 with LOS more than 2 days and 78 with LOS of 2 days or less) from April 2020 to December 2020. Air leak (27.7 per cent), pneumonia (20.2 per cent), pain (15.3 per cent), urinary/renal factors (11.0 per cent), atrial fibrillation (7.0 per cent), respiratory failure (4.5 per cent), cognitive factors/delirium (4.3 per cent), gastrointestinal factors (3.8 per cent), oxygen dependency (2.7 per cent), social factors (2.0 per cent), and pleural effusion (1.4 per cent) were important factors for discharge more than 2 days after surgery. The 30-day readmission rate after discharge was 21 per cent for LOS of 2 days or less and 22 per cent for LOS more than 2 days (P = 0.856). On a multivariate regression model, age (per 5-year increase, odds ratio (OR) 1.29, 95 per cent c.i. 1.01 to 1.66, P = 0.043) and forced expiratory volume in 1 s (FEV1) per cent (per 5 per cent increase, OR 0.89, 95 per cent c.i. 0.81 to 0.98, P = 0.021) were significantly related to discharge after more than 2 days. Conclusion Despite a short median LOS of 2 days, air leak, pneumonia, and pain remain the most important challenges for further improvement of the ERAS programme. Age and FEV1 per cent were statistically significant risk factors for LOS longer than 2 days. Despite a short median LOS of 2 days after VATS lobectomy, air leak, pneumonia, and pain were the most important challenges for further improvement of the ERAS programme. C1 [Huang, Lin; Petersen, Rene Horsleben] Copenhagen Univ Hosp, Rigshosp, Dept Cardiothorac Surg, Copenhagen, Denmark. [Kehlet, Henrik] Copenhagen Univ Hosp, Rigshosp, Sect Surg Pathophysiol, Blegdamsvej 9, DK-2100 Copenhagen O, Denmark. C3 University of Copenhagen; Copenhagen University Hospital; Rigshospitalet; University of Copenhagen; Copenhagen University Hospital; Rigshospitalet RP Kehlet, H (corresponding author), Copenhagen Univ Hosp, Rigshosp, Sect Surg Pathophysiol, Blegdamsvej 9, DK-2100 Copenhagen O, Denmark. EM henrik.kehlet@regionh.dk RI ; Huang, Lin/LTC-7640-2024; Petersen, René Horsleben/KRP-4356-2024 OI Kehlet, Henrik/0000-0002-2209-1711; Huang, Lin/0000-0002-6768-1141; Petersen, René Horsleben/0000-0002-3586-1869 FU China Scholarship Council [201908430204] FX This work was supported by the China Scholarship Council (no. 201908430204 to L.H.). CR Attaar A, 2021, ANN SURG, V273, P163, DOI 10.1097/SLA.0000000000003191 Attaar A, 2017, J THORAC CARDIOV SUR, V153, P690, DOI 10.1016/j.jtcvs.2016.10.003 Batchelor TJP, 2019, EUR J CARDIO-THORAC, V55, P91, DOI 10.1093/ejcts/ezy301 Bendixen M, 2016, LANCET ONCOL, V17, P836, DOI 10.1016/S1470-2045(16)00173-X Bjerregaard LS, 2016, ANESTHESIOLOGY, V124, P1256, DOI 10.1097/ALN.0000000000001112 Brunelli A, 2017, EUR J CARDIO-THORAC, V52, P963, DOI 10.1093/ejcts/ezx105 Carli F, 2020, JAMA SURG, V155, P233, DOI 10.1001/jamasurg.2019.5474 Dong YR, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-222 Dumitra TC, 2020, CAN J SURG, V63, pE349, DOI 10.1503/cjs.002219 Falcoz PE, 2016, EUR J CARDIO-THORAC, V49, P602, DOI 10.1093/ejcts/ezv154 Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146 Forster C, 2021, INTERACT CARDIOV TH, V33, P892, DOI 10.1093/icvts/ivab187 Forster C, 2021, TRANSL LUNG CANCER R, V10, P93, DOI 10.21037/tlcr-20-891 Forster C, 2020, J CARDIOTHOR VASC AN, V34, P1858, DOI 10.1053/j.jvca.2020.01.038 Gharaibeh A., 2014, Int J Med Students, V2, P36, DOI DOI 10.5195/IJMS.2014.76 Hansen HJ, 2012, ANN CARDIOTHORAC SUR, V1, P70, DOI 10.3978/j.issn.2225-319X.2012.04.15 Haro GJ, 2021, ANN SURG, V274, pE1008, DOI 10.1097/SLA.0000000000003719 Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010 Holbek BL, 2019, EUR J CARDIO-THORAC, V55, P673, DOI 10.1093/ejcts/ezy361 Huang L, 2021, PERIOPER MED-LONDON, V10, DOI 10.1186/s13741-021-00199-z Husted H, 2011, ACTA ORTHOP, V82, P679, DOI 10.3109/17453674.2011.636682 Kehlet H, 2020, ANAESTHESIA, V75, pE54, DOI 10.1111/anae.14860 Li SJ, 2017, INT J SURG, V42, P1, DOI 10.1016/j.ijsu.2017.04.016 Licker M, 2017, J THORAC ONCOL, V12, P323, DOI 10.1016/j.jtho.2016.09.125 Linden PA, 2020, J THORAC CARDIOV SUR, V159, P667, DOI 10.1016/j.jtcvs.2019.08.038 Malapert G, 2010, ANN THORAC SURG, V90, P1779, DOI 10.1016/j.athoracsur.2010.07.033 Munk-Madsen P, 2019, COLORECTAL DIS, V21, P1438, DOI 10.1111/codi.14762 Murakami K, 2021, WORLD J SURG, V45, P1569, DOI 10.1007/s00268-020-05935-y Patel DC., 2021, ANN THORAC SURG Petersen RH, 2021, EUR J CARDIO-THORAC, V59, P291, DOI 10.1093/ejcts/ezaa435 Pompili C, 2021, EUR J CARDIO-THORAC, V59, P116, DOI 10.1093/ejcts/ezaa245 Pompili C, 2017, J THORAC CARDIOV SUR, V153, P957, DOI 10.1016/j.jtcvs.2016.11.064 Rogers LJ, 2018, J THORAC CARDIOV SUR, V155, P1843, DOI 10.1016/j.jtcvs.2017.10.151 Wildgaard K, 2012, EUR J CARDIO-THORAC, V41, P1072, DOI 10.1093/ejcts/ezr151 NR 34 TC 49 Z9 54 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 2474-9842 J9 BJS OPEN JI BJS Open PD MAY 2 PY 2022 VL 6 IS 3 AR zrac050 DI 10.1093/bjsopen/zrac050 PG 8 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA 0Z2QV UT WOS:000790922600003 PM 35511502 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Aquino, GJ Chamberlin, J Mercer, M Kocher, M Kabakus, I Akkaya, S Fiegel, M Brady, S Leaphart, N Dippre, A Giovagnoli, V Yacoub, B Jacob, A Gulsun, MA Sahbaee, P Sharma, P Waltz, J Schoepf, UJ Baruah, D Emrich, T Zimmerman, S Field, ME Agha, AM Burt, JR AF Aquino, Gilberto J. Chamberlin, Jordan Mercer, Megan Kocher, Madison Kabakus, Ismail Akkaya, Selcuk Fiegel, Matthew Brady, Sean Leaphart, Nathan Dippre, Andrew Giovagnoli, Vincent Yacoub, Basel Jacob, Athira Gulsun, Mehmet Akif Sahbaee, Pooyan Sharma, Puneet Waltz, Jeffrey Schoepf, U. Joseph Baruah, Dhiraj Emrich, Tilman Zimmerman, Stefan Field, Michael E. Agha, Ali M. Burt, Jeremy R. TI Deep learning model to quantify left atrium volume on routine non-contrast chest CT and predict adverse outcomes SO JOURNAL OF CARDIOVASCULAR COMPUTED TOMOGRAPHY LA English DT Article DE Low-dose computed tomography; Artificial intelligence; Deep learning; Left atrium volume; Heart failure; Atrial fibrillation; Major adverse cardiac and cerebrovascular events; Lung cancer screening ID COMPUTED-TOMOGRAPHY; CARDIAC CT; QUANTIFICATION; SEGMENTATION; ASSOCIATION; EVENTS; SIZE; RISK AB Background: Low-dose computed tomography (LDCT) are performed routinely for lung cancer screening. However, a large amount of nonpulmonary data from these scans remains unassessed. We aimed to validate a deep learning model to automatically segment and measure left atrial (LA) volumes from routine NCCT and evaluate prediction of cardiovascular outcomes. Methods: We retrospectively evaluated 273 patients (median age 69 years, 55.5% male) who underwent LDCT for lung cancer screening. LA volumes were quantified by three expert cardiothoracic radiologists and a prototype AI algorithm. LA volumes were then indexed to the body surface area (BSA). Expert and AI LA volume index (LAVi) were compared and used to predict cardiovascular outcomes within five years. Logistic regression with appropriate univariate statistics were used for modelling outcomes. Results: There was excellent correlation between AI and expert results with an LAV intraclass correlation of 0.950 (0.936-0.960). Bland-Altman plot demonstrated the AI underestimated LAVi by a mean 5.86 mL/m(2). AI-LAVi was associated with new-onset atrial fibrillation (AUC 0.86; OR 1.12, 95% CI 1.08-1.18, p < 0.001), HF hospitalization (AUC 0.90; OR 1.07, 95% CI 1.04-1.13, p < 0.001), and MACCE (AUC 0.68; OR 1.04, 95% CI 1.01-1.07, p = 0.01). Conclusion: This novel deep learning algorithm for automated measurement of LA volume on lung cancer screening scans had excellent agreement with manual quantification. AI-LAVi is significantly associated with increased risk of new-onset atrial fibrillation, HF hospitalization, and major adverse cardiac and cerebrovascular events within 5 years. C1 [Aquino, Gilberto J.; Chamberlin, Jordan; Mercer, Megan; Kocher, Madison; Kabakus, Ismail; Akkaya, Selcuk; Fiegel, Matthew; Brady, Sean; Leaphart, Nathan; Dippre, Andrew; Giovagnoli, Vincent; Yacoub, Basel; Waltz, Jeffrey; Schoepf, U. Joseph; Baruah, Dhiraj; Emrich, Tilman; Burt, Jeremy R.] Med Univ South Carolina, Dept Radiol & Radiol Sci, Charleston, SC 29425 USA. [Jacob, Athira; Gulsun, Mehmet Akif; Sharma, Puneet] Siemens Healthineers, Princeton, NJ USA. [Sahbaee, Pooyan] Siemens Healthineers, Malver, PA USA. [Zimmerman, Stefan] Johns Hopkins Univ Hosp, Dept Radiol & Radiol Sci, Baltimore, MD 21287 USA. [Field, Michael E.] Med Univ South Carolina, Dept Med, Charleston, SC 29425 USA. [Agha, Ali M.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. C3 Medical University of South Carolina; Siemens AG; Siemens USA; Siemens AG; Siemens USA; Johns Hopkins University; Johns Hopkins Medicine; Medical University of South Carolina; Baylor College of Medicine RP Burt, JR (corresponding author), Med Univ South Carolina, Ashley River Tower,25 Courtenay Dr, Charleston, SC 29425 USA. EM burtje@musc.edu RI KABAKUS, ISMAIL/I-9411-2013; field, michael/GQB-4778-2022; Akkaya, Selçuk/X-7125-2018; Aquino, Gilberto/JFS-7780-2023; Daif, Dr Marwa/KTR-9525-2024; Zimmerman, Stefan/U-3269-2019 OI KABAKUS, ISMAIL/0000-0002-8745-339X; Akkaya, Selçuk/0000-0002-6680-1156; Aquino, Gilberto/0000-0002-3707-8114; Dippre, Anew/0000-0002-1238-0317; Emrich, Tilman/0000-0003-4156-7727; Brady, Sean/0000-0002-2435-3084; Chamberlin, Jordan/0000-0002-7083-3492 CR Baskaran L, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232573 Bos D, 2018, EUR RADIOL, V28, P3082, DOI 10.1007/s00330-017-5264-3 Bruns S, 2020, MED PHYS, V47, P5048, DOI 10.1002/mp.14451 Cardona A, 2019, IJC HEART VASC, V23, DOI 10.1016/j.ijcha.2019.100351 Chamberlin J, 2021, BMC MED, V19, DOI 10.1186/s12916-021-01928-3 Commandeur F, 2018, IEEE T MED IMAGING, V37, P1835, DOI 10.1109/TMI.2018.2804799 Du XQ, 2020, INT J COMPUT ASS RAD, V15, P589, DOI 10.1007/s11548-020-02128-9 Fredgart MH, 2018, J CARDIOVASC COMPUT, V12, P316, DOI 10.1016/j.jcct.2018.04.001 Hoit BD, 2014, J AM COLL CARDIOL, V63, P493, DOI 10.1016/j.jacc.2013.10.055 Isgum I, 2010, MED PHYS, V37, P714, DOI 10.1118/1.3284211 Kay FU, 2020, CIRC-CARDIOVASC IMAG, V13, DOI 10.1161/CIRCIMAGING.119.009678 Koh AS, 2015, EUR J NUCL MED MOL I, V42, P1551, DOI 10.1007/s00259-015-3086-6 Kohl SAA, 2018, ADV NEUR IN, V31 Lang RM, 2015, EUR HEART J-CARD IMG, V16, P233, DOI 10.1093/ehjci/jev014 Mahabadi AA, 2016, JACC-CARDIOVASC IMAG, V9, P1177, DOI 10.1016/j.jcmg.2015.12.024 Mahabadi AA, 2014, INT J CARDIOL, V174, P318, DOI 10.1016/j.ijcard.2014.04.068 Olsen FJ, 2016, CIRC-CARDIOVASC IMAG, V9, DOI 10.1161/CIRCIMAGING.116.004947 Shahzad R, 2017, PHYS MED BIOL, V62, P3798, DOI 10.1088/1361-6560/aa63cb Wolf F, 2010, EUR J RADIOL, V75, pE141, DOI 10.1016/j.ejrad.2010.03.020 NR 19 TC 15 Z9 16 U1 0 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA SN 1934-5925 J9 J CARDIOVASC COMPUT JI J. Cardiovasc. Comput. Tomogr. PD MAY-JUN PY 2022 VL 16 IS 3 BP 245 EP 253 DI 10.1016/j.jcct.2021.12.005 EA APR 2022 PG 9 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA 2S5DO UT WOS:000821812800008 PM 34969636 DA 2026-04-17 ER PT J AU Murtaza, M Baig, MMA Ahmed, J Serbanoiu, LI Busnatu, SS AF Murtaza, Minha Baig, Mirza Mehmood Ali Ahmed, Jawad Serbanoiu, Liviu Ionut Busnatu, Stefan Sebastian TI Higher Mortality Associated With New-Onset Atrial Fibrillation in Cancer Patients: A Systematic Review and Meta-Analysis SO FRONTIERS IN CARDIOVASCULAR MEDICINE LA English DT Review DE new-onset atrial fibrillation; cancer; mortality; cardio-oncology; meta-analysis ID LUNG-CANCER; STROKE; ESOPHAGECTOMY; INFLAMMATION; INSIGHTS; HYPOXIA; SURGERY; GROWTH; DEATH; RISK AB Aim: This research was conducted to evaluate the mortality outcome of cancer patients with new-onset atrial fibrillation. We also aimed to assess if there was any confounding relation between the mortality of these patients and surgical intervention. Materials and Methods: A systemic search was conducted from electronic databases (PubMed/Medline, Cochrane Library, and Google Scholar) from inception to 7 February 2022. All statistical analyses were conducted in Review Manager 5.4.1. Studies meeting inclusion criteria were selected. Only those studies that involved cancer patients without pre-existing atrial fibrillation were selected, and mortality rate was compared between the patients who developed atrial fibrillation and those who did not. A random-effect model was used when heterogeneity was seen to pool the studies, and the result was reported in the odds ratio (OR) and the corresponding 95% confidence interval (CI). Results: Eighteen studies were selected for meta-analysis. Statistical analysis showed that the cancer patients who subsequently developed atrial fibrillation had a significantly higher mortality rate as compared to those who did not (OR = 1.90 [1.65, 2.19]; p < 0.00001; I-2 = 100%). We also separately analyzed the mortality risk in the surgery group and the non-surgery group. Statistical analysis showed that there was significantly higher mortality rate associated with new-onset atrial fibrillation in cancer patients in the surgery group (OR= 3.68 [2.29, 5.94]; p < 0.00001; I-2 = 61%) as well as in the non-surgery group (OR = 1.64 [1.39, 1.93]; p < 0.00001; I-2 = 100%). Conclusion: Cancer patients, who subsequently developed atrial fibrillation, had a higher mortality rate as compared to those cancer patients who did not develop atrial fibrillation. A higher mortality rate was seen in both surgical and non-surgical subgroups. This implies that extra care and specific measures must be taken in the management of cancer patients with new-onset atrial fibrillation. C1 [Murtaza, Minha; Baig, Mirza Mehmood Ali; Ahmed, Jawad] Dow Univ Hlth Sci, Internal Med, Karachi, Pakistan. [Serbanoiu, Liviu Ionut; Busnatu, Stefan Sebastian] Carol Davila Univ Med & Pharm, Dept Cardiol, Bucharest, Romania. C3 Dow University of Health Sciences; Carol Davila University of Medicine & Pharmacy RP Baig, MMA (corresponding author), Dow Univ Hlth Sci, Internal Med, Karachi, Pakistan. EM mirzamehmoodalibaig19991971@gmail.com RI Baig, Mirza M/ACP-3195-2022; Busnatu, Stefan/K-7025-2019; Serbanoiu, Liviu Ionut/GQA-8087-2022; Murtaza, Minha/KFR-4066-2024 OI Baig, Mirza M/0000-0003-1653-734X; Busnatu, Stefan/0000-0002-4678-9655; Serbanoiu, Liviu Ionut/0000-0001-5081-2478; Murtaza, Minha/0000-0001-8717-8458 FU Liviu Ionut Serbanoiu FX The Open Access publication fee has been funded by Liviu Ionut Serbanoiu (LS). CR Amar D, 2002, ANESTHESIOLOGY, V96, P352, DOI 10.1097/00000542-200202000-00021 AMBRUS JL, 1975, J MED, V6, P61 Amioka M, 2016, AM J CARDIOL, V118, P1386, DOI 10.1016/j.amjcard.2016.07.049 BECKNIEL.J, 1973, ACTA MED SCAND, V193, P425 Bhatt HV, 2015, J CARDIOTHOR VASC AN, V29, P1333, DOI 10.1053/j.jvca.2015.05.058 Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Ceelen W, 2014, CRIT REV ONCOL HEMAT, V89, P16, DOI 10.1016/j.critrevonc.2013.07.008 Chen YM, 2021, EUR J CLIN PHARMACOL, V77, P849, DOI 10.1007/s00228-021-03132-x Chin JH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154931 Chouaib S, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00021 Constantin GB, 2020, CHIRURGIA-BUCHAREST, V115, P23, DOI 10.21614/chirurgia.115.1.23 Din MAU, 2022, CL LYMPH MYELOM LEUK, V22, P98, DOI 10.1016/j.clml.2021.08.006 Farmakis D, 2014, J AM COLL CARDIOL, V63, P945, DOI 10.1016/j.jacc.2013.11.026 Fauchier L, 2016, AM J MED, V129, DOI 10.1016/j.amjmed.2016.06.045 Fitzpatrick T, 2017, THROMB RES, V155, P101, DOI 10.1016/j.thromres.2017.05.006 GIBBS HR, 1992, J SURG ONCOL, V50, P224, DOI 10.1002/jso.2930500405 Guazzi M, 2006, AM J PHYSIOL-HEART C, V291, pH2396, DOI 10.1152/ajpheart.00437.2006 Guo YT, 2012, J AM COLL CARDIOL, V60, P2263, DOI 10.1016/j.jacc.2012.04.063 Guzzetti S, 2002, CIRCULATION, V106, pE40, DOI 10.1161/01.CIR.0000028399.42411.13 Han HD, 2021, CANCER MED-US, V10, P5661, DOI 10.1002/cam4.4105 Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704 Higgins JPT, 2003, BMJ-BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557 Higuchi S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216239 Hofer SOP, 1999, EUR J SURG ONCOL, V25, P231, DOI 10.1053/ejso.1998.0634 Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385 Imperatori Andrea, 2012, J Cardiothorac Surg, V7, P4, DOI 10.1186/1749-8090-7-4 Ishibashi H, 2020, WORLD J SURG, V44, P3952, DOI 10.1007/s00268-020-05694-w Kotova S, 2017, ANN THORAC SURG, V103, P1566, DOI 10.1016/j.athoracsur.2016.11.007 Lateef N, 2020, J COMMUNITY HOSP INT, V10, P127, DOI 10.1080/20009666.2020.1726571 Liu FW, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.766377 Manolio TA, 1996, STROKE, V27, P1479, DOI 10.1161/01.STR.27.9.1479 Mc Cormack O, 2014, ANN SURG, V260, P772, DOI 10.1097/SLA.0000000000000960 Murthy SC, 2003, J THORAC CARDIOV SUR, V126, P1162, DOI 10.1016/S0022-5223(03)00974-7 Ojima Toshiyasu, 2020, Oncotarget, V11, P2414, DOI [10.18632/oncotarget.27643, 10.18632/oncotarget.27643] Patell R, 2017, AM J CARDIOL, V120, P2182, DOI 10.1016/j.amjcard.2017.08.038 Rao VP, 2012, EUR J CARDIO-THORAC, V42, P438, DOI 10.1093/ejcts/ezs085 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Roy PS, 2016, INDIAN J CANCER, V53, P441, DOI 10.4103/0019-509X.200658 Stawicki SPA, 2011, GEN THORAC CARDIOVAS, V59, P399, DOI 10.1007/s11748-010-0713-9 Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660 Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262 Tu HTH, 2015, INT J STROKE, V10, P534, DOI 10.1111/ijs.12007 Wang H, 2021, J THORAC DIS, V13, DOI 10.21037/jtd-20-1717 WOLF PA, 1978, NEUROLOGY, V28, P973, DOI 10.1212/WNL.28.10.973 Yuan M, 2019, CARDIOL RES PRACT, V2019, DOI 10.1155/2019/8985273 Zaorsky NG, 2017, ANN ONCOL, V28, P400, DOI 10.1093/annonc/mdw604 Zhang LZ, 2016, J CARDIOVASC PHARM, V67, P351, DOI 10.1097/FJC.0000000000000351 Zhu JX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131782 Khan MZ, 2021, J ARRYTHM, V37, P1205, DOI 10.1002/joa3.12589 NR 49 TC 19 Z9 19 U1 0 U2 4 PU FRONTIERS MEDIA SA PI LAUSANNE PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND SN 2297-055X J9 FRONT CARDIOVASC MED JI Front. Cardiovasc. Med. PD APR 14 PY 2022 VL 9 AR 867002 DI 10.3389/fcvm.2022.867002 PG 10 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA 1H2TL UT WOS:000796398900001 PM 35498001 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Liu, XZ Chen, ZM Zhang, SJ AF Liu, Xiangzheng Chen, Zhimao Zhang, Shijie TI Application of Vagus Nerve Branch Preservation in Thoracoscopic Surgery for Early-Stage Lung Cancer SO BIOMED RESEARCH INTERNATIONAL LA English DT Article AB Background. In this study, we introduced a novel surgical strategy to protect vagal nerve branches during radical thoracoscopic surgery in right lung cancer and explored the effects of vagal nerve branch preservation. Methods. We retrospectively studied 53 patients with right-sided lung cancer with clinically staged T1N0M0 between 2019 and 2020. All 53 patients were treated with total thoracoscopic lobectomy and mediastinal lymph node dissection in the same number of lymph node stations. Of these, 22 patients adopted a vagus nerve branch protection strategy during lymph node dissection. Another 31 patients were treated with traditional lymph node dissection as the control group. Results. The characteristics of the patients were similar between the two groups. The operation time and intraoperative bleeding in the protection group were longer than those in the control group. However, the protection group had a lower average postoperative pain score and average postoperative hospital stay. The above difference was not statistically significant. Three cases of arrhythmia occurred in the protection group, including 1 case of tachycardia and 2 cases of atrial fibrillation. In the control group, 13 cases of arrhythmia occurred after the operation, including 8 cases of tachycardia and 5 cases of atrial fibrillation. We also tracked changes in the patients' heart rates throughout the treatment process (excluding patients with arrhythmias). An increased heart rate was observed postoperatively in both groups, but the increase of heart rate of the protection group was smaller than that of the control group; however, the difference was not statistically significant. Conclusions. A vagus nerve branch preservation-based approach to radical surgery is a safe and feasible strategy for right lung cancer treatment, which could significantly reduce the risk of postoperative arrhythmia in patients and may also have a potential role in reducing the length of hospital stay and maintaining heart rate stability in the postoperative period. C1 [Liu, Xiangzheng; Chen, Zhimao; Zhang, Shijie] Peking Univ First Hosp, Dept Thorac Surg, Beijing 100034, Peoples R China. C3 Peking University RP Liu, XZ (corresponding author), Peking Univ First Hosp, Dept Thorac Surg, Beijing 100034, Peoples R China. EM xiangzhengliu266@bjmu.edu.cn RI zhang, shijie/HGF-0836-2022; Liu, Xiangzheng/AAC-4183-2019 OI Liu, Xiangzheng/0000-0003-3757-0907; Chen, Zhimao/0000-0001-6205-9989 FU Youth Clinical Research Fund of Peking University First Hospital [2021CR13] FX The authors appreciate Xueyan Han, M.P.H. (Department of Medical Statistics, Peking University First Hospital, Beijing, China) for her help with data analysis. This research was funded by the Youth Clinical Research Fund of Peking University First Hospital, Grant No. 2021CR13. CR Boone J, 2008, DIS ESOPHAGUS, V21, P226, DOI 10.1111/j.1442-2050.2007.00760.x DeMeester SR, 2008, ANN THORAC SURG, V85, pS747, DOI 10.1016/j.athoracsur.2007.10.102 Deng HY, 2020, ANN THORAC SURG, V109, P1079, DOI 10.1016/j.athoracsur.2019.10.056 Ferlay J, 2015, INT J CANCER, V136, pE359, DOI [10.14343/jcscr.2016.4e1003, 10.1002/ijc.29210] Hoffman RM, 2020, J GEN INTERN MED, V35, P3015, DOI 10.1007/s11606-020-05951-7 Lee SY, 2021, ANN THORAC SURG, V111, P456, DOI 10.1016/j.athoracsur.2020.05.083 Netter F.H., 2014, NETTERS CLIN ANATOMY Song Na-na, 2012, Fudan Xuebao (Yixueban), V39, P117, DOI 10.3969/j.issn.1672-8467.2012.02.002 Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321 Wang JY, 2011, THORAC SURG CLIN, V21, P239, DOI 10.1016/j.thorsurg.2011.01.006 Watanabe A, 2012, SEMIN THORAC CARDIOV, V24, P68, DOI 10.1053/j.semtcvs.2012.03.002 Weijs TJ, 2016, SURG ENDOSC, V30, P3816, DOI 10.1007/s00464-015-4683-y Weijs TJ, 2015, J ANAT, V227, P431, DOI 10.1111/joa.12366 Wolf AS, 2011, ANN THORAC SURG, V92, P1819, DOI 10.1016/j.athoracsur.2011.06.099 Zhang Z., 2010, XIONGXIN WAIKE LINCH, P140 NR 15 TC 3 Z9 3 U1 0 U2 5 PU HINDAWI LTD PI LONDON PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND SN 2314-6133 EI 2314-6141 J9 BIOMED RES INT JI Biomed Res. Int. PD APR 11 PY 2022 VL 2022 AR 5143383 DI 10.1155/2022/5143383 PG 8 WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental WE Science Citation Index Expanded (SCI-EXPANDED) SC Biotechnology & Applied Microbiology; Research & Experimental Medicine GA 1B8YL UT WOS:000792717900003 PM 35445140 OA Green Submitted, hybrid DA 2026-04-17 ER PT J AU Zahid, S Khan, MZ Bapaye, J Altamimi, TS Elkhapery, A Thakkar, S Nepal, M Rai, D Ullah, W Patel, HP Sattar, Y Khan, MU Rahman, AU Balla, S AF Zahid, Salman Khan, Muhammad Zia Bapaye, Jay Altamimi, Tamer Salhab Elkhapery, Ahmed Thakkar, Samarthkumar Nepal, Mahesh Rai, Devesh Ullah, Waqas Patel, Harsh P. Sattar, Yasar Khan, Muhammad Usman Rahman, Asad Ur Balla, Sudarshan TI Outcomes, Trends, and Predictors of Gastrointestinal Bleeding in Patients Undergoing Transcatheter Aortic Valve Implantation (from the National Inpatient Sample) SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID MORTALITY; REPLACEMENT; STENOSIS AB Major bleeding has been identified as one of the most common complications after transcatheter aortic valve implantation (TAVI) with some suffering gastrointestinal bleeding (GIB). This study aimed at assessing the incidence and predictors of GIB after TAVI in the United States. We performed a retrospective analysis of data from the National Inpatient Sample database from 2011 to 2018. A total of 216,023 hospitalizations for TAVI were included. Of the included patients, 2,188 (1%) patients had GIB, whereas 213,835 (99%) patients did not have GIB. The presence of arteriovenous malformation was associated with the highest odds of having a gastrointestinal bleed (odds ratio (OR) 24.8, 95% confidence interval (CI) 17.13 to 35.92). Peptic ulcer disease was associated with an eightfold increased risk of bleeding (OR 8.74, 95% CI, 6.69 to 11.43) followed closely by colorectal cancer (OR 7.89, 95% CI, 5.33 to 11.70). Other comorbidities that were associated with higher propensity-matched rates of GIB were chronic kidney disease (OR 1.27,95% CI, 1.14 to 1.41), congestive heart failure (OR 1.18, 95% CI,1.06 to 1.32), liver disease (OR1.83, 95% CI,1.53 to 2.19), end-stage renal disease (OR 2.08,95% CI, 1.75 to 2.47), atrial fibrillation (OR1.63,95% CI, 1.49 to 1.78), and lung cancer (OR 2.80, 95% CI,1.77 to 4.41). Patients with GIB had higher propensity-matched rates of mortality than those without GIB, (12.1% vs 3.2%, p <0.01). Patients with GIB had a higher median cost of stay ($68,779 vs $46,995, p <0.01) and a longer length of hospital stay (11 vs 3 days, p <0.01). In conclusion, health care use and mortality are higher in hospitalizations of TAVI with a GIB. Baseline comorbidities like peptic ulcer disease, chronic kidney disease, liver disease, atrial fibrillation and, colorectal cancer are significant predictors of this adverse event. (C) 2022 Elsevier Inc. All rights reserved. C1 [Zahid, Salman; Bapaye, Jay; Altamimi, Tamer Salhab; Elkhapery, Ahmed; Thakkar, Samarthkumar; Nepal, Mahesh; Rai, Devesh] Rochester Gen Hosp, Dept Med, Rochester, NY 14621 USA. [Khan, Muhammad Zia; Sattar, Yasar; Khan, Muhammad Usman; Balla, Sudarshan] West Virginia Univ, Div Cardiovasc Med, Heart & Vasc Inst, Morgantown, WV 26506 USA. [Ullah, Waqas] Jefferson Univ Hosp, Dept Cardiovasc Med, Philadelphia, PA USA. [Patel, Harsh P.] Louis Weiss Mem Hosp, Dept Internal Med, Chicago, IL USA. [Rahman, Asad Ur] Cleveland Clin Florida, Dept Gastroenterol, Weston, FL USA. C3 Rochester General Hospital; West Virginia University; Thomas Jefferson University; Cleveland Clinic Foundation RP Zahid, S (corresponding author), Rochester Gen Hosp, Dept Med, Rochester, NY 14621 USA. EM salman.zahid@rochesterregional.org RI sattar, yasar/AAZ-6205-2021; Ullah, Waqas/AAQ-5927-2020; Balla, Sudarshan/ADC-0582-2022; Rai, Devesh/AAW-4510-2021; Zahid, Salman/GPS-5005-2022 OI Rai, Devesh/0000-0003-1287-6440; khan, Muhammad Zia/0000-0001-8473-8069; Elkhapery, Ahmed/0000-0003-0705-1137; Zahid, Salman/0000-0003-2754-9397; Bapaye, Jay/0000-0002-4118-8770 CR Baer C, 2017, SURG CLIN N AM, V97, P529, DOI 10.1016/j.suc.2017.01.004 Bossone E, 2007, CAN J CARDIOL, V23, P223, DOI 10.1016/S0828-282X(07)70749-3 Brouwer J, 2020, NEW ENGL J MED, V383, P1447, DOI 10.1056/NEJMoa2017815 Cao D, 2020, J AM COLL CARDIOL, V75, P2711, DOI 10.1016/j.jacc.2020.03.070 Agudo RG, 2019, NEFROLOGIA, V39, P50, DOI 10.1016/j.nefro.2018.05.010 Généreux P, 2014, J AM COLL CARDIOL, V64, P2605, DOI 10.1016/j.jacc.2014.08.052 Giordana F, 2014, AM J CARDIOL, V114, P1447, DOI 10.1016/j.amjcard.2014.07.081 Kaw D, 2006, SEMIN DIALYSIS, V19, P317, DOI 10.1111/j.1525-139X.2006.00179.x Kazi DS, 2015, J AM COLL CARDIOL, V65, P1411, DOI 10.1016/j.jacc.2015.01.047 Kuno T, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.120.019490 Leon MB, 2010, NEW ENGL J MED, V363, P1597, DOI 10.1056/NEJMoa1008232 Mack MJ, 2019, NEW ENGL J MED, V380, P1695, DOI 10.1056/NEJMoa1814052 Marquis-Gravel G, 2020, J AM COLL CARDIOL, V76, P162, DOI 10.1016/j.jacc.2020.05.031 Quality, 2011, HR HCUP NAT INP SAMP Ranasinghe MP, 2019, J CLIN MED, V8, DOI 10.3390/jcm8020280 Sherwood MW, 2020, CIRC-CARDIOVASC INTE, V13, DOI 10.1161/CIRCINTERVENTIONS.119.008227 Smith CR, 2011, NEW ENGL J MED, V364, P2187, DOI 10.1056/NEJMoa1103510 Spangenberg T, 2015, JACC-CARDIOVASC INTE, V8, P692, DOI 10.1016/j.jcin.2015.02.008 Stanger DE, 2017, CATHETER CARDIO INTE, V90, pE53, DOI 10.1002/ccd.26650 Sterling LH, 2015, INT J CARDIOL, V191, P303, DOI 10.1016/j.ijcard.2015.04.226 Tsai TJ, 2020, GASTROENT RES PRACT, V2020, DOI 10.1155/2020/7206171 Ullah W, 2022, CARDIOVASC REVASCULA, V34, P63, DOI 10.1016/j.carrev.2021.02.002 Webb JG, 2017, J AM COLL CARDIOL, V69, P2253, DOI 10.1016/j.jacc.2017.02.057 Yasar SJ, 2018, J INTERV CARDIOL, V31, P360, DOI 10.1111/joic.12478 NR 24 TC 7 Z9 9 U1 0 U2 2 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 EI 1879-1913 J9 AM J CARDIOL JI Am. J. Cardiol. PD MAY 1 PY 2022 VL 170 BP 83 EP 90 DI 10.1016/j.amjcard.2022.01.022 EA APR 2022 PG 8 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA 1L9VF UT WOS:000799627400013 PM 35193764 DA 2026-04-17 ER PT J AU Medrek, S Szmit, S AF Medrek, Sabina Szmit, Sebastian TI Baseline Electrocardiographic and Echocardiographic Assessment May Help Predict Survival in Lung Cancer Patients-A Prospective Cardio-Oncology Study SO CANCERS LA English DT Article DE cardio-oncology; lung cancer; performance status; cardiovascular comorbidities; ECG; atrial fibrillation; echocardiography; strain rate; survival; prognosis ID SHARED RISK-FACTORS; CARDIOVASCULAR-DISEASE; ATRIAL-FIBRILLATION; HEART-FAILURE; PROGNOSTIC-SIGNIFICANCE; PULMONARY-HYPERTENSION; BREAST-CANCER; ALL-CAUSE; CELL; COMORBIDITIES AB Simple Summary Lung cancer is characterized by a high mortality rate. The main prognostic factors are histopathological and molecular diagnosis as well as clinical advancement. Performance status and comorbidities have an additional impact on the outcome. Assuming that lung cancer is often associated with cardiovascular diseases and the localization of the disease in the chest leads to exercise dyspnea, it seems valuable to objectively determine what echocardiographic parameters correlate with significantly reduced (ECOG = 2) performance status. Some echocardiographic parameters (RVSP, ACT, RV GLS, RV free wall strain, fractional area change) were associated with low performance status which can help to objectively confirm exercise intolerance in lung cancer. Moreover, recognition of atrial fibrillation and high heart rate (>90/min) in ECG strengthens the prediction of earlier death. Meanwhile, finding some positive prognostic factors like RVSP < 21 mmHg or RV free wall strain < -30% and even RV GLS < -25.5% in echocardiography allows planning of more aggressive anticancer treatment. Cardiovascular disease and cancer coexist and lead to exertional dyspnea. The aim of the study was to determine the prognostic significance of cardiac comorbidities, ECG and baseline echocardiography in lung cancer patients with varying degrees of reduced performance status. This prospective study included 104 patients with histopathologically confirmed lung cancer, pre-qualified for systemic treatment due to metastatic or locally advanced malignancy but not eligible for thoracic surgery. The patients underwent a comprehensive cardio-oncological evaluation. Overall survival negative predictors included low ECOG 2 (Eastern Cooperative Oncology Group) performance status, stage IV (bone or liver/adrenal metastases in particular), pleural effusion, the use of analgesics and among cardiac factors, two ECG parameters: atrial fibrillation (HR = 2.39) and heart rate >90/min (HR = 1.67). Among echocardiographic parameters, RVSP > 39 mmHg was a negative predictor (HR = 2.01), while RVSP < 21 mmHg and RV free wall strain < -30% were positive predictors (HR = 0.36 and HR = 0.56, respectively), whereas RV GLS < -25.5% had a borderline significance (HR = 0.59; p = 0.05). Logistical regression analysis showed ECOG = 2 significantly correlated with the following echocardiographic parameters: increasing RVSP, RV GLS, RV free wall strain and decreasing ACT, FAC (p < 0.05). Selected echocardiographic parameters may be helpful in predicting poor performance in lung cancer patients and, supplemented with ECG evaluation, broaden the possibilities of prognostic evaluation. C1 [Medrek, Sabina] Subcarpathian Oncol Ctr, Dept Cardiol, PL-36200 Brzozow, Poland. [Szmit, Sebastian] European Hlth Ctr, Ctr Postgrad Med Educ, Dept Pulm Circulat Thromboembol Dis & Cardiol, PL-05400 Otwock, Poland. RP Szmit, S (corresponding author), European Hlth Ctr, Ctr Postgrad Med Educ, Dept Pulm Circulat Thromboembol Dis & Cardiol, PL-05400 Otwock, Poland. EM sabp@wp.pl; s.szmit@gmail.com RI Szmit, Sebastian/N-2487-2017 OI Szmit, Sebastian/0000-0002-3075-1943 CR Aarts MJ, 2015, CLIN LUNG CANCER, V16, P282, DOI 10.1016/j.cllc.2014.12.003 Al-Kindi SG, 2016, MAYO CLIN PROC, V91, P81, DOI 10.1016/j.mayocp.2015.09.009 Albrecht A, 2021, CANCERS, V13, DOI 10.3390/cancers13102303 Allemani C, 2018, LANCET, V391, P1023, DOI 10.1016/S0140-6736(17)33326-3 Anker MS, 2021, EUR J HEART FAIL, V23, P140, DOI 10.1002/ejhf.2071 Anker MS, 2021, EUR J HEART FAIL, V23, P145, DOI 10.1002/ejhf.2059 Banerjee A, 2022, EUR J HEART FAIL, V24, P466, DOI 10.1002/ejhf.2417 Benjamin EJ, 2019, CIRCULATION, V139, pE56, DOI [10.1161/CIR.0000000000000659, 10.1161/CIR.0000000000000746] Blaes A, 2017, HEART FAIL CLIN, V13, P367, DOI 10.1016/j.hfc.2016.12.006 Blomstrom-Lundqvist C., 2021, EUR HEART J, V42, P373 Brunelli A, 2013, CHEST, V143, pE166, DOI 10.1378/chest.12-2395 Carpeggiani C, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.007104 CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8 Chen L, 2019, INT J CARDIOVAS IMAG, V35, P1009, DOI 10.1007/s10554-019-01590-0 Chu G, 2019, BLOOD REV, V35, P59, DOI 10.1016/j.blre.2019.03.005 Conen D, 2016, JAMA CARDIOL, V1, P389, DOI 10.1001/jamacardio.2016.0280 Cuomo A, 2021, CURR HEART FAIL REP, V18, P191, DOI 10.1007/s11897-021-00517-y Cuomo A, 2021, CURR ONCOL REP, V23, DOI 10.1007/s11912-020-00990-z de Boer RA, 2020, EUR J HEART FAIL, V22, P2272, DOI 10.1002/ejhf.2029 Facchinetti F, 2020, EUR J CANCER, V130, P155, DOI 10.1016/j.ejca.2020.02.023 Friedlaender A, 2020, CLIN LUNG CANCER, V21, pE539, DOI 10.1016/j.cllc.2020.04.006 Goldstraw Peter, 2007, J Thorac Oncol, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a Grossi F, 2003, EUR J CANCER, V39, P1242, DOI 10.1016/S0959-8049(03)00232-6 Guha A, 2022, EUR HEART J, V43, P300, DOI 10.1093/eurheartj/ehab745 Hemu M, 2021, J THORAC DIS, V13, P4845, DOI 10.21037/jtd-21-779 Herrmann J, 2022, EUR HEART J, V43, P280, DOI 10.1093/eurheartj/ehab674 Hubbard MO, 2012, J THORAC CARDIOV SUR, V143, P1307, DOI 10.1016/j.jtcvs.2012.01.078 Huitema MP, 2021, SARCOIDOSIS VASC DIF, V38, DOI 10.36141/Old.v38i4.11376 Iachina M, 2015, LUNG, V193, P291, DOI 10.1007/s00408-014-9675-5 Imperatori A, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-4 Islam KMM, 2015, CANCER EPIDEM BIOMAR, V24, P1079, DOI 10.1158/1055-9965.EPI-15-0036 Jakobsen CB, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6314-9 Jentzer JC, 2022, EUR HEART J-ACUTE CA, V11, P230, DOI 10.1093/ehjacc/zuab127 Jiroutek M.R, 1998, PHARM SCI-IRAN, P1801 Johnson CB, 2016, CAN J CARDIOL, V32, P900, DOI 10.1016/j.cjca.2016.04.008 Keramida K, 2019, EUR J HEART FAIL, V21, P529, DOI 10.1002/ejhf.1385 Kjaergaard J, 2007, AM J CARDIOL, V99, P1146, DOI 10.1016/j.amjcard.2006.11.052 Kocher F, 2015, CLIN LUNG CANCER, V16, P305, DOI 10.1016/j.cllc.2014.12.007 Koene RJ, 2016, CIRCULATION, V133, P1104, DOI 10.1161/CIRCULATIONAHA.115.020406 Kravchenko J, 2015, LUNG CANCER, V88, P85, DOI 10.1016/j.lungcan.2015.01.006 Krzakowski M, 2019, ONCOL CLIN PRACT, V15, P20, DOI 10.5603/OCP.2018.0056 Kuo SW, 2014, J THORAC CARDIOV SUR, V148, P1200, DOI 10.1016/j.jtcvs.2014.04.038 Lang RM, 2015, EUR HEART J-CARD IMG, V16, P233, DOI 10.1093/ehjci/jev014 Libby P, 2019, CARDIOVASC RES, V115, P824, DOI 10.1093/cvr/cvz058 Lipiec P, 2018, KARDIOL POL, V76, P488, DOI 10.5603/KP.2018.0051 Lonn EM, 2014, CLIN RES CARDIOL, V103, P149, DOI 10.1007/s00392-013-0644-4 Lyon AR, 2020, EUR J HEART FAIL, V22, P1945, DOI 10.1002/ejhf.1920 McDonagh TA, 2021, EUR HEART J, V42, P3599, DOI 10.1093/eurheartj/ehab368 Mensink GBM, 1997, EUR HEART J, V18, P1404 Mitchell JD, 2021, JACC-CARDIOONCOL, V3, P360, DOI 10.1016/j.jaccao.2021.06.003 Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710 Novello S, 2016, ANN ONCOL, V27, pv1, DOI 10.1093/annonc/mdw326 Omersa D, 2017, RADIOL ONCOL, V51, P15, DOI 10.1515/raon-2016-0037 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Opolski G, 2011, KARDIOL POL, V69, P520 Ostenfeld EB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102861 Passaro A, 2021, CANCERS, V13, DOI 10.3390/cancers13122935 Rittberg R, 2020, CLIN LUNG CANCER, V21, pE388, DOI 10.1016/j.cllc.2020.02.013 Saliba W, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190324 Sartipy U, 2017, JACC-HEART FAIL, V5, P565, DOI 10.1016/j.jchf.2017.05.001 Sehgal K, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.37120 Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654 Simmons CP, 2015, LUNG CANCER, V88, P304, DOI 10.1016/j.lungcan.2015.03.020 STANLEY KE, 1980, JNCI-J NATL CANCER I, V65, P25 Sueta D, 2016, INT J CARDIOL, V220, P837, DOI 10.1016/j.ijcard.2016.06.330 Tadic M, 2018, INT J CARDIOVAS IMAG, V34, P1581, DOI 10.1007/s10554-018-1379-0 Tong CY, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-20-5035 Vinter N, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.009543 Wachters FM, 2004, ANTICANCER RES, V24, P2079 Wang H, 2021, J THORAC DIS, V13, DOI 10.21037/jtd-20-1717 Wilk M, 2020, BMJ SUPPORT PALLIAT, V10, P404, DOI 10.1136/bmjspcare-2020-002487 YOCK PG, 1984, CIRCULATION, V70, P657, DOI 10.1161/01.CIR.70.4.657 Zaborowska-Szmit M, 2021, CANCERS, V13, DOI 10.3390/cancers13184534 Zaborowska-Szmit M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051268 Zamorano JL, 2016, EUR HEART J, V37, P2768, DOI [10.1093/eurheartj/ehw211, 10.1002/ejhf.654] NR 75 TC 11 Z9 13 U1 0 U2 0 PU MDPI PI BASEL PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND EI 2072-6694 J9 CANCERS JI Cancers PD APR PY 2022 VL 14 IS 8 AR 2010 DI 10.3390/cancers14082010 PG 19 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA 0T3KK UT WOS:000786868600001 PM 35454916 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Szklener, K Michalski, A Zak, K Piwonski, M Mandziuk, S AF Szklener, Katarzyna Michalski, Adam Zak, Klaudia Piwonski, Michal Mandziuk, Slawomir TI Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions SO CELLS LA English DT Review DE ibrutinib; BTK inhibitor; Bruton's tyrosine kinase; cancer; solid tumor ID BRUTONS TYROSINE KINASE; CHRONIC LYMPHOCYTIC-LEUKEMIA; PREVIOUSLY TREATED PATIENTS; CELL LUNG-CANCER; PHASE-II; ATRIAL-FIBRILLATION; TARGETING BTK; TEC-FAMILY; SUPPRESSOR-CELLS; PROMISING TARGET AB Bruton's Tyrosine Kinase (BTK) is considered crucial in the activation and survival of both physiological and malignant B-cells. In recent years, ibrutinib, an oral BTK inhibitor, became a breakthrough therapy for hematological malignancies, such as chronic lymphocytic. However, ibrutinib's feasibility might not end there. Several other kinases with established involvement with solid malignancies (i.e., EGFR, HER2) have been found to be inhibited by this agent. Recent discoveries indicate that BTK is a potential anti-solid tumor therapy target. Consequently, ibrutinib, a BTK-inhibitor, has been studied as a therapeutic option in solid malignancies. While most preclinical studies indicate ibrutinib to be an effective therapeutic option in some specific indications, such as NSCLC and breast cancer, clinical trials contradict these observations. Nevertheless, while ibrutinib failed as a monotherapy, it might become an interesting part of a multidrug regime: not only has a synergism between ibrutinib and other compounds, such as trametinib or dactolisib, been observed in vitro, but this BTK inhibitor has also been established as a radio- and chemosensitizer. This review aims to describe the milestones in translating BTK inhibitors to solid tumors in order to understand the future potential of this agent better. C1 [Szklener, Katarzyna; Michalski, Adam; Zak, Klaudia; Piwonski, Michal; Mandziuk, Slawomir] Med Univ Lublin, Dept Clin Oncol & Chemotherapy, PL-20090 Lublin, Poland. C3 Medical University of Lublin RP Szklener, K (corresponding author), Med Univ Lublin, Dept Clin Oncol & Chemotherapy, PL-20090 Lublin, Poland. EM katarzyna.szklener@op.pl; michalski.g.adam@gmail.com; zakklaudia3@gmail.com; michalpiwonski2@gmail.com; slawomir.mandziuk@umlub.pl RI Szklener, Katarzyna/AAB-3234-2022; Żak, Klaudia/X-6576-2018; Michalski, Adam/AAD-2802-2022 OI Szklener, Katarzyna/0000-0001-8033-3574; Michalski, Adam/0000-0001-9598-373X FU Medical University of Lublin FX The APC was covered by the Medical University of Lublin. CR Aalinkeel R, 2011, IMMUNOL INVEST, V40, P447, DOI 10.3109/08820139.2011.557795 Ahn IE, 2016, BLOOD, V128, P1940, DOI 10.1182/blood-2016-06-722991 Al-Toubah T, 2020, NEUROENDOCRINOLOGY, V110, P377, DOI 10.1159/000502383 Albini A, 2007, NAT REV CANCER, V7, P139, DOI 10.1038/nrc2067 Allain EP, 2020, BRIT J CANCER, V122, P1277, DOI 10.1038/s41416-019-0722-0 Andreu P, 2010, CANCER CELL, V17, P121, DOI 10.1016/j.ccr.2009.12.019 [Anonymous], 2001, BMC Immunol, DOI DOI 10.1186/1471-2172-2-4 Bai MH, 2017, EXP CELL RES, V361, P39, DOI 10.1016/j.yexcr.2017.09.039 Bender AT, 2017, MOL PHARMACOL, V91, P208, DOI 10.1124/mol.116.107037 Bitar C, 2016, JAMA DERMATOL, V152, P698, DOI 10.1001/jamadermatol.2016.0225 Blumenschein GR, 2015, ANN ONCOL, V26, P894, DOI 10.1093/annonc/mdv072 Bradshaw JM, 2010, CELL SIGNAL, V22, P1175, DOI 10.1016/j.cellsig.2010.03.001 Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609] Bubici C, 2014, BRIT J PHARMACOL, V171, P24, DOI 10.1111/bph.12432 Burger JA, 2019, CANCER J, V25, P386, DOI 10.1097/PPO.0000000000000412 Byrd JC, 2014, NEW ENGL J MED, V371, P213, DOI 10.1056/NEJMoa1400376 Byrd JC, 2015, BLOOD, V125, P2497, DOI 10.1182/blood-2014-10-606038 Byrd JC, 2013, NEW ENGL J MED, V369, P32, DOI 10.1056/NEJMoa1215637 Campbell R, 2018, J CLIN MED, V7, DOI 10.3390/jcm7040062 Caron F, 2017, BLOOD ADV, V1, P772, DOI 10.1182/bloodadvances.2016001883 Carter CA, 2016, ANN ONCOL, V27, P693, DOI 10.1093/annonc/mdw008 Charalambous Andriani, 2018, Recent Results Cancer Res, V212, P133, DOI 10.1007/978-3-319-91439-8_7 Chen J, 2016, MOL CANCER THER, V15, P2835, DOI 10.1158/1535-7163.MCT-15-0923 Chen SS, 2016, LEUKEMIA, V30, P833, DOI 10.1038/leu.2015.316 Chen S, 2018, CANCER RES, V78, P5203, DOI 10.1158/0008-5472.CAN-17-3615 Corneth OBJ, 2016, CURR TOP MICROBIOL, V393, P67, DOI 10.1007/82_2015_478 Davids MS, 2014, FUTURE ONCOL, V10, P957, DOI 10.2217/fon.14.51 Dreyling M, 2016, LANCET, V387, P770, DOI 10.1016/S0140-6736(15)00667-4 E JF, 2018, HUM IMMUNOL, V79, P446, DOI 10.1016/j.humimm.2018.03.003 Eifert C, 2013, GENE CHROMOSOME CANC, V52, P961, DOI 10.1002/gcc.22091 Fiorcari S, 2016, ONCOTARGET, V7, P65968, DOI 10.18632/oncotarget.11782 Friedlaender A, 2022, NAT REV CLIN ONCOL, V19, P51, DOI 10.1038/s41571-021-00558-1 Fu ZQ, 2018, TROP J PHARM RES, V17, P589, DOI 10.4314/tjpr.v17i4.4 Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175 Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506 Gao W, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju204 Ghez D, 2018, BLOOD, V131, P1955, DOI 10.1182/blood-2017-11-818286 Gilfillan AM, 2009, IMMUNOL REV, V228, P149, DOI 10.1111/j.1600-065X.2008.00742.x Goddard TD, 2018, PROTEIN SCI, V27, P14, DOI 10.1002/pro.3235 Grabinski N, 2014, INVEST NEW DRUG, V32, P1096, DOI 10.1007/s10637-014-0141-2 Grassilli E, 2016, ONCOGENE, V35, P4368, DOI 10.1038/onc.2015.504 Guinamard R, 1999, J EXP MED, V189, P1461, DOI 10.1084/jem.189.9.1461 Gunderson AJ, 2016, CANCER DISCOV, V6, P270, DOI 10.1158/2159-8290.CD-15-0827 Guo W, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.343 Hainsworth JD, 2010, J THORAC ONCOL, V5, P1630, DOI 10.1097/JTO.0b013e3181e8b3a3 Hammond SP, 2018, BLOOD, V131, P1987, DOI 10.1182/blood-2018-01-826495 Han TT, 2014, CANCER BIOL THER, V15, P3, DOI 10.4161/cbt.26607 Haura EB, 2010, CLIN CANCER RES, V16, P2450, DOI 10.1158/1078-0432.CCR-09-1920 Hendriks RW, 2014, NAT REV CANCER, V14, P219, DOI 10.1038/nrc3702 Hong D, 2019, ONCOLOGY-BASEL, V97, P102, DOI 10.1159/000500571 Honigberg LA, 2010, P NATL ACAD SCI USA, V107, P13075, DOI 10.1073/pnas.1004594107 HU Q, 1995, J BIOL CHEM, V270, P1928, DOI 10.1074/jbc.270.4.1928 Hussain M, 2019, LIFE SCI, V227, P175, DOI 10.1016/j.lfs.2019.04.053 Iberri DJ, 2018, BRIT J HAEMATOL, V180, P164, DOI 10.1111/bjh.14302 Ishfaq M, 2021, CANCERS, V13, DOI 10.3390/cancers13040817 Jain P, 2017, CANCER-AM CANCER SOC, V123, P2268, DOI 10.1002/cncr.30596 Jain P, 2017, CLIN CANCER RES, V23, P2154, DOI 10.1158/1078-0432.CCR-16-1948 Jarboe JS, 2013, RECENT PAT ANTI-CANC, V8, P228, DOI 10.2174/15748928113089990043 Jeong EG, 2008, CLIN CANCER RES, V14, P3716, DOI 10.1158/1078-0432.CCR-07-4839 Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454 Jin Y, 2017, INT IMMUNOPHARMACOL, V53, P42, DOI 10.1016/j.intimp.2017.10.009 Kashiwakura J, 1999, J EXP MED, V190, P1147, DOI 10.1084/jem.190.8.1147 Kil LP, 2013, AM J BLOOD RES, V3, P71 Kim DW, 2021, BRIT J CANCER, V124, P1803, DOI 10.1038/s41416-021-01368-z Kokabee L, 2015, CANCER BIOL THER, V16, P1604, DOI 10.1080/15384047.2015.1078023 Korprasertthaworn P, 2019, BIOCHEM PHARMACOL, V169, DOI 10.1016/j.bcp.2019.08.018 Lampson BL, 2017, BLOOD, V129, P2581, DOI 10.1182/blood-2016-10-742437 Laskin JJ, 2004, CANCER TREAT REV, V30, P1, DOI 10.1016/j.ctrv.2003.10.002 Lavitrano M, 2020, J PATHOL, V250, P134, DOI 10.1002/path.5347 Leong DP, 2016, BLOOD, V128, P138, DOI 10.1182/blood-2016-05-712828 Li N, 2020, CELL MOL LIFE SCI, V77, P4379, DOI 10.1007/s00018-019-03416-7 Li SX, 2015, ONCOL LETT, V10, P2652, DOI 10.3892/ol.2015.3577 Lindvall JM, 2005, IMMUNOL REV, V203, P200, DOI 10.1111/j.0105-2896.2005.00225.x Lipsky AH, 2015, HAEMATOLOGICA, V100, P1571, DOI 10.3324/haematol.2015.126672 Lohse I, 2019, ANTICANCER RES, V39, P4023, DOI 10.21873/anticanres.13558 Lopez-Chavez A, 2015, J CLIN ONCOL, V33, P1000, DOI 10.1200/JCO.2014.58.2007 Loury D, 2013, J CLIN ONCOL, V31 Maik-Rachline G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051194 Mancini M, 2009, NAT REV CANCER, V9, P810, DOI 10.1038/nrc2735 Mano H, 1999, CYTOKINE GROWTH F R, V10, P267, DOI 10.1016/S1359-6101(99)00019-2 Martin V, 2014, FUTURE ONCOL, V10, P1469, DOI [10.2217/FON.14.19, 10.2217/fon.14.19] Massó-Vallés D, 2015, CANCER RES, V75, P1675, DOI 10.1158/0008-5472.CAN-14-2852 Mato AR, 2017, ANN ONCOL, V28, P1050, DOI 10.1093/annonc/mdx031 Mato AR, 2016, BLOOD, V128, P2199, DOI 10.1182/blood-2016-05-716977 McDonald C, 2021, IMMUNOLOGY, V164, P722, DOI 10.1111/imm.13416 Messex JK, 2021, CANCERS, V13, DOI 10.3390/cancers13092198 Metzler JM, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21114154 Miller AT, 2004, IMMUNITY, V21, P67, DOI 10.1016/j.immuni.2004.06.009 Molina-Cerrillo J, 2017, CANCER TREAT REV, V58, P41, DOI 10.1016/j.ctrv.2017.06.001 Mortezaee K, 2020, LIFE SCI, V249, DOI 10.1016/j.lfs.2020.117534 Nisitani S, 2000, P NATL ACAD SCI USA, V97, P2737, DOI 10.1073/pnas.050583597 Novero A, 2014, EXP HEMATOL ONCOL, V3, DOI 10.1186/2162-3619-3-4 Oda A, 2000, BLOOD, V95, P1663 OMRAN AR, 1971, MILBANK MEML FUND Q, V49, P509, DOI 10.2307/3349375 Oxnard GR, 2020, ANN ONCOL, V31, P507, DOI 10.1016/j.annonc.2020.01.013 Pettersen EF, 2021, PROTEIN SCI, V30, P70, DOI 10.1002/pro.3943 Phelan JD, 2018, NATURE, V560, P387, DOI 10.1038/s41586-018-0290-0 Prabaharan CB, 2020, INVEST NEW DRUG, V38, P909, DOI 10.1007/s10637-019-00837-w Puzzolo MC, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.637186 Qiu Y, 2000, ONCOGENE, V19, P5651, DOI 10.1038/sj.onc.1203958 Roth GA, 2018, LANCET, V392, P1736, DOI 10.1016/S0140-6736(18)32203-7 Sagiv-Barfi I, 2015, P NATL ACAD SCI USA, V112, pE966, DOI 10.1073/pnas.1500712112 Salaroglio IC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102505 Schwartzberg PL, 2005, NAT REV IMMUNOL, V5, P284, DOI 10.1038/nri1591 Schwarzbich MA, 2014, RECENT RESULTS CANC, V201, P259, DOI 10.1007/978-3-642-54490-3_17 Shanafelt TD, 2017, LEUKEMIA LYMPHOMA, V58, P1630, DOI 10.1080/10428194.2016.1257795 Singh SP, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0779-z Stiff A, 2016, CANCER RES, V76, P2125, DOI 10.1158/0008-5472.CAN-15-1490 Tamura H, 2018, ONCOL REP, V40, P635, DOI 10.3892/or.2018.6501 Tan BQ, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01548-6 Tan BQ, 2020, BIOMED PHARMACOTHER, V128, DOI 10.1016/j.biopha.2020.110133 Tempero M, 2021, ANN ONCOL, V32, P600, DOI 10.1016/j.annonc.2021.01.070 Tomcsanyi Janos, 2016, JACC Clin Electrophysiol, V2, P847, DOI [10.1016/j.jacep.2016.07.004, 10.1016/j.jacep.2016.07.004] TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256 Uckun FM, 2007, ANTI-CANCER AGENT ME, V7, P624, DOI 10.2174/187152007784111331 Uckun FM, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.650414 Varikuti S, 2020, BRIT J CANCER, V122, P1005, DOI 10.1038/s41416-020-0743-8 Von Suskil M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115707 Wang J, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0549-6 Wang JD, 2016, AM J TRANSL RES, V8, P3003 Wang ML, 2016, LANCET ONCOL, V17, P48, DOI 10.1016/S1470-2045(15)00438-6 Wang ML, 2015, BLOOD, V126, P739, DOI 10.1182/blood-2015-03-635326 Wang ML, 2013, NEW ENGL J MED, V369, P507, DOI 10.1056/NEJMoa1306220 Wang XH, 2016, MOL CANCER THER, V15, P2198, DOI 10.1158/1535-7163.MCT-15-0813 Wei L, 2016, ONCOTARGET, V7, P69961, DOI 10.18632/oncotarget.11572 Wong SC, 2010, EUR J IMMUNOL, V40, P2296, DOI 10.1002/eji.200940288 Woo JR, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-30 Wu D, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001687 Wu H, 2015, ONCOTARGET, V6, P31313, DOI 10.18632/oncotarget.5182 Xia SM, 2020, CELL MOL IMMUNOL, V17, P1042, DOI 10.1038/s41423-019-0270-9 Xie TC, 2016, BIOMED REP, V4, P241, DOI 10.3892/br.2015.553 Xing JJ, 2017, EXP CELL RES, V356, P57, DOI 10.1016/j.yexcr.2017.04.014 Yasuhiro T, 2012, CANCER RES, V72, DOI 10.1158/1538-7445.AM2012-2021 Yun S, 2017, CL LYMPH MYELOM LEUK, V17, P31, DOI 10.1016/j.clml.2016.09.010 Zhang B, 2019, MOL ONCOL, V13, P946, DOI 10.1002/1878-0261.12454 Zhou Y, 2018, INT IMMUNOPHARMACOL, V62, P114, DOI 10.1016/j.intimp.2018.07.002 Zhu Z, 2020, ONCOTARGETS THER, V13, P4113, DOI 10.2147/OTT.S245848 Zucha MA, 2015, ONCOTARGET, V6, P13255 NR 138 TC 29 Z9 37 U1 3 U2 20 PU MDPI PI BASEL PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND EI 2073-4409 J9 CELLS-BASEL JI Cells PD APR PY 2022 VL 11 IS 8 AR 1338 DI 10.3390/cells11081338 PG 22 WC Cell Biology WE Science Citation Index Expanded (SCI-EXPANDED) SC Cell Biology GA 0T6CM UT WOS:000787054600001 PM 35456016 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Xiang, ZT Wu, B Zhang, X Feng, N Wei, YP Xu, JJ Zhang, WX AF Xiang, Zhongtian Wu, Bo Zhang, Xiang Feng, Nan Wei, Yiping Xu, Jianjun Zhang, Wenxiong TI Preoperative Three-Dimensional Lung Simulation Before Thoracoscopic Anatomical Segmentectomy for Lung Cancer: A Systematic Review and Meta-Analysis SO FRONTIERS IN SURGERY LA English DT Review DE segmentectomy; lung cancer; systematic review; meta-analysis; three-dimensional lung simulation ID PULMONARY SEGMENTECTOMY; THORACIC-SURGERY; BRONCHOGRAPHY; ANGIOGRAPHY; LOBECTOMY; TRIALS AB Background: Whether the utilization of preoperative three-dimensional (3D) lung simulation can improve the outcomes of segmentectomy for lung cancer (LC) is still controversial. Our meta-analysis was performed to compare preoperative 3D lung simulation with non-3D procedures in terms of perioperative outcomes. Methods: Seven databases (Embase, Ovid Medline, ScienceDirect, PubMed, Web of Science, Cochrane Library, and Scopus) were searched for eligible articles. Intraoperative outcomes (conversion, operative time, etc.), postoperative indicators (postoperative hospital stay, total number of complications, etc.) and postoperative complications were endpoints. Results: After applying predefined inclusion criteria, we included 8 studies and 989 patients (3D group: 552 patients; non-3D group: 437 patients) in our meta-analysis. The results of the meta-analysis showed that preoperative 3D lung simulation could significantly decrease the blood loss (mean difference [MD]: -16.21 [-24.95 to -7.47]ml, p = 0.0003), operative time (MD: -13.03 [-25.56 to -0.50]ml, p = 0.04), conversion rate (conversion from segmentectomy to thoracotomy or lobectomy) (MD: 0.12 [0.03-0.48], p = 0.003), postoperative hospital stay (MD: -0.25 [-0.46 to 0.04]days, p = 0.02) and total number of complications (MD: 0.59 [0.43-0.82], p = 0.001) compared with non-3D procedures. The number of resected lymph nodes (LNs), postoperative drainage time, postoperative forced expiratory volume in the first second (postoperative FEV1) and postoperative drainage volume were similar in the two groups. Arrhythmia (5.30%), pulmonary air leakage (2.72%), atrial fibrillation (2.20%), pulmonary infection (2.04%), and pneumonia (1.73%) were the top 5 postoperative complications in the 3D group. Conclusions: Preoperative 3D lung simulation was better than non-3D procedures in segmentectomy for LC, with better intraoperative and postoperative outcomes. However, our results should be confirmed in larger prospective randomized controlled trials. C1 [Xiang, Zhongtian; Wu, Bo; Zhang, Xiang; Feng, Nan; Wei, Yiping; Xu, Jianjun; Zhang, Wenxiong] Nanchang Univ, Dept Thorac Surg, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China. C3 Nanchang University RP Zhang, WX (corresponding author), Nanchang Univ, Dept Thorac Surg, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China. EM zwx123dr@126.com RI Wu, Bo/GQA-4365-2022; FENG, NAN/HGD-3255-2022 FU Natural Science Foundation of Jiangxi Province [20212BAB206050]; Science and technology planning project of Health Commission of Jiangxi Province [202110045]; Science and technology planning project of Jiangxi Administration of traditional Chinese Medicine [2020B0108] FX This study was supported by Natural Science Foundation of Jiangxi Province (Grant number: 20212BAB206050), Science and technology planning project of Health Commission of Jiangxi Province (Grant number: 202110045) and Science and technology planning project of Jiangxi Administration of traditional Chinese Medicine (Grant number: 2020B0108). The funding had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. CR [Anonymous], 2018, CANC BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446 Bernicker EH, 2021, ONCOLOGIST, V26, pE1050, DOI 10.1002/onco.13779 Cao JL, 2018, ANN THORAC SURG, V105, P1483, DOI 10.1016/j.athoracsur.2018.01.032 Cavalheri V, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012020.pub2 Chan ACW, 1997, SURG ENDOSC, V11, P438, DOI 10.1007/s004649900385 Chen YM, 2020, WORLD J SURG ONCOL, V18, DOI 10.1186/s12957-020-01998-2 Church TR, 2013, NEW ENGL J MED, V368, P1980, DOI 10.1056/NEJMoa1209120 Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516 Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P380, DOI 10.1016/j.jclinepi.2010.09.011 Hu WB, 2021, J THORAC DIS, V13, P1187, DOI 10.21037/jtd-21-16 Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4 Jiao P, 2017, THORAC CANCER, V8, P3, DOI 10.1111/1759-7714.12387 Langhorne P, 1998, BMJ-BRIT MED J, V316, P471 Liu GL, 2021, SURG TODAY, V51, P172, DOI 10.1007/s00595-020-02009-3 Liu XJ, 2019, TRANSL LUNG CANCER R, V8, P929, DOI 10.21037/tlcr.2019.11.27 Ma Qianli, 2017, J Vis Surg, V3, P21, DOI [10.21037/jovs.2017.02.01, 10.21037/jovs.2017.02.01] Maki R, 2020, SURG TODAY, V50, P1081, DOI 10.1007/s00595-020-01991-y Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535 Nakamura K, 2010, JPN J CLIN ONCOL, V40, P271, DOI 10.1093/jjco/hyp156 Postmus PE, 2017, ANN ONCOL, V28, P1, DOI 10.1093/annonc/mdx222 Qiu B, 2020, TRANSL LUNG CANCER R, V9, P1235, DOI 10.21037/tlcr-20-571 del Aguila MMR, 2014, ALLERGOL IMMUNOPATH, V42, P485, DOI 10.1016/j.aller.2013.03.008 She XW, 2018, THORAC CANCER, V9, P305, DOI 10.1111/1759-7714.12585 Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654 Wells G., 2012, The Newcastle -Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta -analyses, DOI DOI 10.2307/632432 Wu XN, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.661821 Xu GB, 2019, J THORAC DIS, V11, P2058, DOI 10.21037/jtd.2019.04.83 Xu YY, 2017, INTERACT CARDIOV TH, V25, P862, DOI 10.1093/icvts/ivx219 Xue L, 2018, J THORAC DIS, V10, P6598, DOI 10.21037/jtd.2018.10.126 Zou LQ, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.572462 NR 31 TC 12 Z9 13 U1 0 U2 5 PU FRONTIERS MEDIA SA PI LAUSANNE PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND SN 2296-875X J9 FRONT SURG JI Front. Surg. PD MAR 31 PY 2022 VL 9 AR 856293 DI 10.3389/fsurg.2022.856293 PG 10 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA 1V5XF UT WOS:000806161500001 PM 35433806 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Allen, LC Milton, R Bourke, G AF Allen, Luke Ce Milton, Richard Bourke, Grainne TI Multidisciplinary reconstructive management of residual recalcitrant empyema cavity: A retrospective observational cohort study SO JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY LA English DT Article DE Chest wall reconstruction; Microsurgery; Recalcitrant empyema; Multidisciplinary management; Multidisciplinary optimisation; Quality of life ID POSTPNEUMONECTOMY EMPYEMA AB Background: Patients with stage III empyema require chest wall fenestration to enable lung re-expansion and continuous drainage of the persisting empyema cavity. This chronic wound negatively affects patients' exercise tolerance, ability to carry out activities of daily living, and quality of life. Methods: Eight consecutive patients underwent chest wall reconstruction following fenestration and were followed up over a minimum of 12 months. This study included adult patients (over 18 years of age). There were no exclusion criteria. Data were collected retrospectively. Results: Eight patients (six male and two female), with a mean age of 56 years (range, 22-76), were included. All of them had comorbidities including history of neoplasia ( n = 6), atrial fibrillation ( n = 3), and hypertension ( n = 2). Aetiology of empyema included lung cancer resection complicated by bronchopleural fistula ( n = 4), pneumonia ( n = 2), and pleural effusion ( n = 2). Five patients had a low metabolic reserve evident by a low BMI (range, 16-22), and a median malnutrition universal screen tool (MUST) score of 2 (range, 1-4). Following intensive infection control and nutritional support, patients underwent reconstruction 11 months (median; range 5-51) after fenestration. Seven patients were followed up and had no recurrence of empyema and bronchopleural fistula. They all reported significant improvements in their quality of life, and their Eastern Cooperative Oncology Group (ECOG) performance status improved from three to one. One patient died 56 days post-reconstruction from cardiorespiratory failure, which re-quired readmission to hospital. Conclusion: We demonstrate that free tissue reconstruction including multidisciplinary input and optimisation at all stages of care successfully closes residual recalcitrant empyema cavity without recurrence and leads to significant improvements in the quality of life.Crown Copyright (c) 2021 Published by Elsevier Ltd on behalf of British Association of Plastic, Reconstructive and Aesthetic Surgeons. All rights reserved. C1 [Allen, Luke Ce; Bourke, Grainne] Univ Leeds, Fac Med & Hlth Sci, Leeds Sch Med, Leeds LS2 9NL, W Yorkshire, England. [Milton, Richard] Leeds Teaching Hosp Trust, Dept Thorac Surg, Leeds LS9 7TF, W Yorkshire, England. [Bourke, Grainne] Leeds Teaching Hosp Trust, Dept Plast & Reconstruct Surg, Leeds LS9 7TF, W Yorkshire, England. C3 University of Leeds; University of Leeds; University of Leeds RP Allen, LC (corresponding author), Univ Leeds, Fac Med & Hlth Sci, Leeds Sch Med, Leeds LS2 9NL, W Yorkshire, England. EM lukeallen123@live.co.uk OI Bourke, Grainne/0000-0003-0059-8543 CR BATEMAN S., 2012, WOUNDS UK, V8, P65 Cargill TN, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.00541-2019 Cerfolio R J, 2001, Semin Thorac Cardiovasc Surg, V13, P3 Delano Matthew J, 2006, Nutr Clin Pract, V21, P68, DOI 10.1177/011542650602100168 Elia M, 2003, The Must ReportNutritional Screening of Adults: A Multidisciplinary Responsibility, P1 Fuchs P, 2011, J PLAST RECONSTR AES, V64, P335, DOI 10.1016/j.bjps.2010.05.007 Ginsberg R J, 2001, Semin Thorac Cardiovasc Surg, V13, P20 GOLDSTRAW P, 1979, THORAX, V34, P740, DOI 10.1136/thx.34.6.740 Hallock Geoffrey G, 2003, Can J Plast Surg, V11, P216 HAMMOND DC, 1993, PLAST RECONSTR SURG, V91, P1259, DOI 10.1097/00006534-199306000-00011 OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014 Perkins DJ, 1996, ASIA PAC HEAR J, V5, P115 Shen KR, 2017, J THORAC CARDIOV SUR, V153, pE129, DOI 10.1016/j.jtcvs.2017.01.030 Simpson KH, 1996, BRIT J PLAST SURG, V49, P267, DOI 10.1016/S0007-1226(96)90154-X Sirbu H, 2001, Ann Thorac Cardiovasc Surg, V7, P330 Sziklavari Z, 2015, ZBL CHIR, V140, P321, DOI 10.1055/s-0034-1383273 Takanari K, 2010, ANN THORAC SURG, V89, P321, DOI 10.1016/j.athoracsur.2009.02.094 von Haehling S, 2010, J CACHEXIA SARCOPENI, V1, P1, DOI 10.1007/s13539-010-0002-6 Walters J, 2011, BJA EDUC, V11, P229, DOI 10.1093/bjaceaccp/mkr036 Winterton RIS, 2010, J PLAST RECONSTR AES, V63, P1080, DOI 10.1016/j.bjps.2009.05.029 NR 20 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCI LTD PI London PA 125 London Wall, London, ENGLAND SN 1748-6815 EI 1878-0539 J9 J PLAST RECONSTR AES JI J. Plast. Reconstr. Aesthet. Surg. PD MAR PY 2022 VL 75 IS 3 BP 1057 EP 1063 DI 10.1016/j.bjps.2021.09.073 EA MAR 2022 PG 7 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA 1C7WQ UT WOS:000793325500012 PM 34872875 DA 2026-04-17 ER PT J AU Tong, CY Zheng, JJ Wu, JX AF Tong, Chaoyang Zheng, Jijian Wu, Jingxiang TI The effects of paravertebral blockade usage on pulmonary complications, atrial fibrillation and length of hospital stay following thoracoscopic lung cancer surgery SO JOURNAL OF CLINICAL ANESTHESIA LA English DT Article DE Thoracoscopic surgery; Lung cancer; Paravertebral blockade; Atrial fibrillation; Pulmonary complications ID ASSISTED THORACIC-SURGERY; RISK-FACTORS; OPEN LOBECTOMY; IMPACT; PAIN; PREDICTORS; MANAGEMENT; OUTCOMES; SOCIETY AB Study objective: Although combined thoracic paravertebral blockade (TPVB)-general anesthesia (GA) could improve pain control compared to GA alone after thoracoscopic lung cancer surgery, it has not been established whether this improvement in pain control could reduce associated adverse outcomes. Thus, this study aimed to explore the association between TPVB usage and adverse outcomes after thoracoscopic lung cancer surgery. Design: Retrospective cohort study from a prospective database. Setting: A high-volume thoracic center in China. Patients: 13966 consecutive patients who received thoracoscopic lung cancer surgery from January 2016 to December 2018 in Shanghai Chest Hospital were enrolled. Measurements: With a 1:1 propensity score matching (PSM) analysis, adverse outcomes between GA alone and GA-TPVB were investigated. Multivariate and multiple linear regression analysis were used to identify factors and calculate odds radio (OR) for adverse outcomes. Results: The rate of TPVB usage was 14.8% (2070 out of 13,966). TPVB combined with GA was associated with lower rates of postoperative pulmonary complications (PPCs) (30.4% vs 33.5%, P = 0.005) and postoperative atrial fibrillation (POAF) (2.1% vs 2.9%, P = 0.041), and shorter length of hospital stay (LOS) (Median [IQR]; 5 [4-5] vs 5[4-6]) days, P < 0.001) compared to GA alone. After a 1:1 PSM analysis, we investigated adverse outcomes in 2640 (1320 pairs) patients with or without TPVB usage, and this association remained existed, namely, the rates of PPCs (29.8% vs 34.2%, P = 0.014) and POAF (2.2% vs 3.6%, P = 0.028) were lower and LOS was shorter (5[4-5] vs 5[4-6] days, P < 0.001) in the GA-TPVB group. In multivariate analysis, the combination of GA plus TPVB was independent predictor for PPCs (OR = 0.879, 95%CI, 0.793-0.974, P = 0.014) and POAF (OR = 0.714, 95%CI, 0.516-0.988, P = 0.042), respectively. However, in multiple linear analysis, lower rates of PPCs and POAF associated with TPVB usage, rather than TPVB usage, were responsible for the reduced LOS. Conclusions: The usage of TPVB may be a feasible and adjustable approach to reduce the rates of PPCs and POAF and associated LOS in thoracoscopic lung cancer surgery. C1 [Tong, Chaoyang; Zheng, Jijian] Shanghai Jiao Tong Univ, Shanghai Childrens Med Ctr, Sch Med, Dept Anesthesiol, Shanghai, Peoples R China. [Tong, Chaoyang; Wu, Jingxiang] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Anesthesiol, 241 Huaihai Rd West, Shanghai 200030, Peoples R China. C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University RP Wu, JX (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Anesthesiol, 241 Huaihai Rd West, Shanghai 200030, Peoples R China. EM wjx1132xk@163.com RI ; Wu, Jing-xiang/GON-5965-2022 OI Tong, Chaoyang/0000-0003-3859-0782; Wu, Jing-xiang/0000-0002-2858-9668 FU National Natural Science Foundation of China [82071233]; Shanghai Shen Kang Hospital Development Center Project [SHDC2020CR4063] FX This work was supported by National Natural Science Foundation of China (82071233) and Shanghai Shen Kang Hospital Development Center Project (SHDC2020CR4063) . CR Agostini P, 2010, THORAX, V65, P815, DOI 10.1136/thx.2009.123083 Agostini PJ, 2018, J CARDIOTHORAC SURG, V13, DOI 10.1186/s13019-018-0717-6 Aiolfi A, 2021, SURGERY, V169, P436, DOI 10.1016/j.surg.2020.09.010 Alonso-Coello P, 2017, ANESTH ANALG, V125, P162, DOI 10.1213/ANE.0000000000002111 Amar D, 2019, J THORAC CARDIOV SUR, V157, P2493, DOI 10.1016/j.jtcvs.2019.01.075 Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E Austin PC, 2011, MULTIVAR BEHAV RES, V46, P399, DOI 10.1080/00273171.2011.568786 Bhave PD, 2012, AM HEART J, V164, P918, DOI 10.1016/j.ahj.2012.09.004 Chu HC, 2020, BMC ANESTHESIOL, V20, DOI 10.1186/s12871-020-00976-1 Corsini EM, 2021, ANN THORAC SURG, V112, P423, DOI 10.1016/j.athoracsur.2020.09.017 D'Ercole F, 2018, J CARDIOTHOR VASC AN, V32, P915, DOI 10.1053/j.jvca.2017.10.003 Dobrev D, 2019, NAT REV CARDIOL, V16, P417, DOI 10.1038/s41569-019-0166-5 Falcoz PE, 2016, EUR J CARDIO-THORAC, V49, P602, DOI 10.1093/ejcts/ezv154 Ferguson MK, 2014, EUR J CARDIO-THORAC, V45, P660, DOI 10.1093/ejcts/ezt462 Frendl G, 2014, J THORAC CARDIOV SUR, V148, P772, DOI 10.1016/j.jtcvs.2014.06.037 Gialdini G, 2014, JAMA-J AM MED ASSOC, V312, P616, DOI 10.1001/jama.2014.9143 Haïssaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003 Haverkamp W, 2016, CURR OPIN ANESTHESIO, V29, P26, DOI 10.1097/ACO.0000000000000285 Jammer I, 2015, EUR J ANAESTH, V32, P88, DOI 10.1097/EJA.0000000000000118 Kang K, 2020, WORLD J SURG ONCOL, V18, DOI 10.1186/s12957-020-02071-8 Kaufmann KB, 2019, ACTA ANAESTH SCAND, V63, P1009, DOI 10.1111/aas.13388 Kwon ST, 2017, J THORAC CARDIOV SUR, V154, P652, DOI 10.1016/j.jtcvs.2017.02.008 Lanters EAH, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.007879 Li Y, 2015, THORAC CANCER, V6, P704, DOI 10.1111/1759-7714.12241 Liang HR, 2018, ANN SURG, V268, P254, DOI 10.1097/SLA.0000000000002346 Lugg ST, 2016, THORAX, V71, P171, DOI 10.1136/thoraxjnl-2015-207697 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Qiu YW, 2021, EUR J ANAESTH, V38, pS97, DOI 10.1097/EJA.0000000000001450 Sihoe ADL, 2020, RESPIROLOGY, V25, P49, DOI 10.1111/resp.13920 Steinthorsdottir KJ, 2014, EUR J CARDIO-THORAC, V45, P959, DOI 10.1093/ejcts/ezt525 Tane S, 2021, EUR J CARDIO-THORAC Tong CY, 2020, ANN THORAC SURG, V109, P1522, DOI 10.1016/j.athoracsur.2019.12.009 Tong CY, 2019, J THORAC DIS, V11, P5169, DOI 10.21037/jtd.2019.12.13 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Xu JM, 2022, CLIN LUNG CANCER, V23, P170, DOI 10.1016/j.cllc.2021.06.007 Yamamichi T, 2021, ANN THORAC SURG, VS0003 Yang CFJ, 2021, ANN SURG, V273, P595, DOI 10.1097/SLA.0000000000003231 Zhang W, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.38 NR 38 TC 11 Z9 15 U1 1 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA SN 0952-8180 EI 1873-4529 J9 J CLIN ANESTH JI J. Clin. Anesth. PD AUG PY 2022 VL 79 AR 110770 DI 10.1016/j.jclinane.2022.110770 EA MAR 2022 PG 7 WC Anesthesiology WE Science Citation Index Expanded (SCI-EXPANDED) SC Anesthesiology GA 3P9MY UT WOS:000837859000002 PM 35334289 DA 2026-04-17 ER PT J AU Tong, CY Lu, HJ Zhu, HW Wu, JX AF Tong, Chaoyang Lu, Huijie Zhu, Hongwei Wu, Jingxiang TI Impact of body mass index on perioperative and oncological outcomes in elderly patients undergoing minimally invasive McKeown esophagectomy for esophageal squamous cell carcinoma SO CANCER MEDICINE LA English DT Article DE elderly; McKeown; minimally invasive esophagectomy; outcomes; SCC ID ATRIAL-FIBRILLATION; RISK-FACTORS; LUNG-CANCER; MANAGEMENT; OBESITY AB Background The association between elevated body mass index (BMI) and perioperative and oncological outcomes among elderly patients undergoing minimally invasive McKeown esophagectomy (MIE) remains unclear. Methods We performed a single-center retrospective analysis of 526 consecutive patients aged 65 years or older who underwent MIE for esophageal squamous cell carcinoma (SCC) between January 2016 and December 2019. Two groups were stratified by BMI: normal (18.5 <= BMI < 24 kg/m(2)) and elevated groups (BMI >= 24 kg/m(2)). A 1:1 propensity score matching (PSM) analysis was used to compare perioperative and oncological outcomes between the two groups. Results A total of 480 elderly patients were eventually enrolled, with a mean age of 70.2 years (range: 65-87), and 185 patients were eligible for elevated BMI, with a mean BMI of 26.3 +/- 1.9 kg/m(2). Compared with the normal BMI group, the elevated BMI group had prolonged operation time (261.7 +/- 57.2 vs. 278.9 +/- 62.7 mins, p = 0.002) and increased incidence of intraoperative hypoxemia (12.2% vs. 21.6%, p = 0.006). The differences in intraoperative estimated blood loss, transfusion, new-onset arrhythmia, and conversion rates and postoperative outcomes regarding pulmonary and surgical complications, intensive care unit and 30-day readmissions, the length of hospital stay, and oncological outcomes regarding R0 dissection, and the number of dissected lymph nodes between two groups were comparable. After a 1:1 PSM analysis, there was no significant difference in both perioperative and oncological outcomes between two groups. Conclusions Among elderly patients undergoing MIE for esophageal SCC, there was insufficient evidence to demonstrate that elevated BMI could increase perioperative and oncological adverse outcomes. C1 [Tong, Chaoyang; Lu, Huijie; Zhu, Hongwei; Wu, Jingxiang] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Anesthesiol, 241 Huaihai Rd, Shanghai 200030, Peoples R China. [Tong, Chaoyang] Shanghai Jiao Tong Univ, Shanghai Childrens Med Ctr, Sch Med, Dept Anesthesiol, Shanghai, Peoples R China. C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University RP Zhu, HW; Wu, JX (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Anesthesiol, 241 Huaihai Rd, Shanghai 200030, Peoples R China. EM zhuhongwei06@163.com; wjx1132xk@163.com RI Wu, Jing-xiang/GON-5965-2022; zhu, hongwei/LSK-9010-2024; Lu, Huijie/AAQ-6296-2021 OI Wu, Jing-xiang/0000-0002-2858-9668; Tong, Chaoyang/0000-0003-3859-0782; FU National Natural Science Foundation of China [82071233]; Shanghai Shen Kang Hospital Development Center Project [SHDC2020CR4063] FX This work was supported by the National Natural Science Foundation of China (82071233) and the Shanghai Shen Kang Hospital Development Center Project (SHDC2020CR4063). CR Alvarez-Nebreda ML, 2018, J CLIN ANESTH, V47, P33, DOI 10.1016/j.jclinane.2018.02.011 Apovian CM, 2016, AM J MANAG CARE, V22 Austin PC, 2011, MULTIVAR BEHAV RES, V46, P399, DOI 10.1080/00273171.2011.568786 Bollschweiler E, 2017, EXPERT OPIN PHARMACO, V18, P1001, DOI 10.1080/14656566.2017.1334764 Department of Disease Control of the Ministry of Health of the People's Republic of China, 2006, GUIDELINES PREVENTIO, P34 Frendl G, 2014, J THORAC CARDIOV SUR, V148, P772, DOI 10.1016/j.jtcvs.2014.06.037 Gottlieb-Vedi, 2021, ANN SURG Grimminger PP, 2018, ANN NY ACAD SCI, V1434, P254, DOI 10.1111/nyas.13920 Heymsfield SB, 2017, NEW ENGL J MED, V376, P254, DOI 10.1056/NEJMra1514009 Hirano, ANN SURG, V2021 Hurt Ryan T, 2011, JPEN J Parenter Enteral Nutr, V35, p4S, DOI 10.1177/0148607111415110 Jammer I, 2015, EUR J ANAESTH, V32, P88, DOI 10.1097/EJA.0000000000000118 Kilic A, 2009, ANN THORAC SURG, V87, P412, DOI 10.1016/j.athoracsur.2008.10.072 Koh WP, 2010, BRIT J CANCER, V102, P610, DOI 10.1038/sj.bjc.6605496 Lagergren J, 2017, LANCET, V390, P2383, DOI 10.1016/S0140-6736(17)31462-9 Liou DZ, 2018, THORAC SURG CLIN, V28, P27, DOI 10.1016/j.thorsurg.2017.09.004 Melis M., 2015, ANN SURG Miao LS, 2015, J CANCER RES CLIN, V141, P941, DOI 10.1007/s00432-014-1878-x Mitzman B, 2018, ANN THORAC SURG, V106, P973, DOI 10.1016/j.athoracsur.2018.05.056 Sachdeva UM, 2021, ANN THORAC SURG, V112, P1059, DOI 10.1016/j.athoracsur.2020.12.002 Sakamoto T, 2021, ANN SURG, V274, P324, DOI 10.1097/SLA.0000000000003500 Salem AI, 2017, DIS ESOPHAGUS, V30, DOI 10.1111/dote.12484 Sjoquist KM, 2011, LANCET ONCOL, V12, P681, DOI 10.1016/S1470-2045(11)70142-5 Stefan N, 2020, LANCET DIABETES ENDO, V8, P616, DOI 10.1016/S2213-8587(20)30110-8 Tong CY, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-20-5035 Tong CY, 2020, ANN THORAC SURG, V109, P1522, DOI 10.1016/j.athoracsur.2019.12.009 Wightman SC, 2017, DIS ESOPHAGUS, V30, DOI 10.1093/dote/dow006 World Health Organization, 2017, OB OV Xu QL, 2020, J CARDIOTHORAC SURG, V15, DOI 10.1186/s13019-020-01202-2 Yang L, 2009, INT J CANCER, V125, P2136, DOI 10.1002/ijc.24527 NR 30 TC 1 Z9 1 U1 0 U2 3 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2045-7634 J9 CANCER MED-US JI Cancer Med. PD AUG PY 2022 VL 11 IS 15 BP 2913 EP 2922 DI 10.1002/cam4.4660 EA MAR 2022 PG 10 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA 3P1WL UT WOS:000771002000001 PM 35312237 OA Green Submitted, Green Published, gold DA 2026-04-17 ER PT J AU Liu, J Liu, ML Chen, XH AF Liu, Jie Liu, Meilin Chen, Xiahuan TI RETRACTED: Identification of Potential Key Biomarkers of Atrial Fibrillation and Their Correlation with Immune Infiltration in Atrial Tissue (Retracted Article) SO COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE LA English DT Article; Retracted Publication ID LUNG-CANCER; EXPRESSION; GENES AB Objective. To identify potential key biomarkers and characterize immune infiltration in atrial tissue of patients with atrial fibrillation (AF) through bioinformatics analysis. Methods. Differentially expressed genes (DEGs) were identified by the LIMMA package in Bioconductor, and functional and pathway enrichment analyses were undertaken using GO and KEGG. The LASSO logistic regression and BORUTA algorithm were employed to screen for potential novel key markers of AF from all DEGs. Gene set variation analysis was also performed. Single-sample gene set enrichment analysis was employed to quantify the infiltration levels for each immune cell type, and the correlation between hub genes and infiltrating immune cells was analyzed. Results. A total of 52 DEGs were identified, including of 26 downregulated DEGs and 26 upregulated DEGs. DEGs were primarily enriched in the Major Histocompatibility Complex class II protein complex, glucose homeostasis, protein tetramerization, regulation of synapse organization, cytokine activity, heart morphogenesis, and blood circulation. Three downregulated genes and three upregulated genes were screened by LASSO logistic regression and the BORUTA algorithm. Finally, immune infiltration analysis indicated that the atrial tissue of AF patients contained significant infiltration of APC_co_inhibition, Mast_cell, neutrophils, pDCs, T_cell_costimulation, and Th1_cells compared with paired sinus rhythm (SR) atrial tissue, and the three downregulated genes were negatively correlated with the six kinds of immune cells mentioned above. Conclusion. The hub genes identified in this study and the differences in immune infiltration of atrial tissue observed between AF and SR tissue might help to characterize the occurrence and progression of AF. C1 [Liu, Jie; Liu, Meilin; Chen, Xiahuan] Peking Univ First Hosp, Dept Geriatr, Beijing 100034, Peoples R China. C3 Peking University RP Liu, J; Liu, ML (corresponding author), Peking Univ First Hosp, Dept Geriatr, Beijing 100034, Peoples R China. EM liujieyida@126.com; liumeilin@hotmail.com; xiahuan.1984@163.com OI Liu, Meilin/0000-0001-9736-9864 FU PKU-Baidu Fund [2019BD019]; Scientific Research Seed Fund of Peking University First Hospital [2021SF32] FX AcknowledgmentsThis study was supported by the PKU-Baidu Fund (no. 2019BD019) and Scientific Research Seed Fund of Peking University First Hospital (no. 2021SF32). CR Cai WS, 2020, PEERJ, V8, DOI 10.7717/peerj.8390 Diboun I, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-252 Dineley KT, 2001, J NEUROSCI, V21, P4125, DOI 10.1523/JNEUROSCI.21-12-04125.2001 Ellinor PT, 2005, HUM GENET, V118, P179, DOI 10.1007/s00439-005-0034-8 Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01 Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405 Gutierrez A, 2016, CURR CARDIOL REP, V18, DOI 10.1007/s11886-016-0735-8 Hofmann U, 2012, CIRCULATION, V125, P1652, DOI 10.1161/CIRCULATIONAHA.111.044164 Hu L, 2016, TUMOR BIOL, V37, P837, DOI 10.1007/s13277-015-3880-6 Huang CY, 2015, AM J CANCER RES, V5, P3241 Hulsegge Ina, 2009, BMC Proc, V3 Suppl 4, pS10, DOI 10.1186/1753-6561-3-S4-S10 Hutchinson JA, 2017, TRANSPLANTATION, V101, pe188, DOI [10.1097/TP.0000000000001652, 10.1097/TP.0000000000001814] Kornej J, 2014, HAMOSTASEOLOGIE, V34, P9, DOI 10.5482/HAMO-13-09-0051 Kropotova ES, 2014, PATHOL ONCOL RES, V20, P707, DOI 10.1007/s12253-014-9751-4 Le Marchand L, 2008, CANCER RES, V68, P9137, DOI 10.1158/0008-5472.CAN-08-2271 Leek JT, 2007, PLOS GENET, V3, P1724, DOI 10.1371/journal.pgen.0030161 Leek JT, 2012, BIOINFORMATICS, V28, P882, DOI 10.1093/bioinformatics/bts034 Lozano-Velasco E, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165717 Nguyen TN, 2013, INT J CARDIOL, V167, P2412, DOI 10.1016/j.ijcard.2013.01.184 Nguyen VQ, 2008, P NATL ACAD SCI USA, V105, P4880, DOI 10.1073/pnas.0710448105 Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29 Panchal G, 2019, KARDIOL POL, V77, P430, DOI 10.33963/KP.14806 Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007 Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77 Roselli C, 2018, NAT GENET, V50, P1225, DOI 10.1038/s41588-018-0133-9 van Dijk EL, 2014, TRENDS GENET, V30, P418, DOI 10.1016/j.tig.2014.07.001 van Ouwerkerk AF, 2020, CIRC RES, V127, P34, DOI 10.1161/CIRCRESAHA.120.316574 Wu JF, 2020, BIOMED RES INT-UK, V2020, DOI 10.1155/2020/8021208 Xie AM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/648740 Zeng H, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07298-y Zhan DF, 2019, MOL GENET GENOM MED, V7, DOI 10.1002/mgg3.869 Zhang YF, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00184 Zhou DC, 2019, BMC CARDIOVASC DISOR, V19, DOI 10.1186/s12872-019-01300-7 NR 33 TC 2 Z9 2 U1 0 U2 4 PU HINDAWI LTD PI LONDON PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND SN 1748-670X EI 1748-6718 J9 COMPUT MATH METHOD M JI Comput. Math. Method Med. PD MAR 1 PY 2022 VL 2022 AR 4029840 DI 10.1155/2022/4029840 PG 12 WC Mathematical & Computational Biology WE Science Citation Index Expanded (SCI-EXPANDED) SC Mathematical & Computational Biology GA 0F8JI UT WOS:000777600100003 PM 35273648 OA Green Submitted, hybrid DA 2026-04-17 ER PT J AU Tohidinezhad, F Pennetta, F van Loon, J Dekker, A de Ruysscher, D Traverso, A AF Tohidinezhad, Fariba Pennetta, Francesca van Loon, Judith Dekker, Andre de Ruysscher, Dirk Traverso, Alberto TI Prediction models for treatment-induced cardiac toxicity in patients with non-small-cell lung cancer: A systematic review and meta-analysis SO CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY LA English DT Review DE Lung neoplasms; Cardiotoxicity; Machine learning; Forecasting; Artificial intelligence; Outcome ID ATRIAL-FIBRILLATION; RISK-FACTORS; RADIATION-THERAPY; THORACIC-SURGERY; COMPLICATIONS; ARRHYTHMIAS; MORTALITY AB Background: To maximize the likelihood of positive outcome in non-small-cell lung cancer (NSCLC) survivors, potential benefits of treatment modalities have to be weighed against the possibilities of damage to normal tissues, such as the heart. High-quality data-driven evidence regarding appropriate risk stratification strategies is still scarce. The aim of this review is to summarize and appraise available prediction models for treatment-induced cardiac events in patients with NSCLC. Methods: A systematic search of MEDLINE was performed using a Boolean combination of appropriate truncation and indexing terms related to "NSCLC", "prediction models", "cardiac toxicity", and "treatment modalities". The following exclusion criteria were applied: sample-size of less than 100, no significant predictors in multivariate analysis, lack of model specifications, and case-mix studies. The generic inverse variance method was used to pool the summary effect estimate for each predictor. The quality of the papers was assessed using the Prediction model Risk Of Bias Assessment Tool. Results: Of the 3,056 papers retrieved, 28 prediction models were identified, including seven for (chemo-) radiotherapy, one for immunotherapy, and 20 for surgical resection. Forty-one distinct predictors were entered in the prediction models. The pooled effect estimate of the mean heart dose (HR = 1.06, 95%CL1.04-1.08) and history of cardiovascular diseases (HR = 3.1, 95%CI:1.8-5.36) were shown to significantly increase the risk of developing late cardiac toxicity after (chemo-)radiotherapy. Summary estimates of age (OR = 1.17, 95% CI:1.06-1.29), male gender (OR = 1.61, 95%CI:1.4-1.85), and advanced stage (OR = 1.34, 95%CI:1.06-1.69) were significantly associated with higher risk of acute cardiac events after surgery. Risk of bias varied across studies, but analysis was the most concerning domain where none of the studies were judged to be low risk. Conclusion: This review highlights the need for a robust prediction model which can inform patients and clinicians about expected treatment-induced heart damage. Identified clues suggest incorporation of detailed cardiac metrics (substructures' volumes and doses). C1 [Tohidinezhad, Fariba; Pennetta, Francesca; van Loon, Judith; Dekker, Andre; de Ruysscher, Dirk; Traverso, Alberto] Maastricht Univ, Sch Oncol & Dev Biol GROW, Dept Radiat Oncol, Maastro Clin,Med Ctr, Doctor Tanslaan 12, NL-6229 ET Maastricht, Netherlands. C3 Maastricht University; Maastricht University Medical Centre (MUMC) RP Traverso, A (corresponding author), Maastricht Univ, Sch Oncol & Dev Biol GROW, Dept Radiat Oncol, Maastro Clin,Med Ctr, Doctor Tanslaan 12, NL-6229 ET Maastricht, Netherlands. EM alberto.traverso@maastro.nl RI ; Traverso, Alberto/AAS-2766-2020 OI Tohidinezhad, Fariba/0000-0001-8880-3593; Dekker, Andre/0000-0002-0422-7996; Traverso, Alberto/0000-0001-6183-4429 CR Ai D, 2015, J CARDIOTHOR VASC AN, V29, P396, DOI 10.1053/j.jvca.2014.05.013 AMAR D, 1995, CHEST, V108, P349, DOI 10.1378/chest.108.2.349 Anile M, 2012, EUR J CARDIO-THORAC, V41, P1094, DOI 10.1093/ejcts/ezr174 ASAMURA H, 1993, J THORAC CARDIOV SUR, V106, P1104, DOI 10.1016/S0022-5223(19)33985-6 Atkins KM, 2019, J AM COLL CARDIOL, V73, P2976, DOI 10.1016/j.jacc.2019.03.500 Berfield KS, 2019, ANN THORAC SURG, V107, P603, DOI 10.1016/j.athoracsur.2018.07.088 Bernard A, 2017, J THORAC DIS, V9, P3456, DOI 10.21037/jtd.2017.09.42 Bishnoi R, 2020, LUNG CANCER, V150, P172, DOI 10.1016/j.lungcan.2020.10.017 Brunelli A, 2002, CHEST, V121, P1106, DOI 10.1378/chest.121.4.1106 Chen L, 2019, ULTRASOUND MED BIOL, V45, P98, DOI 10.1016/j.ultrasmedbio.2018.09.012 Chun SG, 2017, J CLIN ONCOL, V35, P56, DOI 10.1200/JCO.2016.69.1378 Collins GS, 2015, ANN INTERN MED, V162, P55, DOI 10.7326/M14-0697 D'Errico MP, 2015, INT J RADIAT BIOL, V91, P804, DOI 10.3109/09553002.2015.1027421 Davies S., 2006, J AM STAT ASSOC, V101, P404, DOI [10.2307/30047493, DOI 10.2307/30047493] Dess RT, 2017, J CLIN ONCOL, V35, P1395, DOI 10.1200/JCO.2016.71.6142 Doroshow DB, 2019, CLIN CANCER RES, V25, P4592, DOI 10.1158/1078-0432.CCR-18-1538 Ferlay J., 2018, 9 IARC Garner M, 2017, INTERACT CARDIOV TH, V24, P260, DOI 10.1093/icvts/ivw348 Hardy D, 2010, ANN ONCOL, V21, P1825, DOI 10.1093/annonc/mdq042 Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1016/j.bandl.2008.10.005 Hollings DD, 2010, AM J SURG, V199, P558, DOI 10.1016/j.amjsurg.2009.11.006 Imperatori A, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-4 Isaksson LJ, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00790 Ivanovic J, 2014, INTERACT CARDIOV TH, V18, P340, DOI 10.1093/icvts/ivt520 Iwata T, 2016, SURG TODAY, V46, P877, DOI 10.1007/s00595-015-1258-4 Licker M, 2002, CHEST, V121, P1890, DOI 10.1378/chest.121.6.1890 Ming X, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005051 Moons KGM, 2019, ANN INTERN MED, V170, pW1, DOI 10.7326/M18-1377 Muranishi Y, 2017, SURG TODAY, V47, P252, DOI 10.1007/s00595-016-1380-y Naimi Z, 2021, CANCER RADIOTHER, V25, P229, DOI 10.1016/j.canrad.2020.09.003 Nalbantov G, 2013, RADIOTHER ONCOL, V109, P100, DOI 10.1016/j.radonc.2013.08.035 Neragi-Miandoab Siyamek, 2008, Interact Cardiovasc Thorac Surg, V7, P1039, DOI 10.1510/icvts.2008.181099 Nichols James A, 2019, Biophys Rev, V11, P111, DOI [10.1007/s12551-018-0449-9, 10.1007/s12551-018-0449-9] Niedzielski JS, 2020, ACTA ONCOL, V59, P1193, DOI 10.1080/0284186X.2020.1794034 Ning MS, 2017, INT J RADIAT ONCOL, V99, P70, DOI 10.1016/j.ijrobp.2017.05.022 Nojiri T, 2010, J THORAC CARDIOV SUR, V140, P764, DOI 10.1016/j.jtcvs.2009.11.073 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Osawa K, 2020, HEART VESSELS, V35, P1483, DOI 10.1007/s00380-020-01624-x Page Matthew J, 2021, Int J Surg, V88, P105906, DOI 10.1016/j.ijsu.2021.105906 Pérez-Callejo D, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-1012-4 Sekine Y, 2001, CHEST, V120, P1783, DOI 10.1378/chest.120.6.1783 Sidey-Gibbons JAM, 2019, BMC MED RES METHODOL, V19, DOI 10.1186/s12874-019-0681-4 Ueda T, 2018, GEN THORAC CARDIOVAS, V66, P95, DOI 10.1007/s11748-017-0858-x Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Vojtísek R, 2020, REP PRACT ONCOL RADI, V25, P13, DOI 10.1016/j.rpor.2019.10.007 Walls GM, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00433 Wee L, 2019, FUNDAMENTALS OF CLINICAL DATA SCIENCE, P135, DOI 10.1007/978-3-319-99713-1_10 Wink KCJ, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00292 Wotton R, 2013, J CARDIOTHORAC SURG, V8, DOI 10.1186/1749-8090-8-220 Xin YZ, 2014, EUR J CARDIO-THORAC, V45, P247, DOI 10.1093/ejcts/ezt383 Yegya-Raman N, 2018, J THORAC ONCOL, V13, P1508, DOI 10.1016/j.jtho.2018.05.028 NR 51 TC 11 Z9 14 U1 0 U2 20 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND EI 2405-6308 J9 CLIN TRANSL RAD ONCO JI Clin. Transl. Radiat. Oncol. PD MAR PY 2022 VL 33 BP 134 EP 144 DI 10.1016/j.ctro.2022.02.007 EA FEB 2022 PG 11 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA ZS5QH UT WOS:000768520200021 PM 35243024 OA Green Published, Green Submitted, gold DA 2026-04-17 ER PT J AU Peer, M Azzam, S Kolodii, M Abramov, Y Shaylor, R Verenkin, V Nesher, N Matot, I AF Peer, Michael Azzam, Sharbel Kolodii, Marina Abramov, Yaacov Shaylor, Ruth Verenkin, Vladimir Nesher, Nachum Matot, Idit TI Major Pulmonary Resection for Non-Small Cell Lung Carcinoma during the COVID-19 Pandemic-Single Israeli Center Cross-Sectional Study SO JOURNAL OF CLINICAL MEDICINE LA English DT Article DE major pulmonary resection; non-small cell lung carcinoma; COVID-19 ID THORACIC-SURGERY AB Background: The highly contagious COVID-19 has created unprecedented challenges in providing care to patients with resectable non-small cell lung carcinoma (NSCLC). Surgical management now needs to consider the risks of malignant disease progression by delaying surgery, and those of COVID-19 transmission to patients and operating room staff. The goal of our study was to describe our experience in providing both emergent and elective surgical procedures for patients with NSCLC during the COVID-19 pandemic in Israel, and to present our point of view regarding the safety of performing lung cancer surgery. Methods: This observational cross-sectional study included all consecutive patients with NSCLC who operated at Tel Aviv Medical Center, a large university-affiliated hospital, from February 2020 through December 2020, during the COVID-19 pandemic in Israel. The patients' demographics, COVID-19 preoperative screening results, type and side of surgery, pathology results, morbidity and mortality rates, postoperative complications, including pulmonary complications management, and hospital stay were evaluated. Results: Included in the study were 113 patients, 68 males (60.2%) and 45 females (39.8%), with a median age of 68.2 years (range, 41-89). Of these 113 patients, 83 (73.5%) underwent video-assisted thoracic surgeries (VATS), and 30 (26.5%) underwent thoracotomies. Fifty-five patients (48.7%) were preoperatively screened for COVID-19 and received negative results. Fifty-six postoperative complications were reported in 35 patients (30.9%). A prolonged air leak was detected in 11 patients (9.7%), atrial fibrillation in 11 patients (9.7%), empyema in 5 patients (4.4%), pneumonia in 9 patients (7.9%) and lobar atelectasis in 7 patients (6.2%). Three patients (2.7%) with postoperative pulmonary complications required mechanical ventilation, and two of them (1.6%) underwent tracheostomy. Two patients (1.6%) were postoperatively diagnosed as positive for COVID-19. Conclusions: Our data demonstrate the feasibility and efficacy of implementing precautionary strategies to ensure the safety of lung cancer patients undergoing pulmonary resection during the COVID-19 pandemic. The strategy was equally effective in protecting the surgical staff and healthcare providers, and we recommend performing lung cancer surgery during the pandemic era. C1 [Peer, Michael; Azzam, Sharbel; Kolodii, Marina; Abramov, Yaacov; Nesher, Nachum] Tel Aviv Med Ctr & Sch Med, Dept Thorac Surg, Weizman St 6, IL-6423906 Tel Aviv, Israel. [Shaylor, Ruth; Verenkin, Vladimir; Matot, Idit] Tel Aviv Med Ctr & Sch Med, Dept Anesthesiol, Weizman St 6, IL-6423906 Tel Aviv, Israel. C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine RP Peer, M (corresponding author), Tel Aviv Med Ctr & Sch Med, Dept Thorac Surg, Weizman St 6, IL-6423906 Tel Aviv, Israel. EM michaelpe@tlvmc.gov.il; sharbelazzam8@hotmail.com; marina05060@gmail.com; yyakov@msn.com; ruth@shaylor.co.uk; vladimirv@tlvmc.gov.il; nesher61@gmail.com; iditm@tlvmc.gov.il RI ; Shaylor, Ruth/AAU-8414-2020 OI Abramov, Yaacov/0000-0003-1040-9312; CR Angioni R, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03151-z Antonoff M, 2020, ANN THORAC SURG, V110, P692, DOI [10.1016/j.athoracsur.2020.03.005, 10.1016/j.jtcvs.2020.03.061] Bakhribah H, 2020, CRIT REV ONCOL HEMAT, V156, DOI 10.1016/j.critrevonc.2020.103120 Batchelor TJP, 2019, EUR J CARDIO-THORAC, V55, P91, DOI 10.1093/ejcts/ezy301 Bilkhu R, 2020, TUMORI J, V106, P190, DOI 10.1177/0300891620931568 Brunelli A, 2020, EUR J CARDIO-THORAC, V57, P740, DOI 10.1093/ejcts/ezz287 Cai YX, 2020, J THORAC ONCOL, V15, P1065, DOI 10.1016/j.jtho.2020.04.003 Chang SH, 2020, EUR J CARDIO-THORAC, V58, P1222, DOI 10.1093/ejcts/ezaa332 Ferioli M, 2020, EUR RESPIR REV, V29, DOI 10.1183/16000617.0068-2020 Gonfiotti A, 2020, EUR J CARDIO-THORAC, V58, P598, DOI 10.1093/ejcts/ezaa233 Mejía LH, 2020, EUR J CARDIO-THORAC, V58, P991, DOI 10.1093/ejcts/ezaa324 Jheon S, 2020, ASIAN CARD THORAC AN, V28, P322, DOI 10.1177/0218492320940162 Jin YH, 2020, MILITARY MED RES, V7, DOI [10.1101/2020.05.03.075259, 10.1101/2020.01.31.928481, 10.1186/s40779-020-0233-6, 10.1126/sciadv.ads4229] Kapetanakis EI, 2020, J SURG ONCOL, V122, P124, DOI 10.1002/jso.25988 Li YK, 2020, CURR MED SCI, V40, P295, DOI 10.1007/s11596-020-2176-2 Maurizi G, 2020, ANN THORAC SURG, V110, P353, DOI 10.1016/j.athoracsur.2020.03.015 Merritt RE, 2021, CLIN LUNG CANCER, V22, P156, DOI 10.1016/j.cllc.2020.06.024 O'Sullivan B, 2017, LANCET ONCOL, V18, P849, DOI 10.1016/S1470-2045(17)30438-2 Shaylor R, 2020, J CARDIOTHOR VASC AN, V34, P3211, DOI 10.1053/j.jvca.2020.07.049 Wexner SD, 2020, AM SURGEON, V86, P757, DOI 10.1177/0003134820936614 NR 20 TC 4 Z9 5 U1 0 U2 1 PU MDPI PI BASEL PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND EI 2077-0383 J9 J CLIN MED JI J. Clin. Med. PD FEB PY 2022 VL 11 IS 4 AR 1102 DI 10.3390/jcm11041102 PG 9 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA ZK1EA UT WOS:000762737600001 PM 35207376 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Tong, BC Gu, L Wang, XF Wigle, DA Phillips, JD Harpole, DH Jr Klapper, JA Sporn, T Ready, NE D'Amico, TA AF Tong, Betty C. Gu, Lin Wang, Xiaofei Wigle, Dennis A. Phillips, Joseph D. Harpole Jr, David H. Klapper, Jacob A. Sporn, Thomas Ready, Neal E. D'Amico, Thomas A. TI Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article; Proceedings Paper CT 100th Annual Meeting of the American-Association-for-Thoracic-Surgery (AATS) - A Virtual Learning Experience CY APR 25-MAY 23, 2020 CL ELECTR NETWORK SP Amer Assoc Thorac Surg DE immunotherapy; non-small cell lung cancer; pembrolizumab; surgery ID THORACOSCOPIC LOBECTOMY; SURGERY LOBECTOMY; THORACIC-SURGERY; ATEZOLIZUMAB; CHEMOTHERAPY; MULTICENTER; LANDSCAPE; TUMORS AB Objectives: Pembrolizumab is a programmed death receptor-1 masking antibody approved for metastatic non-small cell lung cancer. This Phase 2 study (NCT02818920) of neoadjuvant pembrolizumab in non-small cell lung cancer had a primary end point of safety and secondary end points of efficacy and correlative science. Methods: Patients with untreated clinical stage IB to IIIA non-small cell lung cancer were enrolled. Two cycles of pembrolizumab (200 mg) were administered before surgery. Standard adjuvant chemotherapy and radiation were encouraged but not required. Four cycles of adjuvant pembrolizumab were provided. Results: Of 35 patients enrolled, 30 received neoadjuvant pembrolizumab and 25 underwent lung resection. Only 1 patient had a delay before surgery attributed to pembrolizumab; this was due to thyroiditis. All patients underwent anatomic resection and mediastinal lymph node dissection; the majority (18/25%, 72%) of patients underwent lobectomy. Of the 25 patients, 23 had an initial minimally invasive approach (92%); 5 of these were converted to thoracotomy (21.7%). R0 resection was achieved in 22 patients (88%), and major pathologic response was observed in 7 of 25 patients (28%). The most common postoperative adverse event was atrial fibrillation, affecting 6 of 25 patients (24%). Median chest tube duration and length of stay were 3 and 4 days, respectively. One patient required readmission to the hospital within 30 days. There was no mortality within 90 days of surgery. Conclusions: In this study, pembrolizumab was safe and well tolerated in the neoadjuvant setting, and its use was not associated with excess surgical morbidity or mortality. Minimally invasive approaches are feasible in this patient population, but may be more challenging than in cases without neoadjuvant immunotherapy. Pathologic response was higher than typically observed with standard neoadjuvant chemotherapy. C1 [Tong, Betty C.; Harpole Jr, David H.; Klapper, Jacob A.; D'Amico, Thomas A.] Duke Univ, Med Ctr, Div Cardiovasc & Thorac Surg, DUMC 3531, Durham, NC 27710 USA. [Gu, Lin; Wang, Xiaofei] Duke Univ, Sch Med, Duke Canc Inst Biostat Shared Resource, Durham, NC USA. [Wigle, Dennis A.] Mayo Clin, Dept Thorac Surg, Rochester, MN USA. [Phillips, Joseph D.] Dartmouth Hitchcock Med Ctr, Dept Surg, Lebanon, NH 03766 USA. [Sporn, Thomas] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA. [Ready, Neal E.] Duke Univ, Med Ctr, Div Med Oncol, Durham, NC USA. C3 Duke University; Duke University; Mayo Clinic; Dartmouth College; Duke University; Duke University RP Tong, BC (corresponding author), Duke Univ, Med Ctr, Div Cardiovasc & Thorac Surg, DUMC 3531, Durham, NC 27710 USA. EM betty.tong@duke.edu RI Wang, Dandan/V-1897-2017; Phillips, Joseph/NRR-7334-2025 FU Merck Co FX Funding Source: Merck & Co. CR [Anonymous], 2017, J NATL CANC I, V109 Bendixen M, 2016, LANCET ONCOL, V17, P836, DOI 10.1016/S1470-2045(16)00173-X Bott MJ, 2019, J THORAC CARDIOV SUR, V158, P269, DOI 10.1016/j.jtcvs.2018.11.124 Delaunay M, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00050-2017 Duma N, 2018, J ONCOL PRACT, V14, P35, DOI 10.1200/JOP.2017.025288 Ettinger DS, 2019, J NATL COMPR CANC NE, V17, P1464, DOI 10.6004/jnccn.2019.0059 Gao SJ, 2017, J THORAC ONCOL, V12, P314, DOI 10.1016/j.jtho.2016.09.122 Heath EI, 2018, ANTICANCER RES, V38, P2235, DOI 10.21873/anticanres.12466 Huang J, 2013, J THORAC DIS, V5, pS267, DOI 10.3978/j.issn.2072-1439.2013.08.24 Lewis J, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00005 Magee DE, 2020, ANN ONCOL, V31, P50, DOI 10.1016/j.annonc.2019.10.008 Massard G, 1998, Chest Surg Clin N Am, V8, P503 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Onaitis MW, 2006, ANN SURG, V244, P420, DOI 10.1097/01.sla.0000234892.79056.63 Park BJ, 2016, J THORAC DIS, V8, pS406, DOI 10.21037/jtd.2016.04.56 Paul S, 2010, J THORAC CARDIOV SUR, V139, P366, DOI 10.1016/j.jtcvs.2009.08.026 Puri V, 2015, J THORAC CARDIOV SUR, V149, P55, DOI 10.1016/j.jtcvs.2014.08.074 Queirolo P, 2017, CANCER TREAT REV, V59, P71, DOI 10.1016/j.ctrv.2017.07.002 Reuss JE, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001282 Rhodin KE, 2020, J THORAC CARDIOV SUR, V159, P1616, DOI 10.1016/j.jtcvs.2019.08.138 Rice JD, 2020, ANN THORAC SURG, V109, P842, DOI 10.1016/j.athoracsur.2019.09.076 Rothwell PM, 2005, LANCET, V365, P82, DOI 10.1016/S0140-6736(04)17670-8 Rusch V, 2018, J THORAC ONCOL, V13, pS369, DOI 10.1016/j.jtho.2018.08.346 Sepesi B, 2019, J THORAC ONCOL, V14, pS241, DOI 10.1016/j.jtho.2019.08.481 Shu CA, 2020, LANCET ONCOL, V21, P786, DOI 10.1016/S1470-2045(20)30140-6 Shum E, 2017, J THORAC ONCOL, V12, pS2005 Shum E, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.e18073 Siegel R.L., CA-CANCER J CLIN, V2020, P7, DOI [10.3322/caac.21590, DOI 10.3322/CAAC.21590] Yang CFJ, 2018, ANN THORAC SURG, V105, P924, DOI 10.1016/j.athoracsur.2017.09.030 NR 29 TC 92 Z9 106 U1 4 U2 24 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 EI 1097-685X J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD FEB PY 2022 VL 163 IS 2 BP 427 EP 436 DI 10.1016/j.jtcvs.2021.02.099 EA JAN 2022 PG 10 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA ZT1GO UT WOS:000768904200015 PM 33985811 DA 2026-04-17 ER PT J AU Hao, JQ Zhou, J Xu, WY Chen, C Zhang, J Peng, HN Liu, LX AF Hao, Jianqi Zhou, Jian Xu, Wenying Chen, Cong Zhang, Jian Peng, Haoning Liu, Lunxu TI Beta-Blocker Landiolol Hydrochloride in Preventing Atrial Fibrillation Following Cardiothoracic Surgery: A Systematic Review and Meta-Analysis SO ANNALS OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Review DE landiolol; atrial fibrillation; cardiothoracic surgery; postoperative complications ID LOW-DOSE LANDIOLOL; CARDIAC-SURGERY; HEART-SURGERY; EFFICACY; ESOPHAGECTOMY; DILTIAZEM; VERAPAMIL; PRESSURE; ESMOLOL; PROTEIN AB Objective: The purpose of this article was to assess the benefit of perioperative administration of the intravenous beta-blocker landiolol hydrochloride in preventing atrial fibrillation (AF) after cardiothoracic surgery. Methods: We performed a systematic search in PubMed, Web of Science, CNKI, and OVID to identify randomized controlled trials (RCTs) and cohorts up to January 2021. Data regarding postoperative atrial fibrillation (POAF) and safety outcomes were extracted. Odds ratios (ORs) with 95% confidence intervals (CIs) were determined using the Mantel- Haenszel method. Meanwhile, subgroup analyses were conducted according to surgery type including lung cancer surgery, esophageal cancer surgery, and cardiac surgery. Results: Seventeen eligible articles involving 1349 patients within 13 RCTs and four cohorts were included in our meta-analysis. Compared with control group, landiolol administration was associated with a significant reduction of the occurrence of AF after cardiothoracic surgery (OR = 0.32, 95% CI 0.23-0.43, P <0.00001). In addition, the results demonstrated that perioperative administration of landiolol hydrochloride minimized the occurrence of postoperative complications (OR = 0.48, 95% CI 0.33-0.70, P = 0.0002). Funnel plots indicated no obvious publication bias. Conclusions: Considering this analysis, landiolol was effective in the prevention of AF after cardiothoracic surgery and did not increase the risk of major postoperative complications. C1 [Hao, Jianqi; Zhou, Jian; Chen, Cong; Zhang, Jian; Peng, Haoning; Liu, Lunxu] Sichuan Univ, West China Hosp, Dept Thorac Surg, 37 Guoxue Alley, Chengdu 610041, Peoples R China. [Hao, Jianqi; Zhou, Jian; Xu, Wenying; Chen, Cong] Sichuan Univ, West China Sch Med, Chengdu, Peoples R China. [Zhang, Jian] Sichuan Univ, Chest Oncol Inst, West China Hosp, Dept Thorac Surg, Chengdu, Peoples R China. C3 Sichuan University; Sichuan University; Sichuan University RP Liu, LX (corresponding author), Sichuan Univ, West China Hosp, Dept Thorac Surg, 37 Guoxue Alley, Chengdu 610041, Peoples R China. EM lunxu_liu@aliyun.com RI ; Peng, Haoning/MTC-9000-2025 OI Zhang, Jian/0000-0001-9877-1601; FU China Postdoctoral Science Foundation [2020TQ0210]; West China Hospital, Sichuan University [2020HXBH108]; 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University [ZYGD18021] FX This work was supported by China Postdoctoral Science Foundation (Grant 2020TQ0210) (ZJ) ; Post-Doctor Research Project, West China Hospital, Sichuan University (Grant 2020HXBH108) (ZJ) ; and the 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (Grant ZYGD18021) (LL) . CR Adelborg K, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.k96 Amar D, 1997, ANN THORAC SURG, V63, P1374 AMAR D, 1995, CHEST, V108, P349, DOI 10.1378/chest.108.2.349 Amar D, 2007, CURR OPIN ANESTHESIO, V20, P43, DOI 10.1097/ACO.0b013e32801158bb Aoki Y, 2020, JA CLIN REP, V6, DOI 10.1186/s40981-020-00338-3 Aoyama H, 2016, GEN THORAC CARDIOVAS, V64, P735, DOI 10.1007/s11748-016-0707-3 Boriani G, 2018, HEART, V104, P882, DOI 10.1136/heartjnl-2017-311546 Cooklin M, 1998, CURR OPIN CARDIOL, V13, P20, DOI 10.1097/00001573-199801000-00004 Crystal E, 2002, CIRCULATION, V106, P75, DOI 10.1161/01.CIR.0000021113.44111.3E Fujii M, 2012, J CARDIOVASC SURG, V53, P369 Fujito K, 2016, EUR J DRUG METAB PH, V41, P157, DOI 10.1007/s13318-014-0244-3 Fujiwara H, 2009, GEN THORAC CARDIOVAS, V57, P132, DOI 10.1007/s11748-008-0341-9 Horikoshi Y, 2017, J CLIN ANESTH, V38, P111, DOI 10.1016/j.jclinane.2017.01.036 IGUCHI S, 1992, CHEM PHARM BULL, V40, P1462 Ikeshita K, 2008, J ANESTH, V22, P361, DOI 10.1007/s00540-008-0640-4 January CT, 2014, J AM COLL CARDIOL, V64, P2246 Johnson LSB, 2016, EUR HEART J-CARD PHA, V2, P81, DOI 10.1093/ehjcvp/pvv056 Li L, 2015, INT J CLIN EXP MED, V8, P10265 LINDGREN L, 1991, BRIT J ANAESTH, V66, P205, DOI 10.1093/bja/66.2.205 Liskmann S, 2006, INT J ORAL MAX IMPL, V21, P543 Liu SX, 2014, PACE, V37, P691, DOI 10.1111/pace.12379 Lo B, 2005, ANN THORAC SURG, V79, P1530, DOI 10.1016/j.athoracsur.2004.10.004 Ma JY, 2006, WORLD J GASTROENTERO, V12, P449, DOI 10.3748/wjg.v12.i3.449 Maisel WH, 2001, ANN INTERN MED, V135, P1061, DOI 10.7326/0003-4819-135-12-200112180-00010 Mathew JP, 1996, JAMA-J AM MED ASSOC, V276, P300, DOI 10.1001/jama.276.4.300 Moher D, 2015, SYST REV-LONDON, V4, DOI 10.1186/2046-4053-4-1 Motomura S, 1998, J CARDIOVASC PHARM, V31, P431, DOI 10.1097/00005344-199803000-00015 Murthy SC, 2003, J THORAC CARDIOV SUR, V126, P1162, DOI 10.1016/S0022-5223(03)00974-7 Nagaoka E, 2014, ANN THORAC CARDIOVAS, V20, P129, DOI 10.5761/atcs.oa.12.02003 Nakanishi K, 2013, J CARDIOTHORAC SURG, V8, DOI 10.1186/1749-8090-8-19 Narayan SM, 1997, LANCET, V350, P943, DOI 10.1016/S0140-6736(97)06359-9 Nojiri T, 2011, GEN THORAC CARDIOVAS, V59, P799, DOI 10.1007/s11748-011-0841-x Ogawa Shinji, 2013, Asian Cardiovasc Thorac Ann, V21, P265, DOI 10.1177/0218492312451166 Ojima T, 2017, BRIT J SURG, V104, P1003, DOI 10.1002/bjs.10548 Okita Toshikazu, 2008, Masui, V57, P953 Plosker GL, 2013, DRUGS, V73, P959, DOI 10.1007/s40265-013-0077-4 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Sakaguchi M, 2012, INT HEART J, V53, P359, DOI 10.1536/ihj.53.359 Sakamoto A, 2014, ADV THER, V31, P440, DOI 10.1007/s12325-014-0116-x Sakamoto A, 2012, CIRC J, V76, P1097, DOI 10.1253/circj.CJ-11-1332 Sasao J, 2001, CAN J ANAESTH, V48, P985, DOI 10.1007/BF03016588 Sezai A, 2015, J THORAC CARDIOV SUR, V150, P957, DOI 10.1016/j.jtcvs.2015.07.003 Sezai A, 2014, ANN THORAC CARDIOVAS, V20, P261, DOI 10.5761/atcs.ed.13-00374 Sezai A, 2012, J THORAC CARDIOV SUR, V144, P1241, DOI 10.1016/j.jtcvs.2012.06.042 Sezai A, 2011, J THORAC CARDIOV SUR, V141, P1478, DOI 10.1016/j.jtcvs.2010.10.045 Stevens RD, 2003, ANESTH ANALG, V97, P623, DOI 10.1213/01.ANE.0000074795.68061.16 Tamura T, 2017, J CLIN ANESTH, V42, P1, DOI 10.1016/j.jclinane.2017.07.009 van Hall G, 2012, CURR OPIN CLIN NUTR, V15, P85, DOI 10.1097/MCO.0b013e32834e6ea2 VanMieghem W, 1996, ANN THORAC SURG, V61, P1083, DOI 10.1016/0003-4975(96)00073-2 Yoshida T, 2017, ESOPHAGUS-TOKYO, V14, P97, DOI 10.1007/s10388-016-0553-5 NR 50 TC 10 Z9 10 U1 0 U2 10 PU Annals Thoracic and Cardiovascular Surgery Editorial Office PI Tokyo PA International Academic Publishing Co., Ltd, c/o Publishing Center, Yamabuki-cho 332-6, Tokyo, Shinjuku-ku, JAPAN SN 1341-1098 EI 2186-1005 J9 ANN THORAC CARDIOVAS JI Ann. Thorac. Cardiovasc. Surg. PY 2022 VL 28 IS 1 BP 18 EP 31 DI 10.5761/atcs.ra.21-00126 PG 14 WC Cardiac & Cardiovascular Systems; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Surgery GA ZK4WR UT WOS:000762990300001 PM 34421096 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Leiva, O AbdelHameid, D Connors, JM Cannon, CP Bhatt, DL AF Leiva, Orly AbdelHameid, Duaa Connors, Jean M. Cannon, Christopher P. Bhatt, Deepak L. TI Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis JACC: CardioOncology State-of-the-Art Review SO JACC: CARDIOONCOLOGY LA English DT Review DE arrhythmia; risk factor; thrombosis ID C-REACTIVE PROTEIN; PERCUTANEOUS CORONARY INTERVENTION; ACUTE MYOCARDIAL-INFARCTION; CLONAL HEMATOPOIESIS; LYSYL OXIDASE; CARDIOVASCULAR EVENTS; LUNG-CANCER; MICROENVIRONMENTAL REGULATION; VENOUS THROMBOEMBOLISM; ANTIPLATELET THERAPY AB Cardiovascular disease and cancer are the 2 leading causes of death worldwide. Emerging evidence suggests common mechanisms between cancer and cardiovascular disease, including atrial fibrillation and atherosclerosis. With advances in cancer therapies, screening, and diagnostics, cancer-specific survival and outcomes have improved. This increase in survival has led to the coincidence of cardiovascular disease, including atrial fibrillation and atherosclerosis, as patients with cancer live longer. Additionally, cancer and cardiovascular disease share several risk factors and underlying path-ophysiologic mechanisms, including inflammation, cancer-related factors including treatment effects, and alterations in platelet function. Patients with cancer are at increased risk for bleeding and thrombosis compared with the general population. Although optimal antithrombotic therapy, including agent choice and duration, has been extensively studied in the general population, this area remains understudied in patients with cancer despite their altered thrombotic and bleeding risk. Future investigation, including incorporation of cancer-specific characteristics to traditional thrombotic and bleeding risk scores, clinical trials in the cancer population, and the development of novel antithrombotic and anti-inflammatory strategies on the basis of shared pathophysiologic mechanisms, is warranted to improve outcomes in this patient population. (J Am Coll Cardiol CardioOnc 2021;3:619-634) (c) 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). C1 [Leiva, Orly; AbdelHameid, Duaa] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA. [Leiva, Orly; AbdelHameid, Duaa; Connors, Jean M.; Cannon, Christopher P.; Bhatt, Deepak L.] Harvard Med Sch, 75 Francis St, Boston, MA 02115 USA. [Connors, Jean M.] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA. [Cannon, Christopher P.; Bhatt, Deepak L.] Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA. C3 Harvard University; Harvard University Medical Affiliates; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard University Medical Affiliates; Brigham & Women's Hospital; Harvard University; Harvard University Medical Affiliates; Brigham & Women's Hospital RP Bhatt, DL (corresponding author), Harvard Med Sch, 75 Francis St, Boston, MA 02115 USA.; Bhatt, DL (corresponding author), Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA. EM dlbhattmd@post.harvard.edu RI Bhatt, Deepak L/Y-3070-2019; Leiva, Orly/HNR-5290-2023; Cannon, Christopher/AAY-7644-2020 OI Bhatt, Deepak L/0000-0002-1278-6245; FU Edwards Lifesciences; Daiichi Sankyo; Ferring Pharmaceuticals; Bayer; Abbott; Afimmune; Amarin; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Cardax; Chiesi; CSL Behring; Eisai; Ethicon; Forest Laboratories; Fractyl; HLS Therapeutics; Idorsia; Ironwood; Ischemix; Janssen; Lexicon; Lilly; Medtronic; MyoKardia; Novo Nordisk; Owkin; Pfizer; PhaseBio; PLx Pharma; Regeneron; Roche; Sanofi; Synaptic; Medicines Company FX Dr Bhatt is an advisory board member for Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, Novo Nordisk, PhaseBio, PLx Pharma, and Regado Biosciences; is on the boards of directors of the Boston VA Research Institute, the Society of Cardiovascular Patient Care, and TobeSoft; is chair of the American Heart Association Quality Oversight Committee; is a member of data monitoring committees for the Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), the Cleveland Clinic (including for the ExCEED trial, funded by Edwards Lifesciences), Contego Medical (chair, PERFORMANCE 2), the Duke Clinical Research Institute, the Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), and the Population Health Research Institute; has received honoraria from the American College of Cardiology (senior associate editor, Clinical Trials and News, ACC.org; vice chair, ACC Accreditation Committee), the Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (editor-in-chief, Harvard Heart Letter), the Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), the Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (editor-in-chief, Journal of Invasive Cardiology), the Journal of the American College of Cardiology (guest editor, associate editor), K2P (cochair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (continuing medical education steering committees), MJH Life Sciences, the Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and US national coleader, funded by Bayer), Slack Publications (chief medical editor, Cardiology Today's Intervention), the Society of Cardiovascular Patient Care (secretary/treasurer), and WebMD (continuing medical education steering committees); is deputy editor of Clinical Cardiology; is chair of the NCDR-ACTION Registry Steering Committee and the VA CART Research and Publications Committee; has received research funding from Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Lexicon, Lilly, Medtronic, MyoKardia, Novo Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi, Synaptic, and The Medicines Company; has received royalties from Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease); is a site coinvestigator for Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), and Svelte; is a trustee of the American College of Cardiology; and has conducted unfunded research for FlowCo, Merck, and Takeda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. CR Abbonante V, 2017, BLOOD, V130, P829, DOI 10.1182/blood-2017-04-777417 Adams TD, 2007, NEW ENGL J MED, V357, P753, DOI 10.1056/NEJMoa066603 Agmon IN, 2021, HEART VESSELS, V36, P1283, DOI 10.1007/s00380-021-01817-y Al-Samkari H, 2020, J THORAC ONCOL, V15, P1497, DOI 10.1016/j.jtho.2020.04.033 Algra AM, 2012, LANCET ONCOL, V13, P518, DOI 10.1016/S1470-2045(12)70112-2 Aspberg S, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2019.104560 Balanescu DV, 2020, INT J CARDIOL, V313, P1, DOI [10.36106/ijar/7206503, 10.1016/j.ijcard.2020.04.050] Ball S, 2019, J AM COLL CARDIOL, V74, P1714, DOI 10.1016/j.jacc.2019.07.079 Bar J, 2019, EUR J CANCER, V120, P122, DOI 10.1016/j.ejca.2019.06.021 Barbui T, 2010, BLOOD, V115, P778, DOI 10.1182/blood-2009-08-238956 Barrett TJ, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax0481 Bharadwaj A, 2020, EUR HEART J, V41, P2183, DOI 10.1093/eurheartj/ehz851 Bhatt DL, 2019, JACC-CARDIOONCOL, V1, P114, DOI 10.1016/j.jaccao.2019.08.004 Bick AG, 2020, CIRCULATION, V141, P124, DOI 10.1161/CIRCULATIONAHA.119.044362 Blom JW, 2005, JAMA-J AM MED ASSOC, V293, P715, DOI 10.1001/jama.293.6.715 Briukhovetska D, 2021, NAT REV CANCER, V21, P481, DOI 10.1038/s41568-021-00363-z Brown JR, 2017, HAEMATOLOGICA, V102, P1796, DOI 10.3324/haematol.2017.171041 Bruni D, 2020, NAT REV CANCER, V20, P662, DOI 10.1038/s41568-020-0285-7 Caldeira D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211228 Calvillo-Argüelles O, 2019, JAMA CARDIOL, V4, P380, DOI 10.1001/jamacardio.2019.0302 Camm AJ, 2010, EUROPACE, V12, P1360, DOI [10.1093/eurheartj/ehq278, 10.1093/europace/euq350] Cardinale D, 2016, ANN SURG, V264, P244, DOI 10.1097/SLA.0000000000001626 Chang YW, 2015, ONCOTARGET, V6, P42733, DOI 10.18632/oncotarget.5811 Chatterjee M, 2017, EUR HEART J, V38, P1993, DOI 10.1093/eurheartj/ehx146 Cheng WL, 2016, INT J CARDIOL, V219, P186, DOI 10.1016/j.ijcard.2016.06.009 Cho MS, 2017, BLOOD, V130, P1235, DOI 10.1182/blood-2017-02-769893 Conen D, 2016, JAMA CARDIOL, V1, P389, DOI 10.1001/jamacardio.2016.0280 Conen D, 2010, EUR HEART J, V31, P1730, DOI 10.1093/eurheartj/ehq146 Coombs CC, 2018, CLIN CANCER RES, V24, P5918, DOI 10.1158/1078-0432.CCR-18-1201 Coombs CC, 2017, CELL STEM CELL, V21, P374, DOI 10.1016/j.stem.2017.07.010 Coppinger JA, 2004, BLOOD, V103, P2096, DOI 10.1182/blood-2003-08-2804 Corr EM, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0964-7 Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322 D'Souza M, 2019, HEART RHYTHM, V16, P343, DOI 10.1016/j.hrthm.2018.10.017 D'Souza M, 2018, EUR J PREV CARDIOL, V25, P651, DOI 10.1177/2047487318759858 Dagenais GR, 2020, LANCET, V395, P785, DOI 10.1016/S0140-6736(19)32007-0 Darby SC, 2013, NEW ENGL J MED, V368, P987, DOI 10.1056/NEJMoa1209825 Davì G, 2007, NEW ENGL J MED, V357, P2482, DOI 10.1056/NEJMra071014 de Palma M, 2017, NAT REV CANCER, V17, P457, DOI 10.1038/nrc.2017.51 De Vita A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84492-3 Douxfils J, 2016, JAMA ONCOL, V2, P625, DOI 10.1001/jamaoncol.2015.5932 Drobni ZD, 2020, CIRCULATION, V142, P2299, DOI 10.1161/CIRCULATIONAHA.120.049981 Edelmann B, 2018, J CLIN INVEST, V128, P4359, DOI 10.1172/JCI90312 Elesber AA, 2006, FREE RADICAL RES, V40, P385, DOI 10.1080/10715760500539154 Everett BM, 2020, J AM COLL CARDIOL, V76, P1660, DOI 10.1016/j.jacc.2020.08.011 Fei M, 2020, FRONT MED-PRC, V14, P81, DOI 10.1007/s11684-019-0692-x Freisling H, 2020, BMC MED, V18, DOI 10.1186/s12916-019-1474-7 Friedrichs K, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00214 Fuster JJ, 2017, SCIENCE, V355, P842, DOI 10.1126/science.aag1381 Ganatra S, 2018, JACC-CLIN ELECTROPHY, V4, P1491, DOI 10.1016/j.jacep.2018.06.004 Gay LJ, 2011, NAT REV CANCER, V11, P123, DOI 10.1038/nrc3004 Ghasemzadeh M, 2017, THROMB RES, V156, P101, DOI 10.1016/j.thromres.2017.06.016 Gil-Bernabé AM, 2012, BLOOD, V119, P3164, DOI 10.1182/blood-2011-08-376426 Gottschlich A, 2021, CANCERS, V13, DOI 10.3390/cancers13030477 Graff J, 2005, CLIN PHARMACOL THER, V78, P468, DOI 10.1016/j.clpt.2005.08.002 Gutierrez A, 2019, THER ADV CARDIO DIS, V13, DOI 10.1177/1753944719860676 Hatakeyama K, 2012, THROMB RES, V129, pE70, DOI 10.1016/j.thromres.2012.01.003 Hayashi T, 2020, CANCERS, V12, DOI 10.3390/cancers12113215 Haykal T, 2019, J CANCER RES CLIN, V145, P1795, DOI 10.1007/s00432-019-02932-0 Heeringa J, 2006, EUR HEART J, V27, P949, DOI 10.1093/eurheartj/ehi825 Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393 Herrmann J, 2016, CIRCULATION, V133, P1272, DOI 10.1161/CIRCULATIONAHA.115.018347 Hershman DL, 2018, J CLIN ONCOL, V36, P2710, DOI 10.1200/JCO.2017.77.4414 Higuchi S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216239 Howard CE, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.012639 Howlader N, 2020, NEW ENGL J MED, V383, P640, DOI 10.1056/NEJMoa1916623 Hu YF, 2015, NAT REV CARDIOL, V12, P230, DOI 10.1038/nrcardio.2015.2 Hu YF, 2013, INT J CARDIOL, V165, P355, DOI 10.1016/j.ijcard.2012.08.036 Hufnagel DH, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218169 Huynh J, 2019, NAT REV CANCER, V19, P82, DOI 10.1038/s41568-018-0090-8 Hyslop SR, 2020, ONCOGENE, V39, P5177, DOI 10.1038/s41388-020-1357-6 Iannaccone M, 2018, EUR HEART J-ACUTE CA, V7, P631, DOI 10.1177/2048872617706501 Icht O, 2021, J THROMB HAEMOST, V19, P1250, DOI 10.1111/jth.15272 Ito D, 2012, HEART VESSELS, V27, P634, DOI 10.1007/s00380-011-0222-5 Jackson SP, 2007, BLOOD, V109, P5087, DOI 10.1182/blood-2006-12-027698 Jacobs EJ, 2007, JNCI-J NATL CANCER I, V99, P608, DOI 10.1093/jnci/djk132 Jaiswal S, 2017, NEW ENGL J MED, V377, P111, DOI 10.1056/NEJMoa1701719 Jaiswal S, 2014, NEW ENGL J MED, V371, P2488, DOI 10.1056/NEJMoa1408617 Jakobsen CB, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6314-9 January C. T, 2014, J AM COLL CARDIOL, V64, P2246, DOI DOI 10.1161/CIRCRESAHA.110.220673 Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618 KAGAN HM, 1981, ARTERIOSCLEROSIS, V1, P287, DOI 10.1161/01.ATV.1.4.287 Kattelus H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205454 Khan SU, 2020, CIRCULATION, V142, P1425, DOI 10.1161/CIRCULATIONAHA.120.046308 Khetarpal SA, 2019, J AM COLL CARDIOL, V74, P578, DOI 10.1016/j.jacc.2019.05.045 Khorana AA, 2018, THROMB RES, V164, pS70, DOI 10.1016/j.thromres.2018.01.036 Khouri MG, 2012, CIRCULATION, V126, P2749, DOI 10.1161/CIRCULATIONAHA.112.100560 Kim YJ, 1998, P NATL ACAD SCI USA, V95, P9325, DOI 10.1073/pnas.95.16.9325 Kitano T, 2020, THROMB HAEMOSTASIS, V120, P714, DOI 10.1055/s-0040-1708484 Kraaijpoel N, 2018, THROMB HAEMOSTASIS, V118, P1439, DOI 10.1055/s-0038-1667001 Kuo MC, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001570 Kwak S, 2020, INT J CARDIOL, V313, P25, DOI 10.1016/j.ijcard.2020.04.085 Kwok CS, 2021, EUR HEART J, V42, P1019, DOI 10.1093/eurheartj/ehaa1032 Lanfranca MP, 2020, GASTROENTEROLOGY, V158, P1417, DOI 10.1053/j.gastro.2019.12.010 Lau ES, 2021, JACC-CARDIOONCOL, V3, P48, DOI 10.1016/j.jaccao.2020.12.003 Lauby-Secretan B, 2016, NEW ENGL J MED, V375, P794, DOI 10.1056/NEJMsr1606602 Leiva O, 2020, J MED VASC, V45, p6S8 Leiva O, 2020, CANCERS, V12, DOI 10.3390/cancers12071958 Leiva O, 2019, INT J HEMATOL, V110, P699, DOI 10.1007/s12185-019-02751-6 Levine GN, 2016, J AM COLL CARDIOL, V68, P1082, DOI [10.1016/j.jacc.2016.07.715, 10.1016/j.jacc.2016.03.513] Li ZY, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.222 Liang X, 2019, J CELL BIOCHEM, V120, P5612, DOI 10.1002/jcb.27844 Liberale L, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122072 Lipshultz SE, 2013, CIRCULATION, V128, P1927, DOI 10.1161/CIR.0b013e3182a88099 Liu PH, 2020, LIVER INT, V40, P2522, DOI 10.1111/liv.14560 LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701 Lust JA, 2016, AM J HEMATOL, V91, P571, DOI 10.1002/ajh.24352 Lust JA, 2009, MAYO CLIN PROC, V84, P114, DOI 10.4065/84.2.114 Ma YF, 2021, PLATELETS, V32, P919, DOI 10.1080/09537104.2020.1810653 Madamanchi NR, 2005, ARTERIOSCL THROM VAS, V25, P950, DOI 10.1161/01.ATV.0000161050.77646.68 Malak S, 2012, BLOOD CELL MOL DIS, V49, P170, DOI 10.1016/j.bcmd.2012.06.004 Mantel Ä, 2017, J AM COLL CARDIOL, V69, P1275, DOI 10.1016/j.jacc.2016.12.033 Mantovani A, 2019, IMMUNITY, V50, P778, DOI 10.1016/j.immuni.2019.03.012 Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217 Marx C, 2019, BLOOD, V134, P1859, DOI 10.1182/blood.2019000518 Matsuura S, 2016, BLOOD, V127, P1493, DOI 10.1182/blood-2015-02-629667 McNeil JJ, 2021, JNCI-J NATL CANCER I, V113, P258, DOI 10.1093/jnci/djaa114 Mechanick JI, 2020, J AM COLL CARDIOL, V75, P525, DOI 10.1016/j.jacc.2019.11.044 Meyre PB, 2020, BMC CARDIOVASC DISOR, V20, DOI 10.1186/s12872-020-01711-x Mohamed MO, 2021, EUR HEART J-ACUTE CA, V10, P829, DOI 10.1093/ehjacc/zuaa032 Moloney JN, 2018, SEMIN CELL DEV BIOL, V80, P50, DOI 10.1016/j.semcdb.2017.05.023 Mukai M, 2018, J ATHEROSCLER THROMB, V25, P994, DOI 10.5551/jat.RV17027 Navi BB, 2017, J AM COLL CARDIOL, V70, P927, DOI 10.1016/j.jacc.2017.06.047 Nguyen MLT, 2021, J GASTROEN HEPATOL, V36, P1334, DOI 10.1111/jgh.15307 Nidorf SM, 2020, NEW ENGL J MED, V383, P1838, DOI 10.1056/NEJMoa2021372 Nuthakki VK, 2004, J VASC SURG, V40, P123, DOI 10.1016/j.jvs.2004.02.028 Olsson AK, 2018, PLATELETS, V29, P569, DOI 10.1080/09537104.2018.1453059 Ornelas A, 2017, CANCER METAST REV, V36, P289, DOI 10.1007/s10555-017-9675-z Ostenfeld EB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102861 Passacquale G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025595 Pastori D, 2021, CANCER-AM CANCER SOC, V127, P2122, DOI 10.1002/cncr.33470 Pastori D, 2020, INT J CANCER, V147, P3424, DOI 10.1002/ijc.33179 Pastori D, 2015, AM HEART J, V170, P490, DOI 10.1016/j.ahj.2015.05.011 Pircher J, 2019, THROMB HAEMOSTASIS, V119, P1274, DOI 10.1055/s-0039-1692983 Placke T, 2012, CANCER RES, V72, P440, DOI 10.1158/0008-5472.CAN-11-1872 Popivanova BK, 2009, CANCER RES, V69, P7884, DOI 10.1158/0008-5472.CAN-09-1451 Prandoni P, 2002, BLOOD, V100, P3484, DOI 10.1182/blood-2002-01-0108 Rachidi S, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aai7911 Ranpura V, 2010, ACTA ONCOL, V49, P287, DOI 10.3109/02841860903524396 Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914 Ridker PM, 2017, LANCET, V390, P1833, DOI 10.1016/S0140-6736(17)32247-X Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401 Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202 Rodríguez C, 2008, CARDIOVASC RES, V79, P7, DOI 10.1093/cvr/cvn102 Rossi C, 1998, J INTERN MED, V244, P49 Rothwell PM, 2012, LANCET, V379, P1591, DOI 10.1016/S0140-6736(12)60209-8 Rothwell PM, 2012, LANCET, V379, P1602, DOI 10.1016/S0140-6736(11)61720-0 Rotter M, 2006, J AM COLL CARDIOL, V47, P1231, DOI 10.1016/j.jacc.2005.12.038 Rudolph V, 2010, NAT MED, V16, P470, DOI 10.1038/nm.2124 Saatci O, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16199-4 Saccullo G, 2012, AM J HEMATOL, V87, P388, DOI 10.1002/ajh.23122 Saliba W, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190324 Sano S, 2019, JACC-BASIC TRANSL SC, V4, P684, DOI 10.1016/j.jacbts.2019.05.013 Schauer DP, 2019, ANN SURG, V269, P95, DOI [10.1097/sla.0000000000002525, 10.1097/SLA.0000000000002525] Schnabel RB, 2009, AM J CARDIOL, V104, P92, DOI 10.1016/j.amjcard.2009.02.053 Setargew YFI, 2021, CANCERS, V13, DOI 10.3390/cancers13030491 Severson EA, 2018, BLOOD, V131, P2501, DOI 10.1182/blood-2018-03-840629 Shaw JR, 2019, J THROMB HAEMOST, V17, P1171, DOI 10.1111/jth.14468 Shirai T, 2017, J THROMB HAEMOST, V15, P513, DOI 10.1111/jth.13604 Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387 Siegel-Axel D, 2008, CARDIOVASC RES, V78, P8, DOI 10.1093/cvr/cvn015 Simon TA, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0728-9 Sitia G, 2012, P NATL ACAD SCI USA, V109, pE2165, DOI 10.1073/pnas.1209182109 Siu CW, 2005, PACE, V28, pS120, DOI 10.1111/j.1540-8159.2005.00024.x Smyth SS, 2009, J THROMB HAEMOST, V7, P1759, DOI 10.1111/j.1538-7836.2009.03586.x Sorensen HT, 2000, NEW ENGL J MED, V343, P1846, DOI 10.1056/NEJM200012213432504 Stanicka J, 2015, J BIOL CHEM, V290, P9348, DOI 10.1074/jbc.M113.510495 Takeuchi T, 2021, INT HEART J, V62, P238, DOI 10.1536/ihj.20-452 Tang Y, 2020, CARDIOVASC DRUG THER, V34, P145, DOI 10.1007/s10557-020-06943-9 Tao DL, 2021, BLOOD, V137, P3201, DOI 10.1182/blood.2019003977 Tardif JC, 2019, NEW ENGL J MED, V381, P2497, DOI 10.1056/NEJMoa1912388 Tawil N, 2021, BLOOD ADV, V5, P1682, DOI 10.1182/bloodadvances.2020002998 Tengesdal IW, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2000915118 Timp JF, 2013, BLOOD, V122, P1712, DOI 10.1182/blood-2013-04-460121 Tu S, 2008, CANCER CELL, V14, P408, DOI 10.1016/j.ccr.2008.10.011 van der Hooft CS, 2004, J AM COLL CARDIOL, V44, P2117, DOI 10.1016/j.jacc.2004.08.053 Vassalle C, 2004, J INTERN MED, V256, P308, DOI 10.1111/j.1365-2796.2004.01373.x Walkey AJ, 2013, AM HEART J, V165, P949, DOI 10.1016/j.ahj.2013.03.020 Wang W, 2018, CIRC RES, V123, pE35, DOI 10.1161/CIRCRESAHA.118.313283 Westerterp M, 2018, CIRCULATION, V138, P898, DOI 10.1161/CIRCULATIONAHA.117.032636 Wilson PWF, 2008, CIRCULATION, V118, P124, DOI 10.1161/CIRCULATIONAHA.108.772962 Winnik S, 2013, INT J CARDIOL, V168, P2453, DOI 10.1016/j.ijcard.2013.03.010 Wolach O, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan8292 Wolin KY, 2010, ONCOLOGIST, V15, P556, DOI 10.1634/theoncologist.2009-0285 Wright JR, 2020, JACC-CARDIOONCOL, V2, P236, DOI 10.1016/j.jaccao.2020.04.009 Wu X, 2019, EUR J NEUROL, V26, P1334, DOI 10.1111/ene.13984 Xiao L, 2020, CIRCULATION, V142, P2443, DOI 10.1161/CIRCULATIONAHA.120.049210 Xu XR, 2018, BLOOD, V131, P1777, DOI 10.1182/blood-2017-05-743187 Yakupovich A, 2020, J THORAC DIS, V12, P223, DOI 10.21037/jtd.2020.01.52 Yang LB, 2020, NATURE, V583, P133, DOI 10.1038/s41586-020-2394-6 Yang T, 2010, HEART RHYTHM, V7, P1246, DOI 10.1016/j.hrthm.2010.05.032 Yang XY, 2020, REDOX BIOL, V30, DOI 10.1016/j.redox.2020.101432 Yao CX, 2018, CIRCULATION, V138, P2227, DOI 10.1161/CIRCULATIONAHA.118.035202 Yuhara H, 2011, AM J GASTROENTEROL, V106, P1911, DOI 10.1038/ajg.2011.301 Zaldivia MTK, 2017, FRONT CARDIOVASC MED, V4, DOI 10.3389/fcvm.2017.00074 Zaslavsky AB, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76351-4 Zeboudj L, 2018, J AM COLL CARDIOL, V71, P160, DOI 10.1016/j.jacc.2017.10.084 Zhao Jian-Meng, 2016, Asian Pac J Cancer Prev, V17, P4295 NR 198 TC 112 Z9 120 U1 0 U2 8 PU ELSEVIER PI AMSTERDAM PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS SN 2666-0873 J9 JACC-CARDIOONCOL JI JACC-Cardiooncol. PD DEC PY 2021 VL 3 IS 5 BP 619 EP 634 DI 10.1016/j.jaccao.2021.08.011 EA DEC 2021 PG 16 WC Oncology; Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Cardiovascular System & Cardiology GA XV4MD UT WOS:000734917000001 PM 34988471 OA gold DA 2026-04-17 ER PT J AU Heil, KM Helmschrott, M Darche, FF Bruckner, T Ehlermann, P Kreusser, MM Doesch, AO Sommer, W Warnecke, G Frey, N Rivinius, R AF Heil, Karsten M. Helmschrott, Matthias Darche, Fabrice F. Bruckner, Tom Ehlermann, Philipp Kreusser, Michael M. Doesch, Andreas O. Sommer, Wiebke Warnecke, Gregor Frey, Norbert Rivinius, Rasmus TI Risk Factors, Treatment and Prognosis of Patients with Lung Cancer after Heart Transplantation SO LIFE-BASEL LA English DT Article DE heart transplantation; immunosuppression; malignancy; mortality; lung cancer; survival ID POSTTRANSPLANT ATRIAL-FIBRILLATION; LONG-TERM SURVIVAL; MALIGNANCY; AMIODARONE; TRENDS; TUMORS AB Long-term survival after heart transplantation (HTX) is impacted by adverse effects of immunosuppressive pharmacotherapy, and post-transplant lung cancer is a common occurrence. This study aimed to examine the risk factors, treatment, and prognosis of patients with post-transplant lung cancer. We included 625 adult patients who received HTX at Heidelberg Heart Center between 1989 and 2018. Patients were stratified by diagnosis and staging of lung cancer after HTX. Analysis comprised donor and recipient characteristics, medications including immunosuppressive drugs, and survival after diagnosis of lung cancer. A total of 41 patients (6.6%) were diagnosed with lung cancer after HTX, 13 patients received curative care and 28 patients had palliative care. Mean time from HTX until diagnosis of lung cancer was 8.6 +/- 4.0 years and 1.8 +/- 2.7 years from diagnosis of lung cancer until last follow-up. Twenty-four patients (58.5%) were switched to an mTOR-inhibitor after diagnosis of lung cancer. Multivariate analysis showed recipient age (HR: 1.05; CI: 1.01-1.10; p = 0.02), COPD (HR: 3.72; CI: 1.88-7.37; p < 0.01), and history of smoking (HR: 20.39; CI: 2.73-152.13; p < 0.01) as risk factors for post-transplant lung cancer. Patients in stages I and II had a significantly better 1-year (100.0% versus 3.6%), 2-year (69.2% versus 0.0%), and 5-year survival (53.8% versus 0.0%) than patients in stages III and IV (p < 0.01). Given the poor prognosis of late-stage post-transplant lung cancer, routine reassessment of current smoking status, providing smoking cessation support, and intensified lung cancer screening in high-risk HTX recipients are advisable. C1 [Heil, Karsten M.; Helmschrott, Matthias; Darche, Fabrice F.; Ehlermann, Philipp; Kreusser, Michael M.; Doesch, Andreas O.; Frey, Norbert; Rivinius, Rasmus] Heidelberg Univ Hosp, Dept Cardiol Angiol & Pneumol, D-69120 Heidelberg, Germany. [Darche, Fabrice F.; Ehlermann, Philipp; Kreusser, Michael M.; Frey, Norbert; Rivinius, Rasmus] German Ctr Cardiovasc Res DZHK, Partner Site Heidelberg Mannheim, D-69120 Heidelberg, Germany. [Bruckner, Tom] Heidelberg Univ, Inst Med Biometry, D-69120 Heidelberg, Germany. [Doesch, Andreas O.] Asklepios Hosp, Dept Pneumol & Oncol, D-36433 Bad Salzungen, Germany. [Sommer, Wiebke; Warnecke, Gregor] Heidelberg Univ Hosp, Dept Cardiac Surg, D-69120 Heidelberg, Germany. C3 Ruprecht Karls University Heidelberg; German Centre for Cardiovascular Research; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg RP Rivinius, R (corresponding author), Heidelberg Univ Hosp, Dept Cardiol Angiol & Pneumol, D-69120 Heidelberg, Germany.; Rivinius, R (corresponding author), German Ctr Cardiovasc Res DZHK, Partner Site Heidelberg Mannheim, D-69120 Heidelberg, Germany. EM karsten.m.heil@gmail.com; matthias.helmschrott@med.uni-heidelberg.de; fabrice.darche@med.uni-heidelberg.de; bruckner@imbi.uni-heidelberg.de; philipp.ehlermann@med.uni-heidelberg.de; michael.kreusser@med.uni-heidelberg.de; andreas.doesch@gmail.com; wiebke.sommer@med.uni-heidelberg.de; gregor.warnecke@med.uni-heidelberg.de; norbert.frey@med.uni-heidelberg.de; rasmus.rivinius@med.uni-heidelberg.de RI Darche, Fabrice/AAE-8467-2021; Rivinius, Rasmus/S-6820-2019; Frey, Norbert/M-7749-2019 OI Rivinius, Rasmus/0000-0003-1146-6319; Frey, Norbert/0000-0001-7611-378X; Darche, Fabrice Fernand/0000-0003-4896-9219 FU Physician-Scientist-Program of the Faculty of Medicine, University of Heidelber [Fabrice Darche and Rasmus Rivinius] Funding Source: Medline; German Heart Foundation/German Foundation of Heart Research [Rasmus Rivinius] Funding Source: Medline CR Bagan P, 2005, ANN THORAC SURG, V79, P438, DOI 10.1016/j.athoracsur.2004.07.037 Brierley J.D., 2017, TNM Classification of Malignant Tumours, Veighth, P105 Bruschi G, 2009, LUNG CANCER, V63, P146, DOI 10.1016/j.lungcan.2008.04.018 Colvin M, 2021, AM J TRANSPLANT, V21, P356, DOI 10.1111/ajt.16492 Crespo-Leiro MG, 2008, AM J TRANSPLANT, V8, P1031, DOI 10.1111/j.1600-6143.2008.02196.x Crespo-Leiro MG, 2011, AM J TRANSPLANT, V11, P1035, DOI 10.1111/j.1600-6143.2011.03515.x Curtil A, 1997, EUR J CARDIO-THORAC, V12, P101, DOI 10.1016/S1010-7940(97)00114-0 Dantal J, 2005, NEW ENGL J MED, V352, P1371, DOI 10.1056/NEJMe058018 Darche FF, 2021, ESC HEART FAIL, V8, P4265, DOI 10.1002/ehf2.13552 Doesch AO, 2010, TRANSPL P, V42, P3694, DOI 10.1016/j.transproceed.2010.07.107 Dorent R, 2000, TRANSPLANT P, V32, P2752, DOI 10.1016/S0041-1345(00)01867-4 Eberle A, 2015, LUNG CANCER, V90, P528, DOI 10.1016/j.lungcan.2015.10.007 Fuchs M, 2019, EUR J CARDIO-THORAC, V55, pI38, DOI 10.1093/ejcts/ezz107 Goldstein DJ, 1995, ANN THORAC SURG, V60, P1783, DOI 10.1016/0003-4975(95)00782-2 Goldstein DJ, 1996, TRANSPLANTATION, V62, P772, DOI 10.1097/00007890-199609270-00013 Hauptman PJ, 2005, J HEART LUNG TRANSPL, V24, P1111, DOI 10.1016/j.healun.2004.06.009 Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401 Hunt SA, 2002, TRANSPL P, V34, P1874, DOI 10.1016/S0041-1345(02)03105-6 Hunt SA, 2006, NEW ENGL J MED, V355, P231, DOI 10.1056/NEJMp068048 Jäämaa-Holmberg S, 2019, ACTA ONCOL, V58, P859, DOI 10.1080/0284186X.2019.1580385 Kirklin JK, 2003, J THORAC CARDIOV SUR, V125, P881, DOI 10.1067/mtc.2003.168 Kumarasinghe G, 2015, J HEART LUNG TRANSPL, V34, P1406, DOI 10.1016/j.healun.2015.05.021 Lateef N, 2016, EXP CLIN TRANSPLANT, V14, P12, DOI 10.6002/ect.2015.0214 Maluccio M, 2003, TRANSPLANTATION, V76, P597, DOI 10.1097/01.TP.0000081399.75231.3B McDonagh TA, 2021, EUR HEART J, V42, P3599, DOI 10.1093/eurheartj/ehab368 Mohammadi S, 2007, THORAC CARDIOV SURG, V55, P438, DOI 10.1055/s-2007-965306 Ortega-Legaspi JM, 2022, HEART, V108, P586, DOI 10.1136/heartjnl-2020-318063 PENN I, 1993, HEMATOL ONCOL CLIN N, V7, P431, DOI 10.1016/S0889-8588(18)30250-8 Pham SM, 1995, ANN THORAC SURG, V60, P1623, DOI 10.1016/0003-4975(95)00120-4 Potaris K, 2005, ANN THORAC SURG, V79, P980, DOI 10.1016/j.athoracsur.2004.05.021 Rahm AK, 2021, ESC HEART FAIL, V8, P3737, DOI 10.1002/ehf2.13494 Rivinius R, 2020, ESC HEART FAIL, V7, P2082, DOI 10.1002/ehf2.12807 Rivinius R, 2020, ESC HEART FAIL, V7, P177, DOI 10.1002/ehf2.12549 Rivinius R, 2019, J THORAC DIS, V11, P5440, DOI 10.21037/jtd.2019.11.45 Rivinius R, 2018, CLIN EPIDEMIOL, V10, P1359, DOI 10.2147/CLEP.S171929 Rivinius R, 2017, DRUG DES DEV THER, V11, P1827, DOI 10.2147/DDDT.S136948 Rivinius R, 2016, DRUG DES DEV THER, V10, P677, DOI 10.2147/DDDT.S96126 Rivinius R, 2014, DRUG DES DEV THER, V9, P93, DOI 10.2147/DDDT.S75464 Stehlik J, 2018, CIRCULATION, V137, P71, DOI 10.1161/CIRCULATIONAHA.117.029753 Valantine H, 2004, J HEART LUNG TRANSPL, V23, pS187, DOI 10.1016/j.healun.2004.03.009 Yagdi T, 2009, J CARDIAC SURG, V24, P572, DOI 10.1111/j.1540-8191.2009.00858.x Youn JC, 2018, J AM COLL CARDIOL, V71, P40, DOI 10.1016/j.jacc.2017.10.077 Zhu YJ, 2021, EUR HEART J, V42, P4934, DOI 10.1093/eurheartj/ehab416 NR 43 TC 8 Z9 9 U1 0 U2 3 PU MDPI PI BASEL PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND EI 2075-1729 J9 LIFE-BASEL JI Life-Basel PD DEC PY 2021 VL 11 IS 12 AR 1344 DI 10.3390/life11121344 PG 15 WC Biology; Microbiology WE Science Citation Index Expanded (SCI-EXPANDED) SC Life Sciences & Biomedicine - Other Topics; Microbiology GA XZ3YP UT WOS:000737591200001 PM 34947875 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Topolnitskiy, E Chekalkin, T Marchenko, E Yasenchuk, Y Kang, SB Kang, JH Obrosov, A AF Topolnitskiy, Evgeniy Chekalkin, Timofey Marchenko, Ekaterina Yasenchuk, Yuri Kang, Seung-Baik Kang, Ji-Hoon Obrosov, Aleksei TI Evaluation of Clinical Performance of TiNi-Based Implants Used in Chest Wall Repair after Resection for Malignant Tumors SO JOURNAL OF FUNCTIONAL BIOMATERIALS LA English DT Article DE non-small cell lung cancer (NSCLC); thoracic lesion; chest wall reconstruction; TiNi artificial rib; TiNi mesh implant ID TITANIUM PLATES; RECONSTRUCTION; COMBINATION AB In this study, we assessed the outcomes after surgical treatment of thoracic post-excision defects in 15 patients, using TiNi knitted surgical meshes and customized artificial TiNi-based ribs. Methods: Eight patients were diagnosed with advanced non-small cell lung cancer (NSCLC) invading the chest wall, of which five patients were T3N0M0, two were T3N1M0, and one was T3N2M0. Squamous cell carcinoma was identified in three of these patients and adenocarcinoma in five. In two cases, chest wall resection and repair were performed for metastases of kidney cancer after radical nephrectomy. Three-dimensional CT reconstruction and X-ray scans were used to plan the surgery and customize the reinforcing TiNi-based implants. All patients received TiNi-based devices and were prospectively followed for a few years. Results: So far, there have been no lethal outcomes, and all implanted devices were consistent in follow-up examinations. Immediate complications were noted in three cases (ejection of air through the pleural drains, paroxysm of atrial fibrillation, and pleuritis), which were conservatively managed. In the long term, no complications, aftereffects, or instability of the thoracic cage were observed. Conclusion: TiNi-based devices used for extensive thoracic lesion repair in this context are promising and reliable biomaterials that demonstrate good functional, clinical, and cosmetic outcomes. C1 [Topolnitskiy, Evgeniy; Chekalkin, Timofey; Marchenko, Ekaterina; Yasenchuk, Yuri; Obrosov, Aleksei] Tomsk State Univ, Lab Med Mat, Tomsk 634045, Russia. [Topolnitskiy, Evgeniy] Siberian State Med Univ, Dept Surg, Tomsk 634050, Russia. [Chekalkin, Timofey; Kang, Ji-Hoon] TiNiKo Co, R&D Ctr, Ochang 28119, South Korea. [Kang, Seung-Baik] Seoul Natl Univ Hosp, Boramae Med Ctr, Seoul 07061, South Korea. [Obrosov, Aleksei] Brandenburg Tech Univ Cottbus, Dept Phys Met & Mat Technol, D-03046 Cottbus, Germany. C3 Tomsk State University; Siberian State Medical University; Seoul National University (SNU); Seoul National University Hospital; Brandenburg University of Technology Cottbus RP Chekalkin, T (corresponding author), Tomsk State Univ, Lab Med Mat, Tomsk 634045, Russia.; Chekalkin, T (corresponding author), TiNiKo Co, R&D Ctr, Ochang 28119, South Korea. EM e_topolnitskyi@mail.ru; tc77@rec.tsu.ru; chaaarmy@mail.ru; wireknitting.ru@gmail.com; ossbkang@gmail.com; hunywell@gmail.com; aleksei.obrosov@b-tu.de RI Obrosov, Aleksei/J-9021-2017; Yasenchuk, Yuri/C-4170-2014; Marchenko, Ekaterina/KGM-1959-2024; Topolnitskiy, Evgeniy/T-5818-2018; Chekalkin, Timofey/B-2776-2014 OI Obrosov, Aleksei/0000-0001-6343-7523; Yasenchuk, Yuri/0000-0003-1364-6559; Marchenko, Ekaterina/0000-0003-4615-5270; Topolnitskiy, Evgeniy/0000-0002-5674-0177; Kang, Seung-Baik/0000-0002-1184-4482; Kang, Ji-hoon/0000-0001-5255-6017; Chekalkin, Timofey/0000-0001-5831-3091 FU Ministry of Education and Science of the Russian Federation [0721-2020-0022] FX FundingThis work was supported by the Ministry of Education and Science of the Russian Federation, project No. 0721-2020-0022. CR Aihara H, 2019, INT J BIOMATER, V2019, DOI 10.1155/2019/4307461 Aranda JL, 2015, EUR J CARDIO-THORAC, V48, pE92, DOI 10.1093/ejcts/ezv265 Berthet JP, 2011, ANN THORAC SURG, V91, P1709, DOI 10.1016/j.athoracsur.2011.02.014 Billè A, 2012, INTERACT CARDIOV TH, V15, P588, DOI 10.1093/icvts/ivs327 Carter BW, 2015, MAGN RESON IMAGING C, V23, P197, DOI 10.1016/j.mric.2015.01.007 Chernyshova A, 2021, J INVEST SURG, V34, P1110, DOI 10.1080/08941939.2020.1745965 David Elizabeth A, 2011, Semin Plast Surg, V25, P16, DOI 10.1055/s-0031-1275167 Dzian A, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957-018-1315-8 Ferrigno P, 2020, J THORAC DIS, V12, P45, DOI 10.21037/jtd.2019.08.08 Gao EJ, 2018, J CARDIOTHORAC SURG, V13, DOI 10.1186/s13019-018-0810-x Gunther V, 2019, BIOMED PHYS ENG EXPR, V5, DOI 10.1088/2057-1976/ab0693 Gunther V, 2019, ADV POWDER TECHNOL, V30, P673, DOI 10.1016/j.apt.2018.12.011 Kokorev O, 2020, SURF TOPOGR-METROL, V8, DOI 10.1088/2051-672X/abc0f9 Kokorev O, 2019, BIOMED PHYS ENG EXPR, V5, DOI 10.1088/2057-1976/aae974 Kress RL, 2018, J CARDIOTHORAC SURG, V13, DOI 10.1186/s13019-018-0812-8 [Кудрявцев Александр Сергеевич Kudrjavtsev A.S.], 2015, Патология кровообращения и кардиохирургия, V19, P124 Kulbakin D, 2016, CASE REP ONCOL, V9, P772, DOI 10.1159/000452790 Loi M, 2020, J THORAC DIS, V12, P22, DOI 10.21037/jtd.2019.07.81 Lu XG, 2020, COLLOID SURFACE B, V188, DOI 10.1016/j.colsurfb.2020.110783 Marulli G, 2020, J THORAC DIS, V12, P3, DOI 10.21037/jtd.2019.07.82 Merritt RE, 2017, THORAC SURG CLIN, V27, P165, DOI 10.1016/j.thorsurg.2017.01.010 Muhamedov M, 2015, J SURG ONCOL, V111, P231, DOI 10.1002/jso.23779 Ong K, 2018, J THORAC DIS, V10, P2890, DOI 10.21037/jtd.2018.04.116 Pfannschmidt J, 2005, THORAC CARDIOV SURG, V53, P234, DOI 10.1055/s-2005-837649 Sandri A, 2020, J THORAC DIS, V12, P17, DOI 10.21037/jtd.2019.06.45 Sanna Stefano, 2017, J Vis Surg, V3, P95, DOI [10.21037/jovs.2017.06.10, 10.21037/jovs.2017.06.10] Seder CW, 2016, J THORAC DIS, V8, pS863, DOI 10.21037/jtd.2016.11.07 Shtin V, 2019, J FUNCT BIOMATER, V10, DOI 10.3390/jfb10030027 Topol'nitskii E B, 2011, Khirurgiia (Mosk), P47 van Oirschot BAJA, 2016, CLIN ORAL IMPLAN RES, V27, pE57, DOI 10.1111/clr.12529 Wada T, 2007, J BONE JOINT SURG BR, V89B, P659, DOI 10.1302/0301-620X.89B5.18498 Wen XP, 2018, J CARDIOTHORAC SURG, V13, DOI [10.1186/S13019-017-0692-3, 10.1186/s13019-017-0692-3] Weyant MJ, 2006, ANN THORAC SURG, V81, P279, DOI 10.1016/j.athoracsur.2005.07.001 Yasenchuk Y, 2021, BIOMED MATER, V16, DOI 10.1088/1748-605X/aba327 Yasenchuk Y, 2019, MATERIALS, V12, DOI 10.3390/ma12152405 Yasenchuk Y, 2019, MATER RES EXPRESS, V6, DOI 10.1088/2053-1591/ab01a1 Zarqane H, 2013, Diagn Interv Imaging, V94, P1095, DOI 10.1016/j.diii.2013.05.006 Zhang H, 2020, J THORAC DIS, V12, P2713, DOI 10.21037/jtd.2020.04.53 [Жеравин Александр Александрович Zheravin A.A.], 2015, [Сибирский онкологический журнал, Sibirskii onkologicheskii zhurnal], P31 NR 39 TC 20 Z9 26 U1 0 U2 17 PU MDPI PI BASEL PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND EI 2079-4983 J9 J FUNCT BIOMATER JI J. Func. Biomater. PD DEC PY 2021 VL 12 IS 4 AR 60 DI 10.3390/jfb12040060 PG 11 WC Engineering, Biomedical; Materials Science, Biomaterials WE Science Citation Index Expanded (SCI-EXPANDED) SC Engineering; Materials Science GA XY7ZH UT WOS:000737185400001 PM 34842727 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Zhang, Z Yan, W AF Zhang, Zhen Yan, Wei TI RETRACTED: Spiral Computed Tomography in the Quantitative Measurement of the Adjacent Structure of the Left Atrial Appendage in Patients with Atrial Fibrillation (Retracted Article) SO JOURNAL OF HEALTHCARE ENGINEERING LA English DT Article; Retracted Publication ID LUNG-CANCER; CT IMAGES AB Cardiac arrhythmias are common clinical cardiovascular diseases. Arrhythmias are abnormalities in the frequency, rhythm, site of origin, conduction velocity, or sequence of excitation of the cardiac impulses. Arrhythmia mechanisms include foldback, altered autonomic rhythm, and triggering mechanisms. It can cause palpitations, dizziness, black dawn, syncope, and angina pectoris and can worsen a preexisting cardiac disease, reduce the quality of life, and increase mortality. Also, by making it one of the constant challenges for the clinical cardiovascular physician, we can get more information. The study included 94 patients with atrial fibers, including 56 men and 38 women aged 57, 46, 11, and 68 years. There are 80 patients with nonatrial fibers, including 44 men and 36 women aged 56, 10, and 83 years. Those who can perform a normal coronary angiography and exclude congenital heart disease, heart valve disease, and other cardiovascular diseases. In both groups, a 256-layer spiral CT examination was performed. A pulmonary vein scanning protocol was applied to the patients with atrial fibrillation, and this can perform normal coronary angiography and exclude those with cardiovascular diseases such as congenital heart disease and valvular heart disease. The purpose of this study is to investigate the anatomical changes of the left atrium and its adjacent structures by applying the 256 nm spiral CT imaging to visualize the left atrium and its adjacent structures and by applying the MPR technology, VR technology, and simulation endoscope techniques. C1 [Zhang, Zhen; Yan, Wei] Youjiang Med Coll Nationalities, Dept Cardiovasc Med, Affiliated Hosp, Baise 533000, Guangxi, Peoples R China. C3 Youjiang Medical University for Nationalities RP Yan, W (corresponding author), Youjiang Med Coll Nationalities, Dept Cardiovasc Med, Affiliated Hosp, Baise 533000, Guangxi, Peoples R China. EM 2197@ymun.edu.cn; 2227@ymun.edu.cn CR Berger N, 2019, INVEST RADIOL, V54, P409, DOI 10.1097/RLI.0000000000000552 Ctvrtlik F, 2019, BIOMED PAP, V163, P212, DOI 10.5507/bp.2019.047 Deng FQ, 2021, J X-RAY SCI TECHNOL, V29, P577, DOI 10.3233/XST-210841 Dias OM, 2018, EXPERT REV RESP MED, V12, P5, DOI 10.1080/17476348.2018.1395282 Fletcher JG, 2019, AM J NEURORADIOL, V40, P1855, DOI 10.3174/ajnr.A6251 Hardy AJ, 2019, MED PHYS, V46, P902, DOI 10.1002/mp.13301 Larsen TC, 2020, CLIN IMAG, V59, P119, DOI 10.1016/j.clinimag.2019.11.004 Lauria M, 2021, MED PHYS, V48, P1823, DOI 10.1002/mp.14759 Leynes AP, 2018, J NUCL MED, V59, P852, DOI 10.2967/jnumed.117.198051 Liang F, 2019, LUNG CANCER, V132, P114, DOI 10.1016/j.lungcan.2019.04.020 Lu W, 2019, EUR J RADIOL, V118, P231, DOI 10.1016/j.ejrad.2019.07.018 Lyu TS, 2019, J INT MED RES, V47, P3699, DOI 10.1177/0300060519858010 Ma LY, 2020, J X-RAY SCI TECHNOL, V28, P939, DOI 10.3233/XST-200662 Rogalla P, 2018, EUR RADIOL, V28, P3922, DOI 10.1007/s00330-018-5315-4 Shim S, 2020, INVEST RADIOL, V55, P515, DOI 10.1097/RLI.0000000000000662 Tanoue S, 2020, CIRC J, V84, P636, DOI 10.1253/circj.CJ-19-0722 Tran LV, 2019, AM J RHINOL ALLERGY, V33, P323, DOI 10.1177/1945892419826228 van't Sant I, 2020, EUR RADIOL, V30, P3101, DOI 10.1007/s00330-019-06524-x Veliz P, 2019, CANCER EPIDEMIOL, V60, P51, DOI 10.1016/j.canep.2019.03.009 Wang HY, 2020, RADIAT ONCOL, V15, DOI 10.1186/s13014-020-01698-x Zhou Qinghua, 2018, Zhongguo Fei Ai Za Zhi, V21, P67, DOI 10.3779/j.issn.1009-3419.2018.02.01 NR 21 TC 0 Z9 0 U1 0 U2 6 PU HINDAWI LTD PI LONDON PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND SN 2040-2295 EI 2040-2309 J9 J HEALTHC ENG JI J. Healthc. Eng. PD NOV 30 PY 2021 VL 2021 AR 9893358 DI 10.1155/2021/9893358 PG 10 WC Health Care Sciences & Services WE Science Citation Index Expanded (SCI-EXPANDED) SC Health Care Sciences & Services GA ZY9OS UT WOS:000772909200003 PM 34888024 OA Green Submitted, hybrid DA 2026-04-17 ER PT J AU Huang, J Tian, Y Li, CW Shen, YF Li, HC Lv, FZ Lin, H Lu, PJ Lin, JL Lau, C Terra, RM Jiang, L Luo, QQ AF Huang, Jia Tian, Yu Li, Chongwu Shen, Yaofeng Li, Hecheng Lv, Fanzhen Lin, Hao Lu, Peiji Lin, Jules Lau, Christopher Terra, Ricardo Mingarini Jiang, Long Luo, Qingquan TI Robotic-assisted thoracic surgery reduces perioperative complications and achieves a similar long-term survival profile as posterolateral thoracotomy in clinical N2 stage non-small cell lung cancer patients: a multicenter, randomized, controlled trial SO TRANSLATIONAL LUNG CANCER RESEARCH LA English DT Article DE Robotic-assisted thoracic surgery (RATS); thoracotomy; non-small cell lung cancer (NSCLC); lymph node metastasis; postoperative complications ID OUTCOMES AB Background: Our previous study demonstrated the safety and short-term efficacy of robotic-assisted thoracic surgery (RATS) in clinical N2 (c-N2) stage non-small cell lung cancer (NSCLC) patients. From this, the present study was devised, in which the follow-up time and sample size were both extended to explore the long-term efficacy and potential benefit in survival of RATS compared with lobectomy in c-N2 stage NSCLC patients. Methods: Patients with c-N2 NSCLS were randomly assigned in a 1:1 ratio to accept operation through thoracotomy or RATS. The da Vinci Surgical System (Si/Xi) was applied in the RATS group, while conventional lobectomy with a rib-spreading incision was applied in the posterolateral thoracotomy group. Primary endpoint was defined as disease free survival and overall survival (OS) of all recruited patients. Results: Compared with posterolateral thoracotomy group (N=72), the RATS group (N=76) had a reduced blood loss (P<0.001), decreased drainage duration (P=0.002), and decreased postoperative pain visual analog score (all P<0.001), but increased overall cost (P<0.001). Meanwhile, no difference in the other postoperative complications (such as air leakage, subcutaneous emphysema, atrial fibrillation etc.) was found between the RATS group and the posterolateral thoracotomy group (all P>0.05). Regarding long-term outcome, no difference in disease-free survival (DFS; P=0.925) or OS (P=0.853) was observed between the RATS group and posterolateral thoracotomy group. Subgroup analyses and multivariable Cox regression analyses also found no difference in DFS or OS between the RATS group and posterolateral thoracotomy groups. Conclusions: RATS reduced intraoperative bleeding, drainage duration, postoperative pain, and achieved similar long-term survival outcomes compared with posterolateral thoracotomy in c-N2 stage NSCLC patients. C1 [Huang, Jia; Tian, Yu; Lin, Hao; Lu, Peiji; Jiang, Long; Luo, Qingquan] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai 200030, Peoples R China. [Li, Chongwu] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Thorac Surg, Shanghai, Peoples R China. [Shen, Yaofeng] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Anesthesiol, Shanghai, Peoples R China. [Li, Hecheng] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Thorac Surg, Sch Med, Shanghai, Peoples R China. [Lv, Fanzhen] Fudan Univ, Dept Thorac Surg, Affiliated Huadong Hosp, Shanghai, Peoples R China. [Lin, Jules] Univ Michigan, Med Ctr, Dept Surg, Sect Thorac Surg, Ann Arbor, MI 48109 USA. [Lau, Christopher] Weill Cornell Med, Dept Cardiothorac Surg, New York, NY USA. [Terra, Ricardo Mingarini] Univ Sao Paulo, Thorac Surg Div, Heart Inst InCor, Hosp Clin Fac Med, Sao Paulo, Brazil. C3 Shanghai Jiao Tong University; Tongji University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Fudan University; University of Michigan System; University of Michigan; Cornell University; Weill Cornell Medicine; Universidade de Sao Paulo RP Jiang, L; Luo, QQ (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai 200030, Peoples R China. EM dylan919@139.com; luoqingquan@hotmail.com RI Jiang, Long/NQE-9391-2025; Lin, Jules/AAK-3200-2021 FU Shanghai Hospital Development Center [SHDC12016113]; National Natural Science Foundation of China [81972176] FX This work was supported by Shanghai Hospital Development Center (Grant Number: SHDC12016113) and the National Natural Science Foundation of China (No. 81972176). CR Branch SK, 2005, J PHARMACEUT BIOMED, V38, P798, DOI 10.1016/j.jpba.2005.02.037 Casiraghi M, 2018, J THORAC DIS, V10, pS3081, DOI 10.21037/jtd.2018.07.90 Chinese Anti-Cancer Association Committee of Lung Cancer Society Lung Cancer Group of Oncology Branch Chinese Medical Association, 2019, Zhonghua Zhongliu Zazhi, V41, P881 Duma N, 2019, MAYO CLIN PROC, V94, P1623, DOI 10.1016/j.mayocp.2019.01.013 Herb JN, 2021, SEMIN THORAC CARDIOV, V33, P547, DOI 10.1053/j.semtcvs.2020.09.008 Hong QY, 2015, CANCER-AM CANCER SOC, V121, P3080, DOI 10.1002/cncr.29584 Hu JJ, 2020, INT J MED ROBOT COMP, V16, DOI 10.1002/rcs.2123 Hu X, 2019, COMB CHEM HIGH T SCR, V22, P169, DOI 10.2174/1386207322666190411113040 Huang J, 2019, TRANSL LUNG CANCER R, V8, P951, DOI 10.21037/tlcr.2019.11.31 Ishikawa N, 2015, ANN THORAC CARDIOVAS, V21, P322, DOI 10.5761/atcs.ra.15-00145 Jiang Y, 2020, J THORAC DIS, V12, P4427, DOI 10.21037/jtd-20-1116 Kanzaki M, 2019, SURG TODAY, V49, P795, DOI 10.1007/s00595-019-01793-x Kneuertz PJ, 2020, CLIN LUNG CANCER, V21, P214, DOI 10.1016/j.cllc.2019.10.004 Lo EM, 2021, UROL CLIN N AM, V48, P71, DOI 10.1016/j.ucl.2020.09.011 Novellis P, 2018, J THORAC DIS, V10, P790, DOI 10.21037/jtd.2018.01.123 Novellis Pierluigi, 2017, J Vis Surg, V3, P39, DOI [10.21037/jovs.2017.03.05, 10.21037/jovs.2017.03.05] Park BJ, 2016, J THORAC DIS, V8, pS406, DOI 10.21037/jtd.2016.04.56 Spaggiari L, 2019, J THORAC ONCOL, V14, P2176, DOI 10.1016/j.jtho.2019.07.032 Veluswamy RR, 2020, CHEST, V157, P1313, DOI 10.1016/j.chest.2019.09.017 Veronesi G, 2016, LUNG CANCER, V101, P28, DOI 10.1016/j.lungcan.2016.09.004 White AA, 2021, J SURG ONCOL, V123, P579, DOI 10.1002/jso.26305 Yang HX, 2017, ANN SURG, V265, P431, DOI 10.1097/SLA.0000000000001708 Zanagnolo V, 2017, J MINIM INVAS GYN, V24, P379, DOI 10.1016/j.jmig.2017.01.006 Zirafa CC, 2019, ANN CARDIOTHORAC SUR, V8, P210, DOI 10.21037/acs.2019.03.03 NR 24 TC 23 Z9 25 U1 1 U2 13 PU AME PUBLISHING COMPANY PI SHATIN PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA SN 2218-6751 EI 2226-4477 J9 TRANSL LUNG CANCER R JI Transl. Lung Cancer Res. PD NOV PY 2021 VL 10 IS 11 BP 4281 EP 4292 DI 10.21037/tlcr-21-898 EA NOV 2021 PG 12 WC Oncology; Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Respiratory System GA XJ5GU UT WOS:000723951700001 PM 35004256 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Hanley, C Donahoe, L Slinger, P AF Hanley, Ciara Donahoe, Laura Slinger, Peter TI "Fit for Surgery? What's New in Preoperative Assessment of the High-Risk Patient Undergoing Pulmonary Resection" SO JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA LA English DT Review DE thoracic surgical procedures; risk assessment; risk factors; spirometry; preoperative care; lung neoplasms ID INTENSIVE-CARE-UNIT; POSTOPERATIVE ATRIAL-FIBRILLATION; MAJOR NONCARDIAC SURGERY; MODIFIED FRAILTY INDEX; LUNG-CANCER PATIENTS; 6-MIN WALK TEST; THORACIC-SURGERY; NATRIURETIC PEPTIDE; AMERICAN-COLLEGE; CARDIOPULMONARY COMPLICATIONS AB Advances in perioperative assessment and diagnostics, together with developments in anesthetic and surgical techniques, have considerably expanded the pool of patients who may be suitable for pulmonary resection. Thoracic surgical patients frequently are perceived to be at high perioperative risk due to advanced age, level of comorbidity, and the risks associated with pulmonary resection, which predispose them to a significantly increased risk of perioperative complications, increased healthcare resource use, and costs. The definition of what is considered "fit for surgery" in thoracic surgery continually is being challenged. However, no internationally standardized definition of prohibitive risk exists. Perioperative assessment traditionally concentrates on the "three-legged stool" of pulmonary mechanical function, parenchymal function, and cardiopulmonary reserve. However, no single criterion should exclude a patient from surgery, and there are other perioperative factors in addition to the tripartite assessment that need to be considered in order to more accurately assess functional capacity and predict individual perioperative risk. In this review, the authors aim to address some of the more erudite concepts that are important in preoperative risk assessment of the patient at potentially prohibitive risk undergoing pulmonary resection for malignancy. (C) 2020 Elsevier Inc. All rights reserved. C1 [Hanley, Ciara; Slinger, Peter] Univ Toronto, Toronto Gen Hosp, Dept Anesthesia & Pain Management, Toronto, ON, Canada. [Donahoe, Laura] Univ Toronto, Toronto Gen Hosp, Div Thorac Surg, Toronto, ON, Canada. C3 University of Toronto; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Health Network Toronto; Toronto General Hospital RP Hanley, C (corresponding author), Univ Hlth Network, Toronto Gen Hosp, Dept Anesthesia & Pain Med, Toronto, ON M5G 2C4, Canada. EM ciara1804@gmail.com OI Hanley, Ciara/0000-0001-6033-6786 CR Advani S, 2019, TRANSL LUNG CANCER R, V8, pS454, DOI 10.21037/tlcr.2019.10.03 Agostini P, 2010, THORAX, V65, P815, DOI 10.1136/thx.2009.123083 Agostini P, 2017, INTERACT CARDIOV TH, V24, P931, DOI 10.1093/icvts/ivx002 Agostini PJ, 2018, J CARDIOTHORAC SURG, V13, DOI 10.1186/s13019-018-0717-6 Amar D, 1997, ANN THORAC SURG, V63, P1374 Amar D, 2000, J THORAC CARDIOV SUR, V120, P790, DOI 10.1067/mtc.2000.109538 Amsterdam EA, 2014, J AM COLL CARDIOL, V64, P2713, DOI [10.1016/j.jacc.2014.10.011, 10.1016/j.jacc.2014.09.017, 10.1161/CIR.0000000000000134] Aps C, 2004, BRIT J ANAESTH, V92, P164, DOI 10.1093/bja/aeh041 Aucoin SD, 2020, ANESTHESIOLOGY, V133, P78, DOI [10.1097/ALN.0000000000003309, 10.1097/ALN.0000000000003257] Avancini A, 2020, ONCOLOGIST, V25, pE555, DOI 10.1634/theoncologist.2019-0463 Baser S, 2006, CLIN LUNG CANCER, V7, P344, DOI 10.3816/CLC.2006.n.017 Batchelor TJP, 2019, EUR J CARDIO-THORAC, V55, P91, DOI 10.1093/ejcts/ezy301 Beckert AK, 2017, ANN THORAC SURG, V103, P956, DOI 10.1016/j.athoracsur.2016.08.078 Beggs T, 2015, CAN J ANESTH, V62, P143, DOI 10.1007/s12630-014-0273-z Bendixen M, 2016, LANCET ONCOL, V17, P836, DOI 10.1016/S1470-2045(16)00173-X Bentov I, 2019, BRIT J ANAESTH, V123, P37, DOI 10.1016/j.bja.2019.03.034 Berry MF, 2010, ANN THORAC SURG, V89, P1044, DOI 10.1016/j.athoracsur.2009.12.065 Biccard BM, 2005, ANAESTHESIA, V60, P588, DOI 10.1111/j.1365-2044.2005.04181.x Bobbio A, 2008, EUR J CARDIO-THORAC, V33, P95, DOI 10.1016/j.ejcts.2007.10.003 BOLTON JWR, 1987, CHEST, V92, P783, DOI 10.1378/chest.92.5.783 Boujibar F, 2018, J THORAC DIS, V10, P2240, DOI 10.21037/jtd.2018.03.161 Bradley A, 2012, EUR RESPIR J, V40, P1496, DOI 10.1183/09031936.00218111 Brown AW, 2018, ANN AM THORAC SOC, V15, P3, DOI 10.1513/AnnalsATS.201703-244FR Brunelli A, 2009, EUR RESPIR J, V34, P17, DOI 10.1183/09031936.00184308 Brunelli A, 2008, ANN THORAC SURG, V86, P240, DOI 10.1016/j.athoracsur.2008.03.025 Brunelli A, 2008, ANN THORAC SURG, V86, P213, DOI 10.1016/j.athoracsur.2008.03.063 Brunelli A, 2020, EUR J CARDIO-THORAC, V57, P455, DOI 10.1093/ejcts/ezz272 Brunelli A, 2017, ANN THORAC SURG, V103, P1641, DOI 10.1016/j.athoracsur.2016.10.061 Brunelli A, 2017, EUR J CARDIO-THORAC, V51, P490, DOI 10.1093/ejcts/ezw319 Brunelli A, 2014, ANN THORAC SURG, V98, P238, DOI 10.1016/j.athoracsur.2014.04.029 Brunelli A, 2013, CHEST, V143, pE166, DOI 10.1378/chest.12-2395 Brunelli A, 2012, ANN THORAC SURG, V93, P1802, DOI 10.1016/j.athoracsur.2012.03.022 Brunelli A, 2010, ANN THORAC SURG, V90, P199, DOI 10.1016/j.athoracsur.2010.03.042 Brunelli A, 2009, CHEST, V135, P1260, DOI 10.1378/chest.08-2059 Burke JR, 2003, ANN THORAC SURG, V76, P1767, DOI 10.1016/S0003-4975(03)00650-7 Burt BM, 2014, J THORAC CARDIOV SUR, V148, P19, DOI 10.1016/j.jtcvs.2014.03.007 Cagini L, 2014, EUR J CARDIO-THORAC, V46, pE74, DOI 10.1093/ejcts/ezu348 Carli F, 2010, BRIT J SURG, V97, P1187, DOI 10.1002/bjs.7102 Cavalheri V, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009955.pub3 Cavalheri V, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012020.pub2 Ceppa DP, 2012, ANN SURG, V256, P487, DOI 10.1097/SLA.0b013e318265819c Chesterfield-Thomas G, 2016, INTERACT CARDIOV TH, V23, P729, DOI 10.1093/icvts/ivw238 Chow WB, 2012, J AM COLL SURGEONS, V215, P453, DOI 10.1016/j.jamcollsurg.2012.06.017 Clark JM, 2019, ANN THORAC SURG, V108, P1006, DOI 10.1016/j.athoracsur.2019.04.057 Clegg A, 2013, LANCET, V381, P752, DOI 10.1016/S0140-6736(12)62167-9 Collum SD, 2017, CAN RESPIR J, V2017, DOI 10.1155/2017/1430350 Deljou A, 2020, J CARDIOTHOR VASC AN, V34, P1506, DOI 10.1053/j.jvca.2019.10.059 DeMeester SR, 1998, J THORAC CARDIOV SUR, V115, P681, DOI 10.1016/S0022-5223(98)70334-4 DeRose JJ, 1998, ANN THORAC SURG, V65, P314, DOI 10.1016/S0003-4975(97)01257-5 Donahoe L, 2017, ANN THORAC SURG, V104, P1179, DOI 10.1016/j.athoracsur.2017.05.024 Donahoe LL, 2017, ANN THORAC SURG, V103, P1730, DOI 10.1016/j.athoracsur.2016.11.076 Donington J, 2012, CHEST, V142, P1620, DOI 10.1378/chest.12-0790 Duceppe E, 2017, CAN J CARDIOL, V33, P17, DOI 10.1016/j.cjca.2016.09.008 Dunne MJ, 2014, INTERACT CARDIOV TH, V18, P667, DOI 10.1093/icvts/ivt542 Englesbe MJ, 2012, ANN SURG, V256, P255, DOI 10.1097/SLA.0b013e31826028b1 Falcoz PE, 2007, J THORAC CARDIOV SUR, V133, P325, DOI 10.1016/j.jtcvs.2006.09.020 Fennelly J, 2017, J THORAC DIS, V9, P789, DOI 10.21037/jtd.2017.03.22 Fernando HC, 2011, ANN THORAC SURG, V92, P1144, DOI 10.1016/j.athoracsur.2011.06.104 Fintelmann FJ, 2018, ANN THORAC SURG, V105, P1507, DOI 10.1016/j.athoracsur.2018.01.013 Fleisher LA, 2020, BRIT J ANAESTH, V125, P224, DOI 10.1016/j.bja.2020.05.053 Fleisher LA, 2014, J AM COLL CARDIOL, V64, pE77, DOI 10.1016/j.jacc.2014.07.944 Frendl G, 2014, J THORAC CARDIOV SUR, V148, P772, DOI 10.1016/j.jtcvs.2014.06.037 Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146 Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528 Galiè N, 2016, EUR HEART J, V37, P67, DOI 10.1093/eurheartj/ehv317 Galiè N, 2009, EUR HEART J, V30, P2493, DOI 10.1093/eurheartj/ehp297 GASS GD, 1986, CHEST, V89, P127, DOI 10.1378/chest.89.1.127 Ha D, 2016, J THORAC ONCOL, V11, P1397, DOI 10.1016/j.jtho.2016.04.021 Han BR, 2019, CLIN INTERV AGING, V14, P947, DOI 10.2147/CIA.S201062 Hanna K, 2019, CURR OPIN CRIT CARE, V25, P717, DOI 10.1097/MCC.0000000000000669 Hirpara DH, 2019, SUPPORT CARE CANCER, V27, P1535, DOI 10.1007/s00520-018-4547-9 Howington JA, 2012, CHEST, V141, P429, DOI 10.1378/chest.10-3013 Hu JJ, 2020, INT J MED ROBOT COMP, V16, DOI 10.1002/rcs.2123 JETTE M, 1990, CLIN CARDIOL, V13, P555, DOI 10.1002/clc.4960130809 Jiang G, 2019, CURRENT CHALLENGES T, V1, P1 Jones LW, 2007, CANCER-AM CANCER SOC, V110, P590, DOI 10.1002/cncr.22830 Jones LW, 2012, LUNG CANCER, V76, P248, DOI 10.1016/j.lungcan.2011.10.009 Jordan Simon, 2008, Thorac Surg Clin, V18, P61, DOI 10.1016/j.thorsurg.2007.11.003 Jung JJ, 2017, THORAC CANCER, V8, P33, DOI 10.1111/1759-7714.12406 Kadiri SB, 2019, J CARDIOTHORAC SURG, V14, DOI 10.1186/s13019-019-0951-6 Karenovics W, 2017, EUR J CARDIO-THORAC, V52, P47, DOI 10.1093/ejcts/ezx030 Keshava HB, 2015, THORAC SURG CLIN, V25, P371, DOI 10.1016/j.thorsurg.2015.07.001 Kim SH, 2019, J CLIN MED, V8, DOI 10.3390/jcm8050744 Kim SW, 2014, JAMA SURG, V149, P633, DOI 10.1001/jamasurg.2014.241 Kneuertz PJ, 2018, J CARDIOTHORAC SURG, V13, DOI 10.1186/s13019-018-0748-z Kolokotroni SM, 2017, INTERACT CARDIOV TH, V24, P783, DOI 10.1093/icvts/ivx007 Laurent H, 2020, EUR J PHYS REHAB MED, V56, P73, DOI 10.23736/S1973-9087.19.05781-2 Levett DZH, 2018, BRIT J ANAESTH, V120, P484, DOI 10.1016/j.bja.2017.10.020 Licker M, 2017, J THORAC ONCOL, V12, P323, DOI 10.1016/j.jtho.2016.09.125 Lim E, 2010, THORAX, V65, P1, DOI 10.1136/thx.2010.145938 Linden PA, 2005, CHEST, V127, P1984, DOI 10.1378/chest.127.6.1984 Liu CK, 2011, CLIN GERIATR MED, V27, P101, DOI 10.1016/j.cger.2010.08.001 Liu ZJ, 2020, ANESTH ANALG, V131, P840, DOI 10.1213/ANE.0000000000004342 Lloyd C, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2018-027262 Lung cancer, 2019, DIAGNOSIS MANAGEMENT Madariaga MLL, 2020, ANN THORAC SURG, V109, P907, DOI 10.1016/j.athoracsur.2019.10.041 Marengoni A, 2018, CHEST, V154, P21, DOI 10.1016/j.chest.2018.02.014 Marhic A, 2019, INTERACT CARDIOV TH, V28, P235, DOI 10.1093/icvts/ivy225 Marjanski T, 2019, INTERACT CARDIOV TH, V28, P368, DOI 10.1093/icvts/ivy258 McCall PJ, 2015, ANAESTHESIA, V70, P1382, DOI 10.1111/anae.13267 McCall PJ, 2019, J THORAC CARDIOV SUR, V158, P556, DOI 10.1016/j.jtcvs.2019.01.067 McIsaac DI, 2020, ANESTH ANALG, V131, P263, DOI 10.1213/ANE.0000000000004475 McIsaac DI, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022057 McKenna RJ, 1996, CHEST, V110, P885, DOI 10.1378/chest.110.4.885 Meyer S, 2013, EUR RESPIR J, V41, P1302, DOI 10.1183/09031936.00089212 Miller JA, 2018, J THORAC DIS, V10, P432, DOI 10.21037/jtd.2017.12.39 Mitnitski A B, 2001, ScientificWorldJournal, V1, P323 Morano MT, 2013, ARCH PHYS MED REHAB, V94, P53, DOI 10.1016/j.apmr.2012.08.206 Nathan SD, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.01914-2018 Nishigori T, 2016, J SURG ONCOL, V113, P678, DOI 10.1002/jso.24214 Nistor C, 2018, RIGHT HEART PATHOLOG Nojiri T, 2015, WORLD J SURG, V39, P1092, DOI 10.1007/s00268-015-2943-6 Nojiri T, 2011, ANN THORAC SURG, V92, P1051, DOI 10.1016/j.athoracsur.2011.03.085 Nojiri T, 2010, EUR J CARDIO-THORAC, V37, P787, DOI 10.1016/j.ejcts.2009.09.043 NOMORI H, 1994, CHEST, V105, P1782, DOI 10.1378/chest.105.6.1782 Norris CM, 2020, ANESTH ANALG, V130, P1524, DOI 10.1213/ANE.0000000000004785 Ohno Y, 2004, AM J ROENTGENOL, V182, P73, DOI 10.2214/ajr.182.1.1820073 Ohno Y, 2007, AM J ROENTGENOL, V189, P400, DOI 10.2214/AJR.07.2084 Okiror L, 2012, INTERACT CARDIOV TH, V14, P31, DOI 10.1093/icvts/ivr060 Older PO, 2017, ANN AM THORAC SOC, V14, pS74, DOI 10.1513/AnnalsATS.201610-780FR Omori T, 2015, ANN THORAC SURG, V100, P954, DOI 10.1016/j.athoracsur.2015.03.094 Oparka J, 2013, INTERACT CARDIOV TH, V17, P159, DOI 10.1093/icvts/ivt097 Otto JM, 2020, CURR ANESTHESIOL REP, V10, P1, DOI 10.1007/s40140-020-00373-x Papageorgiou CV, 2010, MULTIDISCIP RESP MED, V5, P188, DOI 10.1186/2049-6958-5-3-188 Patel NM, 2019, CHEST, V156, P826, DOI 10.1016/j.chest.2019.05.028 Paul S, 2010, J THORAC CARDIOV SUR, V139, P366, DOI 10.1016/j.jtcvs.2009.08.026 Pedoto A, 2009, CURR OPIN ANESTHESIO, V22, P50, DOI 10.1097/ACO.0b013e32831d7b25 Pieretti P, 2006, RESPIRATION, V73, P157, DOI 10.1159/000088096 Pilkington SA, 2015, ANAESTHESIA, V70, P56, DOI 10.1111/anae.12831 Pinheiro L, 2016, CAN RESPIR J, V2016, DOI 10.1155/2016/3981506 Pullamsetti SS, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai9048 Qadri SSA, 2014, EUR J CARDIO-THORAC, V45, P864, DOI 10.1093/ejcts/ezt517 Richardson K, 2017, BRIT J ANAESTH, V119, pI34, DOI 10.1093/bja/aex393 Riedel B, 2020, BRIT J ANAESTH Rockwood K, 2005, CAN MED ASSOC J, V173, P489, DOI 10.1503/cmaj.050051 Rockwood K, 2007, J GERONTOL A-BIOL, V62, P722, DOI 10.1093/gerona/62.7.722 Rodseth RN, 2014, J AM COLL CARDIOL, V63, P170, DOI 10.1016/j.jacc.2013.08.1630 Rol N, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00806-2017 Salati M, 2016, CURR SURG REP, V4, DOI 10.1007/s40137-016-0158-x Sanchez-Lorente D, 2018, J THORAC DIS, V10, pS2593, DOI 10.21037/jtd.2018.08.18 Sekine Y, 2012, EUR RESPIR J, V39, P1230, DOI 10.1183/09031936.00126011 Shahrokni A, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.3545 Shelley BG, 2019, ANAESTHESIA, V74, P1121, DOI 10.1111/anae.14649 Slinger P., 2019, Principles and Practice of Anesthesia for Thoracic Surgery Smith H, 2018, J THORAC DIS, V10, pS3799, DOI 10.21037/jtd.2018.09.144 Song SW, 2007, ANN THORAC SURG, V84, P1838, DOI 10.1016/j.athoracsur.2007.06.074 Spadaro S, 2019, ANESTHESIOLOGY, V131, P266, DOI 10.1097/ALN.0000000000002774 Spruit MA, 2013, AM J RESP CRIT CARE, V188, pE13, DOI 10.1164/rccm.201309-1634ST Subramaniam S, 2018, J AM COLL SURGEONS, V226, P173, DOI 10.1016/j.jamcollsurg.2017.11.005 Subramanyam P, 2018, INDIAN J NUCL MED, V33, P105, DOI 10.4103/ijnm.IJNM_149_17 Suzuki Y, 2016, LUNG CANCER, V101, P92, DOI 10.1016/j.lungcan.2016.08.007 Tarumi S, 2015, J THORAC CARDIOV SUR, V149, P569, DOI 10.1016/j.jtcvs.2014.09.123 Thomas DC, 2017, ANN THORAC SURG, V104, P389, DOI 10.1016/j.athoracsur.2017.02.006 Thuppal S, 2020, ANN THORAC SURG, V109, P902, DOI 10.1016/j.athoracsur.2019.09.023 Toufektzian L, 2015, INTERACT CARDIOV TH, V20, P654, DOI 10.1093/icvts/ivu454 Treanor C, 2018, J CANCER SURVIV, V12, P64, DOI 10.1007/s11764-017-0645-9 Tsiouris A, 2013, J SURG RES, V183, P40, DOI 10.1016/j.jss.2012.11.059 VanMieghem W, 1996, ANN THORAC SURG, V61, P1083, DOI 10.1016/0003-4975(96)00073-2 Varela G, 2006, EUR J CARDIO-THORAC, V30, P644, DOI 10.1016/j.ejcts.2006.07.001 Velanovich V, 2013, J SURG RES, V183, P104, DOI 10.1016/j.jss.2013.01.021 Waatevik M, 2016, EUR RESPIR J, V48, P82, DOI 10.1183/13993003.00975-2015 Wei B, 2014, EUR J CARDIO-THORAC, V45, P1028, DOI 10.1093/ejcts/ezt495 Wesolowski S, 2020, INTERACT CARDIOV TH, V30, P559, DOI 10.1093/icvts/ivz313 Wijeysundera DN, 2003, ANESTH ANALG, V97, P634, DOI 10.1213/01.ANE.0000081732.51871.D2 Wijeysundera DN, 2020, BRIT J ANAESTH, V124, P261, DOI 10.1016/j.bja.2019.11.025 Wijeysundera DN, 2018, LANCET, V391, P2631, DOI 10.1016/S0140-6736(18)31131-0 Wilson ME, 2016, J HEART LUNG TRANSPL, V35, P173, DOI 10.1016/j.healun.2015.10.014 Young DJ, 2019, INTERACT CARDIOV TH, V28, P945, DOI 10.1093/icvts/ivz016 Zhao BC, 2017, CHEST, V151, P149, DOI 10.1016/j.chest.2016.08.1476 NR 169 TC 10 Z9 16 U1 1 U2 10 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1053-0770 EI 1532-8422 J9 J CARDIOTHOR VASC AN JI J. Cardiothorac. Vasc. Anesth. PD DEC PY 2021 VL 35 IS 12 BP 3760 EP 3773 DI 10.1053/j.jvca.2020.11.025 EA NOV 2021 PG 14 WC Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease WE Science Citation Index Expanded (SCI-EXPANDED) SC Anesthesiology; Cardiovascular System & Cardiology; Respiratory System GA WY2OY UT WOS:000719123300043 PM 33454169 DA 2026-04-17 ER PT J AU Lee, H Lee, J Hwang, J Park, S Kim, N Kim, K Lee, H Shum, D Jang, S AF Lee, Hyunjung Lee, Jaehoan Hwang, Juchan Park, Sinyoung Kim, Namyoul Kim, Kideok Lee, Honggun Shum, David Jang, Soojin TI Repurposing Eltrombopag for Multidrug Resistant Staphylococcus aureus Infections SO ANTIBIOTICS-BASEL LA English DT Article DE Staphylococcus aureus; MRSA; drug repurposing; eltrombopag; in vivo efficacy ID CELL; CARRIAGE AB The continuous rise of antimicrobial resistance urgently demands new therapeutic agents for human health. Drug repurposing is an attractive strategy that could significantly save time delivering new antibiotics to clinics. We screened 182 US Food and Drug Administration (FDA)-approved drugs to identify potential antibiotic candidates against Staphylococcus aureus, a major pathogenic bacterium. This screening revealed the significant antibacterial activity of three small molecule drugs against S. aureus: (1) LDK378 (Ceritinib), an anaplastic lymphoma kinase (ALK) inhibitor for the treatment of lung cancer, (2) dronedarone HCl, an antiarrhythmic drug for the treatment of atrial fibrillation, and (3) eltrombopag, a thrombopoietin receptor agonist for the treatment of thrombocytopenia. Among these, eltrombopag showed the highest potency against not only a drug-sensitive S. aureus strain but also 55 clinical isolates including 35 methicillin-resistant S. aureus (Minimum inhibitory concentration, MIC, to inhibit 50% growth [MIC50] = 1.4-3.2 mg/L). Furthermore, we showed that eltrombopag inhibited bacterial growth in a cell infection model and reduced bacterial loads in infected mice, demonstrating its potential as a new antibiotic agent against S. aureus that can overcome current antibiotic resistance. C1 [Lee, Hyunjung; Lee, Jaehoan; Hwang, Juchan; Jang, Soojin] Inst Pasteur Korea, Antimicrobial Resistance Lab, Seongnam Si 13488, South Korea. [Park, Sinyoung] Inst Pasteur Korea, Anim Facil Team, Seongnam Si 13488, South Korea. [Kim, Namyoul; Kim, Kideok; Lee, Honggun; Shum, David] Inst Pasteur Korea, Screening Discovery Platform, Seongnam Si 13488, South Korea. C3 Institut Pasteur Korea; Institut Pasteur Korea; Institut Pasteur Korea RP Jang, S (corresponding author), Inst Pasteur Korea, Antimicrobial Resistance Lab, Seongnam Si 13488, South Korea. EM hyunjung.lee@ip-korea.org; Jellyfocus@outlook.com; juchan.hwang@ip-korea.org; psy6600@daum.net; skaduf@hanmail.net; kideok.kim@ip-korea.org; honggun.lee@ip-korea.org; david.shum@ip-korea.org; soojin.jang@ip-korea.org OI Rahman, Bushra/0009-0006-8241-5294; Lee, Hyunjung/0000-0003-4925-5867; Hwang, Juchan/0000-0002-3207-6769; Kim, Kideok/0000-0002-3706-8821 FU National Research Foundation of Korea (NRF); Korean government (MSIT) [NRF-2017M3A9G6068246, 2019M3E5D5064653] FX This research was funded by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (NRF-2017M3A9G6068246 & 2019M3E5D5064653). CR Acton DS, 2009, EUR J CLIN MICROBIOL, V28, P115, DOI 10.1007/s10096-008-0602-7 [Anonymous], 2012, METHODS DILUTION ANT, V9th Beyer P, 2020, B WORLD HEALTH ORGAN, V98, P151, DOI 10.2471/BLT.20.251751 Chang HC, 2016, J ANTIMICROB CHEMOTH, V71, P449, DOI 10.1093/jac/dkv367 Erickson-Miller CL, 2005, EXP HEMATOL, V33, P85, DOI 10.1016/j.exphem.2004.09.006 Ferruzza S, 2012, TOXICOL IN VITRO, V26, P1252, DOI 10.1016/j.tiv.2012.01.008 Ibberson CB, 2016, INFECT IMMUN, V84, P1917, DOI 10.1128/IAI.01418-15 Ittzes B, 2020, ACTA MICROBIOL IMM H, V67, P133, DOI 10.1556/030.2020.01144 Jeon S, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00819-20 Lane AB, 2018, CASE REP INFECT DIS, V2018, DOI 10.1155/2018/3106305 Le PL, 2020, NAT CHEM, V12, P145, DOI 10.1038/s41557-019-0378-7 Li S, 2015, CLIN LUNG CANCER, V16, P86, DOI 10.1016/j.cllc.2014.09.011 Linzner N, 2021, BIOL CHEM, V402, P333, DOI 10.1515/hsz-2020-0272 Mariadason JM, 2002, CANCER RES, V62, P4791 McGuinness WA, 2017, YALE J BIOL MED, V90, P269 Melander RJ, 2018, MEDCHEMCOMM, V9, P12, DOI [10.1039/C7MD00528H, 10.1039/c7md00528h] Gonzalez-Porras JR, 2018, THER ADV DRUG SAF, V9, P263, DOI 10.1177/2042098618769587 Ray AJ, 2003, CLIN INFECT DIS, V37, P875, DOI 10.1086/377451 Sakamoto JJ, 2001, J BIOL CHEM, V276, P47046, DOI 10.1074/jbc.M106205200 Sambuy Y, 2005, CELL BIOL TOXICOL, V21, P1, DOI 10.1007/s10565-005-0085-6 Squier C, 2002, INFECT CONT HOSP EP, V23, P495, DOI 10.1086/502095 Thakare R, 2017, INT J ANTIMICROB AG, V50, P389, DOI 10.1016/j.ijantimicag.2017.03.020 Vollmer W, 2008, FEMS MICROBIOL REV, V32, P259, DOI 10.1111/j.1574-6976.2007.00099.x NR 23 TC 10 Z9 12 U1 4 U2 12 PU MDPI PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND SN 2079-6382 J9 ANTIBIOTICS-BASEL JI Antibiotics-Basel PD NOV PY 2021 VL 10 IS 11 AR 1372 DI 10.3390/antibiotics10111372 PG 14 WC Infectious Diseases; Pharmacology & Pharmacy WE Science Citation Index Expanded (SCI-EXPANDED) SC Infectious Diseases; Pharmacology & Pharmacy GA XK6VP UT WOS:000727601000001 PM 34827309 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Peer, M Azzam, S Cyjon, A Katsnelson, R Hayat, H Bar, I Merimsky, O AF Peer, Michael Azzam, Sharbel Cyjon, Arnold Katsnelson, Rivka Hayat, Henri Bar, Ilan Merimsky, Ofer TI Major pulmonary resection after neoadjuvant chemotherapy or chemoradiation in potentially resectable stage III non-small cell lung carcinoma SO SCIENTIFIC REPORTS LA English DT Article ID INDUCTION CHEMOTHERAPY; SURGICAL RESECTION; N2 DISEASE; CANCER; PNEUMONECTOMY; MORTALITY; RADIOTHERAPY; THERAPY; MORBIDITY; SURGERY AB The aim of this study was to identify predictors of postoperative outcome and survival of locally advanced non-small cell lung carcinoma (NSCLC) resections after neoadjuvant chemotherapy or chemoradiation. Medical records of all patients with clinical stage III potentially resectable NSCLC initially treated by neoadjuvant chemotherapy or chemoradiation followed by major pulmonary resections were retrieved from the databases of four Israeli Medical Centers between 1999 to 2019. The 124 suitable patients included, 86 males (69.4%) and 38 females (30.6%), with an average age of 64.2 years (range 37-82) and an average hospital stay of 12.6 days (range 5-123). Complete resection was achieved in 92.7% of the patients, while complete pathologic response was achieved in 35.5%. The overall readmission rate was 16.1%. The overall 5-year survival rate was 47.9%. One patient (0.8%) had local recurrence. Postoperative complications were reported in 49.2% of the patients, mainly atrial fibrillation (15.9%) and pneumonia (13.7%), empyema (10.3%), and early bronchopleural fistula (7.3%). The early in-hospital mortality rate was 6.5%, and the 6-month mortality rate was 5.6%. Pre-neoadjuvant bulky mediastinal disease (lymph nodes > 20 mm) (p = 0.034), persistent postoperative N2 disease (p = 0.016), R1 resection (p = 0.027), preoperative N2 multistation disease (p = 0.053) and postoperative stage IIIA (p = 0.001) emerged as negative predictive factors for survival. Our findings demonstrate that neoadjuvant chemotherapy or chemoradiation in locally advanced potentially resectable NSCLC, followed by major pulmonary resection, is a beneficial approach in selected cases. C1 [Peer, Michael; Azzam, Sharbel] Tel Aviv Univ, Tel Aviv Med Ctr, Affiliated Sackler Sch Med, Dept Thorac Surg, Tel Aviv, Israel. [Cyjon, Arnold] Tel Aviv Univ, Shamir Med Ctr, Sackler Sch Med, Dept Oncol, Tel Aviv, Israel. [Katsnelson, Rivka] Kaplan Med Ctr, Dept Oncol, Rehovot, Israel. [Katsnelson, Rivka; Bar, Ilan] Hebrew Univ Jerusalem, Med Sch, Jerusalem, Israel. [Hayat, Henri] Tel Aviv Univ, Wolfson Med Ctr, Sackler Sch Med, Dept Oncol, Tel Aviv, Israel. [Bar, Ilan] Kaplan Med Ctr, Dept Thorac Surg, Rehovot, Israel. [Merimsky, Ofer] Tel Aviv Med Ctr & Sch Med, Sackler Sch Med, Dept Oncol, Tel Aviv, Israel. C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Shamir Medical Center (Assaf Harofeh); Hebrew University of Jerusalem; Kaplan Medical Center; Hebrew University of Jerusalem; Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem; Kaplan Medical Center; Tel Aviv University; Sackler Faculty of Medicine RP Peer, M (corresponding author), Tel Aviv Univ, Tel Aviv Med Ctr, Affiliated Sackler Sch Med, Dept Thorac Surg, Tel Aviv, Israel. EM michaelpe@tlvmc.gov.il CR Albain KS, 2009, LANCET, V374, P379, DOI 10.1016/S0140-6736(09)60737-6 Andre F, 2000, J CLIN ONCOL, V18, P2981, DOI 10.1200/JCO.2000.18.16.2981 [Anonymous], 2009, SABISTON SPENCER SUR Antonia SJ, 2017, NEW ENGL J MED, V377, P1919, DOI 10.1056/NEJMoa1709937 Brambilla E, 2001, EUR RESPIR J, V18, P1059, DOI 10.1183/09031936.01.00275301 Cerfolio RJ, 2008, ANN THORAC SURG, V86, P912, DOI 10.1016/j.athoracsur.2008.04.073 d'Amato TA, 2009, ANN THORAC SURG, V88, P1079, DOI 10.1016/j.athoracsur.2009.06.025 Detterbeck FC, 2009, CHEST, V136, P260, DOI 10.1378/chest.08-0978 Fruchter O, 2011, CHEST, V139, P682, DOI 10.1378/chest.10-1528 Früh M, 2019, J THORAC ONCOL, V14, P115, DOI 10.1016/j.jtho.2018.09.011 Gudbjartsson T, 2008, ANN THORAC SURG, V86, P376, DOI 10.1016/j.athoracsur.2008.04.013 Huber RM, 2019, EUR RESPIR REV, V28, DOI 10.1183/16000617.0024-2019 Kappers I, 2010, LUNG CANCER, V68, P222, DOI 10.1016/j.lungcan.2009.07.001 Kim AW, 2012, J THORAC CARDIOV SUR, V143, P55, DOI 10.1016/j.jtcvs.2011.09.002 Kim HK, 2016, LUNG CANCER, V96, P56, DOI 10.1016/j.lungcan.2016.03.016 Koshy M, 2013, J THORAC ONCOL, V8, P915, DOI 10.1097/JTO.0b013e31828f68b4 Lardinois D, 2006, EUR J CARDIO-THORAC, V30, P787, DOI 10.1016/j.ejcts.2006.08.008 Licker M, 2002, CHEST, V121, P1890, DOI 10.1378/chest.121.6.1890 Mansour Z, 2007, EUR J CARDIO-THORAC, V31, P181, DOI 10.1016/j.ejcts.2006.11.008 Martin J, 2001, ANN THORAC SURG, V72, P1149, DOI 10.1016/S0003-4975(01)02995-2 McElnay PJ, 2015, THORAX, V70, P764, DOI 10.1136/thoraxjnl-2014-206292 Peer M, 2015, HEART LUNG CIRC, V24, P69, DOI 10.1016/j.hlc.2014.07.055 Pless M, 2015, LANCET, V386, P1049, DOI 10.1016/S0140-6736(15)60294-X Pöttgen C, 2017, ONCOTARGET, V8, P41670, DOI 10.18632/oncotarget.16471 Refai M, 2010, EUR J CARDIO-THORAC, V37, P535, DOI 10.1016/j.ejcts.2009.09.018 Rigas JR, 2007, J THORAC ONCOL, V2, pS77, DOI 10.1097/01.JTO.0000269735.21209.bc Ripley RT, 2013, THORAC SURG CLIN, V23, P273, DOI 10.1016/j.thorsurg.2013.04.004 Robinson LA, 2007, CHEST, V132, p243S, DOI 10.1378/chest.07-1379 Rothschild SI., 2021, J CLIN ONCOL, V2, P2 Sonett JR, 2004, ANN THORAC SURG, V78, P1200, DOI 10.1016/j.athoracsur.2004.04.085 Spicer J., 2021, J CLIN ONCOL, V2, P2 Thomas PA, 2015, J THORAC CARDIOV SUR, V149, P73, DOI 10.1016/j.jtcvs.2014.09.063 van Meerbeeck JP, 2007, JNCI-J NATL CANCER I, V99, P442, DOI 10.1093/jnci/djk093 Van Schil P, 2005, EUR RESPIR J, V26, P192, DOI 10.1183/09031936.05.00127204 Weder W, 2010, J THORAC CARDIOV SUR, V139, P1424, DOI 10.1016/j.jtcvs.2010.02.039 Wu YL, 2020, NEW ENGL J MED, V383, P1711, DOI 10.1056/NEJMoa2027071 NR 36 TC 4 Z9 6 U1 0 U2 1 PU NATURE PORTFOLIO PI BERLIN PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD OCT 12 PY 2021 VL 11 IS 1 AR 20232 DI 10.1038/s41598-021-99271-3 PG 11 WC Multidisciplinary Sciences WE Science Citation Index Expanded (SCI-EXPANDED) SC Science & Technology - Other Topics GA WG2MF UT WOS:000706830500041 PM 34642407 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Rosas, D Raez, LE Russo, A Rolfo, C AF Rosas, Daniel Raez, Luis E. Russo, Alessandro Rolfo, Christian TI Neuregulin 1 Gene (NRG1). A Potentially New Targetable Alteration for the Treatment of Lung Cancer SO CANCERS LA English DT Review DE NRG1 fusion; lung cancer; resistance to therapy; target therapy ID NRG1 GENE; BREAST-CANCER; FUSION; HER3; ADENOCARCINOMA; REARRANGEMENTS AB Simple Summary: Treatment in oncology has and will keep evolving into an agnostic approach where therapies are guided more towards the identification and targeting of genetic abnormalities and less by organ of origin of the cancer, as has been done for decades. With every genetic abnormality being identified as a target, the pharmaceutical development of medications targeting these genes has grown, leading to better survival rates, quality of life and a bigger interest in finding new targets. Lung cancer is one of the best examples where targetable genetic abnormalities have led to substantial survival differences compared to patients undergoing empirical conventional chemotherapy. Translocations in the neuregulin 1 gene (NRG1) are one of many gene fusions that are becoming clinically significant, and it has the potential to become a targetable gene with ongoing clinical trials already in Europe and the US. This review aims to portray the importance and latest developments regarding this new fusion in lung cancer treatment. Oncogenic gene fusions are hybrid genes that result from structural DNA rearrangements, leading to unregulated cell proliferation by different mechanisms in a wide variety of cancer. This has led to the development of directed therapies to antagonize a variety of mechanisms that lead to cell growth or proliferation. Multiple oncogene fusions are currently targeted in lung cancer treatment, such as those involving ALK, RET, NTRK and ROS1 among many others. Neuregulin (NRG) gene fusion has been described in the development of normal tissue as well as in a variety of diseases, such as schizophrenia, Hirschsprung's disease, atrial fibrillation and, most recently, the development of various types of solid tumors, such as renal, gastric, pancreatic, breast, colorectal and, more recently, lung cancer. The mechanism for this is that the NRG1 chimeric ligand leads to aberrant activation of ERBB2 signaling via PI3K-AKT and MAPK cellular cascades, leading to cell division and proliferation. Details regarding the incidence of these gene rearrangements are lacking. Limited case reports and case series have evaluated their clinicopathologic features and prognostic significance in the lung cancer population. Taking this into account, NRG1 could become a targetable alteration in selected patients. This review highlights how the knowledge of new molecular mechanisms of NRG1 fusion may help in gaining new insights into the molecular status of lung cancer patients and unveil a novel targetable molecular marker. C1 [Rosas, Daniel] Univ Texas Hlth Sci Ctr San Antonio, Dept Internal Med, San Antonio, TX 78229 USA. [Raez, Luis E.] Florida Int Univ FIU, Thorac Oncol Program, Mem Canc Inst, Mem Hlth Care Syst, Miami, FL 33021 USA. [Russo, Alessandro] AO Papardo, Med Oncol Unit, I-981258 Messina, Italy. [Rolfo, Christian] Mt Sinai Hlth Syst, Clin Res & Ctr Thorac Oncol, Tisch Canc Inst, New York, NY 10029 USA. [Rolfo, Christian] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. C3 University of Texas System; University of Texas at San Antonio; State University System of Florida; Florida International University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai RP Rosas, D (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Internal Med, San Antonio, TX 78229 USA. EM rosasd1@uthscsa.edu; lraez@mhs.net; alessandrorusso@aopapardo.it; christian.rolfo@mssm.edu RI raez, luis/AAL-8829-2020; Russo, Alessandro/P-9929-2019 OI raez, luis/0000-0003-2669-5771; Rosas, Daniel/0000-0001-8909-5760; Russo, Alessandro/0000-0002-3365-1972 CR Billingsley K. Lloyd, 2017, The Daily Caller Cadranel J, 2021, ONCOLOGIST, V26, P7, DOI 10.1634/theoncologist.2020-0379 Dimou A, 2019, CLIN CANCER RES, V25, P4865, DOI 10.1158/1078-0432.CCR-19-1219 Drilon A, 2021, J CLIN ONCOL, V39, P2791, DOI 10.1200/JCO.20.03307 Drilon A, 2018, CANCER DISCOV, V8, P686, DOI 10.1158/2159-8290.CD-17-1004 Dronyk I., 2017, J East Eur sci res (Bratisl), V19, P42 Dugaucquier L, 2020, AM J PHYSIOL-HEART C, V319, pH443, DOI 10.1152/ajpheart.00176.2020 Duruisseaux M, 2016, CANCER MED-US, V5, P3579, DOI 10.1002/cam4.838 Elevation Oncology, 2021, CRESTONE PHAS 2 STUD Fernandez-Cuesta L, 2015, CLIN CANCER RES, V21, P1989, DOI 10.1158/1078-0432.CCR-14-0854 Fernandez-Cuesta L, 2014, CANCER DISCOV, V4, P415, DOI 10.1158/2159-8290.CD-13-0633 German Cancer Research Center, AF ADV NRG1 REARR MA Gunadi, 2018, BMC PEDIATR, V18, DOI 10.1186/s12887-018-1265-x Halama N, 2020, SEMIN NUCL MED, V50, P389, DOI 10.1053/j.semnuclmed.2020.06.003 Hegde GV, 2019, ELIFE, V8, DOI 10.7554/eLife.46551 Hegde GV, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004438 Howarth KD, 2021, BREAST CANCER RES, V23, DOI 10.1186/s13058-020-01377-5 Jones MR, 2017, ANN ONCOL, V28, P3092, DOI 10.1093/annonc/mdx523 Jones MR, 2019, CLIN CANCER RES, V25, P4674, DOI 10.1158/1078-0432.CCR-19-0191 Jonna S, 2019, CLIN CANCER RES, V25, P4966, DOI 10.1158/1078-0432.CCR-19-0160 Kim HS, 2018, LUNG CANCER, V124, P71, DOI 10.1016/j.lungcan.2018.07.026 Laskin J, 2020, ANN ONCOL, V31, P1693, DOI 10.1016/j.annonc.2020.08.2335 Merus N.V., 2021, PHASE 1 3 STUDY MCLA Mouton-Liger F, 2020, ALZHEIMERS RES THER, V12, DOI 10.1186/s13195-020-00655-w Munafò MR, 2006, MOL PSYCHIATR, V11, P539, DOI 10.1038/sj.mp.4001817 Muscarella LA, 2017, LUNG CANCER MANAG, V6, P121, DOI 10.2217/lmt-2017-0018 Muscarella Lucia Anna, 2017, J Thorac Oncol, V12, pe161, DOI [10.1016/j.jtho.2017.05.014, 10.1016/j.jtho.2017.05.014] Navarro-González C, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3930186 Ottawa Hospital Research Institute, 2021, SINGL PAT PROT NRG1 Pan B, 2015, ONCOTARGETS THER, V8, P1185, DOI 10.2147/OTT.S78116 Prentice LM, 2005, ONCOGENE, V24, P7281, DOI 10.1038/sj.onc.1208892 Rain Therapeutics Inc, 2020, PHAS 2 STUD EV CLIN Rajasekaran A, 2020, ASIAN J PSYCHIATR, V54, DOI 10.1016/j.ajp.2020.102363 Schram AM, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.3003 Shin DH, 2018, MOL CANCER THER, V17, P2024, DOI 10.1158/1535-7163.MCT-17-1178 Shin DH, 2016, ONCOTARGET, V7, P69450, DOI 10.18632/oncotarget.11913 Shun L., 2021, OPEN LABELED SINGLE Trombetta D, 2017, CURR MED CHEM, V24, P4213, DOI 10.2174/0929867324666170911170554 Wang YY, 2018, J THORAC DIS, V10, P3166, DOI 10.21037/jtd.2018.05.175 Xia D, 2017, INT J SURG PATHOL, V25, P238, DOI 10.1177/1066896917693092 Yang LT, 2017, INT J ONCOL, V51, P1553, DOI 10.3892/ijo.2017.4130 Yun S, 2018, GASTRIC CANCER, V21, P225, DOI 10.1007/s10120-017-0732-7 Zensun Sci. Tech. Co. Ltd., 2021, MULTICENTER RANDOMIZ Zhang TT, 2018, INT J ONCOL, V53, P685, DOI 10.3892/ijo.2018.4426 Zhou XY, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01082 NR 45 TC 30 Z9 33 U1 0 U2 11 PU MDPI PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND EI 2072-6694 J9 CANCERS JI Cancers PD OCT PY 2021 VL 13 IS 20 AR 5038 DI 10.3390/cancers13205038 PG 9 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA WQ7NY UT WOS:000714000600001 PM 34680187 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Benker, M Citak, N Neuer, T Opitz, I Inci, I AF Benker, Martina Citak, Necati Neuer, Thomas Opitz, Isabelle Inci, Ilhan TI Impact of preoperative comorbidities on postoperative complication rate and outcome in surgically resected non-small cell lung cancer patients SO GENERAL THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article DE NSCLC; Lung resection; Comorbidity; Complication ID FEMALES LIVE LONGER; BODY-MASS INDEX; ATRIAL-FIBRILLATION; RISK-FACTORS; ASSOCIATION; MANAGEMENT; DIAGNOSIS; MORTALITY; SURVIVAL AB Objective This study aimed to analyze whether comorbidities impact postoperative complication rate or survival after anatomical lung resection for non-small cell lung cancer (NSCLC). Methods A retrospective analysis of 1219 patients who underwent NSCLC resection between 2000 and 2015 was performed. Analyzed comorbidities included chronic obstructive lung disease (COPD), hypertension, coronary artery disease (CAD), peripheral artery disease, myocardial infarction history, diabetes mellitus, renal insufficiency and other malignancies. Results Most patients (78.9%) had comorbidities, most commonly hypertension (34.1%) followed by COPD (26.4%) and other malignancies (19%). The overall complication rate was 38.6% (26.4% pulmonary; 14.8% cardiac; and 3.0% gastrointestinal). Hypertension (odds ratio (OR) = 1.492, p = 0.031) was associated with more cardiac complications. Heavy smoking (OR = 1.008, p = 0.003) and low body mass index (BMI) (OR = 0.932, p < 0.001) affected the pulmonary complication rate significantly. None of the included comorbidities affected the overall complication rate or the survival negatively. However, the patient characteristics of advanced age (p < 0.001), low BMI (p = 0.008), and low FEV1 (p = 0.008) affected the overall complication rate as well as survival (each p < 0.001). Conclusion Advanced age, low BMI, and low FEV1 were predictive of greater complication risk and shorter long-term survival in patients who underwent NSCLC resection. Cardiac complications were associated with hypertension and CAD, whereas pulmonary complications were associated with a high pack year count. C1 [Benker, Martina; Citak, Necati; Neuer, Thomas; Opitz, Isabelle; Inci, Ilhan] Zurich Univ Hosp, Dept Thorac Surg, Raemistr 100, CH-8091 Zurich, Switzerland. C3 University of Zurich; University Zurich Hospital RP Inci, I (corresponding author), Zurich Univ Hosp, Dept Thorac Surg, Raemistr 100, CH-8091 Zurich, Switzerland. EM ilhan.inci@usz.ch RI Çitak, Necati/AAE-2169-2020; Inci, Ilhan/GYA-4402-2022 FU Universitat Zurich FX Open Access funding provided by Universitat Zurich. CR Afzal MR, 2019, HEART FAIL CLIN, V15, P543, DOI 10.1016/j.hfc.2019.06.011 Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S Battafarano RJ, 2002, J THORAC CARDIOV SUR, V123, P280, DOI 10.1067/mtc.2002.119338 Benattia A, 2016, J THORAC DIS, V8, DOI 10.21037/jtd.2016.04.38 Blanco R, 2015, ANN ONCOL, V26, P451, DOI 10.1093/annonc/mdu268 Brunelli A, 2013, CHEST, V143, pE166, DOI 10.1378/chest.12-2395 Dogru MV, 2021, ACTA CHIR BELG, V121, P301, DOI 10.1080/00015458.2020.1753147 Ferguson MK, 2014, EUR J CARDIO-THORAC, V45, pE94, DOI 10.1093/ejcts/ezu008 Hollings DD, 2010, AM J SURG, V199, P558, DOI 10.1016/j.amjsurg.2009.11.006 Husain ZA, 2015, CLIN LUNG CANCER, V16, pE183, DOI 10.1016/j.cllc.2015.04.007 Im Y, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1087-x Iwata T, 2016, SURG TODAY, V46, P877, DOI 10.1007/s00595-015-1258-4 Jacobs JP, 2006, ANN THORAC SURG, V81, P1937, DOI 10.1016/j.athoracsur.2005.11.063 Krebsliga, 2020, KREBS SCHW WICHT ZAH Lalley PM, 2013, RESP PHYSIOL NEUROBI, V187, P199, DOI 10.1016/j.resp.2013.03.012 Leduc C, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01721-2016 Lembicz M, 2018, ANN THORAC MED, V13, P101, DOI 10.4103/atm.ATM_274_17 Lowery EM, 2013, CLIN INTERV AGING, V8, P1489, DOI 10.2147/CIA.S51152 NICER National institute for cancer epidemiology and registration, CANC PREV SWITZ 2005 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669 Roth Kjetil, 2008, BMC Pulm Med, V8, P22, DOI 10.1186/1471-2466-8-22 Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287 Takada K, 2019, ANTICANCER RES, V39, P1987, DOI 10.21873/anticanres.13309 Viña J, 2005, FEBS LETT, V579, P2541, DOI 10.1016/j.febslet.2005.03.090 Viña J, 2003, ANTIOXID REDOX SIGN, V5, P549, DOI 10.1089/152308603770310194 Vogelmeier CF, 2017, EUR RESPIR J, V49, DOI [10.1183/13993003.00214-2017, 10.1111/resp.13012, 10.1164/rccm.201701-0218PP, 10.1016/j.arbres.2017.02.001] Xavier RF, 2013, RESPIRATION, V86, P479, DOI 10.1159/000348398 Zhai RH, 2014, CHEST, V145, P346, DOI 10.1378/chest.13-1176 NR 29 TC 29 Z9 32 U1 0 U2 5 PU SPRINGER JAPAN KK PI TOKYO PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005, JAPAN SN 1863-6705 EI 1863-6713 J9 GEN THORAC CARDIOVAS JI Gen. Thorac. Cardiovasc. Surg. PD MAR PY 2022 VL 70 IS 3 BP 248 EP 256 DI 10.1007/s11748-021-01710-5 EA SEP 2021 PG 9 WC Cardiac & Cardiovascular Systems; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Surgery GA ZI1MI UT WOS:000700512500001 PM 34554366 OA Green Submitted, Green Published, hybrid DA 2026-04-17 ER PT J AU Matetic, A Mohamed, M Miller, RJH Kolman, L Lopez-Mattei, J Cheung, WY Brenner, DR Spall, HGCV Graham, M Bianco, C Mamas, MA AF Matetic, Andrija Mohamed, Mohamed Miller, Robert J. H. Kolman, Louis Lopez-Mattei, Juan Cheung, Winson Y. Brenner, Darren R. Spall, Harriette G. C. Van Graham, Michelle Bianco, Christopher Mamas, Mamas A. TI Impact of cancer diagnosis on causes and outcomes of 5.9 million US patients with cardiovascular admissions SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Article DE Cancer; Cardiovascular admission cause; In-hospital outcomes ID ATRIAL-FIBRILLATION; RISK-FACTORS; HEART-FAILURE; DISEASE; SURVIVORS; THROMBOEMBOLISM; INSIGHTS; STROKE AB Introduction: There are limited data on causes of cardiovascular (CV) admissions and associated outcomes among patients with different cancers. Methods: All CV admissions from the US National Inpatient Sample between October 2015 to December 2017 were stratified by cancer type as well as metastatic status. Multivariable logistic regression was performed to determine the adjusted odds ratios (aOR) of in-hospital mortality in different groups. Results: From 5,936,014 eligible CV admissions, cancer was present in 265,221 (4.5%) hospitalizations. There was significant variation in the admission diagnoses among the different cancers, with hematological malignancies being principally associated with heart failure (HF), lung cancer with atrial fibrillation (AF), and colorectal and prostate cancer with acute myocardial infarction (AMI). Admission with haemorrhagic stroke has the highest associated mortality across cancers (20.0-38.4%). In-hospital mortality was higher in cancer than noncancer patients across most CV admissions (P < 0.001) with AF having the worst prognosis. Compared to group without any cancer, the greatest aOR of mortality was associated with lung cancer in AMI (aOR 2.32, 95% CI 2.18-2.47), ischemic stroke (aOR 2.21, 95%CI 2.08-2.34), AF (aOR 4.69, 95%CI 4.32-5.10) and HF (aOR 2.07, 95%CI 1.89-2.27). Conclusions: The most common causes of CV admission to hospital vary in patients with different types of cancer, with AMI being most common in patients with colon cancer, HF in patients with hematological malignancies and AF in patients with lung cancer. Patients with cancer, particularly lung cancer, have greater mortality than noncancer patients after admissions with a CV cause. C1 [Matetic, Andrija] Keele Univ, Keele Cardiovasc Res Grp, Stoke On Trent, Staffs, England. [Miller, Robert J. H.; Kolman, Louis] Univ Hosp Split, Dept Cardiol, Split, Croatia. [Lopez-Mattei, Juan] Univ Calgary, Dept Cardiac Sci, Calgary, AB, Canada. [Cheung, Winson Y.] Univ Texas MD Anderson Canc Ctr, Dept Cardiol, Div Internal Med, Houston, TX USA. [Brenner, Darren R.] Univ Calgary, Dept Med & Oncol, Calgary, AB, Canada. [Spall, Harriette G. C. Van] Univ Calgary, Dept Oncol, Calgary, AB, Canada. [Graham, Michelle] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Div Cardiol, Hamilton, ON, Canada. [Bianco, Christopher] Univ Alberta, Div Cardiol, Edmonton, AB, Canada. [Mamas, Mamas A.] West Virginia Univ Sch Med, Div Cardiol, Morgantown, WV USA. Thomas Jefferson Univ, Dept Cardiol, Amman, PA USA. [Mamas, Mamas A.] Keele Univ, Inst Primary Care & Hlth Sci, Ctr Prognosis Res, Cardiol Keele Cardiovasc Res Grp, Keele, Staffs, England. C3 Keele University; University of Split; University of Calgary; University of Texas System; UTMD Anderson Cancer Center; University of Calgary; University of Calgary; McMaster University; University of Alberta; Thomas Jefferson University; Keele University RP Mamas, MA (corresponding author), Keele Univ, Inst Primary Care & Hlth Sci, Ctr Prognosis Res, Cardiol Keele Cardiovasc Res Grp, Keele, Staffs, England. EM mamasmamas1@yahoo.co.uk RI Mamas, Mamas/A-2549-2019; Miller, Robert/AAR-4196-2021; Lopez-Mattei, Juan/N-4695-2018; Matetic, Andrija/AAK-2351-2020; Mohamed, Mohamed O/S-9668-2017 OI Mamas, Mamas/0000-0001-9241-8890; Van Spall, Harriette Gillian Christine/0000-0002-8370-4569; Miller, Robert/0000-0003-4676-2433; Bianco, Christopher/0000-0001-9677-8180; Mohamed, Mohamed O/0000-0002-9678-5222 CR Agarwal MA, 2018, EUR HEART J-QUAL CAR, V4, P69, DOI 10.1093/ehjqcco/qcx033 Al-Hawwas M, 2018, CURR ONCOL REP, V20, DOI 10.1007/s11912-018-0724-8 Amini M, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10429-0 [Anonymous], 2020, J AM COLL CARDIOL Armenian SH, 2012, BLOOD, V120, P4505, DOI 10.1182/blood-2012-06-437178 Armstrong GT, 2013, J CLIN ONCOL, V31, P3673, DOI 10.1200/JCO.2013.49.3205 Balla S, 2021, CARDIOVASC REVASC ME, V7 Bandyopadhyay D, 2019, IJC HEART VASC, V22, P216, DOI 10.1016/j.ijcha.2019.02.012 Blaes AH, 2019, LANCET, V394, P986, DOI 10.1016/S0140-6736(19)31886-0 Cutting S, 2017, J STROKE CEREBROVASC, V26, P809, DOI 10.1016/j.jstrokecerebrovasdis.2016.10.021 D'Souza M, 2018, EUR J PREV CARDIOL, V25, P651, DOI 10.1177/2047487318759858 Farmakis D, 2014, J AM COLL CARDIOL, V63, P945, DOI 10.1016/j.jacc.2013.11.026 Garatti A, 2020, EUR J CARDIO-THORAC, V58, P528, DOI 10.1093/ejcts/ezaa114 Getz KD, 2019, J CLIN ONCOL, V37, P12, DOI 10.1200/JCO.18.00313 Grymonprez M, 2019, INT J CARDIOL, V276, P118, DOI 10.1016/j.ijcard.2018.09.056 Guha A, 2020, MAYO CLIN PROC, V95, P1865, DOI 10.1016/j.mayocp.2020.05.044 Guha A, 2019, ESC HEART FAIL, V6, P733, DOI 10.1002/ehf2.12450 Gutierrez A, 2019, THER ADV CARDIO DIS, V13, DOI 10.1177/1753944719860676 HCUP National Inpatient Sample (NIS), 2012, Healthcare Cost and Utilization Project (HCUP) Huang S, 2020, AM J TRANSL RES, V12, P4795 Iannaccone M, 2018, EUR HEART J-ACUTE CA, V7, P631, DOI 10.1177/2048872617706501 Jakobsen CB, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6314-9 Kenigsberg B, 2018, JACC-HEART FAIL, V6, P87, DOI 10.1016/j.jchf.2017.08.024 Koene RJ, 2016, CIRCULATION, V133, P1104, DOI 10.1161/CIRCULATIONAHA.115.020406 Libby P, 2019, J AM COLL CARDIOL, V74, P567, DOI 10.1016/j.jacc.2019.06.007 Maisel WH, 2003, AM J CARDIOL, V91, p2D, DOI 10.1016/S0002-9149(02)03373-8 Navi BB, 2017, J AM COLL CARDIOL, V70, P927, DOI 10.1016/j.jacc.2017.06.047 Owusu-Guha J, 2021, INT J STROKE, V16, P150, DOI 10.1177/1747493019895709 Potts JE, 2019, EUR HEART J, V40, P1790, DOI 10.1093/eurheartj/ehy769 Rohrmann S, 2018, EUR HEART J-ACUTE CA, V7, P639, DOI 10.1177/2048872617729636 Ruddy KJ, 2020, CIRC-CARDIOVASC QUAL, V13, DOI 10.1161/CIRCOUTCOMES.119.005984 Siegel R.L., CA-CANCER J CLIN, V2020, P7, DOI [10.3322/caac.21590, DOI 10.3322/CAAC.21590] Strongman H, 2019, LANCET, V394, P1041, DOI 10.1016/S0140-6736(19)31674-5 Swain SM, 2003, CANCER, V97, P2869, DOI 10.1002/cncr.11407 Totzeck M, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.006278 Wanamaker B, 2018, ARRHYTH ELECTROPHYSI, V7, P43, DOI 10.15420/aer.2018.3.2 Yang XY, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01058 Yeh ETH, 2009, J AM COLL CARDIOL, V53, P2231, DOI 10.1016/j.jacc.2009.02.050 Yoo J, 2019, STROKE, V50, P507, DOI 10.1161/STROKEAHA.118.023044 Zamorano JL, 2016, EUR HEART J, V37, P2768, DOI [10.1093/eurheartj/ehw211, 10.1002/ejhf.654] Zaorsky NG, 2017, ANN ONCOL, V28, P400, DOI 10.1093/annonc/mdw604 Zaorsky NG, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13120-6 Zarifa A, 2019, CURR OPIN CARDIOL, V34, P441, DOI 10.1097/HCO.0000000000000641 Zöller B, 2012, EUR J CANCER, V48, P121, DOI 10.1016/j.ejca.2011.09.015 NR 44 TC 26 Z9 27 U1 0 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 EI 1874-1754 J9 INT J CARDIOL JI Int. J. Cardiol. PD OCT 15 PY 2021 VL 341 BP 76 EP 83 DI 10.1016/j.ijcard.2021.07.054 EA SEP 2021 PG 8 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA XD7PU UT WOS:000722897300016 PM 34333019 OA Green Submitted DA 2026-04-17 ER PT J AU Yang, N He, XY Bai, QZ Cui, BQ Gou, YJ AF Yang, Ning He, Xiaoyang Bai, Qizhou Cui, Baiqiang Gou, Yunjiu TI Analysis of the short-term outcomes of biportal robot-assisted lobectomy SO INTERNATIONAL JOURNAL OF MEDICAL ROBOTICS AND COMPUTER ASSISTED SURGERY LA English DT Review DE biportal; lobectomy; lymph node dissection; robot-assisted system ID CELL LUNG-CANCER; THORACOSCOPIC SURGERY; THORACIC-SURGERY; RESECTION; THORACOTOMY; EXPERIENCE AB Background The present study aimed to assess the short-term consequences of biportal robot-assisted lobectomy, validating its safety and effectiveness. Methods A retrospective analysis evaluated the clinical data and short-term results of 18 patients in the single medical group of the centre who underwent biportal robot-assisted lobectomy plus lymph node dissection from November 2020 to March 2021. Results Lobectomy and lymph node dissection could be successfully accomplished in all 18 patients with the assistance of a biportal robot; there was no conversion to thoracotomy during the operation. There were 10 males and 8 females with their ages ranging from 37 to 73 (58.83 +/- 9.07) years. The total operation time was 74-146 (105.06 +/- 18.22) min. Punching time was 2-9 (5.11 +/- 1.74) min. Docking time was 8-16 (11.94 +/- 2.41) min. Console time was 50-104 (78.06 +/- 17.40) min. Chest closing time was 8-17 (10.28 +/- 2.74) min. Blood loss was 60-132 (94.11 +/- 41.41) ml. The number of lymph nodes dissected was 16-30 (21.78 +/- 4.13). Chest tube duration was 2-10 (4.06 +/- 1.98) days. Drainage on the first day following surgery was 100-500 (337.22 +/- 117.01) ml. Total drainage was 370-1100 (692.78 +/- 161.01) ml. Duration of hospital stay was 4-12 (5.89 +/- 1.94) days. The median 24 and 72 h visual analogue score scores were 4 (3-7) and 3 (2-5). Total cost ( yen ) was 51 000-85 000 (68 000 +/- 10 000), respectively. There was one case of atrial fibrillation and one case of pulmonary infection. The complication rate was 11.11%. No serious complications were recorded after surgery, and no deaths occurred within 30 days post-surgery. The final pathological diagnosis revealed 10 cases of squamous cell carcinoma, 7 cases of adenocarcinoma and 1 case of benign disease. Conclusion The biportal robot-assisted lobectomy was found to be safe and effective in the treatment of lung cancer. C1 [Yang, Ning; He, Xiaoyang; Cui, Baiqiang; Gou, Yunjiu] Gansu Univ Chinese Med, Gansu Prov Hosp, Clin Med Coll 1, Lanzhou, Peoples R China. [Yang, Ning; He, Xiaoyang; Bai, Qizhou; Cui, Baiqiang; Gou, Yunjiu] Gansu Prov Hosp, Dept Thorac Surg 1, Lanzhou 730000, Peoples R China. C3 Gansu University of Chinese Medicine RP Gou, YJ (corresponding author), Gansu Prov Hosp, Dept Thorac Surg 1, Lanzhou 730000, Peoples R China. EM gouyunjiu@163.com OI yang, ning/0000-0001-6967-1871 FU Gansu Provincial Health Industry Scientific Research Management Project [GSWSKY2020-50]; Gansu Provincial People's Hospital National Scientific Research Project Cultivation Plan [19SYPYB-28]; Lanzhou Science and Technology Development Guiding Plan [2019-ZD-98] FX Gansu Provincial Health Industry Scientific Research Management Project, Grant/Award Number: GSWSKY2020-50; Gansu Provincial People's Hospital National Scientific Research Project Cultivation Plan, Grant/Award Number: 19SYPYB-28; Lanzhou Science and Technology Development Guiding Plan, Grant/Award Number: 2019-ZD-98 CR Cao C, 2019, ANN THORAC SURG, V108, P1498, DOI 10.1016/j.athoracsur.2019.05.020 Nguyen D, 2019, EUR J CARDIO-THORAC, V55, P427, DOI 10.1093/ejcts/ezy332 Ettinger DS, 2021, J NATL COMPR CANC NE, V19, P254, DOI 10.6004/jnccn.2021.0013 Funai K, 2020, ANN THORAC SURG, V110, pE435, DOI 10.1016/j.athoracsur.2020.04.075 Huang J, 2019, TRANSL LUNG CANCER R, V8, P951, DOI 10.21037/tlcr.2019.11.31 Kang CH, 2019, ANN THORAC SURG, V108, pE401, DOI 10.1016/j.athoracsur.2019.06.072 Kaur MN, 2018, ANN THORAC SURG, V105, P1050, DOI 10.1016/j.athoracsur.2017.11.013 Louie BE, 2016, ANN THORAC SURG, V102, P917, DOI 10.1016/j.athoracsur.2016.03.032 Masmoudi H, 2017, ANN THORAC SURG, V104, P254, DOI 10.1016/j.athoracsur.2017.01.054 Melfi FMA, 2002, EUR J CARDIO-THORAC, V21, P864, DOI 10.1016/S1010-7940(02)00102-1 Nakamura K, 2010, JPN J CLIN ONCOL, V40, P271, DOI 10.1093/jjco/hyp156 Nelson DB, 2019, ANN THORAC SURG, V108, P370, DOI 10.1016/j.athoracsur.2019.03.051 Oh DS, 2017, ANN THORAC SURG, V104, P1733, DOI 10.1016/j.athoracsur.2017.06.020 Pardolesi A, 2012, ANN THORAC SURG, V94, P929, DOI 10.1016/j.athoracsur.2012.04.086 Park BJ, 2006, J THORAC CARDIOV SUR, V131, P54, DOI 10.1016/j.jtcvs.2005.07.031 Pearlstein DP, 2016, ANN THORAC SURG, V102, pE591, DOI 10.1016/j.athoracsur.2016.05.105 Raman V, 2020, JNCI CANCER SPECT, V4, DOI 10.1093/jncics/pkaa031 Raman V, 2018, J THORAC DIS, V10, pS898, DOI 10.21037/jtd.2018.01.172 Rauma V, 2019, CLIN LUNG CANCER, V20, P378, DOI 10.1016/j.cllc.2019.05.010 Smood B, 2018, J ROBOT SURG, V12, P529, DOI 10.1007/s11701-018-0779-4 Song GS, 2019, J THORAC DIS, V11, P2431, DOI 10.21037/jtd.2019.05.71 Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660 Suzuki K, 2019, J THORAC CARDIOV SUR, V158, P895, DOI 10.1016/j.jtcvs.2019.03.090 Van Haren RM, 2018, ANN THORAC SURG, V106, P272, DOI 10.1016/j.athoracsur.2018.01.088 Veronesi G, 2016, LUNG CANCER, V101, P28, DOI 10.1016/j.lungcan.2016.09.004 Veronesi G, 2011, INNOVATIONS, V6, P355, DOI 10.1097/IMI.0b013e3182490093 Whitson BA, 2008, ANN THORAC SURG, V86, P2008, DOI 10.1016/j.athoracsur.2008.07.009 Wilson JL, 2014, ANN THORAC SURG, V97, P1901, DOI 10.1016/j.athoracsur.2014.01.064 Wu H, 2021, EUR J CARDIO-THORAC, V59, P732, DOI 10.1093/ejcts/ezaa426 Yang S, 2018, EUR J CARDIO-THORAC, V53, P348, DOI 10.1093/ejcts/ezx310 Zhang LZ, 2015, INT J CLIN EXP MED, V8, P17804 NR 31 TC 8 Z9 9 U1 0 U2 8 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1478-5951 EI 1478-596X J9 INT J MED ROBOT COMP JI Int. J. Med. Robot. Comput. Assist. Surg. PD DEC PY 2021 VL 17 IS 6 AR e2326 DI 10.1002/rcs.2326 EA SEP 2021 PG 7 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA WS3HB UT WOS:000693314700001 PM 34427397 DA 2026-04-17 ER PT J AU Jain, P Bugarin, JG Guha, A Jain, C Patil, N Shen, T Stanevich, I Nikore, V Margolin, K Ernstoff, M Velcheti, V Barnholtz-Sloan, J Dowlati, A AF Jain, P. Bugarin, J. Gutierrez Guha, A. Jain, C. Patil, N. Shen, T. Stanevich, I. Nikore, V. Margolin, K. Ernstoff, M. Velcheti, V. Barnholtz-Sloan, J. Dowlati, A. TI Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States SO ESMO OPEN LA English DT Article DE immune checkpoint inhibitors; anti-CTLA4; anti-PD-1; anti-PD-L1; cardiovascular adverse events; real-world evidence ID OUTCOMES; CHECKLIST; CANCER; HEALTH AB Background: Immune checkpoint inhibitors (ICIs) can cause life-threatening cardiovascular adverse events (CVAEs) that may not be attributed to therapy. The outcomes of clinical trials may underestimate treatment-related adverse events due to restrictive eligibility, limited sample size, and failure to anticipate selected toxicities. We evaluated the incidence and clinical determinants of CVAEs in real-world population on ICI therapy. Patients and methods: Among 2 687 301 patients diagnosed with cancer from 2011 to 2018, 16 574 received ICIs for any cancer. Patients in the ICI and non-ICI cohorts were matched in a 1 : 1 ratio according to age, sex, National Cancer Institute comorbidity score, and primary cancer. The non-ICI cohort was stratified into patients who received chemotherapy (N = 2875) or targeted agents (N = 4611). All CVAEs, non-cardiac immune-related adverse events occurring after treatment initiation, baseline comorbidities, and treatment details were identified and analyzed using diagnosis and billing codes. Results: Median age was 61 and 65 years in the ICI and non-ICI cohorts, respectively (P < 0.001). ICI patients were predominantly male (P < 0.001). Lung cancer (43.1%), melanoma (30.4%), and renal cell carcinoma (9.9%) were the most common cancer types. CVAE diagnoses in our dataset by incidence proportion (ICI cohort) were stroke (4.6%), heart failure (3.5%), atrial fibrillation (2.1%), conduction disorders (1.5%), myocardial infarction (0.9%), myocarditis (0.05%), vasculitis (0.05%), and pericarditis (0.2%). Anti-cytotoxic T-lymphocyte-associated protein 4 increased the risk of heart failure [versus anti-programmed cell death protein 1; hazard ratio (HR), 1.9; 95% confidence interval (CI) 1.27-2.84] and stroke (HR, 1.7; 95% CI 1.3-2.22). Pneumonitis was associated with heart failure (HR, 2.61; 95% CI 1.23-5.52) and encephalitis with conduction disorders (HR, 4.35; 95% CI 1.6-11.87) in patients on ICIs. Advanced age, primary cancer, nephritis, and anti-cytotoxic T-lymphocyte-associated protein 4 therapy were commonly associated with CVAEs in the adjusted Cox proportional hazards model. Conclusions: Our findings underscore the importance of risk stratification and cardiovascular monitoring for patients on ICI therapy. C1 [Jain, P.; Dowlati, A.] Univ Hosp, CWRU Sch Med, Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA. [Bugarin, J. Gutierrez; Shen, T.; Stanevich, I.; Nikore, V.] Layer 6 AI, Toronto, ON, Canada. [Guha, A.] Harrington Heart & Vasc Inst, Cleveland, OH USA. [Jain, C.] Cleveland Clin Fdn, Lerner Coll Med, 9500 Euclid Ave, Cleveland, OH 44195 USA. [Patil, N.] Univ Hosp Hlth Syst, Res & Educ Inst, Cleveland, OH USA. [Margolin, K.] City Hope Natl Med Ctr, Dept Med Oncol, Duarte, CA USA. [Ernstoff, M.] NCI, ImmunoOncol Branch, Dev Therapeut Program, Div Canc Diag & Treatment, Bethesda, MD 20892 USA. [Velcheti, V.] NYU, Langone Med Ctr, Laura & Isaac Perlmutter Canc Ctr, New York, NY USA. [Barnholtz-Sloan, J.] CWRU Sch Med, Dept Populat & Quantitat Hlth Sci, Cleveland, OH USA. [Barnholtz-Sloan, J.] CWRU Sch Med, Case Comprehens Canc Ctr, Cleveland, OH USA. [Barnholtz-Sloan, J.] Univ Hosp Hlth Syst, Res & Educ, Cleveland, OH USA. C3 University System of Ohio; Case Western Reserve University; University Hospitals of Cleveland; Cleveland Clinic Foundation; University System of Ohio; Case Western Reserve University; University Hospitals of Cleveland; City of Hope; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); NYU Langone Medical Center; New York University; University System of Ohio; Case Western Reserve University; University System of Ohio; Case Western Reserve University; University Hospitals of Cleveland RP Jain, P (corresponding author), Case Western Reserve Univ, Case Comprehens Canc Ctr, Dept Hematol & Med Oncol, Univ Hosp,Seidman Canc Ctr, 11100 Euclid Ave, Cleveland, OH 44106 USA. EM jain.prantesh@gmail.com RI Guha, Avirup/I-2611-2019; Jain, Prantesh/V-5000-2019; Ernstoff, Marc/AFR-4747-2022; Patil, Nirav/C-7691-2018 OI Guha, Avirup/0000-0003-0253-1174; Jain, Prantesh/0000-0003-2771-4612; Ernstoff, Marc/0000-0002-8132-7069; Gutierrez, Jahir/0000-0001-9188-4726; Patil, Nirav/0000-0001-8593-423X; Margolin, Kim/0000-0002-5248-4356 FU University Hospitals Research and Education (UHR&E) Big Data/Health Informatics Pilot Grant [P0466] FX This work was supported by the University Hospitals Research and Education (UHR&E) Big Data/Health Informatics Pilot Grant (P0466) awarded to Dr Prantesh Jain. CR [Anonymous], 2018, IBM MarketScan Research Databases for Health Services Researchers Bour-Jordan H, 2009, IMMUNOL REV, V229, P41, DOI 10.1111/j.1600-065X.2009.00775.x Bu DX, 2011, ARTERIOSCL THROM VAS, V31, P1100, DOI 10.1161/ATVBAHA.111.224709 Corrigan-Curay J, 2018, JAMA-J AM MED ASSOC, V320, P867, DOI 10.1001/jama.2018.10136 Drobni ZD, 2020, CIRCULATION, V142, P2299, DOI 10.1161/CIRCULATIONAHA.120.049981 Escudier M, 2017, CIRCULATION, V136, P2085, DOI 10.1161/CIRCULATIONAHA.117.030571 Fernandez DM, 2019, NAT MED, V25, P1576, DOI 10.1038/s41591-019-0590-4 Gotsman I, 2007, J CLIN INVEST, V117, P2974, DOI 10.1172/JCI31344 Hu YB, 2017, TRANSL LUNG CANCER R, V6, pS8, DOI 10.21037/tlcr.2017.12.10 Johnson DB, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0617-x Johnson DB, 2016, NEW ENGL J MED, V375, P1749, DOI 10.1056/NEJMoa1609214 Lyon AR, 2018, LANCET ONCOL, V19, pE447, DOI 10.1016/S1470-2045(18)30457-1 Mahmood SS, 2018, J AM COLL CARDIOL, V71, P1755, DOI 10.1016/j.jacc.2018.02.037 Martins F, 2019, NAT REV CLIN ONCOL, V16, P563, DOI 10.1038/s41571-019-0218-0 Matsumoto T, 2016, ARTERIOSCL THROM VAS, V36, P1141, DOI 10.1161/ATVBAHA.115.306848 Meijers WC, 2019, CARDIOVASC RES, V115, P844, DOI 10.1093/cvr/cvz035 Miksad RA, 2018, CLIN PHARMACOL THER, V103, P202, DOI 10.1002/cpt.946 Moslehi JJ, 2018, LANCET, V391, P933, DOI 10.1016/S0140-6736(18)30533-6 Oren O, 2020, AM J CARDIOL, V125, P1920, DOI 10.1016/j.amjcard.2020.02.016 Puzanov I, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0300-z Salem JE, 2018, LANCET ONCOL, V19, P1579, DOI 10.1016/S1470-2045(18)30608-9 Schulman KL, 2013, VALUE HEALTH, V16, P655, DOI 10.1016/j.jval.2013.02.006 Stedman M.R., 2019, The impact of different SEER-Medicare claims-based comorbidity indexes on predicting non-cancer mortality for cancer patients Stein-Merlob AF, 2021, CURR CARDIOL REP, V23, DOI 10.1007/s11886-021-01440-3 Wang Hong, 2017, Quant Biosci, V36, P85, DOI [10.22283/qbs.2017.36.2.85, 10.22283/qbs.2017.36.2.85] NR 25 TC 51 Z9 58 U1 1 U2 8 PU ELSEVIER PI AMSTERDAM PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS EI 2059-7029 J9 ESMO OPEN JI ESMO Open PD OCT PY 2021 VL 6 IS 5 DI 10.1016/j.esmoop.2021.100252 EA AUG 2021 PG 11 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA WD2VA UT WOS:000704803800015 PM 34461483 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Sharifi-Rad, J Cruz-Martins, N López-Jornet, P Lopez, EPF Harun, N Yeskaliyeva, B Beyatli, A Sytar, O Shaheen, S Sharopov, F Taheri, Y Docea, AO Calina, D Cho, WLC AF Sharifi-Rad, Javad Cruz-Martins, Natalia Lopez-Jornet, Pia Lopez, Eduardo Pons-Fuster Harun, Nidaa Yeskaliyeva, Balakyz Beyatli, Ahmet Sytar, Oksana Shaheen, Shabnum Sharopov, Farukh Taheri, Yasaman Docea, Anca Oana Calina, Daniela Cho, William C. TI Natural Coumarins: Exploring the Pharmacological Complexity and Underlying Molecular Mechanisms SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY LA English DT Review ID RECURRENT VENOUS THROMBOEMBOLISM; CELL LUNG-CANCER; ANTAGONIST ORAL ANTICOAGULANTS; VITAMIN-K ANTAGONISTS; LOW-DOSE WARFARIN; POST HOC ANALYSIS; ATRIAL-FIBRILLATION; RANDOMIZED-TRIAL; ANTIOXIDANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY AB Coumarins belong to the benzopyrone family commonly found in many medicinal plants. Natural coumarins demonstrated a wide spectrum of pharmacological activities, including anti-inflammatory, anticoagulant, anticancer, antibacterial, antimalarial, casein kinase-2 (CK2) inhibitory, antifungal, antiviral, Alzheimer's disease inhibition, neuroprotective, anticonvulsant, phytoalexins, ulcerogenic, and antihypertensive. There are very few studies on the bioavailability of coumarins; therefore, further investigations are necessitated to study the bioavailability of different coumarins which already showed good biological activities in previous studies. On the evidence of varied pharmacological properties, the present work presents an overall review of the derivation, availability, and biological capacities of coumarins with further consideration of the essential mode of their therapeutic actions. In conclusion, a wide variety of coumarins are available, and their pharmacological activities are of current interest thanks to their synthetic accessibility and riches in medicinal plants. Coumarins perform the valuable function as therapeutic agents in a range of medical fields. C1 [Sharifi-Rad, Javad; Taheri, Yasaman] Shahid Beheshti Univ Med Sci, Phytochem Res Ctr, Tehran, Iran. [Cruz-Martins, Natalia] Univ Porto, Fac Med, Alameda Prof Hernani Monteiro, P-4200319 Porto, Portugal. [Cruz-Martins, Natalia] Univ Porto, Inst Res & Innovat Hlth i3S, P-4200135 Porto, Portugal. [Cruz-Martins, Natalia] Inst Res & Adv Training Hlth Sci & Technol CESPU, Rua Cent Gandra 1317, P-4585116 Gandra, Prd, Portugal. [Lopez-Jornet, Pia; Lopez, Eduardo Pons-Fuster] Clin Odontol Univ Hosp Morales Meseguer, Inst Murciano Invest Biosanit IMIBA Arrixaca UMU, Adv Marques Velez S-N, Murcia 30008, Spain. [Harun, Nidaa] Lahore Coll Women Univ, Lahore, Pakistan. [Yeskaliyeva, Balakyz] Al Farabi Kazakh Natl Univ, Fac Chem & Chem Technol, Alma Ata 050040, Kazakhstan. [Beyatli, Ahmet] Univ Hlth Sci, Dept Med & Aromat Plants, TR-34668 Istanbul, Turkey. [Sytar, Oksana] Taras Shevchenko Natl Univ Kyiv, Inst Biol, Dept Plant Biol Dept, Volodymyrska Str 64, UA-01033 Kiev, Ukraine. [Sytar, Oksana] Slovak Univ Agr, Dept Plant Physiol, A Hlinku 2, Nitra 94976, Slovakia. [Shaheen, Shabnum] LCWU, Dept Plant Physiol, Lahore 54000, Pakistan. [Sharopov, Farukh] Acad Sci Republ Tajikistan, Chinese Tajik Innovat Ctr Nat Prod, Res Inst, Ayni 299-2, Dushanbe 734063, Tajikistan. [Docea, Anca Oana] Univ Med & Pharm Craiova, Dept Toxicol, Craiova 200349, Romania. [Calina, Daniela] Univ Med & Pharm Craiova, Dept Clin Pharm, Craiova 200349, Romania. [Cho, William C.] Queen Elizabeth Hosp, Dept Clin Oncol, Kowloon, Hong Kong, Peoples R China. C3 Shahid Beheshti University Medical Sciences; Universidade do Porto; Universidade do Porto; i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto; Al-Farabi Kazakh National University; Ministry of Education & Science of Ukraine; Taras Shevchenko National University of Kyiv; Slovak University of Agriculture Nitra; Academy of Sciences of Republic of Tajikistan; University of Medicine & Pharmacy of Craiova; University of Medicine & Pharmacy of Craiova RP Sharifi-Rad, J (corresponding author), Shahid Beheshti Univ Med Sci, Phytochem Res Ctr, Tehran, Iran.; Cruz-Martins, N (corresponding author), Univ Porto, Fac Med, Alameda Prof Hernani Monteiro, P-4200319 Porto, Portugal.; Cruz-Martins, N (corresponding author), Univ Porto, Inst Res & Innovat Hlth i3S, P-4200135 Porto, Portugal.; Cruz-Martins, N (corresponding author), Inst Res & Adv Training Hlth Sci & Technol CESPU, Rua Cent Gandra 1317, P-4585116 Gandra, Prd, Portugal.; Calina, D (corresponding author), Univ Med & Pharm Craiova, Dept Clin Pharm, Craiova 200349, Romania.; Cho, WLC (corresponding author), Queen Elizabeth Hosp, Dept Clin Oncol, Kowloon, Hong Kong, Peoples R China. EM javad.sharifirad@gmail.com; ncmartins@med.up.pt; majornet@um.es; edupfl5@hotmail.com; nidaadr@gmail.com; balakyz@mail.ru; ahmet.beyatli@sbu.edu.tr; oksana.sytar@gmail.com; shabnum_shaheen78@hotmail.com; shfarukh@mail.ru; taaheri.yasaman@gmail.com; daoana00@gmail.com; calinadaniela@gmail.com; chocs@ha.org.hk RI Yeskaliyeva, Balakyz/B-2119-2015; Lopez, Eduardo/AAB-7957-2021; Cho, William/H-7429-2019; Sytar, Oksana/H-4673-2014; Calina, Daniela/I-5509-2017; Beyatli, Ahmet/HJH-8207-2023; Sharifi-Rad, Javad/D-5747-2016; Lopez Jornet, Pia/O-5948-2019; Shaheen, Shabnum/C-5547-2016; Docea, Anca Oana/P-5807-2019; Sharopov, Farukh/P-8861-2019; Cruz-Martins, Natália/P-2972-2015 OI Calina, Daniela/0000-0002-1523-9116; Beyatli, Ahmet/0000-0001-5225-6217; Sharifi-Rad, Javad/0000-0002-7301-8151; Lopez Jornet, Pia/0000-0002-3314-8613; Shaheen, Shabnum/0000-0002-7171-6191; Docea, Anca Oana/0000-0002-8162-5955; Sharopov, Farukh/0000-0003-0378-8887; Taheri, Yasaman/0000-0002-0836-236X; Cruz-Martins, Natália/0000-0002-5934-5201 CR Abraham K, 2011, MOL NUTR FOOD RES, V55, P644, DOI 10.1002/mnfr.201000394 Agarwal R., 2000, Biochem Pharmacol, V6, P1042 Al-Amiery AA, 2012, MOLECULES, V17, P5713, DOI 10.3390/molecules17055713 Al-Warhi T, 2020, BIOORG CHEM, V103, DOI 10.1016/j.bioorg.2020.104163 Anand SS, 1999, JAMA-J AM MED ASSOC, V282, P2058, DOI 10.1001/jama.282.21.2058 Esteve-Pastor MA, 2018, INT J CARDIOL, V254, P125, DOI 10.1016/j.ijcard.2017.11.087 Baek NI, 2000, ARCH PHARM RES, V23, P467, DOI 10.1007/BF02976574 Basile A, 2009, MOLECULES, V14, P939, DOI 10.3390/molecules14030939 Blahová J, 2012, SCI WORLD J, DOI 10.1100/2012/263851 Borman P, 2018, TURK J PH MED REHAB, V64, P179, DOI 10.5606/tftrd.2018.3539 Bourgaud F., 2006, Phytochemistry Reviews, V5, P293, DOI 10.1007/s11101-006-9040-2 Bubols GB, 2013, MINI-REV MED CHEM, V13, P318 Buga AM, 2019, ONCOL LETT, V17, P4170, DOI 10.3892/ol.2019.9933 Calina D, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082395 Calina D, 2017, MOL MED REP, V15, P681, DOI 10.3892/mmr.2016.6034 Calina D, 2016, FARMACIA, V64, P946 Cannon CP, 2016, CLIN CARDIOL, V39, P555, DOI 10.1002/clc.22572 CHAHINIAN AP, 1989, J CLIN ONCOL, V7, P993, DOI 10.1200/JCO.1989.7.8.993 Chakthong S, 2012, PHYTOCHEMISTRY, V75, P108, DOI 10.1016/j.phytochem.2011.11.018 Chiang CC, 2010, CHEM BIODIVERS, V7, P1728, DOI 10.1002/cbdv.200900326 Chou SY, 2007, PHYTOTHER RES, V21, P226, DOI 10.1002/ptr.2044 Chow SC, 2014, WIRES COMPUT STAT, V6, P304, DOI 10.1002/wics.1310 Cisowski W, 2001, Z NATURFORSCH C, V56, P930 CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W Dalton J T., 2007, Encyclopedia of Pha. Technology, P164 DALY L, 1991, CLIN EXP METASTAS, V9, P3, DOI 10.1007/BF01831705 DEXEUS FH, 1990, J CLIN ONCOL, V8, P325, DOI 10.1200/JCO.1990.8.2.325 Docea AO, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041233 Docea AO, 2012, ROM J MORPHOL EMBRYO, V53, P683 EGAN D, 1990, DRUG METAB REV, V22, P503, DOI 10.3109/03602539008991449 Eichinger S, 2016, HEMATOL-AM SOC HEMAT, P605, DOI 10.1182/asheducation-2016.1.605 El-Sharkawy E, 2018, Z NATURFORSCH C, V73, P1, DOI 10.1515/znc-2017-0068 EMA, 2012, ASS REP CITR BERG RI Erb M, 2020, PLANT PHYSIOL, V184, P39, DOI 10.1104/pp.20.00433 Escudero GE, 2016, CHEM-BIOL INTERACT, V249, P46, DOI 10.1016/j.cbi.2016.03.010 Evans W., 2009, PHARMACOGNOSY EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002 Martínez-Pérez EF, 2018, BIOMED RES INT-UK, V2018, DOI 10.1155/2018/3819714 Feng DX, 2020, ARCH PHARM, V353, DOI 10.1002/ardp.201900380 Garg SS, 2020, EUR J PHARM SCI, V152, DOI 10.1016/j.ejps.2020.105424 Grabarska A, 2020, MOLECULES, V25, DOI 10.3390/molecules25092046 Grötz KA, 2001, BRIT J ORAL MAX SURG, V39, P34, DOI 10.1054/bjom.2000.0459 Guillon C, 2019, BIOORG CHEM, V89, DOI 10.1016/j.bioorg.2019.103014 Haaland GS, 2017, JAMA INTERN MED, V177, P1774, DOI 10.1001/jamainternmed.2017.5512 Hart RG, 2007, ANN INTERN MED, V146, P857, DOI 10.7326/0003-4819-146-12-200706190-00007 Hassan MZ, 2016, EUR J MED CHEM, V123, P236, DOI 10.1016/j.ejmech.2016.07.056 Hsia CW, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112731 Hu YH, 2019, J ENZYM INHIB MED CH, V34, P1083, DOI 10.1080/14756366.2019.1615484 Huang GJ, 2012, J AGR FOOD CHEM, V60, P1673, DOI 10.1021/jf204297e Huang M, 2015, BIOORG MED CHEM LETT, V25, P508, DOI 10.1016/j.bmcl.2014.12.034 Iranshahi M, 2009, DARU, V17, P99 Islam MS, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.665031 Iwata N, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00174 Kadhum AAH, 2011, INT J MOL SCI, V12, P5747, DOI 10.3390/ijms12095747 Kahale LA, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006466.pub6 KASHMAN Y, 1992, J MED CHEM, V35, P2735, DOI 10.1021/jm00093a004 Khalil N, 2020, MOLECULES, V25, DOI 10.3390/molecules25020301 Kharasch ED, 2000, DRUG METAB DISPOS, V28, P28 Kirsch G, 2016, MOLECULES, V21, DOI 10.3390/molecules21101322 KISTLER JP, 1990, NEW ENGL J MED, V323, P1505 KOKRON O, 1991, ONCOLOGY, V48, P102 Kostova Irena, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P29, DOI 10.2174/1568011053352550 KOUDSTAAL PJ, 1993, LANCET, V342, P1255 Kuo PC, 2004, PLANTA MED, V70, P183, DOI 10.1055/s-2004-815500 Kwon OS, 2011, ARCH PHARM RES, V34, P1561, DOI 10.1007/s12272-011-0919-0 Leal LKAM, 2000, J ETHNOPHARMACOL, V70, P151, DOI 10.1016/S0378-8741(99)00165-8 Lee AYY, 2003, NEW ENGL J MED, V349, P146, DOI 10.1056/NEJMoa025313 Lee Chang-Ryul, 2011, Lab Anim Res, V27, P259, DOI 10.5625/lar.2011.27.3.259 LEVINE M, 1994, LANCET, V343, P886, DOI 10.1016/S0140-6736(94)90008-6 Li HB, 2017, J PHARM PHARMACOL, V69, P1253, DOI 10.1111/jphp.12774 Liang CY, 2017, MOLECULES, V22, DOI 10.3390/molecules22030387 Loncar M, 2020, FOODS, V9, DOI 10.3390/foods9050645 Luo K, 2016, FRONT PLANT SCI, V7, DOI 10.3389/fpls.2016.00972 Ma Xiao, 2020, Eur J Pharmacol, V888, P173578, DOI [10.1016/j.ejphar.2020.173578, 10.1016/j.ejphar.2020.173578] Mahler JL., 1992, Prostate, V20, P112 Majnooni MB, 2020, MOLECULES, V25, DOI 10.3390/molecules25092040 MARSHALL ME, 1990, PROSTATE, V17, P95, DOI 10.1002/pros.2990170203 Martins Borges Maria Fernanda, 2009, V4, P23 Matos MJ, 2013, EUR J MED CHEM, V63, P151, DOI 10.1016/j.ejmech.2013.02.009 Maurer LH, 1997, J CLIN ONCOL, V15, P3378, DOI 10.1200/JCO.1997.15.11.3378 May JM, 2017, J AM CHEM SOC, V139, P17221, DOI 10.1021/jacs.7b07736 MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527 McKee TC, 1996, J NAT PROD, V59, P754, DOI 10.1021/np9603784 Menezes JCJMDS, 2019, EUR J MED CHEM, V182, DOI 10.1016/j.ejmech.2019.111637 Mishra S, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e03217 Mitrut P, 2016, COLORECTAL CANCER - FROM PATHOGENESIS TO TREATMENT, P185, DOI 10.5772/63408 Mousa Shaker A, 2002, Expert Rev Anticancer Ther, V2, P227, DOI 10.1586/14737140.2.2.227 Newman RA, 1998, J PHARM SCI, V87, P1077, DOI 10.1021/js980122d Neyts J, 2009, J MED CHEM, V52, P1486, DOI 10.1021/jm801240d Ntaios G, 2017, STROKE, V48, P2494, DOI 10.1161/STROKEAHA.117.017549 Numonov S, 2019, APPL SCI-BASEL, V9, DOI 10.3390/app9112362 Padureanu R, 2019, J CLIN MED, V8, DOI 10.3390/jcm8111815 PATIL AD, 1993, J MED CHEM, V36, P4131, DOI 10.1021/jm00078a001 PETERSEN P, 1989, LANCET, V1, P175 Poonam V, 2011, CURR MED CHEM, V18, P3758, DOI 10.2174/092986711803414386 Portugal Jose, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P411, DOI 10.2174/1568011033482215 Prins MH, 2013, THROMB J, V11, DOI 10.1186/1477-9560-11-21 Raja SB, 2011, BIOMED PHARMACOTHER, V65, P560, DOI 10.1016/j.biopha.2010.10.010 Reen FJ, 2018, APPL MICROBIOL BIOT, V102, P2063, DOI 10.1007/s00253-018-8787-x Ren QC, 2018, CURR TOP MED CHEM, V18, P101, DOI 10.2174/1568026618666180221114515 RITSCHEL WA, 1981, J CLIN PHARMACOL, V21, P294, DOI 10.1002/j.1552-4604.1981.tb01770.x Rogoveanu OC, 2018, EXP THER MED, V16, P2659, DOI 10.3892/etm.2018.6477 Rohini Sharma Rohini Sharma, 2011, Journal of Chemical and Pharmaceutical Research, V3, P204 Rosselli S, 2009, NAT PROD COMMUN, V4, P1701 Salehi B, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.592654 Salehi B, 2021, PHYTOTHER RES, V35, P1187, DOI 10.1002/ptr.6884 Salehi B, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01300 Salehi B, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10010130 Salehi B, 2019, APPL SCI-BASEL, V9, DOI 10.3390/app9163387 Salehi B, 2019, MOLECULES, V24, DOI 10.3390/molecules24132454 Salehi B, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9030106 Salehi B, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9010006 Sancho R, 2004, J BIOL CHEM, V279, P37349, DOI 10.1074/jbc.M401993200 Sarker SD, 2017, PROG CHEM ORG NAT PR, V106, P241, DOI 10.1007/978-3-319-59542-9_3 Scheau C, 2021, J PERS MED, V11, DOI 10.3390/jpm11060494 Sharifi-Rad J, 2022, CRIT REV FOOD SCI, V62, P8045, DOI 10.1080/10408398.2021.1924612 Sharifi-Rad J, 2020, MEDICINA-LITHUANIA, V56, DOI 10.3390/medicina56090433 Sharifi-Rad M, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00694 Sharopov F., 2018, Vegetation of Central Asia and environs, P163, DOI [DOI 10.1007/978-3-319-99728-5_7, 10.1007/978-3-319-99728-5_7] Shimizu BI, 2014, FRONT PLANT SCI, V5, DOI 10.3389/fpls.2014.00549 Shin E, 2010, BIOL PHARM BULL, V33, P1610, DOI 10.1248/bpb.33.1610 SILBERBERG JM, 1990, J CLIN ONCOL, V8, P182, DOI 10.1200/JCO.1990.8.1.182 Skok Z, 2020, J MED CHEM, V63, P884, DOI 10.1021/acs.jmedchem.9b00726 Spino C, 1998, BIOORG MED CHEM LETT, V8, P3475, DOI 10.1016/S0960-894X(98)00628-3 STANFORD CF, 1979, THORAX, V34, P113, DOI 10.1136/thx.34.1.113 Stefanachi A, 2018, MOLECULES, V23, DOI 10.3390/molecules23020250 STOUT GH, 1964, J ORG CHEM, V29, P3604, DOI 10.1021/jo01035a041 Tagalakis V, 2007, CANCER TREAT REV, V33, P358, DOI 10.1016/j.ctrv.2007.02.004 Tava A, 2001, J ESSENT OIL RES, V13, P367, DOI 10.1080/10412905.2001.9712236 Thomas V, 2017, ANTI-CANCER AGENT ME, V17, P415, DOI 10.2174/1871520616666160902094739 THORNES RD, 1994, J CANCER RES CLIN, V120, pS32, DOI 10.1007/BF01377122 THORNES RD, 1982, LANCET, V2, P328 Timson DJ, 2017, CURR DRUG TARGETS, V18, P500, DOI 10.2174/1389450116666150722141906 Torres R, 2006, PHYTOCHEMISTRY, V67, P984, DOI 10.1016/j.phytochem.2006.03.016 Tripathi A, 2016, COMB CHEM HIGH T SCR, V19, P497, DOI 10.2174/1386207319666160517115158 Tsatsakis A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091295 Ufer M, 2005, CLIN PHARMACOKINET, V44, P1227, DOI 10.2165/00003088-200544120-00003 Venugopala KN, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/963248 Wang C, 2012, J NEUROCHEM, V121, P1007, DOI 10.1111/j.1471-4159.2012.07744.x Wang CM, 2009, J ASIAN NAT PROD RES, V11, P783, DOI 10.1080/10286020903158964 Whang WK, 2005, EXP MOL MED, V37, P436, DOI 10.1038/emm.2005.54 Witaicenis A, 2010, CHEM-BIOL INTERACT, V186, P211, DOI 10.1016/j.cbi.2010.03.045 Witt DM, 2012, SEMIN THROMB HEMOST, V38, P667, DOI 10.1055/s-0032-1324713 Wojciechowski VV, 2017, DARU, V25, DOI 10.1186/s40199-017-0175-z Woodruff S, 2019, J THROMB THROMBOLYS, V47, P495, DOI 10.1007/s11239-019-01833-w Woodruff S, 2016, J THROMB THROMBOLYS, V42, P494, DOI 10.1007/s11239-016-1386-8 Xie Q, 2005, BIOORG MED CHEM LETT, V15, P4953, DOI 10.1016/j.bmcl.2005.08.016 Yang DP, 2010, BIOSCI BIOTECH BIOCH, V74, P1430, DOI 10.1271/bbb.100110 Yun ES, 2011, TOXICOL IN VITRO, V25, P1335, DOI 10.1016/j.tiv.2011.05.001 ZACHARSKI LR, 1981, JAMA-J AM MED ASSOC, V245, P831, DOI 10.1001/jama.245.8.831 ZACHARSKI LR, 1984, CANCER-AM CANCER SOC, V53, P2046, DOI 10.1002/1097-0142(19840515)53:10<2046::AID-CNCR2820531007>3.0.CO;2-F Zlatian O, 2018, EXP THER MED, V16, P4499, DOI 10.3892/etm.2018.6737 Zlatian OM, 2015, ROM J MORPHOL EMBRYO, V56, P175 NR 153 TC 219 Z9 250 U1 6 U2 46 PU HINDAWI LTD PI LONDON PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND SN 1942-0900 EI 1942-0994 J9 OXID MED CELL LONGEV JI Oxidative Med. Cell. Longev. PD AUG 23 PY 2021 VL 2021 AR 6492346 DI 10.1155/2021/6492346 PG 19 WC Cell Biology WE Science Citation Index Expanded (SCI-EXPANDED) SC Cell Biology GA US3FE UT WOS:000697318500001 PM 34531939 OA Green Submitted, hybrid DA 2026-04-17 ER PT J AU Semeraro, GC Meroni, CA Cipolla, CM Cardinale, DM AF Semeraro, Gennaro Carmine Meroni, Carlo Ambrogio Cipolla, Carlo Maria Cardinale, Daniela Maria TI Atrial Fibrillation after Lung Cancer Surgery: Prediction, Prevention and Anticoagulation Management SO CANCERS LA English DT Review DE anticoagulation; amiodarone; beta-blockers; lung cancer; NT-proBNP; postoperative atrial fibrillation; thoracic surgery; surgery complications ID NATRIURETIC PEPTIDE LEVELS; C-REACTIVE PROTEIN; CARDIAC-SURGERY; THORACIC-SURGERY; RISK-FACTORS; POSTPERICARDIOTOMY-SYNDROME; PULMONARY RESECTION; LYMPHOCYTE RATIO; BETA-BLOCKER; TROPONIN-T AB Simple Summary Atrial fibrillation that occurs after surgery raises further questions with respect to spontaneous atrial fibrillation, being an event unquestionably related to the surgical act itself and always quite self-limiting. The purpose of this review is to present the knowledge gained so far, including the most recent findings, regarding this peculiar form of arrhythmia. Its prognostic impact and the possibility of predicting and preventing it were the subject of our analysis, as well as the similarities and differences with spontaneous atrial fibrillation in relation to anticoagulation. Where possible, the search for evidence has focused on studies involving lung cancer patients undergoing thoracic surgery, highlighting any differences with cardiac surgery. Atrial fibrillation (AF) is a common complication of the early postoperative period of various types of surgery, including that for lung cancer. Although induced by the homeostatic alterations related to surgery, there is evidence that it is not a mere stand-alone transitory event, but it represents a relevant complication of surgery, bearing considerable prognostic consequences. Different methods have therefore been explored to predict the occurrence of postoperative atrial fibrillation (POAF) and prevent it. In particular, the age among clinical factors, and N-terminal prohormone of brain natriuretic peptide (NT-proBNP), as a marker, have proven to be good predictors, and the use of beta-blockers or amiodarone in primary prevention seems to reduce its incidence significantly. There is growing evidence that POAF significantly increases the risk of stroke and global mortality in the long term; therefore, it should be managed in the same way as spontaneous atrial fibrillation. In this review, we will present the strongest evidence found so far and the most recent findings regarding the management of POAF, with a special focus on patients undergoing thoracic surgery for lung cancer. C1 [Semeraro, Gennaro Carmine; Cardinale, Daniela Maria] IRCCS, Cardioncol Unit, European Inst Oncol, I-20145 Milan, MI, Italy. [Meroni, Carlo Ambrogio; Cipolla, Carlo Maria] IRCCS, Cardiol Dept, European Inst Oncol, I-20145 Milan, MI, Italy. C3 IRCCS European Institute of Oncology (IEO); IRCCS European Institute of Oncology (IEO) RP Semeraro, GC (corresponding author), IRCCS, Cardioncol Unit, European Inst Oncol, I-20145 Milan, MI, Italy. EM GennaroCarmine.Semeraro@ieo.it; CarloAmbrogio.Meroni@ieo.it; carlo.cipolla@ieo.it; daniela.cardinale@ieo.it RI Cipolla, Carlo/AAO-3897-2020; CARDINALE, DANIELA/AAN-1675-2020 OI Semeraro, Gennaro Carmine/0000-0003-1922-7793; CARDINALE, DANIELA/0000-0002-4038-8033 CR Albini A, 2021, EUR J INTERN MED, V85, P27, DOI 10.1016/j.ejim.2020.12.018 AlTurki A, 2020, CIRC-ARRHYTHMIA ELEC, V13, DOI 10.1161/CIRCEP.119.007437 Amar D, 2015, J THORAC CARDIOV SUR, V149, P1532, DOI 10.1016/j.jtcvs.2014.12.016 Anderson E, 2014, CLIN LAB MED, V34, P537, DOI 10.1016/j.cll.2014.06.012 Aoyama H, 2016, GEN THORAC CARDIOVAS, V64, P735, DOI 10.1007/s11748-016-0707-3 Ata Y, 2009, HEART SURG FORUM, V12, pE211, DOI 10.1532/HSF98.20091014 Auer J, 2004, AM HEART J, V147, P636, DOI 10.1016/j.ahj.2003.10.041 Bessissow A, 2015, J THROMB HAEMOST, V13, pS304, DOI 10.1111/jth.12974 Burgess DC, 2006, EUR HEART J, V27, P2846, DOI 10.1093/eurheartj/ehl272 Cai GL, 2014, WORLD J SURG, V38, P51, DOI 10.1007/s00268-013-2284-2 Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Cardinale D, 2007, CIRCULATION, V115, P1339, DOI 10.1161/CIRCULATIONAHA.106.647008 Cardinale D, 2016, ANN SURG, V264, P244, DOI 10.1097/SLA.0000000000001626 Chaudhary Rahul, 2019, J Atr Fibrillation, V12, P2154, DOI 10.4022/jafib.2154 Chen SJ, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.4934 Chen YL, 2020, ANN THORAC SURG, V109, P1210, DOI 10.1016/j.athoracsur.2019.07.084 Dobrev D, 2019, NAT REV CARDIOL, V16, P417, DOI 10.1038/s41569-019-0166-5 Erdolu B, 2020, HEART SURG FORUM, V23, pE88, DOI 10.1532/hsf.2771 Fabiani I, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010037 Frendl G, 2014, J THORAC CARDIOV SUR, V148, pE153, DOI 10.1016/j.jtcvs.2014.06.036 Geçmen C, 2016, ANATOL J CARDIOL, V16, P655, DOI 10.5152/AnatolJCardiol.2015.6483 Giri S, 2001, LANCET, V357, P830, DOI 10.1016/S0140-6736(00)04196-9 Hernández-Romero D, 2014, EUR J CARDIO-THORAC, V45, P733, DOI 10.1093/ejcts/ezt488 Hidayet S, 2018, ECHOCARDIOGR-J CARD, V35, P661, DOI 10.1111/echo.13833 Higuchi S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216239 Hindricks G, 2021, EUR HEART J, V42, P373, DOI 10.1093/eurheartj/ehaa612 Hochreiter M, 2020, WORLD J SURG, V44, P2295, DOI 10.1007/s00268-020-05444-y Hu J, 2015, EUR J CARDIO-THORAC, V47, P833, DOI 10.1093/ejcts/ezu234 Imazio M, 2014, JAMA-J AM MED ASSOC, V312, P1016, DOI 10.1001/jama.2014.11026 Imazio M, 2011, CIRCULATION, V124, P2290, DOI 10.1161/CIRCULATIONAHA.111.026153 Ishibashi H, 2020, WORLD J SURG, V44, P3952, DOI 10.1007/s00268-020-05694-w Ivanovic J, 2014, INTERACT CARDIOV TH, V18, P340, DOI 10.1093/icvts/ivt520 Iwata T, 2016, SURG TODAY, V46, P877, DOI 10.1007/s00595-015-1258-4 Jakobsen CB, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6314-9 Jakobsen CJ, 1997, J CARDIOTHOR VASC AN, V11, P746, DOI 10.1016/S1053-0770(97)90169-5 Joshi Kirti K, 2015, Hosp Pract (1995), V43, P235, DOI [10.1080/21548331.2015.1096181, 10.1080/21548331.2015.1096181] Kalman JM, 1995, ANN THORAC SURG, V60, P1709, DOI 10.1016/0003-4975(95)00718-0 Kerin NZ, 2011, AM J MED, V124, DOI 10.1016/j.amjmed.2011.04.025 Kim SH, 2021, THORAC CARDIOV SURG, V69, P133, DOI 10.1055/s-0040-1708472 Knayzer B, 2007, J CARDIAC SURG, V22, P117, DOI 10.1111/j.1540-8191.2006.00366.x Koshy AN, 2020, AM J MED, V133, P311, DOI 10.1016/j.amjmed.2019.07.057 Lahoz-Tornos A, 2015, ARCH CARDIOL MEX, V85, P111, DOI 10.1016/j.acmx.2014.12.007 Leal JC, 2012, INTERACT CARDIOV TH, V14, P22, DOI 10.1093/icvts/ivr019 Lederer MR, 2021, INNOVATIONS, V16, P249, DOI 10.1177/1556984521994206 Lee CT, 2019, THORAC CARDIOV SURG, V67, P125, DOI 10.1055/s-0038-1675638 Li T, 2016, AM J THER, V23, pE1586, DOI 10.1097/MJT.0000000000000255 Lin MH, 2019, STROKE, V50, P1364, DOI 10.1161/STROKEAHA.118.023921 Lin YL, 2021, ARCH MED SCI, DOI [10.5114/aoms/131087, 10.5114/aoms/131087, DOI 10.5114/AOMS/131087] Liu Y, 2020, AM J CARDIOVASC DRUG, V20, P271, DOI 10.1007/s40256-019-00380-2 Liu ZY, 2020, HEART LUNG CIRC, V29, P1015, DOI 10.1016/j.hlc.2019.11.021 Lowres N, 2018, INTERACT CARDIOV TH, V26, P504, DOI 10.1093/icvts/ivx348 Makhija Z, 2011, ANN THORAC SURG, V92, P421, DOI 10.1016/j.athoracsur.2011.04.066 Burgos LM, 2019, J THORAC CARDIOV SUR, V157, P2279, DOI 10.1016/j.jtcvs.2018.10.091 Marik PE, 2009, J CRIT CARE, V24, P458, DOI 10.1016/j.jcrc.2008.10.016 Mariscalco G, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000752 Masson S, 2015, EUR J CLIN INVEST, V45, P170, DOI 10.1111/eci.12393 Miller S, 2005, HEART, V91, P618, DOI 10.1136/hrt.2004.033811 Milne B, 2020, J CARDIOTHOR VASC AN, V34, P2832, DOI 10.1053/j.jvca.2020.03.031 Nojiri T, 2015, CHEST, V148, P1285, DOI 10.1378/chest.15-0852 Nojiri T, 2010, J THORAC CARDIOV SUR, V140, P764, DOI 10.1016/j.jtcvs.2009.11.073 Nojiri T, 2010, EUR J CARDIO-THORAC, V37, P787, DOI 10.1016/j.ejcts.2009.09.043 Norhayati MN, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-038364 Oesterte A, 2018, AM J MED, V131, P795, DOI 10.1016/j.amjmed.2018.01.032 Olesen OJ, 2020, EUROPACE, V22, P1182, DOI 10.1093/europace/euaa088 Osawa EA, 2020, J CARDIOTHOR VASC AN, V34, P2940, DOI 10.1053/j.jvca.2020.04.006 Ozaydin M, 2008, INT J CARDIOL, V127, P362, DOI 10.1016/j.ijcard.2007.05.012 Parikka H, 1998, J CARDIOVASC PHARM, V31, P67, DOI 10.1097/00005344-199801000-00010 Pernigo M, 2017, J AM SOC ECHOCARDIOG, V30, P956, DOI 10.1016/j.echo.2017.07.001 Rahman F, 2016, JAMA CARDIOL, V1, P384, DOI 10.1001/jamacardio.2016.0582 Rezaei Y, 2016, J CARDIOVASC PHARM T, V21, P167, DOI 10.1177/1074248415602557 Riber LP, 2014, EUR J CARDIO-THORAC, V45, P120, DOI 10.1093/ejcts/ezt169 Riber LP, 2012, ANN THORAC SURG, V94, P339, DOI 10.1016/j.athoracsur.2011.12.096 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Sakamoto A, 2014, ADV THER, V31, P440, DOI 10.1007/s12325-014-0116-x Sasaki K, 2020, GEN THORAC CARDIOVAS, V68, P1240, DOI 10.1007/s11748-020-01364-9 Seitlinger J, 2021, INTERACT CARDIOV TH, V32, P55, DOI 10.1093/icvts/ivaa220 Simmers D, 2015, J CARDIOTHOR VASC AN, V29, P389, DOI 10.1053/j.jvca.2014.05.015 Skiba MA, 2013, HEART LUNG CIRC, V22, P627, DOI 10.1016/j.hlc.2012.12.017 Smith H, 2018, J THORAC DIS, V10, pS3799, DOI 10.21037/jtd.2018.09.144 Solomon AJ, 2001, AM HEART J, V142, P811, DOI 10.1067/mhj.2001.118738 Solomon AJ, 2000, ANN THORAC SURG, V69, P126, DOI 10.1016/S0003-4975(99)01187-X Terzi A, 1996, THORAC CARDIOV SURG, V44, P300, DOI 10.1055/s-2007-1012041 Turan A, 2020, LANCET, V396, P177, DOI 10.1016/S0140-6736(20)30631-0 VanMieghem W, 1996, ANN THORAC SURG, V61, P1083, DOI 10.1016/0003-4975(96)00073-2 Vretzakis G, 2013, ANESTHESIOL RES PRAC, V2013, DOI 10.1155/2013/413985 Walter E, 2020, J CARDIOTHOR VASC AN, V34, P888, DOI 10.1053/j.jvca.2019.11.003 Wang H, 2021, J THORAC DIS, V13, DOI 10.21037/jtd-20-1717 Wang HS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094005 Weymann A, 2018, KARDIOL POL, V76, P440, DOI 10.5603/KP.a2017.0242 Yamashita K, 2019, THORAC CARDIOV SURG, V67, P107, DOI 10.1055/s-0038-1667065 Yao RJR, 2021, J CARDIAC SURG, V36, P2081, DOI 10.1111/jocs.15396 Zheng H, 2014, J CARDIOVASC PHARM, V64, P285, DOI 10.1097/FJC.0000000000000102 Zhu J, 2012, INTERN MED J, V42, P1078, DOI 10.1111/j.1445-5994.2012.02844.x NR 93 TC 27 Z9 30 U1 1 U2 11 PU MDPI PI BASEL PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND EI 2072-6694 J9 CANCERS JI Cancers PD AUG PY 2021 VL 13 IS 16 AR 4012 DI 10.3390/cancers13164012 PG 17 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA UF7YD UT WOS:000688785300001 PM 34439166 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Naaman, R Lautenschlaeger, T Diab, K AF Naaman, Rami Lautenschlaeger, Tim Diab, Khalil TI Feasibility of Performing Transvascular Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration SO CLINICAL LUNG CANCER LA English DT Article DE Blood vessels; Interventional pulmonology; Lung cancer; Lung nodules; Mediastinal adenopathy ID LUNG-CANCER; PULMONARY-ARTERY; LYMPH-NODES; MEDIASTINOSCOPY AB Endobronchial ultrasound (EBUS) is the modality of choice for the diagnosis and staging of lung cancer. It provides access to multiple lymph node stations, except the areas behind blood vessels. We explored the role of EBUS in the evaluation of lesions behind blood vessels by inserting the needle through the selected blood vessel. We showed that it could be done with a good diagnostic yield and with relative safety. We caution that this is a study done in a single center, and further larger trials are needed. Background: Thoracic vascular structures often preclude transbronchial access to central lung parenchymal lesions and lymph nodes, thereby necessitating either a surgical or transvascular needle aspiration (TVNA) approach for diagnostic sampling. The aim of this study was to evaluate the safety and efficacy of endobronchial ultrasound (EBUS) TVNA in the diagnosis and staging of mediastinal tumors. Patients and Methods: We performed a retrospective analysis of 35 cases of EBUS-TVNA. Cases were reviewed in the Cerner electronic medical records between March 2013 and October 2018. Records were reviewed for patient comorbidities, smoking status, anticoagulation intake, procedural details, sample results, and postprocedural complications. Results: Thirty-five EBUS-TVNA procedures were reviewed. Twenty-nine of them were performed by traversing the main pulmonary artery or its branches. Three involved transvascular access through the azygous vein, 2 via the brachiocephalic artery and 1 through the superior vena cava. Only 4 patients (11.4%) experienced postprocedural complications, which included mild hemoptysis, moderate hemoptysis requiring epinephrine and saline infusion, acute exacerbation of chronic obstructive pulmonary disease, and a rapid ventricular rate on top of preexisting atrial fibrillation. The yield of TVNA for malignancy was 22 (95.6%) of 23 patients. Overall yield was 31 (88.6%) of 35, with a need for additional intervention in 4 (11.4%) of 35 patients. Mutational analysis was adequate when ordered. Conclusion: In our single-center experience, the EBUS-TVNA procedure had a high diagnostic yield and was associated with low rates of postprocedural complications. Further trials are needed to assess its efficacy compared to more invasive procedures. C1 [Naaman, Rami; Diab, Khalil] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA. [Lautenschlaeger, Tim] Indiana Univ Sch Med, Dept Radiat Oncol, Indianapolis, IN 46202 USA. [Diab, Khalil] Indiana Univ Sch Med, Div Pulm & Crit Care Med, Indianapolis, IN 46202 USA. [Diab, Khalil] Lebanese Amer Univ, Sch Med, Blat, Lebanon. C3 Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Lebanese American University RP Diab, K (corresponding author), LAU New York Off, 211 E 46th St, New York, NY 10017 USA. EM khalil.diab@laumcrh.com CR Annema JT, 2010, JAMA-J AM MED ASSOC, V304, P2245, DOI 10.1001/jama.2010.1705 Botana-Rial M, 2012, RESPIRATION, V83, P353, DOI 10.1159/000332925 Boujaoude Z, 2013, J BRONCHOL INTERN PU, V20, P349, DOI 10.1097/LBR.0000000000000011 Cerfolio RJ, 2007, ANN THORAC SURG, V84, P940, DOI 10.1016/j.athoracsur.2007.04.078 Citak N, 2015, THORAC CARDIOV SURG, V63, P568, DOI 10.1055/s-0035-1546463 De Leyn P, 2014, TRANSL LUNG CANCER R, V3, P225, DOI 10.3978/j.issn.2218-6751.2014.08.05 Dusemund F, 2013, RESPIRATION, V86, P430, DOI 10.1159/000354183 Gomez Mario, 2009, Proc Am Thorac Soc, V6, P180, DOI 10.1513/pats.200808-081LC Harris K, 2015, ENDOSC ULTRASOUND, V4, P191, DOI 10.4103/2303-9027.162996 Herth FJF, 2006, THORAX, V61, P795, DOI 10.1136/thx.2005.047829 Horowitz JC, 2013, J BRONCHOL INTERN PU, V20, P93, DOI 10.1097/LBR.0b013e3182814b02 Jeyabalan A, 2016, MOL CLIN ONCOL, V4, P119, DOI 10.3892/mco.2015.672 Leong TL, 2017, CLIN LUNG CANCER, V18, pE467, DOI 10.1016/j.cllc.2017.05.006 Lochowski MP, 2014, VIDEOSURGERY MINIINV, V9, P495, DOI 10.5114/wiitm.2014.44250 McNeill T M, 1966, Ann Thorac Surg, V2, P532 Modi K, 2014, ENDOSC ULTRASOUND, V3, P249, DOI 10.4103/2303-9027.144547 Palamidas AF, 2016, RESPIRATION, V92, P127, DOI 10.1159/000448249 Panchabhai TS, 2015, J BRONCHOL INTERN PU, V22, P306, DOI 10.1097/LBR.0000000000000227 Sheski FD, 2008, CHEST, V133, P264, DOI 10.1378/chest.06-1735 Silvestri GA, 2013, CHEST, V143, pE211, DOI 10.1378/chest.12-2355 Um SW, 2015, J THORAC ONCOL, V10, P331, DOI 10.1097/JTO.0000000000000388 Vincent B, 2006, J THORAC ONCOL, V1, P362, DOI 10.1097/01243894-200605000-00016 von Bartheld MB, 2009, GASTROINTEST ENDOSC, V69, P345, DOI 10.1016/j.gie.2008.06.021 Wallace MB, 2007, ANN THORAC SURG, V84, P1019, DOI 10.1016/j.athoracsur.2007.03.012 Yasufuku K, 2006, CHEST, V130, P710, DOI 10.1378/chest.130.3.710 Yendamuri S, 2012, J THORAC CARDIOV SUR, V144, pS14, DOI 10.1016/j.jtcvs.2012.03.038 NR 26 TC 6 Z9 6 U1 0 U2 2 PU CIG MEDIA GROUP, LP PI DALLAS PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA SN 1525-7304 EI 1938-0690 J9 CLIN LUNG CANCER JI Clin. Lung Cancer PD JUL PY 2021 VL 22 IS 4 BP E595 EP E601 DI 10.1016/j.cllc.2020.10.020 EA JUL 2021 PG 7 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA TX3BU UT WOS:000682964900030 PM 33526380 DA 2026-04-17 ER PT J AU Hemu, M Chiang, CJ Bhatt, PK Ahmed, A Hein, KZ Mourad, T Randall, ME Palomo, AP Kramer, JB Fughhi, I Fogg, L Bonomi, P Okwuosa, TM AF Hemu, Mohamad Chiang, Caleb J. Bhatt, Parva K. Ahmed, Aamir Hein, Kyaw Zaw Mourad, Talal Randall, Megan E. Palomo, Andres P. Kramer, Jason B. Fughhi, Ibtihaj Fogg, Louis Bonomi, Philip Okwuosa, Tochukwu M. TI Associations between sinus tachycardia and adverse cardiovascular outcomes and mortality in cancer patients SO JOURNAL OF THORACIC DISEASE LA English DT Article DE Sinus tachycardia; cancer survivorship; risk prediction; heart failure; outcomes ID RESTING HEART-RATE; LUNG-CANCER; CARDIAC DYSFUNCTION; ALL-CAUSE; FAILURE; DISEASE; CARDIOTOXICITY; COMPLICATIONS; RADIOTHERAPY; PREDICTOR AB Background: Sinus tachycardia in cancer reflects a significant multi-system organ stressor and disease, with sparse literature describing its clinical significance. We assessed cardiovascular (CV) and mortality prognostic implications of sinus tachycardia in cancer patients. Methods: We conducted a case-control study of 622 cancer patients at a U.S. urban medical center from 2008 to 2016. Cases had ECG-confirmed sinus tachycardia [heart rate (HR) >_100 bpm] in >_3 different clinic visits within 1 year of cancer diagnosis excluding a history of pulmonary embolism, thyroid dysfunction, left ventricular ejection fraction <50%, atrial fibrillation/flutter, HR >180 bpm. Adverse CV outcomes (ACVO) were heart failure with preserved ejection fraction (HFpEF), HF with reduced EF (HFrEF), hospital admissions for HF exacerbation (AHFE), acute coronary syndrome (ACS). Regression analyses were conducted to examine the effect of sinus tachycardia on overall ACVO and survival. Results: There were 51 cases, age and sex-matched with 571 controls (mean age 70 +/- 10, 60.5% women, 76.4% Caucasian). In multivariate analysis over a 10-year follow-up period, sinus tachycardia (HR >_100 vs. <100 bpm) was an independent predictor of overall ACVO (OR 2.8, 95% CI: 1.4-5.5; P=0.006). There was increased incidence of HFrEF (OR 3.3, 95% CI: 1.6-6.5; P=0.004) and AHFE (OR 6.3, 95% CI: 1.6-28; P=0.023), but not HFpEF or ACS (P>0.05) compared with controls. Sinus tachycardia was a significant predictor of overall mortality after adjusting for significant covariates (HR 2.9, 95% CI 1.8-5; P<0.001). Conclusions: Independent of typical factors that affect cardiovascular disease, sinus tachycardia around the time of cancer treatment is associated with increased ACVO and mortality in cancer patients at 10 years of follow-up. C1 [Hemu, Mohamad; Chiang, Caleb J.; Bhatt, Parva K.; Ahmed, Aamir; Hein, Kyaw Zaw; Randall, Megan E.; Palomo, Andres P.; Kramer, Jason B.] Rush Univ, Med Ctr, Dept Internal Med, Chicago, IL 60612 USA. [Mourad, Talal] Univ Illinois, Coll Med, Chicago, IL USA. [Fughhi, Ibtihaj; Bonomi, Philip] Rush Univ, Dept Oncol, Med Ctr, Chicago, IL 60612 USA. [Fogg, Louis] Rush Univ, Coll Nursing, Dept Commun Syst & Mental Hlth Nursing, Med Ctr, Chicago, IL 60612 USA. [Okwuosa, Tochukwu M.] Rush Univ, Dept Cardiol, Med Ctr, Director Cardiooncol Serv, Chicago, IL 60612 USA. C3 Rush University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Rush University; Rush University; Rush University RP Okwuosa, TM (corresponding author), Rush Univ, Med Ctr, Med & Cardiol, 1717 West Congress Pkwy,Kellogg Bldg,Suite 328, Chicago, IL 60612 USA.; Okwuosa, TM (corresponding author), Rush Univ, Med Ctr, Cardiooncol Program, 1717 West Congress Pkwy,Kellogg Bldg,Suite 328, Chicago, IL 60612 USA. EM tokwuosa@rush.edu CR Albini A, 2010, JNCI-J NATL CANCER I, V102, P14, DOI 10.1093/jnci/djp440 Ali MK, 1984, CANC CARDIOPULMONARY Anker MS, 2016, EUR J HEART FAIL, V18, P1524, DOI 10.1002/ejhf.670 Böhm M, 2015, J INTERN MED, V278, P38, DOI 10.1111/joim.12333 BOUDOULAS H, 1979, CIRCULATION, V60, P164, DOI 10.1161/01.CIR.60.1.164 Darby SC, 2005, LANCET ONCOL, V6, P557, DOI 10.1016/S1470-2045(05)70251-5 Ewer SM, 2008, DRUG SAFETY, V31, P459, DOI 10.2165/00002018-200831060-00002 Force T, 2007, NAT REV CANCER, V7, P332, DOI 10.1038/nrc2106 Fox K, 2008, LANCET, V372, P817, DOI 10.1016/S0140-6736(08)61171-X Hjalmarson Å, 1999, LANCET, V353, P2001 KANNEL WB, 1987, AM HEART J, V113, P1489, DOI 10.1016/0002-8703(87)90666-1 Lancellotti P, 2013, J AM SOC ECHOCARDIOG, V26, P1013, DOI 10.1016/j.echo.2013.07.005 Lee DH, 2016, BREAST CANCER RES TR, V159, P375, DOI 10.1007/s10549-016-3938-1 Lee MS, 2013, AM J CARDIOL, V112, P1688, DOI 10.1016/j.amjcard.2013.07.031 Lonn EM, 2014, CLIN RES CARDIOL, V103, P149, DOI 10.1007/s00392-013-0644-4 MCBRIDE W, 1990, AM J MED, V89, P21, DOI 10.1016/0002-9343(90)90092-R Mensink GBM, 1997, EUR HEART J, V18, P1404 Opdahl A, 2014, J AM COLL CARDIOL, V63, P1182, DOI 10.1016/j.jacc.2013.11.027 Palatini P, 1997, HYPERTENSION, V30, P1267, DOI 10.1161/01.HYP.30.5.1267 Qdaisat A, 2020, J EMERG MED, V58, P932, DOI 10.1016/j.jemermed.2020.03.039 Reddy YNV, 2016, J AM COLL CARDIOL, V68, P473, DOI 10.1016/j.jacc.2016.05.043 Seidman A, 2002, J CLIN ONCOL, V20, P1215, DOI 10.1200/JCO.20.5.1215 Swain SM, 2003, CANCER, V97, P2869, DOI 10.1002/cncr.11407 Swedberg K, 2010, LANCET, V376, P875, DOI 10.1016/S0140-6736(10)61198-1 Tocchetti CG, 2013, EUR J HEART FAIL, V15, P482, DOI 10.1093/eurjhf/hft008 von Haehling S, 2013, ARCH MED SCI, V9, P261, DOI 10.5114/aoms.2013.34574 Wannamethee G, 1994, J Cardiovasc Risk, V1, P223 Yeung SCJ, 2011, CURR OPIN PULM MED, V17, P260, DOI 10.1097/MCP.0b013e328347bdba NR 28 TC 8 Z9 9 U1 0 U2 1 PU AME PUBLISHING COMPANY PI SHATIN PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA SN 2072-1439 EI 2077-6624 J9 J THORAC DIS JI J. Thorac. Dis. PD AUG PY 2021 VL 13 IS 8 BP 4845 EP 4852 DI 10.21037/jtd-21-779 EA JUL 2021 PG 8 WC Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System GA UZ1DI UT WOS:000684273400001 PM 34527323 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Motono, N Ishikawa, M Iwai, S Iijima, Y Usuda, K Uramoto, H AF Motono, Nozomu Ishikawa, Masahito Iwai, Shun Iijima, Yoshihito Usuda, Katsuo Uramoto, Hidetaka TI Individualization of risk factors for postoperative complication after lung cancer surgery: a retrospective study SO BMC SURGERY LA English DT Article DE Postoperative complication; Risk factor; Non-small cell lung cancer; Surgery ID ASSISTED THORACIC-SURGERY; PULMONARY COMPLICATIONS; ATRIAL-FIBRILLATION; SURGICAL COMPLICATIONS; LOBECTOMY; CLASSIFICATION; MORBIDITY; THORACOTOMY; SOCIETY; VATS AB Background The risk factors for postoperative complications after pulmonary resection in patients with non-small cell lung cancer (NSCLC) have not been elucidated. Methods Clinical data of 956 patients with NSCLC were analyzed. Patient factors such as sex, age, comorbidities, smoking history, respiratory function, and the lobe involved in lung cancer and operative factors such as operative approach and operative procedures were collected and analyzed. Results Male sex (odds ratio [OR]: 1.73, 95% confidence interval [CI]: 1.09-2.75, p = 0.01), coexistence of asthma (OR 2.68, 95% CI 1.19-6.02, p = 0.01), low percentage of forced expiratory volume in 1 s (FEV1) (OR 1.41, 95% CI 1.02-1.95, p = 0.03), and lobectomy or greater resection (OR 2.47, 95% CI 1.66-3.68, p < 0.01) were identified as significant risk factors for postoperative complications. Male sex (OR 1.98; 95% CI 1.03-3.81, p = 0.03) and complete video-assisted thoracic surgery and robot-assisted thoracic surgery (OR 1.64; 95% CI 1.09-2.45; p = 0.01) were identified as significant risk factors for postoperative air leakage. Coexistence of asthma (OR 9.97; 95% CI 3.66-27.38; p < 0.01) was identified as a significant risk factor for postoperative atelectasis or pneumonia. Lobectomy or greater resection (OR 19.71; 95% CI 2.70-143.57; p < 0.01) was identified as a significant risk factor for postoperative arrhythmia. Conclusion Male sex, coexistence of asthma, low percentage of FEV1, and operative procedure were significant risk factors for postoperative complications. Furthermore, risk factors varied according to postoperative complications. C1 [Motono, Nozomu; Ishikawa, Masahito; Iwai, Shun; Iijima, Yoshihito; Usuda, Katsuo; Uramoto, Hidetaka] Kanazawa Med Univ, Dept Thorac Surg, 1-1 Daigaku, Uchinada, Ishikawa 9200293, Japan. C3 Kanazawa Medical University RP Motono, N (corresponding author), Kanazawa Med Univ, Dept Thorac Surg, 1-1 Daigaku, Uchinada, Ishikawa 9200293, Japan. EM motono@kanazawa-med.ac.jp RI Usuda, Katsuo/ABB-5281-2020 CR Agostini P, 2010, THORAX, V65, P815, DOI 10.1136/thx.2009.123083 Agostini PJ, 2018, J CARDIOTHORAC SURG, V13, DOI 10.1186/s13019-018-0717-6 Allen MS, 2006, ANN THORAC SURG, V81, P1013, DOI 10.1016/j.athoracsur.2005.06.066 ASAMURA H, 1993, J THORAC CARDIOV SUR, V106, P1104, DOI 10.1016/S0022-5223(19)33985-6 Berry MF, 2009, ANN THORAC SURG, V88, P1093, DOI 10.1016/j.athoracsur.2009.06.012 Boffa DJ, 2008, J THORAC CARDIOV SUR, V135, P247, DOI 10.1016/j.jtcvs.2007.07.060 BRINKMAN GL, 1963, AM REV RESPIR DIS, V87, P684 Brunelli A, 2020, EUR J CARDIO-THORAC, V57, P740, DOI 10.1093/ejcts/ezz287 CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8 CLAVIEN PA, 1992, SURGERY, V111, P518 Dindo D, 2004, ANN SURG, V240, P205, DOI [10.17116/hirurgia2018090162, 10.1097/01.sla.0000133083.54934.ae] Dogru MV, 2021, ACTA CHIR BELG, V121, P301, DOI 10.1080/00015458.2020.1753147 Flores RM, 2009, J THORAC CARDIOV SUR, V138, P11, DOI 10.1016/j.jtcvs.2009.03.030 Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43 Jing R, 2018, INT J CLIN EXP MED, V11, P285 Katayama H, 2016, SURG TODAY, V46, P668, DOI 10.1007/s00595-015-1236-x Lee JY, 2011, J KOREAN MED SCI, V26, P979, DOI 10.3346/jkms.2011.26.8.979 McKenna RJ, 2006, ANN THORAC SURG, V81, P421, DOI 10.1016/j.athoracsur.2005.07.078 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Park BJ, 2007, J THORAC CARDIOV SUR, V133, P775, DOI 10.1016/j.jtcvs.2006.09.022 Pei GT, 2014, J THORAC DIS, V6, P1230, DOI 10.3978/j.issn.2072-1439.2014.07.23 Rice T W., 1992, Chest Surg North Am, V2, P802, DOI DOI 10.1016/S1052-3359(25)00105-X Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Rueth NM, 2010, ANN THORAC SURG, V89, pS2107, DOI 10.1016/j.athoracsur.2010.03.020 Sakuraba Motoki, 2007, Interact Cardiovasc Thorac Surg, V6, P614, DOI 10.1510/icvts.2007.157701 Stolz AJ, 2008, SURG TODAY, V38, P987, DOI 10.1007/s00595-008-3767-x Villeneuve PJ, 2018, J THORAC DIS, V10, pS3781, DOI 10.21037/jtd.2018.09.26 Whitson BA, 2008, ANN THORAC SURG, V86, P2008, DOI 10.1016/j.athoracsur.2008.07.009 Ziarnik E, 2015, THORAC SURG CLIN, V25, P355, DOI 10.1016/j.thorsurg.2015.04.003 NR 29 TC 43 Z9 49 U1 0 U2 13 PU BMC PI LONDON PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND EI 1471-2482 J9 BMC SURG JI BMC Surg. PD JUL 14 PY 2021 VL 21 IS 1 AR 311 DI 10.1186/s12893-021-01305-0 PG 8 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA TM1JQ UT WOS:000675310100001 PM 34261455 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Han, HD Chen, LP Lin, Z Wei, X Guo, W Yu, YM Wu, C Cao, Y He, J AF Han, Hedong Chen, Longpei Lin, Zhen Wei, Xin Guo, Wei Yu, Yamei Wu, Cheng Cao, Yang He, Jia TI Prevalence, trends, and outcomes of atrial fibrillation in hospitalized patients with metastatic cancer: findings from a national sample SO CANCER MEDICINE LA English DT Article DE atrial fibrillation; cancer; outcomes; prevalence; trends ID RISK-FACTORS; THROMBOEMBOLISM AB Background Epidemiological evidence regarding the link between cancer and atrial fibrillation (AF) are limited and outcomes of metastatic cancer comorbid with AF need to be elucidated. Objective This study aims to evaluate the prevalence, temporal trends, and outcomes of AF in hospitalized metastatic cancer patients. Methods The National Inpatient Sample (NIS) database was used to identify adult patients with metastatic tumors from 2003 to 2014. We analyzed the trends in AF prevalence, in-hospital mortality, total cost, length of stay (LOS), and comorbidities pertaining to metastatic cancer. Multivariable-adjusted models were used to evaluate the association of AF with clinical factors, in-hospital mortality, total cost, and LOS. Results Among 2,478,598 patients with metastatic cancer, 8.74% (216,737) were diagnosed with AF. The proportion of comorbid AF increased from 8.28% in 2003 to 10.06% in 2014 (p < 0.0001). Older age, white race, male, Medicare, higher income, larger hospital bed size, and urban teaching hospital were associated with higher AF occurrence. Among primary tumor sites, lung cancer experienced the highest odds of AF compared to other cancers. Patients with metastasis to lymph node and respiratory organ had higher odds of AF. In metastatic cancer, AF was associated with higher in-hospital mortality (odds ratio: 1.48; 95% confidence interval: 1.43-1.54), 18% longer LOS, and 19% higher cost. Conclusions AF prevalence in metastatic cancer continues to increase from 2003 to 2014. AF is linked to poorer prognosis and higher healthcare resource utilization. As the population ages, optimal preventive and treatment management strategies are needed for metastatic cancer comorbid with AF. C1 [Han, Hedong] Nanjing Univ, Jinling Hosp, Sch Med, Dept Resp & Crit Care Med, Nanjing 210002, Peoples R China. [Han, Hedong; Lin, Zhen; Guo, Wei; Wu, Cheng; He, Jia] Second Mil Med Univ, Dept Hlth Stat, 800 Xiangyin Rd, Shanghai 200433, Peoples R China. [Chen, Longpei] Second Mil Med Univ, Shanghai Changhai Hosp, Dept Med Oncol, Shanghai, Peoples R China. [Wei, Xin] Virginia Commonwealth Univ, Dept Cardiol, Richmond, VA USA. [Wei, Xin] Mt Sinai St Lukes & West Med Ctr, Dept Med, New York, NY USA. [Yu, Yamei] Shanghai Changning Dist Cent Hosp, Dept Cardiol, Shanghai, Peoples R China. [Cao, Yang] Orebro Univ, Sch Med Sci, Clin Epidemiol & Biostat, Orebro, Sweden. [He, Jia] Tongji Univ, Sch Med, Dept Hlth Stat, Shanghai, Peoples R China. C3 Nanjing University; Naval Medical University; Naval Medical University; Virginia Commonwealth University; Mount Sinai West; Mount Sinai Morningside; Orebro University; Tongji University RP Han, HD (corresponding author), Nanjing Univ, Jinling Hosp, Sch Med, Dept Resp & Crit Care Med, Nanjing 210002, Peoples R China.; He, J (corresponding author), Second Mil Med Univ, Dept Hlth Stat, 800 Xiangyin Rd, Shanghai 200433, Peoples R China. EM he_dong1102@126.com; hejia63@yeah.net RI Cao, Yang/C-6185-2008; He, Jia/LBH-8808-2024; Guo, Wei/NLN-7673-2025; Han, Hedong/K-7247-2019 OI Cao, Yang/0000-0002-3552-9153; He, Jia/0000-0002-2338-9501; Guo, Wei/0000-0003-3634-0077; FU National key research and development program of China [2017YFC0908005]; National Thirteenth Five Year Plan Major Special Project [2017ZX09304016]; National Science and Technology Major Project [2017ZX09304030] FX This work was supported by a grant from the National key research and development program of China (No. 2017YFC0908005), the National Thirteenth Five Year Plan Major Special Project (No. 2017ZX09304016) and the National Science and Technology Major Project (No. 2017ZX09304030). CR Alonso A, 2009, AM HEART J, V158, P111, DOI 10.1016/j.ahj.2009.05.010 Austin PC, 2015, STAT MED, V34, P3661, DOI 10.1002/sim.6607 Colilla S, 2013, AM J CARDIOL, V112, P1142, DOI 10.1016/j.amjcard.2013.05.063 Conen D, 2016, JAMA CARDIOL, V1, P389, DOI 10.1001/jamacardio.2016.0280 CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112 Darnell RB, 1996, P NATL ACAD SCI USA, V93, P4529, DOI 10.1073/pnas.93.10.4529 Farmakis D, 2014, J AM COLL CARDIOL, V63, P945, DOI 10.1016/j.jacc.2013.11.026 Guo YT, 2012, J AM COLL CARDIOL, V60, P2263, DOI 10.1016/j.jacc.2012.04.063 Guzzetti S, 2002, AM J MED, V112, P587, DOI 10.1016/S0002-9343(02)01029-X Howlader N., 2013, SEER CANC STAT REV Hu YF, 2013, INT J CARDIOL, V165, P355, DOI 10.1016/j.ijcard.2012.08.036 Imperatori Andrea, 2012, J Cardiothorac Surg, V7, P4, DOI 10.1186/1749-8090-7-4 January CT, 2019, CIRCULATION, V140, pE125, DOI [10.1161/CIR.0000000000000665, 10.1016/j.jacc.2019.01.011] Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037 Mann DL, 2010, PROG CARDIOVASC DIS, V53, P80, DOI 10.1016/j.pcad.2010.05.004 Mery B, 2017, INT J CARDIOL, V240, P196, DOI 10.1016/j.ijcard.2017.03.132 Mohammed KA, 2018, J NATL COMPR CANC NE, V16, P136, DOI 10.6004/jnccn.2017.7037 Nordstrom BL, 2012, PHARMACOEPIDEM DR S, V21, P21, DOI 10.1002/pds.3247 Odutayo A, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i4482 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Patel NJ, 2014, CIRCULATION, V129, P2371, DOI 10.1161/CIRCULATIONAHA.114.008201 Schnabel RB, 2015, LANCET, V386, P154, DOI 10.1016/S0140-6736(14)61774-8 Siegel R., 2019, CA: A Cancer Journal for Clinicians, V69 Southern DA, 2004, MED CARE, V42, P355, DOI 10.1097/01.mlr.0000118861.56848.ee van der Hooft CS, 2004, J AM COLL CARDIOL, V44, P2117, DOI 10.1016/j.jacc.2004.08.053 Velagapudi P, 2011, SOUTH MED J, V104, P667, DOI 10.1097/SMJ.0b013e3182299e6c Walsh Stewart R, 2004, World J Surg Oncol, V2, P40 Xiao XC, 2019, CHEST, V155, P918, DOI 10.1016/j.chest.2018.12.021 NR 28 TC 14 Z9 14 U1 0 U2 6 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2045-7634 J9 CANCER MED-US JI Cancer Med. PD AUG PY 2021 VL 10 IS 16 BP 5661 EP 5670 DI 10.1002/cam4.4105 EA JUL 2021 PG 10 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA UA4MP UT WOS:000670513300001 PM 34235874 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Patel, BM Reinert, NJ Sridharan, ND Thirumala, PD AF Patel, Bansri M. Reinert, Nathan J. Sridharan, Natalie D. Thirumala, Parthasarathy D. TI Predictive Factors of Perioperative Stroke-Related Mortality Following Vascular Surgery: A Retrospective Analysis SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES LA English DT Article DE Perioperative mortality; Perioperative stroke; Perioperative risk stratification; Vascular surgery; Carotid stenosis ID RISK ANALYSIS INDEX; ATRIAL-FIBRILLATION; CAROTID-ENDARTERECTOMY; NEUROLOGIC INJURY; LUNG-CANCER; CARE; HYPOPERFUSION; THROMBECTOMY; PREVENTION; GUIDELINES AB Objective: Vascular surgical procedures have one of the highest risks of perioperative stroke and stroke-related mortality, yet the independent risk factors contributing to this increased mortality have not been described. Perioperative strokes are thought to result from a combination of embolism and hypoperfusion mechanisms. The purpose of this study is to describe the independent predictors of perioperative stroke-related mortality in the vascular surgical population using the Pennsylvania Health Care Cost Containment Council (PHC4) database which collects cause of death data. Methods: This retrospective, case-control study evaluated 4,128 patients aged 18-99 who underwent a vascular, non-carotid surgical procedure and subsequently suffered perioperative mortality. Common surgical comorbidities and risk factors for perioperative stroke, including carotid stenosis and atrial fibrillation, were evaluated in multivariate regression analysis. Results: Patients with carotid stenosis were 2.6 (aOR, 95% CI 1.4-4.5) times more likely to suffer perioperative mortality from stroke than from other causes. Additionally, in-hospital stroke, history of stroke, admission from a healthcare facility, and cancer were all positive predictive factors, whereas atrial fibrillation, emergency admission, hypertension, and diabetes were associated with decreased risk of perioperative stroke-related mortality. Conclusions: Identification of vascular surgical population-specific predictors of stroke-related mortality can help to enhance preoperative risk-stratification tools and guide perioperative management of identified high-risk patients. Increased neurophysiologic monitoring in the perioperative period to prevent delays in diagnosis of perioperative stroke offers a strategy to reduce risk of perioperative stroke-related mortality in vascular surgical patients. C1 [Patel, Bansri M.; Reinert, Nathan J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Sridharan, Natalie D.] Univ Pittsburgh, Med Ctr, Dept Surg, Div Vasc Surg, Pittsburgh, PA USA. [Thirumala, Parthasarathy D.] Univ Pittsburgh, Med Ctr, Dept Neurol, Pittsburgh, PA 15261 USA. [Thirumala, Parthasarathy D.] Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA 15261 USA. C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh RP Thirumala, PD (corresponding author), Univ Pittsburgh, Med Ctr, Dept Neurol, Pittsburgh, PA 15261 USA.; Thirumala, PD (corresponding author), Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA 15261 USA. EM thirumalapd@upmc.edu OI Reinert, Nathan/0000-0001-6764-5522; Patel, Bansri/0000-0002-9292-3421 CR Al-Mufti F, 2017, J INTENSIVE CARE MED, V32, P373, DOI 10.1177/0885066616656361 Benjamin EJ, 2019, CIRCULATION, V139, pE56, DOI [10.1161/CIR.0000000000000659, 10.1161/CIR.0000000000000746] Bond R, 2002, EUR J VASC ENDOVASC, V23, P108, DOI 10.1053/ejvs.2001.1541 Caplan LR, 1998, ARCH NEUROL-CHICAGO, V55, P1475, DOI 10.1001/archneur.55.11.1475 Caplan LR, 2006, CEREBROVASC DIS, V21, P145, DOI 10.1159/000090791 Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Cumbler E, 2015, NEUROHOSPITALIST, V5, P173, DOI 10.1177/1941874415588319 Cumbler E, 2014, STROKE, V45, P231, DOI 10.1161/STROKEAHA.113.003617 Dardiotis E, 2019, INT J ONCOL, V54, P779, DOI 10.3892/ijo.2019.4669 El Halal MGD, 2012, INDIAN J CRIT CARE M, V16, P81, DOI 10.4103/0972-5229.99114 Edmonds HL, 1996, J CARDIOTHOR VASC AN, V10, P15, DOI 10.1016/S1053-0770(96)80174-1 Farooq MU, 2008, CEREBROVASC DIS, V25, P12, DOI 10.1159/000111494 Frendl G, 2014, J THORAC CARDIOV SUR, V148, pE153, DOI 10.1016/j.jtcvs.2014.06.036 Hall DE, 2017, JAMA SURG, V152, P175, DOI 10.1001/jamasurg.2016.4202 Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780 Jovin TG, 2018, NEW ENGL J MED, V378, P1161, DOI 10.1056/NEJMc1801530 Kimura K, 2006, EUR NEUROL, V55, P155, DOI 10.1159/000093574 Lackland DT, 2014, STROKE, V45, P315, DOI 10.1161/01.str.0000437068.30550.cf Likosky DS, 2003, STROKE, V34, P2830, DOI 10.1161/01.STR.0000098650.12386.B3 Lin HJ, 1996, STROKE, V27, P1760, DOI 10.1161/01.STR.27.10.1760 Lin MH, 2019, STROKE, V50, P1364, DOI 10.1161/STROKEAHA.118.023921 Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584 Malhotra K, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00651 Mashour GA, 2014, J NEUROSURG ANESTH, V26, P273, DOI 10.1097/ANA.0000000000000087 Melin AA, 2015, J VASC SURG, V61, P683, DOI 10.1016/j.jvs.2014.10.009 Nwachuku EL, 2015, JAMA NEUROL, V72, P73, DOI 10.1001/jamaneurol.2014.3071 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Patel BM, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.104711 Raghavan S, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.118.011295 Redmond JM, 1996, ANN THORAC SURG, V61, P42, DOI 10.1016/0003-4975(95)00903-5 Reinert NJ, 2020, J PERIOPER PRACT Rennert RC, 2019, NEUROSURGERY, V85, pS4, DOI 10.1093/neuros/nyz042 Schoof J, 2007, J THORAC CARDIOV SUR, V134, P690, DOI 10.1016/j.jtcvs.2007.03.018 Selim M, 2007, NEW ENGL J MED, V356, P706, DOI 10.1056/NEJMra062668 Silvestrini M, 2000, JAMA-J AM MED ASSOC, V283, P2122, DOI 10.1001/jama.283.16.2122 Silvestrini M, 1999, ACTA NEUROL SCAND, V99, P187, DOI 10.1111/j.1600-0404.1999.tb07342.x Sloan MA, 2006, NEUROL CLIN, V24, P631, DOI 10.1016/j.ncl.2006.05.002 Thirumala PD, 2017, J CLIN NEUROL, V13, P351, DOI 10.3988/jcn.2017.13.4.351 Thirumala PD, 2016, J CLIN NEUROSCI, V25, P1, DOI 10.1016/j.jocn.2015.08.014 Vlisides P, 2016, CAN J ANESTH, V63, P193, DOI 10.1007/s12630-015-0494-9 Wilcox T, 2019, STROKE, V50, P2002, DOI 10.1161/STROKEAHA.119.024995 NR 41 TC 5 Z9 5 U1 0 U2 1 PU ELSEVIER PI AMSTERDAM PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS SN 1052-3057 EI 1532-8511 J9 J STROKE CEREBROVASC JI J. Stroke Cerebrovasc. Dis. PD JUL PY 2021 VL 30 IS 7 AR 105833 DI 10.1016/j.jstrokecerebrovasdis.2021.105833 EA MAY 2021 PG 8 WC Neurosciences; Peripheral Vascular Disease WE Science Citation Index Expanded (SCI-EXPANDED) SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA SP9YJ UT WOS:000660018300046 PM 33964544 DA 2026-04-17 ER PT J AU O'Flaherty, M Lloyd-Williams, F Capewell, S Boland, A Maden, M Collins, B Bandosz, P Hyseni, L Kypridemos, C AF O'Flaherty, Martin Lloyd-Williams, Ffion Capewell, Simon Boland, Angela Maden, Michelle Collins, Brendan Bandosz, Piotr Hyseni, Lirije Kypridemos, Chris TI Modelling tool to support decision-making in the NHS Health Check programme: workshops, systematic review and co-production with users SO HEALTH TECHNOLOGY ASSESSMENT LA English DT Review ID CANCER SCREENING INTERVENTIONS; CORONARY-HEART-DISEASE; LOW STAKEHOLDER ENGAGEMENT; BREAST-CANCER; RISK-FACTOR; VEGETABLE CONSUMPTION; CIGARETTE-SMOKING; LUNG-CANCER; PROMOTE MAMMOGRAPHY; ATRIAL-FIBRILLATION AB Background: Local authorities in England commission the NHS Health Check programme to invite everyone aged 40-74 years without pre-existing conditions for risk assessment and eventual intervention, if needed. However, the programme's effectiveness, cost-effectiveness and equity impact remain uncertain. Aim: To develop a validated open-access flexible web-based model that enables local commissioners to quantify the cost-effectiveness and potential for equitable population health gain of the NHS Health Check programme. Objectives: The objectives were as follows: (1) co-produce with stakeholders the desirable features of the user-friendly model; (2) update the evidence base to support model and scenario development; (3) further develop our computational model to allow for developments and changes to the NHS Health Check programme and the diseases it addresses; (4) assess the effectiveness, cost-effectiveness and equity of alternative strategies for implementation to illustrate the use of the tool; and (5) propose a sustainability and implementation plan to deploy our user-friendly computational model at the local level. Design: Co-production workshops surveying the best-performing local authorities and a systematic literature review of strategies to increase uptake of screening programmes informed model use and development. We then co-produced the workHORSE (working Health Outcomes Research Simulation Environment) model to estimate the health, economic and equity impact of different NHS Health Check programme implementations, using illustrative-use cases. Setting: Local authorities in England. Participants: Stakeholders from local authorities, Public Health England, the NHS, the British Heart Foundation, academia and other organisations participated in the workshops. For the local authorities survey, we invited 16 of the best-performing local authorities in England. Interventions: The user interface allows users to vary key parameters that represent programme activities (i.e. invitation, uptake, prescriptions and referrals). Scenarios can be compared with each other. Main outcome measures: Disease cases and case-years prevented or postponed, incremental cost-effectiveness ratios, net monetary benefit and change in slope index of inequality. Results: The survey of best-performing local authorities revealed a diversity of effective approaches to maximise the coverage and uptake of NHS Health Check programme, with no distinct 'best buy'. The umbrella literature review identified a range of effective single interventions. However, these generally need to be combined to maximally improve uptake and health gains. A validated dynamic, stochastic microsimulation model, built on robust epidemiology, enabled service options analysis. Analyses of three contrasting illustrative cases estimated the health, economic and equity impact of optimising the Health Checks, and the added value of obtaining detailed local data. Optimising the programme in Liverpool can become cost-effective and equitable, but simply changing the invitation method will require other programme changes to improve its performance. Detailed data inputs can benefit local analysis. Limitations: Although the approach is extremely flexible, it is complex and requires substantial amounts of data, alongside expertise to both maintain and run. Conclusions: Our project showed that the workHORSE model could be used to estimate the health, economic and equity impact comprehensively at local authority level. It has the potential for further development as a commissioning tool and to stimulate broader discussions on the role of these tools in real-world decision-making. Future work: Future work should focus on improving user interactions with the model, modelling simulation standards, and adapting workHORSE for evaluation, design and implementation support. C1 [O'Flaherty, Martin; Lloyd-Williams, Ffion; Capewell, Simon; Collins, Brendan; Bandosz, Piotr; Hyseni, Lirije; Kypridemos, Chris] Univ Liverpool, Dept Publ Hlth & Policy, Liverpool, Merseyside, England. [Boland, Angela; Maden, Michelle] Univ Liverpool, Liverpool Reviews & Implementat Grp, Liverpool, Merseyside, England. C3 University of Liverpool; University of Liverpool RP O'Flaherty, M (corresponding author), Univ Liverpool, Dept Publ Hlth & Policy, Liverpool, Merseyside, England. EM moflaher@liverpool.ac.uk RI ; Kypridemos, Chris/I-4172-2019; O'Flaherty, Martin/JXM-0484-2024; Bandosz, Piotr/E-4964-2017 OI Capewell, Simon/0000-0003-3960-8999; Collins, Brendan/0000-0002-3023-8189; Kypridemos, Chris/0000-0002-0746-9229; O'Flaherty, Martin/0000-0001-8944-4131; Boland, Angela/0000-0002-5435-8644; Maden, Michelle/0000-0003-4419-6343; Lloyd-Willia, Ffion/0000-0002-9422-8174 FU National Institute for Health Research (NIHR) Health Technology Assessment programme [35] FX This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 35. See the NIHR Journals Library website for further project information. CR Adams J, 2016, PLOS MED, V13, DOI [10.1371/journal.pmed.1001990, 10.1371/journal.pmed.1002045] Agide FD, 2018, EUR J PUBLIC HEALTH, V28, P1156, DOI 10.1093/eurpub/cky197 Agide FD, 2018, EUR J PUBLIC HEALTH, V28, P1149, DOI 10.1093/eurpub/ckx231 Albada A, 2009, PATIENT EDUC COUNS, V77, P155, DOI 10.1016/j.pec.2009.03.005 Albrow R, 2014, ACTA ONCOL, V53, P445, DOI 10.3109/0284186X.2013.869618 Allender S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129683 Anastasi N, 2019, J HEALTH PSYCHOL, V24, P113, DOI 10.1177/1359105317697812 Andersen DF, 1997, SYST DYNAM REV, V13, P107, DOI 10.1002/(SICI)1099-1727(199722)13:2<107::AID-SDR120>3.3.CO;2-Z [Anonymous], **DATA OBJECT**, DOI DOI 10.5255/UKDA-SN-6112-1 [Anonymous], GLOBAL BURDEN DIS ST [Anonymous], **DATA OBJECT**, DOI DOI 10.5255/UKDA-SN-7649-1 [Anonymous], **DATA OBJECT**, DOI DOI 10.5255/UKDA-SN-5809-1 [Anonymous], GREEN BOOK APPR EV C [Anonymous], **DATA OBJECT**, DOI DOI 10.5255/UKDA-SN-5098-1 [Anonymous], 2019, Advancing our health: prevention in the 2020s-consultation document [Anonymous], **DATA OBJECT**, DOI DOI 10.5255/UKDA-SN-6397-2 [Anonymous], 2008, INT STAT CLASS DIS R, V10th [Anonymous], **DATA OBJECT**, DOI DOI 10.5255/UKDA-SN-7260-1 [Anonymous], The NHS Long Term Plan [Anonymous], 2019, BMJ BRIT MED J, DOI DOI 10.1136/BMJ.L5201 [Anonymous], **DATA OBJECT**, DOI DOI 10.5255/UKDA-SN-5675-1 [Anonymous], **DATA OBJECT**, DOI DOI 10.5255/UKDA-SN-5439-1 [Anonymous], **DATA OBJECT**, DOI DOI 10.5255/UKDA-SN-7480-1 Aromataris E, 2015, INT J EVID-BASED HEA, V13, P132, DOI 10.1097/XEB.0000000000000055 Artac M, 2013, J PUBLIC HEALTH-UK, V35, P431, DOI 10.1093/pubmed/fdt069 Asaria M, 2015, HEALTH ECON, V24, P742, DOI 10.1002/hec.3058 Attwood S, 2016, J PUBLIC HEALTH-UK, V38, P560, DOI 10.1093/pubmed/fdv070 Baker C, 2015, J PUBLIC HEALTH-UK, V37, P202, DOI 10.1093/pubmed/fdv053 Bandosz P, 2020, DIABETOLOGIA, V63, P104, DOI 10.1007/s00125-019-05015-4 Barendregt J.J., 2003, Population Health Metrics, V1, P1, DOI [DOI 10.1186/1478-7954-1-4, 10.1186/1478-7954-1-4] Barker D, 1994, FAST TRACK RAD APPRO Baron RC, 2008, AM J PREV MED, V35, pS34, DOI 10.1016/j.amepre.2008.04.002 Baron RC, 2010, AM J PREV MED, V38, P110, DOI 10.1016/j.amepre.2009.09.031 Bellhouse S, 2018, PSYCHO-ONCOLOGY, V27, P1089, DOI 10.1002/pon.4575 Black ME, 2002, CAN J PUBLIC HEALTH, V93, P386, DOI 10.1007/BF03404575 Bonfill X., 2001, The Cochrane Database of Systematic Reviews, V1, DOI [DOI 10.1002/14651858.CD002943, 10.1002/14651858.cd002943, 10.1002/14651858.CD002943] Boshuizen HC, 2012, DEMOGRAPHY, V49, P1259, DOI 10.1007/s13524-012-0122-z Brailsford SC, 2009, WINT SIMUL C PROC, P1791 Braun V., 2006, Res. Psychol., V3, P77, DOI [DOI 10.1191/1478088706QP063OA, DOI 10.1080/14780887.2020.1769238] Briggs AH, 2012, VALUE HEALTH, V15, P835, DOI 10.1016/j.jval.2012.04.014 Brouwers MC, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-111 Bull F C., 2004, PHYS INACTIVITY COMP, V1, P729 Cairney P, 2017, HEALTH RES POLICY SY, V15, DOI 10.1186/s12961-017-0192-x Calder M, 2018, ROY SOC OPEN SCI, V5, DOI 10.1098/rsos.172096 Camilloni L, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-464 Capewell S, 2018, J PUBLIC HEALTH-UK, V40, P350, DOI 10.1093/pubmed/fdx055 Capewell S, 2011, LANCET, V378, P752, DOI 10.1016/S0140-6736(10)62302-1 Capewell Simon, 2008, BMJ, V337, pa1395, DOI 10.1136/bmj.a1395 Caro JJ, 2012, VALUE HEALTH, V15, P796, DOI 10.1016/j.jval.2012.06.012 Casula M, 2017, NUTR METAB CARDIOVAS, V27, P396, DOI 10.1016/j.numecd.2017.03.001 Chan DNS, 2015, EUR J ONCOL NURS, V19, P536, DOI 10.1016/j.ejon.2015.02.015 Chang KCM, 2019, J EPIDEMIOL COMMUN H, V73, P11, DOI 10.1136/jech-2018-210961 Chartered Institute of Public Finance and Accountancy, 2019, EV PREV INV PUBL HLT Cheong AT, 2017, BMC FAM PRACT, V18, DOI 10.1186/s12875-016-0579-8 Christiansen CB, 2016, EUROPACE, V18, P1689, DOI 10.1093/europace/euv401 Claxton K, 2015, HEALTH ECON, V24, P1, DOI 10.1002/hec.3130 Collins B, DO WE INCLUDE HLTH I Collins B, 2020, PREV MED, V130, DOI 10.1016/j.ypmed.2019.105879 Copeland VC, 2018, HEALTH SERV RES, V53, P3170, DOI 10.1111/1475-6773.12806 Corcoran J, 2012, HEALTH SOC WORK, V37, P197, DOI 10.1093/hsw/hls035 Corcoran J, 2010, J WOMENS HEALTH, V19, P1281, DOI 10.1089/jwh.2009.1621 Crandall JP, 2017, BMJ OPEN DIAB RES CA, V5, DOI 10.1136/bmjdrc-2017-000438 Crossan C, 2017, BRIT J GEN PRACT, V67, pE67, DOI 10.3399/bjgp16X687973 Dalton ARH, 2013, EUR J PREV CARDIOL, V20, P142, DOI 10.1177/1741826711428797 Dalton ARH, 2011, J PUBLIC HEALTH-UK, V33, P422, DOI 10.1093/pubmed/fdr034 Dauchet L, 2005, NEUROLOGY, V65, P1193, DOI 10.1212/01.wnl.0000180600.09719.53 Dauchet L, 2006, J NUTR, V136, P2588, DOI 10.1093/jn/136.10.2588 Davies A, 2017, UNDERSTANDING PATTER Davis SM, CHIEF MED OFFICER AN Denhaerynck K, 2003, AM J PREV MED, V25, P195, DOI 10.1016/S0749-3797(03)00201-0 Department of Health Vascular Policy Team, 2008, EC MOD VASC CHECKS 2 Doesken N., Temperature Inversions in Colorado - What are they and what do they mean? Donnelly TT, 2015, J IMMIGR MINOR HEALT, V17, P925, DOI 10.1007/s10903-013-9902-9 Dougherty MK, 2018, JAMA INTERN MED, V178, P1645, DOI 10.1001/jamainternmed.2018.4637 Durance P, 2010, TECHNOL FORECAST SOC, V77, P1488, DOI 10.1016/j.techfore.2010.06.007 Ebrahim S, 2006, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001561.pub2, 10.1002/14651858.CD001561.pub3] Edwards AGK, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001865.pub3 Embrechts P, 2003, HANDBOOKS FINANCE, P329, DOI 10.1016/B978-044450896-6.50010-8 Escoffery C, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-274 Escribà-Agüir V, 2016, CANCER EPIDEMIOL, V44, P22, DOI 10.1016/j.canep.2016.07.009 Evans R, 2005, PATIENT EDUC COUNS, V58, P13, DOI 10.1016/j.pec.2004.06.009 Everett T, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002834.pub2 Ezzati M, 2005, CIRCULATION, V112, P489, DOI 10.1161/CIRCULATIONAHA.104.521708 Ferroni E, 2012, PREV MED, V55, P587, DOI 10.1016/j.ypmed.2012.10.007 Fischer F, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2489-4 Forey BA, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-36 Freebairn L, 2018, BMC MED INFORM DECIS, V18, DOI 10.1186/s12911-018-0707-6 Frerichs L, 2016, AM J PUBLIC HEALTH, V106, P215, DOI 10.2105/AJPH.2015.302944 Frew E, 2019, HEALTH ECON, V28, P1052, DOI 10.1002/hec.3916 Gardner MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055574 Gidlow C, 2015, J PUBLIC HEALTH-UK, V37, P195, DOI 10.1093/pubmed/fdu092 Gilbert N, 2018, JASSS-J ARTIF SOC S, V21, DOI 10.18564/jasss.3669 Gillespie DOS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127927 GOV.UK, FAM RES SURV Government Office for Science, COMP MOD BLACK REV Han HR, 2011, PSYCHO-ONCOLOGY, V20, P341, DOI 10.1002/pon.1754 Han HR, 2009, NURS RES, V58, P246, DOI 10.1097/NNR.0b013e3181ac0f7f He J, 1999, NEW ENGL J MED, V340, P920, DOI 10.1056/NEJM199903253401204 Hex N, 2012, DIABETIC MED, V29, P855, DOI 10.1111/j.1464-5491.2012.03698.x Hinde S, 2017, J PUBLIC HEALTH-HEID, V25, P425, DOI 10.1007/s10389-017-0801-8 Hippisley-Cox J, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005809 HM Treasury, GDP DEFL MARK PRIC M Hou SI, 2011, ASIAN PAC J CANCER P, V12, P3133 Hovmand PS, 2012, SYST RES BEHAV SCI, V29, P179, DOI 10.1002/sres.2105 Huxley RR, 2011, LANCET, V378, P1297, DOI 10.1016/S0140-6736(11)60781-2 Hyndman RJ, 2017, R PACKAGE DEMOGRAPHY Hyndman RJ, 2007, COMPUT STAT DATA AN, V51, P4942, DOI 10.1016/j.csda.2006.07.028 Hyseni L, 2020, BMC HEALTH SERV RES, V20, DOI 10.1186/s12913-020-05268-5 Issaka RB, 2019, PREV MED, V118, P113, DOI 10.1016/j.ypmed.2018.10.021 Ivlev I, 2018, AM J PREV MED, V55, P896, DOI 10.1016/j.amepre.2018.06.016 Jager M, 2019, DIGEST DIS SCI, V64, P2489, DOI 10.1007/s10620-019-05587-6 Jahangirian M, 2015, SIMUL-T SOC MOD SIM, V91, P511, DOI 10.1177/0037549715583150 Jahangirian M, 2015, J OPER RES SOC, V66, P369, DOI 10.1057/jors.2014.1 Janssen B., 2014, Population norms for the EQ-5D, P19, DOI DOI 10.1007/978-94-007-7596-1_3 Javanparast S, 2010, PREV MED, V50, P165, DOI 10.1016/j.ypmed.2010.02.003 Jepson R., 2000, Health Technology Assessment, V4, P1, DOI [10.3310/hta4140, DOI 10.3310/HTA4140] Jorgensen T, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3617 Katerndahl DA, 2009, J EVAL CLIN PRACT, V15, P755, DOI 10.1111/j.1365-2753.2009.01228.x Kelly C, 2018, INT J CLIN PRACT, V72, DOI 10.1111/ijcp.13202 Kerr M, 2012, NEPHROL DIAL TRANSPL, V27, P73, DOI 10.1093/ndt/gfs269 Khalid-de Bakker C, 2011, ENDOSCOPY, V43, P1059, DOI 10.1055/s-0031-1291430 Kim CH, 2014, INT J CANCER, V135, P1918, DOI 10.1002/ijc.28835 King W, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194081 Kneale D, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0577-9 Koerkamp BG, 2011, MED DECIS MAKING, V31, P650, DOI 10.1177/0272989X10381282 Kontis V, 2014, LANCET, V384, P427, DOI 10.1016/S0140-6736(14)60616-4 Krogsboll LT, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009009.pub3 Kypridemos C, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002573 Kypridemos C, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2793 Laudicella M, 2016, BRIT J CANCER, V114, P1286, DOI 10.1038/bjc.2016.77 Law MR, 2003, BRIT MED J, V326, P1423, DOI 10.1136/bmj.326.7404.1423 Lee JT, 2017, PREV MED, V99, P49, DOI 10.1016/j.ypmed.2017.01.005 Lee S, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000269 Legler J, 2002, CANCER EPIDEM BIOMAR, V11, P59 LEVIN M L, 1953, Acta Unio Int Contra Cancrum, V9, P531 Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8 Lewington S, 2007, LANCET, V370, P1829, DOI 10.1016/S0140-6736(07)61778-4 Liang PS, 2009, INT J CANCER, V124, P2406, DOI 10.1002/ijc.24191 Licchetta M, 2016, Fiscal Sustainability Analytical Paper: Fiscal Sustainability and Public Spending on Health Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8 Lloyd-Williams F, 2020, BMC MED INFORM DECIS, V20, DOI 10.1186/s12911-020-01205-y Lu MS, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-413 Luengo-Fernández R, 2006, HEART, V92, P1384, DOI 10.1136/hrt.2005.072173 Luengo-Fernandez R, 2011, J ALZHEIMERS DIS, V27, P187, DOI 10.3233/JAD-2011-102019 Luque JS, 2019, J CANCER EDUC, V34, P412, DOI 10.1007/s13187-018-1321-0 Macacu A, 2015, BREAST CANCER RES TR, V154, P213, DOI 10.1007/s10549-015-3628-4 Mackenbach JP, 1997, SOC SCI MED, V44, P757, DOI 10.1016/S0277-9536(96)00073-1 Mandelblatt JS, 1999, CANCER EPIDEM BIOMAR, V8, P759 McNaughton RJ, 2015, J PUBLIC HEALTH-UK, V37, P218, DOI 10.1093/pubmed/fdu066 Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-10 Mindell J, 2012, INT J EPIDEMIOL, V41, P1585, DOI 10.1093/ije/dyr199 Miners A., 2013, Department of Health proposals for including wider societal benefits into value based pricing: a description and critique Ministry of Housing Communities and Local Government, LOC AUTH REV EXP FIN Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535 Mojica CM, 2018, PREV CHRONIC DIS, V15, DOI 10.5888/pcd15.170218 Moore GF, 2019, EVALUATION-US, V25, P23, DOI 10.1177/1356389018803219 Morrow JB, 2010, J COMMUN HEALTH, V35, P592, DOI 10.1007/s10900-010-9247-4 Morton KL, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013340 Murray CJL, 2013, LANCET, V381, P997, DOI 10.1016/S0140-6736(13)60355-4 Musa J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183924 Mytton OT, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002517 National Institute for Health and Care Excellence, HYP UPD APP J COST E NHS England, REV NAT CANC SCREEN NHS England, CARD DIS CVD NHS Expert Scientific and Clinical Advisory Panel, EM EV NHS HLTH CHECK O'Hagan A, 2019, AM STAT, V73, P69, DOI 10.1080/00031305.2018.1518265 Office for National Statistics, **DATA OBJECT** Office for National Statistics, 2013, ETHNIC GROUP SEX AGE Office for National Statistics, **DATA OBJECT** Office for National Statistics, **DATA OBJECT** Office for National Statistics, **DATA OBJECT** Office of National Statistics, **DATA OBJECT** OHagan T., 2020, SHELF VERSION 4 Oliver K, 2019, HEALTH RES POLICY SY, V17, DOI 10.1186/s12961-019-0432-3 Oono IP, 2011, J PUBLIC HEALTH-UK, V33, P496, DOI 10.1093/pubmed/fdr025 Palmer AJ, 2018, VALUE HEALTH, V21, P724, DOI 10.1016/j.jval.2018.02.002 Perry C, BEHAV INSIGHTS HLTH [Ponti A. World Health Organization - International Agency for Research on Cancer World Health Organization - International Agency for Research on Cancer], 2017, Cancer Screening in the European Union - Report on the Implementation of the Council Recommendation on Cancer Screening Prince M, 2014, DEMENTIA UK Public Health England, CARD DIS PROF Public Health England, 2018, REC TRENDS MORT ENG Public Health England, NHS POP SCREEN IN ST Public Health England, TECHN DOC SUBN ENGL Pujades-Rodriguez M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104671 Punekar YS, 2014, INT J CHRONIC OBSTR, V9, DOI 10.2147/COPD.S54417 Quigley, 2018, ELICITATION SCI ART, DOI DOI 10.1007/978-3-319-65052-4 Raffle AE., 2019, Screening: evidence and practice Rahman A, 2017, GEOSPATIAL HEALTH, V12, P3, DOI 10.4081/gh.2017.495 Rat C, 2018, EUR J CANCER PREV, V27, P227, DOI 10.1097/CEJ.0000000000000344 Rees I, 2018, PREV MED, V111, P323, DOI 10.1016/j.ypmed.2017.11.019 Regional Drug and Therapeutics Centre, 2019, COST COMP CHARTS AUG Rigby RA., 2019, Distributions for Modeling Location, Scale, DOI DOI 10.1201/9780429298547 Robson J, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-008840 Robson J, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007578 Rowen D, 2016, EUR J HEALTH ECON, V17, P733, DOI 10.1007/s10198-015-0718-5 Ruiz M, 2016, INTED 2016 10 ANN TE, DOI [10.21125/inted.2016.0911, DOI 10.21125/INTED.2016.0911] Rutter H, 2017, LANCET, V390, P2602, DOI 10.1016/S0140-6736(17)31267-9 Sabatino SA, 2012, AM J PREV MED, V43, P97, DOI 10.1016/j.amepre.2012.04.009 Saei Ghare Naz Marzieh, 2018, Asian Pac J Cancer Prev, V19, P875, DOI 10.22034/APJCP.2018.19.4.875 Sallis A, 2021, J PUBLIC HEALTH-UK, V43, pE92, DOI 10.1093/pubmed/fdz134 Sarwar N, 2010, LANCET, V375, P2215, DOI 10.1016/s0140-6736(10)60484-9 Sattar N, 2010, LANCET, V375, P735, DOI 10.1016/S0140-6736(09)61965-6 Secginli S, 2017, WORLDV EVID-BASED NU, V14, P316, DOI 10.1111/wvn.12245 Sexton E, 2019, EUR STROKE J, V4, P160, DOI 10.1177/2396987318825484 Siddiqui MRS, 2011, EUR J GEN PRACT, V17, P221, DOI 10.3109/13814788.2011.601412 Sin JP, 1999, INTERVENTIONS INCREA, DOI [10.1136/jms.6.4.170, DOI 10.1136/JMS.6.4.170] Singer DE, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000250 Spaniol Matthew J., 2019, Futures & Foresight Science, V1, DOI 10.1002/ffo2.3 Stasinopoulos D.M., 2017, Flexible regression and smoothing: using GAMLSS in R, DOI [10.1201/b21973, DOI 10.18637/JSS.V085.I04] Stewart S, 2004, HEART, V90, P286, DOI 10.1136/hrt.2002.008748 Stone EG, 2002, ANN INTERN MED, V136, P641, DOI 10.7326/0003-4819-136-9-200205070-00006 Stringhini S, 2017, LANCET, V389, P1229, DOI 10.1016/S0140-6736(16)32380-7 Suen SC, 2018, MED DECIS MAKING, V38, P452, DOI 10.1177/0272989X17741635 Sullivan PW, 2011, MED DECIS MAKING, V31, P800, DOI 10.1177/0272989X11401031 Symmons D, 2002, RHEUMATOLOGY, V41, P793, DOI 10.1093/rheumatology/41.7.793 Tammemägi MC, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001764 Teo CH, 2018, AM J PREV MED, V54, P133, DOI 10.1016/j.amepre.2017.08.028 The Health Foundation, 2020, COMPLEX ADAPTIVE SYS Tricco AC, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0465-6 Tseng DS, 2001, J GEN INTERN MED, V16, P563, DOI 10.1046/j.1525-1497.2001.016008567.x UK Data Service, 2014, HLTH SURV ENGL, DOI [10.5255/UKDA-SN- 7919-1, DOI 10.5255/UKDA-SN-7919-1] UK Data Service, 2009, HLTH SURV ENGL, DOI [10.5255/UKDA-SN- 6732-1, DOI 10.5255/UKDA-SN-6732-1] UK Data Service, 2010, HLTH SURV ENGL, DOI [10.5255/UKDA-SN- 6986-2, DOI 10.5255/UKDA-SN-6986-2] UK Government (2021), POP SCREEN PROGR DET Usher-Smith JA., 2017, NHS Health Check Programme Rapid Evidence Synthesis Usher-Smith JA, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-017717 Uy C, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.7893 van der Graaf P, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4896-1 Verdoodt F, 2015, EUR J CANCER, V51, P2375, DOI 10.1016/j.ejca.2015.07.006 Vernon SW, 2010, JNCI-J NATL CANCER I, V102, P1023, DOI 10.1093/jnci/djq223 Vieira AR, 2016, ANN ONCOL, V27, P81, DOI 10.1093/annonc/mdv381 Vieira J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178945 Volk RJ, 2007, AM J PREV MED, V33, P428, DOI 10.1016/j.amepre.2007.07.030 Volk RJ, 2016, AM J PREV MED, V51, P779, DOI 10.1016/j.amepre.2016.06.022 Wallach-Kildemoes H, 2013, EUR J CLIN PHARMACOL, V69, P1553, DOI 10.1007/s00228-013-1488-6 Wang YP, 2015, LUNG CANCER, V88, P124, DOI 10.1016/j.lungcan.2015.02.015 Ward S, 2007, Health Technol Assess, V11, P1 Webber L, 2014, EUR J EPIDEMIOL, V29, P867, DOI 10.1007/s10654-014-9978-0 Wells KJ, 2011, CANCER EPIDEM BIOMAR, V20, P1580, DOI 10.1158/1055-9965.EPI-11-0276 White M, 2009, WHY DO INTERVENTIONS, DOI [10.1332/ policypress/9781847423207.003.0005, DOI 10.1332/POLICYPRESS/9781847423207.003.0005] WikiBooks, SCRIPT Wobus DZ, 2005, HLTH CARE EXPENSES P WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025 Wormser D, 2011, LANCET, V377, P1085, DOI 10.1016/S0140-6736(11)60105-0 Yabroff KR, 1999, CANCER EPIDEM BIOMAR, V8, P749 NR 245 TC 9 Z9 11 U1 1 U2 14 PU NIHR JOURNALS LIBRARY PI SOUTHAMPTON PA UNIV SOUTHAMPTON, EVALUATION, TRIALS & STUDIES COORDINATING CENTRE, ALPHA HOUSE, ENTERPRISE RD, SOUTHAMPTON, SO16 7NS, ENGLAND SN 1366-5278 EI 2046-4924 J9 HEALTH TECHNOL ASSES JI Health Technol. Assess. PD MAY PY 2021 VL 25 IS 35 BP 1 EP + DI 10.3310/hta25350 PG 235 WC Health Care Sciences & Services WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI) SC Health Care Sciences & Services GA SN5LZ UT WOS:000658332300001 PM 34076574 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Guo, SY Wu, JR Zhou, W Liu, XK Liu, YY Zhang, JY Jia, SS Li, JL Wang, HJ AF Guo, Siyu Wu, Jiarui Zhou, Wei Liu, Xinkui Liu, Yingying Zhang, Jingyuan Jia, Shanshan Li, Jialin Wang, Haojia TI Identification and analysis of key genes associated with acute myocardial infarction by integrated bioinformatics methods SO MEDICINE LA English DT Review DE acute myocardial infarction; bioinformatics; biomarkers; differentially expressed gene ID CELL LUNG-CANCER; INFLAMMATORY RESPONSE; POTENTIAL BIOMARKERS; ATRIAL-FIBRILLATION; HEART-FAILURE; PROTEIN; CHEMOKINES; MICE; COMPLICATIONS; PATHOGENESIS AB Background: Acute myocardial infarction (AMI) is a common disease leading threat to human health around the world. Here we aimed to explore new biomarkers and potential therapeutic targets in AMI through adopting integrated bioinformatics tools. Methods: The gene expression Omnibus (GEO) database was used to obtain genes data of AMI and no-AMI whole blood. Furthermore, differentially expressed genes (DEGs) were screened using the "Limma" package in R 3.6.1 software. Functional and pathway enrichment analyses of DEGs were performed via "Bioconductor" and "GOplot" package in R 3.6.1 software. In order to screen hub DEGs, the STRING version 11.0 database, Cytoscape and molecular complex detection (MCODE) were applied. Correlation among the hub DEGs was evaluated using Pearson's correlation analysis. Results: By performing DEGs analysis, 289 upregulated and 62 downregulated DEGs were successfully identified from GSE66360, respectively. And they were mainly enriched in the terms of neutrophil activation, immune response, cytokine, nuclear factor kappa-B (NF-kappa B) signaling pathway, IL-17 signaling pathway, and tumor necrosis factor (TNF) signaling pathway. Based on the data of protein-protein interaction (PPI), the top 10 hub genes were ranked, including interleukin-8 (CXCL8), TNF, N-formyl peptide receptor 2 (FPR2), growth-regulated alpha protein (CXCL1), transcription factor AP-1 (JUN), interleukin-1 beta (IL1B), platelet basic protein (PPBP), matrix metalloproteinase-9 (MMP9), toll-like receptor 2 (TLR2), and high affinity immunoglobulin epsilon receptor subunit gamma (FCER1G). What's more, the results of correlation analysis demonstrated that there was positive correlation between the 10 hub DEGs. Conclusion: Ten DEGs were identified as potential candidate diagnostic biomarkers for patients with AMI in present study. However, further experiments are needed to confirm the functional pathways and hub genes associated with AMI. C1 [Guo, Siyu; Wu, Jiarui; Zhou, Wei; Liu, Xinkui; Liu, Yingying; Zhang, Jingyuan; Jia, Shanshan; Li, Jialin; Wang, Haojia] Beijing Univ Chinese Med, Sch Chinese Mat Med, Dept Clin Chinese Pharm, Beijing 100102, Peoples R China. RP Wu, JR (corresponding author), Beijing Univ Chinese Med, Sch Chinese Mat Med, Dept Clin Chinese Pharm, Beijing 100102, Peoples R China. EM exogamy@163.com RI Li, Jialin/IYJ-1259-2023; Zhang, Jingyuan/OFM-7855-2025; Liu, Xinkui/IUN-7947-2023 FU National Natural Science Foundation of China [81673829]; Young Scientists Training Program of Beijing University of Chinese Medicine FX The study was financially supported by National Natural Science Foundation of China (Grant Nos. 81673829) and Young Scientists Training Program of Beijing University of Chinese Medicine. CR Antoniades C, 2005, J AM COLL CARDIOL, V46, P1101, DOI 10.1016/j.jacc.2005.05.072 Aversano T, 2002, JAMA-J AM MED ASSOC, V287, P1943, DOI 10.1001/jama.287.15.1943 Aydin S, 2019, VASC HEALTH RISK MAN, V15, P1, DOI 10.2147/VHRM.S166157 Bajaj A, 2015, J INVEST MED, V63, P844, DOI 10.1097/JIM.0000000000000232 Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193 Bates ER, 2016, J AM COLL CARDIOL, V68, P1066, DOI 10.1016/j.jacc.2016.05.086 Berthonneche C, 2004, AM J PHYSIOL-HEART C, V287, pH340, DOI 10.1152/ajpheart.01210.2003 Carbon S, 2017, NUCLEIC ACIDS RES, V45, pD331, DOI 10.1093/nar/gkw1108 Chamberlain J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005073 Chen HM, 2006, HUM MOL GENET, V15, P519, DOI 10.1093/hmg/ddi469 Chen XY, 2018, INT J CLIN EXP PATHO, V11, P1036 Dai WR, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.922492 Dewald O, 2004, AM J PATHOL, V164, P665, DOI 10.1016/S0002-9440(10)63154-9 Dinarello CA, 2018, IMMUNOL REV, V281, P8, DOI 10.1111/imr.12621 Dinarello CA, 2011, EUR J IMMUNOL, V41, P1203, DOI 10.1002/eji.201141550 Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612 Eghbalzadeh K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02313 Frangogiannis NG, 2005, TRENDS CARDIOVAS MED, V15, P163, DOI 10.1016/j.tcm.2005.06.005 Frangogiannis NG, 2007, THROMB HAEMOSTASIS, V97, P738, DOI 10.1160/TH07-01-0022 Frangogiannis NG, 2004, CURR VASC PHARMACOL, V2, P163, DOI 10.2174/1570161043476375 Frangogiannis NG, 2012, CIRC RES, V110, P159, DOI 10.1161/CIRCRESAHA.111.243162 Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313 Gupta S, 2008, INDIAN J CLIN BIOCHE, V23, P89, DOI 10.1007/s12291-008-0021-7 Hazra A, 2016, INDIAN J DERMATOL, V61, P593, DOI 10.4103/0019-5154.193662 Kain V, 2019, PHARMACOL RES, V146, DOI 10.1016/j.phrs.2019.104295 Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27 Khodayari Saeed, 2019, Cell Physiol Biochem, V53, P887, DOI [10.33594/000000180, 10.33594/000000180] Kurrelmeyer KM, 2000, P NATL ACAD SCI USA, V97, P5456, DOI 10.1073/pnas.070036297 Kwon JM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224502 Law MR, 2002, ARCH INTERN MED, V162, P2405, DOI 10.1001/archinte.162.21.2405 Liuzzo G, 2007, J AM COLL CARDIOL, V49, P185, DOI 10.1016/j.jacc.2006.07.071 Lu CY, 2019, J ETHNOPHARMACOL, V241, DOI 10.1016/j.jep.2019.112010 Luo XB, 2019, ONCOL LETT, V18, P6171, DOI 10.3892/ol.2019.10988 Luppi F, 2007, LUNG CANCER, V56, P25, DOI 10.1016/j.lungcan.2006.11.014 Ma J, 2012, J BIOL CHEM, V287, P27480, DOI 10.1074/jbc.M112.358929 Maekawa N, 2002, J AM COLL CARDIOL, V39, P1229, DOI 10.1016/S0735-1097(02)01738-2 Mauro AG, 2019, J CARDIOVASC PHARM, V74, P175, DOI 10.1097/FJC.0000000000000717 Mozaffarian D, 2016, CIRCULATION, V133, pE38, DOI 10.1161/CIR.0000000000000350 Muñoz A, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/610950 Ni MW, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00469 Oldgren J, 2010, HEART, V96, P1451, DOI 10.1136/hrt.2009.188243 Paudel S, 2019, BLOOD, V133, P1335, DOI 10.1182/blood-2018-10-878082 Pei LY, 2020, FOOD SCI NUTR, V8, P1394, DOI 10.1002/fsn3.1406 Pordel S, 2018, J CLIN LAB ANAL, V32, DOI 10.1002/jcla.22402 Qian C, 2019, J CELL BIOCHEM, V120, P7771, DOI 10.1002/jcb.28051 Rahimi K, 2015, J EPIDEMIOL COMMUN H, V69, P1000, DOI 10.1136/jech-2015-205689 Rao SV, 2003, AM J CARDIOL, V91, P936, DOI 10.1016/S0002-9149(03)00107-3 Reed GW, 2017, LANCET, V389, P197, DOI 10.1016/S0140-6736(16)30677-8 Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007 de Porras VR, 2016, SCI REP-UK, V6, DOI 10.1038/srep24675 Saito Y, 2019, J CARDIOL, V74, P95, DOI 10.1016/j.jjcc.2019.04.001 Sepulveda JL, 2020, J MOL DIAGN, V22, P3, DOI 10.1016/j.jmoldx.2019.08.006 Shen YJ, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/9710421 Stein JM, 2009, J PERIODONTOL, V80, P1095, DOI 10.1902/jop.2009.080639 Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131 Veltman D, 2017, J THEOR BIOL, V415, P125, DOI 10.1016/j.jtbi.2016.12.016 Walter W, 2015, BIOINFORMATICS, V31, P2912, DOI 10.1093/bioinformatics/btv300 Xu SS, 2019, J THORAC DIS, V11, P3962, DOI 10.21037/jtd.2019.08.100 Zhan ML, 2018, CAN RESPIR J, V2018, DOI 10.1155/2018/8740491 Zhang P, 2018, INT HEART J, V59, P64, DOI 10.1536/ihj.17-084 Zhou W, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000020340 Zou RJ, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1790-x NR 62 TC 37 Z9 42 U1 3 U2 35 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7974 EI 1536-5964 J9 MEDICINE JI Medicine (Baltimore) PD APR 16 PY 2021 VL 100 IS 15 AR e25553 DI 10.1097/MD.0000000000025553 PG 11 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA SO4PR UT WOS:000658956900080 PM 33847684 OA Green Published, gold DA 2026-04-17 ER PT J AU Jacobson, FL Dezube, AR Bravo-iñiguez, C Kucukak, S Bay, CP Wee, JO Coppolino, AA Jaklitsch, MT Ducko, CT AF Jacobson, Francine L. Dezube, Aaron R. Bravo-iniguez, Carlos Kucukak, Suden Bay, Camden P. Wee, Jon O. Coppolino, Antonio A., III Jaklitsch, Michael T. Ducko, Christopher T. TI Preserving NLST mortality benefits and acceptable morbidity for lung cancer surgery in a community hospital SO JOURNAL OF SURGICAL ONCOLOGY LA English DT Article DE community care network; computed tomography; diagnostic imaging; lung cancer morbidity and mortality; NLST; video‐ assisted thoracoscopic surgery ID LOBECTOMY; RESECTION; TRIAL; PATIENT; VOLUME AB Background and Objectives The aim of this study was to demonstrate whether academic thoracic surgeons could achieve morbidity and mortality rates in community hospitals equivalent to those seen in National Lung Screening Trial (NLST). Methods This was a retrospective review of community hospital lung cancer procedures for clinical Stage I-III non-small-cell lung cancers from 2007 through 2014. Variables include age, comorbidities, computed tomography (CT) characterization, and operative techniques. Results There were 177 patients who had lung cancers removed by a minimally invasive approach (79%), including lobectomy in 127 (72%), segmentectomy in 4 (2%), and wedge-resections in 46 (26%). The median patient age was 71 years (interquartile range [IQR], 63-76). The cohort was primarily female (58%), clinical Stage I (82%), with a median tumor size of 2.3 cm (IQR, 1.5-3.3). The median length of stay was 6 days (range: 1-35). Complications were experienced by 78 (44.1%) patients, most commonly atrial fibrillation in 20 (11.3%) followed by air-leak in 19 (10.7%). There were no in-hospital deaths. Tumor location and extent of resection were associated with complications, while larger tumor size, margin contour, and resection method were associated with air-leak (all p < 0.05). Higher clinical stage and larger tumor size were associated with occult Stage III disease (both p < 0.05). Conclusions The low morbidity and mortality rates from the NLST were achievable in a community setting for early-stage lung cancer. Characterization of cancers using CT imaging identified factors most commonly associated with postoperative complications and the presence of occult Stage III disease. C1 [Jacobson, Francine L.] Brigham & Womens Hosp, Div Thorac Radiol, 75 Francis St, Boston, MA 02115 USA. [Dezube, Aaron R.; Bravo-iniguez, Carlos; Kucukak, Suden; Wee, Jon O.; Coppolino, Antonio A., III; Jaklitsch, Michael T.; Ducko, Christopher T.] Brigham & Womens Hosp, Div Thorac Surg, Boston, MA 02115 USA. [Bay, Camden P.] Brigham & Womens Hosp, Div Radiol, Boston, MA 02115 USA. C3 Harvard University; Harvard University Medical Affiliates; Brigham & Women's Hospital; Harvard University; Harvard University Medical Affiliates; Brigham & Women's Hospital; Harvard University; Harvard University Medical Affiliates; Brigham & Women's Hospital RP Jacobson, FL (corresponding author), Brigham & Womens Hosp, Div Thorac Radiol, 75 Francis St, Boston, MA 02115 USA. EM fjacobson@bwh.harvard.edu RI Bravo Iñiguez, Carlos/IAR-1837-2023 OI Bravo Iñiguez, Carlos/0000-0003-4134-0792 FU Jack Mitchell Thoracic Oncology Fellowship fund FX This study was supported in part through the generous contributions of the Jack Mitchell Thoracic Oncology Fellowship fund, dedicated to improve Thoracic Oncology care. CR Aberle DR, 2019, J THORAC ONCOL, V14, P1732, DOI 10.1016/j.jtho.2019.05.044 Aberle DR, 2011, NEW ENGL J MED, V365, P395, DOI 10.1056/NEJMoa1102873 Al-Sahaf M, 2015, J THORAC DIS, V7, pS152, DOI 10.3978/j.issn.2072-1439.2015.04.08 Allen MS, 2006, ANN THORAC SURG, V81, P1013, DOI 10.1016/j.athoracsur.2005.06.066 [Anonymous], 2009, Stata Statistical Software version 11.1 Burt BM, 2014, J THORAC CARDIOV SUR, V148, P19, DOI 10.1016/j.jtcvs.2014.03.007 Cheng AM, 2015, ONCOLOGY-NY, V29, P160 Darling GE, 2011, J THORAC CARDIOV SUR, V141, P662, DOI 10.1016/j.jtcvs.2010.11.008 Dezube AR, 2020, EXPERT REV ANTICANC, V20, P117, DOI 10.1080/14737140.2020.1723418 Europe PMC, NEW EV SUPP LUNG CAN Giambrone GP, 2016, EUR J CARDIO-THORAC, V49, pE65, DOI 10.1093/ejcts/ezv476 Krist AH, 2021, JAMA-J AM MED ASSOC, V325, P962, DOI 10.1001/jama.2021.1117 NEJM, INFL HOSP VOL SURV R, DOI 10.1056/NEJM200107193450306 Pezzi CM, 2014, J THORAC CARDIOV SUR, V148, P2269, DOI 10.1016/j.jtcvs.2014.07.077 Pinsky PF, 2014, ANN INTERN MED, V161, P627, DOI 10.7326/M14-1484 Shiono S, 2019, J THORAC DIS, V11, pS207, DOI 10.21037/jtd.2019.02.22 Tanner NT, 2017, AM J RESP CRIT CARE, V196, P602, DOI 10.1164/rccm.201705-0914OC Yang CFJ, 2016, ANN THORAC SURG, V101, P1037, DOI 10.1016/j.athoracsur.2015.11.018 NR 18 TC 2 Z9 2 U1 0 U2 1 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4790 EI 1096-9098 J9 J SURG ONCOL JI J. Surg. Oncol. PD JUL PY 2021 VL 124 IS 1 BP 124 EP 134 DI 10.1002/jso.26483 EA APR 2021 PG 11 WC Oncology; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Surgery GA SQ1GX UT WOS:000639320900001 PM 33844848 DA 2026-04-17 ER PT J AU De León, LE Rochefort, MM Bravo-Iñiguez, CE Fox, SW Tarascio, JN Cardin, K DuMontier, C Frain, LN Jaklitsch, MT AF De Leon, Luis E. Rochefort, Matthew M. Bravo-Iniguez, Carlos E. Fox, Sam W. Tarascio, Jeffrey N. Cardin, Kristin DuMontier, Clark Frain, Laura N. Jaklitsch, Michael T. TI Opportunities for quality improvement in the morbidity pattern of older adults undergoing pulmonary lobectomy for cancer SO JOURNAL OF GERIATRIC ONCOLOGY LA English DT Article DE Thoracic surgery; Morbidity; Older adult; Minimally invasive surgery; Postoperative outcomes; Oncology outcomes; Lobectomy AB Background: There is limited information on the frequency of complications among older adults after oncological thoracic surgery in the modern era. We hypothesized that morbidity and mortality in older adults with lung cancer undergoing lobectomy is low and different than that of younger patients undergoing thoracic surgery. Methods: All patients undergoing lobectomy at a large volume academic center between May 2016 and May 2019 were included. Patients were prospectively monitored to grade postoperative morbidity by organ system, based on the Clavien-Dindo classification. Patients were divided into two groups: Group 1 included patients 65?91 years of age, and Group 2 included those <65 years. Results: Of 680 lobectomies in 673 patients, 414(61%) were older than 65 years of age (group 1). Median age at surgery was 68 years (20?91). Median hospital stay was 4 days (1?38) and longer in older adults. Older adults experienced higher rates of grade II and IV complications, mostly driven by an increased incidence of delirium, atrial fibrillation, prolonged air leak, respiratory failure and urinary retention. In this modern cohort, there was only 1 stroke (0.1%), and delirium was reduced to 7%. Patients undergoing minimally invasive (MI) surgery had a lower rate of Grade IV life-threatening complications. Older adults were more likely to be discharged to a rehabilitation facility, however this difference also disappeared with MI surgical procedures. Conclusions: Current morbidity of older adults undergoing lobectomy for cancer is low and is different than that of younger patients. Thoracotomy may be associated with postoperative complications in these patients. Our findings suggest the need to consider MI approaches and broad-based, geriatric-focused perioperative management of older adults undergoing lobectomy. Background: There is limited information on the frequency of complications among older adults after oncological thoracic surgery in the modern era. We hypothesized that morbidity and mortality in older adults with lung cancer undergoing lobectomy is low and different than that of younger patients undergoing thoracic surgery. Methods: All patients undergoing lobectomy at a large volume academic center between May 2016 and May 2019 were included. Patients were prospectively monitored to grade postoperative morbidity by organ system, based on the Clavien-Dindo classification. Patients were divided into two groups: Group 1 included patients 65?91 years of age, and Group 2 included those <65 years. Results: Of 680 lobectomies in 673 patients, 414(61%) were older than 65 years of age (group 1). Median age at surgery was 68 years (20?91). Median hospital stay was 4 days (1?38) and longer in older adults. Older adults experienced higher rates of grade II and IV complications, mostly driven by an increased incidence of delirium, atrial fibrillation, prolonged air leak, respiratory failure and urinary retention. In this modern cohort, there was only 1 stroke (0.1%), and delirium was reduced to 7%. Patients undergoing minimally invasive (MI) surgery had a lower rate of Grade IV life-threatening complications. Older adults were more likely to be discharged to a rehabilitation facility, however this difference also disappeared with MI surgical procedures. Conclusions: Current morbidity of older adults undergoing lobectomy for cancer is low and is different than that of younger patients. Thoracotomy may be associated with postoperative complications in these patients. Our findings suggest the need to consider MI approaches and broad-based, geriatric-focused perioperative management of older adults undergoing lobectomy. ? 2020 Published by Elsevier Ltd. C1 [De Leon, Luis E.; Rochefort, Matthew M.; Bravo-Iniguez, Carlos E.; Fox, Sam W.; Tarascio, Jeffrey N.; Jaklitsch, Michael T.] Harvard Med Sch, Brigham & Womens Hosp, Div Thorac Surg, Boston, MA 02115 USA. [Cardin, Kristin; DuMontier, Clark; Frain, Laura N.] Harvard Med Sch, Brigham & Womens Hosp, Div Aging, Boston, MA 02115 USA. C3 Harvard University; Harvard University Medical Affiliates; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University Medical Affiliates; Brigham & Women's Hospital RP De León, LE (corresponding author), Brigham & Womens Hosp, Div Thorac Surg, 75 Francis St, Boston, MA 02115 USA. EM ldeleonmorales@bwh.harvard.edu RI ; Bravo Iñiguez, Carlos/IAR-1837-2023 OI DuMontier, Clark/0000-0003-2582-7816; Bravo Iñiguez, Carlos/0000-0003-4134-0792 FU Harvard Translational Research in Aging Training Program (National Institute on Aging of the National Institutes of Health) [T32AG023480]; National Institute on Aging [T32AG023480] Funding Source: NIH RePORTER FX Dr. DuMontier is supported by the Harvard Translational Research in Aging Training Program (National Institute on Aging of the National Institutes of Health: T32AG023480). CR Aalami OO, 2003, ARCH SURG-CHICAGO, V138, P1068, DOI 10.1001/archsurg.138.10.1068 Alvis Bret D, 2015, Anesthesiol Clin, V33, P447, DOI [10.1016/j.anclin.2015.05.003, 10.1016/j.anclin.2015.05.003] [Anonymous], 2015, J AM COLL SURGEONS, V220, P136, DOI 10.1016/j.jamcollsurg.2014.10.019 Berry MF, 2009, ANN THORAC SURG, V88, P1093, DOI 10.1016/j.athoracsur.2009.06.012 Cerfolio RJ, 2006, ANN THORAC SURG, V82, P424, DOI 10.1016/j.athoracsur.2006.02.085 Clavien PA, 2009, ANN SURG, V250, P187, DOI 10.1097/SLA.0b013e3181b13ca2 Colby S.L., 2014, PROJECTIONS SIZE COM, P13 Colloca G, 2010, SURG ONCOL, V19, P124, DOI 10.1016/j.suronc.2009.11.011 Demeure MJ, 2006, J AM COLL SURGEONS, V203, P752, DOI 10.1016/j.jamcollsurg.2006.07.032 Drewbrook C, 2016, Open Journal of Thoracic Surgery, V06, P33, DOI [10.4236/ojts.2016.64006, DOI 10.4236/OJTS.2016.64006] Durick D, 1997, CARING OLDER PATIENT, V13 Fong TG, 2009, NAT REV NEUROL, V5, P210, DOI 10.1038/nrneurol.2009.24 Griebling TL, 2013, CURR BLADDER DYSFUNC, V8, P92, DOI 10.1007/s11884-013-0183-x Harada CN, 2013, CLIN GERIATR MED, V29, P737, DOI 10.1016/j.cger.2013.07.002 Hshieh TT, 2008, J GERONTOL A-BIOL, V63, P764, DOI 10.1093/gerona/63.7.764 Jaklitsch MT, 1996, CHEST, V110, P751, DOI 10.1378/chest.110.3.751 Jaklitsch MT, 2004, CRIT REV ONCOL HEMAT, V49, P165, DOI 10.1016/j.critrevonc.2003.08.003 Jiang L, 2014, ANN THORAC SURG, V97, P1008, DOI 10.1016/j.athoracsur.2013.10.031 Jones RN, 2010, AM J GERIAT PSYCHIAT, V18, P117, DOI 10.1097/JGP.0b013e3181b972e8 Kalaria RN, 2012, BRAIN, V135, P2582, DOI 10.1093/brain/aws235 Khan BA, 2018, J AM GERIATR SOC, V66, P2289, DOI 10.1111/jgs.15640 Mueller MR, 2014, J THORAC DIS, V6, P271, DOI 10.3978/j.issn.2072-1439.2013.11.29 Nicolini F, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/736298 Pallis AG, 2014, J GERIATR ONCOL, V5, P204, DOI 10.1016/j.jgo.2013.09.001 Peters R, 2006, POSTGRAD MED J, V82, P84, DOI [10.1136/pgmj.2005.036665, 10.1037/ccp0000896] Robinson TN, 2008, CLIN INTERV AGING, V3, P351, DOI 10.2147/CIA.S2759 Schenning Katie J, 2015, Anesthesiol Clin, V33, P505, DOI [10.1016/j.anclin.2015.05.007, 10.1016/j.anclin.2015.05.007] Schlitzkus LL, 2015, SURG CLIN N AM, V95, P391, DOI 10.1016/j.suc.2014.12.001 SEYMOUR DG, 1983, GERONTOLOGY, V29, P262, DOI 10.1159/000213125 Shiono S, 2013, INTERACT CARDIOV TH, V16, P819, DOI 10.1093/icvts/ivt034 Siroky M B, 2004, Rev Urol, V6 Suppl 1, pS3 Soto-Perez-de-Celis E, 2018, LANCET ONCOL, V19, pE305, DOI 10.1016/S1470-2045(18)30348-6 Suemitsu R, 2009, J THORAC ONCOL, V4, P193, DOI 10.1097/JTO.0b013e318194fc4f U.S. Cancer StatisticsWorking Group, US CANC STAT DAT VIS Venuta F, 2016, J THORAC DIS, V8, pS908, DOI 10.21037/jtd.2016.05.20 NR 35 TC 7 Z9 7 U1 0 U2 1 PU ELSEVIER PI AMSTERDAM PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS SN 1879-4068 EI 1879-4076 J9 J GERIATR ONCOL JI J. Geriatr. Oncol. PD APR PY 2021 VL 12 IS 3 BP 416 EP 421 DI 10.1016/j.jgo.2020.09.016 EA MAR 2021 PG 6 WC Oncology; Geriatrics & Gerontology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Geriatrics & Gerontology GA RE8IS UT WOS:000634391900012 PM 32980269 OA Green Submitted DA 2026-04-17 ER PT J AU Bernard, A Cottenet, J Bonniaud, P Piroth, L Arveux, P Tubert-Bitter, P Quantin, C AF Bernard, Alain Cottenet, Jonathan Bonniaud, Philippe Piroth, Lionel Arveux, Patrick Tubert-Bitter, Pascale Quantin, Catherine TI Comparison of Cancer Patients to Non-Cancer Patients among COVID-19 Inpatients at a National Level SO CANCERS LA English DT Article DE COVID-19; cancer; tumour subtype; mortality; intensive care unit; medico-administrative data; SARS-CoV-2; France ID PREVALENCE; MORTALITY AB Simple Summary Several smaller studies have shown that COVID-19 patients with cancer are at a significantly higher risk of death. Our aim was to compare patients hospitalized for COVID-19 with cancer to those without cancer using national data and to study the effect of cancer on the risk of hospital death and intensive care unit admission. This study shows that, in France, patients with COVID-19 and cancer have a two-fold risk of death when compared to COVID-19 patients without cancer. This study also provides information about the types of cancer for which the prognosis is worse, such as hematological cancers and, among solid tumours, all metastatic cancers but also lung cancers. Our results reinforce the need to implement an organization within facilities to prevent the contamination of patients being treated for cancer and the importance of all measures of physical prevention and of vaccination. (1) Background: Several smaller studies have shown that COVID-19 patients with cancer are at a significantly higher risk of death. Our objective was to compare patients hospitalized for COVID-19 with cancer to those without cancer using national data and to study the effect of cancer on the risk of hospital death and intensive care unit (ICU) admission. (2) Methods: All patients hospitalized in France for COVID-19 in March-April 2020 were included from the French national administrative database, which contains discharge summaries for all hospital admissions in France. Cancer patients were identified within this population. The effect of cancer was estimated with logistic regression, adjusting for age, sex and comorbidities. (3) Results: Among the 89,530 COVID-19 patients, we identified 6201 cancer patients (6.9%). These patients were older and were more likely to be men and to have complications (acute respiratory and kidney failure, venous thrombosis, atrial fibrillation) than those without cancer. In patients with hematological cancer, admission to ICU was significantly more frequent (24.8%) than patients without cancer (16.4%) (p < 0.01). Solid cancer patients without metastasis had a significantly higher mortality risk than patients without cancer (aOR = 1.4 [1.3-1.5]), and the difference was even more marked for metastatic solid cancer patients (aOR = 3.6 [3.2-4.0]). Compared to patients with colorectal cancer, patients with lung cancer, digestive cancer (excluding colorectal cancer) and hematological cancer had a higher mortality risk (aOR = 2.0 [1.6-2.6], 1.6 [1.3-2.1] and 1.4 [1.1-1.8], respectively). (4) Conclusions: This study shows that, in France, patients with COVID-19 and cancer have a two-fold risk of death when compared to COVID-19 patients without cancer. We suggest the need to reorganize facilities to prevent the contamination of patients being treated for cancer, similar to what is already being done in some countries. C1 [Bernard, Alain] CHU Dijon, Bocage Hosp, Dept Thorac & Cardiovasc Surg, 14 Rue Gaffarel,BP 77908, F-21079 Dijon, France. [Cottenet, Jonathan; Quantin, Catherine] Bourgogne Franche Comte Univ, Univ Hosp, Biostat & Bioinformat DIM, BP 77908, F-21079 Dijon, France. [Bonniaud, Philippe] Bourgogne Franche Comte Univ, Fac Med, F-21000 Dijon, France. [Bonniaud, Philippe] Univ Hosp, Pulm Med & Intens Care Unit Dept, Reference Ctr Rare Pulm Dis, BP 77908, F-21079 Dijon, France. [Bonniaud, Philippe; Piroth, Lionel] INSERM, LNC, UMR1231, LipSTIC LabEx Team, F-21000 Dijon, France. [Piroth, Lionel; Quantin, Catherine] Dijon Univ Hosp, INSERM, Clin Epidemiol Clin Trials Unit, CIC 1432,Clin Invest Ctr, F-21000 Dijon, France. [Piroth, Lionel] Univ Hosp, Infect Dis Dept, BP 77908, F-21079 Dijon, France. [Arveux, Patrick] Univ Lausanne, Unisante, Ctr Primary Care & Publ Hlth, CH-1015 Lausanne, Switzerland. [Tubert-Bitter, Pascale; Quantin, Catherine] Paris Saclay Univ, UVSQ, INSERM, CESP,High Dimens Biostat Drug Safety & Genom, F-94800 Villejuif, France. C3 Universite Bourgogne Europe; CHU Dijon Bourgogne; Universite Bourgogne Europe; CHU Dijon Bourgogne; Universite Bourgogne Europe; Universite Bourgogne Europe; CHU Dijon Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Agro; Institut Agro Dijon; Universite Bourgogne Europe; Universite Bourgogne Europe; CHU Dijon Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Bourgogne Europe; CHU Dijon Bourgogne; Swiss School of Public Health (SSPH+); University of Lausanne; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm) RP Quantin, C (corresponding author), Bourgogne Franche Comte Univ, Univ Hosp, Biostat & Bioinformat DIM, BP 77908, F-21079 Dijon, France.; Quantin, C (corresponding author), Dijon Univ Hosp, INSERM, Clin Epidemiol Clin Trials Unit, CIC 1432,Clin Invest Ctr, F-21000 Dijon, France.; Quantin, C (corresponding author), Paris Saclay Univ, UVSQ, INSERM, CESP,High Dimens Biostat Drug Safety & Genom, F-94800 Villejuif, France. EM alain.bernard@chu-dijon.fr; jonathan.cottenet@chu-dijon.fr; philippe.bonniaud@chu-dijon.fr; lionel.piroth@chu-dijon.fr; Patrick.Arveux@unisante.ch; pascale.tubert@inserm.fr; catherine.quantin@chu-dijon.fr RI Tubert-Bitter, Pascale/E-6118-2016; BONNIAUD, Philippe/ITT-4660-2023; Quantin, Catherine/GRJ-8368-2022 OI Cottenet, Jonathan/0009-0002-8501-3312; bernard, alain/0000-0002-5367-0097; BONNIAUD, Philippe/0000-0002-3670-5622; piroth, lionel/0000-0003-4478-1032; Quantin, Catherine/0000-0001-5134-9411 FU CRA (Cancer Research Association) Foundation FX This project was funded by the CRA (Cancer Research Association) Foundation, which had no role in the study. CR Abdihamid O, 2020, CANCER MANAG RES, V12, P8923, DOI 10.2147/CMAR.S272008 Bénézit F, 2020, INFECTION, V48, P489, DOI 10.1007/s15010-019-01388-1 Bouadma L, 2020, INTENS CARE MED, V46, P579, DOI 10.1007/s00134-020-05967-x Brar G, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01580 Bryere J, 2018, EUR J CANCER PREV, V27, P391, DOI 10.1097/CEJ.0000000000000326 Cantuti-Castelvetri L, 2020, SCIENCE, V370, P856, DOI 10.1126/science.abd2985 Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244 Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7 Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422 Della Porta M.G., 2020, study Lancet Haematol., V7, P745, DOI [10.1016/S2352-3026, DOI 10.1016/S2352-3026] Deng GT, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02902-w Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020 Gupta S, 2020, JAMA INTERN MED, V180, P1436, DOI 10.1001/jamainternmed.2020.3596 Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9 Lee LYW, 2020, LANCET ONCOL, V21, P1309, DOI 10.1016/S1470-2045(20)30442-3 Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6 Liu W, 2020, CHINESE MED J-PEKING, V133, P1032, DOI 10.1097/CM9.0000000000000775 McKinney EF, 2018, NAT IMMUNOL, V19, P213, DOI 10.1038/s41590-018-0045-y Moore D, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1024 Piroth L, 2021, LANCET RESP MED, V9, P251, DOI 10.1016/S2213-2600(20)30527-0 Rey G, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-33 Roncati L, 2020, CLIN IMMUNOL, V217, DOI 10.1016/j.clim.2020.108487 Sante Publique France, EP COVID 19 CHIFFR Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831 Stoecklin SB, 2020, EUROSURVEILLANCE, V25, P20, DOI 10.2807/1560-7917.ES.2020.25.6.2000094 Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7 Wang BL, 2020, AGING-US, V12, P6049, DOI 10.18632/aging.103000 Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238 Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3 NR 29 TC 35 Z9 40 U1 0 U2 8 PU MDPI PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND EI 2072-6694 J9 CANCERS JI Cancers PD MAR PY 2021 VL 13 IS 6 AR 1436 DI 10.3390/cancers13061436 PG 15 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA RE7LY UT WOS:000634331900001 PM 33801131 OA Green Submitted, Green Published, gold DA 2026-04-17 ER PT J AU Pastori, D Marang, A Bisson, A Menichelli, D Herbert, J Lip, GYH Fauchier, L AF Pastori, Daniele Marang, Amelie Bisson, Arnaud Menichelli, Danilo Herbert, Julien Lip, Gregory Y. H. Fauchier, Laurent TI Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: A nationwide cohort study SO CANCER LA English DT Article DE atrial fibrillation; bleeding; cancer; mortality; stroke; thromboembolism ID ANTICOAGULATION; STROKE; SCORE; RISK AB Background The number of patients with atrial fibrillation (AF) and cancer is rapidly increasing in clinical practice. The impact of cancer on clinical outcomes in this patient population is unclear, as is the performance of the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol) and CHA(2)DS(2)-VASc (Congestive Heart Failure, Hypertension, Age >= 75 years, Diabetes Mellitus, Stroke or Transient Ischemic Attack, Vascular Disease, Age 65 to 74 Years, Sex Category) scores. Methods This was an observational, retrospective cohort study including 2,435,541 adults hospitalized with AF. The authors investigated the incidence rates (IRs) of all-cause and cardiovascular mortality, ischemic stroke, major bleeding, and intracranial hemorrhage (ICH) according to the presence of cancer and cancer types. Results Overall, 399,344 (16.4%) had cancer, with the most common cancers being metastatic, prostatic, colorectal, lung, breast, and bladder. During a mean follow-up of 2.0 years, cancer increased all-cause mortality (hazard ratio [HR], 2.00; 95% confidence interval [CI], 1.99-2.01). The IR of ischemic stroke was higher with pancreatic cancer (2.8%/y), uterine cancer (2.6%/y), and breast cancer (2.6%/y), whereas it was lower with liver/lung cancer (1.9%/y) and leukemia/myeloma (2.0%/y), in comparison with noncancer patients (2.4%/y). Cancer increased the risk of major bleeding (HR, 1.27; 95% CI, 1.26-1.28) and ICH (HR, 1.07; 95% CI, 1.05-1.10). Leukemia, liver cancer, myeloma, and metastatic cancers showed the highest IRs for major bleeding/ICH. Major bleeding and ICH rates progressively increased with the HAS-BLED score, which showed generally good predictivity with C indexes > 0.70 for all cancer types. The CHA(2)DS(2)-VASc score's predictivity was slightly lower in AF patients with cancer. Conclusions Cancer increased all-cause mortality, major bleeding, and ICH risk in AF patients. The association between cancer and ischemic stroke differed among cancer types, and in some types, the risk of bleeding seemed to exceed the thromboembolic risk. C1 [Pastori, Daniele; Menichelli, Danilo] Sapienza Univ Rome, Dept Clin Internal Anesthesiol & Cardiovasc Sci, Emergency Med Unit, Rome, Italy. [Pastori, Daniele; Lip, Gregory Y. H.] Univ Liverpool, Liverpool Ctr Cardiovasc Sci, Liverpool, Merseyside, England. [Pastori, Daniele; Lip, Gregory Y. H.] Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England. [Marang, Amelie; Bisson, Arnaud; Herbert, Julien; Fauchier, Laurent] Univ Tours, CHU Trousseau, Serv Cardiol, Tours, France. [Marang, Amelie; Bisson, Arnaud; Herbert, Julien; Fauchier, Laurent] Univ Tours, Fac Med, EA7505, Tours, France. [Herbert, Julien] Univ Tours, CHU Tours, Serv Informat Med Epidemiol & Econ Sante, Tours, France. C3 Sapienza University Rome; University of Liverpool; Liverpool Heart & Chest Hospital; Universite de Tours; CHU Tours; Universite de Tours; CHU Tours; Universite de Tours RP Pastori, D (corresponding author), Sapienza Univ Rome, Dept Clin Internal Anesthesiol & Cardiovasc Sci, Viale Policlin 155, I-00161 Rome, Italy. EM daniele.pastori@uniroma1.it RI Lip, Gregory/AEO-0575-2022; Fauchier, Laurent/MTE-2439-2025; pastori, daniele/J-7087-2016; Menichelli, Danilo/W-5498-2018 OI Fauchier, Laurent/0000-0002-9267-1658; pastori, daniele/0000-0001-6357-5213; Menichelli, Danilo/0000-0001-9467-5903 CR Abrahami D, 2020, THROMB HAEMOSTASIS, V120, P1384, DOI 10.1055/s-0040-1714213 Ameri P., 2021, PROG CARDIOVASC DIS Aspberg S, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2019.104560 Atterman A, 2020, J INTERN MED, V288, P457, DOI 10.1111/joim.13092 Bang OY, 2011, J CLIN NEUROL, V7, P53, DOI 10.3988/jcn.2011.7.2.53 Borre ED, 2018, THROMB HAEMOSTASIS, V118, P2171, DOI 10.1055/s-0038-1675400 Chao TF, 2018, THROMB HAEMOSTASIS, V118, P768, DOI 10.1055/s-0038-1636534 Chu G, 2019, BLOOD REV, V35, P59, DOI 10.1016/j.blre.2019.03.005 D'Souza M, 2018, EUR J PREV CARDIOL, V25, P651, DOI 10.1177/2047487318759858 Fauchier L, 2015, OPEN HEART, V2, DOI 10.1136/openhrt-2015-000290 Fradley MG, 2020, JACC-CARDIOONCOL, V2, P747, DOI 10.1016/j.jaccao.2020.09.008 Guo YT, 2020, AM J MED, V133, P1195, DOI 10.1016/j.amjmed.2020.03.019 Herrmann J, 2020, NAT REV CARDIOL, V17, P474, DOI 10.1038/s41569-020-0348-1 Hu YF, 2013, INT J CARDIOL, V165, P355, DOI 10.1016/j.ijcard.2012.08.036 Hung YP, 2019, INT J CARDIOL, V296, P81, DOI 10.1016/j.ijcard.2019.08.021 Kitano T, 2020, THROMB HAEMOSTASIS, V120, P714, DOI 10.1055/s-0040-1708484 Li YG, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.012546 Lip GYH, 2016, J THROMB HAEMOST, V14, P1711, DOI 10.1111/jth.13386 Ording AG, 2017, CANCER MED-US, V6, P1165, DOI 10.1002/cam4.1054 Pastori D, 2020, INT J CANCER, V147, P3424, DOI 10.1002/ijc.33179 Pastori D, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.012596 Pastori D, 2015, INT J CARDIOL, V201, P513, DOI 10.1016/j.ijcard.2015.08.054 Singh GK, 2017, J ENVIRON PUBLIC HEA, V2017, P1, DOI 10.1155/2017/2819372 Tafur AJ, 2017, THROMB HAEMOSTASIS, V117, P1192, DOI 10.1160/TH16-11-0840 Williams BA, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.14874 Yuan M, 2019, CARDIOL RES PRACT, V2019, DOI 10.1155/2019/8985273 NR 26 TC 69 Z9 72 U1 1 U2 8 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD JUN 15 PY 2021 VL 127 IS 12 BP 2122 EP 2129 DI 10.1002/cncr.33470 EA FEB 2021 PG 8 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA SG5JC UT WOS:000621561900001 PM 33631041 OA Bronze DA 2026-04-17 ER PT J AU Takada, N Nishida, H Kondo, Y Oyama, Y Kusaba, T Kadowaki, H Hirakawa, K Iwao, S Kiyooka, S Daa, T AF Takada, Nami Nishida, Haruto Kondo, Yoshihiko Oyama, Yuzo Kusaba, Takahiro Kadowaki, Hiroko Hirakawa, Koji Iwao, Satomi Kiyooka, Seiji Daa, Tsutomu TI Pulmonary wedge aspiration cytology for the rapid diagnosis of pulmonary tumor thrombotic microangiopathy: A case report SO DIAGNOSTIC CYTOPATHOLOGY LA English DT Article DE aspiration cytology; extramammary Paget' s disease; pulmonary hypertension; pulmonary tumor thrombotic microangiopathy; pulmonary wedge aspiration cytology AB Pulmonary tumor thrombotic microangiopathy (PTTM) is a cancer-related pulmonary complication characterized by rapid progression of dyspnea and pulmonary hypertension, occasionally causing sudden death. Given the condition of patients with dyspnea, lung biopsies are limited because of their invasiveness. A 72-year-old man presented with chronic atrial fibrillation and a high right heart load, as determined using ultrasonography. He had previously undergone resection of the left axillary skin secondary to extramammary Paget's disease (EMPD). Clinically, PTTM was suspected and pulmonary wedge aspiration cytology, collected from the pulmonary artery during catherization, was performed. Cytologically, the tumor demonstrated three-dimensional cell clusters with good cohesion and molding by the blood vessel lumen. Additionally, endothelial-like cells were observed at the periphery of the tumor clusters; fibrin was evident in the clusters. The tumor cells were large, round, and had high nuclear/cytoplasmic ratios. The nuclei demonstrated a variety of sizes and were irregularly shaped, with prominent nucleoli; cells undergoing mitosis were evident. The tumor cells were suspected of being poorly differentiated adenocarcinoma cells, consistent with PTTM. Two days after the aspiration cytology, the patient died and a pathological autopsy was performed. Histologically, the PTTM was determined to have caused the pulmonary hypertension and the primary PTTM site was apparently derived from the EMPD. For rapid diagnoses, an understanding of the tumor's cytological features is important and should contribute to early treatment intervention. Aspiration cytology, using pulmonary artery blood samples, during catherization is a useful tool for diagnosing PTTM. C1 [Takada, Nami; Nishida, Haruto; Kondo, Yoshihiko; Oyama, Yuzo; Kusaba, Takahiro; Kadowaki, Hiroko; Hirakawa, Koji; Iwao, Satomi; Kiyooka, Seiji; Daa, Tsutomu] Oita Univ, Dept Diagnost Pathol, Fac Med, Oita, Japan. C3 Oita University RP Nishida, H (corresponding author), Oita Univ, Dept Diagnost Pathol, Fac Med, Hasama Machi 1-1, Yufu 8795593, Japan. EM nharuto@oita-u.ac.jp CR ABATI A, 1994, HUM PATHOL, V25, P257, DOI 10.1016/0046-8177(94)90197-X Banno Aya, 2016, BMJ Case Rep, V2016, DOI [10.1136/bcr-2016-216666, 10.1136/bcr-2016-216666] Fukada I, 2015, CLIN BREAST CANCER, V15, pE167, DOI 10.1016/j.clbc.2014.10.008 Ishiguro T, 2016, INTERNAL MED, V55, P2679, DOI 10.2169/internalmedicine.55.6855 MASSON RG, 1985, CHEST, V88, P908, DOI 10.1378/chest.88.6.908 MASSON RG, 1989, NEW ENGL J MED, V321, P71, DOI 10.1056/NEJM198907133210202 Sato N, 2019, HISTOPATHOLOGY, V74, P892, DOI 10.1111/his.13813 Takada N, 2021, DIAGN CYTOPATHOL, V49, pE277, DOI 10.1002/dc.24707 Uruga H, 2013, INTERNAL MED, V52, P1317, DOI 10.2169/internalmedicine.52.9472 VONHERBAY A, 1990, CANCER, V66, P587, DOI 10.1002/1097-0142(19900801)66:3<587::AID-CNCR2820660330>3.0.CO;2-J NR 10 TC 5 Z9 5 U1 0 U2 2 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 8755-1039 EI 1097-0339 J9 DIAGN CYTOPATHOL JI Diagn. Cytopathol. PD JUL PY 2021 VL 49 IS 7 BP E277 EP E280 DI 10.1002/dc.24707 EA FEB 2021 PG 4 WC Medical Laboratory Technology; Pathology WE Science Citation Index Expanded (SCI-EXPANDED) SC Medical Laboratory Technology; Pathology GA SO2UZ UT WOS:000618162700001 PM 33590672 DA 2026-04-17 ER PT J AU Sobanski, PZ Krajnik, M Goodlin, SJ AF Sobanski, Piotr Z. Krajnik, Malgorzata Goodlin, Sarah J. TI Palliative Care for People Living With Heart Disease-Does Sex Make a Difference? SO FRONTIERS IN CARDIOVASCULAR MEDICINE LA English DT Review DE palliative care; symptom control and palliative care; sex related differences; heart disease; breathlessness; spiritual care; holistic care ID QUALITY-OF-LIFE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SYMPTOM BURDEN; HEALTH-STATUS; DEPRESSIVE SYMPTOMS; FAILURE PATIENTS; LUNG-CANCER; RELIGIOUS INVOLVEMENT; EMERGENCY-DEPARTMENT; ATRIAL-FIBRILLATION AB The distribution of individual heart disease differs among women and men and, parallel to this, among particular age groups. Women are usually affected by cardiovascular disease at an older age than men, and as the prevalence of comorbidities (like diabetes or chronic pain syndromes) grows with age, women suffer from a higher number of symptoms (such as pain and breathlessness) than men. Women live longer, and after a husband or partner's death, they suffer from a stronger sense of loneliness, are more dependent on institutionalized care and have more unaddressed needs than men. Heart failure (HF) is a common end-stage pathway of many cardiovascular diseases and causes substantial symptom burden and suffering despite optimal cardiologic treatment. Modern, personalized medicine makes every effort, including close cooperation between disciplines, to alleviate them as efficiently as possible. Palliative Care (PC) interventions include symptom management, psychosocial and spiritual support. In complex situations they are provided by a specialized multiprofessional team, but usually the application of PC principles by the healthcare team responsible for the person is sufficient. PC should be involved in usual care to improve the quality of life of patients and their relatives as soon as appropriate needs emerge. Even at less advanced stages of disease, PC is an additional layer of support added to disease modifying management, not only at the end-of-life. The relatively scarce data suggest sex-specific differences in symptom pathophysiology, distribution and the requisite management needed for their successful alleviation. This paper summarizes the sex-related differences in PC needs and in the wide range of interventions (from medical treatment to spiritual support) that can be considered to optimally address them. C1 [Sobanski, Piotr Z.] Spital Schwyz, Dept Internal Med, Palliat Care Unit, Schwyz, Switzerland. [Sobanski, Piotr Z.] Spital Schwyz, Dept Internal Med, Competence Ctr, Schwyz, Switzerland. [Krajnik, Malgorzata] Nicolaus Copernicus Univ Torun, Coll Med Bydgoszcz, Dept Palliat Care, Bydgoszcz, Poland. [Goodlin, Sarah J.] Oregon Hlth & Sci Univ, Dept Med, Vet Affairs Portland Hlth Care Syst, Geriatr & Palliat Med,Patient Ctr Educ & Res, Portland, OR 97201 USA. C3 Nicolaus Copernicus University; Ludwik Rydygier Collegium Medicum; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Portland Health Care System RP Sobanski, PZ (corresponding author), Spital Schwyz, Dept Internal Med, Palliat Care Unit, Schwyz, Switzerland.; Sobanski, PZ (corresponding author), Spital Schwyz, Dept Internal Med, Competence Ctr, Schwyz, Switzerland. EM psoban@wp.pl RI Sobanski, Piotr/AAI-4237-2020; Krajnik, Malgorzata/G-8923-2014 OI Krajnik, Malgorzata/0000-0001-9473-6163 FU Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland [WN949] FX Article publication was financed by Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland Internal university grant no. WN949. CR Abdi A, 2019, J RELIG HEALTH, V58, P823, DOI 10.1007/s10943-018-0727-7 Ai AL, 2007, PERS SOC PSYCHOL B, V33, P867, DOI 10.1177/0146167207301008 Alpert CM, 2017, HEART FAIL REV, V22, P25, DOI 10.1007/s10741-016-9581-4 Atherton JJ, 2018, HEART LUNG CIRC, V27, P1123, DOI 10.1016/j.hlc.2018.06.1042 Bakitas M, 2013, J CARD FAIL, V19, P193, DOI 10.1016/j.cardfail.2013.01.011 Bang JS, 2013, INT J CARDIOL, V170, P49, DOI 10.1016/j.ijcard.2013.10.003 Barnes-Harris M, 2019, BMJ SUPPORT PALLIAT, V9, P478, DOI 10.1136/bmjspcare-2018-001749 Barsky AJ, 2001, J GEN INTERN MED, V16, P266, DOI 10.1046/j.1525-1497.2001.016004266.x Bausewein C, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005623.pub2 Bekelman DB, 2008, NAT CLIN PRACT CARD, V5, P250, DOI 10.1038/ncpcardio1154 Bekelman DB, 2007, J GEN INTERN MED, V22, P470, DOI 10.1007/s11606-006-0044-9 Bekelman DB, 2018, JAMA INTERN MED, V178, P511, DOI 10.1001/jamainternmed.2017.8667 Bekelman DB, 2009, J GEN INTERN MED, V24, P592, DOI 10.1007/s11606-009-0931-y Benjamin EJ, 2018, CIRCULATION, V137, pE67, DOI [10.1161/CIR.0000000000000558, 10.1161/CIR.0000000000000485] Best M, 2020, BMC PALLIAT CARE, V19, DOI 10.1186/s12904-019-0508-4 Bhala N, 2013, LANCET, V382, P769, DOI 10.1016/S0140-6736(13)60900-9 Bhardwaj A, 2012, AM HEART J, V164, P793, DOI 10.1016/j.ahj.2012.08.015 Bilbao A, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955-016-0425-7 Brännström M, 2014, EUR J HEART FAIL, V16, P1142, DOI 10.1002/ejhf.151 Brumley R, 2007, J AM GERIATR SOC, V55, P993, DOI 10.1111/j.1532-5415.2007.01234.x Bui AL, 2011, NAT REV CARDIOL, V8, P30, DOI 10.1038/nrcardio.2010.165 Campbell CI, 2010, AM J PUBLIC HEALTH, V100, P2541, DOI 10.2105/AJPH.2009.180646 Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2 Carels RA, 2004, QUAL LIFE RES, V13, P63, DOI 10.1023/B:QURE.0000015301.58054.51 Chang YK, 2020, CIRC-HEART FAIL, V13, DOI 10.1161/CIRCHEARTFAILURE.120.006881 Chou R, 2009, J PAIN, V10, P147, DOI 10.1016/j.jpain.2008.10.007 Clark AL, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19750 Comín-Colet J, 2016, REV ESP CARDIOL, V69, P256, DOI [10.1016/j.recesp.2015.07.034, 10.1016/j.rec.2015.07.030] Conley S, 2015, HEART LUNG, V44, P107, DOI 10.1016/j.hrtlng.2014.07.008 Pinna MAC, 2009, AM J HOSP PALLIAT ME, V26, P89, DOI 10.1177/1049909108327588 Currow DC, 2009, J PAIN SYMPTOM MANAG, V38, P533, DOI 10.1016/j.jpainsymman.2009.01.006 Diamant MJ, 2020, CURR OPIN CARDIOL, V35, P156, DOI 10.1097/HCO.0000000000000712 Dionne-Odom JN, 2014, J PALLIAT MED, V17, P995, DOI 10.1089/jpm.2013.0680 Diop MS, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.013989 Diop MS, 2017, J PALLIAT MED, V20, P84, DOI 10.1089/jpm.2016.0330 Doyle F, 2015, PSYCHOSOM MED, V77, P419, DOI 10.1097/PSY.0000000000000174 Duca F, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19507-7 Ekman I, 2005, J CARD FAIL, V11, P288, DOI 10.1016/j.cardfail.2005.03.007 Ekström MP, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g445 Evangelista LS, 2014, J PALLIAT MED, V17, P75, DOI 10.1089/jpm.2013.0231 Evangelista LS, 2012, J CARD FAIL, V18, P894, DOI 10.1016/j.cardfail.2012.10.019 Evangelista Lorraine S, 2008, Prog Cardiovasc Nurs, V23, P12, DOI 10.1111/j.1751-7117.2008.07275.x Evangelista LS, 2009, EUR J CARDIOVASC NUR, V8, P169, DOI 10.1016/j.ejcnurse.2008.11.003 Falk H, 2016, J NURS SCHOLARSHIP, V48, P569, DOI 10.1111/jnu.12254 Feenstra J, 2002, ARCH INTERN MED, V162, P265, DOI 10.1001/archinte.162.3.265 Fillingim RB, 2009, J PAIN, V10, P447, DOI 10.1016/j.jpain.2008.12.001 Fournier JP, 2015, AM J MED, V128, P418, DOI 10.1016/j.amjmed.2014.10.046 Franchini L, 2020, SUPPORT CARE CANCER, V28, P3227, DOI 10.1007/s00520-019-05155-8 Friedman MM, 2001, HEART LUNG, V30, P98, DOI 10.1067/mhl.2001.114180 Fullerton EF, 2018, CURR OPIN BEHAV SCI, V23, P183, DOI 10.1016/j.cobeha.2018.08.001 Garay A, 2020, J CLIN MED, V9, DOI 10.3390/jcm9092825 Garrido MM, 2014, CLIN THER, V36, P1547, DOI 10.1016/j.clinthera.2014.10.007 Godfrey C, 2006, J CARD FAIL, V12, P307, DOI 10.1016/j.cardfail.2006.01.006 Gomes Tara, 2011, Open Med, V5, pe13 Goodlin SJ, 2012, J CARD FAIL, V18, P776, DOI 10.1016/j.cardfail.2012.07.007 Goodlin SJ, 2009, J AM COLL CARDIOL, V54, P386, DOI 10.1016/j.jacc.2009.02.078 Gottlieb SS, 2004, J AM COLL CARDIOL, V43, P1542, DOI 10.1016/j.jacc.2003.10.064 Graven LJ, 2020, CLIN NURS RES, V29, P73, DOI 10.1177/1054773818757312 Gysels M, 2008, J PAIN SYMPTOM MANAG, V36, P451, DOI 10.1016/j.jpainsymman.2007.11.008 Haedtke CA, 2019, HEART LUNG, V48, P201, DOI 10.1016/j.hrtlng.2019.02.002 Hagedoorn M, 2001, J PSYCHOSOM RES, V51, P693, DOI 10.1016/S0022-3999(01)00279-3 Heerdink ER, 1998, ARCH INTERN MED, V158, P1108, DOI 10.1001/archinte.158.10.1108 Heo S, 2009, HEART LUNG, V38, P100, DOI 10.1016/j.hrtlng.2008.04.002 Ho JM, 2014, J CLIN PSYCHIAT, V75, pE552, DOI 10.4088/JCP.13m08508 Howard C, 2014, NPJ PRIM CARE RESP M, V24, DOI 10.1038/npjpcrm.2014.76 Hughes JW, 2004, ANN BEHAV MED, V28, P179, DOI 10.1207/s15324796abm2803_6 Hupcey JE, 2009, J PALLIAT MED, V12, P531, DOI 10.1089/jpm.2009.0010 Hutchinson A, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-017-0396-4 Hutchinson TA, 2011, WHOLE PERSON CARE: A NEW PARADIGM FOR THE 21ST CENTURY, P1, DOI 10.1007/978-1-4419-9440-0 Hvidtjorn D, 2014, J RELIG HEALTH, V53, P1329, DOI 10.1007/s10943-013-9724-z Janssen-Niemeijer AJ, 2017, J RELIG HEALTH, V56, P1460, DOI 10.1007/s10943-017-0384-2 Jiang W, 2007, AM HEART J, V154, P102, DOI 10.1016/j.ahj.2007.03.043 Jorge Stephane, 2007, BMC Cardiovasc Disord, V7, P16, DOI 10.1186/1471-2261-7-16 Kaplovitch E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134550 Kapoor M, 2019, J NEUROMUSCULAR DIS, V6, P189, DOI 10.3233/JND-180371 Katsuki F, 2014, NEUROSCIENTIST, V20, P509, DOI 10.1177/1073858413514136 Kavalieratos D, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000544 Kavalieratos D, 2014, J PALLIAT MED, V17, P475, DOI 10.1089/jpm.2013.0526 Kazeminezhad B, 2020, J RELIG HEALTH, V59, P19, DOI 10.1007/s10943-018-00757-8 Kearney M., 2000, PLACE HEALING WORKIN Kearney PM, 2006, BMJ-BRIT MED J, V332, P1302, DOI 10.1136/bmj.332.7553.1302 Kessler RC, 2007, ANNU REV CLIN PSYCHO, V3, P137, DOI 10.1146/annurev.clinpsy.3.022806.091444 Khan MZ, 2021, CARDIOVASC REVASCULA, V23, P52, DOI 10.1016/j.carrev.2020.08.024 Khan RF, 2015, JAMA INTERN MED, V175, P1713, DOI 10.1001/jamainternmed.2015.3871 Khariton Y, 2018, JACC-HEART FAIL, V6, P465, DOI 10.1016/j.jchf.2018.02.002 Khodneva Y, 2016, PAIN MED, V17, P444, DOI 10.1111/pme.12916 Kominek C., 2019, PRACT PAIN MANAG, V19, P25 Krejci M.J., 1998, INT J PSYCHOL RELIG, V8, P57, DOI [10.1207/s15327582ijpr0801_7, DOI 10.1207/S15327582IJPR0801_7] Lainscak Mitja, 2003, Eur J Cardiovasc Nurs, V2, P275, DOI 10.1016/S1474-5151(03)00064-1 Lam CSP, 2019, EUR HEART J, V40, P3859, DOI 10.1093/eurheartj/ehz835 Lee CS, 2015, J CARDIOVASC NURS, V30, P517, DOI 10.1097/JCN.0000000000000191 Lee CWS, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003102 Lewis EF, 2007, EUR J HEART FAIL, V9, P83, DOI 10.1016/j.ejheart.2006.10.012 Lien YHH, 2018, AM J MED, V131, P7, DOI 10.1016/j.amjmed.2017.09.002 Lijauco CC, 2020, LIVED EXPERIENCES BR Likar R, 2017, Z GERONTOL GERIATR, V50, P332, DOI 10.1007/s00391-016-1042-0 Liu AY, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.0020 Lum HD, 2016, J PAIN SYMPTOM MANAG, V51, P963, DOI 10.1016/j.jpainsymman.2015.12.328 Luna MJ, 2019, J WOMENS HEALTH, V28, P1513, DOI 10.1089/jwh.2019.7837 Ma RC, 2020, COMPLEMENT THER CLIN, V38, DOI 10.1016/j.ctcp.2019.101071 Mahler DA, 2012, COPD, V9, P522, DOI 10.3109/15412555.2012.701678 Malik FA, 2013, PALLIATIVE MED, V27, P647, DOI 10.1177/0269216313488812 McCullough ME, 2000, HEALTH PSYCHOL, V19, P211, DOI 10.1037//0278-6133.19.3.211 Moller-Leimkuhler Anne Maria, 2007, Dialogues Clin Neurosci, V9, P71 Morgan T, 2016, PALLIATIVE MED, V30, P616, DOI 10.1177/0269216315625857 Murray SA, 2004, PALLIATIVE MED, V18, P39, DOI 10.1191/0269216304pm837oa Murray SA, 2007, J PAIN SYMPTOM MANAG, V34, P393, DOI 10.1016/j.jpainsymman.2006.12.009 Myers J, 2006, J CARD FAIL, V12, P439, DOI 10.1016/j.cardfail.2006.04.004 Naimi E, 2020, J RELIG HEALTH, V59, P920, DOI 10.1007/s10943-018-0698-8 Nordgren Lena, 2003, Eur J Cardiovasc Nurs, V2, P213 O'Connor CM, 2010, J AM COLL CARDIOL, V56, P692, DOI 10.1016/j.jacc.2010.03.068 O'Leary N, 2009, EUR J HEART FAIL, V11, P406, DOI 10.1093/eurjhf/hfp007 O'Meara E, 2007, CIRCULATION, V115, P3111, DOI 10.1161/CIRCULATIONAHA.106.673442 Obiora E, 2013, THORAX, V68, P163, DOI 10.1136/thoraxjnl-2012-202374 Ofstedal MB, 2019, J GERONTOL B-PSYCHOL, V74, pE107, DOI 10.1093/geronb/gby098 OZORAK EW, 1996, J SCI STUD RELIG, V35, P17, DOI 10.2307/1386392 Pantilat SZ, 2012, J HOSP MED, V7, P567, DOI 10.1002/jhm.1925 Park CL, 2016, HEALTH PSYCHOL, V35, P203, DOI 10.1037/hea0000271 Parshall MB, 2012, AM J RESP CRIT CARE, V185, P435, DOI 10.1164/rccm.201111-2042ST Peacock WF, 2008, EMERG MED J, V25, P205, DOI 10.1136/emj.2007.050419 PEARSON SB, 1981, POSTGRAD MED J, V57, P419, DOI 10.1136/pgmj.57.669.419 Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128 Pressler SJ, 2018, J CARDIOVASC NURS, V33, P22, DOI 10.1097/JCN.0000000000000422 Puchalski CM, 2014, J PALLIAT MED, V17, P105, DOI [10.1089/jpm.2014.9427, 10.1089/jpm.2013.9458] Quill TE, 2013, NEW ENGL J MED, V368, P1173, DOI 10.1056/NEJMp1215620 Qureshi WT, 2015, JAMA INTERN MED, V175, P1058, DOI 10.1001/jamainternmed.2015.1045 Rector TS, 2006, J CARD FAIL, V12, P87, DOI 10.1016/j.cardfail.2005.10.002 RECTOR TS, 1992, AM HEART J, V124, P1017, DOI 10.1016/0002-8703(92)90986-6 Rego F, 2018, NEUROPSYCHIATRY-LOND, V08, DOI [10.4172/neuropsychiatry.1000370, 10.4172/Neuropsychiatry.1000370, DOI 10.4172/NEUROPSYCHIATRY.1000370, 10.4172/neuropsychiatry.1000370] Rogers JG, 2017, J AM COLL CARDIOL, V70, P332 Rutledge T, 2006, J AM COLL CARDIOL, V48, P1527, DOI 10.1016/j.jacc.2006.06.055 Sadowski CA, 2009, J POPUL THER CLIN PH, V16, pE322 Sarcon A, 2019, EUR HEART J, V40, P1618, DOI 10.1093/eurheartj/ehz276 Schloesser K, 2021, J PAIN SYMPTOM MANAG, V61, P963, DOI 10.1016/j.jpainsymman.2020.09.034 Sheffler JL, 2021, AGING MENT HEALTH, V25, P2272, DOI 10.1080/13607863.2020.1855626 Sidebottom AC, 2015, J PALLIAT MED, V18, P134, DOI 10.1089/jpm.2014.0192 Simon Steffen T, 2016, Cochrane Database Syst Rev, V10, pCD007354 Simon ST, 2013, J PAIN SYMPTOM MANAG, V45, P1019, DOI 10.1016/j.jpainsymman.2012.06.008 Simon ST, 2013, J PAIN SYMPTOM MANAG, V45, P561, DOI 10.1016/j.jpainsymman.2012.02.022 Skotzko CE, 2000, J CARD FAIL, V6, P300, DOI 10.1054/jcaf.2000.19222 Sobanski PZ, 2020, CARDIOVASC RES, V116, P12, DOI 10.1093/cvr/cvz200 Sorge RE, 2017, J NEUROSCI RES, V95, P1271, DOI 10.1002/jnr.23841 Spathis A, 2017, NPJ PRIM CARE RESP M, V27, DOI 10.1038/s41533-017-0024-z Stanek EJ, 2000, J CARD FAIL, V6, P225, DOI 10.1054/jcaf.2000.9503 Stewart GC, 2019, JACC-HEART FAIL, V7, P602, DOI 10.1016/j.jchf.2019.02.007 Stock EO, 2012, CURR PROB CARDIOLOGY, V37, P450, DOI 10.1016/j.cpcardiol.2012.07.001 Stock JD, 2018, CIRCULATION, V138 Strada EA, 2013, PALLIAT SUPPORT CARE, V11, P205, DOI 10.1017/S1478951512000065 Tesarz J, 2019, EUR HEART J, V40, P1609, DOI 10.1093/eurheartj/ehz111 Thibodeau JT, 2014, JACC-HEART FAIL, V2, P24, DOI 10.1016/j.jchf.2013.07.009 Thompson EH, 2009, J RELIG HEALTH, V48, P317, DOI 10.1007/s10943-008-9202-1 Truby LK, 2020, CIRC-HEART FAIL, V13, DOI 10.1161/CIRCHEARTFAILURE.119.006134 Vaccarino V, 2001, J AM COLL CARDIOL, V38, P199, DOI 10.1016/S0735-1097(01)01334-1 Vicent L, 2017, BMC PALLIAT CARE, V16, DOI 10.1186/s12904-017-0208-x Vozoris NT, 2014, EXPERT REV RESP MED, V8, P661, DOI 10.1586/17476348.2014.957186 WILD L, 1992, Critical Care Nursing Quarterly, V15, P46 Williams BA, 2017, BMC CARDIOVASC DISOR, V17, DOI 10.1186/s12872-017-0555-9 Williams M., 2008, LANGUAGE DYSPNOEA SY Wilson J, 2013, J HOSP PALLIAT NURS, V15, P13, DOI [10.1097/NJH.0b013e31827777fb, 10.1097/NJH.0b013e31827ba343] Wisniewski AM, 2008, J ADDICT DIS, V27, P1, DOI 10.1300/J069v27n01_01 Yu DSF, 2016, J GERIATR CARDIOL, V13, P408, DOI 10.11909/j.issn.1671-5411.2016.05.014 Zambroski Cheryl Hoyt, 2005, Eur J Cardiovasc Nurs, V4, P198, DOI 10.1016/j.ejcnurse.2005.03.010 NR 162 TC 11 Z9 13 U1 0 U2 7 PU FRONTIERS MEDIA SA PI LAUSANNE PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND SN 2297-055X J9 FRONT CARDIOVASC MED JI Front. Cardiovasc. Med. PD FEB 5 PY 2021 VL 8 AR 629752 DI 10.3389/fcvm.2021.629752 PG 14 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI) SC Cardiovascular System & Cardiology GA QJ1MP UT WOS:000619454400001 PM 33634172 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Gong, JL Wang, XF Liu, Z Yao, S Xiao, ZT Zhang, MZ Zhang, ZF AF Gong, Jialin Wang, Xiaofei Liu, Zuo Yao, Shuang Xiao, Zengtuan Zhang, Mengzhe Zhang, Zhenfa TI Risk factors and survival analysis of arrhythmia following lung cancer surgery: a retrospective study SO JOURNAL OF THORACIC DISEASE LA English DT Article DE Lung cancer; surgery; postoperative arrhythmia (PA); prognosis ID NONCARDIAC THORACIC-SURGERY; ATRIAL-FIBRILLATION; SUPRAVENTRICULAR TACHYARRHYTHMIAS; POSTOPERATIVE ARRHYTHMIAS; CARDIAC-ARRHYTHMIAS; COMPLICATIONS; THORACOTOMY; PREVENTION AB Background: Surgical treatment of lung cancer is one of the important treatments for early-stage non small cell lung cancer (NSCLC). However, arrhythmia, especially atrial fibrillation (AF) and supraventricular arrhythmia, are quite common among patients after surgical treatment of lung cancer. The impact of postoperative arrhythmia (PA) on survival is rarely reported. Our aim was to evaluate the risk factors of PA and its impact on overall survival (OS) after lung cancer surgery. Methods: A total of 344 patients diagnosed with NSCLC who underwent lung cancer surgery were enrolled in this study. These patients were divided into two groups based on the occurrence of PA. Univariate and multivariate logistic regression analyses were conducted to identify the risk factors of PA. The Kaplan-Meier method was applied to show the OS differences between the two groups. Results: The incidence of PA was 16% (55/344). Among these 55 patients, 20 had AF, 30 had sinus tachycardia, and 5 had premature beats. A total of 332 patients underwent lung cancer radical resection. Operation type (P<0.001), preoperative abnormal ECG (P=0.032), transfusion (P=0.016), postoperative serum potassium concentration (P=0.001) and clinical stage (P<0.05) were risk factors for PA. PA (HR 2.083, 95% CI, 1.334-3.253; P=0.001), age (HR 1.543, 95% CI, 1.063-2.239; P=0.025) and mediastinal lymph node metastasis (HR 2.655, 95% CI, 1.809-3.897; P<0.001) were independent prognostic risk factors for OS by multivariate cox analysis. Conclusions: We identified PA as an independent prognostic risk factor to predict poor OS in patients who underwent lung cancer surgery and had risk factors for PA. We therefore provides guidance for PA in improving the prognosis of lung cancer patients. C1 [Gong, Jialin; Wang, Xiaofei; Liu, Zuo; Yao, Shuang; Xiao, Zengtuan; Zhang, Mengzhe; Zhang, Zhenfa] Tianjin Med Univ Canc Inst & Hosp, Dept Lung Canc Surg, Huanhu West Rd, Tianjin, Peoples R China. C3 Tianjin Medical University RP Zhang, ZF (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Dept Lung Canc Surg, Huanhu West Rd, Tianjin, Peoples R China. EM zhangzhenfa@tmu.edu.cn FU National Natural Science Foundation of China [81772488] FX This work was funded by the National Natural Science Foundation of China [Grant number 81772488] . CR Ahn HJ, 2005, EUR J CARDIO-THORAC, V28, P19, DOI 10.1016/j.ejcts.2005.01.017 Al-Omari MA, 2008, AM J CARDIOL, V101, P1759, DOI 10.1016/j.amjcard.2008.02.067 Amar D, 1996, CHEST, V110, P437, DOI 10.1378/chest.110.2.437 [Anonymous], 2011, ISRN CARDIOL Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 De Decker K, 2003, ANN THORAC SURG, V75, P1340, DOI 10.1016/S0003-4975(02)04824-5 Ettinger DS, 2012, J NATL COMPR CANC NE, V10, P1236, DOI 10.6004/jnccn.2012.0130 Frendl G, 2014, J THORAC CARDIOV SUR, V148, pE153, DOI 10.1016/j.jtcvs.2014.06.036 GOLDMAN L, 1978, CHEST, V73, P450, DOI 10.1378/chest.73.4.450 Guha A, 2019, EUR HEART J, V40, P3007, DOI 10.1093/eurheartj/ehz649 Haïssaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003 Hogue CW., 2005, Chest, V128, p9S, DOI DOI 10.1378/CHEST.128.2_SUPPL.9S Imperatori Andrea, 2012, J Cardiothorac Surg, V7, P4, DOI 10.1186/1749-8090-7-4 Ivanovic J, 2014, INTERACT CARDIOV TH, V18, P340, DOI 10.1093/icvts/ivt520 Izquierdo J M, 1995, Arch Bronconeumol, V31, P328 Jiang Z, 2009, BRIT J ANAESTH, V103, P364, DOI 10.1093/bja/aep172 Kanzaki R, 2017, SURG TODAY, V47, P795, DOI 10.1007/s00595-016-1436-z Lee G, 2010, EUR HEART J, V31, P2774, DOI 10.1093/eurheartj/ehq224 Liu LL, 1997, AM J PHYSIOL-HEART C, V273, pH805, DOI 10.1152/ajpheart.1997.273.2.H805 Muranishi Y, 2017, SURG TODAY, V47, P252, DOI 10.1007/s00595-016-1380-y Nojiri T, 2015, WORLD J SURG, V39, P1092, DOI 10.1007/s00268-015-2943-6 Oka T, 2001, ANESTH ANALG, V93, P253, DOI 10.1097/00000539-200108000-00003 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 SHIELDS TW, 1968, SURG GYNECOL OBSTETR, V126, P743 Shrivastava Vivek, 2004, Interact Cardiovasc Thorac Surg, V3, P656, DOI 10.1016/j.icvts.2004.08.002 SORENSEN O, 1986, ACTA ANAESTH SCAND, V30, P630, DOI 10.1111/j.1399-6576.1986.tb02489.x Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 VONKNORRING J, 1992, ANN THORAC SURG, V53, P642, DOI 10.1016/0003-4975(92)90325-X Walsh SR, 2006, COLORECTAL DIS, V8, P212, DOI 10.1111/j.1463-1318.2005.00881.x Walsh SR, 2007, ANN ROY COLL SURG, V89, P91, DOI 10.1308/003588407X168253 Wu DH, 2012, ANN THORAC SURG, V94, P193, DOI 10.1016/j.athoracsur.2012.03.057 NR 32 TC 5 Z9 6 U1 0 U2 8 PU AME PUBLISHING COMPANY PI SHATIN PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA SN 2072-1439 EI 2077-6624 J9 J THORAC DIS JI J. Thorac. Dis. PD FEB PY 2021 VL 13 IS 2 DI 10.21037/jtd-20-2740 PG 15 WC Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System GA QP9HA UT WOS:000624138600036 PM 33717558 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Marjanski, T Wnuk, D Dziedzic, R Ostrowski, M Sawicka, W Marjanska, E Rzyman, W AF Marjanski, Tomasz Wnuk, Damian Dziedzic, Robert Ostrowski, Marcin Sawicka, Wioletta Marjanska, Ewa Rzyman, Witold TI Physiological Biomarkers Assessed by Low-Tech Exercise Tests Predict Complications and Overall Survival in Patients Undergoing Pneumonectomy Due to Lung Cancer SO CANCERS LA English DT Article DE lung cancer; pneumonectomy; complications; overall survival; 6-min walking test AB Simple Summary Preoperative results of the 6-min walking test help to identify risk of postoperative complications and increased mortality in patients undergoing lobectomy for lung cancer. The aim of the study was to validate the value of 500 m in 6MWT as an indicator, which differentiates risk of complications in patients undergoing pneumonectomy. 125 patients who underwent pneumonectomy at Thoracic Surgery Department between 2009 and 2018. Additionally, on the day before the surgery, patients performed the 6-min walking test. We analyzed 93 men and 32 women with a median age of 63 years. The cut-off value of 500 m identified patients with increased 90-day mortality, first-year mortality, and overall survival. Patients who covered a distance <= 500 m had an increased risk of atrial fibrillation and cardiac complications. Patients who do not reach the distance of 500 m in 6-min walking test have a high risk of early postoperative death after pneumonectomy. Due to its debilitating character pneumonectomy this is last-resort procedure. Preoperative results of the 6-min walking test (6MWT) help to identify high risk of postoperative complications and increased mortality in patients undergoing lobectomy for lung cancer. The aim of the study was to validate the value of 500 m in 6MWT as an indicator, which differentiates risk of complications in patients undergoing pneumonectomy. 125 patients who underwent pneumonectomy at Thoracic Surgery Department between 2009 and 2018. On the day preceding the surgery, patients underwent 6MWT. The patients were in median age of 63 years. The cut-off value of 500 m identified patients with increased 90-day mortality [17.9% vs. 3.5%, odds ratio (OR) 6.271, 95% confidence interval (CI) 1.528-25.739], first-year mortality (30.7% vs. 11.6%, OR 3.378, 95% CI 1.310-8.709), and overall survival (p = 0.02). Patients who covered a distance <= 500 m had an increased risk of atrial fibrillation (35.9% vs. 16.3%, OR 2.880, 95% CI 1.207-6.870) and cardiac complications (38.4% vs. 19.8%, OR 2.537, 95% CI 1.100-5.849). Patients unable to reach 500 m in 6MWT are in a high risk of postoperative death after pneumonectomy, what may be a result of increased frequency of postoperative cardiac complications. Poor result of 6MWT is a predictor of worse overall survival. C1 [Marjanski, Tomasz; Dziedzic, Robert; Ostrowski, Marcin; Rzyman, Witold] Med Univ Gdansk, Thorac Surg Dept, Sklodowskiej Curie 3A, PL-80211 Gdansk, Poland. [Wnuk, Damian] Med Univ Gdansk, Dept Phys Therapy, Sklodowskiej Curie 3A, PL-80211 Gdansk, Poland. [Sawicka, Wioletta] Med Univ Gdansk, Dept Anaesthesiol & Intens Care, Sklodowskiej Curie 3A, PL-80211 Gdansk, Poland. [Marjanska, Ewa] Gdansk Univ Technol, Fac Management & Econ, Narutowicza 11-12, PL-80233 Gdansk, Poland. C3 Fahrenheit Universities; Medical University Gdansk; Fahrenheit Universities; Medical University Gdansk; Fahrenheit Universities; Medical University Gdansk; Fahrenheit Universities; Gdansk University of Technology RP Marjanski, T (corresponding author), Med Univ Gdansk, Thorac Surg Dept, Sklodowskiej Curie 3A, PL-80211 Gdansk, Poland. EM marjanski@gumed.edu.pl; damian.wnuk@gumed.edu.pl; dziedzic@gumed.edu.pl; marcin.ostrowski@gumed.edu.pl; wioletta.sawicka@gumed.edu.pl; ewa.marjanska@zie.pg.edu.pl; wrzyman@gumed.edu.pl RI ; Marjańska, Ewa/AAS-7003-2020; Ostrowski, Marcin/N-7739-2018; Marjanski, Tomasz/AAE-1639-2019 OI Rzyman, Witold/0000-0002-9044-7791; Ostrowski, Marcin/0000-0001-8129-8299; Marjanski, Tomasz/0000-0002-1260-3269; Sawicka, Wioletta/0000-0003-3336-4241 FU Medical University of Gdansk FX APC was funded by Medical University of Gdansk, language editing was funded by Tomasz Marjanski and Ewa Marjanska. CR Aberle DR, 2011, NEW ENGL J MED, V365, P395, DOI 10.1056/NEJMoa1102873 Albain KS, 2009, LANCET, V374, P379, DOI 10.1016/S0140-6736(09)60737-6 ATS, 2003, AM J RESP CRIT CARE, V167, P211, DOI 10.1164/rccm.167.2.211 Awdeh H, 2015, WORLD J SURG, V39, P1406, DOI 10.1007/s00268-015-2961-4 Bernard A, 2011, J THORAC CARDIOV SUR, V141, P449, DOI 10.1016/j.jtcvs.2010.06.044 Brunelli A, 2005, EUR J CARDIO-THORAC, V27, P367, DOI 10.1016/j.ejcts.2004.11.012 Brunelli A, 2009, EUR RESPIR J, V34, P17, DOI 10.1183/09031936.00184308 Brunelli A, 2020, EUR J CARDIO-THORAC, V57, P740, DOI 10.1093/ejcts/ezz287 Brunelli A, 2013, CHEST, V143, pE166, DOI 10.1378/chest.12-2395 Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111 Dall'Olio FG, 2020, LUNG CANCER, V145, P95, DOI 10.1016/j.lungcan.2020.04.027 de Koning HJ, 2020, NEW ENGL J MED, V382, P503, DOI 10.1056/NEJMoa1911793 Depypere LP, 2020, EUR J CARDIO-THORAC, V58, P752, DOI 10.1093/ejcts/ezaa284 EPSTEIN SK, 1995, CHEST, V107, P311, DOI 10.1378/chest.107.2.311 Falcoz PE, 2007, J THORAC CARDIOV SUR, V133, P325, DOI 10.1016/j.jtcvs.2006.09.020 Goldstraw P, 2016, J THORAC ONCOL, V11, P39, DOI 10.1016/j.jtho.2015.09.009 Graham BL, 2019, AM J RESP CRIT CARE, V200, pE70, DOI 10.1164/rccm.201908-1590ST Ha D, 2016, J THORAC ONCOL, V11, P1397, DOI 10.1016/j.jtho.2016.04.021 HOLDEN DA, 1992, CHEST, V102, P1774, DOI 10.1378/chest.102.6.1774 Jones GD, 2022, ANN SURG, V275, P793, DOI [10.26493/2590-9770.1365.884, 10.1097/SLA.0000000000004065] Jones LW, 2012, LUNG CANCER, V76, P248, DOI 10.1016/j.lungcan.2011.10.009 Kasymjanova G, 2009, J THORAC ONCOL, V4, P602, DOI 10.1097/JTO.0b013e31819e77e8 Kong S, 2020, J PERS MED, V10, DOI 10.3390/jpm10040166 Marjanski T, 2019, INTERACT CARDIOV TH, V28, P368, DOI 10.1093/icvts/ivy258 Marjanski T, 2015, EUR J CARDIO-THORAC, V47, pE213, DOI 10.1093/ejcts/ezv049 Pagès PB, 2017, J THORAC CARDIOV SUR, V153, P184, DOI 10.1016/j.jtcvs.2016.09.060 PIERCE RJ, 1994, AM J RESP CRIT CARE, V150, P947, DOI 10.1164/ajrccm.150.4.7921468 Pompili C, 2021, EUR J CARDIO-THORAC, V59, P116, DOI 10.1093/ejcts/ezaa245 Pompili C, 2013, EUR J CARDIO-THORAC, V43, P905, DOI 10.1093/ejcts/ezs532 Santos BFA, 2016, BRAZ J PHYS THER, V20, P66, DOI 10.1590/bjpt-rbf.2014.0119 Wesolowski S, 2020, INTERACT CARDIOV TH, V30, P559, DOI 10.1093/icvts/ivz313 NR 31 TC 10 Z9 10 U1 0 U2 2 PU MDPI PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND EI 2072-6694 J9 CANCERS JI Cancers PD FEB PY 2021 VL 13 IS 4 AR 735 DI 10.3390/cancers13040735 PG 11 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA QO8FK UT WOS:000623373500001 PM 33578833 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Wang, H Wang, ZX Zhou, MM Chen, JD Yao, F Zhao, L He, B AF Wang, Hao Wang, Zhexin Zhou, Mengmeng Chen, Jindong Yao, Feng Zhao, Liang He, Ben TI Postoperative atrial fibrillation in pneumonectomy for primary lung cancer SO JOURNAL OF THORACIC DISEASE LA English DT Article DE Postoperative atrial fibrillation (POAF); primary lung cancer; pneumonectomy; lobectomy; segmentectomy ID PULMONARY-VEIN; RISK-FACTORS; RESECTION SURGERY; STRETCH AB Background: This study assessed the incidence and risk factors (RFs) of postoperative atrial fibrillation (POAF) and its impact on clinical outcomes in patients undergoing pneumonectomy for lung cancer. Methods: Between 2013 and 2018, this monocentric retrospective study enrolled 324 consecutive pneumonectomy patients for primary lung cancer from our institution and 350 lobectomy and 349 segmentectomy cases matched by age, sex and body mass index (BMI). RF for POAF and postoperative death in pneumonectomy patients were assessed by logistic regression, and long-term outcomes after a median follow-up of 30 (range, 2-61) months by Cox proportional hazard model. Electrophysiology study (EPS) files of 30 AF patients with lung resection history were reviewed. Results: POAF developed more often after pneumonectomy than lobectomy and segmentectomy (23.2% vs. 6.6% vs. 1.4%, respectively; P 0.001). Among 75 pneumonectomy patients with POAF, POAF was solitary in 55 patients (73.3%) and concurrent with other complications in 3 patients (4%). POAF risk after pneumonectomy was 4 and 22 times that after lobectomy and segmentectomy, respectively, with age 60 years and left atrial diameter (LAd) >_35 mm as independent predictors. POAF, infection and hemorrhage were independent RFs for perioperative death after pneumonectomy; however, POAF was not RF for longterm death. Pulmonary vein (PV) trigger was identified in 60% (18/30) of AF patients with lung resection history, with stump PVs being more active than non-stump PVs (38.2% vs. 10.5%, P<0.001). Conclusions: Post-pneumonectomy AF, with remarkable incidence, risk and independent predictors including age >60 years and LAd >_35 mm, was mostly solitary and possibly secondary to stump and non stump PV triggers. POAF, along with infection and hemorrhage, was a RF for perioperative death. C1 [Wang, Hao; Zhou, Mengmeng; Chen, Jindong; Zhao, Liang; He, Ben] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Cardiol, Shanghai, Peoples R China. [Wang, Zhexin; Yao, Feng] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Thorac Surg, Shanghai, Peoples R China. C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University RP Zhao, L; He, B (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Cardiol, Shanghai, Peoples R China.; Yao, F (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Thorac Surg, Shanghai, Peoples R China. EM yaofeng6796678@126.com; zhaoliang80112@126.com; heben241@126.com OI Yao, Feng/0000-0002-9635-9581 FU National Natural Science Foundation of China [81970276]; Cultivation Project for Municipal Hospital Clinical Research of Shenkang Hospital Development Center [SHDC21018X02] FX This research was funded by a grant from the National Natural Science Foundation of China (No. 81970276); Cultivation Project for Municipal Hospital Clinical Research of Shenkang Hospital Development Center (No. SHDC21018X02). CR Amar D, 2019, J THORAC CARDIOV SUR, V157, P2493, DOI 10.1016/j.jtcvs.2019.01.075 Amar D, 2016, J THORAC CARDIOV SUR, V151, P913, DOI 10.1016/j.jtcvs.2015.09.041 Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609] Chen LY, 2018, CIRCULATION, V137, pE623, DOI 10.1161/CIR.0000000000000568 Dobrev D, 2019, NAT REV CARDIOL, V16, P417, DOI 10.1038/s41569-019-0166-5 Echahidi N, 2008, J AM COLL CARDIOL, V51, P793, DOI 10.1016/j.jacc.2007.10.043 Haïssaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003 Hamaguchi S, 2016, BIOL PHARM BULL, V39, P1216, DOI 10.1248/bpb.b15-01013 Heijman J, 2018, CIRC RES, V122, P752, DOI 10.1161/CIRCRESAHA.117.311081 Howington JA, 2013, CHEST, V143, pE278, DOI 10.1378/chest.12-2359 Ishibashi H, 2020, WORLD J SURG, V44, P3952, DOI 10.1007/s00268-020-05694-w Iwata T, 2016, SURG TODAY, V46, P877, DOI 10.1007/s00595-015-1258-4 Kanmanthareddy A, 2015, J CARDIOVASC ELECTR, V26, P385, DOI 10.1111/jce.12619 Khan R, 2004, CARDIOVASC RES, V64, P387, DOI 10.1016/j.cardiores.2004.07.025 Kim DJ, 2007, CHEST, V132, P178, DOI 10.1378/chest.07-0554 Kondo H, 2016, HEART RHYTHM, V13, P241, DOI 10.1016/j.hrthm.2015.07.001 Kowalewski J, 1999, EUR J CARDIO-THORAC, V15, P444, DOI 10.1016/S1010-7940(99)00032-9 Lee SH, 2016, ANAESTHESIA, V71, P1424, DOI 10.1111/anae.13644 Miyasaka Y, 2006, CIRCULATION, V114, P119, DOI 10.1161/CIRCULATIONAHA.105.595140 Muranishi Y, 2017, SURG TODAY, V47, P252, DOI 10.1007/s00595-016-1380-y Neragi-Miandoab Siyamek, 2008, Interact Cardiovasc Thorac Surg, V7, P1039, DOI 10.1510/icvts.2008.181099 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Oral H, 2006, NEW ENGL J MED, V354, P934, DOI 10.1056/NEJMoa050955 Phan K, 2015, EUR J CARDIO-THORAC, V48, P817, DOI 10.1093/ejcts/ezu551 Rena O, 2001, EUR J CARDIO-THORAC, V20, P688, DOI 10.1016/S1010-7940(01)00890-9 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Sanders P, 2003, CIRCULATION, V108, P1461, DOI 10.1161/01.CIR.0000090688.49283.67 Sasaki N, 2013, CIRC J, V77, P494, DOI 10.1253/circj.CJ-12-1053 Smith H, 2020, EUR J CARDIO-THORAC, V57, P874, DOI 10.1093/ejcts/ezz341 Ueda T, 2018, GEN THORAC CARDIOVAS, V66, P95, DOI 10.1007/s11748-017-0858-x Walters TE, 2014, CIRC-ARRHYTHMIA ELEC, V7, P1189, DOI 10.1161/CIRCEP.114.001894 NR 31 TC 23 Z9 24 U1 1 U2 7 PU AME PUBLISHING COMPANY PI SHATIN PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA SN 2072-1439 EI 2077-6624 J9 J THORAC DIS JI J. Thorac. Dis. PD FEB PY 2021 VL 13 IS 2 DI 10.21037/jtd-20-1717 PG 15 WC Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System GA QP9HA UT WOS:000624138600030 PM 33717552 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Grzesk, G Wozniak-Wisniewska, A Blazejewski, J Górny, B Wolowiec, L Rogowicz, D Nowaczyk, A AF Grzesk, Grzegorz Wozniak-Wisniewska, Anita Blazejewski, Jan Gorny, Bartosz Wolowiec, Lukasz Rogowicz, Daniel Nowaczyk, Alicja TI The Interactions of Nintedanib and Oral Anticoagulants-Molecular Mechanisms and Clinical Implications SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES LA English DT Review DE nintedanib; idiopathic pulmonary fibrosis; direct oral anticoagulants ID IDIOPATHIC PULMONARY-FIBROSIS; ATRIAL-FIBRILLATION; FACTOR XA; WARFARIN; TYROSINE; RECEPTOR; SAFETY; DABIGATRAN; EFFICACY; INHIBITOR AB Nintedanib is a synthetic orally active tyrosine kinase inhibitor, whose main action is to inhibit the receptors of the platelet-derived growth factor, fibroblast growth factor and vascular endothelial growth factor families. The drug also affects other kinases, including Src, Flt-3, LCK, LYN. Nintedanib is used in the treatment of idiopathic pulmonary fibrosis, chronic fibrosing interstitial lung diseases and lung cancer. The mechanism of action suggests that nintedanib should be considered one of the potential agents for inhibiting and revising the fibrosis process related to COVID-19 infections. Due to the known induction of coagulation pathways during COVID-19 infections, possible interaction between nintedanib and anticoagulant seems to be an extremely important issue. In theory, nintedanib could increase the bleeding risk, thrombosis and lead to thrombocytopenia. The data from clinical trials on the concomitant use of nintedanib and antithrombotic agents is very limited as this patient group was within the standard exclusion criteria. Nintedanib is an important therapeutic option, despite its interaction with anticoagulants. If anticoagulant therapy is necessary, the more effective and safer option is the concomitant administration of DOACs and nintedanib, especially when drug-monitored therapy will be used in patients at high risk of bleeding complications. C1 [Grzesk, Grzegorz; Wozniak-Wisniewska, Anita; Blazejewski, Jan; Gorny, Bartosz; Wolowiec, Lukasz; Rogowicz, Daniel] Nicolaus Copernicus Univ Torun, Dept Cardiol & Clin Pharmacol, Ludwik Rydygier Coll Med Bydgoszcz, Fac Hlth Sci, PL-87100 Torun, Poland. [Nowaczyk, Alicja] Nicolaus Copernicus Univ Torun, Ludwik Rydygier Coll Med Bydgoszcz, Dept Organ Chem, Fac Pharm, 2 Dr A Jurasza St, PL-85094 Bydgoszcz, Poland. C3 Nicolaus Copernicus University; Nicolaus Copernicus University RP Nowaczyk, A (corresponding author), Nicolaus Copernicus Univ Torun, Ludwik Rydygier Coll Med Bydgoszcz, Dept Organ Chem, Fac Pharm, 2 Dr A Jurasza St, PL-85094 Bydgoszcz, Poland. EM g.grzesk@cm.umk.pl; atww@interia.pl; janbi@o2.pl; gornyb@wp.pl; lordtor111@gmail.com; rogowicz.d@gmail.com; alicja@cm.umk.pl RI Grześk, Grzegorz/AAS-6549-2021; Błażejewski, Jan/G-5200-2014; Nowaczyk, Alicja/MZQ-4694-2025 OI Grześk, Grzegorz/0000-0001-6669-5931; Rogowicz, Daniel/0000-0001-8440-902X; Nowaczyk, Alicja/0000-0003-4945-2369; Wołowiec, Łukasz/0000-0002-7731-6367 FU UMK [WN768] FX This study was supported by the research grant from the UMK no. WN768 for Department of Cardiology and Clinical Pharmacology, Faculty of Health Sciences, CM UMK. CR Almutairi AR, 2017, CLIN THER, V39, P1456, DOI 10.1016/j.clinthera.2017.05.358 [Anonymous], FDA APPROVES FIRST T Ansell JE, 2016, THROMB RES, V146, P113, DOI 10.1016/j.thromres.2016.07.008 Ansell JE, 2014, NEW ENGL J MED, V371, P2141, DOI 10.1056/NEJMc1411800 Rodríguez-Portal JA, 2018, DRUGS R&D, V18, P19, DOI 10.1007/s40268-017-0221-9 Apostolakis S, 2013, THROMB HAEMOSTASIS, V110, P1074, DOI 10.1160/TH13-07-0552 Asao T, 2019, RESPIR INVESTIG, V57, P20, DOI 10.1016/j.resinv.2018.09.001 Awasthi N, 2015, ONCOTARGETS THER, V8, P3691, DOI 10.2147/OTT.S78805 Banks AS, 2015, NATURE, V517, P391, DOI 10.1038/nature13887 Barnes PJ, 2013, NAT REV DRUG DISCOV, V12, P543, DOI 10.1038/nrd4025 Bendstrup E, 2019, RESPIRATION, V97, P173, DOI 10.1159/000495046 Boehringer Ingelheim, 2018, OFEV NINTEDANIB CAPS Bogatkevich GS, 2009, ARTHRITIS RHEUM-US, V60, P3455, DOI 10.1002/art.24935 Brunnemer E, 2018, RESPIRATION, V95, P301, DOI 10.1159/000485933 Case AH, 2017, BMJ OPEN RESPIR RES, V4, DOI 10.1136/bmjresp-2017-000192 Clark JD, 2014, J MED CHEM, V57, P5023, DOI 10.1021/jm401490p Cohen AT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144856 Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561 Corte T, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0276-5 Crestani B, 2019, LANCET RESP MED, V7, P60, DOI 10.1016/S2213-2600(18)30339-4 Czuprynska J, 2017, BRIT J HAEMATOL, V178, P838, DOI 10.1111/bjh.14714 European Medicines Agency, 2018, OFEV SUMMARY PRODUCT European Medicines Agency, 2014, COMMITTEE MEDICINAL Ezekowitz MD, 2009, AM HEART J, V157, P805, DOI 10.1016/j.ahj.2009.02.005 Fang ZZ, 2013, ACS CHEM BIOL, V8, P58, DOI 10.1021/cb300663j FDA Center for Drug Evaluation and Research, 2014, NINTEDANIB CLIN PHAR Giugliano RP, 2013, NEW ENGL J MED, V369, P2093, DOI 10.1056/NEJMoa1310907 Góralczyk T, 2017, Diagnostyka Laboratoryjna, V53, P161, DOI 10.5604/01.3001.0013.7977 Grzesk G, 2018, KARDIOL POL, V76, P1562, DOI 10.5603/KP.a2018.0194 Hart RG, 2007, ANN INTERN MED, V146, P857, DOI 10.7326/0003-4819-146-12-200706190-00007 Heidbuchel H, 2013, EUR HEART J, V34, P2094, DOI 10.1093/eurheartj/eht134 Hilberg F, 2008, CANCER RES, V68, P4774, DOI 10.1158/0008-5472.CAN-07-6307 Hillarp A, 2018, SCAND J CLIN LAB INV, V78, P575, DOI 10.1080/00365513.2018.1522664 Huang M, 2014, TRENDS PHARMACOL SCI, V35, P41, DOI 10.1016/j.tips.2013.11.004 Hughes G, 2016, J CLIN MED, V5, DOI 10.3390/jcm5090078 Hunter T, 1998, PHILOS T R SOC B, V353, P583, DOI 10.1098/rstb.1998.0228 Jdrusik P., 2017, POSTPOWANIE PRZYPADK Jiao QL, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0801-5 Kara-Godek M., 2018, GERONTOL POL, V26, P201 Kasprzak JD, 2016, Folia Cardiologica, V11, P377, DOI [10.5603/fc.2016.0064, 10.5603/fc.2016.0064, DOI 10.5603/FC.2016.0064] Kirchhof P, 2016, KARDIOL POL, V74, P1359, DOI [10.5603/KP.2016.0172, 10.1016/j.rec.2016.11.033] Kitchen S, 2014, BRIT J HAEMATOL, V166, P830, DOI 10.1111/bjh.12975 Korzeniewska-Rybicka I., 2018, MED TRIB, V10, P1 Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389 Lancaster L, 2019, BMJ OPEN RESPIR RES, V6, DOI 10.1136/bmjresp-2018-000397 Lemmens L, 2016, LUNG CANCER MANAG, V5, P29, DOI 10.2217/lmt.15.33 Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011 Liang L, 2016, BIOCHEM BIOPH RES CO, V477, P667, DOI 10.1016/j.bbrc.2016.06.117 Lippi G, 2015, CLIN CHEM LAB MED, V53, P185, DOI 10.1515/cclm-2014-0767 Liu Q, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0793-1 Luedtke D, 2018, EUR J DRUG METAB PH, V43, P533, DOI 10.1007/s13318-018-0467-9 Lukasik M, 2015, NEUROL NEUROCHIR POL, V49, P171, DOI 10.1016/j.pjnns.2015.04.007 Ma WW, 2009, CA-CANCER J CLIN, V59, P111, DOI 10.3322/caac.20003 Majewski S, 2016, ADV RESPIR MED, V84, P114, DOI 10.5603/arm.46993 McCormack PL, 2015, DRUGS, V75, P129, DOI 10.1007/s40265-014-0335-0 Mekaj YH, 2015, THER CLIN RISK MANAG, V11, DOI [10.2147/tcrm.s84210, 10.2147/TCRM.S92222, 10.2147/TCRM.S84210] Milling TJ, 2016, AM J MED, V129, pS80, DOI 10.1016/j.amjmed.2016.06.009 Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955 Noth I, 2012, AM J RESP CRIT CARE, V186, P88, DOI 10.1164/rccm.201202-0314OC O'Brien EC, 2015, EUR HEART J, V36, P3258, DOI 10.1093/eurheartj/ehv476 Ozieraski K., 2017, KARDIOL DYPLOMIE, V6, P1 Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638 Pisters R, 2010, CHEST, V138, P1093, DOI 10.1378/chest.10-0134 Pollack CV, 2017, NEW ENGL J MED, V377, P431, DOI 10.1056/NEJMoa1707278 Pollack Jr CV, 2015, NEW ENGL J MED, V373, P511, DOI 10.1056/NEJMoa1502000 Qin S, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0718-5 Raghu G, 2018, AM J RESP CRIT CARE, V198, pE44, DOI 10.1164/rccm.201807-1255ST Rask-Andersen M, 2014, TRENDS PHARMACOL SCI, V35, P60, DOI 10.1016/j.tips.2014.09.007 Raszeja-Specht A, 2015, Diagnostyka Laboratoryjna, V51, P221, DOI 10.5604/01.3001.0008.2262 Reck M, 2015, LUNG CANCER, V90, P267, DOI 10.1016/j.lungcan.2015.08.003 Reck M, 2014, LANCET ONCOL, V15, P143, DOI 10.1016/S1470-2045(13)70586-2 Richeldi L, 2014, NEW ENGL J MED, V370, P2071, DOI [10.1056/nejmx150012, 10.1056/NEJMoa1402584] Roskoski R Jr, 2018, PHARMACOL RES, V133, P35, DOI 10.1016/j.phrs.2018.04.020 Roskoski R, 2016, PHARMACOL RES, V103, P26, DOI 10.1016/j.phrs.2015.10.021 Roth GJ, 2015, J MED CHEM, V58, P1053, DOI 10.1021/jm501562a Ruff CT, 2014, LANCET, V383, P955, DOI 10.1016/S0140-6736(13)62343-0 Ruff CT, 2010, AM HEART J, V160, P635, DOI 10.1016/j.ahj.2010.06.042 Samuelson BT, 2017, BLOOD REV, V31, P77, DOI 10.1016/j.blre.2016.08.006 Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/S0092-8674(00)00114-8 Shan YB, 2011, J AM CHEM SOC, V133, P9181, DOI 10.1021/ja202726y Stopfer P, 2011, XENOBIOTICA, V41, P297, DOI 10.3109/00498254.2010.545452 Sun C, 2014, TRENDS BIOCHEM SCI, V39, P465, DOI 10.1016/j.tibs.2014.08.010 Tai WT, 2014, J HEPATOL, V61, P89, DOI 10.1016/j.jhep.2014.03.017 Terzyan SS, 2019, J BIOL CHEM, V294, P10428, DOI 10.1074/jbc.RA119.007682 Therapeutic Goods Administration (Australia), 2015, EXTRACT CLIN EVALUAT Tong M, 2015, ACS CHEM BIOL, V10, P190, DOI 10.1021/cb500870a Tripodi A, 2013, CLIN CHEM, V59, P353, DOI 10.1373/clinchem.2012.189704 Varone F, 2018, EXPERT OPIN PHARMACO, V19, P167, DOI 10.1080/14656566.2018.1425681 Venker BT, 2017, J ARTHROPLASTY, V32, P645, DOI 10.1016/j.arth.2016.09.033 Verma A, 2014, CAN J CARDIOL, V30, P1114, DOI 10.1016/j.cjca.2014.08.001 Wind S, 2019, CLIN PHARMACOKINET, V58, P1131, DOI 10.1007/s40262-019-00766-0 Witkowski M, 2016, POSTEP HIG MED DOSW, V70, P43, DOI 10.5604/17322693.1194114 Wollin L, 2015, EUR RESPIR J, V45, P1434, DOI 10.1183/09031936.00174914 Wu P, 2015, TRENDS PHARMACOL SCI, V36, P422, DOI 10.1016/j.tips.2015.04.005 Zawilska K., 2014, J TRANSFUS MED, V7, P93 NR 95 TC 31 Z9 35 U1 0 U2 8 PU MDPI PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND SN 1661-6596 EI 1422-0067 J9 INT J MOL SCI JI Int. J. Mol. Sci. PD JAN PY 2021 VL 22 IS 1 AR 282 DI 10.3390/ijms22010282 PG 19 WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary WE Science Citation Index Expanded (SCI-EXPANDED) SC Biochemistry & Molecular Biology; Chemistry GA PQ1MY UT WOS:000606314100001 PM 33396592 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Leyrat, B Durando, X Veyssiere, H Bernadach, M AF Leyrat, Brice Durando, Xavier Veyssiere, Hugo Bernadach, Maureen TI Durable Response to Crizotinib in a Patient with Pulmonary Adenocarcinoma Harboring MET Intron 14 Mutation: A Case Report SO ONCOTARGETS AND THERAPY LA English DT Article DE crizotinib; next-generation sequencing; MET intron 14 mutation; non-small-cell lung cancer ID CELL LUNG-CANCER; GENE COPY NUMBER; ESMO CONSENSUS CONFERENCE; ANTITUMOR-ACTIVITY; STAGE-I; ALK; AMPLIFICATION; CHEMOTHERAPY; INHIBITORS; ONARTUZUMAB AB Background: For patients with non-epidermal non-small-cell lung cancer (NSCLC), molecular alterations should always be investigated, especially in non-smokers, who have a very high frequency of targetable alterations (EGFR 52%; ALK 8% in particular). MET exon 14 alterations are identified in 3-4% of NSCLCs and MET gene amplification and high protein expression are associated with a poor prognosis. The French recommendations only authorize the use of capmatinib and crizotinib if the mutation concerns exon 14. However, several different types of mutation in exon 14 of MET and its flanking introns can induce a jump in exon 14, activate the MET gene and thus be sensitive to anti-MET tyrosine kinase inhibitors. Case Summary: This case concerns a 76-year-old Caucasian male with a medical history including idiopathic thrombocytopenic purpura, chronic myelomonocytic leukemia (CMML), atrial fibrillation, arterial hypertension, obesity (BMI 36kg/m2), and a 5-10 pack-per-year smoking history. A left upper lobe pulmonary nodule of 12.4 mm was discovered in March 2019. The patient received adjuvant chemotherapy with carboplatin AUC 5 and vinorelbine 25.00 mg/m2. At the end of the adjuvant treatment, the patient was in complete remission for 5 months. In February 2020, the CT scan revealed a mediastinal lymph node progression. A complementary molecular analysis was realized on the initial surgical specimen. A c.3082 +3A>T mutation in the MET gene was identified. This mutation confers susceptibility to antiMET tyrosine kinase inhibitors. Treatment with crizotinib was initiated with an initial dose of 250 mg/day for 15 days and then increased to 250 mg twice a day. After 7 months of treatment with crizotinib, the disease was still stable according to RECIST 1.1. Conclusion: We report here the original case of a patient presenting a lung adenocarcinoma with an intron 14 mutation and having a durable TKI response. C1 [Leyrat, Brice; Durando, Xavier; Bernadach, Maureen] Ctr Jean Perrin, Dept Oncol Med, F-63011 Clermont Ferrand, France. [Leyrat, Brice; Durando, Xavier] Univ Clermont Auvergne, UFR Med, F-63000 Clermont Ferrand, France. [Durando, Xavier; Veyssiere, Hugo; Bernadach, Maureen] Univ Clermont Auvergne, Ctr Jean Perrin, INSERM, Imagerie Mol & Strategies Theranost U1240, F-63011 Clermont Ferrand, France. [Durando, Xavier; Veyssiere, Hugo; Bernadach, Maureen] Ctr Jean Perrin, Ctr Lutte Canc, Div Rech Clin Delegat Rech Clin & Innovat, F-63011 Clermont Ferrand 1, France. [Durando, Xavier; Veyssiere, Hugo; Bernadach, Maureen] Ctr Invest Clin, UMR501, F-63011 Clermont Ferrand, France. C3 UNICANCER; Centre Jean Perrin; Universite Clermont Auvergne (UCA); UNICANCER; Centre Jean Perrin; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Clermont Auvergne (UCA); UNICANCER; Centre Jean Perrin; Institut National de la Sante et de la Recherche Medicale (Inserm) RP Veyssiere, H (corresponding author), Ctr Jean Perrin, Ctr Lutte Canc, Div Rech Clin, 58 Rue Montalembert, F-63011 Clermont Ferrand, France. EM Hugo.VEYSSIERE@clermont.unicancer.fr RI Durando, Xavier/Y-3806-2019 OI Durando, Xavier/0000-0001-6035-3172; VEYSSIERE, Hugo/0000-0003-2202-7362; Bernadach, Maureen/0000-0002-7185-0809 CR Awad MM, 2016, J CLIN ONCOL, V34, P721, DOI 10.1200/JCO.2015.63.4600 Baldacci S, 2018, REV MAL RESPIR, V35, P796, DOI 10.1016/j.rmr.2018.01.011 Besse B, 2014, ANN ONCOL, V25, P1475, DOI 10.1093/annonc/mdu123 Couraud S, 2015, EUR RESPIR J, V45, P1403, DOI 10.1183/09031936.00097214 Cui JJ, 2011, J MED CHEM, V54, P6342, DOI 10.1021/jm2007613 Drilon A, 2020, NAT MED, V26, P47, DOI 10.1038/s41591-019-0716-8 Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478 Engstrom LD, 2017, CLIN CANCER RES, V23, P6661, DOI 10.1158/1078-0432.CCR-17-1192 Feng Y, 2012, J THORAC ONCOL, V7, P459, DOI 10.1097/JTO.0b013e3182417e44 Frampton GM, 2015, CANCER DISCOV, V5, P850, DOI 10.1158/2159-8290.CD-15-0285 Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005 Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205 Guo BP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099399 Guo R, 2019, J CLIN ONCOL, V37 Heist RS, 2016, ONCOLOGIST, V21, P481, DOI 10.1634/theoncologist.2015-0510 Howington JA, 2013, CHEST, V143, pE278, DOI 10.1378/chest.12-2359 Huang CW, 2020, CURR TREAT OPTION ON, V21, DOI 10.1007/s11864-020-0723-5 Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445 Jin Y, 2014, ANN SURG ONCOL, V21, P621, DOI 10.1245/s10434-013-3355-1 Jurmeister P, 2015, LUNG CANCER, V87, P122, DOI 10.1016/j.lungcan.2014.11.018 Kerr KM, 2014, ANN ONCOL, V25, P1681, DOI 10.1093/annonc/mdu145 Klempner SJ, 2017, J THORAC ONCOL, V12, P152, DOI 10.1016/j.jtho.2016.09.127 Kowalczuk O, 2014, TRANSL ONCOL, V7, P605, DOI 10.1016/j.tranon.2014.08.002 Lindeman NI, 2018, ARCH PATHOL LAB MED, V142, P321, DOI 10.5858/arpa.2017-0388-CP Liu XW, 2016, J CLIN ONCOL, V34, P794, DOI 10.1200/JCO.2015.62.0674 Lu S, 2020, J CLIN ONCOL, V38 Ma PC, 2015, CANCER DISCOV, V5, P802, DOI 10.1158/2159-8290.CD-15-0769 Maesako Y, 2014, LEUKEMIA, V28, P1935, DOI 10.1038/leu.2014.166 Maxson JE, 2015, CANCER RES, V75, P2146, DOI 10.1158/0008-5472.CAN-14-1576 Mirati Therapeutics Inc, 2020, PHASE 2 PARALLEL ARM Noro R, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1019-1 Oxnard GR, 2013, J CLIN ONCOL, V31, P1097, DOI 10.1200/JCO.2012.42.9829 Paik PK, 2020, NEW ENGL J MED, V383, P931, DOI 10.1056/NEJMoa2004407 Paik PK, 2019, J CLIN ONCOL, V37 Paik PK, 2015, CANCER DISCOV, V5, P842, DOI 10.1158/2159-8290.CD-14-1467 Paz-Ares L, 2018, NEW ENGL J MED, V379, P2040, DOI 10.1056/NEJMoa1810865 Pisters KMW, 2007, J CLIN ONCOL, V25, P5506, DOI 10.1200/JCO.2007.14.1226 Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774 Recondo G, 2020, CANCER DISCOV, V10, P922, DOI 10.1158/2159-8290.CD-19-1446 Schrock AB, 2016, J THORAC ONCOL, V11, P1493, DOI 10.1016/j.jtho.2016.06.004 Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886 Sierra J Rafael, 2011, Ther Adv Med Oncol, V3, pS21, DOI 10.1177/1758834011422557 Spigel DR, 2017, J CLIN ONCOL, V35, P412, DOI 10.1200/JCO.2016.69.2160 Spigel DR, 2013, J CLIN ONCOL, V31, P4105, DOI 10.1200/JCO.2012.47.4189 Tong JH, 2016, CLIN CANCER RES, V22, P3048, DOI 10.1158/1078-0432.CCR-15-2061 Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012 Weingertner N, 2015, PATHOLOGY, V47, P320, DOI 10.1097/PAT.0000000000000269 Wolf J, 2019, J CLIN ONCOL, V37, DOI 10.1200/jco.2019.37.15_suppl.9004 NR 48 TC 1 Z9 1 U1 0 U2 1 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1178-6930 J9 ONCOTARGETS THER JI OncoTargets Ther. PY 2021 VL 14 BP 3949 EP 3958 DI 10.2147/OTT.S312889 PG 10 WC Biotechnology & Applied Microbiology; Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Biotechnology & Applied Microbiology; Oncology GA TB8JY UT WOS:000668193600001 PM 34234464 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Patella, M Tessitore, A Cianfarani, A Minerva, EM Cafarotti, S AF Patella, M. Tessitore, A. Cianfarani, A. Minerva, E. M. Cafarotti, S. TI Early outcome of anatomical lung resection for non-small cell lung cancer in the elderly SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES LA English DT Article DE MiRNA-106; Pediatric osteosarcoma; PI3K/AKT signaling pathway ID GENERAL THORACIC-SURGERY; EUROPEAN-SOCIETY; OLDER; AGE; GUIDELINES; SURVIVAL; TRIALS; TRENDS; IMPACT AB OBJECTIVE: Surgery is the mainstay of early-stage lung cancer treatment. However, since life expectancy is constantly increasing, we wanted to investigate whether this principle also applies to elderly (<70-year-old) patients. PATIENTS AND METHODS: We analyzed a prospectively maintained database on anatomical lung resections at our institute. Patients were divided in two groups: <70 years and >= 70 years (elderly). Outcome indicators were postoperative cardiopulmonary complications rate and 30-day readmission rate. Baseline and surgical characteristics were compared by mean of t-test, Mann-Whitney U test, chi2 and Fisher exact tests. Propensity score matching was performed to account for differences between groups in the outcome's analysis. RESULTS: We selected 241 patients with lung cancer (2017-2021) who underwent anatomical lung resections. Median age was 70.5 (IQR: 6476). 133 patients (54%) aged 70 and above. Patients and surgical characteristics (comorbidities, lung function, performance status, type and extension of lung resection and surgical approach) were similar among groups, except for atrial fibrillation (p=0.01) and previous cancer history (p<0.0001) which were more frequent in the elderly group. Non-elderly patients were more frequently active smokers (p<0.0001). Cardiopulmonary complications rate was 23%, 30-day readmission rate was 12.6%. We did not observe any significant difference in all the short-term outcome indicators between the elderly and the younger counterpart. Particularly, complications rate (p=0.91) and 30-day readmission (p=0.84) did not differ between groups. CONCLUSIONS: In our series, short-term outcomes are not compromised in elderly patients. The evolution in surgical strategy and expertise contribute to offer surgical resection with curative intent for lung cancer to a large spectrum of patients. C1 [Cafarotti, S.] Ente Osped Cantonale Bellinzona, San Giovanni Hosp, Dept Thorac Surg, Bellinzona, Switzerland. Univ Svizzera Italiana, Lugano, Switzerland. C3 Regional Hospital of Bellinzona & Valleys, San Giovanni; Universita della Svizzera Italiana RP Cafarotti, S (corresponding author), Ente Osped Cantonale Bellinzona, San Giovanni Hosp, Dept Thorac Surg, Bellinzona, Switzerland. RI Minerva, Eleonora/IAR-4599-2023 CR Brunelli A, 2020, EUR J CARDIO-THORAC, V57, P455, DOI 10.1093/ejcts/ezz272 Brunelli A, 2014, EUR J CARDIO-THORAC, V45, P779, DOI 10.1093/ejcts/ezu016 Brunelli A, 2013, CHEST, V143, pE166, DOI 10.1378/chest.12-2395 Brunelli A, 2009, EUR J CARDIO-THORAC, V36, P181, DOI 10.1016/j.ejcts.2009.04.022 Detillon DDEMA, 2018, ANN THORAC SURG, V105, P287, DOI 10.1016/j.athoracsur.2017.07.032 Di Maio M, 2003, BRIT J CANCER, V89, P1013, DOI 10.1038/sj.bjc.6601236 Driessen EJ, 2017, LUNG CANCER, V108, P198, DOI 10.1016/j.lungcan.2017.04.005 Fernandez FG, 2015, ANN THORAC SURG, V99, P368, DOI 10.1016/j.athoracsur.2014.05.104 Gridelli C, 2003, JNCI-J NATL CANCER I, V95, P362, DOI 10.1093/jnci/95.5.362 Gridelli C, 2007, J CLIN ONCOL, V25, P1898, DOI 10.1200/JCO.2006.10.3085 Haasbeek CJA, 2012, ANN ONCOL, V23, P2743, DOI 10.1093/annonc/mds081 Hutchins LF, 1999, NEW ENGL J MED, V341, P2061, DOI 10.1056/NEJM199912303412706 Katayama H, 2021, JPN J CLIN ONCOL, V51, P685, DOI 10.1093/jjco/hyaa257 Kleptko W, 2001, EUR J CARDIO-THORAC, V20, P663, DOI 10.1016/S1010-7940(01)00942-3 Leuven Edwin., 2003, PSMATCH2 Lewis JH, 2003, J CLIN ONCOL, V21, P1383, DOI 10.1200/JCO.2003.08.010 Palma D, 2010, J CLIN ONCOL, V28, P5153, DOI 10.1200/JCO.2010.30.0731 Puri V, 2015, J THORAC CARDIOV SUR, V150, P1496, DOI 10.1016/j.jtcvs.2015.08.067 Quero-Valenzuela F, 2018, J SURG ONCOL, V117, P1239, DOI 10.1002/jso.24973 Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590 Thomas PA, 2021, LUNG CANCER, V152, P86, DOI 10.1016/j.lungcan.2020.12.009 Vansteenkiste J, 2013, ANN ONCOL, V24, P89, DOI 10.1093/annonc/mdt241 Wang WX, 2020, J THORAC DIS, V12, P6731, DOI 10.21037/jtd-20-2221 Wingo PA, 2003, CANCER-AM CANCER SOC, V97, P3133, DOI 10.1002/cncr.11380 Yee KWL, 2003, J CLIN ONCOL, V21, P1618, DOI 10.1200/JCO.2003.12.044 NR 25 TC 5 Z9 6 U1 0 U2 3 PU VERDUCI PUBLISHER PI ROME PA VIA GREGORIO VII, ROME, 186-00165, ITALY SN 1128-3602 J9 EUR REV MED PHARMACO JI Eur. Rev. Med. Pharmacol. Sci. PY 2021 VL 25 IS 16 BP 5129 EP 5136 DI 10.26355/eurrev_202108_26525 PG 8 WC Pharmacology & Pharmacy WE Science Citation Index Expanded (SCI-EXPANDED) SC Pharmacology & Pharmacy GA UP8VZ UT WOS:000695652700010 PM 34486687 DA 2026-04-17 ER PT J AU Piwkowski, C Gabryel, P Roszak, M Perek, B Kasprzyk, M AF Piwkowski, Cezary Gabryel, Piotr Roszak, Magdalena Perek, Bartlomiej Kasprzyk, Mariusz TI Short- and long-term outcomes of thoracoscopic pneumonectomy - single center experience SO VIDEOSURGERY AND OTHER MINIINVASIVE TECHNIQUES LA English DT Article DE thoracoscopy/video-assisted thoracic surgery; lung cancer; minimally invasive surgery; pneumonectomy ID LUNG-CANCER; LOBECTOMY; COMPLICATIONS; RESECTIONS AB Introduction: The video-assisted thoracic surgery (VATS) approach is widely used for pulmonary lobectomy, but its application for pneumonectomy is much less common and outcomes are ambiguous. Aim: To evaluate the feasibility and outcomes of VATS pneumonectomy. Material and methods: This retrospective study included 19 patients with the mean age of 62.6 +/- 5.5 years who were qualified for VATS pneumonectomy between September 1, 2010, and January 31, 2020. Indications and technical aspects were analyzed. Moreover, short- and long-term outcomes were assessed. Results: There were no intraoperative deaths. Conversion to thoracotomy was necessary in 2 (10.5%) patients, because of bleeding in 1 patient and technical reasons in another. One patient died during the in-hospital period due to multi-organ failure as a result of bronchopleural fistula. Five other subjects developed postoperative complications, most often atrial fibrillation (n = 3). One patient was readmitted for empyema of the postpneumonectomy space without bronchopleural fistula. Histopathological examination revealed that the resection was complete (R0) in all cases and the most common type of cancer was squamous cell carcinoma (79%). Seven patients died during the follow-up: 1 because of surgical complications, 4 as a result of cancer progression, and 2 for non-cancer related reasons. Median survival was 47 months. One- and five-year probability of survival estimated by means of the Kaplan-Meier method was 0.88 +/- 0.07 and 0.43 +/- 0.15, respectively. Conclusions: VATS pneumonectomy can be performed safely, without increased risk of intraoperative and postoperative complications. It enables a complete lung cancer resection and is likely to provide good short- and long-term outcomes. C1 [Piwkowski, Cezary; Gabryel, Piotr; Kasprzyk, Mariusz] Poznan Univ Med Sci, Dept Thorac Surg, Poznan, Poland. [Roszak, Magdalena] Poznan Univ Med Sci, Dept Comp Sci & Stat, Poznan, Poland. [Perek, Bartlomiej] Poznan Univ Med Sci, Dept Cardiac Surg & Transplantol, Poznan, Poland. C3 Poznan University of Medical Sciences; Poznan University of Medical Sciences; Poznan University of Medical Sciences RP Gabryel, P (corresponding author), Poznan Univ Med Sci, Dept Thorac Surg, Poznan, Poland. EM piotrgabryel@gmail.com RI Perek, Bartłomiej/AAS-6564-2021; Gabryel, Piotr/F-8517-2014 CR Al-Ameri M, 2018, J THORAC DIS, V10, P3499, DOI 10.21037/jtd.2018.05.177 Alpay L, 2014, VIDEOSURGERY MINIINV, V9, P409, DOI 10.5114/wiitm.2014.44254 Battoo A, 2014, CHEST, V146, P1300, DOI 10.1378/chest.14-0058 Bendixen M, 2016, LANCET ONCOL, V17, P836, DOI 10.1016/S1470-2045(16)00173-X CRAIG SR, 1995, THORAX, V50, P392, DOI 10.1136/thx.50.4.392 Decaluwe H, 2015, EUR J CARDIO-THORAC, V48, P588, DOI 10.1093/ejcts/ezv287 Dziedzic R, 2018, EUR J CARDIO-THORAC, V54, P547, DOI 10.1093/ejcts/ezy101 Gibas A, 2009, KARDIOCHIR TORAKOCHI, V6, P142 Gonzalez-Rivas D, 2013, J THORAC DIS, V5, pS246, DOI 10.3978/j.issn.2072-1439.2013.07.44 Huang J, 2016, J THORAC DIS, V8, P553, DOI 10.21037/jtd.2016.01.63 Jeon JH, 2014, EUR J CARDIO-THORAC, V45, P640, DOI 10.1093/ejcts/ezt460 Kasprzyk M, 2013, NEOPLASMA, V60, P62, DOI [10.4149/neo_2013009, 10.4149/neo_2013_009] Kocher GJ, 2019, J THORAC DIS, V11, P1091, DOI 10.21037/jtd.2019.02.92 Liu YQ, 2016, J THORAC DIS, V8, P3537, DOI 10.21037/jtd.2016.12.24 McKenna RJ, 2006, ANN THORAC SURG, V81, P421, DOI 10.1016/j.athoracsur.2005.07.078 Nagai S, 2014, ANN THORAC SURG, V97, P1908, DOI 10.1016/j.athoracsur.2014.02.022 Nwogu CE, 2010, ANN THORAC SURG, V89, pS2102, DOI 10.1016/j.athoracsur.2010.03.019 Pagès PB, 2017, J THORAC CARDIOV SUR, V153, P184, DOI 10.1016/j.jtcvs.2016.09.060 Piwkowski C, 2013, VIDEOSURGERY MINIINV, V8, P334, DOI 10.5114/wiitm.2011.35633 Piwkowski C, 2012, VIDEOSURGERY MINIINV, V7, P197, DOI 10.5114/wiitm.2011.28869 ROVIARO G, 1993, ANN THORAC SURG, V56, P779, DOI 10.1016/0003-4975(93)90979-R Sahai RK, 2009, ANN THORAC SURG, V88, P1086, DOI 10.1016/j.athoracsur.2009.05.065 Shin JY, 2018, LUNG, V196, P351, DOI 10.1007/s00408-018-0110-1 Yang CFJ, 2019, J THORAC CARDIOV SUR, V158, P252, DOI 10.1016/j.jtcvs.2018.12.001 Ye B, 2019, COMB CHEM HIGH T SCR, V22, P187, DOI 10.2174/1386207322666190415103030 Zhong L, 2019, VIDEOSURGERY MINIINV, V14, P545, DOI 10.5114/wiitm.2019.89986 NR 26 TC 1 Z9 1 U1 0 U2 3 PU TERMEDIA PUBLISHING HOUSE LTD PI POZNAN PA KLEEBERGA ST 2, POZNAN, 61-615, POLAND SN 1895-4588 EI 2299-0054 J9 VIDEOSURGERY MINIINV JI Videosurgery Miniinvasive Tec. PY 2021 VL 16 IS 2 BP 369 EP 376 DI 10.5114/wiitm.2021.103923 PG 8 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA SM3MC UT WOS:000657512800012 PM 34136033 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Huang, C Sun, YG Wu, QJ Ma, C Jiao, P Wang, YZ Huang, W Tian, WX Yu, HB Li, DH Tong, HF AF Huang, Chuan Sun, Yaoguang Wu, Qingjun Ma, Chao Jiao, Peng Wang, Yongzhong Huang, Wen Tian, Wenxin Yu, Hanbo Li, Donghang Tong, Hongfeng TI Simultaneous bilateral pulmonary resection via single-utility port VATS for multiple pulmonary nodules: A single-center experience of 16 cases SO THORACIC CANCER LA English DT Article DE Bilateral; multiple pulmonary nodules; single‐ utility port; video‐ assisted thoracoscopic surgery ID ASSISTED THORACOSCOPIC SURGERY; LUNG-CANCER PATIENTS; THORACIC-SURGERY; SURGICAL-TREATMENT; MANAGEMENT; PAIN AB Background The detection rate of bilateral multiple pulmonary nodules (BMPNs) is increasing due to widespread use of chest computed tomography (CT) screening. However, there is no consensus on the treatment options for BMPNs and whether simultaneous bilateral pulmonary resection is safe remains controversial. The purpose of this study was to evaluate the feasibility and safety of simultaneous bilateral pulmonary resection for BMPNs. Methods A total of 16 consecutive patients with BMPNs who underwent simultaneous bilateral pulmonary resection in Beijing Hospital from June 2013 to July 2020 were enrolled in this study. Clinical characteristics, imaging and pathological features, and perioperative outcomes were retrospectively reviewed. Results There were 10 males and six females included in the study with a mean age of 61.9 (range: 39-78) years. A total of 35 nodules were resected in 16 patients including 12 patients with bilateral primary lung cancer, three patients with primary lung cancer on one side and a benign nodule on the contralateral side, and one patient with bilateral benign nodules. All patients underwent bilateral pulmonary resection via single-utility port video-assisted thoracoscopic surgery (VATS). Nine, four, two, and one patients underwent lobectomy with contralateral segmentectomy or wedge resection, segmentectomy with contralateral wedge resection, bilateral segmentectomy and bilateral wedge resection, respectively. All operations were accomplished successfully without intraoperative blood transfusion, conversion to thoracotomy, major complication and postoperative 90-day death. The mean operation time was 220.1 +/- 65.6 minutes, median thoracic drainage duration was four days (range: 2-8 days), mean pleural drainage was 1387.5 +/- 694.7 mL, and median postoperative hospital stay was seven days (range: 5-18 days). There were three cases (18.8%) of minor complications, including one case of pulmonary air leakage, one case of atrial fibrillation, and one case of poor healing of surgical site. A total of 50% (8/16) of the patients had severe postoperative pain and required additional analgesia. Conclusions For selected patients, simultaneous bilateral pulmonary resection via single-utility port VATS is a safe and feasible minimally invasive procedure for BMPNs. Adequate postoperative analgesia via a multimodal analgesia strategy should be used to prevent postoperative pain. Key points Significant findings of the study The incidence of major complication after minimally invasive bilateral pulmonary resection is low for patients with good pulmonary function, but there is a relatively high incidence of minor complications and pain at the surgical site. Adequate postoperative analgesia via multimodal analgesia strategy should be used to prevent postoperative pain. What this study adds For the treatment of bilateral multiple pulmonary nodules, simultaneous bilateral pulmonary resection via single-utility port video-assisted thoracoscopic surgery is safe and feasible for selected patients. C1 [Huang, Chuan; Sun, Yaoguang; Wu, Qingjun; Ma, Chao; Jiao, Peng; Wang, Yongzhong; Huang, Wen; Tian, Wenxin; Yu, Hanbo; Li, Donghang; Tong, Hongfeng] Chinese Acad Med Sci, Beijing Hosp, Natl Ctr Gerontol, Inst Geriatr Med,Dept Thorac Surg, Beijing, Peoples R China. C3 Chinese Academy of Medical Sciences - Peking Union Medical College; Beijing Hospital RP Tong, HF (corresponding author), Chinese Acad Med Sci, Beijing Hosp, Natl Ctr Gerontol, Inst Geriatr Med,Dept Thorac Surg, Beijing, Peoples R China. EM tonghf0355@163.com RI li, donghang/LYP-0177-2024 CR Aberle DR, 2013, NEW ENGL J MED, V369, P920, DOI 10.1056/NEJMoa1208962 Aberle DR, 2011, NEW ENGL J MED, V365, P395, DOI 10.1056/NEJMoa1102873 Bak SH, 2016, CHEST, V149, P180, DOI 10.1378/chest.15-0034 Bayman EO, 2014, J PAIN, V15, P887, DOI 10.1016/j.jpain.2014.06.005 Chen TF, 2019, BMC SURG, V19, DOI 10.1186/s12893-019-0643-0 Detterbeck FC, 2017, CHEST, V151, P193, DOI 10.1016/j.chest.2016.10.010 Hattori A, 2017, THORAC CARDIOV SURG, V65, P142, DOI 10.1055/s-0036-1572437 Jiang L, 2015, LUNG CANCER, V87, P303, DOI 10.1016/j.lungcan.2014.12.013 Jiao P, 2016, EUR J CARDIO-THORAC, V50, P574, DOI 10.1093/ejcts/ezw061 Kinney MAO, 2012, ANN THORAC SURG, V93, P1242, DOI 10.1016/j.athoracsur.2012.01.031 Leventakos K, 2017, J THORAC ONCOL, V12, P1398, DOI 10.1016/j.jtho.2017.05.013 MARTINI N, 1975, J THORAC CARDIOV SUR, V70, P606 Mun M, 2007, ANN THORAC SURG, V83, P1146, DOI 10.1016/j.athoracsur.2006.10.037 Nakata M, 2004, ANN THORAC SURG, V78, P1194, DOI 10.1016/j.athoracsur.2004.03.102 Peng Z, 2014, PLOS ONE, V9 Qu RR, 2020, J CARDIOTHORAC SURG, V15, DOI 10.1186/s13019-020-01107-0 Shimada Y, 2015, LUNG CANCER, V88, P174, DOI 10.1016/j.lungcan.2015.02.016 Wood DE, 2018, J NATL COMPR CANC NE, V16, P412, DOI 10.6004/jnccn.2018.0020 Wright CD, 2007, ANN THORAC SURG, V83, P893, DOI 10.1016/j.athoracsur.2006.09.078 Xu GQ, 2019, J THORAC DIS, V11, P535, DOI 10.21037/jtd.2019.01.10 Yang HT, 2016, ANN THORAC SURG, V101, P1145, DOI 10.1016/j.athoracsur.2015.09.028 Yang XY, 2018, POSTGRAD MED, V130, P142, DOI 10.1080/00325481.2018.1398048 Yao F, 2016, J THORAC DIS, V8, P469, DOI 10.21037/jtd.2016.02.66 Zhang YX, 2018, J THORAC DIS, V10, P6452, DOI 10.21037/jtd.2018.11.10 Zhang ZR, 2016, SCI REP-UK, V6, DOI 10.1038/srep23252 NR 25 TC 17 Z9 23 U1 0 U2 1 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1759-7706 EI 1759-7714 J9 THORAC CANCER JI Thorac. Cancer PD FEB PY 2021 VL 12 IS 4 BP 525 EP 533 DI 10.1111/1759-7714.13791 EA DEC 2020 PG 9 WC Oncology; Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Respiratory System GA QG7HG UT WOS:000600865600001 PM 33354921 OA Green Submitted, Green Published, gold DA 2026-04-17 ER PT J AU Sorigue, M AF Sorigue, Marc TI Oral anticoagulation in patients with active cancer and atrial fibrillation: current challenges SO POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ LA English DT Review DE atrial fibrillation; anticoagulation; cancer; direct oral anticoagulants ID VENOUS THROMBOEMBOLISM; ISCHEMIC-STROKE; BLEEDING RISK; LUNG-CANCER; WARFARIN; SAFETY; EFFICACY; OUTCOMES; POPULATION; MANAGEMENT AB Atrial fibrillation and cancer are common comorbidities. Given an increased risk of arterial thrombosis caused by the former and an increased risk of bleeding in patients with the latter, the management of anticoagulation in patients in whom they coexist is complex. On the basis of generally low-quality evidence, numerous documents have been published in the past 3 years providing practice points for physicians to offer the best treatment plan to their patients. The present review begins with a summary of these recommendations and then proceeds to outline 9 practical challenges that fit into the larger questions of when and in whom anticoagulation is indicated, and what is the best agent in patients with atrial fibrillation and active cancer. For each of these 9 challenges, the evidence available is presented, the author's personal practical advice is given and the most pressing need to move the field forward is stated. I conclude by emphasizing the need for high-quality evidence and, more practically, by stressing 1) the importance of patient preference and values in the decision on whether and how to anticoagulate, and 2) the need for periodic reassessment of the benefits of anticoagulation with changes in cancer status and treatment plan. C1 [Sorigue, Marc] Univ Autonoma Barcelona, ICO Hosp Germans Trias & Pujol, Josep Carreras Inst, Dept Hematol, Badalona, Spain. C3 Institut Catala d'Oncologia; Institut de Recerca Contra la Leucemia Josep Carreras (IJC); Autonomous University of Barcelona RP Sorigue, M (corresponding author), Univ Autonoma Barcelona, ICO Hosp Germans Trias & Pujol, Josep Carreras Inst, Hematol Lab, Ctra Canyet S-N, Badalona 916, Spain. EM msorigue@iconcologia.net RI sorigue, marc/H-7072-2019 OI sorigue, marc/0000-0002-0587-591X CR Agnelli G, 2020, NEW ENGL J MED, V382, P1599, DOI 10.1056/NEJMoa1915103 Ambrus DB, 2016, THROMB RES, V144, P21, DOI 10.1016/j.thromres.2016.05.028 Amioka M, 2016, AM J CARDIOL, V118, P1386, DOI 10.1016/j.amjcard.2016.07.049 Angelini DE, 2019, AM J HEMATOL, V94, P780, DOI 10.1002/ajh.25494 Apostolakis S, 2012, J AM COLL CARDIOL, V60, P861, DOI 10.1016/j.jacc.2012.06.019 Aryal MR, 2019, BLOOD ADV, V3, P2381, DOI 10.1182/bloodadvances.2019000572 Aspberg S, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2019.104560 Atterman A, 2020, EUROPACE, V22, P58, DOI 10.1093/europace/euz306 Bellesoeur A, 2018, CRIT REV ONCOL HEMAT, V129, P102, DOI 10.1016/j.critrevonc.2018.06.015 Carrier M, 2019, NEW ENGL J MED, V380, P711, DOI 10.1056/NEJMoa1814468 Castellucci LA, 2014, JAMA-J AM MED ASSOC, V312, P1122, DOI 10.1001/jama.2014.10538 Cavallari I, 2020, THROMB HAEMOSTASIS, V120, P314, DOI 10.1055/s-0039-3400300 Chen PC, 2011, STROKE, V42, P3034, DOI 10.1161/STROKEAHA.111.615534 Chu G, 2019, BLOOD REV, V35, P59, DOI 10.1016/j.blre.2019.03.005 Cocho D, 2015, J STROKE CEREBROVASC, V24, P1324, DOI 10.1016/j.jstrokecerebrovasdis.2015.02.006 Cohen AT, 2017, THROMB HAEMOSTASIS, V117, P57, DOI 10.1160/TH15-08-0686 Connolly SJ, 2019, NEW ENGL J MED, V380, P1326, DOI 10.1056/NEJMoa1814051 D'Souza M, 2019, SCAND CARDIOVASC J, V53, P247, DOI 10.1080/14017431.2019.1638517 D'Souza M, 2018, EUR J PREV CARDIOL, V25, P651, DOI 10.1177/2047487318759858 Dawwas GK, 2019, LANCET HAEMATOL, V6, pE20, DOI 10.1016/S2352-3026(18)30191-1 Delluc A, 2019, J THROMB HAEMOST, V17, P1247, DOI 10.1111/jth.14478 Denas G, 2015, THROMB RES, V136, P488, DOI 10.1016/j.thromres.2015.06.011 Edmiston MK, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.010582 Elting LS, 2002, CANCER, V94, P3252, DOI 10.1002/cncr.10603 Fanola CL, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.008987 Farge D, 2019, LANCET ONCOL, V20, pE566, DOI 10.1016/S1470-2045(19)30336-5 Farmakis D, 2014, J AM COLL CARDIOL, V63, P945, DOI 10.1016/j.jacc.2013.11.026 Friberg L, 2012, CIRCULATION, V125, P2298, DOI 10.1161/CIRCULATIONAHA.111.055079 Gallagher AM, 2011, THROMB HAEMOSTASIS, V106, P968, DOI 10.1160/TH11-05-0353 Grazioli S, 2018, THROMB RES, V165, P33, DOI 10.1016/j.thromres.2018.03.011 Guha A, 2019, EUR HEART J, V40, P3007, DOI 10.1093/eurheartj/ehz649 Gutierrez A, 2019, THER ADV CARDIO DIS, V13, DOI 10.1177/1753944719860676 Hart RG, 2000, CEREBROVASC DIS, V10, P39, DOI 10.1159/000016023 Haukoos JS, 2015, JAMA-J AM MED ASSOC, V314, P1637, DOI 10.1001/jama.2015.13480 Hu YF, 2013, INT J CARDIOL, V165, P355, DOI 10.1016/j.ijcard.2012.08.036 Hung YP, 2019, INT J CARDIOL, V296, P81, DOI 10.1016/j.ijcard.2019.08.021 Imperatori Andrea, 2012, J Cardiothorac Surg, V7, P4, DOI 10.1186/1749-8090-7-4 Jabre P, 2011, CIRCULATION, V123, P2094, DOI 10.1161/CIRCULATIONAHA.110.990192 Jakobsen CB, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6314-9 January CT, 2019, CIRCULATION, V140, pE125, DOI [10.1161/CIR.0000000000000665, 10.1016/j.jacc.2019.01.011] Kim K, 2018, KOREAN CIRC J, V48, P406 Kirchhof P, 2016, EUR HEART J, V37, P2893, DOI 10.1093/eurheartj/ehw210 Klouwenberg PMCK, 2017, AM J RESP CRIT CARE, V195, P205, DOI [10.1164/rccm.201603-0618oc, 10.1164/rccm.201603-0618OC, 10.1164/rccm.201603-06180C] Kraaijpoel N, 2019, BLOOD, V133, P291, DOI 10.1182/blood-2018-08-835595 Lardaro T, 2015, AM J EMERG MED, V33, P1483, DOI 10.1016/j.ajem.2015.07.033 Lee YJ, 2016, INT J CARDIOL, V203, P372, DOI 10.1016/j.ijcard.2015.10.166 López-Fernández T, 2019, REV ESP CARDIOL, V72, P749, DOI 10.1016/j.rec.2019.03.019 López-López JA, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j5058 Lubitz SA, 2015, CIRCULATION, V131, P1648, DOI 10.1161/CIRCULATIONAHA.114.014058 Martín-Pérez M, 2019, THROMB HAEMOSTASIS, V119, P66, DOI 10.1055/s-0038-1676519 McBane RD II, 2020, J THROMB HAEMOST, V18, P411, DOI 10.1111/jth.14662 Melloni C, 2017, AM J MED, V130, P1440, DOI 10.1016/j.amjmed.2017.06.026 Melloni C, 2017, EUR HEART J, V3, P192, DOI 10.1093/ehjqcco/qcx004 Mery B, 2017, INT J CARDIOL, V240, P196, DOI 10.1016/j.ijcard.2017.03.132 Navi BB, 2019, RES PRACT THROMB HAE, V3, P639, DOI 10.1002/rth2.12223 Navi BB, 2018, ANN NEUROL, V83, P873, DOI 10.1002/ana.25227 Navi BB, 2017, J AM COLL CARDIOL, V70, P927, DOI 10.1016/j.jacc.2017.06.047 Navi BB, 2015, ANN NEUROL, V77, P291, DOI 10.1002/ana.24325 Nieto JA, 2010, J THROMB HAEMOST, V8, P1216, DOI 10.1111/j.1538-7836.2010.03852.x Ording AG, 2017, CANCER MED-US, V6, P1165, DOI 10.1002/cam4.1054 Sanz AP, 2019, BREAST, V46, P163, DOI 10.1016/j.breast.2019.05.017 Patell R, 2017, AM J CARDIOL, V120, P2182, DOI 10.1016/j.amjcard.2017.08.038 Plaja A, 2019, J THROMB THROMBOLYS, V47, P454, DOI 10.1007/s11239-018-1790-3 Pollack CV, 2017, NEW ENGL J MED, V377, P431, DOI 10.1056/NEJMoa1707278 Posch F, 2015, THROMB RES, V136, P582, DOI 10.1016/j.thromres.2015.07.011 Prandoni P, 2002, BLOOD, V100, P3484, DOI 10.1182/blood-2002-01-0108 Quon M, 2018, CAN J GEN INTERN MED, V13 Quon MJ, 2018, JACC-CLIN ELECTROPHY, V4, P386, DOI 10.1016/j.jacep.2017.08.003 Rahman F, 2016, JAMA CARDIOL, V1, P384, DOI 10.1001/jamacardio.2016.0582 Raskob GE, 2018, NEW ENGL J MED, V378, P615, DOI 10.1056/NEJMoa1711948 Rhea IB, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0797-z Rose AJ, 2007, J GEN INTERN MED, V22, P997, DOI 10.1007/s11606-007-0228-y Ruff CT, 2014, LANCET, V383, P955, DOI 10.1016/S0140-6736(13)62343-0 Russo V, 2018, SEMIN THROMB HEMOST, V44, P370, DOI 10.1055/s-0037-1607436 Samuelson BT, 2017, BLOOD REV, V31, P77, DOI 10.1016/j.blre.2016.08.006 Sarode R, 2013, CIRCULATION, V128, P1234, DOI 10.1161/CIRCULATIONAHA.113.002283 Sato Takao, 2018, J Atr Fibrillation, V11, P2105, DOI [10.4022/jafib.2105, 10.4022/jafib.2105] Schaefer JK, 2016, ANN HEMATOL, V95, P437, DOI 10.1007/s00277-015-2566-x Schwarzbach CJ, 2012, STROKE, V43, P3029, DOI 10.1161/STROKEAHA.112.658625 Shah S, 2018, BLOOD ADV, V2, P200, DOI 10.1182/bloodadvances.2017010694 Short NJ, 2014, ONCOLOGIST, V19, P82, DOI 10.1634/theoncologist.2013-0239 Sorigue M, 2020, LEUKEMIA LYMPHOMA, V61, P1277, DOI 10.1080/10428194.2020.1713321 Sorigue M, 2019, J ONCOL PRACT, V15, P641, DOI 10.1200/JOP.18.00592 Sorigue M, 2018, ANN HEMATOL, V97, P1633, DOI 10.1007/s00277-018-3346-1 Steffel J, 2018, EUR HEART J, V39, P1330, DOI 10.1093/eurheartj/ehy136 Steinberg BA, 2016, J AM COLL CARDIOL, V68, P2597, DOI 10.1016/j.jacc.2016.09.966 Stepien K, 2019, KARDIOL POL, V77, P1186, DOI 10.33963/KP.15042 Thomas L, 2020, JAMA-J AM MED ASSOC, V323, P466, DOI 10.1001/jama.2019.21558 Timp JF, 2013, BLOOD, V122, P1712, DOI 10.1182/blood-2013-04-460121 Trujillo-Santos J, 2008, THROMB HAEMOSTASIS, V100, P435, DOI 10.1160/TH08-02-0125 Tufano A, 2018, SEMIN THROMB HEMOST, V44, P388, DOI 10.1055/s-0038-1648229 Undas A, 2020, ANATOL J CARDIOL, V23, P10, DOI 10.14744/AnatolJCardiol.2019.30766 Vedovati MC, 2018, INT J CARDIOL, V269, P152, DOI 10.1016/j.ijcard.2018.07.138 Verma A, 2018, JACC-CLIN ELECTROPHY, V4, P394, DOI 10.1016/j.jacep.2017.10.014 Wang KL, 2015, STROKE, V46, P2555, DOI 10.1161/STROKEAHA.115.009947 Wu VCC, 2020, J CANCER, V11, P92, DOI 10.7150/jca.36468 Xing LY, 2019, THROMB RES, V178, P101, DOI 10.1016/j.thromres.2019.04.007 Young Annie M, 2018, J Clin Oncol, V36, P2017, DOI 10.1200/JCO.2018.78.8034 Zamorano J, 2016, EUR HEART J-CARD IMG, V17, P9, DOI 10.1093/ehjci/jev282 NR 99 TC 3 Z9 3 U1 0 U2 1 PU MEDYCYNA PRAKTYCZNA SP K SP ZOO PI KRAKOW PA REJTANA 2, KRAKOW, 30-510 AP, POLAND SN 0032-3772 EI 1897-9483 J9 POL ARCH INTERN MED JI Pol. Intern. Med. PD OCT 29 PY 2020 VL 130 IS 10 BP 878 EP 886 DI 10.20452/pamw.15315 PG 9 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA OJ1ME UT WOS:000583730900009 PM 32329983 OA gold DA 2026-04-17 ER PT J AU Piccioni, F Droghetti, A Bertani, A Coccia, C Corcione, A Corsico, AG Crisci, R Curcio, C Del Naja, C Feltracco, P Fontana, D Gonfiotti, A Lopez, C Massullo, D Nosotti, M Ragazzi, R Rispoli, M Romagnoli, S Scala, R Scudeller, L Taurchini, M Tognella, S Umari, M Valenza, F Petrini, F AF Piccioni, Federico Droghetti, Andrea Bertani, Alessandro Coccia, Cecilia Corcione, Antonio Corsico, Angelo Guido Crisci, Roberto Curcio, Carlo Del Naja, Carlo Feltracco, Paolo Fontana, Diego Gonfiotti, Alessandro Lopez, Camillo Massullo, Domenico Nosotti, Mario Ragazzi, Riccardo Rispoli, Marco Romagnoli, Stefano Scala, Raffaele Scudeller, Luigia Taurchini, Marco Tognella, Silvia Umari, Marzia Valenza, Franco Petrini, Flavia CA AIPO SIAARTI SIC SICT SIET SIP TI Recommendations from the Italian intersociety consensus on Perioperative Anesthesa Care in Thoracic surgery (PACTS) part 2: intraoperative and postoperative care SO PERIOPERATIVE MEDICINE LA English DT Article DE Anesthesia; Intraoperative care; Pneumonectomy; Postoperative care; Practice guideline; Thoracic surgery ID ONE-LUNG VENTILATION; DOUBLE-LUMEN TUBE; ASSISTED THORACOSCOPIC SURGERY; STROKE VOLUME VARIATION; ANTERIOR PLANE BLOCK; CONTINUOUS PARAVERTEBRAL BLOCK; DIFFICULT AIRWAY MANAGEMENT; ENHANCED RECOVERY PROGRAMS; ROUTINE CHEST RADIOGRAPHS; PULSE PRESSURE VARIATION AB Introduction Anesthetic care in patients undergoing thoracic surgery presents specific challenges that require a multidisciplinary approach to management. There remains a need for standardized, evidence-based, continuously updated guidelines for perioperative care in these patients. Methods A multidisciplinary expert group, the Perioperative Anesthesia in Thoracic Surgery (PACTS) group, was established to develop recommendations for anesthesia practice in patients undergoing elective lung resection for lung cancer. The project addressed three key areas: preoperative patient assessment and preparation, intraoperative management (surgical and anesthesiologic care), and postoperative care and discharge. A series of clinical questions was developed, and literature searches were performed to inform discussions around these areas, leading to the development of 69 recommendations. The quality of evidence and strength of recommendations were graded using the United States Preventive Services Task Force criteria. Results Recommendations for intraoperative care focus on airway management, and monitoring of vital signs, hemodynamics, blood gases, neuromuscular blockade, and depth of anesthesia. Recommendations for postoperative care focus on the provision of multimodal analgesia, intensive care unit (ICU) care, and specific measures such as chest drainage, mobilization, noninvasive ventilation, and atrial fibrillation prophylaxis. Conclusions These recommendations should help clinicians to improve intraoperative and postoperative management, and thereby achieve better postoperative outcomes in thoracic surgery patients. Further refinement of the recommendations can be anticipated as the literature continues to evolve. C1 [Piccioni, Federico; Valenza, Franco] Fdn IRCCS Ist Nazl Tumori, Dept Crit & Support Care, Milan, Italy. [Droghetti, Andrea] ASST Mantova, Div Thorac Surg, Mantua, Italy. [Bertani, Alessandro] IRCCS ISMETT UPMC, Div Thorac Surg & Lung Transplantat, Dept Treatment & Study Cardiothorac Dis & Cardiot, Palermo, Italy. [Coccia, Cecilia] Natl Canc Inst Regina Elena IRCCS, Dept Anesthesia & Crit Care Med, Rome, Italy. [Corcione, Antonio] Osped Colli, Monaldi Hosp, Dept Crit Care Area, Naples, Italy. [Corsico, Angelo Guido] Univ Pavia, IRCCS Policlin San Matteo Fdn, Div Resp Dis, Pavia, Italy. [Corsico, Angelo Guido] Univ Pavia, Dept Internal Med & Therapeut, Div Resp Dis, Pavia, Italy. [Crisci, Roberto] Univ Aquila, Dept Thorac Surg, Laquila, Italy. [Curcio, Carlo] AORN Colli Vincenzo Monaldi Hosp, Thorac Surg, Naples, Italy. [Del Naja, Carlo; Taurchini, Marco] IRCCS Casa Sollievo Sofferenza, Dept Thorac Surg, San Giovanni Rotondo, FG, Italy. [Feltracco, Paolo] Univ Hosp Padova, Dept Med Anaesthesia & Intens Care, Padua, Italy. [Fontana, Diego] San Giovanni Bosco Hosp, Thorac Surg Unit, Turin, Italy. [Gonfiotti, Alessandro] Univ Hosp Careggi, Thorac Surg Unit, Florence, Italy. [Lopez, Camillo] V Fazzi Hosp, Thorac Surg Unit, Lecce, Italy. [Massullo, Domenico] Azienda Osped Univ S Andrea, Anesthesiol & Intens Care Unit, Rome, Italy. [Nosotti, Mario] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Thorac Surg & Lung Transplant Unit, Milan, Italy. [Ragazzi, Riccardo] Azienda Osped Univ St Anna, Dept Morphol Surg & Expt Med, Ferrara, Italy. [Rispoli, Marco] AORN Colli Vincenzo Monaldi Hosp, Anesthesia & Intens Care, Naples, Italy. [Romagnoli, Stefano] Univ Florence, Sect Anesthesia & Crit Care, Dept Hlth Sci, Florence, Italy. [Romagnoli, Stefano] Careggi Univ Hosp, Dept Anesthesia & Crit Care, Florence, Italy. [Scala, Raffaele] San Donato Hosp, Pneumol & Resp Intens Care Unit, Arezzo, Italy. [Scudeller, Luigia] Fdn IRCCS San Matteo, Sci Direct, Clin Epidemiol Unit, Pavia, Italy. [Tognella, Silvia] Orlandi Gen Hosp, Resp Unit, Verona, Italy. [Umari, Marzia] Cattinara Univ Hosp, Combined Dept Emergency Urgency & Admiss, Trieste, Italy. [Valenza, Franco] Univ Milan, Dept Oncol & Oncohematol, Milan, Italy. [Petrini, Flavia] Chieti Univ Hosp, Dept Anaesthesia Perioperat Med Pain Therapy RRS, Chieti, Italy. C3 Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione (ISMETT); University of Pavia; IRCCS Fondazione San Matteo; University of Pavia; University of L'Aquila; IRCCS Casa Sollievo Della Sofferenza; University of Padua; Azienda Ospedaliera - Universita di Padova; University of Florence; Azienda Ospedaliero Universitaria Careggi; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Ferrara; Arcispedale Sant'Anna; University of Florence; University of Florence; Azienda Ospedaliero Universitaria Careggi; IRCCS Policlinico San Donato; IRCCS Fondazione San Matteo; University of Trieste; University Trieste Hospital; University of Milan RP Piccioni, F (corresponding author), Fdn IRCCS Ist Nazl Tumori, Dept Crit & Support Care, Milan, Italy. EM federico.piccioni@istitutotumori.mi.it RI Massullo, Domenico/AAR-1301-2020; Crisci, Roberto/HNI-0544-2023; Droghetti, Andrea/GQA-9308-2022; GONFIOTTI, Alessandro/AAP-1479-2020; Ragazzi, Riccardo/AAA-5817-2019; Scudeller, Luigia/K-9625-2014; Rispoli, Marco/Z-5874-2019; Nosotti, Mario/AAA-5976-2022; Bertani, Alessandro/AAB-7545-2019; Piccioni, Federico/B-8389-2017; Corsico, Angelo/AAC-8138-2019 OI GONFIOTTI, Alessandro/0000-0003-2724-9474; Scudeller, Luigia/0000-0001-7240-9567; Piccioni, Federico/0000-0002-9589-1891; OGHETTI, Anea/0000-0001-9526-8605 FU MSD Italia Srl FX This work, including travel and meeting expenses, was supported by an unrestricted grant from MSD Italia Srl. The sponsor had no role in selecting the participants, reviewing the literature, defining consensus recommendations, drafting or reviewing the paper, or in the decision to submit the manuscript. CR Agostini P, 2017, INTERACT CARDIOV TH, V24, P931, DOI 10.1093/icvts/ivx002 Agostini PJ, 2018, J CARDIOTHORAC SURG, V13, DOI 10.1186/s13019-018-0717-6 Aguilo R, 1997, CHEST, V112, P117, DOI 10.1378/chest.112.1.117 Ahn HJ, 2012, ANAESTH INTENS CARE, V40, P780, DOI 10.1177/0310057X1204000505 Ahn HJ, 2016, ANESTH ANALG, V122, P186, DOI 10.1213/ANE.0000000000000974 Albrecht E, 2013, ANAESTHESIA, V68, P79, DOI 10.1111/j.1365-2044.2012.07335.x Aldecoa C, 2017, EUR J ANAESTH, V34, P192, DOI 10.1097/EJA.0000000000000594 Allen MS, 2016, ANN THORAC SURG, V102, P925, DOI 10.1016/j.athoracsur.2016.03.115 Alphonso N, 2005, EUR J CARDIO-THORAC, V27, P391, DOI 10.1016/j.ejcts.2004.12.004 [Anonymous], 2015, J AM COLL SURGEONS, V220, P136, DOI 10.1016/j.jamcollsurg.2014.10.019 Auriant I, 2001, AM J RESP CRIT CARE, V164, P1231, DOI 10.1164/ajrccm.164.7.2101089 Baidya DK, 2014, INTERACT CARDIOV TH, V18, P626, DOI 10.1093/icvts/ivt551 Barbagallo M, 2012, RESP CARE, V57, P1418, DOI 10.4187/respcare.00838 Bardoczky G I, 1992, J Cardiothorac Vasc Anesth, V6, P51, DOI 10.1016/1053-0770(91)90045-U Batchelor TJP, 2019, EUR J CARDIO-THORAC, V55, P91, DOI 10.1093/ejcts/ezy301 Beck-Schimmer B, 2016, ANESTHESIOLOGY, V125, P313, DOI 10.1097/ALN.0000000000001164 Bell RF, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004603.pub2 Belze O, 2017, EUR J ANAESTH, V34, P456, DOI 10.1097/EJA.0000000000000655 Berian JR, 2018, ANN SURG, V268, P93, DOI 10.1097/SLA.0000000000002436 Biswas S, 2016, J CLIN DIAGN RES, V10, pUC8, DOI 10.7860/JCDR/2016/19159.8489 Bjerregaard LS, 2018, EUR J CARDIO-THORAC, V53, P209, DOI 10.1093/ejcts/ezx248 Blackshaw WJ, 2018, ANAESTHESIA, V73, P444, DOI 10.1111/anae.14205 Blank RS, 2016, ANESTHESIOLOGY, V124, P1286, DOI 10.1097/ALN.0000000000001100 Blaudszun G, 2012, ANESTHESIOLOGY, V116, P1312, DOI 10.1097/ALN.0b013e31825681cb Block BM, 2003, JAMA-J AM MED ASSOC, V290, P2455, DOI 10.1001/jama.290.18.2455 Bornemann-Cimenti H, 2016, MINERVA ANESTESIOL, V82, P1069 Brodsky JB, 2003, J CARDIOTHOR VASC AN, V17, P289, DOI 10.1016/S1053-0770(03)00046-6 Brunelli A, 2004, ANN THORAC SURG, V77, P1932, DOI 10.1016/j.athoracsur.2003.12.022 Brunelli A, 2009, EUR RESPIR J, V34, P17, DOI 10.1183/09031936.00184308 Brunelli Alessandro, 2005, Interact Cardiovasc Thorac Surg, V4, P609, DOI 10.1510/icvts.2005.116459 Brunelli A, 2008, ANN THORAC SURG, V86, P213, DOI 10.1016/j.athoracsur.2008.03.063 Brunelli A, 2011, EUR J CARDIO-THORAC, V40, P291, DOI 10.1016/j.ejcts.2011.05.020 Campos JH, 2007, CURR OPIN ANESTHESIO, V20, P27, DOI 10.1097/ACO.0b013e3280111e2a Campos JH, 2009, CURR OPIN ANESTHESIO, V22, P4, DOI 10.1097/ACO.0b013e32831a43ab Campos JH, 2003, ANESTH ANALG, V96, P283, DOI 10.1097/00000539-200301000-00056 Campos JH, 2002, ANESTHESIOLOGY, V97, P1295 Cannesson M, 2011, ANESTHESIOLOGY, V115, P231, DOI 10.1097/ALN.0b013e318225b80a Cardenas-Garcia J, 2015, J HOSP MED, V10, P581, DOI 10.1002/jhm.2394 Carron M, 2017, J CLIN ANESTH, V39, P38, DOI 10.1016/j.jclinane.2017.03.004 Cecconi M, 2013, CRIT CARE, V17, DOI 10.1186/cc11823 Cerfolio RJ, 2001, ANN THORAC SURG, V71, P1613, DOI 10.1016/S0003-4975(01)02474-2 Cerfolio RJ., 2001, J THORAC CARDIOV SUR, V122, P318 Chappell D, 2008, ANESTHESIOLOGY, V109, P723, DOI 10.1097/ALN.0b013e3181863117 Chen PT, 2017, ANAESTHESIA, V72, P1097, DOI 10.1111/anae.13984 Chia Yuan-Yi, 2009, Acta Anaesthesiol Taiwan, V47, P173, DOI 10.1016/S1875-4597(09)60051-5 Chiang MH, 2018, MINERVA ANESTESIOL, V84, P216, DOI 10.23736/S0375-9393.17.12033-X Chiappetta M, 2018, ULTRASOUND MED BIOL, V44, P1960, DOI 10.1016/j.ultrasmedbio.2018.05.009 Chou R, 2016, J PAIN, V17, P131, DOI 10.1016/j.jpain.2015.12.008 Clayton-Smith A, 2015, J CARDIOTHOR VASC AN, V29, P955, DOI 10.1053/j.jvca.2014.11.017 Cohen Edmond, 2004, Curr Opin Anaesthesiol, V17, P1, DOI 10.1097/00001503-200402000-00002 Coughlin SM, 2012, CAN J SURG, V55, P264, DOI 10.1503/cjs.001411 Cywinski JB, 2009, J CARDIOTHOR VASC AN, V23, P766, DOI 10.1053/j.jvca.2009.03.022 D'Antini D, 2016, INTENSIVE CARE ME S1, V4, pA442 Danner B, 2012, OPEN J THORACIC SURG, V2, P63, DOI [DOI 10.4236/ojts.2012.23014, 10.4236/ojts.2012.23014, DOI 10.4236/OJTS.2012.23014] Das-Neves-Pereira JC, 2009, EUR J CARDIO-THORAC, V36, P383, DOI 10.1016/j.ejcts.2009.02.020 Davies RG, 2006, BRIT J ANAESTH, V96, P418, DOI 10.1093/bja/ael020 de Bellis M, 2011, EUR J CARDIO-THORAC, V40, P912, DOI 10.1016/j.ejcts.2011.01.070 De Conno E, 2009, ANESTHESIOLOGY, V110, P1316, DOI 10.1097/ALN.0b013e3181a10731 De Hert S, 2014, ANAESTH INTENSIVE TH, V46, P336, DOI 10.5603/AIT.2014.0057 de la Gala F, 2017, BRIT J ANAESTH, V119, P655, DOI 10.1093/bja/aex230 De Oliveira GS Jr, 2013, ANESTHESIOLOGY, V119, P178, DOI 10.1097/ALN.0b013e318297630d De Oliveira GS Jr, 2011, ANESTHESIOLOGY, V115, P575, DOI 10.1097/ALN.0b013e31822a24c2 De Waele M, 2017, J THORAC DIS, V9, P1598, DOI 10.21037/jtd.2017.05.78 Della Rocca G, 2002, Minerva Anestesiol, V68, P681 Devereaux PJ, 2014, NEW ENGL J MED, V370, P1504, DOI 10.1056/NEJMoa1401106 Di Marco P, 2019, BUONE PRATICHE CLIN Ding XB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096233 Dokhan AL, 2016, Journal of the Egyptian Society of Cardio-Thoracic Surgery, V24, P86, DOI [10.1016/j.jescts.2016.04.003, 10.1016/j.jescts.2016.04.003] Dulu A, 2006, CHEST, V130, P73, DOI 10.1016/S0012-3692(15)50955-0 Dumans-Nizard V, 2016, MINERVA ANESTESIOL, V82, P15 Dumans-Nizard V, 2009, J CARDIOTHOR VASC AN, V23, P501, DOI 10.1053/j.jvca.2009.02.002 Duthie DJR, 2013, CURR OPIN ANESTHESIO, V26, P53, DOI 10.1097/ACO.0b013e32835bcff2 Duttchen KM, 2017, J CLIN ANESTH, V41, P11, DOI 10.1016/j.jclinane.2017.05.013 Eagleman SL, 2018, CURR OPIN ANESTHESIO, V31, P431, DOI 10.1097/ACO.0000000000000618 El-Tahan MR, 2018, J CARDIOTHOR VASC AN, V32, P277, DOI 10.1053/j.jvca.2017.08.009 Eshraghi Y, 2014, ANESTH ANALG, V119, P543, DOI 10.1213/ANE.0000000000000319 Fahy BG, 2018, ANESTH ANALG, V126, P111, DOI 10.1213/ANE.0000000000002331 Fawcett WJ, 1999, BRIT J ANAESTH, V83, P302, DOI 10.1093/bja/83.2.302 Ferguson MK, 2009, J THORAC CARDIOV SUR, V138, P1297, DOI 10.1016/j.jtcvs.2009.05.045 Fernando HC, 2011, ANN THORAC SURG, V92, P1144, DOI 10.1016/j.athoracsur.2011.06.104 Filosso PL, 2017, THORAC SURG CLIN, V27, P7, DOI 10.1016/j.thorsurg.2016.08.002 Finnerty DT, 2020, BRIT J ANAESTH, V125, P802, DOI 10.1016/j.bja.2020.06.020 Fiore JF Jr, 2016, J THORAC CARDIOV SUR, V151, P708, DOI 10.1016/j.jtcvs.2015.09.112 Fiorelli S, 2018, J THORAC DIS, V10, P1864, DOI 10.21037/jtd.2018.03.50 Flockton EA, 2008, BRIT J ANAESTH, V100, P622, DOI 10.1093/bja/aen037 Forero M, 2017, SCAND J PAIN, V17, P325, DOI 10.1016/j.sjpain.2017.08.013 Forero M, 2016, REGION ANESTH PAIN M, V41, P621, DOI 10.1097/AAP.0000000000000451 Fortier G, 2001, CAN J ANAESTH, V48, P790, DOI 10.1007/BF03016696 Frendl G, 2014, J THORAC CARDIOV SUR, V148, pE153, DOI 10.1016/j.jtcvs.2014.06.036 Fritz BA, 2016, ANESTH ANALG, V122, P234, DOI 10.1213/ANE.0000000000000989 Gan TJ, 2004, ACTA ANAESTH SCAND, V48, P1194, DOI 10.1111/j.1399-6576.2004.00495.x Gan TJ, 2014, ANESTH ANALG, V118, P85, DOI 10.1213/ANE.0000000000000002 Garner M, 2017, INTERACT CARDIOV TH, V24, P260, DOI 10.1093/icvts/ivw348 Garutti I, 2014, BRIT J ANAESTH, V112, P929, DOI 10.1093/bja/aet477 Gelb AW, 2018, ANESTH ANALG, V126, P2047, DOI 10.1213/ANE.0000000000002927 Gobble RM, 2014, PLAST RECONSTR SURG, V133, P741, DOI 10.1097/01.prs.0000438459.60474.b5 Gocyk W, 2016, ANN THORAC SURG, V102, P1119, DOI 10.1016/j.athoracsur.2016.04.066 Goren O, 2015, BRIT J ANAESTH, V115, P3, DOI 10.1093/bja/aev380 Granell M, 2018, REV ESP ANEST REANIM, V65, P31, DOI 10.1016/j.redar.2017.08.001 Grosen K, 2014, EUR J CARDIO-THORAC, V46, P76, DOI 10.1093/ejcts/ezu032 Gulbahara G, 2010, EUR J CARDIO-THORAC, V37, P467, DOI 10.1016/j.ejcts.2009.05.057 Gustafsson UO, 2012, CLIN NUTR, V31, P783, DOI [10.1016/j.clnu.2012.08.013, 10.1007/s00268-012-1772-0] Hah J, 2018, JAMA SURG, V153, P303, DOI [10.1001/jamasurg.2017.4915, 10.1001/jamasurg.2017.4915] Hamp T, 2015, HEART LUNG VESSEL, V7, P54 Hazelrigg SR, 2002, SURG CLIN N AM, V82, P849, DOI 10.1016/S0039-6109(02)00031-2 Heir JS, 2014, J CARDIOTHOR VASC AN, V28, P870, DOI 10.1053/j.jvca.2013.11.011 Hermanides J, 2012, BRIT J ANAESTH, V109, P144, DOI 10.1093/bja/aes214 Himmelseher S, 2005, ANESTHESIOLOGY, V102, P211, DOI 10.1097/00000542-200501000-00030 Holte K, 2002, J AM COLL SURGEONS, V195, P694, DOI 10.1016/S1072-7515(02)01491-6 Horlocker TT, 2018, REGION ANESTH PAIN M, V43, P263, DOI 10.1097/AAP.0000000000000763 Hristovska AM, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012763 Hu Y, 2014, J CARDIOTHOR VASC AN, V28, P1302, DOI 10.1053/j.jvca.2014.05.009 Huot MP, 2008, CAN J ANAESTH, V55, P337, DOI 10.1007/BF03021488 Iden T, 2015, EUR J ANAESTH, V32, P387, DOI 10.1097/EJA.0000000000000232 Inoue S, 2004, BRIT J ANAESTH, V92, P195, DOI 10.1093/bja/aeh055 Jeong DM, 2017, ANESTH ANALG, V125, P1158, DOI 10.1213/ANE.0000000000002056 Jones NL, 2013, ANAESTHESIA, V68, P179, DOI 10.1111/anae.12067 Joshi GP, 2008, ANESTH ANALG, V107, P1026, DOI 10.1213/01.ane.0000333274.63501.ff Junior Ade P, 2013, BRAZ J ANESSIOL, P63433 Katayama T, 2012, GEN THORAC CARDIOVAS, V60, P811, DOI 10.1007/s11748-012-0149-5 Kaufmann KB, 2017, BRIT J ANAESTH, V118, P852, DOI 10.1093/bja/aew447 Keegan MT, 2007, J CARDIOTHOR VASC AN, V21, P832, DOI 10.1053/j.jvca.2006.12.005 Kendall F, 2017, REV PORT PNEUMOL, V23, P343, DOI 10.1016/j.rppnen.2017.05.003 Khalil AE, 2017, J CARDIOTHOR VASC AN, V31, P152, DOI 10.1053/j.jvca.2016.08.023 Kheterpal S, 2007, ANESTHESIOLOGY, V107, P892, DOI 10.1097/01.anes.0000290588.29668.38 Kim DH, 2018, ANESTH ANALG, V126, P1353, DOI 10.1213/ANE.0000000000002779 Kim HJ, 2019, SURG ENDOSC, V33, P1403, DOI 10.1007/s00464-018-6415-6 Kim SY, 2016, BJOG-INT J OBSTET GY, V123, P580, DOI 10.1111/1471-0528.13785 Kinney MAO, 2012, PAIN PRACT, V12, P175, DOI 10.1111/j.1533-2500.2011.00480.x Klein U, 1998, ANESTHESIOLOGY, V88, P346, DOI 10.1097/00000542-199802000-00012 Knoll H, 2006, ANESTHESIOLOGY, V105, P471, DOI 10.1097/00000542-200609000-00009 Ko SH, 2001, ANESTHESIOLOGY, V95, P640, DOI 10.1097/00000542-200109000-00016 Kobayashi R, 2013, SURG TODAY, V43, P963, DOI 10.1007/s00595-012-0485-1 Kosinski S, 2016, ANAESTH INTENSIVE TH, V48, P280, DOI 10.5603/AIT.2016.0059 Kotova S, 2017, ANN THORAC SURG, V103, P1566, DOI 10.1016/j.athoracsur.2016.11.007 Ladak SSJ, 2009, PAIN MANAG NURS, V10, P94, DOI 10.1016/j.pmn.2008.08.001 Lang P, 2016, EUR J CARDIO-THORAC, V49, P611, DOI 10.1093/ejcts/ezv133 Laskowski K, 2011, CAN J ANESTH, V58, P911, DOI 10.1007/s12630-011-9560-0 Leo F, 2013, ANN THORAC SURG, V96, P1234, DOI 10.1016/j.athoracsur.2013.04.079 Lewis T, 2019, J INTENSIVE CARE MED, V34, P26, DOI 10.1177/0885066616686035 Li PF, 2018, J THORAC DIS, V10, P2712, DOI 10.21037/jtd.2018.04.75 Li SJ, 2017, CANCER MANAG RES, V9, P657, DOI 10.2147/CMAR.S150500 Liao Guangyuan, 2010, J Thorac Dis, V2, P205, DOI 10.3978/j.issn.2072-1439.2010.02.04.4 Licker M, 2016, TURK J ANAESTHESIOL, V44, P227, DOI 10.5152/TJAR.2016.006 Lin W, 2012, ANAESTHESIA, V67, P771, DOI 10.1111/j.1365-2044.2012.07137.x Linden D, 2014, INTERACT CARDIOV TH, V19, P107, DOI 10.1093/icvts/ivu080 Ljungqvist O, 2018, AGING CLIN EXP RES, V30, P249, DOI 10.1007/s40520-018-0905-1 Lohser J, 2015, ANESTH ANALG, V121, P302, DOI 10.1213/ANE.0000000000000808 Longhini F, 2019, CRIT CARE MED, V47, pE506, DOI 10.1097/CCM.0000000000003740 Lorut C, 2014, INTENS CARE MED, V40, P220, DOI 10.1007/s00134-013-3150-2 Lumb AB, 2015, ANESTHESIOLOGY, V122, P932, DOI 10.1097/ALN.0000000000000569 Maher DP, 2017, PAIN MED, V18, P1152, DOI 10.1093/pm/pnw149 Mäkinen MT, 2016, J CARDIOTHOR VASC AN, V30, P973, DOI 10.1053/j.jvca.2016.03.141 Marshall MB, 2002, CHEST, V121, P831, DOI 10.1378/chest.121.3.831 Martin LW, 2018, ANN THORAC SURG, V105, P1597, DOI 10.1016/j.athoracsur.2018.01.080 Martina JR, 2012, ANESTHESIOLOGY, V116, P1092, DOI 10.1097/ALN.0b013e31824f94ed Massot J, 2015, J CARDIOTHOR VASC AN, V29, P1544, DOI 10.1053/j.jvca.2015.04.031 Maund E, 2011, BRIT J ANAESTH, V106, P292, DOI 10.1093/bja/aeq406 McCall PJ, 2015, ANAESTHESIA, V70, P1382, DOI 10.1111/anae.13267 Medlej K, 2018, J EMERG MED, V54, P47, DOI 10.1016/j.jemermed.2017.09.007 Meierhenrich R, 2011, BRIT J ANAESTH, V106, P580, DOI 10.1093/bja/aeq418 Melloul E, 2016, WORLD J SURG, V40, P2425, DOI 10.1007/s00268-016-3700-1 Merli G, 2009, MINERVA ANESTESIOL, V75, P59 Mesa-Guzman M, 2015, J THORAC DIS, V7, P2053, DOI 10.3978/j.issn.2072-1439.2015.11.42 Mets O, 2007, J THORAC CARDIOV SUR, V134, P139, DOI 10.1016/j.jtcvs.2007.02.029 Michard F, 2017, BRIT J ANAESTH, V119, P22, DOI 10.1093/bja/aex138 Miserocchi G, 1997, EUR RESPIR J, V10, P219, DOI 10.1183/09031936.97.10010219 Mishriky BM, 2015, BRIT J ANAESTH, V114, P10, DOI 10.1093/bja/aeu293 Miskovic A, 2017, BRIT J ANAESTH, V118, P317, DOI 10.1093/bja/aex002 Montupil J, 2019, J CARDIOTHOR VASC AN, V33, pS3, DOI 10.1053/j.jvca.2019.03.038 Mortensen K, 2014, BRIT J SURG, V101, P1209, DOI 10.1002/bjs.9582 Motov S, 2017, ANN EMERG MED, V70, P177, DOI 10.1016/j.annemergmed.2016.10.014 Muehling BM, 2008, EUR J CARDIO-THORAC, V34, P174, DOI 10.1016/j.ejcts.2008.04.009 Naguib M, 2018, ANESTH ANALG, V127, P71, DOI 10.1213/ANE.0000000000002670 Naja Z, 2001, ANAESTHESIA, V56, P1184 Narayanaswamy M, 2009, ANESTH ANALG, V108, P1097, DOI 10.1213/ane.0b013e3181999339 Nelson G, 2016, GYNECOL ONCOL, V140, P323, DOI 10.1016/j.ygyno.2015.12.019 Nery FPOS, 2012, RESP CARE, V57, P363, DOI 10.4187/respcare.01267 Nicholson A, 2014, BJS-BRIT J SURG, V101, P172, DOI 10.1002/bjs.9394 Nosotti M, 2015, EUR J CARDIO-THORAC, V48, P428, DOI 10.1093/ejcts/ezu467 Nygren J, 2013, WORLD J SURG, V37, P285, DOI 10.1007/s00268-012-1787-6 Okahara S, 2018, BMC ANESTHESIOL, V18, DOI 10.1186/s12871-018-0476-x Okitsu K, 2017, J CARDIOTHOR VASC AN, V31, P453, DOI 10.1053/j.jvca.2016.06.002 Ökmen K, 2018, ANAESTH CRIT CARE PA, V37, P349, DOI 10.1016/j.accpm.2017.09.005 Ökmen K, 2017, J ANESTH, V31, P579, DOI 10.1007/s00540-017-2364-9 Okur E, 2009, EUR J CARDIO-THORAC, V35, P32, DOI 10.1016/j.ejcts.2008.09.009 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Ong CKS, 2005, ANESTH ANALG, V100, P757, DOI 10.1213/01.ANE.0000144428.98767.0E Ortega R, 2018, NEW ENGL J MED, V378, DOI 10.1056/NEJMvcm1603741 Otto JM, 2017, HAEMATOLOGICA, V102, P1477, DOI 10.3324/haematol.2017.169680 Park BJ, 2007, J THORAC CARDIOV SUR, V133, P775, DOI 10.1016/j.jtcvs.2006.09.022 Park MH, 2018, ANAESTHESIA, V73, P1260, DOI 10.1111/anae.14424 Pehora C, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011770.pub2 Perel A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1872-1 Perrin C, 2007, RESP MED, V101, P1572, DOI 10.1016/j.rmed.2006.12.002 Piccioni F, 2017, J CLIN MONIT COMPUT, V31, P677, DOI 10.1007/s10877-016-9898-5 Pinheiro L, 2015, J BRAS PNEUMOL, V41, P31, DOI [10.1590/S1806-37132015000100005, 10.1590/s1806-37132015000100005] Pintaric TS, 2011, REGION ANESTH PAIN M, V36, P256, DOI 10.1097/AAP.0b013e3182176f42 Pompili C, 2014, ANN THORAC SURG, V98, P490, DOI 10.1016/j.athoracsur.2014.03.043 Potocnik I, 2014, CROAT MED J, V55, P628, DOI 10.3325/cmj.2014.55.628 Punjasawadwong Y, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011283.pub2 Punjasawadwong Y, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003843.pub3 Purugganan RV, 2012, J CARDIOTHOR VASC AN, V26, P845, DOI 10.1053/j.jvca.2012.01.014 Raveglia F, 2014, J THORAC CARDIOV SUR, V147, P469, DOI 10.1016/j.jtcvs.2013.09.024 Reddy S, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1217-5 Reeb J, 2013, INTERACT CARDIOV TH, V17, P995, DOI 10.1093/icvts/ivt352 Riviere S, 2011, EUR J CARDIO-THORAC, V39, P769, DOI 10.1016/j.ejcts.2010.08.016 Rochwerg B, 2019, INTENS CARE MED, V45, P1171, DOI 10.1007/s00134-019-05658-2 Rochwerg B, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02426-2016 Rogers LJ, 2018, J THORAC CARDIOV SUR, V155, P1843, DOI 10.1016/j.jtcvs.2017.10.151 Ruetzler K, 2011, BRIT J ANAESTH, V106, P896, DOI 10.1093/bja/aer086 Russell T, 2013, ANAESTHESIA, V68, P1253, DOI 10.1111/anae.12322 Salati M, 2012, EUR J CARDIO-THORAC, V41, P1083, DOI 10.1093/ejcts/ezr171 Salmasi V, 2017, ANESTHESIOLOGY, V126, P47, DOI 10.1097/ALN.0000000000001432 Santana-Cabrera Luciano, 2010, J Emerg Trauma Shock, V3, P305, DOI 10.4103/0974-2700.66527 Sasaki N, 2014, ANESTHESIOLOGY, V121, P959, DOI 10.1097/ALN.0000000000000440 Sattari Hossein, 2018, Open Access Maced J Med Sci, V6, P1606, DOI [10.3889/oamjms.2018.334, 10.3889/oamjms.2018.334] Scala R, 2018, EUR RESP REV, V27 Scala R, 2011, RESP CARE, V56, P1100, DOI 10.4187/respcare.01157 Scarfe AJ, 2016, EUR J CARDIO-THORAC, V50, P1010, DOI 10.1093/ejcts/ezw168 Schilling T, 2007, BRIT J ANAESTH, V99, P368, DOI 10.1093/bja/aem184 Schilling T, 2011, ANESTHESIOLOGY, V115, P65, DOI 10.1097/ALN.0b013e318214b9de Schuepbach R, 2015, CAN J ANESTH, V62, P762, DOI 10.1007/s12630-015-0329-8 Searl Cait P, 2012, Anesthesiol Clin, V30, P641, DOI 10.1016/j.anclin.2012.08.009 Self WH, 2018, NEW ENGL J MED, V378, P819, DOI 10.1056/NEJMoa1711586 Sepehripour AH, 2012, INTERACT CARDIOV TH, V14, P834, DOI 10.1093/icvts/ivs037 Sessler DI, 2019, BRIT J ANAESTH, V122, P563, DOI 10.1016/j.bja.2019.01.013 Seymour AH, 2002, BRIT J ANAESTH, V89, P661, DOI 10.1093/bja/aef549 Slinger P D, 1989, J Cardiothorac Anesth, V3, P486, DOI 10.1016/S0888-6296(89)97987-8 Smith I, 2011, EUR J ANAESTH, V28, P556, DOI 10.1097/EJA.0b013e3283495ba1 Snäll J, 2013, BRIT J ORAL MAX SURG, V51, P808, DOI 10.1016/j.bjoms.2013.08.015 Solidoro P, 2019, PANMINERVA MED, V61, P367, DOI 10.23736/S0031-0808.18.03565-6 Steinthorsdottir KJ, 2014, EUR J CARDIO-THORAC, V45, P959, DOI 10.1093/ejcts/ezt525 Stéphan F, 2017, RESP CARE, V62, P1193, DOI 10.4187/respcare.05473 Sun B, 2015, J ANESTH, V29, P570, DOI 10.1007/s00540-015-1987-y Thorén H, 2009, J ORAL MAXIL SURG, V67, P1884, DOI 10.1016/j.joms.2009.04.089 Tiippana EM, 2007, ANESTH ANALG, V104, P1545, DOI 10.1213/01.ane.0000261517.27532.80 Torres MFS, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010355.pub3 Touw HR, 2018, ANAESTHESIA, V73, P946, DOI 10.1111/anae.14243 Troquay S, 2013, INTERACT CARDIOVA S1, V17, pS37, DOI [10.1093/icvts/ivt288.141, DOI 10.1093/ICVTS/IVT288.141] Ulm MA, 2016, INT J GYNECOL CANCER, V26, P1320, DOI 10.1097/IGC.0000000000000766 Umari M, 2018, J THORAC DIS, V10, pS542, DOI 10.21037/jtd.2017.12.83 United States Preventive Services Task Force, 2019, GRAD DEF van Waes JAR, 2016, ANESTHESIOLOGY, V124, P35, DOI 10.1097/ALN.0000000000000922 Vegh T., 2014, J Rom Anaesth Intensive Care, V21, P7 Vincent JL, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1435-x Waldron NH, 2013, BRIT J ANAESTH, V110, P191, DOI 10.1093/bja/aes431 Walsh M, 2013, ANESTHESIOLOGY, V119, P507, DOI 10.1097/ALN.0b013e3182a10e26 Warren J, 2011, NUTR CLIN PRACT, V26, P115, DOI 10.1177/0884533611400231 Wasem S, 2013, EUR J ANAESTH, V30, P180, DOI 10.1097/EJA.0b013e32835fe574 Weimann A, 2017, CLIN NUTR, V36, P623, DOI 10.1016/j.clnu.2017.02.013 Weinstein EJ, 2018, COCHRANE DB SYST REV, V4 Wheatley RG, 2001, BRIT J ANAESTH, V87, P47, DOI 10.1093/bja/87.1.47 WilderSmith CH, 1997, ACTA ANAESTH SCAND, V41, P1023, DOI 10.1111/j.1399-6576.1997.tb04830.x Wildes TS, 2019, JAMA-J AM MED ASSOC, V321, P473, DOI 10.1001/jama.2018.22005 Wurnig PN, 2002, EUR J CARDIO-THORAC, V21, P1115, DOI 10.1016/S1010-7940(02)00117-3 Yamauchi Y, 2017, J CARDIOTHORAC SURG, V12, DOI 10.1186/s13019-017-0566-8 Yang HC, 2015, J THORAC DIS, V7, P1960, DOI 10.3978/j.issn.2072-1439.2015.11.11 Yang M, 2011, CHEST, V139, P530, DOI 10.1378/chest.09-2293 Yeung Joyce H Y, 2016, Cochrane Database Syst Rev, V2, pCD009121, DOI 10.1002/14651858.CD009121.pub2 Yoo JY, 2014, J CARDIOTHOR VASC AN, V28, P904, DOI 10.1053/j.jvca.2013.07.019 Young J, 2018, J THORAC CARDIOV SUR, V156, P430, DOI 10.1016/j.jtcvs.2018.02.076 Zakkar M, 2013, INTERACT CARDIOV TH, V17, P716, DOI 10.1093/icvts/ivt301 Zampieri FG, 2016, CURR OPIN CRIT CARE, V22, P533, DOI 10.1097/MCC.0000000000000361 Zaouter C, 2015, J CARDIOTHOR VASC AN, V29, P496, DOI 10.1053/j.jvca.2014.05.022 Zhang J, 2013, CLINICS, V68, P1065, DOI 10.6061/clinics/2013(07)27 Zhang XF, 2016, J CANCER RES THER, V12, P309, DOI 10.4103/0973-1482.200743 Zhou D, 2016, J CARDIOTHORAC SURG, V11, DOI 10.1186/s13019-016-0484-1 Zhu YQ, 2017, J THORAC DIS, V9, P1303, DOI 10.21037/jtd.2017.04.36 NR 269 TC 35 Z9 40 U1 0 U2 11 PU BMC PI LONDON PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND EI 2047-0525 J9 PERIOPER MED-LONDON JI Perioperative Med PD OCT 23 PY 2020 VL 9 IS 1 AR 31 DI 10.1186/s13741-020-00159-z PG 26 WC Anesthesiology; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Anesthesiology; Surgery GA OG3TI UT WOS:000581810500001 PM 33106758 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Hilmi, M Ederhy, S Waintraub, X Funck-Brentano, C Cohen, A Vozy, A Lebrun-Vignes, B Moslehi, J Nguyen, LS Salem, JE AF Hilmi, Marc Ederhy, Stephane Waintraub, Xavier Funck-Brentano, Christian Cohen, Ariel Vozy, Aurore Lebrun-Vignes, Benedicte Moslehi, Javid Nguyen, Lee S. Salem, Joe-Elie TI Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study SO PHARMACEUTICALS LA English DT Review DE gemcitabine; pericarditis; myocardial ischemia; heart failure; arrhythmias; cardio-oncology ID PHASE-III TRIAL; ADVANCED PANCREATIC-CANCER; SINGLE-AGENT GEMCITABINE; CELL LUNG-CANCER; ACUTE MYOCARDIAL-INFARCTION; ATRIAL-FIBRILLATION; 1ST-LINE TREATMENT; DOUBLE-BLIND; OPEN-LABEL; PLUS GEMCITABINE AB Background: Gemcitabine is a nucleoside analog, widely used either alone or in combination, for the treatment of multiple cancers. However, gemcitabine may also be associated with cardiovascular adverse-drug-reactions (CV-ADR). Methods: First, we searched for all cases of cardiotoxicity associated with gemcitabine, published in MEDLINE on 30 May 2019. Then, we used VigiBase, the World Health Organization's global database of individual case safety reports, to compare CV-ADR reporting associated with gemcitabine against the full database between inception and 1 April 2019. We used the information component (IC), an indicator value for disproportionate Bayesian reporting. A positive lower end of the 95% credibility interval for the IC (IC025) >= 0, is deemed significant. Results: In VigiBase, 46,898 reports were associated with gemcitabine on a total of 18,908,940 in the full database. Gemcitabine was associated with higher reporting for myocardial ischemia (MI, n: 119), pericardial diseases (n: 164), supraventricular arrhythmias (SVA, n: 308) and heart failure (HF, n: 484) versus full database with IC025 ranging between 0.40 and 2.81. CV-ADR were associated with cardiovascular death in up to 17% of cases. Conclusion: Treatment with gemcitabine is associated with potentially lethal CV-ADRs, including MI, pericardial diseases, SVA and HF. These events should be considered in patient care and clinical trial design. C1 [Hilmi, Marc; Funck-Brentano, Christian; Vozy, Aurore; Lebrun-Vignes, Benedicte; Nguyen, Lee S.; Salem, Joe-Elie] Sorbonne Univ, Pitie Salpetriere Hosp, AP HP, INSERM CIC 1901,Dept Pharmacol,Reg Pharmacovigila, F-75006 Paris, France. [Ederhy, Stephane; Cohen, Ariel] Sorbonne Univ, St Antoine Hosp, AP HP, Dept Cardiol, F-75006 Paris, France. [Ederhy, Stephane; Cohen, Ariel; Salem, Joe-Elie] Sorbonne Univ, UNICO GRECO APHP Sorbonne Cardiooncol Program, F-75006 Paris, France. [Waintraub, Xavier] Sorbonne Univ, Pitie Salpetriere Hosp, AP HP, Dept Cardiol, F-75006 Paris, France. [Lebrun-Vignes, Benedicte] Univ Paris Est Creteil, EA Epiderme Epidemiol Dermatol & Evaluat Therapeu, F-94000 Creteil, France. [Moslehi, Javid; Salem, Joe-Elie] Vanderbilt Univ, Div Cardiovasc Med, Med Ctr, Cardiooncol Program, Nashville, TN 37232 USA. [Nguyen, Lee S.] Res & Innovat CMC Ambroise Pare, F-92200 Neuilly Sur Seine, France. C3 Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Sorbonne Universite; Hopital Universitaire Saint-Antoine - APHP; Assistance Publique Hopitaux Paris (APHP); Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Sorbonne Universite; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Vanderbilt University RP Salem, JE (corresponding author), Sorbonne Univ, Pitie Salpetriere Hosp, AP HP, INSERM CIC 1901,Dept Pharmacol,Reg Pharmacovigila, F-75006 Paris, France.; Salem, JE (corresponding author), Sorbonne Univ, UNICO GRECO APHP Sorbonne Cardiooncol Program, F-75006 Paris, France.; Salem, JE (corresponding author), Vanderbilt Univ, Div Cardiovasc Med, Med Ctr, Cardiooncol Program, Nashville, TN 37232 USA. EM hilmi.marc@gmail.com; stephane.ederhy@aphp.fr; xavier.waintraub@aphp.fr; christian.funck-brentano@aphp.fr; ariel.cohen@aphp.fr; aurore.vozy@aphp.fr; benedicte.lebrun-vignes@aphp.fr; javid.moslehi@vumc.org; nguyen.lee@icloud.com; joeelie.salem@gmail.com RI ; Funck-Brentano, Christian/V-4753-2019; Hilmi, Marc/NSU-1216-2025 OI Salem, Joe-Elie/0000-0002-0331-3307; NGUYEN, Lee S/0000-0002-6014-6269; Funck-Brentano, Christian/0000-0003-0406-5189; Hilmi, Marc/0000-0003-4762-6740 CR Aapro MS, 1998, ANTI-CANCER DRUG, V9, P191, DOI 10.1097/00001813-199803000-00001 Accordino MK, 2014, J CLIN ONCOL, V32, P2654, DOI 10.1200/JCO.2013.55.0459 Agency E.M., GEMZ Alam S, 2018, CASE REP ONCOL, V11, P221, DOI 10.1159/000488139 Bate A, 1998, EUR J CLIN PHARMACOL, V54, P315, DOI 10.1007/s002280050466 Bdair FM, 2006, ANGIOLOGY, V57, P367, DOI 10.1177/000331970605700314 Biagi C, 2013, EUR J CLIN PHARMACOL, V69, P237, DOI 10.1007/s00228-012-1321-7 Burris HA, 2010, ONCOLOGIST, V15, P1227, DOI 10.1634/theoncologist.2009-0090 Cappuzzo F, 2006, LUNG CANCER-J IASLC, V52, P319, DOI 10.1016/j.lungcan.2006.03.004 Chang LC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178104 Ciotti R, 1999, ANN ONCOL, V10, P997, DOI 10.1023/A:1008305716918 Colucci G, 2010, J CLIN ONCOL, V28, P1645, DOI 10.1200/JCO.2009.25.4433 Conroy T, 2018, NEW ENGL J MED, V379, P2395, DOI 10.1056/NEJMoa1809775 Eli Lilly and Company GEMZAR (Gemcitabine) [package insert], 2014, GEMZAR GEMC PACK INS Evans TRJ, 2017, ANN ONCOL, V28, P354, DOI 10.1093/annonc/mdw607 Ferrari D, 2006, ANTI-CANCER DRUG, V17, P359, DOI 10.1097/00001813-200603000-00016 Gonçalves A, 2012, ANN ONCOL, V23, P2799, DOI 10.1093/annonc/mds135 Grouthier V, 2018, HEART, V104, P1859, DOI 10.1136/heartjnl-2017-312934 Herrmann R, 2007, J CLIN ONCOL, V25, P2212, DOI 10.1200/JCO.2006.09.0886 Humphreys BD, 2004, CANCER-AM CANCER SOC, V100, P2664, DOI 10.1002/cncr.20290 Kalapura T, 1999, ANGIOLOGY, V50, P1021, DOI 10.1177/000331979905001208 Khan Muhammad F, 2014, J Med Case Rep, V8, P220, DOI 10.1186/1752-1947-8-220 Kido H, 2012, JPN J CLIN ONCOL, V42, P845, DOI 10.1093/jjco/hys099 Konstantinopoulos PA, 2020, LANCET ONCOL, V21, P957, DOI 10.1016/S1470-2045(20)30180-7 Lindquist M, 2008, DRUG INF J, V42, P409, DOI 10.1177/009286150804200501 Loehrer PJ, 2011, J CLIN ONCOL, V29, P4105, DOI 10.1200/JCO.2011.34.8904 Melisi D, 2018, BRIT J CANCER, V119, P1208, DOI 10.1038/s41416-018-0246-z Mertz P, 2019, J ALLERGY CLIN IMMUN, V143, P433, DOI 10.1016/j.jaci.2018.09.001 Middleton G, 2017, LANCET ONCOL, V18, P486, DOI 10.1016/S1470-2045(17)30084-0 Mini E, 2006, ANN ONCOL, V17, pV7, DOI 10.1093/annonc/mdj941 Mohebali D, 2017, ESC HEART FAIL, V4, P71, DOI 10.1002/ehf2.12113 Neoptolemos JP, 2017, LANCET, V389, P1011, DOI 10.1016/S0140-6736(16)32409-6 Norén GN, 2013, STAT METHODS MED RES, V22, P57, DOI 10.1177/0962280211403604 Ozturk B, 2009, MED PRIN PRACT, V18, P76, DOI 10.1159/000163051 Piccart MJ, 1997, J CLIN ONCOL, V15, P3149, DOI 10.1200/JCO.1997.15.9.3149 Richards DA, 2011, INVEST NEW DRUG, V29, P144, DOI 10.1007/s10637-009-9307-8 Rothman KJ, 2004, PHARMACOEPIDEM DR S, V13, P519, DOI 10.1002/pds.1001 Rougier P, 2013, EUR J CANCER, V49, P2633, DOI 10.1016/j.ejca.2013.04.002 Roychowdhury DF, 2002, INVEST NEW DRUG, V20, P311, DOI 10.1023/A:1016214032272 Salem JE, 2019, CIRCULATION, V140, P1070, DOI 10.1161/CIRCULATIONAHA.119.040162 Salem JE, 2018, LANCET ONCOL, V19, P1579, DOI 10.1016/S1470-2045(18)30608-9 Santini D, 2000, ANN ONCOL, V11, P479, DOI 10.1023/A:1008380208045 Sederholm C, 2005, J CLIN ONCOL, V23, P8380, DOI 10.1200/JCO.2005.01.2781 Sederholm C, 2002, SEMIN ONCOL, V29, P50, DOI 10.1053/sonc.2002.34276 Semb KA, 1998, J CLIN ONCOL, V16, P3426, DOI 10.1200/JCO.1998.16.10.3426 Shrum KJP, 2014, AM J CLIN ONCOL-CANC, V37, P364, DOI 10.1097/COC.0b013e31827b459a Siddall E, 2017, KIDNEY INT, V92, P37, DOI 10.1016/j.kint.2016.11.029 Spano JP, 2008, LANCET, V371, P2101, DOI 10.1016/S0140-6736(08)60661-3 Tandon VR, 2015, INDIAN J PHARMACOL, V47, P65, DOI 10.4103/0253-7613.150344 Tavil Y, 2007, ONKOLOGIE, V30, P253, DOI 10.1159/000100930 Tayer-Shifman OE, 2009, TUMORI J, V95, P547 Van Cutsem E, 2004, J CLIN ONCOL, V22, P1430, DOI 10.1200/JCO.2004.10.112 Vogl DT, 2005, LEUKEMIA LYMPHOMA, V46, P1313, DOI 10.1080/10428190500158649 Yajima Takashi, 2004, Gan To Kagaku Ryoho, V31, P953 Zamorano JL, 2016, EUR HEART J, V37, P2768, DOI [10.1093/eurheartj/ehw211, 10.1002/ejhf.654] NR 55 TC 30 Z9 33 U1 0 U2 14 PU MDPI PI BASEL PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND EI 1424-8247 J9 PHARMACEUTICALS-BASE JI Pharmaceuticals PD OCT PY 2020 VL 13 IS 10 AR 325 DI 10.3390/ph13100325 PG 19 WC Chemistry, Medicinal; Pharmacology & Pharmacy WE Science Citation Index Expanded (SCI-EXPANDED) SC Pharmacology & Pharmacy GA OL6LN UT WOS:000585449000001 PM 33096756 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Smelt, J Martin, F Al-Sahaf, M Simon, N King, J Veres, L Bille, A Pilling, J Routledge, T Harrison-Phipps, K AF Smelt, Jeremy Martin, Fionna Al-Sahaf, May Simon, Natalie King, Juliet Veres, Lukacs Bille, Andrea Pilling, John Routledge, Tom Harrison-Phipps, Karen TI Retrospective Observational Study into the Early Causes of Death Following Surgery for NSCLC SO THORACIC AND CARDIOVASCULAR SURGEON LA English DT Article DE lung cancer; thoracic surgery; in-hospital mortality; mesenteric ischemia; atrial fibrillation ID COOPERATIVE GROUP TRIALS; HIGH-RISK PATIENTS; LUNG-CANCER; PULMONARY COMPLICATIONS; OPERATIVE MORTALITY; TIME TRENDS; RESECTION; SURVIVAL; OUTCOMES; IMPACT AB Introduction Respiratory failure has historically been the major cause of mortality after elective lung resections. With improved intubation using fiber-optic scopes, better preoperative respiratory risk assessment, more advanced anesthetic single lung ventilation, and minimally invasive surgical technique, this may have changed. Our objective was to assess the main causes of mortality over the past 10 years in patients undergoing elective lung surgery in a major UK center. Materials and Methods A retrospective unit data search was made for all deaths during the 10-year period between January 2007 and December 2016 inclusive. All inpatient deaths within 30 days of an elective anatomical lung resection for lung malignancies were included. Results Three-thousand three-hundred sixteen lung resections for malignancy were performed in the 10-year period. There were 44 (1.3%) deaths during this period, 27 (61.4%) after open lobectomies, 8 (18.2%) after video-assisted thoracoscopic surgery lobectomies, 5 (11.4%) after sleeve lobectomies, and 4 (9%) after pneumonectomies. Causes of death included 24 (54.5%) respiratory failure, 10 (22.7%) ischemic bowel, 4 (9%) coronary events, 2 (4.5%) strokes, 2 (4.5%) on table hemorrhage, 1 (2.3%) massive pulmonary embolus, and 1 (2.3%) postoperative hemorrhage. Conclusion Although respiratory failure is still a major cause of mortality in the postoperative patient, bowel ischemia has been found to be the second greatest cause of death. This study highlights the need to identify those at risk of this fatal complication during preoperative assessment and their postoperative management. C1 [Smelt, Jeremy; Al-Sahaf, May; Simon, Natalie; King, Juliet; Veres, Lukacs; Bille, Andrea; Pilling, John; Routledge, Tom; Harrison-Phipps, Karen] Guys & St Thomas NHS Fdn Trust, Dept Thorac Surg, London, England. [Martin, Fionna] Guys & St Thomas NHS Fdn Trust, Dept Geriatr & Pops Med, London, England. C3 Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust RP Smelt, J (corresponding author), St George Hosp, Dept Cardiothorac Surg, Blackshaw Rd Tooting, London SW17 0QT, England. EM jeremysmelt@doctors.org.uk RI Smelt, Jeremy/AAV-4623-2020 CR Aberle DR, 2011, NEW ENGL J MED, V365, P395, DOI 10.1056/NEJMoa1102873 Ahmed HZ, 2017, CLIN LUNG CANCER, V18, P706, DOI 10.1016/j.cllc.2017.04.009 Al-Sahaf M, 2015, J THORAC DIS, V7, pS152, DOI 10.3978/j.issn.2072-1439.2015.04.08 Beccaria M, 2001, CHEST, V120, P37, DOI 10.1378/chest.120.1.37 Clair DG, 2016, NEW ENGL J MED, V374, P959, DOI 10.1056/NEJMra1503884 Coebergh JW, 2001, EUR J CANCER, V37, pS217 DALES RE, 1993, CHEST, V104, P155, DOI 10.1378/chest.104.1.155 Dyszkiewicz W, 1998, EUR J CARDIO-THORAC, V13, P625, DOI 10.1016/S1010-7940(98)00084-0 Falcoz PE, 2007, J THORAC CARDIOV SUR, V133, P325, DOI 10.1016/j.jtcvs.2006.09.020 Ferguson MK, 2014, ANN THORAC SURG, V97, P1683 Field JK, 2016, THORAX, V71, P161, DOI 10.1136/thoraxjnl-2015-207140 Garner M, 2017, INTERACT CARDIOV TH, V24, P260, DOI 10.1093/icvts/ivw348 GINSBERG RJ, 1983, J THORAC CARDIOV SUR, V86, P654 HamiltonDavies C, 1997, INTENS CARE MED, V23, P276, DOI 10.1007/s001340050328 KEARNEY DJ, 1994, CHEST, V105, P753, DOI 10.1378/chest.105.3.753 Khuri SF, 1997, J AM COLL SURGEONS, V185, P315, DOI 10.1016/S1072-7515(97)00073-2 KnottCraig CJ, 1997, ANN THORAC SURG, V63, P1405, DOI 10.1016/S0003-4975(97)00252-X Licker MJ, 2006, ANN THORAC SURG, V81, P1830, DOI 10.1016/j.athoracsur.2005.11.048 Lim E, 2010, THORAX, V65, P1, DOI 10.1136/thx.2010.145938 Liu LL, 2000, J AM GERIATR SOC, V48, P405, DOI 10.1111/j.1532-5415.2000.tb04698.x Lorusso R, 2014, ANN THORAC SURG, V97, P2219, DOI 10.1016/j.athoracsur.2014.01.029 Mansour KA, 1997, ANN THORAC SURG, V63, P1409 NAKAHARA K, 1988, ANN THORAC SURG, V46, P549, DOI 10.1016/S0003-4975(10)64694-2 Okada M, 2004, ANN THORAC SURG, V77, P1926, DOI 10.1016/j.athoracsur.2004.01.002 Partridge JSL, 2017, BRIT J SURG, V104, P679, DOI 10.1002/bjs.10459 Partridge JSL, 2015, INT J SURG, V18, P57, DOI 10.1016/j.ijsu.2015.04.037 Partridge JSL, 2014, J VASC SURG, V60, P1002, DOI 10.1016/j.jvs.2014.04.041 Partridge JSL, 2012, AGE AGEING, V41, P142, DOI 10.1093/ageing/afr182 Polanczyk CA, 2001, ANN INTERN MED, V134, P637, DOI 10.7326/0003-4819-134-8-200104170-00008 Puri V, 2014, ANN THORAC SURG, V97, P1678, DOI 10.1016/j.athoracsur.2013.12.028 ROXBURGH JC, 1991, ANN THORAC SURG, V51, P800, DOI 10.1016/0003-4975(91)90130-I Sancheti MS, 2016, ANN THORAC SURG, V101, P1043, DOI 10.1016/j.athoracsur.2015.08.088 Sekine Y, 2002, LUNG CANCER-J IASLC, V37, P95, DOI 10.1016/S0169-5002(02)00014-4 Sengupta S, 2015, INDIAN J ANAESTH, V59, P618, DOI 10.4103/0019-5049.165852 Smelt J, 2017, INTERACT CARDIOV TH, V25, psp1 Varela G, 2011, SEMIN THORAC CARDIOV, V23, P297, DOI 10.1053/j.semtcvs.2011.11.001 NR 36 TC 3 Z9 3 U1 0 U2 1 PU GEORG THIEME VERLAG KG PI STUTTGART PA Oswald-Hesse-Strasse 50, D-70469 STUTTGART, GERMANY SN 0171-6425 EI 1439-1902 J9 THORAC CARDIOV SURG JI Thorac. Cardiovasc. Surg. PD OCT PY 2020 VL 68 IS 07 BP 633 EP 638 DI 10.1055/s-0038-1676590 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA OB5KW UT WOS:000578509700012 PM 30586674 DA 2026-04-17 ER PT J AU Zhang, MX Li, LL Zhao, QQ Peng, XD Wu, K Li, X Ruan, YF Bai, R Liu, N Ma, CS AF Zhang, Mengxia Li, Lin-ling Zhao, Qian-qian Peng, Xiao-dong Wu, Kui Li, Xin Ruan, Yan-Fei Bai, Rong Liu, Nian Ma, Chang Sheng TI The Association of New-Onset Atrial Fibrillation and Risk of Cancer: A Systematic Review and Meta-Analysis SO CARDIOLOGY RESEARCH AND PRACTICE LA English DT Review ID INVASIVE BREAST; EPIDEMIOLOGY; DISEASE AB Background. There are distinct results for the relationship between new-onset atrial fibrillation (NOAF) and subsequent incident cancer. To date, no systematic analysis has been conducted on this issue. This study aims to explore the relationship between NOAF and the risk of developing cancer through a meta-analysis with a large sample size.Methods. Electronic databases, such as PubMed and EMBASE, were searched for published relevant studies on NOAF patients diagnosed with cancer after and during follow-ups, including reported records of baseline information and the statistical result of morbidity. Two investigators independently reviewed the articles and extracted the data using uniform standards and definitions. The meta-analysis was conducted using the Cochrane Program Review Manager.Results. This meta-analysis consisted of five cohort studies and one case-control study, which comprised 533,514 participants. The pooled relative risk (RR) for incident cancer was 1.24 (95% CI: 1.10-1.39,P=0.0003). The temporal trend analysis demonstrated that an increased risk of cancer was observed during the initial 90 days (RR: 3.44, 95% CI: 2.29-5.57,P<0.00001), but not after that. Lung cancer (RR: 1.51, 95% CI: 1.47-1.55,P<0.00001) was associated with NOAF, but not colorectal cancer and breast cancer.Conclusion. This meta-analysis provides evidence that NOAF is associated with increased risk of cancer. The risk of incident cancer particularly increases within 90 days after NOAF diagnosis, but not after that. C1 [Zhang, Mengxia; Li, Lin-ling; Zhao, Qian-qian; Peng, Xiao-dong; Wu, Kui; Li, Xin; Ruan, Yan-Fei; Bai, Rong; Liu, Nian; Ma, Chang Sheng] Capital Med Univ, Natl Clin Res Ctr Cardiovasc Dis, Dept Cardiol, Beijing Anzhen Hosp, 2 Anzhen Rd, Beijing 100029, Peoples R China. C3 Capital Medical University RP Liu, N (corresponding author), Capital Med Univ, Natl Clin Res Ctr Cardiovasc Dis, Dept Cardiol, Beijing Anzhen Hosp, 2 Anzhen Rd, Beijing 100029, Peoples R China. EM mengxia_zhang1995@163.com; lilinlingtj@126.com; 18330214678@163.com; pengxd96@gmail.com; wukuielec@163.com; leexin9907@126.com; ruanyanfei@hotmail.com; bairong74@hotmail.com; liunian1973@hotmail.com; chshma@vip.sina.com RI zhao, qianqian/AEF-4159-2022 FU National Natural Science Foundation of China [81870244, 81670291]; Beijing Natural Science Foundation [7192051] FX This work was supported in part by grants from the National Natural Science Foundation of China (nos. 81870244 and 81670291) and the Beijing Natural Science Foundation (no. 7192051). CR Aboumsallem JP, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.013754 Ahern TP, 2014, BREAST CANCER RES TR, V144, P427, DOI 10.1007/s10549-014-2886-x Ahern TP, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2205 Allan V, 2017, THROMB HAEMOSTASIS, V117, P837, DOI 10.1160/TH16-11-0825 Antoni MH, 2006, NAT REV CANCER, V6, P240, DOI 10.1038/nrc1820 Chen ST, 2019, EUR HEART J-QUAL CAR, V5, P145, DOI 10.1093/ehjqcco/qcy040 Chu G, 2019, BLOOD REV, V35, P59, DOI 10.1016/j.blre.2019.03.005 Clemens A, 2014, ANN MED, V46, P672, DOI 10.3109/07853890.2014.952327 Conen D, 2016, JAMA CARDIOL, V1, P389, DOI 10.1001/jamacardio.2016.0280 Farmakis D, 2014, J AM COLL CARDIOL, V63, P945, DOI 10.1016/j.jacc.2013.11.026 Frost L, 2005, AM J MED, V118, P489, DOI 10.1016/j.amjmed.2005.01.031 Haaland GS, 2017, JAMA INTERN MED, V177, P1774, DOI 10.1001/jamainternmed.2017.5512 Hung CS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199901 Hung YP, 2019, INT J CARDIOL, V296, P81, DOI 10.1016/j.ijcard.2019.08.021 MULLER AD, 1994, DIGEST DIS SCI, V39, P2480, DOI 10.1007/BF02087670 Oakland K, 2019, GUT, V68, P776, DOI 10.1136/gutjnl-2018-317807 Ostenfeld EB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102861 Parry CD, 2011, ADDICTION, V106, P1718, DOI 10.1111/j.1360-0443.2011.03605.x Pathak EB, 2016, WOMEN HEALTH ISS, V26, P589, DOI 10.1016/j.whi.2016.08.002 Rahman F, 2016, JAMA CARDIOL, V1, P384, DOI 10.1001/jamacardio.2016.0582 Rahman F, 2014, NAT REV CARDIOL, V11, P639, DOI 10.1038/nrcardio.2014.118 Ridker PM, 2017, CAN MED ASSOC J, V189, pE382, DOI 10.1503/cmaj.161033 Rose-Felker K, 2017, HEART FAIL CLIN, V13, P311, DOI 10.1016/j.hfc.2016.12.007 Saliba W, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190324 Severino P, 2019, CARDIOL RES PRACT, V2019, DOI 10.1155/2019/1208505 Shen CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057399 Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008 Tan BL, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01162 Vinter N, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.009543 Wassertheil-Smoller S, 2017, AM J EPIDEMIOL, V185, P372, DOI 10.1093/aje/kww185 Yang EV, 2003, BRAIN BEHAV IMMUN, V17, pS37 Zuo L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184472 NR 32 TC 14 Z9 15 U1 0 U2 5 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2090-8016 EI 2090-0597 J9 CARDIOL RES PRACT JI Cardiol. Res. Pract. PD SEP 27 PY 2020 VL 2020 AR 2372067 DI 10.1155/2020/2372067 PG 8 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA OF9MG UT WOS:000581521400001 PM 33062319 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Al Sawalhi, S Ding, JR Vannucci, J Li, YP Odeh, A Zhao, DP AF Al Sawalhi, Samer Ding, Junrong Vannucci, Jacopo Li, Yuping Odeh, Ahmad Zhao, Deping TI Perioperative risk factors for atrial fibrillation (AF) in patients underwent uniportal video-assisted thoracoscopic (VATS) pneumonectomy versus open thoracotomy: single center experience SO GENERAL THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article DE Atrial fibrillation; Pneumonectomy; Uniportal VATS ID LUNG-CANCER; LOWER MORBIDITY; SURGERY; LOBECTOMY; INFLAMMATION AB Objectives To evaluate perioperative risk factors for AF in patients undergoing uniportal VATS pneumonectomy versus open thoracotomy, and to investigate mediastinal lymph nodes dissection (MLND) on the occurrence of AF. Methods Patients were divided into 2 groups based on the surgical approach: uniportal VATS and open pneumonectomy. Analysis was done using chi-square test. Multiple variables were tested using univariate analysis. Apvalue <= 0.05 was considered statistically significant. Results Three-hundred and forty-one patients underwent pneumonectomy between 2014 and 2018 in Shanghai Pulmonary Hospital. Fifty-eight patients underwent uniportal VATS, and 283 underwent thoracotomies. AF was the most common event observed. The overall occurrence of peri-operative AF was 33/341 (9.67%). In the uniportal, converted, and open group the incidence of AF was: 3/52 (5.76%), 1/6 (16.6%), and 29/283 (10.42%), respectively. Overall, there was no specific surgical technique correlated with increased incidence of AF (p = 0.432). By univariate analysis; large tumor size > 4.5 cm (p < 0.010), operative time (OT) > 125 min (p < 0.002), and greater volume of blood loss (p < 0.001) increased the risk of AF. Additionally, patients who experienced higher post-operative pain (p < 0.002) were more vulnerable to developing AF. Mortality occurred in one AF patient (1/33, 3%). Number of lymph nodes harvested was not related to AF incidence (p = 0.520). Conclusions Although AF incidence was lower in uniportal group, it was not statistically significant. Large tumor size, long operative time, and increased blood loss were associated with increased risk of perioperative AF. These results need to be confirmed by larger studies. C1 [Al Sawalhi, Samer; Ding, Junrong; Vannucci, Jacopo; Li, Yuping; Zhao, Deping] Tongji Univ, Shanghai Pulm Hosp, Dept Thorac Surg, 507 Zhengmin Rd, Shanghai 200433, Peoples R China. [Vannucci, Jacopo] Univ Rome Sapienza, Policlin Umberto I, Dept Thorac Surg, Rome, Italy. [Odeh, Ahmad] King Faisal Univ, Dept Surg, Al Hasa, Saudi Arabia. C3 Tongji University; Sapienza University Rome; University Hospital Sapienza Rome; King Faisal University RP Zhao, DP (corresponding author), Tongji Univ, Shanghai Pulm Hosp, Dept Thorac Surg, 507 Zhengmin Rd, Shanghai 200433, Peoples R China. EM zdp1992@163.com RI ding, junrong/AAO-7259-2021 CR Akkus M, 2020, ACTA CHIR BELG, V120, P265, DOI 10.1080/00015458.2019.1610259 ANDERSEN JS, 1991, J INTERN MED, V229, P253, DOI 10.1111/j.1365-2796.1991.tb00340.x Colice GL, 2007, CHEST, V132, p161S, DOI 10.1378/chest.07-1359 Dittrich HC, 1999, AM HEART J, V137, P494, DOI 10.1016/S0002-8703(99)70498-9 Gonzalez-Rivas D, 2013, J THORAC DIS, V5, pS246, DOI 10.3978/j.issn.2072-1439.2013.07.44 Gupta DK, 2014, EUR HEART J, V35, P1457, DOI 10.1093/eurheartj/eht500 Harpole DH, 1996, ANN THORAC SURG, V61, P977, DOI 10.1016/0003-4975(95)01174-9 Ishida K, 2006, EUR J CARDIO-THORAC, V29, P501, DOI 10.1016/j.ejcts.2005.12.028 Iwata T, 2016, SURG TODAY, V46, P877, DOI 10.1007/s00595-015-1258-4 Laursen LO, 2016, EUR J CARDIO-THORAC, V49, P870, DOI 10.1093/ejcts/ezv205 Licker M, 2002, CHEST, V121, P1890, DOI 10.1378/chest.121.6.1890 Muranishi Y, 2017, SURG TODAY, V47, P252, DOI 10.1007/s00595-016-1380-y Nakamura E, 2006, J SURG RES, V135, P364, DOI 10.1016/j.jss.2006.04.015 Patterson E, 2006, J AM COLL CARDIOL, V47, P1196, DOI 10.1016/j.jacc.2005.12.023 Paul S, 2010, J THORAC CARDIOV SUR, V139, P366, DOI 10.1016/j.jtcvs.2009.08.026 Riber LP, 2014, ANN THORAC SURG, V98, P1989, DOI 10.1016/j.athoracsur.2014.06.069 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Rozencwajg S, 2017, ANAESTH CRIT CARE PA, V36, P185, DOI 10.1016/j.accpm.2016.04.005 Scridon A, 2015, INFLAMM RES, V64, P383, DOI 10.1007/s00011-015-0827-8 Van Schil PE, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2017.06.45 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Villamizar NR, 2009, J THORAC CARDIOV SUR, V138, P419, DOI 10.1016/j.jtcvs.2009.04.026 Viviano A, 2014, INTERACT CARDIOV TH, V18, P225, DOI 10.1093/icvts/ivt486 Wu DH, 2012, ANN THORAC SURG, V94, P193, DOI 10.1016/j.athoracsur.2012.03.057 Yang CFJ, 2019, J THORAC CARDIOV SUR, V158, P252, DOI 10.1016/j.jtcvs.2018.12.001 NR 25 TC 4 Z9 5 U1 0 U2 7 PU SPRINGER JAPAN KK PI TOKYO PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005, JAPAN SN 1863-6705 EI 1863-6713 J9 GEN THORAC CARDIOVAS JI Gen. Thorac. Cardiovasc. Surg. PD MAR PY 2021 VL 69 IS 3 BP 487 EP 496 DI 10.1007/s11748-020-01491-3 EA SEP 2020 PG 10 WC Cardiac & Cardiovascular Systems; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Surgery GA QK9GQ UT WOS:000572842200001 PM 32979148 DA 2026-04-17 ER PT J AU Shinomiya, S Kaira, K Yamaguchi, O Ishikawa, K Kagamu, H AF Shinomiya, Shun Kaira, Kyoichi Yamaguchi, Ou Ishikawa, Keitaro Kagamu, Hiroshi TI Osimertinib induced cardiomyopathy A case report SO MEDICINE LA English DT Article DE cardiac dysfunction; cardiomyopathy; lung cancer; osimertinib AB Rationale: Cardiotoxicity related to osimertinib, including cardiac failure, QT prolongation, and atrial fibrillation, has been reported as an extremely rare incidence in patients with advanced non-small cell lung cancer (NSCLC). However, little is known about the occurrence of osimertinib-induced cardiomyopathy. Patient concerns: A 76-year old woman was treated with afatinib (40 mg/day) as the 1st line treatment due to recurrence after surgical resection for pulmonary adenocarcinoma. However, she experienced recurrence with positive T790 M, and osimertinib (80 mg/day) was administered as the 2nd line therapy. Diagnosis: Four months after osimertinib initiation, she complained of fever and progressive dyspnea, and a diagnostic endomyocardial biopsy confirmed non-specific cardiomyopathy, indicating osimertinib-induced cardiomyopathy. Interventions and outcomes: She was treated with furosemide, carvedilol, and enalapril, and her cardiac function, her symptoms, and condition improved 3 weeks after the withdrawal of osimertinib. Lessons: Physicians should be alert of the cardiomyopathy-causing potential of osimertinib in advanced NSCLC patients. C1 [Shinomiya, Shun; Kaira, Kyoichi; Yamaguchi, Ou; Ishikawa, Keitaro; Kagamu, Hiroshi] Saitama Univ Hosp, Comprehens Canc Ctr, Int Med Ctr, Dept Resp Med, 1397-1 Yamane, Hidaka City, Saitama 3501298, Japan. RP Kaira, K (corresponding author), Saitama Univ Hosp, Comprehens Canc Ctr, Int Med Ctr, Dept Resp Med, 1397-1 Yamane, Hidaka City, Saitama 3501298, Japan. EM kkaira1970@yahoo.ca.jp CR Anand K, 2019, JACC-CARDIOONCOL, V1, P172, DOI 10.1016/j.jaccao.2019.10.006 Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337 Kaira K, 2020, J THORAC ONCOL Mok TS, 2017, NEW ENGL J MED, V376, P629, DOI 10.1056/NEJMoa1612674 Oyakawa Takuya, 2017, J Thorac Oncol, V12, pe159, DOI [10.1016/j.jtho.2017.05.016, 10.1016/j.jtho.2017.05.016] Reale ML, 2018, American journal of cancer case reports, V6, P52 Watanabe H, 2017, INTERNAL MED, V56, P2195, DOI 10.2169/internalmedicine.8344-16 NR 7 TC 15 Z9 20 U1 0 U2 17 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7974 EI 1536-5964 J9 MEDICINE JI Medicine (Baltimore) PD SEP 25 PY 2020 VL 99 IS 39 AR e22301 DI 10.1097/MD.0000000000022301 PG 4 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA OC8ZT UT WOS:000579445400038 PM 32991436 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Castle, J Blower, E Bundred, NJ Harvey, JR Thachil, J Marshall, A Cox, K Cicconi, S Holcombe, C Palmieri, C Kirwan, CC AF Castle, John Blower, Emma Bundred, Nigel J. Harvey, James R. Thachil, Jecko Marshall, Andrea Cox, Karina Cicconi, Silvia Holcombe, Chris Palmieri, Carlos Kirwan, Cliona C. TI Rivaroxaban compared to no treatment in ER-negative stage I-III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial SO TRIALS LA English DT Article DE Tissue Factor; Thrombin; FXa; DOAC; NOAC; Rivaroxaban; Breast cancer; Clinical trial; Ki67 ID ENDOTHELIAL GROWTH-FACTOR; TISSUE FACTOR EXPRESSION; FACTOR-XA INHIBITOR; D-DIMER LEVELS; VENOUS THROMBOEMBOLISM; ORAL ANTICOAGULANTS; TUMOR PROGRESSION; FACTOR VIIA; THROMBIN; CELLS AB Background: Breast cancer patients are at a four-fold increased risk of developing a venous thromboembolism (VTE), a major cause of death in this group. Conversely, coagulation factors promote tumour growth and metastasis. This has been evidenced in preclinical models, with an inhibitory effect of anticoagulants on cancer growth through proliferative, angiogenic, apoptotic, cancer stem cell and metastatic processes. The extrinsic clotting pathway is also more upregulated in patients in the relatively poorer prognosis oestrogen receptor (ER)-negative breast cancer subgroup, with increased tumour stromal expression of the coagulation factors Tissue Factor and thrombin. Rivaroxaban (Xarelto (R), Bayer AG, Leverkusen, Germany) is a direct oral anticoagulant (DOAC). It is a Factor Xa inhibitor that is routinely prescribed for the prevention of stroke in non-valvular atrial fibrillation and for both VTE prophylaxis and treatment. This trial will assess the anti-proliferative and other anti-cancer progression mechanisms of Rivaroxaban in ER-negative early breast cancer patients. Methods: This UK-based preoperative window-of-opportunity phase II randomised control trial will randomise 88 treatment-naive early breast cancer patients to receive 20 mg OD Rivaroxaban treatment for 11 to 17 days or no treatment. Treatment will be stopped 24 h (range 18-36 h) prior to surgery or repeat core biopsy. All patients will be followed up for 2 weeks following surgery or repeat core biopsy. The primary endpoint is change in tumour Ki67. Secondary outcome measures include tumour markers of apoptosis and angiogenesis, extrinsic clotting pathway activation and systemic markers of metastasis, tumour load and coagulation. Discussion: Laboratory evidence supports an anti-cancer role for anticoagulants; however, this has failed to translate into survival benefit when trialled in patients with metastatic disease or poor prognosis cancers, such as lung cancer. Subgroup analysis supported a potential survival benefit in better prognosis advanced disease patients. This is the first study to investigate the anti-cancer effects of anticoagulants in early breast cancer. C1 [Castle, John; Blower, Emma; Bundred, Nigel J.; Kirwan, Cliona C.] Univ Manchester, Manchester Canc Res Ctr, Wilmslow Rd, Manchester M20 4GJ, Lancs, England. [Bundred, Nigel J.; Harvey, James R.; Kirwan, Cliona C.] Wythenshawe Hosp, Nightingale Ctr, Manchester M23 9LT, Lancs, England. [Thachil, Jecko] Manchester Royal Infirm, Dept Haematol, Manchester M13 9WL, Lancs, England. [Marshall, Andrea] Univ Warwick, Warwick Clin Trials Unit, Coventry CV4 7AL, W Midlands, England. [Cox, Karina] Maidstone Hlth Author, Dept Breast Surg, Maidstone ME16 9QQ, Kent, England. [Cicconi, Silvia] Canc Res UK Liverpool Canc Trials Unit, Liverpool L69 3GL, Merseyside, England. [Holcombe, Chris] Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Breast Unit, Liverpool L3 9TA, Merseyside, England. [Palmieri, Carlos] Dept Mol & Clin Canc Med, Liverpool L69 3GA, Merseyside, England. C3 University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of Manchester; University of Warwick; Cancer Research UK; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital RP Kirwan, CC (corresponding author), Univ Manchester, Manchester Canc Res Ctr, Wilmslow Rd, Manchester M20 4GJ, Lancs, England.; Kirwan, CC (corresponding author), Wythenshawe Hosp, Nightingale Ctr, Manchester M23 9LT, Lancs, England. EM cliona.kirwan@manchester.ac.uk RI ; harvey, james/LRU-4974-2024; Kirwan, Cliona/HHZ-8872-2022 OI Castle, John/0000-0001-8213-9775; Cicconi, Silvia/0000-0001-5507-6203; harvey, james/0000-0002-1359-2186; Cox, Karina Louise/0000-0002-1140-9333; Kirwan, Cliona/0000-0002-1725-4790 FU National Institute for Health Research (NIHR) Clinician Scientist award; NIHR Clinical Research Network; University of Manchester; Association of Breast Surgery (ABS); European Cancer Organisation (ECCO) Fellowship Grant (Joint ECCO-AACR-EORTC-ESMO Workshop 'Methods in Clinical cancer Research'); National Institutes of Health Research (NIHR) [NIHR-CS-011-014] Funding Source: National Institutes of Health Research (NIHR); National Institute for Health Research [NIHR-CS-011-014] Funding Source: researchfish FX This trial is funded by a National Institute for Health Research (NIHR) Clinician Scientist award and the NIHR Clinical Research Network. It is supported by The University of Manchester, the Association of Breast Surgery (ABS) and a European Cancer Organisation (ECCO) Fellowship Grant (Joint ECCO-AACR-EORTC-ESMO Workshop 'Methods in Clinical cancer Research'). Ultimate authority in the study design, collection, management, analysis, interpretation of data, writing of the report and the decision to submit the report for publication remains with the Chief Investigator CCK. CR Ahamed J, 2006, P NATL ACAD SCI USA, V103, P13932, DOI 10.1073/pnas.0606411103 Akl EA, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006652.pub3 [Anonymous], Publication of Scholarly work in Medical Journals Asanuma K, 2004, ONCOLOGY-BASEL, V67, P166, DOI 10.1159/000081004 Batschauer APB, 2010, ANN ONCOL, V21, P1267, DOI 10.1093/annonc/mdp474 BioRender, WEB BAS TOOL LIF SCI Blackwell K, 2000, J CLIN ONCOL, V18, P600, DOI 10.1200/JCO.2000.18.3.600 Blackwell KL, 2004, CLIN CANCER RES, V10, P4083, DOI 10.1158/1078-0432.CCR-03-0695 Carneiro-Lobo TC, 2014, ONCOL REP, V31, P679, DOI 10.3892/or.2013.2880 Castle J, 2016, THROMB RES, V140, pS180, DOI 10.1016/S0049-3848(16)30144-X Cohen AT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160064 Coughlin SR, 2005, J THROMB HAEMOST, V3, P1800, DOI 10.1111/j.1538-7836.2005.01377.x Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229 Cronin-Fenton DP, 2010, BRIT J CANCER, V103, P947, DOI 10.1038/sj.bjc.6605883 Dowsett M, 2005, CLIN CANCER RES, V11, p951S Dowsett M, 2011, JNCI-J NATL CANCER I, V103, P1656, DOI 10.1093/jnci/djr393 Ellis I O., 2016, Pathology reporting of breast disease in surgical excision specimens incorporating the dataset for histological reporting of breast cancer Eriksson BI, 2006, CIRCULATION, V114, P2374, DOI 10.1161/CIRCULATIONAHA.106.642074 Ezzelle J, 2008, J PHARMACEUT BIOMED, V46, P18, DOI 10.1016/j.jpba.2007.10.010 Hjortoe GM, 2004, BLOOD, V103, P3029, DOI 10.1182/blood-2003-10-3417 Hu L, 2004, BLOOD, V104, P2746, DOI 10.1182/blood-2004-03-1047 Jones A, 2009, BRIT J CANCER, V101, P840, DOI 10.1038/sj.bjc.6605210 Karar J, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00051 Kasthuri RS, 2009, J CLIN ONCOL, V27, P4834, DOI 10.1200/JCO.2009.22.6324 Khoury JD, 2010, AM J CLIN PATHOL, V134, P964, DOI 10.1309/AJCPH92SXYLIKKTS Kirwan CC, 2008, BRIT J CANCER, V99, P1000, DOI 10.1038/sj.bjc.6604620 Kirwan CC, 2020, CLIN TRANSL ONCOL, V22, P870, DOI 10.1007/s12094-019-02197-6 Kirwan CC, 2015, CLIN APPL THROMB-HEM, V21, P420, DOI 10.1177/1076029615575071 Kirwan CC, 2011, ANTICANCER RES, V31, P2383 KLEPFISH A, 1993, INT J CANCER, V53, P978 Kubitza D, 2005, CLIN PHARMACOL THER, V78, P412, DOI 10.1016/j.clpt.2005.06.011 Kubitza D, 2005, EUR J CLIN PHARMACOL, V61, P873, DOI 10.1007/s00228-005-0043-5 Lai A, 2014, BRIT J SURG, V101, P742, DOI 10.1002/bjs.9485 Lip GYH, 2016, INT J CARDIOL, V204, P88, DOI 10.1016/j.ijcard.2015.11.084 Liu J, 2006, BIOCHEM BIOPH RES CO, V343, P183, DOI 10.1016/j.bbrc.2006.02.136 Maragoudakis ME, 2001, ENDOTHELIUM-J ENDOTH, V8, P195 Mego M, 2015, THROMB HAEMOSTASIS, V113, P593, DOI 10.1160/TH14-07-0597 Morris DR, 2006, CANCER RES, V66, P307, DOI 10.1158/0008-5472.CAN-05-1735 Mosesson MW, 2005, J THROMB HAEMOST, V3, P1894, DOI 10.1111/j.1538-7836.2005.01365.x Nierodzik ML, 1998, BLOOD, V92, P3694, DOI 10.1182/blood.V92.10.3694.422k40_3694_3700 NIERODZIK ML, 1991, J CLIN INVEST, V87, P229, DOI 10.1172/JCI114976 NIERODZIK MLR, 1992, CANCER RES, V52, P3267 Rak J, 2006, SEMIN THROMB HEMOST, V32, P54, DOI 10.1055/s-2006-933341 Roehrig S, 2005, J MED CHEM, V48, P5900, DOI 10.1021/jm050101d Ruf W, 2012, THROMB RES, V130, pS84, DOI 10.1016/j.thromres.2012.08.285 Saldanha IJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109400 Shaker H, 2020, CANCER MED-US, V9, P1768, DOI 10.1002/cam4.2748 Shaw FL, 2012, J MAMMARY GLAND BIOL, V17, P111, DOI 10.1007/s10911-012-9255-3 Ueno T, 2000, BRIT J CANCER, V83, P164 van Hinsbergh VWM, 2001, ANN NY ACAD SCI, V936, P426 Vedovati MC, 2015, CHEST, V147, P475, DOI 10.1378/chest.14-0402 Walker AJ, 2013, EUR J CANCER, V49, P1404, DOI 10.1016/j.ejca.2012.10.021 WOJTUKIEWICZ MZ, 1993, INT J CANCER, V54, P793, DOI 10.1002/ijc.2910540514 WOJTUKIEWICZ MZ, 1992, THROMB RES, V68, P233, DOI 10.1016/0049-3848(92)90081-K Wojtukiewicz MZ, 2000, THROMB RES, V97, P335, DOI 10.1016/S0049-3848(99)00169-3 Wojtukiewicz MZ, 2003, SEMIN THROMB HEMOST, V29, P291 Yu JL, 2005, BLOOD, V105, P1734, DOI 10.1182/blood-2004-05-2042 Zain Jasmine, 2000, Blood, V95, P3133 Zhang J, 2005, CANCER BIOL THER, V4, P769, DOI 10.4161/cbt.4.7.1871 NR 59 TC 8 Z9 10 U1 0 U2 3 PU BMC PI LONDON PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND EI 1745-6215 J9 TRIALS JI Trials PD AUG 27 PY 2020 VL 21 IS 1 AR 749 DI 10.1186/s13063-020-04675-7 PG 11 WC Medicine, Research & Experimental WE Science Citation Index Expanded (SCI-EXPANDED) SC Research & Experimental Medicine GA NK8FF UT WOS:000566966000003 PM 32854772 OA Green Submitted, Green Published, gold DA 2026-04-17 ER PT J AU Li, HL Han, DT Feng, XT Yu, WJ Xu, TT Ma, T Song, LC AF Li, Honglin Han, Deting Feng, Xiaoteng Yu, Wenjun Xu, Tongtong Ma, Tao Song, Lucheng TI Adverse cardiac events in the treatment of non-small cell lung cancer with programmed death-1and programmed death-ligand 1 inhibitors A protocol for systematic review and meta-analysis SO MEDICINE LA English DT Review DE adverse cardiac events; meta-analysis; non-small cell lung cancer; programmed death-1; programmed death-ligand 1; protocol; systematic review ID HEALTH-ORGANIZATION CLASSIFICATION; NIVOLUMAB; EFFICACY; SAFETY; IMMUNOTHERAPY; CHEMOTHERAPY; MYOCARDITIS; DEFICIENT; TUMORS AB Background: Programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors are immune therapies that have shown great promise in the treatment of multiple cancers. However, immune-related adverse events of PD-1 and PD-L1 inhibitors may limit their use in non-small cell lung cancer (NSCLC). Given the rising number of clinical trials in recent years, it is essential to perform a meta-analysis to provide assess the cardiotoxicity of PD-1/ PD-L1 inhibitors in NSCLC therapy. Method and analysis: The ClinicalTrials.gov, Embase, PubMed, and Cochrane Central Register of Controlled Trials repositories will be searched from their inception to December 2019. The bibliography of the searching process will be imported into Endnote X9 software. Two reviewers independently will screen the literature, extract data, and conduct the risk of bias for every added study. The data analysis will be analyzed using Stata15.0 software. Specific adverse cardiac events will be identified, with particular attention on atrial fibrillation, cardiac arrest, cardiac failure, and pericarditis. This review will be performed as per the Preferred Reporting Item for Systematic Review and meta-analysis statement recommendations. Ethics and dissemination: This study will provide support for the cardiotoxicity linked to the treatment of NSCLC using PD-1/PD-L1 inhibitors. The data in the meta-analysis will be retrieved from completed and published clinical trials; therefore, ethical review and patient informed consent will not be required. PROSPERO number: CRD42020156397. C1 [Li, Honglin; Han, Deting; Yu, Wenjun] Shandong Univ Tradit Chinese Med, Clin Coll 1, Jinan, Shandong, Peoples R China. [Feng, Xiaoteng; Xu, Tongtong; Ma, Tao] Shandong Univ Tradit Chinese Med, Coll Tradit Chinese Med, Jinan, Shandong, Peoples R China. [Song, Lucheng] Shandong Univ, Shandong Prov Qianfoshan Hosp, Affiliated Hosp 1, Shandong Med Univ 1, 16766 Jingshi Rd, Jinan, Shandong, Peoples R China. C3 Shandong University of Traditional Chinese Medicine; Shandong University of Traditional Chinese Medicine; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University RP Song, LC (corresponding author), Shandong Univ, Shandong Prov Qianfoshan Hosp, Affiliated Hosp 1, Shandong Med Univ 1, 16766 Jingshi Rd, Jinan, Shandong, Peoples R China. EM lucheng.s@163.com RI Yu, Wenjun/GRS-8238-2022 FU Shandong Natural Science Foundation [ZR2013HL033] FX This research was supported by the Shandong Natural Science Foundation project (ZR2013HL033). CR Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310 Alsaab HO, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00561 [Anonymous], BMJ CASE REP Arrieta O, 2017, ONCOTARGET, V8, P101994, DOI 10.18632/oncotarget.22025 Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609] Duma N, 2019, MAYO CLIN PROC, V94, P1623, DOI 10.1016/j.mayocp.2019.01.013 Griesinger F, 2019, LUNG CANCER, V135, P196, DOI 10.1016/j.lungcan.2019.07.010 Johnson DB, 2016, NEW ENGL J MED, V375, P1749, DOI 10.1056/NEJMoa1609214 Khunger M, 2018, CLIN LUNG CANCER, V19, pE335, DOI 10.1016/j.cllc.2018.01.002 Kushnir I, 2017, CARDIOLOGY, V136, P49, DOI 10.1159/000447053 Li J, 2018, IMMUNOTHERAPY-UK, V10, P1293, DOI 10.2217/imt-2018-0116 Majem M, 2019, CLIN TRANSL ONCOL, V21, P3, DOI 10.1007/s12094-018-1978-1 Michel L, 2019, IJC HEART VASC, V25, DOI 10.1016/j.ijcha.2019.100420 Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535 Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665 Naidoo J, 2016, ANN ONCOL, V27, P1362, DOI 10.1093/annonc/mdw141 Nishimura H, 2001, SCIENCE, V291, P319, DOI 10.1126/science.291.5502.319 Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9 Rahouma M, 2019, IMMUNOTHERAPY-UK, V11, P725, DOI 10.2217/imt-2018-0118 Rolfo C, 2017, ADV EXP MED BIOL, V995, P97, DOI 10.1007/978-3-319-53156-4_5 Ru CH, 2018, COMB CHEM HIGH T SCR, V21, P711, DOI 10.2174/1386207322666190125150921 Schunemann H BJ., 2013, GRADE handbook Semper H, 2016, LUNG CANCER, V99, P117, DOI 10.1016/j.lungcan.2016.06.025 Shi Min-hua, 2013, Zhonghua Zhong Liu Za Zhi, V35, P85, DOI 10.3760/cma.j.issn.0253-3766.2013.02.002 Shuster JJ., 2011, Res. Synth. Methods, V2, P126, DOI [10.1002/jrsm.38, DOI 10.1002/JRSM.38] Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI [10.3322/caac.21442, 10.3322/caac.21551] Spranger S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006504 Terme M, 2011, CANCER RES, V71, P5393, DOI 10.1158/0008-5472.CAN-11-0993 Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630 Travis WD, 2015, J THORAC ONCOL, V10, P1240, DOI 10.1097/JTO.0000000000000663 Xia LL, 2019, ONCOLOGIST, V24, pS31, DOI 10.1634/theoncologist.2019-IO-S1-s05 Zhao HY, 2019, ONCOL LETT, V17, P857, DOI 10.3892/ol.2018.9678 NR 32 TC 0 Z9 0 U1 0 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7974 EI 1536-5964 J9 MEDICINE JI Medicine (Baltimore) PD AUG 7 PY 2020 VL 99 IS 32 AR e21613 DI 10.1097/MD.0000000000021613 PG 4 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA NC6AV UT WOS:000561299900061 PM 32769920 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Walls, M Walls, GM James, JA Crawford, KT Abdulkhalek, H Lynch, TB Peace, AJ McManus, TE Evans, OR AF Walls, Maria Walls, Gerard M. James, Jacqueline A. Crawford, Kyle T. Abdulkhalek, Hossam Lynch, Tom B. Peace, Aaron J. McManus, Terry E. Evans, O. Rhun TI Spontaneous regression of ALK fusion protein-positive non-small cell lung carcinoma: a case report and review of the literature SO BMC PULMONARY MEDICINE LA English DT Review DE Non-small cell lung cancer; ALK rearrangement; Spontaneous regression; Radiotherapy; Embolism; Cancer immunity; Stroke; Electric therapy; DC cardioversion ID IRREVERSIBLE ELECTROPORATION; SPONTANEOUS REMISSION; CANCER; REARRANGEMENTS; RADIOTHERAPY; TUMORS; ADENOCARCINOMA; MUTATIONS; RESPONSES; LYMPHOMA AB Background ALK-rearrangement is observed in < 5% non-small cell lung cancer (NSCLC) cases and prior to the advent of oral tyrosine kinase inhibitors, the natural history of oncogenic NSCLC was typically poor. Literature relating to regression of treatment-naive NSCLC is limited, and regression without treatment has not been noted in the ALK-rearranged sub-population. Case presentation A 76 year old 'never smoker' female with an ALK-rearranged left upper lobe T2 N0 NSCLC experienced a stroke following elective DC cardioversion for new atrial fibrillation. Following a good recovery, updated imaging demonstrated complete regression of the left upper lobe lesion and a reduction of the previously documented mediastinal lymph node. Remaining atelectasis was non-avid on repeat PET-CT imaging, 8 months from the baseline PET-CT. When the patient developed new symptoms 6 months later a further PET-CT demonstrated FDG-avid local recurrence. She completed 55 Gy in 20 fractions but at 18 months post-radiotherapy there was radiological progression in the lungs with new pulmonary metastases and effusion and new bone metastases. Owing to poor performance status, she was not considered fit for targeted therapy and died 5 months later. Conclusion All reported cases of spontaneous regression in lung cancer have been collated within. Documented precipitants of spontaneous regression across tumour types include biopsy and immune reconstitution; stroke has not been reported previously. The favourable response achieved with radical radiotherapy alone in this unusual case of indolent oncogenic NSCLC reinforces the applicability of radiotherapy in locally advanced ALK-rearranged tumours, in cases not behaving aggressively. As a common embolic event affecting the neurological and pulmonary vasculature is less likely, an immune-mediated mechanism may underpin the phenomenon described in this patient, implying that hitherto unharnessed principles of immuno-oncology may have relevance in oncogenic NSCLC. Alternatively, high electrical voltage applied percutaneously adjacent to the tumour during cardioversion in this patient may have induced local tumour cell lethality. C1 [Walls, Maria] Queens Univ Belfast, Ctr Med Educ, Belfast, Antrim, North Ireland. [Walls, Gerard M.; Crawford, Kyle T.; Lynch, Tom B.; Evans, O. Rhun] Belfast Hlth & Social Care Trust, Clin Oncol Dept, Canc Ctr Belfast City Hosp, Belfast, Antrim, North Ireland. [Walls, Gerard M.; James, Jacqueline A.] Queens Univ Belfast, Patrick G Johnston Ctr Canc Res, Belfast, Antrim, North Ireland. [James, Jacqueline A.] Belfast Hlth & Social Care Trust, Cellular Pathol Dept, Belfast, Antrim, North Ireland. [James, Jacqueline A.] Queens Univ Belfast, Precis Med Ctr Excellence, Hlth Sci Bldg, Belfast, Antrim, North Ireland. [Abdulkhalek, Hossam] Western Hlth & Social Care Trust, Med Oncol Dept, North West Canc Ctr, Derry, North Ireland. [Peace, Aaron J.] Western Hlth & Social Care Trust, Cardiol Dept, Altnagelvin Hosp, Derry, North Ireland. [Peace, Aaron J.] Western Hlth & Social Care Trust, Clin Translat Res & Innovat Ctr, Altnagelvin Hosp, Derry, North Ireland. [McManus, Terry E.] Western Hlth & Social Care Trust, Resp Dept, South West Acute Hosp, Enniskillen, North Ireland. C3 Queens University Belfast; Queens University Belfast; Queens University Belfast RP Walls, GM (corresponding author), Belfast Hlth & Social Care Trust, Clin Oncol Dept, Canc Ctr Belfast City Hosp, Belfast, Antrim, North Ireland.; Walls, GM (corresponding author), Queens Univ Belfast, Patrick G Johnston Ctr Canc Res, Belfast, Antrim, North Ireland. EM g.walls@qub.ac.uk RI ABDULKHALEK, HOSSAM/LKL-8682-2024; Walls, Gerard/I-5652-2019 OI Peace, Aaron/0000-0001-9556-7509; Walls, Gerard/0000-0003-0845-9732 CR [Anonymous], 2015, RADIAT ONCOL, DOI [DOI 10.1002/BDD.1933, DOI 10.1186/s13014-015-0573-7] [Anonymous], GlobAdvHealthMed2013 Ariza-Prota M, 2018, CLIN CASE REP, V6, P995, DOI 10.1002/ccr3.1502 BELL J W, 1970, American Journal of Surgery, V120, P804, DOI 10.1016/S0002-9610(70)80054-X Bhutiani N, 2016, J SURG ONCOL, V114, P181, DOI 10.1002/jso.24288 Boros A, 2017, ONCOTARGET, V8, P25189, DOI 10.18632/oncotarget.15966 Cafferata MA, 2004, LUNG CANCER, V45, P263, DOI 10.1016/j.lungcan.2004.01.026 Camidge DR, 2018, NEW ENGL J MED, V379, P2027, DOI 10.1056/NEJMoa1810171 Camidge DR, 2010, CLIN CANCER RES, V16, P5581, DOI 10.1158/1078-0432.CCR-10-0851 Chaft JE, 2018, LUNG CANCER, V122, P67, DOI 10.1016/j.lungcan.2018.05.020 Chia PL, 2014, CLIN EPIDEMIOL, V6, P423, DOI 10.2147/CLEP.S69718 Choi SM, 2013, AM J RESP CRIT CARE, V188, pE5, DOI 10.1164/rccm.201208-1417IM Chung C, 2015, THORAC CANCER, V6, P805, DOI 10.1111/1759-7714.12221 COLE WH, 1981, J SURG ONCOL, V17, P201, DOI 10.1002/jso.2930170302 Croxford JL, 2013, BLOOD, V121, P2512, DOI 10.1182/blood-2012-08-449025 Detterbeck FC, 2018, J THORAC CARDIOV SUR, V155, P356, DOI 10.1016/j.jtcvs.2017.08.138 Esplin N, 2018, J CLIN CASE REPORTS, V08, P10 EVERSON TC, 1959, JAMA-J AM MED ASSOC, V169, P1758, DOI 10.1001/jama.1959.03000320060014 Ferro S, 2018, MECH TUMOR IMMUNOTHE, P4619 Furukawa M, 2011, ANN THORAC CARDIOVAS, V17, P577, DOI 10.5761/atcs.cr.10.01638 Gainor JF, 2016, CLIN CANCER RES, V22, P4585, DOI 10.1158/1078-0432.CCR-15-3101 Gainor JF, 2013, CLIN CANCER RES, V19, P4273, DOI 10.1158/1078-0432.CCR-13-0318 Gladwish A, 2010, BMJ CASE REP, V2010, P1 Grandgirard J, 2002, ENTOMOL EXP APPL, V103, P239, DOI 10.1046/j.1570-7458.2002.00982.x Haruki T, 2010, SURG TODAY, V40, P1155, DOI 10.1007/s00595-009-4195-2 Hayashi H, 2012, CLIN OUTCOMES THORAC, P4533 Hercbergs A, 1993, JNCI-J NATL CANCER I, V85, P1988 HOEHNER JC, 1995, INT J CANCER, V62, P19, DOI 10.1002/ijc.2910620106 Hwang ED, 2013, TUBERC RESPIR DIS, V75, P214, DOI 10.4046/trd.2013.75.5.214 Jeong Jae Hwa, 2019, Korean J Thorac Cardiovasc Surg, V52, P119, DOI [10.5090/kjtcs.2019.52.2.119, 10.5090/kjtcs.2019.52.2.119] Jiang CL, 2015, IEEE T BIO-MED ENG, V62, P4, DOI 10.1109/TBME.2014.2367543 Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766 Jourabchi N., 2014, Gastrointest. Interv, V3, P8, DOI [DOI 10.1016/J.GII.2014.02.002, 10.1016/j.gii.2014.02.002] Kawamura T, 1999, CELL IMMUNOL, V193, P219, DOI 10.1006/cimm.1999.1477 Kodama H, 2018, J THORAC CARDIOV SUR, V155, P2150, DOI 10.1016/j.jtcvs.2017.11.097 Kumar T, 2010, RESP MED, V104, P1543, DOI 10.1016/j.rmed.2010.04.026 Leo F, 1999, THORAC CARDIOV SURG, V47, P53, DOI 10.1055/s-2007-1013110 Li Ai-Jun, 2003, Hepatobiliary Pancreat Dis Int, V2, P152 Liu P, 2019, CRIZOTINIB INDUCED I LOPEZPASTORINI A, 2015, J MED CASE REP, V9, P2 Marques Cristiana, 2017, Autops Case Rep, V7, P20, DOI [10.4322/acr.2017.025, 10.4322/acr.2017.025] Matsui T, 2018, THORAC CANCER, V9, P1778, DOI 10.1111/1759-7714.12892 Matthiessen LW, 2011, ACTA ONCOL, V50, P621, DOI 10.3109/0284186X.2011.573626 McDonald F, 2018, CLIN ONCOL-UK, V30, P1, DOI [10.1016/j.clon.2017.10.013, 10.1016/j.clon.2017.09.007] Menon MP, 2015, J THORAC ONCOL, V10, pE1, DOI 10.1097/JTO.0000000000000236 Miyazaki K, 2007, RESP MED EXTRA, V3, P83, DOI [DOI 10.1016/J.RMEDX.2007.03.004, 10.1016/j.rmedx.2007.03.004] Miyoshi Y, 2017, ADV RESPIR MED, V85, P246, DOI 10.5603/ARM.a2017.0040 Mizuno T, 2011, CHEST, V140, P527, DOI 10.1378/chest.10-2564 Montalban C, 2001, GUT, V49, P584, DOI 10.1136/gut.49.4.584 Nakamura Y, 2009, LUNG CANCER, V65, P119, DOI 10.1016/j.lungcan.2008.12.020 NAUTS HC, 1989, CANCER SURV, V8, P713 Ogawa R, 2015, ONCOL LETT, V10, P550, DOI 10.3892/ol.2015.3243 Ooi KH, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011291 Park YH, 2016, J THORAC DIS, V8, pE235, DOI 10.21037/jtd.2016.02.19 Pujol JL, 2007, J THORAC ONCOL, V2, P168, DOI 10.1097/JTO.0b013e31802f1c9d Ricci SB, 2010, ONCOL LETT, V1, P941, DOI 10.3892/ol.2010.176 Rooney KP, 2015, CLIN ONCOL-UK, V27, P514, DOI 10.1016/j.clon.2015.05.010 Rosas G, 2019, CRIT REV ONCOL HEMAT, V136, P48, DOI 10.1016/j.critrevonc.2019.02.006 Siva S, 2013, J THORAC ONCOL, V8, pE71, DOI 10.1097/JTO.0b013e318292c55a SMITH RA, 1971, BMJ-BRIT MED J, V2, P563, DOI 10.1136/bmj.2.5761.563 Solomon BJ, 2014, NEW ENGL J MED, V371, P2167, DOI [10.1056/NEJMoa1408440, 10.1056/NEJMx150034] STOLL BA, 1992, BIOTHERAPY, V4, P23, DOI 10.1007/BF02171706 Sugimoto K, 2019, J VASC INTERV RADIOL, V30, P845, DOI 10.1016/j.jvir.2019.03.002 Theelen WSME, 2020, LUNG CANCER, V142, P106, DOI 10.1016/j.lungcan.2020.02.015 Thomson KR, 2011, J VASC INTERV RADIOL, V22, P611, DOI 10.1016/j.jvir.2010.12.014 Tomizawa K, 2015, THORAC CANCER, V6, P655, DOI 10.1111/1759-7714.12201 van MK M, 2015, OMI J RADIOL, V04, P4 Wagstaff PGK, 2016, ONCOTARGETS THER, V9, P2437, DOI [10.2147/OTT.586086, 10.2147/OTT.S88086] Walls G M, 2019, Ulster Med J, V88, P91 Yang P, 2012, J THORAC ONCOL, V7, P90, DOI 10.1097/JTO.0b013e31823c5c32 Yoon HY, 2019, BMC PULM MED, V19, DOI 10.1186/s12890-019-0978-4 Zaballa I, 2010, J COSMOL ASTROPART P, DOI 10.1088/1475-7516/2010/03/002 NR 72 TC 6 Z9 6 U1 0 U2 6 PU BMC PI LONDON PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1471-2466 J9 BMC PULM MED JI BMC Pulm. Med. PD AUG 6 PY 2020 VL 20 IS 1 AR 209 DI 10.1186/s12890-020-01249-w PG 9 WC Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System GA NC3LB UT WOS:000561115300002 PM 32762670 OA Green Submitted, Green Published, gold DA 2026-04-17 ER PT J AU Haywood, N Nickel, I Zhang, A Byler, M Scott, E Julliard, W Blank, RS Martin, LW AF Haywood, Nathan Nickel, Ian Zhang, Aimee Byler, Matthew Scott, Erik Julliard, Walker Blank, Randal S. Martin, Linda W. TI Enhanced Recovery After Thoracic Surgery SO THORACIC SURGERY CLINICS LA English DT Review DE Thoracic surgery; Prehabilitation; Opioid sparing; Early ambulation; Early enteral nutrition ID PATHWAY REDUCES DURATION; INTERCOSTAL NERVE BLOCKS; CHEST TUBE REMOVAL; ATRIAL-FIBRILLATION; LUNG-CANCER; LIPOSOMAL BUPIVACAINE; PULMONARY RESECTION; INTRAVENOUS ANESTHESIA; FAST-TRACK; PATIENT AB Enhanced recovery pathways (ERPs), used across multiple surgical subspecialties, is a multidisciplinary delivery of perioperative care designed to lessen the psychological stress of patients undergoing surgery. Thoracic ERP has been implemented but is not widespread, and variations exist between programs. Evidence of the benefit of thoracic ERP is emerging. This article presents common components of a thoracic surgery ERP and reviews contemporary outcomes. C1 [Haywood, Nathan; Nickel, Ian; Zhang, Aimee; Byler, Matthew; Scott, Erik; Julliard, Walker; Martin, Linda W.] Univ Virginia Hlth Syst, Dept Surg, Div Thorac & Cardiovasc Surg, 1215 Lee St, Charlottesville, VA 22908 USA. [Blank, Randal S.] Univ Virginia Hlth Syst, Div Gen Anesthesiol, Dept Anesthesiol, 1215 Lee St, Charlottesville, VA 22908 USA. [Martin, Linda W.] Univ Virginia Hlth Syst, Thorac Surg, 1215 Lee St, Charlottesville, VA 22908 USA. C3 University of Virginia; University of Virginia (UVA) Health System; University of Virginia; University of Virginia (UVA) Health System; University of Virginia; University of Virginia (UVA) Health System RP Martin, LW (corresponding author), Univ Virginia Hlth Syst, Thorac Surg, 1215 Lee St, Charlottesville, VA 22908 USA. EM LM6YB@virginia.edu RI Nickel, Ian/MBU-9169-2025 OI Nickel, Ian/0000-0003-3458-8802 CR Ahn HJ, 2016, ANESTH ANALG, V122, P186, DOI 10.1213/ANE.0000000000000974 Aloia TA, 2014, J SURG ONCOL, V110, P107, DOI 10.1002/jso.23626 Assouline B, 2016, PAIN, V157, P2854, DOI 10.1097/j.pain.0000000000000705 Batchelor TJP, 2019, CURR OPIN ANESTHESIO, V32, P17, DOI 10.1097/ACO.0000000000000685 Batchelor TJP, 2019, EUR J CARDIO-THORAC, V55, P91, DOI 10.1093/ejcts/ezy301 Bjerregaard LS, 2014, EUR J CARDIO-THORAC, V45, P241, DOI 10.1093/ejcts/ezt376 Boockmann B, 2014, IZA J LABOR POLICY, V3, DOI 10.1186/2193-9004-3-21 Brady M, 2003, Cochrane Database Syst Rev, pCD004423, DOI 10.1002/14651858.CD004423 Brunelli A, 2017, J THORAC CARDIOV SUR, V154, P2084, DOI 10.1016/j.jtcvs.2017.06.037 Brunt LM, 2015, SURGERY, V158, P908 Cardinale D, 2016, ANN SURG, V264, P244, DOI 10.1097/SLA.0000000000001626 Cerfolio RJ., 2001, J THORAC CARDIOV SUR, V122, P318 Cerfolio Robert J, 2010, Thorac Surg Clin, V20, P399, DOI 10.1016/j.thorsurg.2010.04.001 Cerfolio RJ, 2008, J THORAC CARDIOV SUR, V135, P269, DOI 10.1016/j.jtcvs.2007.08.066 Darouiche RO, 2010, NEW ENGL J MED, V362, P18, DOI 10.1056/NEJMoa0810988 Dinic VD, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00014 Fiore JF Jr, 2016, J THORAC CARDIOV SUR, V151, P708, DOI 10.1016/j.jtcvs.2015.09.112 Frendl G, 2014, J THORAC CARDIOV SUR, V148, pE153, DOI 10.1016/j.jtcvs.2014.06.036 Gebhardt R, 2013, J CARDIOTHOR VASC AN, V27, P423, DOI 10.1053/j.jvca.2013.02.017 Grigor EJM, 2017, ANN THORAC SURG, V104, P382, DOI 10.1016/j.athoracsur.2017.05.025 Huang HT, 2018, THORAC CANCER, V9, P83, DOI 10.1111/1759-7714.12541 Imperatori A, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-4 Irshad K, 2002, CAN J SURG, V45, P264 Jankowski CJ, 2017, INT ANESTHESIOL CLIN, V55, P12, DOI 10.1097/AIA.0000000000000157 Jones NL, 2013, ANAESTHESIA, V68, P179, DOI 10.1111/anae.12067 Jung J, 2016, J THORAC DIS, V8, P1814, DOI 10.21037/jtd.2016.06.16 Kawaguchi M, 2017, J ANESTH, V31, P319, DOI 10.1007/s00540-017-2329-z Khalil KG, 2015, ANN THORAC SURG, V100, P2013, DOI 10.1016/j.athoracsur.2015.08.017 Khandhar SJ, 2018, EUR J CARDIO-THORAC, V53, P1192, DOI 10.1093/ejcts/ezy061 Kratzing C, 2011, P NUTR SOC, V70, P311, DOI 10.1017/S0029665111000450 Krebs ED, 2019, J THORAC CARDIOVASC, V159 Kumar G, 2014, ANAESTHESIA, V69, P1138, DOI 10.1111/anae.12713 Lavand'homme P, 2005, ANESTHESIOLOGY, V103, P813, DOI 10.1097/00000542-200510000-00020 Ljungqvist O, 2017, JAMA SURG, V152, P292, DOI 10.1001/jamasurg.2016.4952 Loop T, 2016, CURR OPIN ANESTHESIO, V29, P20, DOI 10.1097/ACO.0000000000000282 Madani A, 2015, SURGERY, V158, P899, DOI 10.1016/j.surg.2015.04.046 Marshall MB, 2002, CHEST, V121, P831, DOI 10.1378/chest.121.3.831 Martin LW, 2019, J THORAC DIS, V11, pS1202, DOI 10.21037/jtd.2019.03.62 Martin LW, 2018, ANN THORAC SURG, V105, P1597, DOI 10.1016/j.athoracsur.2018.01.080 Maruyama R, 2006, GEN THORAC CARDIOVAS, V54, P387, DOI 10.1007/s11748-006-0014-5 Medbery RL, 2019, J THORAC DIS, V11, pS976, DOI 10.21037/jtd.2019.04.08 Mehran RJ, 2017, SEMIN THORAC CARDIOV, V29, P531, DOI 10.1053/j.semtcvs.2017.06.004 Muehling BM, 2008, EUR J CARDIO-THORAC, V34, P174, DOI 10.1016/j.ejcts.2008.04.009 Nelson DB, 2019, J THORAC CARDIOV SUR, V158, P279, DOI 10.1016/j.jtcvs.2019.03.009 Pachella LA, 2019, J PERIANESTH NURS, V34, P1250, DOI 10.1016/j.jopan.2019.05.007 Paci P, 2017, ANN THORAC SURG, V104, P950, DOI 10.1016/j.athoracsur.2017.05.085 Refai M, 2012, EUR J CARDIO-THORAC, V41, P820, DOI 10.1093/ejcts/ezr126 Riber LP, 2014, ANN THORAC SURG, V98, P1989, DOI 10.1016/j.athoracsur.2014.06.069 Rice DC, 2015, ANN THORAC SURG, V99, P1953, DOI 10.1016/j.athoracsur.2015.02.074 Rogers LJ, 2018, J THORAC CARDIOV SUR, V155, P1843, DOI 10.1016/j.jtcvs.2017.10.151 Schilling T, 2011, ANESTHESIOLOGY, V115, P65, DOI 10.1097/ALN.0b013e318214b9de Sedrakyan A, 2005, J THORAC CARDIOV SUR, V129, P997, DOI 10.1016/j.jtcvs.2004.07.042 Semenkovich TR, 2018, SEMIN THORAC CARDIOV, V30, P342, DOI 10.1053/j.semtcvs.2018.06.001 Singh BN, 2015, SURG ENDOSC, V29, P3267, DOI 10.1007/s00464-015-4071-7 Thiele RH, 2016, PERIOPER MED-LONDON, V5, DOI 10.1186/s13741-016-0049-9 Turan A, 2011, ANESTHESIOLOGY, V114, P837, DOI 10.1097/ALN.0b013e318210f560 Van Haren RM, 2018, ANN THORAC SURG, V106, P272, DOI 10.1016/j.athoracsur.2018.01.088 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Verhage RJJ, 2014, BRIT J ANAESTH, V112, P920, DOI 10.1093/bja/aet476 Wald HL, 2008, ARCH SURG-CHICAGO, V143, P551, DOI 10.1001/archsurg.143.6.551 Weimann A, 2006, CLIN NUTR, V25, P224, DOI 10.1016/j.clnu.2006.01.015 Wright CD, 1997, ANN THORAC SURG, V64, P299, DOI 10.1016/S0003-4975(97)00548-1 Zehr KJ, 1998, ANN THORAC SURG, V66, P914, DOI 10.1016/S0003-4975(98)00662-6 Zhao BC, 2017, CHEST, V151, P149, DOI 10.1016/j.chest.2016.08.1476 NR 64 TC 9 Z9 11 U1 1 U2 16 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1547-4127 EI 1558-5069 J9 THORAC SURG CLIN JI Thorac. Surg. Clin. PD AUG PY 2020 VL 30 IS 3 BP 259 EP + DI 10.1016/j.thorsurg.2020.04.005 PG 10 WC Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System; Surgery GA MC7PA UT WOS:000543472800005 PM 32593359 OA Bronze DA 2026-04-17 ER PT J AU Ishibashi, H Wakejima, R Asakawa, A Baba, S Nakashima, Y Seto, K Kobayashi, M Okubo, K AF Ishibashi, Hironori Wakejima, Ryo Asakawa, Ayaka Baba, Shunichi Nakashima, Yasuhiro Seto, Katsutoshi Kobayashi, Masashi Okubo, Kenichi TI Postoperative Atrial Fibrillation in Lung Cancer Lobectomy-Analysis of Risk Factors and Prognosis SO WORLD JOURNAL OF SURGERY LA English DT Article ID SURGERY; ASSOCIATION; MANAGEMENT; RESECTION AB Background The incidence of postoperative atrial fibrillation (POAF) after pulmonary lobectomy ranges from 6.4 to 12.6%. This study aimed to analyze the postoperative risk factors and prognosis for POAF in lobectomy for lung cancer. Methods Data were collected from patients undergoing pulmonary lobectomy from April 2010 to March 2019. We analyzed risk factors for POAF among perioperative factors and compared postoperative complications or overall survival between POAF and non-POAF groups. We classified POAF as either the temporary or non-temporary type and compared perioperative factors, postoperative complications, and overall survival. Results POAF was identified in 49 (5.2%) of the 947 lobectomies. The POAF group included more males, patients with poor performance status (PS), history of paroxysmal atrial fibrillation (AF), chronic obstructive pulmonary disease (COPD), and intraoperative blood transfusions. Poor PS, COPD, previous paroxysmal AF, and intraoperative blood transfusion were independent risk factors for POAF in multivariate analysis. The POAF group had a poorer prognosis than the non-POAF group (p = 0.0045). POAF was divided into 29 temporary and 20 non-temporary types. The onset date of non-temporary-type POAF was significantly later than that of the transient type (P < 0.01), and diabetes mellitus was significantly higher in non-temporary-type POAF. Non-temporary-type POAF had a significantly poorer prognosis in terms of overall survival (p = 0.005). Conclusions Poor PS, COPD, history of PAF, and intraoperative blood transfusion were independent risk factors for POAF. Non-temporary-type POAF occurred significantly later than transient type and caused poorer prognosis after lobectomy for lung cancer. C1 [Ishibashi, Hironori; Wakejima, Ryo; Asakawa, Ayaka; Baba, Shunichi; Nakashima, Yasuhiro; Seto, Katsutoshi; Kobayashi, Masashi; Okubo, Kenichi] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Thorac Surg, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan. C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU) RP Ishibashi, H (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Thorac Surg, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan. EM hishiba.thsr@tmd.ac.jp RI Nakashima, Yasuhiro/MGT-4083-2025 CR AMAR D, 1995, CHEST, V108, P349, DOI 10.1378/chest.108.2.349 Amar D, 2002, ANESTHESIOLOGY, V97, P1618, DOI 10.1097/00000542-200212000-00039 Amar D, 1996, CHEST, V110, P437, DOI 10.1378/chest.110.2.437 Benjamin EJ, 1998, CIRCULATION, V98, P946, DOI 10.1161/01.CIR.98.10.946 Garner M, 2017, INTERACT CARDIOV TH, V24, P260, DOI 10.1093/icvts/ivw348 Imperatori A, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-4 Inoue H, 2014, CIRC J, V78, P1997, DOI 10.1253/circj.CJ-66-0092 Israel CW, 2004, J AM COLL CARDIOL, V43, P47, DOI 10.1016/j.jacc.2003.08.027 Kawaguchi Y, 2018, GEN THORAC CARDIOVAS, V66, P537, DOI 10.1007/s11748-018-0960-8 Lee SH, 2016, ANAESTHESIA, V71, P1424, DOI 10.1111/anae.13644 Mita N, 2017, J CARDIOTHOR VASC AN, V31, P464, DOI 10.1053/j.jvca.2016.09.003 Muranishi Y, 2017, SURG TODAY, V47, P252, DOI 10.1007/s00595-016-1380-y Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Rami-Porta R, 2014, J THORAC ONCOL, V9, P1618, DOI 10.1097/JTO.0000000000000334 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Scridon A, 2015, INFLAMM RES, V64, P383, DOI 10.1007/s00011-015-0827-8 Smith H, 2018, J THORAC DIS, V10, pS3799, DOI 10.21037/jtd.2018.09.144 VanMieghem W, 1996, ANN THORAC SURG, V61, P1083, DOI 10.1016/0003-4975(96)00073-2 Wann LS, 2011, J AM COLL CARDIOL, V57, P223, DOI 10.1016/j.jacc.2010.10.001 NR 19 TC 30 Z9 32 U1 0 U2 5 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0364-2313 EI 1432-2323 J9 WORLD J SURG JI World J.Surg. PD NOV PY 2020 VL 44 IS 11 BP 3952 EP 3959 DI 10.1007/s00268-020-05694-w EA JUL 2020 PG 8 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA NV3XB UT WOS:000549682300004 PM 32681318 DA 2026-04-17 ER PT J AU Akkus, M Öner, E AF Akkus, Murat Oner, Ender TI Can local infiltration of lidocaine reduce the postoperative atrial fibrillation rate in patients undergoing lobectomy for lung cancer? SO ACTA CHIRURGICA BELGICA LA English DT Article DE Atrial fibrillation; lidocaine; lung cancer-surgery; lobectomy (lung) ID THORACIC-SURGERY; ARRHYTHMIAS; EXPRESSION AB Background: Postoperative atrial fibrillation (POAF) occurs frequently after lung cancer surgery. Unfortunately, owing to the multifactorial etiology of POAF, no single drug or intervention can prevent POAF in all cases. The effects of local interventions after lung cancer surgery are unknown. This study investigated the effects of local infiltration of an anesthetic (lidocaine) on the post-lobectomy POAF rate. Methods: This non-randomized study included 81 patients who underwent lobectomy for lung cancer. Patients were divided into a lidocaine-infiltration group comprising patients who received lidocaine infiltration around the pulmonary veins and a no-intervention group. Patients were monitored for the development of POAF during hospitalization. Pre- and postoperative demographic and clinical data were analyzed. Results: AF occurred in 3 (7.5%) of 40 patients in the lidocaine-infiltration group and in 10 (24.39%) of 41 patients in the standard surgical resection group. Overall, it was observed that intraoperative lidocaine infiltration resulted in a lower POAF rate (p<.05). Conclusion: Local infiltration of lidocaine around the pulmonary veins in patients undergoing lobectomy for lung cancer was associated with a lower incidence of POAF, which is attributable to the local anesthetic and autonomic effects of lidocaine. C1 [Akkus, Murat] Mehmet Akif Ersoy Thorac & Cardiovasc Surg Traini, Dept Thorac Surg, Istanbul, Turkey. [Oner, Ender] Mehmet Akif Ersoy Thorac & Cardiovasc Surg Traini, Dept Cardiol, Istanbul, Turkey. C3 Mehmet Akif Ersoy Thoracic Cardiovascular Surgery Education Research Hospital; Mehmet Akif Ersoy Thoracic Cardiovascular Surgery Education Research Hospital RP Akkus, M (corresponding author), Mehmet Akif Ersoy Thorac & Cardiovasc Surg Traini, Dept Thorac Surg, Istanbul, Turkey. EM akkusmdr@gmail.com RI ; Oner, Ender/HNC-5020-2023 OI Akkuş, Murat/0000-0002-3762-6328; Akkus, Murat/0000-0002-1659-1189; Oner, Ender/0000-0003-4987-0958 CR AbramovichSivan S, 1996, CLIN AUTON RES, V6, P313, DOI 10.1007/BF02556301 Agarwal V, 2006, J PEDIATR ORTHOP B, V15, P73, DOI 10.1097/01202412-200601000-00016 Akoum N, 2011, J CARDIOVASC ELECTR, V22, P16, DOI 10.1111/j.1540-8167.2010.01876.x Alston EN, 2011, NEUROPEPTIDES, V45, P33, DOI 10.1016/j.npep.2010.10.002 Chiou CW, 1997, CIRCULATION, V95, P2573, DOI 10.1161/01.CIR.95.11.2573 Costa KPD, 2016, AUTON NEUROSCI-BASIC, V197, P46, DOI 10.1016/j.autneu.2016.04.002 DAVID D, 1990, AM HEART J, V119, P1061, DOI 10.1016/S0002-8703(05)80235-2 Dixit S, 2009, J AM COLL CARDIOL, V54, P2049, DOI 10.1016/j.jacc.2009.09.015 DONALDSON LF, 1994, NEUROSCI LETT, V175, P111, DOI 10.1016/0304-3940(94)91091-X Dyszkiewicz W, 1998, EUR J CARDIO-THORAC, V13, P625, DOI 10.1016/S1010-7940(98)00084-0 Frendl G, 2014, J THORAC CARDIOV SUR, V148, pE153, DOI 10.1016/j.jtcvs.2014.06.036 Fuster V, 2011, J AM COLL CARDIOL, V57, pE101, DOI 10.1016/j.jacc.2010.09.013 Haïssaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003 Imperatori A, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-4 Kankel J, 2012, J PAIN, V13, P1232, DOI 10.1016/j.jpain.2012.09.008 Marshall J, 1883, Br Med J, V2, P1173 Miller JM, 2015, BRAUNWALDS TXB CARDI, P685 Oka T, 2001, ANESTH ANALG, V93, P253, DOI 10.1097/00000539-200108000-00003 Ommen SR, 1997, NEW ENGL J MED, V336, P1429, DOI 10.1056/NEJM199705153362006 Rena O, 2001, EUR J CARDIO-THORAC, V20, P688, DOI 10.1016/S1010-7940(01)00890-9 Riber LP, 2014, ANN THORAC SURG, V98, P1989, DOI 10.1016/j.athoracsur.2014.06.069 SORENSEN O, 1986, ACTA ANAESTH SCAND, V30, P630, DOI 10.1111/j.1399-6576.1986.tb02489.x Tamam Y, 2017, NEUROUROL URODYNAM, V36, P1832, DOI 10.1002/nau.23191 Tan AY, 2007, HEART RHYTHM, V4, pS57, DOI 10.1016/j.hrthm.2006.12.011 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Xie WR, 2007, J NEUROPHYSIOL, V97, P492, DOI 10.1152/jn.00899.2006 Zhang JM, 2004, PAIN, V109, P143, DOI 10.1016/j.pain.2004.01.033 NR 27 TC 6 Z9 6 U1 0 U2 1 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 0001-5458 EI 2577-0160 J9 ACTA CHIR BELG JI Acta Chir. Belg. PD JUL 3 PY 2020 VL 120 IS 4 BP 265 EP 270 DI 10.1080/00015458.2019.1610259 PG 6 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA MX1NZ UT WOS:000557494500001 PM 31010387 DA 2026-04-17 ER PT J AU Kuman, NK Kozaci, LD Sen, S Senturk, E Cokpinar, S Yaman, E Kilicaslan, N Karadag, F AF Kanlioglu Kuman, Nilgun Kozaci, Leyla Didem Sen, Serdar Senturk, Ekrem Cokpinar, Salih Yaman, Ertan Kilicaslan, Naciye Karadag, Fisun TI Prognostic Significance of Inflammatory Markers IL-6, sP-Selectin, TNF-α, BNP-32, and Procalcitonin Levels in Thoracic Surgery SO INDIAN JOURNAL OF SURGERY LA English DT Article DE Thoracic surgical complications; IL-6; sP-Selectin; BNP-32; TNF-alpha; Procalcitonin ID PULMONARY COMPLICATIONS; NATRIURETIC PEPTIDE; ATRIAL-FIBRILLATION; RESPONSE SYNDROME; PREDICTION; CYTOKINES; RESECTION AB Following surgical trauma, alterations of the immune response increased synthesis of proinflammatory cytokines, and lymphocytic proliferation occurs together with increased production of acute-phase reactants. We aimed to identify associations of such parameters regarding complications following major thoracic surgical interventions. Fifty-four cases aged over 18 years, who were planned to undergo surgery for lung cancer (34 cases) or causes other than lung cancer (20 cases), were included. Blood samples were collected preoperatively and postoperatively in the first and sixth hours, and on the first, fourth, and seventh days. Pleural fluid samples were obtained postoperatively in the first hour and on the first and fourth days. High trend of TNF-alpha both in serum and pleural fluid during the early postoperative period and low trend of serum sP-Selectin were associated with incomplete expansion. Regarding atelectasis, most consistent trends belonged to IL-6 and TNF-alpha pleural fluid measurements, both being high. High trend of serum BNP-32 involving preoperative and early postoperative periods and high trend of IL-6 in the pleural fluid were associated with postoperative pneumonia. Regression analysis revealed significant associations of PCT with all complications. TNF-alpha was associated with atelectasis and empyema, and IL-6 with postoperative fever. Our study provided results both consistent and inconsistent with the literature. BNP-32 was not indicative of atrial fibrillation. Among inflammatory markers, serum PCT and TNF-alpha values obtained in the preoperative or early postoperative period might serve as predictors for thoracic surgical complications. C1 [Kanlioglu Kuman, Nilgun; Sen, Serdar; Senturk, Ekrem; Cokpinar, Salih; Yaman, Ertan] Adnan Menderes Univ, Dept Thorac Surg, TR-09100 Aydin, Turkey. [Kozaci, Leyla Didem; Kilicaslan, Naciye] Adnan Menderes Univ, Dept Biochem, Aydin, Turkey. [Karadag, Fisun] Adnan Menderes Univ, Dept Pulmonol, Aydin, Turkey. C3 Adnan Menderes University; Adnan Menderes University; Adnan Menderes University RP Kuman, NK (corresponding author), Adnan Menderes Univ, Dept Thorac Surg, TR-09100 Aydin, Turkey. EM nilkanlioglu@gmail.com RI Kanlıoğlu, Nilgün/AAR-8626-2020 CR Agostini P, 2010, THORAX, V65, P815, DOI 10.1136/thx.2009.123083 AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284 Algar FJ, 2001, ANN THORAC SURG, V72, P1662, DOI 10.1016/S0003-4975(01)03096-X Atwell DM, 1998, ANN THORAC SURG, V66, P1145, DOI 10.1016/S0003-4975(98)00592-X Cagini L, 2014, EUR J CARDIO-THORAC, V46, pE74, DOI 10.1093/ejcts/ezu348 Craig SR, 2001, EUR J CARDIO-THORAC, V20, P455, DOI 10.1016/S1010-7940(01)00841-7 D'Journo XB, 2010, EUR J CARDIO-THORAC, V37, P1144, DOI 10.1016/j.ejcts.2009.11.033 DALES RE, 1993, CHEST, V104, P155, DOI 10.1378/chest.104.1.155 Endo S, 2004, EUR J CARDIO-THORAC, V26, P787, DOI 10.1016/j.ejcts.2004.07.015 Filaire A, 1999, ANN THORAC SURG, V67, P1460, DOI 10.1016/S0003-4975(99)00183-6 Fink-Neuboeck N, 2016, SURGERY, V160, P443, DOI 10.1016/j.surg.2016.04.004 Franke A, 2008, THORAC CARDIOV SURG, V56, P46, DOI 10.1055/s-2007-989250 Franke A, 2005, EUR J CARDIO-THORAC, V28, P569, DOI 10.1016/j.ejcts.2005.07.007 Garutti I, 2019, J CLIN MONIT COMPUT, V33, P1043, DOI 10.1007/s10877-019-00257-4 GERSON MC, 1990, AM J MED, V88, P101, DOI 10.1016/0002-9343(90)90456-N Haraguchi S, 2001, SURG TODAY, V31, P860, DOI 10.1007/s005950170023 Heinisch RH, 2005, VASC HEALTH RISK MAN, V1, P245 Hoksch Beatrix, 2007, Interact Cardiovasc Thorac Surg, V6, P155 Melendez JA, 1998, ANN THORAC SURG, V66, P220, DOI 10.1016/S0003-4975(98)00319-1 Mihara M, 2012, CLIN SCI, V122, P143, DOI 10.1042/CS20110340 Nojiri T, 2011, ANN THORAC SURG, V92, P1051, DOI 10.1016/j.athoracsur.2011.03.085 Ortmann C, 1997, INT J LEGAL MED, V110, P155, DOI 10.1007/s004140050055 Osaka D, 2011, INT J MED SCI, V8, P302, DOI 10.7150/ijms.8.302 Passman RS, 2005, ANN THORAC SURG, V79, P1698, DOI 10.1016/j.athoracsur.2004.10.058 Schutzman LM, 2019, J TRAUMA ACUTE CARE, V86, P583, DOI 10.1097/TA.0000000000002166 Simmers D, 2015, J CARDIOTHOR VASC AN, V29, P389, DOI 10.1053/j.jvca.2014.05.015 Sullivan David R, 2005, Heart Lung Circ, V14, P78, DOI 10.1016/j.hlc.2005.03.002 Takenaka K, 2006, J CRIT CARE, V21, P48, DOI 10.1016/j.jcrc.2005.07.001 NR 28 TC 5 Z9 5 U1 1 U2 7 PU SPRINGER INDIA PI NEW DELHI PA 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA SN 0972-2068 EI 0973-9793 J9 INDIAN J SURG JI Indian J. Surg PD JUN PY 2021 VL 83 IS 3 BP 740 EP 748 DI 10.1007/s12262-020-02494-3 EA JUN 2020 PG 9 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA TS6YO UT WOS:000543625400003 DA 2026-04-17 ER PT J AU Matsumoto, K Sato, S Okumura, M Niwa, H Hida, Y Kaga, K Date, H Nakajima, J Usuda, J Suzuki, M Souma, T Tsuchida, M Miyata, Y Takeshi, N AF Matsumoto, Keitaro Sato, Shuntaro Okumura, Meinoshin Niwa, Hiroshi Hida, Yasuhiro Kaga, Kichizo Date, Hiroshi Nakajima, Jun Usuda, Jitsuo Suzuki, Makoto Souma, Takahiro Tsuchida, Masanori Miyata, Yoshihiro Takeshi, Nagayasu CA Comm Patient Safety Japanese Assoc Chest Surg TI Left upper lobectomy is a risk factor for cerebral infarction after pulmonary resection: a multicentre, retrospective, case-control study in Japan SO SURGERY TODAY LA English DT Article DE Lung cancer; Lobectomy; Cerebral infarction ID LUNG-CANCER; ATRIAL-FIBRILLATION; VEIN-THROMBOSIS; STROKE; SURGERY; STUMP AB Purpose The anatomical site of resected lobes may influence postoperative cerebral infarction. The objective of the current study was to determine if left upper pulmonary lobectomy is a risk factor for postoperative cerebral infarction. Methods This was a retrospective case-control study in patients undergoing pulmonary lobectomy from 2004 to 2013 in Japan. We retrospectively identified 610 patients from 153 institutions who had developed postoperative cerebral infarction following pulmonary lobectomy. The control group consisted of 773 patients who underwent lobectomy without cerebral infarction during a randomly selected single month in 2009 at the same institutions. Results Factors associated with cerebral infarction were age [10-year intervals, odds ratio (OR): 1.46; 95% confidence interval (CI): 1.23-1.73;p < 0.001], male sex (OR 1.92; 95% CI 1.29-2.86;p = 0.001), presence of comorbidities (OR 1.82; 95% CI 1.35-2.44;p < 0.001), perioperative anti-platelet or anti-coagulant drug use (OR 1.71; 95% CI 1.20-2.45;p = 0.003), and lobectomy. Subgroup analyses revealed that cerebral infarction was strongly associated with left upper lobectomy. Conclusions Our findings suggest that left upper lobectomy is associated with a higher risk of cerebral infarction than other types of lobectomy, particularly in the early postoperative period. C1 [Matsumoto, Keitaro; Takeshi, Nagayasu] Nagasaki Univ, Grad Sch Biomed Sci, Dept Surg Oncol, 1-7-1 Sakamoto, Nagasaki 8528501, Japan. [Sato, Shuntaro] Nagasaki Univ Hosp, Clin Res Ctr, Nagasaki, Japan. [Okumura, Meinoshin] Toneyama Hosp, Toyonaka, Osaka, Japan. [Niwa, Hiroshi] Seirei Mikatahara Gen Hosp, Resp Dis Ctr, Div Thorac Surg, Hamamatsu, Shizuoka, Japan. [Hida, Yasuhiro; Kaga, Kichizo] Hokkaido Univ, Grad Sch Med, Dept Cardiovasc & Thorac Surg, Sapporo, Hokkaido, Japan. [Date, Hiroshi] Kyoto Univ, Grad Sch Med, Dept Thorac Surg, Kyoto, Japan. [Nakajima, Jun] Univ Tokyo, Dept Thorac Surg, Tokyo, Japan. [Usuda, Jitsuo] Nippon Med Sch, Dept Thorac Surg, Tokyo, Japan. [Suzuki, Makoto] Kumamoto Univ Hosp, Dept Thorac Surg, Kumamoto, Japan. [Souma, Takahiro] Chiba Univ Hosp, Div Qual & Patient Safety, Chiba, Japan. [Tsuchida, Masanori] Niigata Univ, Grad Sch Med & Dent Sci, Div Thorac & Cardiovasc Surg, Niigata, Japan. [Miyata, Yoshihiro] Hiroshima Univ, Dept Surg Oncol, Hiroshima, Japan. C3 Nagasaki University; Nagasaki University; Hokkaido University; Kyoto University; University of Tokyo; Nippon Medical School; Kumamoto University; Chiba University; Niigata University; Hiroshima University RP Takeshi, N (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Surg Oncol, 1-7-1 Sakamoto, Nagasaki 8528501, Japan. EM nagayasu@nagasaki-u.ac.jp RI Sato, Shuntaro/ACH-2006-2022; Kaga, Kichizo/A-7759-2012; Hida, Yasuhiro/A-7761-2012 OI Sato, Shuntaro/0000-0002-6055-3649; Hida, Yasuhiro/0000-0003-1759-4215 CR ELLEKJAER EF, 1992, STROKE, V23, P829, DOI 10.1161/01.STR.23.6.829 Go AS, 2003, JAMA-J AM MED ASSOC, V290, P2685, DOI 10.1001/jama.290.20.2685 Gual-Capllonch F, 2013, J CLIN ULTRASOUND, V41, P321, DOI 10.1002/jcu.21913 Holmes Holly M, 2009, Thorac Surg Clin, V19, P401, DOI 10.1016/j.thorsurg.2009.06.001 Ichimura H, 2014, ANN THORAC CARDIOVAS, V20, P613, DOI 10.5761/atcs.cr.13-00079 Ikeda Hiroyuki, 2015, NMC Case Rep J, V2, P26, DOI 10.2176/nmccrj.2014-0231 Kam PCA, 1997, ANAESTHESIA, V52, P879, DOI 10.1111/j.1365-2044.1997.136-az0129.x Kleemann T, 2009, J AM SOC ECHOCARDIOG, V22, P1403, DOI 10.1016/j.echo.2009.09.015 Manabe S, 2014, CASE REP NEPHROL DIA, V4, P103, DOI 10.1159/000363224 Masuda M, 2016, GEN THORAC CARDIOVAS, V64, P665, DOI 10.1007/s11748-016-0695-3 Matsumoto K, 2018, SURG TODAY, V48, P571, DOI 10.1007/s00595-017-1620-9 Nojiri T, 2015, SURG TODAY, V45, P740, DOI 10.1007/s00595-014-1032-z Ohtaka K, 2014, J CARDIOTHORAC SURG, V9, DOI 10.1186/s13019-014-0159-8 Ohtaka K, 2013, ANN THORAC SURG, V95, P1924, DOI 10.1016/j.athoracsur.2013.03.005 Ohtaka K, 2012, J THORAC CARDIOV SUR, V143, pE3, DOI 10.1016/j.jtcvs.2011.09.025 Okada M, 2005, CHEST, V128, P2696, DOI 10.1378/chest.128.4.2696 Sawabata N, 2011, J THORAC ONCOL, V6, P1229, DOI 10.1097/JTO.0b013e318219aae2 STODDARD MF, 1995, J AM COLL CARDIOL, V25, P452, DOI 10.1016/0735-1097(94)00396-8 Yamamoto T, 2016, SURG TODAY, V46, P780, DOI 10.1007/s00595-015-1233-0 NR 19 TC 31 Z9 34 U1 0 U2 6 PU SPRINGER PI NEW YORK PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES SN 0941-1291 EI 1436-2813 J9 SURG TODAY JI Surg. Today PD NOV PY 2020 VL 50 IS 11 BP 1383 EP 1392 DI 10.1007/s00595-020-02032-4 EA JUN 2020 PG 10 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA OC9FO UT WOS:000540993800002 PM 32556550 DA 2026-04-17 ER PT J AU Jin, Y Xu, ZF Yan, H He, QJ Yang, XC Luo, PH AF Jin, Ying Xu, Zhifei Yan, Hao He, Qiaojun Yang, Xiaochun Luo, Peihua TI A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors SO FRONTIERS IN PHARMACOLOGY LA English DT Review DE targeted therapies; protein kinases; small-molecule kinase inhibitor; cardiotoxicity; incidence ID CELL LUNG-CANCER; CHRONIC MYELOID-LEUKEMIA; PATIENTS RECEIVING IMATINIB; CONGESTIVE-HEART-FAILURE; OPEN-LABEL; FOLLOW-UP; CARDIOVASCULAR TOXICITY; ATRIAL-FIBRILLATION; DOUBLE-BLIND; SAFETY AB Numerous protein kinases encoded in the genome have become attractive targets for the treatment of different types of cancer. As of January 2020, a total of 52 small-molecule kinase inhibitors (SMKIs) have been approved by the FDA. With the numerous clinical trials and a heavy focus on drug safety, SMKI-induced cardiotoxicity, which is a life-threatening risk, has greatly attracted the attention of researchers. In this review, the SMKIs with cardiotoxicity incidence were described exhaustively. The data were collected from 42 clinical trials, 25 FDA-published documents, seven meta-analysis/systematic reviews, three case reports and more than 50 other types of articles. To date, 73% (38 of 52) of SMKIs have reported treatment-related cardiotoxicity. Among the 38 SMKIs with known cardiotoxicity, the rates of incidence of cardiac adverse events were QT prolongation: 47% (18 of 38), hypertension: 40% (15 of 38), left ventricular dysfunction: 34% (13 of 38), arrhythmia: 34% (13 of 38), heart failure: 26% (10 of 38) and ischemia or myocardial infarction: 29% (11 of 38). In the development process of novel SMKIs, more attention should be paid to balancing the treatment efficacy and the risk of cardiotoxicity. In preclinical drug studies, producing an accurate and reliable cardiotoxicity evaluation model is of key importance. To avoid the clinical potential cardiotoxicity risk and discontinuation of a highly effective drug, patients treated with SMKIs should be proactively monitored on the basis of a global standard. Moreover, the underlying mechanisms of SMKI-induced cardiotoxicity need to be further studied to develop new therapies for SMKI-induced cardiotoxicity. C1 [Jin, Ying; Xu, Zhifei; Yan, Hao; He, Qiaojun; Yang, Xiaochun; Luo, Peihua] Zhejiang Univ, Coll Pharmaceut Sci, Ctr Drug Safety Evaluat & Res, Hangzhou, Peoples R China. C3 Zhejiang University RP Yang, XC; Luo, PH (corresponding author), Zhejiang Univ, Coll Pharmaceut Sci, Ctr Drug Safety Evaluat & Res, Hangzhou, Peoples R China. EM yangxiaochun@zju.edu.cn; peihualuo@zju.edu.cn RI he, qiaojun/F-3198-2010; Yang, Xiaochun/ABP-8866-2022 FU National Natural Science Foundation of China [81872941, 81673522]; Science Technology Plan Project of Zhejiang Province [2019C04010] FX This study was supported by the National Natural Science Foundation of China (81872941 and 81673522) and Science Technology Plan Project of Zhejiang Province (2019C04010). CR Anand K, 2019, JACC-CARDIOONCOL, V1, P172, DOI 10.1016/j.jaccao.2019.10.006 [Anonymous], 2015, NEW ENGL J MED, V373, P1582, DOI 10.1056/NEJMx150036 Ascierto PA, 2016, LANCET ONCOL, V17, P1248, DOI 10.1016/S1470-2045(16)30122-X Atallah E, 2007, BLOOD, V110, P1233, DOI 10.1182/blood-2007-01-070144 Backes AC, 2008, EXPERT OPIN DRUG DIS, V3, P1409, DOI 10.1517/17460440802579975 Balch CM, 2010, J CLIN ONCOL, V28, P2452, DOI 10.1200/JCO.2009.27.1627 Blackhall F, 2017, ESMO OPEN, V2, DOI 10.1136/esmoopen-2017-000219 Blackwell KL, 2010, J CLIN ONCOL, V28, P1124, DOI 10.1200/JCO.2008.21.4437 Bogoyevitch MA, 2007, DRUG DISCOV TODAY, V12, P622, DOI 10.1016/j.drudis.2007.06.008 Branford S, 2009, BLOOD, V114, P5426, DOI 10.1182/blood-2009-08-215939 Bronte E, 2018, PHARMACOL THERAPEUT, V192, P65, DOI 10.1016/j.pharmthera.2018.06.017 Brown JR, 2017, HAEMATOLOGICA, V102, P1796, DOI 10.3324/haematol.2017.171041 Camidge DR, 2018, NEW ENGL J MED, V379, P2027, DOI 10.1056/NEJMoa1810171 Chen JM, 2017, J AM SOC NEPHROL, V28, P94, DOI 10.1681/ASN.2015060670 Cheng H, 2010, CIRC RES, V106, P21, DOI 10.1161/CIRCRESAHA.109.206920 Cohen P, 2001, EUR J BIOCHEM, V268, P5001, DOI 10.1046/j.0014-2956.2001.02473.x Cortes JE, 2013, NEW ENGL J MED, V369, P1783, DOI 10.1056/NEJMoa1306494 Cortes JE, 2018, BLOOD, V132, P393, DOI 10.1182/blood-2016-09-739086 Cortes JE, 2012, NEW ENGL J MED, V367, P2075, DOI 10.1056/NEJMoa1205127 Dorer DJ, 2016, LEUKEMIA RES, V48, P84, DOI 10.1016/j.leukres.2016.07.007 Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867 Dummer R, 2018, LANCET ONCOL, V19, P603, DOI 10.1016/S1470-2045(18)30142-6 Eisen T, 2012, LANCET ONCOL, V13, P1055, DOI 10.1016/S1470-2045(12)70364-9 Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655 Ewer MS, 2014, EUR J CANCER, V50, P2162, DOI 10.1016/j.ejca.2014.05.013 Fala L., 2019, LORBRENA LORLATINIB, P31 Force T, 2007, NAT REV CANCER, V7, P332, DOI 10.1038/nrc2106 Galinsky I, 2009, CLIN J ONCOL NURS, V13, P329, DOI 10.1188/09.CJON.329-335 Garcia-Alvarez A., 2010, Cardiovascular & Hematological Agents in Medicinal Chemistry, V8, P11 Gogas HJ, 2019, EUR J CANCER, V119, P97, DOI 10.1016/j.ejca.2019.07.016 Goss G, 2016, LANCET ONCOL, V17, P1643, DOI 10.1016/S1470-2045(16)30508-3 Grazette LP, 2004, J AM COLL CARDIOL, V44, P2231, DOI 10.1016/j.jacc.2004.08.066 Gu GW, 2016, CURR OPIN PHARMACOL, V31, P97, DOI 10.1016/j.coph.2016.11.005 Hasinoff BB, 2017, CARDIOVASC TOXICOL, V17, P297, DOI 10.1007/s12012-016-9386-7 Hida T, 2017, LANCET, V390, P29, DOI 10.1016/S0140-6736(17)30565-2 Hortobagyi GN, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-1050-7 Hsiao FC, 2016, ACTA CARDIOL SIN, V32, P243, DOI 10.6515/ACS20150629B Hutson TE, 2010, EUR J CANCER, V46, P2432, DOI 10.1016/j.ejca.2010.06.121 Jabbour E, 2014, BLOOD, V123, P494, DOI 10.1182/blood-2013-06-511592 Jacob F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145937 Kantarjian H, 2007, BLOOD, V109, P5143, DOI 10.1182/blood-2006-11-056028 Kantarjian H, 2006, NEW ENGL J MED, V354, P2542, DOI 10.1056/NEJMoa055104 Kantarjian HM, 2012, BLOOD, V119, P1123, DOI 10.1182/blood-2011-08-376087 Kerkelä R, 2006, NAT MED, V12, P908, DOI 10.1038/nm1446 Khozin S, 2015, CLIN CANCER RES, V21, P2436, DOI 10.1158/1078-0432.CCR-14-3157 Kim DW, 2016, LANCET ONCOL, V17, P452, DOI 10.1016/S1470-2045(15)00614-2 Korpanty GJ, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00204 Lamore SD, 2020, CHEM RES TOXICOL, V33, P125, DOI 10.1021/acs.chemrestox.9b00387 Larson RA, 2012, LEUKEMIA, V26, P2197, DOI 10.1038/leu.2012.134 Leong DP, 2016, BLOOD, V128, P138, DOI 10.1182/blood-2016-05-712828 Li WJ, 2015, J AM COLL CARDIOL, V66, P1160, DOI 10.1016/j.jacc.2015.07.025 LIVINGSTON C, 2019, CIRC RES S1, V125, pA756, DOI [10.1161/res.125.suppl_1.756, DOI 10.1161/res.125.suppl_1.756] Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037 Long GV, 2015, LANCET, V386, P444, DOI 10.1016/S0140-6736(15)60898-4 Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762 Markham A, 2017, DRUGS, V77, P1131, DOI 10.1007/s40265-017-0776-3 Miyawaki H, 2020, INTERNAL MED, V59, P229, DOI 10.2169/internalmedicine.3528-19 Mok Tony S, 2017, N Engl J Med, V376, P629, DOI 10.1056/NEJMoa1612674 Montani D, 2012, CIRCULATION, V125, P2128, DOI 10.1161/CIRCULATIONAHA.111.079921 Morcos PN, 2017, CANCER CHEMOTH PHARM, V79, P559, DOI 10.1007/s00280-017-3253-5 Moslehi JJ, 2015, J CLIN ONCOL, V33, P4210, DOI 10.1200/JCO.2015.62.4718 Motzer RJ, 2013, LANCET ONCOL, V14, P552, DOI 10.1016/S1470-2045(13)70093-7 O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457 Perez EA, 2008, MAYO CLIN PROC, V83, P679, DOI 10.4065/83.6.679 Pinkhas Daniel, 2017, Cardiooncology, V3, DOI [10.1186/s40959-017-0024-8, 10.1186/s40959-017-0024-8] Planchard D, 2016, LANCET ONCOL, V17, P984, DOI 10.1016/S1470-2045(16)30146-2 Porta C, 2019, LANCET ONCOL, V20, P1332, DOI 10.1016/S1470-2045(19)30510-8 Qi WX, 2013, BRIT J CLIN PHARMACO, V75, P919, DOI 10.1111/j.1365-2125.2012.04417.x Quintas-Cardama A, 2009, BLOOD, V113, P1619, DOI 10.1182/blood-2008-03-144790 Richards CJ, 2011, J CLIN ONCOL, V29, P3450, DOI 10.1200/JCO.2010.34.4309 Richeldi L, 2014, NEW ENGL J MED, V370, P2071, DOI [10.1056/nejmx150012, 10.1056/NEJMoa1402584] Robert C, 2019, NEW ENGL J MED, V381, P626, DOI 10.1056/NEJMoa1904059 Roskoski R, 2019, PHARMACOL RES, V144, P19, DOI 10.1016/j.phrs.2019.03.006 Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480 Shah RR, 2015, DRUG SAFETY, V38, P693, DOI 10.1007/s40264-015-0300-1 Shaw AT, 2019, ANN ONCOL, V30, P1121, DOI 10.1093/annonc/mdz131 Shaw AT, 2014, NEW ENGL J MED, V370, P1189, DOI 10.1056/NEJMoa1311107 Slamon DJ, 2018, J CLIN ONCOL, V36, P2465, DOI 10.1200/JCO.2018.78.9909 Solomon BJ, 2016, J CLIN ONCOL, V34, P2858, DOI 10.1200/JCO.2015.63.5888 Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137 Spechbach H, 2013, CLIN CASE REP, V1, P20, DOI 10.1002/ccr3.5 Sternberg CN, 2010, J CLIN ONCOL, V28, P1061, DOI 10.1200/JCO.2009.23.9764 Talbert DR, 2015, TOXICOL SCI, V143, P147, DOI 10.1093/toxsci/kfu215 Tartarone A, 2015, FUTURE ONCOL, V11, P2043, DOI 10.2217/fon.15.47 Tolcher AW, 2011, CANCER CHEMOTH PHARM, V67, P751, DOI 10.1007/s00280-010-1372-3 Tripathy D, 2018, LANCET ONCOL, V19, P904, DOI 10.1016/S1470-2045(18)30292-4 U.S. Food and Drug Administration, 2019, ROZLYTREK ENTR CAPS U.S. Food and Drug Administration, 2018, XOSPATA GILT TABL U.S. Food and Drug Administration, 2012, INLYTAR AX TABL U.S. Food and Drug Administration, 2006, SUTENT SUN MAL CAPS U.S. Food and Drug Administration, 2019, BRUKINSA ZAN CAPS U.S. Food and Drug Administration, 2014, OFEVR NINT CAPS U.S. Food and Drug Administration, 2018, TAVALISSE FOST DIS H U.S. Food and Drug Administration, 2012, CABOMETYX CAB TABL U.S. Food and Drug Administration, 2017, ALIQOPA COP INJ U.S. Food and Drug Administration, 2017, ALUNBRIG BRIG TABL U.S. Food and Drug Administration, 2013, IMBRUVICA IBR CAPS U.S. Food and Drug Administration, 2019, BALVERSA ERD TABL U.S. Food and Drug Administration, 2017, VERZENIO AB TABL U.S. Food and Drug Administration, 2017, CALQUENCE AC CAPS U.S. Food and Drug Administration, 2011, CAPRELSAR VAND TABL U.S. Food and Drug Administration, 2012, STIVARGA REG TABL U.S. Food and Drug Administration, 2009, VOTRIENT PAZ TABL U.S. Food and Drug Administration, 2012, ICLUSIG PON TABL U.S. Food and Drug Administration, 2015, ALECENSA AL CAPS U.S. Food and Drug Administration, 2017, RYDAPTR MID CAPS U.S. Food and Drug Administration, 2005, NEXAVAR SOR TABL U.S. Food and Drug Administration, 2018, LORBRENA LORL TABL U.S. Food and Drug Administration, 2019, INREBIC FEDR CAPS U.S. Food and Drug Administration, 2017, KISQALIR RIB TABL U.S. Food and Drug Administration, 2015, LENVIMAR LENV CAPS Ugurel S, 2016, EUR J CANCER, V53, P125, DOI 10.1016/j.ejca.2015.09.013 Verkhivker GM, 2007, BIOINFORMATICS, V23, P1919, DOI 10.1093/bioinformatics/btm277 Verweij J, 2007, EUR J CANCER, V43, P974, DOI 10.1016/j.ejca.2007.01.018 Wang ZX, 2014, EUR J CLIN PHARMACOL, V70, P225, DOI 10.1007/s00228-013-1598-1 Wells SA, 2010, J CLIN ONCOL, V28, P767, DOI 10.1200/JCO.2009.23.6604 Wirth LJ, 2018, CANCER-AM CANCER SOC, V124, P2365, DOI 10.1002/cncr.31344 Wong SF, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-10 Wu P, 2015, TRENDS PHARMACOL SCI, V36, P422, DOI 10.1016/j.tips.2015.04.005 Wu SG, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0777-1 Wu SH, 2008, LANCET ONCOL, V9, P117, DOI 10.1016/S1470-2045(08)70003-2 Xu ZF, 2018, TOXICOL LETT, V296, P39, DOI 10.1016/j.toxlet.2018.08.003 Zang JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030353 Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559 Zhang J, 2017, SCI REP-UK, V7, DOI 10.1038/srep43146 Zhao YQ, 2010, TOXICOL APPL PHARM, V248, P20, DOI 10.1016/j.taap.2010.07.007 Zhu XL, 2009, ACTA ONCOL, V48, P9, DOI 10.1080/02841860802314720 NR 127 TC 68 Z9 80 U1 1 U2 20 PU FRONTIERS MEDIA SA PI LAUSANNE PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND EI 1663-9812 J9 FRONT PHARMACOL JI Front. Pharmacol. PD JUN 12 PY 2020 VL 11 AR 891 DI 10.3389/fphar.2020.00891 PG 16 WC Pharmacology & Pharmacy WE Science Citation Index Expanded (SCI-EXPANDED) SC Pharmacology & Pharmacy GA MD2ZF UT WOS:000543840800001 PM 32595510 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Phillips, JD Porter, ED Beaulieu-Jones, BR Fay, KA Hasson, RM Millington, TM Finley, DJ AF Phillips, Joseph D. Porter, Eleah D. Beaulieu-Jones, Brendin R. Fay, Kayla A. Hasson, Rian M. Millington, Timothy M. Finley, David J. TI Postoperative atrial fibrillation prophylaxis using a novel amiodarone order set SO JOURNAL OF THORACIC DISEASE LA English DT Article DE Atrial fibrillation (AF); thoracic surgery; wedge resection; anatomic lung resection; amiodarone prophylaxis ID LUNG-CANCER SURGERY; THORACIC-SURGERY; WEDGE RESECTION; SURGICAL COMPLICATIONS; SAFETY BENEFITS; RISK-FACTORS; SOCIETY; PREVENTION; MANAGEMENT; CLASSIFICATION AB Background: Studies have demonstrated that chemoprophylaxis following anatomic lung resection can reduce post-operative atrial fibrillation (POAF). However, it is unclear if non-anatomic wedge resection warrants prophylaxis, as previously published rates vary widely. The primary goal of this study was to assess an institutional rate of POAF following anatomic resections with implementation of a novel amiodarone administration regimen compared to wedge resections without prophylaxis. Methods: We performed a retrospective cohort study of a prospectively maintained database and compared anatomic and wedge lung resection patients from 1/2015 to 4/2018. During the study period, a previously unpublished amiodarone order set consisting of a 300 mg IV bolus followed by 400 mg tablets TID x3 days was administered to anatomic resection patients >= 65 who met criteria. Wedge resection patients were not intended to receive amiodarone prophylaxis. The primary outcome was POAF incidence. Risk factors for developing POAF were assessed. Results: A total of 537 patients met inclusion where 56% underwent anatomic resection and 44% wedge resection. Overall, 5.4% of patients experienced POAF. There was a significant reduction in post-anatomic resection POAF as compared to historic rates without prophylaxis (9.3% vs. 20.3%, P<0.001). A single wedge resection patient (0.4%) developed POAF. On multivariable analysis, the only independent POAF risk factor was age >= 65 (OR: 5.41, 95% CI: 1.47-19.85). Conclusions: Administration of our novel amiodarone order set reduces POAF after anatomic resection; however, POAF following wedge resection is too rare to warrant chemoprophylaxis. C1 [Phillips, Joseph D.; Porter, Eleah D.; Fay, Kayla A.; Hasson, Rian M.; Millington, Timothy M.; Finley, David J.] Dartmouth Hitchcock Med Ctr, Dept Surg, Sect Thorac Surg, Lebanon, NH 03756 USA. [Phillips, Joseph D.; Beaulieu-Jones, Brendin R.; Hasson, Rian M.; Millington, Timothy M.; Finley, David J.] Geisel Sch Med Dartmouth, Hanover, NH USA. C3 Dartmouth College; Dartmouth College RP Phillips, JD (corresponding author), Dartmouth Hitchcock Med Ctr, Sect Thorac Surg, 1 Med Ctr Dr, Lebanon, NH 03756 USA. EM Joseph.D.Phillips@hitchcock.org RI Phillips, Joseph/NRR-7334-2025 FU Dartmouth-Hitchcock Cancer Research Fellows Program; NCI Cancer Center Support Grant [5P30CA023108]; Dartmouth Clinical and Translational Science Institute from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) [UL1TR001086] FX The authors wish to thank Niveditta Ramkumar MPH of The Dartmouth Institute for Health Policy and Clinical Practice for review and assistance with the statistical analysis. JDP is supported by The Dartmouth-Hitchcock Cancer Research Fellows Program and by the NCI Cancer Center Support Grant 5P30CA023108 to the Dartmouth-Hitchcock Norris Cotton Cancer Center as well as The Dartmouth Clinical and Translational Science Institute, under award number UL1TR001086 from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH). CR Altorki NK, 2018, LANCET RESP MED, V6, P915, DOI 10.1016/S2213-2600(18)30411-9 Altorki NK, 2016, J THORAC ONCOL, V11, P1984, DOI 10.1016/j.jtho.2016.06.031 Amar D, 2002, ANESTHESIOLOGY, V97, P1618, DOI 10.1097/00000542-200212000-00039 Amar D, 2016, J THORAC CARDIOV SUR, V151, P913, DOI 10.1016/j.jtcvs.2015.09.041 Amar D, 2012, J THORAC CARDIOV SUR, V144, P1249, DOI 10.1016/j.jtcvs.2012.06.051 Amar David, 2008, Anesthesiol Clin, V26, P325, DOI 10.1016/j.anclin.2008.01.001 Anselmi A, 2009, ANN THORAC SURG, V88, P326, DOI 10.1016/j.athoracsur.2009.01.031 Berry MF, 2014, ANN THORAC SURG, V98, P1199, DOI 10.1016/j.athoracsur.2014.05.038 Bolaños-Morales FV, 2018, GEN THORAC CARDIOVAS, V66, P155, DOI 10.1007/s11748-017-0862-1 Charles RH, 2017, J CARDIOTHOR VASC AN, V31, P751, DOI 10.1053/j.jvca.2016.11.004 Clavien PA, 2009, ANN SURG, V250, P187, DOI 10.1097/SLA.0b013e3181b13ca2 Curtis JJ, 1998, ANN THORAC SURG, V66, P1766, DOI 10.1016/S0003-4975(98)00942-4 Dindo D, 2004, ANN SURG, V240, P205, DOI [10.17116/hirurgia2018090162, 10.1097/01.sla.0000133083.54934.ae] Fernando H, 2014, ANN THORAC SURG, V98, P1711 Fernando HC, 2011, ANN THORAC SURG, V92, P1144, DOI 10.1016/j.athoracsur.2011.06.104 Frendl G, 2014, J THORAC CARDIOV SUR, V148, pE153, DOI 10.1016/j.jtcvs.2014.06.036 Garner M, 2017, INTERACT CARDIOV TH, V24, P260, DOI 10.1093/icvts/ivw348 Gialdini G, 2014, JAMA-J AM MED ASSOC, V312, P616, DOI 10.1001/jama.2014.9143 Higashiyama M, 2015, GEN THORAC CARDIOVAS, V63, P320, DOI 10.1007/s11748-015-0544-9 Hou B, 2016, THER ADV RESPIR DIS, V10, P435, DOI 10.1177/1753465816667121 Ito Hiroyuki, 2010, Gan To Kagaku Ryoho, V37, P200 Kondo Haruhiko, 2005, Int J Clin Oncol, V10, P81 Kuzucu A, 2014, SURG TODAY, V44, P131, DOI 10.1007/s00595-012-0484-2 Lanza LA, 2003, ANN THORAC SURG, V75, P223, DOI 10.1016/S0003-4975(02)04285-6 Linden PA, 2014, ANN THORAC SURG, V98, P1705, DOI 10.1016/j.athoracsur.2014.06.017 Mahesh Balakrishnan, 2006, Asian Cardiovasc Thorac Ann, V14, P123 McKenna RJ, 2008, ANN THORAC SURG, V85, pS733, DOI 10.1016/j.athoracsur.2007.11.049 Muranishi Y, 2017, SURG TODAY, V47, P252, DOI 10.1007/s00595-016-1380-y Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Onaitis MW, 2018, ANN THORAC SURG, V105, P309, DOI 10.1016/j.athoracsur.2017.06.071 Riber LP, 2012, ANN THORAC SURG, V94, P339, DOI 10.1016/j.athoracsur.2011.12.096 Riber LP, 2014, ANN THORAC SURG, V98, P1989, DOI 10.1016/j.athoracsur.2014.06.069 Santillan-Doherty P, 2002, WORLD J SURG, V26, P43 Showkathali R, 2006, EMERG MED J, V23, P660, DOI 10.1136/emj.2005.033860 Sugarbaker DJ, 2004, J THORAC CARDIOV SUR, V128, P138, DOI 10.1016/j.jtcvs.2004.02.021 The Society of Thoracic Surgeons, 2018, GEN THOR SURG DAT TR, P45 Tisdale JE, 2009, ANN THORAC SURG, V88, P886, DOI 10.1016/j.athoracsur.2009.04.074 Tsutani Y, 2014, CHEST, V145, P66, DOI 10.1378/chest.13-1094 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Veloso HH, 2004, AM FAM PHYSICIAN, V70, P1448 NR 40 TC 4 Z9 5 U1 0 U2 3 PU AME PUBLISHING COMPANY PI SHATIN PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA SN 2072-1439 EI 2077-6624 J9 J THORAC DIS JI J. Thorac. Dis. PD JUN PY 2020 VL 12 IS 6 BP 3110 EP 3124 DI 10.21037/jtd-20-180 PG 15 WC Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System GA MJ7IP UT WOS:000548261200018 PM 32642233 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Wändell, P Carlsson, AC Li, XJ Sundquist, J Sundquist, K AF Wandell, Per Carlsson, Axel C. Li, Xinjun Sundquist, Jan Sundquist, Kristina TI Levothyroxine treatment is associated with an increased relative risk of overall and organ specific incident cancers - a cohort study of the Swedish population SO CANCER EPIDEMIOLOGY LA English DT Article DE Levothyroxine; Cancer; Gender; Epidemiology ID ATRIAL-FIBRILLATION; HYPOTHYROIDISM; REGISTER AB High thyroid hormone values have been associated with an increased risk of incident cancers, especially breast cancer but also lung cancer and any solid cancers. We explored whether there is an increased risk of overall and cause-specific cancers in those receiving levothyroxine treatment. We included all individuals >= 18 years in Sweden (N = 8,573,313) on January 1 2009, and identified patients with two or more dispensed prescriptions of levothyroxine 2005-2006 (n = 253,193, 3.0 %). A cancer diagnosis in the Swedish Cancer Register 2009-2015 was used as outcome. We excluded patients with a cancer diagnosis before 2005. Cox regression was used (hazard ratios, HRs, and 95 % confidence intervals, CI) with adjustments for age, socioeconomic/neighborhood factors and co-morbidities. Totally 399,751 cases of incident cancer were identified, with a slight increased overall risk associated with levothyroxine treatment for both men, adjusted HR 1.06 (95 % CI 1.03-1.10), and women, adjusted HR 1.08 (95 % CI 1.07-1.10). For men, increased risks were found for cancers of the thyroid gland and other endocrine glands. For women, increased risks were found for cancers of the breast, endometrium, other female genitals (ovaries not included), stomach, colon, liver, pancreas, urinary bladder, skin, leukemia, and unspecified primary tumor. Unlike men, for women, no increased risk was found for cancer of the thyroid gland. In conclusions, levothyroxine treatment was associated with an excess cancer risk, including many different types of cancer, especially among women. Our results need confirmation by other studies, but levothyroxine is recommended to be prescribed only on approved indications. C1 [Wandell, Per; Carlsson, Axel C.] Karolinska Inst, Dept Neurobiol, Div Family Med & Primary Care, Sweden Elect Address Perwandell Kise, Huddinge, Sweden. [Carlsson, Axel C.] Acad Primary Hlth Care Ctr, Stockholm, Stockholm Regio, Sweden. [Li, Xinjun; Sundquist, Jan; Sundquist, Kristina] Lund Univ, Ctr Primary Hlth Care Res, Malmo, Sweden. [Sundquist, Jan; Sundquist, Kristina] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, Dept Family Med & Community Hlth, New York, NY 10029 USA. [Sundquist, Jan; Sundquist, Kristina] Shimane Univ, Ctr Community Based Healthcare Res & Educ CoHRE, Sch Med, Dept Funct Pathol, Matsue, Shimane, Japan. C3 Karolinska Institutet; Lund University; Icahn School of Medicine at Mount Sinai; Shimane University RP Wändell, P (corresponding author), Karolinska Inst, NVS Dept, Div Family Med, Alfred Nobels Alle 23, S-14183 Huddinge, Sweden. EM per.wandell@ki.se RI ; Wändell, Per/H-6251-2011 OI Carlsson, Axel C/0000-0001-6113-0472; Wändell, Per/0000-0001-5169-2965 CR [Anonymous], 2017, CANC SCI RES OPEN AC, DOI 10.15226/csroa.2017.00136 Barlow L, 2009, ACTA ONCOL, V48, P27, DOI 10.1080/02841860802247664 Boursi B, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv084 Brandt J, 2016, BRIT J SURG, V103, P1649, DOI 10.1002/bjs.10284 Cabanillas ME, 2016, LANCET, V388, P2783, DOI 10.1016/S0140-6736(16)30172-6 De Sibio MT, 2014, WORLD J CLIN ONCOL, V5, P503, DOI 10.5306/wjco.v5.i3.503 Dong LB, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957-018-1436-0 Friedman GD, 2009, CANCER CAUSE CONTROL, V20, P1821, DOI 10.1007/s10552-009-9375-2 Hall LC, 2008, J STEROID BIOCHEM, V109, P57, DOI 10.1016/j.jsbmb.2007.12.008 Hsieh MT, 2017, ONCOTARGET, V8, P24237, DOI 10.18632/oncotarget.10757 Hung SH, 2018, J CLIN PHARMACOL, V58, P29, DOI 10.1002/jcph.972 Khan SR, 2016, J CLIN ENDOCR METAB, V101, P5030, DOI 10.1210/jc.2016-2104 KING DB, 1984, J EXP ZOOL, V232, P453, DOI 10.1002/jez.1402320311 Kollati Y, 2017, CURR PHARM DESIGN, V23, P2308, DOI 10.2174/1381612823666170206124255 Krashin E, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00059 Ludvigsson JF, 2016, EUR J EPIDEMIOL, V31, P125, DOI 10.1007/s10654-016-0117-y Masullo LF, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00655 Milano Anthony F, 2018, J Insur Med, V47, P143, DOI [10.17849/insm-47-03-143-158.1, 10.17849/insm-47-03-143-158.1] Ortega-Olvera C, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-1017-8 Rennert G, 2010, JNCI-J NATL CANCER I, V102, P568, DOI 10.1093/jnci/djq042 Shinderman-Maman E, 2016, ONCOGENE, V35, P1977, DOI 10.1038/onc.2015.262 Sogaard M, 2016, EUR J ENDOCRINOL, V174, P409, DOI 10.1530/EJE-15-0989 Takano T, 2017, ENDOCR J, V64, P237, DOI 10.1507/endocrj.EJ17-0026 Tosovic A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2587 Virta LJ, 2011, EUR J CLIN PHARMACOL, V67, P73, DOI 10.1007/s00228-010-0884-4 Wändell P, 2019, CLIN DRUG INVEST, V39, P187, DOI 10.1007/s40261-018-0740-3 Wändell P, 2017, AM J CARDIOL, V120, P1974, DOI 10.1016/j.amjcard.2017.08.013 Wändell P, 2013, FAM PRACT, V30, P506, DOI 10.1093/fampra/cmt033 Wettermark B, 2007, PHARMACOEPIDEM DR S, V16, P726, DOI 10.1002/pds.1294 Wu CC, 2018, ARCH GYNECOL OBSTET, V298, P389, DOI 10.1007/s00404-018-4837-y Zöller B, 2013, EUROPACE, V15, P1119, DOI 10.1093/europace/eut019 NR 31 TC 20 Z9 21 U1 0 U2 8 PU ELSEVIER SCI LTD PI London PA 125 London Wall, London, ENGLAND SN 1877-7821 EI 1877-783X J9 CANCER EPIDEMIOL JI Cancer Epidemiol. PD JUN PY 2020 VL 66 AR 101707 DI 10.1016/j.canep.2020.101707 PG 6 WC Oncology; Public, Environmental & Occupational Health WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Public, Environmental & Occupational Health GA LV0WI UT WOS:000538164000006 PM 32222650 DA 2026-04-17 ER PT J AU Fong, LS Ko, VT Mclaughlin, A Okiwelu, NL Newman, MA Passage, J Sanders, LHA Joshi, PV AF Fong, Laura S. Ko, Viktor Mclaughlin, Aden Okiwelu, Ngozichukwuka Louis Newman, Mark A. Passage, Jurgen Sanders, Lucas H. A. Joshi, Pragnesh V. TI Outcomes of video-assisted thoracoscopic surgery lobectomy in septuagenarians SO ANZ JOURNAL OF SURGERY LA English DT Article DE lobectomy; septuagenarian; video-assisted thoracoscopic surgery ID CELL LUNG-CANCER; THORACIC-SURGERY; VATS LOBECTOMY; THORACOTOMY; EXPERIENCE AB Background Spread of technology and increased surveillance have led to more patients with lung cancers being identified than ever before. Increasingly, patients from the elderly population are referred for surgery; however, many studies do not focus on this patient group. We reviewed the outcomes of septuagenarians who underwent lobectomy via an open thoracotomy (OT) or video-assisted thoracoscopic surgery (VATS) approach to determine whether the VATS approach would result in superior post-operative outcomes. Methods Between January 2010 and June 2016, a total of 96 patients aged 70 years or older underwent a lobectomy for non-small cell lung carcinoma. Patients who underwent resection for metastatic disease, small cell lung cancer or neuroendocrine tumour were excluded. Demographic details, early and late post-operative outcomes including post-operative arrhythmia, myocardial infarction, respiratory failure, cerebrovascular events, infection, prolonged air leak, delirium, readmission and 30-day mortality were studied. Mean follow-up duration was 23 +/- 19.1 months. Results Seventy-five patients underwent lobectomy via a VATS approach and 21 patients underwent lobectomy via an OT approach. There was no 30-day mortality and no difference in overall survival between the two techniques (P = 0.25). There was no significant difference between the two techniques with regard to post-operative stroke, myocardial infarction, atrial fibrillation, pneumonia, delirium or bronchopleural fistula. VATS patients had a significantly shorter mean hospital length of stay (VATS 4.7 days, OT 9.3 days, P = 0.005). Conclusion Septuagenarians with non-small cell lung carcinoma can successfully undergo curative lung resection with a low incidence of post-operative complications. C1 [Fong, Laura S.; Ko, Viktor; Mclaughlin, Aden; Okiwelu, Ngozichukwuka Louis; Newman, Mark A.; Passage, Jurgen; Sanders, Lucas H. A.; Joshi, Pragnesh V.] Sir Charles Gairdner Hosp, Dept Cardiothorac Surg, Hosp Ave, Perth, WA 6009, Australia. [Newman, Mark A.; Joshi, Pragnesh V.] Univ Western Australia, Sch Med, Perth, WA, Australia. [Passage, Jurgen; Joshi, Pragnesh V.] Univ Notre Dame, Sch Med, Fremantle, WA, Australia. [Passage, Jurgen; Joshi, Pragnesh V.] Baird Inst, Dept Cardiothorac Surg, Sydney, NSW, Australia. C3 University of Western Australia; Sir Charles Gairdner Hospital; University of Western Australia; The University of Notre Dame Australia; Baird Institute RP Fong, LS (corresponding author), Sir Charles Gairdner Hosp, Dept Cardiothorac Surg, Hosp Ave, Perth, WA 6009, Australia. EM laura.fong@health.nsw.gov.au OI Joshi, Pragnesh/0000-0003-0742-1134; Fong, Laura/0000-0002-3532-0835 CR Australian Bureau of Statistics, 2013, DEATHS AUSTR Becker R, 2006, B WORLD HEALTH ORGAN, V84, P297 Berry MF, 2009, ANN THORAC SURG, V88, P1093, DOI 10.1016/j.athoracsur.2009.06.012 BLADES B, 1940, J THORACIC SURG, V10, P84 Cattaneo SM, 2008, ANN THORAC SURG, V85, P231, DOI 10.1016/j.athoracsur.2007.07.080 Daniels LJ, 2002, ANN THORAC SURG, V74, P860, DOI 10.1016/S0003-4975(02)03764-5 Fanucchi O, 2011, INTERACT CARDIOV TH, V12, P749, DOI 10.1510/icvts.2010.259002 Flores RM, 2010, WORLD J SURG, V34, P616, DOI 10.1007/s00268-009-0340-8 Hino H, 2015, ANN THORAC CARDIOVAS, V21, P209, DOI 10.5761/atcs.oa.14-00160 Igai Hitoshi, 2009, Interact Cardiovasc Thorac Surg, V9, P274, DOI 10.1510/icvts.2008.199455 Iñiguez CEB, 2016, ANN THORAC SURG, V101, P541, DOI 10.1016/j.athoracsur.2015.08.067 Lee PC, 2016, ANN THORAC SURG, V101, P1116, DOI 10.1016/j.athoracsur.2015.09.073 McKenna RJ, 2006, ANN THORAC SURG, V81, P421, DOI 10.1016/j.athoracsur.2005.07.078 Medbery RL, 2016, J THORAC ONCOL, V11, P222, DOI 10.1016/j.jtho.2015.10.007 Nwogu CE, 2015, ANN THORAC SURG, V99, P399, DOI 10.1016/j.athoracsur.2014.09.018 Pagès PB, 2016, ANN THORAC SURG, V101, P1370, DOI 10.1016/j.athoracsur.2015.10.105 Port JL, 2011, ANN THORAC SURG, V92, P1951, DOI 10.1016/j.athoracsur.2011.06.082 Sui XZ, 2015, ANN THORAC CARDIOVAS, V21, P529, DOI 10.5761/atcs.oa.15-00126 NR 18 TC 7 Z9 7 U1 0 U2 1 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1445-1433 EI 1445-2197 J9 ANZ J SURG JI ANZ J. Surg. PD MAY PY 2020 VL 90 IS 5 BP 752 EP 756 DI 10.1111/ans.15788 EA APR 2020 PG 5 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA LO2HB UT WOS:000529242500001 PM 32348031 DA 2026-04-17 ER PT J AU Qu, RR Hao, ZP Zhang, Y Bie, L Fu, XN Zhang, N AF Qu, Rirong Hao, Zhipeng Zhang, Yang Bie, Lei Fu, Xiangning Zhang, Ni TI Single-center experience of simultaneous bilateral uni-portal video-assisted thoracoscopic surgery for multiple ground-glass opacities SO JOURNAL OF CARDIOTHORACIC SURGERY LA English DT Article DE Multiple ground-glass opacity (GGO); simultaneous; bilateral; video-assisted thoracoscopic surgery (VATS) ID LUNG-CANCER; NODULES HISTOPATHOLOGY; THORACIC-SURGERY; CT; MANAGEMENT; FEATURES; SOCIETY AB Background There is an increasing incidence rate of ground-glass opacity (GGO), especially for multiple GGOs (>= 2). Whether it is safe and feasible to have bilateral simultaneous surgical resection remains unknown. The purpose of this study is to summarize the experience of surgical resection of patients with multiple GGOs in our Hospital in recent years, and to discuss the above questions. Methods Clinical datas of patients who underwent one-stage bilateral uni-portal VATS resections of multiple pulmonary ground glass opacities and had routine pathological examination were collected from May 2016 to May 2019 in our hospital. Results A total of 34 patients underwent simultaneous bilateral surgical resection of multiple GGO lesions, 28 were women,6 were men, the average age of total patients was 57.9 +/- 6.7 years. All patients underwent bilateral uni-portal video-assisted thoracoscopic surgery (Uni-portal VATS), the average intraoperative blood loss was 100.9 +/- 67.7 ml, the average operation time was 140 +/- 74.8 min, the average thoracic drainage time was 2.8 +/- 3.1 days, and the average postoperative hospital stay was 4.2 +/- 4.3 days. Postoperative complications including: 2 cases of infection, 3 cases of atrial fibrillation, and 5 cases of persistent air leakage for more than 3 days. All of them improved after treatment, and there were no serious complications and deaths in perioperative period. A total of 76 GGO lesions were resected, with a total malignancy rate of 81.6%, including 40 were pure GGO, of which 28 were malignant (70%), and the average diameter of them were 9.6 +/- 3.8 mm; 36 were mixed GGO, of which 34 were malignant (94.4%), the average diameter of them were 15.6 +/- 6.6 mm.Mean postoperative follow-up was 28.4 (range, 3-39) months. There was neither recurrence nor deaths at final follow-up. Conclusion The malignancy rate of multiple GGOs is high. Therefore, when the lung function is allowed,one-stage bilateral uni-portal VATS can be considered. According to experience of main surgeon and the frozen biopsy, either sub-lobar resection or lobectomy was acceptable. The risk of postoperative complications and the prognosis were optimal. C1 [Qu, Rirong; Hao, Zhipeng; Bie, Lei; Fu, Xiangning; Zhang, Ni] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Thorac Surg, Jiefang St 1095, Wuhan 430030, Hubei, Peoples R China. [Zhang, Yang] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Obstet & Gynecol, Jiefang St 1095, Wuhan 430030, Huebei, Peoples R China. C3 Huazhong University of Science & Technology; Huazhong University of Science & Technology RP Zhang, N (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Thorac Surg, Jiefang St 1095, Wuhan 430030, Hubei, Peoples R China. EM zhangnidoc@163.com RI Qu, Rirong/JBR-8136-2023; HAO, Zhipeng/AAC-4170-2021 OI Qu, Rirong/0000-0002-3334-3304; CR Bak SH, 2016, CHEST, V149, P180, DOI 10.1378/chest.15-0034 Chang B, 2013, CHEST, V143, P172, DOI 10.1378/chest.11-2501 Chen KZ, 2018, J THORAC CARDIOV SUR, V155, P371, DOI 10.1016/j.jtcvs.2017.08.141 Church TR, 2013, NEW ENGL J MED, V368, P1980, DOI 10.1056/NEJMoa1209120 Dai L, 2016, J THORAC DIS, V8, P855, DOI 10.21037/jtd.2016.03.42 Detterbeck FC, 2016, J THORAC ONCOL, V11, P666, DOI 10.1016/j.jtho.2015.12.113 Hansell DM, 2008, RADIOLOGY, V246, P697, DOI 10.1148/radiol.2462070712 Iino K, 2002, KYOBU GEKA, V55, P448 Lee HY, 2014, AM J ROENTGENOL, V202, pW224, DOI 10.2214/AJR.13.11819 Lee HY, 2011, J THORAC IMAG, V26, P106, DOI 10.1097/RTI.0b013e3181fbaa64 Miller DL, 2002, ANN THORAC SURG, V73, P1545, DOI 10.1016/S0003-4975(02)03525-7 Moon Y, 2016, J THORAC DIS, V8, P1561, DOI 10.21037/jtd.2016.06.34 Naidich DP, 2013, RADIOLOGY, V266, P304, DOI 10.1148/radiol.12120628 Nakata M, 2004, ANN THORAC SURG, V78, P1194, DOI 10.1016/j.athoracsur.2004.03.102 Park CM, 2007, RADIOGRAPHICS, V27, P391, DOI 10.1148/rg.272065061 Shimada Y, 2015, LUNG CANCER, V88, P174, DOI 10.1016/j.lungcan.2015.02.016 Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221 Xu GQ, 2019, J THORAC DIS, V11, P535, DOI 10.21037/jtd.2019.01.10 Yao F, 2016, J THORAC DIS, V8, P469, DOI 10.21037/jtd.2016.02.66 Zhang YL, 2014, ANN SURG ONCOL, V21, P4369, DOI 10.1245/s10434-014-3840-1 Zhang YX, 2018, J THORAC DIS, V10, P6452, DOI 10.21037/jtd.2018.11.10 NR 21 TC 24 Z9 27 U1 0 U2 11 PU BMC PI LONDON PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND EI 1749-8090 J9 J CARDIOTHORAC SURG JI J. Cardiothorac. Surg. PD APR 23 PY 2020 VL 15 IS 1 AR 69 DI 10.1186/s13019-020-01107-0 PG 7 WC Cardiac & Cardiovascular Systems; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Surgery GA LJ1UI UT WOS:000529956800001 PM 32326944 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Dogru, MV Sezen, CB Aker, C Girgin, O Kilimci, U Erduhan, S Metin, M AF Dogru, Mustafa Vedat Sezen, Celal Bugra Aker, Cemal Girgin, Oguz Kilimci, Umut Erduhan, Semih Metin, Muzaffer TI Evaluation of factors affecting morbidity and mortality in pneumonectomy patients SO ACTA CHIRURGICA BELGICA LA English DT Article DE Pneumonectomy; mortality; morbidity; non-small cell lung cancer ID CELL LUNG-CANCER; MAJOR COMPLICATIONS; RISK-FACTORS; CARCINOMA; RESECTION; OUTCOMES; THERAPY; IMPACT AB Background: The aim of this study was to evaluate risk factors associated with morbidity and mortality after pneumonectomy in non-small cell lung cancer patients. Methods: The study included 107 patients who underwent pneumonectomy for non-small cell lung cancer between January 2013 and December 2018. Prognostic factors affecting mortality and morbidity were investigated. Results: The patient group included 10 women (9.3%) and 97 men (90.7%) with a mean age of 59.5 +/- 8.5 years. Seventy-three patients (68.2%) underwent standard pneumonectomy and 34 (31.8%) underwent extended pneumonectomy. Nine patients (8.4%) received induction chemotherapy. Complications occurred in 33 patients (30.8%). Complications were classified as surgical, cardiovascular, pulmonary, or infectious. Charlson Comorbidity Index (CCI) > 3 and right-side resection were significant risk factors for the development of complications. The most common complication was atrial fibrillation. Eleven patients developed a bronchopleural fistula. The 30-day postoperative mortality rate was 6.5% (n = 7). Mortality was not associated with any demographic and surgical characteristics other than CCI > 3 (p = .05). Conclusion: The results of this study indicate that our pneumonectomy outcomes are acceptable despite high morbidity and mortality rates. Appropriate patient selection for pneumonectomy is as important as complication management. High-comorbidity patients should undergo these procedures in experienced centers. C1 [Dogru, Mustafa Vedat; Sezen, Celal Bugra; Aker, Cemal; Girgin, Oguz; Kilimci, Umut; Erduhan, Semih; Metin, Muzaffer] Yedikule Chest Dis & Thorac Surg Training & Res H, Dept Thorac Surg, Istanbul, Turkey. C3 Istanbul Yedikule Chest Diseases & Thoracic Surgery Training & Research Hospital RP Dogru, MV (corresponding author), Yedikule Chest Dis & Thorac Surg Training & Res H, Kazlicesme Mh,Belgrade Kapi Yolu Cad 1, TR-34020 Zeytinburnu Istanbul, Turkey. EM drmvedatdogru@gmail.com RI Sezen, Celal Bugra/A-5198-2019; Dogru, Mustafa Vedat/HHN-7613-2022; Aker, Cemal/AAG-6842-2021; erduhan, semih/AAP-5706-2021; Kilimci, Umut/OMM-8811-2025 OI Sezen, Celal Bugra/0000-0002-2461-2031; Dogru, Mustafa Vedat/0000-0002-2722-3058; Aker, Cemal/0000-0003-1269-7442; erduhan, semih/0000-0002-8799-476X; CR Akin H, 2011, TURK GOGUS KALP DAMA, V19, P391, DOI 10.5606/tgkdc.dergisi.2011.050 Alexiou C, 2001, EUR J CARDIO-THORAC, V20, P476, DOI 10.1016/S1010-7940(01)00823-5 Algar FJ, 2003, EUR J CARDIO-THORAC, V23, P201, DOI 10.1016/S1010-7940(02)00719-4 Alloubi I, 2010, INTERACT CARDIOV TH, V11, P162, DOI 10.1510/icvts.2010.232595 Bernard A, 2001, J THORAC CARDIOV SUR, V121, P1076, DOI 10.1067/mtc.2001.114350 CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8 Darling GE, 2005, ANN THORAC SURG, V79, P433, DOI 10.1016/j.athoracsur.2004.07.009 Evans NR, 2010, J THORAC CARDIOV SUR, V139, P991, DOI 10.1016/j.jtcvs.2009.11.070 Fernandez FG, 2011, ANN THORAC SURG, V92, P244, DOI 10.1016/j.athoracsur.2011.03.021 Galetta D, 2018, ANN THORAC SURG, V105, P1017, DOI 10.1016/j.athoracsur.2017.11.052 Gudbjartsson T, 2008, ANN THORAC SURG, V86, P376, DOI 10.1016/j.athoracsur.2008.04.013 Kalathiya RJ, 2012, SOUTH MED J, V105, P350, DOI 10.1097/SMJ.0b013e31825bc299 Kim AW, 2012, J THORAC CARDIOV SUR, V143, P55, DOI 10.1016/j.jtcvs.2011.09.002 Licker M, 2002, CHEST, V121, P1890, DOI 10.1378/chest.121.6.1890 Mansour Z, 2009, ANN THORAC SURG, V88, P1737, DOI 10.1016/j.athoracsur.2009.07.016 Marret E, 2010, INTERACT CARDIOV TH, V10, P936, DOI 10.1510/icvts.2009.231621 PATEL RL, 1992, ANN THORAC SURG, V54, P84, DOI 10.1016/0003-4975(92)91145-Y Powell ES, 2009, J CARDIOTHORAC SURG, V4, DOI 10.1186/1749-8090-4-41 Powell HA, 2013, THORAX, V68, P826, DOI 10.1136/thoraxjnl-2012-203123 Pricopi C, 2015, INTERACT CARDIOV TH, V20, P316, DOI 10.1093/icvts/ivu417 Ramnath N, 2007, ANN THORAC SURG, V83, P1831, DOI 10.1016/j.athoracsur.2006.12.036 Rostad H, 2006, EUR J CARDIO-THORAC, V29, P824, DOI 10.1016/j.ejcts.2006.01.055 Rusch VW, 2009, J THORAC ONCOL, V4, P568, DOI 10.1097/JTO.0b013e3181a0d82e Sezen CB, 2019, ACTA CHIR BELG, V119, P303, DOI 10.1080/00015458.2018.1527567 Sugarbaker DJ, 2004, J THORAC CARDIOV SUR, V128, P138, DOI 10.1016/j.jtcvs.2004.02.021 Yazgan S., 2018, CURR THORAC SURG, V4, P102 NR 26 TC 12 Z9 14 U1 0 U2 3 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 0001-5458 EI 2577-0160 J9 ACTA CHIR BELG JI Acta Chir. Belg. PD SEP 3 PY 2021 VL 121 IS 5 BP 301 EP 307 DI 10.1080/00015458.2020.1753147 EA APR 2020 PG 7 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA UW7RH UT WOS:000527321600001 PM 32254000 DA 2026-04-17 ER PT J AU Ohsawa, M Tsutani, Y Fujiwara, M Mimae, T Miyata, Y Okada, M AF Ohsawa, Manato Tsutani, Yasuhiro Fujiwara, Makoto Mimae, Takahiro Miyata, Yoshihiro Okada, Morihito TI Predicting Severe Postoperative Complication in Patients With Lung Cancer and Interstitial Pneumonia SO ANNALS OF THORACIC SURGERY LA English DT Article ID DIFFUSING-CAPACITY; PULMONARY RESECTION; ATRIAL-FIBRILLATION; ACUTE EXACERBATION; DISEASE; RISK; IMPACT; CHEMOTHERAPY; MORBIDITY; MORTALITY AB Background. Interstitial pneumonia is linked to lung cancer, and treatment can cause acute exacerbation. We aimed to identify predictors of severe postoperative complications in patients with lung cancer and interstitial pneumonia. Methods. Between April 2007 and April 2017, 199 patients were diagnosed with primary lung cancer and interstitial pneumonia using high-resolution computed tomography. Multivariable logistic regression analyses were performed to identify independent predictors of severe complications (Clavien-Dindo grade IIIa or higher). Results. Multivariable analyses revealed that severe complications were independently predicted by the percent diffusing capacity of the lungs for carbon monoxide (%DLco [odds ratio 0.88; 95% confidence interval, 0.82 to 0.95; P < .001]) and surgical procedures (lobectomy, odds ratio 4.49; 95% confidence interval, 1.86 to 23.32; P = .045). Severe complications occurred in 39.2% of patients with low %DLco (less than 40%) and in 4.2% of patients with high %DLco (greater than 40%). The rates of severe complications were 11.5% for patients who underwent lobectomy and 9.7% for patients who underwent sublobar resection. For patients with low %DLco, the rates of severe complications were 85.7% for those undergoing lobectomy and 23.8% for those undergoing sublobar resection (P = .009). Overall survival (OS) was significantly different between patients with low %DLco (5-year OS 33.5%) and patients with high %DLco (5-year OS 65.3%; P = .001). Among patients with low %DLco, there was a significant difference in OS between patients who underwent lobectomy (5-year OS 0%) and those who underwent sublobar resection (5-year OS 49.6%; P = .029). Conclusions. Severe postoperative complications were predicted by %DLco and surgery type. Sublobar resection might be a better option for patients with low %DLco values (less than 40%). (C) 2020 by The Society of Thoracic Surgeons C1 [Ohsawa, Manato; Tsutani, Yasuhiro; Fujiwara, Makoto; Mimae, Takahiro; Miyata, Yoshihiro; Okada, Morihito] Hiroshima Univ, Dept Surg Oncol, Hiroshima, Hiroshima, Japan. C3 Hiroshima University RP Okada, M (corresponding author), Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Surg Oncol, Minami Ku, 1-2-3 Kasumi, Hiroshima, Hiroshima 7340037, Japan. EM morihito@hiroshima-u.ac.jp RI Mimae, Takahiro/AAA-9416-2021; Tsutani, Yasuhiro/AAD-3835-2022 CR Brunelli A, 2017, ANN THORAC SURG, V104, P1020, DOI 10.1016/j.athoracsur.2017.02.083 Cerfolio RJ, 2002, ANN THORAC SURG, V73, P1727, DOI 10.1016/S0003-4975(02)03531-2 Chen HB, 2017, INT J RADIAT ONCOL, V98, P622, DOI 10.1016/j.ijrobp.2017.03.010 Chiyo M, 2003, J THORAC CARDIOV SUR, V126, P1141, DOI 10.1016/S0022-5223(03)00791-8 Ferguson MK, 2008, ANN THORAC SURG, V85, P1158, DOI 10.1016/j.athoracsur.2007.12.071 Ferguson MK, 2012, EUR J CARDIO-THORAC, V41, pe81, DOI 10.1093/ejcts/ezs049 Ferguson MK, 2009, J THORAC CARDIOV SUR, V138, P1297, DOI 10.1016/j.jtcvs.2009.05.045 Katayama H, 2016, SURG TODAY, V46, P668, DOI 10.1007/s00595-015-1236-x Kenmotsu H, 2015, CANCER CHEMOTH PHARM, V75, P521, DOI 10.1007/s00280-014-2670-y Kenmotsu H, 2011, J THORAC ONCOL, V6, P1242, DOI 10.1097/JTO.0b013e318216ee6b Koizumi Kiyoshi, 2004, Ann Thorac Cardiovasc Surg, V10, P340 KROWKA MJ, 1987, CHEST, V91, P490, DOI 10.1378/chest.91.4.490 Kumar P, 2003, J THORAC CARDIOV SUR, V125, P1321, DOI 10.1016/S0022-5223(03)00028-X Liptay MJ, 2009, J SURG ONCOL, V100, P703, DOI 10.1002/jso.21407 Nadrous HF, 2005, CHEST, V128, P2393, DOI 10.1378/chest.128.4.2393 Okada M, 2005, CHEST, V128, P2696, DOI 10.1378/chest.128.4.2696 Ozeki N, 2017, EUR J CARDIO-THORAC, V52, P969, DOI 10.1093/ejcts/ezx124 Park J, 2001, EUR RESPIR J, V17, P1216, DOI 10.1183/09031936.01.99055301 Raghu G, 2004, BRIT J CANCER, V91, pS3, DOI 10.1038/sj.bjc.6602061 Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Sato T, 2015, GEN THORAC CARDIOVAS, V63, P164, DOI 10.1007/s11748-014-0487-6 Sato T, 2014, J THORAC CARDIOV SUR, V147, P1604, DOI 10.1016/j.jtcvs.2013.09.050 Tsutani Y, 2017, J THORAC CARDIOV SUR, V154, P1089, DOI 10.1016/j.jtcvs.2017.03.116 Ueki N, 2015, J THORAC ONCOL, V10, P116, DOI 10.1097/JTO.0000000000000359 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Watanabe A, 2011, PULM MED, V2011, DOI 10.1155/2011/960316 Yasuda Y, 2018, JPN J CLIN ONCOL, V48, P89, DOI 10.1093/jjco/hyx142 Zhang RY, 2015, ANN THORAC SURG, V99, P1761, DOI 10.1016/j.athoracsur.2015.01.030 NR 29 TC 31 Z9 32 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD APR PY 2020 VL 109 IS 4 BP 1054 EP 1060 DI 10.1016/j.athoracsur.2019.11.012 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA KW1II UT WOS:000520924700034 PM 31887276 DA 2026-04-17 ER PT J AU Wu, CN Wu, XH Yu, DN Ma, WH Shen, CH Cao, Y AF Wu, Cai-Neng Wu, Xin-Hai Yu, Dong-Nan Ma, Wu-Hua Shen, Chun-Hui Cao, Ying TI A single-dose of stellate ganglion block for the prevention of postoperative dysrhythmias in patients undergoing thoracoscopic surgery for cancer A randomised controlled double-blind trial SO EUROPEAN JOURNAL OF ANAESTHESIOLOGY LA English DT Article ID AUTONOMIC NERVOUS-SYSTEM; ATRIAL-FIBRILLATION; SLEEP DISTURBANCES; THORACIC-SURGERY; HOT FLASHES; ARRHYTHMIAS; PAIN; DEPRIVATION; TACHYCARDIA; MECHANISMS AB BACKGROUND New-onset arrhythmias and sleep disturbances are frequently observed during the postoperative period in patients undergoing thoracic surgery. OBJECTIVE We evaluated the effectiveness of a single-dose stellate ganglion block (SGB) to prevent the occurrence of arrhythmias in patients undergoing thoracic surgery for cancer. DESIGN Randomised controlled double-blind study. SETTING Single university hospital. PATIENTS Ninety patients with lung cancer or oesophagal cancer scheduled for elective video-assisted thoracoscopic surgery were randomly randomised into one of two equal groups (the SGB group and control group, n = 40 each). INTERVENTIONS Patients received a single dose of 5 ml of 0.5% ropivacaine during ultrasound-guided SGB before induction of general anaesthesia in the SGB group. MAIN OUTCOME MEASURES Holter ECG was continuously monitored during the first 48 postoperative hours, and sleep state was monitored during the first two postoperative nights. RESULTS The incidences of postoperative supraventricular tachycardias were lower in the SGB group compared with the control group during the first 48 postoperative hours; 11.6 (5/43) vs. 31.8% (14/44), respectively, P = 0.023 (odds ratio 0.28, 95% confidence interval 0.09 to 0.87). The SGB also prolonged the total sleep time and increased the sleep efficiency during the first two postoperative nights. The duration of stage N2 sleep was longer in the SGB group compared with the control group [28 (interquartile range, 14 to 58) to 94 (interquartile range, 69 to 113) min, P = 0.016] on the first postoperative night. There were no differences in the duration of stage N1 and N3 sleep (P = 0.180, 0.086, respectively) on the first postoperative night, and the duration of stage N1, N2 and N3 sleep (P = 0.194, 0.057, 0.405, respectively) on the second postoperative night between the groups. CONCLUSION A pre-operative SGB effectively prevented the occurrence of postoperative supraventricular tachycardias and improves the objective sleep quality in patients undergoing thoracic surgery for cancer. C1 [Wu, Cai-Neng; Ma, Wu-Hua] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Anaesthesiol, Guangzhou, Guangdong, Peoples R China. Peking Univ, Shenzhen Hosp, Dept Anesthesiol, Shenzhen, Guangdong, Peoples R China. [Yu, Dong-Nan] Guangdong Prov Peoples Hosp, Dept Anesthesiol, Guangzhou, Guangdong, Peoples R China. [Shen, Chun-Hui] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Thorac Surg, Guangzhou, Guangdong, Peoples R China. [Cao, Ying] Southern Med Univ, Dept Cardiovasc Pharmacol, Sch Pharmacol Sci, Guangzhou, Guangdong, Peoples R China. C3 Guangzhou University of Chinese Medicine; Peking University; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Guangzhou University of Chinese Medicine; Southern Medical University - China RP Cao, Y (corresponding author), Southern Med Univ, Dept Cardiovasc Pharmacol, Sch Pharmacol Sci, Guangzhou, Guangdong, Peoples R China. EM yingcao1986@163.com RI shen, chunhui/H-4558-2013 CR Ahn HJ, 2005, EUR J CARDIO-THORAC, V28, P19, DOI 10.1016/j.ejcts.2005.01.017 Al-Atassi T, 2014, CAN J CARDIOL, V30, P1202, DOI 10.1016/j.cjca.2014.04.018 Amar D, 2003, J AM COLL CARDIOL, V42, P1262, DOI 10.1016/S0735-1097(03)00955-0 [Anonymous], 2000, CRIT CARE MED S Bayliff CD, 1999, ANN THORAC SURG, V67, P182, DOI 10.1016/S0003-4975(98)01226-0 Brathwaite D, 1998, CHEST, V114, P462, DOI 10.1378/chest.114.2.462 de Oliveira RM, 2012, REV BRAS ANESTESIOL, V62, P10, DOI 10.1016/S0034-7094(12)70098-3 de Zambotti M, 2018, NEUROSCI BIOBEHAV R, V90, P84, DOI 10.1016/j.neubiorev.2018.03.027 Egawa H, 2001, REGION ANESTH PAIN M, V26, P539, DOI 10.1053/rapm.2001.25935 Frendl G, 2014, J THORAC CARDIOV SUR, V148, P772, DOI 10.1016/j.jtcvs.2014.06.037 Fudim M, 2017, J CARDIOVASC ELECTR, V28, P1460, DOI 10.1111/jce.13324 Giambrone GP, 2016, J THORAC CARDIOV SUR, V151, P982, DOI 10.1016/j.jtcvs.2015.11.057 Goel V, 2019, REG ANESTH PAIN MED Haest K, 2012, ANN ONCOL, V23, P1449, DOI 10.1093/annonc/mdr478 Hayase J, 2013, J CARDIOVASC ELECTR, V24, P926, DOI 10.1111/jce.12138 Huang LL, 2019, J THORAC DIS, V11, P1243, DOI 10.21037/jtd.2019.03.104 Kaya FN, 2006, J CARDIOTHOR VASC AN, V20, P639, DOI 10.1053/j.jvca.2006.03.022 Lapar DJ, 2014, ANN THORAC SURG, V98, P527, DOI 10.1016/j.athoracsur.2014.03.039 Leftheriotis D, 2016, HEART RHYTHM, V13, P2111, DOI 10.1016/j.hrthm.2016.06.025 Lin SL, 2013, J CLIN NURS, V22, P1281, DOI 10.1111/jocn.12228 Olshansky B, 2005, PROG CARDIOVASC DIS, V48, P57, DOI 10.1016/j.pcad.2005.06.004 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Park BJ, 2007, J THORAC CARDIOV SUR, V133, P775, DOI 10.1016/j.jtcvs.2006.09.022 Pennathur A, 2008, ANN THORAC SURG, V85, pS751, DOI 10.1016/j.athoracsur.2007.11.078 Rahimzadeh P, 2018, CANCER MANAG RES, V10, P4831, DOI 10.2147/CMAR.S173511 Rosenberg J, 2001, SLEEP MED REV, V5, P129, DOI 10.1053/smrv.2000.0121 Saran T, 2011, BRIT J ANAESTH, V106, P785, DOI 10.1093/bja/aer096 Schwaiblmair M, 2010, CLIN RES CARDIOL, V99, P693, DOI 10.1007/s00392-010-0181-3 Tan AY, 2008, CIRCULATION, V118, P916, DOI 10.1161/CIRCULATIONAHA.108.776203 Tobaldini E, 2014, ARCH ITAL BIOL, V152, P103, DOI 10.12871/000298292014235 Tobaldini E, 2017, NEUROSCI BIOBEHAV R, V74, P321, DOI 10.1016/j.neubiorev.2016.07.004 VANMIEGHEM W, 1994, CHEST, V105, P1642, DOI 10.1378/chest.105.6.1642 Witt CM, 2017, EUROPACE, V19, P1075, DOI 10.1093/europace/eux011 Wu CN, 2018, EUR J ANAESTH, V35, P792, DOI 10.1097/EJA.0000000000000837 NR 34 TC 26 Z9 33 U1 0 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0265-0215 EI 1365-2346 J9 EUR J ANAESTH JI Eur. J. Anaesth. PD APR PY 2020 VL 37 IS 4 BP 323 EP 331 DI 10.1097/EJA.0000000000001137 PG 9 WC Anesthesiology WE Science Citation Index Expanded (SCI-EXPANDED) SC Anesthesiology GA LE0FM UT WOS:000526400400010 PM 31860606 DA 2026-04-17 ER PT J AU Liu, F Hidru, TH Gao, RY Lin, YJ Liu, Y Fang, FQ Liu, JW Li, HH Yang, XL Xia, YL AF Liu, Fei Hidru, Tesfaldet H. Gao, Ruiyuan Lin, Yajuan Liu, Ying Fang, Fengqi Liu, Jiwei Li, Huihua Yang, Xiaolei Xia, Yunlong TI Cancer patients with potential eligibility for vascular endothelial growth factor antagonists use have an increased risk for cardiovascular diseases comorbidities SO JOURNAL OF HYPERTENSION LA English DT Article DE cancer; cardiovascular diseases; hypertension; vascular endothelial growth factor inhibitors ID RENAL-CELL CARCINOMA; BLOOD-PRESSURE; METABOLIC SYNDROME; COLORECTAL-CANCER; HYPERTENSION; MANAGEMENT AB Background: Recent studies have reported the prevalence of cardiovascular diseases (CVDs) among cancer patients following the use of the vascular endothelial growth factor (VEGF) signaling inhibitors. However, data for patients with a history of cancer before active cancer treatment are lacking. This study aims to investigate the distribution of CVD-related comorbidities before cancer treatment in potential VEGF antagonists candidates. Methods: A total of 22 500 newly diagnosed cancer patients registered from 1 January 2011 to 31 December 2017 were included. Cancer patients with colorectal cancer (CRC), renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC), and lung cancer were selected. Results: Hypertension (HTN), coronary heart diseases, atrial fibrillation, and heart failure were top CVD comorbidities among studied cancers. HTN was the most prevalent CVD (26.0%). The prevalence of HTN in RCC, CRC (33.5 and 29.4% respectively) was significantly higher than that in HCC, lung cancer, and thyroid cancer patients (25.1, 24.5, and 23.1%, respectively). Among cancer patients with HTN, the majority of cancer patients fall in grade III (75.7%) and very high cardiovascular risk level (85.4%). Out of the 5847 HTN patients, 26% were not in antihypertensive use, and 34.2% failed to achieve the target blood pressure. Conclusion: Cancer patients carry a high burden of CVD-related comorbidities before the application of VEGF antagonists. HTN is the most prevalent comorbid condition, and cancer patients with HTN constitute substantial cardiovascular risks and a higher co-prevalence of other CVDs. C1 [Liu, Fei; Hidru, Tesfaldet H.; Gao, Ruiyuan; Lin, Yajuan; Liu, Ying; Fang, Fengqi; Liu, Jiwei; Li, Huihua; Yang, Xiaolei; Xia, Yunlong] Dalian Med Univ, Dept Cardiol, Affiliated Hosp 1, Dalian 116011, Liaoning, Peoples R China. C3 Dalian Medical University RP Xia, YL (corresponding author), Dalian Med Univ, Dept Cardiol, Affiliated Hosp 1, Dalian 116011, Liaoning, Peoples R China. EM yunlong_xia@126.com RI liu, ying/NZO-4417-2025 OI liu, ying/0000-0001-9385-992X FU Liaoning Clinical Capacity Construction Funding [LNCCC-D20-2015] FX This study was supported by grants from Liaoning Clinical Capacity Construction Funding (LNCCC-D20-2015). CR Barata PC, 2017, CA-CANCER J CLIN, V67, P507, DOI 10.3322/caac.21411 Bhatt DL, 2006, JAMA-J AM MED ASSOC, V295, P180, DOI 10.1001/jama.295.2.180 Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408 Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7 Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486 Faruque LI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101145 Herrmann J, 2014, MAYO CLIN PROC, V89, P1287, DOI 10.1016/j.mayocp.2014.05.013 Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403 Kaelin WG Jr, 2003, J AM SOC NEPHROL, V14, P2703, DOI 10.1097/01.ASN.0000092803.69761.41 Kim J, 2019, CRIT CARE MED, V47, pE386, DOI 10.1097/CCM.0000000000003654 Klag MJ, 1996, NEW ENGL J MED, V334, P13, DOI 10.1056/NEJM199601043340103 Koene RJ, 2016, CIRCULATION, V133, P1104, DOI 10.1161/CIRCULATIONAHA.115.020406 Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857 Maitland ML, 2010, JNCI-J NATL CANCER I, V102, P596, DOI 10.1093/jnci/djq091 Mancia G, 2005, HYPERTENSION, V45, P1072, DOI 10.1161/01.HYP.0000165672.69176.ed Manzo A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102021 Pearson TA, 2013, CIRCULATION, V127, P1730, DOI 10.1161/CIR.0b013e31828f8a94 Pelucchi C, 2010, EUR J CANCER, V46, P1866, DOI 10.1016/j.ejca.2010.03.010 Radisauskas R, 2016, MEDICINA-LITHUANIA, V52, P89, DOI 10.1016/j.medici.2016.03.002 Schmidinger Manuela, 2013, EJC Suppl, V11, P172, DOI 10.1016/j.ejcsup.2013.07.016 Stocks T, 2011, CANCER-AM CANCER SOC, V117, P2398, DOI 10.1002/cncr.25772 Wang ZW, 2018, CIRCULATION, V137, P2344, DOI 10.1161/CIRCULATIONAHA.117.032380 Weikert S, 2008, AM J EPIDEMIOL, V167, P438, DOI 10.1093/aje/kwm321 Wells SA, 2012, J CLIN ONCOL, V30, P134, DOI 10.1200/JCO.2011.35.5040 Williams B, 2018, EUR HEART J, V39, P3021, DOI [10.1093/eurheartj/ehy339, 10.1016/j.im.2025.104135] Wulkersdorfer B, 2016, CLIN PHARMACOKINET, V55, P47, DOI 10.1007/s40262-015-0302-2 2019, J GERIATR CARDIOL, V16, P182 NR 27 TC 17 Z9 20 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0263-6352 EI 1473-5598 J9 J HYPERTENS JI J. Hypertens. PD MAR PY 2020 VL 38 IS 3 BP 426 EP 433 DI 10.1097/HJH.0000000000002277 PG 8 WC Peripheral Vascular Disease WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA LB3WY UT WOS:000524568900010 PM 31584518 OA Green Published, hybrid DA 2026-04-17 ER PT J AU Polaczek, M Szaro, P Jakubowska, L Zych, J Religioni, J Orlowski, TM AF Polaczek, Mateusz Szaro, Pawel Jakubowska, Lilia Zych, Jacek Religioni, Jaroslaw Orlowski, Tadeusz M. TI Pulmonary veins variations with potential impact in thoracic surgery: a computed-tomography-based atlas SO JOURNAL OF THORACIC DISEASE LA English DT Article DE Pulmonary veins (PVs); anatomy; computed tomography (CT); vascular complications ID ATRIAL-FIBRILLATION; LUNG-CANCER; ANATOMY; PATIENT; SEGMENTECTOMY; ANGIOGRAPHY; RESECTIONS; DRAINAGE AB Background: Pulmonary veins (PVs) are important during segmentectomy. Many case reports prove that they may be the source of bleeding during surgery, especially when anatomical variants are present. We decided to describe venous variations and prepare a computed tomography based atlas of our observations. Methods: The study was conducted using 135 chest computed tomography studies with intra venous iodine contrast injection. The study population contained 86 females and 49 males, mean age was 60. Thirteen people had atrial fibrillation. Images were analysed using radiological workstation. Results: The variations were divided into three categories: atypical topography of the PV, atypical venous outflow to the left atrium (LA), atypical venous vascularization of the lung bronchopulmonary segment. Retrobronchial course of the vein of the posterior segment of the right upper lobe was observed in 8.15%. The most common variant of atrial venous outflow was the direct outflow of the middle lobe vein, observed in 25.19% of cases and the long common trunk of left PVs in 11.11%. The split drainage from the middle lobe into the right superior pulmonary vein (RSPV) and the right inferior pulmonary vein (RIPV) was observed in 9.63% as the full drainage into the RIPV in 2.96%. Conclusions: Long common trunk of left PVs and numerous variants of venous vascularisation of the middle lobe are the variations that may pose potential problems during thoracic surgeries. The frequency is high enough to justify the routine assessment of pulmonary vessels with computed tomography before surgery. C1 [Polaczek, Mateusz; Szaro, Pawel] Med Univ Warsaw, Dept Descript & Clin Anat, Warsaw, Poland. [Polaczek, Mateusz; Zych, Jacek] Natl TB & Lung Dis Res Inst, Dept Lung Dis & Oncol 3, Warsaw, Poland. [Szaro, Pawel] Sahlgrenska Univ Gothenburg, Dept Radiol, Gothenburg, Sweden. [Jakubowska, Lilia] Natl TB & Lung Dis Res Inst, Dept Radiol, Warsaw, Poland. [Religioni, Jaroslaw; Orlowski, Tadeusz M.] Natl TB & Lung Dis Res Inst, Dept Surg, Warsaw, Poland. C3 Medical University of Warsaw RP Polaczek, M (corresponding author), Natl TB & Lung Dis Res Inst, Dept Lung Dis 3, Plocka 26 St, PL-01138 Warsaw, Poland. EM polaczek@me.com RI Szaro, Pawel/ABG-2207-2020 OI Szaro, Pawel/0000-0002-0334-7232 CR Akiba T, 2011, ANN THORAC CARDIOVAS, V17, P501, DOI 10.5761/atcs.cr.10.01595 Akiba T, 2011, GEN THORAC CARDIOVAS, V59, P376, DOI 10.1007/s11748-010-0675-y Akiba T, 2010, GEN THORAC CARDIOVAS, V58, P331, DOI 10.1007/s11748-010-0592-0 Akiba T, 2008, GEN THORAC CARDIOVAS, V56, P413, DOI 10.1007/s11748-008-0258-3 Akiba T, 2009, SURG TODAY, V39, P844, DOI 10.1007/s00595-009-3965-1 Arslan G, 2008, EUR J RADIOL, V67, P300, DOI 10.1016/j.ejrad.2007.07.005 Decaluwe H, 2015, EUR J CARDIO-THORAC, V48, P588, DOI 10.1093/ejcts/ezv287 Gonzalez-Rivas D, 2016, THORAC SURG CLIN, V26, P187, DOI 10.1016/j.thorsurg.2015.12.007 Iwano S, 2013, LUNG CANCER, V81, P410, DOI 10.1016/j.lungcan.2013.06.001 Kaseno K, 2008, AM J CARDIOL, V101, P1638, DOI 10.1016/j.amjcard.2008.01.053 Kato R, 2003, CIRCULATION, V107, P2004, DOI 10.1161/01.CIR.0000061951.81767.4E Maciejewski R., 1995, ATLAS BRONCHO VASCUL Marom EM, 2004, RADIOLOGY, V230, P824, DOI 10.1148/radiol.2303030315 Matsubara T, 2003, ANN THORAC SURG, V75, P1026, DOI 10.1016/S0003-4975(02)03980-2 Nakamura T, 2009, ANN THORAC SURG, V87, P954, DOI 10.1016/j.athoracsur.2008.07.054 Nattel S, 2002, NATURE, V415, P219, DOI 10.1038/415219a Oizumi H, 2014, ANN CARDIOTHORAC SUR, V3, P170, DOI 10.3978/j.issn.2225-319X.2014.02.03 Pearson FG, 2002, THORACIC SURG, P981 Polaczek M, 2019, SURG RADIOL ANAT, V41, P721, DOI 10.1007/s00276-019-02210-1 Polaczek M, 2013, KARDIOCHIR TORAKOCHI, V10, P232, DOI 10.5114/kitp.2013.38098 Schwartzman D, 2003, J AM COLL CARDIOL, V41, P1349, DOI 10.1016/S0735-1097(03)00124-4 Sohns C, 2013, EUROPACE, V15, P1136, DOI 10.1093/europace/eut059 Sugimoto S, 1998, ANN THORAC SURG, V66, P1799, DOI 10.1016/S0003-4975(98)00999-0 Swanson SJ, 2010, SEMIN THORAC CARDIOV, V22, P244, DOI 10.1053/j.semtcvs.2010.10.014 Villa M, 2015, THORAC SURG CLIN, V25, P261, DOI 10.1016/j.thorsurg.2015.04.001 Wannasopha Y, 2012, BIOMED IMAGING INTER, V8, P4 Yamada S, 2010, INTERACT CARDIOV TH, V10, P851, DOI 10.1510/icvts.2009.221804 Yazar F, 2002, EUR J CARDIO-THORAC, V22, P717, DOI 10.1016/S1010-7940(02)00531-6 NR 28 TC 9 Z9 14 U1 0 U2 1 PU AME PUBLISHING COMPANY PI SHATIN PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA SN 2072-1439 EI 2077-6624 J9 J THORAC DIS JI J. Thorac. Dis. PD MAR PY 2020 VL 12 IS 3 BP 383 EP + DI 10.21037/jtd.2020.01.34 PG 19 WC Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System GA KX2UJ UT WOS:000521736500033 PM 32274104 OA Green Submitted, gold DA 2026-04-17 ER PT J AU White, A Kucukak, S Lee, DN Bueno, R Jaklitsch, M Mentzer, S Sugarbaker, D Wee, J Swanson, SJ AF White, Abby Kucukak, Suden Lee, Daniel N. Bueno, Raphael Jaklitsch, Michael Mentzer, Steven Sugarbaker, David Wee, Jon Swanson, Scott J. TI Completion pneumonectomy is safe and effective in select patients with recurrent non-small cell lung cancer SO JOURNAL OF THORACIC DISEASE LA English DT Article DE Lung cancer; surgical technique; perioperative complications ID SURGERY; SURVIVAL AB Background: Locoregional recurrence rates for non-small cell lung cancer (NSCLC) remain high, even following curative surgical resection. While national guidelines advocate surgical resection for locoregional recurrence, it is rarely offered when resection would require completion pneumonectomy, which available literature associates with a 12-36% perioperative mortality and 40-80% morbidity. Additionally, survival advantages to radical surgery in this scenario are largely unknown, particularly because available series often include patients undergoing completion pneumonectomy for benign indications or metastatic disease from other primary sites, making extrapolation to primary lung cancer patients challenging. As systemic therapy options continue to evolve, particularly as it relates to immunotherapy, we expect that there will be more and more opportunities for locoregional surgical control. The aim of this study was to evaluate outcomes following completion pneumonectomy for recurrent NSCLC. Methods: We retrospectively reviewed all patients who underwent completion pneumonectomy for recurrent NSCLC at our institution between 2000 and 2015. Factors affecting perioperative morbidity and mortality, as well as overall survival, were analyzed. Results: Between 2000 and 2015, 28 patients underwent completion pneumonectomy for recurrent lung cancer (14 female, 14 male). The median age was 64.2 years (range, 36.7-84.0). There were 11 left-sided and 17 right-sided operations. Fourteen patients (50.0%) underwent chemotherapy or chemoradiotherapy prior to surgery. Perioperative morbidity was seen in 13 of 28 (46.4%) patients, and atrial fibrillation was the most common complication. Mortality at 30- and 90-day intervals was 3.6%, and 14.3% respectively. Five-year overall survival was 43.1% and was not associated with preoperative chemotherapy or chemoradiotherapy use. Patients over 70 years old (n=5) experienced a statistically higher rate of postoperative complications (100.0% vs. 34.8%, P=0.013), and this translated into a higher mortality rate at 60 and 90 days. Left-sided resections were associated with increased risk of recurrent laryngeal nerve injury (RLN) compared to right-sided resections (36.4% vs. 0%, P=0.016), and those patients with RLN injury were more likely to be reintubated (50.0% vs. 4.2%, P=0.04). Bronchopleural fistula occurred in 1 patient (3.6%). Conclusions: Completion pneumonectomy is a viable treatment option for patients with recurrent NSCLC. We attribute our low risks of major morbidity, such as bronchopleural fistula, to careful patient selection and technique. In patients over 70 years, morbidity is higher which should inform discussion regarding surgical options. C1 [White, Abby; Kucukak, Suden; Lee, Daniel N.; Bueno, Raphael; Jaklitsch, Michael; Mentzer, Steven; Wee, Jon; Swanson, Scott J.] Brigham & Womens Hosp, Div Thorac Surg, 75 Francis St, Boston, MA 02090 USA. [Sugarbaker, David] Baylor Coll Med, Div Gen Thorac Surg, Houston, TX 77030 USA. C3 Harvard University; Harvard University Medical Affiliates; Brigham & Women's Hospital; Baylor College of Medicine RP White, A (corresponding author), Brigham & Womens Hosp, Div Thorac Surg, 75 Francis St, Boston, MA 02090 USA. EM awhite12@bwh.harvard.edu CR Cardillo G, 2012, EUR J CARDIO-THORAC, V42, P405, DOI 10.1093/ejcts/ezs063 Deslauriers J, 2000, CHEST, V117, p104S, DOI 10.1378/chest.117.4_suppl_1.104S Fujimoto T, 2001, J THORAC CARDIOV SUR, V121, P484, DOI 10.1067/mtc.2001.112471 GREGOIRE J, 1993, J THORAC CARDIOV SUR, V105, P918 Kasprzyk M, 2015, KARDIOCHIR TORAKOCHI, V12, P18, DOI 10.5114/kitp.2015.50563 Kozu Y, 2013, EUR J CARDIO-THORAC, V44, pE53, DOI 10.1093/ejcts/ezt192 Mansour K, 2002, ANN THORAC SURG, V74, P883 Miller DL, 2002, ANN THORAC SURG, V74, P876, DOI 10.1016/S0003-4975(02)03855-9 National Comprehensive Cancer Network, aurantium on non-small-cell lung cancer: A research based on network and Puri V, 2013, ANN THORAC SURG, V95, P1885, DOI 10.1016/j.athoracsur.2013.04.014 Tabutin M, 2012, J THORAC ONCOL, V7, P1556, DOI 10.1097/JTO.0b013e31826419d2 Uramoto H, 2014, TRANSL LUNG CANCER R, V3, P242, DOI 10.3978/j.issn.2218-6751.2013.12.05 Whitson BA, 2008, ANN THORAC SURG, V86, P2008, DOI 10.1016/j.athoracsur.2008.07.009 Wright G, 2006, THORAX, V61, P597, DOI 10.1136/thx.2005.051995 NR 14 TC 10 Z9 10 U1 0 U2 0 PU AME PUBLISHING COMPANY PI SHATIN PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA SN 2072-1439 EI 2077-6624 J9 J THORAC DIS JI J. Thorac. Dis. PD MAR PY 2020 VL 12 IS 3 BP 217 EP 222 DI 10.21037/jtd.2020.01.51 PG 6 WC Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System GA KX2UJ UT WOS:000521736500016 PM 32274087 OA Green Submitted, gold DA 2026-04-17 ER PT J AU González-Tallada, A Borrell-Vega, J Coronado, C Morales, P de Miguel, M Ferreira-González, I de Nadal, M AF Gonzalez-Tallada, Anna Borrell-Vega, Jaume Coronado, Carolina Morales, Paula de Miguel, Marcos Ferreira-Gonzalez, Ignacio de Nadal, Miriam TI Myocardial Injury After Noncardiac Surgery: Incidence, Predictive Factors, and Outcome in High-Risk Patients Undergoing Thoracic Surgery: An Observational Study SO JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA LA English DT Article DE thoracic surgery; troponin; myocardial injury after noncardiac surgery; lobectomy; pneumonectomy ID CARDIAC TROPONIN-I; ATRIAL-FIBRILLATION; EUROPEAN-SOCIETY; 30-DAY MORTALITY; OPEN LOBECTOMY; LUNG-CANCER; ASSOCIATION; GUIDELINES; MANAGEMENT AB Objective: The authors aimed to evaluate the incidence of myocardial injury after noncardiac surgery (MINS), its relationship with perioperative variables, and its prognostic implications for 30-day mortality in high-risk thoracic surgery patients. Design: Observational study including cardiovascular high-risk patients undergoing routine postoperative troponin monitoring during the first 2 postoperative days. MINS was diagnosed based on at least 1 troponin I determination >= 0.04 ng/mL with no evidence of a nonischemic etiology. Setting: Tertiary university hospital. Participants: Adult patients with cardiac risk factors, defined as patients >= 65 years old or patients <65 years old with known cardiovascular pathology (history of cardiac, cerebral, or peripheral vascular pathology) who underwent elective thoracic surgery. Measurement and Main Results: Forty-eight patients (27.3%) (95% confidence interval [CI] 20.8%-34.5%) of 177 had diagnostic criteria for MINS. On univariate analysis, an association was found between MINS and smoking (odds ratio [OR] 2.17, 95% CI 1.26-3.76), lobectomy (OR 1.30, 95% CI 1.03-1.66), pneumonectomy (OR 6.72, 95% CI 1.35-33.9), use of vasoactive drugs (OR 1.94, 95% CI 1.03-3.65), and pericardial incision (OR 6.72, 95% CI 1.35-33.9). On multivariate logistic regression analysis, only smoker status and type of surgery were independent risk factors for MINS. No association was found between MINS and 30-day mortality. Conclusions: Based on the findings, the elevated incidence of M1NS after thoracic surgery, the independent relationship with the extent of lung resection, and the fact that MINS was not associated with greater mortality suggest that nonischemic causes may contribute to troponin elevation after thoracic surgeries. (C) 2019 Elsevier Inc. All rights reserved. C1 [Gonzalez-Tallada, Anna; Borrell-Vega, Jaume; Coronado, Carolina; Morales, Paula; de Miguel, Marcos; de Nadal, Miriam] Autonomous Univ Barcelona UAB, Vall dHebron Univ Hosp, Dept Anesthesiol & Intens Care, Ps Vall dHebron 119-129, Barcelona 08035, Spain. [Gonzalez-Tallada, Anna; Borrell-Vega, Jaume; Coronado, Carolina; Morales, Paula; de Miguel, Marcos; de Nadal, Miriam] Univ Autonoma Barcelona, Hosp Vall dHebron, Dept Anesthesiol & Intens Care, Barcelona, Spain. [Ferreira-Gonzalez, Ignacio] Autonomous Univ Barcelona UAB, Vall dHebron Hosp, Cardiol Dept, Epidemiol Unit, Barcelona, Spain. [Ferreira-Gonzalez, Ignacio] Univ Autonoma Barcelona, Hosp Vall dHebron, Cardiol Dept, Epidemiol Unit, Barcelona, Spain. C3 Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Hospital Universitari Vall d'Hebron; Autonomous University of Barcelona; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron RP de Nadal, M (corresponding author), Autonomous Univ Barcelona UAB, Vall dHebron Univ Hosp, Dept Anesthesiol & Intens Care, Ps Vall dHebron 119-129, Barcelona 08035, Spain. EM minadal@vhebron.net RI Borrell-Vega, Jaume/HZI-4279-2023; Ferreira-Gonzalez, Ignacio/K-9939-2017; de Nadal, Miriam/J-8127-2017 OI Borrell-Vega, Jaume/0009-0009-6264-4032; de Nadal, Miriam/0000-0002-4559-2463 CR Biccard BM, 2018, ANN SURG, V268, P357, DOI 10.1097/SLA.0000000000002290 Botto F, 2014, ANESTHESIOLOGY, V120, P564, DOI 10.1097/ALN.0000000000000113 Buse GAL, 2011, ANESTH ANALG, V112, P1019, DOI 10.1213/ANE.0b013e31820f286f Devereaux PJ, 2017, JAMA-J AM MED ASSOC, V317, P1642, DOI 10.1001/jama.2017.4360 Devereaux PJ, 2012, JAMA-J AM MED ASSOC, V307, P2295, DOI 10.1001/jama.2012.5502 Devereaux PJ, 2014, AM HEART J, V167, P804, DOI 10.1016/j.ahj.2014.01.007 Duceppe E, 2017, CAN J CARDIOL, V33, P17, DOI 10.1016/j.cjca.2016.09.008 Falcoz PE, 2016, EUR J CARDIO-THORAC, V49, P602, DOI 10.1093/ejcts/ezv154 Fan YC, 2018, CLIN CHIM ACTA, V477, P48, DOI 10.1016/j.cca.2017.11.040 Gualandro DM, 2014, CURR OPIN CRIT CARE, V20, P472, DOI 10.1097/MCC.0000000000000132 Hua A, 2016, J THORAC DIS, V8, P920, DOI 10.21037/jtd.2016.03.55 Kowalewski J, 1999, EUR J CARDIO-THORAC, V15, P444, DOI 10.1016/S1010-7940(99)00032-9 Kozower BD, 2011, ANN SURG, V254, P1032, DOI 10.1097/SLA.0b013e31821d4bdd Kristensen SD, 2014, EUR J ANAESTH, V31, P517, DOI 10.1097/EJA.0000000000000150 Lim E, 2006, J CARDIOTHORAC SURG, V1, DOI 10.1186/1749-8090-1-37 Lucreziotti S, 2007, REV ESP CARDIOL, V60, P1159, DOI 10.1157/13111788 Mauermann E, 2016, CURR OPIN ANESTHESIO, V29, P403, DOI 10.1097/ACO.0000000000000336 Muley T, 2011, CLIN LAB, V57, P925 Parwani AS, 2013, INT J CARDIOL, V168, P2734, DOI 10.1016/j.ijcard.2013.03.087 Shen JT, 2018, EUR J ANAESTH, V35, P815, DOI 10.1097/EJA.0000000000000868 Swanson SJ, 2012, ANN THORAC SURG, V93, P1027, DOI 10.1016/j.athoracsur.2011.06.007 Thygesen K, 2018, KARDIOL POL, V76, P1383, DOI [10.5603/KP.2018.0203, 10.1016/j.gheart.2018.08.004] van Waes JAR, 2016, ANESTH ANALG, V123, P29, DOI 10.1213/ANE.0000000000001313 VANMIEGHEM W, 1989, RESP MED, V83, P199, DOI 10.1016/S0954-6111(89)80032-0 Vikenes K, 2004, INT J CARDIOL, V96, P403, DOI 10.1016/j.ijcard.2003.08.007 NR 25 TC 27 Z9 33 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1053-0770 EI 1532-8422 J9 J CARDIOTHOR VASC AN JI J. Cardiothorac. Vasc. Anesth. PD FEB PY 2020 VL 34 IS 2 BP 426 EP 432 DI 10.1053/j.jvca.2019.08.014 PG 7 WC Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease WE Science Citation Index Expanded (SCI-EXPANDED) SC Anesthesiology; Cardiovascular System & Cardiology; Respiratory System GA KH0BZ UT WOS:000510314700020 PM 31515189 DA 2026-04-17 ER PT J AU AlTurki, A Marafi, M Proietti, R Cardinale, D Blackwell, R Dorian, P Bessissow, A Vieira, L Greiss, I Essebag, V Healey, JS Huynh, T AF AlTurki, Ahmed Marafi, Mariam Proietti, Riccardo Cardinale, Daniela Blackwell, Robert Dorian, Paul Bessissow, Amal Vieira, Lucy Greiss, Isabelle Essebag, Vidal Healey, Jeff S. Thao Huynh TI Major Adverse Cardiovascular Events Associated With Postoperative Atrial Fibrillation After Noncardiac Surgery A Systematic Review and Meta-Analysis SO CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY LA English DT Review DE atrial fibrillation; general surgery; myocardial infarction; stroke; thoracic surgery ID THORACIC-SURGERY; LUNG-CANCER; NEW-ONSET; NONCARDIOTHORACIC SURGERY; PERIOPERATIVE MANAGEMENT; RISK-FACTORS; STROKE; PREVENTION; IMPACT; ARRHYTHMIAS AB Background: Postoperative atrial fibrillation (POAF) is a frequent occurrence after noncardiac surgery. It remains unclear whether POAF is associated with an increased risk of major adverse events. We aimed to elucidate the risk of stroke, myocardial infarction, and death associated with POAF following noncardiac surgery by a meta-analysis of randomized controlled studies and observational studies. Methods: We searched electronic databases from inception up to August 1, 2019 for all studies that reported stroke or myocardial infarction in adult patients who developed POAF following noncardiac surgery. We used random-effects models to summarize the studies. Results: The final analyses included 28 studies enrolling 2 612 816 patients. At 1-month (10 studies), POAF was associated with an approximate to 3-fold increase in the risk of stroke (weighted mean 2.1% versus 0.7%; odds ratio [OR], 2.82 [95% CI, 2.15-3.70]; P<0.001). POAF was associated with approximate to 4-fold increase in the long-term risk of stroke with (weighted mean, 2.0% versus 0.6%; OR, 4.12 [95% CI, 3.32-5.11]; P <= 0.001) in 8 studies with >= 12-month follow-up. There was a significant overall increase in the risk of stroke and myocardial infarction associated with POAF (weighted mean, 2.5% versus 0.9%; OR, 3.44 [95% CI, 2.38-4.98]; P<0.001) and (weighted mean, 12.6% versus 2.7%; OR, 4.02 [95% CI, 3.08-5.24]; P<0.001), respectively. Furthermore, POAF was associated with a 3-fold increase in all-cause mortality at 30 days (weighted mean, 15.0% versus 5.4%; OR, 3.36 [95% CI, 2.13-5.31]; P<0.001). Conclusions: POAF was associated with markedly higher risk of stroke, myocardial infarction, and all-cause mortality following noncardiac surgery. Future studies are needed to evaluate the impact of optimal cardiovascular pharmacotherapies to prevent POAF and to decrease the risk of major adverse events in these high-risk patients. C1 [AlTurki, Ahmed; Essebag, Vidal; Thao Huynh] McGill Univ, Div Cardiol, Hlth Ctr, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada. [Bessissow, Amal] McGill Univ, Div Gen Internal Med, Hlth Ctr, Montreal, PQ, Canada. [Marafi, Mariam; Vieira, Lucy] Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ, Canada. [Proietti, Riccardo] Univ Padua, Dept Cardiac Thorac & Vasc Sci, Padua, Italy. [Cardinale, Daniela] IRCCS, European Inst Oncol, Cardiol Unit, Milan, Italy. [Blackwell, Robert] Loyola Univ, Hlth Ctr, Dept Urol, Chicago, IL 60611 USA. [Dorian, Paul] Univ Toronto, St Michaels Hosp, Div Cardiol, Toronto, ON, Canada. [Greiss, Isabelle] Univ Montreal, Hlth Ctr, Div Cardiol, Montreal, PQ, Canada. [Healey, Jeff S.] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada. C3 McGill University; McGill University; University of Padua; IRCCS European Institute of Oncology (IEO); Loyola University Chicago; University of Toronto; Saint Michaels Hospital Toronto; Universite de Montreal; McMaster University; Population Health Research Institute RP AlTurki, A (corresponding author), McGill Univ, Div Cardiol, Hlth Ctr, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada. EM ahmedalturkimd@gmail.com RI CARDINALE, DANIELA/AAN-1675-2020; Greiss, Isabelle/AEH-2049-2022; Dorian, Paul/R-6250-2017 OI CARDINALE, DANIELA/0000-0002-4038-8033; Essebag, Vidal/0000-0003-0107-5197; CR Aguilar M, 2019, CAN J CARDIOL, V35, P1423, DOI 10.1016/j.cjca.2019.08.013 Amar D, 2000, J THORAC CARDIOV SUR, V120, P790, DOI 10.1067/mtc.2000.109538 Bessissow A, 2015, J THROMB HAEMOST, V13, pS304, DOI 10.1111/jth.12974 Bhave PD, 2012, AM HEART J, V164, P918, DOI 10.1016/j.ahj.2012.09.004 Blackwell RH, 2015, J UROLOGY, V194, P944, DOI 10.1016/j.juro.2015.03.109 Brathwaite D, 1998, CHEST, V114, P462, DOI 10.1378/chest.114.2.462 Butt JH, 2018, J AM COLL CARDIOL, V72, P2027, DOI 10.1016/j.jacc.2018.07.088 Cardillo G, 2012, EUR J CARDIO-THORAC, V41, P657, DOI 10.1093/ejcts/ezr083 Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Cardinale D, 2007, CIRCULATION, V115, P1339, DOI 10.1161/CIRCULATIONAHA.106.647008 Cardinale D, 2016, ANN SURG, V264, P244, DOI 10.1097/SLA.0000000000001626 Chaikriangkrai Kongkiat, 2015, JACC Clin Electrophysiol, V1, P296, DOI 10.1016/j.jacep.2015.05.009 Chin JH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154931 Conen D, 2019, EUR HEART J, DOI 10.1093/eurheartj/ehz431 Connolly SJ, 2009, NEW ENGL J MED, V360, P2066, DOI 10.1056/NEJMoa0901301 Day RW, 2016, DIS ESOPHAGUS, V29, P583, DOI 10.1111/dote.12355 DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2 Devereaux PJ, 2008, LANCET, V371, P1839, DOI 10.1016/S0140-6736(08)60601-7 Doherty JU, 2017, J AM COLL CARDIOL, V69, P871, DOI 10.1016/j.jacc.2016.11.024 Falcoz PE, 2016, EUR J CARDIO-THORAC, V49, P602, DOI 10.1093/ejcts/ezv154 Falk RH, 2001, NEW ENGL J MED, V344, P1067, DOI 10.1056/NEJM200104053441407 Frendl G, 2014, J THORAC CARDIOV SUR, V148, pE153, DOI 10.1016/j.jtcvs.2014.06.036 Gialdini G, 2014, JAMA-J AM MED ASSOC, V312, P616, DOI 10.1001/jama.2014.9143 Girerd N, 2012, CLIN CARDIOL, V35, P430, DOI 10.1002/clc.21008 Healey JS, 2018, JAMA CARDIOL, V3, P425, DOI 10.1001/jamacardio.2018.0534 Imperatori Andrea, 2012, J Cardiothorac Surg, V7, P4, DOI 10.1186/1749-8090-7-4 January CT, 2014, CIRCULATION, V130, pE199, DOI 10.1161/CIR.0000000000000041 Jorgensen ME, 2014, JAMA-J AM MED ASSOC, V312, P269, DOI 10.1001/jama.2014.8165 Khormaee S, 2018, J ARTHROPLASTY, V33, P3016, DOI 10.1016/j.arth.2018.04.009 Kirchhof P, 2016, EUR HEART J, V37, P2893, DOI 10.1093/eurheartj/ehw210 Lee Christina J-Y, 2017, J Am Coll Cardiol, V69, P2901, DOI [10.1016/j.jacc.2017.04.033, 10.1016/j.jacc.2017.04.033] Ma JY, 2006, WORLD J GASTROENTERO, V12, P449, DOI 10.3748/wjg.v12.i3.449 Maesen B, 2012, EUROPACE, V14, P159, DOI 10.1093/europace/eur208 Mann CJ, 2007, HEART, V93, P45, DOI 10.1136/hrt.2006.099929 Mc Cormack O, 2014, ANN SURG, V260, P772, DOI 10.1097/SLA.0000000000000960 MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527 Mehdi Z, 2016, CLIN MED, V16, P535, DOI 10.7861/clinmedicine.16-6-535 Mitchell LB, 2005, JAMA-J AM MED ASSOC, V294, P3093, DOI 10.1001/jama.294.24.3093 Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535 Murthy SC, 2003, J THORAC CARDIOV SUR, V126, P1162, DOI 10.1016/S0022-5223(03)00974-7 Nassoiy SP, 2016, AM J SURG, V211, P559, DOI 10.1016/j.amjsurg.2015.10.024 Noorani A, 2009, INT J SURG, V7, P24, DOI 10.1016/j.ijsu.2008.09.002 Odutayo A, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i4482 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Polanczyk CA, 1998, ANN INTERN MED, V129, P279, DOI 10.7326/0003-4819-129-4-199808150-00003 Proietti R, 2016, EXPERT REV CARDIOVAS, V14, P761, DOI 10.1586/14779072.2016.1154457 Rao VP, 2012, EUR J CARDIO-THORAC, V42, P438, DOI 10.1093/ejcts/ezs085 Raphael CE, 2018, JACC-CARDIOVASC INTE, V11, P172, DOI 10.1016/j.jcin.2017.08.057 Shibata T, 2015, CIRCULATION, V132, P241, DOI 10.1161/CIRCULATIONAHA.114.015134 Soliman EZ, 2014, JAMA INTERN MED, V174, pE107, DOI 10.1001/jamainternmed.2013.11912 Stawicki SPA, 2011, GEN THORAC CARDIOVAS, V59, P399, DOI 10.1007/s11748-010-0713-9 Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008 Tafur A, 2018, HEART, V104, P1461, DOI 10.1136/heartjnl-2016-310581 Vallurupalli S, 2017, CLIN CARDIOL, V40, P329, DOI 10.1002/clc.22652 Van Gelder IC, 2017, EUR HEART J, V38, P1339, DOI 10.1093/eurheartj/ehx042 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Verma A, 2014, CAN J CARDIOL, V30, P1114, DOI 10.1016/j.cjca.2014.08.001 Winkel TA, 2009, EUR J VASC ENDOVASC, V38, P683, DOI 10.1016/j.ejvs.2009.07.006 Yoshida T, 2018, J CRIT CARE, V44, P267, DOI 10.1016/j.jcrc.2017.11.040 NR 59 TC 75 Z9 88 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-3149 EI 1941-3084 J9 CIRC-ARRHYTHMIA ELEC JI Circ.-Arrhythmia Electrophysiol. PD JAN PY 2020 VL 13 IS 1 AR e007437 DI 10.1161/CIRCEP.119.007437 PG 10 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA KE2VR UT WOS:000508419100002 PM 31944855 DA 2026-04-17 ER PT J AU Fabiani, I Colombo, A Bacchiani, G Cipolla, CM Cardinale, DM AF Fabiani, Iacopo Colombo, Alessandro Bacchiani, Giulia Cipolla, Carlo Maria Cardinale, Daniela Maria TI Incidence, Management, Prevention and Outcome of Post-Operative Atrial Fibrillation in Thoracic Surgical Oncology SO JOURNAL OF CLINICAL MEDICINE LA English DT Review DE atrial fibrillation; brain natriuretic peptide; N-terminal-pro-natriuretic peptide; thoracic surgery; cancer; thrombosis; cardiotoxicity ID LUNG-CANCER SURGERY; NATRIURETIC PEPTIDE LEVELS; 2014 AATS GUIDELINES; RISK-FACTORS; NEW-ONSET; POSTPERICARDIOTOMY-SYNDROME; PULMONARY RESECTION; NONCARDIAC SURGERY; PREOPERATIVE CHEMORADIOTHERAPY; COLORECTAL-CANCER AB Atrial fibrillation (AF) is a common supraventricular arrhythmia, a recognized risk factor for ischemic stroke, as a potential driver for heart failure (HF). Cancer patients have an increased risk for AF, even not including any cancer-specific treatment, as surgery or chemotherapy. The mechanism is multifactorial, with inflammation and changes in autonomic tone as critical actors. Commonly, AF is a recurrent complication of the post-operative period in cancer surgery (especially thoracic). Recent papers confirmed a significant incidence of post-operative (non-cardiac surgery) AF (PAF), partially mitigated by the use of prophylactic (rate o rhythm control) treatments. A relevant difference, in terms of mean hospitalization time, emerges between patients developing PAF and those who do not, while long term impact remains a matter of debate, due to several potential confounding factors. Besides clinical predictors, structural (i.e., echocardiographic) and bio-humoral findings may help in risk prediction tasks. In this respect, pre-operative natriuretic peptides (NPs) concentrations are nowadays recognized as significant independent predictors of perioperative cardiovascular complications (including PAF), while elevated post-operative levels may further enhance risk stratification. The aim of the present paper is to trace the state of the art in terms of incidence, management, prevention, and outcome of PAF in the field of thoracic surgical oncology. C1 [Fabiani, Iacopo; Colombo, Alessandro; Bacchiani, Giulia; Cardinale, Daniela Maria] IRCCS, European Inst Oncol, Cardioncol Unit, I-20141 Milan, Italy. [Colombo, Alessandro; Bacchiani, Giulia; Cipolla, Carlo Maria] IRCCS, European Inst Oncol, Div Cardiol, I-20141 Milan, Italy. C3 IRCCS European Institute of Oncology (IEO); IRCCS European Institute of Oncology (IEO) RP Cardinale, DM (corresponding author), IRCCS, European Inst Oncol, Cardioncol Unit, I-20141 Milan, Italy. EM iacopo.fabiani@ieo.it; alessandro.colombo@ieo.it; giulia.bacchiani@ieo.it; carlo.cipolla@ieo.it; daniela.cardinale@ieo.it RI CARDINALE, DANIELA/AAN-1675-2020; Colombo, Alessandro/AAR-8740-2020; Cipolla, Carlo/AAO-3897-2020 OI CARDINALE, DANIELA/0000-0002-4038-8033; CR Ahlsson A, 2010, EUR J CARDIO-THORAC, V37, P1353, DOI 10.1016/j.ejcts.2009.12.033 Akoum N, 2011, J CARDIOVASC ELECTR, V22, P16, DOI 10.1111/j.1540-8167.2010.01876.x Amar D, 1997, ANN THORAC SURG, V63, P1374 AMAR D, 1995, CHEST, V108, P349, DOI 10.1378/chest.108.2.349 Amar D, 2005, CHEST, V128, P3421, DOI 10.1378/chest.128.5.3421 Amar D, 2016, J THORAC CARDIOV SUR, V151, P913, DOI 10.1016/j.jtcvs.2015.09.041 Amar D, 2012, J THORAC CARDIOV SUR, V144, P1249, DOI 10.1016/j.jtcvs.2012.06.051 Amar David, 2002, Heart Dis, V4, P117 Aviles RJ, 2003, CIRCULATION, V108, P3006, DOI 10.1161/01.CIR.0000103131.70301.4F Bang CN, 2013, INT J CARDIOL, V167, P624, DOI 10.1016/j.ijcard.2012.08.056 Bayliff CD, 1999, ANN THORAC SURG, V67, P182, DOI 10.1016/S0003-4975(98)01226-0 Bhave PD, 2012, AM HEART J, V164, P918, DOI 10.1016/j.ahj.2012.09.004 Biccard BM, 2012, ANAESTHESIA, V67, P55, DOI 10.1111/j.1365-2044.2011.06958.x Blanchard L, 2007, CURR OPIN ANESTHESIO, V20, P53, DOI 10.1097/ACO.0b013e328013d9fd Bobbio A, 2007, EUR J CARDIO-THORAC, V31, P70, DOI 10.1016/j.ejcts.2006.10.020 Boriani G, 2014, EUR HEART J, V35, P508, DOI 10.1093/eurheartj/eht491 Boriani G, 2012, INT J CARDIOL, V159, pE1, DOI 10.1016/j.ijcard.2011.10.134 Butt JH, 2018, J AM COLL CARDIOL, V72, P2027, DOI 10.1016/j.jacc.2018.07.088 Cai GL, 2014, WORLD J SURG, V38, P51, DOI 10.1007/s00268-013-2284-2 Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Cardinale D, 2007, CIRCULATION, V115, P1339, DOI 10.1161/CIRCULATIONAHA.106.647008 Cardinale D, 2018, LUNG CANCER, V123, P155, DOI 10.1016/j.lungcan.2018.07.009 Cardinale D, 2016, ANN SURG, V264, P244, DOI 10.1097/SLA.0000000000001626 Cestari DM, 2004, NEUROLOGY, V62, P2025, DOI 10.1212/01.WNL.0000129912.56486.2B Chen PC, 2011, STROKE, V42, P3034, DOI 10.1161/STROKEAHA.111.615534 Cheng WL, 2016, INT J CARDIOL, V219, P186, DOI 10.1016/j.ijcard.2016.06.009 Chin JH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154931 Chung MK, 2001, CIRCULATION, V104, P2886, DOI 10.1161/hc4901.101760 Ciszewski P, 2013, THORAC CARDIOV SURG, V61, P365, DOI 10.1055/s-0032-1311537 Clerico A, 2011, AM J PHYSIOL-HEART C, V301, pH12, DOI 10.1152/ajpheart.00226.2011 Conen D, 2016, JAMA CARDIOL, V1, P389, DOI 10.1001/jamacardio.2016.0280 Danelich IM, 2014, J AM COLL SURGEONS, V219, P831, DOI 10.1016/j.jamcollsurg.2014.02.038 De Decker K, 2003, ANN THORAC SURG, V75, P1340, DOI 10.1016/S0003-4975(02)04824-5 de Waal BA, 2015, BRIT J ANAESTH, V114, P44, DOI 10.1093/bja/aeu295 Devereaux PJ, 2008, LANCET, V371, P1839, DOI 10.1016/S0140-6736(08)60601-7 DiNicolantonio JJ, 2014, AM J CARDIOL, V113, P565, DOI 10.1016/j.amjcard.2013.10.020 Dixit S, 2009, J AM COLL CARDIOL, V54, P2049, DOI 10.1016/j.jacc.2009.09.015 DONATI S, 2011, ARVO ANNU MEET ABSTR, V2011, DOI DOI 10.5402/2011/203179 Dunning J, 2006, EUR J CARDIO-THORAC, V30, P852, DOI 10.1016/j.ejcts.2006.09.003 El-Chami MF, 2016, PACE, V39, P1083, DOI 10.1111/pace.12949 Erichsen R, 2012, INTERN EMERG MED, V7, P431, DOI 10.1007/s11739-011-0701-9 Farmakis D, 2014, J AM COLL CARDIOL, V63, P945, DOI 10.1016/j.jacc.2013.11.026 Ferreira C, 2015, ARQ BRAS CARDIOL, V105, P519, DOI 10.5935/abc.20150142 Finkel T, 2007, NATURE, V448, P767, DOI 10.1038/nature05985 Fitzpatrick T, 2017, THROMB RES, V155, P101, DOI 10.1016/j.thromres.2017.05.006 Frendl G, 2014, J THORAC CARDIOV SUR, V148, P772, DOI 10.1016/j.jtcvs.2014.06.037 Frendl G, 2014, J THORAC CARDIOV SUR, V148, pE153, DOI 10.1016/j.jtcvs.2014.06.036 Garner M, 2017, INTERACT CARDIOV TH, V24, P260, DOI 10.1093/icvts/ivw348 Gialdini G, 2014, JAMA-J AM MED ASSOC, V312, P616, DOI 10.1001/jama.2014.9143 Guglin M, 2009, EUROPACE, V11, P1579, DOI 10.1093/europace/eup300 Guzzetti S, 2002, AM J MED, V112, P587, DOI 10.1016/S0002-9343(02)01029-X Haïssaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003 Henri C, 2012, CIRC-ARRHYTHMIA ELEC, V5, P61, DOI 10.1161/CIRCEP.111.964569 Higuchi S, 2019, CAN J CARDIOL, V35, P1449, DOI 10.1016/j.cjca.2019.07.008 Higuchi S, 2018, BMC CARDIOVASC DISOR, V18, DOI 10.1186/s12872-018-0862-9 Hu YF, 2015, NAT REV CARDIOL, V12, P230, DOI 10.1038/nrcardio.2015.2 Hu YF, 2013, INT J CARDIOL, V165, P355, DOI 10.1016/j.ijcard.2012.08.036 Imazio M, 2014, JAMA-J AM MED ASSOC, V312, P1016, DOI 10.1001/jama.2014.11026 Imazio M, 2013, AM HEART J, V166, P13, DOI 10.1016/j.ahj.2013.03.025 Imazio M, 2011, CIRCULATION, V124, P2290, DOI 10.1161/CIRCULATIONAHA.111.026153 Imperatori A, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-4 Ivanovic J, 2014, INTERACT CARDIOV TH, V18, P340, DOI 10.1093/icvts/ivt520 Iwata T, 2016, SURG TODAY, V46, P877, DOI 10.1007/s00595-015-1258-4 Jaïs P, 2002, CIRCULATION, V106, P2479, DOI 10.1161/01.CIR.0000036744.39782.9F Jakobsen CJ, 1997, J CARDIOTHOR VASC AN, V11, P746, DOI 10.1016/S1053-0770(97)90169-5 Jibrini MB, 2008, AM J THER, V15, P36, DOI 10.1097/MJT.0b013e31804beb59 Johnson W, 2002, J AM COLL CARDIOL, V39, P1623, DOI 10.1016/S0735-1097(02)01814-4 Kanmanthareddy A, 2015, J CARDIOVASC ELECTR, V26, P385, DOI 10.1111/jce.12619 Karthikeyan G, 2009, J AM COLL CARDIOL, V54, P1599, DOI 10.1016/j.jacc.2009.06.028 Kavurmaci O, 2018, HEART LUNG CIRC, V27, P835, DOI 10.1016/j.hlc.2017.06.729 Kirchhof P, 2016, EUR HEART J, V37, P2893, DOI 10.1093/eurheartj/ehw210 LANDYMORE RW, 1991, EUR J CARDIO-THORAC, V5, P436, DOI 10.1016/1010-7940(91)90191-L Lee CT, 2019, THORAC CARDIOV SURG, V67, P125, DOI 10.1055/s-0038-1675638 Lohani KR, 2015, SURG ENDOSC, V29, P2039, DOI 10.1007/s00464-014-3908-9 Lowres N, 2016, EUR J CARDIO-THORAC, V50, P44, DOI 10.1093/ejcts/ezv486 Ma JY, 2006, WORLD J GASTROENTERO, V12, P449, DOI 10.3748/wjg.v12.i3.449 Maesen B, 2012, EUROPACE, V14, P159, DOI 10.1093/europace/eur208 Mariscalco G, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000752 Masson S, 2015, EUR J CLIN INVEST, V45, P170, DOI 10.1111/eci.12393 Merritt RE, 2012, THORAC SURG CLIN, V22, P13, DOI 10.1016/j.thorsurg.2011.08.016 Mozaffarian D, 2013, J AM COLL CARDIOL, V61, P2194, DOI 10.1016/j.jacc.2013.02.045 Mozaffarian D, 2012, JAMA-J AM MED ASSOC, V308, P2001, DOI 10.1001/jama.2012.28733 Muranishi Y, 2017, SURG TODAY, V47, P252, DOI 10.1007/s00595-016-1380-y Nojiri T, 2015, CHEST, V148, P1285, DOI 10.1378/chest.15-0852 Nojiri T, 2015, SURG TODAY, V45, P740, DOI 10.1007/s00595-014-1032-z Nojiri T, 2012, J THORAC CARDIOV SUR, V143, P488, DOI 10.1016/j.jtcvs.2011.09.003 Nojiri T, 2010, EUR J CARDIO-THORAC, V37, P787, DOI 10.1016/j.ejcts.2009.09.043 Ojima T, 2014, SURG TODAY, V44, P839, DOI 10.1007/s00595-013-0616-3 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Ozaydin M, 2008, INT J CARDIOL, V127, P362, DOI 10.1016/j.ijcard.2007.05.012 Passman RS, 2005, ANN THORAC SURG, V79, P1698, DOI 10.1016/j.athoracsur.2004.10.058 Peer M, 2015, HEART LUNG CIRC, V24, P69, DOI 10.1016/j.hlc.2014.07.055 Polanczyk CA, 1998, ANN INTERN MED, V129, P279, DOI 10.7326/0003-4819-129-4-199808150-00003 Poldermans D, 2008, J AM COLL CARDIOL, V51, P1913, DOI 10.1016/j.jacc.2008.03.005 Reinhart K, 2011, J CARDIOVASC PHARM T, V16, P5, DOI 10.1177/1074248410378120 Rena O, 2001, EUR J CARDIO-THORAC, V20, P688, DOI 10.1016/S1010-7940(01)00890-9 Riber LP, 2012, ANN THORAC SURG, V94, P339, DOI 10.1016/j.athoracsur.2011.12.096 Riber LP, 2014, ANN THORAC SURG, V98, P1989, DOI 10.1016/j.athoracsur.2014.06.069 Rice DC, 2005, ANN THORAC SURG, V79, P391, DOI 10.1016/j.athoracsur.2004.08.045 Rodseth RN, 2014, J AM COLL CARDIOL, V63, P170, DOI 10.1016/j.jacc.2013.08.1630 Rodseth RN, 2013, ANESTHESIOLOGY, V119, P270, DOI 10.1097/ALN.0b013e31829083f1 Rodseth RN, 2011, J AM COLL CARDIOL, V58, P522, DOI 10.1016/j.jacc.2011.04.018 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Salvatici M, 2010, BIOMARKERS, V15, P259, DOI 10.3109/13547500903509351 Schotten U, 2011, PHYSIOL REV, V91, P265, DOI 10.1152/physrev.00031.2009 Schwarzbach CJ, 2012, STROKE, V43, P3029, DOI 10.1161/STROKEAHA.112.658625 Sedrakyan A, 2005, J THORAC CARDIOV SUR, V129, P997, DOI 10.1016/j.jtcvs.2004.07.042 Shrivastava Vivek, 2004, Interact Cardiovasc Thorac Surg, V3, P656, DOI 10.1016/j.icvts.2004.08.002 Siu CW, 2005, PACE, V28, pS120, DOI 10.1111/j.1540-8159.2005.00024.x Struthers A, 2007, EUR HEART J, V28, P1678, DOI 10.1093/eurheartj/ehm234 Terzi A, 1996, THORAC CARDIOV SURG, V44, P300, DOI 10.1055/s-2007-1012041 Tisdale JE, 2010, SEMIN THORAC CARDIOV, V22, P310, DOI 10.1053/j.semtcvs.2010.12.001 Tsujimoto H, 2006, JPN J CLIN ONCOL, V36, P632, DOI 10.1093/jjco/hyl096 Turagam MK, 2016, CARDIOL REV, V24, P76, DOI 10.1097/CRD.0000000000000059 Ueda T, 2018, GEN THORAC CARDIOVAS, V66, P95, DOI 10.1007/s11748-017-0858-x VanMieghem W, 1996, ANN THORAC SURG, V61, P1083, DOI 10.1016/0003-4975(96)00073-2 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Verma A, 2018, J AM COLL CARDIOL, V71, P749, DOI 10.1016/j.jacc.2017.12.034 Wazni OM, 2004, CIRCULATION, V110, P124, DOI 10.1161/01.CIR.0000134481.24511.BC Worden JC, 2014, PHARMACOTHERAPY, V34, P1167, DOI 10.1002/phar.1485 Wu DH, 2012, ANN THORAC SURG, V94, P193, DOI 10.1016/j.athoracsur.2012.03.057 Wu JHY, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.001886 Yilmaz AT, 1996, J CARDIAC SURG, V11, P61, DOI 10.1111/j.1540-8191.1996.tb00010.x Yoshimura M, 2002, AM J MED, V112, P716, DOI 10.1016/S0002-9343(02)01121-X Zamorano JL, 2016, EUR HEART J, V37, P2768, DOI [10.1093/eurheartj/ehw211, 10.1002/ejhf.654] Zhang LZ, 2016, J CARDIOVASC PHARM, V67, P351, DOI 10.1097/FJC.0000000000000351 Zhao BC, 2017, CHEST, V151, P149, DOI 10.1016/j.chest.2016.08.1476 NR 127 TC 13 Z9 17 U1 0 U2 16 PU MDPI PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND EI 2077-0383 J9 J CLIN MED JI J. Clin. Med. PD JAN PY 2020 VL 9 IS 1 AR 37 DI 10.3390/jcm9010037 PG 17 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA KO2OF UT WOS:000515388400037 PM 31878032 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Jiang, HY Zheng, Y Liu, C Bao, Y AF Jiang, Haoyu Zheng, Ying Liu, Chang Bao, Ying TI Postoperative analgesia effects of sulfentanyl plus dexmedetomidine in patients received VATS SO PTERIDINES LA English DT Article DE patient controlled intravenous analgesia; VATS; NSCLC; norepinephrine; dopamine; 5-HT; prostaglandin ID ASSISTED THORACIC-SURGERY; ENHANCED RECOVERY; PAIN MANAGEMENT; CANCER; COMBINATION; RESECTION; PCA AB Background To evaluate sulfentanyl combined with dexmedetomidine hydrochloride on postoperative analgesia in patients who received video-assisted thoracic surgery (VATS) and its effects on serum norepinephrine (NE), dopamine (DA), 5-hydroxytryptamine (5-HT), and prostaglandin (PGE2). Material and Methods Ninety-nine non-small cell lung cancer (NSCLC) patients who received VATS were included in the study. All the patients received intravenous inhalation compound anesthesia. Of the 99 cases, 49 subjects (control group) received sulfentanyl for patient controlled intravenous analgesia (PICA) and other 50 cases (experiment group) received sulfentanyl combined with dexmedetomidine hydrochloride for PICA after operation of VATS. The analgesic effects of the two groups were evaluated according to Visual Analogue Scales (VAS) and the Rruggrmann Comfort Scale (BCS). The serum pain mediator of NE, DA, 5-HT, and PGE2 were examined and compared between the two groups in the first 24 h post-surgery. Results The VAS scores for the experiment group were significant lower than that of control group on the time points of 8, 16, and 24 h post-surgery (p(all)<0.05), and the BCS scores of the experiment group in the time points of 8, 16, and 24 h were significantly higher than that of controls (p<0.05). However, the VAS and BCS scores were not statistical differently in the time point of 1, 2, and 4 h post-surgery (p(all)>0.05). The mean sulfentanyl dosage was 63.01 +/- 5.14 pg and 67.12 +/- 6.91 pg for the experiment and control groups respectively with significant statistical difference (p<0.05). The mean analgesic pump pressing times were 4.30 +/- 1.31 and 5.31 +/- 1.46 for experiment and control groups respectively with significant statistical difference (p<0.05). The serum NE, DA, 5-HT, and PGE2 levels were significantly lower in the experimental group compared to that of control group in the time point of 12 h post-surgery (p(all)<0.05). The side effects of nausea, vomiting, delirium, rash, and hypotension atrial fibrillation were not statistically different between the two groups (p(all)>0.05). Conclusion Patient controlled intravenous analgesia of sulfentanyl combined with dexmedetomidine hydrochloride was effective in reducing the VAS score and serum pain mediators in NSCLC patients who received VAST. C1 [Bao, Ying] Lishui Peoples Hosp, Dept Emergency, Lishui 323000, Zhejiang, Peoples R China. [Jiang, Haoyu; Zheng, Ying] Lishui Peoples Hosp, Dept Gen Surg, Lishui 323000, Zhejiang, Peoples R China. [Liu, Chang] Southwest Med Univ, Dept Anesthesiol, Chinese Med Hosp, Luzhou 646000, Peoples R China. C3 Southwest Medical University RP Bao, Y (corresponding author), Lishui Peoples Hosp, Dept Emergency, Lishui 323000, Zhejiang, Peoples R China. EM 236289149@qq.com RI Zheng, Ying/CAG-6498-2022 CR Abrolat M, 2018, ANASTH INTENSIV NOTF, V53, P270, DOI 10.1055/s-0043-104665 Akça B, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2245-y Alhashemi JA, 2004, CAN J ANAESTH, V51, P342, DOI 10.1007/BF03018237 Brogan SE, 2011, PAIN MED, V12, P1758, DOI 10.1111/j.1526-4637.2011.01262.x Cao MM, 2019, THORAC CANCER, V10, P3, DOI 10.1111/1759-7714.12916 Chen DL, 2018, THORAC CANCER, V9, P1421, DOI 10.1111/1759-7714.12854 CHRUBASIK J, 1992, DRUGS, V43, P799, DOI 10.2165/00003495-199243060-00001 Huang HT, 2018, THORAC CANCER, V9, P83, DOI 10.1111/1759-7714.12541 Jiang L, 2015, PEDIATR CARDIOL, V36, P993, DOI 10.1007/s00246-015-1110-z Kim NY, 2017, INT J MED SCI, V14, P951, DOI 10.7150/ijms.20347 Koryllos A, 2017, J THORAC DIS, V9, P3498, DOI 10.21037/jtd.2017.08.160 Mercadante S, 2010, SURG ONCOL, V19, P173, DOI 10.1016/j.suronc.2009.11.013 Mercieri M, 2018, J THORAC DIS, V10, pS983, DOI 10.21037/jtd.2018.03.152 Nelson LE, 2003, ANESTHESIOLOGY, V98, P428, DOI 10.1097/00000542-200302000-00024 Oshima H, 2017, SAGE OPEN MED, V5, DOI 10.1177/2050312117729920 Pelland A, 2020, CAN J ANESTH, V67, P1475, DOI 10.1007/s12630-020-01707-3 Potvin S, 2009, SYNAPSE, V63, P390, DOI 10.1002/syn.20616 Rahimzadeh P, 2018, BMC ANESTHESIOL, V18, DOI 10.1186/s12871-018-0531-7 Ren CG, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001329 Ripamonti C, 1997, Oncology (Williston Park), V11, P373 Sarkar Arindam, 2018, Anesth Essays Res, V12, P572, DOI [10.4103/aer.aer_70_18, 10.4103/aer.AER_70_18] Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387 Veit S, 2014, ZBL CHIR, V139, pS34, DOI 10.1055/s-0034-1383030 Yang HC, 2015, J THORAC DIS, V7, P1960, DOI 10.3978/j.issn.2072-1439.2015.11.11 Yang J, 2009, NEUROPEPTIDES, V43, P259, DOI 10.1016/j.npep.2009.06.003 NR 25 TC 3 Z9 3 U1 0 U2 7 PU DE GRUYTER POLAND SP Z O O PI WARSAW PA BOGUMILA ZUGA 32A STR, 01-811 WARSAW, MAZOVIA, POLAND SN 0933-4807 EI 2195-4720 J9 PTERIDINES JI Pteridines PD JAN PY 2020 VL 31 IS 1 BP 55 EP 60 DI 10.1515/pteridines-2020-0007 PG 6 WC Biochemistry & Molecular Biology; Biophysics WE Science Citation Index Expanded (SCI-EXPANDED) SC Biochemistry & Molecular Biology; Biophysics GA LU3OW UT WOS:000537669700001 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Zotov, A Vachev, S Borisov, D Troitskiy, A Khabazov, R AF Zotov, Aleksandr Vachev, Sergei Borisov, Daniil Troitskiy, Aleksandr Khabazov, Robert TI Simultaneous Thoracoscopic Approach in a Patient with Long-Standing Persistent Atrial Fibrillation and Primary Lung Cancer: the First Described Case SO BRAZILIAN JOURNAL OF CARDIOVASCULAR SURGERY LA English DT Article DE Lung Cancer Surgery; Atrial Fibrillation (AF); Flutter; Thoracoscopy/VATS; Arrhythmia Therapy (Incl Ablation, Surgery, Drugs) ID CATHETER ABLATION AB Cardiac rhythm disorders are common in many patients with cancer. The management of synchronous long-standing persistent atrial fibrillation and pulmonary lesions remains a serious surgical dilemma due to the lack of clinical data and surgical guidelines. To the best of our knowledge, this is the first described case of simultaneous thoracoscopic pulmonary segmentectomy and left atrial posterior wall and pulmonary vein isolation combined with left atrial appendage resection in a patient with early-stage primary lung cancer and long-standing persistent atrial fibrillation. C1 [Zotov, Aleksandr; Vachev, Sergei; Borisov, Daniil; Troitskiy, Aleksandr; Khabazov, Robert] Fed Res & Clin Ctr, Dept Cardiac Surg, Orehoviy Bulvar 28, Moscow 115682, Russia. RP Borisov, D (corresponding author), Fed Res & Clin Ctr, Dept Cardiac Surg, Orehoviy Bulvar 28, Moscow 115682, Russia. EM dborisov.md@gmail.com RI Troitskiy, Alexander/E-5756-2014; Vachev, Sergey/AEM-7265-2022; Borisov, Daniil/AAO-3715-2020 OI Troitskiy, Alexander/0000-0003-2411-6043; Vachev, Sergey/0000-0002-2747-3057; Borisov, Daniil/0000-0002-1850-5256; Zotov, Aleksandr/0000-0003-2385-7456 CR [Anonymous], 2016, EUR J CARDIO-THORAC, DOI DOI 10.1093/ejcts/ezv180 Doty JR, 2012, INNOVATIONS, V7, P33, DOI 10.1177/155698451200700106 Kim HJ, 2016, INTERACT CARDIOV TH, V22, P729, DOI 10.1093/icvts/ivw027 Probst J, 2016, EUROPACE, V18, P1538, DOI 10.1093/europace/euv438 Yang CFJ, 2012, ANN THORAC SURG, V94, P668, DOI 10.1016/j.athoracsur.2012.03.080 NR 5 TC 1 Z9 1 U1 0 U2 0 PU SOC BRASIL CIRURGIA CARDIOVASC PI SAO PAULO SP PA RUA AFONSO CELSO, 1178, SAO PAULO SP, 04119-061, BRAZIL SN 0102-7638 EI 1678-9741 J9 BRAZ J CARDIOV SURG JI Braz. J. Cardiovasc. Surg. PY 2020 VL 35 IS 5 BP 841 EP 843 DI 10.21470/1678-9741-2019-01430 PG 3 WC Cardiac & Cardiovascular Systems; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Surgery GA OE4TZ UT WOS:000580526100034 PM 33118753 DA 2026-04-17 ER PT J AU Yamamoto, H Hamasaki, T Onda, K Nojiri, T Aragaki, M Horie, N Sato, N Hida, Y AF Yamamoto, Haruko Hamasaki, Toshimitsu Onda, Kaori Nojiri, Takashi Aragaki, Masato Horie, Nao Sato, Norihiro Hida, Yasuhiro TI Landiolol, an ultra-short acting beta-1 blocker, for preventing postoperative lung cancer recurrence: study protocol for a phase III, multicenter randomized trial with two parallel groups of patients SO TRIALS LA English DT Article DE Beta-blocker; Cancer recurrence; Clinical trial; Lung cancer; Landiolol ID ATRIAL-FIBRILLATION; DOSE LANDIOLOL; BREAST-CANCER; SURVIVAL; METAANALYSIS; HYDROCHLORIDE; MORTALITY; EFFICACY; INFUSION; ESMOLOL AB Background: Recurrence of cancer after curative surgery is a major problem after most cancer treatments. Increased sympathetic activity during the perioperative period could promote cancer cell invasion to blood vessels and angiogenesis, resulting in cancer metastasis. Recent studies showed that use of beta blockers can be associated with the prolonged survival of patients with cancer. The objective of this study is to evaluate the preventive effects of landiolol hydrochloride, which is an ultra-short-acting beta-1-selective blocker that has been developed in Japan, on reducing recurrence of cancer after curative surgery for patients with lung cancer. Methods: The present study is a phase III, multicenter, randomized trial with two parallel groups of patients with lung cancer, comparing surgery alone and surgery with landiolol administration for three days during the perioperative period. A total of 400 patients will be enrolled from 12 Japanese institutions. The primary endpoint is two-year relapse-free survival and overall survival after curative surgery for lung cancer. The secondary endpoints are additional treatment after recurrence of cancer, safety events, and the incidence of postoperative complications. Discussion: The principal question addressed in this trial is whether landiolol can reduce recurrence of cancer after curative surgery for lung cancer. C1 [Yamamoto, Haruko; Hamasaki, Toshimitsu; Onda, Kaori] Natl Cerebral & Cardiovasc Ctr, 6-1 Kishibeshimmachi, Suita, Osaka 5648565, Japan. [Nojiri, Takashi] Higashiosaka City Med Ctr, Higashiosaka, Osaka, Japan. [Aragaki, Masato; Horie, Nao; Sato, Norihiro; Hida, Yasuhiro] Hokkaido Univ Hosp, Sapporo, Hokkaido, Japan. C3 National Cerebral & Cardiovascular Center - Japan; Hokkaido University RP Yamamoto, H (corresponding author), Natl Cerebral & Cardiovasc Ctr, 6-1 Kishibeshimmachi, Suita, Osaka 5648565, Japan. EM harukoya@ncvc.go.jp RI Hamasaki, Toshimitsu/N-3851-2015; Aragaki, Masato/AAW-7688-2020; Yamamoto, Haruko/HII-5306-2022; Hida, Yasuhiro/A-7761-2012 OI Hamasaki, Toshimitsu/0000-0002-4928-1160; Hida, Yasuhiro/0000-0003-1759-4215 FU Ono Pharmaceutical Co., Ltd. (Osaka, Japan) FX Ono Pharmaceutical Co., Ltd. (Osaka, Japan), the manufacturer of landiolol, is funding all cost for this study, including central and local organizational costs, central diagnostic and imaging laboratories, meetings, the payment for the regulatory agency, and trial drug. Ono Pharmaceutical Co., Ltd., National Cerebral and Cardiovascular Center, and Hokkaido University had entered into a research agreement before the study started. The design, management, analysis, and reporting of the study are entirely independent of the manufacture of landiolol. CR Allemani C, 2015, LANCET, V385, P977, DOI 10.1016/S0140-6736(14)62038-9 Aoyama H, 2016, GEN THORAC CARDIOVAS, V64, P735, DOI 10.1007/s11748-016-0707-3 Barron TI, 2011, J CLIN ONCOL, V29, P2635, DOI 10.1200/JCO.2010.33.5422 Choi CH, 2014, J CANCER RES CLIN, V140, P1179, DOI 10.1007/s00432-014-1658-7 Cole SW, 2015, NAT REV CANCER, V15, P563, DOI 10.1038/nrc3978 De Giorgi V, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2017.2908 Diaz ES, 2012, GYNECOL ONCOL, V127, P375, DOI 10.1016/j.ygyno.2012.07.102 Goldstraw P, 2016, J THORAC ONCOL, V11, P39, DOI 10.1016/j.jtho.2015.09.009 Krumpl G, 2018, J CARDIOVASC PHARM, V71, P137, DOI 10.1097/FJC.0000000000000554 Krumpl G, 2017, EUR J CLIN PHARMACOL, V73, P417, DOI 10.1007/s00228-016-2176-0 Lemeshow S, 2011, CANCER EPIDEM BIOMAR, V20, P2273, DOI 10.1158/1055-9965.EPI-11-0249 Lu H, 2015, ONCOTARGETS THER, V8, P985, DOI 10.2147/OTT.S78836 Melhem-Bertrandt A, 2011, J CLIN ONCOL, V29, P2645, DOI 10.1200/JCO.2010.33.4441 Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710 Nakano T, 2012, J CLIN PHARM THER, V37, P431, DOI 10.1111/j.1365-2710.2011.01315.x Nojiri T, 2011, GEN THORAC CARDIOVAS, V59, P799, DOI 10.1007/s11748-011-0841-x Powe DG, 2010, ONCOTARGET, V1, P628, DOI 10.18632/oncotarget.197 Sakaguchi M, 2012, INT HEART J, V53, P359, DOI 10.1536/ihj.53.359 Sakamoto A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41520-7 Sezai A, 2011, J THORAC CARDIOV SUR, V141, P1478, DOI 10.1016/j.jtcvs.2010.10.045 Stewart B., 2015, World cancer report 2014 Wang HM, 2013, ANN ONCOL, V24, P1312, DOI 10.1093/annonc/mds616 Yagi K, 2016, Open Journal of Anesthesiology, V06, P119, DOI 10.4236/ojanes.2016.68020 Yap A, 2018, BRIT J ANAESTH, V121, P45, DOI 10.1016/j.bja.2018.03.024 NR 24 TC 8 Z9 9 U1 0 U2 5 PU BMC PI LONDON PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND EI 1745-6215 J9 TRIALS JI Trials PD DEC 11 PY 2019 VL 20 IS 1 AR 715 DI 10.1186/s13063-019-3904-4 PG 6 WC Medicine, Research & Experimental WE Science Citation Index Expanded (SCI-EXPANDED) SC Research & Experimental Medicine GA KC0OA UT WOS:000506885800010 PM 31829248 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Anand, K Ensor, J Trachtenberg, B Bernicker, EH AF Anand, Kartik Ensor, Joe Trachtenberg, Barry Bernicker, Eric H. TI Osimertinib-Induced Cardiotoxicity A Retrospective Review of the FDA Adverse Events Reporting System (FAERS) SO JACC: CARDIOONCOLOGY LA English DT Article DE cardiotoxicity; EGFR mutation; non-small cell lung cancer; osimertinib; QT prolongation ID CELL LUNG-CANCER; 1ST-LINE TREATMENT; EGFR MUTATIONS; OPEN-LABEL; GEFITINIB; CHEMOTHERAPY; TRASTUZUMAB; INHIBITORS; SMOKERS AB OBJECTIVES The goal of this study was to compare the risk of cardiotoxicity with osimertinib versus all other drugs and versus epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) (erlotinib, afatinib, and gefitinib) in the U.S. Food and Drug Administration Adverse Events Reporting System (FAERS), a phamiacovigilance database. BACKGROUND Osimertinib has been shown to improve outcomes in 7790M-positive non-small cell lung cancer patients who progress on EGFR-TKI therapy and in the frontline setting in EGFR mutated non-small cell lung cancer. In pivotal trials, osimertinib was associated with higher rates of cardiotoxicity compared with the control arm. METHODS FAERS was queried for "Cardiac failure," "Electrocardiogram QT-prolonged," "Atrial Fibrillation (AF)," "Myocardial Infarction (MI)," and "Pericardial Effusion" secondary to "Osimertinib," "Ertotinib," "Afatinib," "Gefitinib," and all other drugs from 2016 to 2018. Disproportionality signal analysis was performed by calculating the reporting odds ratio (ROR) with its 95% confidence interval (CI). The ROR was considered significant when the tower limit of the 95% CI was >1.0. RESULTS The ROR (95% CI) for cardiac failure, atrial fibrillation (AF), QT prolongation, myocardial infarction, and pericardial effusion due to osimertinib versus alt other drugs in FAERS was 5.4 (4.2 to 7.1), 4.0 (2.8 to 5.8), 11.2 (7.9 to 15.8), 1.6 (0.9 to 2.6), and 8.2 (4.8 to 14), respectively. The ROR (95% 0) for cardiac failure, AF, QT prolongation, myocardial infarction, and pericardial effusion in comparing osimertinib versus other EGFR-TKIs was 22 (1.5 to 3.2), 2.1 (1.3 to 3.5), 6.6 (3.4 to 12.8), 1.2 (0.6 to 2.3), and 1.6 (0.8 to 3.3). CONCLUSIONS The RORs for cardiac failure, AF, and QT prolongation were higher due to osimertinib compared with other TKIs. Electrocardiographic monitoring for QT prolongation and monitoring for signs and symptoms of heart failure should be considered in patients taking osimertinib. (C) 2019 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. C1 [Anand, Kartik; Bernicker, Eric H.] Houston Methodist Canc Ctr Weill Cornell Med, OPC 24,6445 Main St, Houston, TX 77030 USA. [Ensor, Joe] Houston Methodist Res Inst, Houston, TX USA. [Trachtenberg, Barry] Houston Methodist Hosp, DeBakey Heart & Vasc Inst, Div Cardiol, Houston, TX USA. C3 Houston Methodist; Houston Methodist; Houston Methodist RP Anand, K (corresponding author), Houston Methodist Canc Ctr Weill Cornell Med, OPC 24,6445 Main St, Houston, TX 77030 USA.; Bernicker, EH (corresponding author), Houston Methodist Canc Ctr Weill Cornell Med, Thorac & Uveal Melanoma Med Oncol, OPC 24,6445 Main St, Houston, TX 77030 USA. EM kartikanand88@gmail.com; bernicker@houstonmethodist.org RI ; Anand, Kartik/K-1370-2019 OI Ensor, Joe/0000-0003-3533-4388; Anand, Kartik/0000-0003-4480-1443 CR Anand K, 2019, CLIN LYMPHOMA MYELOM [Anonymous], ASTR PHARM TAGR OS P Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337 D'Angelo SP, 2011, J CLIN ONCOL, V29, P2066, DOI 10.1200/JCO.2010.32.6181 Lin JJ, 2016, J THORAC ONCOL, V11, P556, DOI 10.1016/j.jtho.2015.12.103 Lindeman NI, 2018, J MOL DIAGN, V20, P129, DOI [10.5858/arpa.2017-0388-CP, 10.1016/j.jmoldx.2017.11.004, 10.1016/j.jtho.2017.12.001] Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938 Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530 Mok TS, 2017, NEW ENGL J MED, V376, P629, DOI 10.1056/NEJMoa1612674 Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699 Moslehi JJ, 2015, J CLIN ONCOL, V33, P4210, DOI 10.1200/JCO.2015.62.4718 Noma T, 2007, J CLIN INVEST, V117, P2445, DOI 10.1172/JCI31901 Oyakawa Takuya, 2017, J Thorac Oncol, V12, pe159, DOI [10.1016/j.jtho.2017.05.016, 10.1016/j.jtho.2017.05.016] Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314 Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101 Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X Rothman KJ, 2004, PHARMACOEPIDEM DR S, V13, P519, DOI 10.1002/pds.1001 Salem JE, 2019, J AM COLL CARDIOL, V74, P1667, DOI 10.1016/j.jacc.2019.07.056 Seidman A, 2002, J CLIN ONCOL, V20, P1215, DOI 10.1200/JCO.20.5.1215 Slamon D, 2011, NEW ENGL J MED, V365, P1273, DOI 10.1056/NEJMoa0910383 Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137 Thein K, 2018, ANN ONCOL, V29 Viani GA, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-153 Wu YL, 2014, LANCET ONCOL, V15, P213, DOI 10.1016/S1470-2045(13)70604-1 NR 24 TC 179 Z9 195 U1 1 U2 30 PU ELSEVIER PI AMSTERDAM PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS SN 2666-0873 J9 JACC-CARDIOONCOL JI JACC-Cardiooncol. PD DEC PY 2019 VL 1 IS 2 BP 172 EP 178 DI 10.1016/j.jaccao.2019.10.006 PG 7 WC Oncology; Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Cardiovascular System & Cardiology GA VJ6EG UT WOS:000613113500005 PM 34396179 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Bongiolatti, S Gonfiotti, A Viggiano, D Borgianni, S Politi, L Crisci, R Curcio, C Voltolini, L Amore, D AF Bongiolatti, Stefano Gonfiotti, Alessandro Viggiano, Domenico Borgianni, Sara Politi, Leonardo Crisci, Roberto Curcio, Carlo Voltolini, Luca Amore, Dario CA Italian VATS Grp TI Risk factors and impact of conversion from VATS to open lobectomy: analysis from a national database SO SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES LA English DT Article DE Video-assisted thoracic surgery; Lobectomy; Lung cancer; Conversion; Complications ID ASSISTED THORACOSCOPIC SURGERY; OPEN THORACOTOMY; LUNG-CANCER; CHEMOTHERAPY; PREDICTORS; RESECTION AB Objective The objective of the study is to analyse the causes and impact of conversion from VATS to thoracotomy identifying any possible pre-operative risk factors and related consequences. Methods Data from patient who underwent VATS lobectomy (VATS-L) for NSCLC at VATS Group participating centres were retrospectively analysed and divided in two groups: patients treated with VATS-L and patients who suffered from conversion. Predictors of conversion were assessed with univariate and multivariable exact logistic regression. Complications were evaluated as dependent variables of conversion in a Cox multivariable logistic regression model. Results A total of 4629 patients underwent planned VATS-L for NSCLC and of these, 432 (9.3%) required conversion; the most frequent causes were bleeding (30.4%) and fibro-calcified hilar lymph nodes (23.9%). The independent risk factors at multivariable analysis model were sex male (OR 1.458, p < 0.01), age older than 70 years (OR 1.248, p = 0.036) and the clinically node-positive disease (OR 2.258, p < 0.01). The mortality rate was similar, but the percentage of patients who suffered from any complication (41.7% vs 24.4%, p < 0.01), the complication rate (65% vs 32.2%, p < 0.01), chest tube duration (p < 0.01) and the hospitalisation rate (p < 0.01) were higher for patients converted. Atrial fibrillation (OR 1.471, p = 0.019), prolonged air leak (OR 1.403, p = 0.043), blood transfusions (OR 4.820, p < 0.01), sputum retention (OR 1.80, p = 0.027) and acute kidney failure (OR 2.758, p = 0.03) were significantly associated with conversion at multivariable analysis. Conclusions Conversion is associated with increased surgical morbidity, blood loss and hospital stay. Sex male, old age and the clinical involvement of lymph nodes were the strongest predictors of conversion. C1 [Bongiolatti, Stefano; Gonfiotti, Alessandro; Viggiano, Domenico; Borgianni, Sara; Politi, Leonardo; Voltolini, Luca] Univ Hosp Careggi, Thorac Surg Unit, Largo Brambilla 1, I-50134 Florence, Italy. [Crisci, Roberto] Univ Aquila, Dept Thorac Surg, Laquila, Italy. [Curcio, Carlo] Monaldi Hosp, Div Thorac Surg, Naples, Italy. C3 University of Florence; Azienda Ospedaliero Universitaria Careggi; University of L'Aquila RP Bongiolatti, S (corresponding author), Univ Hosp Careggi, Thorac Surg Unit, Largo Brambilla 1, I-50134 Florence, Italy. EM stefanobongiolatti@gmail.com RI GONFIOTTI, Alessandro/AAP-1479-2020; Bongiolatti, Stefano/AAM-6602-2020; Politi, Letterio Salvatore/AAB-1092-2021; Crisci, Roberto/HNI-0544-2023; Voltolini, Luca/AAC-4944-2022 OI GONFIOTTI, Alessandro/0000-0003-2724-9474; Bongiolatti, Stefano/0000-0003-2722-9270; Viggiano, Domenico/0000-0003-2459-2082; Politi, Letterio Salvatore/0000-0002-6190-6688; CR [Anonymous], NONSM CELL LUNG CANC Augustin F, 2016, SURG ENDOSC, V30, P2415, DOI 10.1007/s00464-015-4492-3 Byun CS, 2015, ANN THORAC SURG, V100, P968, DOI 10.1016/j.athoracsur.2015.04.032 Dindo D, 2004, ANN SURG, V240, P205, DOI [10.17116/hirurgia2018090162, 10.1097/01.sla.0000133083.54934.ae] Falcoz PE, 2016, EUR J CARDIO-THORAC, V49, P602, DOI 10.1093/ejcts/ezv154 Flores RM, 2011, J THORAC CARDIOV SUR, V142, P1412, DOI 10.1016/j.jtcvs.2011.09.028 Gazala S, 2011, INTERACT CARDIOV TH, V12, P962, DOI 10.1510/icvts.2010.259663 Gonfiotti A, 2018, EUR J CARDIO-THORAC, V54, P664, DOI 10.1093/ejcts/ezy098 Gonfiotti Alessandro, 2017, J Vis Surg, V3, P160, DOI [10.21037/jovs.2017.09.06, 10.21037/jovs.2017.09.06] Gonfiotti A, 2016, J THORAC DIS, V8, P3496, DOI 10.21037/jtd.2016.12.45 Gonfiotti A, 2016, J CARDIOTHORAC SURG, V11, DOI 10.1186/s13019-016-0526-8 Gonzalez-Rivas D, 2014, J THORAC DIS, V6, P641, DOI 10.3978/j.issn.2072-1439.2014.05.17 Hennon M, 2011, ANN SURG ONCOL, V18, P3732, DOI 10.1245/s10434-011-1834-9 Laursen LO, 2016, EUR J CARDIO-THORAC, V49, P870, DOI 10.1093/ejcts/ezv205 McKenna Robert J Jr, 2008, Thorac Surg Clin, V18, P275, DOI 10.1016/j.thorsurg.2008.04.004 Onaitis MW, 2006, ANN SURG, V244, P420, DOI 10.1097/01.sla.0000234892.79056.63 Petersen RP, 2007, ANN THORAC SURG, V83, P1245, DOI 10.1016/j.athoracsur.2006.12.029 Petersen RH, 2012, ANN CARDIOTHORAC SUR, V1, P47, DOI 10.3978/j.issn.2225-319X.2012.04.05 Puri V, 2015, J THORAC CARDIOV SUR, V149, P55, DOI 10.1016/j.jtcvs.2014.08.074 Roviaro G, 1992, Surg Laparosc Endosc, V2, P244 Samson P, 2013, J THORAC CARDIOV SUR, V145, P1512, DOI 10.1016/j.jtcvs.2012.05.028 Swanson SJ, 2007, J CLIN ONCOL, V25, P4993, DOI 10.1200/JCO.2007.12.6649 Villamizar NR, 2013, J THORAC CARDIOV SUR, V145, P514, DOI 10.1016/j.jtcvs.2012.10.039 Watanabe A, 2005, SURGERY, V138, P510, DOI 10.1016/j.surg.2005.04.005 Whitson BA, 2007, ANN THORAC SURG, V83, P1965, DOI 10.1016/j.athoracsur.2007.01.049 Yang CFJ, 2016, EUR J CARDIO-THORAC, V49, P1615, DOI 10.1093/ejcts/ezv428 NR 26 TC 34 Z9 39 U1 0 U2 7 PU SPRINGER PI NEW YORK PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES SN 0930-2794 EI 1432-2218 J9 SURG ENDOSC JI Surg. Endosc. PD DEC PY 2019 VL 33 IS 12 BP 3953 EP 3962 DI 10.1007/s00464-019-06682-5 PG 10 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA JT4QX UT WOS:000500976900010 PM 30706153 OA Green Submitted DA 2026-04-17 ER PT J AU Yin, JC Zhao, MN Lu, T Huang, YW Sui, QH Xi, JJ Lin, ZW Xu, ST Wang, Q Zhan, C AF Yin, Jiacheng Zhao, Mengnan Lu, Tao Huang, Yiwei Sui, Qihai Xi, Junjie Lin, Zongwu Xu, Songtao Wang, Qun Zhan, Cheng TI Non-lung cancer specific mortality after lobectomy or sublobectomy in patients with stage IA non-small cell lung cancer ≤2 cm: A propensity score analysis SO JOURNAL OF SURGICAL ONCOLOGY LA English DT Article DE lobectomy; non-lung cancer mortality; non-small cell lung cancer; surveillance; epidemiology; and end results; sublobectomy ID CLINICOPATHOLOGICAL CHARACTERISTICS; PLEOMORPHIC CARCINOMA; ATRIAL-FIBRILLATION; SURVIVAL; OUTCOMES; STATISTICS AB Background and Objectives To investigate non-lung cancer specific mortality between stage IA non-small cell lung cancer (NSCLC) tumors less than and equal to 2 cm treated with lobectomy and sublobectomy. Methods Surveillance, epidemiology, and end results database was queried for patients who underwent lobectomy and sublobectomy. Propensity score matching (PSM) was used to achieve balance in clinicopathological characteristics. We used Fine-and-Gray hazard functions to analyze cause-specific mortality and risk factors. Standardized mortality ratios were calculated to describe cause specific mortality relative to the general population. Results After PSM, 3,844 patients underwent lobectomy and 1,922 patients underwent sublobectomy. Three leading causes of non-lung cancer mortality were cardiovascular disease (CVD), chronic obstructive pulmonary diseases (COPD), and other cancers. The 5-year cumulative non-lung cancer mortality of lobectomy and sublobectomy groups were 11.4% and 14.0%, respectively (P = .090). Multivariate analyses revealed that age, sex, histology, tumor size, and marital status (P < .01) were independent predictors of non-lung cancer specific mortality. In both groups, risks of CVD specific mortality were comparable to that in the general population, whereas the risk of COPD specific mortality was higher relative to the general population. Conclusions As a significant competing event, non-lung cancer specific mortality is comparable between stage IA NSCLC tumors less than equal to 2 cm treated with lobectomy and sublobectomy. C1 [Yin, Jiacheng; Zhao, Mengnan; Lu, Tao; Huang, Yiwei; Xi, Junjie; Lin, Zongwu; Xu, Songtao; Wang, Qun; Zhan, Cheng] Fudan Univ, Zhongshan Hosp, Dept Thorac Surg, 180 Fenglin Rd, Shanghai 200032, Peoples R China. [Sui, Qihai] Fudan Univ, Shanghai Med Coll, Shanghai, Peoples R China. C3 Fudan University; Fudan University RP Wang, Q; Zhan, C (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Thorac Surg, 180 Fenglin Rd, Shanghai 200032, Peoples R China. EM wang.qun@zs-hospital.sh.cn; czhan10@fudan.edu.cn RI Huang, Yiwei/AAQ-1799-2021; Mnegnan, Zhao/MAH-7509-2025; Zhan, Cheng/F-3265-2014 OI Zhan, Cheng/0000-0001-8745-9276 FU National Natural Science Foundation of China [81472225, 81572295] Funding Source: Medline CR Altman DG, 2011, BMJ-BRIT MED J, V343, DOI [10.1136/bmj.d2304, 10.1136/bmj.d2090] Austin PC, 2016, CIRCULATION, V133, P601, DOI 10.1161/CIRCULATIONAHA.115.017719 Berry MF, 2009, ANN THORAC SURG, V88, P1093, DOI 10.1016/j.athoracsur.2009.06.012 Bhave PD, 2012, AM HEART J, V164, P918, DOI 10.1016/j.ahj.2012.09.004 Blasberg JD, 2010, J THORAC ONCOL, V5, P1583, DOI 10.1097/JTO.0b013e3181e77604 Breslow N E, 1987, IARC Sci Publ, P1 Cao JL, 2018, J THORAC CARDIOV SUR, V156, P796, DOI 10.1016/j.jtcvs.2018.03.122 Choi AH, 2012, ANN ONCOL, V23, P2449, DOI 10.1093/annonc/mdr616 Eguchi T, 2017, J CLIN ONCOL, V35, P281, DOI 10.1200/JCO.2016.69.0834 Ewer MS, 2015, NAT REV CARDIOL, V12, P620, DOI 10.1038/nrcardio.2015.133 Farmakis D, 2014, J AM COLL CARDIOL, V63, P945, DOI 10.1016/j.jacc.2013.11.026 Ferlay J, 2018, EUR J CANCER, V103, P356, DOI 10.1016/j.ejca.2018.07.005 Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170 Goldstraw P, 2016, J THORAC ONCOL, V11, P39, DOI 10.1016/j.jtho.2015.09.009 Groth SS, 2010, ANN THORAC SURG, V90, P375, DOI 10.1016/j.athoracsur.2010.04.100 Haque W, 2018, INT J RADIAT ONCOL, V100, P470, DOI 10.1016/j.ijrobp.2017.10.031 Howlader N, 2010, J NATL CANCER I, V102, P1584, DOI 10.1093/jnci/djq366 Kanzaki R, 2017, SURG TODAY, V47, P27, DOI 10.1007/s00595-016-1355-z KAUFMAN MW, 1984, CANCER-AM CANCER SOC, V53, P1908, DOI 10.1002/1097-0142(19840501)53:9<1908::AID-CNCR2820530917>3.0.CO;2-F Kilic A, 2009, ANN THORAC SURG, V87, P1662, DOI 10.1016/j.athoracsur.2009.02.097 Kwon M, 2014, ANN ONCOL, V25, P1208, DOI 10.1093/annonc/mdu128 McCaffrey DF, 2004, PSYCHOL METHODS, V9, P403, DOI 10.1037/1082-989X.9.4.403 Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349 Mochizuki T, 2008, AM J SURG PATHOL, V32, P1727, DOI 10.1097/PAS.0b013e3181804302 Oizumi H, 2009, EUR J CARDIO-THORAC, V36, P374, DOI 10.1016/j.ejcts.2009.03.038 Ou SHI, 2008, J THORAC ONCOL, V3, P880, DOI 10.1097/JTO.0b013e31817dfced Pettiford Brian L, 2007, Thorac Surg Clin, V17, P175, DOI 10.1016/j.thorsurg.2007.03.002 Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI [10.3322/caac.21442, 10.3322/caac.21551] Smith CB, 2017, SEMIN THORAC CARDIOV, V29, P223, DOI 10.1053/j.semtcvs.2017.01.013 Takamochi K, 2011, INTERACT CARDIOV TH, V12, P739, DOI 10.1510/icvts.2010.254821 Wei SH, 2018, J CANCER RES CLIN, V144, P145, DOI 10.1007/s00432-017-2522-3 Williams SB, 2018, JAMA SURG, V153, P881, DOI 10.1001/jamasurg.2018.1680 Yang XD, 2017, J SURG ONCOL, V116, P398, DOI 10.1002/jso.24677 Yin JC, 2018, J THORAC DIS, V10, P4262, DOI 10.21037/jtd.2018.06.71 Zhou HQ, 2018, CLIN LUNG CANCER, V19, pE195, DOI 10.1016/j.cllc.2017.10.016 NR 35 TC 7 Z9 8 U1 0 U2 4 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4790 EI 1096-9098 J9 J SURG ONCOL JI J. Surg. Oncol. PD DEC PY 2019 VL 120 IS 8 BP 1486 EP 1496 DI 10.1002/jso.25724 PG 11 WC Oncology; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Surgery GA JP7SM UT WOS:000498460700027 PM 31602661 DA 2026-04-17 ER PT J AU Tamura, Y Sawabata, N Susaki, Y Nakamura, T Taniguchi, S AF Tamura, Yamato Sawabata, Noriyoshi Susaki, Yoshiyuki Nakamura, Takahito Taniguchi, Shigeki TI Effect of Cardiac Expansion on Postsurgical Pulmonary Resection Recovery SO IN VIVO LA English DT Article DE Cardiac expansion; pulmonary resection; postoperative recovery; left ventricular expansion. ID LUNG-CANCER; ATRIAL-FIBRILLATION; ASSOCIATION; DIAGNOSIS; AGE AB Background/Aim: In patients undergoing lung resection, even when lung and ventricular function are normal, there may be a prolonged delay in postoperative recovery. The effect of left ventricular extension disorders on recovery after pulmonary resection was investigated. Materials and Methods: The postoperative recovery of ninety patients with normal left ventricular ejection fraction and exercise tolerance who underwent anatomical pulmonary resection was evaluated according to the grade of left ventricular expansion (E/e'). Results: Left ventricular extension was normal (<= 8) in 53 cases, moderately restricted (8-12) in 36 cases and severely restricted (>12) in 9 cases. No significant difference was found in the postoperative complication rate. However, the severely restricted group had a significantly higher duration of oxygen administration, intensive care unit stay, and postoperative hospital stay, which were found to be independent predictors of ventricular expansion. Conclusion: Left ventricular expansion dysfunction had a negative effect on postoperative recovery. C1 [Tamura, Yamato; Sawabata, Noriyoshi; Taniguchi, Shigeki] Nara Med Univ, Dept Thorac & Cardiovasc Surg, Nara, Japan. [Sawabata, Noriyoshi; Susaki, Yoshiyuki] Hoshigaoka Med Ctr, Dept Thorac Surg, Osaka, Japan. [Nakamura, Takahito] Hoshigaoka Med Ctr, Dept Resp Med, Osaka, Japan. C3 Nara Medical University RP Sawabata, N (corresponding author), Nara Med Univ Hosp, Dept Gen Thorac Surg, 840 Shijo Cho, Kashihara, Nara 6348522, Japan. EM nsawabata@hotmail.com RI ; Sawabata, Noriyoshi/AAJ-1025-2021 OI Tamura, Yamato/0000-0003-2273-784X; CR Brunelli A, 2013, CHEST, V143, pE166, DOI 10.1378/chest.12-2395 De Sutter J, 2005, AM J CARDIOL, V95, P1020, DOI 10.1016/j.amjcard.2005.01.021 Dindo D, 2004, ANN SURG, V240, P205, DOI [10.17116/hirurgia2018090162, 10.1097/01.sla.0000133083.54934.ae] Iwata T, 2016, SURG TODAY, V46, P877, DOI 10.1007/s00595-015-1258-4 Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244 Li YZ, 2017, ACTA BIOMATER, V55, P120, DOI 10.1016/j.actbio.2017.04.027 Meschiari CA, 2017, GEROSCIENCE, V39, P7, DOI 10.1007/s11357-017-9959-9 Nagueh SF, 2016, J AM SOC ECHOCARDIOG, V29, P277, DOI 10.1016/j.echo.2016.01.011 Nakamura T, 2020, GEN THORAC CARDIOVAS, V68, P49, DOI 10.1007/s11748-019-01153-z Nojiri T, 2012, J THORAC CARDIOV SUR, V143, P488, DOI 10.1016/j.jtcvs.2011.09.003 Nojiri T, 2010, J THORAC CARDIOV SUR, V140, P764, DOI 10.1016/j.jtcvs.2009.11.073 Okami J, 2009, J THORAC ONCOL, V4, P1247, DOI 10.1097/JTO.0b013e3181ae285d Sawabata N, 2015, GEN THORAC CARDIOVAS, V63, P14, DOI 10.1007/s11748-014-0475-x Zile MR, 2002, CIRCULATION, V105, P1387, DOI 10.1161/hc1102.105289 NR 14 TC 1 Z9 1 U1 0 U2 0 PU INT INST ANTICANCER RESEARCH PI ATHENS PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE SN 0258-851X EI 1791-7549 J9 IN VIVO JI In Vivo PD NOV-DEC PY 2019 VL 33 IS 6 BP 1977 EP 1984 DI 10.21873/invivo.11693 PG 8 WC Medicine, Research & Experimental WE Science Citation Index Expanded (SCI-EXPANDED) SC Research & Experimental Medicine GA JI6FW UT WOS:000493564200033 PM 31662527 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Alomar, M Fradley, MG AF Alomar, Mohammed Fradley, Michael G. TI Electrophysiology Translational Considerations in Cardio-Oncology: QT and Beyond SO JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH LA English DT Review DE Cardio-oncology; Arrhythmias; Atrial fibrillation; QT prolongation; Cardiotoxicity ID STEM-CELL TRANSPLANT; ATRIAL-FIBRILLATION; PHASE-I; 5-FLUOROURACIL INFUSION; CHA(2)DS(2)-VASC SCORE; INTERVAL PROLONGATION; ARSENIC TRIOXIDE; RISK-FACTORS; LUNG-CANCER; IBRUTINIB AB With improved screening and the advent of many novel therapeutics, patients with cancer are living longer and often surviving their disease. Cardiovascular complications have significant impact on both short- and long-term morbidity and mortality in these patients. While a great deal of attention has been paid to cardiomyopathy and heart failure, many other cardiotoxicities can occur, often at higher rates. Arrhythmias are a particularly common cardiovascular complication of cancer therapeutics and can range from benign to life threatening. Moreover, management of these rhythm disturbances can be challenging in cancer patients for various reasons including drug interactions, as well as underlying hematologic and metabolic disturbances. In this review, we describe the most common therapeutics associated with arrhythmias in cancer patients and provide a discussion about the potential basic and translational mechanisms leading to the development of the various rhythm disturbances which may help to guide prevention and treatment decisions. Identifier: NCT02928497 C1 [Alomar, Mohammed; Fradley, Michael G.] Univ S Florida, Morsani Coll Med, Div Cardiovasc Med, Cardiooncol Program,MCB CPT, 12902 USF Magnolia Dr, Tampa, FL 33612 USA. [Alomar, Mohammed; Fradley, Michael G.] H Lee Moffitt Canc Ctr & Res Inst, MCB CPT, 12902 USF Magnolia Dr, Tampa, FL 33612 USA. C3 State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute RP Fradley, MG (corresponding author), Univ S Florida, Morsani Coll Med, Div Cardiovasc Med, Cardiooncol Program,MCB CPT, 12902 USF Magnolia Dr, Tampa, FL 33612 USA.; Fradley, MG (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, MCB CPT, 12902 USF Magnolia Dr, Tampa, FL 33612 USA. EM mfradley@health.usf.edu CR AKHTAR SS, 1993, ONCOLOGY, V50, P441 Alsaab HO, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00561 [Anonymous], 2015, AUST PRESCR, V38, P178, DOI 10.18773/austprescr.2015.065 [Anonymous], 2010, MONITORING HLTH SDGS Arbuck S G, 1993, J Natl Cancer Inst Monogr, P117 Armanious MA, 2018, CURR ONCOL REP, V20, DOI 10.1007/s11912-018-0691-0 Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025 AVERSANO RC, 1983, RES COMMUN CHEM PATH, V41, P345 Barbey JT, 2003, J CLIN ONCOL, V21, P3609, DOI 10.1200/JCO.2003.10.009 Bertilsson L, 2002, BRIT J CLIN PHARMACO, V53, P111, DOI 10.1046/j.0306-5251.2001.01548.x BINAH O, 1983, CIRC RES, V53, P655, DOI 10.1161/01.RES.53.5.655 Bischiniotis Theodoros S, 2005, Hellenic J Cardiol, V46, P324 Blackhall FH, 2010, J THORAC ONCOL, V5, P1285, DOI 10.1097/JTO.0b013e3181e3a2d1 Bovelli D, 2010, ANN ONCOL, V21, pv277, DOI 10.1093/annonc/mdq200 Brown JR, 2017, HAEMATOLOGICA, V102, P1796, DOI 10.3324/haematol.2017.171041 Buza V, 2017, CIRC-ARRHYTHMIA ELEC, V10, DOI 10.1161/CIRCEP.117.005443 Byrd JC, 2014, NEW ENGL J MED, V371, P213, DOI 10.1056/NEJMoa1400376 Byrd JC, 2016, NEW ENGL J MED, V374, P323, DOI 10.1056/NEJMoa1509981 Chandrasekhar S, 2019, CURR TREAT OPTION ON, V20, DOI 10.1007/s11864-019-0657-y Chen B, 2007, CARDIOVASC TOXICOL, V7, P114, DOI 10.1007/s12012-007-0005-5 Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561 Coppens M, 2013, EUR HEART J, V34, P170, DOI 10.1093/eurheartj/ehs314 D'Souza M, 2018, EUR J PREV CARDIOL, V25, P651, DOI 10.1177/2047487318759858 Dimopoulos MA, 2018, NEW ENGL J MED, V378, P2399, DOI 10.1056/NEJMoa1802917 Drew BJ, 2010, J AM COLL CARDIOL, V55, P934, DOI [10.1016/j.jacc.2010.01.001, 10.1161/CIRCULATIONAHA.109.192704] Dreyling M, 2016, LANCET, V387, P770, DOI 10.1016/S0140-6736(15)00667-4 Duan Jialin, 2018, Oncotarget, V9, P25738, DOI [10.18632/oncotarget.25008, 10.18632/oncotarget.25008] Farmakis D, 2014, J AM COLL CARDIOL, V63, P945, DOI 10.1016/j.jacc.2013.11.026 Fatema K, 2009, AM J HEMATOL, V84, P499, DOI 10.1002/ajh.21459 Feliz V, 2011, CLIN CARDIOL, V34, P356, DOI 10.1002/clc.20904 Ficker E, 2004, MOL PHARMACOL, V66, P33, DOI 10.1124/mol.66.1.33 Figueroa R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200220 Florido R, 2017, J AM HEART ASSOC, V6, DOI [10.1161/JAHA.117.006915, 10.1161/JAHA.116.003505] Fradley MG, 2019, AM J CARDIOL, V124, P539, DOI 10.1016/j.amjcard.2019.05.029 Fradley MG, 2017, OPEN HEART, V4, DOI 10.1136/openhrt-2017-000701 Fradley Michael G, 2015, Card Electrophysiol Clin, V7, P341, DOI [10.1016/j.ccep.2015.03.013, 10.1016/j.ccep.2015.03.013] Ganatra S, 2018, JACC-CLIN ELECTROPHY, V4, P1491, DOI 10.1016/j.jacep.2018.06.004 Ganatra S, 2018, ONCOLOGIST, V23, P879, DOI 10.1634/theoncologist.2018-0130 Gorelik J, 2003, FEBS LETT, V548, P74, DOI 10.1016/S0014-5793(03)00743-9 Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039 Guglin M, 2009, EUROPACE, V11, P1579, DOI 10.1093/europace/eup300 Guo YT, 2012, J AM COLL CARDIOL, V60, P2263, DOI 10.1016/j.jacc.2012.04.063 Heinzerling L, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0152-y Hidalgo JD, 2004, BONE MARROW TRANSPL, V34, P615, DOI 10.1038/sj.bmt.1704623 Holkova B, 2013, CLIN CANCER RES, V19, P1873, DOI 10.1158/1078-0432.CCR-12-2926 Holmes DR, 2014, J AM COLL CARDIOL, V64, P1, DOI 10.1016/j.jacc.2014.04.029 Honigberg LA, 2010, P NATL ACAD SCI USA, V107, P13075, DOI 10.1073/pnas.1004594107 Hu YF, 2015, NAT REV CARDIOL, V12, P230, DOI 10.1038/nrcardio.2015.2 Imperatori Andrea, 2012, J Cardiothorac Surg, V7, P4, DOI 10.1186/1749-8090-7-4 Infante JR, 2016, CLIN CANCER RES, V22, P5696, DOI 10.1158/1078-0432.CCR-16-1248 Iwasaki YK, 2011, CIRCULATION, V124, P2264, DOI 10.1161/CIRCULATIONAHA.111.019893 January CT, 2019, CIRCULATION, V140, pE125, DOI [10.1161/CIR.0000000000000665, 10.1016/j.jacc.2019.01.011] Jiang L, 2019, HEART RHYTHM, V16, P1374, DOI 10.1016/j.hrthm.2019.04.008 Kamel S, 2015, LEUKEMIA, V29, P783, DOI 10.1038/leu.2014.247 Katsume Y, 2018, INTERNAL MED, V57, P3157, DOI 10.2169/internalmedicine.0255-17 Kavurmaci O, 2018, HEART LUNG CIRC, V27, P835, DOI 10.1016/j.hlc.2017.06.729 Keating MT, 2001, CELL, V104, P569, DOI 10.1016/S0092-8674(01)00243-4 Khan MA, 2012, J PAK MED ASSOC, V62, P430 Kluza J, 2004, ONCOGENE, V23, P7018, DOI 10.1038/sj.onc.1207936 Kosmas C, 2008, J CANCER RES CLIN, V134, P75, DOI 10.1007/s00432-007-0250-9 Kuropkat C, 1999, AM J CLIN ONCOL-CANC, V22, P466, DOI 10.1097/00000421-199910000-00009 Levade M, 2014, BLOOD, V124, P3991, DOI 10.1182/blood-2014-06-583294 Liu Y, 2015, EUR J CLIN PHARMACOL, V71, P541, DOI 10.1007/s00228-015-1831-1 Longhi S, 2015, AMYLOID, V22, P147, DOI 10.3109/13506129.2015.1028616 López-Fernández T, 2019, REV ESP CARDIOL, V72, P749, DOI 10.1016/j.rec.2019.03.019 Lu ZJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003623 Mahmood S, 2018, J AM COLL CARDIOL, V71, P699, DOI [10.1016/S0735-1097(18)31240-3, 10.1016/j.jacc.2018.02.037] Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065 Masoudi F, 2015, J AM COLL CARDIOL, V66, P1497, DOI 10.1016/j.jacc.2015.06.028 Mazur Matylda, 2017, JACC Clin Electrophysiol, V3, P139, DOI [10.1016/j.jacep.2016.08.009, 10.1016/j.jacep.2016.08.009] MCGUIRE WP, 1989, ANN INTERN MED, V111, P273, DOI 10.7326/0003-4819-111-4-273 McMullen JR, 2014, BLOOD, V124, P3829, DOI 10.1182/blood-2014-10-604272 Miklos D, 2017, BLOOD, V130, P2243, DOI 10.1182/blood-2017-07-793786 Morgan T K Jr, 1992, Prog Med Chem, V29, P65, DOI 10.1016/S0079-6468(08)70005-5 Mostaghel EA, 2014, CAN J UROL, V21, P57 Muchtar E, 2016, BONE MARROW TRANSPL, V51, P1449, DOI 10.1038/bmt.2016.174 Mumford JL, 2007, ENVIRON HEALTH PERSP, V115, P690, DOI 10.1289/ehp.9686 Nattel S, 2008, CIRC-ARRHYTHMIA ELEC, V1, P62, DOI 10.1161/CIRCEP.107.754564 O'Brien S, 2018, BLOOD, V131, P1910, DOI 10.1182/blood-2017-10-810044 O'Connor OA, 2015, J CLIN ONCOL, V33, P2492, DOI 10.1200/JCO.2014.59.2782 Ou SHI, 2016, CANCER MED-US, V5, P617, DOI 10.1002/cam4.622 Özcelik C, 2002, P NATL ACAD SCI USA, V99, P8880, DOI 10.1073/pnas.122249299 Passalia C, 2013, TUMORI, V99, pE288, DOI 10.1700/1390.15471 Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638 Patell R, 2017, AM J CARDIOL, V120, P2182, DOI 10.1016/j.amjcard.2017.08.038 Peres E, 2010, BONE MARROW TRANSPL, V45, P149, DOI 10.1038/bmt.2009.97 Petrini I, 2012, CANCER CHEMOTH PHARM, V69, P773, DOI 10.1007/s00280-011-1753-2 Porta-Sánchez A, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.007724 RAABE NK, 1991, ACTA ONCOL, V30, P843, DOI 10.3109/02841869109091832 Raja W, 2013, INDIAN J MED PAEDIAT, V34, P330, DOI 10.4103/0971-5851.125262 Rao PP, 2019, EXP THER MED, V17, P3141, DOI 10.3892/etm.2019.7306 Rhea IB, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0797-z Roboz GJ, 2014, J CLIN ONCOL, V32, P3723, DOI 10.1200/JCO.2013.51.2913 Roden DM, 2004, NEW ENGL J MED, V350, P1013, DOI 10.1056/NEJMra032426 Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122 Sarubbi B, 1997, HEART VESSELS, V12, P262, DOI 10.1007/BF02766801 Shah S, 2018, BLOOD ADV, V2, P200, DOI 10.1182/bloodadvances.2017010694 Shanafelt TD, 2017, LEUKEMIA LYMPHOMA, V58, P1630, DOI 10.1080/10428194.2016.1257795 Siegel D, 2013, HAEMATOLOGICA, V98, P1753, DOI 10.3324/haematol.2013.089334 Singla A, 2013, BIOL BLOOD MARROW TR, V19, P1233, DOI 10.1016/j.bbmt.2013.05.019 Siu CW, 2006, BLOOD, V108, P103, DOI 10.1182/blood-2006-01-0054 Slamon DJ, 2018, J CLIN ONCOL, V36, P2465, DOI 10.1200/JCO.2018.78.9909 Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101 Society AC, 2014, CANC TREATM SURV FAC, P2014 Südhoff T, 2004, ANN ONCOL, V15, P661, DOI 10.1093/annonc/mdh150 Sulpher J, 2014, CASE REP ONCOL MED, V2014, DOI 10.1155/2014/819396 Sun H, 2004, CARDIOVASC RES, V62, P509, DOI 10.1016/j.cardiores.2004.01.029 Tamargo J, 2015, DRUG SAFETY, V38, P129, DOI 10.1007/s40264-014-0258-4 Thomas D, 2006, CURR PHARM DESIGN, V12, P2271, DOI 10.2174/138161206777585102 Treon SP, 2015, NEW ENGL J MED, V372, P1430, DOI 10.1056/NEJMoa1501548 Tse G, 2017, IJC HEART VASC, V14, P8, DOI 10.1016/j.ijcha.2016.11.006 Tuomi JM, 2018, CAN J CARDIOL, V34, P337, DOI 10.1016/j.cjca.2017.12.001 Wang ML, 2013, NEW ENGL J MED, V369, P507, DOI 10.1056/NEJMoa1306220 Wessler JD, 2013, J AM COLL CARDIOL, V61, P2495, DOI 10.1016/j.jacc.2013.02.058 WHITE RL, 1994, CANCER, V74, P3212, DOI 10.1002/1097-0142(19941215)74:12<3212::AID-CNCR2820741221>3.0.CO;2-I Yang XY, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01058 Yuan M, 2018, CARDIOVASC THER, V36, DOI 10.1111/1755-5922.12475 Zamorano JL, 2016, EUR HEART J, V37, P2768, DOI [10.1093/eurheartj/ehw211, 10.1002/ejhf.654] Zellos L, 2009, J THORAC CARDIOV SUR, V137, P453, DOI 10.1016/j.jtcvs.2008.07.055 Zhang Zhushan, 2017, Cardiooncology, V3, DOI [10.1186/s40959-017-0020-z, 10.1007/s12559-017-9484-2, 10.1186/s40959-017-0020-z] Zhao YY, 1998, J BIOL CHEM, V273, P10261, DOI 10.1074/jbc.273.17.10261 Zukkoor S, 2018, DRUG DRUG INTERACTIO NR 122 TC 12 Z9 13 U1 0 U2 21 PU SPRINGER PI NEW YORK PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES SN 1937-5387 EI 1937-5395 J9 J CARDIOVASC TRANSL JI J. Cardiovasc. Transl. Res. PD JUN PY 2020 VL 13 IS 3 SI SI BP 390 EP 401 DI 10.1007/s12265-019-09924-y EA OCT 2019 PG 12 WC Cardiac & Cardiovascular Systems; Medicine, Research & Experimental WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Research & Experimental Medicine GA MK3AC UT WOS:000495051500001 PM 31673900 OA hybrid DA 2026-04-17 ER PT J AU Altinkaynak, D Koktener, A AF Altinkaynak, Derya Koktener, Asli TI Evaluation of pulmonary venous variations in a large cohort Multidetector computed tomography study with new variations SO WIENER KLINISCHE WOCHENSCHRIFT LA English DT Article DE Pulmonary venous anatomy; Computed tomography; Anatomic variations; Thoracic surgery; Atrial fibrillation ID RADIOFREQUENCY CATHETER ABLATION; ATRIAL-FIBRILLATION; VEIN MIMICKING; LUNG-CANCER; DRAINAGE; ANATOMY; ANGIOGRAPHY; OSTIUM AB Objective The aim of this study was to assess pulmonary venous anatomy and to determine the frequency of each drainage pattern in a large cohort using multidetector computed tomography (MDCT) and three-dimensional (3D) imaging. Material and methods The chest CT images of 550 patients were retrospectively reviewed for pulmonary venous anatomy and variant patterns. All CT scans were performed using a 128 detectors row CT scanner after intravenous contrast administration. Pulmonary venous drainage pattern was documented for each patient and frequency of each drainage type was calculated. A useful classification system was used to simplify complex pulmonary venous anatomy. Results The expected typical anatomy was observed in 239 (43.5%) patients. The remaining 311 (56.5%) patients had anatomic variations on the right, left, or both sides. The most common variation was left common vein, seen in 177 (32.2%) patients, followed by accessory right middle lobe vein(s), seen in 112 (20.4%) patients. In the present study the frequency of variant anatomy on the right (34%) and left (33.3%) sides were similar. Conclusion The use of MDCT with 3D imaging is a preferable imaging tool for demonstrating pulmonary venous anatomy in detail, which shows significant variability. Considering the high prevalence of variations in the population, performing preprocedural MDCT may facilitate higher success rates in radiofrequency catheter ablation (RFCA) and help to perform safe and accurate surgery especially in video-assisted thoracic surgery (VATS). C1 [Altinkaynak, Derya] Midyat State Hosp, Dept Radiol, Mardin, Turkey. [Koktener, Asli] Private Ankara Mem Hosp, Dept Radiol, Ankara, Turkey. C3 Mardin Midyat State Hospital RP Altinkaynak, D (corresponding author), Midyat State Hosp, Dept Radiol, Mardin, Turkey. EM karnasderya@yahoo.com RI Koktener, Asli/ACB-3200-2022 CR Akiba T, 2010, GEN THORAC CARDIOVAS, V58, P331, DOI 10.1007/s11748-010-0592-0 ALFKE H, 1995, CARDIOVASC INTER RAD, V18, P406, DOI 10.1007/BF00338311 Anselmino M, 2011, J CARDIOVASC ELECTR, V22, P1, DOI 10.1111/j.1540-8167.2010.01853.x Asai K, 2005, ANN THORAC SURG, V79, P1866, DOI 10.1016/j.athoracsur.2004.12.014 BENFIELD JR, 1971, CHEST, V59, P101, DOI 10.1378/chest.59.1.101 Benini K, 2008, RADIOL MED, V113, P779, DOI 10.1007/s11547-008-0299-9 COLLINS DR, 1982, ANGIOLOGY, V33, P613, DOI 10.1177/000331978203300907 Cronin P, 2004, AM J ROENTGENOL, V183, P767, DOI 10.2214/ajr.183.3.1830767 Ghaye B, 2003, RADIOGRAPHICS, V23, pS19, DOI 10.1148/rg.23si035513 Haïssaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003 Hamdan A, 2009, AM J CARDIOL, V104, P1540, DOI 10.1016/j.amjcard.2009.07.029 Harbi A, 2014, J SAUDI HEART ASSOC, V26, P81, DOI 10.1016/j.jsha.2013.11.007 Hassani C, 2017, RADIOGRAPHICS, V37, P1928, DOI 10.1148/rg.2017170050 HASUO K, 1981, CHEST, V79, P602, DOI 10.1378/chest.79.5.602 Jais P, 1997, CIRCULATION, V95, P572, DOI 10.1161/01.CIR.95.3.572 Jongbloed MRM, 2005, J AM COLL CARDIOL, V45, P343, DOI 10.1016/j.jacc.2004.10.040 Kaseno K, 2008, AM J CARDIOL, V101, P1638, DOI 10.1016/j.amjcard.2008.01.053 Kato R, 2003, CIRCULATION, V107, P2004, DOI 10.1161/01.CIR.0000061951.81767.4E Lickfett L, 2005, J CARDIOVASC ELECTR, V16, P582, DOI 10.1046/j.1540-8167.2005.40724.x Mansour M, 2004, J CARDIOVASC ELECTR, V15, P387, DOI 10.1046/j.1540-8167.2004.03515.x Marom EM, 2004, RADIOLOGY, V230, P824, DOI 10.1148/radiol.2303030315 Matsumoto Isao, 2005, Ann Thorac Cardiovasc Surg, V11, P316 Nakamura T, 2009, ANN THORAC SURG, V87, P954, DOI 10.1016/j.athoracsur.2008.07.054 Prasanna LC, 2014, J CLIN DIAGN RES, V8, P10, DOI 10.7860/JCDR/2014/7649.3992 REY C, 1986, CATHETER CARDIO DIAG, V12, P330, DOI 10.1002/ccd.1810120511 Schwartzman D, 2003, J AM COLL CARDIOL, V41, P1349, DOI 10.1016/S0735-1097(03)00124-4 Sherif HMF, 2013, EUR J CARDIO-THORAC, V44, P792, DOI 10.1093/ejcts/ezt098 Shukla L, 2012, J ANAT SOC INDIA, V61, P5 Stojanovska J, 2008, SEMIN ROENTGENOL, V43, P154, DOI 10.1053/j.ro.2008.01.010 Tekbas G, 2012, WIEN KLIN WOCHENSCHR, V124, P3, DOI 10.1007/s00508-011-0086-9 Thorning C, 2011, CLIN IMAG, V35, P1, DOI 10.1016/j.clinimag.2009.11.005 Toffanin G, 2006, J CARDIOVASC MED, V7, P748, DOI 10.2459/01.JCM.0000247322.57536.04 TRETHEWAY DG, 1974, AM J CARDIOL, V34, P237, DOI 10.1016/0002-9149(74)90203-3 Tsao HM, 2001, J CARDIOVASC ELECTR, V12, P1353, DOI 10.1046/j.1540-8167.2001.01353.x Vonken EPA, 2003, J CARDIOVASC MAGN R, V5, P545, DOI 10.1081/JCMR-120025229 Wang W, 2013, J THORAC CARDIOV SUR, V145, P790, DOI 10.1016/j.jtcvs.2012.03.019 Wannasopha Y, 2012, BIOMED IMAGING INTER, V8, P4 Yamada S, 2010, INTERACT CARDIOV TH, V10, P851, DOI 10.1510/icvts.2009.221804 Yamashita H., 1978, Roentgenologic anatomy of the lung Yamashita S, 2012, EUR J CARDIO-THORAC, V42, P83, DOI 10.1093/ejcts/ezr254 Yazar F, 2002, EUR J CARDIO-THORAC, V22, P717, DOI 10.1016/S1010-7940(02)00531-6 NR 41 TC 15 Z9 19 U1 0 U2 4 PU SPRINGER WIEN PI WIEN PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA SN 0043-5325 EI 1613-7671 J9 WIEN KLIN WOCHENSCHR JI Wien. Klin. Wochen. PD OCT PY 2019 VL 131 IS 19-20 BP 475 EP 484 DI 10.1007/s00508-019-1517-2 PG 10 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA JE3LD UT WOS:000490595300004 PM 31190096 DA 2026-04-17 ER PT J AU Sezen, CB Kocaturk, CI Bilen, S Kalafat, CE Aker, C Karapinar, K AF Sezen, Celal Bugra Kocaturk, Celalettin Ibrahim Bilen, Salih Kalafat, Cem Emrah Aker, Cemal Karapinar, Kemal TI Long-term outcomes of completion pneumonectomy for non-small cell lung cancer SO ACTA CHIRURGICA BELGICA LA English DT Article DE Completion pneumonectomy; non-small cell lung cancer; secondary primary lung cancer; prognostic factors of survival ID OPERATIVE MORTALITY; EXPERIENCE; RESECTION; SURVIVAL; 2ND AB Background: Completion pneumonectomy (CP) is the removal of remaining lung tissue after initial resection. Our aim in this study was to investigate the factors affecting mortality, morbidity, and survival after CP. Methods: Patients who underwent CP in our clinic between January 2000 and December 2015 were evaluated retrospectively. The patients' demographic information, morbidity, mortality, histopathological characteristics, and 2-, 5-, and 10-year survival were evaluated. Results: Of the 32 non-small cell lung cancer patients in the study, 31 (96.9%) were male and one (3.1%) was female. The postoperative mortality rate was 9.4% and the morbidity rate was 46.9%. The most common complication was atrial fibrillation (31.3%). Median survival time was 67 +/- 10.3 months; 5- and 10-year survival rates were 50.3 and 31.2%, respectively. Conclusion: Completion pneumonectomy involves an acceptable mortality rate but high morbidity rate. Based on the results of this study, the interval between initial resection and CP does not affect survival time. C1 [Sezen, Celal Bugra; Kocaturk, Celalettin Ibrahim; Bilen, Salih; Kalafat, Cem Emrah; Aker, Cemal; Karapinar, Kemal] Yedikule Chest Dis & Thorac Surg Training & Res H, Dept Thorac Surg, Istanbul, Turkey. C3 Istanbul Yedikule Chest Diseases & Thoracic Surgery Training & Research Hospital RP Sezen, CB (corresponding author), Yedikule Chest Dis & Thorac Surg Educ & Res Hosp, Belgrade Kapi Yolu Cad 1, Istanbul, Turkey. EM info@bugrasezen.com RI BILEN, SALIH/JNE-6227-2023; Aker, Cemal/AAG-6842-2021; Karapınar, Kemal/ISU-7287-2023; Sezen, Celal Bugra/A-5198-2019 OI BILEN, SALIH/0000-0001-9387-7968; Aker, Cemal/0000-0003-1269-7442; Sezen, Celal Bugra/0000-0002-2461-2031; Kalafat, Cem Emrah/0000-0001-5451-2042 CR Akin H, 2011, TURK GOGUS KALP DAMA, V19, P391, DOI 10.5606/tgkdc.dergisi.2011.050 ALKATTAN K, 1995, J THORAC CARDIOV SUR, V110, P1125, DOI 10.1016/S0022-5223(05)80182-5 Cardillo G, 2012, EUR J CARDIO-THORAC, V42, P405, DOI 10.1093/ejcts/ezs063 Chataigner O, 2008, EUR J CARDIO-THORAC, V33, P837, DOI 10.1016/j.ejcts.2008.02.006 DESLAURIERS J, 1988, ANN THORAC SURG, V46, P133, DOI 10.1016/S0003-4975(10)65883-3 FABER LP, 1993, SEMIN SURG ONCOL, V9, P135, DOI 10.1002/ssu.2980090212 GABLER A, 1980, THORAX, V35, P668, DOI 10.1136/thx.35.9.668 GREGOIRE J, 1993, J THORAC CARDIOV SUR, V105, P918 Guggino G, 2004, EUR J CARDIO-THORAC, V25, P449, DOI 10.1016/j.ejcts.2003.12.002 Hung JJ, 2009, THORAX, V64, P192, DOI 10.1136/thx.2007.094912 JENSIK RJ, 1981, J THORAC CARDIOV SUR, V82, P658 Jungraithmayr W, 2004, EUR J CARDIO-THORAC, V26, P189, DOI 10.1016/j.ejcts.2004.03.028 MARTINI N, 1975, J THORAC CARDIOV SUR, V70, P606 MASSARD G, 1995, ANN THORAC SURG, V59, P196, DOI 10.1016/0003-4975(94)00728-P MCGOVERN EM, 1988, ANN THORAC SURG, V46, P141, DOI 10.1016/S0003-4975(10)65886-9 Miller DL, 2002, ANN THORAC SURG, V74, P876, DOI 10.1016/S0003-4975(02)03855-9 Muysoms FE, 1998, ANN THORAC SURG, V66, P1165, DOI 10.1016/S0003-4975(98)00599-2 Pan XF, 2014, INTERACT CARDIOV TH, V19, P436, DOI 10.1093/icvts/ivu125 Regnard JF, 1999, J THORAC CARDIOV SUR, V117, P1095, DOI 10.1016/S0022-5223(99)70245-X Subotic D, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957-018-1398-2 Subotic D, 2016, EUR RESPIR J, V47, P374, DOI 10.1183/13993003.01490-2015 Terzi A, 2002, EUR J CARDIO-THORAC, V22, P30, DOI 10.1016/S1010-7940(02)00242-7 Thomas PA, 2016, EUR J CARDIO-THORAC, V49, pe38, DOI 10.1093/ejcts/ezv407 Verhagen AFTM, 1996, EUR J CARDIO-THORAC, V10, P238, DOI 10.1016/S1010-7940(96)80145-X Zhang P, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-107 NR 25 TC 3 Z9 3 U1 0 U2 5 PU ACTA MEDICAL BELGICA PI BRUSSELS PA AVENUE CIRCULAIRE 138 A, B-1180 BRUSSELS, BELGIUM SN 0001-5458 J9 ACTA CHIR BELG JI Acta Chir. Belg. PD SEP 3 PY 2019 VL 119 IS 5 BP 303 EP 308 DI 10.1080/00015458.2018.1527567 PG 6 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA IS9BC UT WOS:000482442400005 PM 30821655 DA 2026-04-17 ER PT J AU Polaczek, M Szaro, P Baranska, I Burakowska, B Ciszek, B AF Polaczek, Mateusz Szaro, Pawel Baranska, Inga Burakowska, Barbara Ciszek, Bogdan TI Morphology and morphometry of pulmonary veins and the left atrium in multi-slice computed tomography SO SURGICAL AND RADIOLOGIC ANATOMY LA English DT Article DE Pulmonary veins; Left atrium; Anatomy; Pulmonary vein ostium; Computed tomography; Atrial fibrillation ID CATHETER ABLATION; DRAINAGE PATTERNS; OSTIAL DIAMETER; LUNG-CANCER; FIBRILLATION; ANATOMY; DISTANCE; SURGERY; CT AB PurposePulmonary veins are involved in pathogenesis and treatment of atrial fibrillation and structures at risk during thoracic surgeries. There is lack of data regarding pulmonary vein morphology and morphometry in normal population.MethodsThe study was conducted using 135 chest computed tomography studies with intra-venous iodine contrast injection. The study population contained 86 females and 49 males, mean age was 60. 13 had atrial fibrillation.The studies were analyzed using radiological workstation.ResultsMean dimensions of the left atrium: transverse 52mm, coronal 49mm, and sagittal 35mm. The mean volume of the left atrium was 93cm(3). The mean volume of the left atrium in patients with atrial fibrillation was 176cm(3). The sagittal dimension and the volume of the left atrium were correlated with age, r=0.43 and r=0.42, respectively. Surface area of the left inferior pulmonary vein ostium was 136mm(2), significantly less than the surface area of other ostia of pulmonary veins. The mean distance between two pulmonary veins was 5.42mm on the right and 4.02mm on the left side. 13 types of pulmonary veins outflow patterns were described on the right side and 5 types on the left side. 66.7% of right pulmonary veins and 82% of the left pulmonary veins emptied into the left atrium with two venous trunks on each side (the typical pattern).ConclusionsMorphological features of pulmonary veins and morphometry of the left atrium and pulmonary veins are important for clinical purposes and are in accordance with previous papers. C1 [Polaczek, Mateusz; Szaro, Pawel; Ciszek, Bogdan] Med Univ Warsaw, Dept Descript & Clin Anat, Warsaw, Poland. [Polaczek, Mateusz] Natl TB & Lung Dis Res Inst, Dept Lung Dis & Oncol 3, Plocka 26, PL-01138 Warsaw, Poland. [Szaro, Pawel] Sahlgrenska Univ Gothenburg, Dept Radiol, Gothenburg, Sweden. [Baranska, Inga; Burakowska, Barbara] Natl TB & Lung Dis Res Inst, Dept Radiol, Warsaw, Poland. C3 Medical University of Warsaw RP Polaczek, M (corresponding author), Med Univ Warsaw, Dept Descript & Clin Anat, Warsaw, Poland.; Polaczek, M (corresponding author), Natl TB & Lung Dis Res Inst, Dept Lung Dis & Oncol 3, Plocka 26, PL-01138 Warsaw, Poland. EM polaczek@me.com RI Szaro, Pawel/ABG-2207-2020; Ciszek, Bogdan/N-7879-2018 OI Szaro, Pawel/0000-0002-0334-7232; CR Akiba T, 2011, GEN THORAC CARDIOVAS, V59, P376, DOI 10.1007/s11748-010-0675-y Akiba T, 2009, SURG TODAY, V39, P844, DOI 10.1007/s00595-009-3965-1 Arslan G, 2008, EUR J RADIOL, V67, P300, DOI 10.1016/j.ejrad.2007.07.005 Cronin P, 2007, ACAD RADIOL, V14, P178, DOI 10.1016/j.acra.2006.11.004 Cronin P, 2009, EUR J RADIOL, V71, P61, DOI 10.1016/j.ejrad.2008.04.008 den Uijl DW, 2011, AM J CARDIOL, V107, P243, DOI 10.1016/j.amjcard.2010.08.069 Elliott M, 2011, J CARDIOVASC ELECTR, V22, P8, DOI 10.1111/j.1540-8167.2010.01903.x Fynn SP, 2004, PACE, V27, P1547, DOI 10.1111/j.1540-8159.2004.00675.x Gebhard C, 2014, CARDIOL RES PRACT, V2014, DOI 10.1155/2014/179632 Gonzalez-Rivas D, 2016, THORAC SURG CLIN, V26, P187, DOI 10.1016/j.thorsurg.2015.12.007 Haïssaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003 Hamdan A, 2009, AM J CARDIOL, V104, P1540, DOI 10.1016/j.amjcard.2009.07.029 HIGGINS CB, 1978, AM J ROENTGENOL, V130, P251, DOI 10.2214/ajr.130.2.251 Hof I, 2009, J CARDIOVASC ELECTR, V20, P1005, DOI 10.1111/j.1540-8167.2009.01504.x Ikiz ZAA, 2014, ANADOLU KARDIYOL DER, V14, P674, DOI 10.5152/akd.2014.4968 Irene A, 2017, SURG RADIOL ANAT, V39, P229, DOI 10.1007/s00276-016-1719-5 Kaseno K, 2008, AM J CARDIOL, V101, P1638, DOI 10.1016/j.amjcard.2008.01.053 Kato R, 2003, CIRCULATION, V107, P2004, DOI 10.1161/01.CIR.0000061951.81767.4E Khan R, 2004, CARDIOVASC RES, V64, P387, DOI 10.1016/j.cardiores.2004.07.025 Kirchhof P, 2016, KARDIOL POL, V74, P1359, DOI [10.5603/KP.2016.0172, 10.1016/j.rec.2016.11.033] Klimek-Piotrowska W, 2016, PEERJ, V4, DOI 10.7717/peerj.1579 Lin WS, 2000, CIRCULATION, V101, P1274, DOI 10.1161/01.CIR.101.11.1274 Marom EM, 2004, RADIOLOGY, V230, P824, DOI 10.1148/radiol.2303030315 Merchant FM, 2016, J INTERV CARD ELECTR, V46, P89, DOI 10.1007/s10840-016-0106-9 Nakamura T, 2009, ANN THORAC SURG, V87, P954, DOI 10.1016/j.athoracsur.2008.07.054 Nattel S, 2002, NATURE, V415, P219, DOI 10.1038/415219a Polaczek M, 2013, KARDIOCHIR TORAKOCHI, V10, P232, DOI 10.5114/kitp.2013.38098 Schwartzman D, 2003, J AM COLL CARDIOL, V41, P1349, DOI 10.1016/S0735-1097(03)00124-4 Stanford W, 2005, INT J CARDIOVAS IMAG, V21, P133, DOI 10.1007/s10554-004-5347-5 Tracz W, 2005, ECHOKARDIOGRAFIA PRA, P71 Villa M, 2015, THORAC SURG CLIN, V25, P261, DOI 10.1016/j.thorsurg.2015.04.001 Wannasopha Y, 2012, BIOMED IMAGING INTER, V8, P1 Wozniak-Skowerska I, 2011, INT J CARDIOL, V146, P181, DOI 10.1016/j.ijcard.2009.06.047 Yazar F, 2002, EUR J CARDIO-THORAC, V22, P717, DOI 10.1016/S1010-7940(02)00531-6 Ziarnik E, 2015, THORAC SURG CLIN, V25, P355, DOI 10.1016/j.thorsurg.2015.04.003 NR 35 TC 17 Z9 24 U1 1 U2 21 PU SPRINGER FRANCE PI PARIS PA 22 RUE DE PALESTRO, PARIS, 75002, FRANCE SN 0930-1038 EI 1279-8517 J9 SURG RADIOL ANAT JI Surg. Radiol. Anat. PD JUL PY 2019 VL 41 IS 7 BP 721 EP 730 DI 10.1007/s00276-019-02210-1 PG 10 WC Anatomy & Morphology; Radiology, Nuclear Medicine & Medical Imaging; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Anatomy & Morphology; Radiology, Nuclear Medicine & Medical Imaging; Surgery GA ID4LX UT WOS:000471649400001 PM 30826845 OA Green Submitted, hybrid DA 2026-04-17 ER PT J AU Amar, D Zhang, H Tan, KS Piening, D Rusch, VW Jones, DR AF Amar, David Zhang, Hao Tan, Kay See Piening, Daniel Rusch, Valerie W. Jones, David R. TI A brain natriuretic peptide-based prediction model for atrial fibrillation after thoracic surgery: Development and internal validation SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article DE arrhythmias; complications; lung resection; esophagectomy ID LUNG-CANCER; PULMONARY RESECTION; NONCARDIAC SURGERY; DOUBLE-BLIND; RISK; MANAGEMENT; DYSFUNCTION; PREVENTION; ONSET AB Objective: Postoperative atrial fibrillation (POAF) is common after anatomic thoracic surgery. Elevated preoperative brain natriuretic peptide (BNP) level is strongly associated with risk of POAF. We describe the development and internal validation of a clinical prediction model for POAF that includes BNP and other clinical factors. Methods: Clinical and preoperative BNP data were collected for 635 patients in sinus rhythm before anatomic lung (n = 540) or esophageal (n = 95) resection. The primary outcome was new onset of POAF (>5 minutes) during hospitalization. A prediction model was developed using multivariable logistic regression analysis and internally validated using a bootstrap-resampling approach. Results: POAF occurred in 20% of patients (124 out of 635). BNP level was higher among patients with than without POAF (median, 45 vs 23 pg/mL; P < .0001). The final prediction model included 5 factors: age (odds ratio [OR], 1.05; 95% confidence interval [CI], 1.02-1.08; P = .001), body mass index (OR, 1.05; 95% CI, 1.00-1.09; P = .016), BNP level (75th vs 25th percentile, 57.5 vs 12.5 pg/mL; OR, 2.08; 95% CI, 1.26-3.43; P = .0003), history of atrial fibrillation (OR, 5.91; 95% CI, 2.47-14.11; P < .0001), and extent of surgery (compared with segmentectomy [reference]: pneumonectomy OR, 6.70; 95% CI, 1.91-24.70; esophagectomy OR, 4.93; 95% CI, 1.94-14.06; lobectomy OR, 1.88; 95% CI, 4.90-8.34; overall P = .0002). The model had good calibration and discrimination (C statistic, 0.736). After internal validation, optimism-corrected measures showed similarly good calibration and discrimination (C statistic, 0.720; 95% CI, 0.664-0.765). Conclusions: Our novel prediction model-based interactive calculator can be used to identify patients at high risk of POAF and could be incorporated into practice prevention guidelines. C1 [Amar, David; Zhang, Hao; Piening, Daniel] Mem Sloan Kettering Canc Ctr, Dept Anesthesiol & Crit Care Med, 1275 York Ave,M-304, New York, NY 10021 USA. [Tan, Kay See] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA. [Rusch, Valerie W.; Jones, David R.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA. C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center RP Amar, D (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Anesthesiol & Crit Care Med, 1275 York Ave,M-304, New York, NY 10021 USA. EM amard@mskcc.org OI Jones, David/0000-0002-3318-0146 FU National Institutes of Health Cancer Center [P30 CA008748]; National Cancer Institute [P30CA008748] Funding Source: NIH RePORTER FX Supported in part by National Institutes of Health Cancer Center Support grant P30 CA008748. CR Alonso-Coello P, 2017, ANESTH ANALG, V125, P162, DOI 10.1213/ANE.0000000000002111 Amar D, 2003, J AM COLL CARDIOL, V42, P1262, DOI 10.1016/S0735-1097(03)00955-0 Amar D, 1996, ANN THORAC SURG, V61, P1506, DOI 10.1016/0003-4975(96)00111-7 Amar D, 2016, J THORAC CARDIOV SUR, V151, P913, DOI 10.1016/j.jtcvs.2015.09.041 Amar D, 2012, J THORAC CARDIOV SUR, V144, P1249, DOI 10.1016/j.jtcvs.2012.06.051 Brecher O, 2017, ANESTH ANALG, V124, P1099, DOI 10.1213/ANE.0000000000001471 Cardinale D, 2007, CIRCULATION, V115, P1339, DOI 10.1161/CIRCULATIONAHA.106.647008 Cardinale D, 2016, ANN SURG, V264, P244, DOI 10.1097/SLA.0000000000001626 Frendl G, 2014, J THORAC CARDIOV SUR, V148, P772, DOI 10.1016/j.jtcvs.2014.06.037 Gialdini G, 2014, JAMA-J AM MED ASSOC, V312, P616, DOI 10.1001/jama.2014.9143 January CT, 2014, J AM COLL CARDIOL, V64, P2304, DOI 10.1016/j.jacc.2014.04.004 Karthikeyan G, 2009, J AM COLL CARDIOL, V54, P1599, DOI 10.1016/j.jacc.2009.06.028 Marsiliani D, 2010, EUR REV MED PHARMACO, V14, P855 Mc Cormack O, 2014, ANN SURG, V260, P772, DOI 10.1097/SLA.0000000000000960 Nojiri T, 2015, CHEST, V148, P1285, DOI 10.1378/chest.15-0852 Nojiri T, 2015, WORLD J SURG, V39, P1092, DOI 10.1007/s00268-015-2943-6 Nojiri T, 2012, J THORAC CARDIOV SUR, V143, P488, DOI 10.1016/j.jtcvs.2011.09.003 Nojiri T, 2010, J THORAC CARDIOV SUR, V140, P764, DOI 10.1016/j.jtcvs.2009.11.073 Park BJ, 2007, J THORAC CARDIOV SUR, V133, P775, DOI 10.1016/j.jtcvs.2006.09.022 Passman RS, 2005, ANN THORAC SURG, V79, P1698, DOI 10.1016/j.athoracsur.2004.10.058 Pu ZY, 2019, THORAC CARDIOV SURG, V67, P120, DOI 10.1055/s-0037-1609037 Raman T, 2012, J THORAC CARDIOV SUR, V143, P482, DOI 10.1016/j.jtcvs.2011.08.025 Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9 NR 23 TC 36 Z9 40 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 EI 1097-685X J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD JUN PY 2019 VL 157 IS 6 BP 2493 EP + DI 10.1016/j.jtcvs.2019.01.075 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA HY4RS UT WOS:000468116200118 PM 30826103 OA Green Submitted, Bronze DA 2026-04-17 ER PT J AU Riddersholm, S Tayal, B Kragholm, K Andreasen, JJ Rasmussen, BS Sogaard, P Torp-Pedersen, C Riahi, S AF Riddersholm, Signe Tayal, Bhupendar Kragholm, Kristian Andreasen, Jan Jesper Rasmussen, Bodil Steen Sogaard, Peter Torp-Pedersen, Christian Riahi, Sam TI Incidence of Stroke After Pneumonectomy and Lobectomy A Nationwide, Register-Based Study SO STROKE LA English DT Article DE atrial fibrillation; incidence; pneumonectomy; pulmonary vein; thrombosis ID PULMONARY VEIN-THROMBOSIS; LUNG-CANCER; RISK-FACTOR; PATIENT AB Background and Purpose-After pneumonectomy or lobectomy, at least 1 blind pulmonary vein is left with potential risk of postoperative thromboembolic incidents. We investigated the risk of stroke within this population compared with background and pulmonary wedge resections controls. Methods-We identified 12 965 patients with pneumonectomy or lobectomy and 6400 patients with wedge resection using data from Danish nationwide registries from 1996 to 2016. In multivariate Poisson regression analysis, we estimated incidence rate ratios of stroke for patients undergoing lobectomy or pneumonectomy versus background population controls and patients who underwent wedge resection. We stratified our analysis by days: 0 to 30, 31 to 90, 91 to 180, and 180 to 365 after surgery and performed a subgroup analysis in patients with lung cancer. Results-The incidence rate of stroke was 10.6 per 1000 person-years for time exposed for pneumonectomy or lobectomy and 2.3 per 1000 person-years for patients not exposed for pneumonectomy or lobectomy. In the 0- to 30-day multivariate Poisson regression analysis, compared with the background population, pneumonectomy or lobectomy was associated with an increased risk of stroke both patients with and without atrial fibrillation (incidence rate ratios [IRR]) of 4.66 (95% CI, 2.04-7.12) and 5.43 (95% CI, 3.99-7.41), respectively. Similarly, in patients with lung cancer, the first 30 days after pneumonectomy or lobectomy remained a risk factor for stroke for patients with (IRR, 2.94; 95% CI, 1.39-6.25) and for patients without atrial fibrillation (IRR, 2.56; 95% CI, 1.86-3.59). When compared with wedge resection, 0 to 30 days after lobectomy or pneumonectomy was also associated with increased risk of stroke (IRR, 2.63; 95% CI, 1.19-5.81); however, this association was insignificant in patients with lung cancer (IRR, 2.98; 95% CI, 0.72-12.29). Conclusions-Patients undergoing pneumonectomy or lobectomy had an increased 30 days risk of stroke. Whether the pulmonary vein stump is a risk factor for stroke and whether preventive strategies are relevant require further investigation. C1 [Riddersholm, Signe; Tayal, Bhupendar; Kragholm, Kristian; Sogaard, Peter; Riahi, Sam] Aalborg Univ Hosp, Dept Cardiol, Aalborg, Denmark. [Riddersholm, Signe; Rasmussen, Bodil Steen] Aalborg Univ Hosp, Dept Anaesthesiol & Intens Care Med, Aalborg, Denmark. [Rasmussen, Bodil Steen; Riahi, Sam] Aalborg Univ Hosp, Clin Inst, Aalborg, Denmark. [Andreasen, Jan Jesper] Aalborg Univ Hosp, Dept Cardiothorac Surg, Aalborg, Denmark. [Torp-Pedersen, Christian] Aalborg Univ Hosp, Unit Epidemiol & Biostat, Aalborg, Denmark. [Torp-Pedersen, Christian] Aalborg Univ, Dept Hlth Sci & Technol, Aalborg, Denmark. C3 Aalborg University; Aalborg University Hospital; Aalborg University; Aalborg University Hospital; Aalborg University; Aalborg University Hospital; Aalborg University; Aalborg University Hospital; Aalborg University; Aalborg University Hospital; Aalborg University RP Riddersholm, S (corresponding author), Aalborg Univ Hosp, Dept Cardiol Med, Hobrovej 18-22, DK-9100 Aalborg, Denmark. EM s.riddersholm@rn.dk RI ; Riahi, Sam/AAI-5298-2021; Torp-Pedersen, Christian/E-5931-2013 OI Kragholm, Kristian/0000-0001-9629-8670; Riahi, Sam/0000-0003-1849-9463; Rasmussen, Bodil Steen/0000-0003-2190-145X; CR Asteriou C, 2010, CASE REP ONCOL, V3, P208, DOI 10.1159/000314838 Boffa DJ, 2008, J THORAC CARDIOV SUR, V135, P247, DOI 10.1016/j.jtcvs.2007.07.060 FERGUSON MK, 1995, J THORAC CARDIOV SUR, V109, P275, DOI 10.1016/S0022-5223(95)70389-6 HOLMES CE, 1995, ANN THORAC SURG, V60, P615, DOI 10.1016/0003-4975(95)00537-u Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43 Kildemoes HW, 2011, SCAND J PUBLIC HEALT, V39, P38, DOI 10.1177/1403494810394717 Lynge E, 2011, SCAND J PUBLIC HEALT, V39, P30, DOI 10.1177/1403494811401482 Nagaoka E, 2008, J THORAC CARDIOV SUR, V135, P709, DOI 10.1016/j.jtcvs.2007.11.035 Navi BB, 2018, ANN NEUROL, V83, P873, DOI 10.1002/ana.25227 Ohtaka K, 2014, J CARDIOTHORAC SURG, V9, DOI 10.1186/s13019-014-0159-8 Ohtaka K, 2014, J CARDIOTHORAC SURG, V9, DOI 10.1186/1749-8090-9-5 Ohtaka K, 2013, ANN THORAC SURG, V95, P1924, DOI 10.1016/j.athoracsur.2013.03.005 Ohtaka K, 2012, J THORAC CARDIOV SUR, V143, pE3, DOI 10.1016/j.jtcvs.2011.09.025 Olesen JB, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d124 Oura Hiroyuki, 2005, Kyobu Geka, V58, P137 Pottegård A, 2017, INT J EPIDEMIOL, V46, P798, DOI 10.1093/ije/dyw213 R Development Core Team, 2008, R R PROJ STAT COMP Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Schmidt M, 2015, CLIN EPIDEMIOL, V7, P449, DOI 10.2147/CLEP.S91125 Schmidt M, 2014, EUR J EPIDEMIOL, V29, P541, DOI 10.1007/s10654-014-9930-3 Schwalm S, 2004, J AM SOC ECHOCARDIOG, V17, P487, DOI 10.1016/j.echo.2004.02.003 Shrier I, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-70 Stewart SJ, OVERVIEW PULMONARY R Usui G, INTERN MED VanderWeele TJ, 2017, ANN INTERN MED, V167, P268, DOI 10.7326/M16-2607 Xin YZ, 2014, EUR J CARDIO-THORAC, V45, P247, DOI 10.1093/ejcts/ezt383 Yamamoto T, 2016, SURG TODAY, V46, P780, DOI 10.1007/s00595-015-1233-0 NR 27 TC 16 Z9 17 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD MAY PY 2019 VL 50 IS 5 BP 1052 EP 1059 DI 10.1161/STROKEAHA.118.024496 PG 8 WC Clinical Neurology; Peripheral Vascular Disease WE Science Citation Index Expanded (SCI-EXPANDED) SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA IA1VG UT WOS:000469350000025 PM 31009351 OA Bronze DA 2026-04-17 ER PT J AU Cagini, L Cardaioli, G Andolfi, M Savino, K Eusebi, P Corbelli, I Simoni, S Vannucci, J Sacchini, E Ripandelli, F Matricardi, A Puma, F AF Cagini, Lucio Cardaioli, Gabriela Andolfi, Marco Savino, Ketty Eusebi, Paolo Corbelli, Ilenia Simoni, Simone Vannucci, Jacopo Sacchini, Elisa Ripandelli, Francesco Matricardi, Alberto Puma, Francesco TI Interatrial Shunting Through an Asymptomatic Patent Foramen Ovale in Thoracic Surgery SO ANNALS OF THORACIC SURGERY LA English DT Article; Proceedings Paper CT 26th European Conference on General Thoracic Surgery of the European-Society-of-Thoracic-Surgeons (ESTS) CY MAY 26-30, 2018 CL Ljubljana, SLOVENIA SP European Soc Thorac Surg ID TO-LEFT SHUNT; POSTOPERATIVE PULMONARY COMPLICATIONS; TRANSCRANIAL DOPPLER; CONTRAST ECHOCARDIOGRAPHY; ATRIAL-FIBRILLATION; RISK-FACTORS; PNEUMONECTOMY; MORBIDITY; MIGRAINE; PREVALENCE AB Background. Patent foramen ovale (PFO) is present in as many as 25% of the general population and is considered an irrelevant condition in healthy subjects. Here, we sought to determine an association between an asymptomatic PFO at baseline and postoperative short-term adverse events in patients undergoing major pulmonary resection for lung cancer. In addition, we evaluated for the rate of PFO after pulmonary resections. Methods. This prospective, observational study assessed patients by transcranial Doppler with contrast at baseline and discharge. To confirm interatrial shunting, patients with positive transcranial Doppler at baseline also underwent contrast transthoracic echocardiography. Multivariate logistic regression models were adopted to investigate for independent factors that could have been associated with complications. Backward stepwise procedure was used for model selection. Results. Median age was 67.7 +/- 9.2 years (range, 36 to 86), and 67% were men. Overall, 18 patients underwent pneumonectomy, 11 bilobectomy, and 118 lobectomy; 54% underwent right-sided procedure and 46%, left-sided. One perioperative death was recorded, and 34 patients had one or more cardiopulmonary complications. At baseline, PFO was positive in 25% (37 of 147) and negative in 75% (110 of 147); of the latter, 11% were positive at discharge. Detection of PFO at baseline, on multivariate analysis, was significantly associated with a risk of postoperative complications (odds ratio 2.5; 95% confidence interval: 1.1 to 5.8). Specifically, we observed a significant association between atrial fibrillation and positive PFO at baseline (odds ratio 3.5; 95% confidence interval: 1.4 to 9.0). Conclusions. Preoperative asymptomatic PFO was independently associated with postoperative adverse events. Moreover, 11% of patients who had negative transcranial Doppler studies at baseline had asymptomatic PFOs at discharge. Larger prospective studies are needed to further investigate for a prognostic impact of PFO in thoracic surgery. (C) 2019 by The Society of Thoracic Surgeons C1 Univ Perugia, Med Sch, S Maria della Misericordia Hosp, Div Thorac Surg, Perugia, Italy. Univ Perugia, Med Sch, S Maria della Misericordia Hosp, Div Neurol, Perugia, Italy. Univ Perugia, Med Sch, S Maria della Misericordia Hosp, Sect Cardiol & Cardiovasc Physiopathol, Perugia, Italy. AOU Osped Riuniti Ancona, Div Thorac Surg, Ancona, Italy. C3 Hospital Santa Maria della Misericordia; University of Perugia; University of Perugia; Hospital Santa Maria della Misericordia; University of Perugia; Hospital Santa Maria della Misericordia RP Cagini, L (corresponding author), Univ Perugia, Santa Maria della Misericordia Hosp, Thorac Surg Unit, Piazzale Menghini 1, I-06134 Perugia, Italy. EM lucio.cagini@unipg.it RI ; Eusebi, Paolo/O-2721-2013; Andolfi, Marco/AAM-9091-2020; Corbelli, Ilenia/K-9492-2016; Simoni, Simone/AAB-8901-2019 OI SAVINO, Ketty/0000-0003-3494-0298; Eusebi, Paolo/0000-0002-0715-6396; Andolfi, Marco/0000-0002-0399-7374; Corbelli, Ilenia/0000-0002-1928-1928; Simoni, Simone/0000-0003-3715-660X CR Agostini P, 2010, THORAX, V65, P815, DOI 10.1136/thx.2009.123083 Agresti A, 1998, AM STAT, V52, P119, DOI 10.2307/2685469 Aigner C, 2008, EUR J CARDIO-THORAC, V33, P268, DOI 10.1016/j.ejcts.2007.10.020 [Anonymous], LANG ENV STAT COMP Anzola GP, 1999, NEUROLOGY, V52, P1622, DOI 10.1212/WNL.52.8.1622 Cagini L, 2014, EUR J CARDIO-THORAC, V46, pE74, DOI 10.1093/ejcts/ezu348 Cagini L, 2011, EUR J CARDIO-THORAC, V40, pE71, DOI 10.1016/j.ejcts.2011.03.030 CHEN WJ, 1992, CHEST, V101, P1515, DOI 10.1378/chest.101.6.1515 CHENG TO, 1992, ANN INTERN MED, V116, P875, DOI 10.7326/0003-4819-116-10-875_1 DEBELDER MA, 1992, AM HEART J, V124, P1545, DOI 10.1016/0002-8703(92)90070-C Del Sette M, 1998, CEREBROVASC DIS, V8, P327, DOI 10.1159/000015875 HAGEN PT, 1984, MAYO CLIN PROC, V59, P17, DOI 10.1016/S0025-6196(12)60336-X Harpole DH, 1996, ANN THORAC SURG, V61, P977, DOI 10.1016/0003-4975(95)01174-9 Homma S, 2002, CIRCULATION, V105, P2625, DOI 10.1161/01.CIR.0000017498.88393.44 Jauss M, 2000, CEREBROVASC DIS, V10, P490, DOI 10.1159/000016119 Lefèvre J, 2008, ARCH CARDIOVASC DIS, V101, P213, DOI 10.1016/S1875-2136(08)73695-7 Marini C, 2006, EUR RESPIR J, V28, P174, DOI 10.1183/09031936.06.00006405 Mojadidi MK, 2014, JACC-CARDIOVASC IMAG, V7, P236, DOI 10.1016/j.jcmg.2013.12.011 Ng SY, 2012, ANN THORAC SURG, V93, P1647, DOI 10.1016/j.athoracsur.2012.02.029 PATEL RL, 1992, ANN THORAC SURG, V54, P84, DOI 10.1016/0003-4975(92)91145-Y PEARSON AC, 1991, J AM COLL CARDIOL, V17, P66, DOI 10.1016/0735-1097(91)90705-E Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3 Polanczyk CA, 1998, ANN INTERN MED, V129, P279, DOI 10.7326/0003-4819-129-4-199808150-00003 Porter TR, 2014, J AM SOC ECHOCARDIOG, V27, P797, DOI 10.1016/j.echo.2014.05.011 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Savino K, 2016, INT J CLIN PRACT, V70, P641, DOI 10.1111/ijcp.12842 Scholes RL, 2009, AUST J PHYSIOTHER, V55, P191, DOI 10.1016/S0004-9514(09)70081-9 Schwerzmann M, 2005, NEUROLOGY, V65, P1415, DOI 10.1212/01.wnl.0000179800.73706.20 Shanoudy H, 1998, CHEST, V113, P91, DOI 10.1378/chest.113.1.91 Spencer MP, 2004, J NEUROIMAGING, V14, P342, DOI 10.1177/1051228404268743 STRUNK BL, 1987, AM J CARDIOL, V60, P413, DOI 10.1016/0002-9149(87)90271-2 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 NR 32 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD APR PY 2019 VL 107 IS 4 BP 1040 EP 1045 DI 10.1016/j.athoracsur.2018.10.054 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA HQ3JU UT WOS:000462308000030 PM 30508529 OA Green Submitted DA 2026-04-17 ER PT J AU Hashimoto, H Usui, G Tsugeno, Y Sugita, K Amori, G Morikawa, T Inamura, K AF Hashimoto, Hirotsugu Usui, Genki Tsugeno, Yuta Sugita, Keisuke Amori, Gulanbar Morikawa, Teppei Inamura, Kentaro TI Cerebral Thromboembolism after Lobectomy for Lung Cancer: Pathological Diagnosis and Mechanism of Thrombus Formation SO CANCERS LA English DT Review DE thrombus; pathology; cerebral thromboembolism; lung cancer; lobectomy ID ATRIAL APPENDAGE OCCLUSION; PULMONARY VEIN-THROMBOSIS; ISCHEMIC-STROKE; RISK-FACTORS; TROUSSEAUS-SYNDROME; VENOUS THROMBOSIS; COMPLICATIONS; FIBRILLATION; SURGERY; THROMBECTOMY AB Lung cancer is the leading cause of cancer-related deaths worldwide. Although molecular therapies have emerged as efficacious strategies for the treatment of lung cancer, surgical resection is still recommended as a radical therapeutic option. Currently, lobectomy is regarded as the most reliable radical treatment of primary lung cancer. Among the various complications after lobectomy, cerebral thromboembolism requires attention as a life-threatening complication during the early postoperative period. It occurs in 0.2-1.2% of surgical cases of lung cancer and typically develops following left upper lobectomy with a long pulmonary vein stump (PVS). PVS-associated thrombosis is known to cause cerebral thromboembolism after such procedures; however, distinguishing this specific complication from that caused by postoperative atrial fibrillation is challenging. We summarize herein the diagnostic pathology of thrombus formation in accordance with its thrombogenic mechanism. We focus on the potential utility of the pathological assessment of thrombectomy specimens. The morphological information obtained from these specimens enables the presumption of thrombogenic etiology and provides useful clues to both select an appropriate pharmacotherapy and determine a follow-up treatment for cerebral thromboembolism. C1 [Hashimoto, Hirotsugu; Usui, Genki; Morikawa, Teppei] NTT Med Ctr Tokyo, Dept Diagnost Pathol, Tokyo 1418625, Japan. [Hashimoto, Hirotsugu; Morikawa, Teppei] Tokyo Healthcare Univ, Fac Healthcare, Tokyo 1418648, Japan. [Tsugeno, Yuta; Amori, Gulanbar; Inamura, Kentaro] Japanese Fdn Canc Res, Canc Inst, Div Pathol, Tokyo 1358550, Japan. [Tsugeno, Yuta; Sugita, Keisuke] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Comprehens Pathol, Tokyo 1138510, Japan. C3 Kanto Medical Center NTT EC; Japanese Foundation for Cancer Research; Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU) RP Hashimoto, H (corresponding author), NTT Med Ctr Tokyo, Dept Diagnost Pathol, Tokyo 1418625, Japan.; Hashimoto, H (corresponding author), Tokyo Healthcare Univ, Fac Healthcare, Tokyo 1418648, Japan.; Inamura, K (corresponding author), Japanese Fdn Canc Res, Canc Inst, Div Pathol, Tokyo 1358550, Japan. EM hhashimoto-tki@umin.ac.jp; gusui-tky@umin.ac.jp; yuta.tsugeno@jfcr.or.jp; keisuke.integralugita@gmail.com; obulhasim.gulanbar@jfcr.or.jp; tmorikawa-tky@umin.ac.jp; kentaro.inamura@jfcr.or.jp RI ; Inamura, Kentaro/G-4229-2018; Usui, Genki/GXG-9452-2022 OI Hashimoto, Hirotsugu/0000-0002-1455-4974; Sugita, Keisuke/0000-0002-7978-210X; Inamura, Kentaro/0000-0001-6444-3861; Usui, Genki/0000-0002-6615-8674 FU JSPS KAKENHI [JP18K15103, JP16K08679] FX This study was supported financially by JSPS KAKENHI Grant Number JP18K15103 (H.H.) and JP16K08679 (K.I.). CR Albers GW, 2018, NEW ENGL J MED, V378, P708, DOI 10.1056/NEJMoa1713973 [Anonymous], PATHOLOGIC BASIS DIS [Anonymous], J AM COLL CARDIOL Bateman BT, 2009, ANESTHESIOLOGY, V110, P231, DOI 10.1097/ALN.0b013e318194b5ff Bick RL, 2003, NEW ENGL J MED, V349, P109, DOI 10.1056/NEJMp030086 Boccaccio C, 2005, NATURE, V434, P396, DOI 10.1038/nature03357 Boeckh-Behrens T, 2016, CLIN NEURORADIOL, V26, P189, DOI 10.1007/s00062-014-0347-x Boeckh-Behrens T, 2016, STROKE, V47, P1864, DOI 10.1161/STROKEAHA.116.013105 Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385 CALLANDER N, 1993, WESTERN J MED, V158, P364 CALLANDER NS, 1992, CANCER-AM CANCER SOC, V70, P1194, DOI 10.1002/1097-0142(19920901)70:5<1194::AID-CNCR2820700528>3.0.CO;2-E Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792 Chen J, 2012, ANN THORAC SURG, V94, P2107, DOI 10.1016/j.athoracsur.2012.04.128 Cushman M, 2007, SEMIN HEMATOL, V44, P62, DOI 10.1053/j.seminhematol.2007.02.004 de Groot PM, 2018, SEMIN ULTRASOUND CT, V39, P289, DOI 10.1053/j.sult.2018.02.008 Denko NC, 2001, CANCER RES, V61, P795 Fang Y, 2012, ARTERIOSCL THROM VAS, V32, P979, DOI 10.1161/ATVBAHA.111.244053 Friedman DJ, 2018, JAMA-J AM MED ASSOC, V319, P365, DOI 10.1001/jama.2017.20125 Gadiyaram VK, 2019, J CARDIOVASC ELECTR, V30, P511, DOI 10.1111/jce.13838 Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864 Garofalo M, 2012, NAT MED, V18, P74, DOI 10.1038/nm.2577 Gomez D, 2012, CARDIOVASC RES, V95, P156, DOI 10.1093/cvr/cvs115 Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905 Grau AJ, 2001, STROKE, V32, P2559, DOI 10.1161/hs1101.098524 GRAUS F, 1985, MEDICINE, V64, P16, DOI 10.1097/00005792-198501000-00002 Haïssaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003 Hida T, 2018, CANCER SCI, V109, P2863, DOI 10.1111/cas.13721 Hoffman M, 2001, THROMB HAEMOSTASIS, V85, P958, DOI 10.1055/s-0037-1615947 Hoffman M, 2007, HEMATOL ONCOL CLIN N, V21, P1, DOI 10.1016/j.hoc.2006.11.004 Inamura K, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00193 Jain S, 2007, P NATL ACAD SCI USA, V104, P9024, DOI 10.1073/pnas.0700625104 Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.21254] Jia YL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0580-3 Jiang T, 2018, J THORAC DIS, V10, P3909, DOI 10.21037/jtd.2018.07.61 Jiang WB, 2017, AM J TRANSL RES, V9, P2024 Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780 Kambas K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00385 Kanaan R, 2017, EUR RESPIR REV, V26, DOI 10.1183/16000617.0061-2017 Kimball AS, 2016, FRONT IMMUNOL, V7, P1, DOI 10.3389/fimmu.2016.00236 Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821 Kristinsson SY, 2011, LEUKEMIA LYMPHOMA, V52, P734, DOI 10.3109/10428194.2011.560311 Langer CJ, 2009, J CLIN ONCOL, V27, P1350, DOI 10.1200/JCO.2008.20.4859 Li W, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.126 Loyer X, 2014, CIRC RES, V114, P345, DOI 10.1161/CIRCRESAHA.113.300858 Martin-Ucar AE, 2013, J THORAC DIS, V5, pS194, DOI 10.3978/j.issn.2072-1439.2013.08.41 Matsumoto K, 2018, SURG TODAY, V48, P571, DOI 10.1007/s00595-017-1620-9 Matsumoto N, 2016, J STROKE CEREBROVASC, V25, pE227, DOI 10.1016/j.jstrokecerebrovasdis.2016.08.041 Merli GJ, 2017, ANN INTERN MED, V167, P440, DOI 10.7326/M17-2030 NAGASAKI F, 1982, CHEST, V82, P25, DOI 10.1378/chest.82.1.25 NATHAN H, 1966, CIRCULATION, V34, P412, DOI 10.1161/01.CIR.34.3.412 Ni CW, 2011, AM J PHYSIOL-HEART C, V300, pH1762, DOI 10.1152/ajpheart.00829.2010 Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442 Nojiri T, 2015, SURG TODAY, V45, P740, DOI 10.1007/s00595-014-1032-z Noskovicová N, 2015, AM J RESP CELL MOL, V52, P263, DOI 10.1165/rcmb.2014-0294TR Ohtaka K, 2014, J CARDIOTHORAC SURG, V9, DOI 10.1186/s13019-014-0159-8 Ohtaka K, 2014, J CARDIOTHORAC SURG, V9, DOI 10.1186/1749-8090-9-5 Ohtaka K, 2013, ANN THORAC SURG, V95, P1924, DOI 10.1016/j.athoracsur.2013.03.005 Ohtaka K, 2012, J THORAC CARDIOV SUR, V143, pE3, DOI 10.1016/j.jtcvs.2011.09.025 Oral H, 2006, NEW ENGL J MED, V354, P934, DOI 10.1056/NEJMoa050955 Patell R, 2017, AM J CARDIOL, V120, P2182, DOI 10.1016/j.amjcard.2017.08.038 Petrelli F, 2018, CLIN LUNG CANCER, V19, P315, DOI 10.1016/j.cllc.2018.02.006 Pfeiler S, 2017, HAEMATOLOGICA, V102, P206, DOI 10.3324/haematol.2016.142471 Pillai Jain Bhaskara, 2003, Interact Cardiovasc Thorac Surg, V2, P657, DOI 10.1016/S1569-9293(03)00188-9 PINEO GF, 1973, J LAB CLIN MED, V82, P255 Qin XM, 2010, P NATL ACAD SCI USA, V107, P3240, DOI 10.1073/pnas.0914882107 Razak NBA, 2018, CANCERS, V10, DOI 10.3390/cancers10100380 Roselli M, 2014, CANCER METAST REV, V33, P771, DOI 10.1007/s10555-014-9500-x SACK GH, 1977, MEDICINE, V56, P1, DOI 10.1097/00005792-197756010-00001 Sporns PB, 2017, STROKE, V48, P2206, DOI 10.1161/STROKEAHA.117.016590 Steiner I, 2006, VIRCHOWS ARCH, V449, P88, DOI 10.1007/s00428-006-0197-2 Trousseau A., 1865, CLIN MED HOTEL DIEU, V3, P654 Uhlmann EJ, 2009, J HEART LUNG TRANSPL, V28, P209, DOI 10.1016/j.healun.2008.11.909 Uramoto H, 2001, THORAX, V56, P59, DOI 10.1136/thorax.56.1.59 Usui G, 2019, INTERNAL MED, V58, P1349, DOI 10.2169/internalmedicine.1962-18 Usui G, 2018, J STROKE CEREBROVASC, V27, pE225, DOI 10.1016/j.jstrokecerebrovasdis.2018.05.019 Valentino LA, 1996, BBA-MOL BASIS DIS, V1316, P19, DOI 10.1016/0925-4439(95)00092-5 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Varki A, 2007, BLOOD, V110, P1723, DOI 10.1182/blood-2006-10-053736 Wolf AS, 2011, ANN THORAC SURG, V92, P1819, DOI 10.1016/j.athoracsur.2011.06.099 Xu S., 2016, Cardiovascular Pathology, P85, DOI [10.1016/B978-0-12-420219-1.00003-3, DOI 10.1016/B978-0-12-420219-1.00003-3] Yamamoto T, 2016, SURG TODAY, V46, P780, DOI 10.1007/s00595-015-1233-0 Yao XX, 2018, JAMA-J AM MED ASSOC, V319, P2116, DOI 10.1001/jama.2018.6024 Yoshida A, 2015, AM J SURG PATHOL, V39, P1427, DOI 10.1097/PAS.0000000000000467 NR 83 TC 16 Z9 16 U1 1 U2 7 PU MDPI PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND EI 2072-6694 J9 CANCERS JI Cancers PD APR PY 2019 VL 11 IS 4 AR 488 DI 10.3390/cancers11040488 PG 17 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA HY0BE UT WOS:000467773400056 PM 30959839 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Wang, WT Li, B Wang, Y Piao, HL Zhu, ZC Xu, RH Li, D Liu, KX AF Wang, Weitie Li, Bo Wang, Yong Piao, Hulin Zhu, Zhicheng Xu, Rihao Li, Dan Liu, Kexiang TI Experience of the management of coronary artery bypass graft only on moderate ischemic mitral regurgitation A single-center retrospective study SO MEDICINE LA English DT Article DE coronary artery bypass; echocardiography; ischemic heart disease; mitral ID HEART-FAILURE; REVASCULARIZATION; SURVIVAL; SURGERY; REPAIR AB To summary the impact of off-pump coronary artery bypass grafting (CABG) only on patients with moderate ischemic mitral regurgitation and survival. We retrospectively analyzed 109 patients with coronary artery disease (CAD) complicated by moderate mitral regurgitation, from January, 2008 to December, 2014, in the Department of Cardiovascular Surgery at the No. 2 Hospital of Jilin University undergoing off pump CABG only. Preoperative clinical characteristics, complications after surgery, and outcome (survivor or death) were assessed. We observed the degree of mitral valve regurgitation, left ventricular ejection fraction (LVEF), left ventricular and left atrial size, left ventricular end-diastolic volume (LVEDV) preoperative, and New York Heart Association (NYHA) functional class, postoperative 10 days before discharge, and 6 months and longer after surgery. The statistical data were processed by SPSS 19 software with computer; statistical significant difference with P<.05. Overall in-hospital mortality was 2.75% (3 patients). Patients had lower mean LVEF in the postoperative compared with the preoperative period, but all the patients had higher LVEF since 6 months than preoperative period (P<. 001). Compared with the preoperative dates, postoperative valvular regurgitation, left ventricular and atrial size and LVEDV postoperative 10 days before discharge, 6 months and more longer after surgery reduced significantly (P<. 001). Rapid atrial fibrillation occurred in 19 cases during perioperative and returned to normal before discharge. The symptom of angina was disappeared in all patients before discharge. The mean follow-up time was 60.16 +/- 17.98 months (range 36-96 months). Two patients died of major adverse cardiac events including heart failure and ventricular fibrillation. Three patients died of lung cancer, and 2 patients died of stroke during the longer follow-up. Off-pump CABG can be performed safely in patients with CAD complicated by moderate mitral regurgitation. The efficacy of CABG only is well demonstrated by the significant improvement of LVEF and NYHA functional class, and by the decrease of left ventricular and atrial size, LVEDV, and mitral regurgitation grade. C1 [Wang, Weitie; Li, Bo; Wang, Yong; Piao, Hulin; Zhu, Zhicheng; Xu, Rihao; Li, Dan; Liu, Kexiang] Jilin Univ, Hosp 2, Dept Cardiovasc Surg, Changchun, Jilin, Peoples R China. C3 Jilin University RP Liu, KX (corresponding author), 218 Ziqiang St, Changchun 130041, Jilin, Peoples R China. EM kxliu64@hotmail.com CR Benedetto U, 2009, J CARDIOVASC MED, V10, P109, DOI 10.2459/JCM.0b013e32831c84b0 Bursi F, 2005, CIRCULATION, V111, P295, DOI 10.1161/01.CIR.0000151097.30779.04 Castleberry AW, 2014, CIRCULATION, V129, P2547, DOI 10.1161/CIRCULATIONAHA.113.005223 Chan KMJ, 2012, CIRCULATION, V126, P2502, DOI 10.1161/CIRCULATIONAHA.112.143818 Deja MA, 2012, CIRCULATION, V125, P2639, DOI 10.1161/CIRCULATIONAHA.111.072256 Dudzinski DM, 2014, CARDIOVASC ULTRASOUN, V12, DOI 10.1186/1476-7120-12-46 Fattouch K, 2009, J THORAC CARDIOV SUR, V138, P278, DOI 10.1016/j.jtcvs.2008.11.010 Hernandez-Vaquero D, 2016, J THORAC DIS, V8, P1410, DOI 10.21037/jtd.2016.05.41 Kim BJ, 2018, J THORAC DIS, V10, P3632, DOI 10.21037/jtd.2018.05.148 Kim YH, 2005, ANN THORAC SURG, V79, P1895, DOI 10.1016/j.athoracsur.2004.11.005 Michler RE, 2016, NEW ENGL J MED, V374, P1932, DOI 10.1056/NEJMoa1602003 Michler RE, 2016, NEW ENGL J MED, V11, P1 Mihos CG, 2016, J THORAC DIS, V8, pE94, DOI 10.3978/j.issn.2072-1439.2016.01.27 Salmasi MY, 2018, J CARDIAC SURG, V33, P374, DOI 10.1111/jocs.13722 Sun XT, 2015, J THORAC CARDIOV SUR, V149, P1606, DOI 10.1016/j.jtcvs.2015.02.047 Toktas F, 2016, SAUDI MED J, V37, P853, DOI 10.15537/smj.2016.8.14795 Varma PK, 2017, ANN CARD ANAESTH, V20, P432, DOI 10.4103/aca.ACA_58_17 NR 17 TC 2 Z9 2 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7974 EI 1536-5964 J9 MEDICINE JI Medicine (Baltimore) PD APR PY 2019 VL 98 IS 17 AR e14969 DI 10.1097/MD.0000000000014969 PG 5 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA HX4AS UT WOS:000467337400001 PM 31027050 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Kimura, D Fukuda, I Tsushima, T Sakai, T Umetsu, S Ogasawara, Y Shimamura, N Ohkuma, H AF Kimura, Daisuke Fukuda, Ikuo Tsushima, Takao Sakai, Takehiro Umetsu, Satoko Ogasawara, Yukari Shimamura, Norihito Ohkuma, Hiroki TI Management of acute ischemic stroke after pulmonary resection: incidence and efficacy of endovascular thrombus aspiration SO GENERAL THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article DE Thrombus removal; Acute ischemic stroke; Cerebral infarction; Lung cancer surgery ID POSTOPERATIVE ATRIAL-FIBRILLATION; LEFT UPPER LOBECTOMY; RISK-FACTOR AB ObjectiveWe analyzed acute ischemic stroke by thromboembolism in the early period after lung cancer surgery.MethodsA retrospective review of the clinical records of patients who underwent lung resection for primary lung cancer was performed. Patients who underwent lobectomy, bilobectomy, and pneumonectomy were included. The clinical characteristics of the patients, the incidence of atrial fibrillation (Af) after surgery, and the incidence of acute ischemic stroke were analyzed. The clinical courses of patients having acute ischemic stroke were also reviewed.ResultsIn 4 (0.6%) of 696 patients, acute ischemic stroke occurred in the early period during hospitalization after lung cancer surgery. Acute ischemic stroke occurred within 4 days in three cases and after 4 days in one case. The resection site of the lung was the left side in all cases, and there were three cases of left upper lobectomy and one case of left lower lobectomy. As for the two recent patients, thrombus removal was performed by a neurosurgeon, and both cases achieved successful recanalization. The time between symptom detection and recanalization was 205 and 170min, respectively. One patient was cured without any residual effect of disease, and the other patient's hemiplegia resolved and aphasia improved.ConclusionSince cerebral infarction impairs the patient's quality of life, thrombus removal should be considered if possible. C1 [Kimura, Daisuke; Fukuda, Ikuo; Tsushima, Takao; Sakai, Takehiro; Umetsu, Satoko] Hirosaki Univ, Grad Sch Med, Dept Thorac & Cardiovasc Surg, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan. [Ogasawara, Yukari; Shimamura, Norihito; Ohkuma, Hiroki] Hirosaki Univ, Grad Sch Med, Dept Neurosurg, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan. C3 Hirosaki University; Hirosaki University RP Fukuda, I (corresponding author), Hirosaki Univ, Grad Sch Med, Dept Thorac & Cardiovasc Surg, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan. EM Ikuofuku@hirosaki-u.ac.jp RI Shimamura, Norihito/HMD-1717-2023; Daisuke, Kimura/GXF-5114-2022 CR [Anonymous], 2015, JAPAN STROKE SOC JAP, P69 GRIMM RA, 1995, AM HEART J, V130, P174, DOI 10.1016/0002-8703(95)90253-8 Ikeda Hiroyuki, 2015, NMC Case Rep J, V2, P26, DOI 10.2176/nmccrj.2014-0231 Japanese Circulation Society Joint Working Group, 2014, CIRC J, V78, P2779 Kam PCA, 1997, ANAESTHESIA, V52, P879, DOI 10.1111/j.1365-2044.1997.136-az0129.x Lahtinen J, 2004, ANN THORAC SURG, V77, P1241, DOI 10.1016/j.athoracsur.2003.09.077 Langer D, 2009, STROKE, V40, P2761, DOI 10.1161/STROKEAHA.108.544957 Ohtaka K, 2013, ANN THORAC SURG, V95, P1924, DOI 10.1016/j.athoracsur.2013.03.005 PEARSON AC, 1991, J AM COLL CARDIOL, V18, P1223, DOI 10.1016/0735-1097(91)90539-L Sawabata Noriyoshi, 2011, Nihon Kokyuki Gakkai Zasshi, V49, P327 Tanaka Y., 2014, ICU CCU, V38, P842 Ueda T, 2018, GEN THORAC CARDIOVAS, V66, P95, DOI 10.1007/s11748-017-0858-x Xin YZ, 2014, EUR J CARDIO-THORAC, V45, P247, DOI 10.1093/ejcts/ezt383 Yamamoto T, 2016, SURG TODAY, V46, P780, DOI 10.1007/s00595-015-1233-0 Yamashita T, 2016, HEART RHYTHM, V13, P2377, DOI 10.1016/j.hrthm.2016.09.007 NR 15 TC 9 Z9 9 U1 0 U2 3 PU SPRINGER JAPAN KK PI TOKYO PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN SN 1863-6705 EI 1863-6713 J9 GEN THORAC CARDIOVAS JI Gen. Thorac. Cardiovasc. Surg. PD MAR PY 2019 VL 67 IS 3 BP 306 EP 311 DI 10.1007/s11748-018-1024-9 PG 6 WC Cardiac & Cardiovascular Systems; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Surgery GA HM3VU UT WOS:000459403300006 PM 30367330 DA 2026-04-17 ER PT J AU Lee, CT Strauss, DM Stone, LE Stoltzfus, JC Puc, MM Burfeind, WR AF Lee, Charles T. Strauss, David M. Stone, Lauren E. Stoltzfus, Jill C. Puc, Matthew M. Burfeind, William R. TI Preoperative CHA 2 DS 2 -VASc Score Predicts Postoperative Atrial Fibrillation after Lobectomy SO THORACIC AND CARDIOVASCULAR SURGEON LA English DT Article DE thoracoscopy; VATS; lung cancer treatment; arrhythmia therapy; Maze; surgical ablation ID THORACIC-SURGERY; RISK-FACTORS; LUNG-CANCER; CARDIAC-SURGERY; PROPHYLAXIS; MANAGEMENT; SOCIETY AB Background Postoperative atrial fibrillation (POAF) affects 10 to 20% of noncardiac thoracic surgeries and increases patient morbidity and costs. The purpose of this study is to determine if preoperative CHA (2) DS (2) -VASc score can predict POAF after pulmonary lobectomy for nonsmall cell lung cancer. Methods Patients with complete CHA (2) DS (2) -VASc data who underwent lobectomies from January 2007 to January 2016 at a single institution were analyzed in a retrospective case-control study using a prospective database. An independent samples t -test was used to compare the mean CHA (2) DS (2) -VASc scores of POAF and non-POAF groups. A multivariable logistic regression analysis (MVA) evaluated the independent contribution of variables of the CHA (2) DS (2) -VASc score in predicting POAF. Chi-square test with univariate odds ratios (ORs) was used to determine a statistically significant cutoff score for predicting POAF. Results Of 525 total patients, 82 (15.6%) developed POAF (mean CHA (2) DS (2) -VASc score: 2.7) and 443 (84.4%) did not develop POAF (mean score: 2.3). Mean difference between these groups was significant at 0.43 ( p =0.01; 95% confidence interval [CI]: 0.09-0.76). In the MVA, significant predictors of POAF were age 65 to 74 years (adjusted OR [aOR]=2.45; 95% CI: 1.31-4.70; p =0.006) and age 75 years (aOR=3.11; 95% CI: 1.62-5.95; p =0.0006). Patients with CHA (2) DS (2) -VASc scores 5 had significantly increased OR for POAF (OR=2.59; 95% CI: 1.22-5.50). Conclusions Preoperatively calculated CHA (2) DS (2) -VASc score can predict POAF in patients undergoing pulmonary lobectomy. Age is the most statistically significant independent predictor, and patients with scores 5 have significantly increased risk. Trials for POAF prophylaxis should target this population. C1 [Lee, Charles T.; Strauss, David M.; Stone, Lauren E.; Stoltzfus, Jill C.; Puc, Matthew M.; Burfeind, William R.] St Lukes Univ Hlth Network, Dept Surg, 801 Ostrum St, Bethlehem, PA 18015 USA. [Lee, Charles T.; Strauss, David M.; Stone, Lauren E.; Burfeind, William R.] Temple Univ, Sch Med, Dept Surg, Philadelphia, PA USA. C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University RP Lee, CT (corresponding author), St Lukes Univ Hlth Network, Dept Surg, 801 Ostrum St, Bethlehem, PA 18015 USA. EM charles.lee133@gmail.com RI Lee, Charles/AAW-6627-2021 OI Lee, Charles/0000-0002-2195-9566 CR AMAR D, 1995, CHEST, V108, P349, DOI 10.1378/chest.108.2.349 Amar D, 2000, J THORAC CARDIOV SUR, V120, P790, DOI 10.1067/mtc.2000.109538 Amar D, 1996, CHEST, V110, P437, DOI 10.1378/chest.110.2.437 Anile M, 2012, EUR J CARDIO-THORAC, V41, P1094, DOI 10.1093/ejcts/ezr174 [Anonymous], 2000, CRIT CARE MED S Arsenault KA, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003611.pub3 Bessissow A, 2015, J THROMB HAEMOST, V13, pS304, DOI 10.1111/jth.12974 Bhave PD, 2012, AM HEART J, V164, P918, DOI 10.1016/j.ahj.2012.09.004 Burgess DC, 2006, EUR HEART J, V27, P2846, DOI 10.1093/eurheartj/ehl272 Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Chua S K, 2013, J THORAC CARDIOVASC, V146, P919 Danelich IM, 2014, J AM COLL SURGEONS, V219, P831, DOI 10.1016/j.jamcollsurg.2014.02.038 Detterbeck Frank, 2016, J Vis Surg, V2, P173, DOI [10.21037/jovs.2016.11.03, 10.21037/jovs.2016.11.03] Farmakis D, 2014, J AM COLL CARDIOL, V63, P945, DOI 10.1016/j.jacc.2013.11.026 Fernando HC, 2011, ANN THORAC SURG, V92, P1144, DOI 10.1016/j.athoracsur.2011.06.104 Fuster V, 2011, J AM COLL CARDIOL, V57, pE101, DOI 10.1016/j.jacc.2010.09.013 Hollings DD, 2010, AM J SURG, V199, P558, DOI 10.1016/j.amjsurg.2009.11.006 Hosmer W., 2000, Applied Logistic Regression, VSecond, DOI DOI 10.1002/0471722146 Imperatori A, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-4 Ivanovic J, 2014, INTERACT CARDIOV TH, V18, P340, DOI 10.1093/icvts/ivt520 Kotova S, 2017, ANN THORAC SURG, V103, P1566, DOI 10.1016/j.athoracsur.2016.11.007 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Passman RS, 2005, ANN THORAC SURG, V79, P1698, DOI 10.1016/j.athoracsur.2004.10.058 Polanczyk CA, 1998, ANN INTERN MED, V129, P279, DOI 10.7326/0003-4819-129-4-199808150-00003 Riber LP, 2012, ANN THORAC SURG, V94, P339, DOI 10.1016/j.athoracsur.2011.12.096 Ryu Jae Kean, 2009, Korean Circ J, V39, P93, DOI 10.4070/kcj.2009.39.3.93 Shah RD, 2014, J THORAC DIS, V6, pS631, DOI 10.3978/j.issn.2072-1439.2014.08.02 Simmers D, 2015, J CARDIOTHOR VASC AN, V29, P389, DOI 10.1053/j.jvca.2014.05.015 Tisdale JE, 2010, J THORAC CARDIOV SUR, V140, P45, DOI 10.1016/j.jtcvs.2010.01.026 VanMieghem W, 1996, ANN THORAC SURG, V61, P1083, DOI 10.1016/0003-4975(96)00073-2 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Yin L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123858 NR 32 TC 8 Z9 9 U1 0 U2 0 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0171-6425 EI 1439-1902 J9 THORAC CARDIOV SURG JI Thorac. Cardiovasc. Surg. PD MAR PY 2019 VL 67 IS 2 BP 125 EP 130 DI 10.1055/s-0038-1675638 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA HO8AZ UT WOS:000461173100009 PM 30485896 DA 2026-04-17 ER PT J AU Hattori, A Takamochi, K Kitamura, Y Matsunaga, T Suzuki, K Oh, S Suzuki, K AF Hattori, Aritoshi Takamochi, Kazuya Kitamura, Yoshitaka Matsunaga, Takeshi Suzuki, Kazuhiro Oh, Shiaki Suzuki, Kenji TI Risk factor analysis of cerebral infarction and clinicopathological characteristics of left upper pulmonary vein stump thrombus after lobectomy SO GENERAL THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article; Proceedings Paper CT 70th Annual Scientific Meeting of the Japanese-Association-for-Thoracic-Surgery CY SEP 26-29, 2017 CL Sapporo, JAPAN SP Japanese Assoc Thorac Surg DE Cerebral infarction; Left upper lobectomy; Pulmonary vein stump thrombus; Risk factor ID CANCER STAGING PROJECT; LUNG-CANCER; STROKE; CLASSIFICATION; SURGERY AB ObjectiveWe aimed to analyze the risk factors of postoperative cerebral infarction (CI) and thrombus formation in the left upper pulmonary vein (PV) stump after lobectomy.MethodsWe retrospectively investigated 1670 patients who underwent lobectomy or more intervention, and analyzed the risk factors of postoperative CI. Furthermore, postoperative contrast-enhanced computed tomography (CE-CT) were reviewed in patients who underwent left upper lobectomy (LUL), and risk factors of the thrombus formation in the left upper PV stump were evaluated. Chi-square test or unpaired t test was used to compare the factors.ResultsCerebral infarction was observed in 10 (0.60%) patients, being more significant in patients with left side lesions (90%) who underwent LUL (50%). Eighty percent of the CI cases occurred by day 4 postoperative. CI was found in 1.47% after LUL. Among 339 patients who underwent LUL, CE-CT was performed in 137 (40%) postoperatively. Among them, left upper PV stump thrombus was found in 16 (11.7%), which was statistically significant in higher age and p stage II or more disease (=0.003, 0.040). In contrast, preoperative histories including anticoagulant administration, atrial fibrillation, diabetes mellitus, several surgical procedures or intraoperative factors were not associated statistically with thrombus formation.ConclusionPostoperative CI occurred in the very early-phase after lobectomy, and the incidence was significantly higher in patients undergoing LUL. Because left upper PV stump thrombus was frequently found retrospectively, a prospective observation study would be required to investigate the real incidence of PV stump thrombus after lobectomy. C1 [Hattori, Aritoshi; Takamochi, Kazuya; Kitamura, Yoshitaka; Matsunaga, Takeshi; Oh, Shiaki; Suzuki, Kenji] Juntendo Univ, Dept Gen Thorac Surg, Sch Med, Bunkyo Ku, 1-3 Hongo 3 Chome, Tokyo 1138431, Japan. [Suzuki, Kazuhiro] Juntendo Univ, Sch Med, Dept Radiol, Tokyo, Japan. C3 Juntendo University; Juntendo University RP Hattori, A (corresponding author), Juntendo Univ, Dept Gen Thorac Surg, Sch Med, Bunkyo Ku, 1-3 Hongo 3 Chome, Tokyo 1138431, Japan. EM ahattori@juntendo.ac.jp RI Suzuki, Kazuhiro/AAP-3077-2020 OI Suzuki, Kazuhiro/0000-0003-1781-461X FU Ministry of Health, Labour and Welfare, Japan; Smoking Research Foundation; National Cancer Center Research and Development Fund [26-A-4] FX This work was supported in part by a Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare, Japan; the Smoking Research Foundation, and the National Cancer Center Research and Development Fund (26-A-4). CR Bateman BT, 2009, ANESTHESIOLOGY, V110, P231, DOI 10.1097/ALN.0b013e318194b5ff Fyrenius A, 2001, HEART, V86, P448, DOI 10.1136/heart.86.4.448 Goldstraw Peter, 2007, J Thorac Oncol, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a Gual-Capllonch F, 2013, J CLIN ULTRASOUND, V41, P321, DOI 10.1002/jcu.21913 Ivanovic J, 2014, J AM COLL SURGEONS, V218, P1024, DOI 10.1016/j.jamcollsurg.2013.12.043 Kam PCA, 1997, ANAESTHESIA, V52, P879, DOI 10.1111/j.1365-2044.1997.136-az0129.x Masuda M, 2016, GEN THORAC CARDIOVAS, V64, P665, DOI 10.1007/s11748-016-0695-3 Matsumoto K, 2018, SURG TODAY, V48, P571, DOI 10.1007/s00595-017-1620-9 Moon MH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185140 Nagaoka E, 2008, J THORAC CARDIOV SUR, V135, P709, DOI 10.1016/j.jtcvs.2007.11.035 Ohira S, 2013, ANN THORAC SURG, V96, pE135, DOI 10.1016/j.athoracsur.2013.07.028 Ohtaka K, 2014, J CARDIOTHORAC SURG, V9, DOI 10.1186/s13019-014-0159-8 Ohtaka K, 2014, J CARDIOTHORAC SURG, V9, DOI 10.1186/1749-8090-9-5 Ohtaka K, 2013, ANN THORAC SURG, V95, P1924, DOI 10.1016/j.athoracsur.2013.03.005 Ohtaka K, 2012, J THORAC CARDIOV SUR, V143, pE3, DOI 10.1016/j.jtcvs.2011.09.025 Rusch VW, 2009, J THORAC ONCOL, V4, P568, DOI 10.1097/JTO.0b013e3181a0d82e Schwalm S, 2004, J AM SOC ECHOCARDIOG, V17, P487, DOI 10.1016/j.echo.2004.02.003 Yamamoto T, 2016, SURG TODAY, V46, P780, DOI 10.1007/s00595-015-1233-0 NR 18 TC 42 Z9 51 U1 0 U2 3 PU SPRINGER JAPAN KK PI TOKYO PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN SN 1863-6705 EI 1863-6713 J9 GEN THORAC CARDIOVAS JI Gen. Thorac. Cardiovasc. Surg. PD FEB PY 2019 VL 67 IS 2 BP 247 EP 253 DI 10.1007/s11748-018-1017-8 PG 7 WC Cardiac & Cardiovascular Systems; Surgery WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S) SC Cardiovascular System & Cardiology; Surgery GA HI4MX UT WOS:000456426000009 PM 30251002 DA 2026-04-17 ER PT J AU Kneuertz, PJ Singer, E D'Souza, DM Moffatt-Bruce, SD Merritt, RE AF Kneuertz, Peter J. Singer, Emily D'Souza, Desmond M. Moffatt-Bruce, Susan D. Merritt, Robert E. TI Postoperative complications decrease the cost-effectiveness of robotic-assisted lobectomy SO SURGERY LA English DT Article ID THORACIC-SURGERY LOBECTOMY; RISK MODELS PREDICTORS; CELL LUNG-CANCER; ATRIAL-FIBRILLATION; VARIABILITY IMPLICATIONS; THORACOSCOPIC SURGERY; MAJOR MORBIDITY; WEDGE RESECTION; REHABILITATION; MORTALITY AB Background: Cost of robotic-assisted (RATS) lobectomy remains a major concern. We sought to define variability in cost and factors associated with increased hospital expenses after RATS lobectomy for early stage non-small cell lung cancer. Methods: We performed a retrospective review of patients who underwent RATS lobectomy for stages I-IIIA non-small cell lung cancer at a single institution between 2012 and 2014. Clinical outcomes were linked to hospital financial data. Linear regression analysis was used to test the impact of patient factors and postoperative outcomes on cost. Results: A total of 137 patients underwent RATS lobectomy, predominantly for stage IA (73%, n=100). Overall in-hospital morbidity was 29.2% (n=40), median length of stay was 5 days (range 1-27 days). Postoperative cost accounted for approximately 50% of total cost of hospitalization and varied significantly (mean $9,618.38 +/- $10,779.65), resulting in an average total hospital cost of $19,565 (+/-$11,620.42). Male sex and upper lobe predominant disease were independently associated with increased cost, whereas higher preoperative diffusing capacity of lung for carbon monoxide (DLCO) was cost-protective. Hospital expenses associated with prolonged hospitalization were $2,376.23 per day (95% CI $2,178-2,573.60). The most common complication associated with increased cost was atrial fibrillation ($5,609.13; 95% CI $2,095.42-$9,122.84). Postoperative atelectasis requiring bronchoscopy, respiratory failure, pulmonary embolism, and reoperation were seen less frequently in this cohort of patients but were associated with significant additional cost. Conclusion: Hospital cost of RATS lobectomy can vary significantly. In addition to patient risk factors, differences in cost are mainly driven by postoperative events. Initiatives aimed to reduce common yet expensive complications have the potential to improve overall cost-effectiveness of RATS lobectomy. (C) 2018 Elsevier Inc. All rights reserved. C1 [Kneuertz, Peter J.; Singer, Emily; D'Souza, Desmond M.; Moffatt-Bruce, Susan D.; Merritt, Robert E.] Ohio State Univ, Dept Surg, Wexner Med Ctr, Thorac Surg Div, 410 West 10th Ave,Doan Hall N846, Columbus, OH 43210 USA. C3 University System of Ohio; Ohio State University RP Kneuertz, PJ (corresponding author), Ohio State Univ, Dept Surg, Wexner Med Ctr, Thorac Surg Div, 410 West 10th Ave,Doan Hall N846, Columbus, OH 43210 USA. EM peter.kneuertz@osumc.edu RI Kneuertz, Peter/U-8645-2017 CR Amar D, 2012, J THORAC CARDIOV SUR, V144, P1249, DOI 10.1016/j.jtcvs.2012.06.051 Asteriou C, 2016, J MINIM ACCESS SURG, V12, P209, DOI 10.4103/0972-9941.183483 Birkmeyer JD, 2012, ANN SURG, V255, P1, DOI 10.1097/SLA.0b013e3182402c17 Bobbio A, 2008, EUR J CARDIO-THORAC, V33, P95, DOI 10.1016/j.ejcts.2007.10.003 Cardinale D, 2016, ANN SURG, V264, P244, DOI 10.1097/SLA.0000000000001626 Deen SA, 2014, ANN THORAC SURG, V97, P1000, DOI 10.1016/j.athoracsur.2013.11.021 Dong Q, 2017, WORLD J SURG ONCOL, V15, DOI 10.1186/s12957-016-1072-5 Dyszkiewicz W, 1998, EUR J CARDIO-THORAC, V13, P625, DOI 10.1016/S1010-7940(98)00084-0 Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4 Emmert A, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007633 Falcoz PE, 2016, EUR J CARDIO-THORAC, V49, P602, DOI 10.1093/ejcts/ezv154 Freeman RK, 2014, ANN THORAC SURG, V97, P1692 Geller AD, 2018, J THORAC CARDIOV SUR, V155, P1804, DOI 10.1016/j.jtcvs.2017.11.025 Gómez-Caro A, 2006, ARCH BRONCONEUMOL, V42, P9, DOI 10.1016/S1579-2129(06)60107-9 Higuchi M, 2014, J CARDIOTHORAC SURG, V9, DOI 10.1186/1749-8090-9-88 Kozower BD, 2010, ANN THORAC SURG, V90, P875, DOI 10.1016/j.athoracsur.2010.03.115 Medbery RL, 2014, ANN THORAC SURG, V97, P1686, DOI 10.1016/j.athoracsur.2014.01.021 Nasir BS, 2014, ANN THORAC SURG, V98, P203, DOI 10.1016/j.athoracsur.2014.02.051 Paci P, 2017, ANN THORAC SURG, V104, P950, DOI 10.1016/j.athoracsur.2017.05.085 Park BJ, 2009, MINERVA CHIR, V64, P573 Park BJ, 2016, J THORAC DIS, V8, pS406, DOI 10.21037/jtd.2016.04.56 Paul S, 2014, CHEST, V146, P1505, DOI 10.1378/chest.13-3032 Putnam B, 2010, ANN THORAC SURG, V90, P881 Rajaram R, 2017, ANN THORAC SURG, V103, P1092, DOI 10.1016/j.athoracsur.2016.09.108 Ramadan Omar I, 2017, J Vis Surg, V3, P22, DOI [10.21037/jovs.2017.01.06, 10.21037/jovs.2017.01.06] Ramadan Omar I, 2017, J Vis Surg, V3, P11, DOI [10.21037/jovs.2017.01.04, 10.21037/jovs.2017.01.04] Singer E, 2018, ANN CARDIOTHORAC SUR Spillane J, 2014, J ROBOT SURG, V8, P213, DOI 10.1007/s11701-014-0453-4 Sullivan R, 2015, LANCET ONCOL, V16, P1193, DOI [10.1016/s1470-2045(15)00223-5, 10.1016/S1470-2045(15)00223-5] Swanson SJ, 2014, J THORAC CARDIOV SUR, V147, P929, DOI 10.1016/j.jtcvs.2013.09.046 Tedesco G, 2016, SURG ENDOSC, V30, P5044, DOI 10.1007/s00464-016-4852-7 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Whitson BA, 2008, ANN THORAC SURG, V86, P2008, DOI 10.1016/j.athoracsur.2008.07.009 Zhang LZ, 2015, INT J CLIN EXP MED, V8, P17804 NR 34 TC 18 Z9 20 U1 0 U2 8 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0039-6060 J9 SURGERY JI Surgery PD FEB PY 2019 VL 165 IS 2 BP 455 EP 460 DI 10.1016/j.surg.2018.08.024 PG 6 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA HH8GW UT WOS:000455970900033 PM 30268372 DA 2026-04-17 ER PT J AU Pedoto, A Perrino, AC AF Pedoto, Alessia Perrino, Albert C., Jr. TI Delayed recovery following thoracic surgery: persistent issues and potential interventions SO CURRENT OPINION IN ANESTHESIOLOGY LA English DT Review DE enhanced recovery; failure to rescue; postoperative cognitive dysfunction; postoperative complications; quality of life; thoracic surgery ID PERIOPERATIVE SURGICAL HOME; ATRIAL-FIBRILLATION; LUNG-CANCER; POSTOPERATIVE DELIRIUM; ENHANCED RECOVERY; NATRIURETIC PEPTIDE; FLUID RESUSCITATION; MAJOR SURGERY; COMPLICATIONS; MANAGEMENT AB Purpose of review Lung and esophageal surgery remain a curative option for resectable cancers. However, despite advances in surgical and anesthesia practices, the inclusion of patients with comorbidities that would have previously not been offered curative resection presents additional concerns and challenges. Recent findings Perioperative complication rates remain high and prolonged and/or painful recovery are common. Further, many patients face a permanent decline in their functional status, which negatively affects their quality of life. Examination of the variables associated with high complications following thoracic surgery reveals patient, physician, and institutional factors in the forefront. Anesthesiologist training, Enhanced Recovery After Surgery protocols, and preparations to minimize "failure to rescue'' when a complication does arise are key strategies to address adverse outcomes. Summary Delayed and complicated recovery after thoracic noncardiac surgery persist in current practice. This review analyzes the diverse factors that can impact complications and quality of life after lung surgery and the interventions that can help decrease length of stay and improve return to baseline conditions. C1 [Pedoto, Alessia] Mem Sloan Kettering Canc Ctr, Dept Anesthesiol & Crit Care Med, 1275 York Ave, New York, NY 10021 USA. [Perrino, Albert C., Jr.] Yale Sch Med, Dept Anesthesiol, New Haven, CT USA. [Perrino, Albert C., Jr.] VA Connecticut Healthcare Syst, New Haven, CT USA. C3 Memorial Sloan Kettering Cancer Center; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System RP Pedoto, A (corresponding author), Dept Anesthesia & Intens Care Med, 1275 York Ave,Room M301, New York, NY 10065 USA. EM pedotoa@mskcc.org CR Agzarian J, 2018, J THORAC CARDIOV SUR, V155, P2695, DOI 10.1016/j.jtcvs.2018.01.074 Amar D, 2012, J THORAC CARDIOV SUR, V144, P1249, DOI 10.1016/j.jtcvs.2012.06.051 Arshed S, 2018, CRIT CARE CLIN, V34, P267, DOI 10.1016/j.ccc.2017.12.010 Assaad S, 2013, CURR OPIN ANESTHESIO, V26, P31, DOI 10.1097/ACO.0b013e32835c5cf5 Avidan MS, 2017, LANCET, V390, P267, DOI 10.1016/S0140-6736(17)31467-8 Baldini G, 2018, SURG CLIN N AM, V98, P1149, DOI 10.1016/j.suc.2018.07.004 Batchelor TJP, 2018, EUR J CARDIOTHORAC S Beck N, 2018, ANN THORAC SURG, V106, P412, DOI 10.1016/j.athoracsur.2018.02.074 Caironi P, 2014, NEW ENGL J MED, V370, P1412, DOI 10.1056/NEJMoa1305727 Castellanos I, 2018, J CRIT CARE, V43, P13, DOI 10.1016/j.jcrc.2017.06.027 Cheng XH, 2018, ANN SURG, V267, P37, DOI 10.1097/SLA.0000000000002405 Cooper WO, 2017, JAMA SURG, V152, P522, DOI 10.1001/jamasurg.2016.5703 Corcoran T, 2012, ANESTH ANALG, V114, P640, DOI 10.1213/ANE.0b013e318240d6eb Cypel M, 2018, LANCET ONCOL, V19, P17, DOI 10.1016/S1470-2045(17)30915-4 Deiner S, 2017, JAMA SURG, V152, DOI 10.1001/jamasurg.2017.1505 Dexter E, 2017, J AM COLL SURGEONS, V225, pE9, DOI 10.1016/j.jamcollsurg.2017.07.545 Dexter F, 2017, ANESTH ANALG, V125, P943, DOI 10.1213/ANE.0000000000002017 Dickinson KJ, 2017, ANN THORAC SURG, V103, P1084, DOI 10.1016/j.athoracsur.2016.09.065 Duan X, 2018, BRIT J ANAESTH, V121, P384, DOI 10.1016/j.bja.2018.04.046 Duceppe E, 2017, CAN J CARDIOL, V33, P17, DOI 10.1016/j.cjca.2016.09.008 Durkin C, 2017, CURR OPIN ANESTHESIO, V30, P30, DOI 10.1097/ACO.0000000000000409 Ezer N, 2018, ANN AM THORAC SOC, V15, P76, DOI 10.1513/AnnalsATS.201612-980OC Farjah F, 2017, THORAC SURG CLIN, V27, P257, DOI 10.1016/j.thorsurg.2017.03.005 Ferrah N, 2018, WORLD J SURG, V42, P2329, DOI 10.1007/s00268-018-4465-5 Findlay JM, 2014, ANN SURG, V259, P413, DOI 10.1097/SLA.0000000000000349 Finfer S, 2004, NEW ENGL J MED, V350, P2247 Fleisher LA, 2014, CIRCULATION, V130, pE278, DOI 10.1161/CIR.0000000000000106 Frendl G, 2014, J THORAC CARDIOV SUR, V148, P772, DOI 10.1016/j.jtcvs.2014.06.037 Gupta A, 2018, ANESTHESIOLOGY, V128, P880, DOI 10.1097/ALN.0000000000002136 Hennon M, 2018, ANN SURG ONCOL, V25, P59, DOI 10.1245/s10434-017-5787-5 Hirsch FR, 2017, LANCET, V389, P299, DOI 10.1016/S0140-6736(16)30958-8 Holst LB, 2014, NEW ENGL J MED, V371, P1381, DOI 10.1056/NEJMoa1406617 Ivanovic J, 2018, J HEALTHC QUAL, V40, pE62, DOI 10.1097/JHQ.0000000000000130 Josephs SA, 2018, ANESTH ANALG, V126, P150, DOI 10.1213/ANE.0000000000002299 Kaufmann KB, 2017, BRIT J ANAESTH, V118, P852, DOI 10.1093/bja/aew447 Khullar OV, 2017, ANN THORAC SURG, V104, P245, DOI 10.1016/j.athoracsur.2017.01.110 Kroschinsky F, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1678-1 Larson Sandra Louise, 2018, JBI Database System Rev Implement Rep, V16, P1346, DOI [10.11124/jbisrir-2017-003426, 10.11124/JBISRIR-2017-003426] Lei L, 2017, ANAESTHESIA, V72, P1456, DOI 10.1111/anae.14056 Lei L, 2017, CASE REP SURG, V2017 Levine GN, 2016, CIRCULATION, V134, pE123, DOI 10.1161/CIR.0000000000000404 Licker M, 2014, Curr Anesthesiol Rep, V4, P124, DOI [10.1007/s40140-014-0049-6, DOI 10.1007/S40140-014-0049-6] Lindroth H, 2018, BRIT J ANAESTH, V121, P193, DOI 10.1016/j.bja.2018.01.013 Lu X, 2018, J CLIN ANESTH, V45, P55, DOI 10.1016/j.jclinane.2017.12.002 Lugg ST, 2017, J CARDIOTHORAC SURG, V12, DOI 10.1186/s13019-017-0614-4 Miller D, 2018, COCHRANE DB SYST REV, V8 Nathan H, 2017, ANN SURG ONCOL, V24, P638, DOI 10.1245/s10434-016-5569-5 Nojiri T, 2010, EUR J CARDIO-THORAC, V37, P787, DOI 10.1016/j.ejcts.2009.09.043 Popescu WM, 2017, J CARDIOTHOR VASC AN, V31, P1359, DOI 10.1053/j.jvca.2017.05.021 Quero-Valenzuela F, 2018, J SURG ONCOL, V117, P1239, DOI 10.1002/jso.24973 Refai M, 2018, J THORAC DIS, V10, pS512, DOI 10.21037/jtd.2017.12.87 Rosen JE, 2017, ANN SURG, V266, P383, DOI 10.1097/SLA.0000000000001971 Sun LY, 2018, ANESTHESIOLOGY, V129, P440, DOI 10.1097/ALN.0000000000002298 Sun V, 2018, J CANCER EDUC, V33, P557, DOI 10.1007/s13187-016-1103-5 Taioli E, 2017, J SURG ONCOL, V116, P471, DOI 10.1002/jso.24697 Turan A, 2018, EUR J ANAESTH, V35, P256, DOI 10.1097/EJA.0000000000000701 Veelo DP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172806 Widmer RJ, 2018, AM J MED, V131, DOI 10.1016/j.amjmed.2017.12.025 Williams Aaron M, 2018, Mhealth, V4, P11, DOI [10.21037/mhealth.2018.04.03, 10.21037/mhealth.2018.04.03] Wischmeyer PE, 2018, ANESTH ANALG, V126, P1883, DOI 10.1213/ANE.0000000000002743 Xu H, 2017, J THORAC DIS, V9, P2992, DOI 10.21037/jtd.2017.08.98 Zaccagnino MP, 2017, ANESTH ANALG, V125, P1394, DOI 10.1213/ANE.0000000000002165 ZELDIN RA, 1984, J THORAC CARDIOV SUR, V87, P359 Zhao BC, 2017, CHEST, V151, P149, DOI 10.1016/j.chest.2016.08.1476 2018, J THORAC CARDIOVASC, V155, P2683 2017, ANESTH ANALG, V125, P1089, DOI DOI 10.1213/ANE.0000000000002122 2018, SURGERY, V163, P672, DOI DOI 10.1016/J.SURG.2017.08.015 2018, J THORAC CARDIOVASC, V155, P1254 NR 68 TC 10 Z9 11 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0952-7907 EI 1473-6500 J9 CURR OPIN ANESTHESIO JI Curr. Opin. Anesthesiol. PD FEB PY 2019 VL 32 IS 1 BP 3 EP 9 DI 10.1097/ACO.0000000000000669 PG 7 WC Anesthesiology WE Science Citation Index Expanded (SCI-EXPANDED) SC Anesthesiology GA HX4CR UT WOS:000467342600002 PM 30507683 DA 2026-04-17 ER PT J AU Sato, S Nakamura, A Shimizu, Y Goto, T Kitahara, A Koike, T Okamoto, T Tsuchida, M AF Sato, Seijiro Nakamura, Atsuhiro Shimizu, Yuki Goto, Tatsuya Kitahara, Akihiko Koike, Terumoto Okamoto, Takeshi Tsuchida, Masanori TI Early and mid-term outcomes of simultaneous thoracic endovascular stent grafting and combined resection of thoracic malignancies and the aortic wall SO GENERAL THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article; Proceedings Paper CT 70th Annual Scientific Meeting of the Japanese-Association-for-Thoracic-Surgery CY SEP 26-29, 2017 CL Sapporo, JAPAN SP Japanese Assoc Thorac Surg DE Lung cancer; Thoracic malignancy; Thoracic endovascular stent grafting; One-stage procedure; Combined aortic resection ID CELL LUNG-CANCER; CARDIOPULMONARY BYPASS; SURGICAL RESECTION; SURGERY; PNEUMONECTOMY AB ObjectivesTo aim of this study was to clarify the safety of simultaneous thoracic aortic endografting and combined resection of the aortic wall and thoracic malignancy in a one-stage procedure over the early and mid-term periods.MethodsFrom March 2013 to December 2017, 6 patients underwent aortic endografting followed by one-stage en bloc resection of the tumor and aortic wall. Thoracic surgeons and cardiovascular surgeons discussed predicted tumor invasion range and resection site, stent placement position, stent length and size, and the surgical procedure, taking into account the safe margin.ResultsThe proximal site of aortic endografting was the: aortic arch in 2 cases (subclavian artery (SCA) occlusion in one, and SCA fenestration in one); distal arch just beneath the SCA in 2; descending aorta in 2. Pulmonary resection involved lobectomy in 2 patients, pneumonectomy in 2, and completion pneumonectomy in 1. Aortic resection was limited to the adventitia in 2 cases, extended to the media in 3, and extended to the intima in 1. An endograft-related complication, external iliac artery intimal damage requiring vessel repair, was observed in one case. No complications associated with aortic resection were observed. Two postoperative complications of atrial fibrillation and chylothorax developed. There were no surgery-related deaths. During follow-up, no late endograft-related complications such as migration or endoleaks occurred.ConclusionsEarly and mid-term outcomes of stent graft-related complications are acceptable. Simultaneous thoracic aortic endografting and combined resection of the aortic wall and thoracic malignancies are feasible in one stage on the same day. C1 [Sato, Seijiro; Nakamura, Atsuhiro; Shimizu, Yuki; Goto, Tatsuya; Kitahara, Akihiko; Koike, Terumoto; Okamoto, Takeshi; Tsuchida, Masanori] Niigata Univ, Grad Sch Med & Dent Sci, Div Thorac & Cardiovasc Surg, Chuo Ku, 1-757 Asahimachi Dori, Niigata, Niigata 9518510, Japan. C3 Niigata University RP Sato, S (corresponding author), Niigata Univ, Grad Sch Med & Dent Sci, Div Thorac & Cardiovasc Surg, Chuo Ku, 1-757 Asahimachi Dori, Niigata, Niigata 9518510, Japan. EM seisato@med.niigata-u.ac.jp RI Koike, Terumoto/AAD-5605-2022 CR Akchurin RS, 1997, ARTIF ORGANS, V21, P763, DOI 10.1111/j.1525-1594.1997.tb03738.x Berna P, 2011, ANN THORAC SURG, V91, P591, DOI 10.1016/j.athoracsur.2010.07.045 Byrne JG, 2004, CHEST, V125, P1581, DOI 10.1378/chest.125.4.1581 Collaud S, 2014, J THORAC CARDIOV SUR, V147, P1178, DOI 10.1016/j.jtcvs.2013.12.020 Dartevelle P, 2017, GEN THORAC CARDIOVAS, V65, P321, DOI 10.1007/s11748-017-0752-6 Dejima H, 2016, ANN THORAC CARDIOVAS, V22, P52, DOI 10.5761/atcs.cr.15-00079 Grundmann U, 2000, ANESTHESIOLOGY, V93, P359, DOI 10.1097/00000542-200008000-00013 Langer NB, 2016, ANN THORAC SURG, V102, P902, DOI 10.1016/j.athoracsur.2016.03.044 Lederle FA, 2012, NEW ENGL J MED, V367, P1988, DOI 10.1056/NEJMoa1207481 Marialli G, 2008, J VASC SURG, V47, P868, DOI 10.1016/j.jvs.2007.10.019 Marulli G, 2015, ANN THORAC SURG, V99, P1768, DOI 10.1016/j.athoracsur.2015.01.059 Masuda M, 2016, GEN THORAC CARDIOVAS, V64, P665, DOI 10.1007/s11748-016-0695-3 Mody GN, 2016, ANN THORAC SURG, V101, P1587, DOI 10.1016/j.athoracsur.2015.05.131 Muralidaran A, 2011, J THORAC CARDIOV SUR, V142, P1137, DOI 10.1016/j.jtcvs.2011.07.042 Nagata T, 2013, J THORAC CARDIOV SUR, V146, P238, DOI 10.1016/j.jtcvs.2013.02.070 Ohta M, 2005, J THORAC CARDIOV SUR, V129, P804, DOI 10.1016/j.jtcvs.2004.05.010 Otani Shinichi, 2016, J Vis Surg, V2, P20, DOI 10.3978/j.issn.2221-2965.2016.01.02 Ozawa Y, 2016, POL J RADIOL, V81, P566, DOI 10.12659/PJR.898242 Sato S, 2017, J THORAC DIS, V9, pE1009, DOI 10.21037/jtd.2017.10.101 Seo JS, 2005, J MAGN RESON IMAGING, V22, P234, DOI 10.1002/jmri.20378 Vallières E, 2009, J THORAC ONCOL, V4, P1049, DOI 10.1097/JTO.0b013e3181b27799 Walgram T, 2018, INTERACT CARDIOV TH, V26, P545, DOI 10.1093/icvts/ivx364 Wilhelm W, 2002, SHOCK, V17, P354, DOI 10.1097/00024382-200205000-00002 NR 23 TC 11 Z9 14 U1 0 U2 1 PU SPRINGER JAPAN KK PI TOKYO PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN SN 1863-6705 EI 1863-6713 J9 GEN THORAC CARDIOVAS JI Gen. Thorac. Cardiovasc. Surg. PD FEB PY 2019 VL 67 IS 2 BP 227 EP 233 DI 10.1007/s11748-018-1003-1 PG 7 WC Cardiac & Cardiovascular Systems; Surgery WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S) SC Cardiovascular System & Cardiology; Surgery GA HI4MX UT WOS:000456426000006 PM 30173396 OA Green Submitted, hybrid DA 2026-04-17 ER PT J AU Wang, ML Hung, MH Hsu, HH Chan, KC Cheng, YJ Chen, JS AF Wang, Man-Ling Hung, Ming-Hui Hsu, Hsao-Hsun Chan, Kuang-Cheng Cheng, Ya-Jung Chen, Jin-Shing TI Non-intubated thoracoscopic surgery for lung cancer in patients with impaired pulmonary function SO ANNALS OF TRANSLATIONAL MEDICINE LA English DT Article DE Anesthesia; non-intubated video-assisted thoracoscopic surgery (non-intubated VATS); lung tumor; lung function ID VOLUME REDUCTION; LOBECTOMY; RISK; COMPLICATIONS; ANESTHESIA; PROGNOSIS; SOCIETY; DISEASE; INJURY AB Background: Patients with impaired lung function or chronic obstructive pulmonary disease (COPD) are considered high-risk for intubated general anesthesia, which may preclude them from surgical treatment of their lung cancers. We evaluated the feasibility of non-intubated video-assisted thoracoscopic surgery (VATS) for the surgical management of lung cancer in patients with impaired pulmonary function. Methods: From August 2009 to June 2015, 28 patients with impaired lung function (preoperative forced expiratory volume in 1 second <70% of the predicted value) underwent non-intubated VATS using a combination of thoracic epidural anesthesia or intercostal nerve block, and intra-thoracic vagal block with target-controlled sedation. Results: Eighteen patients had primary lung cancers, 4 had metastatic lung cancers, and 6 had nonmalignant lung tumors. In the patients with primary lung cancer, lobectomy was performed in 4, segmentectomy in 3 and wedge resection in 11, with lymph node sampling adequate for staging. One patient required conversion to intubated one-lung ventilation because of persistent wheezing and labored breathing. Five patients developed air leaks more than 5 days postoperatively while subcutaneous emphysema occurred in 6 patients. Two patients developed acute exacerbations of pre-existing COPD, and new-onset atrial fibrillation after surgery occurred in 1 patient. The median duration of postoperative chest tube drainage was 3 days while the median hospital stay was 6 days. Conclusions: Non-intubated VATS resection for pulmonary tumors is technically feasible. It may be applied as an alternative to intubated general anesthesia in managing lung cancer in selected patients with impaired pulmonary function. C1 [Wang, Man-Ling; Hung, Ming-Hui] Natl Taiwan Univ Hosp, Grad Inst Clin Med, Taipei, Taiwan. [Wang, Man-Ling; Hung, Ming-Hui; Chan, Kuang-Cheng; Cheng, Ya-Jung] Natl Taiwan Univ Hosp, Dept Anesthesiol, Taipei, Taiwan. [Hsu, Hsao-Hsun; Chen, Jin-Shing] Natl Taiwan Univ Hosp, Div Thorac Surg, Dept Surg, 7 Chung Shan South Rd, Taipei, Taiwan. Natl Taiwan Univ, Coll Med, Taipei, Taiwan. C3 National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University RP Chen, JS (corresponding author), Natl Taiwan Univ Hosp, Div Thorac Surg, Dept Surg, 7 Chung Shan South Rd, Taipei, Taiwan. EM chenjs@ntu.edu.tw RI Hung, Ming-Hui/AAS-4520-2020; Wang, Man-Ling/JNS-2606-2023 OI Hung, Ming-Hui/0000-0002-2575-3004; FU National Taiwan University Hospital [NTUH104-P08]; Taiwan Lung Foundation, Taipei, Taiwan [TLF2015-C02] FX This work was supported in part by research grants from National Taiwan University Hospital (NTUH104-P08 to Dr. Chen) and the Taiwan Lung Foundation (TLF2015-C02 to Dr. Chen), Taipei, Taiwan. CR Alam N, 2007, ANN THORAC SURG, V84, P1085, DOI 10.1016/j.athoracsur.2007.05.053 ANTHONISEN NR, 1986, AM REV RESPIR DIS, V133, P14, DOI 10.1164/arrd.1986.133.1.14 Burt BM, 2014, J THORAC CARDIOV SUR, V148, P19, DOI 10.1016/j.jtcvs.2014.03.007 Ceppa DP, 2012, ANN SURG, V256, P487, DOI 10.1097/SLA.0b013e318265819c Chen JS, 2011, ANN SURG, V254, P1038, DOI 10.1097/SLA.0b013e31822ed19b Chen KC, 2014, J THORAC DIS, V6, P31, DOI 10.3978/j.issn.2072-1439.2014.01.01 Chen KC, 2012, J THORAC DIS, V4, P347, DOI 10.3978/j.issn.2072-1439.2012.08.07 Choi H, 2015, CURR OPIN ANESTHESIO, V28, P18, DOI 10.1097/ACO.0000000000000149 Ciccone AM, 2003, J THORAC CARDIOV SUR, V125, P513, DOI 10.1067/mtc.2003.147 Della Rocca G, 2013, CURR OPIN ANESTHESIO, V26, P40, DOI 10.1097/ACO.0b013e32835c4ea2 Fitzmaurice BG, 1999, J CARDIOTHOR VASC AN, V13, P322, DOI 10.1016/S1053-0770(99)90273-2 Grosse-Sundrup M, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6329 Hausman MS, 2015, ANESTH ANALG, V120, P1405, DOI 10.1213/ANE.0000000000000574 Hung MH, 2014, J THORAC DIS, V6, P2, DOI 10.3978/j.issn.2072-1439.2014.01.16 Hung MH, 2013, ANN THORAC SURG, V96, P1209, DOI 10.1016/j.athoracsur.2013.05.065 Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43 Jeon JH, 2014, EUR J CARDIO-THORAC, V45, P640, DOI 10.1093/ejcts/ezt460 Kachare S, 2011, J THORAC CARDIOV SUR, V141, P459, DOI 10.1016/j.jtcvs.2010.05.051 Kim ES, 1999, ANESTHESIOLOGY, V90, P391, DOI 10.1097/00000542-199902000-00010 Marcus MW, 2015, J THORAC DIS, V7, pS156, DOI 10.3978/j.issn.2072-1439.2015.04.19 Marshall HM, 2013, J THORAC DIS, V5, pS524, DOI 10.3978/j.issn.2072-1439.2013.09.06 Murphy GS, 2013, ANESTH ANALG, V117, P133, DOI 10.1213/ANE.0b013e3182742e75 Osuka S, 2015, RESPIR INVESTIG, V53, P117, DOI 10.1016/j.resinv.2015.01.005 Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205 Pompeo E, 2012, J THORAC CARDIOV SUR, V143, P47, DOI 10.1016/j.jtcvs.2011.09.050 Roviaro G, 2004, CHEST, V126, P725, DOI 10.1378/chest.126.3.725 Taylor MD, 2014, J THORAC CARDIOV SUR, V147, P738, DOI 10.1016/j.jtcvs.2013.09.064 Wang BY, 2013, J THORAC ONCOL, V8, P1128, DOI 10.1097/JTO.0b013e31829ceba4 Wang ML, 2018, EUR J CARDIO-THORAC, V53, P1001, DOI 10.1093/ejcts/ezx450 Warner DO, 1999, ANESTHESIOLOGY, V90, P372, DOI 10.1097/00000542-199902000-00007 Wright CD, 2008, ANN THORAC SURG, V85, P1857, DOI 10.1016/j.athoracsur.2008.03.024 Wu CY, 2013, ANN THORAC SURG, V95, P405, DOI 10.1016/j.athoracsur.2012.10.082 Yang JT, 2014, J THORAC DIS, V6, P10, DOI 10.3978/j.issn.2072-1439.2014.01.03 NR 33 TC 30 Z9 32 U1 1 U2 11 PU AME PUBLISHING COMPANY PI SHATIN PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA SN 2305-5839 EI 2305-5847 J9 ANN TRANSL MED JI ANN. TRANSL. MED. PD FEB PY 2019 VL 7 IS 3 AR 40 DI 10.21037/atm.2018.11.58 PG 9 WC Oncology; Medicine, Research & Experimental WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Research & Experimental Medicine GA HJ2XI UT WOS:000457033500002 PM 30906744 OA gold DA 2026-04-17 ER PT J AU Kim, TY Kim, KH AF Kim, Tae Yun Kim, Kyung Hwa TI Case Report: Rapidly Growing Intra-Cardiac Mass Mimicking a Local Recurrence of Lung Cancer or a Thrombus in the Left Atrium SO HEART SURGERY FORUM LA English DT Article AB Cardiac myxoma typically is thought to be a slowgrowing, benign primary. Atrial myxomas can lead to many complications and can also mimic mitral stenosis, infective endocarditis, and other vascular diseases associated with systemic embolization. A 75-year-old woman with a history of lung cancer (pT1cN1, adenocarcinoma), atrial fibrillation, and a cerebral infarction presented with dysarthria and visual disturbances. In our case, we had to consider some questionable issues with the left atrial mass, and whether the recurrence of cerebral events was due to the thrombotic material in the left atrium or from locally recurrent lung cancer from the stump margin of the previously resected left superior pulmonary vein. We present a case with a rapidly-growing left atrial myxoma with a growth rate of 12.60 mm/month, rather than a thrombus or local recurrence of tumor under a medication of non-VKA oral antagonists. C1 [Kim, Tae Yun; Kim, Kyung Hwa] Chonbuk Natl Univ Hosp, Dept Thorac & Cardiovasc Surg, Jeonju, South Korea. [Kim, Kyung Hwa] Chonbuk Natl Univ, Chonbuk Natl Univ Hosp, Biomed Res Inst, Res Inst Clin Med, Jeonju, South Korea. C3 Jeonbuk National University; Jeonbuk National University Hospital; Jeonbuk National University; Jeonbuk National University Hospital RP Kim, KH (corresponding author), Chonbuk Natl Univ, Chonbuk Natl Univ Hosp, Res Inst Clin Med, Dept Thorac & Cardiovasc Surg,Med Sch, 20 Geonji Ro, Jeonju 54907, South Korea.; Kim, KH (corresponding author), Chonbuk Natl Univ Hosp, Biomed Res Inst, 20 Geonji Ro, Jeonju 54907, South Korea. EM uadocjon1314@hanmail.net; tcskimgh@gmail.com CR Hammami R, 2012, CASE REP MED, V2012, DOI 10.1155/2012/518539 Haruki N, 2018, CIRC J, V82, P2682, DOI 10.1253/circj.CJ-18-0081 Andreu JP, 2013, NEUROLOGIA, V28, P529, DOI 10.1016/j.nrl.2013.03.006 REYNEN K, 1995, NEW ENGL J MED, V333, P1610, DOI 10.1056/NEJM199512143332407 Walpot J, 2010, ECHOCARDIOGR-J CARD, V27, pE128, DOI 10.1111/j.1540-8175.2010.01186.x NR 5 TC 1 Z9 2 U1 0 U2 1 PU FORUM MULTIMEDIA PUBLISHING, LLC PI CHARLOTTESVILLE PA 375 GREENBRIER DR, CHARLOTTESVILLE, VA 22901 USA SN 1098-3511 EI 1522-6662 J9 HEART SURG FORUM JI Heart Surg. Forum PY 2019 VL 22 IS 5 BP E317 EP E318 DI 10.1532/HSF98.2479 PG 2 WC Cardiac & Cardiovascular Systems; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Surgery GA IU1LI UT WOS:000483337400002 PM 31596704 DA 2026-04-17 ER PT J AU Rice, SR Li, YR Busch, TM Kim, MM McNulty, S Dimofte, A Zhu, TC Cengel, KA Simone, CB AF Rice, Stephanie R. Li, Yun R. Busch, Theresa M. Kim, Michele M. McNulty, Sally Dimofte, Andrea Zhu, Timothy C. Cengel, Keith A. Simone, Charles B., II TI A Novel Prospective Study Assessing the Combination of Photodynamic Therapy and Proton Radiation Therapy: Safety and Outcomes When Treating Malignant Pleural Mesothelioma SO PHOTOCHEMISTRY AND PHOTOBIOLOGY LA English DT Article ID LUNG-CANCER; EXTRAPLEURAL PNEUMONECTOMY; PROGNOSTIC-FACTORS; RANDOMIZED-TRIAL; PHASE-III; HEMITHORACIC RADIATION; EUROPEAN-ORGANIZATION; LIGHT DOSIMETRY; SURVIVAL; SURGERY AB Malignant pleural mesothelioma remains difficult to treat, with high failure rates despite optimal therapy. We present a novel prospective trial combining proton therapy (PT) and photodynamic therapy (PDT) and the largest-ever mesothelioma PT experience (n = 10). PDT photosensitizers included porfimer sodium (2 mg center dot kg(-1); 24 h drug-light interval) or 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) (4 mg center dot m(-2);48 h) with wavelengths of 630 nm to 60J center dot cm(-2) and 665 nm to 15-45J center dot cm(-2), respectively. With a median age of 69 years, patients were predominantly male (90%) with epithelioid histology (100%) and stage III-IV disease (100%). PT was delivered to a median of 55.0 CGE/1.8-2.0 CGE (range 50-75 CGE) adjuvantly (n = 8) or as salvage therapy (n = 2) following extended pleurectomy/decortication (ePD)/PDT. Two-year local control was 90%, with distant and regional failure rates of 50% and 30%, respectively. All patients received chemotherapy, and four received immunotherapy. Surgical complications included atrial fibrillation (n = 3), pneumonia (n = 2), and deep vein thrombosis (n = 2). Median survival from PT completion was 19.5 months (30.3 months from diagnosis), and 1- and 2-year survival rates were 58% and 29%. No patient experienced CTCAEv4 grade >= 2 acute or late toxicity. Our prolonged survival in very advanced-stage patients compares favorably to survival for PT without PDT and photon therapy with PDT, suggesting possible spatial or systemic cooperativity and immune effect. C1 [Rice, Stephanie R.; Simone, Charles B., II] Univ Maryland, Sch Med, Dept Radiat Oncol, Baltimore, MD 21201 USA. [Li, Yun R.] Univ Calif San Francisco, Dept Radiat Oncol, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA. [Busch, Theresa M.; Kim, Michele M.; McNulty, Sally; Dimofte, Andrea; Zhu, Timothy C.; Cengel, Keith A.] Univ Penn, Dept Radiat Oncol, Perelman Sch Med, Philadelphia, PA 19104 USA. C3 University System of Maryland; University of Maryland Baltimore; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of Pennsylvania RP Simone, CB (corresponding author), Univ Maryland, Sch Med, Dept Radiat Oncol, Baltimore, MD 21201 USA.; Cengel, KA (corresponding author), Univ Penn, Dept Radiat Oncol, Perelman Sch Med, Philadelphia, PA 19104 USA. EM keith.cengel@uphs.upenn.edu; charlessimone@umm.edu RI Kim, Michele/KBD-4844-2024; Zhu, Timothy/AAC-5913-2020; Cengel, Keith/PCT-4725-2025; Rice, Stephanie/L-8734-2019; Busch, Theresa/J-5591-2019 OI Zhu, Timothy/0000-0003-2842-8984; Li, Yun Rose/0000-0002-8077-4975; Rice, Stephanie/0000-0002-2661-935X; Busch, Theresa/0000-0002-5499-8377; Cengel, Keith/0000-0001-6960-5882; Simone, Charles/0000-0002-0867-3694 FU NCI NIH HHS [R01 CA085831, P01 CA087971] Funding Source: Medline CR Allen AM, 2006, INT J RADIAT ONCOL, V65, P640, DOI 10.1016/j.ijrobp.2006.03.012 Alley EW, 2017, TRANSL LUNG CANCER R, V6, P212, DOI 10.21037/tlcr.2017.04.01 [Anonymous], 2017, P AM SOC CLIN ON S18 Badiyan SN, 2018, TRANSL LUNG CANCER R, V7, P189, DOI 10.21037/tlcr.2018.04.07 Balduyck B, 2010, ANN THORAC SURG, V89, P907, DOI 10.1016/j.athoracsur.2009.12.041 BOUTIN C, 1995, CHEST, V108, P754, DOI 10.1378/chest.108.3.754 Bovolato P, 2014, J THORAC ONCOL, V9, P390, DOI 10.1097/JTO.0000000000000064 Brackett CM, 2011, PHOTOCH PHOTOBIO SCI, V10, P649, DOI 10.1039/c0pp00354a Bydder S, 2004, BRIT J CANCER, V91, P9, DOI 10.1038/sj.bjc.6601957 CANTI G, 1994, ANTI-CANCER DRUG, V5, P443, DOI 10.1097/00001813-199408000-00009 Cao C, 2014, LUNG CANCER, V83, P240, DOI 10.1016/j.lungcan.2013.11.026 CARMICHAEL J, 1989, EUR J CANCER CLIN ON, V25, P527, DOI 10.1016/0277-5379(89)90266-6 Chang JY, 2017, JAMA ONCOL, V3, DOI [10.21767/2471-9668.100029, 10.1001/jamaoncol.2017.2032] Chao HH, 2017, J THORAC ONCOL, V12, P281, DOI 10.1016/j.jtho.2016.10.018 Chen B, 2006, CRIT REV EUKAR GENE, V16, P279, DOI 10.1615/CritRevEukarGeneExpr.v16.i4.10 Chen J, 2002, CANCER J, V8, P154, DOI 10.1097/00130404-200203000-00009 Cramer G, 2018, J THORAC DIS, V10, pS2565, DOI 10.21037/jtd.2018.07.65 Curran D, 1998, J CLIN ONCOL, V16, P145, DOI 10.1200/JCO.1998.16.1.145 Davis RW, 2018, LASER SURG MED, V50, P440, DOI 10.1002/lsm.22934 de Graaf-Strukowska L, 1999, INT J RADIAT ONCOL, V43, P511, DOI 10.1016/S0360-3016(98)00409-X de Perrot M, 2016, J THORAC CARDIOV SUR, V151, P468, DOI 10.1016/j.jtcvs.2015.09.129 Dimofte A, 2009, PROC SPIE, V7164, DOI 10.1117/12.809548 Du KL, 2010, CANCER BIOL THER, V10, P425, DOI 10.4161/cbt.10.5.12616 Flores RM, 2007, J THORAC ONCOL, V2, P957, DOI 10.1097/JTO.0b013e31815608d9 Friedberg JS, 2017, ANN THORAC SURG, V103, P912, DOI 10.1016/j.athoracsur.2016.08.071 Friedberg JS, 2012, ANN THORAC SURG, V93, P1658, DOI 10.1016/j.athoracsur.2012.02.009 Friedberg JS, 2011, ANN THORAC SURG, V91, P1738, DOI 10.1016/j.athoracsur.2011.02.062 Friedberg JS, 2003, ANN THORAC SURG, V75, P952, DOI 10.1016/S0003-4975(02)04474-0 Gameiro SR, 2016, INT J RADIAT ONCOL, V95, P120, DOI 10.1016/j.ijrobp.2016.02.022 Garg AD, 2014, PHOTOCH PHOTOBIO SCI, V13, P474, DOI 10.1039/c3pp50333j GORDON W, 1982, INT J RADIAT ONCOL, V8, P19, DOI 10.1016/0360-3016(82)90379-0 Gorini G, 2005, EUR J CANCER PREV, V14, P195, DOI 10.1097/00008469-200506000-00001 Hakkinen AM, 1996, ACTA ONCOL, V35, P451 Hamblin MR, 2004, PHOTOCH PHOTOBIO SCI, V3, P436, DOI 10.1039/b311900a Higgins KA, 2017, INT J RADIAT ONCOL, V97, P128, DOI 10.1016/j.ijrobp.2016.10.001 Kabingu E, 2009, CLIN CANCER RES, V15, P4460, DOI 10.1158/1078-0432.CCR-09-0400 Krayenbuehl J, 2010, INT J RADIAT ONCOL, V78, P628, DOI 10.1016/j.ijrobp.2009.11.006 Li YR., 2015, 16 WORLD C LUNG CANC Lorentini S, 2012, STRAHLENTHER ONKOL, V188, P216, DOI 10.1007/s00066-011-0038-3 Magnani C, 2002, TUMORI, V88, P266, DOI 10.1177/030089160208800403 Matzi Veronika, 2004, Interact Cardiovasc Thorac Surg, V3, P52, DOI 10.1016/S1569-9293(03)00213-5 Milano MT, 2010, J THORAC ONCOL, V5, P1841, DOI 10.1097/JTO.0b013e3181f1cf2b MOLE RH, 1953, BRIT J RADIOL, V26, P234, DOI 10.1259/0007-1285-26-305-234 O'Rourke N, 2007, RADIOTHER ONCOL, V84, P18, DOI 10.1016/j.radonc.2007.05.022 Palma DA, 2013, INT J RADIAT ONCOL, V85, P444, DOI 10.1016/j.ijrobp.2012.04.043 Pass HI, 1997, ANN SURG ONCOL, V4, P628, DOI 10.1007/BF02303746 Postow MA, 2012, NEW ENGL J MED, V366, P925, DOI 10.1056/NEJMoa1112824 Price B, 2004, AM J EPIDEMIOL, V159, P107, DOI 10.1093/aje/kwh025 Rice DC, 2007, INT J RADIAT ONCOL, V69, P350, DOI 10.1016/j.ijrobp.2007.03.011 Robinson BWS, 2005, NEW ENGL J MED, V353, P1591, DOI 10.1056/NEJMra050152 RUFFIE P, 1989, J CLIN ONCOL, V7, P1157, DOI 10.1200/JCO.1989.7.8.1157 Rusch V, 2013, J THORAC CARDIOV SUR, V145, P909, DOI 10.1016/j.jtcvs.2013.01.039 Rusch VW, 2016, J THORAC ONCOL, V11, P2112, DOI 10.1016/j.jtho.2016.09.124 Rusch VW, 2012, J THORAC ONCOL, V7, P1631, DOI 10.1097/JTO.0b013e31826915f1 Rusch VW, 2001, J THORAC CARDIOV SUR, V122, P788, DOI 10.1067/mtc.2001.116560 Rwigema JCM, 2017, CANCER-AM CANCER SOC, V123, P4244, DOI 10.1002/cncr.30870 Saini R, 2016, CANCERS, V8, DOI 10.3390/cancers8090083 Schouwink H, 2001, CHEST, V120, P1167, DOI 10.1378/chest.120.4.1167 Scott B, 2000, TXB LUNG CANC, P273 Shaaban SG, 2018, CLIN LUNG CANCER, V19, pE685, DOI 10.1016/j.cllc.2018.04.019 Shimokawa Takashi, 2016, Int J Part Ther, V3, P61, DOI [10.14338/ijpt-15-00023.1, 10.14338/IJPT-15-00023.1] Simone CB II, 2014, SEMIN ONCOL, V41, P820, DOI 10.1053/j.seminoncol.2014.09.017 Simone CB II, 2012, J THORAC DIS, V4, P63, DOI 10.3978/j.issn.2072-1439.2011.11.05 Skovsen E, 2005, J PHYS CHEM B, V109, P8570, DOI 10.1021/jp051163i Spaggiari L, 2014, ANN THORAC SURG, V97, P1859, DOI 10.1016/j.athoracsur.2014.01.050 Swartling J, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3495720 van Meerbeeck JP, 2005, J CLIN ONCOL, V23, P6881, DOI 10.1200/JCO.20005.14.589 van Zandwijk N, 2013, J THORAC DIS, V5, pE254, DOI 10.3978/j.issn.2072-1439.2013.11.28 VANGELDER T, 1994, EUR RESPIR J, V7, P1035 Veiga C, 2016, INT J RADIAT ONCOL, V95, P549, DOI 10.1016/j.ijrobp.2016.01.055 Verma V, 2018, CLIN LUNG CANCER, V19, pE901, DOI 10.1016/j.cllc.2018.08.007 Verma V, 2018, LUNG CANCER, V120, P7, DOI 10.1016/j.lungcan.2018.03.019 Verma V, 2017, J THORAC ONCOL, V12, P1704, DOI 10.1016/j.jtho.2017.08.012 Vogel J, 2017, INT J RADIAT ONCOL, V99, P427, DOI 10.1016/j.ijrobp.2017.04.022 Vogel J, 2016, RADIOTHER ONCOL, V118, P504, DOI 10.1016/j.radonc.2016.02.003 Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136 Vulcan TG, 2000, LASER SURG MED, V26, P292, DOI 10.1002/(SICI)1096-9101(2000)26:3<292::AID-LSM7>3.3.CO;2-K Zhu T. C., 2015, P SPIE INT SOC OPT E, V9308, P1 Zhu TC, 2005, P SOC PHOTO-OPT INS, V5689, P174, DOI 10.1117/12.590330 Zhu TC, 2003, P SOC PHOTO-OPT INS, V4952, P56, DOI 10.1117/12.474144 Zhu TC, 2015, FRONT PHYS, V3, DOI 10.3389/fphy.2015.00009 Zulaziz N, 2015, HUM CELL, V28, P159, DOI 10.1007/s13577-015-0118-2 NR 82 TC 22 Z9 25 U1 0 U2 11 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0031-8655 EI 1751-1097 J9 PHOTOCHEM PHOTOBIOL JI Photochem. Photobiol. PD JAN-FEB PY 2019 VL 95 IS 1 BP 411 EP 418 DI 10.1111/php.13065 PG 8 WC Biochemistry & Molecular Biology; Biophysics WE Science Citation Index Expanded (SCI-EXPANDED) SC Biochemistry & Molecular Biology; Biophysics GA HJ0HK UT WOS:000456839400040 PM 30485442 OA Green Submitted DA 2026-04-17 ER PT J AU Usui, G Takayama, Y Hashimoto, H Katano, T Yanagiya, M Kusakabe, M Miura, T Matsumoto, J Horiuchi, H Okubo, S AF Usui, Genki Takayama, Yohei Hashimoto, Hirotsugu Katano, Takehiro Yanagiya, Masahiro Kusakabe, Masashi Miura, Tamaki Matsumoto, Jun Horiuchi, Hajime Okubo, Seiji TI Cerebral Embolism Caused by Thrombus in the Pulmonary Vein Stump after Left Lower Lobectomy: A Case Report and Literature Review SO INTERNAL MEDICINE LA English DT Review DE stroke; endovascular thrombectomy; lung cancer ID ATRIAL-FIBRILLATION; PREDICTING STROKE; LUNG-CANCER; RISK-FACTOR; CLASSIFICATION AB Cerebral embolism after left upper lobectomy caused by a thrombus in the pulmonary vein stump (PVS) is a serious complication. However, it is unclear if cerebral embolism can develop after other types of lobectomy. We present a case of a 68-year-old man with cerebral embolism after left lower lobectomy with a longer PVS than normal. There were no clinically suspected sources for the thrombus except for the PVS. This thrombus seemed to have formed in the PVS. The endovascularly removed thrombus contained scattered nuclear debris around neutrophils, suggesting a physiological response caused by tissue injury. C1 [Usui, Genki; Takayama, Yohei; Katano, Takehiro; Okubo, Seiji] NTT Med Ctr Tokyo, Dept Cerebrovasc Med, Tokyo, Japan. [Usui, Genki; Hashimoto, Hirotsugu; Miura, Tamaki; Horiuchi, Hajime] NTT Med Ctr Tokyo, Dept Diagnost Pathol, Tokyo, Japan. [Yanagiya, Masahiro; Matsumoto, Jun] NTT Med Ctr Tokyo, Dept Gen Thorac Surg, Tokyo, Japan. [Kusakabe, Masashi] NTT Med Ctr Tokyo, Dept Radiol, Tokyo, Japan. C3 Kanto Medical Center NTT EC; Kanto Medical Center NTT EC; Kanto Medical Center NTT EC; Kanto Medical Center NTT EC RP Usui, G (corresponding author), NTT Med Ctr Tokyo, Dept Cerebrovasc Med, Tokyo, Japan.; Usui, G (corresponding author), NTT Med Ctr Tokyo, Dept Diagnost Pathol, Tokyo, Japan. EM gusui-tky@umin.ac.jp RI Usui, Genki/GXG-9452-2022; Yanagiya, Masahiro/ABF-4469-2021 OI Usui, Genki/0000-0002-6615-8674; Kusakabe, Masashi/0000-0003-1795-4778 CR Boeckh-Behrens T, 2016, CLIN NEURORADIOL, V26, P189, DOI 10.1007/s00062-014-0347-x Boeckh-Behrens T, 2016, STROKE, V47, P1864, DOI 10.1161/STROKEAHA.116.013105 Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864 Goldstraw Peter, 2007, J Thorac Oncol, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a Gual-Capllonch F, 2013, J CLIN ULTRASOUND, V41, P321, DOI 10.1002/jcu.21913 Hart RG, 2014, LANCET NEUROL, V13, P429, DOI 10.1016/S1474-4422(13)70310-7 Ikeda H, 2014, NMC CASE REP J, V2, P26 Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584 Nakano T, 2017, SURG CASE REP, V3, DOI 10.1186/s40792-017-0376-1 Nuotio I, 2014, JAMA-J AM MED ASSOC, V312, P647, DOI 10.1001/jama.2014.3824 Ohira S, 2013, ANN THORAC SURG, V96, pE135, DOI 10.1016/j.athoracsur.2013.07.028 Ohtaka K, 2014, J CARDIOTHORAC SURG, V9, DOI 10.1186/1749-8090-9-5 Ohtaka K, 2013, ANN THORAC SURG, V95, P1924, DOI 10.1016/j.athoracsur.2013.03.005 Ohtaka K, 2012, J THORAC CARDIOV SUR, V143, pE3, DOI 10.1016/j.jtcvs.2011.09.025 Pfeiler S, 2017, HAEMATOLOGICA, V102, P206, DOI 10.3324/haematol.2016.142471 Sporns PB, 2017, STROKE, V48, P2206, DOI 10.1161/STROKEAHA.117.016590 Usui G, 2018, J STROKE CEREBROVASC, V27, pE225, DOI 10.1016/j.jstrokecerebrovasdis.2018.05.019 Watson T, 2009, LANCET, V373, P155, DOI 10.1016/S0140-6736(09)60040-4 Yamamoto T, 2016, SURG TODAY, V46, P780, DOI 10.1007/s00595-015-1233-0 NR 19 TC 17 Z9 20 U1 0 U2 1 PU JAPAN SOC INTERNAL MEDICINE PI TOKYO PA 34-3 3-CHOME HONGO BUNKYO-KU, TOKYO, 113, JAPAN SN 0918-2918 EI 1349-7235 J9 INTERNAL MED JI Intern. Med. PY 2019 VL 58 IS 9 BP 1349 EP 1354 DI 10.2169/internalmedicine.1962-18 PG 6 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA HX5RJ UT WOS:000467460100025 PM 30568150 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Caso, R Watson, TJ Khaitan, PG Marshall, MB AF Caso, Raul Watson, Thomas J. Khaitan, Puja G. Marshall, M. Blair TI Outcomes of minimally invasive sleeve resection SO JOURNAL OF THORACIC DISEASE LA English DT Article DE Sleeve resection; sleeve lobectomy; bronchoplasty; video-assisted thoracoscopic surgery (VATS); robotic surgery ID ASSISTED THORACIC-SURGERY; THORACOSCOPIC LOBECTOMY; CLINICAL-EXPERIENCE; RECONSTRUCTION; PNEUMONECTOMY; BRONCHOPLASTY; MORBIDITY AB Background: Sleeve resection allows for preservation of lung parenchyma and improved long-term outcomes when compared with pneumonectomy. Little is known about minimally invasive sleeve resection, especially indications, feasibility, technical aspects, complications, and outcomes. We reviewed our institutional experience with sleeve resections via a minimally invasive approach. Methods: We performed a retrospective review of a prospectively maintained database from 01/01/2010 to 11/01/2017. Indications, operative details, pathology, postoperative complications were reviewed and longer-term follow-up was reviewed. Results: Fifteen patients were identified (5 males, 10 females). Details are presented in Table 1. Patients ranged in age from 7 to 82 years (median, 57 years). Approaches included video-assisted thoracoscopic surgery (VATS) and robotic. Airway sleeve resection was performed in all patients with an additional arterioplasty in 4, one patient having a double sleeve. Length of stay ranged from 3 to 10 days (median, 5 days). Indication for surgery included carcinoid in 5 (1 atypical), NSCLC in 6, and 4 additional pathologies. Complications occurred in 6 patients: air leak [2], pericardial effusion [1], transient brachial plexopathy [1], and atrial fibrillation [2]. There were no anastomotic complications. Median follow-up was 4.2 years. There were no anastomotic strictures. Conclusions: In experienced centers, sleeve resection via a minimally invasive approach is feasible with acceptable morbidity and mortality. Results in this small series appear comparable with the open approach. C1 [Caso, Raul; Watson, Thomas J.; Marshall, M. Blair] MedStar Georgetown Univ Hosp, Div Thorac Surg, Washington, DC 20007 USA. [Watson, Thomas J.; Khaitan, Puja G.] MedStar Washington Hosp Ctr, Div Thorac & Esophageal Surg, Washington, DC USA. C3 Georgetown University; MedStar Washington Hospital Center RP Caso, R (corresponding author), MedStar Georgetown Univ Hosp, Dept Surg, 3800 Reservoir Rd NW, Washington, DC 20007 USA. EM Raul.Caso@gunet.georgetown.edu RI Caso, Raul/CAH-3587-2022; Khaitan, Puja/AAQ-6413-2020; Caso, Raul/CAH-3587-2022 OI Caso, Raul/0000-0001-8414-093X; Khaitan, Puja/0000-0001-8654-062X; Caso, Raul/0009-0004-4089-8430 CR Agasthian T, 2013, EUR J CARDIO-THORAC, V44, P616, DOI 10.1093/ejcts/ezt166 Bendixen M, 2016, LANCET ONCOL, V17, P836, DOI 10.1016/S1470-2045(16)00173-X Bertolaccini L, 2014, J THORAC DIS, V6, P1170, DOI 10.3978/j.issn.2072-1439.2014.08.16 Burfeind WR, 2005, ANN THORAC SURG, V80, P418, DOI 10.1016/j.athoracsur.2005.02.058 Gonzalez-Rivas D, 2014, ANN CARDIOTHORAC SUR, V3, pE2, DOI 10.3978/j.issn.2225-319X.2014.03.13 Gonzalez-Rivas D, 2013, J THORAC CARDIOV SUR, V145, P1676, DOI 10.1016/j.jtcvs.2013.02.052 Han Y, 2013, J THORAC DIS, V5, pS301, DOI 10.3978/j.issn.2072-1439.2013.07.16 He JX, 2016, J THORAC DIS, V8, P198, DOI 10.3978/j.issn.2072-1439.2016.01.45 Huang J, 2015, J THORAC DIS, V7, P834, DOI 10.3978/j.issn.2072-1439.2015.04.55 Kaseda S, 2000, ANN THORAC SURG, V70, P1644, DOI 10.1016/S0003-4975(00)01909-3 Li Y, 2013, EUR J CARDIO-THORAC, V44, P1108, DOI 10.1093/ejcts/ezt199 Liu LX, 2014, EUR J CARDIO-THORAC, V46, P493, DOI 10.1093/ejcts/ezu103 Ma ZY, 2007, EUR J CARDIO-THORAC, V32, P20, DOI 10.1016/j.ejcts.2007.03.018 Mahtabifard A, 2008, ANN THORAC SURG, V85, pS729, DOI 10.1016/j.athoracsur.2007.12.001 Maurizi G, 2013, J THORAC ONCOL, V8, P637, DOI 10.1097/JTO.0b013e318286d145 McKenna RJ, 2006, ANN THORAC SURG, V81, P421, DOI 10.1016/j.athoracsur.2005.07.078 Mitchell JD, 1999, J THORAC CARDIOV SUR, V117, P39, DOI 10.1016/S0022-5223(99)70468-X Nakagawa T, 2015, GEN THORAC CARDIOVAS, V63, P640, DOI 10.1007/s11748-014-0517-4 Nakanishi Ryoichi, 2008, Interact Cardiovasc Thorac Surg, V7, P996, DOI 10.1510/icvts.2008.184564 Rendina EA, 2000, SEMIN SURG ONCOL, V18, P165, DOI 10.1002/(SICI)1098-2388(200003)18:2<165::AID-SSU10>3.3.CO;2-D Stallard J, 2010, INTERACT CARDIOV TH, V11, P660, DOI 10.1510/icvts.2010.245506 Storelli E, 2012, EUR J CARDIO-THORAC, V42, P77, DOI 10.1093/ejcts/ezr291 Swanson SJ, 2007, J CLIN ONCOL, V25, P4993, DOI 10.1200/JCO.2007.12.6649 Villamizar NR, 2009, J THORAC CARDIOV SUR, V138, P419, DOI 10.1016/j.jtcvs.2009.04.026 Yu DP, 2013, ASIAN PAC J CANCER P, V14, P6061, DOI 10.7314/APJCP.2013.14.10.6061 Zhou SJ, 2015, J CARDIOTHORAC SURG, V10, DOI 10.1186/s13019-015-0318-6 NR 26 TC 30 Z9 30 U1 0 U2 0 PU AME PUBLISHING COMPANY PI SHATIN PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA SN 2072-1439 EI 2077-6624 J9 J THORAC DIS JI J. Thorac. Dis. PD DEC PY 2018 VL 10 IS 12 BP 6653 EP 6659 DI 10.21037/jtd.2018.10.97 PG 7 WC Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System GA HJ0FY UT WOS:000456834700069 PM 30746210 OA hybrid DA 2026-04-17 ER PT J AU Ellenberger, C Garofano, N Reynaud, T Triponez, F Diaper, J Bridevaux, PO Karenovics, W Licker, M AF Ellenberger, Christoph Garofano, Najia Reynaud, Thomas Triponez, Frederic Diaper, John Bridevaux, Pierre-Olivier Karenovics, Wolfram Licker, Marc TI Patient and procedural features predicting early and mid-term outcome after radical surgery for non-small cell lung cancer SO JOURNAL OF THORACIC DISEASE LA English DT Article DE Postoperative pulmonary complications; lung cancer surgery; postoperative cardiovascular complications; mid-term survival ID LONG-TERM IMPACT; POSTOPERATIVE COMPLICATIONS; RESPIRATORY COMPLICATIONS; NATRIURETIC PEPTIDE; ATRIAL-FIBRILLATION; MORTALITY; RISK; MORBIDITY; SOCIETY; DISEASE AB Background: Postoperative cardiovascular and pulmonary complications (PCVCs and PPCs) are frequent and result in prolonged hospital stay. The aim of this study was to update the risk factors associated with major complications and survival after lung cancer surgery. Methods: This is a post-hoc analysis of a randomized controlled trial that was designed to assess the benefits of preoperative physical training. After enrollment, clinical, biological and functional data as well as intraoperative details were collected. In-hospital PCVCs and PPCs were recorded and survival data were adjudicated up to 4 years after surgery. Results: Data from 151 patients were analyzed. Thirty-day mortality rate was 2.6% and the incidence of PCVCs and PPCs was 15% and 33%, respectively. Stepwise logistic regression analysis showed that, PCVCs were mainly related to elevated plasma levels of brain natriuretic peptides [odds ratios (ORs) =6.0; 95% confidence interval (CI), 1.3-27.3] and performance of a pneumonectomy (OR =9.6; 95% CI, 2.9-31.5) whereas PPCs were associated with the presence of COPD (OR =5.9; 95% CI, 2.4-14.8), current smoking (OR =2.6; 95% CI, 1.1-6.5) and the need for blood transfusion (OR =5.2; 95% CI, 1.2-23.3). Preoperative physical training was a protective factor regarding PPCs (OR =0.13; 95% CI, 0.05-0.34). Cox proportional hazards regression analysis showed that ventilatory inefficiency during exercise (expressed by a ratio >40 of ventilation to carbon dioxide elimination), coronary artery disease, elevated plasma levels of brain natriuretic peptides and the occurrence of PPCs were all predictive of poor survival after surgery. Conclusions: Besides smoking and the extent of lung resection, preexisting cardiopulmonary disease as evidence by elevated levels of brain natriuretic peptides and inefficient ventilation are associated with poor clinical outcome after lung cancer surgery. C1 [Ellenberger, Christoph; Garofano, Najia; Reynaud, Thomas; Diaper, John; Licker, Marc] Univ Hosp Geneva, Dept Anesthesiol Pharmacol & Intens Care, CH-1205 Geneva, Switzerland. [Triponez, Frederic; Karenovics, Wolfram] Univ Hosp Geneva, Div Thorac Surg, Geneva, Switzerland. [Bridevaux, Pierre-Olivier] Hop Valais, Div Chest Med, Sion, Switzerland. C3 University of Geneva; University of Geneva RP Licker, M (corresponding author), Univ Hosp Geneva, Dept Anesthesiol Pharmacol & Intens Care, CH-1205 Geneva, Switzerland.; Licker, M (corresponding author), Univ Geneva, Fac Med, CH-1205 Geneva, Switzerland. EM Marc-Joseph.Licker@hcuge.ch RI licker, marc/HRA-4466-2023; Bridevaux, Pierre-Olivier/AAN-8046-2021; Triponez, Frederic/A-6237-2013 OI licker, marc/0000-0002-3691-4440; Bridevaux, Pierre-Olivier/0000-0002-8021-0950; Daniels, John daniels/0009-0008-9463-8852; Ellenberger, Christoph/0000-0002-6076-303X FU APSI Funds of the University Hospital of Geneva FX This study was supported by the APSI Funds of the University Hospital of Geneva. CR Bard RL, 2006, J HEART LUNG TRANSPL, V25, P589, DOI 10.1016/j.healun.2005.11.448 Brat K, 2016, ANN THORAC SURG, V102, P1725, DOI 10.1016/j.athoracsur.2016.05.070 Brunelli A, 2016, J THORAC DIS, V8, pS840, DOI 10.21037/jtd.2016.03.73 Brunelli A, 2016, EUR J CARDIO-THORAC, V50, P780, DOI 10.1093/ejcts/ezw127 Brunelli A, 2012, ANN THORAC SURG, V93, P1802, DOI 10.1016/j.athoracsur.2012.03.022 Brunelli A, 2009, EUR J CARDIO-THORAC, V36, P181, DOI 10.1016/j.ejcts.2009.04.022 Brunelli A, 2009, CHEST, V135, P1260, DOI 10.1378/chest.08-2059 Cao BC, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j2765 Chen WJ, 2015, LANCET RESP MED, V3, P631, DOI 10.1016/S2213-2600(15)00241-6 Kodama S, 2009, JAMA-J AM MED ASSOC, V301, P2024, DOI 10.1001/jama.2009.681 Licker M, 2011, EUR RESPIR J, V37, P1189, DOI 10.1183/09031936.00069910 Licker M, 1999, EUR J CARDIO-THORAC, V15, P314, DOI 10.1016/S1010-7940(99)00006-8 Licker M, 2017, J THORAC ONCOL, V12, P323, DOI 10.1016/j.jtho.2016.09.125 Licker M, 2009, CRIT CARE, V13, DOI 10.1186/cc7762 Lugg ST, 2016, THORAX, V71, P171, DOI 10.1136/thoraxjnl-2015-207697 Menges P, 2012, EUR SURG RES, V48, P180, DOI 10.1159/000338196 Musallam KM, 2013, JAMA SURG, V148, P755, DOI 10.1001/jamasurg.2013.2360 Nojiri T, 2017, ANN SURG ONCOL, V24, P1135, DOI 10.1245/s10434-016-5655-8 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Payne CJ, 2011, BRIT J ANAESTH, V107, P144, DOI 10.1093/bja/aer119 Richardson K, 2017, BRIT J ANAESTH, V119, pI34, DOI 10.1093/bja/aex393 Rogers LJ, 2018, J THORAC CARDIOV SUR, V155, P1843, DOI 10.1016/j.jtcvs.2017.10.151 Rohde JM, 2014, JAMA-J AM MED ASSOC, V311, P1317, DOI 10.1001/jama.2014.2726 Roth GA, 2015, CIRCULATION, V132, P1667, DOI 10.1161/CIRCULATIONAHA.114.008720 Seely AJE, 2010, ANN THORAC SURG, V90, P936, DOI 10.1016/j.athoracsur.2010.05.014 Shafiek H, 2016, EUR J CARDIO-THORAC, V50, P772, DOI 10.1093/ejcts/ezw104 Thomas DC, 2017, ANN THORAC SURG, V104, P389, DOI 10.1016/j.athoracsur.2017.02.006 Torchio R, 2010, EUR J CARDIO-THORAC, V38, P14, DOI 10.1016/j.ejcts.2010.01.032 Toufektzian L, 2015, INTERACT CARDIOV TH, V20, P654, DOI 10.1093/icvts/ivu454 van Kaam AH, 2004, AM J RESP CRIT CARE, V169, P1046, DOI 10.1164/rccm.200312-1779OC Wang SD, 2017, J THORAC DIS, V9, P5143, DOI 10.21037/jtd.2017.10.144 Weatherald J, 2018, EUR RESP J, V51 NR 32 TC 18 Z9 19 U1 0 U2 8 PU AME PUBLISHING COMPANY PI SHATIN PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA SN 2072-1439 EI 2077-6624 J9 J THORAC DIS JI J. Thorac. Dis. PD NOV PY 2018 VL 10 IS 11 BP 6020 EP 6029 DI 10.21037/jtd.2018.10.36 PG 10 WC Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System GA HC0GL UT WOS:000451475300018 PM 30622773 OA hybrid DA 2026-04-17 ER PT J AU Gil, HI Choe, J Jeong, BH Um, SW Jeon, K Hahn, JY Kim, H Kwon, OJ Chang, YS Lee, K AF Gil, Hyun-Il Choe, Junsu Jeong, Byeong-Ho Um, Sang-Won Jeon, Kyeongman Hahn, Joo-Yong Kim, Hojoong Kwon, O. Jung Chang, Yoon Soo Lee, Kyungjong TI Safety of endobronchial ultrasound-guided transbronchial needle aspiration in patients with lung cancer within a year after percutaneous coronary intervention SO THORACIC CANCER LA English DT Article DE Bronchoscopy; endoscopic ultrasound-guided fine needle aspiration; lung neoplasm; neoplasm staging; percutaneous coronary intervention ID BRONCHOSCOPY; BIOPSY AB Background Methods Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) may be necessary for patients with incidental lung cancer during or after coronary intervention. Although EBUS-TBNA is quite safe, the safety in patients who recently received percutaneous coronary intervention (PCI) has not been demonstrated. The aim of this study was to assess the safety of EBUS-TBNA in patients with lung cancer who underwent PCI within one year. We retrospectively reviewed the medical records of 24 patients who underwent EBUS-TBNA within one year after PCI between May 2009 and June 2017. Cardiovascular complications (death, myocardial infarction, arrhythmia, and acute heart failure) were assessed as primary outcomes. Procedural-related complications were assessed as secondary outcomes. Results Conclusion The coronary artery diseases requiring PCI were: myocardial infarction (n = 10), unstable angina (n = 10), stable angina (n = 2), and silent ischemia (n = 2). The median interval between PCI and EBUS-TBNA was 125 days (interquartile range: 66-180). Atrial fibrillation with a rapid ventricular response temporarily occurred in one patient after EBUS-TBNA. No other significant cardiovascular complications were encountered. Fifteen patients were administered an anti-thrombotic agent the day of EBUS-TBNA, while four had ceased taking the agent < 4 days before EBUS-TBNA, however, there was no significant bleeding among those patients. EBUS-TBNA was safe and did not cause serious adverse events in patients with lung cancer who required tissue confirmation or mediastinal staging within one year after PCI. Incidental lung cancer found during or after a coronary intervention should be actively evaluated by EBUS-TBNA. C1 [Gil, Hyun-Il; Choe, Junsu; Jeong, Byeong-Ho; Um, Sang-Won; Jeon, Kyeongman; Kim, Hojoong; Kwon, O. Jung; Lee, Kyungjong] Sungkyunkwan Univ, Samsung Med Ctr, Div Pulm & Crit Care Med, Dept Med,Sch Med, 81 Irwon Ro, Seoul 06351, South Korea. [Hahn, Joo-Yong] Sungkyunkwan Univ, Samsung Med Ctr, Heart Vasc Stroke Inst, Dept Internal Med,Div Cardiol,Sch Med, Seoul, South Korea. [Chang, Yoon Soo] Yonsei Univ, Grad Sch, Dept Med, Seoul, South Korea. C3 Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Yonsei University RP Lee, K (corresponding author), Sungkyunkwan Univ, Samsung Med Ctr, Div Pulm & Crit Care Med, Dept Med,Sch Med, 81 Irwon Ro, Seoul 06351, South Korea. EM kj2011.lee@samsung.com RI Um, Sang-Won/F-4610-2014; Jeon, Kyeongman/F-5963-2019; choe, junsu/HOH-6600-2023; Hahn, Joo-Yong/AAU-7250-2020 OI Um, Sang-Won/0000-0002-9765-9068; Jeon, Kyeongman/0000-0002-4822-1772; Lee, Kyungjong/0000-0002-1642-8111; Chang, Yoon Soo/0000-0003-3340-4223; CR Adams K, 2009, THORAX, V64, P757, DOI 10.1136/thx.2008.109868 Asano F, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-50 Attaran D, 2008, Acta Med Iran, V46, P95 Bittl JA, 2016, CIRCULATION, V134, pE156, DOI 10.1161/CIR.0000000000000405 Choi YR, 2013, KOREAN J INTERN MED, V28, P660, DOI 10.3904/kjim.2013.28.6.660 Dhooria S, 2015, RESP CARE, V60, P1040, DOI 10.4187/respcare.03779 Du Rand IA, 2013, THORAX, V68, P1, DOI 10.1136/thoraxjnl-2013-203618 Dweik RA, 1996, CHEST, V110, P825, DOI 10.1378/chest.110.3.825 Ernst A, 2003, CHEST, V123, P1693, DOI 10.1378/chest.123.5.1693 Ernst A, 2006, CHEST, V129, P734, DOI 10.1378/chest.129.3.734 Gaga M, 2013, AM J RESP CRIT CARE, V188, P503, DOI 10.1164/rccm.201307-1269ST Grosu HB, 2015, CHEST, V147, P1621, DOI 10.1378/chest.14-1704 Jones AM, 2001, CHEST, V119, P1906, DOI 10.1378/chest.119.6.1906 KOZAK EA, 1994, CHEST, V106, P703, DOI 10.1378/chest.106.3.703 Levine GN, 2016, J AM COLL CARDIOL, V68, P1082, DOI [10.1016/j.jacc.2016.07.715, 10.1016/j.jacc.2016.03.513] Sharif-Kashani Babak, 2010, Acta Med Iran, V48, P385 Stather DR, 2012, RESPIRATION, V83, P330, DOI 10.1159/000335254 Um SW, 2015, J THORAC ONCOL, V10, P331, DOI 10.1097/JTO.0000000000000388 Um SW, 2004, CHEST, V125, P945, DOI 10.1378/chest.125.3.945 Varela-Lema L, 2009, EUR RESPIR J, V33, P1156, DOI 10.1183/09031936.00097908 NR 20 TC 4 Z9 5 U1 0 U2 4 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1759-7706 EI 1759-7714 J9 THORAC CANCER JI Thorac. Cancer PD NOV PY 2018 VL 9 IS 11 BP 1390 EP 1397 DI 10.1111/1759-7714.12846 PG 8 WC Oncology; Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Respiratory System GA HA1PO UT WOS:000449991200007 PM 30156380 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Yang, XY Li, XY Yuan, MC Tian, C Yang, YH Wang, XF Zhang, XY Sun, Y He, TM Han, SJ Chen, G Liu, N Gao, YH Hu, D Xing, YW Shang, HC AF Yang, Xinyu Li, Xinye Yuan, Mengchen Tian, Chao Yang, Yihan Wang, Xiaofeng Zhang, Xiaoyu Sun, Yang He, Tianmai Han, Songjie Chen, Guang Liu, Nian Gao, Yonghong Hu, Dan Xing, Yanwei Shang, Hongcai TI Anticancer Therapy-Induced Atrial Fibrillation: Electrophysiology and Related Mechanisms SO FRONTIERS IN PHARMACOLOGY LA English DT Review DE anticancer therapies; cardiotoxicity; adverse effects; atrial fibrillation; mechanisms ID TUMOR-NECROSIS-FACTOR; MIGRATION INHIBITORY FACTOR; C-REACTIVE PROTEIN; HISTONE DEACETYLASE INHIBITOR; CELL LUNG-CANCER; INTRAOPERATIVE HYPERTHERMIC CISPLATIN; CHROMOBACTERIUM-VIOLACEUM NO-968; CHRONIC LYMPHOCYTIC-LEUKEMIA; MULTIPLE-MYELOMA PATIENTS; DEEP-VEIN THROMBOSIS AB Some well-established immunotherapy, radiotherapy, postoperation, anticancer drugs such as anthracyclines, antimetabolites, human epidermal growth factor receptor 2 blockers, tyrosine kinase inhibitors, alkylating agents, checkpoint inhibitors, and angiogenesis inhibitors, are significantly linked to cardiotoxicity. Cardiotoxicity is a common complication of several cancer treatments. Some studies observed complications of cardiac arrhythmia associated with the treatment of cancer, including atrial fibrillation (AF), supraventricular arrhythmias, and cardiac repolarization abnormalities. AF increases the risk of cardiovascular morbidity and mortality; it is associated with an almost doubled risk of mortality and a nearly 5-fold increase in the risk of stroke. The occurrence of AF is also usually researched in patients with advanced cancer and those undergoing active cancer treatments. During cancer treatments, the incidence rate of AF affects the prognosis of tumor treatment and challenges the treatment strategy. The present article is mainly focused on the cardiotoxicity of cancer treatments. In our review, we discuss these anticancer therapies and how they induce AF and consequently provide information on the precaution of AF during cancer treatment. C1 [Yang, Xinyu; Li, Xinye; Yang, Yihan; Chen, Guang; Xing, Yanwei] Chinese Acad Chinese Med Sci, Guangan Men Hosp, Beijing, Peoples R China. [Yang, Xinyu; Yuan, Mengchen; Tian, Chao; Yang, Yihan; Wang, Xiaofeng; Zhang, Xiaoyu; Sun, Yang; He, Tianmai; Han, Songjie; Gao, Yonghong; Shang, Hongcai] Beijing Univ Chinese Med, Dongzhimen Hosp, Minist Educ, Key Lab Chinese Internal Med, Beijing, Peoples R China. [Li, Xinye] Beijing Univ Chinese Med, Beijing, Peoples R China. [Liu, Nian] Capital Univ Med Sci, Beijing An Zhen Hosp, Dept Cardiol, Beijing, Peoples R China. [Hu, Dan] Wuhan Univ, Renmin Hosp, Dept Cardiol, Wuhan, Hubei, Peoples R China. [Hu, Dan] Wuhan Univ, Renmin Hosp, Cardiovasc Res Inst, Wuhan, Hubei, Peoples R China. [Hu, Dan] Hubei Key Lab Cardiol, Wuhan, Hubei, Peoples R China. [Shang, Hongcai] Guangzhou Med Univ, Inst Integrat Tradit & Western Med, Guangzhou, Guangdong, Peoples R China. C3 Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Wuhan University; Wuhan University; Guangzhou Medical University RP Xing, YW (corresponding author), Chinese Acad Chinese Med Sci, Guangan Men Hosp, Beijing, Peoples R China.; Shang, HC (corresponding author), Beijing Univ Chinese Med, Dongzhimen Hosp, Minist Educ, Key Lab Chinese Internal Med, Beijing, Peoples R China.; Shang, HC (corresponding author), Guangzhou Med Univ, Inst Integrat Tradit & Western Med, Guangzhou, Guangdong, Peoples R China. EM xingyanwei12345@163.com; shanghongcai@126.com RI ; 李, 昕晔/K-7829-2018; li, xinye/K-7829-2018; Zhang, xiaoyu/GXA-3206-2022; shang, hongcai/H-1257-2014 OI Hu, Dan/0000-0002-0994-8434; 李, 昕晔/0000-0001-8131-4981; Yuan, Meng chen/0000-0003-2896-0751; Yang, Xinyu/0009-0004-1441-1553; FU National Key Research and Development Program of China [2017YFC1700400]; National Natural Science Foundation of China [81725024, 81870244, 81430098]; National high-level talent special support plan [W02020052]; Clinical base project of State Administration of traditional Chinese medicine of China [JDZX2015007]; Beijing University of Chinese Medicine [2015-JYBXJQ001] FX The work was supported by the National Key Research and Development Program of China (Grant No. 2017YFC1700400), the National Natural Science Foundation of China (Grant Nos. 81725024, 81870244, and 81430098) and National high-level talent special support plan (No. W02020052), Clinical base project of State Administration of traditional Chinese medicine of China (JDZX2015007), and the outstanding project of Beijing University of Chinese Medicine (2015-JYBXJQ001). CR Abidi MH, 2012, BIOL BLOOD MARROW TR, V18, P1455, DOI 10.1016/j.bbmt.2012.03.010 Albini A, 2010, JNCI-J NATL CANCER I, V102, P14, DOI 10.1093/jnci/djp440 Alifano M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106914 Alloatti G, 1998, J PHARMACOL EXP THER, V284, P561 Amar D, 1996, ANN THORAC SURG, V61, P1506, DOI 10.1016/0003-4975(96)00111-7 Anderson JL, 2013, J AM COLL CARDIOL, V61, P1935, DOI 10.1016/j.jacc.2013.02.001 [Anonymous], 2015, WORLD NOTES ANTIBIOT, DOI DOI 10.13461/J.CNKI.WNA.004903 [Anonymous], CHIN J CANC PREVENT [Anonymous], J CELL SCI R Anselmi A, 2009, ANN THORAC SURG, V88, P326, DOI 10.1016/j.athoracsur.2009.01.031 Arai M, 1998, J MOL CELL CARDIOL, V30, P243, DOI 10.1006/jmcc.1997.0588 Arai Y, 2005, AM J HEMATOL, V78, P317, DOI 10.1002/ajh.20303 Arbuck S G, 1993, J Natl Cancer Inst Monogr, P117 Aviles RJ, 2003, CIRCULATION, V108, P3006, DOI 10.1161/01.CIR.0000103131.70301.4F Aziz S A, 1998, Clin Oncol (R Coll Radiol), V10, P377, DOI 10.1016/S0936-6555(98)80033-2 Balkwill F, 2002, CYTOKINE GROWTH F R, V13, P135, DOI 10.1016/S1359-6101(01)00020-X Balkwill F, 2006, CANCER METAST REV, V25, P409, DOI 10.1007/s10555-006-9005-3 Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628 Beck MA, 1999, P NUTR SOC, V58, P707, DOI 10.1017/S0029665199000920 BERLINER S, 1990, CANCER INVEST, V8, P583, DOI 10.3109/07357909009018924 Bracci L, 2014, CELL DEATH DIFFER, V21, P15, DOI 10.1038/cdd.2013.67 BROUTYBOYE D, 1995, INT J CANCER, V60, P571, DOI 10.1002/ijc.2910600424 Bruins P, 1997, CIRCULATION, V96, P3542 Bryan-Brown T., 1932, Q. J. Pharm. Pharmacol, V5, P205 Burger JA, 2015, NEW ENGL J MED, V373, P2425, DOI 10.1056/NEJMoa1509388 Byrd JC, 2014, NEW ENGL J MED, V371, P213, DOI 10.1056/NEJMoa1400376 Byrd JC, 2015, BLOOD, V125, P2497, DOI 10.1182/blood-2014-10-606038 Camm AJ, 2012, EUR HEART J, V33, P2719, DOI 10.1093/eurheartj/ehs253 Camm AJ, 2010, EUROPACE, V12, P1360, DOI [10.1093/eurheartj/ehq278, 10.1093/europace/euq350] Carver JR, 2007, J CLIN ONCOL, V25, P3991, DOI 10.1200/JCO.2007.10.9777 Chelu MG, 2009, J CLIN INVEST, V119, P1940, DOI 10.1172/JCI37059 Choudhary S, 2013, CARCINOGENESIS, V34, P2891, DOI 10.1093/carcin/bgt239 Chu TF, 2007, LANCET, V370, P2011, DOI 10.1016/S0140-6736(07)61865-0 Chung MK, 2001, CIRCULATION, V104, P2886, DOI 10.1161/hc4901.101760 Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795 Conway DSG, 2004, AM HEART J, V148, P462, DOI 10.1016/j.ahj.2004.01.026 Craig SR, 2001, EUR J CARDIO-THORAC, V20, P455, DOI 10.1016/S1010-7940(01)00841-7 Curigliano G, 2010, PROG CARDIOVASC DIS, V53, P94, DOI 10.1016/j.pcad.2010.05.006 DEFORNI M, 1992, J CLIN ONCOL, V10, P1795, DOI 10.1200/JCO.1992.10.11.1795 Dobrev D, 2011, CARDIOVASC RES, V89, P734, DOI 10.1093/cvr/cvq324 Doherty KR, 2013, TOXICOL APPL PHARM, V272, P245, DOI 10.1016/j.taap.2013.04.027 DORR FA, 1986, CANCER RES, V46, P2562 Duran JM, 2014, CIRC RES, V114, P1700, DOI 10.1161/CIRCRESAHA.114.303200 ElZarrad MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079543 Erichsen R, 2012, INTERN EMERG MED, V7, P431, DOI 10.1007/s11739-011-0701-9 ESKILSSON J, 1988, RADIOTHER ONCOL, V13, P41, DOI 10.1016/0167-8140(88)90296-4 Farmakis D, 2014, J AM COLL CARDIOL, V63, P945, DOI 10.1016/j.jacc.2013.11.026 Feliz V, 2011, CLIN CARDIOL, V34, P356, DOI 10.1002/clc.20904 Ferrari R, 2016, INT J CARDIOL, V203, P22, DOI 10.1016/j.ijcard.2015.10.089 Ferreira C, 2015, ARQ BRAS CARDIOL, V105, P519, DOI 10.5935/abc.20150142 Fildes JE, 2009, J AM COLL CARDIOL, V53, P1013, DOI 10.1016/j.jacc.2008.11.046 Floyd JD, 2005, J CLIN ONCOL, V23, P7685, DOI 10.1200/JCO.2005.08.789 Frickhofen N, 2002, ANN ONCOL, V13, P797, DOI 10.1093/annonc/mdf035 Fuster V, 2011, CIRCULATION, V123, pE269, DOI 10.1161/CIR.0b013e318214876d Gaudino M, 2003, CIRCULATION, V108, P195, DOI 10.1161/01.cir.0000087441.48566.0d Gen W, 2001, BASIC RES CARDIOL, V96, P623, DOI 10.1007/s003950170014 Gertz MA, 2017, AM J HEMATOL, V92, P209, DOI 10.1002/ajh.24557 Gómez-Caro A, 2006, ARCH BRONCONEUMOL, V42, P9, DOI 10.1016/S1579-2129(06)60107-9 Gorelik J, 2003, FEBS LETT, V548, P74, DOI 10.1016/S0014-5793(03)00743-9 Gridelli C, 2001, LUNG CANCER-J IASLC, V31, P277, DOI 10.1016/S0169-5002(00)00194-X Guglin M, 2009, EUROPACE, V11, P1579, DOI 10.1093/europace/eup300 Guo YQ, 2012, CANCER TREAT REV, V38, P904, DOI 10.1016/j.ctrv.2012.04.007 Guo YT, 2015, CHEST, V147, P109, DOI 10.1378/chest.14-0321 Guo YT, 2012, J AM COLL CARDIOL, V60, P2263, DOI 10.1016/j.jacc.2012.04.063 Gupta Anoop K, 2002, Card Electrophysiol Rev, V6, P120, DOI 10.1023/A:1017963928016 Guzzetti S, 2002, CIRCULATION, V106, pE40, DOI 10.1161/01.CIR.0000028399.42411.13 Haudek SB, 2007, J CLIN INVEST, V117, P2692, DOI 10.1172/JCI29134 Heerdt PM, 2012, J MOL CELL CARDIOL, V53, P350, DOI 10.1016/j.yjmcc.2012.05.010 Herman SEM, 2011, BLOOD, V117, P6287, DOI 10.1182/blood-2011-01-328484 Hersey P, 2010, CANCER-AM CANCER SOC, V116, P1526, DOI 10.1002/cncr.24821 Honigberg LA, 2010, P NATL ACAD SCI USA, V107, P13075, DOI 10.1073/pnas.1004594107 Hooning MJ, 2007, JNCI-J NATL CANCER I, V99, P365, DOI 10.1093/jnci/djk064 Hove-Madsen L, 2004, CIRCULATION, V110, P1358, DOI 10.1161/01.CIR.0000141296.59876.87 Hrovatin E, 2006, J CARDIOVASC MED, V7, P637, DOI 10.2459/01.JCM.0000237914.12915.dd Hu YF, 2013, INT J CARDIOL, V165, P355, DOI 10.1016/j.ijcard.2012.08.036 Ifran A, 2005, AM J HEMATOL, V80, P247, DOI 10.1002/ajh.20441 Illiano A, 2000, ANTICANCER RES, V20, P3999 Ioannou K, 2014, INT J ONCOL, V45, P1457, DOI 10.3892/ijo.2014.2551 Issac TT, 2007, J AM COLL CARDIOL, V50, P2021, DOI 10.1016/j.jacc.2007.06.054 Iwasaki YK, 2011, CIRCULATION, V124, P2264, DOI 10.1161/CIRCULATIONAHA.111.019893 Jaworski C, 2013, J AM COLL CARDIOL, V61, P2319, DOI 10.1016/j.jacc.2013.01.090 Jones AL, 2009, BRIT J CANCER, V100, P684, DOI 10.1038/sj.bjc.6604909 Karayiannakis AJ, 2001, ANTICANCER RES, V21, P1355 Kawabata M, 2015, TOXICOL SCI, V143, P374, DOI 10.1093/toxsci/kfu235 KEEFE DL, 1993, J CLIN PHARMACOL, V33, P1060, DOI 10.1002/j.1552-4604.1993.tb01943.x Keefe DL, 2001, SEMIN ONCOL, V28, P2, DOI 10.1053/sonc.2001.26431 Khan MA, 2013, WORLD J CARDIOL, V5, P215, DOI 10.4330/wjc.v5.i7.215 Kilickap S, 2007, SOUTH MED J, V100, P262, DOI 10.1097/01.smj.0000257382.89910.fe Kindt N, 2013, INT J ONCOL, V43, P185, DOI 10.3892/ijo.2013.1944 Klein U, 2009, ANN HEMATOL, V88, P67, DOI 10.1007/s00277-008-0561-1 Kluza J, 2004, ONCOGENE, V23, P7018, DOI 10.1038/sj.onc.1207936 Kumar SK, 2008, BLOOD, V111, P2516, DOI 10.1182/blood-2007-10-116129 KUPARI M, 1990, BONE MARROW TRANSPL, V5, P91 Lai HC, 2011, TOXICOL APPL PHARM, V257, P437, DOI 10.1016/j.taap.2011.10.001 Lara PN, 2005, CLIN CANCER RES, V11, P4444, DOI 10.1158/1078-0432.CCR-04-2602 Lau DH, 2011, J CARDIOVASC ELECTR, V22, P175, DOI 10.1111/j.1540-8167.2010.01851.x Lebedinsky C, 2011, CANCER CHEMOTH PHARM, V68, P1223, DOI 10.1007/s00280-011-1614-z Lee AYY, 2005, DM-DIS MON, V51, P150, DOI 10.1016/j.disamonth.2005.03.010 Lee JY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13354 Lee SH, 2007, LIFE SCI, V80, P1806, DOI 10.1016/j.lfs.2007.02.029 Lenihan DJ, 2004, BLOOD, V104, P655, DOI 10.1182/blood-2003-07-2345 Leong DP, 2016, BLOOD, V128, P138, DOI 10.1182/blood-2016-05-712828 Liu YN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127813 Ma H, 2010, CLIN EXP PHARMACOL P, V37, P460, DOI 10.1111/j.1440-1681.2009.05323.x Ma JY, 2006, WORLD J GASTROENTERO, V12, P449, DOI 10.3748/wjg.v12.i3.449 Madrid AH, 2006, REV ESP CARDIOL, V59, P94 Mawhinney L, 2014, MOL MED, V20, P729, DOI 10.2119/molmed.2014.00136 Mc Cormack O, 2014, ANN SURG, V260, P772, DOI 10.1097/SLA.0000000000000960 McMullen JR, 2014, BLOOD, V124, P3829, DOI 10.1182/blood-2014-10-604272 Mego M, 2007, ANN ONCOL, V18, P1906, DOI 10.1093/annonc/mdm489 MENARD O, 1991, J CLIN ONCOL, V9, P192, DOI 10.1200/JCO.1991.9.1.192 Mery B, 2017, INT J CARDIOL, V240, P196, DOI 10.1016/j.ijcard.2017.03.132 Meydan N, 2005, JPN J CLIN ONCOL, V35, P265, DOI 10.1093/jjco/hyi071 Montella L, 2005, ANN HEMATOL, V84, P192, DOI 10.1007/s00277-004-0867-6 Moreau P, 1999, BONE MARROW TRANSPL, V23, P1003, DOI 10.1038/sj.bmt.1701763 Moslehi JJ, 2016, NEW ENGL J MED, V375, P1457, DOI 10.1056/NEJMra1100265 Nattel S, 2002, NATURE, V415, P219, DOI 10.1038/415219a Nattel S, 2008, CIRC-ARRHYTHMIA ELEC, V1, P62, DOI 10.1161/CIRCEP.107.754564 Neben K, 2002, CLIN CANCER RES, V8, P3377 Neef S, 2010, CIRC RES, V106, P1134, DOI 10.1161/CIRCRESAHA.109.203836 Numico G, 2002, LUNG CANCER, V35, P59, DOI 10.1016/S0169-5002(01)00269-0 O'Neal WT, 2015, AM J CARDIOL, V115, P1090, DOI 10.1016/j.amjcard.2015.01.540 O'Reilly C, 2016, MED RES REV, V36, P440, DOI 10.1002/med.21385 Ojima T, 2014, SURG TODAY, V44, P839, DOI 10.1007/s00595-013-0616-3 Olivieri A, 1998, BONE MARROW TRANSPL, V21, P1049, DOI 10.1038/sj.bmt.1701217 Ott A, 1997, STROKE, V28, P316, DOI 10.1161/01.STR.28.2.316 Ozaki M, 2000, FASEB J, V14, P418, DOI 10.1096/fasebj.14.2.418 Palumbo A, 2008, LEUKEMIA, V22, P414, DOI 10.1038/sj.leu.2405062 Perez Persona Ernesto, 2011, Adv Ther, V28 Suppl 1, P11, DOI 10.1007/s12325-010-0102-x Perez-Verdia A, 2005, PHARMACOTHERAPY, V25, P1271, DOI 10.1592/phco.2005.25.9.1271 Petrella V, 1989, Minerva Med, V80, P305 Pfister DG, 2006, J CLIN ONCOL, V24, P1072, DOI 10.1200/JCO.2004.00.1792 Plumb JA, 2003, MOL CANCER THER, V2, P721 Popivanova BK, 2008, J CLIN INVEST, V118, P560, DOI [10.1172/JCI32453, 10.1172/JC132453] Pretorius L, 2009, AM J PATHOL, V175, P998, DOI 10.2353/ajpath.2009.090126 Priori SG, 2015, EUROPACE, V17, P1601, DOI 10.1093/europace/euv319 Qu YC, 2009, SCAND CARDIOVASC J, V43, P292, DOI 10.1080/14017430802651803 QUEZADO ZMN, 1993, ANN INTERN MED, V118, P31, DOI 10.7326/0003-4819-118-1-199301010-00006 Rao F, 2009, J MOL CELL CARDIOL, V47, P586, DOI 10.1016/j.yjmcc.2009.08.030 Richards WG, 2006, J CLIN ONCOL, V24, P1561, DOI 10.1200/JCO.2005.04.6813 Robertson JFR, 1996, INT J BIOL MARKER, V11, P29, DOI 10.1177/172460089601100106 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Russell RR, 2016, J NUCL CARDIOL, V23, P856, DOI 10.1007/s12350-016-0538-8 Ryder M, 2014, ENDOCR-RELAT CANCER, V21, P371, DOI 10.1530/ERC-13-0499 Sag CM, 2011, J MOL CELL CARDIOL, V51, P749, DOI 10.1016/j.yjmcc.2011.07.016 Saif MW, 2009, EXPERT OPIN DRUG SAF, V8, P191, DOI [10.1517/14740330902733961, 10.1517/14740330902733961 ] Sandor V, 2002, CLIN CANCER RES, V8, P718 Schmitt J, 2009, EUR HEART J, V30, P1038, DOI 10.1093/eurheartj/ehn579 Schwartz RG, 2013, J NUCL CARDIOL, V20, P443, DOI 10.1007/s12350-013-9707-1 Shanafelt TD, 2017, LEUKEMIA LYMPHOMA, V58, P1630, DOI 10.1080/10428194.2016.1257795 Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332 Siemes C, 2006, J CLIN ONCOL, V24, P5216, DOI 10.1200/JCO.2006.07.1381 Siu CW, 2005, PACE, V28, pS120, DOI 10.1111/j.1540-8159.2005.00024.x SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106 Stadler WM, 2006, CLIN GENITOURIN CANC, V5, P57, DOI 10.3816/CGC.2006.n.018 Steele NL, 2008, CLIN CANCER RES, V14, P804, DOI 10.1158/1078-0432.CCR-07-1786 Sudharsan PT, 2006, MOL CELL BIOCHEM, V282, P23, DOI 10.1007/s11010-006-1169-1 Szlosarek PW, 2003, LANCET ONCOL, V4, P565, DOI 10.1016/S1470-2045(03)01196-3 Tahhan AS, 2017, HEART RHYTHM, V14, P1849, DOI 10.1016/j.hrthm.2017.07.028 Tamargo J, 2015, DRUG SAFETY, V38, P129, DOI 10.1007/s40264-014-0258-4 THOMPSON JA, 1994, CANCER RES, V54, P3436 Tilleman TR, 2009, J THORAC CARDIOV SUR, V138, P405, DOI 10.1016/j.jtcvs.2009.02.046 Tomkowski WZ, 2004, SUPPORT CARE CANCER, V12, P53, DOI 10.1007/s00520-003-0533-x Treon SP, 2015, NEW ENGL J MED, V372, P1430, DOI 10.1056/NEJMoa1501548 UEDA H, 1994, J ANTIBIOT, V47, P301 UEDA H, 1994, BIOSCI BIOTECH BIOCH, V58, P1579, DOI 10.1271/bbb.58.1579 van der Vorst EPC, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00373 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Varga ZV, 2015, AM J PHYSIOL-HEART C, V309, pH1453, DOI 10.1152/ajpheart.00554.2015 Varinelli L, 2015, ENDOCR-RELAT CANCER, V22, P759, DOI 10.1530/ERC-15-0299 Veronesi U, 2007, J NATL CANCER I, V99, P727, DOI 10.1093/jnci/djk154 Vest JA, 2005, CIRCULATION, V111, P2025, DOI 10.1161/01.CIR.0000162461.67140.4C Voigt N, 2014, CIRCULATION, V129, P145, DOI 10.1161/CIRCULATIONAHA.113.006641 Voigt N, 2012, CIRCULATION, V125, P2059, DOI 10.1161/CIRCULATIONAHA.111.067306 Wang ML, 2015, BLOOD, V126, P739, DOI 10.1182/blood-2015-03-635326 Wang ZX, 2018, CHINA MED HERALD, V15, P26 Weber D, 2003, J CLIN ONCOL, V21, P16, DOI 10.1200/JCO.2003.03.139 WHITE RL, 1994, CANCER, V74, P3212, DOI 10.1002/1097-0142(19941215)74:12<3212::AID-CNCR2820741221>3.0.CO;2-I Will Y, 2008, TOXICOL SCI, V106, P153, DOI 10.1093/toxsci/kfn157 Wolchok JD, 2015, CELL, V162, P937, DOI 10.1016/j.cell.2015.07.045 WOOLLEY PV, 1982, J CLIN PHARMACOL, V22, P359, DOI 10.1002/j.1552-4604.1982.tb02686.x Xin YF, 2011, BIOL PHARM BULL, V34, P1523, DOI 10.1248/bpb.34.1523 Xing YW, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/464508 Yang T, 2015, CIRCULATION, V132 Yang XY, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00600 Yang XY, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/1569235 Yu C, 2015, ENDOCRINOL DIAB META, DOI 10.1530/EDM-14-0092 Yun S, 2017, CL LYMPH MYELOM LEUK, V17, P31, DOI 10.1016/j.clml.2016.09.010 Zangari M, 2001, BLOOD, V98, P1614, DOI 10.1182/blood.V98.5.1614 Zangari M, 2010, J CLIN ONCOL, V28, P132, DOI 10.1200/JCO.2009.23.0169 Zellos L, 2009, J THORAC CARDIOV SUR, V137, P453, DOI 10.1016/j.jtcvs.2008.07.055 Zhang HN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022874 Zhang Y, 2015, MOL MED REP, V11, P2615, DOI 10.3892/mmr.2014.3116 Zonder JA, 2006, BLOOD, V108, P403, DOI 10.1182/blood-2006-01-0154 NR 194 TC 52 Z9 60 U1 0 U2 9 PU FRONTIERS MEDIA SA PI LAUSANNE PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND EI 1663-9812 J9 FRONT PHARMACOL JI Front. Pharmacol. PD OCT 16 PY 2018 VL 9 AR 1058 DI 10.3389/fphar.2018.01058 PG 14 WC Pharmacology & Pharmacy WE Science Citation Index Expanded (SCI-EXPANDED) SC Pharmacology & Pharmacy GA GX0KU UT WOS:000447399600001 PM 30386232 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Huq, M Balvanz, TM Mambourg, S AF Huq, Mostaqul Balvanz, Tracie M. Mambourg, Scott TI Docetaxel-induced cardiac-respiratory arrest in a patient with chronic atrial fibrillation SO JOURNAL OF ONCOLOGY PHARMACY PRACTICE LA English DT Article DE Docetaxel; cardiac arrest; medication safety ID TAXOTERE(TM); PACLITAXEL AB Docetaxel has been approved by the Food and Drug Administration for the treatment of many cancer types, including breast cancer, head and neck cancer, lung cancer, and prostate cancer. Many severe to life-threatening side effects (Grades 3-5) of docetaxel have been reported in clinical trials, case reports, and Food and Drug Administration Adverse Events Reporting System. These include anaphylactic reactions, febrile neutropenia, fluid retention, acute respiratory distress, pleural effusion, pneumonia, and peripheral neuropathy. There were fewer cardiac toxicities reported for docetaxel as compared to paclitaxel, which were less severe. In this report, we present a clinical case of docetaxel-induced cardiac-respiratory arrest in a 62-year-old Hispanic male patient with stable chronic atrial fibrillation, who has been recently diagnosed with metastatic prostate cancer. The cardiac event developed within 15min of docetaxel infusion during the second cycle of chemotherapy despite using recommended premedication with corticosteroids. C1 [Huq, Mostaqul; Balvanz, Tracie M.; Mambourg, Scott] VA Sierra Nevada Hlth Care Syst, Pharm Serv, US Dept Vet Affairs, Reno, NV 89502 USA. C3 US Department of Veterans Affairs RP Huq, M (corresponding author), VA Sierra Nevada Hlth Care Syst, Res & Oncol, Pharm Serv 119,975 Kirman Ave, Reno, NV 89502 USA. EM mostaqul.huq@va.gov CR [Anonymous], DOC LEX DRUGS LEX [Anonymous], OND LEX DRUGS LEX Arbuck S G, 1993, J Natl Cancer Inst Monogr, P117 Ardavanis A, 2004, ANTI-CANCER DRUG, V15, P581, DOI 10.1097/01.cad.0000131685.06390.b7 Doherty MJ, RESP MED CME, P63, DOI DOI 10.1016/J.RMEDC.2009.01.004 Ho MY, 2014, CANCER MANAG RES, V6, P253, DOI 10.2147/CMAR.S40601 Matsuo K, 2001, Masui, V50, P1113 NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154 Raisch DW, 2011, EXPERT OPIN DRUG SAF, V10, P521, DOI 10.1517/14740338.2011.582865 SCHRIJVERS D, 1993, ANN ONCOL, V4, P610, DOI 10.1093/oxfordjournals.annonc.a058599 Tham EH, 2015, POSTGRAD MED J, V91, P145, DOI 10.1136/postgradmedj-2014-132686 VanDenBerg CM, 2000, AM J HEALTH-SYST PH, V57, P1046, DOI 10.1093/ajhp/57.11.1046 VERWEIJ J, 1994, ANN ONCOL, V5, P495, DOI 10.1093/oxfordjournals.annonc.a058903 NR 13 TC 1 Z9 2 U1 0 U2 7 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1078-1552 EI 1477-092X J9 J ONCOL PHARM PRACT JI J. Oncol. Pharm. Pract. PD OCT PY 2018 VL 24 IS 7 BP 531 EP 536 DI 10.1177/1078155217714860 PG 6 WC Oncology; Pharmacology & Pharmacy WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Pharmacology & Pharmacy GA GV0TR UT WOS:000445777100009 PM 28614979 DA 2026-04-17 ER PT J AU Lydiard, S Caillet, V Ipsen, S O'Brien, R Blanck, O Poulsen, PR Booth, J Keall, P AF Lydiard, Suzanne Caillet, Vincent Ipsen, Svenja O'Brien, Ricky Blanck, Oliver Poulsen, Per Rugaard Booth, Jeremy Keall, Paul TI Investigating multi-leaf collimator tracking in stereotactic arrhythmic radioablation (STAR) treatments for atrial fibrillation SO PHYSICS IN MEDICINE AND BIOLOGY LA English DT Article DE multi-leaf collimator (MLC) tracking; cardiac radioablation; stereotactic radiosurgery; motion compensation; atrial fibrillation ID MLC TRACKING; CARDIAC RADIOSURGERY; LUNG SABR; RADIOTHERAPY; ABLATION; MOTION; MODULATION; TARGETS AB Stereotactic arrhythmia radioablation (STAR) is an emerging treatment option for atrial fibrillation (AF). However, it faces possibly the most challenging motion compensation scenario: both respiratory and cardiac motion. Multi-leaf collimator (MLC) tracking is clinically used for lung cancer treatments but its capabilities with intracardiac targets is unknown. We report the first experimental results of MLC tracking for intracardiac targets. Five AF STAR plans of varying complexity were created. All delivered 5 x 10 Gy to both pulmonary vein antra. Three healthy human target motion trajectories were acquired with ultrasound and programmed into a motion platform. Plans were delivered with a linac to a dosimeter placed on the motion platform. For each motion trace, each plan was delivered with no MLC tracking and with MLC tracking with and without motion prediction. Dosimetric accuracy was assessed with gamma-tests and dose metrics. MLC tracking improved the dosimetric accuracy in all measurements compared to non-tracking experiments. The average 2%/ 2 mm gamma-failure rate was improved from 13.1% with no MLC tracking to 5.9% with MLC tracking (p < 0.001) and 7.2% with MLC tracking and no motion prediction (p < 0.001). MLC tracking significantly improved the consistency between planned and delivered target dose coverage. The 95% target coverage with the prescription dose (V100) was improved from 60% of deliveries with no MLC tracking to 80% of deliveries with MLC tracking (p = 0.03). MLC tracking was successfully implemented for the first time for intracardiac motion compensation. MLC tracking provided significant dosimetric accuracy improvements in AF STAR experiments, even with challenging cardiac and respiratory-induced target motion and complex treatment plans. These results warrant further investigation and optimisation of MLC tracking for intracardiac target motion compensation. C1 [Lydiard, Suzanne; Caillet, Vincent; O'Brien, Ricky; Keall, Paul] Univ Sydney, ACRE Image Inst X, Cent Clin Sch, Sydney, NSW 2006, Australia. [Lydiard, Suzanne; Keall, Paul] Ingham Inst Appl Med Res, Liverpool, NSW 2170, Australia. [Lydiard, Suzanne] Auckland Dist Hlth Board, Dept Radiat Oncol, Auckland 1023, New Zealand. [Caillet, Vincent; Booth, Jeremy] Royal North Shore Hosp, Northern Sydney Canc Ctr, Sydney, NSW, Australia. [Ipsen, Svenja] Univ Lubeck, Inst Robot & Cognit Syst, Lubeck, Germany. [Blanck, Oliver] Univ Med Ctr Schleswig Holstein, Dept Radiat Oncol, Kiel, Germany. [Poulsen, Per Rugaard] Aarhus Univ Hosp, Dept Oncol, Aarhus, Denmark. [Poulsen, Per Rugaard] Aarhus Univ Hosp, Danish Ctr Particle Therapy, Aarhus, Denmark. [Booth, Jeremy] Univ Sydney, Sch Phys, Sydney, NSW 2006, Australia. C3 University of Sydney; Ingham Institute for Applied Medical Research; Auckland District Health Board; Royal North Shore Hospital; University of Sydney; University of Lubeck; University of Kiel; Schleswig Holstein University Hospital; Aarhus University; Aarhus University; University of Sydney RP Lydiard, S (corresponding author), Univ Sydney, ACRE Image Inst X, Cent Clin Sch, Sydney, NSW 2006, Australia.; Lydiard, S (corresponding author), Ingham Inst Appl Med Res, Liverpool, NSW 2170, Australia.; Lydiard, S (corresponding author), Auckland Dist Hlth Board, Dept Radiat Oncol, Auckland 1023, New Zealand. EM slydiard@adhb.govt.nz RI ; Keall, Paul/A-6453-2018; Blanck, Oliver/KQE-0583-2024 OI Caillet, Vincent/0000-0002-9910-8454; Keall, Paul/0000-0003-4803-6507; Poulsen, Per Rugaard/0000-0001-9940-7609; Booth, Jeremy/0000-0003-4004-1109; O'Brien, Ricky/0000-0002-6586-7356; Blanck, Oliver/0000-0003-1391-1308 FU Australian Government NHMRC Program Grants [APP1036078, APP1132471]; Australian Cancer Research Foundation; NHMRC Senior Principal Research Fellowship; Scott Johnson and Varian Medical Systems FX The authors gratefully acknowledge funding from Australian Government NHMRC Program Grants APP1036078 and APP1132471 and the Australian Cancer Research Foundation. PJK is supported by an NHMRC Senior Principal Research Fellowship. The authors gratefully thank Ralf Bruder for his help with acquiring and processing the ultrasound target motion trajectories, Tobias Pommer for his contribution to the plan complexity analysis, Jung Kim for her assistance with the Hexamotion traces, and Helen Ball for her editing assistance. JB acknowledges the support of Scott Johnson and Varian Medical Systems for use of the Calypso system. CR Blanck O, 2016, CUREUS J MED SCIENCE, V8, DOI 10.7759/cureus.705 Blanck O, 2014, INT J RADIAT ONCOL, V89, P590, DOI 10.1016/j.ijrobp.2014.02.036 Bode F, 2015, EUROPACE, V17, P1868, DOI 10.1093/europace/euu406 Booth JT, 2016, RADIOTHER ONCOL, V121, P19, DOI 10.1016/j.radonc.2016.08.025 Caillet V, 2017, RADIOTHER ONCOL, V124, P18, DOI 10.1016/j.radonc.2017.06.016 Cohen RJ, 2010, DIS ESOPHAGUS, V23, P473, DOI 10.1111/j.1442-2050.2009.01037.x Colvill E, 2016, RADIOTHER ONCOL, V119, P159, DOI 10.1016/j.radonc.2016.03.006 Cuculich PS, 2017, NEW ENGL J MED, V377, P2325, DOI 10.1056/NEJMoa1613773 Cvek J., 2014, Cureus, V6, pe190, DOI [10.7759/cureus.190, DOI 10.7759/CUREUS.190] Dan Ruan, 2011, 2011 IEEE Power Engineering and Automation Conference (PEAM 2011), P100, DOI 10.1109/PEAM.2011.6135024 Falk M, 2012, MED PHYS, V39, P1588, DOI 10.1118/1.3685583 Gardner EA, 2016, CUREUS J MED SCIENCE, V8, DOI 10.7759/cureus.703 Hansen R, 2016, MED PHYS, V43, DOI 10.1118/1.4946815 Ipsen S, 2016, PHYS MED BIOL, V61, P7848, DOI 10.1088/0031-9155/61/22/7848 Ipsen S, 2014, MED PHYS, V41, DOI 10.1118/1.4901414 Keall PJ, 2014, MED PHYS, V41, DOI 10.1118/1.4862509 Lehmann HI, 2016, SCI REP-UK, V6, DOI 10.1038/srep38895 Li G, 2017, INT J RADIAT ONCOL, V98, P454, DOI 10.1016/j.ijrobp.2017.02.016 Loo B W, 2015, CIRCULATION, V8, P50 Maguire P J., 2011, Cureus, V3, DOI [DOI 10.7759/CUREUS.32, 10.7759/cureus.32] McNiven AL, 2010, MED PHYS, V37, P505, DOI 10.1118/1.3276775 Murtaza G, 2017, RADIOTHER ONCOL, V122, P109, DOI 10.1016/j.radonc.2016.11.004 Palmer J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089126 Pommer T, 2013, MED PHYS, V40, DOI 10.1118/1.4824434 Poulsen Per R, 2012, Int J Radiat Oncol Biol Phys, V82, pe321, DOI 10.1016/j.ijrobp.2011.03.023 Poulsen PR, 2012, MED PHYS, V39, P6237, DOI 10.1118/1.4754297 Poulsen PR, 2012, INT J RADIAT ONCOL, V83, pE265, DOI 10.1016/j.ijrobp.2011.12.053 Samson MJ, 1999, INT J RADIAT ONCOL, V43, P827, DOI 10.1016/S0360-3016(98)00467-2 Sawant A, 2009, INT J RADIAT ONCOL, V74, P575, DOI 10.1016/j.ijrobp.2008.12.057 Sharma A, 2010, HEART RHYTHM, V7, P802, DOI 10.1016/j.hrthm.2010.02.010 Wijesooriya K, 2005, MED PHYS, V32, P932, DOI 10.1118/1.1876581 Xia P, 2016, CUREUS J MED SCIENCE, V8, DOI 10.7759/cureus.678 Zei PC, 2017, CURR CARDIOL REP, V19, DOI 10.1007/s11886-017-0886-2 NR 33 TC 16 Z9 18 U1 0 U2 7 PU IOP PUBLISHING LTD PI BRISTOL PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND SN 0031-9155 EI 1361-6560 J9 PHYS MED BIOL JI Phys. Med. Biol. PD OCT PY 2018 VL 63 IS 19 AR 195008 DI 10.1088/1361-6560/aadf7c PG 13 WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging WE Science Citation Index Expanded (SCI-EXPANDED) SC Engineering; Radiology, Nuclear Medicine & Medical Imaging GA GV2CL UT WOS:000445892800004 PM 30189419 OA Green Submitted DA 2026-04-17 ER PT J AU Alexandre, J Molsehi, JJ Bersell, KR Funck-Brentano, C Roden, DM Salem, JE AF Alexandre, Joachim Molsehi, Javid J. Bersell, Kevin R. Funck-Brentano, Christian Roden, Dan M. Salem, Joe-Elie TI Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms SO PHARMACOLOGY & THERAPEUTICS LA English DT Review DE Kinase inhibitors; Chemotherapy; Atrial fibrillation; Ventricular tachycardia; QTc interval; Cardiotoxicity ID PREOPERATIVE PLASMA-ALDOSTERONE; MALIGNANT PERICARDIAL-EFFUSION; LEFT-VENTRICULAR DYSFUNCTION; TYROSINE KINASE INHIBITORS; HODGKINS-LYMPHOMA PATIENTS; QTC INTERVAL PROLONGATION; TARGETED CANCER-THERAPIES; HIGH-DOSE CHEMOTHERAPY; SEX STEROID-HORMONES; CELL LUNG-CANCER AB Significant advances in cancer treatment have resulted in decreased cancer related mortality for many malignancies with some cancer types now considered chronic diseases. Despite these improvements, there is increasing recognition that many cancer patients or cancer survivors can develop cardiovascular diseases, either due to the cancer itself or as a result of anticancer therapy. Much attention has focused on heart failure; however, other cardiotoxicities, notably cardiac rhythm disorders, can occur without underlying cardiomyopathy. Supraventricular tachycardias occur in cancer patients treated with cytotoxic chemotherapy (anthracyclines, gemcitabine, cisplatin and alkylating-agents) or kinase-inhibitors (Kis) such as ibrutinib. Ventricular arrhythmias, with a subset of them being torsades-de-pointes (TdP) favored by QTc prolongation have been reported: this may be the result of direct hERG-channel inhibition or a more recently-described mechanism of phosphoinositide-3-kinase inhibition. The major anticancer drugs responsible for QTc prolongation in this context are Kls, arsenic trioxide, anthracyclines, histone deacetylase inhibitors, and selective estrogen receptor modulators. Anticancer drug-induced cardiac rhythm disorders remain an underappreciated complication even by experienced clinicians. Moreover, the causal relationship of a particular anticancer drug with cardiac arrhythmia occurrence remains challenging due in part to patient comorbidities and complex treatment regimens. For example, any cancer patient may also be diagnosed with common diseases such as hypertension, diabetes or heart failure which increase an individual's arrhythmia susceptibility. Further, anticancer drugs are generally usually used in combination, increasing the challenge around establishing causation. Thus, arrhythmias appear to be an underappreciated adverse effect of anticancer agents and the incidence, significance and underlying mechanisms are now being investigated. (C) 2018 Elsevier Inc. All rights reserved. C1 [Alexandre, Joachim] CHU Caen, PICARO Cardiooncol Program, Dept Pharmacol, F-14033 Caen, France. [Alexandre, Joachim] Normandie Univ, UNICAEN, CHU Caen, EA 4650,Signalisat Electrophysiol & Imagerie Les, F-14000 Caen, France. [Molsehi, Javid J.; Salem, Joe-Elie] Vanderbilt Univ, Med Ctr, Dept Med, Cardiooncol Program, Nashville, TN USA. [Bersell, Kevin R.; Roden, Dan M.; Salem, Joe-Elie] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA. [Funck-Brentano, Christian; Salem, Joe-Elie] Sorbonne Univ, INSERM, CIC Paris Est, Pitie Salpetriere Hosp,AP HP,ICAN,Dept Pharmacol, F-75013 Paris, France. [Roden, Dan M.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA. [Roden, Dan M.] Vanderbilt Univ, Med Ctr, Dept Biomed Informat, Nashville, TN USA. C3 CHU de Caen NORMANDIE; Universite de Caen Normandie; Universite de Caen Normandie; CHU de Caen NORMANDIE; Vanderbilt University; Vanderbilt University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Vanderbilt University; Vanderbilt University RP Salem, JE (corresponding author), Hop La Pitie Salpetriere, Ctr Invest Clin Paris Est, 47-83 Bld Hop, F-75651 Paris 13, France. EM joe-elie.salem@aphp.fr RI Funck-Brentano, Christian/V-4753-2019; Roden, Dan/ABD-5412-2021; Alexandre, Joachim/ABE-2490-2020 OI Funck-Brentano, Christian/0000-0003-0406-5189; Salem, Joe-Elie/0000-0002-0331-3307; FU Philippe Foundation; FRM [SPE20170336816] FX The authors declare that there are no conflicts of interest. This study was supported by Philippe Foundation and FRM "SPE20170336816". CR Abehsira G, 2016, J CLIN ENDOCR METAB, V101, P2776, DOI 10.1210/jc.2016-1877 Alexandre J., 2017, BLOOD Alexandre J, 2016, J HYPERTENS, V34, P2449, DOI 10.1097/HJH.0000000000001105 Alexandre J, 2014, EUROPACE, V16, P220, DOI 10.1093/europace/eut289 Alexandre J, 2013, J CARDIOVASC MAGN R, V15, DOI 10.1186/1532-429X-15-12 Amioka M, 2016, AM J CARDIOL, V118, P1386, DOI 10.1016/j.amjcard.2016.07.049 Ando M, 2000, BONE MARROW TRANSPL, V25, P185, DOI 10.1038/sj.bmt.1702106 [Anonymous], EUR HEART J, DOI DOI 10.1093/EURHEARTJ/EHV316 [Anonymous], 2017, BMJ, DOI DOI 10.1136/BMJ.J4530 Arai M, 2000, CIRC RES, V86, P8, DOI 10.1161/01.RES.86.1.8 Armenian SH, 2017, J CLIN ONCOL, V35, P893, DOI 10.1200/JCO.2016.70.5400 Barbey JT, 2003, J CLIN ONCOL, V21, P3609, DOI 10.1200/JCO.2003.10.009 Barros F, 1998, J PHYSIOL-LONDON, V511, P333, DOI 10.1111/j.1469-7793.1998.333bh.x Baumann P, 2008, LEUKEMIA RES, V32, P1144, DOI 10.1016/j.leukres.2007.11.015 Bellinger AM, 2015, CIRCULATION, V132, P2248, DOI 10.1161/CIRCULATIONAHA.115.010484 BINAH O, 1983, CIRC RES, V53, P655, DOI 10.1161/01.RES.53.5.655 Bischiniotis Theodoros S, 2005, Hellenic J Cardiol, V46, P324 Brown JR, 2017, HAEMATOLOGICA, V102, P1796, DOI 10.3324/haematol.2017.171041 Buchbinder EI, 2016, AM J CLIN ONCOL-CANC, V39, P98, DOI 10.1097/COC.0000000000000239 Bugger H, 2011, CANCER CHEMOTH PHARM, V67, P1381, DOI 10.1007/s00280-010-1441-7 Burger JA, 2015, NEW ENGL J MED, V373, P2425, DOI 10.1056/NEJMoa1509388 Burridge PW, 2016, NAT MED, V22, P547, DOI 10.1038/nm.4087 Buza V, 2017, CIRC-ARRHYTHMIA ELEC, V10, DOI 10.1161/CIRCEP.117.005443 Byrd JC, 2014, NEW ENGL J MED, V371, P213, DOI 10.1056/NEJMoa1400376 Byrd JC, 2016, NEW ENGL J MED, V374, P323, DOI 10.1056/NEJMoa1509981 Byrd JC, 2015, BLOOD, V125, P2497, DOI 10.1182/blood-2014-10-606038 Chae YJ, 2015, EUR J PHARMACOL, V752, P1, DOI 10.1016/j.ejphar.2015.01.048 Chai KL, 2017, LEUKEMIA LYMPHOMA, V58, P2811, DOI 10.1080/10428194.2017.1315115 Chanan-Khan A, 2016, LANCET ONCOL, V17, P200, DOI 10.1016/S1470-2045(15)00465-9 Chang HM, 2017, J AM COLL CARDIOL, V70, P2552, DOI [10.1016/j.jacc.2017.09.1095, 10.1016/j.jacc.2017.09.1096] Chang HM, 2017, J AM COLL CARDIOL, V70, P2536, DOI 10.1016/j.jacc.2017.09.1096 Chen Y, 2009, LANCET ONCOL, V10, P981, DOI 10.1016/S1470-2045(09)70229-3 Chequel M, 2016, CURR CLIN PHARMACOL, V11, P150, DOI 10.2174/1574884711666160714162128 Chiu Michael H, 2016, BMC Res Notes, V9, P310, DOI [10.1186/s13104-016-2105-4, 10.1186/s13104-016-2105-4] Chowdhury S, 2016, BIOFACTORS, V42, P647, DOI 10.1002/biof.1301 Chu TF, 2007, LANCET, V370, P2011, DOI 10.1016/S0140-6736(07)61865-0 Curigliano G, 2012, ANN ONCOL, V23, P155, DOI 10.1093/annonc/mds293 Curtis MJ, 2013, PHARMACOL THERAPEUT, V139, P213, DOI 10.1016/j.pharmthera.2013.04.008 Davis RE, 2010, NATURE, V463, P88, DOI 10.1038/nature08638 De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618 Dreyling M, 2016, LANCET, V387, P770, DOI 10.1016/S0140-6736(15)00667-4 Drolet B, 2004, CIRCULATION, V109, P26, DOI 10.1161/01.CIR.0000109484.00668.CE Ducroq J, 2010, BRIT J PHARMACOL, V159, P93, DOI 10.1111/j.1476-5381.2009.00371.x Dugbartey GJ, 2016, TOXICOLOGY, V371, P58, DOI 10.1016/j.tox.2016.10.001 Escudier M, 2017, CIRCULATION, V136, P2085, DOI 10.1161/CIRCULATIONAHA.117.030571 Ewer MS, 2015, NAT REV CARDIOL, V12, P547, DOI 10.1038/nrcardio.2015.65 Feliz V, 2011, CLIN CARDIOL, V34, P356, DOI 10.1002/clc.20904 Fernandez-Chas M, 2018, BRIT J PHARMACOL, V175, P763, DOI 10.1111/bph.14104 Ferrari D, 2006, ANTI-CANCER DRUG, V17, P359, DOI 10.1097/00001813-200603000-00016 Flaherty L, 2014, CANCER J, V20, P18, DOI 10.1097/PPO.0000000000000024 Fraczek J, 2013, EXPERT OPIN DRUG MET, V9, P441, DOI 10.1517/17425255.2013.754011 Fujii Y, 2017, HEART RHYTHM, V14, P98, DOI 10.1016/j.hrthm.2016.10.015 FUNCKBRENTANO C, 1993, AM J CARDIOL, V72, pB17, DOI 10.1016/0002-9149(93)90035-B Fung K, 2018, J ONCOL PHARM PRACT, V24, P525, DOI 10.1177/1078155217720006 Ghatalia P, 2015, BRIT J CANCER, V112, P296, DOI 10.1038/bjc.2014.564 Gougis P, 2017, CRIT REV ONCOL HEMAT, V119, P75, DOI 10.1016/j.critrevonc.2017.08.010 Gridelli C, 2001, LUNG CANCER-J IASLC, V31, P277, DOI 10.1016/S0169-5002(00)00194-X Groarke JD, 2013, NEW ENGL J MED, V369, P1779, DOI 10.1056/NEJMp1313140 Guglin M, 2009, EUROPACE, V11, P1579, DOI 10.1093/europace/eup300 Hanna AD, 2014, MOL PHARMACOL, V86, P438, DOI 10.1124/mol.114.093849 He JY, 2003, AM J PHYSIOL-HEART C, V285, pH661, DOI 10.1152/ajpheart.00686.2002 Heeringa J, 2006, EUR HEART J, V27, P949, DOI 10.1093/eurheartj/ehi825 Heijman J, 2014, CIRC RES, V114, P1483, DOI 10.1161/CIRCRESAHA.114.302226 Honigberg LA, 2010, P NATL ACAD SCI USA, V107, P13075, DOI 10.1073/pnas.1004594107 Horacek J. M., 2009, Experimental Oncology, V31, P115 Hulsmans M, 2017, CELL, V169, P510, DOI 10.1016/j.cell.2017.03.050 Ifran A, 2005, AM J HEMATOL, V80, P247, DOI 10.1002/ajh.20441 Johnson DB, 2016, NEW ENGL J MED, V375, P1749, DOI 10.1056/NEJMoa1609214 Jovenaux L, 2017, INT J CARDIOL, V241, P387, DOI 10.1016/j.ijcard.2017.02.154 Katagi J, 2016, CARDIOVASC TOXICOL, V16, P138, DOI 10.1007/s12012-015-9322-2 Katchman AN, 2006, J PHARMACOL EXP THER, V316, P1098, DOI 10.1124/jpet.105.093393 Keller GA, 2016, CURR DRUG SAF, V11, P86, DOI 10.2174/1574886311207040262 Kiehn J, 1998, J BIOL CHEM, V273, P25285, DOI 10.1074/jbc.273.39.25285 Kilickap S, 2007, SOUTH MED J, V100, P262, DOI 10.1097/01.smj.0000257382.89910.fe Kruidering M, 1997, J PHARMACOL EXP THER, V280, P638 Kuittinen T, 2006, EUR J HAEMATOL, V77, P120, DOI 10.1111/j.1600-0609.2006.00687.x Kuittinen T, 2005, BONE MARROW TRANSPL, V36, P1077, DOI 10.1038/sj.bmt.1705175 Lampson BL, 2017, BLOOD, V129, P2581, DOI 10.1182/blood-2016-10-742437 Lara PN, 2005, CLIN CANCER RES, V11, P4444, DOI 10.1158/1078-0432.CCR-04-2602 Lee HC, 2011, HEART RHYTHM, V8, P1788, DOI 10.1016/j.hrthm.2011.06.032 LEE RE, 1989, J CLIN ONCOL, V7, P7, DOI 10.1200/JCO.1989.7.1.7 LEENHARDT A, 1994, CIRCULATION, V89, P206, DOI 10.1161/01.CIR.89.1.206 Leong DP, 2016, BLOOD, V128, P138, DOI 10.1182/blood-2016-05-712828 Li WJ, 2015, J AM COLL CARDIOL, V66, P1160, DOI 10.1016/j.jacc.2015.07.025 Liu XK, 1998, J PHARMACOL EXP THER, V287, P877 Liu Y, 2015, EUR J CLIN PHARMACOL, V71, P541, DOI 10.1007/s00228-015-1831-1 Locatelli M, 2015, TARGET ONCOL, V10, P27, DOI 10.1007/s11523-014-0325-x López-Otín C, 2010, NAT REV CANCER, V10, P278, DOI 10.1038/nrc2823 Lu HR, 2012, J PHARMACOL TOX MET, V66, P135, DOI 10.1016/j.vascn.2012.03.002 Lu Z, 2012, SCI TRANSL MED, V4, P131, DOI DOI 10.1126/SCITRANSLMED.3003623 Ma X, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171612 Manohar S, 2018, J NEPHROL, V31, P15, DOI 10.1007/s40620-017-0392-z MARGOLIN KA, 1989, J CLIN ONCOL, V7, P486, DOI 10.1200/JCO.1989.7.4.486 McMullen JR, 2014, BLOOD, V124, P3829, DOI 10.1182/blood-2014-10-604272 Mego M, 2007, ANN ONCOL, V18, P1906, DOI 10.1093/annonc/mdm489 Miceli JJ, 2010, CLIN THER, V32, P472, DOI 10.1016/j.clinthera.2010.03.003 Migliaccio A, 2002, J STEROID BIOCHEM, V83, P31, DOI 10.1016/S0960-0760(02)00264-9 Mileshkin LR, 2005, LEUKEMIA LYMPHOMA, V46, P1575, DOI 10.1080/10428190500235884 Milliez P, 2005, J AM COLL CARDIOL, V45, P1243, DOI 10.1016/j.jacc.2005.01.015 Montaigne D, 2013, J AM COLL CARDIOL, V62, P1466, DOI 10.1016/j.jacc.2013.03.061 Morgan T K Jr, 1992, Prog Med Chem, V29, P65, DOI 10.1016/S0079-6468(08)70005-5 Moslehi JJ, 2016, NEW ENGL J MED, V375, P1457, DOI 10.1056/NEJMra1100265 Mulligan SP, 2016, BRIT J HAEMATOL, V175, P359, DOI 10.1111/bjh.14321 Murphy L, 1996, LIFE SCI, V59, P1739, DOI 10.1016/S0024-3205(96)00511-5 Nafees S, 2015, CHEM-BIOL INTERACT, V231, P98, DOI 10.1016/j.cbi.2015.02.021 Nattel S, 2016, NAT REV CARDIOL, V13, P575, DOI 10.1038/nrcardio.2016.118 Nozaki N, 2004, CIRCULATION, V110, P2869, DOI 10.1161/01.CIR.0000146889.46519.27 Olivieri A, 1998, BONE MARROW TRANSPL, V21, P1049, DOI 10.1038/sj.bmt.1701217 Olsson H, 2017, CLIN DRUG INVEST, V37, P873, DOI 10.1007/s40261-017-0547-7 Ostenfeld EB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102861 Oun R, 2017, EUR J PHARMACOL, V811, P125, DOI 10.1016/j.ejphar.2017.05.063 Passalia C, 2013, TUMORI, V99, pE288, DOI 10.1700/1390.15471 Patell R, 2017, AM J CARDIOL, V120, P2182, DOI 10.1016/j.amjcard.2017.08.038 Pereira L, 2017, J MOL CELL CARDIOL, V108, P8, DOI 10.1016/j.yjmcc.2017.04.005 Perel RD, 2006, J CARDIOVASC MAGN R, V8, P789, DOI 10.1080/10976640600737664 Petrini I, 2012, CANCER CHEMOTH PHARM, V69, P773, DOI 10.1007/s00280-011-1753-2 Phillips GL, 2004, BIOL BLOOD MARROW TR, V10, P473, DOI 10.1016/j.bbmt.2004.03.001 Polk A, 2013, CANCER TREAT REV, V39, P974, DOI 10.1016/j.ctrv.2013.03.005 Pollack IF, 1997, CLIN CANCER RES, V3, P1109 PRAGA C, 1979, CANCER TREAT REP, V63, P827 Pretorius L, 2009, AM J PATHOL, V175, P998, DOI 10.2353/ajpath.2009.090126 Priori SG, 2003, NEW ENGL J MED, V348, P1866, DOI 10.1056/NEJMoa022147 Psaty BM, 1997, CIRCULATION, V96, P2455 PUDDU PE, 1988, J ELECTROCARDIOL, V21, P219, DOI 10.1016/0022-0736(88)90096-9 Pugsley MK, 2008, PHARMACOL THERAPEUT, V119, P115, DOI 10.1016/j.pharmthera.2008.05.004 Qanungo S, 2014, BIOMED PHARMACOTHER, V68, P855, DOI 10.1016/j.biopha.2014.08.007 Rathkopf DE, 2013, CANCER CHEMOTH PHARM, V72, P537, DOI 10.1007/s00280-013-2224-8 Riad A, 2008, EUR J HEART FAIL, V10, P233, DOI 10.1016/j.ejheart.2008.01.004 Richards WG, 2006, J CLIN ONCOL, V24, P1561, DOI 10.1200/JCO.2005.04.6813 Roboz GJ, 2014, J CLIN ONCOL, V32, P3723, DOI 10.1200/JCO.2013.51.2913 Roden DM, 2008, BRIT J PHARMACOL, V154, P1502, DOI 10.1038/bjp.2008.238 Roden DM, 2004, NEW ENGL J MED, V350, P1013, DOI 10.1056/NEJMra032426 Rosic G, 2016, TOXICOL LETT, V242, P34, DOI 10.1016/j.toxlet.2015.11.028 Sager PT, 2015, CANCER MED-US, V4, P1178, DOI 10.1002/cam4.467 Saglam H, 2012, OPEN J UROL, V2, P153, DOI [DOI 10.4236/0JU2012.223029, DOI 10.4236/OJU.2012.223029] Salem JE, 2018, J AM SOC ECHOCARDIOG, V31, P231, DOI 10.1016/j.echo.2017.10.017 Salem JE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181875 Salem JE, 2016, PHARMACOL THERAPEUT, V167, P38, DOI 10.1016/j.pharmthera.2016.07.005 Salem JE, 2015, FUND CLIN PHARMACOL, V29, P10, DOI 10.1111/fcp.12091 Sauer AJ, 2007, J AM COLL CARDIOL, V49, P329, DOI 10.1016/j.jacc.2006.08.057 Sciarra A, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003845 Shah RR, 2015, DRUG SAFETY, V38, P693, DOI 10.1007/s40264-015-0300-1 Shah RR, 2013, DRUG SAFETY, V36, P295, DOI 10.1007/s40264-013-0047-5 Sharma ND, 1998, AM J CARDIOL, V81, P238, DOI 10.1016/S0002-9149(97)00888-6 Sharma R, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.004880 Shatzel JJ, 2017, J THROMB HAEMOST, V15, P835, DOI 10.1111/jth.13651 Shopp GM, 2014, ANTICANCER RES, V34, P4733 Shultz MD, 2011, J MED CHEM, V54, P4752, DOI 10.1021/jm200388e Slovacek L, 2008, J CLIN PHARM THER, V33, P453, DOI 10.1111/j.1365-2710.2008.00928.x Smith MR, 2010, J UROLOGY, V184, P2313, DOI 10.1016/j.juro.2010.08.012 STEINBERG JS, 1987, CANCER-AM CANCER SOC, V60, P1213, DOI 10.1002/1097-0142(19870915)60:6<1213::AID-CNCR2820600609>3.0.CO;2-V Stillitano F, 2017, ELIFE, V6, DOI 10.7554/eLife.19406 Strevel EL, 2007, J CLIN ONCOL, V25, P3362, DOI 10.1200/JCO.2006.09.6925 Tam CS, 2008, BLOOD, V112, P516, DOI 10.1182/blood-2008-02-141580 Tamargo J, 2015, DRUG SAFETY, V38, P129, DOI 10.1007/s40264-014-0258-4 Tartarone A, 2015, FUTURE ONCOL, V11, P2043, DOI 10.2217/fon.15.47 Terrar Derek A., 2007, Journal of Pharmacological and Toxicological Methods, V56, P171, DOI 10.1016/j.vascn.2007.04.005 Thomas D, 1999, J BIOL CHEM, V274, P27457, DOI 10.1074/jbc.274.39.27457 Thomas D, 2003, N-S ARCH PHARMACOL, V368, P41, DOI 10.1007/s00210-003-0766-8 Thompson PA, 2016, BRIT J HAEMATOL, V175, P462, DOI 10.1111/bjh.14324 Tian DD, 2014, CURR DRUG METAB, V15, P808 Tomkowski WZ, 1997, LUNG CANCER-J IASLC, V16, P215, DOI 10.1016/S0169-5002(96)00631-9 Tomkowski WZ, 2004, SUPPORT CARE CANCER, V12, P53, DOI 10.1007/s00520-003-0533-x Topkara VK, 2011, J MOL CELL CARDIOL, V51, P594, DOI 10.1016/j.yjmcc.2010.11.003 TRUMP DL, 1992, JNCI-J NATL CANCER I, V84, P1811, DOI 10.1093/jnci/84.23.1811 Venditti P, 1998, CARDIOVASC RES, V38, P695, DOI 10.1016/S0008-6363(98)00034-0 Wang GX, 2001, EUR J PHARMACOL, V423, P99, DOI 10.1016/S0014-2999(01)01096-2 Wiczer TE, 2017, BLOOD ADV, V1, P1739, DOI 10.1182/bloodadvances.2017009720 Woosley RL, 2018, TRENDS CARDIOVAS MED, V28, P94, DOI 10.1016/j.tcm.2017.07.010 Yang T, 2014, CIRCULATION, V130, P224, DOI 10.1161/CIRCULATIONAHA.113.007765 Yeh ETH, 2009, J AM COLL CARDIOL, V53, P2231, DOI 10.1016/j.jacc.2009.02.050 Yoon GJ, 2010, J AM COLL CARDIOL, V56, P1644, DOI 10.1016/j.jacc.2010.07.023 Zamorano JL, 2016, EUR HEART J, V37, P2768, DOI [10.1093/eurheartj/ehw211, 10.1002/ejhf.654] Zang JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030353 NR 174 TC 120 Z9 135 U1 0 U2 18 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0163-7258 J9 PHARMACOL THERAPEUT JI Pharmacol. Ther. PD SEP PY 2018 VL 189 BP 89 EP 103 DI 10.1016/j.pharmthera.2018.04.009 PG 15 WC Pharmacology & Pharmacy WE Science Citation Index Expanded (SCI-EXPANDED) SC Pharmacology & Pharmacy GA GR8NC UT WOS:000442979600007 PM 29698683 DA 2026-04-17 ER PT J AU Scherer, WJ AF Scherer, Warren J. TI Corneal Endothelial Cell Density and Cardiovascular Mortality: A Global Survey and Correlative Meta-Analysis SO CLINICAL ANATOMY LA English DT Article DE cornea; corneal endothelial density; cardiovascular disease; meta-analysis; embryology ID AXENFELD-RIEGER-SYNDROME; ATRIAL-FIBRILLATION RISK; CARDIAC OUTFLOW TRACT; NEURAL CREST CELLS; TRANSCRIPTION FACTORS; OXYGEN LEVELS; PITX2; FOXC1; EXPRESSION; MUTATIONS AB Based on embryological commonalities between eye and heart development, a global, country-specific meta-analysis of normal, adult corneal endothelial cell density (ECD) was performed and correlated against mortality rates secondary to diseases affecting cardiac neural crest cell (CNCC)-derived cardiovascular structures. A country-specific survey of ECD was performed by searching PubMed for studies reporting ECD datasets from normal adults. All eligible datasets were assigned a country of origin. Country-specific weighted mean ECD were calculated based on dataset n. Country-specific disease mortality rates were obtained from the World Health Organization. The correlations between weighted mean ECD and mortality rates secondary to diseases affecting CNCC-derived cardiovascular structures were calculated. As controls, correlations between ECD and noncardiovascular disease mortality were examined. Pearson correlation coefficients (r) corresponding to P-value<0.05 were considered significant. Three hundred ninety-two datasets (39,762 eyes) from 267 source-studies were assigned to 42 countries. Significant correlations were found between ECD and mortality due to coronary heart disease (r = -0.39, P = 0.011), hypertension (r = -0.33, P = 0.033), and all-cause cardiac disease (r = -0.36, P = 0.019). No significant correlations were found between ECD and mortality secondary to the control conditions: inflammatory heart disease (mesoderm-derived tissues) (r = -0.12, P = 0.45), diabetes (r = -0.13, P = 0.41), lung disease (r = -0.21, P = 0.18), liver disease (r = -0.13, P = 0.41), renal disease (r = -0.10, P = 0.53), lung cancer (r = 0.02, P = 0.90), pancreatic cancer (r = 0.24, P = 0.13), malnutrition (r = -0.07, P = 0.66), or all-cause mortality (r = 0.04, P = 0.81). Negative correlations exist between ECD and mortality due to coronary artery disease and hypertension. On a population-based level, adult ECD is correlated to mortality from certain cardiovascular diseases. (C) 2018 Wiley Periodicals, Inc. C1 [Scherer, Warren J.] Envis Eye Specialists, 1250 Belcher Rd South, Largo, FL 33771 USA. RP Scherer, WJ (corresponding author), Envis Eye Specialists, 19208 Pristine Pl, Lutz, FL 33558 USA. EM wjsmd@hotmail.com RI ; scherer, warren/POY-8963-2026 OI Scherer, Warren/0000-0002-2612-0719; CR Aguirre LA, 2015, BMC BIOL, V13, DOI 10.1186/s12915-015-0138-0 Arima Y, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2258 Bailey JNC, 2016, NAT GENET, V48, P189, DOI 10.1038/ng.3482 Chen LS, 2016, INVEST OPHTH VIS SCI, V57, P5023, DOI 10.1167/iovs.16-19700 Chen LS, 2016, INVEST OPHTH VIS SCI, V57, P1072, DOI 10.1167/iovs.15-18103 Dawson DG, 2003, ADLERS PHYSL EYE, P73 Du RF, 2014, OPHTHALMIC GENET, V10, P1 Evans AL, 2005, HUM MOL GENET, V14, P3347, DOI 10.1093/hmg/ddi365 Gripp KW, 2013, AM J MED GENET A, V161A, P114, DOI 10.1002/ajmg.a.35697 Hill M.A., 2017, Embryology advanced cardiac embryology Huang AJW, 2015, INVEST OPHTH VIS SCI, V56, P6483, DOI 10.1167/iovs.15-17191 Huang XB, 2015, INT J MOL MED, V36, P1111, DOI 10.3892/ijmm.2015.2325 Hutson Mary Redmond, 2003, Birth Defects Research, V69, P2, DOI 10.1002/bdrc.10002 Iwao K, 2009, J CLIN INVEST, V119, P1997, DOI 10.1172/JCI38519 JOHNSTON MC, 1979, EXP EYE RES, V29, P27, DOI 10.1016/0014-4835(79)90164-7 Joyce NC, 2003, PROG RETIN EYE RES, V22, P359, DOI 10.1016/S1350-9462(02)00065-4 Khalil A, 2017, J MED IMAGING, V4, DOI [10.24271/garmian.121, 10.1117/1.JMI.4.3.037001] Kirby ML, 2010, CELL ADHES MIGR, V4, P609, DOI 10.4161/cam.4.4.13489 KIRBY ML, 1985, ANAT RECORD, V213, P87, DOI 10.1002/ar.1092130112 KIRBY ML, 1983, SCIENCE, V220, P1059, DOI 10.1126/science.6844926 Kniestedt C, 2006, OPHTHALMOLOGY, V113, P1791, DOI 10.1016/j.ophtha.2006.05.017 Lubitz SA, 2014, J AM COLL CARDIOL, V63, P1200, DOI 10.1016/j.jacc.2013.12.015 Ma HY, 2013, DEV DYNAM, V242, P456, DOI 10.1002/dvdy.23934 MAKITIE J, 1983, INVEST OPHTH VIS SCI, V24, P1029 Martin RIR, 2015, J MOL CELL CARDIOL, V85, P207, DOI 10.1016/j.yjmcc.2015.06.005 MATSUDA M, 1985, ARCH OPHTHALMOL-CHIC, V103, P68 Mears AJ, 1996, AM J HUM GENET, V59, P1321 Mears AJ, 1998, AM J HUM GENET, V63, P1316, DOI 10.1086/302109 Mikhailov AT, 2016, HEART FAIL REV, V21, P783, DOI 10.1007/s10741-016-9569-0 Niederer RL, 2007, BRIT J OPHTHALMOL, V91, P1165, DOI 10.1136/bjo.2006.112656 Nishimura DY, 1998, NAT GENET, V19, P140, DOI 10.1038/493 OLSEN T, 1984, GRAEF ARCH CLIN EXP, V221, P239, DOI 10.1007/BF02134146 Pitchkhadze Anry, 2016, Harefuah, V155, P264 PRICE NC, 1981, BRIT J OPHTHALMOL, V65, P812, DOI 10.1136/bjo.65.12.812 Racz A, 2016, OPHTHALMIC GENET, V37, P281, DOI 10.3109/13816810.2015.1045524 Reis LM, 2012, EUR J HUM GENET, V20, P1224, DOI 10.1038/ejhg.2012.80 Seifi M, 2016, ACTA OPHTHALMOL, V94, pE571, DOI 10.1111/aos.13030 Seo S, 2006, DEV BIOL, V296, P421, DOI 10.1016/j.ydbio.2006.06.012 Siegfried CJ, 2015, AM J OPHTHALMOL, V159, P457, DOI 10.1016/j.ajo.2014.11.026 Silla ZTV, 2014, EXP CELL RES, V322, P381, DOI 10.1016/j.yexcr.2014.01.016 Sun YM, 2016, GENE, V577, P258, DOI 10.1016/j.gene.2015.12.001 TAKAMURA K, 1990, ANAT EMBRYOL, V182, P263 Tao G, 2016, NATURE, V534, P119, DOI 10.1038/nature17959 Titheradge H, 2014, AM J MED GENET A, V164, P1695, DOI 10.1002/ajmg.a.36540 Töpf A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095453 Vieira V, 2006, MOL VIS, V12, P1448 Wei D, 2014, INT J MOL MED, V33, P1201, DOI 10.3892/ijmm.2014.1689 WILSON RS, 1982, BRIT J OPHTHALMOL, V66, P513, DOI 10.1136/bjo.66.8.513 Ye JC, 2016, AM J HUM GENET, V99, P1281, DOI 10.1016/j.ajhg.2016.10.001 YEE RW, 1985, CURR EYE RES, V4, P671, DOI 10.3109/02713688509017661 Zhao CM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124409 NR 51 TC 9 Z9 11 U1 0 U2 4 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0897-3806 EI 1098-2353 J9 CLIN ANAT JI Clin. Anat. PD SEP PY 2018 VL 31 IS 6 BP 927 EP 936 DI 10.1002/ca.23230 PG 10 WC Anatomy & Morphology WE Science Citation Index Expanded (SCI-EXPANDED) SC Anatomy & Morphology GA GY9AR UT WOS:000448931500020 PM 30168608 DA 2026-04-17 ER PT J AU Sundboll, J Veres, K Horváth-Puhó, E Adelborg, K Sorensen, HT AF Sundboll, Jens Veres, Katalin Horvath-Puho, Erzsebet Adelborg, Kasper Sorensen, Henrik Toft TI Risk and Prognosis of Cancer After Lower Limb Arterial Thrombosis SO CIRCULATION LA English DT Article DE epidemiology; neoplasms; prognosis; risk factors; thrombosis ID ATRIAL-FIBRILLATION; PREVALENCE; DIAGNOSIS; SURVIVAL; REGISTRY; QUALITY; FLUTTER; DISEASE AB Background: Venous thromboembolism can be a presenting symptom of cancer, but the association between lower limb arterial thrombosis and cancer is unknown. We therefore examined cancer risk and prognosis of cancer in patients with lower limb arterial thrombosis. Methods: Using nationwide population-based Danish medical registries, we identified all patients diagnosed with first-time lower limb arterial thrombosis (1994-2013) and followed them until the occurrence of any subsequent cancer diagnosis, emigration, death, or November 30, 2013, whichever came first. We computed standardized incidence ratios with 95% confidence intervals as the observed number of cancers relative to the expected number based on national incidence rates by sex, age, and calendar year. To examine the prognostic impact of lower limb arterial thrombosis on all-cause mortality after cancer, we constructed a matched comparison cohort of patients who had cancer without lower limb arterial thrombosis. Results: Among 6600 patients with lower limb arterial thrombosis, we observed 772 subsequent cancers. The risk of any cancer was 2.5% after 6 months of follow-up, increasing to 17.9% after 20 years. During the first 6 months of follow-up, the standardized incidence ratio of any cancer was 3.28 (95% confidence interval, 2.79-3.82). The standardized incidence ratio remained elevated during 7 to 12 months (1.42; 95% confidence interval, 1.09-1.83) and beyond 12 months (1.14; 95% confidence interval, 1.05-1.24). The strongest associations were found for lung cancer and other smoking-related cancers. Lower limb arterial thrombosis also was associated with increased all-cause mortality after colon, lung, urinary bladder, and breast cancer, but not after prostate cancer. Conclusions: Lower limb arterial thrombosis was a marker of occult cancer, especially lung cancer, and was an adverse prognostic factor for mortality in common cancers. C1 [Sundboll, Jens; Veres, Katalin; Horvath-Puho, Erzsebet; Adelborg, Kasper; Sorensen, Henrik Toft] Aarhus Univ Hosp, Dept Clin Epidemiol, Olof Palmes Alle 43-45, DK-8200 Aarhus N, Denmark. C3 Aarhus University RP Sundboll, J (corresponding author), Aarhus Univ Hosp, Dept Clin Epidemiol, Olof Palmes Alle 43-45, DK-8200 Aarhus N, Denmark. EM jens.sundboll@clin.au.dk RI ; Toft Sørensen, Henrik/Z-6181-2019 OI Horváth-Puhó, Erzsébet/0000-0002-3594-2212; Toft Sørensen, Henrik/0000-0003-4299-7040 FU Program for Clinical Research Infrastructure (PROCRIN); Novo Nordisk Foundation; Lundbeck Foundation [R155-2014-2647] Funding Source: researchfish; Novo Nordisk Fonden [NNF14SA0015794] Funding Source: researchfish FX This work was supported by the Program for Clinical Research Infrastructure (PROCRIN) established by the Lundbeck Foundation and the Novo Nordisk Foundation. Neither funding source had a role in the design, conduct, analysis, or reporting of the study. CR Adams BD, 2010, HEMATOL ONCOL CLIN N, V24, P585, DOI 10.1016/j.hoc.2010.03.004 Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309 Breslow N E, 1987, IARC Sci Publ, P1 Caine GJ, 2002, NEOPLASIA, V4, P465, DOI 10.1038/sj.neo.7900263 CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8 Creager MA, 2012, NEW ENGL J MED, V366, P2198, DOI 10.1056/NEJMcp1006054 Erichsen R, 2012, INTERN EMERG MED, V7, P431, DOI 10.1007/s11739-011-0701-9 Furie B, 2008, NEW ENGL J MED, V359, P938, DOI 10.1056/NEJMra0801082 Greenland S, 2008, MODERN EPIDEMIOLOGY, P226 Greenland S. R. K., 2008, MODERN EPIDEMIOLOGY, P55 Guzzetti S, 2008, INTERN EMERG MED, V3, P227, DOI 10.1007/s11739-008-0124-4 Haaland GS, 2017, JAMA INTERN MED, V177, P1774, DOI 10.1001/jamainternmed.2017.5512 Lip GYH, 2002, LANCET ONCOL, V3, P27, DOI 10.1016/S1470-2045(01)00619-2 Norgren L, 2007, J VASC SURG, V45, pS5, DOI 10.1016/j.jvs.2006.12.037 Onega T, 2015, CANCER EPIDEM BIOMAR, V24, P744, DOI 10.1158/1055-9965.EPI-14-1255 Paolino M, 2014, NATURE, V507, P508, DOI 10.1038/nature12998 Porcu P, 2000, LEUKEMIA LYMPHOMA, V39, P1, DOI 10.3109/10428190009053534 Prandoni P, 2009, EUR J INTERN MED, V20, P660, DOI 10.1016/j.ejim.2009.02.001 Rothman KJ., 2008, Modern epidemiology, V3rd, P137, DOI 10.1016/j.annemergmed.2008.06.461 Satagopan JM, 2004, BRIT J CANCER, V91, P1229, DOI 10.1038/sj.bjc.6602102 Schmidt M, 2015, CLIN EPIDEMIOL, V7, P449, DOI 10.2147/CLEP.S91125 Schmidt M, 2014, EUR J EPIDEMIOL, V29, P541, DOI 10.1007/s10654-014-9930-3 Schulman S, 2000, NEW ENGL J MED, V342, P1953, DOI 10.1056/NEJM200006293422604 Selvin E, 2004, CIRCULATION, V110, P738, DOI 10.1161/01.CIR.0000137913.26087.F0 Sorensen HT, 2000, NEW ENGL J MED, V343, P1846, DOI 10.1056/NEJM200012213432504 Sorensen HT, 1998, NEW ENGL J MED, V338, P1169, DOI 10.1056/NEJM199804233381701 Storm HH, 1997, DAN MED BULL, V44, P535 Sundboll J, 2017, INT J CARDIOL, V241, P182, DOI 10.1016/j.ijcard.2017.04.081 Sundboll J, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012832 NR 29 TC 34 Z9 42 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD AUG 14 PY 2018 VL 138 IS 7 BP 669 EP 677 DI 10.1161/CIRCULATIONAHA.117.032617 PG 9 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA GQ2BG UT WOS:000441448800003 PM 29540440 OA Bronze DA 2026-04-17 ER PT J AU Euceda, G Kong, WT Kapoor, A Dilauro, P Ogunnaike, R Chronakos, J AF Euceda, Glenda Kong, Wing-Tai Kapoor, Amber Dilauro, Patricia Ogunnaike, Rahila Chronakos, John TI The Effects of a Comprehensive Care Management Program on Readmission Rates After Acute Exacerbation of COPD at a Community-Based Academic Hospital SO CHRONIC OBSTRUCTIVE PULMONARY DISEASES-JOURNAL OF THE COPD FOUNDATION LA English DT Article DE population health; rehospitalization prevention; risk factors for rehospitalization ID OBSTRUCTIVE PULMONARY-DISEASE; PEOPLE; HEALTH AB Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is one of the leading causes of hospitalization in the United States. Prior investigations suggest clinical and physiological parameters are important determinants for AECOPD readmissions. Strategies aimed at addressing these factors have not resulted in a major reduction of readmissions. We compared patients readmitted after an index AECOPD admission with non-readmitted patients. Patients' age, gender, body mass index, comorbidities (obstructive sleep apnea, chronic hypercapnia, congestive heart failure, lung cancer, pulmonary arterial hypertension, pneumonia, interstitial lung disease, atrial fibrillation, musculoskeletal disorders, cognitive disorders, and anxiety disorders), substance abuse and smoking status were assessed. Some 272 patients were included: 20 patients were readmitted within 30 days of their index hospitalization; 252 patients were not readmitted within 30 days of their index admission. Readmitted patients were significantly more likely to have pneumonia than non-readmitted patients (30.0% versus 13.1%, p< 0.05). No statistically significant difference was seen with respect to other clinical comorbidities. Patients readmitted within 30 days were significantly more likely than non-readmitted patients to have safety issues at home (80.0% versus. 39.3%, p< 0.001), anxiety (60.0% versus 29.8%, p< 0.01), and lack of transportation (35.0% versus 15.5%, p< 0.05). Implementation of a comprehensive care management program (CCMP) was associated with a reduction in readmissions from 21.5% to 13.6% (p< 0.01, 95% confidence interval [CI] 2.08-12.45). A CCMP can reduce readmissions through attention to social variables, optimization of in-hospital care, improved coordination of pre-and post-discharge, a system to better identify problems after discharge, and an office setup that accommodates same-day visits. C1 [Euceda, Glenda; Kong, Wing-Tai; Ogunnaike, Rahila] Danbury Hosp, Western Connecticut Hlth Network, Dept Internal Med, Danbury, CT USA. [Kapoor, Amber] Danbury Hosp, Western Connecticut Hlth Network, Dept Res & Innovat, Danbury, CT USA. [Dilauro, Patricia; Chronakos, John] Danbury Hosp, Western Connecticut Hlth Network, Sect Pulm Med, Dept Internal Med, Danbury, CT USA. RP Chronakos, J (corresponding author), 33 Germantown Rd, Danbury, CT 06810 USA. EM john.chronakos@gmail.com FU Western Connecticut Health Network Foundation FX The study was supported by the Western Connecticut Health Network Foundation. CR Adamson SL, 2016, INT J CHRONIC OBSTR, V11, DOI 10.2147/COPD.S93322 Anecchino Caterina, 2007, Int J Chron Obstruct Pulmon Dis, V2, P567 Baker CL, 2013, INT J CHRONIC OBSTR, V8, P551, DOI 10.2147/COPD.S51507 Bendixen HJ, 2014, SCAND J OCCUP THER, V21, P313, DOI 10.3109/11038128.2014.899621 Bourbeau J, 2003, ARCH INTERN MED, V163, P585, DOI 10.1001/archinte.163.5.585 Braman SS, 2015, COPD-J COPD FDN, V2, P4, DOI 10.15326/jcopdf.2.1.2015.0130 Coventry PA, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-49 Fan VS, 2012, ANN INTERN MED, V156, P673, DOI 10.7326/0003-4819-156-10-201205150-00003 GOLD, 2017, VALUE HEALTH Guarascio AJ, 2013, CLINICOECONOMIC OUTC, V5, P235, DOI 10.2147/CEOR.S34321 Holguin F, 2005, CHEST, V128, P2005, DOI 10.1378/chest.128.4.2005 Keating A, 2011, CHRON RESP DIS, V8, P89, DOI 10.1177/1479972310393756 Kruis AL, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009437.pub2 Laverty AA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116187 Linden A, 2014, AM J MANAG CARE, V20 Macdonald MT, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-191 Park SK, 2013, HEART LUNG, V42, P163, DOI 10.1016/j.hrtlng.2012.07.004 Shah T, 2016, CHEST, V150, P916, DOI 10.1016/j.chest.2016.05.002 Shah T, 2015, CHEST, V147, P1219, DOI 10.1378/chest.14-2181 Singh G, 2016, CHEST, V149, P905, DOI 10.1378/chest.15-0449 van Boven JFM, 2014, RESP MED, V108, P103, DOI 10.1016/j.rmed.2013.08.044 Vestbo J, 2009, THORAX, V64, P939, DOI 10.1136/thx.2009.113662 NR 22 TC 12 Z9 15 U1 1 U2 3 PU COPD FOUNDATION PI DENVER PA COPD FOUNDATION, DENVER, CO 00000 USA SN 2372-952X J9 COPD-J COPD FDN JI Chronic Obstr. Pulm. Dis. PD JUL PY 2018 VL 5 IS 3 BP 185 EP 192 DI 10.15326/jcopdf.5.3.2017.0177 PG 8 WC Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System GA HJ3CY UT WOS:000457048400004 PM 30584582 OA gold DA 2026-04-17 ER PT J AU Kavurmaci, O Akcam, TI Ergonul, AG Turhan, K Cakan, A Cagirici, U AF Kavurmaci, Onder Akcam, Tevfik Ilker Ergonul, Ayse Gul Turhan, Kutsal Cakan, Alpaslan Cagirici, Ufuk TI Is the Risk of Postoperative Atrial Fibrillation Predictable in Patients Undergoing Surgery Due to Primary Lung Cancer? SO HEART LUNG AND CIRCULATION LA English DT Article DE Lung cancer surgery; Postoperative atrial fibrillation; Risk calculation system ID NONCARDIAC THORACIC-SURGERY; SUPRAVENTRICULAR ARRHYTHMIAS; RESECTION; PNEUMONECTOMY; AMIODARONE; MORTALITY AB Background Atrial fibrillation (AF) is a type of cardiac arrhythmia which is commonly seen following lung resection. There is currently no algorithm which can predict which patients will develop postoperative AF (PAF). The present study aims to identify the risk factors for the development of PAF and high-risk patients with PAF along with multiple risk factors. Materials and Methods A total of 887 patients, who underwent lung resection due to primary lung malignancy at our clinic between January 2000 and December 2016, were retrospectively analysed. Group 1 (n = 44) consisted of the patients who developed PAF and Group 2 (n = 843) consisted of the patients without PAF. Age and sex of the patients, comorbidities, previous diagnosis of malignancy, and surgery-related variables were evaluated using statistical methods for their effects on the development of AF. A score was assigned to each identified risk factor and scores of the patients were calculated. The risk of developing PAF was evaluated based on this scoring system. Results We found that >= 60 years of age and the diagnosis of chronic obstructive pulmonary disease (COPD) were significant risk factors for the development of PAF (p < 0.05). The risk of developing PAF was not associated with male sex, previous history of malignancy, presence of comorbidities, and the type of surgery applied. There was an increased risk of AF with increasing scores in the risk calculation system. Conclusion Advanced age and the presence of COPD were found to be associated with an increased risk of developing PAF. In addition we found a significant increase in the risk of developing PAF in the presence of multiple factors, although they did not reach statistical significance alone. C1 [Kavurmaci, Onder; Akcam, Tevfik Ilker; Ergonul, Ayse Gul; Turhan, Kutsal; Cakan, Alpaslan; Cagirici, Ufuk] Ege Univ, Dept Thorac Surg, Sch Med, Izmir, Turkey. C3 Ege University RP Akcam, TI (corresponding author), Ege Univ, Fac Med, Dept Thorac Surg, Izmir, Turkey. EM tevfikilkerakcam@hotmail.com RI Cagirici, Ufuk/X-1303-2018; KAVURMACI, Onder/GQQ-2109-2022; CAKAN, ALPASLAN/JXW-6628-2024; Akcam, Tevfik/AAF-8108-2020; Turhan, Kutsal/K-8641-2019 OI Cagirici, Ufuk/0000-0001-7827-793X; KAVURMACI, Onder/0000-0002-9644-8218; CAKAN, ALPASLAN/0000-0002-4958-0996; CR Amar D, 2002, ANESTHESIOLOGY, V96, P352, DOI 10.1097/00000542-200202000-00021 Anile M, 2012, EUR J CARDIO-THORAC, V41, P1094, DOI 10.1093/ejcts/ezr174 Aoyama H, 2016, GEN THORAC CARDIOVAS, V64, P735, DOI 10.1007/s11748-016-0707-3 Berry MF, 2014, ANN THORAC SURG, V98, P1199, DOI 10.1016/j.athoracsur.2014.05.038 Brathwaite D, 1998, CHEST, V114, P462, DOI 10.1378/chest.114.2.462 Cardinale D, 2016, ANN SURG, V264, P244, DOI 10.1097/SLA.0000000000001626 Garner M, 2017, INTERACT CARDIOV TH, V24, P260, DOI 10.1093/icvts/ivw348 Mansour Z, 2009, ANN THORAC SURG, V88, P1737, DOI 10.1016/j.athoracsur.2009.07.016 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Park BJ, 2007, J THORAC CARDIOV SUR, V133, P775, DOI 10.1016/j.jtcvs.2006.09.022 Passman RS, 2005, ANN THORAC SURG, V79, P1698, DOI 10.1016/j.athoracsur.2004.10.058 Polanczyk CA, 1998, ANN INTERN MED, V129, P279, DOI 10.7326/0003-4819-129-4-199808150-00003 Rena O, 2001, EUR J CARDIO-THORAC, V20, P688, DOI 10.1016/S1010-7940(01)00890-9 Riber LP, 2012, ANN THORAC SURG, V94, P339, DOI 10.1016/j.athoracsur.2011.12.096 Rozencwajg S, 2017, ANAESTH CRIT CARE PA, V36, P185, DOI 10.1016/j.accpm.2016.04.005 Sekine Y, 2001, CHEST, V120, P1783, DOI 10.1378/chest.120.6.1783 TAYLOR GJ, 1987, AM J CARDIOL, V60, P905, DOI 10.1016/0002-9149(87)91045-9 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Zhao BC, 2017, CHEST, V151, P149, DOI 10.1016/j.chest.2016.08.1476 NR 19 TC 13 Z9 18 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1443-9506 EI 1444-2892 J9 HEART LUNG CIRC JI Heart Lung Circ. PD JUL PY 2018 VL 27 IS 7 BP 835 EP 841 DI 10.1016/j.hlc.2017.06.729 PG 7 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA GH8DL UT WOS:000433897100011 PM 28800934 DA 2026-04-17 ER PT J AU Oesterte, A Weber, B Tung, R Choudhry, NK Singh, JP Upadhyay, GA AF Oesterte, Adam Weber, Benjamin Tung, Roderick Choudhry, Niteesh K. Singh, Jagmeet P. Upadhyay, Gaurav A. TI Preventing Postoperative Atrial Fibrillation After Noncardiac Surgery: A Meta-analysis SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE Amiodarone; Atrial fibrillation; Beta-blockers; Calcium channel blockers; Postoperative ID THORACIC-SURGERY; LUNG-CANCER; PULMONARY RESECTION; CARDIAC-SURGERY; PROPHYLACTIC DIGITALIZATION; NATRIURETIC-PEPTIDE; MAGNESIUM-SULFATE; RANDOMIZED-TRIAL; DOUBLE-BLIND; AMIODARONE AB BACKGROUND: Although postoperative atrial fibrillation is common after noncardiac surgery, there is a paucity of data regarding prophylaxis. We sought to determine whether pharmacologic prophylaxis reduces the incidence of postoperative atrial fibrillation after noncardiac surgery. METHODS: We performed an electronic search of Ovid MEDLINE, the Cochrane central register of controlled trials database, and SCOPUS from inception to September 7, 2016 and included prospective randomized studies in which patients in sinus rhythm underwent noncardiac surgery and examined the incidence of postoperative atrial fibrillation as well as secondary safety outcomes. RESULTS: Twenty-one studies including 11,608 patients were included. Types of surgery included vascular surgery (3465 patients), thoracic surgery (2757 patients), general surgery (2292 patients), orthopedic surgery (1756 patients), and other surgery (1338 patients). Beta-blockers (relative risk [RR] 0.32; 95% confidence interval [CI], 0.11-0.87), amiodarone (RR 0.42; 95% CI, 0.26 to 0.67), and statins (RR 0.43; 95% CI, 0.27 to 0.68) reduced postoperative atrial fibrillation compared with placebo or active controls. Calcium channel blockers (RR 0.55; 95% CI, 0.30 to 1.01), digoxin (RR 1.62; 95% CI, 0.95 to 2.76), and magnesium (RR 0.73; 95% CI, 0.23 to 2.33) had no statistically significant effect on postoperative atrial fibrillation incidence. The incidence of adverse events was comparable across agents, except for increased mortality (RR 1.33; 95% CI, 1.03 to 1.37) and bradycardia (RR 2.74; 95% CI, 2.19 to 3.43) in patients receiving beta-blockers. CONCLUSIONS: Pharmacologic prophylaxis with amiodarone, beta-blockers, or statins reduces the incidence of postoperative atrial fibrillation after noncardiac surgery. Amiodarone and statins have a relatively low overall risk of short-term adverse events. (C) 2018 Elsevier Inc. All rights reserved. C1 [Oesterte, Adam; Weber, Benjamin; Tung, Roderick; Upadhyay, Gaurav A.] Univ Chicago, Ctr Arrhythmia Care, 5841 S Maryland Ave,MC 9024, Chicago, IL 60637 USA. [Choudhry, Niteesh K.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA. [Singh, Jagmeet P.] Massachusetts Gen Hosp, Heart Ctr, Boston, MA 02114 USA. C3 University of Chicago; Harvard University; Harvard University Medical Affiliates; Brigham & Women's Hospital; Harvard University; Harvard University Medical Affiliates; Massachusetts General Hospital RP Upadhyay, GA (corresponding author), Univ Chicago, Ctr Arrhythmia Care, 5841 S Maryland Ave,MC 9024, Chicago, IL 60637 USA. EM upadhyay@uchicago.edu OI Tung, Roderick/0000-0002-8513-1303 CR Ai D, 2015, J CARDIOTHOR VASC AN, V29, P1127, DOI 10.1053/j.jvca.2015.01.012 Alonso-Coello P, 2017, ANESTH ANALG, V125, P162, DOI 10.1213/ANE.0000000000002111 Amar D, 1997, ANN THORAC SURG, V63, P1374 Amar D, 2000, J THORAC CARDIOV SUR, V120, P790, DOI 10.1067/mtc.2000.109538 Amar D, 1996, CHEST, V110, P437, DOI 10.1378/chest.110.2.437 Amar D, 2015, J THORAC CARDIOV SUR, V149, P1532, DOI 10.1016/j.jtcvs.2014.12.016 Berry MF, 2014, ANN THORAC SURG, V98, P1199, DOI 10.1016/j.athoracsur.2014.05.038 Bhave PD, 2012, AM HEART J, V164, P918, DOI 10.1016/j.ahj.2012.09.004 Bhave PD, 2012, HEART RHYTHM, V9, P163, DOI 10.1016/j.hrthm.2011.09.003 BORGEAT A, 1991, ANN THORAC SURG, V51, P964, DOI 10.1016/0003-4975(91)91016-O Cardinale D, 2016, ANN SURG, V264, P244, DOI 10.1097/SLA.0000000000001626 Chatterjee S, 2013, PACE, V36, P1017, DOI 10.1111/pace.12140 Chugh SS, 2014, CIRCULATION, V129, P837, DOI 10.1161/CIRCULATIONAHA.113.005119 Ciszewski P, 2013, THORAC CARDIOV SURG, V61, P365, DOI 10.1055/s-0032-1311537 Colilla S, 2013, AM J CARDIOL, V112, P1142, DOI 10.1016/j.amjcard.2013.05.063 Daoud EG, 1997, NEW ENGL J MED, V337, P1785, DOI 10.1056/NEJM199712183372501 Devereaux PJ, 2008, LANCET, V371, P1839, DOI 10.1016/S0140-6736(08)60601-7 Elrakhawy HM, 2014, HEART SURG FORUM, V17, pE308, DOI 10.1532/HSF98.2014412 Fleisher LA, 2014, J AM COLL CARDIOL, V64, pE77, DOI 10.1016/j.jacc.2014.07.944 Frendl G, 2014, J THORAC CARDIOV SUR, V148, pE153, DOI 10.1016/j.jtcvs.2014.06.036 Gialdini G, 2014, JAMA-J AM MED ASSOC, V312, P616, DOI 10.1001/jama.2014.9143 Jakobsen CJ, 1997, J CARDIOTHOR VASC AN, V11, P746, DOI 10.1016/S1053-0770(97)90169-5 Khalil MA, 2013, J ANESTH, V27, P56, DOI 10.1007/s00540-012-1478-3 KROWKA MJ, 1987, CHEST, V91, P490, DOI 10.1378/chest.91.4.490 LINDGREN L, 1991, BRIT J ANAESTH, V66, P205, DOI 10.1093/bja/66.2.205 Lubitz SA, 2015, CIRCULATION, V131, P1648, DOI 10.1161/CIRCULATIONAHA.114.014058 Marjanski T, 2015, EUR J CARDIO-THORAC, V47, pE213, DOI 10.1093/ejcts/ezv049 Moreno SG, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-2 Nojiri T, 2015, CHEST, V148, P1285, DOI 10.1378/chest.15-0852 Nojiri T, 2012, J THORAC CARDIOV SUR, V143, P488, DOI 10.1016/j.jtcvs.2011.09.003 Patel NJ, 2014, CIRCULATION, V129, P2371, DOI 10.1161/CIRCULATIONAHA.114.008201 Patti G, 2006, CIRCULATION, V114, P1455, DOI 10.1161/CIRCULATIONAHA.106.621763 Riber LP, 2012, ANN THORAC SURG, V94, P339, DOI 10.1016/j.athoracsur.2011.12.096 Riber LP, 2014, ANN THORAC SURG, V98, P1989, DOI 10.1016/j.athoracsur.2014.06.069 RITCHIE AJ, 1992, THORAX, V47, P41, DOI 10.1136/thx.47.1.41 RITCHIE AJ, 1990, ANN THORAC SURG, V50, P86, DOI 10.1016/0003-4975(90)90094-M Terzi A, 1996, THORAC CARDIOV SURG, V44, P300, DOI 10.1055/s-2007-1012041 Tisdale JE, 2010, J THORAC CARDIOV SUR, V140, P45, DOI 10.1016/j.jtcvs.2010.01.026 Tisdale JE, 2009, ANN THORAC SURG, V88, P886, DOI 10.1016/j.athoracsur.2009.04.074 Toufektzian L, 2015, INTERACT CARDIOV TH, V20, P654, DOI 10.1093/icvts/ivu454 VanMieghem W, 1996, ANN THORAC SURG, V61, P1083, DOI 10.1016/0003-4975(96)00073-2 VANMIEGHEM W, 1994, CHEST, V105, P1642, DOI 10.1378/chest.105.6.1642 Walsh SR, 2007, ANN ROY COLL SURG, V89, P91, DOI 10.1308/003588407X168253 Wijeysundera DN, 2003, ANESTH ANALG, V97, P634, DOI 10.1213/01.ANE.0000081732.51871.D2 Wijeysundera DN, 2014, CIRCULATION, V130, P2246, DOI 10.1161/CIR.0000000000000104 Winkel TA, 2009, EUR J VASC ENDOVASC, V38, P683, DOI 10.1016/j.ejvs.2009.07.006 Xia JG, 2014, CARDIOLOGY, V128, P285, DOI 10.1159/000362593 Zhao BC, 2017, CHEST, V151, P149, DOI 10.1016/j.chest.2016.08.1476 Zheng Z, 2016, NEW ENGL J MED, V374, P1744, DOI 10.1056/NEJMoa1507750 NR 49 TC 29 Z9 38 U1 0 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 EI 1555-7162 J9 AM J MED JI Am. J. Med. PD JUL PY 2018 VL 131 IS 7 BP 795 EP + DI 10.1016/j.amjmed.2018.01.032 PG 15 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA GK9NC UT WOS:000436577000033 PM 29476748 DA 2026-04-17 ER PT J AU Seviiri, M Lynch, BM Hodge, AM Yang, Y Liew, D English, DR Giles, GG Milne, RL Dugué, PA AF Seviiri, Mathias Lynch, Brigid M. Hodge, Allison M. Yang, Yi Liew, Danny English, Dallas R. Giles, Graham G. Milne, Roger L. Dugue, Pierre-Antoine TI Resting heart rate, temporal changes in resting heart rate, and overall and cause-specific mortality SO HEART LA English DT Article ID ALL-CAUSE MORTALITY; CORONARY-ARTERY-DISEASE; FOLLOW-UP; RISK-FACTOR; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; GENERAL-POPULATION; PHYSICAL-FITNESS; EATING INDEX; CANCER AB Objective Most studies investigating the association between resting heart rate (RHR) and mortality have focused on cardiovascular disease (CVD) mortality, and measured RHR at only one time point. We aimed to assess associations of RHR and changes in RHR over approximately a decade with overall and cause-specific mortality. Methods We used data from participants in the Melbourne Collaborative Cohort Study with RHR measures at baseline (1990-1994; n=41 386; 9846 deaths) and at follow-up (2003-2007; n=21 692; 2818 deaths). RHR measures were taken by trained staff, using Dinamap monitors. Cox models were used to estimate HR and 95% CI for the associations between RHR and mortality. Vital status and cause of death were ascertained until August 2015 and December 2013, respectively. Results After adjustment for confounders, including blood pressure and known medical conditions but not arrhythmias or atrial fibrillation, RHR was associated with a higher risk of death of similar magnitude for CVD (HR per 10 beats per minute (bpm)=1.11, 95% CI 1.07 to 1.16), cancer (HR=1.10, 95% CI 1.06 to 1.13) and other causes (HR=1.20, 95% CI 1.16 to 1.25). Higher mortality was observed for most cancer sites, including breast (HR=1.16, 95% CI 1.03 to 1.31), colorectal (HR=1.18, 95% CI 1.08 to 1.29), kidney (HR=1.27, 95% CI 1.03 to 1.57) and lung cancer (HR=1.19, 95% CI 1.10 to 1.29). Temporal increases in RHR were associated with higher mortality, particularly for individuals whose RHR increased by more than 15 bpm. Conclusions RHR and changes in RHR over a decade are associated with mortality risk, including from causes other than CVD such as breast, colorectal or lung cancer. Monitoring of RHR may have utility in identifying individuals at higher mortality risk. C1 [Seviiri, Mathias; Lynch, Brigid M.; Hodge, Allison M.; Yang, Yi; English, Dallas R.; Giles, Graham G.; Milne, Roger L.; Dugue, Pierre-Antoine] Canc Council Victoria, Canc Epidemiol & Intelligence Div, Melbourne, Vic, Australia. [Lynch, Brigid M.; Hodge, Allison M.; Yang, Yi; English, Dallas R.; Giles, Graham G.; Milne, Roger L.; Dugue, Pierre-Antoine] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Ctr Epidemiol & Biostat, Melbourne, Vic, Australia. [Lynch, Brigid M.] Baker Heart & Diabet Inst, Phys Act Lab, Melbourne, Vic, Australia. [Liew, Danny] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia. C3 Cancer Council Victoria; University of Melbourne; Monash University RP Dugué, PA (corresponding author), Univ Melbourne, Melbourne Sch Populat & Global Hlth, Ctr Epidemiol & Biostat, Canc Council Victoria,Canc Epidemiol & Intelligen, Melbourne, Vic 3004, Australia. EM pdugue@cancervic.org.au RI ; English, Dallas/AAH-5005-2019; Giles, Graham/LCD-5671-2024; Yang, Yi/ABC-6984-2021 OI Lynch, Brigid/0000-0001-8060-547X; English, Dallas/0000-0001-7828-8188; Liew, Danny/0000-0002-0131-623X; Seviiri, Mathias/0000-0002-8610-3283; Hodge, Allison/0000-0001-5464-2197; Giles, Graham/0000-0003-4946-9099; Yang, Yi/0000-0002-7594-6373 FU VicHealth; Cancer Council Victoria; Australian NHMRC [209057, 396414]; NBCF Fellowship [ECF 15-012] FX The MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by the Australian NHMRC grants 209057 and 396414, and by infrastructure provided by Cancer Council Victoria. BML is supported by an NBCF Fellowship (ECF 15-012). CR Akbaraly TN, 2011, AM J CLIN NUTR, V94, P247, DOI 10.3945/ajcn.111.013128 Aladin AI, 2014, AM J CARDIOL, V114, P1701, DOI 10.1016/j.amjcard.2014.08.042 BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250 Chiuve SE, 2012, J NUTR, V142, P1009, DOI 10.3945/jn.111.157222 Cole SW, 2012, CLIN CANCER RES, V18, P1201, DOI 10.1158/1078-0432.CCR-11-0641 Eppinga RN, 2016, NAT GENET, V48, P1557, DOI 10.1038/ng.3708 Erikssen G, 1998, LANCET, V352, P759, DOI 10.1016/S0140-6736(98)02268-5 Fox K, 2008, LANCET, V372, P817, DOI 10.1016/S0140-6736(08)61171-X Fox K, 2007, J AM COLL CARDIOL, V50, P823, DOI 10.1016/j.jacc.2007.04.079 GANN PH, 1995, CANCER EPIDEM BIOMAR, V4, P611 Greenland P, 1999, AM J EPIDEMIOL, V149, P853 Ireland P, 1994, Asia Pac J Clin Nutr, V3, P19 Jensen MT, 2013, HEART, V99, P882, DOI 10.1136/heartjnl-2012-303375 Jouven X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021310 Jouven X, 2009, AM J CARDIOL, V103, P279, DOI 10.1016/j.amjcard.2008.08.071 Kristal-Boneh E, 2000, EUR HEART J, V21, P116, DOI 10.1053/euhj.1999.1741 Lee DH, 2016, BREAST CANCER RES TR, V159, P375, DOI 10.1007/s10549-016-3938-1 MacInnis RJ, 2004, CANCER EPIDEM BIOMAR, V13, P553 Milne R, 2017, INT J EPIDEMIOL Nauman J, 2011, JAMA-J AM MED ASSOC, V306, P2579, DOI 10.1001/jama.2011.1826 Palatini P, 2001, ANN MED, V33, P213, DOI 10.3109/07853890108998748 Reunanen A, 2000, J INTERN MED, V247, P231, DOI 10.1046/j.1365-2796.2000.00602.x Seccareccia F, 2001, AM J PUBLIC HEALTH, V91, P1258, DOI 10.2105/AJPH.91.8.1258 Sharashova E, 2016, J EPIDEMIOL COMMUN H, V70, P902, DOI 10.1136/jech-2015-206663 Sharashova E, 2015, INT J EPIDEMIOL, V44, P1007, DOI 10.1093/ije/dyv061 Strath SJ, 2000, MED SCI SPORT EXER, V32, pS465, DOI 10.1097/00005768-200009001-00005 Suttorp MM, 2015, NEPHROL DIAL TRANSPL, V30, P1418, DOI 10.1093/ndt/gfu325 Thiébaut ACM, 2004, STAT MED, V23, P3803, DOI 10.1002/sim.2098 Thomas F, 2001, J CLIN EPIDEMIOL, V54, P735, DOI 10.1016/S0895-4356(00)00353-X Tverdal A, 2008, EUR HEART J, V29, P2772, DOI 10.1093/eurheartj/ehn435 Vazir A, 2015, EUR HEART J, V36, P669, DOI 10.1093/eurheartj/ehu401 Wu PY, 2016, J HUM NUTR DIET, V29, P363, DOI 10.1111/jhn.12317 Zhang DF, 2016, CAN MED ASSOC J, V188, pE384, DOI 10.1503/cmaj.160050 Zhang DF, 2016, CAN MED ASSOC J, V188, pE53, DOI 10.1503/cmaj.150535 NR 34 TC 58 Z9 67 U1 1 U2 8 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1355-6037 EI 1468-201X J9 HEART JI Heart PD JUL PY 2018 VL 104 IS 13 BP 1076 EP 1085 DI 10.1136/heartjnl-2017-312251 PG 10 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA GM3VJ UT WOS:000438038400008 PM 29269380 DA 2026-04-17 ER PT J AU Martinod, E Chouahnia, K Radu, DM Joudiou, P Uzunhan, Y Bensidhoum, M Portela, AMS Guiraudet, P Peretti, M Destable, MD Solis, A Benachi, S Fialaire-Legendre, A Rouard, H Collon, T Piquet, J Leroy, S Vénissac, N Santini, J Tresallet, C Dutau, H Sebbane, G Cohen, Y Beloucif, S d'Audiffret, AC Petite, H Valeyre, D Carpentier, A Vicaut, E AF Martinod, Emmanuel Chouahnia, Kader Radu, Dana M. Joudiou, Pascal Uzunhan, Yurdagul Bensidhoum, Morad Portela, Ana M. Santos Guiraudet, Patrice Peretti, Marine Destable, Marie-Dominique Solis, Audrey Benachi, Sabiha Fialaire-Legendre, Anne Rouard, Helene Collon, Thierry Piquet, Jacques Leroy, Sylvie Venissac, Nicolas Santini, Joseph Tresallet, Christophe Dutau, Herve Sebbane, Georges Cohen, Yves Beloucif, Sadel d'Audiffret, Alexandre C. Petite, Herve Valeyre, Dominique Carpentier, Alain Vicaut, Eric TI Feasibility of Bioengineered Tracheal and Bronchial Reconstruction Using Stented Aortic Matrices SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID 2-YEAR FOLLOW-UP; LUNG-CANCER; TRACHEOBRONCHIAL TRANSPLANTATION; CARINAL REPLACEMENT; TISSUE; WITHDRAWAL; SOCIETY; CHILD AB IMPORTANCE Airway transplantation could be an option for patients with proximal lung tumor or with end-stage tracheobronchial disease. New methods for airway transplantation remain highly controversial. OBJECrIVE To establish the feasibility of airway bioengineering using a technique based on the implantation of stented aortic matrices. DESIGN, SETTING, AND PARTICIPANTS Uncontrolled single-center cohort study including 20 patients with end-stage tracheal lesions or with proximal lung tumors requiring a pneumonectomy. The study was conducted in Paris, France, from October 2009 through February 2017; final follow-up for all patients occurred on November 2, 2017. EXPOSURES Radical resection of the lesions was performed using standard surgical techniques. After resection, airway reconstruction was performed using a human cryopreserved (-80 degrees C) aortic allograft, which was not matched by the ABO and leukocyte antigen systems. To prevent airway collapse, a custom-made stent was inserted into the allograft. In patients with proximal lung tumors, the lung-sparing intervention of bronchial transplantation was used. MAIN OUTCOMES AND MEASURES The primary outcome was 90-day mortality. The secondary outcome was 90-day morbidity. RESULTS Twenty patients were included in the study (mean age, 54.9 years; age range, 24-79 years; 13 men [65%]). Thirteen patients underwent tracheal (n = 5), bronchial (n = 7), or carinal (n = 1) transplantation. Airway transplantation was not performed in 7 patients for the following reasons: medical contraindication (n = 1), unavoidable pneumonectomy (n = 1), exploratory thoracotomy only (n = 2), and a lobectomy or bilobectomy was possible (n = 3). Among the 20 patients initially included, the overall 90-day mortality rate was 5% (1 patient underwent a carinal transplantation and died). No mortality at 90 days was observed among patients who underwent tracheal or bronchial reconstruction. Among the 13 patients who underwent airway transplantation, major 90-day morbidity events occurred in 4 (30.8%) and included laryngeal edema, acute lung edema, acute respiratory distress syndrome, and atrial fibrillation. There was no adverse event directly related to the surgical technique. Stent removal was performed at a postoperative mean of 18.2 months. At a median follow-up of 3 years 11 months, 10 of the 13 patients (76.9%) were alive. Of these 10 patients, 8 (80%) breathed normally through newly formed airways after stent removal. Regeneration of epithelium and de novo generation of cartilage were observed within aortic matrices from recipient cells. CONCLUSIONS AND RELEVANCE In this uncontrolled study, airway bioengineering using stented aortic matrices demonstrated feasibility for complex tracheal and bronchial reconstruction. Further research is needed to assess efficacy and safety. C1 [Martinod, Emmanuel; Radu, Dana M.; Portela, Ana M. Santos; Guiraudet, Patrice; Peretti, Marine; Destable, Marie-Dominique] Univ Paris 13, Hop Univ Paris Seine St Denis, UFR Sante Med & Biol Humaine, AP HP,Hop Avicenne,Chirurg Thorac & Vasc,Sorbonne, Bobigny, France. [Martinod, Emmanuel; Radu, Dana M.; Guiraudet, Patrice; Carpentier, Alain] Univ Paris 05, Hop Europeen Georges Pompidou, AP HP, Lab Rech Biochirurg,Fdn Alain Carpentier, Paris, France. [Chouahnia, Kader] Univ Paris 13, Sorbonne Paris Cite, Hop Univ Paris Seine St Denis, AP HP,Hop Avicenne,Oncol,UFR Sante Med & Biol Hum, Bobigny, France. [Joudiou, Pascal; Uzunhan, Yurdagul; Valeyre, Dominique] Univ Paris 13, Sorbonne Paris Cite, Hop Univ Paris Seine St Denis,Pneumol, AP HP,Hop Avicenne,UFR Sante Med & Biol Humaine, Bobigny, France. [Bensidhoum, Morad; Petite, Herve] Univ Paris Diderot, Sorbonne Paris Cite, CNRS, UMR 7052,B20A, F-75010 Paris, France. [Bensidhoum, Morad; Petite, Herve] Univ Paris Est, Ecole Natl Vet Alfort, Maisons Alfort, France. [Solis, Audrey; Benachi, Sabiha; Cohen, Yves; Beloucif, Sadel] Univ Paris 13, Sorbonne Paris Cite, Hop Univ Paris Seine St Denis,AP HP, Hop Avicenne,Anesthesie Reanimat,UFR Sante Med &, Bobigny, France. [Fialaire-Legendre, Anne; Rouard, Helene] AP HP, EFS Ile France, Creteil, France. [Collon, Thierry; Piquet, Jacques] Hop Le Raincy Montfermeil, Pneumol, Montfermeil, France. [Leroy, Sylvie; Venissac, Nicolas; Santini, Joseph] Univ Cote Azur, CHU Nice, Pneumol, Chirurg Thorac,Oto Rhino Laryngol, Nice, France. [Tresallet, Christophe] Univ Paris 6 Pierre & Marie Curie, Hop La Pitie Salpetriere, AP HP, Chirurg Digest & Endocrinienne, Paris, France. [Dutau, Herve] Hop Univ Nord, AP HM, Pneumol, Marseille, France. [Sebbane, Georges] Univ Paris 13, Sorbonne Paris Cite, Hop Avicenne,AP HP, Hop Univ Paris Seine St Denis,Geriatr,UFR Sante M, Bobigny, France. [d'Audiffret, Alexandre C.] West Virginia Univ, Div Vasc Surg, Morgantown, WV 26506 USA. [Vicaut, Eric] Univ Paris Diderot, Hop St Louis Lariboisiere Fernand Widal, AP HP, Unite Rech Clin, Paris, France. C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); Ecole Nationale Veterinaire d'Alfort (ENVA); Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Universite Cote d'Azur; CHU Nice; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; West Virginia University; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Hopital Universitaire Saint-Louis - APHP RP Martinod, E (corresponding author), Univ Paris 13, AP HP, Dept Chirurg Thorac & Vasc, 125 Rue Stalingrad, F-93009 Bobigny, France. EM emmanuel.martinod@aphp.fr RI ; Uzunhan, Yurdagul/P-5437-2017; Petite, Herve/E-3478-2016 OI ROUARD, Hélène/0000-0003-0711-2999; Uzunhan, Yurdagul/0000-0002-1607-1407; Radu, Dana/0000-0002-9004-4271; TRESALLET, Christophe/0000-0001-5406-8981; Valeyre, dominique/0000-0003-4470-1776; Guiraudet, Patrice/0000-0001-7506-9713; FU Direction de la Recherche Clinique at Assistance Publique-Hopitaux de Paris FX Funding for the study was provided by the Direction de la Recherche Clinique at Assistance Publique-Hopitaux de Paris. CR Abouarab AA, 2017, ANN THORAC CARDIOVAS, V23, P66, DOI 10.5761/atcs.ra.16-00251 Albain KS, 2009, LANCET, V374, P379, DOI 10.1016/S0140-6736(09)60737-6 Chiang T, 2016, ANN OTO RHINOL LARYN, V125, P873, DOI 10.1177/0003489416656646 Chouillard E, 2016, SURG ENDOSC, V30, P4742, DOI 10.1007/s00464-016-4815-z Claesson-Welsh L, 2016, LANCET, V387, P942, DOI 10.1016/S0140-6736(16)00520-1 Coraux Christelle, 2008, Proc Am Thorac Soc, V5, P689, DOI 10.1513/pats.200801-010AW Delaere P, 2016, J THORAC DIS, V8, pS186, DOI 10.3978/j.issn.2072-1439.2016.01.85 Delaere P, 2010, NEW ENGL J MED, V362, P138, DOI 10.1056/NEJMoa0810653 Delaere PR, 2014, NEW ENGL J MED, V370, P1568, DOI 10.1056/NEJMc1315273 Elliott MJ, 2012, LANCET, V380, P994, DOI 10.1016/S0140-6736(12)60737-5 Fabre D, 2013, ANN THORAC SURG, V96, P1146, DOI 10.1016/j.athoracsur.2013.05.073 Gonfiotti A, 2014, LANCET, V383, P238, DOI 10.1016/S0140-6736(13)62033-4 Grillo H.C., 2004, Surgery of the trachea and bronchi, P839 Hamilton NJ, 2015, AM J TRANSPLANT, V15, P2750, DOI 10.1111/ajt.13318 Jungebluth P, 2016, LANCET, V387, P944 Jungebluth P, 2011, LANCET, V378, P1997, DOI 10.1016/S0140-6736(11)61715-7 Kanemaru SI, 2010, ACTA OTO-LARYNGOL, V130, P79, DOI 10.3109/00016489.2010.496462 Macchiarini P, 2008, LANCET, V372, P2023, DOI 10.1016/S0140-6736(08)61598-6 Mansour Z, 2009, ANN THORAC SURG, V88, P1737, DOI 10.1016/j.athoracsur.2009.07.016 Martinod E, 2000, CR ACAD SCI III-VIE, V323, P455, DOI 10.1016/S0764-4469(00)00150-5 Martinod E, 2005, ANN THORAC SURG, V79, P942, DOI 10.1016/j.athoracsur.2004.08.035 Martinod E, 2003, ANN THORAC SURG, V75, P1572, DOI 10.1016/S0003-4975(03)00120-6 Martinod E, 1999, PRESSE MED, V28, P1638 Martinod E, 2001, J THORAC CARDIOV SUR, V122, P197, DOI 10.1067/mtc.2001.114346 Martinod E, 2017, ANN THORAC SURG, V103, P1631, DOI 10.1016/j.athoracsur.2016.11.027 Martinod E, 2013, EUR J MED RES, V18, DOI 10.1186/2047-783X-18-25 Martinod E, 2011, ANN THORAC SURG, V91, P837, DOI 10.1016/j.athoracsur.2010.11.013 McCulloch P, 2009, LANCET, V374, P1105, DOI 10.1016/S0140-6736(09)61116-8 Oman K, 2005, ANN OTO RHINOL LARYN, V114, P429 Radu DM, 2010, ANN THORAC SURG, V90, P252, DOI 10.1016/j.athoracsur.2010.03.079 Seder CW, 2016, ANN THORAC SURG, V101, P1646, DOI 10.1016/j.athoracsur.2016.02.099 Seguin A, 2006, ANN THORAC SURG, V81, P1068, DOI 10.1016/j.athoracsur.2005.07.079 Seguin A, 2013, J THORAC CARDIOV SUR, V145, P1297, DOI 10.1016/j.jtcvs.2012.09.079 Seguin A, 2009, ANN THORAC SURG, V87, P861, DOI 10.1016/j.athoracsur.2008.11.038 Steinke M, 2015, TISSUE ENG PT A, V21, P573, DOI [10.1089/ten.tea.2014.0200, 10.1089/ten.TEA.2014.0200] Tan Q, 2017, J THORAC DIS, V9, P22, DOI 10.21037/jtd.2017.01.50 Teixeira da Silva Jaime A, 2017, Indian J Med Ethics, V2, P270, DOI [10.20529/ijme.2017.048, 10.20529/IJME.2017.048] Weiss DJ, 2014, CYTOTHERAPY, V16, P1601, DOI 10.1016/j.jcyt.2014.10.012 Wurtz A, 2006, NEW ENGL J MED, V355, P1938, DOI 10.1056/NEJMc066336 Wurtz A, 2010, J THORAC CARDIOV SUR, V140, P387, DOI 10.1016/j.jtcvs.2010.01.043 NR 40 TC 106 Z9 120 U1 1 U2 26 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUN 5 PY 2018 VL 319 IS 21 BP 2212 EP 2222 DI 10.1001/jama.2018.4653 PG 11 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA GI1MA UT WOS:000434133400019 PM 29800033 OA Bronze DA 2026-04-17 ER PT J AU Rupa-Matysek, J Lembicz, M Rogowska, EK Gil, L Komarnicki, M Batura-Gabryel, H AF Rupa-Matysek, Joanna Lembicz, Marta Rogowska, Eliza Katarzyna Gil, Lidia Komarnicki, Mieczyslaw Batura-Gabryel, Halina TI Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients SO MEDICAL ONCOLOGY LA English DT Article DE Lung cancer; Venous thromboembolism; Venous thromboembolism risk assessment models; COMPASS; CAT model ID PATIENTS RECEIVING CHEMOTHERAPY; CHRONIC KIDNEY-DISEASE; AMBULATORY PATIENTS; ATRIAL-FIBRILLATION; AMERICAN SOCIETY; KHORANA SCORE; EVENTS; PROPHYLAXIS; VALIDATION; THROMBOSIS AB The aim of the study was to investigate the prognostic significance of selected risk assessment models (RAMs) for predicting venous thromboembolism (VTE) events in patients undergoing outpatient chemotherapy for lung cancer. We evaluated the following VTE-risk assessment tools: Khorana risk score (KRS), PROTECHT score, CONKO score and COMPASS-cancer-associated thrombosis score (COMPASS-CAT). Retrospective analyses were performed on 118 patients with lung cancer, 20 of whom developed VTE with a median of 2.5 months from diagnosis. Patients receiving gemcitabine-based regimen (25%), patients with a history of atrial fibrillation (AF) and patients with chronic kidney disease developed VTE more often than other patients. In the multivariate analysis, high COMPASS-CAT score (OR 8.73; 95% CI 1.01-75.22, P = 0.049), gemcitabine chemotherapy (OR 3.37; 95% CI 1.09-10.39, P = 0.035) and AF (OR 7.19; 95% CI 1.89-27.33, P = 0.004) were all significantly associated with VTE development. VTE occurred in; 13% (n = 2) of the KRS high-risk group, 17.7% (n = 11) of the PROTECHT high-risk group, 15% (n = 4) of the CONKO high-risk group and 23.8% (n = 20) of the COMPASS-CAT high-risk group (n = 84). Only the COMPASS-CAT score was able to identify 100% of patients who developed VTE, and best discriminated between patients with high and low risk of VTE development (C statistic 0.89). The ROC analysis indicated a cutoff value of 11 points (95% CI 0.821-0.962) for COMPASS-CAT for VTE development in patients with lung cancer. In conclusion, in our study of all the VTE-RAMs analyzed, the COMPASS-CAT model was the most accurate predictor of VTE development in patients with lung cancer. C1 [Rupa-Matysek, Joanna; Gil, Lidia; Komarnicki, Mieczyslaw] Poznan Univ Med Sci, Dept Hematol & Bone Marrow Transplantat, Szamarzewskiego 84, PL-60569 Poznan, Poland. [Lembicz, Marta; Batura-Gabryel, Halina] Poznan Univ Med Sci, Dept Pulmonol Allergol & Resp Oncol, Poznan, Poland. [Rogowska, Eliza Katarzyna] Poznan Univ Med Sci, Students Sci Soc, Poznan, Poland. C3 Poznan University of Medical Sciences; Poznan University of Medical Sciences; Poznan University of Medical Sciences RP Rupa-Matysek, J (corresponding author), Poznan Univ Med Sci, Dept Hematol & Bone Marrow Transplantat, Szamarzewskiego 84, PL-60569 Poznan, Poland. EM rupa.matysek@gmail.com RI ; Rupa-Matysek, Joanna/ABN-9634-2022 OI Lembicz, Marta/0000-0002-1545-4983; Rupa-Matysek, Joanna/0000-0003-1585-6410 CR Agnelli G, 2012, NEW ENGL J MED, V366, P601, DOI 10.1056/NEJMoa1108898 [Anonymous], VERS 1 [Anonymous], 2016, EUR J CARDIO-THORAC, DOI [DOI 10.1093/ejcts/ezw313, 10.1093/ejcts/ezw313] Ashrani AA, 2016, THROMB RES, V139, P29, DOI 10.1016/j.thromres.2016.01.002 Barni S, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-179 CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8 Cheung KL, 2017, AM J KIDNEY DIS, V70, P182, DOI 10.1053/j.ajkd.2016.10.039 Chew HK, 2006, ARCH INTERN MED, V166, P458 Colinet B, 2005, BRIT J CANCER, V93, P1098, DOI 10.1038/sj.bjc.6602836 Connolly GC, 2012, LUNG CANCER, V78, P253, DOI 10.1016/j.lungcan.2012.09.007 Dasanu CA, 2008, EXPERT OPIN DRUG SAF, V7, P703, DOI 10.1517/14740330802374262 Di Nisio M, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008500.pub4 Ek L, 2018, ANN ONCOL, V29, P398, DOI 10.1093/annonc/mdx716 Enga KF, 2015, J THROMB HAEMOST, V13, P10, DOI 10.1111/jth.12762 Farge D, 2016, LANCET ONCOL, V17, pE452, DOI 10.1016/S1470-2045(16)30369-2 Gerotziafas GT, 2017, ONCOLOGIST, V22, P1222, DOI 10.1634/theoncologist.2016-0414 Goldstraw Peter, 2007, J Thorac Oncol, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a Huang H, 2012, J THROMB THROMBOLYS, V34, P446, DOI 10.1007/s11239-012-0741-7 January CT, 2014, CIRCULATION, V130, pE270, DOI 10.1161/CIR.0000000000000142 Jemal Ahmedin., 2009, CA Cancer J Clin, V59, P1, DOI 10.3322/caac.21708 Khorana AA, 2007, J THROMB HAEMOST, V5, P632, DOI 10.1111/j.1538-7836.2007.02374.x Khorana AA, 2008, BLOOD, V111, P4902, DOI 10.1182/blood-2007-10-116327 Khorana AA, 2013, CLINICOECONOMIC OUTC, V5, P101, DOI 10.2147/CEOR.S39964 Khorana AA, 2013, CANCER-AM CANCER SOC, V119, P648, DOI 10.1002/cncr.27772 Königsbrügge O, 2014, THROMB RES, V134, P44, DOI 10.1016/j.thromres.2014.04.002 Kooiman J, 2013, J THROMB HAEMOST, V11, P1968, DOI 10.1111/jth.12411 Kourelis TV, 2014, LUNG CANCER, V86, P358, DOI 10.1016/j.lungcan.2014.10.003 Lyman GH, 2014, J CLIN ONCOL, V32, P1365, DOI 10.1200/JCO.2013.54.1177 Lyman GH, 2013, J CLIN ONCOL, V31, P2189, DOI 10.1200/JCO.2013.49.1118 Macbeth F, 2016, J CLIN ONCOL, V34, P488, DOI 10.1200/JCO.2015.64.0268 Mandalà M, 2011, ANN ONCOL, V22, pvi85, DOI 10.1093/annonc/mdr392 Mansfield AS, 2016, J THROMB HAEMOST, V14, P1773, DOI 10.1111/jth.13378 Mellema WW, 2014, LUNG CANCER, V86, P73, DOI 10.1016/j.lungcan.2014.07.017 Numico G, 2005, CANCER, V103, P994, DOI 10.1002/cncr.20893 Ording AG, 2017, CANCER MED-US, V6, P1165, DOI 10.1002/cam4.1054 Pelzer U, 2013, DEUT MED WOCHENSCHR, V138, P2084, DOI 10.1055/s-0033-1349608 Pritchard ER, 2019, J ONCOL PHARM PRACT, V25, P52, DOI 10.1177/1078155217726158 Shen Q, 2017, J THORAC DIS, V9, P5068, DOI 10.21037/jtd.2017.11.116 Tagalakis V, 2007, J THORAC ONCOL, V2, P729, DOI 10.1097/JTO.0b013e31811ea275 van Es N, 2017, THROMB RES, V150, P30, DOI 10.1016/j.thromres.2016.12.013 van Es N, 2017, HAEMATOLOGICA, V102, P1494, DOI 10.3324/haematol.2017.169060 Verso M, 2012, INTERN EMERG MED, V7, P291, DOI 10.1007/s11739-012-0784-y NR 42 TC 43 Z9 52 U1 0 U2 16 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1357-0560 EI 1559-131X J9 MED ONCOL JI Med. Oncol. PD MAY PY 2018 VL 35 IS 5 AR 63 DI 10.1007/s12032-018-1120-9 PG 10 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA GD6JL UT WOS:000430615100005 PM 29616356 OA Green Submitted, hybrid DA 2026-04-17 ER PT J AU Geller, AD Zheng, H Mathisen, DJ Wright, CD Lanuti, M AF Geller, Abraham D. Zheng, Hui Mathisen, Douglas J. Wright, Cameron D. Lanuti, Michael TI Relative incremental costs of complications of lobectomy for stage I non-small cell lung cancer SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article; Proceedings Paper CT 43rd Annual Meeting of the Western-Thoracic-Surgical-Association CY JUN 21-24, 2017 CL Colorado Springs, CO SP Western Thorac Surg Assoc DE cost; surgical outcomes; lung cancer; lobectomy ID ASSISTED THORACOSCOPIC SURGERY; PATHWAY REDUCES DURATION; OPEN PULMONARY LOBECTOMY; ATRIAL-FIBRILLATION; THORACIC-SURGERY; AIR LEAKS; RESECTION; QUALITY; PREVENTION; TRIAL AB Objective: To evaluate the relative incremental cost of complications after lobectomy for stage I non-small cell lung cancer (NSCLC). Methods: Patients treated with open or video-assisted thoracoscopic surgery (VATS) lobectomy for stage I NSCLC between 2008 and 2014 were selected. A patient registry was queried for all complications recorded during a 90-day postoperative interval. Hospital cost data for each patient was concatenated with clinical data. Linear regression was used to assess the impact on direct hospital costs of specific complications. Results: Among the 488 patients included in this study, 34% experienced >= 1 complication and 17% experienced >= 1 major complication. In patients experiencing complications, atrial arrhythmia (13%), prolonged air leak (8.6%), atelectasis (6.4%), and transfusion requirement (4.5%) were most common. Minor complications increased the relative cost of lobectomy by 29% (95% confidence interval [CI], 23%-34%; P < .001) compared to the cost of an uncomplicated lobectomy. Major complications increased costs by 57% (95% CI, 53%-62%; P < .001). The greatest predictor of increased 90-day cost was major pulmonary complications, which increased cost by 111% (95% CI, 96%-126%; P < .001). Prolonged air leak increased relative mean cost by 22% (95% CI, 10%-33%; P < .001) and pneumonia by 96% (95% CI, 75%-117%; P < .001). Conclusions: Complications, both major and minor, contribute significantly to the total 90-day direct hospital cost of lobectomy for stage I NSCLC. Analysis of 90-day postoperative outcomes more accurately captures costs. Major pulmonary complications, atrial arrhythmia, pneumonia, and prolonged air leak represent 4 high-yield targets for cost reduction. Efforts to control health care spending while improving patient outcomes might optimally focus on reducing complications that incur the greatest relative incremental cost. C1 [Geller, Abraham D.] Harvard Med Sch, Boston, MA USA. [Geller, Abraham D.; Mathisen, Douglas J.; Wright, Cameron D.; Lanuti, Michael] Massachusetts Gen Hosp, Div Thorac Surg, Boston, MA 02114 USA. [Zheng, Hui] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. C3 Harvard University; Harvard Medical School; Harvard University; Harvard University Medical Affiliates; Massachusetts General Hospital; Harvard University; Harvard University Medical Affiliates; Massachusetts General Hospital RP Lanuti, M (corresponding author), 55 Fruit St,Founders 7, Boston, MA 02114 USA. EM mlanuti@mgh.harvard.edu FU Harvard Catalyst, the Harvard Clinical and Translational Science Center; National Center for Research Resources; National Center for Advancing Translational Sciences; National Institutes of Health [8UL1TR000170-05]; Harvard University and its affiliated academic health care centers FX The statistical analysis in this study was funded by Harvard Catalyst, the Harvard Clinical and Translational Science Center, the National Center for Research Resources, National Center for Advancing Translational Sciences, and the National Institutes of Health (Grant 8UL1TR000170-05), as well as financial contributions from Harvard University and its affiliated academic health care centers. CR Allen MS, 2004, ANN THORAC SURG, V77, P1792, DOI 10.1016/j.athoracsur.2003.10.049 Birkmeyer JD, 2012, ANN SURG, V255, P1, DOI 10.1097/SLA.0b013e3182402c17 Boffa DJ, 2014, J THORAC CARDIOV SUR, V148, P637, DOI 10.1016/j.jtcvs.2013.12.045 Brunelli A, 2017, J THORAC CARDIOV SUR, V154, P2084, DOI 10.1016/j.jtcvs.2017.06.037 Brunelli A, 2017, EUR J CARDIO-THORAC, V51, P230, DOI 10.1093/ejcts/ezw307 Brunt LM, 2015, SURGERY, V158, P908 Cardinale D, 2007, CIRCULATION, V115, P1339, DOI 10.1161/CIRCULATIONAHA.106.647008 Cardinale D, 2016, ANN SURG, V264, P244, DOI 10.1097/SLA.0000000000001626 Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000 Dimick JB, 2004, J AM COLL SURGEONS, V199, P531, DOI 10.1016/j.jamcollsurg.2004.05.276 Dimick JB, 2003, J AM COLL SURGEONS, V196, P671, DOI 10.1016/S1072-7515(03)00122-4 Droghetti A, 2006, J THORAC CARDIOV SUR, V132, P556, DOI 10.1016/j.jtcvs.2006.05.033 Elrakhawy HM, 2014, HEART SURG FORUM, V17, pE308, DOI 10.1532/HSF98.2014412 Falcoz PE, 2016, EUR J CARDIO-THORAC, V49, P602, DOI 10.1093/ejcts/ezv154 Farjah F, 2014, ANN THORAC SURG, V98, P191, DOI 10.1016/j.athoracsur.2014.03.024 Fiore JF Jr, 2016, J THORAC CARDIOV SUR, V151, P708, DOI 10.1016/j.jtcvs.2015.09.112 Handy JR, 2011, ANN THORAC SURG, V91, P234, DOI 10.1016/j.athoracsur.2010.08.043 Howington JA, 2012, CHEST, V141, P429, DOI 10.1378/chest.10-3013 Jawitz OK, 2016, SEMIN THORAC CARDIOV, V28, P531, DOI 10.1053/j.semtcvs.2016.06.001 Kazaure HS, 2014, JAMA SURG, V149, P914, DOI 10.1001/jamasurg.2014.1216 Kosinski S, 2016, ANAESTH INTENSIVE TH, V48, P280, DOI 10.5603/AIT.2016.0059 Lapar DJ, 2013, ANN THORAC SURG, V96, P1621, DOI 10.1016/j.athoracsur.2013.05.050 Liberman M, 2010, ANN THORAC SURG, V89, P891, DOI 10.1016/j.athoracsur.2009.12.012 Madani A, 2015, SURGERY, V158, P899, DOI 10.1016/j.surg.2015.04.046 McKenna RJ, 1996, ANN THORAC SURG, V61, P1115, DOI 10.1016/0003-4975(96)00034-3 Muñoz E, 2010, ANN SURG, V251, P195, DOI 10.1097/SLA.0b013e3181cbcc9a Riber LP, 2014, ANN THORAC SURG, V98, P1989, DOI 10.1016/j.athoracsur.2014.06.069 Swanson SJ, 2012, ANN THORAC SURG, V93, P1027, DOI 10.1016/j.athoracsur.2011.06.007 Tisdale JE, 2009, ANN THORAC SURG, V88, P886, DOI 10.1016/j.athoracsur.2009.04.074 NR 29 TC 28 Z9 29 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 EI 1097-685X J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD APR PY 2018 VL 155 IS 4 BP 1804 EP 1811 DI 10.1016/j.jtcvs.2017.11.025 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA FZ5LL UT WOS:000427633800106 PM 29254638 OA Bronze DA 2026-04-17 ER PT J AU Kelsey, KT Wiencke, JK AF Kelsey, Karl T. Wiencke, John K. TI Immunomethylomics: A Novel Cancer Risk Prediction Tool SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Article; Proceedings Paper CT 60th Annual Thomas L. Petty Aspen Lung Conference on Environment and Global Lung Health - Exposure, Susceptibility, and Intervention CY JUN 07-10, 2017 CL Aspen, CO DE immunology; cancer; methylation; epidemiology ID SQUAMOUS-CELL CARCINOMA; REGULATORY T-CELLS; SUPPRESSOR-CELLS; LYMPHOCYTE RATIO; DNA METHYLATION; LUNG-CANCER; PERIPHERAL-CIRCULATION; NEUTROPHIL/LYMPHOCYTE RATIO; ATRIAL-FIBRILLATION; SOMATIC-CELLS AB There is emerging evidence that the immune biology associated with lung and other solid tumors, as well as patient immune genetic traits, contributes to individual survival. At this time, dramatic advances in immunologic approaches to the study and management of human cancers are taking place, including lung and head and neck squamous cell carcinoma. However, major obstacles for therapies are the profound immune alterations in blood and in the tumor microenvironment that arise in tandem with the cancer. Although there is a significant current effort underway across the cancer research community to probe the tumor environment to uncover the dynamics of the immune response, little similar work is being done to understand the dynamics of immune alterations in peripheral blood, despite evidence showing the prognostic relevance of the neutrophil/lymphocyte ratio for these cancers. A prominent feature of cancer-associated inflammation is the generation of myeloid-derived suppressor cells, which arise centrally in bone marrow myelopoiesis and peripherally in response to tumor factors. Two classes of myeloid-derived suppressor cells are recognized: granulocytic and monocytic. To date, such immune factors have not been integrated into molecular classification or prognostication. Here, we advocate for a more complete characterization of patient immune profiles, using DNA from archival peripheral blood after application of methylation profiling (immunomethylomics). At the heart of this technology are cell libraries of differentially methylated regions that provide the "fingerprints" of immune cell subtypes. Going forward, opportunities exist to explore aberrant immune profiles in the context of cancer-associated inflammation, potentially adding significantly to prognostic and mechanistic information for solid tumors. C1 [Kelsey, Karl T.] Brown Univ, Dept Epidemiol, Providence, RI 02912 USA. [Kelsey, Karl T.] Brown Univ, Dept Pathol, Providence, RI 02912 USA. [Kelsey, Karl T.] Brown Univ, Dept Lab Med, Providence, RI 02912 USA. [Wiencke, John K.] Univ Calif San Francisco, Dept Neurol Surg, Inst Human Genet, San Francisco, CA USA. C3 Brown University; Brown University; Brown University; University of California System; University of California San Francisco RP Kelsey, KT (corresponding author), Brown Univ, 70 Ship St, Providence, RI 02912 USA. EM Karl_Kelsey@Brown.edu RI Kelsey, Karl/I-1252-2014 FU National Institutes of Health [1R01CA207360, CA207110]; National Cancer Institute [R01CA207360] Funding Source: NIH RePORTER FX Supported by National Institutes of Health grants 1R01CA207360 (J.K.W.) and CA207110 (K.T.K.). CR Accomando WP, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-3-r50 Accomando WP, 2012, CLIN CANCER RES, V18, P6147, DOI 10.1158/1078-0432.CCR-12-1008 Adah D, 2016, PHARMACOL RES, V110, P25, DOI 10.1016/j.phrs.2016.05.007 Anagnostou V, 2017, CANCER DISCOV, V7, P264, DOI 10.1158/2159-8290.CD-16-0828 Ashworth AB, 2014, CLIN LUNG CANCER, V15, P346, DOI 10.1016/j.cllc.2014.04.003 Avci A, 2014, SCAND CARDIOVASC J, V48, P202, DOI 10.3109/14017431.2014.932922 Bakulski KM, 2016, EPIGENETICS-US, V11, P354, DOI 10.1080/15592294.2016.1161875 Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102 Bocker MT, 2011, BLOOD, V117, pE182, DOI 10.1182/blood-2011-01-331926 Böttcher A, 2013, AURIS NASUS LARYNX, V40, P216, DOI 10.1016/j.anl.2012.07.004 Boland MJ, 2014, CIRC RES, V115, P311, DOI 10.1161/CIRCRESAHA.115.301517 Bozbay M, 2015, J CRIT CARE, V30, P822, DOI 10.1016/j.jcrc.2015.04.115 Califano JA, 2015, CLIN CANCER RES, V21, P30, DOI 10.1158/1078-0432.CCR-14-1716 Calvanese V, 2012, NUCLEIC ACIDS RES, V40, P116, DOI 10.1093/nar/gkr685 Chen C, 2014, INT IMMUNOPHARMACOL, V18, P255, DOI 10.1016/j.intimp.2013.12.004 Chikamatsu K, 2012, CANCER SCI, V103, P976, DOI 10.1111/j.1349-7006.2012.02248.x Christensen BC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000602 Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322 Crane CA, 2014, P NATL ACAD SCI USA, V111, P12823, DOI 10.1073/pnas.1413933111 Czystowska M, 2013, CLIN CANCER RES, V19, P889, DOI 10.1158/1078-0432.CCR-12-2191 De Costa AMA, 2012, CANCER IMMUNOL IMMUN, V61, P927, DOI 10.1007/s00262-011-1154-8 Drennan S, 2013, IMMUNOLOGY, V140, P335, DOI 10.1111/imm.12144 Dumitru CA, 2013, SEMIN CANCER BIOL, V23, P141, DOI 10.1016/j.semcancer.2013.02.005 Dumitru CA, 2012, J LEUKOCYTE BIOL, V91, P591, DOI 10.1189/jlb.0411193 Eruslanov EB, 2017, CANCER IMMUNOL IMMUN, V66, P997, DOI 10.1007/s00262-017-1976-0 Ferris RL, 2015, J CLIN ONCOL, V33, P3293, DOI 10.1200/JCO.2015.61.1509 Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506 Green VL, 2013, CANCER IMMUNOL IMMUN, V62, P863, DOI 10.1007/s00262-013-1395-9 Guthrie GJK, 2013, CRIT REV ONCOL HEMAT, V88, P218, DOI 10.1016/j.critrevonc.2013.03.010 Hagerling C, 2015, TRENDS CELL BIOL, V25, P214, DOI 10.1016/j.tcb.2014.11.001 Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013 Hawkins RD, 2010, CELL STEM CELL, V6, P479, DOI 10.1016/j.stem.2010.03.018 Houseman E Andres, 2015, Curr Environ Health Rep, V2, P145, DOI [10.1007/s40572-015-0050-3, 10.1007/s40572-015-0050-3] Houseman EA, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0527-y Houseman EA, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-86 Ji H, 2010, NATURE, V467, P338, DOI 10.1038/nature09367 Kim S, 2016, EPIGENOMICS-UK, V8, P1185, DOI 10.2217/epi-2016-0037 Koestler DC, 2017, CANCER EPIDEM BIOMAR, V26, P328, DOI 10.1158/1055-9965.EPI-16-0461 Koestler DC, 2013, EPIGENETICS-US, V8, P816, DOI 10.4161/epi.25430 Koinis F, 2016, J THORAC ONCOL, V11, P1263, DOI 10.1016/j.jtho.2016.04.026 Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248 Laurent L, 2010, GENOME RES, V20, P320, DOI 10.1101/gr.101907.109 Lay FD, 2014, GENOME RES, V24, P545, DOI 10.1101/gr.166439.113 LEE MY, 1984, BLOOD, V64, P499 Li XD, 2015, TRENDS IMMUNOL, V36, P344, DOI 10.1016/j.it.2015.04.006 Linsley PS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138726 Lukesova E, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/303929 Munder M, 2006, BLOOD, V108, P1627, DOI 10.1182/blood-2006-11-010389 Naito T, 2013, IMMUNOLOGY, V139, P151, DOI 10.1111/imm.12058 Nazor KL, 2012, CELL STEM CELL, V10, P620, DOI 10.1016/j.stem.2012.02.013 Oberlies J, 2009, J IMMUNOL, V182, P5259, DOI 10.4049/jimmunol.0803523 Oguejiofor K, 2015, BRIT J CANCER, V113, P886, DOI 10.1038/bjc.2015.277 Pan D, 2016, CELL SIGNAL, V28, P1923, DOI 10.1016/j.cellsig.2016.09.008 Parker KH, 2015, ADV CANCER RES, V128, P95, DOI 10.1016/bs.acr.2015.04.002 Partlová S, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/21624011.2014.965570 Peng B, 2015, INT J CLIN EXP MED, V8, P3098 Perisanidis C, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0334-5 Pogoda K, 2016, ONCOL LETT, V12, P4785, DOI 10.3892/ol.2016.5273 Qian X, 2015, CRIT REV ONCOL HEMAT, V95, P337, DOI 10.1016/j.critrevonc.2015.03.009 Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443 Remark R, 2015, AM J RESP CRIT CARE, V191, P377, DOI 10.1164/rccm.201409-1671PP Rieber N, 2013, CLIN EXP IMMUNOL, V174, P45, DOI 10.1111/cei.12143 Rodriguez PC, 2009, CANCER RES, V69, P1553, DOI 10.1158/0008-5472.CAN-08-1921 Romano E, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0059-z Roy S, 2013, P NATL ACAD SCI USA, V110, P4598, DOI 10.1073/pnas.1218682110 Saliba W, 2015, J THROMB HAEMOST, V13, P1971, DOI 10.1111/jth.13006 Schaefer C, 2005, BRIT J CANCER, V92, P913, DOI 10.1038/sj.bjc.6602407 Schmielau J, 2001, CANCER RES, V61, P4756 Seiwert TY, 2016, LANCET ONCOL, V17, P956, DOI 10.1016/S1470-2045(16)30066-3 Serafini P, 2006, SEMIN CANCER BIOL, V16, P53, DOI 10.1016/j.semcancer.2005.07.005 Shao QM, 2015, ARCH MED RES, V46, P199, DOI 10.1016/j.arcmed.2015.03.011 Sudo K, 2000, J EXP MED, V192, P1273, DOI 10.1084/jem.192.9.1273 Templeton AJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju124 Toker A, 2013, J IMMUNOL, V190, P3180, DOI 10.4049/jimmunol.1203473 Trellakis S, 2011, INT J CANCER, V129, P2183, DOI 10.1002/ijc.25892 Turksma AW, 2013, ORAL DIS, V19, P577, DOI 10.1111/odi.12037 Ueda Y, 2005, J EXP MED, V201, P1771, DOI 10.1084/jem.20041419 Varilla V, 2013, EXPERT OPIN BIOL TH, V13, P1241, DOI 10.1517/14712598.2013.810716 Vasquez-Dunddel D, 2013, J CLIN INVEST, V123, P1580, DOI 10.1172/JCI60083 Verdoia M, 2015, DIABETES METAB, V41, P304, DOI 10.1016/j.diabet.2015.01.001 Verdoia M, 2016, ANGIOLOGY, V67, P75, DOI 10.1177/0003319715577529 Wang WJ, 2013, ASIAN PAC J CANCER P, V14, P4671, DOI 10.7314/APJCP.2013.14.8.4671 Weed DT, 2015, CLIN CANCER RES, V21, P39, DOI 10.1158/1078-0432.CCR-14-1711 Wiencke JK, 2016, EPIGENETICS-US, V11, P363, DOI 10.1080/15592294.2016.1163454 Zhao L, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0461-7 NR 85 TC 13 Z9 15 U1 0 U2 5 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD APR PY 2018 VL 15 SU 2 BP S76 EP S80 DI 10.1513/AnnalsATS.201706-477MG PG 5 WC Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S) SC Respiratory System GA GD4SF UT WOS:000430492200004 PM 29676642 DA 2026-04-17 ER PT J AU Moore, JC Trager, L Anzia, LE Saliba, W Bassiouny, M Bhargava, M Chung, M Desai, M Garberich, R Lever, H Lindsay, BD Sengupta, J Tchou, P Wazni, O Wilkoff, BL AF Moore, JoEllyn C. Trager, Lena Anzia, Lucille E. Saliba, Walid Bassiouny, Mohamed Bhargava, Mandeep Chung, Mina Desai, Milind Garberich, Ross Lever, Harry Lindsay, Bruce D. Sengupta, Jay Tchou, Patrick Wazni, Oussama Wilkoff, Bruce L. TI Dofetilide for suppression of atrial fibrillation in hypertrophic cardiomyopathy: A case series and literature review SO PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY LA English DT Review DE antiarrhythmic drug; atrial fibrillation; dofetilide; hypertrophic cardiomyopathy; rhythm control ID MULTICENTER EVALUATIVE RESEARCH; LEFT-VENTRICULAR DYSFUNCTION; SINUS RHYTHM; CATHETER ABLATION; ORAL DOFETILIDE; EFFICACY; SOTALOL; AMIODARONE; SAFETY; MORTALITY AB BackgroundLimited medical options are available for rhythm control in patients with atrial fibrillation (AF) and hypertrophic cardiomyopathy (HCM). There are no published reports of dofetilide use in this population. MethodsA retrospective chart review was conducted on 1,404 patients loaded on dofetilide for AF suppression at the Cleveland Clinic from 2008 to 2012, 25 of whom were found to have HCM. ResultsThe HCM cohort was 32% female, 76% with persistent AF, mean age of 59 10 years, and mean ejection fraction of 54 +/- 9 %. Of the 25 patients, 21 were discharged on dofetilide, three discontinued during loading due to QTc prolongation, and one due to inefficacy. There were no adverse events during loading. Of those discharged on dofetilide, 11/21 (52%) were still on it at a median follow-up of 396 (198, 699) days at the time of the chart review. For those in whom it was discontinued, the median time on the drug was 301 (111, 738) days. Of the 10 patients who discontinued dofetilide during follow-up, six were due to inefficacy, one postablation, one postheart transplant, one due to death secondary to lung cancer, and one due to worsening edema. ConclusionsDofetilide was well tolerated in this group of patients with AF and HCM and it facilitated management of AF in 21/25 (84%) patients. Further research is needed to assess the safety and efficacy of dofetilide in order to develop evidence-based guidelines for the pharmacological management of AF in this population. C1 [Moore, JoEllyn C.; Anzia, Lucille E.; Garberich, Ross; Sengupta, Jay] Minneapolis Heart Inst, Minneapolis, MN USA. [Trager, Lena] Univ Minnesota, Minneapolis, MN USA. [Saliba, Walid; Bassiouny, Mohamed; Bhargava, Mandeep; Chung, Mina; Desai, Milind; Lever, Harry; Lindsay, Bruce D.; Tchou, Patrick; Wazni, Oussama; Wilkoff, Bruce L.] Cleveland Clin, Inst Heart & Vasc, Dept Cardiovasc Med, Cleveland, OH 44106 USA. C3 Minneapolis Heart Institute Foundation; University of Minnesota System; University of Minnesota Twin Cities; Cleveland Clinic Foundation RP Moore, JC (corresponding author), Abbott NW Hosp, Minneapolis Heart Inst, 920 East 28th St,Suite 300, Minneapolis, MN 55407 USA. EM joellyn.moore@allina.com OI Anzia, Lucille/0000-0002-3161-8925 CR Abraham JM, 2015, CIRC-ARRHYTHMIA ELEC, V8, P772, DOI 10.1161/CIRCEP.114.002339 Anand Vidhu, 2016, JACC Clin Electrophysiol, V2, P777, DOI [10.1016/j.jacep.2016.05.007, 10.1016/j.jacep.2016.05.007] [Anonymous], DOFETILIDE MED REV [Anonymous], CLIN THERAPEUT Banchs JE, 2008, J INTERV CARD ELECTR, V23, P111, DOI 10.1007/s10840-008-9290-6 Bassiouny M, 2015, HEART RHYTHM, V12, P1438, DOI 10.1016/j.hrthm.2015.03.042 Brumberg G, 2013, AM J CARDIOL, V112, P505, DOI 10.1016/j.amjcard.2013.04.014 Bunch TJ, 2008, J CARDIOVASC ELECTR, V19, P1009, DOI 10.1111/j.1540-8167.2008.01192.x Campbell TJ, 2000, J AM COLL CARDIOL, V35, p154A Di Donna P, 2010, EUROPACE, V12, P347, DOI 10.1093/europace/euq013 El-Assaad I, 2016, HEART RHYTHM, V13, P2034, DOI 10.1016/j.hrthm.2016.07.016 Gaita F, 2007, AM J CARDIOL, V99, P1575, DOI 10.1016/j.amjcard.2006.12.087 Gersh BJ, 2011, CIRCULATION, V124, P2761, DOI 10.1161/CIR.0b013e318223e230 Greenbaum RA, 1998, CIRCULATION, V98, P633 January CT, 2014, J Am Coll Cardiol, V63, P57 Kim MH, 2011, CLIN THER, V33, P1668, DOI 10.1016/j.clinthera.2011.10.005 Kiticaslan F, 2006, HEART RHYTHM, V3, P275, DOI 10.1016/j.hrthm.2005.11.013 Kober L, 2000, LANCET, V356, P2052, DOI 10.1016/S0140-6736(00)03402-4 Kochiadakis GE, 2000, HEART, V84, P251, DOI 10.1136/heart.84.3.251 Maron BJ, 2014, J AM COLL CARDIOL, V64, P83, DOI 10.1016/j.jacc.2014.05.003 Maron BJ, 2002, JAMA-J AM MED ASSOC, V287, P1308, DOI 10.1001/jama.287.10.1308 MCKENNA WJ, 1981, BRIT HEART J, V46, P173 MCKENNA WJ, 1984, AM J CARDIOL, V54, P802, DOI 10.1016/S0002-9149(84)80212-X Melacini P, 2007, HEART, V93, P708, DOI 10.1136/hrt.2006.099416 Olivotto I, 2001, CIRCULATION, V104, P2517, DOI 10.1161/hc4601.097997 Pedersen HS, 2007, AM J CARDIOL, V100, P876, DOI 10.1016/j.amjcard.2007.04.020 Pedersen OD, 2001, CIRCULATION, V104, P292, DOI 10.1161/01.CIR.104.3.292 Plewan A, 2001, EUR HEART J, V22, P1504, DOI 10.1053/euhj.2000.2546 Prystowsky EN, 2003, J CARDIOVASC ELECTR, V14, pS287, DOI 10.1046/j.1540-8167.2003.90402.x ROBINSON K, 1990, J AM COLL CARDIOL, V15, P1279, DOI 10.1016/S0735-1097(10)80014-2 Sherrid MV, 2005, J AM COLL CARDIOL, V45, P1251, DOI 10.1016/j.jacc.2005.01.012 Singh BN, 2005, NEW ENGL J MED, V352, P1861, DOI 10.1056/NEJMoa041705 Singh S, 2000, CIRCULATION, V102, P2385, DOI 10.1161/01.CIR.102.19.2385 Siontis KC, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001002 TENDERA M, 1993, CARDIOLOGY, V82, P335, DOI 10.1159/000175883 Torp-Pedersen C, 1999, NEW ENGL J MED, V341, P857, DOI 10.1056/NEJM199909163411201 Waldo AL, 1996, LANCET, V348, P7, DOI 10.1016/S0140-6736(96)02149-6 NR 37 TC 23 Z9 26 U1 0 U2 2 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0147-8389 EI 1540-8159 J9 PACE JI PACE-Pacing Clin. Electrophysiol. PD APR PY 2018 VL 41 IS 4 BP 396 EP 401 DI 10.1111/pace.13310 PG 6 WC Cardiac & Cardiovascular Systems; Engineering, Biomedical WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Engineering GA GC9ON UT WOS:000430127800011 PM 29450893 DA 2026-04-17 ER PT J AU Yao, YS Shen, HB Zhou, YJ Yang, ZH Huang, HB AF Yao, Yuanshan Shen, Haibo Zhou, Yinjie Yang, Zhenhua Huang, Hongbo TI Efficacy of thoracoscopic surgery in the treatment of lung cancer in the perioperative period and its effects on serum D-dimer SO ONCOLOGY LETTERS LA English DT Article DE thoracoscopy; lung cancer; perioperative period; serum D-dimer; clinical efficacy ID ASSISTED THORACIC-SURGERY; MUSCLE-SPARING THORACOTOMY; LONG-TERM SURVIVAL; ATRIAL-FIBRILLATION; LOBECTOMY; VATS AB The aim of this study was to investigate the feasibility and safety of thoracoscopic surgery in the treatment of lung cancer and its effect on serum D-dimer. A total of 218 patients with lung cancer treated in the Department of Thoracic Surgery of Ningbo No. 2 Hospital from January 1, 2013 to December 31, 2016, were retrospectively analyzed. Of the 218 patients, 120 patients underwent thoracotomy (thoracotomy group) and 98 patients underwent thoracoscopic surgery (thoracoscopy group). The clinical efficacy in the perioperative period and serum D-dimer level were compared between the two groups. In the present study, the intraoperative blood loss, blood transfusion rate, postoperative hospital stay, thoracic drainage time and volume in the thoracoscopy group were significantly shorter or smaller than those in the thoracotomy group (P< 0.05), but there was no statistically significant difference in the average operation time between the thoracoscopy and the thoracotomy group. The incidence rate from moderate to severe pains in incisions after operation, the use rate of analgesics and the average disappearance time of the pain in incisions in the thoracoscopy were lower than those in the thoracotomy group (P< 0.05). The amount of serum D-dimer immediately after operation in the thoracotomy group was significantly increased compared with that before operation (P< 0.05), but there was no significant increase in the thoracoscopy group. At 24 h after operation, the serum D-dimer level in the two groups was further increased (P< 0.05), and the comparison between the two groups showed that the levels of serum D-dimer in the thoracoscopy group immediately and at 24 h after operation were significantly lower than those in the thoracotomy group (P< 0.05). The incidence rate of postoperative complications in the thoracoscopy was lower than that in the thoracotomy group, but the difference was not statistically significant. Our results show that thoracoscopic surgery is feasible and safe in the treatment of lung cancer. Compared with the thoracotomy group, the intraoperative condition and postoperative recovery have obvious advantages. The postoperative blood of patients is hypercoagulable and D-dimer increased gradually after 24 h. The effect of thoracoscopic surgery on serum D-dimer is relatively less effective. C1 [Yao, Yuanshan; Shen, Haibo; Zhou, Yinjie; Yang, Zhenhua; Huang, Hongbo] Ningbo 2 Hosp, Dept Thorac Surg, 41 Xibei St, Ningbo 315000, Zhejiang, Peoples R China. RP Shen, HB (corresponding author), Ningbo 2 Hosp, Dept Thorac Surg, 41 Xibei St, Ningbo 315000, Zhejiang, Peoples R China. EM abeew4@163.com RI Huang, Hong-bo/AAN-6475-2021 CR Allaix ME, 2014, WORLD J SURG, V38, P976, DOI 10.1007/s00268-013-2336-7 Ay C, 2012, HAEMATOL-HEMATOL J, V97, P1158, DOI 10.3324/haematol.2011.054718 Chen Wanqing, 2010, Zhongguo Fei Ai Za Zhi, V13, P488, DOI 10.3779/j.issn.1009-3419.2010.05.20 Diao DM, 2013, J SURG ONCOL, V108, P34, DOI 10.1002/jso.23339 Flores RM, 2009, J THORAC CARDIOV SUR, V138, P11, DOI 10.1016/j.jtcvs.2009.03.030 Gopaldas RR, 2010, ANN THORAC SURG, V89, P1563, DOI 10.1016/j.athoracsur.2010.02.026 Imperatori Andrea, 2012, J Cardiothorac Surg, V7, P4, DOI 10.1186/1749-8090-7-4 Kuritzky AM, 2015, J AM COLL SURGEONS, V221, P890, DOI 10.1016/j.jamcollsurg.2015.07.001 Laursen LO, 2016, EUR J CARDIO-THORAC, V49, P870, DOI 10.1093/ejcts/ezv205 Muranishi Y, 2017, SURG TODAY, V47, P252, DOI 10.1007/s00595-016-1380-y Nakamura H, 2013, GEN THORAC CARDIOVAS, V61, P127, DOI 10.1007/s11748-012-0185-1 Nwogu CE, 2015, ANN THORAC SURG, V99, P399, DOI 10.1016/j.athoracsur.2014.09.018 Park BJ, 2007, J THORAC CARDIOV SUR, V133, P775, DOI 10.1016/j.jtcvs.2006.09.022 Qi YJ, 2017, J BUON, V22, P462 Spartalis E, 2015, J AM COLL SURGEONS, V221, P890, DOI 10.1016/j.jamcollsurg.2015.07.002 Suzuki M, 2002, J CARDIOVASC SURG, V43, P263 Jemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI [10.1002/cncr.24446, 10.3322/caac.20107] VanDlac AA, 2014, J UROLOGY, V191, P943, DOI 10.1016/j.juro.2013.10.096 Zhang LZ, 2016, J CARDIOVASC PHARM, V67, P351, DOI 10.1097/FJC.0000000000000351 Zhang PP, 2013, EJSO-EUR J SURG ONC, V39, P951, DOI 10.1016/j.ejso.2013.06.008 NR 20 TC 7 Z9 7 U1 0 U2 7 PU SPANDIDOS PUBL LTD PI ATHENS PA POB 18179, ATHENS, 116 10, GREECE SN 1792-1074 EI 1792-1082 J9 ONCOL LETT JI Oncol. Lett. PD APR PY 2018 VL 15 IS 4 BP 4397 EP 4403 DI 10.3892/ol.2018.7839 PG 7 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA GD9HA UT WOS:000430822500047 PM 29552106 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Elbadawi, A Elgendy, IY Ha, LD Baig, B Saad, M Adly, H Ogunbayo, GO Olorunfemi, O Mckillop, MS Maffett, SA AF Elbadawi, Ayman Elgendy, Islam Y. Ha, Le Dung Baig, Basarat Saad, Marwan Adly, Hussain Ogunbayo, Gbolahan O. Olorunfemi, Odunayo Mckillop, Matthew S. Maffett, Scott A. TI In-Hospital Cerebrovascular Outcomes of Patients With Atrial Fibrillation and Cancer (from the National Inpatient Sample Database) SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID CARDIOVASCULAR OUTCOMES; APPENDAGE EXCLUSION; STROKE; RISK; THROMBOEMBOLISM AB Limited data are available regarding the impact of cancer on cerebrovascular accidents in patients with atrial fibrillation (AF). We queried the Nationwide Inpatient Survey Database to identify patients who have diagnostic code for AF. We performed a 1:1 propensity matching based on the CHA(2)DS(2)VASc score and other risk factors between patients with AF who had lung, breast, colon, and esophageal cancer, and those who did not (control). The final cohort included a total of 31,604 patients. The primary outcome of in-hospital cerebrovascular accidents (CVA) was lower in the cancer group than in the control group (4% vs 7%, p < 0.001), but with only a weak association (Phi = 0.067). In-hospital mortality was higher in the cancer group than in the control group (18% vs 11%, p < 0.001; Phi = -0.099). A subgroup analysis according to cancer type showed similar results with a weak association with lower CVA in breast cancer (4% vs 7%; Phi = -0.066, p < 0.001), lung cancer (4% vs 6%; Phi = 0.062, p < 0.001), colon cancer (4% vs 6%; Phi = -0.062, p < 0.001), and esophageal cancer (3% vs 7%; Phi = -0.095, p < 0.001) compared with the control groups. A weak association with higher in-hospital mortality was demonstrated in lung cancer (20% vs 11%; Phi = -0.127, p < 0.001), colon cancer (16% vs 11%; Phi = -0.076, p < 0.001), and esophageal cancer (20% vs 12%; Phi = -0.111, p < 0.001) compared with the control groups, but no significant difference between breast cancer and control groups in mortality (11% vs 11%; Phi = -0.002, p = 0.888). In conclusion, in patients with AF, cancer diagnosis may not add a predictive role for in-hospital CVA beyond the CHADS2VASc score. (C) 2017 Elsevier Inc. All rights reserved. C1 [Elbadawi, Ayman; Ha, Le Dung; Baig, Basarat; Adly, Hussain; Olorunfemi, Odunayo] Rochester Gen Hosp, Dept Internal Med, Rochester, NY 14621 USA. [Elbadawi, Ayman; Saad, Marwan] Ain Shams Univ, Dept Cardiovasc Med, Cairo, Egypt. [Elgendy, Islam Y.; Mckillop, Matthew S.] Univ Florida, Div Cardiovasc Med, Gainesville, FL USA. [Saad, Marwan] Univ Arkansas Med Sci, Dept Cardiovasc Med, Little Rock, AR 72205 USA. [Ogunbayo, Gbolahan O.] Univ Kentucky, Dept Cardiovasc Med, Lexington, KY USA. [Maffett, Scott A.] Ohio State Univ, Dept Cardiovasc Med, Columbus, OH 43210 USA. C3 Rochester General Hospital; Egyptian Knowledge Bank (EKB); Ain Shams University; State University System of Florida; University of Florida; University of Arkansas System; University of Arkansas Medical Sciences; University of Kentucky; University System of Ohio; Ohio State University RP Elbadawi, A (corresponding author), Rochester Gen Hosp, Dept Internal Med, Rochester, NY 14621 USA.; Elbadawi, A (corresponding author), Ain Shams Univ, Dept Cardiovasc Med, Cairo, Egypt. EM Ayman.Elbadawi@rochesterregional.org RI Saad, Marwan/O-8999-2019; Elgendy, Islam/C-3900-2017 OI Elgendy, Islam/0000-0001-9853-7591; McKillop, Matthew/0000-0002-4513-2520; maffett, scott/0000-0002-2905-3080 CR [Anonymous], METHODS APPL AHRQ QU [Anonymous], 2016, EUR J CARDIO-THORAC, DOI [DOI 10.1093/ejcts/ezw313, 10.1093/ejcts/ezw313] Cestari DM, 2004, NEUROLOGY, V62, P2025, DOI 10.1212/01.WNL.0000129912.56486.2B Chin JH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154931 Elbadawi A, 2017, AM J CARDIOL, V120, P953, DOI 10.1016/j.amjcard.2017.06.025 Elbadawi A, 2017, AM J CARDIOL, V119, P2056, DOI 10.1016/j.amjcard.2017.03.037 Erichsen R, 2012, INTERN EMERG MED, V7, P431, DOI 10.1007/s11739-011-0701-9 Farmakis D, 2014, J AM COLL CARDIOL, V63, P945, DOI 10.1016/j.jacc.2013.11.026 Fitzpatrick T, 2017, THROMB RES, V155, P101, DOI 10.1016/j.thromres.2017.05.006 Glotzer TV, 2009, CIRC-ARRHYTHMIA ELEC, V2, P474, DOI 10.1161/CIRCEP.109.849638 Guzzetti S, 2002, CIRCULATION, V106, pE40, DOI 10.1161/01.CIR.0000028399.42411.13 Guzzetti S, 2008, INTERN EMERG MED, V3, P227, DOI 10.1007/s11739-008-0124-4 HCUP Fast Stats, 2021, HCUP fast stats data tools-healthcare cost and utilization project (HCUP) fast stats Ho DE, 2011, J STAT SOFTW, V42 Hu YF, 2013, INT J CARDIOL, V165, P355, DOI 10.1016/j.ijcard.2012.08.036 Imperatori A, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-4 Kono T, 2012, GERIATR GERONTOL INT, V12, P468, DOI 10.1111/j.1447-0594.2011.00796.x Lardaro T, 2015, AM J EMERG MED, V33, P1483, DOI 10.1016/j.ajem.2015.07.033 Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584 Ogunbayo GO, 2017, AM J CARDIOL, V120, P1768, DOI 10.1016/j.amjcard.2017.07.108 Richardson M, 2017, STROKE, V48 Schwarzbach CJ, 2012, STROKE, V43, P3029, DOI 10.1161/STROKEAHA.112.658625 Steiner Claudia, 2002, Eff Clin Pract, V5, P143 Turakhia MP, 2015, CIRC-ARRHYTHMIA ELEC, V8, P1040, DOI 10.1161/CIRCEP.114.003057 Velagapudi P, 2011, SOUTH MED J, V104, P667, DOI 10.1097/SMJ.0b013e3182299e6c NR 25 TC 17 Z9 19 U1 0 U2 2 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 EI 1879-1913 J9 AM J CARDIOL JI Am. J. Cardiol. PD MAR 1 PY 2018 VL 121 IS 5 BP 590 EP 595 DI 10.1016/j.amjcard.2017.11.027 PG 6 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA FX6WI UT WOS:000426227600011 PM 29352566 DA 2026-04-17 ER PT J AU Yang, CFJ Mayne, NR Wang, XF Berry, MF Tong, B Harpole, DH D'Amico, TA Christensen, JD Ready, NE Klapper, JA AF Yang, Chi-Fu Jeffrey Mayne, Nicholas R. Wang, Xiaofei Berry, Mark F. Tong, Betty Harpole, David H., Jr. D'Amico, Thomas A. Christensen, Jared D. Ready, Neal E. Klapper, Jacob A. TI Surgical Outcomes After Neoadjuvant Chemotherapy and Ipilimumab for Non-Small Cell Lung Cancer SO ANNALS OF THORACIC SURGERY LA English DT Article ID 1ST-LINE TREATMENT; PLUS SURGERY; TRIAL; CARBOPLATIN; PACLITAXEL; NIVOLUMAB AB Background. The objective of this study was to evaluate the safety and feasibility of using neoadjuvant chemotherapy plus ipilimumab followed by surgery as a treatment strategy for stage II-IIIA non-small cell lung cancer. Methods. From 2013 to 2017, postoperative data from patients who underwent surgery after neoadjuvant chemotherapy plus ipilimumab in the TOP1201 trial, an open label phase II trial (NCT01820754), were prospectively collected. The surgical outcomes from TOP1201 were compared with outcomes in a historical cohort of patients receiving standard preoperative chemotherapy followed by surgery identified from our institution's prospectively collected thoracic surgery database. Results. In the TOP1201 trial, 13 patients were treated with preoperative chemotherapy and ipilimumab followed by surgery. In the historical cohort, 42 patients received preoperative chemotherapy by a platinum doublet regimen preoperative chemotherapy by a platinum doublet regimen without ipilimumab followed by lobectomy or pneumonectomy. The 30-day mortality in both groups was 0%. The most frequently occurring perioperative complications in the TOP1201 group were prolonged air leak (n = 2, 15%) and urinary tract infection (n = 2, 15%). The most common perioperative complication in the preoperative chemotherapy alone group was atrial fibrillation (n = 6, 14%). One patient (8%) had atrial fibrillation in the TOP1201 group. There was no apparent increased occurrence of adverse surgical outcomes for patients in the TOP1201 group compared with patients receiving standard of care neoadjuvant chemotherapy alone before surgery for stage II-IIIA non-small cell lung cancer. Conclusions. This report is the first to demonstrate the safety and feasibility of surgical resection after treatment with ipilimumab and chemotherapy in stage II-IIIA non-small-cell lung cancer. (C) 2018 by The Society of Thoracic Surgeons C1 Duke Univ, Med Ctr, Durham, NC USA. Stanford Univ, Dept Cardiothorac Surg, Stanford, CA 94305 USA. C3 Duke University; Stanford University RP Klapper, JA (corresponding author), 20 Duke Med Cir, Durham, NC 27710 USA. EM jacob.klapper@duke.edu RI Wang, Dandan/V-1897-2017; Yang, Chi-Fu/AFN-9841-2022 FU BMS [CA 184-203] FX This research was supported by BMS grant CA 184-203. CR Depierre A, 2002, J CLIN ONCOL, V20, P247, DOI 10.1200/JCO.20.1.247 Felip E, 2010, J CLIN ONCOL, V28, P3138, DOI 10.1200/JCO.2009.27.6204 Friedman CF, 2016, JAMA ONCOL, V2, P1346, DOI 10.1001/jamaoncol.2016.1051 Genova C, 2012, EXPERT OPIN BIOL TH, V12, P939, DOI 10.1517/14712598.2012.681371 Gilligan D, 2007, LANCET, V369, P1929, DOI 10.1016/S0140-6736(07)60714-4 Hellmann MD, 2017, LANCET ONCOL, V18, P31, DOI [10.1016/S1470-2045(16)30624-6, 10.1016/s1470-2045(16)30624-6] Hoos A, 2010, SEMIN ONCOL, V37, P533, DOI 10.1053/j.seminoncol.2010.09.015 Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI 10.1056/NEJMoa1504030 Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233 Lynch TJ, 2012, J CLIN ONCOL, V30, P2046, DOI 10.1200/JCO.2011.38.4032 Pisters KMW, 2010, J CLIN ONCOL, V28, P1843, DOI 10.1200/JCO.2009.26.1685 ROSELL R, 1994, NEW ENGL J MED, V330, P153, DOI 10.1056/NEJM199401203300301 ROTH JA, 1994, J NATL CANCER I, V86, P673, DOI 10.1093/jnci/86.9.673 Soo RA, 2017, J THORAC ONCOL, V12, P1183, DOI 10.1016/j.jtho.2017.05.019 NR 14 TC 109 Z9 113 U1 1 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD MAR PY 2018 VL 105 IS 3 BP 924 EP 929 DI 10.1016/j.athoracsur.2017.09.030 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA FX2SP UT WOS:000425912100056 PM 29258674 OA Bronze DA 2026-04-17 ER PT J AU Ueda, T Suzuki, K Matsunaga, T Takamochi, K Oh, S AF Ueda, Takuya Suzuki, Kenji Matsunaga, Takeshi Takamochi, Kazuya Oh, Shiaki TI Postoperative atrial fibrillation is less frequent in pulmonary segmentectomy compared with lobectomy SO GENERAL THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article DE Postoperative atrial fibrillation; Segmentectomy; Lung cancer ID NONCARDIAC THORACIC-SURGERY; CELL LUNG-CANCER; RISK-FACTORS; SUPRAVENTRICULAR ARRHYTHMIAS; RESECTION; OPERATIONS AB Objective The aim of this study was to elucidate the characteristics and predictors of postoperative atrial fibrillation (POAF) from the standpoint of surgical mode. Methods Retrospective analysis was carried out on 607 patients who underwent lobectomy or segmentectomy for clinical stage IA lung cancer. We investigated the clinical factors to determine the predictors of the development of POAF. Results Of the 607 patients, 443 underwent lobectomy, and 164 underwent segmentectomy. POAF developed in 37 patients. Of these, 34 (7.7%) were in the lobectomy group, and 3 (1.8%) in the segmentectomy group. In the univariate analysis for predictors of POAF, age (p < 0.01), history of ischemic heart disease (p = 0.03), FEV1.0% (p < 0.01) and surgical mode (p = 0.01) showed significant differences between the groups. The multivariate analysis revealed that increasing age (p < 0.01, HR 1.059, CI 1.015-1.106), surgical mode (p = 0.02, HR 5.734, CI 1.350-24.361) and FEV1.0% < 70% (p = 0.03, HR 2.182, CI 1.067-4.461) were independent predictors of POAF. Conclusion POAF was significantly less following segmentectomy compared with lobectomy. C1 [Ueda, Takuya; Suzuki, Kenji; Matsunaga, Takeshi; Takamochi, Kazuya; Oh, Shiaki] Juntendo Univ, Sch Med, Dept Gen Thorac Surg, Bunkyo Ku, 1-3 Hongo 3 Chome, Tokyo 1138431, Japan. C3 Juntendo University RP Suzuki, K (corresponding author), Juntendo Univ, Sch Med, Dept Gen Thorac Surg, Bunkyo Ku, 1-3 Hongo 3 Chome, Tokyo 1138431, Japan. EM t-ueda@juntendo.ac.jp; kjsuzuki@juntendo.ac.jp; matsu812@juntendo.ac.jp; ktakamo@juntendo.ac.jp; toh@juntendo.ac.jp RI Ueda, Takuya/KIL-3443-2024 CR Amar D, 2002, ANESTHESIOLOGY, V96, P352, DOI 10.1097/00000542-200202000-00021 Amar D, 1996, CHEST, V110, P437, DOI 10.1378/chest.110.2.437 ASAMURA H, 1993, J THORAC CARDIOV SUR, V106, P1104, DOI 10.1016/S0022-5223(19)33985-6 Chung MK, 2001, CIRCULATION, V104, P2886, DOI 10.1161/hc4901.101760 Dyszkiewicz W, 1998, EUR J CARDIO-THORAC, V13, P625, DOI 10.1016/S1010-7940(98)00084-0 Goldstraw P, 2007, J THORAC ONCOL, V2, P985 Hamatake D, 2012, INTERACT CARDIOV TH, V15, P854, DOI 10.1093/icvts/ivs337 Ivanovic J, 2014, INTERACT CARDIOV TH, V18, P340, DOI 10.1093/icvts/ivt520 KEARNEY DJ, 1994, CHEST, V105, P753, DOI 10.1378/chest.105.3.753 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Passman RS, 2005, ANN THORAC SURG, V79, P1698, DOI 10.1016/j.athoracsur.2004.10.058 Polanczyk CA, 1998, ANN INTERN MED, V129, P279, DOI 10.7326/0003-4819-129-4-199808150-00003 Rena O, 2001, EUR J CARDIO-THORAC, V20, P688, DOI 10.1016/S1010-7940(01)00890-9 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Schuchert MJ, 2012, ANN THORAC SURG, V93, P1780, DOI 10.1016/j.athoracsur.2011.11.074 Sekine Y, 2001, CHEST, V120, P1783, DOI 10.1378/chest.120.6.1783 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 VONKNORRING J, 1992, ANN THORAC SURG, V53, P642, DOI 10.1016/0003-4975(92)90325-X Wu DH, 2012, ANN THORAC SURG, V94, P193, DOI 10.1016/j.athoracsur.2012.03.057 Xin YZ, 2014, EUR J CARDIO-THORAC, V45, P247, DOI 10.1093/ejcts/ezt383 Zhong CX, 2012, ANN THORAC SURG, V94, P362, DOI 10.1016/j.athoracsur.2012.04.047 NR 21 TC 18 Z9 22 U1 0 U2 4 PU SPRINGER JAPAN KK PI TOKYO PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN SN 1863-6705 EI 1863-6713 J9 GEN THORAC CARDIOVAS JI Gen. Thorac. Cardiovasc. Surg. PD FEB PY 2018 VL 66 IS 2 BP 95 EP 100 DI 10.1007/s11748-017-0858-x PG 6 WC Cardiac & Cardiovascular Systems; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Surgery GA FU7KF UT WOS:000424030300006 PM 29134538 DA 2026-04-17 ER PT J AU Chen, LT Jiang, CY AF Chen, Lai-Te Jiang, Chen-Yang TI MicroRNA Expression Profiles Identify Biomarker for Differentiating the Embolic Stroke from Thrombotic Stroke SO BIOMED RESEARCH INTERNATIONAL LA English DT Article ID NETWORKS AB In order to identify potential biomarkers that distinguish the embolic stroke (ES) from thrombotic stroke (TS), a profile of microRNA expression was analyzed. The GSE60319 expression profile was downloaded from the Gene Expression Omnibus (GEO) database. The GEO2R was applied to screen for differentially expressed microRNAs (DEmiRNAs) between the embolic stroke group and thrombotic stroke group. The miRWalk was utilized to predict the target genes of DEmiRNAs. Genes associated with embolic stroke were downloaded from the Comparative Toxicogenomics Database. Cross reference of target genes to disease related genes was conducted to construct the DEmiRNA-gene network. The protein-protein interaction (PPI) network of overlapping genes was evaluated by STRING, using the MCODE and CytoHubba plugin of Cytoscape to identify the modules and hub genes. The enrichment of Kyoto Encyclopedia of Genes and Genomes (KEGG) in modules was performed. There were 30 microRNAs in total identified as DEmiRNAs between embolic stroke and thrombotic stroke groups, of which 8 were upregulated and 22 were downregulated. Among these differentially expressed miRNAs, miR-15a-5p, miR-17-5p, miR-19b-3p, and miR-20a-5p were significantly associated with an ES to TS. Using the miRWalk 3.0 online tool, target genes regulated by DEmiRNAs were predicted. In addition, disease related genes were predicted and compared with target genes of DEmiRNAs. 166 overlapped genes regulated by miR-15a-5p, miR-17-5p, miR-19b-3p, and miR-20a-5p were identified, suggesting their association with diseases that contributed to ES, mainly including atrial fibrillation, mitral valve stenosis, myocardial infarction, and aortic dissection. Therefore, miR-15a-5p, miR-17-5p, miR-19b-3p, and miR-20a-5p were promising candidate biomarkers for differentiating an ES from TS. The PPI network demonstrated that miR-15a-5p, miR-17-5p, miR-19b-3p, and miR-20a-5p were associated with an ES by mainly regulating "CCND1, E2F2, E2F3, ITCH, UBE4A, UBE3C, RBL2, FBXO31, EIF2C4, and EIF2C1". Furthermore, miR-15a-5p and miR-17-5p may function through "cell cycle, prostate cancer, and small cell lung cancer" while miR-19b-3p and miR-20a-5p function through "insulin resistance, hepatitis B, and viral carcinogenesis" and "vasopressin-regulated water reabsorption", respectively. However, these results were approached in the manner of bioinformatics analysis; therefore, further verification is required. C1 [Chen, Lai-Te] Zhejiang Univ, Sch Med, Hangzhou, Zhejiang, Peoples R China. [Jiang, Chen-Yang] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Hangzhou, Zhejiang, Peoples R China. C3 Zhejiang University; Zhejiang University RP Jiang, CY (corresponding author), Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Hangzhou, Zhejiang, Peoples R China. EM 1239663987@qq.com; cyjiang@zju.edu.cn CR Araldi E, 2015, CURR VASC PHARMACOL, V13, P291, DOI 10.2174/15701611113119990012 Aubrecht TG, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1156-y Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193 Chemtob RA, 2017, J CARDIOTHOR VASC AN, V31, P569, DOI 10.1053/j.jvca.2016.10.007 Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128 Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752-0509-8-S4-S11 Davis AP, 2015, NUCLEIC ACIDS RES, V43, pD914, DOI 10.1093/nar/gku935 Dekanty A, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000994 Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002 Evans A, 2001, STROKE, V32, P2828, DOI 10.1161/hs1201.099520 Fang L, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0672-0 Giannakou A, 2018, AM J MED GENET A, V176, P2760, DOI 10.1002/ajmg.a.40527 Hajhosseiny R, 2015, HEART RHYTHM, V12, P2332, DOI 10.1016/j.hrthm.2015.06.038 Iyirhiaro GO, 2014, J BIOL CHEM, V289, P18202, DOI 10.1074/jbc.M114.574145 Kim MN, 2018, ECHOCARDIOGR-J CARD, V35, P817, DOI 10.1111/echo.13843 Kohl M, 2011, METHODS MOL BIOL, V696, P291, DOI 10.1007/978-1-60761-987-1_18 Llombart V, 2013, CURR CARDIOL REV, V9, P340, DOI 10.2174/1573403X10666140214122633 Murabito JM, 2017, AGING CELL, V16, P888, DOI 10.1111/acel.12622 Rivera CG, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-S1-S61 Romero JR, 2013, GLOB HEART, V8, P67, DOI 10.1016/j.gheart.2012.12.007 Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003 Tang SH, 2016, FETAL DIAGN THER, V39, P64, DOI 10.1159/000431320 Toda H, 2018, CIRC J, V82, P775, DOI 10.1253/circj.CJ-17-0747 Tuttolomondo A, 2013, CURR VASC PHARMACOL, V11, P824, DOI 10.2174/157016111106140128113705 Copier CU, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13875-2 Wu J, 2015, INT J CLIN EXP MED, V8, P21071 Yang S, 2018, MOL GENET GENOMICS, V293, P883, DOI 10.1007/s00438-018-1426-5 Yu XW, 2018, EXP THER MED, V16, P2219, DOI 10.3892/etm.2018.6466 Zhang JJ, 2017, MED SCI MONITOR, V23, P3981, DOI 10.12659/MSM.897542 NR 29 TC 20 Z9 23 U1 0 U2 9 PU HINDAWI LTD PI LONDON PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND SN 2314-6133 EI 2314-6141 J9 BIOMED RES INT JI Biomed Res. Int. PY 2018 VL 2018 AR 4514178 DI 10.1155/2018/4514178 PG 6 WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental WE Science Citation Index Expanded (SCI-EXPANDED) SC Biotechnology & Applied Microbiology; Research & Experimental Medicine GA HE8UB UT WOS:000453722000001 PM 30627556 OA Green Submitted, hybrid DA 2026-04-17 ER PT J AU Zewari, S Hadi, L van den Elshouta, F Dekhuijzen, R Heijdra, Y Vos, P AF Zewari, S. Hadi, L. van den Elshouta, F. Dekhuijzen, R. Heijdra, Y. Vos, P. TI Obesity in COPD: Comorbidities with Practical Consequences? SO COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE LA English DT Article DE chronic obstructive pulmonary disease; obesity; prevalence ID BODY-MASS INDEX; OBSTRUCTIVE PULMONARY-DISEASE; HEALTH-CARE UTILIZATION; CARDIOVASCULAR-DISEASE; UNITED-STATES; PREVALENCE; MORTALITY; ASTHMA; RISK; MORBIDITY AB COPD and obesity often coexist and there is a complex interaction between them. Our aim was to evaluate the prevalence of obesity in a secondary care COPD population. Furthermore, the presence of comorbidities in obese (COPDOB) and non-obese COPD (COPDNO) individuals was studied. In 1654 COPD patients (aged >= 18 years) who visited a pulmonologist between January 2015 and December 2015, patient characteristics, pulmonary function tests and comorbidities were obtained from the medical records. Subjects were categorized according their BMI as underweight (<18.5 kg/m(2)), normal weight (18.5-24.9 kg/m(2)), overweight (25.0-29.9 kg/m(2)) or obese (BMI >= 30.0 kg/m(2)). The Charlson comorbidity index and COTE index were used to quantify comorbidities. The prevalence of obesity was 21.8% in our COPD population. Obesity was significantly less common in GOLD stage IV (10.1%) compared to GOLD I (20.5%), II (27.8%) and III (18.9%). COPDOB had different comorbidities compared with COPDNO. Hypertension, diabetes mellitus, atrial fibrillation and congestive heart failure were significantly more prevalent in COPDOB compared with COPDNO. Osteoporosis and lung cancer were significantly more common in COPDNO compared with COPDOB. Obesity is common in patients with COPD and is most prevalent in COPD GOLD I-II and least prevalent in COPD GOLD IV. Obese COPD patients have different comorbidities than non-obese COPD patients. Cardiovascular and metabolic comorbidities, especially hypertension and diabetes mellitus, are highly prevalent in obese COPD patients. Active screening for these conditions should be a priority for physicians treating obese COPD patients. C1 [Zewari, S.; Hadi, L.; van den Elshouta, F.; Vos, P.] Rijnstate hosp, Dept Pulm Dis, Arnhem, Netherlands. [Dekhuijzen, R.; Heijdra, Y.] Radboud Univ Nijmegen, Med Ctr, Dept Pulm Dis, Nijmegen, Netherlands. C3 Rijnstate Hospital; Radboud University Nijmegen RP Zewari, S (corresponding author), Rijnstate hosp, Dept Pulm Dis, Arnhem, Netherlands. EM szewari@rijnstate.nl RI Dekhuijzen, P/H-8024-2014; Heijdra, Yvonne/N-3585-2014 FU GlaxoSmithKline FX This work was supported by an unrestricted grant from GlaxoSmithKline. The funding agency had no involvement in study design, data collection, data analysis, interpretation of data, or writing of the report. CR Alonso Jose Luis Izquierdo, 2010, Arch Bronconeumol, V46 Suppl 3, P18, DOI 10.1016/S0300-2896(10)70022-3 [Anonymous], 2015, Obesity and overweight fact sheet [Anonymous], 2016, GOLD GUID, P1 Austin EJ, 1998, PERS INDIV DIFFER, V24, P421, DOI 10.1016/S0191-8869(97)00175-X Barr RG, 2009, AM J MED, V122, P348, DOI 10.1016/j.amjmed.2008.09.042 Behrens G, 2014, CAN MED ASSOC J, V186, pE457, DOI 10.1503/cmaj.140025 Brink CL van den, 2016, VOLKSGEZOND TOEKOMST Cavaillés A, 2013, EUR RESPIR REV, V22, P454, DOI 10.1183/09059180.00008612 CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77 CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5 CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8 Chatila Wissam M, 2008, Proc Am Thorac Soc, V5, P549, DOI 10.1513/pats.200709-148ET Chen WJ, 2015, LANCET RESP MED, V3, P631, DOI 10.1016/S2213-2600(15)00241-6 Chittal P, 2015, COPD, V12, P14, DOI 10.3109/15412555.2014.915934 Cleutjens F, 2015, AM J RESP CRIT CARE, V191, P1081, DOI 10.1164/rccm.201412-2296RR Curkendall SM, 2006, ANN EPIDEMIOL, V16, P63, DOI 10.1016/j.annepidem.2005.04.008 de Oca MM, 2008, RESP MED, V102, P642, DOI 10.1016/j.rmed.2007.12.025 Divo M, 2012, AM J RESP CRIT CARE, V186, P155, DOI 10.1164/rccm.201201-0034OC Divo MJ, 2014, COPD-J COPD FDN, V1, P229, DOI 10.15326/jcopdf.1.2.2014.0117 Divo MJ, 2015, EUR RESPIR J, V46, P640, DOI 10.1183/09031936.00171614 Eisner MD, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-7 Fabbri LM, 2007, LANCET, V370, P797, DOI 10.1016/S0140-6736(07)61383-X Fan XT, 2006, FIELD METHOD, V18, P223, DOI 10.1177/152822X06289161 Feary JR, 2010, THORAX, V65, P956, DOI 10.1136/thx.2009.128082 Franssen FME, 2008, THORAX, V63, P1110, DOI 10.1136/thx.2007.086827 de Barros ARG, 2013, J BRAS PNEUMOL, V39, P317, DOI 10.1590/S1806-37132013000300008 Guerra S, 2002, CHEST, V122, P1256, DOI 10.1378/chest.122.4.1256 Halbert RJ, 2006, EUR RESPIR J, V28, P523, DOI 10.1183/09031936.06.00124605 Hillas G, 2015, INT J CHRONIC OBSTR, V10, P95, DOI 10.2147/COPD.S54473 Holguin F, 2005, CHEST, V128, P2005, DOI 10.1378/chest.128.4.2005 Incalzi RA, 1997, EUR RESPIR J, V10, P2794, DOI 10.1183/09031936.97.10122794 Jones RCM, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-62 Koniski ML, 2015, INT J CHRONIC OBSTR, V10, P1685, DOI 10.2147/COPD.S87259 Landbo C, 1999, AM J RESP CRIT CARE, V160, P1856, DOI 10.1164/ajrccm.160.6.9902115 Liu Y, 2015, RESP MED, V109, P851, DOI 10.1016/j.rmed.2015.05.006 López-Campos JL, 2016, RESPIROLOGY, V21, P14, DOI 10.1111/resp.12660 Mannino DM, 2008, EUR RESPIR J, V32, P962, DOI 10.1183/09031936.00012408 Mannino DM, 2003, ARCH INTERN MED, V163, P1475, DOI 10.1001/archinte.163.12.1475 Mapel Douglas W, 2005, COPD, V2, P35 Marquis Karine, 2005, J Cardiopulm Rehabil, V25, P226, DOI 10.1097/00008483-200507000-00010 Mihalache A, 2015, Rev Med Suisse, V11, P2151, DOI 10.53738/revmed.2015.11.495.2151 Mihalache A, 2015, REV MED SUISSE, V11, P2154 Nathell L, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-89 O'Donnell DE, 2011, CHEST, V140, P461, DOI 10.1378/chest.10-2582 Ortega FB, 2016, MAYO CLIN PROC, V91, P443, DOI 10.1016/j.mayocp.2016.01.008 QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693 Rossi Francesca Flavia, 2011, Recenti Prog Med, V102, P109, DOI 10.1701/608.7066 Short ME, 2009, J OCCUP ENVIRON MED, V51, P786, DOI 10.1097/JOM.0b013e3181a86671 Soriano JB, 2005, CHEST, V128, P2099, DOI 10.1378/chest.128.4.2099 Steuten Lotte M G, 2006, Prim Care Respir J, V15, P84, DOI 10.1016/j.pcrj.2005.09.001 Torén K, 2016, INT J CHRONIC OBSTR, V11, P927, DOI 10.2147/COPD.S104644 Vanfleteren LEGW, 2013, AM J RESP CRIT CARE, V187, P728, DOI 10.1164/rccm.201209-1665OC Vozoris NT, 2012, CAN RESPIR J, V19, pE18, DOI 10.1155/2012/732618 Walters JA, 2011, PRIM CARE RESP J, V20, P396, DOI 10.4104/pcrj.2011.00039 Wang YC, 2011, LANCET, V378, P815, DOI 10.1016/S0140-6736(11)60814-3 NR 55 TC 18 Z9 24 U1 0 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1541-2555 EI 1541-2563 J9 COPD JI COPD-J. Chronic Obstr. Pulm. Dis. PY 2018 VL 15 IS 5 BP 464 EP 471 DI 10.1080/15412555.2018.1509951 PG 8 WC Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System GA HH3TL UT WOS:000455642300008 PM 30512982 DA 2026-04-17 ER PT J AU Kubomura, Y Ise, Y Wako, T Katayama, S Noro, R Kubota, K AF Kubomura, Yu Ise, Yuya Wako, Tetsuya Katayama, Shirou Noro, Rintaro Kubota, Kaoru TI A Drug Interaction between Crizotinib and Warfarin in Non-Small-Cell Lung Cancer: A Case Report SO JOURNAL OF NIPPON MEDICAL SCHOOL LA English DT Article DE crizotinib; warfarin; drug interaction; prothrombin time-international normalized ratio (PT-INR); non-small-cell lung cancer (NSCLC) ID CHEMOTHERAPY; GEFITINIB; PATIENT AB We report a case of increased prothrombin time-international normalized ratio (PT-INR) when crizotinib and warfarin were co-administered. A 74-year-old Japanese woman presented to the hospital with dyspnea, and was diagnosed with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC). Three years after surgical resection of the tumor, the patient started crizotinib because of the recurrence of NSCLC. She received 2 mg/day warfarin due to a medical history of cerebral infarction and chronic atrial fibrillation. Before crizotinib initiation, the patient's PT-INR was 2.60. After 7 days of daily doses of crizotinib, the patient's PT-INR increased to 3.65. This case report provides the first evidence of a drug interaction between crizotinib and warfarin. C1 [Kubomura, Yu; Ise, Yuya; Wako, Tetsuya; Katayama, Shirou] Nippon Med Coll Hosp, Sect Pharmaceut Serv, Tokyo, Japan. [Noro, Rintaro; Kubota, Kaoru] Nippon Med Sch, Grad Sch Med, Dept Pulm Med & Oncol, Tokyo, Japan. C3 Nippon Medical School; Nippon Medical School RP Ise, Y (corresponding author), Nippon Med Coll Hosp, Sect Pharmaceut Serv, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138603, Japan. EM yuyaise@nms.ac.jp CR Borkowski Andrew A, 2014, Recent Pat Biotechnol, V8, P110, DOI 10.2174/1872208309666140904112003 Cropp JS, 1997, PHARMACOTHERAPY, V17, P917 Ferrari M, 2017, EUR J CLIN PHARMACOL, V73, P699, DOI 10.1007/s00228-017-2248-9 Foxx-Lupo WT, 2016, CLIN GENITOURIN CANC, V14, pE119, DOI 10.1016/j.clgc.2015.09.015 Li Cai, 2007, Journal of Nippon Medical School, V74, P217, DOI 10.1272/jnms.74.217 Onoda S, 2005, JPN J CLIN ONCOL, V35, P478, DOI 10.1093/jjco/hyi122 Segal EM, 2014, J ONCOL PRACT, V10, pE255, DOI 10.1200/JOP.2013.001183 Thomas KS, 2010, AM J HEALTH-SYST PH, V67, P1426, DOI 10.2146/ajhp090202 Timm A, 2013, AM J HEALTH-SYST PH, V70, P943, DOI 10.2146/ajhp120261 Wang Chunyan, 2008, Journal of Nippon Medical School, V75, P96, DOI 10.1272/jnms.75.96 NR 10 TC 5 Z9 7 U1 0 U2 3 PU MEDICAL ASSOC NIPPON MEDICAL SCH PI TOKYO PA 1-1-5, SENDAGI, TOKYO, 113-8602, JAPAN SN 1345-4676 EI 1347-3409 J9 J NIPPON MED SCH JI J. Nippon Med. Sch. PD DEC PY 2017 VL 84 IS 6 BP 291 EP 293 DI 10.1272/jnms.84.291 PG 3 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA FR3RD UT WOS:000418983000006 PM 29279560 OA gold DA 2026-04-17 ER PT J AU Xiao, YJ Meng, C Lin, J Huang, CQ Zhang, XL Long, YY Huang, YD Lin, Y AF Xiao, Yijun Meng, Chen Lin, Jie Huang, Chaoqun Zhang, Xiuli Long, Yanyu Huang, Yide Lin, Yao TI Ouabain targets the Na+/K+-ATPase α3 isoform to inhibit cancer cell proliferation and induce apoptosis SO ONCOLOGY LETTERS LA English DT Article DE ouabain; proliferation; apoptosis; Na+/K+-ATPase ID CARDIOTONIC STEROIDS AB Ouabain has been used for the treatment of heart failure and atrial fibrillation. Its potential anticancer effect has also attracted great interest. The aim of the present study was to evaluate the anticancer effect of ouabain and investigate its molecular target. The effects of ouabain on the viability of and induction of cellular death on OS-RC-2 renal cancer cells were examined using the MTT assay and acridine orange/ethidium bromide staining. The levels of Ca2+ and reactive oxygen species were determined using Fura-3-acetoxymethyl ester and dichloro-dihydro-fluorescein diacetate probes, respectively. Apoptosis was examined using annexin V-fluorescein isothiocyanate/propidium iodide staining and western blotting. The expression profile of the different Na+/K+-ATPase (NKA) isoforms in NCI-H446 small cell lung cancer cells was determined using immunocytochemistry and reverse transcription polymerase chain reaction analysis. In the present study, it was demonstrated that ouabain inhibited cancer cell proliferation and induced apoptosis while no significant difference in the expression of NKA alpha(1) and alpha(3) isoforms was detected following 48 h of ouabain treatment. Furthermore, expression of NKA alpha(3) but not the alpha(1) isoform was associated with ouabain sensitivity. The results of the present study indicated that ouabain targets the NKA alpha(3) isoform, inhibits cancer cell proliferation and induces apoptosis. C1 [Xiao, Yijun; Meng, Chen; Lin, Jie; Huang, Chaoqun; Zhang, Xiuli; Long, Yanyu; Huang, Yide; Lin, Yao] Fujian Normal Univ, Coll Life Sci, Qishan Campus,1 Keji Rd, Fuzhou 350117, Fujian, Peoples R China. C3 Fujian Normal University RP Lin, Y (corresponding author), Fujian Normal Univ, Coll Life Sci, Qishan Campus,1 Keji Rd, Fuzhou 350117, Fujian, Peoples R China. EM yaolin@fjnu.edu.cn RI meng, chen/HKE-5994-2023; Huang, Chaoqun/V-4210-2019 OI Zhang, Xiuli/0009-0003-4929-4417; Huang, Yide/0000-0002-9310-7856 FU National Natural Science Foundation of China [31640053]; Natural Science Foundation of Fujian Province [2016Y0029, 2016J01149, 2016J01146]; open Scientific Foundation of Fujian Key Laboratory [2014ZDSY2002] FX The present study was supported by the National Natural Science Foundation of China (grant no. 31640053), the Natural Science Foundation of Fujian Province (grant nos. 2016Y0029, 2016J01149 and 2016J01146) and the open Scientific Foundation of Fujian Key Laboratory (grant no. 2014ZDSY2002). CR Bechmann MB, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00009 Haux J, 1999, MED HYPOTHESES, V53, P543, DOI 10.1054/mehy.1999.0985 Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710 Jorgensen PL, 2003, ANNU REV PHYSIOL, V65, P817, DOI 10.1146/annurev.physiol.65.092101.142558 Kong D, 2015, CLIN EXP METASTAS, V32, P267, DOI 10.1007/s10585-015-9702-9 Liu J, 2000, J BIOL CHEM, V275, P27838 Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262 MAJNO G, 1995, AM J PATHOL, V146, P3 Mijatovic T, 2007, BBA-REV CANCER, V1776, P32, DOI 10.1016/j.bbcan.2007.06.002 Newman RA, 2008, MOL INTERV, V8, P36, DOI 10.1124/mi.8.1.8 Ninsontia C, 2014, ANTICANCER RES, V34, P5495 Prassas I, 2008, NAT REV DRUG DISCOV, V7, P926, DOI 10.1038/nrd2682 Shin HK, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/537136 SKOU JC, 1957, BIOCHIM BIOPHYS ACTA, V23, P394, DOI 10.1016/0006-3002(57)90343-8 Stenkvist B, 1999, ONCOL REP, V6, P493 Jemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI [10.1002/cncr.24446, 10.3322/caac.20107] Winnicka Katarzyna, 2006, Acta Pol Pharm, V63, P109 Xu ZW, 2011, J STEROID BIOCHEM, V125, P181, DOI 10.1016/j.jsbmb.2010.12.016 Yan XF, 2015, MOL CELL BIOCHEM, V398, P95, DOI 10.1007/s11010-014-2208-y Zhuang LP, 2015, ONCOTARGET, V6, P28183, DOI 10.18632/oncotarget.4726 NR 20 TC 23 Z9 23 U1 1 U2 11 PU SPANDIDOS PUBL LTD PI ATHENS PA POB 18179, ATHENS, 116 10, GREECE SN 1792-1074 EI 1792-1082 J9 ONCOL LETT JI Oncol. Lett. PD DEC PY 2017 VL 14 IS 6 BP 6678 EP 6684 DI 10.3892/ol.2017.7070 PG 7 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA FP0LV UT WOS:000417293400047 PM 29163695 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Hassani, C Saremi, F AF Hassani, Cameron Saremi, Farhood TI Comprehensive Cross-sectional Imaging of the Pulmonary Veins SO RADIOGRAPHICS LA English DT Article ID LEFT UPPER LOBECTOMY; RADIOFREQUENCY CATHETER ABLATION; ATRIAL-SEPTAL-DEFECT; COMPUTED-TOMOGRAPHY; VENOUS CONNECTION; LUNG-CANCER; CT ANGIOGRAPHY; LEVOATRIOCARDINAL VEIN; BRONCHUS INTERMEDIUS; THROMBUS FORMATION AB The pulmonary veins carry oxygenated blood from the lungs to the heart, but their importance to the radiologist extends far beyond this seemingly straightforward function. The anatomy of the pulmonary veins is variable among patients, with several noteworthy variant and anomalous patterns, including supernumerary pulmonary veins, a common ostium, anomalous pulmonary venous return, and levoatriocardinal veins. Differences in pulmonary vein anatomy and the presence of variant or anomalous anatomy can be of critical importance, especially for preoperative planning of pulmonary and cardiac surgery. The enhancement or lack of enhancement of the pulmonary veins can be a clue to clinically important disease, and the relationship of masses to the pulmonary veins can herald cardiac invasion. The pulmonary veins are also an integral part of thoracic interventions, including lung transplantation, pneumonectomy, and radiofrequency ablation for atrial fibrillation. This fact creates a requirement for radiologists to have knowledge of the pre-and postoperative imaging appearances of the pulmonary veins. Many of these procedures are associated with important potential complications involving the pulmonary veins, for which diagnostic imaging plays a critical role. A thorough knowledge of the pulmonary veins and a proper radiologic approach to their evaluation is critical for the busy radiologist who must incorporate the pulmonary veins into a routine "search pattern" at computed tomography (CT) and magnetic resonance imaging. This article is a comprehensive CT-based imaging review of the pulmonary veins, including their embryology, anatomy (typical and anomalous), surgical implications, pulmonary vein thrombosis, pulmonary vein stenosis, pulmonary vein pseudostenosis, and the relationship of tumors to the pulmonary veins. C1 [Hassani, Cameron; Saremi, Farhood] Univ Southern Calif, Keck Hosp, Dept Radiol, 1500 San Pablo St, Los Angeles, CA 90033 USA. C3 University of Southern California; University of Southern California Keck Hospital RP Hassani, C (corresponding author), Univ Southern Calif, Keck Hosp, Dept Radiol, 1500 San Pablo St, Los Angeles, CA 90033 USA. EM ch602nyc@gmail.com FU Magna Cum Laude award FX Recipient of a Magna Cum Laude award for an education exhibit at the 2016 RSNA Annual Meeting. Received March 11, 2017; revision requested May 25 and received June 13; accepted June 30. For this journal-based SA-CME activity, the authors, editor, and reviewers have disclosed no relevant relationships. CR Abujudeh H, 2004, PEDIATR RADIOL, V34, P567, DOI 10.1007/s00247-004-1142-7 Agarwal PP, 2015, AM J ROENTGENOL, V205, pW162, DOI 10.2214/AJR.15.14365 Akiba T, 2013, ANN THORAC SURG, V95, P1227, DOI 10.1016/j.athoracsur.2013.01.011 Akiba T, 2010, GEN THORAC CARDIOVAS, V58, P331, DOI 10.1007/s11748-010-0592-0 Alexander GR, 2009, ANN THORAC SURG, V88, P281, DOI 10.1016/j.athoracsur.2008.09.061 Alsoufi B, 2007, ANN THORAC SURG, V84, P2020, DOI 10.1016/j.athoracsur.2007.05.046 Anderson RH, 2006, DEV DYNAM, V235, P2, DOI 10.1002/dvdy.20578 Asai K, 2014, GEN THORAC CARDIOVAS, V62, P244, DOI 10.1007/s11748-013-0229-1 Beerbaum P, 2001, CIRCULATION, V103, P2476 Beigelman C, 1998, AM J ROENTGENOL, V171, P579, DOI 10.2214/ajr.171.3.9725276 Berecova Z, 2012, J RADIOL CASE REP, V6, P9, DOI 10.3941/jrcr.v6i12.1017 BERNSTEIN HS, 1995, J AM COLL CARDIOL, V26, P995, DOI 10.1016/0735-1097(95)00283-X Bonnet L, 2015, CIRCULATION, V131, P2093, DOI 10.1161/CIRCULATIONAHA.114.011429 BURCH GE, 1954, AM HEART J, V47, P58, DOI 10.1016/0002-8703(54)90211-2 Burri E, 2006, J CARDIOVASC SURG, V47, P609 Cabrera JA, 2002, CIRCULATION, V106, P968, DOI 10.1161/01.CIR.0000026397.78200.C4 Caldarone C, 2006, ANN THORAC SURG, V81, P995 Calkins H, 2012, J INTERV CARD ELECTR, V33, P171, DOI [10.1093/europace/eus027, 10.1007/s10840-012-9672-7] Casula RP, 2001, ANN THORAC SURG, V71, P1373, DOI 10.1016/S0003-4975(00)02369-9 Chen J, 2017, EUR RADIOL, V27, P660, DOI 10.1007/s00330-016-4411-6 Choe DH, 1998, J COMPUT ASSIST TOMO, V22, P587, DOI 10.1097/00004728-199807000-00014 Christow SP, 2000, CIRCULATION, V102, P2159, DOI 10.1161/01.CIR.102.17.2159 Cronin P, 2007, ACAD RADIOL, V14, P178, DOI 10.1016/j.acra.2006.11.004 Cronin P, 2009, EUR J RADIOL, V71, P61, DOI 10.1016/j.ejrad.2008.04.008 DAVIA JE, 1973, AM HEART J, V85, P177, DOI 10.1016/0002-8703(73)90458-4 Debl K, 2009, BRIT J RADIOL, V82, P386, DOI 10.1259/bjr/18500608 Devaney EJ, 2006, ANN THORAC SURG, V81, P992, DOI 10.1016/j.athoracsur.2005.08.020 Diller GP, 2007, CIRCULATION, V115, P1039, DOI 10.1161/CIRCULATIONAHA.105.592386 Dillman JR, 2009, AM J ROENTGENOL, V192, P1272, DOI 10.2214/AJR.08.1526 Drubach LA, 2015, AM J ROENTGENOL, V205, P873, DOI 10.2214/AJR.14.13581 EDWARDS JE, 1960, LAB INVEST, V9, P46 FABER LP, 1990, ANN THORAC SURG, V49, P1016, DOI 10.1016/0003-4975(90)90896-E Ferguson EC, 2007, RADIOGRAPHICS, V27, DOI 10.1148/rg.275065148 Frazier AA, 2007, RADIOGRAPHICS, V27, P867, DOI 10.1148/rg.273065194 Garcia MK, 1996, CHEST, V109, P846, DOI 10.1378/chest.109.3.846 GATHMAN GE, 1970, CIRCULATION, V42, P143, DOI 10.1161/01.CIR.42.1.143 Girod JP, 2007, J AM SOC ECHOCARDIOG, V20, DOI 10.1016/j.echo.2007.04.018 GOODMAN LR, 1972, CHEST, V62, P510, DOI 10.1378/chest.62.4.510 Gotway MB, 2000, J COMPUT ASSIST TOMO, V24, P267, DOI 10.1097/00004728-200003000-00016 GUSTAFSON RA, 1989, J THORAC CARDIOV SUR, V98, P861 GYVESRAY KM, 1987, AM J ROENTGENOL, V148, P1079, DOI 10.2214/ajr.148.6.1079 Hamdan A, 2009, AM J CARDIOL, V104, P1540, DOI 10.1016/j.amjcard.2009.07.029 Haramati LB, 2003, J COMPUT ASSIST TOMO, V27, P743, DOI 10.1097/00004728-200309000-00011 HARLEY HR, 1961, BRIT HEART J, V23, P75 Hauser TH, 2015, J CARDIOVASC MAGN R, V17, DOI 10.1186/s12968-015-0151-z Herlong J R, 2000, Ann Thorac Surg, V69, pS56 Heyneman LE, 2001, AM J ROENTGENOL, V177, P681, DOI 10.2214/ajr.177.3.1770681 Ho CL, 2014, PEDIATR NEONATOL, V55, P407, DOI 10.1016/j.pedneo.2013.01.012 Ho ML, 2009, J THORAC IMAG, V24, P89, DOI 10.1097/RTI.0b013e318194c942 Ho SY, 2001, HEART, V86, P265, DOI 10.1136/heart.86.3.265 Holt DB, 2007, AM J CARDIOL, V99, P568, DOI 10.1016/j.amjcard.2006.09.100 Hong SP, 2014, HERZ, V39, P593, DOI 10.1007/s00059-013-3833-z HSU I, 1976, AM J CARDIOL, V37, P928, DOI 10.1016/0002-9149(76)90121-1 Hubler B, 1997, AM J ROENTGENOL, V169, P1354, DOI 10.2214/ajr.169.5.9353457 Hung ST, 2016, J CARD FAIL, V22, P316, DOI 10.1016/j.cardfail.2015.12.019 Ichimura H, 2014, ANN THORAC CARDIOVAS, V20, P613, DOI 10.5761/atcs.cr.13-00079 Ishii Hiroshi, 2004, Nihon Kokyuki Gakkai Zasshi, V42, P84 JARDIN M, 1986, AM J ROENTGENOL, V147, P457, DOI 10.2214/ajr.147.3.457 Jongbloed MRM, 2005, RADIOLOGY, V234, P702, DOI 10.1148/radiol.2343031047 Jongbloed MRM, 2005, J AM COLL CARDIOL, V45, P343, DOI 10.1016/j.jacc.2004.10.040 Jost CHA, 2005, CIRCULATION, V112, P1953, DOI 10.1161/CIRCULATIONAHA.104.493775 Kameda K, 1988, J Thorac Imaging, V3, P73, DOI 10.1097/00005382-198804000-00009 Karamlou T, 2007, CIRCULATION, V115, P1591, DOI 10.1161/CIRCULATIONAHA.106.635441 Kato R, 2003, CIRCULATION, V107, P2004, DOI 10.1161/01.CIR.0000061951.81767.4E KIM JS, 1995, AM J ROENTGENOL, V165, P1349, DOI 10.2214/ajr.165.6.7484561 KIM NH, 1993, CHEST, V104, P624, DOI 10.1378/chest.104.2.624 Kluge A, 2004, CHEST, V126, P428, DOI 10.1378/chest.126.2.428 Kriss VM, 1995, J THORAC IMAG, V10, P142, DOI 10.1097/00005382-199521000-00013 Kumazoe H, 2008, CLIN IMAG, V32, P61, DOI 10.1016/j.clinimag.2007.05.004 Lacomis JM, 2007, J THORAC IMAG, V22, P63, DOI 10.1097/RTI.0b013e3180317aaf Lickfett L, 2004, J CARDIOVASC ELECTR, V15, P538, DOI 10.1046/j.1540-8167.2004.03499.x Loyalka P, 2012, TEX HEART I J, V39, P560 Maillard JO, 2007, RESPIRATION, V74, P110, DOI 10.1159/000087181 Manabe S, 2014, CASE REP NEPHROL DIA, V4, P103, DOI 10.1159/000363224 Manghat NE, 2012, BRIT J RADIOL, V85, P965, DOI 10.1259/bjr/79302681 Mansour M, 2004, J CARDIOVASC ELECTR, V15, P387, DOI 10.1046/j.1540-8167.2004.03515.x Marom EM, 2004, RADIOLOGY, V230, P824, DOI 10.1148/radiol.2303030315 Mou Y, 2014, J CARDIOTHORAC SURG, V9, DOI 10.1186/s13019-014-0132-6 Nagashima T, 2015, GEN THORAC CARDIOVAS, V63, P354, DOI 10.1007/s11748-015-0531-1 Nanthakumar K, 2004, CHEST, V126, P645, DOI 10.1378/chest.126.2.645 NEILL CA, 1960, B JOHNS HOPKINS HOSP, V107, P1 Neirotti R, 2003, EUR J CARDIO-THORAC, V24, P36 Nelson E, 2000, AM J ROENTGENOL, V174, P531, DOI 10.2214/ajr.174.2.1740531 Ohira S, 2013, ANN THORAC SURG, V96, pE135, DOI 10.1016/j.athoracsur.2013.07.028 Ohtaka K, 2014, J CARDIOTHORAC SURG, V9, DOI 10.1186/s13019-014-0159-8 Ohtaka K, 2014, J CARDIOTHORAC SURG, V9, DOI 10.1186/1749-8090-9-5 Ohtaka K, 2013, ANN THORAC SURG, V95, P1924, DOI 10.1016/j.athoracsur.2013.03.005 PASQUE MK, 1990, ANN THORAC SURG, V49, P785, DOI 10.1016/0003-4975(90)90023-Y Prasanna LC, 2014, J CLIN DIAGN RES, V8, P10, DOI 10.7860/JCDR/2014/7649.3992 Prieto LR, 2008, J CARDIOVASC ELECTR, V19, P673, DOI 10.1111/j.1540-8167.2008.01110.x Rami-Porta R, 2017, CA-CANCER J CLIN, V67, P138, DOI 10.3322/caac.21390 Raptis CA, 2012, RADIOL CLIN N AM, V50, P915, DOI 10.1016/j.rcl.2012.06.001 Remy-Jardin M, 1999, RADIOLOGY, V212, P615, DOI 10.1148/radiology.212.3.r99se02615 Ricci M, 2003, EUR J CARDIO-THORAC, V24, P28, DOI 10.1016/S1010-7940(03)00180-5 Richard Webb W., 2010, Thoracic imaging: pulmonary and cardiovascular radiology Robbins IM, 1998, CIRCULATION, V98, P1769, DOI 10.1161/01.CIR.98.17.1769 ROEHM JOF, 1966, RADIOLOGY, V86, P856, DOI 10.1148/86.5.856 Rossi SE, 2001, RADIOGRAPHICS, V21, P737, DOI 10.1148/radiographics.21.3.g01ma17737 Rostamian A, 2014, J INTERV CARD ELECTR, V40, P63, DOI 10.1007/s10840-014-9885-z Saad EB, 2003, ANN INTERN MED, V138, P634, DOI 10.7326/0003-4819-138-8-200304150-00010 Sahay S, 2012, RESPIROLOGY, V17, P957, DOI 10.1111/j.1440-1843.2012.02180.x Salazar-Mena J, 1999, PEDIATR RADIOL, V29, P578, DOI 10.1007/s002470050651 Saoraya J, 2013, J EMERG MED, V44, pE299, DOI 10.1016/j.jemermed.2012.09.029 Saremi F, 2013, CARDIAC CT MR ADULT Scharf C, 2003, J CARDIOVASC ELECTR, V14, P150, DOI 10.1046/j.1540-8167.2003.02444.x Schröder S, 2001, J CARDIOVASC SURG, V42, P53 Schulman LL, 2001, J AM SOC ECHOCARDIOG, V14, P806, DOI 10.1067/mje.2001.111855 Schwartzman D, 2003, J AM COLL CARDIOL, V41, P1349, DOI 10.1016/S0735-1097(03)00124-4 Seale AN, 2010, CIRCULATION, V122, P2718, DOI 10.1161/CIRCULATIONAHA.110.940825 Sellke F W., 2009, Sabiston and Spencer surgery of the chest, V8th Selvidge SDD, 1999, AM J ROENTGENOL, V172, P1639, DOI 10.2214/ajr.172.6.10350306 SHAH AS, 1995, J CARDIAC SURG, V10, P169 SHAW TRD, 1980, J THORAC CARDIOV SUR, V79, P117 Shen QL, 2013, PEDIATR RADIOL, V43, P827, DOI 10.1007/s00247-012-2609-6 Shimizu R, 2017, J THORAC ONCOL, V12, pS1386, DOI 10.1016/j.jtho.2016.11.1966 Sizarov A, 2011, CIRC-ARRHYTHMIA ELEC, V4, P532, DOI 10.1161/CIRCEP.111.963421 Sogomonian R, 2016, J COMMUNITY HOSP INT, V6, DOI 10.3402/jchimp.v6.30817 Sugarbaker D J., 2014, Adult Chest Surgery, V2nd Takahashi K, 2000, J COMPUT ASSIST TOMO, V24, P557, DOI 10.1097/00004728-200007000-00008 Tekbas G, 2012, WIEN KLIN WOCHENSCHR, V124, P3, DOI 10.1007/s00508-011-0086-9 Thorning C, 2011, CLIN IMAG, V35, P1, DOI 10.1016/j.clinimag.2009.11.005 Tortoriello TA, 2002, TEX HEART I J, V29, P319 Truong MT, 2003, AM J ROENTGENOL, V181, P1109, DOI 10.2214/ajr.181.4.1811109 Uhlmann EJ, 2009, J HEART LUNG TRANSPL, V28, P209, DOI 10.1016/j.healun.2008.11.909 Umeda Yukio, 2015, Kyobu Geka, V68, P967 UYAMA T, 1988, JPN J SURG, V18, P359, DOI 10.1007/BF02471456 van den Berg G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022055 Porres DV, 2013, RADIOGRAPHICS, V33, P999, DOI 10.1148/rg.334125043 Vazquez FJ, 2015, THROMB HAEMOSTASIS, V113, P1151, DOI 10.1160/TH14-11-0933 Wang W, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001853 Wannasopha Y, 2012, Biomed Imaging Interv J, V8, pe4, DOI 10.2349/biij.8.1.e4 WEBB WR, 1984, AM J ROENTGENOL, V142, P907, DOI 10.2214/ajr.142.5.907 Weerasooriya R, 2007, J CARDIOVASC ELECTR, V18, P1116, DOI 10.1111/j.1540-8167.2007.00903.x White CS, 2014, ROTATIONS RADIOLOGY WILLIAMSON WA, 1992, CHEST, V102, P937, DOI 10.1378/chest.102.3.937 Wittkampf FHM, 2003, CIRCULATION, V107, P21, DOI 10.1161/01.CIR.0000047065.49852.8F Wong Ka Kit, 2009, Clin Cardiol, V32, pE67, DOI 10.1002/clc.20473 Yamaji H, 2008, CIRC J, V72, P1460, DOI 10.1253/circj.CJ-08-0055 Yataco Jose, 2004, Respir Care, V49, P1525 NR 139 TC 51 Z9 56 U1 0 U2 9 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0271-5333 J9 RADIOGRAPHICS JI Radiographics PD NOV-DEC PY 2017 VL 37 IS 7 BP 1928 EP 1954 DI 10.1148/rg.2017170050 PG 27 WC Radiology, Nuclear Medicine & Medical Imaging WE Science Citation Index Expanded (SCI-EXPANDED) SC Radiology, Nuclear Medicine & Medical Imaging GA FP3HB UT WOS:000417508200003 PM 29131765 DA 2026-04-17 ER PT J AU Prall, M Eichhorn, A Richter, D Lehmann, HI Constantinescu, A Kaderka, R Lugenbiel, P Thomas, D Bert, C Packer, DL Durante, M Graeff, C AF Prall, Matthias Eichhorn, Anna Richter, Daniel Lehmann, H. Immo Constantinescu, Anna Kaderka, Robert Lugenbiel, Patrick Thomas, Dierk Bert, Christoph Packer, Douglas L. Durante, Marco Graeff, Christian TI Immobilization for carbon ion beam ablation of cardiac structures in a porcine model SO PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS LA English DT Article DE Patient positioning; Motion mitigation; Gating; Cardiac arrhythmia ablation ID CATHETER-FREE ABLATION; PARTICLE THERAPY; ATRIAL-FIBRILLATION; LUNG-CANCER; RADIOSURGERY; RADIOTHERAPY; FEASIBILITY; MOTION AB Introduction: Whereas hadron therapy of static targets is clinically established, treatment of moving organs remains a challenge. One strategy is to minimize motion of surrounding tissue mechanically and to mitigate residual motion with an appropriate irradiation technique. In this technical note, we present and characterize such an immobilization technique for a novel noncancerous application: the irradiation of small targets in hearts with scanned carbon ion beams in a porcine model for elimination of arrhythmias. Material and methods: A device for immobilization was custom-built. Both for the treatment planning 4D-CT scan and for irradiation, breath-hold at end-exhale was enforced using a remotely-controlled respirator. Target motion was thus reduced to heartbeat only. Positioning was verified by orthogonal X-rays followed by couch shift if necessary. Reproducibility of bony anatomy, diaphragm, and heart position after repositioning and between repeated breath-hold maneuvers was evaluated on X-rays and cardiac-gated 4D-CTs. Treatment was post hoc simulated on sequential 4D-CTs for a subset of animals, after immediate repositioning and after a delay of one week, similar to the delay between imaging and irradiation. Results: Breath-hold without repositioning was highly reproducible with an RMS deviation of at most one millimeter. 4D-CTs showed larger deformations in soft tissue, but treatment simulation on sequential images resulted in full target coverage (V95 > 95%). Conclusion: The method of immobilization permitted reproducible positioning of mobile, thoracic targets for range-sensitive particle therapy. The presented immobilization strategy could be a reasonable approach for future animal investigations with the ultimate goal of translation to therapy in men. C1 [Prall, Matthias; Eichhorn, Anna; Richter, Daniel; Constantinescu, Anna; Kaderka, Robert; Durante, Marco; Graeff, Christian] GSI Helmholtzzentrum Schwerionenforsch, Dept Biophys, Planckstr 1, D-64291 Darmstadt, Germany. [Lehmann, H. Immo; Packer, Douglas L.] Mayo Clin, St Marys Hosp, Translat Intervent EP Lab, Rochester, MN USA. [Lehmann, H. Immo] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Lugenbiel, Patrick; Thomas, Dierk] Univ Hosp Heidelberg, Dept Cardiol, Neuenheimer Feld 410, D-69120 Heidelberg, Germany. [Thomas, Dierk] Heidelberg Univ, DZHK German Ctr Cardiovasc Res, Partner Site Heidelberg Mannheim, D-69120 Heidelberg, Germany. [Bert, Christoph] Univ Clin Erlangen, Univ Str 27, D-91054 Erlangen, Germany. [Bert, Christoph] Friedrich Alexander Univ Erlangen Nurnberg, Dept Radiat Oncol, Univ Str 27, D-91054 Erlangen, Germany. [Durante, Marco] Univ Trento, Natl Inst Nucl Phys, Trento Inst Fundamental Phys & Applicat, Via Sommarive 14, Trento, Italy. C3 Helmholtz Association; GSI Helmholtz-Center for Heavy Ion Research; Mayo Clinic; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; German Centre for Cardiovascular Research; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Trento RP Graeff, C (corresponding author), GSI Helmholtzzentrum Schwerionenforsch, Dept Biophys, Planckstr 1, D-64291 Darmstadt, Germany. EM c.graeff@gsi.de RI Graeff, Christian/A-5302-2017; Bert, Christoph/C-2585-2013; Lehmann, H./AAX-8656-2021; Richter, Daniel/M-6970-2013; Thomas, Dierk/V-3940-2017; Durante, Marco/K-1315-2014 OI Graeff, Christian/0000-0002-5296-7649; Bert, Christoph/0000-0002-8539-6600; FU Helmholtz Association FX The Helmholtz Association has funded this work through the Helmholtz-Portfolio Topic "Technology and Medicine". We thank Harry Leidel from the GSI workshop and Elko Schubert for supporting us with the development of the pig immobilization device. CR Bert C, 2011, PHYS MED BIOL, V56, pR113, DOI 10.1088/0031-9155/56/16/R01 Bert C, 2014, PHYS MEDICA, V30, P535, DOI 10.1016/j.ejmp.2014.04.011 Blanck O, 2014, INT J RADIAT ONCOL, V89, P590, DOI 10.1016/j.ijrobp.2014.02.036 Boda-Heggemann J, 2016, INT J RADIAT ONCOL, V94, P478, DOI 10.1016/j.ijrobp.2015.11.049 Bode F, 2015, EUROPACE, V17, P1868, DOI 10.1093/europace/euu406 Cappato R, 2010, CIRC-ARRHYTHMIA ELEC, V3, P32, DOI 10.1161/CIRCEP.109.859116 Constantinescu A, 2016, J CARDIOVASC ELECTR, V27, P335, DOI 10.1111/jce.12888 Cvek J., 2014, Cureus, V6, pe190, DOI [10.7759/cureus.190, DOI 10.7759/CUREUS.190] Graeff C, 2012, MED PHYS, V39, P6004, DOI 10.1118/1.4749964 Krämer M, 2010, EUR PHYS J D, V60, P195, DOI 10.1140/epjd/e2010-00077-8 Lehmann HI, 2016, SCI REP-UK, V6, DOI 10.1038/srep38895 Lehmann HI, 2015, CIRC-ARRHYTHMIA ELEC, V8, P429, DOI 10.1161/CIRCEP.114.002436 Liu W, 2016, INT J RADIAT ONCOL, V95, P523, DOI 10.1016/j.ijrobp.2015.11.002 Mizushima K, 2014, NUCL INSTRUM METH B, V331, P243, DOI 10.1016/j.nimb.2013.12.033 Mori S, 2009, J RADIAT RES, V50, P513, DOI 10.1269/jrr.09032 Schardt D, 2010, REV MOD PHYS, V82, P383, DOI 10.1103/RevModPhys.82.383 Schoemers C, 2015, NUCL INSTRUM METH A, V795, P92, DOI 10.1016/j.nima.2015.05.054 NR 17 TC 6 Z9 6 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1120-1797 EI 1724-191X J9 PHYS MEDICA JI Phys. Medica PD NOV PY 2017 VL 43 BP 134 EP 139 DI 10.1016/j.ejmp.2017.10.016 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging WE Science Citation Index Expanded (SCI-EXPANDED) SC Radiology, Nuclear Medicine & Medical Imaging GA FP5JM UT WOS:000417655800017 PM 29195556 DA 2026-04-17 ER PT J AU Tcherveniakov, P Bogdan, C Chaudhuri, N AF Tcherveniakov, P. Bogdan, C. Chaudhuri, N. TI Crossing the bridge to VATS lobectomy SO ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND LA English DT Article DE Video assisted thoracoscopic surgery; Lobectomy; Lung cancer; Training ID ASSISTED THORACOSCOPIC SURGERY; CELL LUNG-CANCER; THORACOTOMY; OUTCOMES AB INTRODUCTION The impact of the introduction of video assisted thoracoscopic surgery (VATS) on the management of lung cancer 20 years ago has been well documented. However, the uptake of VATS lobectomy in surgical practice worldwide has been slower than expected. We believe that this is partly due to a lack of consensus on how this procedure should be integrated into training programmes. We present our initial experience with a newly developed training model, which could help bridge the divide between open and VATS lobectomy. METHODS Two surgical registrars were initiated into this model, supervised by a single consultant. All cases were performed using a standardised three-port anterior approach with systematic lymph node dissection. Both registrars were scrubbed for each case, alternating as first surgeon and assistant, with the supervising consultant operating the camera. RESULTS Over a 6-month period, 22 lung resections for non-small cell lung carcinoma were performed as VATS lobectomies. Thirteen of them were upper lobectomies. There were no emergency conversions to open surgery. The mean operative time for the registrars was 155 minutes compared with 140 minutes for consultant-led operations (p=0.22). There was no perioperative mortality. The most common postoperative complications were atrial fibrillation (4 cases) and prolonged air leak (3 cases). CONCLUSIONS VATS lobectomy involves a team approach. Especially in upper lobectomies, the assistant surgeon plays a significant role in the operation, often helping with the dissection as well as stapling of the bronchial and vascular structures. With a team consisting of two trainees and a supervising surgeon, the teaching process becomes more intuitive and is accelerated. This should reduce the learning curve considerably and improve safety during training. C1 [Tcherveniakov, P.; Bogdan, C.; Chaudhuri, N.] Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England. C3 University of Leeds RP Tcherveniakov, P (corresponding author), Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England. EM pcherv@hotmail.com CR Decaluwe H, 2015, EUR J CARDIO-THORAC, V48, P588, DOI 10.1093/ejcts/ezv287 Falcoz PE, 2016, EUR J CARDIO-THORAC, V49, P602, DOI 10.1093/ejcts/ezv154 Hartwig MG, 2010, ANN THORAC SURG, V89, pS2098, DOI 10.1016/j.athoracsur.2010.02.102 Jiang GC, 2011, WORLD J SURG ONCOL, V9, DOI 10.1186/1477-7819-9-170 McElnay P, 2014, EUR J CARDIO-THORAC, V46, P100, DOI 10.1093/ejcts/ezt561 Meyerson SL, 2015, ANN THORAC SURG, V100, P401, DOI 10.1016/j.athoracsur.2015.03.087 Nwogu CE, 2015, ANN THORAC SURG, V99, P399, DOI 10.1016/j.athoracsur.2014.09.018 Petersen RH, 2012, ANN CARDIOTHORAC SUR, V1, P47, DOI 10.3978/j.issn.2225-319X.2012.04.05 Puri V, 2015, J THORAC CARDIOV SUR, V149, P55, DOI 10.1016/j.jtcvs.2014.08.074 Reid A, 2013, CHEST, V144, DOI 10.1378/chest.1662734 Villamizar NR, 2009, J THORAC CARDIOV SUR, V138, P419, DOI 10.1016/j.jtcvs.2009.04.026 Walker WS, 2003, EUR J CARDIO-THORAC, V23, P397, DOI 10.1016/S1010-7940(02)00814-X Whitson BA, 2008, ANN THORAC SURG, V86, P2008, DOI 10.1016/j.athoracsur.2008.07.009 NR 13 TC 1 Z9 1 U1 0 U2 1 PU ROYAL COLL SURGEONS ENGLAND PI LONDON PA 35-43 LINCOLN'S INN FIELDS, LONDON WC2A 3PN, ENGLAND SN 0035-8843 EI 1478-7083 J9 ANN ROY COLL SURG JI Ann. R. Coll. Surg. Engl. PD NOV PY 2017 VL 99 IS 8 BP 650 EP 652 DI 10.1308/rcsann.2017.0189 PG 3 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA GG9YO UT WOS:000433057600022 PM 29046091 OA Green Submitted DA 2026-04-17 ER PT J AU Li, X Fu, YL Miao, JB Li, H Hu, B AF Li, Xin Fu, Yili Miao, JinBai Li, Hui Hu, Bin TI Video-assisted thoracoscopic lobectomy after percutaneous coronary intervention in lung cancer patients with concomitant coronary heart disease SO THORACIC CANCER LA English DT Article DE Coronary heart disease; lung cancer; percutaneous coronary intervention; VATS ID NONCARDIAC SURGERY; RISK AB BackgroundIn recent years, based on clinical observations, the number of lung cancer patients with concomitant coronary heart disease (CHD) has gradually increased. However, because of the requirement of long-term anticoagulant therapy after percutaneous coronary intervention (PCI), some of these patients lose the opportunity for surgical treatment, resulting in tumor progression. The objective of this study was to determine the appropriate timing of video-assisted thoracic surgery (VATS) lobectomy after PCI without increasing perioperative cardiovascular risk. MethodsThis study retrospectively analyzed clinical data of patients with a combination of NSCLC and CHD who underwent selective pulmonary lobectomy by VATS in the early postoperative PCI period between 2010 and 2015 at Beijing Chaoyang Hospital, China. ResultsFourteen patients received VATS lobectomy after PCI. The disease had progressed to T stage in two patients after PCI. No perioperative death occurred. Two patients suffered postoperative atrial fibrillation: one had a pulmonary infection, and the other had acute coronary syndrome. All patients recovered and were discharged. ConclusionFor NSCLC patients with severe CHD, the use of VATS lobectomy in the early postoperative PCI period could not only advance the timing of surgery, but may also control perioperative hemorrhage and CHD event risks within acceptable ranges, which could provide more patients with an opportunity to undergo surgical treatment. C1 [Li, Xin; Fu, Yili; Miao, JinBai; Li, Hui; Hu, Bin] Capital Med Univ, Beijing Chaoyang Hosp, Dept Thorac Surg, Gongti South St 8th, Beijing 100020, Peoples R China. C3 Capital Medical University RP Hu, B (corresponding author), Capital Med Univ, Beijing Chaoyang Hosp, Dept Thorac Surg, Gongti South St 8th, Beijing 100020, Peoples R China. EM hubin705@aliyun.com RI Miao, Jinbai/ODI-9183-2025 CR Brichon PY, 2006, EUR J CARDIO-THORAC, V30, P793, DOI 10.1016/j.ejcts.2006.08.012 Brunelli A, 2011, ANN THORAC SURG, V92, P445, DOI 10.1016/j.athoracsur.2011.03.095 Buccheri G, 2004, EUR RESPIR J, V24, P898, DOI 10.1183/09031936.04.00113603 Chatterjee A, 2015, J NUCL CARDIOL, V22, P158, DOI 10.1007/s12350-014-9992-3 Cruden NLM, 2010, CIRC-CARDIOVASC INTE, V3, P236, DOI 10.1161/CIRCINTERVENTIONS.109.934703 Di Sciascio G, 2010, J AM COLL CARDIOL, V56, P550, DOI 10.1016/j.jacc.2010.01.067 FOSTER ED, 1986, ANN THORAC SURG, V41, P42, DOI 10.1016/S0003-4975(10)64494-3 GEDDES DM, 1979, BRIT J DIS CHEST, V73, P1, DOI 10.1016/0007-0971(79)90002-0 HUBER KC, 1992, MAYO CLIN PROC, V67, P15, DOI 10.1016/S0025-6196(12)60271-7 Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43 Kaluza GL, 2000, J AM COLL CARDIOL, V35, P1288, DOI 10.1016/S0735-1097(00)00521-0 O'Rourke N, 2000, CLIN ONCOL-UK, V12, P141, DOI 10.1053/clon.2000.9139 Ohmoto-Sekine Y, 2016, J CARDIOL, V67, P449, DOI 10.1016/j.jjcc.2015.06.010 Schulz S, 2010, EUR HEART J, V31, P2482, DOI 10.1093/eurheartj/ehq330 USUDA K, 1994, CANCER, V74, P2239, DOI 10.1002/1097-0142(19941015)74:8<2239::AID-CNCR2820740806>3.0.CO;2-P Vicenzi MN, 2006, BRIT J ANAESTH, V96, P686, DOI 10.1093/bja/ael083 Widimsky P, 2008, EUR HEART J, V29, P1495, DOI 10.1093/eurheartj/ehn169 NR 17 TC 5 Z9 6 U1 0 U2 2 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1759-7706 EI 1759-7714 J9 THORAC CANCER JI Thorac. Cancer PD SEP PY 2017 VL 8 IS 5 BP 477 EP 481 DI 10.1111/1759-7714.12471 PG 5 WC Oncology; Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Respiratory System GA FF7IG UT WOS:000409189100014 PM 28749044 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Farjah, F AF Farjah, Farhood TI Failure-to-Rescue in Thoracic Surgery SO THORACIC SURGERY CLINICS LA English DT Article DE Failure-to-rescue; Quality improvement; Thoracic surgery ID IN-HOSPITAL MORTALITY; LUNG-CANCER RESECTION; PULMONARY RESECTION; ATRIAL-FIBRILLATION; SURGICAL OUTCOMES; OPERATIVE MORTALITY; RANDOMIZED-TRIAL; QUALITY; VOLUME; CARE AB Variability in outcomes not attributable to case mix or chance is an indicator of low quality care. Failure-to-rescue is an outcome measure defined as death during a hospitalization among patients who experience a complication. Researchers have used this measure to better understand the determinants of an untimely death preventing complications, rescue, or both. Studies repeatedly find that complication rates vary little, if at all, across hospitals ranked by risk-adjusted mortality rates, suggesting that hospitals are equally capable (or incapable) of preventing complications. In contrast, variation in failure-to-rescue rates seems to explain much of the variation in risk-adjusted hospital-level mortality rates. These findings suggest that system-level interventions that allow for the early detection and treatment of complications (ie, rescue) may reduce variability in hospital-level outcomes and improve the quality of thoracic surgical care. C1 [Farjah, Farhood] Univ Washington, Div Cardiothorac Surg, 1959 Northeast Pacific St,Box 356310, Seattle, WA 98195 USA. C3 University of Washington; University of Washington Seattle RP Farjah, F (corresponding author), Univ Washington, Div Cardiothorac Surg, 1959 Northeast Pacific St,Box 356310, Seattle, WA 98195 USA. EM ffarjah@uw.edu CR Agency for Healthcare Research and Quality, 2015, FAIL RESC PERC PAT W Aiken LH, 2003, JAMA-J AM MED ASSOC, V290, P1617, DOI 10.1001/jama.290.12.1617 Aiken LH, 2002, JAMA-J AM MED ASSOC, V288, P1987, DOI 10.1001/jama.288.16.1987 Almoudaris AM, 2013, JAMA SURG, V148, P272, DOI 10.1001/jamasurg.2013.791 [Anonymous], 2014, Nursing shortage fact sheet Arlow Renee L, 2014, Ann Surg Innov Res, V8, P9, DOI 10.1186/s13022-014-0009-3 Bach PB, 2001, NEW ENGL J MED, V345, P181, DOI 10.1056/NEJM200107193450306 Ballard ED, 2008, JT COMM J QUAL PATIE, V34, P474, DOI 10.1016/S1553-7250(08)34060-4 Bhamidipati CM, 2013, J THORAC CARDIOV SUR, V145, P60, DOI 10.1016/j.jtcvs.2012.10.015 Biere SSAY, 2012, LANCET, V379, P1887, DOI 10.1016/S0140-6736(12)60516-9 Birkmeyer JD, 2003, NEW ENGL J MED, V349, P2117, DOI 10.1056/NEJMsa035205 Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337 Birkmeyer JD, 2009, ANNU REV MED, V60, P405, DOI 10.1146/annurev.med.60.062107.101214 Brooke BS, 2012, SURGERY, V151, P651, DOI 10.1016/j.surg.2011.12.001 Brunelli Alessandro, 2006, Interact Cardiovasc Thorac Surg, V5, P92, DOI 10.1510/icvts.2005.118703 Bukur M, 2012, ARCH SURG-CHICAGO, V147, P856, DOI 10.1001/archsurg.2012.1672 Bureau of Labor Statistics, 1997, OCC HOM SEL CHAR 199 Dimick JB, 2004, JAMA-J AM MED ASSOC, V292, P847, DOI 10.1001/jama.292.7.847 DONABEDIAN A, 1966, MILBANK FUND Q, V44, P166, DOI 10.2307/3348969 Etzioni DA, 2015, JAMA-J AM MED ASSOC, V313, P505, DOI 10.1001/jama.2015.90 Farjah F, 2015, J THORAC CARDIOV SUR, V149, P1365, DOI 10.1016/j.jtcvs.2015.01.063 Farjah F, 2014, ANN THORAC SURG, V98, P175, DOI 10.1016/j.athoracsur.2014.03.014 Farjah F, 2009, ANN THORAC SURG, V87, P995, DOI 10.1016/j.athoracsur.2008.12.030 Fernandez FG, 2016, ANN THORAC SURG, V102, P370, DOI 10.1016/j.athoracsur.2016.02.098 Friese CR, 2010, SURGERY, V147, P602, DOI 10.1016/j.surg.2009.03.014 Ghaferi AA, 2011, MED CARE, V49, P1076, DOI 10.1097/MLR.0b013e3182329b97 Ghaferi AA, 2010, J AM COLL SURGEONS, V211, P325, DOI 10.1016/j.jamcollsurg.2010.04.025 Ghaferi AA, 2009, ANN SURG, V250, P1029, DOI 10.1097/SLA.0b013e3181bef697 Ghaferi AA, 2009, NEW ENGL J MED, V361, P1368, DOI 10.1056/NEJMsa0903048 Goodney PP, 2005, ANN SURG, V241, P179 Gopaldas RR, 2013, ANN THORAC SURG, V95, P1064, DOI 10.1016/j.athoracsur.2012.10.038 Grenda TR, 2015, JAMA SURG, V150, P1034, DOI 10.1001/jamasurg.2015.2199 Henneman D, 2013, ANN SURG ONCOL, V20, P3370, DOI 10.1245/s10434-013-3037-z Hillman K, 2005, LANCET, V365, P2091 Katlic MR, 2011, CA-CANCER J CLIN, V61, P382, DOI 10.3322/caac.20119 KIRBY TJ, 1995, J THORAC CARDIOV SUR, V109, P997, DOI 10.1016/S0022-5223(95)70326-8 Kirby TJ, 1995, J THORAC CARDIOVASC, V109, P1001 Kollef MH, 2014, J HOSP MED, V9, P424, DOI 10.1002/jhm.2193 Lawson EH, 2012, ANN SURG, V256, P973, DOI 10.1097/SLA.0b013e31826b4c4f Little AG, 2005, ANN THORAC SURG, V80, P2051, DOI 10.1016/j.athoracsur.2005.06.071 MacKenzie TA, 2015, ANN THORAC SURG, V99, P757, DOI 10.1016/j.athoracsur.2014.11.039 Magee MJ, 2013, ANN THORAC SURG, V96, P1734, DOI 10.1016/j.athoracsur.2013.04.124 MALENKA DJ, 1995, JOINT COMM J QUAL IM, V21, P627, DOI 10.1016/S1070-3241(16)30191-2 Massarweh NN, 2016, JAMA SURG, V151, P1157, DOI 10.1001/jamasurg.2016.2920 Massarweh NN, 2016, ANN SURG Mehta HB, 2016, MED CARE, V54, P180, DOI 10.1097/MLR.0000000000000465 Needleman J, 2002, NEW ENGL J MED, V346, P1715, DOI 10.1056/NEJMsa012247 Nojiri T, 2015, CHEST, V148, P1285, DOI 10.1378/chest.15-0852 O'Connor GT, 1998, ANN THORAC SURG, V66, P1323, DOI 10.1016/S0003-4975(98)00762-0 Osborne NH, 2015, JAMA-J AM MED ASSOC, V313, P496, DOI 10.1001/jama.2015.25 Pasquali SK, 2012, ANN THORAC SURG, V94, P573, DOI 10.1016/j.athoracsur.2012.03.065 Pradarelli JC, 2016, JAMA SURG, V151, DOI 10.1001/jamasurg.2016.3340 Pradarelli JC, 2017, ANN SURG, V265, P502, DOI 10.1097/SLA.0000000000001706 Reames BN, 2014, JAMA SURG, V149, P475, DOI 10.1001/jamasurg.2013.5076 Reddy HG, 2013, ANN THORAC SURG, V95, P1976, DOI 10.1016/j.athoracsur.2013.03.027 Riber LP, 2012, ANN THORAC SURG, V94, P339, DOI 10.1016/j.athoracsur.2011.12.096 Romano PS, 2002, MED CARE, V40, P856, DOI 10.1097/00005650-200210000-00004 Rosen AK, 2005, MED CARE, V43, P873, DOI 10.1097/01.mlr.0000173561.79742.fb Shannon FL, 2012, ANN THORAC SURG, V93, P36, DOI 10.1016/j.athoracsur.2011.07.057 Sheetz KH, 2016, ANN SURG, V263, P692, DOI 10.1097/SLA.0000000000001414 Shiloach M, 2010, J AM COLL SURGEONS, V210, P6, DOI 10.1016/j.jamcollsurg.2009.09.031 Silber JH, 2007, MED CARE, V45, P918, DOI 10.1097/MLR.0b013e31812e01cc SILBER JH, 1992, MED CARE, V30, P615, DOI 10.1097/00005650-199207000-00004 Sukumar S, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002843 The Joint Commission, 2014, PREV VIOL CRIM EV Tisdale JE, 2010, J THORAC CARDIOV SUR, V140, P45, DOI 10.1016/j.jtcvs.2010.01.026 Tisdale JE, 2009, ANN THORAC SURG, V88, P886, DOI 10.1016/j.athoracsur.2009.04.074 Wakeam E, 2014, JAMA SURG, V149, P229, DOI 10.1001/jamasurg.2013.3566 Wood DE, 2009, ANN THORAC SURG, V88, P515, DOI 10.1016/j.athoracsur.2009.04.010 Wright CD, 2008, ANN THORAC SURG, V85, P1857, DOI 10.1016/j.athoracsur.2008.03.024 Yasunaga H, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-129 NR 71 TC 16 Z9 17 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1547-4127 EI 1558-5069 J9 THORAC SURG CLIN JI Thorac. Surg. Clin. PD AUG PY 2017 VL 27 IS 3 BP 257 EP + DI 10.1016/j.thorsurg.2017.03.005 PG 11 WC Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System; Surgery GA FC6WP UT WOS:000406982700007 PM 28647072 DA 2026-04-17 ER PT J AU Fourdrain, A De Dominicis, F Bensussan, M Iquille, J Lafitte, S Michel, D Berna, P AF Fourdrain, A. De Dominicis, F. Bensussan, M. Iquille, J. Lafitte, S. Michel, D. Berna, P. TI Three-dimensional computed tomography angiography of the pulmonary veins and their anatomical variations: involvement in video-assisted thoracoscopic surgery-lobectomy for lung cancer SO FOLIA MORPHOLOGICA LA English DT Article DE pulmonary vein; anatomical variation; lobectomy; lung cancer; left atrium; video-assisted thoracoscopic surgery (VATS) ID RADIOFREQUENCY CATHETER ABLATION; MULTIDETECTOR ROW CT; ATRIAL-FIBRILLATION; VENOUS DRAINAGE AB Background: Identification and section of pulmonary veins are an essential part of anatomical pulmonary resections. Intraoperative misunderstandings of pulmonary venous anatomy can lead to serious complications such as bleeding and delayed lung infarction or necrosis. We evaluated principally the rate of pulmonary venous anatomical variations, and secondarily the reliability and clinical outcomes of a preoperative morphological analysis. Materials and methods: Between November 2012 and October 2013, we studied 100 consecutive patients with highly suspected or diagnosed stage I-II primitive lung cancer lesion. The surgical procedure initially retained was video- assisted thoracoscopic surgery (VATS) pulmonary resections and we studied preoperatively the proximal pulmonary venous anatomy using 64 channels multi-detector computed tomography (CT)-scan angiography to describe the venous anatomical variations. Results: There were 65 men and 35 women with a mean age of 63 years. A pulmonary venous anatomical variation was present in 36 (36%) patients, and right-sided anatomical variations were more frequent than on left-sided ones (25% vs. 11%). The most frequent variation encountered on the right side was the existence of three separate pulmonary veins (16%), and on the left side a single pulmonary vein (8%). Surgical conversion occurred in 21% and we didn't experience a pulmonary venous lesion (0%) or a post-operative lung infarction (0%). Conclusions: We described pulmonary venous anatomical variations and their frequency. Anatomical variations exist and preoperative assessment of pulmonary venous anatomy using CT scan is a useful tool in VATS lobectomy to avoid unnecessary extension of pulmonary resections or iatrogenic complications in lung cancer surgery. C1 [Fourdrain, A.; De Dominicis, F.; Bensussan, M.; Iquille, J.; Lafitte, S.; Michel, D.; Berna, P.] Univ Picardy, Amiens Univ Hosp, Dept Thorac Surg, F-80054 Amiens 1, France. C3 Universite de Picardie Jules Verne (UPJV); CHU Amiens RP Fourdrain, A (corresponding author), Univ Picardy, Amiens Univ Hosp, Dept Thorac Surg, F-80054 Amiens 1, France.; Fourdrain, A (corresponding author), Univ Picardy, Lab Anat & Organogenese, F-80036 Amiens 1, France. EM fourdrain.alex@chu-amiens.fr RI Fourdrain, Alex/PHP-2405-2026 OI berna, pascal/0000-0003-2856-4951 CR Arslan G, 2008, EUR J RADIOL, V67, P300, DOI 10.1016/j.ejrad.2007.07.005 Asai K, 2005, ANN THORAC SURG, V79, P1866, DOI 10.1016/j.athoracsur.2004.12.014 Douglas YL, 2011, INT J CARDIOL, V147, P13, DOI 10.1016/j.ijcard.2010.07.004 Endo S, 2009, ANN THORAC SURG, V87, pE9, DOI 10.1016/j.athoracsur.2008.08.051 Fukuhara K, 2008, EUR J CARDIO-THORAC, V34, P875, DOI 10.1016/j.ejcts.2008.07.014 Jongbloed MRM, 2005, RADIOLOGY, V234, P702, DOI 10.1148/radiol.2343031047 Jongbloed MRM, 2005, J AM COLL CARDIOL, V45, P343, DOI 10.1016/j.jacc.2004.10.040 Lacomis JM, 2003, RADIOGRAPHICS, V23, pS35, DOI 10.1148/rg.23si035508 Lickfett L, 2005, J CARDIOVASC ELECTR, V16, P582, DOI 10.1046/j.1540-8167.2005.40724.x Marom EM, 2004, RADIOLOGY, V230, P824, DOI 10.1148/radiol.2303030315 Minamoto K, 2007, ACTA MED OKAYAMA, V61, P103 Mlcochová H, 2005, PACE, V28, P1073, DOI 10.1111/j.1540-8159.2005.00228.x Nakamura T, 2009, ANN THORAC SURG, V87, P954, DOI 10.1016/j.athoracsur.2008.07.054 Rajeshwari MS, 2012, ISRN PULMONOLOGY, DOI DOI 10.5402/2012/786549 Sasaki H, 2006, CLIN LUNG CANCER, V7, P350, DOI 10.3816/CLC.2006.n.018 Schwartzman D, 2003, J AM COLL CARDIOL, V41, P1349, DOI 10.1016/S0735-1097(03)00124-4 Shukla L, 2012, J ANAT SOC INDIA, V61, P5 Webb S, 2001, CARDIOL YOUNG, V11, P632, DOI 10.1017/S1047951101000993 William L., 2003, EMBRYOLOGIE HUMAINE, P548 Yamada S, 2010, INTERACT CARDIOV TH, V10, P851, DOI 10.1510/icvts.2009.221804 Yamashita H., 1978, ROENTGENOLOGIC ANATO, V1978, P70 NR 21 TC 19 Z9 24 U1 0 U2 3 PU VIA MEDICA PI GDANSK PA UL SWIETOKRZYSKA 73, 80-180 GDANSK, POLAND SN 0015-5659 EI 1644-3284 J9 FOLIA MORPHOL JI Folia Morphol. PD AUG PY 2017 VL 76 IS 3 BP 388 EP 393 DI 10.5603/FM.a2016.0081 PG 6 WC Anatomy & Morphology WE Science Citation Index Expanded (SCI-EXPANDED) SC Anatomy & Morphology GA FG3VM UT WOS:000410127000008 PM 28026848 OA gold DA 2026-04-17 ER PT J AU Alonso-Coello, P Cook, D Xu, SC Sigamani, A Berwanger, O Sivakumaran, S Yang, H Xavier, D Martinez, LX Ibarra, P Rao-Melacini, P Pogue, J Zarnke, K Paniagua, P Ostrander, J Yusuf, S Devereaux, PJ AF Alonso-Coello, Pablo Cook, Deborah Xu, Shou Chun Sigamani, Alben Berwanger, Otavio Sivakumaran, Soori Yang, Homer Xavier, Denis Martinez, Luz Ximena Ibarra, Pedro Rao-Melacini, Purnima Pogue, Janice Zarnke, Kelly Paniagua, Pilar Ostrander, Jack Yusuf, Salim Devereaux, P. J. CA POISE Investigators TI Predictors, Prognosis, and Management of New Clinically Important Atrial Fibrillation After Noncardiac Surgery: A Prospective Cohort Study SO ANESTHESIA AND ANALGESIA LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; THORACIC-SURGERY; CARDIAC-SURGERY; LUNG-CANCER; POISE TRIAL; METOPROLOL AB BACKGROUND: Despite the frequency of new clinically important atrial fibrillation (AF) after non-cardiac surgery and its increased association with the risk of stroke at 30 days, there are limited data informing their prediction, association with outcomes, and management. METHODS: We used the data from the PeriOperative ISchemic Evaluation trial to determine, in patients undergoing noncardiac surgery, the association of new clinically important AF with 30-day outcomes, and to assess management of these patients. We also aimed to derive a clinical prediction rule for new clinically important AF in this population. We defined new clinically important AF as new AF that resulted in symptoms or required treatment. We recorded an electrocardiogram 6 to 12 hours postoperatively and on the 1st, 2nd, and 30th days after surgery. RESULTS: A total of 211 (2.5% [8351 patients]; 95% confidence interval, 2.2%-2.9%) patients developed new clinically important AF within 30 days of randomization (8140 did not develop new AF). AF was independently associated with an increased length of hospital stay by 6.0 days (95% confidence interval, 3.5-8.5 days) and vascular complications (eg, stroke or congestive heart failure). The usage of an oral anticoagulant at the time of hospital discharge among patients with new AF and a CHADS(2) score of 0, 1, 2, 3, and >= 4 was 6.9%, 10.2%, 23.0%, 9.4%, and 33.3%, respectively. Two independent predictors of patients developing new clinically important AF were identified (ie, age and surgery). The prediction rule included the following factors and assigned weights: age >= 85 years (4 points), age 75 to 84 years (3 points), age 65 to 74 years (2 points), intrathoracic surgery (3 points), major vascular surgery (2 points), and intra-abdominal surgery (1 point). The incidence of new AF based on scores of 0 to 1, 2, 3 to 4, and 5 to 6 was 0.5%, 1.0%, 3.1%, and 5.3%, respectively. CONCLUSIONS: Age and surgery are independent predictors of new clinically important AF in the perioperative setting. A minority of patients developing new clinically important AF with high CHADS2 scores are discharged on an oral anticoagulant. There is a need to develop effective and safe interventions to prevent this outcome and to optimize the management of this event when it occurs. C1 [Alonso-Coello, Pablo] CIBERESP, Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain. [Cook, Deborah; Yusuf, Salim; Devereaux, P. J.] McMaster Univ, Dept Med & Clin Epidemiol, Hamilton, ON, Canada. [Cook, Deborah; Yusuf, Salim; Devereaux, P. J.] McMaster Univ, Dept Biostat, Hamilton, ON, Canada. [Xu, Shou Chun] Hypertens League Inst, Beijing, Peoples R China. [Sigamani, Alben] Narayana Hrudyalaya Ltd, Dept Clin Res, Bangalore, Karnataka, India. [Berwanger, Otavio] Hosp Coracao, Res Inst HCor, Heart Hosp, Sao Paulo, Brazil. [Sivakumaran, Soori] Univ Alberta, Dept Med, Edmonton, AB, Canada. [Yang, Homer] Univ Ottawa, Dept Anaesthesia, Ottawa, ON, Canada. [Xavier, Denis] St Johns Med Coll, Bangalore, Karnataka, India. [Xavier, Denis] St Johns Res Inst, Bangalore, Karnataka, India. [Martinez, Luz Ximena] Univ Autonoma Bucaramanga, Dept Med, Bucaramanga, Colombia. [Ibarra, Pedro] Clin Reina Sofia, Dept Anaesthesia, Bogota, Colombia. [Rao-Melacini, Purnima; Pogue, Janice] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada. [Zarnke, Kelly] Univ Calgary, Dept Med, Calgary, AB, Canada. [Paniagua, Pilar] Hosp Sta Creu & St Pau, Dept Anesthesiol, Barcelona, Spain. [Ostrander, Jack] Grey Bruce Hlth Sci, Dept Med, Owen Sound, ON, Canada. [Yusuf, Salim; Devereaux, P. J.] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada. C3 CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Institut de Recerca Sant Pau; McMaster University; McMaster University; Universidade de Sao Paulo; Hospital do Coracao - HCor; University of Alberta; University of Ottawa; St. John's National Academy of Health Sciences; St. John's Medical College; St. John's National Academy of Health Sciences; St. John's Research Institute; Universidad Autonoma de Bucaramanga; McMaster University; Population Health Research Institute; University of Calgary; McMaster University; Population Health Research Institute RP Alonso-Coello, P (corresponding author), Hosp Santa Creu & Sant Pau, Biomed Res Inst Sant Pau IIB St Pau, CIBERESP, Pavellon 18,C St Antoni M Claret 167, Barcelona 08025, Spain. EM palonso@santpau.cat RI Devereaux, PJ/AAF-2862-2019; SIGAMANI, ALBEN/GQH-0406-2022; Alonso-Coello, Pablo/AFK-2890-2022; Elgar, Frank/ABE-7450-2020; Ibarra, Pedro/LDG-4535-2024 OI Berwanger, Otavio/0000-0002-4972-2958; SIGAMANI, ALBEN/0000-0002-6927-1947; Yusuf, Salim/0000-0003-4776-5601; Alonso-Coello, Pablo/0000-0002-8001-8504; FU Canadian Institutes of Health Research; National Health and Medical Research Council of the Commonwealth Government of Australia; Instituto de Salud Carlos III (Ministerio de Sanidad y Consumo) in Spain; British Heart Foundation; AstraZeneca FX Funding for this study was received from the Canadian Institutes of Health Research, the National Health and Medical Research Council of the Commonwealth Government of Australia, the Instituto de Salud Carlos III (Ministerio de Sanidad y Consumo) in Spain, the British Heart Foundation, and AstraZeneca, which provided the study drug and funding for drug labeling, packaging, and shipping, and helped support the cost of some national POISE investigator meetings. CR Austin PC, 2004, AM STAT, V58, P131, DOI 10.1198/0003130043277 Bessissow A, 2015, J THROMB HAEMOST, V13, pS304, DOI 10.1111/jth.12974 Bessissow A, 2015, THROMB HAEMOST S1, pS304 Cardinale D, 2007, CIRCULATION, V115, P1339, DOI 10.1161/CIRCULATIONAHA.106.647008 Devereaux PJ, 2008, LANCET, V371, P1839, DOI 10.1016/S0140-6736(08)60601-7 Devereaux PJ, 2006, AM HEART J, V152, P223, DOI 10.1016/j.ahj.2006.05.019 Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864 GOLDMAN L, 1978, CHEST, V73, P450, DOI 10.1378/chest.73.4.450 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Passman RS, 2005, ANN THORAC SURG, V79, P1698, DOI 10.1016/j.athoracsur.2004.10.058 Polanczyk CA, 1998, ANN INTERN MED, V129, P279, DOI 10.7326/0003-4819-129-4-199808150-00003 Sullivan LM, 2004, STAT MED, V23, P1631, DOI 10.1002/sim.1742 Walsh SR, 2007, ANN ROY COLL SURG, V89, P91, DOI 10.1308/003588407X168253 Weiser TG, 2008, LANCET, V372, P139, DOI 10.1016/S0140-6736(08)60878-8 NR 14 TC 36 Z9 42 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD JUL PY 2017 VL 125 IS 1 BP 162 EP 169 DI 10.1213/ANE.0000000000002111 PG 8 WC Anesthesiology WE Science Citation Index Expanded (SCI-EXPANDED) SC Anesthesiology GA EY1ZB UT WOS:000403766500026 PM 28622175 DA 2026-04-17 ER PT J AU Fitzpatrick, T Carrier, M Le Gal, G AF Fitzpatrick, Tess Carrier, Marc Le Gal, Gregoire TI Cancer, atrial fibrillation, and stroke SO THROMBOSIS RESEARCH LA English DT Review ID RECURRENT VENOUS THROMBOEMBOLISM; ACUTE ISCHEMIC-STROKE; C-REACTIVE PROTEIN; LUNG-CANCER; RISK-FACTORS; THORACIC-SURGERY; DIAGNOSIS; CLASSIFICATION; INFLAMMATION; ARRHYTHMIAS AB Cancer patients appear to be at increased risk for atrial fibrillation. Although surgery and chemotherapy exacerbate this risk, this association is observed even in the absence of any cancer-specific treatment. The underlying mechanism of this is likely multifactorial, but systemic inflammation and autonomic dysregulation are hypothesized to play critical roles. Cancer and atrial fibrillation are both independent risk factors for ischemic stroke; however, it is not clear whether this translates to an increased risk of stroke in patients with both comorbidities. As such, commonly used risk stratification tools including the CHADS2 score currently do not take cancer into account as a variable and it is possible that stroke risk is underestimated in this population. There is a paucity of data regarding anticoagulant choice in cancer patients with atrial fibrillation. Vitamin K antagonists are often preferred over direct oral anticoagulants; however, this may be changing in the near future as new trials specific to this patient population emerge. (C) 2017 Elsevier Ltd. All rights reserved. C1 [Fitzpatrick, Tess] Univ Ottawa, Ottawa Hosp Res Inst, Div Neurol, Ottawa, ON, Canada. [Carrier, Marc; Le Gal, Gregoire] Univ Ottawa, Ottawa Hosp Res Inst, Div Hematol, Ottawa, ON, Canada. C3 University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute RP Le Gal, G (corresponding author), Ottawa Hosp, Div Hematol, Gen Campus,Box 201A,501 Smyth Rd, Ottawa, ON K1H 8L6, Canada. EM glegal@toh.ca RI ; LE GAL, Grégoire/K-1077-2012 OI Fitzpatrick, Tess/0000-0003-4087-4653; LE GAL, Grégoire/0000-0002-9253-248X FU Province of Ontario; Heart and Stroke Foundation of Ontario Clinician Scientist Award; University of Ottawa Department of Medicine Chair on Diagnosis of Venous Thromboembolism FX Gregoire Le Gal holds an Early Researcher Award from the Province of Ontario, a Heart and Stroke Foundation of Ontario Clinician Scientist Award, and a University of Ottawa Department of Medicine Chair on Diagnosis of Venous Thromboembolism. CR ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35 Allin KH, 2011, CRIT REV CL LAB SCI, V48, P155, DOI 10.3109/10408363.2011.599831 Ambrus DB, 2016, THROMB RES, V144, P21, DOI 10.1016/j.thromres.2016.05.028 [Anonymous], JAMA CARDIOL 0525 [Anonymous], S COND EUR SOC CARD Aviles RJ, 2003, CIRCULATION, V108, P3006, DOI 10.1161/01.CIR.0000103131.70301.4F BECKNIEL.J, 1973, ACTA MED SCAND, V193, P425 Cardinale D, 2016, ANN SURG, V264, P244, DOI 10.1097/SLA.0000000000001626 Cestari DM, 2004, NEUROLOGY, V62, P2025, DOI 10.1212/01.WNL.0000129912.56486.2B Chen PC, 2011, STROKE, V42, P3034, DOI 10.1161/STROKEAHA.111.615534 Cheng WL, 2016, INT J CARDIOL, V219, P186, DOI 10.1016/j.ijcard.2016.06.009 Chin JH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154931 Chung MK, 2001, CIRCULATION, V104, P2886, DOI 10.1161/hc4901.101760 Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561 Dipasco PJ, 2011, J SURG ONCOL, V104, P316, DOI 10.1002/jso.21925 Erichsen R, 2012, INTERN EMERG MED, V7, P431, DOI 10.1007/s11739-011-0701-9 Farmakis D, 2014, J AM COLL CARDIOL, V63, P945, DOI 10.1016/j.jacc.2013.11.026 Fatema K, 2009, AM J HEMATOL, V84, P499, DOI 10.1002/ajh.21459 Ferreira C, 2015, ARQ BRAS CARDIOL, V105, P519, DOI 10.5935/abc.20150142 Fitzgerald JL, 2016, DRUG SAFETY, V39, P841, DOI 10.1007/s40264-016-0443-8 Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864 Giugliano RP, 2013, NEW ENGL J MED, V369, P2093, DOI 10.1056/NEJMoa1310907 Gon Y, 2016, ANN CLIN TRANSL NEUR, V3, P280, DOI 10.1002/acn3.291 Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039 Guzzetti S, 2008, INTERN EMERG MED, V3, P227, DOI 10.1007/s11739-008-0124-4 Hu YF, 2013, INT J CARDIOL, V165, P355, DOI 10.1016/j.ijcard.2012.08.036 Imperatori A, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-4 January CT., 2014, J AM COLL CARDIOL Kim MH, 2010, ANN CLIN LAB SCI, V40, P336 Kono T, 2012, GERIATR GERONTOL INT, V12, P468, DOI 10.1111/j.1447-0594.2011.00796.x Lee AYY, 2003, NEW ENGL J MED, V349, P146, DOI 10.1056/NEJMoa025313 Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584 Mathur P, 2016, CL LYMPH MYELOM LEUK, V16, P70, DOI 10.1016/j.clml.2015.10.001 O'Neal WT, 2015, ATHEROSCLEROSIS, V243, P192, DOI 10.1016/j.atherosclerosis.2015.09.009 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Ostenfeld EB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102861 Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638 Prandoni P, 2002, BLOOD, V100, P3484, DOI 10.1182/blood-2002-01-0108 Randhawa Jaskirat, 2014, Clin Adv Hematol Oncol, V12, P675 Schwarzbach CJ, 2012, STROKE, V43, P3029, DOI 10.1161/STROKEAHA.112.658625 Seok JM, 2010, ANN NEUROL, V68, P213, DOI 10.1002/ana.22050 Short NJ, 2014, ONCOLOGIST, V19, P82, DOI 10.1634/theoncologist.2013-0239 Siu CW, 2005, PACE, V28, pS120, DOI 10.1111/j.1540-8159.2005.00024.x Tamargo J, 2012, DISCOV MED, V14, P295 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Viganego F, 2016, CURR CARDIOL REP, V18, DOI 10.1007/s11886-016-0730-0 WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983 Zhang LZ, 2016, J CARDIOVASC PHARM, V67, P351, DOI 10.1097/FJC.0000000000000351 NR 48 TC 35 Z9 41 U1 0 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0049-3848 EI 1879-2472 J9 THROMB RES JI Thromb. Res. PD JUL PY 2017 VL 155 BP 101 EP 105 DI 10.1016/j.thromres.2017.05.006 PG 5 WC Hematology; Peripheral Vascular Disease WE Science Citation Index Expanded (SCI-EXPANDED) SC Hematology; Cardiovascular System & Cardiology GA FA8FO UT WOS:000405681800018 PM 28528288 DA 2026-04-17 ER PT J AU Kanzaki, R Kimura, T Kawamura, T Funaki, S Shintani, Y Minami, M Okumura, M AF Kanzaki, Ryu Kimura, Toru Kawamura, Tomohiro Funaki, Soichiro Shintani, Yasushi Minami, Masato Okumura, Meinoshin TI Outcomes of surgery for lung cancer in patients with atrial fibrillation as a preoperative comorbidity: a decade of experience at a single institution in Japan SO SURGERY TODAY LA English DT Article DE Lung cancer; Atrial fibrillation; Surgery ID SURGICAL COMPLICATIONS; NATRIURETIC PEPTIDE; CLASSIFICATION; RISK AB Purpose To investigate the surgical outcomes of surgery for non-small cell lung cancer (NSCLC) in patients with atrial fibrillation (AF) as a preoperative comorbidity. Methods Among 805 patients who underwent surgery for NSCLC, 27 (3.4%) had a history of AF. We analyzed the perioperative and long-term outcomes of these 27 patients. Results Fourteen patients (52%) had chronic AF and 13 (48%) had paroxysmal AF; being high rates of a comorbid illness. Nineteen patients (70%) underwent lobectomy, and 8 (30%) underwent sublobar resection. Ten patients (37%) received perioperative heparinization. There was no mortality. Other non-AF postoperative complications developed in 8 patients (30%), this incidence being higher than among the patients without AF (16%, 127 out of 778, p = 0.09). A thromboembolic event occurred in one patient (4%). With respect to the long-term outcomes, the 5-year overall survival and disease-free survival rates among the patients with AF were 70.3 and 60.8%, respectively, which were similar to those in the patients without AF (79.8 and 72.6%, p = 0.30 and 0.31). Conclusion Lung cancer surgery in patients with AF is safe and provides favorable long-term outcomes; however, thoracic surgeons should monitor these patients carefully for postoperative thromboembolic events. C1 [Kanzaki, Ryu; Kimura, Toru; Kawamura, Tomohiro; Funaki, Soichiro; Shintani, Yasushi; Minami, Masato; Okumura, Meinoshin] Osaka Univ, Dept Gen Thorac Surg, Grad Sch Med, L5-2-2 Yamadaoka, Suita, Osaka 5650871, Japan. C3 University of Osaka RP Kanzaki, R (corresponding author), Osaka Univ, Dept Gen Thorac Surg, Grad Sch Med, L5-2-2 Yamadaoka, Suita, Osaka 5650871, Japan. EM rkanzaki@tj8.so-net.ne.jp RI Kanzaki, Ryu/Q-8381-2018 OI Kanzaki, Ryu/0000-0002-6492-4021; Kimura, Toru/0000-0003-4504-232X CR [Anonymous], GUID DIAGN TREATM CO Dindo D, 2004, ANN SURG, V240, P205, DOI [10.17116/hirurgia2018090162, 10.1097/01.sla.0000133083.54934.ae] Douketis JD, 2015, NEW ENGL J MED, V373, P823, DOI 10.1056/NEJMoa1501035 Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864 Gu J, 2013, J CARDIOVASC ELECTR, V24, P148, DOI 10.1111/j.1540-8167.2012.02448.x Hollings DD, 2010, AM J SURG, V199, P558, DOI 10.1016/j.amjsurg.2009.11.006 Imperatori A, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-4 Inoue H, 2006, CIRC J, V70, P651, DOI 10.1253/circj.70.651 Inoue H, 2014, CIRC J, V78, P1997, DOI 10.1253/circj.CJ-66-0092 Japan nephrology society, 2012, Nihon Jinzo Gakkai Shi, V54, P1034 Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43 Katayama H, 2016, SURG TODAY, V46, P668, DOI 10.1007/s00595-015-1236-x Lee SH, 2006, CIRC J, V70, P100, DOI 10.1253/circj.70.100 Lubien E, 2002, CIRCULATION, V105, P595, DOI 10.1161/hc0502.103010 MOE GK, 1959, AM HEART J, V58, P59, DOI 10.1016/0002-8703(59)90274-1 Mokhles S, 2015, LUNG CANCER, V87, P283, DOI 10.1016/j.lungcan.2015.01.005 Murasaki Kagari, 2011, Nihon Rinsho, V69 Suppl 9, P567 Ohsawa M, 2005, J EPIDEMIOL, V15, P194, DOI 10.2188/jea.15.194 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Sawabata N, 2014, RESPIR INVESTIG, V52, P317, DOI 10.1016/j.resinv.2014.04.002 Sonobe M, 2011, GEN THORAC CARDIOVAS, V59, P477, DOI 10.1007/s11748-011-0775-3 Takamochi K, 2011, INTERACT CARDIOV TH, V12, P739, DOI 10.1510/icvts.2010.254821 Vaughan Wiliams EM., 1970, Symposium on cardiac arrhythmias, P449 Watanabe H, 2009, AM HEART J, V158, P629, DOI 10.1016/j.ahj.2009.06.031 NR 24 TC 5 Z9 5 U1 0 U2 2 PU SPRINGER PI NEW YORK PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES SN 0941-1291 EI 1436-2813 J9 SURG TODAY JI Surg. Today PD JUL PY 2017 VL 47 IS 7 BP 795 EP 801 DI 10.1007/s00595-016-1436-z PG 7 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA EW9GM UT WOS:000402824800004 PM 27803991 DA 2026-04-17 ER PT J AU Sandri, A Petersen, RH Decaluwé, H Moons, J Ferguson, MK Hansen, HJ Brunelli, A AF Sandri, Alberto Petersen, Rene Horsleben Decaluwe, Herbert Moons, Johnny Ferguson, Mark K. Hansen, Henrik Jessen Brunelli, Alessandro TI Coronary artery disease is associated with an increased mortality rate following video-assisted thoracoscopic lobectomy SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article DE lung cancer; lung resection; coronary artery disease; video-assisted thoracoscopic surgery; mortality; morbidity ID CELL LUNG-CANCER; PROPENSITY-MATCHED ANALYSIS; MODIFIED SCORING SYSTEM; HIGH-RISK PATIENTS; THORACIC-SURGERY; ATRIAL-FIBRILLATION; EUROPEAN-SOCIETY; PULMONARY RESECTION; STAGE-I; MORBIDITY AB Objective: To compare the incidence of major adverse cardiac events (MACE) and mortality following video-assisted thoracoscopic surgery (VATS) lobectomy in patients with and without coronary artery disease (CAD). Methods: Multicentre retrospective analysis of 1699 patients undergoing VATS lobectomy (January 2012-March 2015). CAD definition: previous acute myocardial infarct (AMI), angina, percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG). MACE definition: postoperative acute myocardial ischemia, cardiac arrest or any cardiac death. Propensity score analysis was performed to match patients with and without CAD. Outcomes of the 2 matched groups were compared. Results: The incidence of MACE andmortality for the entire population was 0.4% (7 patients) and 1.7%(29 patients); 218 patients (13%) had a history of CAD: 106 previous AMI, 55 angina, 32 CABG, and 81 PCI. The propensity score yielded 2 well-balanced groups of 218 pairs with and without CAD. MACE (CAD 2 [0.9%] vs no-CAD 1 [0.5%]; P = 1), cardiovascular and pulmonary complications (CAD 61 [28%] vs no-CAD 51 [23%]; P = .3) and postoperative stay (CAD 7.3 days vs no-CAD 6.2 days; P = .3) were not different between the groups. The incidence of atrial fibrillation (CAD 31 [14%] vs no-CAD 18 [8.2%]; P = .07), 30-day mortality (CAD: 11 [5%] vs no-CAD 2 [0.9%]; P = .02) and death among complicated patients (CAD 18% vs no-CAD 3.9%; P = .009) were higher in the CAD group. Conclusions: The incidence of MACE following VATS lobectomy in patients with CAD is low and similar to patients without CAD. However, their risk of postoperative mortality is fivefold higher compared with non-CAD patients, warranting refined preoperative functional evaluation and more intense postoperative monitoring. C1 [Sandri, Alberto; Brunelli, Alessandro] St James Univ Hosp, Dept Thorac Surg, Bexley Wing,Beckett St, Leeds LS9 7TF, W Yorkshire, England. [Petersen, Rene Horsleben; Hansen, Henrik Jessen] Copenhagen Univ Hosp, Dept Cardiothorac Surg, Copenhagen, Denmark. [Decaluwe, Herbert; Moons, Johnny] UZ Leuven, Dept Thorac Surg, Leuven, Belgium. [Ferguson, Mark K.] Univ Chicago, Dept Surg, 5841 S Maryland Ave, Chicago, IL 60637 USA. [Ferguson, Mark K.] Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA. C3 Saint James's University Hospital; University of Copenhagen; Copenhagen University Hospital; KU Leuven; University Hospital Leuven; University of Chicago; University of Chicago; Robert H. Lurie Comprehensive Cancer Center RP Brunelli, A (corresponding author), St James Univ Hosp, Dept Thorac Surg, Bexley Wing,Beckett St, Leeds LS9 7TF, W Yorkshire, England. EM alexit_2000@yahoo.com RI Sani, Alberto/K-6851-2019; Petersen, René Horsleben/KRP-4356-2024; Brunelli, Alessandro/AAV-1415-2020; Moons, Johnny/S-9623-2017; Decaluwe, Herbert/A-2436-2009 OI Sani, Alberto/0000-0001-6421-2270; Petersen, René Horsleben/0000-0002-3586-1869; Brunelli, Alessandro/0000-0002-6505-1656; Moons, Johnny/0000-0003-4553-3102; Savchenko, Oleg/0000-0002-5818-8160; Decaluwe, Herbert/0000-0002-0877-7717 FU Medtronic; Ethicon; Medela; BARD FX Dr Brunelli reports speaker honoraria from BARD. Dr Petersen reports personal fees from Medtronic, Ethicon, and Medela. Dr Hansen reports personal fees from the speakers bureau of Medtronic and BARD. All other authors have nothing to disclose with regard to commercial support. CR Ambrogi V, 2003, EUR J CARDIO-THORAC, V23, P811, DOI 10.1016/S1010-7940(03)00093-9 Austin PC, 2006, STAT MED, V25, P2084, DOI 10.1002/sim.2328 Blackstone EH, 2002, J THORAC CARDIOV SUR, V123, P8, DOI 10.1067/mtc.2002.120329 Brunelli A, 2017, EUR J CARDIO-THORAC, V51, P490, DOI 10.1093/ejcts/ezw319 Brunelli A, 2016, EUR J CARDIO-THORAC, V49, P876, DOI 10.1093/ejcts/ezv216 Brunelli A, 2013, CHEST, V143, pE166, DOI 10.1378/chest.12-2395 Brunelli A, 2010, ANN THORAC SURG, V90, P199, DOI 10.1016/j.athoracsur.2010.03.042 Burt BM, 2014, J THORAC CARDIOV SUR, V148, P19, DOI 10.1016/j.jtcvs.2014.03.007 Ciriaco P, 2002, EUR J CARDIO-THORAC, V22, P35, DOI 10.1016/S1010-7940(02)00209-9 COOK EF, 1989, J CLIN EPIDEMIOL, V42, P317 Demmy TL, 1999, ANN THORAC SURG, V68, P194, DOI 10.1016/S0003-4975(99)00467-1 Falcoz PE, 2016, EUR J CARDIO-THORAC, V49, P602, DOI 10.1093/ejcts/ezv154 Ferguson MK, 2014, ANN THORAC SURG, V97, P1135, DOI 10.1016/j.athoracsur.2013.12.032 Ferguson MK, 2012, EUR J CARDIO-THORAC, V41, P598, DOI 10.1093/ejcts/ezr081 Fernandez FG, 2015, ANN THORAC SURG, V99, P368, DOI 10.1016/j.athoracsur.2014.05.104 Fernandez FG, 2013, ANN THORAC SURG, V95, P1212, DOI 10.1016/j.athoracsur.2013.01.042 Fleisher LA, 2007, CIRCULATION, V116, pE418, DOI 10.1161/CIRCULATIONAHA.107.185699 Howington JA, 2013, CHEST, V143, pE278, DOI 10.1378/chest.12-2359 Ivanovic J, 2014, INTERACT CARDIOV TH, V18, P340, DOI 10.1093/icvts/ivt520 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Paul S, 2010, J THORAC CARDIOV SUR, V139, P366, DOI 10.1016/j.jtcvs.2009.08.026 Puri V, 2014, ANN THORAC SURG, V97, P1678, DOI 10.1016/j.athoracsur.2013.12.028 Sandri A, 2015, INTERACT CARDIOV TH, V21, P761, DOI 10.1093/icvts/ivv254 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Yan TD, 2014, EUR J CARDIO-THORAC, V45, P633, DOI 10.1093/ejcts/ezt463 Zhang RY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124512 NR 26 TC 13 Z9 13 U1 0 U2 7 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 EI 1097-685X J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD JUL PY 2017 VL 154 IS 1 BP 352 EP 357 DI 10.1016/j.jtcvs.2017.03.042 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA FA3WA UT WOS:000405374100093 PM 28412122 OA Bronze DA 2026-04-17 ER PT J AU Li, Y Ma, YL Gao, YY Wang, DD Chen, Q AF Li, Yue Ma, Yin-Lu Gao, Yong-Yin Wang, Dan-Dan Chen, Qing TI Analysis of the risk factors of postoperative cardiopulmonary complications and ability to predicate the risk in patients after lung cancer surgery SO JOURNAL OF THORACIC DISEASE LA English DT Article DE Lung cancer; surgery; lung infection; arrhythmia; risk score ID PREDICTING COMPLICATIONS; PULMONARY RESECTION; ATRIAL-FIBRILLATION; ELDERLY-PATIENTS; CIGARETTE-SMOKE; ARRHYTHMIAS; PROPHYLAXIS; INFECTIONS; RECURRENCE; PNEUMONIA AB Background: Postoperative cardiopulmonary complications might be fatal for patients with lung cancer after surgery. The aim of this study was to identify the risk factors of postoperative cardiopulmonary complications in lung cancer patients and get a fitting formula for predicting incidences of cardiopulmonary complications. Methods: We conducted a retrospective analysis of 653 patients with a diagnosis of lung cancer who underwent a surgery in the Tianjin Medical University Cancer Institute and Hospital (Tianjin, China) from January to December 2014. All patients received lung cancer surgeries. Clinical data was collected for the analysis of the influence factors of cardiopulmonary complication after lung cancer surgeries. The medical statistical analysis program R was used to calculate cardiopulmonary complication probability of classification of quantitative results. Results: Our work showed that ages, lymphocyte count, smoking history, chronic bronchitis history, operation mode and extubation time were significantly associated with lung infection both in univariate and multivariate survival analysis. And ages, smoking history, arrhythmia of electrocardiogram and operation mode were significantly associated with postoperative arrhythmia both in univariate and multivariate survival analysis. Multiple linear regressions were generated with risk factors by program R software. Finally, we got a fitting formula for predicting cardiopulmonary complications. Risk score for each patient could be obtained by this formula. Conclusions: The incidences of pulmonary infection and arrhythmia were high for patients who underwent lung cancer surgery. It is important to discriminate risk factors for each patient for reducing the risk of heart and lung complications. Preoperative quantitative evaluation of cardiopulmonary complication after operation is beneficial to the risk control. C1 [Li, Yue; Ma, Yin-Lu; Gao, Yong-Yin; Wang, Dan-Dan; Chen, Qing] Tianjin Med Univ Canc Inst & Hosp, Dept Cardiopulm Funct, Natl Clin Res Ctr Canc, Tianjin 300060, Peoples R China. [Li, Yue; Ma, Yin-Lu; Gao, Yong-Yin; Wang, Dan-Dan; Chen, Qing] Key Lab Canc Prevent & Therapy, Tianjin 300060, Peoples R China. [Li, Yue; Ma, Yin-Lu; Gao, Yong-Yin; Wang, Dan-Dan; Chen, Qing] Tianjins Clin Res Ctr Canc, Tianjin 300060, Peoples R China. C3 Tianjin Medical University RP Chen, Q (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Dept Cardiopulm Funct, Huanhuxi Rd, Tianjin 300060, Peoples R China. EM chopinliu2006@126.com CR Amar D, 2000, J THORAC CARDIOV SUR, V120, P790, DOI 10.1067/mtc.2000.109538 Andalib A, 2013, J THORAC ONCOL, V8, P554, DOI 10.1097/JTO.0b013e3182862e7e Annessi Valerio, 2009, Asian Cardiovasc Thorac Ann, V17, P272, DOI 10.1177/0218492309104772 Aoyama H, 2016, GEN THORAC CARDIOVAS, V64, P735, DOI 10.1007/s11748-016-0707-3 ASAMURA H, 1993, J THORAC CARDIOV SUR, V106, P1104, DOI 10.1016/S0022-5223(19)33985-6 Barbetakis Nikolaos, 2004, BMC Surg, V4, P7, DOI 10.1186/1471-2482-4-7 Chen L, 2016, AM J RESP CELL MOL, V55, P815, DOI 10.1165/rcmb.2016-0051OC Chkhikvadze V D, 2003, Khirurgiia (Mosk), P15 el Hammami S, 2001, Tunis Med, V79, P617 EPSTEIN SK, 1993, CHEST, V104, P694, DOI 10.1378/chest.104.3.694 Ferguson MK, 2003, EUR J CARDIO-THORAC, V23, P35, DOI 10.1016/S1010-7940(02)00675-9 Iskandar AR, 2017, TOXICOL IN VITRO, V39, P29, DOI 10.1016/j.tiv.2016.11.009 IWAMOTO K, 1993, INTERNAL MED, V32, P274, DOI 10.2169/internalmedicine.32.274 Izquierdo J M, 1995, Arch Bronconeumol, V31, P328 Kelsey CR, 2009, CANCER-AM CANCER SOC, V115, P5218, DOI 10.1002/cncr.24625 Li LL, 2017, LUNG, V195, P295, DOI 10.1007/s00408-017-9997-1 Melendez JA, 1998, ANN THORAC SURG, V66, P220, DOI 10.1016/S0003-4975(98)00319-1 Miura N, 2015, GEN THORAC CARDIOVAS, V63, P401, DOI 10.1007/s11748-015-0546-7 MORICE RC, 1992, CHEST, V101, P356, DOI 10.1378/chest.101.2.356 Nair Abhijit S, 2015, Anesth Essays Res, V9, P263, DOI [10.4103/0259-1162.154048, 10.4103/0259-1162.154048] Okada M, 1998, J THORAC CARDIOV SUR, V116, P949, DOI 10.1016/S0022-5223(98)70045-5 PIERCE RJ, 1994, AM J RESP CRIT CARE, V150, P947, DOI 10.1164/ajrccm.150.4.7921468 Pimentel BAS, 2016, EUR J CLIN MICROBIOL, V35, P927, DOI 10.1007/s10096-016-2617-9 Sanguinetti CM, 2000, INT J ANTIMICROB AG, V16, P467, DOI 10.1016/S0924-8579(00)00277-6 Schussler O, 2006, AM J RESP CRIT CARE, V173, P1161, DOI 10.1164/rccm.200510-1556OC Shiono S, 2007, J THORAC ONCOL, V2, P34, DOI 10.1097/JTO.0b013e31802bafb6 Shiono S, 2013, INTERACT CARDIOV TH, V16, P819, DOI 10.1093/icvts/ivt034 Siegs, 2014, CA CANC J CLIN, V64, P9 Song IH, 2014, EUR J CARDIO-THORAC, V45, P262, DOI 10.1093/ejcts/ezt333 Sumler ML, 2013, SEMIN CARDIOTHORAC V, V17, P9, DOI 10.1177/1089253212453620 TAYLOR RF, 1989, CHEST, V95, P476, DOI 10.1378/chest.95.2.476 Jemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI [10.1002/cncr.24446, 10.3322/caac.20107] VONKNORRING J, 1992, ANN THORAC SURG, V53, P642, DOI 10.1016/0003-4975(92)90325-X Yamauchi Y, 2013, ANN THORAC SURG, V96, P1796, DOI 10.1016/j.athoracsur.2013.06.043 Zhang LZ, 2016, J CARDIOVASC PHARM, V67, P351, DOI 10.1097/FJC.0000000000000351 NR 35 TC 9 Z9 16 U1 1 U2 8 PU AME PUBLISHING COMPANY PI SHATIN PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA SN 2072-1439 EI 2077-6624 J9 J THORAC DIS JI J. Thorac. Dis. PD JUN PY 2017 VL 9 IS 6 BP 1565 EP 1573 DI 10.21037/jtd.2017.05.42 PG 9 WC Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System GA FB0DL UT WOS:000405815000046 PM 28740670 OA hybrid DA 2026-04-17 ER PT J AU Kotova, S Wang, MS Lothrop, K Grunkemeier, G Merry, HE Handy, JR AF Kotova, Svetlana Wang, Mansen Lothrop, Katie Grunkemeier, Gary Merry, Heather E. Handy, John R. TI CHADS2 Score Predicts Postoperative Atrial Fibrillation in Patients Undergoing Elective Pulmonary Lobectomy SO ANNALS OF THORACIC SURGERY LA English DT Article ID NONCARDIAC THORACIC-SURGERY; LUNG-CANCER RESECTION; RISK-FACTORS; NATRIURETIC PEPTIDE; PREVENTION; MANAGEMENT; MORTALITY; DATABASE; SOCIETY; STROKE AB Background. Postoperative atrial fibrillation (PAF) affects 12% to 17% of patients undergoing lobectomy and is associated with increased morbidity. CHADS(2) (congestive heart failure history, hypertension history, age >= 75 years, diabetes mellitus history, and stroke or transient ischemic attack symptoms previously) is used to predict stroke risk in patients with existing AF. It also has been shown also to predict new-onset PAF. Our objective was to determine whether CHADS(2) can predict PAF in patients undergoing lobectomy. Methods. A prospective thoracic surgery clinical database was reviewed to identify adult patients, without prior AF, who underwent elective lobectomy between January 1, 2005, and June 30, 2014. Nonelective and combined operations were excluded. Two groups (PAF and no PAF) were analyzed. Results. PAF developed in 113 of 933 patients with overall incidence of 12% for the entire group. Age (>= 75 years) and coronary artery disease were the only significant preoperative characteristics between the two groups. Intensive care unit readmission, new neurologic events, length of stay, 30-day survival, and hospital mortality were significantly higher in the PAF group as were mean CHADS(2) scores (1.4 and 1.1 respectively, p = 0.0014). Incidence of PAF ranged from 7.9% in low-risk groups to 11% in moderate-risk and 17.7% in high-risk groups, which was also significant, p < 0.0002. Similar findings were noted for CHA(2)DS(2)-VASc (age in years, sex, history of congestive heart failure, history of hypertension, history of stroke/transient ischemic symptoms/thromboembolic events, history of vascular disease, history of diabetes mellitus). Conclusions. Although multiple risk factors for PAF have been described, no easily applicable clinical model exists. Observed rate of PAF was significantly lower then the previously described 12% when CHADS(2) was 0. CHADS(2) can predict PAF in patients undergoing elective lobectomy and can identify patients to selectively institute prophylactic measures in patients at the greatest risk, such as patients with score of 2 or greater. Further validation of this model is warranted in a larger group. (C) 2017 by The Society of Thoracic Surgeons C1 [Kotova, Svetlana] Providence Hlth & Serv, Div Thorac Surg, Ste 6N50,4805 NE Glisan St, Portland, OR 97213 USA. Providence Hlth & Serv, Med Data Res Ctr, Portland, OR USA. RP Kotova, S (corresponding author), Providence Hlth & Serv, Div Thorac Surg, Ste 6N50,4805 NE Glisan St, Portland, OR 97213 USA. EM skotovamd@gmail.com CR Amar D, 2012, J THORAC CARDIOV SUR, V144, P1249, DOI 10.1016/j.jtcvs.2012.06.051 Bhave PD, 2012, AM HEART J, V164, P918, DOI 10.1016/j.ahj.2012.09.004 Boffa DJ, 2014, J THORAC CARDIOV SUR, V148, P637, DOI 10.1016/j.jtcvs.2013.12.045 Cardinale D, 2007, CIRCULATION, V115, P1339, DOI 10.1161/CIRCULATIONAHA.106.647008 Cardinale D, 2016, ANN SURG, V264, P244, DOI 10.1097/SLA.0000000000001626 Coppens M, 2013, EUR HEART J, V34, P170, DOI 10.1093/eurheartj/ehs314 Dunning J, 2006, EUR J CARDIO-THORAC, V30, P852, DOI 10.1016/j.ejcts.2006.09.003 Fernando HC, 2011, ANN THORAC SURG, V92, P1144, DOI 10.1016/j.athoracsur.2011.06.104 Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864 Giambrone GP, 2016, J THORAC CARDIOV SUR, V151, P982, DOI 10.1016/j.jtcvs.2015.11.057 Hollings DD, 2010, AM J SURG, V199, P558, DOI 10.1016/j.amjsurg.2009.11.006 Imperatori A, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-4 Ivanovic J, 2014, INTERACT CARDIOV TH, V18, P340, DOI 10.1093/icvts/ivt520 Kozower BD, 2010, ANN THORAC SURG, V90, P875, DOI 10.1016/j.athoracsur.2010.03.115 Lapar DJ, 2014, ANN THORAC SURG, V98, P527, DOI 10.1016/j.athoracsur.2014.03.039 Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Park BJ, 2007, J THORAC CARDIOV SUR, V133, P775, DOI 10.1016/j.jtcvs.2006.09.022 Passman RS, 2005, ANN THORAC SURG, V79, P1698, DOI 10.1016/j.athoracsur.2004.10.058 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Sareh S, 2014, J SURG RES, V190, P407, DOI 10.1016/j.jss.2014.02.007 Shrivastava Vivek, 2004, Interact Cardiovasc Thorac Surg, V3, P656, DOI 10.1016/j.icvts.2004.08.002 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 NR 23 TC 18 Z9 19 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD MAY PY 2017 VL 103 IS 5 BP 1566 EP 1572 DI 10.1016/j.athoracsur.2016.11.007 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA EW4RN UT WOS:000402488700055 PM 28215423 DA 2026-04-17 ER PT J AU Liu, L Wu, J Zhao, W Huang, MJ AF Liu, Lan Wu, Jing Zhao, Wei Huang, Mei-Juan TI Atrial fibrillation was changed into sinus bradycardia in a ROS1-positive advanced lung adenocarcinoma patient who achieved durable response to Crizotinib A case report and literature review SO MEDICINE LA English DT Article DE atrial fibrillation; cardiotoxicity; crizotinib; lung cancer; ROS1 rearrangement ID CANCER AB Rational: The c-ros oncogene 1 receptor tyrosine kinase (ROS1)-rearrangements represent a new and rare genetic subtype of non-small- cell lung cancer. In recent years, the use of crizotinib in ROS1-rearranged lung cancer exhibits significant clinical efficacy. Crizotinib is generally well tolerated and the most frequent adverse events include visual disorders, gastrointestinal disturbances, cardiac, and endocrine abnormalities. From a cardiac perspective, crizotinib is associated with 2 main cardiac effects, QT interval prolongation and bradycardia. Patient concerns and diagnoses: We reported a case of a 67-year-old man with ROS1-rearranged advanced lung adenocarcinoma. Interventions: Crizotinib was initiated as first-line treatment, combined with whole brain radiation therapy. Outcomes: Interestingly, after treatment of crizotinib, the patient suffered a transient QTc interval prolongation and his persistent atrial fibrillation was changed into sinus bradycardia. Only 22 days after crizotinib treatment, the patient's tumor achieved a partial response. So far the patient has taken crizotinib for > 19 months with no evidence of disease progression. Lessons: The present study demonstrates dramatic benefit of crizotinib for patients with ROS1 rearrangement. Besides, we should caution the cardiac effects caused by crizotinb and our case provides evidence that crizotinib may be safe for patients with atrial fibrillation under close monitoring. C1 [Liu, Lan; Wu, Jing; Zhao, Wei; Huang, Mei-Juan] Sichuan Univ, Dept Thorac Oncol, West China Hosp, Canc Ctr,West China Med Sch, 37 Guo Xue Xiang, Chengdu 610041, Sichuan Provinc, Peoples R China. C3 Sichuan University RP Huang, MJ (corresponding author), Sichuan Univ, Dept Thorac Oncol, West China Hosp, Canc Ctr,West China Med Sch, 37 Guo Xue Xiang, Chengdu 610041, Sichuan Provinc, Peoples R China. EM hmj107@163.com CR Al-Khatib SM, 2003, JAMA-J AM MED ASSOC, V289, P2120, DOI 10.1001/jama.289.16.2120 Bergethon K, 2012, J CLIN ONCOL, V30, P863, DOI 10.1200/JCO.2011.35.6345 Dikopf A, 2015, EXPERT OPIN DRUG SAF, V14, P485, DOI 10.1517/14740338.2015.1007040 Doherty KR, 2013, TOXICOL APPL PHARM, V272, P245, DOI 10.1016/j.taap.2013.04.027 Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448 Lin JJ, 2017, J THORAC ONCOL, V12, P872, DOI 10.1016/j.jtho.2017.01.004 Mazières J, 2015, J CLIN ONCOL, V33, P992, DOI 10.1200/JCO.2014.58.3302 Mescam-Mancini L, 2014, LUNG CANCER, V83, P168, DOI 10.1016/j.lungcan.2013.11.019 Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699 Ou SHI, 2013, CANCER-AM CANCER SOC, V119, P1969, DOI 10.1002/cncr.28040 Prescribing information, 2011, PRESCR INF XALK CRIZ Shaw AT, 2014, NEW ENGL J MED, V371, P1963, DOI 10.1056/NEJMoa1406766 Tartarone A, 2015, FUTURE ONCOL, V11, P2043, DOI 10.2217/fon.15.47 Wiesweg M, 2017, J THORAC ONCOL, V12, P54, DOI 10.1016/j.jtho.2016.08.137 Wu SF, 2015, THORAC CANCER, V6, P413, DOI 10.1111/1759-7714.12191 Yasuda H, 2012, J THORAC ONCOL, V7, P1086, DOI 10.1097/JTO.0b013e3182570919 NR 16 TC 3 Z9 4 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7974 EI 1536-5964 J9 MEDICINE JI Medicine (Baltimore) PD MAY PY 2017 VL 96 IS 21 AR e6979 DI 10.1097/MD.0000000000006979 PG 4 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA EW1JE UT WOS:000402245300042 PM 28538401 OA gold DA 2026-04-17 ER PT J AU Mita, N Kuroda, M Miyoshi, S Saito, S AF Mita, Norikatsu Kuroda, Masataka Miyoshi, Sohtaro Saito, Shigeru TI Association of Preoperative Right and Left Ventricular Diastolic Dysfunction With Postoperative Atrial Fibrillation in Patients Undergoing Lung Surgery: A Prospective Observational Study SO JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA LA English DT Article DE postoperative atrial fibrillation; right ventricular diastolic dysfunction; left ventricular diastolic dysfunction; transesophageal echocardiography ID THORACIC EPIDURAL ANALGESIA; SUPRAVENTRICULAR ARRHYTHMIAS; RIGHT HEART; ECHOCARDIOGRAPHIC EVALUATION; PULMONARY RESECTION; AMERICAN SOCIETY; RISK-FACTORS; GUIDELINES; PREDICTOR AB Objectives: To clarify the relationship between right and left ventricular (RV and LV) diastolic function and postoperative atrial fibrillation (POAF). The early effects of major lung surgery on cardiac function in the intraoperative period during lung surgery were evaluated, using transesophageal echocardiography. Design: Single-center prospective observational study. Setting: A public hospital. Participants: Patients undergoing elective lobectomy with lymph node dissection for lung cancer (n = 116). Interventions: Transesophageal echocardiography examination was performed under general anesthesia before skin incision (preoperative) and after chest closure (postoperative). According to measured echocardiographic variables, ventricular systolic and diastolic functions were classified at each time point. Measurements and Main Results: Of the 116 patients, 24 (20.7%) experienced POAF. Preoperative RV and LV diastolic dysfunction were more common in patients with POAF than in those without POAF (58.3 v 28.3%, p = 0.008; 54.2 v 19.6%, p = 0.001, respectively). Among patients without preoperative diastolic dysfunction, a small number developed RV and LV diastolic dysfunction immediately after surgery (9.2% and 16.5%, respectively) and these distributions were comparable between patients with POAF and those without POAF. RV systolic dysfunction was observed in 6.5% of patients immediately after surgery and was not related to the occurrence of POAF. Multivariate analysis revealed older age, chronic obstructive pulmonary disease (COPD), and preoperative biventricular diastolic dysfunction as risk factors for POAF. Conclusions: Preoperative biventricular diastolic dysfunction, as well as older age and COPD, are associated with POAF in patients undergoing lobectomy. Major lung surgery has minimal early effects on postoperative systolic and diastolic functions. (C) 2017 Elsevier Inc. All rights reserved. C1 [Mita, Norikatsu; Miyoshi, Sohtaro] Saitama Cardiovasc & Resp Ctr, Dept Anesthesiol, 1696 Itai, Kumagaya, Saitama 3600105, Japan. [Kuroda, Masataka; Saito, Shigeru] Gunma Univ, Grad Sch Med, Dept Anesthesiol, Maebashi, Gunma, Japan. C3 Gunma University RP Mita, N (corresponding author), Saitama Cardiovasc & Resp Ctr, Dept Anesthesiol, 1696 Itai, Kumagaya, Saitama 3600105, Japan. EM mita.norikatsu@gmail.com OI Kuroda, Masataka/0009-0006-1077-3973 FU Saitama Cardiovascular and Respiratory Center [15EE]; Grants-in-Aid for Scientific Research [25462399, 16K10953] Funding Source: KAKEN FX This study was supported by a Research Fund from Saitama Cardiovascular and Respiratory Center under Grant (No.15EE). CR AMAR D, 1995, CHEST, V108, P349, DOI 10.1378/chest.108.2.349 Amar D, 2002, ANESTH ANALG, V95, P537, DOI 10.1097/00000539-200209000-00006 Amar D, 2005, CHEST, V128, P3421, DOI 10.1378/chest.128.5.3421 BUTLER J, 1983, CIRCULATION, V67, P1163, DOI 10.1161/01.CIR.67.6.1163 Caputo M, 2011, AM J CARDIOL, V108, P698, DOI 10.1016/j.amjcard.2011.04.018 Cardinale D, 2007, CIRCULATION, V115, P1339, DOI 10.1161/CIRCULATIONAHA.106.647008 Çölkesen Y, 2009, TURK KARDIYOL DERN A, V37, P317 Fabbri LM, 2008, EUR RESPIR J, V31, P204, DOI 10.1183/09031936.00114307 Foroulis CN, 2004, EUR J CARDIO-THORAC, V26, P508, DOI 10.1016/j.ejcts.2004.05.036 Fox J, 2005, J BEHAV EDUC, V14, P1, DOI 10.1007/s10864-005-0957-0 Funk GC, 2008, CHEST, V133, P1354, DOI 10.1378/chest.07-2685 Groban L, 2000, J CARDIOTHOR VASC AN, V14, P662, DOI 10.1053/jcan.2000.18318 Haddad F, 2009, ANESTH ANALG, V108, P407, DOI 10.1213/ane.0b013e31818f8623 Hahn RT, 2014, ANESTH ANALG, V118, P21, DOI 10.1213/ANE.0000000000000016 Haïssaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003 Hilberath JN, 2010, J AM SOC ECHOCARDIOG, V23, P1115, DOI 10.1016/j.echo.2010.08.013 Jiang Z, 2009, BRIT J ANAESTH, V103, P364, DOI 10.1093/bja/aep172 Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244 Komatsu R, 2015, J ANESTH, V29, P47, DOI 10.1007/s00540-014-1865-z Matyal R, 2011, ANESTH ANALG, V113, P449, DOI 10.1213/ANE.0b013e31822649ac Matyal R, 2010, ANN THORAC SURG, V90, P1080, DOI 10.1016/j.athoracsur.2010.05.019 Nojiri T, 2010, J THORAC CARDIOV SUR, V140, P764, DOI 10.1016/j.jtcvs.2009.11.073 Oka T, 2001, ANESTH ANALG, V93, P253, DOI 10.1097/00000539-200108000-00003 OKADA M, 1994, J THORAC CARDIOV SUR, V108, P503, DOI 10.1016/S0022-5223(94)70260-8 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Raman T, 2012, J THORAC CARDIOV SUR, V143, P482, DOI 10.1016/j.jtcvs.2011.08.025 Reed CE, 1996, ANN THORAC SURG, V62, P225, DOI 10.1016/0003-4975(96)00258-5 Rena O, 2001, EUR J CARDIO-THORAC, V20, P688, DOI 10.1016/S1010-7940(01)00890-9 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Rudski LG, 2010, J AM SOC ECHOCARDIOG, V23, P685, DOI 10.1016/j.echo.2010.05.010 Sekine Y, 2001, CHEST, V120, P1783, DOI 10.1378/chest.120.6.1783 Skubas N, 2009, ANESTH ANALG, V108, P48, DOI 10.1213/ane.0b013e31818a6c4c Skubas NJ, 2001, ANESTH ANALG, V93, P14 Swaminathan M, 2011, ANN THORAC SURG, V91, P1844, DOI 10.1016/j.athoracsur.2011.02.008 Tsang TSM, 2002, J AM COLL CARDIOL, V40, P1636, DOI 10.1016/S0735-1097(02)02373-2 Tutar E, 1999, AM J CARDIOL, V83, P1414, DOI 10.1016/S0002-9149(99)00111-3 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Venuta F, 2007, EUR J CARDIO-THORAC, V32, P787, DOI 10.1016/j.ejcts.2007.07.033 NR 38 TC 12 Z9 15 U1 0 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1053-0770 EI 1532-8422 J9 J CARDIOTHOR VASC AN JI J. Cardiothorac. Vasc. Anesth. PD APR PY 2017 VL 31 IS 2 BP 464 EP 473 DI 10.1053/j.jvca.2016.09.003 PG 10 WC Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease WE Science Citation Index Expanded (SCI-EXPANDED) SC Anesthesiology; Cardiovascular System & Cardiology; Respiratory System GA EU1QH UT WOS:000400794400012 PM 27887899 DA 2026-04-17 ER PT J AU Lui, JK McIntosh, LJ Valle, JE Stockl, T Summers, S AF Lui, Justin K. McIntosh, Lacey J. Valle, Jorge Escobar Stockl, Thomas Summers, Stephen TI Facial Drooping, Aphasia, and an Incidental Lung Mass in a Nonsmoker SO JOURNAL OF INTENSIVE CARE MEDICINE LA English DT Article DE squamous cell lung carcinoma; embolic stroke; atrial flutter ID LEFT ATRIAL COMPRESSION; ISCHEMIC-STROKE; FIBRILLATION; CANCER AB Background: Atrial fibrillation and atrial flutter are atrial tachycardias associated with embolic strokes. To date, there have only been a few reports highlighting the incidence of these atrial tachycardias due to mechanical compression of myocardial structures and the pulmonary vasculature in certain mediastinal masses and cysts. Case: We present a case of a 75-year-old gentleman who is a nonsmoker with a history of hypertension who presents with an acute embolic stroke due to atrial flutter likely from mechanical compression from an underlying squamous cell carcinoma of the lung. Conclusion: This case represents, to the best of our knowledge, a rare case of squamous cell carcinoma of the lung in a nonsmoker likely leading to mechanical compression and a resultant atrial tachycardia with an embolic stroke. C1 [Lui, Justin K.; Valle, Jorge Escobar; Summers, Stephen] Univ Massachusetts, Med Sch, Dept Med, 55 Lake Ave North, Worcester, MA 01655 USA. [McIntosh, Lacey J.] Univ Massachusetts, Med Sch, Dept Radiol, Worcester, MA USA. [Stockl, Thomas] Univ Massachusetts, Med Sch, Dept Pathol, Worcester, MA 01605 USA. [Summers, Stephen] Univ Massachusetts, Med Sch, Div Pulm Med, Worcester, MA USA. C3 University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester RP Lui, JK (corresponding author), Univ Massachusetts, Med Sch, Dept Med, 55 Lake Ave North, Worcester, MA 01655 USA. EM justin.lui@umassmemorial.org CR Cetin Karynsa, 2011, Clin Epidemiol, V3, P139, DOI 10.2147/CLEP.S17191 COOPER MJ, 1994, AM HEART J, V127, P950, DOI 10.1016/0002-8703(94)90573-8 Drilon A, 2012, LANCET ONCOL, V13, pE418, DOI 10.1016/S1470-2045(12)70291-7 Kuwabara H, 2012, INDIAN J PATHOL MICR, V55, P513, DOI 10.4103/0377-4929.107794 Mai H, 2015, J CLIN NEUROSCI, V22, P296, DOI 10.1016/j.jocn.2014.05.039 Molina JR, 2008, MAYO CLIN PROC, V83, P584, DOI 10.4065/83.5.584 Ostenfeld EB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102861 Parambil JG, 2006, AM J MED SCI, V331, P336, DOI 10.1097/00000441-200606000-00010 Rahman F, 2016, JAMA CARDIOL, V1, P384, DOI 10.1001/jamacardio.2016.0582 RAWLS WB, 1951, AM HEART J, V41, P311, DOI 10.1016/0002-8703(51)90109-3 Selvik HA, 2014, J STROKE CEREBROVASC, V23, P919, DOI 10.1016/j.jstrokecerebrovasdis.2013.07.041 Sereno M, 2012, CRIT REV ONCOL HEMAT, V84, P327, DOI 10.1016/j.critrevonc.2012.06.009 VOLPI A, 1988, THORAX, V43, P216, DOI 10.1136/thx.43.3.216 NR 13 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0885-0666 EI 1525-1489 J9 J INTENSIVE CARE MED JI J. Intensive Care Med. PD MAR PY 2017 VL 32 IS 3 BP 228 EP 230 DI 10.1177/0885066616676044 PG 3 WC Critical Care Medicine WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA ES7UJ UT WOS:000399756600008 PM 27798316 DA 2026-04-17 ER PT J AU Martín-Martos, F Trujillo-Santos, J del Toro, J Bura-Riviere, A Lorenzo, A Barillari, G Soler, S Mahè, I Sahuquillo, JC Monreal, M AF Martin-Martos, Francisco Trujillo-Santos, Javier del Toro, Jorge Bura-Riviere, Alessandra Lorenzo, Alicia Barillari, Giovanni Soler, Silvia Mahe, Isabelle Carles Sahuquillo, Joan Monreal, Manuel CA RIETE Investigators TI Gender differences in patients with venous thromboembolism and five common sites of cancer SO THROMBOSIS RESEARCH LA English DT Article; Proceedings Paper CT 7th International Symposium on Women's Health Issues in Thrombosis and Haemostasis CY MAR 03-05, 2017 CL Barcelona, SPAIN DE Venous thromboembolism; Gender; Cancer; Anticoagulant drugs; Recurrence; Hemorrhage; Mortality ID RECEIVING ANTICOAGULANT-THERAPY; ATRIAL-FIBRILLATION; RIETE REGISTRY; PULMONARY-EMBOLISM; SEX-DIFFERENCES; RISK AB Background: The outcome of cancer patients with venous thromboembolism (VTE) may differ according to gender. Methods: We used the RIETE database to compare the rate of VTE recurrences, major bleeding and mortality in patients with lung, colorectal, pancreatic, hematologic or gastric cancer during the course of anticoagulation, according to gender. Results: As of January 2016, 11,055 patients with active cancer were enrolled: 1,727 had lung cancer, 1,592 colorectal, 840 hematologic, 517 pancreatic and 459 had gastric cancer. Compared with men (N = 3,130), women (N = 2,005) were more likely to have colorectal, pancreatic or hematologic cancer, and less likely to have lung cancer. Most patients (91%) were initially treated with low-molecular-weight heparin (LMWH), but women received higher daily doses per body weight. Then, 66% kept receiving LMWH for long-term therapy. During the course of anticoagulation, 302 patients developed recurrent VTE, 220 bled and 1,749 died. Compared with men, women had a similar rate of VTE recurrences or major bleeding, and a lower mortality (risk ratio [RR]: 0.90; 95% CI: 0.82-0.99). When separately comparing outcomes according to cancer site, women with lung cancer had a lower mortality (RR: 0.79; 95% CI: 0.70-0.92), those with colorectal cancer had a higher mortality (RR: 1.25; 95% CI: 1.02-1.54) and those with gastric cancer had a higher rate of VTE recurrences than men (RR: 2.47; 95% CI: 1.04-5.89). Conclusions: VTE women with lung, colorectal, pancreatic, haematological or gastric cancer experienced a similar outcome during the course of anticoagulant therapy than men with similar cancers. (C) 2017 Elsevier Ltd. All rights reserved. C1 [Martin-Martos, Francisco; Trujillo-Santos, Javier] Hosp Gen Univ Santa Lucia, Dept Internal Med, Murcia, Spain. [del Toro, Jorge] Hosp Gen Univ Gregorio Maranon, Dept Internal Med, Madrid, Spain. [Bura-Riviere, Alessandra] Hop Rangueil, Dept Vasc Med, Toulouse, France. [Lorenzo, Alicia] Hosp Univ La Paz, Dept Internal Med, Madrid, Spain. [Barillari, Giovanni] Osped Santa Maria Misericordia, Dept Internal Med, Udine, Italy. [Soler, Silvia] Hosp Olot & Comarcal Garrotxa, Dept Internal Med, Girona, Spain. [Mahe, Isabelle] Univ Paris 07, Dept Internal Med, Hop Louis Mourier, Colombes APHP, Paris, France. [Carles Sahuquillo, Joan] Hosp Municipal Badalona, Dept Internal Med, Barcelona, Spain. [Monreal, Manuel] Univ Catolica Murcia, Dept Internal Med, Hosp Univ Germans Trias & Pujol Badalona, Barcelona, Spain. C3 General University Gregorio Maranon Hospital; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Hospital Universitario La Paz; Hospital Santa Maria della Misericordia; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Louis-Mourier - APHP; Hospital Germans Trias i Pujol; Universidad Catolica de Murcia RP Monreal, M (corresponding author), Hosp Badalona Germans Trias & Pujol, Dept Internal Med, Badalona 08916, Barcelona, Spain. EM mmonreal.germanstrias@gencat.cat RI ; Mahé, Isabelle/ABA-3641-2020 OI Trujillo-Santos, Javier/0000-0003-0861-9927; Barillari, Giovanni/0000-0002-0706-8839 FU Sanofi Spain; Bayer Pharma AG FX We express our gratitude to Sanofi Spain for supporting this Registry with an unrestricted educational grant. We also express our gratitude to Bayer Pharma AG for supporting this Registry. Bayer Pharma AG's support was limited to the part of RIETE outside Spain, which accounts for a 23.52% of the total patients included in the RIETE Registry. We also thank the RIETE Registry Coordinating Center, S & H Medical Science Service, for their quality control data, logistic and administrative support. CR Blanco-Molina A, 2014, MEDICINE, V93, P309, DOI 10.1097/MD.0000000000000114 Humphries KH, 2001, CIRCULATION, V103, P2365 Imberti D, 2008, HAEMATOLOGICA, V93, P273, DOI 10.3324/haematol.11458 Kuijer PMM, 1999, ARCH INTERN MED, V159, P457, DOI 10.1001/archinte.159.5.457 Levitan N, 1999, MEDICINE, V78, P285, DOI 10.1097/00005792-199909000-00001 Mahe I, 2017, AM J MED IN PRESS Martín-Martos F, 2015, THROMB RES, V135, pS12, DOI 10.1016/S0049-3848(15)50433-7 Monreal M, 2006, J THROMB HAEMOST, V4, P1950, DOI 10.1111/j.1538-7836.2006.02082.x Nieto JA, 2010, J THROMB HAEMOST, V8, P1216, DOI 10.1111/j.1538-7836.2010.03852.x Poli D, 2013, THROMB RES, V131, P12, DOI 10.1016/j.thromres.2012.10.009 Ruíz-Gimenez N, 2008, THROMB HAEMOSTASIS, V100, P26, DOI 10.1160/TH08-03-0193 Muñoz-Torrero JFS, 2011, J VASC SURG, V54, p26S, DOI 10.1016/j.jvs.2011.05.114 Shen AYJ, 2007, J AM COLL CARDIOL, V50, P309, DOI 10.1016/j.jacc.2007.01.098 Trujillo-Santos J, 2008, THROMB HAEMOSTASIS, V100, P435, DOI 10.1160/TH08-02-0125 Trujillo-Santos J, 2014, THROMB RES, V133, pS29, DOI 10.1016/S0049-3848(14)50005-9 NR 15 TC 11 Z9 12 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0049-3848 J9 THROMB RES JI Thromb. Res. PD MAR PY 2017 VL 151 SU 1 BP S16 EP S20 PG 5 WC Hematology; Peripheral Vascular Disease WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S) SC Hematology; Cardiovascular System & Cardiology GA GB0WJ UT WOS:000428770700004 PM 28262228 DA 2026-04-17 ER PT J AU Kitamura, Y Suzuki, K Teramukai, S Sonobe, M Toyooka, S Nakagawa, Y Yokomise, H Date, H AF Kitamura, Yoshitaka Suzuki, Kenji Teramukai, Satoshi Sonobe, Makoto Toyooka, Shinichi Nakagawa, Yoshihisa Yokomise, Hiroyasu Date, Hiroshi CA Japanese Assoc Chest Surg TI Feasibility of Pulmonary Resection for Lung Cancer in Patients With Coronary Artery Disease or Atrial Fibrillation SO ANNALS OF THORACIC SURGERY LA English DT Article ID DRUG-ELUTING STENTS; NONCARDIAC SURGERY; ANTIPLATELET THERAPY; PREMATURE DISCONTINUATION; PERIOPERATIVE MANAGEMENT; THROMBOSIS; IMPLANTATION; PREDICTORS; OUTCOMES; SOCIETY AB Background. The aim of this study was to clarify the outcomes of lung resection for lung cancer in patients with cardiac disease, especially coronary artery disease, in a large-scale multi-institutional cohort. Methods. We retrospectively analyzed the data on 1,254 patients who underwent major lung resection for lung cancer and had been diagnosed with coronary stenosis, atrial fibrillation, or both, in 58 institutions in Japan between January 2009 and December 2011. The primary outcome was 90-day postoperative mortality or in-hospital death. Results. Among the 1,254 patients, 902 (71.9%) and 452 patients (36.0%) were preoperatively diagnosed with coronary stenosis and atrial fibrillation, respectively, and 951 patients (75.8%) received antiplatelet therapy. Among the patients with coronary stents (n = 532; 42.4%), 204 (16.3%) received drug-eluting stents. The 90-mortality or in-hospital death rate was 2.6% (n = 32), including stent thrombosis (n= 1), thromboembolic events without stent thrombosis (n = 2), and bleeding events (n = 2). In the multivariate analyses, blood transfusion, history of cerebrovascular disease, amount of bleeding, and history of congestive heart failure were associated with a higher independent risk of 90-day mortality or in-hospital death (odds ratio, 9.400, 3.574, 2.827, and 2.945, respectively). Preoperative discontinuation of antiplatelet therapy was not associated with an independent risk of 90-day mortality or in-hospital death on univariate analysis. Conclusions. Major lung resection for lung cancer in patients with coronary artery disease is feasible. Our study suggests that discontinuation of antiplatelet therapy may not increase postoperative complications in patients with coronary artery disease. (C) 2017 by The Society of Thoracic Surgeons C1 Juntendo Univ, Dept Gen Thorac Surg, Sch Med, Tokyo, Japan. Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Biostat, Kyoto, Japan. Kyoto Univ Hosp, Dept Thorac Surg, Kyoto, Japan. Okayama Univ Hosp, Dept Gen Thorac Surg, Okayama, Japan. Tenri Hosp, Div Cardiol, Nara, Japan. Kagawa Univ, Dept Gen Thorac Breast & Endocrinol Surg, Fac Med, Takamatsu, Kagawa 760, Japan. C3 Juntendo University; Kyoto Prefectural University of Medicine; Kyoto University; Okayama University; Tenri Hospital; Kagawa University RP Suzuki, K (corresponding author), Juntendo Univ, Sch Med, Dept Thorac Surg, Bunkyo Ku, 1-3,Hongo 3 Chome, Tokyo 1138431, Japan. EM kjsuzuki@juntendo.ac.jp RI Teramukai, Satoshi/I-2249-2019 OI Teramukai, Satoshi/0000-0003-2184-0597; Kitamura, Yoshitaka/0000-0002-1903-3940 FU Ministry of Health, Labor, and Welfare, Japan FX The authors wish to thank Ms Satomi Sakabayashi of Kyoto Prefectural University of Medicine for her contribution in data analysis. This work was supported in part by a Grant-in-Aid for Cancer Research from the Ministry of Health, Labor, and Welfare, Japan. CR Abualsaud AO, 2010, JACC-CARDIOVASC INTE, V3, P131, DOI 10.1016/j.jcin.2009.11.017 Boffa DJ, 2008, J THORAC CARDIOV SUR, V135, P247, DOI 10.1016/j.jtcvs.2007.07.060 Brichon PY, 2006, EUR J CARDIO-THORAC, V30, P793, DOI 10.1016/j.ejcts.2006.08.012 Ceppa DP, 2011, ANN THORAC SURG, V92, P1971, DOI 10.1016/j.athoracsur.2011.07.052 Cerfolio RJ, 2010, J THORAC CARDIOV SUR, V140, P970, DOI 10.1016/j.jtcvs.2010.07.051 Devereaux PJ, 2014, NEW ENGL J MED, V370, P1494, DOI 10.1056/NEJMoa1401105 Eisenberg MJ, 2009, CIRCULATION, V119, P1634, DOI 10.1161/CIRCULATIONAHA.108.813667 Fleisher LA, 2007, CIRCULATION, V116, pE418, DOI 10.1161/CIRCULATIONAHA.107.185699 Grines CL, 2007, CIRCULATION, V115, P813, DOI 10.1161/CIRCULATIONAHA.106.180944 Iakovou I, 2005, JAMA-J AM MED ASSOC, V293, P2126, DOI 10.1001/jama.293.17.2126 Janssen-Heijnen MLG, 2004, THORAX, V59, P602, DOI 10.1136/thx.2003.018044 Kaluza GL, 2000, J AM COLL CARDIOL, V35, P1288, DOI 10.1016/S0735-1097(00)00521-0 Kimura T, 2010, CARDIOVASC INTERV TH, V25, P29, DOI 10.1007/s12928-009-0005-4 Kimura T, 2009, CIRCULATION, V119, P987, DOI 10.1161/CIRCULATIONAHA.108.808311 Krahn AD, 2009, HEART RHYTHM, V6, P1276, DOI 10.1016/j.hrthm.2009.05.027 Luckie M, 2009, HEART, V95, P1303, DOI 10.1136/hrt.2008.161273 Marcucci C, 2004, BRIT J ANAESTH, V92, P743, DOI 10.1093/bja/aeh110 Miyoshi S, 2011, J JPN ASS CHEST SURG, V25, P124 Sonobe M, 2011, GEN THORAC CARDIOVAS, V59, P477, DOI 10.1007/s11748-011-0775-3 Spertus JA, 2006, CIRCULATION, V113, P2803, DOI 10.1161/CIRCULATIONAHA.106.618066 Takamochi K, 2011, INTERACT CARDIOV TH, V12, P739, DOI 10.1510/icvts.2010.254821 Vicenzi MN, 2006, BRIT J ANAESTH, V96, P686, DOI 10.1093/bja/ael083 Wilson SH, 2003, J AM COLL CARDIOL, V42, P234, DOI 10.1016/S0735-1097(03)00622-3 NR 23 TC 6 Z9 7 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD FEB PY 2017 VL 103 IS 2 BP 432 EP 440 DI 10.1016/j.athoracsur.2016.08.077 PG 9 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA EP1SU UT WOS:000397165400042 PM 27793400 OA Bronze DA 2026-04-17 ER PT J AU Muranishi, Y Sonobe, M Menju, T Aoyama, A Chen-Yoshikawa, TF Sato, T Date, H AF Muranishi, Yusuke Sonobe, Makoto Menju, Toshi Aoyama, Akihiro Chen-Yoshikawa, Toyohumi F. Sato, Toshihiko Date, Hiroshi TI Atrial fibrillation after lung cancer surgery: incidence, severity, and risk factors SO SURGERY TODAY LA English DT Article DE Lung cancer; Surgery; Complication; Atrial fibrillation; Brain infarction ID PULMONARY RESECTION; THORACIC-SURGERY; CLASSIFICATION; COMPLICATIONS; VALIDATION; MORBIDITY; LOBECTOMY; TRIAL; COPD AB Atrial fibrillation (Af) is a common post-operative cardiac complication after lung cancer surgery; however, the type of lung cancer surgery being performed has evolved, remarkably, into minimally invasive surgical procedures. The purpose of this study was to quantify the incidence and severity of post-operative Af and to identify the risk factors for Af, using a recent cohort of lung cancer surgery patients. We reviewed, retrospectively, the medical records of 593 patients, who underwent lung cancer surgery between 2011 and 2013, for the development of post-operative Af. The overall incidence of post-operative Af in our study was 6.4 % (38/593). Three (8 %) of these 38 patients, subsequently, suffered brain infarction. Multivariate analysis revealed that mediastinal lymph node dissection (OR ND-2/ND-0-1 = 3.06; 95 % CI 1.06-10.9) was associated with the development of post-operative Af. Omission of mediastinal lymph dissection for patients with early stage lung cancer and a high risk of Af should be considered to prevent post-operative Af. C1 [Muranishi, Yusuke; Sonobe, Makoto; Menju, Toshi; Aoyama, Akihiro; Chen-Yoshikawa, Toyohumi F.; Sato, Toshihiko; Date, Hiroshi] Kyoto Univ, Dept Thorac Surg, Grad Sch Med, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan. C3 Kyoto University RP Date, H (corresponding author), Kyoto Univ, Dept Thorac Surg, Grad Sch Med, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan. EM hdate@kuhp.kyoto-u.ac.jp OI Menju, Toshi/0000-0002-7341-6002 CR Allen MS, 2006, ANN THORAC SURG, V81, P1013, DOI 10.1016/j.athoracsur.2005.06.066 Amar D, 2007, CURR OPIN ANESTHESIO, V20, P43, DOI 10.1097/ACO.0b013e32801158bb [Anonymous], NIHON JINZO GAKKAI S Audisio RA, 2008, CRIT REV ONCOL HEMAT, V65, P156, DOI 10.1016/j.critrevonc.2007.11.001 Ciriaco P, 2000, EUR J CARDIO-THORAC, V18, P12, DOI 10.1016/S1010-7940(00)00428-0 Devasia RA, 2009, AM J RESP CRIT CARE, V180, P365, DOI 10.1164/rccm.200901-0146OC Dindo D, 2004, ANN SURG, V240, P205, DOI [10.17116/hirurgia2018090162, 10.1097/01.sla.0000133083.54934.ae] Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864 Imperatori A, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-4 Inoue H, 2014, CIRC J, V78, P1997, DOI 10.1253/circj.CJ-66-0092 Ivanovic J, 2014, INTERACT CARDIOV TH, V18, P340, DOI 10.1093/icvts/ivt520 Iwata T, 2015, SURG TODAY, V15, P1 KIRBY TJ, 1995, J THORAC CARDIOV SUR, V109, P997, DOI 10.1016/S0022-5223(95)70326-8 Masuda M, 2014, GEN THORAC CARDIOVAS, V62, P734, DOI 10.1007/s11748-014-0464-0 MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601 NAKAHARA K, 1985, ANN THORAC SURG, V39, P260, DOI 10.1016/S0003-4975(10)62591-X Nielsen VG, 2010, BEST PRACT RES-CLIN, V24, P133, DOI 10.1016/j.bpa.2009.09.012 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Paul S, 2010, J THORAC CARDIOV SUR, V139, P366, DOI 10.1016/j.jtcvs.2009.08.026 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Scott WJ, 2010, J THORAC CARDIOV SUR, V139, P976, DOI 10.1016/j.jtcvs.2009.11.059 Sekine Y, 2001, CHEST, V120, P1783, DOI 10.1378/chest.120.6.1783 Tsukuya G, 2015, ALLERGOL INT, V64, P49, DOI 10.1016/j.alit.2014.06.002 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Wu DH, 2012, ANN THORAC SURG, V94, P193, DOI 10.1016/j.athoracsur.2012.03.057 Yamamoto T, 2015, SURG TODAY, V2015, P1 NR 26 TC 39 Z9 45 U1 0 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0941-1291 EI 1436-2813 J9 SURG TODAY JI Surg. Today PD FEB PY 2017 VL 47 IS 2 BP 252 EP 258 DI 10.1007/s00595-016-1380-y PG 7 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA EH8OY UT WOS:000392033300015 PM 27382978 DA 2026-04-17 ER PT J AU Kadohira, Y Yamada, S Matsuura, E Hayashi, T Morishita, E Nakao, S Asakura, H AF Kadohira, Yasuko Yamada, Shinya Matsuura, Erika Hayashi, Tomoe Morishita, Eriko Nakao, Shinji Asakura, Hidesaku TI Aortic Aneurysm-associated Disseminated Intravascular Coagulation that Responded Well to a Switch from Warfarin to Rivaroxaban SO INTERNAL MEDICINE LA English DT Article DE disseminated intravascular coagulation; aortic aneurysm; fibrinolytic activation; direct oral anticoagulant; rivaroxaban ID TRANEXAMIC ACID; PATIENT; MANAGEMENT AB We describe a case in which uncontrolled chronic disseminated intravascular coagulation (DIC) caused by an aortic aneurysm that was exacerbated by chemotherapy for lung cancer, showed dramatic improvement when warfarin, which was being administered for atrial fibrillation, was replaced by rivaroxaban, a direct oral anticoagulant (DOAC). The present case is interesting because a DOAC was effective in treating DIC due to an aortic aneurysm, whereas warfarin, another oral anticoagulant, was ineffective. In controlling DIC, it is important to inhibit activated coagulation factors such as thrombin and activated factor X, rather than the coagulation factors, which act as substrates. C1 [Kadohira, Yasuko; Yamada, Shinya; Matsuura, Erika; Hayashi, Tomoe; Morishita, Eriko; Nakao, Shinji; Asakura, Hidesaku] Kanazawa Univ Hosp, Dept Hematol, Kanazawa, Ishikawa, Japan. C3 Kanazawa University RP Kadohira, Y (corresponding author), Kanazawa Univ Hosp, Dept Hematol, Kanazawa, Ishikawa, Japan. EM y-kadohira@staff.kanazawa-u.ac.jp FU Grants-in-Aid for Scientific Research [15K08643] Funding Source: KAKEN CR Asakura H, 2014, J INTENSIVE CARE, V2, DOI 10.1186/2052-0492-2-20 Fukuda Naofumi, 2002, Rinsho Ketsueki, V43, P199 Hayashi T, 2014, ANN INTERN MED, V161, P158, DOI 10.7326/L14-5014-3 Iyama S, 2012, BLOOD COAGUL FIBRIN, V23, P548, DOI 10.1097/MBC.0b013e32835510d6 Kawano H, 2015, INTERNAL MED, V54, P2625, DOI 10.2169/internalmedicine.54.4942 Levi M, 1999, NEW ENGL J MED, V341, P586, DOI 10.1056/NEJM199908193410807 Levi M, 2009, BRIT J HAEMATOL, V145, P24, DOI [10.1111/j.1365-2141.2009.07600.x, 10.1111/j.1365-2141.2008.07445.x] Mori K, 1995, Rinsho Ketsueki, V36, P200 Munter G, 2001, ACTA HAEMATOL-BASEL, V105, P97, DOI 10.1159/000046542 Ontachi Y, 2005, CIRC J, V69, P1150, DOI 10.1253/circj.69.1150 Ontachi Y, 2005, HAEMATOLOGICA S, V90, pe83 RUBIN RN, 1992, DRUGS, V44, P963, DOI 10.2165/00003495-199244060-00005 SACK GH, 1977, MEDICINE, V56, P1, DOI 10.1097/00005792-197756010-00001 TAKADA A, 1990, THROMB RES, V58, P101, DOI 10.1016/0049-3848(90)90167-B Wada H, 2014, J INTENSIVE CARE, V2, DOI 10.1186/2052-0492-2-15 NR 15 TC 20 Z9 22 U1 0 U2 0 PU JAPAN SOC INTERNAL MEDICINE PI TOKYO PA 34-3 3-CHOME HONGO BUNKYO-KU, TOKYO, 113, JAPAN SN 0918-2918 EI 1349-7235 J9 INTERNAL MED JI Intern. Med. PY 2017 VL 56 IS 21 BP 2913 EP 2917 DI 10.2169/internalmedicine.8666-16 PG 5 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA FN1EI UT WOS:000415728900017 PM 28943552 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Shi, K Damhofer, H Daalhuisen, J ten Brink, M Richel, DJ Spek, CA AF Shi, Kun Damhofer, Helene Daalhuisen, Joost ten Brink, Marieke Richel, Dick J. Spek, C. Arnold TI Dabigatran Potentiates Gemcitabine-Induced Growth Inhibition of Pancreatic Cancer in Mice SO MOLECULAR MEDICINE LA English DT Article ID PROTEASE-ACTIVATED RECEPTOR-1; MOLECULAR-WEIGHT HEPARIN; DIRECT THROMBIN INHIBITORS; LUNG-CANCER; IN-VITRO; ATRIAL-FIBRILLATION; DEPENDENT MANNER; CELL ACTIVATION; BREAST-CANCER; TISSUE FACTOR AB Pancreatic cancer is one of the most lethal solid malignancies, with few treatment options. We have recently shown that expression of protease activated receptor (PAR)- 1 in the tumor microenvironment drives the progression and induces the chemoresistance of pancreatic cancer. As thrombin is the prototypical PAR-1 agonist, here we address the effects of the direct thrombin inhibitor dabigatran on pancreatic cancer growth and drug resistance in an orthotropic pancreatic cancer model. We show that dabigatran treatment did not affect primary tumor growth, whereas it significantly increased tumor dissemination throughout the peritoneal cavity. Increased dissemination was accompanied by intratumoral bleeding and increased numbers of aberrant and/or collapsed blood vessels in the primary tumors. In combination with gemcitabine, dabigatran treatment limited primary tumor growth, did not induce bleeding complications and prevented tumor cell dissemination. Dabigatran was, however, not as efficient as genetic ablation of PAR-1 in our previous study, suggesting that thrombin is not the main PAR-1 agonist in the setting of pancreatic cancer. Overall, we show that dabigatran potentiates gemcitabine-induced growth inhibition of pancreatic cancer but does not affect primary tumor growth when used as monotherapy. C1 [Shi, Kun; Daalhuisen, Joost; ten Brink, Marieke; Spek, C. Arnold] Univ Amsterdam, Acad Med Ctr, Ctr Expt & Mol Med, Amsterdam, Netherlands. [Damhofer, Helene] Univ Amsterdam, Acad Med Ctr, Lab Expt Oncol & Radiobiol, Ctr Expt Mol Med, Amsterdam, Netherlands. [Richel, Dick J.] Univ Amsterdam, Acad Med Ctr, Dept Med Oncol, Amsterdam, Netherlands. C3 University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam RP Spek, CA (corresponding author), Acad Med Ctr, Ctr Expt & Mol Med, H2-215,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands. EM c.a.spek@amc.nl RI ; Spek, Arnold/AAC-5866-2019 OI Damhofer, Helene/0000-0003-4459-7534; Spek, Arnold/0000-0002-2149-4068 FU Dutch Cancer Foundation [2009-4324, 2014-6782] FX Dabigatran was kindly provided by Dr. Ashley Goss from the CardioMetabolic Disease Research department of Boehringer Ingelheim Pharmaceuticals. This study is supported by grants from the Dutch Cancer Foundation (2009-4324 and 2014-6782). CR Alexander ET, 2016, ONCOTARGET, V7, P85291, DOI 10.18632/oncotarget.13300 Battinelli EM, 2014, BLOOD, V123, P101, DOI 10.1182/blood-2013-02-485011 Borensztajn K, 2010, AM J PATHOL, V177, P2753, DOI 10.2353/ajpath.2010.091107 Borensztajn KS, 2007, PATHOPHYSIOL HAEMO T, V36, P137, DOI 10.1159/000175152 Cardenes HR, 2006, ONCOLOGIST, V11, P612, DOI 10.1634/theoncologist.11-6-612 Chambers RC, 2000, J BIOL CHEM, V275, P35584, DOI 10.1074/jbc.M003188200 Cisowski J, 2011, AM J PATHOL, V179, P513, DOI 10.1016/j.ajpath.2011.03.025 Cooper DM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021484 Cunningham D, 2009, J CLIN ONCOL, V27, P5513, DOI 10.1200/JCO.2009.24.2446 Daley D, 2016, CELL, V166, P1485, DOI 10.1016/j.cell.2016.07.046 de Boer JD, 2015, AM J PHYSIOL-LUNG C, V309, pL768, DOI 10.1152/ajplung.00102.2015 De Monte L, 2011, J EXP MED, V208, P469, DOI 10.1084/jem.20101876 Diaz J, 2012, J ENDOCRINOL, V214, P165, DOI 10.1530/JOE-11-0310 Dineen SP, 2010, CANCER RES, V70, P2852, DOI 10.1158/0008-5472.CAN-09-3892 Duitman J, 2012, P NATL ACAD SCI USA, V109, P9113, DOI 10.1073/pnas.1202641109 Eckman MH, 2011, CIRC-CARDIOVASC QUAL, V4, P14, DOI 10.1161/CIRCOUTCOMES.110.958108 Ezekowitz MD, 2011, CIRCULATION, V124, P95, DOI 10.1161/CIRCULATIONAHA.110.967455 Fischer C, 2007, CELL, V131, P463, DOI 10.1016/j.cell.2007.08.038 Frese KK, 2007, NAT REV CANCER, V7, P645, DOI 10.1038/nrc2192 Fukunaga A, 2004, PANCREAS, V28, pE26, DOI 10.1097/00006676-200401000-00023 Ghaneh P, 2007, GUT, V56, P1134, DOI 10.1136/gut.2006.103333 Goerge T, 2006, CANCER RES, V66, P7766, DOI 10.1158/0008-5472.CAN-05-3897 Gudjonsson B, 2002, J CLIN GASTROENTEROL, V35, P180, DOI 10.1097/00004836-200208000-00011 Gustafsson D, 2003, J INTERN MED, V254, P322, DOI 10.1046/j.1365-2796.2003.01225.x Hankey GJ, 2011, CIRCULATION, V123, P1436, DOI 10.1161/CIRCULATIONAHA.110.004424 Haralabopoulos GC, 1997, AM J PHYSIOL-CELL PH, V273, pC239, DOI 10.1152/ajpcell.1997.273.1.C239 Hwang CI, 2016, J PATHOL, V238, P197, DOI 10.1002/path.4651 Hwang RF, 2008, CANCER RES, V68, P918, DOI 10.1158/0008-5472.CAN-07-5714 Icli F, 2007, J SURG ONCOL, V95, P507, DOI 10.1002/jso.20728 Inman KS, 2014, WORLD J GASTROENTERO, V20, P11160, DOI 10.3748/wjg.v20.i32.11160 Jiang GZ, 2010, GUT, V59, P1535, DOI 10.1136/gut.2009.200105 Knecht W, 2007, J BIOL CHEM, V282, P26089, DOI 10.1074/jbc.M703840200 Kopec AK, 2014, J PHARMACOL EXP THER, V351, P288, DOI 10.1124/jpet.114.218545 Lange S, 2014, J CELL PHYSIOL, V229, P1673, DOI 10.1002/jcp.24612 Macfarlane SR, 2001, PHARMACOL REV, V53, P245 Marangoni MN, 2016, J NEUROIMMUNOL, V297, P159, DOI 10.1016/j.jneuroim.2016.05.018 Mungall Dennis, 2002, Curr Opin Investig Drugs, V3, P905 Nagarakanti R, 2011, CIRCULATION, V123, P131, DOI 10.1161/CIRCULATIONAHA.110.977546 Neesse A, 2011, GUT, V60, P861, DOI 10.1136/gut.2010.226092 Nierodzik ML, 2006, CANCER CELL, V10, P355, DOI 10.1016/j.ccr.2006.10.002 Nutescu EA, 2008, CARDIOL CLIN, V26, P169, DOI 10.1016/j.ccl.2007.12.005 Ochi A, 2012, J EXP MED, V209, P1671, DOI 10.1084/jem.20111706 Partecke LI, 2011, EUR SURG RES, V47, P98, DOI 10.1159/000329413 Petersen LC, 2005, THROMB RES, V116, P75, DOI 10.1016/j.thromres.2004.11.003 Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024 Qiu Wanglong, 2013, Methods Mol Biol, V980, P215, DOI 10.1007/978-1-62703-287-2_11 Queiroz KCS, 2014, INT J CANCER, V135, P2294, DOI 10.1002/ijc.28726 Ramsay AJ, 2008, J BIOL CHEM, V283, P12293, DOI 10.1074/jbc.M709493200 Rudroff C, 2001, EUR J SURG ONCOL, V27, P472, DOI 10.1053/ejso.2001.1141 Ruffell B, 2012, TRENDS IMMUNOL, V33, P119, DOI 10.1016/j.it.2011.12.001 Salah Z, 2012, FASEB J, V26, P2031, DOI 10.1096/fj.11-194704 Schmidlin Fabien, 2001, Current Opinion in Pharmacology, V1, P575, DOI 10.1016/S1471-4892(01)00099-6 Scott KA, 2015, J AM ASSOC NURSE PRA, V27, P190, DOI 10.1002/2327-6924.12161 Shi K, 2013, J THROMB HAEMOST, V11, P1892, DOI 10.1111/jth.12361 Stathis A, 2010, NAT REV CLIN ONCOL, V7, P163, DOI 10.1038/nrclinonc.2009.236 Tsopanoglou NE, 2009, EUR CYTOKINE NETW, V20, P171, DOI 10.1684/ecn.2009.0166 van Doormaal FF, 2011, J CLIN ONCOL, V29, P2071, DOI 10.1200/JCO.2010.31.9293 von Delius S, 2007, THROMB HAEMOSTASIS, V98, P434, DOI 10.1160/TH07-01-0004 VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V Wang BH, 2010, CLIN APPL THROMB-HEM, V16, P674, DOI 10.1177/1076029609354332 Whatcott CJ, 2012, PANCREATIC CANC TUMO, P8 Zeuner A, 2014, CELL DEATH DIFFER, V21, P1877, DOI 10.1038/cdd.2014.105 Zhang W, 2010, CLIN CANCER RES, V16, P3420, DOI 10.1158/1078-0432.CCR-09-2904 Zhang Y, 2012, J THROMB HAEMOST, V10, P411, DOI 10.1111/j.1538-7836.2011.04607.x Zhu LY, 2012, ONCOL REP, V28, P553, DOI 10.3892/or.2012.1851 Ziske C, 2008, PANCREAS, V36, P146, DOI 10.1097/MPA.0b013e3181586cd9 NR 66 TC 17 Z9 21 U1 0 U2 4 PU FEINSTEIN INST MED RES PI MANHASSET PA 350 COMMUNITY DR, MANHASSET, NY 11030 USA SN 1076-1551 EI 1528-3658 J9 MOL MED JI Mol. Med. PY 2017 VL 23 BP 13 EP 23 DI 10.2119/molmed.2016.00214 PG 11 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental WE Science Citation Index Expanded (SCI-EXPANDED) SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA EP6VX UT WOS:000397518100001 PM 28182192 OA Green Accepted, Green Submitted, gold DA 2026-04-17 ER PT J AU Zhao, BC Huang, TY Deng, QW Liu, WF Liu, J Deng, WT Liu, KX Li, C AF Zhao, Bing-Cheng Huang, Tong-Yi Deng, Qi-Wen Liu, Wei-Feng Liu, Jian Deng, Wen-Tao Liu, Ke-Xuan Li, Cai TI Prophylaxis Against Atrial Fibrillation After General Thoracic Surgery SO CHEST LA English DT Article DE atrial fibrillation; meta-analysis; postoperative; thoracic surgery ID LUNG-CANCER; PHARMACOLOGICAL PROPHYLAXIS; AMIODARONE PROPHYLAXIS; PULMONARY RESECTION; MAGNESIUM-SULFATE; DOUBLE-BLIND; PREVENTION; ARRHYTHMIAS; DIGITALIZATION; DILTIAZEM AB BACKGROUND: Postoperative atrial fibrillation/flutter (POAF) is associated with significant morbidity and mortality after general thoracic surgery, but the need for and the best agent for prophylaxis remains obscure. METHODS: A systematic literature search was performed to identify randomized controlled trials that compared regimens for POAF prophylaxis after general thoracic surgery. Randomeffects meta-analyses with trial sequential analyses were performed to compare the effects of medical prophylaxis vs placebo/usual care. The risk of POAF among patients receiving various prophylactic regimens was subjected to Bayesian network meta-analysis. \RESULTS: Twenty-two trials (2,891 patients and 11 regimens) were included. Overall, medical prophylaxis reduced the incidence of POAF (OR, 0.33; 95% CI, 0.22-0.49) but not short-term mortality (OR, 0.85; 95% CI, 0.41-1.73). There was no significant difference in patient withdrawal due to adverse events (OR, 1.67; 95% CI, 0.67-4.16). Trial sequential analysis showed that as of 2012, sufficient evidence had accrued in support of the effectiveness of medical prophylaxis in reducing POAF after general thoracic surgery. In network metaanalysis, beta-blockers, angiotensin-converting enzyme inhibitors, amiodarone, magnesium, and calcium channel blockers significantly reduced the risk of POAF compared with placebo/usual care. b-Blockers had the highest probability of being the most effective agents (OR, 0.12; 95% credible interval [CrI], 0.05-0.27; probability of being best, 77.7%; number needed to treat, 5.2). CONCLUSIONS: The current literature supports the effectiveness and tolerability of medical prophylaxis and the superiority of b-blockers in preventing POAF after general thoracic surgery. b-Blockers are recommended, taking into consideration the status of the bronchopulmonary system. C1 [Zhao, Bing-Cheng; Liu, Jian; Deng, Wen-Tao; Liu, Ke-Xuan; Li, Cai] Southern Med Univ, Nanfang Hosp, Dept Anesthesiol, 1838 Guangzhou Ave N, Guangzhou 510515, Guangdong, Peoples R China. [Zhao, Bing-Cheng; Deng, Qi-Wen; Liu, Wei-Feng] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Anesthesiol, Guangzhou, Guangdong, Peoples R China. [Huang, Tong-Yi] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Ultrasonog, Guangzhou, Guangdong, Peoples R China. C3 Southern Medical University - China; Sun Yat Sen University; Sun Yat Sen University RP Li, C (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Anesthesiol, 1838 Guangzhou Ave N, Guangzhou 510515, Guangdong, Peoples R China. EM licaisysu@163.com RI Zhao, Bingcheng/AAG-8383-2021; Deng, Qiwen/E-9434-2016; Li, cai/JXX-8929-2024; deng, wentao/IZE-8843-2023 OI Liu, Ke-Xuan/0000-0003-0221-366X; Huang, Tongyi/0009-0001-9754-2273; Huang, Tongyi/0000-0003-0737-0568 CR Amar D, 1997, ANN THORAC SURG, V63, P1374 Amar D, 2000, J THORAC CARDIOV SUR, V120, P790, DOI 10.1067/mtc.2000.109538 Amar D, 2002, ANESTHESIOLOGY, V97, P1618, DOI 10.1097/00000542-200212000-00039 Amar D, 2016, J THORAC CARDIOV SUR, V151, P913, DOI 10.1016/j.jtcvs.2015.09.041 Amar D, 2015, J THORAC CARDIOV SUR, V149, P1532, DOI 10.1016/j.jtcvs.2014.12.016 Arsenault KA, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003611.pub3 Bayliff CD, 1999, ANN THORAC SURG, V67, P182, DOI 10.1016/S0003-4975(98)01226-0 BORGEAT A, 1991, ANN THORAC SURG, V51, P964, DOI 10.1016/0003-4975(91)91016-O BORGEAT A, 1989, ANN THORAC SURG, V48, P232, DOI 10.1016/0003-4975(89)90076-3 Bradley D, 2005, CHEST, V128, p39S, DOI 10.1378/chest.128.2_suppl.39S Caldwell DM, 2005, BMJ-BRIT MED J, V331, P897, DOI 10.1136/bmj.331.7521.897 Cardinale D, 2016, ANN SURG, V264, P244, DOI 10.1097/SLA.0000000000001626 Ciszewski P, 2013, THORAC CARDIOV SURG, V61, P365, DOI 10.1055/s-0032-1311537 Curtis JJ, 1998, ANN THORAC SURG, V66, P1766, DOI 10.1016/S0003-4975(98)00942-4 DiNicolantonio JJ, 2014, AM J CARDIOL, V113, P565, DOI 10.1016/j.amjcard.2013.10.020 Dixit S, 2009, J AM COLL CARDIOL, V54, P2049, DOI 10.1016/j.jacc.2009.09.015 Frendl G, 2014, J THORAC CARDIOV SUR, V148, pE153, DOI 10.1016/j.jtcvs.2014.06.036 Gialdini G, 2014, JAMA-J AM MED ASSOC, V312, P616, DOI 10.1001/jama.2014.9143 Higgins J., 2011, COCHRANE COLLABORATI Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385 Jakobsen CJ, 1997, J CARDIOTHOR VASC AN, V11, P746, DOI 10.1016/S1053-0770(97)90169-5 Khalil MA, 2013, J ANESTH, V27, P56, DOI 10.1007/s00540-012-1478-3 Lai Ren-Chun, 2006, Ai Zheng, V25, P609 Lanza LA, 2003, ANN THORAC SURG, V75, P223, DOI 10.1016/S0003-4975(02)04285-6 LINDGREN L, 1991, BRIT J ANAESTH, V66, P205, DOI 10.1093/bja/66.2.205 Mitchell LB, 2011, CAN J CARDIOL, V27, P91, DOI 10.1016/j.cjca.2010.11.005 Nojiri T, 2015, CHEST, V148, P1285, DOI 10.1378/chest.15-0852 Nojiri T, 2012, J THORAC CARDIOV SUR, V143, P488, DOI 10.1016/j.jtcvs.2011.09.003 Riber LP, 2012, ANN THORAC SURG, V94, P339, DOI 10.1016/j.athoracsur.2011.12.096 Riber LP, 2014, ANN THORAC SURG, V98, P1989, DOI 10.1016/j.athoracsur.2014.06.069 RITCHIE AJ, 1992, THORAX, V47, P41, DOI 10.1136/thx.47.1.41 RITCHIE AJ, 1990, ANN THORAC SURG, V50, P86, DOI 10.1016/0003-4975(90)90094-M RITCHIE AJ, 1993, ANN THORAC SURG, V55, P86, DOI 10.1016/0003-4975(93)90478-Z Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Sedrakyan A, 2005, J THORAC CARDIOV SUR, V129, P997, DOI 10.1016/j.jtcvs.2004.07.042 Terzi A, 1996, THORAC CARDIOV SURG, V44, P300, DOI 10.1055/s-2007-1012041 Tiryakioglu O, 2009, J CARDIOTHORAC SURG, V4, DOI 10.1186/1749-8090-4-8 Tisdale JE, 2010, SEMIN THORAC CARDIOV, V22, P310, DOI 10.1053/j.semtcvs.2010.12.001 Tisdale JE, 2010, J THORAC CARDIOV SUR, V140, P45, DOI 10.1016/j.jtcvs.2010.01.026 Tisdale JE, 2009, ANN THORAC SURG, V88, P886, DOI 10.1016/j.athoracsur.2009.04.074 VanMieghem W, 1996, ANN THORAC SURG, V61, P1083, DOI 10.1016/0003-4975(96)00073-2 VANMIEGHEM W, 1994, CHEST, V105, P1642, DOI 10.1378/chest.105.6.1642 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Zheng Z, 2016, NEW ENGL J MED, V374, P1744, DOI 10.1056/NEJMoa1507750 NR 44 TC 43 Z9 52 U1 0 U2 26 PU ELSEVIER PI AMSTERDAM PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS SN 0012-3692 EI 1931-3543 J9 CHEST JI Chest PD JAN PY 2017 VL 151 IS 1 BP 149 EP 159 DI 10.1016/j.chest.2016.08.1476 PG 11 WC Critical Care Medicine; Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine; Respiratory System GA EO0HE UT WOS:000396378100026 PM 27729264 DA 2026-04-17 ER PT J AU Hsu, CK Lai, CC Wang, K Chen, L AF Hsu, Chi-Kuei Lai, Chih-Cheng Wang, Kun Chen, Likwang TI Risk of lung cancer in patients with gastro-esophageal reflux disease: a population-based cohort study SO PEERJ LA English DT Article DE Lung cancer; GERD; Risk factors ID MOLECULAR-MECHANISMS; BARRETTS-ESOPHAGUS; LARYNGEAL; EPIDEMIOLOGY; DEFINITION; ASPIRATION; EXPRESSION AB This large-scale, controlled cohort study estimated the risks of lung cancer in patients with gastro-esophageal reflux disease (GERD) in Taiwan. We conducted this population-based study using data from the National Health Insurance Research Database of Taiwan during the period from 1997 to 2010. Patients with GERD were diagnosed using endoscopy, and controls were matched to patients with GERD at a ratio of 1:4. We identified 15,412 patients with GERD and 60,957 controls. Compared with the controls, the patients with GERD had higher rates lof osteoporosis, diabetes mellitus, asthma, chronic obstructive pulmonary disease, pneumonia, bronchiectasis, depression, anxiety, hypertension, dyslipidemia, chronic liver disease, congestive heart failure, atrial fibrillation, stroke chronic kidney disease, and coronary artery disease (all P <.05). A total of 85 patients had lung cancer among patients with GERD during the follow-up of 42,555 person-years, and the rate of lung cancer was 0.0020 per person year. By contrast, 232 patients had lung cancer among patients without GERD during the follow-up of 175,319 person-years, and the rate of lung cancer was 0.0013 per person-year. By using stepwise Cox regression model, the overall incidence of lung cancer remained significantly higher in the patients with GERD than in the controls (hazard ratio, 1.53; 95% CI [1.19-1.98]). The cumulative incidence lof lung cancer was higher in the patients with GERD than in the controls (P =.0012). In conclusion, our large population-based cohort study provides evidence that GERD may increase the risk of lung cancer in Asians. C1 [Hsu, Chi-Kuei] E Da Hosp, Dept Internal Med, Kaohsiung, Taiwan. [Lai, Chih-Cheng] Chi Mei Med Ctr, Dept Intens Care Med, Tainan, Taiwan. [Wang, Kun] Cardinal Tien Hosp, Dept Internal Med, New Taipei, Taiwan. [Chen, Likwang] Natl Hlth Res Inst, Miaoli, Taiwan. C3 E-Da Hospital; Chi Mei Hospital; National Health Research Institutes - Taiwan RP Wang, K (corresponding author), Cardinal Tien Hosp, Dept Internal Med, New Taipei, Taiwan.; Chen, L (corresponding author), Natl Hlth Res Inst, Miaoli, Taiwan. EM kumvang@mospital.com; likwang@nhri.org.tw RI Hsu, Chi Kuei/IUM-2155-2023; Lai, Chih-Cheng/AFN-1802-2022 FU National Health Research Institutes FX This study was supported by grants from National Health Research Institutes (intramural funding). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. CR Bacciu A, 2004, CLIN OTOLARYNGOL, V29, P545, DOI 10.1111/j.1365-2273.2004.00851.x Blondeau K, 2008, GUT, V57, P1049, DOI 10.1136/gut.2007.146134 Bredenoord AJ, 2013, LANCET, V381, P1933, DOI 10.1016/S0140-6736(12)62171-0 Chen PC, 2011, STROKE, V42, P3034, DOI 10.1161/STROKEAHA.111.615534 D'Ovidio F, 2005, ANN THORAC SURG, V80, P1254, DOI 10.1016/j.athoracsur.2005.03.106 Denlinger CE, 2012, SURG CLIN N AM, V92, P1089, DOI 10.1016/j.suc.2012.07.002 Dvorak K, 2011, ANN NY ACAD SCI, V1232, P381, DOI 10.1111/j.1749-6632.2011.06062.x El-Serag HB, 2007, CLIN GASTROENTEROL H, V5, P17, DOI 10.1016/j.cgh.2006.09.016 El-Serag HB, 2014, GUT, V63, P871, DOI 10.1136/gutjnl-2012-304269 Etzel CJ, 2006, LUNG CANCER, V52, P129, DOI 10.1016/j.lungcan.2005.11.018 Fang Y, 2013, ANN NY ACAD SCI, V1300, P187, DOI 10.1111/nyas.12249 Fukui T, 2013, EUR RESPIR J, V42, P1332, DOI 10.1183/09031936.00144012 Herbella FAM, 2015, WORLD J GASTROENTERO, V21, P815, DOI 10.3748/wjg.v21.i3.815 Jian ZH, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000443 Johnston N, 2012, LARYNGOSCOPE, V122, P1317, DOI 10.1002/lary.23307 Langevin SM, 2013, CANCER EPIDEM BIOMAR, V22, P1061, DOI 10.1158/1055-9965.EPI-13-0183 Lee YL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109444 Liam CK, 2006, LUNG CANCER, V53, P23, DOI 10.1016/j.lungcan.2006.03.009 Mise K, 2010, RESPIROLOGY, V15, P837, DOI 10.1111/j.1440-1843.2010.01777.x Moayyedi P, 2006, LANCET, V367, P2086, DOI 10.1016/S0140-6736(06)68932-0 Morehead RS, 2009, EUR RESPIR REV, V18, P233, DOI 10.1183/09059180.00002509 Pacheco-Galván A, 2011, ARCH BRONCONEUMOL, V47, P195, DOI 10.1016/j.arbres.2011.02.001 Pashinsky YY, 2009, MT SINAI J MED, V76, P24, DOI 10.1002/msj.20088 Patti MG, 2008, J GASTROINTEST SURG, V12, P1900, DOI 10.1007/s11605-008-0674-9 Qadeer MA, 2005, LARYNGOSCOPE, V115, P486, DOI 10.1097/01.mlg.0000157851.24272.41 Rees LEN, 2008, AM J RESP CRIT CARE, V177, P1187, DOI 10.1164/rccm.200706-895OC Salvioli B, 2006, DIGEST LIVER DIS, V38, P879, DOI 10.1016/j.dld.2006.05.012 Sung MW, 2003, LARYNGOSCOPE, V113, P1059, DOI 10.1097/00005537-200306000-00027 Sweet MP, 2009, THORAX, V64, P167, DOI 10.1136/thx.2007.082719 Vaezi MF, 2006, AM J MED, V119, P768, DOI 10.1016/j.amjmed.2006.01.019 Vakil N, 2006, AM J GASTROENTEROL, V101, P1900, DOI 10.1111/j.1572-0241.2006.00630.x Vakil N, 2010, BEST PRACT RES CL GA, V24, P759, DOI 10.1016/j.bpg.2010.09.009 Vereczkei A, 2008, DIS ESOPHAGUS, V21, P457, DOI 10.1111/j.1442-2050.2007.00796.x NR 33 TC 26 Z9 27 U1 0 U2 22 PU PEERJ INC PI LONDON PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND SN 2167-8359 J9 PEERJ JI PeerJ PD DEC 20 PY 2016 VL 4 AR e2753 DI 10.7717/peerj.2753 PG 12 WC Multidisciplinary Sciences WE Science Citation Index Expanded (SCI-EXPANDED) SC Science & Technology - Other Topics GA EF1AO UT WOS:000390057600004 PM 28028458 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Glover, JR Velez-Cubian, FO Zhang, WW Toosi, K Tanvetyanon, T Ng, EP Moodie, CC Garrett, JR Fontaine, JP Toloza, EM AF Glover, Jessica R. Velez-Cubian, Frank O. Zhang, Wei Wei Toosi, Kavian Tanvetyanon, Tawee Ng, Emily P. Moodie, Carla C. Garrett, Joseph R. Fontaine, Jacques P. Toloza, Eric M. TI Effect of gender on perioperative outcomes after robotic-assisted pulmonary lobectomy SO JOURNAL OF THORACIC DISEASE LA English DT Article DE Gender; outcomes; robotic; lobectomy; lung cancer ID CELL LUNG-CANCER; SEX-ASSOCIATED DIFFERENCES; PAIN MANAGEMENT; FEMALE GENDER; AIR LEAKS; RESECTION; SURVIVAL; RISK; METAANALYSIS; IMPACT AB Background: Female gender has been associated with worse outcomes after cardiovascular surgery and critical illness. We investigated the effect of gender on perioperative outcomes following robotic-assisted pulmonary lobectomy. Methods: We retrospectively analyzed 282 consecutive patients who underwent robotic-assisted pulmonary lobectomy by one surgeon over 53 months. Perioperative outcomes and clinically significant intraoperative and postoperative complications, including respiratory and cardiovascular events, were noted. Chi-Square (.2), Fisher's exact test, Analysis of Variance (ANOVA), Student's t-test, and Kruskal-Wallis or Mood's median test were used to compare variables, with significance at P= 0.05. Results: There were 128 men (mean age, 68.8 yr) and 154 women (mean age, 65.9 yr; P= 0.02). Women had higher preoperative forced expiratory volume in 1 second as percent of predicted (FEV1%; P= 0.001). There were more former smokers in the male cohort (P= 0.03) and more nonsmokers in the female cohort (P< 0.001). Women had smaller tumors (3.0 +/- 0.1 vs. 3.5 +/- 0.2 cm, P= 0.04), lower estimated blood loss (EBL) (150 +/- 34 vs. 250 +/- 44 mL, P< 0.001), and shorter operative time (168 +/- 6 vs. 196 +/- 7 min, P= 0.01). Rates of intraoperative complications (7.1% vs. 8.6%, P= 0.65) and of conversion to open lobectomy (7.8% vs. 8.6%; P= 0.81) were similar between genders. Postoperative complications were fewer in women (27.9% vs. 44.5%; P= 0.004), the most common of which, in both women and men, were prolonged air leak for = 7 days (13.0% vs. 22.7%, P= 0.03), atrial fibrillation (7.1% vs. 14.8%, P= 0.04), and pneumonia (7.8% vs. 10.2%, P= 0.49). Hospital length of stay (LOS) (4 +/- 0.3 vs. 5 +/- 0.5 days) was also shorter for women (P= 0.02). Despite the higher postoperative complication rate in men, in-hospital mortality did not differ between genders (P= 0.23). Multivariable analyses did not identify female gender as an independent predictor of post-operative complications. Conclusions: Female gender was associated with rates of intraoperative complications and of conversion to open lobectomy as low as those for men, but with better perioperative outcomes, lower risk of intraoperative bleeding, and fewer postoperative complications. Thus, robotic-assisted pulmonary lobectomy is feasible and safe for women. C1 [Glover, Jessica R.; Toosi, Kavian; Ng, Emily P.] Univ South Florida Hlth, Morsani Coll Med, Tampa, FL USA. [Velez-Cubian, Frank O.; Zhang, Wei Wei; Fontaine, Jacques P.; Toloza, Eric M.] Univ South Florida Hlth, Dept Surg, Morsani Coll Med, Tampa, FL USA. [Tanvetyanon, Tawee; Moodie, Carla C.; Garrett, Joseph R.; Fontaine, Jacques P.; Toloza, Eric M.] H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, Tampa, FL USA. [Fontaine, Jacques P.; Toloza, Eric M.] Univ South Florida Hlth, Dept Oncol Sci, Morsani Coll Med, Tampa, FL USA. C3 State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida RP Toloza, EM (corresponding author), 12902 USF Magnolia Dr,Suite FOB 1, Tampa, FL 33612 USA. EM eric.toloza@moffitt.org FU Summer Scholarly Awards from the Scholarly Concentrations Program; Summer Scholarly Award from the Office of Research, Innovation & Scholarly Endeavors (RISE) at the University of South Florida (USF) Health Morsani College of Medicine FX This research was supported by 2014 Summer Scholarly Awards to JR Glover and EP Ng from the Scholarly Concentrations Program and a 2015 Summer Scholarly Award to K Toosi from the Office of Research, Innovation & Scholarly Endeavors (RISE) at the University of South Florida (USF) Health Morsani College of Medicine. CR Alberg AJ, 2003, CHEST, V123, p21S, DOI 10.1378/chest.123.1_suppl.21S [Anonymous], CANC FACTS FIG 2015 Båtevik R, 2005, LUNG CANCER, V47, P173, DOI 10.1016/j.lungcan.2004.08.014 Bernard A, 2000, ANN THORAC SURG, V70, P1161, DOI 10.1016/S0003-4975(00)01853-1 Berry MF, 2015, ANN THORAC SURG, V100, P271, DOI 10.1016/j.athoracsur.2015.02.076 Bethune Gillian, 2010, J Thorac Dis, V2, P48 Cao C, 2012, ANN CARDIOTHORAC SUR, V1, P3, DOI 10.3978/j.issn.2225-319X.2012.04.03 Ciriaco P, 2000, EUR J CARDIO-THORAC, V18, P12, DOI 10.1016/S1010-7940(00)00428-0 Dela Cruz CS, 2011, CLIN CHEST MED, V32, P605, DOI 10.1016/j.ccm.2011.09.001 Edwards FH, 1998, ANN THORAC SURG, V66, P125, DOI 10.1016/S0003-4975(98)00358-0 Elsayed H, 2012, ANN ROY COLL SURG, V94, P422, DOI 10.1308/003588412X13171221592258 Ferguson MK, 2000, ANN THORAC SURG, V69, P245, DOI 10.1016/S0003-4975(99)01078-4 Forastiere E, 2008, BRIT J ANAESTH, V101, P841, DOI 10.1093/bja/aen309 Gale EAM, 2001, DIABETOLOGIA, V44, P3, DOI 10.1007/s001250051573 Giambrone GP, 2016, J THORAC CARDIOV SUR, V151, P982, DOI 10.1016/j.jtcvs.2015.11.057 Juutilainen A, 2004, DIABETES CARE, V27, P2898, DOI 10.2337/diacare.27.12.2898 Konecny T, 2014, AM J CARDIOL, V114, P272, DOI 10.1016/j.amjcard.2014.04.030 Li SJ, 2016, ANN THORAC SURG, V102, P328, DOI 10.1016/j.athoracsur.2016.01.013 Medbery RL, 2016, ANN THORAC SURG, V102, P1660, DOI 10.1016/j.athoracsur.2016.05.060 Melfi Franca M A, 2008, Thorac Surg Clin, V18, P289, DOI 10.1016/j.thorsurg.2008.06.001 Minami H, 2000, CHEST, V118, P1603, DOI 10.1378/chest.118.6.1603 Mucha Lisa, 2006, Gend Med, V3, P279, DOI 10.1016/S1550-8579(06)80216-0 Mueller MR, 2014, J THORAC DIS, V6, P271, DOI 10.3978/j.issn.2072-1439.2013.11.29 Nakamura H, 2011, ANN THORAC CARDIOVAS, V17, P469, DOI 10.5761/atcs.oa.10.01637 Nasir BS, 2014, ANN THORAC SURG, V98, P203, DOI 10.1016/j.athoracsur.2014.02.051 Neal RD, 2005, BRIT J CANCER, V92, P1971, DOI 10.1038/sj.bjc.6602623 Nguyen LL, 2009, CIRCULATION, V119, P123, DOI 10.1161/CIRCULATIONAHA.108.810341 Nojiri T, 2016, ANN SURG ONCOL North CM, 2013, SEMIN THORAC CARDIOV, V25, P87, DOI 10.1053/j.semtcvs.2013.05.002 Park BJ, 2012, ANN CARDIOTHORAC SUR, V1, P24, DOI 10.3978/j.issn.2225-319X.2012.04.09 Sasco AJ, 2004, LUNG CANCER, V45, pS3, DOI 10.1016/j.lungcan.2004.07.998 Smith LK, 2005, LANCET, V366, P825, DOI 10.1016/S0140-6736(05)67030-4 Song HK, 2008, ANN THORAC SURG, V85, P2040, DOI 10.1016/j.athoracsur.2008.02.082 Tong BC, 2014, J THORAC CARDIOV SUR, V148, P13, DOI 10.1016/j.jtcvs.2014.03.012 Wheatley GH III, 2005, J THORAC CARDIOV SUR, V130, P464, DOI 10.1016/j.jtcvs.2005.02.011 Xiong J, 2016, THORAC CANCER, V7, P215, DOI 10.1111/1759-7714.12314 Zhu WG, 2016, INT J CARDIOL, V218, P259, DOI 10.1016/j.ijcard.2016.05.013 NR 37 TC 9 Z9 9 U1 0 U2 1 PU AME PUBLISHING COMPANY PI SHATIN PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA SN 2072-1439 EI 2077-6624 J9 J THORAC DIS JI J. Thorac. Dis. PD DEC PY 2016 VL 8 IS 12 BP 3614 EP 3624 DI 10.21037/jtd.2016.12.11 PG 11 WC Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System GA EG6SD UT WOS:000391175400082 PM 28149556 OA Green Submitted DA 2026-04-17 ER PT J AU Ma, HF Jian, WY Xu, TT He, YS Rizzo, JA Fang, H AF Ma, Huifen Jian, Weiyan Xu, Tingting He, Yasheng Rizzo, John A. Fang, Hai TI Quality of pharmacoeconomic research in China: A systematic review SO MEDICINE LA English DT Review DE China; pharmacoeconomic; research quality ID CELL LUNG-CANCER; COST-EFFECTIVENESS ANALYSIS; CHRONIC HEPATITIS-B; ECONOMIC-EVALUATION; STRUCTURED ABSTRACTS; MAINTENANCE THERAPY; ATRIAL-FIBRILLATION; UTILITY ANALYSIS; CHEMOTHERAPY; PERSPECTIVE AB Background:The number of pharmacoeconomic publications in the literature from China has risen rapidly, but the quality of pharmacoeconomic publications from China has not been analyzed.Objectives:This study aims to identify all recent pharmacoeconomic publications from China, to critically appraise the reporting quality, and to summarize the results.Methods:Four databases (PubMed, Web of Science, Medline, and EmBase) were searched for original articles published up to December 31, 2014. The Consolidated Health Economic Evaluation Reporting Standards statement including 24 items was used to assess the quality of reporting of these articles.Results:Of 1046 articles identified, 32 studies fulfilled the inclusion criteria. They were published in 23 different journals. Quality of reporting varied between studies, with an average score of 18.7 (SD = 4.33) out of 24 (range 9-23.5). There was an increasing trend of pharmacoeconomic publications and reporting quality over years from 2003 to 2014. According to the Consolidated Health Economic Evaluation Reporting Standards, the reporting quality for the items including title, comparators of method, and measurement of effectiveness are quite low, with less than 50% of studies fully satisfying these reporting standards. In contrast, reporting was good for the items including introduction, study perspective, choice of health outcomes, study parameters, characterizing heterogeneity, and discussion, with more than 75% of the articles satisfying these reporting criteria. The remaining items fell in between these 2 extremes, with 50% to 75% of studies satisfying these criteria.Conclusion:Our study suggests the need for improvement in a number of reporting criteria. But the criteria for which reporting quality was low seem to be limitations that would be straightforward to correct in future studies. C1 [Ma, Huifen; Xu, Tingting; He, Yasheng; Fang, Hai] Peking Univ, China Ctr Hlth Dev Studies, Beijing, Peoples R China. [Jian, Weiyan] Peking Univ, Dept Hlth Policy & Adm, Beijing, Peoples R China. [Rizzo, John A.] SUNY Stony Brook, Dept Econ, Stony Brook, NY 11794 USA. [Rizzo, John A.] SUNY Stony Brook, Dept Prevent Med, Stony Brook, NY 11794 USA. C3 Peking University; Peking University; State University of New York (SUNY) System; Stony Brook University; State University of New York (SUNY) System; Stony Brook University RP Fang, H (corresponding author), Peking Univ, China Ctr Hlth Dev Studies, Beijing, Peoples R China. EM hfang@hsc.pku.edu.cn OI Ma, Huifen/0000-0003-1473-4251 FU National Natural Science Foundation of China [71373013]; Peking University Health Science Center [BJMU20130338] FX Financial support for this study was provided to Dr Hai Fang by a grant from National Natural Science Foundation of China (Grant Number 71373013) and a grant from Peking University Health Science Center (Grant Number BJMU20130338). The funding agreement ensured the authors' independence in designing the study, interpreting the data, writing, and publishing the article. CR Aguiar PM, 2016, J CLIN PHARM THER, V41, P189, DOI 10.1111/jcpt.12384 Auguste P, 2016, TUBERCULOSIS, V99, P81, DOI 10.1016/j.tube.2016.04.007 Brown GC, 2016, DEV OPHTHALMOL, V55, P381, DOI 10.1159/000431205 Bundhun PK, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003276 Chan SL, 2014, ASIA-PAC J CLIN ONCO, V10, P80, DOI 10.1111/ajco.12170 Chang WC, 2008, AUST NZ J OBSTET GYN, V48, P592, DOI 10.1111/j.1479-828X.2008.00908.x Chen W, 2009, VALUE HEALTH, V12, pS82, DOI 10.1111/j.1524-4733.2009.00634.x Chen Z, 2009, VALUE HEALTH, V12, pS85, DOI 10.1111/j.1524-4733.2009.00635.x Chiou CF, 2003, MED CARE, V41, P32, DOI 10.1097/00005650-200301000-00007 Desai PR, 2012, PHARMACOECONOMICS, V30, P749, DOI 10.2165/11590140-000000000-00000 Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275 Drummond MichaelF., 2002, Methods for the Economic Evaluation of Health Care Programmes Gao L, 2012, VALUE HEALTH, V15, pA663, DOI 10.1016/j.jval.2012.08.358 Gao P, 2013, MEDICINA-LITHUANIA, V49, P529, DOI 10.3390/medicina49120083 Gavaza P, 2010, PHARMACOECONOMICS, V28, P539, DOI 10.2165/11536170-000000000-00000 Hartley J, 2014, J MED LIBR ASSOC, V102, P146, DOI 10.3163/1536-5050.102.3.002 Hermanowski TR, 2015, INT J INTEGR CARE, V15 Huang BT, 2011, INT J HEMATOL, V93, P474, DOI 10.1007/s12185-011-0804-0 Husereau D, 2013, VALUE HEALTH, V16, P231, DOI 10.1016/j.jval.2013.02.002 Husereau D, 2013, EUR J HEALTH ECON, V14, P367, DOI 10.1007/s10198-013-0471-6 Husereau D, 2013, INT J TECHNOL ASSESS, V29, P117, DOI 10.1017/S0266462313000160 Jiang Shan, 2014, Value Health Reg Issues, V3, P79, DOI 10.1016/j.vhri.2014.02.010 Jinha AE, 2010, LEARN PUBL, V23, P258, DOI 10.1087/20100308 Lee KKC, 2003, GASTROINTEST ENDOSC, V57, P160, DOI 10.1067/mge.2003.74 Mueller C, 1997, AM J PUBLIC HEALTH, V87, P1626, DOI 10.2105/AJPH.87.10.1626 Neumann PJ, 2000, ANN INTERN MED, V132, P964, DOI 10.7326/0003-4819-132-12-200006200-00007 Ofman Joshua J, 2003, J Manag Care Pharm, V9, P53 Palmer JL, 2010, ADV THER, V27, P814, DOI 10.1007/s12325-010-0078-6 Peng LB, 2009, PHARMACOECONOMICS, V27, P873, DOI 10.2165/11314750-000000000-00000 Rodrigues J, 2014, VALUE HEALTH, V17, pA799, DOI 10.1016/j.jval.2014.08.485 Snoswell C, 2016, JAMA DERMATOL, V152, P702, DOI 10.1001/jamadermatol.2016.0525 Sun ZF, 2014, INT UROL NEPHROL, V46, P1977, DOI 10.1007/s11255-014-0801-3 TADDIO A, 1994, CAN MED ASSOC J, V150, P1611 Tan CQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083396 Wang MA, 2014, CIRC-CARDIOVASC QUAL, V7, P78, DOI 10.1161/CIRCOUTCOMES.113.000674 Wang SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055917 Wei Lai, 2013, Value Health Reg Issues, V2, P48, DOI 10.1016/j.vhri.2013.02.002 WILLIAMS A, 1974, BRIT MED BULL, V30, P252, DOI 10.1093/oxfordjournals.bmb.a071211 Woersching AL, 2016, ANN PHARMACOTHER Wu B, 2014, CARDIOVASC DRUG THER, V28, P87, DOI 10.1007/s10557-013-6490-9 Wu B, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-385 Wu B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032530 Wu B, 2012, CLIN THER, V34, P468, DOI 10.1016/j.clinthera.2012.01.012 Wu B, 2011, CLIN THER, V33, P1446, DOI 10.1016/j.clinthera.2011.09.016 Xiao YL, 2013, J DIGEST DIS, V14, P463, DOI 10.1111/1751-2980.12069 Xie XQ, 2008, VALUE HEALTH, V11, pS23, DOI 10.1111/j.1524-4733.2008.00363.x Yang L, 2009, VALUE HEALTH, V12, pS66, DOI 10.1111/j.1524-4733.2009.00630.x You JHS, 2006, INT J CLIN PHARM TH, V44, P149 You JHS, 2003, ALIMENT PHARM THER, V17, P785, DOI 10.1046/j.1365-2036.2003.01526.x You JHS, 2014, J GEN INTERN MED, V29, P438, DOI 10.1007/s11606-013-2639-2 Yu YF, 2010, CHEMOTHERAPY, V56, P472, DOI 10.1159/000321016 Yuan Y, 2008, VALUE HEALTH, V11, pS11, DOI 10.1111/j.1524-4733.2008.00362.x Zeng XH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088881 Zeng X, 2013, CLIN THER, V35, P54, DOI 10.1016/j.clinthera.2012.12.013 Zhou B, 2012, RADIOLOGY, V262, P1014, DOI 10.1148/radiol.11110552 Zhu J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-39 NR 56 TC 11 Z9 14 U1 1 U2 23 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7974 EI 1536-5964 J9 MEDICINE JI Medicine (Baltimore) PD OCT PY 2016 VL 95 IS 41 AR e5114 DI 10.1097/MD.0000000000005114 PG 8 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA EA1LV UT WOS:000386354700035 PM 27741131 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Cheng, WL Kao, YH Chen, SA Chen, YJ AF Cheng, Wan-Li Kao, Yu-Hsun Chen, Shih-Ann Chen, Yi-Jen TI Pathophysiology of cancer therapy-provoked atrial fibrillation SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Review DE Atrial fibrillation; Cancer surgery; Chemotherapy; Proinflammatory cytokines ID MIGRATION-INHIBITORY FACTOR; TUMOR-NECROSIS-FACTOR; C-REACTIVE PROTEIN; MALIGNANT PERICARDIAL-EFFUSION; STEM-CELL TRANSPLANTATION; PULMONARY VEIN ISOLATION; HIGH-DOSE MELPHALAN; LUNG-CANCER; FACTOR-ALPHA; TNF-ALPHA AB Atrial fibrillation (AF) occurs with increased frequency in cancer patients, especially in patients who undergo surgery or chemotherapy. AF disturbs the prognosis of cancer patients and challenges therapeutic outcomes of cancer treatment. Elucidating the mechanisms of cancer-induced AF would help identify specific strategies for preventing AF occurrence. In addition to concurrent risk factors of cancer and AF, cancer surgery, side effects of anticancer agents, and cancer-associated immune responses play critical roles in the genesis of AF. In this review, we provide succinct potential mechanisms of AF genesis in cancer patients. (C) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Cheng, Wan-Li; Kao, Yu-Hsun; Chen, Yi-Jen] Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan. [Kao, Yu-Hsun] Taipei Med Univ, Wan Fang Hosp, Dept Med Educ & Res, Taipei, Taiwan. [Chen, Shih-Ann] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan. [Chen, Shih-Ann] Taipei Vet Gen Hosp, Div Cardiol, Taipei, Taiwan. [Chen, Shih-Ann] Taipei Vet Gen Hosp, Cardiovasc Res Ctr, Taipei, Taiwan. [Chen, Yi-Jen] Taipei Med Univ, Wan Fang Hosp, Dept Internal Med, Div Cardiovasc Med, Taipei, Taiwan. C3 Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; Taipei Veterans General Hospital; Taipei Municipal WanFang Hospital; Taipei Medical University RP Chen, YJ (corresponding author), Taipei Med Univ, Wan Fang Hosp, Div Cardiovasc Med, 111 Hsin Lung Rd,Sec 3, Taipei 116, Taiwan. EM a9900112@ms15.hinet.net RI Cheng, Ann-Lii/ACM-0936-2022 FU Ministry of Science and Technology, Taiwan [MOST104-2811-B-038-022, NSC102-2628-B-038-002-MY3, MOST104-2314-B-038-071-MY3, NSC100-2628-B-038-001-MY4, NSC102-2314-B-038-003-MY2, NSC102-2325-B-010-005]; Wan Fang Hospital, Taipei Medical University [104-wf-eva-01, 104swf01, 105swf09] FX The present work was supported by grants from the Ministry of Science and Technology, Taiwan (MOST104-2811-B-038-022, NSC102-2628-B-038-002-MY3, MOST104-2314-B-038-071-MY3, NSC100-2628-B-038-001-MY4, NSC102-2314-B-038-003-MY2, NSC102-2325B-010-005, and NSC102-2628-B-038-002-MY3), and Wan Fang Hospital, Taipei Medical University (104-wf-eva-01, 104swf01, and 105swf09). CR Abidi MH, 2013, BIOL BLOOD MARROW TR, V19, P56, DOI 10.1016/j.bbmt.2012.08.003 Abramochkin DV, 2013, PFLUG ARCH EUR J PHY, V465, P1741, DOI 10.1007/s00424-013-1320-2 Adam O, 2008, CIRCULATION, V118, P1285, DOI 10.1161/CIRCULATIONAHA.107.760892 Adao R, 2013, REV PORT CARDIOL, V32, P395, DOI 10.1016/j.repc.2012.11.002 Ai D, 2015, J CARDIOTHOR VASC AN, V29, P1127, DOI 10.1053/j.jvca.2015.01.012 Al-Abed Y, 2011, FUTURE MED CHEM, V3, P45, DOI 10.4155/FMC.10.281 Albini A, 2010, JNCI-J NATL CANCER I, V102, P14, DOI 10.1093/jnci/djp440 Alifano M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106914 Allin KH, 2011, CRIT REV CL LAB SCI, V48, P155, DOI 10.3109/10408363.2011.599831 Amar D, 1996, ANN THORAC SURG, V61, P1506, DOI 10.1016/0003-4975(96)00111-7 Amar D, 2012, J THORAC CARDIOV SUR, V144, P1249, DOI 10.1016/j.jtcvs.2012.06.051 [Anonymous], 2013, SCI WORLD J, DOI DOI 10.1155/2013/209428 [Anonymous], 2012, J Cell Sci Ther [Anonymous], 2011, ISRN CARDIOL Anselmi A, 2009, ANN THORAC SURG, V88, P326, DOI 10.1016/j.athoracsur.2009.01.031 Arai M, 1998, J MOL CELL CARDIOL, V30, P243, DOI 10.1006/jmcc.1997.0588 Asegaonkar SB, 2015, INT J BREAST CANCER, V2015, DOI 10.1155/2015/145647 Asiri YA, 2010, OXID MED CELL LONGEV, V3, P308, DOI 10.4161/oxim.3.5.13107 Aviles RJ, 2003, CIRCULATION, V108, P3006, DOI 10.1161/01.CIR.0000103131.70301.4F Bai Y, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002130 Balkwill F, 2002, CYTOKINE GROWTH F R, V13, P135, DOI 10.1016/S1359-6101(01)00020-X Balkwill F, 2006, CANCER METAST REV, V25, P409, DOI 10.1007/s10555-006-9005-3 Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628 BECKNIEL.J, 1973, ACTA MED SCAND, V193, P425 Bracci L, 2014, CELL DEATH DIFFER, V21, P15, DOI 10.1038/cdd.2013.67 Bruins P, 1997, CIRCULATION, V96, P3542 Burton Elizabeth R, 2009, J Biol, V8, P85, DOI 10.1186/jbiol189 Cacciapaglia F, 2011, AUTOIMMUN REV, V10, P631, DOI 10.1016/j.autrev.2011.04.014 Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200 Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Cardinale D, 2007, CIRCULATION, V115, P1339, DOI 10.1161/CIRCULATIONAHA.106.647008 Cardinale D, 2010, J CLIN ONCOL, V28, P3910, DOI 10.1200/JCO.2009.27.3615 Cavet J, 2000, BONE MARROW TRANSPL, V25, P571, DOI 10.1038/sj.bmt.1702186 Chen PF, 2010, MOL MED, V16, P400, DOI 10.2119/molmed.2009.00128 Chen SA, 1999, CIRCULATION, V100, P1879, DOI 10.1161/01.CIR.100.18.1879 Cheng T, 2012, MOL MED REP, V6, P581, DOI 10.3892/mmr.2012.934 Choudhary S, 2013, CARCINOGENESIS, V34, P2891, DOI 10.1093/carcin/bgt239 Chu TF, 2007, LANCET, V370, P2011, DOI 10.1016/S0140-6736(07)61865-0 Chung MK, 2001, CIRCULATION, V104, P2886, DOI 10.1161/hc4901.101760 Conroy H, 2010, QJM-INT J MED, V103, P831, DOI 10.1093/qjmed/hcq148 Craig SR, 2001, EUR J CARDIO-THORAC, V20, P455, DOI 10.1016/S1010-7940(01)00841-7 Deftereos S, 2012, J AM COLL CARDIOL, V60, P1790, DOI 10.1016/j.jacc.2012.07.031 Deng H, 2011, CHINESE MED J-PEKING, V124, P1976, DOI 10.3760/cma.j.issn.0366-6999.2011.13.010 Doherty KR, 2013, TOXICOL APPL PHARM, V272, P245, DOI 10.1016/j.taap.2013.04.027 Duran JM, 2014, CIRC RES, V114, P1700, DOI 10.1161/CIRCRESAHA.114.303200 Echahidi N, 2007, CIRCULATION, V116, pI213, DOI 10.1161/CIRCULATIONAHA.106.681304 El-Sawalhi MM, 2014, CHEM-BIOL INTERACT, V207, P58, DOI 10.1016/j.cbi.2013.11.008 ElZarrad MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079543 Erichsen R, 2012, INTERN EMERG MED, V7, P431, DOI 10.1007/s11739-011-0701-9 Ewer MS, 2015, NAT REV CARDIOL, V12, P547, DOI 10.1038/nrcardio.2015.65 Falk Jeremy A, 2008, Proc Am Thorac Soc, V5, P543, DOI 10.1513/pats.200708-142ET Farmakis D, 2014, J AM COLL CARDIOL, V63, P945, DOI 10.1016/j.jacc.2013.11.026 Feliz V, 2011, CLIN CARDIOL, V34, P356, DOI 10.1002/clc.20904 Ferreira C, 2015, ARQ BRAS CARDIOL, V105, P519, DOI 10.5935/abc.20150142 Fildes JE, 2009, J AM COLL CARDIOL, V53, P1013, DOI 10.1016/j.jacc.2008.11.046 Finkel T, 2007, NATURE, V448, P767, DOI 10.1038/nature05985 Gaudino M, 2003, CIRCULATION, V108, P195, DOI 10.1161/01.cir.0000087441.48566.0d Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666 Gómez-Caro A, 2006, ARCH BRONCONEUMOL, V42, P9, DOI 10.1016/S1579-2129(06)60107-9 Gorelik J, 2003, FEBS LETT, V548, P74, DOI 10.1016/S0014-5793(03)00743-9 Goudis CA, 2015, INT J CARDIOL, V199, P264, DOI 10.1016/j.ijcard.2015.06.096 Guo YQ, 2012, CANCER TREAT REV, V38, P904, DOI 10.1016/j.ctrv.2012.04.007 Guo YT, 2015, CHEST, V147, P109, DOI 10.1378/chest.14-0321 Guo YT, 2012, J AM COLL CARDIOL, V60, P2263, DOI 10.1016/j.jacc.2012.04.063 Guzzetti S, 2002, CIRCULATION, V106, pE40, DOI 10.1161/01.CIR.0000028399.42411.13 Guzzetti S, 2002, AM J MED, V112, P587, DOI 10.1016/S0002-9343(02)01029-X Guzzetti S, 2008, INTERN EMERG MED, V3, P227, DOI 10.1007/s11739-008-0124-4 Haïssaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003 Hak L, 2009, J INTERF CYTOK RES, V29, P327, DOI 10.1089/jir.2008.0082.2906 Haudek SB, 2007, J CLIN INVEST, V117, P2692, DOI 10.1172/JCI29134 Heerdt PM, 2012, J MOL CELL CARDIOL, V53, P350, DOI 10.1016/j.yjmcc.2012.05.010 Heo T. H., 2016, ONCOTARGET Hernandez AV, 2013, ANN THORAC SURG, V96, P1104, DOI 10.1016/j.athoracsur.2013.04.029 Hindler K, 2006, ONCOLOGIST, V11, P306, DOI 10.1634/theoncologist.11-3-306 Hong RA, 2010, CLIN CARDIOL, V33, P733, DOI 10.1002/clc.20823 Hu YF, 2015, NAT REV CARDIOL, V12, P230, DOI 10.1038/nrcardio.2015.2 Ifran A, 2005, AM J HEMATOL, V80, P247, DOI 10.1002/ajh.20441 Il'yasova D, 2005, CANCER EPIDEM BIOMAR, V14, P2413, DOI 10.1158/1055-9965.EPI-05-0316 Imperatori A, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-4 Ioannou K, 2014, INT J ONCOL, V45, P1457, DOI 10.3892/ijo.2014.2551 Issac TT, 2007, J AM COLL CARDIOL, V50, P2021, DOI 10.1016/j.jacc.2007.06.054 Iwasaki YK, 2011, CIRCULATION, V124, P2264, DOI 10.1161/CIRCULATIONAHA.111.019893 Jaïs P, 2002, CIRCULATION, V106, P2479, DOI 10.1161/01.CIR.0000036744.39782.9F Jones AL, 2009, BRIT J CANCER, V100, P684, DOI 10.1038/sj.bjc.6604909 Kanmanthareddy A, 2015, J CARDIOVASC ELECTR, V26, P385, DOI 10.1111/jce.12619 Karayiannakis AJ, 2001, ANTICANCER RES, V21, P1355 Kawabata M, 2015, TOXICOL SCI, V143, P374, DOI 10.1093/toxsci/kfu235 Khan MA, 2013, WORLD J CARDIOL, V5, P215, DOI 10.4330/wjc.v5.i7.215 Kilickap S, 2007, SOUTH MED J, V100, P262, DOI 10.1097/01.smj.0000257382.89910.fe Kindt N, 2013, INT J ONCOL, V43, P185, DOI 10.3892/ijo.2013.1944 Kloth JSL, 2015, BRIT J CANCER, V112, P1011, DOI 10.1038/bjc.2015.82 Kluza J, 2004, ONCOGENE, V23, P7018, DOI 10.1038/sj.onc.1207936 Koga K, 2013, AM J PHYSIOL-HEART C, V304, pH282, DOI 10.1152/ajpheart.00595.2012 KUPARI M, 1990, BONE MARROW TRANSPL, V5, P91 Lai HC, 2011, TOXICOL APPL PHARM, V257, P437, DOI 10.1016/j.taap.2011.10.001 Lazzerini PE, 2015, ARTHRIT CARE RES, V67, P332, DOI 10.1002/acr.22455 Lee SH, 2007, LIFE SCI, V80, P1806, DOI 10.1016/j.lfs.2007.02.029 Lee TI, 2013, INT J CARDIOL, V165, P299, DOI 10.1016/j.ijcard.2011.08.072 LEVINE ES, 1993, CARDIOVASC RES, V27, P1248, DOI 10.1093/cvr/27.7.1248 Liehn EA, 2013, ARTERIOSCL THROM VAS, V33, P2180, DOI 10.1161/ATVBAHA.113.301633 Lin YK, 2014, INT J CARDIOL, V176, P191, DOI 10.1016/j.ijcard.2014.07.004 Lin ZY, 2013, LIFE SCI, V93, P323, DOI 10.1016/j.lfs.2013.07.002 Liu Yuan, 2003, Di Yi Jun Yi Da Xue Xue Bao, V23, P1169 Liu YN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127813 Lohani KR, 2015, SURG ENDOSC, V29, P2039, DOI 10.1007/s00464-014-3908-9 Ma H, 2010, CLIN EXP PHARMACOL P, V37, P460, DOI 10.1111/j.1440-1681.2009.05323.x Ma JY, 2006, WORLD J GASTROENTERO, V12, P449, DOI 10.3748/wjg.v12.i3.449 Madrid AH, 2006, REV ESP CARDIOL, V59, P94 Maesen B, 2012, EUROPACE, V14, P159, DOI 10.1093/europace/eur208 Mantawy EM, 2014, EUR J PHARMACOL, V728, P107, DOI 10.1016/j.ejphar.2014.01.065 Mawhinney L, 2014, MOL MED, V20, P729, DOI 10.2119/molmed.2014.00136 Mc Cormack O, 2014, ANN SURG, V260, P772, DOI 10.1097/SLA.0000000000000960 Mego M, 2007, ANN ONCOL, V18, P1906, DOI 10.1093/annonc/mdm489 Meléndez GC, 2010, HYPERTENSION, V56, P225, DOI 10.1161/HYPERTENSIONAHA.109.148635 Miller EJ, 2008, NATURE, V451, P578, DOI 10.1038/nature06504 Morand EF, 2002, RHEUMATOLOGY, V41, P558, DOI 10.1093/rheumatology/41.5.558 Moreau P, 1999, BONE MARROW TRANSPL, V23, P1003, DOI 10.1038/sj.bmt.1701763 MULLER AD, 1994, DIGEST DIS SCI, V39, P2480, DOI 10.1007/BF02087670 Murthy SC, 2003, J THORAC CARDIOV SUR, V126, P1162, DOI 10.1016/S0022-5223(03)00974-7 Nagai T, 2011, HYPERTENSION, V57, P208, DOI 10.1161/HYPERTENSIONAHA.110.158915 Narducci ML, 2011, EUROPACE, V13, P1133, DOI 10.1093/europace/eur068 Neves H, 2015, BBA CLIN, V3, P280, DOI 10.1016/j.bbacli.2015.04.001 Nojiri T, 2011, GEN THORAC CARDIOVAS, V59, P799, DOI 10.1007/s11748-011-0841-x Nojiri T, 2010, J THORAC CARDIOV SUR, V140, P764, DOI 10.1016/j.jtcvs.2009.11.073 O'Neal WT, 2015, AM J CARDIOL, V115, P1090, DOI 10.1016/j.amjcard.2015.01.540 O'Reilly C., 2016, MED RES REV Ojima T, 2014, SURG TODAY, V44, P839, DOI 10.1007/s00595-013-0616-3 Olivieri A, 1998, BONE MARROW TRANSPL, V21, P1049, DOI 10.1038/sj.bmt.1701217 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Ostenfeld EB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102861 Ott A, 1997, STROKE, V28, P316, DOI 10.1161/01.STR.28.2.316 Palud A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058718 Perez EA, 2004, J CLIN ONCOL, V22, P322, DOI 10.1200/JCO.2004.01.120 Petrini I, 2012, CANCER CHEMOTH PHARM, V69, P773, DOI 10.1007/s00280-011-1753-2 Phillips GL, 2004, BIOL BLOOD MARROW TR, V10, P473, DOI 10.1016/j.bbmt.2004.03.001 Popivanova BK, 2008, J CLIN INVEST, V118, P560, DOI [10.1172/JCI32453, 10.1172/JC132453] Proietti E, 2012, MOL ONCOL, V6, P1, DOI 10.1016/j.molonc.2011.11.005 Qu YC, 2009, SCAND CARDIOVASC J, V43, P292, DOI 10.1080/14017430802651803 Rao F, 2013, EXP PHYSIOL, V98, P172, DOI 10.1113/expphysiol.2012.066761 Rao F, 2009, J MOL CELL CARDIOL, V47, P586, DOI 10.1016/j.yjmcc.2009.08.030 Rena O, 2001, EUR J CARDIO-THORAC, V20, P688, DOI 10.1016/S1010-7940(01)00890-9 Riber LP, 2014, ANN THORAC SURG, V98, P1989, DOI 10.1016/j.athoracsur.2014.06.069 Richards WG, 2006, J CLIN ONCOL, V24, P1561, DOI 10.1200/JCO.2005.04.6813 Ritchie DS, 2001, BONE MARROW TRANSPL, V28, P101, DOI 10.1038/sj.bmt.1703098 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Sag CM, 2011, J MOL CELL CARDIOL, V51, P749, DOI 10.1016/j.yjmcc.2011.07.016 Sano M, 2000, J BIOL CHEM, V275, P29717, DOI 10.1074/jbc.M003128200 Schmitt J, 2009, EUR HEART J, V30, P1038, DOI 10.1093/eurheartj/ehn579 Sekine Y, 2012, EUR RESPIR J, V39, P1230, DOI 10.1183/09031936.00126011 Siemes C, 2006, J CLIN ONCOL, V24, P5216, DOI 10.1200/JCO.2006.07.1381 Sirohi B, 2000, BONE MARROW TRANSPL, V25, P533, DOI 10.1038/sj.bmt.1702188 Siu CW, 2005, PACE, V28, pS120, DOI 10.1111/j.1540-8159.2005.00024.x Song XX, 2010, AM J PHYSIOL-CELL PH, V299, pC1256, DOI 10.1152/ajpcell.00338.2010 Stoppe C, 2015, ANTIOXID REDOX SIGN, V23, P865, DOI 10.1089/ars.2014.6243 Sudharsan PT, 2006, MOL CELL BIOCHEM, V282, P23, DOI 10.1007/s11010-006-1169-1 Szlosarek PW, 2003, LANCET ONCOL, V4, P565, DOI 10.1016/S1470-2045(03)01196-3 Takahashi K, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-33 Tamargo J, 2015, DRUG SAFETY, V38, P129, DOI 10.1007/s40264-014-0258-4 Tamargo J, 2012, DISCOV MED, V14, P295 Tassinari D, 1997, ANN ONCOL, V8, P1263, DOI 10.1023/A:1008231521553 Tomkowski WZ, 1997, LUNG CANCER-J IASLC, V16, P215, DOI 10.1016/S0169-5002(96)00631-9 Tomkowski WZ, 2004, SUPPORT CARE CANCER, V12, P53, DOI 10.1007/s00520-003-0533-x Vaitkevicius R, 2009, HEART RHYTHM, V6, P221, DOI 10.1016/j.hrthm.2008.10.027 van der Vorst EPC, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00373 Varga ZV, 2015, AM J PHYSIOL-HEART C, V309, pH1453, DOI 10.1152/ajpheart.00554.2015 Varinelli L, 2015, ENDOCR-RELAT CANCER, V22, P759, DOI 10.1530/ERC-15-0299 Vyas D, 2014, ONCOTARGETS THER, V7, P1015, DOI 10.2147/OTT.S60114 Walsh Stewart R, 2004, World J Surg Oncol, V2, P40 Wang SY, 2014, BREAST CANCER RES TR, V146, P411, DOI 10.1007/s10549-014-3029-0 Will Y, 2008, TOXICOL SCI, V106, P153, DOI 10.1093/toxsci/kfn157 Wu ZK, 2008, WORLD J SURG, V32, P2643, DOI 10.1007/s00268-008-9758-7 Xin YF, 2011, BIOL PHARM BULL, V34, P1523, DOI 10.1248/bpb.34.1523 Yang J, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0021128, 10.1371/journal.pone.0024111] Yao X, 2014, PHARMACOL THERAPEUT, V141, P125, DOI 10.1016/j.pharmthera.2013.09.004 Yoshiyama Y, 2003, BIOL PHARM BULL, V26, P893 Zacharias A, 2005, CIRCULATION, V112, P3247, DOI 10.1161/CIRCULATIONAHA.105.553743 Zhang Y, 2015, MOL MED REP, V11, P2615, DOI 10.3892/mmr.2014.3116 NR 177 TC 28 Z9 33 U1 0 U2 20 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 EI 1874-1754 J9 INT J CARDIOL JI Int. J. Cardiol. PD SEP 15 PY 2016 VL 219 BP 186 EP 194 DI 10.1016/j.ijcard.2016.06.009 PG 9 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA DS5JG UT WOS:000380817400033 PM 27327505 DA 2026-04-17 ER PT J AU Chino, H Amano, Y Yamauchi, Y Matsuda, J Takeda, N Tanaka, G Takai, D Nagase, T AF Chino, Haruka Amano, Yosuke Yamauchi, Yasuhiro Matsuda, Jun Takeda, Norihiko Tanaka, Goh Takai, Daiya Nagase, Takahide TI Cardiogenic syncope possibly related to bevacizumab-containing combination chemotherapy for advanced non-small cell lung cancer SO JOURNAL OF THORACIC DISEASE LA English DT Article DE Non-small cell lung cancer (NSCLC); bevacizumab; cardiotoxicity; chemotherapy; vascular endothelial growth factor (VEGF) ID METASTATIC BREAST-CANCER; PLATINUM-BASED CHEMOTHERAPY; RANDOMIZED PHASE-III; 1ST-LINE TREATMENT; PLUS BEVACIZUMAB; ONCOLOGY-GROUP; DOUBLE-BLIND; PACLITAXEL; PLACEBO; TRIAL AB We report the case of a 55-year-old man with stage IV lung adenocarcinoma who received carboplatin-paclitaxel-bevacizumab chemotherapy as second-line therapy. After four cycles of chemotherapy, he experienced syncope with a decrease in blood pressure. Electrocardiography (ECG) revealed atrial fibrillation. Cardiac ultrasonography showed a markedly reduced ejection fraction (45%), with moderate decrease in comparison to that before chemotherapy (66%). Bisoprolol fumarate was initiated, and the conversion to sinus rhythm was detected by ECG 4 days after the syncope. At that time, no improvement in the ejection fraction was detected. Bevacizumab-associated cardiotoxicity was suspected, and bevacizumab maintenance therapy was discontinued, although the chemotherapy achieved a stable disease status based on the Response Evaluation Criteria in Solid Tumors. Two months after bevacizumab cessation, the ejection fraction improved to pretreatment level (62%). To the best of our knowledge, this is the first report on cardiogenic syncope due to left ventricular dysfunction that is most consistent with bevacizumab-associated cardiotoxicity in non-small cell lung cancer (NSCLC). Our results indicate that bevacizumab could lead to cardiotoxicity in patients with NSCLC and suggest the importance of the follow-up cardiac ultrasonography. C1 [Chino, Haruka; Amano, Yosuke; Yamauchi, Yasuhiro; Tanaka, Goh; Nagase, Takahide] Tokyo Univ Hosp, Dept Resp Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo, Japan. [Matsuda, Jun; Takeda, Norihiko] Tokyo Univ Hosp, Dept Cardiovasc Med, Bunkyo Ku, Tokyo, Japan. [Takai, Daiya] Tokyo Univ Hosp, Dept Clin Lab, Bunkyo Ku, Tokyo, Japan. C3 University of Tokyo; University of Tokyo; University of Tokyo RP Chino, H (corresponding author), Tokyo Univ Hosp, Dept Resp Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo, Japan. EM hchino-tky@umin.ac.jp CR Advani RH, 2012, LEUKEMIA LYMPHOMA, V53, P718, DOI 10.3109/10428194.2011.623256 Aghajanian C, 2012, J CLIN ONCOL, V30, P2039, DOI 10.1200/JCO.2012.42.0505 [Anonymous], 2008, AVASTIN BEVACIZUMAB Brana I, 2010, ANN ONCOL, V21, P173, DOI 10.1093/annonc/mdq295 Burger RA, 2011, NEW ENGL J MED, V365, P2473, DOI 10.1056/NEJMoa1104390 Chen ZG, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000975 Chinot OL, 2014, NEW ENGL J MED, V370, P709, DOI 10.1056/NEJMoa1308345 Choueiri TK, 2011, J CLIN ONCOL, V29, P632, DOI 10.1200/JCO.2010.31.9129 Chu TF, 2007, LANCET, V370, P2011, DOI 10.1016/S0140-6736(07)61865-0 D'Adamo DR, 2005, J CLIN ONCOL, V23, P7135, DOI 10.1200/JCO.2005.16.139 des Guetz G, 2011, TARGET ONCOL, V6, P197, DOI 10.1007/s11523-011-0204-7 Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305 Giordano FJ, 2001, P NATL ACAD SCI USA, V98, P5780, DOI 10.1073/pnas.091415198 Groarke John D, 2014, Curr Treat Options Cardiovasc Med, V16, P335, DOI 10.1007/s11936-014-0335-0 Hawkes EA, 2011, J CLIN ONCOL, V29, pE560, DOI 10.1200/JCO.2011.35.5008 Hutchinson L, 2011, NAT REV CLIN ONCOL, V8, P189, DOI [10.1038/nrclinonc.2011.34, 10.1038/nrclinonc.2010.204] May D, 2008, P NATL ACAD SCI USA, V105, P282, DOI 10.1073/pnas.0707778105 Miles DW, 2010, J CLIN ONCOL, V28, P3239, DOI 10.1200/JCO.2008.21.6457 Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113 Miller KD, 2005, J CLIN ONCOL, V23, P792, DOI 10.1200/JCO.2005.05.098 Monsuez JJ, 2010, INT J CARDIOL, V144, P3, DOI 10.1016/j.ijcard.2010.03.003 Nishino K, 2015, LUNG CANCER, V89, P146, DOI 10.1016/j.lungcan.2015.05.022 Patel JD, 2013, J CLIN ONCOL, V31, P4349, DOI 10.1200/JCO.2012.47.9626 Pereg D, 2008, EUR HEART J, V29, P2325, DOI 10.1093/eurheartj/ehn384 Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884 Senkus E, 2011, CANCER TREAT REV, V37, P300, DOI 10.1016/j.ctrv.2010.11.001 Seto T, 2014, LANCET ONCOL, V15, P1236, DOI 10.1016/S1470-2045(14)70381-X Soria JC, 2013, ANN ONCOL, V24, P20, DOI 10.1093/annonc/mds590 Verma N, 2011, J CLIN ONCOL, V29, P603, DOI 10.1200/JCO.2010.32.9060 Yardley DA, 2010, CLIN BREAST CANCER, V10, P119, DOI 10.3816/CBC.2010.n.016 Yeh ETH, 2009, J AM COLL CARDIOL, V53, P2231, DOI 10.1016/j.jacc.2009.02.050 Zhao LD, 2015, ONCOTARGETS THER, V8, DOI 10.2147/OTT.S88102 Zhou CC, 2015, J CLIN ONCOL, V33, P2197, DOI 10.1200/JCO.2014.59.4424 NR 33 TC 6 Z9 8 U1 0 U2 4 PU AME PUBLISHING COMPANY PI SHATIN PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA SN 2072-1439 EI 2077-6624 J9 J THORAC DIS JI J. Thorac. Dis. PD SEP PY 2016 VL 8 IS 9 BP 2646 EP 2650 DI 10.21037/jtd.2016.08.96 PG 5 WC Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System GA DZ1RA UT WOS:000385615400124 PM 27747019 OA Green Submitted, hybrid DA 2026-04-17 ER PT J AU Cardinale, D Sandri, MT Colombo, A Salvatici, M Tedeschi, I Bacchiani, G Beggiato, M Meroni, CA Civelli, M Lamantia, G Colombo, N Veglia, F Casiraghi, M Spaggiari, L Venturino, M Cipolla, CM AF Cardinale, Daniela Sandri, Maria T. Colombo, Alessandro Salvatici, Michela Tedeschi, Ines Bacchiani, Giulia Beggiato, Marta Meroni, Carlo A. Civelli, Maurizio Lamantia, Giuseppina Colombo, Nicola Veglia, Fabrizio Casiraghi, Monica Spaggiari, Lorenzo Venturino, Marco Cipolla, Carlo M. TI Prevention of Atrial Fibrillation in High-risk Patients Undergoing Lung Cancer Surgery The PRESAGE Trial SO ANNALS OF SURGERY LA English DT Article DE losartan; lung cancer surgery; metoprolol; NT-proBNP; postoperative atrial fibrillation ID BRAIN NATRIURETIC PEPTIDE; CHRONIC HEART-FAILURE; NEUROHORMONAL ACTIVATION; PULMONARY RESECTION; CLINICAL-RELEVANCE; BETA-BLOCKER; GUIDELINES; PROPHYLAXIS; MANAGEMENT; REDUCTION AB Objective: We performed a prospective, randomized clinical study to assess whether prophylactic treatment with metoprolol or losartan, initiated soon after lung cancer surgery in patients with elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, reduces the incidence of postoperative atrial fibrillation. Background: Postoperative atrial fibrillation is a well recognized complication after lung cancer surgery, with an incidence as high as 30%. Perioperative increase of NT-proBNP has been demonstrated to be a strong independent predictor of postoperative atrial fibrillation in this setting. Methods: NT-proBNP concentration was measured 24 hours before surgery and soon after surgery in 1116 patients. Three hundred twenty (29%) patients showed a high NT-proBNP value and were enrolled: 108 were assigned to the metoprolol group, 102 to the losartan group, and 110 to the control group. Results: Overall, the incidence of postoperative atrial fibrillation was 20% (n = 64); it was significantly lower in the metoprolol and losartan groups compared with the control group [6%, 12%, and 40%, respectively; relative risk 0.19, 95% confidence intervals (CIs), 0.09-0.37; P < 0.001 in the metoprolol group; and 0.29, 95% CI, 0.16-0.52; P < 0.001 in the losartan group). No significant difference was found when the metoprolol and losartan groups were directly compared (P = 0.21). Conclusions: A prophylactic treatment with metoprolol or losartan, initiated soon after lung cancer surgery in patients with high NT-proBNP levels, significantly reduced the occurrence of postoperative atrial fibrillation. C1 [Cardinale, Daniela] IRCCS, European Inst Oncol, Cardioncol Unit, Milan, Italy. [Sandri, Maria T.; Salvatici, Michela] IRCCS, European Inst Oncol, Div Lab Med, Milan, Italy. [Colombo, Alessandro; Tedeschi, Ines; Bacchiani, Giulia; Beggiato, Marta; Meroni, Carlo A.; Civelli, Maurizio; Lamantia, Giuseppina; Colombo, Nicola; Cipolla, Carlo M.] IRCCS, European Inst Oncol, Div Cardiol, Milan, Italy. [Veglia, Fabrizio] Univ Milan, IRCCS, Ctr Cardiol Monzino, Milan, Italy. [Casiraghi, Monica] IRCCS, European Inst Oncol, Dept Thorac Surg, Milan, Italy. [Spaggiari, Lorenzo] Univ Milan, Sch Med, Dept Thorac Surg, European Inst Oncol,IRCCS, Milan, Italy. [Venturino, Marco] IRCCS, European Inst Oncol, Dept Anaesthesiol, Milan, Italy. C3 IRCCS European Institute of Oncology (IEO); IRCCS European Institute of Oncology (IEO); IRCCS European Institute of Oncology (IEO); IRCCS Centro Cardiologico Monzino; University of Milan; IRCCS European Institute of Oncology (IEO); IRCCS European Institute of Oncology (IEO); University of Milan; IRCCS European Institute of Oncology (IEO) RP Cardinale, D (corresponding author), European Inst Oncol, Cardioncol Unit, Via Ripamonti 435, I-20141 Milan, Italy. EM daniela.cardinale@ieo.it RI Tedeschi, Ines/AAQ-4674-2020; CARDINALE, DANIELA/AAN-1675-2020; Lamantia, Giuseppina/AAP-9965-2020; sani, maria teresa/AAC-3072-2020; Spaggiari, Lorenzo/G-7915-2012; Veglia, Fabrizio/K-1958-2016; Cipolla, Carlo/AAO-3897-2020; Casiraghi, Monica/K-2777-2019; Civelli, Maurizio/AAO-3674-2020 OI Tedeschi, Ines/0000-0002-2270-8689; CARDINALE, DANIELA/0000-0002-4038-8033; Lamantia, Giuseppina/0000-0002-0098-9010; sani, maria teresa/0000-0002-4437-4237; Spaggiari, Lorenzo/0000-0002-1068-3541; Veglia, Fabrizio/0000-0002-9378-8874; Casiraghi, Monica/0000-0001-5986-7811; CR Amar D, 2000, J THORAC CARDIOV SUR, V120, P790, DOI 10.1067/mtc.2000.109538 Amar D, 2012, J THORAC CARDIOV SUR, V144, P1249, DOI 10.1016/j.jtcvs.2012.06.051 Amar David, 2002, Heart Dis, V4, P117 [Anonymous], 2001, B WORLD HEALTH ORGAN, V79, P373, DOI 10.1001/jama.2013.281053 Baran D, 2000, DRUGS, V60, P997, DOI 10.2165/00003495-200060050-00003 Bayliff CD, 1999, ANN THORAC SURG, V67, P182, DOI 10.1016/S0003-4975(98)01226-0 Bhave PD, 2012, AM HEART J, V164, P918, DOI 10.1016/j.ahj.2012.09.004 Bradley D, 2005, CHEST, V128, p39S, DOI 10.1378/chest.128.2_suppl.39S Cai GL, 2014, WORLD J SURG, V38, P51, DOI 10.1007/s00268-013-2284-2 Camm AJ, 2012, EUR HEART J, V33 Cardinale D, 2007, CIRCULATION, V115, P1339, DOI 10.1161/CIRCULATIONAHA.106.647008 Chelazzi C, 2011, ISRN Cardiol, V2011, P203179, DOI 10.5402/2011/203179 Clerico A, 2006, CLIN CHEM LAB MED, V44, P366, DOI 10.1515/CCLM.2006.063 Clerico A, 2002, CLIN CHEM LAB MED, V40, P752, DOI 10.1515/CCLM.2002.129 DiNicolantonio JJ, 2014, AM J CARDIOL, V113, P565, DOI 10.1016/j.amjcard.2013.10.020 Ducharme A, 2006, AM HEART J, V152, P86, DOI 10.1016/j.ahj.2005.06.036 Dunning J, 2006, EUR J CARDIO-THORAC, V30, P852, DOI 10.1016/j.ejcts.2006.09.003 Engelmann MDM, 2005, EUR HEART J, V26, P2083, DOI 10.1093/eurheartj/ehi350 Frendl G, 2014, J THORAC CARDIOV SUR, V148, pE153, DOI 10.1016/j.jtcvs.2014.06.036 Fuster V, 2006, CIRCULATION, V114, pE257, DOI 10.1161/CIRCULATIONAHA.106.177292 Gialdini G, 2014, JAMA-J AM MED ASSOC, V312, P616, DOI 10.1001/jama.2014.9143 Guler N, 2007, ANN THORAC SURG, V83, P532, DOI 10.1016/j.athoracsur.2006.08.040 Gurgo A M, 2008, Minerva Cardioangiol, V56, P581 Ishida K, 2006, EUR J CARDIO-THORAC, V29, P501, DOI 10.1016/j.ejcts.2005.12.028 Jakobsen CJ, 1997, J CARDIOTHOR VASC AN, V11, P746, DOI 10.1016/S1053-0770(97)90169-5 Jibrini MB, 2008, AM J THER, V15, P36, DOI 10.1097/MJT.0b013e31804beb59 Johnson W, 2002, J AM COLL CARDIOL, V39, P1623, DOI 10.1016/S0735-1097(02)01814-4 Kalman JM, 1995, ANN THORAC SURG, V60, P1709, DOI 10.1016/0003-4975(95)00718-0 Karthikeyan G, 2009, J AM COLL CARDIOL, V54, P1599, DOI 10.1016/j.jacc.2009.06.028 Latini R, 2002, CIRCULATION, V106, P2454, DOI 10.1161/01.CIR.0000036747.68104.AC Lee Chang Young, 2011, Korean J Thorac Cardiovasc Surg, V44, P44, DOI 10.5090/kjtcs.2011.44.1.44 Madrid AH, 2002, CIRCULATION, V106, P331, DOI 10.1161/01.CIR.0000022665.18619.83 Maggioni AP, 2005, AM HEART J, V149, P548, DOI 10.1016/j.ahj.2004.09.033 Marsiliani D, 2010, EUR REV MED PHARMACO, V14, P855 Nojiri T, 2011, GEN THORAC CARDIOVAS, V59, P799, DOI 10.1007/s11748-011-0841-x Nojiri T, 2010, EUR J CARDIO-THORAC, V37, P787, DOI 10.1016/j.ejcts.2009.09.043 Ozaydin M, 2008, INT J CARDIOL, V127, P362, DOI 10.1016/j.ijcard.2007.05.012 Reinhart K, 2011, J CARDIOVASC PHARM T, V16, P5, DOI 10.1177/1074248410378120 Riber LP, 2014, ANN THORAC SURG, V98, P1989, DOI 10.1016/j.athoracsur.2014.06.069 Rodseth RN, 2014, J AM COLL CARDIOL, V63, P170, DOI 10.1016/j.jacc.2013.08.1630 Shrivastava Vivek, 2004, Interact Cardiovasc Thorac Surg, V3, P656, DOI 10.1016/j.icvts.2004.08.002 Skov T, 1998, INT J EPIDEMIOL, V27, P91, DOI 10.1093/ije/27.1.91 Tisdale JE, 2010, SEMIN THORAC CARDIOV, V22, P310, DOI 10.1053/j.semtcvs.2010.12.001 Tisdale JE, 2009, ANN THORAC SURG, V88, P886, DOI 10.1016/j.athoracsur.2009.04.074 Ucar HI, 2007, HEART SURG FORUM, V10, pE131, DOI 10.1532/HSF98.20061175 Vetrugno L, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-20 Wachtell K, 2005, J AM COLL CARDIOL, V45, P712, DOI 10.1016/j.jacc.2004.10.068 Wazni OM, 2004, CIRCULATION, V110, P124, DOI 10.1161/01.CIR.0000134481.24511.BC Yoshikawa T, 1996, AM HEART J, V131, P329, DOI 10.1016/S0002-8703(96)90362-2 Yoshimura M, 2002, AM J MED, V112, P716, DOI 10.1016/S0002-9343(02)01121-X YOSHIMURA M, 1994, BRIT HEART J, V72, P528 NR 51 TC 56 Z9 64 U1 1 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD AUG PY 2016 VL 264 IS 2 BP 244 EP 251 DI 10.1097/SLA.0000000000001626 PG 8 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA DS1ZQ UT WOS:000380504400018 PM 26764872 DA 2026-04-17 ER PT J AU Chen, H Xu, GB Zheng, B Zheng, W Zhu, Y Guo, ZH Chen, C AF Chen, Hao Xu, Guobing Zheng, Bin Zheng, Wei Zhu, Yong Guo, Zhaohui Chen, Chun TI Initial experience of single-port video-assisted thoracoscopic surgery sleeve lobectomy and systematic mediastinal lymphadenectomy for non-small-cell lung cancer SO JOURNAL OF THORACIC DISEASE LA English DT Article DE Single-port video-assisted thoracoscopic surgery (single-port VATS); sleeve lobectomy (SL); systematic mediastinal lymphadenectomy; bronchial anastomosis; non-small-cell lung cancer (NSCLC) ID PNEUMONECTOMY; BRONCHOPLASTY; SEGMENTECTOMY; RESECTIONS AB Background: In this study, we evaluate the feasibility and safety of single-port video-assisted thoracoscopic surgery (VATS) sleeve lobectomy (SL) and systematic mediastinal lymphadenectomy and summarize our surgical experience. Methods: From October 2014 to December 2015, eight cases of single-port VATS SL [seven male patients and one female patient, median age 56.0 (range, 38-63) years] were performed by a single group of surgeons in Fujian Medical University Fujian Union Hospital. The median tumor size was 2.7 cm. Types of resection included four right upper, one right lower, and three left upper sleeve lobectomies. Systematic mediastinal lymphadenectomy was performed in all patients. A modified anastomosis technique developed by the author (Chen's technique) was applied for bronchial anastomosis. Postoperative outcome and short-term follow-up data were recorded and analyzed. Results: All eight operations were completed uneventfully with no conversion to thoracotomy or reoperation required. No perioperative death was observed. Major results (medians or percentages) were as follows: operative duration, 234.5 [185-345] min; bronchial anastomosis duration, 38.0 [30-43] min; blood loss, 65.0 [50-200] mL; number of lymph node dissected, 22.5 [18-37]. The postoperative complication rate was 37.5% (three of eight cases, including two pulmonary infections and one atrial fibrillation). All patients recovered and were discharged uneventfully with symptomatic therapy. Pathology showed squamous cell carcinoma in seven patients and adenocarcinoma in one patient; two patients were in TNM stage IB, three in stage IIA, one in stage IIB, and two in stage IIIA. The mean follow-up was 7.5 [2-15] months. There were no tumor recurrences or bronchial anastomotic complications. Conclusions: Single-port VATS SL and mediastinal lymphadenectomy are safe and feasible. Improvements in operating procedures can help facilitate single-port VATS. The application of Chen's technique in bronchial anastomosis is easy and reliable and shows a satisfactory short-term clinical outcome. C1 [Chen, Hao; Xu, Guobing; Zheng, Bin; Zheng, Wei; Zhu, Yong; Guo, Zhaohui; Chen, Chun] Fujian Med Univ, Fujian Union Hosp, Dept Thorac Surg, Fuzhou 350001, Peoples R China. C3 Fujian Medical University RP Chen, C (corresponding author), Fujian Med Univ, Fujian Union Hosp, Dept Thorac Surg, 29 Xinquan Rd, Fuzhou 350000, Peoples R China. EM chenchun0209@163.com RI xu, guobing/AAF-3096-2019; Chen, Huaiyong/G-3822-2014 CR Agasthian T, 2013, EUR J CARDIO-THORAC, V44, P616, DOI 10.1093/ejcts/ezt166 Cheng K, 2016, J THORAC DIS, V8, pS229, DOI 10.3978/j.issn.2072-1439.2016.02.14 Ferguson MK, 2003, ANN THORAC SURG, V76, P1782, DOI 10.1016/S0003-4975(03)01243-8 Gonzalez-Rivas D, 2014, J THORAC DIS, V6, pS674, DOI 10.3978/j.issn.2072-1439.2014.09.17 Gonzalez-Rivas D, 2014, ANN CARDIOTHORAC SUR, V3, pE2, DOI 10.3978/j.issn.2225-319X.2014.03.13 Gonzalez-Rivas D, 2014, INTERACT CARDIOV TH, V18, P237, DOI 10.1093/icvts/ivt441 Gonzalez-Rivas D, 2013, J THORAC CARDIOV SUR, V145, P1676, DOI 10.1016/j.jtcvs.2013.02.052 Gonzalez-Rivas D, 2012, SCI WORLD J, DOI 10.1100/2012/780842 Gonzalez-Rivas D, 2013, ANN THORAC SURG, V95, P426, DOI 10.1016/j.athoracsur.2012.10.070 Hanna JM, 2013, J THORAC DIS, V5, pS182, DOI 10.3978/j.issn.2072-1439.2013.07.08 Li Y, 2013, EUR J CARDIO-THORAC, V44, P1108, DOI 10.1093/ejcts/ezt199 Lyscov A, 2016, J THORAC DIS, V8, pS235, DOI 10.3978/j.issn.2072-1439.2016.02.25 Ma ZY, 2007, EUR J CARDIO-THORAC, V32, P20, DOI 10.1016/j.ejcts.2007.03.018 Mahtabifard A, 2008, ANN THORAC SURG, V85, pS729, DOI 10.1016/j.athoracsur.2007.12.001 Maurizi G, 2013, J THORAC ONCOL, V8, P637, DOI 10.1097/JTO.0b013e318286d145 McKenna RJ, 2006, ANN THORAC SURG, V81, P421, DOI 10.1016/j.athoracsur.2005.07.078 Nakagawa T, 2015, GEN THORAC CARDIOVAS, V63, P640, DOI 10.1007/s11748-014-0517-4 Nakanishi K, 2007, ANN THORAC SURG, V84, P191, DOI 10.1016/j.athoracsur.2007.03.008 Shen YX, 2016, EUR J CARDIO-THORAC, V49, P48, DOI 10.1093/ejcts/ezv358 Wang BY, 2015, ANN SURG, V261, P793, DOI 10.1097/SLA.0000000000000712 Xu GB, 2013, J THORAC DIS, V5, pS298, DOI 10.3978/j.issn.2072-1439.2013.08.29 Zhu Y, 2015, J THORAC DIS, V7, P1241, DOI 10.3978/j.issn.2072-1439.2015.06.02 NR 22 TC 8 Z9 11 U1 0 U2 5 PU PIONEER BIOSCIENCE PUBL CO PI HONG KONG PA 9A GOLD SHINE TOWER, 346-348 QUEEN'S RD CENTRAL, SHEUNG WAN, HONG KONG, 00000, PEOPLES R CHINA SN 2072-1439 EI 2077-6624 J9 J THORAC DIS JI J. Thorac. Dis. PD AUG PY 2016 VL 8 IS 8 BP 2196 EP 2202 DI 10.21037/jtd.2016.07.89 PG 7 WC Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System GA DY3VO UT WOS:000385023800107 PM 27621876 OA hybrid DA 2026-04-17 ER PT J AU Iwata, T Nagato, K Nakajima, T Suzuki, H Yoshida, S Yoshino, I AF Iwata, Takekazu Nagato, Kaoru Nakajima, Takahiro Suzuki, Hidemi Yoshida, Shigetoshi Yoshino, Ichiro TI Risk factors predictive of atrial fibrillation after lung cancer surgery SO SURGERY TODAY LA English DT Review DE Atrial fibrillation; Pulmonary surgery; Risk factor ID NATRIURETIC-PEPTIDE; THORACIC-SURGERY; PULMONARY RESECTION; CARDIOPULMONARY COMPLICATIONS; SUPRAVENTRICULAR ARRHYTHMIAS; THORACOSCOPIC LOBECTOMY; LOWER MORBIDITY; DYSRHYTHMIAS; DYSFUNCTION; AGE AB Postoperative atrial fibrillation (POAF), the most frequent arrhythmia after pulmonary resection, is a cause of both morbidity and mortality. Being able to predict the risk of POAF before surgery would help us evaluate the surgical risk and plan prophylaxis. We investigated the reported preoperative risk factors associated with the incidence of POAF and found that the recommended predictive factors were quite variable. Therefore, we evaluated the previously reported preoperative risk factors for POAF using our institutional data. We discuss our findings in this short review. Male gender, resected lung volume, brain natriuretic peptide (BNP), and left ventricular early transmitral velocity/mitral annular early diastolic velocity (E/e') calculated by echocardiography were suggested as independent predictors for POAF, but the predictive values of each individual parameter were not high. The lack of definitive predictors for POAF warrants further investigations by gathering the reported knowledge, to establish an effective preoperative examination strategy. C1 [Iwata, Takekazu; Nagato, Kaoru; Nakajima, Takahiro; Suzuki, Hidemi; Yoshida, Shigetoshi; Yoshino, Ichiro] Chiba Univ, Grad Sch Med, Dept Gen Thorac Surg, Chuo Ku, 1-8-1 Inohana, Chiba, Chiba 2608670, Japan. C3 Chiba University RP Iwata, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Gen Thorac Surg, Chuo Ku, 1-8-1 Inohana, Chiba, Chiba 2608670, Japan. EM takeiwata-ths@umin.ac.jp RI Suzuki, Hidemi/GVS-5642-2022; Nakajima, Takahiro/GRX-7909-2022; Ichiro, Yoshino/HCH-1137-2022 OI Suzuki, Hidemi/0000-0002-8983-433X; Nakajima, Takahiro/0000-0002-4937-5378; CR Al-Omari MA, 2008, AM J CARDIOL, V101, P1759, DOI 10.1016/j.amjcard.2008.02.067 AMAR D, 1995, CHEST, V108, P349, DOI 10.1378/chest.108.2.349 Amar D, 2002, ANESTHESIOLOGY, V96, P352, DOI 10.1097/00000542-200202000-00021 Amar D, 1996, CHEST, V110, P437, DOI 10.1378/chest.110.2.437 Amar D, 2012, J THORAC CARDIOV SUR, V144, P1249, DOI 10.1016/j.jtcvs.2012.06.051 ASAMURA H, 1993, J THORAC CARDIOV SUR, V106, P1104, DOI 10.1016/S0022-5223(19)33985-6 Brathwaite D, 1998, CHEST, V114, P462, DOI 10.1378/chest.114.2.462 Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Cardinale D, 2007, CIRCULATION, V115, P1339, DOI 10.1161/CIRCULATIONAHA.106.647008 Ciriaco P, 2000, EUR J CARDIO-THORAC, V18, P12, DOI 10.1016/S1010-7940(00)00428-0 Ciszewski P, 2013, INTERACT CARDIOV TH, V17, P680, DOI 10.1093/icvts/ivt238 Curtis JJ, 1998, ANN THORAC SURG, V66, P1766, DOI 10.1016/S0003-4975(98)00942-4 Dyszkiewicz W, 1998, EUR J CARDIO-THORAC, V13, P625, DOI 10.1016/S1010-7940(98)00084-0 Harpole DH, 1996, ANN THORAC SURG, V61, P977, DOI 10.1016/0003-4975(95)01174-9 Hollings DD, 2010, AM J SURG, V199, P558, DOI 10.1016/j.amjsurg.2009.11.006 Imperatori A, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-4 Ivanovic J, 2014, INTERACT CARDIOV TH, V18, P340, DOI 10.1093/icvts/ivt520 Lee Chang Young, 2011, Korean J Thorac Cardiovasc Surg, V44, P44, DOI 10.5090/kjtcs.2011.44.1.44 MASSIE E, 1945, Proc Am Fed Clin Res, V2, P6 Nojiri T, 2015, SURG TODAY, V45, P740, DOI 10.1007/s00595-014-1032-z Nojiri T, 2014, SURG TODAY, V44, P285, DOI 10.1007/s00595-012-0481-5 Nojiri T, 2012, J THORAC CARDIOV SUR, V143, P488, DOI 10.1016/j.jtcvs.2011.09.003 Nojiri T, 2010, J THORAC CARDIOV SUR, V140, P764, DOI 10.1016/j.jtcvs.2009.11.073 Nojiri T, 2010, EUR J CARDIO-THORAC, V37, P787, DOI 10.1016/j.ejcts.2009.09.043 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Park BJ, 2007, J THORAC CARDIOV SUR, V133, P775, DOI 10.1016/j.jtcvs.2006.09.022 Passman RS, 2005, ANN THORAC SURG, V79, P1698, DOI 10.1016/j.athoracsur.2004.10.058 Paul S, 2010, J THORAC CARDIOV SUR, V139, P366, DOI 10.1016/j.jtcvs.2009.08.026 Polanczyk CA, 1998, ANN INTERN MED, V129, P279, DOI 10.7326/0003-4819-129-4-199808150-00003 Raman T, 2012, J THORAC CARDIOV SUR, V143, P482, DOI 10.1016/j.jtcvs.2011.08.025 Rena O, 2001, EUR J CARDIO-THORAC, V20, P688, DOI 10.1016/S1010-7940(01)00890-9 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Sekine Y, 2001, CHEST, V120, P1783, DOI 10.1378/chest.120.6.1783 Tsang TSM, 2002, J AM COLL CARDIOL, V40, P1636, DOI 10.1016/S0735-1097(02)02373-2 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Villamizar NR, 2009, J THORAC CARDIOV SUR, V138, P419, DOI 10.1016/j.jtcvs.2009.04.026 VONKNORRING J, 1992, ANN THORAC SURG, V53, P642, DOI 10.1016/0003-4975(92)90325-X Xin YZ, 2014, EUR J CARDIO-THORAC, V45, P247, DOI 10.1093/ejcts/ezt383 NR 38 TC 38 Z9 44 U1 0 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0941-1291 EI 1436-2813 J9 SURG TODAY JI Surg. Today PD AUG PY 2016 VL 46 IS 8 BP 877 EP 886 DI 10.1007/s00595-015-1258-4 PG 10 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA DQ4PT UT WOS:000379186500001 PM 26471506 DA 2026-04-17 ER PT J AU Ng, EP Velez-Cubian, FO Rodriguez, KL Thau, MR Moodie, CC Garrett, JR Fontaine, JP Toloza, EM AF Ng, Emily P. Velez-Cubian, Frank O. Rodriguez, Kathryn L. Thau, Matthew R. Moodie, Carla C. Garrett, Joseph R. Fontaine, Jacques P. Toloza, Eric M. TI Surgical outcomes associated with postoperative atrial fibrillation after robotic-assisted pulmonary lobectomy: retrospective review of 208 consecutive cases SO JOURNAL OF THORACIC DISEASE LA English DT Review DE Outcomes; atrial fibrillation; robotic; lobectomy; lung cancer ID LUNG-CANCER; THORACIC-SURGERY; RISK-FACTORS; EXPERIENCE AB Background: In this study, we sought to investigate the effect of post-operative atrial fibrillation (POAF) after robotic-assisted video-thoracoscopic pulmonary lobectomy on comorbid postoperative complications, chest tube duration, and hospital length of stay (LOS). Methods: We retrospectively analyzed prospectively collected data from 208 consecutive patients who underwent robotic-assisted pulmonary lobectomy by one surgeon for known or suspected lung cancer. Postoperatively, 39 (18.8%) of these patients experienced POAF during their hospital stay. The occurrence of postoperative complications other than POAF, chest tube duration, and hospital LOS were analyzed in patients with POAF and without POAF. Statistical significance (P <= 0.05) was determined by unpaired Student's t-test or by Chi-square test. Results: Of patients with POAF, 46% also had other concurrent postoperative complications, while only 31% of patients without POAF experienced complications. The average number of postoperative complications experienced by patients with POAF was significantly higher than that experienced by those without POAF (0.9 vs. 0.4, P<0.05). Median chest tube duration in POAF patients (6 days) was significantly higher than in patients without POAF (4 days). A similar result was also seen with hospital LOS, with the median hospital LOS of 8 days in POAF patients being significantly longer than in those without POAF, whose median hospital LOS was 4 days. No other significant difference was detected between the two groups of patients. Conclusions: This study demonstrated the association between the incidence of POAF and a more complicated hospital course. Further studies are needed to determine whether confounders were involved in this association. C1 [Ng, Emily P.; Rodriguez, Kathryn L.; Thau, Matthew R.] Univ S Florida, Morsani Coll Med, Tampa, FL USA. [Velez-Cubian, Frank O.; Fontaine, Jacques P.; Toloza, Eric M.] Univ S Florida, Morsani Coll Med, Dept Surg, Tampa, FL USA. [Moodie, Carla C.; Garrett, Joseph R.; Fontaine, Jacques P.; Toloza, Eric M.] H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, Tampa, FL USA. [Fontaine, Jacques P.; Toloza, Eric M.] Univ S Florida, Morsani Coll Med, Dept Oncol Sci, Tampa, FL USA. C3 State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida RP Toloza, EM (corresponding author), 12902 USF Magnolia Dr,Suite FOB 1, Tampa, FL 33612 USA. EM eric.toloza@moffitt.org FU Scholarly Concentrations Program at the University of South Florida (USF) Health Morsani College of Medicine; Scholarly Excellence, Leadership Experiences, and Collaborative Training (SELECT) Program of the USF Health Morsani College of Medicine; Lehigh Valley Health Network FX This research was supported by a 2013 Summer Scholarly Award to KL Rodriguez and a 2014 Summer Scholarly Award to EP Ng from the Scholarly Concentrations Program at the University of South Florida (USF) Health Morsani College of Medicine and by financial support to MR Thau from the Scholarly Excellence, Leadership Experiences, and Collaborative Training (SELECT) Program of the USF Health Morsani College of Medicine and the Lehigh Valley Health Network. CR Amar D, 1996, CHEST, V110, P437, DOI 10.1378/chest.110.2.437 Augustin F, 2011, SURG ENDOSC, V25, P108, DOI 10.1007/s00464-010-1138-3 Bhave PD, 2012, AM HEART J, V164, P918, DOI 10.1016/j.ahj.2012.09.004 Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Falcoz PE, 2016, EUR J CARDIO-THORAC, V49, P602, DOI 10.1093/ejcts/ezv154 Gharagozloo F, 2008, ANN THORAC SURG, V85, P1880, DOI 10.1016/j.athoracsur.2008.02.085 Gharagozloo F, 2009, ANN THORAC SURG, V88, P380, DOI 10.1016/j.athoracsur.2009.04.039 Imperatori A, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-4 Ivanovic J, 2014, INTERACT CARDIOV TH, V18, P340, DOI 10.1093/icvts/ivt520 Iwata T, 2016, SURG TODAY, V46, P877, DOI 10.1007/s00595-015-1258-4 Jang HJ, 2011, INNOVATIONS, V6, P305, DOI 10.1097/IMI.0b013e3182378b4c Jett G Kimble, 2012, Proc (Bayl Univ Med Cent), V25, P324 Meyer M, 2012, INT J MED ROBOT COMP, V8, P448, DOI 10.1002/rcs.1455 Nakamura H, 2014, ANN THORAC CARDIOVAS, V20, P93, DOI 10.5761/atcs.ra.13-00314 Papiashvilli M, 2012, INNOVATIONS, V7, P15, DOI 10.1097/IMI.0b013e3182566221 Park BJ, 2007, J THORAC CARDIOV SUR, V133, P775, DOI 10.1016/j.jtcvs.2006.09.022 Paul S, 2014, CHEST, V146, P1505, DOI 10.1378/chest.13-3032 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Takagi H, 2012, SURG ENDOSC, V26, P3697, DOI 10.1007/s00464-012-2292-6 Toker A, 2014, J THORAC DIS, V6, pS211, DOI 10.3978/j.issn.2072-1439.2014.05.05 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Velez-Cubian FO, 2015, CANCER CONTROL, V22, P314, DOI 10.1177/107327481502200309 Villamizar NR, 2009, J THORAC CARDIOV SUR, V138, P419, DOI 10.1016/j.jtcvs.2009.04.026 NR 23 TC 7 Z9 7 U1 0 U2 1 PU AME PUBLISHING COMPANY PI SHATIN PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA SN 2072-1439 EI 2077-6624 J9 J THORAC DIS JI J. Thorac. Dis. PD AUG PY 2016 VL 8 IS 8 BP 2079 EP 2085 DI 10.21037/jtd.2016.07.68 PG 7 WC Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System GA DY3VO UT WOS:000385023800093 PM 27621862 OA hybrid DA 2026-04-17 ER PT J AU Pagel, PS Sethi, P Boettcher, BT Dolinski, SY AF Pagel, Paul S. Sethi, Pawan Boettcher, Brent T. Dolinski, Sylvia Y. TI A Pulmonary Venous Blood Flow Problem During Left Upper Lobectomy SO JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA LA English DT Article DE thoracic surgery; pulmonary venous drainage; anatomic variants; pulmonary vein stenosis; pulse-wave Doppler echocardiography; lobectomy; squamous cell lung cancer ID STENOSIS COMPLICATING ABLATION; VEIN OSTIAL DIAMETER; ATRIAL-FIBRILLATION; RADIOFREQUENCY ABLATION; CATHETER ABLATION; 1ST BIFURCATION; MANAGEMENT; DISTANCE; DRAINAGE; ECHOCARDIOGRAPHY C1 [Pagel, Paul S.; Sethi, Pawan; Boettcher, Brent T.; Dolinski, Sylvia Y.] Clement J Zablocki Vet Affairs Med Ctr, Anesthesia Serv, 5000 W Natl Ave, Milwaukee, WI 53295 USA. RP Pagel, PS (corresponding author), Clement J Zablocki Vet Affairs Med Ctr, Anesthesia Serv, 5000 W Natl Ave, Milwaukee, WI 53295 USA. EM pspagel@mcw.edu CR Cronin P, 2007, ACAD RADIOL, V14, P437, DOI 10.1016/j.acra.2007.01.023 Cronin P, 2007, ACAD RADIOL, V14, P178, DOI 10.1016/j.acra.2006.11.004 Cronin P, 2009, EUR J RADIOL, V71, P61, DOI 10.1016/j.ejrad.2008.04.008 Devaney EJ, 2006, ANN THORAC SURG, V81, P992, DOI 10.1016/j.athoracsur.2005.08.020 Dong J, 2005, J CARDIOVASC ELECTR, V16, P845, DOI 10.1111/j.1540-8167.2005.40680.x Ha JW, 1998, J AM SOC ECHOCARDIOG, V11, P393, DOI 10.1016/S0894-7317(98)70109-9 Hickey Edward J, 2011, Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu, V14, P101, DOI 10.1053/j.pcsu.2011.01.007 Jander N, 2005, J AM SOC ECHOCARDIOG, V18, P654, DOI 10.1016/j.echo.2004.10.002 Lo Rito M, J THORAC CA IN PRESS Packer DL, 2005, CIRCULATION, V111, P546, DOI 10.1161/01.CIR.0000154541.58478.36 Pürerfellner H, 2005, CURR OPIN CARDIOL, V20, P484 Pürerfellner H, 2004, AM J CARDIOL, V93, P1428, DOI 10.1016/S0002-9149(04)00297-8 Qureshi AM, 2003, CIRCULATION, V108, P1336, DOI 10.1161/01.CIR.0000086322.21781.6A Rostamian A, 2014, J INTERV CARD ELECTR, V40, P63, DOI 10.1007/s10840-014-9885-z Saad EB, 2003, ANN INTERN MED, V138, P634, DOI 10.7326/0003-4819-138-8-200304150-00010 Saad EB, 2003, CIRCULATION, V108, P3102, DOI 10.1161/01.CIR.0000104569.96907.7F SMALLHORN JF, 1985, AM HEART J, V110, P483, DOI 10.1016/0002-8703(85)90174-7 SNELLEN HA, 1968, CIRCULATION, V38, P45, DOI 10.1161/01.CIR.38.1.45 Spray Thomas L., 1999, Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu, V2, P177 Yun TJ, 2005, J THORAC CARDIOV SUR, V129, P167, DOI 10.1016/j.jtcvs.2004.08.043 NR 20 TC 0 Z9 0 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1053-0770 EI 1532-8422 J9 J CARDIOTHOR VASC AN JI J. Cardiothorac. Vasc. Anesth. PD AUG PY 2016 VL 30 IS 4 BP 1156 EP 1158 DI 10.1053/j.jvca.2016.01.032 PG 3 WC Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease WE Science Citation Index Expanded (SCI-EXPANDED) SC Anesthesiology; Cardiovascular System & Cardiology; Respiratory System GA DT6JI UT WOS:000381590100048 PM 27521974 DA 2026-04-17 ER PT J AU Peluso, D Bianchi, A Bonanno, L Banzato, A AF Peluso, Diletta Bianchi, Alessandra Bonanno, Laura Banzato, Alberto TI Unusual Echocardiographic Appearance of a Cardiac Metastasis From Lung Carcinoma SO JOURNAL OF CLINICAL ULTRASOUND LA English DT Article DE cardiac metastasis; contrast echocardiography; cardiac mass ID MASSES AB During hospitalization in the Oncology Department, a woman with nonsmall cell lung cancer and no previous cardiac event complained of episodes of chest pain and palpitations. Preliminary instrumental examinations diagnosed atrial fibrillation in pericarditis. A subsequent complete transthoracic echocardiogram showed the presence of a large mass involving the left ventricular apex, without echo-contrast enhancement. A thoracic CT with iodized contrast agent revealed its necrotic composition and was concluded as cardiac metastasis. This is an unusual case of a malignant neoplasm showing no contrast enhancement at echocardiogram because of its necrotic composition, mimicking a thrombus. (C) 2015 Wiley Periodicals, Inc. C1 [Peluso, Diletta] Univ Padua, Dept Cardiac Thorac & Vasc Sci, Padua, Italy. [Bianchi, Alessandra; Banzato, Alberto] Veneto Inst Oncol IOV IRCCS, Dept Cardiol, Padua, Italy. [Bonanno, Laura] Veneto Inst Oncol IOV IRCCS, Dept Med Oncol 2, Padua, Italy. C3 University of Padua; IRCCS Istituto Oncologico Veneto (IOV); IRCCS Istituto Oncologico Veneto (IOV) RP Peluso, D (corresponding author), Univ Padua, Dept Cardiac Thorac & Vasc Sci, Padua, Italy. RI Bianchi, Alessandra/IZP-8331-2023; Banzato, Alberto/AAF-2622-2021; Bonanno, Laura/L-2707-2016 OI Bianchi, Alessandra/0000-0003-1566-6000; Banzato, Alberto/0000-0001-5315-5135; Bonanno, Laura/0000-0001-5218-4970 CR Kassop D, 2014, CURR CARDIOVASC IMAG, V7, DOI 10.1007/s12410-014-9281-1 Tang QY, 2015, ULTRASOUND MED BIOL, V41, P2382, DOI 10.1016/j.ultrasmedbio.2015.05.010 Uenishi EK, 2015, CARDIOVASC ULTRASOUN, V13, DOI 10.1186/s12947-015-0018-3 NR 3 TC 2 Z9 2 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0091-2751 EI 1097-0096 J9 J CLIN ULTRASOUND JI J. Clin. Ultrasound PD JUL-AUG PY 2016 VL 44 IS 6 BP 392 EP 394 DI 10.1002/jcu.22325 PG 3 WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging WE Science Citation Index Expanded (SCI-EXPANDED) SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging GA DV3GL UT WOS:000382808900010 PM 26678345 DA 2026-04-17 ER PT J AU Fintelmann, FJ Tuncali, K Puchner, S Gervais, DA Thabet, A Shyn, PB Arellano, RS Tatli, S Mueller, PR Silverman, SG Uppot, RN AF Fintelmann, Florian J. Tuncali, Kemal Puchner, Stefan Gervais, Debra A. Thabet, Ashraf Shyn, Paul B. Arellano, Ronald S. Tatli, Servet Mueller, Peter R. Silverman, Stuart G. Uppot, Raul N. TI Catecholamine Surge during Image-Guided Ablation of Adrenal Gland Metastases: Predictors, Consequences, and Recommendations for Management SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Article ID PERCUTANEOUS RADIOFREQUENCY ABLATION; HYPERTENSIVE CRISIS; SINGLE-INSTITUTION; CRYOABLATION; NEOPLASMS; PATIENT; TUMOR AB Purpose: To identify retrospectively predictors of catecholamine surge during image-guided ablation of metastases to the adrenal gland. Materials and Methods: Between 2001 and 2014, 57 patients (39 men, 18 women; mean age, 65 y +/- 10; age range, 41-81 y) at two academic medical centers underwent ablation of 64 metastatic adrenal tumors from renal cell carcinoma (n = 27), lung cancer (n = 23), melanoma (n = 4), colorectal cancer (n = 3), and other tumors (n = 7). Tumors measured 0.7-11.3 cm (mean, 4 cm +/- 2.5). Modalities included cryoablation (n = 38), radiofrequency (RF) ablation (n = 20), RF ablation with injection of dehydrated ethanol (n = 10), and microwave ablation (n = 4). Fisher exact test, univariate, and multivariate logistical regression analysis was used to evaluate factors predicting hypertensive crisis (HC). Results: HC occurred in 31 sessions (43%). Ventricular tachycardia (n = 1), atrial fibrillation (n = 2), and troponin leak (n = 4) developed during HC episodes. HC was significantly associated with maximum tumor diameter <= 4.5 cm (odds ratio [OR], 26.36; 95% confidence interval [CI], 5.26-131.99; P < .0001) and visualization of nolinal adrenal tissue on CT or MR imaging before the procedure (OR, 8.38; 95% CI, 2.67-25.33; P < .0001). No HC occurred during ablation of metastases in previously irradiated or ablated adrenal glands. Conclusions: Patients at high risk of catecholamine surge during ablation of non hormonally active adrenal metastases can be identified by the presence of normal adrenal tissue and tumor diameter <= 4.5 cm on pre-procedure CT or MR imaging. C1 [Fintelmann, Florian J.; Puchner, Stefan; Gervais, Debra A.; Thabet, Ashraf; Arellano, Ronald S.; Mueller, Peter R.; Uppot, Raul N.] Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St,FND 202, Boston, MA 02111 USA. [Tuncali, Kemal; Shyn, Paul B.; Tatli, Servet; Silverman, Stuart G.] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA. C3 Harvard University; Harvard University Medical Affiliates; Massachusetts General Hospital; Harvard University; Harvard University Medical Affiliates; Brigham & Women's Hospital RP Fintelmann, FJ (corresponding author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St,FND 202, Boston, MA 02111 USA. EM ffintelmann@partners.org RI Uppot, Raul/AAF-1859-2019; Shyn, Paul/KBD-3747-2024 FU Harvard Catalyst program FX We thank Dr. Johann Blauth and Dr. Hang Lee for guidance with the statistical analysis. Dr. Lee is funded through the Harvard Catalyst program. CR Atwell TD, 2006, J VASC INTERV RADIOL, V17, P573, DOI 10.1097/01.RVI.0000197370.83569.33 Boland GWL, 2011, RADIOLOGY, V259, P117, DOI 10.1148/radiol.11100569 Carrafiello G, 2008, CARDIOVASC INTER RAD, V31, P762, DOI 10.1007/s00270-008-9337-1 Chini EN, 2004, ANESTH ANALG, V99, P1867, DOI 10.1213/01.ANE.0000136803.54212.E1 Efremidis SC, 1996, ABDOM IMAGING, V21, P168, DOI 10.1007/s002619900037 Ethier MD, 2013, TECH VASC INTERV RAD, V16, P262, DOI 10.1053/j.tvir.2013.08.008 Keeling AN, 2009, J VASC INTERV RADIOL, V20, P990, DOI 10.1016/j.jvir.2009.03.039 Lo WK, 2006, J VASC INTERV RADIOL, V17, P175, DOI 10.1097/01.RVI.0000188748.51764.CE Mayo-Smith WW, 2004, RADIOLOGY, V231, P225, DOI 10.1148/radiol.2311031007 Onik G, 2003, AM J ROENTGENOL, V181, P495, DOI 10.2214/ajr.181.2.1810495 Pacak K, 2007, J CLIN ENDOCR METAB, V92, P4069, DOI 10.1210/jc.2007-1720 PERLMAN RL, 1977, CLIN ENDOCRINOL META, V6, P551, DOI 10.1016/S0300-595X(77)80071-6 Ryan ER, 2013, RADIOLOGY, V268, P288, DOI 10.1148/radiol.13121462 Sudheendra D, 2006, J VASC INTERV RADIOL, V17, P1367, DOI 10.1097/01.RVI.0000234616.35625.6A U.S. Department of health and human services, 2010, Common terminology criteria for adverse events v4.03 Uppot RN, 2013, AM J ROENTGENOL, V200, P1226, DOI 10.2214/AJR.12.10328 Welch BT, 2014, J VASC INTERV RADIOL, V25, P593, DOI 10.1016/j.jvir.2013.12.013 Welch BT, 2011, RADIOLOGY, V258, P301, DOI 10.1148/radiol.10100631 Wolf FJ, 2012, EUR J RADIOL, V81, P1717, DOI 10.1016/j.ejrad.2011.04.054 Yamakado K, 2012, CARDIOVASC INTER RAD, V35, P1422, DOI 10.1007/s00270-012-0348-6 Yamakado K, 2011, CARDIOVASC INTER RAD, V34, P839, DOI 10.1007/s00270-010-0078-6 NR 21 TC 34 Z9 44 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1051-0443 EI 1535-7732 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD MAR PY 2016 VL 27 IS 3 BP 395 EP 402 DI 10.1016/j.jvir.2015.11.034 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease WE Science Citation Index Expanded (SCI-EXPANDED) SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA DH5TU UT WOS:000372855700014 PM 26724964 DA 2026-04-17 ER PT J AU Falcoz, PE Puyraveau, M Thomas, PA Decaluwe, H Hürtgen, M Petersen, RH Hansen, H Brunelli, A AF Falcoz, Pierre-Emmanuel Puyraveau, Marc Thomas, Pascal-Alexandre Decaluwe, Herbert Huertgen, Martin Petersen, Rene Horsleben Hansen, Henrik Brunelli, Alessandro CA ESTS Database Comm ESTS Minimally Invasive Interest G TI Video-assisted thoracoscopic surgery versus open lobectomy for primary non-small-cell lung cancer: a propensity-matched analysis of outcome from the European Society of Thoracic Surgeon databaseaEuro SO EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY LA English DT Article; Proceedings Paper CT 22nd European Conference on General Thoracic Surgery CY JUN 15-18, 2014 CL Copenhagen, DENMARK DE Lung cancer; Video-assisted thoracoscopic surgery; Lobectomy; Database ID STAGE-I; OCTOGENARIANS; THORACOTOMY; MORBIDITY; MORTALITY; VOLUME AB Video-assisted thoracoscopic anatomical resections are increasingly used in Europe to manage primary lung cancer. The purpose of this study was to compare the outcome following thoracoscopic versus open lobectomy in case-matched groups of patients from the European Society of Thoracic Surgeon (ESTS) database. All patients having lobectomy as the primary procedure via thoracoscopy [video-assisted thoracoscopic surgery (VATS)-L)] or thoracotomy (TH-L) were identified in the ESTS database (January 2007 to December 2013). A propensity score was constructed using several patients' baseline characteristics. The matching using the propensity score was responsible for the minimization of selection bias. A propensity score-matched analysis was performed to compare the incidence of postoperative major complications (according to the ESTS database definitions) and mortality at hospital discharge between the matched groups. After exclusions, 28 771 patients were identified: 26 050 having thoracotomy and 2721 having thoracoscopy. Propensity score yielded two well-matched groups of 2721 patients. Numeric variables were compared by Student's t-tests and categorical variables were compared by McNemar's tests. Compared with TH-L, VATS-L was associated with a lower incidence of total complications [n = 792 (29.1%) vs 863 (31.7%), P = 0.0357], major cardiopulmonary complications [n = 316 (15.9%) vs 435 (19.6%), P = 0.0094], atelectasis requiring bronchoscopy [n = 65 (2.4%) vs 150 (5.5%), P < 0.0001], initial ventilation > 48 h [n = 18 (0.7%) vs 38 (1.4%), P = 0.0075] and wound infection [n = 6 (0.2%) vs 17 (0.6%), P = 0.0218]. There was no difference in the incidence of postoperative atrial fibrillation between the two groups (P = 0.14). Postoperative hospital stay was 2 days shorter in the VATS-L patients (mean: 7.8 vs 9.8 days; P = 0.0003). In terms of outcome at hospital discharge, there were 27 deaths in the VATS-L group (1%) versus 50 in the TH-L group (1.9%, P = 0.0201). Data from the ESTS database confirmed that lobectomy performed through VATS is associated with a lower incidence of complications compared with thoracotomy. C1 [Falcoz, Pierre-Emmanuel] Strasbourg Univ Hosp, Dept Thorac Surg, Strasbourg, France. [Puyraveau, Marc] Besancon Univ Hosp, Clin Methodol Ctr, Besancon, France. [Thomas, Pascal-Alexandre] Marseille Univ Hosp, Dept Thorac Surg, Marseille, France. [Decaluwe, Herbert] Univ Hosp Leuven, Dept Thorac Surg, Leuven, Belgium. [Huertgen, Martin] Univ Teaching Hosp, Dept Thorac Surg, Koblenz, Germany. [Petersen, Rene Horsleben; Hansen, Henrik] Copenhagen Univ Hosp, Rigshosp, Dept Cardiothorac Surg, Copenhagen, Denmark. [Brunelli, Alessandro] St James Univ Hosp, Dept Thorac Surg, Leeds, W Yorkshire, England. C3 CHU Strasbourg; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universite Marie et Louis Pasteur; CHU Besancon; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; KU Leuven; University Hospital Leuven; Rigshospitalet; University of Copenhagen; Copenhagen University Hospital; Saint James's University Hospital RP Falcoz, PE (corresponding author), Strasbourg Univ Hosp, Dept Thorac Surg, Strasbourg, France.; Falcoz, PE (corresponding author), Hop Univ Strasbourg, Nouvel Hop Civil, Dept Thorac Surg, 1 Pl Hop,BP 426, F-67091 Strasbourg, France. EM pierre-emmanuel.falcoz@wanadoo.fr RI Thomas, Pascal/L-3355-2019; Petersen, René Horsleben/KRP-4356-2024; Brunelli, Alessandro/AAV-1415-2020; Falcoz, Pierre-Emmanuel/N-1239-2016; Decaluwe, Herbert/A-2436-2009 OI Thomas, Pascal/0000-0002-3305-6989; Petersen, René Horsleben/0000-0002-3586-1869; Brunelli, Alessandro/0000-0002-6505-1656; Falcoz, Pierre-Emmanuel/0000-0002-5915-5512; Decaluwe, Herbert/0000-0002-0877-7717 CR Austin PC, 2006, STAT MED, V25, P2084, DOI 10.1002/sim.2328 Berry MF, 2014, ANN THORAC SURG, V98, P197, DOI 10.1016/j.athoracsur.2014.03.018 Brunelli A, 2010, Eur J Surg Oncol, V36 Suppl 1, pS93, DOI 10.1016/j.ejso.2010.06.023 Brunelli A, 2014, J THORAC DIS, V6, pS284, DOI 10.3978/j.issn.2072-1439.2014.04.18 Brunelli Alessandro, 2007, Thorac Surg Clin, V17, P387, DOI 10.1016/j.thorsurg.2007.07.011 Burt BM, 2014, J THORAC CARDIOV SUR, V148, P19, DOI 10.1016/j.jtcvs.2014.03.007 Cao C, 2013, INTERACT CARDIOV TH, V16, P244, DOI 10.1093/icvts/ivs472 Falcoz PE, 2014, J THORAC DIS, V6, pS272, DOI 10.3978/j.issn.2072-1439.2014.04.20 Falcoz PE, 2014, J THORAC CARDIOV SUR, V148, P841, DOI 10.1016/j.jtcvs.2014.01.030 Farjah F, 2014, ANN THORAC SURG, V98, P191, DOI 10.1016/j.athoracsur.2014.03.024 Fernandez FG, 2015, ANN THORAC SURG, V99, P368, DOI 10.1016/j.athoracsur.2014.05.104 Howington JA, 2013, CHEST, V143, pE278, DOI 10.1378/chest.12-2359 Mun M, 2008, ANN THORAC SURG, V85, P406, DOI 10.1016/j.athoracsur.2007.10.057 Parson L., 2008, P 26 ANN SAS USERS G Paul S, 2010, J THORAC CARDIOV SUR, V139, P366, DOI 10.1016/j.jtcvs.2009.08.026 Port JL, 2011, ANN THORAC SURG, V92, P1951, DOI 10.1016/j.athoracsur.2011.06.082 Swanson SJ, 2012, ANN THORAC SURG, V93, P1027, DOI 10.1016/j.athoracsur.2011.06.007 Thomas PA, 2014, EUR J CARDIO-THORAC, V45, P652, DOI 10.1093/ejcts/ezt452 Whitson BA, 2008, ANN THORAC SURG, V86, P2008, DOI 10.1016/j.athoracsur.2008.07.009 Yan TD, 2014, EUR J CARDIO-THORAC, V45, P633, DOI 10.1093/ejcts/ezt463 NR 20 TC 348 Z9 385 U1 1 U2 32 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1010-7940 EI 1873-734X J9 EUR J CARDIO-THORAC JI Eur. J. Cardio-Thorac. Surg. PD FEB PY 2016 VL 49 IS 2 BP 602 EP 609 DI 10.1093/ejcts/ezv154 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA DG1IF UT WOS:000371819300045 PM 25913824 OA Bronze DA 2026-04-17 ER PT J AU Haverkamp, W Hachenberg, T AF Haverkamp, Wilhelm Hachenberg, Thomas TI Post-thoracotomy dysrhythmia SO CURRENT OPINION IN ANESTHESIOLOGY LA English DT Review DE antiarrhythmic drugs; atrial fibrillation; noncardiac thoracic surgery; perioperative arrhythmias; post-thoracotomy arrhythmia ID POSTOPERATIVE ATRIAL-FIBRILLATION; NONCARDIAC THORACIC-SURGERY; PULMONARY RESECTION; LUNG-CANCER; PROPHYLAXIS; ARRHYTHMIAS; MANAGEMENT; AMIODARONE; GUIDELINES; SOCIETY AB Purpose of reviewThis article reviews and summarizes the pathophysiology, risk factors, and the management of arrhythmias in patients undergoing noncardiac thoracic surgery.Recent findingsCardiac arrhythmias are common findings in the perioperative period, particularly with increasing age. They often complicate the course of the patient's recovery after operation. The most common postoperative arrhythmia is atrial fibrillation. It requires either a rate or rhythm control strategy, and the need for anticoagulation has to be assessed depending on the duration of the arrhythmia and risk factors. Fortunately, malign sustained ventricular tachyarrhythmias (ventricular tachycardia, ventricular fibrillation) are rare. Acute treatment and, in the absence of a reversible cause, a long-term preventive strategy may be warranted. Transient bradyarrhythmias can be managed by atropine or with temporary pacing.SummaryArrhythmias are common after thoracotomy. Physicians treating patients with postoperative arrhythmias should bear in mind that arrhythmia management does not only comprise a specific therapy for the arrhythmia itself, but also includes the correction of transient and correctable predisposing and causative factors. C1 [Haverkamp, Wilhelm] Charite, Dept Cardiol, Campus Virchow Clin,Augustenburger Pl 1, D-13353 Berlin, Germany. [Hachenberg, Thomas] Univ Magdeburg, Dept Anesthesiol & Intens Care Med, D-39106 Magdeburg, Germany. C3 Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Otto von Guericke University RP Haverkamp, W (corresponding author), Charite, Dept Cardiol, Campus Virchow Clin,Augustenburger Pl 1, D-13353 Berlin, Germany. EM wilhelm.haverkamp@charite.de OI Haverkamp, Wilhelm/0000-0002-6183-2519 CR Breuer G, 2014, CURR OPIN ANESTHESIO, V27, P409, DOI 10.1097/ACO.0000000000000100 Douketis J. D., 2012, CHEST S, V141 Elrakhawy HM, 2014, HEART SURG FORUM, V17, pE308, DOI 10.1532/HSF98.2014412 Fernando HC, 2011, ANN THORAC SURG, V92, P1144, DOI 10.1016/j.athoracsur.2011.06.104 Fleisher LA, 2014, J AM COLL CARDIOL, V64, pE77, DOI 10.1016/j.jacc.2014.07.944 Frendl G, 2014, J THORAC CARDIOV SUR, V148, pE153, DOI 10.1016/j.jtcvs.2014.06.036 GILL J, 1992, DRUGS, V43, P69, DOI 10.2165/00003495-199243010-00007 Heintz KM, 2005, SURG CLIN N AM, V85, P1103, DOI 10.1016/j.suc.2005.09.003 Khalil MA, 2013, J ANESTH, V27, P56, DOI 10.1007/s00540-012-1478-3 Komatsu R, 2015, J ANESTH, V29, P47, DOI 10.1007/s00540-014-1865-z Kowey PR, 2009, CIRC-ARRHYTHMIA ELEC, V2, P652, DOI 10.1161/CIRCEP.109.870204 Kristensen SD, 2014, EUR HEART J, V35, P2383, DOI [10.1093/eurheartj/ehu282, 10.5603/KP.2014.0193] Maesen B, 2012, EUROPACE, V14, P159, DOI 10.1093/europace/eur208 Oka T, 2001, ANESTH ANALG, V93, P253, DOI 10.1097/00000539-200108000-00003 Patel AJ, 2014, INTERACT CARDIOV TH, V19, P111, DOI 10.1093/icvts/ivu082 Peretto G, 2014, CARDIOL RES PRACT, V2014, DOI 10.1155/2014/615987 Riber LP, 2012, ANN THORAC SURG, V94, P339, DOI 10.1016/j.athoracsur.2011.12.096 Riber LP, 2014, ANN THORAC SURG, V98, P1989, DOI 10.1016/j.athoracsur.2014.06.069 Rosen JE, 2014, ANN THORAC SURG, V98, P1953, DOI 10.1016/j.athoracsur.2014.07.007 Sedrakyan A, 2005, J THORAC CARDIOV SUR, V129, P997, DOI 10.1016/j.jtcvs.2004.07.042 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Walsh SR, 2006, BMJ-BRIT MED J, V333, P715, DOI 10.1136/bmj.333.7571.715 NR 22 TC 12 Z9 13 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0952-7907 EI 1473-6500 J9 CURR OPIN ANESTHESIO JI Curr. Opin. Anesthesiol. PD FEB PY 2016 VL 29 IS 1 BP 26 EP 33 DI 10.1097/ACO.0000000000000285 PG 8 WC Anesthesiology WE Science Citation Index Expanded (SCI-EXPANDED) SC Anesthesiology GA DC7TP UT WOS:000369423600005 PM 26658182 DA 2026-04-17 ER PT J AU Kumar, R Lu, SK Minchom, A Sharp, A Davidson, M Gunapala, R Yap, TA Bhosle, J Popat, S O'Brien, MER AF Kumar, Rajiv Lu, Shir Kiong Minchom, Anna Sharp, Adam Davidson, Michael Gunapala, Ranga Yap, Timothy A. Bhosle, Jaishree Popat, Sanjay O'Brien, Mary E. R. TI A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients SO CANCER CHEMOTHERAPY AND PHARMACOLOGY LA English DT Article DE Non-small cell lung cancer; Adenocarcinoma; Capecitabine; Erlotinib; Phase 1 ID CHEMOTHERAPY-NAIVE PATIENTS; RANDOMIZED CONTROLLED-TRIAL; TYROSINE KINASE INHIBITORS; PEMETREXED PLUS CISPLATIN; III TRIAL; DOUBLE-BLIND; DOCETAXEL; METAANALYSIS; GEMCITABINE; INDUCTION AB Erlotinib is active in advanced non-small cell lung cancer (aNSCLC) particularly in patients with EGFR-sensitizing mutations. The thymidylate synthase inhibitors are active in NSCLC, but capecitabine is not well studied. This study explored the safety and activity of this oral combination. This phase Ib trial used a 3 + 3 escalation design with a combination of erlotinib (100 mg daily) with increasing doses of capecitabine (500, 750 and 1000 mg/m(2) BD, 14/21 days), in first- and second-line aNSCLC of adenocarcinoma histology. The DLT was any drug-induced toxicity a parts per thousand yengrade (G)2 causing dose interruption or dose delay during the first 2 cycles. Forty patients were recruited, and 1 patient had an EGFR mutation. Dose escalation stopped at capecitabine 1000 mg/m(2) with expansion to 6 patients due to unpredicted DLTs in 2/6 patients: G2 creatinine rise, G2 anaemia, G3 atrial fibrillation and G3 pneumonia. MTD was capecitabine 750 mg/m(2). First-line dose escalation at the MTD led to unpredicted DLTs in 3/4 patients (G3 troponin rise, G2 rash and G2 hyperbilirubinaemia). MTD expansion in the second-line setting was well tolerated. The most common drug toxicities were gastrointestinal (35 %), followed by skin disorders (28 %). The response rate was 3 % with a disease control rate of 34 %. Median progressive-free survival was 1.6 months (95 % CI 1.4-3.5), and median overall survival was 6.1 months (95 % CI 5.1-10.1). The MTD for the combination of capecitabine and erlotinib is 750 mg/m(2) BD, 14/21 days, and 100 mg daily, respectively, which is lower than predicted. Capecitabine did not improve the efficacy of erlotinib in aNSCLC unselected for EGFR mutation. C1 [Kumar, Rajiv; Lu, Shir Kiong; Davidson, Michael; Gunapala, Ranga; Bhosle, Jaishree; Popat, Sanjay; O'Brien, Mary E. R.] Royal Marsden NHS Fdn Trust, Dept Med, Downs Rd, Sutton, Surrey, England. [Minchom, Anna; Sharp, Adam; Yap, Timothy A.] Inst Canc Res, Downs Rd, Sutton, Surrey, England. [Minchom, Anna; Sharp, Adam; Yap, Timothy A.] Royal Marsden NHS Fdn Trust, Downs Rd, Sutton, Surrey, England. C3 Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust RP O'Brien, MER (corresponding author), Royal Marsden NHS Fdn Trust, Dept Med, Downs Rd, Sutton, Surrey, England. EM Mary.O'Brien@rmh.nhs.uk RI ; Popat, Sanjay/AAO-1634-2021; Kumar, Rajiv/H-6431-2019; Yap, Timothy/AAV-3573-2020 OI Sharp, Adam/0000-0002-3740-1612; Popat, Sanjay/0000-0003-2087-4963; Kumar, Rajiv/0000-0002-9809-3203; Minchom, Anna/0000-0002-9339-7101; FU NIHR Royal Marsden Biomedical Research Centre; National Institute for Health Research [CL-2012-22-001, CL-2014-22-001] Funding Source: researchfish FX We would like to thank all the patients and their families who took part in this clinical trial. We are also very appreciative of the research staff in the Department of Medicine-Lung Cancer Unit, Royal Marsden NHS Foundation Trust. We also acknowledge support from the NIHR Royal Marsden Biomedical Research Centre. CR Aerts JG, 2013, ANN ONCOL, V24, P2860, DOI 10.1093/annonc/mdt341 [Anonymous], IARC CANCERBASE [Anonymous], STATISTICAL METHODS Azzoli CG, 2011, J CLIN ONCOL, V29, P3825, DOI 10.1200/JCO.2010.34.2774 Ciardiello F, 2000, CLIN CANCER RES, V6, P2053 Ciuleanu T, 2009, LANCET, V374, P1432, DOI 10.1016/S0140-6736(09)61497-5 CRUK, 2015, LUNG CANC CANC STAT Garassino MC, 2013, LANCET ONCOL, V14, P981, DOI 10.1016/S1470-2045(13)70310-3 Gatzemeier U, 2007, J CLIN ONCOL, V25, P1545, DOI 10.1200/JCO.2005.05.1474 Giatromanolaki A, 1997, J PATHOL, V181, P196 Hamada C, 2005, J CLIN ONCOL, V23, P4999, DOI 10.1200/JCO.2005.09.017 Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714 Herbst RS, 2005, J CLIN ONCOL, V23, P5892, DOI 10.1200/JCO.2005.02.840 Hughes AN, 2009, J CLIN ONCOL, V27, P1220, DOI 10.1200/JCO.2008.19.3995 Kawaguchi T, 2014, J CLIN ONCOL, V32, P1902, DOI 10.1200/JCO.2013.52.4694 Kim ES, 2008, LANCET, V372, P1809, DOI 10.1016/S0140-6736(08)61758-4 Kindwall-Keller T, 2005, CLIN CANCER RES, V11, P1870, DOI 10.1158/1078-0432.CCR-04-1727 Kubota K, 2015, ANN ONCOL, V26, P1401, DOI 10.1093/annonc/mdv190 Kulke MH, 2007, J CLIN ONCOL, V25, P4787, DOI 10.1200/JCO.2007.11.8521 Lara PN, 2009, J CLIN ONCOL, V27, P2530, DOI 10.1200/JCO.2008.20.1061 Lee CK, 2013, JNCI-J NATL CANCER I, V105, P595, DOI 10.1093/jnci/djt072 Malet-Martino M, 2002, ONCOLOGIST, V7, P288, DOI 10.1634/theoncologist.7-4-288 Myerson JS, 2010, CLIN LUNG CANCER, V11, pE5, DOI 10.3816/CLC.2010.n.047 Okamoto I, 2010, J CLIN ONCOL, V28, P5240, DOI 10.1200/JCO.2010.31.0326 Paz-Ares L, 2012, LANCET ONCOL, V13, P247, DOI 10.1016/S1470-2045(12)70063-3 Paz-Ares LG, 2013, J CLIN ONCOL, V31, P2895, DOI 10.1200/JCO.2012.47.1102 Petrelli F, 2012, CLIN LUNG CANCER, V13, P107, DOI 10.1016/j.cllc.2011.08.005 Reck M, 2014, ANN ONCOL, V25, P27, DOI 10.1093/annonc/mdu199 Rosell R, 2009, NEW ENGL J MED, V361, P958, DOI 10.1056/NEJMoa0904554 Scagliotti GV, 2008, J CLIN ONCOL, V26, P3543, DOI 10.1200/JCO.2007.15.0375 Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753 Wu YL, 2013, LANCET ONCOL, V14, P777, DOI 10.1016/S1470-2045(13)70254-7 Zhao HY, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000249 Zhou C, 2012, J CLIN ONCOL, V30, P7520 Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470-2045(11)70184-X Zhuo ML, 2014, MOL CLIN ONCOL, V2, P953, DOI 10.3892/mco.2014.359 NR 36 TC 10 Z9 10 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0344-5704 EI 1432-0843 J9 CANCER CHEMOTH PHARM JI Cancer Chemother. Pharmacol. PD FEB PY 2016 VL 77 IS 2 BP 375 EP 383 DI 10.1007/s00280-015-2950-1 PG 9 WC Oncology; Pharmacology & Pharmacy WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Pharmacology & Pharmacy GA DD8DO UT WOS:000370155300017 PM 26706729 DA 2026-04-17 ER PT J AU Refai, M Salati, M Tiberi, M Sabbatini, A Gentili, P AF Refai, Majed Salati, Michele Tiberi, Michela Sabbatini, Armando Gentili, Paolo TI Clinical pathway for thoracic surgery in an Italian centre SO JOURNAL OF THORACIC DISEASE LA English DT Review DE Clinical care pathways; postoperative care; quality of care; Uniportal VATS program ID PULMONARY LOBECTOMY; THORACOSCOPIC LOBECTOMY; ATRIAL-FIBRILLATION; PRACTICE GUIDELINES; LUNG-CANCER; MANAGEMENT; PATIENT; REDUCE AB Clinical care pathways are developed to standardize postoperative patient care and the main impetus is to improve quality of care, decrease variation in care and reduce costs. We report the clinical pathway of care adopted at our centre since the introduction of Uniportal VATS program for major lung resections. C1 [Refai, Majed; Salati, Michele; Tiberi, Michela; Sabbatini, Armando] Osped Riuniti Ancona, Div Thorac Surg, Via Conca 1, I-600122 Ancona, Italy. [Refai, Majed] Osped Riuniti Ancona, Div Thorac Surg, Sect Minimally Invas Thorac Surg, I-600122 Ancona, Italy. [Gentili, Paolo] Osped Riuniti Ancona, Anesthesia & Intens Care Unit, I-600122 Ancona, Italy. RP Refai, M (corresponding author), Osped Riuniti Ancona, Div Thorac Surg, Via Conca 1, I-600122 Ancona, Italy. EM majedit@yahoo.com CR [Anonymous], 2005, AM J RESP CRIT CARE, V171, P88 Brunelli A, 2009, EUR RESPIR J, V34, P17, DOI 10.1183/09031936.00184308 Brunelli A, 2013, CHEST, V143, pE166, DOI 10.1378/chest.12-2395 Brunelli A, 2013, EUR J CARDIO-THORAC, V43, P899, DOI 10.1093/ejcts/ezs518 Brunelli Alessandro, 2007, Thorac Surg Clin, V17, P387, DOI 10.1016/j.thorsurg.2007.07.011 Cerfolio RJ., 2001, J THORAC CARDIOV SUR, V122, P318 Every NR, 2000, CIRCULATION, V101, P461, DOI 10.1161/01.CIR.101.4.461 Fernando HC, 2011, ANN THORAC SURG, V92, P1144, DOI 10.1016/j.athoracsur.2011.06.104 Gonzalez-Rivas D, 2013, ANN THORAC SURG, V95, P426, DOI 10.1016/j.athoracsur.2012.10.070 HART R, 1992, HOSPITALS, V66, P56 Korst RJ, 1997, CHEST, V111, P1285, DOI 10.1378/chest.111.5.1285 McCool FD, 2006, CHEST, V129, p250S, DOI 10.1378/chest.129.1_suppl.250S Okur E, 2009, EUR J CARDIO-THORAC, V35, P32, DOI 10.1016/j.ejcts.2008.09.009 Park BJ, 2007, J THORAC CARDIOV SUR, V133, P775, DOI 10.1016/j.jtcvs.2006.09.022 Paul S, 2010, J THORAC CARDIOV SUR, V139, P366, DOI 10.1016/j.jtcvs.2009.08.026 Rajaram R, 2015, J THORAC CARDIOV SUR, V150, P1508, DOI 10.1016/j.jtcvs.2015.05.047 Refai M, 2011, EUR J CARDIO-THORAC, V39, P1043, DOI 10.1016/j.ejcts.2010.09.039 Salati M, 2012, EUR J CARDIO-THORAC, V41, P1083, DOI 10.1093/ejcts/ezr171 Wright CD, 1997, ANN THORAC SURG, V64, P299, DOI 10.1016/S0003-4975(97)00548-1 Zehr KJ, 1998, ANN THORAC SURG, V66, P914, DOI 10.1016/S0003-4975(98)00662-6 NR 20 TC 8 Z9 8 U1 0 U2 5 PU PIONEER BIOSCIENCE PUBL CO PI HONG KONG PA 9A GOLD SHINE TOWER, 346-348 QUEEN'S RD CENTRAL, SHEUNG WAN, HONG KONG, 00000, PEOPLES R CHINA SN 2072-1439 EI 2077-6624 J9 J THORAC DIS JI J. Thorac. Dis. PD FEB PY 2016 VL 8 SU 1 BP S23 EP S28 DI 10.3978/j.issn.2072-1439.2015.12.34 PG 6 WC Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System GA DG5ET UT WOS:000372099100004 PM 26941966 DA 2026-04-17 ER PT J AU Lee, YJ Park, JK Uhm, JS Kim, JY Pak, HN Lee, MH Sung, JH Joung, B AF Lee, Yong-Joon Park, Jin-kyu Uhm, Jae-Sun Kim, Jong-Yun Pak, Hui-Nam Lee, Moon-Hyoung Sung, Jung-Hoon Joung, Boyoung TI Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Article DE Atrial fibrillation; Cancer; Anticoagulation; Stroke; Hemorrhage ID RECURRENT VENOUS THROMBOEMBOLISM; ATRIAL-FIBRILLATION; LUNG-CANCER; STROKE PREVENTION; COLORECTAL-CANCER; WARFARIN THERAPY; LONG-TERM; POPULATION; PREVALENCE; COMPLICATIONS AB Background: The efficacy of oral anticoagulation therapy (OAT) has not been revealed in atrial fibrillation (AF) patients with newly diagnosed cancers. This study evaluated the thromboembolic and bleeding events in AF patients with malignancies according to OAT. Methods and results: In 2168 consecutive non-valvular AF patients with newly diagnosed malignancies, we analyzed the composite endpoints including major adverse cardiac events (MACEs) and major bleeding. Based on a propensity score matching, two groups with 690 matched pairs were created. Patient baseline characteristics were comparable between the matched groups. During a follow-up period of 3.9 +/- 2.8 years, 72 (10%) and 65 (9%) patients had MACEs in the propensity score-matched OAT+ and OAT-groups, respectively (p = 0.461). There was no significant difference in the major bleeding (10% vs. 8%, p = 0.300) and composite endpoints (18% vs. 16%, p = 0.181) between OAT+ and OAT-patients. During the first year after the cancer diagnosis, 66 (48%) MACEs, 52 (41%) major bleedings, and 116 (49%) composite end points of all events occurred. The optimal international normalized ratio (2.0 to 3.0) level was achieved in only 85 (12%) patients. However, 1 year after cancer diagnosis, OAT+ patients with the target therapeutic range of >= 60% demonstrated better cumulative survival free of composite end point than OAT-patients (p= 0.026). Conclusion: During the first year after the cancer diagnosis, OAT did not improve the composite end point because of poor INR control caused by cancer treatment. However, after 1 year after diagnosis of cancer, optimal anticoagulation significantly reduced the composite end point. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Lee, Yong-Joon; Park, Jin-kyu; Uhm, Jae-Sun; Kim, Jong-Yun; Pak, Hui-Nam; Lee, Moon-Hyoung; Joung, Boyoung] Yonsei Univ, Coll Med, Div Cardiol, Seoul 120752, South Korea. [Sung, Jung-Hoon] CHA Univ, Bundang CHA Med Ctr, Div Cardiol, Songnam, South Korea. C3 Yonsei University; Yonsei University Health System; Pochon Cha University RP Joung, B (corresponding author), Yonsei Univ, Coll Med, Yonsei Cardiovasc Hosp, 250 Seungsanno, Seoul 120752, South Korea. EM cby6908@yuhs.ac RI Pak, Hui-Nam/C-4266-2015; Kim, Jong-Youn/B-5332-2011 OI Pak, Hui-Nam/0000-0002-3256-3620; Joung, Boyoung/0000-0001-9036-7225; Lee, Moon-Hyoung/0000-0002-7268-0741; Uhm, Jae-Sun/0000-0002-1611-8172; Kim, Jong-Youn/0000-0001-7040-8771 FU Basic Science Research Program through the National Research Foundation of Korea - Ministry of Education, Science and Technology [NRF-2012R1A2A2A02045367]; Korean Healthcare technology R&D project - Ministry of Health Welfare [HI12C1552] FX This study was supported in part by research grants from the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (NRF-2012R1A2A2A02045367), and a grant from the Korean Healthcare technology R&D project funded by Ministry of Health & Welfare (HI12C1552). CR Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Cowie MR, 1997, LANCET, V350, P1349, DOI 10.1016/S0140-6736(97)06031-5 Cronin-Fenton DP, 2010, BRIT J CANCER, V103, P947, DOI 10.1038/sj.bjc.6605883 Erichsen R, 2012, INTERN EMERG MED, V7, P431, DOI 10.1007/s11739-011-0701-9 Furie KL, 2011, STROKE, V42, P227, DOI 10.1161/STR.0b013e3181f7d043 Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370 Guzzetti S, 2002, AM J MED, V112, P587, DOI 10.1016/S0002-9343(02)01029-X Guzzetti S, 2008, INTERN EMERG MED, V3, P227, DOI 10.1007/s11739-008-0124-4 Heidbuchel H, 2015, EUROPACE Heit JA, 2000, ARCH INTERN MED, V160, P809, DOI 10.1001/archinte.160.6.809 Hutten BA, 2000, J CLIN ONCOL, V18, P3078, DOI 10.1200/JCO.2000.18.17.3078 Imperatori A, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-4 Lanas A, 2006, GUT, V55, P1731, DOI 10.1136/gut.2005.080754 Lee AYY, 2003, NEW ENGL J MED, V349, P146, DOI 10.1056/NEJMoa025313 Lip GYH, 2006, THROMB RES, V118, P321, DOI 10.1016/j.thromres.2005.08.007 MULLER AD, 1994, DIGEST DIS SCI, V39, P2480, DOI 10.1007/BF02087670 O'Neal WT, 2015, AM J CARDIOL, V115, P1090, DOI 10.1016/j.amjcard.2015.01.540 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Ostenfeld EB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102861 Pisters R, 2010, CHEST, V138, P1093, DOI 10.1378/chest.10-0134 Prandoni P, 2002, BLOOD, V100, P3484, DOI 10.1182/blood-2002-01-0108 Ridker PM, 2003, NEW ENGL J MED, V348, P1425, DOI 10.1056/NEJMoa035029 Rose AJ, 2007, J GEN INTERN MED, V22, P997, DOI 10.1007/s11606-007-0228-y ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236 Short NJ, 2014, ONCOLOGIST, V19, P82, DOI 10.1634/theoncologist.2013-0239 Stewart S, 2001, HEART, V86, P516, DOI 10.1136/heart.86.5.516 Thygesen K, 2007, EUR HEART J, V28, P2525 White HD, 2007, ARCH INTERN MED, V167, P239, DOI 10.1001/archinte.167.3.239 NR 28 TC 41 Z9 48 U1 0 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 EI 1874-1754 J9 INT J CARDIOL JI Int. J. Cardiol. PD JAN 15 PY 2016 VL 203 BP 372 EP 378 DI 10.1016/j.ijcard.2015.10.166 PG 7 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA CZ3MC UT WOS:000367007200097 PM 26539960 OA Green Submitted DA 2026-04-17 ER PT J AU Anderson, ME AF Anderson, Mark E. TI Oxidant stress promotes disease by activating CaMKII SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY LA English DT Review DE CaMKII; ox-CaMKII; MsrA; Heart failure; Myocardial infarction; Atrial fibrillation; Sinus node dysfunction; Atherosclerosis; Vascular smooth muscle; Asthma; Cancer ID PROTEIN-KINASE-II; ACUTE MYOCARDIAL-INFARCTION; BASE-LINE CHARACTERISTICS; SINUS NODE DYSFUNCTION; CARDIAC-HYPERTROPHY; BETA-CAROTENE; LUNG-CANCER; MECHANISM; DELTA; INHIBITION AB CaMKII is activated by oxidation of methionine residues residing in the regulatory domain. Oxidized CaMKII (ox-CaMKII) is now thought to participate in cardiovascular and pulmonary diseases and cancer. This invited review summarizes current evidence for the role of ox-CaMKII in disease, considers critical knowledge gaps and suggests new areas for inquiry. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Anderson, Mark E.] Johns Hopkins Sch Med, Johns Hopkins Dept Med, Baltimore, MD 21287 USA. C3 Johns Hopkins University; Johns Hopkins Medicine RP Anderson, ME (corresponding author), Johns Hopkins Sch Med, Johns Hopkins Dept Med, Baltimore, MD 21287 USA. EM mark.anderson@jhmi.edu FU International Society for Heart Research; National Institutes of Health (NIH) [R01-HL079031, R01-HL096652, R01-HL070250, R01-HL071140] FX I thank the International Society for Heart Research for the 2015 Research Achievement Award and am grateful for my collaborators, lab members, colleagues and competitors who have contributed to advancing the CaMKII field. Dr. Qinchuan Wang identified evolution of regulatory domain methionines and created a draft version of Fig. 2. Mr. Shawn Roach produced the artwork for the figures. This work was supported, in part, by National Institutes of Health (NIH) Grants R01-HL079031, R01-HL096652, R01-HL070250, and R01-HL071140. Ms. Giselle Diener provided formatting assistance. CR Albanes D, 1996, J NATL CANCER I, V88, P1560, DOI 10.1093/jnci/88.21.1560 Anderson ME, 1998, J PHARMACOL EXP THER, V287, P996 Backs J, 2009, P NATL ACAD SCI USA, V106, P2342, DOI 10.1073/pnas.0813013106 Benjamin EJ, 1998, CIRCULATION, V98, P946, DOI 10.1161/01.CIR.98.10.946 Chao LH, 2011, CELL, V146, P732, DOI 10.1016/j.cell.2011.07.038 Chelu MG, 2009, J CLIN INVEST, V119, P1940, DOI 10.1172/JCI37059 Christensen MD, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000583 COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800 Coultrap SJ, 2014, J BIOL CHEM, V289, P19458, DOI 10.1074/jbc.M114.558254 Curran J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087495 Erickson JR, 2008, CELL, V133, P462, DOI 10.1016/j.cell.2008.02.048 Erickson JR, 2015, J BIOL CHEM, V290, P25646, DOI 10.1074/jbc.M115.650234 Erickson JR, 2013, NATURE, V502, P372, DOI 10.1038/nature12537 Gutierrez DA, 2013, CARDIOVASC RES, V100, P392, DOI 10.1093/cvr/cvt201 Hart PC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7053 Hayashi M, 2015, CIRC RES, V116, P1887, DOI 10.1161/CIRCRESAHA.116.304521 He BJ, 2011, NAT MED, V17, P1610, DOI 10.1038/nm.2506 Ho HT, 2014, CARDIOVASC RES, V101, P165, DOI 10.1093/cvr/cvt233 Iravanian S, 2008, HEART RHYTHM, V5, pS12, DOI 10.1016/j.hrthm.2008.02.025 Izawa K, 2003, JPN HEART J, V44, P187, DOI 10.1536/jhj.44.187 Jaffer OA, 2015, AM J RESP CELL MOL, V52, P106, DOI 10.1165/rcmb.2013-0519OC JARJOUR NN, 1994, J LAB CLIN MED, V123, P131 Joiner MLA, 2012, NATURE, V491, P269, DOI 10.1038/nature11444 Kerstjens HAM, 2012, NEW ENGL J MED, V367, P1198, DOI 10.1056/NEJMoa1208606 Kreusser MM, 2014, CIRCULATION, V130, P1262, DOI 10.1161/CIRCULATIONAHA.114.006185 KURET J, 1985, J BIOL CHEM, V260, P6427 Lamas GA, 2000, AM HEART J, V140, P541, DOI 10.1067/mhj.2000.109652 Li H, 2010, AM J PHYSIOL-HEART C, V298, pH688, DOI 10.1152/ajpheart.01014.2009 Ling HY, 2013, CIRC RES, V112, P935, DOI 10.1161/CIRCRESAHA.112.276915 Ling HY, 2009, J CLIN INVEST, V119, P1230, DOI 10.1172/JCI38022 Little SC, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa5876 Lonn E, 2005, JAMA-J AM MED ASSOC, V293, P1338, DOI 10.1001/jama.293.11.1338 Luo M, 2013, J CLIN INVEST, V123, P1262, DOI 10.1172/JCI65268 Morita N, 2009, AM J PHYSIOL-HEART C, V297, pH1594, DOI 10.1152/ajpheart.00579.2009 Nesto RW, 1998, CIRCULATION, V97, P12, DOI 10.1161/01.CIR.97.1.12 Neuman RB, 2007, CLIN CHEM, V53, P1652, DOI 10.1373/clinchem.2006.083923 Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802 Prasad AM, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.001949 Purohit A., 2013, CIRCULATION Sanders PN, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006135 Scott JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071550 Shimano M, 2009, HEART RHYTHM, V6, P935, DOI 10.1016/j.hrthm.2009.03.012 Singh MV, 2012, J MOL CELL CARDIOL, V52, P1135, DOI 10.1016/j.yjmcc.2012.01.021 Singh MV, 2009, J CLIN INVEST, V119, P986, DOI 10.1172/JCI35814 Swaminathan PD, 2011, J CLIN INVEST, V121, P3277, DOI 10.1172/JCI57833 Tabas I, 2005, ARTERIOSCL THROM VAS, V25, P2255, DOI 10.1161/01.ATV.0000184783.04864.9f Tessier S, 1999, CIRC RES, V85, P810, DOI 10.1161/01.RES.85.9.810 Timmins JM, 2009, J CLIN INVEST, V119, P2925, DOI 10.1172/JCI38857 van Royen N, 2009, J AM COLL CARDIOL, V55, P17, DOI 10.1016/j.jacc.2009.06.058 Viatchenko-Karpinski S, 2014, J MOL CELL CARDIOL, V76, P247, DOI 10.1016/j.yjmcc.2014.09.009 Wagner S, 2011, CIRC RES, V108, P555, DOI 10.1161/CIRCRESAHA.110.221911 Wang YY, 2015, ONCOTARGET, V6, P11725, DOI 10.18632/oncotarget.3955 WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309 Weinreuter M, 2014, EMBO MOL MED, V6, P1231, DOI 10.15252/emmm.201403848 Westenbrink BD, 2015, CIRC RES, V116, pE28, DOI 10.1161/CIRCRESAHA.116.304682 Wu YJ, 1999, CIRC RES, V84, P906 Wu YJ, 1999, AM J PHYSIOL-HEART C, V276, pH2168, DOI 10.1152/ajpheart.1999.276.6.H2168 Xiang YY, 2007, NAT MED, V13, P862, DOI 10.1038/nm1604 Xie LH, 2009, CIRC RES, V104, P79, DOI 10.1161/CIRCRESAHA.108.183475 Zhang R, 2005, NAT MED, V11, P409, DOI 10.1038/nm1215 Zhu LJ, 2014, VASC PHARMACOL, V60, P75, DOI 10.1016/j.vph.2014.01.001 NR 61 TC 101 Z9 115 U1 0 U2 36 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0022-2828 EI 1095-8584 J9 J MOL CELL CARDIOL JI J. Mol. Cell. Cardiol. PD DEC PY 2015 VL 89 BP 160 EP 167 DI 10.1016/j.yjmcc.2015.10.014 PN B PG 8 WC Cardiac & Cardiovascular Systems; Cell Biology WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Cell Biology GA CZ9KV UT WOS:000367417400007 PM 26475411 OA Green Submitted DA 2026-04-17 ER PT J AU Nojiri, T Yamamoto, K Maeda, H Takeuchi, Y Ose, N Susaki, Y Inoue, M Okumura, M AF Nojiri, Takashi Yamamoto, Kazuhiro Maeda, Hajime Takeuchi, Yukiyasu Ose, Naoko Susaki, Yoshiyuki Inoue, Masayoshi Okumura, Meinoshin TI A Double-Blind Placebo-Controlled Study of the Effects of Olprinone, a Specific Phosphodiesterase III Inhibitor, for Preventing Postoperative Atrial Fibrillation in Patients Undergoing Pulmonary Resection for Lung Cancer SO CHEST LA English DT Article ID C-REACTIVE PROTEIN; NATRIURETIC-PEPTIDE; THORACIC-SURGERY; INJURY; RISK; MILRINONE; LEVEL; HEART AB BACKGROUND: We previously reported that patients with elevated preoperative B-type natriuretic peptide (BNP) levels have an increased risk for postoperative atrial fibrillation following lung cancer surgery. The present study evaluated whether the specific phosphodiesterase 111 inhibitor olprinone can reduce the incidence of postoperative atrial fibrillation in patients with elevated BNP levels undergoing pulmonary resection for lung cancer. METHODS: A prospective randomized study was conducted with 40 patients who had elevated preoperative BNP levels (>= 30 pg/mL) and underwent scheduled lung cancer surgery. All patients were in sinus rhythm at surgery. Low-dose olprinone or placebo was continuously infused for 24 h and started just before anesthesia induction. The primary end point was the incidence of postoperative atrial 'fibrillation. The secondary end points were perioperative hemodynamics and levels of BNP, WBC counts, and C-reactive protein. RESULTS: The incidence of postoperative atrial fibrillation was significantly lower in the olprinone group than in the placebo group (10% vs 60%, P < .001). Patients in the olprinone group showed significantly lower BNP, WBC counts, and C-reactive protein levels after surgery CONCLUSIONS: Continuous infusion of olprinone during lung cancer surgery was safe and reduced the incidence of postoperative atrial fibrillation following pulmonary resection in patients with elevated preoperative BNP levels. C1 [Nojiri, Takashi; Maeda, Hajime; Takeuchi, Yukiyasu; Ose, Naoko; Susaki, Yoshiyuki] Natl Hosp Org, Toneyama Hosp, Dept Gen Thorac Surg, Osaka, Japan. [Nojiri, Takashi] Natl Cerebral & Cardiovasc Ctr, Res Inst, Dept Biochem, Osaka, Japan. [Nojiri, Takashi; Inoue, Masayoshi; Okumura, Meinoshin] Osaka Univ, Grad Sch Med, Dept Gen Thorac Surg, Osaka, Japan. [Yamamoto, Kazuhiro] Tottori Univ, Fac Med, Dept Mol Med & Therapeut, Tottori 680, Japan. C3 National Cerebral & Cardiovascular Center - Japan; University of Osaka; Tottori University RP Nojiri, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Gen Thorac Surg, 2-2 L5 Yamadaoka, Suita, Osaka 5650871, Japan. EM nojirit@thoracic.med.osaka-u.ac.jp FU National Hospital Organization Toneyama Hospital; Eizai Co Ltd.; Grants-in-Aid for Scientific Research [25461058] Funding Source: KAKEN FX The study was internally funded by the National Hospital Organization Toneyama Hospital and partially funded by Eizai Co Ltd. CR Alizade E, 2014, PERFUSION-UK, V29, P265, DOI 10.1177/0267659113513822 AMAR D, 1995, CHEST, V108, P349, DOI 10.1378/chest.108.2.349 Amar D, 2002, ANESTHESIOLOGY, V97, P1618, DOI 10.1097/00000542-200212000-00039 Amar D, 2012, J THORAC CARDIOV SUR, V144, P1249, DOI 10.1016/j.jtcvs.2012.06.051 Bruins P, 1997, CIRCULATION, V96, P3542 Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Cardinale D, 2007, CIRCULATION, V115, P1339, DOI 10.1161/CIRCULATIONAHA.106.647008 Chung MK, 2001, CIRCULATION, V104, P2886, DOI 10.1161/hc4901.101760 Di Paola R, 2011, EUR J PHARMACOL, V650, P612, DOI 10.1016/j.ejphar.2010.10.043 Fleming GA, 2008, CIRCULATION, V118, P1619, DOI 10.1161/CIRCULATIONAHA.108.790162 Gialdini G, 2014, JAMA-J AM MED ASSOC, V312, P616, DOI 10.1001/jama.2014.9143 Hirabayashi Y, 2000, ACTA ANAESTH SCAND, V44, P1128, DOI 10.1034/j.1399-6576.2000.440916.x Koike T, 2008, PULM PHARMACOL THER, V21, P166, DOI 10.1016/j.pupt.2007.01.007 Kuniyoshi Tamotsu, 2005, J Anesth, V19, P295, DOI 10.1007/s00540-005-0340-2 Kurokawa S, 2013, EGYPT J ANAESTH, V29, P343, DOI 10.1016/j.egja.2013.05.010 Landoni G, 2010, J CARDIOTHOR VASC AN, V24, P51, DOI 10.1053/j.jvca.2009.05.031 Matera MG, 2014, EXPERT OPIN INV DRUG, V23, P1267, DOI 10.1517/13543784.2014.921157 McMurray JJV, 2012, EUR HEART J, V33, P1787, DOI 10.1093/eurheartj/ehs104 Mizutani A, 2005, SHOCK, V24, P281, DOI 10.1097/01.shk.0000175555.95676.34 Myou S, 2003, BRIT J CLIN PHARMACO, V55, P341, DOI 10.1046/j.1365-2125.2003.01760.x Nagata E, 2001, ANESTH ANALG, V92, P676, DOI 10.1213/00000539-200103000-00024 Nojiri T, 2012, J THORAC CARDIOV SUR, V143, P488, DOI 10.1016/j.jtcvs.2011.09.003 Nojiri T, 2010, J THORAC CARDIOV SUR, V140, P764, DOI 10.1016/j.jtcvs.2009.11.073 Nojiri T, 2010, EUR J CARDIO-THORAC, V37, P787, DOI 10.1016/j.ejcts.2009.09.043 Nomura Y, 2003, MOL CELL BIOCHEM, V248, P179, DOI 10.1023/A:1024100722413 Okayama N, 2010, ANESTH ANALG, V110, P888, DOI 10.1213/ANE.0b013e3181cb5cdd Orime Y, 1998, Ann Thorac Cardiovasc Surg, V4, P340 Riber LP, 2014, ANN THORAC SURG, V98, P1989, DOI 10.1016/j.athoracsur.2014.06.069 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Sanada S, 2001, CIRCULATION, V104, P705, DOI 10.1161/hc3201.092216 Satoh T, 2003, ANESTHESIOLOGY, V98, P1407, DOI 10.1097/00000542-200306000-00016 Song SW, 2006, ANN THORAC SURG, V81, P1974, DOI 10.1016/j.athoracsur.2006.01.032 Tisdale JE, 2009, ANN THORAC SURG, V88, P886, DOI 10.1016/j.athoracsur.2009.04.074 Tosaka S, 2007, J ANESTH, V21, P176, DOI 10.1007/s00540-006-0485-7 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 NR 35 TC 12 Z9 14 U1 0 U2 12 PU ELSEVIER PI AMSTERDAM PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS SN 0012-3692 EI 1931-3543 J9 CHEST JI Chest PD NOV PY 2015 VL 148 IS 5 BP 1285 EP 1292 DI 10.1378/chest.15-0852 PG 8 WC Critical Care Medicine; Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine; Respiratory System GA DB1MZ UT WOS:000368273600038 PM 26204331 DA 2026-04-17 ER PT J AU Takhar, HS Singhal, N Gowda, R Penniment, M Takhar, P Brown, MP AF Takhar, Harminder S. Singhal, Nimit Gowda, Raghu Penniment, Michael Takhar, Parineet Brown, Michael P. TI Phase I study evaluating the safety and efficacy of oral panobinostat in combination with radiotherapy or chemoradiotherapy in patients with inoperable stage III non-small-cell lung cancer SO ANTI-CANCER DRUGS LA English DT Article DE chemotherapy; locally advanced lung cancer; panobinostat; phase I; radiotherapy ID ANAEROBIOSPIRILLUM-SUCCINICIPRODUCENS BACTEREMIA; HISTONE DEACETYLASE INHIBITORS; THORACIC RADIOTHERAPY; JAPANESE PATIENTS; RADIATION; LBH589; LYMPHOPENIA; ONCOLOGY AB Panobinostat is a radiosensitizing agent and targets the epigenetics of malignancy. This phase I study evaluated the safety and efficacy of combining oral panobinostat with radiotherapy (RT) or chemoradiotherapy (CRT) in patients with inoperable stage III non-small-cell lung cancer. This study had a parallel dose-escalating design combining oral panobinostat twice a week (dose escalations 20, 30, 45 mg) with either palliative RT (group A) or radical CRT (group B) using a standard chemotherapy protocol of cisplatin and etoposide. In group A (RT), nine recruited patients received treatment with oral panobinostat (doses 20, 30, 45 mg) with RT. Two serious adverse events, rapid atrial fibrillation and tracheo-oesophageal fistula, were not attributable to study treatment. The most common grade 3/4 toxicities were thrombocytopenia and lymphopenia, which resolved promptly after cessation of panobinostat. The disease control rate was 66%, the progression-free survival was 3 months and the median overall survival was 9 months. In group B (CRT), panobinostat dose was not escalated beyond 20 mg because of infection-related complications. Serious adverse events included opportunistic infection associated with treatment-related lymphopenia and febrile neutropenia without a source. One patient had cerebral infarct that was not attributed to study treatment. All patients achieved a partial response to treatment. At 33 months of follow-up, all patients were still alive. Panobinostat can be combined with palliative-dose RT at doses up to 45 mg twice a week with tolerable toxicity. Dose-limiting toxicities prevented the dose escalation of the panobinostat with CRT. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved. C1 [Takhar, Harminder S.; Brown, Michael P.] Royal Adelaide Hosp, Canc Clin Trials Unit, N Terrace, Adelaide, SA 5000, Australia. [Takhar, Harminder S.; Singhal, Nimit; Brown, Michael P.] Royal Adelaide Hosp, Dept Med Oncol, Adelaide, SA 5000, Australia. [Gowda, Raghu; Penniment, Michael] Royal Adelaide Hosp, Dept Radiat Oncol, Adelaide, SA 5000, Australia. [Takhar, Parineet] Royal Adelaide Hosp, Dept Med Imaging, Adelaide, SA 5000, Australia. [Brown, Michael P.] SA Pathol, Ctr Canc Biol, Adelaide, SA, Australia. [Brown, Michael P.] Univ S Australia, Adelaide, SA 5001, Australia. [Brown, Michael P.] Univ Adelaide, Discipline Med, Adelaide, SA, Australia. C3 Royal Adelaide Hospital; Royal Adelaide Hospital; Royal Adelaide Hospital; Royal Adelaide Hospital; SA Pathology; Centre for Cancer Biology; Adelaide University; University of South Australia; Adelaide University; University of Adelaide RP Takhar, HS (corresponding author), Royal Adelaide Hosp, Canc Clin Trials Unit, N Terrace, Adelaide, SA 5000, Australia. EM harminder.takhar@health.sa.gov.au RI ; Brown, Michael/C-2081-2014 OI Penniment AM, Michael/0000-0001-8010-0789; Brown, Michael/0000-0002-5796-1932 FU Novartis FX Novartis supplied funding for conduct of the study. CR ABRATT RP, 1995, LUNG CANCER-J IASLC, V13, P137, DOI 10.1016/0169-5002(95)00487-4 [Anonymous], 2014, AUSTR CANC INC MORT Australian Institute of Health and Welfare & Australasian Association of Cancer Registries, 2012, 2012 CANC SER, V74 Bishton MJ, 2011, BLOOD, V117, P3658, DOI 10.1182/blood-2010-11-318055 CAMPBELL AC, 1976, CLIN EXP IMMUNOL, V23, P200 Campian JL, 2013, CANCER INVEST, V31, P183, DOI 10.3109/07357907.2013.767342 Diddee R, 2006, BJA EDUC, V6, P105, DOI 10.1093/bjaceaccp/mkl019 Fadzilah MN, 2009, J MED MICROBIOL, V58, P142, DOI 10.1099/jmm.0.004622-0 Falk SJ, 2002, BRIT MED J, V325, P465, DOI 10.1136/bmj.325.7362.465 Farray D, 2005, J CLIN ONCOL, V23, P3257, DOI 10.1200/JCO.2005.03.008 Ferlay J., 2013, GLOBOCAN 2012 V10 CA, V11 Fukutomi A, 2012, INVEST NEW DRUG, V30, P1096, DOI 10.1007/s10637-011-9666-9 Hanna N, 2008, J CLIN ONCOL, V26, P5755, DOI 10.1200/JCO.2008.17.7840 Iancu-Rubin C, 2012, EXP HEMATOL, V40, P564, DOI 10.1016/j.exphem.2012.02.004 Jett JR, 2007, CHEST, V132, p266S, DOI 10.1378/chest.07-1380 Jones SF, 2012, CANCER CHEMOTH PHARM, V70, P471, DOI 10.1007/s00280-012-1931-x Karagiannis TC, 2006, ONCOGENE, V25, P3885, DOI 10.1038/sj.onc.1209417 Morita S, 2012, INVEST NEW DRUG, V30, P1950, DOI 10.1007/s10637-011-9751-0 Pienaar C, 2003, J CLIN PATHOL, V56, P316, DOI 10.1136/jcp.56.4.316 Prince HM, 2007, J CLIN ONCOL, V25 Secchi Carina, 2005, Braz J Infect Dis, V9, P169, DOI 10.1590/S1413-86702005000200008 Slingerland M, 2014, ANTI-CANCER DRUG, V25, P140, DOI 10.1097/CAD.0000000000000040 Spigel DR, 2010, J CLIN ONCOL, V28, P43, DOI 10.1200/JCO.2009.24.7353 Sundstrom S, 2004, J CLIN ONCOL, V22, P801, DOI 10.1200/JCO.2004.06.123 Tee W, 1998, J CLIN MICROBIOL, V36, P1209, DOI 10.1128/JCM.36.5.1209-1213.1998 Thurn KT, 2011, FUTURE ONCOL, V7, P263, DOI 10.2217/FON.11.2 Yamamoto N, 2010, J CLIN ONCOL, V28, P3739, DOI 10.1200/JCO.2009.24.5050 NR 27 TC 22 Z9 26 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0959-4973 EI 1473-5741 J9 ANTI-CANCER DRUG JI Anti-Cancer Drugs PD NOV PY 2015 VL 26 IS 10 BP 1069 EP 1077 DI 10.1097/CAD.0000000000000282 PG 9 WC Oncology; Pharmacology & Pharmacy WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Pharmacology & Pharmacy GA DD5DJ UT WOS:000369942500008 PM 26317683 DA 2026-04-17 ER PT J AU Ai, D Lasala, J Mehran, JR Xu, G Banchs, J Cata, JP AF Ai, Di Lasala, Javier Mehran, John R. Xu, Gang Banchs, Jose Cata, Juan P. TI Preoperative Echocardiographic Parameters of Diastolic Dysfunction Did Not Provide a Predictive Value for Postoperative Atrial Fibrillation in Lung and Esophageal Cancer Surgery SO JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA LA English DT Article DE postoperative atrial fibrillation; echocardiography; thoracic surgery ID NONCARDIAC THORACIC-SURGERY; CARDIAC-SURGERY; RISK; VOLUME; PEPTIDE; INDEX AB Objective: To evaluate the predictive value of preoperative transthoracic echocardiography in the development of postoperative atrial fibrillation after non-cardiac thoracic surgery. Design: This was a retrospective study. Setting: Academic hospital. Participants: A total of 703 adult patients with non-small cell lung cancer. Interventions: None. Measurements and Main Results: Retrospective data of 177 non-cardiac thoracic surgical oncologic patients undergoing lung or esophageal cancer surgery with preoperative transthoracic echocardiograms (TTE) (within 30 days before surgery) were analyzed. The Wilcoxon rank sum test was used to evaluate the difference in continuous variables. Fisher's exact test or the chi-square test was used to evaluate the association between two categoric variables. Logistic regression models were used for multivariate analysis to include important and significant covariates. Among the demographic and echocardiographic variables measured age, systemic hypertension, e septal, e lateral and E/e ratio were significantly different between patients who would develop postoperative atrial fibrillation (POAF) and those who did not. The logistic regression models only identify age as a predictor factor of POAF. Conclusions: These results were similar to those published elsewhere on POAF incidence and risk factors. The preoperative echocardiographic variables in this study did not provide predictive value for POAF in non-cardiac thoracic surgery. (C) 2015 Elsevier Inc. All rights reserved. C1 [Ai, Di; Lasala, Javier; Cata, Juan P.] Univ Texas MD Anderson Canc Ctr, Dept Anesthesiol & Perioperat Med, Houston, TX 77030 USA. [Banchs, Jose] Univ Texas MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA. [Mehran, John R.] Univ Texas MD Anderson Canc Ctr, Dept Thorac Surg, Houston, TX 77030 USA. [Xu, Gang] Henan Canc Hosp, Dept Anesthesiol, Zhengzhou, Peoples R China. C3 University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Zhengzhou University RP Cata, JP (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Anesthesiol & Perioperat Med, 1515 Holcombe Blvd Unit 0408, Houston, TX 77030 USA. EM jcata@mdanderson.org RI Cata, Juan/AAA-7874-2022 CR Ai D, 2014, J CARDIOTHOR VASC AN Alsaileek AA, 2006, J AM COLL CARDIOL, V47, P1024, DOI 10.1016/j.jacc.2005.09.069 Amar D, 2005, CHEST, V128, P3421, DOI 10.1378/chest.128.5.3421 Candan O, 2013, ECHOCARDIOGR-J CARD, V30, P1061, DOI 10.1111/echo.12222 Chua SK, 2013, CIRC J, V77, P2303, DOI 10.1253/circj.CJ-13-0273 Echahidi N, 2008, J AM COLL CARDIOL, V51, P793, DOI 10.1016/j.jacc.2007.10.043 Fernando HC, 2011, ANN THORAC SURG, V92, P1144, DOI 10.1016/j.athoracsur.2011.06.104 Hakala T, 2002, Scand J Surg, V91, P339 Hakala T, 2002, EUR J CARDIO-THORAC, V22, P939, DOI 10.1016/S1010-7940(02)00565-1 Her AY, 2013, CAN J CARDIOL, V29, P377, DOI 10.1016/j.cjca.2012.06.006 Hollenberg SM, 2000, CRIT CARE MED, V28, pN145, DOI 10.1097/00003246-200010001-00006 Hu J, 2014, EUR J CARDIOTHO 0611 Lang RM, 2005, J AM SOC ECHOCARDIOG, V18, P1440, DOI 10.1016/j.echo.2005.10.005 Ma JY, 2006, WORLD J GASTROENTERO, V12, P449, DOI 10.3748/wjg.v12.i3.449 Maesen B, 2012, EUROPACE, V14, P159, DOI 10.1093/europace/eur208 Nagueh SF, 2009, EUR J ECHOCARDIOGR, V10, P165, DOI [10.1093/ejechocard/jep007, 10.1016/j.echo.2008.11.023] Naito Y, 2013, J ANESTH, V27, P699, DOI 10.1007/s00540-013-1594-8 Nojiri T, 2010, EUR J CARDIO-THORAC, V37, P787, DOI 10.1016/j.ejcts.2009.09.043 Oh JK, 2006, J AM COLL CARDIOL, V47, P500, DOI 10.1016/j.jacc.2005.09.032 Okura H, 2006, HEART, V92, P1248, DOI 10.1136/hrt.2005.082594 Osranek M, 2006, J AM COLL CARDIOL, V48, P779, DOI 10.1016/j.jacc.2006.03.054 Passman RS, 2005, ANN THORAC SURG, V79, P1698, DOI 10.1016/j.athoracsur.2004.10.058 Roshanali F, 2007, CIRCULATION, V116, P2012, DOI 10.1161/CIRCULATIONAHA.107.727081 Schnabel RB, 2009, LANCET, V373, P739, DOI 10.1016/S0140-6736(09)60443-8 Srivastava Piyush M, 2005, Eur J Echocardiogr, V6, P97, DOI 10.1016/j.euje.2004.07.005 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Verheule S, 2003, CIRCULATION, V107, P2615, DOI 10.1161/01.CIR.0000066915.15187.51 Walsh SR, 2007, ANN ROY COLL SURG, V89, P91, DOI 10.1308/003588407X168253 Weis F, 2009, CRIT CARE MED, V37, P1685, DOI 10.1097/CCM.0b013e31819fca77 NR 29 TC 8 Z9 10 U1 0 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1053-0770 EI 1532-8422 J9 J CARDIOTHOR VASC AN JI J. Cardiothorac. Vasc. Anesth. PD OCT PY 2015 VL 29 IS 5 BP 1127 EP 1130 DI 10.1053/j.jvca.2015.01.012 PG 4 WC Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease WE Science Citation Index Expanded (SCI-EXPANDED) SC Anesthesiology; Cardiovascular System & Cardiology; Respiratory System GA CS0WM UT WOS:000361782900003 PM 25976602 DA 2026-04-17 ER PT J AU Simonsen, DF Sogaard, M Bozi, I Horsburgh, CR Thomsen, RW AF Simonsen, Dennis F. Sogaard, Mette Bozi, Imre Horsburgh, Charles R. Thomsen, Reimar W. TI Risk factors for postoperative pneumonia after lung cancer surgery and impact of pneumonia on survival SO RESPIRATORY MEDICINE LA English DT Article DE Lung cancer; Postoperative pneumonia; Risk factors; Clinical epidemiology; Survival ID COMMUNITY-ACQUIRED PNEUMONIA; RESPIRATORY-INFECTIONS; BRONCHIAL COLONIZATION; NOSOCOMIAL PNEUMONIA; ELDERLY-PATIENTS; COMPLICATIONS; MORTALITY; RESECTION; HOSPITALIZATION; MORBIDITY AB Objective: Little is known about risk factors and prognosis for postoperative pneumonia (POP) in patients undergoing therapeutic lung cancer (LC) surgery. Methods: We followed a nationwide population-based cohort of 7479 patients with LC surgery in Denmark 1995-2011. We used logistic regression analysis to examine risk factors for POP within 30 days after surgery. Subsequent survival in patients with POP was analyzed with Cox regression. Results: We identified 268 (3.6%) patients with POP. Important risk factors included advanced age (age >= 80 years: (adjusted odds ratio [aOR] = 3.64; 95% CI: 2.17-6.12) as compared to patients aged 50-59 years), previous pneumonia (aOR = 2.68; 95% CI: 2.02-3.56), obesity (aOR = 1.91; 95% CI: 0.99-3.69), chronic pulmonary disease (aOR = 1.90; 95% CI: 1.40-2.57), alcoholism (aOR = 1.56; 95% CI: 0.81-3.01), and atrial fibrillation (aOR = 1.42; 95% CI: 0.82-2.45). Overall thoracoscopic surgery halved the risk of POP and the highest risk of POP was seen in pneumonectomy performed in open thoracotomy. Among patients surviving the 30-day postoperative period, 31-365 day mortality was 21.6% in POP patients vs. 16.8% in non-POP patients, and 1-5-year mortality was 62.2% vs. 53.0%. Adjusted 31-365 day hazard ratio (HR) of death with POP was 1.31 (95% CI: 1.00-1.73), and 1-5 year HR was 1.22 (95% CI 0.98-1.53). Conclusion: Major risk factors for POP following LC surgery are advanced age, previous pneumonia, obesity, chronic pulmonary disease, alcoholism, and atrial fibrillation. POP is a clinical marker for decreased LC survival. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Simonsen, Dennis F.; Sogaard, Mette; Bozi, Imre; Thomsen, Reimar W.] Aarhus Univ Hosp, Dept Clin Epidemiol, Inst Clin Med, DK-8200 Aarhus N, Denmark. [Horsburgh, Charles R.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA. C3 Aarhus University; Boston University RP Simonsen, DF (corresponding author), Aarhus Univ Hosp, Dept Clin Epidemiol, Olof Palmes Alle 43-45, DK-8200 Aarhus N, Denmark. EM simonsendennis@gmail.com RI ; Thomsen, Reimar/MTB-1719-2025 OI Søgaard, Mette/0000-0002-2830-4968; Thomsen, Reimar/0000-0001-9135-3474; Horsburgh, C/0000-0001-6838-7895 CR Alberg AJ, 2007, CHEST, V132, p29S, DOI 10.1378/chest.07-1347 Alifano M, 2010, EUR J CARDIO-THORAC, V37, P750, DOI 10.1016/j.ejcts.2009.10.013 Almirall J, 2008, EUR RESPIR J, V31, P1274, DOI 10.1183/09031936.00095807 Andalib A, 2013, J THORAC ONCOL, V8, P554, DOI 10.1097/JTO.0b013e3182862e7e Belda J, 2005, CHEST, V128, P1571, DOI 10.1378/chest.128.3.1571 CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8 de Groot P, 2012, RADIOL CLIN N AM, V50, P863, DOI 10.1016/j.rcl.2012.06.006 Deleuran Thomas, 2013, Clin Epidemiol, V5, P31, DOI 10.2147/CLEP.S47473 Díaz-Ravetllat V, 2012, RESP MED, V106, P1463, DOI 10.1016/j.rmed.2012.07.008 Driver Carolyn, 2012, Br J Nurs, V21, P245 Gjerstorff ML, 2011, SCAND J PUBLIC HEALT, V39, P42, DOI 10.1177/1403494810393562 Kornum JB, 2010, EUR RESPIR J, V36, P1330, DOI 10.1183/09031936.00184209 Lash TL, 2009, J CLIN ONCOL, V27, pE55, DOI 10.1200/JCO.2009.24.1877 Lee JY, 2011, J KOREAN MED SCI, V26, P979, DOI 10.3346/jkms.2011.26.8.979 Lynge E, 2011, SCAND J PUBLIC HEALT, V39, P30, DOI 10.1177/1403494811401482 Pedersen CB, 2011, SCAND J PUBLIC HEALT, V39, P22, DOI 10.1177/1403494810387965 Pei GT, 2014, J THORAC DIS, V6, P1230, DOI 10.3978/j.issn.2072-1439.2014.07.23 Ploeg AJ, 2003, EUR J CARDIO-THORAC, V23, P26, DOI 10.1016/S1010-7940(02)00655-3 Schnoor M, 2007, EPIDEMIOL INFECT, V135, P1389, DOI 10.1017/S0950268807007832 Schussler O, 2006, AM J RESP CRIT CARE, V173, P1161, DOI 10.1164/rccm.200510-1556OC Shiono S, 2007, J THORAC ONCOL, V2, P34, DOI 10.1097/JTO.0b013e31802bafb6 Shiono S, 2013, INTERACT CARDIOV TH, V16, P819, DOI 10.1093/icvts/ivt034 Sogaard M, 2014, RESP MED, V108, P1214, DOI 10.1016/j.rmed.2014.05.004 Sogaard Mette, 2013, Clin Epidemiol, V5, P3, DOI 10.2147/CLEP.S47150 Thomas PA, 2015, J THORAC CARDIOV SUR, V149, P73, DOI 10.1016/j.jtcvs.2014.09.063 Thomas PA, 2014, EUR J CARDIO-THORAC, V45, P652, DOI 10.1093/ejcts/ezt452 Thomsen RW, 2006, J INTERN MED, V259, P410, DOI 10.1111/j.1365-2796.2006.01629.x Topal AE, 2012, CARDIOVASC J AFR, V23, DOI 10.5830/CVJA-2012-005 Torres A, 2013, THORAX, V68, P1057, DOI 10.1136/thoraxjnl-2013-204282 Wang Z, 2014, ASIAN PAC J CANCER P, V15, P3071, DOI 10.7314/APJCP.2014.15.7.3071 Whitson BA, 2008, ANN THORAC SURG, V86, P2008, DOI 10.1016/j.athoracsur.2008.07.009 Yamada Y, 2010, EUR J CARDIO-THORAC, V37, P752, DOI 10.1016/j.ejcts.2009.05.039 NR 32 TC 85 Z9 102 U1 0 U2 17 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0954-6111 EI 1532-3064 J9 RESP MED JI Respir. Med. PD OCT PY 2015 VL 109 IS 10 BP 1340 EP 1346 DI 10.1016/j.rmed.2015.07.008 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System GA CS7NZ UT WOS:000362271600017 PM 26209227 OA Bronze DA 2026-04-17 ER PT J AU Wei, B Broussard, B Bryant, A Linsky, P Minnich, DJ Cerfolio, RJ AF Wei, Benjamin Broussard, Brett Bryant, Ayesha Linsky, Paul Minnich, Douglas J. Cerfolio, Robert J. TI Left upper lobectomy after coronary artery bypass grafting SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article DE Coronary artery bypass grafting; left upper lobectomy; internal mammary artery ID INTERNAL THORACIC ARTERY; ATRIAL-FIBRILLATION; RISK-FACTORS; PULMONARY RESECTION; LUNG-CANCER; SURGERY; PRESERVATION AB Objective: Left upper pulmonary lobectomy or segmentectomy after coronary artery bypass grafting (CABG) risks injury to the grafts. We reviewed our experience. Methods: This is a retrospective review of a prospective database from 1 surgeon, of patients who underwent left upper lobectomy after having previous CABG. Results: Between June 1998 and June 2014, a total of 2207 patients underwent lobectomy by 1 surgeon; 458 (21%) had a left upper lobectomy, and 28 (6.1%) had had a previous CABG. Twenty-seven patients (96.4%) had a left internal mammary artery (LIMA) used for the bypass. Twenty-six patients (96.2%) had significant adhesions between their lung and the bypass grafts. Of patients who had a LIMA graft, 25 (92.6%) had the left upper lobe completely dissected free from their grafts, whereas 2 patients (7.1%) had a sliver of their lung left on the grafts. No patient had a postoperative myocardial infarction, and 30-day and 90-day survival rates were both 100%. All patients had a curative resection, and all had complete thoracic lymphadenectomy. Conclusions: Left upper lobectomy after CABG, in patients with previous CABG and LIMA grafting, is safe. Usually the entire lung can be safely mobilized off the bypass grafts; if needed, a small sliver of lung can be left on the grafts. A curative resection is possible with minimal perioperative cardiac morbidity, and excellent 30- and 90-day mortality. C1 [Wei, Benjamin; Broussard, Brett; Bryant, Ayesha; Linsky, Paul; Minnich, Douglas J.; Cerfolio, Robert J.] Univ Alabama Birmingham, Div Cardiothorac Surg, Med Ctr, Birmingham, AL 35294 USA. C3 University of Alabama System; University of Alabama Birmingham RP Cerfolio, RJ (corresponding author), Univ Alabama Birmingham, Div Cardiothorac Surg, Thorac Surg, 703 19th St S,ZRB 739, Birmingham, AL 35294 USA. EM rcerfolio@uabmc.edu RI ; Linsky, Paul/AAY-1110-2021 OI Cerfolio, Robert/0000-0002-5598-599X; Bryant, Ayesha/0000-0002-3704-0319; CR Berry MF, 2014, ANN THORAC SURG, V98, P1199, DOI 10.1016/j.athoracsur.2014.05.038 Cerfolio RJ, 2011, J THORAC CARDIOV SUR, V142, P740, DOI 10.1016/j.jtcvs.2011.07.022 FitzGibbon GM, 1996, J AM COLL CARDIOL, V28, P616, DOI 10.1016/0735-1097(96)00206-9 Funaki S, 2012, INTERACT CARDIOV TH, V15, P928, DOI 10.1093/icvts/ivs299 Goldman S, 2004, J AM COLL CARDIOL, V44, P2149, DOI 10.1016/j.jacc.2004.08.064 Halkos ME, 2003, ANN THORAC SURG, V76, P280, DOI 10.1016/S0003-4975(02)04962-7 Ivanovic J, 2014, INTERACT CARDIOV TH, V18, P340, DOI 10.1093/icvts/ivt520 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Santini M, 2008, J THORAC CARDIOV SUR, V136, P222, DOI 10.1016/j.jtcvs.2007.12.049 Shah AA, 2014, ANN THORAC SURG, V98, P1207, DOI 10.1016/j.athoracsur.2014.05.068 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 NR 11 TC 7 Z9 10 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 EI 1097-685X J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD SEP PY 2015 VL 150 IS 3 BP 531 EP 535 DI 10.1016/j.jtcvs.2015.05.066 PG 5 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA CQ6AE UT WOS:000360686000039 PM 26149098 OA Bronze DA 2026-04-17 ER PT J AU Canestaro, WJ Pritchard, DE Garrison, LP Dubois, R Veenstra, DL AF Canestaro, William J. Pritchard, Daryl E. Garrison, Louis P. Dubois, Robert Veenstra, David L. TI Improving the Efficiency and Quality of the Value Assessment Process for Companion Dagnostic Tests: The Companion test Assessment Tool (CAT) SO JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY LA English DT Article ID POSITIVE LUNG-CANCER; HLA-B REGION; ATRIAL-FIBRILLATION; UNITED-STATES; HYPERSENSITIVITY REACTIONS; ABACAVIR HYPERSENSITIVITY; GENETIC-VARIATIONS; COST-EFFECTIVENESS; DRUG-DEVELOPMENT; WARFARIN AB BACKGROUND: Companion diagnostic tests (CRTs) have emerged as a vital technology in the effective use of an increasing number of targeted drug therapies. /although CDTs can offer a multitude of potential benefits, acsPc.sing their value within a health technology appraisal process can be challenging because of a complex array of factors that influence clinical and economic outcomes. OBJECTIVE: To develop a user-friendly tool to assist managed care and other health care dedsion makers in screening companion tests and determining whether an intensive technology review is necessary and, if so, where the review should be focused to improve efficiency. METHODS: Rrst, we conducted a systematic literature review of CDT costeffectiveness studies to identify value drivers. Second, we conducted key informant interviews with a diverse group of stakeholders to elicit feedback and solicit any additional value drivers and identify desirable attributes for an evidence review tool. A draft tool was developed based on this information that captured value drivers, usability features, and had a particular focus on practical use by nonexperts. Finally, the tool was pilot tested with test developers and managed care evidence evaluators to agsPqs face validity and usability. The tool was also evaluated using several diverse examples of existing companion diagnostics and refined accordingly. RESULTS: identified 65 cost-effectiveness studies of companion diagnostic technologies. The following factors were most commonly identified as value drivers from our literature review: dinical validity of testing; efficacy, safety, and cost of baseline and alternative treatments; cost and mortality of health states; and biomarker prevalence and testing cost. Stakeholders identified the following additional factors that they believed influenced the overall value of a companion test: regulatory status, action ability, utility, and market penetration. 11-=,c factors were used to maximize the efficiency of the evidence review process. Stakeholders also stated that a tool should be easy to use and time efficient. Cognitive interviews with stakeholders led to minor changes in the draft tool to improve usability and relevance. The final tool consisted of 4 sections: (1) eligibility for review (2 questions), (2) prioritization of review (3 questions), (3) clinical review (3 questions), and (4) economic review (5 questions). CONCLUSIONS; Although the evaluation of CDTs can be challenging because of limited evidence and the added complexity of incorporating a diagnostic test into drug treatment decisions, using a pragmatic tool to identify tests that do not need extensive evaluation may improve the efficiency and effectiveness of CDT value assessments. C1 [Canestaro, William J.; Garrison, Louis P.; Veenstra, David L.] Univ Washington, Sch Pharm, Pharmaceut Outcomes Res & Policy Program, H375 HSB Box 357630,1959 NE Pacific St, Seattle, WA 98195 USA. [Pritchard, Daryl E.] Personalized Med Coalit, Sci Policy, Washington, DC USA. [Pritchard, Daryl E.] Natl Pharmaceut Council, Policy Res, Washington, DC USA. [Dubois, Robert] Natl Pharmaceut Council, Washington, DC USA. C3 University of Washington; University of Washington Seattle RP Veenstra, DL (corresponding author), Univ Washington, Sch Pharm, Pharmaceut Outcomes Res & Policy Program, H375 HSB Box 357630,1959 NE Pacific St, Seattle, WA 98195 USA. EM veenstra@uw.edu FU National Pharmaceutical Council (NPC) FX This work was supported by the National Pharmaceutical Council (NPC). Veenstra is consultant to Genentech, Abbott Dx, NPC, and Jazz Pharmaceuticals; Canestaro is consultant to Genentech, MedImmune/AstraZeneca, and NPC; and Garrison is consultant to Genentech, Abbott Dx, and NPC. CR Albain KS, 2010, LANCET ONCOL, V11, P55, DOI 10.1016/S1470-2045(09)70314-6 [Anonymous], AMCP FORM FORM SUBM Baker WL, 2009, J MANAGE CARE PHARM, V15, P244, DOI 10.18553/jmcp.2009.15.3.244 Camidge DR, 2012, NAT REV CLIN ONCOL, V9, P268, DOI 10.1038/nrclinonc.2012.43 Canadian Agency for Drugs and Technologies in Health, 2015, HLTH TECHN ASS SEARC Carlson JJ, 2005, GENET MED, V7, P519, DOI 10.1097/01.GIM.0000182467.79495.e2 Center for the Evaluation of Value and Risk in Health, 2014, COST EFF AN REG Charland SL, 2012, J AM COLL CARDIOL, V59, pE1848, DOI 10.1016/S0735-1097(12)61849-X De Caterina R, 2010, EUR HEART J, V31, P2133, DOI 10.1093/eurheartj/ehq250 Djalalov S, 2011, GENET MED, V13, P89, DOI 10.1097/GIM.0b013e3182003294 Epstein RS, 2010, J AM COLL CARDIOL, V55, P2804, DOI 10.1016/j.jacc.2010.03.009 Epstein RS, 2009, PHARMACOGENOMICS, V10, P149, DOI 10.2217/14622416.10.1.149 Fang MC, 2010, CIRC-CARDIOVASC QUAL, V3, P624, DOI 10.1161/CIRCOUTCOMES.110.937680 Flockhart DA, 2008, GENET MED, V10, P139, DOI 10.1097/GIM.0b013e318163c35f Flowers CR, 2004, PHARMACOECONOMICS, V22, P481, DOI 10.2165/00019053-200422080-00001 Frueh FW, 2008, PHARMACOTHERAPY, V28, P992, DOI 10.1592/phco.28.8.992 Haddow J.E., 2003, Human Genome Epidemiol, P217 Hetherington S, 2002, LANCET, V359, P1121, DOI 10.1016/S0140-6736(02)08158-8 Hetherington S, 2001, CLIN THER, V23, P1603, DOI 10.1016/S0149-2918(01)80132-6 Hughes AR, 2004, PHARMACOGENOMICS, V5, P203, DOI 10.1517/phgs.5.2.203.27481 Hylek EM, 2006, STROKE, V37, P1075, DOI 10.1161/01.STR.0000209239.71702.ce Jorgensen AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044064 Kimmel SE, 2013, NEW ENGL J MED, V369, P2283, DOI 10.1056/NEJMoa1310669 Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448 Liang RJ, 2012, THROMB RES, V130, P38, DOI 10.1016/j.thromres.2011.11.043 Lindh JD, 2009, EUR J CLIN PHARMACOL, V65, P365, DOI 10.1007/s00228-008-0584-5 Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X Mallal S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMoa0706135 Martin AM, 2004, P NATL ACAD SCI USA, V101, P4180, DOI 10.1073/pnas.0307067101 Merlin T, 2013, MED DECIS MAKING, V33, P333, DOI 10.1177/0272989X12452341 Olsen D, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00105 Phillips EJ, 2005, AIDS, V19, P979, DOI 10.1097/01.aids.0000171414.99409.fb Pirmohamed M, 2013, NEW ENGL J MED, V369, P2294, DOI 10.1056/NEJMoa1311386 Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025 Sanderson S, 2005, GENET MED, V7, P97, DOI 10.1097/01.GIM.0000153664.65759.CF Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886 Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945 Surh LC, 2010, PHARMACOGENOMICS, V11, P1637, DOI 10.2217/PGS.10.138 Tang G, 2011, J CLIN ONCOL, V29, P4365, DOI 10.1200/JCO.2011.35.3714 Vegter S, 2008, PHARMACOECONOMICS, V26, P569, DOI 10.2165/00019053-200826070-00005 Waldo AL, 2005, J AM COLL CARDIOL, V46, P1729, DOI 10.1016/j.jacc.2005.06.077 Wong WB, 2010, PHARMACOECONOMICS, V28, P1001, DOI 10.2165/11537410-000000000-00000 Yang LM, 2010, THROMB RES, V125, pE159, DOI 10.1016/j.thromres.2009.10.017 Zineh I, 2004, PHARMACOGENOMICS J, V4, P354, DOI 10.1038/sj.tpj.6500284 Zineh I, 2011, PHARMACOTHERAPY, V31, P729, DOI 10.1592/phco.31.8.729 NR 45 TC 8 Z9 12 U1 1 U2 5 PU ACAD MANAGED CARE PHARMACY PI ALEXANDRIA PA 100 N PITT ST, 400, ALEXANDRIA, VA 22314-3134 USA SN 2376-0540 EI 2376-1032 J9 J MANAG CARE SPEC PH JI J. Manag. Care Spec. Pharm. PD AUG PY 2015 VL 21 IS 8 BP 700 EP 712 DI 10.18553/jmcp.2015.21.8.700 PG 13 WC Health Care Sciences & Services; Pharmacology & Pharmacy WE Science Citation Index Expanded (SCI-EXPANDED) SC Health Care Sciences & Services; Pharmacology & Pharmacy GA DC4KY UT WOS:000369191000008 PM 26233542 OA Green Submitted, Bronze DA 2026-04-17 ER PT J AU Schoepf, D Heun, R AF Schoepf, Dieter Heun, Reinhard TI Anxiety disorders and physical comorbidity: increased prevalence but reduced relevance of specific risk factors for hospital-based mortality during a 12.5-year observation period in general hospital admissions SO EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE LA English DT Article DE Anxiety disorder; Physical comorbidity; General hospital admissions; Hospital-based mortality; Risk factors ID QUALITY-OF-LIFE; CORONARY-HEART-DISEASE; ATRIAL-FIBRILLATION; FOLLOW-UP; EXCESS MORTALITY; MENTAL-DISORDERS; PANIC DISORDER; ALL-CAUSE; DEPRESSION; SCHIZOPHRENIA AB Anxiety disorders (AD) are associated with an increase in physical comorbidities, but the effects of these diseases on hospital-based mortality are unclear. Consequently, we investigated whether the burden of physical comorbidity and its relevance on hospital-based mortality differed between individuals with and without AD during a 12.5-year observation period in general hospital admissions. During 1 January 2000 and 30 June 2012, 11,481 AD individuals were admitted to seven General Manchester Hospitals. All comorbidities with a prevalence a parts per thousand yen1 % were compared with those of 114,810 randomly selected and group-matched hospital controls of the same age and gender, regardless of priority of diagnoses or specialized treatments. Comorbidities that increased the risk of hospital-based mortality (but not mortality outside of the hospital) were identified using multivariate logistic regression analyses. AD individuals compared to controls had a substantial excess comorbidity, but a reduced hospital-based mortality rate. Twenty-two physical comorbidities were increased in AD individuals compared with controls, which included cardiovascular diseases and their risk factors. The most frequent physical comorbidities in AD individuals were hypertension, asthma, cataract, and ischaemic heart disease. Risk factors for hospital-based mortality in AD individuals were lung cancer, alcoholic liver disease, respiratory failure, heart failure, pneumonia, bronchitis, non-specific dementia, breast cancer, COPD, gallbladder calculus, atrial fibrillation, and angina. The impact of atrial fibrillation, angina, and gallbladder calculus on hospital-based mortality was higher in AD individuals than in controls. In contrast, other mortality risk factors had an equal or lower impact on hospital-based mortality in sample comparisons. Therefore AD individuals have a higher burden of physical comorbidity that is associated with a reduced risk of general hospital-based mortality. Atrial fibrillation, angina, and gallbladder calculus are major risk factors for general hospital-based mortality in AD individuals. C1 [Schoepf, Dieter; Heun, Reinhard] Univ Bonn, Dept Psychiat, D-53105 Bonn, Germany. [Heun, Reinhard] Royal Derby Hosp, Dept Psychiat, Radbourne Unit, Derby, England. C3 University of Bonn; University of Nottingham RP Schoepf, D (corresponding author), Univ Bonn, Dept Psychiat, Sigmund Freud Str 25, D-53105 Bonn, Germany. EM dieter.schoepf@ukb.uni-bonn.de OI Schoepf, Dieter/0000-0001-5611-892X CR Andrews G, 2001, BRIT J PSYCHIAT, V178, P145, DOI 10.1192/bjp.178.2.145 [Anonymous], BR MED J [Anonymous], PSYCHIAT DISORDERS N, DOI DOI 10.5772/51623 Atlantis E, 2013, CHEST, V144, P766, DOI 10.1378/chest.12-1911 Baxter AJ, 2015, PSYCHOL MED, V45, P601, DOI 10.1017/S003329171400172X Beary M, 2012, J PSYCHOPHARMACOL, V26, P52, DOI 10.1177/0269881112440512 Brown ES, 2002, J CLIN PSYCHOPHARM, V22, P55, DOI 10.1097/00004714-200202000-00009 Campbell-Sills L, 2013, PSYCHOSOM MED, V75, P713, DOI 10.1097/PSY.0b013e31829def54 Chen YH, 2010, CAN J PSYCHIAT, V55, P43, DOI 10.1177/070674371005500107 Chen YH, 2009, PSYCHOSOM MED, V71, P798, DOI 10.1097/PSY.0b013e3181ad55e3 Cheng YF, 2013, PSYCHOSOM MED, V75, P30, DOI 10.1097/PSY.0b013e318273393a Corrales-Medina VF, 2012, CIRCULATION, V125, P773, DOI 10.1161/CIRCULATIONAHA.111.040766 Coulthard K, 2013, BMC PSYCHIATRY, V13, DOI [10.1155/2013/159850, 10.1186/1471-244X-13-301] Denollet J, 2009, J CLIN EPIDEMIOL, V62, P452, DOI 10.1016/j.jclinepi.2008.08.006 Eaker ED, 2005, PSYCHOSOM MED, V67, P692, DOI 10.1097/01.psy.0000174050.87193.96 Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004 Eramudugolla R, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00056 Evans DL, 2005, BIOL PSYCHIAT, V58, P175, DOI 10.1016/j.biopsych.2005.05.001 Garin N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084794 Grasbeck A, 1996, NEUROPSYCHOBIOLOGY, V33, P118, DOI 10.1159/000119261 Härter MC, 2003, EUR ARCH PSY CLIN N, V253, P313, DOI 10.1007/s00406-003-0449-y Herrmann C, 2000, J PSYCHOSOM RES, V48, P455, DOI 10.1016/S0022-3999(99)00086-0 Heun R, 2013, EUR PSYCHIAT, V28, P40, DOI 10.1016/j.eurpsy.2011.06.001 Hirschfeld Robert M. A., 2001, Prim Care Companion J Clin Psychiatry, V3, P244 Holt RIG, 2013, J AFFECT DISORDERS, V150, P84, DOI 10.1016/j.jad.2013.02.026 Holwerda TJ, 2007, INT J GERIATR PSYCH, V22, P241, DOI 10.1002/gps.1669 Javadi Mohammad-Ali, 2008, J Ophthalmic Vis Res, V3, P52 Kessler RC, 2003, J OCCUP ENVIRON MED, V45, P1257, DOI 10.1097/01.jom.0000100000.70011.bb Kessler RC, 2009, EPIDEMIOL PSICHIAT S, V18, P23, DOI 10.1017/S1121189X00001421 Kroenke K, 2007, ANN INTERN MED, V146, P317, DOI 10.7326/0003-4819-146-5-200703060-00004 Lane D, 2001, PSYCHOSOM MED, V63, P221, DOI 10.1097/00006842-200103000-00005 Lavoie KL, 2006, CHEST, V130, P1039, DOI 10.1378/chest.130.4.1039 Lavretsky H, 2003, INT J GERIATR PSYCH, V18, P183, DOI 10.1002/gps.706 Lee WE, 2006, PSYCHOL MED, V36, P345, DOI 10.1017/S0033291705006847 Leske MC, 1999, OPHTHALMOLOGY, V106, P35, DOI 10.1016/S0161-6420(99)90003-9 Magnani JW, 2011, CIRCULATION, V124, P1982, DOI 10.1161/CIRCULATIONAHA.111.039677 McCauley E, 2007, GEN HOSP PSYCHIAT, V29, P214, DOI 10.1016/j.genhosppsych.2007.02.003 Michael Tanja., 2007, Epidemiology and Psychopharmacology, V6, P136, DOI DOI 10.1016/J.MPPSY.2007.01.007 Mykletun A, 2009, BRIT J PSYCHIAT, V195, P118, DOI 10.1192/bjp.bp.108.054866 Nattel S, 2006, LANCET, V367, P262, DOI 10.1016/S0140-6736(06)68037-9 Nicholson A, 2006, EUR HEART J, V27, P2763, DOI 10.1093/eurheartj/ehl338 Phung TKT, 2007, DEMENT GERIATR COGN, V24, P220, DOI 10.1159/000107084 Player MS, 2011, INT J PSYCHIAT MED, V41, P365, DOI 10.2190/PM.41.4.f Roy-Byrne PP, 2008, GEN HOSP PSYCHIAT, V30, P208, DOI 10.1016/j.genhosppsych.2007.12.006 Rozanski A, 2005, PSYCHOSOM MED, V67, pS47, DOI 10.1097/01.psy.0000164253.69550.49 Russ TC, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4933 Samokhvalov AV, 2010, EUR J CARDIOV PREV R, V17, P706, DOI 10.1097/HJR.0b013e32833a1947 Sareen J, 2006, ARCH INTERN MED, V166, P2109, DOI 10.1001/archinte.166.19.2109 Schoepf D, 2012, EUR PSYCHIAT, V27, P33, DOI 10.1016/j.eurpsy.2011.02.009 Schoepf D, 2003, NERVENARZT, V74, P245, DOI 10.1007/s00115-001-1241-8 Schoepf D, 2014, J AFFECT DISORDERS, V169, P170, DOI 10.1016/j.jad.2014.08.025 Schoepf D, 2014, J PSYCHIATR RES, V52, P28, DOI 10.1016/j.jpsychires.2014.01.010 Schoepf D, 2014, EUR ARCH PSY CLIN N, V264, P3, DOI 10.1007/s00406-013-0436-x Smoller J W, 1999, Semin Clin Neuropsychiatry, V4, P84 Smoller JW, 2007, ARCH GEN PSYCHIAT, V64, P1153, DOI 10.1001/archpsyc.64.10.1153 Smoller JW, 1996, AM J RESP CRIT CARE, V154, P6, DOI 10.1164/ajrccm.154.1.8680700 United Nations Population Division (UNPD), 2012, POP AG DEV 2012 WALL Van Oudenhove L, 2007, PSYCHOSOM MED, V69, P455, DOI 10.1097/PSY.0b013e3180600a4a NR 58 TC 14 Z9 17 U1 0 U2 26 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0940-1334 EI 1433-8491 J9 EUR ARCH PSY CLIN N JI Eur. Arch. Psych. Clin. Neurosci. PD AUG PY 2015 VL 265 IS 5 BP 387 EP 398 DI 10.1007/s00406-014-0566-9 PG 12 WC Clinical Neurology; Psychiatry WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI) SC Neurosciences & Neurology; Psychiatry GA CK1CJ UT WOS:000355942700004 PM 25472881 DA 2026-04-17 ER PT J AU Ziarnik, E Grogan, EL AF Ziarnik, Elena Grogan, Eric L. TI Postlobectomy Early Complications SO THORACIC SURGERY CLINICS LA English DT Article DE Air leak; Atrial fibrillation; Pneumonia/mucous plugging; Right middle lobe torsion; Hemorrhage; Chylothorax; Nerve injury ID GENERAL THORACIC-SURGERY; LUNG-CANCER; RISK-FACTORS; AIR LEAK; PULMONARY COMPLICATIONS; MULTIVARIATE-ANALYSIS; LOBAR TORSION; MANAGEMENT; PROPHYLAXIS; OPERATIONS AB Immediate postoperative complications are common after lobectomy. The most effective management of postoperative crises is prevention, which starts with preoperative preparation and patient screening. There are many factors that can be controlled and improved by the patient. Equally important is patient selection, which is influenced by pulmonary function tests, cardiopulmonary reserve, and preexisting comorbidities. After the operation, the care team can also greatly improve outcomes with aggressive cardiopulmonary therapies, ambulation, vigilant monitoring, and frequent assessments of the patient. Prevention strategies can minimize risks; however, when they occur, a proactive approach may minimize the long-term sequelae. C1 [Ziarnik, Elena] Vanderbilt Univ, Med Ctr, Dept Thorac Surg, Nashville, TN 37232 USA. [Grogan, Eric L.] Vanderbilt Univ, Med Ctr, Tennessee Valley Healthcare Syst, Dept Thorac Surg, Nashville, TN 37232 USA. C3 Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System RP Grogan, EL (corresponding author), Vanderbilt Univ, Med Ctr, Tennessee Valley Healthcare Syst, Dept Thorac Surg, 609 Oxford House,1313 21st Ave South, Nashville, TN 37232 USA. EM eric.grogan@vanderbilt.edu RI Grogan, Eric/MGB-5235-2025 FU Department of Veterans' Affairs, Veterans Health Administration, Health Services Research and Development Service Career Development Award [10-024] FX Dr E.L. Grogan is a recipient of the Department of Veterans' Affairs, Veterans Health Administration, Health Services Research and Development Service Career Development Award (10-024). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans' Affairs. CR Algar FJ, 2001, ANN THORAC SURG, V72, P1662, DOI 10.1016/S0003-4975(01)03096-X Allen MS, 2006, ANN THORAC SURG, V81, P1013, DOI 10.1016/j.athoracsur.2005.06.066 Amar David, 2002, Heart Dis, V4, P117 Apostolakis E, 2006, J CARDIOTHORAC SURG, V1, DOI 10.1186/1749-8090-1-25 ASAMURA H, 1993, J THORAC CARDIOV SUR, V106, P1104, DOI 10.1016/S0022-5223(19)33985-6 ASAMURA H, 1992, J THORAC CARDIOV SUR, V104, P1456 Babu AN, 2010, OP TECH THORAC CARDI, V15, P41 Belda-Sanchís J, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003051.pub3 Berry MF, 2009, ANN THORAC SURG, V88, P1093, DOI 10.1016/j.athoracsur.2009.06.012 Bhattacharyya N, 2003, AURIS NASUS LARYNX, V30, P71, DOI 10.1016/S0385-8146(02)00114-1 Bonde P, 2002, EUR J CARDIO-THORAC, V22, P18, DOI 10.1016/S1010-7940(02)00205-1 Burri E, 2006, J CARDIOVASC SURG, V47, P609 Cerfolio RJ, 1998, ANN THORAC SURG, V66, P1726, DOI 10.1016/S0003-4975(98)00958-8 Cerfolio RJ, 2001, ANN THORAC SURG, V71, P1613, DOI 10.1016/S0003-4975(01)02474-2 Curtis JJ, 1998, ANN THORAC SURG, V66, P1766, DOI 10.1016/S0003-4975(98)00942-4 Deschamps C, 2001, ANN THORAC SURG, V72, P243, DOI 10.1016/S0003-4975(01)02681-9 DESLAURIERS J, 1994, CHEST, V106, pS329, DOI 10.1378/chest.106.6.329S Fell SC, 2005, GEN THORACIC SURG, V7, P425 Fell SC, 2009, GEN THORACIC SURG, V28, P425 Fernando HC, 2011, ANN THORAC SURG, V92, P1144, DOI 10.1016/j.athoracsur.2011.06.104 Fischel RJ, 1998, ANN THORAC SURG, V65, P217, DOI 10.1016/S0003-4975(97)01189-2 Gómez-Caro A, 2007, EUR J CARDIO-THORAC, V31, P203, DOI 10.1016/j.ejcts.2006.11.030 Harpole DH Jr, 1999, J THORAC CARDIOV SUR, V117, P969, DOI 10.1016/S0022-5223(99)70378-8 Hazelrigg SR, 1997, ANN THORAC SURG, V63, P1573, DOI 10.1016/S0003-4975(97)00126-4 Itoh E, 2000, J BIOMED MATER RES, V53, P640, DOI 10.1002/1097-4636(2000)53:6<640::AID-JBM4>3.3.CO;2-C Jones JM, 2003, J THORAC CARDIOV SUR, V126, P303, DOI 10.1016/S0022-5223(03)00119-3 KELLY PJ, 1993, ANN OTO RHINOL LARYN, V102, P743 Kutlu CA, 2003, THORAC CARDIOV SURG, V51, P342 Kutlu CA, 2006, EUR J CARDIO-THORAC, V30, P943, DOI 10.1016/j.ejcts.2006.09.015 Luketich JD, 2005, ANN THORAC SURG, V79, P1845, DOI 10.1016/j.athoracsur.2004.10.055 Malapert G, 2010, ANN THORAC SURG, V90, P1779, DOI 10.1016/j.athoracsur.2010.07.033 Mom T, 2001, J THORAC CARDIOV SUR, V121, P642, DOI 10.1067/mtc.2001.112533 Nakagawa M, 2001, CHEST, V120, P705, DOI 10.1378/chest.120.3.705 Nomori H, 2001, ANN THORAC SURG, V72, P879, DOI 10.1016/S0003-4975(01)02891-0 Penn R., 2005, GEN THORACIC SURG, V9, P566 Riber LP, 2014, ANN THORAC SURG, V98, P1989, DOI 10.1016/j.athoracsur.2014.06.069 Rice T W., 1992, Chest Surg North Am, V2, P802, DOI DOI 10.1016/S1052-3359(25)00105-X Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Rosen JE, 2014, ANN THORAC SURG, V98, P1953, DOI 10.1016/j.athoracsur.2014.07.007 Sakai M, 2014, ANN THORAC SURG, V98, pE119, DOI 10.1016/j.athoracsur.2014.07.080 SCHAMAUN M, 1994, THORAC CARDIOV SURG, V42, P116, DOI 10.1055/s-2007-1016469 Sedrakyan A, 2005, J THORAC CARDIOV SUR, V129, P997, DOI 10.1016/j.jtcvs.2004.07.042 Sirbu H, 1999, THORAC CARDIOV SURG, V47, P73, DOI 10.1055/s-2007-1013114 Stammberger U, 2000, ANN THORAC SURG, V70, P1820, DOI 10.1016/S0003-4975(00)01903-2 Tansley P, 2006, J THORAC CARDIOV SUR, V132, P105, DOI 10.1016/j.jtcvs.2006.02.022 Temes RT, 1998, ANN THORAC SURG, V65, P282, DOI 10.1016/S0003-4975(97)01268-X Uzzaman MM, 2014, ANN THORAC SURG, V97, P365, DOI 10.1016/j.athoracsur.2013.08.013 WARNER MA, 1984, ANESTHESIOLOGY, V60, P380, DOI 10.1097/00000542-198404000-00022 Ziarnik E, CHYLOTHORAX IN PRESS NR 49 TC 59 Z9 71 U1 0 U2 14 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1547-4127 J9 THORAC SURG CLIN JI Thorac. Surg. Clin. PD AUG PY 2015 VL 25 IS 3 BP 355 EP + DI 10.1016/j.thorsurg.2015.04.003 PG 11 WC Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System; Surgery GA CP4ZM UT WOS:000359891100014 PM 26210931 DA 2026-04-17 ER PT J AU Kocher, F Fiegl, M Mian, M Hilbe, W AF Kocher, Florian Fiegl, Michael Mian, Michael Hilbe, Wolfgang TI Cardiovascular Comorbidities and Events in NSCLC: Often Underestimated but Worth Considering SO CLINICAL LUNG CANCER LA English DT Article DE Cardiovascular comorbidities; Cardiovascular events; NSCLC; Outcome; Risk factors ID CELL LUNG-CANCER; UNITED-STATES; RISK-FACTORS; TESTICULAR CANCER; DISEASE; PREVALENCE; TRENDS; IMPROVEMENT; DOCETAXEL; MORTALITY AB Patients with non-small-cell lung cancer (NSCLC) and cardiovascular (CV) disease often share a comparable demographic profile. This retrospective analysis of CV comorbidities, risk factors, CV events, and outcome in a large consecutive NSCLC cohort found that preexisting CV comorbidities and development of CV events are frequently observed in NSCLC patients. For recommendations on impact, prevention, and screening of CV disease in NSCLC, prospective trials are warranted. Introduction: Patients with non-small-cell lung cancer (NSCLC) and cardiovascular (CV) disease often share a comparable demographic profile. The aim of this analysis was to assess the significance and prevalence of preexisting CV comorbidity and events in NSCLC. Patients and Methods: A total of 715 consecutive NSCLC patients diagnosed between 2004 and 2009 at the Medical University of Innsbruck were retrospectively assessed regarding CV comorbidities, risk factors, cancer treatment, CV events occurring after the start of treatment, and outcome. Results: At least one CV comorbidity was present in 462 (67.2%) of 687 evaluable patients. CV events were documented in 68 patients (9.5%), with conduction disorders being the most prevalent (n = 19), followed by cardiomyopathy (n = 13), myocardial infarction (n = 13), sudden CV death (n = 12), need of revascularization (n = 6), and pericardial effusion (n = 5). Median time between diagnosis of NSCLC and CV event was 13.9 months. CV comorbidities and events both showed a direct correlation with increasing age, affecting up to 87.3% and 35.2% of all octogenarians in the study, respectively. The following CV comorbidities were significantly associated with CV events: atrial fibrillation, myocardial infarction, and cardiomyopathy. Overall survival was not reduced in patients experiencing a CV event compared to patients without an event. Conclusion: CV disease and events are frequently observed in NSCLC patients. To provide definitive recommendations on impact, prevention, and screening of CV disease in NSCLC, prospective trials are desirable. (C) 2015 Elsevier Inc. All rights reserved. C1 [Kocher, Florian; Fiegl, Michael; Mian, Michael; Hilbe, Wolfgang] Med Univ Innsbruck, Dept Internal Med 5, Hematol & Oncol, A-6020 Innsbruck, Austria. [Kocher, Florian] Tyrolean Canc Res Inst, Innsbruck, Austria. [Mian, Michael] Hosp Bolzano, Dept Hematol, Bolzano, Italy. [Mian, Michael] Hosp Bolzano, CBMT, Bolzano, Italy. [Hilbe, Wolfgang] Wilhelminenspital Wien, Dept Internal Med 1, Hematol & Oncol, Vienna, Austria. C3 Medical University of Innsbruck; Krankenhaus Bozen; Krankenhaus Bozen; Wilhelminenspital RP Kocher, F (corresponding author), Med Univ Innsbruck, Dept Internal Med 5, Anichstr 35, A-6020 Innsbruck, Austria. EM florian.kocher@i-med.ac.at FU "Verein fur Tumorforschung" (Innsbruck, Austria) FX The authors wish to thank Gabriela Kocher for her editorial support. The study was supported by the "Verein fur Tumorforschung" (A-6020 Innsbruck, Austria). CR Arciero TJ, 2004, AM J MED, V117, P228, DOI 10.1016/j.amjmed.2004.04.008 Brambilla E, 2014, WORLD CANC REPORT D'Agostino RB, 2008, CIRCULATION, V117, P743, DOI 10.1161/CIRCULATIONAHA.107.699579 Driver JA, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2467 Early Breast Canc Trialists Collaborat, 2000, LANCET, V355, P1757, DOI 10.1016/S0140-6736(00)02263-7 Egan BM, 2010, JAMA-J AM MED ASSOC, V303, P2043, DOI 10.1001/jama.2010.650 Ergin A, 2004, AM J MED, V117, P219, DOI 10.1016/j.amjmed.2004.03.017 Fiegl M, 2014, LUNG CANCER, V84, P168, DOI 10.1016/j.lungcan.2014.02.005 FOSSELLA FV, 1994, J CLIN ONCOL, V12, P1238, DOI 10.1200/JCO.1994.12.6.1238 Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370 Haugnes HS, 2010, J CLIN ONCOL, V28, P4649, DOI 10.1200/JCO.2010.29.9362 JONES JM, 1989, CLIN RADIOL, V40, P204, DOI 10.1016/S0009-9260(89)80099-6 Kocher F, MEMO MAGAZINE EUR S1, V7, P8 Laslett LJ, 2012, J AM COLL CARDIOL, V60, pS1, DOI 10.1016/j.jacc.2012.11.002 Lokke A, 2006, THORAX, V61, P935, DOI 10.1136/thx.2006.062802 Pircher A, 2013, ANTICANCER RES, V33, P3831 Roger VL, 2012, CIRCULATION, V125, P188, DOI 10.1161/CIR.0b013e3182456d46 ROWINSKY EK, 1991, J CLIN ONCOL, V9, P1704, DOI 10.1200/JCO.1991.9.9.1704 Selvin E, 2004, CIRCULATION, V110, P738, DOI 10.1161/01.CIR.0000137913.26087.F0 Selvin E, 2014, ANN INTERN MED, V160, P517, DOI 10.7326/M13-2411 Sterlacci W, 2012, EXP GERONTOL, V47, P237, DOI 10.1016/j.exger.2011.12.008 Strumberg D, 2002, ANN ONCOL, V13, P229, DOI 10.1093/annonc/mdf058 NR 22 TC 15 Z9 16 U1 0 U2 1 PU CIG MEDIA GROUP, LP PI DALLAS PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA SN 1525-7304 EI 1938-0690 J9 CLIN LUNG CANCER JI Clin. Lung Cancer PD JUL PY 2015 VL 16 IS 4 BP 305 EP 312 DI 10.1016/j.cllc.2014.12.007 PG 8 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA CJ7IH UT WOS:000355667800008 PM 25659438 DA 2026-04-17 ER PT J AU Levy, JF Meek, PD Rosenberg, MA AF Levy, Joseph F. Meek, Patrick D. Rosenberg, Marjorie A. TI US-Based Drug Cost Parameter Estimation for Economic Evaluations SO MEDICAL DECISION MAKING LA English DT Article DE cost effectiveness analysis; drug costs; health technology assessment; sensitivity analysis ID CELL LUNG-CANCER; ZOLEDRONIC ACID; BONE METASTASES; BREAST-CANCER; ATRIAL-FIBRILLATION; STROKE PREVENTION; PAYER PERSPECTIVE; UNITED-STATES; MYELODYSPLASTIC SYNDROMES; EFFECTIVENESS MODEL AB Introduction. In the United States, more than 10% of national health expenditures are for prescription drugs. Assessing drug costs in US economic evaluation studies is not consistent, as the true acquisition cost of a drug is not known by decision modelers. Current US practice focuses on identifying one reasonable drug cost and imposing some distributional assumption to assess uncertainty. Methods. We propose a set of Rules based on current pharmacy practice that account for the heterogeneity of drug product costs. The set of products derived from our Rules, and their associated costs, form an empirical distribution that can be used for more realistic sensitivity analyses and create transparency in drug cost parameter computation. The Rules specify an algorithmic process to select clinically equivalent drug products that reduce pill burden, use an appropriate package size, and assume uniform weighting of substitutable products. Three diverse examples show derived empirical distributions and are compared with previously reported cost estimates. Results. The shapes of the empirical distributions among the 3 drugs differ dramatically, including multiple modes and different variation. Previously published estimates differed from the means of the empirical distributions. Published ranges for sensitivity analyses did not cover the ranges of the empirical distributions. In one example using lisinopril, the empirical mean cost of substitutable products was $444 (range = $23-$953) as compared with a published estimate of $305 (range = $51-$523). Conclusions. Our Rules create a simple and transparent approach to creating cost estimates of drug products and assessing their variability. The approach is easily modified to include a subset of, or different weighting for, substitutable products. The derived empirical distribution is easily incorporated into 1-way or probabilistic sensitivity analyses. C1 [Levy, Joseph F.] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI 53726 USA. [Meek, Patrick D.] Albany Coll Pharm & Hlth Sci, Dept Pharm, Res Inst Hlth Outcomes, Albany, NY USA. [Rosenberg, Marjorie A.] Univ Wisconsin, Dept Actuarial Sci Risk Management & Insurance, Madison, WI 53726 USA. [Rosenberg, Marjorie A.] Dept Biostat & Med Informat, Madison, WI USA. C3 University of Wisconsin System; University of Wisconsin Madison; Albany College of Pharmacy & Health Sciences; University of Wisconsin System; University of Wisconsin Madison RP Levy, JF (corresponding author), Univ Wisconsin, 610 North Walnut St,WARF Off 753, Madison, WI 53726 USA. EM jflevy@wisc.edu OI Levy, Joseph/0000-0002-9317-5306 FU Clinical and Translational Science Award (CTSA) program of the National Center for Research Resources [1UL1RR025011]; National Institute of Mental Health [T32 MH18029] FX Financial support for this study was provided in part by grants from the Clinical and Translational Science Award (CTSA) program of the National Center for Research Resources 1UL1RR025011 (to Dr. Rosenberg) and the National Institute of Mental Health T32 MH18029 (to Mr. Levy). The funding agreement ensured the authors' independence in designing the study, interpreting the data, writing, and publishing the report. CR Ayvaci MUS, 2013, MED DECIS MAKING, V33, P521, DOI 10.1177/0272989X12470755 Briggs AH, 2012, MED DECIS MAKING, V32, P722, DOI 10.1177/0272989X12458348 Briggs Briggs A A, DECISION MODELLING H Brogan A, 2010, PHARMACOECONOMICS, V28, P129, DOI 10.2165/11587490-000000000-00000 Casciano Roman, 2012, J Med Econ, V15 Suppl 1, P55, DOI 10.3111/13696998.2012.720319 Center for Drug Evaluation and Research Food and Drug Administration, 2014, APPL NUMB 125469ORIG Claxton K, 2005, HEALTH ECON, V14, P339, DOI 10.1002/hec.985 Coleman CI, 2012, AM J CARDIOL, V109, P1020, DOI 10.1016/j.amjcard.2011.11.034 Collier R, 2012, CAN MED ASSOC J, V184, pE117, DOI 10.1503/cmaj.109-4076 Curtiss FR, 2010, J MANAGE CARE PHARM, V16, P492, DOI 10.18553/jmcp.2010.16.7.492 Dorian P, 2014, EUR HEART J, V35, P1897, DOI 10.1093/eurheartj/ehu006 Garrison LP, 2010, VALUE HEALTH, V13, P8, DOI 10.1111/j.1524-4733.2009.00660.x Gencarelli Dawn M, 2002, NHPF Issue Brief, P1 Gidwani Risha, 2012, J Med Econ, V15, P145, DOI 10.3111/13696998.2011.631067 Goulart B, 2011, VALUE HEALTH, V14, P836, DOI 10.1016/j.jval.2011.04.004 Hagan LM, 2013, J VIRAL HEPATITIS, V20, P847, DOI 10.1111/jvh.12111 Harrington AR, 2013, STROKE, V44, P1676, DOI 10.1161/STROKEAHA.111.000402 Hauber AB, 2013, PATIENT PREFER ADHER, V7, P937, DOI 10.2147/PPA.S43465 Hay JW, 2010, VALUE HEALTH, V13, P3, DOI 10.1111/j.1524-4733.2009.00663.x Hayes CS, 2001, AM FAM PHYSICIAN, V63, P1557 Hiligsmann M, 2010, BONE, V47, P34, DOI 10.1016/j.bone.2010.03.009 Kim AS, 2011, STROKE, V42, P2013, DOI 10.1161/STROKEAHA.110.606889 Kymes SM, 2012, AM J MANAG CARE, V18, P33 Laskin BL, 2013, AM J KIDNEY DIS, V61, P22, DOI 10.1053/j.ajkd.2012.06.004 Lathia N, 2013, JNCI-J NATL CANCER I, V105, P1078, DOI 10.1093/jnci/djt182 Lazenby GB, 2012, J LOW GENIT TRACT DI, V16, P275, DOI 10.1097/LGT.0b013e31823cde2f Lee S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047473 Lewis G, 2010, J INT MED RES, V38, P9, DOI 10.1177/147323001003800102 Lidgren M, 2008, ANN ONCOL, V19, P487, DOI 10.1093/annonc/mdm488 Liew D, 2013, CLIN THER, V35, P1110, DOI 10.1016/j.clinthera.2013.06.015 Mauskopf J, 2012, AIDS, V26, P355, DOI 10.1097/QAD.0b013e32834e87e6 Mauskopf J, 2010, PHARMACOECONOMICS, V28, P83, DOI 10.2165/11587470-000000000-00000 Miller SM, 2011, AM J GASTROENTEROL, V106, P1439, DOI 10.1038/ajg.2011.94 Newman Matthew J, 2012, J Oncol Pharm Pract, V18, P394, DOI 10.1177/1078155212438253 Nuijten M, 2009, CURR MED RES OPIN, V25, P1221, DOI 10.1185/03007990902844097 Ofman JJ, 1999, AM J MED, V107, P219, DOI 10.1016/S0002-9343(99)00219-3 Pan F, 2012, CLIN THER, V34, P1966, DOI 10.1016/j.clinthera.2012.07.010 Pan F, 2010, CLIN THER, V32, P2444, DOI 10.1016/j.clinthera.2010.12.003 Park H, 2011, VALUE HEALTH, V14, P1002, DOI 10.1016/j.jval.2011.05.043 Patel JJ, 2012, J EVAL CLIN PRACT, V18, P247, DOI 10.1111/j.1365-2753.2010.01546.x Rosen AB, 2005, ANN INTERN MED, V143, P89, DOI 10.7326/0003-4819-143-2-200507190-00007 Sikirica Vanja, 2012, Pharmacoeconomics, V30, pe1, DOI 10.2165/11632920-000000000-00000 Smith KJ, 2013, AM J MANAG CARE, V19, pE55 Snedecor Sonya J, 2013, J Med Econ, V16, P19, DOI 10.3111/13696998.2012.719054 Snedecor SJ, 2012, CLIN THER, V34, P1334, DOI 10.1016/j.clinthera.2012.04.008 Stopeck Alison, 2012, J Med Econ, V15, P712, DOI 10.3111/13696998.2012.675380 Wielage RC, 2013, APPL HEALTH ECON HEA, V11, P219, DOI 10.1007/s40258-013-0031-3 Wielage RC, 2013, VALUE HEALTH, V16, P334, DOI 10.1016/j.jval.2012.12.006 Willke RJ, 2010, VALUE HEALTH, V13, P1, DOI 10.1111/j.1524-4733.2009.00673.x Wong YN, 2009, CANCER-AM CANCER SOC, V115, P2081, DOI 10.1002/cncr.24246 Woodward TC, 2010, PHARMACOECONOMICS, V28, P751, DOI 10.2165/11538350-000000000-00000 Xie JP, 2012, CLIN BREAST CANCER, V12, P247, DOI 10.1016/j.clbc.2012.04.001 Xie JP, 2011, J MANAGE CARE PHARM, V17, P621, DOI 10.18553/jmcp.2011.17.8.621 Zodet MW, 2012, 12004 AG HEALTHC RES NR 54 TC 6 Z9 8 U1 0 U2 8 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0272-989X EI 1552-681X J9 MED DECIS MAKING JI Med. Decis. Mak. PD JUL PY 2015 VL 35 IS 5 BP 622 EP 632 DI 10.1177/0272989X14563987 PG 11 WC Health Care Sciences & Services; Health Policy & Services; Medical Informatics WE Science Citation Index Expanded (SCI-EXPANDED) SC Health Care Sciences & Services; Medical Informatics GA CK7RZ UT WOS:000356431100007 PM 25532826 OA Green Submitted DA 2026-04-17 ER PT J AU Papiashvili, M Deviri, E Bar, I Sasson, L AF Papiashvili, Michael Deviri, Ehud Bar, Ilan Sasson, Lior TI Lobectomy for Non-Small Cell Lung Cancer after Coronary Artery Bypass Grafting Surgery SO ISRAEL MEDICAL ASSOCIATION JOURNAL LA English DT Article DE lung cancer; coronary artery bypass grafting (CABG); thoracoscopic lobectomy; left internal mammary artery (LIMA); thoracotomy; lobectomy ID THORACOSCOPIC LOBECTOMY; PRESERVATION; THORACOTOMY AB Background: The efficacy of video-assisted thoracoscopic surgery lobectomy in patients with previous coronary artery bypass grafting (CABG) surgery is controversial. Objectives: To investigate whether skeletonized left internal mammary artery (LIMA) mobilization contributes to the development of severe adhesions, which will affect what type of lung surgery (open or closed procedure) will be required in the future. Methods: Eight patients (mean age 73.9 years) with previous CABG surgery using a LIMA to left anterior descending (LAD) graft underwent left-sided lobectomy for operable non-small cell lung carcinoma. Results: The lobectomy by thoracotomy rate was 62.5% (5 patients), generally in patients with tumors in the left upper lobe or in patients post-neoadjuvant chemotherapy, while the video-assisted thoracic surgery lobectomy rate was 37.5% (3 patients). Mean hospital stay was 8.3 days. There was no mortality or major morbidity, apart from six minor complications in four patients (50%) (air leak, atrial fibrillation, atelectasis, pneumonia). Conclusions: Patients with operable non-small cell lung carcinoma following CABG surgery who need left upper lobe resection do not benefit from the video-assisted thoracoscopic surgery technique due to significant adhesions between the LIMA to LAD graft and the lung. The method of preserving a small portion of the lung on the LIMA to LAD graft may help during left upper lobe resections. Adhesions in the left pleural space after LIMA mobilization appear to minimally affect left lower lobe video-assisted thoracoscopic surgery. C1 [Papiashvili, Michael; Deviri, Ehud] Assaf Harofeh Med Ctr, Dept Gen Thorac Surg, IL-70300 Zerifin, Israel. [Papiashvili, Michael; Deviri, Ehud; Sasson, Lior] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel. [Bar, Ilan] Kaplan Med Ctr, Dept Cardiothorac Surg, Rehovot, Israel. [Bar, Ilan] Hebrew Univ Jerusalem, Hadassah Med Sch, Jerusalem, Israel. [Sasson, Lior] Wolfson Med Ctr, Dept Cardiothorac Surg, Holon, Israel. C3 Tel Aviv University; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem; Kaplan Medical Center; Hebrew University of Jerusalem; Tel Aviv University RP Papiashvili, M (corresponding author), Assaf Harofeh Med Ctr, Dept Gen Thorac Surg, IL-70300 Zerifin, Israel. EM michaelp@asaf.health.gov.il CR [Anonymous], 2009, SABISTON SPENCER SUR Brambilla E, 2001, EUR RESPIR J, V18, P1059, DOI 10.1183/09031936.01.00275301 Gazala S, 2011, INTERACT CARDIOV TH, V12, P962, DOI 10.1510/icvts.2010.259663 Gharagozloo F, 2003, ANN THORAC SURG, V76, P1009, DOI 10.1016/S0003-4975(03)00267-4 Halkos ME, 2003, ANN THORAC SURG, V76, P280, DOI 10.1016/S0003-4975(02)04962-7 Ilonen IK, 2011, ACTA ONCOL, V50, P1126, DOI 10.3109/0284186X.2011.555780 Lardinois D, 2006, EUR J CARDIO-THORAC, V30, P787, DOI 10.1016/j.ejcts.2006.08.008 McKenna RJ, 2006, ANN THORAC SURG, V81, P421, DOI 10.1016/j.athoracsur.2005.07.078 McKenna RJ, 2003, ANN THORAC SURG, V76, P1014 Nomori H, 2001, ANN THORAC SURG, V72, P879, DOI 10.1016/S0003-4975(01)02891-0 Paul S, 2010, J THORAC CARDIOV SUR, V139, P366, DOI 10.1016/j.jtcvs.2009.08.026 Santini M, 2008, J THORAC CARDIOV SUR, V136, P222, DOI 10.1016/j.jtcvs.2007.12.049 Scott WJ, 2010, J THORAC CARDIOV SUR, V139, P976, DOI 10.1016/j.jtcvs.2009.11.059 Singhatanadgige Seri, 2006, Journal of the Medical Association of Thailand, V89, P887 Walker WS, 2003, EUR J CARDIO-THORAC, V23, P397, DOI 10.1016/S1010-7940(02)00814-X Whitson BA, 2007, ANN THORAC SURG, V83, P1965, DOI 10.1016/j.athoracsur.2007.01.049 Yan TD, 2009, J CLIN ONCOL, V27, P2553, DOI 10.1200/JCO.2008.18.2733 NR 17 TC 2 Z9 2 U1 0 U2 2 PU ISRAEL MEDICAL ASSOC JOURNAL PI RAMAT GAN PA 2 TWIN TOWERS, 11TH FL, 35 JABOTINSKY ST, PO BOX 3604, RAMAT GAN 52136, ISRAEL SN 1565-1088 J9 ISR MED ASSOC J JI Isr. Med. Assoc. J. PD JUL PY 2015 VL 17 IS 7 BP 430 EP 432 PG 3 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA CO9RZ UT WOS:000359514800008 PM 26357719 DA 2026-04-17 ER PT J AU Sandri, A Papagiannopoulos, K Milton, R Kefaloyannis, E Chaudhuri, N Poyser, E Spencer, N Brunelli, A AF Sandri, Alberto Papagiannopoulos, Kostas Milton, Richard Kefaloyannis, Emmanuel Chaudhuri, Nilanjan Poyser, Emily Spencer, Nicholas Brunelli, Alessandro TI Major morbidity after video-assisted thoracic surgery lung resections: a comparison between the European Society of Thoracic Surgeons definition and the Thoracic Morbidity and Mortality system SO JOURNAL OF THORACIC DISEASE LA English DT Article DE High-risk patients; video assisted thoracoscopic surgery (VATS) lobectomy; lung cancer; complications ID ED AMERICAN-COLLEGE; THORACOSCOPIC LOBECTOMY; CANCER; CLASSIFICATION; THORACOTOMY; MANAGEMENT; DIAGNOSIS; SCORE AB Background: The thoracic morbidity and mortality (TM&M) classification system univocally encodes the postoperative adverse events by their management complexity. This study aims to compare the distribution of the severity of complications according to the TM&M system versus the distribution according to the classification proposed by European Society of Thoracic Surgeons (ESTS) Database in a population of patients submitted to video assisted thoracoscopic surgery (VATS) lung resection. Methods: A total of 227 consecutive patients submitted to VATS lobectomy for lung cancer were analyzed. Any complication developed postoperatively was graded from I to V according to the TM&M system, reflecting the increasing severity of its management. We verified the distribution of the different grades of complications and analyzed their frequency among those defined as "major cardiopulmonary complications" by the ESTS Database. Results: Following the ESTS definitions, 20 were the major cardiopulmonary complications [atrial fibrillation (AF): 10, 50%; adult respiratory distress syndrome (ARDS): 1, 5%; pulmonary embolism: 2, 10%; mechanical ventilation >24 h: 1, 5%; pneumonia: 3, 15%; myocardial infarct: 1, 5%; atelectasis requiring bronchoscopy: 2, 10%] of which 9 (45%) were reclassified as minor complications (grade II) by the TM&M classification system. According to the TM&M system, 10/34 (29.4%) of all complications were considered minor (grade I or II) while 21/34 (71.4%) as major (IIIa: 8, 23.5%; IIIb: 4, 11.7%; IVa: 8, 23.5%; IVb: 1, 2.9%; V: 3, 8.8%). Other 14 surgical complications occurred and were classified as major complications according to the TM& M system. Conclusions: The distribution of postoperative complications differs between the two classification systems. The TM& M grading system questions the traditional classification of major complications following VATS lung resection and may be used as an additional endpoint for outcome analyses. C1 [Sandri, Alberto; Papagiannopoulos, Kostas; Milton, Richard; Kefaloyannis, Emmanuel; Chaudhuri, Nilanjan; Poyser, Emily; Spencer, Nicholas; Brunelli, Alessandro] St James Univ Hosp, Dept Thorac Surg, Leeds LS9 7TF, W Yorkshire, England. C3 Saint James's University Hospital RP Sandri, A (corresponding author), St James Univ Hosp, Dept Thorac Surg, Great George St, Leeds LS9 7TF, W Yorkshire, England. EM sandri.alberto@gmail.com RI Brunelli, Alessandro/AAV-1415-2020; Sani, Alberto/K-6851-2019 OI Brunelli, Alessandro/0000-0002-6505-1656; Papagiannopoulos, Konstantinos/0000-0002-7088-8004; Sani, Alberto/0000-0001-6421-2270 CR Bruce J, 2001, Health Technol Assess, V5, P1 Brunelli A, 2010, Eur J Surg Oncol, V36 Suppl 1, pS93, DOI 10.1016/j.ejso.2010.06.023 Brunelli A, 2013, CHEST, V143, pE166, DOI 10.1378/chest.12-2395 Brunelli A, 2009, EUR J CARDIO-THORAC, V35, P769, DOI 10.1016/j.ejcts.2009.01.037 Burt BM, 2014, J THORAC CARDIOVASC, V148, p[e1, 28] Burt BM, 2014, J THORAC CARDIOV SUR, V148, P19, DOI 10.1016/j.jtcvs.2014.03.007 Cao C, 2013, INTERACT CARDIOV TH, V16, P244, DOI 10.1093/icvts/ivs472 Detterbeck FC, 2013, CHEST, V143, p7S, DOI 10.1378/chest.12-2377 Dindo D, 2004, ANN SURG, V240, P205, DOI [10.17116/hirurgia2018090162, 10.1097/01.sla.0000133083.54934.ae] Downey RJ, 2007, INNOVATIONS, V2, P293, DOI 10.1097/IMI.0b013e3181662c7f Ivanovic J, 2011, ANN THORAC SURG, V91, P387, DOI 10.1016/j.athoracsur.2010.10.035 McKenna RJ, 2006, ANN THORAC SURG, V81, P421, DOI 10.1016/j.athoracsur.2005.07.078 Paul S, 2010, J THORAC CARDIOV SUR, V139, P366, DOI 10.1016/j.jtcvs.2009.08.026 Salati M, 2013, J THORAC DIS, V5, P217, DOI 10.3978/j.issn.2072-1439.2013.05.03 Seely AJE, 2010, ANN THORAC SURG, V90, P936, DOI 10.1016/j.athoracsur.2010.05.014 Solaini L, 2008, SURG ENDOSC, V22, P298, DOI 10.1007/s00464-007-9586-0 Varela G, 2011, ARCH BRONCONEUMOL, V47, P581, DOI 10.1016/j.arbres.2011.05.009 Whitson BA, 2008, ANN THORAC SURG, V86, P2008, DOI 10.1016/j.athoracsur.2008.07.009 NR 18 TC 25 Z9 31 U1 0 U2 3 PU AME PUBLISHING COMPANY PI SHATIN PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA SN 2072-1439 EI 2077-6624 J9 J THORAC DIS JI J. Thorac. Dis. PD JUL PY 2015 VL 7 IS 7 BP 1174 EP 1180 DI 10.3978/j.issn.2072-1439.2015.06.07 PG 7 WC Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System GA CR0LG UT WOS:000361009500030 PM 26380733 DA 2026-04-17 ER PT J AU Velez-Cubian, FO Ng, EP Fontaine, JP Toloza, EM AF Velez-Cubian, Frank O. Ng, Emily P. Fontaine, Jacques P. Toloza, Eric M. TI Robotic-Assisted Videothoracoscopic Surgery of the Lung SO CANCER CONTROL LA English DT Article ID CLINICAL-PRACTICE GUIDELINES; MINIMALLY INVASIVE SURGERY; ED AMERICAN-COLLEGE; THORACOSCOPIC LOBECTOMY; THORACIC-SURGERY; PULMONARY RESECTION; NATIONAL DATABASE; CANCER DIAGNOSIS; LEARNING-CURVE; STAGE-I AB Background: Despite initial concerns about the general safety of videothoracoscopic surgery, minimally invasive videothoracoscopic surgical procedures have advantages over traditional open thoracic surgery via thoracotomy. Robotic-assisted minimally invasive surgery has expanded to almost every surgical specialty, including thoracic surgery. Adding a robotic-assisted surgical system to a videothoracoscopic surgical procedure corrects several shortcomings of videothoracoscopic surgical cameras and instruments. Methods: We performed a literature search on robotic-assisted pulmonary resections and compared the published robotic series data with our experience at the H. Lee Moffitt Cancer Center & Research Institute. All perioperative outcomes, such as intraoperative data, postoperative complications, chest tube duration, hospital length of stay (LOS), and in-hospital mortality rates were noted. Results: Our literature search found 23 series from multiple surgical centers. We divided the literature into 2 groups based on the year published (2005-2010 and 2011-2014). Operative times from earlier studies ranged from 150 to 240 minutes compared with 90 to 242 minutes for later studies. Conversion rates (to open lung resection) from the earlier studies ranged from 0% to 19% compared with 0% to 11% in the later studies. Mortality rates for the earlier studies ranged from 0% to 5% compared with 0% to 2% for the later studies. Since 2010, our group has performed more than 600 robotic-assisted thoracic surgical procedures, including more than 200 robotic-assisted pulmonary lobectomies, which we also divided into 2 groups. Our median skin-to-skin operative time improved from 179 minutes for our early group (n =104) to 172 minutes for our later group (n =104). The overall conversion rate was 9.6% and the emergent conversion rate (for bleeding) was 5% for our robotic-assisted lobectomies. The most common postoperative complications in our cohort were prolonged air leak (> 7 days; 168%) and atrial fibrillation (12%). Hospital LOS for the early series ranged from 3 to 11 days compared with 2 to 6 days for the later series. Median hospital LOS decreased from 6 to 4 days. Our mortality rate was 1.4%; 3 in-hospital deaths occurred in the early 40 cases. Mediastinal lymph node (LN) dissection and detection of occult mediastinal LN metastases were improved during robotic-assisted lobectomy for non-small-cell lung cancer, as demonstrated by an overall 30% upstaging rate, including a 19% nodal upstaging rate, in our cohort. Conclusions: Robotic-assisted videothoracoscopic pulmonary lobectomy appears to be as safe as conventional videothoracoscopic surgical lobectomy, which has decreased perioperative complications and a shorter hospital LOS than open lobectomy. Both mediastinal LN dissection and the early detection of occult mediastinal LN metastatic disease were improved by robotic-assisted videothoracoscopic surgical compared with conventional videothoracoscopic surgical or open thoradotomy. C1 [Velez-Cubian, Frank O.; Fontaine, Jacques P.; Toloza, Eric M.] Univ S Florida, Dept Surg, Morsani Coll Med, Tampa, FL 33620 USA. [Fontaine, Jacques P.; Toloza, Eric M.] Univ S Florida, Dept Oncol Sci, Morsani Coll Med, Tampa, FL USA. [Ng, Emily P.] Univ S Florida, Morsani Coll Med, Tampa, FL USA. [Fontaine, Jacques P.; Toloza, Eric M.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, Tampa, FL 33612 USA. C3 State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute RP Toloza, EM (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr, Tampa, FL 33612 USA. EM Eric.Toloza@Moffitt.org CR Aberle DR, 2011, NEW ENGL J MED, V365, P395, DOI 10.1056/NEJMoa1102873 Adams RD, 2014, ANN THORAC SURG, V97, P1893, DOI 10.1016/j.athoracsur.2014.02.043 Anderson CA, 2007, INNOVATIONS, V2, P254, DOI 10.1097/IMI.0b013e31815e52f1 [Anonymous], 2011, CURR PROB SURG, V48, P577, DOI 10.1067/j.cpsurg.2011.05.002 [Anonymous], 2015, CANC FACTS FIG 2015 Augustin F, 2011, SURG ENDOSC, V25, P108, DOI 10.1007/s00464-010-1138-3 Boffa DJ, 2012, ANN THORAC SURG, V94, P347, DOI 10.1016/j.athoracsur.2012.04.059 BOUTIN C, 1982, CHEST, V82, P44, DOI 10.1378/chest.82.1.44 Cao C, 2012, ANN CARDIOTHORAC SUR, V1, P3, DOI 10.3978/j.issn.2225-319X.2012.04.03 Ceppa DP, 2012, ANN SURG, V256, P487, DOI 10.1097/SLA.0b013e318265819c Cerfolio RJ, 2012, TEX HEART I J, V39, P848 Cerfolio RJ, 2012, ANN THORAC SURG, V94, P1744, DOI 10.1016/j.athoracsur.2012.05.132 Cerfolio RJ, 2011, J THORAC CARDIOV SUR, V142, P740, DOI 10.1016/j.jtcvs.2011.07.022 Choi Min Suk, 2011, Korean J Thorac Cardiovasc Surg, V44, P169, DOI 10.5090/kjtcs.2011.44.2.169 D'Amico TA, 2011, ANN THORAC SURG, V92, P226, DOI 10.1016/j.athoracsur.2011.03.134 Darling GE, 2011, J THORAC CARDIOV SUR, V141, P662, DOI 10.1016/j.jtcvs.2010.11.008 Deen SA, 2014, ANN THORAC SURG, V97, P1000, DOI 10.1016/j.athoracsur.2013.11.021 Demmy TL, 2008, ANN THORAC SURG, V85, pS719, DOI 10.1016/j.athoracsur.2007.09.056 Denlinger CE, 2010, ANN THORAC SURG, V89, P1730, DOI 10.1016/j.athoracsur.2010.02.094 Dylewski MR, 2012, CHINESE J CANCER RES, V24, P259, DOI [10.3978/j.issn.1000-9604.2012.10.05, 10.1007/s11670-012-0261-1] Dylewski MR, 2011, SEMIN THORAC CARDIOV, V23, P36, DOI 10.1053/j.semtcvs.2011.01.005 Flores RM, 2009, J THORAC CARDIOV SUR, V138, P11, DOI 10.1016/j.jtcvs.2009.03.030 Fortes DL, 2011, INNOVATIONS, V6, P237, DOI 10.1097/IMI.0b013e31822ca40c Gharagozloo F, 2008, ANN THORAC SURG, V85, P1880, DOI 10.1016/j.athoracsur.2008.02.085 Gharagozloo F, 2009, ANN THORAC SURG, V88, P380, DOI 10.1016/j.athoracsur.2009.04.039 Giulianotti PC, 2010, INTERACT CARDIOV TH, V11, P388, DOI 10.1510/icvts.2010.239541 Goldstraw Peter, 2007, J Thorac Oncol, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a Handy JR, 2010, EUR J CARDIO-THORAC, V37, P451, DOI 10.1016/j.ejcts.2009.07.037 Howington JA, 2013, CHEST, V143, pE278, DOI 10.1378/chest.12-2359 Ichinose J, 2013, ANN THORAC SURG, V96, P1203, DOI 10.1016/j.athoracsur.2013.05.026 Jacobaeus HC, 1922, SURG GYNECOL OBSTET, V34, P289 Jang HJ, 2011, INNOVATIONS, V6, P305, DOI 10.1097/IMI.0b013e3182378b4c Kajiwara N, 2015, ANN THORAC CARDIOVAS, V21, P95, DOI 10.5761/atcs.oa.14-00076 Kent M, 2014, ANN THORAC SURG, V97, P236, DOI 10.1016/j.athoracsur.2013.07.117 Kernstine KH, 2004, AM J SURG, V188, p89S, DOI 10.1016/j.amjsurg.2004.08.002 Lardinois D, 2006, EUR J CARDIO-THORAC, V30, P787, DOI 10.1016/j.ejcts.2006.08.008 Lee BE, 2014, J THORAC CARDIOV SUR, V147, P724, DOI 10.1016/j.jtcvs.2013.10.002 LEWIS RJ, 1992, ANN THORAC SURG, V54, P80, DOI 10.1016/0003-4975(92)91144-X Li HQ, 1996, AM J ROENTGENOL, V167, P105, DOI 10.2214/ajr.167.1.8659351 Louie BE, 2012, ANN THORAC SURG, V93, P1598, DOI 10.1016/j.athoracsur.2012.01.067 Marchetti GP, 2011, RESPIRATION, V82, P187, DOI 10.1159/000326066 Melfi FM, 2005, MULTIMED MAN CARDIOT, V2005 Melfi FMA, 2014, EUR J CARDIO-THORAC, V46, P626, DOI 10.1093/ejcts/ezu079 Melfi Franca M A, 2008, Thorac Surg Clin, V18, P289, DOI 10.1016/j.thorsurg.2008.06.001 Meyer M, 2012, INT J MED ROBOT COMP, V8, P448, DOI 10.1002/rcs.1455 Modlin IM, 2004, ARCH SURG-CHICAGO, V139, P1110, DOI 10.1001/archsurg.139.10.1110 Mohiuddin K, 2013, J SURG ONCOL, V108, P315, DOI 10.1002/jso.23398 Nasir BS, 2014, ANN THORAC SURG, V98, P203, DOI 10.1016/j.athoracsur.2014.02.051 National Cancer Institute, 2012, CANC TRENDS PROGR RE Ng ATL, 2014, HONG KONG MED J, V20, P241, DOI 10.12809/hkmj134167 Ninan M, 2010, EUR J CARDIO-THORAC, V38, P231, DOI 10.1016/j.ejcts.2010.01.047 Ohuchida K, 2013, CANCER J, V19, P130, DOI 10.1097/PPO.0b013e31828da251 Osarogiagbon RU, 2012, J THORAC ONCOL, V7, P390, DOI 10.1097/JTO.0b013e31823e5e2d Pardolesi A, 2012, ANN THORAC SURG, V94, P929, DOI 10.1016/j.athoracsur.2012.04.086 Park BJ, 2012, ANN CARDIOTHORAC SUR, V1, P56, DOI 10.3978/j.issn.2225-319X.2012.04.10 Park BJ, 2012, ANN CARDIOTHORAC SUR, V1, P24, DOI 10.3978/j.issn.2225-319X.2012.04.09 Park BJ, 2012, J THORAC CARDIOV SUR, V143, P383, DOI 10.1016/j.jtcvs.2011.10.055 Roviaro G, 1992, Surg Laparosc Endosc, V2, P244 Scott WJ, 2010, J THORAC CARDIOV SUR, V139, P976, DOI 10.1016/j.jtcvs.2009.11.059 Socinski MA, 2013, CHEST, V143, pE341, DOI 10.1378/chest.12-2361 Solaini L, 2008, SURG ENDOSC, V22, P298, DOI 10.1007/s00464-007-9586-0 Spaggiari L, 2011, ANN THORAC SURG, V91, pE45, DOI 10.1016/j.athoracsur.2010.12.008 Sugi K, 2000, WORLD J SURG, V24, P27, DOI 10.1007/s002689910006 Suzuki K, 1999, CHEST, V115, P563, DOI 10.1378/chest.115.2.563 Velez-Ciibian F, 2014, CHEST WORLD C 2014 A Velez-Cubian F, 2014, CHEST, V145, DOI 10.1378/chest.1836658 Veronesi G, 2011, INNOVATIONS, V6, P355, DOI 10.1097/IMI.0b013e3182490093 Veronesi G, 2010, J THORAC CARDIOV SUR, V140, P19, DOI 10.1016/j.jtcvs.2009.10.025 Villamizar NR, 2009, J THORAC CARDIOV SUR, V138, P419, DOI 10.1016/j.jtcvs.2009.04.026 WALKER WS, 1993, J THORAC CARDIOV SUR, V106, P1111, DOI 10.1016/S0022-5223(19)33986-8 Wei B, 2014, THORAC SURG CLIN, V24, P177, DOI 10.1016/j.thorsurg.2014.02.001 Wender R, 2013, CA-CANCER J CLIN, V63, P107, DOI 10.3322/caac.21172 Whitson BA, 2007, ANN THORAC SURG, V83, P1965, DOI 10.1016/j.athoracsur.2007.01.049 Wilson JL, 2014, ANN THORAC SURG, V97, P1901, DOI 10.1016/j.athoracsur.2014.01.064 Yan TD, 2009, J CLIN ONCOL, V27, P2553, DOI 10.1200/JCO.2008.18.2733 Zhao H, 2010, WORLD J SURG, V34, P2368, DOI 10.1007/s00268-010-0661-7 NR 76 TC 29 Z9 33 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1073-2748 J9 CANCER CONTROL JI Cancer Control PD JUL PY 2015 VL 22 IS 3 BP 314 EP 325 DI 10.1177/107327481502200309 PG 12 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA CR5ZI UT WOS:000361422500009 PM 26351887 OA Bronze DA 2026-04-17 ER PT J AU Nojiri, T Inoue, M Takeuchi, Y Maeda, H Shintani, Y Sawabata, N Hamasaki, T Okumura, M AF Nojiri, Takashi Inoue, Masayoshi Takeuchi, Yukiyasu Maeda, Hajime Shintani, Yasushi Sawabata, Noriyoshi Hamasaki, Toshimitsu Okumura, Meinoshin TI Impact of cardiopulmonary complications of lung cancer surgery on long-term outcomes SO SURGERY TODAY LA English DT Article DE Lung cancer surgery; Postoperative complications; Long-term outcome ID BRAIN NATRIURETIC PEPTIDE; VENTRICULAR DIASTOLIC DYSFUNCTION; PULMONARY-HYPERTENSION; ATRIAL-FIBRILLATION; HEART-FAILURE; COPD; PREDICTOR; RESECTION; MARKER; TRIAL AB Purpose The impact of postoperative cardiopulmonary complications on long-term outcomes has not been established. We investigated the effects of acute postoperative cardiopulmonary complications not only on cancer recurrence, but also on cardiovascular or respiratory events in the chronic phase after lung cancer surgery. Methods From a prospective single-institution database of 496 consecutive patients, who underwent lung cancer surgery between August, 2008 and December, 2011, medical records, including information about cardiovascular or respiratory events and cancer recurrence in the chronic phase (>6 months) after surgery, were analyzed retrospectively. Results were compared between patients with vs. those without postoperative cardiopulmonary complications in the acute phase. Results Postoperative cardiopulmonary complications were identified in 90 (20 %) patients. There were significantly more cardiovascular or respiratory events in the chronic phase after lung cancer surgery in the patients who had suffered postoperative cardiopulmonary complications in the acute phase than in those who had not (23 vs. 5 %; p < 0.0001). Conclusions Postoperative cardiopulmonary complications in the acute phase were associated with a higher incidence of cardiovascular or respiratory events in the chronic phase after lung cancer surgery. C1 [Nojiri, Takashi; Inoue, Masayoshi; Shintani, Yasushi; Sawabata, Noriyoshi; Okumura, Meinoshin] Osaka Univ, Grad Sch Med, Dept Gen Thorac Surg, Suita, Osaka 5650871, Japan. [Nojiri, Takashi] Natl Cerebral & Cardiovasc Ctr Res Inst, Dept Biochem, Suita, Osaka, Japan. [Takeuchi, Yukiyasu; Maeda, Hajime] Natl Hosp Org Toneyama Hosp, Dept Gen Thorac Surg, Toyonaka, Osaka, Japan. [Hamasaki, Toshimitsu] Osaka Univ, Grad Sch Med, Dept Biomed Stat, Suita, Osaka 5650871, Japan. C3 University of Osaka; National Cerebral & Cardiovascular Center - Japan; University of Osaka RP Nojiri, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Gen Thorac Surg, Yamadaoka 2-2,L5, Suita, Osaka 5650871, Japan. EM nojirit@thoracic.med.osaka-u.ac.jp RI Sawabata, Noriyoshi/AAJ-1025-2021; Hamasaki, Toshimitsu/N-3851-2015 OI Hamasaki, Toshimitsu/0000-0002-4928-1160 FU Grants-in-Aid for Scientific Research [25293301] Funding Source: KAKEN CR Allen MS, 2006, ANN THORAC SURG, V81, P1013, DOI 10.1016/j.athoracsur.2005.06.066 Barr RG, 2010, NEW ENGL J MED, V362, P217, DOI 10.1056/NEJMoa0808836 Birim Ö, 2006, J THORAC CARDIOV SUR, V132, P491, DOI 10.1016/j.jtcvs.2006.04.010 Boffa DJ, 2008, J THORAC CARDIOV SUR, V135, P247, DOI 10.1016/j.jtcvs.2007.07.060 Curkendall SM, 2006, ANN EPIDEMIOL, V16, P63, DOI 10.1016/j.annepidem.2005.04.008 Goto T, 2010, AM J CARDIOL, V106, P87, DOI 10.1016/j.amjcard.2010.01.372 Inoue Y, 2009, INTERNAL MED, V48, P503, DOI 10.2169/internalmedicine.48.1701 Ledwidge M, 2013, JAMA-J AM MED ASSOC, V310, P66, DOI 10.1001/jama.2013.7588 LOUIE EK, 1995, CIRCULATION, V92, P819, DOI 10.1161/01.CIR.92.4.819 Lubien E, 2002, CIRCULATION, V105, P595, DOI 10.1161/hc0502.103010 Nagaya N, 1998, J AM COLL CARDIOL, V31, P202, DOI 10.1016/S0735-1097(97)00452-X Nishikimi T, 1996, HYPERTENSION, V28, P22, DOI 10.1161/01.HYP.28.1.22 Nojiri T, 2011, ANN THORAC SURG, V92, P1051, DOI 10.1016/j.athoracsur.2011.03.085 Nojiri T, 2010, J THORAC CARDIOV SUR, V140, P764, DOI 10.1016/j.jtcvs.2009.11.073 Nojiri T, 2010, EUR J CARDIO-THORAC, V37, P787, DOI 10.1016/j.ejcts.2009.09.043 Reesink HJ, 2007, ANN THORAC SURG, V84, P537, DOI 10.1016/j.athoracsur.2007.04.006 Stolz D, 2008, CHEST, V133, P1088, DOI 10.1378/chest.07-1959 Suzuki M, 2002, HYPERTENS RES, V25, P669 Tsang TSM, 2002, J AM COLL CARDIOL, V40, P1636, DOI 10.1016/S0735-1097(02)02373-2 Win T, 2005, EUR RESPIR J, V25, P594, DOI 10.1183/09031936.05.00077504 NR 20 TC 23 Z9 24 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0941-1291 EI 1436-2813 J9 SURG TODAY JI Surg. Today PD JUN PY 2015 VL 45 IS 6 BP 740 EP 745 DI 10.1007/s00595-014-1032-z PG 6 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA CJ6KW UT WOS:000355603700011 PM 25236860 DA 2026-04-17 ER PT J AU Marjanski, T Wnuk, D Bosakowski, D Szmuda, T Sawicka, W Rzyman, W AF Marjanski, Tomasz Wnuk, Damian Bosakowski, Damian Szmuda, Tomasz Sawicka, Wioletta Rzyman, Witold TI Patients who do not reach a distance of 500 m during the 6-min walk test have an increased risk of postoperative complications and prolonged hospital stay after lobectomy SO EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY LA English DT Article DE Lobectomy; Lung cancer; Complication; Risk assessment ID CELL LUNG-CANCER; PULMONARY RESECTION; OXYGEN-CONSUMPTION; GUIDELINES; SURGERY AB OBJECTIVES: Exercise testing is an additional tool to standard pulmonary assessment before radical pulmonary resection in lung cancer patients. Evidence is lacking, supporting the significance of routine implementation of these simple physiological tests in preoperative evaluation. METHODS: Between April 2009 and October 2011, 253 lung cancer patients, who underwent lobectomy in a single institution, were entered into this study. All of the patients were accepted for resection based on a standard evaluation protocol. Additionally on the day before the surgery, patients performed a 6-min walk test (6MWT). Patients were categorized, depending on the result of 6MWT, in order to stratify their risk of postoperative complications. Threshold values of 6MWT were assessed on the basis of maximum area under ROC curves. RESULTS: There were 148 men and 105 women with a mean age of 63 years. All patients underwent lobectomies due to primary lung cancer. A distance of 500 m and 100% of the predicted 6MWT were taken as threshold values differentiating risk of postoperative complications. The cut-off value of 500 m separates individuals with an increased risk of postoperative complications [60.6 vs 36.9%, odds ratio (OR): 2631; 95% confidence interval (CI): 1.423-4.880] and prolonged hospitalization (7 vs 6 days). By applying a cut-off value of 500 m, the higher incidence of atrial fibrillation (21.2 vs 11.7%; OR: 2019; 95% CI: 0.904-4.484) and higher requirement for blood transfusion (18.1 vs 9.0%; OR: 2222; 95% CI: 0.928-5.289) fairly reached the level of significance. There were no early postoperative deaths in the analysed groups. CONCLUSIONS: Patients who walk < 500 m during the 6MWT before lobectomy have an increased risk of postoperative complications and prolonged hospital stay. C1 [Marjanski, Tomasz; Bosakowski, Damian; Rzyman, Witold] Med Univ Gdansk, Dept Thorac Surg, PL-80952 Gdansk, Poland. [Wnuk, Damian] Med Univ Gdansk, Dept Physiotherapy, PL-80952 Gdansk, Poland. [Szmuda, Tomasz] Med Univ Gdansk, Dept Neurosurg, PL-80952 Gdansk, Poland. [Sawicka, Wioletta] Med Univ Gdansk, Dept Anaesthesiol & Intens Care, PL-80952 Gdansk, Poland. C3 Fahrenheit Universities; Medical University Gdansk; Fahrenheit Universities; Medical University Gdansk; Fahrenheit Universities; Medical University Gdansk; Fahrenheit Universities; Medical University Gdansk RP Marjanski, T (corresponding author), Med Univ Gdansk, Dept Thorac Surg, Smoluchowskiego 17 Str, PL-80952 Gdansk, Poland. EM marjanski@gumed.edu.pl RI ; Marjanski, Tomasz/AAE-1639-2019; Szmuda, Tomasz/AAC-3575-2020 OI Rzyman, Witold/0000-0002-9044-7791; Szmuda, Tomasz/0000-0003-1904-6773 CR BAGG LR, 1984, RESPIRATION, V46, P342, DOI 10.1159/000194711 Beckles MA, 2003, CHEST, V123, p105S, DOI 10.1378/chest.123.1_suppl.105S Benzo RP, 2010, RESPIRATION, V80, P19, DOI 10.1159/000235543 Brunelli A, 2009, EUR RESPIR J, V34, P17, DOI 10.1183/09031936.00184308 Brunelli A, 2012, ANN THORAC SURG, V93, P1796, DOI 10.1016/j.athoracsur.2012.02.068 Chen KZ, 2013, ANN THORAC SURG, V96, P1761, DOI 10.1016/j.athoracsur.2013.06.038 Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111 Enright PL, 1998, AM J RESP CRIT CARE, V158, P1384, DOI 10.1164/ajrccm.158.5.9710086 GUYATT GH, 1985, CAN MED ASSOC J, V132, P919 HOLDEN DA, 1992, CHEST, V102, P1774, DOI 10.1378/chest.102.6.1774 Holland AE, 2009, RESP MED, V103, P1430, DOI 10.1016/j.rmed.2009.04.024 Solway S, 2001, CHEST, V119, P256, DOI 10.1378/chest.119.1.256 Win T, 2006, THORAX, V61, P57 NR 13 TC 47 Z9 59 U1 0 U2 11 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1010-7940 EI 1873-734X J9 EUR J CARDIO-THORAC JI Eur. J. Cardio-Thorac. Surg. PD MAY PY 2015 VL 47 IS 5 BP E213 EP E219 DI 10.1093/ejcts/ezv049 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA CJ0YV UT WOS:000355208200009 PM 25721817 OA Bronze DA 2026-04-17 ER PT J AU Nojiri, T Inoue, M Shintani, Y Takeuchi, Y Maeda, H Hamasaki, T Okumura, M AF Nojiri, Takashi Inoue, Masayoshi Shintani, Yasushi Takeuchi, Yukiyasu Maeda, Hajime Hamasaki, Toshimitsu Okumura, Meinoshin TI B-Type Natriuretic Peptide-Guided Risk Assessment for Postoperative Complications in Lung Cancer Surgery SO WORLD JOURNAL OF SURGERY LA English DT Article ID ATRIAL-FIBRILLATION; DIASTOLIC DYSFUNCTION; PULMONARY RESECTION; HEART-FAILURE; CARDIOPULMONARY COMPLICATIONS; THORACIC-SURGERY; ELDERLY-PATIENTS; HYPERTENSION; PREDICTOR; DIAGNOSIS AB Since lung cancer surgery is still associated with a high complication rate, it is important to efficiently identify patients at high risk for postoperative complications following lung cancer surgery. We previously reported that elderly patients with elevated preoperative B-type natriuretic peptide (BNP) levels (> 30 pg/mL) have an increased risk for postoperative atrial fibrillation and cardiopulmonary complications following lung cancer surgery. The objective of this study was to evaluate the clinical utility of BNP-guided risk classification for postoperative complications after lung cancer surgery. A total of 675 consecutive patients who underwent curative surgery for lung cancer in two specialized thoracic centers between 2007 and 2011 were included in this retrospective study. We evaluated the association between the incidence of postoperative complications and preoperative BNP levels. Univariable and multivariable stepwise logistic regression analyses revealed that an elevated preoperative BNP level was the most significant predictor of postoperative complications. All patients were classified by their preoperative BNP levels into a normal group (< 30 pg/mL), a mildly elevated group (30-100 pg/mL), and a severely elevated group (> 100 pg/mL). The incidence of postoperative complications was significantly higher in the severely and mildly elevated groups than in the control group (85 % and 47 % vs. 11 %, P < 0.0001). Furthermore, there were more severe complications and a higher mortality rate in the severely elevated group. Risk assessment using preoperative BNP levels was clinically useful for the identification of patients at high risk for postoperative complications. C1 [Nojiri, Takashi; Inoue, Masayoshi; Shintani, Yasushi; Okumura, Meinoshin] Osaka Univ, Grad Sch Med, Dept Gen Thorac Surg, Suita, Osaka 5650871, Japan. [Nojiri, Takashi] Natl Cerebral & Cardiovasc Ctr Res Inst, Dept Biochem, Suita, Osaka, Japan. [Takeuchi, Yukiyasu; Maeda, Hajime] Natl Hosp Org Toneyama Hosp, Dept Gen Thorac Surg, Toyonaka, Osaka, Japan. [Hamasaki, Toshimitsu] Osaka Univ, Grad Sch Med, Innovat Clin Trials & Data Sci, Suita, Osaka 5650871, Japan. C3 University of Osaka; National Cerebral & Cardiovascular Center - Japan; University of Osaka RP Nojiri, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Gen Thorac Surg, 2-2 L5 Yamadaoka, Suita, Osaka 5650871, Japan. EM nojirit@thoracic.med.osaka-u.ac.jp RI Hamasaki, Toshimitsu/N-3851-2015 OI Hamasaki, Toshimitsu/0000-0002-4928-1160 CR Abusaid GH, 2009, POSTGRAD MED, V121, P76, DOI 10.3810/pgm.2009.07.2033 Allen MS, 2006, ANN THORAC SURG, V81, P1013, DOI 10.1016/j.athoracsur.2005.06.066 Amar D, 2012, J THORAC CARDIOV SUR, V144, P1249, DOI 10.1016/j.jtcvs.2012.06.051 Barr RG, 2010, NEW ENGL J MED, V362, P217, DOI 10.1056/NEJMoa0808836 Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872 Birim Ö, 2006, J THORAC CARDIOV SUR, V132, P491, DOI 10.1016/j.jtcvs.2006.04.010 Boffa DJ, 2008, J THORAC CARDIOV SUR, V135, P247, DOI 10.1016/j.jtcvs.2007.07.060 Buch P, 2003, EUR RESPIR J, V21, P1012, DOI 10.1183/09031936.03.00051502 Inoue Y, 2009, INTERNAL MED, V48, P503, DOI 10.2169/internalmedicine.48.1701 Jourdain P, 2007, J AM COLL CARDIOL, V49, P1733, DOI 10.1016/j.jacc.2006.10.081 Lubien E, 2002, CIRCULATION, V105, P595, DOI 10.1161/hc0502.103010 Maisel AS, 2002, NEW ENGL J MED, V347, P161, DOI 10.1056/NEJMoa020233 McMurray JJV, 2012, EUR HEART J, V33, P1787, DOI 10.1093/eurheartj/ehs104 Nagaya N, 1998, J AM COLL CARDIOL, V31, P202, DOI 10.1016/S0735-1097(97)00452-X Nojiri T, 2013, EUR J CARDIO-THORAC, V44, P98, DOI 10.1093/ejcts/ezs646 Nojiri T, 2012, EUR J CARDIO-THORAC, V41, P1330, DOI 10.1093/ejcts/ezr202 Nojiri T, 2011, ANN THORAC SURG, V92, P1051, DOI 10.1016/j.athoracsur.2011.03.085 Nojiri T, 2010, J THORAC CARDIOV SUR, V140, P764, DOI 10.1016/j.jtcvs.2009.11.073 Nojiri T, 2010, EUR J CARDIO-THORAC, V37, P787, DOI 10.1016/j.ejcts.2009.09.043 Ryding ADS, 2009, ANESTHESIOLOGY, V111, P311, DOI 10.1097/ALN.0b013e3181aaeb11 Savarese G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058287 Suzuki M, 2002, HYPERTENS RES, V25, P669 Tsang TSM, 2002, J AM COLL CARDIOL, V40, P1636, DOI 10.1016/S0735-1097(02)02373-2 Wiley CL, 2010, CLIN MED RES, V8, P7, DOI 10.3121/cmr.2009.867 Win T, 2005, EUR RESPIR J, V25, P594, DOI 10.1183/09031936.05.00077504 NR 25 TC 21 Z9 21 U1 0 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0364-2313 EI 1432-2323 J9 WORLD J SURG JI World J.Surg. PD MAY PY 2015 VL 39 IS 5 BP 1092 EP 1098 DI 10.1007/s00268-015-2943-6 PG 7 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA CE8HS UT WOS:000352083200005 PM 25585524 DA 2026-04-17 ER PT J AU Toufektzian, L Zisis, C Balaka, C Roussakis, A AF Toufektzian, Levon Zisis, Charalambos Balaka, Christina Roussakis, Antonios TI Effectiveness of brain natriuretic peptide in predicting postoperative atrial fibrillation in patients undergoing non-cardiac thoracic surgery SO INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY LA English DT Article DE Brain natriuretic peptide; Postoperative atrial fibrillation; Non-cardiac thoracic surgery; Lung cancer; Oesophageal cancer ID LUNG-CANCER AB A best evidence topic was written according to a structured protocol. The question addressed was whether plasma brain natriuretic peptide (BNP) levels could effectively predict the occurrence of postoperative atrial fibrillation (AF) in patients undergoing non-cardiac thoracic surgery. A total of 14 papers were identified using the reported search, of which 5 represented the best evidence to answer the clinical question. The authors, date, journal, country, study type, population, outcomes and key results are tabulated. All studies were prospective observational, and all reported a significant association between BNP and N-terminal (NT)-proBNP plasma levels measured in the immediate preoperative period and the incidence of postoperative AF in patients undergoing either anatomical lung resections or oesophagectomy. One study reported a cut-off value of 30 pg/ml above which significantly more patients suffered from postoperative AF (P < 0.0001), while another one reported that this value could predict postoperative AF with a sensitivity of 77% and a specificity of 93%. Another study reported that patients with NT-proBNP levels of 113 pg/ml or above had an 8-fold increased risk of developing postoperative AF. These findings support that BNP or NT-proBNP levels, especially when determined during the preoperative period, if increased, are able to identify patients at risk for the development of postoperative AF after anatomical major lung resection or oesophagectomy. The same does not seem to be true for lesser lung resections. These high-risk patients might have a particular benefit from the administration of prophylactic antiarrhythmic therapy. C1 [Toufektzian, Levon] Guys Hosp, Dept Thorac Surg, London SE1 9RT, England. [Zisis, Charalambos; Balaka, Christina; Roussakis, Antonios] Evangelismos Gen Hosp, Dept Cardiothorac Surg, Athens, Greece. C3 Guy's & St Thomas' NHS Foundation Trust; Evangelismos Hospital RP Toufektzian, L (corresponding author), Guys Hosp, Dept Thorac Surg, London SE1 9RT, England. EM tlevon@gmail.com CR Amar D, 2012, J THORAC CARDIOV SUR, V144, P1249, DOI 10.1016/j.jtcvs.2012.06.051 Cardinale D, 2007, CIRCULATION, V115, P1339, DOI 10.1161/CIRCULATIONAHA.106.647008 Dunning Joel, 2003, Interact Cardiovasc Thorac Surg, V2, P405, DOI 10.1016/S1569-9293(03)00191-9 Gurgo A M, 2008, Minerva Cardioangiol, V56, P581 Hou JL, 2008, WORLD J GASTROENTERO, V14, P2582, DOI 10.3748/wjg.14.2582 Nojiri T, 2010, EUR J CARDIO-THORAC, V37, P787, DOI 10.1016/j.ejcts.2009.09.043 NR 6 TC 18 Z9 20 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1569-9293 EI 1569-9285 J9 INTERACT CARDIOV TH JI Interact Cardiovasc. Thorac. Surg. PD MAY PY 2015 VL 20 IS 5 BP 654 EP U134 DI 10.1093/icvts/ivu454 PG 4 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA CI5LO UT WOS:000354798000017 PM 25630332 DA 2026-04-17 ER PT J AU O'Neal, WT Lakoski, SG Qureshi, W Judd, SE Howard, G Howard, VJ Cushman, M Soliman, EZ AF O'Neal, Wesley T. Lakoski, Susan G. Qureshi, Waqas Judd, Suzanne E. Howard, George Howard, Virginia J. Cushman, Mary Soliman, Elsayed Z. TI Relation Between Cancer and Atrial Fibrillation (from the REasons for Geographic And Racial Differences in Stroke Study) SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID COLORECTAL-CANCER; LUNG-CANCER; COLON-CANCER; RISK-FACTORS; ADENOMA; MEN AB Atrial fibrillation (AF) is common in patients with life-threatening cancer and those undergoing active cancer treatment. However, data from subjects with a history of non-life-threatening cancer and those who do not require active cancer treatment are lacking. A total of 15,428 (mean age 66 +/- 8.9 years; 47% women; 45% blacks) participants from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study with baseline data on previous cancer diagnosis and AF were included. Participants with life-threatening cancer and active cancer treatment within 2 years of study enrollment were excluded. History of cancer was identified using computer-assisted telephone interviews. AF cases were identified from baseline electrocardiogram data and by a self-reported history of a previous diagnosis. Logistic regression was used to examine the cross-sectional association between cancer diagnosis and AF. A total of 2,248 (15%) participants had a diagnosis of cancer and 1,295 (8.4%) had AF. In a multivariable logistic regression model adjusted for sociodemographic characteristics (age, gender, race, education, income, and region of residence) and cardiovascular risk factors (systolic blood pressure, high-density lipoprotein cholesterol, total cholesterol, C-reactive protein, body mass index, smoking, diabetes, antihypertensive and lipid-lowering agents; left ventricular hypertrophy, and cardiovascular disease), those with cancer were more likely to have prevalent AF than those without cancer (odds ratio 1.19, 95% confidence interval 1.02 to 1.38). Subgroup analyses by age, sex, race, cardiovascular disease, and C-reactive protein yielded similar results. In conclusion, AF was more prevalent in participants with a history of non life-threatening cancer and those who did not require active cancer treatment in REGARDS. (C) 2015 Elsevier Inc. All rights reserved. C1 [O'Neal, Wesley T.] Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC 27517 USA. [Qureshi, Waqas; Soliman, Elsayed Z.] Wake Forest Sch Med, Cardiol Sect, Dept Med, Winston Salem, NC USA. [Soliman, Elsayed Z.] Wake Forest Sch Med, Epidemiol Cardiol Res Ctr EPI CARE, Dept Epidemiol & Prevent, Winston Salem, NC USA. [Lakoski, Susan G.] Univ Vermont, Dept Med, Vermont Canc Ctr, Burlington, VT USA. [Judd, Suzanne E.; Howard, George] Univ Alabama Birmingham, Sch Publ Hlth, Dept Biostat, Birmingham, AL 35294 USA. [Howard, George] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA. [Cushman, Mary] Univ Vermont, Coll Med, Dept Med, Cardiovasc Res Inst, Burlington, VT 05405 USA. [Cushman, Mary] Univ Vermont, Coll Med, Dept Pathol, Cardiovasc Res Inst, Burlington, VT 05405 USA. C3 Wake Forest University; Wake Forest University; Wake Forest University; University of Vermont; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Vermont; University of Vermont RP O'Neal, WT (corresponding author), Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC 27517 USA. EM woneal@wakehealth.edu RI ; Cushman, Mary/K-1157-2019; Soliman, Elsayed/AAD-7135-2020; Qureshi, Waqas/H-3498-2019 OI Howard, George/0000-0002-3068-5720; Cushman, Mary/0000-0002-7871-6143; Soliman, Elsayed/0000-0001-5632-8150; Howard, Virginia/0000-0003-4912-9975; O'Neal, Wesley/0000-0003-0751-4760; FU National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Service [U01 NS041588]; National Institute on Aging; National Institute of Neurological Disorders and Stroke [U01NS041588] Funding Source: NIH RePORTER FX This research project is supported by a cooperative agreement U01 NS041588 from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Service. CR Aviles RJ, 2003, CIRCULATION, V108, P3006, DOI 10.1161/01.CIR.0000103131.70301.4F BENJAMIN EJ, 1994, JAMA-J AM MED ASSOC, V271, P840, DOI 10.1001/jama.271.11.840 Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Erichsen R, 2012, INTERN EMERG MED, V7, P431, DOI 10.1007/s11739-011-0701-9 GIOVANNUCCI E, 1995, ANN INTERN MED, V122, P327, DOI 10.7326/0003-4819-122-5-199503010-00002 GIOVANNUCCI E, 1994, J NATL CANCER I, V86, P183, DOI 10.1093/jnci/86.3.183 Guzzetti S, 2002, AM J MED, V112, P587, DOI 10.1016/S0002-9343(02)01029-X Guzzetti S, 2008, INTERN EMERG MED, V3, P227, DOI 10.1007/s11739-008-0124-4 Howard VJ, 2005, NEUROEPIDEMIOLOGY, V25, P135, DOI 10.1159/000086678 Imperatori A, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-4 Kaakeh Y, 2012, DRUGS, V72, P1617, DOI 10.2165/11633140-000000000-00000 Larsson SC, 2005, JNCI-J NATL CANCER I, V97, P1679, DOI 10.1093/jnci/dji375 MULLER AD, 1994, DIGEST DIS SCI, V39, P2480, DOI 10.1007/BF02087670 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Ostenfeld EB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102861 Siemes C, 2006, J CLIN ONCOL, V24, P5216, DOI 10.1200/JCO.2006.07.1381 SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1 Soliman EZ, 2011, STROKE, V42, P2950, DOI 10.1161/STROKEAHA.111.621367 Sorensen HT, 2012, EUR J CANCER, V48, P586, DOI 10.1016/j.ejca.2011.10.032 Watanabe T, 2005, HEART VESSELS, V20, P45, DOI 10.1007/s00380-004-0800-x NR 20 TC 119 Z9 130 U1 0 U2 8 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 EI 1879-1913 J9 AM J CARDIOL JI Am. J. Cardiol. PD APR 15 PY 2015 VL 115 IS 8 BP 1090 EP 1094 DI 10.1016/j.amjcard.2015.01.540 PG 5 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA CG2AQ UT WOS:000353077700013 PM 25711434 DA 2026-04-17 ER PT J AU Ai, D Xu, G Feng, L Yu, J Banchs, J Vaporciyan, AA Cata, JP AF Ai, Di Xu, Gang Feng, Lei Yu, Jun Banchs, Jose Vaporciyan, Ara A. Cata, Juan P. CA Outcomes Res Consortium TI Dexmedetomidine Dos Not Reduce Atrial Fibrillation After Lung Cancer Surgery SO JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA LA English DT Article DE dexmedetomidine; atrial fibrillation; postoperative; noncardiac surgery; lung cancer ID NONCARDIAC THORACIC-SURGERY; CARDIAC-SURGERY; RISK-FACTORS; DYSRHYTHMIAS; ARRHYTHMIAS; PREVENTION; VERAPAMIL AB Objective: To evaluate whether the use of intraoperative dexmedetomidine (DEX) during lung cancer surgery may reduce the incidence of postoperative atrial fibrillation (POAF). Design: A retrospective study. Setting: Academic hospital. Participants: Seven hundred three adult patients with non-small-cell lung cancer. Measurements and Main Results: Patients younger than 18 years of age with a history of atrial fibrillation were excluded. Episodes of atrial fibrillation were identified from electronic medical records and consisted of cardiology consultations, electrocardiogram records, and use of antiarrhythmic medications within the postoperative admission time. The Wilcoxon rank sum test was used to evaluate the difference in a continuous variable between patient groups. Fisher's exact test or the chi-square test was used to evaluate the association between 2 categorical variables. Logistic regression models were used for multivariate analysis. Overall POAF incidence was 136 of 703 (19.35%), with a mean onset of 3.01 +/- 2.03 days after surgery. Among patients, 204 (29.02%) received DEX intraoperatively. Male gender and age were strong predictors of POAF. POAF incidence was comparable between patients who were (n = 93, 21.1%) and were not (n = 43, 18.6%) treated with DEX (p = 0.46). The mean onset time of arrhythmia was similar in both groups (DEX users: 2.93 +/- 2.49 days; non-DEX users: 3.05 +/- 1.79 days; p = 0.146). Conclusion: These results were similar to those published elsewhere on POAF incidence and risk factors. This study could not confirm the hypothesis that the intraoperative use of DEX is associated with a reduced rate of POAF after thoracic surgery for lung cancer. (C) 2015 Elsevier Inc. All rights reserved. C1 [Ai, Di; Cata, Juan P.] Univ Texas MD Anderson Canc Ctr, Dept Anesthesiol & Perioperat Med, Houston, TX 77030 USA. [Xu, Gang] Henan Canc Hosp, Dept Anesthesiol, Zhengzhou, Peoples R China. [Feng, Lei; Yu, Jun] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA. [Banchs, Jose] Univ Texas MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA. [Vaporciyan, Ara A.] Univ Texas MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA. C3 University of Texas System; UTMD Anderson Cancer Center; Zhengzhou University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center RP Cata, JP (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Anesthesiol & Perioperat Med, 1515 Holcombe Blvd,Unit 0408, Houston, TX 77030 USA. EM jcata@mdanderson.org RI Cata, Juan/AAA-7874-2022 FU Cancer Center Support Grant from the University of Texas MD Anderson Cancer Center, Houston, TX; National Cancer Institute [P30CA016672] Funding Source: NIH RePORTER FX This work was supported partially by a Cancer Center Support Grant from the University of Texas MD Anderson Cancer Center, Houston, TX. Dr. Ai, Dr. Xu, Dr. Banchs, and Dr. Cata take responsibility for the integrity of the data, and Ms. Yu and Ms. Feng take responsibility for the accuracy of the data analysis. CR Alqahtani Awad A R, 2010, Heart Views, V11, P57, DOI 10.4103/1995-705X.73212 Amar D, 1997, ANN THORAC SURG, V63, P1374 Amar D, 2002, ANESTHESIOLOGY, V96, P352, DOI 10.1097/00000542-200202000-00021 Amar D, 2005, CHEST, V128, P3421, DOI 10.1378/chest.128.5.3421 Arsenault KA, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003611.pub3 ASAMURA H, 1993, J THORAC CARDIOV SUR, V106, P1104, DOI 10.1016/S0022-5223(19)33985-6 Burgess DC, 2006, EUR HEART J, V27, P2846, DOI 10.1093/eurheartj/ehl272 Curtis JJ, 1998, ANN THORAC SURG, V66, P1766, DOI 10.1016/S0003-4975(98)00942-4 Fuster V, 2006, CIRCULATION, V114, pE257, DOI 10.1161/CIRCULATIONAHA.106.177292 Gertler R, 2001, Proc (Bayl Univ Med Cent), V14, P13 Hammer GB, 2008, ANESTH ANALG, V106, P79, DOI 10.1213/01.ane.0000297421.92857.4e HAYASHI Y, 1991, ANESTHESIOLOGY, V75, P113, DOI 10.1097/00000542-199107000-00018 Iliuta Luminita, 2009, Interact Cardiovasc Thorac Surg, V9, P89, DOI 10.1510/icvts.2009.202465 Kalman JM, 1995, ANN THORAC SURG, V60, P1709, DOI 10.1016/0003-4975(95)00718-0 Kamei M, 2006, CARDIOVASC DRUG THER, V20, P219, DOI 10.1007/s10557-006-8375-7 KAMIBAYASHI T, 1995, ANESTHESIOLOGY, V83, P992, DOI 10.1097/00000542-199511000-00013 LINDGREN L, 1991, BRIT J ANAESTH, V66, P205, DOI 10.1093/bja/66.2.205 Maesen B, 2012, EUROPACE, V14, P159, DOI 10.1093/europace/eur208 Mathew JP, 2004, JAMA-J AM MED ASSOC, V291, P1720, DOI 10.1001/jama.291.14.1720 Nojiri T, 2010, EUR J CARDIO-THORAC, V37, P787, DOI 10.1016/j.ejcts.2009.09.043 Piccini JP, 2013, AM J CARDIOL, V112, P954, DOI 10.1016/j.amjcard.2013.05.029 Polanczyk CA, 1998, ANN INTERN MED, V129, P279, DOI 10.7326/0003-4819-129-4-199808150-00003 VanMieghem W, 1996, ANN THORAC SURG, V61, P1083, DOI 10.1016/0003-4975(96)00073-2 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Walsh SR, 2007, ANN ROY COLL SURG, V89, P91, DOI 10.1308/003588407X168253 Weis F, 2009, CRIT CARE MED, V37, P1685, DOI 10.1097/CCM.0b013e31819fca77 Workman AJ, 2006, J CARDIOVASC ELECTR, V17, P1230, DOI 10.1111/j.1540-8167.2006.00592.x Workman AJ, 2010, N-S ARCH PHARMACOL, V381, P235, DOI 10.1007/s00210-009-0474-0 NR 28 TC 11 Z9 13 U1 0 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1053-0770 EI 1532-8422 J9 J CARDIOTHOR VASC AN JI J. Cardiothorac. Vasc. Anesth. PD APR PY 2015 VL 29 IS 2 BP 396 EP 401 DI 10.1053/j.jvca.2014.05.013 PG 6 WC Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease WE Science Citation Index Expanded (SCI-EXPANDED) SC Anesthesiology; Cardiovascular System & Cardiology; Respiratory System GA CE1GG UT WOS:000351559500022 PM 25440618 DA 2026-04-17 ER PT J AU Kanmanthareddy, A Vallakati, A Yeruva, MR Dixit, S Di Biase, L Mansour, M Boolani, H Gunda, S Bunch, TJ Day, JD Ruskin, JN Buddam, A Koripalli, S Bommana, S Natale, A Lakkireddy, D AF Kanmanthareddy, Arun Vallakati, Ajay Yeruva, Madhu Reddy Dixit, Sanjay Di Biase, Luigi Mansour, Moussa Boolani, Hemant Gunda, Sampath Bunch, T. Jared Day, John D. Ruskin, Jeremy N. Buddam, Avanija Koripalli, Sandeep Bommana, Sudharani Natale, Andrea Lakkireddy, Dhanunjaya TI Pulmonary Vein Isolation for Atrial Fibrillation in the Postpneumonectomy Population: A Feasibility, Safety, and Outcomes Study SO JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY LA English DT Article DE atrial fibrillation ablation; atrial fibrillation after pneumonectomy; catheter ablation of pulmonary vein stump; efficacy of isolation of pulmonary vein stump; pulmonary vein stump ID LUNG-CANCER; INITIATION; TRIGGERS AB AF Ablation in Pulmonary Vein Stumps BackgroundPulmonary vein isolation (PVI) of the remnant pulmonary vein (PV) stumps in pneumonectomy patients has not been well characterized. MethodsThis is a multicenter observational study of patients with a remnant PV stump after pneumonectomy. Consecutive patients with a history of pneumonectomy and who had undergone RF ablation for drug refractory AF were identified from the AF database at the participating institutions. ResultsThere were 15 patients in whom pneumonectomy was performed, for resection of tumors in 10, infection in 4, and bullae in 1 patient and who underwent RF ablation for AF. The mean age was 63 7 years. The stumps were from the right lower PV in 5, left upper PV in 5, left lower PV in 3, and right upper PV in 2 patients. All the PV stumps were electrically active with PV potentials and 9 (60%) of them had triggered activity. PVI was performed in 14 and focal isolation in 1 patient. At 1-year follow-up, 80% were free of AF, off of antiarrhythmic medications. ConclusionPV stumps in AF patients with previous pneumonectomy are electrically active and are frequently the sites of active firing. Isolation of these PV stumps can be accomplished safely and effectively using catheter ablation with no practical concern for PV stenosis or compromising PV stump integrity. C1 [Kanmanthareddy, Arun] Creighton Univ, Div Cardiol, Omaha, NE 68178 USA. [Vallakati, Ajay] Case Western Reserve Univ, MetroHlth Med Ctr, Div Cardiol, Cleveland, OH 44106 USA. [Yeruva, Madhu Reddy; Gunda, Sampath; Bunch, T. Jared; Buddam, Avanija; Koripalli, Sandeep; Bommana, Sudharani; Lakkireddy, Dhanunjaya] Univ Kansas Hosp, KU Cardiovasc Res Inst, Kansas City, KS 66160 USA. [Yeruva, Madhu Reddy; Gunda, Sampath; Bunch, T. Jared; Buddam, Avanija; Koripalli, Sandeep; Bommana, Sudharani; Lakkireddy, Dhanunjaya] Med Ctr, Kansas City, KS 66160 USA. [Dixit, Sanjay] Hosp Univ Penn, Div Cardiol, Philadelphia, PA 19104 USA. [Di Biase, Luigi] Albert Einstein Montefiore Med Ctr, Div Cardiol, Bronx, NY USA. [Mansour, Moussa; Ruskin, Jeremy N.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Boolani, Hemant] Howard Univ Hosp, Div Cardiol, Washington, DC USA. [Day, John D.] Intermt Heart Inst, Div Cardiol, Salt Lake City, UT USA. [Natale, Andrea] St Davids Med Ctr, Texas Cardiac Arrhythmia Inst, Div Elect, Austin, TX USA. C3 Creighton University; University System of Ohio; Case Western Reserve University; MetroHealth System; University of Kansas; University of Kansas Medical Center; University of Pennsylvania; Montefiore Medical Center; Yeshiva University; Harvard University; Harvard University Medical Affiliates; Massachusetts General Hospital; Howard University; Saint David's Medical Center RP Lakkireddy, D (corresponding author), Univ Kansas Hosp, KU Cardiovasc Res Inst, Ctr Excellence Atrial Fibrillat & Electrophysiol, Bloch Heart Rhythm Ctr,Mid Amer Cardiol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA. EM dlakkireddy@kumc.edu RI ; Kanmanthareddy, Arun/J-6217-2013; Koripalli, Venkata/AHE-8019-2022 OI Di Biase, Luigi/0000-0001-6508-4047; FU Advanced Medical Information; CardioInsight; Cardiome; Gilead Sciences; Medtronic; Pfizer FX LDB reports serving as a consultant for Biosense Webster, St. Jude Medical, Medtronic, Biotronik, EpiEP. TJB reports serving as a consultant/advisory board member for Boston Scientific. JNR reports equity interest in InfoBionic and Portola; consulting fees from Advanced Medical Information, CardioInsight, Cardiome, Gilead Sciences, Medtronic, and Pfizer; and honorarium from Sanofi Aventis. Other authors: No disclosures. CR Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Chen SA, 1999, CIRCULATION, V100, P1879, DOI 10.1161/01.CIR.100.18.1879 Dixit S, 2009, J CARDIOVASC ELECTR, V20, P441, DOI 10.1111/j.1540-8167.2008.01338.x Haïssaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003 Ho SY, 2001, HEART, V86, P265, DOI 10.1136/heart.86.3.265 Jaïs P, 2002, CIRCULATION, V106, P2479, DOI 10.1161/01.CIR.0000036744.39782.9F January CT, J Am Coll Konstantinidou M, 2009, EUROPACE, V11, P389, DOI 10.1093/europace/eun368 Mandapati R, 2000, CIRCULATION, V101, P194, DOI 10.1161/01.CIR.101.2.194 Rena O, 2001, EUR J CARDIO-THORAC, V20, P688, DOI 10.1016/S1010-7940(01)00890-9 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Smulders SA, 2007, ANN THORAC SURG, V83, P1986, DOI 10.1016/j.athoracsur.2007.01.036 Terada H, 2000, JPN CIRC J, V64, P474, DOI 10.1253/jcj.64.474 Udyavar AR, 2008, J CARDIOVASC ELECTR, V19, P593, DOI 10.1111/j.1540-8167.2008.01182.x Vaitkevicius R, 2009, HEART RHYTHM, V6, P221, DOI 10.1016/j.hrthm.2008.10.027 Valles E, 2008, J AM COLL CARDIOL, V52, P1413, DOI 10.1016/j.jacc.2008.07.025 Weerasooriya R, 2007, EUROPACE, V9, P1141, DOI 10.1093/europace/eum232 NR 17 TC 25 Z9 28 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1045-3873 EI 1540-8167 J9 J CARDIOVASC ELECTR JI J. Cardiovasc. Electrophysiol. PD APR PY 2015 VL 26 IS 4 BP 385 EP 389 DI 10.1111/jce.12619 PG 5 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA CF8MH UT WOS:000352814300008 PM 25588757 DA 2026-04-17 ER PT J AU Seife, C AF Seife, Charles TI Research Misconduct Identified by the US Food and Drug Administration Out of Sight, Out of Mind, Out of the Peer-Reviewed Literature SO JAMA INTERNAL MEDICINE LA English DT Article ID ATRIAL-FIBRILLATION INSIGHTS; METASTATIC COLORECTAL-CANCER; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; SEVERE LIMB ISCHEMIA; CELL LUNG-CANCER; QUALITY-OF-LIFE; DOUBLE-BLIND; RHEUMATOID-ARTHRITIS; ARISTOTLE TRIAL AB IMPORTANCE Every year, the US Food and Drug Administration (FDA) inspects several hundred clinical sites performing biomedical research on human participants and occasionally finds evidence of substantial departures from good clinical practice and research misconduct. However, the FDA has no systematic method of communicating these findings to the scientific community, leaving open the possibility that research misconduct detected by a government agency goes unremarked in the peer-reviewed literature. OBJECTIVES To identify published clinical trials in which an FDA inspection found significant evidence of objectionable conditions or practices, to describe violations, and to determine whether the violations are mentioned in the peer-reviewed literature. DESIGN AND SETTING Cross-sectional analysis of publicly available documents, dated from January 1, 1998, to September 30, 2013, describing FDA inspections of clinical trial sites in which significant evidence of objectionable conditions or practices was found. MAIN OUTCOMES AND MEASURES For each inspection document that could be linked to a specific published clinical trial, the main measure was a yes/no determination of whether there was mention in the peer-reviewed literature of problems the FDA had identified. RESULTS Fifty-seven published clinical trials were identified for which an FDA inspection of a trial site had found significant evidence of 1 or more of the following problems: falsification or submission of false information, 22 trials (39%); problems with adverse events reporting, 14 trials (25%); protocol violations, 42 trials (74%); inadequate or inaccurate recordkeeping, 35 trials (61%); failure to protect the safety of patients and/or issues with oversight or informed consent, 30 trials (53%); and violations not otherwise categorized, 20 trials (35%). Only 3 of the 78 publications (4%) that resulted from trials in which the FDA found significant violations mentioned the objectionable conditions or practices found during the inspection. No corrections, retractions, expressions of concern, or other comments acknowledging the key issues identified by the inspection were subsequently published. CONCLUSIONS AND RELEVANCE When the FDA finds significant departures from good clinical practice, those findings are seldom reflected in the peer-reviewed literature, even when there is evidence of data fabrication or other forms of research misconduct. C1 NYU, Arthur L Carter Inst Journalism, New York, NY 10012 USA. C3 New York University RP Seife, C (corresponding author), NYU, Arthur L Carter Inst Journalism, 20 Cooper Sq,Ste 628, New York, NY 10012 USA. EM charles.seife@nyu.edu OI Seife, Charles/0000-0001-5309-8716 FU New York University FX All financial and material support for this study was provided by New York University. CR Ajani JA, 2005, J CLIN ONCOL, V23, P5660, DOI 10.1200/JCO.2005.17.376 Ajani Jaffer A, 2002, Gastric Cancer, V5 Suppl 1, P31, DOI 10.1007/s10120-002-0215-2 Alexander JH, 2014, EUR HEART J, V35, P224, DOI 10.1093/eurheartj/eht445 Alexander JH, 2013, AM HEART J, V166, P559, DOI 10.1016/j.ahj.2013.05.025 [Anonymous], 2008, COMMUNICATION [Anonymous], 2001, COMMUNICATION [Anonymous], 2009, COMMUNICATION [Anonymous], 2008, COMMUNICATION [Anonymous], 2000, FORM 483 EIR REGARDI [Anonymous], 2009, Islam Din2 March [Anonymous], FDA INSPECTION RELAT [Anonymous], 2003, COMMUNICATION [Anonymous], 2009, COMMUNICATION [Anonymous], EAR NOSE THROAT J [Anonymous], 2009, COMMUNICATION [Anonymous], 2009, COMMUNICATION [Anonymous], 2008, FORM 483 EIR PATIENT [Anonymous], 2009, COMMNICATION 0818 [Anonymous], 2006, COMMUNICATION [Anonymous], 2003, COMMUNICATION [Anonymous], 2010, COMMUNICATION [Anonymous], 2009, COMMUNICATION [Anonymous], 2011, COMMUNICATION [Anonymous], 2012, NOTICE INITIATION DI [Anonymous], 2004, COMMUNICATION 0922 Belani CP, 2006, LUNG CANCER, V53, P231, DOI 10.1016/j.lungcan.2006.05.003 Bleecker ER, 2012, CHEST, V142, P320, DOI 10.1378/chest.11-1655 Bukowski RM, 2007, J CLIN ONCOL, V25, P4536, DOI 10.1200/JCO.2007.11.5154 Chang AE, 2000, HUM GENE THER, V11, P839, DOI 10.1089/10430340050015455 Dougados M, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2118 File TM Jr, 2002, INT J ANTIMICROB AG, V20, P235, DOI 10.1016/S0924-8579(02)00130-9 Findling RL, 2012, J CHILD ADOL PSYCHOP, V22, P327, DOI 10.1089/cap.2011.0092 Fossella F, 2003, J CLIN ONCOL, V21, P3016, DOI 10.1200/JCO.2003.12.046 Garcia DA, 2013, AM HEART J, V166, P549, DOI 10.1016/j.ahj.2013.05.016 Gibofsky A, 2006, CURR MED RES OPIN, V22, P169, DOI 10.1185/030079906X80341 Gibofsky A, 2011, J RHEUMATOL, V38, P21, DOI 10.3899/jrheum.100347 Kabbinavar FF, 2008, ONCOLOGIST, V13, P1021, DOI 10.1634/theoncologist.2008-0003 Kabbinavar FF, 2009, J CLIN ONCOL, V27, P199, DOI 10.1200/JCO.2008.17.7931 Lasala GP, 2012, INT J CARDIOL, V157, P293, DOI 10.1016/j.ijcard.2012.03.125 Lasala GP, 2012, J THORAC CARDIOV SUR, V144, P377, DOI 10.1016/j.jtcvs.2011.08.053 Lasala GP, 2011, CARDIOVASC REVASCULA, V12, P29, DOI 10.1016/j.carrev.2010.01.001 Lasala GP, 2010, ANGIOLOGY, V61, P551, DOI 10.1177/0003319710364213 Lopes RD, 2012, LANCET, V380, P1749, DOI 10.1016/S0140-6736(12)60986-6 Losordo DW, 2011, CIRC RES, V109, P428, DOI 10.1161/CIRCRESAHA.111.245993 Luterman M, 2003, ENT-EAR NOSE THROAT, V82, P82 Luterman Maynard, 2003, Ear Nose Throat J, V82, P576 Markenson JA, 2011, J RHEUMATOL, V38, P1273, DOI 10.3899/jrheum.101142 McMurray JJV, 2013, CIRC-HEART FAIL, V6, P451, DOI 10.1161/CIRCHEARTFAILURE.112.000143 Messing E, 2006, J UROLOGY, V176, P500, DOI 10.1016/j.juro.2006.03.061 Pathak S, 2013, J CLIN PSYCHIAT, V74, pE100, DOI 10.4088/JCP.11m07424 Povsic TJ, 2012, AM HEART J, V164, P689, DOI 10.1016/j.ahj.2012.06.022 Redman BG, 2008, J IMMUNOTHER, V31, P591, DOI 10.1097/CJI.0b013e31817fd90b Rennard SI, 2009, DRUGS, V69, P549, DOI 10.2165/00003495-200969050-00004 Rosenstock J, 2013, DIABETES OBES METAB, V15, P906, DOI 10.1111/dom.12102 Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086 Schnitzer TJ, 2011, SEMIN ARTHRITIS RHEU, V40, P285, DOI 10.1016/j.semarthrit.2010.06.002 Sheldon E, 2005, CLIN THER, V27, P64, DOI 10.1016/j.clinthera.2005.01.002 Szegedi A, 2012, J CLIN PSYCHOPHARM, V32, P46, DOI 10.1097/JCP.0b013e31823f872f Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720 Tirotta C, 2012, J Anesth Clin Res, V3, P189, DOI [10.4172/2155-6148, DOI 10.4172/2155-6148] US Food and Drug Administration, BIOR MON BIMO METR F US Food and Drug Administration Office of Good Clinical Practice, 2010, INF SHEET GUID IRBS Van Cutsem E, 2006, J CLIN ONCOL, V24, P4991, DOI 10.1200/JCO.2006.06.8429 Wallentin L, 2013, CIRCULATION, V127, P2166, DOI 10.1161/CIRCULATIONAHA.112.142158 Weaver AL, 2006, CURR MED RES OPIN, V22, P185, DOI 10.1185/030079905X65510 Zervos MJ, 2003, J INT MED RES, V31, P157, DOI 10.1177/147323000303100301 NR 66 TC 58 Z9 73 U1 0 U2 16 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD APR PY 2015 VL 175 IS 4 BP 567 EP 577 DI 10.1001/jamainternmed.2014.7774 PG 11 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA CK4FJ UT WOS:000356177100021 PM 25664866 DA 2026-04-17 ER PT J AU Simmers, D Potgieter, D Ryan, L Fahrner, R Rodseth, RN AF Simmers, Dale Potgieter, Danielle Ryan, Lisa Fahrner, Rene Rodseth, Reitze Nils TI The Use of Preoperative B-Type Natriuretic Peptide as a Predictor of Atrial Fibrillation After Thoracic Surgery: Systematic Review and Meta-Analysis SO JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA LA English DT Review DE BNP; NT-proBNP; natriuretic peptides; atrial fibrillation; noncardiac surgery; thoracic surgery ID POSTOPERATIVE CARDIAC EVENTS; THROMBOEMBOLIC PULMONARY-HYPERTENSION; NONCARDIAC VASCULAR-SURGERY; LUNG-CANCER; ORTHOPEDIC-SURGERY; RISK; MORTALITY; COMPLICATIONS; ENDARTERECTOMY; ASSOCIATION AB Objective: To determine whether elevated preoperative B-type natriuretic peptide (NP) measurements are an independent predictor of atrial fibrillation (AF) in patients having thoracic surgery. Design: Systematic review and meta-analysis. Setting: In-hospital and 30 days after thoracic surgery. Participants: The 742 patients who participated in the 5 observational studies. Interventions: None. Measurements and Main Results: EMBASE, OVID Health Star, Ovid Medline, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Pro Quest Dissertations and Theses A&I databases were searched for all studies of noncardiac thoracic surgery patients in whom a preoperative NP was measured up to 1 month before surgery, and that measured the incidence of postoperative AF. Studies were included regardless of their language, sample size, publication status, or study design. Study quality was evaluated using the Newcastle Ottowa Scale. The combined incidence of postoperative AF was 14.5% (n = 108/742), and the NP thresholds used to predict AF varied among studies. An elevated preoperative NP measurement was associated with an OR of 3.13 (95% CI 1.38-7.12; 12 = 87%) for postoperative AF, with the sensitivity analysis reporting an OR of 9.51 (95% CI 4.66-19.40; 12 = 0). Conclusion: Patients with an elevated preoperative NP measurement are at an increased risk of postoperative AF. There may be value in incorporating NP measurement into existing AF risk prediction models. (C) 2015 Elsevier Inc. All rights reserved. C1 [Simmers, Dale; Potgieter, Danielle] Univ KwaZulu Natal, Nelson R Mandela Sch Med, Dept Anaesthet, Durban, South Africa. [Ryan, Lisa; Rodseth, Reitze Nils] Univ KwaZulu Natal, Nelson R Mandela Sch Med, Dept Anaesthet, Perioperat Res Grp, Pietermaritzburg, South Africa. [Fahrner, Rene] Univ Hosp Jena, Div Gen Visceral & Vasc Surg, Jena, Germany. [Rodseth, Reitze Nils] Cleveland Clin, Dept Outcomes Res, Cleveland, OH 44106 USA. C3 University of Kwazulu Natal; University of Kwazulu Natal; Friedrich Schiller University of Jena; Cleveland Clinic Foundation RP Simmers, D (corresponding author), Univ KwaZulu Natal, Nelson R Mandela Sch Med, Dept Anaesthet, Private Bag 7, ZA-4013 Congella, South Africa. EM dalesimmers@mweb.co.za RI RYAN, LISA/IZD-8234-2023; Rodseth, Reitze/B-2471-2010 OI Rodseth, Reitze/0000-0002-3779-7805 CR Amar D, 2012, J THORAC CARDIOV SUR, V144, P1249, DOI 10.1016/j.jtcvs.2012.06.051 Biccard BM, 2014, ANAESTHESIA, V69, P484, DOI 10.1111/anae.12635 Breidthardt T, 2010, EUR J ANAESTH, V27, P690, DOI 10.1097/EJA.0b013e328336c654 Cahill T, 2009, INTENS CARE MED, V35, P281 Cai GL, 2014, WORLD J SURG, V38, P51, DOI 10.1007/s00268-013-2284-2 Cardinale D, 2007, CIRCULATION, V115, P1339, DOI 10.1161/CIRCULATIONAHA.106.647008 Chong CP, 2012, AM J CARDIOL, V109, P1365, DOI 10.1016/j.amjcard.2011.12.032 Chong CP, 2010, AM J CARDIOL, V106, P865, DOI 10.1016/j.amjcard.2010.05.012 Chong CP, 2010, J AM MED DIR ASSOC, V11, P415, DOI 10.1016/j.jamda.2010.01.003 Cuthbertson BH, 2007, ANAESTHESIA, V62, P875, DOI 10.1111/j.1365-2044.2007.05146.x Dernellis J, 2006, HEART, V92, P1645, DOI 10.1136/hrt.2005.085530 DiDomenico RJ, 2005, ANN THORAC SURG, V79, P728, DOI 10.1016/j.athoracsur.2004.03.037 Feringa HHH, 2007, CURR OPIN ANESTHESIO, V20, P254, DOI 10.1097/ACO.0b013e3280c60c50 Feringa HHH, 2006, AM J CARDIOL, V98, P111, DOI 10.1016/j.amjcard.2006.01.058 Goei D, 2008, AM J CARDIOL, V101, P122, DOI 10.1016/j.amjcard.2007.07.058 Goei D, 2011, AM J CARDIOL, V107, P609, DOI 10.1016/j.amjcard.2010.10.021 Goei D, 2010, FUTUR CARDIOL, V6, P603, DOI 10.2217/FCA.10.78 Goei D, 2009, CORONARY ARTERY DIS, V20, P219, DOI 10.1097/MCA.0b013e3283219e47 Hoksch Beatrix, 2007, Interact Cardiovasc Thorac Surg, V6, P155 Hou JL, 2008, WORLD J GASTROENTERO, V14, P2582, DOI 10.3748/wjg.14.2582 Huh IY, 2012, TRANSPL P, V44, P1318, DOI 10.1016/j.transproceed.2012.01.140 Hwang GS, 2011, KOREAN J ANESTHESIOL, V61, P1, DOI 10.4097/kjae.2011.61.1.1 Imperatori A, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-4 Jain D, 2001, J CLIN BASIC CARDIOL, V4, P165 Jeon DS, 2011, KOREAN CIRC J, V41, P9, DOI 10.4070/kcj.2011.41.1.9 Koniari I, 2010, J CARDIOTHORAC SURG, V5, DOI 10.1186/1749-8090-5-121 Lee Chang Young, 2011, Korean J Thorac Cardiovasc Surg, V44, P44, DOI 10.5090/kjtcs.2011.44.1.44 Leibowitz D, 2008, CARDIOLOGY, V110, P266, DOI 10.1159/000112411 Mahla E, 2007, BRIT J ANAESTH, V99, P746, DOI 10.1093/bja/aem285 Nojiri T, 2011, ANN THORAC SURG, V92, P1051, DOI 10.1016/j.athoracsur.2011.03.085 *OTT HLTH RES I, NEWC OTT QUAL ASS SC Passman RS, 2005, ANN THORAC SURG, V79, P1698, DOI 10.1016/j.athoracsur.2004.10.058 Ray P, 2010, ANESTHESIOLOGY, V112, P1023, DOI 10.1097/ALN.0b013e3181d47604 Rodseth RN, 2014, J AM COLL CARDIOL, V63, P170, DOI 10.1016/j.jacc.2013.08.1630 Rodseth RN, 2011, J AM COLL CARDIOL, V58, P522, DOI 10.1016/j.jacc.2011.04.018 Salvatici M, 2010, BIOMARKERS, V15, P259, DOI 10.3109/13547500903509351 Schölzel B, 2011, NETH HEART J, V19, P498, DOI 10.1007/s12471-011-0203-4 Schouten O, 2009, J VASC SURG, V49, P435, DOI 10.1016/j.jvs.2008.08.063 Skinner DL, 2012, SOUTH AFR J ANAESTH, V18, P186, DOI 10.1080/22201173.2012.10872851 Spatenkova V, 2011, NEUROENDOCRINOL LETT, V32, P874 St Peter JV, 2006, CLIN CHEM, V52, P680, DOI 10.1373/clinchem.2005.062562 Surie S, 2012, INTERACT CARDIOV TH, V15, P973, DOI 10.1093/icvts/ivs415 Suttner S, 2005, ANESTH ANALG, V101, P896, DOI 10.1213/01.ANE.0000160532.77128.89 van Gestel YRBM, 2010, COPD, V7, P70, DOI 10.3109/15412550903499472 Van Kuijk JP, 2010, EUR HEART J, V31, P126 Vetrugno L, 2012, J CARDIOTHOR VASC AN, V26, P637, DOI 10.1053/j.jvca.2012.01.018 Villacorta H, 2010, ARQ BRAS CARDIOL, V95, P743, DOI 10.1590/S0066-782X2010005000131 Wiviott SD, 2004, CIRCULATION, V109, P580, DOI 10.1161/01.CIR.0000109491.66226.26 NR 48 TC 30 Z9 37 U1 0 U2 14 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1053-0770 EI 1532-8422 J9 J CARDIOTHOR VASC AN JI J. Cardiothorac. Vasc. Anesth. PD APR PY 2015 VL 29 IS 2 BP 389 EP 395 DI 10.1053/j.jvca.2014.05.015 PG 7 WC Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease WE Science Citation Index Expanded (SCI-EXPANDED) SC Anesthesiology; Cardiovascular System & Cardiology; Respiratory System GA CE1GG UT WOS:000351559500021 PM 25440619 DA 2026-04-17 ER PT J AU Ikeda, H Enatsu, R Yamana, N Nishimura, M Saiki, M AF Ikeda, Hiroyuki Enatsu, Rei Yamana, Norikazu Nishimura, Masaki Saiki, Masaaki TI Multiple extra-ischemic hemorrhages following intravenous thrombolysis in a patient with Trousseau syndrome: case study SO SPRINGERPLUS LA English DT Article DE Trousseau syndrome; Intravenous thrombolysis; Intracerebral hemorrhage; Cerebral infarction; Vascular disorders ID TISSUE-PLASMINOGEN ACTIVATOR; INTRACEREBRAL HEMORRHAGE; SAFE IMPLEMENTATION; RISK-FACTORS; STROKE; CANCER; ALTEPLASE; PATHOGENESIS; ASSOCIATION; THERAPY AB Background: Intracerebral hemorrhage is the most feared complication of intravenous thrombolysis for acute ischemic stroke. Such hemorrhage usually occurs within or at the margin of ischemic or manifestly infarcted brain tissue. A patient with Trousseau syndrome who developed multiple extra-ischemic hemorrhages following intravenous thrombolysis is described. Case description: An 80-year-old Japanese man with no other underlying disease was diagnosed with unresectable advanced lung cancer (stage IV) without brain metastasis and had not yet been treated. The patient suddenly presented with disturbance of consciousness, right hemiplegia, and total aphasia, and was admitted to our hospital. Magnetic resonance imaging revealed acute cerebral infarction extending from the basal ganglia to the corona radiata of the left cerebrum and multiple small areas of bilateral cerebral cortices. Cardiogenic cerebral embolism was considered among the differential diagnoses, but the brain natriuretic peptide level was within the normal range, and no arrhythmias such as atrial fibrillation were observed. With no other causes, the patient was diagnosed with Trousseau syndrome due to hypercoagulability associated with the advanced lung cancer. The patient received intravenous tissue plasminogen activator (t-PA) at 96 minutes after onset of symptoms. His symptoms partially improved, but they suddenly deteriorated at 84 minutes after the thrombolysis. A computed tomography (CT) scan immediately after the neurological deterioration revealed a subcortical hemorrhage in the left occipital lobe. A repeat CT scan the day after onset showed enlargement of the left occipital hemorrhage and two new subcortical hemorrhages in the right frontal and right temporal lobes. These hemorrhages were located in areas remote from the acute ischemic lesions. Conclusion: To the best of our knowledge, this is the first reported case of multiple extra-ischemic hemorrhages following intravenous thrombolysis in a patient with Trousseau syndrome. The course of this case suggests that intravenous t-PA administration for acute ischemic stroke with Trousseau syndrome may be associated with a higher risk of intracranial hemorrhage. C1 [Ikeda, Hiroyuki; Enatsu, Rei; Yamana, Norikazu; Nishimura, Masaki; Saiki, Masaaki] Natl Hosp Org Himeji Med Ctr, Dept Neurosurg, Himeji, Hyogo 6708520, Japan. RP Ikeda, H (corresponding author), Natl Hosp Org Himeji Med Ctr, Dept Neurosurg, 68 Honmachi, Himeji, Hyogo 6708520, Japan. EM rocky@kuhp.kyoto-u.ac.jp RI Ikeda, Hiroyuki/NHP-5639-2025 CR Albers GW, 2000, JAMA-J AM MED ASSOC, V283, P1145, DOI 10.1001/jama.283.9.1145 Bick RL, 2003, NEW ENGL J MED, V349, P109, DOI 10.1056/NEJMp030086 Brott T, 1997, STROKE, V28, P2109, DOI 10.1161/01.STR.28.11.2109 Dzialowski I, 2006, STROKE, V37, P973, DOI 10.1161/01.STR.0000206215.62441.56 Grisold W, 2009, ACTA NEUROL SCAND, V119, P1, DOI 10.1111/j.1600-0404.2008.01059.x Hejna M, 1999, JNCI-J NATL CANCER I, V91, P22, DOI 10.1093/jnci/91.1.22 Hill MD, 2005, CAN MED ASSOC J, V172, P1307, DOI 10.1503/cmaj.1041561 Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a Kim SG, 2010, STROKE, V41, P798, DOI 10.1161/STROKEAHA.109.571356 Kufner A, 2013, EUR J NEUROL, V20, P281, DOI 10.1111/j.1468-1331.2012.03841.x Lees KR, 2010, LANCET, V375, P1695, DOI 10.1016/S0140-6736(10)60491-6 MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401 Masrur S, 2011, J STROKE CEREBROVASC, V20, P124, DOI 10.1016/j.jstrokecerebrovasdis.2009.10.010 Mazya MV, 2014, STROKE, V45, P1657, DOI 10.1161/STROKEAHA.114.004923 Murthy SB, 2013, STROKE, V44, P3573, DOI 10.1161/STROKEAHA.113.003058 Nozaki H, 2012, JPN J STROKE, V34, P269 RICKLES FR, 1983, BLOOD, V62, P14 SACK GH, 1977, MEDICINE, V56, P1, DOI 10.1097/00005792-197756010-00001 Schwarzbach CJ, 2012, STROKE, V43, P3029, DOI 10.1161/STROKEAHA.112.658625 Sutherland DE, 2003, AM J HEMATOL, V72, P43, DOI 10.1002/ajh.10263 Trouillas P, 2006, STROKE, V37, P556, DOI 10.1161/01.STR.0000196942.84707.71 Uchiyama S., 2003, NEUROMED, V58, P463 Varki A, 2007, BLOOD, V110, P1723, DOI 10.1182/blood-2006-10-053736 Vernooij MW, 2008, NEUROLOGY, V70, P1208, DOI 10.1212/01.wnl.0000307750.41970.d9 Wahlgren N, 2007, LANCET, V369, P275, DOI 10.1016/S0140-6736(07)60149-4 Wahrenbrock M, 2003, J CLIN INVEST, V112, P853, DOI 10.1172/JCI200318882 Whiteley WN, 2012, STROKE, V43, P2904, DOI 10.1161/STROKEAHA.112.665331 NR 27 TC 4 Z9 6 U1 0 U2 8 PU SPRINGER INTERNATIONAL PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 2193-1801 J9 SPRINGERPLUS JI SpringerPlus PD MAR 25 PY 2015 VL 4 AR 141 DI 10.1186/s40064-015-0920-z PG 5 WC Multidisciplinary Sciences WE Science Citation Index Expanded (SCI-EXPANDED) SC Science & Technology - Other Topics GA CO5JR UT WOS:000359195900002 PM 25830084 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Kawano, H Kohno, Y Izumida, S Tsuneto, A Fukae, S Takeno, M Koide, Y Maemura, K AF Kawano, Hiroaki Kohno, Yusuke Izumida, Seiya Tsuneto, Akira Fukae, Satoki Takeno, Masayoshi Koide, Yuji Maemura, Koji TI Rivaroxaban Therapy Resulting in the Resolution of Right Atrial Thrombosis Resistant to Ordinary Control with Warfarin in a Patient with Atrial Fibrillation SO INTERNAL MEDICINE LA English DT Article DE atrial fibrillation; anticoagulant; cancer; thrombus; warfarin ID APPENDAGE THROMBUS; DABIGATRAN; EFFICACY; CANCER AB A 72-year-old man with non-valvular atrial fibrillation and metastatic liver and lung cancer after surgery for colon cancer developed thrombosis in the right atrium one month after decreasing the dose of warfarin due to the introduction of double anti-platelet therapy for coronary stent implantation. Restoring the warfarin dose with ordinary control for two months did not result in any changes in the size of the thrombus; however, the subsequent substitution of rivaroxaban (oral treatment with a direct Factor Xa inhibitor) for warfarin ultimately resolved the thrombosis. C1 [Kawano, Hiroaki; Kohno, Yusuke; Izumida, Seiya; Tsuneto, Akira; Fukae, Satoki; Takeno, Masayoshi; Koide, Yuji; Maemura, Koji] Nagasaki Univ, Grad Sch Biomed Sci, Dept Cardiovasc Med, Nagasaki, Japan. C3 Nagasaki University RP Kawano, H (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Cardiovasc Med, Nagasaki, Japan. EM hkawano@nagasaki-u.ac.jp RI ; Koide, Yuji/T-8134-2019 OI Kawano, Hiroaki/0000-0002-0452-4384; FU Grants-in-Aid for Scientific Research [24390199, 22136007] Funding Source: KAKEN CR BICK RL, 1992, SEMIN THROMB HEMOST, V18, P353, DOI 10.1055/s-2007-1002575 DEFOUW NJ, 1990, ADV EXP MED BIOL, V281, P235 Falanga A, 1999, SEMIN THROMB HEMOST, V25, P173, DOI 10.1055/s-2007-994919 Hammerstingl C, 2013, THROMB HAEMOSTASIS, V109, P583, DOI 10.1160/TH12-11-0821 Kaku Bunji, 2013, J Med Case Rep, V7, P238, DOI 10.1186/1752-1947-7-238 Kawakami T, 2013, THROMB J, V11, DOI 10.1186/1477-9560-11-26 Lee AYY, 2005, DM-DIS MON, V51, P150, DOI 10.1016/j.disamonth.2005.03.010 Miller CS, 2012, AM J CARDIOL, V110, P453, DOI 10.1016/j.amjcard.2012.03.049 Morita S, 2013, EUR HEART J, V34, DOI 10.1093/eurheartj/eht148 Varin R, 2013, THROMB RES, V131, pE100, DOI 10.1016/j.thromres.2012.11.029 Vidal A, 2012, J THROMB THROMBOLYS, V34, P545, DOI 10.1007/s11239-012-0747-1 NR 11 TC 7 Z9 8 U1 0 U2 2 PU JAPAN SOC INTERNAL MEDICINE PI TOKYO PA 34-3 3-CHOME HONGO BUNKYO-KU, TOKYO, 113, JAPAN SN 0918-2918 EI 1349-7235 J9 INTERNAL MED JI Intern. Med. PY 2015 VL 54 IS 6 BP 601 EP 604 DI 10.2169/internalmedicine.54.3003 PG 4 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA CE1BZ UT WOS:000351548100011 PM 25786449 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Martucci, N Tracey, M La Rocca, A La Manna, C De Luca, G Rocco, G AF Martucci, Nicola Tracey, Maura La Rocca, Antonello La Manna, Carmine De Luca, Giuseppe Rocco, Gaetano TI A pilot prospective randomized, controlled trial comparing LigaSure™ tissue fusion technology with the ForceTriad™ energy platform to the electrosurgical pencil on rates of atrial fibrillation after pulmonary lobectomy and mediastinal lymphadenectomy SO EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY LA English DT Article DE Atrial fibrillation; Lobectomy; Lung cancer; Lymphadenectomy ID LUNG-CANCER; AMERICAN-COLLEGE; EUROPEAN-SOCIETY; SURGERY; GUIDELINES; CARCINOMA; RESECTION; NUMBER AB OBJECTIVES: The use of bipolar sealing devices during pulmonary resection is particularly useful in thoracoscopic surgery. Theoretically, a bipolar device, which contains the current in a smaller area and completes the current cycle only through the tissue between the electrodes, may reduce the proportion of patients experiencing atrial fibrillation compared with monopolar devices such as the electrosurgical pencil using which the current completes the cycle through the patient. We investigated the impact of the LigaSure (TM) (LS) tissue fusion technology with the ForceTriad (TM) energy platform device on the incidence of postoperative atrial fibrillation and on the reduction of postoperative chest tube output and hospital length of stay after open pulmonary lobectomy. METHODS: A pilot prospective randomized, controlled trial comparing LS tissue fusion technology with the ForceTriad (TM) energy platform to the conventional electrosurgical pencil. Overall, 146 patients with resectable lung cancer were recruited at the Division of Thoracic Surgery of the Istituto Nazionale Tumori, Fondazione Pascale, IRCCS, between January 2011 and July 2013. Of these, 119 candidates to open lobectomy for non-small-cell lung cancer were randomized to either LS tissue fusion technology with the ForceTriad (TM) energy platform (LS: 57 patients) or standard haemostatic procedure (standard treatment, ST: 62 patients) for hilar and mediastinal nodal dissection. The primary end-point was to compare the incidence of postoperative atrial fibrillation of LS compared with ST. The secondary end-point was to compare the efficacy of LS compared with ST in terms of total chest tube drainage, daily chest tube drainage and chest tube duration. RESULTS: There was no statistically significant difference between LS and ST in terms of postoperative atrial fibrillation (P = 0.31). However, LS was associated to significant reduction of duration of both mediastinal nodal dissection (P = 0.017) and the cumulative chest tube drainage (P = 0.025). CONCLUSIONS: The incidence of atrial fibrillation with LS tissue fusion technology with the ForceTriad (TM) energy platform is not reduced as compared with conventional electrosurgical pencil. However, the use of LS during mediastinal nodal dissection is associated to shorter duration of lymphadenectomy and duration of chest tube drainage. C1 [Martucci, Nicola; Tracey, Maura; La Rocca, Antonello; La Manna, Carmine; De Luca, Giuseppe; Rocco, Gaetano] Fdn G Pascale IRCCS, Ist Nazl Tumori, Div Thorac Surg, Dept Thorac Surg & Oncol, I-80131 Naples, Italy. C3 Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Fondazione Pascale RP Rocco, G (corresponding author), Fdn G Pascale IRCCS, Ist Nazl Tumori, Div Thorac Surg, Via M Semmola 81, I-80131 Naples, Italy. EM g.rocco@istitutotumori.na.it RI Rocco, Gaetano/K-4801-2016 OI Rocco, Gaetano/0000-0003-4150-8604 CR Allen MS, 2006, ANN THORAC SURG, V81, P1013, DOI 10.1016/j.athoracsur.2005.06.066 Andrade J, 2014, CIRC RES, V114, P1453, DOI 10.1161/CIRCRESAHA.114.303211 Bertolaccini L, 2014, EUR J CARDIO-THORAC, V45, P693, DOI 10.1093/ejcts/ezt445 Brunelli A, 2009, EUR J CARDIO-THORAC, V36, P181, DOI 10.1016/j.ejcts.2009.04.022 Darling GE, 2011, CHEST, V139, P1124, DOI 10.1378/chest.10-0859 Darling GE, 2011, J THORAC CARDIOV SUR, V141, P662, DOI 10.1016/j.jtcvs.2010.11.008 De Leyn P, 2011, J THORAC CARDIOV SUR, V141, P881, DOI 10.1016/j.jtcvs.2010.09.019 El-Sherif A, 2006, ANN THORAC SURG, V82, P408, DOI 10.1016/j.athoracsur.2006.02.029 Eroglu A, 2007, ANN THORAC SURG, V84, P2076, DOI 10.1016/j.athoracsur.2007.04.119 Fernando HC, 2011, ANN THORAC SURG, V92, P1144, DOI 10.1016/j.athoracsur.2011.06.104 Gajra A, 2003, J CLIN ONCOL, V21, P1029, DOI 10.1200/JCO.2003.07.010 Gonzalez-Rivas D, 2013, ANN THORAC SURG, V95, P426, DOI 10.1016/j.athoracsur.2012.10.070 Lang RM, 2005, J AM SOC ECHOCARDIOG, V18, P1440, DOI 10.1016/j.echo.2005.10.005 Lardinois D, 2006, EUR J CARDIO-THORAC, V30, P787, DOI 10.1016/j.ejcts.2006.08.008 Lesser TG, 2013, J THORAC CARDIOV SUR, V145, P1525, DOI 10.1016/j.jtcvs.2012.11.009 Martin-Suarez Sofia, 2007, Interact Cardiovasc Thorac Surg, V6, P71 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Perez-Lugones A, 2003, J CARDIOVASC ELECTR, V14, P803, DOI 10.1046/j.1540-8167.2003.03075.x Su S, 2014, J THORAC CARDIOV SUR, V148, P756 Su S, 2014, J THORAC CARDIOV SUR, V147, P747, DOI 10.1016/j.jtcvs.2013.10.001 NR 20 TC 10 Z9 11 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1010-7940 EI 1873-734X J9 EUR J CARDIO-THORAC JI Eur. J. Cardio-Thorac. Surg. PD JAN PY 2015 VL 47 IS 1 BP E13 EP E18 DI 10.1093/ejcts/ezu391 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA CE9LZ UT WOS:000352166800004 PM 25312529 OA Bronze DA 2026-04-17 ER PT J AU Peer, M Stav, D Cyjon, A Sandbank, J Vasserman, M Haitov, Z Sasson, L Schreiber, L Ezri, T Priel, IE Hayat, H AF Peer, Michael Stav, David Cyjon, Arnold Sandbank, Judith Vasserman, Margarita Haitov, Zoya Sasson, Lior Schreiber, Letizia Ezri, Tiberiu Priel, Israel E. Hayat, Henri TI Morbidity and Mortality after Major Pulmonary Resections in Patients with Locally Advanced Stage IIIA Non-small Cell Lung Carcinoma Who Underwent Induction Therapy SO HEART LUNG AND CIRCULATION LA English DT Article DE Lung cancer surgery; Thoracotomy; Pneumonectomy; Lobectomy; Chemoradiation; Chemotherapy ID PREOPERATIVE CHEMOTHERAPY; NEOADJUVANT THERAPY; CANCER; RADIOTHERAPY; SURGERY; PNEUMONECTOMY; TRIAL; COMPLICATIONS AB Background The optimal treatment for patients with locally advanced stage IIIA non-small cell lung carcinoma (NSCLC) remains controversial, but induction therapy is increasingly used. The aim of this study was to evaluate mortality, morbidity, hospital stay and frequency of postoperative complications in stage IIIA NSCLC patients that underwent major pulmonary resections after neoadjuvant chemotherapy or chemoradiation. Methods We conducted a retrospective analysis of all patients who underwent major pulmonary resections after induction therapy for locally advanced NSCLC from October 2009 to February 2014. Forty-one patients were included in the study. Results Complete resection was achieved in 40 patients (97.5%). A complete pathologic response was seen in 10 patients (24.4%). Mean hospital stay was 17.7 days (ranged 5-129 days). Early (in-hospital) mortality occurred in 2.4% (one patient after bilobectomy), late (six months) mortality in 4.9% (two patients after right pneumonectomy and bilobectomy), and overall morbidity in 58.5% (24 patients). Postoperative complications included: bronchopleural fistula (BPF) with empyema - three patients, empyema without BPF - five patients, air leak - eight patients, atrial fibrillation - eight patients, pneumonia - eight patients, and lobar atelectasis - four patients. Conclusion Following neoadjuvant therapy for stage IIIA NSCLC, pneumonectomy can be performed with low early and late mortality (0% and 5.8%, respectively), bilobectomy is a high risk operation (16.7% early and 16.7% late mortality); and lobectomy a low risk operation (0% early and late mortality). The need for major pulmonary resections should not be a reason to exclude patients from a potentially curative procedure if it can be performed with acceptable morbidity and mortality rates at an experienced medical centre. C1 [Peer, Michael] Assaf Harofeh Med Ctr, Dept Thorac Surg, IL-70300 Zerifin, Israel. [Peer, Michael; Stav, David; Cyjon, Arnold; Sandbank, Judith; Vasserman, Margarita; Haitov, Zoya] Tel Aviv Univ, Sackler Fac Med, Ramat Aviv, Israel. [Stav, David] Assaf Harofeh Med Ctr, Dept Pulmonol, IL-70300 Zerifin, Israel. [Cyjon, Arnold] Assaf Harofeh Med Ctr, Dept Oncol, IL-70300 Zerifin, Israel. [Sandbank, Judith] Assaf Harofeh Med Ctr, Dept Pathol, IL-70300 Zerifin, Israel. [Vasserman, Margarita] Assaf Harofeh Med Ctr, Inst Diagnost Imaging, IL-70300 Zerifin, Israel. [Haitov, Zoya] Assaf Harofeh Med Ctr, Dept Anesthesiol, IL-70300 Zerifin, Israel. [Sasson, Lior] Edith Wolfson Med Ctr, Dept Cardiothorac Surg, Holon, Israel. [Sasson, Lior; Schreiber, Letizia; Ezri, Tiberiu; Priel, Israel E.; Hayat, Henri] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel. [Schreiber, Letizia] Edith Wolfson Med Ctr, Dept Pathol, Holon, Israel. [Ezri, Tiberiu] Edith Wolfson Med Ctr, Dept Anesthesiol, Holon, Israel. [Priel, Israel E.] Edith Wolfson Med Ctr, Dept Pulm Med, Holon, Israel. [Hayat, Henri] Edith Wolfson Med Ctr, Dept Oncol, Holon, Israel. C3 Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Shamir Medical Center (Assaf Harofeh); Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Tel Aviv University; Shamir Medical Center (Assaf Harofeh); Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Tel Aviv University; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Tel Aviv University; Tel Aviv University; Tel Aviv University RP Peer, M (corresponding author), Assaf Harofeh Med Ctr, Dept Gen Thorac Surg, IL-70300 Zerifin, Israel. EM michaelp@asaf.health.gov.il CR Albain KS, 2009, LANCET, V374, P379, DOI 10.1016/S0140-6736(09)60737-6 Anraku M, SABISTON SPENCER SUR Brambilla E, 2001, EUR RESPIR J, V18, P1059, DOI 10.1183/09031936.01.00275301 Cerfolio RJ, 2005, ANN THORAC SURG, V80, P1224, DOI 10.1016/j.athoracsur.2005.02.091 d'Amato TA, 2009, ANN THORAC SURG, V88, P1079, DOI 10.1016/j.athoracsur.2009.06.025 Decaluwé H, 2009, EUR J CARDIO-THORAC, V36, P433, DOI 10.1016/j.ejcts.2009.04.013 DeCamp MM, 2003, J THORAC CARDIOV SUR, V126, P17, DOI 10.1016/S0022-5223(03)00206-X Fruchter O, 2011, CHEST, V139, P682, DOI 10.1378/chest.10-1528 Gudbjartsson T, 2008, ANN THORAC SURG, V86, P376, DOI 10.1016/j.athoracsur.2008.04.013 Kappers I, 2010, LUNG CANCER, V68, P222, DOI 10.1016/j.lungcan.2009.07.001 Kim AW, 2011, ANN THORAC SURG, V92, P233, DOI 10.1016/j.athoracsur.2011.03.001 Lardinois D, 2006, EUR J CARDIO-THORAC, V30, P787, DOI 10.1016/j.ejcts.2006.08.008 Martin J, 2001, ANN THORAC SURG, V72, P1149, DOI 10.1016/S0003-4975(01)02995-2 Perrot E, 2005, ANN THORAC SURG, V80, P423, DOI 10.1016/j.athoracsur.2005.02.043 Refai M, 2010, EUR J CARDIO-THORAC, V37, P535, DOI 10.1016/j.ejcts.2009.09.018 Rivera C, 2012, LUNG CANCER, V76, P216, DOI 10.1016/j.lungcan.2011.10.010 ROSELL R, 1994, NEW ENGL J MED, V330, P153, DOI 10.1056/NEJM199401203300301 ROTH JA, 1994, J NATL CANCER I, V86, P673, DOI 10.1093/jnci/86.9.673 Sonett JR, 2004, ANN THORAC SURG, V78, P1200, DOI 10.1016/j.athoracsur.2004.04.085 Stamatis G, 2004, LUNG CANCER, V45, pS107, DOI 10.1016/j.lungcan.2004.07.984 Stamatis G, 2002, EUR J CARDIO-THORAC, V22, P292, DOI 10.1016/S1010-7940(02)00266-X van Meerbeeck JP, 2007, JNCI-J NATL CANCER I, V99, P442, DOI 10.1093/jnci/djk093 Van Schil P, 2005, EUR RESPIR J, V26, P192, DOI 10.1183/09031936.05.00127204 Venuta F, 2007, EUR J CARDIO-THORAC, V31, P714, DOI 10.1016/j.ejcts.2007.01.017 Weder W, 2010, J THORAC CARDIOV SUR, V139, P1424, DOI 10.1016/j.jtcvs.2010.02.039 NR 25 TC 9 Z9 12 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA SN 1443-9506 EI 1444-2892 J9 HEART LUNG CIRC JI Heart Lung Circ. PD JAN PY 2015 VL 24 IS 1 BP 69 EP 76 DI 10.1016/j.hlc.2014.07.055 PG 8 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA CD3VO UT WOS:000351011400016 PM 25086910 DA 2026-04-17 ER PT J AU Rydzek, J Gasior, ZT Dabek, J Wojnar, J Skrzypek, M AF Rydzek, Jaroslaw Gasior, Zbigniew T. Dabek, Jozefa Wojnar, Jerzy Skrzypek, Michal TI Assessment of risk factors for mortality in patients with cardiovascular disease and a history of treatment for malignancy SO KARDIOLOGIA POLSKA LA English DT Article DE malignancy; cardiovascular diseases; prognosis; therapy ID CONGESTIVE-HEART-FAILURE; ADVANCED CANCER-PATIENTS; CORONARY-ARTERY-DISEASE; TERMINALLY-ILL PATIENTS; ATRIAL-FIBRILLATION; BREAST-CANCER; SURVIVAL; CHEMOTHERAPY; INTERVENTIONS; PREVALENCE AB Background: Patients with advanced cancer after radio-and/or chemotherapy are increasingly commonly hospitalised in cardiology units due to coexisting cardiovascular diseases (CVD). A rational assessment of mortality risk is an important part of patient preparation for invasive cardiac procedures. One disadvantage of cardiac risk scores is the fact that malignancies are not taken into account. At present, accurate estimation of life expectancy is possible in up to 20% of patients with an advanced malignancy. Aim: To evaluate the effect of selected clinical parameters on survival of patients with CVD and coexisting lung or breast cancer after radio-and/or chemotherapy. An additional aim was to identify patients with a high probability of surviving a year in a good general clinical condition. Methods: The study group involved 326 subjects with established CVD and lung cancer (small-cell or non-small-cell) or breast cancer who were selected from the group of 7818 patients receiving palliative care in the Palium hospice in Czestochowa, Poland, in 2008-2012. The obtained data were collected in a database and subjected to a statistical analysis. Results: The strongest factors associated with an increased risk of death among patients with CVD and coexisting advanced lung or breast cancer after chemo-and/or radiotherapy were the type and stage of malignancy, functional status according to the ECOG classification, and the presence of cachexia. Other factors that had a significant effect on survival included higher severity of heart failure symptoms as evaluated by the New York Heart Association class, decreased left ventricular ejection fraction, presence of ischaemic heart disease, chronic obstructive pulmonary disease, fasting hyperglycaemia, and the severity of fatigue, nausea, and pain. When the effects of drug treatment on survival were analysed, significantly increased survival was observed in patients treated with angiotensin-converting enzyme inhibitors while diuretic and glucocorticosteroid use was associated with decreased survival. Among the evaluated groups of patients with CVD and advanced malignancy after radio-and/or chemotherapy, the highest probability of surviving a year in a relatively good general clinical condition was noted in patients with stage 3 breast cancer without cachexia, ischaemic heart disease and persistent somatic symptoms who were treated with tamoxifen, angiotensin-converting enzyme inhibitors and megestrol acetate. Conclusions: This is the first study that evaluated the combined effect of oncological and cardiovascular risk factors on survival of patients with CVD and coexisting cancer after radio-and/or chemotherapy treatment. When the three groups of cancer patients with different prognosis were compared, the study revealed varying effects of each factor depending on the underlying malignancy. The analysis confirmed the significance of the cumulative risk. The present study showed that malignancy-related prognostic factors are important in the context of cardiac evaluation and treatment of cancer patients. It also showed that further research is needed to clarify these issues. C1 [Rydzek, Jaroslaw] Swietokrzyskie Ctr Cardiol, Kielce, Poland. [Rydzek, Jaroslaw] Voivodship Polyclin Hosp, Czestochowa, Poland. [Gasior, Zbigniew T.; Dabek, Jozefa] Med Univ Silesia, SHS, Dept Cardiol, PL-40635 Katowice, Poland. [Wojnar, Jerzy] Med Univ Silesia, SMK, Dept Internal Med & Oncol Chemotherapy, PL-40635 Katowice, Poland. [Skrzypek, Michal] Med Univ Silesia, SPDLM, Dept Biostat, PL-40635 Katowice, Poland. C3 Medical University of Silesia; Medical University of Silesia; Medical University of Silesia RP Gasior, ZT (corresponding author), Med Univ Silesia, SHS, Dept Cardiol, Ul Ziolowa 45, PL-40635 Katowice, Poland. EM zgasior@sum.edu.pl OI Dąbek, Józefa/0000-0002-8257-6614; Gąsior, Zbigniew/0000-0003-3616-8932 CR [Anonymous], COCHRANE DATABASE SY Braithwaite RS, 2003, J GEN INTERN MED, V18, P937, DOI 10.1046/j.1525-1497.2003.20724.x Buzdar A, 2006, CURR MED RES OPIN, V22, P1575, DOI 10.1185/030079906X120940 Chen YX, 2010, ENDOCR-RELAT CANCER, V17, P39, DOI 10.1677/ERC-08-0296 Christakis NA, 2000, BRIT MED J, V320, P469, DOI 10.1136/bmj.320.7233.469 Clarke MJ, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000486.pub2 Feng JF, 2011, ADV CLIN EXP MED, V20, P473 Fox K, 2008, LANCET, V372, P807, DOI 10.1016/S0140-6736(08)61170-8 Glare P, 2003, BRIT MED J, V327, P195, DOI 10.1136/bmj.327.7408.195 Heeringa J, 2006, EUR HEART J, V27, P949, DOI 10.1093/eurheartj/ehi825 Huiart L, 2005, CHEST, V128, P2640, DOI 10.1378/chest.128.4.2640 Maltoni M, 2005, J CLIN ONCOL, V23, P6240, DOI 10.1200/JCO.2005.06.866 Mizia-Stec K, 2013, KARDIOL POL, V71, P681, DOI 10.5603/KP.2013.0154 Naccarelli GV, 2009, AM J CARDIOL, V104, P1534, DOI 10.1016/j.amjcard.2009.07.022 Palatini P, 2006, J HYPERTENS, V24, P603, DOI 10.1097/01.hjh.0000217838.49842.1e Powe DG, 2010, ONCOTARGET, V1, P628, DOI 10.18632/oncotarget.197 Rosenhek R, 2012, EUR HEART J, V33, P822, DOI 10.1093/eurheartj/ehr061 Schuit KW, 1998, J PAIN SYMPTOM MANAG, V16, P290, DOI 10.1016/S0885-3924(98)00091-8 SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429 Teno J M, 2001, J Palliat Med, V4, P457, DOI 10.1089/109662101753381593 Teunissen SC, 2006, EUR J CANCER, V42, P2510, DOI 10.1016/j.ejca.2006.05.025 Viganò A, 1999, J PALLIATIVE CARE, V15, P32, DOI 10.1177/082585979901500406 Vitetta L, 2001, J PALLIATIVE CARE, V17, P69, DOI 10.1177/082585970101700202 Wozakowska-Kaplon B, 2008, KARDIOL POL, V66, P415 YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501 NR 25 TC 8 Z9 8 U1 0 U2 5 PU VIA MEDICA PI GDANSK PA UL SWIETOKRZYSKA 73, 80-180 GDANSK, POLAND SN 0022-9032 EI 1897-4279 J9 KARDIOL POL JI Kardiol. Pol. PY 2015 VL 73 IS 9 BP 730 EP 739 DI 10.5603/KP.a2015.0071 PG 10 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA CU3DD UT WOS:000363403200004 PM 26390319 OA hybrid DA 2026-04-17 ER PT J AU Elrakhawy, HM Alassal, MA Elsadeck, N Shaalan, A Ezeldin, TH Shalabi, A AF Elrakhawy, Hany M. Alassal, Mohamed A. Elsadeck, Nabil Shaalan, Ayman Ezeldin, Tamer H. Shalabi, Ali TI Predictive Factors of Supraventricular Arrhythmias after Noncardiac Thoracic Surgery: A Multicenter Study SO HEART SURGERY FORUM LA English DT Article ID POSTOPERATIVE ATRIAL-FIBRILLATION; CELL LUNG-CANCER; RISK-FACTORS; PULMONARY RESECTION; PROGNOSTIC-SIGNIFICANCE; AMIODARONE; DILTIAZEM; PNEUMONECTOMY; THORACOTOMY; PROPHYLAXIS AB Background: Supraventricular cardiac arrhythmias are the most common rhythm disturbances in patients following thoracic surgery. The purpose of our study was to determine which of the clinical parameters are the most valuable in predicting postoperative atrial fibrillation (AF) after lung surgery. Methods: Retrospective analysis was carried out on 987 patients after noncardiac thoracic surgery to define the prevalence, associated risk factors, and clinical course of postoperative arrhythmias. There were 822 men and 165 women, age 34 to 78 years (mean age: 61 +/- 8 years). The patients were divided into two groups depending on the occurrence or absence of supraventricular arrhythmia. Group I consisted of 876 patients who were free from rhythm disturbances. The remaining 111 patients exhibited episodes of supraventricular arrhythmia (29 supraventricular tachycardia; 82 AF). These 111 patients were placed in Group II. Preoperative, operative, and postoperative data were reviewed. Statistical analysis was performed. Results: A statistically significant difference was found between the two groups in age, previous history of heart disease, and lung resection, especially pneumonectomy. Conclusion: Age, history of prior heart disease, lung resection, and the extent of pulmonary resection are the main risk factors for postoperative supraventricular arrhythmia in patients undergoing major thoracic operations. C1 [Elrakhawy, Hany M.; Alassal, Mohamed A.; Shaalan, Ayman; Ezeldin, Tamer H.; Shalabi, Ali] Banha Univ, Dept Cardiothorac Surg, Banha, Egypt. [Alassal, Mohamed A.; Shaalan, Ayman] King Fahad Med City, Prince Salman Heart Ctr, Riyadh 11525, Saudi Arabia. [Elsadeck, Nabil] Zagazig Univ, Dept Cardiothorac Surg, Zagazig, Egypt. [Elsadeck, Nabil] Assir Cent Hosp, Abha, Saudi Arabia. [Elrakhawy, Hany M.] Saud Al Babtain Cardiac Ctr, Dept Cardiothorac Surg, Dammam, Saudi Arabia. C3 Egyptian Knowledge Bank (EKB); Benha University; King Fahad Medical City; Egyptian Knowledge Bank (EKB); Zagazig University; Assir Central Hospital RP Alassal, MA (corresponding author), King Fahad Med City, Prince Salman Heart Ctr, Dhabab St,POB 59046, Riyadh 11525, Saudi Arabia. EM dmohamedabdelwahab@gmail.com RI alassal, mohamed/L-2459-2019 CR Amar D, 2000, J THORAC CARDIOV SUR, V120, P790, DOI 10.1067/mtc.2000.109538 Amar D, 2002, ANESTHESIOLOGY, V96, P352, DOI 10.1097/00000542-200202000-00021 Amar D, 1996, ANN THORAC SURG, V61, P1506, DOI 10.1016/0003-4975(96)00111-7 Anile M, 2012, EUR J CARDIO-THORAC, V41, P1094, DOI 10.1093/ejcts/ezr174 ASAMURA H, 1993, J THORAC CARDIOV SUR, V106, P1104, DOI 10.1016/S0022-5223(19)33985-6 Bobbio A, 2007, EUR J CARDIO-THORAC, V31, P70, DOI 10.1016/j.ejcts.2006.10.020 Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Ciriaco P, 2000, EUR J CARDIO-THORAC, V18, P12, DOI 10.1016/S1010-7940(00)00428-0 Dyszkiewicz W, 1998, EUR J CARDIO-THORAC, V13, P625, DOI 10.1016/S1010-7940(98)00084-0 ELLENBOGEN KA, 1991, J AM COLL CARDIOL, V18, P891, DOI 10.1016/0735-1097(91)90743-S Gómez-Caro A, 2006, ARCH BRONCONEUMOL, V42, P9, DOI 10.1016/S1579-2129(06)60107-9 Harpole DH, 1996, ANN THORAC SURG, V61, P977, DOI 10.1016/0003-4975(95)01174-9 Imperatori A, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-4 KROWKA MJ, 1987, CHEST, V91, P490, DOI 10.1378/chest.91.4.490 Lanza LA, 2003, ANN THORAC SURG, V75, P223, DOI 10.1016/S0003-4975(02)04285-6 Neragi-Miandoab Siyamek, 2008, Interact Cardiovasc Thorac Surg, V7, P1039, DOI 10.1510/icvts.2008.181099 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Podrid PJ, 1999, J AM COLL CARDIOL, V34, P340 Polanczyk CA, 1998, ANN INTERN MED, V129, P279, DOI 10.7326/0003-4819-129-4-199808150-00003 Rena O, 2001, EUR J CARDIO-THORAC, V20, P688, DOI 10.1016/S1010-7940(01)00890-9 Sekine Y, 2001, CHEST, V120, P1783, DOI 10.1378/chest.120.6.1783 Tisdale JE, 2009, ANN THORAC SURG, V88, P886, DOI 10.1016/j.athoracsur.2009.04.074 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 VONKNORRING J, 1992, ANN THORAC SURG, V53, P642, DOI 10.1016/0003-4975(92)90325-X ZIOMEK S, 1993, ANN THORAC SURG, V56, P223, DOI 10.1016/0003-4975(93)91151-C NR 25 TC 7 Z9 8 U1 0 U2 3 PU FORUM MULTIMEDIA PUBLISHING, LLC PI CHARLOTTESVILLE PA 375 GREENBRIER DR, CHARLOTTESVILLE, VA 22901 USA SN 1098-3511 EI 1522-6662 J9 HEART SURG FORUM JI Heart Surg. Forum PD DEC PY 2014 VL 17 IS 6 BP E308 EP E312 DI 10.1532/HSF98.2014412 PG 5 WC Cardiac & Cardiovascular Systems; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Surgery GA AZ0CX UT WOS:000347915000008 PM 25586281 OA gold DA 2026-04-17 ER PT J AU Feng, MX Shen, YX Wang, H Tan, LJ Mao, XP Liu, Y Wang, Q AF Feng, Mingxiang Shen, Yaxing Wang, Hao Tan, Lijie Mao, Xuping Liu, Yi Wang, Qun TI Uniportal video assisted thoracoscopic lobectomy: primary experience from an Eastern center SO JOURNAL OF THORACIC DISEASE LA English DT Article DE Lobectomy; minimally invasive surgery; non-small-cell-lung carcinoma (NSCLC) ID THORACIC-SURGERY LOBECTOMY; POSTOPERATIVE PAIN; SEGMENTECTOMY AB Background: Uniportal video-assisted thoracoscopic surgery (VATS) lobectomy is an emerging technique for the surgical resection of non-small cell lung cancer (NSCLC). Besides its wide debates on safety and efficacy throughout the world, there were few report on uniportal VATS from the Eastern countries. In this article, we summarized our primary experience on uniportal VATS lobectomy in an Eastern center. Methods: From October 2013 till February 2014, 54 consecutive uniportal VATS lobectomy were performed in the Department of Thoracic Surgery, Zhongshan Hospital of Fudan University. Patients' clinical features and operative details were recorded. Post-operatively, the morbidity and mortality were recorded to analyze the safety and efficacy of uniportal VATS lobectomy for NSCLCs. Results: Among the 54 planned uniportal VATS lobectomy, there was one conversion to mini-thoracotomy due to lymph node sticking. Extra ports were required in two patients. The uniportal VATS lobectomy was achieved in 51 out of 54 patients (94.4%). The average operation duration was 122.2 +/- 37.5 min (90-160 min). The average volume of estimated blood loss during the operation was 88.8 +/- 47.1 mL (50-200 mL). The mean chest tube duration and hospital stay were 3.2 +/- 1.9 days and 4.6 +/- 2.0 days, respectively. There was no postoperative mortality in this study. Two patients suffered from prolonged air leakage (5 and 7 days), and one atrial fibrillation was observed in this cohort. Conclusions: Based on our primary experience, uniportal VATS lobectomy is a safe and effective procedure for the surgical resection of NSCLCs. The surgical refinements and instrumental improvements would facilitate the technique. Further studies based on larger population are required to determine its benefits towards patients with NSCLCs. C1 [Feng, Mingxiang; Shen, Yaxing; Wang, Hao; Tan, Lijie; Liu, Yi; Wang, Qun] Fudan Univ, Zhongshan Hosp, Dept Thorac Surg, Shanghai 200032, Peoples R China. [Mao, Xuping] Danyang Peoples Hosp Jiangsu Prov, Dept Surg, Danyang 212300, Peoples R China. C3 Fudan University RP Tan, LJ (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Thorac Surg, 180 Fenglin Rd, Shanghai 200032, Peoples R China. EM Tan.lijie@zs-hospital.sh.cn; Mxp_dy@sina.com RI Shen, Yaxing/JBU-4021-2023 CR Alar T, 2013, SURG ENDOSC, V27, P4333, DOI 10.1007/s00464-013-3060-y Andreetti C, 2014, EUR J CARDIO-THORAC, V46, P907, DOI 10.1093/ejcts/ezu092 Berlanga LA, 2011, SURG ENDOSC, V25, P2044, DOI 10.1007/s00464-010-1470-7 Feng M, 2014, ASVIDE, V1, P359 Gonzalez D, 2011, EUR J CARDIO-THORAC, V40, pE21, DOI 10.1016/j.ejcts.2011.02.051 Gonzalez-Rivas D, 2013, INTERACT CARDIOV TH, V17, P889, DOI 10.1093/icvts/ivt340 Gonzalez-Rivas D, 2013, J THORAC DIS, V5, pS246, DOI 10.3978/j.issn.2072-1439.2013.07.44 Gonzalez-Rivas D, 2013, J THORAC CARDIOV SUR, V145, P1676, DOI 10.1016/j.jtcvs.2013.02.052 Gonzalez-Rivas D, 2013, ANN THORAC SURG, V95, P426, DOI 10.1016/j.athoracsur.2012.10.070 Gonzalez-Rivas Diego, 2012, Multimed Man Cardiothorac Surg, V2012, pmms007, DOI 10.1093/mmcts/mms007 Gonzalez-Rivas D, 2012, EUR J CARDIO-THORAC, V42, pE169, DOI 10.1093/ejcts/ezs482 Jutley RS, 2005, EUR J CARDIO-THORAC, V28, P43, DOI 10.1016/j.ejcts.2005.02.039 McKenna RJ, 2006, ANN THORAC SURG, V81, P421, DOI 10.1016/j.athoracsur.2005.07.078 Ng CSH, 2014, INTERACT CARDIOV TH, V19, P661, DOI 10.1093/icvts/ivu200 Nicastri DG, 2008, J THORAC CARDIOV SUR, V135, P642, DOI 10.1016/j.jtcvs.2007.09.014 Rocco G, 2006, J THORAC CARDIOV SUR, V131, P921, DOI 10.1016/j.jtcvs.2005.12.014 Salati Michele, 2008, Interact Cardiovasc Thorac Surg, V7, P63, DOI 10.1510/icvts.2007.165712 Shen YX, 2014, ANN THORAC SURG, V98, P1072, DOI 10.1016/j.athoracsur.2014.04.107 Swanson SJ, 2007, J CLIN ONCOL, V25, P4993, DOI 10.1200/JCO.2007.12.6649 Tam JKC, 2013, ANN THORAC SURG, V96, P1982, DOI 10.1016/j.athoracsur.2013.07.002 Wang BY, 2013, ANN THORAC SURG, V96, P977, DOI 10.1016/j.athoracsur.2013.05.002 NR 21 TC 14 Z9 19 U1 0 U2 4 PU PIONEER BIOSCIENCE PUBL CO PI HONG KONG PA 9A GOLD SHINE TOWER, 346-348 QUEEN'S RD CENTRAL, SHEUNG WAN, HONG KONG, 00000, PEOPLES R CHINA SN 2072-1439 EI 2077-6624 J9 J THORAC DIS JI J. Thorac. Dis. PD DEC PY 2014 VL 6 IS 12 BP 1751 EP 1756 DI 10.3978/j.issn.2072-1439.2014.11.20 PG 6 WC Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System GA CA4DW UT WOS:000348855400034 PM 25589969 DA 2026-04-17 ER PT J AU Riber, LP Larsen, TB Christensen, TD AF Riber, Lars Peter Larsen, Torben Bjerregaard Christensen, Thomas Decker TI Postoperative Atrial Fibrillation Prophylaxis After Lung Surgery: Systematic Review and Meta-Analysis SO ANNALS OF THORACIC SURGERY LA English DT Article ID SUPRAVENTRICULAR ARRHYTHMIA; AMIODARONE PROPHYLAXIS; CARDIAC-ARRHYTHMIAS; MAGNESIUM-SULFATE; PREVENTION; RESECTION; DIGITALIZATION; PNEUMONECTOMY; DYSRHYTHMIAS; THORACOTOMY AB Background. Atrial fibrillation after thoracic surgery is frequent and increases morbidity and mortality. A number of trials have investigated medical prophylaxis for the prevention of atrial fibrillation after surgery for lung cancer. However, the literature is diverse and hence difficult to review. The aim of this study was to evaluate the safety and efficacy of reducing the risk of postoperative atrial fibrillation by the use of medical prophylaxis in patients undergoing surgery for lung cancer. Methods. A systematic review and meta-analysis of randomized, controlled trials investigating prophylactic medical interventions to reduce the risk of postoperative atrial fibrillation was performed. Results. A total number of 10 trials were identified. A significant reduction in the risk of postoperative atrial fibrillation was found with a relative risk of 0.53 (95% confidence interval, 0.42 to 0.67) and a number needed-to-treat of 8.5 (95% confidence interval, 6.4 to 13.3). Amiodarone was found to be the most effective prophylactic agent with a relative risk of 0.32 (95% confidence interval, 0.19 to 0.50) and a number needed-to-treat of 4.8 (95% confidence interval, 3.7 to 7.6) and regarded as safe, with no severe adverse events registered. The risk of atrial fibrillation was overall reduced from 25.1% to 13.4% (p < 0.001) and for amiodarone as a single therapy from 30.4% to 9.6% (p < 0.001). Conclusions. Medical prophylaxis with calcium-channel blockers, magnesium sulfate, or amiodarone significantly reduces the risk of developing atrial fibrillation after lung reduction surgery. However, amiodarone and magnesium sulfate were the most effective and safest drugs causing no increased risk of adverse events. (C) 2014 by The Society of Thoracic Surgeons. C1 [Riber, Lars Peter] Odense Univ Hosp, Dept Cardiothorac & Vasc Surg, Sdr Blvd 29, DK-5000 Odense, Denmark. Odense Univ Hosp, Inst Clin Med, DK-5000 Odense, Denmark. Aalborg Univ Hosp, Dept Cardiol, Cardiovasc Res Ctr, Aalborg, Denmark. Aalborg Univ Hosp, Dept Cardiothorac & Vasc Surg, Aalborg, Denmark. Aalborg Univ Hosp, Inst Clin Med, Aalborg, Denmark. Aalborg Univ, Fac Hlth, Aalborg Thrombosis Res Ctr, Dept Clin Med, Aalborg, Denmark. C3 University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital; Aalborg University; Aalborg University Hospital; Aalborg University; Aalborg University Hospital; Aalborg University; Aalborg University Hospital; Aalborg University RP Riber, LP (corresponding author), Odense Univ Hosp, Dept Cardiothorac & Vasc Surg, Sdr Blvd 29, DK-5000 Odense, Denmark. EM larspeterriber@gmail.com RI Riber, Lars/GRR-9540-2022; Larsen, Torben Bjerregaard/JHS-8123-2023 OI Riber, Lars/0000-0001-6898-2715; Larsen, Torben Bjerregaard/0000-0002-8485-8674 FU AstraZeneca; Boehringer Ingelheim FX Dr Riber discloses financial relationships with AstraZeneca and Boehringer Ingelheim; Dr Larsen with Janssen Scientific Affairs, LLC, Boehringer Ingelheim, Bayer, BMS, Pfizer, Roche Diagnostics, and Takeda; and Dr Christensen with Heim, AstraZeneca, Boehringer Ingelheim, Pfizer, Takeda, and Bristol-Myers Squibb. CR Amar D, 2000, J THORAC CARDIOV SUR, V120, P790, DOI 10.1067/mtc.2000.109538 Amar D, 1996, CHEST, V110, P437, DOI 10.1378/chest.110.2.437 Arsenault Kyle A, 2013, Cochrane Database Syst Rev, pCD003611, DOI 10.1002/14651858.CD003611.pub3 Asamura H, 1969, THORAX, V24, P568 Bailey CC, 1943, NEW ENGL J MED, V229, P356, DOI 10.1056/NEJM194308262290902 Ciriaco P, 2000, EUR J CARDIO-THORAC, V18, P12, DOI 10.1016/S1010-7940(00)00428-0 Curtis JJ, 1998, ANN THORAC SURG, V66, P1766, DOI 10.1016/S0003-4975(98)00942-4 Harpole DH, 1996, ANN THORAC SURG, V61, P977, DOI 10.1016/0003-4975(95)01174-9 Higgins JPT, 2008, COCHRANE HDB SYSTEMA Imperatori Andrea, 2012, J Cardiothorac Surg, V7, P4, DOI 10.1186/1749-8090-7-4 Jakobsen CJ, 1997, J CARDIOTHOR VASC AN, V11, P746, DOI 10.1016/S1053-0770(97)90169-5 KAISER A, 1994, HELV CHIR ACTA, V60, P913 Khalil MA, 2013, J ANESTH, V27, P56, DOI 10.1007/s00540-012-1478-3 KROWKA MJ, 1987, CHEST, V91, P490, DOI 10.1378/chest.91.4.490 Lanza LA, 2003, ANN THORAC SURG, V75, P223, DOI 10.1016/S0003-4975(02)04285-6 LINDGREN L, 1991, BRIT J ANAESTH, V66, P205, DOI 10.1093/bja/66.2.205 Polanczyk CA, 1998, ANN INTERN MED, V129, P279, DOI 10.7326/0003-4819-129-4-199808150-00003 Rena O, 2001, EUR J CARDIO-THORAC, V20, P688, DOI 10.1016/S1010-7940(01)00890-9 Riber LP, 2014, EUR J CARDIO-THORAC, V45, P120, DOI 10.1093/ejcts/ezt169 Riber LP, 2012, ANN THORAC SURG, V94, P339, DOI 10.1016/j.athoracsur.2011.12.096 RITCHIE AJ, 1992, THORAX, V47, P41, DOI 10.1136/thx.47.1.41 Stedman MR, 2011, INT J EPIDEMIOL, V40, P1732, DOI 10.1093/ije/dyp345 Terzi A, 1996, THORAC CARDIOV SURG, V44, P300, DOI 10.1055/s-2007-1012041 Tiryakioglu O, 2009, J CARDIOTHORAC SURG, V4, DOI 10.1186/1749-8090-4-8 Tisdale JE, 2009, ANN THORAC SURG, V88, P886, DOI 10.1016/j.athoracsur.2009.04.074 VanMieghem W, 1996, ANN THORAC SURG, V61, P1083, DOI 10.1016/0003-4975(96)00073-2 VANMIEGHEM W, 1994, CHEST, V105, P1642, DOI 10.1378/chest.105.6.1642 VONKNORRING J, 1992, ANN THORAC SURG, V53, P642, DOI 10.1016/0003-4975(92)90325-X WAHI R, 1989, ANN THORAC SURG, V48, P33, DOI 10.1016/0003-4975(89)90172-0 Zebis LR, 2008, ANN THORAC SURG, V85, P28, DOI 10.1016/j.athoracsur.2007.07.060 NR 30 TC 41 Z9 48 U1 0 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD DEC PY 2014 VL 98 IS 6 BP 1989 EP 1997 DI 10.1016/j.athoracsur.2014.06.069 PG 9 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA AU6WX UT WOS:000345743200023 PM 25283696 OA Bronze DA 2026-04-17 ER PT J AU Cagini, L Andolfi, M Leli, C Potenza, R Ragusa, M Scarnecchia, E Vannucci, J Rodseth, R Puma, F AF Cagini, Lucio Andolfi, Marco Leli, Christian Potenza, Rossella Ragusa, Mark Scarnecchia, Elisa Vannucci, Jacopo Rodseth, Reitze Puma, Francesco TI B-type natriuretic peptide following thoracic surgery: a predictor of postoperative cardiopulmonary complications SO EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY LA English DT Article; Proceedings Paper CT 22nd European Conference on General Thoracic Surgery CY JUN 15-18, 2014 CL Copenhagen, DENMARK DE B-type natriuretic peptide; Cardiovascular complication; Pulmonary complication; Pulmonary resection; Perioperative management; Non-small-cell lung cancer ID CARDIAC RISK-ASSESSMENT; PULMONARY COMPLICATIONS; ATRIAL-FIBRILLATION; NONCARDIAC SURGERY; LUNG-CANCER; RESECTION; GUIDELINES; MORTALITY; DISEASE AB B-type natriuretic peptides (BNPs) are secreted by the human heart in response to ventricular wall stretch or myocardial ischaemia, and predict adverse cardiovascular events and death in the general population. Following non-cardiac surgical procedures, there is growing evidence supporting BNP measurement as a powerful independent predictor of death and perioperative complications. However, the clinical implication of elevated BNP measurements after pulmonary resection has not been completely defined. This study aimed to evaluate the role of BNP in predicting adverse cardiopulmonary events after thoracic surgery. A prospective, short-term, observational cohort study was conducted in a tertiary care hospital, including consecutive patients undergoing scheduled pulmonary resection between April 2012 and October 2013. Baseline clinical details were obtained; serum BNP levels were measured at baseline and on postoperative days 1 and 4. We enrolled 294 consecutive patients, median age 66 [interquartile range (IQR): 57-73], 67% male. There were 2 perioperative deaths, and 52 patients experienced one or more cardiopulmonary complications. The baseline median BNP value was normal (29.5 pg/ml, IQR: 16-57.2), and showed significant postoperative increase, peaking on day 1. Patients who developed postoperative complications had a significantly greater BNP increase (P < 0.0001) when compared with those without complications. A postoperative day 1 BNP measurement of a parts per thousand yen118.5 [receiver operating characteristic area: 0.654; 95% confidence interval (CI): 0.57-0.74; P = 0.001] was associated with a 3-fold risk of developing postoperative cardiopulmonary complications [odds ratio (OR): 2.94; 95% CI: 1.32-6.57; P = 0.008]. Logistic regression analysis showed major pulmonary resections (lobectomies or pneumonectomies), BNP a parts per thousand yen 118.5 and age a parts per thousand yen 65 to be the only independent predictive variables. In the subset of patients undergoing lobectomy or pneumonectomy (n = 226), BNP was the strongest independent predictor of complications (OR: 3.49; 95% CI: 1.51-8.04). Our results show that BNP elevation, measured in the first days after thoracic surgery, is independently associated with postoperative adverse events. In patients undergoing major pulmonary resections, a postoperative BNP elevation is the strongest independent predictor of cardiopulmonary complications. C1 [Cagini, Lucio; Andolfi, Marco; Potenza, Rossella; Ragusa, Mark; Scarnecchia, Elisa; Vannucci, Jacopo; Puma, Francesco] Univ Perugia, Osped S Maria, Thorac Surg Unit, Dept Surg Sci, I-06134 Perugia, Italy. [Leli, Christian] Univ Perugia, Microbiol Sect, Dept Expt Med & Biochem Sci, I-06134 Perugia, Italy. [Rodseth, Reitze] Univ KwaZulu Natal, Nelson R Mandela Sch Med, Greys Hosp, Perioperat Res Grp,Dept Anaesthet, Pietermaritzburg, South Africa. C3 University of Perugia; University of Perugia; University of Kwazulu Natal RP Cagini, L (corresponding author), Univ Perugia, Santa Maria della Misericordia Hosp, Thorac Surg Unit, Dept Surg Sci, Piazzale Menghini 1, I-06134 Perugia, Italy. EM lucio.cagini@unipg.it RI ; Leli, Christian/AAP-9337-2020; Andolfi, Marco/AAM-9091-2020; Rodseth, Reitze/B-2471-2010 OI SCARNECCHIA, ELISA/0000-0003-3817-1852; Potenza, Rossella/0000-0002-0315-9928; Leli, Christian/0000-0002-8689-7028; Puma, Francesco/0000-0002-6861-168X; cagini, lucio/0000-0001-9464-9430; Andolfi, Marco/0000-0002-0399-7374; Rodseth, Reitze/0000-0002-3779-7805 CR Agostini P, 2010, THORAX, V65, P815, DOI 10.1136/thx.2009.123083 Amar D, 2012, J THORAC CARDIOV SUR, V144, P1249, DOI 10.1016/j.jtcvs.2012.06.051 Biccard BM, 2012, ANAESTHESIA, V67, P55, DOI 10.1111/j.1365-2044.2011.06958.x Cagini L, 2011, EUR J CARDIO-THORAC, V40, pE71, DOI 10.1016/j.ejcts.2011.03.030 Cardinale D, 2007, CIRCULATION, V115, P1339, DOI 10.1161/CIRCULATIONAHA.106.647008 Clerico A, 2014, J AM COLL CARDIOL, V63, P181, DOI 10.1016/j.jacc.2013.09.015 Clerico A, 2011, AM J PHYSIOL-HEART C, V301, pH12, DOI 10.1152/ajpheart.00226.2011 Ford MK, 2010, ANN INTERN MED, V152, P26, DOI 10.7326/0003-4819-152-1-201001050-00007 Licker MJ, 2006, ANN THORAC SURG, V81, P1830, DOI 10.1016/j.athoracsur.2005.11.048 Mezzasoma L, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/159349 Mittendorf R, 1999, CLIN OBSTET GYNECOL, V42, P163, DOI 10.1097/00003081-199903000-00020 Morrow DA, 2007, CLIN CHEM, V53, P552, DOI 10.1373/clinchem.2006.084194 Nojiri T, 2011, ANN THORAC SURG, V92, P1051, DOI 10.1016/j.athoracsur.2011.03.085 Nojiri T, 2010, EUR J CARDIO-THORAC, V37, P787, DOI 10.1016/j.ejcts.2009.09.043 Poldermans D, 2009, EUR HEART J, V30, P2769, DOI 10.1093/eurheartj/ehp337 Rodseth RN, 2009, ANAESTHESIA, V64, P165, DOI 10.1111/j.1365-2044.2008.05689.x Rodseth RN, 2014, J AM COLL CARDIOL, V63, P170, DOI 10.1016/j.jacc.2013.08.1630 Rodseth RN, 2013, ANESTHESIOLOGY, V119, P270, DOI 10.1097/ALN.0b013e31829083f1 Scholes RL, 2009, AUST J PHYSIOTHER, V55, P191, DOI 10.1016/S0004-9514(09)70081-9 Stéphan F, 2000, CHEST, V118, P1263, DOI 10.1378/chest.118.5.1263 Struthers A, 2007, EUR HEART J, V28, P1678, DOI 10.1093/eurheartj/ehm234 Tayama K, 2002, ANN THORAC SURG, V73, P1582, DOI 10.1016/S0003-4975(02)03417-3 Thygesen K, 2007, CIRCULATION, V116, P2634, DOI 10.1016/j.jacc.2007.09.011 Vanzetto G, 2007, J NUCL CARDIOL, V14, P835, DOI 10.1016/j.nuclcard.2007.07.011 Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI [10.1016/j.jacc.2013.05.019, 10.1161/CIR.0b013e31829e8776] NR 25 TC 20 Z9 22 U1 0 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1010-7940 EI 1873-734X J9 EUR J CARDIO-THORAC JI Eur. J. Cardio-Thorac. Surg. PD NOV PY 2014 VL 46 IS 5 BP E74 EP E80 DI 10.1093/ejcts/ezu348 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA AT5FD UT WOS:000344968700003 PM 25305285 OA Bronze DA 2026-04-17 ER PT J AU Lanzola, G Ginardi, MG Mazzanti, A Quaglini, S AF Lanzola, G. Ginardi, M. G. Mazzanti, A. Quaglini, S. TI Gquest: Modeling patient questionnaires and administering them through a mobile platform application SO COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE LA English DT Article DE Mobile health; Questionnaires; Quality of life surveys; Computer adaptive testing ID QUALITY-OF-LIFE; POPULATION HEALTH-STATUS; LUNG-CANCER; DAILY DIARY; TRIALS; CARE; COMMUNICATION; TELEMEDICINE; MANAGEMENT; ONCOLOGY AB Background: The use of surveys is becoming popular in the health care industry for acquiring information useful to the accomplishment of several studies. Besides their exploitation on a large scale for conducting epidemiological studies, surveys are being increasingly carried out on a narrower perspective through the administration of questionnaires aimed at assessing the quality of life perceived by patients or their clinical status during mid- or long-term treatments. This is useful for managing resources or optimizing and individualizing treatments. Objectives: This paper describes Gquest, a platform for modeling, generating and administering questionnaires through mobile devices such as smartphones or tablets. Gquest was motivated by the need of administering questionnaires during home treatments, albeit its applicability is rather general. The main requirement was to have a very simple, clean and easy to use platform able to support (a) physicians in the design and delivery of questionnaires and (b) outpatients in sending self-recorded outcomes to the clinical staff. Methods: Gquest has two basic components. The first one is a model devised for representing questionnaires which is extremely flexible. It allows the generation of questions and answers of different types, supports adaptivity in the dialog with the user and enforces simple consistency rules for checking his input. The second component is an application able to run instances of those questionnaires. It downloads questionnaires over the air in terms of XML files from a server and stores them locally into the mobile repository. Questionnaires become then available to the user, who in our case is a patient or one of his relatives. The user can select which one to fill-in, according to his needs and/or the specific treatment protocol. The selected questionnaire may be filled-in all at once or be completed in subsequent steps over time since any input provided is persisted on a local database. Finally, when a questionnaire is closed all the answers are transparently synchronized to a server for further evaluation or statistical purposes. Results: The platform has been exploited and tested in two medical domains where questionnaires have very different purposes; a quality of life pilot survey involving p atients with atrial fibrillation within the EU-funded project MobiGuide, and an investigation of the users' needs during the requirements elicitation phase of a telemedicine project for the safe discharge of fragile patients. Conclusions: Gquest proved to be a suitable tool for dealing with a wide variety of question types and has been positively accepted by the patients enrolled in the pilot study. (C) 2014 Elsevier Ireland Ltd. All rights reserved. C1 [Lanzola, G.; Ginardi, M. G.; Quaglini, S.] Univ Pavia, Dept Elect Comp & Biomed Engn, I-27100 Pavia, Italy. [Mazzanti, A.] IRCCS Fdn S Maugeri, Pavia, Italy. C3 University of Pavia; Istituti Clinici Scientifici Maugeri IRCCS RP Lanzola, G (corresponding author), Univ Pavia, Dipartimento Ingn Ind & Informaz, Via Ferrata 1, I-27100 Pavia, Italy. EM giordano.lanzola@unipv.it RI Mazzanti, Andrea/C-3848-2015; quaglini, silvana/AAC-2687-2022; lanzola, giordano/AAC-2702-2022 OI Mazzanti, Andrea/0000-0002-0208-2172; FU EU MobiGuide project [287811]; Vodafone Foundation Italy FX The authors would like to thank Dr. C. Napolitano and Prof. S. Priori for the pilot study in Fondazione Maugeri, and Profs. F. Mosca and P. Messa from IRCCS Ospedale Maggiore Policlinico di Milano for discussion about fragile patients questionnaires. This work has been partially supported by the EU MobiGuide project under grant agreement no. 287811 and the Vodafone Foundation Italy. CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365 Ades AE, 2013, VALUE HEALTH, V16, P185, DOI 10.1016/j.jval.2012.09.012 Anatchkova MD, 2009, J PAIN, V10, P932, DOI 10.1016/j.jpain.2009.03.007 Azzini I., 2001, P EUROSPEECH 2001 7, P1327 Baker DW, 2005, J CARD FAIL, V11, P36, DOI 10.1016/j.cardfail.2004.05.003 Bergman MJ, 2007, BEST PRACT RES CL RH, V21, P649, DOI 10.1016/j.berh.2007.01.001 Bowling A., 2001, MEASURING DIS REV DI Busija L, 2011, ARTHRIT CARE RES, V63, pS383, DOI 10.1002/acr.20541 Caffo O, 2003, GYNECOL ONCOL, V88, P270, DOI 10.1016/S0090-8258(03)00076-3 Capozzi D, 2013, COMPUT METH PROG BIO, V110, P343, DOI 10.1016/j.cmpb.2013.01.011 Capozzi D, 2010, 2010 COMPLEXITY IN ENGINEERING: COMPENG 2010, PROCEEDINGS, P138, DOI 10.1109/COMPENG.2010.11 Caronni A, 2014, RES DEV DISABIL, V35, P784, DOI 10.1016/j.ridd.2014.01.020 Carr AJ, 2001, BMJ-BRIT MED J, V322, P1240, DOI 10.1136/bmj.322.7296.1240 Cocks K, 2008, EUR J CANCER, V44, P1793, DOI 10.1016/j.ejca.2008.05.008 Couper M.P., 2001, P 53 SESS ISI SURV R Dilzell K., 2014, FAM CANC IN PRESS Falasconi S, 1997, METHOD INFORM MED, V36, P30 Franc S, 2011, DIABETES METAB, V37, P463, DOI 10.1016/j.diabet.2011.06.006 FRASER SCA, 1993, BRIT J CANCER, V67, P341, DOI 10.1038/bjc.1993.62 GEDDES DM, 1990, EUR J CANCER, V26, P484, DOI 10.1016/0277-5379(90)90022-L Kaur PD, 2014, COMPUT METH PROG BIO, V113, P346, DOI 10.1016/j.cmpb.2013.09.013 Kind P, 1998, BMJ-BRIT MED J, V316, P736, DOI 10.1136/bmj.316.7133.736 Kjellsson G, 2014, J HEALTH ECON, V35, P34, DOI 10.1016/j.jhealeco.2014.01.007 Klingeberg T, 2012, COMPUT METH PROG BIO, V106, P89, DOI 10.1016/j.cmpb.2011.12.009 Kocalevent RD, 2009, J CLIN EPIDEMIOL, V62, P278, DOI 10.1016/j.jclinepi.2008.03.003 König HH, 2009, MED CARE, V47, P255, DOI 10.1097/MLR.0b013e318184759e Kosinski M, 2006, J CLIN EPIDEMIOL, V59, P715, DOI 10.1016/j.jclinepi.2005.07.019 Lanzola G., 2014, IFMBE P, V41, P1435, DOI [10.1007/978-3, DOI 10.1007/978-3] Lanzola Giordano, 2014, J Diabetes Sci Technol, V8, P216 Morrison RL, 2010, J OFF STAT, V26, P43 Petersen MA, 2010, EUR J CANCER, V46, P1352, DOI 10.1016/j.ejca.2010.02.011 Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087 Riva A, 1998, ARTIF INTELL MED, V14, P279, DOI 10.1016/S0933-3657(98)00038-4 Salvi D, 2012, COMPUT METH PROG BIO, V107, P45, DOI 10.1016/j.cmpb.2012.03.006 Saris WE., 2007, Wiley series in survey methodology. Design, evaluation Schaefer Caroline, 2014, J Med Econ, V17, P394, DOI 10.3111/13696998.2014.909439 Smyth JD, 2006, INT J INTERNET SCI, V1, P6 Snyder CF, 2013, QUAL LIFE RES, V22, P2685, DOI 10.1007/s11136-013-0387-8 Spertus J, 2011, CIRC-ARRHYTHMIA ELEC, V4, P15, DOI 10.1161/CIRCEP.110.958033 Stefanelli M., 1997, STUD HLTH TECHNOL IN, V52, P28 Taenzer P, 2000, PSYCHO-ONCOLOGY, V9, P203, DOI 10.1002/1099-1611(200005/06)9:3<203::AID-PON453>3.3.CO;2-P Tourangeau R, 2004, PUBLIC OPIN QUART, V68, P368, DOI 10.1093/poq/nfh035 Valente TW, 2007, SOC NETWORKS, V29, P154, DOI 10.1016/j.socnet.2006.07.002 Velikova G, 2004, J CLIN ONCOL, V22, P714, DOI 10.1200/JCO.2004.06.078 Wainer H., 2000, Computerized adaptive testing: A primer, V2nd, DOI DOI 10.4324/9780429464386 NR 45 TC 15 Z9 16 U1 0 U2 16 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0169-2607 EI 1872-7565 J9 COMPUT METH PROG BIO JI Comput. Meth. Programs Biomed. PD NOV PY 2014 VL 117 IS 2 BP 277 EP 291 DI 10.1016/j.cmpb.2014.07.010 PG 15 WC Computer Science, Interdisciplinary Applications; Computer Science, Theory & Methods; Engineering, Biomedical; Medical Informatics WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI) SC Computer Science; Engineering; Medical Informatics GA AQ8PV UT WOS:000343091400022 PM 25154645 DA 2026-04-17 ER PT J AU D'Andrilli, A Maurizi, G Andreetti, C Ciccone, AM Ibrahim, M Poggi, C Venuta, F Rendina, EA AF D'Andrilli, Antonio Maurizi, Giulio Andreetti, Claudio Ciccone, Anna Maria Ibrahim, Mohsen Poggi, Camilla Venuta, Federico Rendina, Erino A. TI Pulmonary Artery Reconstruction With Pulmonary Vein Conduit for Lung Cancer: Medium-Term Results SO ANNALS OF THORACIC SURGERY LA English DT Article; Proceedings Paper CT 50th Annual Meeting of the Society-of-Thoracic-Surgeons (STS) CY JAN 25-30, 2014 CL Orlando, FL SP Soc Thorac Surg ID SLEEVE LOBECTOMY; PROSTHETIC RECONSTRUCTION; RESECTION; PNEUMONECTOMY; ALLOGRAFT AB Background. The use of an autologous pulmonary vein (PV) conduit for reconstruction of the pulmonary artery (PA) in lung-sparing resections was first described in 2009, but to date only two case reports appeared and no medium-term and long-term results have been reported, to our knowledge. We present the first case series with medium-term follow-up. Methods. Between December 2009 and December 2012, 9 patients undergoing PA sleeve resection for centrally located lung cancer received reconstruction by this technique. Three of these patients underwent induction chemotherapy. The venous graft was obtained from the proximal extraparenchymal portion of the superior PV and was sutured to the proximal and distal PA stumps with the standard anastomotic technique. Results. All 9 patients underwent left upper lobectomy with sleeve resection of the PA without associated bronchoplasty. The postoperative morbidity rate was 33% (1 chylothorax, 1 atrial fibrillation, and 1 parenchymal atelectasis). No adverse events related to the reconstructive procedure occurred. There was no postoperative mortality. Complete patency of the reconstructed PA was shown in all patients by postoperative contrast computed tomography every 6 months. All patients are alive at a mean follow-up time of 32 +/- 12.4 months (range, 6 to 42 months). Tumor recurrence has been observed in 2 patients (1 local, 1 systemic). The median survival time is 38 months. The median disease-free survival time is 33 months. Conclusions. Reconstruction of the PA by a PV graft is a feasible and effective option for parenchymal-sparing resections. The PV conduit shows tissue characteristics similar to those of the arterial wall. This technique is safe and is supported by good medium-term results. (C) 2014 by The Society of Thoracic Surgeons C1 Univ Roma La Sapienza, St Andreas Hosp, Dept Thorac Surg, Rome, Italy. Univ Roma La Sapienza, Policlin Umberto 1, Dept Thorac Surg, Rome, Italy. Lorillard Spencer Cenci Fdn, Rome, Italy. C3 Sapienza University Rome; Sapienza University Rome; University Hospital Sapienza Rome RP D'Andrilli, A (corresponding author), St Andreas Hosp, Dept Thorac Surg, Via Grottarossa 1035, I-00189 Rome, Italy. EM adandrilli@hotmail.com RI Rendina, Erino/AAG-7598-2021; ibrahim, mohsen/AAH-5395-2021 OI poggi, camilla/0000-0001-9490-5561; ibrahim, mohsen/0000-0002-9288-2359; maurizi, giulio/0000-0002-6218-6758; Venuta, Federico/0000-0001-9296-877X CR Alifano M, 2009, J THORAC CARDIOV SUR, V137, P1400, DOI 10.1016/j.jtcvs.2008.11.002 Askovich B, 2007, ANN THORAC SURG, V84, P907, DOI 10.1016/j.athoracsur.2007.04.104 Berthet JP, 2013, J THORAC CARDIOV SUR, V146, P1191, DOI 10.1016/j.jtcvs.2013.07.003 Cerezo F, 2009, EUR J CARDIO-THORAC, V36, P422, DOI 10.1016/j.ejcts.2009.03.060 Cerfolio RJ, 2007, ANN THORAC SURG, V83, P1971, DOI 10.1016/j.athoracsur.2007.01.048 D'Andrilli A, 2005, ANN THORAC SURG, V80, P357, DOI 10.1016/j.athoracsur.2004.02.012 D'Andrilli A, 2006, J THORAC CARDIOV SUR, V132, P192, DOI 10.1016/j.jtcvs.2006.03.021 D'Andrilli A, 2011, SURG ONCOL CLIN N AM, V20, P733, DOI 10.1016/j.soc.2011.07.007 Fadel E, 2002, ANN THORAC SURG, V74, P851, DOI 10.1016/S0003-4975(02)03792-X Ferguson MK, 2003, ANN THORAC SURG, V76, P1782, DOI 10.1016/S0003-4975(03)01243-8 Ibrahim M, 2013, THORAC SURG CLIN, V23, P337, DOI 10.1016/j.thorsurg.2013.05.007 Ma ZY, 2007, EUR J CARDIO-THORAC, V32, P20, DOI 10.1016/j.ejcts.2007.03.018 Maurizi G, 2013, J THORAC ONCOL, V8, P637, DOI 10.1097/JTO.0b013e318286d145 Puma F, 2011, EUR J CARDIO-THORAC, V40, pE107, DOI 10.1016/j.ejcts.2011.05.012 READ RC, 1993, ANN THORAC SURG, V55, P850, DOI 10.1016/0003-4975(93)90104-P RENDINA EA, 1995, J THORAC CARDIOV SUR, V110, P867, DOI 10.1016/S0022-5223(95)70128-1 Rendina EA, 1999, ANN THORAC SURG, V68, P995, DOI 10.1016/S0003-4975(99)00738-9 Rendina EA, 2009, THORACIC SURG, P909 Shi WD, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-265 Shrager JB, 2000, ANN THORAC SURG, V70, P234, DOI 10.1016/S0003-4975(00)01492-2 Venuta F, 2009, J THORAC CARDIOV SUR, V138, P1185, DOI 10.1016/j.jtcvs.2009.07.043 YOSHIMI F, 1994, SURG TODAY, V24, P570, DOI 10.1007/BF01884583 NR 22 TC 25 Z9 27 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD SEP PY 2014 VL 98 IS 3 BP 990 EP 995 DI 10.1016/j.athoracsur.2014.04.110 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA AP3NL UT WOS:000341982700037 PM 25038016 DA 2026-04-17 ER PT J AU Frendl, G Sodickson, AC Chung, MK Waldo, AL Gersh, BJ Tisdale, JE Calkins, H Aranki, S Kaneko, T Cassivi, S Smith, SC Darbar, D Wee, JO Waddell, TK Amar, D Adler, D AF Frendl, Gyorgy Sodickson, Alissa C. Chung, Mina K. Waldo, Albert L. Gersh, Bernard J. Tisdale, James E. Calkins, Hugh Aranki, Sary Kaneko, Tsuyoshi Cassivi, Stephen Smith, Sidney C., Jr. Darbar, Dawood Wee, Jon O. Waddell, Thomas K. Amar, David Adler, Dale TI 2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article ID VENTRICULAR RATE CONTROL; AMERICAN-HEART-ASSOCIATION; MAINTAINING SINUS RHYTHM; CRITICALLY ILL PATIENTS; RISK-FACTORS; INTRAVENOUS AMIODARONE; LUNG-CANCER; FOLLOW-UP; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; ANTIARRHYTHMIC-DRUGS C1 [Frendl, Gyorgy; Sodickson, Alissa C.] Brigham & Womens Hosp, Dept Anesthesiol, Boston, MA 02115 USA. [Frendl, Gyorgy; Sodickson, Alissa C.; Aranki, Sary; Kaneko, Tsuyoshi; Wee, Jon O.; Adler, Dale] Harvard Univ, Sch Med, Boston, MA USA. [Chung, Mina K.] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med,Dept Cardiovasc Med, Heart & Vasc Inst,Dept Mol Cardiol,Lerner Res Ins, Cleveland, OH 44106 USA. [Waldo, Albert L.] Case Western Reserve Univ, Dept Med, Div Cardiovasc Med, Cleveland, OH 44106 USA. [Waldo, Albert L.] Univ Hosp Case Med Ctr, Harrington Heart & Vasc Inst, Cleveland, OH USA. [Gersh, Bernard J.] Mayo Clin, Coll Med, Dept Med, Div Cardiovasc Dis & Internal Med, Rochester, MN USA. [Tisdale, James E.] Purdue Univ, Coll Pharm, Dept Pharm Practice, Indianapolis, IN USA. [Tisdale, James E.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Calkins, Hugh] Johns Hopkins Univ, Dept Med, Cardiac Arrhythmia Serv, Baltimore, MD USA. [Aranki, Sary; Kaneko, Tsuyoshi] Brigham & Womens Hosp, Dept Surg, Div Cardiac Surg, Boston, MA 02115 USA. [Cassivi, Stephen] Mayo Clin, Coll Med, Dept Surg, Div Thorac Surg, Rochester, MN USA. [Smith, Sidney C., Jr.] Univ N Carolina, Dept Med, Ctr Heart & Vasc Care, Chapel Hill, NC USA. [Darbar, Dawood] Vanderbilt Univ, Sch Med, Arrhythmia Serv, Div Cardiovasc Med,Dept Med, Nashville, TN 37212 USA. [Wee, Jon O.] Brigham & Womens Hosp, Dept Surg, Div Thorac Surg, Boston, MA 02115 USA. [Waddell, Thomas K.] Univ Toronto, Dept Surg, Div Thorac Surg, Toronto, ON, Canada. [Amar, David] Mem Sloan Kettering Canc Ctr, Dept Anesthesiol & Crit Care Med, New York, NY 10021 USA. [Adler, Dale] Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, Boston, MA 02115 USA. C3 Harvard University; Harvard University Medical Affiliates; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Cleveland Clinic Foundation; University System of Ohio; Case Western Reserve University; University System of Ohio; Case Western Reserve University; University System of Ohio; Case Western Reserve University; Case Western Reserve University Hospital; Mayo Clinic; Purdue University System; Purdue University; Purdue University in Indianapolis; Indiana University System; Indiana University Bloomington; Johns Hopkins University; Harvard University; Harvard University Medical Affiliates; Brigham & Women's Hospital; Mayo Clinic; University of North Carolina; University of North Carolina Chapel Hill; Vanderbilt University; Harvard University; Harvard University Medical Affiliates; Brigham & Women's Hospital; University of Toronto; Memorial Sloan Kettering Cancer Center; Harvard University; Harvard University Medical Affiliates; Brigham & Women's Hospital RP Frendl, G (corresponding author), Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, CWN-L1,75 Francis St, Boston, MA 02115 USA. EM gfrendl@partners.org RI Darbar, Dawood/C-9079-2015; Smith, Sidney/HIR-4896-2022; Frendl, Gyorgy/AAE-5345-2020 OI Darbar, Dawood/0000-0002-4103-5977; Waddell, Thomas/0000-0002-3235-9208; aranki, sary/0000-0002-3129-3403; Frendl, Gyorgy/0000-0001-8918-8553 FU NHLBI NIH HHS [R01 HL111314] Funding Source: Medline CR ABRAMS J, 1985, AM HEART J, V110, P913, DOI 10.1016/0002-8703(85)90185-1 Adlan AMA, 2013, DRUG SAFETY, V36, P93, DOI 10.1007/s40264-012-0012-8 Ahlsson A, 2010, EUR J CARDIO-THORAC, V37, P1353, DOI 10.1016/j.ejcts.2009.12.033 Akoum N, 2011, J CARDIOVASC ELECTR, V22, P16, DOI 10.1111/j.1540-8167.2010.01876.x Amar D, 1997, ANN THORAC SURG, V63, P1374 AMAR D, 1995, CHEST, V108, P349, DOI 10.1378/chest.108.2.349 Amar D, 2000, J THORAC CARDIOV SUR, V120, P790, DOI 10.1067/mtc.2000.109538 Amar D, 2002, ANESTHESIOLOGY, V97, P1618, DOI 10.1097/00000542-200212000-00039 Amar D, 2005, CHEST, V128, P3421, DOI 10.1378/chest.128.5.3421 Amar David, 2002, Heart Dis, V4, P117 Anderson JL, 2013, J AM COLL CARDIOL, V61, P1935, DOI 10.1016/j.jacc.2013.02.001 [Anonymous], 2011, J AM COLL CARDIOL, DOI DOI 10.1016/j.jacc.2010.09.013 [Anonymous], EMERGENCY CARDIOVASC [Anonymous], CHEST S [Anonymous], INTERACT CARDIOVASC [Anonymous], AM J RESP CRIT CARE [Anonymous], CHEST S Auer J, 2004, AM HEART J, V147, P636, DOI 10.1016/j.ahj.2003.10.041 Balser JR, 1997, ANESTHESIOLOGY, V86, P974, DOI 10.1097/00000542-199704000-00028 Barbetakis Nikolaos, 2004, BMC Surg, V4, P7, DOI 10.1186/1471-2482-4-7 Bateman BT, 2009, ANESTHESIOLOGY, V110, P231, DOI 10.1097/ALN.0b013e318194b5ff Bayliff CD, 1999, ANN THORAC SURG, V67, P182, DOI 10.1016/S0003-4975(98)01226-0 Benditt DG, 1999, AM J CARDIOL, V84, P270, DOI 10.1016/S0002-9149(99)00275-1 Bhave PD, 2012, AM HEART J, V164, P918, DOI 10.1016/j.ahj.2012.09.004 Biancari F, 2010, J THORAC CARDIOV SUR, V139, P1158, DOI 10.1016/j.jtcvs.2009.07.012 BLACK IW, 1993, AM HEART J, V126, P375, DOI 10.1016/0002-8703(93)91054-I BLACK IW, 1994, CIRCULATION, V89, P2509, DOI 10.1161/01.CIR.89.6.2509 Blackshear JL, 1996, LANCET, V348, P633 Bobbio A, 2007, EUR J CARDIO-THORAC, V31, P70, DOI 10.1016/j.ejcts.2006.10.020 Boriani G, 1997, ANN INTERN MED, V126, P621, DOI 10.7326/0003-4819-126-8-199704150-00006 Botto F, 2014, ANESTHESIOLOGY, V120, P564, DOI 10.1097/ALN.0000000000000113 Burgess DC, 2006, EUR HEART J, V27, P2846, DOI 10.1093/eurheartj/ehl272 Burton M.E., 2006, APPL PHARMACOKINETIC, V4th Calkins H, 2012, HEART RHYTHM, V9, P632, DOI 10.1016/j.hrthm.2011.12.016 Camm AJ, 2012, EUR HEART J, V33, P2719, DOI 10.1093/eurheartj/ehs253 Camm J, 2012, INT J CARDIOL, V155, P362, DOI 10.1016/j.ijcard.2011.06.012 Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Carlsson J, 2003, J AM COLL CARDIOL, V41, P1690, DOI 10.1016/S0735-1097(03)00332-2 CARMELIET E, 1985, J PHARMACOL EXP THER, V232, P817 CARMELIET E, 1992, J PHARMACOL EXP THER, V262, P809 Chopra V, 2012, ARCH SURG-CHICAGO, V147, P181, DOI 10.1001/archsurg.2011.897 Chung MK, 2005, J AM COLL CARDIOL, V46, P1891, DOI 10.1016/j.jacc.2005.07.040 Ciriaco P, 2000, EUR J CARDIO-THORAC, V18, P12, DOI 10.1016/S1010-7940(00)00428-0 Connolly SJ, 2011, NEW ENGL J MED, V365, P2268, DOI 10.1056/NEJMoa1109867 Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561 Corley SD, 2004, CIRCULATION, V109, P1509, DOI 10.1161/01.CIR.0000121736.16643.11 De Decker K, 2003, ANN THORAC SURG, V75, P1340, DOI 10.1016/S0003-4975(02)04824-5 Delle Karth G, 2001, CRIT CARE MED, V29, P1149, DOI 10.1097/00003246-200106000-00011 Devereaux PJ, 2008, LANCET, V371, P1839, DOI 10.1016/S0140-6736(08)60601-7 DIBIASI P, 1995, EUR J CARDIO-THORAC, V9, P587, DOI 10.1016/S1010-7940(05)80011-9 Dixit S, 2009, J AM COLL CARDIOL, V54, P2049, DOI 10.1016/j.jacc.2009.09.015 Dizon J, 2009, J AM COLL CARDIOL, V54, P2043, DOI 10.1016/j.jacc.2009.08.029 Dorian P, 2005, J CARDIOVASC PHARM T, V10, pS15, DOI 10.1177/10742484050100i403 Doukas G, 2005, JAMA-J AM MED ASSOC, V294, P2323, DOI 10.1001/jama.294.18.2323 Dunning J, 2006, EUR J CARDIO-THORAC, V30, P852, DOI 10.1016/j.ejcts.2006.09.003 ECHIZEN H, 1986, CLIN PHARMACOKINET, V11, P425, DOI 10.2165/00003088-198611060-00002 ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201 Eikelboom JW, 2013, NEW ENGL J MED, V369, P1206, DOI 10.1056/NEJMoa1300615 Epstein AE, 2005, CHEST, V128, p24S, DOI 10.1378/chest.128.2_suppl.24S Fang MC, 2011, J AM COLL CARDIOL, V58, P395, DOI 10.1016/j.jacc.2011.03.031 FANIEL R, 1983, EUR HEART J, V4, P180, DOI 10.1093/oxfordjournals.eurheartj.a061437 Farshi R, 1999, J AM COLL CARDIOL, V33, P304, DOI 10.1016/S0735-1097(98)00561-0 Fauchier L, 2008, J AM COLL CARDIOL, V51, P828, DOI 10.1016/j.jacc.2007.09.063 Fernando HC, 2011, ANN THORAC SURG, V92, P1144, DOI 10.1016/j.athoracsur.2011.06.104 Fuster V, 2006, CIRCULATION, V114, pE257, DOI 10.1161/CIRCULATIONAHA.106.177292 Gage BF, 2006, AM HEART J, V151, P713, DOI 10.1016/j.ahj.2005.04.017 Gammie JS, 2008, ANN THORAC SURG, V85, P909, DOI 10.1016/j.athoracsur.2007.10.097 Geelen P, 1999, AM J CARDIOL, V84, P345, DOI 10.1016/S0002-9149(99)00292-1 Gheorghiade M, 2004, CIRCULATION, V109, P2959, DOI 10.1161/01.CIR.0000132482.95686.87 Gheorghiade M, 2013, EUR HEART J, V34, P1489, DOI 10.1093/eurheartj/eht120 Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039 Haïssaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003 Henri C, 2012, CIRC-ARRHYTHMIA ELEC, V5, P61, DOI 10.1161/CIRCEP.111.964569 Hilleman Daniel E, 2005, Am J Cardiovasc Drugs, V5, P361, DOI 10.2165/00129784-200505060-00003 Hilleman DE, 2002, PHARMACOTHERAPY, V22, P66, DOI 10.1592/phco.22.1.66.33492 Ho KM, 2007, HEART, V93, P1433, DOI 10.1136/hrt.2006.111492 Hohnloser SH, 2000, LANCET, V356, P1789, DOI 10.1016/S0140-6736(00)03230-X Hylek EM, 2003, NEW ENGL J MED, V349, P1019, DOI 10.1056/NEJMoa022913 Imperatori A, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-4 Institute of Medicine (US), 2011, CLIN PRACTICE GUIDEL, DOI DOI 10.17226/13058 Irshad K, 2002, CAN J SURG, V45, P264 ISERI LT, 1992, AM HEART J, V123, P1404, DOI 10.1016/0002-8703(92)91059-A Isiadinso I, 2011, J HEART LUNG TRANSPL, V30, P37, DOI 10.1016/j.healun.2010.07.006 Ivanovic J, 2014, INTERACT CARDIOV TH, V18, P340, DOI 10.1093/icvts/ivt520 Izhar U, 2005, J THORAC CARDIOV SUR, V129, P401, DOI 10.1016/j.jtcvs.2004.06.029 Jakobsen CJ, 1997, J CARDIOTHOR VASC AN, V11, P746, DOI 10.1016/S1053-0770(97)90169-5 January CT., 2014, CIRCULATION, P1, DOI [DOI 10.1161/CIR.0000000000000665, DOI 10.1016/J.JACC.2019.01.011] Jenkins LS, 2005, AM HEART J, V149, P112, DOI 10.1016/j.ahj.2004.03.065 Johnson WD, 2000, EUR J CARDIO-THORAC, V17, P718, DOI 10.1016/S1010-7940(00)00419-X Jordaens L, 1997, EUR HEART J, V18, P643 KAISER A, 1994, HELV CHIR ACTA, V60, P913 Karki K, 1997, EUR HEART J, V18, P649 Karthik S, 2004, ANN THORAC SURG, V77, P1245, DOI 10.1016/j.athoracsur.2003.09.054 Kearon C, 1997, NEW ENGL J MED, V336, P1506, DOI 10.1056/NEJM199705223362107 Khalil MA, 2013, J ANESTH, V27, P56, DOI 10.1007/s00540-012-1478-3 Klein AL, 2001, NEW ENGL J MED, V344, P1411, DOI 10.1056/NEJM200105103441901 Kober L, 2008, NEW ENGL J MED, V358, P2678, DOI 10.1056/NEJMoa0800456 Kowey PR, 2001, PACE, V24, P191, DOI 10.1046/j.1460-9592.2001.00191.x KROWKA MJ, 1987, CHEST, V91, P490, DOI 10.1378/chest.91.4.490 Kumar A, 1996, SOUTHERN MED J, V89, P779, DOI 10.1097/00007611-199608000-00005 Lafuente-Lafuente C, 2006, ARCH INTERN MED, V166, P719, DOI 10.1001/archinte.166.7.719 Lafuente-Lafuente C, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005049.pub2 LANDYMORE RW, 1991, EUR J CARDIO-THORAC, V5, P436, DOI 10.1016/1010-7940(91)90191-L Lanza LA, 2003, ANN THORAC SURG, V75, P223, DOI 10.1016/S0003-4975(02)04285-6 LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449 Lee G, 2010, EUR HEART J, V31, P2774, DOI 10.1093/eurheartj/ehq224 Lee JK, 2000, AM HEART J, V140, P871, DOI 10.1067/mhj.2000.111104 LEE KS, 1992, J PHARMACOL EXP THER, V262, P99 Li J, 2010, HEART RHYTHM, V7, P438, DOI 10.1016/j.hrthm.2009.12.009 Ma Q, 2007, BRIT J CLIN PHARMACO, V64, P263, DOI 10.1111/j.1365-2125.2007.02898.x Mason DP, 2007, ANN THORAC SURG, V84, P1878, DOI 10.1016/j.athoracsur.2007.07.014 MCBRIDE R, 1994, LANCET, V343, P687 McNamara RL, 2003, ANN INTERN MED, V139, P1018, DOI 10.7326/0003-4819-139-12-200312160-00012 Merritt RE, 2012, THORAC SURG CLIN, V22, P13, DOI 10.1016/j.thorsurg.2011.08.016 Mitchell LB, 2011, CAN J CARDIOL, V27, P91, DOI 10.1016/j.cjca.2010.11.005 Mounsey JP, 2000, CIRCULATION, V102, P2665 Naccarelli GV, 2001, MED CLIN N AM, V85, P503, DOI 10.1016/S0025-7125(05)70324-2 NATTEL S, 1988, CARDIOVASC RES, V22, P808, DOI 10.1093/cvr/22.11.808 NATTEL S, 1979, CIRCULATION, V59, P1158, DOI 10.1161/01.CIR.59.6.1158 Nenov NI, 1998, CIRC RES, V83, P1224, DOI 10.1161/01.RES.83.12.1224 Neumar RW, 2010, CIRCULATION, V122, pS729, DOI 10.1161/CIRCULATIONAHA.110.970988 Ng JLW, 2011, ANESTHESIOLOGY, V115, P879, DOI 10.1097/ALN.0b013e31822e9499 Nielsen TD, 2004, CHEST, V126, P496, DOI 10.1378/chest.126.2.496 Olshansky B, 2004, J AM COLL CARDIOL, V43, P1201, DOI 10.1016/j.jacc.2003.11.032 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Paikin JS, 2010, NAT REV CARDIOL, V7, P498, DOI 10.1038/nrcardio.2010.101 Park BJ, 2007, J THORAC CARDIOV SUR, V133, P775, DOI 10.1016/j.jtcvs.2006.09.022 Passman RS, 2005, ANN THORAC SURG, V79, P1698, DOI 10.1016/j.athoracsur.2004.10.058 Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638 Pedersen OD, 2001, CIRCULATION, V104, P292, DOI 10.1161/01.CIR.104.3.292 Pengo V, 2003, AM J CLIN PATHOL, V120, P944, DOI 10.1309/U7164E0XH5UERKRV Perzborn E, 2011, NAT REV DRUG DISCOV, V10, P61, DOI 10.1038/nrd3185 Pisters R, 2010, CHEST, V138, P1093, DOI 10.1378/chest.10-0134 Polanczyk CA, 1998, ANN INTERN MED, V129, P279, DOI 10.7326/0003-4819-129-4-199808150-00003 PRITCHETT ELC, 1991, ANN INTERN MED, V114, P539, DOI 10.7326/0003-4819-114-7-539 Rao VP, 2012, EUR J CARDIO-THORAC, V42, P438, DOI 10.1093/ejcts/ezs085 RASMUSSEN HS, 1988, CLIN CARDIOL, V11, P824, DOI 10.1002/clc.4960111205 Reddy VY, 2013, J AM COLL CARDIOL, V61, P2551, DOI 10.1016/j.jacc.2013.03.035 Reddy VY, 2013, CIRCULATION, V127, P720, DOI 10.1161/CIRCULATIONAHA.112.114389 Reisinger J, 2004, EUR HEART J, V25, P1318, DOI 10.1016/j.ehj.2004.04.030 Rena O, 2001, EUR J CARDIO-THORAC, V20, P688, DOI 10.1016/S1010-7940(01)00890-9 Riber LP, 2012, ANN THORAC SURG, V94, P339, DOI 10.1016/j.athoracsur.2011.12.096 RITCHIE AJ, 1993, ANN THORAC SURG, V55, P86, DOI 10.1016/0003-4975(93)90478-Z RODEN DM, 1986, AM J CARDIOL, V58, pC4, DOI 10.1016/0002-9149(86)90097-4 Romero J, 2013, CIRC-CARDIOVASC IMAG, V6, P185, DOI 10.1161/CIRCIMAGING.112.000153 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Rostron Anthony, 2005, Interact Cardiovasc Thorac Surg, V4, P52, DOI 10.1510/icvts.2004.100339 Roy D, 2008, NEW ENGL J MED, V358, P2667, DOI 10.1056/NEJMoa0708789 Schotten U, 2011, PHYSIOL REV, V91, P265, DOI 10.1152/physrev.00031.2009 Schulman S, 2011, ANN INTERN MED, V155, P653, DOI 10.7326/0003-4819-155-10-201111150-00003 See VY, 2009, CIRC-ARRHYTHMIA ELEC, V2, P504, DOI 10.1161/CIRCEP.109.867978 Seguin P, 2004, CRIT CARE MED, V32, P722, DOI 10.1097/01.CCM.0000114579.56430.E0 Seipel L, 1980, Eur Heart J, V1, P309 Seki A, 1999, BRIT J PHARMACOL, V126, P1153, DOI 10.1038/sj.bjp.0702428 Shah M, 2014, CIRCULATION, V129, P1196, DOI 10.1161/CIRCULATIONAHA.113.004777 Sherwood MW, 2014, CIRCULATION, V129, P1850, DOI 10.1161/CIRCULATIONAHA.113.005754 SINGH BN, 1987, AM HEART J, V114, P121, DOI 10.1016/0002-8703(87)90316-4 Singh S, 2000, CIRCULATION, V102, P2385, DOI 10.1161/01.CIR.102.19.2385 Siu CW, 2009, CRIT CARE MED, V37, P2174, DOI 10.1097/CCM.0b013e3181a02f56 Slavik RS, 2001, PROG CARDIOVASC DIS, V44, P121, DOI 10.1053/pcad.2001.26966 SMITH TW, 1970, J CLIN INVEST, V49, P2377, DOI 10.1172/JCI106457 Soucier Richard, 2003, Med Sci Monit, V9, pPI19 Stambler BS, 1996, CIRCULATION, V94, P1613, DOI 10.1161/01.CIR.94.7.1613 Stangier J, 2008, CLIN PHARMACOKINET, V47, P285, DOI 10.2165/00003088-200847050-00001 STRASBERG B, 1985, INT J CARDIOL, V7, P47, DOI 10.1016/0167-5273(85)90172-X Tamargo J, 2012, DRUG SAFETY, V35, P273, DOI 10.2165/11599950-000000000-00000 Terzi A, 1996, THORAC CARDIOV SURG, V44, P300, DOI 10.1055/s-2007-1012041 Tisdale JE, 2010, SEMIN THORAC CARDIOV, V22, P310, DOI 10.1053/j.semtcvs.2010.12.001 Tisdale JE, 2010, J THORAC CARDIOV SUR, V140, P45, DOI 10.1016/j.jtcvs.2010.01.026 Tisdale JE, 2009, ANN THORAC SURG, V88, P886, DOI 10.1016/j.athoracsur.2009.04.074 Tisdale JE, 1998, AM HEART J, V135, P739, DOI 10.1016/S0002-8703(98)70031-6 Tisdale JE., 2010, *Drug-induced diseases: Prevention, detection, and management*, V2, P485 Todd TRJ, 1997, ANN THORAC SURG, V63, P1381 Torp-Pedersen C, 1999, NEW ENGL J MED, V341, P857, DOI 10.1056/NEJM199909163411201 Trinkley KE, 2013, CURR MED RES OPIN, V29, P1719, DOI 10.1185/03007995.2013.840568 Tse HF, 2001, CLIN EXP PHARMACOL P, V28, P446, DOI 10.1046/j.1440-1681.2001.03454.x Valentine RJ, 2001, J AM COLL SURGEONS, V193, P499, DOI 10.1016/S1072-7515(01)01028-6 Van Gelder IC, 2002, NEW ENGL J MED, V347, P1834, DOI 10.1056/NEJMoa021375 Van Gelder IC, 2010, NEW ENGL J MED, V362, P1363, DOI 10.1056/NEJMoa1001337 Van Spall HGC, 2012, CIRCULATION, V126, P2309, DOI 10.1161/CIRCULATIONAHA.112.101808 VanderLugt JT, 1999, CIRCULATION, V100, P369, DOI 10.1161/01.CIR.100.4.369 VanMieghem W, 1996, ANN THORAC SURG, V61, P1083, DOI 10.1016/0003-4975(96)00073-2 VANMIEGHEM W, 1994, CHEST, V105, P1642, DOI 10.1378/chest.105.6.1642 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Verhaert D, 2009, J AM SOC ECHOCARDIOG, V22, DOI 10.1016/j.echo.2008.12.009 White HD, 2007, ARCH INTERN MED, V167, P239, DOI 10.1001/archinte.167.3.239 Wijeysundera DN, 2003, J AM COLL CARDIOL, V41, P1496, DOI 10.1016/S0735-1097(03)00191-8 WU J, 1990, American Journal of Physiology, V259, pH1842 Wyse DG, 2002, NEW ENGL J MED, V347, P1825, DOI 10.1056/nejmoa021328 Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI [10.1016/j.jacc.2013.05.019, 10.1161/CIR.0b013e31829e8776] YANG T, 1995, CIRCULATION, V91, P1799, DOI 10.1161/01.CIR.91.6.1799 Yilmaz AT, 1996, J CARDIAC SURG, V11, P61, DOI 10.1111/j.1540-8191.1996.tb00010.x NR 192 TC 236 Z9 285 U1 0 U2 9 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 EI 1097-685X J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD SEP PY 2014 VL 148 IS 3 BP E153 EP E193 DI 10.1016/j.jtcvs.2014.06.036 PG 41 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA AN9PF UT WOS:000340938700001 PM 25129609 OA Green Submitted, Bronze DA 2026-04-17 ER PT J AU Sohns, JM Menke, J Staab, W Spiro, J Fasshauer, M Kowallick, JT Bergau, L Zwaka, PA Unterberg-Buchwald, C Lotz, J Schwarz, A AF Sohns, J. M. Menke, J. Staab, W. Spiro, J. Fasshauer, M. Kowallick, J. T. Bergau, L. Zwaka, P. A. Unterberg-Buchwald, C. Lotz, J. Schwarz, A. TI Current Role of Cardiac and Extra-Cardiac Pathologies in Clinically Indicated Cardiac Computed Tomography with Emphasis on Status Before Pulmonary Vein Isolation SO ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN LA English DT Article DE cardiac; CT angiography; angiography; thorax; mediastinum; cost-effectiveness ID RADIOFREQUENCY CATHETER ABLATION; INCIDENTAL EXTRACARDIAC FINDINGS; FIELD-OF-VIEW; ATRIAL-FIBRILLATION; CORONARY-ANGIOGRAPHY; NONCARDIAC FINDINGS; DIAGNOSTIC-ACCURACY; IMAGE INTEGRATION; CT ANGIOGRAPHY; PREVALENCE AB Purpose: The aim of this study was to assess the incidence of cardiac and significant extra-cardiac findings in clinical computed tomography of the heart in patients with atrial fibrillation before pulmonary vein isolation (PVI). Materials and Methods: 224 patients (64 +/- 10 years; male 63 %) with atrial fibrillation were examined by cardiac 64-slice multidetector CT before PVI. Extra-cardiac findings were classified as "significant" if they were recommended to additional diagnostics or therapy, and otherwise as "non-significant". Additionally, cardiac findings were documented in detail. Results: A total of 724 cardiac findings were identified in 203 patients (91 % of patients). Additionally, a total of 619 extra-cardiac findings were identified in 179 patients (80 % of patients). Among these extra-cardiac findings 196 (32 %) were "significant", and 423 (68 %) were "non-significant". In 2 patients (1 %) a previously unknown malignancy was detected (esophageal cancer and lung cancer, local stage, no metastasis). 203 additional imaging diagnostics followed to clarify the "significant" findings (124 additional CT, costs 38 314.69 US dollars). Overall, there were 3.2 cardiac and 2.8 extra-cardiac findings per patient. Extra-cardiac findings appear significantly more frequently in patients over 60 years old, in smokers and in patients with a history of cardiac findings (p < 0.05). Conclusion: Cardiac CT scans before PVI should be screened for extracardiac incidental findings that could have important clinical implications for each patient. Key points: Cardiac and extra-cardiac findings are common in patients with an indication for pulmonary vein isolation on previous CT scans. Malignancies can be detected in 1 % of all patients. 32 % of all extra-cardiac findings can be of significant relevance with consequences for patients. Altogether, there are 3.2 cardiac and 2.8 extra-cardiac findings in patients with indication for pulmonary vein isolation and CT. Extra-cardiac findings appear significantly more frequently in patients over 60 years old, in smokers and in patients with a history of cardiac findings (p < 0.05). Citation Format:. Sohns JM, Menke J, Staab W et al. Current Role of Cardiac and Extra-Cardiac Pathologies in Clinically Indicated Cardiac Computed Tomographywith Emphasis on Status Before Pulmonary Vein Isolation. C1 [Sohns, J. M.; Menke, J.; Staab, W.; Fasshauer, M.; Kowallick, J. T.; Zwaka, P. A.; Lotz, J.; Schwarz, A.] Univ Gottingen, Univ Med Ctr, Inst Diagnost & Intervent Radiol, D-37073 Gottingen, Germany. [Spiro, J.] Univ Hosp Cologne, Cologne, Germany. [Bergau, L.; Unterberg-Buchwald, C.] Univ Gottingen, Med Ctr, D-37073 Gottingen, Germany. [Sohns, J. M.; Lotz, J.] Univ Hosp Cologne, Cologne, Germany. C3 University of Gottingen; University of Gottingen Hospital; University of Cologne; University of Gottingen; University of Cologne RP Sohns, JM (corresponding author), Univ Hosp Gottingen, Inst Diagnost & Intervent Radiol, DZHK, Robert Koch Str 40, D-37075 Gottingen, Germany. EM jan.sohns@med.uni-goettingen.de RI ; Bergau, Leonard/LRT-4028-2024; Lotz, Joachim/G-3376-2015 OI Sommerlath Sohns, Jan/0000-0001-6644-2563; Bergau, Leonard/0000-0001-7025-9315; Lotz, Joachim/0000-0002-1412-2741 CR de Chillou C, 2008, J INTERV CARD ELECTR, V23, P175, DOI 10.1007/s10840-008-9300-8 Earls JP, 2011, RADIOLOGY, V261, P342, DOI 10.1148/radiol.11111099 Fischbach R, 2009, ROFO-FORTSCHR RONTG, V181, P700, DOI 10.1055/s-0028-1109533 Horton KM, 2002, CIRCULATION, V106, P532, DOI 10.1161/01.CIR.0000027136.56615.DE Hunold P, 2001, EUR HEART J, V22, P1748, DOI 10.1053/euhj.2000.2586 Jacobs PCA, 2008, J COMPUT ASSIST TOMO, V32, P214, DOI 10.1097/RCT.0b013e3181585ff2 Johnson KM, 2010, AM J ROENTGENOL, V195, P143, DOI 10.2214/AJR.08.1050 Jongbloed MRM, 2005, RADIOLOGY, V234, P702, DOI 10.1148/radiol.2343031047 Kawano Y, 2007, AM J CARDIOL, V99, P1608, DOI 10.1016/j.amjcard.2007.01.038 Kim TJ, 2010, RADIOLOGY, V255, P369, DOI 10.1148/radiol.10091083 Kistler PM, 2008, EUR HEART J, V29, P3029, DOI 10.1093/eurheartj/ehn453 Kuettner A, 2004, J AM COLL CARDIOL, V43, P831, DOI 10.1016/j.jacc.2003.05.015 Lang RM, 2006, EUR J ECHOCARDIOGR, V7, P79, DOI 10.1016/j.euje.2005.12.014 Lee CI, 2010, AM J ROENTGENOL, V194, P1531, DOI 10.2214/AJR.09.3587 Lessick J, 2005, AM J CARDIOL, V96, P1011, DOI 10.1016/j.amjcard.2005.05.062 Manghat NE, 2005, CLIN RADIOL, V60, P1256, DOI 10.1016/j.crad.2005.06.011 Mark Daniel B, 2010, Catheter Cardiovasc Interv, V76, pE1 Martinek M, 2007, PACE, V30, P1215, DOI 10.1111/j.1540-8159.2007.00843.x Martins RP, 2011, PACE, V34, P1665, DOI 10.1111/j.1540-8159.2011.03194.x Northam M, 2008, AM J ROENTGENOL, V191, P878, DOI 10.2214/AJR.07.2939 Onuma Y, 2006, J AM COLL CARDIOL, V48, P402, DOI 10.1016/j.jacc.2006.04.071 Orme NM, 2010, ARCH INTERN MED, V170, P1525, DOI 10.1001/archinternmed.2010.317 Quint LE, 2011, ACAD RADIOL, V18, P1500, DOI 10.1016/j.acra.2011.08.009 Raff GL, 2005, J AM COLL CARDIOL, V46, P552, DOI 10.1016/j.jacc.2005.05.056 Raman SV, 2005, AM J CARDIOL, V95, P683, DOI 10.1016/j.amjcard.2004.11.014 Schietinger BJ, 2008, AM HEART J, V155, P254, DOI 10.1016/j.ahj.2007.10.008 Schoepf UJ, 2004, CIRCULATION, V109, P2160, DOI 10.1161/01.CIR.0000128813.04325.08 Schragin JG, 2004, J THORAC IMAG, V19, P82, DOI 10.1097/00005382-200404000-00004 Takakuwa KM, 2008, RADIOLOGY, V248, P438, DOI 10.1148/radiol.2482072169 Wann S, 2007, INT J CARDIOVAS IMAG, V23, P379, DOI 10.1007/s10554-006-9177-5 Wissner E, 2009, EUR J RADIOL, V72, P284, DOI 10.1016/j.ejrad.2008.07.004 Wood MA, 2004, AM J CARDIOL, V93, P49, DOI 10.1016/j.amjcard.2003.09.011 Yorgun H, 2010, J COMPUT ASSIST TOMO, V34, P296, DOI 10.1097/RCT.0b013e3181c1d0e4 NR 33 TC 11 Z9 11 U1 0 U2 2 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 1438-9029 EI 1438-9010 J9 ROFO-FORTSCHR RONTG JI Rofo-Fortschr. Gebiet Rontgenstrahlen Bildgeb. Verfahr. PD SEP PY 2014 VL 186 IS 9 BP 860 EP 867 DI 10.1055/s-0034-1366107 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging WE Science Citation Index Expanded (SCI-EXPANDED) SC Radiology, Nuclear Medicine & Medical Imaging GA AN8DG UT WOS:000340832100003 PM 24648234 OA Green Submitted, Bronze DA 2026-04-17 ER PT J AU Pipanmekaporn, T Punjasawadwong, Y Charuluxananan, S Lapisatepun, W Bunburaphong, P Patumanond, J Saeteng, S Chandee, T AF Pipanmekaporn, Tanyong Punjasawadwong, Yodying Charuluxananan, Somrat Lapisatepun, Worawut Bunburaphong, Pavena Patumanond, Jayanton Saeteng, Somchareon Chandee, Theerada TI Incidence of and Risk Factors for Cardiovascular Complications After Thoracic Surgery for Noncancerous Lesions SO JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA LA English DT Article DE cardiovascular complications; cardiac arrhythmias; thoracic surgeries; noncancerous lesions ID LUNG-CANCER; POSTOPERATIVE COMPLICATIONS; COMPLETION PNEUMONECTOMY; ATRIAL-FIBRILLATION; ELECTIVE PNEUMONECTOMY; MYOCARDIAL-ISCHEMIA; PULMONARY RESECTION; OPERATIVE MORTALITY; MAJOR COMPLICATIONS; MORBIDITY AB Objective: The purpose of this study was to determine the incidence of and risk factors for cardiovascular complications after thoracic surgery for noncancerous lesions. Design: Retrospective cohort study. Setting: A tertiary medical center. Participants: All consecutive patients undergoing either thoracotomy or thoracoscopy for noncancerous lesions between 2005 and 2011 were included. Measurements and Main results: The primary outcomes were the incidence and types of cardiovascular complications such as cardiac arrhythmias, cardiac arrest, heart failure, and myocardial ischemia during hospitalization. A total of 719 patients were recruited, 60% of whom had infections. The incidence of cardiovascular complications after thoracic surgery was 6.7% (48 of 719), of which cardiac arrhythmia was the most common (25 of 48, 52%). The multivariate risk regression analysis showed that age >55 years (risk ratio [RR] = 4.0; 95% confidence interval [CI] = 2.1-7.5; p < 0.01), diabetes mellitus (RR = 3.0; 95% CI = 1.7-5.3; p < 0.01), coronary artery disease (RR = 4.8; 95% CI = 2.3-10.2; p < 0.01), duration of surgery >180 minutes (RR = 2.6; 95% CI = 1.3-5.1; p < 0.01), intraoperative hypotension (RR = 2.6; 95% CI = 1.6-4.3; p < 0.01), and positive fluid balance >2,000 mL (RR = 2.5; 95% CI = 1.4-4.5; p < 0.01) were independent risk factors for cardiovascular complications. Conclusions: Knowledge of risk factors could help surgical teams to identify high risk patients and adjust modifiable risk factors including optimization of medical conditions, correction of intraoperative hypotension, and appropriate blood and fluid administration in order to reduce perioperative morbidity and mortality. (C) 2014 Elsevier Inc. All rights reserved. C1 [Pipanmekaporn, Tanyong] Chiang Mai Univ, Fac Med, Clin Epidemiol Program, Chiang Mai 50000, Thailand. [Pipanmekaporn, Tanyong; Punjasawadwong, Yodying; Lapisatepun, Worawut] Chiang Mai Univ, Fac Med, Dept Anesthesiol, Chiang Mai 50000, Thailand. [Charuluxananan, Somrat; Bunburaphong, Pavena] Chulalongkorn Univ, Fac Med, Dept Anesthesiol, Bangkok 10330, Thailand. [Patumanond, Jayanton] Thammasat Univ, Fac Med, Clin Epidemiol Unity, Bangkok, Thailand. [Patumanond, Jayanton] Thammasat Univ, Fac Med, Clin Res Ctr, Bangkok, Thailand. [Saeteng, Somchareon] Chiang Mai Univ, Fac Med, Dept Surg, Chiang Mai 50000, Thailand. [Chandee, Theerada] Thammasat Univ, Fac Med, Dept Anesthesiol, Bangkok, Thailand. C3 Chiang Mai University; Chiang Mai University; Chulalongkorn University; Thammasat University; Thammasat University; Chiang Mai University; Thammasat University RP Punjasawadwong, Y (corresponding author), Chiang Mai Univ, Fac Med, Dept Anesthesiol, Intawarorot St, Chiang Mai 50000, Thailand. EM typunja@gmail.com OI Chandee, Theerada/0000-0002-2806-3543 CR Berry MF, 2010, ANN THORAC SURG, V89, P1044, DOI 10.1016/j.athoracsur.2009.12.065 Berry MF, 2009, ANN THORAC SURG, V88, P1093, DOI 10.1016/j.athoracsur.2009.06.012 Bijker JB, 2007, ANESTHESIOLOGY, V107, P213, DOI 10.1097/01.anes.0000270724.40897.8e Castillo MD, 2007, CURR OPIN ANESTHESIO, V20, P4, DOI 10.1097/ACO.0b013e32801271fa CHARLSON ME, 1989, ANN SURG, V210, P637, DOI 10.1097/00000658-198911000-00012 Christians KK, 2001, AM J SURG, V182, P713, DOI 10.1016/S0002-9610(01)00799-1 Duque JL, 1997, ANN THORAC SURG, V63, P944, DOI 10.1016/S0003-4975(97)00051-9 Fleisher LA, 2007, J AM COLL CARDIOL, V50, P1707, DOI 10.1016/j.jacc.2007.09.001 Groban L, 2000, J CARDIOTHOR VASC AN, V14, P662, DOI 10.1053/jcan.2000.18318 Harpole DH Jr, 1999, J THORAC CARDIOV SUR, V117, P969, DOI 10.1016/S0022-5223(99)70378-8 Hollaus PH, 2003, ANN THORAC SURG, V75, P966, DOI 10.1016/S0003-4975(02)04542-3 Holte K, 2002, BRIT J ANAESTH, V89, P622, DOI 10.1093/bja/aef220 Hu XF, 2013, ANN THORAC SURG, V95, P1899, DOI 10.1016/j.athoracsur.2013.03.051 Kalus JS, 2004, AM J CARDIOL, V94, P1423, DOI 10.1016/j.amjcard.2004.08.017 Lee JH, 2011, EUR J ANAESTH, V28, P39, DOI 10.1097/EJA.0b013e32834089cf Lee TH, 1999, CIRCULATION, V100, P1043, DOI 10.1161/01.CIR.100.10.1043 Licker M, 2002, CHEST, V121, P1890, DOI 10.1378/chest.121.6.1890 Licker M, 1999, EUR J CARDIO-THORAC, V15, P314, DOI 10.1016/S1010-7940(99)00006-8 Lwanga SK, 1991, SAMPLE SIZE DETERMIN, P12 MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601 Marret E, 2010, INTERACT CARDIOV TH, V10, P936, DOI 10.1510/icvts.2009.231621 Massard G, 1996, ANN THORAC SURG, V62, P1033, DOI 10.1016/0003-4975(96)00596-6 Miller DL, 2002, ANN THORAC SURG, V74, P876, DOI 10.1016/S0003-4975(02)03855-9 Moller AM, 2002, EUR J ANAESTH, V19, P57, DOI 10.1017/S0265021502000091 Muysoms FE, 1998, ANN THORAC SURG, V66, P1165, DOI 10.1016/S0003-4975(98)00599-2 Owen RM, 2013, EUR J CARDIO-THORAC, V43, P312, DOI 10.1093/ejcts/ezs284 PATEL RL, 1992, ANN THORAC SURG, V54, P84, DOI 10.1016/0003-4975(92)91145-Y Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Shapiro M, 2010, ANN THORAC SURG, V90, P927, DOI 10.1016/j.athoracsur.2010.05.041 Sherwood JT, 2005, J THORAC CARDIOV SUR, V129, P1258, DOI 10.1016/j.jtcvs.2004.12.053 Suksompong Sirilak, 2012, Asian Cardiovasc Thorac Ann, V20, P182, DOI 10.1177/0218492311436017 vanderWerff YD, 1997, CHEST, V111, P1278, DOI 10.1378/chest.111.5.1278 Vittinghoff E, 2005, STAT BIOL HEALTH, P157, DOI 10.1007/b138825 VONKNORRING J, 1992, ANN THORAC SURG, V53, P642, DOI 10.1016/0003-4975(92)90325-X Walsh M, 2013, ANESTHESIOLOGY, V119, P507, DOI 10.1097/ALN.0b013e3182a10e26 Yano T, 1997, EUR J CARDIO-THORAC, V11, P445, DOI 10.1016/S1010-7940(96)01097-4 Yildizeli B, 2007, EUR J CARDIO-THORAC, V31, P95, DOI 10.1016/j.ejcts.2006.10.031 NR 37 TC 7 Z9 7 U1 0 U2 22 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1053-0770 EI 1532-8422 J9 J CARDIOTHOR VASC AN JI J. Cardiothorac. Vasc. Anesth. PD AUG PY 2014 VL 28 IS 4 BP 948 EP 953 DI 10.1053/j.jvca.2014.02.002 PG 6 WC Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease WE Science Citation Index Expanded (SCI-EXPANDED) SC Anesthesiology; Cardiovascular System & Cardiology; Respiratory System GA AN6VN UT WOS:000340736600018 PM 25107715 DA 2026-04-17 ER PT J AU Farjah, F Varghese, TK Costas, K Krishnadasan, B Farivar, AS Hubka, M Louie, BE Backhus, LM Chong, N Gorden, J Cheng, AM He, H Flum, DR Low, D Aye, R Vallières, E Mulligan, MS Wood, DE AF Farjah, Farhood Varghese, Thomas K. Costas, Kimberley Krishnadasan, Bahirathan Farivar, Alexander S. Hubka, Michal Louie, Brian E. Backhus, Leah M. Chong, Nyen Gorden, Jed Cheng, Aaron M. He, Hao Flum, David R. Low, Donald Aye, Ralph Vallieres, Eric Mulligan, Michael S. Wood, Douglas E. TI Lung Resection Outcomes and Costs in Washington State: A Case for Regional Quality Improvement SO ANNALS OF THORACIC SURGERY LA English DT Article ID LENGTH-OF-STAY; SURGICAL MORTALITY; SURGERY DATABASE; THORACIC-SURGERY; RELIABILITY ADJUSTMENT; INCENTIVE SPIROMETRY; PHYSICIAN LEADERSHIP; ATRIAL-FIBRILLATION; RANKING HOSPITALS; CANCER RESECTION AB Background. A regional quality improvement effort does not exist for thoracic surgery in the United States. To initiate the development of one, we sought to describe temporal trends and hospital-level variability in associated outcomes and costs of pulmonary resection in Washington (WA) State. Methods. A cohort study (2000-2011) was conducted of operated-on lung cancer patients. The WA State discharge database was used to describe outcomes and costs for operations performed at all nonfederal hospitals within the state. Results. Over 12 years, 8,457 lung cancer patients underwent pulmonary resection across 49 hospitals. Inpatient deaths decreased over time (adjusted p-trend = 0.023) but prolonged length of stay did not (adjusted p-trend = 0.880). Inflation-adjusted hospital costs increased over time (adjusted p-trend < 0.001). Among 24 hospitals performing at least 1 resection per year, 5 hospitals were statistical outliers in rates of death (4 lower and 1 higher than the state average), and 13 were outliers with respect to prolonged length of stay (7 higher and 6 lower than the state average) and costs (5 higher and 8 lower than the state average). When evaluated for rates of death and costs, there were hospitals with fewer deaths/lower costs, fewer deaths/higher costs, more deaths/lower costs, and more deaths/higher costs. Conclusions. Variability in outcomes and costs over time and across hospitals suggest opportunities to improve the quality and value of thoracic surgery in WA State. Examples from cardiac surgery suggest that a regional quality improvement collaborative is an effective way to meaningfully and rapidly act upon these opportunities. (C) 2014 by The Society of Thoracic Surgeons C1 [Farjah, Farhood] Univ Washington, Div Cardiothorac Surg, Seattle, WA 98195 USA. Univ Washington, Surg Outcomes Res Ctr, Seattle, WA 98195 USA. Providence Phys Grp Cardiac & Thorac Surg, Everett, WA USA. Franciscan Hlth Syst, Catholic Hlth Initiat, Tacoma, WA USA. Swedish Canc Inst, Thorac Surg Div, Seattle, WA USA. Virginia Mason Med Ctr, Seattle, WA 98101 USA. C3 University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Swedish Cancer Institute; Swedish Health Services; Virginia Mason Medical Center RP Farjah, F (corresponding author), Univ Washington, Div Cardiothorac Surg, 1959 NE Pacific St,Box 356310, Seattle, WA 98195 USA. EM ffarjah@uw.edu RI ; Louie, Brian/AAJ-1840-2020; Flum, David/GPX-7976-2022 OI Farivar, Alexander/0000-0002-4224-958X; Louie, Brian/0000-0002-7599-1000; Gorden, Jed/0000-0003-0683-9547; Vallieres, Eric/0000-0003-1732-2658; Low, Donald E/0000-0002-3735-0958; Aye, Ralph/0000-0003-3726-6673; CR Aberle DR, 2011, NEW ENGL J MED, V365, P395, DOI 10.1056/NEJMoa1102873 Agostini P, 2013, THORAX, V68, P580, DOI 10.1136/thoraxjnl-2012-202785 [Anonymous], LUNG CANC SCREEN [Anonymous], Index of /pub/databases/chembl/ChEMBLdb Arom KV, 1997, ANN THORAC SURG, V64, P1245, DOI 10.1016/S0003-4975(97)00906-5 Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337 Birkmeyer JD, 2009, ANNU REV MED, V60, P405, DOI 10.1146/annurev.med.60.062107.101214 Della Rocca G, 2002, MINERVA ANESTESIOL, V68, P681 DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8 Dimick JB, 2004, JAMA-J AM MED ASSOC, V292, P847, DOI 10.1001/jama.292.7.847 Dimick JB, 2008, J AM COLL SURGEONS, V207, P347, DOI 10.1016/j.jamcollsurg.2008.04.014 Dimick JB, 2012, ANN SURG, V255, P703, DOI 10.1097/SLA.0b013e31824b46ff Dimick JB, 2010, HEALTH SERV RES, V45, P1614, DOI 10.1111/j.1475-6773.2010.01158.x Farjah F, 2012, ANN THORAC SURG, V94, P881, DOI 10.1016/j.athoracsur.2012.04.082 Finks JF, 2011, NEW ENGL J MED, V364, P2128, DOI 10.1056/NEJMsa1010705 Flum DR, BUSINESS QUALITY SUR Goss JR, 2000, ANN THORAC SURG, V70, P695, DOI 10.1016/S0003-4975(00)01391-6 Gosselink R, 2000, CRIT CARE MED, V28, P679, DOI 10.1097/00003246-200003000-00013 Holman WL, 2001, JAMA-J AM MED ASSOC, V285, P3003, DOI 10.1001/jama.285.23.3003 Kozower BD, 2010, ANN THORAC SURG, V90, P875, DOI 10.1016/j.athoracsur.2010.03.115 LaPar DJ, 2012, ANN THORAC SURG, V94, P216, DOI 10.1016/j.athoracsur.2012.03.054 Learn PA, 2010, MED CARE, V48, P1041, DOI 10.1097/MLR.0b013e3181f37d5f Mariotto AB, 2011, JNCI-J NATL CANCER I, V103, P117, DOI 10.1093/jnci/djq495 National Research Council, 2007, LEARN HEALTHC SYST W O'Connor GT, 2000, ANN THORAC SURG, V70, P693, DOI 10.1016/S0003-4975(00)01744-6 Prager RL, 2009, SEMIN THORAC CARDIOV, V21, P20, DOI 10.1053/j.semtcvs.2009.03.008 Riber LP, 2012, ANN THORAC SURG, V94, P339, DOI 10.1016/j.athoracsur.2011.12.096 Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138 Speir AM, 2009, SEMIN THORAC CARDIOV, V21, P12, DOI 10.1053/j.semtcvs.2009.03.005 Tisdale JE, 2009, ANN THORAC SURG, V88, P886, DOI 10.1016/j.athoracsur.2009.04.074 WA State Health Care Authority, 2013, WASH STAT MED PROSP Washington State Department of Health, COMPR HOSP ABSTR REP Wright CD, 2008, ANN THORAC SURG, V85, P1857, DOI 10.1016/j.athoracsur.2008.03.024 NR 33 TC 12 Z9 12 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD JUL PY 2014 VL 98 IS 1 BP 175 EP 181 DI 10.1016/j.athoracsur.2014.03.014 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA AK4ZF UT WOS:000338432600047 PM 24793691 OA Bronze DA 2026-04-17 ER PT J AU Li, XB Zhou, CW Hu, W AF Li, Xiaobing Zhou, Changwei Hu, Wen TI Association between Serum Angiotensin-converting Enzyme 2 Level with Postoperative Morbidity and Mortality after Major Pulmonary Resection in Non-small Cell Lung Cancer Patients SO HEART LUNG AND CIRCULATION LA English DT Article DE Angiotensin-converting enzyme 2; Pulmonary resection; Non-small cell lung cancer; Morbidity; Mortality ID COMORBIDITY; RECEPTOR; SURGERY; ACE2; RISK AB Background To explore the association between serum angiotensin-converting enzyme 2 (ACE2) levels and postoperative morbidity and mortality after major pulmonary resection in non-small cell lung cancer (NSCLC) patients. Methods Preoperative and postoperative serum ACE2 levels in 320 NSCLC patients who underwent major pulmonary resection were measured. The serum ACE2 levels on postoperative day 1 were divided into quartile categories. Results After adjustment for age, sex, body mass index, current smoking status, forced expiratory volume in 1 second, coronary heart disease, hypertension, diabetes mellitus, chronic obstructive pulmonary disease, and tumour clinical stages, the risk of developing postoperative morbidities was significantly higher in the lowest serum ACE2 level quartile than in the highest quartile (hazard ratio, 2.12; 95% CI, 1.57-6.23; p=0.008). NSCLC patients with a serum ACE2 level <= 3.21 ng/mL had significantly higher rates of pneumonia, pleural effusion, atrial fibrillation as well as higher in-hospital mortality after major pulmonary resection, compared with those with a serum ACE2 level >3.21ng/mL. Conclusions The serum ACE2 level one day post surgery is an independent risk factor for postoperative morbidities after major pulmonary resection in NSCLC patients. Thus, it could be used as a prognostic factor for postoperative morbidities after major pulmonary resection in NSCLC patients. C1 [Li, Xiaobing; Zhou, Changwei; Hu, Wen] Cent S Univ, Xiangya Hosp 2, Dept Cardiothorac Surg, Changsha 410011, Hunan, Peoples R China. C3 Central South University RP Hu, W (corresponding author), Cent S Univ, Xiangya Hosp 2, Dept Thorac & Cardiovasc Surg, 138 Renmin Rd, Changsha 410011, Hunan, Peoples R China. EM huwenppk@163.com FU Hunan Provincial Natural Science Foundation, P.R. China [08C2315, 12C3821] FX This work was supported by Hunan Provincial Natural Science Foundation (grants #08C2315 and #12C3821), P.R. China. CR Ambrogi V, 2003, EUR J CARDIO-THORAC, V23, P811, DOI 10.1016/S1010-7940(03)00093-9 Cui Y, 2004, THORAC CARDIOV SURG, V52, P45, DOI 10.1055/s-2004-815801 Der Sarkissian S, 2006, PROG BIOPHYS MOL BIO, V91, P163, DOI 10.1016/j.pbiomolbio.2005.05.011 Domenighetti AA, 2005, HYPERTENSION, V46, P426, DOI 10.1161/01.HYP.0000173069.53699.d9 Hsieh WY, 2012, INT J BIOL SCI, V8, P1197, DOI 10.7150/ijbs.5087 Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712 Janssen-Heijnen MLG, 2007, EUR J CANCER, V43, P2179, DOI 10.1016/j.ejca.2007.06.008 Janssen-Heijnen MLG, 1998, LUNG CANCER, V21, P105, DOI 10.1016/S0169-5002(98)00039-7 Kiely DG, 1997, CARDIOVASC RES, V33, P201, DOI 10.1016/S0008-6363(96)00180-0 Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267 Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145 Licker M, 1999, EUR J CARDIO-THORAC, V15, P314, DOI 10.1016/S1010-7940(99)00006-8 Mazzolai L, 2000, HYPERTENSION, V35, P985, DOI 10.1161/01.HYP.35.4.985 Pan CH, 2007, FEBS LETT, V581, P526, DOI 10.1016/j.febslet.2007.01.014 Pavia R, 2007, J CARDIOVASC SURG, V48, P227 Raizada MK, 2007, J CARDIOVASC PHARM, V50, P112, DOI 10.1097/FJC.0b013e3180986219 Rami-Porta R, 2009, ANN THORAC CARDIOVAS, V15, P4 Reicher-Reiss H, 2001, AM J CARDIOL, V87, P459, DOI 10.1016/S0002-9149(00)01405-3 Senbaklavaci O, 2013, LANGENBECKS ARCH SUR Tikellis C., 2012, INT J PEPT PROT RES, V2012, DOI 10.1155/2012/256294 Travis W., 1999, Histological Typing of Lung and Pleural Tumours Vickers C, 2002, J BIOL CHEM, V277, P14838, DOI 10.1074/jbc.M200581200 Volpino P, 2007, J CARDIOVASC SURG, V48, P375 Zhang HL, 2013, PHARMACOLOGY, V91, P297, DOI 10.1159/000350395 NR 24 TC 8 Z9 8 U1 0 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA SN 1443-9506 EI 1444-2892 J9 HEART LUNG CIRC JI Heart Lung Circ. PD JUL PY 2014 VL 23 IS 7 BP 661 EP 666 DI 10.1016/j.hlc.2013.12.013 PG 6 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA AK2TS UT WOS:000338273000011 PM 24636159 OA Green Submitted, Bronze DA 2026-04-17 ER PT J AU Patel, AJ Hunt, I AF Patel, Akshay J. Hunt, Ian TI Review of the evidence supports role for routine prophylaxis against postoperative supraventricular arrhythmia in patients undergoing pulmonary resection SO INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY LA English DT Article DE Supraventricular arrhythmia; Atrial fibrillation; Anti-arrhythmic prophylaxis; Pulmonary resection ID NONCARDIAC THORACIC-SURGERY; ATRIAL-FIBRILLATION; RISK-FACTORS; LUNG-CANCER; AMIODARONE; PREVENTION; DILTIAZEM; DYSRHYTHMIAS; OPERATIONS AB A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was 'Is there an indication for routine prophylaxis against postoperative supraventricular arrhythmia in patients undergoing pulmonary resection surgery?' Altogether almost 150 papers were found as a result of the reported search, of which 14 represented the best evidence to reach conclusions regarding the issues of interest for this review. The major outcome of interest that was investigated was the incidence of supraventricular arrhythmia (SVA), notably atrial fibrillation (AF). The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes, results and study weakness of the papers were tabulated. Current guidance from the Society of Thoracic Surgeons (STS) supports the use of diltiazem and amiodarone in most patients undergoing major pulmonary resection. Robust data from a large randomized, controlled trial (RCT) showed a reduction from 25 to 15% in the incidence of clinically significant atrial arrhythmia with diltiazem; P < 0.03. Moreover, numerous RCTs have shown that there is a clear benefit with the use of amiodarone in reducing the incidence of postoperative SVA. Of note, one prospective clinical trial randomized 242 patients into a treatment group with amiodarone (n = 122) and a placebo group (n = 120). The incidence of postoperative AF was reduced from 32 to 9% in the active arm; P < 0.001. The risk of acute lung injury with amiodarone has not been substantiated further in more recent clinical trials and has in fact been shown to be safe. The STS guidelines do, however, advise against the use of amiodarone in extensive lung resection such as pneumonectomy. We conclude that there is an indication for routine prophylaxis against postoperative supraventricular arrhythmia in patients undergoing pulmonary resection. However, further data are needed to ascertain the impact of said anti-arrhythmic medications on the length of postoperative hospital stay, intensive care unit stay and cost. Those patients deemed high-risk need to be promptly identified, so the anti-arrhythmic therapy can be tailored to the cohort thus optimizing on cost and safety. C1 [Patel, Akshay J.; Hunt, Ian] St George Hosp, Dept Thorac Surg, London SW17 0PT, England. C3 City St Georges, University of London RP Patel, AJ (corresponding author), St George Hosp, Dept Thorac Surg, Blackshaw Rd, London SW17 0PT, England. EM ajp.788@gmail.com CR Amar D, 1997, ANN THORAC SURG, V63, P1374 Amar D, 2000, J THORAC CARDIOV SUR, V120, P790, DOI 10.1067/mtc.2000.109538 ASAMURA H, 1993, J THORAC CARDIOV SUR, V106, P1104, DOI 10.1016/S0022-5223(19)33985-6 Barbetakis Nikolaos, 2004, BMC Surg, V4, P7, DOI 10.1186/1471-2482-4-7 BORGEAT A, 1991, ANN THORAC SURG, V51, P964, DOI 10.1016/0003-4975(91)91016-O Ciriaco P, 2000, EUR J CARDIO-THORAC, V18, P12, DOI 10.1016/S1010-7940(00)00428-0 Ciszewski P, 2013, THORAC CARDIOV SURG, V61, P365, DOI 10.1055/s-0032-1311537 Curtis JJ, 1998, ANN THORAC SURG, V66, P1766, DOI 10.1016/S0003-4975(98)00942-4 Dunning Joel, 2003, Interact Cardiovasc Thorac Surg, V2, P405, DOI 10.1016/S1569-9293(03)00191-9 Fernando HC, 2011, ANN THORAC SURG, V92, P1144, DOI 10.1016/j.athoracsur.2011.06.104 Jakobsen CJ, 1997, J CARDIOTHOR VASC AN, V11, P746, DOI 10.1016/S1053-0770(97)90169-5 Khalil MA, 2013, J ANESTH, V27, P56, DOI 10.1007/s00540-012-1478-3 Lanza LA, 2003, ANN THORAC SURG, V75, P223, DOI 10.1016/S0003-4975(02)04285-6 Nojiri T, 2012, J THORAC CARDIOV SUR, V143, P488, DOI 10.1016/j.jtcvs.2011.09.003 Rena O, 2001, EUR J CARDIO-THORAC, V20, P688, DOI 10.1016/S1010-7940(01)00890-9 Riber LP, 2012, ANN THORAC SURG, V94, P339, DOI 10.1016/j.athoracsur.2011.12.096 RITCHIE AJ, 1992, THORAX, V47, P41, DOI 10.1136/thx.47.1.41 Shrivastava Vivek, 2004, Interact Cardiovasc Thorac Surg, V3, P656, DOI 10.1016/j.icvts.2004.08.002 Terzi A, 1996, THORAC CARDIOV SURG, V44, P300, DOI 10.1055/s-2007-1012041 Tisdale JE, 2009, ANN THORAC SURG, V88, P886, DOI 10.1016/j.athoracsur.2009.04.074 VanMieghem W, 1996, ANN THORAC SURG, V61, P1083, DOI 10.1016/0003-4975(96)00073-2 VANMIEGHEM W, 1994, CHEST, V105, P1642, DOI 10.1378/chest.105.6.1642 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 NR 23 TC 6 Z9 7 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1569-9293 EI 1569-9285 J9 INTERACT CARDIOV TH JI Interact Cardiovasc. Thorac. Surg. PD JUL PY 2014 VL 19 IS 1 BP 111 EP 116 DI 10.1093/icvts/ivu082 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA AM2HB UT WOS:000339669900028 PM 24667586 OA Bronze DA 2026-04-17 ER PT J AU Farmakis, D Parissis, J Filippatos, G AF Farmakis, Dimitrios Parissis, John Filippatos, Gerasimos TI Insights Into Onco-Cardiology Atrial Fibrillation in Cancer SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Review ID INTRAVENOUS BISPHOSPHONATE THERAPY; MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; LUNG-CANCER; NATRIURETIC-PEPTIDE; PULMONARY RESECTION; THORACIC-SURGERY; HEART-FAILURE; ANTITHROMBOTIC THERAPY; COLORECTAL-CANCER AB Atrial fibrillation (AF) has been found to occur with an increased frequency in patients with malignancies, particularly in those undergoing cancer surgery. The occurrence of AF in cancer may be related to comorbid states or a direct tumor effect or may represent a complication of cancer surgical or medical therapy, whereas inflammation may be a common denominator for both conditions. Treating AF in patients with malignancies is a challenge, especially in terms of antithrombotic therapy, because cancer may result in an increased risk of either thrombosis or hemorrhage and an unpredictable anticoagulation response, whereas thromboembolic risk prediction scores such as CHADS(2) (Cardiac Failure, Hypertension, Age, Diabetes, and Stroke [doubled]) may not be applicable. The general lack of evidence imposes an individualized approach to the management of AF in those patients, although some general recommendations based on current guidelines in noncancer patients and the existing evidence in cancer patients, where available, may be outlined. (C) 2014 by the American College of Cardiology Foundation C1 [Farmakis, Dimitrios] Univ Athens, Sch Med, Dept Internal Med 1, GR-11527 Athens, Greece. [Farmakis, Dimitrios; Parissis, John; Filippatos, Gerasimos] Univ Athens, Sch Med, Dept Cardiol 2, GR-11527 Athens, Greece. C3 National & Kapodistrian University of Athens; National & Kapodistrian University of Athens RP Filippatos, G (corresponding author), Univ Athens, Sch Med, Dept Cardiol 2, Attikon Hosp, 1 Rimini St, GR-11527 Athens, Greece. EM geros@otenet.gr RI Farmakis, Dimitrios/AAK-4509-2020; Filippatos, Gerasimos/ABA-4656-2021 FU Hellenic Cardiological Society; Boehringer-Ingelheim Ellas; Abbott USA; Bayer and Corthera; ORION Pharma FX This paper was partly supported by a grant from the Hellenic Cardiological Society. Dr. Farmakis is a member of the Steering Committee for a trial sponsored by Boehringer-Ingelheim Ellas. Dr. Parissis has received research grants from Abbott USA and ORION Pharma for heart failure; and has received honoraria from Servier International and Menarini International for lectures. Dr. Filippatos is a member of the Steering Committee for trials sponsored by Bayer and Corthera. CR Abonowara A, 2012, CLIN INVEST MED, V35, pE152 Anderson JL, 2013, J AM COLL CARDIOL, V61, P1935, DOI 10.1016/j.jacc.2013.02.001 Arslan C, 2011, SUPPORT CARE CANCER, V19, P425, DOI 10.1007/s00520-010-0868-z Aviles RJ, 2003, CIRCULATION, V108, P3006, DOI 10.1161/01.CIR.0000103131.70301.4F Barbey JT, 2003, J CLIN ONCOL, V21, P3609, DOI 10.1200/JCO.2003.10.009 BECKNIEL.J, 1973, ACTA MED SCAND, V193, P425 Bhave PD, 2012, AM HEART J, V164, P918, DOI 10.1016/j.ahj.2012.09.004 Bickford CL, 2013, AM J MED SCI Büller HR, 2004, CHEST, V126, p401S, DOI 10.1378/chest.126.3_suppl.401S Camm AJ, 2012, EUR HEART J, V33, P2719, DOI 10.1093/eurheartj/ehs253 Camm AJ, 2010, EUROPACE, V12, P1360, DOI [10.1093/eurheartj/ehq278, 10.1093/europace/euq350] Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Cardinale D, 2007, CIRCULATION, V115, P1339, DOI 10.1161/CIRCULATIONAHA.106.647008 Chopra V, 2012, ARCH SURG-CHICAGO, V147, P181, DOI 10.1001/archsurg.2011.897 Chung MK, 2001, CIRCULATION, V104, P2886, DOI 10.1161/hc4901.101760 Ciszewski P, 2013, INTERACT CARDIOV TH, V17, P680, DOI 10.1093/icvts/ivt238 Ciszewski P, 2013, THORAC CARDIOV SURG, V61, P365, DOI 10.1055/s-0032-1311537 Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561 des Guetz G, 2011, TARGET ONCOL, V6, P197, DOI 10.1007/s11523-011-0204-7 Doggrell SA, 2013, EXPERT OPIN DRUG SAF, V12, P421, DOI 10.1517/14740338.2013.780026 Efremidis M, 2008, J CARD FAIL, V14, P232, DOI 10.1016/j.cardfail.2007.10.023 Efremidis M, 2008, HELL J CARDIOL, V49, P19 El-Chami MF, 2010, J AM COLL CARDIOL, V55, P1370, DOI 10.1016/j.jacc.2009.10.058 Erichsen R, 2011, BRIT J CANCER, V105, P881, DOI 10.1038/bjc.2011.338 Erichsen R, 2012, INTERN EMERG MED, V7, P431, DOI 10.1007/s11739-011-0701-9 Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039 Guo YT, 2012, J AM COLL CARDIOL, V60, P2263, DOI 10.1016/j.jacc.2012.04.063 Guzzetti S, 2002, CIRCULATION, V106, pE40, DOI 10.1161/01.CIR.0000028399.42411.13 Guzzetti S, 2002, AM J MED, V112, P587, DOI 10.1016/S0002-9343(02)01029-X Guzzetti S, 2008, INTERN EMERG MED, V3, P227, DOI 10.1007/s11739-008-0124-4 Heit JA, 2000, ARCH INTERN MED, V160, P809, DOI 10.1001/archinte.160.6.809 Hu YF, 2013, INT J CARDIOL, V165, P355, DOI 10.1016/j.ijcard.2012.08.036 Hutten BA, 2000, J CLIN ONCOL, V18, P3078, DOI 10.1200/JCO.2000.18.17.3078 Imperatori A, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-4 Johnston K, 2012, ANN PHARMACOTHER, V46, P1239, DOI 10.1345/aph.1R128 Kaakeh Y, 2012, DRUGS, V72, P1617, DOI 10.2165/11633140-000000000-00000 Khouri MG, 2012, CIRCULATION, V126, P2749, DOI 10.1161/CIRCULATIONAHA.112.100560 Klerk CPW, 2005, J CLIN ONCOL, V23, P2130, DOI 10.1200/JCO.2005.03.134 Lainscak M, 2008, INT J CARDIOL, V128, P311, DOI 10.1016/j.ijcard.2007.12.078 Lee AYY, 2005, DM-DIS MON, V51, P150, DOI 10.1016/j.disamonth.2005.03.010 Lee AYY, 2005, J CLIN ONCOL, V23, P2123, DOI 10.1200/JCO.2005.03.133 Lip GYH, 2012, EUR J HEART FAIL, V14, P681, DOI 10.1093/eurjhf/hfs073 Mann DL, 2010, PROG CARDIOVASC DIS, V53, P80, DOI 10.1016/j.pcad.2010.05.004 Mozaffarian D, 2012, JAMA-J AM MED ASSOC, V308, P2001, DOI 10.1001/jama.2012.28733 Nadir Yona, 2004, Rev Clin Exp Hematol, V8, pE4 Niers TMH, 2007, CRIT REV ONCOL HEMAT, V61, P195, DOI 10.1016/j.critrevonc.2006.07.007 Nojiri T, 2013, EUR J CARDIO-THORAC, V44, P98, DOI 10.1093/ejcts/ezs646 Nojiri T, 2012, EUR J CARDIO-THORAC, V41, P1330, DOI 10.1093/ejcts/ezr202 Nojiri T, 2012, J THORAC CARDIOV SUR, V143, P488, DOI 10.1016/j.jtcvs.2011.09.003 Nojiri T, 2011, GEN THORAC CARDIOVAS, V59, P799, DOI 10.1007/s11748-011-0841-x Nojiri T, 2010, J THORAC CARDIOV SUR, V140, P764, DOI 10.1016/j.jtcvs.2009.11.073 Nojiri T, 2010, EUR J CARDIO-THORAC, V37, P787, DOI 10.1016/j.ejcts.2009.09.043 Ojima T, 2013, SURG TODAY Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638 Riber LP, 2014, EUR J CARDIO-THORAC, V45, P120, DOI 10.1093/ejcts/ezt169 Riber LP, 2012, ANN THORAC SURG, V94, P339, DOI 10.1016/j.athoracsur.2011.12.096 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Salvatici M, 2010, BIOMARKERS, V15, P259, DOI 10.3109/13547500903509351 Simopoulos V, 2013, ANGIOLOGY Siu CW, 2005, PACE, V28, pS120, DOI 10.1111/j.1540-8159.2005.00024.x Skiba MA, 2013, HEART LUNG CIRC, V22, P627, DOI 10.1016/j.hlc.2012.12.017 Sorensen HT, 1998, NEW ENGL J MED, V338, P1169, DOI 10.1056/NEJM199804233381701 Suter TM, 2013, EUR HEART J, V34, P1102, DOI 10.1093/eurheartj/ehs181 van der Hooft CS, 2004, J AM COLL CARDIOL, V44, P2117, DOI 10.1016/j.jacc.2004.08.053 Velagapudi P, 2011, SOUTH MED J, V104, P667, DOI 10.1097/SMJ.0b013e3182299e6c Walsh Stewart R, 2004, World J Surg Oncol, V2, P40 Wilkinson GS, 2010, J CLIN ONCOL, V28, P4898, DOI 10.1200/JCO.2010.28.7524 NR 68 TC 319 Z9 357 U1 0 U2 17 PU ELSEVIER SCIENCE INC PI NEW YORK PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 18 PY 2014 VL 63 IS 10 BP 945 EP 953 DI 10.1016/j.jacc.2013.11.026 PG 9 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA AC4ZG UT WOS:000332529400002 PM 24361314 DA 2026-04-17 ER PT J AU Ivanovic, J Maziak, DE Ramzan, S McGuire, AL Villeneuve, PJ Gilbert, S Sundaresan, RS Shamji, FM Seely, AJE AF Ivanovic, Jelena Maziak, Donna E. Ramzan, Sarah McGuire, Anna L. Villeneuve, Patrick James Gilbert, Sebastien Sundaresan, R. Sudhir Shamji, Farid M. Seely, Andrew J. E. TI Incidence, severity and perioperative risk factors for atrial fibrillation following pulmonary resection SO INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY LA English DT Article DE Atrial fibrillation; Flutter; Lung cancer surgery; Statistics; risk analysis; modelling; Epidemiology ID NONCARDIAC THORACIC-SURGERY; LUNG-CANCER; SUPRAVENTRICULAR ARRHYTHMIA; MORBIDITY; CLASSIFICATION; PNEUMONECTOMY; AMIODARONE; MORTALITY; DILTIAZEM; DYSRHYTHMIAS AB Postoperative atrial fibrillation (PAF) occurs commonly following pulmonary resection. Our aims were to quantify the incidence and severity of PAF using the Thoracic Morbidity & Mortality classification system, and identify risk factors for PAF. All consecutive patients undergoing pulmonary resection at a single centre (January 2008 - April 2010) were enrolled. PAF was defined as postoperative, electrocardiographically documented and requiring initiation of pharmacological therapy. Univariate and multivariate analyses of risk factors associated with the development of PAF were conducted. The incidence of PAF was 11.8% (n = 43) of 363 pulmonary resections (open: n = 173; 47.7%; video-assisted: n = 177; 48.8%; converted: n = 13; 3.6%): sublobar (n = 93; 25.6%), lobectomy (n = 237; 65.3%), bilobectomy (n = 7; 1.9%) and pneumonectomy (n = 24; 6.6%). Twenty-eight cases (65.1%) were uncomplicated/transient, and 15 cases (34.9%) were complicated/persistent PAF, defined as lasting for > 7 days (40.0%), requiring cardioversion (13.3%), vasopressors (33.3%), in-hospital use of anticoagulants (46.7%) and/or anticoagulants on discharge (26.7%). Patients with PAF had increased mean lengths of hospital stay (10.5 days vs 6.9 days; P = 0.04). Peak onset of PAF occurred 2.5 (standard deviation (SD) +/- 1.3) days after pulmonary resection, lasting for 1.8 +/- 2.8 (mean, +/- SD) days. Multivariate analysis identified (relative risk; 95% confidence interval): age >= 70 years (2.3; 1.1-5.1), history of angioplasty/stents/angina (4.0; 1.4-11.3), thoracotomy (3.6; 1.4-9.3), conversion to open thoracotomy (16.5; 2.2-124.0) and extent of surgery/stage (7.1; 1.0-49.4) as predictors of PAF. While the majority of PAF is uncomplicated and transient, one-third of cases lead to persistence or major intervention. Age, coronary artery disease and extent of surgery/stage increase the risk of PAF following pulmonary resection. Identifying patients with elevated risk may lead to targeted prophylaxis to reduce the incidence of PAF. C1 [Ivanovic, Jelena; Ramzan, Sarah] Univ Ottawa, Fac Med, Ottawa, ON, Canada. [Ivanovic, Jelena; Maziak, Donna E.; Seely, Andrew J. E.] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada. [Ivanovic, Jelena; Maziak, Donna E.; McGuire, Anna L.; Villeneuve, Patrick James; Gilbert, Sebastien; Sundaresan, R. Sudhir; Shamji, Farid M.; Seely, Andrew J. E.] Ottawa Gen Hosp, Dept Surg, Div Thorac Surg, Ottawa, ON K1H 8L6, Canada. C3 University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute RP Seely, AJE (corresponding author), Ottawa Gen Hosp, Dept Surg, Div Thorac Surg, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada. EM aseely@ottawahospital.on.ca OI Gilbert, Sebastien/0000-0003-4357-9553; Ivanovic, Jelena/0000-0002-6714-0716 CR Amar D, 1997, ANN THORAC SURG, V63, P1374 Amar D, 2000, J THORAC CARDIOV SUR, V120, P790, DOI 10.1067/mtc.2000.109538 Amar D, 2002, ANESTH ANALG, V95, P537, DOI 10.1097/00000539-200209000-00006 Amar D, 2002, ANESTHESIOLOGY, V96, P352, DOI 10.1097/00000542-200202000-00021 Bobbio A, 2007, EUR J CARDIO-THORAC, V31, P70, DOI 10.1016/j.ejcts.2006.10.020 Chelazzi C, 2011, ISRN CARDIOL, DOI [10.5402/2011/203179, DOI 10.5402/2011/203179.[] Ciriaco P, 2000, EUR J CARDIO-THORAC, V18, P12, DOI 10.1016/S1010-7940(00)00428-0 Dindo D, 2004, ANN SURG, V240, P205, DOI [10.17116/hirurgia2018090162, 10.1097/01.sla.0000133083.54934.ae] Dyszkiewicz W, 1998, EUR J CARDIO-THORAC, V13, P625, DOI 10.1016/S1010-7940(98)00084-0 Gómez-Caro A, 2006, ARCH BRONCONEUMOL, V42, P9, DOI 10.1016/S1579-2129(06)60107-9 Harpole DH, 1996, ANN THORAC SURG, V61, P977, DOI 10.1016/0003-4975(95)01174-9 Hollings DD, 2010, AM J SURG, V199, P558, DOI 10.1016/j.amjsurg.2009.11.006 Ivanovic J, 2011, ANN THORAC SURG, V91, P387, DOI 10.1016/j.athoracsur.2010.10.035 Lanza LA, 2003, ANN THORAC SURG, V75, P223, DOI 10.1016/S0003-4975(02)04285-6 Mansour Z, 2009, ANN THORAC SURG, V88, P1737, DOI 10.1016/j.athoracsur.2009.07.016 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Park BJ, 2007, J THORAC CARDIOV SUR, V133, P775, DOI 10.1016/j.jtcvs.2006.09.022 Passman RS, 2005, ANN THORAC SURG, V79, P1698, DOI 10.1016/j.athoracsur.2004.10.058 Polanczyk CA, 1998, ANN INTERN MED, V129, P279, DOI 10.7326/0003-4819-129-4-199808150-00003 RITCHIE AJ, 1990, ANN THORAC SURG, V50, P86, DOI 10.1016/0003-4975(90)90094-M Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Seely AJE, 2010, ANN THORAC SURG, V90, P936, DOI 10.1016/j.athoracsur.2010.05.014 Tisdale JE, 2010, SEMIN THORAC CARDIOV, V22, P310, DOI 10.1053/j.semtcvs.2010.12.001 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 NR 24 TC 59 Z9 68 U1 0 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1569-9293 EI 1569-9285 J9 INTERACT CARDIOV TH JI Interact Cardiovasc. Thorac. Surg. PD MAR PY 2014 VL 18 IS 3 BP 340 EP 346 DI 10.1093/icvts/ivt520 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA AB8IR UT WOS:000332034100016 PM 24336699 OA Green Published DA 2026-04-17 ER PT J AU Xin, YZ Hida, Y Kaga, K Iimura, Y Shiina, N Ohtaka, K Muto, J Kubota, S Matsui, Y AF Xin, Yanzhong Hida, Yasuhiro Kaga, Kichizo Iimura, Yasuaki Shiina, Nobuyuki Ohtaka, Kazuto Muto, Jun Kubota, Suguru Matsui, Yoshiro TI Left lobectomy might be a risk factor for atrial fibrillation following pulmonary lobectomy SO EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY LA English DT Article DE Arrhythmia; Lobectomy; Lung cancer; Atrial fibrillation; Surgery; B-type natriuretic peptide ID BRAIN NATRIURETIC PEPTIDE; THORACIC-SURGERY; PREDICT; SECRETION; VAGAL; AGE AB To identify risk factors for atrial fibrillation (AF) following lobectomy for a pulmonary malignant tumour. The outcomes of patients who underwent lobectomy from February 2005 to September 2010 were analysed with respect to the development of postoperative AF. Among 186 patients, 20 developed AF and these had significantly higher preoperative B-type natriuretic peptide (BNP) than those without AF. A significantly high incidence of AF following pulmonary lobectomy was demonstrated in the group of patients who were male, underwent a thoracotomy, had a high preoperative value of BNP and underwent a left lobectomy. Multivariate analysis revealed that left lobectomy is the only independent risk factor. The area under the receiver-operating characteristic curve for BNP to predict postoperative AF following a left lobectomy for a pulmonary malignant tumour was 0.82 (95% confidence interval 0.70-0.93; P < 0.05). A BNP level of 24.1 pg/ml had a sensitivity of 90.9% and a specificity of 56% for predicting postoperative AF following left lobectomy for a pulmonary malignant tumour. Left lobectomy is the only independent risk factor for postoperative AF. Elevated BNP is the risk factor for postoperative AF in patients undergoing left pulmonary lobectomy. C1 [Xin, Yanzhong; Hida, Yasuhiro; Kaga, Kichizo; Iimura, Yasuaki; Shiina, Nobuyuki; Ohtaka, Kazuto; Muto, Jun; Kubota, Suguru; Matsui, Yoshiro] Hokkaido Univ, Grad Sch Med, Dept Cardiovasc & Thorac Surg, Sapporo, Hokkaido 0608638, Japan. [Xin, Yanzhong] Harbin Med Univ, Affiliated Hosp 4, Dept Thorac Surg, Harbin, Heilongjiang Pr, Peoples R China. C3 Hokkaido University; Harbin Medical University RP Hida, Y (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Cardiovasc & Thorac Surg, Kita Ku, North 15,West 7, Sapporo, Hokkaido 0608638, Japan. EM yhida@med.hokudai.ac.jp RI Hida, Yasuhiro/A-7761-2012; Kaga, Kichizo/A-7759-2012; Kubota, Suguru/E-1930-2012 OI Hida, Yasuhiro/0000-0003-1759-4215; CR Antoniades C, 2009, CIRCULATION, V120, pS170, DOI 10.1161/CIRCULATIONAHA.108.843599 Boussuges A, 2000, AM J RESP CRIT CARE, V162, P670, DOI 10.1164/ajrccm.162.2.9908056 Chugh SS, 2001, J AM COLL CARDIOL, V37, P371, DOI 10.1016/S0735-1097(00)01107-4 Cowie MR, 1997, LANCET, V350, P1349, DOI 10.1016/S0140-6736(97)06031-5 Curtis JJ, 1998, ANN THORAC SURG, V66, P1766, DOI 10.1016/S0003-4975(98)00942-4 Goetze JP, 2006, EUR HEART J, V27, P1648, DOI 10.1093/eurheartj/ehl109 Hak L, 2009, J INTERF CYTOK RES, V29, P327, DOI 10.1089/jir.2008.0082.2906 Hollings DD, 2010, AM J SURG, V199, P558, DOI 10.1016/j.amjsurg.2009.11.006 LAKE FR, 1989, AUST NZ J MED, V19, P321, DOI 10.1111/j.1445-5994.1989.tb00271.x Lee YS, 2010, J CARDIOL, V56, P348, DOI 10.1016/j.jjcc.2010.07.006 Nojiri T, 2010, EUR J CARDIO-THORAC, V37, P787, DOI 10.1016/j.ejcts.2009.09.043 On YK, 2009, J THORAC CARDIOV SUR, V137, P1515, DOI 10.1016/j.jtcvs.2008.10.022 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Park BJ, 2007, J THORAC CARDIOV SUR, V133, P775, DOI 10.1016/j.jtcvs.2006.09.022 Passino C, 2005, INT J CARDIOL, V104, P39, DOI 10.1016/j.ijcard.2004.09.008 Redfield MM, 2002, J AM COLL CARDIOL, V40, P976, DOI 10.1016/S0735-1097(02)02059-4 Rena O, 2001, EUR J CARDIO-THORAC, V20, P688, DOI 10.1016/S1010-7940(01)00890-9 Sharifov OF, 2000, J CARDIOVASC ELECTR, V11, P1029, DOI 10.1111/j.1540-8167.2000.tb00176.x Tayama K, 2002, ANN THORAC SURG, V73, P1582, DOI 10.1016/S0003-4975(02)03417-3 Tutar E, 1999, AM J CARDIOL, V83, P1414, DOI 10.1016/S0002-9149(99)00111-3 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Villamizar NR, 2009, J THORAC CARDIOV SUR, V138, P419, DOI 10.1016/j.jtcvs.2009.04.026 Wazni OM, 2004, CIRCULATION, V110, P124, DOI 10.1161/01.CIR.0000134481.24511.BC YOSHIMURA M, 1993, CIRCULATION, V87, P464, DOI 10.1161/01.CIR.87.2.464 ZIPES DP, 1974, CARDIOVASC RES, V8, P647, DOI 10.1093/cvr/8.5.647 NR 25 TC 26 Z9 31 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1010-7940 EI 1873-734X J9 EUR J CARDIO-THORAC JI Eur. J. Cardio-Thorac. Surg. PD FEB PY 2014 VL 45 IS 2 BP 247 EP 250 DI 10.1093/ejcts/ezt383 PG 4 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 300BF UT WOS:000330438700015 PM 23921159 OA Bronze DA 2026-04-17 ER PT J AU Riber, LP Christensen, TD Pilegaard, HK AF Riber, Lars P. Christensen, Thomas D. Pilegaard, Hans K. TI Amiodarone is a cost-neutral way of preventing atrial fibrillation after surgery for lung cancer SO EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY LA English DT Article DE Atrial fibrillation; Surgery for lung cancer; Pharmacology (cardiovascular); Postoperative care; Statistics (clinical trial) ID PROPHYLACTIC DIGITALIZATION; PULMONARY RESECTION; THORACIC-SURGERY; PNEUMONECTOMY; ARRHYTHMIAS; DILTIAZEM AB OBJECTIVES: Our aim was to estimate the costs and health benefits of routinely administered postoperative amiodarone as a prophylactic agent in reducing the risk of atrial fibrillation in patients undergoing surgery for lung cancer. METHODS: This was a cost-effectiveness study, based on the randomized, controlled, double-blinded PASCART study, using avoidance of atrial fibrillation as the measure of benefit. Two hundred and fifty-four eligible, consecutively enrolled patients, undergoing surgery for lung cancer at the department of Cardiothoracic and Vascular Surgery, Aarhus University Hospital, Denmark, were included and randomized to receive either 300 mg of amiodarone or placebo (5% aqueous dextrose solution), administered intravenously over 20 min immediately after surgery, followed by 600 mg of amiodarone/placebo orally twice per day (8 a. m. and 6 p. m.) for the first five postoperative days. RESULTS: In the amiodarone group there were 11 cases of atrial fibrillation, compared with 38 in the control group (P < 0.001). There were no differences in the length of hospital stay or resources used. The mean total costs per patient were equal and amounted to (sic)7288 per patient (P = 0.23). There were no signs of adverse developments referable to amiodarone in this prophylactic regime. CONCLUSIONS: For patients undergoing surgery for lung cancer, routine use of postoperative prophylactic intravenous bolus and five subsequent days of oral amiodarone therapy reduces the risk of atrial fibrillation in a cost-neutral manner. C1 [Riber, Lars P.; Christensen, Thomas D.; Pilegaard, Hans K.] Aarhus Univ Hosp, Dept Cardiothorac & Vasc Surg, DK-8000 Aarhus, Denmark. [Riber, Lars P.; Christensen, Thomas D.; Pilegaard, Hans K.] Aarhus Univ Hosp, Inst Clin Med, DK-8000 Aarhus, Denmark. [Riber, Lars P.] Odense Univ Hosp, Dept Cardiothorac & Vasc Surg, DK-5000 Odense C, Denmark. [Riber, Lars P.] Odense Univ Hosp, Inst Clin Med, DK-5000 Odense C, Denmark. C3 Aarhus University; Aarhus University; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital RP Riber, LP (corresponding author), Odense Univ Hosp, Dept Cardiothorac & Vasc Surg, Sdr Blvd 29, DK-5000 Odense C, Denmark. EM larspeterriber@gmail.com RI Riber, Lars/GRR-9540-2022 OI Riber, Lars/0000-0001-6898-2715 CR Amar D, 1997, ANN THORAC SURG, V63, P1374 Amar D, 2000, J THORAC CARDIOV SUR, V120, P790, DOI 10.1067/mtc.2000.109538 Bailey CC, 1943, NEW ENGL J MED, V229, P356, DOI 10.1056/NEJM194308262290902 Barbetakis Nikolaos, 2004, BMC Surg, V4, P7, DOI 10.1186/1471-2482-4-7 BORGEAT A, 1989, ANN THORAC SURG, V48, P232, DOI 10.1016/0003-4975(89)90076-3 Humphries JO, 1998, CLIN CARDIOL, V21, P711 JULER GL, 1969, J THORAC CARDIOV SUR, V58, P352, DOI 10.1016/S0022-5223(19)42584-1 KROWKA MJ, 1987, CHEST, V91, P490, DOI 10.1378/chest.91.4.490 Lanza LA, 2003, ANN THORAC SURG, V75, P223, DOI 10.1016/S0003-4975(02)04285-6 Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987 Riber LP, 2012, ANN THORAC SURG, V94, P339, DOI 10.1016/j.athoracsur.2011.12.096 RITCHIE AJ, 1990, ANN THORAC SURG, V50, P86, DOI 10.1016/0003-4975(90)90094-M SHIELDS TW, 1968, SURG GYNECOL OBSTETR, V126, P743 Tisdale JE, 2009, ANN THORAC SURG, V88, P886, DOI 10.1016/j.athoracsur.2009.04.074 VANMIEGHEM W, 1994, CHEST, V105, P1642, DOI 10.1378/chest.105.6.1642 WAHI R, 1989, ANN THORAC SURG, V48, P33, DOI 10.1016/0003-4975(89)90172-0 Zebis LR, 2007, ANN THORAC SURG, V83, P1326, DOI 10.1016/j.athoracsur.2006.09.096 NR 17 TC 16 Z9 17 U1 0 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1010-7940 EI 1873-734X J9 EUR J CARDIO-THORAC JI Eur. J. Cardio-Thorac. Surg. PD JAN PY 2014 VL 45 IS 1 BP 120 EP 125 DI 10.1093/ejcts/ezt169 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 271JJ UT WOS:000328387600020 PM 23644703 OA Bronze DA 2026-04-17 ER PT J AU Wotton, R Marshall, A Kerr, A Bishay, E Kalkat, M Rajesh, P Steyn, R Naidu, B AF Wotton, Robin Marshall, Andrea Kerr, Amy Bishay, Ehab Kalkat, Maninder Rajesh, Pala Steyn, Richard Naidu, Babu TI Does the revised cardiac risk index predict cardiac complications following elective lung resection? SO JOURNAL OF CARDIOTHORACIC SURGERY LA English DT Article DE Risk factors; Lung; Surgery; Complications; Cardiac arrhythmia ID ATRIAL-FIBRILLATION; SURGERY; VALIDATION; GUIDELINES; MANAGEMENT AB Background: Revised Cardiac Risk Index (RCRI) score and Thoracic Revised Cardiac Risk Index (ThRCRI) score were developed to predict the risks of postoperative major cardiac complications in generic surgical population and thoracic surgery respectively. This study aims to determine the accuracy of these scores in predicting the risk of developing cardiac complications including atrial arrhythmias after lung resection surgery in adults. Methods: We studied 703 patients undergoing lung resection surgery in a tertiary thoracic surgery centre. Observed outcome measures of postoperative cardiac morbidity and mortality were compared against those predicted by risk. Results: Postoperative major cardiac complications and supraventricular arrhythmias occurred in 4.8% of patients. Both index scores had poor discriminative ability for predicting postoperative cardiac complications with an area under receiver operating characteristic (ROC) curve of 0.59 (95% CI 0.51-0.67) for the RCRI score and 0.57 (95% CI 0.49-0.66) for the ThRCRI score. Conclusions: In our cohort, RCRI and ThRCRI scores failed to accurately predict the risk of cardiac complications in patients undergoing elective resection of lung cancer. The British Thoracic Society (BTS) recommendation to seek a cardiology referral for all asymptomatic pre-operative lung resection patients with > 3 RCRI risk factors is thus unlikely to be of clinical benefit. C1 [Wotton, Robin; Kerr, Amy; Bishay, Ehab; Kalkat, Maninder; Rajesh, Pala; Steyn, Richard; Naidu, Babu] Heart England NHS Fdn Trust, Dept Thorac Surg, Birmingham B9 5SS, W Midlands, England. [Marshall, Andrea] Univ Warwick, Warwick Med Sch, Clin Trials Unit, Coventry CV4 7AL, W Midlands, England. [Naidu, Babu] Univ Birmingham, Off Floor Res Labs 8 1, Birmingham B15 2WB, W Midlands, England. C3 Heart of England NHS Foundation Trust; University of Warwick; University of Birmingham RP Naidu, B (corresponding author), Heart England NHS Fdn Trust, Dept Thorac Surg, Birmingham B9 5SS, W Midlands, England. EM b.naidu@bham.ac.uk RI naidu, babu/G-9086-2011 OI naidu, babu/0000-0003-1576-230X CR Amar D, 1996, CHEST, V110, P437, DOI 10.1378/chest.110.2.437 Bertges DJ, 2010, J VASC SURG, V52, P674, DOI 10.1016/j.jvs.2010.03.031 Bobbio A, 2007, EUR J CARDIO-THORAC, V31, P70, DOI 10.1016/j.ejcts.2006.10.020 Brunelli A, 2009, EUR RESPIR J, V34, P17, DOI 10.1183/09031936.00184308 Brunelli A, 2011, ANN THORAC SURG, V92, P445, DOI 10.1016/j.athoracsur.2011.03.095 Brunelli A, 2010, ANN THORAC SURG, V90, P199, DOI 10.1016/j.athoracsur.2010.03.042 DETSKY AS, 1986, J GEN INTERN MED, V1, P211, DOI 10.1007/BF02596184 Ferguson MK, 2012, EUR J CARDIO-THORAC, V41, P598, DOI 10.1093/ejcts/ezr081 Fernando HC, 2011, ANN THORAC SURG, V92, P1144, DOI 10.1016/j.athoracsur.2011.06.104 Fleisher LA, 2007, J AM COLL CARDIOL, V2007, pe159 Ford MK, 2010, ANN INTERN MED, V152, P26, DOI 10.7326/0003-4819-152-1-201001050-00007 Fuster V, 2011, CIRCULATION, V123, pE269, DOI 10.1161/CIR.0b013e318214876d GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601 HOSMER D.W., 1989, APPL LOGISTIC REGRES Lee TH, 1999, CIRCULATION, V100, P1043, DOI 10.1161/01.CIR.100.10.1043 Lim E, 2010, THORAX, V65, P1, DOI 10.1136/thx.2010.145938 Mathew JP, 2004, JAMA-J AM MED ASSOC, V291, P1720, DOI 10.1001/jama.291.14.1720 Neary WD, 2007, BRIT J SURG, V94, P1300, DOI 10.1002/bjs.5809 Parmar CD, 2010, VASC ENDOVASC SURG, V44, P14, DOI 10.1177/1538574409349320 Polanczyk CA, 1998, ANN INTERN MED, V129, P279, DOI 10.7326/0003-4819-129-4-199808150-00003 NR 20 TC 21 Z9 27 U1 0 U2 3 PU BMC PI LONDON PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND EI 1749-8090 J9 J CARDIOTHORAC SURG JI J. Cardiothorac. Surg. PD DEC 1 PY 2013 VL 8 AR 220 DI 10.1186/1749-8090-8-220 PG 7 WC Cardiac & Cardiovascular Systems; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Surgery GA 283BJ UT WOS:000329219100002 PM 24289748 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Ciszewski, P Tyczka, J Nadolski, J Roszak, M Dyszkiewicz, W AF Ciszewski, Pawel Tyczka, Joanna Nadolski, Jacek Roszak, Magdalena Dyszkiewicz, Wojciech TI Lower preoperative fluctuation of heart rate variability is an independent risk factor for postoperative atrial fibrillation in patients undergoing major pulmonary resection SO INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY LA English DT Article DE Heart rate variability; Pulmonary resection; Atrial fibrillation risk factors ID LUNG; ONSET; MORTALITY; SURGERY AB The following study presents a special independent atrial fibrillation (AF) risk factor-preoperative fluctuation of heart rate variability (HRV), as well as other perioperative AF risk factors in patients qualified for pneumonectomy and undergoing pneumonectomy or lobectomy for lung cancer. The prospective study was performed in patients who had undergone anatomical resection for non-small-cell lung cancer. A total of 117 patients (92 men and 25 women) qualified for statistical research. In order to determine the risk factors, all patients were divided into two groups: Group A-98 patients without AF and Group B-19 patients with AF during the perioperative time. A number of different risk factors of AF have been analysed and further divided into preoperative, operative and postoperative. Postoperative AF occurred in 19 patients (16%), all of them were male. The patients with higher short-term HRV parameters (SD1, RMSSD), slower mean heart rate and those with a lower fluctuation of HRV-related parameters (HRV Afternoon, Night, Day (A/N/D)) before the operation, were more prone to AF. Postoperative risk of AF was higher in patients with a higher number of ventricular ectopic beats before the operation, a higher number of supraventricular and ventricular ectopic beats and a higher maximal heart rate after the operation. Statistical analysis revealed that male gender and the extent of pulmonary resection, particularly left pneumonectomy, constituted significant risk factors. AF was more often observed in patients who had ASA physical status score of III, in comparison with ASAI and ASAII patients. Along with other concomitant AF risk factors presented in this work, the evaluation of the fluctuation tendencies of HRV parameters should be taken into consideration before any major lung resection. The balance disturbance between the sympathetic and parasympathetic nervous systems is responsible for AF. C1 [Ciszewski, Pawel; Tyczka, Joanna; Nadolski, Jacek] Poznan Univ Med Sci, Dept Anesthesiol & Intens Care, Poznan, Poland. [Roszak, Magdalena] Poznan Univ Med Sci, Dept Comp Sci & Stat, Poznan, Poland. [Dyszkiewicz, Wojciech] Poznan Univ Med Sci, Dept Thorac Surg, Poznan, Poland. C3 Poznan University of Medical Sciences; Poznan University of Medical Sciences; Poznan University of Medical Sciences RP Ciszewski, P (corresponding author), Os Armii Krajowej 50-8, PL-61377 Poznan, Poland. EM cichypecet@gmail.com FU Wielkopolskie Center of Pulmonology and Thoracosurgery E.J. Zeylands Pulmonary Diseases and Thoracic Surgery Center, Poznan, Poland FX This work was supported by Wielkopolskie Center of Pulmonology and Thoracosurgery E.J. Zeylands Pulmonary Diseases and Thoracic Surgery Center, Szamarzewski street 62, 60-569 Poznan, Poland CR Amar D, 2003, J AM COLL CARDIOL, V42, P1262, DOI 10.1016/S0735-1097(03)00955-0 Amar D, 1996, CHEST, V110, P437, DOI 10.1378/chest.110.2.437 Bailey CC, 1943, NEW ENGL J MED, V229, P356, DOI 10.1056/NEJM194308262290902 Banach M, 2008, MED SCI MONITOR, V14, pCR286 Camm AJ, 1996, CIRCULATION, V93, P1043 Camm AJ, 1996, EUR HEART J, V17, P354 CASOLO G, 1989, AM J CARDIOL, V64, P1162, DOI 10.1016/0002-9149(89)90871-0 Chen PS, 2006, J CARDIOVASC ELECTR, V17, pS2, DOI 10.1111/j.1540-8167.2006.00626.x Damhuis RAM, 1996, EUR RESPIR J, V9, P7, DOI 10.1183/09031936.96.09010007 Dyszkiewicz W, 1998, EUR J CARDIO-THORAC, V13, P625, DOI 10.1016/S1010-7940(98)00084-0 Guzik P., 2009, ASYMETRIA RYTMU SERC Guzzetti S, 2005, EUR HEART J, V26, P357, DOI 10.1093/eurheartj/ehi067 KIRSH MM, 1976, ANN THORAC SURG, V22, P369, DOI 10.1016/S0003-4975(10)64969-7 La Rovere MT, 2003, CIRCULATION, V107, P565, DOI 10.1161/01.CIR.0000047275.25795.17 Maisel WH, 2003, J AM COLL CARDIOL, V42, P1269, DOI 10.1016/S0735-1097(03)00959-8 Musial WJ., 2007, KARD POL, V65, P758 Musialik-Lydka Agata, 2003, Kardiol Pol, V58, P10 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 SAUL JP, 1988, AM J CARDIOL, V61, P1292, DOI 10.1016/0002-9149(88)91172-1 Shin DG, 2006, CIRC J, V70, P94, DOI 10.1253/circj.70.94 Tang SSK, 2008, EUR J CARDIO-THORAC, V34, P898, DOI 10.1016/j.ejcts.2008.06.020 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Vinik Aaron I, 2006, Curr Diab Rep, V6, P424, DOI 10.1007/s11892-006-0074-z Zuanetti G, 1996, CIRCULATION, V94, P432, DOI 10.1161/01.CIR.94.3.432 NR 24 TC 21 Z9 22 U1 0 U2 9 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1569-9293 EI 1569-9285 J9 INTERACT CARDIOV TH JI Interact Cardiovasc. Thorac. Surg. PD OCT PY 2013 VL 17 IS 4 BP 680 EP 686 DI 10.1093/icvts/ivt238 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 228DO UT WOS:000325165800020 PM 23832838 OA Bronze DA 2026-04-17 ER PT J AU Yazici, O Aksoy, S Ucar, O Ozdemir, N Demir, M Sendur, MAN Arik, Z Yaman, S Eren, T Uncu, D Zengin, N AF Yazici, Ozan Aksoy, Sercan Ucar, Ozgul Ozdemir, Nuriye Demir, Mevlut Sendur, Mehmet Ali Nahit Arik, Zafer Yaman, Sebnem Eren, Tulay Uncu, Dogan Zengin, Nurullah TI Arrhythmias during and after zoledronic acid infusion patients with bone metastasis SO MEDICAL ONCOLOGY LA English DT Article DE Zoledronic acid; Side effect; Arrhythmias; Supraventricular; Ventricular ID INTRAVENOUS BISPHOSPHONATE THERAPY; ATRIAL-FIBRILLATION; RISK; RECURRENCE; FLUTTER; REENTRY; DISEASE; WOMEN AB Zoledronic acid (ZA) is one of the important bisphosphonates which is widely used in bone metastatic cancer and osteoporotic patients. In a few studies, it has been reported that treatment with bisphosphonates was associated with an increased risk of atrial fibrillation. We aimed to evaluate the arrhythmias that developed during and immediately after infusion of the ZA. Fifty-two bone metastatic patients were included in the study group. All patients had 24-h Holter monitorization during the first dose ZA infusion day. All of the patients had 4-h basal cardiac rhythm records before ZA infusion and about 19 h after infusion. A short survey including demographic data and past medical history has been completed. None of patients had clinically important arrhythmias before ZA infusion. We divided arrhythmias into two groups as supraventricular and ventricular. We evaluated arrhythmias in pre-infusion, during infusion, and post-infusion periods. ZA was administered 4 mg intravenously (IV) in 15 min. Thirty-three of patients (63.5 %) were male and 19 (36.5 %) patients were female. Mean age of the patients was 53.9 +/- 11.8 years. Most frequent cancers were breast (25 %) and lung cancer (15.3 %). Twelve (23 %) patients had history of mediastinal radiotherapy. In basal records, we detected that twenty-four (46 %) of patients had supraventricular premature complexes (SVPC) or ventricular premature complexes (VPC). Fifteen (28.8 %) of patients had SVPC and fourteen (26.9 %) had VPC during infusion period. After infusion period, 48 (92.3 %) of patients had SVPC and 41 (78.8 %) had VPC. Only 3 patients had no arrhythmia after infusion. Three patients had sinus arrhythmia and two had Mobitz type 2 atrioventricular blocks after infusion. One patient, who had no history of comorbidities and had SVPC in the basal records, developed atrial fibrillation that was refractory to medical cardioversion after 10 days of seventh dose of ZA infusion. In this study, we found that both SVPC and VPC increased in cancer patients treated with ZA. Furthermore, ZA may induce clinically important arrhythmias. C1 [Yazici, Ozan; Ozdemir, Nuriye; Sendur, Mehmet Ali Nahit; Arik, Zafer; Yaman, Sebnem; Eren, Tulay; Uncu, Dogan; Zengin, Nurullah] Ankara Numune Training & Res Hosp, Dept Med Oncol, TR-06100 Ankara, Turkey. [Aksoy, Sercan] Hacettepe Univ, Dept Med Oncol, Inst Canc, Ankara, Turkey. [Ucar, Ozgul; Demir, Mevlut] Ankara Numune Training & Res Hosp, Dept Cardiol, Ankara, Turkey. C3 Ankara Numune Training & Research Hospital; Hacettepe University; Ankara Numune Training & Research Hospital RP Yazici, O (corresponding author), Ankara Numune Training & Res Hosp, Dept Med Oncol, TR-06100 Ankara, Turkey. EM drozanyazici@gmail.com RI AKSOY, SERCAN/S-2480-2019; Sendur, Mehmet/H-7555-2014; DEMIR, MEVLUT/HJP-9815-2023; Zengin, Nurullah/KBQ-0049-2024 OI AKSOY, SERCAN/0000-0003-4984-1049; Sendur, Mehmet/0000-0001-7021-6139; DEMIR, MEVLUT/0000-0002-7484-9969; CR Abrahamsen B, 2009, J INTERN MED, V265, P581, DOI 10.1111/j.1365-2796.2008.02065.x Antzelevitch Charles, 2011, Card Electrophysiol Clin, V3, P23, DOI 10.1016/j.ccep.2010.10.012 Arslan C, 2011, SUPPORT CARE CANCER, V19, P425, DOI 10.1007/s00520-010-0868-z BENJAMIN EJ, 1994, JAMA-J AM MED ASSOC, V271, P840, DOI 10.1001/jama.271.11.840 BIGGER JT, 1977, PROG CARDIOVASC DIS, V19, P255, DOI 10.1016/0033-0620(77)90005-6 Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312 Bunch TJ, 2009, AM J CARDIOL, V103, P824, DOI 10.1016/j.amjcard.2008.11.037 Corrado A, 2007, JOINT BONE SPINE, V74, P32, DOI 10.1016/j.jbspin.2006.06.005 Du RH, 2008, J PHARM PHARMACOL, V60, P1089, DOI 10.1211/jpp.60.8.0015 Erichsen R, 2011, BRIT J CANCER, V105, P881, DOI 10.1038/bjc.2011.338 FRAME LH, 1986, CIRC RES, V58, P495, DOI 10.1161/01.RES.58.4.495 Grosso A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004720 Guo YT, 2012, J AM COLL CARDIOL, V60, P2263, DOI 10.1016/j.jacc.2012.04.063 Heckbert SR, 2008, ARCH INTERN MED, V168, P826, DOI 10.1001/archinte.168.8.826 Ibrahim A, 2003, CLIN CANCER RES, V9, P2394 Kamjoo K, 1997, CIRCULATION, V96, P2048, DOI 10.1161/01.CIR.96.6.2048 Kantor RJ., 1995, Cardiac Arrhythmia: Mechanisms, diagnosis, and management, P1131 Köröglu S, 2012, TURK KARDIYOL DERN A, V40, P499, DOI 10.5543/tkda.2012.64160 Lainscak M, 2008, INT J CARDIOL, V128, P311, DOI 10.1016/j.ijcard.2007.12.078 Loke YK, 2009, DRUG SAFETY, V32, P219, DOI 10.2165/00002018-200932030-00004 Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941 McClung M, 2013, AM J MED, V126, P13, DOI 10.1016/j.amjmed.2012.06.023 Scheller EL, 2011, J CELL BIOCHEM, V112, P3364, DOI 10.1002/jcb.23267 Sorensen HT, 2008, BMJ-BRIT MED J, V336, P813, DOI 10.1136/bmj.39507.551644.BE Takahashi N, 2012, CIRC J, V76, P2318, DOI 10.1253/circj.CJ-12-1099 Wilkinson GS, 2010, J CLIN ONCOL, V28, P4898, DOI 10.1200/JCO.2010.28.7524 Wolf AM, 2006, HAEMATOLOGICA, V91, P1165 Zhuang JH, 2012, EUROPACE, V14, P638, DOI 10.1093/europace/eur364 NR 28 TC 9 Z9 9 U1 0 U2 10 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1357-0560 EI 1559-131X J9 MED ONCOL JI Med. Oncol. PD SEP PY 2013 VL 30 IS 3 AR 609 DI 10.1007/s12032-013-0609-5 PG 5 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA 208FN UT WOS:000323662900090 PM 23690271 DA 2026-04-17 ER PT J AU Dhakal, B Eastwood, D Sukumaran, S Hassler, G Tisol, W Gasparri, M Choong, N Santana-Davila, R AF Dhakal, Binod Eastwood, Daniel Sukumaran, Sunitha Hassler, George Tisol, William Gasparri, Mario Choong, Nicholas Santana-Davila, Rafael TI Morbidities of lung cancer surgery in obese patients SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article ID BODY-MASS INDEX; BRONCHOGENIC-CARCINOMA; HOSPITAL MORTALITY; RESECTION; COMPLICATIONS; METAANALYSIS; RISK; SURVIVAL; OUTCOMES; IMPACT AB Background: Obesity is a risk factor for increased perioperative morbidity and mortality in surgical patients. There have been limited studies to correlate the morbidity of lung cancer resection with obesity. Methods: We performed a retrospective study of patients who underwent surgical resection for lung cancer at the Medical College of Wisconsin, Milwaukee, from 2006 to 2010. Data on patient demographics, weight, pathological findings, and hospital course were abstracted after appropriate institutional review board approval. Perioperative morbidity was defined as atrial fibrillation, heart failure, respiratory failure, pulmonary embolism, or any medical complications arising within 30 days after surgery. The Fisher exact test was used to test the association between body mass index (BMI) and perioperative morbidities. Results: Between 2006 and 2010, 320 lung resections were performed for lung cancer. The median age was 67 (interquartile range, 59-75) years, and 185 (57.8%) were females. A total of 121 (37.8%) of patients had a BMI lower than 25, and 199 (62.18%) patients had a BMI of 25 or higher. The 30-day mortality rate was 1.8%(n = 6) in the whole group; only 2 of these patients had a BMI of 25 or higher. Perioperative morbidity occurred in 28 (23.14%) of patients with a normal BMI and in 47 (23.61%) of patients with a BMI of 25 or higher (P = .54). Specific morbidities encountered by patients with normal versus BMI of 25 or higher were as follows: atrial fibrillation, 11 (9.09%) versus 24 (12.06%) (P = .46); pulmonary embolism, 1 (0.83%) versus 3 (1.51%) (P = 1.0); congestive heart failure, 2 (1.65%) versus 2 (1.01%) (P = .63); renal failure, 4 (3.3%) versus 2 (1.0%) (P = .29); respiratory failure, 12 (9.92%) versus 17 (8.54%) (P = .69); and acute respiratory distress syndrome, 2 (1.65%) versus 1 (0.50%) (P = .55). The median hospital stay was 5 days in the lower BMI group and 4 days in the BMI of 25 or higher group (P = .52). Conclusions: Overweight and normal weight patients do not differ significantly in rates of perioperative morbidities, 30-day mortality, and length of stay. Our study indicates that potential curative surgical resections can be offered to even significantly overweight patients. C1 [Dhakal, Binod] Med Coll Wisconsin, Inst Hlth & Soc, Div Gen Internal Med, Milwaukee, WI 53226 USA. [Sukumaran, Sunitha; Choong, Nicholas; Santana-Davila, Rafael] Med Coll Wisconsin, Inst Hlth & Soc, Div Hematol & Oncol, Milwaukee, WI 53226 USA. [Hassler, George; Tisol, William; Gasparri, Mario] Med Coll Wisconsin, Inst Hlth & Soc, Dept Cardiothorac Surg, Milwaukee, WI 53226 USA. [Eastwood, Daniel] Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA. C3 Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin RP Santana-Davila, R (corresponding author), Med Coll Wisconsin, Div Hematol & Oncol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA. EM rsantana@mcw.edu RI Dhakal, Binod/AAI-2224-2021 FU Clinical and Translational Science award program of the National Center for Research Resources, National Institutes of Health [1UL1RR031973] FX Supported, in part, by grant 1UL1RR031973 from the Clinical and Translational Science award program of the National Center for Research Resources, National Institutes of Health. CR Allen MS, 2006, ANN THORAC SURG, V81, P1013, DOI 10.1016/j.athoracsur.2005.06.066 BERGGREN H, 1984, ANN THORAC SURG, V38, P633, DOI 10.1016/S0003-4975(10)62324-7 Damhuis RAM, 1996, EUR RESPIR J, V9, P7, DOI 10.1183/09031936.96.09010007 DeMaria EJ, 2005, SURG CLIN N AM, V85, P1283, DOI 10.1016/j.suc.2005.09.002 Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723 Klasen J, 2004, OBES SURG, V14, P275, DOI 10.1381/096089204322857708 Larsson SC, 2007, INT J CANCER, V120, P1993, DOI 10.1002/ijc.22535 Mullen JT, 2008, ANN SURG ONCOL, V15, P2164, DOI 10.1245/s10434-008-9990-2 Petrella F, 2011, EUR J CARDIO-THORAC, V39, P738, DOI 10.1016/j.ejcts.2010.09.007 PISUNYER FX, 1993, ANN INTERN MED, V119, P655, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00006 Raebel MA, 2004, ARCH INTERN MED, V164, P2135, DOI 10.1001/archinte.164.19.2135 Ramsey AM, 2011, J GASTROINTEST SURG, V15, P1633, DOI 10.1007/s11605-011-1502-1 Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X ROMANO PS, 1992, CHEST, V101, P1332, DOI 10.1378/chest.101.5.1332 Smith PW, 2007, ANN THORAC SURG, V84, P1098, DOI 10.1016/j.athoracsur.2007.04.033 Stolz AJ, 2005, EUR J CARDIO-THORAC, V27, P334, DOI 10.1016/j.ejcts.2004.11.004 Suemitsu Ryuichi, 2008, Asian Cardiovasc Thorac Ann, V16, P463 Thomas EJ, 1997, AM J MED, V102, P277, DOI 10.1016/S0002-9343(96)00451-2 WEISS W, 1974, AM J SURG, V128, P799, DOI 10.1016/0002-9610(74)90074-9 Wigfield CH, 2006, EUR J CARDIO-THORAC, V29, P434, DOI 10.1016/j.ejcts.2006.01.016 NR 20 TC 26 Z9 28 U1 0 U2 6 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD AUG PY 2013 VL 146 IS 2 BP 379 EP 384 DI 10.1016/j.jtcvs.2013.02.083 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 194LS UT WOS:000322635400021 PM 23618391 OA Bronze DA 2026-04-17 ER PT J AU Sessa, C Shapiro, GI Bhalla, KN Britten, C Jacks, KS Mita, M Papadimitrakopoulou, V Pluard, T Samuel, TA Akimov, M Quadt, C Fernandez-Ibarra, C Lu, H Bailey, S Chica, S Banerji, U AF Sessa, Cristiana Shapiro, Geoffrey I. Bhalla, Kapil N. Britten, Carolyn Jacks, Karen S. Mita, Monica Papadimitrakopoulou, Vali Pluard, Tim Samuel, Thomas A. Akimov, Mikhail Quadt, Cornelia Fernandez-Ibarra, Cristina Lu, Hong Bailey, Stuart Chica, Sandra Banerji, Udai TI First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors SO CLINICAL CANCER RESEARCH LA English DT Article ID SHOCK-PROTEIN 90; BREAST-CANCER; CLINICAL DEVELOPMENT; MOLECULAR CHAPERONE; TANESPIMYCIN 17-AAG; TRASTUZUMAB; NVP-AUY922; FUTURE; TRIAL; EXPRESSION AB Purpose: A phase I study was conducted with the primary objective of determining the maximum tolerated dose (MTD) of AUY922 in patients with advanced solid tumors. Secondary objectives included characterization of the safety, pharmacokinetic, and pharmacodynamic profiles. Patients and Methods: Patients with advanced solid tumors received 1-hour i.v. infusions of AUY922 once a week in a 28-day cycle. An adaptive Bayesian logistic regression model that employed observed dose-limiting toxicities (DLT) in the first treatment cycle was used to guide dose-escalation decisions, with the established MTD to be used in phase II studies. Results: One hundred and one patients were enrolled and explored at doses in the range of 2 to 70mg/m(2). DLTs occurred in 8 patients (22-70 mg/m(2)) and included diarrhea, asthenia/fatigue, anorexia, atrial flutter, and visual symptoms. At 70 mg/m(2), the AUY922 concentration achieved was consistent with active concentrations in a range of xenograft models. There was evidence of target inhibition in peripheral blood mononuclear cells (HSP70 induction) and tumor (client protein depletion and reduction of metabolic activity by F-18-FDG PET). The recommended phase II dose (RP2D) of 70mg/m(2) was proposed on the basis of toxicity and pharmacokinetic and pharmacodynamic profiles. Conclusions: At the RP2D of 70 mg/m(2), AUY922 exhibited acceptable tolerability, and phase II single-agent and combination studies have been initiated in patients with HER2-positive breast, gastric, and non-small cell lung cancers. Clin Cancer Res; 19(13); 3671-80. (C)2013 AACR. C1 [Banerji, Udai] Inst Canc Res, Drug Dev Unit, Sutton, Surrey, England. [Akimov, Mikhail; Quadt, Cornelia; Fernandez-Ibarra, Cristina; Bailey, Stuart] Novartis Pharma AG, Basel, Switzerland. [Shapiro, Geoffrey I.] Dana Farber Canc Inst, Early Drug Dev Ctr, Dept Med Oncol, Boston, MA 02115 USA. [Bhalla, Kapil N.] Univ Kansas Canc Ctr, Kansas City, KS USA. [Britten, Carolyn] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA. [Britten, Carolyn] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Jacks, Karen S.] Nevada Canc Inst, Las Vegas, NV USA. [Mita, Monica] Canc Therapy & Res Ctr S Texas, San Antonio, TX 78229 USA. [Papadimitrakopoulou, Vali] MD Anderson Canc Ctr, Houston, TX USA. [Pluard, Tim] Washington Univ, St Louis, MO USA. [Samuel, Thomas A.] Georgia Hlth Sci Univ, Augusta, GA USA. [Lu, Hong; Chica, Sandra] Novartis Pharmaceut, E Hanover, NJ USA. [Banerji, Udai] Royal Marsden NHS Fdn Trust, Inst Canc Res, Drug Dev Unit, Sutton SM2 5PT, Surrey, England. [Banerji, Udai] Royal Marsden Hosp, Sutton, Surrey, England. C3 University of London; Institute of Cancer Research - UK; Novartis; Harvard University; Harvard University Medical Affiliates; Dana-Farber Cancer Institute; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California San Diego; Nevada Cancer Institute; University of Texas System; University of Texas at San Antonio; University of Texas System; UTMD Anderson Cancer Center; Washington University (WUSTL); University System of Georgia; Augusta University; Novartis; Novartis USA; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust RP Banerji, U (corresponding author), Royal Marsden NHS Fdn Trust, Inst Canc Res, Drug Dev Unit, Sycamore House,Downs Rd, Sutton SM2 5PT, Surrey, England. EM udai.banerji@icr.ac.uk RI ; Shapiro, Geoffrey/IWL-8291-2023 OI Banerji, Udai/0000-0003-1503-3123; Bhalla, Kapil/0000-0001-5209-5126; Shapiro, Geoffrey/0000-0002-3331-4095 FU Novartis Pharmaceuticals; Cancer Research UK; ECMC; NIHR Biomedical Research Centre; National Cancer Institute [P30CA016672] Funding Source: NIH RePORTER; Cancer Research UK [11566] Funding Source: researchfish FX The authors thank the participating patients, their families, all study co-investigators, and research coordinators. Medical editorial assistance was provided by Matthew Naylor, PhD, and was funded by Novartis Pharmaceuticals. The Drug Development Unit at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust acknowledge infrastructural funding from Cancer Research UK, ECMC, and NIHR Biomedical Research Centre for Cancer grants. CR [Anonymous], J CLIN ONCOL S [Anonymous], MOL CANC THER S Babb J, 1998, STAT MED, V17, P1103, DOI 10.1002/(SICI)1097-0258(19980530)17:10<1103::AID-SIM793>3.0.CO;2-9 Banerji U, 2005, J CLIN ONCOL, V23, P4152, DOI 10.1200/JCO.2005.00.612 Banerji U, 2009, CLIN CANCER RES, V15, P9, DOI 10.1158/1078-0432.CCR-08-0132 Brough PA, 2008, J MED CHEM, V51, P196, DOI 10.1021/jm701018h Chandarlapaty S, 2010, ONCOGENE, V29, P325, DOI 10.1038/onc.2009.337 Chiosis G, 2006, ACS CHEM BIOL, V1, P279, DOI 10.1021/cb600224w Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1 Cleary J. M., 2010, J CLIN ONCOL, V28 Demetri GD, 2010, ASCO GASTR CANC S 20 Eccles SA, 2008, CANCER RES, V68, P2850, DOI 10.1158/0008-5472.CAN-07-5256 Gao ZH, 2010, CURR OPIN DRUG DISC, V13, P193 Gaspar N, 2010, MOL CANCER THER, V9, P1219, DOI 10.1158/1535-7163.MCT-09-0683 Goetz MP, 2005, J CLIN ONCOL, V23, P1078, DOI 10.1200/JCO.2005.09.119 Grem JL, 2005, J CLIN ONCOL, V23, P1885, DOI 10.1200/JCO.2005.12.085 Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013 Jensen MR, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1996 Jensen MR, 2009, P AM ASS CANC RES Jhaveri K, 2012, BBA-MOL CELL RES, V1823, P742, DOI 10.1016/j.bbamcr.2011.10.008 Kelland LR, 1999, J NATL CANCER I, V91, P1940, DOI 10.1093/jnci/91.22.1940 Mahalingam D, 2009, BRIT J CANCER, V100, P1523, DOI 10.1038/sj.bjc.6605066 Modi S, 2007, J CLIN ONCOL, V25, P5410, DOI 10.1200/JCO.2007.11.7960 Modi S, 2011, CLIN CANCER RES, V17, P5132, DOI 10.1158/1078-0432.CCR-11-0072 Neckers L, 2012, CLIN CANCER RES, V18, P64, DOI 10.1158/1078-0432.CCR-11-1000 Orloff J, 2009, NAT REV DRUG DISCOV, V8, P949, DOI 10.1038/nrd3025 Pacey S, 2011, CLIN CANCER RES, V17, P1561, DOI 10.1158/1078-0432.CCR-10-1927 Pearl LH, 2008, BIOCHEM J, V410, P439, DOI 10.1042/BJ20071640 Pick E, 2007, CANCER RES, V67, P2932, DOI 10.1158/0008-5472.CAN-06-4511 Rajan A, 2011, CLIN CANCER RES, V17, P6831, DOI 10.1158/1078-0432.CCR-11-0821 Ruiz MIG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001722 Schroder CP, 2011, J CLIN ONCOL, V29 Sequist LV, 2010, J CLIN ONCOL, V28, P4953, DOI 10.1200/JCO.2010.30.8338 Shapiro G., 2010, J CLIN ONCOL, V28, P3069, DOI DOI 10.1200/JCO.2010.28.15_SUPPL.3069 Shimamura T, 2005, CANCER RES, V65, P6401, DOI 10.1158/0008-5472.CAN-05-0933 Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205 Yap TA, 2010, NAT REV CANCER, V10, P514, DOI 10.1038/nrc2870 Young H, 1999, EUR J CANCER, V35, P1773, DOI 10.1016/S0959-8049(99)00229-4 Zheng FF, 2000, CANCER RES, V60, P2090 NR 39 TC 134 Z9 147 U1 0 U2 26 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD JUL 1 PY 2013 VL 19 IS 13 BP 3671 EP 3680 DI 10.1158/1078-0432.CCR-12-3404 PG 10 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA 173RF UT WOS:000321095900034 PM 23757357 DA 2026-04-17 ER PT J AU Warwick, R Mediratta, N Chalmers, J Pullan, M Shaw, M Mcshane, J Poullis, M AF Warwick, Richard Mediratta, Neeraj Chalmers, John Pullan, Mark Shaw, Matthew Mcshane, James Poullis, Michael TI Is single-unit blood transfusion bad post-coronary artery bypass surgery?† SO INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY LA English DT Article; Proceedings Paper CT 26th Annual Meeting of the European-Association-for-Cardio-Thoracic-Surgery (EACTS) CY OCT 27-31, 2012 CL Barcelona, SPAIN SP European Assoc Cardio Thorac Surg (EACTS), Boston Sci Corp DE Coronary; Survival; Blood transfusion ID LONG-TERM SURVIVAL; INTENSIVE-CARE-UNIT; CELL LUNG-CANCER; ATRIAL-FIBRILLATION; INCREASED MORTALITY; CARDIAC-SURGERY; MORBIDITY; GRAFT; REQUIREMENTS; RESECTIONS AB Publications in the surgical literature are very consistent in their conclusions that blood is dangerous with regard to in-hospital mortality, morbidity and long-term survival. Blood is frequently used as a volume expander while simultaneously increasing the haematocrit. We investigated the effects of a single-unit blood transfusion on long-term survival post-cardiac surgery in isolated coronary artery bypass grafting patients. A prospective single-institution cardiac surgery database was analysed involving 4615 patients. Univariate, multivariate stepwise Cox regression analysis and propensity matching were performed to identify whether a single-unit blood transfusion was detrimental to long-term survival. Univariate analysis revealed that blood was significantly associated with a reduced long-term survival even with a single-unit transfused, P = 0.0001. Cox multivariate regression analysis identified age, ejection fraction, preoperative dialysis, logistic EuroSCORE, postoperative CKMB, blood transfusion, urgent operative status and atrial fibrillation as significant factors determining long-term survival. When the Cox regression was repeated with patients who received no blood or only one unit of blood, transfusion was not a risk factor for long-term survival. An interaction analysis revealed that blood transfusion was significantly interacting with preoperative haemoglobin levels, P = 0.02. Propensity analysis demonstrated that a single-unit transfusion is not associated with a detrimental long-term survival, P = 0.3. Cox regression and propensity matching both indicate that a single-unit transfusion is not a significant cause of reduced long-term survival. Preoperative anaemia is a significant confounding factor. Despite demonstrating the negligible risks of a single-unit blood transfusion, we are not advocating liberal transfusion and would recommend changing from a double-unit to a single-unit transfusion policy. We speculate that blood is not bad, but that the underlying reason that it is given might be. C1 [Warwick, Richard; Mediratta, Neeraj; Chalmers, John; Pullan, Mark; Shaw, Matthew; Mcshane, James; Poullis, Michael] Liverpool Heart & Chest Hosp, Dept Cardiac Surg, Liverpool L14 3PE, Merseyside, England. C3 Liverpool Heart & Chest Hospital RP Poullis, M (corresponding author), Liverpool Heart & Chest Hosp, Dept Cardiothorac Surg, Thomas Dr, Liverpool L14 3PE, Merseyside, England. EM mpoullis@hotmail.com RI Poullis, Michael/AAL-2364-2021 OI Shaw, Matthew/0000-0001-9184-5591 CR Attaran S, 2011, INTERACT CARDIOV TH, V13, P288, DOI 10.1510/icvts.2011.270249 Attaran S, 2010, INTERACT CARDIOV TH, V11, P442, DOI 10.1510/icvts.2010.237040 Berger MD, 2012, HAEMATOL-HEMATOL J, V97, P116, DOI 10.3324/haematol.2011.047035 Callaghan FM, 2011, AM J PHYSIOL-HEART C, V300, pH1451, DOI 10.1152/ajpheart.00871.2010 Chohan SS, 2003, VOX SANG, V84, P211, DOI 10.1046/j.1423-0410.2003.00284.x Domanski MJ, 2011, JAMA-J AM MED ASSOC, V305, P585, DOI 10.1001/jama.2011.99 El-Chami MF, 2010, J AM COLL CARDIOL, V55, P1370, DOI 10.1016/j.jacc.2009.10.058 Engoren MC, 2002, ANN THORAC SURG, V74, P1180, DOI 10.1016/S0003-4975(02)03766-9 Fontaine E, 2011, EUR J CARDIO-THORAC, V40, P642, DOI 10.1016/j.ejcts.2010.12.053 Fontaine E, 2011, INTERACT CARDIOV TH, V12, P956, DOI 10.1510/icvts.2010.255323 Fontaine E, 2010, EUR J CARDIO-THORAC, V38, P21, DOI 10.1016/j.ejcts.2010.01.015 Hébert PC, 1999, CRIT CARE, V3, P57, DOI 10.1186/cc310 KESZTHELYI B, 1979, ACTA MED HUNG, V36, P71 Koch CG, 2006, CRIT CARE MED, V34, P1608, DOI 10.1097/01.CCM.0000217920.48559.D8 Kuduvalli M, 2005, EUR J CARDIO-THORAC, V27, P592, DOI 10.1016/j.ejcts.2005.01.030 LOOP FD, 1986, NEW ENGL J MED, V314, P1, DOI 10.1056/NEJM198601023140101 Murphy GJ, 2007, CIRCULATION, V116, P2544, DOI 10.1161/CIRCULATIONAHA.107.698977 Reeves BC, 2008, CURR OPIN CARDIOL, V23, P607, DOI 10.1097/HCO.0b013e328310fc95 Spiess Bruce D, 2004, Semin Cardiothorac Vasc Anesth, V8, P267, DOI 10.1177/108925320400800402 Yun JJ, 2012, ANN THORAC SURG, V94, P2038, DOI 10.1016/j.athoracsur.2012.06.059 NR 20 TC 15 Z9 17 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1569-9293 J9 INTERACT CARDIOV TH JI Interact Cardiovasc. Thorac. Surg. PD JUN PY 2013 VL 16 IS 6 BP 765 EP 770 DI 10.1093/icvts/ivt062 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 151PA UT WOS:000319471400013 PM 23449665 OA Green Submitted, Bronze DA 2026-04-17 ER PT J AU Filosso, PL Ruffini, E Sandri, A Lausi, PO Giobbe, R Oliaro, A AF Filosso, Pier Luigi Ruffini, Enrico Sandri, Alberto Lausi, Paolo Olivo Giobbe, Roberto Oliaro, Alberto TI Efficacy and safety of human fibrinogen-thrombin patch (TachoSil®) in the treatment of postoperative air leakage in patients submitted to redo surgery for lung malignancies: a randomized trial SO INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY LA English DT Article DE Air leak; Chest tube; Redo surgery ID THORACIC-SURGERY; ATRIAL-FIBRILLATION; PULMONARY LOBECTOMY; RISK-FACTORS; RESECTION; DATABASE; SEALANT; SOCIETY; SUCTION AB Previous studies of the human fibrinogen-thrombin patch TachoSil (R) for air leak management in thoracic surgery have excluded patients undergoing redo surgery, a group at high risk of persistent air leaks. This is the first study to assess TachoSil (R) in patients undergoing redo surgery. Patients who had undergone pulmonary resection for primary lung cancer or lung metastasis and were scheduled for completion lobectomy plus lymphadenectomy due to tumour recurrence were eligible. After complete lobectomy, patients with intraoperative Macchiarini grade 3 air leaks (or > 30% of the tidal volume at plethysmographic assessment) were randomized to receive either TachoSil (R) or further lung parenchymal stapling/suturing procedures according to standard surgical practice. A total of 24 patients were randomized to TachoSil (R) (n = 13) or standard treatment (n = 11). Mean duration of surgery was significantly shorter in the TachoSil (R) group than in the standard group (3.6 vs 4.0 h; P = 0.023). The mean duration of air leaks was also significantly reduced in the TachoSil (R) group (4.7 vs 10.0 days; P < 0.001), and the removal of both the first and the second chest tubes occurred earlier (mean 3.8 vs 5.5 days; P = 0.005; and 6.1 vs 10.8 days; P < 0.001, respectively). TachoSil (R) was also effective in reducing persistent (>= 9 days) air leaks (1 vs 7 patients; P = 0.008). There were no significant differences between groups in other postoperative complications. Mean length of hospital stay was significantly shorter in TachoSil (R)-treated patients (6.9 vs 9.5 days; P < 0.001). TachoSil (R) was superior to standard stapling and suturing aerostatic techniques in reducing postoperative air leaks in patients undergoing redo thoracic surgery. C1 [Filosso, Pier Luigi; Ruffini, Enrico; Sandri, Alberto; Lausi, Paolo Olivo; Giobbe, Roberto; Oliaro, Alberto] Univ Turin, Dept Thorac Surg, San Giovanni Battista Hosp, I-10126 Turin, Italy. C3 A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; University of Turin RP Filosso, PL (corresponding author), Univ Turin, Dept Thorac Surg, San Giovanni Battista Hosp, Via Genova 3, I-10126 Turin, Italy. EM pierluigi.filosso@unito.it RI ; Sani, Alberto/K-6851-2019 OI Filosso, Pier Luigi/0000-0002-1210-307X; Oliaro, Alberto/0000-0003-0422-029X; Lausi, Paolo Olivo/0000-0001-6084-5038; Sani, Alberto/0000-0001-6421-2270; Ruffini, Enrico/0000-0002-7225-2456 CR Abolhoda A, 1998, CHEST, V113, P1507, DOI 10.1378/chest.113.6.1507 Anegg U, 2007, EUR J CARDIO-THORAC, V31, P198, DOI 10.1016/j.ejcts.2006.11.033 Anegg Udo, 2008, Interact Cardiovasc Thorac Surg, V7, P292 Bardell T, 2003, Can Respir J, V10, P86 Belda-Sanchis J., 2010, COCHRANE DB SYST REV, V1 Boffa DJ, 2008, J THORAC CARDIOV SUR, V135, P247, DOI 10.1016/j.jtcvs.2007.07.060 Brunelli A, 2004, ANN THORAC SURG, V77, P1932, DOI 10.1016/j.athoracsur.2003.12.022 Cerfolio RJ, 2001, ANN THORAC SURG, V71, P1613, DOI 10.1016/S0003-4975(01)02474-2 Cerfolio Robert James, 2002, Chest Surg Clin N Am, V12, P507, DOI 10.1016/S1052-3359(02)00015-7 De Leyn P, 2011, J THORAC CARDIOV SUR, V141, P881, DOI 10.1016/j.jtcvs.2010.09.019 Droghetti A, 2008, J THORAC CARDIOV SUR, V136, P383, DOI 10.1016/j.jtcvs.2008.04.014 Etz CD, 2009, ANN THORAC SURG, V88, P758, DOI 10.1016/j.athoracsur.2009.04.140 Irshad K, 2002, CAN J SURG, V45, P264 Lang G, 2004, EUR J CARDIO-THORAC, V25, P160, DOI 10.1016/j.ejcts.2003.11.018 Macchiarini P, 1999, J THORAC CARDIOV SUR, V117, P751, DOI 10.1016/S0022-5223(99)70296-5 Marta GM, 2010, EUR J CARDIO-THORAC, V38, P683, DOI 10.1016/j.ejcts.2010.03.061 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Rena Ottavio, 2009, Interact Cardiovasc Thorac Surg, V9, P973, DOI 10.1510/icvts.2009.202770 Rocco Gaetano, 2009, Interact Cardiovasc Thorac Surg, V9, P1, DOI 10.1510/icvts.2009.202648 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Varela G, 2005, EUR J CARDIO-THORAC, V27, P329, DOI 10.1016/j.ejcts.2004.11.005 NR 22 TC 36 Z9 40 U1 0 U2 10 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1569-9293 J9 INTERACT CARDIOV TH JI Interact Cardiovasc. Thorac. Surg. PD MAY PY 2013 VL 16 IS 5 BP 661 EP 666 DI 10.1093/icvts/ivs571 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 132UX UT WOS:000318095300027 PM 23420053 OA Green Submitted, Bronze DA 2026-04-17 ER PT J AU Colaco, RJ Huh, S Nichols, RC Morris, CG D'Agostino, H Flampouri, S Li, ZF Pham, DC Bajwa, AA Hoppe, BS AF Colaco, Rovel J. Huh, Soon Nichols, Romaine C. Morris, Christopher G. D'Agostino, Harry Flampouri, Stella Li, Zuofeng Pham, Dat C. Bajwa, Abubakr A. Hoppe, Bradford S. TI Dosimetric rationale and early experience at UFPTI of thoracic proton therapy and chemotherapy in limited-stage small cell lung cancer SO ACTA ONCOLOGICA LA English DT Article ID MODULATED RADIATION-THERAPY; PHASE-II TRIAL; CONCURRENT CHEMOTHERAPY; BEAM THERAPY; NODAL IRRADIATION; RADIOTHERAPY; ETOPOSIDE; METAANALYSIS; CISPLATIN AB Background. Concurrent chemoradiotherapy (CRT) is the standard of care in patients with limited-stage small cell lung cancer (SCLC). Treatment with conventional x-ray therapy (XRT) is associated with high toxicity rates, particularly acute grade 3+ esophagitis and pneumonitis. We present outcomes for the first known series of limited-stage SCLC patients treated with proton therapy and a dosimetric comparison of lung and esophageal doses with intensity-modulated radiation therapy (IMRT). Material and methods. Six patients were treated: five concurrently and one sequentially. Five patients received 60-66 CGE in 30-34 fractions once daily and one patient received 45 CGE in 30 fractions twice daily. All six patients received prophylactic cranial irradiation. Common Terminology Criteria for Adverse Events, v3.0, was used to grade toxicity. IMRT plans were also generated and compared with proton plans. Results. The median follow-up was 12.0 months. The one-year overall and progression-free survival rates were 83% and 66%, respectively. There were no cases of acute grade 3+ esophagitis or acute grade 2+ pneumonitis, and no other acute grade 3+ non-hematological toxicities were seen. One patient with a history of pulmonary fibrosis and atrial fibrillation developed worsening symptoms four months after treatment requiring oxygen. Three patients died: two of progressive disease and one after a fall; the latter patient was disease-free at 36 months after treatment. Another patient recurred and is alive, while two patients remain disease-free at 12 months of follow-up. Proton therapy proved superior to IMRT across all esophageal and lung dose volume points. Conclusion. In this small series of SCLC patients treated with proton therapy with radical intent, treatment was well tolerated with no cases of acute grade 3+ esophagitis or acute grade 2+ pneumonitis. Dosimetric comparison showed better sparing of lung and esophagus with proton therapy. Proton therapy merits further investigation as a method of reducing the toxicity of CRT. C1 [Colaco, Rovel J.; Huh, Soon; Nichols, Romaine C.; Morris, Christopher G.; Flampouri, Stella; Li, Zuofeng; Hoppe, Bradford S.] Univ Florida, Proton Therapy Inst, Jacksonville, FL 32206 USA. [D'Agostino, Harry] Univ Florida, Coll Med, Dept Thorac Surg, Gainesville, FL USA. [Pham, Dat C.] Univ Florida, Coll Med, Dept Hematol & Med Oncol, Gainesville, FL USA. [Bajwa, Abubakr A.] Univ Florida, Coll Med, Dept Med, Gainesville, FL USA. C3 State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida RP Hoppe, BS (corresponding author), Univ Florida, Proton Therapy Inst, 2015 North Jefferson St, Jacksonville, FL 32206 USA. EM bhoppe@floridaproton.org RI Bajwa, Abubakr/PKG-5057-2026 OI Hoppe, Bradford/0000-0002-2312-5418; Colaco, Rovel/0000-0001-7307-3620 CR [Anonymous], 2010, TNM STAGING LUNG CAN Baas P, 2006, BRIT J CANCER, V94, P625, DOI 10.1038/sj.bjc.6602979 Baka S, 2008, BRIT J CANCER, V99, P442, DOI 10.1038/sj.bjc.6604480 Bonner JA, 1999, J CLIN ONCOL, V17, P2681, DOI 10.1200/JCO.1999.17.9.2681 Chang JY, 2006, INT J RADIAT ONCOL, V65, P1087, DOI 10.1016/j.ijrobp.2006.01.052 Chang JY, 2011, CANCER-AM CANCER SOC, V117, P4707, DOI 10.1002/cncr.26080 Colaco R, 2012, LUNG CANCER, V76, P72, DOI 10.1016/j.lungcan.2011.09.015 De Ruysscher D, 2006, ANN ONCOL, V17, P543, DOI 10.1093/annonc/mdj094 De Ruysscher D, 2006, RADIOTHER ONCOL, V80, P307, DOI 10.1016/j.radonc.2006.07.029 Fried DB, 2004, J CLIN ONCOL, V22, P4837, DOI 10.1200/JCO.2004.01.178 Gomez DR, 2012, INT J RADIAT ONCOL, V84, P1010, DOI 10.1016/j.ijrobp.2012.01.071 Grutters JPC, 2010, RADIOTHER ONCOL, V95, P32, DOI 10.1016/j.radonc.2009.08.003 Hoppe BS, 2012, CLIN LUNG CANCER, V13, P352, DOI 10.1016/j.cllc.2011.11.008 Huncharek M, 2004, ONCOLOGIST, V9, P665, DOI 10.1634/theoncologist.9-6-665 Jeremic B, 1997, J CLIN ONCOL, V15, P893, DOI 10.1200/JCO.1997.15.3.893 Kalemkerian GP, 2013, J NATL COMPR CANC NE, V11, P78, DOI 10.6004/jnccn.2013.0011 Kang YX, 2007, INT J RADIAT ONCOL, V67, P906, DOI 10.1016/j.ijrobp.2006.10.045 Leprieur ÉG, 2012, CANCER RADIOTHER, V16, P257, DOI 10.1016/j.canrad.2012.03.003 Liao ZX, 2011, ACTA ONCOL, V50, P745, DOI 10.3109/0284186X.2011.590148 Nakayama H, 2010, INT J RADIAT ONCOL, V78, P467, DOI 10.1016/j.ijrobp.2009.07.1707 Nichols RC, 2011, TECHNOL CANCER RES T, V10, P317, DOI 10.7785/tcrt.2012.500208 Nichols RC, 2011, CLIN LUNG CANCER, V12, P252, DOI 10.1016/j.cllc.2011.03.027 Nichols RC, 2012, THORAC CANCER, V3, P169, DOI 10.1111/j.1759-7714.2011.00100.x Nichols RC, 2012, THORAC CANCER, V3, P109, DOI 10.1111/j.1759-7714.2011.00098.x Oshiro Y, 2012, J THORAC ONCOL, V7, P370, DOI 10.1097/JTO.0b013e31823c485f Shirvani Shervin M, 2012, Int J Radiat Oncol Biol Phys, V82, pe91, DOI 10.1016/j.ijrobp.2010.12.072 Stahel R A., 1989, Lung Cancer, V5, P119, DOI [10.1016/0169-5002(89)90156-6, DOI 10.1016/0169-5002(89)90156-6] Takada M, 2002, J CLIN ONCOL, V20, P3054, DOI 10.1200/JCO.2002.12.071 Turrisi AT III, 1999, NEW ENGL J MED, V340, P265, DOI 10.1056/NEJM199901283400403 van Loon J, 2010, INT J RADIAT ONCOL, V77, P329, DOI 10.1016/j.ijrobp.2009.04.075 Yeung AR, 2010, AM J CLIN ONCOL-CANC, V33, P276, DOI 10.1097/COC.0b013e3181aaca41 NR 31 TC 19 Z9 21 U1 0 U2 8 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0284-186X J9 ACTA ONCOL JI Acta Oncol. PD APR PY 2013 VL 52 IS 3 BP 506 EP 513 DI 10.3109/0284186X.2013.769063 PG 8 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA 106DT UT WOS:000316123200008 PM 23438357 OA gold DA 2026-04-17 ER PT J AU O'Boyle, F Mediratta, N Chalmers, J Al-Rawi, O Mohan, K Shaw, M Poullis, M AF O'Boyle, Francesca Mediratta, Neeraj Chalmers, John Al-Rawi, Omar Mohan, Kamlesh Shaw, Matthew Poullis, Michael TI Long-term survival of patients with pulmonary disease undergoing coronary artery bypass surgery SO EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY LA English DT Article DE Coronary; Survival; Chronic obstructive pulmonary disease ID CELL LUNG-CANCER; ATRIAL-FIBRILLATION; GRAFT-SURGERY; REVASCULARIZATION; EUROSCORE; RESECTIONS; MORTALITY; OUTCOMES; IMPROVE; COPD AB We sought to investigate the long-term survival of patients with obstructive, restrictive and chronic obstructive pulmonary disease (COPD) as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD). A prospective database was retrospectively analysed and cross-correlated with the UK strategic tracking service to evaluate survival after primary coronary artery bypass grafts (CABG). Univariate and multivariate Cox regression analyses were performed. Three separate multivariate analyses were performed: COPD GOLD criteria for obstructive and/or restrictive lung disease, forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC) and the FEV1/FVC ratio to investigate the effect of FEV1 and FVC individually. We analysed 13 337 primary CABG procedures. The median follow-up was 7 years. Univariate analysis demonstrated that obstructive (P < 0.0001), restrictive (P < 0.0001) and mixed obstructive and restrictive pulmonary disease (P < 0.0001), and COPD as defined by the GOLD criteria (P < 0.0001), are all significant factors determining long-term survival. Cox regression analysis identified age, diabetes, moderate LV, poor LV, peripheral vascular disease, dialysis, left internal mammary artery (LIMA) usage, EuroSCORE, cardiopulmonary bypass and creatinine kinase muscle-brain isoenzyme as significant factors in addition to pulmonary disease that determine long-term survival. Moderate and severe COPD defined by GOLD criteria were significant factors determining long-term survival, but mild COPD had no significant effect. Obstructive and restrictive lung disease were both significant factors determining long-term survival. Restrictive lung disease, however, carried a greater prognostic significance (higher hazard ratio 2.2 vs 1.6) than obstructive. LIMA utilization in patients with COPD was not associated with an increased intensive care unit stay, re-intubation rate or in-hospital mortality rate. Pulmonary disease is a significant factor determining long-term survival. Patients with severe COPD still have a relatively good long-term survival and should not be denied surgery. LIMA utilization in patients with COPD results in a significantly increased long-term survival, without an increased intensive care unit stay, re-intubation rate or in-hospital mortality rate. C1 [O'Boyle, Francesca; Mediratta, Neeraj; Chalmers, John; Al-Rawi, Omar; Mohan, Kamlesh; Shaw, Matthew; Poullis, Michael] Liverpool Heart & Chest Hosp, Dept Cardiac Surg, Liverpool L14 3PE, Merseyside, England. C3 Liverpool Heart & Chest Hospital RP Poullis, M (corresponding author), Liverpool Heart & Chest Hosp, Dept Cardiac Surg, Thomas Dr, Liverpool L14 3PE, Merseyside, England. EM mike.poullis@lhch.nhs.uk RI Poullis, Michael/AAL-2364-2021 OI Shaw, Matthew/0000-0001-9184-5591 CR Angouras DC, 2010, ANN THORAC SURG, V89, P1112, DOI 10.1016/j.athoracsur.2010.01.009 Attaran S, 2011, INTERACT CARDIOV TH, V13, P288, DOI 10.1510/icvts.2011.270249 Attaran S, 2010, INTERACT CARDIOV TH, V11, P442, DOI 10.1510/icvts.2010.237040 Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304 Charytan DM, 2010, NEPHROL DIAL TRANSPL, V25, P3654, DOI 10.1093/ndt/gfq328 De Maria R, 2005, HEART, V91, P779, DOI 10.1136/hrt.2004.037135 Domanski MJ, 2011, JAMA-J AM MED ASSOC, V305, P585, DOI 10.1001/jama.2011.99 El-Chami MF, 2010, J AM COLL CARDIOL, V55, P1370, DOI 10.1016/j.jacc.2009.10.058 Fontaine E, 2011, EUR J CARDIO-THORAC, V40, P642, DOI 10.1016/j.ejcts.2010.12.053 Fontaine E, 2011, INTERACT CARDIOV TH, V12, P956, DOI 10.1510/icvts.2010.255323 Fontaine E, 2010, EUR J CARDIO-THORAC, V38, P21, DOI 10.1016/j.ejcts.2010.01.015 Gao GQ, 2006, ANN THORAC SURG, V82, P806, DOI 10.1016/j.athoracsur.2006.04.032 Leavitt BJ, 2006, CIRCULATION, V114, pI430, DOI 10.1161/CIRCULATIONAHA.105.000943 MacKenzie TA, 2009, ANN THORAC SURG, V87, P463, DOI 10.1016/j.athoracsur.2008.09.042 Medalion B, 2004, CHEST, V125, P56, DOI 10.1378/chest.125.1.56 Nishiyama K, 2010, INT J CARDIOL, V143, P178, DOI 10.1016/j.ijcard.2009.02.010 O'Boyle F, 2012, EUR J CARDIO-THORAC, V42, P101, DOI 10.1093/ejcts/ezr253 Sheridan BC, 2010, ANN THORAC SURG, V89, P1889, DOI 10.1016/j.athoracsur.2010.03.003 Silbernagl S, 2008, RESP COLOR ATLAS PHY, P106 Toumpoulis IK, 2005, ANN THORAC SURG, V79, P1902, DOI 10.1016/j.athoracsur.2004.12.025 NR 20 TC 34 Z9 41 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1010-7940 J9 EUR J CARDIO-THORAC JI Eur. J. Cardio-Thorac. Surg. PD APR PY 2013 VL 43 IS 4 BP 697 EP 703 DI 10.1093/ejcts/ezs454 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 113VB UT WOS:000316696300014 PM 23096454 OA Bronze DA 2026-04-17 ER PT J AU Khalil, MA Al-Agaty, AE Ali, WG Azeem, MSA AF Khalil, Mohamed A. Al-Agaty, Ahmed E. Ali, Wael G. Azeem, Mohsen S. Abdel TI A comparative study between amiodarone and magnesium sulfate as antiarrhythmic agents for prophylaxis against atrial fibrillation following lobectomy SO JOURNAL OF ANESTHESIA LA English DT Article DE Magnesium sulfate; Amiodarone; Atrial fibrillation; Lobectomy ID BYPASS GRAFT-SURGERY; CORONARY-ARTERY; SUPRAVENTRICULAR ARRHYTHMIAS; CARDIAC-SURGERY; LUNG-CANCER; PREVENTION; MANAGEMENT; RESECTION; ASSOCIATION; CARVEDILOL AB Atrial fibrillations are common after thoracic surgery. Amiodarone and magnesium sulfate have been used for the management of atrial fibrillation following cardiac and non-cardiac surgery. However, to our knowledge, comparisons of both drugs with each other and with a control group in relation to the prevention of AF following lung surgery have not been performed. Our primary aim in this study was to prospectively evaluate the prophylactic effects of magnesium sulfate and amiodarone used separately and compare them with a control group analyzed retrospectively during and following lobectomy surgeries. The prophylactic value of amiodarone (group A; 219 patients) administered as an intravenous infusion (15 mg/kg for 48 h postoperatively) after a loading dose (5 mg/kg) was compared with magnesium sulfate (group M; 219 patients) administered intravenously as a loading dose (80 mg/kg magnesium sulfate over 30 min preoperatively) and then as an intravenous infusion (8 mg/kg/h for 48 h) in 438 patients undergoing lobectomy. These two groups were compared with a control group of 219 patients who were analyzed retrospectively. The results showed significantly lower incidences of AF in groups A and M when compared with group C (P < 0.05). There was no significant difference between the amiodarone and magnesium sulfate groups. However, the incidence of postoperative AF was lower in the amiodarone group, where only 21 (10 %) patients developed AF in comparison to 27 (12.5 %) patients in the magnesium sulfate group. Group C showed a higher incidence, 44 (20.5 %) patients, when compared with both groups. In addition, there were significant differences between the three groups concerning intensive care unit (ICU) and total hospital stays (P < 0.05). Our study showed that during the intra- and postoperative periods, both amiodarone and magnesium sulfate are effective at preventing the incidence of atrial fibrillation following lung resection surgery in comparison to the control group. C1 [Khalil, Mohamed A.; Al-Agaty, Ahmed E.; Ali, Wael G.] Cairo Univ, Dept Anesthesia, Fac Med, Giza, Egypt. [Khalil, Mohamed A.] Saad Specialist Hosp, Dept Anesthesia, Al Khobar 30353, Saudi Arabia. [Azeem, Mohsen S. Abdel] Cairo Univ, Dept Crit Care, Fac Med, Giza, Egypt. C3 Egyptian Knowledge Bank (EKB); Cairo University; Saad Specialist Hospital; Egyptian Knowledge Bank (EKB); Cairo University RP Khalil, MA (corresponding author), Saad Specialist Hosp, Dept Anesthesia, Prince Faisal Bin Fahad St, Al Khobar 30353, Saudi Arabia. EM mohamedkhalil404@hotmail.com RI Khalil, Mohamed/O-8897-2018 CR Aerra V, 2006, J CARDIOTHORAC SURG, V1, DOI 10.1186/1749-8090-1-6 AMAR D, 1995, CHEST, V108, P349, DOI 10.1378/chest.108.2.349 Amar D, 2002, ANESTH ANALG, V95, P537, DOI 10.1097/00000539-200209000-00006 [Anonymous], ISRN CARDIOL ASAMURA H, 1993, J THORAC CARDIOV SUR, V106, P1104, DOI 10.1016/S0022-5223(19)33985-6 Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Christians KK, 2001, AM J SURG, V182, P713, DOI 10.1016/S0002-9610(01)00799-1 Ciriaco P, 2000, EUR J CARDIO-THORAC, V18, P12, DOI 10.1016/S1010-7940(00)00428-0 Cook RC, 2009, CIRCULATION, V120, pS163, DOI 10.1161/CIRCULATIONAHA.108.841221 ENGLAND MR, 1992, JAMA-J AM MED ASSOC, V268, P2395, DOI 10.1001/jama.268.17.2395 Forlani S, 2002, ANN THORAC SURG, V74, P720, DOI 10.1016/S0003-4975(02)03773-6 Fuster V, 2006, CIRCULATION, V114, pE257, DOI 10.1161/CIRCULATIONAHA.106.177292 Haghjoo M, 2007, HEART RHYTHM, V4, P1170, DOI 10.1016/j.hrthm.2007.04.022 Hazelrigg SR, 2004, ANN THORAC SURG, V77, P824, DOI 10.1016/j.athoracsur.2003.08.027 Hogue CW Jr, 2005, CHEST, V128, p9S, DOI 10.1378/chest.128.2_suppl.9S Kamei M, 2006, CARDIOVASC DRUG THER, V20, P219, DOI 10.1007/s10557-006-8375-7 Kannel WB, 1998, AM J CARDIOL, V82, p2N, DOI 10.1016/S0002-9149(98)00583-9 Koniari I, 2010, J CARDIOTHORAC SURG, V5, DOI 10.1186/1749-8090-5-121 Lanza LA, 2003, ANN THORAC SURG, V75, P223, DOI 10.1016/S0003-4975(02)04285-6 Mathew JP, 1996, JAMA-J AM MED ASSOC, V276, P300, DOI 10.1001/jama.276.4.300 Nikolaos B, 2004, BMC SURG, V4, P1 Omae T, 2012, J ANESTH, V26, P429, DOI 10.1007/s00540-012-1330-9 Onalan O, 2007, AM J CARDIOL, V99, P1726, DOI 10.1016/j.amjcard.2007.01.057 Rena O, 2001, EUR J CARDIO-THORAC, V20, P688, DOI 10.1016/S1010-7940(01)00890-9 Satur CMR, 1997, ANN ROY COLL SURG, V79, P349 Sekine Y, 2001, CHEST, V120, P1783, DOI 10.1378/chest.120.6.1783 Sood N, 2009, J CARDIOTHOR VASC AN, V23, P22, DOI 10.1053/j.jvca.2008.06.009 Terzi A, 1996, THORAC CARDIOV SURG, V44, P300, DOI 10.1055/s-2007-1012041 Tiryakioglu O, 2009, J CARDIOTHORAC SURG, V4, DOI 10.1186/1749-8090-4-8 VANMIEGHEM W, 1994, CHEST, V105, P1642, DOI 10.1378/chest.105.6.1642 Vaporciyan AA, 2004, J THORAC CARDIOVASC, V95, P537 VONKNORRING J, 1992, ANN THORAC SURG, V53, P642, DOI 10.1016/0003-4975(92)90325-X NR 32 TC 35 Z9 38 U1 0 U2 6 PU SPRINGER JAPAN KK PI TOKYO PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005, JAPAN SN 0913-8668 EI 1438-8359 J9 J ANESTH JI J. Anesth. PD FEB PY 2013 VL 27 IS 1 BP 56 EP 61 DI 10.1007/s00540-012-1478-3 PG 6 WC Anesthesiology WE Science Citation Index Expanded (SCI-EXPANDED) SC Anesthesiology GA 091IG UT WOS:000315042200010 PM 22987136 DA 2026-04-17 ER PT J AU Menger, L Vacchelli, E Kepp, O Eggermont, A Tartour, E Zitvogel, L Kroemer, G Galluzzi, L AF Menger, Laurie Vacchelli, Erika Kepp, Oliver Eggermont, Alexander Tartour, Eric Zitvogel, Laurence Kroemer, Guido Galluzzi, Lorenzo TI Trial watch Cardiac glycosides and cancer therapy SO ONCOIMMUNOLOGY LA English DT Review DE breast carcinoma; Digitalis purpurea; estrogen receptor; immunogenic cell death; ouabain; phytoestrogens ID BREAST-CANCER; LUNG-CANCER; HEPATOCELLULAR-CARCINOMA; CALRETICULIN EXPOSURE; RECEPTOR AGONISTS; ANTICANCER AGENT; SODIUM-PUMP; NA/K-ATPASE; CELL-DEATH; DIGOXIN AB Cardiac glycosides (CGs) are natural compounds sharing the ability to operate as potent inhibitors of the plasma membrane Na+/K+-ATPase, hence promoting-via an indirect mechanism-the intracellular accumulation of Ca2+ ions. In cardiomyocytes, increased intracellular Ca2+ concentrations exert prominent positive inotropic effects, that is, they increase myocardial contractility. Owing to this feature, two CGs, namely digoxin and digitoxin, have extensively been used in the past for the treatment of several cardiac conditions, including distinct types of arrhythmia as well as contractility disorders. Nowadays, digoxin is approved by the FDA and indicated for the treatment of congestive heart failure, atrial fibrillation and atrial flutter with rapid ventricular response, whereas the use of digitoxin has been discontinued in several Western countries. Recently, CGs have been suggested to exert potent antineoplastic effects, notably as they appear to increase the immunogenicity of dying cancer cells. In this Trial Watch, we summarize the mechanisms that underpin the unsuspected anticancer potential of CGs and discuss the progress of clinical studies that have evaluated/are evaluating the safety and efficacy of CGs for oncological indications. C1 [Menger, Laurie; Vacchelli, Erika; Kepp, Oliver; Eggermont, Alexander; Kroemer, Guido; Galluzzi, Lorenzo] Inst Gustave Roussy, Villejuif, France. [Menger, Laurie; Vacchelli, Erika; Kepp, Oliver; Zitvogel, Laurence] Univ Paris 11, Le Kremlin Bicetre, France. [Menger, Laurie; Vacchelli, Erika; Kepp, Oliver] INSERM, U848, Villejuif, France. [Tartour, Eric; Kroemer, Guido] Hop Europeen Georges Pompidou, AP HP, Paris, France. [Tartour, Eric] Univ Paris 06, Paris, France. [Zitvogel, Laurence; Galluzzi, Lorenzo] INSERM, U1015, CICBT507, Villejuif, France. [Kroemer, Guido] Univ Paris 05, Paris, France. [Kroemer, Guido; Galluzzi, Lorenzo] Ctr Rech Cordeliers, Equipe Labelisee Ligue Natl Canc 11, Paris, France. C3 UNICANCER; Gustave Roussy; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Europeen Georges-Pompidou - APHP; Sorbonne Universite; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Sorbonne Universite; Universite Paris Cite RP Kroemer, G (corresponding author), Inst Gustave Roussy, Villejuif, France. EM kroemer@orange.fr; deadoc@vodafone.it RI ; Vacchelli, Erika/AAG-6432-2019; Kroemer, Guido/B-4263-2013; tartour, eric/O-7957-2017; Kepp, Oliver/N-2763-2017; Galluzzi, Lorenzo/AAH-3286-2021; Eggermont, Alexander/ACQ-5262-2022 OI Menger, Laurie/0000-0003-0949-6607; ZITVOGEL, laurence/0000-0003-1596-0998; Vacchelli, Erika/0000-0001-8010-0594; Kroemer, Guido/0000-0002-9334-4405; tartour, eric/0000-0002-7323-468X; Kepp, Oliver/0000-0002-6081-9558; FU European Commission (ArtForce); Agence National de la Recherche (ANR); Ligue contre le Cancer (Equipe labellisee); Fondation pour la Recherche Medicale (FRM); Institut National du Cancer (INCa); LabEx Immuno-Oncologie; Fondation de France; Fondation Bettencourt-Schueller; AXA Chair for Longevity Research; Canceropole Ile-de-France; Paris Alliance of Cancer Research Institutes (PACRI) FX Authors are supported by the European Commission (ArtForce); Agence National de la Recherche (ANR); Ligue contre le Cancer (Equipe labellisee); Fondation pour la Recherche Medicale (FRM); Institut National du Cancer (INCa); LabEx Immuno-Oncologie; Fondation de France; Fondation Bettencourt-Schueller; AXA Chair for Longevity Research; Canceropole Ile-de-France and Paris Alliance of Cancer Research Institutes (PACRI). CR Ahern TP, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2205 [Anonymous], ASCO M [Anonymous], CAN UROL ASS J Apetoh L, 2007, IMMUNOL REV, V220, P47, DOI 10.1111/j.1600-065X.2007.00573.x Atkins MB, 2008, J CLIN ONCOL, V26, P5748, DOI 10.1200/JCO.2008.17.5448 Biggar RJ, 2012, INT J CANCER, V131, P716, DOI 10.1002/ijc.26424 Biggar RJ, 2011, J CLIN ONCOL, V29, P2165, DOI 10.1200/JCO.2010.32.8146 Boehrer S, 2008, BLOOD, V111, P2170, DOI 10.1182/blood-2007-07-100362 Boukerche H, 2004, GENE, V343, P191, DOI 10.1016/j.gene.2004.09.002 Chen JQ, 2006, BREAST CANCER RES TR, V96, P1, DOI 10.1007/s10549-005-9053-3 COVE DH, 1979, LANCET, V2, P204 Dumontet C, 2010, NAT REV DRUG DISCOV, V9, P790, DOI 10.1038/nrd3253 Elbaz HA, 2012, TOXICOL APPL PHARM, V258, P51, DOI 10.1016/j.taap.2011.10.007 Espineda C, 2003, CANCER-AM CANCER SOC, V97, P1859, DOI 10.1002/cncr.11267 Flahavan E, 2012, J CLIN ONCOL, V30 Fürstenwerth H, 2010, INT J CLIN PRACT, V64, P1591, DOI 10.1111/j.1742-1241.2010.02395.x Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384 Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96 Galluzzi L, 2012, ONCOIMMUNOLOGY, V1, P1111, DOI 10.4161/onci.21494 Galluzzi L, 2012, ONCOIMMUNOLOGY, V1, P306, DOI 10.4161/onci.19549 Galluzzi L, 2012, ONCOIMMUNOLOGY, V1, P699, DOI 10.4161/onci.20696 Galluzzi L, 2012, ONCOIMMUNOLOGY, V1, P28, DOI 10.4161/onci.1.1.17938 Gheorghiade M, 2004, CIRCULATION, V109, P2959, DOI 10.1161/01.CIR.0000132482.95686.87 Grimard C, 2005, J CARDIOVASC ELECTR, V16, P807, DOI 10.1111/j.1540-8167.2005.40776.x Haux J, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-11 Haux J, 1999, MED HYPOTHESES, V53, P543, DOI 10.1054/mehy.1999.0985 Haux J., 1999, J Oncol, V31, P14 Joshi AD, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-17 Kayali F, 2009, J CLIN ONCOL, V27 Khan MI, 2007, J CLIN ONCOL, V25 Kroemer G, 2012, ANN REV IMM IN PRESS, V31 LAWRENCE TS, 1988, INT J RADIAT ONCOL, V15, P953, DOI 10.1016/0360-3016(88)90132-0 LEE KS, 1983, NATURE, V302, P790, DOI 10.1038/302790a0 Lefranc F, 2008, NEUROSURGERY, V62, P211, DOI 10.1227/01.NEU.0000311080.43024.0E Li HX, 2011, ONCOL REP, V25, P825, DOI 10.3892/or.2010.1120 Lin Yun, 2008, J Exp Ther Oncol, V7, P195 LONGHURST JC, 1985, J AM COLL CARDIOL, V5, pA99, DOI 10.1016/S0735-1097(85)80468-X López-Lázaro M, 2007, EXPERT OPIN THER TAR, V11, P1043, DOI 10.1517/14728222.11.8.1043 Ma YT, 2011, J EXP MED, V208, P491, DOI 10.1084/jem.20100269 Manunta P, 2009, J HYPERTENS, V27, P9, DOI 10.1097/HJH.0b013e32831cf2c6 Martins I, 2011, ONCOGENE, V30, P1147, DOI 10.1038/onc.2010.500 Mekhail T, 2006, INVEST NEW DRUG, V24, P423, DOI 10.1007/s10637-006-7772-x Meng Z, 2011, J CLIN ONCOL, V29 Meng ZQ, 2009, CANCER-AM CANCER SOC, V115, P5309, DOI 10.1002/cncr.24602 Menger L, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003807 Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347 Mijatovic T, 2007, J PATHOL, V212, P170, DOI 10.1002/path.2172 Mijatovic T, 2007, BBA-REV CANCER, V1776, P32, DOI 10.1016/j.bbcan.2007.06.002 Nasu S, 2002, CANCER LETT, V185, P145, DOI 10.1016/S0304-3835(02)00263-X Newman RA, 2008, MOL INTERV, V8, P36, DOI 10.1124/mi.8.1.8 Niraula S, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.4686 Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523 Panaretakis T, 2009, EMBO J, V28, P578, DOI 10.1038/emboj.2009.1 Pathak S, 2000, ANTI-CANCER DRUG, V11, P455, DOI 10.1097/00001813-200007000-00006 Platz EA, 2011, CANCER DISCOV, V1, P68, DOI 10.1158/2159-8274.CD-10-0020 Prassas I, 2008, NAT REV DRUG DISCOV, V7, P926, DOI 10.1038/nrd2682 Prassas I, 2011, MOL CANCER THER, V10, P2083, DOI 10.1158/1535-7163.MCT-11-0421 Raghavendra PB, 2007, MOL IMMUNOL, V44, P2292, DOI 10.1016/j.molimm.2006.11.009 Rouge TD, 2007, CANCER RES, V67, P6253, DOI 10.1158/0008-5472.CAN-07-0538 RUNGE TM, 1977, AM HEART J, V93, P248, DOI 10.1016/S0002-8703(77)80319-0 Sakai H, 2004, FEBS LETT, V563, P151, DOI 10.1016/S0014-5793(04)00292-3 SCHATZMANN HJ, 1965, BIOCHIM BIOPHYS ACTA, V94, P89, DOI 10.1016/0926-6585(65)90011-7 Senovilla L, 2012, ONCOIMMUNOLOGY, V1, P1323, DOI 10.4161/onci.22009 Senovilla L, 2012, SCIENCE, V337, P1678, DOI 10.1126/science.1224922 SHEN SS, 1978, CANCER RES, V38, P1356 SMITH TW, 1978, NEW ENGL J MED, V299, P545, DOI 10.1056/NEJM197809072991011 SMITH TW, 1982, NEW ENGL J MED, V307, P1357, DOI 10.1056/NEJM198211253072201 Sorsa T, 2004, MOL CELL BIOCHEM, V266, P87, DOI 10.1023/B:MCBI.0000049141.37823.19 Stenkvist B, 1999, ONCOL REP, V6, P493 STENKVIST B, 1979, LANCET, V1, P563 STENKVIST B, 1982, NEW ENGL J MED, V306, P484 STENKVIST B, 1980, ANAL QUANT CYTOL, V2, P49 Tailler M, 2012, ONCOGENE, V31, P3536, DOI 10.1038/onc.2011.521 Vacchelli E, 2013, ONCOIMMUNOL IN PRESS, V2 Vacchelli E, 2012, ONCOIMMUNOL IN PRESS, P1 Vacchelli E, 2012, ONCOIMMUNOLOGY, V1, P894, DOI 10.4161/onci.20931 Vacchelli E, 2012, ONCOIMMUNOLOGY, V1, DOI 10.4161/onci.20459 Vacchelli E, 2012, ONCOIMMUNOLOGY, V1, P179, DOI 10.4161/onci.1.2.19026 Verheye-Dua F, 1998, Radiat Oncol Investig, V6, P109, DOI 10.1002/(SICI)1520-6823(1998)6:3<109::AID-ROI1>3.0.CO;2-1 Wang L, 2011, ANTICANCER RES, V31, P2141 WARREN JV, 1986, AM J CARDIOL, V58, P189, DOI 10.1016/0002-9149(86)90276-6 Weidemann H, 2005, FRONT BIOSCI-LANDMRK, V10, P2165, DOI 10.2741/1688 Xie ZJ, 2005, FRONT BIOSCI-LANDMRK, V10, P3100, DOI 10.2741/1766 Yang PY, 2009, MOL CANCER THER, V8, P2319, DOI 10.1158/1535-7163.MCT-08-1085 NR 84 TC 113 Z9 131 U1 1 U2 43 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 2162-402X J9 ONCOIMMUNOLOGY JI OncoImmunology PD FEB PY 2013 VL 2 IS 2 AR e23082 DI 10.4161/onci.23082 PG 7 WC Oncology; Immunology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Immunology GA 121SF UT WOS:000317263800009 PM 23525565 OA gold DA 2026-04-17 ER PT J AU Sun, YF Zheng, H Chen, QK Bao, MW Jiang, GN Chen, C Gao, W AF Sun, Yifeng Zheng, Hui Chen, Qiankun Bao, Minwei Jiang, Gening Chen, Chang Gao, Wen TI Triple Plasty of Bronchus, Pulmonary Artery, and Superior Vena Cava for Non-Small Cell Lung Cancer SO ANNALS OF THORACIC SURGERY LA English DT Article ID SINGLE-CENTER EXPERIENCE; PROSTHETIC REPLACEMENT; SLEEVE LOBECTOMY; THORACIC-SURGERY; RESECTION; STAGE AB Background. It has been technically challenging to perform simultaneous triple plasty on the superior vena cava (SVC), pulmonary artery (PA), and main bronchus for central-type lung cancers. In the present study, the authors describe a corresponding technique and clinical outcomes of this surgical manipulation. Methods. Clinical data from 4 patients with non-small cell lung cancer (NSCLC) who underwent triple plastic resections and reconstructions were retrospectively reviewed. Three patients received neoadjuvant chemotherapy for pathologically proven locally advanced disease. For pulmonary arteries, sleeve resection with end-to-end anastomosis was performed in 2 patients; tangential resection was used in the other 2 patients. SVC resection with ringed polytetrafluoroethylene (PTFE) graft interposition was performed in 1 patient; the other 3 patients underwent tangential SVC resection. Sleeve resection of the bronchus was performed in all 4 patients. Systemic lymphadenectomy was accomplished in all patients. Results. There was histologic confirmation of large cell carcinoma, adenocarcinoma, squamous cancer, and adeno-squamous cancer, respectively, in these 4 patients. Stage pT4N2M0-IIIB was confirmed in 2 patients, and stage T4N1M0-IIIA and stage T2aN2M0-IIIA were confirmed in the other 2 patients. There were no perioperative deaths. Postoperative atrial fibrillation and prolonged air leakage occurred in 2 patients, respectively. Four patients underwent postoperative chemotherapy and 2 patients were administered radiotherapy. Patients were followed for 21 to 38 months: Two patients had disease-free survival at their 32-month and 38-month follow-ups, and the other 2 patients died 21 and 22 months, respectively, after operation because of remote metastasis. Conclusions. Triple plasty of bronchus, PA, and SVC is both practical and safe for patients with locally advanced NSCLC. For patients with strict indications, the long-term survival is favorable. (Ann Thorac Surg 2013;95:420-5) (c) 2013 by The Society of Thoracic Surgeons C1 [Sun, Yifeng; Zheng, Hui; Chen, Qiankun; Bao, Minwei; Jiang, Gening; Chen, Chang; Gao, Wen] Tongji Univ, Dept Thorac Surg, Shanghai Pulm Hosp, Sch Med, Shanghai 200433, Peoples R China. C3 Tongji University RP Chen, C (corresponding author), Tongji Univ, Dept Thorac Surg, Shanghai Pulm Hosp, Sch Med, 507 Zhengmin Rd, Shanghai 200433, Peoples R China. EM changchenc@hotmail.com RI Chen, Qiankun/OGQ-1615-2025 CR Bakir M, 2011, INTERACT CARDIOV TH, V13, P303, DOI 10.1510/icvts.2011.267872 Cooke DT, 2012, ANN THORAC SURG, V94, P1060, DOI 10.1016/j.athoracsur.2012.04.018 Dartevelle P, 1995, Chest Surg Clin N Am, V5, P345 Hotta K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026646 Mahtabifard A, 2008, ANN THORAC SURG, V85, pS729, DOI 10.1016/j.athoracsur.2007.12.001 Meacci E, 2011, EUR J CARDIO-THORAC, V40, P656, DOI 10.1016/j.ejcts.2010.12.062 Pochesci I, 2008, EUR J CARDIO-THORAC, V34, P673, DOI 10.1016/j.ejcts.2008.05.039 Rendina EA, 2000, SEMIN SURG ONCOL, V18, P165, DOI 10.1002/(SICI)1098-2388(200003)18:2<165::AID-SSU10>3.3.CO;2-D Sekine Yasuo, 2006, Interact Cardiovasc Thorac Surg, V5, P509 Shargall Y, 2004, LUNG CANCER, V45, P357, DOI 10.1016/j.lungcan.2004.02.009 Solli P, 2001, EUR J CARDIO-THORAC, V20, P1045, DOI 10.1016/S1010-7940(01)00908-3 Spaggiari L, 2004, LUNG CANCER-J IASLC, V44, P339, DOI 10.1016/j.lungcan.2003.11.010 Spaggiari L, 2002, EUR J CARDIO-THORAC, V21, P1080, DOI 10.1016/S1010-7940(02)00175-6 Spaggiari L, 2000, ANN THORAC SURG, V69, P233, DOI 10.1016/S0003-4975(99)00867-X Spaggiari L, 2007, ANN THORAC SURG, V83, P223, DOI 10.1016/j.athoracsur.2006.07.075 Sun YF, 2013, ANN THORAC SURG, V95, P420, DOI 10.1016/j.athoracsur.2012.10.036 NR 16 TC 7 Z9 8 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD FEB PY 2013 VL 95 IS 2 BP 420 EP 425 DI 10.1016/j.athoracsur.2012.10.036 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 074DF UT WOS:000313792000016 PM 23267732 OA Bronze DA 2026-04-17 ER PT J AU Nakazawa, K Kanemoto, K Suzuki, H Masuda, M Matsuno, Y Iijima, H Ishikawa, H AF Nakazawa, Kensuke Kanemoto, Koji Suzuki, Hiromichi Masuda, Michiko Matsuno, Yousuke Iijima, Hiroaki Ishikawa, Hiroichi TI Purulent Pericarditis with Concurrent Detection of Streptococcus pneumoniae and Malignant Squamous Cells in Pericardial Fluid SO INTERNAL MEDICINE LA English DT Article DE pneumococcal pericarditis; Streptococcus pneumonia; pericardial effusion; malignancy; lung cancer ID PNEUMOCOCCAL BACTEREMIA; MANAGEMENT; GUIDELINES; DIAGNOSIS; EFFUSION; FISTULA; CANCER AB Pneumococcal pericarditis complicated by a malignant effusion has not been reported previously. We experienced an independent 62-year-old man with lung cancer who was hospitalized for acute onset of atrial flutter and moderate pericardial effusion. He was afebrile; however, pericardiocentesis showed Streptococcus pneumoniae and malignant squamous cells in purulent pericardial fluid. This case shows that clinicians should keep in mind the possibility of afebrile bacterial pericarditis in cancer patients with pericardial effusions and that cultures of pericardial fluid should be performed in such patients along with cytological examinations. C1 [Nakazawa, Kensuke; Kanemoto, Koji; Masuda, Michiko; Matsuno, Yousuke; Iijima, Hiroaki; Ishikawa, Hiroichi] Tsukuba Med Ctr Hosp, Dept Resp Med, Tsukuba, Ibaraki, Japan. [Suzuki, Hiromichi] Tsukuba Med Ctr Hosp, Dept Clin Lab Med, Tsukuba, Ibaraki, Japan. RP Ishikawa, H (corresponding author), Tsukuba Med Ctr Hosp, Dept Resp Med, Tsukuba, Ibaraki, Japan. EM hishikawa@tmch.or.jp CR Czystowska Monika, 2010, Pneumonol Alergol Pol, V78, P296 Giner AM, 2011, INFECTION, V39, P519, DOI 10.1007/s15010-011-0218-1 Go C, 1998, CLIN INFECT DIS, V27, P1338, DOI 10.1086/517730 GOULD K, 1974, ARCH INTERN MED, V134, P923, DOI 10.1001/archinte.134.5.923 Ho PL, 2006, EUR J CLIN MICROBIOL, V25, P323, DOI 10.1007/s10096-006-0139-6 ILAN Y, 1991, JPN HEART J, V32, P315 Kan B, 2006, CLIN MICROBIOL INFEC, V12, P338, DOI 10.1111/j.1469-0691.2006.01363.x Kaufman J, 2003, ANN THORAC SURG, V75, P288, DOI 10.1016/S0003-4975(02)04168-1 KLACSMANN PG, 1977, AM J MED, V63, P666, DOI 10.1016/0002-9343(77)90150-4 Lestuzzi C, 2010, WORLD J CARDIOL, V2, P270, DOI 10.4330/wjc.v2.i9.270 Levy PY, 2003, MEDICINE, V82, P385, DOI 10.1097/01.md.0000101574.54295.73 Maisch B, 2010, PROG CARDIOVASC DIS, V53, P157, DOI 10.1016/j.pcad.2010.06.003 Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159 Nagano N, 2010, INTERACT CARDIOV TH, V10, P459, DOI 10.1510/icvts.2009.224980 Nakagawa C, 2010, INTERNAL MED, V49, P1653, DOI 10.2169/internalmedicine.49.3245 Ruohola A, 2006, CLIN INFECT DIS, V43, P1417, DOI 10.1086/509332 Sokol W, 2001, AM J MED, V111, P19, DOI 10.1016/S0002-9343(01)01027-0 Song JS, 2012, EPIDEMIOL INFECT, V140, P1267, DOI 10.1017/S0950268811001816 Suzuki H, 2013, GERIATR GERONTOL INT, V13, P607, DOI 10.1111/j.1447-0594.2012.00949.x Takayama T, 2013, INTERNAL MED, V52, P243, DOI 10.2169/internalmedicine.52.8673 Tunkel AR, 2004, CLIN INFECT DIS, V39, P1267, DOI 10.1086/425368 WILKES JD, 1995, CANCER, V76, P1377, DOI 10.1002/1097-0142(19951015)76:8<1377::AID-CNCR2820760813>3.0.CO;2-M NR 22 TC 3 Z9 3 U1 0 U2 0 PU JAPAN SOC INTERNAL MEDICINE PI TOKYO PA 34-3 3-CHOME HONGO BUNKYO-KU, TOKYO, 113, JAPAN SN 0918-2918 EI 1349-7235 J9 INTERNAL MED JI Intern. Med. PY 2013 VL 52 IS 12 BP 1413 EP 1416 DI 10.2169/internalmedicine.52.9411 PG 4 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA 170SZ UT WOS:000320875200023 PM 23774558 OA Bronze DA 2026-04-17 ER PT J AU Konge, L Petersen, RH Hansen, HJ Ringsted, C AF Konge, Lars Petersen, Rene Horsleben Hansen, Henrik Jessen Ringsted, Charlotte TI No extensive experience in open procedures is needed to learn lobectomy by video-assisted thoracic surgery SO INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY LA English DT Article DE Thoracoscopy; Lobectomies; Education; Learning curve; Complications; Outcome ID CELL LUNG-CANCER; THORACOSCOPIC LOBECTOMY; THORACOTOMY; CHEMOTHERAPY; RESECTION; OUTCOMES AB OBJECTIVES: Lobectomies done by video-assisted thoracic surgery (VATS) result in fewer complications and less pain and save total costs compared with the traditional approach. However, the majority of procedures are still performed via open thoracotomies, because VATS lobectomy is considered difficult to learn, requiring experience in open surgery, and causing complications in the initial phase of the learning curve. The aim of this study was to describe a training model appreciating patient safety during training and to explore the initial learning curve for a trainee rather inexperienced in open surgery. METHODS: A trainee who had performed 14 lobectomies by thoracotomy was enrolled in a training programme at a high-volume VATS centre. The training model included courses and simulations followed by the selection of suitable patients operated on during close expert supervision. Data regarding time, a variety of quality indicators and complications were collected prospectively and compared with experts' performance. RESULTS: Over 12 months, 29 of 214 VATS lobectomies were performed by the trainee. Twice, the supervisor had to finish the procedure due to technical difficulties. None of the operations were converted to open thoracotomy. Compared with experts, the trainee operated significantly slower [median 120 (range 74-160) vs 100 (range 42-255) min, P = 0.04]; had similar perioperative bleeding [median 100 (range 10-500) vs 50 (range 5-2500) ml, P = 0.79]; had earlier chest tube removal [median 1 (range 1-6) vs 2 (range 1-32) postoperative days, P < 0.001]; and reduced hospital stay [median 3 (range 1-10) vs 4 (range 1-41) days, P < 0.001]. Twenty-three (79%) patients had no complications, while 2 had atrial fibrillation. Pneumothorax after chest tube removal, incisional infection, prolonged pain and need for pleuracentesis were each seen once. CONCLUSIONS: With thorough preparation of trainees and training on selected patients under close supervision, the learning curve can be overcome with good results even if the trainee has limited prior experience in open surgery. C1 [Konge, Lars; Ringsted, Charlotte] Univ Copenhagen, Ctr Clin Educ, Capital Reg Denmark, Copenhagen, Denmark. [Petersen, Rene Horsleben; Hansen, Henrik Jessen] Copenhagen Univ Hosp, Rigshosp, Dept Cardiothorac Surg, Copenhagen, Denmark. C3 University of Copenhagen; Rigshospitalet; University of Copenhagen; Copenhagen University Hospital RP Konge, L (corresponding author), Univ Copenhagen, Kongestien 72, DK-2830 Virum, Denmark. EM lkonge@yahoo.dk RI Petersen, René Horsleben/KRP-4356-2024; Ringsted, Charlotte/AAG-9389-2019 OI Petersen, René Horsleben/0000-0002-3586-1869; CR Amer K, 2011, EUR J CARDIO-THORAC, V39, P173, DOI 10.1016/j.ejcts.2010.05.029 Belgers EHJ, 2010, INTERACT CARDIOV TH, V10, P176, DOI 10.1510/icvts.2009.212878 Boffa DJ, 2012, INTERACT CARDIOV TH, V14, P797, DOI 10.1093/icvts/ivr098 Burfeind WR, 2010, EUR J CARDIO-THORAC, V37, P827, DOI 10.1016/j.ejcts.2009.10.017 Casali G, 2009, EUR J CARDIO-THORAC, V35, P423, DOI 10.1016/j.ejcts.2008.11.008 Detterbeck FC, 2009, CHEST, V136, P260, DOI 10.1378/chest.08-0978 Flores RM, 2011, J THORAC CARDIOV SUR, V142, P1412, DOI 10.1016/j.jtcvs.2011.09.028 Gonzalez D, 2011, EUR J CARDIO-THORAC, V40, pE21, DOI 10.1016/j.ejcts.2011.02.051 Handy JR, 2010, EUR J CARDIO-THORAC, V37, P451, DOI 10.1016/j.ejcts.2009.07.037 Hansen HJ, 2011, SURG ENDOSC, V25, P1263, DOI 10.1007/s00464-010-1355-9 Jones RO, 2008, ANN THORAC SURG, V86, P235, DOI 10.1016/j.athoracsur.2008.03.080 KIRBY TJ, 1995, J THORAC CARDIOV SUR, V109, P997, DOI 10.1016/S0022-5223(95)70326-8 Magill RA, 2007, STAGES LEARNING MOTO, P263 McKenna RJ, 2006, ANN THORAC SURG, V81, P421, DOI 10.1016/j.athoracsur.2005.07.078 McKenna RJ, 2005, CURR OPIN PULM MED, V11, P282, DOI 10.1097/01.mcp.0000166589.08880.44 Nicastri DG, 2008, J THORAC CARDIOV SUR, V135, P642, DOI 10.1016/j.jtcvs.2007.09.014 Onaitis MW, 2006, ANN SURG, V244, P420, DOI 10.1097/01.sla.0000234892.79056.63 Park HS, 2012, ANN THORAC SURG, V93, P372, DOI 10.1016/j.athoracsur.2011.06.054 Petersen RP, 2007, ANN THORAC SURG, V83, P1245, DOI 10.1016/j.athoracsur.2006.12.029 Petersen RH, 2010, EUR J CARDIO-THORAC, V37, P516, DOI 10.1016/j.ejcts.2009.09.012 Swanson SJ, 2007, J CLIN ONCOL, V25, P4993, DOI 10.1200/JCO.2007.12.6649 Swanson SJ, 2012, ANN THORAC SURG, V93, P1027, DOI 10.1016/j.athoracsur.2011.06.007 Tong BC, 2012, EUR J CARDIO-THORAC, V42, P364, DOI 10.1093/ejcts/ezs012 Whitson BA, 2008, ANN THORAC SURG, V86, P2008, DOI 10.1016/j.athoracsur.2008.07.009 Whitson BA, 2007, ANN THORAC SURG, V83, P1965, DOI 10.1016/j.athoracsur.2007.01.049 NR 25 TC 28 Z9 30 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1569-9293 J9 INTERACT CARDIOV TH JI Interact Cardiovasc. Thorac. Surg. PD DEC PY 2012 VL 15 IS 6 BP 961 EP 965 DI 10.1093/icvts/ivs405 PG 5 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 044TV UT WOS:000311647500006 PM 22968956 OA Bronze DA 2026-04-17 ER PT J AU Amar, D Zhang, H Shi, WJ Downey, RJ Bains, MS Park, BJ Flores, R Rizk, N Thaler, HT Rusch, VW AF Amar, David Zhang, Hao Shi, Weiji Downey, Robert J. Bains, Manjit S. Park, Bernard J. Flores, Raja Rizk, Nabil Thaler, Howard T. Rusch, Valerie W. TI Brain natriuretic peptide and risk of atrial fibrillation after thoracic surgery SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article ID LUNG-CANCER; PULMONARY RESECTION; CARDIAC-SURGERY; PROPHYLAXIS; ARRHYTHMIAS AB Objectives: Postoperative atrial fibrillation (POAF) complicating general thoracic surgery is a marker of increased morbidity and stroke risk. Our goal was to determine whether increased preoperative brain natriuretic peptide (BNP) levels are able to stratify patients by the risk of POAF. Methods: Using a prospective database of 415 patients aged 60 years or older, who had undergone lung or esophageal surgery during a 1-year period, the preoperative clinical data, including BNP levels, were compared between patients who developed POAF lasting longer than 5 minutes during hospitalization and those who did not. Results: POAF occurred in 65 (16%) of the 415 patients and was more frequent among patients who had undergone esophagectomy or anatomic lung resection (22% or 58 of 269) compared with those who did not (5% or 7 of 146; P<.0001). After esophagectomy or anatomic lung resection, 46 (34%) of the 135 patients with BNP levels greater than the median (>= 30 pg/mL) developed POAF compared with only 12 (9%) of 134 patients with BNP levels less than 30 pg/mL (P<.0001). The rates of POAF in patients undergoing other thoracic procedures were low and not associated with the BNP levels. Multivariate logistic regression analysis showed that in patients undergoing esophagectomy or anatomic lung resection, older age (5-year increments, odds ratio [OR], 1.28; 95% confidence interval [CI], 1.01-1.61; P=.04), male gender (OR, 2.61; 95% CI, 1.12-4.17; P=.02), and BNP level 30 pg/mL or greater (OR, 4.52; 95% CI, 2.19-9.32; P<.0001) were independent risk factors for POAF. The length of hospital stay was significantly increased in patients who developed POAF compared with those who did not (P<.0001). Conclusions: Among patients undergoing anatomic lung resection or esophagectomy, increased age, male gender, and preoperative BNP level of 30 pg/mL or greater were significant risk factors for the development of POAF. The identification of patients who are more likely to develop POAF will allow the development of trials assessing prevention strategies aimed at reducing this complication. (J Thorac Cardiovasc Surg 2012;144:1249-53) C1 [Amar, David; Zhang, Hao] Mem Sloan Kettering Canc Ctr, Dept Anesthesiol & Crit Care Med, New York, NY 10021 USA. [Shi, Weiji; Thaler, Howard T.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA. [Downey, Robert J.; Bains, Manjit S.; Park, Bernard J.; Flores, Raja; Rizk, Nabil; Rusch, Valerie W.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA. C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center RP Amar, D (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Thorac Anesthesia, 1275 York Ave,M-304, New York, NY 10021 USA. EM amard@mskcc.org OI Rusch, Valerie/0000-0003-2345-6900 CR Amar D, 2000, J THORAC CARDIOV SUR, V120, P790, DOI 10.1067/mtc.2000.109538 Amar D, 2002, ANESTH ANALG, V94, P1132, DOI 10.1097/00000539-200205000-00013 Amar D, 2005, CHEST, V128, P3421, DOI 10.1378/chest.128.5.3421 Cardinale D, 2007, CIRCULATION, V115, P1339, DOI 10.1161/CIRCULATIONAHA.106.647008 Fernando HC, 2011, ANN THORAC SURG, V92, P1144, DOI 10.1016/j.athoracsur.2011.06.104 Gibson PH, 2009, AM HEART J, V158, P244, DOI 10.1016/j.ahj.2009.04.026 Gurgo A M, 2008, Minerva Cardioangiol, V56, P581 Hou JL, 2008, WORLD J GASTROENTERO, V14, P2582, DOI 10.3748/wjg.14.2582 Ishii Y, 2005, CIRCULATION, V111, P2881, DOI 10.1161/CIRCULATIONAHA.104.475194 Karthikeyan G, 2009, J AM COLL CARDIOL, V54, P1599, DOI 10.1016/j.jacc.2009.06.028 Kim YM, 2008, J AM COLL CARDIOL, V51, P68, DOI 10.1016/j.jacc.2007.07.085 Marsiliani D, 2010, EUR REV MED PHARMACO, V14, P855 Nojiri T, 2012, J THORAC CARDIOV SUR, V143, P488, DOI 10.1016/j.jtcvs.2011.09.003 Nojiri T, 2010, J THORAC CARDIOV SUR, V140, P764, DOI 10.1016/j.jtcvs.2009.11.073 Nojiri T, 2010, EUR J CARDIO-THORAC, V37, P787, DOI 10.1016/j.ejcts.2009.09.043 Park BJ, 2007, J THORAC CARDIOV SUR, V133, P775, DOI 10.1016/j.jtcvs.2006.09.022 Passman RS, 2005, ANN THORAC SURG, V79, P1698, DOI 10.1016/j.athoracsur.2004.10.058 Raman T, 2012, J THORAC CARDIOV SUR, V143, P482, DOI 10.1016/j.jtcvs.2011.08.025 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Tisdale JE, 2009, ANN THORAC SURG, V88, P886, DOI 10.1016/j.athoracsur.2009.04.074 Wazni OM, 2004, CIRCULATION, V110, P124, DOI 10.1161/01.CIR.0000134481.24511.BC NR 21 TC 52 Z9 55 U1 0 U2 9 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD NOV PY 2012 VL 144 IS 5 BP 1249 EP 1253 DI 10.1016/j.jtcvs.2012.06.051 PG 5 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 025NZ UT WOS:000310197900043 PM 22841166 OA Bronze DA 2026-04-17 ER PT J AU Lelakowski, J Piekarz, J Rydlewska, A Majewski, J Senderek, T Zabek, A Malecka, B AF Lelakowski, Jacek Piekarz, Justyna Rydlewska, Anna Majewski, Jacek Senderek, Tomasz Zabek, Andrzej Malecka, Barbara TI Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability SO KARDIOLOGIA POLSKA LA English DT Article DE mortality; implantable cardioverter-defibrillator (ICD); parameters affecting survival ID ANTIARRHYTHMIC-DRUG THERAPY; CHRONIC HEART-FAILURE; VENTRICULAR-ARRHYTHMIAS; ESC GUIDELINES; DISEASE; PREVENTION; RISK; AMIODARONE; DEATH AB Background: Proper selection of patients at high risk for sudden cardiac death (SCD) and increasing use of implantable cardioverter-defibrillators (ICD) may contribute to improved survival among patients at the highest SCD risk. Aim: To assess patient survival rate after implantation of an ICD without resynchronisation capability in our own patient population. Using uni- and multivariate analysis, we attempted to identify factors associated with significant worsening of patient survival rate. Methods: From the population of patients who underwent ICD implantation for primary or secondary prevention of SCD in 2008-2010, we selected 376 patients with coronary artery disease or dilated cardiomyopathy (56 females, 320 males). Mean age was 66.1 +/- 11.2 (range 22-89) years. ICD implantation protocols and in-hospital and outpatient records were reviewed retrospectively. We analysed the following clinical and procedural variables: age, gender, left ventricular ejection fraction (LVEF), New York Heart Association (NYHA) functional class, mean heart rate (HR), QRS width, number of antiarrhythmic ICD interventions, type of SCD prevention, ICD type, performing defibrillation threshold testing (DFT) to establish defibrillation safety margin at ICD implantation, ventricular lead location, history of cardiovascular disease and arrhythmia, medications used (amiodarone, sotalol, beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, statins, loop diuretics, aldosterone antagonists). Date and cause of death were established by contacting patient family and/or the hospital to which the patient was admitted shortly before death or the general practitioner caring for the patient (verification of death certificates). Results: During the mean follow-up period of 447 +/- 313 days, 46 patients died of known causes. Causes of death included sudden death in 16 patients, heart failure in 20 patients, and other causes in 10 patients (respiratory failure - 1, bleeding diathesis - 2, lung cancer - 3, colorectal cancer - 1, traffic accident - 1, and stroke - 2 patients). A comparison between primary and secondary prevention patients was performed. Mean QRS width < 118 ms, resting HR < 78 bpm and LVEF > 30% were significant cutoff values for improved survival as determined using the ROC curves. HR > 78 bpm was observed in all SCD patients. In Kaplan-Meier univariate analysis including 27 parameters potentially influencing survival, 10 significant parameters were identified (type of prevention, presence of cardiomyopathy, ventricular tachycardia, HR, QRS width, LVEF, NYHA class, performing DFT, and statin and diuretic treatment). In Cox multivariate analysis, risk of death was increased with mean LVEV < 30% (3-fold increase in risk), no DFT (2-fold increase in risk), NYHA class III or IV (3-fold increase in risk), and no statin use (2-fold increase in risk). Mean HR < 78 bpm and QRS width < 118 ms were independently related to an increased survival. Conclusions: Death rate was higher in patients with LVEF < 30%, NYHA class III or IV, no DFT performed and no statin treatment. In these patients, indications for cardiac resynchronisation therapy should be considered. HR < 78 bpm and QRS width < 118 ms are independent protective factors. HR > 78 bpm was observed in all SCD patients. Sicker ICD patients live for a shorter time. The presence of atrial fibrillation, number of antiarrhythmic ICD interventions, ICD type and revascularisation approach did not affect survival/mortality. C1 [Lelakowski, Jacek; Piekarz, Justyna; Rydlewska, Anna; Majewski, Jacek; Senderek, Tomasz; Zabek, Andrzej; Malecka, Barbara] Jagiellonian Univ, Sch Med, John Paul II Hosp Cracow, Inst Cardiol,Dept Electrocardiol, PL-31302 Krakow, Poland. C3 Jagiellonian University; Collegium Medicum Jagiellonian University RP Lelakowski, J (corresponding author), Jagiellonian Univ, Sch Med, John Paul II Hosp Cracow, Inst Cardiol,Dept Electrocardiol, Ul Pradnicka 80, PL-31302 Krakow, Poland. EM jlelakow@szpitaljp2.krakow.pl RI Ząbek, Andrzej/GPS-9706-2022; Rydlewska, Anna/AAL-5223-2020 OI Ząbek, Andrzej/0000-0001-8331-3210; Senderek, Tomasz/0000-0001-5937-5905 CR Abraham WT, 2002, NEW ENGL J MED, V346, P1845, DOI 10.1056/NEJMoa013168 Bardy GH, 2005, NEW ENGL J MED, V352, P225, DOI 10.1056/NEJMoa043399 Borleffs CJW, 2010, EUR HEART J, V31, P712, DOI 10.1093/eurheartj/ehp497 Buxton AE, 1999, NEW ENGL J MED, V341, P1882, DOI 10.1056/NEJM199912163412503 CHUDZIK M, 2005, FOLIA CARDIOL, V12, P673 Connolly SJ, 2000, CIRCULATION, V101, P1297, DOI 10.1161/01.CIR.101.11.1297 Dickstein K, 2008, EUR HEART J, V29, P2388, DOI 10.1093/eurheartj/ehn309 Dickstein K, 2010, KARDIOL POL, V68, pS475 DiMarco JP, 2003, NEW ENGL J MED, V349, P1836, DOI 10.1056/NEJMra035432 Dulak E, 2009, KARDIOL POL, V67, P837 Hall Burr, 2007, Cardiol J, V14, P463 Hauser RG, 2004, HEART RHYTHM, V1, P399, DOI 10.1016/j.hrthm.2004.05.006 Kuck KH, 2000, CIRCULATION, V102, P748, DOI 10.1161/01.CIR.102.7.748 Lelakowski J, 2010, POL MERK LEK, V171, P153 Lieberman R, 2004, PACE, V27, P883, DOI 10.1111/j.1540-8159.2004.00551.x McAnulty J, 1997, NEW ENGL J MED, V337, P1576 Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601 Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474 Palatini P, 2004, CLIN EXP HYPERTENS, V26, P637, DOI 10.1081/CEH-200031959 Pires LA, 2006, J CARDIOVASC ELECTR, V17, P140, DOI 10.1111/j.1540-8167.2005.00294.x PRZYBYLSKI A, 2006, IMPLANTOWANE KARDIOW Sterlinski M, 2010, KARDIOL POL, V68, P1023 Welsenes GH, 2011, EUROPACE, V13, P389 Zielinski T., 2008, KARDIOL POL, V66, P1258 Zipes DP, 2006, EUR HEART J, V27, P2099, DOI 10.1093/eurheartj/ehl199 NR 25 TC 5 Z9 5 U1 0 U2 10 PU VIA MEDICA PI GDANSK PA UL SWIETOKRZYSKA 73, 80-180 GDANSK, POLAND SN 0022-9032 J9 KARDIOL POL JI Kardiol. Pol. PD NOV PY 2012 VL 70 IS 11 BP 1099 EP 1110 PG 12 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA 050AJ UT WOS:000312024500002 PM 23180517 DA 2026-04-17 ER PT J AU Riber, LP Christensen, TD Jensen, HK Hoejsgaard, A Pilegaard, HK AF Riber, Lars P. Christensen, Thomas D. Jensen, Henrik K. Hoejsgaard, Anette Pilegaard, Hans K. TI Amiodarone Significantly Decreases Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer SO ANNALS OF THORACIC SURGERY LA English DT Article; Proceedings Paper CT Late-Breaking Clinical Trial Abstract Session on Congenital Heart Surgery at the 48th Annual Meeting of the Society-of-Thoracic-Surgeons / Surgical Motion Picture Session CY JAN 28-FEB 01, 2012 CL Fort Lauderdale, FL SP Soc Thorac Surg ID CARDIAC-ARRHYTHMIAS; SUPRAVENTRICULAR ARRHYTHMIA; PROPHYLACTIC DIGITALIZATION; RISK-FACTORS; DYSRHYTHMIAS; THORACOTOMY; MORBIDITY; RESECTION; COMPLICATIONS; PREVENTION AB Background. Postoperative atrial fibrillation occurs in 5% to 65% of patients undergoing thoracic surgery. Although postoperative atrial fibrillation often is regarded as a temporary, benign, operation-related problem, it is associated with a twofold to threefold increase in risk of adverse events, including transient or permanent stroke, acute myocardial infarction, and death. Methods. A total of 254 consecutively eligible enrolled patients undergoing surgery for lung cancer were included in this randomized, controlled, double-blinded trial. Patients received 300 mg of amiodarone or placebo intravenously over 20 minutes immediately after surgery and an oral dose of 600 mg of amiodarone or placebo twice daily during the first 5 postoperative days. Results. The patients in the amiodarone prophylaxis group had a reduction in the risk of atrial fibrillation of 23% (12 to 31); number needed to treat was 4.4 (3.1 to 7.8). A total of 38 in the control group and 11 in the amiodarone group experienced atrial fibrillation (p < 0.001). Adverse effects were observed in 10 patients equally distributed in both trial arms. Conclusions. Postoperative prophylaxis with a high dose of oral amiodarone after an intravenous bolus infusion is a safe, practical, feasible, and effective regimen for patients with lung cancer undergoing surgery. It significantly reduced the incidence of postoperative atrial fibrillation. (Ann Thorac Surg 2012;94:339-46) (c) 2012 by The Society of Thoracic Surgeons C1 [Riber, Lars P.] Aarhus Univ Hosp, Dept Cardiothorac & Vasc Surg, Brendstrupgaardsvej 100, DK-8200 Aarhus N, Denmark. [Riber, Lars P.] Aarhus Univ Hosp, Inst Clin Med, Brendstrupgaardsvej 100, DK-8200 Aarhus N, Denmark. Aarhus Univ Hosp, Dept Cardiol, Aarhus, Denmark. C3 Aarhus University; Aarhus University; Aarhus University RP Riber, LP (corresponding author), Aarhus Univ Hosp, Dept Cardiothorac & Vasc Surg, Brendstrupgaardsvej 100, DK-8200 Aarhus N, Denmark.; Riber, LP (corresponding author), Aarhus Univ Hosp, Inst Clin Med, Brendstrupgaardsvej 100, DK-8200 Aarhus N, Denmark. EM larspeterriber@gmail.com RI Riber, Lars/GRR-9540-2022; Kjærulf Jensen, Henrik/A-7980-2018 OI Riber, Lars/0000-0001-6898-2715; Kjærulf Jensen, Henrik/0000-0003-1802-4302 CR Amar D, 1997, ANN THORAC SURG, V63, P1374 Amar D, 2000, J THORAC CARDIOV SUR, V120, P790, DOI 10.1067/mtc.2000.109538 Amar D, 1996, CHEST, V110, P437, DOI 10.1378/chest.110.2.437 ASAMURA H, 1993, J THORAC CARDIOV SUR, V106, P1104, DOI 10.1016/S0022-5223(19)33985-6 Bailey CC, 1943, NEW ENGL J MED, V229, P356, DOI 10.1056/NEJM194308262290902 Barbetakis Nikolaos, 2004, BMC Surg, V4, P7, DOI 10.1186/1471-2482-4-7 BECKNIEL.J, 1973, ACTA MED SCAND, V193, P425 BORGEAT A, 1989, ANN THORAC SURG, V48, P232, DOI 10.1016/0003-4975(89)90076-3 BREYER RH, 1981, J THORAC CARDIOV SUR, V81, P187 CERNEY CI, 1957, J THORAC SURG, V34, P105 Ciriaco P, 2000, EUR J CARDIO-THORAC, V18, P12, DOI 10.1016/S1010-7940(00)00428-0 Curtis JJ, 1998, ANN THORAC SURG, V66, P1766, DOI 10.1016/S0003-4975(98)00942-4 GHOSH P, 1972, BRIT HEART J, V34, P374 Harpole DH, 1996, ANN THORAC SURG, V61, P977, DOI 10.1016/0003-4975(95)01174-9 JULER GL, 1969, J THORAC CARDIOV SUR, V58, P352, DOI 10.1016/S0022-5223(19)42584-1 KEAGY BA, 1985, ANN THORAC SURG, V40, P349, DOI 10.1016/S0003-4975(10)60065-3 KIRSH MM, 1975, ANN THORAC SURG, V20, P215, DOI 10.1016/S0003-4975(10)63878-7 KROWKA MJ, 1987, CHEST, V91, P490, DOI 10.1378/chest.91.4.490 Lanza LA, 2003, ANN THORAC SURG, V75, P223, DOI 10.1016/S0003-4975(02)04285-6 MASSIE E, 1947, ANN INTERN MED, V26, P231, DOI 10.7326/0003-4819-26-2-231 MOWRY FM, 1964, ANN INTERN MED, V61, P688, DOI 10.7326/0003-4819-61-4-688 Polanczyk CA, 1998, ANN INTERN MED, V129, P279, DOI 10.7326/0003-4819-129-4-199808150-00003 Rena O, 2001, EUR J CARDIO-THORAC, V20, P688, DOI 10.1016/S1010-7940(01)00890-9 RITCHIE AJ, 1990, ANN THORAC SURG, V50, P86, DOI 10.1016/0003-4975(90)90094-M SHIELDS TW, 1968, SURG GYNECOL OBSTETR, V126, P743 STOUGARD J, 1969, THORAX, V24, P568, DOI 10.1136/thx.24.5.568 VANMIEGHEM W, 1994, CHEST, V105, P1642, DOI 10.1378/chest.105.6.1642 VONKNORRING J, 1992, ANN THORAC SURG, V53, P642, DOI 10.1016/0003-4975(92)90325-X WAHI R, 1989, ANN THORAC SURG, V48, P33, DOI 10.1016/0003-4975(89)90172-0 Zebis LR, 2007, ANN THORAC SURG, V83, P1326, DOI 10.1016/j.athoracsur.2006.09.096 NR 30 TC 61 Z9 67 U1 0 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD AUG PY 2012 VL 94 IS 2 BP 339 EP 346 DI 10.1016/j.athoracsur.2011.12.096 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 977YA UT WOS:000306700100011 PM 22516832 OA Bronze DA 2026-04-17 ER PT J AU Fuentes, VL AF Fuentes, Virginia Luis TI ARTERIAL THROMBOEMBOLISM Risks, realities and a rational first-line approach SO JOURNAL OF FELINE MEDICINE AND SURGERY LA English DT Review ID NEWER ORAL ANTICOAGULANTS; HYPERTROPHIC CARDIOMYOPATHY; PLATELET-AGGREGATION; ATRIAL-FIBRILLATION; PREVENT THROMBOEMBOLISM; CATS; ASPIRIN; THERAPY; CLOPIDOGREL; STROKE AB Patient group: Cats with left atrial enlargement secondary to cardiomyopathy are typically predisposed, although cats with hyperthyroidism, pulmonary neoplasia and supravalvular mitral stenosis may also be at risk. Management: Analgesia is the main priority, and severe pain should be managed with methadone or a fentanyl constant rate infusion. Congestive heart failure (CHF) requires treatment with furosemide, but tachypnoea due to pain can mimic signs of CHF. Thrombolytic therapy is not recommended, but antithrombotic treatment should be started as soon as possible. Aspirin and clopidogrel are well tolerated. Evidence base: Several observational studies of ATE have been reported. No randomised, blinded, controlled studies have been reported in cats at risk, for either treatment or prevention of ATE, although such a study comparing aspirin and clopidogrel in cats is currently under way. C1 Royal Vet Coll, Dept Vet Clin Sci, Hatfield AL9 7TA, Herts, England. C3 University of London; University of London Royal Veterinary College RP Fuentes, VL (corresponding author), Royal Vet Coll, Dept Vet Clin Sci, Hawkshead Lane, Hatfield AL9 7TA, Herts, England. EM vluisfuentes@rvc.ac.uk OI Luis Fuentes, Virginia/0000-0001-8076-3806 CR Ahnert AM, 2008, CURR OPIN CARDIOL, V23, P228, DOI 10.1097/HCO.0b013e3282fcd64d Alwood AJ, 2007, J VET INTERN MED, V21, P378, DOI 10.1892/0891-6640(2007)21[378:AEOLHI]2.0.CO;2 Ansell J, 2012, CIRCULATION, V125, P165, DOI 10.1161/CIRCULATIONAHA.111.031153 Bédard C, 2007, VET CLIN PATH, V36, P167, DOI 10.1111/j.1939-165X.2007.tb00203.x Behrend EN, 1996, J AM ANIM HOSP ASSOC, V32, P11, DOI 10.5326/15473317-32-1-11 Cathcart CJ, 2012, J VET EMERG CRIT CAR, V22, P99, DOI 10.1111/j.1476-4431.2011.00681.x Chung I, 2006, INT J CLIN PRACT, V60, P36, DOI 10.1111/j.1368-5031.2005.00676.x Collins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1 Connolly S, 2006, LANCET, V367, P1903, DOI 10.1016/s0140-6736(06)68845-4 Connolly SJ, 2009, NEW ENGL J MED, V360, P2066, DOI 10.1056/NEJMoa0901301 Dennis S, 2010, J VET INTERN MED, V24, P1563 ELDOR A, 1986, THROMB HAEMOSTASIS, V56, P333 FOX PR, 1995, CIRCULATION, V92, P2645, DOI 10.1161/01.CIR.92.9.2645 Furie B, 2008, NEW ENGL J MED, V359, P938, DOI 10.1056/NEJMra0801082 Fuster V, 2011, J AM COLL CARDIOL, V57, pE101, DOI 10.1016/j.jacc.2010.09.013 Goggs R, 2012, J VET EMERG CRIT CAR, V22, P5, DOI 10.1111/j.1476-4431.2011.00704.x Granger CB, 2012, CIRCULATION, V125, P159, DOI 10.1161/CIRCULATIONAHA.111.031146 GRIFFITHS IR, 1979, VET REC, V104, P518, DOI 10.1136/vr.104.23.518 Harpster NK, 1995, KIRKS CURRENT VET TH, V12th, P868 HELENSKI CA, 1987, J VET INTERN MED, V1, P24, DOI 10.1111/j.1939-1676.1987.tb01982.x Hirsh J, 2001, CIRCULATION, V103, P2994, DOI 10.1161/01.CIR.103.24.2994 Hogan DF, 2004, JAVMA-J AM VET MED A, V225, P1406, DOI 10.2460/javma.2004.225.1406 Kapur NK, 2007, CIRCULATION, V115, P67, DOI 10.1161/CIRCULATIONAHA.106.640698 LASTE NJ, 1995, J AM ANIM HOSP ASSOC, V31, P492, DOI 10.5326/15473317-31-6-492 Laste NJ, 2003, ADV SMALL ANIM MED S, V16, P1 Maron BJ, 2002, J AM COLL CARDIOL, V39, P301, DOI 10.1016/S0735-1097(01)01727-2 McMichael MA, 2000, J VET INTERN MED, V14, P507, DOI 10.1892/0891-6640(2000)014<0507:PHBVAA>2.3.CO;2 Moore K. E., 2000, Journal of Veterinary Emergency and Critical Care, V10, P245 Paige CF, 2009, JAVMA-J AM VET MED A, V234, P1398, DOI 10.2460/javma.234.11.1398 Payne J, 2010, J SMALL ANIM PRACT, V51, P540, DOI 10.1111/j.1748-5827.2010.00989.x PION PD, 1988, VET CLIN N AM-SMALL, V18, P79, DOI 10.1016/S0195-5616(88)50008-6 Rush JE, 2002, J AM VET MED ASSOC, V220, P202, DOI 10.2460/javma.2002.220.202 SCHAUB RG, 1982, AM J VET RES, V43, P1647 Schober KE, 2006, J VET INTERN MED, V20, P120, DOI 10.1892/0891-6640(2006)20[120:AOLAAF]2.0.CO;2 Schoeman J P, 1999, J Feline Med Surg, V1, P221, DOI 10.1053/jfms.1999.0049 Smith CE, 2004, JAVMA-J AM VET MED A, V225, P1237, DOI 10.2460/javma.2004.225.1237 Smith SA, 2003, J VET INTERN MED, V17, P73, DOI 10.1892/0891-6640(2003)017<0073:ATICAC>2.3.CO;2 Van De Wiele CM, 2010, J VET INTERN MED, V24, P185, DOI 10.1111/j.1939-1676.2009.0412.x Vizzardi E, 2012, HEART LUNG CIRC, V21, P63, DOI 10.1016/j.hlc.2011.10.005 Volk H, 2011, J FELINE MED SURG, V13, P837, DOI 10.1016/j.jfms.2011.09.005 Wagner Tobias, 2010, J Vet Cardiol, V12, P171, DOI 10.1016/j.jvc.2010.05.003 Welch KM, 2010, J FELINE MED SURG, V12, P122, DOI 10.1016/j.jfms.2009.08.001 WELLES EG, 1994, AM J VET RES, V55, P619 NR 43 TC 69 Z9 86 U1 1 U2 59 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1098-612X EI 1532-2750 J9 J FELINE MED SURG JI J. Feline Med. Surg. PD JUL PY 2012 VL 14 IS 7 BP 459 EP 470 DI 10.1177/1098612X12451547 PG 12 WC Veterinary Sciences WE Science Citation Index Expanded (SCI-EXPANDED) SC Veterinary Sciences GA 057GF UT WOS:000312550300002 PM 22736680 OA Green Submitted DA 2026-04-17 ER PT J AU Kalathiya, RJ Saha, SP AF Kalathiya, Rohan J. Saha, Sibu P. TI Pneumonectomy for Non-Small Cell Lung Cancer: Outcomes Analysis SO SOUTHERN MEDICAL JOURNAL LA English DT Article DE non-small cell lung cancer; pneumonectomy ID INDUCTION THERAPY; COMPLICATIONS; MORTALITY; CHEMOTHERAPY; RADIATION; MORBIDITY; RISKS AB Objective: The purpose of this study was to investigate the morbidity and mortality of 100 consecutive patients with pneumonectomy for non-small cell lung cancer at the University of Kentucky. Methods: We retrospectively reviewed the medical records of 100 consecutive pneumonectomy patients, 1998-2009. Results: The median age of patients was 59 years, with a range of 27 to 79 years. Sixty-eight patients (68%) were men. Fifty-four patients (54%) received left pneumonectomy. Major postoperative complication rate was 39%, with atrial fibrillation being the most common complication, occurring in 26 patients. The overall postoperative mortality rate was 11% (11/100 patients). The mortality rate among right pneumonectomy patients was 17.4% (8/46 patients) compared with 5.6% (3/54 patients) for left pneumonectomy. The postoperative mortality rate among patients receiving neoadjuvant therapy was 14.3% (4/28 patients). In addition, among patients who received neoadjuvant therapy, the mortality rate for right and left pneumonectomy was 21.4% (3/14 patients) and 7.1% (1/14 patients), respectively. The mortality rate among patients older than 70 years at the time of pneumonectomy was 18.2% (2/11 patients). Conclusions: With a postoperative mortality rate of 11% and a major postoperative complication rate of 39%, pneumonectomy for non-small cell lung cancer is associated with high morbidity and mortality. The factors associated with the increased mortality rate include right pneumonectomy, patient age older than 70 years at the time of procedure, and neoadjuvant therapy before pneumonectomy. C1 [Saha, Sibu P.] Univ Kentucky, Coll Med, 900 S Limestone,Room 407, Lexington, KY 40536 USA. Univ Kentucky, Div Cardiothorac Surg, Lexington, KY 40536 USA. C3 University of Kentucky; University of Kentucky RP Saha, SP (corresponding author), Univ Kentucky, Coll Med, 900 S Limestone,Room 407, Lexington, KY 40536 USA. EM ssaha2@uky.edu OI Kalathiya, Rohan/0000-0002-4748-9961 CR Alexiou C, 2001, EUR J CARDIO-THORAC, V20, P476, DOI 10.1016/S1010-7940(01)00823-5 Alloubi I, 2010, INTERACT CARDIOV TH, V11, P162, DOI 10.1510/icvts.2010.232595 Bernard A, 2001, J THORAC CARDIOV SUR, V121, P1076, DOI 10.1067/mtc.2001.114350 Daly BDT, 2006, ANN THORAC SURG, V82, P227, DOI 10.1016/j.athoracsur.2006.02.061 Darling GE, 2005, ANN THORAC SURG, V79, P433, DOI 10.1016/j.athoracsur.2004.07.009 Doddoli C, 2005, J THORAC CARDIOV SUR, V130, P416, DOI 10.1016/j.jtcvs.2004.11.022 FOWLER WC, 1993, ANN THORAC SURG, V55, P986, DOI 10.1016/0003-4975(93)90131-Z Groenendijk RPR, 1999, EUR J SURG, V165, P193 Licker M, 2002, CHEST, V121, P1890, DOI 10.1378/chest.121.6.1890 Marret E, 2010, INTERACT CARDIOV TH, V10, P936, DOI 10.1510/icvts.2009.231621 Martin J, 2001, ANN THORAC SURG, V72, P1149, DOI 10.1016/S0003-4975(01)02995-2 Ng T, 2010, ANN SURG ONCOL, V17, P476, DOI 10.1245/s10434-009-0810-0 Powell ES, 2009, J CARDIOTHORAC SURG, V4, DOI 10.1186/1749-8090-4-41 Ramnath N, 2007, ANN THORAC SURG, V83, P1831, DOI 10.1016/j.athoracsur.2006.12.036 ROMANO PS, 1992, CHEST, V101, P1332, DOI 10.1378/chest.101.5.1332 Rostad H, 2006, EUR J CARDIO-THORAC, V29, P824, DOI 10.1016/j.ejcts.2006.01.055 Sartipy U, 2009, EUR J CARDIO-THORAC, V36, P1069, DOI 10.1016/j.ejcts.2009.05.011 STOLZ A, 2009, J SURG ONCOL, V99, P38, DOI DOI 10.1002/JSO.21181 Venuta F, 2007, EUR J CARDIO-THORAC, V31, P714, DOI 10.1016/j.ejcts.2007.01.017 NR 19 TC 23 Z9 30 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0038-4348 EI 1541-8243 J9 SOUTH MED J JI South.Med.J. PD JUL PY 2012 VL 105 IS 7 BP 350 EP 354 DI 10.1097/SMJ.0b013e31825bc299 PG 5 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA 970FS UT WOS:000306114100006 PM 22766661 DA 2026-04-17 ER PT J AU Tamargo, J Caballero, R Delpón, E AF Tamargo, Juan Caballero, Ricardo Delpon, Eva TI Drug-induced atrial fibrillation SO EXPERT OPINION ON DRUG SAFETY LA English DT Review DE arrhythmia; atrial fibrillation; drug-induced; side effect ID DOBUTAMINE STRESS ECHOCARDIOGRAPHY; OBSTRUCTIVE PULMONARY-DISEASE; CELL LUNG-CANCER; PHASE-II; HEART-FAILURE; SUPRAVENTRICULAR TACHYCARDIA; NEW-ONSET; ELECTROCARDIOGRAPHIC CHANGES; CARDIOPULMONARY TOXICITY; CHEMOTHERAPY TREATMENT AB Introduction: Atrial fibrillation (AF) is the most common arrhythmia and an important cause of hospitalization, morbidity, and mortality. A myriad of drugs can induce AF. However, drug-induced AF (DIAF) receives little attention. Thus, this review is an attempt to attract the attention on this adverse effect. Areas covered: Published reports of drug-induced AF (DIAF) are reviewed in this paper, from January 1974 to December 2011, using the PubMed/Medline database and lateral references. Expert opinion: In most cases, DIAF is paroxysmal and terminates spontaneously, but sometimes AF persists and it is necessary to perform a cardioversion to restore sinus rhythm and avoid progression to persistent AF. Because of the short duration of DIAF, in addition to physicians/patients not being knowledgeable about this side effect, the real incidence and clinical consequences of DIAF are presently unknown. DIAF is an increasing problem, as some widely prescribed drugs can present this adverse effect. The risk is expected to increase in the elderly and in patients with comorbidities. It is important that physicians understand the significance of DIAF, to increase the collaboration between cardiac and non-cardiac professionals, and to educate patients to make them aware of this adverse side effect. C1 [Tamargo, Juan; Caballero, Ricardo; Delpon, Eva] Univ Complutense, Sch Med, Dept Pharmacol, E-28040 Madrid, Spain. C3 Complutense University of Madrid RP Tamargo, J (corresponding author), Univ Complutense, Sch Med, Dept Pharmacol, E-28040 Madrid, Spain. EM jtamargo@med.ucm.es RI Tamargo, Juan/J-7772-2016; Delpon, Eva/K-8631-2014; Caballero, Ricardo/K-3573-2014 OI Tamargo, Juan/0000-0002-7979-7758; Delpon, Eva/0000-0003-4499-8645; Caballero, Ricardo/0000-0002-6424-9687 FU Ministerio de Ciencia e Innovacion [SAF2011-30088, 2011-30112]; Fondo de Investigaciones Sanitarias [PI11/01030, RD06/0009/0014]; Spanish Society of Cardiology FX The authors declare no conflict of interest. This work was supported by Grants from the Ministerio de Ciencia e Innovacion [SAF2011-30088 and 2011-30112], Fondo de Investigaciones Sanitarias [PI11/01030 and Red Heracles RD06/0009/0014] and Spanish Society of Cardiology. CR Abrahamsen B, 2009, J INTERN MED, V265, P581, DOI 10.1111/j.1365-2796.2008.02065.x Albini A, 2010, JNCI-J NATL CANCER I, V102, P14, DOI 10.1093/jnci/djp440 Aliot E., 2003, Annales de Cardiologie et d'Angeiologie, V52, P34, DOI 10.1016/S0003-3928(02)00183-X Ardolino G, 2008, PARKINSONISM RELAT D, V14, P173, DOI 10.1016/j.parkreldis.2007.05.012 Arentz T, 2004, J CARDIOVASC ELECTR, V15, P1041, DOI 10.1046/j.1540-8167.2004.04031.x Argalious M, 2005, CRIT CARE MED, V33, P1327, DOI 10.1097/01.CCM.0000166876.41694.CA Aslam A K, 2001, Am J Ther, V8, P303, DOI 10.1097/00045391-200107000-00013 Awan GM, 2000, AM J MED SCI, V320, P69, DOI 10.1097/00000441-200007000-00011 BELHASSEN B, 1988, AM J CARDIOL, V62, P835, DOI 10.1016/0002-9149(88)91240-4 Bettoni M, 2002, CIRCULATION, V105, P2753, DOI 10.1161/01.CIR.0000018443.44005.D8 Bhuriya R, 2010, INT J CARDIOL, V142, P213, DOI 10.1016/j.ijcard.2009.11.041 Bischiniotis Theodoros S, 2005, Hellenic J Cardiol, V46, P324 Black DM., 2007, N Engl J Med, V356, P1809, DOI [DOI 10.1056/NEJMOA067312, 10.1056/NEJMoa067312] Breeden CC, 1990, ALBUTEROL SPACER IND, P98 BUFF DD, 1991, J CLIN PSYCHIAT, V52, P174 Burger AJ, 2000, AM J CARDIOL, V86, P825, DOI 10.1016/S0002-9149(00)01100-0 Camaiti A, 2001, Eur J Emerg Med, V8, P99 Camm AJ, 2010, EUROPACE, V12, P1360, DOI [10.1093/eurheartj/ehq278, 10.1093/europace/euq350] Carson MP, 2002, OBSTET GYNECOL, V100, P1096, DOI 10.1016/S0029-7844(02)02106-3 Cassinotti A, 2007, EUR J CLIN PHARMACOL, V63, P875, DOI 10.1007/s00228-007-0328-y Ceyhan C, 2004, J CLIN PHARM THER, V29, P267, DOI 10.1111/j.1365-2710.2004.00556.x CHAZAN R, 1995, INT J CLIN PHARM TH, V33, P170 Choragudi Nagaraju L, 2003, Heart Dis, V5, P100, DOI 10.1097/01.HDX.0000061700.11321.1a Christiansen CF, 2009, ARCH INTERN MED, V169, P1677, DOI 10.1001/archinternmed.2009.297 Chung MK, 2001, CIRCULATION, V104, P2886, DOI 10.1161/hc4901.101760 Ciotti R, 1999, ANN ONCOL, V10, P997, DOI 10.1023/A:1008305716918 COWELL RPW, 1994, BRIT HEART J, V71, P569 CROSSON JE, 1994, AM J CARDIOL, V74, P155, DOI 10.1016/0002-9149(94)90089-2 Cuffe MS, 2002, JAMA-J AM MED ASSOC, V287, P1541, DOI 10.1001/jama.287.12.1541 Cummings SR, 2007, NEW ENGL J MED, V356, P1895, DOI 10.1056/NEJMc076132 Dakik HA, 1996, J NUCL CARDIOL, V3, P410, DOI 10.1016/S1071-3581(96)90076-8 Datino T, 2011, HEART RHYTHM, V8, P1426, DOI 10.1016/j.hrthm.2011.04.011 Datino T, 2010, CIRCULATION, V121, P963, DOI 10.1161/CIRCULATIONAHA.109.893107 Daubert GP, 2007, J MED TOXICOL, V3, P56, DOI 10.1007/BF03160909 De Caterina R, 2010, ARCH INTERN MED, V170, P1450, DOI 10.1001/archinternmed.2010.305 DeGiorgio CM, 2010, EPILEPSY BEHAV, V18, P322, DOI 10.1016/j.yebeh.2010.04.043 Devadathan S, 2006, INT J CARDIOL, V107, P112, DOI 10.1016/j.ijcard.2004.11.039 DINDOGRU A, 1978, MED PEDIATR ONCOL, V5, P65, DOI 10.1002/mpo.2950050110 DODD HJ, 1985, BRIT MED J, V291, P706, DOI 10.1136/bmj.291.6497.706 Dogukan Ayhan, 2008, Acta Medica (Hradec Kralove), V51, P63 DOIUCHI J, 1985, CLIN CARDIOL, V8, P176, DOI 10.1002/clc.4960080311 Dutcher JP, 1997, CANCER J SCI AM, V3, P157 Elhendy A, 1998, J NUCL MED, V39, P1662 EMARA MK, 1986, POSTGRAD MED J, V62, P1125, DOI 10.1136/pgmj.62.734.1125 ESKILSSON J, 1988, RADIOTHER ONCOL, V13, P41, DOI 10.1016/0167-8140(88)90296-4 Falk RH, 1998, AM J CARDIOL, V82, p10N, DOI 10.1016/S0002-9149(98)00735-8 Feliz V, 2011, CLIN CARDIOL, V34, P356, DOI 10.1002/clc.20904 Feneck RO, 2001, J CARDIOTHOR VASC AN, V15, P306, DOI 10.1053/jcan.2001.23274 Ferrari D, 2006, ANTI-CANCER DRUG, V17, P359, DOI 10.1097/00001813-200603000-00016 FITTON A, 1990, DRUGS, V39, P308, DOI 10.2165/00003495-199039020-00009 Fleming GA, 2008, CIRCULATION, V118, P1619, DOI 10.1161/CIRCULATIONAHA.108.790162 Floyd JD, 2005, J CLIN ONCOL, V23, P7685, DOI 10.1200/JCO.2005.08.789 Foran JM, 2000, J CLIN ONCOL, V18, P317, DOI 10.1200/JCO.2000.18.2.317 FREDERIKSEN MC, 1983, AM J OBSTET GYNECOL, V145, P108, DOI 10.1016/0002-9378(83)90350-2 Friberg L, 2010, EUR HEART J, V31, P967, DOI 10.1093/eurheartj/ehn599 Frustaci A, 1997, CIRCULATION, V96, P1180, DOI 10.1161/01.CIR.96.4.1180 FUJIMOTO S, 1990, AM J NEPHROL, V10, P231, DOI 10.1159/000168087 Fuster V, 2011, CIRCULATION, V123, pE269, DOI 10.1161/CIR.0b013e318214876d Geleijnse ML, 2000, J AM COLL CARDIOL, V36, P2017, DOI 10.1016/S0735-1097(00)01012-3 Glatter KA, 1999, CIRCULATION, V99, P1034, DOI 10.1161/01.CIR.99.8.1034 Gridelli C, 2001, LUNG CANCER-J IASLC, V31, P277, DOI 10.1016/S0169-5002(00)00194-X Grosso A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004720 Guglin M, 2009, EUROPACE, V11, P1579, DOI 10.1093/europace/eup300 Guzzetti S, 2002, CIRCULATION, V106, pE40, DOI 10.1161/01.CIR.0000028399.42411.13 Hahn IH, 2000, AM J EMERG MED, V18, P642, DOI 10.1053/ajem.2000.9273 Haïssaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003 Hanrahan JP, 2008, MEDICINE, V87, P319, DOI 10.1097/MD.0b013e31818fcc02 Havrilla PL, 2009, ANN PHARMACOTHER, V43, P532, DOI 10.1345/aph.1L544 Hayashi K, 1999, JPN HEART J, V40, P827, DOI 10.1536/jhj.40.827 Heckbert SR, 2008, ARCH INTERN MED, V168, P826, DOI 10.1001/archinte.168.8.826 HENDERSON A, 1992, ANAESTH INTENS CARE, V20, P56, DOI 10.1177/0310057X9202000111 Hewitt RE, 2005, CLIN EXP IMMUNOL, V139, P101, DOI 10.1111/j.1365-2249.2005.02665.x Huerta C, 2005, EPIDEMIOLOGY, V16, P360, DOI 10.1097/01.ede.0000158743.90664.a7 Ifran A, 2005, AM J HEMATOL, V80, P247, DOI 10.1002/ajh.20441 Illiano A, 2000, ANTICANCER RES, V20, P3999 Iqbal Fahad M., 2008, Comprehensive Therapy, V34, P111 ISOMOTO S, 1994, JPN CIRC J, V58, P1 Iwasaki YK, 2011, CIRCULATION, V124, P2264, DOI 10.1161/CIRCULATIONAHA.111.019893 Jara M, 2007, DRUG SAFETY, V30, P1151, DOI 10.2165/00002018-200730120-00007 JEREMIC B, 1990, J CHEMOTHERAPY, V2, P264, DOI 10.1080/1120009X.1990.11739029 Johnson NC, 2006, J EMERG MED, V30, P175, DOI 10.1016/j.jemermed.2005.04.020 Kane GC, 2008, J AM SOC ECHOCARDIOG, V21, P337, DOI 10.1016/j.echo.2007.08.028 Kanei Y, 2008, INT J CARDIOL, V129, pE15, DOI 10.1016/j.ijcard.2007.05.090 Kasinath NS, 2003, CAN J ANAESTH, V50, P229, DOI 10.1007/BF03017789 Keating MJ, 2002, J CLIN ONCOL, V20, P205, DOI 10.1200/JCO.20.1.205 KIAT H, 1995, J AM COLL CARDIOL, V26, P1159, DOI 10.1016/0735-1097(95)00298-7 Kilickap S, 2007, SOUTH MED J, V100, P262, DOI 10.1097/01.smj.0000257382.89910.fe KIRSON LE, 1987, ANESTH ANALG, V66, P283, DOI 10.1213/00000539-198703000-00018 Knecht S, 2008, EUR HEART J, V29, P2125, DOI 10.1093/eurheartj/ehn341 Korantzopoulos P, 2008, INT J CLIN PRACT, V62, P308, DOI 10.1111/j.1742-1241.2007.01505.x Kosmas C, 2008, J CANCER RES CLIN, V134, P75, DOI 10.1007/s00432-007-0250-9 KUPARI M, 1990, BONE MARROW TRANSPL, V5, P91 Kurt IH, 2008, CLIN DRUG INVEST, V28, P527, DOI 10.2165/00044011-200828080-00008 Lainscak M, 2008, INT J CARDIOL, V128, P311, DOI 10.1016/j.ijcard.2007.12.078 Lara PN, 2005, CLIN CANCER RES, V11, P4444, DOI 10.1158/1078-0432.CCR-04-2602 Lashgari S, 2003, OBSTET GYNECOL, V101, P814, DOI 10.1016/S0029-7844(03)00058-9 Lau Dennis H, 2007, Int J Cardiol, V117, pe86, DOI 10.1016/j.ijcard.2006.11.199 LEE RE, 1989, J CLIN ONCOL, V7, P7, DOI 10.1200/JCO.1989.7.1.7 Lenihan DJ, 2004, BLOOD, V104, P655, DOI 10.1182/blood-2003-07-2345 Liu T, 2010, INT J CARDIOL, V145, P365, DOI 10.1016/j.ijcard.2010.02.039 Lombardi D, 2004, TUMORI, V90, P285, DOI 10.1177/030089160409000304 LoVecchio FA, 2000, ANN PHARMACOTHER, V34, P405 Low RA, 1998, J CLIN PSYCHOPHARM, V18, P170, DOI 10.1097/00004714-199804000-00010 MACMAHON JR, 1974, J PEDIATR-US, V84, P613, DOI 10.1016/S0022-3476(74)80701-8 MAISTER AH, 1983, CAN ANAESTH SOC J, V30, P419, DOI 10.1007/BF03007867 MARGOLIN KA, 1989, J CLIN ONCOL, V7, P486, DOI 10.1200/JCO.1989.7.4.486 Massie BM, 1996, AM HEART J, V132, P130, DOI 10.1016/S0002-8703(96)90401-9 MCCUNE KH, 1993, POSTGRAD MED J, V69, P325, DOI 10.1136/pgmj.69.810.325-a McDermott M F, 1999, J Med Syst, V23, P269, DOI 10.1023/A:1020570109720 MCINTOSHYELLIN NL, 1993, J AM COLL CARDIOL, V22, P741, DOI 10.1016/0735-1097(93)90185-4 MCLUCKIE AE, 1993, CHEST, V104, P622, DOI 10.1378/chest.104.2.622 Mebazaa A, 2007, JAMA-J AM MED ASSOC, V297, P1883, DOI 10.1001/jama.297.17.1883 Mego M, 2007, ANN ONCOL, V18, P1906, DOI 10.1093/annonc/mdm489 MENARD O, 1991, J CLIN ONCOL, V9, P192, DOI 10.1200/JCO.1991.9.1.192 MERLI GJ, 1986, ARCH INTERN MED, V146, P45, DOI 10.1001/archinte.146.1.45 MERTES H, 1993, CIRCULATION, V88, P15, DOI 10.1161/01.CIR.88.1.15 Mileshkin LR, 2005, LEUKEMIA LYMPHOMA, V46, P1575, DOI 10.1080/10428190500235884 Montella L, 2005, ANN HEMATOL, V84, P192, DOI 10.1007/s00277-004-0867-6 Moreau P, 1999, BONE MARROW TRANSPL, V23, P1003, DOI 10.1038/sj.bmt.1701763 Morgan DR, 2000, BRIT MED J, V321, P275, DOI 10.1136/bmj.321.7256.275 Moscetti L, 1998, Clin Ter, V149, P377 MURPHY G, 1985, BRIT MED J, V291, P1049, DOI 10.1136/bmj.291.6501.1049-a Nanthakumar K, 2004, CIRCULATION, V109, P1226, DOI 10.1161/01.CIR.0000121423.78120.49 Nattel S, 2002, NATURE, V415, P219, DOI 10.1038/415219a NUNAIN SO, 1992, CARDIOVASC RES, V26, P939, DOI 10.1093/cvr/26.10.939 ODRISCOLL BR, 1989, THORAX, V44, P312, DOI 10.1136/thx.44.4.312 Olin RL, 2007, BREAST J, V13, P211, DOI 10.1111/j.1524-4741.2007.00408.x Olivieri A, 1998, BONE MARROW TRANSPL, V21, P1049, DOI 10.1038/sj.bmt.1701217 Onorati F, 2004, J CARDIOTHOR VASC AN, V18, P409, DOI 10.1053/j.jvca.2004.05.016 OSTER MW, 1981, MED PEDIATR ONCOL, V9, P463, DOI 10.1002/mpo.2950090508 Oteri A, 2010, PEDIATRICS, V126, pE1237, DOI 10.1542/peds.2010-0419 Palma M, 2002, TUMORI, V88, P527, DOI 10.1177/030089160208800618 Parasuraman R, 2006, BJOG-INT J OBSTET GY, V113, P844, DOI 10.1111/j.1471-0528.2006.00964.x Patane S, 2010, INT J CARDIOL, V19, P145 Patanè S, 2010, INT J CARDIOL, V145, pE74, DOI 10.1016/j.ijcard.2008.12.159 Patterson E, 2006, J CARDIOVASC ELECTR, V17, P763, DOI 10.1111/j.1540-8167.2006.00507.x Pazianas M, 2010, J BONE MINER RES, V25, P2, DOI 10.1359/jbmr.091201 Perez-Verdia A, 2005, PHARMACOTHERAPY, V25, P1271, DOI 10.1592/phco.2005.25.9.1271 Petrella V, 1989, Minerva Med, V80, P305 Pfister DG, 2006, J CLIN ONCOL, V24, P1072, DOI 10.1200/JCO.2004.00.1792 Phillips GL, 2004, BIOL BLOOD MARROW TR, V10, P473, DOI 10.1016/j.bbmt.2004.03.001 POLDERMANS D, 1994, AM J CARDIOL, V73, P456, DOI 10.1016/0002-9149(94)90675-0 POLDERMANS D, 1994, ARCH INTERN MED, V154, P2681, DOI 10.1001/archinte.1994.00420230066008 POUKKULA A, 1989, J INTERN MED, V226, P229, DOI 10.1111/j.1365-2796.1989.tb01385.x PRATILA MG, 1982, MT SINAI J MED, V49, P130 QUEZADO ZMN, 1993, ANN INTERN MED, V118, P31, DOI 10.7326/0003-4819-118-1-199301010-00006 Ramanna H, 2001, J AM COLL CARDIOL, V37, P1403, DOI 10.1016/S0735-1097(01)01132-9 Reithmann C, 2003, EUR HEART J, V24, P1264, DOI 10.1016/S0195-668X(03)00233-1 Riccioni G, 2011, INT J IMMUNOPATH PH, V24, P247, DOI 10.1177/039463201102400131 Richards WG, 2006, J CLIN ONCOL, V24, P1561, DOI 10.1200/JCO.2005.04.6813 RIGOTTI NA, 1986, JAMA-J AM MED ASSOC, V255, P1018, DOI 10.1001/jama.255.8.1018 Roden DM, 2006, HANDB EXP PHARMACOL, V171, P73 ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501 ROZENTAL JM, 1989, CANCER, V63, P2475, DOI 10.1002/1097-0142(19890615)63:12<2475::AID-CNCR2820631219>3.0.CO;2-H Sampson KJ, 2008, J PHYSIOL-LONDON, V586, P627, DOI 10.1113/jphysiol.2007.141333 Sandor V, 2002, CLIN CANCER RES, V8, P718 Santini D, 2000, ANN ONCOL, V11, P479, DOI 10.1023/A:1008380208045 Schmidt M, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3450 Schneider RA, 2008, AM J HEALTH-SYST PH, V65, P2122, DOI 10.2146/ajhp070615 Schreiber DH, 2006, J EMERG MED, V31, P61, DOI 10.1016/j.jemermed.2005.08.011 Senkus E, 2011, CANCER TREAT REV, V37, P300, DOI 10.1016/j.ctrv.2010.11.001 Shaibani A, 2009, J PAIN, V10, P818, DOI 10.1016/j.jpain.2009.01.322 SHENASA M, 1988, AM J CARDIOL, V62, P403, DOI 10.1016/0002-9149(88)90967-8 Silverman AJ, 1996, AM J EMERG MED, V14, P300, DOI 10.1016/S0735-6757(96)90182-5 Sirohi B, 2000, BONE MARROW TRANSPL, V25, P533, DOI 10.1038/sj.bmt.1702188 Sorensen HT, 2008, BMJ-BRIT MED J, V336, P813, DOI 10.1136/bmj.39507.551644.BE STEWART PM, 1985, BRIT HEART J, V54, P222 Strickberger SA, 1997, ANN INTERN MED, V127, P417, DOI 10.7326/0003-4819-127-6-199709150-00001 Sueda S, 2001, AM J CARDIOL, V88, P570, DOI 10.1016/S0002-9149(01)01744-1 Sullivan ML, 1999, J EMERG MED, V17, P851, DOI 10.1016/S0736-4679(99)00095-5 Tamargo J, 2004, CARDIOVASC RES, V62, P9, DOI 10.1016/j.cardiores.2003.12.026 Tamargo J, 2006, EXPERT OPIN DRUG SAF, V5, P453, DOI 10.1517/14740338.5.3.453 Tavil Y, 2007, ONKOLOGIE, V30, P253, DOI 10.1159/000100930 Tomkowski WZ, 2004, SUPPORT CARE CANCER, V12, P53, DOI 10.1007/s00520-003-0533-x Tsimberidou AM, 2005, ANN ONCOL, V16, P139, DOI 10.1093/annonc/mdi007 UEDA N, 1988, PEDIATR NEPHROL, V2, P29, DOI 10.1007/BF00870376 van der Hooft CS, 2006, ARCH INTERN MED, V166, P1016, DOI 10.1001/archinte.166.9.1016 van der Hooft CS, 2004, J AM COLL CARDIOL, V44, P2117, DOI 10.1016/j.jacc.2004.08.053 VARKEY S, 1992, BRIT MED J, V304, P548, DOI 10.1136/bmj.304.6826.548-a VARRIALE P, 1993, PACE, V16, P1953, DOI 10.1111/j.1540-8159.1993.tb00987.x Veloso HH, 2005, EMERG MED J, V22, P823, DOI 10.1136/emj.2004.015982 Wahl A, 2004, EUR HEART J, V25, P1230, DOI 10.1016/j.ehj.2003.11.018 Waters BM, 2008, J CLIN PSYCHOPHARM, V28, P354, DOI 10.1097/JCP.0b013e318173082c WEISS RB, 1986, J CLIN ONCOL, V4, P918, DOI 10.1200/JCO.1986.4.6.918 WHITE RL, 1994, CANCER, V74, P3212, DOI 10.1002/1097-0142(19941215)74:12<3212::AID-CNCR2820741221>3.0.CO;2-I WHITE WB, 1985, ARCH GEN PSYCHIAT, V42, P424 WIRTZ CE, 1995, WESTERN J MED, V162, P268 Wooten M D, 2000, Del Med J, V72, P517 Yaylaci S, 2011, CLIN TOXICOL, V49, P440, DOI 10.3109/15563650.2011.588605 Yeh ETH, 2009, J AM COLL CARDIOL, V53, P2231, DOI 10.1016/j.jacc.2009.02.050 Zingler VC, 2005, EUR NEUROL, V54, P28, DOI 10.1159/000087242 NR 191 TC 26 Z9 32 U1 0 U2 9 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1474-0338 EI 1744-764X J9 EXPERT OPIN DRUG SAF JI Expert Opin. Drug Saf. PD JUL PY 2012 VL 11 IS 4 BP 615 EP 634 DI 10.1517/14740338.2012.698609 PG 20 WC Pharmacology & Pharmacy WE Science Citation Index Expanded (SCI-EXPANDED) SC Pharmacology & Pharmacy GA 964NB UT WOS:000305701300009 PM 22724662 DA 2026-04-17 ER PT J AU Wu, DH Xu, MY Mao, T Cao, H Wu, DJ Shen, YF AF Wu, De-hua Xu, Mei-ying Mao, Teng Cao, Hui Wu, Dong-jin Shen, Yao-feng TI Risk Factors for Intraoperative Atrial Fibrillation: A Retrospective Analysis of 10,563 Lung Operations in a Single Center SO ANNALS OF THORACIC SURGERY LA English DT Article ID NONCARDIAC THORACIC-SURGERY; CANCER; ARRHYTHMIAS; AGE AB Background. Risk factors of postoperative atrial fibrillation (AF) in patients undergoing general thoracic operations have been extensively studied. This study investigated risk factors for intraoperative AF. Identification of patients vulnerable for intraoperative AF during lung operations will benefit from improved preoperative and intraoperative management that will ultimately decrease intraoperative complications. This study retrospectively evaluated the risk factors for intraoperative AF during lung operations. Methods. Medical records of 10,638 patients who underwent lung operations from January 1, 2006, to May 20, 2011, at the Shanghai Chest Hospital were reviewed. The analysis excluded 75 patients with preoperative AF or nonsinus rhythm or who were taking antiarrhythmic drugs before the operation. The final analysis included 10,563 patients. Univariate and multivariate analyses were performed to identify risk factors for intraoperative AF. Results. The overall incidence of intraoperative AF was 3.27% (346 of 10,563). Multivariable logistic analysis identified increasing age, male sex, lung cancer, general anesthesia plus paravertebral block, open operation, resection of one or more lobes, and increased operation time as risk factors of intraoperative AF. In 40.73% of patients, intraoperative AF occurred during lymph node dissection. Conclusions. We identified seven risk factors for intraoperative AF in patients receiving lung operations. These findings may eventually help us to improve preoperative and intraoperative management to minimize intraoperative AF. (Ann Thorac Surg 2012;xx:xxx) (C) 2012 by The Society of Thoracic Surgeons C1 [Xu, Mei-ying] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Anesthesiol, Shanghai 200032, Peoples R China. Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Thorac Surg, Shanghai 200032, Peoples R China. C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University RP Xu, MY (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Anesthesiol, 241 Huaihai Rd, Shanghai 200032, Peoples R China. EM xumeiying1960@yahoo.cn OI Xu, Meiying/0000-0002-1085-3328 FU Shanghai Municipal Hospital Technology Joint Project Foundation [SHDC12010222]; Science and Technology Development Foundation of Shanghai Chest Hospital [YZ10-12] FX This work was supported by grants from Shanghai Municipal Hospital Technology Joint Project Foundation (SHDC12010222 to Mei-ying Xu) and Science and Technology Development Foundation of Shanghai Chest Hospital (YZ10-12 to Mei-ying Xu). We acknowledge the assistance of Drs Xiao-hua Ying (Department of Epidemiology and Public Health Medicine, Fudan University, Shanghai, China) and Jian-feng Luo (Department of Medical Statistics, Fudan University, Shanghai, China) with data analysis. CR Amar D, 2002, ANESTHESIOLOGY, V97, P1618, DOI 10.1097/00000542-200212000-00039 Amar D, 2002, ANESTHESIOLOGY, V96, P352, DOI 10.1097/00000542-200202000-00021 Amar D, 2005, CHEST, V128, P3421, DOI 10.1378/chest.128.5.3421 Amar D, 2006, ANN THORAC SURG, V82, P1057, DOI 10.1016/j.athoracsur.2006.03.103 Amar D, 2007, CURR OPIN ANESTHESIO, V20, P43, DOI 10.1097/ACO.0b013e32801158bb Angele MK, 2000, SHOCK, V14, P81, DOI 10.1097/00024382-200014020-00001 ASAMURA H, 1993, J THORAC CARDIOV SUR, V106, P1104, DOI 10.1016/S0022-5223(19)33985-6 Barbetakis Nikolaos, 2004, BMC Surg, V4, P7, DOI 10.1186/1471-2482-4-7 Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Cardinale D, 2007, CIRCULATION, V115, P1339, DOI 10.1161/CIRCULATIONAHA.106.647008 Dixit S, 2009, J AM COLL CARDIOL, V54, P2049, DOI 10.1016/j.jacc.2009.09.015 Dyszkiewicz W, 1998, EUR J CARDIO-THORAC, V13, P625, DOI 10.1016/S1010-7940(98)00084-0 Gómez-Caro A, 2006, ARCH BRONCONEUMOL, V42, P9, DOI 10.1016/S1579-2129(06)60107-9 Harpole DH, 1996, ANN THORAC SURG, V61, P977, DOI 10.1016/0003-4975(95)01174-9 Hollings DD, 2010, AM J SURG, V199, P558, DOI 10.1016/j.amjsurg.2009.11.006 Kimmerly DS, 2007, AM J PHYSIOL-REG I, V292, pR715, DOI 10.1152/ajpregu.00366.2006 Materazzo C, 2007, EUR J CARDIO-THORAC, V31, P812, DOI 10.1016/j.ejcts.2007.02.007 Mayson Sarah E, 2007, Cardiol Rev, V15, P231, DOI 10.1097/CRD.0b013e31813e62bb Messina M, 2009, MINERVA ANESTESIOL, V75, P616 Nugent AC, 2011, INT J PSYCHOPHYSIOL, V80, P182, DOI 10.1016/j.ijpsycho.2011.03.001 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Park BJ, 2007, J THORAC CARDIOV SUR, V133, P775, DOI 10.1016/j.jtcvs.2006.09.022 Polanczyk CA, 1998, ANN INTERN MED, V129, P279, DOI 10.7326/0003-4819-129-4-199808150-00003 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Sekine Y, 2001, CHEST, V120, P1783, DOI 10.1378/chest.120.6.1783 Shen J, 2009, INNOVATIONS, V4, P248, DOI 10.1097/imi.0b013e3181bb370f Tisdale JE, 2010, SEMIN THORAC CARDIOV, V22, P310, DOI 10.1053/j.semtcvs.2010.12.001 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Wu DH, 2012, ANN THORAC SURG, V94, P193, DOI 10.1016/j.athoracsur.2012.03.057 NR 29 TC 25 Z9 32 U1 0 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD JUL PY 2012 VL 94 IS 1 BP 193 EP 198 DI 10.1016/j.athoracsur.2012.03.057 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 965XS UT WOS:000305801600038 PM 22607788 DA 2026-04-17 ER PT J AU Ahluwalia, SC Gross, CP Chaudhry, SI Ning, YM Leo-Summers, L Van Ness, PH Fried, TR AF Ahluwalia, Sangeeta C. Gross, Cary P. Chaudhry, Sarwat I. Ning, Yuming M. Leo-Summers, Linda Van Ness, Peter H. Fried, Terri R. TI Impact of Comorbidity on Mortality Among Older Persons with Advanced Heart Failure SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE heart failure; mortality; comorbidity ID DIFFERENTIAL PROGNOSTIC IMPACT; CHRONIC KIDNEY-DISEASE; POPULATION; HOSPITALIZATIONS; ASSOCIATION; PREVALENCE; CANCER AB Care for patients with advanced heart failure (HF) has traditionally focused on managing HF alone; however, little is known about the prevalence and contribution of comorbidity to mortality among this population. We compared the impact of comorbidity on mortality in older adults with HF with high mortality risk and those with lower mortality risk, as defined by presence or absence of a prior hospitalization for HF, respectively. This was a retrospective cohort study (2002-2006) of 18,322 age-matched and gender-matched Medicare beneficiaries. We used the baseline year of 2002 to ascertain HF hospitalization history, in order to identify beneficiaries at either high or low risk of future HF mortality. We calculated the prevalence of 19 comorbidities and overall comorbidity burden, defined as a count of conditions, among both high and low risk beneficiaries, in 2002. Proportional hazards regressions were used to determine the effect of individual comorbidity and comorbidity burden on mortality between 2002 and 2006 among both groups. Most comorbidities were significantly more prevalent among hospitalized versus non-hospitalized beneficiaries; myocardial infarction, atrial fibrillation, kidney disease (CKD), chronic obstructive pulmonary disease (COPD), and hip fracture were more than twice as prevalent in the hospitalized group. Among hospitalized beneficiaries, myocardial infarction, diabetes, COPD, CKD, dementia, depression, hip fracture, stroke, colorectal cancer and lung cancer were each significantly associated with increased hazard of dying (hazard ratios [HRs]: 1.16-1.93), adjusting for age, gender and race. The mortality risk associated with most comorbidities was higher among non-hospitalized beneficiaries (HRs: 1.32-3.78). Comorbidity confers a significantly increased mortality risk even among older adults with an overall high mortality risk due to HF. Clinicians who routinely care for this population should consider the impact of comorbidity on outcomes in their overall management of HF. Such information may also be useful when considering the risks and benefits of aggressive, high-intensity life-prolonging interventions. C1 [Ahluwalia, Sangeeta C.] VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Provider Behav, Los Angeles, CA 90064 USA. [Gross, Cary P.; Chaudhry, Sarwat I.] Yale Univ, Sch Med, Dept Med, Gen Internal Med Sect, New Haven, CT 06510 USA. [Ning, Yuming M.; Leo-Summers, Linda; Van Ness, Peter H.] Yale Univ, Sch Med, Program Aging, New Haven, CT USA. [Van Ness, Peter H.; Fried, Terri R.] Yale Univ, Sch Med, Dept Internal Med, Sect Geriatr, New Haven, CT 06510 USA. [Fried, Terri R.] VA Connecticut Healthcare Syst, Clin Epidemiol Res Ctr, West Haven, CT USA. C3 US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; Yale University; Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System RP Ahluwalia, SC (corresponding author), VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Provider Behav, 11301 Wilshire Blvd 111-G, Los Angeles, CA 90064 USA. EM sangeeta.ahluwalia@va.gov FU National Institute on Aging [T32AG1934, K24 AG028443, K23AG030986]; Office of Academic Affiliation's VA at the VA Greater Los Angeles HSR&D Center of Excellence; Claude D. Pepper Older Americans Independence Center at Yale University School of Medicine (NIH/NIA) [2P30AG021342-06]; National Institute on Aging [P30AG021342] Funding Source: NIH RePORTER FX Dr. Ahluwalia was supported by a training grant from the National Institute on Aging (T32AG1934) and is currently supported by an Office of Academic Affiliation's VA Associated Health Postdoctoral Fellowship Program at the VA Greater Los Angeles HSR&D Center of Excellence. Dr. Fried is a recipient of a Midcareer Investigator Award in Patient-Oriented Research from the National Institute on Aging (K24 AG028443). Dr. Chaudhry is the recipient of a Paul Beeson/K23 Career Development Award (K23AG030986) from the National Institute on Aging. Supported by the Claude D. Pepper Older Americans Independence Center at Yale University School of Medicine (#2P30AG021342-06 NIH/NIA). CR Ahmed A, 2007, AM J CARDIOL, V99, P393, DOI 10.1016/j.amjcard.2006.08.042 Alho OP, 2007, HEAD NECK-J SCI SPEC, V29, P913, DOI 10.1002/hed.20608 Boyd CM, 2005, JAMA-J AM MED ASSOC, V294, P716, DOI 10.1001/jama.294.6.716 Braunstein JB, 2003, J AM COLL CARDIOL, V42, P1226, DOI 10.1016/S0735-1097(03)00947-1 Bruch C, 2007, INT J CARDIOL, V118, P375, DOI 10.1016/j.ijcard.2006.06.066 Cohen MB, 2007, AM J GERIATR CARDIOL, V16, P171, DOI 10.1111/j.1076-7460.2007.06563.x Corell P, 2007, EUR J HEART FAIL, V9, P258, DOI 10.1016/j.ejheart.2006.08.004 Dickstein K, 2006, EUR J HEART FAIL, V8, P74, DOI 10.1016/j.ejheart.2005.04.010 From AM, 2006, AM J MED, V119, P591, DOI 10.1016/j.amjmed.2006.05.024 Havranek EP, 2002, AM HEART J, V143, P412, DOI 10.1067/mhj.2002.120773 Jessup M, 2009, CIRCULATION, V119, P1977, DOI 10.1161/CIRCULATIONAHA.109.192064 Joynt KE, 2004, J CARD FAIL, V10, P258, DOI 10.1016/j.cardfail.2003.09.008 Klabunde CN, 2002, MED CARE, V40, P26 LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085 MacIntyre K, 2000, CIRCULATION, V102, P1126, DOI 10.1161/01.CIR.102.10.1126 Marengoni A, 2009, J AM GERIATR SOC, V57, P225, DOI 10.1111/j.1532-5415.2008.02109.x McCullough PA, 2002, J AM COLL CARDIOL, V39, P60, DOI 10.1016/S0735-1097(01)01700-4 Metra M, 2007, EUR J HEART FAIL, V9, P684, DOI 10.1016/j.ejheart.2007.04.003 Read WL, 2004, J CLIN ONCOL, V22, P3099, DOI 10.1200/JCO.2004.08.040 Rudiger A, 2005, EUR J HEART FAIL, V7, P662, DOI 10.1016/j.ejheart.2005.01.014 Rusinaru D, 2008, AM J CARDIOL, V101, P353, DOI 10.1016/j.amjcard.2007.08.046 Setoguchi S, 2007, AM HEART J, V154, P260, DOI 10.1016/j.ahj.2007.01.041 Setoguchi S, 2009, CAN MED ASSOC J, V180, P611, DOI 10.1503/cmaj.080769 Silverberg DS, 2006, SEMIN NEPHROL, V26, P296, DOI 10.1016/j.semnephrol.2006.05.006 Tetsche MS, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-31 NR 25 TC 69 Z9 82 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2012 VL 27 IS 5 BP 513 EP 519 DI 10.1007/s11606-011-1930-3 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC Health Care Sciences & Services; General & Internal Medicine GA 926YM UT WOS:000302869300009 PM 22095572 OA Green Submitted, Bronze DA 2026-04-17 ER PT J AU Anile, M Telha, V Diso, D De Giacomo, T Sciomer, S Rendina, EA Coloni, GF Venuta, F AF Anile, Marco Telha, Valbona Diso, Daniele De Giacomo, Tiziano Sciomer, Susanna Rendina, Erino Angelo Coloni, Giorgio Furio Venuta, Federico TI Left atrial size predicts the onset of atrial fibrillation after major pulmonary resections SO EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY LA English DT Article DE Atrial fibrillation; Pulmonary resection; Echocardiography ID NONCARDIAC THORACIC-SURGERY; LUNG-CANCER; RISK-FACTORS; SUPRAVENTRICULAR ARRHYTHMIAS; PROGNOSTIC-SIGNIFICANCE; MORTALITY; SOCIETY; VEINS AB Atrial fibrillation (AF) is a frequent complication after pulmonary resections. Notwithstanding prevention and early treatment it may show a negative impact on the outcome. We assessed the role of echocardiographic variables to predict the onset of this complication. One-hundred and thirty-four patients were prospectively evaluated: 72 (53.7%) (Group I) underwent lobectomy or pneumonectomy; 62 (46.3%) receiving minor thoracic procedures were included in Group II. Previous AF was the only exclusion criteria. All patients preoperatively underwent bidimensional echocardiography. Demographics, type of resection, histology, staging, diagnosis of chronic obstructive pulmonary disease , induction chemotherapy, smoking history, magnesium levels, other cardiologic diseases, electrocardiographic and echocardiographic findings (atrial and ventricular diameters, left atrial area, left ventricular ejection fraction and diastolic dysfunction) were assessed. Preoperative variables did no't show any statistically significant difference between the groups. In 21 patients (15.7%) AF was observed 3.7 +/- 1.8 days after surgery. All AF episodes occurred in Group I. Three patients (2.2%) with AF died during the postoperative course. The left atrial diameter and area were significantly enlarged in patients with AF (P = 0.001 and P < 0.0002); 18 AF episodes (86%) occurred in patients with atrial enlargement. At univariate analysis low postoperative magnesium levels, LV diastolic dysfunction, left atrial antero-posterior diameter > 40 mm, left atrial area above 20 mm(2) and extended resections were statistically significant. At multivariate analysis only left atrial area enlargement was an independent predictive prognostic factor for postoperative AF. Echocardiograpic left atrial size evaluation may be useful to predict the onset of postoperative AF in patients undergoing lobectomy and pneumonectomy. C1 [Venuta, Federico] Univ Roma La Sapienza, Policlin Umberto I, Fdn Eleonora Lorillard Spencer Cenci, Cattedra Chirurg Toracica,Dept Thorac Surg, Rome, Italy. C3 Sapienza University Rome; University Hospital Sapienza Rome RP Venuta, F (corresponding author), Univ Roma La Sapienza, Policlin Umberto I, Fdn Eleonora Lorillard Spencer Cenci, Cattedra Chirurg Toracica,Dept Thorac Surg, Rome, Italy. EM federico.venuta@uniroma1.it RI Rendina, Erino/AAG-7598-2021; anile, marco/JXM-4235-2024; De Giacomo, Tiziano/M-6722-2015; Diso, Daniele/AAI-7101-2020 OI Venuta, Federico/0000-0001-9296-877X; De Giacomo, Tiziano/0000-0003-1061-5773; Diso, Daniele/0000-0002-4514-0678; Sciomer, Susanna/0000-0001-9487-833X CR Amar D, 2002, ANESTHESIOLOGY, V96, P352, DOI 10.1097/00000542-200202000-00021 ASAMURA H, 1993, J THORAC CARDIOV SUR, V106, P1104, DOI 10.1016/S0022-5223(19)33985-6 Brathwaite D, 1998, CHEST, V114, P462, DOI 10.1378/chest.114.2.462 Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Dyszkiewicz W, 1998, EUR J CARDIO-THORAC, V13, P625, DOI 10.1016/S1010-7940(98)00084-0 Haïssaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003 Hassink RJ, 2003, J AM COLL CARDIOL, V42, P1108, DOI 10.1016/S0735-1097(03)00918-5 KROWKA MJ, 1987, CHEST, V91, P490, DOI 10.1378/chest.91.4.490 Lang RM, 2005, J AM SOC ECHOCARDIOG, V18, P1440, DOI 10.1016/j.echo.2005.10.005 Nagarakanti R, 2008, J INTERV CARD ELECTR, V22, P111, DOI 10.1007/s10840-008-9203-8 Nojiri T, 2010, J THORAC CARDIOV SUR, V140, P764, DOI 10.1016/j.jtcvs.2009.11.073 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Osranek M, 2006, J AM COLL CARDIOL, V48, P779, DOI 10.1016/j.jacc.2006.03.054 Passman RS, 2005, ANN THORAC SURG, V79, P1698, DOI 10.1016/j.athoracsur.2004.10.058 Polanczyk CA, 1998, ANN INTERN MED, V129, P279, DOI 10.7326/0003-4819-129-4-199808150-00003 Rena O, 2001, EUR J CARDIO-THORAC, V20, P688, DOI 10.1016/S1010-7940(01)00890-9 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Sekine Y, 2001, CHEST, V120, P1783, DOI 10.1378/chest.120.6.1783 TAYLOR GJ, 1987, AM J CARDIOL, V60, P905, DOI 10.1016/0002-9149(87)91045-9 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Venuta F, 2007, EUR J CARDIO-THORAC, V32, P787, DOI 10.1016/j.ejcts.2007.07.033 Venuta F, 2007, EUR J CARDIO-THORAC, V31, P714, DOI 10.1016/j.ejcts.2007.01.017 NR 22 TC 23 Z9 24 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1010-7940 J9 EUR J CARDIO-THORAC JI Eur. J. Cardio-Thorac. Surg. PD MAY PY 2012 VL 41 IS 5 BP 1094 EP 1097 DI 10.1093/ejcts/ezr174 PG 4 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 930TA UT WOS:000303161800037 PM 22219455 OA Bronze DA 2026-04-17 ER PT J AU Bert, C Engenhart-Cabillic, R Durante, M AF Bert, Christoph Engenhart-Cabillic, Rita Durante, Marco TI Particle therapy for noncancer diseases SO MEDICAL PHYSICS LA English DT Article DE biomedical equipment; cancer; radiation therapy; tumours ID CARBON ION RADIOTHERAPY; PROTON-BEAM THERAPY; CELL LUNG-CANCER; STEREOTACTIC RADIOSURGERY; RADIATION-THERAPY; HEPATOCELLULAR-CARCINOMA; RESPIRATORY MOTION; MOVING TARGETS; MONTE-CARLO; VERIFICATION AB Radiation therapy using high-energy charged particles is generally acknowledged as a powerful new technique in cancer treatment. However, particle therapy in oncology is still controversial, specifically because it is unclear whether the putative clinical advantages justify the high additional costs. However, particle therapy can find important applications in the management of noncancer diseases, especially in radiosurgery. Extension to other diseases and targets (both cranial and extracranial) may widen the applications of the technique and decrease the cost/benefit ratio of the accelerator facilities. Future challenges in this field include the use of different particles and energies, motion management in particle body radiotherapy and extension to new targets currently treated by catheter ablation (atrial fibrillation and renal denervation) or stereotactic radiation therapy (trigeminal neuralgia, epilepsy, and macular degeneration). Particle body radiosurgery could be a future key application of accelerator-based particle therapy facilities in 10 years from today. (C) 2012 American Association of Physicists in Medicine. [http://dx.doi.org/10.1118/1.3691903] C1 [Bert, Christoph; Durante, Marco] GSI Helmholtzzentrum Schwerionenforsch, Dept Biophys, D-64291 Darmstadt, Germany. [Durante, Marco] Tech Univ Darmstadt, Inst Festkorperphys, D-64289 Darmstadt, Germany. [Durante, Marco] Goethe Univ Frankfurt, Frankfurt Inst Adv Studies, D-60438 Frankfurt, Germany. [Engenhart-Cabillic, Rita] Univ Marburg, Ctr Radiol, Dept Radiat Therapy, D-35043 Marburg, Germany. C3 Helmholtz Association; GSI Helmholtz-Center for Heavy Ion Research; Technical University of Darmstadt; Goethe University Frankfurt; Philipps University Marburg RP Durante, M (corresponding author), GSI Helmholtzzentrum Schwerionenforsch, Dept Biophys, Planckstr 1, D-64291 Darmstadt, Germany. EM m.durante@gsi.de RI Bert, Christoph/C-2585-2013; Durante, Marco/K-1315-2014 OI Bert, Christoph/0000-0002-8539-6600; Durante, Marco/0000-0002-4615-553X FU SIEMENS AG; EU FX Research on particle therapy at GSI is partly supported by SIEMENS AG and EU FP7 project ULICE and ENVISION. CR Abrosimov N. K., 2006, Journal of Physics: Conference Series, V41, P424, DOI 10.1088/1742-6596/41/1/047 Amino M, 2006, CARDIOVASC RES, V72, P412, DOI 10.1016/j.cardiores.2006.09.010 Amino M, 2010, AM J PHYSIOL-HEART C, V298, pH1014, DOI 10.1152/ajpheart.00160.2009 Andisheh B, 2009, J NEUROSURG, V111, P919, DOI 10.3171/2007.10.17205 Aoka Y, 2004, LANCET ONCOL, V5, P636, DOI 10.1016/S1470-2045(04)01600-6 Aubuchon AC, 2011, INT J RADIAT ONCOL, V81, P1059, DOI 10.1016/j.ijrobp.2010.07.010 Barker FG, 2003, J NEUROSURG, V99, P254, DOI 10.3171/jns.2003.99.2.0254 Benedict SH, 2008, MED PHYS, V35, P4262, DOI 10.1118/1.2969268 Bert C, 2011, PHYS MED BIOL, V56, pR113, DOI 10.1088/0031-9155/56/16/R01 Bert C, 2008, PHYS MED BIOL, V53, P2253, DOI 10.1088/0031-9155/53/9/003 Bert C, 2007, RADIAT ONCOL, V2, DOI 10.1186/1748-717X-2-24 Bert C, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-61 Bertucci A, 2007, RADIAT ENVIRON BIOPH, V46, P107, DOI 10.1007/s00411-006-0088-6 Biederer J, 2003, RADIOLOGY, V226, P250, DOI 10.1148/radiol.2261011275 Brada M, 2009, CANCER J, V15, P319, DOI 10.1097/PPO.0b013e3181b6127c Brahme A., 2004, INT J RADIAT ONCOL, V58, P203 Bush DA, 2004, CHEST, V126, P1198, DOI 10.1378/chest.126.4.1198 Chalam KV, 2011, RETINA-J RET VIT DIS, V31, P169, DOI 10.1097/IAE.0b013e3181dee621 Chang EF, 2010, NEUROLOGY, V74, P165, DOI 10.1212/WNL.0b013e3181c9185d Cheema A, 2006, J INTERV CARD ELECTR, V15, P145, DOI 10.1007/s10840-006-9005-9 Chen Clark C, 2007, Neurosurg Focus, V23, pE5 Chiba T, 2005, CLIN CANCER RES, V11, P3799, DOI 10.1158/1078-0432.CCR-04-1350 Chong BW, 2007, SEMIN NEUROL, V27, P385, DOI 10.1055/s-2007-985339 Clery D, 2010, SCIENCE, V327, P142, DOI 10.1126/science.327.5962.142 Depauw N, 2011, PHYS MED BIOL, V56, P2407, DOI 10.1088/0031-9155/56/8/006 Dieterich S, 2008, MED PHYS, V35, P5684, DOI 10.1118/1.3020593 Dropcho EJ, 2010, NEUROL CLIN, V28, P217, DOI 10.1016/j.ncl.2009.09.008 Durante M, 2008, NAT REV CANCER, V8, P465, DOI 10.1038/nrc2391 Durante M, 2011, REV MOD PHYS, V83, P1245, DOI 10.1103/RevModPhys.83.1245 Durante M, 2010, NAT REV CLIN ONCOL, V7, P37, DOI 10.1038/nrclinonc.2009.183 Eckermann M., 2011, PTCOG 50 2011 Elsässer T, 2010, INT J RADIAT ONCOL, V78, P1177, DOI 10.1016/j.ijrobp.2010.05.014 Esler MD, 2010, LANCET, V376, P1903, DOI 10.1016/S0140-6736(10)62039-9 Fenwick JD, 2006, SEMIN RADIAT ONCOL, V16, P199, DOI 10.1016/j.semradonc.2006.04.002 Followill DS, 2007, MED PHYS, V34, P2070, DOI 10.1118/1.2737158 Friberg S, 2009, ACTA ONCOL, V48, P822, DOI 10.1080/02841860902824917 Fuster V, 2006, EUROPACE, V8, P651, DOI 10.1093/europace/eul097 Gertner M, 2010, MED PHYS, V37, P600, DOI 10.1118/1.3291648 Hahn SM, 2009, RETINA-J RET VIT DIS, V29, pS30, DOI 10.1097/IAE.0b013e3181ad2692 Halperin EC, 2006, LANCET ONCOL, V7, P676, DOI 10.1016/S1470-2045(06)70795-1 Han B, 2011, MED PHYS, V38, P1903, DOI 10.1118/1.3555039 Hanlon J, 2009, MED PHYS, V36, P3671, DOI 10.1118/1.3168554 Jäkel O, 2008, MED PHYS, V35, P5653, DOI 10.1118/1.3002307 Jones GC, 2011, CASE REP MED, V2011, DOI 10.1155/2011/258910 Kato H, 2004, INT J RADIAT ONCOL, V59, P1468, DOI 10.1016/j.ijrobp.2004.01.032 KJELLBERG RN, 1983, NEW ENGL J MED, V309, P269, DOI 10.1056/NEJM198308043090503 KOEHLER AM, 1968, SCIENCE, V160, P303, DOI 10.1126/science.160.3825.303 Koto M, 2004, RADIOTHER ONCOL, V71, P147, DOI 10.1016/j.radonc.2004.02.007 Kraft G, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/2/025001 LARSSON B, 1958, NATURE, V182, P1222, DOI 10.1038/1821222a0 LEKSELL D, 1989, NEUROSURGERY, V24, P297 LEVY RP, 1989, NEUROSURGERY, V24, P841, DOI 10.1227/00006123-198906000-00009 Liao ZX, 2011, ACTA ONCOL, V50, P745, DOI 10.3109/0284186X.2011.590148 Lopez BC, 2004, J NEUROL NEUROSUR PS, V75, P1019, DOI 10.1136/jnnp.2003.018564 Luumlchtenborg R, 2011, MED PHYS, V38, P5448, DOI 10.1118/1.3633891 Merchant TE, 2009, CANCER J, V15, P298, DOI 10.1097/PPO.0b013e3181b6d4b7 Merrill FE, 2009, AIP CONF PROC, V1195, P667 Minohara S, 2000, INT J RADIAT ONCOL, V47, P1097, DOI 10.1016/S0360-3016(00)00524-1 Miyamoto T, 2003, RADIOTHER ONCOL, V66, P127, DOI 10.1016/S0167-8140(02)00367-5 Miyamoto T, 2007, J THORAC ONCOL, V2, P916, DOI 10.1097/JTO.0b013e3181560a68 Mori S, 2007, INT J RADIAT ONCOL, V69, P308, DOI 10.1016/j.ijrobp.2007.05.018 Newhauser WD, 2011, NAT REV CANCER, V11, P438, DOI 10.1038/nrc3069 Niranjan Ajay, 2008, Prog Neurol Surg, V21, P32, DOI 10.1159/000156557 Nomiya T, 2008, INT J RADIAT ONCOL, V72, P828, DOI 10.1016/j.ijrobp.2008.01.043 Okada T, 2010, J RADIAT RES, V51, P355, DOI 10.1269/jrr.10016 Paganetti H, 2005, MED PHYS, V32, P2548, DOI 10.1118/1.1949807 Parodi K, 2009, MED PHYS, V36, P4230, DOI 10.1118/1.3196236 Paulis L, 2010, NAT REV CARDIOL, V7, P431, DOI 10.1038/nrcardio.2010.85 Petrarca R, 2011, CLIN OPHTHALMOL, V5, P57, DOI 10.2147/OPTH.S16444 PHILLIPS MH, 1992, PHYS MED BIOL, V37, P223, DOI 10.1088/0031-9155/37/1/016 Pommier P, 2010, RADIOTHER ONCOL, V96, P243, DOI 10.1016/j.radonc.2010.04.010 Quigg M, 2008, ARCH NEUROL-CHICAGO, V65, P177, DOI 10.1001/archneurol.2007.40 Rietzel E, 2010, MED PHYS, V37, P449, DOI 10.1118/1.3250856 Rigg PA, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.220101 Sadowski J, 2011, HYPERTENSION, V57, P911, DOI 10.1161/HYPERTENSIONAHA.110.163014 Saito N, 2009, PHYS MED BIOL, V54, P4849, DOI 10.1088/0031-9155/54/16/001 Schardt D, 2010, REV MOD PHYS, V82, P383, DOI 10.1103/RevModPhys.82.383 Schippers JM, 2011, ACTA ONCOL, V50, P838, DOI 10.3109/0284186X.2011.582513 Schulz-Ertner D, 2007, J CLIN ONCOL, V25, P953, DOI 10.1200/JCO.2006.09.7816 Schwartz TH, 2010, EPILEPSY CURR, V10, P150, DOI 10.1111/j.1535-7511.2010.01385.x Seco J, 2011, MED PHYS, V38, P622, DOI 10.1118/1.3496327 SEIFERT V, 1994, J NEUROSURG, V81, P683, DOI 10.3171/jns.1994.81.5.0683 Sharma A, 2010, HEART RHYTHM, V7, P802, DOI 10.1016/j.hrthm.2010.02.010 Silander H, 2004, ACTA NEUROL SCAND, V109, P85, DOI 10.1046/j.1600-0404.2003.00154.x Smeenk RJ, 2010, RADIOTHER ONCOL, V95, P277, DOI 10.1016/j.radonc.2010.04.016 Smith AR, 2009, MED PHYS, V36, P556, DOI 10.1118/1.3058485 STEINBERG GK, 1990, NEW ENGL J MED, V323, P96, DOI 10.1056/NEJM199007123230205 Suit H, 2008, RADIOTHER ONCOL, V86, P148, DOI 10.1016/j.radonc.2007.12.024 Suit H, 2010, RADIOTHER ONCOL, V95, P3, DOI 10.1016/j.radonc.2010.01.015 Sullivan RM, 2010, HEART RHYTHM, V7, P811, DOI 10.1016/j.hrthm.2010.02.033 SURAMO I, 1984, ACTA RADIOL DIAGN, V25, P129, DOI 10.1177/028418518402500208 Terasawa T, 2009, ANN INTERN MED, V151, P556, DOI 10.7326/0003-4819-151-8-200910200-00145 Terasawa T, 2009, ANN INTERN MED, V151, P191, DOI 10.7326/0003-4819-151-3-200908040-00131 Tipton K, 2011, ANN INTERN MED, V154, P737, DOI 10.7326/0003-4819-154-11-201106070-00343 TOBIAS CA, 1985, RADIAT RES, V103, P1, DOI 10.2307/3576668 Tsuji H, 2005, INT J RADIAT ONCOL, V63, P1153, DOI 10.1016/j.ijrobp.2005.04.022 URIE M, 1984, PHYS MED BIOL, V29, P553, DOI 10.1088/0031-9155/29/5/008 Vatnitsky SM, 1999, PHYS MED BIOL, V44, P2789, DOI 10.1088/0031-9155/44/11/308 Vernimmen FJAI, 2005, INT J RADIAT ONCOL, V62, P44, DOI 10.1016/j.ijrobp.2004.09.008 Vinogradskiy YY, 2009, MED PHYS, V36, P3438, DOI 10.1118/1.3157233 Yang HY, 2011, INT J RADIAT BIOL, V87, P311, DOI 10.3109/09553002.2010.537431 Yuan A, 2011, SEMIN OPHTHALMOL, V26, P149, DOI 10.3109/08820538.2011.570846 Zakrzewska J M., 2009, BMJ Clinical Evidence, V2009, P1207 Zambarakji HJ, 2006, OPHTHALMOLOGY, V113, P2012, DOI 10.1016/j.ophtha.2006.05.036 Zenklusen SM, 2010, PHYS MED BIOL, V55, P5103, DOI 10.1088/0031-9155/55/17/014 NR 105 TC 46 Z9 51 U1 1 U2 16 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0094-2405 EI 2473-4209 J9 MED PHYS JI Med. Phys. PD APR PY 2012 VL 39 IS 4 BP 1716 EP 1727 DI 10.1118/1.3691903 PG 12 WC Radiology, Nuclear Medicine & Medical Imaging WE Science Citation Index Expanded (SCI-EXPANDED) SC Radiology, Nuclear Medicine & Medical Imaging GA 919ZY UT WOS:000302371900005 PM 22482597 OA Bronze DA 2026-04-17 ER PT J AU Mitchell, JD Yu, JA Bishop, A Weyant, MJ Pomerantz, M AF Mitchell, John D. Yu, Jessica A. Bishop, Amy Weyant, Michael J. Pomerantz, Marvin TI Thoracoscopic Lobectomy and Segmentectomy for Infectious Lung Disease SO ANNALS OF THORACIC SURGERY LA English DT Article; Proceedings Paper CT 47th Annual Meeting of the Society-of-Thoracic-Surgeons / Surgical Motion Picture Session CY JAN 31-FEB 02, 2011 CL San Diego, CA SP Soc Thorac Surg ID ASSISTED THORACIC-SURGERY; SURGICAL-MANAGEMENT; LOWER MORBIDITY; RESECTION; BRONCHIECTASIS; CHEMOTHERAPY; EXPERIENCE; SAFE AB Background. The potential benefits of thoracoscopic lobectomy and segmentectomy for early stage non small cell lung cancer have been well documented in the literature. However, little is known about the use of these techniques in patients requiring resection for infectious or inflammatory lung disease. Methods. Using a prospectively collected database, we performed a retrospective review of consecutive operations from July 2004 to June 2010. All patients who underwent elective thoracoscopic lobectomy or segmentectomy for focal bronchiectasis or cavitary lung disease associated with active pulmonary infection were included. Results. In all, 212 resections were performed in 171 patients. The average age was 59 years (range, 26 to 82 years). Patients were predominately white (93%) and female (93%). Indications for surgery included recurrent active infection, hemoptysis, or antibiotic intolerance associated with focal bronchiectasis (86%), cavitary disease (7%), or both (7%). Operations included 126 lobectomies, 73 segmentectomies, 10 lobe plus segmental resections, and 3 bilobectomies. Conversion to thoracotomy occurred in 10 patients. The operative mortality rate was zero. Complications occurred in 9%, consisting largely of prolonged air leak and atrial fibrillation. The mean hospital length of stay was 3.7 days. Conclusions. Thoracoscopic lobectomy and segmentectomy for individuals with infectious lung disease can be accomplished safely with minimal morbidity and mortality. These techniques may provide the optimal surgical approach for patients with focal bronchiectasis or cavitary lung disease requiring resection. (Ann Thorac Surg 2012;93:1033-40) (C) 2012 by The Society of Thoracic Surgeons C1 [Mitchell, John D.] Univ Colorado, Div Cardiothorac Surg, Sch Med, Ctr Surg Treatment Lung Infect, Aurora, CO 80045 USA. Univ Colorado, Sect Gen Thorac Surg, Sch Med, Aurora, CO 80045 USA. C3 University of Colorado System; University of Colorado Anschutz; University of Colorado System; University of Colorado Anschutz RP Mitchell, JD (corresponding author), Univ Colorado, Div Cardiothorac Surg, Sch Med, Ctr Surg Treatment Lung Infect, C-310,Anschutz Med Campus,Acad Off 1,Room 6607,12, Aurora, CO 80045 USA. EM john.mitchell@ucdenver.edu CR Atkins BZ, 2007, ANN THORAC SURG, V84, P1107, DOI 10.1016/j.athoracsur.2007.05.013 Balkanli K, 2003, EUR J CARDIO-THORAC, V24, P699, DOI 10.1016/S1010-7940(03)00497-4 Burfeind WR, 2010, EUR J CARDIO-THORAC, V37, P827, DOI 10.1016/j.ejcts.2009.10.017 Eren S, 2007, J THORAC CARDIOV SUR, V134, P392, DOI 10.1016/j.jtcvs.2007.04.024 Fujimoto T, 2001, ANN THORAC SURG, V72, P1711, DOI 10.1016/S0003-4975(01)03085-5 Griffith DE, 2007, AM J RESP CRIT CARE, V175, P367, DOI 10.1164/rccm.200604-571ST Hartwig MG, 2010, ANN THORAC SURG, V89, pS2098, DOI 10.1016/j.athoracsur.2010.02.102 Lee JG, 2011, ANN THORAC SURG, V91, P344, DOI 10.1016/j.athoracsur.2010.09.031 Leshnower BG, 2010, ANN THORAC SURG, V89, P1571, DOI 10.1016/j.athoracsur.2010.01.061 McKenna RJ, 2006, ANN THORAC SURG, V81, P421, DOI 10.1016/j.athoracsur.2005.07.078 Mitchell JD, 2008, ANN THORAC SURG, V85, P1887, DOI 10.1016/j.athoracsur.2008.02.041 O'Donnell AE, 2008, CHEST, V134, P815, DOI 10.1378/chest.08-0776 Onaitis MW, 2006, ANN SURG, V244, P420, DOI 10.1097/01.sla.0000234892.79056.63 Paul S, 2010, J THORAC CARDIOV SUR, V139, P366, DOI 10.1016/j.jtcvs.2009.08.026 Petersen RP, 2007, ANN THORAC SURG, V83, P1245, DOI 10.1016/j.athoracsur.2006.12.029 Prieto D, 2001, EUR J CARDIO-THORAC, V20, P19, DOI 10.1016/S1010-7940(01)00746-1 Villamizar NR, 2009, J THORAC CARDIOV SUR, V138, P419, DOI 10.1016/j.jtcvs.2009.04.026 Watanabe M, 2006, ANN THORAC SURG, V81, P2026, DOI 10.1016/j.athoracsur.2006.01.031 Weber A, 2001, EUR J CARDIO-THORAC, V20, P443, DOI 10.1016/S1010-7940(01)00689-3 Zhang P, 2011, ANN THORAC SURG, V91, P239, DOI 10.1016/j.athoracsur.2010.08.035 Zhang P, 2010, ANN THORAC SURG, V90, P246, DOI 10.1016/j.athoracsur.2010.03.064 NR 21 TC 58 Z9 65 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD APR PY 2012 VL 93 IS 4 BP 1033 EP 1040 DI 10.1016/j.athoracsur.2012.01.012 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 916RF UT WOS:000302120200014 PM 22386091 DA 2026-04-17 ER PT J AU Wu, JP Wu, Q Yang, Y Du, ZZ Sun, HF AF Wu Jun-ping Wu Qi Yang Yang Du Zhong-zhen Sun Hong-fen TI Idiopathic pulmonary vein thrombosis extending to left atrium: a case report with a literature review SO CHINESE MEDICAL JOURNAL LA English DT Article DE pulmonary vein thrombosis; left atrium mass ID LUNG TRANSPLANTATION AB Pulmonary vein thrombosis is a rare disease and is usually represented as a complication of atrial fibrillation, pulmonary tumors, and lobectomy. Although it is a potentially life threatening condition, the venous disease is easy to misdiagnose because of the non-specific symptoms. In this article, we present a 30-year-old patient who suffered from pulmonary vein thrombosis without any causes. He was diagnosed with other pulmonary disorders till the thrombus within the pulmonary vein extended into the left atrium. Left atrium mass resection and a left lower lobectomy were undertaken with relative urgency. The postoperative course was uneventful. The patient received a long course of oral anticoagulant therapy. Chin Med J 2012;125(5):1197-1200 C1 [Wu Jun-ping; Wu Qi; Yang Yang; Du Zhong-zhen; Sun Hong-fen] Tianjin Hai He Hosp, Div Pulm Med, Tianjin Inst Resp Dis, Tianjin 300350, Peoples R China. C3 Tianjin University RP Wu, Q (corresponding author), Tianjin Hai He Hosp, Div Pulm Med, Tianjin Inst Resp Dis, Tianjin 300350, Peoples R China. EM wqw572004@yahoo.com.cn CR Alexander GR, 2009, ANN THORAC SURG, V88, P281, DOI 10.1016/j.athoracsur.2008.09.061 Cavaco RA, 2009, CASES J, V9156, P1 Cywinski JB, 2005, J CARDIOTHOR VASC AN, V19, P225, DOI 10.1053/j.jvca.2005.01.004 DYE TE, 1977, J THORAC CARDIOV SUR, V74, P137 GYVESRAY KM, 1987, AM J ROENTGENOL, V148, P1079, DOI 10.2214/ajr.148.6.1079 HOVAGUIMIAN H, 1991, CHEST, V99, P1515, DOI 10.1378/chest.99.6.1515 KIM NH, 1993, CHEST, V104, P624, DOI 10.1378/chest.104.2.624 MichelCherqui M, 1997, CHEST, V111, P1229, DOI 10.1378/chest.111.5.1229 Mumoli N, 2010, J EMERG MED SARSAM MAI, 1993, J HEART LUNG TRANSPL, V12, P17 Schulman LL, 2001, J AM SOC ECHOCARDIOG, V14, P806, DOI 10.1067/mje.2001.111855 Selvidge SDD, 1999, AM J ROENTGENOL, V172, P1639, DOI 10.2214/ajr.172.6.10350306 WILLIAMSON WA, 1992, CHEST, V102, P937, DOI 10.1378/chest.102.3.937 Wyatt RI, 1953, AM J PATHOL, V29, P291 NR 14 TC 14 Z9 17 U1 0 U2 0 PU CHINESE MEDICAL ASSOC PI BEIJING PA 42 DONGSI XIDAJIE, BEIJING 100710, PEOPLES R CHINA SN 0366-6999 J9 CHINESE MED J-PEKING JI Chin. Med. J. PD MAR 20 PY 2012 VL 125 IS 6 BP 1197 EP 1200 DI 10.3760/cma.j.issn.0366-6999.2012.06.043 PG 4 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA 927BS UT WOS:000302882500045 PM 22613556 DA 2026-04-17 ER PT J AU Wendler, A Wehling, M AF Wendler, Alexandra Wehling, Martin TI Translatability scoring in drug development: eight case studies SO JOURNAL OF TRANSLATIONAL MEDICINE LA English DT Article DE Dabigatran; Ipilimumab; Gefitinib; Vilazodone; Latrepirdine; Semagacestat; Translatability Score; Translational medicine; Drug development ID CELL LUNG-CANCER; RECEPTOR TYROSINE KINASE; GAMMA-SECRETASE INHIBITOR; SEROTONIN-REUPTAKE INHIBITOR; NONVALVULAR ATRIAL-FIBRILLATION; PREVIOUSLY TREATED PATIENTS; MAJOR DEPRESSIVE DISORDER; DIRECT THROMBIN INHIBITOR; ALZHEIMERS-DISEASE; METASTATIC MELANOMA AB Translational medicine describes the transfer of basic in vitro and in vivo data into human applications. In the light of low rates of market approvals for new medical entities, better strategies to predict the risk of drug development should be used to increase output and reduce costs. Recently, a scoring system to assess the translatability of early drug projects has been proposed. Here eight drugs from different therapeutic areas have been subjected to a retrospective test-run in this system fictively located at the phase II-III transition. The scores gained here underline the importance of biomarker quality which is pivotal to decrease the risk of the project in all cases. This is particularly evident for gefitinib. The EGFR mutation status is a breakthrough biomarker to predict therapeutic success which made this compound clinically acceptable, and this is plausibly reflected by a considerable increase of the translatability score. For psychiatric and Alzheimer's drugs, and for a CETP-inhibitor, the lack of suitable biomarkers and animal models is reflected by a low translatability score, well correlating with the excessive translational risk in these areas. These case studies document the apparent utility of the scoring system, at least under retrospective conditions, as the scores correlate with the outcomes at the level of market approval. Prospective validation is still missing, but these case studies are encouraging. C1 [Wendler, Alexandra; Wehling, Martin] Heidelberg Univ, Fac Med Mannheim, Inst Expt & Clin Pharmacol & Toxicol Clin Pharmac, D-68169 Mannheim, Germany. C3 Ruprecht Karls University Heidelberg RP Wehling, M (corresponding author), Heidelberg Univ, Fac Med Mannheim, Inst Expt & Clin Pharmacol & Toxicol Clin Pharmac, Maybachstr 14, D-68169 Mannheim, Germany. EM martin.wehling@medma.uni-heidelberg.de FU Sanofi-Aventis; Novartis; Takeda; Roche; Pfizer; Bristol-Myers; Daichii-Sankyo; Lilly; Novo-Nordisk FX AW has nothing to declare. MW was employed by AstraZeneca R&D, Mlndal, as director of discovery medicine (= translational medicine) from 2004-2006, while on sabbatical leave from his professorship at the University of Heidelberg. After return to this position in January 2007, he received lecturing and consulting fees from Sanofi-Aventis, Novartis, Takeda, Roche, Pfizer, Bristol-Myers, Daichii-Sankyo, Lilly and Novo-Nordisk. CR Adamec R, 2004, EUR J PHARMACOL, V504, P65, DOI 10.1016/j.ejphar.2004.09.009 Agarwala SS, 2010, MELANOMA RES, V20, P1, DOI 10.1097/CMR.0b013e328333bbc8 Agarwala SS, 2009, EXPERT REV ANTICANC, V9, P587, DOI 10.1586/ERA.09.25 [Anonymous], ANN N Y ACAD SCI Artigas F, 1996, TRENDS NEUROSCI, V19, P378, DOI 10.1016/S0166-2236(96)10037-0 Attia P, 2005, J CLIN ONCOL, V23, P6043, DOI 10.1200/JCO.2005.06.205 Bachurin S, 2001, ANN NY ACAD SCI, V939, P425 Bachurin SO, 2003, ANN NY ACAD SCI, V993, P334, DOI 10.1111/j.1749-6632.2003.tb07541.x Ballard C, 2011, LANCET, V377, P1019, DOI 10.1016/S0140-6736(10)61349-9 Barber RC, 2010, J AM OSTEOPATH ASSOC, V110, pS10 Bartoszyk GD, 1997, EUR J PHARMACOL, V322, P147, DOI 10.1016/S0014-2999(96)00999-5 Baselga J, 2002, J CLIN ONCOL, V20, P4292, DOI 10.1200/JCO.2002.03.100 Berk M, 1997, INT CLIN PSYCHOPHARM, V12, P137, DOI 10.1097/00004850-199705000-00003 Blier P, 1997, INT CLIN PSYCHOPHARM, V12, pS21, DOI 10.1097/00004850-199707003-00004 Boggs LN, 1996, J NEUROCHEM, V67, P1324 Chan KC, 2001, BJS-BRIT J SURG, V88, P412, DOI 10.1046/j.1365-2168.2001.01686.x Ciardiello F, 2001, CLIN CANCER RES, V7, P2958 Ciardiello F, 2000, CLIN CANCER RES, V6, P2053 Ciardiello F, 2001, CLIN CANCER RES, V7, P1459 CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0 Cohen MH, 2004, CLIN CANCER RES, V10, P1212, DOI 10.1158/1078-0432.CCR-03-0564 Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561 Dawson LA, 2009, CNS NEUROSCI THER, V15, P107, DOI 10.1111/j.1755-5949.2008.00067.x Doody RS, 2008, LANCET, V372, P207, DOI 10.1016/S0140-6736(08)61074-0 Eggermont AMM, 2004, EUR J CANCER, V40, P1825, DOI 10.1016/j.ejca.2004.04.030 Eikelboom JW, 2006, THROMB HAEMOSTASIS, V96, P547, DOI 10.1160/TH06-05-0290 Eriksson BI, 2005, J THROMB HAEMOST, V3, P103, DOI 10.1111/j.1538-7836.2004.01100.x Eriksson BI, 2004, J THROMB HAEMOST, V2, P1573, DOI 10.1111/j.1538-7836.2004.00890.x Eton O, 2002, J CLIN ONCOL, V20, P2045, DOI 10.1200/JCO.2002.07.044 Ezekowitz MD, 2007, AM J CARDIOL, V100, P1419, DOI 10.1016/j.amjcard.2007.06.034 Fareed J, 2003, CLIN APPL THROMB-HEM, V9, P101, DOI 10.1177/107602960300900202 Finet JE, 2009, CARDIOL CLIN, V27, P45, DOI 10.1016/j.ccl.2008.09.005 Fleisher AS, 2008, ARCH NEUROL-CHICAGO, V65, P1031, DOI 10.1001/archneur.65.8.1031 Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038 Furukawa TA, 2010, J PSYCHOSOM RES, V68, P581, DOI 10.1016/j.jpsychores.2009.05.003 GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0 Giaccone G, 2004, J CLIN ONCOL, V22, P777, DOI 10.1200/JCO.2004.08.001 Grigor'ev VV, 2003, B EXP BIOL MED+, V136, P474, DOI 10.1023/B:BEBM.0000017097.75818.14 Gupta A, 2010, J CANCER RES THER, V6, P362, DOI 10.4103/0973-1482.73372 HAMILTON M, 1980, J CLIN PSYCHIAT, V41, P21 Hauschild A, 2001, BRIT J CANCER, V84, P1036, DOI 10.1054/bjoc.2001.1731 Herbst RS, 2004, J CLIN ONCOL, V22, P785, DOI 10.1200/JCO.2004.07.215 Herbst RS, 2002, J CLIN ONCOL, V20, P3815, DOI 10.1200/JCO.2002.03.038 Hjorth S, 2000, J PSYCHOPHARMACOL, V14, P177, DOI 10.1177/026988110001400208 Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466 Hodi FS, 2003, P NATL ACAD SCI USA, V100, P4712, DOI 10.1073/pnas.0830997100 Holmes C, 2008, LANCET, V372, P216, DOI 10.1016/S0140-6736(08)61075-2 Hughes ZA, 2005, EUR J PHARMACOL, V510, P49, DOI 10.1016/j.ejphar.2005.01.018 Khan A, 2009, EXPERT OPIN INV DRUG, V18, P1753, DOI 10.1517/13543780903286396 Kim ES, 2008, LANCET, V372, P1809, DOI 10.1016/S0140-6736(08)61758-4 Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009 Korman AJ, 2006, ADV IMMUNOL, V90, P297, DOI 10.1016/S0065-2776(06)90008-X Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149 LANGDELL RD, 1953, J LAB CLIN MED, V41, P637 Lanz TA, 2004, J PHARMACOL EXP THER, V309, P49, DOI 10.1124/jpet.103.060715 Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734 Lermontova NN, 2000, B EXP BIOL MED+, V129, P544, DOI 10.1007/BF02434871 Lermontova NN, 2001, B EXP BIOL MED+, V132, P1079 Lôo H, 2002, INT CLIN PSYCHOPHARM, V17, P239 Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938 Maiese K, 2009, OXID MED CELL LONGEV, V2, P279, DOI 10.4161/oxim.2.5.9990 Maker AV, 2005, ANN SURG ONCOL, V12, P1005, DOI 10.1245/ASO.2005.03.536 MARTINS RN, 1995, NEUROREPORT, V6, P1513, DOI 10.1097/00001756-199507310-00012 Melero I, 2007, NAT REV CANCER, V7, P95, DOI 10.1038/nrc2051 Miller G, 2010, SCIENCE, V327, P1309, DOI 10.1126/science.327.5971.1309 Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699 Morse MA, 2005, CURR OPIN MOL THER, V7, P588 Mungall Dennis, 2002, Curr Opin Investig Drugs, V3, P905 Murck H, 2001, PSYCHOPHARMACOLOGY, V155, P187, DOI 10.1007/s002130100703 Nakagawa K, 2003, ANN ONCOL, V14, P922, DOI 10.1093/annonc/mdg250 Nishida K, 2010, EUROPACE, V12, P160, DOI 10.1093/europace/eup328 Nordberg A, 2007, CURR OPIN NEUROL, V20, P398, DOI 10.1097/WCO.0b013e3281a47744 Norman P, 2001, Curr Opin Investig Drugs, V2, P428 Nutescu EA, 2004, ANN PHARMACOTHER, V38, P99, DOI 10.1345/aph.1D066 O'Day SJ, 2010, ANN ONCOL, V21, P1712, DOI 10.1093/annonc/mdq013 Olshansky Brian, 2005, Expert Rev Cardiovasc Ther, V3, P571, DOI 10.1586/14779072.3.4.571 Overwijk W W, 2001, Curr Protoc Immunol, VChapter 20, DOI 10.1002/0471142735.im2001s39 Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314 Page ME, 2002, J PHARMACOL EXP THER, V302, P1220, DOI 10.1124/jpet.102.034280 Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101 Perez V, 1997, LANCET, V349, P1594, DOI 10.1016/S0140-6736(96)08007-5 Petrella T, 2007, CANCER TREAT REV, V33, P484, DOI 10.1016/j.ctrv.2007.04.003 POLLER L, 1980, SCAND J HAEMATOL, V25, P49 Potpara TS, 2010, CURR PHARM DESIGN, V16, P3455 REBECK GW, 1993, NEURON, V11, P575 Ribas A, 2005, J CLIN ONCOL, V23, P8968, DOI 10.1200/JCO.2005.01.109 Ribas Antoni, 2007, Update Cancer Ther, V2, P133, DOI 10.1016/j.uct.2007.09.001 Rickels K, 2009, J CLIN PSYCHIAT, V70, P326, DOI 10.4088/JCP.08m04637 Romero L, 1996, NEUROPSYCHOPHARMACOL, V15, P349, DOI 10.1016/0893-133X(95)00240-E Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100 Saijo N, 2003, CANCER CHEMOTH PHARM, V52, pS97, DOI 10.1007/s00280-003-0596-x Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864 Schmidt-Lucke C, 2007, THROMB RES, V119, P27, DOI 10.1016/j.thromres.2005.11.016 Siemers E, 2005, CLIN NEUROPHARMACOL, V28, P126, DOI 10.1097/01.wnf.0000167360.27670.29 Siemers ER, 2006, NEUROLOGY, V66, P602, DOI 10.1212/01.WNL.0000198762.41312.E1 Siemers ER, 2007, CLIN NEUROPHARMACOL, V30, P317, DOI 10.1097/WNF.0b013e31805b7660 Sirotnak FM, 2000, CLIN CANCER RES, V6, P4885 Thatcher N, 2005, LANCET, V366, P1527, DOI 10.1016/S0140-6736(05)67625-8 Treit D, 2001, EUR J PHARMACOL, V414, P245, DOI 10.1016/S0014-2999(01)00799-3 Weber J, 2009, CLIN CANCER RES, V15, P5591, DOI 10.1158/1078-0432.CCR-09-1024 Wehling M, 2006, EUR J CLIN PHARMACOL, V62, P91, DOI 10.1007/s00228-005-0060-4 Wehling M, 2011, DRUG DISCOV TODAY, V16, P1076, DOI 10.1016/j.drudis.2011.07.008 Wehling M, 2009, NAT REV DRUG DISCOV, V8, P541, DOI 10.1038/nrd2898 Wendler A, 2010, CURR OPIN PHARMACOL, V10, P601, DOI 10.1016/j.coph.2010.05.009 Wolchok JD, 2010, LANCET ONCOL, V11, P155, DOI 10.1016/S1470-2045(09)70334-1 Wolchok JD, 2009, CLIN CANCER RES, V15, P7412, DOI 10.1158/1078-0432.CCR-09-1624 Zhang ST, 2010, J ALZHEIMERS DIS, V21, P389, DOI 10.3233/JAD-2010-100174 Zhang YW, 2011, MOL BRAIN, V4, DOI 10.1186/1756-6606-4-3 NR 108 TC 32 Z9 34 U1 0 U2 9 PU BMC PI LONDON PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND EI 1479-5876 J9 J TRANSL MED JI J. Transl. Med. PD MAR 7 PY 2012 VL 10 AR 39 DI 10.1186/1479-5876-10-39 PG 11 WC Medicine, Research & Experimental WE Science Citation Index Expanded (SCI-EXPANDED) SC Research & Experimental Medicine GA 931GB UT WOS:000303203200001 PM 22397594 OA Green Submitted, Green Accepted, gold DA 2026-04-17 ER PT J AU Amer, K Khan, AZ Vohra, H Saad, R AF Amer, Khalid Khan, Ali-Zamir Vohra, Hunaid Saad, Rasheed TI Is it safe to include octogenarians at the start of a video-assisted thoracic surgery lobectomy programme? SO EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY LA English DT Article DE Video-assisted thoracic surgery; Lobectomy; Non-small-cell lung cancer; Systematic nodal dissection; Octogenarians ID CELL LUNG-CANCER; END RESULTS DATABASE; LONG-TERM SURVIVAL; ELDERLY-PATIENTS; RESECTION; EPIDEMIOLOGY; SURVEILLANCE; GUIDELINES; EQUIVALENT; CISPLATIN AB The study aimed to investigate the safety of including patients >= 80 years of age at the start of a video-assisted thoracic surgery major pulmonary resection (VMPR) programme. Patients were considered for VMPR if the computed tomography/positron emission tomography (CT/PET) was suggestive of T1-3, N0-1 and M0 lesion. Age was not a criterion for exclusion at the very start of the programme. Data were collected prospectively and comparison made between two groups, (A) < 80 years of age and (B) >= 80 years, in terms of preoperative risk factors, oncological and functional data, operative results, postoperative complications and survival. Between April 2005 and January 2011, 200 consecutive patients were considered for VMPR. A total of 160 had non-small-cell lung cancer, of whom 136 were in group A, with a median age of 66.5 (range: 42.8-79.4 years) and 24 in group B with a median age of 82 (range: 80-85.5 years). In group B, 13 were men and 11 were women. Rate of conversion to thoracotomy was similar (3 (12.5%) in group B vs 17 (12.5%) in group A, p = 0.65), and so was the mean hospital stay (5.8 +/- 3.3 days in group B vs 5.9 +/- 4.6 days in group A, p = 0.899). Admission to intensive care unit and atrial fibrillation were significantly higher in octogenarians (six (25%) and six (25%) in group B vs eight (5.9%) and nine (6.6%) in group A, p = 0.008 and p = 0.012, respectively). There was significantly less mean days of air leak in octogenarians (0.06 +/- 0.3 days in group B vs 2.8 +/- 5.6 days in group A, p = 0.000). Otherwise, there were no age-related differences in relation to morbidity, mortality and the 3-year survival rate. Octogenarians undergoing VMPR have a higher incidence of atrial fibrillation and admission to the intensive care unit for cardiopulmonary support but otherwise are no different from younger age groups when it comes to rate of conversion to thoracotomy, hospital stay, morbidity and mortality. Age should not be an excuse to deny the elderly curative VATS resection. In our experience, accepting octogenarians early in the VMPR programme did not compromise the outcome results. C1 [Amer, Khalid; Vohra, Hunaid; Saad, Rasheed] Southampton Gen Hosp, Cardiovasc & Thorac Unit, Southampton SO16 6YD, Hants, England. [Khan, Ali-Zamir] Medanta Inst Minimally Invas Surg, The Medicity, Haryana, India. C3 University of Southampton RP Amer, K (corresponding author), Southampton Gen Hosp, Cardiovasc & Thorac Unit, Tremona Rd, Southampton SO16 6YD, Hants, England. EM khalid.amer@btinternet.com OI Khan, Ali Zamir/0000-0002-7711-7042 CR Aoki T, 2003, EUR J CARDIO-THORAC, V23, P446, DOI 10.1016/S1010-7940(03)00014-9 Berry MF, 2011, EUR J CARDIO-THORAC, V39, P989, DOI 10.1016/j.ejcts.2010.09.038 Booton R, 2003, THORAX, V58, P711, DOI 10.1136/thorax.58.8.711 Brown JS, 1996, THORAX, V51, P564, DOI 10.1136/thx.51.6.564 Burfeind WR, 2008, J THORAC CARDIOV SUR, V136, P597, DOI 10.1016/j.jtcvs.2008.02.093 Chambers A, 2010, INTERACT CARDIOV TH, V10, P1015, DOI 10.1510/icvts.2010.233189 Darling GE, 2011, CHEST, V139, P1124, DOI 10.1378/chest.10-0859 de Perrot M, 1999, EUR RESPIR J, V14, P419, DOI 10.1034/j.1399-3003.1999.14b29.x Douillard JY, 2006, LANCET ONCOL, V7, P719, DOI 10.1016/S1470-2045(06)70804-X Fanucchi O, 2011, INTERACT CARDIOV TH, V12, P749, DOI 10.1510/icvts.2010.259002 Fountain SW, 2001, THORAX, V56, P89 Heerdt Paul M, 2009, Thorac Surg Clin, V19, P345, DOI 10.1016/j.thorsurg.2009.06.006 JUHL B, 1975, Acta Anaesthesiologica Scandinavica Supplementum, V57, P39 Lardinois D, 2006, EUR J CARDIO-THORAC, V30, P787, DOI 10.1016/j.ejcts.2006.08.008 Le Chevalier T, 2004, NEW ENGL J MED, V350, P351, DOI 10.1056/nejmoa031644 Lim E, 2010, THORAX, V65, P1, DOI 10.1136/thx.2010.145938 Mery CM, 2005, CHEST, V128, P237, DOI 10.1378/chest.128.1.237 MOUNTAIN CF, 1987, J SURG ONCOL, V35, P147, DOI 10.1002/jso.2930350302 Mun M, 2008, ANN THORAC SURG, V85, P406, DOI 10.1016/j.athoracsur.2007.10.057 Okami J, 2010, ANN THORAC SURG, V90, P1651, DOI 10.1016/j.athoracsur.2010.06.090 Owonikoko TK, 2007, J CLIN ONCOL, V25, P5570, DOI 10.1200/JCO.2007.12.5435 Seder CW, 2009, ANN THORAC SURG, V88, P216, DOI 10.1016/j.athoracsur.2009.04.017 Union Internationale Contre le Cancer, 1997, TNM CLASS MAL TUM, P93 Walker W S, 1998, Semin Thorac Cardiovasc Surg, V10, P291 Wise J, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c3057 NR 25 TC 10 Z9 13 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1010-7940 J9 EUR J CARDIO-THORAC JI Eur. J. Cardio-Thorac. Surg. PD FEB PY 2012 VL 41 IS 2 BP 346 EP 352 DI 10.1016/j.ejcts.2011.05.038 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 891ST UT WOS:000300237600024 PM 21900023 DA 2026-04-17 ER PT J AU Casella, M Perna, F Pontone, G Dello Russo, A Andreini, D Pelargonio, G Riva, S Fassini, G Pepi, M Ballerini, G Moltrasio, M Majocchi, B Bartoletti, S Formenti, A Santangeli, P Di Biase, L Natale, A Tondo, C AF Casella, Michela Perna, Francesco Pontone, Gianluca Dello Russo, Antonio Andreini, Daniele Pelargonio, Gemma Riva, Stefania Fassini, Gaetano Pepi, Mauro Ballerini, Giovanni Moltrasio, Massimo Majocchi, Benedetta Bartoletti, Stefano Formenti, Alberto Santangeli, Pasquale Di Biase, Luigi Natale, Andrea Tondo, Claudio TI Prevalence and clinical significance of collateral findings detected by chest computed tomography in patients undergoing atrial fibrillation ablation SO EUROPACE LA English DT Article DE Collateral findings; Incidental findings; Chest computed tomography; Image integration; Atrial fibrillation ablation ID INCIDENTAL FINDINGS; NONCARDIAC FINDINGS; CATHETER ABLATION; ANGIOGRAPHY; MANAGEMENT; EFFICACY; SCANS AB Aims Chest computed tomography (CT) scanning is increasingly used as an imaging technique in patients undergoing atrial fibrillation (AF) catheter ablation. Chest CT scans visualize organs other than the heart and collateral findings may be identified incidentally. Our study aims to assess the prevalence and clinical relevance of such collateral findings in patients undergoing AF ablation. Methods and results One hundred and seventy-three patients (127 males, age 59 +/- 10 years) underwent chest CT scan for image integration in AF ablation. Collateral findings from visualized thoracic and upper abdominal organs were collected. Findings that required further investigations or treatment according to current guidelines were considered as clinically significant. A total of 164 collateral findings were identified in 97 (56%) patients, and most patients showed abnormalities of the lungs (67 patients, 39%). Forty-nine (28%) patients had clinically significant findings needing further investigation and 17 (10%) of them required specific treatments, including three cases (1.7%) of lung malignancy. Conclusions Chest CT images acquired for integration in AF ablation should be read thoroughly as they may serve as a screening tool for otherwise unrecognized clinically significant conditions of the heart, lungs, or other visualized organs. C1 [Casella, Michela; Pontone, Gianluca; Dello Russo, Antonio; Andreini, Daniele; Riva, Stefania; Fassini, Gaetano; Pepi, Mauro; Ballerini, Giovanni; Moltrasio, Massimo; Majocchi, Benedetta; Bartoletti, Stefano; Formenti, Alberto; Tondo, Claudio] Ctr Cardiol Monzino IRCCS, Cardiac Arrhythmia Res Ctr, Milan, Italy. [Perna, Francesco; Pelargonio, Gemma] Univ Cattolica Sacro Cuore, I-00168 Rome, Italy. [Santangeli, Pasquale; Di Biase, Luigi; Natale, Andrea] St Davids Med Ctr, Texas Cardiac Arrhythmia Inst, Austin, TX USA. C3 IRCCS Centro Cardiologico Monzino; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Saint David's Medical Center RP Casella, M (corresponding author), Ctr Cardiol Monzino IRCCS, Cardiac Arrhythmia Res Ctr, Milan, Italy. EM michela.casella@ccfm.it RI Andreini, Daniele/ABG-9647-2020; Santangeli, Pasquale/ACT-6302-2022; Perna, Francesco/K-4813-2018; Tondo, Claudio/S-4671-2019; Casella, Michela/Y-9354-2019; Dello Russo, Antonio/AAB-5030-2022 OI Santangeli, Pasquale/0000-0002-0023-9666; Perna, Francesco/0000-0002-9019-9492; Di Biase, Luigi/0000-0001-6508-4047; Casella, Michela/0000-0002-5322-1742; Pontone, Gianluca/0000-0002-1339-6679; Pelargonio, Gemma/0000-0003-3236-3458; Dello Russo, Antonio/0000-0001-7737-421X FU St Jude Medical; Boston Scientific; Medtronic; Biosense Webster FX C.T. has served as a member of the advisory board of Biosense Webster and has been a consultant for, and received lecture fees from, St Jude Medical. A. N. has received compensation for belonging to the speakers' bureau for St Jude Medical, Boston Scientific, Medtronic, and Biosense Webster and has received a research grant from St Jude Medical. A. N. is also a consultant for Biosense Webster. L. D. B. is a consultant for Hansen Medical and Biosense Webster. The other authors declare no significant relationships with industry. CR Alpert JB, 2011, RADIOL CLIN N AM, V49, P267, DOI 10.1016/j.rcl.2010.10.005 Bartoletti S, 2010, J AM COLL CARDIOL, V55, P702, DOI 10.1016/j.jacc.2009.11.025 Berland LL, 2010, J AM COLL RADIOL, V7, P754, DOI 10.1016/j.jacr.2010.06.013 Bertaglia E, 2009, EUROPACE, V11, P1004, DOI 10.1093/europace/eup152 Budoff MJ, 2006, CATHETER CARDIO INTE, V68, P965, DOI 10.1002/ccd.20924 Cademartiri F, 2007, RADIOL MED, V112, P937, DOI 10.1007/s11547-007-0194-9 Cappato R, 2010, CIRC-ARRHYTHMIA ELEC, V3, P32, DOI 10.1161/CIRCEP.109.859116 Chen LY, 2007, HEART RHYTHM, V4, pS1, DOI 10.1016/j.hrthm.2006.12.018 Dewey M, 2007, EUR RADIOL, V17, P2038, DOI 10.1007/s00330-006-0570-1 Dong J, 2006, J CARDIOVASC ELECTR, V17, P459, DOI 10.1111/j.1540-8167.2006.00425.x Estes NAM, 2007, J INTERV CARD ELECTR, V20, P127, DOI 10.1007/s10840-007-9182-1 Gottlieb I, 2008, J CARDIOVASC ELECTR, V19, P247, DOI 10.1111/j.1540-8167.2007.01043.x Henschke CI, 2006, NEW ENGL J MED, V355, P1763, DOI 10.1056/NEJMoa060476 Horton KM, 2002, CIRCULATION, V106, P532, DOI 10.1161/01.CIR.0000027136.56615.DE Hunold P, 2001, EUR HEART J, V22, P1748, DOI 10.1053/euhj.2000.2586 Jacobs PCA, 2008, J COMPUT ASSIST TOMO, V32, P214, DOI 10.1097/RCT.0b013e3181585ff2 JONES EC, 1992, AM J ROENTGENOL, V158, P535, DOI 10.2214/ajr.158.3.1738990 Kalra MK, 2007, CATHETER CARDIO INTE, V70, P324, DOI 10.1002/ccd.21155 Lacomis JM, 2006, J INTERV CARD ELECTR, V16, P7, DOI 10.1007/s10840-006-9016-6 Law YM, 2008, J MED IMAG RADIAT ON, V52, P49, DOI 10.1111/j.1440-1673.2007.01911.x MacHaalany J, 2009, J AM COLL CARDIOL, V54, P1533, DOI 10.1016/j.jacc.2009.06.026 MacMahon H, 2005, RADIOLOGY, V237, P395, DOI 10.1148/radiol.2372041887 Onuma Y, 2006, J AM COLL CARDIOL, V48, P402, DOI 10.1016/j.jacc.2006.04.071 Sra J, 2008, J INTERV CARD ELECTR, V22, P145, DOI 10.1007/s10840-007-9199-5 van't Westeinde SC, 2008, LUNG CANCER, V60, P151, DOI 10.1016/j.lungcan.2008.01.020 Wann LS, 2011, HEART RHYTHM, V8, P157, DOI 10.1016/j.hrthm.2010.11.047 NR 26 TC 9 Z9 10 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1099-5129 EI 1532-2092 J9 EUROPACE JI Europace PD FEB PY 2012 VL 14 IS 2 BP 209 EP 216 DI 10.1093/europace/eur300 PG 8 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA 879SA UT WOS:000299351300012 PM 21933801 OA Green Submitted, Bronze DA 2026-04-17 ER PT J AU Nojiri, T Yamamoto, K Maeda, H Takeuchi, Y Funakoshi, Y Inoue, M Okumura, M AF Nojiri, Takashi Yamamoto, Kazuhiro Maeda, Hajime Takeuchi, Yukiyasu Funakoshi, Yasunobu Inoue, Masayoshi Okumura, Meinoshin TI Effect of low-dose human atrial natriuretic peptide on postoperative atrial fibrillation in patients undergoing pulmonary resection for lung cancer: A double-blind, placebo-controlled study SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article ID NONCARDIAC THORACIC-SURGERY; CARDIAC-SURGERY; CONTINUOUS-INFUSION; INFLAMMATION AB Objectives: We previously reported that patients with preoperative B-type natriuretic peptide levels of 30 pg/mL or more have increased risk of postoperative atrial fibrillation after pulmonary resection. This study evaluated the effects of human atrial natriuretic peptide on postoperative atrial fibrillation in patients undergoing pulmonary resection for lung cancer. Methods: A prospective, randomized study was conducted with 40 patients who had preoperative elevated B-type natriuretic peptide (>= 30 pg/mL) and underwent a scheduled pulmonary resection for lung cancer. Results were compared between patients who received low-dose human atrial natriuretic peptide and those who received a placebo. The primary end point was the incidence of postoperative atrial fibrillation during the first 4 days after surgery. Results: The incidence of postoperative atrial fibrillation was significantly lower in the human atrial natriuretic peptide group than in the placebo group (10% vs 60%; P<.001). Patients in the human atrial natriuretic peptide group also showed significantly lower white blood cell counts and C-reactive protein levels after surgery. Conclusions: Continuous infusion of low-dose human atrial natriuretic peptide during lung cancer surgery had a prophylactic effect against postoperative atrial fibrillation after pulmonary resection in patients with preoperative elevation of B-type natriuretic peptide levels. A larger sample size is needed to establish the safety and efficacy of this intervention. (J Thorac Cardiovasc Surg 2012;143:488-94) C1 [Nojiri, Takashi; Maeda, Hajime; Takeuchi, Yukiyasu; Funakoshi, Yasunobu] Natl Hosp Org Toneyama Hosp, Dept Gen Thorac Surg, Toyonaka, Osaka, Japan. [Nojiri, Takashi; Inoue, Masayoshi; Okumura, Meinoshin] Osaka Univ, Grad Sch Med, Dept Gen Thorac Surg, Suita, Osaka, Japan. [Yamamoto, Kazuhiro] Osaka Univ, Grad Sch Med, Dept Cardiol, Suita, Osaka, Japan. C3 University of Osaka; University of Osaka RP Nojiri, T (corresponding author), Toneyama Natl Hosp, Dept Gen Thorac Surg, Toneyama 5-1-1, Toyonaka, Osaka 5608552, Japan. EM nojirit@thoracic.med.osaka-u.ac.jp FU Grants-in-Aid for Scientific Research [23791581] Funding Source: KAKEN CR AMAR D, 1995, CHEST, V108, P349, DOI 10.1378/chest.108.2.349 [Anonymous], MED SCI MONIT Aviles RJ, 2003, CIRCULATION, V108, P3006, DOI 10.1161/01.CIR.0000103131.70301.4F Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Cardinale D, 2007, CIRCULATION, V115, P1339, DOI 10.1161/CIRCULATIONAHA.106.647008 Chen MC, 2008, AM J CARDIOL, V102, P861, DOI 10.1016/j.amjcard.2008.05.038 Ishii Y, 2005, CIRCULATION, V111, P2881, DOI 10.1161/CIRCULATIONAHA.104.475194 Kasama S, 2008, EUR HEART J, V29, P1485, DOI 10.1093/eurheartj/ehn206 Nattel S, 2000, ANNU REV PHYSIOL, V62, P51, DOI 10.1146/annurev.physiol.62.1.51 Nishikimi T, 2006, CARDIOVASC RES, V69, P318, DOI 10.1016/j.cardiores.2005.10.001 Nojiri T, 2010, J THORAC CARDIOV SUR, V140, P764, DOI 10.1016/j.jtcvs.2009.11.073 Nojiri T, 2010, EUR J CARDIO-THORAC, V37, P787, DOI 10.1016/j.ejcts.2009.09.043 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 SAITO Y, 1987, CIRCULATION, V76, P115, DOI 10.1161/01.CIR.76.1.115 Sezai A, 2006, CIRC J, V70, P1426, DOI 10.1253/circj.70.1426 Sezai A, 2009, J AM COLL CARDIOL, V54, P1058, DOI 10.1016/j.jacc.2009.05.047 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Woods RL, 2004, CLIN EXP PHARMACOL P, V31, P791, DOI 10.1111/j.0305-1870.2004.04073.x Yoshida T, 2008, INT J CARDIOL, V123, P147, DOI 10.1016/j.ijcard.2006.12.005 NR 19 TC 30 Z9 32 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD FEB PY 2012 VL 143 IS 2 BP 488 EP 494 DI 10.1016/j.jtcvs.2011.09.003 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 879GP UT WOS:000299318000039 PM 21992849 OA Bronze DA 2026-04-17 ER PT J AU Raman, T Roistacher, N Liu, J Zhang, H Shi, WJ Thaler, HT Amar, D AF Raman, Tina Roistacher, Nancy Liu, Jennifer Zhang, Hao Shi, Weiji Thaler, Howard T. Amar, David TI Preoperative left atrial dysfunction and risk of postoperative atrial fibrillation complicating thoracic surgery SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article ID LUNG-CANCER; NATRIURETIC PEPTIDE; PREDICTIVE-VALUE; CARDIAC-SURGERY; VOLUME; ECHOCARDIOGRAPHY; RESECTION; SOCIETY AB Objective: Postoperative atrial fibrillation complicating general thoracic surgery increases morbidity and stroke risk. We aimed to determine whether preoperative atrial dysfunction or other echocardiographic markers are associated with postoperative atrial fibrillation. Methods: In 191 patients who had undergone anatomic lung or esophageal resection, preoperative clinical and echocardiographic data were compared between patients with and without postoperative atrial fibrillation. Presence of postoperative atrial fibrillation lasting more than 5 minutes during hospitalization was detected using continuous telemetry or 12-lead electrocardiography. Maximal left atrial volume and indices of left atrial function were assessed. Results: Patients with postoperative atrial fibrillation (33/191, 17%) were older (71 +/- 5 years vs 64 +/- 12 years, P < .0001), were taking beta-blockers more often, had greater left atrial volume, had decreased left atrial emptying fraction, and had lower E' and A' septal velocities compared with patients without postoperative atrial fibrillation. The incidence of postoperative atrial fibrillation in patients with left atrial volume 32 mL/m(2) or greater was 37% (11/30) and greater than in those with left atrial volume less than 32 mL/m(2) (14%, 22/160, P = .002). Length of hospital stay was significantly increased in patients with postoperative atrial fibrillation compared with patients without (P = .04). Older age was significantly associated with greater beta-blocker use and left atrial volume and lower left atrial emptying fraction. On multivariate analysis, lower left atrial emptying fraction (odds ratio, 1.03 per unit decrement; 95% confidence interval, 1.002-1.065; P = .04) and preoperative use of beta-blockers (odds ratio, 2.82; 95% confidence interval, 1.18-6.77; P = .02) were the only independent risk factors associated with postoperative atrial fibrillation. Conclusions: These data show that an echocardiogram before major thoracic surgery, increased use of preoperative b-blockers, and decreased left atrial emptying fraction were associated with postoperative atrial fibrillation. Echocardiographic predictors of left atrial mechanical dysfunction may prove clinically useful in risk stratifying patients in whom postoperative atrial fibrillation is more likely to develop and to benefit from prevention strategies aimed at mitigating atrial function before surgery. (J Thorac Cardiovasc Surg 2012;143:482-7) C1 [Raman, Tina; Zhang, Hao; Amar, David] Mem Sloan Kettering Canc Ctr, Dept Anesthesiol & Crit Care Med, New York, NY 10021 USA. [Roistacher, Nancy; Liu, Jennifer] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA. [Shi, Weiji; Thaler, Howard T.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA. C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center RP Amar, D (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Anesthesiol & Crit Care Med, 1275 York Ave,M-304, New York, NY 10021 USA. EM amard@mskcc.org CR Alsaileek AA, 2006, J AM COLL CARDIOL, V47, P1024, DOI 10.1016/j.jacc.2005.09.069 AMAR D, 1995, CHEST, V108, P349, DOI 10.1378/chest.108.2.349 Amar D, 2002, ANESTHESIOLOGY, V96, P352, DOI 10.1097/00000542-200202000-00021 Amar D, 2005, CHEST, V128, P3421, DOI 10.1378/chest.128.5.3421 Amar D, 2006, ANN THORAC SURG, V82, P1057, DOI 10.1016/j.athoracsur.2006.03.103 Benedetto U, 2007, ANN THORAC SURG, V83, P83, DOI 10.1016/j.athoracsur.2006.08.038 Cardinale D, 2007, CIRCULATION, V115, P1339, DOI 10.1161/CIRCULATIONAHA.106.647008 Chen YJ, 1998, J AM COLL CARDIOL, V32, P732, DOI 10.1016/S0735-1097(98)00305-2 HENRY WL, 1976, CIRCULATION, V53, P273, DOI 10.1161/01.CIR.53.2.273 Hou JL, 2008, WORLD J GASTROENTERO, V14, P2582, DOI 10.3748/wjg.14.2582 Lang RM, 2005, J AM SOC ECHOCARDIOG, V18, P1440, DOI 10.1016/j.echo.2005.10.005 Maisel WH, 2001, ANN INTERN MED, V135, P1061, DOI 10.7326/0003-4819-135-12-200112180-00010 Nojiri T, 2010, J THORAC CARDIOV SUR, V140, P764, DOI 10.1016/j.jtcvs.2009.11.073 Nojiri T, 2010, EUR J CARDIO-THORAC, V37, P787, DOI 10.1016/j.ejcts.2009.09.043 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Osranek M, 2006, J AM COLL CARDIOL, V48, P779, DOI 10.1016/j.jacc.2006.03.054 Park BJ, 2007, J THORAC CARDIOV SUR, V133, P775, DOI 10.1016/j.jtcvs.2006.09.022 Passman RS, 2005, ANN THORAC SURG, V79, P1698, DOI 10.1016/j.athoracsur.2004.10.058 Polanczyk CA, 1998, ANN INTERN MED, V129, P279, DOI 10.7326/0003-4819-129-4-199808150-00003 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Roshanali F, 2007, CIRCULATION, V116, P2012, DOI 10.1161/CIRCULATIONAHA.107.727081 Simek C L, 1995, J Am Soc Echocardiogr, V8, P37, DOI 10.1016/S0894-7317(05)80356-6 Tsang TSM, 2002, AM J CARDIOL, V90, P1284, DOI 10.1016/S0002-9149(02)02864-3 Tsang TSM, 2001, MAYO CLIN PROC, V76, P467, DOI 10.4065/76.5.467 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 NR 25 TC 36 Z9 39 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD FEB PY 2012 VL 143 IS 2 BP 482 EP 487 DI 10.1016/j.jtcvs.2011.08.025 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 879GP UT WOS:000299318000038 PM 21955478 OA Bronze DA 2026-04-17 ER PT J AU Imperatori, A Mariscalco, G Riganti, G Rotolo, N Conti, V Dominioni, L AF Imperatori, Andrea Mariscalco, Giovanni Riganti, Giuditta Rotolo, Nicola Conti, Valentina Dominioni, Lorenzo TI Atrial fibrillation after pulmonary lobectomy for lung cancer affects long-term survival in a prospective single-center study SO JOURNAL OF CARDIOTHORACIC SURGERY LA English DT Article DE Pulmonary lobectomy; Lung cancer; Atrial fibrillation; Arrhythmia; Prognosis; Mortality ID NONCARDIAC THORACIC-SURGERY; GUIDELINES 2ND EDITION; CORONARY SURGERY; CARDIAC-SURGERY; RISK-FACTORS; STAGE-I; MORTALITY; RESECTION AB Background: Atrial fibrillation (AF) after thoracic surgery is a continuing source of morbidity and mortality. The effect of postoperative AF on long-term survival however has not been studied. Our aim was to evaluate the impact of AF on early outcome and on survival > 5 years after pulmonary lobectomy for lung cancer. Methods: From 1996 to June 2009, 454 consecutive patients undergoing lobectomy for lung cancer were enrolled and followed-up until death or study end (October 2010). Patients with postoperative AF were identified; AF was investigated with reference to its predictors and to short-and long-term survival (> 5 years). Results: Hospital mortality accounted for 7 patients (1.5%), while postoperative AF occurred in 45 (9.9%). Independent AF predictors were: preoperative paroxysmal AF (odds ratio [OR] 5.91; 95% CI 2.07 to 16.88), postoperative blood transfusion (OR 3.61; 95% CI 1.67 to 7.82) and postoperative fibro-bronchoscopy (OR 3.39; 95% CI 1.48 to 7.79). Patients with AF experienced higher hospital mortality (6.7% vs. 1.0%, p = 0.024), longer hospitalization (15.3 +/- 10.1 vs. 12.2 +/- 5.2 days, p = 0.001) and higher intensive care unit admission rate (13.3% vs. 3.9%, p = 0.015). The median follow-up was 36 months (maximum: 179 months). Among the 445 discharged subjects with complete follow-up, postoperative AF was not an independent predictor of mortality; however, among the 151 5-year survivors, postoperative AF independently predicted poorer long-term survival (HR 3.75; 95% CI 1.44 to 9.08). Conclusion: AF after pulmonary lobectomy for lung cancer, in addition to causing higher hospital morbidity and mortality, predicts poorer long-term outcome in 5-year survivors. C1 [Imperatori, Andrea; Riganti, Giuditta; Rotolo, Nicola; Conti, Valentina; Dominioni, Lorenzo] Univ Insubria, Varese Univ Hosp, Ctr Thorac Surg, Dept Surg & Morphol Sci, Varese, Italy. [Mariscalco, Giovanni] Univ Insubria, Varese Univ Hosp, Cardiac Surg Unit, Dept Surg & Morphol Sci, Varese, Italy. C3 University of Insubria; University of Insubria RP Imperatori, A (corresponding author), Univ Insubria, Varese Univ Hosp, Ctr Thorac Surg, Dept Surg & Morphol Sci, Varese, Italy. EM andrea.imperatori@uninsubria.it RI Mariscalco, Giovanni/AAN-3223-2020; Rotolo, Nicola/AAE-2168-2019 OI Mariscalco, Giovanni/0000-0001-8200-2269; Rotolo, Nicola/0000-0003-1325-9284; IMPERATORI, Andrea Selenito/0000-0001-6281-1800 CR Amar D, 1996, CHEST, V110, P437, DOI 10.1378/chest.110.2.437 Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 De Decker K, 2003, ANN THORAC SURG, V75, P1340, DOI 10.1016/S0003-4975(02)04824-5 Fransen E, 1999, CHEST, V116, P1233, DOI 10.1378/chest.116.5.1233 Goette A, 2002, CARDIOVASC RES, V54, P390, DOI 10.1016/S0008-6363(02)00251-1 Groth SS, 2010, ANN THORAC SURG, V90, P375, DOI 10.1016/j.athoracsur.2010.04.100 Kalman JM, 1995, ANN THORAC SURG, V60, P1709, DOI 10.1016/0003-4975(95)00718-0 Mariscalco G, 2008, CIRCULATION, V118, P1612, DOI 10.1161/CIRCULATIONAHA.108.777789 Mariscalco G, 2006, J THORAC CARDIOV SUR, V131, P1364, DOI 10.1016/j.jtcvs.2006.01.040 Mariscalco G, 2009, ANN THORAC SURG, V88, P1871, DOI 10.1016/j.athoracsur.2009.07.074 Mariscalco G, 2009, NICOTINE TOB RES, V11, P58, DOI 10.1093/ntr/ntn011 Mathew JP, 1996, JAMA-J AM MED ASSOC, V276, P300, DOI 10.1001/jama.276.4.300 Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710 Murthy SC, 2003, J THORAC CARDIOV SUR, V126, P1162, DOI 10.1016/S0022-5223(03)00974-7 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 Robinson LA, 2007, CHEST, V132, p243S, DOI 10.1378/chest.07-1379 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Rubins J, 2007, CHEST, V132, p355S, DOI 10.1378/chest.07-1390 Scott WJ, 2007, CHEST, V132, p234S, DOI 10.1378/chest.07-1378 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983 NR 21 TC 102 Z9 108 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1749-8090 J9 J CARDIOTHORAC SURG JI J. Cardiothorac. Surg. PD JAN 10 PY 2012 VL 7 AR 4 DI 10.1186/1749-8090-7-4 PG 8 WC Cardiac & Cardiovascular Systems; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Surgery GA 900LT UT WOS:000300889300001 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Daher, IN Queen, S Banchs, J AF Daher, Iyad N. Queen, Saulette Banchs, Jose TI Fluoroscopically Guided Transesophageal Echocardiogram in a Patient with Esophageal Stents SO ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES LA English DT Article DE TEE; infective endocarditis AB A 73-year-old man with history of coronary artery disease and bypass surgery, atrial fibrillation, and left lower lobe nonsmall cell lung cancer was admitted with recurrent pneumonia and was referred for transesophageal echocardiogram for suspected aortic valve endocarditis by transthoracic echocardiography. The patient had a history of radiation treatment for lung cancer 6 years ago. He had subsequently developed esophageal strictures requiring repeated dilatations, and eventually repeated esophageal stenting. Recurrent aspiration pneumonia led to the discovery of stent erosion into his trachea leading to tracheoesophageal fistula. A covered Y tracheal stent was placed to close the fistulous tract, but persistent aspiration was noted. The cross-sectional diameter of the esophageal stents was determined to be larger than the transesophageal echocardiography (TEE) probe. TEE was performed under fluoroscopy for added safety. The esophageal stent position was confirmed with fluoroscopy before and after the procedure and the TEE probe remained inside the distal stent in the midesophageal position during the entire procedure. Small mobile vegetation was seen on the right coronary cusp and the noncoronary cusp showed a smaller vegetation. The patient tolerated the procedure well and there were no complications. Infectious disease consultation was obtained and antibiotic regimen was modified accordingly. Although there are studies addressing the safety of TEE in patients with esophageal varices, to our knowledge, there is no report of TEE being performed in patients with esophageal or tracheoesophageal stents. This case illustrates that TEE may be performed in patients with esophageal stents under careful fluoroscopic guidance. (Echocardiography 2012;29:E5-E7) C1 [Daher, Iyad N.; Banchs, Jose] Univ Texas MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA. [Queen, Saulette] Univ Texas Hlth Sci, Dept Cardiol, Houston, TX USA. C3 University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston RP Banchs, J (corresponding author), 1400 Herman P Pressler,Room 11-5030, Houston, TX 77030 USA. EM jbanchs@mdanderson.org CR Hilberath JN, 2010, J AM SOC ECHOCARDIOG, V23, P1115, DOI 10.1016/j.echo.2010.08.013 KHANDHERIA BK, 1994, MAYO CLIN PROC, V69, P856, DOI 10.1016/S0025-6196(12)61788-1 Ryan Elizabeth W., 2000, Cardiology Clinics, V18, P773, DOI 10.1016/S0733-8651(05)70179-X Spier BJ, 2009, J AM SOC ECHOCARDIOG, V22, P396, DOI 10.1016/j.echo.2009.01.002 NR 4 TC 0 Z9 0 U1 0 U2 1 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0742-2822 EI 1540-8175 J9 ECHOCARDIOGR-J CARD JI Echocardiography-J. Cardiovasc. Ultrasound Allied Tech. PD JAN PY 2012 VL 29 IS 1 BP E5 EP E7 DI 10.1111/j.1540-8175.2011.01536.x PG 3 WC Cardiac & Cardiovascular Systems WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA 876HL UT WOS:000299098300002 PM 21988195 DA 2026-04-17 ER PT J AU Martins, RP Muresan, L Sellal, JM Mandry, D Régent, D Jarmouni, S Groben, L Zinzius, PY Schwartz, J Brembilla-Perrot, B Magnin-Poul, I Andronache, M Aliot, E De Chillou, C AF Martins, Raphael Pedro Muresan, Lucian Sellal, Jean-Marc Mandry, Damien Regent, Denis Jarmouni, Soumaya Groben, Laurent Zinzius, Pierre-Yves Schwartz, Jerome Brembilla-Perrot, Beatrice Magnin-Poul, Isabelle Andronache, Marius Aliot, Etienne De Chillou, Christian TI Incidental Extracardiac Findings in Cardiac Computed Tomography Performed before Radiofrequency Ablation of Atrial Fibrillation SO PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY LA English DT Article DE atrial fibrillation; ablation; cardiac CT scan; incidental findings ID SIGNIFICANT NONCARDIAC FINDINGS; CATHETER ABLATION; IMAGE INTEGRATION; CLINICAL-OUTCOMES; MAPPING SYSTEM; PREVALENCE; CT; ANGIOGRAPHY; IMPACT; ABNORMALITIES AB Background: Radiofrequency ablation has became a validated therapeutic technique for symptomatic drug refractory atrial fibrillation (AF). Cardiac computed tomography (CT) is used to evaluate left atrial (LA) anatomy in order to improve AF ablation. The analysis of noncardiac structures during cardiac CT may identify clinically significant incidental findings (IFs). The objective of this study was to determine the prevalence of IF in patients undergoing AF catheter ablation. Methods: Between February 2008 and March 2010, all patients planned for a first procedure of AF or LA tachycardia (LAT) ablation underwent a cardiac CT scan and were retrospectively included in this study. Extracardiac IFs were considered to be present if an abnormality was identified without previous clinical suspicion or known disease. Results: Two hundred and fifty patients (55.2 +/- 9.6 years of age, 82.4% men) were enrolled (133 paroxysmal, 43 persistent, 58 permanent AF, and 16 LAT). Fifty-eight patients (23.2%) had a total of 76 IFs. Patients with IF were significantly older (59.5 +/- 8.2 vs 53.8 +/- 9.7 years old, P < 0.001). No relationship existed between the type of arrhythmia and IF existence. The majority of IFs were pulmonary (50%), with 15.8% of pulmonary emphysema. Two cases of lung cancer and of pulmonary fibrosis, 15 mediastinal adenopathies, and three congenital coronary arteries anomalies were found. Conclusions: Cardiac CT scan is a useful tool to evaluate LA morphology before AF ablation. However, as a considerable prevalence of IF was found in our study, extracardiac structures should be routinely analyzed to detect unknown conditions, which could require specific management. (PACE 2011; 34: 1665-1670) C1 [Martins, Raphael Pedro] CHU Rennes, Serv Cardiol & Malad Vascul, F-35000 Rennes, France. [Martins, Raphael Pedro] Univ Rennes 1, LTSI, Rennes, France. [Martins, Raphael Pedro] INSERM, U642, Rennes, France. [Martins, Raphael Pedro] INSERM, CIC IT 804, Rennes, France. [Muresan, Lucian; Sellal, Jean-Marc; Jarmouni, Soumaya; Groben, Laurent; Zinzius, Pierre-Yves; Schwartz, Jerome; Brembilla-Perrot, Beatrice; Magnin-Poul, Isabelle; Andronache, Marius; Aliot, Etienne; De Chillou, Christian] CHU Nancy, Serv Cardiol, Nancy, France. [Sellal, Jean-Marc; Mandry, Damien; Regent, Denis; Groben, Laurent; Zinzius, Pierre-Yves; Schwartz, Jerome; Aliot, Etienne; De Chillou, Christian] Nancy Univ, Nancy, France. [Mandry, Damien; Regent, Denis] CHU Nancy, Serv Radiol, Nancy, France. [Mandry, Damien; Regent, Denis] INSERM, U947, Nancy, France. C3 CHU Rennes; Universite de Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; Universite de Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Nancy; Universite de Lorraine; CHU de Nancy; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine RP Martins, RP (corresponding author), CHU Rennes, Serv Cardiol & Malad Vascul, 2 Rue Henri Le Guilloux, F-35000 Rennes, France. EM raphael.pmartins@gmail.com RI Muresan, Lucian/AAN-3803-2020; Mandry, Damien/F-4677-2011; Martins, Raphael/ABD-5268-2020; de+CHILLOU, Christian/AAV-3626-2021; SELLAL, Jean-Marc/AAX-7975-2020 CR Bluemke DA, 2008, CIRCULATION, V118, P586, DOI 10.1161/CIRCULATIONAHA.108.189695 Budoff Matthew J, 2007, J Cardiovasc Comput Tomogr, V1, P97, DOI 10.1016/j.jcct.2007.04.002 Cappato R, 2005, CIRCULATION, V111, P1100, DOI 10.1161/01.CIR.0000157153.30978.67 de Chillou C, 2008, J INTERV CARD ELECTR, V23, P175, DOI 10.1007/s10840-008-9300-8 Gil BN, 2007, J COMPUT ASSIST TOMO, V31, P1, DOI 10.1097/01.rct.0000233125.83184.33 Haïssaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003 Haller S, 2006, AM J ROENTGENOL, V187, P105, DOI 10.2214/AJR.04.1988 Heeringa J, 2008, AM HEART J, V156, P1163, DOI 10.1016/j.ahj.2008.08.003 Horton KM, 2002, CIRCULATION, V106, P532, DOI 10.1161/01.CIR.0000027136.56615.DE Hunold P, 2001, EUR HEART J, V22, P1748, DOI 10.1053/euhj.2000.2586 Kawano Y, 2007, AM J CARDIOL, V99, P1608, DOI 10.1016/j.amjcard.2007.01.038 Killeen Ronan P, 2009, J Cardiovasc Comput Tomogr, V3, P361, DOI 10.1016/j.jcct.2009.10.007 Killeen Ronan P, 2009, J Cardiovasc Comput Tomogr, V3, P293, DOI 10.1016/j.jcct.2009.05.003 Kirsch J, 2007, J THORAC IMAG, V22, P330, DOI 10.1097/RTI.0b013e31813434a9 Kistler PM, 2006, J CARDIOVASC ELECTR, V17, P1093, DOI 10.1111/j.1540-8167.2006.00594.x Kistler PM, 2008, EUR HEART J, V29, P3029, DOI 10.1093/eurheartj/ehn453 Koonce J, 2009, EUR RADIOL, V19, P570, DOI 10.1007/s00330-008-1195-3 Law YM, 2008, J MED IMAG RADIAT ON, V52, P49, DOI 10.1111/j.1440-1673.2007.01911.x Lee SH, 2008, J THORAC IMAG, V23, P216, DOI 10.1097/RTI.0b013e318166a485 MacHaalany J, 2009, J AM COLL CARDIOL, V54, P1533, DOI 10.1016/j.jacc.2009.06.026 Martinek M, 2007, PACE, V30, P1215, DOI 10.1111/j.1540-8159.2007.00843.x Mueller J, 2007, AM J ROENTGENOL, V189, P414, DOI 10.2214/AJR.06.0736 Onuma Y, 2006, J AM COLL CARDIOL, V48, P402, DOI 10.1016/j.jacc.2006.04.071 Pappone C, 1999, CIRCULATION, V100, P1203, DOI 10.1161/01.CIR.100.11.1203 Piorkowski C, 2006, HEART RHYTHM, V3, P317, DOI 10.1016/j.hrthm.2005.11.027 Richmond L, 2008, J CARDIOVASC ELECTR, V19, P821, DOI 10.1111/j.1540-8167.2008.01127.x Schietinger BJ, 2008, AM HEART J, V155, P254, DOI 10.1016/j.ahj.2007.10.008 Sosnouski D, 2007, J THORAC IMAG, V22, P77, DOI 10.1097/RTI.0b013e3180317a5b Wissner E, 2009, EUR J RADIOL, V72, P284, DOI 10.1016/j.ejrad.2008.07.004 YAMANAKA O, 1990, CATHETER CARDIO DIAG, V21, P28, DOI 10.1002/ccd.1810210110 NR 30 TC 9 Z9 9 U1 0 U2 4 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0147-8389 EI 1540-8159 J9 PACE JI PACE-Pacing Clin. Electrophysiol. PD DEC PY 2011 VL 34 IS 12 BP 1665 EP 1670 DI 10.1111/j.1540-8159.2011.03194.x PG 6 WC Cardiac & Cardiovascular Systems; Engineering, Biomedical WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Engineering GA 860HZ UT WOS:000297940700016 PM 21913945 DA 2026-04-17 ER PT J AU Sabaté, S Mases, A Guilera, N Canet, J Castillo, J Orrego, C Sabaté, A Fita, G Parramón, F Paniagua, P Rodríguez, A Sabaté, M AF Sabate, S. Mases, A. Guilera, N. Canet, J. Castillo, J. Orrego, C. Sabate, A. Fita, G. Parramon, F. Paniagua, P. Rodriguez, A. Sabate, M. CA ANESCARDIOCAT Grp TI Incidence and predictors of major perioperative adverse cardiac and cerebrovascular events in non-cardiac surgery SO BRITISH JOURNAL OF ANAESTHESIA LA English DT Article DE cerebrovascular disorders/complications; cohort studies; heart diseases/complications; operative statistics and numerical data; postoperative complications; prospective studies; risk assessment; risk factors; safety management ID LOGISTIC-REGRESSION ANALYSIS; INTRAOPERATIVE HYPOTENSION; MYOCARDIAL-INFARCTION; ATRIAL-FIBRILLATION; HEART-DISEASE; RISK INDEX; SURGICAL-PATIENTS; 1-YEAR MORTALITY; CELL TRANSFUSION; LUNG-CANCER AB Background. Major adverse cardiac and cerebrovascular events (MACCE) represent the most common cause of serious perioperative morbidity and mortality. Our aim was to identify risk factors for MACCE in a broad surgical population with intermediate-to-high surgery-specific risk and to build and validate a model to predict the risk of MACCE. Methods. A prospective, multicentre study of patients undergoing surgical procedures under general or regional anaesthesia in 23 hospitals. The main outcome was the occurrence of at least one perioperative MACCE, defined as any of the following complications from admittance to discharge: cardiac death, cerebrovascular death, non-fatal cardiac arrest, acute myocardial infarction, congestive heart failure, new cardiac arrhythmia, angina, or stroke. The MACCE predictive index was based on beta-coefficients and validated in an external data set. Results. Of 3387 patients recruited, 146 ( 4.3%) developed at least one MACCE. The regression model identified seven independent risk factors for MACCE: history of coronary artery disease, history of chronic congestive heart failure, chronic kidney disease, history of cerebrovascular disease, preoperative abnormal ECG, intraoperative hypotension, and blood transfusion. The area under the receiver-operating characteristic curve was 75.9% (95% confidence interval, 71.2-80.6%). Conclusions. The risk score based on seven objective and easily assessed factors can accurately predict MACCE occurrence after non-cardiac surgery in a population at intermediate-to-high surgery-specific risk. C1 [Sabate, S.] Fundacio Puigvert IUNA, Dept Anaesthesiol, Barcelona 08025, Spain. [Mases, A.] Hosp Mar, Dept Anaesthesiol, Barcelona, Spain. [Guilera, N.; Rodriguez, A.] Hosp Sabadell, Dept Anaesthesiol, Sabadell, Spain. [Canet, J.] Hosp Badalona Germans Trias & Pujol, Dept Anaesthesiol, Badalona, Spain. [Castillo, J.] Hosp Esperanza, Dept Anaesthesiol, Barcelona, Spain. [Orrego, C.] Autonomous Univ Barcelona, Avedis Donabedian Inst, Barcelona, Spain. [Orrego, C.] CIBER Epidemiol & Publ Hlth CIBERESP, Barcelona, Spain. [Sabate, A.] Hosp Univ Bellvitge, Dept Anaesthesiol, Barcelona, Spain. [Fita, G.] Hosp Clin Barcelona, Dept Anaesthesiol, Barcelona, Spain. [Sabate, M.] Hosp Clin Barcelona, Dept Cardiol, Barcelona, Spain. [Parramon, F.] Hosp Univ Josep Trueta, Dept Anaesthesiol, Girona, Spain. [Paniagua, P.] Hosp Santa Creu & Sant Pau, Dept Anaesthesiol, Barcelona, Spain. C3 Fundacio Puigvert; Hospital del Mar Research Institute; Hospital del Mar; Autonomous University of Barcelona; Parc Tauli Hospital Universitari; Hospital Germans Trias i Pujol; Autonomous University of Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; Universitat de Girona; Girona University Hospital Dr. Josep Trueta; Hospital of Santa Creu i Sant Pau RP Sabaté, S (corresponding author), Fundacio Puigvert IUNA, Dept Anaesthesiol, Carrer Cartagena 340, Barcelona 08025, Spain. EM 29285sst@comb.cat RI Sabate, Antoni/GRJ-7806-2022; Sabaté Tenas, Manel/AAX-7245-2021; Sabaté, Sergi/AAC-2619-2019; Roiguez, Anna/AAE-3980-2020 OI Sabate, Antoni/0000-0002-0813-026X; Sabaté Tenas, Manel/0000-0002-2316-3705; Sabaté, Sergi/0000-0001-7582-2832; Mases, Anna/0000-0003-1122-1186; Gine Serven, Marta/0000-0002-4958-4364; Roiguez, Anna/0000-0003-4441-147X; Orrego, Carola/0000-0002-2978-6268 FU Catalan Public Health Service (Departament de Salut de la Generalitat de Catalunya) within the World Alliance of Patient Safety in Catalonia, Spain FX Supported by the Catalan Public Health Service (Departament de Salut de la Generalitat de Catalunya) within the framework of World Alliance of Patient Safety in Catalonia, Spain. The funding sources had no role in the design or conduct of the study; the collection, management, analysis, or interpretation of the data; or the preparation, review, or approval of the manuscript. Presented in part at Euroanaesthesia 2009 Congress, Milan, Italy, June 6-9, 2009. CR Ackland GL, 2010, BRIT J ANAESTH, V105, P744, DOI 10.1093/bja/aeq245 Alpert JS, 2000, EUR HEART J, V21, P1502, DOI 10.1053/euhj.2000.2305 Amar D, 1996, CHEST, V110, P437, DOI 10.1378/chest.110.2.437 Beattie WS, 2009, ANESTHESIOLOGY, V110, P574, DOI 10.1097/ALN.0b013e31819878d3 Bijker JB, 2007, ANESTHESIOLOGY, V107, P213, DOI 10.1097/01.anes.0000270724.40897.8e Bijker JB, 2009, ANESTHESIOLOGY, V111, P1217, DOI 10.1097/ALN.0b013e3181c14930 Boersma E, 2005, AM J MED, V118, P1134, DOI 10.1016/j.amjmed.2005.01.064 Bursi F, 2009, EUR J VASC ENDOVASC, V37, P311, DOI 10.1016/j.ejvs.2008.12.002 Canet J, 2010, ANESTHESIOLOGY, V113, P1338, DOI 10.1097/ALN.0b013e3181fc6e0a CHARLSON ME, 1990, ANN SURG, V212, P66, DOI 10.1097/00000658-199007000-00010 CHARLSON ME, 1990, ANN SURG, V212, P567, DOI 10.1097/00000658-199011000-00003 Chassot PG, 2002, BRIT J ANAESTH, V89, P747, DOI 10.1093/bja/aef244 Cutlip DE, 2007, CIRCULATION, V115, P2344, DOI 10.1161/CIRCULATIONAHA.106.685313 Davenport DL, 2007, J AM COLL SURGEONS, V204, P1199, DOI 10.1016/j.jamcollsurg.2007.02.065 Devereaux PJ, 2008, LANCET, V371, P1839, DOI 10.1016/S0140-6736(08)60601-7 Devereaux PJ, 2005, CAN MED ASSOC J, V173, P779, DOI 10.1503/cmaj.050316 Eagle KA, 2002, CIRCULATION, V105, P1257, DOI 10.1161/hc1002.104956 FLEISHER LA, 1995, JAMA-J AM MED ASSOC, V274, P1671, DOI 10.1001/jama.1995.03530210025013 Fleisher LA, 2007, J AM COLL CARDIOL, V50, P1707, DOI 10.1016/j.jacc.2007.09.001 Ford MK, 2010, ANN INTERN MED, V152, P26, DOI 10.7326/0003-4819-152-1-201001050-00007 Gawande AA, 2007, J AM COLL SURGEONS, V204, P201, DOI 10.1016/j.jamcollsurg.2006.11.011 GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601 Kheterpal S, 2009, ANESTHESIOLOGY, V110, P58, DOI 10.1097/ALN.0b013e318190b6dc Koch CG, 2006, ANN THORAC SURG, V82, P1747, DOI 10.1016/j.athoracsur.2006.05.045 Kuduvalli M, 2005, EUR J CARDIO-THORAC, V27, P592, DOI 10.1016/j.ejcts.2005.01.030 Lee TH, 1999, CIRCULATION, V100, P1043, DOI 10.1161/01.CIR.100.10.1043 Liu H, 2002, DATA MIN KNOWL DISC, V6, P393, DOI 10.1023/A:1016304305535 Mahla E, 1998, ANESTH ANALG, V86, P16 Marrugat J, 2003, J EPIDEMIOL COMMUN H, V57, P634, DOI 10.1136/jech.57.8.634 Masia R, 1998, J EPIDEMIOL COMMUN H, V52, P707, DOI 10.1136/jech.52.11.707 Meierhenrich R, 2010, CRIT CARE, V14, DOI 10.1186/cc9057 OKELLY B, 1992, JAMA-J AM MED ASSOC, V268, P217, DOI 10.1001/jama.268.2.217 Onaitis M, 2010, ANN THORAC SURG, V90, P368, DOI 10.1016/j.athoracsur.2010.03.100 PASTORE JO, 1978, CIRCULATION, V57, P677, DOI 10.1161/01.CIR.57.4.677 Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3 Poldermans D, 2008, J AM COLL CARDIOL, V51, P1913, DOI 10.1016/j.jacc.2008.03.005 Poldermans D, 2009, EUR HEART J, V30, P2769, DOI 10.1093/eurheartj/ehp337 Priebe HJ, 2005, BRIT J ANAESTH, V95, P3, DOI 10.1093/bja/aei063 Sabaté S, 2008, ANN FR ANESTH, V27, P371, DOI 10.1016/j.annfar.2008.03.010 Sacco RL, 2006, STROKE, V37, P577, DOI 10.1161/01.STR.0000199147.30016.74 Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9 Klei WA, 2007, ANN SURG, V246, P165, DOI 10.1097/01.sla.0000261737.62514.63 VERSCHUREN WMM, 1995, JAMA-J AM MED ASSOC, V274, P131, DOI 10.1001/jama.274.2.131 Walsh SR, 2007, ANN ROY COLL SURG, V89, P91, DOI 10.1308/003588407X168253 Whitson BA, 2010, J SURG RES, V158, P20, DOI 10.1016/j.jss.2008.10.015 Wijeysundera DN, 2010, BRIT MED J, V340, DOI 10.1136/bmj.b5526 NR 46 TC 152 Z9 187 U1 0 U2 23 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0007-0912 EI 1471-6771 J9 BRIT J ANAESTH JI Br. J. Anaesth. PD DEC PY 2011 VL 107 IS 6 BP 879 EP 890 DI 10.1093/bja/aer268 PG 12 WC Anesthesiology WE Science Citation Index Expanded (SCI-EXPANDED) SC Anesthesiology GA 849VG UT WOS:000297152800006 PM 21890661 DA 2026-04-17 ER PT J AU Fernando, HC Jaklitsch, MT Walsh, GL Tisdale, JE Bridges, CD Mitchell, JD Shrager, JB AF Fernando, Hiran C. Jaklitsch, Michael T. Walsh, Garrett L. Tisdale, James E. Bridges, Charles D. Mitchell, John D. Shrager, Joseph B. TI The Society of Thoracic Surgeons Practice Guideline on the Prophylaxis and Management of Atrial Fibrillation Associated With General Thoracic Surgery: Executive Summary SO ANNALS OF THORACIC SURGERY LA English DT Article ID SUPRAVENTRICULAR ARRHYTHMIA; CARDIAC-SURGERY; RISK-FACTORS; ANTITHROMBOTIC THERAPY; RANDOMIZED-TRIAL; PREVENT STROKE; LUNG-CANCER; AMIODARONE; ANTICOAGULATION; METAANALYSIS C1 [Shrager, Joseph B.] Stanford Univ, Sch Med, Div Thorac Surg, Dept Cardiothorac Surg, Stanford, CA 94305 USA. Boston Univ, Sch Med, Boston Med Ctr, Dept Cardiothorac Surg, Boston, MA 02118 USA. Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Thorac Surg, Boston, MA 02115 USA. Univ Texas MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA. Purdue Univ, Coll Pharm, Dept Pharm Practice, Indianapolis, IN USA. Indiana Univ, Sch Med, Div Clin Pharmacol, Indianapolis, IN USA. Univ Penn, Sch Med, Div Cardiovasc Surg, Philadelphia, PA 19104 USA. Univ Colorado, Sch Med, Div Cardiothorac Surg, Aurora, CO USA. VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. C3 Stanford University; Boston University; Boston Medical Center; Harvard University; Harvard University Medical Affiliates; Brigham & Women's Hospital; Harvard Medical School; University of Texas System; UTMD Anderson Cancer Center; Purdue University System; Purdue University; Purdue University in Indianapolis; Indiana University System; Indiana University Indianapolis; University of Pennsylvania; University of Colorado System; University of Colorado Anschutz; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System RP Shrager, JB (corresponding author), Stanford Univ, Sch Med, Div Thorac Surg, Dept Cardiothorac Surg, 300 Pasteur Dr,Falk Bldg,2nd Flr, Stanford, CA 94305 USA. EM shrager@stanford.edu OI Fernando, Hiran/0000-0002-5330-7036 CR Allen MS, 1996, MAYO CLIN PROC, V71, P351, DOI 10.4065/71.4.351 Amar D, 1997, ANN THORAC SURG, V63, P1374 Amar D, 2000, J THORAC CARDIOV SUR, V120, P790, DOI 10.1067/mtc.2000.109538 [Anonymous], 1989, NEW ENGL J MED, V321, P406 Aranki SF, 1996, CIRCULATION, V94, P390, DOI 10.1161/01.CIR.94.3.390 ASAMURA H, 1993, J THORAC CARDIOV SUR, V106, P1104, DOI 10.1016/S0022-5223(19)33985-6 Ashrafian H, 2001, CHEST, V120, P275, DOI 10.1378/chest.120.1.275 Balser JR, 1998, ANESTHESIOLOGY, V89, P1052, DOI 10.1097/00000542-199811000-00004 Barbetakis Nikolaos, 2004, BMC Surg, V4, P7, DOI 10.1186/1471-2482-4-7 Bayliff CD, 1999, ANN THORAC SURG, V67, P182, DOI 10.1016/S0003-4975(98)01226-0 Blackshear JL, 1996, LANCET, V348, P633 BORGEAT A, 1989, ANN THORAC SURG, V48, P232, DOI 10.1016/0003-4975(89)90076-3 Brass LM, 1997, STROKE, V28, P2382, DOI 10.1161/01.STR.28.12.2382 Burgess DC, 2006, EUR HEART J, V27, P2846, DOI 10.1093/eurheartj/ehl272 Ciriaco P, 2000, EUR J CARDIO-THORAC, V18, P12, DOI 10.1016/S1010-7940(00)00428-0 Connolly SJ, 2009, NEW ENGL J MED, V360, P2066, DOI 10.1056/NEJMoa0901301 CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W Curtis JJ, 1998, ANN THORAC SURG, V66, P1766, DOI 10.1016/S0003-4975(98)00942-4 Daniels LJ, 2002, ANN THORAC SURG, V74, P860, DOI 10.1016/S0003-4975(02)03764-5 Daoud EG, 2004, CARDIOL CLIN, V22, P159, DOI 10.1016/S0733-8651(03)00136-X del Arco C, 2005, ANN EMERG MED, V46, P424, DOI 10.1016/j.annemergmed.2005.03.002 Diener HC, 1996, J NEUROL SCI, V143, P1, DOI 10.1016/S0022-510X(96)00308-5 Dunning Joel, 2004, Interact Cardiovasc Thorac Surg, V3, P503, DOI 10.1016/j.icvts.2004.05.004 Epstein AE, 2005, CHEST, V128, p24S, DOI 10.1378/chest.128.2_suppl.24S EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002 Foroulis CN, 2003, EUR J CARDIO-THORAC, V23, P384, DOI 10.1016/S1010-7940(02)00797-2 Gage BF, 2004, CIRCULATION, V110, P2287, DOI 10.1161/01.CIR.0000145172.55640.93 Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864 GOTLEY DC, 1990, BRIT J SURG, V77, P815, DOI 10.1002/bjs.1800770732 GREENSPON AJ, 1991, CIRCULATION, V84, P407 Harpole DH, 1996, ANN THORAC SURG, V61, P977, DOI 10.1016/0003-4975(95)01174-9 Hart RG, 1999, STROKE, V30, P1223, DOI 10.1161/01.STR.30.6.1223 Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003 Hart RG, 2007, ANN INTERN MED, V146, P857, DOI 10.7326/0003-4819-146-12-200706190-00007 Hilleman DE, 2002, PHARMACOTHERAPY, V22, P66, DOI 10.1592/phco.22.1.66.33492 Hylek EM, 1996, NEW ENGL J MED, V335, P540, DOI 10.1056/NEJM199608223350802 Irshad K, 2002, CAN J SURG, V45, P264 Izhar U, 2005, J THORAC CARDIOV SUR, V129, P401, DOI 10.1016/j.jtcvs.2004.06.029 Jakobsen CJ, 1997, J CARDIOTHOR VASC AN, V11, P746, DOI 10.1016/S1053-0770(97)90169-5 KAISER A, 1994, HELV CHIR ACTA, V60, P913 Kalman JM, 1995, ANN THORAC SURG, V60, P1709, DOI 10.1016/0003-4975(95)00718-0 KAY GN, 1988, AM J CARDIOL, V62, P490, DOI 10.1016/0002-9149(88)90991-5 Khosla Sandeep, 2003, Am J Ther, V10, P48, DOI 10.1097/00045391-200301000-00011 KISTLER JP, 1990, NEW ENGL J MED, V323, P1505 KOWEY PR, 1992, AM J CARDIOL, V69, P963, DOI 10.1016/0002-9149(92)90802-6 KROWKA MJ, 1987, CHEST, V91, P490, DOI 10.1378/chest.91.4.490 LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449 Lee John K, 2003, Card Electrophysiol Rev, V7, P178, DOI 10.1023/A:1027428003609 LINDGREN L, 1991, BRIT J ANAESTH, V66, P205, DOI 10.1093/bja/66.2.205 Luketich J D, 1998, JSLS, V2, P243 MALOUF JF, 1993, EUR HEART J, V14, P1451, DOI 10.1093/eurheartj/14.11.1451 MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527 McNamara RL, 2003, ANN INTERN MED, V139, P1018, DOI 10.7326/0003-4819-139-12-200312160-00012 Murthy SC, 2003, J THORAC CARDIOV SUR, V126, P1162, DOI 10.1016/S0022-5223(03)00974-7 NATTEL S, 1979, CIRCULATION, V59, P1158, DOI 10.1161/01.CIR.59.6.1158 Nielsen TD, 2004, CHEST, V126, P496, DOI 10.1378/chest.126.2.496 Olshansky B, 2004, J AM COLL CARDIOL, V43, P1201, DOI 10.1016/j.jacc.2003.11.032 Olshansky B, 2005, AM J CARDIOL, V95, P404, DOI 10.1016/j.amjcard.2004.09.044 Ormiston Thomas M, 2003, Heart Fail Monit, V4, P45 PETERSEN P, 1989, LANCET, V1, P175 Polanczyk CA, 1998, ANN INTERN MED, V129, P279, DOI 10.7326/0003-4819-129-4-199808150-00003 Reisinger J, 2004, EUR HEART J, V25, P1318, DOI 10.1016/j.ehj.2004.04.030 Rena O, 2001, EUR J CARDIO-THORAC, V20, P688, DOI 10.1016/S1010-7940(01)00890-9 RITCHIE AJ, 1993, ANN THORAC SURG, V55, P86, DOI 10.1016/0003-4975(93)90478-Z Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Sabel MS, 2002, ANN SURG ONCOL, V9, P210, DOI 10.1245/aso.2002.9.2.210 Sedrakyan A, 2005, J THORAC CARDIOV SUR, V129, P997, DOI 10.1016/j.jtcvs.2004.07.042 Shiga T, 2004, AM J MED, V117, P325, DOI 10.1016/j.amjmed.2004.03.030 SOUCIER R, 2003, MED SCI MONITOR, V9, pP119 STOUGARD J, 1969, THORAX, V24, P568, DOI 10.1136/thx.24.5.568 Stroke Prevention in Atrial Fibrillation Investigators, 1995, J Stroke Cerebrovasc Dis, V5, P147, DOI 10.1016/S1052-3057(10)80166-1 Terzi A, 1996, THORAC CARDIOV SURG, V44, P300, DOI 10.1055/s-2007-1012041 Tisdale JE, 2010, J THORAC CARDIOV SUR, V140, P45, DOI 10.1016/j.jtcvs.2010.01.026 Tisdale JE, 2009, ANN THORAC SURG, V88, P886, DOI 10.1016/j.athoracsur.2009.04.074 Tisdale JE, 1998, AM HEART J, V135, P739, DOI 10.1016/S0002-8703(98)70031-6 Valentine RJ, 2001, J AM COLL SURGEONS, V193, P499, DOI 10.1016/S1072-7515(01)01028-6 van der Woude HJ, 2005, CHEST, V127, P818, DOI 10.1378/chest.127.3.818 VanMieghem W, 1996, ANN THORAC SURG, V61, P1083, DOI 10.1016/0003-4975(96)00073-2 VANMIEGHEM W, 1994, CHEST, V105, P1642, DOI 10.1378/chest.105.6.1642 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 NR 80 TC 81 Z9 87 U1 0 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD SEP PY 2011 VL 92 IS 3 BP 1144 EP 1152 DI 10.1016/j.athoracsur.2011.06.104 PG 9 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 811WJ UT WOS:000294247400091 PM 21871327 DA 2026-04-17 ER PT J AU Nojiri, T Inoue, M Yamamoto, K Maeda, H Takeuchi, Y Funakoshi, Y Okumura, M AF Nojiri, Takashi Inoue, Masayoshi Yamamoto, Kazuhiro Maeda, Hajime Takeuchi, Yukiyasu Funakoshi, Yasunobu Okumura, Meinoshin TI B-Type Natriuretic Peptide as a Predictor of Postoperative Cardiopulmonary Complications in Elderly Patients Undergoing Pulmonary Resection for Lung Cancer SO ANNALS OF THORACIC SURGERY LA English DT Article ID RIGHT-VENTRICULAR DYSFUNCTION; END RESULTS DATABASE; LONG-TERM SURVIVAL; HEART-FAILURE; DIASTOLIC DYSFUNCTION; ATRIAL-FIBRILLATION; SURGERY; HYPERTENSION; EPIDEMIOLOGY; SURVEILLANCE AB Background. The objective of the present study was to evaluate the utility of B-type natriuretic peptide for prediction of postoperative cardiopulmonary complications in elderly patients undergoing pulmonary resection for lung cancer. Methods. A prospective observational study was performed involving 80 consecutive patients aged 75 years or older who underwent a scheduled pulmonary resection for lung cancer in two specialized thoracic centers between January 2008 and June 2010. Baseline clinical details were obtained, and spirometry and examination of serum B-type natriuretic peptide levels were performed before surgery. The primary endpoint was the incidence of postoperative cardiopulmonary complications. Results. Postoperative cardiopulmonary complications were identified in 34 (43%) patients; these patients had significantly higher preoperative B-type natriuretic peptide levels than those without cardiopulmonary complications (84.0 +/- 93.7 pg/mL vs 22.0 +/- 18.2 pg/mL; p < 0.0001). The area under the receiver operating characteristic curve for B-type natriuretic peptide to predict postoperative cardiopulmonary complications after pulmonary resection for lung cancer was 0.85 (95% confidence interval 0.76 to 0.94; p < 0.0001). A B-type natriuretic peptide value of 30 pg/mL had a sensitivity of 79% and a specificity of 83% for predicting postoperative cardiopulmonary complications after pulmonary resection for lung cancer. The incidences of both cardiovascular and respiratory complications were significantly higher in patients with preoperative B-type natriuretic peptide levels of 30 pg/mL or more. Conclusions. Preoperative B-type natriuretic peptide level could be a useful predictor of postoperative cardiopulmonary complications in elderly patients after pulmonary resection for lung cancer. (Ann Thorac Surg 2011;92:1051-5) (C) 2011 by The Society of Thoracic Surgeons C1 [Nojiri, Takashi] Osaka Univ, Grad Sch Med, Dept Gen Thorac Surg, Suita, Osaka 5650871, Japan. Osaka Univ, Grad Sch Med, Dept Cardiol, Suita, Osaka 5650871, Japan. Toneyama Natl Hosp, Dept Gen Thorac Surg, Toyonaka, Osaka, Japan. C3 University of Osaka; University of Osaka RP Nojiri, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Gen Thorac Surg, Yamadaoka 2-2,L5, Suita, Osaka 5650871, Japan. EM nojirit@thoracic.med.osaka-u.ac.jp CR Al-Omari MA, 2008, AM J CARDIOL, V101, P1759, DOI 10.1016/j.amjcard.2008.02.067 AMAR D, 1995, CHEST, V108, P349, DOI 10.1378/chest.108.2.349 Bando M, 1999, RESP MED, V93, P507, DOI 10.1016/S0954-6111(99)90094-X Birim Ö, 2005, EUR J CARDIO-THORAC, V28, P759, DOI 10.1016/j.ejcts.2005.06.046 Birim Ö, 2006, J THORAC CARDIOV SUR, V132, P491, DOI 10.1016/j.jtcvs.2006.04.010 Cowie MR, 1997, LANCET, V350, P1349, DOI 10.1016/S0140-6736(97)06031-5 Cuthbertson BH, 2007, ANAESTHESIA, V62, P875, DOI 10.1111/j.1365-2044.2007.05146.x Dal-Bianco JP, 2008, MAYO CLIN PROC, V83, P289, DOI 10.4065/83.3.289 Goto T, 2010, AM J CARDIOL, V106, P87, DOI 10.1016/j.amjcard.2010.01.372 Leuchte HH, 2004, J AM COLL CARDIOL, V43, P764, DOI 10.1016/j.jacc.2003.09.051 LOUIE EK, 1995, CIRCULATION, V92, P819, DOI 10.1161/01.CIR.92.4.819 Lubien E, 2002, CIRCULATION, V105, P595, DOI 10.1161/hc0502.103010 Mery CM, 2005, CHEST, V128, P237, DOI 10.1378/chest.128.1.237 Nagaya N, 1998, J AM COLL CARDIOL, V31, P202, DOI 10.1016/S0735-1097(97)00452-X Nojiri T, 2010, EUR J CARDIO-THORAC, V37, P787, DOI 10.1016/j.ejcts.2009.09.043 Owonikoko TK, 2007, J CLIN ONCOL, V25, P5570, DOI 10.1200/JCO.2007.12.5435 Pales RE, 1993, CHEST, V104, P155 Reesink HJ, 2007, ANN THORAC SURG, V84, P537, DOI 10.1016/j.athoracsur.2007.04.006 Tsutamoto T, 1997, CIRCULATION, V96, P509 NR 19 TC 29 Z9 30 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD SEP PY 2011 VL 92 IS 3 BP 1051 EP 1055 DI 10.1016/j.athoracsur.2011.03.085 PG 5 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 811WJ UT WOS:000294247400059 PM 21871299 DA 2026-04-17 ER PT J AU Cagini, L Capozzi, R Tassi, V Savignani, C Quintaliani, G Reboldi, G Puma, F AF Cagini, Lucio Capozzi, Rosanna Tassi, Valentina Savignani, Claudia Quintaliani, Giuseppe Reboldi, Gianpaolo Puma, Francesco TI Fluid and electrolyte balance after major thoracic surgery by bioimpedance and endocrine evaluation SO EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY LA English DT Article; Proceedings Paper CT 18th European Conference on General Thoracic Surgery of the European-Society-of-Thoracic-Surgeons CY MAY 30-JUN 02, 2010 CL Valladolid, SPAIN SP European Soc Thorac Surg DE Pulmonary surgical procedures; Fluid balance; Brain natriuretic peptide (BNP); Bioimpedance analysis (BIA) ID NATRIURETIC PEPTIDE; PULMONARY RESECTION; LUNG-CANCER; ATRIAL-FIBRILLATION; RECOVERY; TRIAL AB Objective: Weight gain with oedema development is a complication of major surgical procedures with an incidence as high as 40%. Fluid retention is not always clinically evident and it is reported despite fluid-restriction regime. The causes are several and not totally clear. We performed a prospective study to assess the amount of fluid accumulation and redistribution observed after major thoracic surgery. Methods: In 49 patients submitted to lobectomy with systematic lymph node dissection for lung cancer, we measured preoperatively and on the postoperative days 1, 2, 4 and 7, body weight, fluid balance, brain natriuretic peptide (BNP) and bioimpedance analysis (BIA)-derived parameters resistance (R) and reactance (X(c)). Results: The postoperative course was characterised by significant changes. Mean increase in body weight was 2.7 kg ((1.9-3.4); p < 0.001) on postoperative day 2. Most of the patients had a negative basal fluid balance (-244 ml (-520 to -50)), whereas, on postoperative day 2, we observed a positive and significant change (+968 ml (646-1456), p < 0.001)). Total body R and X(c) fell on the first day (p < 0.001), anticipating the changes in weight and fluid balance. BNP increased on day 1, immediately after surgery, and remained significantly above basal values for the entire observation period (p < 0.001), in the absence of clinical signs of heart failure. Conclusion: The three methods used consistently showed a significant fluid retention over the course of the study. BIA was an easy, reproducible and non-invasive method for the estimation and early detection of fluid retention. Increase in BNP may be related to the systemic reaction to stress and to the decreased pulmonary vascular bed. We found no correlation between fluid retention and length of anaesthesia, sex, age, blood loss and body mass index. The clinical and prognostic implication of weight gain may be relevant to patient's health. (C) 2011 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved. C1 [Cagini, Lucio; Capozzi, Rosanna; Tassi, Valentina; Puma, Francesco] Univ Perugia, Osped S Maria della Misericordia, Thorac Surg Unit, I-06156 Perugia, Italy. [Savignani, Claudia; Quintaliani, Giuseppe] Univ Perugia, Osped S Maria della Misericordia, Dept Nephrol Dialysis, I-06156 Perugia, Italy. [Reboldi, Gianpaolo] Univ Perugia, Osped S Maria della Misericordia, Dept Internal Med, I-06156 Perugia, Italy. C3 University of Perugia; Hospital Santa Maria della Misericordia; Hospital Santa Maria della Misericordia; University of Perugia; Hospital Santa Maria della Misericordia; University of Perugia RP Cagini, L (corresponding author), Univ Perugia, Osped S Maria della Misericordia, Thorac Surg Unit, I-06156 Perugia, Italy. EM lucio.cagini@unipg.it RI ; Reboldi, Gianpaolo/A-3444-2009; Tassi, Valentina/OJU-9356-2025 OI Puma, Francesco/0000-0002-6861-168X; cagini, lucio/0000-0001-9464-9430; Reboldi, Gianpaolo/0000-0002-9877-0702; CR Ackland GL, 2004, BRIT J ANAESTH, V92, P134, DOI 10.1093/bja/aeh015 [Anonymous], 2015, AJCC Cancer Staging Manual Aroom KR, 2009, J SURG RES, V153, P23, DOI 10.1016/j.jss.2008.04.019 Brandstrup B, 2003, ANN SURG, V238, P641, DOI 10.1097/01.sla.0000094387.50865.23 Brandstrup B, 2006, BEST PRACT RES-CLIN, V20, P265, DOI 10.1016/j.bpa.2005.10.007 Cardinale D, 2007, CIRCULATION, V115, P1339, DOI 10.1161/CIRCULATIONAHA.106.647008 Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109 Hoksch Beatrix, 2007, Interact Cardiovasc Thorac Surg, V6, P155 Holte K, 2002, BRIT J ANAESTH, V89, P622, DOI 10.1093/bja/aef220 Itobi E, 2006, BJS-BRIT J SURG, V93, P354, DOI 10.1002/bjs.5259 Jordan S, 2000, EUR RESPIR J, V15, P790, DOI 10.1034/j.1399-3003.2000.15d26.x Kotler DP, 1996, AM J CLIN NUTR, V64, P489 Lobo DN, 2006, BEST PRACT RES-CLIN, V20, P439, DOI 10.1016/j.bpa.2006.03.004 Lobo DN, 2002, LANCET, V359, P1812, DOI 10.1016/S0140-6736(02)08711-1 LOWELL JA, 1990, CRIT CARE MED, V18, P728, DOI 10.1097/00003246-199007000-00010 Maisel AS, 2002, NEW ENGL J MED, V347, P161, DOI 10.1056/NEJMoa020233 Mohamed MK, 2005, ANN ONCOL, V16, P780, DOI 10.1093/annonc/mdi157 Nojiri T, 2010, EUR J CARDIO-THORAC, V37, P787, DOI 10.1016/j.ejcts.2009.09.043 OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014 Powell-Tuck J, British Consensus Guidelines on Intravenous Fluid Therapy for Adult Surgical Patients (GIFTASUP) Rosenthal MH, 1999, CHEST, V115, p106S, DOI 10.1378/chest.115.suppl_2.106S Slinger P, 1999, Curr Opin Anaesthesiol, V12, P49, DOI 10.1097/00001503-199902000-00009 Sweeney KJ, 2005, BJS-BRIT J SURG, V92, P989, DOI 10.1002/bjs.4844 Tayama K, 2002, ANN THORAC SURG, V73, P1582, DOI 10.1016/S0003-4975(02)03417-3 Wei SH, 2008, ANN THORAC SURG, V86, P266, DOI 10.1016/j.athoracsur.2008.03.017 NR 25 TC 25 Z9 28 U1 0 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1010-7940 J9 EUR J CARDIO-THORAC JI Eur. J. Cardio-Thorac. Surg. PD AUG PY 2011 VL 40 IS 2 BP E71 EP E76 DI 10.1016/j.ejcts.2011.03.030 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 791TX UT WOS:000292690200001 PM 21530295 DA 2026-04-17 ER PT J AU Rueth, NM Parsons, HM Habermann, EB Groth, SS Virnig, BA Tuttle, TM Andrade, RS Maddaus, MA D'Cunha, J AF Rueth, Natasha M. Parsons, Helen M. Habermann, Elizabeth B. Groth, Shawn S. Virnig, Beth A. Tuttle, Todd M. Andrade, Rafael S. Maddaus, Michael A. D'Cunha, Jonathan TI The Long-term Impact of Surgical Complications After Resection of Stage I Nonsmall Cell Lung Cancer A Population-based Survival Analysis SO ANNALS OF SURGERY LA English DT Article; Proceedings Paper CT 46th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY JUN 04-08, 2010 CL Chicago, IL SP Amer Soc Clin Oncol ID POSTOPERATIVE ATRIAL-FIBRILLATION; ASSISTED THORACIC-SURGERY; HOSPITAL VOLUME; LOBECTOMY; THORACOTOMY; MORTALITY; VATS AB Objective: Surgical morbidity may influence long-term cancer survival. Because resection of early stage nonsmall cell lung cancer (NSCLC) is primary therapy, we sought to determine the survival impact of surgical complications for elderly patients undergoing resection of stage I NSCLC. Methods: Using the linked Surveillance Epidemiology and End Results-Medicare database (2000-2005), we identified elderly patients who underwent lobectomy for stage I NSCLC. We then assessed the unadjusted association between in-hospital, postoperative complications, and long-term survival for patients who survived more than 30 days after resection using the Kaplan-Meier method. Finally, we used Cox proportional hazards regression to evaluate the relationship between postoperative complications and 5-year cancer-specific (CSS) and overall survival (OS) after adjusting for patient, tumor, and treatment characteristics. Results: We identified 3996 eligible patients. The overall in-hospital, postoperative complication rate was 54.2%. Pulmonary complications were the most common (n = 1464) followed by cardiac (n = 916). Unadjusted 5-year CSS was significantly worse for those who had an in-hospital, postoperative complication (70.9%) compared to those who did not (78.9%, P < 0.001). OS was also significantly worse (P < 0.001) for patients who developed a complication. Complications continued to predict worse 5-year CSS and OS after adjusting for patient, tumor, and treatment characteristics (HR: 1.38, 95% CI, 1.17-1.64). Conclusions: The occurrence of in-hospital postoperative complications was an independent predictor of worse 5-year CSS after resection of stage I NSCLC. Importantly, the impact of surgical complications extends well after the initial perioperative period. These findings may help identify important targets for best practice guidelines and quality-of-care measures. C1 [D'Cunha, Jonathan] Univ Minnesota, Dept Surg, Div Thorac & Foregut Surg, Minneapolis, MN 55455 USA. [Parsons, Helen M.; Virnig, Beth A.] Univ Minnesota, Sch Publ Hlth, Div Hlth Policy & Management, Minneapolis, MN 55455 USA. [Virnig, Beth A.; Tuttle, Todd M.; Maddaus, Michael A.; D'Cunha, Jonathan] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA. C3 University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities RP D'Cunha, J (corresponding author), Univ Minnesota, Dept Surg, Div Thorac & Foregut Surg, MMC 207,420 Delaware St SE, Minneapolis, MN 55455 USA. EM jdcunha@umn.edu OI Habermann, Elizabeth/0000-0002-1140-003X; Tuttle, Todd/0000-0001-6603-2062 CR Allen MS, 2006, ANN THORAC SURG, V81, P1013, DOI 10.1016/j.athoracsur.2005.06.066 [Anonymous], CLIN PRACT GUID ONC [Anonymous], CANC STAG HDB AJCC C [Anonymous], Annual report to the nation 2021: special topic: patient economic burden of cancer care Bach PB, 2001, NEW ENGL J MED, V345, P181, DOI 10.1056/NEJM200107193450306 Bilimoria KY, 2008, J AM COLL SURGEONS, V207, P510, DOI 10.1016/j.jamcollsurg.2008.04.033 Birim Ö, 2005, EUR J CARDIO-THORAC, V28, P759, DOI 10.1016/j.ejcts.2005.06.046 BLUMBERG N, 1988, ANN SURG, V207, P410, DOI 10.1097/00000658-198804000-00007 Boffa DJ, 2008, J THORAC CARDIOV SUR, V135, P247, DOI 10.1016/j.jtcvs.2007.07.060 Bramer S, 2010, ANN THORAC SURG, V90, P443, DOI 10.1016/j.athoracsur.2010.03.083 Carless PA, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002042.pub2 Filardo G, 2010, ANN THORAC SURG, V90, P474, DOI 10.1016/j.athoracsur.2010.02.081 Flores RM, 2009, J THORAC CARDIOV SUR, V138, P11, DOI 10.1016/j.jtcvs.2009.03.030 Ginsberg RJ., 1995, ANN THORAC SURG, V60, P615, DOI DOI 10.1016/0003-4975(95)00537-U Greenblatt DY, 2010, ANN SURG, V251, P659, DOI 10.1097/SLA.0b013e3181d3d27c HOLMES CE, 1995, ANN THORAC SURG, V60, P615, DOI 10.1016/0003-4975(95)00537-u Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563 KIRBY TJ, 1995, J THORAC CARDIOV SUR, V109, P997, DOI 10.1016/S0022-5223(95)70326-8 Kirby TJ, 1995, J THORAC CARDIOVASC, V109, P1001 Klabunde CN, 2007, ANN EPIDEMIOL, V17, P584, DOI 10.1016/j.annepidem.2007.03.011 Ou SHI, 2007, CANCER-AM CANCER SOC, V110, P1532, DOI 10.1002/cncr.22938 Rueth NM, 2010, ANN THORAC SURG, V89, pS2107, DOI 10.1016/j.athoracsur.2010.03.020 Schipper PH, 2009, ANN THORAC SURG, V88, P1566, DOI 10.1016/j.athoracsur.2009.08.055 Schrag D, 2003, J SURG ONCOL, V83, P68, DOI 10.1002/jso.10244 Verhoef C, 2007, ANN SURG ONCOL, V14, P1678, DOI 10.1245/s10434-006-9333-0 Vogel TR, 2010, J AM COLL SURGEONS, V211, P784, DOI 10.1016/j.jamcollsurg.2010.08.009 Warren JL, 2002, MED CARE, V40, P3 Whitson BA, 2008, ANN THORAC SURG, V86, P1735, DOI 10.1016/j.athoracsur.2008.07.001 Whitson BA, 2007, ANN THORAC SURG, V83, P1965, DOI 10.1016/j.athoracsur.2007.01.049 Yang XY, 2009, WORLD J SURG, V33, P1857, DOI 10.1007/s00268-009-0137-9 Zaydfudim V, 2009, ARCH SURG-CHICAGO, V144, P656, DOI 10.1001/archsurg.2009.117 NR 31 TC 70 Z9 82 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD AUG PY 2011 VL 254 IS 2 BP 368 EP 374 DI 10.1097/SLA.0b013e31822150fe PG 7 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S) SC Surgery GA 794OC UT WOS:000292908700027 PM 21617585 DA 2026-04-17 ER PT J AU Subbiah, IM Lenihan, DJ Tsimberidou, AM AF Subbiah, Ishwaria M. Lenihan, Daniel J. Tsimberidou, Apostolia M. TI Cardiovascular Toxicity Profiles of Vascular-Disrupting Agents SO ONCOLOGIST LA English DT Article DE Vascular-disrupting agent; Hypertension; Cardiovascular toxicity; Combretastatin; Phase 1 ID COMBRETASTATIN A-4 PHOSPHATE; PHASE-I TRIAL; 5,6-DIMETHYLXANTHENONE-4-ACETIC ACID DMXAA; ADVANCED SOLID TUMORS; CELL LUNG-CANCER; TARGETING AGENT; ANTIVASCULAR AGENT; A4 PHOSPHATE; ASA404 VADIMEZAN; CARBOPLATIN AB Background. Vascular-disrupting agents (VDAs) represent a new class of chemotherapeutic agent that targets the existing vasculature in solid tumors. Preclinical and early-phase trials have demonstrated the promising therapeutic benefits of VDAs but have also uncovered a distinctive toxicity profile highlighted by cardiovascular events. Methods. We reviewed all preclinical and prospective phase I-III clinical trials published up to August 2010 in MEDLINE and the American Association of Cancer Research and American Society of Clinical Oncology meeting abstracts of small-molecule VDAs, including combretastatin A4 phosphate (CA4P), combretastatin A1 phosphate (CA1P), MPC-6827, ZD6126, AVE8062, and ASA404. Results. Phase I and II studies of CA1P, ASA404, MPC-6827, and CA4P all reported cardiovascular toxicities, with the most common cardiac events being National Cancer Institute Common Toxicity Criteria (version 3) grade 1-3 hypertension, tachyarrhythmias and bradyarrhythmias, atrial fibrillation, and myocardial infarction. Cardiac events were dose-limiting toxicities in phase I trials with VDA monotherapy and combination therapy. Conclusions. Early-phase trials of VDAs have revealed a cardiovascular toxicity profile similar to that of their vascular-targeting counterparts, the angiogenesis inhibitors. As these agents are added to the mainstream chemotherapeutic arsenal, careful identification of baseline cardiovascular risk factors would seem to be a prudent strategy. Close collaboration with cardiology colleagues for early indicators of serious cardiac adverse events will likely minimize toxicity while optimizing the therapeutic potential of VDAs and ultimately enhancing patient outcomes. The Oncologist 2011; 16: 1120-1130 C1 [Tsimberidou, Apostolia M.] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA. [Subbiah, Ishwaria M.] Univ Texas Med Sch Houston, Dept Internal Med, Houston, TX USA. [Lenihan, Daniel J.] Vanderbilt Heart & Vasc Inst, Div Cardiovasc Med, Nashville, TN USA. C3 University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; Vanderbilt University RP Tsimberidou, AM (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, 1515 Holcombe Blvd,Unit 455, Houston, TX 77030 USA. EM atsimber@mdanderson.org RI ; Subbiah, Ishwaria M/AAW-1733-2021 OI Tsimberidou, Apostolia M/0000-0003-2713-233X; Subbiah, Ishwaria M/0000-0002-0758-7911 CR Anthony S. P., 2008, J CLIN ONCOL, V26, P2531, DOI DOI 10.1200/JCO.2008.26.15SUPP1.2531 Atkinson JM, 2010, CANCER RES, V70, P6902, DOI 10.1158/0008-5472.CAN-10-1440 Baguley BC, 1997, ONCOL RES, V9, P55 Baguley BC, 2003, LANCET ONCOL, V4, P141, DOI 10.1016/S1470-2045(03)01018-0 Baguley BC, 2010, P 101 ANN M AM ASS C Bello CL, 2009, CLIN CANCER RES, V15, P7045, DOI 10.1158/1078-0432.CCR-09-1521 Bilenker JH, 2005, CLIN CANCER RES, V11, P1527, DOI 10.1158/1078-0432.CCR-04-1434 Breitbart E, 2010, P 101 ANN M AM ASS C Cai SX, 2007, RECENT PAT ANTI-CANC, V2, P79, DOI 10.2174/157489207779561462 Cardinale D, 2010, J CLIN ONCOL, V28, P3910, DOI 10.1200/JCO.2009.27.3615 Chen CP, 2010, ANTICANCER RES, V30, P2813 Chong G, 2010, J CLIN ONCOL, V28, P3054 Davis PD, 2002, CANCER RES, V62, P7247 Delmonte A, 2009, EXPERT OPIN INV DRUG, V18, P1541, DOI 10.1517/13543780903213697 DeRemer DL, 2008, CLIN THER, V30, P1956, DOI 10.1016/j.clinthera.2008.11.014 Desai J, 2009, J CLIN ONCOL, V27 Dowlati A, 2002, CANCER RES, V62, P3408 Evans DB, 2010, P 101 ANN M AM ASS C Folkes LK, 2007, CHEM RES TOXICOL, V20, P1885, DOI 10.1021/tx7002195 Galbraith SM, 2001, ANTICANCER RES, V21, P93 Garon EB, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.7587 Gridelli C, 2009, ONCOLOGIST, V14, P612, DOI 10.1634/theoncologist.2008-0287 Hida T, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.e13106 Hinnen P, 2007, BRIT J CANCER, V96, P1159, DOI 10.1038/sj.bjc.6603694 Huang A, 2010, P 101 ANN M AM ASS C Hwu W., 2010, J CLIN ONCOL S, V28, DOI DOI 10.1200/JCO.2010.28.15_SUPPL.8531 Jameson MB, 2003, BRIT J CANCER, V88, P1844, DOI 10.1038/sj.bjc.6600992 Johnson FM, 2010, CANCER-AM CANCER SOC, V116, P1582, DOI 10.1002/cncr.24927 Konerding MA, 2001, BRIT J CANCER, V84, P1354, DOI 10.1054/bjoc.2001.1809 Kremmidiotis G, 2010, MOL CANCER THER, V9, P1562, DOI 10.1158/1535-7163.MCT-09-0815 Kuo CC, 2004, CANCER RES, V64, P4621, DOI 10.1158/0008-5472.CAN-03-3474 Lee JW, 2009, CLIN CANCER RES, V15, P2695, DOI 10.1158/1078-0432.CCR-08-2966 LoRusso PM, 2008, INVEST NEW DRUG, V26, P159, DOI 10.1007/s10637-008-9112-9 Madlambayan GJ, 2010, BLOOD, V116, P1539, DOI 10.1182/blood-2009-06-230474 Maitland ML, 2010, JNCI-J NATL CANCER I, V102, P596, DOI 10.1093/jnci/djq091 McKeage MJ, 2009, LUNG CANCER, V65, P192, DOI 10.1016/j.lungcan.2009.03.027 Millward M, 2009, J CLIN ONCOL, V27 Mita A.C., 2008, J CLIN ONCOL, V26, P3525 Nathan PD, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.3550 Ng Q., 2005, J CLIN ONCOL, V23 Novartis Oncology, NOVARTIS ONCOLOGY AT Philpott M, 1995, CANCER CHEMOTH PHARM, V36, P143 Pilat MJ, 2006, J CELL BIOCHEM, V99, P1021, DOI 10.1002/jcb.20783 Pili R, 2010, CLIN CANCER RES, V16, P2906, DOI 10.1158/1078-0432.CCR-09-3026 Pleiman CM, 2007, P 98 ANN M AM ASS CA RICART AD, 2006, J CLIN ONCOL, V24, P3096 Rustin GJ, 2010, BRIT J CANCER, V102, P1355, DOI 10.1038/sj.bjc.6605650 Rustin GJS, 2003, J CLIN ONCOL, V21, P2815, DOI 10.1200/JCO.2003.05.185 Rustin GJS, 2003, BRIT J CANCER, V88, P1160, DOI 10.1038/sj.bjc.6600885 Sarkiss MG, 2007, CANCER, V109, P621, DOI 10.1002/cncr.22434 Savvides P, 2006, J CLIN ONCOL Siemann DW, 2008, ANTICANCER RES, V28, P2027 Siemann DW, 2005, CLIN CANCER RES, V11, P416 Stevenson JP, 2003, J CLIN ONCOL, V21, P4428, DOI 10.1200/JCO.2003.12.986 Thaker PH, 2007, CELL CYCLE, V6, P430, DOI 10.4161/cc.6.4.3829 Tozer GM, 1999, CANCER RES, V59, P1626 Tozer GM, 2001, CANCER RES, V61, P6413 Traynor AM, 2010, INVEST NEW DRUG, V28, P509, DOI 10.1007/s10637-009-9264-2 Tresca P, 2010, J CLIN ONCOL S, V28, P3023 Triozzi P, 2010, P 101 ANN M AM ASS C Tsimberidou AM, 2009, P 100 ANN M AM ASS C Wachsberger PR, 2005, CLIN CANCER RES, V11, P835 Wang LCS, 2006, ONCOL RES, V16, P1 Wang LCS, 2009, NEOPLASIA, V11, P793, DOI 10.1593/neo.09506 Zweifel M, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.2594 NR 65 TC 81 Z9 89 U1 0 U2 27 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 EI 1549-490X J9 ONCOLOGIST JI Oncologist PD AUG PY 2011 VL 16 IS 8 BP 1120 EP 1130 DI 10.1634/theoncologist.2010-0432 PG 11 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA 812KH UT WOS:000294291800009 PM 21742963 OA Green Published, Bronze DA 2026-04-17 ER PT J AU Venkatesh, V Verdini, D Ghoshhajra, B AF Venkatesh, Vikram Verdini, Daniel Ghoshhajra, Brian TI Normal Magnetic Resonance Imaging of the Thorax SO MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA LA English DT Article DE Magnetic resonance imaging; Thorax; MR pulse sequences; Intrathoracic structures ID PATENT FORAMEN OVALE; CELL LUNG-CANCER; PULMONARY VEIN; ATRIAL-FIBRILLATION; GASTROESOPHAGEAL JUNCTION; CATHETER ABLATION; LYMPH-NODES; MR; ANATOMY; CT AB The soft tissue contrast properties of magnetic resonance (MR) allow excellent discrimination of most intrathoracic structures other than the lungs, and allow good insight into normal anatomy. Using MR imaging, the normal cardiorespiratory system, including portions of the lungs and pleural spaces, as well as the mediastinal, chest wall, and cardiac structures can be well depicted. In addition, using newer MR pulse sequences, dynamic ECG-gated imaging can also be achieved, which allows a window into the normal functional processes of these organs. C1 [Venkatesh, Vikram; Verdini, Daniel; Ghoshhajra, Brian] Massachusetts Gen Hosp, Dept Radiol, Cardiac MR PET CT Program, Boston, MA 02114 USA. C3 Harvard University; Harvard University Medical Affiliates; Massachusetts General Hospital RP Ghoshhajra, B (corresponding author), Massachusetts Gen Hosp, Dept Radiol, Cardiac MR PET CT Program, 55 Fruit St, Boston, MA 02114 USA. EM bghoshhajra@partners.org RI Ghoshhajra, Brian/J-2114-2016 OI Ghoshhajra, Brian/0000-0002-3865-3432 CR Anderson RH, 2004, J ANAT, V205, P159, DOI 10.1111/j.0021-8782.2004.00330.x Anderson RH, 2002, HEART, V88, P104, DOI 10.1136/heart.88.1.104 Anderson RH, 1998, ANN THORAC SURG, V66, P616, DOI 10.1016/S0003-4975(98)00574-8 Anderson RH, 2007, EUROPACE, V9, P3, DOI 10.1093/europace/eum200 Bhatt MR, 2009, J THORAC CARDIOV SUR, V138, P1123, DOI 10.1016/j.jtcvs.2008.10.056 Bogaert J, 2005, CLIN CARDIAC MR Boxt LM, 1999, RADIOL CLIN N AM, V37, P379, DOI 10.1016/S0033-8389(05)70100-7 Burman ED, 2008, CIRC-CARDIOVASC IMAG, V1, P104, DOI 10.1161/CIRCIMAGING.108.768911 Cerqueira MD, 2002, CIRCULATION, V105, P539, DOI 10.1161/hc0402.102975 Curcic J, 2010, RADIOLOGY, V257, P115, DOI 10.1148/radiol.10092340 Davies RR, 2006, ANN THORAC SURG, V81, P169, DOI 10.1016/j.athoracsur.2005.06.026 DEGEER G, 1986, RADIOLOGY, V158, P313, DOI 10.1148/radiology.158.2.3941858 Faust RA, 2002, INT J PEDIATR OTORHI, V65, P27, DOI 10.1016/S0165-5876(02)00123-4 Faust RA, 2001, LARYNGOSCOPE, V111, P2187, DOI 10.1097/00005537-200112000-00022 FELSON B, 1969, SEMIN ROENTGENOL, V4, P41, DOI 10.1016/0037-198X(69)90016-9 FORTIER M, 1994, RADIOGRAPHICS, V14, P597, DOI 10.1148/radiographics.14.3.8066274 HAGEN PT, 1984, MAYO CLIN PROC, V59, P17, DOI 10.1016/S0025-6196(12)60336-X Hasegawa I, 2008, J THORAC IMAG, V23, P157, DOI 10.1097/RTI.0b013e318166d2f5 Hofmann U, 1991, Prog Pediatr Surg, V27, P221 Kaseno K, 2008, AM J CARDIOL, V101, P1638, DOI 10.1016/j.amjcard.2008.01.053 Kasprian G, 2006, EUR J RADIOL, V57, P261, DOI 10.1016/j.ejrad.2005.11.031 Kato R, 2003, CIRCULATION, V107, P2004, DOI 10.1161/01.CIR.0000061951.81767.4E Kauczor HU, 2000, EUR J RADIOL, V34, P196, DOI 10.1016/S0720-048X(00)00199-6 Khaja A, 2005, PACE, V28, P855, DOI 10.1111/j.1540-8159.2005.00168.x Krasuski RA, 2009, JAMA-J AM MED ASSOC, V302, P290, DOI 10.1001/jama.2009.1012 Kulinna-Cosentini C, 2007, J MAGN RESON IMAGING, V25, P749, DOI 10.1002/jmri.20868 Kwong RY, 2008, CONTEMP CARDIOL, P1, DOI 10.1007/978-1-59745-306-6 LEE VS, 2005, CARDIOVASCULAR MRI P LENNON EA, 1965, BRIT J RADIOL, V38, P937, DOI 10.1259/0007-1285-38-456-937 Lickfett L, 2004, J CARDIOVASC ELECTR, V15, P538, DOI 10.1046/j.1540-8167.2004.03499.x Lin Fay Y, 2008, J Cardiovasc Comput Tomogr, V2, P298, DOI 10.1016/j.jcct.2008.08.002 Lin FY, 2009, ACAD RADIOL, V16, P981, DOI 10.1016/j.acra.2009.02.013 Manabe T, 2009, ABDOM IMAGING, V34, P419, DOI 10.1007/s00261-006-9093-0 Mansour M, 2004, J CARDIOVASC ELECTR, V15, P387, DOI 10.1046/j.1540-8167.2004.03515.x MASUI T, 1992, RADIOLOGY, V182, P369, DOI 10.1148/radiology.182.2.1732952 MCLOUD TC, 1991, AM J ROENTGENOL, V156, P1145, DOI 10.2214/ajr.156.6.2028857 McLoud TC, 1998, CLIN CHEST MED, V19, P261, DOI 10.1016/S0272-5231(05)70076-9 Meng J, 2010, PACE, V33, P661, DOI 10.1111/j.1540-8159.2009.02671.x MILLER S, 2004, CARDIAC IMAGING REQU Misselt AJ, 2008, MAGN RESON IMAGING C, V16, P185, DOI 10.1016/j.mric.2008.02.011 MOORE AV, 1983, AM J ROENTGENOL, V141, P241, DOI 10.2214/ajr.141.2.241 Moore K.L.D., 2005, CLIN ORIENTED ANATOM, V5 Mountain CF, 1997, CHEST, V111, P1718, DOI 10.1378/chest.111.6.1718 Nakayama J, 2010, J COMPUT ASSIST TOMO, V34, P1, DOI 10.1097/RCT.0b013e3181a9cc07 Natsis KI, 2009, SURG RADIOL ANAT, V31, P319, DOI 10.1007/s00276-008-0442-2 Ortiz-Pérez JT, 2008, JACC-CARDIOVASC IMAG, V1, P282, DOI 10.1016/j.jcmg.2008.01.014 Partridge JB, 2009, CLIN ANAT, V22, P77, DOI 10.1002/ca.20646 Ramaswamy P, 2007, J AM SOC ECHOCARDIOG, V20, P1011, DOI 10.1016/j.echo.2007.03.017 Rienmüller R, 2004, RADIOL CLIN N AM, V42, P587, DOI 10.1016/j.rcl.2004.03.003 ROBERTS HC, 2009, THORAC SURG CLIN, V19, pR5 Roberts Heidi C, 2009, Thorac Surg Clin, V19, P431, DOI 10.1016/j.thorsurg.2009.08.008 Scharf C, 2003, J CARDIOVASC ELECTR, V14, P150, DOI 10.1046/j.1540-8167.2003.02444.x SECHTEM U, 1986, AM J ROENTGENOL, V147, P245, DOI 10.2214/ajr.147.2.245 Smith WHT, 2001, BRIT J RADIOL, V74, P384, DOI 10.1259/bjr.74.880.740384 SOULEN RL, 1985, AM J CARDIOL, V55, P480, DOI 10.1016/0002-9149(85)90398-4 Taylor AM, 1997, J MAGN RESON IMAGING, V7, P629, DOI 10.1002/jmri.1880070404 Vasan R S, 1995, J Am Soc Echocardiogr, V8, P793, DOI 10.1016/S0894-7317(05)80003-3 NR 57 TC 3 Z9 3 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1064-9689 EI 1557-9786 J9 MAGN RESON IMAGING C JI Magn. Reson. Imaging Clin. N. Am. PD AUG PY 2011 VL 19 IS 3 BP 489 EP 506 DI 10.1016/j.mric.2011.05.014 PG 18 WC Radiology, Nuclear Medicine & Medical Imaging WE Science Citation Index Expanded (SCI-EXPANDED) SC Radiology, Nuclear Medicine & Medical Imaging GA 817ET UT WOS:000294654800006 PM 21816327 DA 2026-04-17 ER PT J AU Fu, Q Li, QZ Liang, DG Ruan, XH Wang, ZX Wei, MX AF Fu Qiang Li Quan-zheng Liang De-gang Ruan Xin-hua Wang Zan-xin Wei Min-xin TI Early and long-term results of combined cardiac surgery and neoplastic resection in patients with concomitant severe heart disease and neoplasms SO CHINESE MEDICAL JOURNAL LA English DT Article DE combined operation; cardiac surgery, neoplastic resection ID COMBINED PULMONARY RESECTION; LUNG-CANCER; CARDIOPULMONARY BYPASS; OPERATION; REVASCULARIZATION; PNEUMONECTOMY; STERNOTOMY AB Background It is a surgical dilemma when patients present with both severe heart disease and neoplasms. The best surgical treatment remains controversial. This study aimed to analyze the early and long-term results of simultaneous surgical treatment of severe heart disease and neoplasms. Methods We reviewed the clinical records of 15 patients who underwent simultaneous neoplastic resection and cardiac surgery between September 2006 and January 2011. There were 5 male and 10 female patients. The mean age was (59.2+/-12.5) years and the mean left ventricular ejection fraction was (57.4+/-11.0)%. All patients were followed up completely for a period of 12 to 51 months (mean, (33.1+/-11.2) months). Results Fifteen patients underwent simultaneous cardiac surgery and neoplastic resection. Cardiac procedures consisted of off pump coronary artery bypass grafting (n=7), aortic valve replacement (n=3), mitral valve replacement (n=3), mitral valve replacement with coronary artery bypass grafting (n=1) and left atrial myxoma resection (n=1). Neoplastic resection consisted of lung cancer resection (n=5), colonic cancer resection (n=3), gallbladder resection (n=1), colonic cancer resection with gallbladder resection (n=1), hysterectomy (n=2), hysterectomy with bilateral salpingo-oophorectomy (n=2) and left ovariectomy (n=1). Pathological examination confirmed malignant disease in 10 patients and benign disease in 5 patients. There were no perioperative myocardial infarctions, stroke, pericardial tamponade, renal failure or hospital deaths. The most frequent complications were atrial fibrillation (33.3%), pneumonia (26.7%), low cardiac output syndrome (6.7%) and delayed healing of surgical wounds (6.7%). There was 1 late death 42 months after surgery for recurrent malignant disease. At 1 and 3 years, survival rates were 100% (Kaplan-Meier method). Conclusions Simultaneous cardiac surgery and neoplastic resection was not associated with increased early or late morbidity or mortality. Cardiopulmonary bypass does not appear to adversely affect survival in patients with malignant disease. The long-term survival was determined by tumor stage. Chin Med J 2011;124(13):1939-1942 C1 [Fu Qiang; Li Quan-zheng; Liang De-gang; Ruan Xin-hua; Wang Zan-xin; Wei Min-xin] Tianjin Med Univ, Gen Hosp, Dept Cardiovasc Surg, Tianjin 300052, Peoples R China. C3 Tianjin Medical University RP Wei, MX (corresponding author), Tianjin Med Univ, Gen Hosp, Dept Cardiovasc Surg, Tianjin 300052, Peoples R China. EM minxinw@126.com RI Wang, Zanxin/KCK-7537-2024 CR Darwazah AK, 2010, J CARDIAC SURG, V25, P1, DOI 10.1111/j.1540-8191.2008.00778.x Davydov MI, 2001, EUR J CARDIO-THORAC, V20, P1020, DOI 10.1016/S1010-7940(01)00922-8 DELARIVIERE AB, 1995, EUR J CARDIO-THORAC, V9, P310 DYSZKIEWICZ W, 2001, POL PRZEGL CHIR POL, V73, P861 Dyszkiewicz W, 2008, EUR J CARDIO-THORAC, V34, P531, DOI 10.1016/j.ejcts.2008.05.017 Hasegawa S, 2002, J THORAC CARDIOV SUR, V124, P635, DOI 10.1067/mtc.2002.125060 Hensens AG, 1999, J CARDIOVASC SURG, V40, P161 Johnson JA, 1996, AM SURGEON, V62, P300 Kirchmeyer M, 2000, THORAC CARDIOV SURG, V48, P240, DOI 10.1055/s-2000-6889 LAFRANCESCA S, 1995, TEX HEART I J, V22, P296 Mariani MA, 2001, ANN THORAC SURG, V71, P1343, DOI 10.1016/S0003-4975(00)02355-9 MILLER DL, 1994, ANN THORAC SURG, V58, P989, DOI 10.1016/0003-4975(94)90442-1 Ochi M, 2000, JPN CIRC J, V64, P13, DOI 10.1253/jcj.64.13 Rao V, 1996, ANN THORAC SURG, V62, P342, DOI 10.1016/0003-4975(96)00206-8 See WM, 1996, ANN THORAC SURG, V62, P346 TAKAHASHI T, 1995, SURG TODAY, V25, P131, DOI 10.1007/BF00311084 TERZI A, 1994, EUR J CARDIO-THORAC, V8, P580, DOI 10.1016/1010-7940(94)90039-6 Tsuji Y, 2005, ARCH SURG-CHICAGO, V140, P1109, DOI 10.1001/archsurg.140.11.1109 URSCHEL HC, 1986, ANN THORAC SURG, V41, P130, DOI 10.1016/S0003-4975(10)62652-5 Voets AJ, 1997, EUR J CARDIO-THORAC, V12, P713, DOI 10.1016/S1010-7940(97)00240-6 Watanabe S, 2000, Kyobu Geka, V53, P353 Wu M, 2003, CHINESE MED J-PEKING, V116, P873 NR 22 TC 15 Z9 16 U1 0 U2 5 PU CHINESE MEDICAL ASSOC PI BEIJING PA 42 DONGSI XIDAJIE, BEIJING 100710, PEOPLES R CHINA SN 0366-6999 J9 CHINESE MED J-PEKING JI Chin. Med. J. PD JUL 5 PY 2011 VL 124 IS 13 BP 1939 EP 1942 DI 10.3760/cma.j.issn.0366-6999.2011.13.004 PG 4 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA 802EB UT WOS:000293491000004 PM 22088450 DA 2026-04-17 ER PT J AU Saran, T Perkins, GD Javed, MA Annam, V Leong, L Gao, F Stedman, R AF Saran, T. Perkins, G. D. Javed, M. A. Annam, V. Leong, L. Gao, F. Stedman, R. TI Does the prophylactic administration of magnesium sulphate to patients undergoing thoracotomy prevent postoperative supraventricular arrhythmias? A randomized controlled trial SO BRITISH JOURNAL OF ANAESTHESIA LA English DT Article DE complications, arrhythmia; ions, magnesium; prevention; surgery, non-cardiac; surgery, thoracic ID ATRIAL-FIBRILLATION; SYMPTOMATIC TACHYDYSRHYTHMIAS; CARDIAC DYSRHYTHMIA; THORACIC-SURGERY; LUNG-CANCER; DIGITALIZATION; TACHYARRHYTHMIA; PNEUMONECTOMY; ESOPHAGECTOMY; DILTIAZEM AB Background. Supraventricular arrhythmias (SVA) are common after thoracic surgery and are associated with increased morbidity and mortality. This prospective, randomized, double-blind, placebo-controlled trial examined the effects of perioperative magnesium on the development of postoperative SVA. Methods. Two hundred patients undergoing thoracotomy for lobectomy, bi-lobectomy, pneumonectomy, or oesophagectomy were recruited and randomly allocated into two groups. The treatment group received magnesium (5 g daily) intraoperatively, and on days 1 and 2 after operation, the control group received placebo. The primary outcome of the study was the development of SVA within the first 5 days after operation. Results. There were 100 patients in each arm of the study, with one withdrawal and three lost to follow-up in the treatment group and four withdrawals in the control group. Ninety-six patients received magnesium and 96 received placebo. There was no difference in the incidence of SVA between the treatment and control groups, 16.7% (16/96) vs 25% (24/96), P=0.16. In the predefined subgroup analysis, patients at highest risk of arrhythmias (those undergoing pneumonectomy) had a significant reduction in the frequency of SVA, 11.1% (2/18) vs 52.9% (9/17), P=0.008. There were no differences in hospital length of stay or mortality. Patients receiving i.v. magnesium experienced a higher frequency of minor side-effects (stinging at injection site). The treatment was otherwise well tolerated. Conclusions. Overall, prophylactic magnesium did not reduce the incidence of SVA in patients undergoing thoracotomy. However, it reduced the incidence of SVA in the high-risk cohort of patients undergoing pneumonectomy. (ISRCTN22028180.) C1 [Saran, T.; Perkins, G. D.; Javed, M. A.; Annam, V.; Leong, L.; Gao, F.; Stedman, R.] Heart England NHS Fdn Trust, Acad Dept Anaesthesia Crit Care & Pain, Birmingham B9 5SS, W Midlands, England. [Saran, T.; Perkins, G. D.; Gao, F.] Univ Warwick, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England. C3 Heart of England NHS Foundation Trust; University of Warwick RP Saran, T (corresponding author), Coventry & Warwickshire NHS Trust, Dept Anaesthesia, Univ Hosp, Coventry CV2 2DX, W Midlands, England. EM taj.saran@uhcw.nhs.uk RI Perkins, Gavin/E-7613-2010; Stedman, Robin/D-4654-2011 OI Perkins, Gavin/0000-0003-3027-7548; Javed, Muhammad Ahsan/0000-0003-0402-2285; FU British Heart Foundation [PG/05/029]; European Association of Cardiothoracic Anesthesiologists FX The study was supported by British Heart Foundation, grant number PG/05/029, and European Association of Cardiothoracic Anesthesiologists. CR Amar D, 1997, ANN THORAC SURG, V63, P1374 AMAR D, 1995, CHEST, V108, P349, DOI 10.1378/chest.108.2.349 Amar D, 2000, J THORAC CARDIOV SUR, V120, P790, DOI 10.1067/mtc.2000.109538 Amar D, 1998, Chest Surg Clin N Am, V8, P479 Amar D, 1996, ANN THORAC SURG, V61, P1506, DOI 10.1016/0003-4975(96)00111-7 AMAR D, 1998, CHEST SURG CLIN N AM, V8, pR7 Bayliff CD, 1999, ANN THORAC SURG, V67, P182, DOI 10.1016/S0003-4975(98)01226-0 Ciriaco P, 2000, EUR J CARDIO-THORAC, V18, P12, DOI 10.1016/S1010-7940(00)00428-0 Figas-Powajbo Elzbieta, 2007, Pol Arch Med Wewn, V117, P290 Harpole DH, 1996, ANN THORAC SURG, V61, P977, DOI 10.1016/0003-4975(95)01174-9 Jakobsen CJ, 1997, J CARDIOTHOR VASC AN, V11, P746, DOI 10.1016/S1053-0770(97)90169-5 James MFM, 2009, BRIT J ANAESTH, V103, P465, DOI 10.1093/bja/aep242 KROWKA MJ, 1987, CHEST, V91, P490, DOI 10.1378/chest.91.4.490 LINDGREN L, 1991, BRIT J ANAESTH, V66, P205, DOI 10.1093/bja/66.2.205 Rena O, 2001, EUR J CARDIO-THORAC, V20, P688, DOI 10.1016/S1010-7940(01)00890-9 RITCHIE AJ, 1993, EUR J CARDIO-THORAC, V7, P420, DOI 10.1016/1010-7940(93)90006-W RITCHIE AJ, 1992, THORAX, V47, P41, DOI 10.1136/thx.47.1.41 RITCHIE AJ, 1990, ANN THORAC SURG, V50, P86, DOI 10.1016/0003-4975(90)90094-M RITCHIE AJ, 1993, ANN THORAC SURG, V55, P86, DOI 10.1016/0003-4975(93)90478-Z Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Sedrakyan A, 2005, J THORAC CARDIOV SUR, V129, P997, DOI 10.1016/j.jtcvs.2004.07.042 Terzi A, 1996, THORAC CARDIOV SURG, V44, P300, DOI 10.1055/s-2007-1012041 VanMieghem W, 1996, ANN THORAC SURG, V61, P1083, DOI 10.1016/0003-4975(96)00073-2 VANMIEGHEM W, 1994, CHEST, V105, P1642, DOI 10.1378/chest.105.6.1642 VONKNORRING J, 1992, ANN THORAC SURG, V53, P642, DOI 10.1016/0003-4975(92)90325-X NR 25 TC 22 Z9 26 U1 0 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0007-0912 EI 1471-6771 J9 BRIT J ANAESTH JI Br. J. Anaesth. PD JUN PY 2011 VL 106 IS 6 BP 785 EP 791 DI 10.1093/bja/aer096 PG 7 WC Anesthesiology WE Science Citation Index Expanded (SCI-EXPANDED) SC Anesthesiology GA 766WM UT WOS:000290817300004 PM 21558066 DA 2026-04-17 ER PT J AU Soto-Matos, A Szyldergemajn, S Extremera, S Miguel-Lillo, B Alfaro, V Coronado, C Lardelli, P Roy, E Corrado, CS Kahatt, C AF Soto-Matos, Arturo Szyldergemajn, Sergio Extremera, Sonia Miguel-Lillo, Bernardo Alfaro, Vicente Coronado, Cinthya Lardelli, Pilar Roy, Elena Silvia Corrado, Claudia Kahatt, Carmen TI Plitidepsin Has a Safe Cardiac Profile: A Comprehensive Analysis SO MARINE DRUGS LA English DT Article DE plitidepsin; cardiac toxicity; single agent; chemotherapy; cancer ID CELL LUNG-CANCER; EVERY 2 WEEKS; PHASE-II; 2ND-LINE THERAPY; BIWEEKLY PLITIDEPSIN; MARINE ORIGIN; SOLID TUMORS; APLIDINE; CARDIOTOXICITY; INFUSION AB Plitidepsin is a cyclic depsipeptide of marine origin in clinical development in cancer patients. Previously, some depsipeptides have been linked to increased cardiac toxicity. Clinical databases were searched for cardiac adverse events (CAEs) that occurred in clinical trials with the single-agent plitidepsin. Demographic, clinical and pharmacological variables were explored by univariate and multivariate logistic regression analysis. Forty-six of 578 treated patients (8.0%) had at least one CAE (11 patients (1.9%) with plitidepsin-related CAEs), none with fatal outcome as a direct consequence. The more frequent CAEs were rhythm abnormalities (n = 31; 5.4%), mostly atrial fibrillation/flutter (n = 15; 2.6%). Of note, life-threatening ventricular arrhythmias did not occur. Myocardial injury events (n = 17; 3.0%) included possible ischemic-related and non-ischemic events. Other events (miscellaneous, n = 6; 1.0%) were not related to plitidepsin. Significant associations were found with prostate or pancreas cancer primary diagnosis (p = 0.0017), known baseline cardiac risk factors (p = 0.0072), myalgia present at baseline (p = 0.0140), hemoglobin levels lower than 10 g/dL (p = 0.0208) and grade >= 2 hypokalemia (p = 0.0095). Treatment-related variables (plitidepsin dose, number of cycles, schedule and/or total cumulative dose) were not associated. Electrocardiograms performed before and after plitidepsin administration (n = 136) detected no relevant effect on QTc interval. None of the pharmacokinetic parameters analyzed had a significant impact on the probability of developing a CAE. In conclusion, the most frequent CAE type was atrial fibrillation/atrial flutter, although its frequency was not different to that reported in the age-matched healthy population, while other CAEs types were rare. No dose-cumulative pattern was observed, and no treatment-related variables were associated with CAEs. Relevant risk factors identified were related to the patient's condition and/or to disease-related characteristics rather than to drug exposure. Therefore, the current analysis supports a safe cardiac risk profile for single-agent plitidepsin in cancer patients. C1 [Soto-Matos, Arturo; Szyldergemajn, Sergio; Extremera, Sonia; Miguel-Lillo, Bernardo; Alfaro, Vicente; Coronado, Cinthya; Lardelli, Pilar; Roy, Elena; Silvia Corrado, Claudia; Kahatt, Carmen] Pharma Mar SA, Clin Oncol, Madrid 28770, Spain. C3 PharmaMar RP Alfaro, V (corresponding author), Pharma Mar SA, Clin Oncol, Madrid 28770, Spain. EM asoto@pharmamar.com; sszyldergemajn@pharmamar.com; sextremera@pharmamar.com; bdemiguel@pharmamar.com; valfaro@pharmamar.com; ccoronado@pharmamar.com; plardelli@pharmamar.com; eroy@pharmamar.com; cscorrado@pharmamar.com; ckahatt@pharmamar.com OI Alfaro, Vicente/0000-0002-0150-2390; Szyldergemajn, Sergio/0009-0009-0223-5691 CR Bagnes C, 2010, CURR DRUG SAF, V5, P93, DOI 10.2174/157488610789869111 Baudin E, 2010, AM J CLIN ONCOL-CANC, V33, P83, DOI 10.1097/COC.0b013e31819fdf5e Biscardi M, 2005, ANN ONCOL, V16, P1667, DOI 10.1093/annonc/mdi311 Broggini M, 2003, LEUKEMIA, V17, P52, DOI 10.1038/sj.leu.2402788 Carver JR, 2007, J CLIN ONCOL, V25, P3991, DOI 10.1200/JCO.2007.10.9777 Ciruelos E. M., 2002, P AN M AM SOC CLIN, V21, P106 Cuadrado A, 2004, ONCOGENE, V23, P4673, DOI 10.1038/sj.onc.1207636 Depenbrock H, 1998, BRIT J CANCER, V78, P739, DOI 10.1038/bjc.1998.570 Dumez H, 2009, MAR DRUGS, V7, P451, DOI 10.3390/md7030451 Eisen T, 2009, LUNG CANCER, V64, P60, DOI 10.1016/j.lungcan.2008.06.017 Eisen T, 2009, MELANOMA RES, V19, P185, DOI 10.1097/CMR.0b013e32832bbde6 Ewer MS, 2005, J CLIN ONCOL, V23, P2900, DOI 10.1200/JCO.2005.05.827 Faivre S, 2005, J CLIN ONCOL, V23, P7871, DOI 10.1200/JCO.2005.09.357 FERME C, 2010, P T CELL LYMPH FOR M, P76 Fiuza Manuela, 2009, Adv Ther, V26 Suppl 1, pS9, DOI 10.1007/s12325-009-0048-z Floyd JD, 2005, J CLIN ONCOL, V23, P7685, DOI 10.1200/JCO.2005.08.789 FOSSA SD, 1992, ANN ONCOL, V3, P361, DOI 10.1093/oxfordjournals.annonc.a058207 García-Fernández LF, 2002, ONCOGENE, V21, P7533, DOI 10.1038/sj.onc.1205972 González-Santiago L, 2006, CELL DEATH DIFFER, V13, P1968, DOI 10.1038/sj.cdd.4401898 Izquierdo MA, 2008, CLIN CANCER RES, V14, P3105, DOI 10.1158/1078-0432.CCR-07-1652 Jurcut R, 2008, SUPPORT CARE CANCER, V16, P437, DOI 10.1007/s00520-007-0397-6 Keefe DL, 2002, ONCOLOGIST, V7, P65, DOI 10.1634/theoncologist.7-1-65 Kishi S, 2000, INT J HEMATOL, V71, P172 Lenihan DJ, 2004, BLOOD, V104, P655, DOI 10.1182/blood-2003-07-2345 Maroun JA, 2006, ANN ONCOL, V17, P1371, DOI 10.1093/annonc/mdl165 MAURER MS, 1995, AM J CARDIOL, V75, P788, DOI 10.1016/S0002-9149(99)80412-3 Munoz MJ, 2007, P 2007 AACR ANN M LO Nalda-Molina R, 2009, CANCER CHEMOTH PHARM, V64, P97, DOI 10.1007/s00280-008-0841-4 Ng R, 2006, SEMIN ONCOL, V33, P2, DOI 10.1053/j.seminoncol.2005.11.001 Peschel C, 2008, LUNG CANCER, V60, P374, DOI 10.1016/j.lungcan.2007.10.019 Piekarz RL, 2006, CLIN CANCER RES, V12, P3762, DOI 10.1158/1078-0432.CCR-05-2095 Pronzato P, 2006, CANCER TREAT REV, V32, pS1, DOI 10.1016/j.ctrv.2006.04.008 *RATE STEER COMM, 2009, AM HEART J, V157 Rinehart K. L., 1991, Patent No. [WO9104985A1, 9104985] Rinehart KL, 1989, GB Appl, Patent No. [89/22,026, 8922026] ROCHE B, 2007, SPLG0600 QTEST LABS Sanoski CA, 2010, AM J HEALTH-SYST PH, V67, pS11, DOI 10.2146/ajhp100148 Schöffski P, 2009, MAR DRUGS, V7, P57, DOI 10.3390/md7010057 Seidman A, 2002, J CLIN ONCOL, V20, P1215, DOI 10.1200/JCO.20.5.1215 Shah MH, 2006, CLIN CANCER RES, V12, P3997, DOI 10.1158/1078-0432.CCR-05-2689 Straight AM, 2006, CANCER CHEMOTH PHARM, V57, P7, DOI 10.1007/s00280-005-0014-7 Strevel EL, 2007, J CLIN ONCOL, V25, P3362, DOI 10.1200/JCO.2006.09.6925 Taraboletti G, 2004, BRIT J CANCER, V90, P2418, DOI 10.1038/sj.bjc.6601864 Tessler DA, 2006, AM J SURG, V191, P191, DOI 10.1016/j.amjsurg.2005.08.029 Mateos MV, 2010, CLIN CANCER RES, V16, P3260, DOI 10.1158/1078-0432.CCR-10-0469 Weinstein SJ, 2009, CANCER EPIDEM BIOMAR, V18, P2643, DOI 10.1158/1055-9965.EPI-09-0322 NR 46 TC 9 Z9 9 U1 0 U2 6 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 1660-3397 J9 MAR DRUGS JI Mar. Drugs PD JUN PY 2011 VL 9 IS 6 BP 1007 EP 1023 DI 10.3390/md9061007 PG 17 WC Chemistry, Medicinal; Pharmacology & Pharmacy WE Science Citation Index Expanded (SCI-EXPANDED) SC Pharmacology & Pharmacy GA 791AQ UT WOS:000292632600008 PM 21747745 OA Green Submitted, gold DA 2026-04-17 ER PT J AU Thomson, KR Cheung, W Ellis, SJ Federman, D Kavnoudias, H Loader-Oliver, D Roberts, S Evans, P Ball, C Haydon, A AF Thomson, Kenneth R. Cheung, Wa Ellis, Samantha J. Federman, Dean Kavnoudias, Helen Loader-Oliver, Deirdre Roberts, Stuart Evans, Peter Ball, Christine Haydon, Andrew TI Investigation of the Safety of Irreversible Electroporation in Humans SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Article ID PERCUTANEOUS RADIOFREQUENCY ABLATION; HIGH ELECTRIC-FIELDS; HEPATOCELLULAR-CARCINOMA; TUMORS; MANAGEMENT; NEOPLASMS AB Purpose: A single-center prospective nonrandomized cohort study was performed to investigate the safety of irreversible electroporation (IRE) for tumor ablation in humans. Materials and Methods: Thirty-eight volunteers with advanced malignancy of the liver, kidney, or lung (69 separate tumors) unresponsive to alternative treatment were subjected to IRE under general anesthesia. Clinical examination, biochemistry, and computed tomography (CT) scans of the treated organ were performed before, immediately after, and at I month and 3 months after the procedure. Results: No mortalities occurred at 30 days. Transient ventricular arrhythmia occurred in four patients, and electrocardiographically (ECG) synchronized delivery was used subsequently in the remaining 30 patients, with two further arrhythmias (supraventricular tachycardia and atrial fibrillation). One patient developed obstruction of the upper ureter after IRE. One adrenal gland was unintentionally directly electroporated, which produced transient severe hypertension. There was no other evidence of adjacent organ damage related to the electroporation. Other adverse events were not directly related to IRE, but two patients developed temporary neurapraxia as a result of arm extension during a prolonged period of anesthesia. Although not a primary aim of this preliminary study, complete target tumor ablation verified by CT was achieved in 46 of the 69 tumors treated with IRE (66%). Most treatment failures occurred in renal and lung tumors. Biopsy in three patients showed coagulative necrosis in the regions treated by IRE. Conclusions: IRE appears to be safe for human clinical use provided ECG-synchronized delivery is used. Comparative evaluation with alternative ablative technologies is warranted. C1 [Thomson, Kenneth R.; Cheung, Wa; Ellis, Samantha J.; Federman, Dean; Kavnoudias, Helen; Loader-Oliver, Deirdre] Monash Univ, Alfred Hosp, Dept Radiol, Prahran, Vic 3181, Australia. [Roberts, Stuart] Monash Univ, Alfred Hosp, Dept Gastroenterol, Prahran, Vic 3181, Australia. [Evans, Peter] Monash Univ, Alfred Hosp, Dept Surg, Prahran, Vic 3181, Australia. [Ball, Christine] Monash Univ, Alfred Hosp, Dept Anaesthesia, Prahran, Vic 3181, Australia. [Haydon, Andrew] Monash Univ, Alfred Hosp, Dept Med Oncol, Prahran, Vic 3181, Australia. C3 Florey Institute of Neuroscience & Mental Health; Howard Florey Institute Affiliates; Monash University; Florey Institute of Neuroscience & Mental Health; Howard Florey Institute Affiliates; Monash University; Monash University; Florey Institute of Neuroscience & Mental Health; Howard Florey Institute Affiliates; Florey Institute of Neuroscience & Mental Health; Howard Florey Institute Affiliates; Monash University; Monash University; Florey Institute of Neuroscience & Mental Health; Howard Florey Institute Affiliates RP Thomson, KR (corresponding author), Monash Univ, Alfred Hosp, Dept Radiol, POB 315, Prahran, Vic 3181, Australia. EM k.thomson@alfred.org.au RI ; Ball, Christine/ACH-4434-2022 OI Ellis, Samantha/0000-0002-4807-9358; Ball, Christine Mary/0000-0002-2094-8232; Roberts, Stuart/0000-0002-9015-7997 FU Department of Radiology at Alfred Hospital, AngioDynamics (Queensbury, New York) FX Research support for the Department of Radiology (K.R.T.) at Alfred Hospital was received by AngioDynamics (Queensbury, New York). CR Akahane M, 2005, RADIOGRAPHICS, V25, pS57, DOI 10.1148/rg.25si055505 Ball C, 2010, ANESTH ANALG, V110, P1305, DOI 10.1213/ANE.0b013e3181d27b30 Bertacchini C, 2007, TECHNOL CANCER RES T, V6, P313, DOI 10.1177/153303460700600408 Bojarski JD, 2005, AM J ROENTGENOL, V185, P466, DOI 10.2214/ajr.185.2.01850466 Brown DB, 2005, J VASC INTERV RADIOL, V16, P597, DOI 10.1097/01.RVI.0000156097.63027.7B Davalos RV, 2005, ANN BIOMED ENG, V33, P223, DOI 10.1007/s10439-005-8981-8 Dupuy DE, 2001, J VASC INTERV RADIOL, V12, P1135, DOI 10.1016/S1051-0443(07)61670-4 Edd JF, 2007, TECHNOL CANCER RES T, V6, P275, DOI 10.1177/153303460700600403 Farrell MA, 2003, AM J ROENTGENOL, V181, P1315, DOI 10.2214/ajr.181.5.1811315 Gervais DA, 2005, AM J ROENTGENOL, V185, P64, DOI 10.2214/ajr.185.1.01850064 Gillams Alice, 2008, Cancer Imaging, V8 Spec No A, pS1, DOI 10.1102/1470-7330.2008.9001 Goldberg SN, 2000, AM J ROENTGENOL, V174, P323, DOI 10.2214/ajr.174.2.1740323 HAMILTON WA, 1967, BIOCHIM BIOPHYS ACTA, V148, P789, DOI 10.1016/0304-4165(67)90053-0 Lee EW, 2007, TECHNOL CANCER RES T, V6, P287, DOI 10.1177/153303460700600404 Lencioni R, 2005, RADIOLOGY, V234, P961, DOI 10.1148/radiol.2343040350 LIVRAGHI T, 2000, RADIOLOGY, V217, P18 Maor E, 2007, TECHNOL CANCER RES T, V6, P307, DOI 10.1177/153303460700600407 Melikov KC, 2001, BIOPHYS J, V80, P1829, DOI 10.1016/S0006-3495(01)76153-X NEUMANN E, 1982, EMBO J, V1, P841, DOI 10.1002/j.1460-2075.1982.tb01257.x Onik G, 2007, TECHNOL CANCER RES T, V6, P295, DOI 10.1177/153303460700600405 PITMAN M I, 1988, Arthroscopy, V4, P250, DOI 10.1016/S0749-8063(88)80039-2 Rubinsky B, 2007, TECHNOL CANCER RES T, V6, P255, DOI 10.1177/153303460700600401 Weaver JC, 1996, BIOELECTROCH BIOENER, V41, P135, DOI 10.1016/S0302-4598(96)05062-3 Yamakado K, 2003, J VASC INTERV RADIOL, V14, P1183, DOI 10.1097/01.RVI.0000086530.86489.05 Zhu JC, 2009, ANN THORAC SURG, V87, P1023, DOI 10.1016/j.athoracsur.2008.11.017 NR 25 TC 375 Z9 484 U1 1 U2 58 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1051-0443 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD MAY PY 2011 VL 22 IS 5 BP 611 EP 621 DI 10.1016/j.jvir.2010.12.014 PG 11 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease WE Science Citation Index Expanded (SCI-EXPANDED) SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA 760XT UT WOS:000290358700004 PM 21439847 DA 2026-04-17 ER PT J AU Arslan, C Aksoy, S Dizdar, O Dede, DS Harputluoglu, H Altundag, K AF Arslan, Cagatay Aksoy, Sercan Dizdar, Omer Dede, Didem S. Harputluoglu, Hakan Altundag, Kadri TI Zoledronic acid and atrial fibrillation in cancer patients SO SUPPORTIVE CARE IN CANCER LA English DT Article DE Zoledronic acid; Side effect; Arrhythmias; Atrial fibrillation; Cancer ID RISK; INFLAMMATION; PREVALENCE; FRACTURES; THERAPIES; DISEASE AB Treatment with a bisphosphonate was found to be associated with a significantly increased risk for atrial fibrillation (AF) in a few studies. A recent study showed that once-yearly infusions of intravenous zoledronic acid (ZA) significantly increased the risk of serious AF in postmenopausal women with osteoporosis. This study was conducted to determine the frequency of atrial fibrillation among cancer patients receiving the standard treatment of ZA. Patients with bone metastases who presented to our outpatient clinic for any reason (routine control, chemotherapy, or ZA administration) were included in the study. All patients had been receiving 4 mg ZA at 4-week intervals, with each dose administered over 15 min. A short survey was completed and standard 12-lead ECG recordings were obtained. One hundred and twenty-four cancer patients with documented bone metastases were evaluated. Mean age of the patients was 55 +/- 13.0 years, 60% of the patients were female. Forty-one percent of the patients had breast cancer, 18% had non-small cell lung cancer, and the remainder had other solid tumors. Mean duration of ZA administration was 13.4 +/- 15.0 months. Mean total cumulative dose was 54 +/- 15.0 mg per patient. Sixty patients (48%) had previously been treated with anthracycline-containing regimens, and 37 (30%) had received chest radiotherapy that might affect the heart. Twenty-three percent of the patients had hypertension, 10% had diabetes mellitus, 3.7% had myocardial infarction history, 1.9% had congestive heart failure, and 1% had valvular disease; 10.5% were current smokers and 32% ex-smokers. On ECG evaluation, we observed normal sinus rhythm in 58%, sinus tachycardia in 15%, sinus bradicardia in 3.2%, and ventricular extrasystole in 5.7% of the patients. There was no AF in any of the cases. There was no increase in the risk of AF frequency in cancer patients who were treated with intravenous ZA, although most of the patients had additional risk factors including previous treatment with cardiotoxic agents or with chest radiotherapy. We believe that the risk of AF is negligible in this patient population and does not affect treatment decisions. C1 [Arslan, Cagatay; Aksoy, Sercan; Dizdar, Omer; Dede, Didem S.; Harputluoglu, Hakan; Altundag, Kadri] Hacettepe Univ, Inst Oncol, Dept Med Oncol, TR-06100 Ankara, Turkey. C3 Hacettepe University RP Arslan, C (corresponding author), Hacettepe Univ, Inst Oncol, Dept Med Oncol, TR-06100 Ankara, Turkey. EM arslancagatay@yahoo.com RI Dede, Didem/LFT-5319-2024; Dizdar, Omer/PFQ-9744-2025; AKSOY, SERCAN/S-2480-2019; harputluoglu, hakan/ABI-6451-2020; Arslan, Cagatay/I-1932-2016 OI Dede, Didem/0000-0002-9158-8764; AKSOY, SERCAN/0000-0003-4984-1049; CR Abrahamsen B, 2009, J INTERN MED, V265, P581, DOI 10.1111/j.1365-2796.2008.02065.x BENJAMIN EJ, 1994, JAMA-J AM MED ASSOC, V271, P840, DOI 10.1001/jama.271.11.840 Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312 Bunch TJ, 2009, AM J CARDIOL, V103, P824, DOI 10.1016/j.amjcard.2008.11.037 Chung MK, 2001, CIRCULATION, V104, P2886, DOI 10.1161/hc4901.101760 Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322 de Azambuja E, 2009, TARGET ONCOL, V4, P77, DOI 10.1007/s11523-009-0112-2 Grosso A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004720 Guzzetti S, 2002, CIRCULATION, V106, pE40, DOI 10.1161/01.CIR.0000028399.42411.13 Guzzetti S, 2008, INTERN EMERG MED, V3, P227, DOI 10.1007/s11739-008-0124-4 Heckbert SR, 2008, ARCH INTERN MED, V168, P826, DOI 10.1001/archinte.168.8.826 Huang WF, 2010, MENOPAUSE, V17, P57, DOI 10.1097/gme.0b013e3181b34749 Ibrahim A, 2003, CLIN CANCER RES, V9, P2394 KANNEL WB, 1983, AM HEART J, V106, P389, DOI 10.1016/0002-8703(83)90208-9 Lainscak M, 2008, INT J CARDIOL, V128, P311, DOI 10.1016/j.ijcard.2007.12.078 Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941 Rugo Hope S., 2004, CECIL TXB MED, P1124 Siu CW, 2005, PACE, V28, pS120, DOI 10.1111/j.1540-8159.2005.00024.x Sorensen HT, 2008, BMJ-BRIT MED J, V336, P813, DOI 10.1136/bmj.39507.551644.BE van der Hooft CS, 2006, ARCH INTERN MED, V166, P1016, DOI 10.1001/archinte.166.9.1016 van der Hooft CS, 2004, J AM COLL CARDIOL, V44, P2117, DOI 10.1016/j.jacc.2004.08.053 WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983 Woolf AD, 2003, BMJ-BRIT MED J, V327, P89, DOI 10.1136/bmj.327.7406.89 Wu FPK, 2003, DIS COLON RECTUM, V46, P147, DOI 10.1007/s10350-004-6516-2 NR 24 TC 21 Z9 24 U1 1 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0941-4355 EI 1433-7339 J9 SUPPORT CARE CANCER JI Support. Care Cancer PD MAR PY 2011 VL 19 IS 3 BP 425 EP 430 DI 10.1007/s00520-010-0868-z PG 6 WC Oncology; Health Care Sciences & Services; Rehabilitation WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Health Care Sciences & Services; Rehabilitation GA 728CL UT WOS:000287851500013 PM 20358384 DA 2026-04-17 ER PT J AU [Anonymous] AF [Anonymous] TI Abstracts of the 2010th Encouragement Award's Memorial Lectures of the 78th Annual Meeting of the Medical Association of Nippon Medical School Date: September 4, 2010 Place: Nippon Medical School, Japan SO JOURNAL OF NIPPON MEDICAL SCHOOL LA English DT Article ID ATRIAL-FIBRILLATION; LUNG-CANCER; EXPRESSION; INFLAMMATION CR Aviles RJ, 2003, CIRCULATION, V108, P3006, DOI 10.1161/01.CIR.0000103131.70301.4F Chung MK, 2004, NAT CLIN PRACT CARD, V1, P56, DOI 10.1038/ncpcardio0027 Hirono K, 2006, J AM COLL CARDIOL, V48, P1257, DOI 10.1016/j.jacc.2006.02.077 Kane D, 2003, ARTHRITIS RHEUM, V48, P1676, DOI 10.1002/art.10988 Kannel WB, 1998, AM J CARDIOL, V82, p2N, DOI 10.1016/S0002-9149(98)00583-9 McCormick MM, 2005, J BIOL CHEM, V280, P41521, DOI 10.1074/jbc.M509442200 Seike M, 2005, PROTEOMICS, V5, P2939, DOI 10.1002/pmic.200401166 Seike M, 2007, JNCI-J NATL CANCER I, V99, P1257, DOI 10.1093/jnci/djm083 Seike M, 2009, P NATL ACAD SCI USA, V106, P12085, DOI 10.1073/pnas.0905234106 Tibble JA, 2001, DRUG TODAY, V37, P85, DOI 10.1358/dot.2001.37.2.614846 Viemann D, 2005, BLOOD, V105, P2955, DOI 10.1182/blood-2004-07-2520 NR 11 TC 0 Z9 0 U1 0 U2 7 PU MEDICAL ASSOC NIPPON MEDICAL SCH PI TOKYO PA 1-1-5, SENDAGI, TOKYO, 113-8602, JAPAN SN 1345-4676 EI 1347-3409 J9 J NIPPON MED SCH JI J. Nippon Med. Sch. PD FEB PY 2011 VL 78 IS 1 BP 46 EP 64 PG 19 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA 775YR UT WOS:000291500000009 DA 2026-04-17 ER PT J AU Augustin, F Bodner, J Wykypiel, H Schwinghammer, C Schmid, T AF Augustin, Florian Bodner, Johannes Wykypiel, Heinz Schwinghammer, Christoph Schmid, Thomas TI Initial experience with robotic lung lobectomy: report of two different approaches SO SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES LA English DT Article DE Lobectomy; Lung; Minimally invasive; Robotics; VATS ID ASSISTED THORACIC-SURGERY; THORACOSCOPIC LOBECTOMY AB Surgical resection is the gold standard for treatment of early-stage lung tumors. Different minimally invasive approaches are currently under investigation: In addition to conventional video-assisted thoracoscopic surgery (VATS), robotic technology with the da Vinci System has emerged over the past 10 years. In this series, 26 patients (12 women and 14 men; median age, 65 years) underwent a robotic lobectomy for early-stage lung tumors (clinical stage IA or IB) or centrally located metastases. The resected lobes included four left upper lobes, six left lower lobes, eight right upper lobes, and eight right lower lobes. Five intraoperative conversions to open thoracotomy were performed due to one major bleeding, two minor bleedings, one variant course of the pulmonary artery, and one extended resection. The postoperative complications included two prolonged air leaks, one colonic perforation, and one atrial fibrillation. The median hospital stay was 11 days (range, 7-53 days). One 30-day mortality (3.8%) occurred due to respiratory failure. The overall median operative time was 228 min (range, 162-375 min). For the first five patients, the posterior approach was used. Thereafter, the authors switched to an anterior approach, thus enabling an easier hilar dissection. Technical modification within this series also included the introduction of a new vessel sealing device. Robotic lobectomy was proved to be feasible and safe in our initial series in a learning curve setting. Changes in patient positioning and approach as well as technical modifications resulted in shorter operative times. A longer follow-up period and randomized controlled trials are necessary to evaluate a potential benefit over open and conventional VATS approaches. C1 [Augustin, Florian; Bodner, Johannes; Wykypiel, Heinz; Schwinghammer, Christoph; Schmid, Thomas] Innsbruck Med Univ, Dept Visceral Transplant & Thorac Surg, A-6020 Innsbruck, Austria. C3 Medical University of Innsbruck RP Augustin, F (corresponding author), Innsbruck Med Univ, Dept Visceral Transplant & Thorac Surg, Anichstr 35, A-6020 Innsbruck, Austria. EM florian.augustin@i-med.ac.at RI ; Augustin, Florian/AEZ-6085-2022 OI Schwinghammer, Christoph/0000-0003-0701-2461; CR Argenziano M, 2006, ANN THORAC SURG, V81, P1666, DOI 10.1016/j.athoracsur.2005.11.007 Augustin F, 2006, INT J MED ROBOT COMP, V2, P262, DOI 10.1002/rcs.84 Bodner J, 2004, EUR J CARDIO-THORAC, V25, P844, DOI 10.1016/j.ejcts.2004.02.001 Bodner J, 2004, ANN THORAC SURG, V78, P259, DOI 10.1016/j.athoracsur.2004.02.006 Bodner JC, 2005, ANN THORAC SURG, V80, P1202, DOI 10.1016/j.athoracsur.2005.03.061 D'Amico Thomas A, 2008, Thorac Surg Clin, V18, P259, DOI 10.1016/j.thorsurg.2008.04.002 Dieter RA, 1997, INT SURG, V82, P232 Gharagozloo F, 2008, ANN THORAC SURG, V85, P1880, DOI 10.1016/j.athoracsur.2008.02.085 Grogan Eric L, 2008, Thorac Surg Clin, V18, P249, DOI 10.1016/j.thorsurg.2008.04.007 Ishikawa N, 2006, SURG ENDOSC, V20, P1782, DOI 10.1007/s00464-005-0410-4 Manser R, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004699.pub2 MCKENNA RJ, 1994, J THORAC CARDIOV SUR, V107, P879 McKenna Robert J Jr, 2008, Thorac Surg Clin, V18, P275, DOI 10.1016/j.thorsurg.2008.04.004 Melfi Franca M A, 2008, Thorac Surg Clin, V18, P289, DOI 10.1016/j.thorsurg.2008.06.001 Park BJ, 2006, J THORAC CARDIOV SUR, V131, P54, DOI 10.1016/j.jtcvs.2005.07.031 Petersen RP, 2007, ANN THORAC SURG, V83, P1245, DOI 10.1016/j.athoracsur.2006.12.029 Rocco Gaetano, 2008, Thorac Surg Clin, V18, P235, DOI 10.1016/j.thorsurg.2008.06.002 SCHMID T, 2002, EUR SURG, V34, P155 Solaini L, 2008, SURG ENDOSC, V22, P298, DOI 10.1007/s00464-007-9586-0 Swanson SJ, 2007, J CLIN ONCOL, V25, P4993, DOI 10.1200/JCO.2007.12.6649 Wexner SD, 2009, SURG ENDOSC, V23, P438, DOI 10.1007/s00464-008-0202-8 Whitson BA, 2008, ANN THORAC SURG, V86, P2008, DOI 10.1016/j.athoracsur.2008.07.009 Yan TD, 2009, J CLIN ONCOL, V27, P2553, DOI 10.1200/JCO.2008.18.2733 NR 23 TC 50 Z9 60 U1 0 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0930-2794 EI 1432-2218 J9 SURG ENDOSC JI Surg. Endosc. PD JAN PY 2011 VL 25 IS 1 BP 108 EP 113 DI 10.1007/s00464-010-1138-3 PG 6 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA 700OP UT WOS:000285754000016 PM 20559664 DA 2026-04-17 ER PT J AU Koh, E Hoshino, H Saitoh, Y Iida, K AF Koh, Eitetsu Hoshino, Hidehisa Saitoh, Yukio Iida, Koji TI Favorable outcome using a maze procedure for left pneumonectomy combined with resection of the left atrium in stage IIIB lung cancer SO INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY LA English DT Article DE Lung cancer; Left atrium; Pulmonary artery; Atrial fibrillation; Maze procedure AB We report a case of a 67-year-old woman with stage IIIB locally advanced non-small cell lung cancer who had also suffered from hyperthyroidism with persistent atrial fibrillation (AF). Thiamazole provided euthyroid status, but medication failed to resolve AF. A computed tomography (CT)-scan revealed a 5x5-cm mass in the left hilar region that involved the left atrium (LA) and bifurcation of the pulmonary artery. Left pneumonectomy, LA partial resection and reconstruction of the bifurcation of the pulmonary artery were performed. In addition, a maze procedure was performed using cardiopulmonary bypass and cardiac arrest. We present the first case report of advanced lung cancer surgery with a maze procedure. Follow-up by CT-scan 34 months later did not show any recurrence and attacks of AF (no medication after surgery) were completely resolved after the operation. (C) 2010 Published by European Association for Cardio-Thoracic Surgery. All rights reserved. C1 [Koh, Eitetsu; Hoshino, Hidehisa] Narita Red Cross Hosp, Dept Thorac Surg, Narita City, Chiba 2868523, Japan. [Saitoh, Yukio] Natl Hosp Org, Chiba Med Ctr, Dept Thorac Surg, Chiba 2600022, Japan. [Iida, Koji] Narita Red Cross Hosp, Dept Cardiovasc Surg, Narita City, Chiba 2868523, Japan. RP Koh, E (corresponding author), Narita Red Cross Hosp, Dept Thorac Surg, 1-90 Iidacho, Narita City, Chiba 2868523, Japan. EM eitetsuk@gmail.com CR COX JL, 1991, J THORAC CARDIOV SUR, V101, P569, DOI 10.1016/s0022-5223(19)36684-x Itoh A, 2006, EUR J CARDIO-THORAC, V29, P1030, DOI 10.1016/j.ejcts.2006.03.028 MOUNTAIN CF, 1986, CHEST, V89, pS225, DOI 10.1378/chest.89.4.225S Stulak JM, 2010, ANN THORAC SURG, V89, P1395, DOI 10.1016/j.athoracsur.2010.02.018 Suzuki K, 2004, ANN THORAC SURG, V78, P1184, DOI 10.1016/j.athoracsur.2004.04.066 TSUCHIYA R, 1994, ANN THORAC SURG, V57, P960, DOI 10.1016/0003-4975(94)90214-3 NR 6 TC 2 Z9 3 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1569-9293 EI 1569-9285 J9 INTERACT CARDIOV TH JI Interact Cardiovasc. Thorac. Surg. PD DEC PY 2010 VL 11 IS 6 BP 825 EP 826 DI 10.1510/icvts.2010.238972 PG 2 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA V25NB UT WOS:000208483600034 PM 20724427 OA Bronze DA 2026-04-17 ER PT J AU Matyal, R Mahmood, F Hess, P Zhao, XQ Mitchell, J Maslow, A Gangadharan, S DeCamp, M AF Matyal, Robina Mahmood, Feroze Hess, Philip Zhao, Xiaoqin Mitchell, John Maslow, Andrew Gangadharan, Sidhu DeCamp, Malcolm TI Right Ventricular Echocardiographic Predictors of Postoperative Supraventricular Arrhythmias After Thoracic Surgery: A Pilot Study SO ANNALS OF THORACIC SURGERY LA English DT Article; Proceedings Paper CT 46th Annual Meeting of the Society-of-Thoracic-Surgeons CY JAN 25-27, 2010 CL Ft Lauderdale, FL SP Soc Thorac Surg ID MYOCARDIAL PERFORMANCE INDEX; CHRONIC PULMONARY-DISEASE; LONE ATRIAL-FIBRILLATION; TEI INDEX; RISK-FACTORS; CARDIAC AMYLOIDOSIS; ANESTHETIZED LAMBS; AMERICAN-SOCIETY; TISSUE DOPPLER; LUNG-CANCER AB Background. We used echocardiographically derived myocardial performance index (MPI) to assess changes in global right ventricular function with lung isolation. We hypothesized that changes in MPI with lung isolation may be related to the incidence of postoperative supraventricular tachycardia (SVT). Methods. Transesophageal echocardiographic examinations were performed after induction of general anesthesia in patients undergoing elective lung resections. Doppler tissue imaging was used to calculate MPI at baseline and 10 minutes after institution of one-lung ventilation (OLV). Arrhythmias occurring within the first 5 postoperative days were recorded. Results. Fifty-nine patients completed the study. Nineteen of 59 patients with a normal baseline MPI (<0.40) had a higher incidence of SVT as compared with patients with an abnormal baseline MPI (42% versus 10%; p = 0.012). The MPI worsened during OLV in 46 patients; aworsening of MPI with lung isolation that was normal at baseline was associated with higher incidence of SVT (57% versus 0%; p = 0.045) compared with a worsening of MPI in patients with an abnormal baseline MPI (13% versus 6%; p = 0.62). A normal baseline MPI value that worsened after OLV, left atrial dilation, and advanced age were identified as predictors of postoperative SVT. Conclusions. Lung isolation is associated with acute changes in global right ventricular function. A normal baseline MPI that worsens after lung isolation is a better predictor of postoperative SVT as compared with baseline abnormal MPI that does not worsen after lung isolation. Myocardial performance index has a potential to be used as a right ventricular stress test to tolerate OLV before thoracic surgery. (Ann Thorac Surg 2010;90:1080-7) (c) 2010 by The Society of Thoracic Surgeons C1 [Matyal, Robina] Beth Israel Deaconess Med Ctr, Dept Anesthesia & Crit Care & Cardiothorac Surg, Boston, MA 02215 USA. Harvard Univ, Sch Med, Boston, MA USA. Brown Univ, Rhode Isl Hosp, Sch Med, Dept Anesthesia & Crit Care, Providence, RI 02903 USA. C3 Harvard University; Harvard University Medical Affiliates; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University RP Matyal, R (corresponding author), Beth Israel Deaconess Med Ctr, Dept Anesthesia & Crit Care & Cardiothorac Surg, 330 Brookline Ave, Boston, MA 02215 USA. EM rmatyal@bidmc.harvard.edu RI Gangadharan, Sidhu/ABD-3000-2020; Hess, Philip/A-8577-2013; Mahmood, Feroze/B-1383-2008; zhao, xiaoqing/KWT-6534-2024 OI Gangadharan, Sidhu/0000-0002-9357-6169; Mitchell, John/0000-0001-6087-5210; Hess, Philip/0000-0002-1206-0102; Mahmood, Feroze/0000-0002-7071-0476; CR AMAR D, 1995, CHEST, V108, P349, DOI 10.1378/chest.108.2.349 Amar D, 2002, ANESTH ANALG, V95, P537, DOI 10.1097/00000539-200209000-00006 Amar D, 2002, ANESTHESIOLOGY, V96, P352, DOI 10.1097/00000542-200202000-00021 Amar D, 1996, CHEST, V110, P437, DOI 10.1378/chest.110.2.437 Aranki SF, 1996, CIRCULATION, V94, P390, DOI 10.1161/01.CIR.94.3.390 Arriagada G, 2008, EUROPACE, V10, P9, DOI 10.1093/europace/eum233 Blanchard DG, 2009, JACC-CARDIOVASC IMAG, V2, P143, DOI 10.1016/j.jcmg.2008.10.012 Burgess MI, 2002, J AM SOC ECHOCARDIOG, V15, P633, DOI 10.1067/mje.2002.118526 Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Chen R, 2004, ACTA PHYSIOL SCAND, V180, P13, DOI 10.1046/j.0001-6772.2003.01201.x Chen RL, 2004, AM J PHYSIOL-HEART C, V286, pH1008, DOI 10.1152/ajpheart.00724.2003 Cohen E, 1997, Chest Surg Clin N Am, V7, P753 Foroulis CN, 2003, EUR J CARDIO-THORAC, V23, P384, DOI 10.1016/S1010-7940(02)00797-2 Fragata JI, 1996, PEDIATR CARDIOL, V17, P77, DOI 10.1007/BF02505087 Franz MR, 2003, PROG BIOPHYS MOL BIO, V82, P163, DOI 10.1016/S0079-6107(03)00013-0 Gondi S, 2007, ECHOCARDIOGR-J CARD, V24, P522, DOI 10.1111/j.1540-8175.2007.00430.x Greyson C, 2000, AM J PHYSIOL-HEART C, V278, pH1414, DOI 10.1152/ajpheart.2000.278.5.H1414 Grignola JC, 2006, INT J CARDIOL, V113, P25, DOI 10.1016/j.ijcard.2005.10.012 Haddad F, 2008, CIRCULATION, V117, P1436, DOI 10.1161/CIRCULATIONAHA.107.653576 HENRY WL, 1976, CIRCULATION, V53, P273, DOI 10.1161/01.CIR.53.2.273 Kim WH, 2004, J AM SOC ECHOCARDIOG, V17, P45, DOI 10.1016/j.echo.2003.09.006 KIRSH MM, 1975, ANN THORAC SURG, V20, P215, DOI 10.1016/S0003-4975(10)63878-7 Kowalewski J, 1999, EUR J CARDIO-THORAC, V15, P444, DOI 10.1016/S1010-7940(99)00032-9 Lang RM, 2005, J AM SOC ECHOCARDIOG, V18, P1440, DOI 10.1016/j.echo.2005.10.005 Mahmood F, 2008, J CARDIOTHOR VASC AN, V22, P706, DOI 10.1053/j.jvca.2008.04.006 Mariscalco G, 2006, J THORAC CARDIOV SUR, V131, P1364, DOI 10.1016/j.jtcvs.2006.01.040 Matyal R, 2010, ANN THORAC SURG, V90, P1080, DOI 10.1016/j.athoracsur.2010.05.019 Meluzin J, 2005, J AM SOC ECHOCARDIOG, V18, P435, DOI 10.1016/j.echo.2005.02.004 Mont L, 2008, EUROPACE, V10, P15, DOI 10.1093/europace/eum263 NAKAMURA K, 1995, RESPIRATION, V62, P237 Park BJ, 2007, J THORAC CARDIOV SUR, V133, P775, DOI 10.1016/j.jtcvs.2006.09.022 Psaty BM, 1997, CIRCULATION, V96, P2455 RAINES RA, 1976, AM J PHYSIOL, V231, P1395, DOI 10.1152/ajplegacy.1976.231.5.1395 Rena O, 2001, EUR J CARDIO-THORAC, V20, P688, DOI 10.1016/S1010-7940(01)00890-9 Schiller NB, 2009, JACC-CARDIOVASC IMAG, V2, P150, DOI 10.1016/j.jcmg.2008.11.006 Shanewise JS, 1999, ANESTH ANALG, V89, P870, DOI 10.1097/00000539-199910000-00010 Tei C, 1995, J Cardiol, V26, P357 Tei C, 1997, J AM SOC ECHOCARDIOG, V10, P169, DOI 10.1016/S0894-7317(97)70090-7 Tei CW, 1996, J AM COLL CARDIOL, V28, P658, DOI 10.1016/0735-1097(96)00202-1 Tousignant CP, 2008, J CARDIOTHOR VASC AN, V22, P400, DOI 10.1053/j.jvca.2007.07.014 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Yeo TC, 1998, AM J CARDIOL, V81, P1157, DOI 10.1016/S0002-9149(98)00140-4 NR 42 TC 29 Z9 29 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD OCT PY 2010 VL 90 IS 4 BP 1080 EP 1087 DI 10.1016/j.athoracsur.2010.05.019 PG 9 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 654CE UT WOS:000282145000004 PM 20868791 DA 2026-04-17 ER PT J AU Nojiri, T Maeda, H Takeuchi, Y Funakoshi, Y Maekura, R Yamamoto, K Okumura, M AF Nojiri, Takashi Maeda, Hajime Takeuchi, Yukiyasu Funakoshi, Yasunobu Maekura, Ryoji Yamamoto, Kazuhiro Okumura, Meinoshin TI Predictive value of preoperative tissue Doppler echocardiographic analysis for postoperative atrial fibrillation after pulmonary resection for lung cancer SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article ID VENTRICULAR DIASTOLIC FUNCTION; NONCARDIAC THORACIC-SURGERY; EJECTION FRACTION; FILLING PRESSURES; HEART-FAILURE; CATHETERIZATION; DYSFUNCTION; DISEASE; UTILITY; COPD AB Objective: The objective of the present study was to evaluate the utility of tissue Doppler imaging for predicting the development of postoperative atrial fibrillation. Methods: In this prospective observational study, we evaluated 126 patients with lung cancer who underwent a lobectomy during the 18-month period from August 2007 to January 2009. Preoperative evaluations for all patients included tissue Doppler imaging in addition to conventional echocardiographic analysis. The study end point was the development of postoperative atrial fibrillation. Results: Postoperative atrial fibrillation was identified in 29 (23%) patients, in whom significantly higher early transmitral velocity/tissue Doppler mitral annular early diastolic velocity values were noted compared with those seen in patients without atrial fibrillation (9.76 +/- 2.3 vs 7.14 +/- 1.7, P < .0001). The area under the receiver operating characteristic curve for early transmitral velocity/tissue Doppler mitral annular early diastolic velocity to predict postoperative atrial fibrillation after pulmonary resection for lung cancer was 0.83 (95% confidence interval, 0.74-0.92; P < .001). An early transmitral velocity/tissue Doppler mitral annular early diastolic velocity value of greater than 8 had a sensitivity of 90% and a specificity of 73% for predicting postoperative atrial fibrillation. Conclusions: Postoperative atrial fibrillation after pulmonary resection might be associated with left ventricular diastolic dysfunction before surgical intervention revealed by using tissue Doppler imaging. Additional studies to establish the significance of tissue Doppler imaging as a tool to predict postoperative atrial fibrillation could contribute to improvements in lung cancer treatments. (J Thorac Cardiovasc Surg 2010;140:764-8) C1 [Nojiri, Takashi; Maeda, Hajime; Takeuchi, Yukiyasu; Funakoshi, Yasunobu] Toneyama Natl Hosp, Dept Gen Thorac Surg, Toyonaka, Osaka 5608552, Japan. [Maekura, Ryoji] Toneyama Natl Hosp, Dept Cardiol, Toyonaka, Osaka 5608552, Japan. [Yamamoto, Kazuhiro] Osaka Univ, Grad Sch Med, Dept Cardiol, Suita, Osaka, Japan. [Okumura, Meinoshin] Osaka Univ, Grad Sch Med, Dept Gen Thorac Surg, Suita, Osaka, Japan. C3 University of Osaka; University of Osaka RP Nojiri, T (corresponding author), Toneyama Natl Hosp, Dept Gen Thorac Surg, Toneyama 5-1-1, Toyonaka, Osaka 5608552, Japan. EM nojirit@thoracic.med.osaka-u.ac.jp CR Acil T, 2007, AM J CARDIOL, V100, P1383, DOI 10.1016/j.amjcard.2007.06.025 Al-Omari MA, 2008, AM J CARDIOL, V101, P1759, DOI 10.1016/j.amjcard.2008.02.067 Almuntaser I, 2007, AM J CARDIOL, V100, P1771, DOI 10.1016/j.amjcard.2007.07.029 AMAR D, 1995, CHEST, V108, P349, DOI 10.1378/chest.108.2.349 Boussuges A, 2000, AM J RESP CRIT CARE, V162, P670, DOI 10.1164/ajrccm.162.2.9908056 BUTLER J, 1983, CIRCULATION, V67, P1163, DOI 10.1161/01.CIR.67.6.1163 Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 CURRIE PJ, 1985, J AM COLL CARDIOL, V6, P750, DOI 10.1016/S0735-1097(85)80477-0 DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613 Funk GC, 2008, CHEST, V133, P1354, DOI 10.1378/chest.07-2685 Kasner M, 2007, CIRCULATION, V116, P637, DOI 10.1161/CIRCULATIONAHA.106.661983 LOUIE EK, 1995, CIRCULATION, V92, P819, DOI 10.1161/01.CIR.92.4.819 Matsubara Y, 2005, CHEST, V128, P3519, DOI 10.1378/chest.128.5.3519 Nagueh SF, 1997, J AM COLL CARDIOL, V30, P1527, DOI 10.1016/S0735-1097(97)00344-6 NAKAHARA K, 1985, ANN THORAC SURG, V39, P260, DOI 10.1016/S0003-4975(10)62591-X Ommen SR, 2000, CIRCULATION, V102, P1788 Paulus WJ, 2007, EUR HEART J, V28, P2539, DOI 10.1093/eurheartj/ehm037 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Sekine Y, 2001, CHEST, V120, P1783, DOI 10.1378/chest.120.6.1783 Tsang TSM, 2002, J AM COLL CARDIOL, V40, P1636, DOI 10.1016/S0735-1097(02)02373-2 Tutar E, 1999, AM J CARDIOL, V83, P1414, DOI 10.1016/S0002-9149(99)00111-3 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Yamamoto K, 1997, J AM COLL CARDIOL, V30, P1819, DOI 10.1016/S0735-1097(97)00390-2 Yamamoto K, 1996, HEART, V75, P27, DOI 10.1136/hrt.75.6_Suppl_2.27 NR 24 TC 41 Z9 43 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 EI 1097-685X J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD OCT PY 2010 VL 140 IS 4 BP 764 EP 768 DI 10.1016/j.jtcvs.2009.11.073 PG 5 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 651YO UT WOS:000281965300007 PM 20691999 OA Bronze DA 2026-04-17 ER PT J AU Aujollet, N Meyer, M Cailliod, R Combier, F Coignet, Y Campard, S Facy, O Bernard, A Girard, C AF Aujollet, Nathalie Meyer, Marjorie Cailliod, Romain Combier, Fanny Coignet, Yann Campard, Sebastien Facy, Olivier Bernard, Alain Girard, Claude TI High N-Terminal Pro-B-Type Natriuretic Peptide: A Biomarker of Lung Cancer? SO CLINICAL LUNG CANCER LA English DT Article DE Atrial fibrillation; Cardiac biomarker; Dysthyroidy; NT-proBNP ID ACUTE HEART-FAILURE; EMERGENCY DIAGNOSIS; BNP; ASSOCIATION; PREDICTION; DYSPNEA; MARKERS; FAMILY; MEMBER AB Background: The level of N-terminal pro-B-type natriuretic peptide (NT-proBNP) is affected by many known factors. Our study aimed to evaluate whether other factors, in particular lung cancer, could be responsible for an increase in NT-proBNP levels in a population with no known risk factors for elevated NT-proBNP. Patients and Methods: This study was based on the RIABO (Recueil de l'Ischemie au Bloc Operatoire) database, a single-center registry that prospectively records in elective noncardiac surgery. Patients aged > 75 years and those presenting with 1 or more known risk factors for high NT-proBNP were excluded. Patients were divided into 2 groups according to preoperative NT-proBNP levels: (>= 125 pg/mL or < 125 pg/mL). Results: Between October 2005 and February 2007, 439 patients were eligible for inclusion. Among 35 patients with lung cancer, 26 (74%) had elevated NT-proBNP (>= 125 pg/mL), versus 9 (26%) with NT-proBNP < 125 pg/mL (P < .0001). By multivariate analysis, the presence of lung cancer was an independent risk factor for a level of NT-proBNP >= 125 pg/mL (odds ratio, 7; 95% CI, 2.9-17; P < .0001). We also observed an independent relationship between NT-proBNP >= 125 pg/mL and age, female sex, smoking status, and C-reactive protein levels. Conclusion: In our study, patients with lung cancer were 7 times more likely to have elevated NT-proBNP (>= 125 pg/mL). The presence of lung cancer should therefore be taken into account when interpreting NT-proBNP levels. Further studies are warranted to explore the diagnostic value of this marker in lung cancer and to identify the cause of the elevation. C1 [Aujollet, Nathalie; Meyer, Marjorie; Combier, Fanny; Coignet, Yann; Campard, Sebastien; Girard, Claude] Bocage Univ Hosp, Dept Anesthesie & Reanimat, F-21000 Dijon, France. [Bernard, Alain] Bocage Univ Hosp, Dept Thorac Surg, F-21000 Dijon, France. [Facy, Olivier] Bocage Univ Hosp, Dept Digest Surg, F-21000 Dijon, France. [Cailliod, Romain] Bocage Univ Hosp, Dept Med Informat, F-21000 Dijon, France. C3 Universite Bourgogne Europe; CHU Dijon Bourgogne; Universite Bourgogne Europe; CHU Dijon Bourgogne; Universite Bourgogne Europe; CHU Dijon Bourgogne; Universite Bourgogne Europe; CHU Dijon Bourgogne RP Aujollet, N (corresponding author), Bocage Univ Hosp, Dept Anesthesie & Reanimat, 2 Blvd Lattre de Tassigny, F-21000 Dijon, France. EM naujollet@yahoo.fr RI facy, olivier/AAQ-2293-2021 OI facy, olivier/0000-0002-5619-8963 CR Andrews N, 2001, CARDIOVASC SURG, V9, P254, DOI 10.1016/S0967-2109(00)00139-3 Baggish AL, 2008, AM J CARDIOL, V101, p49A, DOI 10.1016/j.amjcard.2007.11.020 Baker M, 2005, NAT BIOTECHNOL, V23, P297, DOI 10.1038/nbt0305-297 Bayes-Genis A, 2008, AM J CARDIOL, V101, p89A, DOI 10.1016/j.amjcard.2007.11.030 Bibbins-Domingo K, 2007, JAMA-J AM MED ASSOC, V297, P169, DOI 10.1001/jama.297.2.169 COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580 Collinson PO, 2008, SCAND J CLIN LAB INV, V68, P104, DOI 10.1080/00365510802150265 Daniels LB, 2007, J AM COLL CARDIOL, V50, P2357, DOI 10.1016/j.jacc.2007.09.021 de Lemos JA, 2003, LANCET, V362, P316, DOI 10.1016/S0140-6736(03)13976-1 DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2 Feringa HHH, 2007, HEART, V93, P226, DOI 10.1136/hrt.2006.093716 Harrell F.E., 2001, Springer Series in Statistics, DOI DOI 10.1007/978-1-4757-3462-1 Heikkilä K, 2007, J EPIDEMIOL COMMUN H, V61, P824, DOI 10.1136/jech.2006.051292 Hilbe JM, 2009, CH CRC TEXT STAT SCI, P1 Hildebrandt P, 2008, AM J CARDIOL, V101, p25A, DOI 10.1016/j.amjcard.2007.11.016 HOSMER DW, 1980, COMMUN STAT A-THEOR, V9, P1043, DOI 10.1080/03610928008827941 James SK, 2003, CIRCULATION, V108, P275, DOI 10.1161/01.CIR.0000079170.10579.DC Januzzi JL, 2005, AM J CARDIOL, V95, P948, DOI 10.1016/j.amjcard.2004.12.032 Jones AE, 2003, ANN EMERG MED, V42, P714, DOI 10.1016/S0196-0644(03)00622-X Lafaras C, 2009, ONKOLOGIE, V32, P389, DOI 10.1159/000218368 Logeart D, 2002, J AM COLL CARDIOL, V40, P1794, DOI 10.1016/S0735-1097(02)02482-8 Maisel AS, 2002, NEW ENGL J MED, V347, P161, DOI 10.1056/NEJMoa020233 Maisel AS, 2004, AM HEART J, V147, P1078, DOI 10.1016/j.ahj.2004.01.013 McLean AS, 2007, CRIT CARE MED, V35, P1019, DOI 10.1097/01.CCM.0000259469.24364.31 Morello A, 2007, AM HEART J, V153, P90, DOI 10.1016/j.ahj.2006.10.005 Mueller C, 2007, SWISS MED WKLY, V137, P4 Sánchez-Moreno C, 2004, STROKE, V35, P163, DOI 10.1161/01.STR.0000105391.62306.2E SCHWEITZ H, 1992, J BIOL CHEM, V267, P13928 Staub D, 2005, AM J MED, V118, DOI 10.1016/j.amjmed.2005.05.020 Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9 SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0 Tonstad S, 2009, INT J CLIN PRACT, V63, P1634, DOI 10.1111/j.1742-1241.2009.02179.x Tung RH, 2006, ANN EMERG MED, V48, P66, DOI 10.1016/j.annemergmed.2005.12.022 Vila G, 2008, J APPL PHYSIOL, V105, P1741, DOI 10.1152/japplphysiol.90442.2008 Wei T, 2005, INT J CLIN PRACT, V59, P891, DOI 10.1111/j.1368-5031.2005.00584.x Wu FY, 2003, CANCER RES, V63, P8318 NR 37 TC 16 Z9 18 U1 0 U2 3 PU CIG MEDIA GROUP, LP PI DALLAS PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA SN 1525-7304 EI 1938-0690 J9 CLIN LUNG CANCER JI Clin. Lung Cancer PD SEP PY 2010 VL 11 IS 5 BP 341 EP 345 DI 10.3816/CLC.2010.n.043 PG 5 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA 649KT UT WOS:000281769000007 PM 20837460 DA 2026-04-17 ER PT J AU Thomas, KS Billingsley, A Amarshi, N Nair, BA AF Thomas, Kelly S. Billingsley, Amanda Amarshi, Naseem Nair, Balagopalan A. TI Elevated International Normalized Ratio associated with concomitant warfarin and erlotinib SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY LA English DT Article DE Anticoagulants; Antineoplastic agents; Dosage; Drug interactions; Erlotinib; International normalized ratio; Lung neoplasms; Phytonadione; Toxicity; Venous thromboembolism; Vitamins; Warfarin ID PHASE-III AB Purpose. The case of a patient who developed elevated International Normalized Ratio (INR) values after concomitant administration of warfarin and erlotinib is reported Summary. A 47-year-old Caucasian man with a history of atrial fibrillation, anxiety, and a 40-pack-year smoking history was diagnosed with advanced, moderately differentiated adenocarcinoma of the lung. Soon after being diagnosed with non-small-cell lung cancer, warfarin was initiated for the treatment of a venous thromboembolism The patient's warfarin dosage was adjusted to reach a target INR of 2-3. His INR was relatively stable (2 1-3 2) for at least eight weeks before erlotinib was added to the chemotherapy regimen The patient developed a well-disseminated rash and diarrhea soon after starting erlotinib. Seven days after the initiation of erlotinib therapy, the patient's INR value increased from 28 to 5.3, with no concurrent changes in warfarin dosage, other medications, or diet. After withholding two doses of warfarin, the patient's INR value increased to 9 1, and the patient developed an elbow hematoma His anticoagulation was rapidly reversed with the administration of subcutaneous phytonadione. The patient elected to discontinue erlotinib nine days after its initiation The next day, his INR value was 24 The patient returned to the hematology-oncology clinic for follow-up two days later, where his INR was found to be 0 9 Conclusion. Concomitant administration of erlotinib and warfarin resulted in an increase in INR values in a 47-year-old man with advanced lung cancer. C1 [Thomas, Kelly S.; Amarshi, Naseem] Cent Arkansas Vet Healthcare Syst, Serv Pharm, Little Rock, AR 72205 USA. [Billingsley, Amanda] VA Palo Alto Hlth Care Syst, Serv Pharm, Palo Alto, CA USA. [Nair, Balagopalan A.] Hematol Oncol Associates, Little Rock, AR USA. C3 US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System RP Thomas, KS (corresponding author), Cent Arkansas Vet Healthcare Syst, Serv Pharm, 4300 W 7th St,Slot 119, Little Rock, AR 72205 USA. EM kelly.thomas@va.gov RI Thomas Craig, Kelly Jean/ABE-6181-2021 CR *AM CANC SOC CANC, 2009, AM CANC SOC CANC FAC Gatzemeier U, 2007, J CLIN ONCOL, V25, P1545, DOI 10.1200/JCO.2005.05.1474 *GEN OSI PHARM, 2007, TARC ERL PACK INS Giaccone G, 2005, J CLIN ONCOL, V23, P3235, DOI 10.1200/JCO.2005.08.409 Grenader T, 2007, LUNG CANCER, V57, P404, DOI 10.1016/j.lungcan.2007.02.011 Herbst RS, 2005, J CLIN ONCOL, V23, P5892, DOI 10.1200/JCO.2005.02.840 Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43 Kearon C, 2008, CHEST, V133, p454S, DOI 10.1378/chest.08-0658 Lehmann DF, 2000, PHARMACOTHERAPY, V20, P1464, DOI 10.1592/phco.20.19.1464.34860 *LEX COMP, 2008, LEX DRUGS ONL MARCUS R, 1990, GOODMAN GILMANS PHAR, P1563 Maréchal JD, 2006, DRUG METAB DISPOS, V34, P534, DOI 10.1124/dmd.105.007625 MCELNAY JC, 1983, DRUGS, V25, P495, DOI 10.2165/00003495-198325050-00003 NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154 RAKLUT A, 2008, EUR J CLIN PHARMACOL, V64, P31 SELLERS EM, 1970, NEW ENGL J MED, V283, P827, DOI 10.1056/NEJM197010152831601 Smith JK, 1999, ANN PHARMACOTHER, V33, P301, DOI 10.1345/aph.18171 2007, COUMADIN WARFARIN PA 2008, DATA FILE GENENTECH NR 19 TC 24 Z9 27 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-2082 EI 1535-2900 J9 AM J HEALTH-SYST PH JI Am. J. Health-Syst. Pharm. PD SEP 1 PY 2010 VL 67 IS 17 BP 1426 EP 1429 DI 10.2146/ajhp090202 PG 4 WC Pharmacology & Pharmacy WE Science Citation Index Expanded (SCI-EXPANDED) SC Pharmacology & Pharmacy GA 648UB UT WOS:000281718700008 PM 20720241 DA 2026-04-17 ER PT J AU Goto, T Maeshima, A Oyamada, Y Wakaki, M Hamaguchi, R Kato, R AF Goto, Taichiro Maeshima, Arafumi Oyamada, Yoshitaka Wakaki, Misa Hamaguchi, Reo Kato, Ryoichi TI Uracil-Tegafur-Induced Pleural Effusion Following Lung Cancer Surgery SO ANNALS OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article DE UFT; lung cancer; adjuvant chemotherapy; pleural effusion ID RETINOIC ACID SYNDROME; ADJUVANT CHEMOTHERAPY; METAANALYSIS; TRIAL; UFT AB The patient was a 75-year-old female with a history of no smoking. Under a diagnosis of lung cancer, she underwent a right lower lobectomy in March 2008. She was started on oral Uracil-Tegafur (UFT) (400 mg/day) from April and in May developed fatigue, respiratory discomfort, and tachycardiac atrial fibrillation. Chest X-ray film showed an increase in right pleural effusion. Thoracentesis revealed a yellowish, serous exudate containing predominantly lymphocytes, with no evidence of malignancy. Despite continued diuretic administration for 5 months from July, it was difficult to control the pleural effusion, and her activities of daily living remained low. In December of the same year, the oral administration of UFT was terminated, which 2 weeks later resulted in a marked decrease in pleural effusion on chest X-ray film. Respiratory discomfort and fatigue also subsided, and her general condition improved markedly. Herein we report a case of oral UFT-induced pleural effusion following lung cancer surgery. (Ann Thorac Cardiovasc Surg 2010; 16: 281-285) C1 [Goto, Taichiro] Natl Hosp Org Tokyo Med Ctr, Dept Gen Thorac Surg, Meguro Ku, Tokyo 1528902, Japan. [Maeshima, Arafumi] Natl Hosp Org Tokyo Med Ctr, Dept Pathol, Tokyo 1528902, Japan. [Oyamada, Yoshitaka; Wakaki, Misa; Hamaguchi, Reo] Natl Hosp Org Tokyo Med Ctr, Dept Resp Med, Tokyo 1528902, Japan. C3 National Hospital Organization Tokyo Medical Center; National Hospital Organization Tokyo Medical Center; National Hospital Organization Tokyo Medical Center RP Goto, T (corresponding author), Natl Hosp Org Tokyo Med Ctr, Dept Gen Thorac Surg, Meguro Ku, 2-5-1 Higashigaoka, Tokyo 1528902, Japan. RI Goto, Taichiro/AAM-5276-2020 CR FRANKEL SR, 1992, ANN INTERN MED, V117, P292, DOI 10.7326/0003-4819-117-4-292 Goldsby R, 2002, J PEDIAT HEMATOL ONC, V24, P694, DOI 10.1097/00043426-200211000-00020 GUNSTREAM SR, 1983, CANCER TREAT REP, V67, P301 Hamada C, 2005, J CLIN ONCOL, V23, P4999, DOI 10.1200/JCO.2005.09.017 Hotta K, 2004, J CLIN ONCOL, V22, P3860, DOI 10.1200/JCO.2004.01.153 Jung JI, 2002, AM J ROENTGENOL, V178, P475, DOI 10.2214/ajr.178.2.1780475 Kato H, 2004, NEW ENGL J MED, V350, P1713, DOI 10.1056/NEJMoa032792 Nakagawa K, 2006, BRIT J CANCER, V95, P817, DOI 10.1038/sj.bjc.6603336 Nakagawa M, 2005, ANN ONCOL, V16, P75, DOI 10.1093/annonc/mdi008 SAXON RR, 1991, AM J ROENTGENOL, V156, P281, DOI 10.2214/ajr.156.2.1898799 Tanaka F, 2004, CANCER SCI, V95, P371, DOI 10.1111/j.1349-7006.2004.tb03218.x Tsuchiya T, 2007, LUNG CANCER, V56, P341, DOI 10.1016/j.lungcan.2007.01.019 VOGELZANG PJ, 1992, CHEST, V101, P746, DOI 10.1378/chest.101.3.746 WALDEN PAM, 1977, BRIT MED J, V2, P867, DOI 10.1136/bmj.2.6091.867 NR 14 TC 0 Z9 0 U1 0 U2 0 PU MEDICAL TRIBUNE INC PI CHIYODA-KU PA ED COMM ANNALS THORACIC CARDIOVASCULAR SURG, 2-1 NIBANCHO, CHIYODA-KU, TOKYO 102-0084, JAPAN SN 1341-1098 J9 ANN THORAC CARDIOVAS JI Ann. Thorac. Cardiovasc. Surg. PD AUG PY 2010 VL 16 IS 4 BP 281 EP 285 PG 5 WC Cardiac & Cardiovascular Systems; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Surgery GA 645VA UT WOS:000281493100012 PM 21057448 DA 2026-04-17 ER PT J AU Onaitis, M D'Amico, T Zhao, Y O'Brien, S Harpole, D AF Onaitis, Mark D'Amico, Thomas Zhao, Yue O'Brien, Sean Harpole, David TI Risk Factors for Atrial Fibrillation After Lung Cancer Surgery: Analysis of The Society of Thoracic Surgeons General Thoracic Surgery Database SO ANNALS OF THORACIC SURGERY LA English DT Article; Proceedings Paper CT Surgical Motion Picture Session of the 46th Annual Meeting of the Society-of-Thoracic-Surgeons CY JAN 24-27, 2010 CL Fort Lauderdale, FL SP Soc Thorac Surg ID ARRHYTHMIAS; AGE; PNEUMONECTOMY; THORACOTOMY; PROPHYLAXIS; RESECTION; GENDER; ONSET AB Background. Atrial fibrillation is responsible for significant morbidity after lung cancer surgery, and preoperative and perioperative risk factors are not well described. Methods. The Society of Thoracic Surgeons (STS) database was queried for all lobectomy and pneumonectomy patients with a diagnosis of lung cancer. A multivariable logistic regression model was developed to predict the risk of atrial arrhythmia as a function of preoperative and perioperative factors. Generalized estimating equations methodology was used to account for correlation among observations from the same institution. Missing data were handled using the method of chained equations with 10 randomly imputed data sets. Results. A total of 13,906 patients who underwent resection for lung cancer at participating institutions had complete information for postoperative atrial arrhythmia, of whom 1,755 (12.6%) experienced the outcome. Multivariable logistic analysis indentified increasing age, increasing extent of operation, male sex, nonblack race, and stage II or greater tumors as predictors of postoperative atrial fibrillation. Conclusions. Analysis of the STS database has identified five variables that predict postoperative atrial fibrillation. This predictive model may be useful to develop strategies for risk stratification, prophylaxis, and treatment. (Ann Thorac Surg 2010;90:368-74) (C) 2010 by The Society of Thoracic Surgeons C1 [Onaitis, Mark] Duke Univ, Dept Surg, Durham, NC 27710 USA. Duke Clin Res Inst, Durham, NC USA. C3 Duke University; Duke University RP Onaitis, M (corresponding author), Duke Univ, Dept Surg, DUMC Box 3305, Durham, NC 27710 USA. EM mark.onaitis@duke.edu CR Amar D, 2000, J THORAC CARDIOV SUR, V120, P790, DOI 10.1067/mtc.2000.109538 Amar D, 2003, J AM COLL CARDIOL, V42, P1262, DOI 10.1016/S0735-1097(03)00955-0 Amar D, 2002, ANESTHESIOLOGY, V96, P352, DOI 10.1097/00000542-200202000-00021 Amar D, 1996, CHEST, V110, P437, DOI 10.1378/chest.110.2.437 ASAMURA H, 1993, J THORAC CARDIOV SUR, V106, P1104, DOI 10.1016/S0022-5223(19)33985-6 Brathwaite D, 1998, CHEST, V114, P462, DOI 10.1378/chest.114.2.462 GOLDMAN L, 1978, CHEST, V73, P450, DOI 10.1378/chest.73.4.450 Haïssaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003 Harpole DH, 1996, ANN THORAC SURG, V61, P977, DOI 10.1016/0003-4975(95)01174-9 KROWKA MJ, 1987, CHEST, V91, P490, DOI 10.1378/chest.91.4.490 Lanza LA, 2003, ANN THORAC SURG, V75, P223, DOI 10.1016/S0003-4975(02)04285-6 Larsen JA, 1998, J CARDIOVASC ELECTR, V9, P655, DOI 10.1111/j.1540-8167.1998.tb00950.x Passman RS, 2005, ANN THORAC SURG, V79, P1698, DOI 10.1016/j.athoracsur.2004.10.058 Polanczyk CA, 1998, ANN INTERN MED, V129, P279, DOI 10.7326/0003-4819-129-4-199808150-00003 Rena O, 2001, EUR J CARDIO-THORAC, V20, P688, DOI 10.1016/S1010-7940(01)00890-9 RITCHIE AJ, 1990, ANN THORAC SURG, V50, P86, DOI 10.1016/0003-4975(90)90094-M Rubin DonaldB., 1987, MULTIPLE IMPUTATIONS, DOI DOI 10.1002/9780470316696 Tada H, 2001, AM J CARDIOL, V88, P436, DOI 10.1016/S0002-9149(01)01698-8 VANBUUREN S, 2006, J STAT COMPUT SIM, P76 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 VONKNORRING J, 1992, ANN THORAC SURG, V53, P642, DOI 10.1016/0003-4975(92)90325-X Watson T, 2010, CHEST, V137, P869, DOI 10.1378/chest.09-1426 NR 22 TC 184 Z9 209 U1 1 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD AUG PY 2010 VL 90 IS 2 BP 368 EP 374 DI 10.1016/j.athoracsur.2010.03.100 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 634IU UT WOS:000280575100002 PM 20667313 DA 2026-04-17 ER PT J AU Rehm, J Baliunas, D Borges, GLG Graham, K Irving, H Kehoe, T Parry, CD Patra, J Popova, S Poznyak, V Roerecke, M Room, R Samokhvalov, AV Taylor, B AF Rehm, Juergen Baliunas, Dolly Borges, Guilherme L. G. Graham, Kathryn Irving, Hyacinth Kehoe, Tara Parry, Charles D. Patra, Jayadeep Popova, Svetlana Poznyak, Vladimir Roerecke, Michael Room, Robin Samokhvalov, Andriy V. Taylor, Benjamin TI The relation between different dimensions of alcohol consumption and burden of disease: an overview SO ADDICTION LA English DT Article DE Alcohol; average volume; burden of disease; injury; morbidity; mortality; patterns of drinking; risk relation ID CORONARY-HEART-DISEASE; RISKY SEXUAL-BEHAVIOR; LUNG-CANCER RISK; ATRIAL-FIBRILLATION; DRINKING PATTERN; POOLED ANALYSIS; BREAST-CANCER; CARDIOVASCULAR-DISEASE; INSULIN SENSITIVITY; COLORECTAL-CANCER AB Aims As part of a larger study to estimate the global burden of disease and injury attributable to alcohol: to evaluate the evidence for a causal impact of average volume of alcohol consumption and pattern of drinking on diseases and injuries; to quantify relationships identified as causal based on published meta-analyses; to separate the impact on mortality versus morbidity where possible; and to assess the impact of the quality of alcohol on burden of disease. Methods Systematic literature reviews were used to identify alcohol-related diseases, birth complications and injuries using standard epidemiological criteria to determine causality. The extent of the risk relations was taken from meta-analyses. Results Evidence of a causal impact of average volume of alcohol consumption was found for the following major diseases: tuberculosis, mouth, nasopharynx, other pharynx and oropharynx cancer, oesophageal cancer, colon and rectum cancer, liver cancer, female breast cancer, diabetes mellitus, alcohol use disorders, unipolar depressive disorders, epilepsy, hypertensive heart disease, ischaemic heart disease (IHD), ischaemic and haemorrhagic stroke, conduction disorders and other dysrhythmias, lower respiratory infections (pneumonia), cirrhosis of the liver, preterm birth complications and fetal alcohol syndrome. Dose-response relationships could be quantified for all disease categories except for depressive disorders, with the relative risk increasing with increased level of alcohol consumption for most diseases. Both average volume and drinking pattern were linked causally to IHD, fetal alcohol syndrome and unintentional and intentional injuries. For IHD, ischaemic stroke and diabetes mellitus beneficial effects were observed for patterns of light to moderate drinking without heavy drinking occasions (as defined by 60+ g pure alcohol per day). For several disease and injury categories, the effects were stronger on mortality compared to morbidity. There was insufficient evidence to establish whether quality of alcohol had a major impact on disease burden. Conclusions Overall, these findings indicate that alcohol impacts many disease outcomes causally, both chronic and acute, and injuries. In addition, a pattern of heavy episodic drinking increases risk for some disease and all injury outcomes. Future studies need to address a number of methodological issues, especially the differential role of average volume versus drinking pattern, in order to obtain more accurate risk estimates and to understand more clearly the nature of alcohol-disease relationships. C1 [Rehm, Juergen; Baliunas, Dolly; Graham, Kathryn; Irving, Hyacinth; Kehoe, Tara; Patra, Jayadeep; Popova, Svetlana; Roerecke, Michael; Samokhvalov, Andriy V.; Taylor, Benjamin] Ctr Addict & Mental Hlth, Toronto, ON M5S 2S1, Canada. [Rehm, Juergen; Baliunas, Dolly; Popova, Svetlana; Roerecke, Michael; Taylor, Benjamin] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada. [Rehm, Juergen] Tech Univ Dresden, Inst Clin Psychol & Psychotherapy, Dresden, Germany. [Borges, Guilherme L. G.] Natl Inst Psychiat, Div Epidemiol & Psychosocial Res, Mexico City, DF, Mexico. [Graham, Kathryn] Univ Western Ontario, Dept Psychol, London, ON, Canada. [Graham, Kathryn] Curtin Univ Technol, Natl Drug Res Inst, Perth, WA, Australia. [Parry, Charles D.] MRC, Alcohol & Drug Abuse Res Unit, Cape Town, South Africa. [Parry, Charles D.] Univ Stellenbosch, Dept Psychiat, Cape Town, South Africa. [Popova, Svetlana] Univ Toronto, Factor Inwentash Fac SocialWork, Toronto, ON, Canada. [Poznyak, Vladimir] World Hlth Org, Dept Mental Hlth & Substance Abuse, Geneva, Switzerland. [Room, Robin] Univ Melbourne, Sch Populat Hlth, Melbourne, Vic 3010, Australia. [Room, Robin] Turning Point Alcohol & Drug Ctr, AER Ctr Alcohol Policy Res, Fitzroy, Vic, Australia. C3 University of Toronto; Centre for Addiction & Mental Health - Canada; University of Toronto; Technische Universitat Dresden; Instituto Nacional de Psiquiatria Ramon de la Fuente Muniz; Western University (University of Western Ontario); Curtin University; Stellenbosch University; University of Toronto; World Health Organization; University of Melbourne; Turning Point Alcohol & Drug Centre - Australia RP Rehm, J (corresponding author), Ctr Addict & Mental Hlth, 33 Russell St,Room 2035, Toronto, ON M5S 2S1, Canada. EM jtrehm@aol.com RI ; Baliunas, Dolly/AAB-8131-2021; Room, Robin/ABH-8505-2020; Parry, Charles/A-2906-2009; Roerecke, Michael/Z-2803-2019; Rehm, Jürgen/K-2147-2012; Patra, Jayadeep/OML-3735-2025 OI Samokhvalov, Aniy/0000-0001-6091-3045; Baliunas, Dolly/0000-0001-5685-0715; Room, Robin/0000-0002-5618-385X; Parry, Charles/0000-0001-9787-2785; Borges, Guilherme/0000-0002-3269-0507; FU NIAAA [HHSN267200700041C]; Global Burden of Disease and Injury 2005 Project; Centre for Addiction and Mental Health in Toronto, Canada; Ontario Ministry of Health and Long Term Care FX The authors are grateful to the journal Addiction for providing an opportunity to update an earlier article [Rehm J., Room R., Graham K., Monteiro M., Gmel G., Sempos C.T. (2003). The relationship of average volume of alcohol consumption and patterns of drinking to burden of disease-an overview. Addiction, 98(10), 1209-1228]. NIAAA (contract no. HHSN267200700041C 'Alcohol- and Drug-Attributable Burden of Disease and Injury in the US' to the first author), the Global Burden of Disease and Injury 2005 Project, and the Centre for Addiction and Mental Health in Toronto, Canada provided financial and/or technical support for this study. In addition, support to CAMH for scientists' salaries and infrastructure has been provided by the Ontario Ministry of Health and Long Term Care. The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official views of the NIAAA or NIH or those of the Ministry of Health and Long Term Care. We would like to thank G. Gmel, B. Grant, R. Norman, P. Shuper and T. Vos for helpful comments on earlier versions of this text and for advising on the systematic reviews. CR ABEL EL, 1982, HUM BIOL, V54, P421 ABEL EL, 1995, ALCOHOL ALCOHOLISM, V30, P345 Agarwal DP, 2002, ALCOHOL ALCOHOLISM, V37, P409, DOI 10.1093/alcalc/37.5.409 AHLUWALIA B, 1992, ALCOHOL, V9, P395, DOI 10.1016/0741-8329(92)90038-C Albertsen K, 2004, AM J EPIDEMIOL, V159, P155, DOI 10.1093/aje/kwh034 Altieri A, 2005, ORAL ONCOL, V41, P956, DOI 10.1016/j.oraloncology.2005.02.004 [Anonymous], 2004, MOONSHINE MARKETS IS [Anonymous], 1999, EPIDEMIOLOGIC BASIS [Anonymous], 1994, BIOL EXPRESSION BIOL [Anonymous], 2007, INT CLASS DIS REL HL, V10th [Anonymous], COCHRANE DATABASE SY Ashley M.J., 2000, Contemporary Drug Problems, V27, P735 Baan R, 2007, LANCET ONCOL, V8, P292, DOI 10.1016/S1470-2045(07)70099-2 Bagnardi V, 2001, ALCOHOL RES HEALTH, V25, P263 Bagnardi V, 2008, J EPIDEMIOL COMMUN H, V62, P615, DOI 10.1136/jech.2007.065607 BALBAO CEB, 2009, ADV CARDIOVASC DIS, V3, P53 BALIUNAS D, 2008, INT J PUBLI IN PRESS Baliunas DO, 2009, DIABETES CARE, V32, P2123, DOI 10.2337/dc09-0227 BALLENGER JC, 1978, BRIT J PSYCHIAT, V133, P1, DOI 10.1192/bjp.133.1.1 Bandera EV, 2001, CANCER EPIDEM BIOMAR, V10, P813 Baraona E, 1998, RECENT DEV ALCOHOL, V14, P97, DOI 10.1007/0-306-47148-5_5 Barclay G.A., 2008, Advances in Psychiatric Treatment, V14, p139 151, DOI [10.1192/apt.bp.105.001263, DOI 10.1192/APT.BP.105.001263] BAUTISTA AP, 2005, COMPREHENSIVE HDB AL, P491 Becker U., 2005, COMPREHENSIVE HDB AL, P467 BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446 Behnam SM, 2005, CUTIS, V76, P181 BEILIN LJ, 1992, CLIN EXP HYPERTENS A, V14, P119, DOI 10.3109/10641969209036176 BENJAMIN EJ, 1994, JAMA-J AM MED ASSOC, V271, P840, DOI 10.1001/jama.271.11.840 Beral V, 2002, BRIT J CANCER, V87, P1234, DOI 10.1038/sj.bjc.6600596 Beulens JWJ, 2007, ANN INTERN MED, V146, P10, DOI 10.7326/0003-4819-146-1-200701020-00004 Boffetta P, 2006, LANCET ONCOL, V7, P149, DOI 10.1016/S1470-2045(06)70577-0 BOLOGNIA JL, 2008, PSORIASIS DERMATOLOG Bowcock AM, 2005, IMMUNOL RES, V32, P45, DOI 10.1385/IR:32:1-3:045 Braithwaite RS, 2005, ALCOHOL CLIN EXP RES, V29, P1190, DOI 10.1097/01.ALC.0000171937.87731.28 Bruun Kettil., 1975, ALCOHOL CONTROL POLI Buford Bill., 1991, THUGS CAMARGO CA, 1989, STROKE, V20, P1611, DOI 10.1161/01.STR.20.12.1611 Carlsson S, 2005, DIABETOLOGIA, V48, P1051, DOI 10.1007/s00125-005-1768-5 Challis J.R.G., 1988, P2177 Chao C, 2007, CANCER EPIDEM BIOMAR, V16, P2436, DOI 10.1158/1055-9965.EPI-07-0386 CHAUD M, 1994, PROSTAG LEUKOTR ESS, V51, P47, DOI 10.1016/0952-3278(94)90177-5 Cho EY, 2004, ANN INTERN MED, V140, P603, DOI 10.7326/0003-4819-140-8-200404200-00007 COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616 Cohen AD, 1999, CLIN DERMATOL, V17, P411, DOI 10.1016/S0738-081X(99)00025-5 Collins MA, 2009, ALCOHOL CLIN EXP RES, V33, P206, DOI 10.1111/j.1530-0277.2008.00828.x Cook JL, 1998, PROSTAG LEUKOTR ESS, V58, P135, DOI 10.1016/S0952-3278(98)90153-3 Corrao G, 2004, PREV MED, V38, P613, DOI 10.1016/j.ypmed.2003.11.027 Corrao G, 2000, ADDICTION, V95, P1505, DOI 10.1046/j.1360-0443.2000.951015056.x Corrao G, 1999, ADDICTION, V94, P1551, DOI 10.1046/j.1360-0443.1999.9410155111.x CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702 CRIQUI MH, 1994, LANCET, V344, P1719, DOI 10.1016/S0140-6736(94)92883-5 CRIQUI MH, 1994, CONTEMP DRUG PROBL, V21, P125, DOI DOI 10.1177/009145099402100113 DAM AM, 1985, EPILEPSIA, V26, P227, DOI 10.1111/j.1528-1157.1985.tb05410.x Davies MJ, 2002, JAMA-J AM MED ASSOC, V287, P2559, DOI 10.1001/jama.287.19.2559 Dawson DA, 2000, J SUBST ABUSE, V12, P1, DOI 10.1016/S0899-3289(00)00037-7 Di Castelnuovo A, 2002, CIRCULATION, V105, P2836, DOI 10.1161/01.CIR.0000018653.19696.01 Di Castelnuovo A, 2006, ARCH INTERN MED, V166, P2437, DOI 10.1001/archinte.166.22.2437 Dika E, 2007, Curr Probl Dermatol, V35, P118, DOI 10.1159/000106419 Dorgan JF, 2002, JNCI-J NATL CANCER I, V94, P606 DULLI DA, 2005, COMPREHENSIVE HDB AL, V2, P627 Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629 Ellison RC, 2001, AM J EPIDEMIOL, V154, P740, DOI 10.1093/aje/154.8.740 ELMAS MM, 1993, J PHARMACOL EXP THER, V264, P1198 English D.R., 1995, QUANTIFICATION DRUG, V1995 EVSTAFYEV VV, 1989, VESTN DERMATOL VENER, P72 Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6 Farkas A, 2003, ARCH DERMATOL RES, V295, P56, DOI 10.1007/s00403-003-0399-2 Feigin VL, 2005, STROKE, V36, P2773, DOI 10.1161/01.STR.0000190838.02954.e8 FERNANDEZSOLA J, 1995, ARCH INTERN MED, V155, P1649, DOI 10.1001/archinte.155.15.1649 Fillmore KM, 2006, ADDICT RES THEORY, V14, P101, DOI 10.1080/16066350500497983 Fisher JC, 2007, SEX TRANSM DIS, V34, P856, DOI 10.1097/OLQ.0b013e318067b4fd Fisher RS, 2005, EPILEPSIA, V46, P470, DOI 10.1111/j.0013-9580.2005.66104.x Freedland Eric S., 1993, Journal of Emergency Medicine, V11, P463, DOI 10.1016/0736-4679(93)90251-2 Freudenheim JL, 2005, AM J CLIN NUTR, V82, P657, DOI 10.1093/ajcn/82.3.657 Frick U., 2004, Comparative Quantification of health risks: Global and regional burden of disease attributable to selected risk factors, V1, P959 Friedman H, 2006, FEMS IMMUNOL MED MIC, V47, P330, DOI 10.1111/j.1574-695X.2006.00097.x Fujimoto W.Y., 2000, AM J MED, V108, p9S, DOI [DOI 10.1016/S0002-9343(00)00337-5, 10.1016/s0002-9343(00)00337-5] Gelfand JM, 2005, ARCH DERMATOL, V141, P1537, DOI 10.1001/archderm.141.12.1537 GINSBURG IH, 1993, INT J DERMATOL, V32, P587, DOI 10.1111/j.1365-4362.1993.tb05031.x Gmel G, 2003, ALCOHOL RES HEALTH, V27, P52 Golding M, 1996, INT REV PSYCHIATR, V8, P253, DOI 10.3109/09540269609046309 GOTTLIEB SL, 1995, NAT MED, V1, P442, DOI 10.1038/nm0595-442 Gourevitch P., 1998, WE WISH INFORM YOU T GRAVES AB, 1991, INT J EPIDEMIOL, V20, pS48, DOI 10.1093/ije/20.Supplement_2.S48 Greenfield TK, 2008, ADDICTION, V103, P1082, DOI 10.1111/j.1360-0443.2008.02197.x GUPTA MA, 1993, J AM ACAD DERMATOL, V28, P730, DOI 10.1016/0190-9622(93)70101-X Gutjahr E, 2001, EUR ADDICT RES, V7, P117, DOI 10.1159/000050729 HalpernFelsher BL, 1996, J ADOLESCENT HEALTH, V19, P331, DOI 10.1016/S1054-139X(96)00024-9 Hanley JA, 2001, J EPIDEMIOL COMMUN H, V55, P508, DOI 10.1136/jech.55.7.508 Hendershot CS, 2009, JAIDS-J ACQ IMM DEF, V52, P180, DOI 10.1097/QAI.0b013e3181b18b6e Henderson J, 2007, BJOG-INT J OBSTET GY, V114, P243, DOI 10.1111/j.1471-0528.2006.01163.x Henderson J, 2007, J EPIDEMIOL COMMUN H, V61, P1069, DOI 10.1136/jech.2006.054213 Hendriks HFJ, 2007, ANN EPIDEMIOL, V17, pS40, DOI 10.1016/j.annepidem.2007.01.009 HIGGINS EM, 1993, BRIT J DERMATOL, V129, P749, DOI 10.1111/j.1365-2133.1993.tb03349.x HIGGINS EM, 1994, J AM ACAD DERMATOL, V30, P1048, DOI 10.1016/S0190-9622(09)80167-9 HIGGINS EM, 1994, BRIT MED BULL, V50, P85, DOI 10.1093/oxfordjournals.bmb.a072887 Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1016/j.bandl.2008.10.005 HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503 Hillbom M, 2003, CNS DRUGS, V17, P1013, DOI 10.2165/00023210-200317140-00002 Hines LM, 2001, NEW ENGL J MED, V344, P549, DOI 10.1056/NEJM200102223440802 Howard AA, 2004, ANN INTERN MED, V140, P211, DOI 10.7326/0003-4819-140-6-200403160-00011 *ICAP, 2008, REV 3 NONC ALC 3 REG Imhof A, 2001, LANCET, V357, P763, DOI 10.1016/S0140-6736(00)04170-2 Irving HM, 2009, J PANCREAS, V10, P387 Jakubowiak WM, 2007, INT J TUBERC LUNG D, V11, P46 KALICHMAN SC, 1995, J PERS ASSESS, V65, P586, DOI 10.1207/s15327752jpa6503_16 Kalichman SC, 1996, ARCH SEX BEHAV, V25, P141, DOI 10.1007/BF02437933 Kalichman SC, 2007, JAIDS-J ACQ IMM DEF, V44, P594, DOI 10.1097/QAI.0b013e3180415e07 Kalichman SC, 2007, PREV SCI, V8, P141, DOI 10.1007/s11121-006-0061-2 Kalichman S, 2008, ANN BEHAV MED, V36, P270, DOI 10.1007/s12160-008-9067-2 Kanteres F, 2009, ADDICTION, V104, P752, DOI 10.1111/j.1360-0443.2009.02507.x Kesmodel U, 2000, EPIDEMIOLOGY, V11, P512, DOI 10.1097/00001648-200009000-00005 Key J, 2006, CANCER CAUSE CONTROL, V17, P759, DOI 10.1007/s10552-006-0011-0 Kiechl S, 1996, BRIT MED J, V313, P1040 Kirby B, 2008, BRIT J DERMATOL, V158, P138, DOI 10.1111/j.1365-2133.2007.08299.x Klatsky AL, 2003, AM J EPIDEMIOL, V158, P585, DOI 10.1093/aje/kwg184 KLATSKY AL, 1990, AM J CARDIOL, V66, P1237, DOI 10.1016/0002-9149(90)91107-H Klatsky AL, 2007, PHARMACOL RES, V55, P237, DOI 10.1016/j.phrs.2007.01.011 KNUPFER G, 1987, BRIT J ADDICT, V82, P547 KOIVULA I, 1994, AM J MED, V96, P313, DOI 10.1016/0002-9343(94)90060-4 Koivula IH, 2001, COMMUNITY-ACQUIRED PNEUMONIA, P13 Koppes LLJ, 2006, DIABETOLOGIA, V49, P648, DOI 10.1007/s00125-005-0127-x Koppes LLJ, 2005, DIABETES CARE, V28, P719, DOI 10.2337/diacare.28.3.719 Korte JE, 2002, AM J EPIDEMIOL, V155, P496, DOI 10.1093/aje/155.6.496 Kostovic Kresimir, 2004, Acta Dermatovenerol Croat, V12, P181 KRAHN AD, 1995, AM J MED, V98, P476, DOI 10.1016/S0002-9343(99)80348-9 Krueger JG, 2002, J AM ACAD DERMATOL, V46, P1, DOI 10.1067/mjd.2002.120568 La Vecchia C, 2008, EUR J CANCER PREV, V17, P116, DOI 10.1097/CEJ.0b013e3282b6fd40 Lachenmeier DW, 2008, FOOD CHEM TOXICOL, V46, P2903, DOI 10.1016/j.fct.2008.05.034 Lachenmeier DW, 2007, ALCOHOL CLIN EXP RES, V31, P1613, DOI 10.1111/j.1530-0277.2007.00474.x Lachenmeier DW, 2009, ADDICTION, V104, P875, DOI 10.1111/j.1360-0443.2009.02587.x Lachenmeier DW, 2009, DEUT LEBENSM-RUNDSCH, V105, P507 Lachenmeier DW, 2009, ADDICTION, V104, P533, DOI 10.1111/j.1360-0443.2009.02516.x LARROQUE B, 1993, AM J EPIDEMIOL, V137, P941, DOI 10.1093/oxfordjournals.aje.a116764 Lazarus R, 1997, AM J EPIDEMIOL, V145, P909, DOI 10.1093/oxfordjournals.aje.a009050 Leigh BC, 2002, SEX TRANSM DIS, V29, P476, DOI 10.1097/00007435-200208000-00008 LEIGH BC, 1993, AM PSYCHOL, V48, P1035, DOI 10.1037/0003-066X.48.10.1035 Leone M, 2002, NEUROL SCI, V23, P99, DOI 10.1007/s100720200034 Leone M, 1997, NEUROLOGY, V48, P614, DOI 10.1212/WNL.48.3.614 Leone M., 1994, ALCOLOGIA, V6, P215 Lerch MM, 2003, PANCREAS, V27, P291, DOI 10.1097/00006676-200311000-00003 Letenneur L, 2004, BIOMED PHARMACOTHER, V58, P95, DOI 10.1016/j.biopha.2003.12.004 Letenneur L, 2007, ANN EPIDEMIOL, V17, pS43, DOI 10.1016/j.annepidem.2007.01.010 Lewis SJ, 2005, CANCER EPIDEM BIOMAR, V14, P1967, DOI 10.1158/1055-9965.EPI-05-0196 LIEBER CS, 1988, NEW ENGL J MED, V319, P1639 LINDEGARD B, 1986, DERMATOLOGICA, V172, P298, DOI 10.1159/000249365 LITTLE RE, 1986, AM J EPIDEMIOL, V123, P270, DOI 10.1093/oxfordjournals.aje.a114235 Lönnroth K, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-289 LOWENSTEIN SR, 1983, ARCH INTERN MED, V143, P1882, DOI 10.1001/archinte.143.10.1882 Lucas DL, 2005, J AM COLL CARDIOL, V45, P1916, DOI 10.1016/j.jacc.2005.02.075 Lundsberg LS, 1997, ANN EPIDEMIOL, V7, P498, DOI 10.1016/S1047-2797(97)00081-1 Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442 MAYER EJ, 1993, CIRCULATION, V88, P2190, DOI 10.1161/01.CIR.88.5.2190 Mazzaglia G, 2001, ADDICTION, V96, P1743, DOI 10.1046/j.1360-0443.2001.961217434.x MCDONALD AD, 1992, AM J PUBLIC HEALTH, V82, P87, DOI 10.2105/AJPH.82.1.87 McElduff P, 1997, BRIT MED J, V314, P1159, DOI 10.1136/bmj.314.7088.1159 McKee M, 1998, J ROY SOC MED, V91, P402, DOI 10.1177/014107689809100802 MCKENZIE CR, 1996, ALCOHOL CARDIOVASCUL, P413 Meyer N, 2008, ANN DERMATOL VENER, V135, pS259, DOI 10.1016/S0151-9638(08)70545-3 MITCHELL SN, 1992, PROSTAG OTH LIPID M, V44, P457, DOI 10.1016/0090-6980(92)90140-O Mizoue T, 2008, AM J EPIDEMIOL, V167, P1397, DOI 10.1093/aje/kwn073 Moskal A, 2007, INT J CANCER, V120, P664, DOI 10.1002/ijc.22299 Moskalewicz J, 1985, Contemporary Drug Problems, V12, P117 Mueller J, 2000, INT SECURITY, V25, P42, DOI 10.1162/016228800560381 Mukamal KJ, 2005, CIRCULATION, V112, P1736, DOI 10.1161/CIRCULATIONAHA.105.547844 Mukamal KJ, 2003, NEW ENGL J MED, V348, P109, DOI 10.1056/NEJMoa022095 Mukamal KJ, 2001, ALCOHOL RES HEALTH, V25, P255 Mukamal KJ, 2001, JAMA-J AM MED ASSOC, V285, P1965, DOI 10.1001/jama.285.15.1965 Murray CJL, 2007, LANCET, V370, P109, DOI 10.1016/S0140-6736(07)61064-2 Murray RP, 2002, AM J EPIDEMIOL, V155, P242, DOI 10.1093/aje/155.3.242 Naldi Luigi, 2004, Current Drug Targets - Inflammation and Allergy, V3, P121, DOI 10.2174/1568010043343958 Nelson S, 2002, NAT REV IMMUNOL, V2, P205, DOI 10.1038/nri744 Neuman MG, 2006, SUBST USE MISUSE, V41, P1395, DOI 10.1080/10826080600846235 Neuman MG, 2003, ALCOHOL RES HEALTH, V27, P307 NG SKC, 1988, NEW ENGL J MED, V319, P666 Odendaal HJ, 2008, GYNECOL OBSTET INVES, V67, P1, DOI 10.1159/000150597 OGUNNIYI A, 1987, EPILEPSIA, V28, P280, DOI 10.1111/j.1528-1157.1987.tb04219.x PAKRASI PL, 1983, PROSTAGLANDINS, V26, P991, DOI 10.1016/0090-6980(83)90160-0 Panza F, 2008, J NUTR HEALTH AGING, V12, P376, DOI 10.1007/BF02982669 Parascandola M, 2001, J EPIDEMIOL COMMUN H, V55, P905, DOI 10.1136/jech.55.12.905 Parazzini F, 2003, EUR J CLIN NUTR, V57, P1345, DOI 10.1038/sj.ejcn.1601690 Parry C, 2009, ADDICTION, V104, P331, DOI 10.1111/j.1360-0443.2008.02500.x Peters R, 2008, AGE AGEING, V37, P505, DOI 10.1093/ageing/afn095 Planas F, 2006, REV ESP CARDIOL, V59, P1106, DOI 10.1157/13095779 POIKOLAINEN K, 1983, INT J EPIDEMIOL, V12, P151, DOI 10.1093/ije/12.2.151 POIKOLAINEN K, 1990, BMJ-BRIT MED J, V300, P780, DOI 10.1136/bmj.300.6727.780 Puddey IB, 1999, ADDICTION, V94, P649, DOI 10.1046/j.1360-0443.1999.9456493.x Purdue MP, 2009, AM J EPIDEMIOL, V169, P132, DOI 10.1093/aje/kwn306 RANDIN D, 1995, NEW ENGL J MED, V332, P1733, DOI 10.1056/NEJM199506293322601 RANKIN JG, 1994, CONTEMP DRUG PROBL, V21, P45 Rathlev NK, 2006, J EMERG MED, V31, P157, DOI 10.1016/j.jemermed.2005.09.012 REEDER VC, 1996, ALCOHOL CARDIOVASCUL, P391 Rehm J, 2003, ADDICTION, V98, P1209, DOI 10.1046/j.1360-0443.2003.00467.x Rehm J, 2008, AM J EPIDEMIOL, V168, P866, DOI 10.1093/aje/kwn093 Rehm J, 2007, ADDICT RES THEORY, V15, P20 Rehm J, 2006, ADDICTION, V101, P373, DOI 10.1111/j.1360-0443.2005.01338.x Rehm J, 2003, EUR ADDICT RES, V9, P147, DOI 10.1159/000072221 Rehm J, 2003, J CARDIOVASC RISK, V10, P15, DOI 10.1097/00043798-200302000-00004 Rehm J., 2009, Alcohol, social development and infectious disease REHM J, 2010, DRUG ALCOHO IN PRESS REHM J, 2009, DRUG ALCOHO IN PRESS Rehm J, 2008, INT J METH PSYCH RES, V17, P141, DOI 10.1002/mpr.259 Rehm J, 2007, INT J EPIDEMIOL, V36, P458, DOI 10.1093/ije/dyl294 Rehm J, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-450 Rehm J, 2009, INT J EPIDEMIOL, V38, P154, DOI 10.1093/ije/dyn209 Rehm J, 2009, LANCET, V373, P2223, DOI 10.1016/S0140-6736(09)60746-7 Rehm J, 2006, ADDICTION, V101, P1679, DOI 10.1111/j.1360-0443.2006.01678.x RENAUD S, 1993, HLTH ISSUES RELATED, P81 Reynolds K, 2003, JAMA-J AM MED ASSOC, V289, P579, DOI 10.1001/jama.289.5.579 RICH EC, 1985, ARCH INTERN MED, V145, P830, DOI 10.1001/archinte.145.5.830 Ridolfo B., 2001, The Quantification of Drug-Caused Mortality and Morbidity in Australia, 1998 Rimm EB, 1999, BMJ-BRIT MED J, V319, P1523, DOI 10.1136/bmj.319.7224.1523 Rimm EB, 2007, ANN EPIDEMIOL, V17, pS3, DOI 10.1016/j.annepidem.2007.01.002 ROERECKE M, 2010, AM J EPIDEMIOL Room R, 2001, SOC SCI MED, V53, P189, DOI 10.1016/S0277-9536(00)00330-0 Rossow I, 2001, ADDICTION, V96, pS77 Rothman K.J., 2008, Modern Epidemiology, P87 ROYSTON P, 1994, J ROY STAT SOC C, V43, P429, DOI 10.2307/2986270 Rush Benjamin., 1785, An inquiry into the effects of ardent spirits upon the human body and mind: With an account of the means of preventing, and of the remedies for curing them Salaspuro M, 2009, ADDICTION, V104, P551, DOI 10.1111/j.1360-0443.2009.02546.x SAMOKHVALOV AV, 2010, EPILEPSIA IN PRESS Sarkola T, 2002, ALCOHOL CLIN EXP RES, V26, P239, DOI 10.1111/j.1530-0277.2002.tb02530.x Schäfer T, 2006, DERMATOLOGY, V212, P327, DOI 10.1159/000092283 SCHAFER T, 1997, EPIDEMIOLOGISCHES UN, P158 Schoonderwoerd BA, 2008, EUROPACE, V10, P668, DOI 10.1093/europace/eun124 SCHUTZ H, 1990, STROKE, V21, P1412, DOI 10.1161/01.STR.21.10.1412 Seitz HK, 2007, ALCOHOL RES HEALTH, V30, P38 Seitz HK, 2007, NAT REV CANCER, V7, P599, DOI 10.1038/nrc2191 SHAPER AG, 1988, LANCET, V2, P1267 Shimazu T, 2008, JPN J CLIN ONCOL, V38, P8, DOI 10.1093/jjco/hym152 SHUPER PA, 2010, ALCOHOL ALC IN PRESS Shuper PA, 2009, AIDS BEHAV, V13, P1021, DOI 10.1007/s10461-009-9589-z Sierksma A, 2004, DIABETES CARE, V27, P184, DOI 10.2337/diacare.27.1.184 Sierksma A, 2002, EUR J CLIN NUTR, V56, P1130, DOI 10.1038/sj.ejcn.1601459 Single E, 1999, AM J PUBLIC HEALTH, V89, P385, DOI 10.2105/AJPH.89.3.385 Single E., 1996, COSTS SUBSTANCE ABUS Singletary KW, 2001, JAMA-J AM MED ASSOC, V286, P2143, DOI 10.1001/jama.286.17.2143 Singletary SE, 2003, ANN SURG, V237, P474, DOI 10.1097/00000658-200304000-00007 Sjögren H, 2000, ALCOHOL ALCOHOLISM, V35, P601, DOI 10.1093/alcalc/35.6.601 Smith KE, 2000, J AM ACAD DERMATOL, V43, P1, DOI 10.1067/mjd.2000.104512 Smith-Warner SA, 1998, JAMA-J AM MED ASSOC, V279, P535, DOI 10.1001/jama.279.7.535 Stockwell T, 1997, ADDICT RES, V5, P1, DOI 10.3109/16066359709005577 SUH I, 1992, ANN INTERN MED, V116, P881, DOI 10.7326/0003-4819-116-11-881 Sundell L, 2008, STROKE, V39, P3179, DOI 10.1161/STROKEAHA.108.520817 Suzuki R, 2008, INT J CANCER, V122, P1832, DOI 10.1002/ijc.23184 Svärdsudd K, 1998, ALCOHOL CLIN EXP RES, V22, p307S, DOI 10.1111/j.1530-0277.1998.tb04383.x Szabo G, 1997, ALCOHOL HEALTH RES W, V21, P30 Szabo G, 2007, PANCREATOLOGY, V7, P115, DOI 10.1159/000104236 Szabo G, 2009, ALCOHOL CLIN EXP RES, V33, P220, DOI 10.1111/j.1530-0277.2008.00842.x Tanasescu M, 2001, J AM COLL CARDIOL, V38, P1836, DOI 10.1016/S0735-1097(01)01655-2 Tattersall SJN, 2008, INTERN MED J, V38, P592, DOI 10.1111/j.1445-5994.2008.01715.x Taylor B, 2008, AM J EPIDEMIOL, V168, P1119, DOI 10.1093/aje/kwn215 Taylor B, 2009, ADDICTION, V104, P1981, DOI 10.1111/j.1360-0443.2009.02694.x Teunissen LL, 1996, STROKE, V27, P544, DOI 10.1161/01.STR.27.3.544 Trevisan M, 2001, ANN EPIDEMIOL, V11, P312, DOI 10.1016/S1047-2797(00)00183-6 Trevisan M, 2001, AM J EPIDEMIOL, V153, pS97 Tyas SL, 2001, ALCOHOL RES HEALTH, V25, P299 Vincenti G E, 1987, J R Army Med Corps, V133, P77 Vonlaufen A, 2007, ALCOHOL RES HEALTH, V30, P48 Wakai K, 2007, JPN J CLIN ONCOL, V37, P168, DOI 10.1093/jjco/hyl146 WALTER SD, 1980, AM J EPIDEMIOL, V112, P409, DOI 10.1093/oxfordjournals.aje.a113007 Wannamethee SG, 2003, ARCH INTERN MED, V163, P1329, DOI 10.1001/archinte.163.11.1329 Wannamethee SG, 2003, AM J CLIN NUTR, V77, P1312, DOI 10.1093/ajcn/77.5.1312 Weinhardt L S, 2000, Annu Rev Sex Res, V11, P125 Wilhelmsen L, 2001, J INTERN MED, V250, P382, DOI 10.1046/j.1365-2796.2001.00902.x WIMALASENA J, 1994, ALCOHOL CLIN EXP RES, V18, P369, DOI 10.1111/j.1530-0277.1994.tb00027.x Wolf R, 1999, CLIN DERMATOL, V17, P423, DOI 10.1016/S0738-081X(99)00028-0 Woolf SE, 2009, AIDS BEHAV, V13, P757, DOI 10.1007/s10461-007-9354-0 Yu H, 1999, MED HYPOTHESES, V52, P491, DOI 10.1054/mehy.1998.0828 Zaghloul SS, 2004, ARCH DERMATOL, V140, P408, DOI 10.1001/archderm.140.4.408 Zakhari S, 1997, ALCOHOL HEALTH RES W, V21, P21 Zaridze D, 2009, INT J EPIDEMIOL, V38, P143, DOI 10.1093/ije/dyn160 Zaridze D, 2009, LANCET, V373, P2201, DOI 10.1016/S0140-6736(09)61034-5 Zeka A, 2003, CANCER CAUSE CONTROL, V14, P897, DOI 10.1023/B:CACO.0000003854.34221.a8 Zeng Jun, 2003, Zhonghua Liu Xing Bing Xue Za Zhi, V24, P116 ZUCKERMAN BS, 1986, DEV MED CHILD NEUROL, V28, P649 NR 277 TC 870 Z9 1031 U1 3 U2 191 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD MAY PY 2010 VL 105 IS 5 BP 817 EP 843 DI 10.1111/j.1360-0443.2010.02899.x PG 27 WC Substance Abuse; Psychiatry WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI) SC Substance Abuse; Psychiatry GA 581IN UT WOS:000276516000013 PM 20331573 OA Green Submitted DA 2026-04-17 ER PT J AU Salvatici, M Cardinale, D Spaggiari, L Veglia, F Tedesco, CC Solli, P Cipolla, CM Zorzino, L Passerini, R Riggio, D Cassatella, MC Sandri, MT AF Salvatici, Michela Cardinale, Daniela Spaggiari, Lorenzo Veglia, Fabrizio Tedesco, Calogero Claudio Solli, Piergiorgio Cipolla, Carlo Maria Zorzino, Laura Passerini, Rita Riggio, Daniela Cassatella, Maria Cristina Sandri, Maria Teresa TI Atrial fibrillation after thoracic surgery for lung cancer: use of a single cut-off value of N-terminal pro-B type natriuretic peptide to identify patients at risk SO BIOMARKERS LA English DT Article DE Atrial fibrillation; NT-proBNP; natriuretic peptides; thoracic surgery; lung cancer disease ID HEART-FAILURE; DIASTOLIC DYSFUNCTION; NONCARDIAC SURGERY; PREDICTION RULE; CARDIAC-SURGERY; COMPLICATIONS; ARRHYTHMIAS; UTILITY; MARKER; CARE AB Postoperative atrial fibrillation (AF) is a well-known complication occurring after thoracic surgery. B-type natriuretic peptide has recently been investigated as a predictive marker of postoperative AF after cardiac surgery. The aim of this study was to evaluate a definite cut-off for N-terminal pro-B type natriuretic peptide (NT-proBNP) in predicting postoperative AF in lung cancer patients. NT-proBNP was determined before and after surgery in 400 patients. Cardiac function was monitored by continuous postoperative ECG and clinical cardiological evaluation. AF occurred in 18% of the patients. Receiver operating characteristic curve analyses identified a cut-off of 182.3 ng l= 5% weight loss, and 91% underwent positron emission tomography staging. Induction chemotherapy with pegfilgrastim support was well tolerated and active (partial response rate, 24%; stable disease, 76%; and early progression, 0%). Twenty-one patients initiated the concurrent chemoradiation, and 20 patients completed therapy to 74 Gy. The primary toxicities of concurrent chemoradiation were grade 3 esophagitis (19.5%) and cardiac arrhythmia (atrial fibrillation) (9.5%). The median progression-free survival and overall survival were 9 months (95% confidence intervals [Cl]: 7-13 months) and 16 months (95% CI: 10-20 months), respectively. Conclusions: Treatment with induction chemotherapy and gefitinib concurrent with 3-dimensional TCRT has an acceptable toxicity and tolerability, but the survival results were disappointing. C1 [Stinchcombe, Thomas E.; Lee, Carrie B.; Hayes, D. Neil; Socinski, Mark A.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Div Hematol Oncol, Multidisciplinary Thorac Oncol Program, Chapel Hill, NC 27599 USA. [Morris, David E.; Halle, Jan S.; Rosenman, Julian G.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Div Radiat Oncol, Multidisciplinary Thorac Oncol Program, Chapel Hill, NC 27599 USA. [Moore, Dominic T.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Div Biostat & Data Management, Chapel Hill, NC 27599 USA. [Rivera, M. Patricia] Univ N Carolina, Lineberger Comprehens Canc Ctr, Div Pulm Med, Chapel Hill, NC 27599 USA. C3 University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill RP Stinchcombe, TE (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Div Hematol Oncol, Multidisciplinary Thorac Oncol Program, 3009 Old Clin Bldg,CB 7305, Chapel Hill, NC 27599 USA. EM Thomas_Stinchcombe@med.unc.edu RI Hayes, D Neil/AIA-2263-2022; Lee, Carrie/AAT-6939-2021 OI Hayes, D Neil/0000-0001-6203-7771; CR Ardizzoni A, 2007, J NATL CANCER I, V99, P847, DOI 10.1093/jnci/djk196 Ball D, 2007, J THORAC ONCOL, V2, pS633 Bianco C, 2002, CLIN CANCER RES, V8, P3250 BLACKSTOCK AW, 2006, ASCO M ABSTR, V24 Blumenschein GR, 2007, J THORAC ONCOL, V2, pS342, DOI 10.1097/01.JTO.0000283159.34357.b3 BULZEBRUCK H, 1992, CANCER-AM CANCER SOC, V70, P1102, DOI 10.1002/1097-0142(19920901)70:5<1102::AID-CNCR2820700514>3.0.CO;2-5 CALVERT AH, 1989, J CLIN ONCOL, V7, P1748, DOI 10.1200/JCO.1989.7.11.1748 Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478 Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038 Giaccone G, 2004, J CLIN ONCOL, V22, P777, DOI 10.1200/JCO.2004.08.001 Hanna NH, 2007, J CLIN ONCOL, V25 Herbst RS, 2004, J CLIN ONCOL, V22, P785, DOI 10.1200/JCO.2004.07.215 Hotta K, 2004, J CLIN ONCOL, V22, P3852, DOI 10.1200/JCO.2004.02.109 Huber RM, 2006, J CLIN ONCOL, V24, P4397, DOI 10.1200/JCO.2005.05.4163 Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43 KELLY K, 2005, J CLIN ONCOL, V23 KELLY K, 2007, ASCO M ABSTR, V25 Kim DW, 2004, INT J RADIAT ONCOL, V59, P11, DOI 10.1016/j.ijrobp.2003.11.042 Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238 Kosaka T, 2006, CLIN CANCER RES, V12, P5764, DOI 10.1158/1078-0432.CCR-06-0714 Krause M, 2005, RADIOTHER ONCOL, V74, P109, DOI 10.1016/j.radonc.2004.10.011 Krause M, 2007, RADIOTHER ONCOL, V83, P316, DOI 10.1016/j.radonc.2007.04.014 Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149 LEE CB, 2006, ASCO M ABSTR, V24 Movsas B, 2005, J CLIN ONCOL, V23, P2145, DOI 10.1200/JCO.2005.07.167 Ochs JS, 2004, INT J RADIAT ONCOL, V58, P941, DOI 10.1016/j.ijrobp.2003.09.094 Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073 Pfister DG, 2004, J CLIN ONCOL, V22, P330, DOI 10.1200/JCO.2004.09.053 READY N, 2006, ASCO M ABSTR, V24 Shih JY, 2005, NEW ENGL J MED, V353, P207, DOI 10.1056/NEJM200507143530217 Socinski MA, 2004, J CLIN ONCOL, V22, P4341, DOI 10.1200/JCO.2004.03.022 Socinski MA, 2002, CANCER-AM CANCER SOC, V95, P1520, DOI 10.1002/cncr.10852 Socinski MA, 2001, CANCER, V92, P1213, DOI 10.1002/1097-0142(20010901)92:5<1213::AID-CNCR1440>3.0.CO;2-0 Socinski MA, 2001, J CLIN ONCOL, V19, P1078, DOI 10.1200/JCO.2001.19.4.1078 SOCINSKI MA, 2003, LUNG CANCER S4, V41, pS239 Solomon B, 2003, INT J RADIAT ONCOL, V55, P713, DOI 10.1016/S0360-3016(02)04357-2 Stinchcombe TE, 2006, LUNG CANCER, V52, P67, DOI 10.1016/j.lungcan.2005.11.008 Toyooka S, 2005, NEW ENGL J MED, V352, P2136 Vikis H, 2007, CANCER RES, V67, P4665, DOI 10.1158/0008-5472.CAN-07-0217 Vokes EE, 2007, J CLIN ONCOL, V25, P1698, DOI 10.1200/JCO.2006.07.3569 World Health Organization, 1979, HDB REP RES CANC TRE Yang P, 2005, CHEST, V128, P452, DOI 10.1378/chest.128.1.452 NR 42 TC 68 Z9 70 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD MAR PY 2008 VL 3 IS 3 BP 250 EP 257 DI 10.1097/JTO.0b013e3181653cf4 PG 8 WC Oncology; Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Respiratory System GA 280GR UT WOS:000254414300008 PM 18317067 OA Bronze DA 2026-04-17 ER PT J AU Carboni, GL Vogt, A Küster, JR Berg, P Wagnetz, D Schmid, RA Dutly, AE AF Carboni, Giovanni L. Vogt, Andreas Kuester, Jan R. Berg, Peter Wagnetz, Dirk Schmid, Ratph A. Dutly, Andre E. TI Reduction of airspace after lung resection through controlled paralysis of the diaphragm SO EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY LA English DT Article; Proceedings Paper CT 21st Annual Meeting of the European-Association-for-Cardio-Thoracic-Surgery CY SEP 16-19, 2007 CL Geneva, SWITZERLAND SP European Assoc Cardio Thorac Surg DE lung neoplasm; postoperative complications; chest tubes; feasibility studies ID PLEURAL SPACE AB Objectives: Residual airspace following thoracic resections is a common clinical problem. Persistent air teak, prolonged drainage time, and reduced hemostasis extend hospital stay and morbidity. We report a trial of pharmacologic-induced diaphragmatic paralysis through continuous paraphrenic injection of lidocaine to reduced residual airspace. The objectives were confirmation of diaphragmatic paralysis and possible procedure related complications. Methods: Six eligible patients undergoing resectional surgery (lobectomy or bilobectomy) were included. Inclusion criteria consisted of: postoperative predicted FEV1 greater than 1300 ml, right-sided resection, absence of parenchymal lung disease, no class III antiarrhythmic therapy, absence of hypersensitivity reactions to lidocaine, no signs of infection, and informed consent. Upon completion of resection an epidural catheter was attached in the periphrenic tissue on the proximal pericardial surface, externalized through a separate parasternal incision, and connected to a perfusing system injecting lidocaine 1% at a rate of 3 ml/h (30 mg/h). Postoperative ICU surveillance for 24 h and daily measurement of vital signs, drainage output, and bedside spirometry were performed. Within 48 h fluoroscopic confirmation of diaphragmatic paralysis was obtained. The catheter removal coincided with the chest tube removal when no procedural related complications occurred. Results: None of the patients reported respiratory impairment. Diaphragmatic paralysis was documented in all patients. Upon removal of catheter or discontinuation of lidocaine prompt return of diaphragmatic motility was noticed. Two patients showed postoperative hemodynamic irrelevant atrial fibrillation. Conclusion: Postoperative paraphrenic catheter administration of lidocaine to ensure reversible diaphragmatic paralysis is safe and reproducible. Further studies have to assess a benefit in terms of reduction in morbidity, drainage time, and hospital stay, and determine the patients who will profit. (C) 2007 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved. C1 [Carboni, Giovanni L.; Kuester, Jan R.; Wagnetz, Dirk; Schmid, Ratph A.; Dutly, Andre E.] Univ Hosp Bern, Div Gen Thorac Surg, CH-3010 Bern, Switzerland. [Vogt, Andreas] Univ Hosp Bern, Dept Anesthesiol, CH-3010 Bern, Switzerland. [Berg, Peter] Univ Hosp Bern, Div Pulmonol, CH-3010 Bern, Switzerland. C3 University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern RP Schmid, RA (corresponding author), Univ Hosp Bern, Div Gen Thorac Surg, CH-3010 Bern, Switzerland. EM ralph.schmid@insel.ch RI ; Vogt, Andreas/NYS-3951-2025; Carboni, Giovanni/AAA-1780-2021 OI Schmid, Ralph Alexander/0000-0003-0699-079X; Vogt, Andreas/0000-0002-3676-7188; CR Alphonso N, 2005, EUR J CARDIO-THORAC, V27, P391, DOI 10.1016/j.ejcts.2004.12.004 Clavero JM, 2007, ANN THORAC SURG, V83, P1216, DOI 10.1016/j.athoracsur.2006.04.079 HANSEN J L, 1957, Acta Chir Scand, V112, P485 HOPKINS RA, 1985, ANN THORAC SURG, V40, P181, DOI 10.1016/S0003-4975(10)60016-1 IVERSON LIG, 1976, AM J SURG, V132, P263, DOI 10.1016/0002-9610(76)90058-1 Martini N., 2002, THORACIC SURG, P981 Okur E, 2001, EUR J CARDIO-THORAC, V20, P1012, DOI 10.1016/S1010-7940(01)00947-2 Shields TW, 2000, GEN THORACIC SURG, P481 Solak O, 2007, CAN J SURG, V50, P39 Toker A, 2003, THORAC CARDIOV SURG, V51, P93, DOI 10.1055/s-2003-38990 WAREHAM EE, 1956, J THORAC SURG, V31, P593 NR 11 TC 11 Z9 12 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1010-7940 J9 EUR J CARDIO-THORAC JI Eur. J. Cardio-Thorac. Surg. PD FEB PY 2008 VL 33 IS 2 BP 272 EP 275 DI 10.1016/j.ejcts.2007.10.023 PG 4 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 270XC UT WOS:000253752500034 PM 18061470 OA Green Submitted, Bronze DA 2026-04-17 ER PT J AU Juan, O Esteban, E Sotillo, J Alberola, V AF Juan, Oscar Esteban, Esther Sotillo, Jose Alberola, Vicente TI Atrial flutter and myocardial infarction-like ECG changes as manifestations of left ventricle involvement from lung carcinoma SO CLINICAL & TRANSLATIONAL ONCOLOGY LA English DT Article; Proceedings Paper CT 12th World Conference on Lung Cancer CY SEP 02-06, 2007 CL Seoul, SOUTH KOREA DE cardiac metastases; lung cancer; ST changes; myocardial infarction ID CANCER; HEART; EXPERIENCE; TUMORS AB Lung cancer involvement of the heart is not unusual, but in most cases is silent. Arrhythmia and electrocardiographic findings suggesting an acute myocardial infarction could be the first manifestation of myocardial infiltration by the tumour. Echocardiography could be a valuable tool to define the diagnosis in patients with lung cancer and newly diagnosed arrhythmia or ST-T wave alterations. When echocardiographics findings are not conclusive, magnetic resonance imaging (MRI) allows differentiation between tumour and myocardium. C1 [Juan, Oscar; Alberola, Vicente] Hosp Arnau Vilanova, Dept Med Oncol, ES-46015 Valencia, Spain. [Esteban, Esther; Sotillo, Jose] Hosp Arnau Vilanova, Dept Cardiol, ES-46015 Valencia, Spain. RP Juan, O (corresponding author), Hosp Arnau Vilanova, Dept Med Oncol, San Clemente 12, ES-46015 Valencia, Spain. EM juan_osc@gva.es OI Juan-Vidal, Oscar/0000-0002-7772-9030 CR ABE S, 1991, JPN J MED, V30, P213 Abraham K P, 1990, Am J Cardiovasc Pathol, V3, P195 Chiles C, 2001, RADIOGRAPHICS, V21, P439, DOI 10.1148/radiographics.21.2.g01mr15439 Kinjo Y, 2006, INTERNAL MED, V45, P113, DOI 10.2169/internalmedicine.45.1559 KLATT EC, 1990, CANCER-AM CANCER SOC, V65, P1456, DOI 10.1002/1097-0142(19900315)65:6<1456::AID-CNCR2820650634>3.0.CO;2-5 LAM KY, 1993, ARCH PATHOL LAB MED, V117, P1027 LESTUZZI C, 1989, CHEST, V95, P980, DOI 10.1378/chest.95.5.980 MACGEE W, 1991, VIRCHOWS ARCH A, V419, P183, DOI 10.1007/BF01626346 Ratto GB, 2004, ANN THORAC SURG, V78, P234, DOI 10.1016/j.athoracsur.2004.01.023 Yao NS, 1999, AM J EMERG MED, V17, P86, DOI 10.1016/S0735-6757(99)90026-8 NR 10 TC 3 Z9 3 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1699-048X J9 CLIN TRANSL ONCOL JI Clin. Transl. Oncol. PD FEB PY 2008 VL 10 IS 2 BP 125 EP 127 DI 10.1007/s12094-008-0166-0 PG 3 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S) SC Oncology GA 316JH UT WOS:000256945100010 PM 18258512 DA 2026-04-17 ER PT J AU Mahtabifard, A Fuller, CB McKenna, RJ AF Mahtabifard, Ali Fuller, Clark B. McKenna, Robert J., Jr. TI Video-assisted thoracic surgery sleeve lobectomy: A case series SO ANNALS OF THORACIC SURGERY LA English DT Article; Proceedings Paper CT Minimally Invasive Thoracis Surgery Summit Conference CY JUN 08-09, 2007 CL New York, NY ID THORACOSCOPIC LOBECTOMY; VATS LOBECTOMY; THORACOTOMY; EXPERIENCE; CARCINOMA; CANCER AB Background. As thoracic surgery moves towards more minimally invasive procedures, such as video-assisted thoracic surgery (VATS) lobectomy, conversion from a VATS to open thoracotomy has been required for a sleeve resection. This article reports a large experience of VATS sleeve lobectomy. Methods. We reviewed our thoracic surgery database of more than 1500 VATS lobectomies for VATS sleeve resections. Preoperative, operative, and perioperative outcome variables, including morbidity and mortality were examined. Results. Identified were 13 patients (median age, 59 years; range, 16 to 82 years) who underwent VATS sleeve lobectomy. There were no conversions to thoracotomy. Diagnoses included non-small cell lung cancer in 8 patients, typical carcinoid in 4, and metastatic sarcoma in 1 patient. Median tumor size was 2.1 cm (range, 0 to 6.6 cm). Median data were operative time, 167 minutes (range, 90 to 300 minutes); blood loss, 250 mL (range, 75 to 800 mL); chest tube drainage, 692 mL (range, 459 to 1590 mL); and chest tube duration, 3 days (range, 2 to 6 days). Median intensive care unit stay was 0 days (range, 0 to 4 days), and median hospital stay was 3 days (range, 2 to 8 days). No complications occurred in 9 patients (69%). Morbidity in the remaining 4 patients included 1 patient each with atrial fibrillation, anastomotic stricture, reintubation, and bronchial tear requiring repair. There were no deaths at 30 days. Conclusions. In experienced centers, VATS sleeve lobectomy is possible with acceptable morbidity and mortality as well as short length of stay. C1 [Mahtabifard, Ali; Fuller, Clark B.; McKenna, Robert J., Jr.] Cedars Sinai Med Ctr, Dept Thorac Surg, Los Angeles, CA 90048 USA. C3 Cedars Sinai Medical Center RP Mahtabifard, A (corresponding author), Cedars Sinai Med Ctr, Dept Thorac Surg, 8635 W 3rd St,Ste 975W, Los Angeles, CA 90048 USA. EM mahtabifarda@cshs.org CR Demmy TL, 1999, ANN THORAC SURG, V68, P194, DOI 10.1016/S0003-4975(99)00467-1 GIUDICELLI R, 1994, EUR J CARDIO-THORAC, V8, P254, DOI 10.1016/1010-7940(94)90156-2 Hoksch B, 2003, ZBL CHIR, V128, P106, DOI 10.1055/s-2003-37763 Kaseda Shizuka, 2002, Nihon Geka Gakkai Zasshi, V103, P717 Lewis R J, 1998, Semin Thorac Cardiovasc Surg, V10, P332 McKenna R Jr, 1995, Chest Surg Clin N Am, V5, P223 MCKENNA RJ, 1994, CHEST, V106, P1902, DOI 10.1378/chest.106.6.1902 McKenna RJ, 2006, ANN THORAC SURG, V81, P421, DOI 10.1016/j.athoracsur.2005.07.078 McKenna RJ, 1998, ANN THORAC SURG, V66, P1903, DOI 10.1016/S0003-4975(98)01166-7 Nakata M, 2000, ANN THORAC SURG, V70, P938, DOI 10.1016/S0003-4975(00)01513-7 Nomori H, 2003, SURG TODAY, V33, P7, DOI 10.1007/s005950300001 Santambrogio L, 2002, CHEST, V121, P635, DOI 10.1378/chest.121.2.635 SUGI K, 2003, JPN J THORAC SURG, V56, P928 Sugiura H, 1999, SURG LAPARO ENDO PER, V9, P403, DOI 10.1097/00019509-199912000-00007 Walker W S, 1998, Semin Thorac Cardiovasc Surg, V10, P291 Walker WS, 2003, EUR J CARDIO-THORAC, V23, P397, DOI 10.1016/S1010-7940(02)00814-X Yim APC, 2000, ANN THORAC SURG, V70, P243, DOI 10.1016/S0003-4975(00)01258-3 NR 17 TC 135 Z9 167 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD FEB PY 2008 VL 85 IS 2 BP S729 EP S732 DI 10.1016/j.athoracsur.2007.12.001 PG 4 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 255NO UT WOS:000252664900091 PM 18222205 OA Bronze DA 2026-04-17 ER PT J AU McKenna, RJ Mahtabifard, A Yap, J McKenna, R Fuller, C Merhadi, A Hakimian, B AF McKenna, Robert J., Jr. Mahtabifard, Ali Yap, Johnnie McKenna, Robert, III Fuller, Clark Merhadi, Amin Hakimian, Behrooz TI Wedge resection and brachytherapy for lung cancer in patients with poor pulmonary function SO ANNALS OF THORACIC SURGERY LA English DT Article; Proceedings Paper CT Minimally Invasive Thoracis Surgery Summit Conference CY JUN 08-09, 2007 CL New York, NY ID LIMITED RESECTION; SEGMENTECTOMY; LOBECTOMY AB Background. Although lobectomy is the standard for lung cancer because a wedge resection has a 3 to 5 times greater incidence of local recurrence, poor pulmonary function may preclude lobectomy. For these patients, low-dose-rate brachytherapy has recently been used to decrease local recurrence after sublobar resection. Current techniques expose operating room personnel and patient contacts to unnecessary radioactivity risks. We present our technique of sublobar resection combined with afterload catheters for high-dose-rate brachytherapy for patient benefit with minimal risk to others. Methods. Forty-eight patients (25 women, 23 men) underwent wedge resection, node dissection, and brachytherapy. A remote-afterloading high-dose-rate unit for radiation produced a median dose of 2450 cGy (350 cGy per fraction over 7 fractions twice daily for 4 days). The dose was prescribed to 1 cm deep to the stapled line. Biologically, this dose is approximately 5000 cGy and above (180 cGy/d equivalent) at the depth of 5 mm in reference to the resection margin. Results. Two patients died. The length of mean stay was 5.5 days (median, 5 days). Complications included prolonged air leak in 5 patients, atrial fibrillation in 5, pneumonia in 3, trapped lung in 2, and 1 each with empyema, bleeding, and recurrent laryngeal nerve injury. Three patients required a blood transfusion. Within the follow-up of 1 to 27 months, there were four recurrences. Conclusions. Wedge resection and brachytherapy appears to be a reasonable treatment for patients with lung cancer and pulmonary function that prohibits a lobectomy. C1 [McKenna, Robert J., Jr.; Mahtabifard, Ali; Yap, Johnnie; McKenna, Robert, III; Fuller, Clark; Merhadi, Amin; Hakimian, Behrooz] Cedars Sinai Med Ctr, Dept Thorac Surg, Los Angeles, CA 90048 USA. [McKenna, Robert J., Jr.; Mahtabifard, Ali; Yap, Johnnie; McKenna, Robert, III; Fuller, Clark; Merhadi, Amin; Hakimian, Behrooz] Univ Penn, Philadelphia, PA 19104 USA. C3 Cedars Sinai Medical Center; University of Pennsylvania RP McKenna, RJ (corresponding author), Cedars Sinai Med Ctr, Dept Thorac Surg, 8635 W 3rd,Ste 975W, Los Angeles, CA 90048 USA. EM mckennar@cshs.org CR HOLMES CE, 1995, ANN THORAC SURG, V60, P615, DOI 10.1016/0003-4975(95)00537-u Kodama K, 1997, J THORAC CARDIOV SUR, V114, P347, DOI 10.1016/S0022-5223(97)70179-X Lee W, 2003, ANN THORAC SURG, V75, P237, DOI 10.1016/S0003-4975(02)04098-5 Okada M, 2001, ANN THORAC SURG, V71, P956, DOI 10.1016/S0003-4975(00)02223-2 Santos R, 2003, SURGERY, V134, P691, DOI 10.1016/S0039-6060(03)00327-1 SHENNIB H, 2000, INT RAD ONCOL BIO S, V48 WARREN WH, 1994, J THORAC CARDIOV SUR, V107, P1087, DOI 10.1016/S0022-5223(12)70385-9 Yoshikawa K, 2002, ANN THORAC SURG, V73, P1055, DOI 10.1016/S0003-4975(01)03466-X NR 8 TC 21 Z9 21 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD FEB PY 2008 VL 85 IS 2 BP S733 EP S736 DI 10.1016/j.athoracsur.2007.11.049 PG 4 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 255NO UT WOS:000252664900092 PM 18222206 OA Bronze DA 2026-04-17 ER PT J AU Cerfolio, RJ Bryant, AS AF Cerfolio, Robert J. Bryant, Ayesha S. TI Surgical techniques and results for partial or circumferential sleeve resection of the pulmonary artery for patients with non-small cell lung cancer SO ANNALS OF THORACIC SURGERY LA English DT Article; Proceedings Paper CT 53rd Annual Meeting of the Southern-Thoracic-Surgical-Association CY NOV 08-11, 2006 CL Tucson, AZ SP SE Thorac Surg Assoc ID LOBECTOMY; PNEUMONECTOMY; RECONSTRUCTION AB Background. We assessed our experience with partial or circumferential resection of the pulmonary artery during lobectomy. Methods. We retrospectively reviewed a prospective electronic database of patients who underwent pulmonary artery resection. The technique used was an R0 resection with end-to-end anastomosis only if needed, distal control of the pulmonary artery by clamping the vein ( not the artery), and no postoperative anticoagulation. Results. Between October 1998 and June 6, 2006, 42 (3.2%) of 1328 patients who underwent lobectomy performed by one surgeon required resection of the pulmonary artery ( 38 partial, 4 circumferential) to achieve a margin-negative resection and avoid pneumonectomy. Of these, 41 had non-small cell lung cancer, and 23 (55%) had neoadjuvant chemoradiotherapy ( median dose of 60 Gy). Right upper lobectomy was performed in 2 patients and a left upper lobectomy in 40. A negative bronchial and vascular margin was achieved in all. Morbidity occurred in 11 patients ( atrial fibrillation in 6) and left recurrent laryngeal neurapraxia in 2. Aspiration resulted in one operative death. Follow-up ( median, 48 months) showed no local recurrence on the pulmonary artery and normal blood flow through it. Five-year survival was 60%. Conclusions. Pulmonary artery resection and reconstruction to avoid pneumonectomy can be performed safely, even in a highly irradiated field. Clamping of the remaining pulmonary vein for distal control is safe and affords more room. Circumferential resection with end-to-end anastomosis of the pulmonary artery is rarely required. Partial resection is safe, does not impede blood flow, and does not compromise local recurrence rates. Postoperative anticoagulation is not needed. C1 Univ Alabama, Div Cardiothorac Surg, Dept Surg, Birmingham, AL 35294 USA. Univ Alabama, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA. C3 University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham RP Cerfolio, RJ (corresponding author), Univ Alabama, Div Cardiothorac Surg, Dept Surg, 1900 Univ Blvd,THT 712, Birmingham, AL 35294 USA. EM robert.cerfolio@ccc.uab.edu OI Bryant, Ayesha/0000-0002-3704-0319; Cerfolio, Robert/0000-0002-5598-599X CR Cerfolio RJ, 2005, ANN THORAC SURG, V80, P1224, DOI 10.1016/j.athoracsur.2005.02.091 Cerfolio RJ, 2005, ANN THORAC SURG, V80, P1017, DOI 10.1016/j.athoracsur.2005.03.091 Cerfolio RJ, 2004, ANN THORAC SURG, V78, P1017, DOI 10.1016/j.athoracsur.2004.02.067 Cerfolio RJ, 2006, J THORAC CARDIOV SUR, V131, P1229, DOI 10.1016/j.jtcvs.2005.08.070 DESLAURIERS J, 1986, J THORAC CARDIOV SUR, V92, P871 Ferguson MK, 2003, ANN THORAC SURG, V76, P1782, DOI 10.1016/S0003-4975(03)01243-8 HAWES RH, 1994, ENDOSCOPY, V26, P784, DOI 10.1055/s-2007-1009106 IBRAHIM M, 2004, MMCTS, V67, P1 Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5 Jiménez MF, 2006, ARCH BRONCONEUMOL, V42, P160, DOI 10.1157/13086620 Ludwig C, 2005, ANN THORAC SURG, V79, P968, DOI 10.1016/j.athoracsur.2004.08.062 Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710 RENDINA EA, 1992, J THORAC CARDIOV SUR, V104, P888 Rendina EA, 1999, ANN THORAC SURG, V68, P995, DOI 10.1016/S0003-4975(99)00738-9 Rendina EA, 2000, SEMIN SURG ONCOL, V18, P165, DOI 10.1002/(SICI)1098-2388(200003)18:2<165::AID-SSU10>3.3.CO;2-D NR 15 TC 58 Z9 66 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD JUN PY 2007 VL 83 IS 6 BP 1971 EP 1977 DI 10.1016/j.athoracsur.2007.01.048 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 172GD UT WOS:000246791200008 PM 17532380 DA 2026-04-17 ER PT J AU Whitson, BA Andrade, RS Boettcher, A Bardales, R Kratzke, RA Dahlberg, PS Maddaus, MA AF Whitson, Bryan A. Andrade, Rafael S. Boettcher, Adam Bardales, Ricardo Kratzke, Robert A. Dahlberg, Peter S. Maddaus, Michael A. TI Video-assisted thoracoscopic surgery is more favorable than thoracotomy for resection of clinical stage I non-small cell lung cancer SO ANNALS OF THORACIC SURGERY LA English DT Article ID THORACIC-SURGERY; PULMONARY RESECTION; VATS LOBECTOMY; OCTOGENARIANS; EXPERIENCE; MANAGEMENT; MORBIDITY; PROGNOSIS; CARCINOMA; STRATEGY AB Background. Lobectomy for patients with clinical stage I non-small cell lung cancer (NSCLC) can be performed by thoracotomy or by video-assisted thoracoscopic surgery ( VATS). We compared the operative characteristics and postoperative course for patients with clinical stage I NSCLC who underwent lobectomy by VATS or thoracotomy. Methods. We retrospectively reviewed the charts of all patients undergoing lobectomy for clinical stage I NSCLC from January 1, 1998, through June 30, 2005. Results. We performed 147 lobectomies ( 88 thoracotomy, 59 VATS) in 147 patients with clinical stage I NSCLC. Patient demographics were similar between groups; however, VATS patients had more hypertension ( p = 0.0114), chronic renal insufficiency ( p = 0.0479), and previous malignancies ( p = 0.0086). The two groups did not differ in pathologic stage, tumor size, histologic results, or number of positive nodes. More total nodes were identified in thoracotomy patients ( p = 0.0001), and they had a shorter intensive care unit stay ( p = 0.0224). VATS patients had significantly less postoperative pneumonia ( p = 0.0023). VATS patients trended toward fewer chest tube days and a shorter hospital length of stay. The two groups did not differ in operative time, blood loss, atrial fibrillation, or number of ventilator days. Median survival between the cohorts was similar (> 7.9 years thoracotomy versus > 4.6 years VATS, log-rank p = 0.6939). Conclusions. Patients undergoing VATS lobectomy for clinical stage I NSCLC, despite having more comorbidities, had fewer postoperative complications. The approaches are equivalent in operative time, blood loss, length of stay, and survival rate. Compared with thoracotomy, VATS lobectomy for patients with clinical stage I NSCLC appears to be a less morbid operation. C1 Univ Minnesota, Dept Surg, Med Ctr, Sect Thorac & Foregut Surg, Minneapolis, MN 55455 USA. Univ Minnesota, Med Ctr, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA. C3 University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities RP Whitson, BA (corresponding author), Univ Minnesota, Dept Surg, Med Ctr, Sect Thorac & Foregut Surg, MMC 207,420 Delaware St SE, Minneapolis, MN 55455 USA. EM bwhit@umn.edu RI Whitson, Bryan/B-5725-2009 OI Whitson, Bryan/0000-0003-0040-3638 CR Aoki T, 2003, EUR J CARDIO-THORAC, V23, P446, DOI 10.1016/S1010-7940(03)00014-9 Barlési F, 2005, CHEST, V128, P3475, DOI 10.1378/chest.128.5.3475 BARRERA R, 2005, INTERNET J PULMONARY, V5 Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1 Cerfolio RJ, 2002, SURG CLIN N AM, V82, P833, DOI 10.1016/S0039-6109(02)00026-9 Cerfolio RJ, 2005, CHEST, V128, P816, DOI 10.1378/chest.128.2.816 Cerfolio RJ, 2002, ANN THORAC SURG, V73, P1727, DOI 10.1016/S0003-4975(02)03531-2 DESLAURIERS J, 1994, CHEST, V106, pS329, DOI 10.1378/chest.106.6.329S Dominguez-Ventura A, 2006, ANN THORAC SURG, V82, P1175, DOI 10.1016/j.athoracsur.2006.04.052 GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3 Gharagozloo F, 2003, ANN THORAC SURG, V76, P1009, DOI 10.1016/S0003-4975(03)00267-4 Ginsberg RJ, 1995, ANN THORAC SURG, V60, P22, DOI DOI 10.1016/0003-4975(95)00537-U HOLMES CE, 1995, ANN THORAC SURG, V60, P615, DOI 10.1016/0003-4975(95)00537-u Horan T.C., 2004, HOSP EPIDEMIOLOGY IN, V3rd, P1659 Hulscher JBF, 2002, NEW ENGL J MED, V347, P1662, DOI 10.1056/NEJMoa022343 Iizasa T, 2004, ANN THORAC SURG, V77, P1896, DOI 10.1016/j.athoracsur.2003.10.014 Imperatori Andrea, 2006, Surg Infect (Larchmt), V7 Suppl 2, pS57 Iwasaki A, 2004, EUR J CARDIO-THORAC, V26, P158, DOI 10.1016/j.ejcts.2004.02.033 Kaseda S, 2000, ANN THORAC SURG, V70, P1644, DOI 10.1016/S0003-4975(00)01909-3 Luketich J D, 2000, Clin Lung Cancer, V2, P56, DOI 10.3816/CLC.2000.n.018 Luketich JD, 2003, ANN SURG, V238, P486, DOI 10.1097/01.sla.0000089858.40725.68 McKenna RJ, 2006, ANN THORAC SURG, V81, P421, DOI 10.1016/j.athoracsur.2005.07.078 McKenna RJ, 2005, CANCER J, V11, P73, DOI 10.1097/00130404-200501000-00011 McKenna RJ, 1998, ANN THORAC SURG, V66, P1903, DOI 10.1016/S0003-4975(98)01166-7 Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710 Muraoka M, 2006, GEN THORAC CARDIOVAS, V54, P49, DOI 10.1007/BF02744600 Ohtsuka T, 2004, CHEST, V125, P1742, DOI 10.1378/chest.125.5.1742 Onaitis MW, 2006, ANN SURG, V244, P420, DOI 10.1097/01.sla.0000234892.79056.63 Petersen RP, 2006, ANN THORAC SURG, V82, P214, DOI 10.1016/j.athoracsur.2006.02.051 Roviaro G, 2004, CHEST, V126, P725, DOI 10.1378/chest.126.3.725 Strand TE, 2006, THORAX, V61, P710, DOI 10.1136/thx.2005.056481 Sugi K, 2000, WORLD J SURG, V24, P27, DOI 10.1007/s002689910006 Sugi K, 2000, Jpn J Thorac Cardiovasc Surg, V48, P161 Walker WS, 2003, EUR J CARDIO-THORAC, V23, P397, DOI 10.1016/S1010-7940(02)00814-X Yim APC, 2000, ANN THORAC SURG, V70, P243, DOI 10.1016/S0003-4975(00)01258-3 NR 35 TC 241 Z9 275 U1 0 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD JUN PY 2007 VL 83 IS 6 BP 1965 EP 1970 DI 10.1016/j.athoracsur.2007.01.049 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 172GD UT WOS:000246791200007 PM 17532379 DA 2026-04-17 ER PT J AU Petersen, RP Pham, D Burfeind, WR Hanish, SI Toloza, EM Harpole, DH D'Amico, TA AF Petersen, Rebecca P. Pham, DuyKhanh Burfeind, William R. Hanish, Steven I. Toloza, Eric M. Harpole, David H., Jr. D'Amico, Thomas A. TI Thoracoscopic lobectomy facilitates the delivery of chemotherapy after resection for lung cancer SO ANNALS OF THORACIC SURGERY LA English DT Article; Proceedings Paper CT 53rd Annual Meeting of the Southern-Thoracic-Surgical-Association CY NOV 08-11, 2006 CL Tucson, AZ SP SE Thorac Surg Assoc ID ASSISTED THORACIC-SURGERY; LIMITED THORACOTOMY; PULMONARY-FUNCTION; EFFECTIVE STRATEGY; VATS LOBECTOMY; SAFE; EXPERIENCE; SURVIVAL AB Background. We conducted a study of patients who underwent anatomic resection with adjuvant chemotherapy to determine if thoracoscopic lobectomy enables more effective administration of adjuvant chemotherapy than lobectomy by thoracotomy. Methods. We reviewed the outcomes of 100 consecutive patients with non-small cell lung cancer (NSCLC) who underwent lobectomy and received adjuvant chemotherapy (1999 to 2004). The variables analyzed were time to initiation of chemotherapy, percentage of planned regimen received, number of delayed or reduced chemotherapy doses, toxicity grade, length of hospitalization, chest tube duration, 30-day mortality, and major complications (pneumonia, respiratory failure, atrial fibrillation). The chi(2) test and Student t test were used to compare dichotomous and continuous variables, respectively. Results. Complete resection was performed by thoracotomy in 43 patients and by thoracoscopy in 57 (no conversions). All patients received adjuvant chemotherapy, and 20 (20%) received adjuvant radiation therapy: 13 (30%) of 43 in the thoracotomy group and 7 (12%) of 57 in the thoracoscopy group (p = 0.04). Patients undergoing thoracoscopic lobectomy had significantly fewer delayed (18% versus 58%, p < 0.001) and reduced (26% versus 49%, p = 0.02) chemotherapy doses. A higher percentage of patients undergoing thoracoscopic resection received 75% or more of their planned adjuvant regimen without delayed or reduced doses (61% versus 40%, p = 0.03). There were no significant differences in time to initiation of chemotherapy or toxicity. Patients undergoing a thoracoscopic lobectomy had a shorter median length of hospitalization (4 days versus 5 days, p = 0.02). Conclusions. Thoracoscopy was associated with an overall higher compliance rate and fewer delayed or reduced doses of chemotherapy in patients receiving adjuvant chemotherapy. C1 Duke Univ, Med Ctr, Dept Surg, Div Thorac Surg, Durham, NC 27710 USA. C3 Duke University RP D'Amico, TA (corresponding author), Duke Univ, Med Ctr, Dept Surg, Div Thorac Surg, Box 3496,Duke S Room 3589, Durham, NC 27710 USA. EM damic001@mc.duke.edu CR [Anonymous], 2004, Oper Tech Thorac Cardiovasc Surg, DOI DOI 10.1053/J.OPTECHSTCVS.2004.05.002 BONADONNA G, 1995, NEW ENGL J MED, V332, P901, DOI 10.1056/NEJM199504063321401 Daniels LJ, 2002, ANN THORAC SURG, V74, P860, DOI 10.1016/S0003-4975(02)03764-5 Demmy TL, 2005, ANN THORAC SURG, V79, P1744, DOI 10.1016/j.athoracsur.2004.05.015 Demmy TL, 1999, ANN THORAC SURG, V68, P194, DOI 10.1016/S0003-4975(99)00467-1 DOUILLARD JY, 2005, J CLIN ONCOL, V23, pA7013 Koizumi Kiyoshi, 2003, Ann Thorac Cardiovasc Surg, V9, P14 Lally BE, 2006, J CLIN ONCOL, V24, P2998, DOI 10.1200/JCO.2005.04.6110 Le Chevalier T, 2004, NEW ENGL J MED, V350, P351, DOI 10.1056/nejmoa031644 Lohrisch C, 2006, J CLIN ONCOL, V24, P4888, DOI 10.1200/JCO.2005.01.6089 MCKENNA RJ, 1994, CHEST, V106, P1902, DOI 10.1378/chest.106.6.1902 McKenna RJ, 2006, ANN THORAC SURG, V81, P421, DOI 10.1016/j.athoracsur.2005.07.078 Nagahiro I, 2001, ANN THORAC SURG, V72, P362, DOI 10.1016/S0003-4975(01)02804-1 Nakata M, 2000, ANN THORAC SURG, V70, P938, DOI 10.1016/S0003-4975(00)01513-7 National Comprehensive Cancer Network, 2004, J Natl Compr Canc Netw, V2, P94 Nomori H, 2003, SURG TODAY, V33, P7, DOI 10.1007/s005950300001 Nomori H, 2001, ANN THORAC SURG, V72, P879, DOI 10.1016/S0003-4975(01)02891-0 Onaitis MW, 2006, ANN SURG, V244, P420, DOI 10.1097/01.sla.0000234892.79056.63 Petersen RP, 2006, ANN THORAC SURG, V82, P214, DOI 10.1016/j.athoracsur.2006.02.051 RAPP E, 1988, J CLIN ONCOL, V6, P633, DOI 10.1200/JCO.1988.6.4.633 Roviaro G, 1998, Semin Thorac Cardiovasc Surg, V10, P313 Strauss GM, 2004, J CLIN ONCOL, V22, p621S SUGUIRA H, 1999, SURG LAPARO ENDO PER, V9, P403 Swanson SJ, 2002, P AN M AM SOC CLIN, V21, p290a Walker WS, 2003, EUR J CARDIO-THORAC, V23, P397, DOI 10.1016/S1010-7940(02)00814-X Winton T, 2005, NEW ENGL J MED, V352, P2589, DOI 10.1056/NEJMoa043623 Yim APC, 2000, ANN THORAC SURG, V70, P243, DOI 10.1016/S0003-4975(00)01258-3 NR 27 TC 233 Z9 257 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD APR PY 2007 VL 83 IS 4 BP 1245 EP 1250 DI 10.1016/j.athoracsur.2006.12.029 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 149WZ UT WOS:000245178900003 PM 17383320 DA 2026-04-17 ER PT J AU Cardinale, D Colombo, A Sandri, MT Lamantia, G Colombo, N Civelli, M Salvatici, M Veronesi, G Veglia, F Fiorentini, C Spaggiari, L Cipolla, CM AF Cardinale, Daniela Colombo, Alessandro Sandri, Maria T. Lamantia, Giuseppina Colombo, Nicola Civelli, Maurizio Salvatici, Michela Veronesi, Giulia Veglia, Fabrizio Fiorentini, Cesare Spaggiari, Lorenzo Cipolla, Carlo M. TI Increased perioperative N-terminal pro-B-type natriuretic peptide levels predict atrial fibrillation after thoracic surgery for lung cancer SO CIRCULATION LA English DT Article DE atrial fibrillation; natriuretic peptides; thoracic surgery ID RISK-FACTORS; ARRHYTHMIAS; RULE AB Background-Postoperative atrial fibrillation (AF) is a complication of thoracic surgery for lung cancer, with a reported incidence that can run as high as 42%. Recently, it has been observed retrospectively that B-type natriuretic peptide predicts AF after cardiac surgery. We performed a prospective study to evaluate the role of N-terminal pro-B-type natriuretic peptide (NT-proBNP) as a marker for risk stratification of postoperative AF in patients undergoing thoracic surgery for lung cancer. Methods and Results-We measured NT-proBNP levels in 400 patients (mean age, 62 +/- 10 years; 271 men) 24 hours before and 1 hour after surgery. The primary end point of the study was the incidence of postoperative AF. Overall, postoperative AF occurred in 72 patients (18%). Eighty-eight patients (22%) showed an elevated perioperative NT-proBNP value. When patients with either preoperatively or postoperatively elevated NT-proBNP were pooled, a greater incidence of AF was observed compared with patients with normal values (64% versus 5%; P < 0.001). At multivariable analysis, adjusted for age, gender, major comorbidities, echocardiography parameters, pneumonectomy, and medications, both preoperative and postoperative NT-proBNP values were independent predictors of AF (relative risk, 27.9; 95% CI, 13.2 to 58.9; P < 0.001 for preoperative NT-proBNP elevation; relative risk, 20.1; 95% CI, 5.8 to 69.4; P < 0.001 for postoperative NT-proBNP elevation). Conclusions- Elevation of perioperative NT-proBNP is a strong independent predictor of postoperative AF in patients undergoing thoracic surgery for lung cancer. This finding should facilitate studies of therapies to reduce AF in selected high-risk patients. C1 European Inst Oncol, Cardiol Unit, IRCCS, I-20141 Milan, Italy. European Inst Oncol, Lab Med Unit, IRCCS, I-20141 Milan, Italy. European Inst Oncol, Div Thorac Surg, IRCCS, I-20141 Milan, Italy. Univ Milan, IRCCS, Ctr Cardiol Monzino, Milan, Italy. C3 IRCCS European Institute of Oncology (IEO); IRCCS European Institute of Oncology (IEO); IRCCS European Institute of Oncology (IEO); IRCCS Centro Cardiologico Monzino; University of Milan RP Cardinale, D (corresponding author), European Inst Oncol, Cardiol Unit, IRCCS, Via Ripamonti 435, I-20141 Milan, Italy. EM daniela.cardinale@ieo.it RI Spaggiari, Lorenzo/G-7915-2012; Lamantia, Giuseppina/AAP-9965-2020; Veglia, Fabrizio/K-1958-2016; CARDINALE, DANIELA/AAN-1675-2020; sani, maria teresa/AAC-3072-2020; Civelli, Maurizio/AAO-3674-2020; Veronesi, Giulia/AAA-6327-2021 OI Spaggiari, Lorenzo/0000-0002-1068-3541; Lamantia, Giuseppina/0000-0002-0098-9010; Veglia, Fabrizio/0000-0002-9378-8874; CARDINALE, DANIELA/0000-0002-4038-8033; sani, maria teresa/0000-0002-4437-4237; CR AMAR D, 1995, CHEST, V108, P349, DOI 10.1378/chest.108.2.349 Amar D, 2004, J AM COLL CARDIOL, V44, P1248, DOI 10.1016/j.jacc.2004.05.078 Amar David, 2002, Heart Dis, V4, P117 [Anonymous], 2002, Am J Kidney Dis, V39, pS17 ASAMURA H, 1993, J THORAC CARDIOV SUR, V106, P1104, DOI 10.1016/S0022-5223(19)33985-6 Barbetakis Nikolaos, 2004, BMC Surg, V4, P7, DOI 10.1186/1471-2482-4-7 Brathwaite D, 1998, CHEST, V114, P462, DOI 10.1378/chest.114.2.462 Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Christians KK, 2001, AM J SURG, V182, P713, DOI 10.1016/S0002-9610(01)00799-1 Clerico A, 2004, CLIN CHEM, V50, P33, DOI 10.1373/clinchem.2003.024760 COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580 CRESWELL LL, 1993, ANN THORAC SURG, V56, P539, DOI 10.1016/0003-4975(93)90894-N De Decker K, 2003, ANN THORAC SURG, V75, P1340, DOI 10.1016/S0003-4975(02)04824-5 Dyszkiewicz W, 1998, EUR J CARDIO-THORAC, V13, P625, DOI 10.1016/S1010-7940(98)00084-0 Ellinor PT, 2005, J AM COLL CARDIOL, V45, P82, DOI 10.1016/j.jacc.2004.09.045 Fuster V, 2001, J AM COLL CARDIOL, V38, P1231, DOI 10.1016/S0735-1097(01)01587-X Jason P, 2005, CRIT CARE MED, V33, P2094, DOI 10.1097/01.CCM.0000178351.03327.9F KROWKA MJ, 1987, CHEST, V91, P490, DOI 10.1378/chest.91.4.490 Ma JY, 2006, WORLD J GASTROENTERO, V12, P449, DOI 10.3748/wjg.v12.i3.449 Maisel WH, 2001, ANN INTERN MED, V135, P1061, DOI 10.7326/0003-4819-135-12-200112180-00010 McKie PM, 2005, MAYO CLIN PROC, V80, P1029, DOI 10.4065/80.8.1029 Mohamed MK, 2005, ANN ONCOL, V16, P780, DOI 10.1093/annonc/mdi157 OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014 Ommen SR, 1997, NEW ENGL J MED, V336, P1429, DOI 10.1056/NEJM199705153362006 Passman RS, 2005, ANN THORAC SURG, V79, P1698, DOI 10.1016/j.athoracsur.2004.10.058 Polanczyk CA, 1998, ANN INTERN MED, V129, P279, DOI 10.7326/0003-4819-129-4-199808150-00003 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Troughton RW, 2000, LANCET, V355, P1126, DOI 10.1016/S0140-6736(00)02060-2 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 WAHI R, 1989, ANN THORAC SURG, V48, P33, DOI 10.1016/0003-4975(89)90172-0 Wang TJ, 2004, NEW ENGL J MED, V350, P655, DOI 10.1056/NEJMoa031994 Wazni OM, 2004, CIRCULATION, V110, P124, DOI 10.1161/01.CIR.0000134481.24511.BC NR 32 TC 86 Z9 95 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD MAR 20 PY 2007 VL 115 IS 11 BP 1339 EP 1344 DI 10.1161/CIRCULATIONAHA.106.647008 PG 6 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology GA 147WK UT WOS:000245034300003 PM 17339553 OA Bronze DA 2026-04-17 ER PT J AU Park, BJ Zhang, H Rusch, VW Amar, D AF Park, Bernard J. Zhang, Hao Rusch, Valerie W. Amar, David TI Video-assisted thoracic surgery does not reduce the incidence of postoperative atrial fibrillation after pulmonary lobectomy SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article ID CELL LUNG-CANCER; THORACOSCOPIC LOBECTOMY; THORACOTOMY; EXPERIENCE; CARCINOMA; OPERATION; PROGNOSIS; RESECTION; VATS AB Objective: The objective was to define the incidence of atrial fibrillation after video-assisted thoracic surgery lobectomy and determine whether video-assisted thoracic surgery reduces atrial fibrillation rate compared with thoracotomy. Methods: With the use of a single-institution database of patients who underwent lobectomy for clinical stage I non-small cell lung cancer, 389 patients were identified who were in sinus rhythm preoperatively and received no prophylactic antiarrhythmics. Patients undergoing video-assisted thoracic surgery were age and gender matched with those undergoing thoracotomy. Results: After matching, 122 patients undergoing video-assisted thoracic surgery and 122 patients undergoing thoracotomy were eligible for analysis. Patients undergoing video-assisted thoracic surgery had a higher preoperative diffusion capacity ( 92% +/- 28% vs 80% +/- 18% predicted, P = .001) and a lower rate of induction chemotherapy ( 5/122, 4% vs 11/122, 11%, P = .05) than patients undergoing thoracotomy. Atrial fibrillation occurred in 12% of patients ( 15/122) undergoing video-assisted thoracic surgery and 16% of patients ( 20/122) undergoing thoracotomy ( P = .36). Overall, complications were lower in the video-assisted thoracic surgery group ( 17.2% vs 27.9%, P = .046). Patients with atrial fibrillation were older in both video-assisted thoracic surgery ( 73 +/- 7 years vs 66 +/- 9 years, P = .002) and thoracotomy groups ( 72 +/- 7 years vs 66 +/- 10 years, P = .005). Length of stay for patients with atrial fibrillation was greater in both video- assisted thoracic surgery ( 6.0 +/- 1.5 days vs 4.7 +/- 2.5 days, P = .01) and thoracotomy groups ( 9.2 +/- 4.3 days vs 6.8 +/- 3.6 days, P = .03). Conclusions: Regardless of surgical approach, atrial fibrillation after lobectomy occurred with equal frequency. This supports the theory that autonomic denervation and stress-mediated neurohumoral mechanisms are responsible for the pathogenesis of postoperative atrial fibrillation. Prophylaxis regimens against atrial fibrillation should be the same for either operative approach. C1 Mem Sloan Kettering Canc Ctr, Dept Surg, Thorac Serv, New York, NY 10021 USA. Mem Sloan Kettering Canc Ctr, Dept Anesthesiol & Crit Care Med, New York, NY 10021 USA. C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center RP Park, BJ (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, Thorac Serv, 1275 York Ave,Room C-867, New York, NY 10021 USA. EM parkb@mskcc.org OI Rusch, Valerie/0000-0003-2345-6900 CR Amar D, 2000, J THORAC CARDIOV SUR, V120, P790, DOI 10.1067/mtc.2000.109538 Amar D, 2002, ANESTHESIOLOGY, V97, P1618, DOI 10.1097/00000542-200212000-00039 Amar D, 2002, ANESTHESIOLOGY, V96, P352, DOI 10.1097/00000542-200202000-00021 Amar D, 2005, CHEST, V128, P3421, DOI 10.1378/chest.128.5.3421 Daniels LJ, 2002, ANN THORAC SURG, V74, P860, DOI 10.1016/S0003-4975(02)03764-5 Demmy TL, 1999, ANN THORAC SURG, V68, P194, DOI 10.1016/S0003-4975(99)00467-1 Gharagozloo F, 2003, ANN THORAC SURG, V76, P1009, DOI 10.1016/S0003-4975(03)00267-4 Gridelli C, 2002, LUNG CANCER, V38, pS67 Gridelli C, 1997, EUR J CANCER, V33, P2313, DOI 10.1016/S0959-8049(97)10050-8 Jaklitsch MT, 1996, CHEST, V110, P751, DOI 10.1378/chest.110.3.751 Kaseda S, 2000, ANN THORAC SURG, V70, P1644, DOI 10.1016/S0003-4975(00)01909-3 KIRBY TJ, 1993, ANN THORAC SURG, V56, P784, DOI 10.1016/0003-4975(93)90980-V LANDRENEAU RJ, 1993, ANN THORAC SURG, V56, P1285, DOI 10.1016/0003-4975(93)90667-7 LEWIS RJ, 1993, ANN THORAC SURG, V56, P762, DOI 10.1016/0003-4975(93)90975-N McKenna RJ, 2006, ANN THORAC SURG, V81, P421, DOI 10.1016/j.athoracsur.2005.07.078 McKenna RJ, 1998, ANN THORAC SURG, V66, P1903, DOI 10.1016/S0003-4975(98)01166-7 MCKENNA RJ, 1994, J THORAC CARDIOV SUR, V107, P879 Passman RS, 2005, ANN THORAC SURG, V79, P1698, DOI 10.1016/j.athoracsur.2004.10.058 Polanczyk CA, 1998, ANN INTERN MED, V129, P279, DOI 10.7326/0003-4819-129-4-199808150-00003 Roselli EE, 2005, J THORAC CARDIOV SUR, V130, P438, DOI 10.1016/j.jtcvs.2005.02.010 Sugi K, 2000, WORLD J SURG, V24, P27, DOI 10.1007/s002689910006 Thomas P, 2002, EUR J CARDIO-THORAC, V21, P1094, DOI 10.1016/S1010-7940(02)00179-3 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 Walker WS, 2003, EUR J CARDIO-THORAC, V23, P397, DOI 10.1016/S1010-7940(02)00814-X WALKER WS, 1993, J THORAC CARDIOV SUR, V106, P1111, DOI 10.1016/S0022-5223(19)33986-8 Yancik R, 2000, HEMATOL ONCOL CLIN N, V14, P17, DOI 10.1016/S0889-8588(05)70275-6 NR 26 TC 105 Z9 117 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 EI 1097-685X J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD MAR PY 2007 VL 133 IS 3 BP 775 EP 779 DI 10.1016/j.jtcvs.2006.09.022 PG 5 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 139OO UT WOS:000244441800029 PM 17320583 OA Bronze DA 2026-04-17 ER PT J AU Tavil, Y Arslan, U Okyay, K Sen, N Boyaci, B AF Tavil, Yusuf Arslan, Ugur Okyay, Kaan Sen, Nihat Boyaci, Bulent TI Atrial fibrillation induced by gemcitabine treatment in a 65-year-old man SO ONKOLOGIE LA English DT Article DE gemcitabine; chemotherapy; atrial fibrillation ID CELL LUNG-CANCER; PHASE-II; SAFETY PROFILE; TOXICITY; MANIFESTATION AB Background: Gemcitabine, a pyrimidine analogue, is a cell cycle-specific antineoplastic agent that is structurally related to cytarabine. Major side effects of the treatment with gemcitabine are hepatic dysfunction, myelo-suppression, renal impairment and pulmonary toxicity. Development of atrial fibrillation (AF) during gemcitabine treatment is very rare and was reported in only 2 case reports in the literature. Case Report: We report the case of a 65-year-old man who developed AF under gemcitabine therapy for non-small cell lung cancer (stage IIIB). In this patient, AF was intrinsically associated with chemotherapy administration which triggered arrhythmia. Conclusion: Although AF caused by gemcitabine appears to be rare, patients at risk of developing atrial fibrillation should be closely monitored for this complication. C1 Gazi Univ, Sch Med, Dept Cardiol, Ankara, Turkey. C3 Gazi University RP Tavil, Y (corresponding author), Gazi Univ, Sch Med, Dept Cardiol, Erzurum Gul S 5-23, Ankara, Turkey. EM yusuftavil@gmail.com RI Arslan, Uğur/F-4993-2014; okyay, kaan/AAK-7355-2020 OI Arslan, Uğur/0000-0001-8572-3571; okyay, kaan/0000-0001-6134-8826 CR ABRATT RP, 1994, J CLIN ONCOL, V12, P1535, DOI 10.1200/JCO.1994.12.8.1535 Chugh SS, 2001, J AM COLL CARDIOL, V37, P371, DOI 10.1016/S0735-1097(00)01107-4 Ciotti R, 1999, ANN ONCOL, V10, P997, DOI 10.1023/A:1008305716918 Ferrari D, 2006, ANTI-CANCER DRUG, V17, P359, DOI 10.1097/00001813-200603000-00016 Green MR, 1996, SEMIN ONCOL, V23, P32 Gridelli C, 2001, LUNG CANCER-J IASLC, V31, P277, DOI 10.1016/S0169-5002(00)00194-X HEINEMANN V, 1988, CANCER RES, V48, P4024 Illiano A, 2000, ANTICANCER RES, V20, P3999 LILENBAUM RC, 1993, J CLIN ONCOL, V11, P1391, DOI 10.1200/JCO.1993.11.7.1391 Santini D, 2000, ANN ONCOL, V11, P479, DOI 10.1023/A:1008380208045 STORNIOLO AM, 1997, SEMIN ONCOL S7, V24, P2 Tonato M, 1995, ANTI-CANCER DRUG, V6, P27, DOI 10.1097/00001813-199512006-00005 van der Hooft CS, 2004, J AM COLL CARDIOL, V44, P2117, DOI 10.1016/j.jacc.2004.08.053 WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983 NR 14 TC 8 Z9 8 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0378-584X J9 ONKOLOGIE JI Onkologie PY 2007 VL 30 IS 5 BP 253 EP 255 DI 10.1159/000100930 PG 3 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA 162CH UT WOS:000246063900006 PM 17460420 DA 2026-04-17 ER PT J AU Dominguez-Ventura, A Allen, MS Cassivi, SD Nichols, FC Deschamps, C Pairolero, PC AF Dominguez-Ventura, Alberto Allen, Mark S. Cassivi, Stephen D. Nichols, Francis C., III Deschamps, Claude Pairolero, Peter C. TI Lung cancer in octogenarians: Factors affecting morbidity and mortality after pulmonary resection SO ANNALS OF THORACIC SURGERY LA English DT Article; Proceedings Paper CT 42nd Annual Meeting of the Society-of-Thoracic-Surgeons CY JAN 30-FEB 01, 2006 CL Chicago, IL SP Soc Thorac Surg ID SURGICAL-TREATMENT; COMPLICATIONS; CARCINOMA; AGE AB Background. Predictors of morbidity and mortality after pulmonary resection for lung cancer in patients 80 years of age or older are unknown. Methods. The medical records of all patients 80 years of age or older who had pulmonary resection for lung cancer from January 1985 through September 2004 were reviewed. Results. There were 379 patients (248 men, 131 women). Median age was 82 years (range, 80 to 95 years). Pneumonectomy was performed in 25 patients (6.6%), bilobectomy in 7 (1.8%), lobectomy in 240 (63.3%), segmentectomy in 29 (7.7%), and wedge excision in 78 (20.6%). The cancer was squamous cell carcinoma in 143 patients (37.7%), adenocarcinoma in 166 (43.8%), bronchoalveolar cell carcinoma in 47 (12.4%), and other in 23 (6.1%). Complications occurred in 182 patients (48.0%). These included atrial fibrillation in 75 patients, pneumonia in 27, and retained secretions requiring bronchoscopy in 37. Morbidity predictors were male sex (odds ratio [OR], 1.6), hemoptysis (OR, 2.3), and previous stroke (OR, 3.8). Asymptomatic patients had a significantly decreased probability of complications (OR, 0.56). Operative mortality was 6.3% (24 of 379); significant predictors were congestive heart failure (OR, 6.0) and prior myocardial infarction (OR, 4.3). Factors not associated with mortality included previous myocardial revascularization, renal insufficiency (creatinine > 1.5 mg/dL), and diabetes mellitus. Conclusions. Pulmonary resection for lung cancer in octogenarians is feasible. Congestive heart failure and myocardial infarction, however, correlated with a significant increase in mortality. Prior myocardial revascularization, renal insufficiency, and diabetes were not associated with increased morbidity and mortality. C1 Mayo Clin & Mayo Fdn, Div Gen Thorac Surg, Coll Med, Rochester, MN 55905 USA. C3 Mayo Clinic RP Allen, MS (corresponding author), Mayo Clin & Mayo Fdn, Div Gen Thorac Surg, Coll Med, 200 1st St SW, Rochester, MN 55905 USA. EM allen.mark@mayo.edu CR [Anonymous], 2004, US INTERIM PROJECTIO Aoki T, 2003, EUR J CARDIO-THORAC, V23, P446, DOI 10.1016/S1010-7940(03)00014-9 Aoki T, 2000, EUR J CARDIO-THORAC, V18, P662, DOI 10.1016/S1010-7940(00)00573-X Brock MV, 2004, ANN THORAC SURG, V77, P271, DOI 10.1016/S0003-4975(03)01470-X Hanagiri T, 1999, LUNG CANCER-J IASLC, V23, P129, DOI 10.1016/S0169-5002(99)00006-9 Hillner BE, 1998, CANCER, V83, P1930, DOI 10.1002/(SICI)1097-0142(19981101)83:9<1930::AID-CNCR8>3.0.CO;2-X Hutchins LF, 1999, NEW ENGL J MED, V341, P2061, DOI 10.1056/NEJM199912303412706 *NAT CTR HLTH STAT, 2004, US LIF TABL NAT VIT NAUNHEIM KS, 1994, EUR J CARDIO-THORAC, V8, P453, DOI 10.1016/1010-7940(94)90013-2 OSAKI T, 1994, ANN THORAC SURG, V57, P188, DOI 10.1016/0003-4975(94)90392-1 Pagni S, 1997, ANN THORAC SURG, V63, P785, DOI 10.1016/S0003-4975(96)01150-2 Port JL, 2004, CHEST, V126, P733, DOI 10.1378/chest.126.3.733 Rosenthal R., 2001, PRINCIPLES PRACTICE SHIRAKUSA T, 1989, THORAX, V44, P189, DOI 10.1136/thx.44.3.189 Wang J, 1999, ANN THORAC SURG, V67, P1444, DOI 10.1016/S0003-4975(99)00255-6 NR 15 TC 90 Z9 100 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD OCT PY 2006 VL 82 IS 4 BP 1175 EP 1179 DI 10.1016/j.athoracsur.2006.04.052 PG 5 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 086XQ UT WOS:000240706800002 PM 16996903 OA Bronze DA 2026-04-17 ER PT J AU Molinari, F Fink, C Risse, F Tuengerthal, S Bonomo, L Kauczor, HU AF Molinari, Francesco Fink, Christian Risse, Frank Tuengerthal, Siegfried Bonomo, Lorenzo Kauczor, Hans-Ulrich TI Assessment of differential pulmonary blood flow using perfusion magnetic resonance imaging - Comparison with radionuclide perfusion scintigraphy SO INVESTIGATIVE RADIOLOGY LA English DT Article DE lung; magnetic resonance imaging (MRI); perfusion; blood flow; functional imaging ID SINGLE-LUNG TRANSPLANTATION; CONTRAST-ENHANCED MRI; VEIN STENOSIS; RADIOFREQUENCY ABLATION; QUANTITATIVE ASSESSMENT; ATRIAL-FIBRILLATION; CYSTIC-FIBROSIS; QUANTIFICATION; TIME; ANGIOGRAPHY AB Objectives: We sought to assess the agreement between lung perfusion ratios calculated from pulmonary perfusion magnetic resonance imaging (MRI) and those calculated from radionuclide (RN) perfasion scintigraphy. Materials and Methods: A retrospective analysis of MR and RN perfusion scans was conducted in 23 patients (mean age, 60 +/- 14 years) with different lung diseases (lung cancer 15, chronic obstructive pulmonary disease = 4, cystic fibrosis 2, and mesothelioma = 2). Pulmonary perfusion was assessed by a time-resolved contrast-enhanced 3D gradient-echo pulse sequence using parallel imaging and view sharing (TR = 1.9 milliseconds; TE = 0.8 milliseconds; parallel imaging acceleration factor = 2; partition thickness = 4 mm; matrix = 256 X 96; in-plane spatial resolution = 1.87 x 3.75 mm; scan time for each 3D dataset = 1.5 seconds), using gadolinium-based contrast agents (injection flow rate = 5 mL/s, dose = 0.1 mmol/kg of body weight). The peak concentration (PC) of the contrast agent bolus, the pulmonary blood flow (PBF), and blood volume (PBV) were computed from the signal-time curves of the lung. Left-to-right ratios of pulmonary perfasion were calculated from the MR parameters and RN counts. The agreement between these ratios was assessed for side prevalence (sign test) and quantitatively (Deming-regression). Results: MR and RN ratios agreed on side prevalence in 21 patients (91%) with PC, in 20 (87%) with PBF, and in 17 (74%) with PBV. The MR estimations of left-to-right perfusion ratios correlated significantly with those of RN perfusion scans (P < 0.01). The correlation was higher using PC (r = 0.67) and PBF (r = 0.66) than using PBV (r = 0.50). The MR ratios computed from PBF showed the highest accuracy, followed by those from PC and PBV. Independently from the MR parameter used, in some patients the quantitative difference between the MR and RN ratios was not negligible. Conclusions: Pulmonary perfusion MRI can be used to assess the differential blood flow of the lung. Further studies in a larger group of patients are required to fully confirm the clinical suitability of this imaging method. C1 Catholic Univ Rome, Dept Radiol Sci, I-00168 Rome, Italy. DKFZ, Dept Radiol, Heidelberg, Germany. Univ Munich, Inst Clin Radiol, Munich, Germany. Univ Clin Grosshadern, Munich, Germany. Thoraxklin, Dept Radiol, Heidelberg, Germany. C3 Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Helmholtz Association; German Cancer Research Center (DKFZ); University of Munich; University of Munich; Ruprecht Karls University Heidelberg RP Molinari, F (corresponding author), Catholic Univ Rome, Dept Radiol Sci, L F Vito 1, I-00168 Rome, Italy. EM fmolinari@rm.unicatt.it RI Risse, Frank/A-4552-2012; Kauczor, Hans-Ulrich/AAU-5955-2021; Molinari, Francesco/K-7719-2013 CR Bankier AA, 2004, J MAGN RESON IMAGING, V20, P961, DOI 10.1002/jmri.20198 BERGIN CJ, 1991, RADIOLOGY, V180, P845, DOI 10.1148/radiology.180.3.1871305 Bjortuft O, 1996, EUR RESPIR J, V9, P2007, DOI 10.1183/09031936.96.09102007 Carr JC, 2002, ACAD RADIOL, V9, P1407, DOI 10.1016/S1076-6332(03)80668-2 COMBLEET PJ, 1979, CLIN CHEM, V25, P432 CUTILLO AG, 1991, J APPL PHYSIOL, V70, P2145, DOI 10.1152/jappl.1991.70.5.2145 Donahue KM, 1997, JMRI-J MAGN RESON IM, V7, P102, DOI 10.1002/jmri.1880070114 Fink C, 2005, INVEST RADIOL, V40, P72, DOI 10.1097/01.rli.0000149252.42679.78 Fink C, 2004, RADIOLOGY, V231, P175, DOI 10.1148/radiol.2311030193 Fink C, 2004, ROFO-FORTSCHR RONTG, V176, P170 Fink C, 2003, INVEST RADIOL, V38, P482, DOI 10.1097/00004424-200308000-00002 Fink C, 2005, INVEST RADIOL, V40, P40 Fratz S, 2002, CIRCULATION, V106, P1510, DOI 10.1161/01.CIR.0000029103.26029.1E Hardoff R, 2000, J NUCL MED, V41, P1771 Hatabu H, 1996, MAGNET RESON MED, V36, P503, DOI 10.1002/mrm.1910360402 Hatabu H, 1999, MAGNET RESON MED, V42, P1033, DOI 10.1002/(SICI)1522-2594(199912)42:6<1033::AID-MRM7>3.0.CO;2-7 Itti E, 2004, NUCL MED COMMUN, V25, P563, DOI 10.1097/01.mnm.0000126508.96340.1d Iwasawa T, 2002, J MAGN RESON IMAGING, V15, P685, DOI 10.1002/jmri.10121 Jerosch-Herold M, 1998, MED PHYS, V25, P73, DOI 10.1118/1.598163 Kluge A, 2004, CHEST, V126, P428, DOI 10.1378/chest.126.2.428 Lee VS, 1997, AM J ROENTGENOL, V169, P1125, DOI 10.2214/ajr.169.4.9308476 Levin DL, 2001, MAGNET RESON MED, V46, P166, DOI 10.1002/mrm.1172 Mai VM, 2001, J MAGN RESON IMAGING, V13, P954, DOI 10.1002/jmri.1137 Matsuoka S, 2001, J MAGN RESON IMAGING, V14, P580, DOI 10.1002/jmri.1222 MEIER P, 1954, J APPL PHYSIOL, V6, P731, DOI 10.1152/jappl.1954.6.12.731 Nikolaou K, 2004, INVEST RADIOL, V39, P537, DOI 10.1097/01.rli.0000133813.22873.47 Ohno Y, 2004, J MAGN RESON IMAGING, V20, P353, DOI 10.1002/jmri.20137 Ohno Y, 2004, AM J ROENTGENOL, V182, P73, DOI 10.2214/ajr.182.1.1820073 OSullivan J, 1997, J HEART LUNG TRANSPL, V16, P1168 PELC N J, 1991, Magnetic Resonance Quarterly, V7, P229 RISSE F, 2004, MAGMA, V17, P208 Robbins IM, 1998, CIRCULATION, V98, P1769, DOI 10.1161/01.CIR.98.17.1769 Roman K, 2005, PEDIATR RADIOL, V35, P295, DOI 10.1007/s00247-004-1344-z SILVERMAN JM, 1993, RADIOLOGY, V189, P699, DOI 10.1148/radiology.189.3.8234693 Stanchina ML, 2002, J HEART LUNG TRANSPL, V21, P217, DOI 10.1016/S1053-2498(01)00376-X Wang SC, 1997, RADIOLOGY, V205, P243, DOI 10.1148/radiology.205.1.9314992 WEISSKOFF RM, 1993, MAGN RESON MED, V29, P553, DOI 10.1002/mrm.1910290420 Yang M, 2001, J COMPUT ASSIST TOMO, V25, P34, DOI 10.1097/00004728-200101000-00006 Zheng J, 2001, J MAGN RESON IMAGING, V14, P425, DOI 10.1002/jmri.1203 NR 39 TC 47 Z9 49 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0020-9996 J9 INVEST RADIOL JI Invest. Radiol. PD AUG PY 2006 VL 41 IS 8 BP 624 EP 630 DI 10.1097/01.rli.0000225399.65609.45 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging WE Science Citation Index Expanded (SCI-EXPANDED) SC Radiology, Nuclear Medicine & Medical Imaging GA 067VO UT WOS:000239330900004 PM 16829745 DA 2026-04-17 ER PT J AU Ferrari, D Carbone, C Codecà, C Fumagalli, L Gilardi, L Marussi, D Tartaro, T Oldani, S Zannier, F Foa, P AF Ferrari, Daris Carbone, Claudia Codeca, Carla Fumagalli, Luca Gilardi, Laura Marussi, Desire Tartaro, Tiziana Oldani, Sabina Zannier, Francesca Foa, Paolo TI Gemcitabine and atrial fibrillation:: a rare manifestation of chemotherapy toxicity SO ANTI-CANCER DRUGS LA English DT Article DE atrial fibrilation; cardiac toxicity; gemcitabine ID CELL LUNG-CANCER; PHASE-II AB Gemcitabine is a purine analog with known activity in many solid tumors, namely lung, breast, pancreatic, genitourinary and head/neck cancers. Cardiac toxicity is a rare event and only one report previously described atrial fibrillation (AF) as a consequence of gemcitabine infusion. We report two cases of women suffering from lung cancer who were treated with gemcitabine. Both patients were admitted to hospital for paroxysmal AF occurring 12-24 h after the infusion of the drug. In the first case a sinus rhythm was spontaneously repristinated when AF occurred for the first time, while the second episode required an anti-arrhythmic drug to interrupt the dysrhythmia. In the second case, the patient had to be treated with digitalis glycoside to control the ventricular response without attaining a sinus rhythm. We could not recognize any other precipitating factor beyond the infusion of gemcitabine as a cause for the arrhythmia. Both cases were treated with gemcitabine for lung cancer and we observed the appearance of AF less than 24 h after drug administration. We assume that 2',2'-difluorodeoxyuridine, an active metabolite of gemcitabine, could be responsible for the toxic effect. We conclude that AF is an unusual, but potentially dangerous, side-effect of gemcitabine infusion. The arrhythmia should be suspected whenever patients complain of dyspnea and palpitations beginning 12-24 h after treatment. In these cases, the treatment of AF consists of anti-arrhythmic drugs in order to repristinate a sinus rhythm or control the heart rate. C1 Sao Paolo Univ Hosp, Div Med Oncol, Milan, Italy. RP Ferrari, D (corresponding author), Sao Paolo Univ Hosp, Div Med Oncol, Milan, Italy. EM daris.ferrari@ao-sanpaolo.it RI Gilardi, Laura/AAO-5719-2020 CR ABBRUZZESE JL, 1991, J CLIN ONCOL, V9, P491, DOI 10.1200/JCO.1991.9.3.491 [Anonymous], SEMINARS ONCOLOGY S7 Aziz S A, 1998, Clin Oncol (R Coll Radiol), V10, P377, DOI 10.1016/S0936-6555(98)80033-2 DAVIDOFF S, 2005, RESP MED GIANNI L, 2003, MED ONCOLOGICA, V7, P631 Gridelli C, 2001, LUNG CANCER-J IASLC, V31, P277, DOI 10.1016/S0169-5002(00)00194-X Illiano A, 2000, ANTICANCER RES, V20, P3999 MACHOVER D, 1986, J CLIN ONCOL, V4, P685, DOI 10.1200/JCO.1986.4.5.685 Narayan SM, 1997, LANCET, V350, P943, DOI 10.1016/S0140-6736(97)06359-9 Pavlakis N, 1997, CANCER, V80, P286, DOI 10.1002/(SICI)1097-0142(19970715)80:2<286::AID-CNCR17>3.0.CO;2-Q Petrella V, 1989, Minerva Med, V80, P305 Plunkett W, 1995, ANTI-CANCER DRUG, V6, P7, DOI 10.1097/00001813-199512006-00002 PLUNKETT W, 1995, SEMIN ONCOL, V32, P3 Santini D, 2000, ANN ONCOL, V11, P479, DOI 10.1023/A:1008380208045 STORNIOLO AM, 1997, SEMIN ONCOL S7, V24, P2 WILLIAMS GH, 1995, HEART DIS, P1901 WOOD AJJ, 1998, HARRISONS PRINCIPLES, P422 NR 17 TC 27 Z9 31 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0959-4973 J9 ANTI-CANCER DRUG JI Anti-Cancer Drugs PD MAR PY 2006 VL 17 IS 3 BP 359 EP 361 DI 10.1097/00001813-200603000-00016 PG 3 WC Oncology; Pharmacology & Pharmacy WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Pharmacology & Pharmacy GA 137TV UT WOS:000244316000016 PM 16520666 DA 2026-04-17 ER PT J AU Ma, JY Wang, Y Zhao, YF Wu, Z Liu, LX Kou, YL Yang, JJ AF Ma, Jian-Yang Wang, Yun Zhao, Yong-Fan Wu, Zhu Liu, Lun-Xu Kou, Ying-Li Yang, Jun-Jie TI Atrial fibrillation after surgery for esophageal carcinoma: Clinical and prognostic significance SO WORLD JOURNAL OF GASTROENTEROLOGY LA English DT Article DE esophageal carcinoma; atrial fibrillation; surgery ID NONCARDIAC THORACIC-SURGERY; SYMPTOMATIC TACHYDYSRHYTHMIAS; RISK-FACTORS; LUNG-CANCER; ARRHYTHMIAS; OPERATIONS; MECHANISMS; AGE AB AIM: To retrospectively evaluate the clinical relevance, perioperative risk factors, outcome of different pharmacological prophylaxis, and short-term prognostic value of atrial fibrillation (AF) after surgery for esophageal carcinoma. METHODS: We retrospectively studied 63 patients with AF after surgery for esophageal carcinoma in comparison with 126 patients without AF after esophagectomy during the same time. Postoperative AF incidence was related to different clinical factors possibly involved in its occurrence and short-term survival. RESULTS: A strong relationship was observed between AF and postoperative hypoxia, history of chronic obstructive pulmonary disease (COPD), postoperative thoracic-gastric dilatation, age older than 65 years, male sex and history of cardiac disease. No difference was observed between the two groups with regard to short-term mortality and length of hospital stay. CONCLUSIONS: AF occurs more frequently after esophagectomy in aged and male patients. Other factors contributing to postoperative AF are history of COPD and cardiac disease, postoperative hypoxia and thoracic-gastric dilatation. (C) 2006 The WJG Press. All rights reserved. C1 Sichuan Univ, W China Hosp, Dept Thorac & Cardiovasc Surg, Chengdu 610041, Sichuan Prov, Peoples R China. C3 Sichuan University RP Wang, Y (corresponding author), Sichuan Univ, W China Hosp, Dept Thorac & Cardiovasc Surg, Chengdu 610041, Sichuan Prov, Peoples R China. EM yunwang2004@163.com CR AMAR D, 1995, CHEST, V108, P349, DOI 10.1378/chest.108.2.349 Amar D, 2002, ANESTHESIOLOGY, V96, P352, DOI 10.1097/00000542-200202000-00021 Amar D, 1996, ANN THORAC SURG, V61, P1506, DOI 10.1016/0003-4975(96)00111-7 Angele MK, 2000, SHOCK, V14, P81, DOI 10.1097/00024382-200014020-00001 ASAMURA H, 1993, J THORAC CARDIOV SUR, V106, P1104, DOI 10.1016/S0022-5223(19)33985-6 Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Chung MK, 2001, CIRCULATION, V104, P2886, DOI 10.1161/hc4901.101760 LIE JT, 1988, MAYO CLIN PROC, V63, P552, DOI 10.1016/S0025-6196(12)64885-X Nielsen TD, 2004, CHEST, V126, P496, DOI 10.1378/chest.126.2.496 Polanczyk CA, 1998, ANN INTERN MED, V129, P279, DOI 10.7326/0003-4819-129-4-199808150-00003 Sekine Y, 2001, CHEST, V120, P1783, DOI 10.1378/chest.120.6.1783 VanMieghem W, 1996, ANN THORAC SURG, V61, P1083, DOI 10.1016/0003-4975(96)00073-2 VANMIEGHEM W, 1994, CHEST, V105, P1642, DOI 10.1378/chest.105.6.1642 VANMIEGHEM W, 1996, ANN THORAC SURG, V61, P1086 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 WEI JY, 1992, NEW ENGL J MED, V327, P1735, DOI 10.1056/NEJM199212103272408 NR 16 TC 48 Z9 53 U1 0 U2 4 PU W J G PRESS PI BEIJING PA PO BOX 2345, BEIJING 100023, PEOPLES R CHINA SN 1007-9327 J9 WORLD J GASTROENTERO JI World J. Gastroenterol. PD JAN 21 PY 2006 VL 12 IS 3 BP 449 EP 452 DI 10.3748/wjg.v12.i3.449 PG 4 WC Gastroenterology & Hepatology WE Science Citation Index Expanded (SCI-EXPANDED) SC Gastroenterology & Hepatology GA 076YI UT WOS:000239994100016 PM 16489647 OA hybrid DA 2026-04-17 ER PT J AU Ciriaco, P Casiraghi, M Melloni, G Carretta, A Libretti, L Augello, G Zannini, P AF Ciriaco, P Casiraghi, M Melloni, G Carretta, A Libretti, L Augello, G Zannini, P TI Pulmonary resection for non-small-cell lung cancer in patients on hemodialysis: Clinical outcome and long-term results SO WORLD JOURNAL OF SURGERY LA English DT Article ID DIALYSIS AB Patients on hemodialysis (HD) who undergo surgery represent a high risk group requiring careful perioperative management to avoid electrolyte imbalance and hemodynamic instability. The aim of the study was to analyze the postoperative outcome in terms of complications and survival of a group of patients on HD who had undergone pulmonary resection for non-small cell lung cancer (NSCLC). Six patients on HD underwent seven pulmonary resections at our institution from 1998 to 2003. The underlying kidney disease was nephrosclerosis in two patients and glomerulonephritis in four. The mean levels of blood urea nitrogen and serum creatinine were 107 +/- 11.5 mg/dl and 7.9 +/- 0.64 mg/dl, respectively. The mean preoperative PO2 and FEV1 were 77.6 +/- 2.4 mmHg and 2.4 +/- 0.16 liters, respectively. The histologic diagnosis was squamous cell carcinoma in four cases and adenocarcinoma in three. One patient underwent two lung resections in 4 years for two primary lung cancers. Five patients underwent lobectomy, one underwent a wedge resection, and in one case pneumonectomy was performed after neoadjuvant chemotherapy. There was no operative mortality. Postoperatively, atrial fibrillation occurred in two patients associated with sputum retention in both, and two other patients had hyperkalemia (complication rate 57%). One patient died of cardiac complications 27 months after surgery. The remaining five patients are currently alive with no evidence of disease. Patients on HD who undergo lung resection have a high rate of postoperative complications. Although the underlying disease influences long-term survival, radical lung resection in NSCLC patients is recommended in selected cases. Careful metabolic, hematologic, and pharmaceutical management is mandatory during the perioperative period. C1 Vita Salute Univ, Sci Inst H San Raffaele, Dept Thorac Surg, I-20132 Milan, Italy. Vita Salute Univ, Sci Inst H San Raffaele, Dept Cardiol, I-20132 Milan, Italy. C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele RP Ciriaco, P (corresponding author), Vita Salute Univ, Sci Inst H San Raffaele, Dept Thorac Surg, Via Olgettina 60, I-20132 Milan, Italy. EM paola.ciriaco@hsr.it RI carretta, angelo/AAG-7749-2019; Ciriaco, Paola/H-5716-2012; Casiraghi, Monica/K-2777-2019 OI carretta, angelo/0000-0003-4471-2643; Ciriaco, Paola/0000-0001-5421-7676; Casiraghi, Monica/0000-0001-5986-7811 CR KANTOR AF, 1987, AM J EPIDEMIOL, V126, P370, DOI 10.1093/oxfordjournals.aje.a114668 KELLERMAN PS, 1994, ARCH INTERN MED, V154, P1674, DOI 10.1001/archinte.154.15.1674 Maisonneuve P, 1999, LANCET, V354, P93, DOI 10.1016/S0140-6736(99)06154-1 PASTAN SO, 1988, HEART DISEASE, P1828 PINSON CW, 1986, AM J SURG, V151, P567, DOI 10.1016/0002-9610(86)90548-9 Tsuchida M, 2001, ANN THORAC SURG, V71, P435, DOI 10.1016/S0003-4975(00)02226-8 Watanabe R, 2003, BRIT J CANCER, V88, P25, DOI 10.1038/sj.bjc.6600687 NR 7 TC 28 Z9 33 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0364-2313 J9 WORLD J SURG JI World J.Surg. PD NOV PY 2005 VL 29 IS 11 BP 1516 EP 1519 DI 10.1007/s00268-005-0047-4 PG 4 WC Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA 979YJ UT WOS:000232980800024 PM 16222451 DA 2026-04-17 ER PT J AU Roselli, EE Murthy, SC Rice, TW Houghtaling, PL Pierce, CD Karchmer, DP Blackstone, EH AF Roselli, EE Murthy, SC Rice, TW Houghtaling, PL Pierce, CD Karchmer, DP Blackstone, EH TI Atrial fibrillation complicating lung cancer resection SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article ID NONCARDIAC THORACIC-SURGERY; RISK-FACTORS; PROGNOSTIC-SIGNIFICANCE; CARDIOLOGY COMMITTEE; PULMONARY RESECTION; EUROPEAN-SOCIETY; ARRHYTHMIAS; PREDICTORS; PNEUMONECTOMY; DYSRHYTHMIAS AB Objective: To (1) characterize atrial fibrillation complicating lung cancer resection, (2) evaluate its temporal relationship to other postoperative complications, and (3) assess its economics. Methods: From January 1998 to August 2002, 604 patients underwent anatomic lung cancer resection. Atrial fibrillation prevalence, onset, and temporal associations with other postoperative complications were determined. Propensity matching was used to assess economics. Results: Atrial fibrillation occurred in 113 patients (19%), peaking on postoperative day 2. Older age, male gender, heart failure, clamshell incision, and right pneumonectomy were risk factors (P < .01). Although atrial fibrillation was solitary in 75 patients (66%), other postoperative complications occurred in 38. Respiratory and infectious complications were temporally linked with atrial fibrillation onset. In 91 propensity-matched pairs, patients developing atrial fibrillation had more other postoperative complications (30% vs. 9%, P < .0004), had longer postoperative stays (median 8 vs 5 days, P < .0001), incurred higher costs (cost ratio 1.8, 68% confidence limits 1.6-2.1), and had higher in-hospital mortality (8% vs 0%, P = .01). Even when atrial fibrillation was a solitary complication, hospital stay was longer (median 7 vs 5 days, P < .0001), and cost was higher (cost ratio 1.5, 68% confidence limits 1.2-1.6). Conclusion: Atrial fibrillation occurs in 1 in 5 patients after lung cancer resection, with peak onset on postoperative day 2. Risk factors are both patient and procedure related, and atrial fibrillation may herald other serious complications. Although often solitary, atrial fibrillation is associated with longer hospital stay and higher cost. It therefore requires prompt treatment and should stimulate investigation for other problems. C1 Cleveland Clin Fdn, Dept Thorac & Cardiovasc Surg, Cleveland, OH 44195 USA. Cleveland Clin Fdn, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA. C3 Cleveland Clinic Foundation; Cleveland Clinic Foundation RP Murthy, SC (corresponding author), Cleveland Clin Fdn, Dept Thorac & Cardiovasc Surg, 9500 Euclid Ave, Cleveland, OH 44195 USA. EM murthysl@ccf.org RI Pierce, Christopher/E-1870-2013; Rice, Thomas/E-2186-2012 OI Blackstone, Eugene/0000-0001-9839-3567 CR Alpert JS, 2000, J AM COLL CARDIOL, V36, P959, DOI 10.1016/S0735-1097(00)00804-4 AMAR D, 1995, CHEST, V108, P349, DOI 10.1378/chest.108.2.349 Arozullah AM, 2001, ANN INTERN MED, V135, P847, DOI 10.7326/0003-4819-135-10-200111200-00005 ASAMURA H, 1993, J THORAC CARDIOV SUR, V106, P1104, DOI 10.1016/S0022-5223(19)33985-6 Aviles RJ, 2003, CIRCULATION, V108, P3006, DOI 10.1161/01.CIR.0000103131.70301.4F Barbetakis Nikolaos, 2004, BMC Surg, V4, P7, DOI 10.1186/1471-2482-4-7 BLACKSTONE EH, 1986, J AM STAT ASSOC, V81, P615, DOI 10.2307/2288989 Blackstone EH, 2002, J THORAC CARDIOV SUR, V123, P8, DOI 10.1067/mtc.2002.120329 Blackstone EH, 2001, J THORAC CARDIOV SUR, V122, P1063, DOI 10.1067/mtc.2001.119858 BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644 Breiman L, 1996, MACH LEARN, V24, P123, DOI 10.1007/bf00058655 Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Ciriaco P, 2000, EUR J CARDIO-THORAC, V18, P12, DOI 10.1016/S1010-7940(00)00428-0 Curtis JJ, 1998, ANN THORAC SURG, V66, P1766, DOI 10.1016/S0003-4975(98)00942-4 Dyszkiewicz W, 1998, EUR J CARDIO-THORAC, V13, P625, DOI 10.1016/S1010-7940(98)00084-0 FALK H, 1982, BILIRUBIN, V1, P7 Fuster V, 2001, EUR HEART J, V22, P1852, DOI 10.1053/euhj.2001.2983 Harpole DH, 1996, ANN THORAC SURG, V61, P977, DOI 10.1016/0003-4975(95)01174-9 Kannel WB, 1998, AM J CARDIOL, V82, p2N, DOI 10.1016/S0002-9149(98)00583-9 Kim K, 2004, J THORAC CARDIOV SUR, V127, P850, DOI 10.1016/j.jtcvs.2003.11.020 KROWKA MJ, 1987, CHEST, V91, P490, DOI 10.1378/chest.91.4.490 Lanza LA, 2003, ANN THORAC SURG, V75, P223, DOI 10.1016/S0003-4975(02)04285-6 Mathew JP, 1996, JAMA-J AM MED ASSOC, V276, P300, DOI 10.1001/jama.276.4.300 Murthy SC, 2003, J THORAC CARDIOV SUR, V126, P1162, DOI 10.1016/S0022-5223(03)00974-7 NEUNSTEIN SM, 1998, J CARDIOTHOR VASC AN, V12, P659 Okereke L, 2005, ANN THORAC SURG, V79, P1167, DOI 10.1016/j.arthoracsur.2004.08.069 Rena O, 2001, EUR J CARDIO-THORAC, V20, P688, DOI 10.1016/S1010-7940(01)00890-9 ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41 Vaporciyan AA, 2004, J THORAC CARDIOV SUR, V127, P779, DOI 10.1016/j.jtcvs.2003.07.011 VONKNORRING J, 1992, ANN THORAC SURG, V53, P642, DOI 10.1016/0003-4975(92)90325-X NR 30 TC 155 Z9 177 U1 0 U2 6 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 EI 1097-685X J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD AUG PY 2005 VL 130 IS 2 BP 438 EP 444 DI 10.1016/j.jtcvs.2005.02.010 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 953IL UT WOS:000231069700031 PM 16077410 OA Bronze DA 2026-04-17 ER PT J AU Lara, PN Mack, PC Synold, T Frankel, P Longmate, J Gumerlock, PH Doroshow, JH Gandara, DR AF Lara, PN Mack, PC Synold, T Frankel, P Longmate, J Gumerlock, PH Doroshow, JH Gandara, DR TI The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: A California cancer consortium phase I pharmacokinetic and molecular correlative trial SO CLINICAL CANCER RESEARCH LA English DT Article ID HUMAN EPIDERMOID CARCINOMA; CELL LUNG-CARCINOMA; PROTEIN-KINASE; SELECTIVE INHIBITOR; 7-HYDROXYSTAUROSPORINE UCN-01; ALPHA(1)-ACID GLYCOPROTEIN; ANTITUMOR-ACTIVITY; ANTICANCER DRUG; ARREST; TARGETS AB Background: UCN-01 (7-hydroxy-staurosporine) is a novel antineoplastic agent targeting cyclin-dependent kinases, which shows potent in vitro and in vivo activity against a broad range of tumor types. Our group has previously shown that UCN-01 potentiates the apoptotic response of agents such as cisplatin in vitro by preventing sequence-specific abrogation of G(2) arrest caused by DNA-damaging chemotherapies. Patients and Methods: This National Cancer Institute-sponsored phase I trial was designed to determine the safety, maximum tolerated dose, and pharmacokinetics of escalating doses of cisplatin in combination with UCN-01 in patients with advanced malignant solid tumors, as well as to do molecular correlative studies on tumor specimens. Cisplatin was infused over 1 hour before UCN-01 (45 mg/m(2)/d) given as a 72-hour continuous infusion. Escalation of cisplatin was planned through five dose levels at 20, 30, 45, 60, and 75 mg/m(2). Results: Ten patients were accrued. Accrual was halted at dose level 2 (cisplatin, 30 mg/m(2)) due to dose-limiting toxicities consisting of grade 5 sepsis with respiratory failure associated with grade 3 creatinine (one patient) and grade 3 atrial fibrillation (one patient). Plasma and salivary pharmacokinetics of UCN-01 were unaffected by cisplatin. Pretreatment and post-treatment tumor biopsies showed that UCN-01 was active against a key molecular target, the checkpoint kinase Chk1. Conclusions: This phase I trial failed to achieve targeted therapeutic dose levels of cisplatin when combined with prolonged infusion UCN-01. However, because preclinical data indicate that UCN-01 potentiates response to platinum, further studies with alternative dose schedules of the combination, or with other platinum analogues, are warranted. C1 Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA. City Hope Comprehens Canc Ctr, Duarte, CA USA. C3 University of California System; University of California Davis; City of Hope RP Lara, PN (corresponding author), Univ Calif Davis, Ctr Canc, 4501 X St, Sacramento, CA 95817 USA. EM primo.lara@ucdmc.ucdavis.edu RI ; Doroshow, James/NWH-8363-2025; Sabatini, Darío/AAB-6699-2019 OI Frankel, Paul/0000-0003-2231-6121; Longmate, Jeffrey/0000-0002-0869-7928; Synold, Timothy/0000-0002-4075-2544; Gandara, David Raymond/0000-0003-1784-048X FU NCI NIH HHS [CA63265, N01 CM17101, CA62505] Funding Source: Medline CR AKINAGA S, 1993, CANCER CHEMOTH PHARM, V32, P183, DOI 10.1007/BF00685833 AKINAGA S, 1994, CANCER CHEMOTH PHARM, V33, P273 AKINAGA S, 1991, CANCER RES, V51, P4888 Akiyama T, 1997, CANCER RES, V57, P1495 Bunch RT, 1997, CELL GROWTH DIFFER, V8, P779 Busby EC, 2000, CANCER RES, V60, P2108 Fuse E, 1999, CANCER RES, V59, P1054 Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600 Grosios K, 2001, Curr Opin Investig Drugs, V2, P287 Kawabe T, 2004, MOL CANCER THER, V3, P513 Kawakami K, 1996, BIOCHEM BIOPH RES CO, V219, P778, DOI 10.1006/bbrc.1996.0310 Kohn EA, 2002, J BIOL CHEM, V277, P26553, DOI 10.1074/jbc.M202040200 Kurata N, 1998, J CHROMATOGR B, V708, P223, DOI 10.1016/S0378-4347(97)00642-7 Lee SI, 1999, BIOCHEM PHARMACOL, V58, P1713, DOI 10.1016/S0006-2952(99)00258-0 Mack P. C., 1997, Journal of Investigative Medicine, V45, p153A Mack PC, 2003, CANCER CHEMOTH PHARM, V51, P337, DOI 10.1007/s00280-003-0571-6 Mack PC, 1999, CLIN CANCER RES, V5, P2596 Pollack IF, 1996, J NEUROSURG, V84, P1024, DOI 10.3171/jns.1996.84.6.1024 Sausville EA, 2001, J CLIN ONCOL, V19, P2319, DOI 10.1200/JCO.2001.19.8.2319 Senderowicz Adrian M, 2002, Cancer Chemother Biol Response Modif, V20, P169 SEYNAEVE CM, 1993, CANCER RES, V53, P2081 Sparreboom A, 2004, CLIN CANCER RES, V10, P6840, DOI 10.1158/1078-0432.CCR-04-0805 TAKAHASHI I, 1987, J ANTIBIOT, V40, P1782, DOI 10.7164/antibiotics.40.1782 TAMURA T, 1999, P AN M AM SOC CLIN, V18, P611 Tenzer A., 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P35, DOI 10.2174/1568011033353533 Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956 Yu Q, 2002, CANCER RES, V62, P5743 NR 27 TC 80 Z9 92 U1 0 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD JUN 15 PY 2005 VL 11 IS 12 BP 4444 EP 4450 DI 10.1158/1078-0432.CCR-04-2602 PG 7 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA 934RM UT WOS:000229725900024 PM 15958629 DA 2026-04-17 ER PT J AU Shaw, AD Vaporciyan, AA Wu, XF King, TM Spitz, MR Putnam, JB Dickey, BF AF Shaw, AD Vaporciyan, AA Wu, XF King, TM Spitz, MR Putnam, JB Dickey, BF TI Inflammatory gene polymorphisms influence risk of postoperative morbidity after lung resection SO ANNALS OF THORACIC SURGERY LA English DT Article ID ANGIOTENSIN-CONVERTING ENZYME; C-REACTIVE PROTEIN; PROMOTER POLYMORPHISM; ATRIAL-FIBRILLATION; INTERLEUKIN-6; MORTALITY; PULMONARY; DISEASE; SUSCEPTIBILITY; COMPLICATIONS AB Background. Polymorphisms in genes encoding proteins involved in the inflammatory response may lead to a differential response to a noxious stimulus. We hypothesized that proinflammatory alleles at candidate loci would predispose patients undergoing lung resection to cardiopulmonary complications with a presumed inflammatory cause. Methods. We determined the genotypes at six candidate loci in 155 patients who underwent 160 lung resection operations at our center. We correlated these results with data from our clinical database, constructed a model predicting the risk of postoperative complications, and assessed its adequacy using receiver operating characteristic curve methodology. Results. Preexisting cardiovascular disease (p < 0.001), primary lung cancer (p = 0.009), extent of lung resection (p = 0.042), interleukin 6 genotype (p = 0.017), and tumor necrosis factor genotype (p = 0.005) were significantly associated with complications. The odds ratio for complications for rare allele homozygosity was 3.9 (95% confidence interval, 1.4 to 10.4) for interleukin 6 and 15.3 (95% confidence interval, 1.7 to 131.4) for tumor necrosis factor. In multivariate analysis we found that cardiovascular disease (p < 0.001; odds ratio, 4.0 [95% confidence interval, 1.9 to 8.6]), interleukin 6 genotype (p = 0.027; odds ratio, 1.8 [95% confidence interval, 1.1 to 3.1]), and tumor necrosis factor genotype (p = 0.011; odds ratio, 2.5 [95% confidence interval, 1.2 to 3.1]) were independently predictive of complications, with an area under the receiver operating characteristic curve for the entire model of 0.765. Conclusions. Carriage of specific alleles, and homozygosity in particular, at loci within the interleukin 6 and tumor necrosis factor genes appears to contribute to the risk of experiencing an adverse event after lung resection. (c) 2005 by The Society of Thoracic Surgeons. C1 Univ Texas, MD Anderson Canc Ctr, Div Anesthesiol & Crit Care Med, Houston, TX 77030 USA. Univ Texas, MD Anderson Canc Ctr, Dept Thorac Surg, Houston, TX 77030 USA. Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA. Univ Texas, MD Anderson Canc Ctr, Dept Pulm Med, Houston, TX 77030 USA. Univ Texas, Sch Med, Dept Internal Med, Houston, TX USA. Vanderbilt Univ, Med Ctr, Dept Thorac Surg, Nashville, TN USA. C3 University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; Vanderbilt University RP Shaw, AD (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Crit Care Med, Unit 112,1515 Holocombe Blvd, Houston, TX 77030 USA. EM ashaw@mdanderson.org OI Shaw, Anew/0000-0002-0566-8005; Dickey, Burton/0000-0002-4780-1847; Putnam, Joe/0000-0002-7504-2104 CR Chung MK, 2001, CIRCULATION, V104, P2886, DOI 10.1161/hc4901.101760 Donahue BS, 2003, ANESTHESIOLOGY, V99, P1287, DOI 10.1097/00000542-200312000-00009 Donahue BS, 2003, CIRCULATION, V107, P1003, DOI 10.1161/01.CIR.0000051864.28048.01 Ferguson M K, 1999, Chest Surg Clin N Am, V9, P339 FERGUSON MK, 1988, J THORAC CARDIOV SUR, V96, P894 FERGUSON MK, 1995, J THORAC CARDIOV SUR, V109, P275, DOI 10.1016/S0022-5223(95)70389-6 Fernández-Llama P, 1998, KIDNEY INT, V53, P1743, DOI 10.1046/j.1523-1755.1998.00946.x FernandezReal JM, 1997, DIABETES, V46, P1468, DOI 10.2337/diabetes.46.9.1468 Gaudino M, 2003, CIRCULATION, V108, P195, DOI 10.1161/01.cir.0000087441.48566.0d Gaudino M, 2003, J THORAC CARDIOV SUR, V126, P1107, DOI 10.1016/S0022-5223(03)00396-9 Gaudino Mario, 2002, Ital Heart J Suppl, V3, P646 Graham EA, 1933, J AMER MED ASSOC, V101, P1371, DOI 10.1001/jama.1933.02740430017005 Hingorani AD, 1999, CIRCULATION, V100, P1515, DOI 10.1161/01.CIR.100.14.1515 Hofstetter W, 2002, ANN SURG, V236, P376, DOI 10.1097/00000658-200209000-00014 Hosmer DW, 1997, STAT MED, V16, P965 Humphries SE, 2001, EUR HEART J, V22, P2243, DOI 10.1053/euhj.2001.2678 Jagoe RT, 2001, ANN THORAC SURG, V71, P936, DOI 10.1016/S0003-4975(00)02006-3 Jahromi MM, 2000, J INTERF CYTOK RES, V20, P885, DOI 10.1089/10799900050163253 Jones KG, 2001, CIRCULATION, V103, P2260 Little J, 2002, AM J EPIDEMIOL, V156, P300, DOI 10.1093/oxfordjournals.aje.a000179 Lorenz E, 2002, ARCH INTERN MED, V162, P1028, DOI 10.1001/archinte.162.9.1028 Marshall RP, 2002, AM J RESP CRIT CARE, V166, P646, DOI 10.1164/rccm.2108086 Sata N, 2004, JPN HEART J, V45, P441, DOI 10.1536/jhj.45.441 Schlüter B, 2002, CRIT CARE MED, V30, P32, DOI 10.1097/00003246-200201000-00005 Schwartz DA, 2002, CHEST, V121, p62S, DOI 10.1378/chest.121.3_suppl.62S Swisher SG, 2000, J THORAC CARDIOV SUR, V119, P1126, DOI 10.1067/mtc.2000.105644 Vaporciyan AA, 2002, ANN THORAC SURG, V73, P420, DOI 10.1016/S0003-4975(01)03443-9 WAHI R, 1989, ANN THORAC SURG, V48, P33, DOI 10.1016/0003-4975(89)90172-0 WALSH GL, 1994, ANN THORAC SURG, V58, P704, DOI 10.1016/0003-4975(94)90731-5 Yoon HJ, 2002, CLIN GENET, V62, P128, DOI 10.1034/j.1399-0004.2002.620205.x NR 30 TC 26 Z9 27 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD MAY PY 2005 VL 79 IS 5 BP 1704 EP 1710 DI 10.1016/j.athoracsur.2004.10.010 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 922YR UT WOS:000228876300038 PM 15854959 DA 2026-04-17 ER PT J AU Stewart, DJ Martin-Ucar, AE Edwards, JG West, K Waller, DA AF Stewart, DJ Martin-Ucar, AE Edwards, JG West, K Waller, DA TI Extra-pleural pneumonectomy for malignant pleural mesothelioma: the risks of induction chemotherapy, right-sided procedures and prolonged operations SO EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY LA English DT Article; Proceedings Paper CT 18th Annual Meeting of the European-Association-for-Cardiothoracic-Surgery/12th Annual Meeting of the European-Society-of-Thoracic-Surgeons CY SEP 12-15, 2004 CL Leipzig, GERMANY SP European Assoc Cardiothorac Surg, European Soc Thorac Surg DE pleural mesothelioma; extra-pleural pneumonectomy; morbidity; risk factors ID INHALED NITRIC-OXIDE; PULMONARY RESECTION; EXTRAPLEURAL PNEUMONECTOMY; RADICAL SURGERY; LUNG-CANCER; MANAGEMENT; MORBIDITY; COMPLICATIONS; GUIDELINES; MORTALITY AB Objective: With the increasing incidence of malignant pleural mesothelioma and renewed interest in radical surgery as a therapeutic option, we have examined our experience of extra-pleural pneumonectomy, to document the incidence and management of its peri-operative complications. Methods: This analysis was conducted using prospectively entered data contained within the departmental database, with additional information from retrospective case note review. Details of patient selection criteria and operative modifications are included. Results: Over a 59-month period, extra-pleural pneumonectomy was carried out on 74 patients (66 men; 8 women; median age 57 years). Fifteen patients (20%) received cisplatin-doublet induction chemotherapy. The majority (80%) of patients had epithelial tumours and 85% of patients had disease in International Mesothelioma Interest Group stages III and IV. The 30-day post-operative mortality was 6.75% (five patients) and significant morbidity was recorded in 47 patients (63%). Major complications included those of technical origin (diaphragmatic patch dehiscence 8.1%; chylothorax 6.7%; intra-thoracic haemorrhage 6.7%; bronchopleural fistula 6.7%), cardiovascular morbidity (atrial fibrillation 17.5%; mediastinal shift with subacute tamponade 10.8%; right ventricular failure 4%; pulmonary embolus 2.7%) and respiratory morbidity (pneumonia 10.8%; acute lung injury 8.1%). Admission to intensive care was required in 19 patients (26%). Univariate analysis identified the incidence of acute lung injury and mediastinal shift to be significantly associated with induction chemotherapy (P=0.005 and 0.014 respectively). In addition to this, laterality of operation influenced respiratory morbidity (P=0.018) and admission to intensive care (P=0.025). Finally, prolonged operations (greater than the median) were associated with an increased risk of technical (P=0.018) and gastro-intestinal (P=0.023) complications. Conclusions: Extra-pleural pneumonectomy is associated with a high rate of morbidity, but an acceptable mortality rate can be achieved with increasing peri-operative experience. Surgery following induction chemotherapy requires extra vigilance for the development of post-operative respiratory complications. (c) 2005 Elsevier B.V. All rights reserved. C1 Glenfield Gen Hosp, Dept Thorac Surg, Leicester LE3 9QP, Leics, England. Glenfield Gen Hosp, Dept Anaesthet, Leicester LE3 9QP, Leics, England. C3 University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital RP Stewart, DJ (corresponding author), Glenfield Gen Hosp, Dept Thorac Surg, Groby Rd, Leicester LE3 9QP, Leics, England. EM parkstewart@aol.com RI Edwards, John/P-9759-2016; Stewart, Duncan/AAN-6056-2021 OI Edwards, John/0000-0002-7935-5327; CR Ashley Z, 2002, INHAL TOXICOL, V14, P1175, DOI 10.1080/08958370290084854 Bernard A, 2001, J THORAC CARDIOV SUR, V121, P1076, DOI 10.1067/mtc.2001.114350 BERNARD GR, 1994, INTENS CARE MED, V20, P225, DOI 10.1007/BF01704707 BUTCHART EG, 1976, THORAX, V31, P15, DOI 10.1136/thx.31.1.15 Cuthbertson BH, 1997, INTENS CARE MED, V23, P1212, DOI 10.1007/s001340050488 Fountain SW, 2001, THORAX, V56, P89 Harpole DH, 1996, ANN THORAC SURG, V61, P977, DOI 10.1016/0003-4975(95)01174-9 Jordan S, 2000, EUR RESPIR J, V15, P790, DOI 10.1034/j.1399-3003.2000.15d26.x Kowalewski J, 1999, EUR J CARDIO-THORAC, V15, P444, DOI 10.1016/S1010-7940(99)00032-9 Kutlu CA, 2000, ANN THORAC SURG, V69, P376, DOI 10.1016/S0003-4975(99)01090-5 Leo F, 2004, ANN THORAC SURG, V77, P260, DOI 10.1016/S0003-4975(03)01487-5 Martin J, 2001, ANN THORAC SURG, V72, P1149, DOI 10.1016/S0003-4975(01)02995-2 MARTINUCAR A, 2004, IN PRESS ANN THORAC McNeil K, 2003, THORAX, V58, P157, DOI 10.1136/thorax.58.2.157 Pilling JE, 2004, EUR J CARDIO-THORAC, V25, P497, DOI 10.1016/j.ejcts.2003.12.001 Pilling JE, 2004, ANN THORAC SURG, V77, P1039, DOI 10.1016/S0003-4975(03)01601-1 Rusch VW, 1996, LUNG CANCER-J IASLC, V14, P1, DOI 10.1016/0169-5002(95)00508-0 Stewart D, 2003, EUR J CARDIO-THORAC, V24, P1019, DOI 10.1016/S1010-7940(03)00609-2 Sugarbaker DJ, 2004, J THORAC CARDIOV SUR, V128, P138, DOI 10.1016/j.jtcvs.2004.02.021 SUGARBAKER DJ, 1992, ANN THORAC SURG, V54, P941, DOI 10.1016/0003-4975(92)90654-M Vaporciyan AA, 2004, J AM COLL SURGEONS, V198, P266, DOI 10.1016/j.jamcollsurg.2003.09.022 Waller DA, 2003, CURR OPIN ONCOL, V15, P139, DOI 10.1097/00001622-200303000-00004 Waller DA, 1996, ANN THORAC SURG, V61, P1435, DOI 10.1016/0003-4975(96)00103-8 Weder W, 2004, J CLIN ONCOL, V22, P3451, DOI 10.1200/JCO.2004.10.071 Zacharski LR, 2002, CANCER LETT, V186, P1, DOI 10.1016/S0304-3835(02)00258-6 NR 25 TC 62 Z9 65 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1010-7940 J9 EUR J CARDIO-THORAC JI Eur. J. Cardio-Thorac. Surg. PD MAR PY 2005 VL 27 IS 3 BP 373 EP 378 DI 10.1016/j.ejcts.2004.12.028 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 909PK UT WOS:000227871900004 PM 15740941 DA 2026-04-17 ER PT J AU Caine, GJ Lip, GYH Stonelake, PS Ryan, P Blann, AD AF Caine, GJ Lip, GYH Stonelake, PS Ryan, P Blann, AD TI Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma SO THROMBOSIS AND HAEMOSTASIS LA English DT Article DE angiogenesis; cancer; interleukin-6; platelets; soluble P-selectin ID ENDOTHELIAL GROWTH-FACTOR; SOLUBLE P-SELECTIN; TISSUE FACTOR; CANCER-PATIENTS; PLASMA-LEVELS; FACTOR VEGF; ATRIAL-FIBRILLATION; SERUM-LEVELS; LUNG-CANCER; INTERLEUKIN-6 AB In health, haemostasis and angiogenesis are tightly regulated processes, but may become deregulated in cancer. Recent evidence suggests that platelet activation may link these processes as platelets can release angiogenic factors such as vascular endothelial growth factor (VEGF). Furthermore, inflammation has also been implicated in regulating both coagulation and angiogenesis, possibly by activating platelets directly and increasing, for example, plasma fibrinogen. We hypothesized relationships between plasma markers of the processes in two common forms of cancer. Plasma levels of VEGF (reflecting angiogenesis), soluble P-selectin, (marking platelet activation), tissue factor [TF], fibrinogen and fibrin D-dimer (coagulation markers), and serum levels of IL-6 (inflammation) were measured by ELISA in 30 patients with biopsy-proven breast cancer, 30 patients with biopsy-proven prostate cancer, and 30 age- and sex-matched controls for each group. Prostate specific antigen was also measured in the men. Release of VEGF from IL-6 stimulated platelets was assessed by ELISA. Plasma levels of IL-6 (P <0.02),VEGF, soluble P-selectin, fibrinogen, and fibrin D-dimer (all p <0.01) were significantly raised in breast cancer, whereas VEGF soluble P-selectin, fibrin D-dimer (all p <0.01) and fibrinogen (p <0.05) were significantly raised in prostate cancer. Significant correlations were found between IL-6 and VEGF (p <0.01), and IL-6 and soluble P-selectin (p = 0.038) in breast cancer. Further experiments demonstrated an in vitro IL-6 induced dose-dependent release of VEGF from platelets. In conclusion, strong relationships between IL6 and VEGF, but not with coagulation or platelet markers, and release of VEGF from IL-6 stimulated platelets, suggest a role for inflammation and platelets in angiogenesis. C1 Univ Birmingham, Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham B18 7QH, W Midlands, England. City Hosp, Dept Surg, Birmingham, W Midlands, England. City Hosp, Dept Urol, Birmingham, W Midlands, England. C3 University of Birmingham; University of Birmingham; University of Birmingham RP Blann, AD (corresponding author), Univ Birmingham, City Hosp, Dept Med, Dudley Rd, Birmingham B18 7QH, W Midlands, England. EM a.blann@bham.ac.uk RI Lip, Gregory/AEO-0575-2022 CR Akakura K, 2003, PROSTATE, V56, P106, DOI 10.1002/pros.10231 Altman D.G., 1991, PRACTICAL STAT MED R, V1st, DOI DOI 10.1201/9780429258589 Bachelot T, 2003, BRIT J CANCER, V88, P1721, DOI 10.1038/sj.bjc.6600956 Banks RE, 1998, BRIT J CANCER, V77, P956, DOI 10.1038/bjc.1998.158 Belgore FM, 2001, AM J HEMATOL, V66, P59, DOI 10.1002/1096-8652(200101)66:1<59::AID-AJH1011>3.3.CO;2-Q Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028 Benoy Ina, 2002, Clin Breast Cancer, V2, P311, DOI 10.3816/CBC.2002.n.008 Blann AD, 2003, EUR HEART J, V24, P2166, DOI 10.1016/j.ehj.2003.08.021 Blann AD, 1997, ATHEROSCLEROSIS, V128, P135, DOI 10.1016/S0021-9150(96)05980-1 Blann AD, 2001, BLOOD COAGUL FIBRIN, V12, P43, DOI 10.1097/00001721-200101000-00007 Blay JY, 1997, INT J CANCER, V72, P424, DOI 10.1002/(SICI)1097-0215(19970729)72:3<424::AID-IJC9>3.0.CO;2-R Bromberg ME, 1999, THROMB HAEMOSTASIS, V82, P88 Caine GJ, 2002, NEOPLASIA, V4, P465, DOI 10.1038/sj.neo.7900263 CAINE GJ, 2004, IN PRESS ANN MED DVORAK HF, 1995, AM J PATHOL, V146, P1029 Ferrara N, 2000, RECENT PROG HORM RES, V55, P15 Ferrari L, 2003, INT J ONCOL, V22, P1081 Folkman J, 1996, NAT MED, V2, P167, DOI 10.1038/nm0296-167 FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4 Griffioen AW, 2000, PHARMACOL REV, V52, P237 Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7 Haznedaroglu IC, 2000, HAEMATOLOGIA, V30, P27, DOI 10.1163/15685590051129841 KAKKAR AK, 1995, LANCET, V346, P1004, DOI 10.1016/S0140-6736(95)91690-3 Kamath S, 2002, STROKE, V33, P1237, DOI 10.1161/01.STR.0000013739.82306.7F Lip GYH, 2002, LANCET ONCOL, V3, P27, DOI 10.1016/S1470-2045(01)00619-2 Makin AJ, 2003, CLIN SCI, V104, P397, DOI 10.1042/CS20020182 Mohle R, 1997, P NATL ACAD SCI USA, V94, P663, DOI 10.1073/pnas.94.2.663 Nakashima J, 2000, CLIN CANCER RES, V6, P2702 O'Byrne KJ, 2000, BRIT J CANCER, V82, P1895, DOI 10.1054/bjoc.1999.1115 Osterud B, 1997, THROMB HAEMOSTASIS, V78, P755 Pfitzenmaier J, 2003, CANCER, V97, P1211, DOI 10.1002/cncr.11178 Roldán V, 2003, EUR HEART J, V24, P1373, DOI 10.1016/S0195-668X(03)00239-2 Roselli M, 2003, THROMB HAEMOSTASIS, V89, P177 Roselli M, 2002, INT J BIOL MARKER, V17, P56, DOI 10.1177/172460080201700107 Salgado R, 2003, INT J CANCER, V103, P642, DOI 10.1002/ijc.10833 Salgado R, 2002, BRIT J CANCER, V87, P1437, DOI 10.1038/sj.bjc.6600655 Salgado R, 1999, BRIT J CANCER, V80, P892, DOI 10.1038/sj.bjc.6690437 Salgado Roberto, 2001, Angiogenesis, V4, P37, DOI 10.1023/A:1016611230747 Schadendorf D, 1996, DERMATOLOGY, V192, P89, DOI 10.1159/000246328 Ueno T, 2000, BRIT J CANCER, V83, P164 Verheul HMW, 2000, BLOOD, V96, P4216, DOI 10.1182/blood.V96.13.4216 Verheul HMW, 1997, CLIN CANCER RES, V3, P2187 Vermeulen PB, 1999, BRIT J CANCER, V79, P370 Wise GJ, 2000, J UROLOGY, V164, P722, DOI 10.1016/S0022-5347(05)67289-8 NR 44 TC 76 Z9 86 U1 0 U2 8 PU GEORG THIEME VERLAG KG PI STUTTGART PA Oswald-Hesse-Strasse 50, D-70469 STUTTGART, GERMANY SN 0340-6245 EI 2567-689X J9 THROMB HAEMOSTASIS JI Thromb. Haemost. PD JUL PY 2004 VL 92 IS 1 BP 185 EP 190 DI 10.1160/TH03-11-0679 PG 6 WC Hematology; Peripheral Vascular Disease WE Science Citation Index Expanded (SCI-EXPANDED) SC Hematology; Cardiovascular System & Cardiology GA 838KC UT WOS:000222711200023 PM 15213860 DA 2026-04-17 ER PT J AU Bobbio, A Carbognani, P Grapeggia, M Rusca, M Sartori, F Bobbio, P Rea, F AF Bobbio, A Carbognani, P Grapeggia, M Rusca, M Sartori, F Bobbio, P Rea, F TI Surgical outcome of combined pulmonary and atrial resection for lung cancer SO THORACIC AND CARDIOVASCULAR SURGEON LA English DT Article DE extended resection; lung cancer; left atrium ID GREAT-VESSELS; SURGERY; CHEMORADIOTHERAPY AB Objectives: The study was carried out to assess the short and long-term outcome of patients with non-small cell lung cancer infiltrating the left atrium treated by surgery. Methods: We retrospectively collected the hospital files of twenty-three consecutive patients operated on between 1982 and 2001 in two units of Thoracic Surgery. Four patients received an induction regimen. Fourteen right pneumonectomies, 8 left pneumonectomies and 1 right inferior lobectomy were performed. No cardiopulmonary bypass was employed. Results: In all patients the diagnosis of T4 atrial invasion was confirmed by pathological examination. A complete resection was achieved in nineteen patients (83%). With respect to nodal staging, there were 13 NO, 5 N1 and 4 N2 cases, respectively. Two deaths occurred during the one month postoperative period (9%). Three patients had postoperative atrial fibrillation. Two other patients had postpneumonectomy empyema without bronchopleural fistula and recovered, one after thoracoscopic debridement and the second after open window thoracostomy. Follow-up was completed on September 2002; only one patient was lost to follow-up. Median survival, excluding the perioperative mortality, was 20 months (range 4-62 months). The survival rate, calculated with the Kaplan-Meier method, was estimated as 63% at I year, 21% at 3 years and 10% at 5 years. Using a Cox model analysis, lymph node stage and completeness of resection were not independent prognostic factors. Conclusions: In cases of NSCLC with left atrial invasion complete resection is technically feasible in most instances without cardiopulmonary bypass. The acceptable operative risk and the encouraging long-term survival observed in this series suggest that NSCLC invading the left atrium should not be systematically considered as a definitive contraindication to surgery. C1 Univ Parma, Unit Thorac Surg, I-43100 Parma, Italy. Univ Padua, Unit Thorac Surg, I-35100 Padua, Italy. C3 University of Parma; University of Padua RP Bobbio, A (corresponding author), Univ Parma, Unit Thorac Surg, Viale Gramsci 14, I-43100 Parma, Italy. EM antonboa@hotmail.com RI Carbognani, Paolo/AAC-2610-2019 CR [Anonymous], J COMPUTATIONAL GRAP Doddoli C, 2001, EUR J CARDIO-THORAC, V20, P339, DOI 10.1016/S1010-7940(01)00759-X Fukuse T, 1997, EUR J CARDIO-THORAC, V11, P664, DOI 10.1016/S1010-7940(96)01140-2 Grunenwald DH, 2001, J THORAC CARDIOV SUR, V122, P796, DOI 10.1067/mtc.2001.116472 Hsu CP, 1996, EUR J SURG ONCOL, V22, P171, DOI 10.1016/S0748-7983(96)90775-1 MARTINI N, 1994, ANN THORAC SURG, V58, P1447, DOI 10.1016/0003-4975(94)91933-X Shirakusa T, 1998, Ann Thorac Cardiovasc Surg, V4, P110 Stamatis G, 1999, ANN THORAC SURG, V68, P1144, DOI 10.1016/S0003-4975(99)00976-5 Takahashi K, 2000, J COMPUT ASSIST TOMO, V24, P557, DOI 10.1097/00004728-200007000-00008 Takahashi T, 1999, Jpn J Thorac Cardiovasc Surg, V47, P383 TSUCHIYA R, 1994, ANN THORAC SURG, V57, P960, DOI 10.1016/0003-4975(94)90214-3 NR 11 TC 27 Z9 36 U1 0 U2 0 PU GEORG THIEME VERLAG KG PI STUTTGART PA Oswald-Hesse-Strasse 50, D-70469 STUTTGART, GERMANY SN 0171-6425 EI 1439-1902 J9 THORAC CARDIOV SURG JI Thorac. Cardiovasc. Surg. PD JUN PY 2004 VL 52 IS 3 BP 180 EP 182 DI 10.1055/s-2004-817813 PG 3 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 832XT UT WOS:000222301700010 PM 15192780 DA 2026-04-17 ER PT J AU Schwam, E AF Schwam, E TI B-type natriuretic peptide for diagnosis of heart failure in emergency department patients: A critical appraisal SO ACADEMIC EMERGENCY MEDICINE LA English DT Article DE heart failure; B-type; natriuretic peptide; BNP testing ID LIKELIHOOD RATIOS; MANAGEMENT; UTILITY; IMPACT; ASSAY AB The diagnosis of heart failure in the outpatient setting can be difficult. A rapid assay for B-type natriuretic peptide (BNP) has been advocated for the diagnosis of heart failure, using a single cutoff of 100 pg/mL. BNP is produced by both the right and left cardiac ventricles and is elevated in a variety of conditions, including heart failure, pulmonary hypertension, cor pulmonale, pulmonary embolism, left ventricular hypertrophy, renal failure, circulatory overload, acute coronary syndromes, atrial fibrillation, lung cancer, and sepsis. This multitude of causes of BNP elevation imposes limits on its diagnostic use for heart failure. The literature on the use of BNP testing for diagnosis of heart failure is reviewed, and improved guidelines for its interpretation are suggested. C1 Sturdy Mem Hosp, Emergency Care Ctr, Attleboro, MA 02703 USA. Brown Univ, Sch Med, Dept Med, Div Emergency Med, Providence, RI 02912 USA. C3 Brown University RP Schwam, E (corresponding author), Sturdy Mem Hosp, Emergency Care Ctr, POB 2963,211 Pk St, Attleboro, MA 02703 USA. EM schwam@massmed.org CR Badgett RG, 1997, JAMA-J AM MED ASSOC, V277, P1712, DOI 10.1001/jama.277.21.1712 Brown MD, 2003, ANN EMERG MED, V42, P292, DOI 10.1067/mem.2003.274 Choi BCK, 1998, AM J EPIDEMIOL, V148, P1127 Dao Q, 2001, J AM COLL CARDIOL, V37, P379, DOI 10.1016/S0735-1097(00)01156-6 FAGAN TJ, 1975, NEW ENGL J MED, V293, P257 HADEN SR, 1999, ANN EMERG MED MAY, P575 Hohl Corinne M, 2003, CJEM, V5, P162 Hunt SA, 2001, CIRCULATION, V104, P2996, DOI 10.1161/hc4901.102568 Inoue S, 2000, J CARD FAIL, V6, P92, DOI 10.1054/jcaf.2000.8185 Jones AE, 2003, ANN EMERG MED, V42, P714, DOI 10.1016/S0196-0644(03)00622-X Kucher N, 2003, CIRCULATION, V107, P2545, DOI 10.1161/01.CIR.0000074039.45523.BE Lainchbury JG, 2003, J AM COLL CARDIOL, V42, P728, DOI 10.1016/S0735-1097(03)00787-3 Logeart D, 2002, J AM COLL CARDIOL, V40, P1794, DOI 10.1016/S0735-1097(02)02482-8 Maisel AS, 2002, NEW ENGL J MED, V347, P161, DOI 10.1056/NEJMoa020233 Maisel AS, 2003, J AM COLL CARDIOL, V41, P2010, DOI 10.1016/S0735-1097(03)00405-4 McCullough PA, 2003, AM J KIDNEY DIS, V41, P571, DOI 10.1053/ajkd.2003.50118 McCullough PA, 2002, CIRCULATION, V106, P416, DOI 10.1161/01.CIR.0000025242.79963.4C MCCULLOUGH PA, 2003, AM COLL CARD ANN SCI McCullough Peter A, 2003, Rev Cardiovasc Med, V4, P72 Morrison LK, 2002, J AM COLL CARDIOL, V39, P202, DOI 10.1016/S0735-1097(01)01744-2 PAUKER SG, 1980, NEW ENGL J MED, V302, P1109, DOI 10.1056/NEJM198005153022003 SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V Tabbibizar R, 2002, CURR OPIN CARDIOL, V17, P340, DOI 10.1097/00001573-200207000-00003 Tateishi J, 2000, CLIN CARDIOL, V23, P776, DOI 10.1002/clc.4960231016 Vasan RS, 2002, JAMA-J AM MED ASSOC, V288, P1252, DOI 10.1001/jama.288.10.1252 Villacorta Humberto, 2002, Arq. Bras. Cardiol., V79, P569 Wang TJ, 2002, AM J CARDIOL, V90, P254, DOI 10.1016/S0002-9149(02)02464-5 NR 27 TC 39 Z9 42 U1 0 U2 3 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1069-6563 EI 1553-2712 J9 ACAD EMERG MED JI Acad. Emerg. Med. PD JUN PY 2004 VL 11 IS 6 BP 686 EP 691 DI 10.1197/j.aem.2003.12.024 PG 6 WC Emergency Medicine WE Science Citation Index Expanded (SCI-EXPANDED) SC Emergency Medicine GA 827ND UT WOS:000221905700013 PM 15175210 DA 2026-04-17 ER PT J AU Choong, CK Meyers, BF Battafarano, RJ Guthrie, TJ Davis, GE Patterson, GA Cooper, JD AF Choong, CK Meyers, BF Battafarano, RJ Guthrie, TJ Davis, GE Patterson, GA Cooper, JD TI Lung cancer resection combined with lung volume reduction in patients with severe emphysema SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article; Proceedings Paper CT 83rd Annual Meeting of the American-Association-for-Thoracic-Surgery CY MAY 04-07, 2003 CL BOSTON, MA SP Amer Assoc Thorac Surg ID PULMONARY-FUNCTION; BRONCHOGENIC-CARCINOMA; LOBECTOMY; MANAGEMENT; RADIATION; DISEASE AB Objective: Certain patients with resectable lung cancer and severe respiratory limitation due to emphysema may have a suitable operative risk by combining cancer resection with lung volume reduction surgery. The purpose of this study is to review our experience with such patients. Methods: A review was conducted on 21 patients with lung cancer in the setting of severe emphysema who underwent an operation designed to provide complete cancer resection and volume reduction effect. Results: In the 21 patients, the mean preoperative forced expiratory volume in 1 second was 0.7 +/- 0.2 L (29% predicted), residual volume was 5.5 +/- 1.0 L (271%), and diffusing capacity for carbon monoxide was 8.0 +/- 2.2 mL/min/mm Hg (34% predicted). In 9 patients, the cancer was located in a severely emphysematous lobe and the lung volume reduction surgery component of the procedure was accomplished with lobectomy alone. In the remaining 12 patients, the cancer resection lobectomy (n = 9) and wedge resection (n = 3) were supplemented with lung volume reduction surgery. Final pathologic staging was stage I in 16 patients, stage II in 2 patients, and stage III in 2 patients. One patient was found to have stage IV disease due to multifocal tumors in separate lobes. There were no hospital deaths. Postoperative complications included prolonged air leak in 11 patients, atrial fibrillation in 6 patients, and reintubation for ventilatory assistance in 2 patients. All patients showed improved lung function postoperatively. Survival was 100% and 62.7% at 1 and 5 years, respectively. Conclusions: Patients with severe emphysema and resectable lung cancer who have a favorable anatomy for lung volume reduction surgery may undergo a combined cancer resection and lung volume reduction surgery with an acceptable risk and good long-term survival. C1 Washington Univ, Sch Med, Dept Surg, Div Cardiothorac Surg, St Louis, MO 63110 USA. Barnes Jewish Hosp, Jacqueline Mariitz Lung Ctr, St Louis, MO 63110 USA. C3 Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL) RP Cooper, JD (corresponding author), Washington Univ, Sch Med, Dept Surg, Div Cardiothorac Surg, 1 Barnes Jewish Hosp Plaza,3108 Queeny Tower, St Louis, MO 63110 USA. EM cooperjd@msnotes.wustl.edu RI Cooper, Jonathan/C-8117-2009 CR ALI MK, 1980, CHEST, V77, P337, DOI 10.1378/chest.77.3.337 BEZJAK A, 1993, WORLD J SURG, V17, P741, DOI 10.1007/BF01659084 BOUSHY SF, 1971, CHEST, V59, P383, DOI 10.1378/chest.59.4.383 Carretta A, 1999, EUR J CARDIO-THORAC, V15, P602, DOI 10.1016/S1010-7940(99)00062-7 Ciccone AM, 2003, J THORAC CARDIOV SUR, V125, P513, DOI 10.1067/mtc.2003.147 COOPER JD, 1995, J THORAC CARDIOV SUR, V109, P106, DOI 10.1016/S0022-5223(95)70426-4 Cooper JD, 1996, J THORAC CARDIOV SUR, V112, P1319, DOI 10.1016/S0022-5223(96)70147-2 DeMeester SR, 1998, J THORAC CARDIOV SUR, V115, P681, DOI 10.1016/S0022-5223(98)70334-4 Edwards JG, 2001, THORAX, V56, P791, DOI 10.1136/thorax.56.10.791 FERGUSON MK, 1988, J THORAC CARDIOVASC, V96, P90 KASKOWITZ L, 1993, INT J RADIAT ONCOL, V27, P517, DOI 10.1016/0360-3016(93)90374-5 Korst RJ, 1998, ANN THORAC SURG, V66, P898, DOI 10.1016/S0003-4975(98)00697-3 KRISTERSSON S, 1973, SCAND J RESPIR DIS, V54, P315 MILLER JI, 1993, J THORAC CARDIOV SUR, V105, P347, DOI 10.1016/S0022-5223(19)33821-8 MILLER JI, 1981, SURG GYNECOL OBSTET, V153, P893 MURREN JR, 1993, CLIN CHEST MED, V14, P161 OLSEN GN, 1973, HOSP PRACT, V8, P137 SAMET JM, 1993, CHEST, V103, P20 VIAL WC, 1986, AM J MED SCI, V291, P130, DOI 10.1097/00000441-198602000-00011 WERNLY JA, 1980, J THORAC CARDIOV SUR, V80, P535 NR 20 TC 74 Z9 75 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 EI 1097-685X J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD MAY PY 2004 VL 127 IS 5 BP 1323 EP 1331 DI 10.1016/j.jtcvs.2003.11.046 PG 9 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 816UK UT WOS:000221134600014 PM 15115989 OA Bronze DA 2026-04-17 ER PT J AU Vaporciyan, AA Correa, AM Rice, DC Roth, JA Smythe, WR Swisher, SG Walsh, GL Putnam, JB Jr AF Vaporciyan, AA Correa, AM Rice, DC Roth, JA Smythe, WR Swisher, SG Walsh, GL Putnam, JB Jr TI Risk factors associated with atrial fibrillation after noncardiac thoracic surgery: Analysis of 2588 patients SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article ID BREAST-CANCER; LUNG-CANCER; SYMPTOMATIC TACHYDYSRHYTHMIAS; SUPRAVENTRICULAR ARRHYTHMIAS; PROPHYLACTIC DIGITALIZATION; PROGNOSTIC-SIGNIFICANCE; PULMONARY RESECTION; MORTALITY; PNEUMONECTOMY; DYSRHYTHMIA AB Objective: The purpose of this study was to identify risk factors associated with the onset of atrial fibrillation after thoracic surgery to allow more targeted interventions in patients with the highest risk. Methods: A comprehensive prospective database was used to identify patients undergoing major thoracic surgery from January 1, 1998, through December 31, 2002. Data collection was performed at point of contact: at preoperative evaluation, the time of the operation, discharge, and postoperative visits. All patients undergoing resection of a lung, the esophagus, the chest wall, or a mediastinal mass were included in this study. Univariate and multivariate analyses of factors associated with the development of atrial fibrillation were analyzed. Results: There were 2588 patients who. met the inclusion criteria. The overall incidence of atrial fibrillation was 12.3% (n = 319). Categories of disease were primary lung cancer, pulmonary metastasis, esophageal cancer, intrathoracic metastasis, benign lung disease, other mediastinal tumors, mesothelioma, chest wall tumors, benign esophagus, and "other." Patients with atrial fibrillation had increased mean lengths of hospital stay, mortality rates, and mean hospital charges. Univariate analysis evaluated age, sex, disease category, comorbidities, preoperative therapy, and procedure, and significant variables were entered into the multivariate analysis. Significant variables (relative risk; 95% confidence interval) in the multivariate analysis were male sex (1.72; 1.29-2.28), age 50 to 59 years (1.70; 1.01-2.88), age 60 to 69 years (4.49; 2.79-7.22), age 70 years or greater (5.30; 3.28-8.59), history of congestive heart failure (2.51; 1.06-6.24), history of arrhythmias (1.92; 1.22-3.02), history of peripheral vascular disease (1.65; 0.93-2.92), resection of mediastinal tumor or thymectomy (2.36; 0.95-5.88), lobectomy (3.89; 2.19-6.91), bilobectomy (7.16; 3.02-16.96), pneumonectomy (8.91; 4.59-17.28), esophagectomy (2.95; 1.55-5.62), and intraoperative transfusions (1.39; 0.98-1.98). Conclusions: The significant variables identified by means of multivariate analysis were associated with the occurrence of atrial fibrillation. Preventive therapies in selected populations might reduce the incidence of atrial fibrillation. C1 Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA. C3 University of Texas System; UTMD Anderson Cancer Center RP Vaporciyan, AA (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, 1515 Holcombe Blvd, Houston, TX 77030 USA. EM avaporci@mdanderson.org OI Putnam, Joe/0000-0002-7504-2104 CR AMAR D, 1995, CHEST, V108, P349, DOI 10.1378/chest.108.2.349 Amar D, 2000, J THORAC CARDIOV SUR, V120, P790, DOI 10.1067/mtc.2000.109538 Amar D, 2002, ANESTHESIOLOGY, V96, P352, DOI 10.1097/00000542-200202000-00021 Amar D, 1996, ANN THORAC SURG, V61, P1506, DOI 10.1016/0003-4975(96)00111-7 Angele MK, 2000, SHOCK, V14, P81, DOI 10.1097/00024382-200014020-00001 ASAMURA H, 1993, J THORAC CARDIOV SUR, V106, P1104, DOI 10.1016/S0022-5223(19)33985-6 Bailey CC, 1943, NEW ENGL J MED, V229, P356, DOI 10.1056/NEJM194308262290902 Brathwaite D, 1998, CHEST, V114, P462, DOI 10.1378/chest.114.2.462 Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Chung MK, 2001, CIRCULATION, V104, P2886, DOI 10.1161/hc4901.101760 Dyszkiewicz W, 1998, EUR J CARDIO-THORAC, V13, P625, DOI 10.1016/S1010-7940(98)00084-0 ELLENBOGEN KA, 1991, J AM COLL CARDIOL, V18, P891, DOI 10.1016/0735-1097(91)90743-S Gagliardi G, 1998, RADIOTHER ONCOL, V46, P63, DOI 10.1016/S0167-8140(97)00167-9 Gyenes G, 1997, EUR J NUCL MED, V24, P286, DOI 10.1007/BF01728765 Gyenes G, 1998, RADIOTHER ONCOL, V48, P185, DOI 10.1016/S0167-8140(98)00062-0 Gyenes G, 1998, ACTA ONCOL, V37, P241, DOI 10.1080/028418698429522 Haïssaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003 Hardenbergh P, 2001, BREAST CANCER RES TR, V69, P231 Harpole DH, 1996, ANN THORAC SURG, V61, P977, DOI 10.1016/0003-4975(95)01174-9 Kleine P, 1999, EUR J CARDIO-THORAC, V15, P525, DOI 10.1016/S1010-7940(99)00035-4 KROWKA MJ, 1987, CHEST, V91, P490, DOI 10.1378/chest.91.4.490 Lanza LA, 2003, ANN THORAC SURG, V75, P223, DOI 10.1016/S0003-4975(02)04285-6 Podrid PJ, 1999, J AM COLL CARDIOL, V34, P340 Polanczyk CA, 1998, ANN INTERN MED, V129, P279, DOI 10.7326/0003-4819-129-4-199808150-00003 Rena O, 2001, EUR J CARDIO-THORAC, V20, P688, DOI 10.1016/S1010-7940(01)00890-9 RITCHIE AJ, 1990, ANN THORAC SURG, V50, P86, DOI 10.1016/0003-4975(90)90094-M RITCHIE AJ, 1993, ANN THORAC SURG, V55, P86, DOI 10.1016/0003-4975(93)90478-Z Sekine Y, 2001, CHEST, V120, P1783, DOI 10.1378/chest.120.6.1783 TAYLOR GJ, 1987, AM J CARDIOL, V60, P905, DOI 10.1016/0002-9149(87)91045-9 VONKNORRING J, 1992, ANN THORAC SURG, V53, P642, DOI 10.1016/0003-4975(92)90325-X NR 30 TC 269 Z9 304 U1 0 U2 9 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 EI 1097-685X J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD MAR PY 2004 VL 127 IS 3 BP 779 EP 786 DI 10.1016/j.jtcvs.2003.07.011 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 801SK UT WOS:000220115400026 PM 15001907 OA Bronze DA 2026-04-17 ER PT J AU Tomkowski, WZ Wisniewska, J Szturmowicz, M Kuca, P Burakowski, J Kober, J Fijalkowska, A AF Tomkowski, WZ Wisniewska, J Szturmowicz, M Kuca, P Burakowski, J Kober, J Fijalkowska, A TI Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade SO SUPPORTIVE CARE IN CANCER LA English DT Article DE malignant pericardial effusion; cisplatin; cardiac tamponade; intrapericardial treatment ID PRIMARY MANAGEMENT; LUNG-CANCER; SCLEROSIS; PERICARDIOCENTESIS; MINOCYCLINE; BLEOMYCIN AB Goals. To evaluate the effectiveness and side effects of intrapericardial administration of cisplatin in prevention of recurrent malignant pericardial effusion.Patients and methods. Forty-six patients (33 men, 13 women; mean age 55.6+/-10.5 years) entered this study. The diagnosis of malignancy was based upon histological examination of samples from primary tumor. The majority of patients suffered from a neoplasm localized in the thorax (41 out of 46 patients; 89%). In 35 cases, pericardiocentesis, and in 11 cases, video-assisted thoracoscopic surgery (VATS) of pericardium was performed. Malignant etiology of pericardial fluid was confirmed by cytological examination, histology being obtained by VATS pericardial biopsy or by echocardiography (ECG). If daily drainage of pericardial fluid observed during 5-7 days exceeded 50 ml, cisplatin was instilled according to one of three regimens: (1) 10 mg of cisplatin dissolved in 20 ml of normal saline administered over 5 min during 5 consecutive days directly into the pericardial space (39 patients); (2) 50 mg of cisplatin dissolved in 100 ml of normal saline administered during 30 min (six patients); and (3) 20 mg of cisplatin dissolved in 40 ml of normal saline administered over 10 min during 5 consecutive days (one patient). Treatment was considered as successful when recurrence of symptoms of large pericardial effusion was not observed in ECG and other interventions directed to the pericardium were not required. Efficacy of investigated treatment was assessed also in the group of patients with survival longer than 30 days. Safety of treatment was assessed in the whole group of patients. Results. Because of advanced malignancy eight out of 46 patients (17.4%) survived less than 30 days. Thirty-eight out of 46 cases (82.6%) survived more than 30 days. Positive effect of intrapericardial treatment with cisplatin was achieved in 43 out of 46 patients (93.5%) in the entire investigated group and in 35 out of 38 patients (92%) who survived more than 30 days. In the subgroup of patients with non-small cell lung cancer (NSCLC) and survival longer than 30 days, high efficacy was documented (29 out of 31 cases; 93.5%). Median survival time in the group of 38 patients who survived more than 30 days was 102.5 days. Atrial fibrillation due to cisplatin administration was observed in seven out of 46 patients (15.2%). Sclerosis of the pericardial space without symptoms of constriction occurred in five out of 46 cases (10.9%). Conclusions. Cisplatin administered directly into the pericardial space is a very effective and relatively safe method of treatment of recurrent malignant pericardial effusion, especially in the course of NSCLC. C1 Natl TB & Lung Dis Res Inst, Intens Care Unit, PL-01138 Warsaw, Poland. Natl TB & Lung Dis Res Inst, Dept Chest Med, Warsaw, Poland. RP Tomkowski, WZ (corresponding author), Natl TB & Lung Dis Res Inst, Intens Care Unit, Plocka 26, PL-01138 Warsaw, Poland. EM w.tomkowski@igichp.edu.pl RI Fijalkowska, Anna/V-3994-2018 OI Fijalkowska, Anna/0000-0002-2225-9684 CR Colleoni M, 1998, J CLIN ONCOL, V16, P2371, DOI 10.1200/JCO.1998.16.7.2371 DeCamp MM, 1997, CHEST, V112, pS291, DOI 10.1378/chest.112.4_Supplement.291S Fagan SM, 1999, CHEST, V116, P275, DOI 10.1378/chest.116.2.275 Girardi LN, 1997, ANN THORAC SURG, V64, P1422, DOI 10.1016/S0003-4975(97)00992-2 KLATT EC, 1990, CANCER-AM CANCER SOC, V65, P1456, DOI 10.1002/1097-0142(19900315)65:6<1456::AID-CNCR2820650634>3.0.CO;2-5 Lashevsky I, 1996, CHEST, V109, P1452, DOI 10.1378/chest.109.6.1452 Liu G, 1996, J CLIN ONCOL, V14, P3141, DOI 10.1200/JCO.1996.14.12.3141 MAGHFOOR I, 2000, CLIN ONCOLOGY, P922 Maher EA, 1996, J THORAC CARDIOV SUR, V112, P637, DOI 10.1016/S0022-5223(96)70046-6 Maisch B, 2002, EUR HEART J, V23, P1625, DOI 10.1053/euhj.2002.3328 Markiewicz W, 1998, CHEST, V113, P861, DOI 10.1378/chest.113.4.861 Martinoni A, 2000, HERZ, V25, P787, DOI 10.1007/PL00001998 Mercé T, 1998, AM J MED, V105, P106, DOI 10.1016/S0002-9343(98)00192-2 PRESS OW, 1987, JAMA-J AM MED ASSOC, V257, P1088, DOI 10.1001/jama.257.8.1088 SHEPHERD FA, 1987, AM J CARDIOL, V60, P1161, DOI 10.1016/0002-9149(87)90411-5 SPODICK DH, 1997, PERICARDIUM COMPREHE, P301 Susini G, 1993, J Cardiothorac Vasc Anesth, V7, P178, DOI 10.1016/1053-0770(93)90213-5 TAMURA A, 1992, CANCER, V70, P437, DOI 10.1002/1097-0142(19920715)70:2<437::AID-CNCR2820700211>3.0.CO;2-L THURBER DL, 1962, CIRCULATION, V26, P228, DOI 10.1161/01.CIR.26.2.228 Tomkowski W, 1997, SUPPORT CARE CANCER, V5, P64, DOI 10.1007/BF01681964 Tomkowski W Z, 1997, Monaldi Arch Chest Dis, V52, P221 Tomkowski WZ, 1997, LUNG CANCER-J IASLC, V16, P215, DOI 10.1016/S0169-5002(96)00631-9 Tondini M, 1995, Monaldi Arch Chest Dis, V50, P86 Tsang TSM, 1998, MAYO CLIN PROC, V73, P647, DOI 10.4065/73.7.647 Tsang TSM, 2000, MAYO CLIN PROC, V75, P248 VAITKUS PT, 1994, JAMA-J AM MED ASSOC, V272, P59, DOI 10.1001/jama.272.1.59 YANO T, 1994, ONCOLOGY-BASEL, V51, P507 ZWISCHENBERGER JB, 2000, LUNG CANC PRINCIPLES, P1038 NR 28 TC 34 Z9 37 U1 0 U2 5 PU SPRINGER PI NEW YORK PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES SN 0941-4355 EI 1433-7339 J9 SUPPORT CARE CANCER JI Support. Care Cancer PD JAN PY 2004 VL 12 IS 1 BP 53 EP 57 DI 10.1007/s00520-003-0533-x PG 5 WC Oncology; Health Care Sciences & Services; Rehabilitation WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Health Care Sciences & Services; Rehabilitation GA 765PL UT WOS:000188292500009 PM 14505155 DA 2026-04-17 ER PT J AU Sakuragi, T Sakao, Y Furukawa, K Rititake, K Ohtsubo, S Okazaki, Y Natsuaki, M Itoh, T AF Sakuragi, T Sakao, Y Furukawa, K Rititake, K Ohtsubo, S Okazaki, Y Natsuaki, M Itoh, T TI Successful management of acute pulmonary embolism after surgery for lung cancer SO EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY LA English DT Article DE acute pulmonary embolism; deep venous thrombus; lobectomy; mediastinal lymph node dissection; lung cancer; argatroban ID THROMBOEMBOLISM; THROMBOLYSIS; THROMBIN AB Objective: Although many case reports of acute pulmonary embolism (APE) have been published, the literature dealing with the management of APE after resection of lung cancer is limited. This report describes seven cases of successful management of APE after surgery for lung cancer and discusses how to manage this problematic complication. Methods: The medical charts of seven patients with APE after lobectomy and complete mediastinal lymphnode dissection were retrospectively reviewed. Results: Six patients collapsed during their first attempt at walking after surgery in conjunction with a dramatic respiratory change. All these patients promptly underwent enhanced spiral computed tomography (CT) scanning. Bilateral clots were detected in all patients and one patient with a deep venous thrombus (DVT) in the femoral vein had a temporary inferior vena cava filter implanted. Non-surgical therapy was used for six patients: thrombolysis (systemic urokinase) and anticoagulant (heparin or argatroban) for four patients and only anticoagulant therapy started on the day after the operation using argatroban for two. There were no bleeding problems with these thrombolysis and/or anticoagulant therapies except in one case of hemorrhage induced by heparin usage on the day after the operation. None of the cases required allotransfusion in connection with these therapies. Thromboembolectomy was performed for one patient who was hemodynamically unstable due to massive embolism and primary atrial fibrillation. All patients were discharged from our hospital without major complications. Conclusions: Patients with pulmonary embolism after surgery for lung cancer can be treated aggressively with anticoagulants with/without fibrinolitics or even with pulmonary embolectomy on cardiopulmonary bypass, without excessive risk of bleeding complications. Enhanced spiral CT scanning was very helpful for making a simultaneous diagnosis of APE and DVT. The use of argatroban in conjunction with activated clotting time monitoring should be effective without causing bleeding problems during the early stages after pulmonary resection for lung cancer. (C) 2003 Elsevier B.V. All rights reserved. C1 Saga Med Sch, Dept Cardiovasc & Thorac Surg, Saga 8498501, Japan. C3 Saga University RP Sakuragi, T (corresponding author), Saga Med Sch, Dept Cardiovasc & Thorac Surg, 5-1-1 Nabeshima, Saga 8498501, Japan. EM sakurat@post.saga-med.ac.jp OI Sakao, Yukinori/0000-0002-6826-2280 CR Chen Q, 2001, EUR J CARDIO-THORAC, V19, P223, DOI 10.1016/S1010-7940(00)00648-5 Chuang T H, 1966, Ann Thorac Surg, V2, P290 COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805 GEBITEKIN C, 1993, 7 ANN M EUR ASS CARD, P113 GIRARD P, 1993, AM REV RESPIR DIS, V147, P1595, DOI 10.1164/ajrccm/147.6_Pt_1.1595 GORE I, 1964, ARCH INTERN MED, V113, P323, DOI 10.1001/archinte.1964.00280090009003 HYERS TM, 1992, CHEST, V102, pS408, DOI 10.1378/chest.102.4_Supplement.408S Inoue F, 1984, Rinsho Kyobu Geka, V4, P473 Kalweit G, 1996, EUR J CARDIO-THORAC, V10, P242, DOI 10.1016/S1010-7940(96)80146-1 Kamiyoshihara M, 2001, Kyobu Geka, V54, P1149 Kataoka D, 2002, Kyobu Geka, V55, P1157 KUDA T, 1991, JJLC, V31, P547 Lobato EB, 1999, J CARDIOTHOR VASC AN, V13, P105, DOI 10.1016/S1053-0770(99)90184-2 More RS, 1996, POSTGRAD MED J, V72, P157, DOI 10.1136/pgmj.72.845.157 Muramatsu T, 2000, JPN ASS CHEST SURG, V14, P660 Nakamura M, 2001, CLIN CARDIOL, V24, P132, DOI 10.1002/clc.4960240207 NAKANO T, 1997, JPN J PHLEBOL, V8, P211 OHTEKI H, 2002, JPN J THORAC CARDIOV, V48, P39 Okabe K, 1999, Kyobu Geka, V52, P1010 OKAMOTO S, 1981, BIOCHEM BIOPH RES CO, V101, P440, DOI 10.1016/0006-291X(81)91279-1 SATUR CMR, 1991, ANN THORAC SURG, V52, P122, DOI 10.1016/0003-4975(91)91432-U Sayeed RA, 1999, ANN THORAC SURG, V67, P1785, DOI 10.1016/S0003-4975(99)00346-X SCHMID C, 1991, ANN THORAC SURG, V52, P1102, DOI 10.1016/0003-4975(91)91288-7 TAMAO Y, 1986, THROMB HAEMOSTASIS, V56, P28 ZIOMEK S, 1993, ANN THORAC SURG, V56, P223, DOI 10.1016/0003-4975(93)91151-C NR 25 TC 27 Z9 34 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1010-7940 EI 1873-734X J9 EUR J CARDIO-THORAC JI Eur. J. Cardio-Thorac. Surg. PD OCT PY 2003 VL 24 IS 4 BP 580 EP 587 DI 10.1016/S1010-7940(03)00392-0 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 730AV UT WOS:000185807800022 PM 14500078 OA Green Submitted, Bronze DA 2026-04-17 ER PT J AU Baron, O Jouan, J Sagan, C Despins, P Michaud, JL Duveau, D AF Baron, O Jouan, J Sagan, C Despins, P Michaud, JL Duveau, D TI Resection of bronchopulmonary cancers invading the left atrium - Benefit of cardiopulmonary bypass SO THORACIC AND CARDIOVASCULAR SURGEON LA English DT Article DE cardiopulmonary bypass; lung cancer; surgery ID CELL LUNG-CANCER; PULMONARY RESECTION; OPERATION AB Aims: Cardiopulmonary bypass (CPB) for extended lung resections involving great vessels and other mediastinal organs remains controversial, especially due to CPB-related haemorrhagic and immunological issues. Here, we will retrospectively analyse the results obtained with such procedure. Material and Methods: Between January 1994 and February 2001, four patients underwent surgery under CPB for lung carcinoma in our department. Three patients were male and one female; mean age was 58.8 +/- 6.3 years. The patients suffered from malignant pulmonary lesions involving the left atrium (T4 or stage IIIb) - two epidermoid carcinoma, one adenocarcinoma and one large-cell carcinoma. Procedures were performed under complete CPB with aortic cross-clamping in all but one patient who underwent hypothermic ventricular fibrillation. Mean CPB duration was 86.7 +/- 26.5 min. Results: There were no hospital mortalities (D30). Mean duration for assisted ventilated support was 9.5 +/- 2.5 hours, 2.5 +/- 1 days for ICU stay and 14.3 +/- 1 days for hospital stay. Operation-related complications were rare. Two patients presented with transient postoperative atrial fibrillation. Only one patient had to undergo reoperation for compressive haemopericardium drainage at D23. The mean quantity of transfused packed red blood cell packs was 2.7 +/- 1.7. Two patients survived over three years after surgery and one patient is still alive at 72 months without any recurrent symptom. Conclusion: in some cases of T4 lung cancer considered inoperable, CPB permits extended lung resections offering significant hope for survival at 86.7 +/- 26.5 min. Results: There were no hospital mortalities (D30). Mean duration for assisted ventilated support was 9.5 +/- 2.5 hours, 2.5 +/- 1 days for ICU stay and 14.3 +/- 1 days for hospital stay. Operation-related complications were rare. Two patients presented with transient postoperative atrial fibrillation. Only one patient had to undergo reoperation for compressive haemopericardium drainage at D23. The mean quantity of transfused packed red blood cell packs was 2.7 +/- 1.7. Two patients survived over three years after surgery and one patient is still alive at 72 months without any recurrent symptom. Conclusion: in some cases of T4 lung cancer considered inoperable, CPB permits extended lung resections offering significant hope for survival at an acceptable operative risk. C1 Hop R&G Laennec, Serv Chirurg Cardio Thorac & Vasc, F-44093 Nantes 1, France. Hop R&G Laennec, Cardiothorac & Vasc Surg Dept, F-44093 Nantes, France. Hop R&G Laennec, Anatomo Pathol Dept, F-44093 Nantes 1, France. C3 Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes RP Baron, O (corresponding author), Hop R&G Laennec, Serv Chirurg Cardio Thorac & Vasc, F-44093 Nantes 1, France. CR André F, 1999, B CANCER, V86, P867 Bailey C P, 1971, Ann Thorac Surg, V11, P140 DELARIVIERE AB, 1995, EUR J CARDIO-THORAC, V9, P310 Grunenwald D, 1997, J NATL CANCER I, V89, P88, DOI 10.1093/jnci/89.1.88 International Union against Cancer, 1997, TNM CLASS MAL TUM, P93 KIRKLIN JK, 1983, J THORAC CARDIOV SUR, V86, P845 Klepetko W, 1999, ANN THORAC SURG, V67, P340, DOI 10.1016/S0003-4975(98)01244-2 MILLER DL, 1994, ANN THORAC SURG, V58, P989, DOI 10.1016/0003-4975(94)90442-1 Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710 Rao V, 1996, ANN THORAC SURG, V62, P342, DOI 10.1016/0003-4975(96)00206-8 REGNARD JF, 1996, HUITIEME J PATHOLOGI RICCI C, 1994, ANN THORAC SURG, V57, P627, DOI 10.1016/0003-4975(94)90556-8 SHIRAKUSA T, 1991, THORAX, V46, P484, DOI 10.1136/thx.46.7.484 Toty L, 1966, Ann Chir Thorac Cardiovasc, V5, P137 TSUCHIYA R, 1994, ANN THORAC SURG, V57, P960, DOI 10.1016/0003-4975(94)90214-3 VANRAEMDONCK DE, 1992, ANN THORAC SURG, V54, P999, DOI 10.1016/0003-4975(92)90677-V WOODS FM, 1961, NEW ENGL J MED, V264, P492, DOI 10.1056/NEJM196103092641006 ZETTER BR, 1990, NEW ENGL J MED, V322, P605 NR 18 TC 17 Z9 18 U1 0 U2 0 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0171-6425 J9 THORAC CARDIOV SURG JI Thorac. Cardiovasc. Surg. PD JUN PY 2003 VL 51 IS 3 BP 159 EP 161 PG 3 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 702JJ UT WOS:000184220500008 PM 12833206 DA 2026-04-17 ER PT J AU Wirth, LJ Lucca, J Ostler, P Fidias, P Lynch, C Jänne, PA Herbst, RS Johnson, BE Sugarbaker, DJ Mathisen, DJ Lukanich, JM Choi, NC Berman, SM Skarin, AT AF Wirth, LJ Lucca, J Ostler, P Fidias, P Lynch, C Jänne, PA Herbst, RS Johnson, BE Sugarbaker, DJ Mathisen, DJ Lukanich, JM Choi, NC Berman, SM Skarin, AT TI Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: A phase I study SO CLINICAL CANCER RESEARCH LA English DT Article; Proceedings Paper CT 37th Annual Meeting of the American-Society-of-Clinical-Oncology CY MAY 12-15, 2001 CL SAN FRANCISCO, CA SP Amer Soc Clin Oncol ID THORACIC RADIATION-THERAPY; COMPARING PERIOPERATIVE CHEMOTHERAPY; TWICE-DAILY RADIATION; RANDOMIZED-TRIAL; ONCOLOGY-GROUP; FAILURE PATTERNS; CONCOMITANT; CARCINOMA; SURVIVAL; PACLITAXEL AB Purpose: To determine the maximum-tolerated dose of docetaxel (DOC) in combination with carboplatin (CAR) and thoracic radiotherapy (RT), in the setting of trimodality treatment of patients with stage III non-small cell lung cancer (NSCLC). Experimental Design: Thirty-two patients with biopsy-proven stage IIIA (n = 20) or IIIB (n = 12) NSCLC were given two initial cycles of CAR (area under the curve = 6) and DOC (75 mg/m(2)), subsequent RT (54 Gy) with concurrent weekly CAR (area under the curve = 2), and DOC at six dose levels from 10 to 40 mg/m(2), then surgery if the patient's disease was resectable. Results: Three patients did not complete induction computed tomography (CT). Twenty-nine patients received concurrent CT/RT. Fifteen patients were eligible for surgery. Dose-limiting toxicities occurred in 2 patients, at dose levels two (atrial fibrillation) and three (transaminitis). The maximum-tolerated dose, as defined by the protocol, was not reached, although grade 3 and 4 toxicities were encountered at all dose levels. The most common more than or equal to grades 3 toxicities were neutropenia, nausea, vomiting, and fatigue. Four patients (13.3%) responded to induction CT. Ten patients (38.5%) responded to CT/RT. Eight surgical patients (57.1%) were downstaged, including 3 pathologic complete responses. Median relapse free and overall survivals are 8.5 and 12 months. One-year and estimated 2-year survival rates are 56.3 and 34.3%. Conclusion: This new regimen for stage III NSCLC of induction CAR/DOC, then weekly CAR/DOC with concurrent RT followed by surgery, can be safely administered and offers encouraging results. DOC at 30 mg/m(2) in combination with CAR and RT is recommended for Phase II study. C1 Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Surg, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. C3 Harvard University; Harvard University Medical Affiliates; Dana-Farber Cancer Institute; Harvard University; Harvard University Medical Affiliates; Dana-Farber Cancer Institute; Harvard University; Harvard University Medical Affiliates; Dana-Farber Cancer Institute; Harvard University; Harvard University Medical Affiliates; Massachusetts General Hospital; Harvard University; Harvard University Medical Affiliates; Brigham & Women's Hospital; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Harvard University Medical Affiliates; Beth Israel Deaconess Medical Center RP Skarin, AT (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA. EM askarin@partners.org CR AAMDAL S, 1998, P AN M AM SOC CLIN, V17, P476 ALBAIN KS, 1995, J CLIN ONCOL, V13, P1880, DOI 10.1200/JCO.1995.13.8.1880 Belani CP, 1996, SEMIN ONCOL, V23, P113 Belani CP, 1999, SEMIN ONCOL, V26, P44 Byhardt RW, 1999, ONCOLOGY-NY, V13, P116 Byhardt RW, 1998, INT J RADIAT ONCOL, V42, P469, DOI 10.1016/S0360-3016(98)00251-X CALVERT AH, 1989, J CLIN ONCOL, V7, P1748, DOI 10.1200/JCO.1989.7.11.1748 CEMY T, 1994, BRIT J CANCER, V70, P384 Choi NC, 1997, J CLIN ONCOL, V15, P712, DOI 10.1200/JCO.1997.15.2.712 Choy H, 1998, J CLIN ONCOL, V16, P3316, DOI 10.1200/JCO.1998.16.10.3316 Choy H, 2001, LUNG CANCER, V34, P441, DOI 10.1016/S0169-5002(01)00279-3 Curran WJ, 2000, P AN M AM SOC CLIN, V19, p484a Dillman RO, 1996, J NATL CANCER I, V88, P1210, DOI 10.1093/jnci/88.17.1210 DILLMAN RO, 1990, NEW ENGL J MED, V323, P940, DOI 10.1056/NEJM199010043231403 Elias AD, 1997, LUNG CANCER-J IASLC, V17, P147, DOI 10.1016/S0169-5002(97)00658-2 ELIAS AD, 1994, AM J CLIN ONCOL-CANC, V17, P26, DOI 10.1097/00000421-199402000-00007 Fossella F., 2001, European Journal of Cancer, V37, pS154, DOI 10.1016/S0959-8049(01)81054-6 Fossella FV, 2000, J CLIN ONCOL, V18, P2354, DOI 10.1200/JCO.2000.18.12.2354 FOSSELLA FV, 1994, J CLIN ONCOL, V12, P1238, DOI 10.1200/JCO.1994.12.6.1238 FRANCIS PA, 1994, J CLIN ONCOL, V12, P1232, DOI 10.1200/JCO.1994.12.6.1232 Furuse K, 1999, J CLIN ONCOL, V17, P2692, DOI 10.1200/JCO.1999.17.9.2692 HENNEQUIN C, 1995, BRIT J CANCER, V71, P1194, DOI 10.1038/bjc.1995.232 Janne Pasi A, 2002, Clin Lung Cancer, V3 Suppl 2, pS37, DOI 10.3816/CLC.2002.s.012 Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23 KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868 KENG P, 2000, P AN M AM SOC CLIN, V19, P662 Komaki R, 1997, INT J RADIAT ONCOL, V39, P537, DOI 10.1016/S0360-3016(97)00365-9 Koukourakis MI, 1998, EUR J CANCER, V34, P838, DOI 10.1016/S0959-8049(97)10101-0 Koukourakis MI, 1999, BRIT J CANCER, V80, P1792, DOI 10.1038/sj.bjc.6690599 Kris MG, 2001, SEMIN ONCOL, V28, P1, DOI 10.1053/sonc.2001.18387 KUBOTA K, 2000, P AN M AM SOC CLIN, V19, P535 Kumar P, 1996, CANCER, V77, P2393, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2393::AID-CNCR31>3.3.CO;2-8 Langer CJ, 1999, SEMIN RADIAT ONCOL, V9, P108 LECHEVALIER T, 1991, JNCI-J NATL CANCER I, V83, P417, DOI 10.1093/jnci/83.6.417 Mason KA, 1997, CLIN CANCER RES, V3, P2431 Mason KA, 1999, CLIN CANCER RES, V5, P4191 Mattson K, 2000, LUNG CANCER, V29, P205, DOI 10.1016/S0169-5002(00)00122-7 Mauer AM, 1998, J CLIN ONCOL, V16, P159, DOI 10.1200/JCO.1998.16.1.159 MILLER VA, 1995, CANCER-AM CANCER SOC, V75, P968, DOI 10.1002/1097-0142(19950215)75:4<968::AID-CNCR2820750411>3.0.CO;2-Y Moriyama A, 2000, ANN ONCOL, V11, P110 Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710 ROSELL R, 1994, NEW ENGL J MED, V330, P153, DOI 10.1056/NEJM199401203300301 Roth JA, 1998, LUNG CANCER-J IASLC, V21, P1, DOI 10.1016/S0169-5002(98)00046-4 ROTH JA, 1994, J NATL CANCER I, V86, P673, DOI 10.1093/jnci/86.9.673 Sause W, 2000, CHEST, V117, P358, DOI 10.1378/chest.117.2.358 SCHAAKEKONING C, 1992, NEW ENGL J MED, V326, P524, DOI 10.1056/NEJM199202203260805 Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954 SEGAWA Y, 2000, P AN M AM SOC CLIN, V19, P504 Shepherd FA, 2000, J CLIN ONCOL, V18, P2095, DOI 10.1200/JCO.2000.18.10.2095 SISTERMANNS J, 1999, P AN M AM SOC CLIN, V18, P522 SKARIN A, 1989, J SURG ONCOL, V40, P266, DOI 10.1002/jso.2930400413 Socinski MA, 2001, CANCER, V92, P1213, DOI 10.1002/1097-0142(20010901)92:5<1213::AID-CNCR1440>3.0.CO;2-0 Socinski MA, 2000, CANCER-AM CANCER SOC, V89, P534 Thomas M, 1999, J CLIN ONCOL, V17, P1185, DOI 10.1200/JCO.1999.17.4.1185 NR 54 TC 11 Z9 12 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD MAY PY 2003 VL 9 IS 5 BP 1698 EP 1704 PG 7 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S) SC Oncology GA 677MY UT WOS:000182813200016 PM 12738723 DA 2026-04-17 ER PT J AU Saad, EB Marrouche, NF Saad, CP Ha, E Bash, D White, RD Rhodes, J Prieto, L Martin, DO Saliba, WI Schweikert, RA Natale, A AF Saad, EB Marrouche, NF Saad, CP Ha, E Bash, D White, RD Rhodes, J Prieto, L Martin, DO Saliba, WI Schweikert, RA Natale, A TI Pulmonary vein stenosis after catheter ablation of atrial fibrillation. Emergence of a new clinical syndrome SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID ECTOPIC BEATS; RADIOFREQUENCY ABLATION; INITIATION; SYSTEM AB Background: Pulmonary vein isolation is a new, effective curative procedure for selected patients with atrial fibrillation. Pulmonary vein stenosis is a potential complication and may lead to symptoms that are often underrecognized. Objective: To describe the clinical course and symptoms associated with pulmonary vein stenosis developing after ablation in the pulmonary veins. Design: Retrospective study. Setting: Tertiary care referral center. Patients: 335 patients referred for catheter ablation of drug-refractory atrial fibrillation. Intervention: Pulmonary vein electrical isolation using radiofrequency catheter ablation. Measurements: Three months after ablation, patients underwent routine screening for pulmonary vein stenosis with spiral computed tomography. Screening was considered earlier if symptoms suggestive of stenosis developed and was repeated at 6 and 12 months if any pulmonary vein narrowing was observed. Pulmonary vein angiography and dilatation were offered to patients with severe (>70%) stenosis. Results: Severe pulmonary vein stenosis was detected in 18 patients (5% [95% Cl, 3.2% to 8.4%]) a mean (+SD) of 5.2 +/- 2.6 months after ablation. Eight of these 18 patients (44%) were asymptomatic, but 8 (44%) reported shortness of breath, 7 (39%) reported cough, and 5 (28%) reported hemoptysis. Radiologic abnormalities were present in 9 patients (50%) and led to diagnoses of pneumonia (4 patients), lung cancer (1 patient), and pulmonary embolism (2 patients). Pulmonary vein stenosis was not considered in any patient during the initial work-up. Dilatation of the affected vein was performed in 12 patients. Postintervention lung perfusion scans revealed significant improvement in lung flow. Conclusions: Severe pulmonary vein stenosis after catheter ablation of atrial fibrillation is associated with respiritory symptoms that frequently mimic more common diseases, often leading to erroneous diagnostic and therapeutic procedures. Awareness of this syndrome is important for proper and prompt management. C1 Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA. C3 Cleveland Clinic Foundation RP Natale, A (corresponding author), Cleveland Clin Fdn, Dept Cardiovasc Med, 9500 Euclid Ave,Desk F15, Cleveland, OH 44195 USA. EM natalea@cce.org OI White, Richard D/0000-0002-1133-7819 CR Chen SA, 2000, J CARDIOVASC ELECTR, V11, P218 Chen SA, 1999, CIRCULATION, V100, P1879, DOI 10.1161/01.CIR.100.18.1879 Cole CR, 2001, CIRCULATION, V104, P567 Cooper JM, 2001, CIRCULATION, V104, P3010, DOI 10.1161/hc5001.101503 Haïssaguerre M, 2000, CIRCULATION, V101, P1409, DOI 10.1161/01.CIR.101.12.1409 Haïssaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003 Kanagaratnam L, 2001, PACE, V24, P1774, DOI 10.1046/j.1460-9592.2001.01774.x Lin WS, 2000, CIRCULATION, V101, P1274, DOI 10.1161/01.CIR.101.11.1274 Marrouche NF, 2002, J AM COLL CARDIOL, V40, P464, DOI 10.1016/S0735-1097(02)01972-1 Natale A, 2000, CIRCULATION, V102, P1879, DOI 10.1161/01.CIR.102.16.1879 Natale A, 1999, PACE, V22, P1634, DOI 10.1111/j.1540-8159.1999.tb00383.x Oral H, 2002, CIRCULATION, V105, P1077, DOI 10.1161/hc0902.104712 Robbins IM, 1998, CIRCULATION, V98, P1769, DOI 10.1161/01.CIR.98.17.1769 Scanavacca MI, 2000, J CARDIOVASC ELECTR, V11, P677, DOI 10.1111/j.1540-8167.2000.tb00030.x Yang M, 2001, J COMPUT ASSIST TOMO, V25, P34, DOI 10.1097/00004728-200101000-00006 Yu WC, 2001, J CARDIOVASC ELECTR, V12, P887, DOI 10.1046/j.1540-8167.2001.00887.x NR 16 TC 186 Z9 199 U1 1 U2 3 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572, UNITED STATES SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 15 PY 2003 VL 138 IS 8 BP 634 EP 638 DI 10.7326/0003-4819-138-8-200304150-00010 PG 5 WC Medicine, General & Internal WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine GA 666JH UT WOS:000182173800005 PM 12693885 DA 2026-04-17 ER PT J AU Daniels, LJ Balderson, SS Onaitis, MW D'Amico, TA AF Daniels, LJ Balderson, SS Onaitis, MW D'Amico, TA TI Thoracoscopic lobectomy: A safe and effective strategy for patients with stage I lung cancer SO ANNALS OF THORACIC SURGERY LA English DT Article; Proceedings Paper CT 48th Annual Meeting of the Southern-Thoracic-Surgical-Association CY NOV 08-10, 2001 CL SAN ANTONIO, TX SP SO Thorac Surg Assoc ID ASSISTED THORACIC-SURGERY; MAJOR PULMONARY RESECTIONS; THORACOTOMY; TUMORS AB Background. Thoracoscopic lobectomy is emerging as a potential alternative to thoracotomy for early stage lung cancer. The issues of safety and oncologic efficacy should be analyzed before recommending this procedure for widespread use. Methods. Thoracoscopic lobectomy was attempted in 110 consecutive patients (age, 35 to 81 years) with tumors that were judged to be amenable to lobectomy over a 26-month period. Exclusion criteria included tumors greater than 5 cm in diameter, T3 tumors, endobronchial tumors visible at bronchoscopy, the use of induction therapy, extensive N1 disease on computed tomographic scan, and N2 disease at mediastinoscopy. The procedures were performed without rib spreading using two ports and included anatomic hilar dissection and individual vessel stapling. Results. Thoracoscopic lobectomy and mediastinal lymph dissection was successfully performed in 108 patients (98.2%); 2 patients required conversion to thoracotomy to control bleeding in the setting of dense hilar adenopathy. There were no intraoperative deaths and 4 perioperative deaths (3.6%) caused by pneumonia and associated adult respiratory distress syndrome (3 patients) and stroke (1 patient). Major complications included pneumonia (5 patients), stroke (1 patient), and return to the operating room to revise the bronchial closure (1 patient). Minor complications included prolonged air leak (6 patients), atrial fibrillation (4 patients), blood transfusion (2 patients) and ileus (1 patient). Median time to chest tube removal was 3 days, and median length of stay was 3 days. Conclusions. Thoracoscopic lobectomy is a safe and effective strategy for patients with early stage lung cancer. Long-term follow-up is required to determine if recurrence rate and 5-year survival are comparable with thoracotomy for lobectomy. (C) 2002 by The Society of Thoracic Surgeons. C1 Duke Univ, Med Ctr, Dept Surg, Div Cardiothorac Surg, Durham, NC 27710 USA. C3 Duke University RP D'Amico, TA (corresponding author), Duke Univ, Med Ctr, Dept Surg, Div Cardiothorac Surg, Box 3496,3589 Clin Res 2, Durham, NC 27710 USA. EM damic001@mc.duke.edu CR Demmy TL, 1999, ANN THORAC SURG, V68, P194, DOI 10.1016/S0003-4975(99)00467-1 Downey RJ, 1996, J THORAC CARDIOV SUR, V111, P954, DOI 10.1016/S0022-5223(96)70370-7 HAZELRIGG SR, 1993, ANN THORAC SURG, V56, P787, DOI 10.1016/0003-4975(93)90981-M KIRBY TJ, 1993, ANN THORAC SURG, V56, P784, DOI 10.1016/0003-4975(93)90980-V KIRBY TJ, 1995, J THORAC CARDIOV SUR, V109, P997, DOI 10.1016/S0022-5223(95)70326-8 LEWIS RJ, 1992, ANN THORAC SURG, V54, P421, DOI 10.1016/0003-4975(92)90431-3 LEWIS RJ, 1992, ANN THORAC SURG, V54, P80, DOI 10.1016/0003-4975(92)91144-X MARTINI N, 1995, J THORAC CARDIOV SUR, V109, P120, DOI 10.1016/S0022-5223(95)70427-2 Martini N, 1995, Chest Surg Clin N Am, V5, P189 McKenna RJ, 1998, ANN THORAC SURG, V66, P1903, DOI 10.1016/S0003-4975(98)01166-7 MCLOUD TC, 1992, RADIOLOGY, V182, P319, DOI 10.1148/radiology.182.2.1732943 MOUNTAIN CF, 1977, ANN THORAC SURG, V24, P365, DOI 10.1016/S0003-4975(10)63416-9 Nagahiro I, 2001, ANN THORAC SURG, V72, P362, DOI 10.1016/S0003-4975(01)02804-1 Nomori H, 2001, ANN THORAC SURG, V72, P879, DOI 10.1016/S0003-4975(01)02891-0 ROBERTS JR, 1996, CHEST, V116, pS45 Roviaro G, 1992, Surg Laparosc Endosc, V2, P244 ROVIARO G, 1993, ANN THORAC SURG, V56, P779, DOI 10.1016/0003-4975(93)90979-R Solaini L, 2001, EUR J CARDIO-THORAC, V20, P437, DOI 10.1016/S1010-7940(01)00850-8 STAPLES CA, 1988, RADIOLOGY, V167, P367, DOI 10.1148/radiology.167.2.3357944 Sugi K, 2000, WORLD J SURG, V24, P27, DOI 10.1007/s002689910006 Sugiura H, 1999, SURG LAPARO ENDO PER, V9, P403, DOI 10.1097/00019509-199912000-00007 WALKER WS, 1994, BRIT J SURG, V81, P81, DOI 10.1002/bjs.1800810126 Weber A, 2001, EUR J CARDIO-THORAC, V20, P443, DOI 10.1016/S1010-7940(01)00689-3 Yim APC, 2000, ANN THORAC SURG, V70, P243, DOI 10.1016/S0003-4975(00)01258-3 Yim APC, 1998, ANN THORAC SURG, V66, P1155, DOI 10.1016/S0003-4975(98)00622-5 NR 25 TC 110 Z9 118 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD SEP PY 2002 VL 74 IS 3 BP 860 EP 864 AR PII S0003-4975(02)03764-5 DI 10.1016/S0003-4975(02)03764-5 PG 5 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 591MH UT WOS:000177883900049 PM 12238851 OA Bronze DA 2026-04-17 ER PT J AU Numico, G Castiglione, F Granetto, C Garrone, O Mariani, G Di Costanzo, G La Ciura, P Gasco, M Ostellino, O Porcile, G Merlano, M AF Numico, G Castiglione, F Granetto, C Garrone, O Mariani, G Di Costanzo, G La Ciura, P Gasco, M Ostellino, O Porcile, G Merlano, M TI Single-agent pegylated liposomal doxorubicin (Caelix®) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial SO LUNG CANCER LA English DT Article DE non-small-cell lung cancer; chemotherapy; second-line; liposomal doxorubicin ID PHASE-II; 2ND-LINE TREATMENT; DOCETAXEL; EFFICACY; VINORELBINE; GROWTH; HEAD AB Polyethylene glycol-coated (pegylated) liposomal doxorubicin (PLD) is a new formulation of doxorubicin with peculiar pharmacokinetic and pharmacodinamic properties, a favorable toxic profile and a demonstrated activity in solid tumors. We tested PLD in locally advanced or metastatic NSCLC patients, progressed after a platinuin-based first-line chemotherapy. PLD was administered at the dose of 35 mg/m(2) every 21 days. After the first six patients had been accrued, due to the low toxicity shown in the first six patients, the dose was escalated to 45 mg/m(2). Seventeen patients were enrolled in the study and were considered eligible for evaluation of toxicity and response. Stomatitis, palmar-plantar erythrodysaesthesia (PPE) and asthenia were the most common toxicities and affected approximately half of the treated patients. Stomatitis occurred in 8/17 patients and was grade 3-4 in three. PPE was seen in 9/17 and was grade 3 in one. In the group treated at the dose of 45 mg/m(2) PPE was more frequent and severe and required treatment delay in some cases. Other toxicities were equally distributed among the two groups. Hematological toxicity was not common and never reached grade 3-4. However, one patient with grade 2 leucopenia had pneumonia and died. Clinically evident heart failure was never recorded. Left ventricular ejection fraction was assessed in three patients after PLD treatment (in one case after the first course, due to the occurrence of atrial fibrillation, and in two cases after six courses) and was unchanged compared to pre-treatment assessment. One confirmed partial response was observed (5.8%); five patients (29.4%) had stable disease (including one minor response) and nine (52.9%) had disease progression. Median time to progression was 9.5 weeks, median survival 18.6 weeks. PLD at the doses employed in this study can be safely administered and has shown activity in platinum pretreated NSCLC patients. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved. C1 S Croce & Carle Gen Hosp, Med Oncol Unit, Cuneo, Italy. S Lazzaro Hosp, Med Oncol Serv, Alba, Italy. RP Numico, G (corresponding author), S Croce & Carle Gen Hosp, Med Oncol Unit, Cuneo, Italy. EM gnumico@libero.it RI Garrone, Ornella/HHS-9402-2022; Porcile, Gabriel/NBX-8715-2025; Mariani, Gabriella Lucia/AAA-4112-2021; Numico, Gianmauro/AAE-4489-2020 OI Garrone, Ornella/0000-0001-7359-5410; Mariani, Gabriella Lucia/0000-0001-6882-4944; Numico, Gianmauro/0000-0003-3253-2960 CR Alberts DS, 1997, DRUGS, V54, P30, DOI 10.2165/00003495-199700544-00007 Amantea M, 1999, HUM EXP TOXICOL, V18, P17, DOI 10.1191/096032799678839347 BAAS P, 1999, P AN M AM SOC CLIN, V18, pA495 Belani CP, 1998, SEMIN ONCOL, V25, P10 BERRY G, 1996, P AN M AM SOC CLIN, V15, P303 Buccheri G, 1997, LUNG CANCER-J IASLC, V18, P57, DOI 10.1016/S0169-5002(97)00045-7 BURRIS H, 1993, P AN M AM SOC CLIN, V12, P335 Caponigro F, 2000, ANN ONCOL, V11, P339, DOI 10.1023/A:1008319618638 Coukell AJ, 1997, DRUGS, V53, P520, DOI 10.2165/00003495-199753030-00011 Crinò L, 1999, J CLIN ONCOL, V17, P2081, DOI 10.1200/JCO.1999.17.7.2081 Fossella FV, 2000, J CLIN ONCOL, V18, P2354, DOI 10.1200/JCO.2000.18.12.2354 FOSSELLA FV, 1995, J CLIN ONCOL, V13, P645, DOI 10.1200/JCO.1995.13.3.645 Gabizon A, 1997, DRUGS, V54, P15, DOI 10.2165/00003495-199700544-00005 GANDARA DR, 1997, P AN M AM SOC CLIN, V16, pA454 GARFIELD DH, 1998, P AN M AM SOC CLIN, V17, pA484 Gridelli C, 1999, ANTICANCER RES, V19, P4535 KOLETSKY A, 1999, P AN M AM SOC CLIN, V18, pA512 Koukourakis MI, 1999, J CLIN ONCOL, V17, P3512, DOI 10.1200/JCO.1999.17.11.3512 Martoni A, 1999, ANN ONCOL, V10, P19, DOI 10.1023/A:1008335701357 Martoni A, 1998, LUNG CANCER-J IASLC, V22, P31, DOI 10.1016/S0169-5002(98)00065-8 Muggia FM, 1997, DRUGS, V54, P22, DOI 10.2165/00003495-199700544-00006 RADICE P, 1999, P AN M AM SOC CLIN, V18, pA520 RAPP E, 1988, J CLIN ONCOL, V6, P633, DOI 10.1200/JCO.1988.6.4.633 ROBINET G, 1997, P AN M AM SOC CLIN, V16, P480 Sakakibara T, 1996, CANCER RES, V56, P3743 Shepherd FA, 2000, J CLIN ONCOL, V18, P2095, DOI 10.1200/JCO.2000.18.10.2095 SIMON R, 1987, CANCER TREAT REP, V71, P1079 WILLIAMS SS, 1993, CANCER RES, V53, P3964 Working PK, 1996, HUM EXP TOXICOL, V15, P751 NR 29 TC 27 Z9 31 U1 0 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0169-5002 EI 1872-8332 J9 LUNG CANCER JI Lung Cancer PD JAN PY 2002 VL 35 IS 1 BP 59 EP 64 AR PII S0169-5002(01)00269-0 DI 10.1016/S0169-5002(01)00269-0 PG 6 WC Oncology; Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Respiratory System GA 525JF UT WOS:000174065200010 PM 11750714 DA 2026-04-17 ER PT J AU Sekine, Y Kesler, KA Behnia, M Brooks-Brunn, J Sekine, E Brown, JW AF Sekine, Y Kesler, KA Behnia, M Brooks-Brunn, J Sekine, E Brown, JW TI COPD may increase the incidence of refractory supraventricular arrhythmias following pulmonary resection for non-small cell lung cancer SO CHEST LA English DT Article DE cardiac arrhythmia; COPD; multivariate analysis; non-small cell lung cancer; postoperative cardiac complications; pulmonary resection ID PROGNOSTIC-SIGNIFICANCE; ATRIAL-FIBRILLATION; THORACIC-SURGERY; RISK-FACTORS; THORACOTOMY; COMPLICATIONS; PNEUMONECTOMY; DYSRHYTHMIAS; OPERATIONS; MORBIDITY AB Purpose: This study investigated the association of COPD and postoperative cardiac arrhythmias, specifically supraventricular tachycardia (SVT), as well as mortality in patients undergoing pulmonary resection for non-small cell lung cancer (NSCLC). Methods: A retrospective chart review of 244 patients who had undergone lung resection for NSCLC at Indiana University Hospital between 1992 and 1997 was undertaken. COPD, which was defined as an FEV1 of less than or equal to 70% predicted and an FEV1/FVC ratio of less than or equal to 70% based on the results of a preoperative pulmonary function test (PFT), was diagnosed in 78 of the 244 patients (COPD group). In the remaining 166 patients, the results of preoperative PFTs did not meet these criteria (non-COPD group). Both groups were otherwise well-matched with respect to multiple variables, including age, comorbid conditions, extent of pulmonary resection, and final pathologic stage. The incidence of cardiac arrhythmias and operative mortality were compared between the two groups using univariate and multivariate analysis. Results: Seventy-six patients (31.9%) experienced new onsets of postoperative SVT, with 58 of these patients (76.3%) demonstrating atrial fibrillation. The COPD group had a 58.7% incidence of SVT (n = 44) compared to a 27.0% incidence (n = 44) in the non-COPD group (p < 0.001). Moreover, following initial digoxin therapy, the COPD group required more second-line antiarrhythmic therapy than did the non-COPD group (66.7% vs 37.8%, respectively; p = 0.003). Overall, there were 16 operative deaths (6.6%), and the mortality rate was significantly higher in the COPD group (14.1%) than in the non-COPD group (3.0%; p = 0.004). Patients who developed SVT had a significantly longer hospital course than did patients who did not (p < 0.0001). Thirteen of the 16 patients who died experienced SVT; however, SVT was not an independent ride factor for death. Finally, of the 19 variables evaluated, major resection (ie, pneumonectomy and bilobectomy) and COPD were identified as independent risk factors for the development of cardiac arrhythmias (p = 0.0 033 and p = 0.0 009, respectively). Conclusion: Patients with COPD, as defined by the results of preoperative PFTs, are at significantly higher risk for SVT, and in particular SVT refractory to digoxin, following pulmonary resection for NSCLC. Although SVT was not an independent risk factor for death, a significantly longer hospitalization was observed. C1 Indiana Univ, Med Ctr, Div Cardiothorac Surg, Indianapolis, IN 46202 USA. Indiana Univ, Med Ctr, Dept Surg, Indianapolis, IN 46202 USA. Indiana Univ, Med Ctr, Dept Med, Indianapolis, IN 46202 USA. Indiana Univ, Med Ctr, Div Pulm Allergy Crit Care & Occupat Med, Indianapolis, IN 46202 USA. C3 Indiana University System; Indiana University Indianapolis; Indiana University System; Indiana University Indianapolis; Indiana University System; Indiana University Indianapolis; Indiana University System; Indiana University Indianapolis RP Kesler, KA (corresponding author), Indiana Univ, Med Ctr, Div Cardiothorac Surg, 545 Barnhill Dr,EH 215, Indianapolis, IN 46202 USA. RI Behnia, Mehrdad/IZQ-2739-2023 CR AMAR D, 1995, CHEST, V108, P349, DOI 10.1378/chest.108.2.349 ASAMURA H, 1993, J THORAC CARDIOV SUR, V106, P1104, DOI 10.1016/S0022-5223(19)33985-6 Bayliff CD, 1999, ANN THORAC SURG, V67, P182, DOI 10.1016/S0003-4975(98)01226-0 Brathwaite D, 1998, CHEST, V114, P462, DOI 10.1378/chest.114.2.462 Brunelli A, 1999, ANN THORAC SURG, V67, P329, DOI 10.1016/S0003-4975(98)00822-4 Buist A S., 1994, Textbook of respiratory medicine, P1259 Cardinale D, 1999, ANN THORAC SURG, V68, P1827, DOI 10.1016/S0003-4975(99)00712-2 Ciriaco P, 2000, EUR J CARDIO-THORAC, V18, P12, DOI 10.1016/S1010-7940(00)00428-0 Curtis JJ, 1998, ANN THORAC SURG, V66, P1766, DOI 10.1016/S0003-4975(98)00942-4 EPSTEIN SK, 1993, CHEST, V104, P694, DOI 10.1378/chest.104.3.694 Gorecka D, 1997, Monaldi Arch Chest Dis, V52, P278 Harpole DH, 1996, ANN THORAC SURG, V61, P977, DOI 10.1016/0003-4975(95)01174-9 JUHL B, 1975, Acta Anaesthesiologica Scandinavica Supplementum, V57, P39 KEARNEY DJ, 1994, CHEST, V105, P753, DOI 10.1378/chest.105.3.753 KROWKA MJ, 1987, CHEST, V91, P490, DOI 10.1378/chest.91.4.490 LINDGREN L, 1991, BRIT J ANAESTH, V66, P205, DOI 10.1093/bja/66.2.205 MARKOS J, 1989, AM REV RESPIR DIS, V139, P902, DOI 10.1164/ajrccm/139.4.902 MORICE RC, 1992, CHEST, V101, P356, DOI 10.1378/chest.101.2.356 OLSEN GN, 1975, AM REV RESPIR DIS, V111, P379 OLSEN GN, 1989, CHEST, V95, P267, DOI 10.1378/chest.95.2.267 Polanczyk CA, 1998, ANN INTERN MED, V129, P279, DOI 10.7326/0003-4819-129-4-199808150-00003 RITCHIE AJ, 1990, ANN THORAC SURG, V50, P86, DOI 10.1016/0003-4975(90)90094-M VanMieghem W, 1996, ANN THORAC SURG, V61, P1083, DOI 10.1016/0003-4975(96)00073-2 VONKNORRING J, 1992, ANN THORAC SURG, V53, P642, DOI 10.1016/0003-4975(92)90325-X ZIBRAK JD, 1990, ANN INTERN MED, V112, P763, DOI 10.7326/0003-4819-112-10-763 NR 25 TC 74 Z9 82 U1 0 U2 6 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD DEC PY 2001 VL 120 IS 6 BP 1783 EP 1790 DI 10.1378/chest.120.6.1783 PG 8 WC Critical Care Medicine; Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC General & Internal Medicine; Respiratory System GA 504EF UT WOS:000172843800010 PM 11742902 DA 2026-04-17 ER PT J AU Oka, T Ozawa, Y Ohkubo, Y AF Oka, T Ozawa, Y Ohkubo, Y TI Thoracic epidural bupivacaine attenuates supraventricular tachyarrhythmias after pulmonary resection SO ANESTHESIA AND ANALGESIA LA English DT Article ID ATRIAL-FIBRILLATION; ARRHYTHMIAS; THORACOTOMY; DOGS; EPINEPHRINE; OPERATIONS; ANESTHESIA; BYPASS AB Supraventricular tachyarrhythmias after pulmonary surgery are well described. Some investigators suggest that tachyarrhythmias after thoracic operations may result from the relative sympathotonic status produced by injury to the cardiac parasympathetic nerves. We examined whether postoperative thoracic sympathetic blockade by thoracic epidural bupivacaine might reduce the tachyarrhythmias after pulmonary resection. Fifty patients with lung cancer were randomized to receive epidural bupivacaine (Group B) or epidural morphine (Group M). Patients in Group B were given 6 to 10 mL of 0.25% bupivacaine epidurally, followed by epidural infusion at 3 to 5 mL/h for 3 days, and patients in Group M were given 2 to 3 mg morphine epidurally, followed by morphine infusion at a rate of 0.2 mg/h. Tachyarrhythmias were diagnosed by using the continuous heart rate trend and arrhythmia trend with a central monitoring system. Postoperative analgesia was not statistically different between groups. However, the incidence of postoperative tachyarrhythmias in Group B was significantly less than in Group M (1 of 23 vs 7 of 25, P = 0.0497, Fisher's exact test). The continuous infusion of thoracic epidural bupivacaine can reduce supraventricular tachyarrhythmias compared with epidural morphine infusion, presumably because of attenuation of the sympathotonic status after pulmonary resection. C1 Tochigi Canc Ctr Hosp, Div Anesthesia, Utsunomiya, Tochigi 3200834, Japan. C3 Tochigi Prefectural Cancer Center RP Oka, T (corresponding author), Tochigi Canc Ctr Hosp, Div Anesthesia, 4-9-13 Yohnan, Utsunomiya, Tochigi 3200834, Japan. CR [Anonymous], 1995, ANESTHESIA THORACIC ASAMURA H, 1993, J THORAC CARDIOV SUR, V106, P1104, DOI 10.1016/S0022-5223(19)33985-6 Balser JR, 1998, ANESTHESIOLOGY, V89, P1052, DOI 10.1097/00000542-199811000-00004 BORGEAT A, 1991, ANN THORAC SURG, V51, P964, DOI 10.1016/0003-4975(91)91016-O Bruelle P, 1996, ANESTH ANALG, V82, P648, DOI 10.1097/00000539-199603000-00038 CHAPIN JC, 1980, ANESTHESIOLOGY, V52, P23, DOI 10.1097/00000542-198001000-00006 Cooklin M, 1998, CURR OPIN CARDIOL, V13, P20, DOI 10.1097/00001573-199801000-00004 Coumel P, 1996, J CARDIOVASC ELECTR, V7, P999, DOI 10.1111/j.1540-8167.1996.tb00474.x COUMEL P, 1990, CLIN CARDIOL, V13, P209, DOI 10.1002/clc.4960130311 HASENBOS M, 1985, ACTA ANAESTH SCAND, V29, P572, DOI 10.1111/j.1399-6576.1985.tb02256.x Jakobsen CJ, 1997, J CARDIOTHOR VASC AN, V11, P746, DOI 10.1016/S1053-0770(97)90169-5 Kalman JM, 1995, ANN THORAC SURG, V60, P1709, DOI 10.1016/0003-4975(95)00718-0 KAMIBAYASHI T, 1995, ANESTHESIOLOGY, V82, P129, DOI 10.1097/00000542-199501000-00017 Kimura T, 1996, ANESTHESIOLOGY, V84, P1068, DOI 10.1097/00000542-199605000-00008 KROWKA MJ, 1987, CHEST, V91, P490, DOI 10.1378/chest.91.4.490 MOWRY FM, 1964, ANN INTERN MED, V61, P688, DOI 10.7326/0003-4819-61-4-688 Oka T, 1999, Masui, V48, P118 OTTENI JC, 1983, ANESTHESIOLOGY, V59, P358, DOI 10.1097/00000542-198310000-00019 Sun LS, 1997, CRIT CARE MED, V25, P1990, DOI 10.1097/00003246-199712000-00015 VONKNORRING J, 1992, ANN THORAC SURG, V53, P642, DOI 10.1016/0003-4975(92)90325-X WYNDHAM CRC, 1982, INT J CARDIOL, V2, P199, DOI 10.1016/0167-5273(82)90033-X YEH SJ, 1989, AM HEART J, V117, P1041, DOI 10.1016/0002-8703(89)90860-0 NR 22 TC 64 Z9 78 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD AUG PY 2001 VL 93 IS 2 BP 253 EP 259 DI 10.1097/00000539-200108000-00003 PG 7 WC Anesthesiology WE Science Citation Index Expanded (SCI-EXPANDED) SC Anesthesiology GA 456YU UT WOS:000170111000003 PM 11473839 DA 2026-04-17 ER PT J AU Joo, JB DeBord, JR Montgomery, CE Munns, JR Marshall, JS Paulsen, JK Anderson, RC Meyer, LE Estes, NC AF Joo, JB DeBord, JR Montgomery, CE Munns, JR Marshall, JS Paulsen, JK Anderson, RC Meyer, LE Estes, NC TI Perioperative factors as predictors of operative mortality and morbidity in pneumonectomy SO AMERICAN SURGEON LA English DT Article; Proceedings Paper CT 43rd Annual Meeting of the Midwest-Surgical-Association CY AUG 13-16, 2000 CL MACKINAC ISL, MICHIGAN SP Midwest Surg Assoc ID LUNG-CANCER AB Pneumonectomy for lung cancer is associated with significant morbidity and mortality. Risk factors for the morbidity and mortality have been reported, but consistent conclusive data are undetermined. Current accepted 30-day mortality rates for pneumonectomy range from 7 to 11 per cent. The objective of this study is to determine whether various perioperative factors can serve as predictors of morbidity and mortality in pneumonectomy patients and to review outcome data on patients undergoing pneumonectomy for lung cancer. A total of 105 patients undergoing pneumonectomy for lung cancer from 1988 through 1998 are studied in a retrospective chart review. The main outcome measure is the 30-day operative mortality and morbidity, Complications occurring in 10 per cent or more of the patients included atrial fibrillation (33.3%), respiratory failure (23.8%), pneumonia (21.9%), and bronchopleural fistula (12.4%). The 30-day mortality rate was 10.5 per cent (11 deaths). By Fisher's exact test for Chi-square only three statistically significant mortality factors were identified: respiratory failure (P < 0.021), sepsis (P < 0.008), and male sex (P < 0.031); respiratory failure, sepsis, and sex were predictors of death. Significant correlation could not be made to predict postoperative morbidity, Overall long-term clinical outcome for pneumonectomy as lung cancer treatment was poor. Clinical judgment remains an essential factor when considering pneumonectomy as an option for lung cancer treatment. C1 Univ Illinois, Coll Med, Dept Surg, Peoria, IL 61603 USA. C3 University of Illinois System; University of Illinois Peoria RP DeBord, JR (corresponding author), Univ Illinois, Coll Med, Dept Surg, 420 NE Glen Oak,Suite 301, Peoria, IL 61603 USA. OI Meyer, Lynne/0000-0003-0043-5699 CR ALKATTAN K, 1995, EUR J CARDIO-THORAC, V9, P479, DOI 10.1016/S1010-7940(95)80045-X Ferguson M K, 1999, Chest Surg Clin N Am, V9, P339 GINSBERG RJ, 1983, J THORAC CARDIOV SUR, V86, P654 Graham EA, 1933, J AMER MED ASSOC, V101, P1371, DOI 10.1001/jama.1933.02740430017005 Kopec SE, 1998, CHEST, V114, P1158, DOI 10.1378/chest.114.4.1158 Mitsudomi T, 1996, J SURG ONCOL, V61, P218, DOI 10.1002/(SICI)1096-9098(199603)61:3<218::AID-JSO11>3.3.CO;2-Q ROMANO PS, 1992, CHEST, V101, P1332, DOI 10.1378/chest.101.5.1332 Swartz DE, 1997, CAN J SURG, V40, P437 TURNAGE WS, 1993, CHEST, V103, P1646, DOI 10.1378/chest.103.6.1646 NR 9 TC 22 Z9 26 U1 0 U2 1 PU SOUTHEASTERN SURGICAL CONGRESS PI ATLANTA PA 141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA SN 0003-1348 J9 AM SURGEON JI Am. Surg. PD APR PY 2001 VL 67 IS 4 BP 318 EP 321 PG 4 WC Surgery WE Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED) SC Surgery GA 419ZK UT WOS:000167979300007 PM 11307996 DA 2026-04-17 ER PT J AU Gridelli, C Cigolari, S Gallo, C Manzione, L Ianniello, GP Frontini, L Ferraù, F Robbiati, SF Adamo, V Gasparini, G Novello, S Perrone, F AF Gridelli, C Cigolari, S Gallo, C Manzione, L Ianniello, GP Frontini, L Ferraù, F Robbiati, SF Adamo, V Gasparini, G Novello, S Perrone, F CA MILES Investigators TI Activity and toxicity of gemcitabine and gemcitabine plus vinorelbine in advanced non-small-cell lung cancer elderly patients -: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial SO LUNG CANCER LA English DT Article DE NSCLC; elderly; chemotherapy; gemcitabine; vinorelbine; randomised phase II study ID SURVIVAL; AGE AB Background: Following the demonstration that vinorelbine improves survival and quality of life compared with best supportive care in elderly patients with advanced non-small-cell lung cancer (NSCLC), we started the three-arm prospective Multicenter Italian Lung Cancer in the Elderly Study (MILES) trial of vinorelbine, gemcitabine and gemcitabine + vinorelbine. Design: Within the randomized phase 3 trial. pilot single-stage phase 2 studies were planned for gemcitabine and for gemcitabine + vinorelbine. Eligible patients are aged 70 or more, with stage IV or IIIb (with metastatic supraclavear nodes or malignant pleural effusion) NSCLC. Single-agent gemcitabine is given at 1200 mg/m(2) on days 1 and 8: in the combination, gemcitabine is given at 1000 mg/m(2) and vinorelbine at 25 mg/m(2), both on days and 8. every 3 weeks. Results: As planned 49 patients were enrolled in each group. Median age was 74 in both groups. Two-thirds of patients had stage IV disease. The response rate was 18.4% (95% exact CI 8.8-32.0) with both treatments. With single-agent gemcitabine: main toxicities: were grade 4 thrombocytopenia and grade 2 hepatic toxicity. in one patient each. and grade 2 pulmonary toxicity in two patients. With gemcitabine + vinorelbine combination there were grade 4 neutropenia and thrombocytopenia tone patient each). grade 3 anemia requiring red blood cell transfusion (two patients), and grade 4 fever in two patients. Four patients, with severe cardiac comorbidities. suffered grade 3 heart toxicity with atrial flutter or fibrillation, followed by congestive heart failure responsive to treatment. Conclusion: Both single-agent gemcitabine and the gemcitabine + vinorelbine combination are sufficiently active and tolerable to allow continuation of the MILES study. (C) 2001 Elsevier science Ireland Ltd. All rights reserved. C1 Ist Nazl Studio & Cura Tumori, Div Oncol Med B, I-80131 Naples, Italy. RP Gridelli, C (corresponding author), Ist Nazl Studio & Cura Tumori, Div Oncol Med B, Via M Semmola, I-80131 Naples, Italy. RI Perrone, Francesco/AAB-8283-2022; GALLO, CIRO/AAA-9241-2019; novello, silvia/K-6335-2016; Gridelli, Cesare/AAA-8621-2019 OI терехова, дарина/0009-0007-2262-899X; GALLO, CIRO/0000-0002-7939-3104; CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365 ALBERTI W, 1995, BRIT MED J, V311, P899 BERGMAN B, 1994, EUR J CANCER, V30A, P635, DOI 10.1016/0959-8049(94)90535-5 Feliu J, 1999, CANCER-AM CANCER SOC, V86, P1463, DOI 10.1002/(SICI)1097-0142(19991015)86:8<1463::AID-CNCR12>3.0.CO;2-N Gridelli C, 1999, JNCI-J NATL CANCER I, V91, P66 Gridelli C, 1997, EUR J CANCER, V33, P392, DOI 10.1016/S0959-8049(96)00471-6 Gridelli C, 2000, BRIT J CANCER, V83, P707, DOI 10.1054/bjoc.2000.1341 Hutchins LF, 1999, NEW ENGL J MED, V341, P2061, DOI 10.1056/NEJM199912303412706 Martin C, 1997, AGING-CLIN EXP RES, V9, P297, DOI 10.1007/BF03341832 MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 Monfardini S, 1996, CANCER-AM CANCER SOC, V77, P395, DOI 10.1002/(SICI)1097-0142(19960115)77:2<395::AID-CNCR24>3.0.CO;2-W SHEPHERD FA, 1997, SEMIN ONCOL S7, V24, P50 Vercelli M, 1997, TUMORI, V83, P490, DOI 10.1177/030089169708300111 Vercelli M, 1998, EUR J CANCER, V34, P2264, DOI 10.1016/S0959-8049(98)00325-6 NR 14 TC 107 Z9 118 U1 0 U2 3 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0169-5002 J9 LUNG CANCER-J IASLC JI Lung Cancer PD FEB-MAR PY 2001 VL 31 IS 2-3 BP 277 EP 284 DI 10.1016/S0169-5002(00)00194-X PG 8 WC Oncology; Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Respiratory System GA 401AQ UT WOS:000166905100021 PM 11165408 DA 2026-04-17 ER PT J AU Illiano, A Barletta, E De Marino, V Battiloro, C Barzelloni, M Scognamiglio, F Rossi, N Zampa, G De Bellis, M Gridelli, C AF Illiano, A Barletta, E De Marino, V Battiloro, C Barzelloni, M Scognamiglio, F Rossi, N Zampa, G De Bellis, M Gridelli, C TI New triplet chemotherapy combination with carboplatin, paclitaxel and gemcitabine plus amifostine support in advanced non small cell lung cancer: a phase II study SO ANTICANCER RESEARCH LA English DT Article DE non small cell lung cancer; new triplet chemotherapy combination; amifostine; phase II study ID ONCOLOGY-GROUP; CISPLATIN; TRIAL; VINORELBINE; ETOPOSIDE AB New triplet chemotherapy combinations are under investigation in advanced non small cell lung cancer (NSCLC). Carboplatin, plus paclitaxel, plus gemcitabine is among the most active and promising regimens. The use of more aggressive chemotherapy in order to improve results can increase toxicity. Amifostine (WR-2721) reduces toxicity of radiotherapy and chemotherapy and protects selectively a number of normal but not neoplastic, tissue. Based on this background, we performed a phase II study on carboplatin, plus paclitaxel, plus gemcitabine with amifostine support in advanced NSCLC. Patients received chemotherapy at the following dosage: carboplatin AUC 5 i.v., at day 1; paclitaxel 175 mg/m(2), iv. by 3-hour infusion, at day 1; gemcitabine 1000 mg/m(2) iv. by 3-hour infusion, at days 1 and 8; every 3 weeks for a maximum of 6 cycles. Amifostine was administered at the dose of 740 mg/m(2), i.v., at day 1 of each cycle. Seventeen patients entered the study. They were prevalently male, median age was 62 years, PS (ECOG) was 0 in 10 cases (58.8%), 1 in 6 (35.3%) and 2 in 1 (5.9%). Histology was epidermoid in 8 cases (47%) and adenocarcinoma in 9 (53%). We observed 8 (47.5%) objective responses with 2 (11.7%) complete responses. Median time to progression and median survival were 24 and 36 weeks, respectively. Treatment was well tolerated. The main toxicity was as follows: grade 3 neutropenia, grade 2 thrombocytopenia and grade 3 anemia in one (5.8%) case; grade 2 peripheral neurologic toxicity in 3 (17.6%) patients; grade 2 cardiac toxicity (atrial fibrillation) in one case; and grade 3 respiratory toxicity (dispnoea) in one patient. These data indicate that this combination has promising activity and tolerability. A randomized trial comparing carboplatin plus paclitaxel, plus gemcitabine versus carboplatin, plus paclitaxel, plus gemcitabine, plus amifostine in advanced NSCLC is warranted. C1 Ist Nazl Tumori, Div Oncol Med B, I-80131 Naples, Italy. Osped Monaldi, Div Pneumol 6, Naples, Italy. Ist Nazl Tumori, Div Chirurg Torac, Naples, Italy. Osped Civile, Div Med, Polla, SA, Italy. Osped S Giacomo ASL RMA, Serv Oncol, Rome, Italy. Ist Nazl Tumori, Serv Endoscopia, Naples, Italy. RP Gridelli, C (corresponding author), Ist Nazl Tumori, Div Oncol Med B, Via M Semmola 3, I-80131 Naples, Italy. EM cgridelli@sirio-oncology.it RI Gridelli, Cesare/AAA-8621-2019 CR BETTICHER DC, 1995, BRIT J CANCER, V72, P1551, DOI 10.1038/bjc.1995.546 Bonomi P, 2000, J CLIN ONCOL, V18, P623, DOI 10.1200/JCO.2000.18.3.623 Bunn PA, 1998, SEMIN ONCOL, V25, P55 CAPIZZI RL, 1995, EJC SUPPL, V31, P58 Cardenal F, 1999, J CLIN ONCOL, V17, P12, DOI 10.1200/JCO.1999.17.1.12 Comella P, 1999, J CLIN ONCOL, V17, P1526, DOI 10.1200/JCO.1999.17.5.1526 CRINO L, 1995, ANN ONCOL, V6, P347, DOI 10.1093/oxfordjournals.annonc.a059183 Crinò L, 1999, J CLIN ONCOL, V17, P3522, DOI 10.1200/JCO.1999.17.11.3522 DORTA J, 1998, P AN M AM SOC CLIN, V17, pA482 Favaretto A, 1998, ANN ONCOL, V9, P91 FISHMAN DA, 1998, P AN M AM SOC CLIN, V17, pA417 Frasci G, 1999, J CLIN ONCOL, V17, P2316, DOI 10.1200/JCO.1999.17.8.2316 Giaccone G, 1998, J CLIN ONCOL, V16, P2133, DOI 10.1200/JCO.1998.16.6.2133 Ginopoulos P, 1999, LUNG CANCER-J IASLC, V23, P31, DOI 10.1016/S0169-5002(98)00091-9 GONZALESBARON M, 1998, P AN M AM SOC CLIN, V17, pA469 GRIDELLI C, IN PRESS LUNG CANC HAINSWORTH JD, 1998, P AN M AM SOC CLIN, V17, pA471 KELLY K, 1998, P AN M AM SOC CLIN, V17, pA490 Kemp G, 1996, J CLIN ONCOL, V14, P2101, DOI 10.1200/JCO.1996.14.7.2101 LECHEVALIER T, 1994, J CLIN ONCOL, V12, P360, DOI 10.1200/JCO.1994.12.2.360 MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 *NONSM CELL LUNG C, 1999, BRIT MED J, V311, P899 PETERS GJ, 1995, EJC SUPPL, V31, P1 Schiller JH, 1996, J CLIN ONCOL, V14, P1913, DOI 10.1200/JCO.1996.14.6.1913 Sorensen JB, 1999, ANN ONCOL, V10, P1043, DOI 10.1023/A:1008352900990 YUHAS JM, 1980, CANCER CLIN TRIALS, V3, P211 NR 26 TC 13 Z9 18 U1 0 U2 1 PU INT INST ANTICANCER RESEARCH PI ATHENS PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE SN 0250-7005 EI 1791-7530 J9 ANTICANCER RES JI Anticancer Res. PD SEP-OCT PY 2000 VL 20 IS 5C BP 3999 EP 4003 PG 5 WC Oncology WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology GA 379GT UT WOS:000165634200062 PM 11268491 DA 2026-04-17 ER PT J AU Ciriaco, P Mazzone, P Canneto, B Zannini, P AF Ciriaco, P Mazzone, P Canneto, B Zannini, P TI Supraventricular arrhythmia following lung resection for non-small cell lung cancer and its treatment with amiodarone SO EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY LA English DT Article; Proceedings Paper CT 13th Annual Meeting of the European-Association-for-Cardio-Thoracic-Surgery CY SEP 05-08, 1999 CL GLASGOW, SCOTLAND SP European Assoc Cardio Thorac Surg DE lung cancer; supraventricular arrhythmia; amiodarone; thoracotomy ID THORACIC OPERATIONS; ATRIAL-FIBRILLATION; RISK-FACTORS; PNEUMONECTOMY; DYSRHYTHMIAS; PREVENTION; DILTIAZEM; INFUSION; DIGOXIN; SURGERY AB Objective: From January 1998 to February 1999, 160 patients undergoing lung resection for non-small cell lung cancer were studied to define factors that increase the risk of postoperative supraventricular arrhythmia (SA) and to assess the effectiveness of amiodarone as an antiarrhythmic drug. Methods: All patients were monitored intraoperatively and postoperatively up to day 3. Onset of SA was documented with EGG. Amiodarone was administered to those who developed SA with a loading dose of 5 mg/kg in 30 min and a maintenance dose of 15 mg/kg in 24 h. Results: Mean age was 64 years (range 27-83 years). There were nine wedge resections, six segmentectomies, 127 lobectomies and 18 pneumonectomies. Twenty-two patients (13%) had SA, all of which were atrial fibrillations. The incidence of supraventricular arrhythmia with pneumonectomy and lobectomy was 33 and 12%, respectively (P = 0.02). None of the patients who had a minor resection developed SA. The peak incidence of onset of SA occurred on postoperative day 2 and lasted from 1 to 12 days (average 3.4 days). Sinus rhythm was achieved with amiodarone in 20 patients (90.9%) with no side effects. Two patients received electrical cardioversion because hemodynamically unstable. Mean preoperative pO(2) and pCO(2) were lower in patients with SA: pO(2) 80.8 vs. 85 mmHg (P = 0.04); pCO(2) 35.5 vs. 38 mmHg (P = 0.01). Patients with concomitant cardiopulmonary diseases presented an odds ratio for postoperative arrhythmia of 12.4 (confidence interval 4.5-34.1) (P < 0.0001). Conclusion: Concomitant cardiopulmonary diseases, lower pO(2), pCO(2) and extent of surgery increase the risk of postoperative SA after lung resection for non-small cell lung cancer. Cardiac monitoring in patients at risk is recommended. Amiodarone was both safe and effective in establishing and maintaining sinus rhythm. (C) 2000 Elsevier Science B.V. All rights reserved. C1 Univ Milan, San Raffaele Sci Inst, Div Thorac Surg, I-20132 Milan, Italy. Univ Milan, San Raffaele Sci Inst, Div Cardiol, I-20132 Milan, Italy. C3 University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele RP Ciriaco, P (corresponding author), Univ Milan, San Raffaele Sci Inst, Div Thorac Surg, Via Olgettina 60, I-20132 Milan, Italy. RI Ciriaco, Paola/H-5716-2012; Mazzone, Patrizio/HHC-7625-2022 OI Ciriaco, Paola/0000-0001-5421-7676; CR Amar D, 1997, ANN THORAC SURG, V63, P1374 ASAMURA H, 1993, J THORAC CARDIOV SUR, V106, P1104, DOI 10.1016/S0022-5223(19)33985-6 BORGEAT A, 1991, ANN THORAC SURG, V51, P964, DOI 10.1016/0003-4975(91)91016-O Curtis JJ, 1998, ANN THORAC SURG, V66, P1766, DOI 10.1016/S0003-4975(98)00942-4 DOVAL HC, 1994, LANCET, V344, P493, DOI 10.1016/S0140-6736(94)91895-3 ELLENBOGEN KA, 1991, J AM COLL CARDIOL, V18, P891, DOI 10.1016/0735-1097(91)90743-S GRABOYS TB, 1983, AM HEART J, V106, P870, DOI 10.1016/0002-8703(83)90009-1 Harpole DH, 1996, ANN THORAC SURG, V61, P977, DOI 10.1016/0003-4975(95)01174-9 KEAGY BA, 1985, ANN THORAC SURG, V40, P39 KERIN NZ, 1988, CLIN CARDIOL, V11, P31 KROWKA MJ, 1987, CHEST, V91, P490, DOI 10.1378/chest.91.4.490 RICHIE AJ, 1990, ANN THORAC SURG, V50, P86 Terzi A, 1996, THORAC CARDIOV SURG, V44, P300, DOI 10.1055/s-2007-1012041 VanMieghem W, 1996, ANN THORAC SURG, V61, P1083, DOI 10.1016/0003-4975(96)00073-2 VANMIEGHEM W, 1994, CHEST, V105, P1642, DOI 10.1378/chest.105.6.1642 VONKNORRING J, 1992, ANN THORAC SURG, V53, P642, DOI 10.1016/0003-4975(92)90325-X WEI JY, 1992, NEW ENGL J MED, V327, P1735, DOI 10.1056/NEJM199212103272408 NR 17 TC 37 Z9 41 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1010-7940 J9 EUR J CARDIO-THORAC JI Eur. J. Cardio-Thorac. Surg. PD JUL PY 2000 VL 18 IS 1 BP 12 EP 16 DI 10.1016/S1010-7940(00)00428-0 PG 5 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 344GR UT WOS:000088751300003 PM 10869934 OA Bronze DA 2026-04-17 ER PT J AU Cardinale, D Martinoni, A Cipolla, CM Civelli, M Lamantia, G Fiorentini, C Mezzetti, M AF Cardinale, D Martinoni, A Cipolla, CM Civelli, M Lamantia, G Fiorentini, C Mezzetti, M TI Atrial fibrillation after operation for lung cancer: Clinical and prognostic significance SO ANNALS OF THORACIC SURGERY LA English DT Article ID CARDIAC DYSRHYTHMIAS; THORACIC OPERATIONS; RISK-FACTORS; ARRHYTHMIAS; SURGERY; PNEUMONECTOMY; THORACOTOMY; RESECTION; PATHOLOGY; MORBIDITY AB Background. Atrial fibrillation is a common complication of early postoperative period in lung cancer thoracotomy. Its clinical incidence and short- and long-term impact on overall mortality has never been definitely assessed; moreover, it is unclear whether the arrhythmia represents an independent cardiac risk factor. Methods. We prospectively studied 233 consecutive patients undergoing operation for lung cancer (170 with non-small-cell lung cancer). Postoperative atrial fibrillation incidence was related to different clinical factors possibly involved in its occurrence and to both short- and long-term survival. Results. Atrial fibrillation occurred in 28 patients (12%) (same percentage in non-small-cell lung cancer); a strong relationship was observed between arrhythmia and age, history of hypertension and associated lymph node resection. The mean hospitalization time was 14 +/- 4 days in patients developing atrial fibrillation and 13 +/- 4 days in those who did not (p = not significant). No difference was observed between the two groups with regard to short- or long-term mortality or to long-term atrial fibrillation recurrences, also when considering the entire population and only non-small-cell lung cancer, separately. Conclusions. At our institution, early atrial fibrillation occurrence after operation for lung cancer does not show any negative impact on short- and long-term mortality or on recurrence rate. (C) 1999 by The Society of Thoracic Surgeons. C1 Univ Milan, Cardiol Unit, Ist Europeo Oncol, Ist Ricovero & Cura,Carattere Sci, I-20141 Milan, Italy. Univ Milan, Thorac Surg Div, Ist Europeo Oncol, Ist Ricovero & Cura,Carattere Sci, I-20141 Milan, Italy. C3 University of Milan; IRCCS European Institute of Oncology (IEO); IRCCS European Institute of Oncology (IEO); University of Milan RP Cardinale, D (corresponding author), Univ Milan, Cardiol Unit, Ist Europeo Oncol, Ist Ricovero & Cura,Carattere Sci, Via Ripamonti 435, I-20141 Milan, Italy. RI Lamantia, Giuseppina/AAP-9965-2020; Civelli, Maurizio/AAO-3674-2020; CARDINALE, DANIELA/AAN-1675-2020; Martinoni, Alessandro/HHC-5847-2022 OI CARDINALE, DANIELA/0000-0002-4038-8033; CR AMAR D, 1995, CHEST, V108, P349, DOI 10.1378/chest.108.2.349 Amar D, 1996, CHEST, V110, P437, DOI 10.1378/chest.110.2.437 Aranki SF, 1996, CIRCULATION, V94, P390, DOI 10.1161/01.CIR.94.3.390 ASAMURA H, 1993, J THORAC CARDIOV SUR, V106, P1104, DOI 10.1016/S0022-5223(19)33985-6 BORGEAT A, 1991, ANN THORAC SURG, V51, P964, DOI 10.1016/0003-4975(91)91016-O BURT M, 1995, GLENNS THORACIC CARD, P421 CRESWELL LL, 1993, ANN THORAC SURG, V56, P539, DOI 10.1016/0003-4975(93)90894-N DAVIES MJ, 1972, BRIT HEART J, V34, P520 GHOSH P, 1972, BRIT HEART J, V34, P374 GOLDMAN L, 1992, HEART DIS TXB CARDIO, P1708 Harpole DH, 1996, ANN THORAC SURG, V61, P977, DOI 10.1016/0003-4975(95)01174-9 KEARNEY DJ, 1994, CHEST, V105, P753, DOI 10.1378/chest.105.3.753 KIRSH MM, 1975, ANN THORAC SURG, V20, P215, DOI 10.1016/S0003-4975(10)63878-7 KROWKA MJ, 1987, CHEST, V91, P490, DOI 10.1378/chest.91.4.490 LIE JT, 1988, MAYO CLIN PROC, V63, P552, DOI 10.1016/S0025-6196(12)64885-X LINDGREN L, 1991, BRIT J ANAESTH, V66, P205, DOI 10.1093/bja/66.2.205 MARK JBD, 1966, J THORAC CARDIOV SUR, V51, P30, DOI 10.1016/S0022-5223(19)43270-4 RITCHIE AJ, 1992, THORAX, V47, P41, DOI 10.1136/thx.47.1.41 VanMieghem W, 1996, ANN THORAC SURG, V61, P1083, DOI 10.1016/0003-4975(96)00073-2 VANMIEGHEM W, 1994, CHEST, V105, P1642, DOI 10.1378/chest.105.6.1642 VONKNORRING J, 1992, ANN THORAC SURG, V53, P642, DOI 10.1016/0003-4975(92)90325-X WAHI R, 1989, ANN THORAC SURG, V48, P33, DOI 10.1016/0003-4975(89)90172-0 NR 22 TC 76 Z9 83 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD NOV PY 1999 VL 68 IS 5 BP 1827 EP 1831 DI 10.1016/S0003-4975(99)00712-2 PG 5 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 259HF UT WOS:000083887900053 PM 10585066 OA Bronze DA 2026-04-17 ER PT J AU Neustein, SM Kahn, P Krellenstein, DJ Cohen, E AF Neustein, SM Kahn, P Krellenstein, DJ Cohen, E TI Incidence of arrhythmias after thoracic surgery: Thoracotomy versus video-assisted thoracoscopy SO JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA LA English DT Article DE thoracotomy; video-assisted thoracoscopy; thoracic surgery; arrhythmias; supraventricular tachycardia; atrial fibrillation ID PROPHYLACTIC DIGITALIZATION; ATRIAL-FIBRILLATION; LUNG-CANCER; PNEUMONECTOMY; COMPLICATIONS; OPERATIONS; VERAPAMIL AB Purpose: Atrial arrhythmias, especially supraventricular tachycardia (SVT) and atrial fibrillation, are common after thoracotomy and lung surgery. There are few existing data on the incidence of postoperative arrhythmias after video-assisted thoracoscopy (VAT). The purpose of the present investigation was to retrospectively determine the incidence of postoperative arrhythmias in patients who underwent VAT compared with those who underwent thoracotomy, and which factors are associated with an increased risk for arrhythmias in both groups. Design: A retrospective investigation. Setting: A metropolitan university hospital. Participants: The medical records of 124 patients who underwent thoracotomy and 81 patients who underwent VAT over a 2-year period were reviewed. Measurements and Main Results: There was a 17% incidence of atrial arrhythmias after thoracotomy and 10% after VAT, but the difference was not statistically significant. In both groups, atrial fibrillation was the most common atrial arrhythmia. Conclusion: Patients receiving digoxin were at higher risk for postoperative arrhythmias. Patients older than 65 years were at risk for arrhythmias after thoracotomy and patients older than 80 years were at risk for arrhythmias after VAT. Patients who had postoperative arrhythmias had prolonged hospital stays compared with patients who did not have arrhythmias. Copyright (C) 1998 by W.B. Saunders Company. C1 CUNY, Mt Sinai Med Ctr, Dept Anesthesiol, New York, NY 10029 USA. C3 City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai RP Neustein, SM (corresponding author), CUNY, Mt Sinai Med Ctr, Dept Anesthesiol, 1 Gustave L Levy Pl,Box 1010, New York, NY 10029 USA. CR AMAR D, 1995, CHEST, V108, P349, DOI 10.1378/chest.108.2.349 Bailey CC, 1943, NEW ENGL J MED, V229, P356, DOI 10.1056/NEJM194308262290902 BECKNIEL.J, 1973, ACTA MED SCAND, V193, P425 DEVA AK, 1994, AUST NZ J SURG, V64, P705, DOI 10.1111/j.1445-2197.1994.tb02063.x Harpole DH, 1996, ANN THORAC SURG, V61, P977, DOI 10.1016/0003-4975(95)01174-9 Jaklitsch MT, 1996, CHEST, V110, P751, DOI 10.1378/chest.110.3.751 Jakobsen CJ, 1997, J CARDIOTHOR VASC AN, V11, P746, DOI 10.1016/S1053-0770(97)90169-5 KAISER LR, 1993, ANN THORAC SURG, V56, P796, DOI 10.1016/0003-4975(93)90983-O LINDGREN L, 1991, BRIT J ANAESTH, V66, P205, DOI 10.1093/bja/66.2.205 MACK MJ, 1992, ANN THORAC SURG, V54, P403, DOI 10.1016/0003-4975(92)90428-7 Mitsudomi T, 1996, J SURG ONCOL, V61, P218, DOI 10.1002/(SICI)1096-9098(199603)61:3<218::AID-JSO11>3.3.CO;2-Q MOWRY FM, 1964, ANN INTERN MED, V61, P688, DOI 10.7326/0003-4819-61-4-688 RITCHIE AJ, 1990, ANN THORAC SURG, V50, P86, DOI 10.1016/0003-4975(90)90094-M RITCHIE AJ, 1993, ANN THORAC SURG, V55, P86, DOI 10.1016/0003-4975(93)90478-Z SHIELDS TW, 1968, SURG GYNECOL OBSTETR, V126, P743 VanMieghem W, 1996, ANN THORAC SURG, V61, P1083, DOI 10.1016/0003-4975(96)00073-2 VONKNORRING J, 1992, ANN THORAC SURG, V53, P642, DOI 10.1016/0003-4975(92)90325-X NR 17 TC 12 Z9 12 U1 0 U2 1 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 1053-0770 J9 J CARDIOTHOR VASC AN JI J. Cardiothorac. Vasc. Anesth. PD DEC PY 1998 VL 12 IS 6 BP 659 EP 661 DI 10.1016/S1053-0770(98)90238-5 PG 3 WC Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease WE Science Citation Index Expanded (SCI-EXPANDED) SC Anesthesiology; Cardiovascular System & Cardiology; Respiratory System GA 146HX UT WOS:000077424200010 PM 9854663 DA 2026-04-17 ER PT J AU Dudgeon, DJ Lertzman, M AF Dudgeon, DJ Lertzman, M TI Dyspnea in the advanced cancer patient SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE dyspnea; etiology; terminal cancer patients ID MANAGEMENT; PAIN; BREATHLESSNESS; MECHANISMS; SYMPTOMS; DISEASE AB Optimal management of dyspnea in terminal cancer patients requires an understanding of the responsible pathophysiological mechanisms. This prospective study assessed visual analogue scales (VAS) of shortness of breath (SOB) and anxiety, bedside spirometry, maximum inspiratory pressure (MIP), chest radiography, arterial blood gases, hemoglobin, and electrocardiogram, if indicated, in 100 terminally ill cancer patients. Forty-nine percent of the patients had lung cancer. The median VAS scores for SOB and anxiety were 53 mm and 29 mm, respectively. Spirometry was abnormal in 93% of patients, with 5% having obstructive, 41% restrictive, and 47% mixed patterns. The median MIP was -16 cm H2O. Sixty-five percent of the patients had parenchymal or pleural involvement on chest radiograph. Twenty-nine percent had evidence of cardiac ischemia, recent or current myocardial infarction or atrial fibrillation. Patients had a median of five different abnormalities that could have contributed to their shortness of breath. Only anxiety (p = 0.001), a history smoking (p = 0.02), and pCO(2) levels were statistically significantly correlated with SOB VAS scores. The potentially correctable causes of dyspnea included hypoxia (40%), anemia (20%), and bronchospasm (52%). The finding of very low MIPs suggests severe respiratory muscle weakness may contribute significantly to dyspnea in this patient population. Further studies are needed to confirm this finding and characterize the underlying pathophysiology. (C) U.S. Cancer Pain Relief Committee, 1998. C1 Queens Univ, Dept Internal Med, Kingston, ON K7L 3N6, Canada. St Boniface Gen Hosp, Sect Resp Med, Winnipeg, MB, Canada. Univ Manitoba, Dept Internal Med, Winnipeg, MB, Canada. C3 Queens University - Canada; University of Manitoba; Saint Boniface Hospital; Children's Hospital Research Institute of Manitoba (CHRIM); University of Manitoba RP Dudgeon, DJ (corresponding author), Queens Univ, Dept Internal Med, Room 2025,Etherington Hall,Stuart St, Kingston, ON K7L 3N6, Canada. CR AHLES TA, 1984, J PSYCHOSOM RES, V28, P121, DOI 10.1016/0022-3999(84)90004-7 AHMEDZAI S, 1988, RESPIR DIS PRACT OCT, P20 ALTOSE MD, 1985, CHEST, V88, pS77, DOI 10.1378/chest.88.2.77S CARRIERI VK, 1984, HEART LUNG, V13, P436 CHERNIACK NS, 1987, CLIN CHEST MED, V8, P207 Cohen J., 1988, STAT POWER ANAL BEHA, V2nd, P75, DOI DOI 10.1016/B978-0-12-179060-8.50008-6 CONGLETON J, 1995, RESP MED, V89, P291, DOI 10.1016/0954-6111(95)90090-X Cowcher K, 1990, J Pain Symptom Manage, V5, P320, DOI 10.1016/0885-3924(90)90048-O Curtis E B, 1991, J Palliat Care, V7, P25 DUDGEON D, 1996, P AN M AM SOC CLIN, V15, P165 Dudgeon DJ, 1996, HEMATOL ONCOL CLIN N, V10, P157, DOI 10.1016/S0889-8588(05)70332-4 EAKIN EG, 1993, QUAL LIFE RES, V2, P181, DOI 10.1007/BF00435222 Fainsinger R, 1991, J Palliat Care, V7, P5 Fishbein D, 1989, J Pain Symptom Manage, V4, P76, DOI 10.1016/0885-3924(89)90027-4 FREEDMAN S, 1992, BREATHLESSNESS, P117 GROSSMAN SA, 1991, J PAIN SYMPTOM MANAG, V6, P53, DOI 10.1016/0885-3924(91)90518-9 HEYSE-MOORE L H, 1991, Palliative Medicine, V5, P20, DOI 10.1177/026921639100500105 HEYSEMOORE LH, 1989, BRIT J CLIN PRACT, V43, P273 HIGGINSON I, 1989, J ROY SOC MED, V82, P264, DOI 10.1177/014107688908200507 HOWELL J, 1992, BREATHLESSNESS, P149 KELLNER R, 1992, GEN HOSP PSYCHIAT, V14, P20, DOI 10.1016/0163-8343(92)90022-3 MAHLER DA, 1987, CLIN CHEST MED, V8, P215 Mancini DM, 1992, HEART FAILURE, V8, P183 MANNING HL, 1995, NEW ENGL J MED, V333, P1547, DOI 10.1056/NEJM199512073332307 MUERS MF, 1993, THORAX, V48, P339, DOI 10.1136/thx.48.4.339 REUBEN DB, 1986, CHEST, V89, P234, DOI 10.1378/chest.89.2.234 SCHWARTZSTEIN RM, 1990, LUNG, V168, P185, DOI 10.1007/BF02719692 SIMON PM, 1990, AM REV RESPIR DIS, V142, P1009, DOI 10.1164/ajrccm/142.5.1009 TOBIN MJ, 1990, ARCH INTERN MED, V150, P1604, DOI 10.1001/archinte.150.8.1604 TWYCROSS RG, 1990, THERAPEUTICS TERMINA NR 30 TC 109 Z9 112 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD OCT PY 1998 VL 16 IS 4 BP 212 EP 219 DI 10.1016/S0885-3924(98)00065-7 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology WE Science Citation Index Expanded (SCI-EXPANDED) SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 130KT UT WOS:000076519800002 PM 9803048 OA Bronze DA 2026-04-17 ER PT J AU Dyszkiewicz, W Skrzypczak, M AF Dyszkiewicz, W Skrzypczak, M TI Atrial fibrillation after surgery of the lung: clinical analysis of risk factors SO EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY LA English DT Article; Proceedings Paper CT 11th Annual Meeting of the European-Association-for-Cardio-Thoracic-Surgery CY SEP 28-OCT 01, 1997 CL COPENHAGEN, DENMARK SP European Assoc Cardio Thorac Surg DE surgery of the lung; postoperative supraventricular arrhythmia ID THORACOTOMY; CANCER AB Objective: The aim of this study was to determine which of the clinical parameters are the most valuable in predicting postoperative atrial fibrillation after lung surgery. Materials and methods: Retrospective analysis was carried out on 298 patients after pulmonary resection necessitated mainly by lung cancer. The following parameters were investigated: age and sex, disturbances of cardiac rhythm, history of ischemic heart disease, diabetes and atherosclerosis, NYHA classification and type of surgical procedure. In addition, the duration of surgery, variations in oxygen saturation, changes in systemic blood pressure and heart-rate were noted intraoperatively. Statistical analysis was performed using Fisher's exact test. Results and conclusions: Atrial fibrillation occurred in 25 cases (8.4%) and more frequently after pneumonectomy (24%). Other factors contributing to atrial fibrillation after lung surgery were: history of ischemic heart disease, congestive heart failure, intraoperative cardiac arrest and the need for rethoracotomy. (C) 1998 Published by Elsevier Science B.V. All rights reserved. C1 Karol Marcinkowski Univ Med Sci, Dept Thorac Surg, Poznan, Poland. C3 Poznan University of Medical Sciences RP Dyszkiewicz, W (corresponding author), Karol Marcinkowski Univ Med Sci, Dept Thorac Surg, 62 Szamarzewski St, Poznan, Poland. CR BECKNIEL.J, 1973, ACTA MED SCAND, V193, P425 CHENG TO, 1982, ANN THORAC SURG, V3, P528 COX JL, 1993, ANN THORAC SURG, V56, P405, DOI 10.1016/0003-4975(93)90871-E MOTTA G, 1989, ACTA CHIR BELG, V89, P161 RITCHIE AJ, 1992, THORAX, V47, P41, DOI 10.1136/thx.47.1.41 VONKNORRING J, 1992, ANN THORAC SURG, V53, P642, DOI 10.1016/0003-4975(92)90325-X ZIOMEK S, 1993, ANN THORAC SURG, V56, P223, DOI 10.1016/0003-4975(93)91151-C NR 7 TC 42 Z9 49 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1010-7940 J9 EUR J CARDIO-THORAC JI Eur. J. Cardio-Thorac. Surg. PD JUN PY 1998 VL 13 IS 6 BP 625 EP 627 DI 10.1016/S1010-7940(98)00084-0 PG 3 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 111WF UT WOS:000075460900003 PM 9686791 OA Bronze DA 2026-04-17 ER PT J AU Tomkowski, WZ Filipecki, S AF Tomkowski, WZ Filipecki, S TI Intrapericardial cisplatin for the management of patients with large malignant pericardial effusion in the course of the lung cancer SO LUNG CANCER LA English DT Article DE malignant pericardial effusion; lung cancer; intrapericardial cisplatin administration; cardiac tamponade ID TETRACYCLINE SCLEROSIS; CARDIAC-TAMPONADE; INSTILLATION; BLEOMYCIN AB Patients with cardiac tamponade or large malignant pericardial effusion, who survived longer than 30 days after withdrawal of catheter from the pericardial space, entered the study. Main goal of investigations was: evaluation of the effectiveness and side-effects of intrapericardial administration of cisplatin in cases with malignant pericardial effusion (MPE) and cardiac tamponade or large pericardial effusion in a course of the lung cancer. Sixteen patients (four women and 12 men), mean age 53 years, median age 57 years, range 27-70 years, entered this retrospective study. After pericardiocentesis and insertion of a polyurethane catheter, pericardial fluid was drained. Malignant etiology of pericardial fluid was confirmed by cytological examination and/or by echocardiography. The diagnosis of malignancy was based upon histological examination of samples obtained from primary tumor. After confirmation of MPE cisplatin (10 mg in 20 ml normal saline) was instilled over 5 min during 1-5 consecutive days (maximal total cisplatin dose in single course: 50 mg) directly into pericardial space. If a large pericardial fluid reoccurred the courses with intrapericardial administration of cisplatin were repeated. Treatment was considered successful if the patient with malignant effusion survived 30 days without recurrence of symptoms of large pericardial effusion and no other interventions directed to the pericardium were required. In 14 (87.5%) cases malignant pericardial effusion was confirmed by cytological analysis of pericardial fluid. In two cases echocardiography confirmed metastatic tumors to the pericardium. Positive effect of intrapericardial treatment with cisplatin was achieved in 15 cases (93.75%). Mean survival period in the whole group was 6.59 months (+/- 6.2 months), median survival period was 3.7 months, range 2-24.1 months. There were no complications related to the pericardiocentesis. Transient atrial fibrillation was detected in three patients (18.8%). Mild nausea occurred in one case. No hypotension and retrosternal pain were observed. Cisplatin administered directly into pericardial space (CAP) seems to be effective and safe. No sclerosis of the pericardial space was observed after CAP. (C) 1997 Elsevier Science Ireland Ltd. RP Tomkowski, WZ (corresponding author), NATL INST TB & LUNG DIS,PLOCKA 26,PL-01138 WARSAW,POLAND. CR BINDI M, 1987, TUMORI J, V73, P163, DOI 10.1177/030089168707300213 CORMICAN MC, 1990, BRIT HEART J, V63, P61 DAVIS S, 1984, J CLIN ONCOL, V2, P631, DOI 10.1200/JCO.1984.2.6.631 FIORENTINO MV, 1988, CANCER-AM CANCER SOC, V62, P1904, DOI 10.1002/1097-0142(19881101)62:9<1904::AID-CNCR2820620906>3.0.CO;2-U IMAMURA T, 1991, CANCER-AM CANCER SOC, V68, P259, DOI 10.1002/1097-0142(19910715)68:2<259::AID-CNCR2820680207>3.0.CO;2-V LEE LN, 1994, THORAX, V49, P594, DOI 10.1136/thx.49.6.594 MARKMAN M, 1985, CANCER DRUG DELIV, V1, P49 MARTINI N, 1977, AM J ROENTGENOL, V128, P639, DOI 10.2214/ajr.128.4.639 SHEPHERD FA, 1987, AM J CARDIOL, V60, P1161, DOI 10.1016/0002-9149(87)90411-5 SMITH FE, 1974, CANCER, V33, P47, DOI 10.1002/1097-0142(197401)33:1<47::AID-CNCR2820330110>3.0.CO;2-8 TAMURA A, 1992, CANCER, V70, P427 TOMKOWSKI W, 1994, J CANCER RES CLIN, V120, P434, DOI 10.1007/BF01240144 Tondini M, 1995, Monaldi Arch Chest Dis, V50, P86 VAITKUS PT, 1994, JAMA-J AM MED ASSOC, V272, P59, DOI 10.1001/jama.272.1.59 VANBELLE SJP, 1987, INT J CARDIOL, V16, P155, DOI 10.1016/0167-5273(87)90246-4 VANDERGAAST A, 1989, EUR J CANCER CLIN ON, V25, P1505, DOI 10.1016/0277-5379(89)90112-0 NR 16 TC 33 Z9 36 U1 0 U2 4 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0169-5002 J9 LUNG CANCER-J IASLC JI Lung Cancer PD MAR PY 1997 VL 16 IS 2-3 BP 215 EP 222 DI 10.1016/S0169-5002(96)00631-9 PG 8 WC Oncology; Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Oncology; Respiratory System GA WW986 UT WOS:A1997WW98600008 PM 9152952 DA 2026-04-17 ER PT J AU Schulzer, M Mancini, GBJ AF Schulzer, M Mancini, GBJ TI 'Unqualified success' and 'unmitigated failure': Number-needed-to-treat-related concepts for assessing treatment efficacy in the presence of treatment-induced adverse events SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY LA English DT Article DE treatment efficacy; adverse events; NNT ID ATRIAL-FIBRILLATION; STROKE PREVENTION; GOLD STANDARD; CHOLECYSTECTOMY; PERSPECTIVE AB Background. Common indices for the quantal assessment of treatment efficacy are reviewed, The absolute risk reduction is a practical index for public health considerations. Its reciprocal has been termed the 'Number Needed to Treat' (NNT), representing the health effort that must on average be expended to accomplish one tangible treatment target. We extend the NNT to evaluate outcome combinations of treatment benefits versus treatment harms. Methods. We describe the mathematical context of the NNT, and extend it to evaluate outcome combinations (treatment success/failure with/without treatment-induced adverse effects) in a treated population. These extensions are carried out assuming either independence or positive association between treatment benefit and treatment harm. A method is provided for calculating the standard errors of these extended NNT values. Applications to cost-effectiveness analysis are discussed. Results. We calculate NNT in three recent therapeutic studies. The results of a trial of the prevention of strokes with warfarin in patients with non-valvular atrial fibrillation are analysed to evaluate treatment success (stroke prevention) against treatment-induced bleeds. An NNT-related cost-benefit analysis is also carried out. We also analyse the results of a study of two modalities of chemotherapeutic treatment in small-cell lung cancer, and of two modalities of surgical intervention in the treatment of cholelithiasis. Conclusions. The NNT are useful in direct evaluation of outcome-specific treatment benefits versus treatment-induced harms. They may also be used in cost-effectiveness analyses and are helpful in guiding public health programmes towards the identification of optimal treatment strategies. C1 UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER,BC V5Z 1M9,CANADA. UNIV BRITISH COLUMBIA,DEPT STAT,VANCOUVER,BC V6T 1W5,CANADA. C3 University of British Columbia; University of British Columbia CR [Anonymous], CLIN EPIDEMIOLOGY BA ASPLUND K, 1993, CEREBROVASC DIS, V3, P34, DOI 10.1159/000108747 BERKSON J, 1958, J AM STAT ASSOC, V53, P28, DOI 10.2307/2282563 EKHOLM BP, 1990, STAT METHODOLOGY PHA, P117 FEINSTEIN AR, 1973, CLIN PHARMACOL THER, V14, P291 FELLER W, 1965, INTRO PROBABILITY TH, V1, P155 FLEISS JL, 1981, STATISTICAL METHODS, P90 GUSTAFSSON C, 1992, BRIT MED J, V305, P1457, DOI 10.1136/bmj.305.6867.1457 LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605 MCSHERRY CK, 1989, AM J SURG, V158, P174, DOI 10.1016/0002-9610(89)90246-8 NAGLIE IG, 1992, MED DECIS MAKING, V12, P239, DOI 10.1177/0272989X9201200401 Persson U, 1990, Int J Technol Assess Health Care, V6, P125 RAO CR, 1973, LINEAR STATISTICAL I RIEGELMAN R, 1993, MED DECIS MAKING, V13, P247, DOI 10.1177/0272989X9301300312 SHEPS MC, 1958, NEW ENGL J MED, V259, P1210, DOI 10.1056/NEJM195812182592505 SHEPS MC, 1961, AM J PUBLIC HEALTH N, V51, P547, DOI 10.2105/AJPH.51.4.547 SOPER NJ, 1992, ARCH SURG-CHICAGO, V127, P917 SOUHAMI RL, 1994, J CLIN ONCOL, V12, P1806, DOI 10.1200/JCO.1994.12.9.1806 STIFF G, 1994, BRIT J SURG, V81, P1368, DOI 10.1002/bjs.1800810939 1990, NEW ENGL J MED, V323, P1505 NR 20 TC 59 Z9 62 U1 0 U2 1 PU OXFORD UNIV PRESS UNITED KINGDOM PI OXFORD PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP SN 0300-5771 J9 INT J EPIDEMIOL JI Int. J. Epidemiol. PD AUG PY 1996 VL 25 IS 4 BP 704 EP 712 DI 10.1093/ije/25.4.704 PG 9 WC Public, Environmental & Occupational Health WE Science Citation Index Expanded (SCI-EXPANDED) SC Public, Environmental & Occupational Health GA VH220 UT WOS:A1996VH22000002 PM 8921446 OA Bronze DA 2026-04-17 ER PT J AU CRAIG, SR WALKER, WS AF CRAIG, SR WALKER, WS TI INITIAL EXPERIENCE OF VIDEO-ASSISTED THORACOSCOPIC PNEUMONECTOMY SO THORAX LA English DT Article DE THORACOSCOPIC SURGERY; PNEUMONECTOMY ID PULMONARY LOBECTOMY AB Background - Preliminary experience of video assisted thoracoscopic pneumonectomy in six patients with bronchogenic carcinoma is described. Methods - Four left and two right pneumonectomies were performed under video thoracoscopic imaging. Thoracoscopic instruments were passed through two separate stab incisions on the lateral chest wall and a separate 6 cm submammary incision was also created to allow further access for instrumentation and removal of the resected lung. In this initial experience resection was restricted to patients with bronchogenic carcinomas of less than 6 cm in diameter who had no involvement of the mediastinum. Results - There were no operative deaths and no complications attributable to the technique. One patient developed postoperative atrial fibrillation and a small sacral sore and one patient was readmitted with abdominal pain and pyrexia which settled following exclusion of post pneumonectomy empyema. The remaining four patients made a rapid uncomplicated postoperative recovery with less pain and discomfort than that normally associated with a standard posterolateral thoracotomy. Postoperatively the mean (SD) patient controlled morphine consumption was 1.36 (1.90) mg per hour in the first 36 hours compared with the unit mean for open thoracotomy of 1.73 (1.68) mg per hour. The mean linear visual analogue pain score was 15.4 (15.6) in the first 24 hours compared with the unit mean for open thoracotomy of 34.5 (8.5). Conclusions - Video assisted thoracoscopic pneumonectomy can be performed safely in patients who have stage I and stage II bronchogenic carcinomas, up to 6 cm in diameter, with no mediastinal involvement on mediastinoscopy and thoracic computed tomographic assessment. This technique may result in less postoperative pain and discomfort and should allow a quicker return to normal activities. C1 CITY HOSP EDINBURGH,DEPT THORAC SURG,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND. CR DONNELLY RJ, 1992, THORAX, V47, P490, DOI 10.1136/thx.47.7.490 GINSBERG RJ, 1991, LUNG CANCER S, V7, pA83 GIUDICELLI R, 1994, EUR J CARDIO-THORAC, V8, P254, DOI 10.1016/1010-7940(94)90156-2 ICHINOSE Y, 1994, J THORAC CARDIOV SUR, V108, P684 KIRBY TJ, 1993, ANN THORAC SURG, V56, P1248, DOI 10.1016/0003-4975(93)90661-Z MCKENNA RJ, 1994, J THORAC CARDIOV SUR, V107, P879 NDUKA CC, 1994, BRIT J SURG, V81, P648, DOI 10.1002/bjs.1800810506 ROVIARO G, 1993, ANN THORAC SURG, V56, P779, DOI 10.1016/0003-4975(93)90979-R THURER RL, 1993, ANN THORAC SURG, V56, P199, DOI 10.1016/0003-4975(93)90448-Q WAKABAYASHI A, 1991, J THORAC CARDIOV SUR, V102, P721 WALKER WS, 1993, THORAX, V48, P921, DOI 10.1136/thx.48.9.921 WALKER WS, 1994, BRIT J SURG, V81, P81, DOI 10.1002/bjs.1800810126 WALKER WS, 1993, J THORAC CARDIOV SUR, V106, P1111, DOI 10.1016/S0022-5223(19)33986-8 WARREN WH, 1994, J THORAC CARDIOV SUR, V107, P1087, DOI 10.1016/S0022-5223(12)70385-9 NR 14 TC 34 Z9 38 U1 0 U2 0 PU BRITISH MED JOURNAL PUBL GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR SN 0040-6376 J9 THORAX JI Thorax PD APR PY 1995 VL 50 IS 4 BP 392 EP 395 DI 10.1136/thx.50.4.392 PG 4 WC Respiratory System WE Science Citation Index Expanded (SCI-EXPANDED) SC Respiratory System GA QR733 UT WOS:A1995QR73300015 PM 7785013 OA Green Submitted, Bronze DA 2026-04-17 ER PT J AU MATHISEN, DJ GRILLO, HC AF MATHISEN, DJ GRILLO, HC TI CARINAL RESECTION FOR BRONCHOGENIC-CARCINOMA SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article; Proceedings Paper CT 70TH ANNUAL MEETING OF THE AMERICAN ASSOC FOR THORACIC SURGERY CY MAY 07-09, 1990 CL TORONTO, CANADA SP AMER ASSOC THORAC SURG ID TRACHEAL SLEEVE PNEUMONECTOMY; LUNG; VENTILATION AB Techniques are available for carinal resection and reconstruction for bronchogenic carcinoma involving the carina. Successful outcome depends on careful patient selection, thorough preoperative evaluation, careful anesthetic management, strict attention to surgical technique, and compulsive postoperative care. Since 1973 we have performed 37 carinal resections for bronchogenic carcinoma: 21 right carinal pneumonectomies, 7 carinal resections, 7 carina plus lobe resections, and 2 carina plus pneumonectomy stump resections. Five patients had diseased N2 nodes and 13 patients had diseased N1 nodes. Complications included pulmonary (8), vocal cord paresis (3), atrial fibrillation (9), anastomotic stenosis (4), and anastomotic separation (3). There were 3 early postoperative deaths (8%). All were related to adult respiratory distress syndrome and were unresponsive to aggressive treatment. There were 4 late postoperative deaths between 2 and 4 months (10.9%). All late postoperative deaths were related to anastomotic complications (stenosis [1] and separation [3]. There are 5 absolute 5-year survivors and an actuarial 5-year survival rate of 19%. RP MATHISEN, DJ (corresponding author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT OBSTET GYNECOL,WARREN 1109,BOSTON,MA 02114, USA. CR BRIA WF, 1983, J THORAC CARDIOV SUR, V86, P186 DARTEVELLE PG, 1988, ANN THORAC SURG, V46, P68, DOI 10.1016/S0003-4975(10)65855-9 DESLAURIERS J, 1978, ANN THORAC SURG, V28, P465 DESLAURIERS J, 1985, INT TRENDS GEN THORA, V1, P139 ELBAZ N, 1982, ANN THORAC SURG, V34, P564, DOI 10.1016/S0003-4975(10)63004-4 GINSBERG RJ, 1983, J THORAC CARDIOV SUR, V86, P654 GRILLO HC, 1982, ANN THORAC SURG, V34, P356, DOI 10.1016/S0003-4975(10)61394-X GRILLO HC, 1990, ANN THORAC SURG, V49, P69, DOI 10.1016/0003-4975(90)90358-D GRILLO HC, 1982, AM J SURG, V143, P694, DOI 10.1016/0002-9610(82)90038-1 ISHIHARA T, 1977, J THORAC CARDIOV SUR, V73, P936 JENSIK RJ, 1982, J THORAC CARDIOV SUR, V84, P489 KANAREK DJ, 1983, THORACIC ONCOLOGY, P103 MATHEY J, 1966, J THORAC CARDIOV SUR, V51, P1 NARUKE T, 1977, J THORAC CARDIOV SUR, V73, P927 PEARSON FG, 1984, J THORAC CARDIOV SUR, V88, P511 Perelman M, 1980, World J Surg, V4, P583 WILSON RS, 1987, INT TRENDS GENERAL T, V2, P3 ZELDIN RA, 1984, J THORAC CARDIOV SUR, V87, P359 NR 18 TC 80 Z9 84 U1 0 U2 4 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD JUL PY 1991 VL 102 IS 1 BP 16 EP 23 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery WE Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED) SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA FW773 UT WOS:A1991FW77300003 PM 2072721 DA 2026-04-17 ER EF